diff --git "a/oms/vec_who_3/storage_nodes/docstore.json" "b/oms/vec_who_3/storage_nodes/docstore.json"
deleted file mode 100644--- "a/oms/vec_who_3/storage_nodes/docstore.json"
+++ /dev/null
@@ -1 +0,0 @@
-{"docstore/data": {"a31587f5-80d9-4809-ba6c-865cc6d57693": {"__data__": {"id_": "a31587f5-80d9-4809-ba6c-865cc6d57693", "embedding": null, "metadata": {"page_label": "1", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar presente en el documento:\n\n### Resumen del Contexto\nEl documento titulado \"WHO - Technical Report Series 961\" es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se proporciona contenido espec\u00edfico en el texto, los informes de esta serie suelen abordar temas relacionados con la salud p\u00fablica, investigaciones cient\u00edficas, recomendaciones sobre pr\u00e1cticas de salud y pol\u00edticas sanitarias.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS presentadas en el informe t\u00e9cnico 961?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS ha emitido en este informe, que podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el informe WHO TRS 961 y c\u00f3mo se relacionan con las tendencias actuales en salud global?**\n   - Esta pregunta se enfoca en identificar los temas tratados en el informe y su relevancia en el contexto de los desaf\u00edos actuales en salud p\u00fablica a nivel mundial.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas de investigaci\u00f3n se utilizaron para recopilar los datos presentados en el informe WHO TRS 961?**\n   - Esta pregunta busca detalles sobre las t\u00e9cnicas y enfoques de investigaci\u00f3n que respaldan las conclusiones del informe, lo que podr\u00eda ser \u00fatil para investigadores y acad\u00e9micos interesados en la validez de los datos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otras fuentes, dado que se centran en el contenido particular del informe de la OMS.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, recomendaciones, investigaci\u00f3n, pol\u00edticas sanitarias"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a6ef094-cfc3-49bc-96bf-f3a9cf1b9eaa", "node_type": "4", "metadata": {"page_label": "1", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f2b78f-8b97-4eae-a1fd-f965eca10ede": {"__data__": {"id_": "b8f2b78f-8b97-4eae-a1fd-f965eca10ede", "embedding": null, "metadata": {"page_label": "2", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series ; no. 961)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceutical \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120961 8  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2011\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications \u2014 whether for sale or for noncommercial distribution \u2014 should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es el \"Cuarenta y quinto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas\", publicado en la Serie de Informes T\u00e9cnicos de la OMS (n\u00famero 961). Este informe aborda est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n de la industria farmac\u00e9utica y control de calidad. Tambi\u00e9n incluye informaci\u00f3n sobre la obtenci\u00f3n de publicaciones de la OMS, as\u00ed como una declaraci\u00f3n de responsabilidad sobre la interpretaci\u00f3n y uso del material presentado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales est\u00e1ndares discutidos en el informe sobre preparaciones farmac\u00e9uticas y c\u00f3mo se relacionan con la calidad del producto final?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los est\u00e1ndares mencionados en el informe y su impacto en la calidad de las preparaciones farmac\u00e9uticas.\n\n2. **\u00bfQu\u00e9 recomendaciones hace la OMS en relaci\u00f3n con la legislaci\u00f3n de la industria farmac\u00e9utica en el contexto de este informe?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que la OMS proporciona sobre la legislaci\u00f3n en la industria farmac\u00e9utica, que pueden no estar disponibles en otras fuentes.\n\n3. **\u00bfC\u00f3mo se asegura la OMS de la veracidad de la informaci\u00f3n presentada en este informe y cu\u00e1les son las limitaciones de esta verificaci\u00f3n?**\n   - Esta pregunta indaga sobre los m\u00e9todos de verificaci\u00f3n utilizados por la OMS y las limitaciones que pueden existir en la informaci\u00f3n presentada, lo que puede no ser evidente en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" de la Organizaci\u00f3n Mundial de la Salud (OMS) se centra en temas relevantes de salud p\u00fablica y proporciona recomendaciones y directrices basadas en investigaciones cient\u00edficas. Aunque no se presenta contenido espec\u00edfico en el texto, se pueden inferir los siguientes temas clave y entidades:\n\n#### Temas Clave:\n1. **Recomendaciones de Salud P\u00fablica**: Directrices emitidas por la OMS para mejorar las pr\u00e1cticas de salud y pol\u00edticas sanitarias.\n2. **Investigaci\u00f3n Cient\u00edfica**: An\u00e1lisis y estudios que respaldan las conclusiones y recomendaciones del informe.\n3. **Tendencias en Salud Global**: Relaci\u00f3n de los temas tratados en el informe con los desaf\u00edos actuales en el \u00e1mbito de la salud a nivel mundial.\n4. **Metodolog\u00edas de Investigaci\u00f3n**: T\u00e9cnicas y enfoques utilizados para recopilar y analizar datos en el contexto del informe.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la elaboraci\u00f3n del informe y de la promoci\u00f3n de la salud p\u00fablica a nivel global.\n- **Informe T\u00e9cnico**: Tipo de documento que presenta hallazgos y recomendaciones sobre temas espec\u00edficos de salud.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos que podr\u00edan ser relevantes en el informe, aunque no se disponga de contenido espec\u00edfico en el texto proporcionado.", "excerpt_keywords": "Keywords: pharmaceutical standards, quality control, WHO report, drug legislation, health technology"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e754d05f-506f-4b4f-a402-b86461b618aa", "node_type": "4", "metadata": {"page_label": "2", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series ; no. 961)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceutical \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120961 8  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2011\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications \u2014 whether for sale or for noncommercial distribution \u2014 should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c73c08f8d024e61e6bcbfef3770e230111c2c7e5d4d38c17f5612c1e7e92b027", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series ; no. 961)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceutical \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120961 8  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2011\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications \u2014 whether for sale or for noncommercial distribution \u2014 should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2397, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1376bc00-53db-495a-8f54-b2bb554036fe": {"__data__": {"id_": "1376bc00-53db-495a-8f54-b2bb554036fe", "embedding": null, "metadata": {"page_label": "3", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   6  \n   2.1 International collaboration  \n   6  \n   2.1.1 Collaboration with international organizations and agencies  \n   6  \n   European Directorate for the Quality of Medicines and HealthCare (Council of Europe)  \n   6  \n   The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n   6  \n   United Nations Children's Fund  \n   7  \n   2.1.2 Pharmacopoeial Discussion Group  \n   8  \n   2.1.3 International Conference on Harmonisation  \n   9  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   9  \n   2.2 Cross-cutting issues in pharmaceuticals \u2013 quality assurance issues  \n   10  \n   2.2.1 Essential medicines  \n   10  \n   2.2.2 Herbal and complementary medicines  \n   11  \n   2.2.3 Regulatory support  \n   12\n\n3. **Joint session with the Expert Committee on Biological Standardization**  \n   13\n\n4. **Quality control \u2013 specifications and tests**  \n   14  \n   4.1 *The International Pharmacopoeia*  \n   14  \n   4.2 Current work plan and future work programme  \n   15  \n   4.3 Specifications for medicines, including children's medicines  \n   16  \n   4.3.1 Medicines for HIV and related conditions  \n   16  \n   4.3.2 Antimalarial medicines  \n   16  \n   4.3.3 Antituberculosis medicines  \n   17  \n   4.3.4 Anti-infectives  \n   18  \n   4.3.5 Other medicines  \n   19  \n   4.4 Revision of texts of *The International Pharmacopoeia*  \n   19  \n   4.4.1 Antimalarials: artemisinin derivatives  \n   19  \n   4.4.2 Other medicines  \n   20  \n   4.5 Review of published general monographs for dosage forms and associated method texts  \n   21  \n   4.5.1 Pharmacopoeial Discussion Group: harmonized general texts  \n   21  \n   4.5.2 Uniformity of content for single-dose preparations  \n   23  \n   4.6 General policy topics and general revision issues for *The International Pharmacopoeia*  \n   24  \n   4.6.1 Update on dissolution tests  \n   24  \n   4.6.2 Dry powders  \n   25\n\n5. **Quality control \u2013 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)**  \n   28  \n   5.1 Update on transfer of International Chemical Reference Substances  \n   28  \n   5.2 Proposal for an accelerated release of International Chemical Reference Standards  \n   29  \n   5.3 Proposed first International Standard for biosynthetic human insulin  \n   30", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda temas relacionados con la pol\u00edtica general de colaboraci\u00f3n internacional en el \u00e1mbito de la calidad de los medicamentos. Se discuten las colaboraciones con diversas organizaciones internacionales, as\u00ed como cuestiones transversales en farmac\u00e9uticos, incluyendo la calidad y la regulaci\u00f3n de medicamentos esenciales, herbales y complementarios. Tambi\u00e9n se detalla el control de calidad, especificaciones y pruebas, incluyendo la revisi\u00f3n de textos de la Farmacopea Internacional y la propuesta de est\u00e1ndares internacionales para sustancias qu\u00edmicas y espectros infrarrojos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 organizaciones internacionales se mencionan en el documento como colaboradoras en la mejora de la calidad de los medicamentos y cu\u00e1les son sus roles espec\u00edficos?**\n   - Esta pregunta busca respuestas sobre la naturaleza de la colaboraci\u00f3n y el impacto de cada organizaci\u00f3n en la calidad de los medicamentos.\n\n2. **\u00bfCu\u00e1les son las especificaciones y pruebas propuestas para los medicamentos dirigidos a condiciones espec\u00edficas como el VIH, la malaria y la tuberculosis?**\n   - Esta pregunta se centra en los detalles t\u00e9cnicos y las normativas espec\u00edficas que se aplican a medicamentos para estas condiciones, que pueden no estar disponibles en otras fuentes.\n\n3. **\u00bfQu\u00e9 actualizaciones se han propuesto en relaci\u00f3n con los est\u00e1ndares internacionales para las sustancias qu\u00edmicas de referencia y c\u00f3mo se espera que impacten en la calidad de los medicamentos?**\n   - Esta pregunta busca informaci\u00f3n sobre las propuestas recientes y su relevancia en el contexto de la regulaci\u00f3n y control de calidad de los medicamentos a nivel internacional. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **T\u00edtulo del Documento**: Cuarenta y quinto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas (WHO Technical Report Series, no. 961).\n\n2. **Temas Principales**:\n   - **Est\u00e1ndares para Preparaciones Farmac\u00e9uticas**: Discusi\u00f3n sobre los est\u00e1ndares que deben cumplir las preparaciones farmac\u00e9uticas.\n   - **Tecnolog\u00eda Farmac\u00e9utica**: Normativas y est\u00e1ndares relacionados con la tecnolog\u00eda utilizada en la industria farmac\u00e9utica.\n   - **Legislaci\u00f3n de la Industria Farmac\u00e9utica**: Recomendaciones y regulaciones que afectan a la industria farmac\u00e9utica.\n   - **Control de Calidad**: M\u00e9todos y pr\u00e1cticas para asegurar la calidad de los productos farmac\u00e9uticos.\n\n3. **Entidades**:\n   - **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad responsable de la publicaci\u00f3n y contenido del informe.\n   - **WHO Press**: Entidad encargada de la distribuci\u00f3n de las publicaciones de la OMS.\n\n4. **Informaci\u00f3n Adicional**:\n   - **ISBN y ISSN**: Identificadores del documento (ISBN 978 92 4 120961 8, ISSN 0512-3054).\n   - **Declaraci\u00f3n de Responsabilidad**: Aclaraciones sobre la veracidad de la informaci\u00f3n y la responsabilidad del lector en la interpretaci\u00f3n del material.\n   - **Ubicaci\u00f3n de la OMS**: Direcci\u00f3n de la sede de la OMS en Ginebra, Suiza.\n\nEste resumen destaca los aspectos fundamentales del informe, as\u00ed como las entidades involucradas en su creaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, international collaboration, pharmacopoeia, drug regulation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c963115b-9aa0-4e23-a1e7-76d051e60ab3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   6  \n   2.1 International collaboration  \n   6  \n   2.1.1 Collaboration with international organizations and agencies  \n   6  \n   European Directorate for the Quality of Medicines and HealthCare (Council of Europe)  \n   6  \n   The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n   6  \n   United Nations Children's Fund  \n   7  \n   2.1.2 Pharmacopoeial Discussion Group  \n   8  \n   2.1.3 International Conference on Harmonisation  \n   9  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   9  \n   2.2 Cross-cutting issues in pharmaceuticals \u2013 quality assurance issues  \n   10  \n   2.2.1 Essential medicines  \n   10  \n   2.2.2 Herbal and complementary medicines  \n   11  \n   2.2.3 Regulatory support  \n   12\n\n3. **Joint session with the Expert Committee on Biological Standardization**  \n   13\n\n4. **Quality control \u2013 specifications and tests**  \n   14  \n   4.1 *The International Pharmacopoeia*  \n   14  \n   4.2 Current work plan and future work programme  \n   15  \n   4.3 Specifications for medicines, including children's medicines  \n   16  \n   4.3.1 Medicines for HIV and related conditions  \n   16  \n   4.3.2 Antimalarial medicines  \n   16  \n   4.3.3 Antituberculosis medicines  \n   17  \n   4.3.4 Anti-infectives  \n   18  \n   4.3.5 Other medicines  \n   19  \n   4.4 Revision of texts of *The International Pharmacopoeia*  \n   19  \n   4.4.1 Antimalarials: artemisinin derivatives  \n   19  \n   4.4.2 Other medicines  \n   20  \n   4.5 Review of published general monographs for dosage forms and associated method texts  \n   21  \n   4.5.1 Pharmacopoeial Discussion Group: harmonized general texts  \n   21  \n   4.5.2 Uniformity of content for single-dose preparations  \n   23  \n   4.6 General policy topics and general revision issues for *The International Pharmacopoeia*  \n   24  \n   4.6.1 Update on dissolution tests  \n   24  \n   4.6.2 Dry powders  \n   25\n\n5. **Quality control \u2013 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)**  \n   28  \n   5.1 Update on transfer of International Chemical Reference Substances  \n   28  \n   5.2 Proposal for an accelerated release of International Chemical Reference Standards  \n   29  \n   5.3 Proposed first International Standard for biosynthetic human insulin  \n   30", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "22369eff5bf80efd922756920b14d432eb5193f963f70814564eccbf4870905e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   6  \n   2.1 International collaboration  \n   6  \n   2.1.1 Collaboration with international organizations and agencies  \n   6  \n   European Directorate for the Quality of Medicines and HealthCare (Council of Europe)  \n   6  \n   The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n   6  \n   United Nations Children's Fund  \n   7  \n   2.1.2 Pharmacopoeial Discussion Group  \n   8  \n   2.1.3 International Conference on Harmonisation  \n   9  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   9  \n   2.2 Cross-cutting issues in pharmaceuticals \u2013 quality assurance issues  \n   10  \n   2.2.1 Essential medicines  \n   10  \n   2.2.2 Herbal and complementary medicines  \n   11  \n   2.2.3 Regulatory support  \n   12\n\n3. **Joint session with the Expert Committee on Biological Standardization**  \n   13\n\n4. **Quality control \u2013 specifications and tests**  \n   14  \n   4.1 *The International Pharmacopoeia*  \n   14  \n   4.2 Current work plan and future work programme  \n   15  \n   4.3 Specifications for medicines, including children's medicines  \n   16  \n   4.3.1 Medicines for HIV and related conditions  \n   16  \n   4.3.2 Antimalarial medicines  \n   16  \n   4.3.3 Antituberculosis medicines  \n   17  \n   4.3.4 Anti-infectives  \n   18  \n   4.3.5 Other medicines  \n   19  \n   4.4 Revision of texts of *The International Pharmacopoeia*  \n   19  \n   4.4.1 Antimalarials: artemisinin derivatives  \n   19  \n   4.4.2 Other medicines  \n   20  \n   4.5 Review of published general monographs for dosage forms and associated method texts  \n   21  \n   4.5.1 Pharmacopoeial Discussion Group: harmonized general texts  \n   21  \n   4.5.2 Uniformity of content for single-dose preparations  \n   23  \n   4.6 General policy topics and general revision issues for *The International Pharmacopoeia*  \n   24  \n   4.6.1 Update on dissolution tests  \n   24  \n   4.6.2 Dry powders  \n   25\n\n5. **Quality control \u2013 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)**  \n   28  \n   5.1 Update on transfer of International Chemical Reference Substances  \n   28  \n   5.2 Proposal for an accelerated release of International Chemical Reference Standards  \n   29  \n   5.3 Proposed first International Standard for biosynthetic human insulin  \n   30", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2373, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "684152ea-734c-47e8-88be-4f84085af171": {"__data__": {"id_": "684152ea-734c-47e8-88be-4f84085af171", "embedding": null, "metadata": {"page_label": "4", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6. Quality control \u2013 national laboratories  \n   6.1 External Quality Assurance Assessment Scheme 31  \n   6.2 WHO good practices for pharmaceutical microbiology laboratories 32  \n\n7. Quality assurance \u2013 good manufacturing practices  \n   7.1 Update of WHO good manufacturing practices: main principles for pharmaceutical products 33  \n   7.2 WHO good manufacturing practices for blood establishments 33  \n   7.3 Update of WHO good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 34  \n   7.4 Update of WHO good manufacturing practices: Water for pharmaceutical use 34  \n   7.5 Revision of WHO good manufacturing practices: Sterile pharmaceutical products 35  \n\n8. Quality Assurance \u2013 new approaches  \n   8.1 WHO guidelines on quality risk management 35  \n   8.2 WHO guidelines on technology transfer 36  \n\n9. Quality assurance \u2013 distribution and trade of pharmaceuticals  \n   9.1 Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services 36  \n   9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products 38  \n   9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 38  \n      9.3.1 Update on current activities 38  \n      9.3.2 Questions and answers 39  \n\n10. Prequalification of priority essential medicines  \n    10.1 Update on the WHO Prequalification of Medicines Programme 39  \n    10.2 Procedure for prequalification of pharmaceutical products 41  \n    10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities 41  \n\n11. Prequalification of quality control laboratories  \n    11.1 Update of activities 41  \n    11.2 Procedure for prequalifying laboratories 42  \n    11.3 Update on the WHO guidelines for preparing a laboratory information file 43  \n\n12. Prequalification of active pharmaceutical ingredients 44  \n\n13. Regulatory guidance  \n    13.1 WHO guidelines for preparing a site master file 44  \n    13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format 45  \n    13.3 Guidelines on submission of documentation for a multisource (generic) finished product: quality part 45  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos de la calidad y regulaci\u00f3n en la industria farmac\u00e9utica. Se centra en la calidad del control en laboratorios nacionales, las buenas pr\u00e1cticas de fabricaci\u00f3n, la precalificaci\u00f3n de medicamentos esenciales y laboratorios de control de calidad, as\u00ed como la orientaci\u00f3n regulatoria para productos farmac\u00e9uticos. Se incluyen actualizaciones sobre esquemas de aseguramiento de calidad, directrices sobre gesti\u00f3n de riesgos y pr\u00e1cticas de farmacia, as\u00ed como procedimientos para la prequalificaci\u00f3n de productos y laboratorios.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las actualizaciones m\u00e1s recientes sobre las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan el documento?**\n   - Esta pregunta se puede responder al revisar las secciones que abordan las actualizaciones de las buenas pr\u00e1cticas de fabricaci\u00f3n, incluyendo principios para productos farmac\u00e9uticos, pr\u00e1cticas para establecimientos de sangre y sistemas de ventilaci\u00f3n.\n\n2. **\u00bfQu\u00e9 procedimientos se describen para la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad?**\n   - El contexto proporciona detalles sobre los procedimientos espec\u00edficos para la precalificaci\u00f3n de medicamentos esenciales y laboratorios, as\u00ed como la gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n necesaria.\n\n3. **\u00bfQu\u00e9 directrices ofrece la OMS sobre la gesti\u00f3n de riesgos en la calidad de los productos farmac\u00e9uticos?**\n   - La secci\u00f3n sobre nuevas aproximaciones incluye directrices espec\u00edficas sobre la gesti\u00f3n de riesgos, lo que permite entender c\u00f3mo la OMS aborda este aspecto cr\u00edtico en la calidad farmac\u00e9utica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que se encuentra en el contexto y que puede no estar disponible en otras fuentes.", "prev_section_summary": "El documento \"WHO - Technical Report Series 961\" aborda varios temas clave relacionados con la calidad de los medicamentos y la colaboraci\u00f3n internacional en este \u00e1mbito. A continuaci\u00f3n se presenta un resumen de los temas y entidades m\u00e1s relevantes:\n\n### Temas Clave\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de la calidad de los medicamentos a nivel global.\n\n2. **Pol\u00edtica General**:\n   - **Colaboraci\u00f3n Internacional**: Se discuten las colaboraciones con diversas organizaciones y agencias internacionales que trabajan en la mejora de la calidad de los medicamentos.\n   - **Cuestiones Transversales en Farmac\u00e9uticos**: Se abordan temas de aseguramiento de calidad, incluyendo medicamentos esenciales y productos herbales y complementarios.\n\n3. **Control de Calidad**:\n   - **Especificaciones y Pruebas**: Se detallan las especificaciones para diferentes tipos de medicamentos, incluyendo aquellos dirigidos a condiciones espec\u00edficas como VIH, malaria y tuberculosis.\n   - **Revisi\u00f3n de la Farmacopea Internacional**: Se menciona la revisi\u00f3n de textos y monograf\u00edas relacionadas con la calidad de los medicamentos.\n\n4. **Materiales de Referencia Internacional**: Se discuten los est\u00e1ndares internacionales para sustancias qu\u00edmicas de referencia y espectros infrarrojos, as\u00ed como propuestas para su actualizaci\u00f3n y aceleraci\u00f3n en la liberaci\u00f3n.\n\n### Entidades Mencionadas\n\n- **European Directorate for the Quality of Medicines and HealthCare**: Colabora en la regulaci\u00f3n y calidad de los medicamentos en Europa.\n- **The Global Fund to Fight AIDS, Tuberculosis and Malaria**: Trabaja en la lucha contra estas enfermedades a trav\u00e9s de la mejora de la calidad de los medicamentos.\n- **United Nations Children's Fund (UNICEF)**: Se involucra en la provisi\u00f3n de medicamentos esenciales para la salud infantil.\n- **Pharmacopoeial Discussion Group**: Grupo que trabaja en la armonizaci\u00f3n de textos farmacop\u00e9icos.\n- **International Conference on Harmonisation**: Se enfoca en la armonizaci\u00f3n de regulaciones y est\u00e1ndares en la industria farmac\u00e9utica.\n- **International Conference of Drug Regulatory Authorities**: Re\u00fane a autoridades reguladoras para discutir y mejorar la regulaci\u00f3n de medicamentos.\n\nEste resumen destaca la importancia de la colaboraci\u00f3n internacional y el control de calidad en el \u00e1mbito farmac\u00e9utico, as\u00ed como las entidades clave que participan en estos esfuerzos.", "excerpt_keywords": "Keywords: quality control, good manufacturing practices, prequalification, pharmaceutical regulations, risk management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a59ec511-ba1c-4bd0-817a-b3db692fc091", "node_type": "4", "metadata": {"page_label": "4", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6. Quality control \u2013 national laboratories  \n   6.1 External Quality Assurance Assessment Scheme 31  \n   6.2 WHO good practices for pharmaceutical microbiology laboratories 32  \n\n7. Quality assurance \u2013 good manufacturing practices  \n   7.1 Update of WHO good manufacturing practices: main principles for pharmaceutical products 33  \n   7.2 WHO good manufacturing practices for blood establishments 33  \n   7.3 Update of WHO good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 34  \n   7.4 Update of WHO good manufacturing practices: Water for pharmaceutical use 34  \n   7.5 Revision of WHO good manufacturing practices: Sterile pharmaceutical products 35  \n\n8. Quality Assurance \u2013 new approaches  \n   8.1 WHO guidelines on quality risk management 35  \n   8.2 WHO guidelines on technology transfer 36  \n\n9. Quality assurance \u2013 distribution and trade of pharmaceuticals  \n   9.1 Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services 36  \n   9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products 38  \n   9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 38  \n      9.3.1 Update on current activities 38  \n      9.3.2 Questions and answers 39  \n\n10. Prequalification of priority essential medicines  \n    10.1 Update on the WHO Prequalification of Medicines Programme 39  \n    10.2 Procedure for prequalification of pharmaceutical products 41  \n    10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities 41  \n\n11. Prequalification of quality control laboratories  \n    11.1 Update of activities 41  \n    11.2 Procedure for prequalifying laboratories 42  \n    11.3 Update on the WHO guidelines for preparing a laboratory information file 43  \n\n12. Prequalification of active pharmaceutical ingredients 44  \n\n13. Regulatory guidance  \n    13.1 WHO guidelines for preparing a site master file 44  \n    13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format 45  \n    13.3 Guidelines on submission of documentation for a multisource (generic) finished product: quality part 45  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "26fa67d79a7b3b3502e16494bfc72767200ab881cc6c61077d5e97db29fb71b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6. Quality control \u2013 national laboratories  \n   6.1 External Quality Assurance Assessment Scheme 31  \n   6.2 WHO good practices for pharmaceutical microbiology laboratories 32  \n\n7. Quality assurance \u2013 good manufacturing practices  \n   7.1 Update of WHO good manufacturing practices: main principles for pharmaceutical products 33  \n   7.2 WHO good manufacturing practices for blood establishments 33  \n   7.3 Update of WHO good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 34  \n   7.4 Update of WHO good manufacturing practices: Water for pharmaceutical use 34  \n   7.5 Revision of WHO good manufacturing practices: Sterile pharmaceutical products 35  \n\n8. Quality Assurance \u2013 new approaches  \n   8.1 WHO guidelines on quality risk management 35  \n   8.2 WHO guidelines on technology transfer 36  \n\n9. Quality assurance \u2013 distribution and trade of pharmaceuticals  \n   9.1 Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services 36  \n   9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products 38  \n   9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 38  \n      9.3.1 Update on current activities 38  \n      9.3.2 Questions and answers 39  \n\n10. Prequalification of priority essential medicines  \n    10.1 Update on the WHO Prequalification of Medicines Programme 39  \n    10.2 Procedure for prequalification of pharmaceutical products 41  \n    10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities 41  \n\n11. Prequalification of quality control laboratories  \n    11.1 Update of activities 41  \n    11.2 Procedure for prequalifying laboratories 42  \n    11.3 Update on the WHO guidelines for preparing a laboratory information file 43  \n\n12. Prequalification of active pharmaceutical ingredients 44  \n\n13. Regulatory guidance  \n    13.1 WHO guidelines for preparing a site master file 44  \n    13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format 45  \n    13.3 Guidelines on submission of documentation for a multisource (generic) finished product: quality part 45", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa1bc67-b137-4238-be34-8e4fd01c28ea": {"__data__": {"id_": "ffa1bc67-b137-4238-be34-8e4fd01c28ea", "embedding": null, "metadata": {"page_label": "5", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n13.4 Pharmaceutical development for multisource (generic) pharmaceutical products 46\n\n13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System 46\n\n13.6 Development of paediatric medicines: pharmaceutical development 47\n\n13.7 Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients 47\n\n14. Nomenclature, terminology and databases 48\n   14.1 New definition for \u201csubstandard medicines\u201d 48\n   14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d 49\n   14.3 International Nonproprietary Names (INN) for pharmaceutical substances 51\n\n15. Summary and recommendations 51\n\nAcknowledgements 58\n\nAnnex 1\nRelease procedure of International Chemical Reference Substances 67\n\nAnnex 2\nWHO good practices for pharmaceutical microbiology laboratories 69\n\nAnnex 3\nWHO good manufacturing practices: main principles for pharmaceutical products 94\n\nAnnex 4\nWHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) 148\n\nAnnex 5\nWHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 215\n\nAnnex 6\nWHO good manufacturing practices for sterile pharmaceutical products 261\n\nAnnex 7\nWHO guidelines on transfer of technology in pharmaceutical manufacturing 285\n\nAnnex 8\nGood pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) 310\n\nAnnex 9\nModel guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) 324\n\nAnnex 10\nProcedure for prequalification of pharmaceutical products 373\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con el desarrollo y la regulaci\u00f3n de productos farmac\u00e9uticos. Incluye secciones sobre el desarrollo de medicamentos gen\u00e9ricos, la clasificaci\u00f3n de medicamentos esenciales, la calidad de ingredientes activos, y la nomenclatura de medicamentos. Adem\u00e1s, se presentan buenas pr\u00e1cticas de fabricaci\u00f3n y directrices para el manejo de productos farmac\u00e9uticos sensibles a la temperatura, as\u00ed como procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos?**\n   - Esta pregunta se centra en la secci\u00f3n 13.7 del documento, que aborda espec\u00edficamente los est\u00e1ndares de calidad necesarios para la artemisinina.\n\n2. **\u00bfQu\u00e9 define la OMS como \"medicamentos subest\u00e1ndar\" y c\u00f3mo se diferencia de los \"medicamentos falsificados\"?**\n   - Esta pregunta se relaciona con la secci\u00f3n 14.1 y 14.2, donde se presentan nuevas definiciones y clasificaciones de medicamentos, lo que permite entender las diferencias clave entre estos t\u00e9rminos.\n\n3. **\u00bfCu\u00e1les son las principales directrices de la OMS para las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta se refiere a la secci\u00f3n 14.6, que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n espec\u00edficas para productos farmac\u00e9uticos est\u00e9riles, proporcionando informaci\u00f3n sobre los est\u00e1ndares que deben seguirse en su producci\u00f3n. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que probablemente no se encuentre f\u00e1cilmente en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda varios temas fundamentales relacionados con la calidad y regulaci\u00f3n en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave\n\n1. **Control de Calidad en Laboratorios Nacionales**\n   - Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa.\n   - Buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica.\n\n2. **Aseguramiento de Calidad y Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**\n   - Actualizaciones sobre principios de BPF para productos farmac\u00e9uticos.\n   - Buenas pr\u00e1cticas para establecimientos de sangre.\n   - BPF para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en formas farmac\u00e9uticas no est\u00e9riles.\n   - BPF para agua de uso farmac\u00e9utico.\n   - Revisi\u00f3n de BPF para productos farmac\u00e9uticos est\u00e9riles.\n\n3. **Nuevas Aproximaciones en Aseguramiento de Calidad**\n   - Directrices sobre gesti\u00f3n de riesgos de calidad.\n   - Directrices sobre transferencia de tecnolog\u00eda.\n\n4. **Distribuci\u00f3n y Comercio de Productos Farmac\u00e9uticos**\n   - Directrices conjuntas FIP/OMS sobre buenas pr\u00e1cticas de farmacia.\n   - Orientaci\u00f3n para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y temperatura.\n   - Esquema de Certificaci\u00f3n de la OMS sobre la calidad de productos farmac\u00e9uticos en comercio internacional.\n\n5. **Precalificaci\u00f3n de Medicamentos Esenciales**\n   - Actualizaci\u00f3n del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n   - Procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n   - Gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos innovadores.\n\n6. **Precalificaci\u00f3n de Laboratorios de Control de Calidad**\n   - Actualizaci\u00f3n de actividades relacionadas.\n   - Procedimientos para la precalificaci\u00f3n de laboratorios.\n   - Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio.\n\n7. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos**\n\n8. **Orientaci\u00f3n Regulatoria**\n   - Directrices para la preparaci\u00f3n de un archivo maestro del sitio.\n   - Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para productos terminados multisource (gen\u00e9ricos).\n\n#### Entidades Mencionadas\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de establecer directrices y est\u00e1ndares en la industria farmac\u00e9utica.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Colaboraci\u00f3n con la OMS en la elaboraci\u00f3n de directrices sobre buenas pr\u00e1cticas de farmacia.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad y regulaci\u00f3n en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical development, quality requirements, essential medicines, good manufacturing practices, prequalification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73edfbe1-7061-4358-a6f4-32dedc58c618", "node_type": "4", "metadata": {"page_label": "5", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n13.4 Pharmaceutical development for multisource (generic) pharmaceutical products 46\n\n13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System 46\n\n13.6 Development of paediatric medicines: pharmaceutical development 47\n\n13.7 Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients 47\n\n14. Nomenclature, terminology and databases 48\n   14.1 New definition for \u201csubstandard medicines\u201d 48\n   14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d 49\n   14.3 International Nonproprietary Names (INN) for pharmaceutical substances 51\n\n15. Summary and recommendations 51\n\nAcknowledgements 58\n\nAnnex 1\nRelease procedure of International Chemical Reference Substances 67\n\nAnnex 2\nWHO good practices for pharmaceutical microbiology laboratories 69\n\nAnnex 3\nWHO good manufacturing practices: main principles for pharmaceutical products 94\n\nAnnex 4\nWHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) 148\n\nAnnex 5\nWHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 215\n\nAnnex 6\nWHO good manufacturing practices for sterile pharmaceutical products 261\n\nAnnex 7\nWHO guidelines on transfer of technology in pharmaceutical manufacturing 285\n\nAnnex 8\nGood pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) 310\n\nAnnex 9\nModel guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) 324\n\nAnnex 10\nProcedure for prequalification of pharmaceutical products 373\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5acf554a6d596942bb23f3caa9dbd70f307509325623ecafaaf82246e3d86864", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n13.4 Pharmaceutical development for multisource (generic) pharmaceutical products 46\n\n13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System 46\n\n13.6 Development of paediatric medicines: pharmaceutical development 47\n\n13.7 Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients 47\n\n14. Nomenclature, terminology and databases 48\n   14.1 New definition for \u201csubstandard medicines\u201d 48\n   14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d 49\n   14.3 International Nonproprietary Names (INN) for pharmaceutical substances 51\n\n15. Summary and recommendations 51\n\nAcknowledgements 58\n\nAnnex 1\nRelease procedure of International Chemical Reference Substances 67\n\nAnnex 2\nWHO good practices for pharmaceutical microbiology laboratories 69\n\nAnnex 3\nWHO good manufacturing practices: main principles for pharmaceutical products 94\n\nAnnex 4\nWHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) 148\n\nAnnex 5\nWHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 215\n\nAnnex 6\nWHO good manufacturing practices for sterile pharmaceutical products 261\n\nAnnex 7\nWHO guidelines on transfer of technology in pharmaceutical manufacturing 285\n\nAnnex 8\nGood pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) 310\n\nAnnex 9\nModel guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) 324\n\nAnnex 10\nProcedure for prequalification of pharmaceutical products 373\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1825, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a1ecab18-de64-436a-8798-0d489a43a096": {"__data__": {"id_": "a1ecab18-de64-436a-8798-0d489a43a096", "embedding": null, "metadata": {"page_label": "6", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 11  \nGuidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities  391\n\nAnnex 12  \nPrequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies  393\n\nAnnex 13  \nWHO guidelines for preparing a laboratory information file  403\n\nAnnex 14  \nWHO guidelines for drafting a site master file  409\n\nAnnex 15  \nGuidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format  417\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 se aborda en el Anexo 11 del documento?**\n   - El Anexo 11 del documento trata sobre las \"Gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas\". Este anexo proporciona directrices sobre c\u00f3mo presentar la documentaci\u00f3n necesaria para que un producto farmac\u00e9utico innovador sea considerado para la precalificaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito del Anexo 12 en el informe?**\n   - El Anexo 12 se centra en la \"Precalificaci\u00f3n de laboratorios de control de calidad\". Su prop\u00f3sito es establecer un procedimiento para evaluar la aceptabilidad, en principio, de los laboratorios de control de calidad que ser\u00e1n utilizados por las agencias de las Naciones Unidas, asegurando que cumplan con los est\u00e1ndares necesarios.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se espera en un archivo de informaci\u00f3n de laboratorio seg\u00fan el Anexo 13?**\n   - El Anexo 13 proporciona las \"Gu\u00edas de la OMS para preparar un archivo de informaci\u00f3n de laboratorio\". Este anexo detalla la informaci\u00f3n que debe incluirse en dicho archivo, que es esencial para la evaluaci\u00f3n de la calidad y la seguridad de los productos farmac\u00e9uticos, as\u00ed como para facilitar la comunicaci\u00f3n entre los laboratorios y las autoridades reguladoras.\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 961\" incluye varios anexos que ofrecen directrices y procedimientos relacionados con la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad. Estos anexos son cruciales para asegurar que los productos y laboratorios cumplan con los est\u00e1ndares internacionales establecidos por la OMS y otras autoridades regulatorias.\n\n### Preguntas adicionales basadas en el resumen:\n1. **\u00bfQu\u00e9 importancia tienen los anexos en el contexto de la precalificaci\u00f3n de productos farmac\u00e9uticos?**\n2. **\u00bfC\u00f3mo contribuyen las gu\u00edas de la OMS a la estandarizaci\u00f3n de los procesos de evaluaci\u00f3n de laboratorios de control de calidad?**\n3. **\u00bfQu\u00e9 se entiende por \"dossier de producto\" en el contexto del Anexo 15 y por qu\u00e9 es relevante?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda una variedad de temas relacionados con el desarrollo, regulaci\u00f3n y buenas pr\u00e1cticas en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n1. **Desarrollo Farmac\u00e9utico**:\n   - **Medicamentos Multifuente (Gen\u00e9ricos)**: Secci\u00f3n 13.4 que trata sobre el desarrollo de productos farmac\u00e9uticos gen\u00e9ricos.\n   - **Medicamentos Pedi\u00e1tricos**: Secci\u00f3n 13.6 que se enfoca en el desarrollo de medicamentos para ni\u00f1os.\n\n2. **Clasificaci\u00f3n de Medicamentos**:\n   - **Medicamentos Esenciales**: Secci\u00f3n 13.5 que clasifica los medicamentos administrados por v\u00eda oral seg\u00fan el Sistema de Clasificaci\u00f3n Biofarmac\u00e9utica.\n\n3. **Calidad de Ingredientes Activos**:\n   - **Artemisinina**: Secci\u00f3n 13.7 que establece los requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos.\n\n4. **Nomenclatura y Terminolog\u00eda**:\n   - **Medicamentos Subest\u00e1ndar**: Nueva definici\u00f3n presentada en la secci\u00f3n 14.1.\n   - **Medicamentos Falsificados**: Definiciones y diferencias en la secci\u00f3n 14.2.\n   - **Nombres No Propietarios Internacionales (INN)**: Secci\u00f3n 14.3 que aborda la nomenclatura de sustancias farmac\u00e9uticas.\n\n5. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n**:\n   - Directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos, incluyendo secciones espec\u00edficas para productos est\u00e9riles y no est\u00e9riles, as\u00ed como para laboratorios de microbiolog\u00eda.\n\n6. **Anexos**:\n   - Procedimientos y gu\u00edas adicionales sobre la liberaci\u00f3n de sustancias qu\u00edmicas de referencia, almacenamiento y transporte de productos farmac\u00e9uticos sensibles a la temperatura, y procedimientos de precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de las directrices y recomendaciones presentadas en el documento.\n- **Artemisinina**: Ingrediente activo clave en el tratamiento de la malaria.\n- **Medicamentos Esenciales**: Categor\u00eda de medicamentos que son fundamentales para satisfacer las necesidades de salud de la poblaci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad, la regulaci\u00f3n y las buenas pr\u00e1cticas en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, quality control laboratories, WHO guidelines, product dossiers"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e852ec3e-5c14-408f-ad9a-ffc3506ebb54", "node_type": "4", "metadata": {"page_label": "6", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 11  \nGuidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities  391\n\nAnnex 12  \nPrequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies  393\n\nAnnex 13  \nWHO guidelines for preparing a laboratory information file  403\n\nAnnex 14  \nWHO guidelines for drafting a site master file  409\n\nAnnex 15  \nGuidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format  417\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fcb48f6fc05bff5a43f775387487b27b26fcfda8801ba3c326fda4389c63723b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\nAnnex 11  \nGuidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities  391\n\nAnnex 12  \nPrequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies  393\n\nAnnex 13  \nWHO guidelines for preparing a laboratory information file  403\n\nAnnex 14  \nWHO guidelines for drafting a site master file  409\n\nAnnex 15  \nGuidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format  417\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 697, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f8e63b-79a0-4780-bb54-004cf6cac52d": {"__data__": {"id_": "d8f8e63b-79a0-4780-bb54-004cf6cac52d", "embedding": null, "metadata": {"page_label": "7", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 18\u201322 October 2010\n\n## Members\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana *(Chairperson)*\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia *(Co-Chairperson)*\n\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n- **Mr Jean-Michel Caudron**, Braine-le-Ch\u00e2teau, Belgium\n\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa\n\n- **Ms Nilka M. Guerrero Rivas**, Head of Quality Assurance, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama\n\n- **Professor Jos Hoogmartens**, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium\n\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\u00b9\n\n- **Dr Toru Kawanishi**, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan\n\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Rapporteur)*\n\n- **Professor Tam\u00e1s L. Pa\u00e1l**, President, Scientific Board, National Institute of Pharmacy, and Professor, University of Szeged, Budapest, Hungary\n\n## Temporary Advisers\n\n- **Dr Lucette Cargill**, Director, Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica\n\n- **Mr Antonio Carlos da Costa Bezerra**, Senior Pharmacist, Brazilian Health Surveillance Agency, Brasilia, Brazil\n\n- **Professor Konstantin Keller**, Director and Professor, Federal Ministry of Health, Bonn, Germany\n\n- **Professor Henning G. Kristensen**, Vedbaek, Denmark\n\n- **Ms Gugu N. Mahlangu**, Acting Director for Laboratory Services, Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe de la **Comisi\u00f3n de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**, que tuvo lugar en Ginebra del 18 al 22 de octubre de 2010. La reuni\u00f3n reuni\u00f3 a expertos de diversas partes del mundo, incluyendo acad\u00e9micos y funcionarios de agencias de salud, para discutir y establecer est\u00e1ndares en la preparaci\u00f3n de productos farmac\u00e9uticos. Se mencionan los miembros y asesores temporales que participaron en la reuni\u00f3n, destacando sus roles y afiliaciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes fueron los co-rapporteurs de la reuni\u00f3n y cu\u00e1l es su afiliaci\u00f3n?**\n   - Respuesta: Los co-rapporteurs fueron **Mr Eshetu Wondemagegnehu Biwota** de Addis Ababa, Etiop\u00eda, y **Dr Justina A. Molzon**, Associate Director for International Programs en el Center for Drug Evaluation and Research de la US Food and Drug Administration, Silver Spring, MD, USA.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1\u00f3 el Profesor Ivan Addae-Mensah en la reuni\u00f3n?**\n   - Respuesta: El Profesor Ivan Addae-Mensah fue el **Chairperson** (presidente) de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre la participaci\u00f3n del Profesor Jin Shaohong en la reuni\u00f3n?**\n   - Respuesta: El Profesor Jin Shaohong, Executive Deputy Director del National Institute for the Control of Pharmaceutical and Biological Products en el Ministerio de Salud P\u00fablica de Beijing, Rep\u00fablica Popular de China, **no pudo asistir** a la reuni\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Documentaci\u00f3n para Precalificaci\u00f3n**:\n   - **Anexo 11**: Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos innovadores aprobados por autoridades regulatorias estrictas.\n\n2. **Laboratorios de Control de Calidad**:\n   - **Anexo 12**: Procedimiento para la precalificaci\u00f3n de laboratorios de control de calidad, enfocado en su aceptabilidad para uso por agencias de las Naciones Unidas.\n\n3. **Informaci\u00f3n de Laboratorio**:\n   - **Anexo 13**: Gu\u00edas de la OMS para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio, que incluye informaci\u00f3n esencial para la evaluaci\u00f3n de calidad y seguridad.\n\n4. **Archivo Maestro del Sitio**:\n   - **Anexo 14**: Directrices de la OMS para la redacci\u00f3n de un archivo maestro del sitio, que detalla la informaci\u00f3n sobre las instalaciones y procesos de un laboratorio o fabricante.\n\n5. **Dossier de Producto**:\n   - **Anexo 15**: Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para productos terminados multisource (gen\u00e9ricos), incluyendo el formato general para la preparaci\u00f3n de dossiers de productos en formato de documento t\u00e9cnico com\u00fan.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona las directrices y procedimientos mencionados en los anexos.\n- **Agencias de las Naciones Unidas**: Entidades que utilizar\u00e1n los laboratorios de control de calidad precalificados.\n- **Productos farmac\u00e9uticos**: Incluye tanto productos innovadores como gen\u00e9ricos que deben cumplir con est\u00e1ndares de calidad y seguridad.\n\n### Importancia:\nEstos anexos son fundamentales para asegurar que los productos farmac\u00e9uticos y los laboratorios de control de calidad cumplan con los est\u00e1ndares internacionales, promoviendo la seguridad y eficacia de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, expert committee, quality assurance, global health"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1e995c61-7702-49bd-94e2-3ec7b9a869f2", "node_type": "4", "metadata": {"page_label": "7", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 18\u201322 October 2010\n\n## Members\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana *(Chairperson)*\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia *(Co-Chairperson)*\n\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n- **Mr Jean-Michel Caudron**, Braine-le-Ch\u00e2teau, Belgium\n\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa\n\n- **Ms Nilka M. Guerrero Rivas**, Head of Quality Assurance, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama\n\n- **Professor Jos Hoogmartens**, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium\n\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\u00b9\n\n- **Dr Toru Kawanishi**, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan\n\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Rapporteur)*\n\n- **Professor Tam\u00e1s L. Pa\u00e1l**, President, Scientific Board, National Institute of Pharmacy, and Professor, University of Szeged, Budapest, Hungary\n\n## Temporary Advisers\n\n- **Dr Lucette Cargill**, Director, Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica\n\n- **Mr Antonio Carlos da Costa Bezerra**, Senior Pharmacist, Brazilian Health Surveillance Agency, Brasilia, Brazil\n\n- **Professor Konstantin Keller**, Director and Professor, Federal Ministry of Health, Bonn, Germany\n\n- **Professor Henning G. Kristensen**, Vedbaek, Denmark\n\n- **Ms Gugu N. Mahlangu**, Acting Director for Laboratory Services, Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "63e04d0a42c61232d9ae271e327f32f6daf125583f46a4cd3cb80cb9bb5a3ec2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 18\u201322 October 2010\n\n## Members\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana *(Chairperson)*\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia *(Co-Chairperson)*\n\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n- **Mr Jean-Michel Caudron**, Braine-le-Ch\u00e2teau, Belgium\n\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa\n\n- **Ms Nilka M. Guerrero Rivas**, Head of Quality Assurance, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama\n\n- **Professor Jos Hoogmartens**, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium\n\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\u00b9\n\n- **Dr Toru Kawanishi**, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan\n\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Rapporteur)*\n\n- **Professor Tam\u00e1s L. Pa\u00e1l**, President, Scientific Board, National Institute of Pharmacy, and Professor, University of Szeged, Budapest, Hungary\n\n## Temporary Advisers\n\n- **Dr Lucette Cargill**, Director, Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica\n\n- **Mr Antonio Carlos da Costa Bezerra**, Senior Pharmacist, Brazilian Health Surveillance Agency, Brasilia, Brazil\n\n- **Professor Konstantin Keller**, Director and Professor, Federal Ministry of Health, Bonn, Germany\n\n- **Professor Henning G. Kristensen**, Vedbaek, Denmark\n\n- **Ms Gugu N. Mahlangu**, Acting Director for Laboratory Services, Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe\n\n----\n\n\u00b9 Unable to attend.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2131, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec10afe-30bc-42d0-962b-cf9155c2cfe8": {"__data__": {"id_": "4ec10afe-30bc-42d0-962b-cf9155c2cfe8", "embedding": null, "metadata": {"page_label": "8", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ms Lynda Paleshnuik, Senior Quality Assessor, Val-des-Mont, QC, Canada\n\nMs Eija Pelkonen,\u00b2 Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n\nMs Marie-Louise Rabouhans, Chiswick, London, England\n\nDr Jean-Louis Robert, Head, Official Medicines Control Laboratory, Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n\nDr Saranjit Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India\n\nMr Deryck Smith, Principal Specialist, SSI, Cleanrooms Division, Gauteng, South Africa\n\nDr Angelika Spreitzhofer,\u00b2 AGES PharmMed GmbH, Vienna, Austria\n\n# Representation from United Nations offices\u00b3\n\n**United Nations Children\u2019s Fund (UNICEF)**  \nDr Peter Svarrer Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from specialized agencies and related organizations\u2074\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**  \nMs Joelle Daviaud, Senior QA Technical Officer, Pharmaceutical Management Unit  \nand Mr Raghu Kumar Krishna Swamy, Geneva, Switzerland\n\n**World Intellectual Property Organization (WIPO)**  \nMs Konji Sebati, Consultant, Department for Traditional Knowledge and Global Challenges  \nand Ms Maria Soledad Iglesias-Vega, Program Officer, Department of External Relations, Geneva, Switzerland\n\n**The World Bank**  \nDr Andreas Seiter, Senior Health Specialist \u2014 Pharmaceuticals, Health, Nutrition and Population, Washington, DC, USA\n\n**World Customs Organization (WCO)**  \nMr Alvaro Fernandez Acebes, Technical Officer, Tariff and Trade Affairs Directorate, Brussels, Belgium\n\n**World Trade Organization (WTO)**  \nMr Roger Kampf, Counsellor, Intellectual Property Division, Geneva, Switzerland\n\n# Representation from intergovernmental organizations\u2075\n\n**European Union (EU)**  \nMs Jinna Lee, Permanent Delegation of the European Union, Geneva, Switzerland\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria.  \n\u2075 Unable to attend: European Medicines Agency (EMA), London, England.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y presenta una lista de participantes en una reuni\u00f3n, incluyendo representantes de diversas organizaciones, agencias de la ONU y organismos intergubernamentales. Se mencionan nombres, cargos y ubicaciones de los asistentes, as\u00ed como aquellos que no pudieron asistir. La reuni\u00f3n parece centrarse en temas relacionados con la calidad y regulaci\u00f3n de medicamentos, con la participaci\u00f3n de expertos de diferentes pa\u00edses y organizaciones internacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 roles desempe\u00f1an los representantes de las organizaciones mencionadas en el contexto de la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta busca profundizar en las funciones espec\u00edficas de cada representante y c\u00f3mo contribuyen a la regulaci\u00f3n y control de medicamentos a nivel internacional.\n\n2. **\u00bfCu\u00e1les son las implicaciones de la ausencia de representantes de organizaciones clave como el PNUD y la EMA en esta reuni\u00f3n?**\n   - Esta pregunta permite explorar c\u00f3mo la falta de participaci\u00f3n de estas organizaciones podr\u00eda afectar las decisiones y recomendaciones que surjan de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos podr\u00edan haber sido discutidos en la reuni\u00f3n, considerando la diversidad de expertos presentes?**\n   - Esta pregunta invita a especular sobre los posibles temas de discusi\u00f3n basados en la experiencia y los roles de los participantes, lo que podr\u00eda incluir la calidad de los medicamentos, la propiedad intelectual y la cooperaci\u00f3n internacional en salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un informe de la **Comisi\u00f3n de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**, que se llev\u00f3 a cabo en Ginebra del 18 al 22 de octubre de 2010. La reuni\u00f3n reuni\u00f3 a un grupo diverso de expertos en farmacolog\u00eda y regulaci\u00f3n de medicamentos de diferentes pa\u00edses, con el objetivo de discutir y establecer est\u00e1ndares para la preparaci\u00f3n de productos farmac\u00e9uticos.\n\n#### Temas Clave:\n- **Establecimiento de est\u00e1ndares**: La reuni\u00f3n se centr\u00f3 en la creaci\u00f3n de especificaciones para la preparaci\u00f3n de productos farmac\u00e9uticos.\n- **Colaboraci\u00f3n internacional**: Participaci\u00f3n de expertos de diversas naciones, reflejando un enfoque global en la regulaci\u00f3n de medicamentos.\n- **Roles y responsabilidades**: Se detallan los roles de los miembros y asesores temporales, destacando sus afiliaciones y contribuciones.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Organismo que convoc\u00f3 la reuni\u00f3n.\n- **Miembros de la Comisi\u00f3n**:\n  - **Profesor Ivan Addae-Mensah** (Ghana) - Chairperson\n  - **Profesor Saleh A. Bawazir** (Arabia Saudita) - Co-Chairperson\n  - **Mr Eshetu Wondemagegnehu Biwota** (Etiop\u00eda) - Co-Rapporteur\n  - **Dr Justina A. Molzon** (EE. UU.) - Co-Rapporteur\n  - Otros miembros de B\u00e9lgica, Sud\u00e1frica, Panam\u00e1, China, Jap\u00f3n, y Hungr\u00eda.\n- **Asesores Temporales**: Expertos de Jamaica, Brasil, Alemania, Dinamarca y Zimbabue.\n\nEste informe destaca la importancia de la cooperaci\u00f3n internacional en la regulaci\u00f3n de productos farmac\u00e9uticos y el establecimiento de est\u00e1ndares de calidad.", "excerpt_keywords": "Keywords: WHO, pharmaceutical regulation, international cooperation, quality assurance, expert meeting"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fd2485c8-6655-4995-aa39-2fdb789fd598", "node_type": "4", "metadata": {"page_label": "8", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ms Lynda Paleshnuik, Senior Quality Assessor, Val-des-Mont, QC, Canada\n\nMs Eija Pelkonen,\u00b2 Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n\nMs Marie-Louise Rabouhans, Chiswick, London, England\n\nDr Jean-Louis Robert, Head, Official Medicines Control Laboratory, Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n\nDr Saranjit Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India\n\nMr Deryck Smith, Principal Specialist, SSI, Cleanrooms Division, Gauteng, South Africa\n\nDr Angelika Spreitzhofer,\u00b2 AGES PharmMed GmbH, Vienna, Austria\n\n# Representation from United Nations offices\u00b3\n\n**United Nations Children\u2019s Fund (UNICEF)**  \nDr Peter Svarrer Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from specialized agencies and related organizations\u2074\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**  \nMs Joelle Daviaud, Senior QA Technical Officer, Pharmaceutical Management Unit  \nand Mr Raghu Kumar Krishna Swamy, Geneva, Switzerland\n\n**World Intellectual Property Organization (WIPO)**  \nMs Konji Sebati, Consultant, Department for Traditional Knowledge and Global Challenges  \nand Ms Maria Soledad Iglesias-Vega, Program Officer, Department of External Relations, Geneva, Switzerland\n\n**The World Bank**  \nDr Andreas Seiter, Senior Health Specialist \u2014 Pharmaceuticals, Health, Nutrition and Population, Washington, DC, USA\n\n**World Customs Organization (WCO)**  \nMr Alvaro Fernandez Acebes, Technical Officer, Tariff and Trade Affairs Directorate, Brussels, Belgium\n\n**World Trade Organization (WTO)**  \nMr Roger Kampf, Counsellor, Intellectual Property Division, Geneva, Switzerland\n\n# Representation from intergovernmental organizations\u2075\n\n**European Union (EU)**  \nMs Jinna Lee, Permanent Delegation of the European Union, Geneva, Switzerland\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria.  \n\u2075 Unable to attend: European Medicines Agency (EMA), London, England.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ae59bbcb2c662deee556e3ef1bf100885929ec6bfaa2d46a70f228655369767f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ms Lynda Paleshnuik, Senior Quality Assessor, Val-des-Mont, QC, Canada\n\nMs Eija Pelkonen,\u00b2 Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n\nMs Marie-Louise Rabouhans, Chiswick, London, England\n\nDr Jean-Louis Robert, Head, Official Medicines Control Laboratory, Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n\nDr Saranjit Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India\n\nMr Deryck Smith, Principal Specialist, SSI, Cleanrooms Division, Gauteng, South Africa\n\nDr Angelika Spreitzhofer,\u00b2 AGES PharmMed GmbH, Vienna, Austria\n\n# Representation from United Nations offices\u00b3\n\n**United Nations Children\u2019s Fund (UNICEF)**  \nDr Peter Svarrer Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from specialized agencies and related organizations\u2074\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**  \nMs Joelle Daviaud, Senior QA Technical Officer, Pharmaceutical Management Unit  \nand Mr Raghu Kumar Krishna Swamy, Geneva, Switzerland\n\n**World Intellectual Property Organization (WIPO)**  \nMs Konji Sebati, Consultant, Department for Traditional Knowledge and Global Challenges  \nand Ms Maria Soledad Iglesias-Vega, Program Officer, Department of External Relations, Geneva, Switzerland\n\n**The World Bank**  \nDr Andreas Seiter, Senior Health Specialist \u2014 Pharmaceuticals, Health, Nutrition and Population, Washington, DC, USA\n\n**World Customs Organization (WCO)**  \nMr Alvaro Fernandez Acebes, Technical Officer, Tariff and Trade Affairs Directorate, Brussels, Belgium\n\n**World Trade Organization (WTO)**  \nMr Roger Kampf, Counsellor, Intellectual Property Division, Geneva, Switzerland\n\n# Representation from intergovernmental organizations\u2075\n\n**European Union (EU)**  \nMs Jinna Lee, Permanent Delegation of the European Union, Geneva, Switzerland\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria.  \n\u2075 Unable to attend: European Medicines Agency (EMA), London, England.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2289, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f86065bd-66f5-40df-ae5e-68b8d956dda3": {"__data__": {"id_": "f86065bd-66f5-40df-ae5e-68b8d956dda3", "embedding": null, "metadata": {"page_label": "9", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Representation from Nongovernmental Organizations\n\n**Commonwealth Pharmacists Association (CPA)**  \nProfessor Douglas Oliver, Chairman, South Africa Pharmacology Society, North-West University, South Africa\n\n**European Chemical Industry Council (CEFIC)/APIC**  \nDr Boris Pimentel, Board Member, APIC, and Global Regulatory Affairs Manager, DSM Nutritional Products AG, Basel, Switzerland\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**  \nDr Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA  \nand Dr Rodney Horder, Consultant, Abbott Quality & Regulatory, Torquay, United Kingdom\n\n**International Generic Pharmaceutical Alliance (IGPA)**  \nDr Nicholas Cappuccino, General Partner, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n**International Pharmaceutical Excipients Council (IPEC)**  \nMrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n**International Pharmaceutical Federation (FIP)**  \nMr A.J.M. Hoek, General Secretary and CEO  \nand Mr Xuan Hao Chan, Manager, Professional and Scientific Affairs, The Hague, The Netherlands\n\n**World Self-Medication Industry (WSMI)**  \nDr David Webber, Director General, Ferney-Voltaire, France\n\n# Observers\n\n**Brazilian Health Surveillance Agency (ANVISA)**  \nMr Mateus R. Cerqueira, Specialist in Regulation and Health Surveillance, International Affairs Office, Brasilia, DF, Brazil\n\n**Pharmaceutical Inspection Co-operation Scheme (PIC/S)**  \nMs Helena Bai\u00e3o, First Deputy Chairperson, PIC/S, Inspection and Licensing Directorate, Inspection Department, National Authority of Medicines and Health Products, I.P., Lisbon, Portugal\n\n# Pharmacopoeias\n\n**British Pharmacopoeia Commission**  \nMr Richard Turner, Secretariat, London, England\n\n----\n\n6 Unable to attend: International Society for Pharmaceutical Engineering (ISPE), Tampa, Florida, USA.  \n7 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacope\u00eda Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; Pharmacopoeia of the Republic of Korea, Seoul, Republic of Korea; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y presenta una representaci\u00f3n de diversas organizaciones no gubernamentales (ONG) relacionadas con la farmacolog\u00eda y la industria farmac\u00e9utica. Se mencionan representantes de varias organizaciones, como la Commonwealth Pharmacists Association, la International Federation of Pharmaceutical Manufacturers and Associations, y la World Self-Medication Industry, entre otras. Tambi\u00e9n se incluyen observadores de agencias reguladoras como ANVISA y PIC/S, as\u00ed como representantes de diversas farmacopeas. Adem\u00e1s, se se\u00f1ala que algunas organizaciones no pudieron asistir a la reuni\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son los representantes de la International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) y cu\u00e1les son sus roles espec\u00edficos?**\n   - Respuesta: Los representantes de la IFPMA son el Dr. Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, y el Dr. Rodney Horder, Consultant, Abbott Quality & Regulatory.\n\n2. **\u00bfQu\u00e9 organizaciones no gubernamentales est\u00e1n representadas en el documento y qu\u00e9 pa\u00edses representan sus miembros?**\n   - Respuesta: Las organizaciones no gubernamentales representadas incluyen la Commonwealth Pharmacists Association (Sud\u00e1frica), el European Chemical Industry Council (Suiza), la International Generic Pharmaceutical Alliance (EE. UU.), la International Pharmaceutical Excipients Council (B\u00e9lgica), la International Pharmaceutical Federation (Pa\u00edses Bajos), y la World Self-Medication Industry (Francia).\n\n3. **\u00bfQu\u00e9 farmacopeas y organizaciones no pudieron asistir a la reuni\u00f3n mencionada en el documento?**\n   - Respuesta: Las organizaciones que no pudieron asistir incluyen la International Society for Pharmaceutical Engineering (ISPE) de EE. UU., as\u00ed como varias farmacopeas como la Farmacopea Argentina, la Farmacope\u00eda Brasileira, la Pharmacopoeia of the People's Republic of China, la Indian Pharmacopoeia, la Japanese Pharmacopoeia, la Pharmacopoeia of the Republic of Korea, y la State Pharmacopoeia of the Russian Federation.\n\n### Resumen de Nivel Superior\n\nEl documento proporciona una visi\u00f3n general de la participaci\u00f3n de diversas organizaciones no gubernamentales y agencias reguladoras en el \u00e1mbito farmac\u00e9utico, destacando sus representantes y roles. Tambi\u00e9n menciona la ausencia de ciertas organizaciones y farmacopeas, lo que puede indicar la diversidad y la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y la calidad de los productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de participantes en una reuni\u00f3n relacionada con la calidad y regulaci\u00f3n de medicamentos, en el marco de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961). Los asistentes incluyen representantes de diversas organizaciones, agencias de la ONU y organismos intergubernamentales, destacando sus nombres, cargos y ubicaciones.\n\n### Temas Clave:\n1. **Calidad y Regulaci\u00f3n de Medicamentos**: La reuni\u00f3n se centra en la discusi\u00f3n de temas relacionados con la calidad de los medicamentos y su regulaci\u00f3n a nivel internacional.\n2. **Colaboraci\u00f3n Internacional**: Se evidencia la participaci\u00f3n de expertos de diferentes pa\u00edses y organizaciones, lo que sugiere un enfoque en la cooperaci\u00f3n internacional en salud p\u00fablica.\n\n### Entidades Representadas:\n- **Organizaciones de la ONU**: \n  - UNICEF (Dr. Peter Svarrer Jakobsen)\n  \n- **Agencias Especializadas y Organizaciones Relacionadas**:\n  - The Global Fund to Fight AIDS, Tuberculosis and Malaria (Ms. Joelle Daviaud y Mr. Raghu Kumar Krishna Swamy)\n  - World Intellectual Property Organization (WIPO) (Ms. Konji Sebati y Ms. Maria Soledad Iglesias-Vega)\n  - The World Bank (Dr. Andreas Seiter)\n  - World Customs Organization (WCO) (Mr. Alvaro Fernandez Acebes)\n  - World Trade Organization (WTO) (Mr. Roger Kampf)\n\n- **Organizaciones Intergubernamentales**:\n  - Uni\u00f3n Europea (EU) (Ms. Jinna Lee)\n\n### Ausencias Notables:\nSe menciona que no pudieron asistir representantes de organizaciones clave como el Programa de las Naciones Unidas para el Desarrollo (PNUD) y la Agencia Europea de Medicamentos (EMA), lo que podr\u00eda tener implicaciones en las decisiones y recomendaciones de la reuni\u00f3n. \n\nEn resumen, la secci\u00f3n destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la diversidad de expertos presentes, as\u00ed como las ausencias que podr\u00edan afectar el desarrollo de las discusiones.", "excerpt_keywords": "Keywords: pharmaceutical regulation, nongovernmental organizations, international collaboration, pharmacopoeias, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5ed767ab-bedc-4e23-92fc-fca7dd7cbabb", "node_type": "4", "metadata": {"page_label": "9", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Representation from Nongovernmental Organizations\n\n**Commonwealth Pharmacists Association (CPA)**  \nProfessor Douglas Oliver, Chairman, South Africa Pharmacology Society, North-West University, South Africa\n\n**European Chemical Industry Council (CEFIC)/APIC**  \nDr Boris Pimentel, Board Member, APIC, and Global Regulatory Affairs Manager, DSM Nutritional Products AG, Basel, Switzerland\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**  \nDr Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA  \nand Dr Rodney Horder, Consultant, Abbott Quality & Regulatory, Torquay, United Kingdom\n\n**International Generic Pharmaceutical Alliance (IGPA)**  \nDr Nicholas Cappuccino, General Partner, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n**International Pharmaceutical Excipients Council (IPEC)**  \nMrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n**International Pharmaceutical Federation (FIP)**  \nMr A.J.M. Hoek, General Secretary and CEO  \nand Mr Xuan Hao Chan, Manager, Professional and Scientific Affairs, The Hague, The Netherlands\n\n**World Self-Medication Industry (WSMI)**  \nDr David Webber, Director General, Ferney-Voltaire, France\n\n# Observers\n\n**Brazilian Health Surveillance Agency (ANVISA)**  \nMr Mateus R. Cerqueira, Specialist in Regulation and Health Surveillance, International Affairs Office, Brasilia, DF, Brazil\n\n**Pharmaceutical Inspection Co-operation Scheme (PIC/S)**  \nMs Helena Bai\u00e3o, First Deputy Chairperson, PIC/S, Inspection and Licensing Directorate, Inspection Department, National Authority of Medicines and Health Products, I.P., Lisbon, Portugal\n\n# Pharmacopoeias\n\n**British Pharmacopoeia Commission**  \nMr Richard Turner, Secretariat, London, England\n\n----\n\n6 Unable to attend: International Society for Pharmaceutical Engineering (ISPE), Tampa, Florida, USA.  \n7 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacope\u00eda Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; Pharmacopoeia of the Republic of Korea, Seoul, Republic of Korea; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "39780496537ab3c88d0575d33f2d47734ed062f01dff4df8418ddb37e6cd227d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Representation from Nongovernmental Organizations\n\n**Commonwealth Pharmacists Association (CPA)**  \nProfessor Douglas Oliver, Chairman, South Africa Pharmacology Society, North-West University, South Africa\n\n**European Chemical Industry Council (CEFIC)/APIC**  \nDr Boris Pimentel, Board Member, APIC, and Global Regulatory Affairs Manager, DSM Nutritional Products AG, Basel, Switzerland\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**  \nDr Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA  \nand Dr Rodney Horder, Consultant, Abbott Quality & Regulatory, Torquay, United Kingdom\n\n**International Generic Pharmaceutical Alliance (IGPA)**  \nDr Nicholas Cappuccino, General Partner, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n**International Pharmaceutical Excipients Council (IPEC)**  \nMrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n**International Pharmaceutical Federation (FIP)**  \nMr A.J.M. Hoek, General Secretary and CEO  \nand Mr Xuan Hao Chan, Manager, Professional and Scientific Affairs, The Hague, The Netherlands\n\n**World Self-Medication Industry (WSMI)**  \nDr David Webber, Director General, Ferney-Voltaire, France\n\n# Observers\n\n**Brazilian Health Surveillance Agency (ANVISA)**  \nMr Mateus R. Cerqueira, Specialist in Regulation and Health Surveillance, International Affairs Office, Brasilia, DF, Brazil\n\n**Pharmaceutical Inspection Co-operation Scheme (PIC/S)**  \nMs Helena Bai\u00e3o, First Deputy Chairperson, PIC/S, Inspection and Licensing Directorate, Inspection Department, National Authority of Medicines and Health Products, I.P., Lisbon, Portugal\n\n# Pharmacopoeias\n\n**British Pharmacopoeia Commission**  \nMr Richard Turner, Secretariat, London, England\n\n----\n\n6 Unable to attend: International Society for Pharmaceutical Engineering (ISPE), Tampa, Florida, USA.  \n7 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacope\u00eda Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; Pharmacopoeia of the Republic of Korea, Seoul, Republic of Korea; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2346, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8d980cc6-49e5-4aea-bdfb-290f64850447": {"__data__": {"id_": "8d980cc6-49e5-4aea-bdfb-290f64850447", "embedding": null, "metadata": {"page_label": "10", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# European Pharmacopoeia<sup>8</sup>\nCouncil of Europe, Strasbourg, France\n\n# United States Pharmacopeia\nDr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n- Regional Office for Africa, Brazzaville, Republic of Congo\n- Regional Office for the Americas, Pan American Health Organization, Washington, DC, United States of America\n- Regional Office for the Eastern Mediterranean, Cairo, Egypt\n- Regional Office for Europe, Copenhagen, Denmark\n- Regional Office for South-East Asia, New Delhi, India\n- Regional Office for the Western Pacific, Manila, Philippines\n\n## WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services,<sup>9</sup> WHO, Geneva, Switzerland\n- Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n- Dr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland *(Secretary)*\n- Ms C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr H. Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Chemwolo, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Ms S.C. Croft, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Fake, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr A. Gould, Manager, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr J.R. Kuwana, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\n----\n\n<sup>8</sup> See Council of Europe.  \n<sup>9</sup> Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye la representaci\u00f3n de diversas oficinas regionales de la OMS y miembros del secretariado. Se menciona la participaci\u00f3n de la Farmacopea Europea y la Farmacopea de los Estados Unidos, as\u00ed como los nombres y cargos de varios funcionarios de la OMS que est\u00e1n involucrados en programas relacionados con la calidad y seguridad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQui\u00e9nes son los representantes de las oficinas regionales de la OMS mencionados en el informe y cu\u00e1les son sus ubicaciones?**\n   - Respuesta: Los representantes de las oficinas regionales de la OMS son: \n     - Oficina Regional para \u00c1frica, Brazzaville, Rep\u00fablica del Congo\n     - Oficina Regional para las Am\u00e9ricas, Washington, DC, Estados Unidos\n     - Oficina Regional para el Mediterr\u00e1neo Oriental, El Cairo, Egipto\n     - Oficina Regional para Europa, Copenhague, Dinamarca\n     - Oficina Regional para el Sudeste Asi\u00e1tico, Nueva Delhi, India\n     - Oficina Regional para el Pac\u00edfico Occidental, Manila, Filipinas.\n\n2. **\u00bfQu\u00e9 roles desempe\u00f1an los miembros del secretariado de la OMS mencionados en el documento?**\n   - Respuesta: Los roles incluyen:\n     - Dr. C.F. Etienne: Asistente del Director General, Sistemas de Salud y Servicios.\n     - Dr. H.V. Hogerzeil: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n     - Dr. L. R\u00e4go: Coordinador de Aseguramiento de Calidad y Seguridad: Medicamentos.\n     - Dr. S. Kopp: Gerente del Programa de Aseguramiento de Calidad de Medicamentos (Secretario).\n     - Otros miembros est\u00e1n involucrados en programas de calidad y precalificaci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre la Farmacopea Europea y la Farmacopea de los Estados Unidos en el contexto del informe?**\n   - Respuesta: Se menciona que la Farmacopea Europea es publicada por el Consejo de Europa en Estrasburgo, Francia, y que la Farmacopea de los Estados Unidos est\u00e1 representada por la Dra. Karen A. Russo, Vicepresidenta de la Divisi\u00f3n de Normas Documentarias de Peque\u00f1as Mol\u00e9culas en Rockville, MD, EE. UU.", "prev_section_summary": "La secci\u00f3n proporciona una representaci\u00f3n de diversas organizaciones no gubernamentales (ONG) y agencias reguladoras en el \u00e1mbito farmac\u00e9utico, destacando sus representantes y roles. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Participaci\u00f3n de ONG**: Se presentan representantes de varias ONG relacionadas con la farmacolog\u00eda y la industria farmac\u00e9utica.\n2. **Observadores de Agencias Reguladoras**: Se mencionan representantes de agencias reguladoras que observan las actividades de las ONG.\n3. **Farmacopeas**: Se incluye informaci\u00f3n sobre farmacopeas y la ausencia de ciertas organizaciones en la reuni\u00f3n.\n\n### Entidades Mencionadas:\n- **ONG Representadas**:\n  - **Commonwealth Pharmacists Association (CPA)**: Representada por el Profesor Douglas Oliver (Sud\u00e1frica).\n  - **European Chemical Industry Council (CEFIC)/APIC**: Representado por el Dr. Boris Pimentel (Suiza).\n  - **International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**: Representada por el Dr. Michael G. Beatrice y el Dr. Rodney Horder (EE. UU. y Reino Unido).\n  - **International Generic Pharmaceutical Alliance (IGPA)**: Representado por el Dr. Nicholas Cappuccino (EE. UU.).\n  - **International Pharmaceutical Excipients Council (IPEC)**: Representada por la Sra. Beam Suffolk (B\u00e9lgica).\n  - **International Pharmaceutical Federation (FIP)**: Representada por el Sr. A.J.M. Hoek y el Sr. Xuan Hao Chan (Pa\u00edses Bajos).\n  - **World Self-Medication Industry (WSMI)**: Representado por el Dr. David Webber (Francia).\n\n- **Observadores**:\n  - **Brazilian Health Surveillance Agency (ANVISA)**: Representado por el Sr. Mateus R. Cerqueira (Brasil).\n  - **Pharmaceutical Inspection Co-operation Scheme (PIC/S)**: Representada por la Sra. Helena Bai\u00e3o (Portugal).\n\n- **Farmacopeas que no asistieron**:\n  - International Society for Pharmaceutical Engineering (ISPE) (EE. UU.).\n  - Farmacopea Argentina (Argentina).\n  - Farmacope\u00eda Brasileira (Brasil).\n  - Pharmacopoeia of the People's Republic of China (China).\n  - Indian Pharmacopoeia (India).\n  - Japanese Pharmacopoeia (Jap\u00f3n).\n  - Pharmacopoeia of the Republic of Korea (Corea del Sur).\n  - State Pharmacopoeia of the Russian Federation (Rusia).\n\nEste resumen destaca la diversidad de la participaci\u00f3n internacional en la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos, as\u00ed como la importancia de la colaboraci\u00f3n entre diferentes entidades.", "excerpt_keywords": "Keywords: WHO, Pharmacopoeia, Medicines Quality Assurance, Regional Offices, Health Systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8f891e8-8c19-415a-af50-d6c4dda34d92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# European Pharmacopoeia<sup>8</sup>\nCouncil of Europe, Strasbourg, France\n\n# United States Pharmacopeia\nDr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n- Regional Office for Africa, Brazzaville, Republic of Congo\n- Regional Office for the Americas, Pan American Health Organization, Washington, DC, United States of America\n- Regional Office for the Eastern Mediterranean, Cairo, Egypt\n- Regional Office for Europe, Copenhagen, Denmark\n- Regional Office for South-East Asia, New Delhi, India\n- Regional Office for the Western Pacific, Manila, Philippines\n\n## WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services,<sup>9</sup> WHO, Geneva, Switzerland\n- Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n- Dr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland *(Secretary)*\n- Ms C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr H. Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Chemwolo, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Ms S.C. Croft, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Fake, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr A. Gould, Manager, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr J.R. Kuwana, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\n----\n\n<sup>8</sup> See Council of Europe.  \n<sup>9</sup> Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "326024fa23c2ac55a271824656032b808af652e8818a7f21225b769a6a4899f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# European Pharmacopoeia<sup>8</sup>\nCouncil of Europe, Strasbourg, France\n\n# United States Pharmacopeia\nDr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n- Regional Office for Africa, Brazzaville, Republic of Congo\n- Regional Office for the Americas, Pan American Health Organization, Washington, DC, United States of America\n- Regional Office for the Eastern Mediterranean, Cairo, Egypt\n- Regional Office for Europe, Copenhagen, Denmark\n- Regional Office for South-East Asia, New Delhi, India\n- Regional Office for the Western Pacific, Manila, Philippines\n\n## WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services,<sup>9</sup> WHO, Geneva, Switzerland\n- Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n- Dr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland *(Secretary)*\n- Ms C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr H. Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Chemwolo, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Ms S.C. Croft, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Fake, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr A. Gould, Manager, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr J.R. Kuwana, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\n----\n\n<sup>8</sup> See Council of Europe.  \n<sup>9</sup> Unable to attend.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2210, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1c6b71ab-1bbe-498b-b331-3c0f4c1c4bf2": {"__data__": {"id_": "1c6b71ab-1bbe-498b-b331-3c0f4c1c4bf2", "embedding": null, "metadata": {"page_label": "11", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Mr D. Mubangizi, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr J. Sabartova, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Smid, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Stahl, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs I. Streipa, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A.J. van Zyl, Head, Inspections, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs Hua Yin, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nDr G.B. Forte, Coordinator, Medicines Programme Coordination, WHO, Geneva, Switzerland\n\nDr S. Hill, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr R.O. Laing, Medicines Information and Evidence, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr K. Weerasuriya, Medicines Access and Rational Use, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". En \u00e9l se mencionan varios profesionales que trabajan en el Programa de Precalificaci\u00f3n de Medicamentos y otros programas relacionados con la calidad, seguridad y acceso a los medicamentos. Estos individuos desempe\u00f1an roles clave en la regulaci\u00f3n y evaluaci\u00f3n de medicamentos a nivel internacional.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de Dr. A.J. van Zyl dentro del Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: Dr. A.J. van Zyl es el Jefe de Inspecciones en el Programa de Precalificaci\u00f3n de Medicamentos, lo que implica que supervisa las inspecciones relacionadas con la calidad y seguridad de los medicamentos.\n\n2. **\u00bfQu\u00e9 programas adicionales, adem\u00e1s del Programa de Precalificaci\u00f3n de Medicamentos, est\u00e1n representados por los profesionales mencionados en el documento?**\n   - Respuesta: Adem\u00e1s del Programa de Precalificaci\u00f3n de Medicamentos, se mencionan el Programa de Soporte Regulatorio de Medicamentos, el Programa de Coordinaci\u00f3n de Medicamentos, y el \u00e1rea de Acceso y Uso Racional de Medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de experiencia o enfoque tiene la Sra. Hua Yin en el contexto de la OMS?**\n   - Respuesta: La Sra. Hua Yin trabaja en el Programa de Precalificaci\u00f3n de Medicamentos, lo que sugiere que su enfoque est\u00e1 relacionado con la evaluaci\u00f3n y aseguramiento de la calidad y seguridad de los medicamentos a nivel internacional, aunque el documento no especifica su rol exacto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que destaca la colaboraci\u00f3n y representaci\u00f3n de diversas entidades en el \u00e1mbito de la calidad y seguridad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Farmacopeas**:\n   - **Farmacopea Europea**: Publicada por el Consejo de Europa, ubicada en Estrasburgo, Francia.\n   - **Farmacopea de los Estados Unidos**: Representada por la Dra. Karen A. Russo, Vicepresidenta de la Divisi\u00f3n de Normas Documentarias de Peque\u00f1as Mol\u00e9culas, Rockville, MD, EE. UU.\n\n2. **Representaci\u00f3n de Oficinas Regionales de la OMS**:\n   - **Oficina Regional para \u00c1frica**: Brazzaville, Rep\u00fablica del Congo.\n   - **Oficina Regional para las Am\u00e9ricas**: Washington, DC, Estados Unidos.\n   - **Oficina Regional para el Mediterr\u00e1neo Oriental**: El Cairo, Egipto.\n   - **Oficina Regional para Europa**: Copenhague, Dinamarca.\n   - **Oficina Regional para el Sudeste Asi\u00e1tico**: Nueva Delhi, India.\n   - **Oficina Regional para el Pac\u00edfico Occidental**: Manila, Filipinas.\n\n3. **Secretariado de la OMS**:\n   - **Dr. C.F. Etienne**: Asistente del Director General, Sistemas de Salud y Servicios.\n   - **Dr. H.V. Hogerzeil**: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n   - **Dr. L. R\u00e4go**: Coordinador de Aseguramiento de Calidad y Seguridad: Medicamentos.\n   - **Dr. S. Kopp**: Gerente del Programa de Aseguramiento de Calidad de Medicamentos (Secretario).\n   - Otros miembros involucrados en programas de calidad y precalificaci\u00f3n de medicamentos.\n\nEste informe resalta la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, as\u00ed como la participaci\u00f3n activa de diversas oficinas y expertos en el campo.", "excerpt_keywords": "Keywords: WHO, Prequalification, Medicines, Quality Assurance, Safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3dd9cfa2-f03d-4d4c-bd2c-67586ce1fb35", "node_type": "4", "metadata": {"page_label": "11", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Mr D. Mubangizi, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr J. Sabartova, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Smid, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Stahl, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs I. Streipa, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A.J. van Zyl, Head, Inspections, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs Hua Yin, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nDr G.B. Forte, Coordinator, Medicines Programme Coordination, WHO, Geneva, Switzerland\n\nDr S. Hill, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr R.O. Laing, Medicines Information and Evidence, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr K. Weerasuriya, Medicines Access and Rational Use, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "25a56929c53c207fb2adea2c8ac67dc6c7ea525dada789344a72b781e867d8c1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Mr D. Mubangizi, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr J. Sabartova, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Smid, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Stahl, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs I. Streipa, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A.J. van Zyl, Head, Inspections, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs Hua Yin, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nDr G.B. Forte, Coordinator, Medicines Programme Coordination, WHO, Geneva, Switzerland\n\nDr S. Hill, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr R.O. Laing, Medicines Information and Evidence, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr K. Weerasuriya, Medicines Access and Rational Use, WHO, Geneva, Switzerland", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1561, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a37ff2e6-b21b-487a-b9bf-b84829cea23b": {"__data__": {"id_": "a37ff2e6-b21b-487a-b9bf-b84829cea23b", "embedding": null, "metadata": {"page_label": "12", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers and temporary advisers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\n**Dr Nilka Guerrero Rivas:** Her Institute at the University Octavio M\u00e9ndez Pereira in Panama performs, as part of its public health mandate, as reference laboratory for quality control of pharmaceutical products, fixed-fee quality control services for local manufacturers, including Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 and Laboratorios Rigar/Panam\u00e1.\n\n**Professor Henning Kristensen:** His wife is a former employee of Novo Nordisk and holds approximately US$ 20,000 in stocks in this company. The WHO Expert Committee on Specifications for Pharmaceutical Preparations does not consider any of the products manufactured by Novo Nordisk.\n\nProfessor I. Addae-Mensah, Professor S. Bawazir, Mr E. Wondemagegnehu Biwota, Dr L. Cargill, Mr J.-M. Caudron, Mr A.C. da Costa Bezerra, Professor T.G. Dekker, Professor J. Hoogmartens, Dr T. Kawanishi, Dr K. Keller, Dr G.N. Mahlangu, Dr J.A. Molzon, Professor T.L. Pa\u00e1l, Dr L. Paleshnuik, Ms M.-L. Rabouhans, Dr J.-L. Robert, Dr S. Singh and Mr D. Smith reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las declaraciones de inter\u00e9s de los miembros y asesores temporales del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas. Se mencionan dos casos espec\u00edficos de conflictos de inter\u00e9s: uno relacionado con la Dra. Nilka Guerrero Rivas, quien trabaja en un laboratorio de control de calidad en Panam\u00e1, y otro con el Profesor Henning Kristensen, cuya esposa tiene acciones en Novo Nordisk. Adem\u00e1s, se indica que otros miembros del comit\u00e9 no reportaron conflictos de inter\u00e9s.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de servicios ofrece el Instituto de la Dra. Nilka Guerrero Rivas y a qui\u00e9nes est\u00e1n dirigidos?**\n   - Respuesta: El Instituto de la Dra. Nilka Guerrero Rivas ofrece servicios de control de calidad de productos farmac\u00e9uticos y servicios de control de calidad a tarifa fija para fabricantes locales, incluyendo Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 y Laboratorios Rigar/Panam\u00e1.\n\n2. **\u00bfCu\u00e1l es la relaci\u00f3n del Profesor Henning Kristensen con Novo Nordisk y c\u00f3mo afecta esto a su participaci\u00f3n en el comit\u00e9?**\n   - Respuesta: La esposa del Profesor Henning Kristensen es una ex-empleada de Novo Nordisk y posee aproximadamente US$ 20,000 en acciones de la compa\u00f1\u00eda. Sin embargo, el Comit\u00e9 de Expertos de la OMS no considera ning\u00fan producto fabricado por Novo Nordisk, lo que mitiga el posible conflicto de inter\u00e9s.\n\n3. **\u00bfQu\u00e9 medidas se toman en el Comit\u00e9 de Expertos de la OMS para asegurar la transparencia en cuanto a los conflictos de inter\u00e9s?**\n   - Respuesta: Los miembros y asesores del Comit\u00e9 de Expertos deben declarar cualquier conflicto de inter\u00e9s, como se evidencia en las declaraciones presentadas por la Dra. Nilka Guerrero Rivas y el Profesor Henning Kristensen, as\u00ed como la confirmaci\u00f3n de que otros miembros no tienen conflictos de inter\u00e9s. Esto ayuda a mantener la transparencia y la integridad del proceso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado se centra en el informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Precalificaci\u00f3n de Medicamentos**: El documento destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos, que se enfoca en asegurar la calidad y seguridad de los medicamentos a nivel internacional.\n2. **Calidad y Seguridad de Medicamentos**: Se enfatiza la necesidad de garantizar que los medicamentos cumplan con est\u00e1ndares internacionales de calidad y seguridad.\n3. **Acceso y Uso Racional de Medicamentos**: Se menciona la importancia de facilitar el acceso a medicamentos y promover su uso racional en la poblaci\u00f3n.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n responsable de la salud p\u00fablica internacional.\n- **Profesionales del Programa de Precalificaci\u00f3n de Medicamentos**:\n  - Mr. D. Mubangizi\n  - Dr. J. Sabartova\n  - Dr. M. Smid\n  - Dr. M. Stahl\n  - Mrs. I. Streipa\n  - Dr. A.J. van Zyl (Jefe de Inspecciones)\n  - Mr. W.Z. Worku\n  - Mrs. Hua Yin\n- **Otros Programas y Coordinadores**:\n  - Dr. S. Azatyan (Programa de Soporte Regulatorio de Medicamentos)\n  - Dr. G.B. Forte (Coordinador, Programa de Coordinaci\u00f3n de Medicamentos)\n  - Dr. S. Hill, Dr. C. Ondari, Dr. K. Weerasuriya (Acceso y Uso Racional de Medicamentos)\n  - Dr. R.O. Laing (Informaci\u00f3n y Evidencia sobre Medicamentos)\n  - Ms. Y. Maruyama (Medicina Tradicional)\n\nEste resumen destaca la estructura del documento y los roles de los profesionales involucrados en la regulaci\u00f3n y evaluaci\u00f3n de medicamentos, as\u00ed como la misi\u00f3n de la OMS en la promoci\u00f3n de la salud global.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, conflict of interest, quality control, expert committee"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3e87e20c-d4a0-4c89-a29a-8a5d0760116e", "node_type": "4", "metadata": {"page_label": "12", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers and temporary advisers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\n**Dr Nilka Guerrero Rivas:** Her Institute at the University Octavio M\u00e9ndez Pereira in Panama performs, as part of its public health mandate, as reference laboratory for quality control of pharmaceutical products, fixed-fee quality control services for local manufacturers, including Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 and Laboratorios Rigar/Panam\u00e1.\n\n**Professor Henning Kristensen:** His wife is a former employee of Novo Nordisk and holds approximately US$ 20,000 in stocks in this company. The WHO Expert Committee on Specifications for Pharmaceutical Preparations does not consider any of the products manufactured by Novo Nordisk.\n\nProfessor I. Addae-Mensah, Professor S. Bawazir, Mr E. Wondemagegnehu Biwota, Dr L. Cargill, Mr J.-M. Caudron, Mr A.C. da Costa Bezerra, Professor T.G. Dekker, Professor J. Hoogmartens, Dr T. Kawanishi, Dr K. Keller, Dr G.N. Mahlangu, Dr J.A. Molzon, Professor T.L. Pa\u00e1l, Dr L. Paleshnuik, Ms M.-L. Rabouhans, Dr J.-L. Robert, Dr S. Singh and Mr D. Smith reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "98d120e214bc3506ce92921358764b5678653464cda775334ee43c7ba4add705", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Declarations of interest\n\nMembers and temporary advisers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\n**Dr Nilka Guerrero Rivas:** Her Institute at the University Octavio M\u00e9ndez Pereira in Panama performs, as part of its public health mandate, as reference laboratory for quality control of pharmaceutical products, fixed-fee quality control services for local manufacturers, including Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 and Laboratorios Rigar/Panam\u00e1.\n\n**Professor Henning Kristensen:** His wife is a former employee of Novo Nordisk and holds approximately US$ 20,000 in stocks in this company. The WHO Expert Committee on Specifications for Pharmaceutical Preparations does not consider any of the products manufactured by Novo Nordisk.\n\nProfessor I. Addae-Mensah, Professor S. Bawazir, Mr E. Wondemagegnehu Biwota, Dr L. Cargill, Mr J.-M. Caudron, Mr A.C. da Costa Bezerra, Professor T.G. Dekker, Professor J. Hoogmartens, Dr T. Kawanishi, Dr K. Keller, Dr G.N. Mahlangu, Dr J.A. Molzon, Professor T.L. Pa\u00e1l, Dr L. Paleshnuik, Ms M.-L. Rabouhans, Dr J.-L. Robert, Dr S. Singh and Mr D. Smith reported no conflict of interest.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1215, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "139e3cf3-b165-4a36-910a-0c528b03bb20": {"__data__": {"id_": "139e3cf3-b165-4a36-910a-0c528b03bb20", "embedding": null, "metadata": {"page_label": "13", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 18 to 22 October 2010. Dr Hans V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies, opened the meeting, and on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fifth meeting of the Expert Committee. He expressed his appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines and for its major contributions with technical expertise as well as with practical laboratory studies.\n\nDr Hogerzeil welcomed the members of the Committee and temporary advisers; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Industrial Development Organization, World Intellectual Property Organization, the World Bank, World Customs Organization, World Trade Organization, European Union, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, Commonwealth Pharmacists Association, European Chemical Industry Council/APIC, International Federation of Pharmaceutical Manufacturers Association, International Generic Pharmaceutical Alliance, International Pharmaceutical Federation and the World Self-Medication Industry; representatives of the Pharmacopoeias of Great Britain and of the United States of America; representatives from WHO Collaborating Centres in Hungary and South Africa; and observers from the Brazilian Health Surveillance Agency and from the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nDr C.F. Etienne, Assistant Director-General for the Health Systems and Services Cluster, who was unable to attend the meeting, welcomed the Expert Committee with a written speech and acknowledged the elected Chairs, i.e. Professors I. Addae-Mensah (Chairperson) and S. Bawazir (Co-Chairperson), and the Co-Rapporteurs, Dr J.A. Molzon and Mr E. Wondemagegnehu Biwota.\n\nShe stated that the open session of the forty-fifth WHO Expert Committee on Specifications for Pharmaceutical Preparations had been organized in order to respond to the interest raised by Member States during the World Health Assembly held in May 2010 on the quality of medicines. The aim was to provide more information on this Expert Committee in an open and transparent manner. All the materials relating to the Expert Committee, both concerning the past and ongoing work, were to be found on their web sites. The Expert Committee members and the WHO Secretariat were here to explain the work related to the Committee and to respond to any questions.\n\nPoor quality of medicines and \u201cspurious/falsely-labelled/falsified/counterfeit medicines\u201d are unfortunately a major threat to public health.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas se reuni\u00f3 en Ginebra del 18 al 22 de octubre de 2010. Durante la reuni\u00f3n, se discuti\u00f3 la calidad de los medicamentos, un tema de gran preocupaci\u00f3n para los Estados Miembros, especialmente tras la Asamblea Mundial de la Salud de mayo de 2010. Se destac\u00f3 la importancia de la experiencia del Comit\u00e9 en el aseguramiento de la calidad de los medicamentos y se mencionaron diversas organizaciones y representantes que participaron en la reuni\u00f3n. La calidad deficiente de los medicamentos y la presencia de medicamentos falsificados son amenazas significativas para la salud p\u00fablica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales objetivos de la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2010?**\n   - La reuni\u00f3n se organiz\u00f3 para abordar el inter\u00e9s de los Estados Miembros sobre la calidad de los medicamentos, proporcionando informaci\u00f3n sobre el trabajo del Comit\u00e9 de manera abierta y transparente.\n\n2. **\u00bfQu\u00e9 organizaciones y representantes estuvieron presentes en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Estuvieron presentes representantes de UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, la Organizaci\u00f3n Mundial de la Propiedad Intelectual, el Banco Mundial, la Organizaci\u00f3n Mundial del Comercio, entre otros.\n\n3. **\u00bfQu\u00e9 amenazas a la salud p\u00fablica se mencionaron en el contexto de la calidad de los medicamentos?**\n   - Se mencion\u00f3 que la calidad deficiente de los medicamentos y la existencia de \"medicamentos espurios/falsamente etiquetados/falsificados/contrabandeados\" son amenazas importantes para la salud p\u00fablica.\n\n### Resumen de Nivel Superior\n\nLa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2010 se centr\u00f3 en la calidad de los medicamentos, un tema cr\u00edtico para la salud p\u00fablica. Se destac\u00f3 la participaci\u00f3n de diversas organizaciones internacionales y se abordaron las preocupaciones sobre los medicamentos falsificados y de baja calidad. La reuni\u00f3n busc\u00f3 proporcionar claridad y transparencia sobre el trabajo del Comit\u00e9 y su relevancia en el contexto global de la salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Declaraciones de Inter\u00e9s**: La secci\u00f3n se centra en las declaraciones de inter\u00e9s de los miembros y asesores temporales del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **Dr. Nilka Guerrero Rivas**:\n   - **Instituci\u00f3n**: Universidad Octavio M\u00e9ndez Pereira, Panam\u00e1.\n   - **Servicios**: Control de calidad de productos farmac\u00e9uticos y servicios de control de calidad a tarifa fija para fabricantes locales.\n   - **Clientes**: Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 y Laboratorios Rigar/Panam\u00e1.\n\n3. **Profesor Henning Kristensen**:\n   - **Relaci\u00f3n con Novo Nordisk**: Su esposa es ex-empleada de la compa\u00f1\u00eda y posee acciones valoradas en aproximadamente US$ 20,000.\n   - **Impacto en el Comit\u00e9**: El Comit\u00e9 no considera productos de Novo Nordisk, lo que reduce el riesgo de conflicto de inter\u00e9s.\n\n4. **Otros Miembros**: Un grupo de miembros del comit\u00e9, incluyendo a profesores y otros profesionales, no reportaron conflictos de inter\u00e9s.\n\n5. **Transparencia**: Se enfatiza la importancia de declarar conflictos de inter\u00e9s para mantener la integridad y transparencia en el proceso del comit\u00e9.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality assurance, counterfeit medicines, public health"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8bfc126-4867-494f-8b13-5cf80484ad1d", "node_type": "4", "metadata": {"page_label": "13", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 18 to 22 October 2010. Dr Hans V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies, opened the meeting, and on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fifth meeting of the Expert Committee. He expressed his appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines and for its major contributions with technical expertise as well as with practical laboratory studies.\n\nDr Hogerzeil welcomed the members of the Committee and temporary advisers; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Industrial Development Organization, World Intellectual Property Organization, the World Bank, World Customs Organization, World Trade Organization, European Union, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, Commonwealth Pharmacists Association, European Chemical Industry Council/APIC, International Federation of Pharmaceutical Manufacturers Association, International Generic Pharmaceutical Alliance, International Pharmaceutical Federation and the World Self-Medication Industry; representatives of the Pharmacopoeias of Great Britain and of the United States of America; representatives from WHO Collaborating Centres in Hungary and South Africa; and observers from the Brazilian Health Surveillance Agency and from the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nDr C.F. Etienne, Assistant Director-General for the Health Systems and Services Cluster, who was unable to attend the meeting, welcomed the Expert Committee with a written speech and acknowledged the elected Chairs, i.e. Professors I. Addae-Mensah (Chairperson) and S. Bawazir (Co-Chairperson), and the Co-Rapporteurs, Dr J.A. Molzon and Mr E. Wondemagegnehu Biwota.\n\nShe stated that the open session of the forty-fifth WHO Expert Committee on Specifications for Pharmaceutical Preparations had been organized in order to respond to the interest raised by Member States during the World Health Assembly held in May 2010 on the quality of medicines. The aim was to provide more information on this Expert Committee in an open and transparent manner. All the materials relating to the Expert Committee, both concerning the past and ongoing work, were to be found on their web sites. The Expert Committee members and the WHO Secretariat were here to explain the work related to the Committee and to respond to any questions.\n\nPoor quality of medicines and \u201cspurious/falsely-labelled/falsified/counterfeit medicines\u201d are unfortunately a major threat to public health.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "85cae54e9d049b0c8ae82f0d22f846c372b96f618eec176a0e5b5df66e707f14", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 18 to 22 October 2010. Dr Hans V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies, opened the meeting, and on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fifth meeting of the Expert Committee. He expressed his appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines and for its major contributions with technical expertise as well as with practical laboratory studies.\n\nDr Hogerzeil welcomed the members of the Committee and temporary advisers; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Industrial Development Organization, World Intellectual Property Organization, the World Bank, World Customs Organization, World Trade Organization, European Union, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, Commonwealth Pharmacists Association, European Chemical Industry Council/APIC, International Federation of Pharmaceutical Manufacturers Association, International Generic Pharmaceutical Alliance, International Pharmaceutical Federation and the World Self-Medication Industry; representatives of the Pharmacopoeias of Great Britain and of the United States of America; representatives from WHO Collaborating Centres in Hungary and South Africa; and observers from the Brazilian Health Surveillance Agency and from the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nDr C.F. Etienne, Assistant Director-General for the Health Systems and Services Cluster, who was unable to attend the meeting, welcomed the Expert Committee with a written speech and acknowledged the elected Chairs, i.e. Professors I. Addae-Mensah (Chairperson) and S. Bawazir (Co-Chairperson), and the Co-Rapporteurs, Dr J.A. Molzon and Mr E. Wondemagegnehu Biwota.\n\nShe stated that the open session of the forty-fifth WHO Expert Committee on Specifications for Pharmaceutical Preparations had been organized in order to respond to the interest raised by Member States during the World Health Assembly held in May 2010 on the quality of medicines. The aim was to provide more information on this Expert Committee in an open and transparent manner. All the materials relating to the Expert Committee, both concerning the past and ongoing work, were to be found on their web sites. The Expert Committee members and the WHO Secretariat were here to explain the work related to the Committee and to respond to any questions.\n\nPoor quality of medicines and \u201cspurious/falsely-labelled/falsified/counterfeit medicines\u201d are unfortunately a major threat to public health.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2847, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1c371707-9d18-45d3-b60a-882483ac3f24": {"__data__": {"id_": "1c371707-9d18-45d3-b60a-882483ac3f24", "embedding": null, "metadata": {"page_label": "14", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "putting the health of numerous patients at risk and the trust of the patients in their health systems at stake; thus this was of critical importance for WHO.\n\nWHO has been involved in medicines quality assurance and quality control since 1948. This Committee was created in the very first World Health Assembly. Its work had already begun in 1947, during the transition of health matters previously dealt with under the League of Nations. Thus it is one of WHO\u2019s oldest programmes.\n\nStrong links exist with other WHO activities, such as support of national medicines regulatory authorities (NMRAs), the Prequalification of Medicines Programme, the Expert Committee on Biological Standardization, the Expert Committee on Selection and Use of Essential Medicines, Traditional Medicine and specific disease programmes.\n\nThe normative activities covered by this Expert Committee not only directly serve WHO Member States, but also, through implementation by programmes within WHO, international organizations as well, such as, UNICEF and The Global Fund to Fight AIDS, Tuberculosis and Malaria.\n\nMost of these activities have in the past been funded from WHO\u2019s regular budget. Nowadays more than 80% of the finance is secured through extrabudgetary funding by donors, such as the European Union, UNITAID, and the Bill & Melinda Gates Foundation.\n\nDr Hogerzeil stated that the work of the Expert Committee within the Quality Assurance and Safety: Medicines team was becoming a focus of interest. The meetings of the Expert Committee used to be held every two years but had been held annually for the past four years in response to the increased need for normative work. The work of the Expert Committee is of the highest level of normative work existing at WHO and the outcome of each meeting is published in the WHO Technical Report Series, which is then presented to the WHO governing bodies at the Executive Board meeting, usually in May.\n\nMembers of the Expert Committee are invited in a personal capacity and do not represent their respective governments.\n\nThe work of *The International Pharmacopoeia* and the WHO Prequalification of Medicines Programme is based entirely on the work of the Expert Committee on Specifications for Pharmaceutical Preparations; all guidance documents are sent out worldwide for comments, revised and finally adopted by the Expert Committee.\n\nWhile the normative work is unique, norms and standards is one of the key activities of the United Nations system. Dr Hogerzeil stated that WHO was supporting medicines related activities in nearly 100 countries.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Historia y Evoluci\u00f3n de la OMS en Aseguramiento de Calidad de Medicamentos**: La Organizaci\u00f3n Mundial de la Salud (OMS) ha estado involucrada en la garant\u00eda de calidad de los medicamentos desde 1948, con un enfoque en la creaci\u00f3n de normas y est\u00e1ndares que beneficien a los Estados miembros y organizaciones internacionales.\n\n2. **Financiamiento y Actividades Normativas**: Aunque hist\u00f3ricamente la OMS ha financiado sus actividades a trav\u00e9s de su presupuesto regular, actualmente m\u00e1s del 80% de los fondos provienen de donantes externos, lo que refleja un cambio en la forma en que se asegura la calidad de los medicamentos a nivel global.\n\n3. **Importancia del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos de la OMS en Especificaciones para Preparaciones Farmac\u00e9uticas juega un papel crucial en la creaci\u00f3n de normas y gu\u00edas que son adoptadas a nivel mundial, y su trabajo ha aumentado en frecuencia debido a la creciente necesidad de regulaci\u00f3n en el sector de la salud.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1les son las principales fuentes de financiamiento para las actividades de la OMS relacionadas con la calidad de los medicamentos en la actualidad?**\n   - Respuesta: M\u00e1s del 80% de la financiaci\u00f3n proviene de donantes externos, como la Uni\u00f3n Europea, UNITAID y la Fundaci\u00f3n Bill y Melinda Gates.\n\n2. **\u00bfQu\u00e9 cambios se han realizado en la frecuencia de las reuniones del Comit\u00e9 de Expertos de la OMS y por qu\u00e9?**\n   - Respuesta: Las reuniones del Comit\u00e9 de Expertos sol\u00edan celebrarse cada dos a\u00f1os, pero han pasado a ser anuales en los \u00faltimos cuatro a\u00f1os debido a la creciente necesidad de trabajo normativo.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1a el Comit\u00e9 de Expertos en la creaci\u00f3n de documentos de orientaci\u00f3n para la calidad de los medicamentos?**\n   - Respuesta: El trabajo del Comit\u00e9 de Expertos es fundamental para la elaboraci\u00f3n de *La Farmacopea Internacional* y el Programa de Precalificaci\u00f3n de Medicamentos de la OMS, donde todos los documentos de orientaci\u00f3n son enviados a nivel mundial para comentarios, revisados y finalmente adoptados por el Comit\u00e9.", "prev_section_summary": "### Temas Clave\n\n1. **Reuni\u00f3n del Comit\u00e9 de Expertos de la OMS**: El Comit\u00e9 se reuni\u00f3 en Ginebra del 18 al 22 de octubre de 2010 para discutir la calidad de los medicamentos, un tema de gran preocupaci\u00f3n para los Estados Miembros.\n\n2. **Agradecimientos y Bienvenida**: Dr. Hans V. Hogerzeil, Director del Departamento de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas, abri\u00f3 la reuni\u00f3n y agradeci\u00f3 al Comit\u00e9 por su experiencia en el aseguramiento de la calidad de los medicamentos.\n\n3. **Participaci\u00f3n de Organizaciones Internacionales**: Se destac\u00f3 la presencia de representantes de diversas organizaciones, incluyendo UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, y la Organizaci\u00f3n Mundial de la Propiedad Intelectual, entre otros.\n\n4. **Objetivos de la Reuni\u00f3n**: La sesi\u00f3n abierta se organiz\u00f3 para abordar el inter\u00e9s de los Estados Miembros sobre la calidad de los medicamentos, proporcionando informaci\u00f3n de manera transparente.\n\n5. **Amenazas a la Salud P\u00fablica**: Se mencion\u00f3 que la calidad deficiente de los medicamentos y la existencia de medicamentos falsificados son amenazas significativas para la salud p\u00fablica.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **UNICEF (Fondo de las Naciones Unidas para la Infancia)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Organizaci\u00f3n Mundial de la Propiedad Intelectual (OMPI)**\n- **Banco Mundial**\n- **Organizaci\u00f3n Mundial del Comercio (OMC)**\n- **Uni\u00f3n Europea**\n- **Consejo de Europa/Directorio Europeo para la Calidad de Medicamentos y Atenci\u00f3n Sanitaria**\n- **Asociaci\u00f3n de Farmac\u00e9uticos de la Commonwealth**\n- **Consejo de la Industria Qu\u00edmica Europea/APIC**\n- **Federaci\u00f3n Internacional de Asociaciones de Fabricantes Farmac\u00e9uticos**\n- **Alianza Internacional de Medicamentos Gen\u00e9ricos**\n- **Federaci\u00f3n Internacional Farmac\u00e9utica**\n- **Industria Mundial de la Automedicaci\u00f3n**\n- **Agencia de Vigilancia Sanitaria de Brasil**\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica (PIC/S)**\n\nEste resumen destaca los puntos clave y las entidades involucradas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, enfoc\u00e1ndose en la calidad de los medicamentos y su impacto en la salud p\u00fablica.", "excerpt_keywords": "Keywords: WHO, medicines quality assurance, Expert Committee, funding, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1ec53c41-f4c8-4d4e-a0b3-80a38bdbc8fc", "node_type": "4", "metadata": {"page_label": "14", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "putting the health of numerous patients at risk and the trust of the patients in their health systems at stake; thus this was of critical importance for WHO.\n\nWHO has been involved in medicines quality assurance and quality control since 1948. This Committee was created in the very first World Health Assembly. Its work had already begun in 1947, during the transition of health matters previously dealt with under the League of Nations. Thus it is one of WHO\u2019s oldest programmes.\n\nStrong links exist with other WHO activities, such as support of national medicines regulatory authorities (NMRAs), the Prequalification of Medicines Programme, the Expert Committee on Biological Standardization, the Expert Committee on Selection and Use of Essential Medicines, Traditional Medicine and specific disease programmes.\n\nThe normative activities covered by this Expert Committee not only directly serve WHO Member States, but also, through implementation by programmes within WHO, international organizations as well, such as, UNICEF and The Global Fund to Fight AIDS, Tuberculosis and Malaria.\n\nMost of these activities have in the past been funded from WHO\u2019s regular budget. Nowadays more than 80% of the finance is secured through extrabudgetary funding by donors, such as the European Union, UNITAID, and the Bill & Melinda Gates Foundation.\n\nDr Hogerzeil stated that the work of the Expert Committee within the Quality Assurance and Safety: Medicines team was becoming a focus of interest. The meetings of the Expert Committee used to be held every two years but had been held annually for the past four years in response to the increased need for normative work. The work of the Expert Committee is of the highest level of normative work existing at WHO and the outcome of each meeting is published in the WHO Technical Report Series, which is then presented to the WHO governing bodies at the Executive Board meeting, usually in May.\n\nMembers of the Expert Committee are invited in a personal capacity and do not represent their respective governments.\n\nThe work of *The International Pharmacopoeia* and the WHO Prequalification of Medicines Programme is based entirely on the work of the Expert Committee on Specifications for Pharmaceutical Preparations; all guidance documents are sent out worldwide for comments, revised and finally adopted by the Expert Committee.\n\nWhile the normative work is unique, norms and standards is one of the key activities of the United Nations system. Dr Hogerzeil stated that WHO was supporting medicines related activities in nearly 100 countries.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6d7ff7ee1113ed1c1ddfa5469be4a4076849f93847fd4c8be763ad46b4483399", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "putting the health of numerous patients at risk and the trust of the patients in their health systems at stake; thus this was of critical importance for WHO.\n\nWHO has been involved in medicines quality assurance and quality control since 1948. This Committee was created in the very first World Health Assembly. Its work had already begun in 1947, during the transition of health matters previously dealt with under the League of Nations. Thus it is one of WHO\u2019s oldest programmes.\n\nStrong links exist with other WHO activities, such as support of national medicines regulatory authorities (NMRAs), the Prequalification of Medicines Programme, the Expert Committee on Biological Standardization, the Expert Committee on Selection and Use of Essential Medicines, Traditional Medicine and specific disease programmes.\n\nThe normative activities covered by this Expert Committee not only directly serve WHO Member States, but also, through implementation by programmes within WHO, international organizations as well, such as, UNICEF and The Global Fund to Fight AIDS, Tuberculosis and Malaria.\n\nMost of these activities have in the past been funded from WHO\u2019s regular budget. Nowadays more than 80% of the finance is secured through extrabudgetary funding by donors, such as the European Union, UNITAID, and the Bill & Melinda Gates Foundation.\n\nDr Hogerzeil stated that the work of the Expert Committee within the Quality Assurance and Safety: Medicines team was becoming a focus of interest. The meetings of the Expert Committee used to be held every two years but had been held annually for the past four years in response to the increased need for normative work. The work of the Expert Committee is of the highest level of normative work existing at WHO and the outcome of each meeting is published in the WHO Technical Report Series, which is then presented to the WHO governing bodies at the Executive Board meeting, usually in May.\n\nMembers of the Expert Committee are invited in a personal capacity and do not represent their respective governments.\n\nThe work of *The International Pharmacopoeia* and the WHO Prequalification of Medicines Programme is based entirely on the work of the Expert Committee on Specifications for Pharmaceutical Preparations; all guidance documents are sent out worldwide for comments, revised and finally adopted by the Expert Committee.\n\nWhile the normative work is unique, norms and standards is one of the key activities of the United Nations system. Dr Hogerzeil stated that WHO was supporting medicines related activities in nearly 100 countries.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2586, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "706a44cc-c5f7-4c06-80ff-6dc663e5e3f7": {"__data__": {"id_": "706a44cc-c5f7-4c06-80ff-6dc663e5e3f7", "embedding": null, "metadata": {"page_label": "15", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In the medicines area, standard-setting work continues to be a pillar of WHO\u2019s activities and priorities.\n\nOverall the Expert Committee structure has been and will continue to be the \u201cbackbone\u201d of the Organization\u2019s standard-setting process.\n\nThe work of this Expert Committee is important for WHO Member States, United Nations agencies and international organizations, and in-house for all medicines-related programmes.\n\nWork of this Expert Committee is closely linked to other organizations, for example, the European Medicines Agency (EMA), the European Directorate for the Quality of Medicines and HealthCare (EDQM), the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Children\u2019s Fund (UNICEF), World Intellectual Property Organization (WIPO), the World Bank, International Pharmaceutical Federation (FIP), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), International Generic Pharmaceutical Alliance (IGPA), World Self-Medication Industry (WSMI), national and regional pharmacopoeias, and other clusters, institutions, bodies, authorities and other WHO Expert Committees.\n\nExperts and WHO staff are committed to this important work, which enables quality medicines to reach the patients.\n\nQuality for some essential medicines with a major health impact, e.g. for the treatment of tuberculosis and malaria, is still a problem worldwide. This is especially notable when looking at submission for prequalification dossiers and also in recent articles published by colleagues from M\u00e9decins sans Fronti\u00e8res (MSF) and related nongovernmental organizations. However, the international (donor) community is becoming increasingly aware about the problem of poor quality drugs, and countries with the above problem are more open to recognizing it. Nevertheless, there is still a long way to go before poor people will also gain access to good quality medicines.\n\n*Open session*\n\nThe open session, held on Monday, 18 October 2010, was opened by Dr H.V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies on behalf of Dr C.F. Etienne, Assistant Director-General, Health Systems and Services. Dr Hogerzeil welcomed representation from a number of Permanent Representatives to the United Nations Offices, International Organizations based in Geneva, and Specialized Agencies in Switzerland; representatives from the WHO Regional Offices for Africa, the Americas (Pan American Health", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS destaca la importancia del trabajo de los Comit\u00e9s de Expertos en el establecimiento de est\u00e1ndares para medicamentos, que es fundamental para las actividades y prioridades de la organizaci\u00f3n. Este trabajo est\u00e1 vinculado a diversas organizaciones internacionales y es crucial para garantizar que los medicamentos de calidad lleguen a los pacientes. A pesar de los esfuerzos, la calidad de algunos medicamentos esenciales, especialmente para el tratamiento de enfermedades como la tuberculosis y la malaria, sigue siendo un problema a nivel mundial. La comunidad internacional est\u00e1 cada vez m\u00e1s consciente de este problema, pero a\u00fan queda un largo camino por recorrer para asegurar que las personas con menos recursos tengan acceso a medicamentos de buena calidad.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 papel desempe\u00f1an los Comit\u00e9s de Expertos en el proceso de establecimiento de est\u00e1ndares de la OMS?**\n   - Los Comit\u00e9s de Expertos son considerados la \"columna vertebral\" del proceso de establecimiento de est\u00e1ndares de la OMS, siendo fundamentales para las actividades relacionadas con medicamentos y para asegurar que estos cumplan con los requisitos de calidad.\n\n2. **\u00bfCu\u00e1les son algunos de los desaf\u00edos actuales en la calidad de los medicamentos esenciales mencionados en el documento?**\n   - Se menciona que la calidad de medicamentos esenciales para el tratamiento de enfermedades como la tuberculosis y la malaria sigue siendo un problema a nivel mundial, especialmente en lo que respecta a la presentaci\u00f3n de expedientes de precalificaci\u00f3n y en informes de organizaciones como M\u00e9dicos Sin Fronteras.\n\n3. **\u00bfQu\u00e9 acciones se est\u00e1n tomando para abordar el problema de los medicamentos de mala calidad a nivel internacional?**\n   - La comunidad internacional, incluidos donantes y pa\u00edses afectados, est\u00e1 comenzando a reconocer el problema de los medicamentos de mala calidad, lo que indica un aumento en la conciencia y la disposici\u00f3n para abordar esta cuesti\u00f3n, aunque a\u00fan queda mucho por hacer para garantizar el acceso a medicamentos de calidad para las poblaciones m\u00e1s vulnerables.\n\n### Resumen de Nivel Superior\nEl documento de la OMS subraya la importancia de los Comit\u00e9s de Expertos en el establecimiento de est\u00e1ndares para medicamentos, destacando su papel en la mejora de la calidad de los medicamentos a nivel global. A pesar de los esfuerzos realizados, persisten desaf\u00edos significativos en la calidad de medicamentos esenciales, especialmente en el contexto de enfermedades cr\u00edticas. La creciente conciencia de la comunidad internacional sobre estos problemas es un paso positivo, pero se requiere un esfuerzo continuo para garantizar que todos, especialmente los m\u00e1s desfavorecidos, tengan acceso a medicamentos de calidad.", "prev_section_summary": "### Temas Clave:\n\n1. **Historia de la OMS en Aseguramiento de Calidad de Medicamentos**: La OMS ha estado involucrada en la garant\u00eda de calidad de los medicamentos desde 1948, siendo uno de sus programas m\u00e1s antiguos, con un enfoque en la creaci\u00f3n de normas y est\u00e1ndares.\n\n2. **Financiamiento**: M\u00e1s del 80% de las actividades relacionadas con la calidad de los medicamentos son financiadas actualmente a trav\u00e9s de donantes externos, en lugar del presupuesto regular de la OMS.\n\n3. **Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas es fundamental para la creaci\u00f3n de normas y gu\u00edas, y ha aumentado la frecuencia de sus reuniones a anuales debido a la creciente necesidad de trabajo normativo.\n\n4. **Colaboraci\u00f3n Internacional**: Las actividades normativas de la OMS no solo benefician a los Estados miembros, sino tambi\u00e9n a organizaciones internacionales como UNICEF y el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria.\n\n5. **Publicaciones y Normas**: Los resultados de las reuniones del Comit\u00e9 de Expertos se publican en la Serie de Informes T\u00e9cnicos de la OMS y son presentados a los cuerpos de gobierno de la OMS.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Agencia de la ONU responsable de la salud p\u00fablica internacional.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que establece normas y gu\u00edas para la calidad de los medicamentos.\n- **Uni\u00f3n Europea**: Donante externo que financia actividades de la OMS.\n- **UNITAID**: Organizaci\u00f3n que apoya la financiaci\u00f3n de medicamentos y tratamientos.\n- **Fundaci\u00f3n Bill y Melinda Gates**: Donante que contribuye a las actividades de la OMS.\n- **UNICEF**: Organizaci\u00f3n de la ONU que trabaja en la salud y bienestar de los ni\u00f1os.\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: Organizaci\u00f3n que colabora con la OMS en actividades relacionadas con la salud.", "excerpt_keywords": "Keywords: WHO, standard-setting, quality medicines, Expert Committee, essential medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2383af1-4acf-4bcd-a8dd-c2a52649cbb7", "node_type": "4", "metadata": {"page_label": "15", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In the medicines area, standard-setting work continues to be a pillar of WHO\u2019s activities and priorities.\n\nOverall the Expert Committee structure has been and will continue to be the \u201cbackbone\u201d of the Organization\u2019s standard-setting process.\n\nThe work of this Expert Committee is important for WHO Member States, United Nations agencies and international organizations, and in-house for all medicines-related programmes.\n\nWork of this Expert Committee is closely linked to other organizations, for example, the European Medicines Agency (EMA), the European Directorate for the Quality of Medicines and HealthCare (EDQM), the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Children\u2019s Fund (UNICEF), World Intellectual Property Organization (WIPO), the World Bank, International Pharmaceutical Federation (FIP), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), International Generic Pharmaceutical Alliance (IGPA), World Self-Medication Industry (WSMI), national and regional pharmacopoeias, and other clusters, institutions, bodies, authorities and other WHO Expert Committees.\n\nExperts and WHO staff are committed to this important work, which enables quality medicines to reach the patients.\n\nQuality for some essential medicines with a major health impact, e.g. for the treatment of tuberculosis and malaria, is still a problem worldwide. This is especially notable when looking at submission for prequalification dossiers and also in recent articles published by colleagues from M\u00e9decins sans Fronti\u00e8res (MSF) and related nongovernmental organizations. However, the international (donor) community is becoming increasingly aware about the problem of poor quality drugs, and countries with the above problem are more open to recognizing it. Nevertheless, there is still a long way to go before poor people will also gain access to good quality medicines.\n\n*Open session*\n\nThe open session, held on Monday, 18 October 2010, was opened by Dr H.V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies on behalf of Dr C.F. Etienne, Assistant Director-General, Health Systems and Services. Dr Hogerzeil welcomed representation from a number of Permanent Representatives to the United Nations Offices, International Organizations based in Geneva, and Specialized Agencies in Switzerland; representatives from the WHO Regional Offices for Africa, the Americas (Pan American Health", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cb318a777de33783fadec88b8691f089dfa3deb699ea1c72a030c96a5e7ae39a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In the medicines area, standard-setting work continues to be a pillar of WHO\u2019s activities and priorities.\n\nOverall the Expert Committee structure has been and will continue to be the \u201cbackbone\u201d of the Organization\u2019s standard-setting process.\n\nThe work of this Expert Committee is important for WHO Member States, United Nations agencies and international organizations, and in-house for all medicines-related programmes.\n\nWork of this Expert Committee is closely linked to other organizations, for example, the European Medicines Agency (EMA), the European Directorate for the Quality of Medicines and HealthCare (EDQM), the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Children\u2019s Fund (UNICEF), World Intellectual Property Organization (WIPO), the World Bank, International Pharmaceutical Federation (FIP), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), International Generic Pharmaceutical Alliance (IGPA), World Self-Medication Industry (WSMI), national and regional pharmacopoeias, and other clusters, institutions, bodies, authorities and other WHO Expert Committees.\n\nExperts and WHO staff are committed to this important work, which enables quality medicines to reach the patients.\n\nQuality for some essential medicines with a major health impact, e.g. for the treatment of tuberculosis and malaria, is still a problem worldwide. This is especially notable when looking at submission for prequalification dossiers and also in recent articles published by colleagues from M\u00e9decins sans Fronti\u00e8res (MSF) and related nongovernmental organizations. However, the international (donor) community is becoming increasingly aware about the problem of poor quality drugs, and countries with the above problem are more open to recognizing it. Nevertheless, there is still a long way to go before poor people will also gain access to good quality medicines.\n\n*Open session*\n\nThe open session, held on Monday, 18 October 2010, was opened by Dr H.V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies on behalf of Dr C.F. Etienne, Assistant Director-General, Health Systems and Services. Dr Hogerzeil welcomed representation from a number of Permanent Representatives to the United Nations Offices, International Organizations based in Geneva, and Specialized Agencies in Switzerland; representatives from the WHO Regional Offices for Africa, the Americas (Pan American Health", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2456, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "244a31bc-dbb4-41c1-950a-dbd88695f224": {"__data__": {"id_": "244a31bc-dbb4-41c1-950a-dbd88695f224", "embedding": null, "metadata": {"page_label": "16", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Overview of WHO Expert Committee Presentation\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations provided an overview of the processes involved and the key areas covered. Time was allowed for questions, comments, and suggestions following the Secretary\u2019s presentation.\n\n## Recommendation\n\nIt was recommended that the key points of the Secretary\u2019s presentation be developed into a short article for wider dissemination to highlight the importance of the Expert Committee\u2019s work over the years and the need for normative standards and maintenance of quality guidelines.\n\nThe presentation would also be sent to interested parties and posted on the Medicines website.\n\n## Questions and Responses\n\nQuestions were asked regarding WHO guidelines, particularly concerning implementation, use of standards for procurement, and financing.\n\nThe Coordinator of the Quality Assurance and Safety: Medicines team replied that the guidelines were developed for use and implementation by Member States, and within WHO they were used within the Prequalification of Medicines Programme. Many partners and international organizations, such as the Global Fund, also use the guidance developed by this Expert Committee.\n\nA question was posed about specifications for neglected diseases, such as Chagas\u2019 disease and leishmania, which seemed to be missing from the work plan. The Secretary replied that the Quality Assurance and Safety: Medicines team would investigate this further when reviewing the Expert Committee\u2019s work plan.\n\n## Support and Contributions\n\nThe Secretary noted that significant support was received from national authorities and quality control laboratories, and that experts contribute significantly without necessarily being paid by WHO.\n\n## Co-Chairperson's Statement\n\nThe Co-Chairperson stated his 25 years of experience in implementing guidelines from WHO to raise the quality of NMRAs. He emphasized that without WHO\u2019s involvement, research for guidelines would largely be conducted by developed countries. WHO good manufacturing practices (GMP) as adopted by the Expert Committee on Specifications for Pharmaceutical Preparations are used by many countries.\n\n## Concerns Raised\n\nThe focus of comments by the Expert Committee members was on the impact of funding cuts, which were undermining normative functions supporting prequalification and assisting Member States\u2019 responsibilities and expectations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento presenta un resumen de la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas. Se discuten los procesos y \u00e1reas clave abordadas por el Secretario del Comit\u00e9, as\u00ed como la importancia de las normas y directrices de calidad en la farmac\u00e9utica. Se plantean preguntas sobre la implementaci\u00f3n de las directrices de la OMS, el uso de est\u00e1ndares para la adquisici\u00f3n de medicamentos y la financiaci\u00f3n. Tambi\u00e9n se menciona la falta de atenci\u00f3n a enfermedades desatendidas en el plan de trabajo del Comit\u00e9. Adem\u00e1s, se destaca el apoyo recibido de autoridades nacionales y laboratorios de control de calidad, as\u00ed como las preocupaciones sobre los recortes de financiaci\u00f3n que afectan las funciones normativas del Comit\u00e9.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para abordar la falta de especificaciones para enfermedades desatendidas como la enfermedad de Chagas y la leishmaniasis en el plan de trabajo del Comit\u00e9?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones espec\u00edficas que se est\u00e1n considerando para incluir estas enfermedades en las directrices de la OMS, lo cual no se detalla en el documento.\n\n2. **\u00bfC\u00f3mo se est\u00e1n utilizando las directrices de la OMS en el Programa de Precalificaci\u00f3n de Medicamentos y qu\u00e9 impacto tienen en los pa\u00edses en desarrollo?**\n   - Esta pregunta se centra en el uso pr\u00e1ctico de las directrices de la OMS y su efecto en la calidad de los medicamentos en pa\u00edses que enfrentan desaf\u00edos en la regulaci\u00f3n y adquisici\u00f3n de productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 estrategias se est\u00e1n considerando para mitigar el impacto de los recortes de financiaci\u00f3n en las funciones normativas del Comit\u00e9 y en el apoyo a los Estados Miembros?**\n   - Esta pregunta busca entender las posibles soluciones o planes que el Comit\u00e9 podr\u00eda estar considerando para enfrentar los desaf\u00edos financieros que afectan su capacidad de operaci\u00f3n y apoyo a los pa\u00edses.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia del Establecimiento de Est\u00e1ndares**: El trabajo de establecimiento de est\u00e1ndares en el \u00e1rea de medicamentos es fundamental para las actividades y prioridades de la OMS.\n\n2. **Estructura de los Comit\u00e9s de Expertos**: Los Comit\u00e9s de Expertos son considerados la \"columna vertebral\" del proceso de establecimiento de est\u00e1ndares de la OMS, desempe\u00f1ando un papel crucial en la garant\u00eda de calidad de los medicamentos.\n\n3. **Colaboraci\u00f3n Internacional**: El trabajo de los Comit\u00e9s de Expertos est\u00e1 estrechamente vinculado a diversas organizaciones internacionales, lo que resalta la importancia de la colaboraci\u00f3n en la mejora de la calidad de los medicamentos.\n\n4. **Desaf\u00edos en la Calidad de Medicamentos**: A pesar de los esfuerzos, la calidad de algunos medicamentos esenciales, especialmente para el tratamiento de enfermedades como la tuberculosis y la malaria, sigue siendo un problema a nivel mundial.\n\n5. **Conciencia Internacional**: La comunidad internacional, incluidos donantes y pa\u00edses afectados, est\u00e1 cada vez m\u00e1s consciente del problema de los medicamentos de mala calidad, aunque a\u00fan queda mucho por hacer para garantizar el acceso a medicamentos de calidad para las poblaciones vulnerables.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Agencia Europea de Medicamentos (EMA)**\n- **Direcci\u00f3n Europea para la Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Fondo de las Naciones Unidas para la Infancia (UNICEF)**\n- **Organizaci\u00f3n Mundial de la Propiedad Intelectual (WIPO)**\n- **Banco Mundial**\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**\n- **Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA)**\n- **Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA)**\n- **Industria Mundial de la Autocuidado (WSMI)**\n- **M\u00e9dicos Sin Fronteras (MSF)**\n\nEste resumen destaca la relevancia del trabajo de la OMS y sus Comit\u00e9s de Expertos en la mejora de la calidad de los medicamentos a nivel global, as\u00ed como los desaf\u00edos persistentes que enfrentan en este \u00e1mbito.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality assurance, neglected diseases, funding cuts"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6500ca0c-105b-4a3f-baf7-7c711681d3c6", "node_type": "4", "metadata": {"page_label": "16", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Overview of WHO Expert Committee Presentation\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations provided an overview of the processes involved and the key areas covered. Time was allowed for questions, comments, and suggestions following the Secretary\u2019s presentation.\n\n## Recommendation\n\nIt was recommended that the key points of the Secretary\u2019s presentation be developed into a short article for wider dissemination to highlight the importance of the Expert Committee\u2019s work over the years and the need for normative standards and maintenance of quality guidelines.\n\nThe presentation would also be sent to interested parties and posted on the Medicines website.\n\n## Questions and Responses\n\nQuestions were asked regarding WHO guidelines, particularly concerning implementation, use of standards for procurement, and financing.\n\nThe Coordinator of the Quality Assurance and Safety: Medicines team replied that the guidelines were developed for use and implementation by Member States, and within WHO they were used within the Prequalification of Medicines Programme. Many partners and international organizations, such as the Global Fund, also use the guidance developed by this Expert Committee.\n\nA question was posed about specifications for neglected diseases, such as Chagas\u2019 disease and leishmania, which seemed to be missing from the work plan. The Secretary replied that the Quality Assurance and Safety: Medicines team would investigate this further when reviewing the Expert Committee\u2019s work plan.\n\n## Support and Contributions\n\nThe Secretary noted that significant support was received from national authorities and quality control laboratories, and that experts contribute significantly without necessarily being paid by WHO.\n\n## Co-Chairperson's Statement\n\nThe Co-Chairperson stated his 25 years of experience in implementing guidelines from WHO to raise the quality of NMRAs. He emphasized that without WHO\u2019s involvement, research for guidelines would largely be conducted by developed countries. WHO good manufacturing practices (GMP) as adopted by the Expert Committee on Specifications for Pharmaceutical Preparations are used by many countries.\n\n## Concerns Raised\n\nThe focus of comments by the Expert Committee members was on the impact of funding cuts, which were undermining normative functions supporting prequalification and assisting Member States\u2019 responsibilities and expectations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "491dbf280e017dc963ab67690ed7803c3aa0b49b162492927629776646e987e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Overview of WHO Expert Committee Presentation\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations provided an overview of the processes involved and the key areas covered. Time was allowed for questions, comments, and suggestions following the Secretary\u2019s presentation.\n\n## Recommendation\n\nIt was recommended that the key points of the Secretary\u2019s presentation be developed into a short article for wider dissemination to highlight the importance of the Expert Committee\u2019s work over the years and the need for normative standards and maintenance of quality guidelines.\n\nThe presentation would also be sent to interested parties and posted on the Medicines website.\n\n## Questions and Responses\n\nQuestions were asked regarding WHO guidelines, particularly concerning implementation, use of standards for procurement, and financing.\n\nThe Coordinator of the Quality Assurance and Safety: Medicines team replied that the guidelines were developed for use and implementation by Member States, and within WHO they were used within the Prequalification of Medicines Programme. Many partners and international organizations, such as the Global Fund, also use the guidance developed by this Expert Committee.\n\nA question was posed about specifications for neglected diseases, such as Chagas\u2019 disease and leishmania, which seemed to be missing from the work plan. The Secretary replied that the Quality Assurance and Safety: Medicines team would investigate this further when reviewing the Expert Committee\u2019s work plan.\n\n## Support and Contributions\n\nThe Secretary noted that significant support was received from national authorities and quality control laboratories, and that experts contribute significantly without necessarily being paid by WHO.\n\n## Co-Chairperson's Statement\n\nThe Co-Chairperson stated his 25 years of experience in implementing guidelines from WHO to raise the quality of NMRAs. He emphasized that without WHO\u2019s involvement, research for guidelines would largely be conducted by developed countries. WHO good manufacturing practices (GMP) as adopted by the Expert Committee on Specifications for Pharmaceutical Preparations are used by many countries.\n\n## Concerns Raised\n\nThe focus of comments by the Expert Committee members was on the impact of funding cuts, which were undermining normative functions supporting prequalification and assisting Member States\u2019 responsibilities and expectations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2451, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "56a41663-bc1a-47c1-8b8e-c417dbf9da4e": {"__data__": {"id_": "56a41663-bc1a-47c1-8b8e-c417dbf9da4e", "embedding": null, "metadata": {"page_label": "17", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee members were concerned about the serious problems regarding the funding of WHO\u2019s normative work in the area of quality assurance.\n\n**Update on spurious/falsely-labelled/falsified/counterfeit medicines**\n\nDiscussion took place during the World Health Assembly in May 2010 regarding the *International Medical Products Anti-Counterfeiting Taskforce* (IMPACT) and issues regarding spurious/falsely-labelled/falsified/counterfeit medicines in general. The organization of an intergovernmental working group for Member States was currently ongoing based on a World Health Assembly decision. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly. Several background papers were provided in the Expert Committee file regarding nomenclature and legal issues relating to substandard/spurious/falsely-labelled/falsified/counterfeit medicines. WHO has currently put on hold activities related to serving the Secretariat for IMPACT. The Director-General of WHO reconfirmed that spurious/falsely-labelled/falsified/counterfeit medicines are an important issue for the Organization.\n\nThe WHO Anti-Counterfeiting Programme is part of the Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines work plan and team.\n\n**Major publications since October 2009**\n\n- The forty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 957) was ready for its presentation to the WHO Executive Board meeting held in May 2010. It is now available in printed and electronic form and published copies were distributed to the participants at the forty-fifth meeting of the Expert Committee.\n\n**In the pipeline**\n\n- The Second supplement to the fourth edition of *The International Pharmacopoeia* would soon be available on CD-ROM and online.\n- A CD-ROM including all 60 current WHO quality assurance guidelines adopted by the Expert Committee on Specifications for Pharmaceutical Preparations would be available in a comprehensive and structured form by the end of 2010.\n\n**Expert Committee meeting topics**\n\nA variety of aspects relating to quality assurance were discussed, which involved more than 80 documents (including 30 quality assurance-related...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las preocupaciones del Comit\u00e9 de Expertos de la OMS sobre la financiaci\u00f3n de su trabajo normativo en el \u00e1rea de aseguramiento de la calidad. Se discuten los problemas relacionados con medicamentos falsificados y la creaci\u00f3n de un grupo de trabajo intergubernamental. Tambi\u00e9n se mencionan publicaciones recientes y futuras en el \u00e1mbito de la calidad de los medicamentos, as\u00ed como la organizaci\u00f3n de documentos relevantes para la reuni\u00f3n del Comit\u00e9 de Expertos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales preocupaciones del Comit\u00e9 de Expertos de la OMS respecto a la financiaci\u00f3n de su trabajo en calidad?**\n   - El Comit\u00e9 de Expertos est\u00e1 preocupado por los problemas serios relacionados con la financiaci\u00f3n de las actividades normativas de la OMS en el \u00e1rea de aseguramiento de la calidad.\n\n2. **\u00bfQu\u00e9 acciones se est\u00e1n tomando en relaci\u00f3n con el Taskforce Internacional de Productos M\u00e9dicos Anti-Falsificaci\u00f3n (IMPACT)?**\n   - Actualmente, la OMS ha puesto en espera las actividades relacionadas con el servicio de la Secretar\u00eda para IMPACT, aunque se est\u00e1n organizando trabajos intergubernamentales basados en decisiones de la Asamblea Mundial de la Salud.\n\n3. **\u00bfQu\u00e9 publicaciones importantes se han producido desde octubre de 2009 y cu\u00e1les son las futuras disponibilidades en el \u00e1mbito de la calidad de los medicamentos?**\n   - Desde octubre de 2009, se ha presentado el informe n\u00famero 44 del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas. En el futuro, se espera que el segundo suplemento de la cuarta edici\u00f3n de *The International Pharmacopoeia* est\u00e9 disponible en CD-ROM y en l\u00ednea, as\u00ed como un CD-ROM que contenga todas las directrices de aseguramiento de calidad de la OMS adoptadas por el Comit\u00e9 de Expertos.\n\n### Resumen de Nivel Superior\n\nEl documento aborda la situaci\u00f3n actual de la OMS en relaci\u00f3n con la calidad de los medicamentos, destacando la preocupaci\u00f3n por la financiaci\u00f3n y el impacto de los medicamentos falsificados. Se mencionan esfuerzos para abordar estos problemas a trav\u00e9s de la creaci\u00f3n de grupos de trabajo y la publicaci\u00f3n de informes y directrices relevantes. La OMS contin\u00faa trabajando en la mejora de sus pol\u00edticas y pr\u00e1cticas en el \u00e1mbito de la calidad de los medicamentos.", "prev_section_summary": "### Temas Clave\n\n1. **Presentaci\u00f3n del Comit\u00e9 de Expertos de la OMS**: Se proporcion\u00f3 un resumen de los procesos y \u00e1reas clave abordadas por el Secretario del Comit\u00e9 sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **Recomendaciones**: Se sugiri\u00f3 desarrollar un art\u00edculo corto para difundir la importancia del trabajo del Comit\u00e9 y la necesidad de normas y directrices de calidad.\n\n3. **Preguntas y Respuestas**: Se discutieron temas sobre la implementaci\u00f3n de las directrices de la OMS, el uso de est\u00e1ndares para la adquisici\u00f3n de medicamentos y cuestiones de financiaci\u00f3n.\n\n4. **Enfermedades Desatendidas**: Se plante\u00f3 la falta de especificaciones para enfermedades como la enfermedad de Chagas y la leishmaniasis en el plan de trabajo del Comit\u00e9.\n\n5. **Apoyo y Contribuciones**: Se destac\u00f3 el apoyo recibido de autoridades nacionales y laboratorios de control de calidad, as\u00ed como la contribuci\u00f3n de expertos no remunerados por la OMS.\n\n6. **Declaraci\u00f3n del Co-Presidente**: Se enfatiz\u00f3 la importancia de la participaci\u00f3n de la OMS en la investigaci\u00f3n y desarrollo de directrices, especialmente en pa\u00edses en desarrollo.\n\n7. **Preocupaciones sobre Financiaci\u00f3n**: Se expresaron inquietudes sobre el impacto de los recortes de financiaci\u00f3n en las funciones normativas del Comit\u00e9 y en el apoyo a los Estados Miembros.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n de directrices y normas en el \u00e1mbito farmac\u00e9utico.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo encargado de desarrollar y revisar normas y directrices.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**: Iniciativa que utiliza las directrices del Comit\u00e9 para asegurar la calidad de los medicamentos.\n- **Global Fund**: Organizaci\u00f3n internacional que utiliza las directrices desarrolladas por el Comit\u00e9.\n- **Autoridades Nacionales y Laboratorios de Control de Calidad**: Entidades que brindan apoyo significativo al trabajo del Comit\u00e9.", "excerpt_keywords": "Keywords: WHO, quality assurance, counterfeit medicines, IMPACT, pharmaceutical preparations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "67ef6095-1560-47a4-b7ae-15e54bb45a6b", "node_type": "4", "metadata": {"page_label": "17", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee members were concerned about the serious problems regarding the funding of WHO\u2019s normative work in the area of quality assurance.\n\n**Update on spurious/falsely-labelled/falsified/counterfeit medicines**\n\nDiscussion took place during the World Health Assembly in May 2010 regarding the *International Medical Products Anti-Counterfeiting Taskforce* (IMPACT) and issues regarding spurious/falsely-labelled/falsified/counterfeit medicines in general. The organization of an intergovernmental working group for Member States was currently ongoing based on a World Health Assembly decision. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly. Several background papers were provided in the Expert Committee file regarding nomenclature and legal issues relating to substandard/spurious/falsely-labelled/falsified/counterfeit medicines. WHO has currently put on hold activities related to serving the Secretariat for IMPACT. The Director-General of WHO reconfirmed that spurious/falsely-labelled/falsified/counterfeit medicines are an important issue for the Organization.\n\nThe WHO Anti-Counterfeiting Programme is part of the Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines work plan and team.\n\n**Major publications since October 2009**\n\n- The forty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 957) was ready for its presentation to the WHO Executive Board meeting held in May 2010. It is now available in printed and electronic form and published copies were distributed to the participants at the forty-fifth meeting of the Expert Committee.\n\n**In the pipeline**\n\n- The Second supplement to the fourth edition of *The International Pharmacopoeia* would soon be available on CD-ROM and online.\n- A CD-ROM including all 60 current WHO quality assurance guidelines adopted by the Expert Committee on Specifications for Pharmaceutical Preparations would be available in a comprehensive and structured form by the end of 2010.\n\n**Expert Committee meeting topics**\n\nA variety of aspects relating to quality assurance were discussed, which involved more than 80 documents (including 30 quality assurance-related...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b846b2efbf56a850f7adb7b72ad904a7b5949b96ec4c678a47120b9c17b2eb88", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee members were concerned about the serious problems regarding the funding of WHO\u2019s normative work in the area of quality assurance.\n\n**Update on spurious/falsely-labelled/falsified/counterfeit medicines**\n\nDiscussion took place during the World Health Assembly in May 2010 regarding the *International Medical Products Anti-Counterfeiting Taskforce* (IMPACT) and issues regarding spurious/falsely-labelled/falsified/counterfeit medicines in general. The organization of an intergovernmental working group for Member States was currently ongoing based on a World Health Assembly decision. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly. Several background papers were provided in the Expert Committee file regarding nomenclature and legal issues relating to substandard/spurious/falsely-labelled/falsified/counterfeit medicines. WHO has currently put on hold activities related to serving the Secretariat for IMPACT. The Director-General of WHO reconfirmed that spurious/falsely-labelled/falsified/counterfeit medicines are an important issue for the Organization.\n\nThe WHO Anti-Counterfeiting Programme is part of the Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines work plan and team.\n\n**Major publications since October 2009**\n\n- The forty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 957) was ready for its presentation to the WHO Executive Board meeting held in May 2010. It is now available in printed and electronic form and published copies were distributed to the participants at the forty-fifth meeting of the Expert Committee.\n\n**In the pipeline**\n\n- The Second supplement to the fourth edition of *The International Pharmacopoeia* would soon be available on CD-ROM and online.\n- A CD-ROM including all 60 current WHO quality assurance guidelines adopted by the Expert Committee on Specifications for Pharmaceutical Preparations would be available in a comprehensive and structured form by the end of 2010.\n\n**Expert Committee meeting topics**\n\nA variety of aspects relating to quality assurance were discussed, which involved more than 80 documents (including 30 quality assurance-related...", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2361, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c7b70f42-c995-4d85-a9a9-4c3530365396": {"__data__": {"id_": "c7b70f42-c995-4d85-a9a9-4c3530365396", "embedding": null, "metadata": {"page_label": "18", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General Policy\n\n## 2. International Collaboration\n\n### 2.1 International Collaboration\n\n#### 2.1.1 Collaboration with International Organizations and Agencies\n\n**European Directorate for the Quality of Medicines and HealthCare (Council of Europe)**\n\nA short update on the collaboration between the European Directorate for the Quality of Medicines and HealthCare (EDQM) and the WHO activities under this Expert Committee was given.\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\nThe Global Fund to Fight AIDS, Tuberculosis and Malaria works in partnership with governments, civil society, the private sector and affected communities.\n\nOf the approved Global Fund budget, 37% is used for medicines and health products. For instance, of US$ 19.4 billion approved by the Board, 62% was used for HIV/AIDS, 22% for malaria and 16% for tuberculosis. By region this amounts to: sub-Saharan Africa, 57%; East Asia and Pacific, 14%; Eastern Europe and Central Asia, 7%; South Asia, 9%; Middle East and North Africa, 6%. Overall the Global Fund has 600 active grants in 144 countries.\n\nThe Global Fund's quality policy for pharmaceuticals has been revised following advice from this Expert Committee and since 2009 the policy has been based on three criteria:\n\n- **Clinical criteria** \u2014 medicines listed in WHO, national or institutional standard treatment guidelines (if not listed in one of the standard treatment guidelines, medicines require justification for selection from applicants or recipients).\n\n- **Quality criteria** \u2014 authorization of a product in the recipient country is necessary for all products. In the case of antiretrovirals (ARVs) and medicines for treating TB and malaria, WHO prequalification or authorization by stringent regulatory authorities (SRAs) or recommendation by the Expert Review Panel (ERP) is applied.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n Internacional en Salud**: El documento aborda la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y diversas organizaciones internacionales, destacando la importancia de trabajar en conjunto para mejorar la calidad de los medicamentos y productos de salud a nivel global.\n\n2. **El Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: Se presenta informaci\u00f3n sobre el presupuesto del Fondo Global, que destina una parte significativa a medicamentos y productos de salud, y se detalla c\u00f3mo se distribuyen estos fondos por regi\u00f3n y enfermedad.\n\n3. **Pol\u00edtica de Calidad de Productos Farmac\u00e9uticos**: Se describe la pol\u00edtica de calidad del Fondo Global para los productos farmac\u00e9uticos, que se basa en criterios cl\u00ednicos y de calidad, incluyendo la necesidad de autorizaci\u00f3n en el pa\u00eds receptor y la pre-calificaci\u00f3n por parte de la OMS o autoridades regulatorias estrictas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios cl\u00ednicos que deben cumplir los medicamentos para ser aprobados por el Fondo Global?**\n   - Respuesta: Los medicamentos deben estar listados en las gu\u00edas de tratamiento est\u00e1ndar de la OMS, nacionales o institucionales. Si no est\u00e1n listados, se requiere justificaci\u00f3n para su selecci\u00f3n por parte de los solicitantes o beneficiarios.\n\n2. **\u00bfQu\u00e9 porcentaje del presupuesto aprobado por el Fondo Global se destina a la lucha contra el VIH/SIDA, la malaria y la tuberculosis?**\n   - Respuesta: Del presupuesto aprobado de US$ 19.4 mil millones, el 62% se destina al VIH/SIDA, el 22% a la malaria y el 16% a la tuberculosis.\n\n3. **\u00bfQu\u00e9 requisitos de autorizaci\u00f3n se aplican a los productos farmac\u00e9uticos en el contexto del Fondo Global?**\n   - Respuesta: Es necesaria la autorizaci\u00f3n de un producto en el pa\u00eds receptor para todos los productos. En el caso de antirretrovirales y medicamentos para tratar la tuberculosis y la malaria, se aplica la pre-calificaci\u00f3n de la OMS o la autorizaci\u00f3n por parte de autoridades regulatorias estrictas (SRA) o la recomendaci\u00f3n del Panel de Revisi\u00f3n de Expertos (ERP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Preocupaciones sobre Financiaci\u00f3n**: \n   - El Comit\u00e9 de Expertos de la OMS expresa su preocupaci\u00f3n por los problemas serios relacionados con la financiaci\u00f3n de su trabajo normativo en el \u00e1rea de aseguramiento de la calidad.\n\n2. **Medicamentos Falsificados**:\n   - Se discutieron temas sobre medicamentos espurios, falsamente etiquetados, falsificados y de contrabando durante la Asamblea Mundial de la Salud en mayo de 2010.\n   - Se est\u00e1 organizando un grupo de trabajo intergubernamental para abordar estos problemas, aunque las actividades de la OMS relacionadas con el Taskforce Internacional de Productos M\u00e9dicos Anti-Falsificaci\u00f3n (IMPACT) est\u00e1n actualmente en espera.\n\n3. **Publicaciones Importantes**:\n   - Se menciona la disponibilidad del informe n\u00famero 44 del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas (WHO Technical Report Series, No. 957), que fue presentado en mayo de 2010.\n\n4. **Futuras Disponibilidades**:\n   - Se anticipa la publicaci\u00f3n del segundo suplemento de la cuarta edici\u00f3n de *The International Pharmacopoeia* en CD-ROM y en l\u00ednea.\n   - Un CD-ROM que incluir\u00e1 todas las directrices actuales de aseguramiento de calidad de la OMS adoptadas por el Comit\u00e9 de Expertos estar\u00e1 disponible a finales de 2010.\n\n5. **Temas de Reuni\u00f3n del Comit\u00e9 de Expertos**:\n   - Se discutieron diversos aspectos relacionados con el aseguramiento de la calidad, abarcando m\u00e1s de 80 documentos, incluidos 30 relacionados con la calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable de la salud p\u00fablica a nivel global.\n- **IMPACT (International Medical Products Anti-Counterfeiting Taskforce)**: Grupo de trabajo enfocado en combatir la falsificaci\u00f3n de productos m\u00e9dicos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que asesora a la OMS sobre especificaciones y calidad de los medicamentos.\n- **Asamblea Mundial de la Salud**: \u00d3rgano decisorio de la OMS donde se discuten temas de salud global. \n\nEste resumen destaca las preocupaciones sobre la financiaci\u00f3n y la calidad de los medicamentos, as\u00ed como las iniciativas y publicaciones recientes de la OMS en este \u00e1mbito.", "excerpt_keywords": "Keywords: International Collaboration, Global Fund, Pharmaceuticals Quality, HIV/AIDS, Health Products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93aa5da2-439c-4cda-b1a3-441ce01c6961", "node_type": "4", "metadata": {"page_label": "18", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General Policy\n\n## 2. International Collaboration\n\n### 2.1 International Collaboration\n\n#### 2.1.1 Collaboration with International Organizations and Agencies\n\n**European Directorate for the Quality of Medicines and HealthCare (Council of Europe)**\n\nA short update on the collaboration between the European Directorate for the Quality of Medicines and HealthCare (EDQM) and the WHO activities under this Expert Committee was given.\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\nThe Global Fund to Fight AIDS, Tuberculosis and Malaria works in partnership with governments, civil society, the private sector and affected communities.\n\nOf the approved Global Fund budget, 37% is used for medicines and health products. For instance, of US$ 19.4 billion approved by the Board, 62% was used for HIV/AIDS, 22% for malaria and 16% for tuberculosis. By region this amounts to: sub-Saharan Africa, 57%; East Asia and Pacific, 14%; Eastern Europe and Central Asia, 7%; South Asia, 9%; Middle East and North Africa, 6%. Overall the Global Fund has 600 active grants in 144 countries.\n\nThe Global Fund's quality policy for pharmaceuticals has been revised following advice from this Expert Committee and since 2009 the policy has been based on three criteria:\n\n- **Clinical criteria** \u2014 medicines listed in WHO, national or institutional standard treatment guidelines (if not listed in one of the standard treatment guidelines, medicines require justification for selection from applicants or recipients).\n\n- **Quality criteria** \u2014 authorization of a product in the recipient country is necessary for all products. In the case of antiretrovirals (ARVs) and medicines for treating TB and malaria, WHO prequalification or authorization by stringent regulatory authorities (SRAs) or recommendation by the Expert Review Panel (ERP) is applied.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d5e61fbf0a3c0cddebff6ab290b17b16ddfc17a395e86cdf263147a557b6d1a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# General Policy\n\n## 2. International Collaboration\n\n### 2.1 International Collaboration\n\n#### 2.1.1 Collaboration with International Organizations and Agencies\n\n**European Directorate for the Quality of Medicines and HealthCare (Council of Europe)**\n\nA short update on the collaboration between the European Directorate for the Quality of Medicines and HealthCare (EDQM) and the WHO activities under this Expert Committee was given.\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\nThe Global Fund to Fight AIDS, Tuberculosis and Malaria works in partnership with governments, civil society, the private sector and affected communities.\n\nOf the approved Global Fund budget, 37% is used for medicines and health products. For instance, of US$ 19.4 billion approved by the Board, 62% was used for HIV/AIDS, 22% for malaria and 16% for tuberculosis. By region this amounts to: sub-Saharan Africa, 57%; East Asia and Pacific, 14%; Eastern Europe and Central Asia, 7%; South Asia, 9%; Middle East and North Africa, 6%. Overall the Global Fund has 600 active grants in 144 countries.\n\nThe Global Fund's quality policy for pharmaceuticals has been revised following advice from this Expert Committee and since 2009 the policy has been based on three criteria:\n\n- **Clinical criteria** \u2014 medicines listed in WHO, national or institutional standard treatment guidelines (if not listed in one of the standard treatment guidelines, medicines require justification for selection from applicants or recipients).\n\n- **Quality criteria** \u2014 authorization of a product in the recipient country is necessary for all products. In the case of antiretrovirals (ARVs) and medicines for treating TB and malaria, WHO prequalification or authorization by stringent regulatory authorities (SRAs) or recommendation by the Expert Review Panel (ERP) is applied.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1846, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6806560e-3e9c-4257-ac4e-0a84d41a1961": {"__data__": {"id_": "6806560e-3e9c-4257-ac4e-0a84d41a1961", "embedding": null, "metadata": {"page_label": "19", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- *Quality monitoring* \u2014 quality of products is monitored all along the supply chain recipients and the results are reported to The Global Fund.\n\nThe ERP hosted by WHO lessens potential use or benefits associated with the use of finished pharmaceutical products (FPPs) that are not WHO-prequalified or SRA-authorized. Eligibility criteria for dossier submission include products being manufactured at a GMP site and having already submitted a dossier to WHO for prequalification or SRA review. Recommendations by ERP are valid for 12 months.\n\nSince 2009 the number of products permitted for use based on different approaches are 51 based on ERP advice, 18 prequalified by WHO and 7 approved by SRAs.\n\nChallenges for The Global Fund include: an increased demand for malaria, tuberculosis and opportunistic infections (OI) medicines of assured quality; finding quality control laboratories with Global Fund requirements; and strengthening national regulatory capacity and regulatory networks for harmonization.\n\n### United Nations Children's Fund\n\nThe Expert Committee was briefed on the role of the Supply Division of the United Nations Children's Fund (UNICEF) which was established in 1946.\n\nOne of the main activities is the timely supply of quality medicines to countries and communities in need. The role of the Supply Division is to:\n\n- oversee UNICEF's global procurement and logistic operations;\n- procure supplies on behalf of UNICEF and procurement services partners; and\n- ensure that high quality, good value supplies reach children and their families quickly.\n\nProcurement of pharmaceuticals by UNICEF involves prequalification of supplies, which is based on assessment of suppliers by undertaking:\n\n- a review of the documentation submitted and/or GMP inspection to ensure compliance with WHO GMP requirements; and\n- assessment of products using the WHO Product Questionnaire in WHO Technical Report Series, No. 937.\n\nLocal authorities are invited to participate in GMP decisions based on:\n\n- the regulatory environment in the country of origin and prior experience of UNICEF; and\n- GMP inspection by UNICEF or a representative selected by UNICEF.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro, destacando el papel de la Organizaci\u00f3n Mundial de la Salud (OMS) y el Fondo de las Naciones Unidas para la Infancia (UNICEF). La OMS, a trav\u00e9s de su Programa de Evaluaci\u00f3n de Productos (ERP), establece criterios de elegibilidad para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, asegurando que solo aquellos fabricados en sitios que cumplen con las Buenas Pr\u00e1cticas de Manufactura (GMP) sean considerados. Desde 2009, se han permitido varios productos para su uso, y se identifican desaf\u00edos en la demanda de medicamentos de calidad para enfermedades como la malaria y la tuberculosis. Por su parte, UNICEF se encarga de la adquisici\u00f3n y log\u00edstica de medicamentos, asegurando que lleguen a las comunidades necesitadas, y tambi\u00e9n realiza evaluaciones de proveedores para garantizar el cumplimiento de los est\u00e1ndares de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplir los productos farmac\u00e9uticos para ser elegibles para la presentaci\u00f3n de dossiers ante la OMS?**\n   - Respuesta: Los productos deben ser fabricados en un sitio que cumpla con las Buenas Pr\u00e1cticas de Manufactura (GMP) y haber presentado previamente un dossier a la OMS para su precalificaci\u00f3n o revisi\u00f3n por una Autoridad Reguladora de Salud (SRA).\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el ERP de la OMS en la autorizaci\u00f3n de productos farmac\u00e9uticos y cu\u00e1l es la duraci\u00f3n de sus recomendaciones?**\n   - Respuesta: El ERP de la OMS eval\u00faa y reduce el uso de productos farmac\u00e9uticos terminados que no est\u00e1n precalificados por la OMS o autorizados por una SRA. Las recomendaciones del ERP son v\u00e1lidas por un per\u00edodo de 12 meses.\n\n3. **\u00bfC\u00f3mo se involucran las autoridades locales en las decisiones sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) en el proceso de adquisici\u00f3n de medicamentos por parte de UNICEF?**\n   - Respuesta: Las autoridades locales son invitadas a participar en las decisiones sobre GMP bas\u00e1ndose en el entorno regulatorio del pa\u00eds de origen y la experiencia previa de UNICEF, as\u00ed como en las inspecciones GMP realizadas por UNICEF o un representante designado por UNICEF.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n Internacional en Salud**: Se destaca la importancia de la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y diversas organizaciones internacionales para mejorar la calidad de los medicamentos y productos de salud a nivel global.\n\n2. **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: \n   - **Asociaciones**: Trabaja en conjunto con gobiernos, sociedad civil, sector privado y comunidades afectadas.\n   - **Presupuesto**: De un total de US$ 19.4 mil millones, se destina el 37% a medicamentos y productos de salud, con un desglose del 62% para VIH/SIDA, 22% para malaria y 16% para tuberculosis.\n   - **Distribuci\u00f3n Regional**: Los fondos se distribuyen principalmente en sub-Sahara (57%), Asia Oriental y Pac\u00edfico (14%), Europa del Este y Asia Central (7%), Asia del Sur (9%) y Medio Oriente y \u00c1frica del Norte (6%).\n\n3. **Pol\u00edtica de Calidad de Productos Farmac\u00e9uticos del Fondo Global**:\n   - **Criterios Cl\u00ednicos**: Los medicamentos deben estar listados en las gu\u00edas de tratamiento est\u00e1ndar de la OMS o requerir justificaci\u00f3n si no est\u00e1n incluidos.\n   - **Criterios de Calidad**: Se requiere autorizaci\u00f3n del producto en el pa\u00eds receptor. Para antirretrovirales y medicamentos para tuberculosis y malaria, se aplica la pre-calificaci\u00f3n de la OMS o autorizaci\u00f3n por autoridades regulatorias estrictas (SRA) o recomendaci\u00f3n del Panel de Revisi\u00f3n de Expertos (ERP).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Direcci\u00f3n Europea para la Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (Consejo de Europa)**", "excerpt_keywords": "Keywords: quality monitoring, pharmaceutical products, WHO prequalification, UNICEF procurement, regulatory capacity"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "82cde47b-c7e3-4546-80f5-6c3ef0117d3c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- *Quality monitoring* \u2014 quality of products is monitored all along the supply chain recipients and the results are reported to The Global Fund.\n\nThe ERP hosted by WHO lessens potential use or benefits associated with the use of finished pharmaceutical products (FPPs) that are not WHO-prequalified or SRA-authorized. Eligibility criteria for dossier submission include products being manufactured at a GMP site and having already submitted a dossier to WHO for prequalification or SRA review. Recommendations by ERP are valid for 12 months.\n\nSince 2009 the number of products permitted for use based on different approaches are 51 based on ERP advice, 18 prequalified by WHO and 7 approved by SRAs.\n\nChallenges for The Global Fund include: an increased demand for malaria, tuberculosis and opportunistic infections (OI) medicines of assured quality; finding quality control laboratories with Global Fund requirements; and strengthening national regulatory capacity and regulatory networks for harmonization.\n\n### United Nations Children's Fund\n\nThe Expert Committee was briefed on the role of the Supply Division of the United Nations Children's Fund (UNICEF) which was established in 1946.\n\nOne of the main activities is the timely supply of quality medicines to countries and communities in need. The role of the Supply Division is to:\n\n- oversee UNICEF's global procurement and logistic operations;\n- procure supplies on behalf of UNICEF and procurement services partners; and\n- ensure that high quality, good value supplies reach children and their families quickly.\n\nProcurement of pharmaceuticals by UNICEF involves prequalification of supplies, which is based on assessment of suppliers by undertaking:\n\n- a review of the documentation submitted and/or GMP inspection to ensure compliance with WHO GMP requirements; and\n- assessment of products using the WHO Product Questionnaire in WHO Technical Report Series, No. 937.\n\nLocal authorities are invited to participate in GMP decisions based on:\n\n- the regulatory environment in the country of origin and prior experience of UNICEF; and\n- GMP inspection by UNICEF or a representative selected by UNICEF.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "59a57ec72b5346b305c24ee5e81072e48864a800a1c4df0eddc2a4b1a322dd7f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- *Quality monitoring* \u2014 quality of products is monitored all along the supply chain recipients and the results are reported to The Global Fund.\n\nThe ERP hosted by WHO lessens potential use or benefits associated with the use of finished pharmaceutical products (FPPs) that are not WHO-prequalified or SRA-authorized. Eligibility criteria for dossier submission include products being manufactured at a GMP site and having already submitted a dossier to WHO for prequalification or SRA review. Recommendations by ERP are valid for 12 months.\n\nSince 2009 the number of products permitted for use based on different approaches are 51 based on ERP advice, 18 prequalified by WHO and 7 approved by SRAs.\n\nChallenges for The Global Fund include: an increased demand for malaria, tuberculosis and opportunistic infections (OI) medicines of assured quality; finding quality control laboratories with Global Fund requirements; and strengthening national regulatory capacity and regulatory networks for harmonization.\n\n### United Nations Children's Fund\n\nThe Expert Committee was briefed on the role of the Supply Division of the United Nations Children's Fund (UNICEF) which was established in 1946.\n\nOne of the main activities is the timely supply of quality medicines to countries and communities in need. The role of the Supply Division is to:\n\n- oversee UNICEF's global procurement and logistic operations;\n- procure supplies on behalf of UNICEF and procurement services partners; and\n- ensure that high quality, good value supplies reach children and their families quickly.\n\nProcurement of pharmaceuticals by UNICEF involves prequalification of supplies, which is based on assessment of suppliers by undertaking:\n\n- a review of the documentation submitted and/or GMP inspection to ensure compliance with WHO GMP requirements; and\n- assessment of products using the WHO Product Questionnaire in WHO Technical Report Series, No. 937.\n\nLocal authorities are invited to participate in GMP decisions based on:\n\n- the regulatory environment in the country of origin and prior experience of UNICEF; and\n- GMP inspection by UNICEF or a representative selected by UNICEF.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2160, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2809b67-3469-4a57-8e29-ccf56d8e06cd": {"__data__": {"id_": "c2809b67-3469-4a57-8e29-ccf56d8e06cd", "embedding": null, "metadata": {"page_label": "20", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Contract manufacture is only accepted if the subcontractor is also approved by UNICEF.\n\nInspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines.\n\nDuring 2006\u20132009, 89 GMP inspections were carried out and 27 companies failed (30%). In the case of GMP noncompliance (failure), a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nUNICEF does GMP in collaboration with local authorities and also carries out joint inspection with WHO, ICRC and MSF. It is also a partner to PIC/S.\n\nIn the case of prequalification of vaccines, HIV/AIDS, malaria and tuberculosis products:\n\n- products must be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that its products are identical to those assessed by WHO; and\n- UNICEF's purchase is \u201ctraced\u201d in WHO/UNICEF GMP inspection.\n\n## 2.1.2 Pharmacopoeial Discussion Group\n\nA brief update was given by the representative from the Japanese Pharmacopoeia on the current activities of the Pharmacopoeial Discussion Group (PDG) which consists of the European Pharmacopoeia (PhEur), Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP). At present, 27 of the 34 general chapters and 40 of the 63 excipient monographs of the current PDG work programme have been harmonized by these three pharmacopoeias. During the latest PDG meeting, a revision of the general chapter for Dissolution and corrections to Capillary electrophoresis were signed off. The sign-offs for excipients included revisions to previously harmonized excipient monographs. This exercise is aimed at achieving a higher level of harmonization of previously signed-off monographs. Harmonization has been achieved on nine of the 10 general chapters identified by the ICH Q6A Guideline. PDG\u2019s submission of Bulk and tapped density and bacterial endotoxins enabled the ICH Q4B to sign off the two texts at step 2. PDG re-emphasized the importance of consistent regulatory positions on harmonized text. At their joint meeting, PDG and ICH Q4B reflected on additional ways in which to accelerate declaration of regulatory interchangeability of pharmacopoeial texts.\n\nThe PDG parties agreed to provide their harmonized texts for the general methods in order to further enhance harmonization and to enable WHO to revise its text currently included in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Inspecciones de GMP y Colaboraci\u00f3n de UNICEF**: Durante el per\u00edodo de 2006 a 2009, UNICEF llev\u00f3 a cabo 89 inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP), de las cuales el 30% resultaron en fallos. UNICEF colabora con autoridades locales y realiza inspecciones conjuntas con organizaciones como la OMS, ICRC y MSF. Adem\u00e1s, para la precalificaci\u00f3n de productos relacionados con enfermedades como el VIH/SIDA, malaria y tuberculosis, es esencial que los productos est\u00e9n prequalificados por la OMS.\n\n2. **Grupo de Discusi\u00f3n Farmacopeica (PDG)**: El PDG, que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos, ha logrado armonizar una parte significativa de sus cap\u00edtulos generales y monograf\u00edas de excipientes. En su \u00faltima reuni\u00f3n, se firmaron revisiones importantes y se discutieron formas de acelerar la declaraci\u00f3n de intercambiabilidad regulatoria de los textos farmacopeicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones toma UNICEF en caso de incumplimiento de GMP por parte de una empresa?**\n   - En caso de incumplimiento de GMP, UNICEF env\u00eda un informe detallado de la inspecci\u00f3n a la empresa con una solicitud para que respondan dentro de un mes.\n\n2. **\u00bfCu\u00e1ntas de las monograf\u00edas de excipientes del programa de trabajo actual del PDG han sido armonizadas hasta la fecha?**\n   - Hasta el momento, 40 de las 63 monograf\u00edas de excipientes del programa de trabajo actual del PDG han sido armonizadas.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplir los productos para ser precalificados por UNICEF en relaci\u00f3n con las vacunas y tratamientos para enfermedades espec\u00edficas?**\n   - Los productos deben estar precalificados por la OMS, el proveedor debe confirmar que sus productos son id\u00e9nticos a los evaluados por la OMS, y la compra de UNICEF debe ser \"rastreada\" en la inspecci\u00f3n GMP de la OMS/UNICEF.", "prev_section_summary": "La secci\u00f3n aborda la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro, destacando el papel de dos entidades clave: la Organizaci\u00f3n Mundial de la Salud (OMS) y el Fondo de las Naciones Unidas para la Infancia (UNICEF).\n\n### Temas Clave:\n\n1. **Monitoreo de Calidad**: Se enfatiza la importancia de monitorear la calidad de los productos farmac\u00e9uticos en toda la cadena de suministro, con informes de resultados al Fondo Global.\n\n2. **Programa de Evaluaci\u00f3n de Productos (ERP)**: La OMS, a trav\u00e9s del ERP, establece criterios de elegibilidad para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, asegurando que solo se consideren aquellos fabricados en sitios que cumplen con las Buenas Pr\u00e1cticas de Manufactura (GMP). Las recomendaciones del ERP son v\u00e1lidas por 12 meses.\n\n3. **Desaf\u00edos para el Fondo Global**: Se identifican retos como el aumento de la demanda de medicamentos de calidad para enfermedades como malaria y tuberculosis, la necesidad de laboratorios de control de calidad que cumplan con los requisitos del Fondo Global, y el fortalecimiento de la capacidad regulatoria nacional.\n\n4. **Rol de UNICEF**: La Divisi\u00f3n de Suministros de UNICEF se encarga de la adquisici\u00f3n y log\u00edstica de medicamentos, asegurando que lleguen a las comunidades necesitadas. Esto incluye la pre-calificaci\u00f3n de suministros mediante la evaluaci\u00f3n de proveedores y el cumplimiento de los est\u00e1ndares de calidad de la OMS.\n\n5. **Participaci\u00f3n de Autoridades Locales**: Las autoridades locales son invitadas a participar en decisiones sobre GMP, considerando el entorno regulatorio del pa\u00eds de origen y la experiencia previa de UNICEF.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de establecer est\u00e1ndares y monitorear la calidad de los productos farmac\u00e9uticos.\n- **Fondo de las Naciones Unidas para la Infancia (UNICEF)**: Encargado de la adquisici\u00f3n y distribuci\u00f3n de medicamentos de calidad a comunidades necesitadas. \n- **Fondo Global**: Entidad que recibe informes sobre la calidad de los productos y enfrenta desaf\u00edos en la provisi\u00f3n de medicamentos de calidad. \n\nEste resumen destaca la colaboraci\u00f3n entre estas entidades para garantizar el acceso a medicamentos de calidad y la importancia de la regulaci\u00f3n y el monitoreo en la cadena de suministro farmac\u00e9utica.", "excerpt_keywords": "Keywords: UNICEF, GMP inspections, pharmacopoeial harmonization, WHO prequalification, pharmaceutical quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5c1196e0-1ef0-4d74-8944-72040e76d9ca", "node_type": "4", "metadata": {"page_label": "20", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Contract manufacture is only accepted if the subcontractor is also approved by UNICEF.\n\nInspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines.\n\nDuring 2006\u20132009, 89 GMP inspections were carried out and 27 companies failed (30%). In the case of GMP noncompliance (failure), a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nUNICEF does GMP in collaboration with local authorities and also carries out joint inspection with WHO, ICRC and MSF. It is also a partner to PIC/S.\n\nIn the case of prequalification of vaccines, HIV/AIDS, malaria and tuberculosis products:\n\n- products must be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that its products are identical to those assessed by WHO; and\n- UNICEF's purchase is \u201ctraced\u201d in WHO/UNICEF GMP inspection.\n\n## 2.1.2 Pharmacopoeial Discussion Group\n\nA brief update was given by the representative from the Japanese Pharmacopoeia on the current activities of the Pharmacopoeial Discussion Group (PDG) which consists of the European Pharmacopoeia (PhEur), Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP). At present, 27 of the 34 general chapters and 40 of the 63 excipient monographs of the current PDG work programme have been harmonized by these three pharmacopoeias. During the latest PDG meeting, a revision of the general chapter for Dissolution and corrections to Capillary electrophoresis were signed off. The sign-offs for excipients included revisions to previously harmonized excipient monographs. This exercise is aimed at achieving a higher level of harmonization of previously signed-off monographs. Harmonization has been achieved on nine of the 10 general chapters identified by the ICH Q6A Guideline. PDG\u2019s submission of Bulk and tapped density and bacterial endotoxins enabled the ICH Q4B to sign off the two texts at step 2. PDG re-emphasized the importance of consistent regulatory positions on harmonized text. At their joint meeting, PDG and ICH Q4B reflected on additional ways in which to accelerate declaration of regulatory interchangeability of pharmacopoeial texts.\n\nThe PDG parties agreed to provide their harmonized texts for the general methods in order to further enhance harmonization and to enable WHO to revise its text currently included in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3f123131836fee0582b0f19dd1d664bb8a4690182e7eb1f66ef80df84e893238", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Contract manufacture is only accepted if the subcontractor is also approved by UNICEF.\n\nInspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines.\n\nDuring 2006\u20132009, 89 GMP inspections were carried out and 27 companies failed (30%). In the case of GMP noncompliance (failure), a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nUNICEF does GMP in collaboration with local authorities and also carries out joint inspection with WHO, ICRC and MSF. It is also a partner to PIC/S.\n\nIn the case of prequalification of vaccines, HIV/AIDS, malaria and tuberculosis products:\n\n- products must be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that its products are identical to those assessed by WHO; and\n- UNICEF's purchase is \u201ctraced\u201d in WHO/UNICEF GMP inspection.\n\n## 2.1.2 Pharmacopoeial Discussion Group\n\nA brief update was given by the representative from the Japanese Pharmacopoeia on the current activities of the Pharmacopoeial Discussion Group (PDG) which consists of the European Pharmacopoeia (PhEur), Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP). At present, 27 of the 34 general chapters and 40 of the 63 excipient monographs of the current PDG work programme have been harmonized by these three pharmacopoeias. During the latest PDG meeting, a revision of the general chapter for Dissolution and corrections to Capillary electrophoresis were signed off. The sign-offs for excipients included revisions to previously harmonized excipient monographs. This exercise is aimed at achieving a higher level of harmonization of previously signed-off monographs. Harmonization has been achieved on nine of the 10 general chapters identified by the ICH Q6A Guideline. PDG\u2019s submission of Bulk and tapped density and bacterial endotoxins enabled the ICH Q4B to sign off the two texts at step 2. PDG re-emphasized the importance of consistent regulatory positions on harmonized text. At their joint meeting, PDG and ICH Q4B reflected on additional ways in which to accelerate declaration of regulatory interchangeability of pharmacopoeial texts.\n\nThe PDG parties agreed to provide their harmonized texts for the general methods in order to further enhance harmonization and to enable WHO to revise its text currently included in *The International Pharmacopoeia*.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2423, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e80a7397-6b1a-4efa-8a4b-500e045757f5": {"__data__": {"id_": "e80a7397-6b1a-4efa-8a4b-500e045757f5", "embedding": null, "metadata": {"page_label": "21", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.1.3 International Conference on Harmonisation\n\nThe Expert Committee was informed about the International Conference on Harmonisation (ICH) meeting held in Tallinn, Estonia from 5 to 10 June 2010, with a focus on the area of quality of pharmaceuticals. It was reported that the highlight of this meeting was the progress made in the global implementation of ICH.\n\nGuidelines Q8 (*Pharmaceutical development*), Q9 (*Quality risk management*) and Q10 (*Pharmaceutical quality system*) reflect the new paradigm in pharmaceutical quality towards more process\u2013product understanding and process control rather than end-product testing. The ICH Quality Implementation Working Group (IWG) had held its first training workshop in Tallinn. The training consisted of a case-study representing the different phases of the life-cycle of a pharmaceutical product. The training was subsequently held in Washington, DC (USA) and in Tokyo (Japan).\n\nFurther progress was made on the harmonization of pharmacopoeial texts in the three ICH regions, with the aim of reducing testing requirements. Two annexes for the Q4B Guideline *Evaluation and recommendation of pharmacopoeial text for use in the ICH regions* (Annex 11 on *Capillary electrophoresis* and Annex 12 on *Analytical sieving*) reached Step 4, and another two annexes (Annex 13 on *Bulk and tapped density* and Annex 14 on *Bacterial endotoxin*) reached Step 2. These texts will also be considered for further harmonization within the context of *The International Pharmacopoeia*.\n\nThe Q3D Expert Working Group (EWG) began work on guidelines that will provide limits for *Metal impurities* in medicines, products and ingredients both qualitatively and quantitatively.\n\nThe ICH Steering Committee approved the establishment of an EWG for a new multidisciplinary topic (M7) on *Genotoxic impurities*. The guidelines will describe the evaluation, qualification and control of these impurities in medicines during development and after licensing.\n\n## 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe Committee was provided with an update on the 14th International Conference of Drug Regulatory Authorities (ICDRA) hosted by the Health Sciences Authority of Singapore (HSA) together with WHO from 30 November to 3 December 2010 in Singapore. In conjunction with the 14th ICDRA, a pre-conference, entitled \u201cEffective collaboration: the future for medicines regulation,\u201d was to be held at the same location from 28 to 29 November 2010.\n\nGlobalization and rapid advances in information technology have brought about countless benefits and have improved living standards, but they...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto se centra en dos eventos importantes relacionados con la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos: la reuni\u00f3n de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) en Tallin, Estonia, y la 14\u00aa Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA) en Singapur. Durante la reuni\u00f3n del ICH, se discutieron avances en la implementaci\u00f3n de directrices que promueven un enfoque m\u00e1s comprensivo hacia la calidad farmac\u00e9utica, as\u00ed como la armonizaci\u00f3n de textos farmacop\u00e9icos. Tambi\u00e9n se mencionaron nuevas directrices sobre impurezas met\u00e1licas y genot\u00f3xicas en medicamentos. La ICDRA se centr\u00f3 en la colaboraci\u00f3n efectiva en la regulaci\u00f3n de medicamentos en un contexto de globalizaci\u00f3n y avances tecnol\u00f3gicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales directrices discutidas en la reuni\u00f3n del ICH y c\u00f3mo reflejan el nuevo paradigma en la calidad farmac\u00e9utica?**\n   - Respuesta: Las principales directrices discutidas son Q8 (*Desarrollo farmac\u00e9utico*), Q9 (*Gesti\u00f3n de riesgos de calidad*) y Q10 (*Sistema de calidad farmac\u00e9utica*), que enfatizan la comprensi\u00f3n del proceso y el control del mismo en lugar de solo la prueba del producto final.\n\n2. **\u00bfQu\u00e9 avances se lograron en la armonizaci\u00f3n de textos farmacop\u00e9icos durante la reuni\u00f3n del ICH y cu\u00e1les son los anexos que alcanzaron diferentes etapas?**\n   - Respuesta: Se lograron avances en la armonizaci\u00f3n de textos farmacop\u00e9icos, con dos anexos (Anexo 11 sobre *Electroforesis capilar* y Anexo 12 sobre *Tamizado anal\u00edtico*) alcanzando el Paso 4, y otros dos anexos (Anexo 13 sobre *Densidad a granel y apilada* y Anexo 14 sobre *Endotoxinas bacterianas*) alcanzando el Paso 2.\n\n3. **\u00bfQu\u00e9 temas se abordaron en la 14\u00aa ICDRA y cu\u00e1l fue el enfoque principal de la pre-conferencia?**\n   - Respuesta: En la 14\u00aa ICDRA se abordaron temas relacionados con la regulaci\u00f3n de medicamentos en un contexto global. El enfoque principal de la pre-conferencia fue \"Colaboraci\u00f3n efectiva: el futuro de la regulaci\u00f3n de medicamentos\".\n\n### Resumen de Nivel Superior\n\nLa reuni\u00f3n del ICH en Tallin se centr\u00f3 en la calidad de los productos farmac\u00e9uticos, destacando la importancia de un enfoque m\u00e1s integral hacia la calidad y la reducci\u00f3n de requisitos de prueba a trav\u00e9s de la armonizaci\u00f3n de textos. La 14\u00aa ICDRA en Singapur se enfoc\u00f3 en la colaboraci\u00f3n en la regulaci\u00f3n de medicamentos, reconociendo los desaf\u00edos y oportunidades presentados por la globalizaci\u00f3n y la tecnolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - UNICEF realiza inspecciones de GMP para asegurar el cumplimiento de las directrices de la OMS.\n   - Entre 2006 y 2009, se llevaron a cabo 89 inspecciones, de las cuales 27 empresas (30%) no cumplieron con los est\u00e1ndares.\n   - En caso de incumplimiento, se env\u00eda un informe detallado a la empresa con un plazo de respuesta de un mes.\n   - UNICEF colabora con autoridades locales y realiza inspecciones conjuntas con la OMS, el Comit\u00e9 Internacional de la Cruz Roja (ICRC) y M\u00e9dicos Sin Fronteras (MSF).\n\n2. **Precalificaci\u00f3n de Productos**:\n   - Para productos relacionados con VIH/SIDA, malaria y tuberculosis, deben estar precalificados por la OMS y confirmados por el proveedor como id\u00e9nticos a los evaluados por la OMS.\n   - Las compras de UNICEF deben ser rastreadas en las inspecciones GMP de la OMS/UNICEF.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica (PDG)**:\n   - Compuesto por la Farmacopea Europea (PhEur), la Farmacopea Japonesa (JP) y la Farmacopea de los Estados Unidos (USP).\n   - Se han armonizado 27 de los 34 cap\u00edtulos generales y 40 de las 63 monograf\u00edas de excipientes en el programa de trabajo actual.\n   - Se firmaron revisiones importantes en la \u00faltima reuni\u00f3n, incluyendo la disoluci\u00f3n y la electroforesis capilar.\n   - Se enfatiza la importancia de posiciones regulatorias consistentes sobre textos armonizados.\n\n4. **Harmonizaci\u00f3n y Regulaci\u00f3n**:\n   - Se ha logrado armonizaci\u00f3n en nueve de los diez cap\u00edtulos generales identificados por la Gu\u00eda ICH Q6A.\n   - Se discuten formas de acelerar la declaraci\u00f3n de intercambiabilidad regulatoria de los textos farmacopeicos.\n\n### Entidades Clave:\n- **UNICEF**: Organizaci\u00f3n que realiza inspecciones de GMP y colabora en la precalificaci\u00f3n de productos.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Establece directrices de GMP y precalificaci\u00f3n de productos.\n- **ICRC (Comit\u00e9 Internacional de la Cruz Roja)** y **MSF (M\u00e9dicos Sin Fronteras)**: Organizaciones con las que UNICEF colabora en inspecciones.\n- **PDG (Pharmacopoeial Discussion Group)**: Grupo que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos, trabajando en la armonizaci\u00f3n de textos farmacopeicos.", "excerpt_keywords": "Keywords: International Conference on Harmonisation, pharmaceutical quality, guidelines, harmonization, genotoxic impurities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1934e0f7-e4ce-4eee-a7bc-722897bf7e30", "node_type": "4", "metadata": {"page_label": "21", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.1.3 International Conference on Harmonisation\n\nThe Expert Committee was informed about the International Conference on Harmonisation (ICH) meeting held in Tallinn, Estonia from 5 to 10 June 2010, with a focus on the area of quality of pharmaceuticals. It was reported that the highlight of this meeting was the progress made in the global implementation of ICH.\n\nGuidelines Q8 (*Pharmaceutical development*), Q9 (*Quality risk management*) and Q10 (*Pharmaceutical quality system*) reflect the new paradigm in pharmaceutical quality towards more process\u2013product understanding and process control rather than end-product testing. The ICH Quality Implementation Working Group (IWG) had held its first training workshop in Tallinn. The training consisted of a case-study representing the different phases of the life-cycle of a pharmaceutical product. The training was subsequently held in Washington, DC (USA) and in Tokyo (Japan).\n\nFurther progress was made on the harmonization of pharmacopoeial texts in the three ICH regions, with the aim of reducing testing requirements. Two annexes for the Q4B Guideline *Evaluation and recommendation of pharmacopoeial text for use in the ICH regions* (Annex 11 on *Capillary electrophoresis* and Annex 12 on *Analytical sieving*) reached Step 4, and another two annexes (Annex 13 on *Bulk and tapped density* and Annex 14 on *Bacterial endotoxin*) reached Step 2. These texts will also be considered for further harmonization within the context of *The International Pharmacopoeia*.\n\nThe Q3D Expert Working Group (EWG) began work on guidelines that will provide limits for *Metal impurities* in medicines, products and ingredients both qualitatively and quantitatively.\n\nThe ICH Steering Committee approved the establishment of an EWG for a new multidisciplinary topic (M7) on *Genotoxic impurities*. The guidelines will describe the evaluation, qualification and control of these impurities in medicines during development and after licensing.\n\n## 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe Committee was provided with an update on the 14th International Conference of Drug Regulatory Authorities (ICDRA) hosted by the Health Sciences Authority of Singapore (HSA) together with WHO from 30 November to 3 December 2010 in Singapore. In conjunction with the 14th ICDRA, a pre-conference, entitled \u201cEffective collaboration: the future for medicines regulation,\u201d was to be held at the same location from 28 to 29 November 2010.\n\nGlobalization and rapid advances in information technology have brought about countless benefits and have improved living standards, but they...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ba140b8647100ae465dd40e26df78e4c0831401abddee698a3eaf749b470fece", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.1.3 International Conference on Harmonisation\n\nThe Expert Committee was informed about the International Conference on Harmonisation (ICH) meeting held in Tallinn, Estonia from 5 to 10 June 2010, with a focus on the area of quality of pharmaceuticals. It was reported that the highlight of this meeting was the progress made in the global implementation of ICH.\n\nGuidelines Q8 (*Pharmaceutical development*), Q9 (*Quality risk management*) and Q10 (*Pharmaceutical quality system*) reflect the new paradigm in pharmaceutical quality towards more process\u2013product understanding and process control rather than end-product testing. The ICH Quality Implementation Working Group (IWG) had held its first training workshop in Tallinn. The training consisted of a case-study representing the different phases of the life-cycle of a pharmaceutical product. The training was subsequently held in Washington, DC (USA) and in Tokyo (Japan).\n\nFurther progress was made on the harmonization of pharmacopoeial texts in the three ICH regions, with the aim of reducing testing requirements. Two annexes for the Q4B Guideline *Evaluation and recommendation of pharmacopoeial text for use in the ICH regions* (Annex 11 on *Capillary electrophoresis* and Annex 12 on *Analytical sieving*) reached Step 4, and another two annexes (Annex 13 on *Bulk and tapped density* and Annex 14 on *Bacterial endotoxin*) reached Step 2. These texts will also be considered for further harmonization within the context of *The International Pharmacopoeia*.\n\nThe Q3D Expert Working Group (EWG) began work on guidelines that will provide limits for *Metal impurities* in medicines, products and ingredients both qualitatively and quantitatively.\n\nThe ICH Steering Committee approved the establishment of an EWG for a new multidisciplinary topic (M7) on *Genotoxic impurities*. The guidelines will describe the evaluation, qualification and control of these impurities in medicines during development and after licensing.\n\n## 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe Committee was provided with an update on the 14th International Conference of Drug Regulatory Authorities (ICDRA) hosted by the Health Sciences Authority of Singapore (HSA) together with WHO from 30 November to 3 December 2010 in Singapore. In conjunction with the 14th ICDRA, a pre-conference, entitled \u201cEffective collaboration: the future for medicines regulation,\u201d was to be held at the same location from 28 to 29 November 2010.\n\nGlobalization and rapid advances in information technology have brought about countless benefits and have improved living standards, but they...", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2639, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "50477378-2887-453f-ac6c-7b6e79633095": {"__data__": {"id_": "50477378-2887-453f-ac6c-7b6e79633095", "embedding": null, "metadata": {"page_label": "22", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have also raised new challenges for public health and NMRAs. Increasing sophistication of health products, the development of cutting-edge technologies and extensive use of the Internet pose many challenges to the regulatory authorities of both developing and developed countries. ICDRA is a unique platform for NMRAs of WHO Member States to meet and discuss ways to strengthen collaboration and address issues of common concern. The organizing committee elaborated a programme that will provide opportunities for medicines regulators and interested stakeholders to share and discuss current and topical issues of global concern, for example, the H1N1 influenza situation, and access to high-quality medicines.\n\nThe pre-meeting would be open to other parties upon registration and would discuss collaboration and cooperation between NMRAs focusing on assessment and inspection.\n\n## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Essential medicines\n\nAn update on the activities of the Expert Committee on Selection and Use of Essential Medicines was given by its Secretary. Currently, the WHO Model List of Essential Medicines (EML) lists all medicines that are recommended for adults and children, including formulations. The 2nd WHO Model List of Essential Medicines for children (EMLc) includes children's medicines, together with age restrictions and medicines for neonates. However, at the moment there are certain discrepancies and difficulties between the two lists. For example, section 8.4 for palliative care does not list any medicines listed for adults and has a long list for children. It was explained that certain national contexts may not be evidence-based and made little use of the WHO Model List.\n\nThe Expert Committee was briefed on the project Better Medicines for Children, which provides intensive support to Ghana, two states in India and to the United Republic of Tanzania. Work is commencing with francophone African countries and there is ongoing support to other regions in aspects of implementation.\n\nThe eighteenth meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines will be held in Accra, Ghana from 21 to 25 March 2011. The agenda includes discussion on dosage forms, fixed-dose combinations, extemporaneous preparations, and ongoing application reviews.\n\nThe Committee recommended that the Expert Committee on Selection and Use of Essential Medicines consult with it on all issues relating to quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en los desaf\u00edos actuales que enfrentan las autoridades reguladoras de medicamentos (NMRAs) en el contexto de la creciente sofisticaci\u00f3n de los productos de salud y el uso de tecnolog\u00edas avanzadas. Se menciona la importancia de la colaboraci\u00f3n entre NMRAs a trav\u00e9s de la ICDRA y se discuten temas relacionados con la selecci\u00f3n y uso de medicamentos esenciales, incluyendo las discrepancias entre las listas de medicamentos esenciales para adultos y ni\u00f1os. Tambi\u00e9n se destaca el proyecto \"Better Medicines for Children\" y se anuncia la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos de la OMS sobre la selecci\u00f3n y uso de medicamentos esenciales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales discrepancias entre la Lista Modelo de Medicamentos Esenciales de la OMS para adultos y la de ni\u00f1os, y c\u00f3mo afectan estas diferencias a la atenci\u00f3n m\u00e9dica en diferentes contextos nacionales?**\n   - Esta pregunta busca profundizar en las implicaciones pr\u00e1cticas de las discrepancias mencionadas en el documento, que no se abordan en otros lugares.\n\n2. **\u00bfQu\u00e9 tipo de apoyo se est\u00e1 brindando a los pa\u00edses involucrados en el proyecto \"Better Medicines for Children\" y cu\u00e1les son los objetivos espec\u00edficos de este proyecto?**\n   - Esta pregunta se centra en los detalles del proyecto y su impacto en la mejora de la calidad de los medicamentos para ni\u00f1os, informaci\u00f3n que puede no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos se discutir\u00e1n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos sobre la selecci\u00f3n y uso de medicamentos esenciales en Accra, Ghana, y por qu\u00e9 son relevantes para la calidad de los medicamentos?**\n   - Esta pregunta busca obtener informaci\u00f3n sobre la agenda de la reuni\u00f3n y su relevancia, lo que puede no estar ampliamente documentado en otros contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. **Conferencia Internacional sobre Armonizaci\u00f3n (ICH)**\n   - **Evento**: Reuni\u00f3n en Tallin, Estonia (5-10 de junio de 2010).\n   - **Enfoque**: Calidad de los productos farmac\u00e9uticos.\n   - **Directrices Principales**:\n     - **Q8**: Desarrollo farmac\u00e9utico.\n     - **Q9**: Gesti\u00f3n de riesgos de calidad.\n     - **Q10**: Sistema de calidad farmac\u00e9utica.\n   - **Nuevo Paradigma**: Enfoque en la comprensi\u00f3n del proceso y control en lugar de solo pruebas del producto final.\n   - **Avances en Armonizaci\u00f3n**:\n     - Anexos alcanzados:\n       - **Paso 4**: Anexo 11 (*Electroforesis capilar*), Anexo 12 (*Tamizado anal\u00edtico*).\n       - **Paso 2**: Anexo 13 (*Densidad a granel y apilada*), Anexo 14 (*Endotoxinas bacterianas*).\n   - **Nuevas Iniciativas**:\n     - **Q3D EWG**: L\u00edmites para impurezas met\u00e1licas en medicamentos.\n     - **M7 EWG**: Directrices sobre impurezas genot\u00f3xicas.\n\n#### 2. **Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA)**\n   - **Evento**: 14\u00aa ICDRA en Singapur (30 de noviembre - 3 de diciembre de 2010).\n   - **Colaboraci\u00f3n**: Organizada por la Autoridad de Ciencias de la Salud de Singapur y la OMS.\n   - **Pre-conferencia**: \"Colaboraci\u00f3n efectiva: el futuro de la regulaci\u00f3n de medicamentos\" (28-29 de noviembre de 2010).\n   - **Contexto**: Enfoque en la regulaci\u00f3n de medicamentos en un entorno de globalizaci\u00f3n y avances tecnol\u00f3gicos.\n\n### Entidades Clave\n- **ICH**: Conferencia Internacional sobre Armonizaci\u00f3n.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **HSA**: Autoridad de Ciencias de la Salud de Singapur.\n- **Q3D EWG**: Grupo de trabajo sobre impurezas met\u00e1licas.\n- **M7 EWG**: Grupo de trabajo sobre impurezas genot\u00f3xicas. \n\nEste resumen destaca los eventos, directrices y enfoques discutidos en las reuniones, as\u00ed como las entidades involucradas en la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: NMRAs, essential medicines, quality assurance, ICDRA, Better Medicines for Children"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7028b56b-2994-46d1-82dc-9277c758f3e7", "node_type": "4", "metadata": {"page_label": "22", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have also raised new challenges for public health and NMRAs. Increasing sophistication of health products, the development of cutting-edge technologies and extensive use of the Internet pose many challenges to the regulatory authorities of both developing and developed countries. ICDRA is a unique platform for NMRAs of WHO Member States to meet and discuss ways to strengthen collaboration and address issues of common concern. The organizing committee elaborated a programme that will provide opportunities for medicines regulators and interested stakeholders to share and discuss current and topical issues of global concern, for example, the H1N1 influenza situation, and access to high-quality medicines.\n\nThe pre-meeting would be open to other parties upon registration and would discuss collaboration and cooperation between NMRAs focusing on assessment and inspection.\n\n## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Essential medicines\n\nAn update on the activities of the Expert Committee on Selection and Use of Essential Medicines was given by its Secretary. Currently, the WHO Model List of Essential Medicines (EML) lists all medicines that are recommended for adults and children, including formulations. The 2nd WHO Model List of Essential Medicines for children (EMLc) includes children's medicines, together with age restrictions and medicines for neonates. However, at the moment there are certain discrepancies and difficulties between the two lists. For example, section 8.4 for palliative care does not list any medicines listed for adults and has a long list for children. It was explained that certain national contexts may not be evidence-based and made little use of the WHO Model List.\n\nThe Expert Committee was briefed on the project Better Medicines for Children, which provides intensive support to Ghana, two states in India and to the United Republic of Tanzania. Work is commencing with francophone African countries and there is ongoing support to other regions in aspects of implementation.\n\nThe eighteenth meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines will be held in Accra, Ghana from 21 to 25 March 2011. The agenda includes discussion on dosage forms, fixed-dose combinations, extemporaneous preparations, and ongoing application reviews.\n\nThe Committee recommended that the Expert Committee on Selection and Use of Essential Medicines consult with it on all issues relating to quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e3472e073ac2e7e25194512417071e54ac00e592984163d82684417c0c1454a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "have also raised new challenges for public health and NMRAs. Increasing sophistication of health products, the development of cutting-edge technologies and extensive use of the Internet pose many challenges to the regulatory authorities of both developing and developed countries. ICDRA is a unique platform for NMRAs of WHO Member States to meet and discuss ways to strengthen collaboration and address issues of common concern. The organizing committee elaborated a programme that will provide opportunities for medicines regulators and interested stakeholders to share and discuss current and topical issues of global concern, for example, the H1N1 influenza situation, and access to high-quality medicines.\n\nThe pre-meeting would be open to other parties upon registration and would discuss collaboration and cooperation between NMRAs focusing on assessment and inspection.\n\n## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Essential medicines\n\nAn update on the activities of the Expert Committee on Selection and Use of Essential Medicines was given by its Secretary. Currently, the WHO Model List of Essential Medicines (EML) lists all medicines that are recommended for adults and children, including formulations. The 2nd WHO Model List of Essential Medicines for children (EMLc) includes children's medicines, together with age restrictions and medicines for neonates. However, at the moment there are certain discrepancies and difficulties between the two lists. For example, section 8.4 for palliative care does not list any medicines listed for adults and has a long list for children. It was explained that certain national contexts may not be evidence-based and made little use of the WHO Model List.\n\nThe Expert Committee was briefed on the project Better Medicines for Children, which provides intensive support to Ghana, two states in India and to the United Republic of Tanzania. Work is commencing with francophone African countries and there is ongoing support to other regions in aspects of implementation.\n\nThe eighteenth meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines will be held in Accra, Ghana from 21 to 25 March 2011. The agenda includes discussion on dosage forms, fixed-dose combinations, extemporaneous preparations, and ongoing application reviews.\n\nThe Committee recommended that the Expert Committee on Selection and Use of Essential Medicines consult with it on all issues relating to quality assurance of medicines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2524, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "40ac988c-786a-4169-9dd0-bb88047256ea": {"__data__": {"id_": "40ac988c-786a-4169-9dd0-bb88047256ea", "embedding": null, "metadata": {"page_label": "23", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2.2 Herbal and complementary medicines\n\nThe Traditional Medicine team, which used to be part of the Department of Essential Medicines and Pharmaceutical Policies is now under the Department of Health Policy, Development and Services. The resolution on traditional medicine adopted at the 62nd World Health Assembly in 2010 serves as the basis for its activities. The resolution requests WHO to strengthen cooperation with collaborating centres, research institutions and nongovernmental organizations in order to share evidence-based information and to support training programmes for national capacity building in the field of traditional medicines. It also requested WHO to continue providing technical guidance to support countries in ensuring the safety, efficacy and quality of traditional medicine, provide policy guidance to countries on how to integrate traditional medicine into health systems, and update the WHO traditional medicine strategy based on countries\u2019 progress and new challenges.\n\nStrategic objectives and priority areas of the Programme include:\n\n- Capitalization on the potential contribution of traditional medicines to self-care and to people-centred primary care;\n- Modality of integration of traditional medicines into health systems;\n- Promoting agreement and consensus on criteria for endorsement, integration and evaluation of traditional medicine as a subsystem of national health systems; and\n- Strengthening research to promote the quality, safety and efficacy of traditional medicines and products.\n\nAn update on the activities undertaken in 2010 in the area of quality and safety of herbal medicines included the following:\n\n- *Quality control methods for medicinal plant materials* \u2014 updated edition (currently in preparation for printing)\n- *Key technical issues of quality impacting on the safety of homeopathic medicines* (printed in 2010)\n- *Guidelines for selecting substances for quality control of herbal medicines* (in preparation)\n- *Good processing practices for herbal materials* (in preparation)\n- *Guidelines on safety management of toxic medicinal plants and monographs on selected commonly used toxic medicinal plants* (in preparation)\n\nImportant WHO documents on medicinal plants developed by the Programme include:\n\n*WHO monographs on selected medicinal plants* \u2014 Volumes 1, 2, 3 and 4. These monographs provide scientific information on safety, efficacy and quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl equipo de Medicina Tradicional de la OMS, ahora bajo el Departamento de Pol\u00edticas de Salud, se basa en una resoluci\u00f3n adoptada en 2010 para fortalecer la cooperaci\u00f3n en el \u00e1mbito de las medicinas tradicionales. Esta resoluci\u00f3n busca asegurar la seguridad, eficacia y calidad de las medicinas tradicionales, as\u00ed como su integraci\u00f3n en los sistemas de salud. Se destacan objetivos estrat\u00e9gicos como la promoci\u00f3n de la auto-cuidado y la investigaci\u00f3n sobre la calidad y seguridad de las medicinas herbales. Adem\u00e1s, se mencionan varias actividades y documentos importantes relacionados con el control de calidad y la gesti\u00f3n de plantas medicinales t\u00f3xicas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los objetivos estrat\u00e9gicos del Programa de Medicina Tradicional de la OMS seg\u00fan la resoluci\u00f3n de 2010?**\n   - Esta pregunta busca respuestas sobre los objetivos espec\u00edficos que gu\u00edan las actividades del programa, que no se encuentran f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 documentos importantes ha desarrollado la OMS en relaci\u00f3n con las plantas medicinales y cu\u00e1les son sus enfoques principales?**\n   - Esta pregunta se centra en los documentos espec\u00edficos mencionados en el contexto, proporcionando informaci\u00f3n sobre su contenido y prop\u00f3sito.\n\n3. **\u00bfQu\u00e9 actividades se llevaron a cabo en 2010 para mejorar la calidad y seguridad de las medicinas herbales?**\n   - Esta pregunta busca detalles sobre las iniciativas espec\u00edficas que se implementaron en ese a\u00f1o, lo que puede no estar documentado en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desaf\u00edos para la Salud P\u00fablica y NMRAs**:\n   - La creciente sofisticaci\u00f3n de los productos de salud, el desarrollo de tecnolog\u00edas avanzadas y el uso extensivo de Internet presentan nuevos retos para las autoridades reguladoras de medicamentos (NMRAs) en pa\u00edses en desarrollo y desarrollados.\n\n2. **ICDRA**:\n   - La ICDRA (International Conference of Drug Regulatory Authorities) es una plataforma \u00fanica para que las NMRAs de los Estados Miembros de la OMS se re\u00fanan y discutan formas de fortalecer la colaboraci\u00f3n y abordar problemas de inter\u00e9s com\u00fan, como la situaci\u00f3n de la influenza H1N1 y el acceso a medicamentos de alta calidad.\n\n3. **Medicamentos Esenciales**:\n   - Se actualiz\u00f3 sobre las actividades del Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales. La Lista Modelo de Medicamentos Esenciales de la OMS (EML) incluye medicamentos recomendados para adultos y ni\u00f1os, pero existen discrepancias entre la EML y la Lista Modelo de Medicamentos Esenciales para Ni\u00f1os (EMLc), especialmente en el \u00e1rea de cuidados paliativos.\n\n4. **Proyecto \"Better Medicines for Children\"**:\n   - Este proyecto brinda apoyo intensivo a Ghana, dos estados en India y la Rep\u00fablica Unida de Tanzania, y est\u00e1 comenzando a trabajar con pa\u00edses franc\u00f3fonos de \u00c1frica. Su objetivo es mejorar la calidad de los medicamentos para ni\u00f1os.\n\n5. **Pr\u00f3xima Reuni\u00f3n del Comit\u00e9 de Expertos**:\n   - La d\u00e9cimo octava reuni\u00f3n del Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales se llevar\u00e1 a cabo en Accra, Ghana, del 21 al 25 de marzo de 2011. La agenda incluir\u00e1 discusiones sobre formas de dosificaci\u00f3n, combinaciones de dosis fijas, preparaciones extempor\u00e1neas y revisiones de aplicaciones en curso.\n\n6. **Recomendaciones del Comit\u00e9**:\n   - Se recomend\u00f3 que el Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales consulte sobre todos los temas relacionados con la garant\u00eda de calidad de los medicamentos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que coordina las actividades de salud p\u00fablica y regula medicamentos esenciales.\n- **NMRAs (Autoridades Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n de medicamentos en diferentes pa\u00edses.\n- **ICDRA**: Conferencia Internacional de Autoridades Reguladoras de Medicamentos.\n- **Ghana, India, Rep\u00fablica Unida de Tanzania**: Pa\u00edses que reciben apoyo del proyecto \"Better Medicines for Children\".", "excerpt_keywords": "Keywords: traditional medicine, herbal medicines, WHO, quality control, safety management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "28274d98-b7c5-4399-ba80-8aa8a181a954", "node_type": "4", "metadata": {"page_label": "23", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2.2 Herbal and complementary medicines\n\nThe Traditional Medicine team, which used to be part of the Department of Essential Medicines and Pharmaceutical Policies is now under the Department of Health Policy, Development and Services. The resolution on traditional medicine adopted at the 62nd World Health Assembly in 2010 serves as the basis for its activities. The resolution requests WHO to strengthen cooperation with collaborating centres, research institutions and nongovernmental organizations in order to share evidence-based information and to support training programmes for national capacity building in the field of traditional medicines. It also requested WHO to continue providing technical guidance to support countries in ensuring the safety, efficacy and quality of traditional medicine, provide policy guidance to countries on how to integrate traditional medicine into health systems, and update the WHO traditional medicine strategy based on countries\u2019 progress and new challenges.\n\nStrategic objectives and priority areas of the Programme include:\n\n- Capitalization on the potential contribution of traditional medicines to self-care and to people-centred primary care;\n- Modality of integration of traditional medicines into health systems;\n- Promoting agreement and consensus on criteria for endorsement, integration and evaluation of traditional medicine as a subsystem of national health systems; and\n- Strengthening research to promote the quality, safety and efficacy of traditional medicines and products.\n\nAn update on the activities undertaken in 2010 in the area of quality and safety of herbal medicines included the following:\n\n- *Quality control methods for medicinal plant materials* \u2014 updated edition (currently in preparation for printing)\n- *Key technical issues of quality impacting on the safety of homeopathic medicines* (printed in 2010)\n- *Guidelines for selecting substances for quality control of herbal medicines* (in preparation)\n- *Good processing practices for herbal materials* (in preparation)\n- *Guidelines on safety management of toxic medicinal plants and monographs on selected commonly used toxic medicinal plants* (in preparation)\n\nImportant WHO documents on medicinal plants developed by the Programme include:\n\n*WHO monographs on selected medicinal plants* \u2014 Volumes 1, 2, 3 and 4. These monographs provide scientific information on safety, efficacy and quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c5b7d4a17a5466d198f93d77bf40d7bfa097c241263688b807bcaf5dbb11940f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.2.2 Herbal and complementary medicines\n\nThe Traditional Medicine team, which used to be part of the Department of Essential Medicines and Pharmaceutical Policies is now under the Department of Health Policy, Development and Services. The resolution on traditional medicine adopted at the 62nd World Health Assembly in 2010 serves as the basis for its activities. The resolution requests WHO to strengthen cooperation with collaborating centres, research institutions and nongovernmental organizations in order to share evidence-based information and to support training programmes for national capacity building in the field of traditional medicines. It also requested WHO to continue providing technical guidance to support countries in ensuring the safety, efficacy and quality of traditional medicine, provide policy guidance to countries on how to integrate traditional medicine into health systems, and update the WHO traditional medicine strategy based on countries\u2019 progress and new challenges.\n\nStrategic objectives and priority areas of the Programme include:\n\n- Capitalization on the potential contribution of traditional medicines to self-care and to people-centred primary care;\n- Modality of integration of traditional medicines into health systems;\n- Promoting agreement and consensus on criteria for endorsement, integration and evaluation of traditional medicine as a subsystem of national health systems; and\n- Strengthening research to promote the quality, safety and efficacy of traditional medicines and products.\n\nAn update on the activities undertaken in 2010 in the area of quality and safety of herbal medicines included the following:\n\n- *Quality control methods for medicinal plant materials* \u2014 updated edition (currently in preparation for printing)\n- *Key technical issues of quality impacting on the safety of homeopathic medicines* (printed in 2010)\n- *Guidelines for selecting substances for quality control of herbal medicines* (in preparation)\n- *Good processing practices for herbal materials* (in preparation)\n- *Guidelines on safety management of toxic medicinal plants and monographs on selected commonly used toxic medicinal plants* (in preparation)\n\nImportant WHO documents on medicinal plants developed by the Programme include:\n\n*WHO monographs on selected medicinal plants* \u2014 Volumes 1, 2, 3 and 4. These monographs provide scientific information on safety, efficacy and quality.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2426, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4e3c8add-2de2-4754-9221-cecf48510225": {"__data__": {"id_": "4e3c8add-2de2-4754-9221-cecf48510225", "embedding": null, "metadata": {"page_label": "24", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality control of widely used medicinal plants as well as providing models to assist countries in developing their own monographs or formularies.\n\n*WHO monographs on selected medicinal plants used in the Newly Independent States* (2010). The publication is available in English and in Russian and includes monographs adopted from existing WHO monographs, and of which 14 are new.\n\nWork is also being done to expand the evidence base on the quality, safety and efficacy of herbal medicines, including review and analysis of reports of clinical studies; technical documents on the safety of herbal medicines with reference to interaction with other medicines; and key technical issues of research methodologies.\n\nAnother ongoing activity is the 2nd WHO Global Survey on Material Policy and Regulation of Traditional Medicine. The objective of the survey is to assess the impact of implementation of the WHO Traditional Medicine Strategy: 2002\u20132005 and 2004\u20132007. The survey attempts to collect updated and more comprehensive information relating to practices and qualifications and to monitor progress in Member States. It also aims to identify new needs of each Member State and to update the WHO Traditional Medicine Strategy.\n\nBasic training guidelines, benchmarks and manuals developed in 2010 include: osteopathy; Tuina; Nua Thai; therapies using herbal medicines \u2014 Chinese traditional medicines; ayurvedic medicine; Unani medicine; naturopathic medicine; and naturopathy.\n\n### 2.2.3 Regulatory support\n\nAll WHO\u2019s normative work in the area of quality, safety and efficacy is intended to support NMRAs and is developed with them through the global consultative processes referred to above. The core functions of WHO\u2019s Medicines Regulatory Support Programme include the provision of direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory work; facilitating communication; and promoting harmonization among NMRAs. Country support involves assessing medicines regulatory systems to identify needs, preparing institutional plans and providing technical support and capacity building, based on WHO\u2019s data collection tools and methodology.\n\nThe Programme Manager of the Medicines Regulatory Support Programme briefed the Expert Committee members on the current activities of this programme. To date 51 assessments have been made of 47 regulatory systems, with the involvement of regional offices, and in close collaboration with the capacity-building teams from the WHO Secretariat. Technical", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monograf\u00edas de plantas medicinales**: La OMS ha desarrollado monograf\u00edas sobre plantas medicinales utilizadas en los Estados Independientes Nuevos, incluyendo 14 nuevas monograf\u00edas, con el objetivo de proporcionar modelos para que los pa\u00edses desarrollen sus propios formularios y monograf\u00edas.\n\n2. **Evidencia sobre medicamentos herbales**: Se est\u00e1 trabajando para expandir la base de evidencia sobre la calidad, seguridad y eficacia de los medicamentos herbales, lo que incluye la revisi\u00f3n de estudios cl\u00ednicos y documentos t\u00e9cnicos sobre la seguridad de estos medicamentos.\n\n3. **Encuesta global sobre medicina tradicional**: La OMS est\u00e1 llevando a cabo la 2\u00aa Encuesta Global sobre Pol\u00edtica y Regulaci\u00f3n de la Medicina Tradicional para evaluar el impacto de la Estrategia de Medicina Tradicional de la OMS y recopilar informaci\u00f3n actualizada sobre pr\u00e1cticas y necesidades en los Estados Miembros.\n\n4. **Apoyo regulatorio**: El Programa de Apoyo Regulatorio de Medicamentos de la OMS se centra en fortalecer la regulaci\u00f3n de medicamentos en los pa\u00edses, proporcionando apoyo t\u00e9cnico y herramientas para mejorar los sistemas regulatorios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos de la 2\u00aa Encuesta Global sobre Pol\u00edtica y Regulaci\u00f3n de la Medicina Tradicional de la OMS?**\n   - Esta pregunta busca detalles sobre los objetivos y el enfoque de la encuesta, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipos de terapias y medicinas se incluyen en las pautas de formaci\u00f3n b\u00e1sica desarrolladas por la OMS en 2010?**\n   - Esta pregunta se centra en las terapias espec\u00edficas mencionadas en el contexto, proporcionando informaci\u00f3n que podr\u00eda no estar ampliamente disponible.\n\n3. **\u00bfCu\u00e1ntas evaluaciones de sistemas regulatorios se han realizado hasta la fecha y qu\u00e9 implicaciones tienen para el fortalecimiento de la regulaci\u00f3n de medicamentos en los pa\u00edses?**\n   - Esta pregunta busca informaci\u00f3n cuantitativa y cualitativa sobre el impacto de las evaluaciones realizadas por la OMS en la regulaci\u00f3n de medicamentos, que puede no estar documentada en otros lugares.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Equipo de Medicina Tradicional de la OMS**:\n   - Ahora forma parte del Departamento de Pol\u00edticas de Salud, Desarrollo y Servicios.\n   - Basado en la resoluci\u00f3n adoptada en la 62\u00aa Asamblea Mundial de la Salud en 2010.\n\n2. **Resoluci\u00f3n de 2010**:\n   - Busca fortalecer la cooperaci\u00f3n con centros colaboradores, instituciones de investigaci\u00f3n y organizaciones no gubernamentales.\n   - Enfocada en compartir informaci\u00f3n basada en evidencia y apoyar programas de capacitaci\u00f3n para el desarrollo de capacidades nacionales en medicina tradicional.\n   - Proporcionar orientaci\u00f3n t\u00e9cnica para asegurar la seguridad, eficacia y calidad de la medicina tradicional.\n   - Integrar la medicina tradicional en los sistemas de salud y actualizar la estrategia de medicina tradicional de la OMS.\n\n3. **Objetivos estrat\u00e9gicos del Programa**:\n   - Contribuci\u00f3n de las medicinas tradicionales al autocuidado y atenci\u00f3n primaria centrada en las personas.\n   - Modalidades de integraci\u00f3n de las medicinas tradicionales en los sistemas de salud.\n   - Promoci\u00f3n de criterios para la evaluaci\u00f3n y la integraci\u00f3n de la medicina tradicional en los sistemas de salud nacionales.\n   - Fortalecimiento de la investigaci\u00f3n sobre la calidad, seguridad y eficacia de las medicinas y productos tradicionales.\n\n4. **Actividades de 2010**:\n   - Actualizaci\u00f3n de m\u00e9todos de control de calidad para materiales de plantas medicinales.\n   - Publicaci\u00f3n de cuestiones t\u00e9cnicas clave sobre la calidad y seguridad de los medicamentos homeop\u00e1ticos.\n   - Desarrollo de directrices para la selecci\u00f3n de sustancias para el control de calidad de las medicinas herbales.\n   - Buenas pr\u00e1cticas de procesamiento para materiales herbales.\n   - Directrices sobre la gesti\u00f3n de la seguridad de plantas medicinales t\u00f3xicas y monograf\u00edas sobre plantas t\u00f3xicas com\u00fanmente utilizadas.\n\n5. **Documentos importantes de la OMS**:\n   - Monograf\u00edas de la OMS sobre plantas medicinales seleccionadas (Vol\u00famenes 1, 2, 3 y 4), que proporcionan informaci\u00f3n cient\u00edfica sobre seguridad, eficacia y calidad.\n\n### Entidades clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica global.\n- **Medicinas tradicionales**: Incluye pr\u00e1cticas y productos que se basan en tradiciones culturales y conocimientos ancestrales.\n- **Centros colaboradores, instituciones de investigaci\u00f3n y ONG**: Entidades con las que la OMS busca colaborar para fortalecer la medicina tradicional.", "excerpt_keywords": "Keywords: medicinal plants, herbal medicines, WHO Traditional Medicine Strategy, regulatory support, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "962f93e4-ba47-4cdf-83cf-de27676441ec", "node_type": "4", "metadata": {"page_label": "24", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality control of widely used medicinal plants as well as providing models to assist countries in developing their own monographs or formularies.\n\n*WHO monographs on selected medicinal plants used in the Newly Independent States* (2010). The publication is available in English and in Russian and includes monographs adopted from existing WHO monographs, and of which 14 are new.\n\nWork is also being done to expand the evidence base on the quality, safety and efficacy of herbal medicines, including review and analysis of reports of clinical studies; technical documents on the safety of herbal medicines with reference to interaction with other medicines; and key technical issues of research methodologies.\n\nAnother ongoing activity is the 2nd WHO Global Survey on Material Policy and Regulation of Traditional Medicine. The objective of the survey is to assess the impact of implementation of the WHO Traditional Medicine Strategy: 2002\u20132005 and 2004\u20132007. The survey attempts to collect updated and more comprehensive information relating to practices and qualifications and to monitor progress in Member States. It also aims to identify new needs of each Member State and to update the WHO Traditional Medicine Strategy.\n\nBasic training guidelines, benchmarks and manuals developed in 2010 include: osteopathy; Tuina; Nua Thai; therapies using herbal medicines \u2014 Chinese traditional medicines; ayurvedic medicine; Unani medicine; naturopathic medicine; and naturopathy.\n\n### 2.2.3 Regulatory support\n\nAll WHO\u2019s normative work in the area of quality, safety and efficacy is intended to support NMRAs and is developed with them through the global consultative processes referred to above. The core functions of WHO\u2019s Medicines Regulatory Support Programme include the provision of direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory work; facilitating communication; and promoting harmonization among NMRAs. Country support involves assessing medicines regulatory systems to identify needs, preparing institutional plans and providing technical support and capacity building, based on WHO\u2019s data collection tools and methodology.\n\nThe Programme Manager of the Medicines Regulatory Support Programme briefed the Expert Committee members on the current activities of this programme. To date 51 assessments have been made of 47 regulatory systems, with the involvement of regional offices, and in close collaboration with the capacity-building teams from the WHO Secretariat. Technical", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ffe1ea0b008ad62b21e2a3a75c31539edf7c749883fe38f0c7ecdb11355980c9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "quality control of widely used medicinal plants as well as providing models to assist countries in developing their own monographs or formularies.\n\n*WHO monographs on selected medicinal plants used in the Newly Independent States* (2010). The publication is available in English and in Russian and includes monographs adopted from existing WHO monographs, and of which 14 are new.\n\nWork is also being done to expand the evidence base on the quality, safety and efficacy of herbal medicines, including review and analysis of reports of clinical studies; technical documents on the safety of herbal medicines with reference to interaction with other medicines; and key technical issues of research methodologies.\n\nAnother ongoing activity is the 2nd WHO Global Survey on Material Policy and Regulation of Traditional Medicine. The objective of the survey is to assess the impact of implementation of the WHO Traditional Medicine Strategy: 2002\u20132005 and 2004\u20132007. The survey attempts to collect updated and more comprehensive information relating to practices and qualifications and to monitor progress in Member States. It also aims to identify new needs of each Member State and to update the WHO Traditional Medicine Strategy.\n\nBasic training guidelines, benchmarks and manuals developed in 2010 include: osteopathy; Tuina; Nua Thai; therapies using herbal medicines \u2014 Chinese traditional medicines; ayurvedic medicine; Unani medicine; naturopathic medicine; and naturopathy.\n\n### 2.2.3 Regulatory support\n\nAll WHO\u2019s normative work in the area of quality, safety and efficacy is intended to support NMRAs and is developed with them through the global consultative processes referred to above. The core functions of WHO\u2019s Medicines Regulatory Support Programme include the provision of direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory work; facilitating communication; and promoting harmonization among NMRAs. Country support involves assessing medicines regulatory systems to identify needs, preparing institutional plans and providing technical support and capacity building, based on WHO\u2019s data collection tools and methodology.\n\nThe Programme Manager of the Medicines Regulatory Support Programme briefed the Expert Committee members on the current activities of this programme. To date 51 assessments have been made of 47 regulatory systems, with the involvement of regional offices, and in close collaboration with the capacity-building teams from the WHO Secretariat. Technical", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2580, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f535be60-caa2-4dce-9c8e-357625b5ace9": {"__data__": {"id_": "f535be60-caa2-4dce-9c8e-357625b5ace9", "embedding": null, "metadata": {"page_label": "25", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Joint Session with the Expert Committee on Biological Standardization\n\nAssistance has also been given to regional harmonization initiatives and for supporting the participation of bodies such as the Southern African Development Community, the East African Community and the Caribbean Community.\n\nIn response to the need for continuous learning by the staff of NMRAs, WHO has delivered training courses on the assessment of quality, safety and efficacy in the marketing authorization process in all WHO regions, involving participants from more than 50 Member States. To support the work and decision-making processes of NMRAs, a model for medicines regulation \u2014 the WHO Medicines Regulatory Package \u2014 has been developed, field-tested and implemented in seven African countries as a tool for exchange of regulatory information and for building regulatory capacity.\n\nThe African Medicines Registration Harmonization Initiative has been established in response to the increased responsibilities placed on national regulatory systems. WHO is working with the Department for International Development of the United Kingdom of Great Britain and Northern Ireland, the World Bank, the Bill & Melinda Gates Foundation, the William J. Clinton Foundation and the New Partnership for Africa Development (NEPAD) to improve health in Africa by increasing the availability of medical products that meet standards for safety, efficacy and quality through regional regulatory harmonization. The issue was discussed at the Second African Medicines Regulatory Authorities Conference (held in Maputo, 16\u201318 November 2009) which brought together 54 heads and staff of NMRAs from 40 countries. A World Bank Trust Fund has been established to pool donors\u2019 contributions to the initiative.\n\nWHO has continued to work closely with the NMRAs of Member States from all WHO regions in facilitating information exchange and knowledge transfer. Cooperation with regional networks \u2014 such as DRUGNET, which concerns the Newly Independent States \u2014 has enabled regulatory support to be provided to a large number of countries. Training has been offered to inspectors in conducting inspections of GMP, while quality control laboratories have received training in good practices for managing pharmaceutical laboratories in order to achieve a good level of quality assurance. Numerous capacity-building workshops have been organized with regulators, including workshops on new pharmaceutical legislation and on regulating medicines promotion.\n\n## 3. Joint Session with the Expert Committee on Biological Standardization\n\nThe joint session raised the following three topics that were of common interest:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento aborda las iniciativas de la Organizaci\u00f3n Mundial de la Salud (OMS) para mejorar la regulaci\u00f3n de medicamentos en \u00c1frica y otras regiones. Se menciona la capacitaci\u00f3n de personal de Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en la evaluaci\u00f3n de calidad, seguridad y eficacia de productos m\u00e9dicos. Adem\u00e1s, se destaca la creaci\u00f3n de la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos Africanos y la colaboraci\u00f3n con diversas organizaciones para aumentar la disponibilidad de productos m\u00e9dicos que cumplan con est\u00e1ndares de calidad. Tambi\u00e9n se discuten esfuerzos de intercambio de informaci\u00f3n y capacitaci\u00f3n en buenas pr\u00e1cticas de manufactura y gesti\u00f3n de laboratorios farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 modelo ha desarrollado la OMS para apoyar la regulaci\u00f3n de medicamentos y en cu\u00e1ntos pa\u00edses africanos se ha implementado?**\n   - Respuesta: La OMS ha desarrollado el \"WHO Medicines Regulatory Package\", que ha sido implementado en siete pa\u00edses africanos como herramienta para el intercambio de informaci\u00f3n regulatoria y para construir capacidad regulatoria.\n\n2. **\u00bfCu\u00e1les son las organizaciones con las que la OMS colabora para mejorar la salud en \u00c1frica a trav\u00e9s de la armonizaci\u00f3n regulatoria?**\n   - Respuesta: La OMS colabora con el Departamento para el Desarrollo Internacional del Reino Unido, el Banco Mundial, la Fundaci\u00f3n Bill y Melinda Gates, la Fundaci\u00f3n William J. Clinton y la Nueva Alianza para el Desarrollo de \u00c1frica (NEPAD).\n\n3. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se ha ofrecido a los inspectores y laboratorios de control de calidad en el contexto de la regulaci\u00f3n de medicamentos?**\n   - Respuesta: Se ha ofrecido capacitaci\u00f3n a inspectores en la realizaci\u00f3n de inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) y a laboratorios de control de calidad en buenas pr\u00e1cticas para la gesti\u00f3n de laboratorios farmac\u00e9uticos, con el fin de lograr un buen nivel de aseguramiento de la calidad.\n\n### Resumen de Nivel Superior\n\nEl documento destaca los esfuerzos de la OMS para fortalecer la regulaci\u00f3n de medicamentos a trav\u00e9s de la capacitaci\u00f3n de personal, el desarrollo de modelos regulatorios y la colaboraci\u00f3n con diversas organizaciones. Se enfatiza la importancia de la armonizaci\u00f3n regional y el intercambio de informaci\u00f3n para mejorar la calidad y disponibilidad de productos m\u00e9dicos en \u00c1frica y otras regiones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00edas de Plantas Medicinales**:\n   - La OMS ha desarrollado monograf\u00edas sobre plantas medicinales utilizadas en los Estados Independientes Nuevos, incluyendo 14 nuevas monograf\u00edas. Estas monograf\u00edas sirven como modelos para que los pa\u00edses creen sus propios formularios y monograf\u00edas.\n\n2. **Evidencia sobre Medicamentos Herbales**:\n   - Se est\u00e1 trabajando en expandir la base de evidencia sobre la calidad, seguridad y eficacia de los medicamentos herbales. Esto incluye la revisi\u00f3n de estudios cl\u00ednicos y la elaboraci\u00f3n de documentos t\u00e9cnicos sobre la seguridad de estos medicamentos, as\u00ed como su interacci\u00f3n con otros f\u00e1rmacos.\n\n3. **2\u00aa Encuesta Global sobre Medicina Tradicional**:\n   - La OMS est\u00e1 llevando a cabo esta encuesta para evaluar el impacto de la Estrategia de Medicina Tradicional de la OMS y recopilar informaci\u00f3n actualizada sobre pr\u00e1cticas y necesidades en los Estados Miembros. La encuesta busca identificar nuevas necesidades y actualizar la estrategia.\n\n4. **Apoyo Regulatorio**:\n   - El Programa de Apoyo Regulatorio de Medicamentos de la OMS se centra en fortalecer la regulaci\u00f3n de medicamentos en los pa\u00edses. Esto incluye la provisi\u00f3n de apoyo t\u00e9cnico, herramientas para mejorar los sistemas regulatorios y la promoci\u00f3n de la armonizaci\u00f3n entre las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs).\n\n5. **Pautas de Formaci\u00f3n B\u00e1sica**:\n   - En 2010, se desarrollaron pautas de formaci\u00f3n que abarcan diversas terapias, incluyendo osteopat\u00eda, Tuina, Nua Thai, medicinas tradicionales chinas, medicina ayurv\u00e9dica, medicina Unani, medicina naturop\u00e1tica y naturopat\u00eda.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de la regulaci\u00f3n y apoyo en el \u00e1mbito de la medicina tradicional y los medicamentos herbales.\n- **NMRAs (Autoridades Nacionales de Regulaci\u00f3n de Medicamentos)**: Entidades que se benefician del apoyo regulatorio y de las evaluaciones realizadas por la OMS.\n- **Estados Independientes Nuevos**: Regiones espec\u00edficas donde se han desarrollado las monograf\u00edas de plantas medicinales. \n\nEste resumen destaca los esfuerzos de la OMS en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional y los medicamentos herbales, as\u00ed como su compromiso con la capacitaci\u00f3n y el fortalecimiento de los sistemas regulatorios en los pa\u00edses miembros.", "excerpt_keywords": "Keywords: WHO, medicines regulation, training, Africa, harmonization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "890d8145-8a8c-441e-b648-5c670348eedd", "node_type": "4", "metadata": {"page_label": "25", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Joint Session with the Expert Committee on Biological Standardization\n\nAssistance has also been given to regional harmonization initiatives and for supporting the participation of bodies such as the Southern African Development Community, the East African Community and the Caribbean Community.\n\nIn response to the need for continuous learning by the staff of NMRAs, WHO has delivered training courses on the assessment of quality, safety and efficacy in the marketing authorization process in all WHO regions, involving participants from more than 50 Member States. To support the work and decision-making processes of NMRAs, a model for medicines regulation \u2014 the WHO Medicines Regulatory Package \u2014 has been developed, field-tested and implemented in seven African countries as a tool for exchange of regulatory information and for building regulatory capacity.\n\nThe African Medicines Registration Harmonization Initiative has been established in response to the increased responsibilities placed on national regulatory systems. WHO is working with the Department for International Development of the United Kingdom of Great Britain and Northern Ireland, the World Bank, the Bill & Melinda Gates Foundation, the William J. Clinton Foundation and the New Partnership for Africa Development (NEPAD) to improve health in Africa by increasing the availability of medical products that meet standards for safety, efficacy and quality through regional regulatory harmonization. The issue was discussed at the Second African Medicines Regulatory Authorities Conference (held in Maputo, 16\u201318 November 2009) which brought together 54 heads and staff of NMRAs from 40 countries. A World Bank Trust Fund has been established to pool donors\u2019 contributions to the initiative.\n\nWHO has continued to work closely with the NMRAs of Member States from all WHO regions in facilitating information exchange and knowledge transfer. Cooperation with regional networks \u2014 such as DRUGNET, which concerns the Newly Independent States \u2014 has enabled regulatory support to be provided to a large number of countries. Training has been offered to inspectors in conducting inspections of GMP, while quality control laboratories have received training in good practices for managing pharmaceutical laboratories in order to achieve a good level of quality assurance. Numerous capacity-building workshops have been organized with regulators, including workshops on new pharmaceutical legislation and on regulating medicines promotion.\n\n## 3. Joint Session with the Expert Committee on Biological Standardization\n\nThe joint session raised the following three topics that were of common interest:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f6a6a8ad0dc96e44e7f6467d94f79bba7e895f55eeabcddbe97c9b4ffea6eca5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Joint Session with the Expert Committee on Biological Standardization\n\nAssistance has also been given to regional harmonization initiatives and for supporting the participation of bodies such as the Southern African Development Community, the East African Community and the Caribbean Community.\n\nIn response to the need for continuous learning by the staff of NMRAs, WHO has delivered training courses on the assessment of quality, safety and efficacy in the marketing authorization process in all WHO regions, involving participants from more than 50 Member States. To support the work and decision-making processes of NMRAs, a model for medicines regulation \u2014 the WHO Medicines Regulatory Package \u2014 has been developed, field-tested and implemented in seven African countries as a tool for exchange of regulatory information and for building regulatory capacity.\n\nThe African Medicines Registration Harmonization Initiative has been established in response to the increased responsibilities placed on national regulatory systems. WHO is working with the Department for International Development of the United Kingdom of Great Britain and Northern Ireland, the World Bank, the Bill & Melinda Gates Foundation, the William J. Clinton Foundation and the New Partnership for Africa Development (NEPAD) to improve health in Africa by increasing the availability of medical products that meet standards for safety, efficacy and quality through regional regulatory harmonization. The issue was discussed at the Second African Medicines Regulatory Authorities Conference (held in Maputo, 16\u201318 November 2009) which brought together 54 heads and staff of NMRAs from 40 countries. A World Bank Trust Fund has been established to pool donors\u2019 contributions to the initiative.\n\nWHO has continued to work closely with the NMRAs of Member States from all WHO regions in facilitating information exchange and knowledge transfer. Cooperation with regional networks \u2014 such as DRUGNET, which concerns the Newly Independent States \u2014 has enabled regulatory support to be provided to a large number of countries. Training has been offered to inspectors in conducting inspections of GMP, while quality control laboratories have received training in good practices for managing pharmaceutical laboratories in order to achieve a good level of quality assurance. Numerous capacity-building workshops have been organized with regulators, including workshops on new pharmaceutical legislation and on regulating medicines promotion.\n\n## 3. Joint Session with the Expert Committee on Biological Standardization\n\nThe joint session raised the following three topics that were of common interest:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2667, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "46bcff2e-e72f-4633-8c60-988b689058a0": {"__data__": {"id_": "46bcff2e-e72f-4633-8c60-988b689058a0", "embedding": null, "metadata": {"page_label": "26", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products;\n\u2014 Proposal to initiate a project to evaluate a candidate International Standard for Human Recombinant Insulin; and\n\u2014 WHO GMP for blood establishments.\n\nEach of these topics was discussed jointly and again in each Committee's sessions; each Committee has taken appropriate action in a coordinated manner. Further details and recommendations are included under the specific sections of this report.\n\nThe Expert Committee appreciated the opportunity for joint discussion between the two Expert Committees of issues of mutual interest.\n\nThe conclusion and recommendation was that work should progress and the Expert Committees on Specifications for Pharmaceutical Preparations and on Biological Standardization should continue to collaborate on topics of common interest.\n\n## 4. Quality control \u2014 specifications and tests\n\n### 4.1 The International Pharmacopoeia\n\n**Second supplement**\n\nAn update was presented on *The International Pharmacopoeia* (Ph.Int.) activities and work plan. The Expert Committee noted that the work on the compilation of the Second supplement to the fourth edition was progressing and that it would be published as a replacement CD-ROM and an online version.\n\nThis publication would comprise new and revised texts adopted by the Expert Committee since 2007.\n\nAs per the work process, the final version of the monographs adopted during the present meeting would be made available on the WHO Medicines web site once completed and would subsequently be compiled into a publication.\n\n**Collaboration with other pharmacopoeias**\n\nThe Secretariat reported to the Expert Committee that an enhanced collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia* had commenced.\n\nThis collaboration between The Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland (MHRA), which hosts *The British Pharmacopoeia* and WHO, which hosts *The International Pharmacopoeia*, was aimed at developing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n entre Comit\u00e9s de Expertos**: Se llev\u00f3 a cabo una discusi\u00f3n conjunta entre dos Comit\u00e9s de Expertos de la OMS sobre temas de inter\u00e9s mutuo, incluyendo la gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura, la evaluaci\u00f3n de un est\u00e1ndar internacional para la insulina humana recombinante y las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre. Se recomend\u00f3 que ambos Comit\u00e9s contin\u00faen colaborando en estos temas.\n\n2. **Actualizaci\u00f3n sobre la Farmacopea Internacional**: Se present\u00f3 un informe sobre el progreso de la compilaci\u00f3n del Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional*. Este suplemento incluir\u00e1 textos nuevos y revisados adoptados desde 2007 y se publicar\u00e1 en formato CD-ROM y en l\u00ednea. Adem\u00e1s, se destac\u00f3 la colaboraci\u00f3n mejorada entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas espec\u00edficos discutidos en la reuni\u00f3n conjunta de los Comit\u00e9s de Expertos de la OMS?**\n   - Los temas discutidos incluyen la gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura, la propuesta para evaluar un est\u00e1ndar internacional para la insulina humana recombinante y las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n\n2. **\u00bfQu\u00e9 novedades se esperan en la publicaci\u00f3n del Segundo suplemento de *La Farmacopea Internacional*?**\n   - Se espera que el Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional* incluya nuevos y revisados textos adoptados desde 2007, y se publicar\u00e1 tanto en formato CD-ROM como en l\u00ednea.\n\n3. **\u00bfQu\u00e9 objetivos tiene la colaboraci\u00f3n entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*?**\n   - La colaboraci\u00f3n tiene como objetivo desarrollar y mejorar la armonizaci\u00f3n de los est\u00e1ndares farmac\u00e9uticos entre ambas farmacopeas, facilitando as\u00ed un mejor control de calidad y especificaciones en la producci\u00f3n de productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n aborda los esfuerzos de la Organizaci\u00f3n Mundial de la Salud (OMS) para mejorar la regulaci\u00f3n de medicamentos, especialmente en \u00c1frica, a trav\u00e9s de diversas iniciativas y colaboraciones. Los temas clave incluyen:\n\n1. **Capacitaci\u00f3n de Personal**: La OMS ha proporcionado cursos de formaci\u00f3n a los empleados de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) sobre la evaluaci\u00f3n de calidad, seguridad y eficacia en el proceso de autorizaci\u00f3n de comercializaci\u00f3n, involucrando a m\u00e1s de 50 Estados Miembros.\n\n2. **Modelo Regulatorio**: Se ha desarrollado y implementado el \"WHO Medicines Regulatory Package\" en siete pa\u00edses africanos, como herramienta para el intercambio de informaci\u00f3n regulatoria y para fortalecer la capacidad regulatoria.\n\n3. **Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos Africanos**: Esta iniciativa se ha establecido para abordar las crecientes responsabilidades de los sistemas regulatorios nacionales, con el objetivo de aumentar la disponibilidad de productos m\u00e9dicos que cumplan con est\u00e1ndares de calidad.\n\n4. **Colaboraciones**: La OMS trabaja con varias organizaciones, incluyendo el Departamento para el Desarrollo Internacional del Reino Unido, el Banco Mundial, la Fundaci\u00f3n Bill y Melinda Gates, la Fundaci\u00f3n William J. Clinton y la Nueva Alianza para el Desarrollo de \u00c1frica (NEPAD), para mejorar la salud en \u00c1frica mediante la armonizaci\u00f3n regulatoria.\n\n5. **Intercambio de Informaci\u00f3n y Capacitaci\u00f3n**: Se han facilitado intercambios de informaci\u00f3n y transferencia de conocimientos entre NMRAs de diferentes regiones, as\u00ed como capacitaci\u00f3n a inspectores en Buenas Pr\u00e1cticas de Manufactura (GMP) y a laboratorios de control de calidad en buenas pr\u00e1cticas de gesti\u00f3n.\n\nEn resumen, la OMS est\u00e1 trabajando activamente para fortalecer la regulaci\u00f3n de medicamentos a trav\u00e9s de la capacitaci\u00f3n, el desarrollo de modelos regulatorios y la colaboraci\u00f3n con diversas entidades, enfatizando la importancia de la armonizaci\u00f3n regional y el intercambio de informaci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceutical products, International Pharmacopoeia, quality control, collaboration, WHO GMP"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ca2b0f9f-d597-4167-a55d-194ff807b120", "node_type": "4", "metadata": {"page_label": "26", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products;\n\u2014 Proposal to initiate a project to evaluate a candidate International Standard for Human Recombinant Insulin; and\n\u2014 WHO GMP for blood establishments.\n\nEach of these topics was discussed jointly and again in each Committee's sessions; each Committee has taken appropriate action in a coordinated manner. Further details and recommendations are included under the specific sections of this report.\n\nThe Expert Committee appreciated the opportunity for joint discussion between the two Expert Committees of issues of mutual interest.\n\nThe conclusion and recommendation was that work should progress and the Expert Committees on Specifications for Pharmaceutical Preparations and on Biological Standardization should continue to collaborate on topics of common interest.\n\n## 4. Quality control \u2014 specifications and tests\n\n### 4.1 The International Pharmacopoeia\n\n**Second supplement**\n\nAn update was presented on *The International Pharmacopoeia* (Ph.Int.) activities and work plan. The Expert Committee noted that the work on the compilation of the Second supplement to the fourth edition was progressing and that it would be published as a replacement CD-ROM and an online version.\n\nThis publication would comprise new and revised texts adopted by the Expert Committee since 2007.\n\nAs per the work process, the final version of the monographs adopted during the present meeting would be made available on the WHO Medicines web site once completed and would subsequently be compiled into a publication.\n\n**Collaboration with other pharmacopoeias**\n\nThe Secretariat reported to the Expert Committee that an enhanced collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia* had commenced.\n\nThis collaboration between The Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland (MHRA), which hosts *The British Pharmacopoeia* and WHO, which hosts *The International Pharmacopoeia*, was aimed at developing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "78e28515efb53ead3f7a68957064232b94b49908edb65cf8f75b57bad87fdf6c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# \u2014 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products;\n\u2014 Proposal to initiate a project to evaluate a candidate International Standard for Human Recombinant Insulin; and\n\u2014 WHO GMP for blood establishments.\n\nEach of these topics was discussed jointly and again in each Committee's sessions; each Committee has taken appropriate action in a coordinated manner. Further details and recommendations are included under the specific sections of this report.\n\nThe Expert Committee appreciated the opportunity for joint discussion between the two Expert Committees of issues of mutual interest.\n\nThe conclusion and recommendation was that work should progress and the Expert Committees on Specifications for Pharmaceutical Preparations and on Biological Standardization should continue to collaborate on topics of common interest.\n\n## 4. Quality control \u2014 specifications and tests\n\n### 4.1 The International Pharmacopoeia\n\n**Second supplement**\n\nAn update was presented on *The International Pharmacopoeia* (Ph.Int.) activities and work plan. The Expert Committee noted that the work on the compilation of the Second supplement to the fourth edition was progressing and that it would be published as a replacement CD-ROM and an online version.\n\nThis publication would comprise new and revised texts adopted by the Expert Committee since 2007.\n\nAs per the work process, the final version of the monographs adopted during the present meeting would be made available on the WHO Medicines web site once completed and would subsequently be compiled into a publication.\n\n**Collaboration with other pharmacopoeias**\n\nThe Secretariat reported to the Expert Committee that an enhanced collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia* had commenced.\n\nThis collaboration between The Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland (MHRA), which hosts *The British Pharmacopoeia* and WHO, which hosts *The International Pharmacopoeia*, was aimed at developing.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2097, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f30e4055-334a-429f-a3ec-019f8c0827d3": {"__data__": {"id_": "f30e4055-334a-429f-a3ec-019f8c0827d3", "embedding": null, "metadata": {"page_label": "27", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "a closer cooperation and exchange in the field of quality specifications for medicines, which would be based on common priorities as identified by both pharmacopoeias in their respective work plans.\n\nIt was foreseen that by sharing their experience in the development of specifications for formulated products, this collaboration would be of mutual benefit for these pharmacopoeias, notably in making more specifications available to users.\n\nThe Secretariat informed the Expert Committee that, in the context of this cooperation, work had been rapidly initiated with a pilot phase comprising three monographs for anti-infectives (amoxicillin oral suspension, metronidazole oral suspension, sulfamethoxazole and trimethoprim tablets) that could be developed and discussed at the meeting of the Expert Committee.\n\nNoting that this collaboration was to be formalized by an agreement between the two organizations hosting the pharmacopoeias, the Expert Committee welcomed this initiative and the outcome of this pilot phase in adopting the presented texts (see section 4.3.4 of this report on specifications for anti-infectives).\n\n### 4.2 Current work plan and future work programme\n\nBased on the 2010 work plan, the Expert Committee discussed and reviewed:\n\n\u2014 the current development status of the monographs; and  \n\u2014 new proposals for developing specifications for active substances and dosage forms, including those for paediatric use.\n\nNew proposals were made, taking into account:\n\n- substances remaining in the current work plan;\n- substances initially listed in the previously adopted work programmes that were then prioritized, based on the importance of the products for the treatment of WHO priority diseases (including HIV/AIDS, tuberculosis, malaria, programmes and diseases with high prevalence in developing countries);\n- new additions from the updated sixteenth WHO Model List of Essential Medicines (March 2010) and the updated second WHO Model List of Essential Medicines for Children (March 2010);\n- new additions from the expressions of interest within the WHO Prequalification of Medicines Programme; and\n- requests for medicines recommended in WHO\u2019s specific disease programmes.\n\nCategories covered in the work programme included medicines used in the treatment of HIV/AIDS, malaria, tuberculosis, as well as anti-infectives (anthelmintics, antibacterial, antiprotozoal, antifungal, antiviral).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla la cooperaci\u00f3n entre dos organizaciones que albergan farmacopoeias, enfoc\u00e1ndose en el desarrollo de especificaciones de calidad para medicamentos. Se menciona una fase piloto que incluye tres monograf\u00edas para anti-infectivos, y se discuten propuestas para el desarrollo de especificaciones de sustancias activas y formas de dosificaci\u00f3n, con un \u00e9nfasis particular en medicamentos para el tratamiento de enfermedades prioritarias de la OMS, como el VIH/SIDA, la tuberculosis y la malaria. Adem\u00e1s, se abordan las prioridades basadas en la lista de medicamentos esenciales de la OMS y las solicitudes de medicamentos recomendados en programas espec\u00edficos de enfermedades.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres anti-infectivos que se incluyeron en la fase piloto de colaboraci\u00f3n entre las farmacopoeias?**\n   - Respuesta: Los tres anti-infectivos son amoxicilina en suspensi\u00f3n oral, metronidazol en suspensi\u00f3n oral y tabletas de sulfametoxazol y trimetoprima.\n\n2. **\u00bfQu\u00e9 criterios se utilizaron para priorizar las sustancias en el plan de trabajo actual de la OMS?**\n   - Respuesta: Las sustancias se priorizaron en funci\u00f3n de su importancia para el tratamiento de enfermedades prioritarias de la OMS, as\u00ed como de su inclusi\u00f3n en la lista actualizada de medicamentos esenciales y las expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n\n3. **\u00bfQu\u00e9 categor\u00edas de medicamentos se abordan en el programa de trabajo mencionado en el documento?**\n   - Respuesta: Las categor\u00edas de medicamentos incluyen aquellos utilizados en el tratamiento del VIH/SIDA, malaria, tuberculosis, as\u00ed como anti-infectivos (anthelminticos, antibacterianos, antiprotozoarios, antif\u00fangicos y antivirales).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n entre Comit\u00e9s de Expertos de la OMS**:\n   - Se discutieron temas de inter\u00e9s mutuo, incluyendo:\n     - Gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n     - Evaluaci\u00f3n de un est\u00e1ndar internacional para la insulina humana recombinante.\n     - Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n   - Se recomend\u00f3 que los Comit\u00e9s contin\u00faen colaborando en estos temas.\n\n2. **Actualizaci\u00f3n sobre *La Farmacopea Internacional***:\n   - Se present\u00f3 un informe sobre el progreso del Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional* (Ph.Int.).\n   - Este suplemento incluir\u00e1 nuevos y revisados textos adoptados desde 2007 y se publicar\u00e1 en formato CD-ROM y en l\u00ednea.\n   - La versi\u00f3n final de los monograf\u00edas adoptadas se publicar\u00e1 en el sitio web de Medicamentos de la OMS.\n\n3. **Colaboraci\u00f3n con otras farmacopeas**:\n   - Se inici\u00f3 una colaboraci\u00f3n mejorada entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*.\n   - Esta colaboraci\u00f3n involucra a la Agencia de Medicamentos y Productos de Salud del Reino Unido (MHRA) y la OMS, con el objetivo de desarrollar y armonizar est\u00e1ndares farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Coordinadora de las discusiones y publicaciones.\n- **Comit\u00e9s de Expertos**: Dos comit\u00e9s involucrados en la discusi\u00f3n de temas farmac\u00e9uticos y biol\u00f3gicos.\n- **La Farmacopea Internacional**: Publicaci\u00f3n que est\u00e1 en proceso de actualizaci\u00f3n.\n- **La Farmacopea Brit\u00e1nica**: Colaboradora en el desarrollo de est\u00e1ndares farmac\u00e9uticos.\n- **MHRA**: Agencia reguladora del Reino Unido que participa en la colaboraci\u00f3n con la OMS.", "excerpt_keywords": "Keywords: pharmacopoeias, quality specifications, anti-infectives, WHO Model List, collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "858e9273-6024-4417-abc7-428e6d7556ca", "node_type": "4", "metadata": {"page_label": "27", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "a closer cooperation and exchange in the field of quality specifications for medicines, which would be based on common priorities as identified by both pharmacopoeias in their respective work plans.\n\nIt was foreseen that by sharing their experience in the development of specifications for formulated products, this collaboration would be of mutual benefit for these pharmacopoeias, notably in making more specifications available to users.\n\nThe Secretariat informed the Expert Committee that, in the context of this cooperation, work had been rapidly initiated with a pilot phase comprising three monographs for anti-infectives (amoxicillin oral suspension, metronidazole oral suspension, sulfamethoxazole and trimethoprim tablets) that could be developed and discussed at the meeting of the Expert Committee.\n\nNoting that this collaboration was to be formalized by an agreement between the two organizations hosting the pharmacopoeias, the Expert Committee welcomed this initiative and the outcome of this pilot phase in adopting the presented texts (see section 4.3.4 of this report on specifications for anti-infectives).\n\n### 4.2 Current work plan and future work programme\n\nBased on the 2010 work plan, the Expert Committee discussed and reviewed:\n\n\u2014 the current development status of the monographs; and  \n\u2014 new proposals for developing specifications for active substances and dosage forms, including those for paediatric use.\n\nNew proposals were made, taking into account:\n\n- substances remaining in the current work plan;\n- substances initially listed in the previously adopted work programmes that were then prioritized, based on the importance of the products for the treatment of WHO priority diseases (including HIV/AIDS, tuberculosis, malaria, programmes and diseases with high prevalence in developing countries);\n- new additions from the updated sixteenth WHO Model List of Essential Medicines (March 2010) and the updated second WHO Model List of Essential Medicines for Children (March 2010);\n- new additions from the expressions of interest within the WHO Prequalification of Medicines Programme; and\n- requests for medicines recommended in WHO\u2019s specific disease programmes.\n\nCategories covered in the work programme included medicines used in the treatment of HIV/AIDS, malaria, tuberculosis, as well as anti-infectives (anthelmintics, antibacterial, antiprotozoal, antifungal, antiviral).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "758aed7a89209dc21cd4b1ed55da76329bfb6325306252a70a02ec2e050199a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "a closer cooperation and exchange in the field of quality specifications for medicines, which would be based on common priorities as identified by both pharmacopoeias in their respective work plans.\n\nIt was foreseen that by sharing their experience in the development of specifications for formulated products, this collaboration would be of mutual benefit for these pharmacopoeias, notably in making more specifications available to users.\n\nThe Secretariat informed the Expert Committee that, in the context of this cooperation, work had been rapidly initiated with a pilot phase comprising three monographs for anti-infectives (amoxicillin oral suspension, metronidazole oral suspension, sulfamethoxazole and trimethoprim tablets) that could be developed and discussed at the meeting of the Expert Committee.\n\nNoting that this collaboration was to be formalized by an agreement between the two organizations hosting the pharmacopoeias, the Expert Committee welcomed this initiative and the outcome of this pilot phase in adopting the presented texts (see section 4.3.4 of this report on specifications for anti-infectives).\n\n### 4.2 Current work plan and future work programme\n\nBased on the 2010 work plan, the Expert Committee discussed and reviewed:\n\n\u2014 the current development status of the monographs; and  \n\u2014 new proposals for developing specifications for active substances and dosage forms, including those for paediatric use.\n\nNew proposals were made, taking into account:\n\n- substances remaining in the current work plan;\n- substances initially listed in the previously adopted work programmes that were then prioritized, based on the importance of the products for the treatment of WHO priority diseases (including HIV/AIDS, tuberculosis, malaria, programmes and diseases with high prevalence in developing countries);\n- new additions from the updated sixteenth WHO Model List of Essential Medicines (March 2010) and the updated second WHO Model List of Essential Medicines for Children (March 2010);\n- new additions from the expressions of interest within the WHO Prequalification of Medicines Programme; and\n- requests for medicines recommended in WHO\u2019s specific disease programmes.\n\nCategories covered in the work programme included medicines used in the treatment of HIV/AIDS, malaria, tuberculosis, as well as anti-infectives (anthelmintics, antibacterial, antiprotozoal, antifungal, antiviral).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2411, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1e656917-84f3-4359-898a-18076fe0501c": {"__data__": {"id_": "1e656917-84f3-4359-898a-18076fe0501c", "embedding": null, "metadata": {"page_label": "28", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Medicines, Including Children's Medicines\n\n## 4.3.1 Medicines for HIV and Related Conditions\n\nNew monographs for the following ARVs were presented to the Expert Committee for discussion:\n\n**Dosage Forms:**\n\n- didanosine capsules\n- efavirenz tablets\n- emtricitabine capsules\n- emtricitabine and tenofovir tablets\n- emtricitabine, tenofovir and efavirenz tablets.\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.2 Antimalarial Medicines\n\nNew monographs for the following antimalarials were presented to the Expert Committee for discussion:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las especificaciones de medicamentos, incluyendo aquellos para ni\u00f1os. En la secci\u00f3n 4.3.1, se discuten nuevos monogr\u00e1ficos para medicamentos antirretrovirales (ARVs) utilizados en el tratamiento del VIH y condiciones relacionadas. Se presentan varias formas de dosificaci\u00f3n, como c\u00e1psulas de didanosina y tabletas de efavirenz, que fueron adoptadas con cambios acordados tras un proceso consultivo. La secci\u00f3n 4.3.2 menciona que tambi\u00e9n se presentaron nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n espec\u00edficas de los medicamentos antirretrovirales (ARVs) que fueron discutidas y adoptadas por el Comit\u00e9 de Expertos?**\n   - Respuesta: Las formas de dosificaci\u00f3n discutidas y adoptadas incluyen c\u00e1psulas de didanosina, tabletas de efavirenz, c\u00e1psulas de emtricitabina, tabletas de emtricitabina y tenofovir, y tabletas de emtricitabina, tenofovir y efavirenz.\n\n2. **\u00bfQu\u00e9 proceso se sigui\u00f3 para la adopci\u00f3n de los monogr\u00e1ficos de los medicamentos antirretrovirales?**\n   - Respuesta: Los monogr\u00e1ficos fueron adoptados tras la inclusi\u00f3n de cambios acordados, basados en comentarios recibidos durante el proceso consultivo normal y en las discusiones mantenidas.\n\n3. **\u00bfQu\u00e9 se menciona sobre los nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos en el documento?**\n   - Respuesta: Se indica que nuevos monogr\u00e1ficos para antimalariales fueron presentados al Comit\u00e9 de Expertos para discusi\u00f3n, aunque no se detallan los medicamentos espec\u00edficos en el texto proporcionado.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otros documentos o contextos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Cooperaci\u00f3n entre Organizaciones**: Se establece una colaboraci\u00f3n entre dos organizaciones que albergan farmacopoeias, enfoc\u00e1ndose en el desarrollo de especificaciones de calidad para medicamentos.\n\n2. **Fase Piloto**: Se inici\u00f3 una fase piloto que incluye tres monograf\u00edas para anti-infectivos:\n   - Amoxicilina en suspensi\u00f3n oral\n   - Metronidazol en suspensi\u00f3n oral\n   - Tabletas de sulfametoxazol y trimetoprima\n\n3. **Beneficios de la Colaboraci\u00f3n**: La cooperaci\u00f3n busca compartir experiencias en el desarrollo de especificaciones, lo que beneficiar\u00e1 a ambas farmacopoeias al aumentar la disponibilidad de especificaciones para los usuarios.\n\n4. **Plan de Trabajo Actual y Futuro**: Se revisaron el estado de desarrollo de las monograf\u00edas y se discutieron nuevas propuestas para especificaciones de sustancias activas y formas de dosificaci\u00f3n, con un enfoque en el uso pedi\u00e1trico.\n\n5. **Criterios de Priorizaci\u00f3n**: Las sustancias se priorizan seg\u00fan su importancia para el tratamiento de enfermedades prioritarias de la OMS, incluyendo VIH/SIDA, tuberculosis y malaria, as\u00ed como su inclusi\u00f3n en la lista de medicamentos esenciales de la OMS.\n\n6. **Categor\u00edas de Medicamentos**: El programa de trabajo abarca medicamentos para:\n   - VIH/SIDA\n   - Malaria\n   - Tuberculosis\n   - Anti-infectivos (anthelminticos, antibacterianos, antiprotozoarios, antif\u00fangicos, antivirales)\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Expert Committee** (Comit\u00e9 de Expertos)\n- **Farmacopeas** (organizaciones que desarrollan especificaciones de calidad para medicamentos)\n- **Medicamentos Esenciales de la OMS** (listas de medicamentos priorizados para el tratamiento de enfermedades)", "excerpt_keywords": "Keywords: medicines, HIV, antimalarials, specifications, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "83944ce6-be92-4986-826b-98a11f37d929", "node_type": "4", "metadata": {"page_label": "28", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Medicines, Including Children's Medicines\n\n## 4.3.1 Medicines for HIV and Related Conditions\n\nNew monographs for the following ARVs were presented to the Expert Committee for discussion:\n\n**Dosage Forms:**\n\n- didanosine capsules\n- efavirenz tablets\n- emtricitabine capsules\n- emtricitabine and tenofovir tablets\n- emtricitabine, tenofovir and efavirenz tablets.\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.2 Antimalarial Medicines\n\nNew monographs for the following antimalarials were presented to the Expert Committee for discussion:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ab2f8300c5ab317f70d16d4e9661a40413a08c00c7f50033015572d62e20e6ee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Specifications for Medicines, Including Children's Medicines\n\n## 4.3.1 Medicines for HIV and Related Conditions\n\nNew monographs for the following ARVs were presented to the Expert Committee for discussion:\n\n**Dosage Forms:**\n\n- didanosine capsules\n- efavirenz tablets\n- emtricitabine capsules\n- emtricitabine and tenofovir tablets\n- emtricitabine, tenofovir and efavirenz tablets.\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.2 Antimalarial Medicines\n\nNew monographs for the following antimalarials were presented to the Expert Committee for discussion:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 784, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d4ef04-9a29-4c51-aee8-71564d5541ea": {"__data__": {"id_": "e5d4ef04-9a29-4c51-aee8-71564d5541ea", "embedding": null, "metadata": {"page_label": "29", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage forms\n- mefloquine tablets\n- sulfadoxine and pyrimethamine tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nWhile carrying out the work for the general revision on the artemisinin derivatives monographs (artemether, artemisinin, artemotil, artenimol, artesunate and their associated dosage forms), the opportunity was taken to develop in parallel a new specification for the parenteral preparation of artesunate, which is particularly recommended in the treatment of severe malaria.\n\nThe following monograph could, therefore, be presented to the Expert Committee for discussion:\n\n**dosage form**\n- artesunate for injection.\n\nThe monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.3 Antituberculosis medicines\n\nNew monographs for the following antituberculosis active substances and dosage forms were presented to the Expert Committee for discussion:\n\n**active pharmaceutical ingredients (APIs)**\n- capreomycin sulfate\n- ofloxacin\n- levofloxacin\n\n**dosage forms**\n- capreomycin injection\n- ofloxacin tablets\n- levofloxacin tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nThe following monograph was presented to the Expert Committee in October 2009 for addition to *The International Pharmacopoeia*:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla la adopci\u00f3n de nuevas monograf\u00edas para diversas formas de dosificaci\u00f3n de medicamentos, incluyendo antimal\u00e1ricos y antituberculosos. Se menciona la revisi\u00f3n de monograf\u00edas de derivados de artemisinina y la introducci\u00f3n de una nueva especificaci\u00f3n para la preparaci\u00f3n parenteral de artesunato, recomendada para el tratamiento de la malaria severa. Tambi\u00e9n se presentan nuevas monograf\u00edas para ingredientes farmac\u00e9uticos activos (APIs) y sus formas de dosificaci\u00f3n asociadas en el contexto de medicamentos antituberculosos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 cambios se acordaron para las monograf\u00edas de los medicamentos mencionados en el informe y c\u00f3mo se incorporaron en el proceso de revisi\u00f3n?**\n   - Esta pregunta busca detalles sobre los cambios espec\u00edficos que se discutieron y acordaron durante el proceso consultivo, que no se detallan expl\u00edcitamente en el texto.\n\n2. **\u00bfCu\u00e1l es la importancia del artesunato para inyecci\u00f3n en el tratamiento de la malaria severa y c\u00f3mo se compara con otras formas de dosificaci\u00f3n de artemisinina?**\n   - Esta pregunta se centra en la relevancia cl\u00ednica del artesunato para inyecci\u00f3n y su papel en comparaci\u00f3n con otros tratamientos, lo que podr\u00eda no estar claramente indicado en el documento.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para la adopci\u00f3n de nuevas monograf\u00edas en la OMS y c\u00f3mo se asegura la calidad de los medicamentos a trav\u00e9s de este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios y procedimientos espec\u00edficos que la OMS sigue para garantizar que las nuevas monograf\u00edas cumplan con los est\u00e1ndares de calidad y eficacia, lo cual no se aborda directamente en el texto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Principal: Especificaciones de Medicamentos, Incluyendo Medicamentos para Ni\u00f1os**\n\n1. **Medicamentos Antirretrovirales (ARVs) para VIH y Condiciones Relacionadas:**\n   - Se presentaron nuevos monogr\u00e1ficos para discusi\u00f3n por parte del Comit\u00e9 de Expertos.\n   - **Formas de Dosificaci\u00f3n Presentadas:**\n     - C\u00e1psulas de didanosina\n     - Tabletas de efavirenz\n     - C\u00e1psulas de emtricitabina\n     - Tabletas de emtricitabina y tenofovir\n     - Tabletas de emtricitabina, tenofovir y efavirenz\n   - Los monogr\u00e1ficos fueron adoptados con cambios acordados, tras un proceso consultivo normal.\n\n2. **Medicamentos Antimal\u00e1ricos:**\n   - Nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos tambi\u00e9n fueron presentados al Comit\u00e9 de Expertos para discusi\u00f3n, aunque no se especifican los medicamentos en el texto proporcionado.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Comit\u00e9 de Expertos**\n- **Medicamentos Antirretrovirales (ARVs)**\n- **Medicamentos Antimal\u00e1ricos**\n- **Formas de Dosificaci\u00f3n:**\n  - Didanosina\n  - Efavirenz\n  - Emtricitabina\n  - Tenofovir\n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo los tipos de medicamentos discutidos y el proceso de adopci\u00f3n de los monogr\u00e1ficos.", "excerpt_keywords": "dosage forms, artesunate, antituberculosis, monographs, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d2eb902-2a57-4609-8a86-8a8874e0a8b2", "node_type": "4", "metadata": {"page_label": "29", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage forms\n- mefloquine tablets\n- sulfadoxine and pyrimethamine tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nWhile carrying out the work for the general revision on the artemisinin derivatives monographs (artemether, artemisinin, artemotil, artenimol, artesunate and their associated dosage forms), the opportunity was taken to develop in parallel a new specification for the parenteral preparation of artesunate, which is particularly recommended in the treatment of severe malaria.\n\nThe following monograph could, therefore, be presented to the Expert Committee for discussion:\n\n**dosage form**\n- artesunate for injection.\n\nThe monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.3 Antituberculosis medicines\n\nNew monographs for the following antituberculosis active substances and dosage forms were presented to the Expert Committee for discussion:\n\n**active pharmaceutical ingredients (APIs)**\n- capreomycin sulfate\n- ofloxacin\n- levofloxacin\n\n**dosage forms**\n- capreomycin injection\n- ofloxacin tablets\n- levofloxacin tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nThe following monograph was presented to the Expert Committee in October 2009 for addition to *The International Pharmacopoeia*:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "37a5591f33d5b56b6ecb679865d583bcf4b250bb51a3e5fa2cea4355a57127c2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# dosage forms\n- mefloquine tablets\n- sulfadoxine and pyrimethamine tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nWhile carrying out the work for the general revision on the artemisinin derivatives monographs (artemether, artemisinin, artemotil, artenimol, artesunate and their associated dosage forms), the opportunity was taken to develop in parallel a new specification for the parenteral preparation of artesunate, which is particularly recommended in the treatment of severe malaria.\n\nThe following monograph could, therefore, be presented to the Expert Committee for discussion:\n\n**dosage form**\n- artesunate for injection.\n\nThe monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.3 Antituberculosis medicines\n\nNew monographs for the following antituberculosis active substances and dosage forms were presented to the Expert Committee for discussion:\n\n**active pharmaceutical ingredients (APIs)**\n- capreomycin sulfate\n- ofloxacin\n- levofloxacin\n\n**dosage forms**\n- capreomycin injection\n- ofloxacin tablets\n- levofloxacin tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nThe following monograph was presented to the Expert Committee in October 2009 for addition to *The International Pharmacopoeia*:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1876, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "244bacfa-f2ef-491c-a309-9bfccff41560": {"__data__": {"id_": "244bacfa-f2ef-491c-a309-9bfccff41560", "embedding": null, "metadata": {"page_label": "30", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage form\n\n- kanamycin injection\n\nAlthough the monograph was adopted, recirculation was recommended by the Expert Committee requesting comments on the shifting of the determination of the conversion factor from international units (IU) to micrograms.\n\nTo avoid the use of an arbitrary conversion factor, a revised version of the text was proposed for discussion during the consultation on specifications for medicines and quality control issues held in May 2010, where it was agreed that the replacement of the current microbiological assay by a high-performance liquid chromatography (HPLC) method would be preferable as this would allow direct expression of the quantities of kanamycin in terms of mass.\n\nIt was recognized, however, that the application of HPLC to this substance would be subject to detection difficulties owing to the poor absorbance properties of kanamycin in ultraviolet (UV). Possible HPLC methods and their suitability for inclusion in Ph.Int. were thus discussed and it was finally recommended that a UV detection method using derivatization be developed, rather than a method using more sophisticated detectors such as electrochemical ones that may not be widely available. While this HPLC method was still under investigation, it was agreed that, once ready, the revised monograph would be circulated for comment.\n\nMeanwhile, and in order to make the monograph available to users, it was agreed that the text adopted in October 2009 be posted on the WHO Medicines web site with an appropriate *Note from the Secretariat* indicating that a forthcoming revision was envisaged for the assay.\n\nThe Expert Committee endorsed the recommendations made by the participants at the consultation.\n\n## 4.3.4 Anti-infectives\n\nNew monographs for the active dosage forms of the following anti-infectives were presented to the Expert Committee for discussion:\n\n- amoxicillin oral suspension<sup>10</sup>\n- levamisole tablets\n- metronidazole oral suspension<sup>10</sup>\n- sulfamethoxazole and trimethoprim tablets<sup>10</sup>\n\n----\n\n<sup>10</sup> These monographs were developed in the context of collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia*, on which these texts are based.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monograf\u00eda de Kanamicina**: La monograf\u00eda de kanamicina fue adoptada, pero se recomend\u00f3 su recirculaci\u00f3n para discutir el cambio en el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos. Se propuso reemplazar el ensayo microbiol\u00f3gico actual por un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para expresar las cantidades de kanamicina en t\u00e9rminos de masa, aunque se reconocieron dificultades en la detecci\u00f3n debido a las propiedades de absorbancia del compuesto.\n\n2. **Desarrollo de Nuevas Monograf\u00edas**: Se presentaron nuevas monograf\u00edas para varios anti-infectivos, incluyendo amoxicilina, levamisol, metronidazol y sulfametoxazol con trimetoprima, en el contexto de una colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos respald\u00f3 las recomendaciones de los participantes en la consulta sobre especificaciones para medicamentos y cuestiones de control de calidad, y se acord\u00f3 que la versi\u00f3n adoptada en octubre de 2009 se publicara en el sitio web de la OMS con una nota indicando que se prev\u00e9 una revisi\u00f3n futura.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las dificultades espec\u00edficas que se anticipan al aplicar el m\u00e9todo HPLC para la kanamicina, y qu\u00e9 soluciones se proponen para superarlas?**\n   - La aplicaci\u00f3n de HPLC a la kanamicina enfrenta dificultades de detecci\u00f3n debido a sus pobres propiedades de absorbancia en UV. Se propone desarrollar un m\u00e9todo de detecci\u00f3n UV utilizando derivatizaci\u00f3n como soluci\u00f3n.\n\n2. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en la conversi\u00f3n de unidades para la kanamicina y por qu\u00e9 se considera necesario evitar un factor de conversi\u00f3n arbitrario?**\n   - Se est\u00e1 considerando cambiar la determinaci\u00f3n del factor de conversi\u00f3n de IU a microgramos para evitar el uso de un factor de conversi\u00f3n arbitrario, lo que podr\u00eda llevar a inconsistencias en la dosificaci\u00f3n y efectividad del medicamento.\n\n3. **\u00bfQu\u00e9 colaboraci\u00f3n se menciona en el desarrollo de las nuevas monograf\u00edas de anti-infectivos y cu\u00e1l es su relevancia?**\n   - Las nuevas monograf\u00edas para anti-infectivos fueron desarrolladas en colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*, lo que es relevante porque asegura que las monograf\u00edas est\u00e9n basadas en est\u00e1ndares internacionales y mejores pr\u00e1cticas en farmacolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00edas de Medicamentos**:\n   - Se adoptaron nuevas monograf\u00edas para diversas formas de dosificaci\u00f3n de medicamentos, incluyendo:\n     - **Antimal\u00e1ricos**:\n       - Tabletas de mefloquina.\n       - Tabletas de sulfadoxina y pirimetamina.\n       - Artesunato para inyecci\u00f3n (nueva especificaci\u00f3n para la preparaci\u00f3n parenteral, recomendada para el tratamiento de malaria severa).\n     - **Antituberculosos**:\n       - Ingredientes farmac\u00e9uticos activos (APIs):\n         - Sulfato de capreomicina.\n         - Ofloxacino.\n         - Levofloxacino.\n       - Formas de dosificaci\u00f3n:\n         - Inyecci\u00f3n de capreomicina.\n         - Tabletas de ofloxacino.\n         - Tabletas de levofloxacino.\n\n2. **Proceso de Adopci\u00f3n**:\n   - Las monograf\u00edas fueron adoptadas con la inclusi\u00f3n de cambios acordados, basados en comentarios recibidos durante el proceso consultivo normal, siguiendo los pasos establecidos para el desarrollo de nuevas monograf\u00edas.\n\n3. **Importancia del Artesunato**:\n   - Se destaca la relevancia del artesunato para inyecci\u00f3n en el tratamiento de la malaria severa, en comparaci\u00f3n con otras formas de dosificaci\u00f3n de artemisinina.\n\n4. **Criterios de Calidad**:\n   - Se menciona que la adopci\u00f3n de nuevas monograf\u00edas se basa en un proceso consultivo que asegura la calidad y eficacia de los medicamentos, aunque no se detallan los criterios espec\u00edficos en el texto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medicamentos**:\n  - Mefloquina\n  - Sulfadoxina\n  - Pirimetamina\n  - Artesunato\n  - Capreomicina\n  - Ofloxacino\n  - Levofloxacino\n- **Formas de Dosificaci\u00f3n**:\n  - Tabletas\n  - Inyecci\u00f3n\n\nEste resumen abarca los aspectos m\u00e1s relevantes del contenido, destacando las nuevas monograf\u00edas adoptadas y el proceso que las respalda.", "excerpt_keywords": "Keywords: kanamycin, HPLC, anti-infectives, monographs, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a0931613-4d59-4955-9199-fcb35bd775bc", "node_type": "4", "metadata": {"page_label": "30", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage form\n\n- kanamycin injection\n\nAlthough the monograph was adopted, recirculation was recommended by the Expert Committee requesting comments on the shifting of the determination of the conversion factor from international units (IU) to micrograms.\n\nTo avoid the use of an arbitrary conversion factor, a revised version of the text was proposed for discussion during the consultation on specifications for medicines and quality control issues held in May 2010, where it was agreed that the replacement of the current microbiological assay by a high-performance liquid chromatography (HPLC) method would be preferable as this would allow direct expression of the quantities of kanamycin in terms of mass.\n\nIt was recognized, however, that the application of HPLC to this substance would be subject to detection difficulties owing to the poor absorbance properties of kanamycin in ultraviolet (UV). Possible HPLC methods and their suitability for inclusion in Ph.Int. were thus discussed and it was finally recommended that a UV detection method using derivatization be developed, rather than a method using more sophisticated detectors such as electrochemical ones that may not be widely available. While this HPLC method was still under investigation, it was agreed that, once ready, the revised monograph would be circulated for comment.\n\nMeanwhile, and in order to make the monograph available to users, it was agreed that the text adopted in October 2009 be posted on the WHO Medicines web site with an appropriate *Note from the Secretariat* indicating that a forthcoming revision was envisaged for the assay.\n\nThe Expert Committee endorsed the recommendations made by the participants at the consultation.\n\n## 4.3.4 Anti-infectives\n\nNew monographs for the active dosage forms of the following anti-infectives were presented to the Expert Committee for discussion:\n\n- amoxicillin oral suspension<sup>10</sup>\n- levamisole tablets\n- metronidazole oral suspension<sup>10</sup>\n- sulfamethoxazole and trimethoprim tablets<sup>10</sup>\n\n----\n\n<sup>10</sup> These monographs were developed in the context of collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia*, on which these texts are based.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ed4a5fa1a81a8ac9124dcae2b2969cd08d2c63f309d78fd904f4d78232cde950", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# dosage form\n\n- kanamycin injection\n\nAlthough the monograph was adopted, recirculation was recommended by the Expert Committee requesting comments on the shifting of the determination of the conversion factor from international units (IU) to micrograms.\n\nTo avoid the use of an arbitrary conversion factor, a revised version of the text was proposed for discussion during the consultation on specifications for medicines and quality control issues held in May 2010, where it was agreed that the replacement of the current microbiological assay by a high-performance liquid chromatography (HPLC) method would be preferable as this would allow direct expression of the quantities of kanamycin in terms of mass.\n\nIt was recognized, however, that the application of HPLC to this substance would be subject to detection difficulties owing to the poor absorbance properties of kanamycin in ultraviolet (UV). Possible HPLC methods and their suitability for inclusion in Ph.Int. were thus discussed and it was finally recommended that a UV detection method using derivatization be developed, rather than a method using more sophisticated detectors such as electrochemical ones that may not be widely available. While this HPLC method was still under investigation, it was agreed that, once ready, the revised monograph would be circulated for comment.\n\nMeanwhile, and in order to make the monograph available to users, it was agreed that the text adopted in October 2009 be posted on the WHO Medicines web site with an appropriate *Note from the Secretariat* indicating that a forthcoming revision was envisaged for the assay.\n\nThe Expert Committee endorsed the recommendations made by the participants at the consultation.\n\n## 4.3.4 Anti-infectives\n\nNew monographs for the active dosage forms of the following anti-infectives were presented to the Expert Committee for discussion:\n\n- amoxicillin oral suspension<sup>10</sup>\n- levamisole tablets\n- metronidazole oral suspension<sup>10</sup>\n- sulfamethoxazole and trimethoprim tablets<sup>10</sup>\n\n----\n\n<sup>10</sup> These monographs were developed in the context of collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia*, on which these texts are based.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c353204a-4539-4877-8d2f-920d257a9348": {"__data__": {"id_": "c353204a-4539-4877-8d2f-920d257a9348", "embedding": null, "metadata": {"page_label": "31", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n### 4.3.5 Other medicines\n\nNew monographs for the following dosage forms were presented to the Expert Committee for discussion:\n\n- levonorgestrel tablets\n- oseltamivir capsules\n- sodium bicarbonate intravenous injection\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.4 Revision of texts of The International Pharmacopoeia\n\n### 4.4.1 Antimalarials: artemisinin derivatives\n\nSince 2008, extensive revision work had been initiated for the general revision of the artemisinin derivatives monographs of *The International Pharmacopoeia*.\n\nParticular aspects that required revision were the method used for the Related substances test and the Assay; and the addition of potential impurities shown to be controlled by the requirements of the monographs.\n\n**Artesunate**\n\nSubsequent to the development of a new monograph for artesunate for injection, the monograph for artesunate, revised in 2009, needed further modification to add specific requirements for the API intended to be used for parenteral preparations. A newly revised text was thus presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n**Other artemisinin derivatives**\n\nThis general revision of artemisinin derivatives involved about 15 texts. Monographs for artesunate and artesunate tablets had already been adopted in October 2009. Prioritization for revision had been proposed for the rest of this series in order to make the most useful monographs available to users in a timely manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas monograf\u00edas**: Se presentaron nuevas monograf\u00edas para varios medicamentos, incluyendo tabletas de levonorgestrel, c\u00e1psulas de oseltamivir e inyecci\u00f3n intravenosa de bicarbonato de sodio. Estas monograf\u00edas fueron adoptadas tras la inclusi\u00f3n de cambios acordados y comentarios recibidos durante el proceso consultivo.\n\n2. **Revisi\u00f3n de monograf\u00edas de derivados de artemisinina**: Desde 2008, se ha llevado a cabo una revisi\u00f3n extensa de las monograf\u00edas de los derivados de artemisinina en *The International Pharmacopoeia*. Se han realizado modificaciones espec\u00edficas en la monograf\u00eda de artesunato, especialmente para su uso en preparaciones parenterales, y se ha priorizado la revisi\u00f3n de otros derivados.\n\n3. **Proceso de consulta y modificaci\u00f3n**: Las monograf\u00edas adoptadas y revisadas se basan en un proceso de consulta p\u00fablica y discusi\u00f3n, asegurando que se incorporen los comentarios y se realicen las modificaciones necesarias para cumplir con los est\u00e1ndares requeridos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios espec\u00edficos se realizaron en la monograf\u00eda de artesunato para inyecci\u00f3n en comparaci\u00f3n con la versi\u00f3n revisada en 2009?**\n   - La monograf\u00eda de artesunato para inyecci\u00f3n fue modificada para incluir requisitos espec\u00edficos para el principio activo (API) destinado a preparaciones parenterales, lo que no estaba presente en la versi\u00f3n anterior.\n\n2. **\u00bfCu\u00e1ntos textos en total se est\u00e1n revisando en la serie de derivados de artemisinina y cu\u00e1les ya han sido adoptados?**\n   - Aproximadamente 15 textos est\u00e1n siendo revisados en la serie de derivados de artemisinina. Las monograf\u00edas para artesunato y tabletas de artesunato ya fueron adoptadas en octubre de 2009.\n\n3. **\u00bfCu\u00e1l es el proceso seguido para la adopci\u00f3n de nuevas monograf\u00edas seg\u00fan el contexto proporcionado?**\n   - El proceso para la adopci\u00f3n de nuevas monograf\u00edas incluye la presentaci\u00f3n de los textos a un Comit\u00e9 de Expertos, la discusi\u00f3n de los mismos, la inclusi\u00f3n de cambios acordados y la consideraci\u00f3n de comentarios recibidos durante el proceso consultivo normal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00eda de Kanamicina**:\n   - **Forma de Dosificaci\u00f3n**: Inyecci\u00f3n de kanamicina.\n   - **Recomendaciones del Comit\u00e9 de Expertos**: Se adopt\u00f3 la monograf\u00eda, pero se recomend\u00f3 su recirculaci\u00f3n para discutir el cambio en el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos.\n   - **M\u00e9todo Propuesto**: Se sugiere reemplazar el ensayo microbiol\u00f3gico actual por un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para expresar las cantidades de kanamicina en t\u00e9rminos de masa.\n   - **Desaf\u00edos**: Dificultades de detecci\u00f3n debido a las pobres propiedades de absorbancia de kanamicina en UV.\n   - **Soluci\u00f3n Propuesta**: Desarrollo de un m\u00e9todo de detecci\u00f3n UV utilizando derivatizaci\u00f3n.\n\n2. **Desarrollo de Nuevas Monograf\u00edas de Anti-infectivos**:\n   - **Anti-infectivos Presentados**:\n     - Amoxicilina (suspensi\u00f3n oral)\n     - Levamisol (tabletas)\n     - Metronidazol (suspensi\u00f3n oral)\n     - Sulfametoxazol y trimetoprima (tabletas)\n   - **Colaboraci\u00f3n**: Estas monograf\u00edas fueron desarrolladas en colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*.\n\n3. **Publicaci\u00f3n y Revisi\u00f3n**:\n   - Se acord\u00f3 que la versi\u00f3n adoptada en octubre de 2009 se publicara en el sitio web de la OMS con una nota indicando que se prev\u00e9 una revisi\u00f3n futura.\n\n4. **Endoso del Comit\u00e9 de Expertos**: El Comit\u00e9 respald\u00f3 las recomendaciones de los participantes en la consulta sobre especificaciones para medicamentos y control de calidad.\n\n### Entidades Clave\n- **Kanamicina**: Antibi\u00f3tico en forma de inyecci\u00f3n.\n- **HPLC**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **The International Pharmacopoeia**: Referencia internacional para est\u00e1ndares de medicamentos.\n- **The British Pharmacopoeia**: Referencia nacional para est\u00e1ndares de medicamentos en el Reino Unido.", "excerpt_keywords": "Keywords: monographs, artemisinin, WHO, pharmacopoeia, levonorgestrel"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7e892882-30bc-4641-8370-d2bc7584b710", "node_type": "4", "metadata": {"page_label": "31", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n### 4.3.5 Other medicines\n\nNew monographs for the following dosage forms were presented to the Expert Committee for discussion:\n\n- levonorgestrel tablets\n- oseltamivir capsules\n- sodium bicarbonate intravenous injection\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.4 Revision of texts of The International Pharmacopoeia\n\n### 4.4.1 Antimalarials: artemisinin derivatives\n\nSince 2008, extensive revision work had been initiated for the general revision of the artemisinin derivatives monographs of *The International Pharmacopoeia*.\n\nParticular aspects that required revision were the method used for the Related substances test and the Assay; and the addition of potential impurities shown to be controlled by the requirements of the monographs.\n\n**Artesunate**\n\nSubsequent to the development of a new monograph for artesunate for injection, the monograph for artesunate, revised in 2009, needed further modification to add specific requirements for the API intended to be used for parenteral preparations. A newly revised text was thus presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n**Other artemisinin derivatives**\n\nThis general revision of artemisinin derivatives involved about 15 texts. Monographs for artesunate and artesunate tablets had already been adopted in October 2009. Prioritization for revision had been proposed for the rest of this series in order to make the most useful monographs available to users in a timely manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "421dc2fbb27adf6e448f64195a5893007f2349ccfd76b45d57327c0e7e65c5c9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n### 4.3.5 Other medicines\n\nNew monographs for the following dosage forms were presented to the Expert Committee for discussion:\n\n- levonorgestrel tablets\n- oseltamivir capsules\n- sodium bicarbonate intravenous injection\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.4 Revision of texts of The International Pharmacopoeia\n\n### 4.4.1 Antimalarials: artemisinin derivatives\n\nSince 2008, extensive revision work had been initiated for the general revision of the artemisinin derivatives monographs of *The International Pharmacopoeia*.\n\nParticular aspects that required revision were the method used for the Related substances test and the Assay; and the addition of potential impurities shown to be controlled by the requirements of the monographs.\n\n**Artesunate**\n\nSubsequent to the development of a new monograph for artesunate for injection, the monograph for artesunate, revised in 2009, needed further modification to add specific requirements for the API intended to be used for parenteral preparations. A newly revised text was thus presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n**Other artemisinin derivatives**\n\nThis general revision of artemisinin derivatives involved about 15 texts. Monographs for artesunate and artesunate tablets had already been adopted in October 2009. Prioritization for revision had been proposed for the rest of this series in order to make the most useful monographs available to users in a timely manner.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2102, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b40c9031-0f19-4a9b-9733-dcfdc05b8b7a": {"__data__": {"id_": "b40c9031-0f19-4a9b-9733-dcfdc05b8b7a", "embedding": null, "metadata": {"page_label": "32", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In line with the WHO treatment guidelines for malaria, where the use of these antimalarials as a monotherapy was no longer prescribed, the Expert Committee agreed that while revising the monographs for the corresponding monocomponent dosage forms, priority would be assigned to the products that could be co-packaged.\n\nThe Expert Committee was pleased to note that work had progressed, notably for the API monographs on artenimol (dihydroartemisinin) and artemether. Further, it was acknowledged that the development of other specifications had been initiated for fixed-dose combination medicines used in the combination therapy, such as that for artesunate and amodiaquine tablets or artenimol and piperaquine phosphate tablets.\n\n### 4.4.2 Other medicines\n\n**Oseltamivir phosphate**\n\nThe monograph for oseltamivir phosphate was initially adopted in October 2008. A revision of this text was presented in October 2009 after receipt of several comments on the tests for Sulfated ash and Related substances, leading to the adoption of a revised text where only the correction proposed for the Related substances test was retained. To respond to the continuing difficulties encountered by users when carrying out the test for sulfated ash, a revised version of this monograph was considered.\n\nThe Expert Committee adopted the newly revised text, which now harmonized the Ph.Int. text to the specifications for oseltamivir phosphate, also available in other pharmacopoeias (Ph.Eur and USP).\n\n**Heparins**\n\nA brief update was presented on the revision of the Heparins monographs decided upon in 2009, in order to include an electrophoresis method capable of detecting potential glycosaminoglycan impurities of heparin (dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate). The Expert Committee noted that the revision work had been initiated.\n\n**Retinol**\n\nVitamin A supplementation therapy was supported by several initiatives of WHO and partner organizations. UNICEF had expressed interest in pharmacopoeial specifications for oral dosage forms containing retinol concentrate, oily form, to fight vitamin A deficiency, xerophthalmia and nutritional blindness.\n\nTo satisfy these needs, draft versions of the monographs:\n\n- retinol concentrate, oily form\n- paediatric retinol capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices de tratamiento para la malaria, destacando la importancia de no usar antimal\u00e1ricos como monoterapia. Se menciona el progreso en la revisi\u00f3n de monograf\u00edas para medicamentos antimal\u00e1ricos, as\u00ed como la adopci\u00f3n de nuevas especificaciones para otros medicamentos, como oseltamivir, heparinas y retinol. Se enfatiza la necesidad de co-empaquetar productos y la armonizaci\u00f3n de especificaciones con otras farmacopeas. Adem\u00e1s, se discuten iniciativas para combatir la deficiencia de vitamina A.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se consideraron para priorizar los productos en la revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos?**\n   - La Expert Committee acord\u00f3 que se asignar\u00eda prioridad a los productos que pudieran ser co-empaquetados, en l\u00ednea con las directrices de tratamiento de la OMS para la malaria.\n\n2. **\u00bfCu\u00e1les fueron las principales modificaciones realizadas en la monograf\u00eda de oseltamivir fosfato desde su adopci\u00f3n inicial?**\n   - La monograf\u00eda fue revisada para abordar comentarios sobre las pruebas de cenizas sulfatadas y sustancias relacionadas, resultando en una versi\u00f3n revisada que armoniza el texto con las especificaciones de otras farmacopeas, como Ph.Eur y USP.\n\n3. **\u00bfQu\u00e9 iniciativas apoyan la terapia de suplementaci\u00f3n de vitamina A y qu\u00e9 especificaciones farmacop\u00e9uticas se est\u00e1n desarrollando?**\n   - La OMS y organizaciones asociadas, como UNICEF, apoyan la terapia de suplementaci\u00f3n de vitamina A, y se est\u00e1n desarrollando especificaciones farmacop\u00e9uticas para formas orales que contienen concentrado de retinol en forma oleosa y c\u00e1psulas pedi\u00e1tricas de retinol.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Adopci\u00f3n de Nuevas Monograf\u00edas**:\n   - Se presentaron nuevas monograf\u00edas para:\n     - **Levonorgestrel** (tabletas)\n     - **Oseltamivir** (c\u00e1psulas)\n     - **Bicarbonato de sodio** (inyecci\u00f3n intravenosa)\n   - Las monograf\u00edas fueron adoptadas tras la inclusi\u00f3n de cambios acordados y comentarios del proceso consultivo.\n\n2. **Revisi\u00f3n de Monograf\u00edas de Derivados de Artemisinina**:\n   - Desde 2008, se ha llevado a cabo una revisi\u00f3n extensa de las monograf\u00edas de derivados de artemisinina en *The International Pharmacopoeia*.\n   - Se revisaron aspectos como el m\u00e9todo para la prueba de sustancias relacionadas y el ensayo, as\u00ed como la inclusi\u00f3n de impurezas potenciales.\n\n3. **Modificaci\u00f3n de la Monograf\u00eda de Artesunato**:\n   - La monograf\u00eda de **Artesunato** para inyecci\u00f3n fue revisada para incluir requisitos espec\u00edficos para el principio activo (API) destinado a preparaciones parenterales.\n   - Se adopt\u00f3 un texto revisado basado en comentarios de la consulta p\u00fablica y discusiones.\n\n4. **Revisi\u00f3n General de Derivados de Artemisinina**:\n   - Aproximadamente **15 textos** est\u00e1n siendo revisados en esta serie.\n   - Las monograf\u00edas para **Artesunato** y **tabletas de Artesunato** ya fueron adoptadas en octubre de 2009.\n   - Se propuso priorizar la revisi\u00f3n de los restantes textos para su disponibilidad oportuna.\n\n### Entidades Clave\n- **Medicamentos**: Levonorgestrel, Oseltamivir, Bicarbonato de sodio, Artesunato.\n- **Documentos**: *The International Pharmacopoeia*.\n- **Comit\u00e9**: Comit\u00e9 de Expertos.\n- **Proceso**: Proceso consultivo, adopci\u00f3n de monograf\u00edas, revisi\u00f3n de textos.", "excerpt_keywords": "Keywords: malaria treatment, oseltamivir phosphate, heparins, vitamin A supplementation, pharmacopoeial specifications"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b2115570-1b4e-4bd4-a479-f6eb1fbcb4a4", "node_type": "4", "metadata": {"page_label": "32", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In line with the WHO treatment guidelines for malaria, where the use of these antimalarials as a monotherapy was no longer prescribed, the Expert Committee agreed that while revising the monographs for the corresponding monocomponent dosage forms, priority would be assigned to the products that could be co-packaged.\n\nThe Expert Committee was pleased to note that work had progressed, notably for the API monographs on artenimol (dihydroartemisinin) and artemether. Further, it was acknowledged that the development of other specifications had been initiated for fixed-dose combination medicines used in the combination therapy, such as that for artesunate and amodiaquine tablets or artenimol and piperaquine phosphate tablets.\n\n### 4.4.2 Other medicines\n\n**Oseltamivir phosphate**\n\nThe monograph for oseltamivir phosphate was initially adopted in October 2008. A revision of this text was presented in October 2009 after receipt of several comments on the tests for Sulfated ash and Related substances, leading to the adoption of a revised text where only the correction proposed for the Related substances test was retained. To respond to the continuing difficulties encountered by users when carrying out the test for sulfated ash, a revised version of this monograph was considered.\n\nThe Expert Committee adopted the newly revised text, which now harmonized the Ph.Int. text to the specifications for oseltamivir phosphate, also available in other pharmacopoeias (Ph.Eur and USP).\n\n**Heparins**\n\nA brief update was presented on the revision of the Heparins monographs decided upon in 2009, in order to include an electrophoresis method capable of detecting potential glycosaminoglycan impurities of heparin (dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate). The Expert Committee noted that the revision work had been initiated.\n\n**Retinol**\n\nVitamin A supplementation therapy was supported by several initiatives of WHO and partner organizations. UNICEF had expressed interest in pharmacopoeial specifications for oral dosage forms containing retinol concentrate, oily form, to fight vitamin A deficiency, xerophthalmia and nutritional blindness.\n\nTo satisfy these needs, draft versions of the monographs:\n\n- retinol concentrate, oily form\n- paediatric retinol capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "971c43ddb8d12f7f2e730e738ee3b2a978d0ce25a7e3f5a2de4e3bc8f2e411db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "In line with the WHO treatment guidelines for malaria, where the use of these antimalarials as a monotherapy was no longer prescribed, the Expert Committee agreed that while revising the monographs for the corresponding monocomponent dosage forms, priority would be assigned to the products that could be co-packaged.\n\nThe Expert Committee was pleased to note that work had progressed, notably for the API monographs on artenimol (dihydroartemisinin) and artemether. Further, it was acknowledged that the development of other specifications had been initiated for fixed-dose combination medicines used in the combination therapy, such as that for artesunate and amodiaquine tablets or artenimol and piperaquine phosphate tablets.\n\n### 4.4.2 Other medicines\n\n**Oseltamivir phosphate**\n\nThe monograph for oseltamivir phosphate was initially adopted in October 2008. A revision of this text was presented in October 2009 after receipt of several comments on the tests for Sulfated ash and Related substances, leading to the adoption of a revised text where only the correction proposed for the Related substances test was retained. To respond to the continuing difficulties encountered by users when carrying out the test for sulfated ash, a revised version of this monograph was considered.\n\nThe Expert Committee adopted the newly revised text, which now harmonized the Ph.Int. text to the specifications for oseltamivir phosphate, also available in other pharmacopoeias (Ph.Eur and USP).\n\n**Heparins**\n\nA brief update was presented on the revision of the Heparins monographs decided upon in 2009, in order to include an electrophoresis method capable of detecting potential glycosaminoglycan impurities of heparin (dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate). The Expert Committee noted that the revision work had been initiated.\n\n**Retinol**\n\nVitamin A supplementation therapy was supported by several initiatives of WHO and partner organizations. UNICEF had expressed interest in pharmacopoeial specifications for oral dosage forms containing retinol concentrate, oily form, to fight vitamin A deficiency, xerophthalmia and nutritional blindness.\n\nTo satisfy these needs, draft versions of the monographs:\n\n- retinol concentrate, oily form\n- paediatric retinol capsules", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2302, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b1719e63-8e25-4dbe-9c52-34584f173a6b": {"__data__": {"id_": "b1719e63-8e25-4dbe-9c52-34584f173a6b", "embedding": null, "metadata": {"page_label": "33", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Paediatric Retinol Oral Solution\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monograph on retinol concentrate, oily form, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\nPaediatric vitamin A soft-gel capsules have a unique mode of delivery. They are furnished with a small nipple which can be cut off so that the liquid content can be easily squeezed into the mouth of a child. The Committee decided to subsume this dosage form under the monograph on vitamin A oral solution, considering the soft gelatin shell as a single-unit container and the liquid content as the actual dosage form. The Expert Committee recommended that the monograph on paediatric retinol oral solution be modified so that its specifications can also be applied to these single-dose units. The capsule monograph was then to be withdrawn.\n\n# Paracetamol\n\nDraft versions of the monographs:\n\n- Paracetamol oral solution\n- Paracetamol oral suspension\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monographs, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 4.5 Review of Published General Monographs for Dosage Forms and Associated Method Texts\n\n### 4.5.1 Pharmacopoeial Discussion Group: Harmonized General Texts\n\nThe Expert Committee members were updated on the discussions and recommendations of the informal consultation held in May 2010. Ph.Int. general methods, as discussed during previous Expert Committee meetings, are suggested for revision, taking into account the texts harmonized by the PDG (*European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia*).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Monograf\u00eda sobre la Soluci\u00f3n Oral de Retinol Pedi\u00e1trico**: En agosto de 2010, se discutieron y revisaron las especificaciones para la soluci\u00f3n oral de retinol pedi\u00e1trico, que incluye un nuevo formato de c\u00e1psulas de gel blando. La monograf\u00eda fue adoptada por el Comit\u00e9 de Expertos, que decidi\u00f3 incluir las c\u00e1psulas como una forma de dosificaci\u00f3n bajo la misma monograf\u00eda.\n\n2. **Monograf\u00edas de Paracetamol**: Se prepararon y discutieron borradores de monograf\u00edas para soluciones y suspensiones orales de paracetamol. Estas monograf\u00edas fueron adoptadas por el Comit\u00e9 de Expertos, con cambios acordados basados en comentarios recibidos.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica**: Se actualiz\u00f3 a los miembros del Comit\u00e9 de Expertos sobre las recomendaciones de una consulta informal en mayo de 2010, sugiriendo revisiones a los m\u00e9todos generales de la Ph.Int. en armon\u00eda con textos de farmacopeas europeas, japonesas y estadounidenses.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas \u00fanicas tienen las c\u00e1psulas de gel blando de vitamina A pedi\u00e1trica y c\u00f3mo se integran en la monograf\u00eda de la soluci\u00f3n oral de retinol?**\n   - Las c\u00e1psulas de gel blando tienen un peque\u00f1o pez\u00f3n que se puede cortar para facilitar la administraci\u00f3n del contenido l\u00edquido a un ni\u00f1o. El Comit\u00e9 decidi\u00f3 incluir este formato bajo la monograf\u00eda de la soluci\u00f3n oral de vitamina A, considerando la c\u00e1psula como un contenedor de unidad \u00fanica.\n\n2. **\u00bfCu\u00e1les fueron los pasos seguidos para la adopci\u00f3n de las monograf\u00edas de paracetamol y qu\u00e9 cambios se acordaron?**\n   - Las monograf\u00edas de paracetamol fueron preparadas y discutidas en una teleconferencia en agosto de 2010, se circularon borradores y se recopilaron comentarios. Las versiones revisadas fueron presentadas en la 45\u00aa reuni\u00f3n del Comit\u00e9 de Expertos, donde se adoptaron con la inclusi\u00f3n de cambios acordados basados en los comentarios recibidos.\n\n3. **\u00bfQu\u00e9 recomendaciones surgieron de la consulta informal de mayo de 2010 respecto a los m\u00e9todos generales de la Ph.Int.?**\n   - Se sugiri\u00f3 que los m\u00e9todos generales de la Ph.Int. sean revisados, teniendo en cuenta los textos armonizados por el Grupo de Discusi\u00f3n Farmacopeica (PDG), que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Directrices de Tratamiento para la Malaria**:\n   - La OMS ha dejado de prescribir antimal\u00e1ricos como monoterapia.\n   - Se prioriza la revisi\u00f3n de monograf\u00edas para productos que puedan ser co-empaquetados.\n\n2. **Progreso en Monograf\u00edas de Antimal\u00e1ricos**:\n   - Se ha avanzado en las monograf\u00edas de artenimol (dihidroartemisina) y artem\u00e9ter.\n   - Se han iniciado especificaciones para medicamentos de combinaci\u00f3n de dosis fijas, como artesunato y amodiaquina, y artenimol y fosfato de piperaquina.\n\n3. **Oseltamivir Fosfato**:\n   - La monograf\u00eda fue adoptada inicialmente en octubre de 2008 y revisada en 2009.\n   - Se realizaron correcciones en las pruebas de cenizas sulfatadas y sustancias relacionadas, armonizando el texto con otras farmacopeas (Ph.Eur y USP).\n\n4. **Heparinas**:\n   - Se est\u00e1 revisando la monograf\u00eda de heparinas para incluir un m\u00e9todo de electroforesis que detecte impurezas potenciales de glicosaminoglicanos.\n\n5. **Retinol (Vitamina A)**:\n   - La OMS y UNICEF apoyan la terapia de suplementaci\u00f3n de vitamina A.\n   - Se est\u00e1n desarrollando especificaciones farmacop\u00e9uticas para formas orales que contienen concentrado de retinol en forma oleosa y c\u00e1psulas pedi\u00e1tricas de retinol.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **UNICEF**\n- **Artenimol (dihidroartemisina)**\n- **Artem\u00e9ter**\n- **Oseltamivir Fosfato**\n- **Heparinas**\n- **Retinol (Vitamina A)**\n\nEste resumen destaca los avances en la regulaci\u00f3n y especificaciones de medicamentos, as\u00ed como las iniciativas para abordar problemas de salud p\u00fablica como la malaria y la deficiencia de vitamina A.", "excerpt_keywords": "Keywords: Retinol, Paracetamol, Pediatric, Monographs, Pharmacopoeia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "11d257e1-c843-48e3-b272-d43c0ba75edb", "node_type": "4", "metadata": {"page_label": "33", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Paediatric Retinol Oral Solution\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monograph on retinol concentrate, oily form, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\nPaediatric vitamin A soft-gel capsules have a unique mode of delivery. They are furnished with a small nipple which can be cut off so that the liquid content can be easily squeezed into the mouth of a child. The Committee decided to subsume this dosage form under the monograph on vitamin A oral solution, considering the soft gelatin shell as a single-unit container and the liquid content as the actual dosage form. The Expert Committee recommended that the monograph on paediatric retinol oral solution be modified so that its specifications can also be applied to these single-dose units. The capsule monograph was then to be withdrawn.\n\n# Paracetamol\n\nDraft versions of the monographs:\n\n- Paracetamol oral solution\n- Paracetamol oral suspension\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monographs, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 4.5 Review of Published General Monographs for Dosage Forms and Associated Method Texts\n\n### 4.5.1 Pharmacopoeial Discussion Group: Harmonized General Texts\n\nThe Expert Committee members were updated on the discussions and recommendations of the informal consultation held in May 2010. Ph.Int. general methods, as discussed during previous Expert Committee meetings, are suggested for revision, taking into account the texts harmonized by the PDG (*European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia*).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a8a014b609646de229634dd37602f341d34ad5526324fc931a9c0fbe6b030e72", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Paediatric Retinol Oral Solution\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monograph on retinol concentrate, oily form, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\nPaediatric vitamin A soft-gel capsules have a unique mode of delivery. They are furnished with a small nipple which can be cut off so that the liquid content can be easily squeezed into the mouth of a child. The Committee decided to subsume this dosage form under the monograph on vitamin A oral solution, considering the soft gelatin shell as a single-unit container and the liquid content as the actual dosage form. The Expert Committee recommended that the monograph on paediatric retinol oral solution be modified so that its specifications can also be applied to these single-dose units. The capsule monograph was then to be withdrawn.\n\n# Paracetamol\n\nDraft versions of the monographs:\n\n- Paracetamol oral solution\n- Paracetamol oral suspension\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monographs, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 4.5 Review of Published General Monographs for Dosage Forms and Associated Method Texts\n\n### 4.5.1 Pharmacopoeial Discussion Group: Harmonized General Texts\n\nThe Expert Committee members were updated on the discussions and recommendations of the informal consultation held in May 2010. Ph.Int. general methods, as discussed during previous Expert Committee meetings, are suggested for revision, taking into account the texts harmonized by the PDG (*European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia*).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2258, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5b9ad6-787b-4d09-adf2-6dce80785c54": {"__data__": {"id_": "0a5b9ad6-787b-4d09-adf2-6dce80785c54", "embedding": null, "metadata": {"page_label": "34", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "During their 42nd and 44th meetings, the Expert Committee endorsed the suggestion that \u201cthe relevant method texts of *The International Pharmacopoeia* should be reviewed alongside the finalized, harmonized PDG texts in order to identify any differences and to ascertain to what extent it might be appropriate to revise the texts of *The International Pharmacopoeia*. Any proposed changes would then be circulated in accordance with the usual WHO consultation process. Once the suggested actions had been identified and agreed by the Expert Committee, the WHO Secretariat would contact the PDG, as appropriate, with regard to its decisions on the use of PDG harmonized texts\u201d.\n\nFollowing this recommendation, a formal request was formulated by the WHO Secretariat to the PDG, which resulted in authorization being given by all three pharmacopoeias of the PDG to use the sign-off text as a basis for publication in *The International Pharmacopoeia* and agreeing that the text needed to be converted into the style of *The International Pharmacopoeia*.\n\nThe Expert Committee agreed that individual PDG method texts might be included in the Ph.Int. as follows, either as:\n\n- **methods supporting the text requirements of the Ph.Int. monographs**: included within the Methods of analysis section either in place of an existing method or as a new method.  \n  In the case of a method intended to replace an existing method, it might be possible to publish both for an interim period so that the \u201cold\u201d method can be used until the relevant monographs are revised; or\n- **methods provided as guidance** with a specific reference made in the Ph.Int. monographs: included within the Supplementary information section; or\n- **as general information** to which no reference is made within the Ph.Int. monographs: included within the Supplementary information section.\n\nRevisions to existing Ph.Int. texts would be circulated in accordance with the usual WHO consultation process.\n\nIn the case of a new text to be included in the Method of analysis section of the Ph.Int., it was recommended to indicate the monographs (published and under elaboration) to which it was intended that the new texts should apply.\n\nThe PDG harmonized general methods reviewed and covered by this approach were the following:\n\n- Residue on ignition/sulfated ash\n- Test for extractable volume of parenteral preparations\n- Test for particulate contamination: subvisible particles\n- Microbial examination of non-sterile products: microbial enumeration tests\n- Microbial examination of non-sterile products: tests for specified microorganisms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento detalla las recomendaciones del Comit\u00e9 de Expertos de la OMS sobre la revisi\u00f3n de los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG (Pharmacopoeial Discussion Group). Se sugiere que se identifiquen las diferencias entre los textos y se eval\u00fae la necesidad de revisarlos. Se establece un proceso para incluir m\u00e9todos del PDG en *The International Pharmacopoeia*, ya sea como m\u00e9todos que apoyan los requisitos de los monograf\u00edas, como m\u00e9todos de orientaci\u00f3n, o como informaci\u00f3n general. Adem\u00e1s, se mencionan m\u00e9todos espec\u00edficos que han sido armonizados y revisados bajo este enfoque.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se utilizar\u00e1n para determinar si un m\u00e9todo del PDG debe reemplazar un m\u00e9todo existente en *The International Pharmacopoeia*?**\n   - Esta pregunta busca entender el proceso de evaluaci\u00f3n y decisi\u00f3n que se seguir\u00e1 para la inclusi\u00f3n o sustituci\u00f3n de m\u00e9todos.\n\n2. **\u00bfC\u00f3mo se llevar\u00e1 a cabo el proceso de consulta de la OMS para las revisiones de los textos existentes de *The International Pharmacopoeia*?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se implementar\u00e1n para asegurar que las revisiones sean adecuadamente discutidas y aprobadas.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la inclusi\u00f3n de m\u00e9todos como \"informaci\u00f3n general\" en comparaci\u00f3n con aquellos que son \"m\u00e9todos de orientaci\u00f3n\" en el contexto de las monograf\u00edas de *The International Pharmacopoeia*?**\n   - Esta pregunta busca aclarar las diferencias en el uso y la aplicaci\u00f3n de los m\u00e9todos seg\u00fan su clasificaci\u00f3n en el documento.\n\n### Resumen de Nivel Superior\n\nEl Comit\u00e9 de Expertos de la OMS ha recomendado revisar los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG. Se han establecido criterios para la inclusi\u00f3n de m\u00e9todos, que pueden ser utilizados como soporte para monograf\u00edas, como orientaci\u00f3n, o como informaci\u00f3n general. Se enfatiza la importancia de un proceso de consulta para las revisiones y se identifican m\u00e9todos espec\u00edficos que han sido armonizados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Soluci\u00f3n Oral de Retinol Pedi\u00e1trico**:\n   - Se discutieron y revisaron especificaciones en agosto de 2010.\n   - Se adopt\u00f3 una monograf\u00eda sobre el concentrado de retinol en forma oleosa, con cambios acordados.\n   - Las c\u00e1psulas de gel blando de vitamina A pedi\u00e1trica se integraron en la monograf\u00eda de soluci\u00f3n oral, consider\u00e1ndose como un contenedor de unidad \u00fanica.\n\n2. **Monograf\u00edas de Paracetamol**:\n   - Se prepararon borradores para soluciones y suspensiones orales de paracetamol.\n   - Las monograf\u00edas fueron adoptadas por el Comit\u00e9 de Expertos, con inclusi\u00f3n de cambios basados en comentarios recibidos.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica**:\n   - Se actualiz\u00f3 a los miembros del Comit\u00e9 sobre recomendaciones de una consulta informal en mayo de 2010.\n   - Se sugiri\u00f3 la revisi\u00f3n de m\u00e9todos generales de la Ph.Int. en armon\u00eda con textos de farmacopeas europeas, japonesas y estadounidenses.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo responsable de la adopci\u00f3n de monograf\u00edas.\n- **Retinol**: Compuesto discutido en la monograf\u00eda pedi\u00e1trica.\n- **Paracetamol**: Medicamento para el cual se desarrollaron monograf\u00edas.\n- **Pharmacopoeial Discussion Group (PDG)**: Grupo que armoniza textos de farmacopeas.\n- **Farmacopeas**: Documentos de referencia como la Farmacopea Europea, Japonesa y de los Estados Unidos.", "excerpt_keywords": "Keywords: International Pharmacopoeia, Expert Committee, PDG harmonization, method texts, WHO consultation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b178ca83-ad45-4659-b54b-8ad877711275", "node_type": "4", "metadata": {"page_label": "34", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "During their 42nd and 44th meetings, the Expert Committee endorsed the suggestion that \u201cthe relevant method texts of *The International Pharmacopoeia* should be reviewed alongside the finalized, harmonized PDG texts in order to identify any differences and to ascertain to what extent it might be appropriate to revise the texts of *The International Pharmacopoeia*. Any proposed changes would then be circulated in accordance with the usual WHO consultation process. Once the suggested actions had been identified and agreed by the Expert Committee, the WHO Secretariat would contact the PDG, as appropriate, with regard to its decisions on the use of PDG harmonized texts\u201d.\n\nFollowing this recommendation, a formal request was formulated by the WHO Secretariat to the PDG, which resulted in authorization being given by all three pharmacopoeias of the PDG to use the sign-off text as a basis for publication in *The International Pharmacopoeia* and agreeing that the text needed to be converted into the style of *The International Pharmacopoeia*.\n\nThe Expert Committee agreed that individual PDG method texts might be included in the Ph.Int. as follows, either as:\n\n- **methods supporting the text requirements of the Ph.Int. monographs**: included within the Methods of analysis section either in place of an existing method or as a new method.  \n  In the case of a method intended to replace an existing method, it might be possible to publish both for an interim period so that the \u201cold\u201d method can be used until the relevant monographs are revised; or\n- **methods provided as guidance** with a specific reference made in the Ph.Int. monographs: included within the Supplementary information section; or\n- **as general information** to which no reference is made within the Ph.Int. monographs: included within the Supplementary information section.\n\nRevisions to existing Ph.Int. texts would be circulated in accordance with the usual WHO consultation process.\n\nIn the case of a new text to be included in the Method of analysis section of the Ph.Int., it was recommended to indicate the monographs (published and under elaboration) to which it was intended that the new texts should apply.\n\nThe PDG harmonized general methods reviewed and covered by this approach were the following:\n\n- Residue on ignition/sulfated ash\n- Test for extractable volume of parenteral preparations\n- Test for particulate contamination: subvisible particles\n- Microbial examination of non-sterile products: microbial enumeration tests\n- Microbial examination of non-sterile products: tests for specified microorganisms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "96beffc197a183f209ecd0945b19a031aa32bd970da599618b66eb45da8848b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "During their 42nd and 44th meetings, the Expert Committee endorsed the suggestion that \u201cthe relevant method texts of *The International Pharmacopoeia* should be reviewed alongside the finalized, harmonized PDG texts in order to identify any differences and to ascertain to what extent it might be appropriate to revise the texts of *The International Pharmacopoeia*. Any proposed changes would then be circulated in accordance with the usual WHO consultation process. Once the suggested actions had been identified and agreed by the Expert Committee, the WHO Secretariat would contact the PDG, as appropriate, with regard to its decisions on the use of PDG harmonized texts\u201d.\n\nFollowing this recommendation, a formal request was formulated by the WHO Secretariat to the PDG, which resulted in authorization being given by all three pharmacopoeias of the PDG to use the sign-off text as a basis for publication in *The International Pharmacopoeia* and agreeing that the text needed to be converted into the style of *The International Pharmacopoeia*.\n\nThe Expert Committee agreed that individual PDG method texts might be included in the Ph.Int. as follows, either as:\n\n- **methods supporting the text requirements of the Ph.Int. monographs**: included within the Methods of analysis section either in place of an existing method or as a new method.  \n  In the case of a method intended to replace an existing method, it might be possible to publish both for an interim period so that the \u201cold\u201d method can be used until the relevant monographs are revised; or\n- **methods provided as guidance** with a specific reference made in the Ph.Int. monographs: included within the Supplementary information section; or\n- **as general information** to which no reference is made within the Ph.Int. monographs: included within the Supplementary information section.\n\nRevisions to existing Ph.Int. texts would be circulated in accordance with the usual WHO consultation process.\n\nIn the case of a new text to be included in the Method of analysis section of the Ph.Int., it was recommended to indicate the monographs (published and under elaboration) to which it was intended that the new texts should apply.\n\nThe PDG harmonized general methods reviewed and covered by this approach were the following:\n\n- Residue on ignition/sulfated ash\n- Test for extractable volume of parenteral preparations\n- Test for particulate contamination: subvisible particles\n- Microbial examination of non-sterile products: microbial enumeration tests\n- Microbial examination of non-sterile products: tests for specified microorganisms", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2603, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b712c83b-cf5d-4f8c-ac1a-b11f05f8d68f": {"__data__": {"id_": "b712c83b-cf5d-4f8c-ac1a-b11f05f8d68f", "embedding": null, "metadata": {"page_label": "35", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\nHarmonization of the tests was still under discussion at the PDG and would be considered at a later date.\n\nThe Expert Committee endorsed the proposals presented and the general approach outlined in the background paper. It advised that clear indications be added to the proposed revised texts when circulating them for comment to explain the approach followed for each harmonized method (e.g. revision, addition or for supplementary information).\n\nThe Expert Committee also recommended that once a harmonized PDG method was included in the Ph.Int. a mechanism would be needed to ensure that any further change implemented in the PDG texts be captured in the corresponding text published in Ph.Int.\n\n### 4.5.2 Uniformity of content for single-dose preparations\n\nThe Expert Committee discussed the application of the test for uniformity of content as described in Method 5.1 of the Ph.Int. for fixed-dose combinations (FDCs) in view of the increasing importance of these products.\n\nThe Expert Committee recommended that, in deciding whether a requirement should be included in monographs for FDC tablets or capsules, where none of the APIs are present in less than 5 mg, each case would be judged on its merits. During development of the monograph, account would be taken of the WHO FDC guidelines. A test for uniformity of content of one or more of the active ingredients would be specified for application to the relevant tablet/capsule strength(s). Meanwhile, in accordance with the new approach adopted on the implementation of PDG harmonized texts in the Ph.Int., the general method text 5.1 would not be modified. It was noted that, in the absence of a requirement for uniformity of content in a specific, individual tablet/capsule monograph, compliance with the test for uniformity of mass (5.2) was usually required by means of the relevant general monograph.\n\nThe Expert Committee recommended that, when a requirement for uniformity was specified in a monograph:\n\n\u2014 wherever possible, the analytical method would be described in the individual monograph; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Harmonizaci\u00f3n de M\u00e9todos de Prueba**: El Comit\u00e9 de Expertos est\u00e1 trabajando en la armonizaci\u00f3n de m\u00e9todos de prueba para productos farmac\u00e9uticos, incluyendo criterios de aceptaci\u00f3n para productos no est\u00e9riles y pruebas espec\u00edficas como la disoluci\u00f3n y la uniformidad de contenido. Se discute la necesidad de un mecanismo para actualizar los textos armonizados en la Farmacopea Internacional (Ph.Int).\n\n2. **Uniformidad de Contenido en Preparaciones de Dosis \u00danica**: Se aborda la aplicaci\u00f3n de pruebas de uniformidad de contenido para combinaciones de dosis fijas (FDCs), destacando que cada caso se evaluar\u00e1 individualmente y se tendr\u00e1n en cuenta las directrices de la OMS. Se recomienda que, cuando se especifique un requisito de uniformidad en un monogr\u00e1fico, se describa el m\u00e9todo anal\u00edtico correspondiente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al decidir si incluir un requisito de uniformidad de contenido en los monogr\u00e1ficos de tabletas o c\u00e1psulas de combinaciones de dosis fijas (FDCs)?**\n   - Se deben considerar los m\u00e9ritos de cada caso, especialmente si ninguno de los ingredientes activos (APIs) est\u00e1 presente en menos de 5 mg, y se tendr\u00e1n en cuenta las directrices de la OMS para FDC.\n\n2. **\u00bfQu\u00e9 se recomienda hacer cuando se especifica un requisito de uniformidad en un monogr\u00e1fico?**\n   - Se recomienda que, siempre que sea posible, el m\u00e9todo anal\u00edtico se describa en el monogr\u00e1fico individual correspondiente.\n\n3. **\u00bfCu\u00e1l es la relaci\u00f3n entre la prueba de uniformidad de contenido y la prueba de uniformidad de masa en el contexto de los monogr\u00e1ficos de tabletas/c\u00e1psulas?**\n   - En ausencia de un requisito espec\u00edfico para la uniformidad de contenido en un monogr\u00e1fico individual, generalmente se requiere el cumplimiento de la prueba de uniformidad de masa (5.2) a trav\u00e9s del monogr\u00e1fico general relevante.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de M\u00e9todos**: Se recomienda revisar los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG para identificar diferencias y evaluar la necesidad de revisiones.\n\n2. **Proceso de Inclusi\u00f3n**: Se establecen criterios para la inclusi\u00f3n de m\u00e9todos del PDG en *The International Pharmacopoeia*, que pueden ser:\n   - M\u00e9todos que apoyan los requisitos de las monograf\u00edas.\n   - M\u00e9todos de orientaci\u00f3n.\n   - Informaci\u00f3n general sin referencia espec\u00edfica en las monograf\u00edas.\n\n3. **Consulta de la OMS**: Las revisiones de los textos existentes se llevar\u00e1n a cabo siguiendo el proceso de consulta habitual de la OMS.\n\n4. **M\u00e9todos Espec\u00edficos**: Se mencionan m\u00e9todos espec\u00edficos que han sido armonizados y revisados, incluyendo pruebas para residuos, volumen extra\u00edble, contaminaci\u00f3n particulada y ex\u00e1menes microbianos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n y consulta de los textos.\n- **Pharmacopoeial Discussion Group (PDG)**: Grupo que proporciona textos armonizados que se est\u00e1n considerando para su inclusi\u00f3n.\n- **The International Pharmacopoeia**: Documento que contiene los m\u00e9todos y monograf\u00edas que se est\u00e1n revisando y actualizando.\n- **M\u00e9todos Espec\u00edficos**:\n  - Residuo en ignici\u00f3n/ash sulfatado.\n  - Volumen extra\u00edble de preparaciones parenterales.\n  - Contaminaci\u00f3n particulada: part\u00edculas subvisibles.\n  - Examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana.\n  - Examen microbiano de productos no est\u00e9riles: pruebas para microorganismos espec\u00edficos. \n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo el proceso de revisi\u00f3n y los m\u00e9todos espec\u00edficos que se est\u00e1n considerando para su inclusi\u00f3n en *The International Pharmacopoeia*.", "excerpt_keywords": "Harmonization, Pharmaceutical, Uniformity, Fixed-dose combinations, Analytical methods"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e288a05f-9d27-4894-9c72-312ce8b11337", "node_type": "4", "metadata": {"page_label": "35", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\nHarmonization of the tests was still under discussion at the PDG and would be considered at a later date.\n\nThe Expert Committee endorsed the proposals presented and the general approach outlined in the background paper. It advised that clear indications be added to the proposed revised texts when circulating them for comment to explain the approach followed for each harmonized method (e.g. revision, addition or for supplementary information).\n\nThe Expert Committee also recommended that once a harmonized PDG method was included in the Ph.Int. a mechanism would be needed to ensure that any further change implemented in the PDG texts be captured in the corresponding text published in Ph.Int.\n\n### 4.5.2 Uniformity of content for single-dose preparations\n\nThe Expert Committee discussed the application of the test for uniformity of content as described in Method 5.1 of the Ph.Int. for fixed-dose combinations (FDCs) in view of the increasing importance of these products.\n\nThe Expert Committee recommended that, in deciding whether a requirement should be included in monographs for FDC tablets or capsules, where none of the APIs are present in less than 5 mg, each case would be judged on its merits. During development of the monograph, account would be taken of the WHO FDC guidelines. A test for uniformity of content of one or more of the active ingredients would be specified for application to the relevant tablet/capsule strength(s). Meanwhile, in accordance with the new approach adopted on the implementation of PDG harmonized texts in the Ph.Int., the general method text 5.1 would not be modified. It was noted that, in the absence of a requirement for uniformity of content in a specific, individual tablet/capsule monograph, compliance with the test for uniformity of mass (5.2) was usually required by means of the relevant general monograph.\n\nThe Expert Committee recommended that, when a requirement for uniformity was specified in a monograph:\n\n\u2014 wherever possible, the analytical method would be described in the individual monograph; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6c2850fa68634fc4892794627a4f6e0a59acb45f3be6f9b66a82310069cb03a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\nHarmonization of the tests was still under discussion at the PDG and would be considered at a later date.\n\nThe Expert Committee endorsed the proposals presented and the general approach outlined in the background paper. It advised that clear indications be added to the proposed revised texts when circulating them for comment to explain the approach followed for each harmonized method (e.g. revision, addition or for supplementary information).\n\nThe Expert Committee also recommended that once a harmonized PDG method was included in the Ph.Int. a mechanism would be needed to ensure that any further change implemented in the PDG texts be captured in the corresponding text published in Ph.Int.\n\n### 4.5.2 Uniformity of content for single-dose preparations\n\nThe Expert Committee discussed the application of the test for uniformity of content as described in Method 5.1 of the Ph.Int. for fixed-dose combinations (FDCs) in view of the increasing importance of these products.\n\nThe Expert Committee recommended that, in deciding whether a requirement should be included in monographs for FDC tablets or capsules, where none of the APIs are present in less than 5 mg, each case would be judged on its merits. During development of the monograph, account would be taken of the WHO FDC guidelines. A test for uniformity of content of one or more of the active ingredients would be specified for application to the relevant tablet/capsule strength(s). Meanwhile, in accordance with the new approach adopted on the implementation of PDG harmonized texts in the Ph.Int., the general method text 5.1 would not be modified. It was noted that, in the absence of a requirement for uniformity of content in a specific, individual tablet/capsule monograph, compliance with the test for uniformity of mass (5.2) was usually required by means of the relevant general monograph.\n\nThe Expert Committee recommended that, when a requirement for uniformity was specified in a monograph:\n\n\u2014 wherever possible, the analytical method would be described in the individual monograph; and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2312, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f728f6-2cba-45d2-a78b-54ffdf5a239f": {"__data__": {"id_": "e1f728f6-2cba-45d2-a78b-54ffdf5a239f", "embedding": null, "metadata": {"page_label": "36", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 General policy topics and general revision issues for The International Pharmacopoeia\n\n## 4.6.1 Update on dissolution tests\n\nFollowing the discussions held at several Expert Committee meetings and during consultations on the issue of the addition of dissolution tests in specific monographs, a document summarizing the previous discussions and recommendations was presented to the Expert Committee.\n\nThe main recommendations and priorities endorsed by the Expert Committee during previous discussions were as follows:\n\n- A standardized dissolution test would be applied to tablets and capsules containing highly soluble APIs:\n  - As an alternative to disintegration (using a defined format, that applied, for example, to the monograph of isoniazid and ethambutol hydrochloride tablets),\n  - Subject to amendment of the criteria; and\n- The development of additional dissolution tests would be further reviewed.\n\nIn line with these recommendations, a dissolution test had recently been developed for a certain number of new or published monographs for products with highly soluble APIs (for example, during the process of the general revision on artemisinin derivatives). However, work still needed to be done on those monographs where a cross-reference to the general method was made.\n\nIn view of the amount of work that these revisions would require, it was proposed that priority for revision be given to those monographs where a statement clearly indicated that the test was under development or where a reference to the general method without requirements was made and to those monographs that were already assigned priority due to bioavailability or poor solubility problems (as identified in the 31st report of the Expert Committee and indicated with an asterisk* within the list below).\n\nThis represented 16 monographs, extracted from the list of preparations presented in Annex 1 of document QSM/EC/07.21, amended to include affected monographs published since 2007:\n\n- ampicillin capsules\n- artemether capsules\n- artemether tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento aborda las actualizaciones sobre las pruebas de disoluci\u00f3n en la Farmacopea Internacional, destacando las recomendaciones del Comit\u00e9 de Expertos sobre la aplicaci\u00f3n de pruebas estandarizadas para tabletas y c\u00e1psulas que contienen principios activos altamente solubles. Se menciona la necesidad de desarrollar pruebas adicionales y se priorizan ciertas monograf\u00edas para revisi\u00f3n, especialmente aquellas con problemas de bioavailability o solubilidad. Se enumeran ejemplos de monograf\u00edas afectadas, como las c\u00e1psulas de ampicilina y artemeter.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se deben considerar para la enmienda de las pruebas de disoluci\u00f3n en las monograf\u00edas de la Farmacopea Internacional?**\n   - Esta pregunta busca detalles sobre los criterios que el Comit\u00e9 de Expertos considera al modificar las pruebas de disoluci\u00f3n, que no se especifican en el resumen.\n\n2. **\u00bfQu\u00e9 monograf\u00edas se consideran prioritarias para la revisi\u00f3n debido a problemas de bioavailability o solubilidad, y cu\u00e1les son los criterios para su selecci\u00f3n?**\n   - Esta pregunta se centra en entender c\u00f3mo se determina la prioridad de revisi\u00f3n de las monograf\u00edas y qu\u00e9 caracter\u00edsticas espec\u00edficas las hacen elegibles.\n\n3. **\u00bfQu\u00e9 avances se han realizado en el desarrollo de pruebas de disoluci\u00f3n para los derivados de artemisinina y qu\u00e9 desaf\u00edos persisten en este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre el progreso espec\u00edfico en las pruebas de disoluci\u00f3n para un grupo particular de medicamentos y los obst\u00e1culos que a\u00fan deben superarse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Harmonizaci\u00f3n de M\u00e9todos de Prueba**:\n   - Se est\u00e1 trabajando en la armonizaci\u00f3n de m\u00e9todos de prueba para productos farmac\u00e9uticos no est\u00e9riles.\n   - Se discuten criterios de aceptaci\u00f3n y pruebas espec\u00edficas como la disoluci\u00f3n, la uniformidad de contenido, y la friabilidad de tabletas.\n   - Se recomienda establecer un mecanismo para actualizar los textos armonizados en la Farmacopea Internacional (Ph.Int) conforme se realicen cambios en los textos del PDG.\n\n2. **Uniformidad de Contenido en Preparaciones de Dosis \u00danica**:\n   - Se analiza la aplicaci\u00f3n de la prueba de uniformidad de contenido para combinaciones de dosis fijas (FDCs).\n   - Cada caso se evaluar\u00e1 individualmente, considerando las directrices de la OMS, especialmente si los ingredientes activos (APIs) est\u00e1n presentes en cantidades superiores a 5 mg.\n   - Se sugiere que, cuando se especifique un requisito de uniformidad en un monogr\u00e1fico, se incluya la descripci\u00f3n del m\u00e9todo anal\u00edtico correspondiente.\n\n3. **Relaci\u00f3n entre Pruebas**:\n   - En ausencia de un requisito espec\u00edfico para la uniformidad de contenido en un monogr\u00e1fico individual, se requiere el cumplimiento de la prueba de uniformidad de masa (5.2) a trav\u00e9s del monogr\u00e1fico general relevante.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo que discute y recomienda sobre m\u00e9todos de prueba y criterios de aceptaci\u00f3n.\n- **Farmacopea Internacional (Ph.Int)**: Documento que contiene est\u00e1ndares para productos farmac\u00e9uticos.\n- **Combinaciones de Dosis Fijas (FDCs)**: Preparaciones que contienen dos o m\u00e1s ingredientes activos en una sola forma de dosificaci\u00f3n.\n- **M\u00e9todos de Prueba**: Incluyen pruebas de disoluci\u00f3n, uniformidad de contenido, y pruebas de esterilidad, entre otros.", "excerpt_keywords": "Keywords: dissolution tests, International Pharmacopoeia, Expert Committee, bioavailability, artemisinin derivatives"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8013bd4d-774e-43fc-a3a6-8e48d19fae17", "node_type": "4", "metadata": {"page_label": "36", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 General policy topics and general revision issues for The International Pharmacopoeia\n\n## 4.6.1 Update on dissolution tests\n\nFollowing the discussions held at several Expert Committee meetings and during consultations on the issue of the addition of dissolution tests in specific monographs, a document summarizing the previous discussions and recommendations was presented to the Expert Committee.\n\nThe main recommendations and priorities endorsed by the Expert Committee during previous discussions were as follows:\n\n- A standardized dissolution test would be applied to tablets and capsules containing highly soluble APIs:\n  - As an alternative to disintegration (using a defined format, that applied, for example, to the monograph of isoniazid and ethambutol hydrochloride tablets),\n  - Subject to amendment of the criteria; and\n- The development of additional dissolution tests would be further reviewed.\n\nIn line with these recommendations, a dissolution test had recently been developed for a certain number of new or published monographs for products with highly soluble APIs (for example, during the process of the general revision on artemisinin derivatives). However, work still needed to be done on those monographs where a cross-reference to the general method was made.\n\nIn view of the amount of work that these revisions would require, it was proposed that priority for revision be given to those monographs where a statement clearly indicated that the test was under development or where a reference to the general method without requirements was made and to those monographs that were already assigned priority due to bioavailability or poor solubility problems (as identified in the 31st report of the Expert Committee and indicated with an asterisk* within the list below).\n\nThis represented 16 monographs, extracted from the list of preparations presented in Annex 1 of document QSM/EC/07.21, amended to include affected monographs published since 2007:\n\n- ampicillin capsules\n- artemether capsules\n- artemether tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "92a1b26728a41b0a3321b4cda77adcbc34e02c8c692439540d41e6c14eeb6fd8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.6 General policy topics and general revision issues for The International Pharmacopoeia\n\n## 4.6.1 Update on dissolution tests\n\nFollowing the discussions held at several Expert Committee meetings and during consultations on the issue of the addition of dissolution tests in specific monographs, a document summarizing the previous discussions and recommendations was presented to the Expert Committee.\n\nThe main recommendations and priorities endorsed by the Expert Committee during previous discussions were as follows:\n\n- A standardized dissolution test would be applied to tablets and capsules containing highly soluble APIs:\n  - As an alternative to disintegration (using a defined format, that applied, for example, to the monograph of isoniazid and ethambutol hydrochloride tablets),\n  - Subject to amendment of the criteria; and\n- The development of additional dissolution tests would be further reviewed.\n\nIn line with these recommendations, a dissolution test had recently been developed for a certain number of new or published monographs for products with highly soluble APIs (for example, during the process of the general revision on artemisinin derivatives). However, work still needed to be done on those monographs where a cross-reference to the general method was made.\n\nIn view of the amount of work that these revisions would require, it was proposed that priority for revision be given to those monographs where a statement clearly indicated that the test was under development or where a reference to the general method without requirements was made and to those monographs that were already assigned priority due to bioavailability or poor solubility problems (as identified in the 31st report of the Expert Committee and indicated with an asterisk* within the list below).\n\nThis represented 16 monographs, extracted from the list of preparations presented in Annex 1 of document QSM/EC/07.21, amended to include affected monographs published since 2007:\n\n- ampicillin capsules\n- artemether capsules\n- artemether tablets", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2045, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "43036a63-3ff0-4a3b-98f0-7b847bdd7a6a": {"__data__": {"id_": "43036a63-3ff0-4a3b-98f0-7b847bdd7a6a", "embedding": null, "metadata": {"page_label": "37", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- artemisinin capsules\n- artemisinin tablets\n- artenimol tablets\n- carbamazepine tablets\n- erythromycin ethylsuccinate tablets*\n- erythromycin stearate tablets*\n- griseofulvin tablets*\n- ibuprofen tablets\n- indometacin tablets\n- phenytoin sodium tablets*\n- rifampicin, isoniazid and ethambutol tablets\n- rifampicin and isoniazid dispersible tablets\n- rifampicin, isoniazid and pyrazinamide dispersible tablets\n\nThis priority list was discussed during the consultation held in May 2010, where it was recommended that priority should indeed be assigned to those monographs listed, with the exception, however, of the following monographs on artemisinin derivatives, the products of which were no longer marketed and, therefore, a revision was not required:\n\n- artemether capsules\n- artemether tablets\n- artemisinin capsules\n- artemisinin tablets\n\nIn order to be able to rapidly develop and include a dissolution test in the monographs that have been identified, the Expert Committee endorsed the recommendation that a pragmatic approach be followed, based on methods that are publicly available.\n\nThe Expert Committee further recommended that general guidance be developed for the dissolution test so that a clear general policy could be established on when to include this test in new monographs, preferably, if at all possible, at the early stages of their development.\n\n### 4.6.2 Dry powders\n\nWith the development of the monograph on amoxicillin oral suspension in collaboration with The British Pharmacopoeia (BP), the issue of how to deal in The International Pharmacopoeia with formulations that are intended to be modified by the patient before use was raised. It was noted that the two pharmacopoeias had different approaches for these formulations:\n\n- BP was considering the final product (i.e. the reconstituted solution, suspension or injection) and reflecting this in the monograph titles (in this case Amoxicillin oral suspension); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Prioridad en Monograf\u00edas de Medicamentos**: Durante una consulta en mayo de 2010, se discuti\u00f3 una lista de monograf\u00edas prioritarias para el desarrollo, excluyendo ciertos derivados de artemisinina que ya no estaban en el mercado. Se enfatiz\u00f3 la necesidad de un enfoque pragm\u00e1tico para el desarrollo de pruebas de disoluci\u00f3n en estas monograf\u00edas.\n\n2. **Enfoque sobre Formulaciones Modificadas**: Se abord\u00f3 la cuesti\u00f3n de c\u00f3mo manejar las formulaciones que los pacientes deben modificar antes de su uso, destacando las diferencias entre la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en cuanto a la consideraci\u00f3n del producto final en sus monograf\u00edas.\n\n3. **Desarrollo de Pruebas de Disoluci\u00f3n**: Se recomend\u00f3 que se desarrollara una gu\u00eda general para las pruebas de disoluci\u00f3n, estableciendo una pol\u00edtica clara sobre cu\u00e1ndo incluir estas pruebas en nuevas monograf\u00edas, preferiblemente desde las etapas iniciales de desarrollo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los medicamentos que fueron excluidos de la revisi\u00f3n de monograf\u00edas debido a que ya no estaban en el mercado?**\n   - Los medicamentos excluidos son: artemether c\u00e1psulas, artemether tabletas, artemisinin c\u00e1psulas y artemisinin tabletas.\n\n2. **\u00bfQu\u00e9 enfoque se recomienda para el desarrollo de pruebas de disoluci\u00f3n en las monograf\u00edas identificadas?**\n   - Se recomienda un enfoque pragm\u00e1tico basado en m\u00e9todos que son p\u00fablicamente disponibles, junto con el desarrollo de una gu\u00eda general para establecer una pol\u00edtica clara sobre la inclusi\u00f3n de pruebas de disoluci\u00f3n en nuevas monograf\u00edas.\n\n3. **\u00bfC\u00f3mo difieren la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en su tratamiento de formulaciones que deben ser modificadas por el paciente?**\n   - La Farmacopea Brit\u00e1nica considera el producto final (como la soluci\u00f3n reconstituida, suspensi\u00f3n o inyecci\u00f3n) y refleja esto en los t\u00edtulos de las monograf\u00edas, mientras que la Farmacopea Internacional aborda estas formulaciones de manera diferente, aunque el texto no especifica c\u00f3mo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Actualizaci\u00f3n sobre Pruebas de Disoluci\u00f3n**: Se discuten las recomendaciones del Comit\u00e9 de Expertos sobre la implementaci\u00f3n de pruebas de disoluci\u00f3n estandarizadas para tabletas y c\u00e1psulas que contienen principios activos altamente solubles.\n  \n2. **Pruebas Estandarizadas**: Se propone que estas pruebas se utilicen como alternativa a las pruebas de desintegraci\u00f3n, con la posibilidad de enmendar los criterios existentes.\n\n3. **Desarrollo de Nuevas Pruebas**: Se menciona la necesidad de revisar el desarrollo de pruebas adicionales de disoluci\u00f3n.\n\n4. **Prioridades de Revisi\u00f3n**: Se establece que la revisi\u00f3n debe centrarse en monograf\u00edas donde se indique que la prueba est\u00e1 en desarrollo o donde se haga referencia a un m\u00e9todo general sin requisitos espec\u00edficos, as\u00ed como en aquellas con problemas de bioavailability o solubilidad.\n\n5. **Monograf\u00edas Afectadas**: Se identifican 16 monograf\u00edas prioritarias para revisi\u00f3n, incluyendo ejemplos espec\u00edficos como las c\u00e1psulas de ampicilina y artemeter.\n\n#### Entidades:\n- **Comit\u00e9 de Expertos**: Grupo responsable de discutir y recomendar cambios en las pruebas de disoluci\u00f3n.\n- **Farmacopea Internacional**: Documento regulador que incluye monograf\u00edas de medicamentos.\n- **Principios Activos Altamente Solubles (APIs)**: Sustancias que se consideran para la aplicaci\u00f3n de pruebas de disoluci\u00f3n estandarizadas.\n- **Monograf\u00edas**: Documentos espec\u00edficos que describen los est\u00e1ndares para productos farmac\u00e9uticos, como:\n  - C\u00e1psulas de ampicilina\n  - C\u00e1psulas de artemeter\n  - Tabletas de artemeter\n\nEste resumen destaca la importancia de las pruebas de disoluci\u00f3n en la regulaci\u00f3n de medicamentos y la necesidad de priorizar ciertas monograf\u00edas para asegurar la calidad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: artemisinin, dissolution test, pharmacopoeia, monographs, drug formulation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9834bc1c-22b5-4a86-94e3-e1e43e85e974", "node_type": "4", "metadata": {"page_label": "37", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- artemisinin capsules\n- artemisinin tablets\n- artenimol tablets\n- carbamazepine tablets\n- erythromycin ethylsuccinate tablets*\n- erythromycin stearate tablets*\n- griseofulvin tablets*\n- ibuprofen tablets\n- indometacin tablets\n- phenytoin sodium tablets*\n- rifampicin, isoniazid and ethambutol tablets\n- rifampicin and isoniazid dispersible tablets\n- rifampicin, isoniazid and pyrazinamide dispersible tablets\n\nThis priority list was discussed during the consultation held in May 2010, where it was recommended that priority should indeed be assigned to those monographs listed, with the exception, however, of the following monographs on artemisinin derivatives, the products of which were no longer marketed and, therefore, a revision was not required:\n\n- artemether capsules\n- artemether tablets\n- artemisinin capsules\n- artemisinin tablets\n\nIn order to be able to rapidly develop and include a dissolution test in the monographs that have been identified, the Expert Committee endorsed the recommendation that a pragmatic approach be followed, based on methods that are publicly available.\n\nThe Expert Committee further recommended that general guidance be developed for the dissolution test so that a clear general policy could be established on when to include this test in new monographs, preferably, if at all possible, at the early stages of their development.\n\n### 4.6.2 Dry powders\n\nWith the development of the monograph on amoxicillin oral suspension in collaboration with The British Pharmacopoeia (BP), the issue of how to deal in The International Pharmacopoeia with formulations that are intended to be modified by the patient before use was raised. It was noted that the two pharmacopoeias had different approaches for these formulations:\n\n- BP was considering the final product (i.e. the reconstituted solution, suspension or injection) and reflecting this in the monograph titles (in this case Amoxicillin oral suspension); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c1c773afdb26700afec33052df96e1f66c2d4c022a785dbdfdfdbf9f42985dee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- artemisinin capsules\n- artemisinin tablets\n- artenimol tablets\n- carbamazepine tablets\n- erythromycin ethylsuccinate tablets*\n- erythromycin stearate tablets*\n- griseofulvin tablets*\n- ibuprofen tablets\n- indometacin tablets\n- phenytoin sodium tablets*\n- rifampicin, isoniazid and ethambutol tablets\n- rifampicin and isoniazid dispersible tablets\n- rifampicin, isoniazid and pyrazinamide dispersible tablets\n\nThis priority list was discussed during the consultation held in May 2010, where it was recommended that priority should indeed be assigned to those monographs listed, with the exception, however, of the following monographs on artemisinin derivatives, the products of which were no longer marketed and, therefore, a revision was not required:\n\n- artemether capsules\n- artemether tablets\n- artemisinin capsules\n- artemisinin tablets\n\nIn order to be able to rapidly develop and include a dissolution test in the monographs that have been identified, the Expert Committee endorsed the recommendation that a pragmatic approach be followed, based on methods that are publicly available.\n\nThe Expert Committee further recommended that general guidance be developed for the dissolution test so that a clear general policy could be established on when to include this test in new monographs, preferably, if at all possible, at the early stages of their development.\n\n### 4.6.2 Dry powders\n\nWith the development of the monograph on amoxicillin oral suspension in collaboration with The British Pharmacopoeia (BP), the issue of how to deal in The International Pharmacopoeia with formulations that are intended to be modified by the patient before use was raised. It was noted that the two pharmacopoeias had different approaches for these formulations:\n\n- BP was considering the final product (i.e. the reconstituted solution, suspension or injection) and reflecting this in the monograph titles (in this case Amoxicillin oral suspension); and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1946, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b94bef14-cf9e-4fc1-8980-b0f656f5e6e6": {"__data__": {"id_": "b94bef14-cf9e-4fc1-8980-b0f656f5e6e6", "embedding": null, "metadata": {"page_label": "38", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Ph.Int. had so far been taking into consideration the product before reconstitution (i.e. the powders \u2014 several examples of powders for injections or oral powders can be found in the fourth edition).\n\nWhen discussing the draft monograph on amoxicillin oral suspension during the consultation held in May 2010, it was recommended that a standardized policy be followed in *The International Pharmacopoeia* for monographs on oral solutions or suspensions that need to be reconstituted from powders.\n\nIt was recognized during the consultation that the particular case of powders for injections which are also formulations that should be reconstituted before use, was not affected by the policy to be defined for powders for oral use, because these reconstituted formulations were to be used immediately after reconstitution and, therefore, were not intended to be kept and eventually stored for analysis purposes, for reasons concerning stability and sterility.\n\nThe Expert Committee recommended distinguishing from now on in the titles of the Ph.Int. monographs between the injections that are manufactured as liquid preparations and those intended to be reconstituted before use from a powder, by adding the preposition \u201cfor\u201d in the title of the monographs on reconstituted injections.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrate this approach:\n\n\u2014 Capreomycin *powder for injections* revised to Capreomycin *for injection*  \n\u2014 Artesunate *powder for injections* revised to Artesunate *for injection*\n\nThis revision has also been applied to the following texts, adopted in October 2009 and available on the WHO Medicines web site:\n\n\u2014 Amikacin *powder for injections* revised to Amikacin *for injection*  \n\u2014 Kanamycin *powder for injections* revised to Kanamycin *for injection*\n\nFor the published monographs (listed below) on powders for injection, which now require revision, it was recommended that the same approach be followed. Any revision of the current titles could be made when the opportunity arose, either when the monographs in question were revised for technical reasons or on publication of a new edition:\n\n\u2014 amphotericin B powder for injections  \n\u2014 ampicillin sodium powder for injections  \n\u2014 benzylpenicillin potassium powder for injections  \n\u2014 cloxacillin sodium powder for injections  \n\u2014 pentamidine isetionate powder for injections  \n\u2014 prednisolone sodium succinate powder for injections  \n\u2014 procaine benzylpenicillin powder for injections  \n\u2014 streptomycin sulfate powder for injections", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS discute la necesidad de estandarizar las pol\u00edticas en la *Farmacopea Internacional* (Ph.Int.) para las monograf\u00edas de soluciones orales o suspensiones que deben ser reconstituidas a partir de polvos. Durante una consulta en mayo de 2010, se recomend\u00f3 distinguir entre inyecciones que se fabrican como preparaciones l\u00edquidas y aquellas que deben ser reconstituidas antes de su uso. Se propuso modificar los t\u00edtulos de las monograf\u00edas para reflejar esta distinci\u00f3n, a\u00f1adiendo la preposici\u00f3n \"para\" en los t\u00edtulos de las inyecciones reconstituidas. Se presentan ejemplos de monograf\u00edas que han sido revisadas y se sugiere que las monograf\u00edas publicadas que a\u00fan no han sido actualizadas sigan este mismo enfoque.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n por la que las formulaciones reconstituidas de polvos para inyecci\u00f3n no se ven afectadas por la pol\u00edtica que se define para los polvos de uso oral?**\n   - Las formulaciones reconstituidas de polvos para inyecci\u00f3n deben ser utilizadas inmediatamente despu\u00e9s de la reconstituci\u00f3n y no est\u00e1n destinadas a ser almacenadas para an\u00e1lisis, debido a preocupaciones sobre la estabilidad y la esterilidad.\n\n2. **\u00bfQu\u00e9 cambios se proponen en los t\u00edtulos de las monograf\u00edas de la Ph.Int. para las inyecciones reconstituidas y por qu\u00e9?**\n   - Se propone a\u00f1adir la preposici\u00f3n \"para\" en los t\u00edtulos de las monograf\u00edas de inyecciones reconstituidas para distinguirlas de las inyecciones que se fabrican como preparaciones l\u00edquidas, facilitando as\u00ed la identificaci\u00f3n de su forma de preparaci\u00f3n.\n\n3. **\u00bfCu\u00e1les son algunos ejemplos de monograf\u00edas que han sido revisadas y c\u00f3mo se han modificado sus t\u00edtulos?**\n   - Ejemplos de monograf\u00edas que han sido revisadas incluyen: \n     - Capreomycin *powder for injections* se revis\u00f3 a Capreomycin *for injection*.\n     - Artesunate *powder for injections* se revis\u00f3 a Artesunate *for injection*.\n     - Adem\u00e1s, se menciona que otras monograf\u00edas publicadas, como la de ampicilina y la de estreptomicina, tambi\u00e9n requieren revisi\u00f3n siguiendo este enfoque.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prioridad en Monograf\u00edas de Medicamentos**:\n   - Se discuti\u00f3 una lista de monograf\u00edas prioritarias durante una consulta en mayo de 2010.\n   - Se excluyeron ciertos derivados de artemisinina (artemether y artemisinin) de la revisi\u00f3n debido a que ya no estaban en el mercado.\n\n2. **Medicamentos Listados**:\n   - Medicamentos en la lista de prioridad incluyen:\n     - Artemisinin c\u00e1psulas y tabletas\n     - Artenimol tabletas\n     - Carbamazepina tabletas\n     - Erythromycin ethylsuccinate tabletas\n     - Erythromycin stearate tabletas\n     - Griseofulvin tabletas\n     - Ibuprofeno tabletas\n     - Indometacina tabletas\n     - Phenytoin sodium tabletas\n     - Rifampicina, isoniazida y etambutol tabletas\n     - Rifampicina e isoniazida tabletas dispersables\n     - Rifampicina, isoniazida y pirazinamida tabletas dispersables\n\n3. **Desarrollo de Pruebas de Disoluci\u00f3n**:\n   - Se recomend\u00f3 un enfoque pragm\u00e1tico para el desarrollo de pruebas de disoluci\u00f3n en las monograf\u00edas identificadas, utilizando m\u00e9todos disponibles p\u00fablicamente.\n   - Se sugiri\u00f3 la creaci\u00f3n de una gu\u00eda general para establecer pol\u00edticas claras sobre la inclusi\u00f3n de pruebas de disoluci\u00f3n en nuevas monograf\u00edas, preferiblemente desde las etapas iniciales de desarrollo.\n\n4. **Formulaciones Modificadas por el Paciente**:\n   - Se abord\u00f3 la diferencia entre la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en el tratamiento de formulaciones que deben ser modificadas por el paciente.\n   - La Farmacopea Brit\u00e1nica considera el producto final (soluci\u00f3n reconstituida, suspensi\u00f3n o inyecci\u00f3n) en sus monograf\u00edas, mientras que la Farmacopea Internacional tiene un enfoque diferente.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Medicamentos**: Artemisinin, Carbamazepina, Erythromycin, Griseofulvin, Ibuprofeno, Indometacina, Phenytoin, Rifampicina, Isoniazida, Etambutol, Pirazinamida.\n- **Consultas**: Consulta de mayo de 2010.\n- **Farmacopeas**: Farmacopea Brit\u00e1nica (BP), Farmacopea Internacional.", "excerpt_keywords": "Pharmacopoeia, reconstitution, injections, monographs, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7f8bf3f0-dc32-4b98-af10-0e9489068176", "node_type": "4", "metadata": {"page_label": "38", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Ph.Int. had so far been taking into consideration the product before reconstitution (i.e. the powders \u2014 several examples of powders for injections or oral powders can be found in the fourth edition).\n\nWhen discussing the draft monograph on amoxicillin oral suspension during the consultation held in May 2010, it was recommended that a standardized policy be followed in *The International Pharmacopoeia* for monographs on oral solutions or suspensions that need to be reconstituted from powders.\n\nIt was recognized during the consultation that the particular case of powders for injections which are also formulations that should be reconstituted before use, was not affected by the policy to be defined for powders for oral use, because these reconstituted formulations were to be used immediately after reconstitution and, therefore, were not intended to be kept and eventually stored for analysis purposes, for reasons concerning stability and sterility.\n\nThe Expert Committee recommended distinguishing from now on in the titles of the Ph.Int. monographs between the injections that are manufactured as liquid preparations and those intended to be reconstituted before use from a powder, by adding the preposition \u201cfor\u201d in the title of the monographs on reconstituted injections.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrate this approach:\n\n\u2014 Capreomycin *powder for injections* revised to Capreomycin *for injection*  \n\u2014 Artesunate *powder for injections* revised to Artesunate *for injection*\n\nThis revision has also been applied to the following texts, adopted in October 2009 and available on the WHO Medicines web site:\n\n\u2014 Amikacin *powder for injections* revised to Amikacin *for injection*  \n\u2014 Kanamycin *powder for injections* revised to Kanamycin *for injection*\n\nFor the published monographs (listed below) on powders for injection, which now require revision, it was recommended that the same approach be followed. Any revision of the current titles could be made when the opportunity arose, either when the monographs in question were revised for technical reasons or on publication of a new edition:\n\n\u2014 amphotericin B powder for injections  \n\u2014 ampicillin sodium powder for injections  \n\u2014 benzylpenicillin potassium powder for injections  \n\u2014 cloxacillin sodium powder for injections  \n\u2014 pentamidine isetionate powder for injections  \n\u2014 prednisolone sodium succinate powder for injections  \n\u2014 procaine benzylpenicillin powder for injections  \n\u2014 streptomycin sulfate powder for injections", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a803e474e633001e81a29e06f59d102426d82d644c21200045f3c1d451c2b8e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 Ph.Int. had so far been taking into consideration the product before reconstitution (i.e. the powders \u2014 several examples of powders for injections or oral powders can be found in the fourth edition).\n\nWhen discussing the draft monograph on amoxicillin oral suspension during the consultation held in May 2010, it was recommended that a standardized policy be followed in *The International Pharmacopoeia* for monographs on oral solutions or suspensions that need to be reconstituted from powders.\n\nIt was recognized during the consultation that the particular case of powders for injections which are also formulations that should be reconstituted before use, was not affected by the policy to be defined for powders for oral use, because these reconstituted formulations were to be used immediately after reconstitution and, therefore, were not intended to be kept and eventually stored for analysis purposes, for reasons concerning stability and sterility.\n\nThe Expert Committee recommended distinguishing from now on in the titles of the Ph.Int. monographs between the injections that are manufactured as liquid preparations and those intended to be reconstituted before use from a powder, by adding the preposition \u201cfor\u201d in the title of the monographs on reconstituted injections.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrate this approach:\n\n\u2014 Capreomycin *powder for injections* revised to Capreomycin *for injection*  \n\u2014 Artesunate *powder for injections* revised to Artesunate *for injection*\n\nThis revision has also been applied to the following texts, adopted in October 2009 and available on the WHO Medicines web site:\n\n\u2014 Amikacin *powder for injections* revised to Amikacin *for injection*  \n\u2014 Kanamycin *powder for injections* revised to Kanamycin *for injection*\n\nFor the published monographs (listed below) on powders for injection, which now require revision, it was recommended that the same approach be followed. Any revision of the current titles could be made when the opportunity arose, either when the monographs in question were revised for technical reasons or on publication of a new edition:\n\n\u2014 amphotericin B powder for injections  \n\u2014 ampicillin sodium powder for injections  \n\u2014 benzylpenicillin potassium powder for injections  \n\u2014 cloxacillin sodium powder for injections  \n\u2014 pentamidine isetionate powder for injections  \n\u2014 prednisolone sodium succinate powder for injections  \n\u2014 procaine benzylpenicillin powder for injections  \n\u2014 streptomycin sulfate powder for injections", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2551, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1039ab9a-2418-408c-8868-416ed97f22ca": {"__data__": {"id_": "1039ab9a-2418-408c-8868-416ed97f22ca", "embedding": null, "metadata": {"page_label": "39", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "As regards oral suspensions or solutions reconstituted from powders it was recommended to consider the final preparation throughout the monograph. This approach was reflected in the text for amoxicillin oral suspension presented for discussion and adopted at the present meeting, when considering the aspects of the monograph, as described hereafter.\n\nBased on the above, the Expert Committee adopted the following new policy for such monographs.\n\n**Title of the monograph.** Title and requirements of the monograph would correspond to the final preparation rather than the powder.\n\n**Definition.** Any distinction, as to whether the oral suspension or solution needed to be reconstituted or was directly manufactured as a liquid, would be mentioned under Definition. Any necessary indication on the reconstitution of the final preparation would be given in this section as well.\n\n**Reference to general monographs.** Compliance of the final product with the general monograph for \u201cLiquid preparations for oral use\u201d and that of the powder with the section of the monograph entitled \u201cPowders for oral solutions, oral suspensions and oral drops\u201d would be maintained, as it is currently mentioned in published monographs on powders for oral use.\n\n**Manufacture.** When specific requirements referring to the powder needed to be included in the monograph, they would be mentioned by means of a statement or a test with or without specific limits, under this section (e.g. Test for water content).\n\nIt was also recognized that the quality of the reconstituted product during the in-use period as stated on the label should be considered. It was, therefore, proposed to cover this aspect by introducing, under the Manufacture section, a requirement with a minimum limit to be met at the end of the defined in-use period for content, with a statement as follows:\n\n\u201cThe product is formulated in such a way that when the suspension is constituted following manufacturer\u2019s instructions, stored at the temperature for the in-use period stated on the label and assayed using the method described below under Assay, it contains not less than 80.0% of the amount of amoxicillin (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S) stated on the label.\u201d\n\n**Tests.** Amounts to be taken for testing would be expressed in terms of quantities of the reconstituted solution or suspension and not the powder.\n\nFor example, \u201cdilute an accurately weighed *quantity of the oral suspension containing the equivalent of 60 mg of amoxicillin*.\u201d\n\nThe published monographs on oral powders should be revised in accordance with this new policy. It was recommended to follow the same approach as above for the future revisions of monographs for powders for injections.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento discute una nueva pol\u00edtica adoptada por el Comit\u00e9 de Expertos de la OMS para las monograf\u00edas de suspensiones orales o soluciones reconstituidas a partir de polvos. Se enfatiza que el t\u00edtulo y los requisitos de la monograf\u00eda deben corresponder a la preparaci\u00f3n final, no al polvo. Se establecen definiciones claras, referencias a monograf\u00edas generales, requisitos de fabricaci\u00f3n y pruebas espec\u00edficas para asegurar la calidad del producto reconstituido durante su per\u00edodo de uso. Se menciona la importancia de que el producto contenga al menos el 80% de la cantidad de amoxicilina indicada en la etiqueta al final del per\u00edodo de uso.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 porcentaje m\u00ednimo de amoxicilina debe contener el producto reconstituido al final del per\u00edodo de uso seg\u00fan la nueva pol\u00edtica adoptada?**\n   - Respuesta: El producto debe contener no menos del 80.0% de la cantidad de amoxicilina indicada en la etiqueta al final del per\u00edodo de uso.\n\n2. **\u00bfC\u00f3mo se debe expresar la cantidad para las pruebas en las monograf\u00edas de suspensiones orales seg\u00fan la nueva pol\u00edtica?**\n   - Respuesta: Las cantidades para las pruebas deben expresarse en t\u00e9rminos de cantidades de la soluci\u00f3n o suspensi\u00f3n reconstituida y no del polvo.\n\n3. **\u00bfQu\u00e9 cambios se proponen para las monograf\u00edas publicadas sobre polvos orales en relaci\u00f3n con la nueva pol\u00edtica?**\n   - Respuesta: Se recomienda que las monograf\u00edas publicadas sobre polvos orales sean revisadas de acuerdo con la nueva pol\u00edtica adoptada, siguiendo el mismo enfoque para futuras revisiones de monograf\u00edas de polvos para inyecciones.", "prev_section_summary": "### Temas Clave\n\n1. **Estandarizaci\u00f3n de Monograf\u00edas**: Se discute la necesidad de establecer una pol\u00edtica estandarizada en la *Farmacopea Internacional* (Ph.Int.) para las monograf\u00edas de soluciones orales o suspensiones que deben ser reconstituidas a partir de polvos.\n\n2. **Distinci\u00f3n entre Formulaciones**: Se recomienda distinguir entre inyecciones que se fabrican como preparaciones l\u00edquidas y aquellas que deben ser reconstituidas antes de su uso. \n\n3. **Modificaci\u00f3n de T\u00edtulos**: Se propone a\u00f1adir la preposici\u00f3n \"para\" en los t\u00edtulos de las monograf\u00edas de inyecciones reconstituidas para facilitar su identificaci\u00f3n.\n\n4. **Ejemplos de Revisiones**: Se presentan ejemplos de monograf\u00edas que han sido revisadas y c\u00f3mo se han modificado sus t\u00edtulos, as\u00ed como la recomendaci\u00f3n de revisar otras monograf\u00edas publicadas.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: *WHO - Technical Report Series 961*\n- **Consultas**: Consulta de mayo de 2010\n- **Formulaciones**: \n  - Capreomycin\n  - Artesunate\n  - Amikacin\n  - Kanamycin\n  - Amfotericina B\n  - Ampicilina s\u00f3dica\n  - Benzilpenicilina pot\u00e1sica\n  - Cloxacilina s\u00f3dica\n  - Pentamidina isetionato\n  - Prednisolona s\u00f3dica succinato\n  - Benzilpenicilina proca\u00edna\n  - Estreptomicina sulfato\n\n### Conclusi\u00f3n\n\nEl documento enfatiza la importancia de una nomenclatura clara y estandarizada en la farmacolog\u00eda para asegurar la correcta identificaci\u00f3n y uso de las formulaciones inyectables, especialmente aquellas que requieren reconstituci\u00f3n.", "excerpt_keywords": "Keywords: oral suspensions, amoxicillin, reconstitution, monographs, quality standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a7c171f4-c774-4d8f-a95e-31ade53f23bd", "node_type": "4", "metadata": {"page_label": "39", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "As regards oral suspensions or solutions reconstituted from powders it was recommended to consider the final preparation throughout the monograph. This approach was reflected in the text for amoxicillin oral suspension presented for discussion and adopted at the present meeting, when considering the aspects of the monograph, as described hereafter.\n\nBased on the above, the Expert Committee adopted the following new policy for such monographs.\n\n**Title of the monograph.** Title and requirements of the monograph would correspond to the final preparation rather than the powder.\n\n**Definition.** Any distinction, as to whether the oral suspension or solution needed to be reconstituted or was directly manufactured as a liquid, would be mentioned under Definition. Any necessary indication on the reconstitution of the final preparation would be given in this section as well.\n\n**Reference to general monographs.** Compliance of the final product with the general monograph for \u201cLiquid preparations for oral use\u201d and that of the powder with the section of the monograph entitled \u201cPowders for oral solutions, oral suspensions and oral drops\u201d would be maintained, as it is currently mentioned in published monographs on powders for oral use.\n\n**Manufacture.** When specific requirements referring to the powder needed to be included in the monograph, they would be mentioned by means of a statement or a test with or without specific limits, under this section (e.g. Test for water content).\n\nIt was also recognized that the quality of the reconstituted product during the in-use period as stated on the label should be considered. It was, therefore, proposed to cover this aspect by introducing, under the Manufacture section, a requirement with a minimum limit to be met at the end of the defined in-use period for content, with a statement as follows:\n\n\u201cThe product is formulated in such a way that when the suspension is constituted following manufacturer\u2019s instructions, stored at the temperature for the in-use period stated on the label and assayed using the method described below under Assay, it contains not less than 80.0% of the amount of amoxicillin (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S) stated on the label.\u201d\n\n**Tests.** Amounts to be taken for testing would be expressed in terms of quantities of the reconstituted solution or suspension and not the powder.\n\nFor example, \u201cdilute an accurately weighed *quantity of the oral suspension containing the equivalent of 60 mg of amoxicillin*.\u201d\n\nThe published monographs on oral powders should be revised in accordance with this new policy. It was recommended to follow the same approach as above for the future revisions of monographs for powders for injections.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "379d8e8f227843685971c9f7eeacc8be0fe224da06966b5ebb2bd945287e95f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "As regards oral suspensions or solutions reconstituted from powders it was recommended to consider the final preparation throughout the monograph. This approach was reflected in the text for amoxicillin oral suspension presented for discussion and adopted at the present meeting, when considering the aspects of the monograph, as described hereafter.\n\nBased on the above, the Expert Committee adopted the following new policy for such monographs.\n\n**Title of the monograph.** Title and requirements of the monograph would correspond to the final preparation rather than the powder.\n\n**Definition.** Any distinction, as to whether the oral suspension or solution needed to be reconstituted or was directly manufactured as a liquid, would be mentioned under Definition. Any necessary indication on the reconstitution of the final preparation would be given in this section as well.\n\n**Reference to general monographs.** Compliance of the final product with the general monograph for \u201cLiquid preparations for oral use\u201d and that of the powder with the section of the monograph entitled \u201cPowders for oral solutions, oral suspensions and oral drops\u201d would be maintained, as it is currently mentioned in published monographs on powders for oral use.\n\n**Manufacture.** When specific requirements referring to the powder needed to be included in the monograph, they would be mentioned by means of a statement or a test with or without specific limits, under this section (e.g. Test for water content).\n\nIt was also recognized that the quality of the reconstituted product during the in-use period as stated on the label should be considered. It was, therefore, proposed to cover this aspect by introducing, under the Manufacture section, a requirement with a minimum limit to be met at the end of the defined in-use period for content, with a statement as follows:\n\n\u201cThe product is formulated in such a way that when the suspension is constituted following manufacturer\u2019s instructions, stored at the temperature for the in-use period stated on the label and assayed using the method described below under Assay, it contains not less than 80.0% of the amount of amoxicillin (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S) stated on the label.\u201d\n\n**Tests.** Amounts to be taken for testing would be expressed in terms of quantities of the reconstituted solution or suspension and not the powder.\n\nFor example, \u201cdilute an accurately weighed *quantity of the oral suspension containing the equivalent of 60 mg of amoxicillin*.\u201d\n\nThe published monographs on oral powders should be revised in accordance with this new policy. It was recommended to follow the same approach as above for the future revisions of monographs for powders for injections.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2698, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "70301980-32b3-4bb6-99e5-59fd0e688887": {"__data__": {"id_": "70301980-32b3-4bb6-99e5-59fd0e688887", "embedding": null, "metadata": {"page_label": "40", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 5.1 Update on transfer of International Chemical Reference Substances\n\nIn April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe took over the responsibility for the establishment, preparation, storage and distribution of WHO International Chemical Reference Standards (ICRS) from Apoteket AB, the previous WHO Collaborating Centre for Chemical Reference Substances. Reference material that was held and distributed by Apoteket AB will from now on be distributed by EDQM.\n\nStart-up meetings were held in June and September 2010 in Strasbourg, France. Essential agreements were made as follows:\n\n1. For the analytical characterization of the reference substances, EDQM will follow the general *WHO Guidelines for the establishment, maintenance and distribution of chemical reference substances*, last revised and adopted during the 41st meeting of the Expert Committee on Specifications for Pharmaceutical Preparations.\n2. In the first campaign EDQM will establish as a priority the following 10 ICRS (Table 1).\n\n**Table 1**  \nPriority International Chemical Reference Substances for establishment by EDQM\n\n| No. | Substance |\n| - | - |\n| 1 | artemisinin |\n| 2 | lumefantrine for system suitability |\n| 3 | artenimol |\n| 4 | artesunate |\n| 5 | artemether |\n| 6 | efavirenz impurity B |\n| 7 | lopinavir |\n| 8 | emtricitabine |\n| 9 | tenofovir disoproxil fumarate |\n| 10 | alpha-artemether |\n\n\nThe Expert Committee members expressed their appreciation for these new developments in light of the technical expertise and experience of EDQM in establishing primary reference standards. This new collaboration was considered to enhance the availability of ICRS and thus foster the use of...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en la transferencia de la responsabilidad de los Est\u00e1ndares Internacionales de Referencia Qu\u00edmica (ICRS) de la Organizaci\u00f3n Mundial de la Salud (OMS) al Directorado Europeo para la Calidad de los Medicamentos y la Atenci\u00f3n Sanitaria (EDQM) en 2010. Se menciona que EDQM asumi\u00f3 esta responsabilidad de Apoteket AB y que se llevaron a cabo reuniones para establecer acuerdos sobre la caracterizaci\u00f3n anal\u00edtica de las sustancias de referencia. Se presenta una lista de diez sustancias qu\u00edmicas prioritarias que EDQM se comprometi\u00f3 a establecer en su primera campa\u00f1a.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que EDQM seguir\u00e1 para la caracterizaci\u00f3n anal\u00edtica de los ICRS?**\n   - EDQM seguir\u00e1 las *Directrices de la OMS para el establecimiento, mantenimiento y distribuci\u00f3n de sustancias de referencia qu\u00edmica*, que fueron revisadas y adoptadas en la 41\u00aa reuni\u00f3n del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **\u00bfQu\u00e9 importancia tiene la colaboraci\u00f3n entre la OMS y el EDQM en el contexto de los ICRS?**\n   - La colaboraci\u00f3n se considera importante porque se espera que mejore la disponibilidad de los ICRS, lo que a su vez fomentar\u00e1 su uso en la industria farmac\u00e9utica y en la investigaci\u00f3n.\n\n3. **\u00bfCu\u00e1les son las diez sustancias qu\u00edmicas que EDQM ha priorizado para su establecimiento como ICRS?**\n   - Las diez sustancias prioritarias son: artemisinin, lumefantrine para la idoneidad del sistema, artenimol, artesunate, artemether, impureza B de efavirenz, lopinavir, emtricitabina, tenofovir disoproxil fumarato y alpha-artemether.", "prev_section_summary": "### Temas Clave:\n1. **Nueva Pol\u00edtica para Monograf\u00edas**: Se adopta una nueva pol\u00edtica para las monograf\u00edas de suspensiones orales o soluciones reconstituidas a partir de polvos, enfoc\u00e1ndose en la preparaci\u00f3n final en lugar del polvo.\n   \n2. **T\u00edtulo y Definici\u00f3n**: El t\u00edtulo y los requisitos de la monograf\u00eda deben corresponder a la preparaci\u00f3n final. Se definen claramente las distinciones entre suspensiones reconstituidas y soluciones fabricadas directamente.\n\n3. **Cumplimiento de Monograf\u00edas Generales**: Se mantiene la conformidad del producto final con las monograf\u00edas generales para \"Preparaciones l\u00edquidas para uso oral\" y con la secci\u00f3n correspondiente a \"Polvos para soluciones orales, suspensiones orales y gotas orales\".\n\n4. **Requisitos de Fabricaci\u00f3n**: Se introducen requisitos espec\u00edficos para asegurar la calidad del producto reconstituido, incluyendo un l\u00edmite m\u00ednimo de contenido de amoxicilina.\n\n5. **Pruebas**: Las cantidades para las pruebas deben expresarse en t\u00e9rminos de la soluci\u00f3n o suspensi\u00f3n reconstituida, no del polvo.\n\n6. **Revisi\u00f3n de Monograf\u00edas Publicadas**: Se recomienda revisar las monograf\u00edas publicadas sobre polvos orales y seguir el mismo enfoque para futuras revisiones de monograf\u00edas de polvos para inyecciones.\n\n### Entidades:\n- **Comit\u00e9 de Expertos de la OMS**: Organismo que adopta la nueva pol\u00edtica.\n- **Amoxicilina (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S)**: Compuesto cuya cantidad debe ser verificada en el producto reconstituido.\n- **Monograf\u00edas**: Documentos que establecen los requisitos y est\u00e1ndares para las preparaciones farmac\u00e9uticas.\n- **Preparaciones l\u00edquidas para uso oral**: Categor\u00eda general bajo la cual se clasifica el producto final.\n- **Polvos para soluciones orales, suspensiones orales y gotas orales**: Secci\u00f3n de la monograf\u00eda que se relaciona con los polvos utilizados para la reconstituci\u00f3n.\n\n### Resumen:\nEl documento establece una nueva pol\u00edtica para las monograf\u00edas de suspensiones orales y soluciones reconstituidas, enfatizando que los t\u00edtulos y requisitos deben referirse a la preparaci\u00f3n final. Se definen claramente las distinciones entre diferentes tipos de preparaciones, se mantienen los est\u00e1ndares de calidad y se introducen requisitos espec\u00edficos para asegurar que el producto reconstituido contenga al menos el 80% de amoxicilina al final del per\u00edodo de uso. Adem\u00e1s, se recomienda revisar las monograf\u00edas existentes para alinearlas con esta nueva pol\u00edtica.", "excerpt_keywords": "Keywords: International Chemical Reference Substances, EDQM, WHO Guidelines, pharmaceutical standards, reference materials"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1ea1f372-1c23-4a48-8f69-f34b0e1ea580", "node_type": "4", "metadata": {"page_label": "40", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 5.1 Update on transfer of International Chemical Reference Substances\n\nIn April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe took over the responsibility for the establishment, preparation, storage and distribution of WHO International Chemical Reference Standards (ICRS) from Apoteket AB, the previous WHO Collaborating Centre for Chemical Reference Substances. Reference material that was held and distributed by Apoteket AB will from now on be distributed by EDQM.\n\nStart-up meetings were held in June and September 2010 in Strasbourg, France. Essential agreements were made as follows:\n\n1. For the analytical characterization of the reference substances, EDQM will follow the general *WHO Guidelines for the establishment, maintenance and distribution of chemical reference substances*, last revised and adopted during the 41st meeting of the Expert Committee on Specifications for Pharmaceutical Preparations.\n2. In the first campaign EDQM will establish as a priority the following 10 ICRS (Table 1).\n\n**Table 1**  \nPriority International Chemical Reference Substances for establishment by EDQM\n\n| No. | Substance |\n| - | - |\n| 1 | artemisinin |\n| 2 | lumefantrine for system suitability |\n| 3 | artenimol |\n| 4 | artesunate |\n| 5 | artemether |\n| 6 | efavirenz impurity B |\n| 7 | lopinavir |\n| 8 | emtricitabine |\n| 9 | tenofovir disoproxil fumarate |\n| 10 | alpha-artemether |\n\n\nThe Expert Committee members expressed their appreciation for these new developments in light of the technical expertise and experience of EDQM in establishing primary reference standards. This new collaboration was considered to enhance the availability of ICRS and thus foster the use of...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "76257e26500fd450629d64c54b032d723cdbbebb43decd2cfa9985cb1f53125f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 5.1 Update on transfer of International Chemical Reference Substances\n\nIn April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe took over the responsibility for the establishment, preparation, storage and distribution of WHO International Chemical Reference Standards (ICRS) from Apoteket AB, the previous WHO Collaborating Centre for Chemical Reference Substances. Reference material that was held and distributed by Apoteket AB will from now on be distributed by EDQM.\n\nStart-up meetings were held in June and September 2010 in Strasbourg, France. Essential agreements were made as follows:\n\n1. For the analytical characterization of the reference substances, EDQM will follow the general *WHO Guidelines for the establishment, maintenance and distribution of chemical reference substances*, last revised and adopted during the 41st meeting of the Expert Committee on Specifications for Pharmaceutical Preparations.\n2. In the first campaign EDQM will establish as a priority the following 10 ICRS (Table 1).\n\n**Table 1**  \nPriority International Chemical Reference Substances for establishment by EDQM\n\n| No. | Substance |\n| - | - |\n| 1 | artemisinin |\n| 2 | lumefantrine for system suitability |\n| 3 | artenimol |\n| 4 | artesunate |\n| 5 | artemether |\n| 6 | efavirenz impurity B |\n| 7 | lopinavir |\n| 8 | emtricitabine |\n| 9 | tenofovir disoproxil fumarate |\n| 10 | alpha-artemether |\n\n\nThe Expert Committee members expressed their appreciation for these new developments in light of the technical expertise and experience of EDQM in establishing primary reference standards. This new collaboration was considered to enhance the availability of ICRS and thus foster the use of...", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1890, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2c61ee16-b87c-48e6-9186-51b71cec377e": {"__data__": {"id_": "2c61ee16-b87c-48e6-9186-51b71cec377e", "embedding": null, "metadata": {"page_label": "41", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The International Pharmacopoeia as a reference for specifications and analytical methods for medicines of major public health impact.\n\nThe Expert Committee took note of the report and endorsed the agreements made.\n\n### 5.2 Proposal for an accelerated release of International Chemical References Standards\n\nICRS were in the past first provisionally adopted by the Expert Panel and then finally adopted by the Expert Committee during its annual meeting. The following process was followed:\n\n> \"Newly established International Chemical Reference Substances, proposed by the WHO Collaborating Centre for Chemical Reference Substances on the basis of adequate testing and characterization, are included in the Centre's annual report. The report is circulated, inter alia, to members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, who are requested to consider the proposals carefully together with the attached analytical documentation, and to notify the Centre of any reservations or adverse comment within three months of the date of mailing. In these cases the Centre will proceed with any consultations or additional analyses necessary for the validation.\n>\n> If no adverse comments are received within the three-month period, the proposed new International Chemical Reference Substance may be considered provisionally adopted. It will be considered for final adoption during the subsequent meeting of the Expert Committee.\"[^11]\n\nEDQM will issue an individual analytical report after the establishment of a new reference substance, after the analysis of candidate material for stock replenishment and after monitoring the stability of material in stock.\n\nThe Secretariat made the proposal that these analytical case-reports be reviewed a priori by the Secretariat with assistance from the collaborating laboratory. If the testing is performed according to the above-mentioned adopted guidelines and if the candidate material is considered to be suitable to serve as a reference material the ICRS will be released provisionally. The Secretariat will contact the collaborating laboratory for assistance in the case that the analytical testing reveals information that requires further consideration. The distribution of the ICRS could start after the provisional release.\n\n[^11]: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790, p. 15).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en el proceso de adopci\u00f3n de Sustancias de Referencia Qu\u00edmica Internacional (ICRS) por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se describe c\u00f3mo estas sustancias son propuestas, revisadas y adoptadas provisionalmente antes de su adopci\u00f3n final. El proceso incluye la evaluaci\u00f3n de informes anal\u00edticos y la consideraci\u00f3n de comentarios de expertos. Adem\u00e1s, se menciona la colaboraci\u00f3n con laboratorios para asegurar que las pruebas se realicen de acuerdo con las pautas establecidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el proceso que sigue una Sustancia de Referencia Qu\u00edmica Internacional (ICRS) desde su propuesta hasta su adopci\u00f3n provisional?**\n   - El proceso incluye la propuesta por el Centro de Referencia Qu\u00edmica de la OMS, la circulaci\u00f3n del informe a los miembros del Panel Asesor, la consideraci\u00f3n de comentarios durante un per\u00edodo de tres meses, y la adopci\u00f3n provisional si no se reciben objeciones.\n\n2. **\u00bfQu\u00e9 papel juega el EDQM en la creaci\u00f3n de nuevas Sustancias de Referencia Qu\u00edmica Internacional (ICRS)?**\n   - El EDQM emite un informe anal\u00edtico individual despu\u00e9s de establecer una nueva sustancia de referencia, analizando el material candidato y monitoreando la estabilidad del material en stock.\n\n3. **\u00bfQu\u00e9 sucede si se reciben comentarios adversos sobre una propuesta de ICRS durante el per\u00edodo de revisi\u00f3n de tres meses?**\n   - Si se reciben comentarios adversos, el Centro proceder\u00e1 con consultas o an\u00e1lisis adicionales necesarios para la validaci\u00f3n de la sustancia propuesta antes de su adopci\u00f3n provisional.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Transferencia de Responsabilidad**: En abril de 2010, el Directorado Europeo para la Calidad de los Medicamentos y la Atenci\u00f3n Sanitaria (EDQM) asumi\u00f3 la responsabilidad de los Est\u00e1ndares Internacionales de Referencia Qu\u00edmica (ICRS) de la OMS, anteriormente gestionados por Apoteket AB.\n\n2. **Reuniones de Inicio**: Se llevaron a cabo reuniones en junio y septiembre de 2010 en Estrasburgo, Francia, donde se establecieron acuerdos esenciales sobre la caracterizaci\u00f3n anal\u00edtica de las sustancias de referencia.\n\n3. **Directrices de la OMS**: EDQM seguir\u00e1 las *Directrices de la OMS para el establecimiento, mantenimiento y distribuci\u00f3n de sustancias de referencia qu\u00edmica*, revisadas en la 41\u00aa reuni\u00f3n del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n4. **Sustancias Qu\u00edmicas Prioritarias**: EDQM se comprometi\u00f3 a establecer diez ICRS prioritarios en su primera campa\u00f1a, que son:\n   - Artemisinin\n   - Lumefantrine para la idoneidad del sistema\n   - Artenimol\n   - Artesunate\n   - Artemether\n   - Impureza B de efavirenz\n   - Lopinavir\n   - Emtricitabina\n   - Tenofovir disoproxil fumarato\n   - Alpha-artemether\n\n5. **Colaboraci\u00f3n OMS-EDQM**: La colaboraci\u00f3n entre la OMS y el EDQM se considera crucial para mejorar la disponibilidad de los ICRS, lo que fomentar\u00e1 su uso en la industria farmac\u00e9utica y en la investigaci\u00f3n. \n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Directorate for the Quality of Medicines & HealthCare (EDQM)**\n- **Apoteket AB**\n- **Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas**", "excerpt_keywords": "Keywords: International Chemical Reference Standards, WHO, pharmacopoeia, analytical methods, public health"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3521c9d5-63ab-4889-9c96-72cbcd59bb52", "node_type": "4", "metadata": {"page_label": "41", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The International Pharmacopoeia as a reference for specifications and analytical methods for medicines of major public health impact.\n\nThe Expert Committee took note of the report and endorsed the agreements made.\n\n### 5.2 Proposal for an accelerated release of International Chemical References Standards\n\nICRS were in the past first provisionally adopted by the Expert Panel and then finally adopted by the Expert Committee during its annual meeting. The following process was followed:\n\n> \"Newly established International Chemical Reference Substances, proposed by the WHO Collaborating Centre for Chemical Reference Substances on the basis of adequate testing and characterization, are included in the Centre's annual report. The report is circulated, inter alia, to members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, who are requested to consider the proposals carefully together with the attached analytical documentation, and to notify the Centre of any reservations or adverse comment within three months of the date of mailing. In these cases the Centre will proceed with any consultations or additional analyses necessary for the validation.\n>\n> If no adverse comments are received within the three-month period, the proposed new International Chemical Reference Substance may be considered provisionally adopted. It will be considered for final adoption during the subsequent meeting of the Expert Committee.\"[^11]\n\nEDQM will issue an individual analytical report after the establishment of a new reference substance, after the analysis of candidate material for stock replenishment and after monitoring the stability of material in stock.\n\nThe Secretariat made the proposal that these analytical case-reports be reviewed a priori by the Secretariat with assistance from the collaborating laboratory. If the testing is performed according to the above-mentioned adopted guidelines and if the candidate material is considered to be suitable to serve as a reference material the ICRS will be released provisionally. The Secretariat will contact the collaborating laboratory for assistance in the case that the analytical testing reveals information that requires further consideration. The distribution of the ICRS could start after the provisional release.\n\n[^11]: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790, p. 15).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c1d8338640b4d59d94b5df5209a49b13a10ea7798421ecafe6a56e469eaf8be9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The International Pharmacopoeia as a reference for specifications and analytical methods for medicines of major public health impact.\n\nThe Expert Committee took note of the report and endorsed the agreements made.\n\n### 5.2 Proposal for an accelerated release of International Chemical References Standards\n\nICRS were in the past first provisionally adopted by the Expert Panel and then finally adopted by the Expert Committee during its annual meeting. The following process was followed:\n\n> \"Newly established International Chemical Reference Substances, proposed by the WHO Collaborating Centre for Chemical Reference Substances on the basis of adequate testing and characterization, are included in the Centre's annual report. The report is circulated, inter alia, to members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, who are requested to consider the proposals carefully together with the attached analytical documentation, and to notify the Centre of any reservations or adverse comment within three months of the date of mailing. In these cases the Centre will proceed with any consultations or additional analyses necessary for the validation.\n>\n> If no adverse comments are received within the three-month period, the proposed new International Chemical Reference Substance may be considered provisionally adopted. It will be considered for final adoption during the subsequent meeting of the Expert Committee.\"[^11]\n\nEDQM will issue an individual analytical report after the establishment of a new reference substance, after the analysis of candidate material for stock replenishment and after monitoring the stability of material in stock.\n\nThe Secretariat made the proposal that these analytical case-reports be reviewed a priori by the Secretariat with assistance from the collaborating laboratory. If the testing is performed according to the above-mentioned adopted guidelines and if the candidate material is considered to be suitable to serve as a reference material the ICRS will be released provisionally. The Secretariat will contact the collaborating laboratory for assistance in the case that the analytical testing reveals information that requires further consideration. The distribution of the ICRS could start after the provisional release.\n\n[^11]: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790, p. 15).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2512, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "29d1fae7-8d93-437f-b8d1-b9acb29548eb": {"__data__": {"id_": "29d1fae7-8d93-437f-b8d1-b9acb29548eb", "embedding": null, "metadata": {"page_label": "42", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The analytical case-reports, together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS, are then distributed first to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for comment, then again to the Expert Panel for adoption. The analytical case-reports are appended to the annual report as annexes.\n\nThe proposed simplification of the process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.\n\nSupport for the accelerated release procedure to speed up the availability of ICRS was given by the Committee.\n\nThe Expert Committee members approved this new procedure (Annex 1).\n\n### 5.3 Proposed first International Standard for biosynthetic human insulin\n\nIn a joint session with the Expert Committee on Biological Standardization, the Committee discussed an initiative to evaluate a candidate International Standard for Human Recombinant Insulin.\n\nThe WHO Expert Committee on Biological Standardization establishes International Biological Reference preparations of complex composition that require the use of biological or immunological assays for appropriate characterization.\n\nReference standards (ICRS) for physicochemical assays are described in the *International Pharmacopoeia*. These are endorsed by the Expert Committee on Specifications for Pharmaceutical Preparations.\n\nThe Expert Committee on Biological Standardization agreed with a proposal to develop a reference preparation so that it continues to be possible to define the IU and also to investigate potential use of the reference preparations in the diagnostic area. The Expert Committee on Specifications for Pharmaceutical Preparations noted that diagnostics was outside its mandate. Both Expert Committees considered that further work was needed to make a decision on whether the proposed reference material would be of potential use in the therapeutic area. Both Committees requested WHO to publish a statement on the conversion factor between activity and mass units.\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations recommended developing International Chemical Reference Standards on Insulin to be used as primary standards in physical and physicochemical assays.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Establecimiento de ICRS**: El proceso de establecimiento de Sustancias de Referencia Internacionales (ICRS) se ha simplificado para permitir una respuesta m\u00e1s r\u00e1pida de la OMS a la demanda urgente de estas sustancias. Los informes anal\u00edticos y el informe anual consolidado del EDQM se distribuyen a los paneles de expertos para su revisi\u00f3n y adopci\u00f3n.\n\n2. **Propuesta de Est\u00e1ndar Internacional para Insulina**: Se discuti\u00f3 la evaluaci\u00f3n de un candidato para un Est\u00e1ndar Internacional de Insulina Recombinante Humana en una sesi\u00f3n conjunta con el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica. Se acord\u00f3 desarrollar preparaciones de referencia para definir unidades internacionales (IU) y explorar su uso potencial en el \u00e1rea diagn\u00f3stica.\n\n3. **Recomendaciones de los Comit\u00e9s de Expertos**: Los Comit\u00e9s de Expertos recomendaron el desarrollo de Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina, que se utilizar\u00e1n como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito de simplificar el proceso de establecimiento de ICRS seg\u00fan el contexto?**\n   - La simplificaci\u00f3n del proceso tiene como objetivo acelerar el establecimiento de nuevas sustancias de referencia y permitir que la OMS responda m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS.\n\n2. **\u00bfQu\u00e9 se acord\u00f3 en la sesi\u00f3n conjunta sobre el Est\u00e1ndar Internacional de Insulina Recombinante Humana?**\n   - Se acord\u00f3 desarrollar una preparaci\u00f3n de referencia para seguir definiendo la unidad internacional (IU) y explorar su posible uso en el \u00e1rea diagn\u00f3stica, aunque se reconoci\u00f3 que el diagn\u00f3stico est\u00e1 fuera del mandato del Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n3. **\u00bfQu\u00e9 recomendaci\u00f3n se hizo respecto a los Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina?**\n   - Se recomend\u00f3 desarrollar Est\u00e1ndares de Referencia Qu\u00edmica Internacionales sobre insulina para ser utilizados como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Sustancias de Referencia Qu\u00edmica Internacional (ICRS):** \n   - Proceso de adopci\u00f3n que incluye propuestas, revisi\u00f3n y adopci\u00f3n provisional por parte de la OMS.\n   - Importancia de la evaluaci\u00f3n de informes anal\u00edticos y la consideraci\u00f3n de comentarios de expertos.\n\n2. **Proceso de Adopci\u00f3n:**\n   - Propuestas realizadas por el Centro de Referencia Qu\u00edmica de la OMS.\n   - Circulaci\u00f3n de informes a miembros del Panel Asesor de la OMS.\n   - Per\u00edodo de revisi\u00f3n de tres meses para recibir comentarios adversos.\n   - Adopci\u00f3n provisional si no hay objeciones, seguida de una consideraci\u00f3n final en la reuni\u00f3n anual del Comit\u00e9 de Expertos.\n\n3. **Rol del EDQM:**\n   - Emisi\u00f3n de informes anal\u00edticos individuales tras el establecimiento de nuevas sustancias de referencia.\n   - An\u00e1lisis de material candidato y monitoreo de la estabilidad del material en stock.\n\n4. **Revisi\u00f3n de Informes Anal\u00edticos:**\n   - Propuesta de revisi\u00f3n a priori de informes anal\u00edticos por parte de la Secretar\u00eda con ayuda de laboratorios colaboradores.\n   - Provisionalidad en la liberaci\u00f3n de ICRS basada en pruebas adecuadas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la propuesta y adopci\u00f3n de ICRS.\n- **Centro de Referencia Qu\u00edmica de la OMS:** Proponente de nuevas sustancias de referencia.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas:** Receptor de informes para revisi\u00f3n.\n- **EDQM (European Directorate for the Quality of Medicines):** Encargado de emitir informes anal\u00edticos y monitorear la estabilidad de las sustancias de referencia.\n\nEste resumen destaca los procesos y entidades involucradas en la adopci\u00f3n de ICRS, as\u00ed como la importancia de la colaboraci\u00f3n y la revisi\u00f3n anal\u00edtica en el contexto de la salud p\u00fablica.", "excerpt_keywords": "Keywords: ICRS, WHO, International Standard, Insulin, Reference Standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d6deb826-0abe-4faf-bc01-dc256f059da7", "node_type": "4", "metadata": {"page_label": "42", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The analytical case-reports, together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS, are then distributed first to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for comment, then again to the Expert Panel for adoption. The analytical case-reports are appended to the annual report as annexes.\n\nThe proposed simplification of the process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.\n\nSupport for the accelerated release procedure to speed up the availability of ICRS was given by the Committee.\n\nThe Expert Committee members approved this new procedure (Annex 1).\n\n### 5.3 Proposed first International Standard for biosynthetic human insulin\n\nIn a joint session with the Expert Committee on Biological Standardization, the Committee discussed an initiative to evaluate a candidate International Standard for Human Recombinant Insulin.\n\nThe WHO Expert Committee on Biological Standardization establishes International Biological Reference preparations of complex composition that require the use of biological or immunological assays for appropriate characterization.\n\nReference standards (ICRS) for physicochemical assays are described in the *International Pharmacopoeia*. These are endorsed by the Expert Committee on Specifications for Pharmaceutical Preparations.\n\nThe Expert Committee on Biological Standardization agreed with a proposal to develop a reference preparation so that it continues to be possible to define the IU and also to investigate potential use of the reference preparations in the diagnostic area. The Expert Committee on Specifications for Pharmaceutical Preparations noted that diagnostics was outside its mandate. Both Expert Committees considered that further work was needed to make a decision on whether the proposed reference material would be of potential use in the therapeutic area. Both Committees requested WHO to publish a statement on the conversion factor between activity and mass units.\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations recommended developing International Chemical Reference Standards on Insulin to be used as primary standards in physical and physicochemical assays.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "370b0ea828243b5a876c9e170f2856fb4397cfd16686e9589c7e1d25629a7f07", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The analytical case-reports, together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS, are then distributed first to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for comment, then again to the Expert Panel for adoption. The analytical case-reports are appended to the annual report as annexes.\n\nThe proposed simplification of the process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.\n\nSupport for the accelerated release procedure to speed up the availability of ICRS was given by the Committee.\n\nThe Expert Committee members approved this new procedure (Annex 1).\n\n### 5.3 Proposed first International Standard for biosynthetic human insulin\n\nIn a joint session with the Expert Committee on Biological Standardization, the Committee discussed an initiative to evaluate a candidate International Standard for Human Recombinant Insulin.\n\nThe WHO Expert Committee on Biological Standardization establishes International Biological Reference preparations of complex composition that require the use of biological or immunological assays for appropriate characterization.\n\nReference standards (ICRS) for physicochemical assays are described in the *International Pharmacopoeia*. These are endorsed by the Expert Committee on Specifications for Pharmaceutical Preparations.\n\nThe Expert Committee on Biological Standardization agreed with a proposal to develop a reference preparation so that it continues to be possible to define the IU and also to investigate potential use of the reference preparations in the diagnostic area. The Expert Committee on Specifications for Pharmaceutical Preparations noted that diagnostics was outside its mandate. Both Expert Committees considered that further work was needed to make a decision on whether the proposed reference material would be of potential use in the therapeutic area. Both Committees requested WHO to publish a statement on the conversion factor between activity and mass units.\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations recommended developing International Chemical Reference Standards on Insulin to be used as primary standards in physical and physicochemical assays.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2490, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "df576e40-de5a-455a-97b7-1315332744a9": {"__data__": {"id_": "df576e40-de5a-455a-97b7-1315332744a9", "embedding": null, "metadata": {"page_label": "43", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control \u2014 National Laboratories\n\n## 6.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aims to give each participating laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system should reinforce mutual confidence within the network.\n\nCurrently, WHO has been able to maintain this service and provides samples and testing protocols for Phase 5 of the EQAAS programme. Some 60 quality control laboratories from all six WHO regions have been invited to participate in this Scheme.\n\n### Phase 5 \u2014 Procedure 1: Assay by Water-Free Titration\n\nParticipants were requested to determine the content of metronidazole in a common sample according to a method described in the monograph on metronidazole published in the fourth edition of *The International Pharmacopoeia*. Fifty-two participants submitted their results.\n\nTwelve laboratories (23% of the participants) reported results that were either questionable or unsatisfactory. These laboratories were invited to share their investigations with WHO into the cause of the failure and their corrective and preventive actions. The laboratories concerned were informed by the Secretariat about the main approaches to dealing with questionable or unsatisfactory results.\n\n### Phase 5 \u2014 Procedure 2: Semi-Microdetermination of Water by Karl-Fischer\n\nThe study is currently taking place. The Committee was informed about the time lines.\n\n### Overview of Planned Proficiency Tests in Phase 5\n\nThe planned proficiency tests were presented to the Committee and are listed in Table 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en el Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS) de la OMS, que permite a los laboratorios participantes medir su rendimiento mediante pruebas de muestras ciegas. Se menciona que actualmente hay 60 laboratorios de control de calidad de las seis regiones de la OMS participando en la Fase 5 del programa. Se describen dos procedimientos espec\u00edficos: el primero, relacionado con la determinaci\u00f3n del contenido de metronidazol, donde el 23% de los laboratorios reportaron resultados cuestionables o insatisfactorios; y el segundo, que se centra en la determinaci\u00f3n de agua mediante el m\u00e9todo de Karl-Fischer, que est\u00e1 en curso. Tambi\u00e9n se menciona que se presentaron pruebas de competencia planificadas para la Fase 5.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 porcentaje de laboratorios participantes en la Fase 5 del EQAAS reportaron resultados cuestionables o insatisfactorios en el an\u00e1lisis de metronidazol?**\n   - Respuesta: El 23% de los laboratorios participantes reportaron resultados cuestionables o insatisfactorios.\n\n2. **\u00bfQu\u00e9 acciones se les solicit\u00f3 a los laboratorios que reportaron resultados insatisfactorios en la Fase 5, Procedimiento 1?**\n   - Respuesta: Se les invit\u00f3 a compartir sus investigaciones sobre la causa del fallo y las acciones correctivas y preventivas que implementaron.\n\n3. **\u00bfCu\u00e1l es el objetivo principal del Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS) seg\u00fan el texto?**\n   - Respuesta: El objetivo principal es permitir que cada laboratorio participante mida su rendimiento a trav\u00e9s de un sistema confidencial de pruebas de muestras ciegas y determine su capacidad para realizar un procedimiento anal\u00edtico espec\u00edfico dentro de una red de laboratorios de control gubernamental, reforzando as\u00ed la confianza mutua en la red.", "prev_section_summary": "### Temas Clave:\n\n1. **Establecimiento de ICRS**:\n   - Se ha simplificado el proceso para la creaci\u00f3n de Sustancias de Referencia Internacionales (ICRS) con el fin de responder m\u00e1s r\u00e1pidamente a la demanda urgente de estas sustancias.\n   - Los informes anal\u00edticos y el informe anual del EDQM se distribuyen a los paneles de expertos para su revisi\u00f3n y adopci\u00f3n.\n\n2. **Propuesta de Est\u00e1ndar Internacional para Insulina Recombinante Humana**:\n   - Se discuti\u00f3 la evaluaci\u00f3n de un candidato para un Est\u00e1ndar Internacional de Insulina Recombinante Humana en una sesi\u00f3n conjunta con el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica.\n   - Se acord\u00f3 desarrollar preparaciones de referencia para definir unidades internacionales (IU) y explorar su uso en el \u00e1rea diagn\u00f3stica.\n\n3. **Recomendaciones de los Comit\u00e9s de Expertos**:\n   - Se recomend\u00f3 el desarrollo de Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina, que se utilizar\u00e1n como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que supervisa el establecimiento de ICRS.\n- **EDQM (European Directorate for the Quality of Medicines & HealthCare)**: Entidad que elabora informes anuales sobre actividades relacionadas con ICRS.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que establece preparaciones de referencia biol\u00f3gica y discute est\u00e1ndares internacionales.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Panel que respalda los est\u00e1ndares de referencia para ensayos fisicoqu\u00edmicos.\n- **Insulina Recombinante Humana**: Sustancia objeto de evaluaci\u00f3n para establecer un est\u00e1ndar internacional. \n\nEste resumen destaca los aspectos fundamentales y las entidades involucradas en el proceso de establecimiento de ICRS y la propuesta de un est\u00e1ndar internacional para la insulina.", "excerpt_keywords": "Quality Assurance, EQAAS, Metronidazole, Proficiency Tests, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6aba167-edd1-4aeb-abca-e7bcb31731b9", "node_type": "4", "metadata": {"page_label": "43", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control \u2014 National Laboratories\n\n## 6.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aims to give each participating laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system should reinforce mutual confidence within the network.\n\nCurrently, WHO has been able to maintain this service and provides samples and testing protocols for Phase 5 of the EQAAS programme. Some 60 quality control laboratories from all six WHO regions have been invited to participate in this Scheme.\n\n### Phase 5 \u2014 Procedure 1: Assay by Water-Free Titration\n\nParticipants were requested to determine the content of metronidazole in a common sample according to a method described in the monograph on metronidazole published in the fourth edition of *The International Pharmacopoeia*. Fifty-two participants submitted their results.\n\nTwelve laboratories (23% of the participants) reported results that were either questionable or unsatisfactory. These laboratories were invited to share their investigations with WHO into the cause of the failure and their corrective and preventive actions. The laboratories concerned were informed by the Secretariat about the main approaches to dealing with questionable or unsatisfactory results.\n\n### Phase 5 \u2014 Procedure 2: Semi-Microdetermination of Water by Karl-Fischer\n\nThe study is currently taking place. The Committee was informed about the time lines.\n\n### Overview of Planned Proficiency Tests in Phase 5\n\nThe planned proficiency tests were presented to the Committee and are listed in Table 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dd371154e63398f2c7fa1a47c5bd8e6784b12416187b425c2d864ace802f5f9e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Control \u2014 National Laboratories\n\n## 6.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aims to give each participating laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system should reinforce mutual confidence within the network.\n\nCurrently, WHO has been able to maintain this service and provides samples and testing protocols for Phase 5 of the EQAAS programme. Some 60 quality control laboratories from all six WHO regions have been invited to participate in this Scheme.\n\n### Phase 5 \u2014 Procedure 1: Assay by Water-Free Titration\n\nParticipants were requested to determine the content of metronidazole in a common sample according to a method described in the monograph on metronidazole published in the fourth edition of *The International Pharmacopoeia*. Fifty-two participants submitted their results.\n\nTwelve laboratories (23% of the participants) reported results that were either questionable or unsatisfactory. These laboratories were invited to share their investigations with WHO into the cause of the failure and their corrective and preventive actions. The laboratories concerned were informed by the Secretariat about the main approaches to dealing with questionable or unsatisfactory results.\n\n### Phase 5 \u2014 Procedure 2: Semi-Microdetermination of Water by Karl-Fischer\n\nThe study is currently taking place. The Committee was informed about the time lines.\n\n### Overview of Planned Proficiency Tests in Phase 5\n\nThe planned proficiency tests were presented to the Committee and are listed in Table 2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1772, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b72473e7-dcf5-462c-93c6-1a0c8d6fae57": {"__data__": {"id_": "b72473e7-dcf5-462c-93c6-1a0c8d6fae57", "embedding": null, "metadata": {"page_label": "44", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Number | Test | Sample | Return of results by |\n| - | - | - | - |\n| 5.3 | Dissolution test | Artemether and lumefantrine tablets | 1 April 2011 |\n| 5.4 | Density and pH measurement | Abacavir oral solution | 15 September 2011 |\n| 5.5 | Assay by high-performance liquid chromatography | Amodiaquine and artesunate tablets | 15 March 2012 |\n| 5.6 | Dissolution test | Rifampicin capsules | 15 August 2012 |\n| 5.7 | Related substances by thin-layer chromatography | Artemether and lumefantrine oral suspension | 15 December 2012 |\n\n\nA discussion was held and questions were posed about the performance of laboratories and whether a change in personnel, e.g. laboratory staff, had an influence on performance. It was suggested that cross-checks be made to see whether in laboratories that had failures, these had been triggered by changes in personnel.\n\nThe Committee took note of the latest activities in this programme and fully supported the work carried out to assist quality control laboratories in their capacity-building efforts.\n\n### 6.2 WHO good practices for pharmaceutical microbiology laboratories\n\nFurther to the revision of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation with a specific text for pharmaceutical microbiology laboratories.\n\nA draft document was presented to the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its 44th meeting and circulated for comments in accordance with the usual procedure. A revised draft was discussed during the informal consultation on quality assurance systems, medicines and risk analysis in May 2010 and mailed out for comments. These responses were currently under evaluation.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evaluaci\u00f3n del rendimiento de laboratorios**: Se llev\u00f3 a cabo una discusi\u00f3n sobre el rendimiento de los laboratorios de control de calidad, centr\u00e1ndose en c\u00f3mo los cambios en el personal podr\u00edan afectar los resultados. Se sugiri\u00f3 realizar verificaciones cruzadas para identificar si las fallas en los laboratorios estaban relacionadas con cambios en el personal.\n\n2. **Revisi\u00f3n de buenas pr\u00e1cticas de microbiolog\u00eda farmac\u00e9utica**: Se present\u00f3 un borrador de directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica a la Comisi\u00f3n de Expertos de la OMS. Estas directrices se desarrollaron a partir de la revisi\u00f3n de las buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y est\u00e1n en proceso de evaluaci\u00f3n tras recibir comentarios de especialistas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas se realizaron en los laboratorios y cu\u00e1les fueron las fechas de retorno de resultados?**\n   - Las pruebas incluyeron un test de disoluci\u00f3n para tabletas de artemeter y lumefantrina, medici\u00f3n de densidad y pH para soluci\u00f3n oral de abacavir, y un ensayo por cromatograf\u00eda l\u00edquida de alta eficacia para tabletas de amodiaquina y artesunato, entre otros. Las fechas de retorno de resultados var\u00edan desde el 1 de abril de 2011 hasta el 15 de diciembre de 2012.\n\n2. **\u00bfQu\u00e9 acciones se sugirieron para abordar las fallas en el rendimiento de los laboratorios?**\n   - Se sugiri\u00f3 realizar verificaciones cruzadas para determinar si las fallas en los laboratorios estaban relacionadas con cambios en el personal, lo que podr\u00eda ayudar a identificar \u00e1reas de mejora en la gesti\u00f3n del personal y el rendimiento del laboratorio.\n\n3. **\u00bfCu\u00e1l es el estado actual de las directrices de buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica?**\n   - Las directrices fueron adoptadas, pero est\u00e1n sujetas a revisi\u00f3n por un grupo de especialistas seleccionados, quienes evaluar\u00e1n los comentarios recibidos. Actualmente, las respuestas a la consulta est\u00e1n en proceso de evaluaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS)**:\n   - Objetivo: Permitir a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas y evaluar su capacidad para realizar procedimientos anal\u00edticos espec\u00edficos.\n   - Importancia: Refuerza la confianza mutua dentro de la red de laboratorios de control gubernamental.\n\n2. **Participaci\u00f3n**:\n   - N\u00famero de laboratorios: 60 laboratorios de control de calidad de las seis regiones de la OMS est\u00e1n participando en la Fase 5 del programa.\n\n3. **Fase 5 \u2014 Procedimientos**:\n   - **Procedimiento 1: Determinaci\u00f3n de metronidazol**:\n     - M\u00e9todo: Titraci\u00f3n sin agua, seg\u00fan la monograf\u00eda en *The International Pharmacopoeia*.\n     - Resultados: 52 participantes; 12 laboratorios (23%) reportaron resultados cuestionables o insatisfactorios.\n     - Acciones: Se solicit\u00f3 a los laboratorios que compartieran sus investigaciones sobre las causas de los fallos y las acciones correctivas implementadas.\n   \n   - **Procedimiento 2: Determinaci\u00f3n de agua por Karl-Fischer**:\n     - Estado: Actualmente en curso, con informaci\u00f3n sobre los plazos proporcionada al Comit\u00e9.\n\n4. **Pruebas de Competencia Planificadas**:\n   - Se presentaron pruebas de competencia planificadas para la Fase 5, que est\u00e1n listadas en una tabla (Tabla 2).\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable del EQAAS.\n- **Metronidazol**: Sustancia analizada en el Procedimiento 1.\n- **Karl-Fischer**: M\u00e9todo utilizado en el Procedimiento 2 para la determinaci\u00f3n de agua.", "excerpt_keywords": "Keywords: laboratory performance, quality control, WHO guidelines, pharmaceutical microbiology, capacity-building"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7c369f30-cee6-4cc7-9639-358aa3e1bad2", "node_type": "4", "metadata": {"page_label": "44", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Number | Test | Sample | Return of results by |\n| - | - | - | - |\n| 5.3 | Dissolution test | Artemether and lumefantrine tablets | 1 April 2011 |\n| 5.4 | Density and pH measurement | Abacavir oral solution | 15 September 2011 |\n| 5.5 | Assay by high-performance liquid chromatography | Amodiaquine and artesunate tablets | 15 March 2012 |\n| 5.6 | Dissolution test | Rifampicin capsules | 15 August 2012 |\n| 5.7 | Related substances by thin-layer chromatography | Artemether and lumefantrine oral suspension | 15 December 2012 |\n\n\nA discussion was held and questions were posed about the performance of laboratories and whether a change in personnel, e.g. laboratory staff, had an influence on performance. It was suggested that cross-checks be made to see whether in laboratories that had failures, these had been triggered by changes in personnel.\n\nThe Committee took note of the latest activities in this programme and fully supported the work carried out to assist quality control laboratories in their capacity-building efforts.\n\n### 6.2 WHO good practices for pharmaceutical microbiology laboratories\n\nFurther to the revision of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation with a specific text for pharmaceutical microbiology laboratories.\n\nA draft document was presented to the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its 44th meeting and circulated for comments in accordance with the usual procedure. A revised draft was discussed during the informal consultation on quality assurance systems, medicines and risk analysis in May 2010 and mailed out for comments. These responses were currently under evaluation.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2af67a0bab3229d98cbf6600b48ba4354e237120d5de0fd728554faa187d9112", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Number | Test | Sample | Return of results by |\n| - | - | - | - |\n| 5.3 | Dissolution test | Artemether and lumefantrine tablets | 1 April 2011 |\n| 5.4 | Density and pH measurement | Abacavir oral solution | 15 September 2011 |\n| 5.5 | Assay by high-performance liquid chromatography | Amodiaquine and artesunate tablets | 15 March 2012 |\n| 5.6 | Dissolution test | Rifampicin capsules | 15 August 2012 |\n| 5.7 | Related substances by thin-layer chromatography | Artemether and lumefantrine oral suspension | 15 December 2012 |\n\n\nA discussion was held and questions were posed about the performance of laboratories and whether a change in personnel, e.g. laboratory staff, had an influence on performance. It was suggested that cross-checks be made to see whether in laboratories that had failures, these had been triggered by changes in personnel.\n\nThe Committee took note of the latest activities in this programme and fully supported the work carried out to assist quality control laboratories in their capacity-building efforts.\n\n### 6.2 WHO good practices for pharmaceutical microbiology laboratories\n\nFurther to the revision of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation with a specific text for pharmaceutical microbiology laboratories.\n\nA draft document was presented to the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its 44th meeting and circulated for comments in accordance with the usual procedure. A revised draft was discussed during the informal consultation on quality assurance systems, medicines and risk analysis in May 2010 and mailed out for comments. These responses were currently under evaluation.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2041, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "981e7f2d-0535-45b5-a00c-509383e0840c": {"__data__": {"id_": "981e7f2d-0535-45b5-a00c-509383e0840c", "embedding": null, "metadata": {"page_label": "45", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Assurance \u2014 Good Manufacturing Practices\n\n## 7.1 Update of WHO GMP Main Principles for Pharmaceutical Products\n\nProposals for updating the WHO GMP main principles were discussed at various informal consultations and received as feedback to the increased implementation of this text. Discussion during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009, revealed the need to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d in the *WHO good manufacturing practices (GMP): main principles for pharmaceutical products*.\n\nIn addition, several updates have been suggested to further enhance and include the concept of risk management (in paragraphs 1.2 and 1.4 and 1.5 (new) of the text), replacement of \u201cdrugs\u201d by \u201cmedicines\u201d and inclusion of the concept of a \u201cquality unit\u201d in the section on key personnel and related paragraphs in other parts of the text.\n\nThe Expert Committee agreed to update the guidelines accordingly and recommended publication of the entire guidelines as an Annex to its report in order to replace the one previously published as Annex 4, WHO Technical Report Series, No. 908 in 2003 (Annex 3).\n\n## 7.2 WHO GMP for Blood Establishments\n\nBased on recent discussions worldwide, including during the 63rd World Health Assembly, quality assurance for blood products has received increased attention. New concepts for blood establishments and blood collection are being discussed internationally as, currently, large amounts of blood samples have to be discarded. The World Health Assembly resolution was passed with the intention of strengthening the regulatory oversight for blood products. In response to these efforts, and in order to serve Member States, new good practices for blood establishments were drafted.\n\nRelying on the expertise of the specialists in the Expert Committee on Biological Standardization \u2014 blood products track, the Expert Committee on Specifications for Pharmaceutical Preparations agreed to consider this new GMP text in order to provide Member States with the full set of WHO GMP texts in a comprehensive manner. The new GMP text describes the full series of steps to be covered by blood establishments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la actualizaci\u00f3n de los principios de Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos y establece nuevas directrices para los establecimientos de sangre. Se discuten propuestas para mejorar la calidad y la gesti\u00f3n de riesgos en la producci\u00f3n de medicamentos, as\u00ed como la necesidad de un enfoque m\u00e1s riguroso en la regulaci\u00f3n de productos sangu\u00edneos. Se menciona la incorporaci\u00f3n de un nuevo apartado sobre la revisi\u00f3n de la calidad del producto y la inclusi\u00f3n de un \"unidad de calidad\" en el personal clave.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios espec\u00edficos se han propuesto en la secci\u00f3n sobre \"Product quality review\" en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos?**\n   - Respuesta: Se ha propuesto la incorporaci\u00f3n de una nueva secci\u00f3n (1.6) sobre \"Product quality review\" en el Cap\u00edtulo 1: \"Quality assurance\", as\u00ed como la inclusi\u00f3n del concepto de gesti\u00f3n de riesgos en varios p\u00e1rrafos del texto.\n\n2. **\u00bfCu\u00e1l es el objetivo de la resoluci\u00f3n de la Asamblea Mundial de la Salud en relaci\u00f3n con los productos sangu\u00edneos y qu\u00e9 nuevas pr\u00e1cticas se han desarrollado como respuesta?**\n   - Respuesta: La resoluci\u00f3n tiene como objetivo fortalecer la supervisi\u00f3n regulatoria de los productos sangu\u00edneos, y se han redactado nuevas Buenas Pr\u00e1cticas para los establecimientos de sangre para abordar la alta tasa de descarte de muestras de sangre.\n\n3. **\u00bfC\u00f3mo se planea integrar el nuevo texto de GMP para los establecimientos de sangre con los textos existentes de la OMS?**\n   - Respuesta: El nuevo texto de GMP para los establecimientos de sangre se integrar\u00e1 en un conjunto completo de textos de GMP de la OMS, asegurando que los Estados Miembros tengan acceso a una gu\u00eda integral sobre las pr\u00e1cticas de calidad en la producci\u00f3n de productos sangu\u00edneos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n del Rendimiento de Laboratorios**:\n   - Se discuti\u00f3 el rendimiento de los laboratorios de control de calidad, con \u00e9nfasis en c\u00f3mo los cambios en el personal pueden afectar los resultados. \n   - Se propuso realizar verificaciones cruzadas para identificar si las fallas en los laboratorios estaban relacionadas con cambios en el personal.\n\n2. **Pruebas Realizadas**:\n   - Se presentaron diversas pruebas realizadas en laboratorios, incluyendo:\n     - **Test de disoluci\u00f3n** para tabletas de artemeter y lumefantrina (resultado el 1 de abril de 2011).\n     - **Medici\u00f3n de densidad y pH** para soluci\u00f3n oral de abacavir (resultado el 15 de septiembre de 2011).\n     - **Ensayo por cromatograf\u00eda l\u00edquida de alta eficacia** para tabletas de amodiaquina y artesunato (resultado el 15 de marzo de 2012).\n     - **Test de disoluci\u00f3n** para c\u00e1psulas de rifampicina (resultado el 15 de agosto de 2012).\n     - **Sustancias relacionadas por cromatograf\u00eda en capa fina** para suspensi\u00f3n oral de artemeter y lumefantrina (resultado el 15 de diciembre de 2012).\n\n3. **Buenas Pr\u00e1cticas de Microbiolog\u00eda Farmac\u00e9utica**:\n   - Se present\u00f3 un borrador de directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica a la Comisi\u00f3n de Expertos de la OMS.\n   - Estas directrices se desarrollaron a partir de la revisi\u00f3n de buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y est\u00e1n en proceso de evaluaci\u00f3n tras recibir comentarios de especialistas.\n   - Las directrices fueron adoptadas, pero est\u00e1n sujetas a revisi\u00f3n por un grupo de especialistas seleccionados.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n y adopci\u00f3n de buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que eval\u00faa y discute las directrices y pr\u00e1cticas en laboratorios.\n- **Laboratorios de Control de Calidad**: Entidades que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, quality assurance, pharmaceutical products, blood establishments, risk management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f2709bb6-7851-466e-af5c-e6bf28107485", "node_type": "4", "metadata": {"page_label": "45", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Assurance \u2014 Good Manufacturing Practices\n\n## 7.1 Update of WHO GMP Main Principles for Pharmaceutical Products\n\nProposals for updating the WHO GMP main principles were discussed at various informal consultations and received as feedback to the increased implementation of this text. Discussion during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009, revealed the need to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d in the *WHO good manufacturing practices (GMP): main principles for pharmaceutical products*.\n\nIn addition, several updates have been suggested to further enhance and include the concept of risk management (in paragraphs 1.2 and 1.4 and 1.5 (new) of the text), replacement of \u201cdrugs\u201d by \u201cmedicines\u201d and inclusion of the concept of a \u201cquality unit\u201d in the section on key personnel and related paragraphs in other parts of the text.\n\nThe Expert Committee agreed to update the guidelines accordingly and recommended publication of the entire guidelines as an Annex to its report in order to replace the one previously published as Annex 4, WHO Technical Report Series, No. 908 in 2003 (Annex 3).\n\n## 7.2 WHO GMP for Blood Establishments\n\nBased on recent discussions worldwide, including during the 63rd World Health Assembly, quality assurance for blood products has received increased attention. New concepts for blood establishments and blood collection are being discussed internationally as, currently, large amounts of blood samples have to be discarded. The World Health Assembly resolution was passed with the intention of strengthening the regulatory oversight for blood products. In response to these efforts, and in order to serve Member States, new good practices for blood establishments were drafted.\n\nRelying on the expertise of the specialists in the Expert Committee on Biological Standardization \u2014 blood products track, the Expert Committee on Specifications for Pharmaceutical Preparations agreed to consider this new GMP text in order to provide Member States with the full set of WHO GMP texts in a comprehensive manner. The new GMP text describes the full series of steps to be covered by blood establishments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "06804c77490e960eac2e4b4909c9e082389ba00bb8ef844ba9f478e8915f29cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Assurance \u2014 Good Manufacturing Practices\n\n## 7.1 Update of WHO GMP Main Principles for Pharmaceutical Products\n\nProposals for updating the WHO GMP main principles were discussed at various informal consultations and received as feedback to the increased implementation of this text. Discussion during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009, revealed the need to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d in the *WHO good manufacturing practices (GMP): main principles for pharmaceutical products*.\n\nIn addition, several updates have been suggested to further enhance and include the concept of risk management (in paragraphs 1.2 and 1.4 and 1.5 (new) of the text), replacement of \u201cdrugs\u201d by \u201cmedicines\u201d and inclusion of the concept of a \u201cquality unit\u201d in the section on key personnel and related paragraphs in other parts of the text.\n\nThe Expert Committee agreed to update the guidelines accordingly and recommended publication of the entire guidelines as an Annex to its report in order to replace the one previously published as Annex 4, WHO Technical Report Series, No. 908 in 2003 (Annex 3).\n\n## 7.2 WHO GMP for Blood Establishments\n\nBased on recent discussions worldwide, including during the 63rd World Health Assembly, quality assurance for blood products has received increased attention. New concepts for blood establishments and blood collection are being discussed internationally as, currently, large amounts of blood samples have to be discarded. The World Health Assembly resolution was passed with the intention of strengthening the regulatory oversight for blood products. In response to these efforts, and in order to serve Member States, new good practices for blood establishments were drafted.\n\nRelying on the expertise of the specialists in the Expert Committee on Biological Standardization \u2014 blood products track, the Expert Committee on Specifications for Pharmaceutical Preparations agreed to consider this new GMP text in order to provide Member States with the full set of WHO GMP texts in a comprehensive manner. The new GMP text describes the full series of steps to be covered by blood establishments.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2301, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "95fa52ac-7261-4be6-a584-89687d11c5ba": {"__data__": {"id_": "95fa52ac-7261-4be6-a584-89687d11c5ba", "embedding": null, "metadata": {"page_label": "46", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\na special taskforce, widely reviewed in-house and by WHO Regions, as well as by the blood regulatory network. Moreover, it was posted on the web for public comments.\n\nThe Expert Committee members considered this text to be more comprehensive than the texts for the rest of the pharmaceutical products. However, due to the special environment in which the new guidance will be used, it was found to be acceptable in this format to make it more user-friendly, as the users of this text are traditionally not used to working with the overall applied GMP principles.\n\nThe new good practices were adopted as amended by the specialists in the Expert Committee on Biological Standardization blood products track (Annex 4). It was recommended to add an explanatory note as to why it is more comprehensive than the guidelines for other pharmaceutical products.\n\n### 7.3 Update of WHO GMP for heating, ventilation and air-conditioning for non-sterile pharmaceutical dosage forms\n\nThe supplementary guidelines on GMP for heating, ventilation and air-conditioning (HVAC) for non-sterile pharmaceutical dosage forms were published in 2006. This text was considered to be rather unique in the NMRA-related environment.\n\nFeedback was received from inspectors and users suggesting that this text would benefit from an update in order to allow for inclusion of new trends in this area and to harmonize with other related new documents published, e.g. by the International Organization for Standardization (ISO). Comments received when circulating the proposal were discussed in an informal consultation on quality assurance systems, medicines and risk analysis on 4\u20136 May 2010. The Expert Committee members reviewed the proposed text and requested technical assistance from specialists in this area. A small subgroup was created which looked at the additional comments received prior to and during the Expert Committee meeting.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this review for their final adoption of the guidelines (Annex 5). The Committee further recommended publication of the entire guidelines as an annex to the report.\n\n### 7.4 Update of WHO GMP: Water for pharmaceutical use\n\nThe *WHO good manufacturing practices: water for pharmaceutical use* was adopted by the Expert Committee on Specifications for Pharmaceutical Preparations in 2005 and published in its thirty-ninth report, WHO Technical\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas buenas pr\u00e1cticas**: Se menciona que un grupo de expertos revis\u00f3 y adopt\u00f3 nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos, destacando la necesidad de hacer el texto m\u00e1s accesible para los usuarios que no est\u00e1n familiarizados con los principios generales de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **Actualizaci\u00f3n de directrices sobre HVAC**: Se discute la necesidad de actualizar las directrices sobre calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para formas farmac\u00e9uticas no est\u00e9riles, en respuesta a comentarios de inspectores y usuarios, as\u00ed como para alinearse con nuevas normativas internacionales.\n\n3. **Revisi\u00f3n de las pr\u00e1cticas de agua para uso farmac\u00e9utico**: Se menciona que las buenas pr\u00e1cticas de manufactura relacionadas con el agua para uso farmac\u00e9utico fueron adoptadas en 2005 y que se est\u00e1 considerando su revisi\u00f3n para asegurar que se mantengan actualizadas y relevantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfPor qu\u00e9 se consider\u00f3 necesario hacer el texto de las nuevas buenas pr\u00e1cticas m\u00e1s accesible para los usuarios?**\n   - La necesidad de hacer el texto m\u00e1s accesible se debe a que los usuarios de este texto tradicionalmente no est\u00e1n familiarizados con los principios generales de las Buenas Pr\u00e1cticas de Manufactura (GMP), lo que podr\u00eda dificultar su comprensi\u00f3n y aplicaci\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de comentarios se recibieron sobre las directrices de HVAC y c\u00f3mo se abordaron?**\n   - Se recibieron comentarios de inspectores y usuarios que suger\u00edan que las directrices sobre HVAC se beneficiar\u00edan de una actualizaci\u00f3n para incluir nuevas tendencias y armonizar con documentos recientes de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO). Estos comentarios fueron discutidos en una consulta informal y se form\u00f3 un subgrupo para revisar las observaciones adicionales antes de la adopci\u00f3n final.\n\n3. **\u00bfCu\u00e1l fue el proceso seguido para la adopci\u00f3n de las nuevas buenas pr\u00e1cticas en productos biol\u00f3gicos?**\n   - Las nuevas buenas pr\u00e1cticas fueron revisadas por un grupo de expertos, quienes consideraron el texto m\u00e1s completo que otros relacionados con productos farmac\u00e9uticos. Se adoptaron en su formato actual, con la recomendaci\u00f3n de incluir una nota explicativa sobre su mayor amplitud en comparaci\u00f3n con otras gu\u00edas, y se realizaron enmiendas basadas en las sugerencias de los especialistas en la materia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de los Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se discutieron propuestas para actualizar los principios de GMP de la OMS para productos farmac\u00e9uticos.\n   - Se incorporar\u00e1 una nueva secci\u00f3n (1.6) sobre \"Revisi\u00f3n de la calidad del producto\" en el Cap\u00edtulo 1: \"Aseguramiento de la calidad\".\n   - Se sugiere incluir el concepto de gesti\u00f3n de riesgos y reemplazar \"drugs\" por \"medicines\".\n   - Se introduce el concepto de \"unidad de calidad\" en el personal clave.\n\n2. **Buenas Pr\u00e1cticas de Manufactura para Establecimientos de Sangre**:\n   - La calidad de los productos sangu\u00edneos ha recibido mayor atenci\u00f3n a nivel mundial, especialmente tras la 63\u00aa Asamblea Mundial de la Salud.\n   - Se discuten nuevos conceptos para los establecimientos de sangre debido al alto descarte de muestras.\n   - La resoluci\u00f3n de la Asamblea busca fortalecer la supervisi\u00f3n regulatoria de los productos sangu\u00edneos.\n   - Se han redactado nuevas Buenas Pr\u00e1cticas para los establecimientos de sangre, integr\u00e1ndose en un conjunto completo de textos de GMP de la OMS.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y directrices sobre la calidad de productos farmac\u00e9uticos y sangu\u00edneos.\n- **Asamblea Mundial de la Salud**: Foro donde se discuten y aprueban resoluciones relacionadas con la salud global.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y actualiza las directrices de GMP y asegura la implementaci\u00f3n de buenas pr\u00e1cticas en la producci\u00f3n de medicamentos y productos sangu\u00edneos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, Biological Standardization, HVAC guidelines, Pharmaceutical use"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53db57f2-b686-4280-84e1-50c909e495fb", "node_type": "4", "metadata": {"page_label": "46", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\na special taskforce, widely reviewed in-house and by WHO Regions, as well as by the blood regulatory network. Moreover, it was posted on the web for public comments.\n\nThe Expert Committee members considered this text to be more comprehensive than the texts for the rest of the pharmaceutical products. However, due to the special environment in which the new guidance will be used, it was found to be acceptable in this format to make it more user-friendly, as the users of this text are traditionally not used to working with the overall applied GMP principles.\n\nThe new good practices were adopted as amended by the specialists in the Expert Committee on Biological Standardization blood products track (Annex 4). It was recommended to add an explanatory note as to why it is more comprehensive than the guidelines for other pharmaceutical products.\n\n### 7.3 Update of WHO GMP for heating, ventilation and air-conditioning for non-sterile pharmaceutical dosage forms\n\nThe supplementary guidelines on GMP for heating, ventilation and air-conditioning (HVAC) for non-sterile pharmaceutical dosage forms were published in 2006. This text was considered to be rather unique in the NMRA-related environment.\n\nFeedback was received from inspectors and users suggesting that this text would benefit from an update in order to allow for inclusion of new trends in this area and to harmonize with other related new documents published, e.g. by the International Organization for Standardization (ISO). Comments received when circulating the proposal were discussed in an informal consultation on quality assurance systems, medicines and risk analysis on 4\u20136 May 2010. The Expert Committee members reviewed the proposed text and requested technical assistance from specialists in this area. A small subgroup was created which looked at the additional comments received prior to and during the Expert Committee meeting.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this review for their final adoption of the guidelines (Annex 5). The Committee further recommended publication of the entire guidelines as an annex to the report.\n\n### 7.4 Update of WHO GMP: Water for pharmaceutical use\n\nThe *WHO good manufacturing practices: water for pharmaceutical use* was adopted by the Expert Committee on Specifications for Pharmaceutical Preparations in 2005 and published in its thirty-ninth report, WHO Technical\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c18ed2b49d9a67a505d1f8fb04db13db01791446529d85fc3dfce84c60226ba9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "a special taskforce, widely reviewed in-house and by WHO Regions, as well as by the blood regulatory network. Moreover, it was posted on the web for public comments.\n\nThe Expert Committee members considered this text to be more comprehensive than the texts for the rest of the pharmaceutical products. However, due to the special environment in which the new guidance will be used, it was found to be acceptable in this format to make it more user-friendly, as the users of this text are traditionally not used to working with the overall applied GMP principles.\n\nThe new good practices were adopted as amended by the specialists in the Expert Committee on Biological Standardization blood products track (Annex 4). It was recommended to add an explanatory note as to why it is more comprehensive than the guidelines for other pharmaceutical products.\n\n### 7.3 Update of WHO GMP for heating, ventilation and air-conditioning for non-sterile pharmaceutical dosage forms\n\nThe supplementary guidelines on GMP for heating, ventilation and air-conditioning (HVAC) for non-sterile pharmaceutical dosage forms were published in 2006. This text was considered to be rather unique in the NMRA-related environment.\n\nFeedback was received from inspectors and users suggesting that this text would benefit from an update in order to allow for inclusion of new trends in this area and to harmonize with other related new documents published, e.g. by the International Organization for Standardization (ISO). Comments received when circulating the proposal were discussed in an informal consultation on quality assurance systems, medicines and risk analysis on 4\u20136 May 2010. The Expert Committee members reviewed the proposed text and requested technical assistance from specialists in this area. A small subgroup was created which looked at the additional comments received prior to and during the Expert Committee meeting.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this review for their final adoption of the guidelines (Annex 5). The Committee further recommended publication of the entire guidelines as an annex to the report.\n\n### 7.4 Update of WHO GMP: Water for pharmaceutical use\n\nThe *WHO good manufacturing practices: water for pharmaceutical use* was adopted by the Expert Committee on Specifications for Pharmaceutical Preparations in 2005 and published in its thirty-ninth report, WHO Technical", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2560, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "87811e47-752d-4576-876c-c0d3d99665e6": {"__data__": {"id_": "87811e47-752d-4576-876c-c0d3d99665e6", "embedding": null, "metadata": {"page_label": "47", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Revision of WHO GMP: Sterile pharmaceutical products\n\nDuring the 44th WHO Expert Committee on Specifications for Pharmaceutical Preparations in 2009, **GMP on sterile pharmaceutical products** were adopted in a revised version as Annex 4 to the Expert Committee report and published in the WHO Technical Report Series, No. 957, 2010. Since then a proposal for a maintenance process had been received and submitted to the Expert Committee members.\n\nThe Expert Committee reviewed all proposed changes in detail and found them to be of good editorial nature involving no change to the technical requirements. The Expert Committee members agreed to all modifications and recommended, in order to make the updated text easily available and to avoid confusion and misinterpretation, to republish the text in its entirety as Annex 6.\n\nThe Expert Committee members took this opportunity to recommend that the Secretariat should develop a general policy with regard to future maintenance processes and present it to the Expert Committee at its forty-sixth meeting.\n\n# Quality Assurance \u2014 new approaches\n\n## WHO guidelines on quality risk management\n\nIn response to the recommendations of the 44th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, the Secretariat had initiated the drafting of the **WHO guidelines on quality risk management**. The initial draft structure was reviewed at the informal consultation on quality assurance systems, medicines and risk analysis held in May 2010 and further elaborated thereafter. Upon circulation, numerous comments were received.\n\nThe Expert Committee members expressed their general support for this document which included more detail than other international guidance, e.g. the ICH Q9. It was recommended that a group of experts should continue to work on the document to bring it to a more mature level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos est\u00e9riles, adoptadas por el Comit\u00e9 de Expertos de la OMS en 2009. Se menciona la revisi\u00f3n de cambios editoriales sin alteraciones t\u00e9cnicas significativas y la recomendaci\u00f3n de republicar el texto actualizado. Adem\u00e1s, se aborda el desarrollo de directrices sobre gesti\u00f3n de riesgos de calidad, en respuesta a las recomendaciones del mismo comit\u00e9, destacando la necesidad de un enfoque m\u00e1s detallado que otras gu\u00edas internacionales.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 modificaciones se realizaron en las GMP de productos farmac\u00e9uticos est\u00e9riles durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Las modificaciones fueron de naturaleza editorial y no implicaron cambios en los requisitos t\u00e9cnicos. Se acord\u00f3 repubicar el texto en su totalidad como Anexo 6 para evitar confusiones.\n\n2. **\u00bfCu\u00e1l fue la recomendaci\u00f3n del Comit\u00e9 de Expertos respecto al proceso de mantenimiento de las GMP en el futuro?**\n   - Se recomend\u00f3 que la Secretar\u00eda desarrolle una pol\u00edtica general sobre los procesos de mantenimiento y que se presente en la 46\u00aa reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la elaboraci\u00f3n de las directrices de la OMS sobre gesti\u00f3n de riesgos de calidad?**\n   - Se revis\u00f3 una estructura inicial del documento en una consulta informal y se recibieron numerosos comentarios. Los miembros del Comit\u00e9 expresaron su apoyo general, destacando que el documento inclu\u00eda m\u00e1s detalles que otras gu\u00edas internacionales, como el ICH Q9. Se recomend\u00f3 que un grupo de expertos contin\u00fae trabajando en el documento para mejorarlo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Nuevas Buenas Pr\u00e1cticas para Productos Biol\u00f3gicos**:\n   - Se adoptaron nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos, revisadas por un grupo de expertos y la red reguladora de sangre de la OMS.\n   - Se enfatiz\u00f3 la necesidad de hacer el texto m\u00e1s accesible para usuarios que no est\u00e1n familiarizados con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Se recomend\u00f3 incluir una nota explicativa sobre la amplitud del texto en comparaci\u00f3n con otras gu\u00edas farmac\u00e9uticas.\n\n2. **Actualizaci\u00f3n de Directrices sobre HVAC**:\n   - Las directrices sobre calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para formas farmac\u00e9uticas no est\u00e9riles, publicadas en 2006, necesitan actualizaci\u00f3n.\n   - Se recibieron comentarios de inspectores y usuarios que sugirieron incluir nuevas tendencias y armonizar con documentos de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO).\n   - Se realiz\u00f3 una consulta informal y se form\u00f3 un subgrupo para revisar los comentarios antes de la adopci\u00f3n final de las directrices.\n\n3. **Revisi\u00f3n de Buenas Pr\u00e1cticas de Agua para Uso Farmac\u00e9utico**:\n   - Las buenas pr\u00e1cticas de manufactura relacionadas con el agua para uso farmac\u00e9utico fueron adoptadas en 2005.\n   - Se est\u00e1 considerando su revisi\u00f3n para asegurar que se mantengan actualizadas y relevantes.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la adopci\u00f3n y revisi\u00f3n de las buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que revis\u00f3 y adopt\u00f3 las nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos.\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Entidad con la que se busca armonizar las directrices de HVAC.\n- **NMRA (Autoridad Nacional de Regulaci\u00f3n de Medicamentos)**: Contexto en el que se consideran las directrices de HVAC.", "excerpt_keywords": "Keywords: GMP, sterile pharmaceutical products, quality risk management, WHO guidelines, Expert Committee"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1046723d-2572-45db-9fa0-a3a684a20ec9", "node_type": "4", "metadata": {"page_label": "47", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Revision of WHO GMP: Sterile pharmaceutical products\n\nDuring the 44th WHO Expert Committee on Specifications for Pharmaceutical Preparations in 2009, **GMP on sterile pharmaceutical products** were adopted in a revised version as Annex 4 to the Expert Committee report and published in the WHO Technical Report Series, No. 957, 2010. Since then a proposal for a maintenance process had been received and submitted to the Expert Committee members.\n\nThe Expert Committee reviewed all proposed changes in detail and found them to be of good editorial nature involving no change to the technical requirements. The Expert Committee members agreed to all modifications and recommended, in order to make the updated text easily available and to avoid confusion and misinterpretation, to republish the text in its entirety as Annex 6.\n\nThe Expert Committee members took this opportunity to recommend that the Secretariat should develop a general policy with regard to future maintenance processes and present it to the Expert Committee at its forty-sixth meeting.\n\n# Quality Assurance \u2014 new approaches\n\n## WHO guidelines on quality risk management\n\nIn response to the recommendations of the 44th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, the Secretariat had initiated the drafting of the **WHO guidelines on quality risk management**. The initial draft structure was reviewed at the informal consultation on quality assurance systems, medicines and risk analysis held in May 2010 and further elaborated thereafter. Upon circulation, numerous comments were received.\n\nThe Expert Committee members expressed their general support for this document which included more detail than other international guidance, e.g. the ICH Q9. It was recommended that a group of experts should continue to work on the document to bring it to a more mature level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "59aa605aee9eddd837ade4a3a42b0f59dc223d364f3cf0ead2925070d11e534e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Revision of WHO GMP: Sterile pharmaceutical products\n\nDuring the 44th WHO Expert Committee on Specifications for Pharmaceutical Preparations in 2009, **GMP on sterile pharmaceutical products** were adopted in a revised version as Annex 4 to the Expert Committee report and published in the WHO Technical Report Series, No. 957, 2010. Since then a proposal for a maintenance process had been received and submitted to the Expert Committee members.\n\nThe Expert Committee reviewed all proposed changes in detail and found them to be of good editorial nature involving no change to the technical requirements. The Expert Committee members agreed to all modifications and recommended, in order to make the updated text easily available and to avoid confusion and misinterpretation, to republish the text in its entirety as Annex 6.\n\nThe Expert Committee members took this opportunity to recommend that the Secretariat should develop a general policy with regard to future maintenance processes and present it to the Expert Committee at its forty-sixth meeting.\n\n# Quality Assurance \u2014 new approaches\n\n## WHO guidelines on quality risk management\n\nIn response to the recommendations of the 44th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, the Secretariat had initiated the drafting of the **WHO guidelines on quality risk management**. The initial draft structure was reviewed at the informal consultation on quality assurance systems, medicines and risk analysis held in May 2010 and further elaborated thereafter. Upon circulation, numerous comments were received.\n\nThe Expert Committee members expressed their general support for this document which included more detail than other international guidance, e.g. the ICH Q9. It was recommended that a group of experts should continue to work on the document to bring it to a more mature level.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1882, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3347c8eb-f557-4f31-af2b-37b7324fb09d": {"__data__": {"id_": "3347c8eb-f557-4f31-af2b-37b7324fb09d", "embedding": null, "metadata": {"page_label": "48", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 WHO guidelines on technology transfer\n\nThe Expert Committee members reviewed the feedback on the newly proposed *WHO guiding principles on transfer of technology in pharmaceutical manufacturing*. It was noted that a large number of comments were received. A small group was then constituted to discuss the feedback obtained both in the meeting and following circulation.\n\nThe Expert Committee subsequently reviewed the outcome of these discussions and adopted the revised text as Annex 7.\n\n# 9. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 9.1 Good pharmacy practice: standards for quality of pharmacy services\n\nThe Expert Committee members were briefed in detail about the steps undertaken towards a revision of the joint WHO/FIP good pharmacy practice (GPP) in order to accommodate new trends and developments.\n\nThe first text on good pharmacy practice had been submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on GPP was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO Guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out a strong commitment towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines Strategy), WHA54.13 (Strengthening health systems in developing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda dos temas principales: las directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica y la garant\u00eda de calidad en la distribuci\u00f3n y comercio de productos farmac\u00e9uticos. Se menciona la revisi\u00f3n de los principios de la OMS sobre la transferencia de tecnolog\u00eda, as\u00ed como la evoluci\u00f3n de las buenas pr\u00e1cticas de farmacia (GPP) desde su primera publicaci\u00f3n en 1999. Adem\u00e1s, se destaca la colaboraci\u00f3n de la FIP con varios pa\u00edses para desarrollar est\u00e1ndares nacionales de GPP y la adopci\u00f3n de la Declaraci\u00f3n de Bangkok en 2007, que reafirma el compromiso de elevar los est\u00e1ndares de los servicios farmac\u00e9uticos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron los principales cambios en las buenas pr\u00e1cticas de farmacia (GPP) desde su primera publicaci\u00f3n en 1999 hasta la revisi\u00f3n actual mencionada en el documento?**\n   - Esta pregunta busca detalles sobre las actualizaciones y cambios espec\u00edficos en las GPP que se han implementado a lo largo de los a\u00f1os.\n\n2. **\u00bfQu\u00e9 pa\u00edses participaron en el estudio piloto para desarrollar est\u00e1ndares nacionales de GPP entre 2005 y 2007, y cu\u00e1l fue el objetivo de este estudio?**\n   - Esta pregunta se centra en la colaboraci\u00f3n internacional y los objetivos espec\u00edficos del estudio piloto mencionado en el contexto.\n\n3. **\u00bfQu\u00e9 resoluciones de la Asamblea Mundial de la Salud son relevantes para las pr\u00e1cticas farmac\u00e9uticas y c\u00f3mo han influido en la evoluci\u00f3n de las GPP?**\n   - Esta pregunta busca informaci\u00f3n sobre la relaci\u00f3n entre las resoluciones de la OMS y su impacto en las pr\u00e1cticas farmac\u00e9uticas, lo que puede no estar ampliamente documentado en otros lugares.", "prev_section_summary": "### Temas Clave:\n1. **Revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se adoptaron modificaciones editoriales a las GMP para productos farmac\u00e9uticos est\u00e9riles durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2009, con el objetivo de repubicar el texto actualizado como Anexo 6.\n\n2. **Proceso de Mantenimiento**: Se recomend\u00f3 que la Secretar\u00eda de la OMS desarrolle una pol\u00edtica general sobre los procesos de mantenimiento de las GMP y que esta se presente en la 46\u00aa reuni\u00f3n del Comit\u00e9.\n\n3. **Gesti\u00f3n de Riesgos de Calidad**: Se inici\u00f3 la redacci\u00f3n de las directrices de la OMS sobre gesti\u00f3n de riesgos de calidad, con un enfoque m\u00e1s detallado que otras gu\u00edas internacionales, como el ICH Q9. Se recibi\u00f3 apoyo general del Comit\u00e9 para continuar el desarrollo del documento.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la adopci\u00f3n y revisi\u00f3n de las GMP y de la elaboraci\u00f3n de directrices sobre gesti\u00f3n de riesgos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y aprueba las modificaciones a las GMP y otras directrices relacionadas con la calidad de los productos farmac\u00e9uticos.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que proporciona gu\u00edas internacionales, mencionada en comparaci\u00f3n con las nuevas directrices de la OMS. \n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo las acciones tomadas y las recomendaciones formuladas por el Comit\u00e9 de Expertos de la OMS.", "excerpt_keywords": "Keywords: technology transfer, good pharmacy practice, WHO guidelines, pharmaceutical manufacturing, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "36cff4f7-671f-4cad-acc9-7c1bc4e09f4b", "node_type": "4", "metadata": {"page_label": "48", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 WHO guidelines on technology transfer\n\nThe Expert Committee members reviewed the feedback on the newly proposed *WHO guiding principles on transfer of technology in pharmaceutical manufacturing*. It was noted that a large number of comments were received. A small group was then constituted to discuss the feedback obtained both in the meeting and following circulation.\n\nThe Expert Committee subsequently reviewed the outcome of these discussions and adopted the revised text as Annex 7.\n\n# 9. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 9.1 Good pharmacy practice: standards for quality of pharmacy services\n\nThe Expert Committee members were briefed in detail about the steps undertaken towards a revision of the joint WHO/FIP good pharmacy practice (GPP) in order to accommodate new trends and developments.\n\nThe first text on good pharmacy practice had been submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on GPP was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO Guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out a strong commitment towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines Strategy), WHA54.13 (Strengthening health systems in developing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a3b2c23c9508080c98f72924fa7226b81dc98d0b37333a2e21c06b4bb98af02b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.2 WHO guidelines on technology transfer\n\nThe Expert Committee members reviewed the feedback on the newly proposed *WHO guiding principles on transfer of technology in pharmaceutical manufacturing*. It was noted that a large number of comments were received. A small group was then constituted to discuss the feedback obtained both in the meeting and following circulation.\n\nThe Expert Committee subsequently reviewed the outcome of these discussions and adopted the revised text as Annex 7.\n\n# 9. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 9.1 Good pharmacy practice: standards for quality of pharmacy services\n\nThe Expert Committee members were briefed in detail about the steps undertaken towards a revision of the joint WHO/FIP good pharmacy practice (GPP) in order to accommodate new trends and developments.\n\nThe first text on good pharmacy practice had been submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on GPP was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO Guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out a strong commitment towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines Strategy), WHA54.13 (Strengthening health systems in developing", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2348, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "eb56b330-ba5c-4bc4-b603-2df536ebb47f": {"__data__": {"id_": "eb56b330-ba5c-4bc4-b603-2df536ebb47f", "embedding": null, "metadata": {"page_label": "49", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Content\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 124 national Member Organizations, relevant experts and WHO. A proposal for this initiative was presented to the Committee on Specifications for Pharmaceutical Preparations at its forty-third meeting in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.\n\nThe revised GPP proposal was widely circulated for comments within the FIP and WHO consultation process. The outcome was presented to the FIP Member Organizations at their annual meeting in September 2010 and subsequent to additional discussions, it was adopted in principle with a view to presenting it to this Expert Committee.\n\nThis newly revised guidance is intended to serve as a standard forming a baseline to be adjusted to the needs in a specific country. The document is directed at civil society and Member States.\n\nThe Expert Committee members acknowledged the role of pharmacists in the supply chain. It was considered that it is up to each country itself to determine what can be done according to its regulatory framework. The Expert Committee also noted the shortage of pharmacists in numerous developing countries.\n\nThe Expert Committee welcomed the updated GPP, discussed several modifications to the text and adopted it in its revised form as new standards for quality of pharmacy services (Annex 8).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto describe el proceso de actualizaci\u00f3n de las directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP) liderado por la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) desde 2007. Se menciona la creaci\u00f3n de un grupo de trabajo, consultas con expertos y la revisi\u00f3n de est\u00e1ndares nacionales en al menos 37 pa\u00edses. El resultado de este proceso fue la adopci\u00f3n de nuevas normas para la calidad de los servicios farmac\u00e9uticos, que se presentaron a la Comisi\u00f3n de Expertos de la OMS. Tambi\u00e9n se destaca la importancia del papel de los farmac\u00e9uticos en la cadena de suministro y la escasez de estos profesionales en muchos pa\u00edses en desarrollo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales objetivos identificados por el grupo de trabajo de la FIP en su primera reuni\u00f3n en 2007?**\n   - Respuesta: El grupo de trabajo se reuni\u00f3 para identificar los problemas clave que necesitaban ser considerados en la revisi\u00f3n de las directrices sobre GPP.\n\n2. **\u00bfQu\u00e9 pa\u00edses estuvieron representados en la consulta de expertos organizada por la FIP en 2008 y qu\u00e9 roles desempe\u00f1aron sus representantes?**\n   - Respuesta: En la consulta de expertos en 2008, participaron representantes de Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania, as\u00ed como miembros de la FIP y expertos invitados, quienes aportaron sus conocimientos y experiencias en el \u00e1mbito farmac\u00e9utico.\n\n3. **\u00bfQu\u00e9 se discuti\u00f3 en la reuni\u00f3n de la Comisi\u00f3n de Expertos en relaci\u00f3n con la escasez de farmac\u00e9uticos en pa\u00edses en desarrollo?**\n   - Respuesta: La Comisi\u00f3n de Expertos reconoci\u00f3 la escasez de farmac\u00e9uticos en numerosos pa\u00edses en desarrollo y consider\u00f3 que cada pa\u00eds debe determinar lo que puede hacerse seg\u00fan su marco regulatorio.\n\n### Resumen de Nivel Superior\n\nEl proceso de actualizaci\u00f3n de las directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP) por parte de la FIP y la OMS se inici\u00f3 en 2007 y culmin\u00f3 con la adopci\u00f3n de nuevas normas en 2010. Este proceso incluy\u00f3 consultas con expertos y una revisi\u00f3n exhaustiva de est\u00e1ndares en varios pa\u00edses. Se enfatiz\u00f3 la importancia del papel de los farmac\u00e9uticos y se abord\u00f3 la problem\u00e1tica de su escasez en pa\u00edses en desarrollo, dejando a cada naci\u00f3n la responsabilidad de adaptar las directrices a su contexto regulatorio.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Transferencia de Tecnolog\u00eda**:\n   - Se revisaron los principios de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica.\n   - Se constituy\u00f3 un grupo peque\u00f1o para discutir el feedback recibido y se adopt\u00f3 un texto revisado como Anexo 7.\n\n2. **Buenas Pr\u00e1cticas de Farmacia (GPP)**:\n   - Se abord\u00f3 la revisi\u00f3n de las GPP en colaboraci\u00f3n con la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) para adaptarse a nuevas tendencias y desarrollos.\n   - La primera versi\u00f3n de las GPP fue presentada en 1994 y se public\u00f3 oficialmente en 1999.\n\n3. **Colaboraci\u00f3n Internacional**:\n   - Se realiz\u00f3 un estudio piloto entre 2005 y 2007 en varios pa\u00edses (Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam) para desarrollar est\u00e1ndares nacionales de GPP.\n   - En 2007, se adopt\u00f3 la \"Declaraci\u00f3n de Bangkok sobre buenas pr\u00e1cticas de farmacia en entornos comunitarios\" en la Regi\u00f3n del Sudeste Asi\u00e1tico.\n\n4. **Impacto de Resoluciones de la OMS**:\n   - Se mencionan resoluciones recientes de la Asamblea Mundial de la Salud (WHA54.11 y WHA54.13) que son relevantes para la evoluci\u00f3n de las GPP y la mejora de los sistemas de salud.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece directrices y est\u00e1ndares en salud p\u00fablica.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Colabora con la OMS en el desarrollo de buenas pr\u00e1cticas de farmacia.\n- **Expert Committee**: Grupo de expertos que revisa y adopta directrices y principios en el \u00e1mbito farmac\u00e9utico.\n- **Pa\u00edses Participantes**: Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Farmacia, FIP, OMS, est\u00e1ndares farmac\u00e9uticos, escasez de farmac\u00e9uticos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bc0ad7e0-8243-4837-84f8-497dab1b19ff", "node_type": "4", "metadata": {"page_label": "49", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Content\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 124 national Member Organizations, relevant experts and WHO. A proposal for this initiative was presented to the Committee on Specifications for Pharmaceutical Preparations at its forty-third meeting in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.\n\nThe revised GPP proposal was widely circulated for comments within the FIP and WHO consultation process. The outcome was presented to the FIP Member Organizations at their annual meeting in September 2010 and subsequent to additional discussions, it was adopted in principle with a view to presenting it to this Expert Committee.\n\nThis newly revised guidance is intended to serve as a standard forming a baseline to be adjusted to the needs in a specific country. The document is directed at civil society and Member States.\n\nThe Expert Committee members acknowledged the role of pharmacists in the supply chain. It was considered that it is up to each country itself to determine what can be done according to its regulatory framework. The Expert Committee also noted the shortage of pharmacists in numerous developing countries.\n\nThe Expert Committee welcomed the updated GPP, discussed several modifications to the text and adopted it in its revised form as new standards for quality of pharmacy services (Annex 8).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "78d94a93d6f3b400335595f73299e879bfbcf2c4589574a01017964575aa94fa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Document Content\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 124 national Member Organizations, relevant experts and WHO. A proposal for this initiative was presented to the Committee on Specifications for Pharmaceutical Preparations at its forty-third meeting in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.\n\nThe revised GPP proposal was widely circulated for comments within the FIP and WHO consultation process. The outcome was presented to the FIP Member Organizations at their annual meeting in September 2010 and subsequent to additional discussions, it was adopted in principle with a view to presenting it to this Expert Committee.\n\nThis newly revised guidance is intended to serve as a standard forming a baseline to be adjusted to the needs in a specific country. The document is directed at civil society and Member States.\n\nThe Expert Committee members acknowledged the role of pharmacists in the supply chain. It was considered that it is up to each country itself to determine what can be done according to its regulatory framework. The Expert Committee also noted the shortage of pharmacists in numerous developing countries.\n\nThe Expert Committee welcomed the updated GPP, discussed several modifications to the text and adopted it in its revised form as new standards for quality of pharmacy services (Annex 8).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2405, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2f9343-ce5b-427e-8697-d082ec8b5126": {"__data__": {"id_": "1a2f9343-ce5b-427e-8697-d082ec8b5126", "embedding": null, "metadata": {"page_label": "50", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products\n\nThe Expert Committee was briefed about the history and steps involved in the development of this new guidance in the joint session with the Expert Committee on Biological Standardization. After making suitable amendments, the Expert Committee on Biological Standardization and the Expert Committee on Specifications for Pharmaceutical Preparations recommended that the Guidelines be adopted and appended to their respective reports. In addition, the Expert Committee on Biological Standardization recommended:\n\n- that an addendum to the document be developed for labile blood products; and\n- that WHO consider providing guidance to national regulatory authorities on how to define transport requirements for time- and temperature-sensitive pharmaceutical products (TTSPS).\n\nDuring the joint session with the Expert Committee on Biological Standardization it was recommended to refer to \u201csuspect\u201d products in section 8.5 to allow for dealing with problems related to the quality of the product not covered in other sections of the document.\n\nThe Expert Committee adopted the text with the changes proposed (Annex 9).\n\n## 9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n### 9.3.1 Update on current activities\n\nThe Expert Committee was updated on the WHO Certification Scheme. The Committee was informed that a Circular Letter had been sent to Member States on 15 January 2010 asking them to comment on the report of the Expert Committee on Specifications for Pharmaceutical Preparations and to provide updated contact addresses of the respective competent authorities of Member States participating in the WHO Certification Scheme. The response received so far had been extremely low and comments received on the suggestions and recommendations made in previous Expert Committee meetings lacked uniformity. Countries made a number of requests to be covered by the Certification Scheme such as attachment of summary product characteristics (SPC), access to the WHO assessment report, creation of low-risk products, a separate certificate for low-risk products, and inclusion of a date of validity of the issued certificate, among others.\n\nThe Committee was also informed that Poland had joined the WHO pharmaceutical starting materials certification scheme (SMACS).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Gu\u00eda sobre almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y temperatura**: Se discute el desarrollo de nuevas directrices para el manejo de productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento y transporte, con \u00e9nfasis en la necesidad de abordar productos labiles como los productos sangu\u00edneos.\n\n2. **Actualizaci\u00f3n sobre el esquema de certificaci\u00f3n de la OMS**: Se proporciona informaci\u00f3n sobre el estado actual del esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional, destacando la baja respuesta de los Estados Miembros y las solicitudes espec\u00edficas de los pa\u00edses para mejorar el esquema.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hicieron para el manejo de productos sangu\u00edneos labiles en la nueva gu\u00eda de la OMS?**\n   - La Expert Committee recomend\u00f3 que se desarrollara un adendum a la gu\u00eda para abordar espec\u00edficamente los productos sangu\u00edneos labiles.\n\n2. **\u00bfCu\u00e1les fueron algunas de las solicitudes realizadas por los pa\u00edses en relaci\u00f3n con el esquema de certificaci\u00f3n de la OMS?**\n   - Los pa\u00edses solicitaron la inclusi\u00f3n de caracter\u00edsticas del producto resumidas (SPC), acceso al informe de evaluaci\u00f3n de la OMS, la creaci\u00f3n de productos de bajo riesgo, un certificado separado para estos productos y la inclusi\u00f3n de una fecha de validez en el certificado emitido.\n\n3. **\u00bfQu\u00e9 desaf\u00edos se identificaron en la respuesta de los Estados Miembros al informe de la Expert Committee sobre las Preparaciones Farmac\u00e9uticas?**\n   - Se observ\u00f3 una respuesta extremadamente baja de los Estados Miembros y una falta de uniformidad en los comentarios sobre las sugerencias y recomendaciones de reuniones anteriores del Comit\u00e9.", "prev_section_summary": "### Temas Clave\n\n1. **Actualizaci\u00f3n de Directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP)**: La Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 en 2007 un proceso para actualizar las directrices de GPP para alinearlas con los est\u00e1ndares contempor\u00e1neos de pr\u00e1ctica.\n\n2. **Consulta de Expertos**: En 2008, se llev\u00f3 a cabo una consulta de expertos en Basilea, Suiza, donde participaron representantes de diversas organizaciones y pa\u00edses, incluyendo Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania.\n\n3. **Revisi\u00f3n de Est\u00e1ndares Nacionales**: El grupo de trabajo de la FIP revis\u00f3 los est\u00e1ndares nacionales de GPP en al menos 37 pa\u00edses y estableci\u00f3 un marco temporal para consultar a las 124 organizaciones nacionales miembros de la FIP y a expertos relevantes.\n\n4. **Adopci\u00f3n de Nuevas Normas**: Las nuevas directrices fueron presentadas y adoptadas en principio por las organizaciones miembros de la FIP en 2010, con el objetivo de servir como un est\u00e1ndar adaptable a las necesidades espec\u00edficas de cada pa\u00eds.\n\n5. **Rol de los Farmac\u00e9uticos**: Se reconoci\u00f3 la importancia del papel de los farmac\u00e9uticos en la cadena de suministro y se destac\u00f3 la escasez de estos profesionales en muchos pa\u00edses en desarrollo.\n\n### Entidades Involucradas\n\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organismo que lidera la actualizaci\u00f3n de las directrices de GPP.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Colaboradora en el proceso de consulta y revisi\u00f3n.\n- **Representantes de Pa\u00edses**: Incluyendo asesores de medicamentos de Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Entidad que recibi\u00f3 propuestas y reportes sobre la actualizaci\u00f3n de GPP.\n- **Organizaciones Miembros de la FIP**: Participantes en el proceso de consulta y adopci\u00f3n de las nuevas normas. \n\nEste resumen destaca los aspectos fundamentales del proceso de actualizaci\u00f3n de las directrices de GPP y las entidades clave involucradas en este esfuerzo.", "excerpt_keywords": "Keywords: pharmaceutical products, storage and transport, WHO Certification Scheme, temperature-sensitive, labile blood products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7bc6d502-8762-4cf9-8534-12cb7c55f9e3", "node_type": "4", "metadata": {"page_label": "50", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products\n\nThe Expert Committee was briefed about the history and steps involved in the development of this new guidance in the joint session with the Expert Committee on Biological Standardization. After making suitable amendments, the Expert Committee on Biological Standardization and the Expert Committee on Specifications for Pharmaceutical Preparations recommended that the Guidelines be adopted and appended to their respective reports. In addition, the Expert Committee on Biological Standardization recommended:\n\n- that an addendum to the document be developed for labile blood products; and\n- that WHO consider providing guidance to national regulatory authorities on how to define transport requirements for time- and temperature-sensitive pharmaceutical products (TTSPS).\n\nDuring the joint session with the Expert Committee on Biological Standardization it was recommended to refer to \u201csuspect\u201d products in section 8.5 to allow for dealing with problems related to the quality of the product not covered in other sections of the document.\n\nThe Expert Committee adopted the text with the changes proposed (Annex 9).\n\n## 9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n### 9.3.1 Update on current activities\n\nThe Expert Committee was updated on the WHO Certification Scheme. The Committee was informed that a Circular Letter had been sent to Member States on 15 January 2010 asking them to comment on the report of the Expert Committee on Specifications for Pharmaceutical Preparations and to provide updated contact addresses of the respective competent authorities of Member States participating in the WHO Certification Scheme. The response received so far had been extremely low and comments received on the suggestions and recommendations made in previous Expert Committee meetings lacked uniformity. Countries made a number of requests to be covered by the Certification Scheme such as attachment of summary product characteristics (SPC), access to the WHO assessment report, creation of low-risk products, a separate certificate for low-risk products, and inclusion of a date of validity of the issued certificate, among others.\n\nThe Committee was also informed that Poland had joined the WHO pharmaceutical starting materials certification scheme (SMACS).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "16387feee4aec46f4a4d27527f9d42613c4ea28f26447a8d2f0d2b4b4e8a1501", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products\n\nThe Expert Committee was briefed about the history and steps involved in the development of this new guidance in the joint session with the Expert Committee on Biological Standardization. After making suitable amendments, the Expert Committee on Biological Standardization and the Expert Committee on Specifications for Pharmaceutical Preparations recommended that the Guidelines be adopted and appended to their respective reports. In addition, the Expert Committee on Biological Standardization recommended:\n\n- that an addendum to the document be developed for labile blood products; and\n- that WHO consider providing guidance to national regulatory authorities on how to define transport requirements for time- and temperature-sensitive pharmaceutical products (TTSPS).\n\nDuring the joint session with the Expert Committee on Biological Standardization it was recommended to refer to \u201csuspect\u201d products in section 8.5 to allow for dealing with problems related to the quality of the product not covered in other sections of the document.\n\nThe Expert Committee adopted the text with the changes proposed (Annex 9).\n\n## 9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n### 9.3.1 Update on current activities\n\nThe Expert Committee was updated on the WHO Certification Scheme. The Committee was informed that a Circular Letter had been sent to Member States on 15 January 2010 asking them to comment on the report of the Expert Committee on Specifications for Pharmaceutical Preparations and to provide updated contact addresses of the respective competent authorities of Member States participating in the WHO Certification Scheme. The response received so far had been extremely low and comments received on the suggestions and recommendations made in previous Expert Committee meetings lacked uniformity. Countries made a number of requests to be covered by the Certification Scheme such as attachment of summary product characteristics (SPC), access to the WHO assessment report, creation of low-risk products, a separate certificate for low-risk products, and inclusion of a date of validity of the issued certificate, among others.\n\nThe Committee was also informed that Poland had joined the WHO pharmaceutical starting materials certification scheme (SMACS).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2431, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c1f33f-a21e-4a1e-9ba6-84f1d875f8c4": {"__data__": {"id_": "b9c1f33f-a21e-4a1e-9ba6-84f1d875f8c4", "embedding": null, "metadata": {"page_label": "51", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the update and recommended further encouragement to Member States to respond to the Circular Letter, e.g. during the forthcoming ICDRA meeting.\n\n### 9.3.2 Questions and answers\n\nBased on the Committee\u2019s recommendations, a question and answer paper was prepared on the function of the Scheme for posting on the WHO web site and for publication in *WHO Drug Information*, with the possibility for receiving comments and reviewing any question(s) and answers.\n\nThe Expert Committee noted the updated report from the Secretariat.\n\n## 10. Prequalification of priority essential medicines\n\n### 10.1 Update on the WHO Prequalification of Medicines Programme\n\nThe Manager of the WHO Prequalification of Medicines Programme briefed the Expert Committee on the existing procedure for prequalification of pharmaceutical products and activities undertaken so far. He said that the Programme provided services to United Nations and international agencies that procure and purchase medicines with donated funds. The work of the Programme includes dossier assessment and inspection of manufacturers, clinical trial sites and laboratories to ensure compliance with good practices. So far the Programme has prequalified 39 medicines of which three are manufactured in Africa (one in South Africa, one in Uganda and one in Zimbabwe). The Programme also has prequalified laboratories; for details see section 11.1.\n\nAnother activity of the Prequalification of Medicines Programme is to build NMRA capacity by conducting training seminars and providing technical assistance.\n\nThe Committee was informed that the Programme had also been active in quality surveys of antimalarials (QAMSA) in six African countries in 2008\u20132009. The activity involves collection of sample antimalarial drugs, using a standard protocol, from different levels of the supply chain, public and private as well as formal and informal outlets. The survey was conducted through WHO cooperation with the NMRAs from participating countries. Trained survey teams in each country were responsible for collecting samples according to national sampling plans from different distribution levels, including the informal market in at least three geographical regions of high malaria prevalence. In total 935 samples were collected from April to June 2008 and screened. Based on predefined criteria, 306 samples (from 64 manufacturers and 218 sampling sites) were selected for full quality control testing in the WHO-prequalified laboratory in South Africa and in the United States Pharmacopeia (USP) laboratory in the USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Actualizaci\u00f3n sobre el Programa de Precalificaci\u00f3n de Medicamentos de la OMS**: El Programa de Precalificaci\u00f3n de Medicamentos de la OMS se encarga de evaluar y certificar la calidad de los productos farmac\u00e9uticos para su uso en programas de salud p\u00fablica. Hasta la fecha, ha precalificado 39 medicamentos, de los cuales tres son fabricados en \u00c1frica. Adem\u00e1s, el programa realiza capacitaciones y asistencia t\u00e9cnica a las Autoridades Reguladoras Nacionales de Medicamentos (NMRA) y ha llevado a cabo encuestas de calidad de antimal\u00e1ricos en varios pa\u00edses africanos.\n\n2. **Actividades de Capacitaci\u00f3n y Asistencia T\u00e9cnica**: El Programa no solo se enfoca en la precalificaci\u00f3n de medicamentos, sino que tambi\u00e9n trabaja en el fortalecimiento de las capacidades de las NMRA mediante seminarios de capacitaci\u00f3n y asistencia t\u00e9cnica, lo que es crucial para mejorar la regulaci\u00f3n y la calidad de los medicamentos en los pa\u00edses en desarrollo.\n\n3. **Encuestas de Calidad de Antimal\u00e1ricos**: En 2008-2009, el Programa realiz\u00f3 encuestas de calidad de antimal\u00e1ricos en seis pa\u00edses africanos, recolectando y analizando muestras de medicamentos para asegurar su calidad y eficacia. Este esfuerzo es parte de un enfoque m\u00e1s amplio para combatir la malaria y mejorar la disponibilidad de medicamentos de calidad en el continente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios utilizados para seleccionar las muestras de medicamentos antimal\u00e1ricos en las encuestas de calidad realizadas por la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los criterios de selecci\u00f3n que no se detalla en el contexto, pero que son cruciales para entender la metodolog\u00eda de las encuestas.\n\n2. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se ofrece a las NMRA a trav\u00e9s del Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Esta pregunta se centra en los detalles de las capacitaciones y el tipo de asistencia t\u00e9cnica que se proporciona, lo cual no se menciona expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 pasos se siguen despu\u00e9s de que un medicamento es precalificado por la OMS?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso posterior a la precalificaci\u00f3n, incluyendo c\u00f3mo se monitorea la calidad de los medicamentos precalificados y qu\u00e9 acciones se toman si se detectan problemas, lo cual no se aborda en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gu\u00eda sobre Almacenamiento y Transporte de Productos Farmac\u00e9uticos Sensibles al Tiempo y Temperatura**:\n   - Se desarrollaron nuevas directrices para el manejo de productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento y transporte.\n   - Se recomend\u00f3 la creaci\u00f3n de un adendum para abordar espec\u00edficamente los productos sangu\u00edneos labiles.\n   - Se sugiri\u00f3 que la OMS proporcione orientaci\u00f3n a las autoridades regulatorias nacionales sobre los requisitos de transporte para productos farmac\u00e9uticos sensibles al tiempo y temperatura (TTSPS).\n\n2. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Se present\u00f3 una actualizaci\u00f3n sobre el esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional.\n   - Se destac\u00f3 la baja respuesta de los Estados Miembros a la solicitud de comentarios sobre el informe del Comit\u00e9 de Expertos sobre Preparaciones Farmac\u00e9uticas.\n   - Se mencionaron solicitudes espec\u00edficas de los pa\u00edses, como la inclusi\u00f3n de caracter\u00edsticas del producto resumidas (SPC), acceso a informes de evaluaci\u00f3n de la OMS, creaci\u00f3n de productos de bajo riesgo, un certificado separado para estos productos y la inclusi\u00f3n de una fecha de validez en los certificados emitidos.\n\n3. **Entidades Involucradas**:\n   - **Comit\u00e9 de Expertos de la OMS**: Incluye el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y el Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas.\n   - **Estados Miembros de la OMS**: Participan en el esquema de certificaci\u00f3n y proporcionan comentarios sobre las directrices.\n   - **Polonia**: Se uni\u00f3 al esquema de certificaci\u00f3n de materiales de partida farmac\u00e9uticos de la OMS (SMACS). \n\nEste resumen destaca los principales temas tratados en la secci\u00f3n, as\u00ed como las entidades clave involucradas en el desarrollo y la implementaci\u00f3n de las directrices y el esquema de certificaci\u00f3n.", "excerpt_keywords": "Keywords: WHO, Prequalification, Medicines, Antimalarials, NMRA"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19dccc4c-6b5e-4816-a660-c1de83206033", "node_type": "4", "metadata": {"page_label": "51", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the update and recommended further encouragement to Member States to respond to the Circular Letter, e.g. during the forthcoming ICDRA meeting.\n\n### 9.3.2 Questions and answers\n\nBased on the Committee\u2019s recommendations, a question and answer paper was prepared on the function of the Scheme for posting on the WHO web site and for publication in *WHO Drug Information*, with the possibility for receiving comments and reviewing any question(s) and answers.\n\nThe Expert Committee noted the updated report from the Secretariat.\n\n## 10. Prequalification of priority essential medicines\n\n### 10.1 Update on the WHO Prequalification of Medicines Programme\n\nThe Manager of the WHO Prequalification of Medicines Programme briefed the Expert Committee on the existing procedure for prequalification of pharmaceutical products and activities undertaken so far. He said that the Programme provided services to United Nations and international agencies that procure and purchase medicines with donated funds. The work of the Programme includes dossier assessment and inspection of manufacturers, clinical trial sites and laboratories to ensure compliance with good practices. So far the Programme has prequalified 39 medicines of which three are manufactured in Africa (one in South Africa, one in Uganda and one in Zimbabwe). The Programme also has prequalified laboratories; for details see section 11.1.\n\nAnother activity of the Prequalification of Medicines Programme is to build NMRA capacity by conducting training seminars and providing technical assistance.\n\nThe Committee was informed that the Programme had also been active in quality surveys of antimalarials (QAMSA) in six African countries in 2008\u20132009. The activity involves collection of sample antimalarial drugs, using a standard protocol, from different levels of the supply chain, public and private as well as formal and informal outlets. The survey was conducted through WHO cooperation with the NMRAs from participating countries. Trained survey teams in each country were responsible for collecting samples according to national sampling plans from different distribution levels, including the informal market in at least three geographical regions of high malaria prevalence. In total 935 samples were collected from April to June 2008 and screened. Based on predefined criteria, 306 samples (from 64 manufacturers and 218 sampling sites) were selected for full quality control testing in the WHO-prequalified laboratory in South Africa and in the United States Pharmacopeia (USP) laboratory in the USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6a4c65d8b41dead9d1320f0caff06a8ecf67eb22f4e9cf4627efb99b7adbe021", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Committee noted the update and recommended further encouragement to Member States to respond to the Circular Letter, e.g. during the forthcoming ICDRA meeting.\n\n### 9.3.2 Questions and answers\n\nBased on the Committee\u2019s recommendations, a question and answer paper was prepared on the function of the Scheme for posting on the WHO web site and for publication in *WHO Drug Information*, with the possibility for receiving comments and reviewing any question(s) and answers.\n\nThe Expert Committee noted the updated report from the Secretariat.\n\n## 10. Prequalification of priority essential medicines\n\n### 10.1 Update on the WHO Prequalification of Medicines Programme\n\nThe Manager of the WHO Prequalification of Medicines Programme briefed the Expert Committee on the existing procedure for prequalification of pharmaceutical products and activities undertaken so far. He said that the Programme provided services to United Nations and international agencies that procure and purchase medicines with donated funds. The work of the Programme includes dossier assessment and inspection of manufacturers, clinical trial sites and laboratories to ensure compliance with good practices. So far the Programme has prequalified 39 medicines of which three are manufactured in Africa (one in South Africa, one in Uganda and one in Zimbabwe). The Programme also has prequalified laboratories; for details see section 11.1.\n\nAnother activity of the Prequalification of Medicines Programme is to build NMRA capacity by conducting training seminars and providing technical assistance.\n\nThe Committee was informed that the Programme had also been active in quality surveys of antimalarials (QAMSA) in six African countries in 2008\u20132009. The activity involves collection of sample antimalarial drugs, using a standard protocol, from different levels of the supply chain, public and private as well as formal and informal outlets. The survey was conducted through WHO cooperation with the NMRAs from participating countries. Trained survey teams in each country were responsible for collecting samples according to national sampling plans from different distribution levels, including the informal market in at least three geographical regions of high malaria prevalence. In total 935 samples were collected from April to June 2008 and screened. Based on predefined criteria, 306 samples (from 64 manufacturers and 218 sampling sites) were selected for full quality control testing in the WHO-prequalified laboratory in South Africa and in the United States Pharmacopeia (USP) laboratory in the USA.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2586, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "32db387a-b2af-4e41-8049-63230d49b395": {"__data__": {"id_": "32db387a-b2af-4e41-8049-63230d49b395", "embedding": null, "metadata": {"page_label": "52", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Testing was coordinated by WHO and specifications of *The International Pharmacopoeia* or USP were used.\n\nDuring the survey, data were collected that made it possible to relate the results of quality testing to distribution levels, geographical regions, domestic production or import, registration status and prequalification status.\n\nOf 306 samples selected for laboratory testing, 267 were fully tested and 28.5% of them failed to comply with specifications. Although noncompliance with pre-established criteria cannot be directly related to a risk for patients' health, such a high failure rate indicates a substantial problem with the quality of antimalarials present in distribution channels.\n\nComparison of results obtained during laboratory testing with the screening method indicated a substantially lower sensitivity of the latter to detect noncompliance in dissolution and in assay/related substances test (15% and 42% detected, respectively).\n\nThe difference between WHO-prequalified and non-WHO-prequalified products was striking. The failure rate of samples of non-prequalified co-packed samples was more than 10 times higher than that of samples of WHO-prequalified co-packed samples. In total three failures were identified. Two were not critical for patients\u2019 health and the third had a content of one API that was 8% below the acceptance limit. This demonstrates that medicines for which quality was confirmed by WHO prequalification have a much lower quality risk than do non-prequalified products.\n\nAnother quality survey of antituberculosis medicines was also carried out in 2009 in East European countries and Newly Independent States (NIS); 291 samples were collected and tested by independent laboratories. Among the samples collected and tested, a small percentage of samples (isoniazid, ofloxacin and rifampicin) failed to pass the test. None of the WHO-prequalified products failed to comply with specifications.\n\nThe Expert Committee reconfirmed that results obtained with screening tests should always be treated with caution and only be used for qualitative and semiquantitative testing. The results of this survey have again demonstrated that in situations requiring regulatory or forensic decisions, laboratory quality control testing should always be applied.\n\nThe Expert Committee acknowledged with satisfaction the work done by the Prequalification of Medicines Programme, in particular the WHO quality monitoring project, and advised the Programme to publish the results of the survey and use the publication to promote awareness among countries. It was noted that when the report was ready the Expert Committee members would be provided with copies. The Committee was pleased to note that", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Calidad de Medicamentos Antimal\u00e1ricos**: Se realiz\u00f3 una encuesta sobre la calidad de antimal\u00e1ricos, donde se analizaron 306 muestras, de las cuales el 28.5% no cumpli\u00f3 con las especificaciones. Se observ\u00f3 una diferencia significativa en la tasa de fallos entre productos precalificados por la OMS y aquellos que no lo estaban.\n\n2. **Comparaci\u00f3n de M\u00e9todos de Prueba**: Se compararon los resultados de pruebas de laboratorio con m\u00e9todos de cribado, encontrando que el m\u00e9todo de cribado ten\u00eda una sensibilidad considerablemente menor para detectar incumplimientos en las pruebas de disoluci\u00f3n y en el an\u00e1lisis de sustancias relacionadas.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos reafirm\u00f3 la importancia de utilizar pruebas de control de calidad de laboratorio en situaciones que requieren decisiones regulatorias o forenses, y recomend\u00f3 la publicaci\u00f3n de los resultados de la encuesta para aumentar la conciencia sobre la calidad de los medicamentos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1l fue la tasa de incumplimiento de las muestras de antimal\u00e1ricos en la encuesta realizada por la OMS y qu\u00e9 implicaciones tiene esto para la salud p\u00fablica?**\n   - La tasa de incumplimiento fue del 28.5%, lo que indica un problema significativo con la calidad de los antimal\u00e1ricos en los canales de distribuci\u00f3n, aunque no se puede relacionar directamente con un riesgo para la salud de los pacientes.\n\n2. **\u00bfQu\u00e9 diferencias se encontraron entre los productos prequalificados por la OMS y los no prequalificados en t\u00e9rminos de calidad?**\n   - Los productos no prequalificados tuvieron una tasa de fallos m\u00e1s de 10 veces mayor que los productos prequalificados por la OMS, lo que demuestra que la precalificaci\u00f3n est\u00e1 asociada con un menor riesgo de calidad.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a los m\u00e9todos de prueba y la publicaci\u00f3n de resultados?**\n   - El Comit\u00e9 recomend\u00f3 tratar los resultados de las pruebas de cribado con cautela y utilizar pruebas de control de calidad de laboratorio para decisiones regulatorias. Tambi\u00e9n aconsej\u00f3 publicar los resultados de la encuesta para aumentar la conciencia en los pa\u00edses sobre la calidad de los medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**:\n   - **Objetivo**: Evaluar y certificar la calidad de productos farmac\u00e9uticos para su uso en programas de salud p\u00fablica.\n   - **Resultados**: Hasta la fecha, se han precalificado 39 medicamentos, de los cuales tres son fabricados en \u00c1frica (Sud\u00e1frica, Uganda y Zimbabue).\n   - **Actividades**: Incluye evaluaci\u00f3n de expedientes, inspecci\u00f3n de fabricantes, sitios de ensayos cl\u00ednicos y laboratorios para asegurar el cumplimiento de buenas pr\u00e1cticas.\n\n2. **Capacitaci\u00f3n y Asistencia T\u00e9cnica**:\n   - **Enfoque**: Fortalecimiento de las capacidades de las Autoridades Reguladoras Nacionales de Medicamentos (NMRA) mediante seminarios de capacitaci\u00f3n y asistencia t\u00e9cnica.\n\n3. **Encuestas de Calidad de Antimal\u00e1ricos (QAMSA)**:\n   - **Contexto**: Realizadas en seis pa\u00edses africanos entre 2008 y 2009.\n   - **Metodolog\u00eda**: Recolecci\u00f3n de muestras de medicamentos antimal\u00e1ricos de diferentes niveles de la cadena de suministro, tanto del sector p\u00fablico como privado, as\u00ed como del mercado informal.\n   - **Resultados**: Se recolectaron 935 muestras, de las cuales 306 fueron seleccionadas para pruebas de control de calidad en laboratorios precalificados por la OMS y en el laboratorio de la Farmacopea de los Estados Unidos (USP).\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable del Programa de Precalificaci\u00f3n de Medicamentos.\n- **NMRA (Autoridades Reguladoras Nacionales de Medicamentos)**: Entidades que se benefician de la capacitaci\u00f3n y asistencia t\u00e9cnica del programa.\n- **Laboratorios Precalificados**: Laboratorios que cumplen con los est\u00e1ndares de calidad establecidos por la OMS para realizar pruebas de control de calidad.\n\nEste resumen destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos de la OMS en la mejora de la calidad de los medicamentos, as\u00ed como sus esfuerzos en la capacitaci\u00f3n de las autoridades reguladoras y la realizaci\u00f3n de encuestas de calidad en el contexto de la lucha contra la malaria.", "excerpt_keywords": "Keywords: antimalarials, quality testing, WHO prequalification, noncompliance, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b8b39cd2-537d-41bb-9b8e-db31a27218f0", "node_type": "4", "metadata": {"page_label": "52", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Testing was coordinated by WHO and specifications of *The International Pharmacopoeia* or USP were used.\n\nDuring the survey, data were collected that made it possible to relate the results of quality testing to distribution levels, geographical regions, domestic production or import, registration status and prequalification status.\n\nOf 306 samples selected for laboratory testing, 267 were fully tested and 28.5% of them failed to comply with specifications. Although noncompliance with pre-established criteria cannot be directly related to a risk for patients' health, such a high failure rate indicates a substantial problem with the quality of antimalarials present in distribution channels.\n\nComparison of results obtained during laboratory testing with the screening method indicated a substantially lower sensitivity of the latter to detect noncompliance in dissolution and in assay/related substances test (15% and 42% detected, respectively).\n\nThe difference between WHO-prequalified and non-WHO-prequalified products was striking. The failure rate of samples of non-prequalified co-packed samples was more than 10 times higher than that of samples of WHO-prequalified co-packed samples. In total three failures were identified. Two were not critical for patients\u2019 health and the third had a content of one API that was 8% below the acceptance limit. This demonstrates that medicines for which quality was confirmed by WHO prequalification have a much lower quality risk than do non-prequalified products.\n\nAnother quality survey of antituberculosis medicines was also carried out in 2009 in East European countries and Newly Independent States (NIS); 291 samples were collected and tested by independent laboratories. Among the samples collected and tested, a small percentage of samples (isoniazid, ofloxacin and rifampicin) failed to pass the test. None of the WHO-prequalified products failed to comply with specifications.\n\nThe Expert Committee reconfirmed that results obtained with screening tests should always be treated with caution and only be used for qualitative and semiquantitative testing. The results of this survey have again demonstrated that in situations requiring regulatory or forensic decisions, laboratory quality control testing should always be applied.\n\nThe Expert Committee acknowledged with satisfaction the work done by the Prequalification of Medicines Programme, in particular the WHO quality monitoring project, and advised the Programme to publish the results of the survey and use the publication to promote awareness among countries. It was noted that when the report was ready the Expert Committee members would be provided with copies. The Committee was pleased to note that", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7e2faa0c8d547295bd2fa5a599850c8837bb231d00a77503dc3dabf00c8faaf9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Testing was coordinated by WHO and specifications of *The International Pharmacopoeia* or USP were used.\n\nDuring the survey, data were collected that made it possible to relate the results of quality testing to distribution levels, geographical regions, domestic production or import, registration status and prequalification status.\n\nOf 306 samples selected for laboratory testing, 267 were fully tested and 28.5% of them failed to comply with specifications. Although noncompliance with pre-established criteria cannot be directly related to a risk for patients' health, such a high failure rate indicates a substantial problem with the quality of antimalarials present in distribution channels.\n\nComparison of results obtained during laboratory testing with the screening method indicated a substantially lower sensitivity of the latter to detect noncompliance in dissolution and in assay/related substances test (15% and 42% detected, respectively).\n\nThe difference between WHO-prequalified and non-WHO-prequalified products was striking. The failure rate of samples of non-prequalified co-packed samples was more than 10 times higher than that of samples of WHO-prequalified co-packed samples. In total three failures were identified. Two were not critical for patients\u2019 health and the third had a content of one API that was 8% below the acceptance limit. This demonstrates that medicines for which quality was confirmed by WHO prequalification have a much lower quality risk than do non-prequalified products.\n\nAnother quality survey of antituberculosis medicines was also carried out in 2009 in East European countries and Newly Independent States (NIS); 291 samples were collected and tested by independent laboratories. Among the samples collected and tested, a small percentage of samples (isoniazid, ofloxacin and rifampicin) failed to pass the test. None of the WHO-prequalified products failed to comply with specifications.\n\nThe Expert Committee reconfirmed that results obtained with screening tests should always be treated with caution and only be used for qualitative and semiquantitative testing. The results of this survey have again demonstrated that in situations requiring regulatory or forensic decisions, laboratory quality control testing should always be applied.\n\nThe Expert Committee acknowledged with satisfaction the work done by the Prequalification of Medicines Programme, in particular the WHO quality monitoring project, and advised the Programme to publish the results of the survey and use the publication to promote awareness among countries. It was noted that when the report was ready the Expert Committee members would be provided with copies. The Committee was pleased to note that", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2724, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa44765-a1ed-461b-9a17-ff548e3dbbc8": {"__data__": {"id_": "5fa44765-a1ed-461b-9a17-ff548e3dbbc8", "embedding": null, "metadata": {"page_label": "53", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the detailed conclusions of the report would be published and put on the Prequalification of Medicines Programme web site. The Committee took note that the failure of prequalified products, in the above-reported studies on the antimalarial and tuberculosis medicines, was much less than for non-prequalified products, which is an important indicator for the work of the Prequalification of Medicines Programme.\n\n### 10.2 Procedure for prequalification of pharmaceutical products\n\nFollowing the update, the Manager of the Prequalification of Medicines Programme briefed the Expert Committee on the proposed modifications to the existing procedure for prequalification. Following discussion, the Committee adopted the document as recommended (Annex 10), provided no major comments were received during the remaining consultation period and with the understanding that WHO\u2019s Legal Counsel would be consulted during this update process.\n\n### 10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities\n\nWHO recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. A proposal was, therefore, presented to facilitate the submission of documentation to the Prequalification of Medicines Programme for those products approved by such authorities. This proposal would be applicable where an applicant and a stringent regulatory authority (SRA) can agree to share information on an innovator FPP with WHO. WHO will then consider such an FPP for inclusion in the list of WHO-prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe guide summarizing this proposal was discussed. A definition of SRAs and stability conditions prevailing in hot and humid countries are specially included in this document. A comment was made regarding the possible expansion of NMRAs beyond SRA, i.e. ICH and associated members.\n\nThe Expert Committee adopted the guide as amended (Annex 11).\n\n## 11. Prequalification of quality control laboratories\n\n### 11.1 Update of activities\n\nThe Prequalification of Quality Control Laboratories Programme was established in 2004 for quality control laboratories in Africa. It is a voluntary", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Precalificaci\u00f3n de Medicamentos**: El informe destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos de la OMS, se\u00f1alando que los productos precalificados tienen una tasa de fallos significativamente menor en estudios sobre medicamentos antipal\u00fadicos y antituberculosos en comparaci\u00f3n con los productos no precalificados.\n\n2. **Modificaciones al Procedimiento de Precalificaci\u00f3n**: Se discuten modificaciones propuestas al procedimiento existente para la precalificaci\u00f3n de productos farmac\u00e9uticos, que fueron adoptadas por el Comit\u00e9, sujeto a la consulta con el Asesor Legal de la OMS.\n\n3. **Gu\u00eda para la Documentaci\u00f3n de Productos Innovadores**: Se presenta una gu\u00eda para facilitar la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas, con el objetivo de incluir estos productos en la lista de productos precalificados por la OMS.\n\n4. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad**: Se menciona la creaci\u00f3n del Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad en 2004, destinado a laboratorios en \u00c1frica, como un esfuerzo voluntario para asegurar la calidad en el control de medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los indicadores clave que demuestran la efectividad del Programa de Precalificaci\u00f3n de Medicamentos de la OMS en comparaci\u00f3n con productos no precalificados?**\n   - Respuesta: La tasa de fallos de los productos precalificados en estudios sobre medicamentos antipal\u00fadicos y antituberculosos es significativamente menor que la de los productos no precalificados, lo que indica una mayor efectividad y confiabilidad de los productos precalificados.\n\n2. **\u00bfQu\u00e9 modificaciones espec\u00edficas se propusieron al procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos y cu\u00e1l es el proceso para su adopci\u00f3n final?**\n   - Respuesta: Se propusieron modificaciones al procedimiento existente, que fueron adoptadas por el Comit\u00e9, siempre que no se recibieran comentarios importantes durante el per\u00edodo de consulta restante y con la condici\u00f3n de que se consultara a la Asesor\u00eda Legal de la OMS durante el proceso de actualizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 criterios se establecen en la gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos innovadores aprobados por autoridades regulatorias estrictas?**\n   - Respuesta: La gu\u00eda establece que se facilitar\u00e1 la presentaci\u00f3n de documentaci\u00f3n para productos aprobados por autoridades regulatorias estrictas, siempre que el solicitante y la autoridad puedan acordar compartir informaci\u00f3n con la OMS, y se incluyen definiciones de autoridades regulatorias estrictas (SRA) y condiciones de estabilidad en pa\u00edses c\u00e1lidos y h\u00famedos.", "prev_section_summary": "### Temas Clave:\n\n1. **Calidad de Medicamentos Antimal\u00e1ricos**: Se realiz\u00f3 una encuesta sobre la calidad de antimal\u00e1ricos, donde se analizaron 306 muestras. De estas, el 28.5% no cumpli\u00f3 con las especificaciones, lo que indica un problema significativo en la calidad de los medicamentos en los canales de distribuci\u00f3n.\n\n2. **Comparaci\u00f3n de M\u00e9todos de Prueba**: Se observ\u00f3 que los m\u00e9todos de cribado tienen una sensibilidad considerablemente menor para detectar incumplimientos en pruebas de disoluci\u00f3n y an\u00e1lisis de sustancias relacionadas, con tasas de detecci\u00f3n del 15% y 42%, respectivamente.\n\n3. **Diferencias entre Productos Precalificados y No Precalificados**: Los productos no precalificados por la OMS presentaron una tasa de fallos m\u00e1s de 10 veces mayor que los productos precalificados, lo que resalta la importancia de la precalificaci\u00f3n en la reducci\u00f3n del riesgo de calidad.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 enfatiz\u00f3 la necesidad de utilizar pruebas de control de calidad de laboratorio en decisiones regulatorias y forenses, y recomend\u00f3 la publicaci\u00f3n de los resultados de la encuesta para aumentar la conciencia sobre la calidad de los medicamentos.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Coordin\u00f3 las pruebas y supervis\u00f3 la calidad de los medicamentos.\n- **The International Pharmacopoeia**: Se utilizaron sus especificaciones para las pruebas de calidad.\n- **Medicamentos Antimal\u00e1ricos**: El foco principal de la encuesta.\n- **Medicamentos Antituberculosis**: Se mencion\u00f3 una encuesta adicional realizada en 2009 en Europa del Este y Estados Independientes Nuevos (NIS).\n- **Comit\u00e9 de Expertos**: Grupo que revis\u00f3 y recomend\u00f3 acciones basadas en los resultados de la encuesta.\n\nEste resumen destaca los problemas de calidad en los medicamentos antimal\u00e1ricos, la efectividad de los m\u00e9todos de prueba, la importancia de la precalificaci\u00f3n y las recomendaciones para mejorar la regulaci\u00f3n y la conciencia sobre la calidad de los medicamentos.", "excerpt_keywords": "Keywords: Prequalification, Pharmaceuticals, Quality Control, Regulatory Authorities, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21c057ff-80f0-4c74-970b-85efb1b45776", "node_type": "4", "metadata": {"page_label": "53", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the detailed conclusions of the report would be published and put on the Prequalification of Medicines Programme web site. The Committee took note that the failure of prequalified products, in the above-reported studies on the antimalarial and tuberculosis medicines, was much less than for non-prequalified products, which is an important indicator for the work of the Prequalification of Medicines Programme.\n\n### 10.2 Procedure for prequalification of pharmaceutical products\n\nFollowing the update, the Manager of the Prequalification of Medicines Programme briefed the Expert Committee on the proposed modifications to the existing procedure for prequalification. Following discussion, the Committee adopted the document as recommended (Annex 10), provided no major comments were received during the remaining consultation period and with the understanding that WHO\u2019s Legal Counsel would be consulted during this update process.\n\n### 10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities\n\nWHO recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. A proposal was, therefore, presented to facilitate the submission of documentation to the Prequalification of Medicines Programme for those products approved by such authorities. This proposal would be applicable where an applicant and a stringent regulatory authority (SRA) can agree to share information on an innovator FPP with WHO. WHO will then consider such an FPP for inclusion in the list of WHO-prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe guide summarizing this proposal was discussed. A definition of SRAs and stability conditions prevailing in hot and humid countries are specially included in this document. A comment was made regarding the possible expansion of NMRAs beyond SRA, i.e. ICH and associated members.\n\nThe Expert Committee adopted the guide as amended (Annex 11).\n\n## 11. Prequalification of quality control laboratories\n\n### 11.1 Update of activities\n\nThe Prequalification of Quality Control Laboratories Programme was established in 2004 for quality control laboratories in Africa. It is a voluntary", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "923db9bcb9f81ec77861a88ee621bf6bea193e84e2bd81640aff07b5f8501b91", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the detailed conclusions of the report would be published and put on the Prequalification of Medicines Programme web site. The Committee took note that the failure of prequalified products, in the above-reported studies on the antimalarial and tuberculosis medicines, was much less than for non-prequalified products, which is an important indicator for the work of the Prequalification of Medicines Programme.\n\n### 10.2 Procedure for prequalification of pharmaceutical products\n\nFollowing the update, the Manager of the Prequalification of Medicines Programme briefed the Expert Committee on the proposed modifications to the existing procedure for prequalification. Following discussion, the Committee adopted the document as recommended (Annex 10), provided no major comments were received during the remaining consultation period and with the understanding that WHO\u2019s Legal Counsel would be consulted during this update process.\n\n### 10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities\n\nWHO recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. A proposal was, therefore, presented to facilitate the submission of documentation to the Prequalification of Medicines Programme for those products approved by such authorities. This proposal would be applicable where an applicant and a stringent regulatory authority (SRA) can agree to share information on an innovator FPP with WHO. WHO will then consider such an FPP for inclusion in the list of WHO-prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe guide summarizing this proposal was discussed. A definition of SRAs and stability conditions prevailing in hot and humid countries are specially included in this document. A comment was made regarding the possible expansion of NMRAs beyond SRA, i.e. ICH and associated members.\n\nThe Expert Committee adopted the guide as amended (Annex 11).\n\n## 11. Prequalification of quality control laboratories\n\n### 11.1 Update of activities\n\nThe Prequalification of Quality Control Laboratories Programme was established in 2004 for quality control laboratories in Africa. It is a voluntary", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2505, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5be04e97-dd90-42e6-8f48-fed6c01cefe3": {"__data__": {"id_": "5be04e97-dd90-42e6-8f48-fed6c01cefe3", "embedding": null, "metadata": {"page_label": "54", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda rodear el documento:\n\n### Resumen del Contexto\nEl documento mencionado es parte de la Serie de Informes T\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el Informe 961. Esta serie se centra en la investigaci\u00f3n y las recomendaciones sobre temas de salud p\u00fablica, pol\u00edticas de salud, y pr\u00e1cticas m\u00e9dicas. Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, es probable que aborde temas relevantes para la salud global, la prevenci\u00f3n de enfermedades, y el desarrollo de pol\u00edticas sanitarias.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe 961 sobre la prevenci\u00f3n de enfermedades infecciosas?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS podr\u00eda haber emitido en este informe en particular.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas de investigaci\u00f3n se discuten en el Informe 961 para evaluar la efectividad de las intervenciones de salud p\u00fablica?**\n   - Esta pregunta se centra en las t\u00e9cnicas o enfoques que la OMS podr\u00eda haber utilizado o recomendado para medir el impacto de las pol\u00edticas de salud.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 961 con otros informes anteriores de la OMS en t\u00e9rminos de evoluci\u00f3n de las pol\u00edticas de salud global?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda proporcionar una visi\u00f3n sobre c\u00f3mo han cambiado las recomendaciones y enfoques a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, y que son relevantes para el contexto de salud p\u00fablica abordado por la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**:\n   - Importancia del programa en la reducci\u00f3n de la tasa de fallos de productos precalificados en comparaci\u00f3n con productos no precalificados, especialmente en medicamentos antipal\u00fadicos y antituberculosos.\n\n2. **Modificaciones al Procedimiento de Precalificaci\u00f3n**:\n   - Se discutieron y adoptaron modificaciones al procedimiento existente para la precalificaci\u00f3n de productos farmac\u00e9uticos, con la condici\u00f3n de que no se recibieran comentarios significativos durante el per\u00edodo de consulta y que se consultara a la Asesor\u00eda Legal de la OMS.\n\n3. **Gu\u00eda para la Documentaci\u00f3n de Productos Innovadores**:\n   - Se present\u00f3 una gu\u00eda para facilitar la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas (SRA). Esta gu\u00eda incluye definiciones de SRA y condiciones de estabilidad en climas c\u00e1lidos y h\u00famedos.\n\n4. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad**:\n   - Establecido en 2004, este programa se centra en laboratorios de control de calidad en \u00c1frica y es un esfuerzo voluntario para asegurar la calidad en el control de medicamentos.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Responsable de la implementaci\u00f3n y supervisi\u00f3n del Programa de Precalificaci\u00f3n de Medicamentos y de la gu\u00eda para la documentaci\u00f3n de productos innovadores.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y adopta modificaciones y gu\u00edas relacionadas con la precalificaci\u00f3n de medicamentos.\n- **Autoridades Regulatorias Estrictas (SRA)**: Entidades que eval\u00faan productos farmac\u00e9uticos bajo est\u00e1ndares rigurosos de calidad, seguridad y eficacia.\n- **Laboratorios de Control de Calidad**: Instituciones que participan en el Programa de Precalificaci\u00f3n para asegurar la calidad de los medicamentos en \u00c1frica.", "excerpt_keywords": "Keywords: OMS, precalificaci\u00f3n, medicamentos, salud p\u00fablica, pol\u00edticas sanitarias"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "354bc02a-4e1c-47f3-a7f9-1a7434b7b944", "node_type": "4", "metadata": {"page_label": "54", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf14604-33db-4c89-82aa-9608279f1a21": {"__data__": {"id_": "6cf14604-33db-4c89-82aa-9608279f1a21", "embedding": null, "metadata": {"page_label": "55", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Update on WHO Guidelines\n\npharmaceutical products also led to the need for some amendments of the procedure for prequalification of quality control laboratories.\n\nThe first draft revision of the procedure was mailed out for comments in March 2010 and discussed during the informal consultation held on 10\u201312 May 2010. Based on this discussion the second draft was prepared and submitted to the WHO Legal Counsel for comments. The comments of the WHO Legal Counsel were implemented in this third draft revision.\n\nOn the basis of the above, the revised text is proposed to replace the previously published procedure.\n\nThe discussion focused on the cooperation with other authorities doing audits. The proposal includes rules for prioritization of laboratories applying for prequalification and rules for monitoring of laboratories after prequalification.\n\nIt was suggested to include United Nations agencies in the appropriate paragraphs of the revised procedure.\n\nThe new procedure was adopted including the changes proposed and discussed (Annex 12).\n\n## 11.3 Update on the WHO guidelines for preparing a laboratory information file\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to the *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have been recently revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both guidelines at its forty-third meeting in 2008 and recommended that if the WHO guidelines on *Good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above the revised text is proposed to replace the previously published guidelines. It was presented in track-change mode in order to show the changes that had been made.\n\nThe Expert Committee adopted the revised guidelines as proposed (Annex 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona una actualizaci\u00f3n sobre las directrices de la OMS relacionadas con la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se menciona la revisi\u00f3n de procedimientos y directrices, incluyendo la cooperaci\u00f3n con otras autoridades y la inclusi\u00f3n de agencias de las Naciones Unidas. Tambi\u00e9n se discute la necesidad de revisar las directrices sobre buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y c\u00f3mo estas revisiones est\u00e1n interrelacionadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales modificaciones propuestas en el procedimiento de precalificaci\u00f3n de laboratorios de control de calidad seg\u00fan la discusi\u00f3n de mayo de 2010?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las modificaciones discutidas y adoptadas en el nuevo procedimiento.\n\n2. **\u00bfQu\u00e9 relaci\u00f3n existe entre las *Guidelines for preparing a laboratory information file* y las *WHO guidelines on good practices for pharmaceutical quality control laboratories*?**\n   - Esta pregunta se centra en la conexi\u00f3n entre las dos directrices y c\u00f3mo se influencian mutuamente.\n\n3. **\u00bfQu\u00e9 recomendaciones se hicieron en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2008 respecto a la revisi\u00f3n de las directrices de preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio?**\n   - Esta pregunta busca informaci\u00f3n sobre las recomendaciones espec\u00edficas que llevaron a la revisi\u00f3n de las directrices.\n\n### Resumen de Nivel Superior\n\nEl documento detalla las actualizaciones en las directrices de la OMS para la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se discuten las revisiones necesarias y la cooperaci\u00f3n con otras autoridades, as\u00ed como la adopci\u00f3n de nuevas directrices que reflejan cambios en el enfoque de la OMS hacia la calidad en el control farmac\u00e9utico.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Documento:** WHO - Technical Report Series 961  \n**Tipo de Documento:** Informe T\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS)  \n**Contenido General:** Aunque el contenido espec\u00edfico no est\u00e1 disponible, se infiere que el informe aborda temas relacionados con la salud p\u00fablica, pol\u00edticas de salud y pr\u00e1cticas m\u00e9dicas. \n\n#### Temas Clave:\n1. **Prevenci\u00f3n de Enfermedades:** Posibles recomendaciones y directrices de la OMS sobre c\u00f3mo prevenir enfermedades infecciosas.\n2. **Investigaci\u00f3n en Salud P\u00fablica:** Metodolog\u00edas para evaluar la efectividad de intervenciones en salud p\u00fablica.\n3. **Evoluci\u00f3n de Pol\u00edticas de Salud:** Comparaci\u00f3n y conexi\u00f3n con informes anteriores de la OMS, analizando c\u00f3mo han cambiado las recomendaciones a lo largo del tiempo.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico (Informe 961):** Parte de la serie de informes que aborda temas de salud global.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en el contexto del Informe 961 de la OMS, destacando su enfoque en la salud p\u00fablica y la prevenci\u00f3n de enfermedades.", "excerpt_keywords": "Keywords: WHO guidelines, laboratory prequalification, quality control, pharmaceutical preparations, good practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "029fdbe0-b0dc-48e2-9ad5-1d5882355445", "node_type": "4", "metadata": {"page_label": "55", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Update on WHO Guidelines\n\npharmaceutical products also led to the need for some amendments of the procedure for prequalification of quality control laboratories.\n\nThe first draft revision of the procedure was mailed out for comments in March 2010 and discussed during the informal consultation held on 10\u201312 May 2010. Based on this discussion the second draft was prepared and submitted to the WHO Legal Counsel for comments. The comments of the WHO Legal Counsel were implemented in this third draft revision.\n\nOn the basis of the above, the revised text is proposed to replace the previously published procedure.\n\nThe discussion focused on the cooperation with other authorities doing audits. The proposal includes rules for prioritization of laboratories applying for prequalification and rules for monitoring of laboratories after prequalification.\n\nIt was suggested to include United Nations agencies in the appropriate paragraphs of the revised procedure.\n\nThe new procedure was adopted including the changes proposed and discussed (Annex 12).\n\n## 11.3 Update on the WHO guidelines for preparing a laboratory information file\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to the *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have been recently revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both guidelines at its forty-third meeting in 2008 and recommended that if the WHO guidelines on *Good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above the revised text is proposed to replace the previously published guidelines. It was presented in track-change mode in order to show the changes that had been made.\n\nThe Expert Committee adopted the revised guidelines as proposed (Annex 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c2fc2291709bf7f32402ee1dcc60119c6a081b65dc2738068f429dca082e9a98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Update on WHO Guidelines\n\npharmaceutical products also led to the need for some amendments of the procedure for prequalification of quality control laboratories.\n\nThe first draft revision of the procedure was mailed out for comments in March 2010 and discussed during the informal consultation held on 10\u201312 May 2010. Based on this discussion the second draft was prepared and submitted to the WHO Legal Counsel for comments. The comments of the WHO Legal Counsel were implemented in this third draft revision.\n\nOn the basis of the above, the revised text is proposed to replace the previously published procedure.\n\nThe discussion focused on the cooperation with other authorities doing audits. The proposal includes rules for prioritization of laboratories applying for prequalification and rules for monitoring of laboratories after prequalification.\n\nIt was suggested to include United Nations agencies in the appropriate paragraphs of the revised procedure.\n\nThe new procedure was adopted including the changes proposed and discussed (Annex 12).\n\n## 11.3 Update on the WHO guidelines for preparing a laboratory information file\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to the *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have been recently revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both guidelines at its forty-third meeting in 2008 and recommended that if the WHO guidelines on *Good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above the revised text is proposed to replace the previously published guidelines. It was presented in track-change mode in order to show the changes that had been made.\n\nThe Expert Committee adopted the revised guidelines as proposed (Annex 13).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2294, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c3bb808f-8705-42da-b258-e8d8e8818aa4": {"__data__": {"id_": "c3bb808f-8705-42da-b258-e8d8e8818aa4", "embedding": null, "metadata": {"page_label": "56", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Prequalification of active pharmaceutical ingredients\n\nThe Manager of the WHO Prequalification of Medicines Programme provided an update on the Programme and the prequalification of active pharmaceutical ingredients (APIs).\n\nThe Programme facilitates access to quality medicines through assessment of products and inspection of manufacturing sites. Since good-quality APIs are vital to the production of good-quality medicines, and in response to requests from Member States, the Programme has started a pilot project to prequalify APIs. Details of the pilot project are posted on the Prequalification of Medicines Programme web site.\n\nThe API prequalification procedure, which will guide this process, was adopted by the Expert Committee in 2008 and is published as Annex 4 in the WHO Technical Report Series, No. 953, Annex 4.\n\nPrequalification of APIs consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements. Prequalification of an API is done with specific reference to the manufacturing details and quality controls described in the APIMF submitted for assessment.\n\nWHO-prequalified APIs are listed on the WHO List of prequalified active pharmaceutical ingredients. The list provides United Nations agencies, NMRAs and others with information on APIs that have been found to meet WHO-recommended quality standards. It is believed that identification of sources of good-quality APIs will facilitate the manufacture of good-quality FPPs needed for procurement by United Nations agencies and disease treatment programmes.\n\nThe Expert Committee noted with appreciation these new developments.\n\n# 13. Regulatory guidance\n\n## 13.1 WHO guidelines for preparing a site master file\n\nThe Committee was informed about the current style used in the WHO Prequalification of Medicines Programme for the submission of a site master file (SMF) and its intent to review it through the Expert Committee and the related consultation process. The SMF has been in place for a number of years within the context of the inspections carried out in the Prequalification of Medicines Programme. When the document including the SMF was circulated globally, numerous comments were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs)**: La OMS ha iniciado un proyecto piloto para la precalificaci\u00f3n de APIs, que es esencial para garantizar la calidad de los medicamentos. Este proceso incluye la evaluaci\u00f3n de archivos maestros de APIs y la inspecci\u00f3n de los sitios de fabricaci\u00f3n para asegurar el cumplimiento de las normas y est\u00e1ndares de la OMS.\n\n2. **Gu\u00edas Regulatorias de la OMS**: La OMS est\u00e1 revisando las directrices para la preparaci\u00f3n de un archivo maestro del sitio (SMF) en el contexto de su Programa de Precalificaci\u00f3n de Medicamentos. Este documento ha sido utilizado durante varios a\u00f1os y ha recibido comentarios globales para su mejora.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los dos componentes principales del procedimiento de precalificaci\u00f3n de APIs seg\u00fan la OMS?**\n   - Respuesta: Los dos componentes principales son la evaluaci\u00f3n del archivo maestro de API (APIMF) para verificar el cumplimiento con las normas y est\u00e1ndares de la OMS, y la evaluaci\u00f3n de los sitios de fabricaci\u00f3n de API para verificar el cumplimiento con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n proporciona la lista de APIs precalificadas por la OMS a las agencias de la ONU y a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs)?**\n   - Respuesta: La lista proporciona informaci\u00f3n sobre los APIs que han sido encontrados en cumplimiento con los est\u00e1ndares de calidad recomendados por la OMS, facilitando as\u00ed la identificaci\u00f3n de fuentes de APIs de buena calidad para la fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs).\n\n3. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en el archivo maestro del sitio (SMF) y por qu\u00e9?**\n   - Respuesta: Se est\u00e1 considerando una revisi\u00f3n del estilo actual del SMF utilizado en el Programa de Precalificaci\u00f3n de Medicamentos de la OMS, debido a los numerosos comentarios recibidos globalmente tras la circulaci\u00f3n del documento. Esto busca mejorar la claridad y efectividad del SMF en el contexto de las inspecciones.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Procedimientos de Precalificaci\u00f3n**: Se discuten enmiendas al procedimiento de precalificaci\u00f3n de laboratorios de control de calidad, incluyendo la priorizaci\u00f3n de solicitudes y el monitoreo post-precalificaci\u00f3n.\n\n2. **Cooperaci\u00f3n con Otras Autoridades**: Se enfatiza la importancia de colaborar con otras autoridades que realizan auditor\u00edas, as\u00ed como la inclusi\u00f3n de agencias de las Naciones Unidas en el procedimiento revisado.\n\n3. **Actualizaci\u00f3n de Directrices**: Se presenta una actualizaci\u00f3n sobre las *Guidelines for preparing a laboratory information file* y su relaci\u00f3n con las *WHO guidelines on good practices for pharmaceutical quality control laboratories*.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: En 2008, se recomend\u00f3 la revisi\u00f3n de las directrices de preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio en funci\u00f3n de las revisiones de las directrices sobre buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n y revisi\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopta y revisa las directrices relacionadas con la calidad farmac\u00e9utica.\n- **Agencias de las Naciones Unidas**: Se sugiere su inclusi\u00f3n en el procedimiento revisado para mejorar la cooperaci\u00f3n.\n\n### Resumen General\n\nEl documento aborda las actualizaciones en las directrices de la OMS sobre la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se destacan las revisiones necesarias, la cooperaci\u00f3n con otras autoridades y la adopci\u00f3n de nuevas directrices que reflejan un enfoque renovado hacia la calidad en el control farmac\u00e9utico.", "excerpt_keywords": "Keywords: prequalification, active pharmaceutical ingredients, WHO guidelines, site master file, quality standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "578a1f9a-5c3a-4f83-9bd3-cecea869edc2", "node_type": "4", "metadata": {"page_label": "56", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Prequalification of active pharmaceutical ingredients\n\nThe Manager of the WHO Prequalification of Medicines Programme provided an update on the Programme and the prequalification of active pharmaceutical ingredients (APIs).\n\nThe Programme facilitates access to quality medicines through assessment of products and inspection of manufacturing sites. Since good-quality APIs are vital to the production of good-quality medicines, and in response to requests from Member States, the Programme has started a pilot project to prequalify APIs. Details of the pilot project are posted on the Prequalification of Medicines Programme web site.\n\nThe API prequalification procedure, which will guide this process, was adopted by the Expert Committee in 2008 and is published as Annex 4 in the WHO Technical Report Series, No. 953, Annex 4.\n\nPrequalification of APIs consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements. Prequalification of an API is done with specific reference to the manufacturing details and quality controls described in the APIMF submitted for assessment.\n\nWHO-prequalified APIs are listed on the WHO List of prequalified active pharmaceutical ingredients. The list provides United Nations agencies, NMRAs and others with information on APIs that have been found to meet WHO-recommended quality standards. It is believed that identification of sources of good-quality APIs will facilitate the manufacture of good-quality FPPs needed for procurement by United Nations agencies and disease treatment programmes.\n\nThe Expert Committee noted with appreciation these new developments.\n\n# 13. Regulatory guidance\n\n## 13.1 WHO guidelines for preparing a site master file\n\nThe Committee was informed about the current style used in the WHO Prequalification of Medicines Programme for the submission of a site master file (SMF) and its intent to review it through the Expert Committee and the related consultation process. The SMF has been in place for a number of years within the context of the inspections carried out in the Prequalification of Medicines Programme. When the document including the SMF was circulated globally, numerous comments were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f40fe22f487da8045dc46af3cd20f047fb013e73317fa40a6b2240bfe7708970", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12. Prequalification of active pharmaceutical ingredients\n\nThe Manager of the WHO Prequalification of Medicines Programme provided an update on the Programme and the prequalification of active pharmaceutical ingredients (APIs).\n\nThe Programme facilitates access to quality medicines through assessment of products and inspection of manufacturing sites. Since good-quality APIs are vital to the production of good-quality medicines, and in response to requests from Member States, the Programme has started a pilot project to prequalify APIs. Details of the pilot project are posted on the Prequalification of Medicines Programme web site.\n\nThe API prequalification procedure, which will guide this process, was adopted by the Expert Committee in 2008 and is published as Annex 4 in the WHO Technical Report Series, No. 953, Annex 4.\n\nPrequalification of APIs consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements. Prequalification of an API is done with specific reference to the manufacturing details and quality controls described in the APIMF submitted for assessment.\n\nWHO-prequalified APIs are listed on the WHO List of prequalified active pharmaceutical ingredients. The list provides United Nations agencies, NMRAs and others with information on APIs that have been found to meet WHO-recommended quality standards. It is believed that identification of sources of good-quality APIs will facilitate the manufacture of good-quality FPPs needed for procurement by United Nations agencies and disease treatment programmes.\n\nThe Expert Committee noted with appreciation these new developments.\n\n# 13. Regulatory guidance\n\n## 13.1 WHO guidelines for preparing a site master file\n\nThe Committee was informed about the current style used in the WHO Prequalification of Medicines Programme for the submission of a site master file (SMF) and its intent to review it through the Expert Committee and the related consultation process. The SMF has been in place for a number of years within the context of the inspections carried out in the Prequalification of Medicines Programme. When the document including the SMF was circulated globally, numerous comments were received.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2377, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0d72cca8-2cfe-4d80-93d8-44b00852c8fe": {"__data__": {"id_": "0d72cca8-2cfe-4d80-93d8-44b00852c8fe", "embedding": null, "metadata": {"page_label": "57", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Based on the new developments and the comments received, the proposal was made to align the current WHO format with the new PIC/S format which was being finalized. This would address the majority of the comments received and be in line with the intent to harmonize internationally.\n\nThe Expert Committee recommended that the current WHO format used in prequalification be harmonized with the new PIC/S format and adopted the site master file (Annex 14).\n\n### 13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format\n\nThe document was presented to the Expert Committee together with the guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part. It was proposed to create a short document explaining how the two documents fitted together to assist NMRAs and companies in implementing the documents.\n\nThe Expert Committee adopted these guidelines with a view to enhancing exchange of information between NMRAs and also the Prequalification of Medicines Programme (Annex 15).\n\n### 13.3 Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part\n\nThe newly proposed *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* was adapted from the one used in the WHO Prequalification of Medicines Programme with the intent to serve NMRAs wishing to update their generic medicine registration process. It was meant to be used together with the *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): preparation of product dossiers (PDS) in common technical document (CTD) format* (see section 13.2).\n\nThe guidelines were developed with the intent to update and not to increase the requirements. It was considered to be helpful to developing countries wishing to update requirements for generics and would also assist in switching to a CTD format.\n\nNumerous comments were received, reviewed and discussed at the meeting. The ICH Q11 Manufacturing development of drug substances: treatment of starting materials, is expected to reach the deadline for public comment in the near future and should also be considered when further developing this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Harmonizaci\u00f3n de formatos**: Se propone alinear el formato actual de la OMS con el nuevo formato de PIC/S para abordar comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **Gu\u00edas para productos farmac\u00e9uticos multisource**: Se presentan nuevas gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos, con el objetivo de facilitar la actualizaci\u00f3n de los procesos de registro en las Autoridades Reguladoras Nacionales (NMRAs) y mejorar el intercambio de informaci\u00f3n.\n\n3. **Desarrollo de directrices**: Las nuevas directrices est\u00e1n dise\u00f1adas para actualizar los requisitos sin aumentarlos, ayudando especialmente a los pa\u00edses en desarrollo a adoptar un formato t\u00e9cnico com\u00fan (CTD) para la documentaci\u00f3n de productos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de la propuesta de alineaci\u00f3n entre el formato de la OMS y el formato de PIC/S?**\n   - El objetivo principal es abordar la mayor\u00eda de los comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **\u00bfC\u00f3mo se espera que las nuevas gu\u00edas sobre la presentaci\u00f3n de documentaci\u00f3n beneficien a las NMRAs y a las empresas?**\n   - Se espera que las nuevas gu\u00edas faciliten la actualizaci\u00f3n de los procesos de registro de medicamentos gen\u00e9ricos en las NMRAs y mejoren el intercambio de informaci\u00f3n entre estas autoridades y el Programa de Precalificaci\u00f3n de Medicamentos.\n\n3. **\u00bfQu\u00e9 se considera al desarrollar las nuevas directrices para productos farmac\u00e9uticos gen\u00e9ricos?**\n   - Se considera que las directrices est\u00e1n dise\u00f1adas para actualizar los requisitos existentes sin aumentarlos, lo que es especialmente \u00fatil para los pa\u00edses en desarrollo que buscan modernizar sus requisitos para medicamentos gen\u00e9ricos y facilitar la transici\u00f3n a un formato de documento t\u00e9cnico com\u00fan (CTD).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs)**:\n   - La OMS ha iniciado un **proyecto piloto** para la precalificaci\u00f3n de APIs, esencial para asegurar la calidad de los medicamentos.\n   - El proceso incluye la **evaluaci\u00f3n del archivo maestro de API (APIMF)** y la **inspecci\u00f3n de los sitios de fabricaci\u00f3n** para verificar el cumplimiento de las normas y est\u00e1ndares de la OMS.\n   - La **lista de APIs precalificadas** por la OMS proporciona informaci\u00f3n a agencias de la ONU y Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) sobre APIs que cumplen con los est\u00e1ndares de calidad recomendados.\n\n2. **Gu\u00edas Regulatorias de la OMS**:\n   - Se est\u00e1 revisando el **archivo maestro del sitio (SMF)** utilizado en el Programa de Precalificaci\u00f3n de Medicamentos, con el objetivo de mejorar su claridad y efectividad tras recibir numerosos comentarios globales.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la precalificaci\u00f3n de medicamentos y APIs.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que son esenciales para la producci\u00f3n de medicamentos de calidad.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades que regulan y supervisan la calidad de los medicamentos en sus respectivos pa\u00edses.\n- **FPPs (Productos Farmac\u00e9uticos Terminados)**: Medicamentos que se producen a partir de APIs precalificados.\n\nEste resumen destaca la importancia de la precalificaci\u00f3n de APIs y las gu\u00edas regulatorias de la OMS para garantizar el acceso a medicamentos de calidad a nivel global.", "excerpt_keywords": "Keywords: WHO, PIC/S, guidelines, multisource, harmonization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c688a84f-539f-41c4-944a-430f5b7f3294", "node_type": "4", "metadata": {"page_label": "57", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Based on the new developments and the comments received, the proposal was made to align the current WHO format with the new PIC/S format which was being finalized. This would address the majority of the comments received and be in line with the intent to harmonize internationally.\n\nThe Expert Committee recommended that the current WHO format used in prequalification be harmonized with the new PIC/S format and adopted the site master file (Annex 14).\n\n### 13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format\n\nThe document was presented to the Expert Committee together with the guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part. It was proposed to create a short document explaining how the two documents fitted together to assist NMRAs and companies in implementing the documents.\n\nThe Expert Committee adopted these guidelines with a view to enhancing exchange of information between NMRAs and also the Prequalification of Medicines Programme (Annex 15).\n\n### 13.3 Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part\n\nThe newly proposed *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* was adapted from the one used in the WHO Prequalification of Medicines Programme with the intent to serve NMRAs wishing to update their generic medicine registration process. It was meant to be used together with the *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): preparation of product dossiers (PDS) in common technical document (CTD) format* (see section 13.2).\n\nThe guidelines were developed with the intent to update and not to increase the requirements. It was considered to be helpful to developing countries wishing to update requirements for generics and would also assist in switching to a CTD format.\n\nNumerous comments were received, reviewed and discussed at the meeting. The ICH Q11 Manufacturing development of drug substances: treatment of starting materials, is expected to reach the deadline for public comment in the near future and should also be considered when further developing this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "285ae6a371eb5cc2e716928f0335368c5eef91dd3d0ccd31f6294ddf2b6af601", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Based on the new developments and the comments received, the proposal was made to align the current WHO format with the new PIC/S format which was being finalized. This would address the majority of the comments received and be in line with the intent to harmonize internationally.\n\nThe Expert Committee recommended that the current WHO format used in prequalification be harmonized with the new PIC/S format and adopted the site master file (Annex 14).\n\n### 13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format\n\nThe document was presented to the Expert Committee together with the guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part. It was proposed to create a short document explaining how the two documents fitted together to assist NMRAs and companies in implementing the documents.\n\nThe Expert Committee adopted these guidelines with a view to enhancing exchange of information between NMRAs and also the Prequalification of Medicines Programme (Annex 15).\n\n### 13.3 Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part\n\nThe newly proposed *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* was adapted from the one used in the WHO Prequalification of Medicines Programme with the intent to serve NMRAs wishing to update their generic medicine registration process. It was meant to be used together with the *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): preparation of product dossiers (PDS) in common technical document (CTD) format* (see section 13.2).\n\nThe guidelines were developed with the intent to update and not to increase the requirements. It was considered to be helpful to developing countries wishing to update requirements for generics and would also assist in switching to a CTD format.\n\nNumerous comments were received, reviewed and discussed at the meeting. The ICH Q11 Manufacturing development of drug substances: treatment of starting materials, is expected to reach the deadline for public comment in the near future and should also be considered when further developing this document.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2406, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "36d6631b-7702-4c7b-befd-8f39fce6a2c9": {"__data__": {"id_": "36d6631b-7702-4c7b-befd-8f39fce6a2c9", "embedding": null, "metadata": {"page_label": "58", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted that the guidelines were more advanced than the present ones used by a number of Member States.\n\nThe Expert Committee recommended that the document be provisionally adopted and that it should be issued in a pilot phase after consolidation of comments within the Prequalification of Medicines Programme.\n\n### 13.4 Pharmaceutical development for multisource (generic) pharmaceutical products\n\nThe Expert Committee was briefed on the progress regarding the new guidance on pharmaceutical development for multisource (generic) pharmaceutical products. The draft guidance was widely circulated for comments and underwent a major revision during the informal consultation in April 2010; thereafter numerous comments were received. The Expert Committee reviewed the feedback and considered that the comments received would need to be revisited by a group of experts. It was also suggested that the document be reorganized to follow the CTD format in order to bring it in line with the other approaches recommended by the Committee during the present meeting.\n\nThe Expert Committee recommended following the normal procedure, organizing an informal consultation and providing feedback to the next Expert Committee meeting.\n\n### 13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System\n\nThe WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines in Frankfurt, Germany, provided a report with a proposal to update the *Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms* published in 2006, with a view to including the new medicines selected for inclusion in the Model list of Essential Medicines (EML) since 2006.\n\nThe Expert Committee members:\n\n- endorsed the follow-up and continuation of this update;\n- endorsed the efforts to update the list by adding the new EML entries through publication of those that are unambiguously classified in the report;\n- advised that WHO collaborating centres should be contacted and that laboratories collaborating in the development of new monographs for *The International Pharmacopoeia* should collaborate by possibly either undertaking the solubility studies or by providing APIs to the WHO Collaborating Centre in Frankfurt;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas directrices**: El Comit\u00e9 de Expertos recomend\u00f3 la adopci\u00f3n provisional de nuevas directrices que son m\u00e1s avanzadas que las actualmente utilizadas por varios Estados Miembros, sugiriendo que se emita en una fase piloto tras la consolidaci\u00f3n de comentarios.\n\n2. **Desarrollo farmac\u00e9utico para productos farmac\u00e9uticos multisource**: Se discuti\u00f3 el progreso de nuevas orientaciones sobre el desarrollo farmac\u00e9utico de productos gen\u00e9ricos, con la necesidad de revisar los comentarios recibidos y reorganizar el documento seg\u00fan el formato CTD.\n\n3. **Clasificaci\u00f3n de medicamentos en la Lista Modelo de Medicamentos Esenciales de la OMS**: Se present\u00f3 una propuesta para actualizar los requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata, con el objetivo de incluir nuevos medicamentos en la lista desde 2006, y se recomend\u00f3 la colaboraci\u00f3n entre centros y laboratorios para estudios de solubilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 se recomend\u00f3 respecto a la adopci\u00f3n de las nuevas directrices y cu\u00e1l es el siguiente paso propuesto?**\n   - Se recomend\u00f3 que el documento sea adoptado provisionalmente y que se emita en una fase piloto despu\u00e9s de consolidar los comentarios dentro del Programa de Precalificaci\u00f3n de Medicamentos.\n\n2. **\u00bfQu\u00e9 cambios se sugirieron para el documento sobre el desarrollo farmac\u00e9utico de productos multisource y por qu\u00e9?**\n   - Se sugiri\u00f3 reorganizar el documento para seguir el formato CTD, con el fin de alinearlo con otros enfoques recomendados por el Comit\u00e9, tras recibir numerosos comentarios durante la consulta informal.\n\n3. **\u00bfCu\u00e1l fue la propuesta presentada por el Centro Colaborador de la OMS en Frankfurt respecto a la bioequivalencia y qu\u00e9 acciones se recomendaron?**\n   - Se propuso actualizar el documento sobre la exenci\u00f3n de requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales, y se recomend\u00f3 contactar a centros colaboradores y laboratorios para realizar estudios de solubilidad o proporcionar APIs.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Harmonizaci\u00f3n de formatos**:\n   - Se propone alinear el formato actual de la OMS con el nuevo formato de PIC/S, con el objetivo de abordar comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **Gu\u00edas para productos farmac\u00e9uticos multisource**:\n   - Se presentan nuevas gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos (FPP), que buscan facilitar la actualizaci\u00f3n de los procesos de registro en las Autoridades Reguladoras Nacionales (NMRAs) y mejorar el intercambio de informaci\u00f3n entre estas y el Programa de Precalificaci\u00f3n de Medicamentos.\n\n3. **Desarrollo de directrices**:\n   - Las nuevas directrices est\u00e1n dise\u00f1adas para actualizar los requisitos existentes sin aumentarlos, lo que es especialmente \u00fatil para los pa\u00edses en desarrollo que buscan modernizar sus requisitos para medicamentos gen\u00e9ricos y facilitar la transici\u00f3n a un formato de documento t\u00e9cnico com\u00fan (CTD).\n\n### Entidades mencionadas:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que propone la alineaci\u00f3n de formatos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n cuyo formato se busca adoptar.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades que se beneficiar\u00e1n de las nuevas gu\u00edas.\n- **ICH (International Council for Harmonisation)**: Consejo que est\u00e1 desarrollando directrices relacionadas con la fabricaci\u00f3n de sustancias farmac\u00e9uticas. \n\n### Conclusi\u00f3n:\nLa secci\u00f3n aborda la necesidad de armonizar los formatos de documentaci\u00f3n para la precalificaci\u00f3n de medicamentos, presentando nuevas gu\u00edas que faciliten la actualizaci\u00f3n de procesos en las NMRAs y apoyen a los pa\u00edses en desarrollo en la adopci\u00f3n de est\u00e1ndares internacionales.", "excerpt_keywords": "Keywords: guidelines, pharmaceutical development, bioequivalence, essential medicines, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "558b4ae6-3fd2-46af-9672-bfcc3e76ea40", "node_type": "4", "metadata": {"page_label": "58", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted that the guidelines were more advanced than the present ones used by a number of Member States.\n\nThe Expert Committee recommended that the document be provisionally adopted and that it should be issued in a pilot phase after consolidation of comments within the Prequalification of Medicines Programme.\n\n### 13.4 Pharmaceutical development for multisource (generic) pharmaceutical products\n\nThe Expert Committee was briefed on the progress regarding the new guidance on pharmaceutical development for multisource (generic) pharmaceutical products. The draft guidance was widely circulated for comments and underwent a major revision during the informal consultation in April 2010; thereafter numerous comments were received. The Expert Committee reviewed the feedback and considered that the comments received would need to be revisited by a group of experts. It was also suggested that the document be reorganized to follow the CTD format in order to bring it in line with the other approaches recommended by the Committee during the present meeting.\n\nThe Expert Committee recommended following the normal procedure, organizing an informal consultation and providing feedback to the next Expert Committee meeting.\n\n### 13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System\n\nThe WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines in Frankfurt, Germany, provided a report with a proposal to update the *Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms* published in 2006, with a view to including the new medicines selected for inclusion in the Model list of Essential Medicines (EML) since 2006.\n\nThe Expert Committee members:\n\n- endorsed the follow-up and continuation of this update;\n- endorsed the efforts to update the list by adding the new EML entries through publication of those that are unambiguously classified in the report;\n- advised that WHO collaborating centres should be contacted and that laboratories collaborating in the development of new monographs for *The International Pharmacopoeia* should collaborate by possibly either undertaking the solubility studies or by providing APIs to the WHO Collaborating Centre in Frankfurt;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1cd39faeda79ec5c96db77698b780b9bf3372de57b42bd89bb543a961b9638a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Committee noted that the guidelines were more advanced than the present ones used by a number of Member States.\n\nThe Expert Committee recommended that the document be provisionally adopted and that it should be issued in a pilot phase after consolidation of comments within the Prequalification of Medicines Programme.\n\n### 13.4 Pharmaceutical development for multisource (generic) pharmaceutical products\n\nThe Expert Committee was briefed on the progress regarding the new guidance on pharmaceutical development for multisource (generic) pharmaceutical products. The draft guidance was widely circulated for comments and underwent a major revision during the informal consultation in April 2010; thereafter numerous comments were received. The Expert Committee reviewed the feedback and considered that the comments received would need to be revisited by a group of experts. It was also suggested that the document be reorganized to follow the CTD format in order to bring it in line with the other approaches recommended by the Committee during the present meeting.\n\nThe Expert Committee recommended following the normal procedure, organizing an informal consultation and providing feedback to the next Expert Committee meeting.\n\n### 13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System\n\nThe WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines in Frankfurt, Germany, provided a report with a proposal to update the *Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms* published in 2006, with a view to including the new medicines selected for inclusion in the Model list of Essential Medicines (EML) since 2006.\n\nThe Expert Committee members:\n\n- endorsed the follow-up and continuation of this update;\n- endorsed the efforts to update the list by adding the new EML entries through publication of those that are unambiguously classified in the report;\n- advised that WHO collaborating centres should be contacted and that laboratories collaborating in the development of new monographs for *The International Pharmacopoeia* should collaborate by possibly either undertaking the solubility studies or by providing APIs to the WHO Collaborating Centre in Frankfurt;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2379, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ea0ffe74-7b38-48cc-a630-44d8541e9c77": {"__data__": {"id_": "ea0ffe74-7b38-48cc-a630-44d8541e9c77", "embedding": null, "metadata": {"page_label": "59", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Development of paediatric medicines: pharmaceutical development\n\nThe document summarizing the *Points to consider in the development of paediatric medicines: pharmaceutical development* was discussed at the informal WHO consultation on pharmaceutical development of paediatric medicines and pharmaceutical development for multisource (generic) pharmaceutical products, which was held in Geneva on 29\u201330 April 2010.\n\nThe Expert Committee was provided with a short history of the document, including previous comments and proposed further revision. It reviewed the main comments in detail.\n\nThe Expert Committee recommended that taste-masking and palatability should be addressed in more detail in the text provided, with special reference to other WHO documents, including, e.g. the one on zinc tablets.\n\nThe Expert Committee recommended that the revised version of this document should again be circulated widely for comments, including to the paediatric regulatory network. Progress would be reported to the next Expert Committee meeting.\n\nThe Committee noted that the guidelines currently under development did not include any details on extemporaneous preparations. The Expert Committee recommended that the paediatric regulatory network, and especially the group dealing with extemporaneous preparations, take advantage of the expertise provided by this Expert Committee.\n\n# Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients\n\nThe Secretariat briefed the Expert Committee on the history and purpose of the document which was prepared in response to the need expressed by major donor organizations.\n\nIt was discussed that on various occasions the quality control specifications applicable to active substances are used not only per se but also as starting materials for the production of other active substances. An illustrative example was provided.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento discutido en la consulta informal de la OMS sobre el desarrollo de medicamentos pedi\u00e1tricos aborda aspectos clave en la formulaci\u00f3n y desarrollo de medicamentos para ni\u00f1os, incluyendo la importancia de la palatabilidad y el enmascaramiento del sabor. Se recomienda que el documento revisado se comparta ampliamente para recibir comentarios, especialmente del grupo regulador pedi\u00e1trico. Adem\u00e1s, se menciona la necesidad de establecer requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos activos antimal\u00e1ricos, en respuesta a las necesidades de organizaciones donantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos sobre el enmascaramiento del sabor y la palatabilidad se sugiri\u00f3 que se incluyeran en el documento revisado sobre medicamentos pedi\u00e1tricos?**\n   - La Expert Committee recomend\u00f3 que se abordara el enmascaramiento del sabor y la palatabilidad en m\u00e1s detalle, haciendo referencia a otros documentos de la OMS, como el que trata sobre tabletas de zinc.\n\n2. **\u00bfCu\u00e1l es la importancia de la red reguladora pedi\u00e1trica en el contexto del desarrollo de medicamentos pedi\u00e1tricos seg\u00fan el documento?**\n   - La red reguladora pedi\u00e1trica es crucial para proporcionar comentarios sobre el documento revisado y se sugiere que aproveche la experiencia del Comit\u00e9 de Expertos, especialmente en lo que respecta a las preparaciones extempor\u00e1neas.\n\n3. **\u00bfQu\u00e9 se discuti\u00f3 sobre las especificaciones de control de calidad aplicables a las sustancias activas en el contexto de la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos?**\n   - Se discuti\u00f3 que las especificaciones de control de calidad para las sustancias activas no solo se utilizan por s\u00ed mismas, sino tambi\u00e9n como materias primas para la producci\u00f3n de otras sustancias activas, lo que subraya la importancia de establecer requisitos de calidad adecuados.", "prev_section_summary": "### Temas Clave\n\n1. **Adopci\u00f3n de Nuevas Directrices**: Se recomienda la adopci\u00f3n provisional de nuevas directrices m\u00e1s avanzadas que las actualmente utilizadas por varios Estados Miembros, con la intenci\u00f3n de emitirlas en una fase piloto tras la consolidaci\u00f3n de comentarios.\n\n2. **Desarrollo Farmac\u00e9utico para Productos Gen\u00e9ricos**: Se discute el progreso en la elaboraci\u00f3n de nuevas orientaciones sobre el desarrollo farmac\u00e9utico de productos multisource (gen\u00e9ricos). Se sugiere reorganizar el documento seg\u00fan el formato CTD y realizar una consulta informal para revisar los comentarios recibidos.\n\n3. **Clasificaci\u00f3n de Medicamentos en la Lista Modelo de Medicamentos Esenciales**: Se presenta una propuesta para actualizar los requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales, con el objetivo de incluir nuevos medicamentos desde 2006. Se recomienda la colaboraci\u00f3n entre centros y laboratorios para realizar estudios de solubilidad.\n\n### Entidades\n\n- **Comit\u00e9 de Expertos**: Grupo que revisa y recomienda acciones sobre directrices y documentos relacionados con medicamentos.\n- **Programa de Precalificaci\u00f3n de Medicamentos**: Iniciativa de la OMS para asegurar la calidad de los medicamentos.\n- **Centro Colaborador de la OMS en Frankfurt**: Entidad que proporciona informes y propuestas sobre bioequivalencia.\n- **Lista Modelo de Medicamentos Esenciales (EML)**: Lista de medicamentos considerados esenciales por la OMS.\n- **CTD (Common Technical Document)**: Formato recomendado para la presentaci\u00f3n de informaci\u00f3n sobre medicamentos.\n\nEste resumen destaca los puntos clave y las entidades involucradas en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: paediatric medicines, taste-masking, quality control, artemisinin, pharmaceutical development"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d470028-b78e-436e-ba7d-6b59b593418c", "node_type": "4", "metadata": {"page_label": "59", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Development of paediatric medicines: pharmaceutical development\n\nThe document summarizing the *Points to consider in the development of paediatric medicines: pharmaceutical development* was discussed at the informal WHO consultation on pharmaceutical development of paediatric medicines and pharmaceutical development for multisource (generic) pharmaceutical products, which was held in Geneva on 29\u201330 April 2010.\n\nThe Expert Committee was provided with a short history of the document, including previous comments and proposed further revision. It reviewed the main comments in detail.\n\nThe Expert Committee recommended that taste-masking and palatability should be addressed in more detail in the text provided, with special reference to other WHO documents, including, e.g. the one on zinc tablets.\n\nThe Expert Committee recommended that the revised version of this document should again be circulated widely for comments, including to the paediatric regulatory network. Progress would be reported to the next Expert Committee meeting.\n\nThe Committee noted that the guidelines currently under development did not include any details on extemporaneous preparations. The Expert Committee recommended that the paediatric regulatory network, and especially the group dealing with extemporaneous preparations, take advantage of the expertise provided by this Expert Committee.\n\n# Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients\n\nThe Secretariat briefed the Expert Committee on the history and purpose of the document which was prepared in response to the need expressed by major donor organizations.\n\nIt was discussed that on various occasions the quality control specifications applicable to active substances are used not only per se but also as starting materials for the production of other active substances. An illustrative example was provided.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e92318abf5276cbc8f75fb132f11025674d872e31af218a62b6bf4484748b309", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Development of paediatric medicines: pharmaceutical development\n\nThe document summarizing the *Points to consider in the development of paediatric medicines: pharmaceutical development* was discussed at the informal WHO consultation on pharmaceutical development of paediatric medicines and pharmaceutical development for multisource (generic) pharmaceutical products, which was held in Geneva on 29\u201330 April 2010.\n\nThe Expert Committee was provided with a short history of the document, including previous comments and proposed further revision. It reviewed the main comments in detail.\n\nThe Expert Committee recommended that taste-masking and palatability should be addressed in more detail in the text provided, with special reference to other WHO documents, including, e.g. the one on zinc tablets.\n\nThe Expert Committee recommended that the revised version of this document should again be circulated widely for comments, including to the paediatric regulatory network. Progress would be reported to the next Expert Committee meeting.\n\nThe Committee noted that the guidelines currently under development did not include any details on extemporaneous preparations. The Expert Committee recommended that the paediatric regulatory network, and especially the group dealing with extemporaneous preparations, take advantage of the expertise provided by this Expert Committee.\n\n# Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients\n\nThe Secretariat briefed the Expert Committee on the history and purpose of the document which was prepared in response to the need expressed by major donor organizations.\n\nIt was discussed that on various occasions the quality control specifications applicable to active substances are used not only per se but also as starting materials for the production of other active substances. An illustrative example was provided.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1932, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ac122610-e46f-4792-8cbd-3fc19d40f92d": {"__data__": {"id_": "ac122610-e46f-4792-8cbd-3fc19d40f92d", "embedding": null, "metadata": {"page_label": "60", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "example is artemisinin which is an important API itself and also serves as a starting material for the production of artemisinin-derived antimalarials.\n\nThe main challenge identified is that some national authorities require the same quality standard for an API and for a starting material. However, it was considered sufficient that a starting material has a quality that guarantees that the final product meets a relevant pharmacopoeial standard. Demanding a quality for a starting material that is too exacting will increase the price and in consequence reduce the availability of the API.\n\nWorking document QAS/10.349/Rev.1 has been prepared to clarify the need for different quality levels. It includes a specification for artemisinin used as a starting material for the synthesis of artemisinin derivatives.\n\nThe original paper was circulated for comments in March\u2013April 2010. Comments were consolidated and the revised draft, based on an additional review by a subgroup of experts in August 2010, was presented to the Expert Committee.\n\nThe assignment of possible impurities to signals in the chromatographic assay for related substances is based on literature data and regarded as tentative until further experimental validation has been obtained.\n\nFinalization of the impurity profile was required and would determine when the document could be discussed. The manufacturer was contacted to submit the starting material needed to carry out the analyses at the laboratory level.\n\nIt was noted that a WHO botanical \u201cmonograph\u201d was available which detailed the cultivation and collection of the starting material.\n\nThe Expert Committee recognized the need to finalize the impurity profile before the document could be completed. It further recommended that the document be revised by a subgroup of experts in light of the comments received.\n\n## 14. Nomenclature, terminology and databases\n\n### 14.1 New definition for \u201csubstandard medicines\u201d\n\nIn connection with the discussions during the meetings of the WHO governing bodies, the terminology for \u201csubstandard medicines\u201d was raised during the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\nWithin the context of the work of this Expert Committee no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was frequently raised a \u201cQuestion and Answer\u201d section had been introduced on the WHO web site. On the basis of this the Expert Committee proposed during its 44th meeting to circulate a slightly modified proposal for the elaboration of a new definition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Desaf\u00edos en la regulaci\u00f3n de materias primas farmac\u00e9uticas**: El texto discute la problem\u00e1tica que enfrentan las autoridades nacionales al exigir est\u00e1ndares de calidad id\u00e9nticos para los ingredientes farmac\u00e9uticos activos (API) y los materiales de partida. Se argumenta que un est\u00e1ndar de calidad adecuado para los materiales de partida es suficiente si garantiza que el producto final cumpla con los est\u00e1ndares farmacop\u00e9icos relevantes.\n\n2. **Desarrollo de documentos de especificaci\u00f3n**: Se menciona el trabajo realizado en el documento QAS/10.349/Rev.1, que busca aclarar la necesidad de diferentes niveles de calidad para los materiales de partida, espec\u00edficamente para la artemisinina, un API importante. Este documento ha pasado por varias revisiones y se requiere la finalizaci\u00f3n del perfil de impurezas antes de su discusi\u00f3n final.\n\n3. **Terminolog\u00eda sobre medicamentos subest\u00e1ndar**: Se aborda la falta de una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\" en el contexto de las discusiones de la OMS. Se propone la elaboraci\u00f3n de una nueva definici\u00f3n, destacando la importancia de establecer un marco terminol\u00f3gico claro en el \u00e1mbito farmac\u00e9utico.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfPor qu\u00e9 se considera suficiente que un material de partida tenga un est\u00e1ndar de calidad que garantice que el producto final cumpla con un est\u00e1ndar farmacop\u00e9ico relevante?**\n   - Esta pregunta busca profundizar en la l\u00f3gica detr\u00e1s de la regulaci\u00f3n de calidad y c\u00f3mo se relaciona con la disponibilidad y el costo de los APIs.\n\n2. **\u00bfQu\u00e9 pasos se han tomado para finalizar el perfil de impurezas de la artemisinina y por qu\u00e9 es crucial para la discusi\u00f3n del documento QAS/10.349/Rev.1?**\n   - Esta pregunta se centra en el proceso de validaci\u00f3n y la importancia de los perfiles de impurezas en la regulaci\u00f3n de los materiales de partida.\n\n3. **\u00bfQu\u00e9 modificaciones se propusieron en la definici\u00f3n de \"medicamentos subest\u00e1ndar\" durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Esta pregunta busca obtener detalles sobre las discusiones y propuestas espec\u00edficas que se hicieron en relaci\u00f3n con la terminolog\u00eda de medicamentos subest\u00e1ndar, lo que podr\u00eda no estar ampliamente documentado en otras fuentes.", "prev_section_summary": "### Temas Clave\n\n1. **Desarrollo de Medicamentos Pedi\u00e1tricos**:\n   - Se discutieron los *Puntos a considerar en el desarrollo de medicamentos pedi\u00e1tricos* en una consulta informal de la OMS.\n   - Se enfatiz\u00f3 la importancia del enmascaramiento del sabor y la palatabilidad en la formulaci\u00f3n de medicamentos para ni\u00f1os.\n   - Se recomend\u00f3 que el documento revisado se compartiera ampliamente para recibir comentarios, especialmente de la red reguladora pedi\u00e1trica.\n\n2. **Requisitos de Calidad para la Artemisinina**:\n   - Se abordaron las especificaciones de control de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos activos antimal\u00e1ricos.\n   - Se destac\u00f3 que estas especificaciones no solo se aplican a las sustancias activas en s\u00ed, sino tambi\u00e9n como materias primas para la producci\u00f3n de otras sustancias activas.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que facilit\u00f3 la consulta y discusi\u00f3n sobre el desarrollo de medicamentos pedi\u00e1tricos.\n- **Comit\u00e9 de Expertos**: Grupo que revis\u00f3 el documento y proporcion\u00f3 recomendaciones sobre el desarrollo de medicamentos pedi\u00e1tricos y la calidad de la artemisinina.\n- **Red Reguladora Pedi\u00e1trica**: Entidad recomendada para proporcionar comentarios sobre el documento revisado y aprovechar la experiencia del Comit\u00e9 de Expertos.\n- **Organizaciones Donantes**: Entidades que expresaron la necesidad de establecer requisitos de calidad para la artemisinina.", "excerpt_keywords": "Keywords: artemisinin, quality standards, pharmaceutical preparations, impurity profile, substandard medicines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cbd2c5d4-241d-4509-9841-cdb001ad0149", "node_type": "4", "metadata": {"page_label": "60", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "example is artemisinin which is an important API itself and also serves as a starting material for the production of artemisinin-derived antimalarials.\n\nThe main challenge identified is that some national authorities require the same quality standard for an API and for a starting material. However, it was considered sufficient that a starting material has a quality that guarantees that the final product meets a relevant pharmacopoeial standard. Demanding a quality for a starting material that is too exacting will increase the price and in consequence reduce the availability of the API.\n\nWorking document QAS/10.349/Rev.1 has been prepared to clarify the need for different quality levels. It includes a specification for artemisinin used as a starting material for the synthesis of artemisinin derivatives.\n\nThe original paper was circulated for comments in March\u2013April 2010. Comments were consolidated and the revised draft, based on an additional review by a subgroup of experts in August 2010, was presented to the Expert Committee.\n\nThe assignment of possible impurities to signals in the chromatographic assay for related substances is based on literature data and regarded as tentative until further experimental validation has been obtained.\n\nFinalization of the impurity profile was required and would determine when the document could be discussed. The manufacturer was contacted to submit the starting material needed to carry out the analyses at the laboratory level.\n\nIt was noted that a WHO botanical \u201cmonograph\u201d was available which detailed the cultivation and collection of the starting material.\n\nThe Expert Committee recognized the need to finalize the impurity profile before the document could be completed. It further recommended that the document be revised by a subgroup of experts in light of the comments received.\n\n## 14. Nomenclature, terminology and databases\n\n### 14.1 New definition for \u201csubstandard medicines\u201d\n\nIn connection with the discussions during the meetings of the WHO governing bodies, the terminology for \u201csubstandard medicines\u201d was raised during the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\nWithin the context of the work of this Expert Committee no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was frequently raised a \u201cQuestion and Answer\u201d section had been introduced on the WHO web site. On the basis of this the Expert Committee proposed during its 44th meeting to circulate a slightly modified proposal for the elaboration of a new definition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2641e64ea5c09b7be2ae07998bb6353087d6e9796d412fb07d4e6ace8ec9ddf4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "example is artemisinin which is an important API itself and also serves as a starting material for the production of artemisinin-derived antimalarials.\n\nThe main challenge identified is that some national authorities require the same quality standard for an API and for a starting material. However, it was considered sufficient that a starting material has a quality that guarantees that the final product meets a relevant pharmacopoeial standard. Demanding a quality for a starting material that is too exacting will increase the price and in consequence reduce the availability of the API.\n\nWorking document QAS/10.349/Rev.1 has been prepared to clarify the need for different quality levels. It includes a specification for artemisinin used as a starting material for the synthesis of artemisinin derivatives.\n\nThe original paper was circulated for comments in March\u2013April 2010. Comments were consolidated and the revised draft, based on an additional review by a subgroup of experts in August 2010, was presented to the Expert Committee.\n\nThe assignment of possible impurities to signals in the chromatographic assay for related substances is based on literature data and regarded as tentative until further experimental validation has been obtained.\n\nFinalization of the impurity profile was required and would determine when the document could be discussed. The manufacturer was contacted to submit the starting material needed to carry out the analyses at the laboratory level.\n\nIt was noted that a WHO botanical \u201cmonograph\u201d was available which detailed the cultivation and collection of the starting material.\n\nThe Expert Committee recognized the need to finalize the impurity profile before the document could be completed. It further recommended that the document be revised by a subgroup of experts in light of the comments received.\n\n## 14. Nomenclature, terminology and databases\n\n### 14.1 New definition for \u201csubstandard medicines\u201d\n\nIn connection with the discussions during the meetings of the WHO governing bodies, the terminology for \u201csubstandard medicines\u201d was raised during the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\nWithin the context of the work of this Expert Committee no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was frequently raised a \u201cQuestion and Answer\u201d section had been introduced on the WHO web site. On the basis of this the Expert Committee proposed during its 44th meeting to circulate a slightly modified proposal for the elaboration of a new definition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2604, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "16cd16d3-72f1-45d5-80b5-739d23fdf9f6": {"__data__": {"id_": "16cd16d3-72f1-45d5-80b5-739d23fdf9f6", "embedding": null, "metadata": {"page_label": "61", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The comments received upon circulation were reviewed during the following two WHO consultations which took place in Geneva: Quality assurance systems, medicines and risk analysis (4\u20136 May 2010); and Specifications for medicines and quality control laboratory issues (10\u201312 May 2010). An extensive discussion took place on the feedback received and additional input was provided by all experts who participated in the consultations. On the basis of this outcome a new revised definition was suggested and reviewed by the Expert Committee.\n\nThe Chair noted that it was not feasible to write a definition for every country in the world, but there was a need to provide sufficient background so that countries could interpret the underlying concepts. The Expert Committee recommended that the definition be reviewed by a legal expert to ensure that the text covers both standards and specifications in an appropriate manner.\n\nThe following new proposal was discussed based on the comments received and adopted by the Expert Committee:\n\n\u201cSubstandard medicines are pharmaceutical products that fail to meet either their quality standards or their specifications, or both.12\n\nEach pharmaceutical product that a manufacturer produces has to comply with quality assurance standards and specifications, at release and throughout its shelf-life, according to the requirements of the territory of use. Normally, these standards and specifications are reviewed, assessed and approved by the applicable national or regional medicines regulatory authority before the product is authorized for marketing.\u201d\n\n## 14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d\n\nIn connection with the discussions during the WHO governing bodies\u2019 meetings, the terminology for \u201ccounterfeit medicines\u201d has been raised since 2008. During the 63rd World Health Assembly the proposal was made that, until consensus could be reached, the following term should be used: \u201csubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d.\n\nWithin the context of the work of this Expert Committee, definitions for \u201ccounterfeit medicines\u201d were included in the glossary of the various WHO guidelines, e.g. in the WHO Good distribution practices for pharmaceutical products (40th report, 2006), the WHO Guidelines for inspection of drug distribution channels (35th report, 1999); and the WHO Guidelines on import procedures for pharmaceutical products (34th report, 1996).13\n\n----\n\n12 Modified after review by the WHO Legal Counsel.  \n13 WHO Database on Quality Assurance (http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en las discusiones y definiciones relacionadas con los medicamentos subest\u00e1ndar y falsificados, abordadas en consultas de la OMS en 2010. Se destaca la necesidad de establecer definiciones claras que puedan ser interpretadas por diferentes pa\u00edses, as\u00ed como la importancia de que los productos farmac\u00e9uticos cumplan con est\u00e1ndares de calidad y especificaciones aprobadas por las autoridades reguladoras. Adem\u00e1s, se menciona la evoluci\u00f3n del t\u00e9rmino \"medicamentos falsificados\" y la propuesta de un t\u00e9rmino m\u00e1s inclusivo que abarque varias categor\u00edas de productos m\u00e9dicos problem\u00e1ticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la definici\u00f3n adoptada por el Comit\u00e9 de Expertos de la OMS para los medicamentos subest\u00e1ndar y qu\u00e9 criterios deben cumplir los productos farmac\u00e9uticos?**\n   - Respuesta: Los medicamentos subest\u00e1ndar son aquellos productos farmac\u00e9uticos que no cumplen con sus est\u00e1ndares de calidad o especificaciones, o ambos. Cada producto debe cumplir con los est\u00e1ndares de calidad y especificaciones desde su liberaci\u00f3n y a lo largo de su vida \u00fatil, seg\u00fan los requisitos del territorio de uso.\n\n2. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a la revisi\u00f3n de la definici\u00f3n de medicamentos subest\u00e1ndar y qui\u00e9n deber\u00eda realizar esta revisi\u00f3n?**\n   - Respuesta: El Comit\u00e9 de Expertos recomend\u00f3 que la definici\u00f3n fuera revisada por un experto legal para asegurar que el texto cubriera adecuadamente tanto los est\u00e1ndares como las especificaciones.\n\n3. **\u00bfQu\u00e9 t\u00e9rmino se propuso utilizar en la 63\u00aa Asamblea Mundial de la Salud para referirse a los medicamentos falsificados y cu\u00e1l es su significado?**\n   - Respuesta: Se propuso utilizar el t\u00e9rmino \"substandard/spurious/falsely-labelled/falsified/counterfeit medical products\" hasta que se alcanzara un consenso. Este t\u00e9rmino abarca una variedad de productos m\u00e9dicos que pueden ser problem\u00e1ticos, incluyendo aquellos que son subest\u00e1ndar, falsamente etiquetados o falsificados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desaf\u00edos en la Regulaci\u00f3n de Materias Primas Farmac\u00e9uticas**:\n   - Se discute la problem\u00e1tica de que algunas autoridades nacionales exigen los mismos est\u00e1ndares de calidad para los ingredientes farmac\u00e9uticos activos (API) y los materiales de partida. \n   - Se argumenta que un est\u00e1ndar de calidad adecuado para los materiales de partida es suficiente si asegura que el producto final cumpla con los est\u00e1ndares farmacop\u00e9icos relevantes.\n\n2. **Especificaci\u00f3n de Artemisinina**:\n   - Se menciona el documento de trabajo QAS/10.349/Rev.1, que busca aclarar la necesidad de diferentes niveles de calidad, espec\u00edficamente para la artemisinina, que es un API importante y material de partida para antimal\u00e1ricos derivados.\n   - El documento ha pasado por varias revisiones y se requiere la finalizaci\u00f3n del perfil de impurezas antes de su discusi\u00f3n final.\n\n3. **Terminolog\u00eda sobre Medicamentos Subest\u00e1ndar**:\n   - Se aborda la falta de una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\" en el contexto de las discusiones de la OMS.\n   - Se propone la elaboraci\u00f3n de una nueva definici\u00f3n, destacando la importancia de establecer un marco terminol\u00f3gico claro en el \u00e1mbito farmac\u00e9utico.\n\n### Entidades Clave\n- **Artemisinina**: Ingrediente farmac\u00e9utico activo y material de partida para la producci\u00f3n de antimal\u00e1ricos.\n- **Documento QAS/10.349/Rev.1**: Documento de trabajo que especifica los niveles de calidad para la artemisinina.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que discute y propone definiciones y est\u00e1ndares en el \u00e1mbito farmac\u00e9utico.\n- **Medicamentos Subest\u00e1ndar**: T\u00e9rmino que carece de una definici\u00f3n oficial en el contexto de la OMS, pero que se est\u00e1 trabajando para clarificar.\n\nEste resumen destaca los principales desaf\u00edos en la regulaci\u00f3n de materias primas farmac\u00e9uticas, el desarrollo de especificaciones para la artemisinina y la necesidad de una terminolog\u00eda clara sobre medicamentos subest\u00e1ndar.", "excerpt_keywords": "Keywords: substandard medicines, counterfeit medicines, quality assurance, WHO consultations, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a06d718b-4607-4c86-a9c3-dd5b6089e88d", "node_type": "4", "metadata": {"page_label": "61", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The comments received upon circulation were reviewed during the following two WHO consultations which took place in Geneva: Quality assurance systems, medicines and risk analysis (4\u20136 May 2010); and Specifications for medicines and quality control laboratory issues (10\u201312 May 2010). An extensive discussion took place on the feedback received and additional input was provided by all experts who participated in the consultations. On the basis of this outcome a new revised definition was suggested and reviewed by the Expert Committee.\n\nThe Chair noted that it was not feasible to write a definition for every country in the world, but there was a need to provide sufficient background so that countries could interpret the underlying concepts. The Expert Committee recommended that the definition be reviewed by a legal expert to ensure that the text covers both standards and specifications in an appropriate manner.\n\nThe following new proposal was discussed based on the comments received and adopted by the Expert Committee:\n\n\u201cSubstandard medicines are pharmaceutical products that fail to meet either their quality standards or their specifications, or both.12\n\nEach pharmaceutical product that a manufacturer produces has to comply with quality assurance standards and specifications, at release and throughout its shelf-life, according to the requirements of the territory of use. Normally, these standards and specifications are reviewed, assessed and approved by the applicable national or regional medicines regulatory authority before the product is authorized for marketing.\u201d\n\n## 14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d\n\nIn connection with the discussions during the WHO governing bodies\u2019 meetings, the terminology for \u201ccounterfeit medicines\u201d has been raised since 2008. During the 63rd World Health Assembly the proposal was made that, until consensus could be reached, the following term should be used: \u201csubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d.\n\nWithin the context of the work of this Expert Committee, definitions for \u201ccounterfeit medicines\u201d were included in the glossary of the various WHO guidelines, e.g. in the WHO Good distribution practices for pharmaceutical products (40th report, 2006), the WHO Guidelines for inspection of drug distribution channels (35th report, 1999); and the WHO Guidelines on import procedures for pharmaceutical products (34th report, 1996).13\n\n----\n\n12 Modified after review by the WHO Legal Counsel.  \n13 WHO Database on Quality Assurance (http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "05b3362b8b77ab2be58adc024ab1d622bc08ab9e3df9acb2cd3c8cc08125d4b3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The comments received upon circulation were reviewed during the following two WHO consultations which took place in Geneva: Quality assurance systems, medicines and risk analysis (4\u20136 May 2010); and Specifications for medicines and quality control laboratory issues (10\u201312 May 2010). An extensive discussion took place on the feedback received and additional input was provided by all experts who participated in the consultations. On the basis of this outcome a new revised definition was suggested and reviewed by the Expert Committee.\n\nThe Chair noted that it was not feasible to write a definition for every country in the world, but there was a need to provide sufficient background so that countries could interpret the underlying concepts. The Expert Committee recommended that the definition be reviewed by a legal expert to ensure that the text covers both standards and specifications in an appropriate manner.\n\nThe following new proposal was discussed based on the comments received and adopted by the Expert Committee:\n\n\u201cSubstandard medicines are pharmaceutical products that fail to meet either their quality standards or their specifications, or both.12\n\nEach pharmaceutical product that a manufacturer produces has to comply with quality assurance standards and specifications, at release and throughout its shelf-life, according to the requirements of the territory of use. Normally, these standards and specifications are reviewed, assessed and approved by the applicable national or regional medicines regulatory authority before the product is authorized for marketing.\u201d\n\n## 14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d\n\nIn connection with the discussions during the WHO governing bodies\u2019 meetings, the terminology for \u201ccounterfeit medicines\u201d has been raised since 2008. During the 63rd World Health Assembly the proposal was made that, until consensus could be reached, the following term should be used: \u201csubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d.\n\nWithin the context of the work of this Expert Committee, definitions for \u201ccounterfeit medicines\u201d were included in the glossary of the various WHO guidelines, e.g. in the WHO Good distribution practices for pharmaceutical products (40th report, 2006), the WHO Guidelines for inspection of drug distribution channels (35th report, 1999); and the WHO Guidelines on import procedures for pharmaceutical products (34th report, 1996).13\n\n----\n\n12 Modified after review by the WHO Legal Counsel.  \n13 WHO Database on Quality Assurance (http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2642, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2feba45-2e4d-4a22-b29d-813aa0654ee0": {"__data__": {"id_": "c2feba45-2e4d-4a22-b29d-813aa0654ee0", "embedding": null, "metadata": {"page_label": "62", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Within the context of the work of the IMPACT Annual Meeting held in December 2008 (Hammamet, Tunisia) and based on the work carried out in the IMPACT Working Group on Legislative and Regulatory Infrastructure, a new definition was developed. This definition is included in the document entitled *Draft principles and elements for national legislation against counterfeit medical products* which was sent out for comments.\n\nTriggered by the governing bodies' discussion, a Circular Letter was mailed inviting Member States to share the terms and details of what national legislations regarded as \u201ccounterfeit medicines\u201d. The feedback was summarized by specialists and posted as a preliminary report on the WHO website to allow for additional feedback. The responses of Member States to the Circular Letter of the Director-General of WHO were presented to the Expert Committee. They related to:\n\n- definitions of \u201ccounterfeit medicines\u201d in the Member States;\n- Member States\u2019 national legislation; and\n- definition included in the above-cited IMPACT document.\n\nIt was explained that different types of legislation address the problem in the various Member States, which led to the diversity of responses. Also, English is not necessarily the language used in the national or regional legislations, which adds to the complexity. Many Member States are, however, in line with the current WHO definition. The Expert Committee took note that, although the majority of Member States supported the IMPACT definition and document, a considerable number of Member States did not, for various reasons.\n\nThe Expert Committee members fully recognized that spurious/falsely-labelled/falsified/counterfeit medical products presented a major public health problem. Several political and technical issues were raised. There was discussion whether or not APIs and excipients should be included in the definition and whether it was better to address \u201cmedicines\u201d only rather than the broader category of \u201cmedical products\u201d.\n\nThe Expert Committee took note that there was neither agreement among the Member States\u2019 definitions nor the terms used in the various legal contexts. However, several participants indicated that whatever the decision was on the future terminology within the WHO context, the word \u201ccounterfeit\u201d was already widely used by the public.\n\nDuring the 63rd World Health Assembly all Member States adopted by consensus the decision to have a working group on \u201cSubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d and had requested\n\n----\n\n[^14]: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl contexto se centra en la reuni\u00f3n anual de IMPACT celebrada en diciembre de 2008 en Hammamet, T\u00fanez, donde se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\". Se solicit\u00f3 a los Estados Miembros que compartieran sus legislaciones nacionales sobre este tema, lo que result\u00f3 en una diversidad de respuestas debido a diferencias en los marcos legales y el uso de distintos idiomas. Aunque muchos Estados Miembros apoyaron la definici\u00f3n de la OMS, otros no lo hicieron por diversas razones. Se discutieron cuestiones pol\u00edticas y t\u00e9cnicas, incluyendo la inclusi\u00f3n de ingredientes activos y excipientes en la definici\u00f3n. Durante la 63\u00aa Asamblea Mundial de la Salud, se decidi\u00f3 establecer un grupo de trabajo sobre productos m\u00e9dicos subest\u00e1ndar y falsificados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron las principales razones por las que algunos Estados Miembros no apoyaron la definici\u00f3n de \"medicamentos falsificados\" propuesta por la OMS?**\n   - Esta pregunta busca explorar las razones espec\u00edficas detr\u00e1s de la falta de consenso entre los Estados Miembros, que no se detallan en el contexto.\n\n2. **\u00bfQu\u00e9 tipo de legislaciones nacionales se identificaron en las respuestas de los Estados Miembros sobre los \"medicamentos falsificados\"?**\n   - Esta pregunta se centra en los diferentes enfoques legislativos que adoptan los Estados Miembros, lo que podr\u00eda proporcionar ejemplos concretos de c\u00f3mo se aborda el problema en distintas jurisdicciones.\n\n3. **\u00bfQu\u00e9 implicaciones pol\u00edticas y t\u00e9cnicas se discutieron en relaci\u00f3n con la inclusi\u00f3n de APIs y excipientes en la definici\u00f3n de \"medicamentos falsificados\"?**\n   - Esta pregunta busca profundizar en las discusiones espec\u00edficas que tuvieron lugar sobre la definici\u00f3n y c\u00f3mo estas implicaciones podr\u00edan afectar la regulaci\u00f3n y el control de productos m\u00e9dicos.", "prev_section_summary": "### Temas Clave\n\n1. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**: Se establece que los medicamentos subest\u00e1ndar son aquellos que no cumplen con sus est\u00e1ndares de calidad o especificaciones, o ambos. Se enfatiza la necesidad de que cada producto farmac\u00e9utico cumpla con estos criterios desde su liberaci\u00f3n y a lo largo de su vida \u00fatil, conforme a los requisitos del territorio de uso.\n\n2. **Revisi\u00f3n de Definiciones**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 que la definici\u00f3n de medicamentos subest\u00e1ndar sea revisada por un experto legal para asegurar que aborde adecuadamente tanto los est\u00e1ndares como las especificaciones.\n\n3. **Terminolog\u00eda de Medicamentos Falsificados**: Se discute la evoluci\u00f3n del t\u00e9rmino \"medicamentos falsificados\" y se propone un t\u00e9rmino m\u00e1s inclusivo: \"substandard/spurious/falsely-labelled/falsified/counterfeit medical products\", que abarca diversas categor\u00edas de productos m\u00e9dicos problem\u00e1ticos.\n\n4. **Consultas de la OMS**: Se mencionan dos consultas de la OMS realizadas en Ginebra en 2010, donde se revisaron los comentarios recibidos y se discutieron las definiciones y est\u00e1ndares relacionados con la calidad de los medicamentos.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que lidera las discusiones sobre est\u00e1ndares y definiciones de medicamentos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y propone definiciones y est\u00e1ndares relacionados con los medicamentos.\n- **Asamblea Mundial de la Salud**: Evento donde se discuten temas de salud global, incluyendo la terminolog\u00eda de medicamentos falsificados.\n- **Autoridades Reguladoras Nacionales o Regionales**: Entidades que revisan, eval\u00faan y aprueban los est\u00e1ndares y especificaciones de los productos farmac\u00e9uticos antes de su comercializaci\u00f3n.", "excerpt_keywords": "Keywords: counterfeit medicines, WHO, IMPACT, public health, legislation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0403bbe6-f9ca-4ddf-b1b5-8fd54f73505d", "node_type": "4", "metadata": {"page_label": "62", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Within the context of the work of the IMPACT Annual Meeting held in December 2008 (Hammamet, Tunisia) and based on the work carried out in the IMPACT Working Group on Legislative and Regulatory Infrastructure, a new definition was developed. This definition is included in the document entitled *Draft principles and elements for national legislation against counterfeit medical products* which was sent out for comments.\n\nTriggered by the governing bodies' discussion, a Circular Letter was mailed inviting Member States to share the terms and details of what national legislations regarded as \u201ccounterfeit medicines\u201d. The feedback was summarized by specialists and posted as a preliminary report on the WHO website to allow for additional feedback. The responses of Member States to the Circular Letter of the Director-General of WHO were presented to the Expert Committee. They related to:\n\n- definitions of \u201ccounterfeit medicines\u201d in the Member States;\n- Member States\u2019 national legislation; and\n- definition included in the above-cited IMPACT document.\n\nIt was explained that different types of legislation address the problem in the various Member States, which led to the diversity of responses. Also, English is not necessarily the language used in the national or regional legislations, which adds to the complexity. Many Member States are, however, in line with the current WHO definition. The Expert Committee took note that, although the majority of Member States supported the IMPACT definition and document, a considerable number of Member States did not, for various reasons.\n\nThe Expert Committee members fully recognized that spurious/falsely-labelled/falsified/counterfeit medical products presented a major public health problem. Several political and technical issues were raised. There was discussion whether or not APIs and excipients should be included in the definition and whether it was better to address \u201cmedicines\u201d only rather than the broader category of \u201cmedical products\u201d.\n\nThe Expert Committee took note that there was neither agreement among the Member States\u2019 definitions nor the terms used in the various legal contexts. However, several participants indicated that whatever the decision was on the future terminology within the WHO context, the word \u201ccounterfeit\u201d was already widely used by the public.\n\nDuring the 63rd World Health Assembly all Member States adopted by consensus the decision to have a working group on \u201cSubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d and had requested\n\n----\n\n[^14]: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e0d033bac04c72d6ae46aca5e84e687ce4d576217a19a651d0467a7f8403340b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Within the context of the work of the IMPACT Annual Meeting held in December 2008 (Hammamet, Tunisia) and based on the work carried out in the IMPACT Working Group on Legislative and Regulatory Infrastructure, a new definition was developed. This definition is included in the document entitled *Draft principles and elements for national legislation against counterfeit medical products* which was sent out for comments.\n\nTriggered by the governing bodies' discussion, a Circular Letter was mailed inviting Member States to share the terms and details of what national legislations regarded as \u201ccounterfeit medicines\u201d. The feedback was summarized by specialists and posted as a preliminary report on the WHO website to allow for additional feedback. The responses of Member States to the Circular Letter of the Director-General of WHO were presented to the Expert Committee. They related to:\n\n- definitions of \u201ccounterfeit medicines\u201d in the Member States;\n- Member States\u2019 national legislation; and\n- definition included in the above-cited IMPACT document.\n\nIt was explained that different types of legislation address the problem in the various Member States, which led to the diversity of responses. Also, English is not necessarily the language used in the national or regional legislations, which adds to the complexity. Many Member States are, however, in line with the current WHO definition. The Expert Committee took note that, although the majority of Member States supported the IMPACT definition and document, a considerable number of Member States did not, for various reasons.\n\nThe Expert Committee members fully recognized that spurious/falsely-labelled/falsified/counterfeit medical products presented a major public health problem. Several political and technical issues were raised. There was discussion whether or not APIs and excipients should be included in the definition and whether it was better to address \u201cmedicines\u201d only rather than the broader category of \u201cmedical products\u201d.\n\nThe Expert Committee took note that there was neither agreement among the Member States\u2019 definitions nor the terms used in the various legal contexts. However, several participants indicated that whatever the decision was on the future terminology within the WHO context, the word \u201ccounterfeit\u201d was already widely used by the public.\n\nDuring the 63rd World Health Assembly all Member States adopted by consensus the decision to have a working group on \u201cSubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d and had requested\n\n----\n\n[^14]: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2644, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1242b20e-6ff8-491d-b960-ba331aacc7f8": {"__data__": {"id_": "1242b20e-6ff8-491d-b960-ba331aacc7f8", "embedding": null, "metadata": {"page_label": "63", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the Director-General of WHO to convene a meeting to discuss this issue. It was, therefore, agreed that in light of the Member States\u2019 decision, a specially constituted working group would be the most appropriate forum to discuss this issue and that the Expert Committee on Specifications for Pharmaceutical Preparations should, therefore, not take the discussion further for the time being.\n\nIn summary, further to the discussions, the Expert Committee recommended that:\n\n- the working group of the Member States considers the WHO and the IMPACT definitions in order to develop an appropriate definition and include an explanation that will avoid confusion;\n- in so doing WHO should address the issue and its public health consequences instead of concentrating on the terminologies; and\n- as the first step, the work of this Committee should concentrate on medicines.\n\n### 14.3 International Nonproprietary Names (INN) for pharmaceutical substances\n\nVarious background materials including the cumulative list of International Nonproprietary Names (INN) were presented by the Manager of the INN Programme, including the use of stems and radicals in the selection of INN for pharmaceutical substances.\n\nINN online application architecture was described. It was scheduled for implementation with the USA being used as beta tester. A training programme for industry would be held in January\u2013February 2011. An instruction manual was available and two systems would be used at the beginning: online and also paper submissions.\n\nDuring 2009\u20132010, WHO published 299 Proposed INNs and 252 Recommended INNs in lists 101-104 of proposed and lists 61-64 of recommended INNs, respectively. Discussion was based around the number of new INNs, objections to proposed INNs and a recent request for substitution of a recommended INN due to possible confusion between two INNs.\n\nThe Expert Committee noted the report.\n\n### 15. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General of WHO in the area of quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas recomend\u00f3 la creaci\u00f3n de un grupo de trabajo de los Estados Miembros para desarrollar definiciones adecuadas y abordar las consecuencias de salud p\u00fablica relacionadas con la terminolog\u00eda, enfoc\u00e1ndose inicialmente en los medicamentos.\n\n2. **Nombres No Propietarios Internacionales (INN)**: Se present\u00f3 informaci\u00f3n sobre el uso de nombres no propietarios internacionales (INN) para sustancias farmac\u00e9uticas, incluyendo la arquitectura de la aplicaci\u00f3n en l\u00ednea para la gesti\u00f3n de INN, que se implementar\u00e1 con Estados Unidos como beta tester. Durante el per\u00edodo 2009-2010, se publicaron 299 INN propuestos y 252 INN recomendados.\n\n3. **Funci\u00f3n del Comit\u00e9 de Expertos**: El Comit\u00e9 proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final, asesorando al Director General de la OMS en temas de aseguramiento de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 se acord\u00f3 respecto a la discusi\u00f3n de las definiciones de la OMS y de IMPACT?**\n   - Se acord\u00f3 que un grupo de trabajo especialmente constituido ser\u00eda el foro m\u00e1s apropiado para discutir las definiciones de la OMS y de IMPACT, y que el Comit\u00e9 de Expertos no continuar\u00eda con la discusi\u00f3n por el momento.\n\n2. **\u00bfCu\u00e1ntos INN propuestos y recomendados public\u00f3 la OMS durante el per\u00edodo 2009-2010?**\n   - Durante el per\u00edodo 2009-2010, la OMS public\u00f3 299 INN propuestos y 252 INN recomendados.\n\n3. **\u00bfCu\u00e1l es el enfoque inicial del trabajo del Comit\u00e9 de Expertos en relaci\u00f3n con los medicamentos?**\n   - El enfoque inicial del trabajo del Comit\u00e9 de Expertos debe concentrarse en los medicamentos, abordando las definiciones y sus consecuencias en la salud p\u00fablica en lugar de centrarse \u00fanicamente en la terminolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Definici\u00f3n de Medicamentos Falsificados:** Se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\" durante la reuni\u00f3n anual de IMPACT en diciembre de 2008, que se incluy\u00f3 en un documento para comentarios.\n2. **Diversidad Legislativa:** Las respuestas de los Estados Miembros revelaron una diversidad en las definiciones y legislaciones nacionales sobre medicamentos falsificados, influenciada por diferencias en los marcos legales y el uso de distintos idiomas.\n3. **Apoyo y Oposici\u00f3n a la Definici\u00f3n de la OMS:** Aunque la mayor\u00eda de los Estados Miembros apoyaron la definici\u00f3n de la OMS, un n\u00famero considerable no lo hizo, lo que gener\u00f3 discusiones sobre las razones detr\u00e1s de esta falta de consenso.\n4. **Cuestiones Pol\u00edticas y T\u00e9cnicas:** Se discutieron implicaciones sobre si incluir ingredientes activos (APIs) y excipientes en la definici\u00f3n, as\u00ed como la preferencia por abordar solo \"medicamentos\" en lugar de \"productos m\u00e9dicos\" en general.\n5. **Creaci\u00f3n de un Grupo de Trabajo:** Durante la 63\u00aa Asamblea Mundial de la Salud, se decidi\u00f3 establecer un grupo de trabajo sobre productos m\u00e9dicos subest\u00e1ndar y falsificados.\n\n**Entidades:**\n- **IMPACT:** Grupo de trabajo que se centra en la infraestructura legislativa y regulatoria relacionada con los medicamentos falsificados.\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad que lidera la discusi\u00f3n y desarrollo de definiciones y principios sobre medicamentos falsificados.\n- **Estados Miembros:** Pa\u00edses que participan en la OMS y que proporcionan retroalimentaci\u00f3n sobre sus legislaciones nacionales.\n- **Comit\u00e9 de Expertos:** Grupo que revisa las respuestas de los Estados Miembros y discute las definiciones y t\u00e9rminos relacionados con los medicamentos falsificados. \n\nEste resumen destaca la importancia de la colaboraci\u00f3n internacional en la lucha contra los medicamentos falsificados y las complejidades que surgen de las diferencias legislativas y ling\u00fc\u00edsticas entre los Estados Miembros.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, International Nonproprietary Names, quality assurance, working group"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f850563-9241-4302-9568-eb85e14ede57", "node_type": "4", "metadata": {"page_label": "63", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the Director-General of WHO to convene a meeting to discuss this issue. It was, therefore, agreed that in light of the Member States\u2019 decision, a specially constituted working group would be the most appropriate forum to discuss this issue and that the Expert Committee on Specifications for Pharmaceutical Preparations should, therefore, not take the discussion further for the time being.\n\nIn summary, further to the discussions, the Expert Committee recommended that:\n\n- the working group of the Member States considers the WHO and the IMPACT definitions in order to develop an appropriate definition and include an explanation that will avoid confusion;\n- in so doing WHO should address the issue and its public health consequences instead of concentrating on the terminologies; and\n- as the first step, the work of this Committee should concentrate on medicines.\n\n### 14.3 International Nonproprietary Names (INN) for pharmaceutical substances\n\nVarious background materials including the cumulative list of International Nonproprietary Names (INN) were presented by the Manager of the INN Programme, including the use of stems and radicals in the selection of INN for pharmaceutical substances.\n\nINN online application architecture was described. It was scheduled for implementation with the USA being used as beta tester. A training programme for industry would be held in January\u2013February 2011. An instruction manual was available and two systems would be used at the beginning: online and also paper submissions.\n\nDuring 2009\u20132010, WHO published 299 Proposed INNs and 252 Recommended INNs in lists 101-104 of proposed and lists 61-64 of recommended INNs, respectively. Discussion was based around the number of new INNs, objections to proposed INNs and a recent request for substitution of a recommended INN due to possible confusion between two INNs.\n\nThe Expert Committee noted the report.\n\n### 15. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General of WHO in the area of quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "61350a30db7b2dea795e95e14f6a7bcec86aa050f175f02b61d720edbf34a542", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the Director-General of WHO to convene a meeting to discuss this issue. It was, therefore, agreed that in light of the Member States\u2019 decision, a specially constituted working group would be the most appropriate forum to discuss this issue and that the Expert Committee on Specifications for Pharmaceutical Preparations should, therefore, not take the discussion further for the time being.\n\nIn summary, further to the discussions, the Expert Committee recommended that:\n\n- the working group of the Member States considers the WHO and the IMPACT definitions in order to develop an appropriate definition and include an explanation that will avoid confusion;\n- in so doing WHO should address the issue and its public health consequences instead of concentrating on the terminologies; and\n- as the first step, the work of this Committee should concentrate on medicines.\n\n### 14.3 International Nonproprietary Names (INN) for pharmaceutical substances\n\nVarious background materials including the cumulative list of International Nonproprietary Names (INN) were presented by the Manager of the INN Programme, including the use of stems and radicals in the selection of INN for pharmaceutical substances.\n\nINN online application architecture was described. It was scheduled for implementation with the USA being used as beta tester. A training programme for industry would be held in January\u2013February 2011. An instruction manual was available and two systems would be used at the beginning: online and also paper submissions.\n\nDuring 2009\u20132010, WHO published 299 Proposed INNs and 252 Recommended INNs in lists 101-104 of proposed and lists 61-64 of recommended INNs, respectively. Discussion was based around the number of new INNs, objections to proposed INNs and a recent request for substitution of a recommended INN due to possible confusion between two INNs.\n\nThe Expert Committee noted the report.\n\n### 15. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General of WHO in the area of quality assurance of medicines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2238, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b93eac3e-dc0c-42ec-80d8-0e50e65779f4": {"__data__": {"id_": "b93eac3e-dc0c-42ec-80d8-0e50e65779f4", "embedding": null, "metadata": {"page_label": "64", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.\n\nThe activities discussed during this Expert Committee meeting have broad inter- and intrastructural relationships and links. There are joint activities, specifically with the WHO Expert Committees on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Prequalification of Medicines Programme managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF to combat circulation of substandard medicines and to work towards access to good-quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son las principales funciones del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS y c\u00f3mo se relacionan con otros comit\u00e9s de la OMS?**\n   - Esta pregunta busca detallar las funciones espec\u00edficas del Comit\u00e9 y su interacci\u00f3n con otros comit\u00e9s de la OMS, lo que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfC\u00f3mo contribuye el Comit\u00e9 a la implementaci\u00f3n de programas internacionales como el Programa de Precalificaci\u00f3n de Medicamentos y la Iniciativa Roll Back Malaria?**\n   - Esta pregunta se centra en el impacto pr\u00e1ctico de las recomendaciones del Comit\u00e9 en programas espec\u00edficos, lo que puede no estar documentado en otros lugares.\n\n3. **\u00bfQu\u00e9 procesos se siguen para desarrollar las normas y directrices internacionales en el \u00e1mbito de la calidad de los medicamentos, seg\u00fan el Comit\u00e9?**\n   - Esta pregunta busca entender el proceso de consenso internacional que se utiliza para establecer las normas, un aspecto que puede no ser ampliamente discutido en otras fuentes.\n\n### Resumen de nivel superior del contexto:\n\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS tiene m\u00e1s de 60 a\u00f1os de historia y se ha dedicado a proporcionar recomendaciones claras y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos. Sus actividades est\u00e1n interconectadas con otros comit\u00e9s de la OMS y son fundamentales para el funcionamiento de programas internacionales, como el de Precalificaci\u00f3n de Medicamentos. Las directrices y normas que desarrolla el Comit\u00e9 son utilizadas por Estados Miembros y organizaciones internacionales para combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de buena calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Grupo de Trabajo de Estados Miembros**: Se acord\u00f3 la creaci\u00f3n de un grupo de trabajo constituido especialmente para discutir las definiciones de la OMS y de IMPACT, evitando que el Comit\u00e9 de Expertos contin\u00fae con la discusi\u00f3n por el momento.\n\n2. **Recomendaciones del Comit\u00e9 de Expertos**:\n   - Desarrollar definiciones adecuadas que eviten confusiones.\n   - Abordar las consecuencias de salud p\u00fablica en lugar de centrarse solo en la terminolog\u00eda.\n   - Enfocar el trabajo inicial en los medicamentos.\n\n3. **Nombres No Propietarios Internacionales (INN)**:\n   - Se presentaron materiales sobre INN, incluyendo una lista acumulativa y el uso de ra\u00edces en la selecci\u00f3n de nombres.\n   - Se describi\u00f3 la arquitectura de la aplicaci\u00f3n en l\u00ednea para la gesti\u00f3n de INN, con Estados Unidos como beta tester.\n   - Durante 2009-2010, se publicaron 299 INN propuestos y 252 INN recomendados.\n\n4. **Funci\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**:\n   - Proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final.\n   - Asesora al Director General de la OMS en temas de aseguramiento de calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica a nivel internacional.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que asesora sobre la calidad de los medicamentos.\n- **INN (Nombres No Propietarios Internacionales)**: Sistema de nomenclatura para sustancias farmac\u00e9uticas.", "excerpt_keywords": "Keywords: Expert Committee, Pharmaceutical Preparations, quality assurance, international guidelines, WHO Member States"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9d4aa148-243b-4dca-a061-e3a0480c1bd6", "node_type": "4", "metadata": {"page_label": "64", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.\n\nThe activities discussed during this Expert Committee meeting have broad inter- and intrastructural relationships and links. There are joint activities, specifically with the WHO Expert Committees on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Prequalification of Medicines Programme managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF to combat circulation of substandard medicines and to work towards access to good-quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5acbbf983458f3ae99ae72004d61bdb357511d482f7bdd0198b63f620902ef3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The Expert Committee on Specifications for Pharmaceutical Preparations is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.\n\nThe activities discussed during this Expert Committee meeting have broad inter- and intrastructural relationships and links. There are joint activities, specifically with the WHO Expert Committees on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Prequalification of Medicines Programme managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF to combat circulation of substandard medicines and to work towards access to good-quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2907, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f15c450b-21c3-4dc7-9621-eacd28689eab": {"__data__": {"id_": "f15c450b-21c3-4dc7-9621-eacd28689eab", "embedding": null, "metadata": {"page_label": "65", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The following new guidelines were adopted and recommended for use:\n\n- Release procedure of International Chemical Reference Substances (Annex 1)\n- WHO good practices for pharmaceutical microbiology laboratories (Annex 2)\n- WHO good manufacturing practices: main principles for pharmaceutical products (Annex 3)\n- WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) (Annex 4)\n- WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (Annex 5)\n- WHO good manufacturing practices for sterile pharmaceutical products (Annex 6)\n- WHO guidelines on transfer of technology in pharmaceutical manufacturing (Annex 7)\n- Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) (Annex 8)\n- Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) (Annex 9)\n- Procedure for prequalification of pharmaceutical products (Annex 10)\n- Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities (Annex 11)\n- Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (Annex 12)\n- WHO guidelines for preparing a laboratory information file (Annex 13)\n- WHO guidelines for drafting a site master file (Annex 14)\n- Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format (Annex 15)\n\nFor inclusion in *The International Pharmacopoeia*\n\nThe following monographs were adopted:\n\n- *For antiretroviral medicines*\n  - efavirenz tablets\n  - didanosine capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta nuevas directrices adoptadas para el uso en la industria farmac\u00e9utica, que incluyen procedimientos de liberaci\u00f3n de sustancias qu\u00edmicas de referencia internacional, buenas pr\u00e1cticas de fabricaci\u00f3n y microbiolog\u00eda, as\u00ed como gu\u00edas para la precalificaci\u00f3n de productos farmac\u00e9uticos. Adem\u00e1s, se han adoptado monograf\u00edas para medicamentos antirretrovirales, espec\u00edficamente efavirenz y didanosina.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales directrices adoptadas por la OMS para las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las principales directrices incluyen: \n     - Buenas pr\u00e1cticas de fabricaci\u00f3n: principios principales para productos farmac\u00e9uticos (Anexo 3).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles (Anexo 6).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre (Anexo 4).\n\n2. **\u00bfQu\u00e9 monograf\u00edas espec\u00edficas se han adoptado para los medicamentos antirretrovirales en *The International Pharmacopoeia*?**\n   - Respuesta: Se han adoptado las siguientes monograf\u00edas para medicamentos antirretrovirales:\n     - Efavirenz en tabletas.\n     - Didanosina en c\u00e1psulas.\n\n3. **\u00bfQu\u00e9 procedimiento se recomienda para la precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan las nuevas directrices de la OMS?**\n   - Respuesta: Se recomienda un procedimiento espec\u00edfico para la precalificaci\u00f3n de productos farmac\u00e9uticos (Anexo 10), que incluye una gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas (Anexo 11).", "prev_section_summary": "### Temas Clave:\n\n1. **Historia y Funci\u00f3n del Comit\u00e9**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS tiene m\u00e1s de 60 a\u00f1os de historia, habiendo sido fundado en 1947. Su principal funci\u00f3n es proporcionar recomendaciones claras y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos.\n\n2. **Desarrollo de Normas y Directrices**: Las normas en el \u00e1mbito de la calidad de los medicamentos son desarrolladas a trav\u00e9s de un proceso de consenso internacional, lo que garantiza que las recomendaciones sean pr\u00e1cticas y aplicables a nivel global.\n\n3. **Interconexi\u00f3n con Otros Comit\u00e9s**: El Comit\u00e9 colabora con otros comit\u00e9s de la OMS, como el de Estandarizaci\u00f3n Biol\u00f3gica y el de Selecci\u00f3n y Uso de Medicamentos Esenciales, as\u00ed como su Subcomit\u00e9 sobre Medicamentos para Ni\u00f1os.\n\n4. **Contribuci\u00f3n a Programas Internacionales**: El Comit\u00e9 apoya el Programa de Precalificaci\u00f3n de Medicamentos de la ONU y otras iniciativas importantes como el Programa Roll Back Malaria y Stop TB, proporcionando las directrices necesarias para su funcionamiento.\n\n5. **Impacto en la Salud Global**: Las recomendaciones del Comit\u00e9 est\u00e1n dise\u00f1adas para ayudar a los Estados Miembros, organizaciones internacionales y agencias de la ONU a combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de buena calidad.\n\n### Entidades Clave:\n\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS**: Organismo responsable de establecer normas y directrices para la calidad de los medicamentos.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que gestiona el Comit\u00e9 y sus actividades.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la ONU**: Iniciativa que se beneficia de las directrices del Comit\u00e9.\n- **Global Fund to Fight AIDS, Tuberculosis and Malaria**: Organizaci\u00f3n que utiliza las recomendaciones del Comit\u00e9 para mejorar la calidad de los medicamentos.\n- **UNICEF**: Organizaci\u00f3n que tambi\u00e9n se apoya en las directrices del Comit\u00e9 para asegurar el acceso a medicamentos de calidad, especialmente para ni\u00f1os. \n\n### Conclusi\u00f3n:\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS desempe\u00f1a un papel crucial en la garant\u00eda de la calidad de los medicamentos a nivel internacional, colaborando con diversas entidades y programas para mejorar la salud global.", "excerpt_keywords": "Keywords: WHO guidelines, pharmaceutical microbiology, good manufacturing practices, antiretroviral medicines, prequalification procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7385c5da-6f7c-466f-be7b-2f6fc8830d18", "node_type": "4", "metadata": {"page_label": "65", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The following new guidelines were adopted and recommended for use:\n\n- Release procedure of International Chemical Reference Substances (Annex 1)\n- WHO good practices for pharmaceutical microbiology laboratories (Annex 2)\n- WHO good manufacturing practices: main principles for pharmaceutical products (Annex 3)\n- WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) (Annex 4)\n- WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (Annex 5)\n- WHO good manufacturing practices for sterile pharmaceutical products (Annex 6)\n- WHO guidelines on transfer of technology in pharmaceutical manufacturing (Annex 7)\n- Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) (Annex 8)\n- Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) (Annex 9)\n- Procedure for prequalification of pharmaceutical products (Annex 10)\n- Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities (Annex 11)\n- Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (Annex 12)\n- WHO guidelines for preparing a laboratory information file (Annex 13)\n- WHO guidelines for drafting a site master file (Annex 14)\n- Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format (Annex 15)\n\nFor inclusion in *The International Pharmacopoeia*\n\nThe following monographs were adopted:\n\n- *For antiretroviral medicines*\n  - efavirenz tablets\n  - didanosine capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "acef6e7d0bcb6798e5f7baa432eb569ab250b14d2f825b087d47b930c937df0b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The following new guidelines were adopted and recommended for use:\n\n- Release procedure of International Chemical Reference Substances (Annex 1)\n- WHO good practices for pharmaceutical microbiology laboratories (Annex 2)\n- WHO good manufacturing practices: main principles for pharmaceutical products (Annex 3)\n- WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) (Annex 4)\n- WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (Annex 5)\n- WHO good manufacturing practices for sterile pharmaceutical products (Annex 6)\n- WHO guidelines on transfer of technology in pharmaceutical manufacturing (Annex 7)\n- Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) (Annex 8)\n- Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) (Annex 9)\n- Procedure for prequalification of pharmaceutical products (Annex 10)\n- Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities (Annex 11)\n- Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (Annex 12)\n- WHO guidelines for preparing a laboratory information file (Annex 13)\n- WHO guidelines for drafting a site master file (Annex 14)\n- Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format (Annex 15)\n\nFor inclusion in *The International Pharmacopoeia*\n\nThe following monographs were adopted:\n\n- *For antiretroviral medicines*\n  - efavirenz tablets\n  - didanosine capsules", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1955, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "44efd664-50a9-423b-9cf5-c94d7ceac684": {"__data__": {"id_": "44efd664-50a9-423b-9cf5-c94d7ceac684", "embedding": null, "metadata": {"page_label": "66", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "emtricitabine capsules  \nemtricitabine and tenofovir tablets  \nefavirenz, emtricitabine and tenofovir tablets  \n\n- *For antimalarial medicines*  \n  artesunate  \n  artesunate for injection  \n  mefloquine tablets  \n  sulfadoxine and pyrimethamine tablets  \n\n- *For antituberculosis medicines*  \n  capreomycin sulfate  \n  capreomycin for injection  \n  ofloxacin  \n  ofloxacin tablets  \n  levofloxacin  \n  levofloxacin tablets  \n\n- *For anti-infectives*  \n  amoxicillin oral suspension  \n  levamisole tablets  \n  metronidazole oral suspension  \n  sulfamethoxazole and trimethoprim tablets  \n\n- *For other medicines*  \n  oseltamivir phosphate  \n  oseltamivir capsules  \n  sodium bicarbonate intravenous infusion  \n  paracetamol oral solution  \n  paracetamol oral suspension  \n  levonorgestrel tablets  \n  retinol concentrate  \n\n**General policy topics and general revision issues for:**  \n- uniformity of content for single-dose preparations  \n- oral suspension/solutions reconstituted from powder  \n- dissolution testing  \n\n**Harmonization with PDG general texts for the following:**  \n- Residue on ignition/sulfated ash  \n- Test for extractable volume of parenteral preparations  \n- Test for particulate contamination: subvisible particles  \n- Microbial examination of non-sterile products: microbial enumeration tests  \n- Microbial examination of non-sterile products: tests for specified microorganisms  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Medicamentos listados**: El documento proporciona una lista de medicamentos clasificados en varias categor\u00edas, incluyendo antirretrovirales, antimal\u00e1ricos, antituberculosos, antiinfecciosos y otros medicamentos. Cada categor\u00eda incluye nombres espec\u00edficos de medicamentos y sus formas de presentaci\u00f3n.\n\n2. **Temas de pol\u00edtica general y cuestiones de revisi\u00f3n**: Se mencionan temas de pol\u00edtica general relacionados con la uniformidad de contenido en preparaciones de dosis \u00fanica, as\u00ed como cuestiones sobre la reconstituci\u00f3n de soluciones orales y pruebas de disoluci\u00f3n.\n\n3. **Harmonizaci\u00f3n con textos generales de PDG**: El documento tambi\u00e9n aborda la necesidad de armonizaci\u00f3n con textos generales de la Farmacopea de la OMS (PDG) en relaci\u00f3n con pruebas espec\u00edficas, como residuos de ignici\u00f3n, volumen extra\u00edble de preparaciones parenterales, y ex\u00e1menes microbianos de productos no est\u00e9riles.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los medicamentos antituberculosos mencionados en el documento y qu\u00e9 formas de presentaci\u00f3n tienen?**\n   - Respuesta: Los medicamentos antituberculosos mencionados son capreomycin sulfate (sulfato de capreomicina), capreomycin for injection (capreomicina para inyecci\u00f3n), ofloxacin (ofloxacino), ofloxacin tablets (tabletas de ofloxacino), levofloxacin (levofloxacino) y levofloxacin tablets (tabletas de levofloxacino).\n\n2. **\u00bfQu\u00e9 temas de pol\u00edtica general se abordan en relaci\u00f3n con las preparaciones de dosis \u00fanica y las soluciones orales?**\n   - Respuesta: Se abordan temas de uniformidad de contenido para preparaciones de dosis \u00fanica, la reconstituci\u00f3n de soluciones orales a partir de polvo y las pruebas de disoluci\u00f3n.\n\n3. **\u00bfQu\u00e9 pruebas espec\u00edficas se mencionan para la armonizaci\u00f3n con los textos generales de PDG?**\n   - Respuesta: Las pruebas espec\u00edficas mencionadas para la armonizaci\u00f3n incluyen: Residue on ignition/sulfated ash (residuos de ignici\u00f3n/ash sulfatada), Test for extractable volume of parenteral preparations (prueba para el volumen extra\u00edble de preparaciones parenterales), Test for particulate contamination: subvisible particles (prueba para contaminaci\u00f3n particulada: part\u00edculas subvisibles), y Microbial examination of non-sterile products: microbial enumeration tests (examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta una serie de nuevas directrices y monograf\u00edas adoptadas para mejorar las pr\u00e1cticas en la industria farmac\u00e9utica. Los temas clave incluyen:\n\n1. **Directrices Adoptadas**:\n   - Procedimientos para la liberaci\u00f3n de sustancias qu\u00edmicas de referencia internacional.\n   - Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, incluyendo:\n     - Principios generales de BPF.\n     - BPF para productos farmac\u00e9uticos est\u00e9riles.\n     - BPF para establecimientos de sangre.\n   - Buenas pr\u00e1cticas de microbiolog\u00eda farmac\u00e9utica.\n   - Directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica.\n   - Normas de pr\u00e1ctica farmac\u00e9utica y almacenamiento de productos farmac\u00e9uticos sensibles al tiempo y temperatura.\n   - Procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad.\n\n2. **Monograf\u00edas Adoptadas para Medicamentos Antirretrovirales**:\n   - Efavirenz en tabletas.\n   - Didanosina en c\u00e1psulas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices y recomendaciones.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos antirretrovirales como efavirenz y didanosina.\n- **Anexos**: Documentos que detallan cada una de las directrices y procedimientos adoptados.\n\nEste resumen destaca la importancia de las nuevas directrices para asegurar la calidad y seguridad en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos, as\u00ed como la inclusi\u00f3n de monograf\u00edas espec\u00edficas en *The International Pharmacopoeia*.", "excerpt_keywords": "Keywords: emtricitabine, antimalarial, antituberculosis, harmonization, pharmaceutical guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f359c971-0ddf-415b-9b3f-12ac4c54293b", "node_type": "4", "metadata": {"page_label": "66", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "emtricitabine capsules  \nemtricitabine and tenofovir tablets  \nefavirenz, emtricitabine and tenofovir tablets  \n\n- *For antimalarial medicines*  \n  artesunate  \n  artesunate for injection  \n  mefloquine tablets  \n  sulfadoxine and pyrimethamine tablets  \n\n- *For antituberculosis medicines*  \n  capreomycin sulfate  \n  capreomycin for injection  \n  ofloxacin  \n  ofloxacin tablets  \n  levofloxacin  \n  levofloxacin tablets  \n\n- *For anti-infectives*  \n  amoxicillin oral suspension  \n  levamisole tablets  \n  metronidazole oral suspension  \n  sulfamethoxazole and trimethoprim tablets  \n\n- *For other medicines*  \n  oseltamivir phosphate  \n  oseltamivir capsules  \n  sodium bicarbonate intravenous infusion  \n  paracetamol oral solution  \n  paracetamol oral suspension  \n  levonorgestrel tablets  \n  retinol concentrate  \n\n**General policy topics and general revision issues for:**  \n- uniformity of content for single-dose preparations  \n- oral suspension/solutions reconstituted from powder  \n- dissolution testing  \n\n**Harmonization with PDG general texts for the following:**  \n- Residue on ignition/sulfated ash  \n- Test for extractable volume of parenteral preparations  \n- Test for particulate contamination: subvisible particles  \n- Microbial examination of non-sterile products: microbial enumeration tests  \n- Microbial examination of non-sterile products: tests for specified microorganisms  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "97bc8e9e15457aaab6eda0524753185a07481f3812e3ea56735dde706b702c63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "emtricitabine capsules  \nemtricitabine and tenofovir tablets  \nefavirenz, emtricitabine and tenofovir tablets  \n\n- *For antimalarial medicines*  \n  artesunate  \n  artesunate for injection  \n  mefloquine tablets  \n  sulfadoxine and pyrimethamine tablets  \n\n- *For antituberculosis medicines*  \n  capreomycin sulfate  \n  capreomycin for injection  \n  ofloxacin  \n  ofloxacin tablets  \n  levofloxacin  \n  levofloxacin tablets  \n\n- *For anti-infectives*  \n  amoxicillin oral suspension  \n  levamisole tablets  \n  metronidazole oral suspension  \n  sulfamethoxazole and trimethoprim tablets  \n\n- *For other medicines*  \n  oseltamivir phosphate  \n  oseltamivir capsules  \n  sodium bicarbonate intravenous infusion  \n  paracetamol oral solution  \n  paracetamol oral suspension  \n  levonorgestrel tablets  \n  retinol concentrate  \n\n**General policy topics and general revision issues for:**  \n- uniformity of content for single-dose preparations  \n- oral suspension/solutions reconstituted from powder  \n- dissolution testing  \n\n**Harmonization with PDG general texts for the following:**  \n- Residue on ignition/sulfated ash  \n- Test for extractable volume of parenteral preparations  \n- Test for particulate contamination: subvisible particles  \n- Microbial examination of non-sterile products: microbial enumeration tests  \n- Microbial examination of non-sterile products: tests for specified microorganisms", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1401, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "24d1aa3d-f3c4-44cf-8875-36ec3f4fe43a": {"__data__": {"id_": "24d1aa3d-f3c4-44cf-8875-36ec3f4fe43a", "embedding": null, "metadata": {"page_label": "67", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\n**International reference standards:**\n- New procedure for the release of International Chemical Reference Substances (see also Annex 1)\n- General policy regarding international standards for human recombinant insulin\n\nThe following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.\n\n**Overall policy**\n- To prepare overviews on the key activities and on the history and working process of this Expert Committee for wide dissemination and information.\n- To prepare a general policy paper for future maintenance, revision and update of WHO guidelines adopted by this Expert Committee.\n\n**The International Pharmacopoeia**\n- Continue development of specifications for medicines, general methods and texts and general supplementary information in accordance with the work plan and as decided at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods.\n- Continue the preparatory work on the Second supplement to *The International Pharmacopoeia*, fourth edition and towards the fifth edition, especially in electronic form (CD-ROM and online).\n\n**International Chemical Reference Substances (ICRS)**\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements to the ICRS web site.\n- Continue the efforts to further enhance the development of new ICRS.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos relacionados con la calidad y los est\u00e1ndares de los productos farmac\u00e9uticos. Se discuten criterios de aceptaci\u00f3n para la evaluaci\u00f3n microbiana de productos no est\u00e9riles, as\u00ed como pruebas de disoluci\u00f3n, desintegraci\u00f3n y esterilidad. Tambi\u00e9n se menciona la importancia de las sustancias qu\u00edmicas de referencia internacional y se establecen recomendaciones para el desarrollo de especificaciones y directrices. Se enfatiza la colaboraci\u00f3n internacional y la necesidad de mantener y actualizar las gu\u00edas de la OMS.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la evaluaci\u00f3n microbiana de productos no est\u00e9riles seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los criterios establecidos para la evaluaci\u00f3n de productos farmac\u00e9uticos no est\u00e9riles, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 acciones se sugieren para la promoci\u00f3n y desarrollo de las Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)?**\n   - Esta pregunta se centra en las iniciativas espec\u00edficas mencionadas en el documento para mejorar el uso y desarrollo de las ICRS, proporcionando informaci\u00f3n que puede no estar disponible en otros lugares.\n\n3. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para la actualizaci\u00f3n y mantenimiento de las gu\u00edas de la OMS adoptadas por el Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso y las pol\u00edticas que se est\u00e1n implementando para asegurar que las gu\u00edas de la OMS se mantengan actualizadas y relevantes, un aspecto que puede no ser ampliamente discutido en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Medicamentos Listados**:\n   - **Antirretrovirales**:\n     - Emtricitabina (c\u00e1psulas)\n     - Emtricitabina y tenofovir (tabletas)\n     - Efavirenz, emtricitabina y tenofovir (tabletas)\n   - **Antimal\u00e1ricos**:\n     - Artesunato\n     - Artesunato para inyecci\u00f3n\n     - Mefloquina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas)\n   - **Antituberculosos**:\n     - Sulfato de capreomicina\n     - Capreomicina para inyecci\u00f3n\n     - Ofloxacino\n     - Ofloxacino (tabletas)\n     - Levofloxacino\n     - Levofloxacino (tabletas)\n   - **Anti-infectivos**:\n     - Amoxicilina (suspensi\u00f3n oral)\n     - Levamisole (tabletas)\n     - Metronidazol (suspensi\u00f3n oral)\n     - Sulfametoxazol y trimetoprim (tabletas)\n   - **Otros Medicamentos**:\n     - Fosfato de oseltamivir\n     - Oseltamivir (c\u00e1psulas)\n     - Bicarbonato de sodio (infusi\u00f3n intravenosa)\n     - Paracetamol (soluci\u00f3n oral y suspensi\u00f3n oral)\n     - Tabletas de levonorgestrel\n     - Concentrado de retinol\n\n2. **Temas de Pol\u00edtica General y Cuestiones de Revisi\u00f3n**:\n   - Uniformidad de contenido para preparaciones de dosis \u00fanica.\n   - Reconstituci\u00f3n de soluciones orales a partir de polvo.\n   - Pruebas de disoluci\u00f3n.\n\n3. **Harmonizaci\u00f3n con Textos Generales de PDG**:\n   - Residuo de ignici\u00f3n/ash sulfatada.\n   - Prueba para el volumen extra\u00edble de preparaciones parenterales.\n   - Prueba para contaminaci\u00f3n particulada: part\u00edculas subvisibles.\n   - Examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana.\n   - Examen microbiano de productos no est\u00e9riles: pruebas para microorganismos espec\u00edficos.\n\nEste resumen destaca los medicamentos clasificados en diferentes categor\u00edas, los temas de pol\u00edtica general relacionados con la uniformidad y las pruebas, as\u00ed como la necesidad de armonizaci\u00f3n con los est\u00e1ndares de la Farmacopea de la OMS.", "excerpt_keywords": "Keywords: microbial examination, pharmaceutical standards, International Pharmacopoeia, quality assurance, chemical reference substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "34b318e3-92af-428c-ab83-d12200205b1b", "node_type": "4", "metadata": {"page_label": "67", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\n**International reference standards:**\n- New procedure for the release of International Chemical Reference Substances (see also Annex 1)\n- General policy regarding international standards for human recombinant insulin\n\nThe following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.\n\n**Overall policy**\n- To prepare overviews on the key activities and on the history and working process of this Expert Committee for wide dissemination and information.\n- To prepare a general policy paper for future maintenance, revision and update of WHO guidelines adopted by this Expert Committee.\n\n**The International Pharmacopoeia**\n- Continue development of specifications for medicines, general methods and texts and general supplementary information in accordance with the work plan and as decided at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods.\n- Continue the preparatory work on the Second supplement to *The International Pharmacopoeia*, fourth edition and towards the fifth edition, especially in electronic form (CD-ROM and online).\n\n**International Chemical Reference Substances (ICRS)**\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements to the ICRS web site.\n- Continue the efforts to further enhance the development of new ICRS.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "77aa4caa7e2c5ac77c88edd420112126e4efeeab1b5c9fd5212a655669dc653f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\n**International reference standards:**\n- New procedure for the release of International Chemical Reference Substances (see also Annex 1)\n- General policy regarding international standards for human recombinant insulin\n\nThe following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.\n\n**Overall policy**\n- To prepare overviews on the key activities and on the history and working process of this Expert Committee for wide dissemination and information.\n- To prepare a general policy paper for future maintenance, revision and update of WHO guidelines adopted by this Expert Committee.\n\n**The International Pharmacopoeia**\n- Continue development of specifications for medicines, general methods and texts and general supplementary information in accordance with the work plan and as decided at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods.\n- Continue the preparatory work on the Second supplement to *The International Pharmacopoeia*, fourth edition and towards the fifth edition, especially in electronic form (CD-ROM and online).\n\n**International Chemical Reference Substances (ICRS)**\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements to the ICRS web site.\n- Continue the efforts to further enhance the development of new ICRS.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1928, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "99e4d7fc-0bb7-4fd7-a96a-a992d4440eb9": {"__data__": {"id_": "99e4d7fc-0bb7-4fd7-a96a-a992d4440eb9", "embedding": null, "metadata": {"page_label": "68", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# External Quality Assurance Assessment Scheme (EQAAS)\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories, Phase 5, test series 3 onwards.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Continue the consultation process with regard to a revision of GMP: water for pharmaceutical use.\n- Continue the consultation process on Quality risk management principles with a view to updating the WHO guidelines on hazard analysis and critical control points (HACCP) to cover new trends.\n- Finalize the special guidance for artemisinin as a starting material for production of antimalarials based on the confirmation of the impurity profile through additional laboratory analysis.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce in consultation with WHO Member States and the WHO Legal Counsel.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the Development of paediatric medicines: pharmaceutical development. Points to consider.\n- Continue the development of the Pharmaceutical development for multisource (generic) pharmaceutical products.\n- Continue the update of the Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms published in 2006, with a view to including the new medicines selected for the WHO Model List of Essential Medicines (EML).\n- Report back to the next Expert Committee meeting on the pilot project undertaken by the Prequalification of Medicines Programme regarding the implementation of the provisionally adopted Guidelines on submission of documentation for multisource (generic) finished pharmaceutical product: quality part.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas iniciativas y procesos relacionados con la calidad de los productos farmac\u00e9uticos. Se enfoca en la continuaci\u00f3n del Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS) para laboratorios de control de calidad, la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP), la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional, y la gu\u00eda regulatoria para el desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource. Tambi\u00e9n se menciona la importancia de actualizar la terminolog\u00eda de aseguramiento de calidad.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se est\u00e1n tomando para la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos biol\u00f3gicos?**\n   - Esta pregunta busca detalles sobre el proceso de revisi\u00f3n de GMP, que se menciona en el contexto, y c\u00f3mo se est\u00e1 llevando a cabo bajo la direcci\u00f3n del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n implementando para actualizar las directrices de la OMS sobre el an\u00e1lisis de riesgos y los puntos cr\u00edticos de control (HACCP)?**\n   - Esta pregunta se centra en el proceso de consulta mencionado en el contexto sobre la actualizaci\u00f3n de las directrices de HACCP, buscando informaci\u00f3n sobre las nuevas tendencias que se est\u00e1n considerando.\n\n3. **\u00bfC\u00f3mo se est\u00e1 llevando a cabo la consulta con los Estados Miembros de la OMS respecto al Esquema de Certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional?**\n   - Esta pregunta indaga sobre el proceso de consulta y colaboraci\u00f3n con los Estados Miembros en relaci\u00f3n con la certificaci\u00f3n de productos farmac\u00e9uticos, buscando detalles sobre la interacci\u00f3n y los pasos espec\u00edficos que se est\u00e1n tomando.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos fundamentales relacionados con la calidad y los est\u00e1ndares de los productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Evaluaci\u00f3n Microbiana**:\n   - Criterios de aceptaci\u00f3n para productos farmac\u00e9uticos no est\u00e9riles.\n   - M\u00e9todos de prueba como la prueba de disoluci\u00f3n, desintegraci\u00f3n, esterilidad y friabilidad de tabletas.\n\n2. **Est\u00e1ndares Internacionales**:\n   - Procedimientos para la liberaci\u00f3n de Sustancias Qu\u00edmicas de Referencia Internacional (ICRS).\n   - Pol\u00edticas generales sobre est\u00e1ndares internacionales para insulina recombinante humana.\n\n3. **Recomendaciones de Calidad**:\n   - Desarrollo de especificaciones y directrices mediante un proceso consultivo internacional.\n   - Necesidad de informar sobre el progreso de las acciones sugeridas al Comit\u00e9 de Expertos en su pr\u00f3xima reuni\u00f3n.\n\n4. **Pol\u00edtica General**:\n   - Preparaci\u00f3n de res\u00famenes sobre actividades clave y el proceso de trabajo del Comit\u00e9 de Expertos.\n   - Elaboraci\u00f3n de un documento de pol\u00edtica general para el mantenimiento y actualizaci\u00f3n de las gu\u00edas de la OMS.\n\n5. **Farmacopea Internacional**:\n   - Continuaci\u00f3n del desarrollo de especificaciones para medicamentos y m\u00e9todos generales.\n   - Colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales.\n   - Trabajo preparatorio para suplementos de la Farmacopea Internacional.\n\n6. **Promoci\u00f3n de ICRS**:\n   - Actividades para promover el uso de ICRS, incluyendo ofertas promocionales a autoridades nacionales.\n   - Desarrollo de nuevas ICRS.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer est\u00e1ndares y gu\u00edas en el \u00e1mbito de la salud p\u00fablica y farmac\u00e9utica.\n- **Comit\u00e9 de Expertos**: Grupo encargado de revisar y recomendar acciones relacionadas con la calidad de los productos farmac\u00e9uticos.\n- **Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)**: Sustancias utilizadas como referencia en la evaluaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la calidad y los est\u00e1ndares en la producci\u00f3n farmac\u00e9utica, as\u00ed como el enfoque colaborativo y consultivo adoptado por la OMS para el desarrollo de gu\u00edas y pol\u00edticas.", "excerpt_keywords": "Keywords: EQAAS, GMP, pharmaceutical quality, WHO Certification Scheme, regulatory guidance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "972cc3cd-eb70-41c7-998d-08cfe2d94c14", "node_type": "4", "metadata": {"page_label": "68", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# External Quality Assurance Assessment Scheme (EQAAS)\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories, Phase 5, test series 3 onwards.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Continue the consultation process with regard to a revision of GMP: water for pharmaceutical use.\n- Continue the consultation process on Quality risk management principles with a view to updating the WHO guidelines on hazard analysis and critical control points (HACCP) to cover new trends.\n- Finalize the special guidance for artemisinin as a starting material for production of antimalarials based on the confirmation of the impurity profile through additional laboratory analysis.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce in consultation with WHO Member States and the WHO Legal Counsel.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the Development of paediatric medicines: pharmaceutical development. Points to consider.\n- Continue the development of the Pharmaceutical development for multisource (generic) pharmaceutical products.\n- Continue the update of the Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms published in 2006, with a view to including the new medicines selected for the WHO Model List of Essential Medicines (EML).\n- Report back to the next Expert Committee meeting on the pilot project undertaken by the Prequalification of Medicines Programme regarding the implementation of the provisionally adopted Guidelines on submission of documentation for multisource (generic) finished pharmaceutical product: quality part.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4ad1530419e557b41ed09152d01073373ff1d238e1f7e6cd7cb8b16ba5f73a6b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# External Quality Assurance Assessment Scheme (EQAAS)\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories, Phase 5, test series 3 onwards.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Continue the consultation process with regard to a revision of GMP: water for pharmaceutical use.\n- Continue the consultation process on Quality risk management principles with a view to updating the WHO guidelines on hazard analysis and critical control points (HACCP) to cover new trends.\n- Finalize the special guidance for artemisinin as a starting material for production of antimalarials based on the confirmation of the impurity profile through additional laboratory analysis.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce in consultation with WHO Member States and the WHO Legal Counsel.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the Development of paediatric medicines: pharmaceutical development. Points to consider.\n- Continue the development of the Pharmaceutical development for multisource (generic) pharmaceutical products.\n- Continue the update of the Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms published in 2006, with a view to including the new medicines selected for the WHO Model List of Essential Medicines (EML).\n- Report back to the next Expert Committee meeting on the pilot project undertaken by the Prequalification of Medicines Programme regarding the implementation of the provisionally adopted Guidelines on submission of documentation for multisource (generic) finished pharmaceutical product: quality part.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2192, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0ab2f86c-4e05-4827-9d78-31ed6db870ad": {"__data__": {"id_": "0ab2f86c-4e05-4827-9d78-31ed6db870ad", "embedding": null, "metadata": {"page_label": "69", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Working Group of Member States regarding the terminology for \"spurious/falsely-labelled/falsified/counterfeit medical products\", with a view to further discussion of the outcome during the next meeting of the Expert Committee.\n\n**Pharmacopoeia references**\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n**WHO databases**\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la terminolog\u00eda relacionada con productos m\u00e9dicos falsificados y la necesidad de retroalimentaci\u00f3n de los Estados Miembros. Tambi\u00e9n se menciona la actualizaci\u00f3n de referencias de farmacopeas y la importancia de mantener bases de datos sobre nomenclatura y nombres no comerciales (INN) en el sitio web de Aseguramiento de la Calidad de Medicamentos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el objetivo principal de la retroalimentaci\u00f3n solicitada a los Estados Miembros sobre la terminolog\u00eda de productos m\u00e9dicos falsificados?**\n   - La retroalimentaci\u00f3n busca facilitar una discusi\u00f3n m\u00e1s profunda sobre la terminolog\u00eda utilizada para describir productos m\u00e9dicos que son \"espurios\", \"falsamente etiquetados\", \"falsificados\" o \"de contrabando\", con el fin de llegar a un consenso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **\u00bfQu\u00e9 tipo de actualizaciones se planean realizar en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS?**\n   - Se planea publicar una actualizaci\u00f3n de las referencias y detalles de contacto para las farmacopeas nacionales, regionales e internacionales, asegurando que la informaci\u00f3n est\u00e9 actualizada y accesible.\n\n3. **\u00bfQu\u00e9 bases de datos espec\u00edficas se mencionan que la OMS se compromete a mantener y actualizar?**\n   - La OMS se compromete a mantener la base de datos consolidada sobre nomenclatura utilizada en el aseguramiento de la calidad, as\u00ed como la base de datos de Nombres Comunes Internacionales (INN), asegurando su disponibilidad en el sitio web.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**:\n   - Continuaci\u00f3n del EQAAS para laboratorios de control de calidad farmac\u00e9utica, espec\u00edficamente en la Fase 5, serie de pruebas 3 en adelante.\n\n2. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Revisi\u00f3n de GMP para productos biol\u00f3gicos bajo el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica.\n   - Consulta sobre la revisi\u00f3n de GMP relacionada con el agua para uso farmac\u00e9utico.\n   - Actualizaci\u00f3n de las directrices de gesti\u00f3n de riesgos de calidad, incluyendo HACCP, para adaptarse a nuevas tendencias.\n   - Finalizaci\u00f3n de la gu\u00eda especial para la artemisinina como materia prima en la producci\u00f3n de antimal\u00e1ricos.\n\n3. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Proceso de consulta con Estados Miembros sobre la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional.\n\n4. **Orientaci\u00f3n regulatoria**:\n   - Desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource (gen\u00e9ricos).\n   - Actualizaci\u00f3n de la propuesta para eximir requisitos de bioequivalencia in vivo para formas de dosificaci\u00f3n oral s\u00f3lida de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales de la OMS.\n   - Informe sobre un proyecto piloto del Programa de Precalificaci\u00f3n de Medicamentos relacionado con la documentaci\u00f3n de productos farmac\u00e9uticos multisource.\n\n5. **Terminolog\u00eda de aseguramiento de calidad**:\n   - Disponibilidad amplia de una base de datos actualizada sobre terminolog\u00eda de aseguramiento de calidad.\n\n### Entidades involucradas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de las iniciativas mencionadas.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado de la revisi\u00f3n de GMP para productos biol\u00f3gicos.\n- **Estados Miembros de la OMS**: Participantes en el proceso de consulta sobre la certificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: terminology, spurious medical products, pharmacopoeia, WHO databases, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e7792b55-ae8a-439c-be5f-0e7b6cde7d9c", "node_type": "4", "metadata": {"page_label": "69", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Working Group of Member States regarding the terminology for \"spurious/falsely-labelled/falsified/counterfeit medical products\", with a view to further discussion of the outcome during the next meeting of the Expert Committee.\n\n**Pharmacopoeia references**\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n**WHO databases**\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "02bd050cc70a93d4a344ac6b6660c08342463a0783abe15f6cbd45bc48e794e8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Provide feedback from the Working Group of Member States regarding the terminology for \"spurious/falsely-labelled/falsified/counterfeit medical products\", with a view to further discussion of the outcome during the next meeting of the Expert Committee.\n\n**Pharmacopoeia references**\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n**WHO databases**\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 624, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c4dc1831-7a7a-4ec0-842f-1a8e2c6407ab": {"__data__": {"id_": "c4dc1831-7a7a-4ec0-842f-1a8e2c6407ab", "embedding": null, "metadata": {"page_label": "70", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy, Dr H. Schmidt and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Union, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, Florida, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica, Facultad de Farmacia, Universidad.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Reconocimiento de Contribuciones**: El documento destaca el agradecimiento del Comit\u00e9 a varias personas y organizaciones que jugaron un papel crucial en la preparaci\u00f3n y desarrollo de la reuni\u00f3n, as\u00ed como en la elaboraci\u00f3n de la gu\u00eda t\u00e9cnica presentada en el informe.\n\n2. **Financiamiento del Informe**: Se menciona que la gu\u00eda t\u00e9cnica incluida en el informe fue producida con el apoyo financiero de entidades como la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Colaboraciones Internacionales**: El informe reconoce las contribuciones de una amplia gama de agencias, instituciones y organizaciones de diferentes pa\u00edses que colaboraron en el trabajo del Comit\u00e9, lo que refleja un esfuerzo global en el \u00e1mbito de la calidad y seguridad de los medicamentos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQu\u00e9 entidades financiaron la gu\u00eda t\u00e9cnica incluida en el informe?**\n   - El informe menciona que la gu\u00eda t\u00e9cnica fue producida con la asistencia financiera de la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n2. **\u00bfQui\u00e9nes fueron las personas clave reconocidas por el Comit\u00e9 en la preparaci\u00f3n del informe?**\n   - El Comit\u00e9 agradeci\u00f3 especialmente a Mrs. W. Bonny, Ms. M. Gaspard, Dr. S. Kopp, Ms. C. Mendy, Dr. H. Schmidt y Dr. L. R\u00e4go por su papel instrumental en la preparaci\u00f3n y desarrollo de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de organizaciones y agencias fueron reconocidas por sus contribuciones al trabajo del Comit\u00e9?**\n   - El informe reconoce una variedad de organizaciones, incluyendo agencias gubernamentales, asociaciones de la industria farmac\u00e9utica, y centros de colaboraci\u00f3n de la OMS, provenientes de diferentes pa\u00edses, como la Agencia Danesa de Medicamentos, la Agencia Europea de Medicamentos, y el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, entre otros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Retroalimentaci\u00f3n de Estados Miembros**: Se solicita a los Estados Miembros que proporcionen comentarios sobre la terminolog\u00eda relacionada con productos m\u00e9dicos falsificados, con el objetivo de discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **Actualizaci\u00f3n de Farmacopeas**: Se planea actualizar las referencias y los detalles de contacto de las farmacopeas nacionales, regionales e internacionales en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS.\n\n3. **Mantenimiento de Bases de Datos**:\n   - **Base de Datos de Nomenclatura**: La OMS se compromete a mantener la base de datos consolidada sobre nomenclatura utilizada en el aseguramiento de la calidad.\n   - **Base de Datos de Nombres Comunes Internacionales (INN)**: La OMS tambi\u00e9n mantendr\u00e1 la base de datos de INN y asegurar\u00e1 su disponibilidad en el sitio web.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la regulaci\u00f3n y aseguramiento de la calidad de medicamentos.\n- **Estados Miembros**: Pa\u00edses que forman parte de la OMS y que est\u00e1n involucrados en la retroalimentaci\u00f3n sobre la terminolog\u00eda.\n- **Comit\u00e9 de Expertos**: Grupo que discutir\u00e1 la retroalimentaci\u00f3n y los resultados relacionados con la terminolog\u00eda de productos m\u00e9dicos falsificados.", "excerpt_keywords": "Keywords: acknowledgements, WHO, pharmaceutical policies, technical guidance, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab770d45-947b-4b8c-be20-71b05a6e31a4", "node_type": "4", "metadata": {"page_label": "70", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy, Dr H. Schmidt and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Union, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, Florida, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica, Facultad de Farmacia, Universidad.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d815259ac9853531287b1e49b92b2c7eec8cb5631dc25c541724ba8be1d078df", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy, Dr H. Schmidt and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Union, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, Florida, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica, Facultad de Farmacia, Universidad.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3309, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3a40dc8f-f02e-4852-92b2-3e6e59f2f609": {"__data__": {"id_": "3a40dc8f-f02e-4852-92b2-3e6e59f2f609", "embedding": null, "metadata": {"page_label": "71", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto del documento mencionado:\n\n1. **\u00bfCu\u00e1l es el objetivo principal del Informe T\u00e9cnico de la OMS en la Serie 961?**\n   - Esta pregunta busca entender el prop\u00f3sito y los objetivos espec\u00edficos del informe, que pueden no estar claramente delineados en otros documentos o res\u00famenes.\n\n2. **\u00bfQu\u00e9 recomendaciones clave se presentan en el Informe T\u00e9cnico de la OMS 961 para mejorar la salud p\u00fablica?**\n   - Esta pregunta se centra en las recomendaciones pr\u00e1cticas que el informe puede ofrecer, las cuales podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en el desarrollo del Informe T\u00e9cnico de la OMS 961 para recopilar y analizar datos?**\n   - Esta pregunta indaga sobre los m\u00e9todos espec\u00edficos empleados en la investigaci\u00f3n y an\u00e1lisis que sustentan las conclusiones del informe, lo que puede ser crucial para evaluar la validez de los resultados.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas relevantes en el \u00e1mbito de la salud p\u00fablica, proporcionando an\u00e1lisis, recomendaciones y directrices basadas en la evidencia. Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, es probable que incluya informaci\u00f3n sobre pol\u00edticas de salud, pr\u00e1cticas recomendadas y metodolog\u00edas de investigaci\u00f3n.", "prev_section_summary": "La secci\u00f3n de \"Agradecimientos\" del informe de la OMS destaca varios temas clave y entidades que contribuyeron a la preparaci\u00f3n y desarrollo del documento:\n\n1. **Reconocimiento a Individuos Clave**: Se agradece especialmente a varias personas, incluyendo a Mrs. W. Bonny, Ms. M. Gaspard, Dr. S. Kopp, Ms. C. Mendy, Dr. H. Schmidt y Dr. L. R\u00e4go, por su papel fundamental en la organizaci\u00f3n de la reuni\u00f3n.\n\n2. **Financiamiento del Informe**: La gu\u00eda t\u00e9cnica presentada en el informe fue elaborada con el apoyo financiero de la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Colaboraciones Internacionales**: Se reconoce la valiosa contribuci\u00f3n de diversas agencias, instituciones y organizaciones de todo el mundo, que incluyen:\n   - **Agencias Gubernamentales**: Como la Agencia Danesa de Medicamentos y la Agencia Europea de Medicamentos.\n   - **Organizaciones Internacionales**: Incluyendo el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, UNICEF y el Programa de las Naciones Unidas para el Desarrollo.\n   - **Asociaciones de la Industria**: Como la Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas y la Asociaci\u00f3n Internacional de Gen\u00e9ricos.\n   - **Centros de Control de Calidad**: De varios pa\u00edses, como el Laboratorio Nacional de Control de Productos Farmac\u00e9uticos en Argelia y el Instituto Nacional de Medicamentos en Argentina.\n\nEste reconocimiento refleja un esfuerzo global y colaborativo en el \u00e1mbito de la calidad y seguridad de los medicamentos.", "excerpt_keywords": "Keywords: OMS, Informe T\u00e9cnico, salud p\u00fablica, recomendaciones, colaboraci\u00f3n internacional"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "35e7f3ca-b825-404c-91b1-53a00dddc5aa", "node_type": "4", "metadata": {"page_label": "71", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c34a58b8-6924-4a41-b918-433456f6e639": {"__data__": {"id_": "c34a58b8-6924-4a41-b918-433456f6e639", "embedding": null, "metadata": {"page_label": "72", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification of Medicines Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Dr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiaiche, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, and Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla diversas colaboraciones y programas relacionados con la calidad y regulaci\u00f3n de medicamentos a nivel internacional. Se mencionan m\u00faltiples centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses, as\u00ed como programas espec\u00edficos que abordan temas como la lucha contra medicamentos falsificados, productos biol\u00f3gicos, malaria, VIH/SIDA, y el acceso y uso racional de medicamentos. Tambi\u00e9n se enumeran varios expertos y representantes de diferentes instituciones y pa\u00edses que participan en estas iniciativas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales programas de la OMS mencionados en el informe que se enfocan en la calidad y seguridad de los medicamentos?**\n   - Esta pregunta busca identificar los programas espec\u00edficos de la OMS que se centran en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 instituciones y pa\u00edses est\u00e1n involucrados en la colaboraci\u00f3n con la OMS para la garant\u00eda de calidad de los medicamentos?**\n   - Esta pregunta se enfoca en las instituciones y pa\u00edses espec\u00edficos que colaboran con la OMS, proporcionando una visi\u00f3n m\u00e1s clara de la red internacional de apoyo en la regulaci\u00f3n de medicamentos.\n\n3. **\u00bfQui\u00e9nes son algunos de los expertos y representantes clave mencionados en el informe que contribuyen a los programas de la OMS?**\n   - Esta pregunta busca resaltar a individuos espec\u00edficos que tienen un papel importante en los esfuerzos de la OMS, lo que puede no estar disponible en otras fuentes.\n\n### Resumen de Nivel Superior\nEl informe de la OMS destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos. Se enumeran varios programas y centros de colaboraci\u00f3n que trabajan en \u00e1reas cr\u00edticas como la lucha contra medicamentos falsificados y la mejora del acceso a medicamentos esenciales. Adem\u00e1s, se menciona una lista de expertos y representantes de diversas instituciones que contribuyen a estos esfuerzos, reflejando un enfoque global en la salud p\u00fablica y la seguridad de los medicamentos.", "prev_section_summary": "El documento \"WHO - Technical Report Series 961\" es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Aunque no se proporciona contenido espec\u00edfico en el extracto, se pueden identificar algunos temas clave y entidades relacionadas:\n\n### Temas Clave:\n1. **Objetivo del Informe**: El informe tiene como prop\u00f3sito principal abordar y analizar cuestiones relevantes para la salud p\u00fablica.\n2. **Recomendaciones**: Se espera que el informe presente recomendaciones pr\u00e1cticas para mejorar la salud p\u00fablica, dirigidas a profesionales de la salud y responsables de pol\u00edticas.\n3. **Metodolog\u00edas de Investigaci\u00f3n**: El informe probablemente detalla las metodolog\u00edas utilizadas para recopilar y analizar datos, lo que es crucial para validar las conclusiones presentadas.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe y de la promoci\u00f3n de la salud a nivel global.\n- **Salud P\u00fablica**: \u00c1rea de enfoque del informe, que incluye pol\u00edticas, pr\u00e1cticas y recomendaciones para mejorar la salud de las poblaciones.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y su potencial impacto en la formulaci\u00f3n de pol\u00edticas y pr\u00e1cticas de salud.", "excerpt_keywords": "Keywords: WHO, drug quality assurance, pharmaceutical regulation, anti-counterfeiting, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3259638f-4c0d-452a-93a1-bd2d1b0866e3", "node_type": "4", "metadata": {"page_label": "72", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification of Medicines Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Dr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiaiche, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, and Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d2afc772855946d519d3f7f5138a8a918f52744697eb4cff303760844fcbf8d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification of Medicines Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Dr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiaiche, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, and Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3560, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "abb4277d-ae9e-422d-ad20-de692a007b7b": {"__data__": {"id_": "abb4277d-ae9e-422d-ad20-de692a007b7b", "embedding": null, "metadata": {"page_label": "73", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, IL, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr A. Bevilacqua, US Pharmacopeia, Bedford, MA, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr J. Bishop III, Review Management Staff, Office of the Director, Center for Biologics Evaluation and Research/FDA, Rockville, MD, USA; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare Products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Ms A. Bukirwa, National (Food and) Drug Authority, Kampala, Uganda; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Casties, St Lucia; Dr. D. Calam, Wiltshire, England; Dr N. Cappuccino, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Paulo Cenizo, Southern African Pharmaceutical Regulatory Affairs Association (SAPRAA), Randburg, South Africa; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People\u2019s Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Mr M.M. Das, Kolkata, India; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development, Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr Laurent De-Moor, GlaxoSmithKline, Belgium; Dr M. Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Dr V. Divecha, Cipla, India; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de participantes de diversas organizaciones y pa\u00edses en el \u00e1mbito de la regulaci\u00f3n y la calidad de productos farmac\u00e9uticos. Los participantes provienen de instituciones como la FDA de EE. UU., la Agencia Europea de Medicamentos, y varias universidades y asociaciones farmac\u00e9uticas. Este contexto destaca la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la importancia de la calidad en la industria farmac\u00e9utica.\n\n### Preguntas Generadas\n\n1. **\u00bfCu\u00e1les son las principales organizaciones representadas por los participantes mencionados en el informe y qu\u00e9 roles desempe\u00f1an en la regulaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta busca identificar las organizaciones clave y sus funciones espec\u00edficas en el contexto de la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos, lo que puede no estar claramente documentado en otros lugares.\n\n2. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados en la lista de participantes y c\u00f3mo refleja esto la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta se centra en la diversidad geogr\u00e1fica de los participantes y c\u00f3mo su inclusi\u00f3n en el informe indica un esfuerzo global para abordar los desaf\u00edos en la regulaci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de experiencia y especializaci\u00f3n aportan los individuos mencionados en el informe a la discusi\u00f3n sobre la calidad y regulaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca profundizar en las credenciales y \u00e1reas de especializaci\u00f3n de los participantes, lo que puede proporcionar una visi\u00f3n m\u00e1s clara de la experiencia colectiva que se re\u00fane para abordar temas cr\u00edticos en la industria farmac\u00e9utica.", "prev_section_summary": "El contenido de la secci\u00f3n del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) se centra en la colaboraci\u00f3n internacional para la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Colaboraci\u00f3n Internacional**: Se destaca la importancia de la cooperaci\u00f3n entre diferentes pa\u00edses y organizaciones para garantizar la calidad y seguridad de los medicamentos.\n2. **Programas de la OMS**: Se enumeran varios programas espec\u00edficos que abordan temas cr\u00edticos como la lucha contra medicamentos falsificados, productos biol\u00f3gicos, malaria, VIH/SIDA, y el acceso y uso racional de medicamentos.\n3. **Centros de Colaboraci\u00f3n**: Se mencionan m\u00faltiples centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses que trabajan en la garant\u00eda de calidad de los medicamentos.\n4. **Expertos y Representantes**: Se identifican a varios expertos y representantes de diversas instituciones que contribuyen a los esfuerzos de la OMS en la regulaci\u00f3n de medicamentos.\n\n### Entidades Mencionadas:\n- **Centros de Colaboraci\u00f3n de la OMS**:\n  - Pharmaceutical Control Bureau, Malasia\n  - National Institute for the Control of Pharmaceutical and Biological Products, China\n  - Health Sciences Authority, Singapur\n  - North-West University, Sud\u00e1frica\n  - Institute for Pharmaceutical Sciences, Suiza\n  - Bureau of Drug and Narcotics, Tailandia\n\n- **Programas de la OMS**:\n  - Anti-Counterfeiting Medicines Programme\n  - Blood Products and Related Biologicals Programme\n  - Global Malaria Programme\n  - HIV/AIDS Programme\n  - International Medical Products Anti-Counterfeiting Taskforce (IMPACT)\n  - Medicines Regulatory Support Programme\n  - Prequalification of Medicines Programme\n  - Quality and Safety: Medicines Team\n  - Traditional Medicine Team\n\n- **Oficinas Regionales de la OMS**:\n  - Oficina Regional para \u00c1frica\n  - Oficina Regional para las Am\u00e9ricas\n  - Oficina Regional para el Mediterr\u00e1neo Oriental\n  - Oficina Regional para Europa\n  - Oficina Regional para el Sudeste Asi\u00e1tico\n  - Oficina Regional para el Pac\u00edfico Occidental\n\n- **Expertos y Representantes**:\n  - Mrs T. Abdul Sattar, Om\u00e1n\n  - Dr. E. Adams, B\u00e9lgica\n  - Dr. M. Adarkwah-Yiadom, Ghana\n  - Professor I. Addae-Mensah, Ghana\n  - Dr. R. Andrews, Inglaterra\n  - Dr. H. Batista, EE. UU.\n  - Professor S.A. Bawazir, Arabia Saudita\n\nEste resumen refleja el enfoque global de la OMS en la salud p\u00fablica y la seguridad de los medicamentos, destacando la colaboraci\u00f3n entre diversas entidades y expertos en el campo.", "excerpt_keywords": "Keywords: pharmaceutical regulation, international collaboration, quality assurance, WHO participants, drug safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0047ba1a-3e68-47f8-b9eb-39feaf091cfb", "node_type": "4", "metadata": {"page_label": "73", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, IL, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr A. Bevilacqua, US Pharmacopeia, Bedford, MA, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr J. Bishop III, Review Management Staff, Office of the Director, Center for Biologics Evaluation and Research/FDA, Rockville, MD, USA; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare Products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Ms A. Bukirwa, National (Food and) Drug Authority, Kampala, Uganda; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Casties, St Lucia; Dr. D. Calam, Wiltshire, England; Dr N. Cappuccino, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Paulo Cenizo, Southern African Pharmaceutical Regulatory Affairs Association (SAPRAA), Randburg, South Africa; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People\u2019s Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Mr M.M. Das, Kolkata, India; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development, Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr Laurent De-Moor, GlaxoSmithKline, Belgium; Dr M. Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Dr V. Divecha, Cipla, India; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e5f9c562c2761de5f32dc964b282c5bc3ae46565f205d93dcc132fdb4fad6528", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, IL, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr A. Bevilacqua, US Pharmacopeia, Bedford, MA, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr J. Bishop III, Review Management Staff, Office of the Director, Center for Biologics Evaluation and Research/FDA, Rockville, MD, USA; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare Products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Ms A. Bukirwa, National (Food and) Drug Authority, Kampala, Uganda; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Casties, St Lucia; Dr. D. Calam, Wiltshire, England; Dr N. Cappuccino, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Paulo Cenizo, Southern African Pharmaceutical Regulatory Affairs Association (SAPRAA), Randburg, South Africa; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People\u2019s Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Mr M.M. Das, Kolkata, India; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development, Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr Laurent De-Moor, GlaxoSmithKline, Belgium; Dr M. Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Dr V. Divecha, Cipla, India; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3764, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9819b5-1fd0-4ebd-9f5b-6a173b56f7ff": {"__data__": {"id_": "ed9819b5-1fd0-4ebd-9f5b-6a173b56f7ff", "embedding": null, "metadata": {"page_label": "74", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que probablemente contiene informaci\u00f3n t\u00e9cnica y recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre un tema espec\u00edfico relacionado con la salud p\u00fablica. Sin embargo, el contenido espec\u00edfico no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el informe t\u00e9cnico 961 sobre el tema tratado?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las recomendaciones que la OMS ha hecho en este informe, que podr\u00eda ser crucial para profesionales de la salud o investigadores.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para recopilar datos en el informe t\u00e9cnico de la OMS 961?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques que la OMS pudo haber utilizado para obtener y analizar datos, lo que es fundamental para entender la validez y aplicabilidad de los hallazgos.\n\n3. **\u00bfQu\u00e9 impacto ha tenido el informe t\u00e9cnico 961 en las pol\u00edticas de salud p\u00fablica desde su publicaci\u00f3n?**\n   - Esta pregunta busca explorar las repercusiones y cambios en las pol\u00edticas de salud p\u00fablica que podr\u00edan haber resultado de las conclusiones y recomendaciones del informe, lo que es relevante para evaluar su influencia en la pr\u00e1ctica de la salud global.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar f\u00e1cilmente disponible en otros documentos o fuentes.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de participantes de diversas organizaciones y pa\u00edses que est\u00e1n involucrados en la regulaci\u00f3n y calidad de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se destaca la participaci\u00f3n de representantes de m\u00faltiples pa\u00edses y organizaciones, lo que refleja un esfuerzo global en la regulaci\u00f3n de medicamentos.\n\n2. **Diversidad de Organizaciones**: Las entidades representadas incluyen la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA), la Agencia Europea de Medicamentos, la Organizaci\u00f3n Mundial de la Salud (OMS), as\u00ed como diversas universidades y asociaciones farmac\u00e9uticas.\n\n3. **Expertise y Roles**: Los participantes tienen roles variados, desde directores y gerentes en agencias regulatorias hasta acad\u00e9micos y profesionales de la industria farmac\u00e9utica, lo que aporta una amplia gama de experiencia y especializaci\u00f3n en el \u00e1mbito de la calidad y regulaci\u00f3n de productos farmac\u00e9uticos.\n\n4. **Importancia de la Calidad**: La inclusi\u00f3n de expertos en calidad y regulaci\u00f3n subraya la relevancia de mantener altos est\u00e1ndares en la industria farmac\u00e9utica para garantizar la seguridad y eficacia de los medicamentos.\n\nEn resumen, la secci\u00f3n resalta la importancia de la colaboraci\u00f3n internacional y la diversidad de experiencia en la regulaci\u00f3n y calidad de productos farmac\u00e9uticos, con un enfoque en la participaci\u00f3n de entidades clave en el \u00e1mbito.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n, productos farmac\u00e9uticos, colaboraci\u00f3n internacional, calidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "95f156ba-4603-449a-8285-4b92d1d80841", "node_type": "4", "metadata": {"page_label": "74", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7d3688c8-8707-4c44-aaf5-347975317eb2": {"__data__": {"id_": "7d3688c8-8707-4c44-aaf5-347975317eb2", "embedding": null, "metadata": {"page_label": "75", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Petaling Jaya, Indonesia; Dr R. J\u00e4hnke, Global Pharma Health Fund e.V., Frankfurt, Germany; Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Junttonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Ms H. Kavale, Cipla, Mumbai, India; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr K. Keller, Director and Professor, Federal Ministry of Health, Bonn, Germany; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr L. Kerr, Scientific Operations Adviser, Office of Laboratories and Scientific Services, Therapeutic Goods Administration, Woden, ACT, Australia; Professor Kazuko Kimura, Institute of Medicine, Pharmacy and Health Sciences, Kanazawa University, Kanazawa-city, Japan; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Ms S. Kox, Senior Director Scientific Affairs, European Generic Medicines Association, Brussels, Belgium; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, ACT, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupferman, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4er, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, ACT, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr R. Luigetti, Emea, Europe; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/ Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Dr F. Malik, Pakistan; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoost, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proviene del \"WHO - Technical Report Series 961\" y menciona una lista de profesionales y sus respectivas instituciones en el \u00e1mbito de la salud y la farmacolog\u00eda. Los participantes provienen de diversas partes del mundo, incluyendo Europa, Asia, \u00c1frica y Am\u00e9rica, y representan una variedad de roles, desde inspectores farmac\u00e9uticos hasta directores de investigaci\u00f3n y desarrollo en grandes empresas farmac\u00e9uticas. Este informe parece estar relacionado con la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1l es el papel de Dr. R. J\u00e4hnke en el contexto del informe y qu\u00e9 organizaci\u00f3n representa?**\n   - Respuesta: Dr. R. J\u00e4hnke es parte del Global Pharma Health Fund e.V. y su papel podr\u00eda estar relacionado con la promoci\u00f3n de la salud global y la regulaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 tipo de instituciones est\u00e1n representadas por los profesionales mencionados en el informe?**\n   - Respuesta: Las instituciones incluyen agencias nacionales de medicamentos, universidades, empresas farmac\u00e9uticas, y organizaciones internacionales, lo que indica una colaboraci\u00f3n global en la regulaci\u00f3n y control de productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la diversidad geogr\u00e1fica de los participantes en la regulaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el informe?**\n   - Respuesta: La diversidad geogr\u00e1fica sugiere un enfoque global en la regulaci\u00f3n de productos farmac\u00e9uticos, lo que puede contribuir a la armonizaci\u00f3n de est\u00e1ndares y pr\u00e1cticas en diferentes pa\u00edses, mejorando as\u00ed la seguridad y eficacia de los medicamentos a nivel mundial.\n\n### Resumen de Nivel Superior\nEl informe de la OMS destaca la colaboraci\u00f3n internacional en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, con la participaci\u00f3n de expertos de diversas instituciones y pa\u00edses. Esto refleja un esfuerzo conjunto para abordar los desaf\u00edos en la calidad y control de productos farmac\u00e9uticos y biol\u00f3gicos, promoviendo la salud p\u00fablica a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda temas t\u00e9cnicos y recomendaciones relacionadas con la salud p\u00fablica. Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Recomendaciones de Salud P\u00fablica**: El informe probablemente incluye directrices y sugerencias para mejorar la salud p\u00fablica a nivel global.\n2. **Metodolog\u00eda de Investigaci\u00f3n**: Es probable que se discutan las metodolog\u00edas utilizadas para la recopilaci\u00f3n y an\u00e1lisis de datos, lo que es esencial para la credibilidad de los hallazgos.\n3. **Impacto en Pol\u00edticas de Salud**: El informe podr\u00eda analizar c\u00f3mo sus recomendaciones han influido en las pol\u00edticas de salud p\u00fablica desde su publicaci\u00f3n.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe, que se centra en mejorar la salud a nivel mundial.\n- **Salud P\u00fablica**: El \u00e1mbito general al que se dirigen las recomendaciones y hallazgos del informe.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: pharmaceutical regulation, global health, quality control, international collaboration, health sciences"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c89c5f9e-c1d8-4803-bb80-6221b8f6b131", "node_type": "4", "metadata": {"page_label": "75", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Petaling Jaya, Indonesia; Dr R. J\u00e4hnke, Global Pharma Health Fund e.V., Frankfurt, Germany; Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Junttonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Ms H. Kavale, Cipla, Mumbai, India; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr K. Keller, Director and Professor, Federal Ministry of Health, Bonn, Germany; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr L. Kerr, Scientific Operations Adviser, Office of Laboratories and Scientific Services, Therapeutic Goods Administration, Woden, ACT, Australia; Professor Kazuko Kimura, Institute of Medicine, Pharmacy and Health Sciences, Kanazawa University, Kanazawa-city, Japan; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Ms S. Kox, Senior Director Scientific Affairs, European Generic Medicines Association, Brussels, Belgium; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, ACT, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupferman, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4er, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, ACT, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr R. Luigetti, Emea, Europe; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/ Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Dr F. Malik, Pakistan; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoost, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2fe531f549e717dafc6ea1bc539a4769b9afcb6f56783f07fa3f5d87726e1c8a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Petaling Jaya, Indonesia; Dr R. J\u00e4hnke, Global Pharma Health Fund e.V., Frankfurt, Germany; Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Junttonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Ms H. Kavale, Cipla, Mumbai, India; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr K. Keller, Director and Professor, Federal Ministry of Health, Bonn, Germany; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr L. Kerr, Scientific Operations Adviser, Office of Laboratories and Scientific Services, Therapeutic Goods Administration, Woden, ACT, Australia; Professor Kazuko Kimura, Institute of Medicine, Pharmacy and Health Sciences, Kanazawa University, Kanazawa-city, Japan; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Ms S. Kox, Senior Director Scientific Affairs, European Generic Medicines Association, Brussels, Belgium; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, ACT, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupferman, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4er, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, ACT, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr R. Luigetti, Emea, Europe; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/ Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Dr F. Malik, Pakistan; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoost, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3772, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bcbbadd4-9664-4909-b472-e732179ab0cc": {"__data__": {"id_": "bcbbadd4-9664-4909-b472-e732179ab0cc", "embedding": null, "metadata": {"page_label": "76", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 76 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe de la OMS en la p\u00e1gina 76 del Technical Report Series 961?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina del informe.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el Technical Report Series 961 y c\u00f3mo se relacionan con las pol\u00edticas de salud actuales?**\n   - Esta pregunta se centra en el contexto m\u00e1s amplio del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe para evaluar los problemas de salud discutidos en el Technical Report Series 961?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos que la OMS emplea en sus informes t\u00e9cnicos, lo cual puede ser crucial para entender la validez de las recomendaciones presentadas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, dado que se centran en el contenido particular del informe y su contexto.", "prev_section_summary": "La secci\u00f3n del documento \"WHO - Technical Report Series 961\" destaca la participaci\u00f3n de una amplia variedad de profesionales en el \u00e1mbito de la salud y la farmacolog\u00eda, provenientes de diferentes partes del mundo. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se enfatiza la importancia de la cooperaci\u00f3n global en la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos, con la participaci\u00f3n de expertos de diversas instituciones.\n\n2. **Diversidad de Instituciones**: Los participantes representan una mezcla de agencias nacionales de medicamentos, universidades, empresas farmac\u00e9uticas y organizaciones internacionales, lo que refleja un enfoque multidisciplinario en la regulaci\u00f3n farmac\u00e9utica.\n\n3. **Roles de los Participantes**: Los profesionales mencionados ocupan diversos roles, desde inspectores farmac\u00e9uticos hasta directores de investigaci\u00f3n y desarrollo, lo que sugiere un esfuerzo conjunto para abordar los desaf\u00edos en la calidad y control de medicamentos.\n\n4. **Importancia de la Diversidad Geogr\u00e1fica**: La variedad geogr\u00e1fica de los participantes indica un enfoque global que puede contribuir a la armonizaci\u00f3n de est\u00e1ndares y pr\u00e1cticas en la regulaci\u00f3n de productos farmac\u00e9uticos, mejorando as\u00ed la seguridad y eficacia de los medicamentos a nivel mundial.\n\nEntidades clave mencionadas incluyen:\n- **Organizaciones**: Global Pharma Health Fund e.V., GlaxoSmithKline, Pfizer Global R&D, European Directorate for the Quality of Medicines and Healthcare, Therapeutic Goods Administration, entre otras.\n- **Profesionales**: Dr. R. J\u00e4hnke, Dr. M. James, Professor Jin Shaohong, Dr. P. Jones, entre otros, que representan diversas instituciones de diferentes pa\u00edses, incluyendo Alemania, Jap\u00f3n, Francia, India, y m\u00e1s.\n\nEn resumen, el informe resalta la importancia de la colaboraci\u00f3n internacional y la diversidad en la regulaci\u00f3n farmac\u00e9utica, con el objetivo de promover la salud p\u00fablica a nivel global.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, colaboraci\u00f3n internacional, salud p\u00fablica, diversidad geogr\u00e1fica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c7e2495b-99f0-48ff-9c4c-fa9978e99111", "node_type": "4", "metadata": {"page_label": "76", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6f1629b2-3e89-4256-86ef-7619a1761189": {"__data__": {"id_": "6f1629b2-3e89-4256-86ef-7619a1761189", "embedding": null, "metadata": {"page_label": "77", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 77 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en la p\u00e1gina 77 del informe \"WHO - Technical Report Series 961\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina, relacionada con la salud p\u00fablica o recomendaciones de la OMS.\n\n2. **\u00bfQu\u00e9 temas generales se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 961 con esos temas?**\n   - Esta pregunta permite explorar el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe espec\u00edfico se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas o enfoques se utilizan en el informe \"WHO - Technical Report Series 961\" para abordar los problemas de salud discutidos?**\n   - Esta pregunta se centra en las t\u00e9cnicas o m\u00e9todos que la OMS podr\u00eda haber utilizado en el informe, lo que podr\u00eda ser relevante para investigadores o profesionales de la salud interesados en la implementaci\u00f3n de pol\u00edticas basadas en evidencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento mencionado, \"WHO - Technical Report Series 961\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico de la p\u00e1gina 76 no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Informes T\u00e9cnicos**: La serie aborda temas relacionados con la salud p\u00fablica, recomendaciones para la pr\u00e1ctica cl\u00ednica y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Un tema central del informe, que puede incluir hallazgos sobre enfermedades, intervenciones de salud y estrategias de prevenci\u00f3n.\n\n4. **Metodolog\u00edas de Evaluaci\u00f3n**: Aunque no se detalla en el contenido proporcionado, es probable que el informe utilice diversas metodolog\u00edas para evaluar problemas de salud y formular recomendaciones.\n\n5. **Pol\u00edticas de Salud**: El informe puede relacionar sus hallazgos con las pol\u00edticas de salud actuales, sugiriendo c\u00f3mo se pueden aplicar las recomendaciones en la pr\u00e1ctica.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y su potencial impacto en las pol\u00edticas y pr\u00e1cticas de salud.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informes t\u00e9cnicos, pol\u00edticas de salud, metodolog\u00edas de evaluaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "94b1c634-0d86-46f1-951c-ef30ed9c2287", "node_type": "4", "metadata": {"page_label": "77", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3aaa60ec-9d5b-4f72-898e-c3996f001293": {"__data__": {"id_": "3aaa60ec-9d5b-4f72-898e-c3996f001293", "embedding": null, "metadata": {"page_label": "78", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones sobre pr\u00e1cticas y pol\u00edticas en el \u00e1mbito de la salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 78 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el informe t\u00e9cnico 961 sobre la salud p\u00fablica?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones que podr\u00edan estar incluidas en el informe, que son relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en la p\u00e1gina 78 del informe WHO TRS 961?**\n   - Aunque el contenido no est\u00e1 disponible, esta pregunta se centra en el contenido espec\u00edfico de esa p\u00e1gina, que podr\u00eda contener informaci\u00f3n crucial sobre un tema particular.\n\n3. **\u00bfC\u00f3mo se relaciona el informe WHO TRS 961 con otros informes t\u00e9cnicos anteriores de la OMS?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda ayudar a entender la evoluci\u00f3n de las recomendaciones y pol\u00edticas de salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que se centran en el contenido espec\u00edfico del informe y su contexto en la serie de informes de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS) que se enfoca en temas de salud p\u00fablica y recomendaciones para pol\u00edticas de salud. Aunque el contenido espec\u00edfico de la p\u00e1gina 77 no est\u00e1 disponible, se puede inferir que el informe aborda hallazgos relevantes y metodolog\u00edas en el \u00e1mbito de la salud.\n\n#### Temas Clave:\n- **Salud P\u00fablica:** El informe probablemente discute cuestiones cr\u00edticas relacionadas con la salud de la poblaci\u00f3n.\n- **Investigaci\u00f3n M\u00e9dica:** Es posible que se presenten hallazgos de investigaciones recientes en el campo de la medicina.\n- **Pol\u00edticas de Salud:** Se espera que el informe ofrezca recomendaciones para la formulaci\u00f3n de pol\u00edticas basadas en evidencia.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la publicaci\u00f3n del informe.\n- **Informe T\u00e9cnico:** Parte de la serie de informes t\u00e9cnicos que la OMS publica regularmente.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en el contexto del informe, aunque no se dispone de detalles espec\u00edficos del contenido de la p\u00e1gina 77.", "excerpt_keywords": "Keywords: salud p\u00fablica, OMS, informe t\u00e9cnico, pol\u00edticas de salud, investigaci\u00f3n m\u00e9dica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d15597a0-776e-4dca-ac6e-593a55ebc256", "node_type": "4", "metadata": {"page_label": "78", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1bea7730-0992-49d1-8bff-f10e485183f8": {"__data__": {"id_": "1bea7730-0992-49d1-8bff-f10e485183f8", "embedding": null, "metadata": {"page_label": "79", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## Release procedure of International Chemical Reference Substances\n\nInternational Chemical Reference Substances (ICRS) were in the past first provisionally adopted by the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and then finally adopted by the Expert Committee on Specifications for Pharmaceutical Preparations during its annual meeting.\n\nSince April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) has been responsible for the establishment, preparation, storage and distribution of WHO ICRS. For the analytical characterization of ICRS, EDQM follows the *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n\nEDQM will issue an individual analytical report after:\n\n- the establishment of a new reference substance;\n- analysis of candidate material for stock replenishment; and\n- monitoring the stability of material in stock.\n\nThe Expert Committee members newly adopted the following procedure:\n\nAnalytical case-reports to be reviewed *a priori* by the Secretariat with assistance from the collaborating laboratories. If the testing has been performed according to the above-mentioned adopted guidelines (1) and the candidate material has been proven to be suitable, the Secretariat with assistance from the collaborating laboratories, will then in future provisionally release the ICRS. The distribution of the ICRS will start after the provisional release.\n\nThe analytical case-reports together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS will then be distributed to the WHO Expert Committee on Specifications for Pharmaceutical Preparations for adoption. The analytical case-reports will be appended to the annual report as annexes.\n\nThe new process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS. The new procedure is illustrated in Figure 1.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento describe el procedimiento de liberaci\u00f3n de las Sustancias de Referencia Qu\u00edmica Internacional (ICRS) por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Desde abril de 2010, la Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) es responsable de la creaci\u00f3n, preparaci\u00f3n, almacenamiento y distribuci\u00f3n de las ICRS. Se establece un proceso para la revisi\u00f3n de informes anal\u00edticos que permite la liberaci\u00f3n provisional de las ICRS, facilitando as\u00ed una respuesta m\u00e1s r\u00e1pida a la demanda urgente de estas sustancias. Los informes anal\u00edticos se revisan antes de la liberaci\u00f3n y se distribuyen al Comit\u00e9 de Expertos de la OMS para su adopci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 organismo es responsable de la preparaci\u00f3n y distribuci\u00f3n de las ICRS desde abril de 2010 y cu\u00e1les son sus funciones espec\u00edficas en este proceso?**\n   - Respuesta: La Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) es responsable de la creaci\u00f3n, preparaci\u00f3n, almacenamiento y distribuci\u00f3n de las ICRS. Sus funciones incluyen la emisi\u00f3n de informes anal\u00edticos individuales tras el establecimiento de nuevas sustancias de referencia, el an\u00e1lisis de materiales candidatos para reabastecimiento y el monitoreo de la estabilidad del material en stock.\n\n2. **\u00bfCu\u00e1l es el procedimiento adoptado por el Comit\u00e9 de Expertos para la revisi\u00f3n de los informes anal\u00edticos antes de la liberaci\u00f3n de las ICRS?**\n   - Respuesta: Los informes anal\u00edticos son revisados *a priori* por la Secretar\u00eda con la asistencia de laboratorios colaboradores. Si las pruebas se han realizado de acuerdo con las directrices adoptadas y el material candidato ha demostrado ser adecuado, la Secretar\u00eda proceder\u00e1 a liberar provisionalmente la ICRS.\n\n3. **\u00bfQu\u00e9 cambios se implementaron en el proceso de establecimiento de nuevas sustancias de referencia para mejorar la respuesta a la demanda urgente de ICRS?**\n   - Respuesta: Se implement\u00f3 un nuevo proceso que acelera el establecimiento de nuevas sustancias de referencia, permitiendo a la OMS reaccionar m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS. Esto incluye la revisi\u00f3n anticipada de informes anal\u00edticos y la distribuci\u00f3n de estos informes junto con un informe anual consolidado al Comit\u00e9 de Expertos para su adopci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Documento:** WHO - Technical Report Series 961  \n**Entidad:** Organizaci\u00f3n Mundial de la Salud (OMS)  \n**Tipo de Documento:** Informe t\u00e9cnico sobre salud p\u00fablica  \n\n#### Temas Clave:\n1. **Salud P\u00fablica:** El informe aborda temas relevantes para la salud p\u00fablica, incluyendo recomendaciones y pol\u00edticas.\n2. **Investigaci\u00f3n M\u00e9dica:** Se espera que el documento incluya hallazgos de investigaciones que impactan la salud global.\n3. **Pr\u00e1cticas y Pol\u00edticas de Salud:** El informe probablemente proporciona directrices sobre pr\u00e1cticas recomendadas en el \u00e1mbito de la salud.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad responsable de la publicaci\u00f3n del informe y de la formulaci\u00f3n de pol\u00edticas de salud a nivel global.\n- **Informe T\u00e9cnico:** Parte de una serie que busca informar y guiar a profesionales de la salud y responsables de pol\u00edticas.\n\n### Conclusi\u00f3n\nEl informe WHO TRS 961 es un documento t\u00e9cnico que se centra en la salud p\u00fablica y las recomendaciones de la OMS, aunque el contenido espec\u00edfico de la p\u00e1gina 78 no est\u00e1 disponible en el contexto proporcionado. Las preguntas formuladas buscan profundizar en el contenido y la relevancia del informe en el \u00e1mbito de la salud.", "excerpt_keywords": "Keywords: International Chemical Reference Substances, EDQM, WHO, analytical reports, release procedure"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7ea24d60-7933-46f2-b85b-0b641832d927", "node_type": "4", "metadata": {"page_label": "79", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## Release procedure of International Chemical Reference Substances\n\nInternational Chemical Reference Substances (ICRS) were in the past first provisionally adopted by the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and then finally adopted by the Expert Committee on Specifications for Pharmaceutical Preparations during its annual meeting.\n\nSince April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) has been responsible for the establishment, preparation, storage and distribution of WHO ICRS. For the analytical characterization of ICRS, EDQM follows the *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n\nEDQM will issue an individual analytical report after:\n\n- the establishment of a new reference substance;\n- analysis of candidate material for stock replenishment; and\n- monitoring the stability of material in stock.\n\nThe Expert Committee members newly adopted the following procedure:\n\nAnalytical case-reports to be reviewed *a priori* by the Secretariat with assistance from the collaborating laboratories. If the testing has been performed according to the above-mentioned adopted guidelines (1) and the candidate material has been proven to be suitable, the Secretariat with assistance from the collaborating laboratories, will then in future provisionally release the ICRS. The distribution of the ICRS will start after the provisional release.\n\nThe analytical case-reports together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS will then be distributed to the WHO Expert Committee on Specifications for Pharmaceutical Preparations for adoption. The analytical case-reports will be appended to the annual report as annexes.\n\nThe new process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS. The new procedure is illustrated in Figure 1.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bf38b9b4b8752ce0e37d617416a4431d108433ec2951af0fc4700be315ce81a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 1\n\n## Release procedure of International Chemical Reference Substances\n\nInternational Chemical Reference Substances (ICRS) were in the past first provisionally adopted by the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and then finally adopted by the Expert Committee on Specifications for Pharmaceutical Preparations during its annual meeting.\n\nSince April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) has been responsible for the establishment, preparation, storage and distribution of WHO ICRS. For the analytical characterization of ICRS, EDQM follows the *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n\nEDQM will issue an individual analytical report after:\n\n- the establishment of a new reference substance;\n- analysis of candidate material for stock replenishment; and\n- monitoring the stability of material in stock.\n\nThe Expert Committee members newly adopted the following procedure:\n\nAnalytical case-reports to be reviewed *a priori* by the Secretariat with assistance from the collaborating laboratories. If the testing has been performed according to the above-mentioned adopted guidelines (1) and the candidate material has been proven to be suitable, the Secretariat with assistance from the collaborating laboratories, will then in future provisionally release the ICRS. The distribution of the ICRS will start after the provisional release.\n\nThe analytical case-reports together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS will then be distributed to the WHO Expert Committee on Specifications for Pharmaceutical Preparations for adoption. The analytical case-reports will be appended to the annual report as annexes.\n\nThe new process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS. The new procedure is illustrated in Figure 1.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2182, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "79a8960d-8976-42bc-b47c-593b0438894a": {"__data__": {"id_": "79a8960d-8976-42bc-b47c-593b0438894a", "embedding": null, "metadata": {"page_label": "80", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# New procedure\n\n1. **EDQM characterizes candidate material and issues analytical report**\n\n2. **WHO Secretariat, with assistance from the collaborating laboratories, reviews documentation and releases ICRS provisionally**\n\n3. **EDQM starts distribution of ICRS**\n\n4. **WHO Secretariat submits case-reports together with annual report to the Expert Committee**\n\n5. **Final release of ICRS by Expert Committee**\n\n- **Feedback to EDQM**\n\n----\n\n*EDQM, European Directorate for the Quality of Medicines & HealthCare; ICRS, International Chemical Reference Substances.*\n\n# Reference\n\n1. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790), p. 15.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en un nuevo procedimiento relacionado con la caracterizaci\u00f3n y distribuci\u00f3n de sustancias qu\u00edmicas de referencia internacional (ICRS) por parte de la Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) y la Secretar\u00eda de la OMS. Se describen los pasos que incluyen la caracterizaci\u00f3n del material candidato, la revisi\u00f3n de la documentaci\u00f3n, la distribuci\u00f3n provisional de ICRS, la presentaci\u00f3n de informes al Comit\u00e9 de Expertos y la liberaci\u00f3n final de ICRS. Tambi\u00e9n se menciona la importancia del feedback a EDQM.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de la EDQM en el proceso de caracterizaci\u00f3n y distribuci\u00f3n de ICRS?**\n   - Respuesta: La EDQM se encarga de caracterizar el material candidato y emitir un informe anal\u00edtico, as\u00ed como iniciar la distribuci\u00f3n de las ICRS.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n revisa la Secretar\u00eda de la OMS antes de liberar provisionalmente las ICRS?**\n   - Respuesta: La Secretar\u00eda de la OMS, con la ayuda de laboratorios colaboradores, revisa la documentaci\u00f3n relacionada con el material candidato antes de liberar las ICRS de manera provisional.\n\n3. **\u00bfQu\u00e9 sucede despu\u00e9s de que la Secretar\u00eda de la OMS presenta los informes de casos y el informe anual al Comit\u00e9 de Expertos?**\n   - Respuesta: Despu\u00e9s de la presentaci\u00f3n, el Comit\u00e9 de Expertos realiza la liberaci\u00f3n final de las ICRS y proporciona retroalimentaci\u00f3n a la EDQM.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sustancias de Referencia Qu\u00edmica Internacional (ICRS)**:\n   - Definici\u00f3n: Sustancias utilizadas como est\u00e1ndares en an\u00e1lisis qu\u00edmicos y farmac\u00e9uticos.\n\n2. **Responsabilidad de la EDQM**:\n   - Desde abril de 2010, la **Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM)** es responsable de:\n     - Establecimiento\n     - Preparaci\u00f3n\n     - Almacenamiento\n     - Distribuci\u00f3n de las ICRS.\n   - Emisi\u00f3n de informes anal\u00edticos individuales tras:\n     - Establecimiento de nuevas sustancias de referencia.\n     - An\u00e1lisis de materiales candidatos para reabastecimiento.\n     - Monitoreo de la estabilidad del material en stock.\n\n3. **Procedimiento de Revisi\u00f3n y Liberaci\u00f3n**:\n   - Los informes anal\u00edticos son revisados *a priori* por la Secretar\u00eda con ayuda de laboratorios colaboradores.\n   - Si el material candidato es adecuado, se procede a la liberaci\u00f3n provisional de las ICRS.\n   - La distribuci\u00f3n de las ICRS comienza tras esta liberaci\u00f3n provisional.\n\n4. **Informes y Adopci\u00f3n**:\n   - Los informes anal\u00edticos se distribuyen junto con un informe anual consolidado al **Comit\u00e9 de Expertos de la OMS** para su adopci\u00f3n.\n   - Los informes anal\u00edticos se anexan al informe anual.\n\n5. **Objetivo del Nuevo Proceso**:\n   - Acelerar el establecimiento de nuevas sustancias de referencia.\n   - Permitir a la OMS reaccionar m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS.\n\n6. **Provisiones Adicionales**:\n   - Si se requieren disposiciones expl\u00edcitas adicionales para la liberaci\u00f3n de sustancias de referencia, se presentar\u00e1n al Comit\u00e9 de Expertos para su aprobaci\u00f3n. \n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional.\n- **EDQM (Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria)**: Entidad encargada de la calidad de medicamentos en Europa y responsable de las ICRS desde 2010.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopta las ICRS y revisa los informes anal\u00edticos.", "excerpt_keywords": "Keywords: EDQM, ICRS, WHO Secretariat, analytical report, Expert Committee"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2adec23b-e344-4ffa-8a54-c9c1ee8fb8e4", "node_type": "4", "metadata": {"page_label": "80", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# New procedure\n\n1. **EDQM characterizes candidate material and issues analytical report**\n\n2. **WHO Secretariat, with assistance from the collaborating laboratories, reviews documentation and releases ICRS provisionally**\n\n3. **EDQM starts distribution of ICRS**\n\n4. **WHO Secretariat submits case-reports together with annual report to the Expert Committee**\n\n5. **Final release of ICRS by Expert Committee**\n\n- **Feedback to EDQM**\n\n----\n\n*EDQM, European Directorate for the Quality of Medicines & HealthCare; ICRS, International Chemical Reference Substances.*\n\n# Reference\n\n1. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790), p. 15.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7b0e60f605aa62e30621d23cb583f6aa90691914bca4d55593ea64a789b7c747", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# New procedure\n\n1. **EDQM characterizes candidate material and issues analytical report**\n\n2. **WHO Secretariat, with assistance from the collaborating laboratories, reviews documentation and releases ICRS provisionally**\n\n3. **EDQM starts distribution of ICRS**\n\n4. **WHO Secretariat submits case-reports together with annual report to the Expert Committee**\n\n5. **Final release of ICRS by Expert Committee**\n\n- **Feedback to EDQM**\n\n----\n\n*EDQM, European Directorate for the Quality of Medicines & HealthCare; ICRS, International Chemical Reference Substances.*\n\n# Reference\n\n1. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790), p. 15.*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 763, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5041f021-5224-4701-aaa4-81917fbcfca6": {"__data__": {"id_": "5041f021-5224-4701-aaa4-81917fbcfca6", "embedding": null, "metadata": {"page_label": "81", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good practices for pharmaceutical microbiology laboratories\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in 2009 a revised version of the *Good practices for pharmaceutical quality control laboratories* (1).\n\nDuring the inspections carried out when prequalifying laboratories, the inspectors had noticed that some of the texts of these guidelines might benefit from additional guidance, with a special focus on microbiology.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of developing a new text on good practices for pharmaceutical microbiology laboratories.\n\nThe following text is proposed to cover this specific type of laboratory.\n\n### Introduction and scope of document\n\n### Glossary\n\n1. **Personnel**\n\n2. **Environment**\n   - 2.1 Premises\n   - 2.2 Environmental monitoring in the laboratory\n   - 2.3 Cleaning, disinfection and hygiene\n   - 2.4 Sterility test facilities\n\n3. **Validation of test methods**\n\n4. **Equipment**\n   - 4.1 Maintenance of equipment\n   - 4.2 Qualification\n   - 4.3 Calibration, performance verification and monitoring of use\n\n5. **Reagents and culture media**\n   - 5.1 Reagents\n   - 5.2 Media\n   - 5.3 Labelling\n   - 5.4 Organism resuscitation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento es un anexo del *Technical Report Series 961* de la OMS, que se centra en las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica. Se menciona que, tras las inspecciones de laboratorios, se identific\u00f3 la necesidad de proporcionar orientaci\u00f3n adicional en microbiolog\u00eda. El texto propuesto abarca aspectos como el personal, el entorno, la validaci\u00f3n de m\u00e9todos de prueba, el equipo y los reactivos y medios de cultivo.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos del entorno del laboratorio se abordan en las buenas pr\u00e1cticas propuestas por la OMS?**\n   - Respuesta: El documento menciona varios aspectos del entorno del laboratorio, incluyendo las instalaciones (premises), el monitoreo ambiental, la limpieza, desinfecci\u00f3n e higiene, y las instalaciones para pruebas de esterilidad.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para la validaci\u00f3n de m\u00e9todos de prueba en laboratorios de microbiolog\u00eda farmac\u00e9utica seg\u00fan la OMS?**\n   - Respuesta: Aunque el texto no proporciona detalles espec\u00edficos en el fragmento, se menciona que la validaci\u00f3n de m\u00e9todos de prueba es un tema importante que se aborda en el documento, sugiriendo que se deben seguir protocolos rigurosos para asegurar la fiabilidad y precisi\u00f3n de los m\u00e9todos utilizados.\n\n3. **\u00bfQu\u00e9 se incluye en la secci\u00f3n sobre reactivos y medios de cultivo en las buenas pr\u00e1cticas de la OMS?**\n   - Respuesta: La secci\u00f3n sobre reactivos y medios de cultivo incluye consideraciones sobre los reactivos en general, los medios de cultivo, el etiquetado de estos, y la resucitaci\u00f3n de organismos, lo que es crucial para asegurar la calidad y efectividad de los cultivos microbiol\u00f3gicos en el laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Procedimiento Nuevo**: Se describe un nuevo procedimiento para la caracterizaci\u00f3n y distribuci\u00f3n de sustancias qu\u00edmicas de referencia internacional (ICRS).\n2. **Caracterizaci\u00f3n y An\u00e1lisis**: La EDQM se encarga de caracterizar el material candidato y emitir un informe anal\u00edtico.\n3. **Revisi\u00f3n de Documentaci\u00f3n**: La Secretar\u00eda de la OMS, con la ayuda de laboratorios colaboradores, revisa la documentaci\u00f3n antes de liberar provisionalmente las ICRS.\n4. **Distribuci\u00f3n de ICRS**: La EDQM inicia la distribuci\u00f3n de las ICRS tras su caracterizaci\u00f3n.\n5. **Informes al Comit\u00e9 de Expertos**: La Secretar\u00eda de la OMS presenta informes de casos y un informe anual al Comit\u00e9 de Expertos.\n6. **Liberaci\u00f3n Final**: El Comit\u00e9 de Expertos realiza la liberaci\u00f3n final de las ICRS y proporciona retroalimentaci\u00f3n a la EDQM.\n\n**Entidades:**\n- **EDQM**: Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **ICRS**: Sustancias Qu\u00edmicas de Referencia Internacional.\n- **Comit\u00e9 de Expertos**: Grupo encargado de la revisi\u00f3n y liberaci\u00f3n final de las ICRS. \n\nEste resumen destaca los pasos del nuevo procedimiento y las entidades involucradas en el proceso de caracterizaci\u00f3n y distribuci\u00f3n de ICRS.", "excerpt_keywords": "Keywords: WHO, pharmaceutical microbiology, good practices, laboratory guidelines, validation methods"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5b27cfd1-6645-4e47-84e6-8ce6dfb2f491", "node_type": "4", "metadata": {"page_label": "81", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good practices for pharmaceutical microbiology laboratories\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in 2009 a revised version of the *Good practices for pharmaceutical quality control laboratories* (1).\n\nDuring the inspections carried out when prequalifying laboratories, the inspectors had noticed that some of the texts of these guidelines might benefit from additional guidance, with a special focus on microbiology.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of developing a new text on good practices for pharmaceutical microbiology laboratories.\n\nThe following text is proposed to cover this specific type of laboratory.\n\n### Introduction and scope of document\n\n### Glossary\n\n1. **Personnel**\n\n2. **Environment**\n   - 2.1 Premises\n   - 2.2 Environmental monitoring in the laboratory\n   - 2.3 Cleaning, disinfection and hygiene\n   - 2.4 Sterility test facilities\n\n3. **Validation of test methods**\n\n4. **Equipment**\n   - 4.1 Maintenance of equipment\n   - 4.2 Qualification\n   - 4.3 Calibration, performance verification and monitoring of use\n\n5. **Reagents and culture media**\n   - 5.1 Reagents\n   - 5.2 Media\n   - 5.3 Labelling\n   - 5.4 Organism resuscitation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "12e66645c50b8c2ddaf4941a4f6fa4f98e3d249033803efc9a86efe486b0445a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 2\n\n## WHO good practices for pharmaceutical microbiology laboratories\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in 2009 a revised version of the *Good practices for pharmaceutical quality control laboratories* (1).\n\nDuring the inspections carried out when prequalifying laboratories, the inspectors had noticed that some of the texts of these guidelines might benefit from additional guidance, with a special focus on microbiology.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of developing a new text on good practices for pharmaceutical microbiology laboratories.\n\nThe following text is proposed to cover this specific type of laboratory.\n\n### Introduction and scope of document\n\n### Glossary\n\n1. **Personnel**\n\n2. **Environment**\n   - 2.1 Premises\n   - 2.2 Environmental monitoring in the laboratory\n   - 2.3 Cleaning, disinfection and hygiene\n   - 2.4 Sterility test facilities\n\n3. **Validation of test methods**\n\n4. **Equipment**\n   - 4.1 Maintenance of equipment\n   - 4.2 Qualification\n   - 4.3 Calibration, performance verification and monitoring of use\n\n5. **Reagents and culture media**\n   - 5.1 Reagents\n   - 5.2 Media\n   - 5.3 Labelling\n   - 5.4 Organism resuscitation", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1303, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d5838c7f-b2dd-4006-b2ce-f76927c2db2f": {"__data__": {"id_": "d5838c7f-b2dd-4006-b2ce-f76927c2db2f", "embedding": null, "metadata": {"page_label": "82", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n6.1 International standards and pharmacopoeial reference substances  \n6.2 Reference cultures\n\n7. Sampling\n\n8. Sample handling and identification\n\n9. Disposal of contaminated waste\n\n10. Quality assurance of results and quality control of performance  \n10.1 Internal quality control\n\n11. Testing procedures\n\n12. Test reports\n\nReferences\n\nFurther reading\n\n## Appendix 1\nExamples of zones in which operations could be carried out\n\n## Appendix 2\nExamples of maintenance of equipment\n\n## Appendix 3\nExamples of calibration checks and intervals for different laboratory equipment\n\n## Appendix 4\nExamples of equipment qualification and monitoring\n\n## Appendix 5\nGeneral use of reference cultures", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la calidad y el control en laboratorios, incluyendo materiales de referencia, procedimientos de muestreo, manejo de muestras, eliminaci\u00f3n de desechos contaminados, aseguramiento de la calidad, y procedimientos de prueba. Adem\u00e1s, incluye ap\u00e9ndices que ofrecen ejemplos pr\u00e1cticos sobre operaciones, mantenimiento de equipos, calibraci\u00f3n y uso de cultivos de referencia.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los ejemplos de mantenimiento de equipos que se mencionan en el Ap\u00e9ndice 2 del informe?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las pr\u00e1cticas de mantenimiento recomendadas para asegurar el funcionamiento adecuado de los equipos de laboratorio.\n\n2. **\u00bfQu\u00e9 tipos de controles de calidad interna se sugieren en la secci\u00f3n 10.1 del documento?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos de control de calidad interna que se deben implementar para garantizar la fiabilidad de los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 se entiende por \"cultivos de referencia\" y cu\u00e1l es su uso general seg\u00fan el Ap\u00e9ndice 5?**\n   - Esta pregunta busca una definici\u00f3n y explicaci\u00f3n del prop\u00f3sito de los cultivos de referencia en el contexto de las pruebas de laboratorio, as\u00ed como ejemplos de su aplicaci\u00f3n pr\u00e1ctica.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nEl anexo 2 del *Technical Report Series 961* de la OMS se centra en las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionados en la secci\u00f3n:\n\n1. **Contexto y Justificaci\u00f3n**:\n   - La OMS revis\u00f3 las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* en 2009.\n   - Se identific\u00f3 la necesidad de proporcionar orientaci\u00f3n adicional en microbiolog\u00eda durante las inspecciones de laboratorios.\n\n2. **Estructura del Documento**:\n   - **Introducci\u00f3n y alcance**: Define el prop\u00f3sito del documento.\n   - **Glosario**: Incluye t\u00e9rminos clave utilizados en el documento.\n\n3. **Temas Principales**:\n   - **Personal**: Consideraciones sobre la capacitaci\u00f3n y competencias del personal en el laboratorio.\n   - **Entorno**: \n     - **Instalaciones (Premises)**: Dise\u00f1o y mantenimiento de las instalaciones del laboratorio.\n     - **Monitoreo ambiental**: Estrategias para asegurar un ambiente controlado.\n     - **Limpieza, desinfecci\u00f3n e higiene**: Protocolos para mantener la limpieza y la seguridad.\n     - **Instalaciones para pruebas de esterilidad**: Espacios espec\u00edficos para realizar pruebas de esterilidad.\n   - **Validaci\u00f3n de m\u00e9todos de prueba**: Importancia de validar los m\u00e9todos utilizados en el laboratorio.\n   - **Equipo**: \n     - **Mantenimiento**: Procedimientos para el mantenimiento adecuado del equipo.\n     - **Calificaci\u00f3n**: Aseguramiento de que el equipo cumple con los est\u00e1ndares requeridos.\n     - **Calibraci\u00f3n y verificaci\u00f3n de rendimiento**: Monitoreo continuo del uso y precisi\u00f3n del equipo.\n   - **Reactivos y medios de cultivo**: \n     - **Reactivos**: Consideraciones sobre la calidad y manejo de reactivos.\n     - **Medios de cultivo**: Importancia de los medios utilizados para el crecimiento microbiol\u00f3gico.\n     - **Etiquetado**: Normas para el etiquetado adecuado de reactivos y medios.\n     - **Resucitaci\u00f3n de organismos**: M\u00e9todos para la recuperaci\u00f3n y mantenimiento de cultivos microbiol\u00f3gicos.\n\nEste resumen destaca la importancia de seguir buenas pr\u00e1cticas en laboratorios de microbiolog\u00eda farmac\u00e9utica para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: reference materials, quality assurance, laboratory procedures, microbiology, equipment maintenance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1d1cbdab-74ac-4489-8c0d-72223073dd35", "node_type": "4", "metadata": {"page_label": "82", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n6.1 International standards and pharmacopoeial reference substances  \n6.2 Reference cultures\n\n7. Sampling\n\n8. Sample handling and identification\n\n9. Disposal of contaminated waste\n\n10. Quality assurance of results and quality control of performance  \n10.1 Internal quality control\n\n11. Testing procedures\n\n12. Test reports\n\nReferences\n\nFurther reading\n\n## Appendix 1\nExamples of zones in which operations could be carried out\n\n## Appendix 2\nExamples of maintenance of equipment\n\n## Appendix 3\nExamples of calibration checks and intervals for different laboratory equipment\n\n## Appendix 4\nExamples of equipment qualification and monitoring\n\n## Appendix 5\nGeneral use of reference cultures", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "aeda9612595864eacbb444a991fcb84bc01b2da85d1615a3b4008839f7e9a114", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6. Reference materials and reference cultures\n6.1 International standards and pharmacopoeial reference substances  \n6.2 Reference cultures\n\n7. Sampling\n\n8. Sample handling and identification\n\n9. Disposal of contaminated waste\n\n10. Quality assurance of results and quality control of performance  \n10.1 Internal quality control\n\n11. Testing procedures\n\n12. Test reports\n\nReferences\n\nFurther reading\n\n## Appendix 1\nExamples of zones in which operations could be carried out\n\n## Appendix 2\nExamples of maintenance of equipment\n\n## Appendix 3\nExamples of calibration checks and intervals for different laboratory equipment\n\n## Appendix 4\nExamples of equipment qualification and monitoring\n\n## Appendix 5\nGeneral use of reference cultures", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 735, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ce200727-3ba2-4149-b1d1-a4d8127a4db5": {"__data__": {"id_": "ce200727-3ba2-4149-b1d1-a4d8127a4db5", "embedding": null, "metadata": {"page_label": "83", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction and scope of document\n\nPharmaceutical microbiology laboratories may be involved in:\n\n- sterility testing;\n- detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and moulds) and testing for bacterial endotoxins in different materials (e.g. starting materials, water), products, surfaces, garments and the environment; and\n- assay using microorganisms as part of the test system.\n\nThese guidelines relate to all microbiology laboratories involved in the above-mentioned testing activities, whether they are independent or a department or unit of a pharmaceutical manufacturing facility.\n\nThese guidelines are based on and supplement the requirements described in *Good practices for pharmaceutical quality control laboratories* (1); *General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision* (2); *The International Pharmacopoeia, Fourth Edition* (3); *First Supplement to The International Pharmacopoeia, Fourth Edition* (4); and *ISO/IEC 17025* (5).\n\n# Glossary\n\n**calibration**  \nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n**certified reference material**  \nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides the value of the specified property, its associated uncertainty and a statement of metrological traceability.\n\n**limit of detection**  \nThe lowest number of microorganisms that can be detected, but in numbers that cannot be estimated accurately.\n\n**precision**  \nThe degree of agreement among individual results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, *Technical Report Series 961*, establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica que realizan pruebas de esterilidad, detecci\u00f3n e identificaci\u00f3n de microorganismos, y ensayos utilizando microorganismos. Estas directrices son aplicables a laboratorios independientes y a departamentos dentro de instalaciones de fabricaci\u00f3n farmac\u00e9utica. Adem\u00e1s, se incluyen definiciones clave relacionadas con la calibraci\u00f3n, materiales de referencia certificados, l\u00edmites de detecci\u00f3n y precisi\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de pruebas microbiol\u00f3gicas est\u00e1n cubiertas por las directrices de la OMS en el documento?**\n   - Las directrices cubren pruebas de esterilidad, detecci\u00f3n, aislamiento, enumeraci\u00f3n e identificaci\u00f3n de microorganismos (bacterias, levaduras y mohos), as\u00ed como pruebas de endotoxinas bacterianas en diversos materiales, productos, superficies, prendas y el entorno.\n\n2. **\u00bfCu\u00e1les son las bases sobre las que se fundamentan estas directrices?**\n   - Estas directrices se basan en y complementan los requisitos descritos en documentos como *Good practices for pharmaceutical quality control laboratories*, *The International Pharmacopoeia*, y normas como *ISO/IEC 17025*.\n\n3. **\u00bfQu\u00e9 se entiende por \"material de referencia certificado\" seg\u00fan el documento?**\n   - Un material de referencia certificado es aquel que ha sido caracterizado mediante un procedimiento metrol\u00f3gicamente v\u00e1lido para una o m\u00e1s propiedades especificadas, y que viene acompa\u00f1ado de un certificado que proporciona el valor de la propiedad especificada, su incertidumbre asociada y una declaraci\u00f3n de trazabilidad metrol\u00f3gica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Materiales de referencia y cultivos de referencia**:\n   - Secci\u00f3n 6 aborda la importancia de los est\u00e1ndares internacionales y las sustancias de referencia farmacop\u00e9utica, as\u00ed como el uso de cultivos de referencia en laboratorios.\n\n2. **Muestreo**:\n   - Secci\u00f3n 7 se centra en los procedimientos de muestreo, que son fundamentales para la obtenci\u00f3n de muestras representativas.\n\n3. **Manejo e identificaci\u00f3n de muestras**:\n   - Secci\u00f3n 8 trata sobre c\u00f3mo manejar e identificar adecuadamente las muestras para evitar contaminaciones y asegurar la integridad de los resultados.\n\n4. **Eliminaci\u00f3n de desechos contaminados**:\n   - Secci\u00f3n 9 discute las pr\u00e1cticas adecuadas para la disposici\u00f3n de residuos contaminados, un aspecto cr\u00edtico para la seguridad en el laboratorio.\n\n5. **Aseguramiento de la calidad y control de calidad**:\n   - Secci\u00f3n 10 se enfoca en la garant\u00eda de resultados de calidad y el control de rendimiento, incluyendo controles de calidad internos en la subsecci\u00f3n 10.1.\n\n6. **Procedimientos de prueba**:\n   - Secci\u00f3n 11 describe los m\u00e9todos y procedimientos utilizados para realizar pruebas en el laboratorio.\n\n7. **Informes de prueba**:\n   - Secci\u00f3n 12 se refiere a la elaboraci\u00f3n y presentaci\u00f3n de informes de prueba, que son esenciales para la comunicaci\u00f3n de resultados.\n\n8. **Ap\u00e9ndices**:\n   - **Ap\u00e9ndice 1**: Ejemplos de zonas para operaciones de laboratorio.\n   - **Ap\u00e9ndice 2**: Ejemplos de mantenimiento de equipos.\n   - **Ap\u00e9ndice 3**: Ejemplos de verificaciones de calibraci\u00f3n y sus intervalos.\n   - **Ap\u00e9ndice 4**: Ejemplos de calificaci\u00f3n y monitoreo de equipos.\n   - **Ap\u00e9ndice 5**: Uso general de cultivos de referencia.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el informe.\n- **Laboratorios**: Contexto en el que se aplican los procedimientos y est\u00e1ndares mencionados.\n- **Cultivos de referencia**: Elementos esenciales para la validaci\u00f3n de pruebas en laboratorios.\n- **Contaminaci\u00f3n**: Riesgo que se aborda en la eliminaci\u00f3n de desechos y manejo de muestras.\n- **Calidad**: Concepto central en el aseguramiento de resultados y control de rendimiento. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de los est\u00e1ndares y procedimientos en el contexto de la calidad en laboratorios.", "excerpt_keywords": "Keywords: pharmaceutical microbiology, sterility testing, certified reference material, limit of detection, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f57177f4-3da1-400a-b3af-0aaa415f6838", "node_type": "4", "metadata": {"page_label": "83", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction and scope of document\n\nPharmaceutical microbiology laboratories may be involved in:\n\n- sterility testing;\n- detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and moulds) and testing for bacterial endotoxins in different materials (e.g. starting materials, water), products, surfaces, garments and the environment; and\n- assay using microorganisms as part of the test system.\n\nThese guidelines relate to all microbiology laboratories involved in the above-mentioned testing activities, whether they are independent or a department or unit of a pharmaceutical manufacturing facility.\n\nThese guidelines are based on and supplement the requirements described in *Good practices for pharmaceutical quality control laboratories* (1); *General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision* (2); *The International Pharmacopoeia, Fourth Edition* (3); *First Supplement to The International Pharmacopoeia, Fourth Edition* (4); and *ISO/IEC 17025* (5).\n\n# Glossary\n\n**calibration**  \nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n**certified reference material**  \nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides the value of the specified property, its associated uncertainty and a statement of metrological traceability.\n\n**limit of detection**  \nThe lowest number of microorganisms that can be detected, but in numbers that cannot be estimated accurately.\n\n**precision**  \nThe degree of agreement among individual results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1a816c2b952f1f7ccb320aebfe17f123a6e34474ea7570983db7b4d08141ce5a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction and scope of document\n\nPharmaceutical microbiology laboratories may be involved in:\n\n- sterility testing;\n- detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and moulds) and testing for bacterial endotoxins in different materials (e.g. starting materials, water), products, surfaces, garments and the environment; and\n- assay using microorganisms as part of the test system.\n\nThese guidelines relate to all microbiology laboratories involved in the above-mentioned testing activities, whether they are independent or a department or unit of a pharmaceutical manufacturing facility.\n\nThese guidelines are based on and supplement the requirements described in *Good practices for pharmaceutical quality control laboratories* (1); *General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision* (2); *The International Pharmacopoeia, Fourth Edition* (3); *First Supplement to The International Pharmacopoeia, Fourth Edition* (4); and *ISO/IEC 17025* (5).\n\n# Glossary\n\n**calibration**  \nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n**certified reference material**  \nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides the value of the specified property, its associated uncertainty and a statement of metrological traceability.\n\n**limit of detection**  \nThe lowest number of microorganisms that can be detected, but in numbers that cannot be estimated accurately.\n\n**precision**  \nThe degree of agreement among individual results.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1968, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "04376628-07b7-4fed-8993-c968dcdccd13": {"__data__": {"id_": "04376628-07b7-4fed-8993-c968dcdccd13", "embedding": null, "metadata": {"page_label": "84", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# quantitation limit (limit of quantitation)\n\nApplied to quantitative microbiological tests. The lowest number of microorganisms within a defined variability that may be counted under the experimental conditions of the method under evaluation.\n\n# reference cultures\n\nCollective term for reference strain and reference stocks.\n\n# reference material\n\nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process.\n\n# reference method\n\nA method which has been validated as being fit for purpose, with which an alternative method may be compared.\n\n# reference stocks\n\nA set of separate identical cultures obtained by a single subculture from the reference strain (6).\n\n# reference strains\n\nMicroorganisms defined at least to the genus and species level, catalogued and described according to its characteristics and preferably stating its origin (6). Normally obtained from a recognized national or international collection.\n\n# repeatability\n\nCloseness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).\n\n# reproducibility\n\nReproducibility expresses precision between laboratories.\n\n# robustness (or ruggedness)\n\nThe ability of the procedure to provide analytical results of acceptable accuracy and precision under a variety of conditions.\n\n# sensitivity\n\nThe fraction of the total number of positive cultures or colonies correctly assigned in the presumptive inspection (7).\n\n# specificity (selectivity)\n\nThe ability of the method to detect the required range of microorganisms that might be present in the test sample.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 961\" aborda conceptos clave relacionados con pruebas microbiol\u00f3gicas cuantitativas. Se definen t\u00e9rminos como l\u00edmite de cuantificaci\u00f3n, cultivos de referencia, m\u00e9todos de referencia, y se discuten aspectos de precisi\u00f3n y exactitud en mediciones microbiol\u00f3gicas, incluyendo repetibilidad, reproducibilidad, robustez, sensibilidad y especificidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la importancia del l\u00edmite de cuantificaci\u00f3n en las pruebas microbiol\u00f3gicas y c\u00f3mo se determina?**\n   - Esta pregunta busca profundizar en el concepto de l\u00edmite de cuantificaci\u00f3n, que se menciona en el contexto, y su relevancia en la pr\u00e1ctica de pruebas microbiol\u00f3gicas.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para validar un m\u00e9todo de referencia y c\u00f3mo se compara con m\u00e9todos alternativos?**\n   - Esta pregunta se centra en el proceso de validaci\u00f3n de m\u00e9todos de referencia, un aspecto clave mencionado en el texto, y busca entender los criterios espec\u00edficos que se aplican.\n\n3. **\u00bfC\u00f3mo se define y mide la robustez de un procedimiento anal\u00edtico en microbiolog\u00eda?**\n   - Esta pregunta explora el concepto de robustez, que se describe en el contexto, y busca detalles sobre c\u00f3mo se eval\u00faa en la pr\u00e1ctica.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona definiciones y explicaciones sobre t\u00e9rminos y conceptos fundamentales en la microbiolog\u00eda cuantitativa, enfatizando la importancia de la precisi\u00f3n y la exactitud en las mediciones. Se abordan aspectos como la validaci\u00f3n de m\u00e9todos, la homogeneidad de los materiales de referencia y la capacidad de los m\u00e9todos para detectar microorganismos espec\u00edficos. Estos conceptos son esenciales para garantizar la fiabilidad de los resultados en pruebas microbiol\u00f3gicas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, *Technical Report Series 961*, aborda las directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, centr\u00e1ndose en las siguientes \u00e1reas clave:\n\n1. **Actividades de Laboratorio**:\n   - Pruebas de esterilidad.\n   - Detecci\u00f3n, aislamiento, enumeraci\u00f3n e identificaci\u00f3n de microorganismos (bacterias, levaduras y mohos).\n   - Pruebas de endotoxinas bacterianas en diversos materiales, productos, superficies, prendas y el entorno.\n   - Ensayos que utilizan microorganismos como parte del sistema de prueba.\n\n2. **Aplicabilidad**:\n   - Las directrices son relevantes para todos los laboratorios de microbiolog\u00eda, ya sean independientes o parte de una instalaci\u00f3n de fabricaci\u00f3n farmac\u00e9utica.\n\n3. **Fundamentaci\u00f3n**:\n   - Las directrices complementan requisitos establecidos en documentos como:\n     - *Good practices for pharmaceutical quality control laboratories*.\n     - *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n     - *The International Pharmacopoeia* (Cuarta Edici\u00f3n y su Primer Suplemento).\n     - Normas como *ISO/IEC 17025*.\n\n4. **Glosario de T\u00e9rminos Clave**:\n   - **Calibraci\u00f3n**: Proceso para establecer la relaci\u00f3n entre los valores indicados por un instrumento y los valores conocidos de un est\u00e1ndar de referencia.\n   - **Material de referencia certificado**: Material caracterizado por un procedimiento metrol\u00f3gicamente v\u00e1lido, acompa\u00f1ado de un certificado que proporciona el valor de una propiedad especificada y su incertidumbre.\n   - **L\u00edmite de detecci\u00f3n**: La menor cantidad de microorganismos que puede ser detectada, aunque no se pueda estimar con precisi\u00f3n.\n   - **Precisi\u00f3n**: Grado de acuerdo entre resultados individuales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Entidades que realizan las pruebas mencionadas.\n- **Documentos de Referencia**: Incluyen pr\u00e1cticas de control de calidad, farmacopoeias y normas ISO.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: microbiology, quantitation limit, reference method, sensitivity, reproducibility"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "858eb68a-5a72-4859-b4e7-12449b9c3c2a", "node_type": "4", "metadata": {"page_label": "84", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# quantitation limit (limit of quantitation)\n\nApplied to quantitative microbiological tests. The lowest number of microorganisms within a defined variability that may be counted under the experimental conditions of the method under evaluation.\n\n# reference cultures\n\nCollective term for reference strain and reference stocks.\n\n# reference material\n\nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process.\n\n# reference method\n\nA method which has been validated as being fit for purpose, with which an alternative method may be compared.\n\n# reference stocks\n\nA set of separate identical cultures obtained by a single subculture from the reference strain (6).\n\n# reference strains\n\nMicroorganisms defined at least to the genus and species level, catalogued and described according to its characteristics and preferably stating its origin (6). Normally obtained from a recognized national or international collection.\n\n# repeatability\n\nCloseness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).\n\n# reproducibility\n\nReproducibility expresses precision between laboratories.\n\n# robustness (or ruggedness)\n\nThe ability of the procedure to provide analytical results of acceptable accuracy and precision under a variety of conditions.\n\n# sensitivity\n\nThe fraction of the total number of positive cultures or colonies correctly assigned in the presumptive inspection (7).\n\n# specificity (selectivity)\n\nThe ability of the method to detect the required range of microorganisms that might be present in the test sample.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c78002d45254258925fcd20464df541bfb13ed080ea82ccd463d4a2b464eb25e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# quantitation limit (limit of quantitation)\n\nApplied to quantitative microbiological tests. The lowest number of microorganisms within a defined variability that may be counted under the experimental conditions of the method under evaluation.\n\n# reference cultures\n\nCollective term for reference strain and reference stocks.\n\n# reference material\n\nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process.\n\n# reference method\n\nA method which has been validated as being fit for purpose, with which an alternative method may be compared.\n\n# reference stocks\n\nA set of separate identical cultures obtained by a single subculture from the reference strain (6).\n\n# reference strains\n\nMicroorganisms defined at least to the genus and species level, catalogued and described according to its characteristics and preferably stating its origin (6). Normally obtained from a recognized national or international collection.\n\n# repeatability\n\nCloseness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).\n\n# reproducibility\n\nReproducibility expresses precision between laboratories.\n\n# robustness (or ruggedness)\n\nThe ability of the procedure to provide analytical results of acceptable accuracy and precision under a variety of conditions.\n\n# sensitivity\n\nThe fraction of the total number of positive cultures or colonies correctly assigned in the presumptive inspection (7).\n\n# specificity (selectivity)\n\nThe ability of the method to detect the required range of microorganisms that might be present in the test sample.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1730, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b1c80ef4-9fa6-4379-a50e-34e12f717087": {"__data__": {"id_": "b1c80ef4-9fa6-4379-a50e-34e12f717087", "embedding": null, "metadata": {"page_label": "85", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n1. **Validation**\n\n   Action of proving, in accordance with the principles of good practice quality guidelines and regulations (GxP), that any procedure, process, equipment (including the software or hardware used), material, activity or system actually and consistently leads to the expected results.\n\n2. **Verification**\n\n   The application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine compliance with GxP principles.\n\n3. **Working Culture**\n\n   A primary subculture from a reference stock (6).\n\n## 1. Personnel\n\n1.1 Microbiological testing should be performed and supervised by an experienced person, qualified in microbiology or equivalent. Staff should have basic training in microbiology and relevant practical experience before being allowed to perform work covered by the scope of testing.\n\n1.2 Current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications should be maintained. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n1.3 If the laboratory includes opinions and interpretations of test results in reports, this should be done by authorized personnel with suitable experience and relevant knowledge of the specific application including, for example, regulatory and technological requirements and acceptability criteria.\n\n1.4 The laboratory management should ensure that all personnel have received adequate training for the competent performance of tests and operation of equipment. This should include training in basic techniques, e.g. plate pouring, counting of colonies, aseptic technique, media preparation, serial dilutions, and basic techniques in identification, with acceptability determined using objective criteria where relevant. Personnel may only perform tests on samples if they are either recognized as competent to do so, or if they do so under adequate supervision. Competence should be monitored continuously with provision for retraining where necessary. Where a method or technique is not in regular use, the competency of the personnel to perform the test should be verified before testing is undertaken. In some cases it is acceptable to relate competence to a general technique or instrument being used rather than to particular methods.\n\n1.5 Personnel should be trained in necessary procedures for containment of microorganisms within the laboratory facility.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Validaci\u00f3n y Verificaci\u00f3n**: El documento establece definiciones claras de validaci\u00f3n y verificaci\u00f3n en el contexto de las buenas pr\u00e1cticas de calidad (GxP), enfatizando la importancia de demostrar que los procedimientos y sistemas cumplen consistentemente con los resultados esperados.\n\n2. **Requisitos de Personal**: Se detallan las calificaciones y la formaci\u00f3n necesarias para el personal que realiza pruebas microbiol\u00f3gicas, as\u00ed como la importancia de mantener registros actualizados de las competencias y experiencias del personal t\u00e9cnico.\n\n3. **Capacitaci\u00f3n y Competencia**: Se subraya la necesidad de que el personal reciba capacitaci\u00f3n adecuada en t\u00e9cnicas microbiol\u00f3gicas y en procedimientos de contenci\u00f3n de microorganismos, asegurando que solo personal competente realice pruebas y que se lleve a cabo un monitoreo continuo de la competencia.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n se requiere para el personal que realiza pruebas microbiol\u00f3gicas seg\u00fan el documento?**\n   - El personal debe tener formaci\u00f3n b\u00e1sica en microbiolog\u00eda y experiencia pr\u00e1ctica relevante antes de realizar trabajos cubiertos por el alcance de las pruebas. Adem\u00e1s, deben recibir capacitaci\u00f3n en t\u00e9cnicas espec\u00edficas como el vertido de placas, conteo de colonias, t\u00e9cnica as\u00e9ptica, preparaci\u00f3n de medios y diluciones seriadas.\n\n2. **\u00bfC\u00f3mo se asegura la competencia del personal en el laboratorio?**\n   - La competencia del personal debe ser monitoreada continuamente, y se debe proporcionar reentrenamiento cuando sea necesario. Si un m\u00e9todo o t\u00e9cnica no se utiliza regularmente, la competencia del personal para realizar la prueba debe ser verificada antes de que se lleve a cabo la prueba.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar al incluir opiniones e interpretaciones de resultados de pruebas en los informes del laboratorio?**\n   - Las opiniones e interpretaciones de los resultados de las pruebas deben ser realizadas por personal autorizado que tenga experiencia adecuada y conocimiento relevante de la aplicaci\u00f3n espec\u00edfica, incluyendo requisitos regulatorios y tecnol\u00f3gicos, as\u00ed como criterios de aceptabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **L\u00edmite de Cuantificaci\u00f3n (Quantitation Limit)**: Se refiere al n\u00famero m\u00e1s bajo de microorganismos que puede contarse en condiciones experimentales definidas durante pruebas microbiol\u00f3gicas cuantitativas.\n\n2. **Cultivos de Referencia**: T\u00e9rmino colectivo que incluye cepas de referencia y stocks de referencia, utilizados para asegurar la consistencia en las pruebas.\n\n3. **Material de Referencia**: Material que es homog\u00e9neo y estable en propiedades espec\u00edficas, validado para su uso en procesos de medici\u00f3n.\n\n4. **M\u00e9todo de Referencia**: M\u00e9todo validado que sirve como est\u00e1ndar para comparar otros m\u00e9todos alternativos.\n\n5. **Stocks de Referencia**: Culturas id\u00e9nticas obtenidas a partir de una \u00fanica subcultivo de una cepa de referencia.\n\n6. **Cepas de Referencia**: Microorganismos catalogados y descritos al menos a nivel de g\u00e9nero y especie, normalmente obtenidos de colecciones reconocidas.\n\n7. **Repetibilidad**: Grado de concordancia entre resultados de mediciones sucesivas bajo las mismas condiciones.\n\n8. **Reproducibilidad**: Precisi\u00f3n de los resultados entre diferentes laboratorios.\n\n9. **Robustez (o Rugosidad)**: Capacidad de un procedimiento para proporcionar resultados anal\u00edticos precisos y exactos bajo diversas condiciones.\n\n10. **Sensibilidad**: Proporci\u00f3n de cultivos o colonias positivas correctamente identificadas en una inspecci\u00f3n presuntiva.\n\n11. **Especificidad (Selectividad)**: Capacidad del m\u00e9todo para detectar un rango espec\u00edfico de microorganismos en una muestra de prueba.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **ISO**: Organizaci\u00f3n que proporciona est\u00e1ndares para la medici\u00f3n y evaluaci\u00f3n en microbiolog\u00eda.\n\nEste resumen destaca los conceptos fundamentales y las definiciones esenciales que son cruciales para la pr\u00e1ctica de pruebas microbiol\u00f3gicas cuantitativas, enfatizando la importancia de la precisi\u00f3n y la validaci\u00f3n de m\u00e9todos.", "excerpt_keywords": "Keywords: validation, verification, microbiological testing, personnel training, good practice quality guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1b9dedcb-fe53-4715-8668-6ffb821bef57", "node_type": "4", "metadata": {"page_label": "85", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n1. **Validation**\n\n   Action of proving, in accordance with the principles of good practice quality guidelines and regulations (GxP), that any procedure, process, equipment (including the software or hardware used), material, activity or system actually and consistently leads to the expected results.\n\n2. **Verification**\n\n   The application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine compliance with GxP principles.\n\n3. **Working Culture**\n\n   A primary subculture from a reference stock (6).\n\n## 1. Personnel\n\n1.1 Microbiological testing should be performed and supervised by an experienced person, qualified in microbiology or equivalent. Staff should have basic training in microbiology and relevant practical experience before being allowed to perform work covered by the scope of testing.\n\n1.2 Current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications should be maintained. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n1.3 If the laboratory includes opinions and interpretations of test results in reports, this should be done by authorized personnel with suitable experience and relevant knowledge of the specific application including, for example, regulatory and technological requirements and acceptability criteria.\n\n1.4 The laboratory management should ensure that all personnel have received adequate training for the competent performance of tests and operation of equipment. This should include training in basic techniques, e.g. plate pouring, counting of colonies, aseptic technique, media preparation, serial dilutions, and basic techniques in identification, with acceptability determined using objective criteria where relevant. Personnel may only perform tests on samples if they are either recognized as competent to do so, or if they do so under adequate supervision. Competence should be monitored continuously with provision for retraining where necessary. Where a method or technique is not in regular use, the competency of the personnel to perform the test should be verified before testing is undertaken. In some cases it is acceptable to relate competence to a general technique or instrument being used rather than to particular methods.\n\n1.5 Personnel should be trained in necessary procedures for containment of microorganisms within the laboratory facility.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ee4dad45fdf1522b091262850c490dcf16967500938d3f822a3bc1568219e551", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Personnel\n\n1. **Validation**\n\n   Action of proving, in accordance with the principles of good practice quality guidelines and regulations (GxP), that any procedure, process, equipment (including the software or hardware used), material, activity or system actually and consistently leads to the expected results.\n\n2. **Verification**\n\n   The application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine compliance with GxP principles.\n\n3. **Working Culture**\n\n   A primary subculture from a reference stock (6).\n\n## 1. Personnel\n\n1.1 Microbiological testing should be performed and supervised by an experienced person, qualified in microbiology or equivalent. Staff should have basic training in microbiology and relevant practical experience before being allowed to perform work covered by the scope of testing.\n\n1.2 Current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications should be maintained. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n1.3 If the laboratory includes opinions and interpretations of test results in reports, this should be done by authorized personnel with suitable experience and relevant knowledge of the specific application including, for example, regulatory and technological requirements and acceptability criteria.\n\n1.4 The laboratory management should ensure that all personnel have received adequate training for the competent performance of tests and operation of equipment. This should include training in basic techniques, e.g. plate pouring, counting of colonies, aseptic technique, media preparation, serial dilutions, and basic techniques in identification, with acceptability determined using objective criteria where relevant. Personnel may only perform tests on samples if they are either recognized as competent to do so, or if they do so under adequate supervision. Competence should be monitored continuously with provision for retraining where necessary. Where a method or technique is not in regular use, the competency of the personnel to perform the test should be verified before testing is undertaken. In some cases it is acceptable to relate competence to a general technique or instrument being used rather than to particular methods.\n\n1.5 Personnel should be trained in necessary procedures for containment of microorganisms within the laboratory facility.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2495, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "40b7fea4-8170-438d-bd3c-8711682ebec1": {"__data__": {"id_": "40b7fea4-8170-438d-bd3c-8711682ebec1", "embedding": null, "metadata": {"page_label": "86", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Environment\n\n## 2.1 Premises\n\n2.1.1 Microbiology laboratories and certain support equipment (e.g. autoclaves and glassware) should be dedicated and separated from other areas, especially from production areas.\n\n2.1.2 Microbiology laboratories should be designed to suit the operations to be carried out in them. There should be sufficient space for all activities to avoid mix ups, contamination and cross-contamination. There should be adequate suitable space for samples, reference organisms, media (if necessary, with cooling), testing and records. Due to the nature of some materials (e.g. sterile media versus reference organisms or incubated cultures), separate storage locations may be necessary.\n\n2.1.3 Laboratories should be appropriately designed and should take into account the suitability of construction materials to enable appropriate cleaning, disinfection and minimize the risks of contamination.\n\n2.1.4 There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions, including temperature and humidity controls where required, should be in place for microbiological laboratories. The air supplied to the laboratory should be of appropriate quality and should not be a source of contamination.\n\n2.1.5 Access to the microbiological laboratory should be restricted to authorized personnel. Personnel should be made aware of:\n\n- the appropriate entry and exit procedures including gowning;\n- the intended use of a particular area;\n- the restrictions imposed on working within such areas;\n- the reasons for imposing such restrictions; and\n- the appropriate containment levels.\n\n2.1.6 Laboratory activities, such as sample preparation, media and equipment preparation and enumeration of microorganisms, should be segregated by space or at least in time, so as to minimize risks of cross-contamination, false-positive results and false-negative results. Where non-dedicated areas are used, risk management principles should be applied. Sterility testing should always be performed in a dedicated area.\n\n2.1.7 Consideration should be given to designing appropriate classified areas for the operations to be performed within the microbiology laboratory. The classification should be based on the criticality of the product and the operations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Dise\u00f1o y separaci\u00f3n de laboratorios**: Los laboratorios de microbiolog\u00eda deben estar dise\u00f1ados espec\u00edficamente para sus operaciones, con suficiente espacio para evitar la contaminaci\u00f3n y el cruce de muestras. Adem\u00e1s, deben estar separados de otras \u00e1reas, especialmente de las de producci\u00f3n.\n\n2. **Control de acceso y procedimientos**: El acceso a los laboratorios microbiol\u00f3gicos debe ser restringido a personal autorizado, que debe estar informado sobre los procedimientos de entrada y salida, el uso de las \u00e1reas y las restricciones pertinentes.\n\n3. **Manejo de actividades y clasificaci\u00f3n de \u00e1reas**: Las actividades dentro del laboratorio deben estar segregadas para minimizar riesgos de contaminaci\u00f3n. Adem\u00e1s, se debe considerar la clasificaci\u00f3n de \u00e1reas seg\u00fan la criticidad del producto y las operaciones realizadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar un laboratorio de microbiolog\u00eda para evitar la contaminaci\u00f3n?**\n   - Esta pregunta se centra en los aspectos espec\u00edficos del dise\u00f1o del laboratorio, como el espacio, los materiales de construcci\u00f3n y la segregaci\u00f3n de actividades.\n\n2. **\u00bfCu\u00e1les son los procedimientos que el personal debe seguir al acceder a un laboratorio microbiol\u00f3gico?**\n   - Esta pregunta busca detalles sobre los procedimientos de entrada y salida, as\u00ed como las restricciones que deben conocer los empleados.\n\n3. **\u00bfC\u00f3mo se deben clasificar las \u00e1reas dentro de un laboratorio de microbiolog\u00eda y qu\u00e9 factores influyen en esta clasificaci\u00f3n?**\n   - Esta pregunta se enfoca en la clasificaci\u00f3n de \u00e1reas dentro del laboratorio y los criterios que determinan dicha clasificaci\u00f3n, como la criticidad del producto y las operaciones realizadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n y Verificaci\u00f3n**:\n   - **Validaci\u00f3n**: Proceso de demostrar que procedimientos, procesos, equipos y sistemas cumplen consistentemente con los resultados esperados, de acuerdo con las buenas pr\u00e1cticas de calidad (GxP).\n   - **Verificaci\u00f3n**: Aplicaci\u00f3n de m\u00e9todos y evaluaciones para determinar el cumplimiento de los principios GxP.\n\n2. **Requisitos de Personal**:\n   - **Calificaciones**: El personal que realiza pruebas microbiol\u00f3gicas debe ser experimentado y calificado en microbiolog\u00eda o equivalente.\n   - **Formaci\u00f3n**: Se requiere formaci\u00f3n b\u00e1sica en microbiolog\u00eda y experiencia pr\u00e1ctica relevante antes de realizar pruebas.\n\n3. **Registros de Personal**:\n   - Mantener descripciones de trabajo actualizadas y registros de calificaciones, formaci\u00f3n y experiencia de todo el personal t\u00e9cnico involucrado en pruebas, calibraciones, validaciones y verificaciones.\n\n4. **Opiniones e Interpretaciones**:\n   - Solo personal autorizado con experiencia y conocimiento relevante debe incluir opiniones e interpretaciones de resultados en los informes del laboratorio.\n\n5. **Capacitaci\u00f3n y Competencia**:\n   - El personal debe recibir capacitaci\u00f3n adecuada en t\u00e9cnicas microbiol\u00f3gicas y operaci\u00f3n de equipos, incluyendo t\u00e9cnicas como vertido de placas, conteo de colonias, t\u00e9cnica as\u00e9ptica, preparaci\u00f3n de medios y diluciones seriadas.\n   - La competencia del personal debe ser monitoreada continuamente, con provisiones para reentrenamiento cuando sea necesario.\n\n6. **Contenci\u00f3n de Microorganismos**:\n   - El personal debe estar capacitado en procedimientos necesarios para la contenci\u00f3n de microorganismos dentro de las instalaciones del laboratorio.\n\n### Entidades Clave\n- **GxP**: Buenas pr\u00e1cticas de calidad.\n- **Microbiolog\u00eda**: Campo de estudio relevante para el personal.\n- **Laboratorio**: Entidad donde se realizan las pruebas microbiol\u00f3gicas.\n- **Personal Autorizado**: Individuos con la experiencia y conocimiento necesarios para interpretar resultados.", "excerpt_keywords": "Keywords: microbiology laboratories, contamination control, access procedures, laboratory design, classified areas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "54de6d59-2eed-4668-bc36-4b405330cba9", "node_type": "4", "metadata": {"page_label": "86", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Environment\n\n## 2.1 Premises\n\n2.1.1 Microbiology laboratories and certain support equipment (e.g. autoclaves and glassware) should be dedicated and separated from other areas, especially from production areas.\n\n2.1.2 Microbiology laboratories should be designed to suit the operations to be carried out in them. There should be sufficient space for all activities to avoid mix ups, contamination and cross-contamination. There should be adequate suitable space for samples, reference organisms, media (if necessary, with cooling), testing and records. Due to the nature of some materials (e.g. sterile media versus reference organisms or incubated cultures), separate storage locations may be necessary.\n\n2.1.3 Laboratories should be appropriately designed and should take into account the suitability of construction materials to enable appropriate cleaning, disinfection and minimize the risks of contamination.\n\n2.1.4 There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions, including temperature and humidity controls where required, should be in place for microbiological laboratories. The air supplied to the laboratory should be of appropriate quality and should not be a source of contamination.\n\n2.1.5 Access to the microbiological laboratory should be restricted to authorized personnel. Personnel should be made aware of:\n\n- the appropriate entry and exit procedures including gowning;\n- the intended use of a particular area;\n- the restrictions imposed on working within such areas;\n- the reasons for imposing such restrictions; and\n- the appropriate containment levels.\n\n2.1.6 Laboratory activities, such as sample preparation, media and equipment preparation and enumeration of microorganisms, should be segregated by space or at least in time, so as to minimize risks of cross-contamination, false-positive results and false-negative results. Where non-dedicated areas are used, risk management principles should be applied. Sterility testing should always be performed in a dedicated area.\n\n2.1.7 Consideration should be given to designing appropriate classified areas for the operations to be performed within the microbiology laboratory. The classification should be based on the criticality of the product and the operations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a6dff3ba7d43537c4f5ba1d5f6d1792c13159cfb1876164c0baa3dbf1ad9c91a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Environment\n\n## 2.1 Premises\n\n2.1.1 Microbiology laboratories and certain support equipment (e.g. autoclaves and glassware) should be dedicated and separated from other areas, especially from production areas.\n\n2.1.2 Microbiology laboratories should be designed to suit the operations to be carried out in them. There should be sufficient space for all activities to avoid mix ups, contamination and cross-contamination. There should be adequate suitable space for samples, reference organisms, media (if necessary, with cooling), testing and records. Due to the nature of some materials (e.g. sterile media versus reference organisms or incubated cultures), separate storage locations may be necessary.\n\n2.1.3 Laboratories should be appropriately designed and should take into account the suitability of construction materials to enable appropriate cleaning, disinfection and minimize the risks of contamination.\n\n2.1.4 There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions, including temperature and humidity controls where required, should be in place for microbiological laboratories. The air supplied to the laboratory should be of appropriate quality and should not be a source of contamination.\n\n2.1.5 Access to the microbiological laboratory should be restricted to authorized personnel. Personnel should be made aware of:\n\n- the appropriate entry and exit procedures including gowning;\n- the intended use of a particular area;\n- the restrictions imposed on working within such areas;\n- the reasons for imposing such restrictions; and\n- the appropriate containment levels.\n\n2.1.6 Laboratory activities, such as sample preparation, media and equipment preparation and enumeration of microorganisms, should be segregated by space or at least in time, so as to minimize risks of cross-contamination, false-positive results and false-negative results. Where non-dedicated areas are used, risk management principles should be applied. Sterility testing should always be performed in a dedicated area.\n\n2.1.7 Consideration should be given to designing appropriate classified areas for the operations to be performed within the microbiology laboratory. The classification should be based on the criticality of the product and the operations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2313, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2baaeac0-3da2-4794-a8cc-46dc65e9818a": {"__data__": {"id_": "2baaeac0-3da2-4794-a8cc-46dc65e9818a", "embedding": null, "metadata": {"page_label": "87", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Environmental monitoring in the laboratory\n\n2.2.1 Where necessary and appropriate (e.g. in areas for sterility testing) an environmental monitoring programme should be in place which covers, for example, use of active air monitoring, air settling or contact plates, temperature and pressure differentials. Alert and action limits should be defined. Trending of environmental monitoring results should be carried out.\n\n# 2.3 Cleaning, disinfection and hygiene\n\n2.3.1 There should be a documented cleaning and disinfection programme. Results of environmental monitoring should be considered where relevant.\n\n2.3.2 There should be a procedure for dealing with spillages.\n\n2.3.3 Adequate hand-washing and hand-disinfection facilities should be available.\n\n# 2.4 Sterility test facilities\n\n2.4.1 Sterility test facilities have specific environmental requirements to ensure the integrity of tests carried out. *WHO good manufacturing practices (GMP) for sterile pharmaceutical products* (8) requires that sterility testing should be carried out and specifies requirements for sterility testing. This section details the clean-room requirements for a sterility test facility.\n\n2.4.2 Sterility testing should be performed under aseptic conditions, which should be equivalent to air quality standards required for the aseptic manufacture of pharmaceutical products. The premises, services and equipment should be subject to the appropriate qualification process.\n\n2.4.3 The sterility testing should be carried out within a Grade A unidirectional airflow protected zone or a biosafety cabinet (if warranted), which should be located within a clean room with a Grade B background. Alternatively, the testing can be carried out within a barrier isolator. Care should be taken with the design of the facility layout and room airflow patterns, to ensure that the unidirectional airflow patterns are not disrupted.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles, enfoc\u00e1ndose en la importancia del monitoreo ambiental, la limpieza y desinfecci\u00f3n, as\u00ed como los requisitos espec\u00edficos para las instalaciones de pruebas de esterilidad. Se enfatiza la necesidad de mantener condiciones ambientales controladas y procedimientos adecuados para garantizar la integridad de las pruebas de esterilidad.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en un programa de monitoreo ambiental en \u00e1reas de pruebas de esterilidad?**\n   - Respuesta: Un programa de monitoreo ambiental debe incluir el uso de monitoreo activo del aire, placas de contacto, monitoreo de asentamiento de aire, as\u00ed como el control de diferenciales de temperatura y presi\u00f3n. Tambi\u00e9n se deben definir l\u00edmites de alerta y acci\u00f3n, y realizar un seguimiento de los resultados del monitoreo ambiental.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para llevar a cabo pruebas de esterilidad seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS?**\n   - Respuesta: Las pruebas de esterilidad deben realizarse bajo condiciones as\u00e9pticas equivalentes a los est\u00e1ndares de calidad del aire requeridos para la fabricaci\u00f3n as\u00e9ptica de productos farmac\u00e9uticos. Esto incluye realizar las pruebas en una zona de flujo de aire unidireccional de Grado A o en una cabina de bioseguridad, dentro de una sala limpia con un fondo de Grado B.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la higiene y la limpieza en las instalaciones de pruebas de esterilidad?**\n   - Respuesta: Debe existir un programa documentado de limpieza y desinfecci\u00f3n, procedimientos para manejar derrames, y se deben proporcionar instalaciones adecuadas para el lavado y desinfecci\u00f3n de manos. Adem\u00e1s, los resultados del monitoreo ambiental deben ser considerados donde sea relevante.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de Laboratorios de Microbiolog\u00eda**:\n   - Los laboratorios deben ser dedicados y separados de otras \u00e1reas, especialmente de las de producci\u00f3n.\n   - Deben estar dise\u00f1ados para las operaciones espec\u00edficas, con suficiente espacio para evitar contaminaci\u00f3n y confusiones.\n   - Es necesario considerar los materiales de construcci\u00f3n para facilitar la limpieza y desinfecci\u00f3n.\n\n2. **Control de Aire**:\n   - Se requiere un suministro de aire separado para los laboratorios y las \u00e1reas de producci\u00f3n, con unidades de manejo de aire y controles de temperatura y humedad.\n\n3. **Acceso Restringido**:\n   - El acceso a los laboratorios debe ser limitado a personal autorizado, que debe estar informado sobre procedimientos de entrada y salida, uso de \u00e1reas y restricciones.\n\n4. **Segregaci\u00f3n de Actividades**:\n   - Las actividades dentro del laboratorio deben estar segregadas por espacio o tiempo para minimizar riesgos de contaminaci\u00f3n y errores en los resultados.\n   - Las pruebas de esterilidad deben realizarse en \u00e1reas dedicadas.\n\n5. **Clasificaci\u00f3n de \u00c1reas**:\n   - Se debe considerar la clasificaci\u00f3n de \u00e1reas dentro del laboratorio seg\u00fan la criticidad del producto y las operaciones realizadas.\n\n### Entidades Clave\n- **Laboratorios de Microbiolog\u00eda**: Espacios dedicados para la realizaci\u00f3n de pruebas microbiol\u00f3gicas.\n- **Equipos de Soporte**: Incluyen autoclaves y material de vidrio.\n- **Personal Autorizado**: Empleados que tienen acceso a las \u00e1reas restringidas del laboratorio.\n- **Contaminaci\u00f3n**: Riesgo que se busca minimizar mediante el dise\u00f1o y las pr\u00e1cticas de laboratorio.\n- **Pruebas de Esterilidad**: Actividades cr\u00edticas que deben realizarse en \u00e1reas espec\u00edficas para asegurar resultados confiables.", "excerpt_keywords": "Keywords: environmental monitoring, sterility testing, good manufacturing practices, cleaning and disinfection, aseptic conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7a0374cf-db31-4df6-b1c5-e88e80c8755e", "node_type": "4", "metadata": {"page_label": "87", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Environmental monitoring in the laboratory\n\n2.2.1 Where necessary and appropriate (e.g. in areas for sterility testing) an environmental monitoring programme should be in place which covers, for example, use of active air monitoring, air settling or contact plates, temperature and pressure differentials. Alert and action limits should be defined. Trending of environmental monitoring results should be carried out.\n\n# 2.3 Cleaning, disinfection and hygiene\n\n2.3.1 There should be a documented cleaning and disinfection programme. Results of environmental monitoring should be considered where relevant.\n\n2.3.2 There should be a procedure for dealing with spillages.\n\n2.3.3 Adequate hand-washing and hand-disinfection facilities should be available.\n\n# 2.4 Sterility test facilities\n\n2.4.1 Sterility test facilities have specific environmental requirements to ensure the integrity of tests carried out. *WHO good manufacturing practices (GMP) for sterile pharmaceutical products* (8) requires that sterility testing should be carried out and specifies requirements for sterility testing. This section details the clean-room requirements for a sterility test facility.\n\n2.4.2 Sterility testing should be performed under aseptic conditions, which should be equivalent to air quality standards required for the aseptic manufacture of pharmaceutical products. The premises, services and equipment should be subject to the appropriate qualification process.\n\n2.4.3 The sterility testing should be carried out within a Grade A unidirectional airflow protected zone or a biosafety cabinet (if warranted), which should be located within a clean room with a Grade B background. Alternatively, the testing can be carried out within a barrier isolator. Care should be taken with the design of the facility layout and room airflow patterns, to ensure that the unidirectional airflow patterns are not disrupted.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f6dff82a973b71ce0d1495b474f01ea2c5bbb517a8545f6e870f281070b6c3e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.2 Environmental monitoring in the laboratory\n\n2.2.1 Where necessary and appropriate (e.g. in areas for sterility testing) an environmental monitoring programme should be in place which covers, for example, use of active air monitoring, air settling or contact plates, temperature and pressure differentials. Alert and action limits should be defined. Trending of environmental monitoring results should be carried out.\n\n# 2.3 Cleaning, disinfection and hygiene\n\n2.3.1 There should be a documented cleaning and disinfection programme. Results of environmental monitoring should be considered where relevant.\n\n2.3.2 There should be a procedure for dealing with spillages.\n\n2.3.3 Adequate hand-washing and hand-disinfection facilities should be available.\n\n# 2.4 Sterility test facilities\n\n2.4.1 Sterility test facilities have specific environmental requirements to ensure the integrity of tests carried out. *WHO good manufacturing practices (GMP) for sterile pharmaceutical products* (8) requires that sterility testing should be carried out and specifies requirements for sterility testing. This section details the clean-room requirements for a sterility test facility.\n\n2.4.2 Sterility testing should be performed under aseptic conditions, which should be equivalent to air quality standards required for the aseptic manufacture of pharmaceutical products. The premises, services and equipment should be subject to the appropriate qualification process.\n\n2.4.3 The sterility testing should be carried out within a Grade A unidirectional airflow protected zone or a biosafety cabinet (if warranted), which should be located within a clean room with a Grade B background. Alternatively, the testing can be carried out within a barrier isolator. Care should be taken with the design of the facility layout and room airflow patterns, to ensure that the unidirectional airflow patterns are not disrupted.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1905, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d212b6-51f0-4c9d-ac3d-da282f274808": {"__data__": {"id_": "c6d212b6-51f0-4c9d-ac3d-da282f274808", "embedding": null, "metadata": {"page_label": "88", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4.4 \nThe clean-room classification and air-handling equipment of the sterility test facilities should be requalified at least annually by a competent person or contractor. The environment should comply with the non-viable and viable limits, and verification of high efficiency particulate air (HEPA) filter integrity and room airflows should be performed. However, an alternative frequency of the monitoring may be justified based on quality risk management (QRM). Mapping locations for sample points for routine monitoring should be documented, as well as exposure duration, and frequency of all types of microbiological environmental monitoring should be specified in written procedures.\n\n## 2.4.5 \nAir supplied to Grade A and B zones should be via terminal HEPA filters.\n\n## 2.4.6 \nAppropriate airflow alarms and pressure differentials and indication instruments should be provided (*GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms* (8); and *GMP for sterile pharmaceutical products* (8)).\n\n## 2.4.7 \nRoom pressure readings should be taken and recorded from externally mounted gauges unless a validated continuous monitoring system is installed. As a minimum, readings should be taken prior to entry of the operator to the test suite. Pressure gauges should be labelled to indicate the area served and the acceptable specification.\n\n## 2.4.8 \nEntry to the clean room should be via a system of airlocks and a change room where operators are required to don suitable clean-room garments. The final change room should be under \u201cat rest\u201d conditions of the same grade as the room it serves. Change rooms should be of adequate size for ease of changing. There should be clear demarcation of the different zones.\n\n## 2.4.9 \nGarments for the sterility test operator should comply with the principles of section 10 of *WHO GMP for sterile pharmaceutical products* (8). Operators should be trained and certified in gowning procedures with training records maintained.\n\n## 2.4.10 \nThe fittings and finishes of the premises should comply with section 11 of *WHO GMP for sterile pharmaceutical products* (8).\n\n## 2.4.11 \nEnvironmental microbiological monitoring should reflect the facility used (room or isolator) and include a combination of air and surface sampling methods appropriate to the facility, such as:\n\n- active air sampling;\n- settle (exposure) plates;\n- surface contact \u2014 replicate organism detection and counting (RODAC) plates, swabs or flexible films;\n- operators\u2019 glove prints.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda las normativas y procedimientos necesarios para garantizar la esterilidad en las instalaciones de pruebas de esterilidad. Se enfatiza la importancia de la clasificaci\u00f3n de salas limpias, el manejo del aire, la capacitaci\u00f3n de los operadores y el monitoreo microbiol\u00f3gico ambiental. Se establecen requisitos espec\u00edficos para la revalidaci\u00f3n de equipos, el uso de filtros HEPA, la toma de lecturas de presi\u00f3n, y la vestimenta adecuada para los operadores, as\u00ed como la documentaci\u00f3n de los procedimientos de monitoreo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la frecuencia m\u00ednima recomendada para la revalidaci\u00f3n de la clasificaci\u00f3n de salas limpias y el equipo de manejo de aire en las instalaciones de pruebas de esterilidad?**\n   - La revalidaci\u00f3n debe realizarse al menos anualmente por una persona o contratista competente.\n\n2. **\u00bfQu\u00e9 tipo de m\u00e9todos de muestreo microbiol\u00f3gico ambiental se deben utilizar en las instalaciones de pruebas de esterilidad?**\n   - Se deben utilizar m\u00e9todos como muestreo de aire activo, placas de asentamiento, placas RODAC, hisopos o pel\u00edculas flexibles, y huellas de guantes de los operadores.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplirse para la vestimenta de los operadores en las instalaciones de pruebas de esterilidad?**\n   - Los operadores deben usar prendas que cumplan con los principios establecidos en la secci\u00f3n 10 de las *GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles* y deben estar capacitados y certificados en los procedimientos de vestimenta, manteniendo registros de capacitaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo Ambiental**: Se establece la necesidad de un programa de monitoreo ambiental en \u00e1reas de pruebas de esterilidad, que incluya t\u00e9cnicas como el monitoreo activo del aire, el uso de placas de contacto y el control de temperatura y presi\u00f3n. Se deben definir l\u00edmites de alerta y acci\u00f3n, y realizar un seguimiento de los resultados.\n\n2. **Limpieza y Desinfecci\u00f3n**: Es fundamental contar con un programa documentado de limpieza y desinfecci\u00f3n, as\u00ed como procedimientos para manejar derrames. Tambi\u00e9n se requiere la disponibilidad de instalaciones adecuadas para el lavado y desinfecci\u00f3n de manos.\n\n3. **Instalaciones de Pruebas de Esterilidad**: Las instalaciones deben cumplir con requisitos ambientales espec\u00edficos para garantizar la integridad de las pruebas. Las pruebas de esterilidad deben realizarse bajo condiciones as\u00e9pticas en zonas de flujo de aire unidireccional de Grado A o en cabinas de bioseguridad, dentro de un entorno de sala limpia de Grado B.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles.\n- **Grado A y Grado B**: Clasificaciones de calidad del aire en salas limpias que son cr\u00edticas para la realizaci\u00f3n de pruebas de esterilidad.\n- **Asepsia**: Condiciones necesarias para llevar a cabo pruebas de esterilidad, asegurando que no haya contaminaci\u00f3n.\n- **Monitoreo Ambiental**: Proceso de supervisi\u00f3n de las condiciones ambientales en laboratorios, especialmente en \u00e1reas cr\u00edticas como las de pruebas de esterilidad.\n\n### Resumen General:\nEl documento de la OMS enfatiza la importancia del monitoreo ambiental, la limpieza y desinfecci\u00f3n, y los requisitos espec\u00edficos para las instalaciones de pruebas de esterilidad, con el objetivo de garantizar la integridad y la calidad de los productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: clean-room classification, sterility testing, HEPA filters, microbiological monitoring, gowning procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ba02e8f9-bd26-48a1-860f-feaa710fa1c0", "node_type": "4", "metadata": {"page_label": "88", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4.4 \nThe clean-room classification and air-handling equipment of the sterility test facilities should be requalified at least annually by a competent person or contractor. The environment should comply with the non-viable and viable limits, and verification of high efficiency particulate air (HEPA) filter integrity and room airflows should be performed. However, an alternative frequency of the monitoring may be justified based on quality risk management (QRM). Mapping locations for sample points for routine monitoring should be documented, as well as exposure duration, and frequency of all types of microbiological environmental monitoring should be specified in written procedures.\n\n## 2.4.5 \nAir supplied to Grade A and B zones should be via terminal HEPA filters.\n\n## 2.4.6 \nAppropriate airflow alarms and pressure differentials and indication instruments should be provided (*GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms* (8); and *GMP for sterile pharmaceutical products* (8)).\n\n## 2.4.7 \nRoom pressure readings should be taken and recorded from externally mounted gauges unless a validated continuous monitoring system is installed. As a minimum, readings should be taken prior to entry of the operator to the test suite. Pressure gauges should be labelled to indicate the area served and the acceptable specification.\n\n## 2.4.8 \nEntry to the clean room should be via a system of airlocks and a change room where operators are required to don suitable clean-room garments. The final change room should be under \u201cat rest\u201d conditions of the same grade as the room it serves. Change rooms should be of adequate size for ease of changing. There should be clear demarcation of the different zones.\n\n## 2.4.9 \nGarments for the sterility test operator should comply with the principles of section 10 of *WHO GMP for sterile pharmaceutical products* (8). Operators should be trained and certified in gowning procedures with training records maintained.\n\n## 2.4.10 \nThe fittings and finishes of the premises should comply with section 11 of *WHO GMP for sterile pharmaceutical products* (8).\n\n## 2.4.11 \nEnvironmental microbiological monitoring should reflect the facility used (room or isolator) and include a combination of air and surface sampling methods appropriate to the facility, such as:\n\n- active air sampling;\n- settle (exposure) plates;\n- surface contact \u2014 replicate organism detection and counting (RODAC) plates, swabs or flexible films;\n- operators\u2019 glove prints.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1b3ac5eab094d82c25bfb16b4e5410d1e00e65c5aac3b7daa2c2de892df92963", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.4.4 \nThe clean-room classification and air-handling equipment of the sterility test facilities should be requalified at least annually by a competent person or contractor. The environment should comply with the non-viable and viable limits, and verification of high efficiency particulate air (HEPA) filter integrity and room airflows should be performed. However, an alternative frequency of the monitoring may be justified based on quality risk management (QRM). Mapping locations for sample points for routine monitoring should be documented, as well as exposure duration, and frequency of all types of microbiological environmental monitoring should be specified in written procedures.\n\n## 2.4.5 \nAir supplied to Grade A and B zones should be via terminal HEPA filters.\n\n## 2.4.6 \nAppropriate airflow alarms and pressure differentials and indication instruments should be provided (*GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms* (8); and *GMP for sterile pharmaceutical products* (8)).\n\n## 2.4.7 \nRoom pressure readings should be taken and recorded from externally mounted gauges unless a validated continuous monitoring system is installed. As a minimum, readings should be taken prior to entry of the operator to the test suite. Pressure gauges should be labelled to indicate the area served and the acceptable specification.\n\n## 2.4.8 \nEntry to the clean room should be via a system of airlocks and a change room where operators are required to don suitable clean-room garments. The final change room should be under \u201cat rest\u201d conditions of the same grade as the room it serves. Change rooms should be of adequate size for ease of changing. There should be clear demarcation of the different zones.\n\n## 2.4.9 \nGarments for the sterility test operator should comply with the principles of section 10 of *WHO GMP for sterile pharmaceutical products* (8). Operators should be trained and certified in gowning procedures with training records maintained.\n\n## 2.4.10 \nThe fittings and finishes of the premises should comply with section 11 of *WHO GMP for sterile pharmaceutical products* (8).\n\n## 2.4.11 \nEnvironmental microbiological monitoring should reflect the facility used (room or isolator) and include a combination of air and surface sampling methods appropriate to the facility, such as:\n\n- active air sampling;\n- settle (exposure) plates;\n- surface contact \u2014 replicate organism detection and counting (RODAC) plates, swabs or flexible films;\n- operators\u2019 glove prints.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2540, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a284f471-df50-4b7e-8d42-b5e73a18156b": {"__data__": {"id_": "a284f471-df50-4b7e-8d42-b5e73a18156b", "embedding": null, "metadata": {"page_label": "89", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Microbial environmental monitoring of the sterility test zone should be performed during every work session under operational (dynamic) conditions.\n\nThere should be written specifications, including appropriate alert and action limits for microbial contamination. Limits for microbiological environmental monitoring are given in the *WHO GMP for sterile pharmaceutical products* (8).\n\n## 3. Validation of test methods\n\n3.1 Standard (pharmacopoeial) test methods are considered to be validated. However, the specific test method to be used by a specific laboratory for testing of a specific product needs to be shown to be suitable for use in recovering bacteria, yeast and mould in the presence of the specific product. The laboratory should demonstrate that the performance criteria of the standard test method can be met by the laboratory before introducing the test for routine purposes (method verification) and that the specific test method for the specific product is suitable (test method suitability including positive and negative controls).\n\n3.2 Test methods not based on compendial or other recognized references should be validated before use. The validation should comprise, where appropriate, determining accuracy, precision, specificity, limit of detection, limit of quantitation, linearity and robustness. Potentially inhibitory effects from the sample should be taken into account when testing different types of sample. The results should be evaluated with appropriate statistical methods, e.g. as described in the national, regional or international pharmacopoeias.\n\n## 4. Equipment\n\nEach item of equipment, instrument or other device used for testing, verification and calibration should be uniquely identified.\n\nAs part of its quality system, a laboratory should have a documented programme for the qualification, calibration, performance verification, maintenance and a system for monitoring the use of its equipment.\n\n### 4.1 Maintenance of equipment\n\n4.1.1 Maintenance of essential equipment should be carried out at predetermined intervals in accordance with a documented procedure. Detailed records should be kept. (For examples of maintenance of equipment and intervals see Appendix 2.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del monitoreo ambiental microbiano en zonas de pruebas de esterilidad, la validaci\u00f3n de m\u00e9todos de prueba y el mantenimiento de equipos en laboratorios. Se enfatiza que los m\u00e9todos de prueba deben ser adecuados para el producto espec\u00edfico y que el equipo utilizado debe ser identificado y mantenido de acuerdo con procedimientos documentados.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios de rendimiento que un laboratorio debe demostrar para validar un m\u00e9todo de prueba est\u00e1ndar antes de su uso rutinario?**\n   - El laboratorio debe demostrar que puede cumplir con los criterios de rendimiento del m\u00e9todo de prueba est\u00e1ndar, lo que incluye la verificaci\u00f3n del m\u00e9todo y la adecuaci\u00f3n del m\u00e9todo espec\u00edfico para el producto, incluyendo controles positivos y negativos.\n\n2. **\u00bfQu\u00e9 aspectos deben considerarse al validar m\u00e9todos de prueba que no se basan en referencias reconocidas?**\n   - La validaci\u00f3n debe incluir la determinaci\u00f3n de la precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y robustez. Adem\u00e1s, se deben tener en cuenta los efectos inhibitorios potenciales del muestreo.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para el mantenimiento del equipo esencial en un laboratorio?**\n   - El mantenimiento del equipo esencial debe realizarse a intervalos predeterminados de acuerdo con un procedimiento documentado, y se deben mantener registros detallados de dicho mantenimiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revalidaci\u00f3n de Instalaciones**:\n   - La clasificaci\u00f3n de salas limpias y el equipo de manejo de aire en las instalaciones de pruebas de esterilidad deben revalidarse al menos anualmente por personal competente.\n\n2. **Control del Aire**:\n   - El aire en las zonas de Grado A y B debe suministrarse a trav\u00e9s de filtros HEPA terminales.\n   - Se deben proporcionar alarmas de flujo de aire y instrumentos de indicaci\u00f3n de diferencias de presi\u00f3n.\n\n3. **Monitoreo de Presi\u00f3n**:\n   - Las lecturas de presi\u00f3n deben tomarse de man\u00f3metros montados externamente, registr\u00e1ndose antes de la entrada del operador a la sala de pruebas.\n\n4. **Acceso a la Sala Limpia**:\n   - El acceso debe realizarse a trav\u00e9s de un sistema de airelocks y una sala de cambio donde los operadores deben usar prendas adecuadas.\n\n5. **Vestimenta de los Operadores**:\n   - Las prendas deben cumplir con los principios de las *GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles* y los operadores deben estar capacitados y certificados en los procedimientos de vestimenta.\n\n6. **Monitoreo Microbiol\u00f3gico Ambiental**:\n   - Debe incluir m\u00e9todos de muestreo de aire y superficie, como muestreo de aire activo, placas de asentamiento, placas RODAC, hisopos y huellas de guantes.\n\n7. **Documentaci\u00f3n y Procedimientos**:\n   - Se debe documentar la ubicaci\u00f3n de los puntos de muestreo y especificar la duraci\u00f3n de la exposici\u00f3n y la frecuencia de monitoreo microbiol\u00f3gico en procedimientos escritos.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que regulan la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n- **HEPA (Filtros de Aire de Alta Eficiencia)**: Tecnolog\u00eda utilizada para el manejo del aire en salas limpias.\n- **RODAC (Replicate Organism Detection and Counting)**: M\u00e9todo de muestreo para monitoreo microbiol\u00f3gico.\n\nEste resumen destaca los aspectos esenciales relacionados con la esterilidad en las instalaciones de pruebas, enfatizando la importancia de la revalidaci\u00f3n, el control ambiental y la capacitaci\u00f3n del personal.", "excerpt_keywords": "Keywords: microbial monitoring, sterility testing, method validation, equipment maintenance, WHO GMP"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c00ab3a-349c-46fc-be03-e412490148dd", "node_type": "4", "metadata": {"page_label": "89", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Microbial environmental monitoring of the sterility test zone should be performed during every work session under operational (dynamic) conditions.\n\nThere should be written specifications, including appropriate alert and action limits for microbial contamination. Limits for microbiological environmental monitoring are given in the *WHO GMP for sterile pharmaceutical products* (8).\n\n## 3. Validation of test methods\n\n3.1 Standard (pharmacopoeial) test methods are considered to be validated. However, the specific test method to be used by a specific laboratory for testing of a specific product needs to be shown to be suitable for use in recovering bacteria, yeast and mould in the presence of the specific product. The laboratory should demonstrate that the performance criteria of the standard test method can be met by the laboratory before introducing the test for routine purposes (method verification) and that the specific test method for the specific product is suitable (test method suitability including positive and negative controls).\n\n3.2 Test methods not based on compendial or other recognized references should be validated before use. The validation should comprise, where appropriate, determining accuracy, precision, specificity, limit of detection, limit of quantitation, linearity and robustness. Potentially inhibitory effects from the sample should be taken into account when testing different types of sample. The results should be evaluated with appropriate statistical methods, e.g. as described in the national, regional or international pharmacopoeias.\n\n## 4. Equipment\n\nEach item of equipment, instrument or other device used for testing, verification and calibration should be uniquely identified.\n\nAs part of its quality system, a laboratory should have a documented programme for the qualification, calibration, performance verification, maintenance and a system for monitoring the use of its equipment.\n\n### 4.1 Maintenance of equipment\n\n4.1.1 Maintenance of essential equipment should be carried out at predetermined intervals in accordance with a documented procedure. Detailed records should be kept. (For examples of maintenance of equipment and intervals see Appendix 2.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "00e4c069b1b4bfbe0dd10fb9494ff886cf25bb7ac93c50b24cf2423e50d7a04f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Microbial environmental monitoring of the sterility test zone should be performed during every work session under operational (dynamic) conditions.\n\nThere should be written specifications, including appropriate alert and action limits for microbial contamination. Limits for microbiological environmental monitoring are given in the *WHO GMP for sterile pharmaceutical products* (8).\n\n## 3. Validation of test methods\n\n3.1 Standard (pharmacopoeial) test methods are considered to be validated. However, the specific test method to be used by a specific laboratory for testing of a specific product needs to be shown to be suitable for use in recovering bacteria, yeast and mould in the presence of the specific product. The laboratory should demonstrate that the performance criteria of the standard test method can be met by the laboratory before introducing the test for routine purposes (method verification) and that the specific test method for the specific product is suitable (test method suitability including positive and negative controls).\n\n3.2 Test methods not based on compendial or other recognized references should be validated before use. The validation should comprise, where appropriate, determining accuracy, precision, specificity, limit of detection, limit of quantitation, linearity and robustness. Potentially inhibitory effects from the sample should be taken into account when testing different types of sample. The results should be evaluated with appropriate statistical methods, e.g. as described in the national, regional or international pharmacopoeias.\n\n## 4. Equipment\n\nEach item of equipment, instrument or other device used for testing, verification and calibration should be uniquely identified.\n\nAs part of its quality system, a laboratory should have a documented programme for the qualification, calibration, performance verification, maintenance and a system for monitoring the use of its equipment.\n\n### 4.1 Maintenance of equipment\n\n4.1.1 Maintenance of essential equipment should be carried out at predetermined intervals in accordance with a documented procedure. Detailed records should be kept. (For examples of maintenance of equipment and intervals see Appendix 2.)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2213, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "76177e2f-e484-4f14-bb76-32c9f801fdf8": {"__data__": {"id_": "76177e2f-e484-4f14-bb76-32c9f801fdf8", "embedding": null, "metadata": {"page_label": "90", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Qualification\n\n4.2.1 For qualification of equipment see sections 8 and 12 in *Good practices for pharmaceutical quality control laboratories* (1).\n\n# 4.3 Calibration, performance verification and monitoring of use\n\n4.3.1 The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n4.3.2 The frequency of calibration and performance verification will be determined by documented experience and will be based on need, type and previous performance of the equipment. Intervals between calibration and verification should be shorter than the time the equipment has been found to take to drift outside acceptable limits. (For examples of calibration checks and intervals for different laboratory equipment, see Appendix 3; and for equipment qualification and monitoring, see Appendix 4.) The performance of the equipment should conform to predefined acceptance criteria.\n\n## 4.3.3 Temperature measurement devices\n\n4.3.3.1 Where temperature has a direct effect on the result of an analysis or is critical for the correct performance of equipment, temperature measuring devices should be of appropriate quality to achieve the accuracy required (e.g. liquid-in-glass thermometers, thermocouples and platinum resistance thermometers (PRTs) used in incubators and autoclaves).\n\n4.3.3.2 Calibration of devices should be traceable to national or international standards for temperature.\n\n## 4.3.4 Incubators, water-baths and ovens\n\nThe stability of temperature, uniformity of temperature distribution and time required to achieve equilibrium conditions in incubators, water-baths, ovens and temperature-controlled rooms should be established initially and documented, in particular with respect to typical uses (for example, position, space between, and height of, stacks of Petri dishes). The constancy of the characteristics recorded during initial validation of the equipment should be checked and recorded after each significant repair or modification. The operating temperature of this type of equipment should be monitored and records retained. The use of the equipment should be considered when determining what temperature controls are required.\n\n## 4.3.5 Autoclaves, including media preparators\n\n4.3.5.1 Autoclaves should be capable of meeting specified time and temperature tolerances; monitoring pressure alone is not acceptable. Sensors", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre la calificaci\u00f3n, calibraci\u00f3n y verificaci\u00f3n del rendimiento de equipos en laboratorios de control de calidad farmac\u00e9utica. Se enfatiza la importancia de mantener registros claros sobre la calibraci\u00f3n y el servicio de los instrumentos, as\u00ed como la necesidad de que los dispositivos de medici\u00f3n de temperatura sean de calidad adecuada y calibrados de acuerdo con est\u00e1ndares nacionales o internacionales. Tambi\u00e9n se abordan aspectos espec\u00edficos sobre incubadoras, ba\u00f1os de agua, hornos y autoclaves, destacando la necesidad de documentar la estabilidad y uniformidad de la temperatura, as\u00ed como los requisitos de monitoreo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que los dispositivos de medici\u00f3n de temperatura sean considerados de calidad adecuada en un laboratorio?**\n   - Respuesta: Los dispositivos de medici\u00f3n de temperatura deben ser de calidad apropiada para lograr la precisi\u00f3n requerida, como term\u00f3metros de l\u00edquido en vidrio, termopares y term\u00f3metros de resistencia de platino (PRTs) utilizados en incubadoras y autoclaves.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia de calibraci\u00f3n y verificaci\u00f3n del rendimiento de los equipos en un laboratorio?**\n   - Respuesta: La frecuencia de calibraci\u00f3n y verificaci\u00f3n se determina mediante experiencia documentada y se basa en la necesidad, el tipo y el rendimiento previo del equipo. Los intervalos deben ser m\u00e1s cortos que el tiempo que el equipo ha demostrado tardar en desviarse de los l\u00edmites aceptables.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse despu\u00e9s de una reparaci\u00f3n o modificaci\u00f3n significativa de un equipo de laboratorio?**\n   - Respuesta: Despu\u00e9s de una reparaci\u00f3n o modificaci\u00f3n significativa, se debe verificar y registrar la constancia de las caracter\u00edsticas que se documentaron durante la validaci\u00f3n inicial del equipo. Adem\u00e1s, se debe monitorear la temperatura de operaci\u00f3n y conservar los registros correspondientes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Monitoreo Ambiental Microbiano**:\n   - Se debe realizar un monitoreo ambiental microbiano en la zona de pruebas de esterilidad durante cada sesi\u00f3n de trabajo bajo condiciones operativas (din\u00e1micas).\n   - Es necesario establecer especificaciones escritas que incluyan l\u00edmites de alerta y acci\u00f3n para la contaminaci\u00f3n microbiana, conforme a las directrices de la *OMS GMP para productos farmac\u00e9uticos est\u00e9riles*.\n\n2. **Validaci\u00f3n de M\u00e9todos de Prueba**:\n   - Los m\u00e9todos de prueba est\u00e1ndar (farmacopeicos) se consideran validados, pero cada laboratorio debe demostrar que el m\u00e9todo espec\u00edfico es adecuado para recuperar microorganismos en presencia del producto espec\u00edfico.\n   - Para m\u00e9todos no basados en referencias reconocidas, se debe validar su precisi\u00f3n, exactitud, especificidad, l\u00edmites de detecci\u00f3n y cuantificaci\u00f3n, linealidad y robustez, considerando efectos inhibitorios potenciales del muestreo.\n\n3. **Equipos de Laboratorio**:\n   - Cada equipo, instrumento o dispositivo utilizado para pruebas debe ser identificado de manera \u00fanica.\n   - Los laboratorios deben tener un programa documentado para la calificaci\u00f3n, calibraci\u00f3n, verificaci\u00f3n de rendimiento y mantenimiento del equipo, as\u00ed como un sistema para monitorear su uso.\n\n4. **Mantenimiento de Equipos**:\n   - El mantenimiento del equipo esencial debe realizarse a intervalos predeterminados seg\u00fan un procedimiento documentado, y se deben mantener registros detallados de dicho mantenimiento.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece directrices sobre buenas pr\u00e1cticas de manufactura (GMP).\n- **M\u00e9todos de Prueba**: Incluyen m\u00e9todos est\u00e1ndar y no est\u00e1ndar que requieren validaci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Aspecto cr\u00edtico a monitorear en laboratorios de pruebas de esterilidad.\n- **Equipos de Laboratorio**: Elementos esenciales que deben ser mantenidos y verificados regularmente.", "excerpt_keywords": "Keywords: qualification, calibration, temperature measurement, pharmaceutical quality control, equipment performance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "243e3a78-bb63-495d-a81e-2e09fdb2d3f5", "node_type": "4", "metadata": {"page_label": "90", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Qualification\n\n4.2.1 For qualification of equipment see sections 8 and 12 in *Good practices for pharmaceutical quality control laboratories* (1).\n\n# 4.3 Calibration, performance verification and monitoring of use\n\n4.3.1 The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n4.3.2 The frequency of calibration and performance verification will be determined by documented experience and will be based on need, type and previous performance of the equipment. Intervals between calibration and verification should be shorter than the time the equipment has been found to take to drift outside acceptable limits. (For examples of calibration checks and intervals for different laboratory equipment, see Appendix 3; and for equipment qualification and monitoring, see Appendix 4.) The performance of the equipment should conform to predefined acceptance criteria.\n\n## 4.3.3 Temperature measurement devices\n\n4.3.3.1 Where temperature has a direct effect on the result of an analysis or is critical for the correct performance of equipment, temperature measuring devices should be of appropriate quality to achieve the accuracy required (e.g. liquid-in-glass thermometers, thermocouples and platinum resistance thermometers (PRTs) used in incubators and autoclaves).\n\n4.3.3.2 Calibration of devices should be traceable to national or international standards for temperature.\n\n## 4.3.4 Incubators, water-baths and ovens\n\nThe stability of temperature, uniformity of temperature distribution and time required to achieve equilibrium conditions in incubators, water-baths, ovens and temperature-controlled rooms should be established initially and documented, in particular with respect to typical uses (for example, position, space between, and height of, stacks of Petri dishes). The constancy of the characteristics recorded during initial validation of the equipment should be checked and recorded after each significant repair or modification. The operating temperature of this type of equipment should be monitored and records retained. The use of the equipment should be considered when determining what temperature controls are required.\n\n## 4.3.5 Autoclaves, including media preparators\n\n4.3.5.1 Autoclaves should be capable of meeting specified time and temperature tolerances; monitoring pressure alone is not acceptable. Sensors", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4f381d1f6c8157c2245807578461e1c159c9610700205c87b4c1edbfe6c1becf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.2 Qualification\n\n4.2.1 For qualification of equipment see sections 8 and 12 in *Good practices for pharmaceutical quality control laboratories* (1).\n\n# 4.3 Calibration, performance verification and monitoring of use\n\n4.3.1 The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n4.3.2 The frequency of calibration and performance verification will be determined by documented experience and will be based on need, type and previous performance of the equipment. Intervals between calibration and verification should be shorter than the time the equipment has been found to take to drift outside acceptable limits. (For examples of calibration checks and intervals for different laboratory equipment, see Appendix 3; and for equipment qualification and monitoring, see Appendix 4.) The performance of the equipment should conform to predefined acceptance criteria.\n\n## 4.3.3 Temperature measurement devices\n\n4.3.3.1 Where temperature has a direct effect on the result of an analysis or is critical for the correct performance of equipment, temperature measuring devices should be of appropriate quality to achieve the accuracy required (e.g. liquid-in-glass thermometers, thermocouples and platinum resistance thermometers (PRTs) used in incubators and autoclaves).\n\n4.3.3.2 Calibration of devices should be traceable to national or international standards for temperature.\n\n## 4.3.4 Incubators, water-baths and ovens\n\nThe stability of temperature, uniformity of temperature distribution and time required to achieve equilibrium conditions in incubators, water-baths, ovens and temperature-controlled rooms should be established initially and documented, in particular with respect to typical uses (for example, position, space between, and height of, stacks of Petri dishes). The constancy of the characteristics recorded during initial validation of the equipment should be checked and recorded after each significant repair or modification. The operating temperature of this type of equipment should be monitored and records retained. The use of the equipment should be considered when determining what temperature controls are required.\n\n## 4.3.5 Autoclaves, including media preparators\n\n4.3.5.1 Autoclaves should be capable of meeting specified time and temperature tolerances; monitoring pressure alone is not acceptable. Sensors", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2427, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff3464c-65b3-4c83-b133-8f350c209acf": {"__data__": {"id_": "4ff3464c-65b3-4c83-b133-8f350c209acf", "embedding": null, "metadata": {"page_label": "91", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "used for controlling or monitoring operating cycles require calibration and the performance of timers should be verified.\n\n4.3.5.2 Initial validation should include performance studies (spatial temperature distribution surveys) for each operating cycle and each load configuration used in practice. This process must be repeated after any significant repair or modification (e.g. replacement of thermoregulator probe or programmer, change to loading arrangements or operating cycle) or where indicated by the results of quality control checks on media or risk assessment. Sufficient temperature sensors should be positioned within the load (e.g. in containers filled with liquid/medium) to enable location differences to be demonstrated. In the case of media preparators, where uniform heating cannot be demonstrated by other means, the use of two sensors, one adjacent to the control probe and one remote from it, would generally be considered appropriate. Validation and revalidation should consider the suitability of come-up and come-down times as well as time at sterilization temperature.\n\n4.3.5.3 Clear operating instructions should be provided based on the heating profiles determined for typical uses during validation/revalidation. Acceptance/rejection criteria should be established and records of autoclave operations, including temperature and time, maintained for every cycle.\n\n4.3.5.4 Monitoring may be achieved by one of the following:\n\n- using a thermocouple and recorder to produce a chart or printout;\n- direct observation and recording of maximum temperature achieved and time at that temperature.\n\nIn addition to directly monitoring the temperature of an autoclave, the effectiveness of its operation during each cycle may be checked by the use of chemical or biological indicators for sterilization or decontamination purposes. Autoclave tape or indicator strips should be used only to show that a load has been processed, not to demonstrate completion of an acceptable cycle.\n\nLaboratories should have a separate autoclave for decontamination. However, in exceptional cases one autoclave may be acceptable provided that extensive precautions are taken to separate decontamination and sterilization loads, and a documented cleaning programme is in place to address both the internal and external environment of the autoclave.\n\n### 4.3.6 Weights and balances\n\nWeights and balances shall be calibrated traceably at regular intervals (according to their intended use) using appropriate standard weights traceable to certified standard weights.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Validaci\u00f3n y monitoreo de autoclaves**: El documento establece la importancia de la validaci\u00f3n inicial y la revalidaci\u00f3n de autoclaves, incluyendo la realizaci\u00f3n de estudios de rendimiento y la colocaci\u00f3n adecuada de sensores de temperatura. Se enfatiza la necesidad de seguir procedimientos claros y mantener registros detallados de cada ciclo de operaci\u00f3n.\n\n2. **Calibraci\u00f3n de equipos de pesaje**: Se menciona que los pesos y balances deben ser calibrados de manera trazable y regular, utilizando pesos est\u00e1ndar apropiados que est\u00e9n certificados, lo cual es crucial para asegurar la precisi\u00f3n en las mediciones.\n\n3. **Separaci\u00f3n de cargas de esterilizaci\u00f3n y descontaminaci\u00f3n**: Se discute la necesidad de tener autoclaves separados para descontaminaci\u00f3n y esterilizaci\u00f3n, aunque se permiten excepciones bajo estrictas condiciones de limpieza y separaci\u00f3n de cargas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la revalidaci\u00f3n de un autoclave despu\u00e9s de una modificaci\u00f3n significativa?**\n   - La revalidaci\u00f3n debe incluir la repetici\u00f3n de estudios de rendimiento, como encuestas de distribuci\u00f3n de temperatura, y la colocaci\u00f3n de sensores de temperatura en el interior de la carga para demostrar diferencias de ubicaci\u00f3n. Adem\u00e1s, se deben considerar los tiempos de calentamiento y enfriamiento, as\u00ed como el tiempo a la temperatura de esterilizaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n y rechazo que deben establecerse para las operaciones de autoclave?**\n   - Los criterios de aceptaci\u00f3n y rechazo deben basarse en las instrucciones operativas claras derivadas de los perfiles de calentamiento determinados durante la validaci\u00f3n/revalidaci\u00f3n. Adem\u00e1s, se deben mantener registros de las operaciones del autoclave, incluyendo temperatura y tiempo, para cada ciclo.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se utiliza un solo autoclave para descontaminaci\u00f3n y esterilizaci\u00f3n?**\n   - En casos excepcionales donde se utilice un solo autoclave, se deben tomar precauciones extensas para separar las cargas de descontaminaci\u00f3n y esterilizaci\u00f3n. Tambi\u00e9n es necesario implementar un programa de limpieza documentado que aborde tanto el entorno interno como externo del autoclave.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n de Equipos**:\n   - Se refiere a la validaci\u00f3n de equipos en laboratorios de control de calidad farmac\u00e9utica, con referencia a secciones espec\u00edficas de buenas pr\u00e1cticas.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n del Rendimiento**:\n   - Importancia de documentar la fecha de calibraci\u00f3n y el servicio de los instrumentos.\n   - La frecuencia de calibraci\u00f3n se basa en la experiencia documentada, el tipo de equipo y su rendimiento previo.\n   - Se deben establecer intervalos de calibraci\u00f3n m\u00e1s cortos que el tiempo que el equipo tarda en desviarse de los l\u00edmites aceptables.\n\n3. **Dispositivos de Medici\u00f3n de Temperatura**:\n   - Los dispositivos deben ser de calidad adecuada para lograr la precisi\u00f3n necesaria (ej. term\u00f3metros de l\u00edquido en vidrio, termopares, term\u00f3metros de resistencia de platino).\n   - La calibraci\u00f3n debe ser trazable a est\u00e1ndares nacionales o internacionales.\n\n4. **Incubadoras, Ba\u00f1os de Agua y Hornos**:\n   - Necesidad de establecer y documentar la estabilidad y uniformidad de la temperatura.\n   - Monitoreo de la temperatura de operaci\u00f3n y conservaci\u00f3n de registros despu\u00e9s de reparaciones o modificaciones significativas.\n\n5. **Autoclaves**:\n   - Deben cumplir con tolerancias espec\u00edficas de tiempo y temperatura; el monitoreo de presi\u00f3n no es suficiente.\n\n### Entidades Clave\n- **Equipos de Laboratorio**: Incluyen incubadoras, autoclaves, term\u00f3metros, etc.\n- **Est\u00e1ndares de Calibraci\u00f3n**: Nacionales e internacionales.\n- **Documentaci\u00f3n**: Registros de calibraci\u00f3n, verificaci\u00f3n y mantenimiento de equipos.\n- **Condiciones de Operaci\u00f3n**: Estabilidad y uniformidad de la temperatura en equipos de laboratorio. \n\nEste resumen destaca la importancia de la calificaci\u00f3n, calibraci\u00f3n y monitoreo de equipos en laboratorios farmac\u00e9uticos, as\u00ed como los est\u00e1ndares de calidad necesarios para asegurar resultados precisos y confiables.", "excerpt_keywords": "Keywords: autoclave validation, temperature monitoring, calibration, sterilization procedures, laboratory equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "06f98a8f-f3be-4136-8c86-56975dbc825c", "node_type": "4", "metadata": {"page_label": "91", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "used for controlling or monitoring operating cycles require calibration and the performance of timers should be verified.\n\n4.3.5.2 Initial validation should include performance studies (spatial temperature distribution surveys) for each operating cycle and each load configuration used in practice. This process must be repeated after any significant repair or modification (e.g. replacement of thermoregulator probe or programmer, change to loading arrangements or operating cycle) or where indicated by the results of quality control checks on media or risk assessment. Sufficient temperature sensors should be positioned within the load (e.g. in containers filled with liquid/medium) to enable location differences to be demonstrated. In the case of media preparators, where uniform heating cannot be demonstrated by other means, the use of two sensors, one adjacent to the control probe and one remote from it, would generally be considered appropriate. Validation and revalidation should consider the suitability of come-up and come-down times as well as time at sterilization temperature.\n\n4.3.5.3 Clear operating instructions should be provided based on the heating profiles determined for typical uses during validation/revalidation. Acceptance/rejection criteria should be established and records of autoclave operations, including temperature and time, maintained for every cycle.\n\n4.3.5.4 Monitoring may be achieved by one of the following:\n\n- using a thermocouple and recorder to produce a chart or printout;\n- direct observation and recording of maximum temperature achieved and time at that temperature.\n\nIn addition to directly monitoring the temperature of an autoclave, the effectiveness of its operation during each cycle may be checked by the use of chemical or biological indicators for sterilization or decontamination purposes. Autoclave tape or indicator strips should be used only to show that a load has been processed, not to demonstrate completion of an acceptable cycle.\n\nLaboratories should have a separate autoclave for decontamination. However, in exceptional cases one autoclave may be acceptable provided that extensive precautions are taken to separate decontamination and sterilization loads, and a documented cleaning programme is in place to address both the internal and external environment of the autoclave.\n\n### 4.3.6 Weights and balances\n\nWeights and balances shall be calibrated traceably at regular intervals (according to their intended use) using appropriate standard weights traceable to certified standard weights.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dab2964a3bfc930b39f1ce9d33fe464f053f96c9de6c0eb4d70c1fffc7248655", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "used for controlling or monitoring operating cycles require calibration and the performance of timers should be verified.\n\n4.3.5.2 Initial validation should include performance studies (spatial temperature distribution surveys) for each operating cycle and each load configuration used in practice. This process must be repeated after any significant repair or modification (e.g. replacement of thermoregulator probe or programmer, change to loading arrangements or operating cycle) or where indicated by the results of quality control checks on media or risk assessment. Sufficient temperature sensors should be positioned within the load (e.g. in containers filled with liquid/medium) to enable location differences to be demonstrated. In the case of media preparators, where uniform heating cannot be demonstrated by other means, the use of two sensors, one adjacent to the control probe and one remote from it, would generally be considered appropriate. Validation and revalidation should consider the suitability of come-up and come-down times as well as time at sterilization temperature.\n\n4.3.5.3 Clear operating instructions should be provided based on the heating profiles determined for typical uses during validation/revalidation. Acceptance/rejection criteria should be established and records of autoclave operations, including temperature and time, maintained for every cycle.\n\n4.3.5.4 Monitoring may be achieved by one of the following:\n\n- using a thermocouple and recorder to produce a chart or printout;\n- direct observation and recording of maximum temperature achieved and time at that temperature.\n\nIn addition to directly monitoring the temperature of an autoclave, the effectiveness of its operation during each cycle may be checked by the use of chemical or biological indicators for sterilization or decontamination purposes. Autoclave tape or indicator strips should be used only to show that a load has been processed, not to demonstrate completion of an acceptable cycle.\n\nLaboratories should have a separate autoclave for decontamination. However, in exceptional cases one autoclave may be acceptable provided that extensive precautions are taken to separate decontamination and sterilization loads, and a documented cleaning programme is in place to address both the internal and external environment of the autoclave.\n\n### 4.3.6 Weights and balances\n\nWeights and balances shall be calibrated traceably at regular intervals (according to their intended use) using appropriate standard weights traceable to certified standard weights.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2562, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4946f072-18e1-4f55-9234-292e759fb79e": {"__data__": {"id_": "4946f072-18e1-4f55-9234-292e759fb79e", "embedding": null, "metadata": {"page_label": "92", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.7 Volumetric equipment\n\n4.3.7.1 Microbiology laboratories should carry out initial verification of volumetric equipment (automatic dispensers, dispenser/diluters, mechanical hand pipettes and disposable pipettes) and then make regular checks, as appropriate, to ensure that the equipment is performing within the required specification. Initial verification should not be necessary for glassware which has been certified to a specific tolerance. Equipment should be checked for the accuracy of the delivered volume against the set volume (for several different settings in the case of variable volume instruments) and the precision of the repeat deliveries should be measured.\n\n4.3.7.2 For \u201csingle-use\u201d disposable volumetric equipment, laboratories should obtain supplies from companies with a recognized and relevant quality system. After initial validation of the suitability of the equipment, it is recommended that random checks on accuracy are carried out. If the supplier does not have a recognized quality system, laboratories should check each batch of equipment for suitability.\n\n# 4.3.8 Other equipment\n\nConductivity meters, oxygen meters, pH meters and other similar instruments should be verified regularly or before each use. The buffers used for verification purposes should be stored in appropriate conditions and should be marked with an expiry date.\n\nWhere humidity is important to the outcome of the test, hygrometers should be calibrated, the calibration being traceable to national or international standards.\n\nTimers, including the autoclave timer, should be verified using a calibrated timer or national time signal.\n\nWhen centrifuges are used in test procedures, an assessment of the rotations per minute (RPM) should be made. Where it is critical, the centrifuge should be calibrated.\n\n# 5. Reagents and culture media\n\nLaboratories should ensure that the quality of reagents and media used is appropriate for the test concerned.\n\n## 5.1 Reagents\n\n5.1.1 Laboratories should verify the suitability of each batch of reagents critical for the test, initially and during its shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) proporciona directrices sobre la verificaci\u00f3n y el mantenimiento de equipos volum\u00e9tricos y otros instrumentos utilizados en laboratorios de microbiolog\u00eda. Se enfatiza la importancia de realizar verificaciones iniciales y controles regulares para asegurar que el equipo funcione dentro de las especificaciones requeridas. Tambi\u00e9n se menciona la necesidad de obtener suministros de equipos desechables de empresas con sistemas de calidad reconocidos y de realizar verificaciones aleatorias de precisi\u00f3n. Adem\u00e1s, se abordan otros equipos como medidores de pH, conductividad y centrifugadoras, destacando la importancia de la calibraci\u00f3n y verificaci\u00f3n regular. Por \u00faltimo, se subraya la necesidad de garantizar la calidad de los reactivos y medios de cultivo utilizados en las pruebas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de verificaci\u00f3n inicial se recomienda para los equipos volum\u00e9tricos en laboratorios de microbiolog\u00eda?**\n   - Se recomienda que los laboratorios realicen una verificaci\u00f3n inicial de los equipos volum\u00e9tricos, como dispensadores autom\u00e1ticos y pipetas, y luego realicen controles regulares para asegurar que el equipo est\u00e9 funcionando dentro de las especificaciones requeridas.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los laboratorios al adquirir equipos volum\u00e9tricos desechables de proveedores sin un sistema de calidad reconocido?**\n   - Si el proveedor no tiene un sistema de calidad reconocido, los laboratorios deben verificar cada lote de equipo desechable para asegurar su idoneidad.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la verificaci\u00f3n de instrumentos como medidores de pH y conductividad?**\n   - Los medidores de pH, conductividad y otros instrumentos similares deben ser verificados regularmente o antes de cada uso, y los buffers utilizados para la verificaci\u00f3n deben ser almacenados adecuadamente y marcados con una fecha de caducidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n y Monitoreo de Autoclaves**:\n   - **Importancia de la Validaci\u00f3n**: Se requiere realizar estudios de rendimiento y encuestas de distribuci\u00f3n de temperatura para cada ciclo operativo y configuraci\u00f3n de carga.\n   - **Revalidaci\u00f3n**: Debe llevarse a cabo despu\u00e9s de reparaciones significativas o modificaciones, y se deben utilizar sensores de temperatura para demostrar diferencias de ubicaci\u00f3n dentro de la carga.\n   - **Instrucciones Operativas**: Se deben proporcionar instrucciones claras basadas en los perfiles de calentamiento determinados durante la validaci\u00f3n.\n   - **Registros de Operaci\u00f3n**: Es esencial mantener registros detallados de cada ciclo, incluyendo temperatura y tiempo.\n\n2. **Monitoreo de Temperatura**:\n   - **M\u00e9todos de Monitoreo**: Se pueden utilizar termopares y grabadores, as\u00ed como la observaci\u00f3n directa de la temperatura m\u00e1xima alcanzada.\n   - **Indicadores de Esterilizaci\u00f3n**: Se sugiere el uso de indicadores qu\u00edmicos o biol\u00f3gicos para verificar la efectividad del ciclo de esterilizaci\u00f3n.\n\n3. **Separaci\u00f3n de Cargas**:\n   - **Autoclaves para Descontaminaci\u00f3n y Esterilizaci\u00f3n**: Se recomienda tener autoclaves separados para cada prop\u00f3sito, aunque se permiten excepciones bajo estrictas condiciones de limpieza y separaci\u00f3n de cargas.\n\n4. **Calibraci\u00f3n de Equipos de Pesaje**:\n   - **Pesos y Balances**: Deben ser calibrados de manera trazable y regular, utilizando pesos est\u00e1ndar certificados para asegurar la precisi\u00f3n en las mediciones.\n\n### Entidades Clave\n- **Autoclaves**: Equipos utilizados para la esterilizaci\u00f3n y descontaminaci\u00f3n.\n- **Sensores de Temperatura**: Dispositivos utilizados para medir la temperatura dentro de las cargas.\n- **Termopares**: Herramientas para el monitoreo de temperatura.\n- **Indicadores Qu\u00edmicos/Biol\u00f3gicos**: M\u00e9todos para verificar la efectividad de la esterilizaci\u00f3n.\n- **Pesos y Balances**: Equipos de medici\u00f3n que requieren calibraci\u00f3n regular. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el monitoreo y la calibraci\u00f3n en los procesos de esterilizaci\u00f3n y medici\u00f3n en laboratorios.", "excerpt_keywords": "Keywords: volumetric equipment, microbiology laboratories, verification, reagents, calibration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3a8efb1-dd28-4771-86f1-ecc02e4af675", "node_type": "4", "metadata": {"page_label": "92", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.7 Volumetric equipment\n\n4.3.7.1 Microbiology laboratories should carry out initial verification of volumetric equipment (automatic dispensers, dispenser/diluters, mechanical hand pipettes and disposable pipettes) and then make regular checks, as appropriate, to ensure that the equipment is performing within the required specification. Initial verification should not be necessary for glassware which has been certified to a specific tolerance. Equipment should be checked for the accuracy of the delivered volume against the set volume (for several different settings in the case of variable volume instruments) and the precision of the repeat deliveries should be measured.\n\n4.3.7.2 For \u201csingle-use\u201d disposable volumetric equipment, laboratories should obtain supplies from companies with a recognized and relevant quality system. After initial validation of the suitability of the equipment, it is recommended that random checks on accuracy are carried out. If the supplier does not have a recognized quality system, laboratories should check each batch of equipment for suitability.\n\n# 4.3.8 Other equipment\n\nConductivity meters, oxygen meters, pH meters and other similar instruments should be verified regularly or before each use. The buffers used for verification purposes should be stored in appropriate conditions and should be marked with an expiry date.\n\nWhere humidity is important to the outcome of the test, hygrometers should be calibrated, the calibration being traceable to national or international standards.\n\nTimers, including the autoclave timer, should be verified using a calibrated timer or national time signal.\n\nWhen centrifuges are used in test procedures, an assessment of the rotations per minute (RPM) should be made. Where it is critical, the centrifuge should be calibrated.\n\n# 5. Reagents and culture media\n\nLaboratories should ensure that the quality of reagents and media used is appropriate for the test concerned.\n\n## 5.1 Reagents\n\n5.1.1 Laboratories should verify the suitability of each batch of reagents critical for the test, initially and during its shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "31fe6c4d4db0f5e13bae936799a239e9ba6b81d5a06fd41e4dc7913ea9172b76", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.3.7 Volumetric equipment\n\n4.3.7.1 Microbiology laboratories should carry out initial verification of volumetric equipment (automatic dispensers, dispenser/diluters, mechanical hand pipettes and disposable pipettes) and then make regular checks, as appropriate, to ensure that the equipment is performing within the required specification. Initial verification should not be necessary for glassware which has been certified to a specific tolerance. Equipment should be checked for the accuracy of the delivered volume against the set volume (for several different settings in the case of variable volume instruments) and the precision of the repeat deliveries should be measured.\n\n4.3.7.2 For \u201csingle-use\u201d disposable volumetric equipment, laboratories should obtain supplies from companies with a recognized and relevant quality system. After initial validation of the suitability of the equipment, it is recommended that random checks on accuracy are carried out. If the supplier does not have a recognized quality system, laboratories should check each batch of equipment for suitability.\n\n# 4.3.8 Other equipment\n\nConductivity meters, oxygen meters, pH meters and other similar instruments should be verified regularly or before each use. The buffers used for verification purposes should be stored in appropriate conditions and should be marked with an expiry date.\n\nWhere humidity is important to the outcome of the test, hygrometers should be calibrated, the calibration being traceable to national or international standards.\n\nTimers, including the autoclave timer, should be verified using a calibrated timer or national time signal.\n\nWhen centrifuges are used in test procedures, an assessment of the rotations per minute (RPM) should be made. Where it is critical, the centrifuge should be calibrated.\n\n# 5. Reagents and culture media\n\nLaboratories should ensure that the quality of reagents and media used is appropriate for the test concerned.\n\n## 5.1 Reagents\n\n5.1.1 Laboratories should verify the suitability of each batch of reagents critical for the test, initially and during its shelf-life.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2111, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "53ab478d-6501-4582-bb74-1256e4d15850": {"__data__": {"id_": "53ab478d-6501-4582-bb74-1256e4d15850", "embedding": null, "metadata": {"page_label": "93", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.2 Media\n\n5.2.1 Media may be prepared in-house or purchased either partially or fully prepared. Vendors of purchased media should be approved and qualified. The qualified vendor may certify some of the quality parameters listed subsequently. Growth promotion and, if appropriate, other suitable performance tests (see section 5.2.2) should be done on all media on every batch and on every shipment. Where the supplier of fully prepared media is qualified and provides growth promotion certification per batch of media and transportation conditions have been qualified, the user may rely on the manufacturer\u2019s certificate with periodic verification of his or her results.\n\n5.2.2 The suitable performance of culture media, diluents and other suspension fluids should be checked, where relevant, with regard to:\n\n- recovery or survival maintenance of target organisms. Recovery of 50\u2013200% (after inoculation of not more than 100 colony-forming units (CFU or cfu) should be demonstrated;\n- inhibition or suppression of non-target organisms;\n- biochemical (differential and diagnostic) properties; and\n- other appropriate properties (e.g. pH, volume and sterility).\n\nQuantitative procedures for evaluation of recovery or survival are preferred.\n\n5.2.3 Raw materials (both commercial dehydrated formulations and individual constituents) and media should be stored under appropriate conditions recommended by the manufacturer, e.g. cool, dry and dark. All containers, especially those for dehydrated media, should be sealed tightly. Dehydrated media that are caked or cracked or show a colour change should not be used.\n\n5.2.4 Water of a suitable microbiological quality and which is free from bactericidal, inhibitory or interfering substances, should be used for preparation unless the test method specifies otherwise.\n\n5.2.5 Media containing antimetabolites or inhibitors should be prepared using dedicated glassware, as carry-over of these agents into other media could inhibit the growth and detection of microorganisms present in the sample under test. If dedicated glassware is not used, washing procedures for glassware should be validated.\n\n5.2.6 Repartition of media after sterilization should be performed under unidirectional airflow (UDAF) to minimize potential for environmental contamination. This should be considered a minimum requirement for media to be used in relation to sterile product testing. This includes the cooling of media, as container lids will need to be removed during cooling to prevent build-up of condensation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Preparaci\u00f3n y Certificaci\u00f3n de Medios**: Los medios de cultivo pueden ser preparados internamente o adquiridos de proveedores calificados. Es esencial que se realicen pruebas de promoci\u00f3n de crecimiento y otros tests de rendimiento en cada lote y env\u00edo de medios, garantizando as\u00ed su calidad y eficacia.\n\n2. **Evaluaci\u00f3n del Rendimiento de Medios**: Se deben verificar varios par\u00e1metros de rendimiento de los medios, incluyendo la recuperaci\u00f3n de organismos objetivo, la inhibici\u00f3n de organismos no deseados, y propiedades bioqu\u00edmicas y f\u00edsicas como pH y esterilidad.\n\n3. **Almacenamiento y Manejo de Medios**: Los medios y sus componentes deben almacenarse en condiciones adecuadas para mantener su calidad. Adem\u00e1s, se deben seguir procedimientos espec\u00edficos para la preparaci\u00f3n y manipulaci\u00f3n de medios que contengan antimetabolitos o inhibidores, as\u00ed como para la repartici\u00f3n despu\u00e9s de la esterilizaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplir los proveedores de medios de cultivo para ser considerados calificados?**\n   - Los proveedores deben ser aprobados y calificados, y pueden certificar algunos de los par\u00e1metros de calidad de los medios que ofrecen.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros espec\u00edficos que se deben evaluar para asegurar el rendimiento adecuado de los medios de cultivo?**\n   - Se deben evaluar la recuperaci\u00f3n o mantenimiento de supervivencia de organismos objetivo (50-200%), la inhibici\u00f3n de organismos no deseados, propiedades bioqu\u00edmicas, y otras propiedades relevantes como pH, volumen y esterilidad.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar la contaminaci\u00f3n ambiental durante la repartici\u00f3n de medios despu\u00e9s de la esterilizaci\u00f3n?**\n   - La repartici\u00f3n debe realizarse bajo flujo de aire unidireccional (UDAF) y se deben retirar las tapas de los contenedores durante el enfriamiento para prevenir la acumulaci\u00f3n de condensaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Equipos Volum\u00e9tricos**:\n   - **Verificaci\u00f3n Inicial**: Los laboratorios de microbiolog\u00eda deben realizar una verificaci\u00f3n inicial de equipos volum\u00e9tricos (dispensadores autom\u00e1ticos, pipetas mec\u00e1nicas y desechables) y controles regulares para asegurar su correcto funcionamiento.\n   - **Tolerancia de Cristaler\u00eda**: No se requiere verificaci\u00f3n inicial para cristaler\u00eda certificada con tolerancias espec\u00edficas.\n   - **Precisi\u00f3n y Exactitud**: Se debe comprobar la precisi\u00f3n del volumen entregado en comparaci\u00f3n con el volumen establecido y medir la precisi\u00f3n de las entregas repetidas.\n\n2. **Equipos Desechables**:\n   - **Proveedores**: Los laboratorios deben adquirir equipos volum\u00e9tricos desechables de empresas con sistemas de calidad reconocidos.\n   - **Controles Aleatorios**: Se recomienda realizar verificaciones aleatorias de precisi\u00f3n tras la validaci\u00f3n inicial. Si el proveedor carece de un sistema de calidad reconocido, se debe verificar cada lote.\n\n3. **Otros Equipos**:\n   - **Instrumentos de Medici\u00f3n**: Medidores de pH, conductividad y ox\u00edgeno deben ser verificados regularmente o antes de cada uso, con buffers almacenados adecuadamente y con fecha de caducidad.\n   - **Higr\u00f3metros y Centrifugadoras**: Los higr\u00f3metros deben calibrarse y la calibraci\u00f3n debe ser trazable a est\u00e1ndares nacionales o internacionales. Las centrifugadoras deben ser evaluadas en RPM y calibradas si es cr\u00edtico.\n\n4. **Reactivos y Medios de Cultivo**:\n   - **Calidad de Reactivos**: Los laboratorios deben asegurar que la calidad de los reactivos y medios de cultivo sea adecuada para las pruebas realizadas.\n   - **Verificaci\u00f3n de Reactivos**: Se debe verificar la idoneidad de cada lote de reactivos cr\u00edticos inicialmente y durante su vida \u00fatil.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Laboratorios de Microbiolog\u00eda**: Entidad responsable de la verificaci\u00f3n y mantenimiento de equipos.\n- **Equipos Volum\u00e9tricos**: Incluyen dispensadores autom\u00e1ticos, pipetas mec\u00e1nicas y desechables.\n- **Instrumentos de Medici\u00f3n**: Medidores de pH, conductividad, ox\u00edgeno, higr\u00f3metros y centrifugadoras.\n- **Reactivos y Medios de Cultivo**: Elementos cr\u00edticos para la realizaci\u00f3n de pruebas en laboratorios.", "excerpt_keywords": "Keywords: media preparation, quality certification, microbial testing, storage conditions, contamination prevention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "195520c2-8974-4a5b-80ab-424f6d7aa24f", "node_type": "4", "metadata": {"page_label": "93", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.2 Media\n\n5.2.1 Media may be prepared in-house or purchased either partially or fully prepared. Vendors of purchased media should be approved and qualified. The qualified vendor may certify some of the quality parameters listed subsequently. Growth promotion and, if appropriate, other suitable performance tests (see section 5.2.2) should be done on all media on every batch and on every shipment. Where the supplier of fully prepared media is qualified and provides growth promotion certification per batch of media and transportation conditions have been qualified, the user may rely on the manufacturer\u2019s certificate with periodic verification of his or her results.\n\n5.2.2 The suitable performance of culture media, diluents and other suspension fluids should be checked, where relevant, with regard to:\n\n- recovery or survival maintenance of target organisms. Recovery of 50\u2013200% (after inoculation of not more than 100 colony-forming units (CFU or cfu) should be demonstrated;\n- inhibition or suppression of non-target organisms;\n- biochemical (differential and diagnostic) properties; and\n- other appropriate properties (e.g. pH, volume and sterility).\n\nQuantitative procedures for evaluation of recovery or survival are preferred.\n\n5.2.3 Raw materials (both commercial dehydrated formulations and individual constituents) and media should be stored under appropriate conditions recommended by the manufacturer, e.g. cool, dry and dark. All containers, especially those for dehydrated media, should be sealed tightly. Dehydrated media that are caked or cracked or show a colour change should not be used.\n\n5.2.4 Water of a suitable microbiological quality and which is free from bactericidal, inhibitory or interfering substances, should be used for preparation unless the test method specifies otherwise.\n\n5.2.5 Media containing antimetabolites or inhibitors should be prepared using dedicated glassware, as carry-over of these agents into other media could inhibit the growth and detection of microorganisms present in the sample under test. If dedicated glassware is not used, washing procedures for glassware should be validated.\n\n5.2.6 Repartition of media after sterilization should be performed under unidirectional airflow (UDAF) to minimize potential for environmental contamination. This should be considered a minimum requirement for media to be used in relation to sterile product testing. This includes the cooling of media, as container lids will need to be removed during cooling to prevent build-up of condensation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3870c8d591798549c955cd551f049932258ef811a2535d970cdfd4154b2ba592", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.2 Media\n\n5.2.1 Media may be prepared in-house or purchased either partially or fully prepared. Vendors of purchased media should be approved and qualified. The qualified vendor may certify some of the quality parameters listed subsequently. Growth promotion and, if appropriate, other suitable performance tests (see section 5.2.2) should be done on all media on every batch and on every shipment. Where the supplier of fully prepared media is qualified and provides growth promotion certification per batch of media and transportation conditions have been qualified, the user may rely on the manufacturer\u2019s certificate with periodic verification of his or her results.\n\n5.2.2 The suitable performance of culture media, diluents and other suspension fluids should be checked, where relevant, with regard to:\n\n- recovery or survival maintenance of target organisms. Recovery of 50\u2013200% (after inoculation of not more than 100 colony-forming units (CFU or cfu) should be demonstrated;\n- inhibition or suppression of non-target organisms;\n- biochemical (differential and diagnostic) properties; and\n- other appropriate properties (e.g. pH, volume and sterility).\n\nQuantitative procedures for evaluation of recovery or survival are preferred.\n\n5.2.3 Raw materials (both commercial dehydrated formulations and individual constituents) and media should be stored under appropriate conditions recommended by the manufacturer, e.g. cool, dry and dark. All containers, especially those for dehydrated media, should be sealed tightly. Dehydrated media that are caked or cracked or show a colour change should not be used.\n\n5.2.4 Water of a suitable microbiological quality and which is free from bactericidal, inhibitory or interfering substances, should be used for preparation unless the test method specifies otherwise.\n\n5.2.5 Media containing antimetabolites or inhibitors should be prepared using dedicated glassware, as carry-over of these agents into other media could inhibit the growth and detection of microorganisms present in the sample under test. If dedicated glassware is not used, washing procedures for glassware should be validated.\n\n5.2.6 Repartition of media after sterilization should be performed under unidirectional airflow (UDAF) to minimize potential for environmental contamination. This should be considered a minimum requirement for media to be used in relation to sterile product testing. This includes the cooling of media, as container lids will need to be removed during cooling to prevent build-up of condensation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2542, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "63885521-a2be-4269-9aac-2e1bcc1dfebe": {"__data__": {"id_": "63885521-a2be-4269-9aac-2e1bcc1dfebe", "embedding": null, "metadata": {"page_label": "94", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2.7\n\nPlated media which is to be irradiated may require the addition of an antioxidant and free radical scavenger to provide protection from the effects of the irradiation process. The irradiated media should be validated by performing quantitative growth promotion testing on both irradiated and non-irradiated media.\n\n## 5.2.8\n\nShelf-life of prepared media under defined storage conditions shall be determined and verified.\n\n## 5.2.9\n\nBatches of media should be identifiable and their conformance with quality specifications documented. For purchased media the user laboratory should ensure that it will be notified by the manufacturer of any changes to the quality specification.\n\n## 5.2.10\n\nMedia should be prepared in accordance with any manufacturer\u2019s instructions, taking into careful account specifications such as time and temperature for sterilization.\n\n## 5.2.11\n\nMicrowave devices should not be used for the melting of media due to the inconsistent distribution of the heating process.\n\n## 5.3 Labelling\n\n5.3.1 Laboratories should ensure that all reagents (including stock solutions), media, diluents and other suspending fluids are adequately labelled to indicate, as appropriate, identity, concentration, storage conditions, preparation date, validated expiry date and/or recommended storage periods. The person responsible for preparation should be identifiable from records.\n\n## 5.4 Organism resuscitation\n\n5.4.1 Organism resuscitation is required where test methodologies may produce sublethally injured cells. For example, exposure to:\n\n- injurious effects of processing, e.g. heat;\n- antimicrobial agents;\n- preservatives;\n- extremes of osmotic pressure; and\n- extremes of pH.\n\n5.4.2 Organism resuscitation may be achieved by:\n\n- exposure to a liquid media like a simple salt solution at room temperature for 2 hours;\n- exposure to a solid repair medium for 4\u20136 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda directrices sobre la preparaci\u00f3n y manejo de medios de cultivo en laboratorios. Se enfatiza la importancia de la irradiaci\u00f3n de medios, la identificaci\u00f3n y documentaci\u00f3n de lotes, el etiquetado adecuado de reactivos y la resucitaci\u00f3n de organismos que pueden haber sufrido da\u00f1os subletales. Se mencionan pr\u00e1cticas espec\u00edficas para garantizar la calidad y la eficacia de los medios de cultivo, as\u00ed como la necesidad de seguir las instrucciones del fabricante y evitar el uso de microondas para la fusi\u00f3n de medios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de aditivos se recomienda agregar a los medios de cultivo que ser\u00e1n irradiados y por qu\u00e9?**\n   - Respuesta: Se recomienda la adici\u00f3n de un antioxidante y un captador de radicales libres para proteger los medios de cultivo de los efectos del proceso de irradiaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para la resucitaci\u00f3n de organismos que han sido expuestos a condiciones que podr\u00edan da\u00f1arlos?**\n   - Respuesta: La resucitaci\u00f3n de organismos puede lograrse mediante la exposici\u00f3n a un medio l\u00edquido, como una soluci\u00f3n salina simple a temperatura ambiente durante 2 horas, o mediante la exposici\u00f3n a un medio s\u00f3lido de reparaci\u00f3n durante 4 a 6 horas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los reactivos y medios de cultivo en el laboratorio?**\n   - Respuesta: Las etiquetas deben indicar, seg\u00fan corresponda, la identidad, concentraci\u00f3n, condiciones de almacenamiento, fecha de preparaci\u00f3n, fecha de caducidad validada y/o per\u00edodos de almacenamiento recomendados. Adem\u00e1s, debe ser identificable la persona responsable de la preparaci\u00f3n a partir de los registros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n 5.2 - Medios\n\n1. **Preparaci\u00f3n de Medios**:\n   - Los medios de cultivo pueden ser preparados internamente o adquiridos de proveedores calificados.\n   - Es fundamental que los proveedores certifiquen algunos par\u00e1metros de calidad y que se realicen pruebas de promoci\u00f3n de crecimiento en cada lote y env\u00edo.\n\n2. **Evaluaci\u00f3n del Rendimiento**:\n   - Se deben verificar varios par\u00e1metros de rendimiento de los medios, incluyendo:\n     - Recuperaci\u00f3n o mantenimiento de supervivencia de organismos objetivo (50-200%).\n     - Inhibici\u00f3n de organismos no deseados.\n     - Propiedades bioqu\u00edmicas (diferenciales y diagn\u00f3sticas).\n     - Otras propiedades relevantes como pH, volumen y esterilidad.\n   - Se prefieren procedimientos cuantitativos para la evaluaci\u00f3n de recuperaci\u00f3n o supervivencia.\n\n3. **Almacenamiento y Manejo**:\n   - Los medios y sus componentes deben almacenarse en condiciones adecuadas (frescos, secos y oscuros).\n   - Los contenedores deben estar sellados y los medios deshidratados que presenten cambios (caked, agrietados o de color alterado) no deben usarse.\n\n4. **Calidad del Agua**:\n   - Se debe utilizar agua de calidad microbiol\u00f3gica adecuada, libre de sustancias bactericidas, inhibidoras o interferentes, a menos que el m\u00e9todo de prueba indique lo contrario.\n\n5. **Manipulaci\u00f3n de Medios con Antimetabolitos**:\n   - Los medios que contienen antimetabolitos o inhibidores deben prepararse con vidrio dedicado para evitar la contaminaci\u00f3n cruzada.\n   - Si no se utiliza vidrio dedicado, se deben validar los procedimientos de lavado.\n\n6. **Repartici\u00f3n de Medios**:\n   - La repartici\u00f3n de medios despu\u00e9s de la esterilizaci\u00f3n debe realizarse bajo flujo de aire unidireccional (UDAF) para minimizar la contaminaci\u00f3n ambiental.\n   - Durante el enfriamiento, las tapas de los contenedores deben retirarse para evitar la acumulaci\u00f3n de condensaci\u00f3n.\n\n### Entidades Clave:\n- **Medios de Cultivo**: Preparaci\u00f3n, evaluaci\u00f3n y almacenamiento.\n- **Proveedores Calificados**: Certificaci\u00f3n de calidad y pruebas de rendimiento.\n- **Par\u00e1metros de Rendimiento**: Recuperaci\u00f3n, inhibici\u00f3n, propiedades bioqu\u00edmicas y f\u00edsicas.\n- **Condiciones de Almacenamiento**: Fresco, seco, oscuro.\n- **Agua Microbiol\u00f3gicamente Adecuada**: Libre de contaminantes.\n- **Flujo de Aire Unidireccional (UDAF)**: Para la repartici\u00f3n y enfriamiento de medios.", "excerpt_keywords": "Keywords: media preparation, irradiation, organism resuscitation, quality specifications, laboratory practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "83aad718-a0a9-4e33-9e0d-b5e62433e42c", "node_type": "4", "metadata": {"page_label": "94", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2.7\n\nPlated media which is to be irradiated may require the addition of an antioxidant and free radical scavenger to provide protection from the effects of the irradiation process. The irradiated media should be validated by performing quantitative growth promotion testing on both irradiated and non-irradiated media.\n\n## 5.2.8\n\nShelf-life of prepared media under defined storage conditions shall be determined and verified.\n\n## 5.2.9\n\nBatches of media should be identifiable and their conformance with quality specifications documented. For purchased media the user laboratory should ensure that it will be notified by the manufacturer of any changes to the quality specification.\n\n## 5.2.10\n\nMedia should be prepared in accordance with any manufacturer\u2019s instructions, taking into careful account specifications such as time and temperature for sterilization.\n\n## 5.2.11\n\nMicrowave devices should not be used for the melting of media due to the inconsistent distribution of the heating process.\n\n## 5.3 Labelling\n\n5.3.1 Laboratories should ensure that all reagents (including stock solutions), media, diluents and other suspending fluids are adequately labelled to indicate, as appropriate, identity, concentration, storage conditions, preparation date, validated expiry date and/or recommended storage periods. The person responsible for preparation should be identifiable from records.\n\n## 5.4 Organism resuscitation\n\n5.4.1 Organism resuscitation is required where test methodologies may produce sublethally injured cells. For example, exposure to:\n\n- injurious effects of processing, e.g. heat;\n- antimicrobial agents;\n- preservatives;\n- extremes of osmotic pressure; and\n- extremes of pH.\n\n5.4.2 Organism resuscitation may be achieved by:\n\n- exposure to a liquid media like a simple salt solution at room temperature for 2 hours;\n- exposure to a solid repair medium for 4\u20136 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8ab19580695d5ce112d4abe4a862e0658acfc8bc7ed40e485ccf11aef634b42d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 5.2.7\n\nPlated media which is to be irradiated may require the addition of an antioxidant and free radical scavenger to provide protection from the effects of the irradiation process. The irradiated media should be validated by performing quantitative growth promotion testing on both irradiated and non-irradiated media.\n\n## 5.2.8\n\nShelf-life of prepared media under defined storage conditions shall be determined and verified.\n\n## 5.2.9\n\nBatches of media should be identifiable and their conformance with quality specifications documented. For purchased media the user laboratory should ensure that it will be notified by the manufacturer of any changes to the quality specification.\n\n## 5.2.10\n\nMedia should be prepared in accordance with any manufacturer\u2019s instructions, taking into careful account specifications such as time and temperature for sterilization.\n\n## 5.2.11\n\nMicrowave devices should not be used for the melting of media due to the inconsistent distribution of the heating process.\n\n## 5.3 Labelling\n\n5.3.1 Laboratories should ensure that all reagents (including stock solutions), media, diluents and other suspending fluids are adequately labelled to indicate, as appropriate, identity, concentration, storage conditions, preparation date, validated expiry date and/or recommended storage periods. The person responsible for preparation should be identifiable from records.\n\n## 5.4 Organism resuscitation\n\n5.4.1 Organism resuscitation is required where test methodologies may produce sublethally injured cells. For example, exposure to:\n\n- injurious effects of processing, e.g. heat;\n- antimicrobial agents;\n- preservatives;\n- extremes of osmotic pressure; and\n- extremes of pH.\n\n5.4.2 Organism resuscitation may be achieved by:\n\n- exposure to a liquid media like a simple salt solution at room temperature for 2 hours;\n- exposure to a solid repair medium for 4\u20136 hours.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1892, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6bcb0688-ea6c-4e2a-9cf0-8918d51c2152": {"__data__": {"id_": "6bcb0688-ea6c-4e2a-9cf0-8918d51c2152", "embedding": null, "metadata": {"page_label": "95", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n\n## 6.1 International standards and pharmacopoeial reference substances\n\n6.1.1 Reference materials and certified reference materials are generally used in a microbiological laboratory to qualify, verify and calibrate equipment.\n\nWhenever possible these reference materials should be used in appropriate matrices.\n\nInternational standards and pharmacopoeial reference substances are employed, for example, to:\n\n- determine potency or content;\n- validate methods;\n- enable comparison of methods;\n- perform positive controls; and\n- perform growth promotion tests.\n\nIf possible reference materials should be used in appropriate matrices.\n\n## 6.2 Reference cultures\n\n6.2.1 Reference cultures are required for establishing acceptable performance of media (including test kits), for validating methods, for verifying the suitability of test methods and for assessing or evaluating ongoing performance. Traceability is necessary, for example, when establishing media performance for test kit and method validations. To demonstrate traceability, laboratories must use reference strains of microorganisms obtained directly from a recognized national or international collection, where these exist. Alternatively, commercial derivatives for which all relevant properties have been shown by the laboratory to be equivalent at the point of use may be used.\n\n6.2.2 Reference strains may be subcultured once to provide reference stocks. Purity and biochemical checks should be made in parallel as appropriate. It is recommended to store reference stocks in aliquots either deep-frozen or lyophilized. Working cultures for routine use should be primary subcultures from the reference stock (see Appendix 5 on general use of reference cultures). If reference stocks have been thawed, they must not be refrozen and reused.\n\n6.2.3 Working stocks should not normally be subcultured. Usually not more than five generations (or passages) from the original reference strain can be subcultured if defined by a standard method or laboratories can", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de los materiales de referencia y las culturas de referencia en laboratorios microbiol\u00f3gicos. Se destacan dos secciones principales: \n\n1. **Materiales de referencia y sustancias de referencia farmacop\u00e9uticas**: Se utilizan para calificar, verificar y calibrar equipos, as\u00ed como para determinar la potencia, validar m\u00e9todos y realizar controles positivos.\n\n2. **Culturas de referencia**: Son esenciales para establecer el rendimiento aceptable de medios y kits de prueba, validar m\u00e9todos y evaluar el rendimiento continuo. Se enfatiza la necesidad de trazabilidad mediante el uso de cepas de microorganismos de colecciones reconocidas y se dan recomendaciones sobre el manejo y almacenamiento de estas cepas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el almacenamiento de las cepas de referencia y por qu\u00e9 es importante seguir estas recomendaciones?**\n   - Las cepas de referencia deben almacenarse en al\u00edcuotas, ya sea congeladas en profundidad o liofilizadas. Esto es importante para mantener la viabilidad y pureza de las cepas, evitando la contaminaci\u00f3n y asegurando que las cepas utilizadas en experimentos sean representativas de la cepa original.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse para que un laboratorio utilice derivados comerciales de cepas de referencia?**\n   - Los derivados comerciales deben haber demostrado que todas sus propiedades relevantes son equivalentes a las de la cepa de referencia original en el punto de uso, asegurando as\u00ed la validez de los resultados obtenidos con estos derivados.\n\n3. **\u00bfQu\u00e9 limitaciones existen en el subcultivo de las cepas de referencia y cu\u00e1l es la raz\u00f3n detr\u00e1s de estas limitaciones?**\n   - Normalmente, las cepas de trabajo no deben subcultivarse m\u00e1s de cinco generaciones (o pasajes) a partir de la cepa de referencia original. Esto se debe a que el subcultivo excesivo puede llevar a cambios gen\u00e9ticos o fenot\u00edpicos que comprometan la validez de los resultados experimentales y la comparabilidad con los est\u00e1ndares establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Irradiaci\u00f3n de Medios de Cultivo**:\n   - Se sugiere la adici\u00f3n de un **antioxidante** y un **captador de radicales libres** para proteger los medios de cultivo de los efectos de la irradiaci\u00f3n.\n   - Es necesario validar los medios irradiados mediante pruebas cuantitativas de promoci\u00f3n del crecimiento.\n\n2. **Vida \u00datil de los Medios**:\n   - Se debe determinar y verificar la vida \u00fatil de los medios preparados bajo condiciones de almacenamiento definidas.\n\n3. **Identificaci\u00f3n y Documentaci\u00f3n de Lotes**:\n   - Los lotes de medios deben ser identificables y su conformidad con las especificaciones de calidad debe estar documentada.\n   - Los laboratorios deben ser notificados por los fabricantes sobre cualquier cambio en las especificaciones de calidad de los medios comprados.\n\n4. **Instrucciones del Fabricante**:\n   - Los medios deben prepararse de acuerdo con las instrucciones del fabricante, considerando cuidadosamente el tiempo y la temperatura para la esterilizaci\u00f3n.\n\n5. **Uso de Microondas**:\n   - No se deben utilizar dispositivos de microondas para la fusi\u00f3n de medios debido a la distribuci\u00f3n inconsistente del calor.\n\n6. **Etiquetado**:\n   - Todos los reactivos, medios, diluyentes y otros fluidos deben estar adecuadamente etiquetados, indicando identidad, concentraci\u00f3n, condiciones de almacenamiento, fecha de preparaci\u00f3n, fecha de caducidad validada y/o per\u00edodos de almacenamiento recomendados.\n   - La persona responsable de la preparaci\u00f3n debe ser identificable a partir de los registros.\n\n7. **Resucitaci\u00f3n de Organismos**:\n   - La resucitaci\u00f3n es necesaria para c\u00e9lulas que pueden haber sufrido da\u00f1os subletales debido a factores como calor, agentes antimicrobianos, conservantes, presi\u00f3n osm\u00f3tica extrema y pH extremo.\n   - M\u00e9todos de resucitaci\u00f3n incluyen:\n     - Exposici\u00f3n a un medio l\u00edquido (soluci\u00f3n salina simple) a temperatura ambiente durante 2 horas.\n     - Exposici\u00f3n a un medio s\u00f3lido de reparaci\u00f3n durante 4 a 6 horas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medios de Cultivo**\n- **Antioxidantes**\n- **Captadores de Radicales Libres**\n- **Vida \u00datil**\n- **Etiquetado**\n- **Resucitaci\u00f3n de Organismos**\n- **Condiciones de Almacenamiento**", "excerpt_keywords": "Keywords: reference materials, microbiological laboratory, traceability, reference cultures, international standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a653341d-c746-4c05-b737-30dcda557729", "node_type": "4", "metadata": {"page_label": "95", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n\n## 6.1 International standards and pharmacopoeial reference substances\n\n6.1.1 Reference materials and certified reference materials are generally used in a microbiological laboratory to qualify, verify and calibrate equipment.\n\nWhenever possible these reference materials should be used in appropriate matrices.\n\nInternational standards and pharmacopoeial reference substances are employed, for example, to:\n\n- determine potency or content;\n- validate methods;\n- enable comparison of methods;\n- perform positive controls; and\n- perform growth promotion tests.\n\nIf possible reference materials should be used in appropriate matrices.\n\n## 6.2 Reference cultures\n\n6.2.1 Reference cultures are required for establishing acceptable performance of media (including test kits), for validating methods, for verifying the suitability of test methods and for assessing or evaluating ongoing performance. Traceability is necessary, for example, when establishing media performance for test kit and method validations. To demonstrate traceability, laboratories must use reference strains of microorganisms obtained directly from a recognized national or international collection, where these exist. Alternatively, commercial derivatives for which all relevant properties have been shown by the laboratory to be equivalent at the point of use may be used.\n\n6.2.2 Reference strains may be subcultured once to provide reference stocks. Purity and biochemical checks should be made in parallel as appropriate. It is recommended to store reference stocks in aliquots either deep-frozen or lyophilized. Working cultures for routine use should be primary subcultures from the reference stock (see Appendix 5 on general use of reference cultures). If reference stocks have been thawed, they must not be refrozen and reused.\n\n6.2.3 Working stocks should not normally be subcultured. Usually not more than five generations (or passages) from the original reference strain can be subcultured if defined by a standard method or laboratories can", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3c6579bb631bed227515d566f6523b09d29ded23cea7cb52b20e82f427ee93e7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6. Reference materials and reference cultures\n\n## 6.1 International standards and pharmacopoeial reference substances\n\n6.1.1 Reference materials and certified reference materials are generally used in a microbiological laboratory to qualify, verify and calibrate equipment.\n\nWhenever possible these reference materials should be used in appropriate matrices.\n\nInternational standards and pharmacopoeial reference substances are employed, for example, to:\n\n- determine potency or content;\n- validate methods;\n- enable comparison of methods;\n- perform positive controls; and\n- perform growth promotion tests.\n\nIf possible reference materials should be used in appropriate matrices.\n\n## 6.2 Reference cultures\n\n6.2.1 Reference cultures are required for establishing acceptable performance of media (including test kits), for validating methods, for verifying the suitability of test methods and for assessing or evaluating ongoing performance. Traceability is necessary, for example, when establishing media performance for test kit and method validations. To demonstrate traceability, laboratories must use reference strains of microorganisms obtained directly from a recognized national or international collection, where these exist. Alternatively, commercial derivatives for which all relevant properties have been shown by the laboratory to be equivalent at the point of use may be used.\n\n6.2.2 Reference strains may be subcultured once to provide reference stocks. Purity and biochemical checks should be made in parallel as appropriate. It is recommended to store reference stocks in aliquots either deep-frozen or lyophilized. Working cultures for routine use should be primary subcultures from the reference stock (see Appendix 5 on general use of reference cultures). If reference stocks have been thawed, they must not be refrozen and reused.\n\n6.2.3 Working stocks should not normally be subcultured. Usually not more than five generations (or passages) from the original reference strain can be subcultured if defined by a standard method or laboratories can", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2069, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "de8c1d12-f15c-4006-98b1-bf2e62e7b5ca": {"__data__": {"id_": "de8c1d12-f15c-4006-98b1-bf2e62e7b5ca", "embedding": null, "metadata": {"page_label": "96", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sampling\n\nFor general principles reference is made to *Good practices for pharmaceutical quality control laboratories (1)*.\n\n7.1 Where testing laboratories are responsible for primary sampling to obtain test items, it is strongly recommended that this sampling be covered by a quality assurance system and it should be subject to regular audits.\n\n7.2 Any disinfection processes used in obtaining the sample (e.g. disinfection of sample points) should not compromise the microbial level within the sample.\n\n7.3 Transport and storage of samples should be under conditions that maintain the integrity of the sample (e.g. chilled or frozen where appropriate). Testing of the samples should be performed as soon as possible after sampling. For samples where a growth in the microbial population during transport and storage is possible it should be demonstrated that the storage conditions, time and temperature, will not affect the accuracy of the testing result. The storage conditions should be monitored and records kept. The responsibility for transport, storage between sampling and arrival at the testing laboratory should be clearly documented.\n\n7.4 Sampling should only be performed by trained personnel. It should be carried out aseptically using sterile equipment. Appropriate precautions should be taken to ensure that sample integrity is maintained through the use of sterile sealed containers for the collection of samples where appropriate. It may be necessary to monitor environmental conditions, for example, air contamination and temperature, at the sampling site. Time of sampling should be recorded, if appropriate.\n\n# Sample handling and identification\n\n8.1 The laboratory should have procedures that cover the delivery and receipt of samples and sample identification. If there is insufficient sample or the sample is in poor condition due to physical deterioration, incorrect temperature, torn packaging or deficient labelling, the laboratory should consult with the client before deciding whether to test or refuse the sample.\n\n8.2 The laboratory should record all relevant information, e.g.\n\n- date and, where relevant, the time of receipt;\n- condition of the sample on receipt and, when necessary, temperature; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para los laboratorios de control de calidad farmac\u00e9utica, centr\u00e1ndose en los procedimientos de muestreo y manejo de muestras. Se enfatiza la importancia de un sistema de aseguramiento de la calidad en el muestreo, la necesidad de mantener la integridad de las muestras durante el transporte y almacenamiento, y la capacitaci\u00f3n del personal encargado de realizar el muestreo. Tambi\u00e9n se mencionan procedimientos para la identificaci\u00f3n y manejo de muestras en el laboratorio, as\u00ed como la documentaci\u00f3n necesaria para garantizar la trazabilidad y la calidad de los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que los procesos de desinfecci\u00f3n no afecten el nivel microbiano de la muestra?**\n   - El documento menciona que cualquier proceso de desinfecci\u00f3n utilizado en la obtenci\u00f3n de la muestra no debe comprometer el nivel microbiano dentro de la misma. Esto implica que se deben seleccionar m\u00e9todos de desinfecci\u00f3n que sean efectivos pero que no alteren la composici\u00f3n microbiana de la muestra.\n\n2. **\u00bfCu\u00e1les son las responsabilidades documentadas en el transporte y almacenamiento de muestras entre el muestreo y la llegada al laboratorio de pruebas?**\n   - La responsabilidad del transporte y almacenamiento debe estar claramente documentada, incluyendo las condiciones de almacenamiento, el tiempo y la temperatura, para asegurar que la integridad de la muestra se mantenga y que no se afecten los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n relevante debe registrar el laboratorio al recibir una muestra?**\n   - El laboratorio debe registrar informaci\u00f3n como la fecha y, cuando sea relevante, la hora de recepci\u00f3n; la condici\u00f3n de la muestra al recibirla; y, cuando sea necesario, la temperatura de la muestra. Esto es crucial para evaluar la calidad y la idoneidad de la muestra para su an\u00e1lisis.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n\n1. **Materiales de Referencia**:\n   - Utilizados en laboratorios microbiol\u00f3gicos para calificar, verificar y calibrar equipos.\n   - Aplicaciones incluyen la determinaci\u00f3n de potencia, validaci\u00f3n de m\u00e9todos, comparaci\u00f3n de m\u00e9todos, controles positivos y pruebas de promoci\u00f3n de crecimiento.\n\n2. **Culturas de Referencia**:\n   - Esenciales para establecer el rendimiento aceptable de medios y kits de prueba, validar m\u00e9todos y evaluar el rendimiento continuo.\n   - La trazabilidad es crucial, requiriendo el uso de cepas de microorganismos de colecciones reconocidas o derivados comerciales equivalentes.\n\n3. **Almacenamiento y Manejo**:\n   - Las cepas de referencia deben almacenarse en al\u00edcuotas, ya sea congeladas en profundidad o liofilizadas, para mantener su viabilidad y pureza.\n   - Se recomienda que las cepas de trabajo sean subcultivos primarios de las cepas de referencia.\n\n4. **Limitaciones en el Subcultivo**:\n   - No se deben subcultivar las cepas de trabajo m\u00e1s de cinco generaciones a partir de la cepa de referencia original para evitar cambios que comprometan la validez de los resultados.\n\n#### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Materiales de Referencia**: Incluyen est\u00e1ndares internacionales y sustancias de referencia farmacop\u00e9uticas.\n- **Culturas de Referencia**: Cepas de microorganismos utilizadas para asegurar la calidad y validez en pruebas microbiol\u00f3gicas.\n- **Colecciones Nacionales o Internacionales**: Fuentes reconocidas de cepas de referencia.\n- **Derivados Comerciales**: Cepas que han demostrado equivalencia con las cepas de referencia originales.\n\nEste resumen destaca la importancia de los materiales y culturas de referencia en la microbiolog\u00eda, as\u00ed como las mejores pr\u00e1cticas para su manejo y uso en laboratorios.", "excerpt_keywords": "Keywords: sampling, quality assurance, microbial integrity, sample handling, laboratory procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8fcfdf11-b583-4247-b20c-27787e337598", "node_type": "4", "metadata": {"page_label": "96", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sampling\n\nFor general principles reference is made to *Good practices for pharmaceutical quality control laboratories (1)*.\n\n7.1 Where testing laboratories are responsible for primary sampling to obtain test items, it is strongly recommended that this sampling be covered by a quality assurance system and it should be subject to regular audits.\n\n7.2 Any disinfection processes used in obtaining the sample (e.g. disinfection of sample points) should not compromise the microbial level within the sample.\n\n7.3 Transport and storage of samples should be under conditions that maintain the integrity of the sample (e.g. chilled or frozen where appropriate). Testing of the samples should be performed as soon as possible after sampling. For samples where a growth in the microbial population during transport and storage is possible it should be demonstrated that the storage conditions, time and temperature, will not affect the accuracy of the testing result. The storage conditions should be monitored and records kept. The responsibility for transport, storage between sampling and arrival at the testing laboratory should be clearly documented.\n\n7.4 Sampling should only be performed by trained personnel. It should be carried out aseptically using sterile equipment. Appropriate precautions should be taken to ensure that sample integrity is maintained through the use of sterile sealed containers for the collection of samples where appropriate. It may be necessary to monitor environmental conditions, for example, air contamination and temperature, at the sampling site. Time of sampling should be recorded, if appropriate.\n\n# Sample handling and identification\n\n8.1 The laboratory should have procedures that cover the delivery and receipt of samples and sample identification. If there is insufficient sample or the sample is in poor condition due to physical deterioration, incorrect temperature, torn packaging or deficient labelling, the laboratory should consult with the client before deciding whether to test or refuse the sample.\n\n8.2 The laboratory should record all relevant information, e.g.\n\n- date and, where relevant, the time of receipt;\n- condition of the sample on receipt and, when necessary, temperature; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3357ac4e7d886c5c5883f71513b2598a06dcb4029a5719654af79d89de767b9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Sampling\n\nFor general principles reference is made to *Good practices for pharmaceutical quality control laboratories (1)*.\n\n7.1 Where testing laboratories are responsible for primary sampling to obtain test items, it is strongly recommended that this sampling be covered by a quality assurance system and it should be subject to regular audits.\n\n7.2 Any disinfection processes used in obtaining the sample (e.g. disinfection of sample points) should not compromise the microbial level within the sample.\n\n7.3 Transport and storage of samples should be under conditions that maintain the integrity of the sample (e.g. chilled or frozen where appropriate). Testing of the samples should be performed as soon as possible after sampling. For samples where a growth in the microbial population during transport and storage is possible it should be demonstrated that the storage conditions, time and temperature, will not affect the accuracy of the testing result. The storage conditions should be monitored and records kept. The responsibility for transport, storage between sampling and arrival at the testing laboratory should be clearly documented.\n\n7.4 Sampling should only be performed by trained personnel. It should be carried out aseptically using sterile equipment. Appropriate precautions should be taken to ensure that sample integrity is maintained through the use of sterile sealed containers for the collection of samples where appropriate. It may be necessary to monitor environmental conditions, for example, air contamination and temperature, at the sampling site. Time of sampling should be recorded, if appropriate.\n\n# Sample handling and identification\n\n8.1 The laboratory should have procedures that cover the delivery and receipt of samples and sample identification. If there is insufficient sample or the sample is in poor condition due to physical deterioration, incorrect temperature, torn packaging or deficient labelling, the laboratory should consult with the client before deciding whether to test or refuse the sample.\n\n8.2 The laboratory should record all relevant information, e.g.\n\n- date and, where relevant, the time of receipt;\n- condition of the sample on receipt and, when necessary, temperature; and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2237, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c68d64ae-6777-4bbe-912b-a56b98454000": {"__data__": {"id_": "c68d64ae-6777-4bbe-912b-a56b98454000", "embedding": null, "metadata": {"page_label": "97", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.3\n\nSamples awaiting testing should be stored under suitable conditions to minimize changes to any microbial population present. Storage conditions should be validated, defined and recorded.\n\n# 8.4\n\nThe packaging and labels of samples may be highly contaminated and should be handled and stored with care so as to avoid any spread of contamination. Disinfection processes applied to the outer container should not affect the integrity of the sample. It should be noted that alcohol is not sporicidal.\n\n# 8.5\n\nSubsampling by the laboratory immediately prior to testing may be required as part of the test method. It may be appropriate that it is performed according to national or international standards, where they exist, or by validated in-house methods. Subsampling procedures should be designed to collect a representative sample.\n\n# 8.6\n\nThere should be a written procedure for the retention and disposal of samples. If sample integrity can be maintained it may be appropriate that samples are stored until the test results are obtained, or longer if required. Laboratory sample portions that are known to be contaminated should be decontaminated prior to being discarded (see section 11.1).\n\n# 9. Disposal of contaminated waste\n\n9.1 The procedures for the disposal of contaminated materials should be designed to minimize the possibility of contaminating the test environment or materials. It is a matter of good laboratory management and should conform to national/international environmental or health and safety regulations.\n\n# 10. Quality assurance of results and quality control of performance\n\n## 10.1 Internal quality control\n\n10.1.1 The laboratory should have a system of internal quality assurance or quality control (e.g. handling deviations, use of spiked samples, replicate testing and participation in proficiency testing, where appropriate) to ensure the consistency of results from day to day and their conformity with defined criteria.\n\n# 11. Testing procedures\n\n11.1 Testing should normally be performed according to procedures described in the national, regional and international pharmacopoeias.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y directrices para el manejo de muestras en laboratorios, incluyendo el almacenamiento, la manipulaci\u00f3n, el muestreo, la disposici\u00f3n de desechos contaminados y el aseguramiento de la calidad de los resultados. Se enfatiza la importancia de mantener la integridad de las muestras, seguir procedimientos estandarizados y cumplir con regulaciones ambientales y de salud. Tambi\u00e9n se menciona la necesidad de un control de calidad interno para asegurar la consistencia de los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones adecuadas para el almacenamiento de muestras que est\u00e1n a la espera de pruebas, y por qu\u00e9 es importante validar estas condiciones?**\n   - Respuesta: Las muestras deben ser almacenadas bajo condiciones adecuadas que minimicen los cambios en la poblaci\u00f3n microbiana presente. Es importante validar estas condiciones para asegurar que las muestras mantengan su integridad y que los resultados de las pruebas sean confiables.\n\n2. **\u00bfQu\u00e9 precauciones deben tomarse al manejar el embalaje y las etiquetas de las muestras, y por qu\u00e9 el alcohol no es adecuado para la desinfecci\u00f3n de contenedores externos?**\n   - Respuesta: El embalaje y las etiquetas pueden estar altamente contaminados y deben ser manejados con cuidado para evitar la propagaci\u00f3n de la contaminaci\u00f3n. El alcohol no es adecuado para la desinfecci\u00f3n de contenedores externos porque no es esporicida, lo que significa que no puede eliminar esporas de microorganismos que podr\u00edan comprometer la muestra.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la retenci\u00f3n y disposici\u00f3n de muestras contaminadas, y qu\u00e9 se debe hacer antes de desechar porciones de muestras contaminadas?**\n   - Respuesta: Debe existir un procedimiento escrito para la retenci\u00f3n y disposici\u00f3n de muestras. Las muestras contaminadas deben ser decontaminadas antes de ser descartadas para evitar riesgos de contaminaci\u00f3n en el entorno de prueba.", "prev_section_summary": "### Temas Clave\n\n1. **Principios Generales de Muestreo**: Se hace referencia a las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, enfatizando la importancia de un sistema de aseguramiento de la calidad en el muestreo.\n\n2. **Calidad y Auditor\u00eda**: Se recomienda que el muestreo est\u00e9 cubierto por un sistema de calidad y sea objeto de auditor\u00edas regulares.\n\n3. **Desinfecci\u00f3n**: Los procesos de desinfecci\u00f3n no deben comprometer el nivel microbiano de la muestra.\n\n4. **Transporte y Almacenamiento**: Las muestras deben transportarse y almacenarse en condiciones que mantengan su integridad, y se deben documentar las responsabilidades y condiciones de almacenamiento.\n\n5. **Capacitaci\u00f3n del Personal**: El muestreo debe ser realizado por personal capacitado y utilizando equipos est\u00e9riles.\n\n6. **Manejo e Identificaci\u00f3n de Muestras**: Se deben establecer procedimientos para la entrega, recepci\u00f3n e identificaci\u00f3n de muestras, as\u00ed como registrar informaci\u00f3n relevante sobre su estado.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades responsables del muestreo y an\u00e1lisis de muestras.\n- **Personal Capacitado**: Individuos que realizan el muestreo y manejo de muestras.\n- **Condiciones de Almacenamiento**: Factores como temperatura y tiempo que afectan la integridad de las muestras.\n- **Sistemas de Aseguramiento de la Calidad**: Protocolos que garantizan la calidad en el proceso de muestreo y an\u00e1lisis. \n\nEste resumen destaca la importancia de seguir procedimientos estandarizados y documentados para asegurar la calidad y la integridad de las muestras en el contexto de laboratorios farmac\u00e9uticos.", "excerpt_keywords": "Keywords: samples, contamination, quality assurance, disposal, testing procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16898a0e-9a65-4267-9ff2-a09f28762b19", "node_type": "4", "metadata": {"page_label": "97", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.3\n\nSamples awaiting testing should be stored under suitable conditions to minimize changes to any microbial population present. Storage conditions should be validated, defined and recorded.\n\n# 8.4\n\nThe packaging and labels of samples may be highly contaminated and should be handled and stored with care so as to avoid any spread of contamination. Disinfection processes applied to the outer container should not affect the integrity of the sample. It should be noted that alcohol is not sporicidal.\n\n# 8.5\n\nSubsampling by the laboratory immediately prior to testing may be required as part of the test method. It may be appropriate that it is performed according to national or international standards, where they exist, or by validated in-house methods. Subsampling procedures should be designed to collect a representative sample.\n\n# 8.6\n\nThere should be a written procedure for the retention and disposal of samples. If sample integrity can be maintained it may be appropriate that samples are stored until the test results are obtained, or longer if required. Laboratory sample portions that are known to be contaminated should be decontaminated prior to being discarded (see section 11.1).\n\n# 9. Disposal of contaminated waste\n\n9.1 The procedures for the disposal of contaminated materials should be designed to minimize the possibility of contaminating the test environment or materials. It is a matter of good laboratory management and should conform to national/international environmental or health and safety regulations.\n\n# 10. Quality assurance of results and quality control of performance\n\n## 10.1 Internal quality control\n\n10.1.1 The laboratory should have a system of internal quality assurance or quality control (e.g. handling deviations, use of spiked samples, replicate testing and participation in proficiency testing, where appropriate) to ensure the consistency of results from day to day and their conformity with defined criteria.\n\n# 11. Testing procedures\n\n11.1 Testing should normally be performed according to procedures described in the national, regional and international pharmacopoeias.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f185b406867551033b08f34815096adb38aa0923beb125cda8cadf1d0470d3b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8.3\n\nSamples awaiting testing should be stored under suitable conditions to minimize changes to any microbial population present. Storage conditions should be validated, defined and recorded.\n\n# 8.4\n\nThe packaging and labels of samples may be highly contaminated and should be handled and stored with care so as to avoid any spread of contamination. Disinfection processes applied to the outer container should not affect the integrity of the sample. It should be noted that alcohol is not sporicidal.\n\n# 8.5\n\nSubsampling by the laboratory immediately prior to testing may be required as part of the test method. It may be appropriate that it is performed according to national or international standards, where they exist, or by validated in-house methods. Subsampling procedures should be designed to collect a representative sample.\n\n# 8.6\n\nThere should be a written procedure for the retention and disposal of samples. If sample integrity can be maintained it may be appropriate that samples are stored until the test results are obtained, or longer if required. Laboratory sample portions that are known to be contaminated should be decontaminated prior to being discarded (see section 11.1).\n\n# 9. Disposal of contaminated waste\n\n9.1 The procedures for the disposal of contaminated materials should be designed to minimize the possibility of contaminating the test environment or materials. It is a matter of good laboratory management and should conform to national/international environmental or health and safety regulations.\n\n# 10. Quality assurance of results and quality control of performance\n\n## 10.1 Internal quality control\n\n10.1.1 The laboratory should have a system of internal quality assurance or quality control (e.g. handling deviations, use of spiked samples, replicate testing and participation in proficiency testing, where appropriate) to ensure the consistency of results from day to day and their conformity with defined criteria.\n\n# 11. Testing procedures\n\n11.1 Testing should normally be performed according to procedures described in the national, regional and international pharmacopoeias.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2123, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "128ac73b-dac6-4511-a87e-e3f9c8b839cb": {"__data__": {"id_": "128ac73b-dac6-4511-a87e-e3f9c8b839cb", "embedding": null, "metadata": {"page_label": "98", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Test reports\n\n12.1 If the result of the enumeration is negative, it should be reported as \u201cnot detected for a defined unit\u201d or \u201cless than the detection limit for a defined unit\u201d. The result should not be given as \u201czero for a defined unit\u201d unless it is a regulatory requirement. Qualitative test results should be reported as \u201cdetected/not detected in a defined quantity or volume\u201d. They may also be expressed as \u201cless than a specified number of organisms for a defined unit\u201d where the specified number of organisms exceeds the detection limit of the method and this has been agreed with the client. In the raw data the result should not be given as zero for a defined unit unless it is a regulatory requirement. A reported value of \u201c0\u201d may be used for data entry and calculations or trend analysis in electronic databases.\n\n12.2 Where an estimate of the uncertainty of the test result is expressed on the test report, any limitations (particularly if the estimate does not include the component contributed by the distribution of microorganisms within the sample) have to be made clear to the client.\n\n# References\n\n1. Good Practices for pharmaceutical quality control laboratories. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 957, 2010, Annex 1.\n\n2. General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.* Geneva, World Health Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.\n\n3. *The International Pharmacopoeia,* Fourth Edition. Geneva, World Health Organization, 2006. Also available on CD-ROM.\n\n4. *The International Pharmacopoeia,* Fourth Edition, First Supplement. Geneva, World Health Organization, 2008. Also available on CD-ROM.\n\n5. ISO/IEC 17025 (2005) *General requirements for the competence of testing and calibration laboratories.*\n\n6. ISO 11133-1 (2000) *Microbiology of food and animal feeding stuffs \u2014 Guidelines on preparation and production of culture media \u2014 Part 1: General guidelines on quality assurance for the preparation of culture media in the laboratory.*\n\n7. ISO 13843 (2000) *Water quality \u2014 Guidance on validation of microbiological methods.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para la elaboraci\u00f3n de informes de pruebas microbiol\u00f3gicas. Se especifica c\u00f3mo deben reportarse los resultados negativos, enfatizando que no deben ser presentados como \"cero\" a menos que sea un requisito regulatorio. Tambi\u00e9n se menciona la importancia de comunicar cualquier limitaci\u00f3n en la estimaci\u00f3n de la incertidumbre de los resultados. Adem\u00e1s, se citan referencias relevantes que respaldan estas pr\u00e1cticas, incluyendo normas ISO y documentos de la OMS.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de reportar un resultado negativo como \"cero\" en un informe de pruebas microbiol\u00f3gicas, y en qu\u00e9 situaciones esto es aceptable?**\n   - Esta pregunta busca profundizar en las consecuencias de un mal reporte y las excepciones a la regla.\n\n2. **\u00bfQu\u00e9 consideraciones deben tener en cuenta los laboratorios al estimar la incertidumbre de los resultados de las pruebas microbiol\u00f3gicas?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos y las limitaciones que deben ser comunicadas al cliente.\n\n3. **\u00bfC\u00f3mo se deben manejar los datos de entrada y an\u00e1lisis de tendencias en bases de datos electr\u00f3nicas cuando se reportan resultados de pruebas microbiol\u00f3gicas?**\n   - Esta pregunta explora el uso de valores reportados y su impacto en el an\u00e1lisis de datos, lo cual no se detalla ampliamente en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que puede no estar disponible en otros documentos o contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento de Muestras**:\n   - Las muestras deben ser almacenadas en condiciones adecuadas para minimizar cambios en la poblaci\u00f3n microbiana.\n   - Es crucial validar y registrar estas condiciones para mantener la integridad de las muestras.\n\n2. **Manejo de Embalajes y Etiquetas**:\n   - Los embalajes y etiquetas pueden estar contaminados y deben ser manipulados con cuidado para evitar la propagaci\u00f3n de la contaminaci\u00f3n.\n   - Se destaca que el alcohol no es esporicida, lo que limita su efectividad en la desinfecci\u00f3n de contenedores externos.\n\n3. **Submuestreo**:\n   - Puede ser necesario realizar submuestreo antes de las pruebas, siguiendo est\u00e1ndares nacionales o internacionales o m\u00e9todos internos validados.\n   - Los procedimientos de submuestreo deben asegurar la recolecci\u00f3n de muestras representativas.\n\n4. **Retenci\u00f3n y Disposici\u00f3n de Muestras**:\n   - Debe existir un procedimiento escrito para la retenci\u00f3n y disposici\u00f3n de muestras.\n   - Las muestras contaminadas deben ser decontaminadas antes de ser desechadas.\n\n5. **Disposici\u00f3n de Desechos Contaminados**:\n   - Los procedimientos de disposici\u00f3n deben minimizar la contaminaci\u00f3n del entorno de prueba y cumplir con regulaciones ambientales y de salud.\n\n6. **Aseguramiento de Calidad**:\n   - Se requiere un sistema de control de calidad interno en el laboratorio para asegurar la consistencia de los resultados y su conformidad con criterios definidos.\n\n7. **Procedimientos de Prueba**:\n   - Las pruebas deben realizarse de acuerdo con procedimientos establecidos en farmacopoeias nacionales, regionales e internacionales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorio**: Entidad responsable de realizar pruebas y manejar muestras.\n- **Muestras**: Elementos que se est\u00e1n probando y que requieren manejo cuidadoso.\n- **Contaminaci\u00f3n**: Riesgo asociado al manejo de muestras y embalajes.\n- **Regulaciones Ambientales y de Salud**: Normativas que deben seguirse en la disposici\u00f3n de desechos contaminados.", "excerpt_keywords": "Keywords: microbiological testing, reporting standards, uncertainty estimation, WHO guidelines, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0888c69c-878b-4e1d-87a3-bf11351f4411", "node_type": "4", "metadata": {"page_label": "98", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Test reports\n\n12.1 If the result of the enumeration is negative, it should be reported as \u201cnot detected for a defined unit\u201d or \u201cless than the detection limit for a defined unit\u201d. The result should not be given as \u201czero for a defined unit\u201d unless it is a regulatory requirement. Qualitative test results should be reported as \u201cdetected/not detected in a defined quantity or volume\u201d. They may also be expressed as \u201cless than a specified number of organisms for a defined unit\u201d where the specified number of organisms exceeds the detection limit of the method and this has been agreed with the client. In the raw data the result should not be given as zero for a defined unit unless it is a regulatory requirement. A reported value of \u201c0\u201d may be used for data entry and calculations or trend analysis in electronic databases.\n\n12.2 Where an estimate of the uncertainty of the test result is expressed on the test report, any limitations (particularly if the estimate does not include the component contributed by the distribution of microorganisms within the sample) have to be made clear to the client.\n\n# References\n\n1. Good Practices for pharmaceutical quality control laboratories. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 957, 2010, Annex 1.\n\n2. General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.* Geneva, World Health Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.\n\n3. *The International Pharmacopoeia,* Fourth Edition. Geneva, World Health Organization, 2006. Also available on CD-ROM.\n\n4. *The International Pharmacopoeia,* Fourth Edition, First Supplement. Geneva, World Health Organization, 2008. Also available on CD-ROM.\n\n5. ISO/IEC 17025 (2005) *General requirements for the competence of testing and calibration laboratories.*\n\n6. ISO 11133-1 (2000) *Microbiology of food and animal feeding stuffs \u2014 Guidelines on preparation and production of culture media \u2014 Part 1: General guidelines on quality assurance for the preparation of culture media in the laboratory.*\n\n7. ISO 13843 (2000) *Water quality \u2014 Guidance on validation of microbiological methods.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d42244ef216de69055b4ec1dcf52c2b45dd29fdc28ef1220803719dd10318a33", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12. Test reports\n\n12.1 If the result of the enumeration is negative, it should be reported as \u201cnot detected for a defined unit\u201d or \u201cless than the detection limit for a defined unit\u201d. The result should not be given as \u201czero for a defined unit\u201d unless it is a regulatory requirement. Qualitative test results should be reported as \u201cdetected/not detected in a defined quantity or volume\u201d. They may also be expressed as \u201cless than a specified number of organisms for a defined unit\u201d where the specified number of organisms exceeds the detection limit of the method and this has been agreed with the client. In the raw data the result should not be given as zero for a defined unit unless it is a regulatory requirement. A reported value of \u201c0\u201d may be used for data entry and calculations or trend analysis in electronic databases.\n\n12.2 Where an estimate of the uncertainty of the test result is expressed on the test report, any limitations (particularly if the estimate does not include the component contributed by the distribution of microorganisms within the sample) have to be made clear to the client.\n\n# References\n\n1. Good Practices for pharmaceutical quality control laboratories. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 957, 2010, Annex 1.\n\n2. General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.* Geneva, World Health Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.\n\n3. *The International Pharmacopoeia,* Fourth Edition. Geneva, World Health Organization, 2006. Also available on CD-ROM.\n\n4. *The International Pharmacopoeia,* Fourth Edition, First Supplement. Geneva, World Health Organization, 2008. Also available on CD-ROM.\n\n5. ISO/IEC 17025 (2005) *General requirements for the competence of testing and calibration laboratories.*\n\n6. ISO 11133-1 (2000) *Microbiology of food and animal feeding stuffs \u2014 Guidelines on preparation and production of culture media \u2014 Part 1: General guidelines on quality assurance for the preparation of culture media in the laboratory.*\n\n7. ISO 13843 (2000) *Water quality \u2014 Guidance on validation of microbiological methods.*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2378, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ebbbcf7a-42f2-458b-b933-93aa7944914e": {"__data__": {"id_": "ebbbcf7a-42f2-458b-b933-93aa7944914e", "embedding": null, "metadata": {"page_label": "99", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8. WHO good manufacturing practices: main principles for pharmaceutical products. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, 2nd updated edition. Good manufacturing practices (GMP) and inspection.* Geneva, World Health Organization, 2007, and subsequent updates, including WHO GMP for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, Annex 6, 2011; and GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, 2011, Annex 5.\n\n# Further reading\n\n- ISO 7218 (2007) *Microbiology of food and animal feeding stuffs \u2014 General requirements and guidance for microbiological examinations.*\n\n- ISO 6887-1 (1999) *Microbiology of food and animal feeding stuffs \u2014 Preparation of test samples, initial suspension and decimal dilutions for microbiological examination \u2014 Part 1: General rules for the preparation of the initial suspension and decimal dilutions.*\n\n- ISO Guide 30 (1992) *Terms and definitions used in connection with reference materials.*\n\n- ISO 9000 (2008) *Quality management systems \u2014 fundamentals and vocabulary.*\n\n- ISO Guide 99 (1993) *International vocabulary of basic and general terms in metrology (VIM).*\n\n- ISO (CIPM):1995. *Guide to the expression of uncertainty in measurements.*\n\n- Draft ISO/DIS 16140. (1999) *Food microbiology. Protocol for the validation of alternative methods.*\n\n- Draft ISO/FDIS (2003) 11133-2. *Microbiology of food and animal feeding stuffs. Guidelines on preparation and production of culture media. Part 2 \u2014 Practical guidelines on performance testing on culture media.*\n\n- EN 12741 (1999). *Biotechnology \u2014 Laboratories for research, development and analysis \u2014 Guidance for biotechnology laboratory operations.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las Buenas Pr\u00e1cticas de Manufactura (BPM) seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS), destacando los principios fundamentales para la producci\u00f3n de productos farmac\u00e9uticos. Se menciona la importancia de la calidad en la fabricaci\u00f3n y se hace referencia a varias normas ISO relacionadas con la microbiolog\u00eda y la gesti\u00f3n de calidad. Adem\u00e1s, se incluyen gu\u00edas sobre la preparaci\u00f3n de medios de cultivo y la validaci\u00f3n de m\u00e9todos alternativos en microbiolog\u00eda.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales principios de las Buenas Pr\u00e1cticas de Manufactura (BPM) seg\u00fan la OMS, y c\u00f3mo se aplican a los productos farmac\u00e9uticos est\u00e9riles y no est\u00e9riles?**\n   - Esta pregunta busca una respuesta detallada sobre los principios espec\u00edficos de BPM y su aplicaci\u00f3n en diferentes tipos de productos farmac\u00e9uticos, que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 actualizaciones se han realizado en las gu\u00edas de BPM desde la publicaci\u00f3n de la segunda edici\u00f3n de \"Quality assurance of pharmaceuticals\" en 2007?**\n   - Esta pregunta se enfoca en las modificaciones y mejoras en las gu\u00edas de BPM desde 2007, lo que puede no estar documentado en otras publicaciones.\n\n3. **\u00bfC\u00f3mo se relacionan las normas ISO mencionadas en el documento con la implementaci\u00f3n de Buenas Pr\u00e1cticas de Manufactura en la industria farmac\u00e9utica?**\n   - Esta pregunta busca una conexi\u00f3n espec\u00edfica entre las normas ISO y las BPM, proporcionando un an\u00e1lisis que puede no estar disponible en otras fuentes.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre las Buenas Pr\u00e1cticas de Manufactura (BPM) para productos farmac\u00e9uticos, enfatizando la importancia de la calidad y la seguridad en la producci\u00f3n. Se mencionan varias normas ISO que complementan estas pr\u00e1cticas, abordando aspectos de microbiolog\u00eda y gesti\u00f3n de calidad. Las actualizaciones y anexos espec\u00edficos de las gu\u00edas de BPM son cruciales para asegurar que los est\u00e1ndares se mantengan al d\u00eda con los avances en la industria.", "prev_section_summary": "### Temas Clave\n\n1. **Reportes de Resultados Negativos**: Los resultados negativos en pruebas microbiol\u00f3gicas deben ser reportados como \"no detectado para una unidad definida\" o \"menos que el l\u00edmite de detecci\u00f3n para una unidad definida\". No se debe utilizar \"cero\" a menos que sea un requisito regulatorio.\n\n2. **Resultados Cualitativos**: Deben ser reportados como \"detectado/no detectado en una cantidad o volumen definido\". Tambi\u00e9n pueden expresarse como \"menos de un n\u00famero espec\u00edfico de organismos para una unidad definida\", siempre que este n\u00famero supere el l\u00edmite de detecci\u00f3n y haya sido acordado con el cliente.\n\n3. **Manejo de Datos en Bases Electr\u00f3nicas**: Un valor reportado de \"0\" puede ser utilizado para la entrada de datos y c\u00e1lculos o an\u00e1lisis de tendencias en bases de datos electr\u00f3nicas, pero no debe ser utilizado en el informe a menos que sea un requisito regulatorio.\n\n4. **Estimaci\u00f3n de Incertidumbre**: Si se expresa una estimaci\u00f3n de la incertidumbre del resultado de la prueba, se deben aclarar las limitaciones, especialmente si la estimaci\u00f3n no incluye la variabilidad de los microorganismos en la muestra.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **ISO/IEC 17025**: Norma que establece requisitos para la competencia de laboratorios de ensayo y calibraci\u00f3n.\n- **ISO 11133-1**: Norma que proporciona directrices sobre la preparaci\u00f3n y producci\u00f3n de medios de cultivo en microbiolog\u00eda.\n- **ISO 13843**: Norma que ofrece orientaci\u00f3n sobre la validaci\u00f3n de m\u00e9todos microbiol\u00f3gicos en calidad del agua.\n\n### Referencias\n\nSe citan varias referencias relevantes que respaldan las pr\u00e1cticas recomendadas, incluyendo informes de la OMS y normas ISO.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Manufactura, farmac\u00e9uticos, OMS, normas ISO, calidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0ad953cb-de46-4ef8-972c-06d1b64601d3", "node_type": "4", "metadata": {"page_label": "99", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8. WHO good manufacturing practices: main principles for pharmaceutical products. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, 2nd updated edition. Good manufacturing practices (GMP) and inspection.* Geneva, World Health Organization, 2007, and subsequent updates, including WHO GMP for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, Annex 6, 2011; and GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, 2011, Annex 5.\n\n# Further reading\n\n- ISO 7218 (2007) *Microbiology of food and animal feeding stuffs \u2014 General requirements and guidance for microbiological examinations.*\n\n- ISO 6887-1 (1999) *Microbiology of food and animal feeding stuffs \u2014 Preparation of test samples, initial suspension and decimal dilutions for microbiological examination \u2014 Part 1: General rules for the preparation of the initial suspension and decimal dilutions.*\n\n- ISO Guide 30 (1992) *Terms and definitions used in connection with reference materials.*\n\n- ISO 9000 (2008) *Quality management systems \u2014 fundamentals and vocabulary.*\n\n- ISO Guide 99 (1993) *International vocabulary of basic and general terms in metrology (VIM).*\n\n- ISO (CIPM):1995. *Guide to the expression of uncertainty in measurements.*\n\n- Draft ISO/DIS 16140. (1999) *Food microbiology. Protocol for the validation of alternative methods.*\n\n- Draft ISO/FDIS (2003) 11133-2. *Microbiology of food and animal feeding stuffs. Guidelines on preparation and production of culture media. Part 2 \u2014 Practical guidelines on performance testing on culture media.*\n\n- EN 12741 (1999). *Biotechnology \u2014 Laboratories for research, development and analysis \u2014 Guidance for biotechnology laboratory operations.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b4cf3e374f45cfa3e399891c5f609390ce818bf3250f5770c26c9ad0a6135626", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8. WHO good manufacturing practices: main principles for pharmaceutical products. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, 2nd updated edition. Good manufacturing practices (GMP) and inspection.* Geneva, World Health Organization, 2007, and subsequent updates, including WHO GMP for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, Annex 6, 2011; and GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, 2011, Annex 5.\n\n# Further reading\n\n- ISO 7218 (2007) *Microbiology of food and animal feeding stuffs \u2014 General requirements and guidance for microbiological examinations.*\n\n- ISO 6887-1 (1999) *Microbiology of food and animal feeding stuffs \u2014 Preparation of test samples, initial suspension and decimal dilutions for microbiological examination \u2014 Part 1: General rules for the preparation of the initial suspension and decimal dilutions.*\n\n- ISO Guide 30 (1992) *Terms and definitions used in connection with reference materials.*\n\n- ISO 9000 (2008) *Quality management systems \u2014 fundamentals and vocabulary.*\n\n- ISO Guide 99 (1993) *International vocabulary of basic and general terms in metrology (VIM).*\n\n- ISO (CIPM):1995. *Guide to the expression of uncertainty in measurements.*\n\n- Draft ISO/DIS 16140. (1999) *Food microbiology. Protocol for the validation of alternative methods.*\n\n- Draft ISO/FDIS (2003) 11133-2. *Microbiology of food and animal feeding stuffs. Guidelines on preparation and production of culture media. Part 2 \u2014 Practical guidelines on performance testing on culture media.*\n\n- EN 12741 (1999). *Biotechnology \u2014 Laboratories for research, development and analysis \u2014 Guidance for biotechnology laboratory operations.*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2083, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0f3680c6-556c-490d-a69b-ebbcbbb722d1": {"__data__": {"id_": "0f3680c6-556c-490d-a69b-ebbcbbb722d1", "embedding": null, "metadata": {"page_label": "100", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Examples of zones in which operations could be carried out\n\nThe zones are designed as the following grades, during the installation and monitoring can be carried out, e.g. through appropriate air supply.\n\n| Zone | Installation grade | Proposed |\n| - | - | - |\n| Sample receipt | Unclassified | Unclassified |\n| Media preparation | Unclassified | Unclassified |\n| Autoclave loading | Unclassified | Unclassified |\n| Autoclave unloading, inside the sterility testing area | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 UDAF | Grade A | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to UDAF | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 isolator | Grade A (NVP and microbiology only) | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to isolator | Unclassified | Unclassified |\n| Incubator | Unclassified | Unclassified |\n| Enumeration | Unclassifieda | Unclassifieda |\n| Decontamination | Unclassified | Unclassified |\n\n\ncfu, colony-forming unit.  \n<sup>a</sup> Critical steps should be done under laminar flow.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta ejemplos de zonas en las que se pueden llevar a cabo operaciones relacionadas con pruebas de esterilidad. Estas zonas est\u00e1n clasificadas seg\u00fan diferentes grados de instalaci\u00f3n y proponen est\u00e1ndares de calidad del aire, medidos en unidades de formaci\u00f3n de colonias (cfu). Las zonas incluyen desde la recepci\u00f3n de muestras hasta la preparaci\u00f3n de medios y la carga y descarga de autoclaves, con un enfoque particular en las \u00e1reas de pruebas de esterilidad.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 grado de instalaci\u00f3n se requiere para la descarga del autoclave dentro del \u00e1rea de pruebas de esterilidad?**\n   - Respuesta: La descarga del autoclave dentro del \u00e1rea de pruebas de esterilidad requiere un grado B, con un est\u00e1ndar de calidad del aire de ISO 5 (turbulento) y menos de 10 cfu/m\u00b3.\n\n2. **\u00bfCu\u00e1les son las especificaciones de calidad del aire para las pruebas de esterilidad en un aislador?**\n   - Respuesta: Las pruebas de esterilidad en un aislador requieren un grado A (solo para NVP y microbiolog\u00eda), con un est\u00e1ndar de calidad del aire de ISO 5 (UDAF) y menos de 1 cfu/m\u00b3.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar durante los pasos cr\u00edticos en la enumeraci\u00f3n?**\n   - Respuesta: Durante los pasos cr\u00edticos en la enumeraci\u00f3n, se deben realizar bajo flujo laminar, ya que se indica que son pasos cr\u00edticos que requieren un ambiente controlado.", "prev_section_summary": "### Temas Clave\n\n1. **Buenas Pr\u00e1cticas de Manufactura (BPM)**: Se destacan los principios fundamentales de las BPM seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS) para la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n\n2. **Calidad en la Fabricaci\u00f3n**: Se enfatiza la importancia de mantener altos est\u00e1ndares de calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n\n3. **Normas ISO**: Se mencionan varias normas ISO relevantes que complementan las BPM, abarcando aspectos de microbiolog\u00eda, gesti\u00f3n de calidad y metrolog\u00eda.\n\n4. **Actualizaciones de Gu\u00edas**: Se hace referencia a las actualizaciones de las gu\u00edas de BPM desde 2007, incluyendo anexos espec\u00edficos que abordan temas como sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado para productos farmac\u00e9uticos no est\u00e9riles.\n\n5. **Microbiolog\u00eda y Validaci\u00f3n**: Se incluyen gu\u00edas sobre la preparaci\u00f3n de medios de cultivo y la validaci\u00f3n de m\u00e9todos alternativos en microbiolog\u00eda, lo que es crucial para asegurar la calidad en la producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las BPM y las gu\u00edas relacionadas.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Cuerpo que establece normas internacionales, mencionadas en el documento, que son relevantes para la BPM.\n- **Documentos y Normas ISO**: Incluyen ISO 7218, ISO 6887-1, ISO 9000, entre otros, que proporcionan directrices sobre microbiolog\u00eda y gesti\u00f3n de calidad.\n- **WHO Technical Report Series**: Serie de informes t\u00e9cnicos de la OMS que incluye las gu\u00edas de BPM y sus actualizaciones.\n\n### Resumen General\n\nEl documento de la OMS aborda las Buenas Pr\u00e1cticas de Manufactura (BPM) para productos farmac\u00e9uticos, subrayando la importancia de la calidad y la seguridad en la producci\u00f3n. Se mencionan diversas normas ISO que respaldan estas pr\u00e1cticas, as\u00ed como actualizaciones en las gu\u00edas de BPM desde 2007. Adem\u00e1s, se incluyen directrices sobre microbiolog\u00eda y validaci\u00f3n de m\u00e9todos, esenciales para mantener est\u00e1ndares de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: sterility testing, installation grade, air quality standards, Good Manufacturing Practices, ISO standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "788bc9cc-9680-4e71-ab52-953614b5a72c", "node_type": "4", "metadata": {"page_label": "100", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Examples of zones in which operations could be carried out\n\nThe zones are designed as the following grades, during the installation and monitoring can be carried out, e.g. through appropriate air supply.\n\n| Zone | Installation grade | Proposed |\n| - | - | - |\n| Sample receipt | Unclassified | Unclassified |\n| Media preparation | Unclassified | Unclassified |\n| Autoclave loading | Unclassified | Unclassified |\n| Autoclave unloading, inside the sterility testing area | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 UDAF | Grade A | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to UDAF | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 isolator | Grade A (NVP and microbiology only) | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to isolator | Unclassified | Unclassified |\n| Incubator | Unclassified | Unclassified |\n| Enumeration | Unclassifieda | Unclassifieda |\n| Decontamination | Unclassified | Unclassified |\n\n\ncfu, colony-forming unit.  \n<sup>a</sup> Critical steps should be done under laminar flow.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a038c48ec03288eb16937280f007ec2720619d45b42c69ef5b6b422449baf874", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 1\n\n## Examples of zones in which operations could be carried out\n\nThe zones are designed as the following grades, during the installation and monitoring can be carried out, e.g. through appropriate air supply.\n\n| Zone | Installation grade | Proposed |\n| - | - | - |\n| Sample receipt | Unclassified | Unclassified |\n| Media preparation | Unclassified | Unclassified |\n| Autoclave loading | Unclassified | Unclassified |\n| Autoclave unloading, inside the sterility testing area | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 UDAF | Grade A | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to UDAF | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 isolator | Grade A (NVP and microbiology only) | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to isolator | Unclassified | Unclassified |\n| Incubator | Unclassified | Unclassified |\n| Enumeration | Unclassifieda | Unclassifieda |\n| Decontamination | Unclassified | Unclassified |\n\n\ncfu, colony-forming unit.  \n<sup>a</sup> Critical steps should be done under laminar flow.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1101, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c5488713-7813-4cf0-bf40-be4dc52c5c5c": {"__data__": {"id_": "c5488713-7813-4cf0-bf40-be4dc52c5c5c", "embedding": null, "metadata": {"page_label": "101", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Examples of maintenance of equipment\n\nThis information is provided as an example and the frequency will be based on the need, type and previous performance of the equipment and on the recommendations in suppliers\u2019 manuals.\n\n| Type of equipment | Requirement | Suggested frequency | |\n| - | - | - | - |\n| \u2014 Incubators \u2014 Fridges \u2014 Freezers, ovens | Clean and disinfect internal surfaces | \u2014 Monthly \u2014 When required (e.g. every 3 months) \u2014 When required (e.g. annually) | |\n| | Water-baths | Empty, clean, disinfect and refill | \u2014 Monthly, or every 6 months if biocide used |\n| | Centrifuges | \u2014 Service | \u2014 Annually |\n| \u2014 Clean and disinfect | | \u2014 Each use | |\n| Autoclaves | \u2014 Make visual checks of gasket, clean/drain chamber | \u2014 Regularly, as recommended by manufacturer | |\n| | \u2014 Full service | \u2014 Annually or as recommended by manufacturer | |\n| | \u2014 Safety check of pressure vessel | \u2014 Annually | |\n| Safety cabinets unidirectional cabinets | Full service and mechanical check | Annually or as recommended by manufacturer | |\n| Microscopes | Full maintenance service | Annually | |\n| pH meters | Clean electrode | Each use | |\n| Balances, gravimetric diluters | \u2014 Clean | \u2014 Each use | |\n| | \u2014 Service | \u2014 Annually | |\n| Stills | Clean and descale | As required (e.g. every 3 months) | |\n| De-ionizers, reverse osmosis units | Replace cartridge/membrane | As recommended by manufacturer | |\n| Anaerobic jars | Clean/disinfect | After each use | |\n| Media dispensers, volumetric equipment, pipettes and general service equipment | Decontaminate, clean and sterilize as appropriate | Each use | |\n| Spiral platers | \u2014 Service | \u2014 Annually | |\n| | \u2014 Decontaminate, clean and sterilize | \u2014 Each use | |\n| Laboratory | \u2014 Clean and disinfect working surfaces | \u2014 Daily and during use | |\n| | \u2014 Clean floors, disinfect sinks and basins | \u2014 Daily | |\n| | \u2014 Clean and disinfect other surfaces | \u2014 Every 3 months | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 961) que proporciona ejemplos de mantenimiento de equipos en laboratorios. Se detalla la frecuencia y los requisitos de mantenimiento para diversos tipos de equipos, como incubadoras, autoclaves, microscopios, y otros. La informaci\u00f3n se basa en la necesidad, el tipo de equipo, su rendimiento previo y las recomendaciones de los manuales de los proveedores.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la frecuencia recomendada para limpiar y desinfectar las superficies internas de incubadoras, refrigeradores y congeladores?**\n   - Respuesta: Se recomienda limpiar y desinfectar las superficies internas de estos equipos mensualmente, cuando sea necesario (por ejemplo, cada 3 meses) o anualmente.\n\n2. **\u00bfQu\u00e9 procedimiento se sugiere para el mantenimiento de los autoclaves y con qu\u00e9 frecuencia debe realizarse?**\n   - Respuesta: Para los autoclaves, se sugiere hacer revisiones visuales del sello, limpiar y drenar la c\u00e1mara regularmente seg\u00fan lo recomendado por el fabricante, realizar un servicio completo anualmente o seg\u00fan lo indicado por el fabricante, y realizar una verificaci\u00f3n de seguridad del recipiente a presi\u00f3n anualmente.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse con los frascos anaer\u00f3bicos despu\u00e9s de cada uso?**\n   - Respuesta: Los frascos anaer\u00f3bicos deben limpiarse y desinfectarse despu\u00e9s de cada uso.\n\n### Resumen de Nivel Superior\n\nEl ap\u00e9ndice proporciona directrices sobre el mantenimiento de equipos de laboratorio, enfatizando la importancia de seguir las recomendaciones de los fabricantes y ajustar la frecuencia de mantenimiento seg\u00fan el uso y el rendimiento del equipo. Se abordan diversos tipos de equipos y se especifican las acciones de limpieza, desinfecci\u00f3n y servicio necesarias para garantizar su correcto funcionamiento y seguridad.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Zonas de operaci\u00f3n**: El documento describe diferentes zonas donde se pueden realizar operaciones relacionadas con pruebas de esterilidad, cada una con un grado de instalaci\u00f3n espec\u00edfico.\n\n2. **Clasificaci\u00f3n de zonas**:\n   - **Unclassified**: Zonas como recepci\u00f3n de muestras, preparaci\u00f3n de medios, carga y descarga de autoclaves, incubadoras, enumeraci\u00f3n y decontaminaci\u00f3n no tienen una clasificaci\u00f3n espec\u00edfica.\n   - **Grade A**: Se requiere para pruebas de esterilidad en un aislador y UDAF, con est\u00e1ndares de calidad del aire muy estrictos.\n   - **Grade B**: Aplicable a la descarga del autoclave y pruebas de esterilidad en el fondo de UDAF, con est\u00e1ndares de calidad del aire menos estrictos que Grade A.\n\n3. **Est\u00e1ndares de calidad del aire**: Se especifican los est\u00e1ndares de calidad del aire en t\u00e9rminos de unidades de formaci\u00f3n de colonias (cfu), que son cr\u00edticos para garantizar la esterilidad en las operaciones.\n\n4. **Precauciones en pasos cr\u00edticos**: Se menciona que los pasos cr\u00edticos en la enumeraci\u00f3n deben realizarse bajo flujo laminar para mantener un ambiente controlado.\n\n5. **Entidades**:\n   - **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n   - **cfu (unidad formadora de colonias)**: Medida utilizada para evaluar la calidad del aire en las zonas de operaci\u00f3n.\n\nEste resumen destaca la importancia de la clasificaci\u00f3n de las zonas y los est\u00e1ndares de calidad del aire en las operaciones de pruebas de esterilidad, as\u00ed como las precauciones necesarias para mantener la integridad del proceso.", "excerpt_keywords": "Keywords: maintenance, laboratory equipment, cleaning, disinfection, frequency"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24c480c9-75f4-44b8-8cc8-f800d35474d7", "node_type": "4", "metadata": {"page_label": "101", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Examples of maintenance of equipment\n\nThis information is provided as an example and the frequency will be based on the need, type and previous performance of the equipment and on the recommendations in suppliers\u2019 manuals.\n\n| Type of equipment | Requirement | Suggested frequency | |\n| - | - | - | - |\n| \u2014 Incubators \u2014 Fridges \u2014 Freezers, ovens | Clean and disinfect internal surfaces | \u2014 Monthly \u2014 When required (e.g. every 3 months) \u2014 When required (e.g. annually) | |\n| | Water-baths | Empty, clean, disinfect and refill | \u2014 Monthly, or every 6 months if biocide used |\n| | Centrifuges | \u2014 Service | \u2014 Annually |\n| \u2014 Clean and disinfect | | \u2014 Each use | |\n| Autoclaves | \u2014 Make visual checks of gasket, clean/drain chamber | \u2014 Regularly, as recommended by manufacturer | |\n| | \u2014 Full service | \u2014 Annually or as recommended by manufacturer | |\n| | \u2014 Safety check of pressure vessel | \u2014 Annually | |\n| Safety cabinets unidirectional cabinets | Full service and mechanical check | Annually or as recommended by manufacturer | |\n| Microscopes | Full maintenance service | Annually | |\n| pH meters | Clean electrode | Each use | |\n| Balances, gravimetric diluters | \u2014 Clean | \u2014 Each use | |\n| | \u2014 Service | \u2014 Annually | |\n| Stills | Clean and descale | As required (e.g. every 3 months) | |\n| De-ionizers, reverse osmosis units | Replace cartridge/membrane | As recommended by manufacturer | |\n| Anaerobic jars | Clean/disinfect | After each use | |\n| Media dispensers, volumetric equipment, pipettes and general service equipment | Decontaminate, clean and sterilize as appropriate | Each use | |\n| Spiral platers | \u2014 Service | \u2014 Annually | |\n| | \u2014 Decontaminate, clean and sterilize | \u2014 Each use | |\n| Laboratory | \u2014 Clean and disinfect working surfaces | \u2014 Daily and during use | |\n| | \u2014 Clean floors, disinfect sinks and basins | \u2014 Daily | |\n| | \u2014 Clean and disinfect other surfaces | \u2014 Every 3 months | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "515b46b1cd9a37e3e4bf9b4d7b135c86c30c315e906682ebef86ea7085501976", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 2\n\n## Examples of maintenance of equipment\n\nThis information is provided as an example and the frequency will be based on the need, type and previous performance of the equipment and on the recommendations in suppliers\u2019 manuals.\n\n| Type of equipment | Requirement | Suggested frequency | |\n| - | - | - | - |\n| \u2014 Incubators \u2014 Fridges \u2014 Freezers, ovens | Clean and disinfect internal surfaces | \u2014 Monthly \u2014 When required (e.g. every 3 months) \u2014 When required (e.g. annually) | |\n| | Water-baths | Empty, clean, disinfect and refill | \u2014 Monthly, or every 6 months if biocide used |\n| | Centrifuges | \u2014 Service | \u2014 Annually |\n| \u2014 Clean and disinfect | | \u2014 Each use | |\n| Autoclaves | \u2014 Make visual checks of gasket, clean/drain chamber | \u2014 Regularly, as recommended by manufacturer | |\n| | \u2014 Full service | \u2014 Annually or as recommended by manufacturer | |\n| | \u2014 Safety check of pressure vessel | \u2014 Annually | |\n| Safety cabinets unidirectional cabinets | Full service and mechanical check | Annually or as recommended by manufacturer | |\n| Microscopes | Full maintenance service | Annually | |\n| pH meters | Clean electrode | Each use | |\n| Balances, gravimetric diluters | \u2014 Clean | \u2014 Each use | |\n| | \u2014 Service | \u2014 Annually | |\n| Stills | Clean and descale | As required (e.g. every 3 months) | |\n| De-ionizers, reverse osmosis units | Replace cartridge/membrane | As recommended by manufacturer | |\n| Anaerobic jars | Clean/disinfect | After each use | |\n| Media dispensers, volumetric equipment, pipettes and general service equipment | Decontaminate, clean and sterilize as appropriate | Each use | |\n| Spiral platers | \u2014 Service | \u2014 Annually | |\n| | \u2014 Decontaminate, clean and sterilize | \u2014 Each use | |\n| Laboratory | \u2014 Clean and disinfect working surfaces | \u2014 Daily and during use | |\n| | \u2014 Clean floors, disinfect sinks and basins | \u2014 Daily | |\n| | \u2014 Clean and disinfect other surfaces | \u2014 Every 3 months | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1924, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "30b9505c-7f22-4880-a817-b50f40b84fb9": {"__data__": {"id_": "30b9505c-7f22-4880-a817-b50f40b84fb9", "embedding": null, "metadata": {"page_label": "102", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 3\n\n## Examples of calibration checks and intervals for different laboratory equipment\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Reference thermometers (liquid-in-glass) | Full traceable recalibration Single point (e.g. ice-point check) | Every 3 years Annually |\n| Reference thermocouples | Full traceable recalibration Check against reference thermometer | Every 3 years Annually |\n| Working thermometers and working thermocouples | Check against reference thermometer at ice-point and/or working temperature range | Annually |\n| Balances | Full traceable calibration | Annually |\n| Calibration weights | Full traceable calibration | Annually |\n| Check weight(s) | Check against calibrated weight or check on balance immediately following traceable calibration | Annually |\n| Volumetric glassware | Gravimetric calibration to required tolerance | Annually |\n| Microscopes | Traceable calibration of stage micrometer (where appropriate) | Initially |\n| Hygrometers | Traceable calibration | Annually |\n| Centrifuges | Traceable calibration or check against an independent tachometer, as appropriate | Annually |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (Serie 961) que presenta ejemplos de controles de calibraci\u00f3n y sus intervalos para diferentes equipos de laboratorio. Se destaca que la frecuencia de calibraci\u00f3n debe basarse en la necesidad, el tipo de equipo, su rendimiento previo y su criticidad. Se proporciona una tabla que detalla el tipo de equipo, los requisitos de calibraci\u00f3n y la frecuencia sugerida para cada uno.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 factores deben considerarse al determinar la frecuencia de calibraci\u00f3n de los equipos de laboratorio seg\u00fan el documento?**\n   - Respuesta: La frecuencia de calibraci\u00f3n debe basarse en la necesidad, el tipo de equipo, el rendimiento previo y la criticidad del equipo.\n\n2. **\u00bfCu\u00e1l es la diferencia en la frecuencia de calibraci\u00f3n entre term\u00f3metros de referencia y term\u00f3metros de trabajo seg\u00fan el ap\u00e9ndice?**\n   - Respuesta: Los term\u00f3metros de referencia requieren recalibraci\u00f3n completa y trazable cada 3 a\u00f1os, mientras que los term\u00f3metros de trabajo deben ser verificados anualmente contra un term\u00f3metro de referencia.\n\n3. **\u00bfQu\u00e9 tipo de calibraci\u00f3n se sugiere para los microscopios y en qu\u00e9 momento debe realizarse?**\n   - Respuesta: Se sugiere una calibraci\u00f3n trazable del micr\u00f3metro de etapa (donde sea apropiado) y debe realizarse inicialmente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Secci\u00f3n:** Ap\u00e9ndice 2 - Ejemplos de mantenimiento de equipos\n\n**Temas Clave:**\n1. **Mantenimiento de Equipos de Laboratorio:** Se proporciona una gu\u00eda sobre la frecuencia y los requisitos de mantenimiento para diversos equipos de laboratorio.\n2. **Frecuencia de Mantenimiento:** La frecuencia de mantenimiento se basa en la necesidad, el tipo de equipo, su rendimiento previo y las recomendaciones de los manuales de los proveedores.\n3. **Tipos de Equipos y Requisitos:**\n   - **Incubadoras, Refrigeradores, Congeladores y Hornos:** Limpieza y desinfecci\u00f3n mensual, trimestral o anual.\n   - **Ba\u00f1os de Agua:** Vaciar, limpiar, desinfectar y rellenar mensualmente o cada seis meses si se utiliza biocida.\n   - **Centr\u00edfugas:** Servicio anual.\n   - **Autoclaves:** Revisiones visuales, limpieza y drenaje regular, servicio completo anual y verificaci\u00f3n de seguridad anual.\n   - **Cabinetes de Seguridad y Microscopios:** Servicio completo y chequeo mec\u00e1nico anual.\n   - **Electrodos de pH y Balanzas:** Limpieza y servicio anuales.\n   - **Frascos Anaer\u00f3bicos:** Limpieza y desinfecci\u00f3n despu\u00e9s de cada uso.\n   - **Laboratorio:** Limpieza y desinfecci\u00f3n diaria de superficies de trabajo, suelos y otros espacios cada tres meses.\n\n**Entidades:**\n- **Equipos de Laboratorio:** Incubadoras, refrigeradores, congeladores, autoclaves, microscopios, pH metros, balanzas, frascos anaer\u00f3bicos, etc.\n- **Requisitos de Mantenimiento:** Limpieza, desinfecci\u00f3n, servicio, chequeo mec\u00e1nico, reemplazo de cartuchos/membranas.\n- **Frecuencia Recomendada:** Mensual, trimestral, anual, seg\u00fan el uso y las recomendaciones del fabricante.\n\n**Importancia:** Este ap\u00e9ndice enfatiza la necesidad de seguir las recomendaciones de los fabricantes y ajustar la frecuencia de mantenimiento seg\u00fan el uso y el rendimiento del equipo para garantizar su correcto funcionamiento y seguridad.", "excerpt_keywords": "Keywords: calibration, laboratory equipment, traceable, maintenance frequency, technical report"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "597feba6-d4a7-46a7-9b4d-a18e03a5f246", "node_type": "4", "metadata": {"page_label": "102", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 3\n\n## Examples of calibration checks and intervals for different laboratory equipment\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Reference thermometers (liquid-in-glass) | Full traceable recalibration Single point (e.g. ice-point check) | Every 3 years Annually |\n| Reference thermocouples | Full traceable recalibration Check against reference thermometer | Every 3 years Annually |\n| Working thermometers and working thermocouples | Check against reference thermometer at ice-point and/or working temperature range | Annually |\n| Balances | Full traceable calibration | Annually |\n| Calibration weights | Full traceable calibration | Annually |\n| Check weight(s) | Check against calibrated weight or check on balance immediately following traceable calibration | Annually |\n| Volumetric glassware | Gravimetric calibration to required tolerance | Annually |\n| Microscopes | Traceable calibration of stage micrometer (where appropriate) | Initially |\n| Hygrometers | Traceable calibration | Annually |\n| Centrifuges | Traceable calibration or check against an independent tachometer, as appropriate | Annually |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b60cb2756c1ac336834c439d004c9a20c23c825cbf7acf5aa449569f5cf70336", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 3\n\n## Examples of calibration checks and intervals for different laboratory equipment\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Reference thermometers (liquid-in-glass) | Full traceable recalibration Single point (e.g. ice-point check) | Every 3 years Annually |\n| Reference thermocouples | Full traceable recalibration Check against reference thermometer | Every 3 years Annually |\n| Working thermometers and working thermocouples | Check against reference thermometer at ice-point and/or working temperature range | Annually |\n| Balances | Full traceable calibration | Annually |\n| Calibration weights | Full traceable calibration | Annually |\n| Check weight(s) | Check against calibrated weight or check on balance immediately following traceable calibration | Annually |\n| Volumetric glassware | Gravimetric calibration to required tolerance | Annually |\n| Microscopes | Traceable calibration of stage micrometer (where appropriate) | Initially |\n| Hygrometers | Traceable calibration | Annually |\n| Centrifuges | Traceable calibration or check against an independent tachometer, as appropriate | Annually |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1305, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2060f4b8-afae-44bc-9689-b6a18dbcf4c3": {"__data__": {"id_": "2060f4b8-afae-44bc-9689-b6a18dbcf4c3", "embedding": null, "metadata": {"page_label": "103", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n\n## Examples of equipment qualification and monitoring\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Temperature-controlled equipment (incubators, baths, fridges, freezers) | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Daily/each use |\n| Sterilizing ovens | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Autoclaves | \u2014 Establish characteristics for loads/cycles \u2014 Monitor temperature/pressure/time | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Grade A areas used for sterility testing: \u2022 safety unidirectional cabinets \u2022 isolators | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, every year and after repair/modification \u2014 Each use \u2014 6-monthly \u2014 6-monthly |\n| Unidirectional cabinets | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, and after repair/modification \u2014 Weekly \u2014 6-monthly \u2014 6-monthly |\n| Timers | Check against national time signal | Annually |\n| Microscopes | Check alignment | Daily/each use |\n| pH meters | Adjust using at least two buffers of suitable quality | Daily/each use |\n| Balances | Check zero, and reading against check weight | Daily/each use |\n| De-ionizers and reverse osmosis units | \u2014 Check conductivity \u2014 Check for microbial contamination | \u2014 Weekly \u2014 Monthly |\n| Gravimetric diluters | \u2014 Check weight of volume dispensed \u2014 Check dilution ratio | \u2014 Daily \u2014 Daily |\n| Media dispensers | Check volume dispensed | Each adjustment or replacement |\n| Pipettors/pipettes | Check accuracy and precision of volume dispensed | Regularly (to be defined by taking account of the frequency and nature of use) |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta ejemplos de calificaci\u00f3n y monitoreo de equipos utilizados en laboratorios y entornos de investigaci\u00f3n. Se detalla el tipo de equipo, los requisitos necesarios para su funcionamiento adecuado y la frecuencia sugerida para las verificaciones y mantenimientos. La informaci\u00f3n est\u00e1 dise\u00f1ada para asegurar la estabilidad, uniformidad y precisi\u00f3n de los equipos cr\u00edticos, lo que es esencial para garantizar la calidad y la seguridad en los procesos de investigaci\u00f3n y pruebas.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de monitoreo se recomienda para los equipos de temperatura controlada, y con qu\u00e9 frecuencia se debe realizar?**\n   - Respuesta: Se recomienda establecer la estabilidad y uniformidad de la temperatura y monitorear la temperatura. La frecuencia sugerida es inicialmente cada 2 a\u00f1os y despu\u00e9s de reparaciones o modificaciones, y diariamente o en cada uso.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para los gabinetes unidireccionales y qu\u00e9 frecuencia de monitoreo se sugiere?**\n   - Respuesta: Los requisitos incluyen establecer el rendimiento, monitoreo microbiol\u00f3gico, monitoreo del flujo de aire y pruebas de integridad de los filtros HEPA. La frecuencia sugerida es inicialmente y despu\u00e9s de reparaciones o modificaciones, semanalmente, cada 6 meses y cada 6 meses, respectivamente.\n\n3. **\u00bfQu\u00e9 procedimientos se deben seguir para verificar la precisi\u00f3n de los pipetores/pipetas y con qu\u00e9 frecuencia se debe realizar esta verificaci\u00f3n?**\n   - Respuesta: Se debe verificar la precisi\u00f3n y exactitud del volumen dispensado. La frecuencia de esta verificaci\u00f3n debe definirse regularmente, teniendo en cuenta la frecuencia y la naturaleza del uso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl ap\u00e9ndice 3 del Informe T\u00e9cnico de la OMS (Serie 961) se centra en los controles de calibraci\u00f3n y los intervalos recomendados para diversos equipos de laboratorio. Los temas clave incluyen:\n\n1. **Frecuencia de Calibraci\u00f3n**: La frecuencia de calibraci\u00f3n debe determinarse en funci\u00f3n de la necesidad, el tipo de equipo, el rendimiento previo y la criticidad del mismo.\n\n2. **Tipos de Equipos y Requisitos**: Se presenta una tabla que clasifica diferentes tipos de equipos de laboratorio, sus requisitos de calibraci\u00f3n y la frecuencia sugerida para cada uno. Los equipos mencionados incluyen:\n   - Term\u00f3metros de referencia\n   - Termocuplas de referencia\n   - Term\u00f3metros y termocuplas de trabajo\n   - Balanzas\n   - Pesas de calibraci\u00f3n\n   - Vidrio volum\u00e9trico\n   - Microsc\u00f3pios\n   - Higr\u00f3metros\n   - Centr\u00edfugas\n\n3. **Intervalos de Calibraci\u00f3n**: La tabla sugiere diferentes intervalos de calibraci\u00f3n, que var\u00edan desde anualmente hasta cada tres a\u00f1os, dependiendo del tipo de equipo.\n\n4. **Calibraci\u00f3n Trazable**: Se enfatiza la importancia de la calibraci\u00f3n trazable para asegurar la precisi\u00f3n y confiabilidad de los equipos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Informe T\u00e9cnico (Serie 961)**\n- **Equipos de laboratorio**: term\u00f3metros, termocuplas, balanzas, pesas, vidrio volum\u00e9trico, microscopios, higr\u00f3metros, centr\u00edfugas.\n- **Frecuencia de calibraci\u00f3n**: anualmente, cada 3 a\u00f1os, inicialmente.\n\nEste resumen destaca la importancia de la calibraci\u00f3n adecuada en los laboratorios para garantizar resultados precisos y confiables.", "excerpt_keywords": "Keywords: equipment qualification, monitoring frequency, laboratory standards, temperature control, microbiological testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "106b2a9b-27cb-4721-8947-b22239a78b2a", "node_type": "4", "metadata": {"page_label": "103", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n\n## Examples of equipment qualification and monitoring\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Temperature-controlled equipment (incubators, baths, fridges, freezers) | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Daily/each use |\n| Sterilizing ovens | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Autoclaves | \u2014 Establish characteristics for loads/cycles \u2014 Monitor temperature/pressure/time | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Grade A areas used for sterility testing: \u2022 safety unidirectional cabinets \u2022 isolators | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, every year and after repair/modification \u2014 Each use \u2014 6-monthly \u2014 6-monthly |\n| Unidirectional cabinets | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, and after repair/modification \u2014 Weekly \u2014 6-monthly \u2014 6-monthly |\n| Timers | Check against national time signal | Annually |\n| Microscopes | Check alignment | Daily/each use |\n| pH meters | Adjust using at least two buffers of suitable quality | Daily/each use |\n| Balances | Check zero, and reading against check weight | Daily/each use |\n| De-ionizers and reverse osmosis units | \u2014 Check conductivity \u2014 Check for microbial contamination | \u2014 Weekly \u2014 Monthly |\n| Gravimetric diluters | \u2014 Check weight of volume dispensed \u2014 Check dilution ratio | \u2014 Daily \u2014 Daily |\n| Media dispensers | Check volume dispensed | Each adjustment or replacement |\n| Pipettors/pipettes | Check accuracy and precision of volume dispensed | Regularly (to be defined by taking account of the frequency and nature of use) |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e8856f58e67ef18acc3f1b5e6fb6bb32d654ce5e4e303aa15e25cde018370951", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 4\n\n## Examples of equipment qualification and monitoring\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Temperature-controlled equipment (incubators, baths, fridges, freezers) | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Daily/each use |\n| Sterilizing ovens | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Autoclaves | \u2014 Establish characteristics for loads/cycles \u2014 Monitor temperature/pressure/time | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Grade A areas used for sterility testing: \u2022 safety unidirectional cabinets \u2022 isolators | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, every year and after repair/modification \u2014 Each use \u2014 6-monthly \u2014 6-monthly |\n| Unidirectional cabinets | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, and after repair/modification \u2014 Weekly \u2014 6-monthly \u2014 6-monthly |\n| Timers | Check against national time signal | Annually |\n| Microscopes | Check alignment | Daily/each use |\n| pH meters | Adjust using at least two buffers of suitable quality | Daily/each use |\n| Balances | Check zero, and reading against check weight | Daily/each use |\n| De-ionizers and reverse osmosis units | \u2014 Check conductivity \u2014 Check for microbial contamination | \u2014 Weekly \u2014 Monthly |\n| Gravimetric diluters | \u2014 Check weight of volume dispensed \u2014 Check dilution ratio | \u2014 Daily \u2014 Daily |\n| Media dispensers | Check volume dispensed | Each adjustment or replacement |\n| Pipettors/pipettes | Check accuracy and precision of volume dispensed | Regularly (to be defined by taking account of the frequency and nature of use) |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2101, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e44102cb-7058-4c2f-a6f2-ac483141a9d4": {"__data__": {"id_": "e44102cb-7058-4c2f-a6f2-ac483141a9d4", "embedding": null, "metadata": {"page_label": "104", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n## Examples of equipment qualification and monitoring (continued)\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Spiral platers | \u2014 Establish performance against conventional method \u2014 Check stylus condition and the art start and end-points \u2014 Check volume dispensed | \u2014 Initially and annually \u2014 Daily/each use \u2014 Monthly |\n| Colony counters | Check against number counted manually | Annually |\n| Centrifuges | Check speed against a calibrated and independent tachometer | Annually |\n| Anaerobic jars/incubators | Check with anaerobic indicator | Each use |\n| Laboratory environment | Monitor for airborne and surface microbial contamination using, e.g. air samplers, settle plates, contact plates or swabs | Based on risk assessment, an appropriate environmental monitoring programme should be established |\n\n\nHEPA, high-efficiency particulate air.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, \"Technical Report Series 961\", incluye un ap\u00e9ndice que detalla ejemplos de calificaci\u00f3n y monitoreo de equipos en laboratorios. Se presentan diferentes tipos de equipos, los requisitos para su funcionamiento y la frecuencia sugerida para las verificaciones necesarias. Esto es crucial para asegurar la calidad y la precisi\u00f3n en los resultados de los laboratorios.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de verificaci\u00f3n se sugiere realizar inicialmente y anualmente para los platers espirales?**\n   - Respuesta: Se sugiere establecer el rendimiento contra el m\u00e9todo convencional, verificar la condici\u00f3n del estilete y los puntos de inicio y final, as\u00ed como comprobar el volumen dispensado.\n\n2. **\u00bfCon qu\u00e9 frecuencia se debe verificar la velocidad de las centr\u00edfugas y qu\u00e9 herramienta se recomienda para esta verificaci\u00f3n?**\n   - Respuesta: La velocidad de las centr\u00edfugas debe verificarse anualmente utilizando un tac\u00f3metro calibrado e independiente.\n\n3. **\u00bfQu\u00e9 tipo de monitoreo ambiental se recomienda para los laboratorios y c\u00f3mo se debe establecer la frecuencia de este monitoreo?**\n   - Respuesta: Se recomienda monitorear la contaminaci\u00f3n microbiana en el aire y en superficies utilizando muestreadores de aire, placas de asentamiento, placas de contacto o hisopos. La frecuencia de este monitoreo debe basarse en una evaluaci\u00f3n de riesgos, estableciendo un programa de monitoreo ambiental apropiado.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **Calificaci\u00f3n y monitoreo de equipos:** El documento proporciona ejemplos de c\u00f3mo calificar y monitorear diversos equipos utilizados en laboratorios y entornos de investigaci\u00f3n.\n2. **Requisitos de funcionamiento:** Se detallan los requisitos espec\u00edficos que cada tipo de equipo debe cumplir para asegurar su correcto funcionamiento.\n3. **Frecuencia de verificaci\u00f3n:** Se sugiere una frecuencia de verificaci\u00f3n y mantenimiento basada en la necesidad, tipo de equipo, rendimiento previo y criticidad del mismo.\n\n**Entidades:**\n- **Equipos mencionados:**\n  - Equipos controlados por temperatura (incubadoras, ba\u00f1os, refrigeradores, congeladores)\n  - Hornos de esterilizaci\u00f3n\n  - Autoclaves\n  - Gabinetes unidireccionales de seguridad\n  - Aisladores\n  - Temporizadores\n  - Microscopios\n  - Medidores de pH\n  - Balanzas\n  - Desionizadores y unidades de \u00f3smosis inversa\n  - Dilutores gravim\u00e9tricos\n  - Dispensadores de medios\n  - Pipetores/pipetas\n\n- **Requisitos de monitoreo:**\n  - Estabilidad y uniformidad de temperatura\n  - Monitoreo microbiol\u00f3gico\n  - Monitoreo del flujo de aire\n  - Pruebas de integridad de filtros HEPA\n  - Verificaci\u00f3n de precisi\u00f3n y exactitud\n\n- **Frecuencias sugeridas:**\n  - Inicialmente cada 2 a\u00f1os, anualmente, semanalmente, diariamente, y en cada uso, dependiendo del equipo y su funci\u00f3n.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y el monitoreo de equipos en el contexto de la investigaci\u00f3n y la calidad en laboratorios, asegurando que se mantengan est\u00e1ndares adecuados para la seguridad y eficacia de los procesos.", "excerpt_keywords": "Keywords: equipment qualification, laboratory monitoring, microbial contamination, frequency of checks, WHO Technical Report"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f428e5b-084c-401f-baf0-720797e09aa0", "node_type": "4", "metadata": {"page_label": "104", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n## Examples of equipment qualification and monitoring (continued)\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Spiral platers | \u2014 Establish performance against conventional method \u2014 Check stylus condition and the art start and end-points \u2014 Check volume dispensed | \u2014 Initially and annually \u2014 Daily/each use \u2014 Monthly |\n| Colony counters | Check against number counted manually | Annually |\n| Centrifuges | Check speed against a calibrated and independent tachometer | Annually |\n| Anaerobic jars/incubators | Check with anaerobic indicator | Each use |\n| Laboratory environment | Monitor for airborne and surface microbial contamination using, e.g. air samplers, settle plates, contact plates or swabs | Based on risk assessment, an appropriate environmental monitoring programme should be established |\n\n\nHEPA, high-efficiency particulate air.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c10b82e28d64da6e33fc96cbd23ca2b9bc6e0d6adb2f5e0930ff2666a9e02976", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 4\n## Examples of equipment qualification and monitoring (continued)\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Spiral platers | \u2014 Establish performance against conventional method \u2014 Check stylus condition and the art start and end-points \u2014 Check volume dispensed | \u2014 Initially and annually \u2014 Daily/each use \u2014 Monthly |\n| Colony counters | Check against number counted manually | Annually |\n| Centrifuges | Check speed against a calibrated and independent tachometer | Annually |\n| Anaerobic jars/incubators | Check with anaerobic indicator | Each use |\n| Laboratory environment | Monitor for airborne and surface microbial contamination using, e.g. air samplers, settle plates, contact plates or swabs | Based on risk assessment, an appropriate environmental monitoring programme should be established |\n\n\nHEPA, high-efficiency particulate air.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 887, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9d46c7-4dc9-4cb3-a735-f3904eb54ff8": {"__data__": {"id_": "ca9d46c7-4dc9-4cb3-a735-f3904eb54ff8", "embedding": null, "metadata": {"page_label": "105", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 5\n\n## General use of reference cultures\n\n**Reference strain**  \nfrom source recognized by accreditation body\n\n**Reference stock G1**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G2**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G3**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G4**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\nAll parts of the process should be fully documented and detailed records of all stages must be maintained. Purity checks and biochemical tests should be made as appropriate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) incluye un ap\u00e9ndice que detalla el uso general de cultivos de referencia en laboratorios. Se describen diferentes tipos de cultivos de referencia (G1, G2, G3, G4), sus condiciones de almacenamiento y uso, as\u00ed como la importancia de mantener registros detallados y realizar pruebas de pureza y bioqu\u00edmicas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los cultivos de referencia G1, G2, G3 y G4?**\n   - Respuesta: Todos los cultivos de referencia deben ser almacenados en condiciones como liofilizaci\u00f3n, almacenamiento en nitr\u00f3geno l\u00edquido o congelaci\u00f3n profunda, aunque el texto no especifica las condiciones exactas para cada uno.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el manejo de cultivos de referencia seg\u00fan el ap\u00e9ndice?**\n   - Respuesta: Se requiere que todas las partes del proceso est\u00e9n completamente documentadas y que se mantengan registros detallados de todas las etapas.\n\n3. **\u00bfQu\u00e9 tipo de pruebas se deben realizar en los cultivos de referencia y por qu\u00e9 son importantes?**\n   - Respuesta: Se deben realizar pruebas de pureza y pruebas bioqu\u00edmicas, ya que son importantes para asegurar la calidad y la validez de los cultivos utilizados en los experimentos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Calificaci\u00f3n y Monitoreo de Equipos**: La secci\u00f3n proporciona ejemplos de c\u00f3mo calificar y monitorear diferentes tipos de equipos utilizados en laboratorios, lo cual es esencial para garantizar la calidad y precisi\u00f3n de los resultados.\n\n2. **Tipos de Equipos**:\n   - **Platers Espirales**: Se requiere establecer el rendimiento en comparaci\u00f3n con m\u00e9todos convencionales, verificar la condici\u00f3n del estilete y comprobar el volumen dispensado.\n   - **Contadores de Colonias**: Se debe verificar el conteo manualmente, con una frecuencia anual.\n   - **Centr\u00edfugas**: La velocidad debe ser verificada anualmente utilizando un tac\u00f3metro calibrado.\n   - **Frascos/Incubadoras Anaerobias**: Se debe verificar el indicador anaerobio en cada uso.\n   - **Entorno de Laboratorio**: Se recomienda monitorear la contaminaci\u00f3n microbiana en el aire y superficies, estableciendo un programa de monitoreo ambiental basado en una evaluaci\u00f3n de riesgos.\n\n3. **Frecuencia de Verificaci\u00f3n**: Se especifica la frecuencia sugerida para cada tipo de equipo, que var\u00eda desde verificaciones diarias hasta anuales, dependiendo del equipo y su uso.\n\n4. **Monitoreo Ambiental**: Se enfatiza la importancia de establecer un programa de monitoreo ambiental adecuado para asegurar un entorno de laboratorio seguro y controlado.\n\n5. **Terminolog\u00eda**: Se menciona el t\u00e9rmino HEPA (filtro de aire de alta eficiencia), que es relevante para la filtraci\u00f3n de aire en entornos de laboratorio.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y el monitoreo sistem\u00e1tico de equipos en laboratorios para mantener est\u00e1ndares de calidad y seguridad.", "excerpt_keywords": "Keywords: reference cultures, storage conditions, purity checks, biochemical tests, laboratory documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93e0de66-568c-4ce4-9ab2-2f1a6dd9cf32", "node_type": "4", "metadata": {"page_label": "105", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 5\n\n## General use of reference cultures\n\n**Reference strain**  \nfrom source recognized by accreditation body\n\n**Reference stock G1**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G2**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G3**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G4**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\nAll parts of the process should be fully documented and detailed records of all stages must be maintained. Purity checks and biochemical tests should be made as appropriate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ba4e10bdcc82a6fb856a2bc9046a52d129b2fde9d132e7685ae2f2d71ff48d6a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 5\n\n## General use of reference cultures\n\n**Reference strain**  \nfrom source recognized by accreditation body\n\n**Reference stock G1**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G2**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G3**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G4**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\nAll parts of the process should be fully documented and detailed records of all stages must be maintained. Purity checks and biochemical tests should be made as appropriate.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1190, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cf80f5b0-1fb0-46d9-b684-56d263cefe9b": {"__data__": {"id_": "cf80f5b0-1fb0-46d9-b684-56d263cefe9b", "embedding": null, "metadata": {"page_label": "106", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products: main principles\n\n### Introduction\n\n### General considerations\n\n### Glossary\n\n### Quality management in the medicines industry: philosophy and essential elements\n\n1. **Quality assurance**  \n   Product quality review\n\n2. **Good manufacturing practices for pharmaceutical products**\n\n3. **Sanitation and hygiene**\n\n4. **Qualification and validation**\n\n5. **Complaints**\n\n6. **Product recalls**\n\n7. **Contract production and analysis**  \n   General  \n   The contract giver  \n   The contract accepter  \n   The contract\n\n8. **Self-inspection, quality audits and supplier\u2019s audits and approval**  \n   Items for self-inspection  \n   Self-inspection team  \n   Frequency of self-inspection  \n   Self-inspection report  \n   Follow-up action  \n   Quality audit  \n   Suppliers\u2019 audits and approval\n\n9. **Personnel**  \n   General  \n   Key personnel\n\n10. **Training**\n\n11. **Personal hygiene**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, destacando principios clave como la gesti\u00f3n de calidad, la higiene, la capacitaci\u00f3n del personal y la auditor\u00eda de calidad. Se abordan aspectos esenciales como la garant\u00eda de calidad, la validaci\u00f3n, la gesti\u00f3n de quejas y los procedimientos de retiro de productos. Tambi\u00e9n se discuten las responsabilidades en la producci\u00f3n y an\u00e1lisis por contrato, as\u00ed como la importancia de la autoinspecci\u00f3n y la auditor\u00eda de proveedores.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los elementos esenciales de la gesti\u00f3n de calidad en la industria farmac\u00e9utica seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre la filosof\u00eda y los elementos que constituyen la gesti\u00f3n de calidad, que son fundamentales para asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir en caso de quejas y retiradas de productos seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n?**\n   - Esta pregunta se centra en los protocolos establecidos para manejar quejas y retiradas, lo que es crucial para la seguridad del paciente y la integridad del producto.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la autoinspecci\u00f3n y auditor\u00eda de proveedores seg\u00fan el documento?**\n   - Esta pregunta indaga sobre los criterios y procedimientos espec\u00edficos que se deben seguir durante la autoinspecci\u00f3n y la auditor\u00eda de proveedores, lo que es vital para mantener est\u00e1ndares de calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Cultivos de referencia**: Se mencionan diferentes tipos de cultivos de referencia (G1, G2, G3, G4) que son esenciales para la investigaci\u00f3n y el control de calidad en laboratorios.\n\n2. **Condiciones de almacenamiento**: Todos los cultivos de referencia deben ser almacenados en condiciones espec\u00edficas, como liofilizaci\u00f3n, almacenamiento en nitr\u00f3geno l\u00edquido o congelaci\u00f3n profunda, aunque no se detallan las condiciones exactas para cada tipo.\n\n3. **Cultivos de trabajo**: Se hace referencia a las condiciones y tiempos de almacenamiento recomendados para los cultivos de trabajo, que son utilizados de manera rutinaria.\n\n4. **Documentaci\u00f3n y registros**: Se enfatiza la importancia de mantener una documentaci\u00f3n completa y registros detallados de todas las etapas del manejo de cultivos de referencia.\n\n5. **Pruebas de calidad**: Se requiere realizar pruebas de pureza y bioqu\u00edmicas para asegurar la calidad y validez de los cultivos utilizados en experimentos.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el informe t\u00e9cnico.\n- **Cultivos de referencia**: G1, G2, G3, G4.\n- **Condiciones de almacenamiento**: Liofilizaci\u00f3n, nitr\u00f3geno l\u00edquido, congelaci\u00f3n profunda.\n- **Documentaci\u00f3n**: Registros detallados de procesos y pruebas de calidad.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, gesti\u00f3n de calidad, auditor\u00eda, higiene, formaci\u00f3n del personal"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "86e35b7d-b110-4385-bfdf-79f0a9610f8b", "node_type": "4", "metadata": {"page_label": "106", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products: main principles\n\n### Introduction\n\n### General considerations\n\n### Glossary\n\n### Quality management in the medicines industry: philosophy and essential elements\n\n1. **Quality assurance**  \n   Product quality review\n\n2. **Good manufacturing practices for pharmaceutical products**\n\n3. **Sanitation and hygiene**\n\n4. **Qualification and validation**\n\n5. **Complaints**\n\n6. **Product recalls**\n\n7. **Contract production and analysis**  \n   General  \n   The contract giver  \n   The contract accepter  \n   The contract\n\n8. **Self-inspection, quality audits and supplier\u2019s audits and approval**  \n   Items for self-inspection  \n   Self-inspection team  \n   Frequency of self-inspection  \n   Self-inspection report  \n   Follow-up action  \n   Quality audit  \n   Suppliers\u2019 audits and approval\n\n9. **Personnel**  \n   General  \n   Key personnel\n\n10. **Training**\n\n11. **Personal hygiene**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "384faa9ce4422c89830c49086ae791400e125671d92f8abc28d50506715872a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products: main principles\n\n### Introduction\n\n### General considerations\n\n### Glossary\n\n### Quality management in the medicines industry: philosophy and essential elements\n\n1. **Quality assurance**  \n   Product quality review\n\n2. **Good manufacturing practices for pharmaceutical products**\n\n3. **Sanitation and hygiene**\n\n4. **Qualification and validation**\n\n5. **Complaints**\n\n6. **Product recalls**\n\n7. **Contract production and analysis**  \n   General  \n   The contract giver  \n   The contract accepter  \n   The contract\n\n8. **Self-inspection, quality audits and supplier\u2019s audits and approval**  \n   Items for self-inspection  \n   Self-inspection team  \n   Frequency of self-inspection  \n   Self-inspection report  \n   Follow-up action  \n   Quality audit  \n   Suppliers\u2019 audits and approval\n\n9. **Personnel**  \n   General  \n   Key personnel\n\n10. **Training**\n\n11. **Personal hygiene**", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 954, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "954a9543-aa64-45f4-af7c-cede1097d9d8": {"__data__": {"id_": "954a9543-aa64-45f4-af7c-cede1097d9d8", "embedding": null, "metadata": {"page_label": "107", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n12. Premises  \n   General  \n   Ancillary areas  \n   Storage areas  \n   Weighing areas  \n   Production areas  \n   Quality control areas  \n\n13. Equipment  \n\n14. Materials  \n   General  \n   Starting materials  \n   Packaging materials  \n   Intermediate and bulk products  \n   Finished products  \n   Rejected, recovered, reprocessed and reworked materials  \n   Recalled products  \n   Returned goods  \n   Reagents and culture media  \n   Reference standards  \n   Waste materials  \n   Miscellaneous  \n\n15. Documentation  \n   General  \n   Documents required  \n\n16. Good practices in production  \n   General  \n   Prevention of cross-contamination and bacterial contamination during production  \n   Processing operations  \n   Packaging operations  \n\n17. Good practices in quality control  \n   Control of starting materials and intermediate, bulk and finished products  \n   Test requirements  \n   Batch record review  \n   Stability studies  \n\nReferences\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la producci\u00f3n y control de calidad en la industria farmac\u00e9utica. Se detallan las instalaciones necesarias, el equipo, los materiales, la documentaci\u00f3n requerida y las buenas pr\u00e1cticas tanto en producci\u00f3n como en control de calidad. Se enfatiza la importancia de prevenir la contaminaci\u00f3n cruzada y se establecen requisitos para el control de materiales y productos en diferentes etapas del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas que se deben considerar al evaluar las instalaciones de producci\u00f3n seg\u00fan el informe?**\n   - El informe menciona varias \u00e1reas que deben ser evaluadas, incluyendo \u00e1reas generales, \u00e1reas auxiliares, \u00e1reas de almacenamiento, \u00e1reas de pesaje, \u00e1reas de producci\u00f3n y \u00e1reas de control de calidad.\n\n2. **\u00bfQu\u00e9 tipos de materiales se clasifican en el informe y cu\u00e1les son sus categor\u00edas espec\u00edficas?**\n   - Los materiales se clasifican en varias categor\u00edas, que incluyen materiales de partida, materiales de embalaje, productos intermedios y a granel, productos terminados, materiales rechazados, recuperados, reprocesados y re-trabajados, productos retirados, bienes devueltos, reactivos y medios de cultivo, est\u00e1ndares de referencia, materiales de desecho y otros materiales diversos.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas se recomiendan para prevenir la contaminaci\u00f3n durante el proceso de producci\u00f3n?**\n   - Se recomienda implementar buenas pr\u00e1cticas en la producci\u00f3n, que incluyen la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la contaminaci\u00f3n bacteriana, as\u00ed como la correcta ejecuci\u00f3n de operaciones de procesamiento y embalaje.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 3 del documento \"WHO - Technical Report Series 961\" aborda las **buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)** para productos farmac\u00e9uticos, destacando los siguientes temas clave:\n\n1. **Gesti\u00f3n de Calidad**: Se enfatiza la importancia de la **garant\u00eda de calidad** y la revisi\u00f3n de la calidad del producto como elementos fundamentales en la industria farmac\u00e9utica.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n**: Se describen los principios y procedimientos que deben seguirse para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n3. **Sanitaci\u00f3n e Higiene**: Se subraya la necesidad de mantener altos est\u00e1ndares de higiene en el proceso de fabricaci\u00f3n.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n**: Se discuten los procesos necesarios para validar equipos y procedimientos en la producci\u00f3n.\n\n5. **Gesti\u00f3n de Quejas**: Se establecen protocolos para manejar quejas de los consumidores y asegurar la respuesta adecuada.\n\n6. **Retiradas de Productos**: Se detallan los procedimientos a seguir en caso de que sea necesario retirar productos del mercado.\n\n7. **Producci\u00f3n y An\u00e1lisis por Contrato**: Se abordan las responsabilidades de las partes involucradas en la producci\u00f3n y an\u00e1lisis de productos farmac\u00e9uticos bajo contrato.\n\n8. **Autoinspecci\u00f3n y Auditor\u00edas**: Se describen los elementos y procedimientos para llevar a cabo autoinspecciones y auditor\u00edas de calidad, as\u00ed como la aprobaci\u00f3n de proveedores.\n\n9. **Personal**: Se menciona la importancia del personal clave y su capacitaci\u00f3n en el cumplimiento de las BPF.\n\n10. **Capacitaci\u00f3n**: Se destaca la necesidad de formaci\u00f3n continua del personal para mantener est\u00e1ndares de calidad.\n\n11. **Higiene Personal**: Se enfatiza la importancia de la higiene personal de los empleados en el entorno de fabricaci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **BPF (Buenas Pr\u00e1cticas de Fabricaci\u00f3n)**: Conjunto de principios y procedimientos para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n- **Calidad**: Concepto central en la gesti\u00f3n de productos farmac\u00e9uticos.\n- **Personal Clave**: Empleados responsables de mantener los est\u00e1ndares de calidad.\n- **Auditor\u00edas**: Proceso de revisi\u00f3n y evaluaci\u00f3n de pr\u00e1cticas de calidad.\n\nEste resumen proporciona una visi\u00f3n general de los principios y pr\u00e1cticas esenciales que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: producci\u00f3n farmac\u00e9utica, buenas pr\u00e1cticas, control de calidad, materiales, instalaciones"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3906fb76-3e23-42f2-b88f-eda7f26bd97d", "node_type": "4", "metadata": {"page_label": "107", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n12. Premises  \n   General  \n   Ancillary areas  \n   Storage areas  \n   Weighing areas  \n   Production areas  \n   Quality control areas  \n\n13. Equipment  \n\n14. Materials  \n   General  \n   Starting materials  \n   Packaging materials  \n   Intermediate and bulk products  \n   Finished products  \n   Rejected, recovered, reprocessed and reworked materials  \n   Recalled products  \n   Returned goods  \n   Reagents and culture media  \n   Reference standards  \n   Waste materials  \n   Miscellaneous  \n\n15. Documentation  \n   General  \n   Documents required  \n\n16. Good practices in production  \n   General  \n   Prevention of cross-contamination and bacterial contamination during production  \n   Processing operations  \n   Packaging operations  \n\n17. Good practices in quality control  \n   Control of starting materials and intermediate, bulk and finished products  \n   Test requirements  \n   Batch record review  \n   Stability studies  \n\nReferences\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9a8d5bd4c2972ada1b06e6eeea22e01b3369518a92458912b921aeade00f37b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "12. Premises  \n   General  \n   Ancillary areas  \n   Storage areas  \n   Weighing areas  \n   Production areas  \n   Quality control areas  \n\n13. Equipment  \n\n14. Materials  \n   General  \n   Starting materials  \n   Packaging materials  \n   Intermediate and bulk products  \n   Finished products  \n   Rejected, recovered, reprocessed and reworked materials  \n   Recalled products  \n   Returned goods  \n   Reagents and culture media  \n   Reference standards  \n   Waste materials  \n   Miscellaneous  \n\n15. Documentation  \n   General  \n   Documents required  \n\n16. Good practices in production  \n   General  \n   Prevention of cross-contamination and bacterial contamination during production  \n   Processing operations  \n   Packaging operations  \n\n17. Good practices in quality control  \n   Control of starting materials and intermediate, bulk and finished products  \n   Test requirements  \n   Batch record review  \n   Stability studies  \n\nReferences", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 942, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b58538-14ad-498f-ac60-127c6269436e": {"__data__": {"id_": "a0b58538-14ad-498f-ac60-127c6269436e", "embedding": null, "metadata": {"page_label": "108", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe first WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth World Health Assembly (resolution WHA20.34). It was subsequently submitted to the Twenty-first World Health Assembly under the title \u201cDraft requirements for good manufacturing practice in the manufacture and quality control of medicines and pharmaceutical specialities\u201d and was accepted.\n\nThe revised text was discussed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its twenty-second report. The text was then reproduced (with some revisions) in 1971 in the Supplement to the second edition of *The International Pharmacopoeia*.\n\nIn 1969, when the World Health Assembly recommended the first version of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce in resolution WHA22.50, it accepted at the same time the GMP text as an integral part of the Scheme. Revised versions of both the Certification Scheme and the GMP text were adopted in 1975 by resolution WHA28.65. Since then, the Certification Scheme has been extended to include the certification of:\n\n- veterinary products administered to food-producing animals;\n- starting materials for use in dosage forms, when they are subject to control by legislation in both the exporting Member State and the importing Member State;\n- information on safety and efficacy (resolution WHA41.18, 1988).\n\nIn 1992, the revised draft requirements for GMP were presented in three parts, of which only Parts One and Two are reproduced in this document (1).\n\n\u201cQuality management in the medicines industry: philosophy and essential elements\u201d, outlines the general concepts of quality assurance (QA) as well as the principal components or subsystems of GMP, which are joint responsibilities of top management and of production and quality control management. These include hygiene, validation, self-inspection, personnel, premises, equipment, materials and documentation.\n\n\u201cGood practices in production and quality control\u201d, provides guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of QA.\n\nThese two parts were subsequently supplemented by further guidelines which are integral parts of these GMP for pharmaceutical products. All these texts are available on the Medicines web page (http.www.who.int/).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona una visi\u00f3n general de la evoluci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS). Se menciona que el primer borrador de GMP fue preparado en 1967 y aceptado por la Asamblea Mundial de la Salud. A lo largo de los a\u00f1os, se han revisado y ampliado tanto el texto de GMP como el esquema de certificaci\u00f3n de productos farmac\u00e9uticos. En 1992, se presentaron requisitos revisados para GMP en tres partes, de las cuales solo se incluyen dos en el documento. Se destacan los conceptos de gesti\u00f3n de calidad y las responsabilidades compartidas entre la alta direcci\u00f3n y la gesti\u00f3n de producci\u00f3n y control de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes principales de las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan el documento de la OMS?**\n   - Respuesta: Los componentes principales de GMP incluyen higiene, validaci\u00f3n, autoinspecci\u00f3n, personal, instalaciones, equipos, materiales y documentaci\u00f3n.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en el esquema de certificaci\u00f3n de productos farmac\u00e9uticos desde su adopci\u00f3n inicial en 1969?**\n   - Respuesta: Desde su adopci\u00f3n inicial, el esquema de certificaci\u00f3n se ha ampliado para incluir la certificaci\u00f3n de productos veterinarios administrados a animales de producci\u00f3n, materiales iniciales para formas de dosificaci\u00f3n bajo control legislativo y la informaci\u00f3n sobre seguridad y eficacia.\n\n3. **\u00bfQu\u00e9 partes del documento de requisitos revisados para GMP se incluyen en el informe de la OMS de 1992?**\n   - Respuesta: En el informe de 1992, se incluyen las Partes Uno y Dos de los requisitos revisados para GMP, que abordan la gesti\u00f3n de calidad en la industria de medicamentos y las buenas pr\u00e1cticas en producci\u00f3n y control de calidad.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS detalla la historia y evoluci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) desde su creaci\u00f3n en 1967, resaltando su importancia en la calidad de los productos farmac\u00e9uticos. Se discuten los principios de gesti\u00f3n de calidad y las responsabilidades compartidas entre diferentes niveles de gesti\u00f3n en la industria farmac\u00e9utica. Adem\u00e1s, se menciona la evoluci\u00f3n del esquema de certificaci\u00f3n de productos farmac\u00e9uticos, que ha sido ampliado para incluir m\u00e1s categor\u00edas de productos y requisitos.\n\n### Preguntas Adicionales\n\n1. **\u00bfQu\u00e9 resoluci\u00f3n de la Asamblea Mundial de la Salud acept\u00f3 el texto de GMP como parte del esquema de certificaci\u00f3n en 1969?**\n   - Respuesta: La resoluci\u00f3n WHA22.50.\n\n2. **\u00bfQu\u00e9 documento de la OMS se menciona como una fuente de informaci\u00f3n sobre las pr\u00e1cticas de calidad en la industria de medicamentos?**\n   - Respuesta: El documento titulado \u201cQuality management in the medicines industry: philosophy and essential elements\u201d.\n\n3. **\u00bfQu\u00e9 a\u00f1o se menciona como el de la adopci\u00f3n de versiones revisadas del esquema de certificaci\u00f3n y el texto de GMP?**\n   - Respuesta: 1975, bajo la resoluci\u00f3n WHA28.65.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos fundamentales en la producci\u00f3n y control de calidad en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Instalaciones (Premises)**:\n   - **\u00c1reas Generales**: Espacios comunes y de acceso.\n   - **\u00c1reas Auxiliares**: Espacios que apoyan la producci\u00f3n.\n   - **\u00c1reas de Almacenamiento**: Espacios para guardar materiales y productos.\n   - **\u00c1reas de Pesaje**: Espacios designados para la medici\u00f3n de ingredientes.\n   - **\u00c1reas de Producci\u00f3n**: Espacios donde se lleva a cabo la fabricaci\u00f3n.\n   - **\u00c1reas de Control de Calidad**: Espacios dedicados a la verificaci\u00f3n de calidad.\n\n2. **Equipamiento (Equipment)**:\n   - Se menciona la importancia de contar con el equipo adecuado para la producci\u00f3n y control de calidad.\n\n3. **Materiales (Materials)**:\n   - **Materiales de Partida**: Ingredientes iniciales para la producci\u00f3n.\n   - **Materiales de Embalaje**: Materiales utilizados para el empaquetado de productos.\n   - **Productos Intermedios y a Granel**: Productos en diferentes etapas de producci\u00f3n.\n   - **Productos Terminados**: Productos listos para la distribuci\u00f3n.\n   - **Materiales Rechazados, Recuperados, Reprocesados y Re-trabajados**: Materiales que no cumplen con los est\u00e1ndares y su manejo.\n   - **Productos Retirados y Bienes Devueltos**: Productos que han sido retirados del mercado o devueltos por clientes.\n   - **Reactivos y Medios de Cultivo**: Sustancias utilizadas en pruebas y cultivos.\n   - **Est\u00e1ndares de Referencia**: Materiales utilizados para calibraci\u00f3n y control.\n   - **Materiales de Desecho**: Residuos generados durante el proceso.\n   - **Materiales Diversos**: Otros materiales no clasificados en las categor\u00edas anteriores.\n\n4. **Documentaci\u00f3n (Documentation)**:\n   - Importancia de la documentaci\u00f3n general y de los documentos requeridos para asegurar la trazabilidad y cumplimiento de normativas.\n\n5. **Buenas Pr\u00e1cticas en Producci\u00f3n (Good Practices in Production)**:\n   - Prevenci\u00f3n de contaminaci\u00f3n cruzada y bacteriana.\n   - Ejecuci\u00f3n adecuada de operaciones de procesamiento y embalaje.\n\n6. **Buenas Pr\u00e1cticas en Control de Calidad (Good Practices in Quality Control)**:\n   - Control de materiales y productos en diferentes etapas.\n   - Requisitos de pruebas y revisi\u00f3n de registros de lotes.\n   - Estudios de estabilidad para asegurar la calidad a lo largo del tiempo.\n\n### Conclusi\u00f3n\nEl informe enfatiza la importancia de mantener est\u00e1ndares rigurosos en las instalaciones, el uso de materiales adecuados, la documentaci\u00f3n precisa y la implementaci\u00f3n de buenas pr\u00e1cticas para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, pharmaceutical quality, certification scheme, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9735e006-04ff-45e5-8e8e-a94f50298bce", "node_type": "4", "metadata": {"page_label": "108", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe first WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth World Health Assembly (resolution WHA20.34). It was subsequently submitted to the Twenty-first World Health Assembly under the title \u201cDraft requirements for good manufacturing practice in the manufacture and quality control of medicines and pharmaceutical specialities\u201d and was accepted.\n\nThe revised text was discussed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its twenty-second report. The text was then reproduced (with some revisions) in 1971 in the Supplement to the second edition of *The International Pharmacopoeia*.\n\nIn 1969, when the World Health Assembly recommended the first version of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce in resolution WHA22.50, it accepted at the same time the GMP text as an integral part of the Scheme. Revised versions of both the Certification Scheme and the GMP text were adopted in 1975 by resolution WHA28.65. Since then, the Certification Scheme has been extended to include the certification of:\n\n- veterinary products administered to food-producing animals;\n- starting materials for use in dosage forms, when they are subject to control by legislation in both the exporting Member State and the importing Member State;\n- information on safety and efficacy (resolution WHA41.18, 1988).\n\nIn 1992, the revised draft requirements for GMP were presented in three parts, of which only Parts One and Two are reproduced in this document (1).\n\n\u201cQuality management in the medicines industry: philosophy and essential elements\u201d, outlines the general concepts of quality assurance (QA) as well as the principal components or subsystems of GMP, which are joint responsibilities of top management and of production and quality control management. These include hygiene, validation, self-inspection, personnel, premises, equipment, materials and documentation.\n\n\u201cGood practices in production and quality control\u201d, provides guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of QA.\n\nThese two parts were subsequently supplemented by further guidelines which are integral parts of these GMP for pharmaceutical products. All these texts are available on the Medicines web page (http.www.who.int/).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "41f4dac0f6bee67217414e19d7381a31569edfc7ebc6c0b960388aa29ec05f2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe first WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth World Health Assembly (resolution WHA20.34). It was subsequently submitted to the Twenty-first World Health Assembly under the title \u201cDraft requirements for good manufacturing practice in the manufacture and quality control of medicines and pharmaceutical specialities\u201d and was accepted.\n\nThe revised text was discussed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its twenty-second report. The text was then reproduced (with some revisions) in 1971 in the Supplement to the second edition of *The International Pharmacopoeia*.\n\nIn 1969, when the World Health Assembly recommended the first version of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce in resolution WHA22.50, it accepted at the same time the GMP text as an integral part of the Scheme. Revised versions of both the Certification Scheme and the GMP text were adopted in 1975 by resolution WHA28.65. Since then, the Certification Scheme has been extended to include the certification of:\n\n- veterinary products administered to food-producing animals;\n- starting materials for use in dosage forms, when they are subject to control by legislation in both the exporting Member State and the importing Member State;\n- information on safety and efficacy (resolution WHA41.18, 1988).\n\nIn 1992, the revised draft requirements for GMP were presented in three parts, of which only Parts One and Two are reproduced in this document (1).\n\n\u201cQuality management in the medicines industry: philosophy and essential elements\u201d, outlines the general concepts of quality assurance (QA) as well as the principal components or subsystems of GMP, which are joint responsibilities of top management and of production and quality control management. These include hygiene, validation, self-inspection, personnel, premises, equipment, materials and documentation.\n\n\u201cGood practices in production and quality control\u201d, provides guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of QA.\n\nThese two parts were subsequently supplemented by further guidelines which are integral parts of these GMP for pharmaceutical products. All these texts are available on the Medicines web page (http.www.who.int/).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2507, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5dac3e96-a633-49d9-8788-9ccfef29d9bd": {"__data__": {"id_": "5dac3e96-a633-49d9-8788-9ccfef29d9bd", "embedding": null, "metadata": {"page_label": "109", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medicines/organization/qsm/activities/qualityassurance/gmp/gmpcover.html).\n\nConsiderable developments in GMP have taken place in the intervening years, and important national and international documents, including new revisions, have appeared (2,3,4,5). Thus the necessity to revise the main principles and incorporate the concept of validation.\n\nAmong other feedback which was discussed during the consultation on WHO guidelines for medicines quality assurance, quality control (QC) laboratories and transfer of technology on 27\u201331 July 2009, the need was identified to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d.\n\nIn addition, several updates were suggested to further enhance the guidelines and include the concept of risk management, replacing \u201cdrugs\u201d by the term \u201cmedicines\u201d and newly introduce the concept of a \u201cquality unit\u201d.\n\n# General considerations\n\nLicensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status, which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry.\n\nThe guide is applicable to operations for the manufacture of medicines in their finished dosage forms, including large-scale processes in hospitals and the preparation of supplies for use in clinical trials.\n\nThe good practices outlined below are to be considered general guides[^1], and they may be adapted to meet individual needs. The equivalence of alternative approaches to QA, however, should be validated. The guide as a whole does not cover safety aspects for the personnel engaged in manufacture or environmental protection: these are normally governed by national legislation. A new concept of hazard analysis related to the risks in production and personnel safety is also newly recommended (Annex 7). The manufacturer should assure the safety of workers and take the necessary measures to prevent pollution of the external environment.\n\n[^1]: The word \u201cshould\u201d in the text means a strong recommendation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 961\", aborda los desarrollos recientes en las Buenas Pr\u00e1cticas de Manufactura (GMP) y la necesidad de actualizar las directrices para asegurar la calidad de los medicamentos. Se enfatiza la importancia de la validaci\u00f3n, la gesti\u00f3n de riesgos y la introducci\u00f3n de un \"unidad de calidad\". Adem\u00e1s, se establece que los productos farmac\u00e9uticos deben ser fabricados por fabricantes autorizados y que las pr\u00e1cticas recomendadas pueden adaptarse a las necesidades individuales, siempre que se valide la equivalencia de los enfoques alternativos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 cambios se han propuesto en las directrices de GMP en relaci\u00f3n con la terminolog\u00eda utilizada para referirse a los medicamentos?**\n   - Respuesta: Se ha propuesto reemplazar el t\u00e9rmino \"drugs\" por \"medicines\" en las directrices de GMP.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito del nuevo concepto de \"an\u00e1lisis de peligros\" mencionado en el documento?**\n   - Respuesta: El nuevo concepto de an\u00e1lisis de peligros se recomienda para abordar los riesgos en la producci\u00f3n y la seguridad del personal, asegurando que los fabricantes tomen medidas para proteger a los trabajadores y prevenir la contaminaci\u00f3n del medio ambiente.\n\n3. **\u00bfC\u00f3mo se utilizar\u00e1 la gu\u00eda de GMP en el contexto de la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional?**\n   - Respuesta: La gu\u00eda de GMP se utilizar\u00e1 como est\u00e1ndar para justificar el estado de GMP, lo que es un elemento del esquema de certificaci\u00f3n de la OMS sobre la calidad de los productos farmac\u00e9uticos que se mueven en el comercio internacional, a trav\u00e9s de la evaluaci\u00f3n de solicitudes de autorizaciones de fabricaci\u00f3n y como base para la inspecci\u00f3n de instalaciones de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Historia de las Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - El primer borrador de GMP fue preparado en 1967 por consultores a solicitud de la Asamblea Mundial de la Salud.\n   - Aceptaci\u00f3n del texto en la vig\u00e9sima primera Asamblea Mundial de la Salud.\n\n2. **Evoluci\u00f3n y Revisi\u00f3n**:\n   - El texto fue discutido por el Comit\u00e9 de Expertos de la OMS en 1968 y publicado en 1971 en *The International Pharmacopoeia*.\n   - En 1969, la Asamblea Mundial de la Salud acept\u00f3 el texto de GMP como parte del esquema de certificaci\u00f3n de productos farmac\u00e9uticos (resoluci\u00f3n WHA22.50).\n   - En 1975, se adoptaron versiones revisadas del esquema de certificaci\u00f3n y del texto de GMP (resoluci\u00f3n WHA28.65).\n\n3. **Ampliaci\u00f3n del Esquema de Certificaci\u00f3n**:\n   - Inclusi\u00f3n de productos veterinarios, materiales iniciales para formas de dosificaci\u00f3n y requisitos de informaci\u00f3n sobre seguridad y eficacia.\n\n4. **Requisitos Revisados de GMP (1992)**:\n   - Presentaci\u00f3n de requisitos en tres partes, de las cuales se incluyen las Partes Uno y Dos en el documento.\n   - Parte Uno: \"Quality management in the medicines industry: philosophy and essential elements\", que aborda conceptos de aseguramiento de calidad y componentes de GMP.\n   - Parte Dos: \"Good practices in production and quality control\", que proporciona orientaci\u00f3n sobre acciones para producci\u00f3n y control de calidad.\n\n5. **Componentes Principales de GMP**:\n   - Higiene, validaci\u00f3n, autoinspecci\u00f3n, personal, instalaciones, equipos, materiales y documentaci\u00f3n.\n\n6. **Acceso a Documentos**:\n   - Todos los textos relacionados est\u00e1n disponibles en la p\u00e1gina web de Medicamentos de la OMS.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la creaci\u00f3n y revisi\u00f3n de las GMP.\n- **Asamblea Mundial de la Salud**: Cuerpo que aprob\u00f3 el texto de GMP y el esquema de certificaci\u00f3n.\n- **Resoluciones**: WHA20.34, WHA22.50, WHA28.65, WHA41.18.\n- **Documentos**: *The International Pharmacopoeia*, \"Quality management in the medicines industry\", \"Good practices in production and quality control\". \n\nEste resumen destaca la evoluci\u00f3n de las GMP, su importancia en la industria farmac\u00e9utica y los componentes esenciales que garantizan la calidad de los productos.", "excerpt_keywords": "Keywords: GMP, quality assurance, medicines, risk management, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c27229c8-5df7-476b-98a2-0adc504ed4c2", "node_type": "4", "metadata": {"page_label": "109", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medicines/organization/qsm/activities/qualityassurance/gmp/gmpcover.html).\n\nConsiderable developments in GMP have taken place in the intervening years, and important national and international documents, including new revisions, have appeared (2,3,4,5). Thus the necessity to revise the main principles and incorporate the concept of validation.\n\nAmong other feedback which was discussed during the consultation on WHO guidelines for medicines quality assurance, quality control (QC) laboratories and transfer of technology on 27\u201331 July 2009, the need was identified to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d.\n\nIn addition, several updates were suggested to further enhance the guidelines and include the concept of risk management, replacing \u201cdrugs\u201d by the term \u201cmedicines\u201d and newly introduce the concept of a \u201cquality unit\u201d.\n\n# General considerations\n\nLicensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status, which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry.\n\nThe guide is applicable to operations for the manufacture of medicines in their finished dosage forms, including large-scale processes in hospitals and the preparation of supplies for use in clinical trials.\n\nThe good practices outlined below are to be considered general guides[^1], and they may be adapted to meet individual needs. The equivalence of alternative approaches to QA, however, should be validated. The guide as a whole does not cover safety aspects for the personnel engaged in manufacture or environmental protection: these are normally governed by national legislation. A new concept of hazard analysis related to the risks in production and personnel safety is also newly recommended (Annex 7). The manufacturer should assure the safety of workers and take the necessary measures to prevent pollution of the external environment.\n\n[^1]: The word \u201cshould\u201d in the text means a strong recommendation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dbe975449e6bdcc6a37364443d5bccc2487a5a0bff062afb6c62fd9c08699999", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "medicines/organization/qsm/activities/qualityassurance/gmp/gmpcover.html).\n\nConsiderable developments in GMP have taken place in the intervening years, and important national and international documents, including new revisions, have appeared (2,3,4,5). Thus the necessity to revise the main principles and incorporate the concept of validation.\n\nAmong other feedback which was discussed during the consultation on WHO guidelines for medicines quality assurance, quality control (QC) laboratories and transfer of technology on 27\u201331 July 2009, the need was identified to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d.\n\nIn addition, several updates were suggested to further enhance the guidelines and include the concept of risk management, replacing \u201cdrugs\u201d by the term \u201cmedicines\u201d and newly introduce the concept of a \u201cquality unit\u201d.\n\n# General considerations\n\nLicensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status, which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry.\n\nThe guide is applicable to operations for the manufacture of medicines in their finished dosage forms, including large-scale processes in hospitals and the preparation of supplies for use in clinical trials.\n\nThe good practices outlined below are to be considered general guides[^1], and they may be adapted to meet individual needs. The equivalence of alternative approaches to QA, however, should be validated. The guide as a whole does not cover safety aspects for the personnel engaged in manufacture or environmental protection: these are normally governed by national legislation. A new concept of hazard analysis related to the risks in production and personnel safety is also newly recommended (Annex 7). The manufacturer should assure the safety of workers and take the necessary measures to prevent pollution of the external environment.\n\n[^1]: The word \u201cshould\u201d in the text means a strong recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2554, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d39414-e870-4385-ba92-02d492357943": {"__data__": {"id_": "d6d39414-e870-4385-ba92-02d492357943", "embedding": null, "metadata": {"page_label": "110", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "International Nonproprietary Names (INN) for pharmaceutical substances designated by WHO should be used when available, together with other designated names.\n\n# Glossary\n\nThe definitions given below apply to the terms used in this guide.\n\nThey may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for use either by people or for goods and/or equipment.\n\n**authorized person**  \nThe person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n\n**batch (or lot)**  \nA defined quantity of starting material, packaging material, or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch. In the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. In continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis, etc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" proporciona definiciones clave relacionadas con la fabricaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos. Incluye t\u00e9rminos como \"ingrediente farmac\u00e9utico activo\" (API), \"airlock\", \"persona autorizada\", \"lote\" y \"n\u00famero de lote\". Estas definiciones son esenciales para entender los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica, as\u00ed como la importancia de utilizar nombres no propietarios internacionales (INN) para las sustancias farmac\u00e9uticas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de un \"airlock\" en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un \"airlock\" es un espacio cerrado con dos o m\u00e1s puertas que se utiliza para controlar el flujo de aire entre habitaciones de diferentes clases de limpieza, permitiendo el acceso a personas o bienes y/o equipos sin comprometer la limpieza del entorno.\n\n2. **\u00bfQu\u00e9 criterios debe cumplir una \"persona autorizada\" seg\u00fan el contexto del documento?**\n   - Respuesta: La \"persona autorizada\" es reconocida por la autoridad reguladora nacional y tiene la responsabilidad de asegurar que cada lote de producto terminado haya sido fabricado, probado y aprobado para su liberaci\u00f3n de acuerdo con las leyes y regulaciones vigentes en el pa\u00eds.\n\n3. **\u00bfC\u00f3mo se define un \"lote\" en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un \"lote\" se define como una cantidad determinada de material inicial, material de embalaje o producto procesado en un solo proceso o serie de procesos, con la expectativa de que sea homog\u00e9neo. Puede dividirse en sub-lotes que luego se combinan para formar un lote final homog\u00e9neo.", "prev_section_summary": "### Temas Clave\n1. **Desarrollo de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han realizado importantes avances en las GMP, lo que ha llevado a la necesidad de revisar y actualizar las directrices existentes.\n   \n2. **Incorporaci\u00f3n de Nuevos Conceptos**: Se sugiere la inclusi\u00f3n de un nuevo apartado sobre \"Revisi\u00f3n de la calidad del producto\" y la introducci\u00f3n del concepto de \"unidad de calidad\".\n\n3. **Terminolog\u00eda Actualizada**: Se propone reemplazar el t\u00e9rmino \"drugs\" por \"medicines\" en las directrices.\n\n4. **Gesti\u00f3n de Riesgos**: Se enfatiza la importancia de incorporar la gesti\u00f3n de riesgos en las pr\u00e1cticas de calidad.\n\n5. **Fabricaci\u00f3n Autorizada**: Los productos farmac\u00e9uticos deben ser fabricados \u00fanicamente por fabricantes autorizados, cuyas actividades son inspeccionadas regularmente por autoridades competentes.\n\n6. **Gu\u00eda de GMP como Est\u00e1ndar**: La gu\u00eda de GMP se utilizar\u00e1 como est\u00e1ndar para justificar el estado de GMP y como base para la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional.\n\n7. **An\u00e1lisis de Peligros**: Se recomienda un nuevo concepto de an\u00e1lisis de peligros para abordar los riesgos en la producci\u00f3n y la seguridad del personal.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices y est\u00e1ndares para la calidad de los medicamentos.\n- **Fabricantes Autorizados**: Entidades que poseen la autorizaci\u00f3n para fabricar productos farmac\u00e9uticos.\n- **Autoridades Nacionales Competentes**: Organismos responsables de la inspecci\u00f3n y regulaci\u00f3n de las pr\u00e1cticas de fabricaci\u00f3n de medicamentos.\n- **Laboratorios de Control de Calidad (QC)**: Entidades que aseguran la calidad de los productos farmac\u00e9uticos a trav\u00e9s de pruebas y an\u00e1lisis.\n\n### Resumen\nEl documento de la OMS, \"Technical Report Series 961\", aborda la necesidad de actualizar las Buenas Pr\u00e1cticas de Manufactura (GMP) para asegurar la calidad de los medicamentos. Se proponen cambios en la terminolog\u00eda, la incorporaci\u00f3n de nuevos conceptos como la gesti\u00f3n de riesgos y la revisi\u00f3n de la calidad del producto, y se establece que solo los fabricantes autorizados pueden producir medicamentos. La gu\u00eda de GMP servir\u00e1 como est\u00e1ndar para la certificaci\u00f3n de productos en el comercio internacional y se recomienda un an\u00e1lisis de peligros para garantizar la seguridad del personal y del medio ambiente.", "excerpt_keywords": "Keywords: pharmaceutical, active ingredient, airlock, batch number, regulatory authority"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f93398a3-9fb1-40c4-83fe-4ce3a7d251fe", "node_type": "4", "metadata": {"page_label": "110", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "International Nonproprietary Names (INN) for pharmaceutical substances designated by WHO should be used when available, together with other designated names.\n\n# Glossary\n\nThe definitions given below apply to the terms used in this guide.\n\nThey may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for use either by people or for goods and/or equipment.\n\n**authorized person**  \nThe person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n\n**batch (or lot)**  \nA defined quantity of starting material, packaging material, or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch. In the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. In continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis, etc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4301404057f4941dabed4d7dd4e75ce59064758652131514a0a12601a04d38c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "International Nonproprietary Names (INN) for pharmaceutical substances designated by WHO should be used when available, together with other designated names.\n\n# Glossary\n\nThe definitions given below apply to the terms used in this guide.\n\nThey may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for use either by people or for goods and/or equipment.\n\n**authorized person**  \nThe person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n\n**batch (or lot)**  \nA defined quantity of starting material, packaging material, or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch. In the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. In continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis, etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2240, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "65e270d1-6244-4912-94c5-b437946a0b3a": {"__data__": {"id_": "65e270d1-6244-4912-94c5-b437946a0b3a", "embedding": null, "metadata": {"page_label": "111", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# batch records\n\nAll documents associated with the manufacture of a batch of bulk product or finished product. They provide a history of each batch of product and of all circumstances pertinent to the quality of the final product.\n\n# bulk product\n\nAny product that has completed all processing stages up to, but not including, final packaging.\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording, and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n# clean area\n\nAn area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation, and retention of contaminants within the area.\n\n# consignment (or delivery)\n\nThe quantity of a pharmaceutical(s), made by one manufacturer and supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include material belonging to more than one batch.\n\n# contamination\n\nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material or intermediate during production, sampling, packaging or repackaging, storage or transport.\n\n# critical operation\n\nAn operation in the manufacturing process that may cause variation in the quality of the pharmaceutical product.\n\n# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# finished product\n\nA finished dosage form that has undergone all stages of manufacture, including packaging in its final container and labelling.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones y procedimientos cr\u00edticos para asegurar la calidad y seguridad de los productos. Se discuten t\u00e9rminos como \"registros de lote\", \"producto a granel\", \"calibraci\u00f3n\", \"\u00e1rea limpia\", \"contaminaci\u00f3n\", \"operaci\u00f3n cr\u00edtica\", \"contaminaci\u00f3n cruzada\" y \"producto terminado\".\n\n### Preguntas:\n1. **\u00bfQu\u00e9 documentos son necesarios para garantizar la calidad de un lote de producto farmac\u00e9utico y qu\u00e9 informaci\u00f3n espec\u00edfica deben contener?**\n   - Esta pregunta se centra en los \"registros de lote\" y su importancia en el proceso de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las medidas que se deben tomar para evitar la contaminaci\u00f3n cruzada durante la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta aborda el concepto de \"contaminaci\u00f3n cruzada\" y las pr\u00e1cticas necesarias para prevenirla, lo que es crucial para la seguridad del producto.\n\n3. **\u00bfQu\u00e9 criterios se deben establecer para la calibraci\u00f3n de instrumentos de medici\u00f3n en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se enfoca en el proceso de \"calibraci\u00f3n\" y los l\u00edmites de aceptaci\u00f3n que son esenciales para asegurar la precisi\u00f3n en la medici\u00f3n durante la producci\u00f3n.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otras fuentes, centr\u00e1ndose en los procedimientos y definiciones clave del contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda conceptos fundamentales en la fabricaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos, proporcionando definiciones esenciales que son cruciales para la comprensi\u00f3n de los procesos de producci\u00f3n y control de calidad en la industria. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Nombres No Propietarios Internacionales (INN)**: Se enfatiza la importancia de utilizar los INN designados por la OMS para las sustancias farmac\u00e9uticas, junto con otros nombres designados.\n\n2. **Definiciones Clave**:\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia o mezcla utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efectos directos en el tratamiento de enfermedades.\n   - **Airlock**: Espacio cerrado con m\u00faltiples puertas que controla el flujo de aire entre habitaciones de diferentes niveles de limpieza, utilizado para el acceso seguro de personas y equipos.\n   - **Persona Autorizada**: Individuo reconocido por la autoridad reguladora nacional, responsable de asegurar que cada lote de producto terminado cumpla con las regulaciones y leyes vigentes.\n   - **Lote (Batch)**: Cantidad definida de material procesado en un solo proceso, esperado ser homog\u00e9neo, que puede dividirse en sub-lotes.\n   - **N\u00famero de Lote (Batch Number)**: Combinaci\u00f3n distintiva de n\u00fameros y/o letras que identifica de manera \u00fanica un lote en etiquetas y registros.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que designa los INN para sustancias farmac\u00e9uticas.\n- **Autoridad Reguladora Nacional**: Organismo que reconoce a la persona autorizada y establece las normativas para la fabricaci\u00f3n y liberaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los t\u00e9rminos y conceptos esenciales que son fundamentales para la regulaci\u00f3n y producci\u00f3n en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: batch records, bulk product, calibration, contamination, finished product"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "98c91bf7-a815-4f49-9ee7-f0a206532709", "node_type": "4", "metadata": {"page_label": "111", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# batch records\n\nAll documents associated with the manufacture of a batch of bulk product or finished product. They provide a history of each batch of product and of all circumstances pertinent to the quality of the final product.\n\n# bulk product\n\nAny product that has completed all processing stages up to, but not including, final packaging.\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording, and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n# clean area\n\nAn area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation, and retention of contaminants within the area.\n\n# consignment (or delivery)\n\nThe quantity of a pharmaceutical(s), made by one manufacturer and supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include material belonging to more than one batch.\n\n# contamination\n\nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material or intermediate during production, sampling, packaging or repackaging, storage or transport.\n\n# critical operation\n\nAn operation in the manufacturing process that may cause variation in the quality of the pharmaceutical product.\n\n# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# finished product\n\nA finished dosage form that has undergone all stages of manufacture, including packaging in its final container and labelling.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f9c0b0f2802691885ab7d19f65e0372fd7bdaf2ff1c6536eabef3a4ef74f8c04", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# batch records\n\nAll documents associated with the manufacture of a batch of bulk product or finished product. They provide a history of each batch of product and of all circumstances pertinent to the quality of the final product.\n\n# bulk product\n\nAny product that has completed all processing stages up to, but not including, final packaging.\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording, and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n# clean area\n\nAn area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation, and retention of contaminants within the area.\n\n# consignment (or delivery)\n\nThe quantity of a pharmaceutical(s), made by one manufacturer and supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include material belonging to more than one batch.\n\n# contamination\n\nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material or intermediate during production, sampling, packaging or repackaging, storage or transport.\n\n# critical operation\n\nAn operation in the manufacturing process that may cause variation in the quality of the pharmaceutical product.\n\n# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# finished product\n\nA finished dosage form that has undergone all stages of manufacture, including packaging in its final container and labelling.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1949, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dd90313b-6e2a-484c-83ac-371dd5bcb57e": {"__data__": {"id_": "dd90313b-6e2a-484c-83ac-371dd5bcb57e", "embedding": null, "metadata": {"page_label": "112", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# In-Process Control\n\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# Intermediate Product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk product.\n\n# Large-Volume Parenterals\n\nSterile solutions intended for parenteral application with a volume of 100 ml or more in one container of the finished dosage form.\n\n# Manufacture\n\nAll operations of purchase of materials and products, production, quality control (QC), release, storage and distribution of pharmaceutical products, and the related controls.\n\n# Manufacturer\n\nA company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals.\n\n# Marketing Authorization (Product Licence, Registration Certificate)\n\nA legal document issued by the competent medicines regulatory authority that establishes the detailed composition and formulation of the product and the pharmacopoeial or other recognized specifications of its ingredients and of the final product itself, and includes details of packaging, labelling and shelf-life.\n\n# Master Formula\n\nA document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.\n\n# Master Record\n\nA document or set of documents that serve as a basis for the batch documentation (blank batch record).\n\n# Packaging\n\nAll operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 961 aborda varios conceptos clave relacionados con la producci\u00f3n y control de productos farmac\u00e9uticos. Se definen t\u00e9rminos como \"control en proceso\", \"producto intermedio\", \"parenterales de gran volumen\", \"fabricaci\u00f3n\", \"fabricante\", \"autorizaci\u00f3n de comercializaci\u00f3n\", \"f\u00f3rmula maestra\", \"registro maestro\" y \"empaquetado\". Cada uno de estos t\u00e9rminos se relaciona con las operaciones y regulaciones necesarias para garantizar que los productos farmac\u00e9uticos cumplan con las especificaciones y est\u00e1ndares de calidad.\n\n### Preguntas\n1. **\u00bfQu\u00e9 incluye el control en proceso durante la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: El control en proceso incluye las verificaciones realizadas durante la producci\u00f3n para monitorear y, si es necesario, ajustar el proceso para asegurar que el producto cumpla con sus especificaciones. Tambi\u00e9n puede incluir el control del entorno o del equipo.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto intermedio y un producto terminado en el contexto de la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un producto intermedio es un producto que ha sido parcialmente procesado y que debe someterse a pasos adicionales de fabricaci\u00f3n antes de convertirse en un producto a granel, mientras que un producto terminado es aquel que ha completado todos los procesos de fabricaci\u00f3n y est\u00e1 listo para su distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en una autorizaci\u00f3n de comercializaci\u00f3n para un producto farmac\u00e9utico?**\n   - Respuesta: Una autorizaci\u00f3n de comercializaci\u00f3n incluye un documento legal emitido por la autoridad reguladora competente que establece la composici\u00f3n detallada y la formulaci\u00f3n del producto, las especificaciones reconocidas de sus ingredientes y del producto final, as\u00ed como detalles sobre el empaquetado, etiquetado y vida \u00fatil del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Registros de Lote**: Documentos que registran la fabricaci\u00f3n de un lote de producto farmac\u00e9utico, proporcionando un historial y detalles relevantes para asegurar la calidad del producto final.\n\n2. **Producto a Granel**: Se refiere a productos que han completado todas las etapas de procesamiento, excepto el empaquetado final.\n\n3. **Calibraci\u00f3n**: Proceso que establece la relaci\u00f3n entre los valores medidos por un instrumento y los valores de un est\u00e1ndar de referencia, incluyendo la necesidad de establecer l\u00edmites de aceptaci\u00f3n para los resultados.\n\n4. **\u00c1rea Limpia**: Espacio controlado ambientalmente para minimizar la contaminaci\u00f3n particulada y microbiana, dise\u00f1ado para reducir la introducci\u00f3n y retenci\u00f3n de contaminantes.\n\n5. **Consignaci\u00f3n (o Entrega)**: Cantidad de productos farmac\u00e9uticos suministrados por un fabricante en respuesta a un pedido, que puede incluir m\u00faltiples paquetes o contenedores.\n\n6. **Contaminaci\u00f3n**: Introducci\u00f3n no deseada de impurezas qu\u00edmicas o microbiol\u00f3gicas en materiales durante diversas etapas de producci\u00f3n y transporte.\n\n7. **Operaci\u00f3n Cr\u00edtica**: Etapa en el proceso de fabricaci\u00f3n que puede afectar la calidad del producto farmac\u00e9utico.\n\n8. **Contaminaci\u00f3n Cruzada**: Contaminaci\u00f3n de un material o producto con otro durante el proceso de producci\u00f3n.\n\n9. **Producto Terminado**: Forma de dosificaci\u00f3n que ha completado todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado y etiquetado final.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren un control riguroso en su fabricaci\u00f3n para garantizar su calidad y seguridad.\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de los procedimientos y controles para asegurar la calidad del producto final.", "excerpt_keywords": "Keywords: In-Process Control, Intermediate Product, Marketing Authorization, Master Formula, Large-Volume Parenterals"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "27116857-0b72-4473-9308-685cab6e04f3", "node_type": "4", "metadata": {"page_label": "112", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# In-Process Control\n\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# Intermediate Product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk product.\n\n# Large-Volume Parenterals\n\nSterile solutions intended for parenteral application with a volume of 100 ml or more in one container of the finished dosage form.\n\n# Manufacture\n\nAll operations of purchase of materials and products, production, quality control (QC), release, storage and distribution of pharmaceutical products, and the related controls.\n\n# Manufacturer\n\nA company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals.\n\n# Marketing Authorization (Product Licence, Registration Certificate)\n\nA legal document issued by the competent medicines regulatory authority that establishes the detailed composition and formulation of the product and the pharmacopoeial or other recognized specifications of its ingredients and of the final product itself, and includes details of packaging, labelling and shelf-life.\n\n# Master Formula\n\nA document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.\n\n# Master Record\n\nA document or set of documents that serve as a basis for the batch documentation (blank batch record).\n\n# Packaging\n\nAll operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1209ad98467393feff6a319a4b0bc4725a89c1483a15971a7c96bf09459638cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# In-Process Control\n\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# Intermediate Product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk product.\n\n# Large-Volume Parenterals\n\nSterile solutions intended for parenteral application with a volume of 100 ml or more in one container of the finished dosage form.\n\n# Manufacture\n\nAll operations of purchase of materials and products, production, quality control (QC), release, storage and distribution of pharmaceutical products, and the related controls.\n\n# Manufacturer\n\nA company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals.\n\n# Marketing Authorization (Product Licence, Registration Certificate)\n\nA legal document issued by the competent medicines regulatory authority that establishes the detailed composition and formulation of the product and the pharmacopoeial or other recognized specifications of its ingredients and of the final product itself, and includes details of packaging, labelling and shelf-life.\n\n# Master Formula\n\nA document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.\n\n# Master Record\n\nA document or set of documents that serve as a basis for the batch documentation (blank batch record).\n\n# Packaging\n\nAll operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2041, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "45d0c3fd-66f4-4b83-905c-818d550d556e": {"__data__": {"id_": "45d0c3fd-66f4-4b83-905c-818d550d556e", "embedding": null, "metadata": {"page_label": "113", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# packaging material\n\nAny material, including printed material, employed in the packaging of a pharmaceutical, but excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product.\n\n# pharmaceutical product\n\nAny material or product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form, that is subject to control by pharmaceutical legislation in the exporting state and/or the importing state.\n\n# production\n\nAll operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product.\n\n# qualification\n\nAction of proving that any premises, systems and items of equipment work correctly and actually lead to the expected results. The meaning of the word \u201cvalidation\u201d is sometimes extended to incorporate the concept of qualification.\n\n# quality assurance\n\nSee Part One (6).\n\n# quality control\n\nSee Part One (6).\n\n# quality unit(s)\n\nAn organizational unit independent of production which fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\n\nThe status of starting or packaging materials, intermediates, or bulk or finished products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n# reconciliation\n\nA comparison between the theoretical quantity and the actual quantity.\n\n# recovery\n\nThe introduction of all or part of previous batches (or of redistilled solvents and similar products) of the required quality into another batch at a defined stage.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Definici\u00f3n de Materiales de Empaque**: El documento define qu\u00e9 se entiende por materiales de empaque en el contexto farmac\u00e9utico, diferenciando entre materiales primarios y secundarios, y excluyendo el empaque exterior utilizado para transporte.\n\n2. **Concepto de Producto Farmac\u00e9utico**: Se establece que un producto farmac\u00e9utico puede ser cualquier material destinado al uso humano o veterinario, que est\u00e9 sujeto a la legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador o importador.\n\n3. **Proceso de Producci\u00f3n**: Se describe el proceso completo de producci\u00f3n de un producto farmac\u00e9utico, desde la recepci\u00f3n de materiales hasta la finalizaci\u00f3n del producto, incluyendo etapas como el etiquetado y el envasado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre los materiales de empaque primarios y secundarios en la industria farmac\u00e9utica?**\n   - Esta pregunta busca una aclaraci\u00f3n sobre la clasificaci\u00f3n de los materiales de empaque, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 implica el proceso de calificaci\u00f3n en la producci\u00f3n farmac\u00e9utica y c\u00f3mo se relaciona con la validaci\u00f3n?**\n   - Esta pregunta se centra en el concepto de calificaci\u00f3n y su relaci\u00f3n con la validaci\u00f3n, proporcionando una comprensi\u00f3n m\u00e1s profunda de estos t\u00e9rminos t\u00e9cnicos.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las unidades de calidad en la organizaci\u00f3n de producci\u00f3n farmac\u00e9utica y c\u00f3mo se estructuran?**\n   - Esta pregunta busca informaci\u00f3n sobre la estructura y funciones de las unidades de calidad, que es un aspecto crucial en la garant\u00eda de la calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en la Serie de Informes T\u00e9cnicos 961 aborda varios conceptos fundamentales relacionados con la producci\u00f3n y control de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Control en Proceso**: Se refiere a las verificaciones realizadas durante la producci\u00f3n para asegurar que el producto cumpla con sus especificaciones, incluyendo el control del entorno y del equipo.\n\n2. **Producto Intermedio**: Es un producto que ha sido parcialmente procesado y que requiere pasos adicionales de fabricaci\u00f3n antes de convertirse en un producto a granel.\n\n3. **Parenterales de Gran Volumen**: Soluciones est\u00e9riles destinadas a la aplicaci\u00f3n parenteral con un volumen de 100 ml o m\u00e1s en un solo contenedor.\n\n4. **Fabricaci\u00f3n**: Engloba todas las operaciones relacionadas con la compra de materiales, producci\u00f3n, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n5. **Fabricante**: Una empresa que realiza operaciones como producci\u00f3n, empaquetado, reempaquetado, etiquetado y reetiquetado de productos farmac\u00e9uticos.\n\n6. **Autorizaci\u00f3n de Comercializaci\u00f3n**: Documento legal emitido por la autoridad reguladora que establece la composici\u00f3n, formulaci\u00f3n, especificaciones y detalles de empaquetado y etiquetado del producto.\n\n7. **F\u00f3rmula Maestra**: Documento que especifica los materiales iniciales, sus cantidades, materiales de empaquetado y procedimientos necesarios para producir una cantidad espec\u00edfica de un producto terminado.\n\n8. **Registro Maestro**: Documento que sirve como base para la documentaci\u00f3n de lotes.\n\n9. **Embalaje**: Todas las operaciones, incluyendo el llenado y etiquetado, que un producto a granel debe pasar para convertirse en un producto terminado.\n\n### Conclusi\u00f3n\nEstos t\u00e9rminos y conceptos son esenciales para entender el proceso de fabricaci\u00f3n y control de calidad en la industria farmac\u00e9utica, asegurando que los productos cumplan con los est\u00e1ndares requeridos para su seguridad y eficacia.", "excerpt_keywords": "Keywords: packaging material, pharmaceutical product, production, quality assurance, qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "81be738d-dbc4-4bcc-827c-4686cd9c6e93", "node_type": "4", "metadata": {"page_label": "113", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# packaging material\n\nAny material, including printed material, employed in the packaging of a pharmaceutical, but excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product.\n\n# pharmaceutical product\n\nAny material or product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form, that is subject to control by pharmaceutical legislation in the exporting state and/or the importing state.\n\n# production\n\nAll operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product.\n\n# qualification\n\nAction of proving that any premises, systems and items of equipment work correctly and actually lead to the expected results. The meaning of the word \u201cvalidation\u201d is sometimes extended to incorporate the concept of qualification.\n\n# quality assurance\n\nSee Part One (6).\n\n# quality control\n\nSee Part One (6).\n\n# quality unit(s)\n\nAn organizational unit independent of production which fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\n\nThe status of starting or packaging materials, intermediates, or bulk or finished products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n# reconciliation\n\nA comparison between the theoretical quantity and the actual quantity.\n\n# recovery\n\nThe introduction of all or part of previous batches (or of redistilled solvents and similar products) of the required quality into another batch at a defined stage.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "18be9b7d8bf076b3b59e006576fb5fcb76c3fceff3363df28694adf36cd95ea2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# packaging material\n\nAny material, including printed material, employed in the packaging of a pharmaceutical, but excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product.\n\n# pharmaceutical product\n\nAny material or product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form, that is subject to control by pharmaceutical legislation in the exporting state and/or the importing state.\n\n# production\n\nAll operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product.\n\n# qualification\n\nAction of proving that any premises, systems and items of equipment work correctly and actually lead to the expected results. The meaning of the word \u201cvalidation\u201d is sometimes extended to incorporate the concept of qualification.\n\n# quality assurance\n\nSee Part One (6).\n\n# quality control\n\nSee Part One (6).\n\n# quality unit(s)\n\nAn organizational unit independent of production which fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\n\nThe status of starting or packaging materials, intermediates, or bulk or finished products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n# reconciliation\n\nA comparison between the theoretical quantity and the actual quantity.\n\n# recovery\n\nThe introduction of all or part of previous batches (or of redistilled solvents and similar products) of the required quality into another batch at a defined stage.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1966, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2b2418f3-34a4-4344-8404-a249f12e4f19": {"__data__": {"id_": "2b2418f3-34a4-4344-8404-a249f12e4f19", "embedding": null, "metadata": {"page_label": "114", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "stage of manufacture. It includes the removal of impurities from waste to obtain a pure substance or the recovery of used materials for a separate use.\n\n**reprocessing**  \nSubjecting all or part of a batch or lot of an in-process medicine, bulk process intermediate (final biological bulk intermediate) or bulk product of a single batch/lot to a previous step in the validated manufacturing process due to failure to meet predetermined specifications. Reprocessing procedures are foreseen as occasionally necessary for biological medicines and, in such cases, are validated and pre-approved as part of the marketing authorization.\n\n**reworking**  \nSubjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre-approved as part of the marketing authorization.\n\n**self-contained area**  \nPremises which provide complete and total separation of all aspects of an operation, including personnel and equipment movement, with well established procedures, controls and monitoring. This includes physical barriers as well as separate air-handling systems, but does not necessarily imply two distinct and separate buildings.\n\n**specification**  \nA list of detailed requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation.\n\n**standard operating procedure (SOP)**  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning; validation; cleaning of premises and environmental control; sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n**starting material**  \nAny substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials.\n\n**validation**  \nAction of proving, in accordance with the principles of GMP, that any procedure, process, equipment, material, activity or system actually leads to the expected results (see also qualification).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones y procedimientos relacionados con la reprocesamiento y reworking de medicamentos, la importancia de \u00e1reas auto contenidas, especificaciones de calidad, procedimientos operativos est\u00e1ndar (SOP), materiales de inicio y el proceso de validaci\u00f3n. Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares de calidad y seguridad establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre reprocessing y reworking en el contexto de la fabricaci\u00f3n de medicamentos?**\n   - Respuesta: El reprocessing implica someter una parte de un lote de un medicamento en proceso a un paso anterior en el proceso de fabricaci\u00f3n validado debido a que no cumple con especificaciones predeterminadas, y est\u00e1 preaprobado como parte de la autorizaci\u00f3n de comercializaci\u00f3n. En cambio, el reworking se refiere a someter un producto final o intermedio a un proceso alternativo debido a un fallo en las especificaciones, y no est\u00e1 preaprobado.\n\n2. **\u00bfQu\u00e9 se entiende por un \u00e1rea auto contenida y por qu\u00e9 es importante en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Un \u00e1rea auto contenida es un espacio que proporciona separaci\u00f3n total de todos los aspectos de una operaci\u00f3n, incluyendo el movimiento de personal y equipos, con procedimientos y controles bien establecidos. Es importante porque ayuda a prevenir la contaminaci\u00f3n cruzada y asegura que se mantengan las condiciones de calidad necesarias durante la fabricaci\u00f3n.\n\n3. **\u00bfQu\u00e9 papel juegan las especificaciones en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las especificaciones son una lista de requisitos detallados que los productos o materiales utilizados en la fabricaci\u00f3n deben cumplir. Sirven como base para la evaluaci\u00f3n de calidad, asegurando que los productos finales sean seguros y efectivos para su uso.", "prev_section_summary": "### Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Materiales de Empaque**:\n   - Definici\u00f3n: Materiales utilizados en el empaque de productos farmac\u00e9uticos, excluyendo el empaque exterior para transporte.\n   - Clasificaci\u00f3n: Primarios (en contacto directo con el producto) y secundarios (sin contacto directo).\n\n2. **Producto Farmac\u00e9utico**:\n   - Definici\u00f3n: Material o producto destinado al uso humano o veterinario, presentado en forma de dosis terminada o como materia prima, sujeto a legislaci\u00f3n farmac\u00e9utica.\n\n3. **Producci\u00f3n**:\n   - Proceso: Incluye todas las operaciones desde la recepci\u00f3n de materiales hasta la finalizaci\u00f3n del producto, abarcando procesamiento, empaque, etiquetado y reetiquetado.\n\n4. **Calificaci\u00f3n**:\n   - Definici\u00f3n: Proceso de demostrar que instalaciones, sistemas y equipos funcionan correctamente y producen los resultados esperados. Relaci\u00f3n con la validaci\u00f3n.\n\n5. **Unidades de Calidad**:\n   - Estructura: Unidad organizativa independiente de producci\u00f3n que cumple funciones de aseguramiento y control de calidad, que puede ser una unidad separada o un grupo \u00fanico.\n\n6. **Otros T\u00e9rminos Clave**:\n   - **Cuarentena**: Estado de materiales aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n   - **Reconciliaci\u00f3n**: Comparaci\u00f3n entre la cantidad te\u00f3rica y la cantidad real.\n   - **Recuperaci\u00f3n**: Introducci\u00f3n de lotes anteriores de calidad requerida en un nuevo lote en una etapa definida.\n\n### Entidades:\n- **Organizaci\u00f3n**: Unidades de calidad (QA y QC).\n- **Legislaci\u00f3n**: Legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador e importador.\n- **Productos**: Productos farmac\u00e9uticos, materiales de empaque, materias primas.", "excerpt_keywords": "Keywords: reprocessing, reworking, self-contained area, specifications, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3833504c-700e-4bc5-9bad-a5ab10b8e627", "node_type": "4", "metadata": {"page_label": "114", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "stage of manufacture. It includes the removal of impurities from waste to obtain a pure substance or the recovery of used materials for a separate use.\n\n**reprocessing**  \nSubjecting all or part of a batch or lot of an in-process medicine, bulk process intermediate (final biological bulk intermediate) or bulk product of a single batch/lot to a previous step in the validated manufacturing process due to failure to meet predetermined specifications. Reprocessing procedures are foreseen as occasionally necessary for biological medicines and, in such cases, are validated and pre-approved as part of the marketing authorization.\n\n**reworking**  \nSubjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre-approved as part of the marketing authorization.\n\n**self-contained area**  \nPremises which provide complete and total separation of all aspects of an operation, including personnel and equipment movement, with well established procedures, controls and monitoring. This includes physical barriers as well as separate air-handling systems, but does not necessarily imply two distinct and separate buildings.\n\n**specification**  \nA list of detailed requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation.\n\n**standard operating procedure (SOP)**  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning; validation; cleaning of premises and environmental control; sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n**starting material**  \nAny substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials.\n\n**validation**  \nAction of proving, in accordance with the principles of GMP, that any procedure, process, equipment, material, activity or system actually leads to the expected results (see also qualification).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "28a414e91e94ea704d0c9c114c2b7e5bea21fe3886bf3f30ce2cddce30908c8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "stage of manufacture. It includes the removal of impurities from waste to obtain a pure substance or the recovery of used materials for a separate use.\n\n**reprocessing**  \nSubjecting all or part of a batch or lot of an in-process medicine, bulk process intermediate (final biological bulk intermediate) or bulk product of a single batch/lot to a previous step in the validated manufacturing process due to failure to meet predetermined specifications. Reprocessing procedures are foreseen as occasionally necessary for biological medicines and, in such cases, are validated and pre-approved as part of the marketing authorization.\n\n**reworking**  \nSubjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre-approved as part of the marketing authorization.\n\n**self-contained area**  \nPremises which provide complete and total separation of all aspects of an operation, including personnel and equipment movement, with well established procedures, controls and monitoring. This includes physical barriers as well as separate air-handling systems, but does not necessarily imply two distinct and separate buildings.\n\n**specification**  \nA list of detailed requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation.\n\n**standard operating procedure (SOP)**  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning; validation; cleaning of premises and environmental control; sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n**starting material**  \nAny substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials.\n\n**validation**  \nAction of proving, in accordance with the principles of GMP, that any procedure, process, equipment, material, activity or system actually leads to the expected results (see also qualification).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2288, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2c8cd534-3ffc-44c8-9b97-db383f6fc67c": {"__data__": {"id_": "2c8cd534-3ffc-44c8-9b97-db383f6fc67c", "embedding": null, "metadata": {"page_label": "115", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality management in the medicines industry: philosophy and essential elements\n\nIn the medicines industry at large, quality management is usually defined as the aspect of management function that determines and implements the \u201cquality policy\u201d, i.e. the overall intention and direction of an organization regarding quality, as formally expressed and authorized by top management.\n\nThe basic elements of quality management are:\n\n\u2014 an appropriate infrastructure or \u201cquality system\u201d, encompassing the organizational structure, procedures, processes and resources; and  \n\u2014 systematic actions necessary to ensure adequate confidence that a product (or service) will satisfy given requirements for quality.\n\nThe totality of these actions is termed \u201cquality assurance\u201d (QA). Within an organization, QA serves as a management tool. In contractual situations, QA also serves to generate confidence in the supplier.\n\nThe concepts of QA, GMP, QC and quality risk management (QRM) are interrelated aspects of quality management and should be the responsibility of all personnel. They are described here in order to emphasize their relationship and their fundamental importance to the production and control of pharmaceutical products.\n\n## 1. Quality assurance\n\n### 1.1 Principle\n\nQA is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use. QA, therefore, incorporates GMP and other factors, including those outside the scope of this guide such as product design and development.\n\n### 1.2 The system of QA appropriate to the manufacture of pharmaceutical products should ensure that:\n\n(a) pharmaceutical products are designed and developed in a way that takes account of the requirements of GMP and other associated codes such\n\n----\n\n<sup>6</sup> Good manufacturing practices for pharmaceutical products, Part One. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Definici\u00f3n de gesti\u00f3n de calidad en la industria farmac\u00e9utica**: La gesti\u00f3n de calidad se refiere a la funci\u00f3n de gesti\u00f3n que establece y aplica la pol\u00edtica de calidad de una organizaci\u00f3n, asegurando que los productos farmac\u00e9uticos cumplan con los requisitos de calidad necesarios para su uso previsto.\n\n2. **Elementos b\u00e1sicos de la gesti\u00f3n de calidad**: Incluyen un sistema de calidad adecuado que abarca la estructura organizativa, procedimientos, procesos y recursos, as\u00ed como acciones sistem\u00e1ticas para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n3. **Relaci\u00f3n entre QA, GMP, QC y QRM**: Estos conceptos son aspectos interrelacionados de la gesti\u00f3n de calidad que deben ser responsabilidad de todo el personal involucrado en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de la gesti\u00f3n de calidad para el dise\u00f1o y desarrollo de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en c\u00f3mo la gesti\u00f3n de calidad influye en las etapas iniciales de creaci\u00f3n de un producto, lo que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 papel juega la garant\u00eda de calidad (QA) como herramienta de gesti\u00f3n dentro de una organizaci\u00f3n farmac\u00e9utica?**\n   - Aqu\u00ed se busca entender el uso pr\u00e1ctico de QA como un mecanismo de control y confianza, un aspecto que puede no ser ampliamente discutido en otros contextos.\n\n3. **\u00bfC\u00f3mo se relacionan los conceptos de QA, GMP, QC y QRM en la pr\u00e1ctica diaria de la industria farmac\u00e9utica?**\n   - Esta pregunta explora la interconexi\u00f3n de estos conceptos en la operaci\u00f3n diaria, lo que puede no ser evidente en otros textos que abordan cada uno de estos temas de manera aislada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reprocessing**: Proceso que implica someter un lote de medicamento en proceso a un paso anterior en la fabricaci\u00f3n debido a que no cumple con especificaciones predeterminadas. Este procedimiento es validado y preaprobado como parte de la autorizaci\u00f3n de comercializaci\u00f3n, especialmente en medicamentos biol\u00f3gicos.\n\n2. **Reworking**: Proceso que consiste en someter un producto final o intermedio a un proceso alternativo debido a un fallo en las especificaciones. A diferencia del reprocessing, el reworking es un evento inesperado y no est\u00e1 preaprobado.\n\n3. **\u00c1rea Auto Contenida**: Espacio que proporciona separaci\u00f3n total de todos los aspectos de una operaci\u00f3n, incluyendo el movimiento de personal y equipos, con procedimientos y controles bien establecidos. Es crucial para prevenir la contaminaci\u00f3n cruzada y mantener la calidad.\n\n4. **Especificaciones**: Lista de requisitos detallados que los productos o materiales deben cumplir durante la fabricaci\u00f3n. Son fundamentales para la evaluaci\u00f3n de calidad.\n\n5. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones que no son espec\u00edficas de un producto o material en particular. Incluye aspectos como operaci\u00f3n de equipos, mantenimiento, limpieza y control ambiental.\n\n6. **Material de Inicio**: Sustancia de calidad definida utilizada en la producci\u00f3n de un producto farmac\u00e9utico, excluyendo materiales de embalaje.\n\n7. **Validaci\u00f3n**: Proceso de demostrar que cualquier procedimiento, proceso, equipo, material, actividad o sistema cumple con los resultados esperados, de acuerdo con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medicamentos Biol\u00f3gicos**\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**\n- **Productos Farmac\u00e9uticos**\n- **Autorizaci\u00f3n de Comercializaci\u00f3n** \n\nEste resumen abarca los conceptos fundamentales y las entidades relevantes en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: quality management, quality assurance, pharmaceutical products, good manufacturing practices, quality risk management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6132a061-25a2-46a9-bf20-bc4885c781f0", "node_type": "4", "metadata": {"page_label": "115", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality management in the medicines industry: philosophy and essential elements\n\nIn the medicines industry at large, quality management is usually defined as the aspect of management function that determines and implements the \u201cquality policy\u201d, i.e. the overall intention and direction of an organization regarding quality, as formally expressed and authorized by top management.\n\nThe basic elements of quality management are:\n\n\u2014 an appropriate infrastructure or \u201cquality system\u201d, encompassing the organizational structure, procedures, processes and resources; and  \n\u2014 systematic actions necessary to ensure adequate confidence that a product (or service) will satisfy given requirements for quality.\n\nThe totality of these actions is termed \u201cquality assurance\u201d (QA). Within an organization, QA serves as a management tool. In contractual situations, QA also serves to generate confidence in the supplier.\n\nThe concepts of QA, GMP, QC and quality risk management (QRM) are interrelated aspects of quality management and should be the responsibility of all personnel. They are described here in order to emphasize their relationship and their fundamental importance to the production and control of pharmaceutical products.\n\n## 1. Quality assurance\n\n### 1.1 Principle\n\nQA is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use. QA, therefore, incorporates GMP and other factors, including those outside the scope of this guide such as product design and development.\n\n### 1.2 The system of QA appropriate to the manufacture of pharmaceutical products should ensure that:\n\n(a) pharmaceutical products are designed and developed in a way that takes account of the requirements of GMP and other associated codes such\n\n----\n\n<sup>6</sup> Good manufacturing practices for pharmaceutical products, Part One. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ad6c81e11d4a3dd1303da23099b051ccd2be1c168e7f04417f0e6d2dbe85c6a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality management in the medicines industry: philosophy and essential elements\n\nIn the medicines industry at large, quality management is usually defined as the aspect of management function that determines and implements the \u201cquality policy\u201d, i.e. the overall intention and direction of an organization regarding quality, as formally expressed and authorized by top management.\n\nThe basic elements of quality management are:\n\n\u2014 an appropriate infrastructure or \u201cquality system\u201d, encompassing the organizational structure, procedures, processes and resources; and  \n\u2014 systematic actions necessary to ensure adequate confidence that a product (or service) will satisfy given requirements for quality.\n\nThe totality of these actions is termed \u201cquality assurance\u201d (QA). Within an organization, QA serves as a management tool. In contractual situations, QA also serves to generate confidence in the supplier.\n\nThe concepts of QA, GMP, QC and quality risk management (QRM) are interrelated aspects of quality management and should be the responsibility of all personnel. They are described here in order to emphasize their relationship and their fundamental importance to the production and control of pharmaceutical products.\n\n## 1. Quality assurance\n\n### 1.1 Principle\n\nQA is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use. QA, therefore, incorporates GMP and other factors, including those outside the scope of this guide such as product design and development.\n\n### 1.2 The system of QA appropriate to the manufacture of pharmaceutical products should ensure that:\n\n(a) pharmaceutical products are designed and developed in a way that takes account of the requirements of GMP and other associated codes such\n\n----\n\n<sup>6</sup> Good manufacturing practices for pharmaceutical products, Part One. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2571, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1f19a8f7-2bec-4fc8-a888-386a761cbdfc": {"__data__": {"id_": "1f19a8f7-2bec-4fc8-a888-386a761cbdfc", "embedding": null, "metadata": {"page_label": "116", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nas those of good laboratory practice (GLP)<sup>7</sup> and good clinical practice (GCP);\n\n(b) production and control operations are clearly specified in a written form and GMP requirements are adopted;\n\n(c) managerial responsibilities are clearly specified in job descriptions;\n\n(d) arrangements are made for the manufacture, supply and use of the correct starting and packaging materials;\n\n(e) all necessary controls on starting materials, intermediate products, and bulk products and other in-process controls, calibrations, and validations are carried out;\n\n(f) the finished product is correctly processed and checked, according to the defined procedures;\n\n(g) pharmaceutical products are not sold or supplied before the authorized persons (see also sections 9.11 & 9.12) have certified that each production batch has been produced and controlled in accordance with the requirements of the marketing authorization and any other regulations relevant to the production, control and release of pharmaceutical products;\n\n(h) satisfactory arrangements exist to ensure, as far as possible, that the pharmaceutical products are stored by the manufacturer, distributed, and subsequently handled so that quality is maintained throughout their shelf-life;\n\n(i) there is a procedure for self-inspection and/or quality audit that regularly appraises the effectiveness and applicability of the QA system;\n\n(j) deviations are reported, investigated and recorded;\n\n(k) there is a system for approving changes that may have an impact on product quality;\n\n(l) regular evaluations of the quality of pharmaceutical products should be conducted with the objective of verifying the consistency of the process and ensuring its continuous improvement; and\n\n(m) there is a system for QRM.\n\n1.3 The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the marketing authorization and do not place patients at risk due to inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment of staff in many different departments and at all levels within the company, the company\u2019s\n\n----\n\n<sup>7</sup> This is a code governing the testing of chemicals to obtain data on their properties and ensuring safety with respect to human health and the environment. It is different from that described in \"Good laboratory practices in governmental drug control laboratories\" in the Thirtieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 748, 1987, Annex 1).\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Responsabilidad del Fabricante**: El fabricante de productos farmac\u00e9uticos debe asumir la responsabilidad de garantizar que los productos sean aptos para su uso previsto, cumplan con los requisitos de autorizaci\u00f3n de comercializaci\u00f3n y no representen un riesgo para los pacientes debido a deficiencias en seguridad, calidad o eficacia. Esta responsabilidad recae en la alta direcci\u00f3n y requiere la participaci\u00f3n de todo el personal en diferentes departamentos.\n\n2. **Pr\u00e1cticas de Calidad**: Se establecen varios requisitos y procedimientos para asegurar la calidad de los productos farmac\u00e9uticos, incluyendo la especificaci\u00f3n de operaciones de producci\u00f3n y control, la gesti\u00f3n de materiales, la realizaci\u00f3n de controles necesarios, y la implementaci\u00f3n de auditor\u00edas de calidad. Adem\u00e1s, se requiere un sistema para la gesti\u00f3n de riesgos de calidad (QRM).\n\n3. **Evaluaci\u00f3n y Mejora Continua**: Es fundamental realizar evaluaciones regulares de la calidad de los productos farmac\u00e9uticos para verificar la consistencia del proceso y asegurar la mejora continua. Esto incluye la gesti\u00f3n de desviaciones y la aprobaci\u00f3n de cambios que puedan afectar la calidad del producto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar que los productos farmac\u00e9uticos no se vendan o suministren antes de recibir la certificaci\u00f3n de las personas autorizadas?**\n   - Esta pregunta se centra en el proceso de certificaci\u00f3n y control de calidad antes de la comercializaci\u00f3n de los productos.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben estar claramente definidas en las descripciones de trabajo dentro de una empresa farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre la asignaci\u00f3n de responsabilidades en la gesti\u00f3n de calidad y producci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de controles y auditor\u00edas se deben implementar para evaluar la efectividad del sistema de aseguramiento de calidad (QA) en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se enfoca en los mecanismos de evaluaci\u00f3n y auditor\u00eda que aseguran la calidad y la mejora continua en el proceso de producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Tema principal: Gesti\u00f3n de calidad en la industria farmac\u00e9utica**\n- **Definici\u00f3n**: La gesti\u00f3n de calidad se refiere a la funci\u00f3n de gesti\u00f3n que establece y aplica la pol\u00edtica de calidad de una organizaci\u00f3n, asegurando que los productos farmac\u00e9uticos cumplan con los requisitos de calidad necesarios para su uso previsto.\n\n**Elementos b\u00e1sicos de la gesti\u00f3n de calidad**:\n1. **Sistema de calidad**: Infraestructura que incluye la estructura organizativa, procedimientos, procesos y recursos.\n2. **Acciones sistem\u00e1ticas**: Acciones necesarias para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n**Conceptos interrelacionados**:\n- **Garant\u00eda de calidad (QA)**: Herramienta de gesti\u00f3n que asegura que los productos farmac\u00e9uticos cumplen con los est\u00e1ndares de calidad requeridos.\n- **Buenas pr\u00e1cticas de manufactura (GMP)**: Normativas que deben seguirse en la producci\u00f3n de productos farmac\u00e9uticos.\n- **Control de calidad (QC)**: Proceso de asegurar que los productos cumplen con los est\u00e1ndares de calidad.\n- **Gesti\u00f3n de riesgos de calidad (QRM)**: Enfoque para identificar y gestionar riesgos que pueden afectar la calidad del producto.\n\n**Responsabilidad**: La gesti\u00f3n de calidad es responsabilidad de todo el personal involucrado en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n**Implicaciones para el dise\u00f1o y desarrollo de productos**: La gesti\u00f3n de calidad influye en las etapas iniciales de creaci\u00f3n de un producto, asegurando que se consideren los requisitos de GMP y otros c\u00f3digos asociados.\n\n**Papel de QA**: Act\u00faa como un mecanismo de control y confianza dentro de la organizaci\u00f3n y en situaciones contractuales.\n\n### Entidades clave:\n- **Organizaci\u00f3n**: Entidad que implementa la pol\u00edtica de calidad.\n- **Productos farmac\u00e9uticos**: Objetos de la gesti\u00f3n de calidad.\n- **Normativas**: GMP, QC, QRM que gu\u00edan la gesti\u00f3n de calidad en la industria.", "excerpt_keywords": "Keywords: calidad farmac\u00e9utica, buenas pr\u00e1cticas de manufactura, gesti\u00f3n de riesgos, auditor\u00eda de calidad, responsabilidad del fabricante"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "caaa73ce-3153-4f64-a933-2c91e37e375c", "node_type": "4", "metadata": {"page_label": "116", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nas those of good laboratory practice (GLP)<sup>7</sup> and good clinical practice (GCP);\n\n(b) production and control operations are clearly specified in a written form and GMP requirements are adopted;\n\n(c) managerial responsibilities are clearly specified in job descriptions;\n\n(d) arrangements are made for the manufacture, supply and use of the correct starting and packaging materials;\n\n(e) all necessary controls on starting materials, intermediate products, and bulk products and other in-process controls, calibrations, and validations are carried out;\n\n(f) the finished product is correctly processed and checked, according to the defined procedures;\n\n(g) pharmaceutical products are not sold or supplied before the authorized persons (see also sections 9.11 & 9.12) have certified that each production batch has been produced and controlled in accordance with the requirements of the marketing authorization and any other regulations relevant to the production, control and release of pharmaceutical products;\n\n(h) satisfactory arrangements exist to ensure, as far as possible, that the pharmaceutical products are stored by the manufacturer, distributed, and subsequently handled so that quality is maintained throughout their shelf-life;\n\n(i) there is a procedure for self-inspection and/or quality audit that regularly appraises the effectiveness and applicability of the QA system;\n\n(j) deviations are reported, investigated and recorded;\n\n(k) there is a system for approving changes that may have an impact on product quality;\n\n(l) regular evaluations of the quality of pharmaceutical products should be conducted with the objective of verifying the consistency of the process and ensuring its continuous improvement; and\n\n(m) there is a system for QRM.\n\n1.3 The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the marketing authorization and do not place patients at risk due to inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment of staff in many different departments and at all levels within the company, the company\u2019s\n\n----\n\n<sup>7</sup> This is a code governing the testing of chemicals to obtain data on their properties and ensuring safety with respect to human health and the environment. It is different from that described in \"Good laboratory practices in governmental drug control laboratories\" in the Thirtieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 748, 1987, Annex 1).\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dbe0fa22fa526d59b077cce35fada1a435fc2182634a91281e00ac2470c5d36e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "as those of good laboratory practice (GLP)<sup>7</sup> and good clinical practice (GCP);\n\n(b) production and control operations are clearly specified in a written form and GMP requirements are adopted;\n\n(c) managerial responsibilities are clearly specified in job descriptions;\n\n(d) arrangements are made for the manufacture, supply and use of the correct starting and packaging materials;\n\n(e) all necessary controls on starting materials, intermediate products, and bulk products and other in-process controls, calibrations, and validations are carried out;\n\n(f) the finished product is correctly processed and checked, according to the defined procedures;\n\n(g) pharmaceutical products are not sold or supplied before the authorized persons (see also sections 9.11 & 9.12) have certified that each production batch has been produced and controlled in accordance with the requirements of the marketing authorization and any other regulations relevant to the production, control and release of pharmaceutical products;\n\n(h) satisfactory arrangements exist to ensure, as far as possible, that the pharmaceutical products are stored by the manufacturer, distributed, and subsequently handled so that quality is maintained throughout their shelf-life;\n\n(i) there is a procedure for self-inspection and/or quality audit that regularly appraises the effectiveness and applicability of the QA system;\n\n(j) deviations are reported, investigated and recorded;\n\n(k) there is a system for approving changes that may have an impact on product quality;\n\n(l) regular evaluations of the quality of pharmaceutical products should be conducted with the objective of verifying the consistency of the process and ensuring its continuous improvement; and\n\n(m) there is a system for QRM.\n\n1.3 The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the marketing authorization and do not place patients at risk due to inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment of staff in many different departments and at all levels within the company, the company\u2019s\n\n----\n\n<sup>7</sup> This is a code governing the testing of chemicals to obtain data on their properties and ensuring safety with respect to human health and the environment. It is different from that described in \"Good laboratory practices in governmental drug control laboratories\" in the Thirtieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 748, 1987, Annex 1).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2719, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb3e331-167f-4e0a-90c5-8672d3f672f5": {"__data__": {"id_": "4cb3e331-167f-4e0a-90c5-8672d3f672f5", "embedding": null, "metadata": {"page_label": "117", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Product Quality Review\n\nsuppliers, and the distributors. To achieve the quality objective reliably there must be a comprehensively designed and correctly implemented system of QA incorporating GMP and QC. It should be fully documented and its effectiveness monitored. All parts of the QA system should be adequately staffed with competent personnel, and should have suitable and sufficient premises, equipment and facilities.\n\n1.4 QRM is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively.\n\n1.5 QRM should ensure that:\n\n- the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient; and\n- the level of effort, formality and documentation of the QRM process is commensurate with the level of risk.\n\n## Product Quality Review\n\n1.6 Regular, periodic or rolling quality reviews of all medicinal products, including export-only products, should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product to highlight any trends and to identify product and process improvements. Such reviews should normally be conducted and documented annually, taking into account previous reviews, and should include at least:\n\n(i) a review of starting materials and packaging materials used for the product, especially those from new sources;\n\n(ii) a review of critical in-process controls and finished product results;\n\n(iii) a review of all batches that failed to meet established specification(s) and their investigation;\n\n(iv) a review of all significant deviations or non-conformances, the related investigations and the effectiveness of resultant corrective and preventive actions taken;\n\n(v) a review of all changes made to the processes or analytical methods;\n\n(vi) a review of dossier variations submitted, granted or refused;\n\n(vii) a review of the results of the stability monitoring programme and any adverse trends;\n\n(viii) a review of all quality-related returns, complaints and recalls and the investigations performed at the time;\n\n(ix) a review of adequacy of any other previous corrective actions on product process or equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de un sistema de aseguramiento de calidad (QA) en la producci\u00f3n de productos medicinales. Este sistema debe incluir buenas pr\u00e1cticas de manufactura (GMP) y control de calidad (QC), y debe ser dise\u00f1ado e implementado de manera integral. Se introduce el concepto de gesti\u00f3n de riesgos de calidad (QRM), que es un proceso sistem\u00e1tico para evaluar y controlar los riesgos que pueden afectar la calidad del producto. Adem\u00e1s, se enfatiza la necesidad de realizar revisiones peri\u00f3dicas de calidad de los productos medicinales para asegurar la consistencia del proceso y la adecuaci\u00f3n de las especificaciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en un sistema de aseguramiento de calidad (QA) para productos medicinales?**\n   - Respuesta: Un sistema de QA debe incluir un dise\u00f1o integral, implementaci\u00f3n correcta, documentaci\u00f3n completa, monitoreo de efectividad, personal competente, y contar con instalaciones, equipos y recursos adecuados.\n\n2. **\u00bfQu\u00e9 aspectos se deben revisar durante una revisi\u00f3n de calidad peri\u00f3dica de productos medicinales?**\n   - Respuesta: Las revisiones deben incluir la evaluaci\u00f3n de materiales de inicio y empaque, controles cr\u00edticos en proceso, resultados de productos terminados, lotes que no cumplieron especificaciones, desviaciones significativas, cambios en procesos o m\u00e9todos anal\u00edticos, variaciones en dossiers, resultados de programas de monitoreo de estabilidad, quejas y devoluciones relacionadas con la calidad, y la efectividad de acciones correctivas previas.\n\n3. **\u00bfC\u00f3mo se debe abordar la gesti\u00f3n de riesgos de calidad (QRM) en relaci\u00f3n con la protecci\u00f3n del paciente?**\n   - Respuesta: La QRM debe basarse en conocimientos cient\u00edficos y experiencias del proceso, asegurando que la evaluaci\u00f3n del riesgo est\u00e9 vinculada a la protecci\u00f3n del paciente. Adem\u00e1s, el nivel de formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo identificado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Responsabilidad del Fabricante**: \n   - El fabricante de productos farmac\u00e9uticos debe garantizar que los productos sean seguros, eficaces y de calidad, cumpliendo con los requisitos de autorizaci\u00f3n de comercializaci\u00f3n. Esta responsabilidad es asumida por la alta direcci\u00f3n y requiere la colaboraci\u00f3n de todo el personal.\n\n2. **Pr\u00e1cticas de Calidad**: \n   - Se establecen procedimientos claros para la producci\u00f3n y control de productos farmac\u00e9uticos, incluyendo:\n     - Especificaci\u00f3n de operaciones de producci\u00f3n y control.\n     - Gesti\u00f3n adecuada de materiales de inicio y empaque.\n     - Realizaci\u00f3n de controles y auditor\u00edas de calidad.\n     - Implementaci\u00f3n de un sistema de gesti\u00f3n de riesgos de calidad (QRM).\n\n3. **Evaluaci\u00f3n y Mejora Continua**: \n   - Es esencial llevar a cabo evaluaciones regulares de la calidad para asegurar la consistencia del proceso y fomentar la mejora continua. Esto incluye la gesti\u00f3n de desviaciones y la aprobaci\u00f3n de cambios que puedan afectar la calidad del producto.\n\n### Entidades Clave\n\n- **GLP (Good Laboratory Practice)**: Buenas pr\u00e1cticas de laboratorio.\n- **GCP (Good Clinical Practice)**: Buenas pr\u00e1cticas cl\u00ednicas.\n- **GMP (Good Manufacturing Practice)**: Buenas pr\u00e1cticas de manufactura.\n- **QA (Quality Assurance)**: Aseguramiento de la calidad.\n- **QRM (Quality Risk Management)**: Gesti\u00f3n de riesgos de calidad.\n- **Autorizaci\u00f3n de Comercializaci\u00f3n**: Requisitos regulatorios para la venta de productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la responsabilidad del fabricante en la calidad de los productos farmac\u00e9uticos y los procedimientos necesarios para garantizar su seguridad y eficacia.", "excerpt_keywords": "Keywords: Quality Assurance, Quality Risk Management, Good Manufacturing Practice, Product Quality Review, Pharmaceutical Compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ebd17cfd-fd16-4463-ba49-164922c6b3b3", "node_type": "4", "metadata": {"page_label": "117", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Product Quality Review\n\nsuppliers, and the distributors. To achieve the quality objective reliably there must be a comprehensively designed and correctly implemented system of QA incorporating GMP and QC. It should be fully documented and its effectiveness monitored. All parts of the QA system should be adequately staffed with competent personnel, and should have suitable and sufficient premises, equipment and facilities.\n\n1.4 QRM is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively.\n\n1.5 QRM should ensure that:\n\n- the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient; and\n- the level of effort, formality and documentation of the QRM process is commensurate with the level of risk.\n\n## Product Quality Review\n\n1.6 Regular, periodic or rolling quality reviews of all medicinal products, including export-only products, should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product to highlight any trends and to identify product and process improvements. Such reviews should normally be conducted and documented annually, taking into account previous reviews, and should include at least:\n\n(i) a review of starting materials and packaging materials used for the product, especially those from new sources;\n\n(ii) a review of critical in-process controls and finished product results;\n\n(iii) a review of all batches that failed to meet established specification(s) and their investigation;\n\n(iv) a review of all significant deviations or non-conformances, the related investigations and the effectiveness of resultant corrective and preventive actions taken;\n\n(v) a review of all changes made to the processes or analytical methods;\n\n(vi) a review of dossier variations submitted, granted or refused;\n\n(vii) a review of the results of the stability monitoring programme and any adverse trends;\n\n(viii) a review of all quality-related returns, complaints and recalls and the investigations performed at the time;\n\n(ix) a review of adequacy of any other previous corrective actions on product process or equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a5adca3b6d224d2865cf88526512d8de1646ac0a5495076132ea0ad3c5deb7e6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Product Quality Review\n\nsuppliers, and the distributors. To achieve the quality objective reliably there must be a comprehensively designed and correctly implemented system of QA incorporating GMP and QC. It should be fully documented and its effectiveness monitored. All parts of the QA system should be adequately staffed with competent personnel, and should have suitable and sufficient premises, equipment and facilities.\n\n1.4 QRM is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively.\n\n1.5 QRM should ensure that:\n\n- the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient; and\n- the level of effort, formality and documentation of the QRM process is commensurate with the level of risk.\n\n## Product Quality Review\n\n1.6 Regular, periodic or rolling quality reviews of all medicinal products, including export-only products, should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product to highlight any trends and to identify product and process improvements. Such reviews should normally be conducted and documented annually, taking into account previous reviews, and should include at least:\n\n(i) a review of starting materials and packaging materials used for the product, especially those from new sources;\n\n(ii) a review of critical in-process controls and finished product results;\n\n(iii) a review of all batches that failed to meet established specification(s) and their investigation;\n\n(iv) a review of all significant deviations or non-conformances, the related investigations and the effectiveness of resultant corrective and preventive actions taken;\n\n(v) a review of all changes made to the processes or analytical methods;\n\n(vi) a review of dossier variations submitted, granted or refused;\n\n(vii) a review of the results of the stability monitoring programme and any adverse trends;\n\n(viii) a review of all quality-related returns, complaints and recalls and the investigations performed at the time;\n\n(ix) a review of adequacy of any other previous corrective actions on product process or equipment;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2375, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f960de94-9ee4-4f3e-b8ba-d1d2b952d849": {"__data__": {"id_": "f960de94-9ee4-4f3e-b8ba-d1d2b952d849", "embedding": null, "metadata": {"page_label": "118", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(x) for new dossiers and variations to the dossiers, a review of post-marketing commitments;\n\n(xi) the qualification status of relevant equipment and utilities, e.g. heating, ventilation and air-conditioning (HVAC), water, or compressed gases; and\n\n(xii) a review of technical agreements to ensure that they are up to date.\n\nThe manufacturer and marketing authorization holder, where different, should evaluate the results of this review and an assessment should be made whether corrective and preventive action or any revalidation should be undertaken. Reasons for such corrective actions should be documented. Agreed corrective and preventive actions should be completed in a timely and effective manner. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures should be verified during self-inspection.\n\nQuality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, or sterile products, where scientifically justified.\n\nWhere the marketing authorization holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the quality review. The authorized person responsible for final batch certification, together with the marketing authorization holder, should ensure that the quality review is performed in a timely manner and is accurate.\n\n## 2. Good manufacturing practices for pharmaceutical products\n\n2.1 GMP is that part of QA which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization. GMP are aimed primarily at diminishing the risks inherent in any pharmaceutical production.\n\nSuch risks are essentially of two types: cross-contamination (in particular of unexpected contaminants) and mix ups (confusion) caused by, for example, false labels being put on containers. Under GMP:\n\n(a) all manufacturing processes are clearly defined, systematically reviewed in the light of experience, and shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications;\n\n(b) qualification and validation are performed;\n\n(c) all necessary resources are provided, including:\n   (i) appropriately qualified and trained personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla los procedimientos y pr\u00e1cticas de calidad que deben seguirse en la revisi\u00f3n de productos farmac\u00e9uticos, incluyendo la evaluaci\u00f3n de compromisos post-comercializaci\u00f3n, la calificaci\u00f3n de equipos y utilidades, y la revisi\u00f3n de acuerdos t\u00e9cnicos. Se enfatiza la importancia de las Buenas Pr\u00e1cticas de Manufactura (GMP) para garantizar que los productos se produzcan de manera consistente y cumplan con los est\u00e1ndares de calidad requeridos. Tambi\u00e9n se menciona la necesidad de documentaci\u00f3n y gesti\u00f3n de acciones correctivas y preventivas, as\u00ed como la importancia de la capacitaci\u00f3n del personal.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para asegurar que las acciones correctivas y preventivas se implementen de manera efectiva en la revisi\u00f3n de calidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en el proceso de gesti\u00f3n de acciones correctivas y preventivas, que incluye la documentaci\u00f3n de razones, la finalizaci\u00f3n oportuna de las acciones acordadas y la verificaci\u00f3n de la efectividad durante la autoinspecci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los tipos de riesgos que las Buenas Pr\u00e1cticas de Manufactura (GMP) buscan minimizar en la producci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta aborda los riesgos espec\u00edficos mencionados en el documento, como la contaminaci\u00f3n cruzada y los errores de etiquetado, y c\u00f3mo las GMP est\u00e1n dise\u00f1adas para mitigarlos.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplirse en un acuerdo t\u00e9cnico entre el titular de la autorizaci\u00f3n de comercializaci\u00f3n y el fabricante cuando son entidades diferentes?**\n   - Esta pregunta se enfoca en la necesidad de un acuerdo t\u00e9cnico que defina las responsabilidades de cada parte en la producci\u00f3n de la revisi\u00f3n de calidad, asegurando que se realice de manera precisa y oportuna.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Aseguramiento de Calidad (QA):** \n   - Importancia de un sistema de QA bien dise\u00f1ado e implementado que incluya Buenas Pr\u00e1cticas de Manufactura (GMP) y Control de Calidad (QC).\n   - Necesidad de documentaci\u00f3n completa y monitoreo de la efectividad del sistema.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM):**\n   - Proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar riesgos que afectan la calidad del producto medicinal.\n   - Evaluaci\u00f3n basada en conocimientos cient\u00edficos y experiencia, vinculada a la protecci\u00f3n del paciente.\n   - Proporcionalidad entre el nivel de riesgo y el esfuerzo/documentaci\u00f3n del proceso de QRM.\n\n3. **Revisiones de Calidad de Productos Medicinales:**\n   - Realizaci\u00f3n de revisiones peri\u00f3dicas para verificar la consistencia del proceso y la adecuaci\u00f3n de especificaciones.\n   - Elementos a revisar incluyen materiales de inicio, controles en proceso, resultados de productos terminados, lotes no conformes, desviaciones significativas, cambios en procesos, variaciones de dossiers, resultados de programas de estabilidad, quejas y devoluciones, y efectividad de acciones correctivas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre la calidad de productos medicinales.\n- **Medicamentos:** Productos cuya calidad debe ser asegurada a trav\u00e9s de un sistema de QA y revisiones peri\u00f3dicas.\n- **Proveedores y Distribuidores:** Entidades involucradas en la cadena de suministro de productos medicinales.\n- **Personal Competente:** Recurso humano necesario para implementar y mantener el sistema de QA.\n- **Materiales de Inicio y Empaque:** Componentes cr\u00edticos que deben ser revisados en el proceso de aseguramiento de calidad.\n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para garantizar la calidad de los productos medicinales, as\u00ed como la necesidad de una gesti\u00f3n de riesgos adecuada para proteger la salud del paciente.", "excerpt_keywords": "Keywords: quality assurance, good manufacturing practices, pharmaceutical production, corrective actions, technical agreements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "50bd8d52-ded6-4de9-b1e7-851cc6c8eea8", "node_type": "4", "metadata": {"page_label": "118", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(x) for new dossiers and variations to the dossiers, a review of post-marketing commitments;\n\n(xi) the qualification status of relevant equipment and utilities, e.g. heating, ventilation and air-conditioning (HVAC), water, or compressed gases; and\n\n(xii) a review of technical agreements to ensure that they are up to date.\n\nThe manufacturer and marketing authorization holder, where different, should evaluate the results of this review and an assessment should be made whether corrective and preventive action or any revalidation should be undertaken. Reasons for such corrective actions should be documented. Agreed corrective and preventive actions should be completed in a timely and effective manner. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures should be verified during self-inspection.\n\nQuality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, or sterile products, where scientifically justified.\n\nWhere the marketing authorization holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the quality review. The authorized person responsible for final batch certification, together with the marketing authorization holder, should ensure that the quality review is performed in a timely manner and is accurate.\n\n## 2. Good manufacturing practices for pharmaceutical products\n\n2.1 GMP is that part of QA which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization. GMP are aimed primarily at diminishing the risks inherent in any pharmaceutical production.\n\nSuch risks are essentially of two types: cross-contamination (in particular of unexpected contaminants) and mix ups (confusion) caused by, for example, false labels being put on containers. Under GMP:\n\n(a) all manufacturing processes are clearly defined, systematically reviewed in the light of experience, and shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications;\n\n(b) qualification and validation are performed;\n\n(c) all necessary resources are provided, including:\n   (i) appropriately qualified and trained personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "62e4d498e9dc57d6ae2833d456c9149dd28db22387f4da376b42ed4acb825dd7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(x) for new dossiers and variations to the dossiers, a review of post-marketing commitments;\n\n(xi) the qualification status of relevant equipment and utilities, e.g. heating, ventilation and air-conditioning (HVAC), water, or compressed gases; and\n\n(xii) a review of technical agreements to ensure that they are up to date.\n\nThe manufacturer and marketing authorization holder, where different, should evaluate the results of this review and an assessment should be made whether corrective and preventive action or any revalidation should be undertaken. Reasons for such corrective actions should be documented. Agreed corrective and preventive actions should be completed in a timely and effective manner. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures should be verified during self-inspection.\n\nQuality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, or sterile products, where scientifically justified.\n\nWhere the marketing authorization holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the quality review. The authorized person responsible for final batch certification, together with the marketing authorization holder, should ensure that the quality review is performed in a timely manner and is accurate.\n\n## 2. Good manufacturing practices for pharmaceutical products\n\n2.1 GMP is that part of QA which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization. GMP are aimed primarily at diminishing the risks inherent in any pharmaceutical production.\n\nSuch risks are essentially of two types: cross-contamination (in particular of unexpected contaminants) and mix ups (confusion) caused by, for example, false labels being put on containers. Under GMP:\n\n(a) all manufacturing processes are clearly defined, systematically reviewed in the light of experience, and shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications;\n\n(b) qualification and validation are performed;\n\n(c) all necessary resources are provided, including:\n   (i) appropriately qualified and trained personnel;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2422, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b6278983-f599-49b1-b2b0-ccc27a83e987": {"__data__": {"id_": "b6278983-f599-49b1-b2b0-ccc27a83e987", "embedding": null, "metadata": {"page_label": "119", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n(ii)   adequate premises and space;\n(iii)  suitable equipment and services;\n(iv)   appropriate materials, containers and labels;\n(v)    approved procedures and instructions;\n(vi)   suitable storage and transport;\n(vii)  adequate personnel, laboratories and equipment for in-process\n       controls;\n(d)    instructions and procedures are written in clear and unambiguous\n       language, specifically applicable to the facilities provided;\n(e)    operators are trained to carry out procedures correctly;\n(f)    records are made (manually and/or by recording instruments) during\n       manufacture to show that all the steps required by the defined procedures\n       and instructions have in fact been taken and that the quantity and\n       quality of the product are as expected; any significant deviations are\n       fully recorded and investigated;\n(g)    records covering manufacture and distribution, which enable the\n       complete history of a batch to be traced, are retained in a comprehensible\n       and accessible form;\n(h)    the proper storage and distribution of the products minimizes any risk\n       to their quality;\n(i)    a system is available to recall any batch of product from sale or supply;\n(j)    complaints about marketed products are examined, the causes of\n       quality defects investigated, and appropriate measures taken in respect\n       of the defective products to prevent recurrence.\n\n3. **Sanitation and hygiene**\n\n3.1  A high level of sanitation and hygiene should be practised in every\n     aspect of the manufacture of medicines products. The scope of sanitation and\n     hygiene covers personnel, premises, equipment and apparatus, production\n     materials and containers, products for cleaning and disinfection, and anything\n     that could become a source of contamination to the product. Potential sources\n     of contamination should be eliminated through an integrated comprehensive\n     programme of sanitation and hygiene. (For *Personal hygiene* see section 11,\n     and for *sanitation* see section 12, \u201cPremises\u201d.)\n\n4. **Qualification and validation**\n\n4.1  In accordance with GMP, each pharmaceutical company should\n     identify what qualification and validation work is required to prove that the\n     critical aspects of their particular operation are controlled.\n\n4.2  The key elements of a qualification and validation programme of a\n     company should be clearly defined and documented in a validation master plan.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 961 aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener instalaciones adecuadas, equipos apropiados, procedimientos claros, y un alto nivel de sanidad e higiene en todas las etapas de la fabricaci\u00f3n. Adem\u00e1s, se menciona la necesidad de un sistema de calificaci\u00f3n y validaci\u00f3n para asegurar que los procesos cr\u00edticos est\u00e9n controlados y documentados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben estar documentados en un plan maestro de validaci\u00f3n seg\u00fan las Buenas Pr\u00e1cticas de Manufactura (GMP)?**\n   - Respuesta: Los elementos clave de un programa de calificaci\u00f3n y validaci\u00f3n deben estar claramente definidos y documentados en un plan maestro de validaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en caso de que se identifiquen desviaciones significativas durante el proceso de fabricaci\u00f3n?**\n   - Respuesta: Cualquier desviaci\u00f3n significativa debe ser completamente registrada e investigada para determinar su causa y tomar las medidas apropiadas para prevenir su recurrencia.\n\n3. **\u00bfQu\u00e9 aspectos de la sanidad y la higiene se deben considerar en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Se debe practicar un alto nivel de sanidad y higiene en todos los aspectos de la fabricaci\u00f3n, incluyendo el personal, las instalaciones, el equipo, los materiales de producci\u00f3n, los productos de limpieza y desinfecci\u00f3n, y cualquier cosa que pueda convertirse en una fuente de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Calidad de Productos Farmac\u00e9uticos**:\n   - Importancia de realizar revisiones de calidad que incluyan compromisos post-comercializaci\u00f3n, estado de calificaci\u00f3n de equipos y utilidades, y revisi\u00f3n de acuerdos t\u00e9cnicos.\n   - Evaluaci\u00f3n de resultados y necesidad de acciones correctivas y preventivas documentadas.\n\n2. **Acciones Correctivas y Preventivas**:\n   - Procedimientos de gesti\u00f3n para asegurar que las acciones acordadas se implementen de manera oportuna y efectiva.\n   - Verificaci\u00f3n de la efectividad de estas acciones durante autoinspecciones.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Definici\u00f3n de GMP como parte del aseguramiento de calidad (QA) que garantiza la producci\u00f3n consistente de productos farmac\u00e9uticos de acuerdo con est\u00e1ndares de calidad.\n   - Enfoque en la reducci\u00f3n de riesgos como la contaminaci\u00f3n cruzada y confusiones por etiquetado incorrecto.\n\n4. **Requisitos de Acuerdos T\u00e9cnicos**:\n   - Necesidad de un acuerdo t\u00e9cnico entre el titular de la autorizaci\u00f3n de comercializaci\u00f3n y el fabricante cuando son entidades diferentes, definiendo responsabilidades en la producci\u00f3n de la revisi\u00f3n de calidad.\n\n5. **Recursos Necesarios**:\n   - Importancia de contar con personal calificado y capacitado para llevar a cabo los procesos de manufactura y asegurar la calidad del producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre pr\u00e1cticas de calidad en la producci\u00f3n farmac\u00e9utica.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad responsable de la revisi\u00f3n de calidad y cumplimiento de est\u00e1ndares.\n- **Fabricante**: Entidad que produce los productos farmac\u00e9uticos y debe cumplir con las GMP.\n- **Personal Calificado**: Recursos humanos necesarios para garantizar la calidad en la producci\u00f3n. \n\nEste resumen destaca los aspectos fundamentales relacionados con la calidad y la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las entidades involucradas en estos procesos.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Manufactura, sanidad, higiene, calificaci\u00f3n, validaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8706bb8-96e5-4e4f-9c46-6e8a67a86b2b", "node_type": "4", "metadata": {"page_label": "119", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n(ii)   adequate premises and space;\n(iii)  suitable equipment and services;\n(iv)   appropriate materials, containers and labels;\n(v)    approved procedures and instructions;\n(vi)   suitable storage and transport;\n(vii)  adequate personnel, laboratories and equipment for in-process\n       controls;\n(d)    instructions and procedures are written in clear and unambiguous\n       language, specifically applicable to the facilities provided;\n(e)    operators are trained to carry out procedures correctly;\n(f)    records are made (manually and/or by recording instruments) during\n       manufacture to show that all the steps required by the defined procedures\n       and instructions have in fact been taken and that the quantity and\n       quality of the product are as expected; any significant deviations are\n       fully recorded and investigated;\n(g)    records covering manufacture and distribution, which enable the\n       complete history of a batch to be traced, are retained in a comprehensible\n       and accessible form;\n(h)    the proper storage and distribution of the products minimizes any risk\n       to their quality;\n(i)    a system is available to recall any batch of product from sale or supply;\n(j)    complaints about marketed products are examined, the causes of\n       quality defects investigated, and appropriate measures taken in respect\n       of the defective products to prevent recurrence.\n\n3. **Sanitation and hygiene**\n\n3.1  A high level of sanitation and hygiene should be practised in every\n     aspect of the manufacture of medicines products. The scope of sanitation and\n     hygiene covers personnel, premises, equipment and apparatus, production\n     materials and containers, products for cleaning and disinfection, and anything\n     that could become a source of contamination to the product. Potential sources\n     of contamination should be eliminated through an integrated comprehensive\n     programme of sanitation and hygiene. (For *Personal hygiene* see section 11,\n     and for *sanitation* see section 12, \u201cPremises\u201d.)\n\n4. **Qualification and validation**\n\n4.1  In accordance with GMP, each pharmaceutical company should\n     identify what qualification and validation work is required to prove that the\n     critical aspects of their particular operation are controlled.\n\n4.2  The key elements of a qualification and validation programme of a\n     company should be clearly defined and documented in a validation master plan.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6afbef4c4aa35effaaba7483311f793b2f6f9994973a79c5987ba08ad18fbe9f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n(ii)   adequate premises and space;\n(iii)  suitable equipment and services;\n(iv)   appropriate materials, containers and labels;\n(v)    approved procedures and instructions;\n(vi)   suitable storage and transport;\n(vii)  adequate personnel, laboratories and equipment for in-process\n       controls;\n(d)    instructions and procedures are written in clear and unambiguous\n       language, specifically applicable to the facilities provided;\n(e)    operators are trained to carry out procedures correctly;\n(f)    records are made (manually and/or by recording instruments) during\n       manufacture to show that all the steps required by the defined procedures\n       and instructions have in fact been taken and that the quantity and\n       quality of the product are as expected; any significant deviations are\n       fully recorded and investigated;\n(g)    records covering manufacture and distribution, which enable the\n       complete history of a batch to be traced, are retained in a comprehensible\n       and accessible form;\n(h)    the proper storage and distribution of the products minimizes any risk\n       to their quality;\n(i)    a system is available to recall any batch of product from sale or supply;\n(j)    complaints about marketed products are examined, the causes of\n       quality defects investigated, and appropriate measures taken in respect\n       of the defective products to prevent recurrence.\n\n3. **Sanitation and hygiene**\n\n3.1  A high level of sanitation and hygiene should be practised in every\n     aspect of the manufacture of medicines products. The scope of sanitation and\n     hygiene covers personnel, premises, equipment and apparatus, production\n     materials and containers, products for cleaning and disinfection, and anything\n     that could become a source of contamination to the product. Potential sources\n     of contamination should be eliminated through an integrated comprehensive\n     programme of sanitation and hygiene. (For *Personal hygiene* see section 11,\n     and for *sanitation* see section 12, \u201cPremises\u201d.)\n\n4. **Qualification and validation**\n\n4.1  In accordance with GMP, each pharmaceutical company should\n     identify what qualification and validation work is required to prove that the\n     critical aspects of their particular operation are controlled.\n\n4.2  The key elements of a qualification and validation programme of a\n     company should be clearly defined and documented in a validation master plan.\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2483, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ed623c95-7706-443e-958d-168637c15095": {"__data__": {"id_": "ed623c95-7706-443e-958d-168637c15095", "embedding": null, "metadata": {"page_label": "120", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 Qualification and validation should establish and provide documentary evidence that:\n\n(a) the premises, supporting utilities, equipment and processes have been designed in accordance with the requirements for GMP (design qualification or DQ);\n\n(b) the premises, supporting utilities and equipment have been built and installed in compliance with their design specifications (installation qualification or IQ);\n\n(c) the premises, supporting utilities and equipment operate in accordance with their design specifications (operational qualification or OQ);\n\n(d) a specific process will consistently produce a product meeting its predetermined specifications and quality attributes (process validation or PV, also called performance qualification or PQ).\n\n4.4 Any aspect of operation, including significant changes to the premises, facilities, equipment or processes, which may affect the quality of the product, directly or indirectly, should be qualified and validated.\n\n4.5 Qualification and validation should not be considered as one-off exercises. An ongoing programme should follow their first implementation and should be based on an annual review.\n\n4.6 The commitment to maintain continued validation status should be stated in the relevant company documentation, such as the quality manual or validation master plan.\n\n4.7 The responsibility of performing validation should be clearly defined.\n\n4.8 Validation studies are an essential part of GMP and should be conducted in accordance with predefined and approved protocols.\n\n4.9 A written report summarizing the results recorded and the conclusions reached should be prepared and stored.\n\n4.10 Processes and procedures should be established on the basis of the results of the validation performed.\n\n4.11 Particular attention should be paid to the validation of analytical test methods, automated systems and cleaning procedures.\n\n# 5. Complaints\n\n## 5.1 Principle\n\nAll complaints and other information concerning potentially defective products should be carefully reviewed according to written procedures and the corrective action should be taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP). Se detallan los diferentes tipos de calificaci\u00f3n (DQ, IQ, OQ, PV/PQ) y se enfatiza que la calificaci\u00f3n y validaci\u00f3n no son ejercicios \u00fanicos, sino que deben ser parte de un programa continuo. Adem\u00e1s, se menciona la necesidad de revisar y actuar sobre las quejas relacionadas con productos potencialmente defectuosos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los cuatro tipos de calificaci\u00f3n mencionados en el documento y qu\u00e9 aspectos espec\u00edficos eval\u00faan?**\n   - Respuesta: Los cuatro tipos de calificaci\u00f3n son: \n     - **Design Qualification (DQ)**: Eval\u00faa si las instalaciones, utilidades, equipos y procesos est\u00e1n dise\u00f1ados de acuerdo con los requisitos de GMP.\n     - **Installation Qualification (IQ)**: Verifica que las instalaciones, utilidades y equipos se hayan construido e instalado conforme a las especificaciones de dise\u00f1o.\n     - **Operational Qualification (OQ)**: Asegura que las instalaciones, utilidades y equipos operen de acuerdo con sus especificaciones de dise\u00f1o.\n     - **Process Validation (PV) o Performance Qualification (PQ)**: Confirma que un proceso espec\u00edfico producir\u00e1 consistentemente un producto que cumpla con las especificaciones y atributos de calidad predeterminados.\n\n2. **\u00bfPor qu\u00e9 es importante que la calificaci\u00f3n y validaci\u00f3n se consideren como un programa continuo y no como ejercicios \u00fanicos?**\n   - Respuesta: Es importante porque cualquier aspecto de la operaci\u00f3n, incluidos cambios significativos en las instalaciones, equipos o procesos, puede afectar la calidad del producto. Un programa continuo permite realizar revisiones anuales y mantener la validez de los procesos, asegurando que se cumplan los est\u00e1ndares de calidad de manera constante.\n\n3. **\u00bfQu\u00e9 se debe hacer con las quejas relacionadas con productos potencialmente defectuosos seg\u00fan el documento?**\n   - Respuesta: Todas las quejas y la informaci\u00f3n relacionada con productos potencialmente defectuosos deben ser revisadas cuidadosamente de acuerdo con procedimientos escritos, y se deben tomar acciones correctivas basadas en esa revisi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se enfatiza la importancia de mantener est\u00e1ndares adecuados en la producci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Elementos esenciales para la manufactura**:\n   - **Instalaciones y espacio adecuados**: Se requiere un entorno f\u00edsico que cumpla con los est\u00e1ndares necesarios.\n   - **Equipos y servicios apropiados**: Deben estar disponibles para asegurar la calidad del proceso.\n   - **Materiales, contenedores y etiquetas**: Deben ser adecuados y aprobados para su uso.\n   - **Procedimientos e instrucciones aprobadas**: Deben estar documentados y ser claros.\n   - **Almacenamiento y transporte adecuados**: Para minimizar riesgos a la calidad del producto.\n   - **Personal capacitado**: Los operadores deben estar entrenados para seguir los procedimientos correctamente.\n\n3. **Documentaci\u00f3n y registros**:\n   - Se deben mantener registros durante la fabricaci\u00f3n para demostrar que se han seguido todos los pasos requeridos.\n   - Los registros deben permitir rastrear la historia completa de un lote y ser accesibles.\n\n4. **Sistema de gesti\u00f3n de quejas**:\n   - Las quejas sobre productos comercializados deben ser investigadas y se deben tomar medidas para prevenir recurrencias.\n\n5. **Sanidad e higiene**:\n   - Se debe mantener un alto nivel de sanidad e higiene en todos los aspectos de la fabricaci\u00f3n, abarcando personal, instalaciones, equipos, materiales de producci\u00f3n y limpieza.\n\n6. **Calificaci\u00f3n y validaci\u00f3n**:\n   - Cada empresa farmac\u00e9utica debe identificar y documentar el trabajo de calificaci\u00f3n y validaci\u00f3n necesario para controlar los aspectos cr\u00edticos de sus operaciones.\n   - Los elementos clave de este programa deben estar claramente definidos en un plan maestro de validaci\u00f3n.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos farmac\u00e9uticos**: El foco del documento.\n- **Personal**: Operadores y personal involucrado en la manufactura.\n- **Equipos y materiales**: Elementos necesarios para la producci\u00f3n.\n- **Registros**: Documentaci\u00f3n necesaria para asegurar la trazabilidad y el cumplimiento de los procedimientos.", "excerpt_keywords": "Keywords: calificaci\u00f3n, validaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura, quejas, documentaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3da5286d-4d06-4b84-bbfd-fac1da6895bf", "node_type": "4", "metadata": {"page_label": "120", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 Qualification and validation should establish and provide documentary evidence that:\n\n(a) the premises, supporting utilities, equipment and processes have been designed in accordance with the requirements for GMP (design qualification or DQ);\n\n(b) the premises, supporting utilities and equipment have been built and installed in compliance with their design specifications (installation qualification or IQ);\n\n(c) the premises, supporting utilities and equipment operate in accordance with their design specifications (operational qualification or OQ);\n\n(d) a specific process will consistently produce a product meeting its predetermined specifications and quality attributes (process validation or PV, also called performance qualification or PQ).\n\n4.4 Any aspect of operation, including significant changes to the premises, facilities, equipment or processes, which may affect the quality of the product, directly or indirectly, should be qualified and validated.\n\n4.5 Qualification and validation should not be considered as one-off exercises. An ongoing programme should follow their first implementation and should be based on an annual review.\n\n4.6 The commitment to maintain continued validation status should be stated in the relevant company documentation, such as the quality manual or validation master plan.\n\n4.7 The responsibility of performing validation should be clearly defined.\n\n4.8 Validation studies are an essential part of GMP and should be conducted in accordance with predefined and approved protocols.\n\n4.9 A written report summarizing the results recorded and the conclusions reached should be prepared and stored.\n\n4.10 Processes and procedures should be established on the basis of the results of the validation performed.\n\n4.11 Particular attention should be paid to the validation of analytical test methods, automated systems and cleaning procedures.\n\n# 5. Complaints\n\n## 5.1 Principle\n\nAll complaints and other information concerning potentially defective products should be carefully reviewed according to written procedures and the corrective action should be taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2a580d7c2de72212a7b9fbe1263f9b1b249b0402f3d1cc13a511edc068176463", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.3 Qualification and validation should establish and provide documentary evidence that:\n\n(a) the premises, supporting utilities, equipment and processes have been designed in accordance with the requirements for GMP (design qualification or DQ);\n\n(b) the premises, supporting utilities and equipment have been built and installed in compliance with their design specifications (installation qualification or IQ);\n\n(c) the premises, supporting utilities and equipment operate in accordance with their design specifications (operational qualification or OQ);\n\n(d) a specific process will consistently produce a product meeting its predetermined specifications and quality attributes (process validation or PV, also called performance qualification or PQ).\n\n4.4 Any aspect of operation, including significant changes to the premises, facilities, equipment or processes, which may affect the quality of the product, directly or indirectly, should be qualified and validated.\n\n4.5 Qualification and validation should not be considered as one-off exercises. An ongoing programme should follow their first implementation and should be based on an annual review.\n\n4.6 The commitment to maintain continued validation status should be stated in the relevant company documentation, such as the quality manual or validation master plan.\n\n4.7 The responsibility of performing validation should be clearly defined.\n\n4.8 Validation studies are an essential part of GMP and should be conducted in accordance with predefined and approved protocols.\n\n4.9 A written report summarizing the results recorded and the conclusions reached should be prepared and stored.\n\n4.10 Processes and procedures should be established on the basis of the results of the validation performed.\n\n4.11 Particular attention should be paid to the validation of analytical test methods, automated systems and cleaning procedures.\n\n# 5. Complaints\n\n## 5.1 Principle\n\nAll complaints and other information concerning potentially defective products should be carefully reviewed according to written procedures and the corrective action should be taken.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2108, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f8bad3e5-3294-4daa-a4f8-5518307f7cc3": {"__data__": {"id_": "f8bad3e5-3294-4daa-a4f8-5518307f7cc3", "embedding": null, "metadata": {"page_label": "121", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2\n\nA person responsible for handling the complaints and deciding the measures to be taken should be designated, together with sufficient supporting staff to assist him or her. If this person is different from the authorized person, the latter should be made aware of any complaint, investigation or recall.\n\n## 5.3\n\nThere should be written procedures describing the action to be taken, including the need to consider a recall, in the case of a complaint concerning a possible product defect.\n\n## 5.4\n\nSpecial attention should be given to establishing whether a complaint was caused because of a suspect product.\n\n## 5.5\n\nAny complaint concerning a product defect should be recorded with all the original details and thoroughly investigated. The person responsible for QC should normally be involved in the review of such investigations.\n\n## 5.6\n\nIf a product defect is discovered or suspected in a batch, consideration should be given to whether other batches should be checked in order to determine whether they are also affected. In particular, other batches that may contain reprocessed product from the defective batch should be investigated.\n\n## 5.7\n\nWhere necessary, appropriate follow-up action, possibly including product recall, should be taken after investigation and evaluation of the complaint.\n\n## 5.8\n\nAll decisions made and measures taken as a result of a complaint should be recorded and referenced to the corresponding batch records.\n\n## 5.9\n\nComplaints records should be regularly reviewed for any indication of specific or recurring problems that require attention and might justify the recall of marketed products.\n\n## 5.10\n\nThe competent authorities should be informed if a manufacturer is considering action following possibly faulty manufacture, product deterioration, a suspect product or any other serious quality problems with a product.\n\n## 6. Product recalls\n\n### 6.1 Principle\n\nThere should be a system to recall from the market, promptly and effectively, products known or suspected to be defective.\n\n### 6.2\n\nThe authorized person should be responsible for the execution and coordination of recalls. He/she should have sufficient staff to handle all aspects of the recalls with the appropriate degree of urgency.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y responsabilidades relacionados con la gesti\u00f3n de quejas y la retirada de productos del mercado en caso de defectos. Se establece la necesidad de designar a una persona responsable de manejar quejas, investigar defectos y coordinar retiradas de productos. Se enfatiza la importancia de tener procedimientos escritos, registrar quejas y decisiones, y mantener informadas a las autoridades competentes sobre problemas de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para investigar una queja sobre un posible defecto de producto y qui\u00e9n debe estar involucrado en este proceso?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que deben seguirse y en la participaci\u00f3n del personal de control de calidad (QC) en la investigaci\u00f3n de quejas.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al decidir si se debe realizar un retiro de producto tras recibir una queja?**\n   - Esta pregunta busca detalles sobre los factores que influyen en la decisi\u00f3n de llevar a cabo un retiro de producto, incluyendo la evaluaci\u00f3n de la queja y la posible afectaci\u00f3n de otros lotes.\n\n3. **\u00bfC\u00f3mo se deben documentar y revisar las quejas para identificar problemas recurrentes que puedan justificar un retiro de productos comercializados?**\n   - Esta pregunta se enfoca en la importancia de la documentaci\u00f3n y el an\u00e1lisis de las quejas para detectar patrones que requieran atenci\u00f3n y posibles acciones correctivas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se encuentra f\u00e1cilmente en otros documentos o contextos, bas\u00e1ndose en los procedimientos y responsabilidades descritos en el texto.", "prev_section_summary": "### Temas Clave:\n\n1. **Calificaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de establecer y proporcionar evidencia documental de que las instalaciones, utilidades, equipos y procesos cumplen con los requisitos de las Buenas Pr\u00e1cticas de Manufactura (GMP) a trav\u00e9s de diferentes tipos de calificaci\u00f3n:\n   - **Design Qualification (DQ)**: Dise\u00f1o conforme a GMP.\n   - **Installation Qualification (IQ)**: Construcci\u00f3n e instalaci\u00f3n seg\u00fan especificaciones.\n   - **Operational Qualification (OQ)**: Operaci\u00f3n conforme a especificaciones.\n   - **Process Validation (PV) o Performance Qualification (PQ)**: Producci\u00f3n consistente de productos que cumplen con especificaciones.\n\n2. **Programa Continuo**: La calificaci\u00f3n y validaci\u00f3n deben ser parte de un programa continuo, no ejercicios \u00fanicos, con revisiones anuales para asegurar la calidad del producto.\n\n3. **Documentaci\u00f3n y Responsabilidad**: Se requiere que la documentaci\u00f3n relevante, como el manual de calidad o el plan maestro de validaci\u00f3n, indique el compromiso de mantener el estado de validaci\u00f3n. Adem\u00e1s, la responsabilidad de realizar la validaci\u00f3n debe estar claramente definida.\n\n4. **Estudios de Validaci\u00f3n**: Deben realizarse de acuerdo con protocolos predefinidos y aprobados, y se debe preparar un informe escrito que resuma los resultados y conclusiones.\n\n5. **Quejas de Productos**: Todas las quejas sobre productos potencialmente defectuosos deben ser revisadas cuidadosamente y se deben tomar acciones correctivas seg\u00fan procedimientos escritos.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativa que gu\u00eda la calificaci\u00f3n y validaci\u00f3n.\n- **Tipos de Calificaci\u00f3n**: DQ, IQ, OQ, PV/PQ.\n- **Documentaci\u00f3n**: Manual de calidad, plan maestro de validaci\u00f3n.\n- **Quejas**: Informaci\u00f3n sobre productos defectuosos que requiere revisi\u00f3n y acci\u00f3n correctiva. \n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en la manufactura de productos, as\u00ed como la necesidad de un enfoque sistem\u00e1tico y continuo para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: complaints management, product recall, quality control, defect investigation, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8261ec14-fd23-41a9-9d24-b5920d1f94f5", "node_type": "4", "metadata": {"page_label": "121", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2\n\nA person responsible for handling the complaints and deciding the measures to be taken should be designated, together with sufficient supporting staff to assist him or her. If this person is different from the authorized person, the latter should be made aware of any complaint, investigation or recall.\n\n## 5.3\n\nThere should be written procedures describing the action to be taken, including the need to consider a recall, in the case of a complaint concerning a possible product defect.\n\n## 5.4\n\nSpecial attention should be given to establishing whether a complaint was caused because of a suspect product.\n\n## 5.5\n\nAny complaint concerning a product defect should be recorded with all the original details and thoroughly investigated. The person responsible for QC should normally be involved in the review of such investigations.\n\n## 5.6\n\nIf a product defect is discovered or suspected in a batch, consideration should be given to whether other batches should be checked in order to determine whether they are also affected. In particular, other batches that may contain reprocessed product from the defective batch should be investigated.\n\n## 5.7\n\nWhere necessary, appropriate follow-up action, possibly including product recall, should be taken after investigation and evaluation of the complaint.\n\n## 5.8\n\nAll decisions made and measures taken as a result of a complaint should be recorded and referenced to the corresponding batch records.\n\n## 5.9\n\nComplaints records should be regularly reviewed for any indication of specific or recurring problems that require attention and might justify the recall of marketed products.\n\n## 5.10\n\nThe competent authorities should be informed if a manufacturer is considering action following possibly faulty manufacture, product deterioration, a suspect product or any other serious quality problems with a product.\n\n## 6. Product recalls\n\n### 6.1 Principle\n\nThere should be a system to recall from the market, promptly and effectively, products known or suspected to be defective.\n\n### 6.2\n\nThe authorized person should be responsible for the execution and coordination of recalls. He/she should have sufficient staff to handle all aspects of the recalls with the appropriate degree of urgency.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1d75228486af5811df20c141b9dbfe6f7f63c2fb18ad9e2581c18ee07f25e5d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 5.2\n\nA person responsible for handling the complaints and deciding the measures to be taken should be designated, together with sufficient supporting staff to assist him or her. If this person is different from the authorized person, the latter should be made aware of any complaint, investigation or recall.\n\n## 5.3\n\nThere should be written procedures describing the action to be taken, including the need to consider a recall, in the case of a complaint concerning a possible product defect.\n\n## 5.4\n\nSpecial attention should be given to establishing whether a complaint was caused because of a suspect product.\n\n## 5.5\n\nAny complaint concerning a product defect should be recorded with all the original details and thoroughly investigated. The person responsible for QC should normally be involved in the review of such investigations.\n\n## 5.6\n\nIf a product defect is discovered or suspected in a batch, consideration should be given to whether other batches should be checked in order to determine whether they are also affected. In particular, other batches that may contain reprocessed product from the defective batch should be investigated.\n\n## 5.7\n\nWhere necessary, appropriate follow-up action, possibly including product recall, should be taken after investigation and evaluation of the complaint.\n\n## 5.8\n\nAll decisions made and measures taken as a result of a complaint should be recorded and referenced to the corresponding batch records.\n\n## 5.9\n\nComplaints records should be regularly reviewed for any indication of specific or recurring problems that require attention and might justify the recall of marketed products.\n\n## 5.10\n\nThe competent authorities should be informed if a manufacturer is considering action following possibly faulty manufacture, product deterioration, a suspect product or any other serious quality problems with a product.\n\n## 6. Product recalls\n\n### 6.1 Principle\n\nThere should be a system to recall from the market, promptly and effectively, products known or suspected to be defective.\n\n### 6.2\n\nThe authorized person should be responsible for the execution and coordination of recalls. He/she should have sufficient staff to handle all aspects of the recalls with the appropriate degree of urgency.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2248, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1ca778f3-c1d6-4d68-b989-f5a1df68de59": {"__data__": {"id_": "1ca778f3-c1d6-4d68-b989-f5a1df68de59", "embedding": null, "metadata": {"page_label": "122", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.3 \nThere should be established written procedures, which are regularly reviewed and updated, for the organization of any recall activity. Recall operations should be capable of being initiated promptly down to the required level in the distribution chain.\n\n6.4 \nAn instruction should be included in the written procedures to store recalled products in a secure segregated area while their fate is decided.\n\n6.5 \nAll competent authorities of all countries to which a given product has been distributed should be promptly informed of any intention to recall the product because it is, or is suspected of being, defective.\n\n6.6 \nThe distribution records should be readily available to the authorized person, and they should contain sufficient information on wholesalers and directly supplied customers (including, for exported products, those who have received samples for clinical tests and medical samples) to permit an effective recall.\n\n6.7 \nThe progress of the recall process should be monitored and recorded. Records should include the disposition of the product. A final report should be issued, including a reconciliation between the delivered and recovered quantities of the products.\n\n6.8 \nThe effectiveness of the arrangements for recalls should be tested and evaluated from time to time.\n\n# 7. Contract production and analysis\n\n7.1 Principle. \nContract production and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings that could result in a product or work or analysis of unsatisfactory quality.\n\n## General\n\n7.2 \nAll arrangements for contract production and analysis, including any proposed changes in technical or other arrangements, should be in accordance with the marketing authorization for the product concerned.\n\n7.3 \nThe contract should permit the contract giver to audit the facilities of the contract acceptor.\n\n7.4 \nIn the case of contract analysis, the final approval for release must be given by the authorized person.\n\n## The contract giver\n\n7.5 \nThe contract giver is responsible for assessing the competence of the contract acceptor in successfully carrying out the work or tests required, for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la gesti\u00f3n de retiros de productos y la producci\u00f3n y an\u00e1lisis por contrato. Se enfatiza la importancia de tener procedimientos escritos para las actividades de retiro, la comunicaci\u00f3n con las autoridades competentes, el mantenimiento de registros de distribuci\u00f3n, y la evaluaci\u00f3n de la efectividad de los procesos de retiro. Adem\u00e1s, se aborda la necesidad de definir y controlar adecuadamente los acuerdos de producci\u00f3n y an\u00e1lisis por contrato, asegurando que se cumplan los requisitos de autorizaci\u00f3n de comercializaci\u00f3n y que el contratante tenga la capacidad de auditar al contratista.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben establecerse para garantizar que las operaciones de retiro de productos se inicien de manera oportuna en la cadena de distribuci\u00f3n?**\n   - Respuesta: Se deben establecer procedimientos escritos que sean revisados y actualizados regularmente, permitiendo que las operaciones de retiro se inicien de manera r\u00e1pida y efectiva en todos los niveles de la cadena de distribuci\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener los registros de distribuci\u00f3n para facilitar un retiro efectivo de productos?**\n   - Respuesta: Los registros de distribuci\u00f3n deben contener informaci\u00f3n suficiente sobre los mayoristas y los clientes directamente suministrados, incluyendo aquellos que han recibido muestras para pruebas cl\u00ednicas y muestras m\u00e9dicas, para permitir un retiro efectivo.\n\n3. **\u00bfCu\u00e1l es la responsabilidad del contratante en relaci\u00f3n con la competencia del contratista en el contexto de la producci\u00f3n y an\u00e1lisis por contrato?**\n   - Respuesta: El contratante es responsable de evaluar la competencia del contratista para llevar a cabo con \u00e9xito el trabajo o las pruebas requeridas, asegurando que se cumplan los est\u00e1ndares de calidad necesarios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Responsabilidad en la Gesti\u00f3n de Quejas:**\n   - Designaci\u00f3n de una persona responsable para manejar quejas y tomar decisiones sobre medidas a seguir.\n   - Importancia de contar con personal de apoyo adecuado.\n\n2. **Procedimientos Escritos:**\n   - Necesidad de tener procedimientos documentados para abordar quejas y considerar retiradas de productos en caso de defectos.\n\n3. **Investigaci\u00f3n de Quejas:**\n   - Registro detallado de quejas sobre defectos de productos y la implicaci\u00f3n del personal de control de calidad (QC) en las investigaciones.\n\n4. **Evaluaci\u00f3n de Lotes:**\n   - Consideraci\u00f3n de la revisi\u00f3n de otros lotes si se descubre o sospecha un defecto en un lote espec\u00edfico.\n\n5. **Acciones de Seguimiento:**\n   - Implementaci\u00f3n de acciones adecuadas, incluyendo retiradas de productos, tras la evaluaci\u00f3n de quejas.\n\n6. **Documentaci\u00f3n y Revisi\u00f3n:**\n   - Registro de decisiones y medidas tomadas en respuesta a quejas, as\u00ed como revisi\u00f3n regular de registros de quejas para identificar problemas recurrentes.\n\n7. **Comunicaci\u00f3n con Autoridades:**\n   - Obligaci\u00f3n de informar a las autoridades competentes sobre acciones relacionadas con fabricaci\u00f3n defectuosa o problemas graves de calidad.\n\n8. **Sistema de Retiro de Productos:**\n   - Establecimiento de un sistema efectivo para retirar del mercado productos defectuosos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre la gesti\u00f3n de quejas y retiradas de productos.\n- **Persona Responsable:** Individuo designado para manejar quejas y coordinar acciones.\n- **Personal de Control de Calidad (QC):** Equipo involucrado en la investigaci\u00f3n de quejas sobre defectos de productos.\n- **Autoridades Competentes:** Entidades reguladoras que deben ser informadas sobre problemas de calidad y acciones a tomar.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de quejas y retiradas de productos, as\u00ed como la necesidad de procedimientos claros y comunicaci\u00f3n efectiva con las autoridades.", "excerpt_keywords": "Keywords: recall procedures, contract production, quality assurance, distribution records, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ea434e57-1b3a-42fc-93db-d91f93cad7e9", "node_type": "4", "metadata": {"page_label": "122", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.3 \nThere should be established written procedures, which are regularly reviewed and updated, for the organization of any recall activity. Recall operations should be capable of being initiated promptly down to the required level in the distribution chain.\n\n6.4 \nAn instruction should be included in the written procedures to store recalled products in a secure segregated area while their fate is decided.\n\n6.5 \nAll competent authorities of all countries to which a given product has been distributed should be promptly informed of any intention to recall the product because it is, or is suspected of being, defective.\n\n6.6 \nThe distribution records should be readily available to the authorized person, and they should contain sufficient information on wholesalers and directly supplied customers (including, for exported products, those who have received samples for clinical tests and medical samples) to permit an effective recall.\n\n6.7 \nThe progress of the recall process should be monitored and recorded. Records should include the disposition of the product. A final report should be issued, including a reconciliation between the delivered and recovered quantities of the products.\n\n6.8 \nThe effectiveness of the arrangements for recalls should be tested and evaluated from time to time.\n\n# 7. Contract production and analysis\n\n7.1 Principle. \nContract production and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings that could result in a product or work or analysis of unsatisfactory quality.\n\n## General\n\n7.2 \nAll arrangements for contract production and analysis, including any proposed changes in technical or other arrangements, should be in accordance with the marketing authorization for the product concerned.\n\n7.3 \nThe contract should permit the contract giver to audit the facilities of the contract acceptor.\n\n7.4 \nIn the case of contract analysis, the final approval for release must be given by the authorized person.\n\n## The contract giver\n\n7.5 \nThe contract giver is responsible for assessing the competence of the contract acceptor in successfully carrying out the work or tests required, for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a6998392805534be100b88cea8571e3da865a19d29fa60dc74cea6153183db51", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.3 \nThere should be established written procedures, which are regularly reviewed and updated, for the organization of any recall activity. Recall operations should be capable of being initiated promptly down to the required level in the distribution chain.\n\n6.4 \nAn instruction should be included in the written procedures to store recalled products in a secure segregated area while their fate is decided.\n\n6.5 \nAll competent authorities of all countries to which a given product has been distributed should be promptly informed of any intention to recall the product because it is, or is suspected of being, defective.\n\n6.6 \nThe distribution records should be readily available to the authorized person, and they should contain sufficient information on wholesalers and directly supplied customers (including, for exported products, those who have received samples for clinical tests and medical samples) to permit an effective recall.\n\n6.7 \nThe progress of the recall process should be monitored and recorded. Records should include the disposition of the product. A final report should be issued, including a reconciliation between the delivered and recovered quantities of the products.\n\n6.8 \nThe effectiveness of the arrangements for recalls should be tested and evaluated from time to time.\n\n# 7. Contract production and analysis\n\n7.1 Principle. \nContract production and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings that could result in a product or work or analysis of unsatisfactory quality.\n\n## General\n\n7.2 \nAll arrangements for contract production and analysis, including any proposed changes in technical or other arrangements, should be in accordance with the marketing authorization for the product concerned.\n\n7.3 \nThe contract should permit the contract giver to audit the facilities of the contract acceptor.\n\n7.4 \nIn the case of contract analysis, the final approval for release must be given by the authorized person.\n\n## The contract giver\n\n7.5 \nThe contract giver is responsible for assessing the competence of the contract acceptor in successfully carrying out the work or tests required, for", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2167, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3f276451-e722-4213-b843-2b740cffc9de": {"__data__": {"id_": "3f276451-e722-4213-b843-2b740cffc9de", "embedding": null, "metadata": {"page_label": "123", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# The Contract\n\n7.6 The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations correctly in accordance with the marketing authorization and any other legal requirements. The contract giver should ensure that the contract acceptor is fully aware of any problems associated with the product, work or tests that might pose a hazard to premises, equipment, personnel, other materials or other products.\n\n7.7 The contract giver should ensure that all processed products and materials delivered by the contract acceptor comply with their specifications or that the product has been released by the authorized person.\n\n## The Contract Acceptor\n\n7.8 The contract acceptor must have adequate premises, equipment, knowledge, and experience and competent personnel to carry out satisfactorily the work ordered by the contract giver. Contract manufacture may be undertaken only by a manufacturer who holds a manufacturing authorization.\n\n7.9 The contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements. Arrangements made between the contract acceptor and any third party should ensure that the manufacturing and analytical information is made available in the same way as between the original contract giver and contract acceptor.\n\n7.10 The contract acceptor should refrain from any activity that may adversely affect the quality of the product manufactured and/or analysed for the contract giver.\n\n## The Contract\n\n7.11 There must be a written contract between the contract giver and the contract acceptor which clearly establishes the responsibilities of each party.\n\n7.12 The contract must clearly state the way in which the authorized person, in releasing each batch of product for sale or issuing the certificate of analysis, exercises his or her full responsibility and ensures that each batch has been manufactured in, and checked for, compliance with the requirements of the marketing authorization.\n\n7.13 Technical aspects of the contract should be drawn up by competent persons suitably knowledgeable in pharmaceutical technology, analysis and GMP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las responsabilidades y requisitos de las partes involucradas en un contrato de fabricaci\u00f3n en el \u00e1mbito farmac\u00e9utico. Se detalla la obligaci\u00f3n del \"contract giver\" (quien otorga el contrato) de proporcionar informaci\u00f3n necesaria y asegurar que el \"contract acceptor\" (quien acepta el contrato) cumpla con las especificaciones y normativas. Tambi\u00e9n se enfatiza la necesidad de que el \"contract acceptor\" tenga las instalaciones, el equipo y el personal competente para llevar a cabo el trabajo. Adem\u00e1s, se establece que debe existir un contrato escrito que defina claramente las responsabilidades de ambas partes y que los aspectos t\u00e9cnicos del contrato deben ser elaborados por personas competentes en tecnolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe proporcionar el contract giver al contract acceptor para asegurar el cumplimiento de las operaciones contratadas?**\n   - El contract giver debe proporcionar toda la informaci\u00f3n necesaria para llevar a cabo las operaciones de acuerdo con la autorizaci\u00f3n de comercializaci\u00f3n y otros requisitos legales, as\u00ed como informar sobre cualquier problema que pueda representar un riesgo.\n\n2. **\u00bfCu\u00e1les son las condiciones que debe cumplir el contract acceptor para llevar a cabo el trabajo solicitado?**\n   - El contract acceptor debe contar con instalaciones adecuadas, equipo, conocimiento, experiencia y personal competente para realizar satisfactoriamente el trabajo ordenado por el contract giver.\n\n3. **\u00bfQu\u00e9 debe incluir el contrato escrito entre el contract giver y el contract acceptor?**\n   - El contrato debe establecer claramente las responsabilidades de cada parte y detallar c\u00f3mo el personal autorizado ejerce su responsabilidad al liberar cada lote de producto para la venta o emitir el certificado de an\u00e1lisis, asegurando que cada lote cumple con los requisitos de la autorizaci\u00f3n de comercializaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos de Retiro de Productos**:\n   - Importancia de establecer procedimientos escritos para la organizaci\u00f3n de actividades de retiro.\n   - Necesidad de iniciar operaciones de retiro de manera r\u00e1pida en la cadena de distribuci\u00f3n.\n   - Almacenamiento seguro de productos retirados mientras se decide su destino.\n\n2. **Comunicaci\u00f3n con Autoridades Competentes**:\n   - Obligatoriedad de informar a las autoridades de todos los pa\u00edses donde se distribuy\u00f3 el producto sobre cualquier intenci\u00f3n de retiro debido a defectos.\n\n3. **Registros de Distribuci\u00f3n**:\n   - Los registros deben ser accesibles y contener informaci\u00f3n suficiente sobre mayoristas y clientes para facilitar un retiro efectivo.\n\n4. **Monitoreo y Evaluaci\u00f3n del Proceso de Retiro**:\n   - Registro del progreso del proceso de retiro y disposici\u00f3n del producto.\n   - Emisi\u00f3n de un informe final que incluya la reconciliaci\u00f3n de cantidades entregadas y recuperadas.\n   - Evaluaci\u00f3n peri\u00f3dica de la efectividad de los procedimientos de retiro.\n\n5. **Producci\u00f3n y An\u00e1lisis por Contrato**:\n   - Definici\u00f3n y control adecuados de los acuerdos de producci\u00f3n y an\u00e1lisis para evitar malentendidos.\n   - Cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n en todos los arreglos.\n   - Derecho del contratante a auditar las instalaciones del contratista.\n   - Aprobaci\u00f3n final de an\u00e1lisis por parte de una persona autorizada.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que proporciona las directrices.\n- **Autoridades Competentes**: Organismos responsables en cada pa\u00eds que deben ser informados sobre retiros.\n- **Contratante y Contratista**: Partes involucradas en la producci\u00f3n y an\u00e1lisis por contrato, donde el contratante eval\u00faa la competencia del contratista. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de retiros de productos y la producci\u00f3n por contrato, asegurando la calidad y la seguridad en el proceso.", "excerpt_keywords": "Keywords: contract giver, contract acceptor, pharmaceutical manufacturing, marketing authorization, good manufacturing practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c9790b68-a89f-4505-af93-725cd407b856", "node_type": "4", "metadata": {"page_label": "123", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# The Contract\n\n7.6 The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations correctly in accordance with the marketing authorization and any other legal requirements. The contract giver should ensure that the contract acceptor is fully aware of any problems associated with the product, work or tests that might pose a hazard to premises, equipment, personnel, other materials or other products.\n\n7.7 The contract giver should ensure that all processed products and materials delivered by the contract acceptor comply with their specifications or that the product has been released by the authorized person.\n\n## The Contract Acceptor\n\n7.8 The contract acceptor must have adequate premises, equipment, knowledge, and experience and competent personnel to carry out satisfactorily the work ordered by the contract giver. Contract manufacture may be undertaken only by a manufacturer who holds a manufacturing authorization.\n\n7.9 The contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements. Arrangements made between the contract acceptor and any third party should ensure that the manufacturing and analytical information is made available in the same way as between the original contract giver and contract acceptor.\n\n7.10 The contract acceptor should refrain from any activity that may adversely affect the quality of the product manufactured and/or analysed for the contract giver.\n\n## The Contract\n\n7.11 There must be a written contract between the contract giver and the contract acceptor which clearly establishes the responsibilities of each party.\n\n7.12 The contract must clearly state the way in which the authorized person, in releasing each batch of product for sale or issuing the certificate of analysis, exercises his or her full responsibility and ensures that each batch has been manufactured in, and checked for, compliance with the requirements of the marketing authorization.\n\n7.13 Technical aspects of the contract should be drawn up by competent persons suitably knowledgeable in pharmaceutical technology, analysis and GMP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ecd26a4f852e1d3f14116b75e01d78451f7aa0f18ef8fb61742b58e396501c5d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# The Contract\n\n7.6 The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations correctly in accordance with the marketing authorization and any other legal requirements. The contract giver should ensure that the contract acceptor is fully aware of any problems associated with the product, work or tests that might pose a hazard to premises, equipment, personnel, other materials or other products.\n\n7.7 The contract giver should ensure that all processed products and materials delivered by the contract acceptor comply with their specifications or that the product has been released by the authorized person.\n\n## The Contract Acceptor\n\n7.8 The contract acceptor must have adequate premises, equipment, knowledge, and experience and competent personnel to carry out satisfactorily the work ordered by the contract giver. Contract manufacture may be undertaken only by a manufacturer who holds a manufacturing authorization.\n\n7.9 The contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements. Arrangements made between the contract acceptor and any third party should ensure that the manufacturing and analytical information is made available in the same way as between the original contract giver and contract acceptor.\n\n7.10 The contract acceptor should refrain from any activity that may adversely affect the quality of the product manufactured and/or analysed for the contract giver.\n\n## The Contract\n\n7.11 There must be a written contract between the contract giver and the contract acceptor which clearly establishes the responsibilities of each party.\n\n7.12 The contract must clearly state the way in which the authorized person, in releasing each batch of product for sale or issuing the certificate of analysis, exercises his or her full responsibility and ensures that each batch has been manufactured in, and checked for, compliance with the requirements of the marketing authorization.\n\n7.13 Technical aspects of the contract should be drawn up by competent persons suitably knowledgeable in pharmaceutical technology, analysis and GMP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2250, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8c1a6659-7e9a-4c51-9328-9be86746bbd6": {"__data__": {"id_": "8c1a6659-7e9a-4c51-9328-9be86746bbd6", "embedding": null, "metadata": {"page_label": "124", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.14 \nAll arrangements for production and analysis must be in accordance with the marketing authorization and agreed by both parties.\n\n7.15 \nThe contract should describe clearly who is responsible for purchasing, testing and releasing materials and for undertaking production and QC, including in-process controls, and who has responsibility for sampling and analysis. In the case of contract analysis, the contract should state whether or not the contract acceptor should take samples at the premises of the manufacturer.\n\n7.16 \nManufacturing, analytical, distribution records and reference samples should be kept by, or be available to, the contract giver. Any records relevant to assessing the quality of a product in the event of complaints or a suspected defect must be accessible and specified in the defect/recall procedures of the contract giver.\n\n7.17 \nThe contract should describe the handling of starting materials, intermediate and bulk products and finished products if they are rejected. It should also describe the procedure to be followed if the contract analysis shows that the tested product must be rejected.\n\n# 8. Self-inspection, quality audits and supplier\u2019s audits and approval\n\n8.1 **Principle.** \nThe purpose of self-inspection is to evaluate the manufacturer\u2019s compliance with GMP in all aspects of production and QC. The self-inspection programme should be designed to detect any shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections should be performed routinely, and may be, in addition, performed on special occasions, e.g. in the case of product recalls or repeated rejections, or when an inspection by the health authorities is announced. The team responsible for self-inspection should consist of personnel who can evaluate the implementation of GMP objectively. All recommendations for corrective action should be implemented. The procedure for self-inspection should be documented, and there should be an effective follow-up programme.\n\n## Items for self-inspection\n\n8.2 \nWritten instructions for self-inspection should be established to provide a minimum and uniform standard of requirements. These may include questionnaires on GMP requirements covering at least the following items:\n\n(a) personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Producci\u00f3n y An\u00e1lisis**: El documento establece que todos los arreglos para la producci\u00f3n y an\u00e1lisis de productos deben estar en conformidad con la autorizaci\u00f3n de comercializaci\u00f3n y ser acordados por ambas partes involucradas en el contrato. Se enfatiza la importancia de definir claramente las responsabilidades de cada parte en el proceso de producci\u00f3n y control de calidad (QC).\n\n2. **Autocontrol y Auditor\u00edas**: Se detalla la importancia de la autoinspecci\u00f3n como un medio para evaluar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los aspectos de la producci\u00f3n y el control de calidad. Se sugiere que estas autoinspecciones se realicen de manera rutinaria y en ocasiones especiales, y que se documenten adecuadamente.\n\n3. **Manejo de Productos Rechazados**: El documento tambi\u00e9n aborda c\u00f3mo manejar los materiales y productos que son rechazados, as\u00ed como los procedimientos a seguir en caso de que un an\u00e1lisis de contrato indique que un producto debe ser rechazado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos deben ser considerados en el contrato para la gesti\u00f3n de materiales rechazados?**\n   - El contrato debe describir claramente el manejo de los materiales iniciales, intermedios, productos a granel y productos terminados que sean rechazados. Tambi\u00e9n debe incluir el procedimiento a seguir si el an\u00e1lisis de contrato determina que un producto debe ser rechazado.\n\n2. **\u00bfCu\u00e1l es el objetivo principal de la autoinspecci\u00f3n seg\u00fan el documento?**\n   - El objetivo principal de la autoinspecci\u00f3n es evaluar el cumplimiento del fabricante con las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los aspectos de producci\u00f3n y control de calidad, as\u00ed como detectar cualquier deficiencia en la implementaci\u00f3n de GMP y recomendar acciones correctivas necesarias.\n\n3. **\u00bfQu\u00e9 tipo de personal debe formar parte del equipo responsable de la autoinspecci\u00f3n?**\n   - El equipo responsable de la autoinspecci\u00f3n debe estar compuesto por personal que pueda evaluar objetivamente la implementaci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP). Esto asegura que las evaluaciones sean imparciales y efectivas.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidades del Contract Giver**:\n   - Proporcionar informaci\u00f3n necesaria para las operaciones contratadas.\n   - Asegurar que el contract acceptor est\u00e9 informado sobre problemas que puedan representar riesgos.\n   - Verificar que los productos y materiales procesados cumplan con las especificaciones.\n\n2. **Requisitos para el Contract Acceptor**:\n   - Contar con instalaciones, equipo, conocimiento y personal competente.\n   - No subcontratar el trabajo sin la aprobaci\u00f3n del contract giver.\n   - Evitar actividades que puedan afectar la calidad del producto.\n\n3. **Contrato Escrito**:\n   - Debe establecer claramente las responsabilidades de ambas partes.\n   - Incluir detalles sobre la responsabilidad del personal autorizado en la liberaci\u00f3n de lotes y emisi\u00f3n de certificados de an\u00e1lisis.\n   - Los aspectos t\u00e9cnicos deben ser elaborados por expertos en tecnolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP).\n\n### Entidades\n\n- **Contract Giver**: Parte que otorga el contrato y tiene la responsabilidad de proporcionar informaci\u00f3n y asegurar el cumplimiento de especificaciones.\n- **Contract Acceptor**: Parte que acepta el contrato y debe cumplir con requisitos espec\u00edficos para realizar el trabajo.\n- **Autorizaci\u00f3n de Fabricaci\u00f3n**: Licencia necesaria para que el contract acceptor realice la fabricaci\u00f3n.\n- **Personal Autorizado**: Individuo responsable de liberar lotes de productos y emitir certificados de an\u00e1lisis.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que deben seguirse para asegurar la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: production, quality control, self-inspection, contract management, Good Manufacturing Practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b86d61f6-6b7d-4796-93f0-2ce2de15733e", "node_type": "4", "metadata": {"page_label": "124", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.14 \nAll arrangements for production and analysis must be in accordance with the marketing authorization and agreed by both parties.\n\n7.15 \nThe contract should describe clearly who is responsible for purchasing, testing and releasing materials and for undertaking production and QC, including in-process controls, and who has responsibility for sampling and analysis. In the case of contract analysis, the contract should state whether or not the contract acceptor should take samples at the premises of the manufacturer.\n\n7.16 \nManufacturing, analytical, distribution records and reference samples should be kept by, or be available to, the contract giver. Any records relevant to assessing the quality of a product in the event of complaints or a suspected defect must be accessible and specified in the defect/recall procedures of the contract giver.\n\n7.17 \nThe contract should describe the handling of starting materials, intermediate and bulk products and finished products if they are rejected. It should also describe the procedure to be followed if the contract analysis shows that the tested product must be rejected.\n\n# 8. Self-inspection, quality audits and supplier\u2019s audits and approval\n\n8.1 **Principle.** \nThe purpose of self-inspection is to evaluate the manufacturer\u2019s compliance with GMP in all aspects of production and QC. The self-inspection programme should be designed to detect any shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections should be performed routinely, and may be, in addition, performed on special occasions, e.g. in the case of product recalls or repeated rejections, or when an inspection by the health authorities is announced. The team responsible for self-inspection should consist of personnel who can evaluate the implementation of GMP objectively. All recommendations for corrective action should be implemented. The procedure for self-inspection should be documented, and there should be an effective follow-up programme.\n\n## Items for self-inspection\n\n8.2 \nWritten instructions for self-inspection should be established to provide a minimum and uniform standard of requirements. These may include questionnaires on GMP requirements covering at least the following items:\n\n(a) personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e7448b34b34e2e266659658f48a51c12d6eca8552b74d4042709e27caa920d16", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.14 \nAll arrangements for production and analysis must be in accordance with the marketing authorization and agreed by both parties.\n\n7.15 \nThe contract should describe clearly who is responsible for purchasing, testing and releasing materials and for undertaking production and QC, including in-process controls, and who has responsibility for sampling and analysis. In the case of contract analysis, the contract should state whether or not the contract acceptor should take samples at the premises of the manufacturer.\n\n7.16 \nManufacturing, analytical, distribution records and reference samples should be kept by, or be available to, the contract giver. Any records relevant to assessing the quality of a product in the event of complaints or a suspected defect must be accessible and specified in the defect/recall procedures of the contract giver.\n\n7.17 \nThe contract should describe the handling of starting materials, intermediate and bulk products and finished products if they are rejected. It should also describe the procedure to be followed if the contract analysis shows that the tested product must be rejected.\n\n# 8. Self-inspection, quality audits and supplier\u2019s audits and approval\n\n8.1 **Principle.** \nThe purpose of self-inspection is to evaluate the manufacturer\u2019s compliance with GMP in all aspects of production and QC. The self-inspection programme should be designed to detect any shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections should be performed routinely, and may be, in addition, performed on special occasions, e.g. in the case of product recalls or repeated rejections, or when an inspection by the health authorities is announced. The team responsible for self-inspection should consist of personnel who can evaluate the implementation of GMP objectively. All recommendations for corrective action should be implemented. The procedure for self-inspection should be documented, and there should be an effective follow-up programme.\n\n## Items for self-inspection\n\n8.2 \nWritten instructions for self-inspection should be established to provide a minimum and uniform standard of requirements. These may include questionnaires on GMP requirements covering at least the following items:\n\n(a) personnel;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2294, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d754f115-f7b2-491d-a714-71726f52b7da": {"__data__": {"id_": "d754f115-f7b2-491d-a714-71726f52b7da", "embedding": null, "metadata": {"page_label": "125", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(b) premises including personnel facilities;  \n(c) maintenance of buildings and equipment;  \n(d) storage of starting materials and finished products;  \n(e) equipment;  \n(f) production and in-process controls;  \n(g) QC;  \n(h) documentation;  \n(i) sanitation and hygiene;  \n(j) validation and revalidation programmes;  \n(k) calibration of instruments or measurement systems;  \n(l) recall procedures;  \n(m) complaints management;  \n(n) labels control;  \n(o) results of previous self-inspections and any corrective steps taken.  \n\n# Self-inspection team\n\n8.3 Management should appoint a self-inspection team consisting of experts in their respective fields and familiar with GMP. The members of the team may be appointed from inside or outside the company.\n\n# Frequency of self-inspection\n\n8.4 The frequency at which self-inspections are conducted may depend on company requirements but should preferably be at least once a year. The frequency should be stated in the procedure.\n\n# Self-inspection report\n\n8.5 A report should be made at the completion of a self-inspection. The report should include:\n\n(a) self-inspection results;  \n(b) evaluation and conclusions; and  \n(c) recommended corrective actions.\n\n# Follow-up action\n\n8.6 There should be an effective follow-up programme. The company management should evaluate both the self-inspection report and the corrective actions as necessary.\n\n# Quality audit\n\n8.7 It may be useful to supplement self-inspections with a quality audit. A quality audit consists of an examination and assessment of all or part of the quality system with the specific purpose of improving the system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Importancia de la autoinspecci\u00f3n en GMP**: La autoinspecci\u00f3n es un proceso cr\u00edtico en la gesti\u00f3n de la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en evaluar diversos aspectos de las instalaciones, el equipo, los controles de producci\u00f3n y otros elementos clave para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **Estructura y frecuencia de la autoinspecci\u00f3n**: La autoinspecci\u00f3n debe ser realizada por un equipo designado por la direcci\u00f3n, compuesto por expertos en sus respectivos campos. Se recomienda que estas autoinspecciones se realicen al menos una vez al a\u00f1o, y los resultados deben ser documentados en un informe que incluya hallazgos, evaluaciones y acciones correctivas recomendadas.\n\n3. **Seguimiento y auditor\u00eda de calidad**: Despu\u00e9s de la autoinspecci\u00f3n, es esencial implementar un programa de seguimiento efectivo para evaluar los informes y las acciones correctivas. Adem\u00e1s, se sugiere complementar las autoinspecciones con auditor\u00edas de calidad para mejorar el sistema de gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar a los miembros del equipo de autoinspecci\u00f3n?**\n   - La selecci\u00f3n debe basarse en la experiencia y el conocimiento de los miembros en sus respectivos campos, as\u00ed como su familiaridad con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **\u00bfQu\u00e9 elementos espec\u00edficos deben incluirse en el informe de autoinspecci\u00f3n?**\n   - El informe debe incluir los resultados de la autoinspecci\u00f3n, una evaluaci\u00f3n y conclusiones, as\u00ed como las acciones correctivas recomendadas.\n\n3. **\u00bfCu\u00e1l es la relaci\u00f3n entre la autoinspecci\u00f3n y la auditor\u00eda de calidad en el contexto de GMP?**\n   - La auditor\u00eda de calidad complementa la autoinspecci\u00f3n al proporcionar una evaluaci\u00f3n m\u00e1s amplia y detallada del sistema de calidad, con el objetivo de identificar \u00e1reas de mejora y asegurar el cumplimiento de los est\u00e1ndares de calidad.", "prev_section_summary": "### Temas Clave\n\n1. **Producci\u00f3n y An\u00e1lisis**: Se establece que todos los arreglos para la producci\u00f3n y an\u00e1lisis deben cumplir con la autorizaci\u00f3n de comercializaci\u00f3n y ser acordados por ambas partes. Es crucial definir las responsabilidades de cada parte en el proceso de producci\u00f3n y control de calidad (QC).\n\n2. **Responsabilidades Contractuales**: El contrato debe especificar qui\u00e9n es responsable de la compra, prueba y liberaci\u00f3n de materiales, as\u00ed como de la producci\u00f3n y el control de calidad, incluyendo controles en proceso y an\u00e1lisis de muestras.\n\n3. **Manejo de Productos Rechazados**: Se debe detallar en el contrato c\u00f3mo se manejar\u00e1n los materiales y productos rechazados, as\u00ed como el procedimiento a seguir si un an\u00e1lisis indica que un producto debe ser rechazado.\n\n4. **Autoinspecci\u00f3n y Auditor\u00edas**: La autoinspecci\u00f3n es fundamental para evaluar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP). Debe realizarse de manera rutinaria y documentarse adecuadamente, con un equipo que eval\u00fae objetivamente la implementaci\u00f3n de GMP.\n\n5. **Documentaci\u00f3n y Registros**: Los registros de fabricaci\u00f3n, an\u00e1lisis y distribuci\u00f3n deben estar disponibles para el contratante, y cualquier registro relevante para evaluar la calidad del producto debe ser accesible en caso de quejas o defectos.\n\n### Entidades\n\n- **Partes Contratantes**: Contratante (contract giver) y contratista (contract acceptor).\n- **Productos**: Materiales iniciales, intermedios, productos a granel y productos terminados.\n- **Normativas**: Buenas Pr\u00e1cticas de Manufactura (GMP).\n- **Documentaci\u00f3n**: Contratos, registros de producci\u00f3n y an\u00e1lisis, procedimientos de defectos/recalls.\n- **Equipo de Autoinspecci\u00f3n**: Personal capacitado para evaluar la implementaci\u00f3n de GMP.\n\nEste resumen destaca la importancia de la claridad en los contratos, la responsabilidad en la producci\u00f3n y el an\u00e1lisis, y la necesidad de un sistema robusto de autoinspecci\u00f3n para garantizar la calidad y el cumplimiento normativo.", "excerpt_keywords": "Keywords: self-inspection, GMP, quality audit, corrective actions, documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13a6e3e6-0034-40c1-8998-7fcfb9309841", "node_type": "4", "metadata": {"page_label": "125", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(b) premises including personnel facilities;  \n(c) maintenance of buildings and equipment;  \n(d) storage of starting materials and finished products;  \n(e) equipment;  \n(f) production and in-process controls;  \n(g) QC;  \n(h) documentation;  \n(i) sanitation and hygiene;  \n(j) validation and revalidation programmes;  \n(k) calibration of instruments or measurement systems;  \n(l) recall procedures;  \n(m) complaints management;  \n(n) labels control;  \n(o) results of previous self-inspections and any corrective steps taken.  \n\n# Self-inspection team\n\n8.3 Management should appoint a self-inspection team consisting of experts in their respective fields and familiar with GMP. The members of the team may be appointed from inside or outside the company.\n\n# Frequency of self-inspection\n\n8.4 The frequency at which self-inspections are conducted may depend on company requirements but should preferably be at least once a year. The frequency should be stated in the procedure.\n\n# Self-inspection report\n\n8.5 A report should be made at the completion of a self-inspection. The report should include:\n\n(a) self-inspection results;  \n(b) evaluation and conclusions; and  \n(c) recommended corrective actions.\n\n# Follow-up action\n\n8.6 There should be an effective follow-up programme. The company management should evaluate both the self-inspection report and the corrective actions as necessary.\n\n# Quality audit\n\n8.7 It may be useful to supplement self-inspections with a quality audit. A quality audit consists of an examination and assessment of all or part of the quality system with the specific purpose of improving the system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0b74d94aeab2d7bb2a648fc0ecc2d1004b0ddbe4911c457946c287b3793d31f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(b) premises including personnel facilities;  \n(c) maintenance of buildings and equipment;  \n(d) storage of starting materials and finished products;  \n(e) equipment;  \n(f) production and in-process controls;  \n(g) QC;  \n(h) documentation;  \n(i) sanitation and hygiene;  \n(j) validation and revalidation programmes;  \n(k) calibration of instruments or measurement systems;  \n(l) recall procedures;  \n(m) complaints management;  \n(n) labels control;  \n(o) results of previous self-inspections and any corrective steps taken.  \n\n# Self-inspection team\n\n8.3 Management should appoint a self-inspection team consisting of experts in their respective fields and familiar with GMP. The members of the team may be appointed from inside or outside the company.\n\n# Frequency of self-inspection\n\n8.4 The frequency at which self-inspections are conducted may depend on company requirements but should preferably be at least once a year. The frequency should be stated in the procedure.\n\n# Self-inspection report\n\n8.5 A report should be made at the completion of a self-inspection. The report should include:\n\n(a) self-inspection results;  \n(b) evaluation and conclusions; and  \n(c) recommended corrective actions.\n\n# Follow-up action\n\n8.6 There should be an effective follow-up programme. The company management should evaluate both the self-inspection report and the corrective actions as necessary.\n\n# Quality audit\n\n8.7 It may be useful to supplement self-inspections with a quality audit. A quality audit consists of an examination and assessment of all or part of the quality system with the specific purpose of improving the system.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1627, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7b210a65-917f-40ad-a97d-fd462a804b0c": {"__data__": {"id_": "7b210a65-917f-40ad-a97d-fd462a804b0c", "embedding": null, "metadata": {"page_label": "126", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of a quality system with the specific purpose of improving it. A quality audit is usually conducted by outside or independent specialists or a team designated by the management for this purpose. Such audits may also be extended to suppliers and contractors (see section 7, \u201cContract production and analysis\u201d).\n\n### Suppliers\u2019 audits and approval\n\n8.8 The person responsible for QC should have responsibility together with other relevant departments for approving suppliers who can reliably supply starting and packaging materials that meet established specifications.\n\n8.9 Before suppliers are approved and included in the approved supplier\u2019s list or specifications, they should be evaluated. The evaluation should take into account a supplier\u2019s history and the nature of the materials to be supplied. If an audit is required, it should determine the supplier\u2019s ability to conform with GMP standards.\n\n## 9. Personnel\n\n### 9.1 Principle\n\nThe establishment and maintenance of a satisfactory system of QA and the correct manufacture and control of pharmaceutical products and active ingredients rely upon people. For this reason there must be sufficient qualified personnel to carry out all the tasks for which the manufacturer is responsible. Individual responsibilities should be clearly defined and understood by the persons concerned and recorded as written descriptions.\n\n### General\n\n9.2 The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. The responsibilities placed on any one individual should not be so extensive so as to present any risk to quality.\n\n9.3 Responsible staff should have its specific duties recorded in written descriptions and adequate authority to carry out its responsibilities.\n\nIts duties may be delegated to designated deputies of a satisfactory qualification level. There should be no gaps or unexplained overlaps in the responsibilities of personnel concerned with the application of GMP. The manufacturer should have an organization chart.\n\n9.4 All personnel should be aware of the principles of GMP that affect them and receive initial and continuing training, including hygiene instructions, relevant to their needs. All personnel should be motivated to support the establishment and maintenance of high quality standards.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la importancia de los sistemas de calidad (QA) y de control de calidad (QC) en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se menciona la necesidad de realizar auditor\u00edas de calidad, tanto internas como externas, y la evaluaci\u00f3n de proveedores para asegurar que cumplan con las especificaciones establecidas. Adem\u00e1s, se destaca la importancia del personal calificado en la implementaci\u00f3n de buenas pr\u00e1cticas de manufactura (GMP), as\u00ed como la necesidad de definir claramente las responsabilidades y proporcionar formaci\u00f3n continua al personal.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben considerarse al evaluar a un proveedor antes de su aprobaci\u00f3n en la lista de proveedores?**\n   - El texto menciona que la evaluaci\u00f3n debe tener en cuenta la historia del proveedor y la naturaleza de los materiales que se suministrar\u00e1n, as\u00ed como la capacidad del proveedor para cumplir con los est\u00e1ndares de GMP.\n\n2. **\u00bfCu\u00e1l es la importancia de la formaci\u00f3n continua del personal en el contexto de las buenas pr\u00e1cticas de manufactura (GMP)?**\n   - La formaci\u00f3n continua es crucial para que todo el personal est\u00e9 al tanto de los principios de GMP que les afectan, lo que contribuye a mantener altos est\u00e1ndares de calidad en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfC\u00f3mo se debe estructurar la organizaci\u00f3n del personal para evitar solapamientos o vac\u00edos en las responsabilidades relacionadas con GMP?**\n   - La organizaci\u00f3n del personal debe estar claramente definida mediante un organigrama, y las responsabilidades deben estar registradas en descripciones escritas, asegurando que no haya solapamientos o vac\u00edos en las funciones de quienes aplican las GMP.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia de la Autoinspecci\u00f3n**: La autoinspecci\u00f3n es fundamental para garantizar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) en la industria farmac\u00e9utica, evaluando aspectos cr\u00edticos como instalaciones, equipos y controles de producci\u00f3n.\n\n2. **Composici\u00f3n del Equipo de Autoinspecci\u00f3n**: La direcci\u00f3n debe designar un equipo de autoinspecci\u00f3n compuesto por expertos en sus respectivos campos, que est\u00e9n familiarizados con las GMP. Los miembros pueden ser internos o externos a la empresa.\n\n3. **Frecuencia de Autoinspecci\u00f3n**: Se recomienda que las autoinspecciones se realicen al menos una vez al a\u00f1o, y esta frecuencia debe estar claramente definida en los procedimientos de la empresa.\n\n4. **Informe de Autoinspecci\u00f3n**: Al finalizar una autoinspecci\u00f3n, se debe elaborar un informe que incluya los resultados, evaluaciones, conclusiones y acciones correctivas recomendadas.\n\n5. **Programa de Seguimiento**: Es esencial implementar un programa de seguimiento efectivo para evaluar los informes de autoinspecci\u00f3n y las acciones correctivas.\n\n6. **Auditor\u00eda de Calidad**: Se sugiere complementar las autoinspecciones con auditor\u00edas de calidad, que proporcionan una evaluaci\u00f3n m\u00e1s exhaustiva del sistema de calidad con el objetivo de identificar \u00e1reas de mejora.\n\n### Entidades\n\n- **Autoinspecci\u00f3n**: Proceso de evaluaci\u00f3n interna para asegurar el cumplimiento de GMP.\n- **Equipo de Autoinspecci\u00f3n**: Grupo designado por la direcci\u00f3n, compuesto por expertos en GMP.\n- **Frecuencia**: Al menos una vez al a\u00f1o.\n- **Informe de Autoinspecci\u00f3n**: Documento que resume los hallazgos y recomendaciones tras la autoinspecci\u00f3n.\n- **Programa de Seguimiento**: Proceso para evaluar la implementaci\u00f3n de acciones correctivas.\n- **Auditor\u00eda de Calidad**: Evaluaci\u00f3n adicional del sistema de calidad para mejorar su eficacia.", "excerpt_keywords": "Keywords: quality audit, suppliers' approval, GMP standards, qualified personnel, training"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b4291a05-af7e-45ad-8c11-9b68b322ba11", "node_type": "4", "metadata": {"page_label": "126", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of a quality system with the specific purpose of improving it. A quality audit is usually conducted by outside or independent specialists or a team designated by the management for this purpose. Such audits may also be extended to suppliers and contractors (see section 7, \u201cContract production and analysis\u201d).\n\n### Suppliers\u2019 audits and approval\n\n8.8 The person responsible for QC should have responsibility together with other relevant departments for approving suppliers who can reliably supply starting and packaging materials that meet established specifications.\n\n8.9 Before suppliers are approved and included in the approved supplier\u2019s list or specifications, they should be evaluated. The evaluation should take into account a supplier\u2019s history and the nature of the materials to be supplied. If an audit is required, it should determine the supplier\u2019s ability to conform with GMP standards.\n\n## 9. Personnel\n\n### 9.1 Principle\n\nThe establishment and maintenance of a satisfactory system of QA and the correct manufacture and control of pharmaceutical products and active ingredients rely upon people. For this reason there must be sufficient qualified personnel to carry out all the tasks for which the manufacturer is responsible. Individual responsibilities should be clearly defined and understood by the persons concerned and recorded as written descriptions.\n\n### General\n\n9.2 The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. The responsibilities placed on any one individual should not be so extensive so as to present any risk to quality.\n\n9.3 Responsible staff should have its specific duties recorded in written descriptions and adequate authority to carry out its responsibilities.\n\nIts duties may be delegated to designated deputies of a satisfactory qualification level. There should be no gaps or unexplained overlaps in the responsibilities of personnel concerned with the application of GMP. The manufacturer should have an organization chart.\n\n9.4 All personnel should be aware of the principles of GMP that affect them and receive initial and continuing training, including hygiene instructions, relevant to their needs. All personnel should be motivated to support the establishment and maintenance of high quality standards.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4674ab72b91ef850ebc6ca43d0fd90ac35cf15ae88e5c21335530f11cdd601b3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "of a quality system with the specific purpose of improving it. A quality audit is usually conducted by outside or independent specialists or a team designated by the management for this purpose. Such audits may also be extended to suppliers and contractors (see section 7, \u201cContract production and analysis\u201d).\n\n### Suppliers\u2019 audits and approval\n\n8.8 The person responsible for QC should have responsibility together with other relevant departments for approving suppliers who can reliably supply starting and packaging materials that meet established specifications.\n\n8.9 Before suppliers are approved and included in the approved supplier\u2019s list or specifications, they should be evaluated. The evaluation should take into account a supplier\u2019s history and the nature of the materials to be supplied. If an audit is required, it should determine the supplier\u2019s ability to conform with GMP standards.\n\n## 9. Personnel\n\n### 9.1 Principle\n\nThe establishment and maintenance of a satisfactory system of QA and the correct manufacture and control of pharmaceutical products and active ingredients rely upon people. For this reason there must be sufficient qualified personnel to carry out all the tasks for which the manufacturer is responsible. Individual responsibilities should be clearly defined and understood by the persons concerned and recorded as written descriptions.\n\n### General\n\n9.2 The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. The responsibilities placed on any one individual should not be so extensive so as to present any risk to quality.\n\n9.3 Responsible staff should have its specific duties recorded in written descriptions and adequate authority to carry out its responsibilities.\n\nIts duties may be delegated to designated deputies of a satisfactory qualification level. There should be no gaps or unexplained overlaps in the responsibilities of personnel concerned with the application of GMP. The manufacturer should have an organization chart.\n\n9.4 All personnel should be aware of the principles of GMP that affect them and receive initial and continuing training, including hygiene instructions, relevant to their needs. All personnel should be motivated to support the establishment and maintenance of high quality standards.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2325, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "10555d1a-0ee7-4970-8519-36296c2b12ac": {"__data__": {"id_": "10555d1a-0ee7-4970-8519-36296c2b12ac", "embedding": null, "metadata": {"page_label": "127", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key Personnel\n\n9.5 Steps should be taken to prevent unauthorized people from entering production, storage and QC areas. Personnel who do not work in these areas should not use them as a passageway.\n\n## Key Personnel\n\n9.6 Key personnel include the heads of production, the head(s) of quality unit(s) and the authorized person. The quality unit(s) typically comprise the quality assurance and quality control functions. In some cases, these could be combined in one department. The authorized person may also be responsible for one or more of these quality unit(s). Normally, key posts should be occupied by full-time personnel. The heads of production and quality unit(s) should be independent of each other. In large organizations, it may be necessary to delegate some of the functions; however, the responsibility cannot be delegated.\n\n9.7 Key personnel responsible for supervising the production and quality unit(s) for pharmaceutical products should possess the qualifications of a scientific education and practical experience required by national legislation. Their education should include the study of an appropriate combination of:\n\n- (a) chemistry (analytical or organic) or biochemistry;\n- (b) chemical engineering;\n- (c) microbiology;\n- (d) pharmaceutical sciences and technology;\n- (e) pharmacology and toxicology;\n- (f) physiology; and\n- (g) other related sciences.\n\nThey should also have adequate practical experience in the manufacture and QA of pharmaceutical products. In order to gain such experience, a preparatory period may be required, during which they should exercise their duties under professional guidance. The scientific education and practical experience of experts should be such as to enable them to exercise independent professional judgement, based on the application of scientific principles and understanding to the practical problems encountered in the manufacture and QC of pharmaceutical products.\n\n9.8 The heads of the production and the quality unit(s) generally have some shared, or jointly exercised, responsibilities relating to quality.\n\nThese may include, depending on national regulations:\n\n- (a) authorization of written procedures and other documents, including amendments;\n- (b) monitoring and control of the manufacturing environment;\n- (c) plant hygiene;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la gesti\u00f3n de personal clave en la producci\u00f3n y control de calidad de productos farmac\u00e9uticos. Se enfatiza la importancia de prevenir el acceso no autorizado a \u00e1reas cr\u00edticas, la independencia de los jefes de producci\u00f3n y calidad, y la necesidad de que el personal clave posea una educaci\u00f3n cient\u00edfica adecuada y experiencia pr\u00e1ctica. Adem\u00e1s, se mencionan las responsabilidades compartidas entre los jefes de producci\u00f3n y calidad en relaci\u00f3n con la calidad del producto.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las calificaciones educativas y la experiencia pr\u00e1ctica requeridas para el personal clave en la producci\u00f3n y control de calidad de productos farmac\u00e9uticos?**\n   - El contexto detalla que el personal clave debe tener una educaci\u00f3n cient\u00edfica que incluya qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda, fisiolog\u00eda y otras ciencias relacionadas, as\u00ed como experiencia pr\u00e1ctica en la fabricaci\u00f3n y aseguramiento de calidad de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Se menciona que se deben tomar pasos para prevenir que personas no autorizadas ingresen a las \u00e1reas de producci\u00f3n, almacenamiento y control de calidad, y que el personal que no trabaja en estas \u00e1reas no debe usarlas como pasadizos.\n\n3. **\u00bfQu\u00e9 responsabilidades comparten los jefes de producci\u00f3n y de las unidades de calidad en el contexto de la calidad del producto?**\n   - Seg\u00fan el documento, los jefes de producci\u00f3n y de las unidades de calidad generalmente comparten responsabilidades relacionadas con la calidad, que pueden incluir la autorizaci\u00f3n de procedimientos escritos, el monitoreo y control del entorno de fabricaci\u00f3n, y la higiene de la planta, dependiendo de las regulaciones nacionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Calidad (QA) y Control de Calidad (QC)**:\n   - Importancia de las auditor\u00edas de calidad, tanto internas como externas, para mejorar los sistemas de calidad.\n   - Las auditor\u00edas pueden ser realizadas por especialistas externos o equipos designados por la direcci\u00f3n.\n\n2. **Auditor\u00edas y Aprobaci\u00f3n de Proveedores**:\n   - El responsable de QC debe colaborar con otros departamentos para aprobar proveedores que suministren materiales que cumplan con las especificaciones.\n   - La evaluaci\u00f3n de proveedores debe considerar su historial, la naturaleza de los materiales y su capacidad para cumplir con los est\u00e1ndares de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **Personal Calificado**:\n   - La correcta fabricaci\u00f3n y control de productos farmac\u00e9uticos dependen de contar con personal calificado.\n   - Es esencial definir claramente las responsabilidades del personal y documentarlas por escrito.\n   - La organizaci\u00f3n del personal debe estar estructurada para evitar solapamientos o vac\u00edos en las responsabilidades relacionadas con GMP.\n\n4. **Formaci\u00f3n Continua**:\n   - Todo el personal debe recibir formaci\u00f3n inicial y continua sobre los principios de GMP y otros aspectos relevantes, incluyendo instrucciones de higiene.\n   - La motivaci\u00f3n del personal es clave para mantener altos est\u00e1ndares de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Fabricante de productos farmac\u00e9uticos.\n- **Roles**: Responsable de QC, personal calificado, personal de apoyo.\n- **Documentaci\u00f3n**: Descripciones escritas de responsabilidades, organigrama.\n- **Normativas**: Buenas Pr\u00e1cticas de Manufactura (GMP). \n\nEste resumen destaca la importancia de un sistema de calidad robusto, la evaluaci\u00f3n de proveedores, la capacitaci\u00f3n del personal y la claridad en las responsabilidades para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmaceutical production, quality assurance, key personnel, regulatory compliance, scientific education"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "660b518a-62ff-46c2-be27-0a10f9fc2a1a", "node_type": "4", "metadata": {"page_label": "127", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key Personnel\n\n9.5 Steps should be taken to prevent unauthorized people from entering production, storage and QC areas. Personnel who do not work in these areas should not use them as a passageway.\n\n## Key Personnel\n\n9.6 Key personnel include the heads of production, the head(s) of quality unit(s) and the authorized person. The quality unit(s) typically comprise the quality assurance and quality control functions. In some cases, these could be combined in one department. The authorized person may also be responsible for one or more of these quality unit(s). Normally, key posts should be occupied by full-time personnel. The heads of production and quality unit(s) should be independent of each other. In large organizations, it may be necessary to delegate some of the functions; however, the responsibility cannot be delegated.\n\n9.7 Key personnel responsible for supervising the production and quality unit(s) for pharmaceutical products should possess the qualifications of a scientific education and practical experience required by national legislation. Their education should include the study of an appropriate combination of:\n\n- (a) chemistry (analytical or organic) or biochemistry;\n- (b) chemical engineering;\n- (c) microbiology;\n- (d) pharmaceutical sciences and technology;\n- (e) pharmacology and toxicology;\n- (f) physiology; and\n- (g) other related sciences.\n\nThey should also have adequate practical experience in the manufacture and QA of pharmaceutical products. In order to gain such experience, a preparatory period may be required, during which they should exercise their duties under professional guidance. The scientific education and practical experience of experts should be such as to enable them to exercise independent professional judgement, based on the application of scientific principles and understanding to the practical problems encountered in the manufacture and QC of pharmaceutical products.\n\n9.8 The heads of the production and the quality unit(s) generally have some shared, or jointly exercised, responsibilities relating to quality.\n\nThese may include, depending on national regulations:\n\n- (a) authorization of written procedures and other documents, including amendments;\n- (b) monitoring and control of the manufacturing environment;\n- (c) plant hygiene;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e57a859445585068b5e0a2d96a2c28f7539ff73dcd4075d7e660b257cf9432c8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Key Personnel\n\n9.5 Steps should be taken to prevent unauthorized people from entering production, storage and QC areas. Personnel who do not work in these areas should not use them as a passageway.\n\n## Key Personnel\n\n9.6 Key personnel include the heads of production, the head(s) of quality unit(s) and the authorized person. The quality unit(s) typically comprise the quality assurance and quality control functions. In some cases, these could be combined in one department. The authorized person may also be responsible for one or more of these quality unit(s). Normally, key posts should be occupied by full-time personnel. The heads of production and quality unit(s) should be independent of each other. In large organizations, it may be necessary to delegate some of the functions; however, the responsibility cannot be delegated.\n\n9.7 Key personnel responsible for supervising the production and quality unit(s) for pharmaceutical products should possess the qualifications of a scientific education and practical experience required by national legislation. Their education should include the study of an appropriate combination of:\n\n- (a) chemistry (analytical or organic) or biochemistry;\n- (b) chemical engineering;\n- (c) microbiology;\n- (d) pharmaceutical sciences and technology;\n- (e) pharmacology and toxicology;\n- (f) physiology; and\n- (g) other related sciences.\n\nThey should also have adequate practical experience in the manufacture and QA of pharmaceutical products. In order to gain such experience, a preparatory period may be required, during which they should exercise their duties under professional guidance. The scientific education and practical experience of experts should be such as to enable them to exercise independent professional judgement, based on the application of scientific principles and understanding to the practical problems encountered in the manufacture and QC of pharmaceutical products.\n\n9.8 The heads of the production and the quality unit(s) generally have some shared, or jointly exercised, responsibilities relating to quality.\n\nThese may include, depending on national regulations:\n\n- (a) authorization of written procedures and other documents, including amendments;\n- (b) monitoring and control of the manufacturing environment;\n- (c) plant hygiene;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2307, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a2550d3e-d860-4512-9bc4-90ecbfb3b335": {"__data__": {"id_": "a2550d3e-d860-4512-9bc4-90ecbfb3b335", "embedding": null, "metadata": {"page_label": "128", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) process validation and calibration of analytical apparatus;  \n(e) training, including the application and principles of QA;  \n(f) approval and monitoring of suppliers of materials;  \n(g) approval and monitoring of contract manufacturers;  \n(h) designation and monitoring of storage conditions for materials and products;  \n(i) performance and evaluation of in-process controls;  \n(j) retention of records;  \n(k) monitoring of compliance with GMP requirements; and  \n(l) inspection, investigation and taking of samples in order to monitor factors that may affect product quality.  \n\n9.9 The head of the production generally has the following responsibilities:\n\n(a) to ensure that products are produced and stored according to the appropriate documentation in order to obtain the required quality;  \n(b) to approve the instructions relating to production operations, including the in-process controls, and to ensure their strict implementation;  \n(c) to ensure that the production records are evaluated and signed by a designated person;  \n(d) to check the maintenance of the department, premises and equipment;  \n(e) to ensure that the appropriate process validations and calibrations of control equipment are performed and recorded and the reports made available;  \n(f) to ensure that the required initial and continuing training of production personnel is carried out and adapted according to need.  \n\n9.10 The head(s) of the quality unit(s) generally have the following responsibilities:\n\n(a) to approve or reject starting materials, packaging materials, and intermediate, bulk and finished products in relation with their specifications;  \n(b) to evaluate batch records;  \n(c) to ensure that all necessary testing is carried out;  \n(d) to approve sampling instructions, specifications, test methods and other QC procedures;  \n(e) to approve and monitor analyses carried out under contract;  \n(f) to check the maintenance of the department, premises and equipment;  \n(g) to ensure that the appropriate validations, including those of analytical procedures, and calibrations of control equipment are carried out;  \n(h) to ensure that the required initial and continuing training of quality unit personnel is carried out and adapted according to need.  \n(i) establishment, implementation and maintenance of the quality system;  \n(j) supervision of the regular internal audits or self-inspections;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades de los l\u00edderes en producci\u00f3n y calidad dentro de un sistema de gesti\u00f3n de calidad (QA) en la industria farmac\u00e9utica. Se enfatiza la importancia de la validaci\u00f3n de procesos, la capacitaci\u00f3n del personal, la aprobaci\u00f3n y monitoreo de materiales y proveedores, as\u00ed como el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP). Las responsabilidades est\u00e1n divididas entre el jefe de producci\u00f3n y el jefe de la unidad de calidad, cada uno con tareas espec\u00edficas que aseguran la calidad y la conformidad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos que debe seguir el jefe de producci\u00f3n para garantizar que los productos se produzcan y almacenen de acuerdo con la documentaci\u00f3n adecuada?**\n   - Esta pregunta se centra en el proceso espec\u00edfico que el jefe de producci\u00f3n debe seguir, lo que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n inicial y continua se requiere para el personal de producci\u00f3n y c\u00f3mo se adapta seg\u00fan las necesidades?**\n   - Esta pregunta busca informaci\u00f3n sobre el contenido y la adaptaci\u00f3n de la formaci\u00f3n, que no se menciona en detalle en el contexto.\n\n3. **\u00bfC\u00f3mo se lleva a cabo la supervisi\u00f3n de las auditor\u00edas internas o autoinspecciones en la unidad de calidad?**\n   - Esta pregunta se enfoca en el proceso de supervisi\u00f3n de auditor\u00edas, que no se aborda en profundidad en el texto proporcionado.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS establece un marco para la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, destacando la importancia de la validaci\u00f3n de procesos, la capacitaci\u00f3n del personal y el cumplimiento de las regulaciones. Los l\u00edderes en producci\u00f3n y calidad tienen responsabilidades espec\u00edficas que aseguran que los productos cumplan con los est\u00e1ndares requeridos, desde la aprobaci\u00f3n de materiales hasta la supervisi\u00f3n de auditor\u00edas internas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prevenci\u00f3n de Acceso No Autorizado**:\n   - Se deben implementar medidas para evitar que personas no autorizadas ingresen a las \u00e1reas de producci\u00f3n, almacenamiento y control de calidad (QC).\n\n2. **Personal Clave**:\n   - Incluye a los jefes de producci\u00f3n, jefes de unidades de calidad y personas autorizadas.\n   - Las unidades de calidad abarcan funciones de aseguramiento y control de calidad, que pueden estar combinadas en un solo departamento.\n\n3. **Independencia de Funciones**:\n   - Los jefes de producci\u00f3n y de las unidades de calidad deben ser independientes entre s\u00ed, aunque en organizaciones grandes puede ser necesario delegar algunas funciones, manteniendo la responsabilidad.\n\n4. **Calificaciones Requeridas**:\n   - El personal clave debe tener educaci\u00f3n cient\u00edfica y experiencia pr\u00e1ctica, que incluya disciplinas como qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda y fisiolog\u00eda.\n\n5. **Experiencia Pr\u00e1ctica**:\n   - Se requiere experiencia adecuada en la fabricaci\u00f3n y aseguramiento de calidad de productos farmac\u00e9uticos, con un per\u00edodo preparatorio bajo supervisi\u00f3n profesional.\n\n6. **Responsabilidades Compartidas**:\n   - Los jefes de producci\u00f3n y de las unidades de calidad comparten responsabilidades relacionadas con la calidad, que pueden incluir la autorizaci\u00f3n de procedimientos, monitoreo del entorno de fabricaci\u00f3n y mantenimiento de la higiene de la planta.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Personal Clave**: Jefes de producci\u00f3n, jefes de unidades de calidad, persona autorizada.\n- **\u00c1reas Cr\u00edticas**: Producci\u00f3n, almacenamiento, control de calidad (QC).\n- **Disciplinas Cient\u00edficas**: Qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda, fisiolog\u00eda. \n\nEste resumen destaca la importancia de la educaci\u00f3n, experiencia y organizaci\u00f3n del personal clave en la industria farmac\u00e9utica, as\u00ed como las medidas de seguridad necesarias para mantener la integridad de las \u00e1reas de producci\u00f3n y control de calidad.", "excerpt_keywords": "Keywords: calidad, producci\u00f3n, validaci\u00f3n de procesos, capacitaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "901ff636-16c5-4fdf-9703-58f14701d39f", "node_type": "4", "metadata": {"page_label": "128", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) process validation and calibration of analytical apparatus;  \n(e) training, including the application and principles of QA;  \n(f) approval and monitoring of suppliers of materials;  \n(g) approval and monitoring of contract manufacturers;  \n(h) designation and monitoring of storage conditions for materials and products;  \n(i) performance and evaluation of in-process controls;  \n(j) retention of records;  \n(k) monitoring of compliance with GMP requirements; and  \n(l) inspection, investigation and taking of samples in order to monitor factors that may affect product quality.  \n\n9.9 The head of the production generally has the following responsibilities:\n\n(a) to ensure that products are produced and stored according to the appropriate documentation in order to obtain the required quality;  \n(b) to approve the instructions relating to production operations, including the in-process controls, and to ensure their strict implementation;  \n(c) to ensure that the production records are evaluated and signed by a designated person;  \n(d) to check the maintenance of the department, premises and equipment;  \n(e) to ensure that the appropriate process validations and calibrations of control equipment are performed and recorded and the reports made available;  \n(f) to ensure that the required initial and continuing training of production personnel is carried out and adapted according to need.  \n\n9.10 The head(s) of the quality unit(s) generally have the following responsibilities:\n\n(a) to approve or reject starting materials, packaging materials, and intermediate, bulk and finished products in relation with their specifications;  \n(b) to evaluate batch records;  \n(c) to ensure that all necessary testing is carried out;  \n(d) to approve sampling instructions, specifications, test methods and other QC procedures;  \n(e) to approve and monitor analyses carried out under contract;  \n(f) to check the maintenance of the department, premises and equipment;  \n(g) to ensure that the appropriate validations, including those of analytical procedures, and calibrations of control equipment are carried out;  \n(h) to ensure that the required initial and continuing training of quality unit personnel is carried out and adapted according to need.  \n(i) establishment, implementation and maintenance of the quality system;  \n(j) supervision of the regular internal audits or self-inspections;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b0b010a9fd29d081e59dbb878a083177fbed903a452e68f9564f27bd15cd9930", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(d) process validation and calibration of analytical apparatus;  \n(e) training, including the application and principles of QA;  \n(f) approval and monitoring of suppliers of materials;  \n(g) approval and monitoring of contract manufacturers;  \n(h) designation and monitoring of storage conditions for materials and products;  \n(i) performance and evaluation of in-process controls;  \n(j) retention of records;  \n(k) monitoring of compliance with GMP requirements; and  \n(l) inspection, investigation and taking of samples in order to monitor factors that may affect product quality.  \n\n9.9 The head of the production generally has the following responsibilities:\n\n(a) to ensure that products are produced and stored according to the appropriate documentation in order to obtain the required quality;  \n(b) to approve the instructions relating to production operations, including the in-process controls, and to ensure their strict implementation;  \n(c) to ensure that the production records are evaluated and signed by a designated person;  \n(d) to check the maintenance of the department, premises and equipment;  \n(e) to ensure that the appropriate process validations and calibrations of control equipment are performed and recorded and the reports made available;  \n(f) to ensure that the required initial and continuing training of production personnel is carried out and adapted according to need.  \n\n9.10 The head(s) of the quality unit(s) generally have the following responsibilities:\n\n(a) to approve or reject starting materials, packaging materials, and intermediate, bulk and finished products in relation with their specifications;  \n(b) to evaluate batch records;  \n(c) to ensure that all necessary testing is carried out;  \n(d) to approve sampling instructions, specifications, test methods and other QC procedures;  \n(e) to approve and monitor analyses carried out under contract;  \n(f) to check the maintenance of the department, premises and equipment;  \n(g) to ensure that the appropriate validations, including those of analytical procedures, and calibrations of control equipment are carried out;  \n(h) to ensure that the required initial and continuing training of quality unit personnel is carried out and adapted according to need.  \n(i) establishment, implementation and maintenance of the quality system;  \n(j) supervision of the regular internal audits or self-inspections;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2400, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3f5de2c0-ba1f-47f8-879d-398ca06db321": {"__data__": {"id_": "3f5de2c0-ba1f-47f8-879d-398ca06db321", "embedding": null, "metadata": {"page_label": "129", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(k) participation in external audit (vendor audit);  \n(l) participation in validation programmes.\n\nOther duties of QC are summarized in sections 17.3 and 17.4.\n\n9.11 The authorized person is responsible for compliance with technical or regulatory requirements related to the quality of finished products and the approval of the release of the finished product for sale or supply.\n\n9.12 Assessment of finished products should embrace all relevant factors, including the production conditions, the results of in-process testing, the manufacturing (including packaging) documentation, compliance with the specification for the finished product, and an examination of the finished pack.\n\n9.13 No batch of product is to be released for sale or supply prior to certification by the authorized person(s). In certain countries, by law, the batch release is a task of the authorized person from production together with the authorized person from QC.\n\n9.14 The authorized person responsible for approving a batch for release should always ensure that the following requirements have been met:\n\n(a) the marketing authorization and the manufacturing authorization requirements for the product have been met for the batch concerned;  \n(b) the principles and guidelines of GMP, as laid down in the guidelines published by WHO, have been followed;  \n(c) the principal manufacturing and testing processes have been validated, if different;  \n(d) all the necessary checks and tests have been performed and account taken of the production conditions and manufacturing records;  \n(e) any planned changes or deviations in manufacturing or quality control have been notified in accordance with a well-defined reporting system before any product is released. Such changes may need notification to, and approval by, the medicines regulatory authority;  \n(f) any additional sampling, inspection, tests and checks have been carried out or initiated, as appropriate, to cover planned changes and deviations;  \n(g) all necessary production and QC documentation has been completed and endorsed by supervisors trained in appropriate disciplines;  \n(h) appropriate audits, self-inspections and spot-checks are carried out by experienced and trained staff;  \n(i) approval has been given by the head of QC; and  \n(j) all relevant factors have been considered, including any not specifically associated with the output batch directly under review (e.g. subdivision of output batches from a common input, factors associated with continuous production runs).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades y requisitos relacionados con la calidad de los productos terminados en el \u00e1mbito de la fabricaci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de la certificaci\u00f3n por parte de una persona autorizada antes de que un lote de producto sea liberado para la venta o suministro. Se enumeran los criterios que deben cumplirse para la aprobaci\u00f3n de un lote, incluyendo el cumplimiento de las autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n, la validaci\u00f3n de procesos, la realizaci\u00f3n de pruebas y controles necesarios, y la consideraci\u00f3n de cualquier cambio o desviaci\u00f3n en la producci\u00f3n o control de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones legales de la liberaci\u00f3n de un lote de producto en pa\u00edses donde se requiere la certificaci\u00f3n conjunta de la persona autorizada de producci\u00f3n y la de control de calidad?**\n   - Esta pregunta aborda la responsabilidad legal y las consecuencias de no cumplir con los requisitos de liberaci\u00f3n de lotes en diferentes jurisdicciones.\n\n2. **\u00bfQu\u00e9 tipo de auditor\u00edas y autoinspecciones se consideran apropiadas seg\u00fan el contexto del documento, y qui\u00e9n debe llevarlas a cabo?**\n   - Esta pregunta se centra en los procedimientos de auditor\u00eda y autoinspecci\u00f3n, as\u00ed como en la capacitaci\u00f3n y experiencia del personal encargado de realizarlas.\n\n3. **\u00bfQu\u00e9 factores adicionales deben ser considerados por la persona autorizada al evaluar un lote, m\u00e1s all\u00e1 de los criterios espec\u00edficos mencionados en el documento?**\n   - Esta pregunta busca explorar los factores no espec\u00edficos que pueden influir en la decisi\u00f3n de liberar un lote, lo que podr\u00eda incluir aspectos de producci\u00f3n continua o subdivisiones de lotes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Responsabilidades en la Producci\u00f3n:**\n   - Validaci\u00f3n de procesos y calibraci\u00f3n de equipos anal\u00edticos.\n   - Capacitaci\u00f3n del personal en principios de gesti\u00f3n de calidad (QA).\n   - Aprobaci\u00f3n y monitoreo de proveedores y fabricantes contratados.\n   - Monitoreo de condiciones de almacenamiento y cumplimiento de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Evaluaci\u00f3n de controles en proceso y retenci\u00f3n de registros.\n\n2. **Responsabilidades en la Unidad de Calidad:**\n   - Aprobaci\u00f3n o rechazo de materiales y productos seg\u00fan especificaciones.\n   - Evaluaci\u00f3n de registros de lotes y aseguramiento de pruebas necesarias.\n   - Aprobaci\u00f3n de instrucciones de muestreo y procedimientos de control de calidad (QC).\n   - Supervisi\u00f3n de auditor\u00edas internas y mantenimiento del sistema de calidad.\n\n3. **Capacitaci\u00f3n y Formaci\u00f3n:**\n   - Importancia de la formaci\u00f3n inicial y continua del personal de producci\u00f3n y calidad, adapt\u00e1ndose a las necesidades.\n\n4. **Cumplimiento Normativo:**\n   - Monitoreo de la conformidad con los requisitos de GMP y la implementaci\u00f3n de auditor\u00edas internas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que proporciona directrices sobre gesti\u00f3n de calidad en la industria farmac\u00e9utica.\n- **Jefe de Producci\u00f3n:** Responsable de asegurar la calidad en la producci\u00f3n y almacenamiento de productos.\n- **Jefe de la Unidad de Calidad:** Encargado de la aprobaci\u00f3n de materiales y productos, as\u00ed como de la supervisi\u00f3n de la calidad.\n- **Personal de Producci\u00f3n y Calidad:** Requiere formaci\u00f3n y capacitaci\u00f3n continua para cumplir con los est\u00e1ndares de calidad.\n\nEste resumen destaca la estructura de responsabilidades y la importancia de la calidad en la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de formaci\u00f3n y cumplimiento normativo.", "excerpt_keywords": "Keywords: calidad, autorizaci\u00f3n, liberaci\u00f3n de lotes, Buenas Pr\u00e1cticas de Manufactura, auditor\u00edas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0373e499-7b6e-4575-ad0a-7ce3de8e4edb", "node_type": "4", "metadata": {"page_label": "129", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(k) participation in external audit (vendor audit);  \n(l) participation in validation programmes.\n\nOther duties of QC are summarized in sections 17.3 and 17.4.\n\n9.11 The authorized person is responsible for compliance with technical or regulatory requirements related to the quality of finished products and the approval of the release of the finished product for sale or supply.\n\n9.12 Assessment of finished products should embrace all relevant factors, including the production conditions, the results of in-process testing, the manufacturing (including packaging) documentation, compliance with the specification for the finished product, and an examination of the finished pack.\n\n9.13 No batch of product is to be released for sale or supply prior to certification by the authorized person(s). In certain countries, by law, the batch release is a task of the authorized person from production together with the authorized person from QC.\n\n9.14 The authorized person responsible for approving a batch for release should always ensure that the following requirements have been met:\n\n(a) the marketing authorization and the manufacturing authorization requirements for the product have been met for the batch concerned;  \n(b) the principles and guidelines of GMP, as laid down in the guidelines published by WHO, have been followed;  \n(c) the principal manufacturing and testing processes have been validated, if different;  \n(d) all the necessary checks and tests have been performed and account taken of the production conditions and manufacturing records;  \n(e) any planned changes or deviations in manufacturing or quality control have been notified in accordance with a well-defined reporting system before any product is released. Such changes may need notification to, and approval by, the medicines regulatory authority;  \n(f) any additional sampling, inspection, tests and checks have been carried out or initiated, as appropriate, to cover planned changes and deviations;  \n(g) all necessary production and QC documentation has been completed and endorsed by supervisors trained in appropriate disciplines;  \n(h) appropriate audits, self-inspections and spot-checks are carried out by experienced and trained staff;  \n(i) approval has been given by the head of QC; and  \n(j) all relevant factors have been considered, including any not specifically associated with the output batch directly under review (e.g. subdivision of output batches from a common input, factors associated with continuous production runs).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f7bf9c92eb6a3ebeecb7832fd1da3d02aaae59d6ab305924a4eb027b4f4004db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(k) participation in external audit (vendor audit);  \n(l) participation in validation programmes.\n\nOther duties of QC are summarized in sections 17.3 and 17.4.\n\n9.11 The authorized person is responsible for compliance with technical or regulatory requirements related to the quality of finished products and the approval of the release of the finished product for sale or supply.\n\n9.12 Assessment of finished products should embrace all relevant factors, including the production conditions, the results of in-process testing, the manufacturing (including packaging) documentation, compliance with the specification for the finished product, and an examination of the finished pack.\n\n9.13 No batch of product is to be released for sale or supply prior to certification by the authorized person(s). In certain countries, by law, the batch release is a task of the authorized person from production together with the authorized person from QC.\n\n9.14 The authorized person responsible for approving a batch for release should always ensure that the following requirements have been met:\n\n(a) the marketing authorization and the manufacturing authorization requirements for the product have been met for the batch concerned;  \n(b) the principles and guidelines of GMP, as laid down in the guidelines published by WHO, have been followed;  \n(c) the principal manufacturing and testing processes have been validated, if different;  \n(d) all the necessary checks and tests have been performed and account taken of the production conditions and manufacturing records;  \n(e) any planned changes or deviations in manufacturing or quality control have been notified in accordance with a well-defined reporting system before any product is released. Such changes may need notification to, and approval by, the medicines regulatory authority;  \n(f) any additional sampling, inspection, tests and checks have been carried out or initiated, as appropriate, to cover planned changes and deviations;  \n(g) all necessary production and QC documentation has been completed and endorsed by supervisors trained in appropriate disciplines;  \n(h) appropriate audits, self-inspections and spot-checks are carried out by experienced and trained staff;  \n(i) approval has been given by the head of QC; and  \n(j) all relevant factors have been considered, including any not specifically associated with the output batch directly under review (e.g. subdivision of output batches from a common input, factors associated with continuous production runs).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2524, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a36199ad-3c03-4429-8b5c-e57d5e634193": {"__data__": {"id_": "a36199ad-3c03-4429-8b5c-e57d5e634193", "embedding": null, "metadata": {"page_label": "130", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10. Training\n\n10.1 The manufacturer should provide training in accordance with a written programme for all personnel whose duties take them into manufacturing areas or into control laboratories (including the technical, maintenance and cleaning personnel) and for other personnel as required.\n\n10.2 Besides basic training on the theory and practice of GMP, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness periodically assessed. Approved training programmes should be available. Training records should be kept.\n\n10.3 Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitizing materials are handled, should be given specific training.\n\n10.4 The concept of QA and all the measures which aid its understanding and implementation should be fully discussed during the training sessions.\n\n10.5 Visitors or untrained personnel should preferably not be taken into the production and QC areas. If this is unavoidable, they should be given relevant information in advance (particularly about personal hygiene) and the prescribed protective clothing. They should be closely supervised.\n\n10.6 Consultant and contract staff should be qualified for the services they provide. Evidence of this should be included in the training records.\n\n# 11. Personal hygiene\n\n11.1 All personnel, prior to and during employment, as appropriate, should undergo health examinations. Personnel conducting visual inspections should also undergo periodic eye examinations.\n\n11.2 All personnel should be trained in the practices of personal hygiene. A high level of personal hygiene should be observed by all those concerned with manufacturing processes. In particular, personnel should be instructed to wash their hands before entering production areas. Signs to this effect should be posted and instructions observed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos cruciales de la formaci\u00f3n y la higiene personal en el \u00e1mbito de la fabricaci\u00f3n y el control de calidad (QC) de productos. Se enfatiza la importancia de proporcionar capacitaci\u00f3n adecuada a todo el personal involucrado en estas \u00e1reas, as\u00ed como la necesidad de mantener altos est\u00e1ndares de higiene personal. Se detallan las responsabilidades del fabricante en cuanto a la formaci\u00f3n, la supervisi\u00f3n de visitantes y la calificaci\u00f3n del personal contratado. Adem\u00e1s, se menciona la importancia de realizar ex\u00e1menes de salud y de instruir al personal sobre pr\u00e1cticas de higiene.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n espec\u00edfica se debe proporcionar al personal que trabaja en \u00e1reas donde hay un riesgo de contaminaci\u00f3n?**\n   - El personal que trabaja en \u00e1reas donde la contaminaci\u00f3n es un riesgo, como \u00e1reas limpias o donde se manejan materiales altamente activos, t\u00f3xicos, infecciosos o sensibilizantes, debe recibir una formaci\u00f3n espec\u00edfica relacionada con esos riesgos.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que los visitantes o el personal no capacitado no interfieran en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Se recomienda que los visitantes o el personal no capacitado no sean llevados a las \u00e1reas de producci\u00f3n y QC. Si esto es inevitable, deben recibir informaci\u00f3n relevante sobre higiene personal y usar la vestimenta protectora prescrita, adem\u00e1s de ser supervisados de cerca.\n\n3. **\u00bfQu\u00e9 registros deben mantenerse en relaci\u00f3n con la formaci\u00f3n del personal y por qu\u00e9 son importantes?**\n   - Se deben mantener registros de formaci\u00f3n que incluyan evidencia de la calificaci\u00f3n del personal, especialmente para consultores y personal contratado. Estos registros son importantes para demostrar que el personal est\u00e1 adecuadamente capacitado para realizar los servicios que proporcionan, lo que contribuye a la calidad y seguridad en los procesos de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad de la Persona Autorizada**: La persona autorizada es responsable de garantizar el cumplimiento de los requisitos t\u00e9cnicos y regulatorios relacionados con la calidad de los productos terminados y de aprobar la liberaci\u00f3n de estos para la venta o suministro.\n\n2. **Evaluaci\u00f3n de Productos Terminados**: La evaluaci\u00f3n debe considerar factores relevantes como las condiciones de producci\u00f3n, resultados de pruebas en proceso, documentaci\u00f3n de fabricaci\u00f3n y cumplimiento de especificaciones.\n\n3. **Certificaci\u00f3n de Lotes**: Ning\u00fan lote puede ser liberado para venta o suministro sin la certificaci\u00f3n de la persona autorizada. En algunos pa\u00edses, esto requiere la certificaci\u00f3n conjunta de la persona autorizada de producci\u00f3n y la de control de calidad.\n\n4. **Requisitos para la Liberaci\u00f3n de Lotes**: Se enumeran varios requisitos que deben cumplirse antes de la liberaci\u00f3n de un lote, incluyendo autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n, cumplimiento de Buenas Pr\u00e1cticas de Manufactura (GMP), validaci\u00f3n de procesos, y realizaci\u00f3n de controles y pruebas necesarias.\n\n5. **Auditor\u00edas y Autoinspecciones**: Se requiere que se realicen auditor\u00edas, autoinspecciones y controles por parte de personal experimentado y capacitado.\n\n6. **Consideraci\u00f3n de Factores Adicionales**: La persona autorizada debe considerar factores adicionales que puedan influir en la decisi\u00f3n de liberar un lote, m\u00e1s all\u00e1 de los criterios espec\u00edficos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que publica las directrices y normas relacionadas con la calidad en la fabricaci\u00f3n farmac\u00e9utica.\n- **Persona Autorizada**: Profesional responsable de la certificaci\u00f3n y liberaci\u00f3n de productos terminados.\n- **Reguladores de Medicamentos**: Autoridades que pueden requerir notificaci\u00f3n y aprobaci\u00f3n de cambios en la producci\u00f3n o control de calidad.\n- **Documentaci\u00f3n de Producci\u00f3n y Control de Calidad (QC)**: Registros necesarios para la evaluaci\u00f3n y liberaci\u00f3n de lotes.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Principios y directrices que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: training, personal hygiene, GMP, contamination, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e20a861-0f16-4c1b-a5bd-9c1f9cef05a7", "node_type": "4", "metadata": {"page_label": "130", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10. Training\n\n10.1 The manufacturer should provide training in accordance with a written programme for all personnel whose duties take them into manufacturing areas or into control laboratories (including the technical, maintenance and cleaning personnel) and for other personnel as required.\n\n10.2 Besides basic training on the theory and practice of GMP, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness periodically assessed. Approved training programmes should be available. Training records should be kept.\n\n10.3 Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitizing materials are handled, should be given specific training.\n\n10.4 The concept of QA and all the measures which aid its understanding and implementation should be fully discussed during the training sessions.\n\n10.5 Visitors or untrained personnel should preferably not be taken into the production and QC areas. If this is unavoidable, they should be given relevant information in advance (particularly about personal hygiene) and the prescribed protective clothing. They should be closely supervised.\n\n10.6 Consultant and contract staff should be qualified for the services they provide. Evidence of this should be included in the training records.\n\n# 11. Personal hygiene\n\n11.1 All personnel, prior to and during employment, as appropriate, should undergo health examinations. Personnel conducting visual inspections should also undergo periodic eye examinations.\n\n11.2 All personnel should be trained in the practices of personal hygiene. A high level of personal hygiene should be observed by all those concerned with manufacturing processes. In particular, personnel should be instructed to wash their hands before entering production areas. Signs to this effect should be posted and instructions observed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "39355489b27de7503ed376e713f902765a0775fe185508ac6744b12e317a9dcb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 10. Training\n\n10.1 The manufacturer should provide training in accordance with a written programme for all personnel whose duties take them into manufacturing areas or into control laboratories (including the technical, maintenance and cleaning personnel) and for other personnel as required.\n\n10.2 Besides basic training on the theory and practice of GMP, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness periodically assessed. Approved training programmes should be available. Training records should be kept.\n\n10.3 Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitizing materials are handled, should be given specific training.\n\n10.4 The concept of QA and all the measures which aid its understanding and implementation should be fully discussed during the training sessions.\n\n10.5 Visitors or untrained personnel should preferably not be taken into the production and QC areas. If this is unavoidable, they should be given relevant information in advance (particularly about personal hygiene) and the prescribed protective clothing. They should be closely supervised.\n\n10.6 Consultant and contract staff should be qualified for the services they provide. Evidence of this should be included in the training records.\n\n# 11. Personal hygiene\n\n11.1 All personnel, prior to and during employment, as appropriate, should undergo health examinations. Personnel conducting visual inspections should also undergo periodic eye examinations.\n\n11.2 All personnel should be trained in the practices of personal hygiene. A high level of personal hygiene should be observed by all those concerned with manufacturing processes. In particular, personnel should be instructed to wash their hands before entering production areas. Signs to this effect should be posted and instructions observed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1987, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ebb719-8515-48a2-808f-4f63d1040161": {"__data__": {"id_": "b9ebb719-8515-48a2-808f-4f63d1040161", "embedding": null, "metadata": {"page_label": "131", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3\nAny person shown at any time to have an apparent illness or open lesions that may adversely affect the quality of products should not be allowed to handle starting materials, packaging materials, in-process materials or medicines products until the condition is no longer judged to be a risk.\n\n11.4 All employees should be instructed and encouraged to report to their immediate supervisor any conditions (relating to plant, equipment or personnel) that they consider may adversely affect the products.\n\n11.5 Direct contact should be avoided between the operator\u2019s hands and starting materials, primary packaging materials and intermediate or bulk product.\n\n11.6 To ensure protection of the product from contamination, personnel should wear clean body coverings appropriate to the duties they perform, including appropriate hair covering. Used clothes, if reusable, should be stored in separate closed containers until properly laundered and, if necessary, disinfected or sterilized.\n\n11.7 Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and personal medicines should not be permitted in production, laboratory and storage areas, or in any other areas where they might adversely influence product quality.\n\n11.8 Personal hygiene procedures including the use of protective clothing should apply to all persons entering production areas, whether they are temporary or full-time employees or nonemployees, e.g. contractors\u2019 employees, visitors, senior managers and inspectors.\n\n# 12. Premises\n\n12.1 **Principle.** Premises must be located, designed, constructed, adapted and maintained to suit the operations to be carried out.\n\n## General\n\n12.2 The layout and design of premises must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and in general, any adverse effect on the quality of products.\n\n12.3 Where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of powder), measures should be taken to avoid cross-contamination and facilitate cleaning.\n\n12.4 Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimum risk of causing any contamination of materials or products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la higiene y el dise\u00f1o de las instalaciones en la producci\u00f3n de medicamentos. Se enfatiza la importancia de la salud del personal, la limpieza de las instalaciones y la prevenci\u00f3n de la contaminaci\u00f3n para asegurar la calidad de los productos. Se proh\u00edben actividades que puedan comprometer la higiene en \u00e1reas de producci\u00f3n y se requiere que todos los individuos que ingresen a estas \u00e1reas sigan procedimientos de higiene estrictos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si un empleado presenta una enfermedad aparente o lesiones abiertas?**\n   - Cualquier persona que presente una enfermedad aparente o lesiones abiertas que puedan afectar la calidad de los productos no debe manejar materiales hasta que su condici\u00f3n ya no se considere un riesgo.\n\n2. **\u00bfQu\u00e9 tipo de ropa y medidas de higiene se requieren para el personal en \u00e1reas de producci\u00f3n?**\n   - El personal debe usar ropa limpia adecuada a sus funciones, incluyendo cubiertas para el cabello. La ropa usada, si es reutilizable, debe almacenarse en contenedores cerrados hasta su lavado y, si es necesario, desinfecci\u00f3n o esterilizaci\u00f3n.\n\n3. **\u00bfC\u00f3mo debe estar dise\u00f1ada la disposici\u00f3n de las instalaciones para minimizar riesgos en la producci\u00f3n?**\n   - La disposici\u00f3n y dise\u00f1o de las instalaciones deben minimizar el riesgo de errores y permitir una limpieza y mantenimiento efectivos para evitar la contaminaci\u00f3n cruzada y la acumulaci\u00f3n de polvo o suciedad, asegurando as\u00ed la calidad de los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Formaci\u00f3n del Personal**:\n   - Importancia de proporcionar capacitaci\u00f3n adecuada a todo el personal que trabaja en \u00e1reas de fabricaci\u00f3n y laboratorios de control.\n   - Necesidad de formaci\u00f3n espec\u00edfica para personal en \u00e1reas de riesgo de contaminaci\u00f3n.\n   - Requisitos de formaci\u00f3n continua y evaluaci\u00f3n de su efectividad.\n   - Mantenimiento de registros de formaci\u00f3n.\n\n2. **Higiene Personal**:\n   - Ex\u00e1menes de salud para todo el personal antes y durante el empleo.\n   - Capacitaci\u00f3n en pr\u00e1cticas de higiene personal.\n   - Instrucciones espec\u00edficas sobre el lavado de manos antes de ingresar a \u00e1reas de producci\u00f3n.\n\n3. **Supervisi\u00f3n de Visitantes**:\n   - Restricciones sobre la entrada de visitantes o personal no capacitado en \u00e1reas de producci\u00f3n y control de calidad.\n   - Provisi\u00f3n de informaci\u00f3n relevante y equipo de protecci\u00f3n para visitantes, junto con supervisi\u00f3n cercana.\n\n4. **Calificaci\u00f3n del Personal Contratado**:\n   - Requisitos de calificaci\u00f3n para consultores y personal contratado, con evidencia documentada en los registros de formaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Personal**: Incluye t\u00e9cnicos, mantenimiento, limpieza y otros involucrados en la fabricaci\u00f3n y control de calidad.\n- **\u00c1reas de Riesgo**: Espacios donde se manejan materiales peligrosos o donde la contaminaci\u00f3n es un riesgo.\n- **Registros de Formaci\u00f3n**: Documentaci\u00f3n que evidencia la capacitaci\u00f3n recibida por el personal.\n- **Pr\u00e1cticas de Higiene**: Normas y procedimientos que deben seguirse para mantener altos est\u00e1ndares de higiene personal.", "excerpt_keywords": "Keywords: hygiene, contamination, production, premises, personal protective equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0c47e034-ffd0-4a59-bf70-381392ec61d6", "node_type": "4", "metadata": {"page_label": "131", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3\nAny person shown at any time to have an apparent illness or open lesions that may adversely affect the quality of products should not be allowed to handle starting materials, packaging materials, in-process materials or medicines products until the condition is no longer judged to be a risk.\n\n11.4 All employees should be instructed and encouraged to report to their immediate supervisor any conditions (relating to plant, equipment or personnel) that they consider may adversely affect the products.\n\n11.5 Direct contact should be avoided between the operator\u2019s hands and starting materials, primary packaging materials and intermediate or bulk product.\n\n11.6 To ensure protection of the product from contamination, personnel should wear clean body coverings appropriate to the duties they perform, including appropriate hair covering. Used clothes, if reusable, should be stored in separate closed containers until properly laundered and, if necessary, disinfected or sterilized.\n\n11.7 Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and personal medicines should not be permitted in production, laboratory and storage areas, or in any other areas where they might adversely influence product quality.\n\n11.8 Personal hygiene procedures including the use of protective clothing should apply to all persons entering production areas, whether they are temporary or full-time employees or nonemployees, e.g. contractors\u2019 employees, visitors, senior managers and inspectors.\n\n# 12. Premises\n\n12.1 **Principle.** Premises must be located, designed, constructed, adapted and maintained to suit the operations to be carried out.\n\n## General\n\n12.2 The layout and design of premises must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and in general, any adverse effect on the quality of products.\n\n12.3 Where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of powder), measures should be taken to avoid cross-contamination and facilitate cleaning.\n\n12.4 Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimum risk of causing any contamination of materials or products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3576e3051b07360b9eb20bf6570c9b88e6b4b49a232f161e8fd560ccceceea68", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.3\nAny person shown at any time to have an apparent illness or open lesions that may adversely affect the quality of products should not be allowed to handle starting materials, packaging materials, in-process materials or medicines products until the condition is no longer judged to be a risk.\n\n11.4 All employees should be instructed and encouraged to report to their immediate supervisor any conditions (relating to plant, equipment or personnel) that they consider may adversely affect the products.\n\n11.5 Direct contact should be avoided between the operator\u2019s hands and starting materials, primary packaging materials and intermediate or bulk product.\n\n11.6 To ensure protection of the product from contamination, personnel should wear clean body coverings appropriate to the duties they perform, including appropriate hair covering. Used clothes, if reusable, should be stored in separate closed containers until properly laundered and, if necessary, disinfected or sterilized.\n\n11.7 Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and personal medicines should not be permitted in production, laboratory and storage areas, or in any other areas where they might adversely influence product quality.\n\n11.8 Personal hygiene procedures including the use of protective clothing should apply to all persons entering production areas, whether they are temporary or full-time employees or nonemployees, e.g. contractors\u2019 employees, visitors, senior managers and inspectors.\n\n# 12. Premises\n\n12.1 **Principle.** Premises must be located, designed, constructed, adapted and maintained to suit the operations to be carried out.\n\n## General\n\n12.2 The layout and design of premises must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and in general, any adverse effect on the quality of products.\n\n12.3 Where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of powder), measures should be taken to avoid cross-contamination and facilitate cleaning.\n\n12.4 Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimum risk of causing any contamination of materials or products.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2344, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ababaf3e-21ef-41b3-bc8d-1d130753de1a": {"__data__": {"id_": "ababaf3e-21ef-41b3-bc8d-1d130753de1a", "embedding": null, "metadata": {"page_label": "132", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.5 \nPremises used for the manufacture of finished products should be suitably designed and constructed to facilitate good sanitation.\n\n12.6 \nPremises should be carefully maintained, and it should be ensured that repair and maintenance operations do not present any hazard to the quality of products.\n\n12.7 \nPremises should be cleaned and, where applicable, disinfected according to detailed written procedures. Records should be maintained.\n\n12.8 \nElectrical supply, lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\n12.9 \nPremises should be designed and equipped so as to afford maximum protection against the entry of insects, birds or other animals. There should be a procedure for rodent and pest control.\n\n12.10 \nPremises should be designed to ensure the logical flow of materials and personnel.\n\n## Ancillary areas\n\n12.11 \nRest and refreshment rooms should be separate from manufacturing and control areas.\n\n12.12 \nFacilities for changing and storing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas.\n\n12.13 \nMaintenance workshops should if possible be separated from production areas. Whenever parts and tools are stored in the production area, they should be kept in rooms or lockers reserved for that use.\n\n12.14 \nAnimal houses should be well isolated from other areas, with separate entrance (animal access) and air-handling facilities.\n\n## Storage areas\n\n12.15 \nStorage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products with proper separation and segregation: starting and packaging materials, intermediates, bulk and finished products, products in quarantine, and released, rejected, returned or recalled products.\n\n12.16 \nStorage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean, dry, sufficiently lit and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre el dise\u00f1o y mantenimiento de las instalaciones utilizadas para la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la sanidad, el mantenimiento adecuado, la limpieza, el control de plagas, y la separaci\u00f3n de \u00e1reas espec\u00edficas para garantizar la calidad y seguridad de los productos. Tambi\u00e9n se abordan las condiciones de almacenamiento y la organizaci\u00f3n de las \u00e1reas auxiliares, como los vestuarios y los talleres de mantenimiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para garantizar la limpieza y desinfecci\u00f3n de las instalaciones de fabricaci\u00f3n?**\n   - El contexto menciona que las instalaciones deben ser limpiadas y desinfectadas de acuerdo con procedimientos escritos detallados, y que se deben mantener registros de estas actividades.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar \u00e1reas de almacenamiento para productos farmac\u00e9uticos?**\n   - Las \u00e1reas de almacenamiento deben tener suficiente capacidad para permitir un almacenamiento ordenado de diferentes categor\u00edas de materiales y productos, asegurando la separaci\u00f3n y segregaci\u00f3n adecuadas.\n\n3. **\u00bfQu\u00e9 tipo de instalaciones auxiliares se requieren para el personal que trabaja en las \u00e1reas de producci\u00f3n?**\n   - Se requiere que las instalaciones para cambiar y almacenar ropa, as\u00ed como las de lavado y aseo, sean f\u00e1cilmente accesibles y adecuadas para el n\u00famero de usuarios, y que los ba\u00f1os no se comuniquen directamente con las \u00e1reas de producci\u00f3n o almacenamiento.", "prev_section_summary": "### Temas Clave\n\n1. **Salud del Personal**: Se establece que cualquier persona con enfermedades aparentes o lesiones abiertas no debe manejar materiales hasta que su condici\u00f3n no represente un riesgo para la calidad del producto.\n\n2. **Reportes de Condiciones Adversas**: Se alienta a los empleados a informar sobre cualquier condici\u00f3n que pueda afectar negativamente la calidad de los productos.\n\n3. **Prevenci\u00f3n de Contaminaci\u00f3n**: Se deben evitar el contacto directo entre las manos del operador y los materiales, y se requiere el uso de ropa limpia y adecuada, as\u00ed como cubiertas para el cabello.\n\n4. **Prohibiciones en \u00c1reas de Producci\u00f3n**: Se proh\u00edben actividades como fumar, comer o beber en \u00e1reas de producci\u00f3n y almacenamiento para mantener la calidad del producto.\n\n5. **Higiene Personal**: Todos los individuos que ingresen a las \u00e1reas de producci\u00f3n deben seguir estrictos procedimientos de higiene.\n\n6. **Dise\u00f1o y Mantenimiento de Instalaciones**: Las instalaciones deben estar dise\u00f1adas y mantenidas para minimizar errores y evitar la contaminaci\u00f3n cruzada, as\u00ed como facilitar la limpieza.\n\n7. **Control de Polvo**: Se deben implementar medidas para evitar la generaci\u00f3n de polvo y facilitar la limpieza en \u00e1reas donde se manipulan materiales en polvo.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Empleados**: Personal que debe seguir las normas de higiene y reportar condiciones adversas.\n- **Materiales**: Incluyen materiales de inicio, empaques y productos en proceso.\n- **Instalaciones**: Deben estar dise\u00f1adas y mantenidas adecuadamente para la producci\u00f3n de medicamentos.\n- **Contaminaci\u00f3n**: Riesgo que se busca minimizar a trav\u00e9s de pr\u00e1cticas de higiene y dise\u00f1o de instalaciones.\n\nEste resumen destaca la importancia de la salud del personal y el dise\u00f1o adecuado de las instalaciones para asegurar la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: sanitation, pharmaceutical manufacturing, storage conditions, pest control, facility design"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3fd74cf-835f-47c4-816f-b55a5fa1ccd8", "node_type": "4", "metadata": {"page_label": "132", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.5 \nPremises used for the manufacture of finished products should be suitably designed and constructed to facilitate good sanitation.\n\n12.6 \nPremises should be carefully maintained, and it should be ensured that repair and maintenance operations do not present any hazard to the quality of products.\n\n12.7 \nPremises should be cleaned and, where applicable, disinfected according to detailed written procedures. Records should be maintained.\n\n12.8 \nElectrical supply, lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\n12.9 \nPremises should be designed and equipped so as to afford maximum protection against the entry of insects, birds or other animals. There should be a procedure for rodent and pest control.\n\n12.10 \nPremises should be designed to ensure the logical flow of materials and personnel.\n\n## Ancillary areas\n\n12.11 \nRest and refreshment rooms should be separate from manufacturing and control areas.\n\n12.12 \nFacilities for changing and storing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas.\n\n12.13 \nMaintenance workshops should if possible be separated from production areas. Whenever parts and tools are stored in the production area, they should be kept in rooms or lockers reserved for that use.\n\n12.14 \nAnimal houses should be well isolated from other areas, with separate entrance (animal access) and air-handling facilities.\n\n## Storage areas\n\n12.15 \nStorage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products with proper separation and segregation: starting and packaging materials, intermediates, bulk and finished products, products in quarantine, and released, rejected, returned or recalled products.\n\n12.16 \nStorage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean, dry, sufficiently lit and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "30731b8b7be04a87c8c5c4a9caa1e09ccfa89030346329f6f1c81ca98a02c265", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12.5 \nPremises used for the manufacture of finished products should be suitably designed and constructed to facilitate good sanitation.\n\n12.6 \nPremises should be carefully maintained, and it should be ensured that repair and maintenance operations do not present any hazard to the quality of products.\n\n12.7 \nPremises should be cleaned and, where applicable, disinfected according to detailed written procedures. Records should be maintained.\n\n12.8 \nElectrical supply, lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\n12.9 \nPremises should be designed and equipped so as to afford maximum protection against the entry of insects, birds or other animals. There should be a procedure for rodent and pest control.\n\n12.10 \nPremises should be designed to ensure the logical flow of materials and personnel.\n\n## Ancillary areas\n\n12.11 \nRest and refreshment rooms should be separate from manufacturing and control areas.\n\n12.12 \nFacilities for changing and storing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas.\n\n12.13 \nMaintenance workshops should if possible be separated from production areas. Whenever parts and tools are stored in the production area, they should be kept in rooms or lockers reserved for that use.\n\n12.14 \nAnimal houses should be well isolated from other areas, with separate entrance (animal access) and air-handling facilities.\n\n## Storage areas\n\n12.15 \nStorage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products with proper separation and segregation: starting and packaging materials, intermediates, bulk and finished products, products in quarantine, and released, rejected, returned or recalled products.\n\n12.16 \nStorage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean, dry, sufficiently lit and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2187, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3c7a9c42-5b07-46e1-9554-7645f1e1ff00": {"__data__": {"id_": "3c7a9c42-5b07-46e1-9554-7645f1e1ff00", "embedding": null, "metadata": {"page_label": "133", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling Guidelines\n\nMaintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, controlled, monitored and recorded where appropriate.\n\n## Receiving and Dispatch\n\n12.17 Receiving and dispatch bays should be separated and protect materials and products from the weather. Receiving areas should be designed and equipped to allow containers of incoming materials to be cleaned if necessary before storage.\n\n12.18 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authorized personnel. Any system replacing the physical quarantine should give equivalent security.\n\n12.19 Segregation should be provided for the storage of rejected, recalled, or returned materials or products.\n\n12.20 Highly active and radioactive materials, narcotics, other dangerous medicines, and substances presenting special risks of abuse, fire or explosion should be stored in safe and secure areas.\n\n12.21 Printed packaging materials are considered critical to the conformity of the pharmaceutical product to its labelling and special attention should be paid to sampling and the safe and secure storage of these materials.\n\n12.22 There should normally be a separate sampling area for starting materials. (If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination.)\n\n## Weighing Areas\n\n12.23 The weighing of starting materials and the estimation of yield by weighing should be carried out in separate weighing areas designed for that use, for example, with provisions for dust control. Such areas may be part of either storage or production areas.\n\n## Production Areas\n\n12.24 In order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular pharmaceutical products, such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. live microorganisms). The production of certain other highly active products, such as some antibiotics, hormones, cytotoxic substances and certain non-pharmaceutical products, should not be conducted in the same facilities. In exceptional cases, the principle of campaign working in the same facilities can be accepted provided that specific precautions are taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre el almacenamiento y manejo de materiales farmac\u00e9uticos, enfatizando la importancia de mantener condiciones adecuadas de temperatura y humedad. Se detallan procedimientos para la recepci\u00f3n y despacho de materiales, la segregaci\u00f3n de productos rechazados o en cuarentena, y el almacenamiento seguro de sustancias peligrosas. Tambi\u00e9n se abordan \u00e1reas espec\u00edficas para el pesaje de materiales y la producci\u00f3n de productos farmac\u00e9uticos, destacando la necesidad de instalaciones dedicadas para evitar la contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para garantizar la seguridad en el almacenamiento de materiales altamente activos y peligrosos?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de seguridad que no se mencionan expl\u00edcitamente en otras fuentes, como el tipo de controles de acceso o las caracter\u00edsticas de las \u00e1reas de almacenamiento.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al dise\u00f1ar un \u00e1rea de muestreo para materiales de inicio, y c\u00f3mo se debe prevenir la contaminaci\u00f3n durante el muestreo?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos y operativos del muestreo, que pueden no estar ampliamente cubiertos en otras directrices.\n\n3. **\u00bfQu\u00e9 precauciones espec\u00edficas se deben tomar al realizar trabajos de campa\u00f1a en instalaciones que producen productos farmac\u00e9uticos altamente activos?**\n   - Esta pregunta busca informaci\u00f3n sobre las medidas de seguridad y protocolos que deben implementarse en situaciones excepcionales, lo cual puede no estar claramente definido en otras normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Las instalaciones para la fabricaci\u00f3n de productos farmac\u00e9uticos deben estar dise\u00f1adas y construidas para facilitar una buena sanidad.\n\n2. **Mantenimiento y Limpieza**:\n   - Es esencial que las instalaciones se mantengan adecuadamente y que las operaciones de reparaci\u00f3n no comprometan la calidad de los productos.\n   - Se deben seguir procedimientos escritos detallados para la limpieza y desinfecci\u00f3n, manteniendo registros de estas actividades.\n\n3. **Condiciones Ambientales**:\n   - La electricidad, iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n deben ser adecuadas para no afectar negativamente los productos farmac\u00e9uticos ni el funcionamiento del equipo.\n\n4. **Control de Plagas**:\n   - Las instalaciones deben protegerse contra la entrada de insectos, aves y otros animales, implementando procedimientos de control de roedores y plagas.\n\n5. **Flujo L\u00f3gico de Materiales y Personal**:\n   - El dise\u00f1o de las instalaciones debe asegurar un flujo l\u00f3gico de materiales y personal.\n\n6. **\u00c1reas Auxiliares**:\n   - Las salas de descanso y refrigerio deben estar separadas de las \u00e1reas de fabricaci\u00f3n y control.\n   - Las instalaciones para cambiar y almacenar ropa, as\u00ed como para el lavado y aseo, deben ser accesibles y adecuadas para el n\u00famero de usuarios, evitando la comunicaci\u00f3n directa de los ba\u00f1os con las \u00e1reas de producci\u00f3n.\n\n7. **Talleres de Mantenimiento**:\n   - Los talleres de mantenimiento deben estar separados de las \u00e1reas de producci\u00f3n siempre que sea posible.\n\n8. **Almacenamiento**:\n   - Las \u00e1reas de almacenamiento deben tener suficiente capacidad para un almacenamiento ordenado y adecuado de diferentes categor\u00edas de materiales y productos, asegurando la separaci\u00f3n y segregaci\u00f3n necesarias.\n   - Deben garantizarse buenas condiciones de almacenamiento, siendo limpias, secas y bien iluminadas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **Productos Farmac\u00e9uticos**: Objetivo principal de las instalaciones descritas.\n- **Instalaciones de Fabricaci\u00f3n**: Espacios donde se producen los productos farmac\u00e9uticos.\n- **\u00c1reas Auxiliares**: Espacios como vestuarios y talleres que apoyan la producci\u00f3n.\n- **Condiciones de Almacenamiento**: Requisitos para el almacenamiento seguro de productos.", "excerpt_keywords": "Keywords: storage guidelines, pharmaceutical safety, contamination prevention, handling procedures, production facilities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9fc19df6-6a3d-4de8-9b9f-eae38f213ab5", "node_type": "4", "metadata": {"page_label": "133", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling Guidelines\n\nMaintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, controlled, monitored and recorded where appropriate.\n\n## Receiving and Dispatch\n\n12.17 Receiving and dispatch bays should be separated and protect materials and products from the weather. Receiving areas should be designed and equipped to allow containers of incoming materials to be cleaned if necessary before storage.\n\n12.18 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authorized personnel. Any system replacing the physical quarantine should give equivalent security.\n\n12.19 Segregation should be provided for the storage of rejected, recalled, or returned materials or products.\n\n12.20 Highly active and radioactive materials, narcotics, other dangerous medicines, and substances presenting special risks of abuse, fire or explosion should be stored in safe and secure areas.\n\n12.21 Printed packaging materials are considered critical to the conformity of the pharmaceutical product to its labelling and special attention should be paid to sampling and the safe and secure storage of these materials.\n\n12.22 There should normally be a separate sampling area for starting materials. (If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination.)\n\n## Weighing Areas\n\n12.23 The weighing of starting materials and the estimation of yield by weighing should be carried out in separate weighing areas designed for that use, for example, with provisions for dust control. Such areas may be part of either storage or production areas.\n\n## Production Areas\n\n12.24 In order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular pharmaceutical products, such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. live microorganisms). The production of certain other highly active products, such as some antibiotics, hormones, cytotoxic substances and certain non-pharmaceutical products, should not be conducted in the same facilities. In exceptional cases, the principle of campaign working in the same facilities can be accepted provided that specific precautions are taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3dcef8047f88d123cde88c3aec18006c0bd2d5e9387de82a0af7c53c61a5e6b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Storage and Handling Guidelines\n\nMaintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, controlled, monitored and recorded where appropriate.\n\n## Receiving and Dispatch\n\n12.17 Receiving and dispatch bays should be separated and protect materials and products from the weather. Receiving areas should be designed and equipped to allow containers of incoming materials to be cleaned if necessary before storage.\n\n12.18 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authorized personnel. Any system replacing the physical quarantine should give equivalent security.\n\n12.19 Segregation should be provided for the storage of rejected, recalled, or returned materials or products.\n\n12.20 Highly active and radioactive materials, narcotics, other dangerous medicines, and substances presenting special risks of abuse, fire or explosion should be stored in safe and secure areas.\n\n12.21 Printed packaging materials are considered critical to the conformity of the pharmaceutical product to its labelling and special attention should be paid to sampling and the safe and secure storage of these materials.\n\n12.22 There should normally be a separate sampling area for starting materials. (If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination.)\n\n## Weighing Areas\n\n12.23 The weighing of starting materials and the estimation of yield by weighing should be carried out in separate weighing areas designed for that use, for example, with provisions for dust control. Such areas may be part of either storage or production areas.\n\n## Production Areas\n\n12.24 In order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular pharmaceutical products, such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. live microorganisms). The production of certain other highly active products, such as some antibiotics, hormones, cytotoxic substances and certain non-pharmaceutical products, should not be conducted in the same facilities. In exceptional cases, the principle of campaign working in the same facilities can be accepted provided that specific precautions are taken.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2462, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "60c21ef0-940d-4830-8ea2-f055c159f5f8": {"__data__": {"id_": "60c21ef0-940d-4830-8ea2-f055c159f5f8", "embedding": null, "metadata": {"page_label": "134", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and the necessary validations (including cleaning validation) are made. The manufacture of technical poisons, such as pesticides and herbicides, should not be allowed in premises used for the manufacture of pharmaceutical products.\n\n12.25 Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresponding to the sequence of the operations and to the requisite cleanliness levels.\n\n12.26 The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as to minimize the risk of confusion between different pharmaceutical products or their components, to avoid cross-contamination, and to minimize the risk of omission or wrong application of any of the manufacturing or control steps.\n\n12.27 Where starting and primary packaging materials and intermediate or bulk products are exposed to the environment, interior surfaces (walls, floors and ceilings) should be smooth and free from cracks and open joints, should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.\n\n12.28 Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses that are difficult to clean. As far as possible, for maintenance purposes, they should be accessible from outside the manufacturing areas.\n\n12.29 Drains should be of adequate size and designed and equipped to prevent back-flow. Open channels should be avoided where possible, but if they are necessary they should be shallow to facilitate cleaning and disinfection.\n\n12.30 Production areas should be effectively ventilated, with air-control facilities (including filtration of air to a sufficient level to prevent contamination and cross-contamination, as well as control of temperature and, where necessary, humidity) appropriate to the products handled, to the operations undertaken and to the external environment. These areas should be regularly monitored during both production and non-production periods to ensure compliance with their design specifications.\n\n12.31 Premises for the packaging of pharmaceutical products should be specifically designed and laid out so as to avoid mix-ups, contamination or cross-contamination.\n\n12.32 Production areas should be well lit, particularly where visual online controls are carried out.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto extra\u00eddo del documento de la OMS (Informe T\u00e9cnico 961) aborda las directrices para el dise\u00f1o y la disposici\u00f3n de las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de las \u00e1reas de producci\u00f3n, la prevenci\u00f3n de la contaminaci\u00f3n cruzada, y la adecuada ventilaci\u00f3n y mantenimiento de las instalaciones. Tambi\u00e9n se menciona la necesidad de que los materiales y productos est\u00e9n protegidos del ambiente y que las \u00e1reas de producci\u00f3n est\u00e9n bien iluminadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las superficies interiores de las instalaciones donde se manejan materiales farmac\u00e9uticos expuestos al ambiente?**\n   - Respuesta: Las superficies interiores (paredes, pisos y techos) deben ser lisas, estar libres de grietas y juntas abiertas, no desprender part\u00edculas, y permitir una limpieza y desinfecci\u00f3n efectivas.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar el sistema de drenaje en las \u00e1reas de producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los desag\u00fces deben ser de tama\u00f1o adecuado y dise\u00f1ados para prevenir el retroceso de agua. Se deben evitar canales abiertos siempre que sea posible, y si son necesarios, deben ser poco profundos para facilitar la limpieza y desinfecci\u00f3n.\n\n3. **\u00bfC\u00f3mo se debe garantizar la ventilaci\u00f3n adecuada en las \u00e1reas de producci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las \u00e1reas de producci\u00f3n deben estar efectivamente ventiladas, con instalaciones de control de aire que incluyan filtraci\u00f3n para prevenir la contaminaci\u00f3n y control de temperatura y humedad, seg\u00fan sea necesario. Estas \u00e1reas deben ser monitoreadas regularmente para asegurar el cumplimiento de las especificaciones de dise\u00f1o.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre el dise\u00f1o y la operaci\u00f3n de instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de los espacios, la prevenci\u00f3n de la contaminaci\u00f3n y la ventilaci\u00f3n adecuada. Estas medidas son esenciales para asegurar la calidad y seguridad de los productos farmac\u00e9uticos fabricados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Almacenamiento y Manejo:**\n   - Importancia de mantener condiciones adecuadas de temperatura y humedad.\n   - Necesidad de controlar, monitorear y registrar condiciones especiales de almacenamiento.\n\n2. **Recepci\u00f3n y Despacho:**\n   - Separaci\u00f3n de \u00e1reas de recepci\u00f3n y despacho para proteger materiales de las inclemencias del tiempo.\n   - Limpieza de contenedores de materiales entrantes antes del almacenamiento.\n   - \u00c1reas de cuarentena claramente marcadas y restringidas a personal autorizado.\n\n3. **Segregaci\u00f3n de Materiales:**\n   - Almacenamiento separado para materiales rechazados, retirados o devueltos.\n   - Almacenamiento seguro de materiales altamente activos, radiactivos, narc\u00f3ticos y sustancias peligrosas.\n\n4. **Muestreo:**\n   - Importancia de un \u00e1rea de muestreo separada para materiales de inicio.\n   - Prevenci\u00f3n de contaminaci\u00f3n durante el muestreo.\n\n5. **\u00c1reas de Pesaje:**\n   - Pesaje de materiales de inicio en \u00e1reas dise\u00f1adas espec\u00edficamente para ese prop\u00f3sito, con control de polvo.\n\n6. **\u00c1reas de Producci\u00f3n:**\n   - Instalaciones dedicadas y auto-contenidas para la producci\u00f3n de productos farmac\u00e9uticos sensibles.\n   - Prohibici\u00f3n de producci\u00f3n de ciertos productos altamente activos en las mismas instalaciones, salvo en casos excepcionales con precauciones espec\u00edficas.\n\n**Entidades:**\n\n- **Materiales Farmac\u00e9uticos:** Incluyen sustancias altamente activas, radiactivas, narc\u00f3ticos y otros medicamentos peligrosos.\n- **\u00c1reas de Almacenamiento:** Espacios designados para el almacenamiento seguro de materiales y productos.\n- **Personal Autorizado:** Individuos con permiso para acceder a \u00e1reas restringidas, especialmente en zonas de cuarentena.\n- **Instalaciones de Producci\u00f3n:** Espacios dedicados a la fabricaci\u00f3n de productos farmac\u00e9uticos, que deben cumplir con est\u00e1ndares de seguridad para evitar la contaminaci\u00f3n cruzada.\n\nEste resumen destaca la importancia de las pr\u00e1cticas de almacenamiento y manejo en la industria farmac\u00e9utica, as\u00ed como las medidas de seguridad necesarias para proteger tanto los productos como a las personas involucradas en su manejo.", "excerpt_keywords": "Keywords: pharmaceutical manufacturing, contamination prevention, facility design, ventilation standards, cleanliness requirements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd5fc366-13d1-420e-b455-db4bb5498200", "node_type": "4", "metadata": {"page_label": "134", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and the necessary validations (including cleaning validation) are made. The manufacture of technical poisons, such as pesticides and herbicides, should not be allowed in premises used for the manufacture of pharmaceutical products.\n\n12.25 Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresponding to the sequence of the operations and to the requisite cleanliness levels.\n\n12.26 The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as to minimize the risk of confusion between different pharmaceutical products or their components, to avoid cross-contamination, and to minimize the risk of omission or wrong application of any of the manufacturing or control steps.\n\n12.27 Where starting and primary packaging materials and intermediate or bulk products are exposed to the environment, interior surfaces (walls, floors and ceilings) should be smooth and free from cracks and open joints, should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.\n\n12.28 Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses that are difficult to clean. As far as possible, for maintenance purposes, they should be accessible from outside the manufacturing areas.\n\n12.29 Drains should be of adequate size and designed and equipped to prevent back-flow. Open channels should be avoided where possible, but if they are necessary they should be shallow to facilitate cleaning and disinfection.\n\n12.30 Production areas should be effectively ventilated, with air-control facilities (including filtration of air to a sufficient level to prevent contamination and cross-contamination, as well as control of temperature and, where necessary, humidity) appropriate to the products handled, to the operations undertaken and to the external environment. These areas should be regularly monitored during both production and non-production periods to ensure compliance with their design specifications.\n\n12.31 Premises for the packaging of pharmaceutical products should be specifically designed and laid out so as to avoid mix-ups, contamination or cross-contamination.\n\n12.32 Production areas should be well lit, particularly where visual online controls are carried out.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9a86a0039a625c4557ea204b026ed319ca5493fa3626de5a633648b3eb759919", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and the necessary validations (including cleaning validation) are made. The manufacture of technical poisons, such as pesticides and herbicides, should not be allowed in premises used for the manufacture of pharmaceutical products.\n\n12.25 Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresponding to the sequence of the operations and to the requisite cleanliness levels.\n\n12.26 The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as to minimize the risk of confusion between different pharmaceutical products or their components, to avoid cross-contamination, and to minimize the risk of omission or wrong application of any of the manufacturing or control steps.\n\n12.27 Where starting and primary packaging materials and intermediate or bulk products are exposed to the environment, interior surfaces (walls, floors and ceilings) should be smooth and free from cracks and open joints, should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.\n\n12.28 Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses that are difficult to clean. As far as possible, for maintenance purposes, they should be accessible from outside the manufacturing areas.\n\n12.29 Drains should be of adequate size and designed and equipped to prevent back-flow. Open channels should be avoided where possible, but if they are necessary they should be shallow to facilitate cleaning and disinfection.\n\n12.30 Production areas should be effectively ventilated, with air-control facilities (including filtration of air to a sufficient level to prevent contamination and cross-contamination, as well as control of temperature and, where necessary, humidity) appropriate to the products handled, to the operations undertaken and to the external environment. These areas should be regularly monitored during both production and non-production periods to ensure compliance with their design specifications.\n\n12.31 Premises for the packaging of pharmaceutical products should be specifically designed and laid out so as to avoid mix-ups, contamination or cross-contamination.\n\n12.32 Production areas should be well lit, particularly where visual online controls are carried out.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2444, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9466d7a9-7c50-48c4-ad40-e2874e28b3da": {"__data__": {"id_": "9466d7a9-7c50-48c4-ad40-e2874e28b3da", "embedding": null, "metadata": {"page_label": "135", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality control areas\n\n12.33 QC laboratories should be separated from production areas. Areas where biological, microbiological or radioisotope test methods are employed should be separated from each other.\n\n12.34 QC laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix ups and cross-contamination. There should be adequate suitable storage space for samples, reference standards (if necessary, with cooling), solvents, reagents and records.\n\n12.35 The design of the laboratories should take into account the suitability of construction materials, prevention of fumes and ventilation. There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions are needed for biological, microbiological and radioisotope laboratories.\n\n12.36 A separate room may be needed for instruments to protect them against electrical interference, vibration, contact with excessive moisture and other external factors, or where it is necessary to isolate the instruments.\n\n# Equipment\n\n13.1 Equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. The layout and design of equipment must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and, in general, any adverse effect on the quality of products.\n\n13.2 Equipment should be installed in such a way as to minimize any risk of error or of contamination.\n\n13.3 Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.\n\n13.4 All service pipings and devices should be adequately marked and special attention paid to the provision of non-interchangeable connections or adaptors for dangerous gases and liquids.\n\n13.5 Balances and other measuring equipment of an appropriate range and precision should be available for production and control operations and should be calibrated on a scheduled basis.\n\n13.6 Production equipment should be thoroughly cleaned on a scheduled basis.\n\n13.7 Laboratory equipment and instruments should be suited to the testing procedures undertaken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las \u00e1reas de control de calidad (QC) y el equipamiento necesario en laboratorios. Se enfatiza la importancia de separar los laboratorios de QC de las \u00e1reas de producci\u00f3n, as\u00ed como la necesidad de un dise\u00f1o adecuado para evitar la contaminaci\u00f3n cruzada y asegurar un ambiente de trabajo seguro y eficiente. Se detallan requisitos espec\u00edficos para el dise\u00f1o de laboratorios, la instalaci\u00f3n de equipos y la limpieza programada, as\u00ed como la importancia de etiquetar adecuadamente las tuber\u00edas y conexiones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de laboratorios de control de calidad seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca respuestas sobre los aspectos espec\u00edficos del dise\u00f1o de laboratorios que se mencionan en el texto, como la separaci\u00f3n de \u00e1reas, el espacio adecuado y la ventilaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para minimizar el riesgo de contaminaci\u00f3n en el equipamiento de producci\u00f3n y control?**\n   - Aqu\u00ed se busca informaci\u00f3n sobre las pr\u00e1cticas recomendadas para la instalaci\u00f3n y mantenimiento del equipamiento, as\u00ed como la limpieza programada.\n\n3. **\u00bfQu\u00e9 tipo de etiquetado y marcado es necesario para las tuber\u00edas y dispositivos de servicio en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de etiquetado y marcado para garantizar la seguridad y la correcta identificaci\u00f3n de los contenidos en las instalaciones de laboratorio.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o de Instalaciones**: La disposici\u00f3n de las instalaciones debe seguir un orden l\u00f3gico que facilite la producci\u00f3n y cumpla con los niveles de limpieza requeridos.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n**: Se deben tomar medidas para minimizar el riesgo de confusi\u00f3n entre productos farmac\u00e9uticos, evitar la contaminaci\u00f3n cruzada y asegurar la correcta aplicaci\u00f3n de los pasos de fabricaci\u00f3n y control.\n\n3. **Superficies Interiores**: Las superficies donde se manejan materiales expuestos al ambiente deben ser lisas, sin grietas, no desprender part\u00edculas y permitir una limpieza y desinfecci\u00f3n efectivas.\n\n4. **Sistema de Drenaje**: Los desag\u00fces deben ser adecuados para prevenir el retroceso de agua y facilitar la limpieza, evitando canales abiertos siempre que sea posible.\n\n5. **Ventilaci\u00f3n**: Las \u00e1reas de producci\u00f3n deben estar bien ventiladas, con sistemas de control de aire que incluyan filtraci\u00f3n y control de temperatura y humedad, y deben ser monitoreadas regularmente.\n\n6. **Iluminaci\u00f3n**: Las \u00e1reas de producci\u00f3n deben estar bien iluminadas, especialmente donde se realizan controles visuales.\n\n7. **Dise\u00f1o de \u00c1reas de Empaque**: Las instalaciones para el empaque de productos farmac\u00e9uticos deben estar dise\u00f1adas para evitar confusiones y contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Productos cuya fabricaci\u00f3n se regula en el documento.\n- **Materiales de Empaque**: Incluyen materiales de inicio y empaque primario.\n- **Contaminaci\u00f3n Cruzada**: Riesgo que se busca prevenir en las instalaciones.\n- **Instalaciones de Producci\u00f3n**: Espacios donde se lleva a cabo la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Sistemas de Ventilaci\u00f3n y Drenaje**: Elementos cr\u00edticos en el dise\u00f1o de las instalaciones.\n\n### Resumen General\nEl documento de la OMS establece directrices para el dise\u00f1o y operaci\u00f3n de instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de los espacios, la prevenci\u00f3n de la contaminaci\u00f3n y la adecuada ventilaci\u00f3n. Estas medidas son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: quality control, laboratory design, contamination prevention, equipment maintenance, air supply"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15c08a2c-fae2-4c62-b775-40e72f27298b", "node_type": "4", "metadata": {"page_label": "135", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality control areas\n\n12.33 QC laboratories should be separated from production areas. Areas where biological, microbiological or radioisotope test methods are employed should be separated from each other.\n\n12.34 QC laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix ups and cross-contamination. There should be adequate suitable storage space for samples, reference standards (if necessary, with cooling), solvents, reagents and records.\n\n12.35 The design of the laboratories should take into account the suitability of construction materials, prevention of fumes and ventilation. There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions are needed for biological, microbiological and radioisotope laboratories.\n\n12.36 A separate room may be needed for instruments to protect them against electrical interference, vibration, contact with excessive moisture and other external factors, or where it is necessary to isolate the instruments.\n\n# Equipment\n\n13.1 Equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. The layout and design of equipment must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and, in general, any adverse effect on the quality of products.\n\n13.2 Equipment should be installed in such a way as to minimize any risk of error or of contamination.\n\n13.3 Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.\n\n13.4 All service pipings and devices should be adequately marked and special attention paid to the provision of non-interchangeable connections or adaptors for dangerous gases and liquids.\n\n13.5 Balances and other measuring equipment of an appropriate range and precision should be available for production and control operations and should be calibrated on a scheduled basis.\n\n13.6 Production equipment should be thoroughly cleaned on a scheduled basis.\n\n13.7 Laboratory equipment and instruments should be suited to the testing procedures undertaken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f67f52a90e7d04585c974846be5e220849c58ea8ae8dba0fb1f1382c3dffc65c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality control areas\n\n12.33 QC laboratories should be separated from production areas. Areas where biological, microbiological or radioisotope test methods are employed should be separated from each other.\n\n12.34 QC laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix ups and cross-contamination. There should be adequate suitable storage space for samples, reference standards (if necessary, with cooling), solvents, reagents and records.\n\n12.35 The design of the laboratories should take into account the suitability of construction materials, prevention of fumes and ventilation. There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions are needed for biological, microbiological and radioisotope laboratories.\n\n12.36 A separate room may be needed for instruments to protect them against electrical interference, vibration, contact with excessive moisture and other external factors, or where it is necessary to isolate the instruments.\n\n# Equipment\n\n13.1 Equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. The layout and design of equipment must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and, in general, any adverse effect on the quality of products.\n\n13.2 Equipment should be installed in such a way as to minimize any risk of error or of contamination.\n\n13.3 Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.\n\n13.4 All service pipings and devices should be adequately marked and special attention paid to the provision of non-interchangeable connections or adaptors for dangerous gases and liquids.\n\n13.5 Balances and other measuring equipment of an appropriate range and precision should be available for production and control operations and should be calibrated on a scheduled basis.\n\n13.6 Production equipment should be thoroughly cleaned on a scheduled basis.\n\n13.7 Laboratory equipment and instruments should be suited to the testing procedures undertaken.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2245, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "613bca58-f01c-479a-adc4-9a562a3e8cd7": {"__data__": {"id_": "613bca58-f01c-479a-adc4-9a562a3e8cd7", "embedding": null, "metadata": {"page_label": "136", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13.8\n\nWashing, cleaning and drying equipment should be chosen and used so as not to be a source of contamination.\n\n# 13.9\n\nProduction equipment should not present any hazard to the products. The parts of the production equipment that come into contact with the product must not be reactive, additive, or absorptive to an extent that would affect the quality of the product.\n\n# 13.10\n\nDefective equipment should be removed from production and QC areas. If this is not possible, it should be clearly labelled as defective to prevent use.\n\n# 13.11\n\nClosed equipment should be used whenever appropriate. Where open equipment is used or equipment is opened, precautions should be taken to minimize contamination.\n\n# 13.12\n\nNon-dedicated equipment should be cleaned according to validated cleaning procedures between production of different pharmaceutical products to prevent cross-contamination.\n\n# 13.13\n\nCurrent drawings of critical equipment and support systems should be maintained.\n\n# 14. Materials\n\n## 14.1 Principle\n\nThe main objective of a pharmaceutical plant is to produce finished products for patients\u2019 use from a combination of materials (starting and packaging).\n\n## 14.2\n\nMaterials include starting materials, packaging materials, gases, solvents, process aids, reagents and labelling materials.\n\n### General\n\n## 14.3\n\nNo materials used for operations such as cleaning, lubrication of equipment and pest control, should come into direct contact with the product. Where possible, such materials should be of a suitable grade (e.g. food grade) to minimize health risks.\n\n## 14.4\n\nAll incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.\n\n## 14.5\n\nAll materials and products should be stored under the appropriate conditions established by the manufacturer and in an orderly fashion to permit batch segregation and stock rotation by a first-expire, first-out rule.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece directrices sobre el uso y mantenimiento de equipos en plantas farmac\u00e9uticas, as\u00ed como sobre la gesti\u00f3n de materiales. Se enfatiza la importancia de evitar la contaminaci\u00f3n, asegurar que el equipo no represente un peligro para los productos, y mantener un manejo adecuado de los materiales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse con respecto al equipo defectuoso en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Respuesta: El equipo defectuoso debe ser retirado de las \u00e1reas de producci\u00f3n y control de calidad. Si no es posible retirarlo, debe ser claramente etiquetado como defectuoso para prevenir su uso.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para el almacenamiento de materiales y productos en una planta farmac\u00e9utica?**\n   - Respuesta: Todos los materiales y productos deben ser almacenados bajo las condiciones apropiadas establecidas por el fabricante y de manera ordenada para permitir la segregaci\u00f3n de lotes y la rotaci\u00f3n de stock seg\u00fan la regla de primero en caducar, primero en salir.\n\n3. **\u00bfQu\u00e9 tipo de materiales se deben evitar en contacto directo con los productos farmac\u00e9uticos y por qu\u00e9?**\n   - Respuesta: No se deben utilizar materiales para operaciones como limpieza, lubricaci\u00f3n de equipos y control de plagas que entren en contacto directo con el producto. Estos materiales deben ser de un grado adecuado (por ejemplo, grado alimenticio) para minimizar los riesgos para la salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Separaci\u00f3n de Laboratorios de Control de Calidad (QC):**\n   - Los laboratorios de QC deben estar separados de las \u00e1reas de producci\u00f3n.\n   - Se requiere separaci\u00f3n entre \u00e1reas que emplean m\u00e9todos de prueba biol\u00f3gicos, microbiol\u00f3gicos o de radiois\u00f3topos.\n\n2. **Dise\u00f1o de Laboratorios:**\n   - Los laboratorios deben ser dise\u00f1ados para las operaciones espec\u00edficas que se llevar\u00e1n a cabo.\n   - Es necesario proporcionar suficiente espacio para evitar confusiones y contaminaci\u00f3n cruzada.\n   - Debe haber almacenamiento adecuado para muestras, est\u00e1ndares de referencia, solventes, reactivos y registros.\n\n3. **Materiales y Ventilaci\u00f3n:**\n   - Se debe considerar la idoneidad de los materiales de construcci\u00f3n y la prevenci\u00f3n de humos.\n   - Se requiere un suministro de aire separado para laboratorios y \u00e1reas de producci\u00f3n, as\u00ed como unidades de manejo de aire espec\u00edficas para laboratorios biol\u00f3gicos, microbiol\u00f3gicos y de radiois\u00f3topos.\n\n4. **Protecci\u00f3n de Equipos:**\n   - Puede ser necesario un cuarto separado para instrumentos para protegerlos de interferencias el\u00e9ctricas, vibraciones y humedad excesiva.\n\n5. **Equipamiento:**\n   - El equipamiento debe estar ubicado, dise\u00f1ado y mantenido para minimizar errores y permitir una limpieza efectiva.\n   - Las tuber\u00edas fijas deben estar claramente etiquetadas para indicar su contenido y direcci\u00f3n de flujo.\n   - Se deben proporcionar conexiones no intercambiables para gases y l\u00edquidos peligrosos.\n\n6. **Calibraci\u00f3n y Limpieza:**\n   - Se requiere que los equipos de medici\u00f3n est\u00e9n disponibles y calibrados regularmente.\n   - El equipo de producci\u00f3n debe limpiarse de manera programada.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Laboratorios de Control de Calidad (QC)**\n- **Equipos de medici\u00f3n (balanzas, instrumentos de laboratorio)**\n- **Materiales de construcci\u00f3n**\n- **Sistemas de ventilaci\u00f3n y manejo de aire**\n- **Sustancias peligrosas (gases y l\u00edquidos)**\n\nEste resumen destaca la importancia de la separaci\u00f3n, el dise\u00f1o adecuado, la limpieza y el etiquetado en los laboratorios de control de calidad, as\u00ed como las pr\u00e1cticas recomendadas para el equipamiento y su mantenimiento.", "excerpt_keywords": "Keywords: contamination, pharmaceutical equipment, materials management, quality control, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "423eeb76-d73e-4c97-beb6-5990d14068f8", "node_type": "4", "metadata": {"page_label": "136", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13.8\n\nWashing, cleaning and drying equipment should be chosen and used so as not to be a source of contamination.\n\n# 13.9\n\nProduction equipment should not present any hazard to the products. The parts of the production equipment that come into contact with the product must not be reactive, additive, or absorptive to an extent that would affect the quality of the product.\n\n# 13.10\n\nDefective equipment should be removed from production and QC areas. If this is not possible, it should be clearly labelled as defective to prevent use.\n\n# 13.11\n\nClosed equipment should be used whenever appropriate. Where open equipment is used or equipment is opened, precautions should be taken to minimize contamination.\n\n# 13.12\n\nNon-dedicated equipment should be cleaned according to validated cleaning procedures between production of different pharmaceutical products to prevent cross-contamination.\n\n# 13.13\n\nCurrent drawings of critical equipment and support systems should be maintained.\n\n# 14. Materials\n\n## 14.1 Principle\n\nThe main objective of a pharmaceutical plant is to produce finished products for patients\u2019 use from a combination of materials (starting and packaging).\n\n## 14.2\n\nMaterials include starting materials, packaging materials, gases, solvents, process aids, reagents and labelling materials.\n\n### General\n\n## 14.3\n\nNo materials used for operations such as cleaning, lubrication of equipment and pest control, should come into direct contact with the product. Where possible, such materials should be of a suitable grade (e.g. food grade) to minimize health risks.\n\n## 14.4\n\nAll incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.\n\n## 14.5\n\nAll materials and products should be stored under the appropriate conditions established by the manufacturer and in an orderly fashion to permit batch segregation and stock rotation by a first-expire, first-out rule.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "56de18d54b3c9360d478699dfba62803313f958bda506a3d2487ba4416c01ea6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 13.8\n\nWashing, cleaning and drying equipment should be chosen and used so as not to be a source of contamination.\n\n# 13.9\n\nProduction equipment should not present any hazard to the products. The parts of the production equipment that come into contact with the product must not be reactive, additive, or absorptive to an extent that would affect the quality of the product.\n\n# 13.10\n\nDefective equipment should be removed from production and QC areas. If this is not possible, it should be clearly labelled as defective to prevent use.\n\n# 13.11\n\nClosed equipment should be used whenever appropriate. Where open equipment is used or equipment is opened, precautions should be taken to minimize contamination.\n\n# 13.12\n\nNon-dedicated equipment should be cleaned according to validated cleaning procedures between production of different pharmaceutical products to prevent cross-contamination.\n\n# 13.13\n\nCurrent drawings of critical equipment and support systems should be maintained.\n\n# 14. Materials\n\n## 14.1 Principle\n\nThe main objective of a pharmaceutical plant is to produce finished products for patients\u2019 use from a combination of materials (starting and packaging).\n\n## 14.2\n\nMaterials include starting materials, packaging materials, gases, solvents, process aids, reagents and labelling materials.\n\n### General\n\n## 14.3\n\nNo materials used for operations such as cleaning, lubrication of equipment and pest control, should come into direct contact with the product. Where possible, such materials should be of a suitable grade (e.g. food grade) to minimize health risks.\n\n## 14.4\n\nAll incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.\n\n## 14.5\n\nAll materials and products should be stored under the appropriate conditions established by the manufacturer and in an orderly fashion to permit batch segregation and stock rotation by a first-expire, first-out rule.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1973, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fd3560fc-e6ef-4fef-b07d-4871ba2e9a1f": {"__data__": {"id_": "fd3560fc-e6ef-4fef-b07d-4871ba2e9a1f", "embedding": null, "metadata": {"page_label": "137", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Starting materials\n\n14.6 Water used in the manufacture of pharmaceutical products should be suitable for its intended use.\n\n## Starting materials\n\n14.7 The purchase of starting materials is an important operation that should involve staff who have a particular and thorough knowledge of the products and suppliers.\n\n14.8 Starting materials should be purchased only from approved suppliers and, where possible, directly from the producer. It is also recommended that the specifications established by the manufacturer for the starting materials be discussed with the suppliers. It is of benefit that all critical aspects of the production and control of the starting material in question, including handling, labelling and packaging requirements as well as complaints and rejection procedures, are contractually agreed between the manufacturer and the supplier.\n\n14.9 For each consignment, the containers should be checked for at least integrity of package and seal and for correspondence between the order, the delivery note, and the supplier\u2019s labels.\n\n14.10 All incoming materials should be checked to ensure that the consignment corresponds to the order. Containers should be cleaned where necessary and labelled, if required, with the prescribed information. Where additional labels are attached to containers, the original information should not be lost.\n\n14.11 Damage to containers and any other problem that might adversely affect the quality of a material should be recorded and reported to the QC department and investigated.\n\n14.12 If one delivery of material is made up of different batches, each batch must be considered as separate for sampling, testing and release.\n\n14.13 Starting materials in the storage area should be appropriately labelled. Labels should bear at least the following information:\n\n- (a) the designated name of the product and the internal code reference where applicable;\n- (b) the batch number given by the supplier and, on receipt, the control or batch number given by the manufacturer, if any, documented so as to ensure traceability;\n- (c) the status of the contents (e.g. on quarantine, on test, released, rejected, returned, recalled);\n- (d) where appropriate, an expiry date or a date beyond which retesting is necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la gesti\u00f3n de materiales de partida en la fabricaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la compra, el control de calidad y el etiquetado adecuado. Se enfatiza que el agua utilizada debe ser adecuada para su prop\u00f3sito, que los materiales deben ser adquiridos de proveedores aprobados, y que se deben seguir procedimientos rigurosos para asegurar la integridad y trazabilidad de los materiales. Adem\u00e1s, se menciona la necesidad de registrar cualquier da\u00f1o a los contenedores y de etiquetar adecuadamente los materiales en el \u00e1rea de almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluir una etiqueta en los materiales de partida almacenados?**\n   - Las etiquetas deben incluir el nombre designado del producto, el n\u00famero de lote proporcionado por el proveedor, el n\u00famero de control o lote del fabricante, el estado del contenido y, si es pertinente, una fecha de caducidad o una fecha para rean\u00e1lisis.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si se recibe un lote de material que contiene diferentes lotes?**\n   - Cada lote debe ser considerado como separado para los procesos de muestreo, pruebas y liberaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta da\u00f1o en los contenedores de materiales de partida?**\n   - Cualquier da\u00f1o a los contenedores o problemas que puedan afectar la calidad del material deben ser registrados, reportados al departamento de control de calidad (QC) e investigados.", "prev_section_summary": "### Temas Clave\n\n1. **Equipos de Producci\u00f3n**:\n   - Importancia de elegir y utilizar equipos de lavado, limpieza y secado que no sean fuentes de contaminaci\u00f3n.\n   - Los equipos de producci\u00f3n no deben representar peligros para los productos; las partes en contacto con el producto no deben ser reactivas, aditivas o absorbentes.\n   - El equipo defectuoso debe ser retirado o etiquetado claramente para prevenir su uso.\n   - Se debe utilizar equipo cerrado siempre que sea posible y tomar precauciones con el equipo abierto para minimizar la contaminaci\u00f3n.\n   - El equipo no dedicado debe limpiarse seg\u00fan procedimientos validados para evitar la contaminaci\u00f3n cruzada.\n   - Mantener dibujos actuales de equipos cr\u00edticos y sistemas de soporte.\n\n2. **Gesti\u00f3n de Materiales**:\n   - El objetivo principal de una planta farmac\u00e9utica es producir productos terminados a partir de una combinaci\u00f3n de materiales.\n   - Los materiales incluyen materias primas, materiales de embalaje, gases, solventes, ayudas de proceso, reactivos y materiales de etiquetado.\n   - Los materiales utilizados para limpieza, lubricaci\u00f3n y control de plagas no deben entrar en contacto directo con los productos y deben ser de un grado adecuado para minimizar riesgos de salud.\n   - Todos los materiales y productos deben ser puestos en cuarentena inmediatamente despu\u00e9s de su recepci\u00f3n o procesamiento.\n   - Almacenamiento de materiales y productos debe realizarse bajo condiciones apropiadas y de manera ordenada, siguiendo la regla de primero en caducar, primero en salir.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: WHO - Technical Report Series 961\n- **Secciones**: \n  - Equipos de producci\u00f3n (Secci\u00f3n 13)\n  - Gesti\u00f3n de materiales (Secci\u00f3n 14)\n- **Tipos de Materiales**: \n  - Materiales de inicio\n  - Materiales de embalaje\n  - Gases\n  - Solventes\n  - Ayudas de proceso\n  - Reactivos\n  - Materiales de etiquetado\n\nEste resumen destaca la importancia de la calidad y seguridad en la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de un manejo adecuado de equipos y materiales.", "excerpt_keywords": "Keywords: starting materials, pharmaceutical manufacturing, quality control, supplier approval, labeling requirements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9bc7d670-f000-4e31-9722-50542d0f6f50", "node_type": "4", "metadata": {"page_label": "137", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Starting materials\n\n14.6 Water used in the manufacture of pharmaceutical products should be suitable for its intended use.\n\n## Starting materials\n\n14.7 The purchase of starting materials is an important operation that should involve staff who have a particular and thorough knowledge of the products and suppliers.\n\n14.8 Starting materials should be purchased only from approved suppliers and, where possible, directly from the producer. It is also recommended that the specifications established by the manufacturer for the starting materials be discussed with the suppliers. It is of benefit that all critical aspects of the production and control of the starting material in question, including handling, labelling and packaging requirements as well as complaints and rejection procedures, are contractually agreed between the manufacturer and the supplier.\n\n14.9 For each consignment, the containers should be checked for at least integrity of package and seal and for correspondence between the order, the delivery note, and the supplier\u2019s labels.\n\n14.10 All incoming materials should be checked to ensure that the consignment corresponds to the order. Containers should be cleaned where necessary and labelled, if required, with the prescribed information. Where additional labels are attached to containers, the original information should not be lost.\n\n14.11 Damage to containers and any other problem that might adversely affect the quality of a material should be recorded and reported to the QC department and investigated.\n\n14.12 If one delivery of material is made up of different batches, each batch must be considered as separate for sampling, testing and release.\n\n14.13 Starting materials in the storage area should be appropriately labelled. Labels should bear at least the following information:\n\n- (a) the designated name of the product and the internal code reference where applicable;\n- (b) the batch number given by the supplier and, on receipt, the control or batch number given by the manufacturer, if any, documented so as to ensure traceability;\n- (c) the status of the contents (e.g. on quarantine, on test, released, rejected, returned, recalled);\n- (d) where appropriate, an expiry date or a date beyond which retesting is necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6fb2ef8308b4db631f38ae23d97c4c03193bac70f550e72e145f4d340482189c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Starting materials\n\n14.6 Water used in the manufacture of pharmaceutical products should be suitable for its intended use.\n\n## Starting materials\n\n14.7 The purchase of starting materials is an important operation that should involve staff who have a particular and thorough knowledge of the products and suppliers.\n\n14.8 Starting materials should be purchased only from approved suppliers and, where possible, directly from the producer. It is also recommended that the specifications established by the manufacturer for the starting materials be discussed with the suppliers. It is of benefit that all critical aspects of the production and control of the starting material in question, including handling, labelling and packaging requirements as well as complaints and rejection procedures, are contractually agreed between the manufacturer and the supplier.\n\n14.9 For each consignment, the containers should be checked for at least integrity of package and seal and for correspondence between the order, the delivery note, and the supplier\u2019s labels.\n\n14.10 All incoming materials should be checked to ensure that the consignment corresponds to the order. Containers should be cleaned where necessary and labelled, if required, with the prescribed information. Where additional labels are attached to containers, the original information should not be lost.\n\n14.11 Damage to containers and any other problem that might adversely affect the quality of a material should be recorded and reported to the QC department and investigated.\n\n14.12 If one delivery of material is made up of different batches, each batch must be considered as separate for sampling, testing and release.\n\n14.13 Starting materials in the storage area should be appropriately labelled. Labels should bear at least the following information:\n\n- (a) the designated name of the product and the internal code reference where applicable;\n- (b) the batch number given by the supplier and, on receipt, the control or batch number given by the manufacturer, if any, documented so as to ensure traceability;\n- (c) the status of the contents (e.g. on quarantine, on test, released, rejected, returned, recalled);\n- (d) where appropriate, an expiry date or a date beyond which retesting is necessary.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2265, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e5ab1182-3a60-4e25-bdfa-111e3c4b58c7": {"__data__": {"id_": "e5ab1182-3a60-4e25-bdfa-111e3c4b58c7", "embedding": null, "metadata": {"page_label": "138", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When fully validated computerized storage systems are used, not all of the above information need be in a legible form on the label.\n\n14.14 There should be appropriate procedures or measures to ensure the identity of the contents of each container of starting material.\n\nBulk containers from which samples have been drawn should be identified.\n\n14.15 Only starting materials released by the QC department and within their shelf-life should be used.\n\n14.16 Starting materials should be dispensed only by designated persons, following a written procedure, to ensure that the correct materials are accurately weighed or measured into clean and properly labelled containers.\n\n14.17 Each dispensed material and its weight or volume should be independently checked and the check recorded.\n\n14.18 Materials dispensed for each batch of the final product should be kept together and conspicuously labelled as such.\n\n# Packaging materials\n\n14.19 The purchase, handling and control of primary and printed packaging materials should be as for starting materials.\n\n14.20 Particular attention should be paid to printed packaging materials. They should be stored in secure conditions so as to exclude the possibility of unauthorized access. Roll feed labels should be used wherever possible. Cut labels and other loose printed materials should be stored and transported in separate closed containers so as to avoid mix-ups. Packaging materials should be issued for use only by designated personnel following an approved and documented procedure.\n\n14.21 Each delivery or batch of printed or primary packaging material should be given a specific reference number or identification mark.\n\n14.22 Outdated or obsolete primary packaging material or printed packaging material should be destroyed and its disposal recorded.\n\n14.23 All products and packaging materials to be used should be checked on delivery to the packaging department for quantity, identity and conformity with the packaging instructions.\n\n# Intermediate and bulk products\n\n14.24 Intermediate and bulk products should be kept under appropriate conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el manejo y control de materiales de inicio, materiales de embalaje y productos intermedios y a granel en un entorno de producci\u00f3n. Se enfatiza la importancia de la identificaci\u00f3n, el almacenamiento seguro, la dispensaci\u00f3n controlada y la verificaci\u00f3n de los materiales utilizados en la fabricaci\u00f3n de productos. Se menciona la necesidad de procedimientos escritos y la designaci\u00f3n de personal responsable para garantizar la calidad y la conformidad de los materiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar la identidad de los contenidos de los contenedores de materiales de inicio?**\n   - Respuesta: Deben implementarse procedimientos o medidas apropiadas para garantizar la identidad de los contenidos de cada contenedor de materiales de inicio, y los contenedores a granel de los cuales se han extra\u00eddo muestras deben estar identificados.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar con respecto a los materiales de embalaje impresos para evitar accesos no autorizados?**\n   - Respuesta: Los materiales de embalaje impresos deben almacenarse en condiciones seguras para excluir la posibilidad de acceso no autorizado. Adem\u00e1s, se deben utilizar etiquetas de alimentaci\u00f3n en rollo siempre que sea posible, y las etiquetas cortadas y otros materiales impresos sueltos deben almacenarse y transportarse en contenedores cerrados separados para evitar confusiones.\n\n3. **\u00bfC\u00f3mo se debe manejar el material de embalaje obsoleto o caducado?**\n   - Respuesta: El material de embalaje primario o impreso que est\u00e9 obsoleto o caducado debe ser destruido, y su disposici\u00f3n debe ser registrada adecuadamente.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otros documentos o contextos, centr\u00e1ndose en los procedimientos y medidas de control mencionados en el texto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Agua en la Fabricaci\u00f3n**: El agua utilizada en la producci\u00f3n de productos farmac\u00e9uticos debe ser adecuada para su uso previsto.\n\n2. **Compra de Materiales de Partida**: \n   - La adquisici\u00f3n de materiales de partida es crucial y debe ser realizada por personal con conocimiento espec\u00edfico de los productos y proveedores.\n   - Los materiales deben ser comprados solo de proveedores aprobados y, preferiblemente, directamente del productor.\n\n3. **Especificaciones y Acuerdos**: \n   - Se recomienda discutir las especificaciones de los materiales con los proveedores y formalizar contractualmente aspectos cr\u00edticos como manejo, etiquetado, requisitos de empaque, y procedimientos de quejas y rechazos.\n\n4. **Control de Calidad en Recepci\u00f3n**: \n   - Se deben verificar los contenedores para asegurar la integridad del paquete y la correspondencia entre el pedido, la nota de entrega y las etiquetas del proveedor.\n   - Todos los materiales entrantes deben ser revisados para confirmar que coinciden con el pedido.\n\n5. **Manejo de Contenedores Da\u00f1ados**: \n   - Cualquier da\u00f1o a los contenedores debe ser registrado, reportado al departamento de control de calidad (QC) e investigado.\n\n6. **Lotes Diferentes**: \n   - Si un env\u00edo incluye diferentes lotes, cada lote debe ser tratado como separado para muestreo, pruebas y liberaci\u00f3n.\n\n7. **Etiquetado de Materiales**: \n   - Los materiales en el \u00e1rea de almacenamiento deben estar etiquetados adecuadamente, incluyendo informaci\u00f3n como el nombre del producto, n\u00famero de lote, estado del contenido y, si es pertinente, fechas de caducidad o rean\u00e1lisis.\n\n### Entidades Clave\n- **Materiales de Partida**: Ingredientes utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Proveedores**: Entidades que suministran los materiales de partida.\n- **Departamento de Control de Calidad (QC)**: Unidad responsable de la supervisi\u00f3n de la calidad de los materiales y productos.\n- **Lotes**: Grupos de materiales que se manejan y controlan de manera individual en el proceso de producci\u00f3n.", "excerpt_keywords": "Keywords: starting materials, packaging materials, quality control, labeling procedures, inventory management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "750969e6-90ce-4315-b235-66f93f22186e", "node_type": "4", "metadata": {"page_label": "138", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When fully validated computerized storage systems are used, not all of the above information need be in a legible form on the label.\n\n14.14 There should be appropriate procedures or measures to ensure the identity of the contents of each container of starting material.\n\nBulk containers from which samples have been drawn should be identified.\n\n14.15 Only starting materials released by the QC department and within their shelf-life should be used.\n\n14.16 Starting materials should be dispensed only by designated persons, following a written procedure, to ensure that the correct materials are accurately weighed or measured into clean and properly labelled containers.\n\n14.17 Each dispensed material and its weight or volume should be independently checked and the check recorded.\n\n14.18 Materials dispensed for each batch of the final product should be kept together and conspicuously labelled as such.\n\n# Packaging materials\n\n14.19 The purchase, handling and control of primary and printed packaging materials should be as for starting materials.\n\n14.20 Particular attention should be paid to printed packaging materials. They should be stored in secure conditions so as to exclude the possibility of unauthorized access. Roll feed labels should be used wherever possible. Cut labels and other loose printed materials should be stored and transported in separate closed containers so as to avoid mix-ups. Packaging materials should be issued for use only by designated personnel following an approved and documented procedure.\n\n14.21 Each delivery or batch of printed or primary packaging material should be given a specific reference number or identification mark.\n\n14.22 Outdated or obsolete primary packaging material or printed packaging material should be destroyed and its disposal recorded.\n\n14.23 All products and packaging materials to be used should be checked on delivery to the packaging department for quantity, identity and conformity with the packaging instructions.\n\n# Intermediate and bulk products\n\n14.24 Intermediate and bulk products should be kept under appropriate conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "decfabbd333d4c8edce730127578b45a9c5bc0bfa9644831d5f9052d799002fa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "When fully validated computerized storage systems are used, not all of the above information need be in a legible form on the label.\n\n14.14 There should be appropriate procedures or measures to ensure the identity of the contents of each container of starting material.\n\nBulk containers from which samples have been drawn should be identified.\n\n14.15 Only starting materials released by the QC department and within their shelf-life should be used.\n\n14.16 Starting materials should be dispensed only by designated persons, following a written procedure, to ensure that the correct materials are accurately weighed or measured into clean and properly labelled containers.\n\n14.17 Each dispensed material and its weight or volume should be independently checked and the check recorded.\n\n14.18 Materials dispensed for each batch of the final product should be kept together and conspicuously labelled as such.\n\n# Packaging materials\n\n14.19 The purchase, handling and control of primary and printed packaging materials should be as for starting materials.\n\n14.20 Particular attention should be paid to printed packaging materials. They should be stored in secure conditions so as to exclude the possibility of unauthorized access. Roll feed labels should be used wherever possible. Cut labels and other loose printed materials should be stored and transported in separate closed containers so as to avoid mix-ups. Packaging materials should be issued for use only by designated personnel following an approved and documented procedure.\n\n14.21 Each delivery or batch of printed or primary packaging material should be given a specific reference number or identification mark.\n\n14.22 Outdated or obsolete primary packaging material or printed packaging material should be destroyed and its disposal recorded.\n\n14.23 All products and packaging materials to be used should be checked on delivery to the packaging department for quantity, identity and conformity with the packaging instructions.\n\n# Intermediate and bulk products\n\n14.24 Intermediate and bulk products should be kept under appropriate conditions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2102, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "219e52ee-f8c8-44d6-b8b0-8cd189cf367e": {"__data__": {"id_": "219e52ee-f8c8-44d6-b8b0-8cd189cf367e", "embedding": null, "metadata": {"page_label": "139", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n14.25 Intermediate and bulk products purchased as such should be handled on receipt as though they were starting materials.\n\n## Finished Products\n\n14.26 Finished products should be held in quarantine until their final release, after which they should be stored as usable stock under conditions established by the manufacturer.\n\n14.27 The evaluation of finished products and the documentation necessary for release of a product for sale are described in section 17, \"Good practices in quality control\".\n\n## Rejected, Recovered, Reprocessed and Reworked Materials\n\n14.28 Rejected materials and products should be clearly marked as such and stored separately in restricted areas. They should either be returned to the suppliers or, where appropriate, reprocessed or destroyed in a timely manner. Whatever action is taken should be approved by authorized personnel and recorded.\n\n14.29 The reworking or recovery of rejected products should be exceptional. It is permitted only if the quality of the final product is not affected, if the specifications are met, and if it is done in accordance with a defined and authorized procedure after evaluation of the risks involved. A record should be kept of the reworking or recovery. A reworked batch should be given a new batch number.\n\n14.30 The introduction of all or part of earlier batches, conforming to the required quality, into a batch of the same product at a defined stage of manufacture should be authorized beforehand. This recovery should be carried out in accordance with a defined procedure after evaluation of the risks involved, including any possible effect on shelf-life. The recovery should be recorded.\n\n14.31 The need for additional testing of any finished product that has been reprocessed, reworked or into which a recovered product has been incorporated, should be considered by the QC department.\n\n## Recalled Products\n\n14.32 Recalled products should be identified and stored separately in a secure area until a decision is taken on their fate. The decision should be made as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Manejo de Productos Terminados**: Los productos terminados deben ser mantenidos en cuarentena hasta su liberaci\u00f3n final y almacenados bajo condiciones espec\u00edficas establecidas por el fabricante. La evaluaci\u00f3n y documentaci\u00f3n necesarias para su liberaci\u00f3n se detallan en una secci\u00f3n dedicada a las buenas pr\u00e1cticas en control de calidad.\n\n2. **Gesti\u00f3n de Materiales Rechazados y Recuperados**: Los materiales y productos rechazados deben ser claramente marcados y almacenados en \u00e1reas restringidas. Su reprocesamiento o destrucci\u00f3n debe ser aprobado por personal autorizado. La recuperaci\u00f3n de productos rechazados es excepcional y debe cumplir con criterios espec\u00edficos para asegurar que la calidad del producto final no se vea afectada.\n\n3. **Productos Retirados**: Los productos que han sido retirados del mercado deben ser identificados y almacenados de manera segura hasta que se tome una decisi\u00f3n sobre su destino, la cual debe ser realizada lo m\u00e1s pronto posible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la reintroducci\u00f3n de lotes anteriores en un nuevo lote de producto?**\n   - La introducci\u00f3n de lotes anteriores en un nuevo lote debe ser autorizada previamente y realizada de acuerdo con un procedimiento definido, tras una evaluaci\u00f3n de riesgos que considere el impacto en la vida \u00fatil del producto.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse para que un producto rechazado pueda ser reprocesado o recuperado?**\n   - El reprocesamiento o recuperaci\u00f3n de productos rechazados solo es permitido si la calidad del producto final no se ve afectada, se cumplen las especificaciones y se realiza conforme a un procedimiento autorizado tras una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfCu\u00e1l es el protocolo para el almacenamiento de productos retirados del mercado?**\n   - Los productos retirados deben ser identificados y almacenados en un \u00e1rea segura hasta que se tome una decisi\u00f3n sobre su destino, y esta decisi\u00f3n debe ser realizada lo m\u00e1s pronto posible.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Identificaci\u00f3n de Materiales de Inicio**:\n   - Se deben implementar procedimientos para asegurar la identidad de los contenidos de cada contenedor de materiales de inicio.\n   - Los contenedores a granel de los cuales se han extra\u00eddo muestras deben estar identificados.\n\n2. **Control de Calidad**:\n   - Solo se deben utilizar materiales de inicio que hayan sido liberados por el departamento de Control de Calidad (QC) y que est\u00e9n dentro de su vida \u00fatil.\n\n3. **Dispensaci\u00f3n de Materiales**:\n   - La dispensaci\u00f3n de materiales debe ser realizada \u00fanicamente por personal designado, siguiendo procedimientos escritos para asegurar la precisi\u00f3n en el pesaje o medici\u00f3n en contenedores limpios y debidamente etiquetados.\n   - Cada material dispensado y su peso o volumen deben ser verificados de manera independiente y registrados.\n\n4. **Manejo de Materiales de Embalaje**:\n   - La compra, manejo y control de materiales de embalaje primarios e impresos deben seguir procedimientos similares a los de los materiales de inicio.\n   - Los materiales de embalaje impresos deben ser almacenados en condiciones seguras para prevenir accesos no autorizados, utilizando etiquetas de alimentaci\u00f3n en rollo siempre que sea posible.\n\n5. **Control de Materiales Obsoletos**:\n   - Los materiales de embalaje primario o impreso que est\u00e9n obsoletos o caducados deben ser destruidos y su disposici\u00f3n registrada.\n\n6. **Verificaci\u00f3n de Productos y Materiales**:\n   - Todos los productos y materiales de embalaje deben ser verificados al momento de la entrega al departamento de embalaje para asegurar cantidad, identidad y conformidad con las instrucciones de embalaje.\n\n7. **Condiciones de Almacenamiento**:\n   - Los productos intermedios y a granel deben ser mantenidos bajo condiciones apropiadas.\n\n### Entidades Clave\n- **Materiales de Inicio**: Materias primas utilizadas en la producci\u00f3n.\n- **Control de Calidad (QC)**: Departamento responsable de la verificaci\u00f3n de la calidad de los materiales.\n- **Materiales de Embalaje**: Incluye materiales primarios e impresos utilizados para el empaquetado de productos.\n- **Personal Designado**: Empleados autorizados para manejar y dispensar materiales.\n- **Procedimientos Escritos**: Documentaci\u00f3n que gu\u00eda las pr\u00e1cticas de manejo y control de materiales. \n\nEste resumen destaca la importancia de los procedimientos de control y la seguridad en el manejo de materiales en un entorno de producci\u00f3n, asegurando la calidad y la conformidad de los productos finales.", "excerpt_keywords": "Keywords: Finished Products, Quality Control, Rejected Materials, Reprocessing, Recalled Products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5acc770d-4fbf-4092-b743-e63da6b8dbb7", "node_type": "4", "metadata": {"page_label": "139", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n14.25 Intermediate and bulk products purchased as such should be handled on receipt as though they were starting materials.\n\n## Finished Products\n\n14.26 Finished products should be held in quarantine until their final release, after which they should be stored as usable stock under conditions established by the manufacturer.\n\n14.27 The evaluation of finished products and the documentation necessary for release of a product for sale are described in section 17, \"Good practices in quality control\".\n\n## Rejected, Recovered, Reprocessed and Reworked Materials\n\n14.28 Rejected materials and products should be clearly marked as such and stored separately in restricted areas. They should either be returned to the suppliers or, where appropriate, reprocessed or destroyed in a timely manner. Whatever action is taken should be approved by authorized personnel and recorded.\n\n14.29 The reworking or recovery of rejected products should be exceptional. It is permitted only if the quality of the final product is not affected, if the specifications are met, and if it is done in accordance with a defined and authorized procedure after evaluation of the risks involved. A record should be kept of the reworking or recovery. A reworked batch should be given a new batch number.\n\n14.30 The introduction of all or part of earlier batches, conforming to the required quality, into a batch of the same product at a defined stage of manufacture should be authorized beforehand. This recovery should be carried out in accordance with a defined procedure after evaluation of the risks involved, including any possible effect on shelf-life. The recovery should be recorded.\n\n14.31 The need for additional testing of any finished product that has been reprocessed, reworked or into which a recovered product has been incorporated, should be considered by the QC department.\n\n## Recalled Products\n\n14.32 Recalled products should be identified and stored separately in a secure area until a decision is taken on their fate. The decision should be made as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4365ac7b7ed6e50136a590f940e012cfc5955837a46221e5836a0661d0cbea3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Finished Products\n\n14.25 Intermediate and bulk products purchased as such should be handled on receipt as though they were starting materials.\n\n## Finished Products\n\n14.26 Finished products should be held in quarantine until their final release, after which they should be stored as usable stock under conditions established by the manufacturer.\n\n14.27 The evaluation of finished products and the documentation necessary for release of a product for sale are described in section 17, \"Good practices in quality control\".\n\n## Rejected, Recovered, Reprocessed and Reworked Materials\n\n14.28 Rejected materials and products should be clearly marked as such and stored separately in restricted areas. They should either be returned to the suppliers or, where appropriate, reprocessed or destroyed in a timely manner. Whatever action is taken should be approved by authorized personnel and recorded.\n\n14.29 The reworking or recovery of rejected products should be exceptional. It is permitted only if the quality of the final product is not affected, if the specifications are met, and if it is done in accordance with a defined and authorized procedure after evaluation of the risks involved. A record should be kept of the reworking or recovery. A reworked batch should be given a new batch number.\n\n14.30 The introduction of all or part of earlier batches, conforming to the required quality, into a batch of the same product at a defined stage of manufacture should be authorized beforehand. This recovery should be carried out in accordance with a defined procedure after evaluation of the risks involved, including any possible effect on shelf-life. The recovery should be recorded.\n\n14.31 The need for additional testing of any finished product that has been reprocessed, reworked or into which a recovered product has been incorporated, should be considered by the QC department.\n\n## Recalled Products\n\n14.32 Recalled products should be identified and stored separately in a secure area until a decision is taken on their fate. The decision should be made as soon as possible.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2080, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dc795fc0-17d2-47bf-ae5c-1c6ff48c6963": {"__data__": {"id_": "dc795fc0-17d2-47bf-ae5c-1c6ff48c6963", "embedding": null, "metadata": {"page_label": "140", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Returned goods\n\n14.33 Products returned from the market should be destroyed unless it is certain that their quality is satisfactory; in such cases they may be considered for resale or relabelling, or alternative action taken only after they have been critically assessed by the QC function in accordance with a written procedure. The nature of the product, any special storage conditions it requires, its condition and history, and the time elapsed since it was issued should all be taken into account in this assessment. Where any doubt arises over the quality of the product, it should not be considered suitable for reissue or reuse.\n\nAny action taken should be appropriately recorded.\n\n# Reagents and culture media\n\n14.34 There should be records for the receipt and preparation of reagents and culture media.\n\n14.35 Reagents made up in the laboratory should be prepared according to written procedures and appropriately labelled. The label should indicate the concentration, standardization factor, shelf-life, the date when restandardization is due, and the storage conditions. The label should be signed and dated by the person preparing the reagent.\n\n14.36 Both positive and negative controls should be applied to verify the suitability of culture media each time they are prepared and used. The size of the inoculum used in positive controls should be appropriate to the sensitivity required.\n\n# Reference standards\n\n14.37 Whenever official reference standards exist, these should preferably be used.\n\n14.38 Official reference standards should be used only for the purpose described in the appropriate monograph.\n\n14.39 Reference standards prepared by the producer should be tested, released and stored in the same way as official standards. They should be kept under the responsibility of a designated person in a secure area.\n\n14.40 Secondary or working standards may be established by the application of appropriate tests and checks at regular intervals to ensure standardization.\n\n14.41 Reference standards should be properly labelled with at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda procedimientos relacionados con la gesti\u00f3n de productos devueltos, reactivos y medios de cultivo, as\u00ed como est\u00e1ndares de referencia. Se establece que los productos devueltos deben ser destruidos a menos que se confirme su calidad, y se deben seguir procedimientos escritos para su evaluaci\u00f3n. Adem\u00e1s, se requiere un registro detallado de la recepci\u00f3n y preparaci\u00f3n de reactivos, que deben estar etiquetados adecuadamente. Se enfatiza la importancia de utilizar est\u00e1ndares de referencia oficiales y de mantener un control riguroso sobre los est\u00e1ndares preparados por el productor.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al evaluar la calidad de un producto devuelto antes de decidir su reventa o reutilizaci\u00f3n?**\n   - La evaluaci\u00f3n debe considerar la naturaleza del producto, las condiciones especiales de almacenamiento requeridas, su estado y historial, y el tiempo transcurrido desde su emisi\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluir la etiqueta de un reactivo preparado en el laboratorio?**\n   - La etiqueta debe indicar la concentraci\u00f3n, el factor de estandarizaci\u00f3n, la vida \u00fatil, la fecha en que se debe reestandarizar y las condiciones de almacenamiento, adem\u00e1s de estar firmada y fechada por la persona que lo prepar\u00f3.\n\n3. **\u00bfC\u00f3mo se deben manejar los est\u00e1ndares de referencia preparados por el productor en comparaci\u00f3n con los est\u00e1ndares oficiales?**\n   - Los est\u00e1ndares de referencia preparados por el productor deben ser probados, liberados y almacenados de la misma manera que los est\u00e1ndares oficiales, y deben estar bajo la responsabilidad de una persona designada en un \u00e1rea segura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Terminados**:\n   - Los productos terminados deben ser mantenidos en cuarentena hasta su liberaci\u00f3n final.\n   - Deben ser almacenados bajo condiciones espec\u00edficas establecidas por el fabricante.\n   - La evaluaci\u00f3n y documentaci\u00f3n para la liberaci\u00f3n se detalla en la secci\u00f3n sobre buenas pr\u00e1cticas en control de calidad.\n\n2. **Gesti\u00f3n de Materiales Rechazados**:\n   - Los materiales y productos rechazados deben ser claramente marcados y almacenados en \u00e1reas restringidas.\n   - Deben ser devueltos a los proveedores o reprocesados/destruidos de manera oportuna, con aprobaci\u00f3n y registro por parte de personal autorizado.\n   - La recuperaci\u00f3n de productos rechazados es excepcional y debe cumplir con criterios espec\u00edficos para asegurar la calidad del producto final.\n\n3. **Reintroducci\u00f3n de Lotes Anteriores**:\n   - La introducci\u00f3n de lotes anteriores en un nuevo lote debe ser autorizada y realizada conforme a un procedimiento definido, tras una evaluaci\u00f3n de riesgos.\n\n4. **Productos Retirados**:\n   - Los productos retirados del mercado deben ser identificados y almacenados en un \u00e1rea segura hasta que se tome una decisi\u00f3n sobre su destino, la cual debe ser realizada lo m\u00e1s pronto posible.\n\n### Entidades Clave\n- **Productos Terminados**: Productos que han completado su proceso de fabricaci\u00f3n.\n- **Materiales Rechazados**: Productos o materiales que no cumplen con los est\u00e1ndares de calidad.\n- **Reprocesamiento**: Proceso de volver a trabajar productos rechazados.\n- **Productos Retirados**: Productos que han sido retirados del mercado por razones de seguridad o calidad.\n- **Personal Autorizado**: Individuos con la autoridad para aprobar acciones relacionadas con la gesti\u00f3n de productos y materiales. \n\nEste resumen abarca los procedimientos y regulaciones clave para el manejo de productos terminados, materiales rechazados y productos retirados, enfatizando la importancia de la calidad y la documentaci\u00f3n en el proceso.", "excerpt_keywords": "Keywords: returned goods, quality assessment, reagents, reference standards, laboratory procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2d829f2-8188-4b0c-8a61-d916556c8a2e", "node_type": "4", "metadata": {"page_label": "140", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Returned goods\n\n14.33 Products returned from the market should be destroyed unless it is certain that their quality is satisfactory; in such cases they may be considered for resale or relabelling, or alternative action taken only after they have been critically assessed by the QC function in accordance with a written procedure. The nature of the product, any special storage conditions it requires, its condition and history, and the time elapsed since it was issued should all be taken into account in this assessment. Where any doubt arises over the quality of the product, it should not be considered suitable for reissue or reuse.\n\nAny action taken should be appropriately recorded.\n\n# Reagents and culture media\n\n14.34 There should be records for the receipt and preparation of reagents and culture media.\n\n14.35 Reagents made up in the laboratory should be prepared according to written procedures and appropriately labelled. The label should indicate the concentration, standardization factor, shelf-life, the date when restandardization is due, and the storage conditions. The label should be signed and dated by the person preparing the reagent.\n\n14.36 Both positive and negative controls should be applied to verify the suitability of culture media each time they are prepared and used. The size of the inoculum used in positive controls should be appropriate to the sensitivity required.\n\n# Reference standards\n\n14.37 Whenever official reference standards exist, these should preferably be used.\n\n14.38 Official reference standards should be used only for the purpose described in the appropriate monograph.\n\n14.39 Reference standards prepared by the producer should be tested, released and stored in the same way as official standards. They should be kept under the responsibility of a designated person in a secure area.\n\n14.40 Secondary or working standards may be established by the application of appropriate tests and checks at regular intervals to ensure standardization.\n\n14.41 Reference standards should be properly labelled with at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "304ccaf2689b2c59f43614885e2a9c693681c9e5242488f7d1184bcc596f6d54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Returned goods\n\n14.33 Products returned from the market should be destroyed unless it is certain that their quality is satisfactory; in such cases they may be considered for resale or relabelling, or alternative action taken only after they have been critically assessed by the QC function in accordance with a written procedure. The nature of the product, any special storage conditions it requires, its condition and history, and the time elapsed since it was issued should all be taken into account in this assessment. Where any doubt arises over the quality of the product, it should not be considered suitable for reissue or reuse.\n\nAny action taken should be appropriately recorded.\n\n# Reagents and culture media\n\n14.34 There should be records for the receipt and preparation of reagents and culture media.\n\n14.35 Reagents made up in the laboratory should be prepared according to written procedures and appropriately labelled. The label should indicate the concentration, standardization factor, shelf-life, the date when restandardization is due, and the storage conditions. The label should be signed and dated by the person preparing the reagent.\n\n14.36 Both positive and negative controls should be applied to verify the suitability of culture media each time they are prepared and used. The size of the inoculum used in positive controls should be appropriate to the sensitivity required.\n\n# Reference standards\n\n14.37 Whenever official reference standards exist, these should preferably be used.\n\n14.38 Official reference standards should be used only for the purpose described in the appropriate monograph.\n\n14.39 Reference standards prepared by the producer should be tested, released and stored in the same way as official standards. They should be kept under the responsibility of a designated person in a secure area.\n\n14.40 Secondary or working standards may be established by the application of appropriate tests and checks at regular intervals to ensure standardization.\n\n14.41 Reference standards should be properly labelled with at least the following information:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2089, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "63956f82-650d-45d4-8c49-2a474d1aa82c": {"__data__": {"id_": "63956f82-650d-45d4-8c49-2a474d1aa82c", "embedding": null, "metadata": {"page_label": "141", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) name of the material;  \n(b) batch or lot number and control number;  \n(c) date of preparation;  \n(d) shelf-life;  \n(e) potency;  \n(f) storage conditions.\n\n14.42 All in-house reference standards should be standardized against an official reference standard, when available, initially and at regular intervals thereafter.\n\n14.43 All reference standards should be stored and used in a manner that will not adversely affect their quality.\n\n### Waste materials\n\n14.44 Provision should be made for the proper and safe storage of waste materials awaiting disposal. Toxic substances and flammable materials should be stored in suitably designed, separate, enclosed cupboards, as required by national legislation.\n\n14.45 Waste material should not be allowed to accumulate. It should be collected in suitable receptacles for removal to collection points outside the buildings and disposed of safely and in a sanitary manner at regular and frequent intervals.\n\n### Miscellaneous\n\n14.46 Rodenticides, insecticides, fumigating agents and sanitizing materials should not be permitted to contaminate equipment, starting materials, packaging materials, in-process materials or finished products.\n\n## 15. Documentation\n\n15.1 **Principle.** Good documentation is an essential part of the quality assurance system and, as such, should exist for all aspects of GMP. Its aims are to define the specifications and procedures for all materials and methods of manufacture and control; to ensure that all personnel concerned with manufacture know what to do and when to do it; to ensure that authorized persons have all the information necessary to decide whether or not to release a batch of a medicine for sale, to ensure the existence of documented evidence, traceability, and to provide records and an audit trail that will permit investigation. It ensures the availability of the data needed for validation, review and statistical analysis. The design and use of documents depend upon the manufacturer. In some cases some or all of the documents described below may be brought together, but they will usually be separate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la gesti\u00f3n de est\u00e1ndares de referencia, el manejo de materiales de desecho y la importancia de la documentaci\u00f3n en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP). Se enfatiza la necesidad de estandarizar los est\u00e1ndares de referencia, almacenar adecuadamente los materiales de desecho y mantener una documentaci\u00f3n rigurosa para asegurar la calidad y la trazabilidad en la producci\u00f3n de medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el almacenamiento de est\u00e1ndares de referencia in-house seg\u00fan las directrices de la OMS?**\n   - Respuesta: Todos los est\u00e1ndares de referencia in-house deben ser estandarizados contra un est\u00e1ndar de referencia oficial, cuando est\u00e9 disponible, inicialmente y a intervalos regulares. Adem\u00e1s, deben ser almacenados y utilizados de manera que no afecten negativamente su calidad.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para el manejo de materiales de desecho que contienen sustancias t\u00f3xicas o inflamables?**\n   - Respuesta: Se debe proporcionar un almacenamiento adecuado y seguro para los materiales de desecho, asegurando que las sustancias t\u00f3xicas y los materiales inflamables se guarden en armarios separados y dise\u00f1ados espec\u00edficamente, de acuerdo con la legislaci\u00f3n nacional.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito principal de la documentaci\u00f3n en el sistema de aseguramiento de calidad seg\u00fan las directrices de la OMS?**\n   - Respuesta: El prop\u00f3sito principal de la documentaci\u00f3n es definir las especificaciones y procedimientos para todos los materiales y m\u00e9todos de fabricaci\u00f3n y control, asegurando que el personal sepa qu\u00e9 hacer y cu\u00e1ndo, y proporcionando la informaci\u00f3n necesaria para decidir sobre la liberaci\u00f3n de lotes de medicamentos, as\u00ed como para garantizar la existencia de evidencia documentada y trazabilidad.", "prev_section_summary": "### Temas Clave\n\n1. **Productos Devueltos**:\n   - Los productos devueltos deben ser destruidos a menos que se confirme su calidad.\n   - La evaluaci\u00f3n de la calidad debe considerar la naturaleza del producto, condiciones de almacenamiento, estado, historial y tiempo desde su emisi\u00f3n.\n   - Cualquier acci\u00f3n tomada debe ser registrada adecuadamente.\n\n2. **Reactivos y Medios de Cultivo**:\n   - Se deben mantener registros de recepci\u00f3n y preparaci\u00f3n de reactivos y medios de cultivo.\n   - Los reactivos deben ser preparados seg\u00fan procedimientos escritos y etiquetados con informaci\u00f3n espec\u00edfica (concentraci\u00f3n, factor de estandarizaci\u00f3n, vida \u00fatil, fecha de reestandarizaci\u00f3n y condiciones de almacenamiento).\n   - Se deben aplicar controles positivos y negativos para verificar la idoneidad de los medios de cultivo.\n\n3. **Est\u00e1ndares de Referencia**:\n   - Se deben utilizar est\u00e1ndares de referencia oficiales siempre que existan.\n   - Los est\u00e1ndares de referencia preparados por el productor deben ser probados y almacenados de manera similar a los est\u00e1ndares oficiales, bajo la responsabilidad de una persona designada.\n   - Se pueden establecer est\u00e1ndares secundarios o de trabajo mediante pruebas y controles regulares.\n   - Los est\u00e1ndares de referencia deben estar etiquetados con informaci\u00f3n relevante.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos**: Elementos devueltos del mercado que requieren evaluaci\u00f3n de calidad.\n- **Reactivos**: Sustancias qu\u00edmicas preparadas en el laboratorio que deben ser etiquetadas y registradas.\n- **Medios de Cultivo**: Sustancias utilizadas para cultivar microorganismos, que requieren controles de calidad.\n- **Est\u00e1ndares de Referencia**: Normas oficiales y preparadas por el productor que garantizan la calidad y consistencia de los productos.", "excerpt_keywords": "Keywords: est\u00e1ndares de referencia, gesti\u00f3n de desechos, documentaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura, calidad y trazabilidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fbe8be77-2b56-4196-8191-929433d9773e", "node_type": "4", "metadata": {"page_label": "141", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) name of the material;  \n(b) batch or lot number and control number;  \n(c) date of preparation;  \n(d) shelf-life;  \n(e) potency;  \n(f) storage conditions.\n\n14.42 All in-house reference standards should be standardized against an official reference standard, when available, initially and at regular intervals thereafter.\n\n14.43 All reference standards should be stored and used in a manner that will not adversely affect their quality.\n\n### Waste materials\n\n14.44 Provision should be made for the proper and safe storage of waste materials awaiting disposal. Toxic substances and flammable materials should be stored in suitably designed, separate, enclosed cupboards, as required by national legislation.\n\n14.45 Waste material should not be allowed to accumulate. It should be collected in suitable receptacles for removal to collection points outside the buildings and disposed of safely and in a sanitary manner at regular and frequent intervals.\n\n### Miscellaneous\n\n14.46 Rodenticides, insecticides, fumigating agents and sanitizing materials should not be permitted to contaminate equipment, starting materials, packaging materials, in-process materials or finished products.\n\n## 15. Documentation\n\n15.1 **Principle.** Good documentation is an essential part of the quality assurance system and, as such, should exist for all aspects of GMP. Its aims are to define the specifications and procedures for all materials and methods of manufacture and control; to ensure that all personnel concerned with manufacture know what to do and when to do it; to ensure that authorized persons have all the information necessary to decide whether or not to release a batch of a medicine for sale, to ensure the existence of documented evidence, traceability, and to provide records and an audit trail that will permit investigation. It ensures the availability of the data needed for validation, review and statistical analysis. The design and use of documents depend upon the manufacturer. In some cases some or all of the documents described below may be brought together, but they will usually be separate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "77976dc38596c706bc655c54915ab7abb2107477d9694f30d5d4818de1174aac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(a) name of the material;  \n(b) batch or lot number and control number;  \n(c) date of preparation;  \n(d) shelf-life;  \n(e) potency;  \n(f) storage conditions.\n\n14.42 All in-house reference standards should be standardized against an official reference standard, when available, initially and at regular intervals thereafter.\n\n14.43 All reference standards should be stored and used in a manner that will not adversely affect their quality.\n\n### Waste materials\n\n14.44 Provision should be made for the proper and safe storage of waste materials awaiting disposal. Toxic substances and flammable materials should be stored in suitably designed, separate, enclosed cupboards, as required by national legislation.\n\n14.45 Waste material should not be allowed to accumulate. It should be collected in suitable receptacles for removal to collection points outside the buildings and disposed of safely and in a sanitary manner at regular and frequent intervals.\n\n### Miscellaneous\n\n14.46 Rodenticides, insecticides, fumigating agents and sanitizing materials should not be permitted to contaminate equipment, starting materials, packaging materials, in-process materials or finished products.\n\n## 15. Documentation\n\n15.1 **Principle.** Good documentation is an essential part of the quality assurance system and, as such, should exist for all aspects of GMP. Its aims are to define the specifications and procedures for all materials and methods of manufacture and control; to ensure that all personnel concerned with manufacture know what to do and when to do it; to ensure that authorized persons have all the information necessary to decide whether or not to release a batch of a medicine for sale, to ensure the existence of documented evidence, traceability, and to provide records and an audit trail that will permit investigation. It ensures the availability of the data needed for validation, review and statistical analysis. The design and use of documents depend upon the manufacturer. In some cases some or all of the documents described below may be brought together, but they will usually be separate.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2105, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "398848c8-ac16-4cb6-9a9f-55051b4791e5": {"__data__": {"id_": "398848c8-ac16-4cb6-9a9f-55051b4791e5", "embedding": null, "metadata": {"page_label": "142", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General\n\n15.2 Documents should be designed, prepared, reviewed and distributed with care. They should comply with the relevant parts of the manufacturing and marketing authorizations.\n\n15.3 Documents should be approved, signed and dated by the appropriate responsible persons. No document should be changed without authorization and approval.\n\n15.4 Documents should have unambiguous contents: the title, nature and purpose should be clearly stated. They should be laid out in an orderly fashion and be easy to check. Reproduced documents should be clear and legible. The reproduction of working documents from master documents must not allow any error to be introduced through the reproduction process.\n\n15.5 Documents should be regularly reviewed and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version. Superseded documents should be retained for a specific period of time.\n\n15.6 Where documents require the entry of data, these entries should be clear, legible and indelible. Sufficient space should be provided for such entries.\n\n15.7 Any alteration made to a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.\n\n15.8 Records should be made or completed when any action is taken and in such a way that all significant activities concerning the manufacture of pharmaceutical products are traceable. Records should be retained for at least one year after the expiry date of the finished product.\n\n15.9 Data (and records for storage) may be recorded by electronic data-processing systems or by photographic or other reliable means. Master formulae and detailed standard operating procedures (SOPs) relating to the system in use should be available and the accuracy of the records should be checked. If documentation is handled by electronic data-processing methods, only authorized persons should be able to enter or modify data in the computer, and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked. Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper print-outs or other means. It is particularly important that, during the period of retention, the data are readily available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre la gesti\u00f3n de documentos en el \u00e1mbito de la fabricaci\u00f3n y comercializaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de dise\u00f1ar, revisar y distribuir documentos con cuidado, asegurando que sean claros, legibles y actualizados. Tambi\u00e9n se establece la necesidad de que los documentos sean aprobados por personas responsables y que cualquier alteraci\u00f3n sea debidamente registrada. Adem\u00e1s, se menciona la importancia de mantener registros precisos y accesibles, ya sea en formato f\u00edsico o electr\u00f3nico, y de garantizar la trazabilidad de las actividades significativas relacionadas con la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los documentos no sean utilizados inadvertidamente despu\u00e9s de ser revisados?**\n   - El contexto menciona que debe existir un sistema para prevenir el uso inadvertido de versiones supersedidas de documentos, y que estos deben ser retenidos por un per\u00edodo espec\u00edfico.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la integridad de los datos registrados electr\u00f3nicamente?**\n   - Se indica que solo personas autorizadas deben poder ingresar o modificar datos en sistemas electr\u00f3nicos, y que debe haber un registro de cambios y eliminaciones. Adem\u00e1s, el acceso debe estar restringido por contrase\u00f1as y la entrada de datos cr\u00edticos debe ser verificada de manera independiente.\n\n3. **\u00bfCu\u00e1l es el tiempo m\u00ednimo que se deben conservar los registros relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Los registros deben ser retenidos por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto terminado, asegurando as\u00ed la trazabilidad de las actividades significativas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Est\u00e1ndares de Referencia:**\n   - **Estandarizaci\u00f3n:** Los est\u00e1ndares de referencia in-house deben ser estandarizados contra un est\u00e1ndar oficial disponible, tanto al inicio como en intervalos regulares.\n   - **Almacenamiento:** Deben ser almacenados y utilizados de manera que no se comprometa su calidad.\n\n2. **Manejo de Materiales de Desecho:**\n   - **Almacenamiento Seguro:** Se debe garantizar un almacenamiento adecuado y seguro para los materiales de desecho, especialmente aquellos que contienen sustancias t\u00f3xicas o inflamables, en armarios dise\u00f1ados espec\u00edficamente.\n   - **Eliminaci\u00f3n:** Los materiales de desecho no deben acumularse y deben ser recolectados y eliminados de manera segura y sanitaria de forma regular.\n\n3. **Contaminaci\u00f3n:**\n   - **Prohibici\u00f3n de Contaminantes:** Se proh\u00edbe que rodenticidas, insecticidas, agentes de fumigaci\u00f3n y materiales de saneamiento contaminen equipos, materiales de inicio, materiales de envasado, materiales en proceso o productos terminados.\n\n4. **Documentaci\u00f3n:**\n   - **Importancia:** La documentaci\u00f3n es esencial para el sistema de aseguramiento de calidad y debe existir para todos los aspectos de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - **Objetivos:** Definir especificaciones y procedimientos, asegurar que el personal sepa qu\u00e9 hacer y cu\u00e1ndo, proporcionar informaci\u00f3n para la liberaci\u00f3n de lotes de medicamentos, y garantizar la existencia de evidencia documentada y trazabilidad.\n   - **Dise\u00f1o y Uso:** La forma y uso de los documentos dependen del fabricante, y aunque algunos documentos pueden combinarse, generalmente son separados.\n\n### Entidades Clave:\n- **Materiales:** Est\u00e1ndares de referencia, materiales de desecho.\n- **Sustancias:** T\u00f3xicas, inflamables, rodenticidas, insecticidas, agentes de fumigaci\u00f3n.\n- **Documentaci\u00f3n:** Especificaciones, procedimientos, registros, auditor\u00edas.\n- **Normativas:** Buenas Pr\u00e1cticas de Manufactura (GMP), legislaci\u00f3n nacional.", "excerpt_keywords": "Keywords: documentos, fabricaci\u00f3n, registros, autorizaci\u00f3n, trazabilidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "39661e39-ffb1-4b39-93dd-9ab9ccb2448b", "node_type": "4", "metadata": {"page_label": "142", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General\n\n15.2 Documents should be designed, prepared, reviewed and distributed with care. They should comply with the relevant parts of the manufacturing and marketing authorizations.\n\n15.3 Documents should be approved, signed and dated by the appropriate responsible persons. No document should be changed without authorization and approval.\n\n15.4 Documents should have unambiguous contents: the title, nature and purpose should be clearly stated. They should be laid out in an orderly fashion and be easy to check. Reproduced documents should be clear and legible. The reproduction of working documents from master documents must not allow any error to be introduced through the reproduction process.\n\n15.5 Documents should be regularly reviewed and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version. Superseded documents should be retained for a specific period of time.\n\n15.6 Where documents require the entry of data, these entries should be clear, legible and indelible. Sufficient space should be provided for such entries.\n\n15.7 Any alteration made to a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.\n\n15.8 Records should be made or completed when any action is taken and in such a way that all significant activities concerning the manufacture of pharmaceutical products are traceable. Records should be retained for at least one year after the expiry date of the finished product.\n\n15.9 Data (and records for storage) may be recorded by electronic data-processing systems or by photographic or other reliable means. Master formulae and detailed standard operating procedures (SOPs) relating to the system in use should be available and the accuracy of the records should be checked. If documentation is handled by electronic data-processing methods, only authorized persons should be able to enter or modify data in the computer, and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked. Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper print-outs or other means. It is particularly important that, during the period of retention, the data are readily available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "da477a3a38b8e08697f5145c4dd6bea6edefbc9b3760d5a0cc95f30693d33eea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# General\n\n15.2 Documents should be designed, prepared, reviewed and distributed with care. They should comply with the relevant parts of the manufacturing and marketing authorizations.\n\n15.3 Documents should be approved, signed and dated by the appropriate responsible persons. No document should be changed without authorization and approval.\n\n15.4 Documents should have unambiguous contents: the title, nature and purpose should be clearly stated. They should be laid out in an orderly fashion and be easy to check. Reproduced documents should be clear and legible. The reproduction of working documents from master documents must not allow any error to be introduced through the reproduction process.\n\n15.5 Documents should be regularly reviewed and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version. Superseded documents should be retained for a specific period of time.\n\n15.6 Where documents require the entry of data, these entries should be clear, legible and indelible. Sufficient space should be provided for such entries.\n\n15.7 Any alteration made to a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.\n\n15.8 Records should be made or completed when any action is taken and in such a way that all significant activities concerning the manufacture of pharmaceutical products are traceable. Records should be retained for at least one year after the expiry date of the finished product.\n\n15.9 Data (and records for storage) may be recorded by electronic data-processing systems or by photographic or other reliable means. Master formulae and detailed standard operating procedures (SOPs) relating to the system in use should be available and the accuracy of the records should be checked. If documentation is handled by electronic data-processing methods, only authorized persons should be able to enter or modify data in the computer, and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked. Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper print-outs or other means. It is particularly important that, during the period of retention, the data are readily available.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2458, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "64f99230-4c11-4200-83a5-57ec1aa8b6b5": {"__data__": {"id_": "64f99230-4c11-4200-83a5-57ec1aa8b6b5", "embedding": null, "metadata": {"page_label": "143", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documents required\n\n## Labels\n\n15.10 Labels applied to containers, equipment or premises should be clear, unambiguous and in the company\u2019s agreed format. It is often helpful in addition to the wording on the labels to use colours to indicate status (e.g. quarantined, accepted, rejected, clean).\n\n15.11 All finished medicines products should be identified by labelling, as required by the national legislation, bearing at least the following information:\n\n- (a) the name of the medicines product;\n- (b) a list of the active ingredients (if applicable, with the INNs), showing the amount of each present and a statement of the net contents (e.g. number of dosage units, weight, volume);\n- (c) the batch number assigned by the manufacturer;\n- (d) the expiry date in an uncoded form;\n- (e) any special storage conditions or handling precautions that may be necessary;\n- (f) directions for use, and warnings and precautions that may be necessary;\n- (g) the name and address of the manufacturer or the company or the person responsible for placing the product on the market.\n\n15.12 For reference standards, the label and/or accompanying document should indicate potency or concentration, date of manufacture, expiry date, date the closure is first opened, storage conditions and control number, as appropriate.\n\n## Specifications and testing procedures\n\n15.13 Testing procedures described in documents should be validated in the context of available facilities and equipment before they are adopted for routine testing.\n\n15.14 There should be appropriately authorized and dated specifications, including tests on identity, content, purity and quality, for starting and packaging materials and for finished products; where appropriate, they should also be available for intermediate or bulk products. Specifications for water, solvents and reagents (e.g. acids and bases) used in production should be included.\n\n15.15 Each specification should be approved, signed and dated, and maintained by the QC, QA units or documentation centre. Specifications for starting materials, intermediates, and bulk, finished products and packaging materials are referred to in sections 15.18\u201315.21.\n\n15.16 Periodic revisions of the specifications may be necessary to comply with new editions of the national pharmacopoeia or other official compendia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el etiquetado de productos farmac\u00e9uticos y las especificaciones y procedimientos de prueba necesarios para garantizar la calidad y seguridad de los medicamentos. Se enfatiza la importancia de que las etiquetas sean claras y contengan informaci\u00f3n esencial como el nombre del producto, ingredientes activos, n\u00famero de lote, fecha de caducidad, condiciones de almacenamiento, y m\u00e1s. Adem\u00e1s, se menciona que los procedimientos de prueba deben ser validados y que las especificaciones deben ser autorizadas y mantenidas adecuadamente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluirse en la etiqueta de un producto farmac\u00e9utico seg\u00fan la legislaci\u00f3n nacional?**\n   - La etiqueta debe incluir el nombre del producto, una lista de ingredientes activos, el n\u00famero de lote, la fecha de caducidad, condiciones de almacenamiento, instrucciones de uso, y la informaci\u00f3n del fabricante.\n\n2. **\u00bfQu\u00e9 se debe indicar en la etiqueta de los est\u00e1ndares de referencia?**\n   - La etiqueta debe indicar la potencia o concentraci\u00f3n, la fecha de fabricaci\u00f3n, la fecha de caducidad, la fecha en que se abri\u00f3 por primera vez, las condiciones de almacenamiento y el n\u00famero de control, seg\u00fan sea apropiado.\n\n3. **\u00bfCu\u00e1l es el proceso para la aprobaci\u00f3n y mantenimiento de las especificaciones de los productos farmac\u00e9uticos?**\n   - Cada especificaci\u00f3n debe ser aprobada, firmada y fechada, y mantenida por las unidades de Control de Calidad (QC), Aseguramiento de Calidad (QA) o el centro de documentaci\u00f3n. Adem\u00e1s, las especificaciones deben ser revisadas peri\u00f3dicamente para cumplir con las nuevas ediciones de la farmacopea nacional u otros compendios oficiales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Importancia de dise\u00f1ar, preparar, revisar y distribuir documentos con cuidado.\n   - Cumplimiento de las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n.\n\n2. **Aprobaci\u00f3n y Autorizaci\u00f3n**:\n   - Documentos deben ser aprobados, firmados y fechados por personas responsables.\n   - Cambios en documentos requieren autorizaci\u00f3n y aprobaci\u00f3n.\n\n3. **Claridad y Legibilidad**:\n   - Contenido de documentos debe ser claro y sin ambig\u00fcedades.\n   - Documentos reproducidos deben ser legibles y sin errores de reproducci\u00f3n.\n\n4. **Revisi\u00f3n y Actualizaci\u00f3n**:\n   - Documentos deben ser revisados regularmente y mantenerse actualizados.\n   - Sistema para prevenir el uso inadvertido de versiones supersedidas.\n\n5. **Registro de Datos**:\n   - Entradas de datos deben ser claras, legibles e indelebles.\n   - Espacio suficiente debe ser proporcionado para las entradas.\n\n6. **Alteraciones de Documentos**:\n   - Cualquier alteraci\u00f3n debe ser firmada y fechada, permitiendo la lectura de la informaci\u00f3n original.\n   - Registro de la raz\u00f3n de la alteraci\u00f3n cuando sea apropiado.\n\n7. **Trazabilidad de Registros**:\n   - Registros deben ser completados para todas las acciones significativas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n   - Retenci\u00f3n de registros por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto.\n\n8. **Manejo Electr\u00f3nico de Datos**:\n   - Uso de sistemas electr\u00f3nicos para registrar datos, con acceso restringido a personas autorizadas.\n   - Registro de cambios y eliminaciones, con verificaci\u00f3n independiente de datos cr\u00edticos.\n   - Protecci\u00f3n de registros electr\u00f3nicos mediante copias de seguridad.\n\n### Entidades Clave\n- **Documentos**: Incluyen formularios, registros y procedimientos operativos est\u00e1ndar (SOPs).\n- **Personas Responsables**: Aquellos que aprueban y firman documentos.\n- **Datos**: Informaci\u00f3n registrada en documentos, ya sea en formato f\u00edsico o electr\u00f3nico.\n- **Registros**: Documentaci\u00f3n de actividades significativas en la fabricaci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de documentos y registros en el contexto de la fabricaci\u00f3n y comercializaci\u00f3n de productos farmac\u00e9uticos, enfatizando la claridad, la trazabilidad y la seguridad de los datos.", "excerpt_keywords": "Keywords: labeling, specifications, quality control, pharmaceuticals, testing procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2209a194-ed92-47a6-acac-2f1b58e3757b", "node_type": "4", "metadata": {"page_label": "143", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documents required\n\n## Labels\n\n15.10 Labels applied to containers, equipment or premises should be clear, unambiguous and in the company\u2019s agreed format. It is often helpful in addition to the wording on the labels to use colours to indicate status (e.g. quarantined, accepted, rejected, clean).\n\n15.11 All finished medicines products should be identified by labelling, as required by the national legislation, bearing at least the following information:\n\n- (a) the name of the medicines product;\n- (b) a list of the active ingredients (if applicable, with the INNs), showing the amount of each present and a statement of the net contents (e.g. number of dosage units, weight, volume);\n- (c) the batch number assigned by the manufacturer;\n- (d) the expiry date in an uncoded form;\n- (e) any special storage conditions or handling precautions that may be necessary;\n- (f) directions for use, and warnings and precautions that may be necessary;\n- (g) the name and address of the manufacturer or the company or the person responsible for placing the product on the market.\n\n15.12 For reference standards, the label and/or accompanying document should indicate potency or concentration, date of manufacture, expiry date, date the closure is first opened, storage conditions and control number, as appropriate.\n\n## Specifications and testing procedures\n\n15.13 Testing procedures described in documents should be validated in the context of available facilities and equipment before they are adopted for routine testing.\n\n15.14 There should be appropriately authorized and dated specifications, including tests on identity, content, purity and quality, for starting and packaging materials and for finished products; where appropriate, they should also be available for intermediate or bulk products. Specifications for water, solvents and reagents (e.g. acids and bases) used in production should be included.\n\n15.15 Each specification should be approved, signed and dated, and maintained by the QC, QA units or documentation centre. Specifications for starting materials, intermediates, and bulk, finished products and packaging materials are referred to in sections 15.18\u201315.21.\n\n15.16 Periodic revisions of the specifications may be necessary to comply with new editions of the national pharmacopoeia or other official compendia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d83877742e9c7b61fb766f3b9c270b526b2e20cc53e23b3bb8a74e25fb976034", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Documents required\n\n## Labels\n\n15.10 Labels applied to containers, equipment or premises should be clear, unambiguous and in the company\u2019s agreed format. It is often helpful in addition to the wording on the labels to use colours to indicate status (e.g. quarantined, accepted, rejected, clean).\n\n15.11 All finished medicines products should be identified by labelling, as required by the national legislation, bearing at least the following information:\n\n- (a) the name of the medicines product;\n- (b) a list of the active ingredients (if applicable, with the INNs), showing the amount of each present and a statement of the net contents (e.g. number of dosage units, weight, volume);\n- (c) the batch number assigned by the manufacturer;\n- (d) the expiry date in an uncoded form;\n- (e) any special storage conditions or handling precautions that may be necessary;\n- (f) directions for use, and warnings and precautions that may be necessary;\n- (g) the name and address of the manufacturer or the company or the person responsible for placing the product on the market.\n\n15.12 For reference standards, the label and/or accompanying document should indicate potency or concentration, date of manufacture, expiry date, date the closure is first opened, storage conditions and control number, as appropriate.\n\n## Specifications and testing procedures\n\n15.13 Testing procedures described in documents should be validated in the context of available facilities and equipment before they are adopted for routine testing.\n\n15.14 There should be appropriately authorized and dated specifications, including tests on identity, content, purity and quality, for starting and packaging materials and for finished products; where appropriate, they should also be available for intermediate or bulk products. Specifications for water, solvents and reagents (e.g. acids and bases) used in production should be included.\n\n15.15 Each specification should be approved, signed and dated, and maintained by the QC, QA units or documentation centre. Specifications for starting materials, intermediates, and bulk, finished products and packaging materials are referred to in sections 15.18\u201315.21.\n\n15.16 Periodic revisions of the specifications may be necessary to comply with new editions of the national pharmacopoeia or other official compendia.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2329, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a13168f9-79d8-4a7c-8eae-70ab564d4a2b": {"__data__": {"id_": "a13168f9-79d8-4a7c-8eae-70ab564d4a2b", "embedding": null, "metadata": {"page_label": "144", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Starting and Packaging Materials\n\n15.17 Pharmacopoeias, reference standards, reference spectra and other reference materials should be available in the QC laboratory.\n\n## Specifications for Starting and Packaging Materials\n\n15.18 Specifications for starting, primary and printed packaging materials should provide, if applicable, a description of the materials, including:\n\n- (a) the designated name (if applicable, the INN) and internal code reference;\n- (b) the reference, if any, to a pharmacopoeial monograph;\n- (c) qualitative and quantitative requirements with acceptance limits.\n\nDepending on the company\u2019s practice other data may be added to the specification, such as:\n\n- (a) the supplier and the original producer of the materials;\n- (b) a specimen of printed materials;\n- (c) directions for sampling and testing, or a reference to procedures;\n- (d) storage conditions and precautions;\n- (e) the maximum period of storage before re-examination.\n\nPackaging material should conform to specifications, and should be compatible with the material and/or with the medicines product it contains.\n\nThe material should be examined for compliance with the specification, and for defects as well as for the correctness of identity markings.\n\n15.19 Documents describing testing procedures should state the required frequency for re-assaying each starting material, as determined by its stability.\n\n## Specifications for Intermediate and Bulk Products\n\n15.20 Specifications for intermediate and bulk products should be available. The specifications should be similar to specifications for starting materials or for finished products, as appropriate.\n\n## Specifications for Finished Products\n\n15.21 Specifications for finished products should include:\n\n- (a) the designated name of the product and the code reference, where applicable;\n- (b) the designated name(s) of the active ingredient(s) (if applicable, with the INN(s));\n- (c) the formula or a reference to the formula;\n- (d) a description of the dosage form and package details;\n- (e) directions for sampling and testing or a reference to procedures;\n- (f) the qualitative and quantitative requirements, with acceptance limits;\n- (g) the storage conditions and precautions, where applicable;\n- (h) the shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de materiales de referencia deben estar disponibles en el laboratorio de control de calidad (QC)?**\n   - En el laboratorio de control de calidad (QC) deben estar disponibles farmacopoeias, est\u00e1ndares de referencia, espectros de referencia y otros materiales de referencia.\n\n2. **\u00bfCu\u00e1les son algunos de los datos adicionales que pueden incluirse en las especificaciones de los materiales de embalaje, seg\u00fan las pr\u00e1cticas de la empresa?**\n   - Adem\u00e1s de la descripci\u00f3n de los materiales, las especificaciones pueden incluir: (a) el proveedor y el productor original de los materiales; (b) una muestra de los materiales impresos; (c) direcciones para el muestreo y pruebas, o una referencia a los procedimientos; (d) condiciones de almacenamiento y precauciones; y (e) el per\u00edodo m\u00e1ximo de almacenamiento antes de la re-examinaci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las especificaciones de los productos terminados?**\n   - Las especificaciones de los productos terminados deben incluir: (a) el nombre designado del producto y la referencia del c\u00f3digo, si corresponde; (b) el nombre(s) de los ingredientes activos (si corresponde, con el INN(s)); (c) la f\u00f3rmula o una referencia a la f\u00f3rmula; (d) una descripci\u00f3n de la forma de dosificaci\u00f3n y detalles del paquete; (e) direcciones para el muestreo y pruebas o una referencia a los procedimientos; (f) los requisitos cualitativos y cuantitativos, con l\u00edmites de aceptaci\u00f3n; (g) las condiciones de almacenamiento y precauciones, si corresponde; y (h) la vida \u00fatil.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona especificaciones detalladas para los materiales de inicio, intermedios, a granel y productos terminados en el contexto de la fabricaci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de tener materiales de referencia en el laboratorio de control de calidad y se describen los requisitos que deben cumplirse para asegurar la calidad y la conformidad de los materiales y productos. Las especificaciones incluyen detalles sobre la identificaci\u00f3n, pruebas, almacenamiento y vida \u00fatil de los productos, as\u00ed como la documentaci\u00f3n necesaria para los procedimientos de prueba.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n#### Temas clave:\n1. **Etiquetado de productos farmac\u00e9uticos**:\n   - Importancia de etiquetas claras y sin ambig\u00fcedades.\n   - Uso de colores para indicar el estado de los productos (cuarentena, aceptado, rechazado, limpio).\n   - Informaci\u00f3n m\u00ednima requerida en las etiquetas seg\u00fan la legislaci\u00f3n nacional, que incluye:\n     - Nombre del producto.\n     - Lista de ingredientes activos y cantidades.\n     - N\u00famero de lote.\n     - Fecha de caducidad.\n     - Condiciones de almacenamiento y precauciones.\n     - Instrucciones de uso y advertencias.\n     - Informaci\u00f3n del fabricante.\n\n2. **Est\u00e1ndares de referencia**:\n   - Etiquetas deben incluir potencia o concentraci\u00f3n, fechas relevantes (fabricaci\u00f3n, caducidad, apertura), condiciones de almacenamiento y n\u00famero de control.\n\n3. **Especificaciones y procedimientos de prueba**:\n   - Validaci\u00f3n de procedimientos de prueba antes de su adopci\u00f3n.\n   - Especificaciones autorizadas y fechadas para materiales de inicio, intermedios, productos terminados y materiales de embalaje.\n   - Mantenimiento y revisi\u00f3n peri\u00f3dica de especificaciones para cumplir con actualizaciones de farmacopeas nacionales u otros compendios oficiales.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Control de Calidad (QC)**: Unidad responsable de la aprobaci\u00f3n y mantenimiento de especificaciones.\n- **Aseguramiento de Calidad (QA)**: Unidad que tambi\u00e9n participa en la gesti\u00f3n de especificaciones.\n- **Productos farmac\u00e9uticos**: Objetos de las regulaciones y requisitos de etiquetado y especificaciones.\n- **Legislaci\u00f3n nacional**: Marco legal que establece los requisitos de etiquetado y especificaciones.", "excerpt_keywords": "Keywords: specifications, quality control, pharmacopoeias, packaging materials, finished products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19830688-c984-47d5-9222-4f1acc29a4d0", "node_type": "4", "metadata": {"page_label": "144", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Starting and Packaging Materials\n\n15.17 Pharmacopoeias, reference standards, reference spectra and other reference materials should be available in the QC laboratory.\n\n## Specifications for Starting and Packaging Materials\n\n15.18 Specifications for starting, primary and printed packaging materials should provide, if applicable, a description of the materials, including:\n\n- (a) the designated name (if applicable, the INN) and internal code reference;\n- (b) the reference, if any, to a pharmacopoeial monograph;\n- (c) qualitative and quantitative requirements with acceptance limits.\n\nDepending on the company\u2019s practice other data may be added to the specification, such as:\n\n- (a) the supplier and the original producer of the materials;\n- (b) a specimen of printed materials;\n- (c) directions for sampling and testing, or a reference to procedures;\n- (d) storage conditions and precautions;\n- (e) the maximum period of storage before re-examination.\n\nPackaging material should conform to specifications, and should be compatible with the material and/or with the medicines product it contains.\n\nThe material should be examined for compliance with the specification, and for defects as well as for the correctness of identity markings.\n\n15.19 Documents describing testing procedures should state the required frequency for re-assaying each starting material, as determined by its stability.\n\n## Specifications for Intermediate and Bulk Products\n\n15.20 Specifications for intermediate and bulk products should be available. The specifications should be similar to specifications for starting materials or for finished products, as appropriate.\n\n## Specifications for Finished Products\n\n15.21 Specifications for finished products should include:\n\n- (a) the designated name of the product and the code reference, where applicable;\n- (b) the designated name(s) of the active ingredient(s) (if applicable, with the INN(s));\n- (c) the formula or a reference to the formula;\n- (d) a description of the dosage form and package details;\n- (e) directions for sampling and testing or a reference to procedures;\n- (f) the qualitative and quantitative requirements, with acceptance limits;\n- (g) the storage conditions and precautions, where applicable;\n- (h) the shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e0dce4f91e2db30197b1dd42d4c8ffc918aeeeffc405e756ce1b0cce6b474c2c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Specifications for Starting and Packaging Materials\n\n15.17 Pharmacopoeias, reference standards, reference spectra and other reference materials should be available in the QC laboratory.\n\n## Specifications for Starting and Packaging Materials\n\n15.18 Specifications for starting, primary and printed packaging materials should provide, if applicable, a description of the materials, including:\n\n- (a) the designated name (if applicable, the INN) and internal code reference;\n- (b) the reference, if any, to a pharmacopoeial monograph;\n- (c) qualitative and quantitative requirements with acceptance limits.\n\nDepending on the company\u2019s practice other data may be added to the specification, such as:\n\n- (a) the supplier and the original producer of the materials;\n- (b) a specimen of printed materials;\n- (c) directions for sampling and testing, or a reference to procedures;\n- (d) storage conditions and precautions;\n- (e) the maximum period of storage before re-examination.\n\nPackaging material should conform to specifications, and should be compatible with the material and/or with the medicines product it contains.\n\nThe material should be examined for compliance with the specification, and for defects as well as for the correctness of identity markings.\n\n15.19 Documents describing testing procedures should state the required frequency for re-assaying each starting material, as determined by its stability.\n\n## Specifications for Intermediate and Bulk Products\n\n15.20 Specifications for intermediate and bulk products should be available. The specifications should be similar to specifications for starting materials or for finished products, as appropriate.\n\n## Specifications for Finished Products\n\n15.21 Specifications for finished products should include:\n\n- (a) the designated name of the product and the code reference, where applicable;\n- (b) the designated name(s) of the active ingredient(s) (if applicable, with the INN(s));\n- (c) the formula or a reference to the formula;\n- (d) a description of the dosage form and package details;\n- (e) directions for sampling and testing or a reference to procedures;\n- (f) the qualitative and quantitative requirements, with acceptance limits;\n- (g) the storage conditions and precautions, where applicable;\n- (h) the shelf-life.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2287, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0ffffb41-24dd-474a-bd4e-75371b2690fb": {"__data__": {"id_": "0ffffb41-24dd-474a-bd4e-75371b2690fb", "embedding": null, "metadata": {"page_label": "145", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Master formulae\n\n15.22 A formally authorized master formula should exist for each product and batch size to be manufactured.\n\n15.23 The master formula should include:\n\n(a) the name of the product, with a product reference code relating to its specification;\n\n(b) a description of the dosage form, strength of the product and batch size;\n\n(c) a list of all starting materials to be used (if applicable, with the INNs), with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing);\n\n(d) a statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable;\n\n(e) a statement of the processing location and the principal equipment to be used;\n\n(f) the methods, or reference to the methods, to be used for preparing and operating the critical equipment, e.g. cleaning (especially after a change in product), assembling, calibrating, sterilizing, use;\n\n(g) detailed step-wise processing instructions (e.g. checks on materials, pretreatments, sequence for adding materials, mixing times, temperatures);\n\n(h) the instructions for any in-process controls with their limits;\n\n(i) where necessary, the requirements for storage of the products, including the container, the labelling, and any special storage conditions;\n\n(j) any special precautions to be observed.\n\n# Packaging instructions\n\n15.24 Formally authorized packaging instructions should exist for each product, pack size and type. These should normally include, or make reference to:\n\n(a) the name of the product;\n\n(b) a description of its pharmaceutical form, strength and, where applicable, method of application;\n\n(c) the pack size expressed in terms of the number, weight or volume of the product in the final container;\n\n(d) a complete list of all the packaging materials required for a standard batch size, including quantities, sizes and types, with the code or reference number relating to the specifications for each packaging material;\n\n(e) where appropriate, an example or reproduction of the relevant printed packaging materials and specimens, indicating where the batch number and expiry date of the product have been marked;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con res\u00famenes de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la elaboraci\u00f3n de f\u00f3rmulas maestras y las instrucciones de empaque para productos farmac\u00e9uticos. Se enfatiza la importancia de tener una f\u00f3rmula maestra autorizada para cada producto y tama\u00f1o de lote, que incluya detalles sobre los ingredientes, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento. Asimismo, se requiere que existan instrucciones de empaque formalmente autorizadas que detallen los materiales y el etiquetado necesarios.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la f\u00f3rmula maestra de un producto farmac\u00e9utico seg\u00fan las directrices de la OMS?**\n   - La f\u00f3rmula maestra debe incluir el nombre del producto, una descripci\u00f3n de la forma de dosificaci\u00f3n, la lista de materiales iniciales, el rendimiento final esperado, la ubicaci\u00f3n del procesamiento, los m\u00e9todos de operaci\u00f3n del equipo cr\u00edtico, instrucciones de procesamiento detalladas, controles en proceso, requisitos de almacenamiento y precauciones especiales.\n\n2. **\u00bfCu\u00e1les son los elementos esenciales que deben estar presentes en las instrucciones de empaque para un producto farmac\u00e9utico?**\n   - Las instrucciones de empaque deben incluir el nombre del producto, una descripci\u00f3n de su forma farmac\u00e9utica y m\u00e9todo de aplicaci\u00f3n, el tama\u00f1o del paquete, una lista completa de los materiales de empaque requeridos y, si es necesario, ejemplos de los materiales impresos que indiquen el n\u00famero de lote y la fecha de caducidad.\n\n3. **\u00bfPor qu\u00e9 es importante mencionar cualquier sustancia que pueda desaparecer durante el procesamiento en la f\u00f3rmula maestra?**\n   - Es crucial mencionar estas sustancias para asegurar que se tenga en cuenta su posible p\u00e9rdida durante el proceso de fabricaci\u00f3n, lo que puede afectar el rendimiento final del producto y su conformidad con las especificaciones establecidas. Esto ayuda a garantizar la calidad y la eficacia del producto farmac\u00e9utico final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Materiales de Referencia en el Laboratorio de Control de Calidad (QC)**:\n   - Importancia de tener farmacopoeias, est\u00e1ndares de referencia, espectros de referencia y otros materiales de referencia disponibles.\n\n2. **Especificaciones para Materiales de Inicio y Embalaje**:\n   - Descripci\u00f3n de materiales, incluyendo nombre designado, referencia a monograf\u00edas farmacopoeiales, y requisitos cualitativos y cuantitativos.\n   - Datos adicionales que pueden incluirse: proveedor, productor original, muestra de materiales impresos, direcciones para muestreo y pruebas, condiciones de almacenamiento, y per\u00edodo m\u00e1ximo de almacenamiento antes de re-examinaci\u00f3n.\n\n3. **Cumplimiento y Compatibilidad**:\n   - Los materiales de embalaje deben cumplir con las especificaciones y ser compatibles con el producto medicinal que contienen.\n   - Examen de los materiales para verificar conformidad, defectos y marcas de identidad.\n\n4. **Frecuencia de Rean\u00e1lisis**:\n   - Documentos de procedimientos de prueba deben indicar la frecuencia requerida para el rean\u00e1lisis de cada material de inicio, basado en su estabilidad.\n\n5. **Especificaciones para Productos Intermedios y a Granel**:\n   - Disponibilidad de especificaciones que sean similares a las de los materiales de inicio o productos terminados, seg\u00fan corresponda.\n\n6. **Especificaciones para Productos Terminados**:\n   - Informaci\u00f3n que debe incluirse: nombre designado del producto, nombre(s) de ingredientes activos, f\u00f3rmula, descripci\u00f3n de la forma de dosificaci\u00f3n y detalles del paquete, direcciones para muestreo y pruebas, requisitos cualitativos y cuantitativos, condiciones de almacenamiento, y vida \u00fatil.\n\n### Entidades Clave:\n- **Laboratorio de Control de Calidad (QC)**\n- **Materiales de Inicio**\n- **Materiales de Embalaje**\n- **Productos Intermedios**\n- **Productos a Granel**\n- **Productos Terminados**\n- **Farmacopoeias**\n- **Est\u00e1ndares de Referencia**\n- **Espectros de Referencia**\n- **Ingredientes Activos**\n- **INN (Nombre Com\u00fan Internacional)**\n\nEste resumen destaca la importancia de las especificaciones y el cumplimiento en la fabricaci\u00f3n farmac\u00e9utica, asegurando la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: master formula, packaging instructions, pharmaceutical products, quality control, manufacturing specifications"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7ee095bb-b29a-4577-9a56-522eade188df", "node_type": "4", "metadata": {"page_label": "145", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Master formulae\n\n15.22 A formally authorized master formula should exist for each product and batch size to be manufactured.\n\n15.23 The master formula should include:\n\n(a) the name of the product, with a product reference code relating to its specification;\n\n(b) a description of the dosage form, strength of the product and batch size;\n\n(c) a list of all starting materials to be used (if applicable, with the INNs), with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing);\n\n(d) a statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable;\n\n(e) a statement of the processing location and the principal equipment to be used;\n\n(f) the methods, or reference to the methods, to be used for preparing and operating the critical equipment, e.g. cleaning (especially after a change in product), assembling, calibrating, sterilizing, use;\n\n(g) detailed step-wise processing instructions (e.g. checks on materials, pretreatments, sequence for adding materials, mixing times, temperatures);\n\n(h) the instructions for any in-process controls with their limits;\n\n(i) where necessary, the requirements for storage of the products, including the container, the labelling, and any special storage conditions;\n\n(j) any special precautions to be observed.\n\n# Packaging instructions\n\n15.24 Formally authorized packaging instructions should exist for each product, pack size and type. These should normally include, or make reference to:\n\n(a) the name of the product;\n\n(b) a description of its pharmaceutical form, strength and, where applicable, method of application;\n\n(c) the pack size expressed in terms of the number, weight or volume of the product in the final container;\n\n(d) a complete list of all the packaging materials required for a standard batch size, including quantities, sizes and types, with the code or reference number relating to the specifications for each packaging material;\n\n(e) where appropriate, an example or reproduction of the relevant printed packaging materials and specimens, indicating where the batch number and expiry date of the product have been marked;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3c57b86e1de3896942ec64ca553215fc70f1d372c704d7fdbc0252d8aa4842bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Master formulae\n\n15.22 A formally authorized master formula should exist for each product and batch size to be manufactured.\n\n15.23 The master formula should include:\n\n(a) the name of the product, with a product reference code relating to its specification;\n\n(b) a description of the dosage form, strength of the product and batch size;\n\n(c) a list of all starting materials to be used (if applicable, with the INNs), with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing);\n\n(d) a statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable;\n\n(e) a statement of the processing location and the principal equipment to be used;\n\n(f) the methods, or reference to the methods, to be used for preparing and operating the critical equipment, e.g. cleaning (especially after a change in product), assembling, calibrating, sterilizing, use;\n\n(g) detailed step-wise processing instructions (e.g. checks on materials, pretreatments, sequence for adding materials, mixing times, temperatures);\n\n(h) the instructions for any in-process controls with their limits;\n\n(i) where necessary, the requirements for storage of the products, including the container, the labelling, and any special storage conditions;\n\n(j) any special precautions to be observed.\n\n# Packaging instructions\n\n15.24 Formally authorized packaging instructions should exist for each product, pack size and type. These should normally include, or make reference to:\n\n(a) the name of the product;\n\n(b) a description of its pharmaceutical form, strength and, where applicable, method of application;\n\n(c) the pack size expressed in terms of the number, weight or volume of the product in the final container;\n\n(d) a complete list of all the packaging materials required for a standard batch size, including quantities, sizes and types, with the code or reference number relating to the specifications for each packaging material;\n\n(e) where appropriate, an example or reproduction of the relevant printed packaging materials and specimens, indicating where the batch number and expiry date of the product have been marked;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2280, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a01450-5853-4f1d-bf27-6ced91adb5a9": {"__data__": {"id_": "c2a01450-5853-4f1d-bf27-6ced91adb5a9", "embedding": null, "metadata": {"page_label": "146", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(f) special precautions to be observed, including a careful examination of the packaging area and equipment in order to ascertain the line clearance before and after packaging operations;\n\n(g) a description of the packaging operation, including any significant subsidiary operations, and equipment to be used;\n\n(h) details of in-process controls with instructions for sampling and acceptance limits.\n\n## Batch processing records\n\n15.25 A batch processing record should be kept for each batch processed. It should be based on the relevant parts of the currently approved specifications on the record. The method of preparation of such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.26 Before any processing begins, a check should be made that the equipment and work station are clear of previous products, documents, or materials not required for the planned process, and that the equipment is clean and suitable for use. This check should be recorded.\n\n15.27 During processing, the following information should be recorded at the time each action is taken, and after completion the record should be dated and signed by the person responsible for the processing operations:\n\n(a) the name of the product;\n\n(b) the number of the batch being manufactured;\n\n(c) dates and times of commencement, of significant intermediate stages, and of completion of production;\n\n(d) the name of the person responsible for each stage of production;\n\n(e) the initials of the operator(s) of different significant steps of production and, where appropriate, of the person(s) who checked each of these operations (e.g. weighing);\n\n(f) the batch number and/or analytical control number and the quantity of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added);\n\n(g) any relevant processing operation or event and the major equipment used;\n\n(h) the in-process controls performed, the initials of the person(s) carrying them out, and the results obtained;\n\n(i) the amount of product obtained at different and pertinent stages of manufacture (yield), together with comments or explanations for significant deviations from the expected yield;\n\n(j) notes on special problems including details, with signed authorization for any deviation from the master formula.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proviene del \"WHO - Technical Report Series 961\" y se centra en los procedimientos de registro y control durante el procesamiento de lotes en la producci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de mantener registros precisos y detallados para cada lote, asegurando que se sigan las especificaciones aprobadas y que se realicen controles en proceso. Se describen las precauciones especiales que deben observarse antes y despu\u00e9s de las operaciones de envasado, as\u00ed como la informaci\u00f3n que debe registrarse durante el procesamiento, incluyendo detalles sobre el producto, el lote, los operadores, y cualquier desviaci\u00f3n de los procedimientos est\u00e1ndar.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe registrarse antes de comenzar el procesamiento de un lote y por qu\u00e9 es importante este registro?**\n   - Respuesta: Antes de comenzar el procesamiento, se debe registrar que el equipo y el \u00e1rea de trabajo est\u00e1n libres de productos, documentos o materiales no requeridos, y que el equipo est\u00e1 limpio y adecuado para su uso. Este registro es importante para garantizar que no haya contaminaci\u00f3n cruzada y que el proceso se realice en condiciones \u00f3ptimas.\n\n2. **\u00bfCu\u00e1les son las consecuencias de no seguir las recomendaciones sobre la preparaci\u00f3n de registros de procesamiento de lotes?**\n   - Respuesta: No seguir las recomendaciones puede llevar a errores en la documentaci\u00f3n, lo que podr\u00eda resultar en problemas de calidad del producto, incumplimiento de regulaciones, y potencialmente en la retirada de productos del mercado. Adem\u00e1s, podr\u00eda dificultar la trazabilidad y la identificaci\u00f3n de problemas en el proceso de producci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de autorizaciones son necesarias en caso de desviaciones del procedimiento est\u00e1ndar durante el procesamiento de un lote?**\n   - Respuesta: En caso de desviaciones del procedimiento est\u00e1ndar, se deben incluir notas sobre problemas especiales, junto con detalles y la autorizaci\u00f3n firmada para cualquier desviaci\u00f3n de la f\u00f3rmula maestra. Esto asegura que cualquier cambio est\u00e9 documentado y aprobado por la persona responsable, manteniendo la integridad del proceso de producci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices para el registro y control de procesos en la producci\u00f3n farmac\u00e9utica, subrayando la importancia de la documentaci\u00f3n precisa y la limpieza del equipo. Se detallan los requisitos para los registros de procesamiento de lotes, incluyendo la informaci\u00f3n que debe ser recopilada y las precauciones que deben tomarse para asegurar la calidad y la conformidad del producto final.", "prev_section_summary": "### Temas Clave:\n\n1. **F\u00f3rmula Maestra**: La secci\u00f3n establece la necesidad de una f\u00f3rmula maestra formalmente autorizada para cada producto y tama\u00f1o de lote. Esta f\u00f3rmula debe contener informaci\u00f3n detallada sobre el producto, los materiales iniciales, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento.\n\n2. **Instrucciones de Empaque**: Se requiere que existan instrucciones de empaque autorizadas que especifiquen los materiales de empaque, el etiquetado y otros detalles relevantes para cada producto.\n\n3. **Control de Calidad**: Se enfatiza la importancia de los controles en proceso y las precauciones especiales para garantizar la calidad y la eficacia del producto final.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **F\u00f3rmula Maestra**: Documento que detalla la fabricaci\u00f3n de un producto farmac\u00e9utico.\n- **Materiales Iniciales**: Ingredientes utilizados en la producci\u00f3n del producto.\n- **Instrucciones de Empaque**: Directrices sobre c\u00f3mo empaquetar el producto farmac\u00e9utico.\n- **Producto Farmac\u00e9utico**: El resultado final que se fabrica y empaqueta.\n- **Lote**: Cantidad espec\u00edfica de producto fabricado en un proceso de producci\u00f3n.\n\n### Resumen:\n\nEl documento de la OMS establece directrices sobre la creaci\u00f3n de f\u00f3rmulas maestras y las instrucciones de empaque para productos farmac\u00e9uticos. Se requiere que cada producto tenga una f\u00f3rmula maestra autorizada que incluya detalles sobre el nombre del producto, la forma de dosificaci\u00f3n, los materiales iniciales, el rendimiento esperado, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento. Adem\u00e1s, las instrucciones de empaque deben detallar el nombre del producto, su forma farmac\u00e9utica, el tama\u00f1o del paquete y los materiales de empaque necesarios. Estas directrices son fundamentales para asegurar la calidad y la conformidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: batch processing, quality control, pharmaceutical production, documentation, in-process controls"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2fc10379-e88d-4215-aa3b-b2cb0870dc2a", "node_type": "4", "metadata": {"page_label": "146", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(f) special precautions to be observed, including a careful examination of the packaging area and equipment in order to ascertain the line clearance before and after packaging operations;\n\n(g) a description of the packaging operation, including any significant subsidiary operations, and equipment to be used;\n\n(h) details of in-process controls with instructions for sampling and acceptance limits.\n\n## Batch processing records\n\n15.25 A batch processing record should be kept for each batch processed. It should be based on the relevant parts of the currently approved specifications on the record. The method of preparation of such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.26 Before any processing begins, a check should be made that the equipment and work station are clear of previous products, documents, or materials not required for the planned process, and that the equipment is clean and suitable for use. This check should be recorded.\n\n15.27 During processing, the following information should be recorded at the time each action is taken, and after completion the record should be dated and signed by the person responsible for the processing operations:\n\n(a) the name of the product;\n\n(b) the number of the batch being manufactured;\n\n(c) dates and times of commencement, of significant intermediate stages, and of completion of production;\n\n(d) the name of the person responsible for each stage of production;\n\n(e) the initials of the operator(s) of different significant steps of production and, where appropriate, of the person(s) who checked each of these operations (e.g. weighing);\n\n(f) the batch number and/or analytical control number and the quantity of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added);\n\n(g) any relevant processing operation or event and the major equipment used;\n\n(h) the in-process controls performed, the initials of the person(s) carrying them out, and the results obtained;\n\n(i) the amount of product obtained at different and pertinent stages of manufacture (yield), together with comments or explanations for significant deviations from the expected yield;\n\n(j) notes on special problems including details, with signed authorization for any deviation from the master formula.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "38e9906779910ac26e2b62e9e0435285d4a96b00dcf98ea6ed72c120d93be300", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(f) special precautions to be observed, including a careful examination of the packaging area and equipment in order to ascertain the line clearance before and after packaging operations;\n\n(g) a description of the packaging operation, including any significant subsidiary operations, and equipment to be used;\n\n(h) details of in-process controls with instructions for sampling and acceptance limits.\n\n## Batch processing records\n\n15.25 A batch processing record should be kept for each batch processed. It should be based on the relevant parts of the currently approved specifications on the record. The method of preparation of such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.26 Before any processing begins, a check should be made that the equipment and work station are clear of previous products, documents, or materials not required for the planned process, and that the equipment is clean and suitable for use. This check should be recorded.\n\n15.27 During processing, the following information should be recorded at the time each action is taken, and after completion the record should be dated and signed by the person responsible for the processing operations:\n\n(a) the name of the product;\n\n(b) the number of the batch being manufactured;\n\n(c) dates and times of commencement, of significant intermediate stages, and of completion of production;\n\n(d) the name of the person responsible for each stage of production;\n\n(e) the initials of the operator(s) of different significant steps of production and, where appropriate, of the person(s) who checked each of these operations (e.g. weighing);\n\n(f) the batch number and/or analytical control number and the quantity of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added);\n\n(g) any relevant processing operation or event and the major equipment used;\n\n(h) the in-process controls performed, the initials of the person(s) carrying them out, and the results obtained;\n\n(i) the amount of product obtained at different and pertinent stages of manufacture (yield), together with comments or explanations for significant deviations from the expected yield;\n\n(j) notes on special problems including details, with signed authorization for any deviation from the master formula.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2422, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "144d48d2-1dcf-4e8f-895c-68db421f2c56": {"__data__": {"id_": "144d48d2-1dcf-4e8f-895c-68db421f2c56", "embedding": null, "metadata": {"page_label": "147", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Batch Packaging Records\n\n15.28 A batch packaging record should be kept for each batch or part batch processed. It should be based on the relevant parts of the approved packaging instructions, and the method of preparing such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.29 Before any packaging operation begins, checks should be made that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations, and that equipment is clean and suitable for use. These checks should be recorded.\n\n15.30 The following information should be recorded at the time each action is taken, and the date and the person responsible should be clearly identified by signature or electronic password:\n\n(a) the name of the product, the batch number and the quantity of bulk product to be packed, as well as the batch number and the planned quantity of finished product that will be obtained, the quantity actually obtained and the reconciliation;\n\n(b) the date(s) and time(s) of the packaging operations;\n\n(c) the name of the responsible person carrying out the packaging operation;\n\n(d) the initials of the operators of the different significant steps;\n\n(e) the checks made for identity and conformity with the packaging instructions, including the results of in-process controls;\n\n(f) details of the packaging operations carried out, including references to equipment and the packaging lines used, and, when necessary, the instructions for keeping the product unpacked or a record of returning product that has not been packaged to the storage area;\n\n(g) whenever possible, samples of the printed packaging materials used, including specimens bearing the approval for the printing of and regular check (where appropriate) of the batch number, expiry date, and any additional overprinting;\n\n(h) notes on any special problems, including details of any deviation from the packaging instructions, with written authorization by an appropriate person;\n\n(i) the quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of product obtained to permit an adequate reconciliation.\n\n# Standard Operating Procedures and Records\n\n15.31 SOPs and associated records of actions taken or, where appropriate, conclusions reached should be available for:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre la creaci\u00f3n y mantenimiento de registros de empaquetado de lotes en el contexto de la producci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de seguir las instrucciones de empaquetado aprobadas y de registrar informaci\u00f3n cr\u00edtica durante el proceso de empaquetado para garantizar la trazabilidad y la conformidad. Se detallan los elementos espec\u00edficos que deben ser documentados, como el nombre del producto, el n\u00famero de lote, las cantidades, las fechas y los responsables, as\u00ed como cualquier problema especial que surja durante el proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluirse en un registro de empaquetado de lotes y por qu\u00e9 es importante cada uno de estos elementos?**\n   - Esta pregunta busca una explicaci\u00f3n detallada de cada elemento requerido en el registro y su relevancia para la calidad y la trazabilidad del producto.\n\n2. **\u00bfCu\u00e1les son las consecuencias de no seguir las directrices establecidas para la creaci\u00f3n de registros de empaquetado de lotes?**\n   - Esta pregunta se centra en las implicaciones legales, de calidad y de seguridad que pueden surgir si no se cumplen las normativas descritas.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si se identifica una desviaci\u00f3n de las instrucciones de empaquetado durante el proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre los pasos espec\u00edficos que deben tomarse en caso de desviaciones, incluyendo la documentaci\u00f3n y la autorizaci\u00f3n necesaria.\n\n### Resumen de Nivel Superior\n\nEl documento establece normas claras para la documentaci\u00f3n y el control de los procesos de empaquetado en la industria farmac\u00e9utica, subrayando la importancia de la precisi\u00f3n y la conformidad con las instrucciones aprobadas. Se requiere que se mantengan registros detallados para cada lote, lo que ayuda a garantizar la calidad del producto y la seguridad del consumidor. Adem\u00e1s, se enfatiza la necesidad de procedimientos operativos est\u00e1ndar (SOP) y registros asociados para asegurar que todas las acciones y decisiones sean trazables y verificables.", "prev_section_summary": "### Temas Clave\n\n1. **Precauciones Especiales en el Envasado**: Se enfatiza la necesidad de examinar cuidadosamente el \u00e1rea de envasado y el equipo para asegurar la limpieza de la l\u00ednea antes y despu\u00e9s de las operaciones de envasado.\n\n2. **Registros de Procesamiento de Lotes**: Se requiere mantener un registro detallado para cada lote procesado, basado en especificaciones aprobadas, con un enfoque en evitar errores en la documentaci\u00f3n.\n\n3. **Verificaci\u00f3n Previa al Procesamiento**: Antes de iniciar el procesamiento, es crucial verificar que el equipo y el \u00e1rea de trabajo est\u00e9n libres de materiales no requeridos y que el equipo est\u00e9 limpio y adecuado para su uso.\n\n4. **Documentaci\u00f3n Durante el Procesamiento**: Se debe registrar informaci\u00f3n clave durante el procesamiento, incluyendo el nombre del producto, n\u00famero de lote, fechas y horas de producci\u00f3n, responsables de cada etapa, y resultados de controles en proceso.\n\n5. **Autorizaciones para Desviaciones**: Cualquier desviaci\u00f3n del procedimiento est\u00e1ndar debe ser documentada y autorizada, asegurando que se mantenga la integridad del proceso de producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: WHO - Technical Report Series 961\n- **Secci\u00f3n**: Registros de procesamiento de lotes\n- **Elementos de Registro**: Nombre del producto, n\u00famero de lote, fechas y horas, responsables, iniciales de operadores, n\u00famero de control anal\u00edtico, cantidad de materiales, operaciones relevantes, controles en proceso, rendimiento del producto, notas sobre problemas especiales.\n- **Recomendaciones**: Uso de programas inform\u00e1ticos validados para la preparaci\u00f3n de registros, evitar la transcripci\u00f3n de documentos aprobados. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y la conformidad del producto final.", "excerpt_keywords": "Keywords: batch packaging records, pharmaceutical production, documentation, standard operating procedures, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7650e8ea-75db-4b65-b8b2-c0840e94899f", "node_type": "4", "metadata": {"page_label": "147", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Batch Packaging Records\n\n15.28 A batch packaging record should be kept for each batch or part batch processed. It should be based on the relevant parts of the approved packaging instructions, and the method of preparing such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.29 Before any packaging operation begins, checks should be made that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations, and that equipment is clean and suitable for use. These checks should be recorded.\n\n15.30 The following information should be recorded at the time each action is taken, and the date and the person responsible should be clearly identified by signature or electronic password:\n\n(a) the name of the product, the batch number and the quantity of bulk product to be packed, as well as the batch number and the planned quantity of finished product that will be obtained, the quantity actually obtained and the reconciliation;\n\n(b) the date(s) and time(s) of the packaging operations;\n\n(c) the name of the responsible person carrying out the packaging operation;\n\n(d) the initials of the operators of the different significant steps;\n\n(e) the checks made for identity and conformity with the packaging instructions, including the results of in-process controls;\n\n(f) details of the packaging operations carried out, including references to equipment and the packaging lines used, and, when necessary, the instructions for keeping the product unpacked or a record of returning product that has not been packaged to the storage area;\n\n(g) whenever possible, samples of the printed packaging materials used, including specimens bearing the approval for the printing of and regular check (where appropriate) of the batch number, expiry date, and any additional overprinting;\n\n(h) notes on any special problems, including details of any deviation from the packaging instructions, with written authorization by an appropriate person;\n\n(i) the quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of product obtained to permit an adequate reconciliation.\n\n# Standard Operating Procedures and Records\n\n15.31 SOPs and associated records of actions taken or, where appropriate, conclusions reached should be available for:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dcff9d25df27e2da107bc6dd6c990311979054716be8228c64fd43e5b1934c9b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Batch Packaging Records\n\n15.28 A batch packaging record should be kept for each batch or part batch processed. It should be based on the relevant parts of the approved packaging instructions, and the method of preparing such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.29 Before any packaging operation begins, checks should be made that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations, and that equipment is clean and suitable for use. These checks should be recorded.\n\n15.30 The following information should be recorded at the time each action is taken, and the date and the person responsible should be clearly identified by signature or electronic password:\n\n(a) the name of the product, the batch number and the quantity of bulk product to be packed, as well as the batch number and the planned quantity of finished product that will be obtained, the quantity actually obtained and the reconciliation;\n\n(b) the date(s) and time(s) of the packaging operations;\n\n(c) the name of the responsible person carrying out the packaging operation;\n\n(d) the initials of the operators of the different significant steps;\n\n(e) the checks made for identity and conformity with the packaging instructions, including the results of in-process controls;\n\n(f) details of the packaging operations carried out, including references to equipment and the packaging lines used, and, when necessary, the instructions for keeping the product unpacked or a record of returning product that has not been packaged to the storage area;\n\n(g) whenever possible, samples of the printed packaging materials used, including specimens bearing the approval for the printing of and regular check (where appropriate) of the batch number, expiry date, and any additional overprinting;\n\n(h) notes on any special problems, including details of any deviation from the packaging instructions, with written authorization by an appropriate person;\n\n(i) the quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of product obtained to permit an adequate reconciliation.\n\n# Standard Operating Procedures and Records\n\n15.31 SOPs and associated records of actions taken or, where appropriate, conclusions reached should be available for:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2515, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f1fe2044-1745-4137-8d35-a67cf31d4db1": {"__data__": {"id_": "f1fe2044-1745-4137-8d35-a67cf31d4db1", "embedding": null, "metadata": {"page_label": "148", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) equipment assembly and validation;  \n(b) analytical apparatus and calibration;  \n(c) maintenance, cleaning and sanitization;  \n(d) personnel matters including qualification, training, clothing and hygiene;  \n(e) environmental monitoring;  \n(f) pest control;  \n(g) complaints;  \n(h) recalls;  \n(i) returns.  \n\n15.32 There should be SOPs and records for the receipt of each delivery of starting material and primary and printed packaging material.\n\n15.33 The records of the receipts should include:\n\n(a) the name of the material on the delivery note and the containers;  \n(b) the \u201cin-house\u201d name and/or code of material if different from (a);  \n(c) the date of receipt;  \n(d) the supplier\u2019s name and, if possible, manufacturer\u2019s name;  \n(e) the manufacturer\u2019s batch or reference number;  \n(f) the total quantity, and number of containers received;  \n(g) the batch number assigned after receipt;  \n(h) any relevant comment (e.g. state of the containers).\n\n15.34 There should be SOPs for the internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate.\n\n15.35 SOPs should be available for each instrument and piece of equipment (e.g. use, calibration, cleaning, maintenance) and placed in close proximity to the equipment.\n\n15.36 There should be SOPs for sampling, which specify the person(s) authorized to take samples.\n\n15.37 The sampling instructions should include:\n\n(a) the method of sampling and the sampling plan;  \n(b) the equipment to be used;  \n(c) any precautions to be observed to avoid contamination of the material or any deterioration in its quality;  \n(d) the amount(s) of sample(s) to be taken;  \n(e) instructions for any required subdivision of the sample;  \n(f) the type of sample container(s) to be used, and whether they are for aseptic sampling or for normal sampling, and labelling;  \n(g) any specific precautions to be observed, especially in regard to the sampling of sterile or noxious material.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOPs)**: El documento enfatiza la importancia de contar con SOPs para diversas actividades relacionadas con la recepci\u00f3n, almacenamiento, muestreo y manejo de materiales en un entorno regulado. Esto incluye la validaci\u00f3n de equipos, calibraci\u00f3n de aparatos anal\u00edticos, mantenimiento y limpieza, as\u00ed como la formaci\u00f3n y calificaci\u00f3n del personal.\n\n2. **Registros de Recepci\u00f3n**: Se detalla la necesidad de mantener registros precisos de la recepci\u00f3n de materiales, que deben incluir informaci\u00f3n espec\u00edfica sobre el proveedor, el material recibido y su estado. Esto es crucial para asegurar la trazabilidad y la calidad de los materiales utilizados en la producci\u00f3n.\n\n3. **Muestreo y Precauciones**: Se subraya la importancia de tener instrucciones claras para el muestreo, incluyendo m\u00e9todos, equipos y precauciones necesarias para evitar la contaminaci\u00f3n y asegurar la calidad del material muestreado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de recepci\u00f3n de materiales seg\u00fan el documento?**\n   - Respuesta: Los registros de recepci\u00f3n deben incluir el nombre del material, el nombre \"in-house\" o c\u00f3digo, la fecha de recepci\u00f3n, el nombre del proveedor y, si es posible, del fabricante, el n\u00famero de lote o referencia del fabricante, la cantidad total y el n\u00famero de contenedores recibidos, el n\u00famero de lote asignado despu\u00e9s de la recepci\u00f3n y cualquier comentario relevante sobre el estado de los contenedores.\n\n2. **\u00bfCu\u00e1les son las precauciones que deben observarse durante el muestreo de materiales, especialmente en el caso de materiales est\u00e9riles o nocivos?**\n   - Respuesta: Las instrucciones de muestreo deben incluir precauciones para evitar la contaminaci\u00f3n del material y cualquier deterioro en su calidad, as\u00ed como especificaciones sobre el tipo de contenedor de muestra a utilizar y las precauciones espec\u00edficas a observar en el muestreo de materiales est\u00e9riles o nocivos.\n\n3. **\u00bfPor qu\u00e9 es importante que los SOPs est\u00e9n disponibles y ubicados cerca de cada instrumento y equipo?**\n   - Respuesta: Es importante que los SOPs est\u00e9n disponibles y ubicados cerca de cada instrumento y equipo para garantizar que el personal tenga acceso inmediato a las instrucciones necesarias para el uso, calibraci\u00f3n, limpieza y mantenimiento, lo que ayuda a asegurar la correcta operaci\u00f3n y la calidad de los procesos.", "prev_section_summary": "### Temas Clave\n\n1. **Registros de Empaquetado de Lotes**: Se requiere mantener un registro para cada lote o parte de lote procesado, basado en instrucciones de empaquetado aprobadas.\n\n2. **Prevenci\u00f3n de Errores**: La preparaci\u00f3n de registros debe dise\u00f1arse para evitar errores, recomend\u00e1ndose el uso de programas inform\u00e1ticos validados en lugar de la transcripci\u00f3n manual.\n\n3. **Verificaci\u00f3n Previa al Empaque**: Antes de iniciar las operaciones de empaquetado, se deben realizar verificaciones para asegurar que el equipo y el \u00e1rea de trabajo est\u00e9n limpios y libres de materiales no necesarios.\n\n4. **Informaci\u00f3n a Registrar**: Se debe documentar informaci\u00f3n cr\u00edtica durante el proceso de empaquetado, incluyendo:\n   - Nombre del producto y n\u00famero de lote.\n   - Cantidades de producto a empaquetar y obtenidas.\n   - Fechas y horas de las operaciones.\n   - Identificaci\u00f3n de la persona responsable y operadores.\n   - Resultados de controles en proceso.\n   - Detalles de las operaciones de empaquetado.\n   - Muestras de materiales de empaquetado impresos.\n   - Notas sobre problemas especiales y desviaciones.\n   - Cantidades y referencias de materiales impresos utilizados.\n\n5. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Se enfatiza la importancia de tener SOPs y registros asociados para asegurar la trazabilidad y la verificaci\u00f3n de acciones y decisiones.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS).\n- **Documentos**: Instrucciones de empaquetado aprobadas, registros de empaquetado de lotes, SOPs.\n- **Elementos de Registro**: Nombre del producto, n\u00famero de lote, cantidades, fechas, responsables, resultados de controles, materiales de empaquetado.\n- **Acciones**: Verificaciones, documentaci\u00f3n de problemas, autorizaci\u00f3n de desviaciones.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control en el proceso de empaquetado en la industria farmac\u00e9utica, asegurando la calidad y la seguridad del producto.", "excerpt_keywords": "Keywords: SOPs, material receipt, sampling instructions, quality control, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25989f5e-bdc0-44fc-8ef1-e5782fd460a7", "node_type": "4", "metadata": {"page_label": "148", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) equipment assembly and validation;  \n(b) analytical apparatus and calibration;  \n(c) maintenance, cleaning and sanitization;  \n(d) personnel matters including qualification, training, clothing and hygiene;  \n(e) environmental monitoring;  \n(f) pest control;  \n(g) complaints;  \n(h) recalls;  \n(i) returns.  \n\n15.32 There should be SOPs and records for the receipt of each delivery of starting material and primary and printed packaging material.\n\n15.33 The records of the receipts should include:\n\n(a) the name of the material on the delivery note and the containers;  \n(b) the \u201cin-house\u201d name and/or code of material if different from (a);  \n(c) the date of receipt;  \n(d) the supplier\u2019s name and, if possible, manufacturer\u2019s name;  \n(e) the manufacturer\u2019s batch or reference number;  \n(f) the total quantity, and number of containers received;  \n(g) the batch number assigned after receipt;  \n(h) any relevant comment (e.g. state of the containers).\n\n15.34 There should be SOPs for the internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate.\n\n15.35 SOPs should be available for each instrument and piece of equipment (e.g. use, calibration, cleaning, maintenance) and placed in close proximity to the equipment.\n\n15.36 There should be SOPs for sampling, which specify the person(s) authorized to take samples.\n\n15.37 The sampling instructions should include:\n\n(a) the method of sampling and the sampling plan;  \n(b) the equipment to be used;  \n(c) any precautions to be observed to avoid contamination of the material or any deterioration in its quality;  \n(d) the amount(s) of sample(s) to be taken;  \n(e) instructions for any required subdivision of the sample;  \n(f) the type of sample container(s) to be used, and whether they are for aseptic sampling or for normal sampling, and labelling;  \n(g) any specific precautions to be observed, especially in regard to the sampling of sterile or noxious material.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a22db98555165a7a89c28d156fd625301d5c4a1ba630ff825c66150bf1abe47d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(a) equipment assembly and validation;  \n(b) analytical apparatus and calibration;  \n(c) maintenance, cleaning and sanitization;  \n(d) personnel matters including qualification, training, clothing and hygiene;  \n(e) environmental monitoring;  \n(f) pest control;  \n(g) complaints;  \n(h) recalls;  \n(i) returns.  \n\n15.32 There should be SOPs and records for the receipt of each delivery of starting material and primary and printed packaging material.\n\n15.33 The records of the receipts should include:\n\n(a) the name of the material on the delivery note and the containers;  \n(b) the \u201cin-house\u201d name and/or code of material if different from (a);  \n(c) the date of receipt;  \n(d) the supplier\u2019s name and, if possible, manufacturer\u2019s name;  \n(e) the manufacturer\u2019s batch or reference number;  \n(f) the total quantity, and number of containers received;  \n(g) the batch number assigned after receipt;  \n(h) any relevant comment (e.g. state of the containers).\n\n15.34 There should be SOPs for the internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate.\n\n15.35 SOPs should be available for each instrument and piece of equipment (e.g. use, calibration, cleaning, maintenance) and placed in close proximity to the equipment.\n\n15.36 There should be SOPs for sampling, which specify the person(s) authorized to take samples.\n\n15.37 The sampling instructions should include:\n\n(a) the method of sampling and the sampling plan;  \n(b) the equipment to be used;  \n(c) any precautions to be observed to avoid contamination of the material or any deterioration in its quality;  \n(d) the amount(s) of sample(s) to be taken;  \n(e) instructions for any required subdivision of the sample;  \n(f) the type of sample container(s) to be used, and whether they are for aseptic sampling or for normal sampling, and labelling;  \n(g) any specific precautions to be observed, especially in regard to the sampling of sterile or noxious material.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1983, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8693c261-81af-4e3b-b385-b3bedfb45311": {"__data__": {"id_": "8693c261-81af-4e3b-b385-b3bedfb45311", "embedding": null, "metadata": {"page_label": "149", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 15.38 \nThere should be an SOP describing the details of the batch (lot) numbering system, with the objective of ensuring that each batch of intermediate, bulk or finished product is identified with a specific batch number.\n\n# 15.39 \nThe SOPs for batch numbering that are applied to the processing stage and to the respective packaging stage should be related to each other.\n\n# 15.40 \nThe SOP for batch numbering should ensure that the same batch numbers will not be used repeatedly; this applies also to reprocessing.\n\n# 15.41 \nBatch-number allocation should be immediately recorded, e.g. in a logbook. The record should include at least the date of allocation, product identity and size of batch.\n\n# 15.42 \nThere should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded.\n\n# 15.43 \nAnalysis records should include at least the following data:\n\n(a) the name of the material or product and, where applicable, dosage form;  \n(b) the batch number and, where appropriate, the manufacturer and/or supplier;  \n(c) references to the relevant specifications and testing procedures;  \n(d) test results, including observations and calculations, and reference to any specifications (limits);  \n(e) date(s) and reference number(s) of testing;  \n(f) the initials of the persons who performed the testing;  \n(g) the date and initials of the persons who verified the testing and the calculations, where appropriate;  \n(h) a clear statement of release or rejection (or other status decision) and the dated signature of the designated responsible person.\n\n# 15.44 \nWritten release and rejection procedures should be available for materials and products, and in particular for the release for sale of the finished product by an authorized person.\n\n# 15.45 \nRecords should be maintained of the distribution of each batch of a product in order, e.g. to facilitate the recall of the batch if necessary.\n\n# 15.46 \nRecords should be kept for major and critical equipment, as appropriate, of any validations, calibrations, maintenance, cleaning, or repair operations, including dates and the identity of the people who carried these operations out.\n\n# 15.47 \nThe use of major and critical equipment and the areas where products have been processed should be appropriately recorded in chronological order.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl contexto se centra en la importancia de establecer procedimientos operativos est\u00e1ndar (SOP) para el sistema de numeraci\u00f3n de lotes en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la necesidad de un registro adecuado de la asignaci\u00f3n de n\u00fameros de lote, la realizaci\u00f3n de pruebas en diferentes etapas de producci\u00f3n, y el mantenimiento de registros de an\u00e1lisis, liberaci\u00f3n y distribuci\u00f3n de productos. Tambi\u00e9n se menciona la importancia de documentar el uso y mantenimiento de equipos cr\u00edticos.\n\n### Preguntas espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluirse en el registro de asignaci\u00f3n de n\u00fameros de lote seg\u00fan el SOP?**\n   - Respuesta: El registro debe incluir al menos la fecha de asignaci\u00f3n, la identidad del producto y el tama\u00f1o del lote.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben estar presentes en los registros de an\u00e1lisis de materiales y productos?**\n   - Respuesta: Los registros de an\u00e1lisis deben incluir el nombre del material o producto, el n\u00famero de lote, referencias a especificaciones y procedimientos de prueba, resultados de pruebas, fechas y n\u00fameros de referencia de las pruebas, iniciales de los responsables de las pruebas, y una declaraci\u00f3n clara de liberaci\u00f3n o rechazo con la firma del responsable designado.\n\n3. **\u00bfQu\u00e9 procedimientos deben estar disponibles para la liberaci\u00f3n y rechazo de productos terminados?**\n   - Respuesta: Deben existir procedimientos escritos para la liberaci\u00f3n y rechazo de materiales y productos, especialmente para la liberaci\u00f3n para la venta del producto terminado por una persona autorizada.\n\n### Resumen de nivel superior\nEl documento establece directrices para asegurar la trazabilidad y la calidad en la producci\u00f3n de productos farmac\u00e9uticos mediante la implementaci\u00f3n de SOPs para la numeraci\u00f3n de lotes, pruebas de calidad y mantenimiento de registros. Se destaca la importancia de la documentaci\u00f3n en cada etapa del proceso de fabricaci\u00f3n, desde la asignaci\u00f3n de n\u00fameros de lote hasta la liberaci\u00f3n de productos, para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOPs)**:\n   - Importancia de contar con SOPs para diversas actividades en entornos regulados, incluyendo:\n     - Ensamblaje y validaci\u00f3n de equipos.\n     - Calibraci\u00f3n de aparatos anal\u00edticos.\n     - Mantenimiento, limpieza y sanitizaci\u00f3n.\n     - Formaci\u00f3n y calificaci\u00f3n del personal.\n     - Monitoreo ambiental y control de plagas.\n     - Manejo de quejas, retiradas y devoluciones.\n\n2. **Registros de Recepci\u00f3n**:\n   - Necesidad de mantener registros detallados para cada entrega de materiales iniciales y empaques.\n   - Informaci\u00f3n que debe incluirse en los registros:\n     - Nombre del material.\n     - Nombre \"in-house\" o c\u00f3digo.\n     - Fecha de recepci\u00f3n.\n     - Nombre del proveedor y, si es posible, del fabricante.\n     - N\u00famero de lote o referencia del fabricante.\n     - Cantidad total y n\u00famero de contenedores recibidos.\n     - N\u00famero de lote asignado despu\u00e9s de la recepci\u00f3n.\n     - Comentarios relevantes sobre el estado de los contenedores.\n\n3. **Muestreo y Precauciones**:\n   - Importancia de tener SOPs para el muestreo, especificando:\n     - M\u00e9todo de muestreo y plan de muestreo.\n     - Equipos a utilizar.\n     - Precauciones para evitar contaminaci\u00f3n y deterioro de la calidad del material.\n     - Cantidades de muestra a tomar y subdivisi\u00f3n de muestras.\n     - Tipo de contenedor de muestra y etiquetado.\n     - Precauciones espec\u00edficas para materiales est\u00e9riles o nocivos.\n\n4. **Accesibilidad de SOPs**:\n   - Los SOPs deben estar disponibles y ubicados cerca de cada instrumento y equipo para asegurar que el personal tenga acceso inmediato a las instrucciones necesarias para su correcto uso y mantenimiento.\n\n### Entidades Clave\n- **Materiales**: Materiales iniciales, empaques primarios y secundarios.\n- **Proveedores**: Nombres de proveedores y fabricantes.\n- **Equipos**: Instrumentos y equipos utilizados en el proceso.\n- **Personal**: Personal autorizado para el muestreo y manejo de materiales.\n- **Documentaci\u00f3n**: Registros de recepci\u00f3n y SOPs.", "excerpt_keywords": "Keywords: SOP, batch numbering, quality control, product release, traceability"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c0d94ae8-2c67-4d75-959a-e2c2734d3803", "node_type": "4", "metadata": {"page_label": "149", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 15.38 \nThere should be an SOP describing the details of the batch (lot) numbering system, with the objective of ensuring that each batch of intermediate, bulk or finished product is identified with a specific batch number.\n\n# 15.39 \nThe SOPs for batch numbering that are applied to the processing stage and to the respective packaging stage should be related to each other.\n\n# 15.40 \nThe SOP for batch numbering should ensure that the same batch numbers will not be used repeatedly; this applies also to reprocessing.\n\n# 15.41 \nBatch-number allocation should be immediately recorded, e.g. in a logbook. The record should include at least the date of allocation, product identity and size of batch.\n\n# 15.42 \nThere should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded.\n\n# 15.43 \nAnalysis records should include at least the following data:\n\n(a) the name of the material or product and, where applicable, dosage form;  \n(b) the batch number and, where appropriate, the manufacturer and/or supplier;  \n(c) references to the relevant specifications and testing procedures;  \n(d) test results, including observations and calculations, and reference to any specifications (limits);  \n(e) date(s) and reference number(s) of testing;  \n(f) the initials of the persons who performed the testing;  \n(g) the date and initials of the persons who verified the testing and the calculations, where appropriate;  \n(h) a clear statement of release or rejection (or other status decision) and the dated signature of the designated responsible person.\n\n# 15.44 \nWritten release and rejection procedures should be available for materials and products, and in particular for the release for sale of the finished product by an authorized person.\n\n# 15.45 \nRecords should be maintained of the distribution of each batch of a product in order, e.g. to facilitate the recall of the batch if necessary.\n\n# 15.46 \nRecords should be kept for major and critical equipment, as appropriate, of any validations, calibrations, maintenance, cleaning, or repair operations, including dates and the identity of the people who carried these operations out.\n\n# 15.47 \nThe use of major and critical equipment and the areas where products have been processed should be appropriately recorded in chronological order.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e86b5a69b28fe1a090e1624c9a8a6d44496d7e16a54313afb88e7f2cf9444693", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 15.38 \nThere should be an SOP describing the details of the batch (lot) numbering system, with the objective of ensuring that each batch of intermediate, bulk or finished product is identified with a specific batch number.\n\n# 15.39 \nThe SOPs for batch numbering that are applied to the processing stage and to the respective packaging stage should be related to each other.\n\n# 15.40 \nThe SOP for batch numbering should ensure that the same batch numbers will not be used repeatedly; this applies also to reprocessing.\n\n# 15.41 \nBatch-number allocation should be immediately recorded, e.g. in a logbook. The record should include at least the date of allocation, product identity and size of batch.\n\n# 15.42 \nThere should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded.\n\n# 15.43 \nAnalysis records should include at least the following data:\n\n(a) the name of the material or product and, where applicable, dosage form;  \n(b) the batch number and, where appropriate, the manufacturer and/or supplier;  \n(c) references to the relevant specifications and testing procedures;  \n(d) test results, including observations and calculations, and reference to any specifications (limits);  \n(e) date(s) and reference number(s) of testing;  \n(f) the initials of the persons who performed the testing;  \n(g) the date and initials of the persons who verified the testing and the calculations, where appropriate;  \n(h) a clear statement of release or rejection (or other status decision) and the dated signature of the designated responsible person.\n\n# 15.44 \nWritten release and rejection procedures should be available for materials and products, and in particular for the release for sale of the finished product by an authorized person.\n\n# 15.45 \nRecords should be maintained of the distribution of each batch of a product in order, e.g. to facilitate the recall of the batch if necessary.\n\n# 15.46 \nRecords should be kept for major and critical equipment, as appropriate, of any validations, calibrations, maintenance, cleaning, or repair operations, including dates and the identity of the people who carried these operations out.\n\n# 15.47 \nThe use of major and critical equipment and the areas where products have been processed should be appropriately recorded in chronological order.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "45518f1b-86bf-4879-a76f-2140fc7fe659": {"__data__": {"id_": "45518f1b-86bf-4879-a76f-2140fc7fe659", "embedding": null, "metadata": {"page_label": "150", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Good Practices in Production\n\n## 16.1 Principle\n\nProduction operations must follow clearly defined procedures in accordance with manufacturing and marketing authorizations, with the objective of obtaining products of the requisite quality.\n\n### General\n\n16.2 All handling of materials and products, such as receipt and cleaning, quarantine, sampling, storage, labelling, dispensing, processing, packaging, and distribution should be done in accordance with written procedures or instructions and, where necessary, recorded.\n\n16.3 Any deviation from instructions or procedures should be avoided as far as possible. If deviations occur, they should be done in accordance with an approved procedure. The authorization of the deviation should be approved in writing by a designated person, with the involvement of the QC department, when appropriate.\n\n16.4 Checks on yields and reconciliation of quantities should be carried out as necessary to ensure that there are no discrepancies outside acceptable limits.\n\n16.5 Operations on different products should not be carried out simultaneously or consecutively in the same room or area unless there is no risk of mix-up or cross-contamination.\n\n16.6 At all times during processing, all materials, bulk containers, major items of equipment, and where appropriate, the rooms and packaging lines being used should be labelled or otherwise identified with an indication of the product or material being processed, its strength (where applicable) and the batch number. Where applicable, this indication should also mention the stage of production. In some cases, it may be useful to also record the name of the previous product that has been processed.\n\n16.7 Access to production premises should be restricted to authorized personnel.\n\n16.8 Normally, non-medicinal products should not be produced in areas or with equipment destined for the production of pharmaceutical products.\n\n16.9 In-process controls are usually performed within the production area. The performance of such in-process controls should not have any", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" establece buenas pr\u00e1cticas en la producci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de seguir procedimientos claramente definidos para garantizar la calidad del producto. Se abordan aspectos como el manejo de materiales, la gesti\u00f3n de desviaciones, el control de procesos y la restricci\u00f3n de acceso a las \u00e1reas de producci\u00f3n. Tambi\u00e9n se menciona la necesidad de etiquetar adecuadamente todos los materiales y equipos utilizados en el proceso de producci\u00f3n.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para manejar materiales y productos en la producci\u00f3n farmac\u00e9utica?**\n   - El manejo de materiales y productos debe realizarse de acuerdo con procedimientos escritos que incluyan recepci\u00f3n, limpieza, cuarentena, muestreo, almacenamiento, etiquetado, dispensaci\u00f3n, procesamiento, envasado y distribuci\u00f3n.\n\n2. **\u00bfQu\u00e9 debe hacerse en caso de que se produzcan desviaciones de los procedimientos establecidos?**\n   - Las desviaciones deben evitarse en la medida de lo posible. Si ocurren, deben seguir un procedimiento aprobado y ser autorizadas por una persona designada, con la participaci\u00f3n del departamento de control de calidad (QC) cuando sea apropiado.\n\n3. **\u00bfPor qu\u00e9 es importante etiquetar adecuadamente los materiales y equipos durante el procesamiento?**\n   - Es crucial etiquetar todos los materiales, contenedores a granel, equipos y \u00e1reas de producci\u00f3n para identificar claramente el producto o material que se est\u00e1 procesando, su fuerza y el n\u00famero de lote, lo que ayuda a prevenir confusiones y contaminaci\u00f3n cruzada.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Se enfatiza la necesidad de establecer SOPs para el sistema de numeraci\u00f3n de lotes en la fabricaci\u00f3n de productos farmac\u00e9uticos, asegurando que cada lote est\u00e9 identificado de manera \u00fanica.\n\n2. **Registro de N\u00fameros de Lote**: La asignaci\u00f3n de n\u00fameros de lote debe ser registrada de inmediato, incluyendo informaci\u00f3n como la fecha de asignaci\u00f3n, la identidad del producto y el tama\u00f1o del lote.\n\n3. **Pruebas y An\u00e1lisis**: Se requieren procedimientos escritos para la realizaci\u00f3n de pruebas en diferentes etapas de fabricaci\u00f3n, as\u00ed como registros detallados de los an\u00e1lisis realizados, que incluyan resultados, especificaciones y responsables.\n\n4. **Liberaci\u00f3n y Rechazo de Productos**: Deben existir procedimientos documentados para la liberaci\u00f3n y rechazo de materiales y productos, especialmente para la autorizaci\u00f3n de la venta de productos terminados.\n\n5. **Mantenimiento de Registros**: Es crucial mantener registros de la distribuci\u00f3n de cada lote, as\u00ed como de las operaciones de validaci\u00f3n, calibraci\u00f3n, mantenimiento y limpieza de equipos cr\u00edticos.\n\n6. **Trazabilidad**: La documentaci\u00f3n adecuada en cada etapa del proceso de fabricaci\u00f3n es esencial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.\n\n### Entidades\n\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen los procedimientos para la numeraci\u00f3n de lotes y pruebas.\n- **Lotes**: Grupos de productos intermedios, a granel o terminados identificados por un n\u00famero espec\u00edfico.\n- **Registros de An\u00e1lisis**: Documentos que contienen datos sobre pruebas realizadas, incluyendo resultados y responsables.\n- **Productos**: Materiales farmac\u00e9uticos que son objeto de pruebas y liberaci\u00f3n.\n- **Equipos Cr\u00edticos**: Equipos importantes en el proceso de fabricaci\u00f3n que requieren mantenimiento y validaci\u00f3n.\n- **Autorizados**: Personas responsables de la liberaci\u00f3n de productos terminados para la venta. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y los procedimientos estandarizados en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y la trazabilidad de los productos.", "excerpt_keywords": "Keywords: production practices, pharmaceutical quality, standard procedures, deviation management, in-process controls"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "475ae1cb-457f-43ee-b265-e372ef46493a", "node_type": "4", "metadata": {"page_label": "150", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Good Practices in Production\n\n## 16.1 Principle\n\nProduction operations must follow clearly defined procedures in accordance with manufacturing and marketing authorizations, with the objective of obtaining products of the requisite quality.\n\n### General\n\n16.2 All handling of materials and products, such as receipt and cleaning, quarantine, sampling, storage, labelling, dispensing, processing, packaging, and distribution should be done in accordance with written procedures or instructions and, where necessary, recorded.\n\n16.3 Any deviation from instructions or procedures should be avoided as far as possible. If deviations occur, they should be done in accordance with an approved procedure. The authorization of the deviation should be approved in writing by a designated person, with the involvement of the QC department, when appropriate.\n\n16.4 Checks on yields and reconciliation of quantities should be carried out as necessary to ensure that there are no discrepancies outside acceptable limits.\n\n16.5 Operations on different products should not be carried out simultaneously or consecutively in the same room or area unless there is no risk of mix-up or cross-contamination.\n\n16.6 At all times during processing, all materials, bulk containers, major items of equipment, and where appropriate, the rooms and packaging lines being used should be labelled or otherwise identified with an indication of the product or material being processed, its strength (where applicable) and the batch number. Where applicable, this indication should also mention the stage of production. In some cases, it may be useful to also record the name of the previous product that has been processed.\n\n16.7 Access to production premises should be restricted to authorized personnel.\n\n16.8 Normally, non-medicinal products should not be produced in areas or with equipment destined for the production of pharmaceutical products.\n\n16.9 In-process controls are usually performed within the production area. The performance of such in-process controls should not have any", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ae3daf058343ba930823c0d30e1c3ca5b82b2155d30aedafbd04713ad9066dcd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Good Practices in Production\n\n## 16.1 Principle\n\nProduction operations must follow clearly defined procedures in accordance with manufacturing and marketing authorizations, with the objective of obtaining products of the requisite quality.\n\n### General\n\n16.2 All handling of materials and products, such as receipt and cleaning, quarantine, sampling, storage, labelling, dispensing, processing, packaging, and distribution should be done in accordance with written procedures or instructions and, where necessary, recorded.\n\n16.3 Any deviation from instructions or procedures should be avoided as far as possible. If deviations occur, they should be done in accordance with an approved procedure. The authorization of the deviation should be approved in writing by a designated person, with the involvement of the QC department, when appropriate.\n\n16.4 Checks on yields and reconciliation of quantities should be carried out as necessary to ensure that there are no discrepancies outside acceptable limits.\n\n16.5 Operations on different products should not be carried out simultaneously or consecutively in the same room or area unless there is no risk of mix-up or cross-contamination.\n\n16.6 At all times during processing, all materials, bulk containers, major items of equipment, and where appropriate, the rooms and packaging lines being used should be labelled or otherwise identified with an indication of the product or material being processed, its strength (where applicable) and the batch number. Where applicable, this indication should also mention the stage of production. In some cases, it may be useful to also record the name of the previous product that has been processed.\n\n16.7 Access to production premises should be restricted to authorized personnel.\n\n16.8 Normally, non-medicinal products should not be produced in areas or with equipment destined for the production of pharmaceutical products.\n\n16.9 In-process controls are usually performed within the production area. The performance of such in-process controls should not have any", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2059, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "924e713f-3586-44ad-8ee0-c6a52e34579a": {"__data__": {"id_": "924e713f-3586-44ad-8ee0-c6a52e34579a", "embedding": null, "metadata": {"page_label": "151", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Prevention of Cross-Contamination and Bacterial Contamination During Production\n\n16.10 When dry materials and products are used in production, special precautions should be taken to prevent the generation and dissemination of dust. Provision should be made for proper air control (e.g. supply and extraction of air of suitable quality).\n\n16.11 Contamination of a starting material or of a product by another material or product must be avoided. This risk of accidental cross-contamination arises from the uncontrolled release of dust, gases, particles, vapours, sprays or organisms from materials and products in process, from residues on equipment, from intruding insects, and from operators\u2019 clothing, skin, etc. The significance of this risk varies with the type of contaminant and of the product being contaminated.\n\nAmong the most hazardous contaminants are highly sensitizing materials, biological preparations such as living organisms, certain hormones, cytotoxic substances, and other highly active materials.\n\nProducts in which contamination is likely to be most significant are those administered by injection or applied to open wounds and those given in large doses and/or over a long time.\n\n16.12 Cross-contamination should be avoided by taking appropriate technical or organizational measures, for example:\n\n(a) carrying out production in dedicated and self-contained areas (which may be required for products such as penicillins, live vaccines, live bacterial preparations and certain other biologicals);\n\n(b) conducting campaign production (separation in time) followed by appropriate cleaning in accordance with a validated cleaning procedure;\n\n(c) providing appropriately designed airlocks, pressure differentials, and air supply and extraction systems;\n\n(d) minimizing the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;\n\n(e) wearing protective clothing where products or materials are handled;\n\n(f) using cleaning and decontamination procedures of known effectiveness;\n\n(g) using a \u201cclosed system\u201d in production;\n\n(h) testing for residues;\n\n(i) using cleanliness status labels on equipment.\n\n16.13 Measures to prevent cross-contamination and their effectiveness should be checked periodically according to SOPs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS aborda la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la contaminaci\u00f3n bacteriana durante la producci\u00f3n de materiales y productos. Se enfatiza la importancia de tomar precauciones especiales al manejar materiales secos para evitar la generaci\u00f3n de polvo y la contaminaci\u00f3n accidental. Se describen diversas medidas t\u00e9cnicas y organizativas que deben implementarse para minimizar el riesgo de contaminaci\u00f3n, especialmente en productos que se administran por inyecci\u00f3n o se aplican a heridas abiertas. Adem\u00e1s, se menciona la necesidad de verificar peri\u00f3dicamente la efectividad de estas medidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tipos de contaminantes que se consideran m\u00e1s peligrosos en el contexto de la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Entre los contaminantes m\u00e1s peligrosos se encuentran materiales altamente sensibilizantes, preparaciones biol\u00f3gicas como organismos vivos, ciertas hormonas, sustancias citot\u00f3xicas y otros materiales altamente activos.\n\n2. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la contaminaci\u00f3n cruzada en la producci\u00f3n de productos como penicilinas y vacunas vivas?**\n   - Respuesta: Se deben llevar a cabo la producci\u00f3n en \u00e1reas dedicadas y autoconfinadas, realizar producci\u00f3n por campa\u00f1as seguida de limpieza adecuada, y proporcionar sistemas de aire dise\u00f1ados apropiadamente, entre otras medidas.\n\n3. **\u00bfCon qu\u00e9 frecuencia deben revisarse las medidas implementadas para prevenir la contaminaci\u00f3n cruzada y c\u00f3mo se debe llevar a cabo esta revisi\u00f3n?**\n   - Respuesta: Las medidas para prevenir la contaminaci\u00f3n cruzada y su efectividad deben ser verificadas peri\u00f3dicamente de acuerdo con los Procedimientos Operativos Est\u00e1ndar (SOPs).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Procedimientos Definidos:** La producci\u00f3n debe seguir procedimientos claramente establecidos que cumplan con las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n para asegurar la calidad del producto.\n\n2. **Manejo de Materiales:** Se deben seguir instrucciones escritas para todas las etapas del manejo de materiales y productos, incluyendo recepci\u00f3n, limpieza, almacenamiento, etiquetado, y distribuci\u00f3n.\n\n3. **Desviaciones:** Las desviaciones de los procedimientos deben ser evitadas y, si ocurren, deben ser autorizadas por una persona designada y, cuando sea necesario, involucrar al departamento de control de calidad.\n\n4. **Control de Calidad:** Se deben realizar verificaciones de rendimiento y reconciliaci\u00f3n de cantidades para evitar discrepancias.\n\n5. **Prevenci\u00f3n de Contaminaci\u00f3n:** No se deben realizar operaciones de diferentes productos simult\u00e1neamente en la misma \u00e1rea a menos que no haya riesgo de mezcla o contaminaci\u00f3n cruzada.\n\n6. **Etiquetado:** Todos los materiales y equipos deben estar etiquetados adecuadamente para identificar el producto, su fuerza y el n\u00famero de lote, as\u00ed como la etapa de producci\u00f3n.\n\n7. **Acceso Restringido:** El acceso a las \u00e1reas de producci\u00f3n debe ser limitado a personal autorizado.\n\n8. **Producci\u00f3n de Productos No Medicinales:** No se deben producir productos no medicinales en \u00e1reas o con equipos destinados a productos farmac\u00e9uticos.\n\n9. **Controles en Proceso:** Los controles en proceso se realizan dentro del \u00e1rea de producci\u00f3n y son esenciales para asegurar la calidad.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite el documento.\n- **Departamento de Control de Calidad (QC):** Involucrado en la autorizaci\u00f3n de desviaciones.\n- **Personal Autorizado:** Solo este grupo debe tener acceso a las instalaciones de producci\u00f3n.\n- **Productos Farmac\u00e9uticos:** El enfoque principal del documento.\n- **Productos No Medicinales:** Se menciona su producci\u00f3n y las restricciones asociadas.\n\nEste resumen destaca la importancia de seguir buenas pr\u00e1cticas en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: cross-contamination, bacterial contamination, production safety, pharmaceutical manufacturing, air control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cbd116d1-16ee-46f7-a1c4-9d4e3a6d51bd", "node_type": "4", "metadata": {"page_label": "151", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Prevention of Cross-Contamination and Bacterial Contamination During Production\n\n16.10 When dry materials and products are used in production, special precautions should be taken to prevent the generation and dissemination of dust. Provision should be made for proper air control (e.g. supply and extraction of air of suitable quality).\n\n16.11 Contamination of a starting material or of a product by another material or product must be avoided. This risk of accidental cross-contamination arises from the uncontrolled release of dust, gases, particles, vapours, sprays or organisms from materials and products in process, from residues on equipment, from intruding insects, and from operators\u2019 clothing, skin, etc. The significance of this risk varies with the type of contaminant and of the product being contaminated.\n\nAmong the most hazardous contaminants are highly sensitizing materials, biological preparations such as living organisms, certain hormones, cytotoxic substances, and other highly active materials.\n\nProducts in which contamination is likely to be most significant are those administered by injection or applied to open wounds and those given in large doses and/or over a long time.\n\n16.12 Cross-contamination should be avoided by taking appropriate technical or organizational measures, for example:\n\n(a) carrying out production in dedicated and self-contained areas (which may be required for products such as penicillins, live vaccines, live bacterial preparations and certain other biologicals);\n\n(b) conducting campaign production (separation in time) followed by appropriate cleaning in accordance with a validated cleaning procedure;\n\n(c) providing appropriately designed airlocks, pressure differentials, and air supply and extraction systems;\n\n(d) minimizing the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;\n\n(e) wearing protective clothing where products or materials are handled;\n\n(f) using cleaning and decontamination procedures of known effectiveness;\n\n(g) using a \u201cclosed system\u201d in production;\n\n(h) testing for residues;\n\n(i) using cleanliness status labels on equipment.\n\n16.13 Measures to prevent cross-contamination and their effectiveness should be checked periodically according to SOPs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3e054fb6c7ab87a271df36e6c4016e8e723b3a46c03540628e918bdda7176062", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Prevention of Cross-Contamination and Bacterial Contamination During Production\n\n16.10 When dry materials and products are used in production, special precautions should be taken to prevent the generation and dissemination of dust. Provision should be made for proper air control (e.g. supply and extraction of air of suitable quality).\n\n16.11 Contamination of a starting material or of a product by another material or product must be avoided. This risk of accidental cross-contamination arises from the uncontrolled release of dust, gases, particles, vapours, sprays or organisms from materials and products in process, from residues on equipment, from intruding insects, and from operators\u2019 clothing, skin, etc. The significance of this risk varies with the type of contaminant and of the product being contaminated.\n\nAmong the most hazardous contaminants are highly sensitizing materials, biological preparations such as living organisms, certain hormones, cytotoxic substances, and other highly active materials.\n\nProducts in which contamination is likely to be most significant are those administered by injection or applied to open wounds and those given in large doses and/or over a long time.\n\n16.12 Cross-contamination should be avoided by taking appropriate technical or organizational measures, for example:\n\n(a) carrying out production in dedicated and self-contained areas (which may be required for products such as penicillins, live vaccines, live bacterial preparations and certain other biologicals);\n\n(b) conducting campaign production (separation in time) followed by appropriate cleaning in accordance with a validated cleaning procedure;\n\n(c) providing appropriately designed airlocks, pressure differentials, and air supply and extraction systems;\n\n(d) minimizing the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;\n\n(e) wearing protective clothing where products or materials are handled;\n\n(f) using cleaning and decontamination procedures of known effectiveness;\n\n(g) using a \u201cclosed system\u201d in production;\n\n(h) testing for residues;\n\n(i) using cleanliness status labels on equipment.\n\n16.13 Measures to prevent cross-contamination and their effectiveness should be checked periodically according to SOPs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2286, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c136df7d-8c91-489a-ad09-0ca70ef663ad": {"__data__": {"id_": "c136df7d-8c91-489a-ad09-0ca70ef663ad", "embedding": null, "metadata": {"page_label": "152", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing Operations\n\n16.14 Production areas where susceptible products are processed should undergo periodic environmental monitoring (e.g. for microbiological monitoring and particulate matter where appropriate).\n\n## Processing Operations\n\n16.15 Before any processing operation is started, steps should be taken to ensure that the work area and equipment are clean and free from any starting materials, products, product residues, labels or documents not required for the current operation.\n\n16.16 Any necessary in-process controls and environmental controls should be carried out and recorded.\n\n16.17 Means should be instituted of indicating failures of equipment or of services (e.g. water, gas) to equipment. Defective equipment should be withdrawn from use until the defect has been rectified. After use, production equipment should be cleaned without delay according to detailed written procedures and stored under clean and dry conditions in a separate area or in a manner that will prevent contamination.\n\n16.18 Time limits for storage of equipment after cleaning and before use should be stated and based on data.\n\n16.19 Containers for filling should be cleaned before filling. Attention should be given to avoiding and removing any contaminants such as glass fragments and metal particles.\n\n16.20 Any significant deviation from the expected yield should be recorded and investigated.\n\n16.21 Checks should be carried out to ensure that pipelines and other pieces of equipment used for the transportation of products from one area to another are connected in a correct manner.\n\n16.22 Pipes used for conveying distilled or deionized water and, where appropriate, other water pipes should be sanitized and stored according to written procedures that detail the action limits for microbiological contamination and the measures to be taken.\n\n16.23 Measuring, weighing, recording, and control equipment and instruments should be serviced and calibrated at prespecified intervals and records maintained. To ensure satisfactory functioning, instruments should be checked daily or prior to use for performing analytical tests. The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n16.24 Repair and maintenance operations should not present any hazard to the quality of the products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las operaciones de procesamiento en \u00e1reas de producci\u00f3n de productos susceptibles. Se enfatiza la importancia de la limpieza y el monitoreo ambiental, as\u00ed como el control de equipos y procesos para garantizar la calidad y seguridad de los productos. Se establecen procedimientos para la limpieza de equipos, el almacenamiento adecuado, la calibraci\u00f3n de instrumentos y la gesti\u00f3n de desviaciones en los rendimientos esperados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la limpieza y almacenamiento de equipos de producci\u00f3n despu\u00e9s de su uso?**\n   - El contexto menciona que despu\u00e9s de usar el equipo de producci\u00f3n, este debe ser limpiado sin demora seg\u00fan procedimientos escritos detallados y almacenado en condiciones limpias y secas, en un \u00e1rea separada o de manera que se evite la contaminaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en caso de que se detecte un fallo en el equipo o en los servicios relacionados?**\n   - Se debe establecer un sistema para indicar fallos en el equipo o servicios (como agua o gas). El equipo defectuoso debe ser retirado de uso hasta que se haya rectificado el defecto.\n\n3. **\u00bfQu\u00e9 acciones se deben tomar si se observa una desviaci\u00f3n significativa del rendimiento esperado durante el procesamiento?**\n   - Cualquier desviaci\u00f3n significativa del rendimiento esperado debe ser registrada e investigada para determinar las causas y tomar las medidas correctivas necesarias.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre las operaciones de procesamiento en \u00e1reas de producci\u00f3n, destacando la importancia de la limpieza, el monitoreo ambiental y el control de equipos. Se establecen procedimientos para asegurar que el equipo est\u00e9 limpio y libre de contaminantes, as\u00ed como la necesidad de registrar y abordar cualquier desviaci\u00f3n en los procesos de producci\u00f3n. Adem\u00e1s, se enfatiza la calibraci\u00f3n y el mantenimiento de los instrumentos utilizados en el procesamiento para garantizar su correcto funcionamiento y la calidad del producto final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada:**\n   - Importancia de evitar la contaminaci\u00f3n de materiales y productos durante la producci\u00f3n, especialmente en el manejo de materiales secos que pueden generar polvo.\n\n2. **Contaminantes Peligrosos:**\n   - Identificaci\u00f3n de contaminantes altamente peligrosos, incluyendo materiales sensibilizantes, organismos vivos, hormonas, sustancias citot\u00f3xicas y otros materiales activos.\n\n3. **Productos de Alto Riesgo:**\n   - Enfoque en productos que se administran por inyecci\u00f3n, se aplican a heridas abiertas o se administran en grandes dosis y/o por per\u00edodos prolongados.\n\n4. **Medidas T\u00e9cnicas y Organizativas:**\n   - Estrategias para prevenir la contaminaci\u00f3n cruzada, como la producci\u00f3n en \u00e1reas dedicadas, limpieza adecuada, sistemas de aire controlados, uso de ropa protectora, y procedimientos de limpieza efectivos.\n\n5. **Revisi\u00f3n y Verificaci\u00f3n:**\n   - Necesidad de revisar peri\u00f3dicamente la efectividad de las medidas implementadas seg\u00fan Procedimientos Operativos Est\u00e1ndar (SOPs).\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos:** Incluyen penicilinas, vacunas vivas y otros biol\u00f3gicos.\n- **Contaminantes:** Materiales sensibilizantes, organismos vivos, hormonas, sustancias citot\u00f3xicas.\n- **Procedimientos Operativos Est\u00e1ndar (SOPs):** Normas para la revisi\u00f3n de medidas de prevenci\u00f3n.\n\nEste resumen destaca la importancia de la prevenci\u00f3n de la contaminaci\u00f3n en la producci\u00f3n farmac\u00e9utica y las medidas necesarias para garantizar la seguridad y eficacia de los productos.", "excerpt_keywords": "Keywords: processing operations, environmental monitoring, equipment cleaning, contamination prevention, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "66bda493-22aa-4818-b6ba-93abfbb77e68", "node_type": "4", "metadata": {"page_label": "152", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing Operations\n\n16.14 Production areas where susceptible products are processed should undergo periodic environmental monitoring (e.g. for microbiological monitoring and particulate matter where appropriate).\n\n## Processing Operations\n\n16.15 Before any processing operation is started, steps should be taken to ensure that the work area and equipment are clean and free from any starting materials, products, product residues, labels or documents not required for the current operation.\n\n16.16 Any necessary in-process controls and environmental controls should be carried out and recorded.\n\n16.17 Means should be instituted of indicating failures of equipment or of services (e.g. water, gas) to equipment. Defective equipment should be withdrawn from use until the defect has been rectified. After use, production equipment should be cleaned without delay according to detailed written procedures and stored under clean and dry conditions in a separate area or in a manner that will prevent contamination.\n\n16.18 Time limits for storage of equipment after cleaning and before use should be stated and based on data.\n\n16.19 Containers for filling should be cleaned before filling. Attention should be given to avoiding and removing any contaminants such as glass fragments and metal particles.\n\n16.20 Any significant deviation from the expected yield should be recorded and investigated.\n\n16.21 Checks should be carried out to ensure that pipelines and other pieces of equipment used for the transportation of products from one area to another are connected in a correct manner.\n\n16.22 Pipes used for conveying distilled or deionized water and, where appropriate, other water pipes should be sanitized and stored according to written procedures that detail the action limits for microbiological contamination and the measures to be taken.\n\n16.23 Measuring, weighing, recording, and control equipment and instruments should be serviced and calibrated at prespecified intervals and records maintained. To ensure satisfactory functioning, instruments should be checked daily or prior to use for performing analytical tests. The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n16.24 Repair and maintenance operations should not present any hazard to the quality of the products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "41c760c60a3547a65a7bf1970185512591d49746848267b6d43afee017b8949d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Processing Operations\n\n16.14 Production areas where susceptible products are processed should undergo periodic environmental monitoring (e.g. for microbiological monitoring and particulate matter where appropriate).\n\n## Processing Operations\n\n16.15 Before any processing operation is started, steps should be taken to ensure that the work area and equipment are clean and free from any starting materials, products, product residues, labels or documents not required for the current operation.\n\n16.16 Any necessary in-process controls and environmental controls should be carried out and recorded.\n\n16.17 Means should be instituted of indicating failures of equipment or of services (e.g. water, gas) to equipment. Defective equipment should be withdrawn from use until the defect has been rectified. After use, production equipment should be cleaned without delay according to detailed written procedures and stored under clean and dry conditions in a separate area or in a manner that will prevent contamination.\n\n16.18 Time limits for storage of equipment after cleaning and before use should be stated and based on data.\n\n16.19 Containers for filling should be cleaned before filling. Attention should be given to avoiding and removing any contaminants such as glass fragments and metal particles.\n\n16.20 Any significant deviation from the expected yield should be recorded and investigated.\n\n16.21 Checks should be carried out to ensure that pipelines and other pieces of equipment used for the transportation of products from one area to another are connected in a correct manner.\n\n16.22 Pipes used for conveying distilled or deionized water and, where appropriate, other water pipes should be sanitized and stored according to written procedures that detail the action limits for microbiological contamination and the measures to be taken.\n\n16.23 Measuring, weighing, recording, and control equipment and instruments should be serviced and calibrated at prespecified intervals and records maintained. To ensure satisfactory functioning, instruments should be checked daily or prior to use for performing analytical tests. The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n16.24 Repair and maintenance operations should not present any hazard to the quality of the products.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2377, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "10a304a3-12bb-4a33-ba8a-79c7c3f845df": {"__data__": {"id_": "10a304a3-12bb-4a33-ba8a-79c7c3f845df", "embedding": null, "metadata": {"page_label": "153", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Packaging Operations\n\n16.25 When the programme for packaging operations is being set up, particular attention should be given to minimizing the risk of cross-contamination, mix-ups or substitutions. Different products should not be packaged in close proximity unless there is physical segregation or an alternative system that will provide equal assurance.\n\n16.26 Before packaging operations are begun, steps should be taken to ensure that the work area, packaging lines, printing machines and other equipment are clean and free from any products, materials or documents used previously and which are not required for the current operation. The line clearance should be performed according to an appropriate procedure and checklist, and recorded.\n\n16.27 The name and batch number of the product being handled should be displayed at each packaging station or line.\n\n16.28 Normally, filling and sealing should be followed as quickly as possible by labelling. If labelling is delayed, appropriate procedures should be applied to ensure that no mix ups or mislabelling can occur.\n\n16.29 The correct performance of any printing (e.g. of code numbers or expiry dates) done separately or in the course of the packaging should be checked and recorded. Attention should be paid to printing by hand, which should be rechecked at regular intervals.\n\n16.30 Special care should be taken when cut labels are used and when overprinting is carried out off-line, and in hand-packaging operations. Roll feed labels are normally preferable to cut labels in helping to avoid mix ups. Online verification of all labels by automated electronic means can be helpful in preventing mix ups, but checks should be made to ensure that any electronic code readers, label counters, or similar devices are operating correctly. When labels are attached manually, in-process control checks should be performed more frequently.\n\n16.31 Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing.\n\n16.32 Regular online control of the product during packaging should include at least checks on:\n\n- (a) the general appearance of the packages;\n- (b) whether the packages are complete;\n- (c) whether the correct products and packaging materials are used;\n- (d) whether any overprinting is correct;\n- (e) the correct functioning of line monitors.\n\nSamples taken away from the packaging line should not be returned.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Minimizaci\u00f3n de Riesgos en Operaciones de Empaque**: El documento enfatiza la importancia de establecer un programa de operaciones de empaque que minimice el riesgo de contaminaci\u00f3n cruzada, confusiones o sustituciones. Se requiere que los productos diferentes no se empaquen en proximidad a menos que haya segregaci\u00f3n f\u00edsica o un sistema alternativo que garantice la seguridad.\n\n2. **Limpieza y Preparaci\u00f3n del \u00c1rea de Trabajo**: Antes de iniciar las operaciones de empaque, es crucial asegurar que el \u00e1rea de trabajo y los equipos est\u00e9n limpios y libres de materiales no necesarios. Esto incluye la realizaci\u00f3n de un procedimiento de limpieza de l\u00ednea que debe ser documentado.\n\n3. **Control de Calidad Durante el Empaque**: Se deben realizar controles regulares durante el empaque para verificar la apariencia de los paquetes, la correcci\u00f3n de los productos y materiales utilizados, y el correcto funcionamiento de los monitores de l\u00ednea. Adem\u00e1s, se deben tomar precauciones especiales al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que el \u00e1rea de trabajo est\u00e9 limpia antes de comenzar las operaciones de empaque?**\n   - El documento menciona que se deben tomar pasos para garantizar que el \u00e1rea de trabajo, las l\u00edneas de empaque, las m\u00e1quinas de impresi\u00f3n y otros equipos est\u00e9n limpios y libres de productos, materiales o documentos no necesarios. Esto debe realizarse mediante un procedimiento de limpieza de l\u00ednea que debe ser registrado.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el uso de etiquetas en las operaciones de empaque?**\n   - Se recomienda tener especial cuidado al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea. Las etiquetas de alimentaci\u00f3n en rollo son preferibles a las etiquetas cortadas para evitar confusiones. Adem\u00e1s, se sugiere la verificaci\u00f3n en l\u00ednea de todas las etiquetas mediante medios electr\u00f3nicos automatizados y realizar controles m\u00e1s frecuentes cuando las etiquetas se adjuntan manualmente.\n\n3. **\u00bfQu\u00e9 aspectos se deben verificar durante el control en l\u00ednea del producto durante el empaque?**\n   - El control en l\u00ednea del producto debe incluir al menos las siguientes verificaciones: (a) la apariencia general de los paquetes; (b) si los paquetes est\u00e1n completos; (c) si se est\u00e1n utilizando los productos y materiales de empaque correctos; (d) si cualquier sobreimpresi\u00f3n es correcta; y (e) el correcto funcionamiento de los monitores de l\u00ednea.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo Ambiental**: Se requiere un monitoreo ambiental peri\u00f3dico en \u00e1reas de producci\u00f3n de productos susceptibles, incluyendo controles microbiol\u00f3gicos y de part\u00edculas.\n\n2. **Limpieza y Preparaci\u00f3n**: Antes de iniciar cualquier operaci\u00f3n de procesamiento, es esencial que el \u00e1rea de trabajo y el equipo est\u00e9n limpios y libres de materiales no necesarios.\n\n3. **Controles en Proceso**: Se deben realizar y registrar controles necesarios durante el proceso y en el ambiente.\n\n4. **Gesti\u00f3n de Fallos**: Deben establecerse medios para indicar fallos en el equipo o servicios. El equipo defectuoso debe ser retirado hasta que se solucione el problema.\n\n5. **Almacenamiento de Equipos**: Despu\u00e9s de su uso, el equipo debe limpiarse de inmediato y almacenarse en condiciones limpias y secas para evitar la contaminaci\u00f3n.\n\n6. **Desviaciones en Rendimiento**: Cualquier desviaci\u00f3n significativa del rendimiento esperado debe ser registrada e investigada.\n\n7. **Conexiones de Equipos**: Se deben verificar las conexiones de tuber\u00edas y equipos utilizados para el transporte de productos.\n\n8. **Sanitizaci\u00f3n de Tuber\u00edas**: Las tuber\u00edas que transportan agua destilada o desionizada deben ser sanitizadas y almacenadas seg\u00fan procedimientos escritos.\n\n9. **Calibraci\u00f3n de Instrumentos**: Los equipos de medici\u00f3n y control deben ser calibrados y mantenidos a intervalos preestablecidos, con registros adecuados.\n\n10. **Mantenimiento Seguro**: Las operaciones de reparaci\u00f3n y mantenimiento no deben comprometer la calidad de los productos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Equipos de Producci\u00f3n**: Herramientas y maquinaria utilizadas en el procesamiento.\n- **Contaminantes**: Elementos no deseados como fragmentos de vidrio y part\u00edculas met\u00e1licas.\n- **Procedimientos Escritos**: Documentaci\u00f3n que detalla los pasos a seguir para la limpieza y mantenimiento.\n- **Controles Microbiol\u00f3gicos**: Medidas para asegurar la calidad microbiol\u00f3gica de los productos.\n- **Instrumentos de Medici\u00f3n**: Equipos utilizados para realizar pruebas anal\u00edticas y controles de calidad. \n\nEste resumen destaca la importancia de la limpieza, el monitoreo y el control en las operaciones de procesamiento para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: packaging operations, cross-contamination, line clearance, quality control, labeling procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2578a11-a3ce-43df-bc2d-3ea5195cae6c", "node_type": "4", "metadata": {"page_label": "153", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Packaging Operations\n\n16.25 When the programme for packaging operations is being set up, particular attention should be given to minimizing the risk of cross-contamination, mix-ups or substitutions. Different products should not be packaged in close proximity unless there is physical segregation or an alternative system that will provide equal assurance.\n\n16.26 Before packaging operations are begun, steps should be taken to ensure that the work area, packaging lines, printing machines and other equipment are clean and free from any products, materials or documents used previously and which are not required for the current operation. The line clearance should be performed according to an appropriate procedure and checklist, and recorded.\n\n16.27 The name and batch number of the product being handled should be displayed at each packaging station or line.\n\n16.28 Normally, filling and sealing should be followed as quickly as possible by labelling. If labelling is delayed, appropriate procedures should be applied to ensure that no mix ups or mislabelling can occur.\n\n16.29 The correct performance of any printing (e.g. of code numbers or expiry dates) done separately or in the course of the packaging should be checked and recorded. Attention should be paid to printing by hand, which should be rechecked at regular intervals.\n\n16.30 Special care should be taken when cut labels are used and when overprinting is carried out off-line, and in hand-packaging operations. Roll feed labels are normally preferable to cut labels in helping to avoid mix ups. Online verification of all labels by automated electronic means can be helpful in preventing mix ups, but checks should be made to ensure that any electronic code readers, label counters, or similar devices are operating correctly. When labels are attached manually, in-process control checks should be performed more frequently.\n\n16.31 Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing.\n\n16.32 Regular online control of the product during packaging should include at least checks on:\n\n- (a) the general appearance of the packages;\n- (b) whether the packages are complete;\n- (c) whether the correct products and packaging materials are used;\n- (d) whether any overprinting is correct;\n- (e) the correct functioning of line monitors.\n\nSamples taken away from the packaging line should not be returned.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "16a25604df25092a3ca7b9e53398a8cc2c8b777b0d08273eb53bd8fba26ef98e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Packaging Operations\n\n16.25 When the programme for packaging operations is being set up, particular attention should be given to minimizing the risk of cross-contamination, mix-ups or substitutions. Different products should not be packaged in close proximity unless there is physical segregation or an alternative system that will provide equal assurance.\n\n16.26 Before packaging operations are begun, steps should be taken to ensure that the work area, packaging lines, printing machines and other equipment are clean and free from any products, materials or documents used previously and which are not required for the current operation. The line clearance should be performed according to an appropriate procedure and checklist, and recorded.\n\n16.27 The name and batch number of the product being handled should be displayed at each packaging station or line.\n\n16.28 Normally, filling and sealing should be followed as quickly as possible by labelling. If labelling is delayed, appropriate procedures should be applied to ensure that no mix ups or mislabelling can occur.\n\n16.29 The correct performance of any printing (e.g. of code numbers or expiry dates) done separately or in the course of the packaging should be checked and recorded. Attention should be paid to printing by hand, which should be rechecked at regular intervals.\n\n16.30 Special care should be taken when cut labels are used and when overprinting is carried out off-line, and in hand-packaging operations. Roll feed labels are normally preferable to cut labels in helping to avoid mix ups. Online verification of all labels by automated electronic means can be helpful in preventing mix ups, but checks should be made to ensure that any electronic code readers, label counters, or similar devices are operating correctly. When labels are attached manually, in-process control checks should be performed more frequently.\n\n16.31 Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing.\n\n16.32 Regular online control of the product during packaging should include at least checks on:\n\n- (a) the general appearance of the packages;\n- (b) whether the packages are complete;\n- (c) whether the correct products and packaging materials are used;\n- (d) whether any overprinting is correct;\n- (e) the correct functioning of line monitors.\n\nSamples taken away from the packaging line should not be returned.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2426, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "84e6010c-73b2-46f1-a102-bdc36f325fb8": {"__data__": {"id_": "84e6010c-73b2-46f1-a102-bdc36f325fb8", "embedding": null, "metadata": {"page_label": "154", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 16.33 \nProducts that have been involved in an unusual event during packaging should be reintroduced into the process only after special inspection, investigation and approval by authorized personnel. A detailed record should be kept of this operation.\n\n16.34 \nAny significant or unusual discrepancy observed during reconciliation of the amount of bulk product and printed packaging materials and the number of units produced should be investigated, satisfactorily accounted for, and recorded before release.\n\n16.35 \nUpon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed and the destruction recorded. A documented procedure requiring checks to be performed before returning unused materials should be followed if uncoded printed materials are returned to stock.\n\n16.36 \nProduction records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet production specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n# 17. Good practices in quality control\n\n17.1 \nQC is the part of GMP concerned with sampling, specifications and testing, and with the organization and documentation which ensure that the necessary and relevant tests are actually carried out and that materials are not released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. QC is not confined to laboratory operations, but may be involved in many decisions concerning the quality of the product.\n\n17.2 \nThe independence of QC from production is considered fundamental.\n\n17.3 \nEach manufacturer should have a QC function. The QC function should be independent of other departments and under the authority of a person with appropriate qualifications and experience, who has one or several control laboratories at his or her disposal. Adequate resources must be available to ensure that all the QC arrangements are effectively and reliably carried out. The basic requirements for QC are as follows:\n\n(a) adequate facilities, trained personnel and approved procedures must be available for sampling, inspecting, and testing starting materials,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Procedimientos de Reintroducci\u00f3n de Productos**: Los productos que han experimentado eventos inusuales durante el empaquetado deben ser reintroducidos en el proceso solo despu\u00e9s de una inspecci\u00f3n especial, investigaci\u00f3n y aprobaci\u00f3n por parte del personal autorizado. Es fundamental mantener un registro detallado de esta operaci\u00f3n.\n\n2. **Investigaci\u00f3n de Discrepancias**: Cualquier discrepancia significativa observada durante la reconciliaci\u00f3n de productos y materiales de empaquetado debe ser investigada y registrada antes de la liberaci\u00f3n del producto. Esto incluye la revisi\u00f3n de registros de producci\u00f3n y la investigaci\u00f3n de cualquier divergencia en las especificaciones de producci\u00f3n.\n\n3. **Pr\u00e1cticas de Control de Calidad (QC)**: El control de calidad es una parte esencial de las Buenas Pr\u00e1cticas de Manufactura (GMP) que se ocupa de la muestreo, especificaciones y pruebas. La independencia del QC respecto a la producci\u00f3n es fundamental, y cada fabricante debe contar con una funci\u00f3n de QC que tenga recursos adecuados para llevar a cabo sus responsabilidades.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para reintroducir un producto en el proceso de empaquetado despu\u00e9s de un evento inusual?**\n   - La reintroducci\u00f3n de un producto en el proceso de empaquetado tras un evento inusual requiere una inspecci\u00f3n especial, una investigaci\u00f3n y la aprobaci\u00f3n de personal autorizado. Adem\u00e1s, se debe mantener un registro detallado de esta operaci\u00f3n.\n\n2. **\u00bfC\u00f3mo se debe manejar una discrepancia significativa observada durante la reconciliaci\u00f3n de productos?**\n   - Cualquier discrepancia significativa debe ser investigada, satisfactoriamente contabilizada y registrada antes de la liberaci\u00f3n del producto. Esto incluye revisar los registros de producci\u00f3n y, si es necesario, investigar otros lotes del mismo producto o productos asociados.\n\n3. **\u00bfCu\u00e1les son los requisitos b\u00e1sicos para una funci\u00f3n de control de calidad (QC) en un fabricante?**\n   - Los requisitos b\u00e1sicos para una funci\u00f3n de QC incluyen la disponibilidad de instalaciones adecuadas, personal capacitado y procedimientos aprobados para el muestreo, inspecci\u00f3n y prueba de materiales de inicio. Adem\u00e1s, la funci\u00f3n de QC debe ser independiente de otros departamentos y estar bajo la autoridad de una persona con las calificaciones y experiencia adecuadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n sobre Operaciones de Empaque\n\n1. **Minimizaci\u00f3n de Riesgos**: Se enfatiza la importancia de establecer un programa de operaciones de empaque que minimice el riesgo de contaminaci\u00f3n cruzada, confusiones o sustituciones. Se proh\u00edbe empaquetar productos diferentes en proximidad a menos que haya segregaci\u00f3n f\u00edsica o un sistema alternativo que garantice la seguridad.\n\n2. **Limpieza del \u00c1rea de Trabajo**: Antes de iniciar las operaciones de empaque, es esencial asegurar que el \u00e1rea de trabajo, las l\u00edneas de empaque, las m\u00e1quinas de impresi\u00f3n y otros equipos est\u00e9n limpios y libres de materiales no necesarios. Esto debe incluir un procedimiento de limpieza de l\u00ednea documentado.\n\n3. **Identificaci\u00f3n del Producto**: El nombre y el n\u00famero de lote del producto deben estar visibles en cada estaci\u00f3n o l\u00ednea de empaque.\n\n4. **Control de Etiquetado**: El llenado y sellado deben ser seguidos r\u00e1pidamente por el etiquetado. Si hay retrasos, se deben aplicar procedimientos para evitar confusiones o errores en el etiquetado.\n\n5. **Verificaci\u00f3n de Impresi\u00f3n**: Se debe verificar y registrar la correcta impresi\u00f3n de n\u00fameros de c\u00f3digo o fechas de caducidad, prestando especial atenci\u00f3n a la impresi\u00f3n manual.\n\n6. **Uso de Etiquetas**: Se debe tener cuidado al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea. Las etiquetas de alimentaci\u00f3n en rollo son preferibles para evitar confusiones. Se recomienda la verificaci\u00f3n en l\u00ednea de etiquetas mediante medios electr\u00f3nicos automatizados y controles m\u00e1s frecuentes para etiquetas manuales.\n\n7. **Control de Calidad Durante el Empaque**: Se deben realizar verificaciones regulares durante el empaque que incluyan la apariencia de los paquetes, la completitud de los mismos, el uso correcto de productos y materiales de empaque, la correcci\u00f3n de sobreimpresiones y el funcionamiento de los monitores de l\u00ednea.\n\n8. **Manejo de Muestras**: Las muestras que se retiran de la l\u00ednea de empaque no deben ser devueltas.\n\n### Entidades Clave\n- **Productos**: Elementos que se empaquetan.\n- **L\u00ednea de Empaque**: Equipos y estaciones donde se realizan las operaciones de empaque.\n- **Etiquetas**: Material utilizado para identificar productos.\n- **Procedimientos de Limpieza**: Protocolos para asegurar la limpieza del \u00e1rea de trabajo.\n- **Control de Calidad**: Proceso de verificaci\u00f3n durante las operaciones de empaque. \n\nEste resumen destaca la importancia de la seguridad, limpieza y control de calidad en las operaciones de empaque para garantizar la integridad del producto.", "excerpt_keywords": "Keywords: packaging, quality control, inspection, discrepancies, Good Manufacturing Practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9baf9cfe-003e-4e10-a38b-b2b997f6c97b", "node_type": "4", "metadata": {"page_label": "154", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 16.33 \nProducts that have been involved in an unusual event during packaging should be reintroduced into the process only after special inspection, investigation and approval by authorized personnel. A detailed record should be kept of this operation.\n\n16.34 \nAny significant or unusual discrepancy observed during reconciliation of the amount of bulk product and printed packaging materials and the number of units produced should be investigated, satisfactorily accounted for, and recorded before release.\n\n16.35 \nUpon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed and the destruction recorded. A documented procedure requiring checks to be performed before returning unused materials should be followed if uncoded printed materials are returned to stock.\n\n16.36 \nProduction records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet production specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n# 17. Good practices in quality control\n\n17.1 \nQC is the part of GMP concerned with sampling, specifications and testing, and with the organization and documentation which ensure that the necessary and relevant tests are actually carried out and that materials are not released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. QC is not confined to laboratory operations, but may be involved in many decisions concerning the quality of the product.\n\n17.2 \nThe independence of QC from production is considered fundamental.\n\n17.3 \nEach manufacturer should have a QC function. The QC function should be independent of other departments and under the authority of a person with appropriate qualifications and experience, who has one or several control laboratories at his or her disposal. Adequate resources must be available to ensure that all the QC arrangements are effectively and reliably carried out. The basic requirements for QC are as follows:\n\n(a) adequate facilities, trained personnel and approved procedures must be available for sampling, inspecting, and testing starting materials,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a750befd79b11dda88be507cdcf435ddf9bbe782488eaa2ea1f51018736ab1b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 16.33 \nProducts that have been involved in an unusual event during packaging should be reintroduced into the process only after special inspection, investigation and approval by authorized personnel. A detailed record should be kept of this operation.\n\n16.34 \nAny significant or unusual discrepancy observed during reconciliation of the amount of bulk product and printed packaging materials and the number of units produced should be investigated, satisfactorily accounted for, and recorded before release.\n\n16.35 \nUpon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed and the destruction recorded. A documented procedure requiring checks to be performed before returning unused materials should be followed if uncoded printed materials are returned to stock.\n\n16.36 \nProduction records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet production specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n# 17. Good practices in quality control\n\n17.1 \nQC is the part of GMP concerned with sampling, specifications and testing, and with the organization and documentation which ensure that the necessary and relevant tests are actually carried out and that materials are not released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. QC is not confined to laboratory operations, but may be involved in many decisions concerning the quality of the product.\n\n17.2 \nThe independence of QC from production is considered fundamental.\n\n17.3 \nEach manufacturer should have a QC function. The QC function should be independent of other departments and under the authority of a person with appropriate qualifications and experience, who has one or several control laboratories at his or her disposal. Adequate resources must be available to ensure that all the QC arrangements are effectively and reliably carried out. The basic requirements for QC are as follows:\n\n(a) adequate facilities, trained personnel and approved procedures must be available for sampling, inspecting, and testing starting materials,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2492, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6bc684c3-945a-494c-bbec-71e427f6b3a7": {"__data__": {"id_": "6bc684c3-945a-494c-bbec-71e427f6b3a7", "embedding": null, "metadata": {"page_label": "155", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\npackaging materials, and intermediate, bulk, and finished products, \nand where appropriate for monitoring environmental conditions for \nGMP purposes; \n(b) samples of starting materials, packaging materials, intermediate \nproducts, bulk products and finished products must be taken by methods \nand personnel approved of by the QC department; \n(c) qualification and validation; \n(d) records must be made (manually and/or by recording instruments) \ndemonstrating that all the required sampling, inspecting and testing \nprocedures have actually been carried out and that any deviations have \nbeen fully recorded and investigated; \n(e) the finished products must contain ingredients complying with the \nqualitative and quantitative composition of the product described in \nthe marketing authorization; the ingredients must be of the required \npurity, in their proper container and correctly labelled; \n(f) records must be made of the results of inspecting and testing the materials \nand intermediate, bulk and finished products against specifications; \nproduct assessment must include a review and evaluation of the \nrelevant production documentation and an assessment of deviations \nfrom specified procedures; \n(g) sufficient samples of starting materials and products must be retained \nto permit future examination of the product if necessary; the retained \nproduct must be kept in its final pack unless the pack is exceptionally \nlarge. \n\n17.4 QC as a whole will also have other duties, such as to establish, \nvalidate and implement all QC procedures, to evaluate, maintain, and store \nthe reference standards for substances, to ensure the correct labelling of \ncontainers of materials and products, to ensure that the stability of the active \npharmaceutical ingredients (APIs) and products is monitored, to participate \nin the investigation of complaints related to the quality of the product, and \nto participate in environmental monitoring. All these operations should be \ncarried out in accordance with written procedures and, where necessary, \nrecorded. \n\n17.5 QC personnel must have access to production areas for sampling and \ninvestigation as appropriate. \n\n**Control of starting materials and intermediate, \nbulk and finished products**\n\n17.6 All tests should follow the instructions given in the relevant \nwritten test procedure for each material or product. The result should \nbe checked by the supervisor before the material or product is released \nor rejected.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl texto se centra en los procedimientos de control de calidad (QC) en la producci\u00f3n farmac\u00e9utica, destacando la importancia de la toma de muestras, la validaci\u00f3n de procesos, el registro de resultados y la garant\u00eda de que los productos terminados cumplan con las especificaciones establecidas. Se enfatiza la necesidad de que el personal de QC tenga acceso a las \u00e1reas de producci\u00f3n y que todas las operaciones se realicen de acuerdo con procedimientos escritos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la toma de muestras de materiales y productos en el contexto de control de calidad?**\n   - Respuesta: Las muestras de materiales y productos deben ser tomadas por m\u00e9todos y personal aprobados por el departamento de control de calidad (QC), asegurando que se sigan las instrucciones de los procedimientos de prueba escritos.\n\n2. **\u00bfQu\u00e9 registros son necesarios para demostrar que se han cumplido los procedimientos de muestreo, inspecci\u00f3n y prueba?**\n   - Respuesta: Se deben realizar registros manuales y/o mediante instrumentos de grabaci\u00f3n que demuestren que todos los procedimientos requeridos han sido llevados a cabo, y que cualquier desviaci\u00f3n ha sido completamente registrada e investigada.\n\n3. **\u00bfCu\u00e1les son algunas de las responsabilidades adicionales del departamento de control de calidad (QC) m\u00e1s all\u00e1 de la inspecci\u00f3n de productos?**\n   - Respuesta: Adem\u00e1s de la inspecci\u00f3n de productos, el departamento de QC tiene la responsabilidad de establecer, validar e implementar todos los procedimientos de QC, evaluar y mantener est\u00e1ndares de referencia, asegurar el etiquetado correcto de los envases, monitorear la estabilidad de los ingredientes farmac\u00e9uticos activos (APIs) y participar en la investigaci\u00f3n de quejas relacionadas con la calidad del producto.", "prev_section_summary": "### Temas Clave:\n\n1. **Reintroducci\u00f3n de Productos**: Los productos que han tenido eventos inusuales durante el empaquetado deben ser reintroducidos solo despu\u00e9s de una inspecci\u00f3n especial, investigaci\u00f3n y aprobaci\u00f3n por parte de personal autorizado, manteniendo un registro detallado de la operaci\u00f3n.\n\n2. **Investigaci\u00f3n de Discrepancias**: Cualquier discrepancia significativa observada durante la reconciliaci\u00f3n de productos y materiales de empaquetado debe ser investigada y registrada antes de la liberaci\u00f3n del producto. Esto incluye revisar los registros de producci\u00f3n y, si es necesario, investigar otros lotes relacionados.\n\n3. **Destrucci\u00f3n de Materiales No Utilizados**: Al finalizar una operaci\u00f3n de empaquetado, los materiales de empaquetado no utilizados deben ser destruidos y documentados adecuadamente.\n\n4. **Control de Calidad (QC)**: El control de calidad es esencial en las Buenas Pr\u00e1cticas de Manufactura (GMP) y se ocupa de muestreo, especificaciones y pruebas. La independencia del QC respecto a la producci\u00f3n es fundamental, y cada fabricante debe contar con una funci\u00f3n de QC con recursos adecuados.\n\n5. **Requisitos para la Funci\u00f3n de QC**: La funci\u00f3n de QC debe tener instalaciones adecuadas, personal capacitado y procedimientos aprobados para el muestreo, inspecci\u00f3n y prueba de materiales de inicio.\n\n### Entidades:\n\n- **Productos**: Elementos involucrados en el proceso de empaquetado.\n- **Personal Autorizado**: Individuos responsables de la inspecci\u00f3n y aprobaci\u00f3n de productos.\n- **Registros de Producci\u00f3n**: Documentaci\u00f3n que debe ser revisada durante el proceso de liberaci\u00f3n de lotes.\n- **Materiales de Empaque**: Incluyen materiales codificados y no codificados utilizados en el empaquetado de productos.\n- **Control de Calidad (QC)**: Funci\u00f3n que asegura que los productos cumplan con los est\u00e1ndares de calidad antes de su liberaci\u00f3n.\n- **Manufactura**: Proceso de producci\u00f3n que debe seguir las Buenas Pr\u00e1cticas de Manufactura (GMP).", "excerpt_keywords": "Keywords: control de calidad, muestreo, productos farmac\u00e9uticos, validaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "188da637-1a00-4772-9d35-a7137bc7eb22", "node_type": "4", "metadata": {"page_label": "155", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\npackaging materials, and intermediate, bulk, and finished products, \nand where appropriate for monitoring environmental conditions for \nGMP purposes; \n(b) samples of starting materials, packaging materials, intermediate \nproducts, bulk products and finished products must be taken by methods \nand personnel approved of by the QC department; \n(c) qualification and validation; \n(d) records must be made (manually and/or by recording instruments) \ndemonstrating that all the required sampling, inspecting and testing \nprocedures have actually been carried out and that any deviations have \nbeen fully recorded and investigated; \n(e) the finished products must contain ingredients complying with the \nqualitative and quantitative composition of the product described in \nthe marketing authorization; the ingredients must be of the required \npurity, in their proper container and correctly labelled; \n(f) records must be made of the results of inspecting and testing the materials \nand intermediate, bulk and finished products against specifications; \nproduct assessment must include a review and evaluation of the \nrelevant production documentation and an assessment of deviations \nfrom specified procedures; \n(g) sufficient samples of starting materials and products must be retained \nto permit future examination of the product if necessary; the retained \nproduct must be kept in its final pack unless the pack is exceptionally \nlarge. \n\n17.4 QC as a whole will also have other duties, such as to establish, \nvalidate and implement all QC procedures, to evaluate, maintain, and store \nthe reference standards for substances, to ensure the correct labelling of \ncontainers of materials and products, to ensure that the stability of the active \npharmaceutical ingredients (APIs) and products is monitored, to participate \nin the investigation of complaints related to the quality of the product, and \nto participate in environmental monitoring. All these operations should be \ncarried out in accordance with written procedures and, where necessary, \nrecorded. \n\n17.5 QC personnel must have access to production areas for sampling and \ninvestigation as appropriate. \n\n**Control of starting materials and intermediate, \nbulk and finished products**\n\n17.6 All tests should follow the instructions given in the relevant \nwritten test procedure for each material or product. The result should \nbe checked by the supervisor before the material or product is released \nor rejected.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d8477ee40578b09158305b34be815ba574e465cdde0d144cc06c9c39459950dc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\npackaging materials, and intermediate, bulk, and finished products, \nand where appropriate for monitoring environmental conditions for \nGMP purposes; \n(b) samples of starting materials, packaging materials, intermediate \nproducts, bulk products and finished products must be taken by methods \nand personnel approved of by the QC department; \n(c) qualification and validation; \n(d) records must be made (manually and/or by recording instruments) \ndemonstrating that all the required sampling, inspecting and testing \nprocedures have actually been carried out and that any deviations have \nbeen fully recorded and investigated; \n(e) the finished products must contain ingredients complying with the \nqualitative and quantitative composition of the product described in \nthe marketing authorization; the ingredients must be of the required \npurity, in their proper container and correctly labelled; \n(f) records must be made of the results of inspecting and testing the materials \nand intermediate, bulk and finished products against specifications; \nproduct assessment must include a review and evaluation of the \nrelevant production documentation and an assessment of deviations \nfrom specified procedures; \n(g) sufficient samples of starting materials and products must be retained \nto permit future examination of the product if necessary; the retained \nproduct must be kept in its final pack unless the pack is exceptionally \nlarge. \n\n17.4 QC as a whole will also have other duties, such as to establish, \nvalidate and implement all QC procedures, to evaluate, maintain, and store \nthe reference standards for substances, to ensure the correct labelling of \ncontainers of materials and products, to ensure that the stability of the active \npharmaceutical ingredients (APIs) and products is monitored, to participate \nin the investigation of complaints related to the quality of the product, and \nto participate in environmental monitoring. All these operations should be \ncarried out in accordance with written procedures and, where necessary, \nrecorded. \n\n17.5 QC personnel must have access to production areas for sampling and \ninvestigation as appropriate. \n\n**Control of starting materials and intermediate, \nbulk and finished products**\n\n17.6 All tests should follow the instructions given in the relevant \nwritten test procedure for each material or product. The result should \nbe checked by the supervisor before the material or product is released \nor rejected.\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2479, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f70c88-8dfa-4c2f-b442-3875c39f0a69": {"__data__": {"id_": "d8f70c88-8dfa-4c2f-b442-3875c39f0a69", "embedding": null, "metadata": {"page_label": "156", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 17.7 \nSamples should be representative of the batches of material from which they are taken in accordance with the approved written procedure.\n\n# 17.8 \nSampling should be carried out so as to avoid contamination or other adverse effects on quality. The containers that have been sampled should be marked accordingly and carefully resealed after sampling.\n\n# 17.9 \nCare should be taken during sampling to guard against contamination or mix up of, or by, the material being sampled. All sampling equipment that comes into contact with the material should be clean. Some particularly hazardous or potent materials may require special precautions.\n\n# 17.10 \nSampling equipment should be cleaned and, if necessary, sterilized before and after each use and stored separately from other laboratory equipment.\n\n# 17.11 \nEach sample container should bear a label indicating:\n\n(a) the name of the sampled material;  \n(b) the batch or lot number;  \n(c) the number of the container from which the sample has been taken;  \n(d) the number of the sample;  \n(e) the signature of the person who has taken the sample;  \n(f) the date of sampling.\n\n# 17.12 \nOut-of-specification results obtained during testing of materials or products should be investigated in accordance with an approved procedure. Records should be maintained.\n\n## Test requirements\n\n### Starting and packaging materials\n\n# 17.13 \nBefore releasing a starting or packaging material for use, the QC manager should ensure that the materials have been tested for conformity with specifications for identity, strength, purity and other quality parameters.\n\n# 17.14 \nAn identity test should be conducted on a sample from each container of starting material (see also section 14.14).\n\nIt is permissible to sample only a proportion of the containers where a validated procedure has been established to ensure that no single container of starting material has been incorrectly labelled.\n\nThis validation should take account of at least the following aspects:\n\n- the nature and status of the manufacturer and of the supplier and their understanding of the GMP requirements;\n- the QA system of the manufacturer of the starting material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de muestreo y pruebas de materiales de inicio y empaquetado seg\u00fan las normas de Buenas Pr\u00e1cticas de Manufactura (GMP) establecidas por la OMS. Se enfatiza la importancia de que las muestras sean representativas, la limpieza y esterilizaci\u00f3n del equipo de muestreo, el etiquetado adecuado de los contenedores de muestra, y la necesidad de realizar pruebas de identidad y conformidad antes de liberar materiales para su uso. Tambi\u00e9n se menciona la investigaci\u00f3n de resultados fuera de especificaci\u00f3n y la validaci\u00f3n de procedimientos de muestreo.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar que las muestras sean representativas de los lotes de material?**\n   - La respuesta se puede encontrar en la secci\u00f3n 17.7, que establece que las muestras deben ser representativas de los lotes de material de acuerdo con un procedimiento escrito aprobado.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de cada contenedor de muestra?**\n   - Seg\u00fan la secci\u00f3n 17.11, cada contenedor de muestra debe llevar una etiqueta que indique el nombre del material muestreado, el n\u00famero de lote, el n\u00famero del contenedor, el n\u00famero de la muestra, la firma de la persona que tom\u00f3 la muestra y la fecha de muestreo.\n\n3. **\u00bfCu\u00e1les son los aspectos que deben considerarse al validar un procedimiento de muestreo para materiales de inicio?**\n   - La validaci\u00f3n debe tener en cuenta la naturaleza y el estado del fabricante y del proveedor, as\u00ed como su comprensi\u00f3n de los requisitos de GMP y el sistema de aseguramiento de calidad del fabricante del material de inicio, como se menciona en la secci\u00f3n 17.14.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Control de Calidad (QC):** Se enfatiza la importancia de los procedimientos de control de calidad en la producci\u00f3n farmac\u00e9utica, incluyendo la toma de muestras, la inspecci\u00f3n y la validaci\u00f3n de productos.\n\n2. **Muestreo de Materiales:** Se requiere que las muestras de materiales (iniciadores, empaques, productos intermedios, a granel y terminados) sean tomadas por m\u00e9todos y personal aprobados por el departamento de QC.\n\n3. **Registro de Procedimientos:** Es esencial llevar registros manuales y/o mediante instrumentos que demuestren que se han cumplido todos los procedimientos de muestreo, inspecci\u00f3n y prueba, as\u00ed como registrar cualquier desviaci\u00f3n.\n\n4. **Cumplimiento de Especificaciones:** Los productos terminados deben cumplir con la composici\u00f3n cualitativa y cuantitativa descrita en la autorizaci\u00f3n de comercializaci\u00f3n, y los ingredientes deben ser de la pureza requerida y correctamente etiquetados.\n\n5. **Responsabilidades del Departamento de QC:** Adem\u00e1s de la inspecci\u00f3n, el departamento de QC debe establecer y validar procedimientos, mantener est\u00e1ndares de referencia, monitorear la estabilidad de los ingredientes activos y participar en la investigaci\u00f3n de quejas sobre la calidad del producto.\n\n6. **Acceso a \u00c1reas de Producci\u00f3n:** El personal de QC debe tener acceso a las \u00e1reas de producci\u00f3n para realizar muestreos e investigaciones.\n\n7. **Procedimientos de Prueba:** Todos los tests deben seguir las instrucciones de los procedimientos de prueba escritos, y los resultados deben ser verificados por un supervisor antes de liberar o rechazar un material o producto.\n\n**Entidades:**\n\n- **Materiales:** Iniciadores, materiales de empaque, productos intermedios, productos a granel, productos terminados.\n- **Departamento de Control de Calidad (QC):** Responsable de la implementaci\u00f3n y supervisi\u00f3n de los procedimientos de control de calidad.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs):** Sustancias cuya estabilidad debe ser monitoreada.\n- **Documentaci\u00f3n de Producci\u00f3n:** Registros que deben ser revisados y evaluados como parte del proceso de control de calidad.\n\nEste resumen destaca la importancia de los procedimientos de control de calidad en la industria farmac\u00e9utica y las responsabilidades del personal involucrado en asegurar que los productos cumplan con los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: muestreo, control de calidad, Buenas Pr\u00e1cticas de Manufactura, etiquetado, validaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "873ddd4a-bb00-402e-bb3f-cb0925e89263", "node_type": "4", "metadata": {"page_label": "156", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 17.7 \nSamples should be representative of the batches of material from which they are taken in accordance with the approved written procedure.\n\n# 17.8 \nSampling should be carried out so as to avoid contamination or other adverse effects on quality. The containers that have been sampled should be marked accordingly and carefully resealed after sampling.\n\n# 17.9 \nCare should be taken during sampling to guard against contamination or mix up of, or by, the material being sampled. All sampling equipment that comes into contact with the material should be clean. Some particularly hazardous or potent materials may require special precautions.\n\n# 17.10 \nSampling equipment should be cleaned and, if necessary, sterilized before and after each use and stored separately from other laboratory equipment.\n\n# 17.11 \nEach sample container should bear a label indicating:\n\n(a) the name of the sampled material;  \n(b) the batch or lot number;  \n(c) the number of the container from which the sample has been taken;  \n(d) the number of the sample;  \n(e) the signature of the person who has taken the sample;  \n(f) the date of sampling.\n\n# 17.12 \nOut-of-specification results obtained during testing of materials or products should be investigated in accordance with an approved procedure. Records should be maintained.\n\n## Test requirements\n\n### Starting and packaging materials\n\n# 17.13 \nBefore releasing a starting or packaging material for use, the QC manager should ensure that the materials have been tested for conformity with specifications for identity, strength, purity and other quality parameters.\n\n# 17.14 \nAn identity test should be conducted on a sample from each container of starting material (see also section 14.14).\n\nIt is permissible to sample only a proportion of the containers where a validated procedure has been established to ensure that no single container of starting material has been incorrectly labelled.\n\nThis validation should take account of at least the following aspects:\n\n- the nature and status of the manufacturer and of the supplier and their understanding of the GMP requirements;\n- the QA system of the manufacturer of the starting material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ea87d0e6b6f9806e2ce106960299084137d9d4de1dfc9bcae66182963eac368a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 17.7 \nSamples should be representative of the batches of material from which they are taken in accordance with the approved written procedure.\n\n# 17.8 \nSampling should be carried out so as to avoid contamination or other adverse effects on quality. The containers that have been sampled should be marked accordingly and carefully resealed after sampling.\n\n# 17.9 \nCare should be taken during sampling to guard against contamination or mix up of, or by, the material being sampled. All sampling equipment that comes into contact with the material should be clean. Some particularly hazardous or potent materials may require special precautions.\n\n# 17.10 \nSampling equipment should be cleaned and, if necessary, sterilized before and after each use and stored separately from other laboratory equipment.\n\n# 17.11 \nEach sample container should bear a label indicating:\n\n(a) the name of the sampled material;  \n(b) the batch or lot number;  \n(c) the number of the container from which the sample has been taken;  \n(d) the number of the sample;  \n(e) the signature of the person who has taken the sample;  \n(f) the date of sampling.\n\n# 17.12 \nOut-of-specification results obtained during testing of materials or products should be investigated in accordance with an approved procedure. Records should be maintained.\n\n## Test requirements\n\n### Starting and packaging materials\n\n# 17.13 \nBefore releasing a starting or packaging material for use, the QC manager should ensure that the materials have been tested for conformity with specifications for identity, strength, purity and other quality parameters.\n\n# 17.14 \nAn identity test should be conducted on a sample from each container of starting material (see also section 14.14).\n\nIt is permissible to sample only a proportion of the containers where a validated procedure has been established to ensure that no single container of starting material has been incorrectly labelled.\n\nThis validation should take account of at least the following aspects:\n\n- the nature and status of the manufacturer and of the supplier and their understanding of the GMP requirements;\n- the QA system of the manufacturer of the starting material;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2177, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "198e0c74-b97d-4d8e-8962-94cf7b764c26": {"__data__": {"id_": "198e0c74-b97d-4d8e-8962-94cf7b764c26", "embedding": null, "metadata": {"page_label": "157", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the manufacturing conditions under which the starting material is produced and controlled; and  \n\u2014 the nature of the starting material and the medicinal products in which it will be used.\n\nUnder such a system it is possible that a validated procedure for exemption from the requirement for identity testing of each incoming container of starting material could be accepted for the following:\n\n\u2014 starting materials coming from a single product manufacturer or plant;  \nor  \n\u2014 starting materials coming directly from a manufacturer, or in the manufacturer\u2019s sealed container where there is a history of reliability, and regular audits of the manufacturer\u2019s QA system are conducted by the purchaser (the manufacturer of the medicinal product) or by an officially accredited body.\n\nIt is improbable that such a procedure could be satisfactorily validated for either:\n\n\u2014 starting materials supplied by intermediaries, such as brokers, where the source of manufacture is unknown or not audited; or  \n\u2014 starting materials for use in parenteral products.\n\n17.15 Each batch (lot) of printed packaging materials must be examined following receipt.\n\n17.16 In lieu of full testing by the manufacturer, a certificate of analysis may be accepted from the supplier, provided that the manufacturer establishes the reliability of the supplier\u2019s analysis through appropriate periodic validation of the supplier\u2019s test results (see sections 8.8 and 8.9) and through on-site audits of the supplier\u2019s capabilities. (This does not affect section 17.15.) Certificates must be originals (not photocopies) or otherwise have their authenticity assured. Certificates must contain at least the following information (7):\n\n(a) identification (name and address) of the issuing supplier;  \n(b) signature of the competent official, and statement of his or her qualifications;  \n(c) the name of the material tested;  \n(d) the batch number of the material tested;  \n(e) the specifications and methods used;  \n(f) the test results obtained;  \n(g) the date of testing.\n\n*In-process control*  \n17.17 In-process control records should be maintained and form a part of the batch records (see section 15.25).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda las condiciones de fabricaci\u00f3n y control de los materiales de partida utilizados en la producci\u00f3n de productos medicinales. Se discuten procedimientos para la exenci\u00f3n de pruebas de identidad de los materiales de partida, especialmente en situaciones donde hay un historial de fiabilidad del fabricante. Tambi\u00e9n se menciona la aceptaci\u00f3n de certificados de an\u00e1lisis de proveedores, as\u00ed como la necesidad de mantener registros de control en proceso como parte de la documentaci\u00f3n de lotes.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede aceptar un procedimiento validado para la exenci\u00f3n de pruebas de identidad de los materiales de partida?**\n   - Respuesta: Se puede aceptar un procedimiento validado para la exenci\u00f3n de pruebas de identidad si los materiales de partida provienen de un \u00fanico fabricante o planta, o si provienen directamente de un fabricante en un contenedor sellado, siempre que haya un historial de fiabilidad y se realicen auditor\u00edas regulares del sistema de aseguramiento de calidad del fabricante.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener un certificado de an\u00e1lisis aceptado por el fabricante?**\n   - Respuesta: Un certificado de an\u00e1lisis debe contener la identificaci\u00f3n del proveedor, la firma de un funcionario competente, el nombre del material probado, el n\u00famero de lote, las especificaciones y m\u00e9todos utilizados, los resultados de las pruebas obtenidos y la fecha de la prueba.\n\n3. **\u00bfQu\u00e9 se debe hacer con cada lote de materiales de embalaje impresos tras su recepci\u00f3n?**\n   - Respuesta: Cada lote de materiales de embalaje impresos debe ser examinado tras su recepci\u00f3n, seg\u00fan lo indicado en la secci\u00f3n 17.15 del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Muestreo Representativo**:\n   - Las muestras deben ser representativas de los lotes de material, siguiendo un procedimiento escrito aprobado (Secci\u00f3n 17.7).\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n**:\n   - Se deben tomar medidas para evitar la contaminaci\u00f3n y otros efectos adversos en la calidad durante el muestreo (Secci\u00f3n 17.8 y 17.9).\n   - El equipo de muestreo debe estar limpio y, en caso necesario, esterilizado antes y despu\u00e9s de su uso (Secci\u00f3n 17.10).\n\n3. **Etiquetado de Contenedores de Muestra**:\n   - Cada contenedor de muestra debe estar etiquetado con informaci\u00f3n espec\u00edfica, incluyendo el nombre del material, n\u00famero de lote, n\u00famero del contenedor, n\u00famero de muestra, firma del muestreador y fecha de muestreo (Secci\u00f3n 17.11).\n\n4. **Investigaci\u00f3n de Resultados Fuera de Especificaci\u00f3n**:\n   - Los resultados que no cumplan con las especificaciones deben ser investigados de acuerdo con un procedimiento aprobado, y se deben mantener registros (Secci\u00f3n 17.12).\n\n5. **Requisitos de Prueba para Materiales de Inicio y Empaque**:\n   - Antes de liberar materiales para su uso, el gerente de control de calidad debe asegurarse de que se hayan probado para verificar su conformidad con las especificaciones de identidad, fuerza, pureza y otros par\u00e1metros de calidad (Secci\u00f3n 17.13).\n   - Se debe realizar una prueba de identidad en una muestra de cada contenedor de material de inicio, con la posibilidad de muestrear solo una proporci\u00f3n de los contenedores si se ha establecido un procedimiento validado (Secci\u00f3n 17.14).\n\n6. **Validaci\u00f3n de Procedimientos de Muestreo**:\n   - La validaci\u00f3n de los procedimientos de muestreo debe considerar la naturaleza y estado del fabricante y proveedor, su comprensi\u00f3n de los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) y el sistema de aseguramiento de calidad del fabricante del material de inicio (Secci\u00f3n 17.14).\n\n### Entidades Clave\n- **Organizaci\u00f3n**: OMS (Organizaci\u00f3n Mundial de la Salud)\n- **Documentos**: Buenas Pr\u00e1cticas de Manufactura (GMP), Procedimientos aprobados\n- **Roles**: Gerente de Control de Calidad (QC Manager)\n- **Materiales**: Materiales de inicio y empaquetado, Muestras, Contenedores de muestra\n- **Par\u00e1metros de Calidad**: Identidad, Fuerza, Pureza, Conformidad\n\nEste resumen destaca la importancia de seguir procedimientos rigurosos en el muestreo y pruebas de materiales para garantizar la calidad y seguridad en la manufactura.", "excerpt_keywords": "Keywords: starting materials, identity testing, certificate of analysis, quality assurance, in-process control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92024896-d8dc-40ec-8113-cfbf90b70e0f", "node_type": "4", "metadata": {"page_label": "157", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the manufacturing conditions under which the starting material is produced and controlled; and  \n\u2014 the nature of the starting material and the medicinal products in which it will be used.\n\nUnder such a system it is possible that a validated procedure for exemption from the requirement for identity testing of each incoming container of starting material could be accepted for the following:\n\n\u2014 starting materials coming from a single product manufacturer or plant;  \nor  \n\u2014 starting materials coming directly from a manufacturer, or in the manufacturer\u2019s sealed container where there is a history of reliability, and regular audits of the manufacturer\u2019s QA system are conducted by the purchaser (the manufacturer of the medicinal product) or by an officially accredited body.\n\nIt is improbable that such a procedure could be satisfactorily validated for either:\n\n\u2014 starting materials supplied by intermediaries, such as brokers, where the source of manufacture is unknown or not audited; or  \n\u2014 starting materials for use in parenteral products.\n\n17.15 Each batch (lot) of printed packaging materials must be examined following receipt.\n\n17.16 In lieu of full testing by the manufacturer, a certificate of analysis may be accepted from the supplier, provided that the manufacturer establishes the reliability of the supplier\u2019s analysis through appropriate periodic validation of the supplier\u2019s test results (see sections 8.8 and 8.9) and through on-site audits of the supplier\u2019s capabilities. (This does not affect section 17.15.) Certificates must be originals (not photocopies) or otherwise have their authenticity assured. Certificates must contain at least the following information (7):\n\n(a) identification (name and address) of the issuing supplier;  \n(b) signature of the competent official, and statement of his or her qualifications;  \n(c) the name of the material tested;  \n(d) the batch number of the material tested;  \n(e) the specifications and methods used;  \n(f) the test results obtained;  \n(g) the date of testing.\n\n*In-process control*  \n17.17 In-process control records should be maintained and form a part of the batch records (see section 15.25).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bc064111f1a8c2c2e4b682b665bfc6b8bc46bb72b48c454630ea6b47a946ba0e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 the manufacturing conditions under which the starting material is produced and controlled; and  \n\u2014 the nature of the starting material and the medicinal products in which it will be used.\n\nUnder such a system it is possible that a validated procedure for exemption from the requirement for identity testing of each incoming container of starting material could be accepted for the following:\n\n\u2014 starting materials coming from a single product manufacturer or plant;  \nor  \n\u2014 starting materials coming directly from a manufacturer, or in the manufacturer\u2019s sealed container where there is a history of reliability, and regular audits of the manufacturer\u2019s QA system are conducted by the purchaser (the manufacturer of the medicinal product) or by an officially accredited body.\n\nIt is improbable that such a procedure could be satisfactorily validated for either:\n\n\u2014 starting materials supplied by intermediaries, such as brokers, where the source of manufacture is unknown or not audited; or  \n\u2014 starting materials for use in parenteral products.\n\n17.15 Each batch (lot) of printed packaging materials must be examined following receipt.\n\n17.16 In lieu of full testing by the manufacturer, a certificate of analysis may be accepted from the supplier, provided that the manufacturer establishes the reliability of the supplier\u2019s analysis through appropriate periodic validation of the supplier\u2019s test results (see sections 8.8 and 8.9) and through on-site audits of the supplier\u2019s capabilities. (This does not affect section 17.15.) Certificates must be originals (not photocopies) or otherwise have their authenticity assured. Certificates must contain at least the following information (7):\n\n(a) identification (name and address) of the issuing supplier;  \n(b) signature of the competent official, and statement of his or her qualifications;  \n(c) the name of the material tested;  \n(d) the batch number of the material tested;  \n(e) the specifications and methods used;  \n(f) the test results obtained;  \n(g) the date of testing.\n\n*In-process control*  \n17.17 In-process control records should be maintained and form a part of the batch records (see section 15.25).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2170, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "007d50e8-a64a-459e-bd3f-aed6f0dece60": {"__data__": {"id_": "007d50e8-a64a-459e-bd3f-aed6f0dece60", "embedding": null, "metadata": {"page_label": "158", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n17.18 For each batch of medicines product, there should be an appropriate laboratory determination of satisfactory conformity to its finished product specification prior to release.\n\n17.19 Products failing to meet the established specifications or any other relevant quality criteria should be rejected.\n\n## Batch Record Review\n\n17.20 QC records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet its specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n17.21 Retention samples from each batch of finished product should be kept for at least one year after the expiry date. Finished products should usually be kept in their final packaging and stored under the recommended conditions. If exceptionally large packages are produced, smaller samples might be stored in appropriate containers. Samples of active starting materials should be retained for at least one year beyond the expiry date of the corresponding finished product. Other starting materials (other than solvents, gases and water) should be retained for a minimum of two years if their stability allows. Retention samples of materials and products should be of a size sufficient to permit at least two full re-examinations.\n\n## Stability Studies\n\n17.22 QC should evaluate the quality and stability of finished pharmaceutical products and, when necessary, of starting materials and intermediate products.\n\n17.23 QC should establish expiry dates and shelf-life specifications on the basis of stability tests related to storage conditions.\n\n17.24 A written programme for ongoing stability determination should be developed and implemented to include elements such as:\n\n- (a) a complete description of the medicine involved in the study;\n- (b) the complete set of testing parameters and methods, describing all tests for potency, purity, and physical characteristics and documented evidence that these tests indicate stability;\n- (c) provision for the inclusion of a sufficient number of batches;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las normas y procedimientos relacionados con la calidad y la estabilidad de los productos farmac\u00e9uticos terminados. Se enfatiza la importancia de realizar determinaciones de conformidad en cada lote de medicamentos antes de su liberaci\u00f3n, as\u00ed como la necesidad de revisar los registros de control de calidad (QC) y llevar a cabo investigaciones en caso de discrepancias. Adem\u00e1s, se establecen directrices sobre la retenci\u00f3n de muestras y la realizaci\u00f3n de estudios de estabilidad para garantizar que los productos mantengan su calidad a lo largo de su vida \u00fatil.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si un lote de producto farmac\u00e9utico no cumple con las especificaciones establecidas?**\n   - Respuesta: Los productos que no cumplan con las especificaciones establecidas o cualquier otro criterio de calidad relevante deben ser rechazados. Adem\u00e1s, cualquier divergencia o fallo en un lote debe ser investigado a fondo, y la investigaci\u00f3n puede extenderse a otros lotes del mismo producto y a otros productos asociados.\n\n2. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras de retenci\u00f3n de los productos terminados y de los materiales de partida activos?**\n   - Respuesta: Las muestras de retenci\u00f3n de cada lote de producto terminado deben conservarse durante al menos un a\u00f1o despu\u00e9s de la fecha de caducidad. Las muestras de materiales de partida activos deben conservarse durante al menos un a\u00f1o m\u00e1s all\u00e1 de la fecha de caducidad del producto terminado correspondiente.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un programa escrito para la determinaci\u00f3n continua de la estabilidad de los productos farmac\u00e9uticos?**\n   - Respuesta: El programa debe incluir una descripci\u00f3n completa del medicamento involucrado en el estudio, un conjunto completo de par\u00e1metros y m\u00e9todos de prueba que describan todas las pruebas de potencia, pureza y caracter\u00edsticas f\u00edsicas, as\u00ed como evidencia documentada de que estas pruebas indican estabilidad. Tambi\u00e9n debe haber provisiones para incluir un n\u00famero suficiente de lotes en el estudio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Condiciones de Fabricaci\u00f3n y Control:** Se discuten las condiciones bajo las cuales se producen y controlan los materiales de partida utilizados en la fabricaci\u00f3n de productos medicinales.\n2. **Exenci\u00f3n de Pruebas de Identidad:** Se establece un procedimiento validado para la exenci\u00f3n de pruebas de identidad de los materiales de partida, aplicable en situaciones espec\u00edficas, como cuando los materiales provienen de un \u00fanico fabricante confiable.\n3. **Certificados de An\u00e1lisis:** Se permite la aceptaci\u00f3n de certificados de an\u00e1lisis de proveedores en lugar de pruebas completas, siempre que se valide la fiabilidad del an\u00e1lisis del proveedor mediante auditor\u00edas y validaciones peri\u00f3dicas.\n4. **Examen de Materiales de Embalaje:** Cada lote de materiales de embalaje impresos debe ser examinado tras su recepci\u00f3n.\n5. **Registros de Control en Proceso:** Se enfatiza la importancia de mantener registros de control en proceso como parte de la documentaci\u00f3n de lotes.\n\n**Entidades:**\n- **Materiales de Partida:** Sustancias utilizadas en la fabricaci\u00f3n de productos medicinales.\n- **Fabricantes:** Entidades que producen los materiales de partida y los productos medicinales.\n- **Proveedores:** Entidades que suministran materiales y pueden emitir certificados de an\u00e1lisis.\n- **Auditor\u00edas:** Evaluaciones realizadas para asegurar la calidad y fiabilidad de los fabricantes y proveedores.\n- **Certificados de An\u00e1lisis:** Documentos que validan la calidad y especificaciones de los materiales probados.\n\nEste resumen destaca los aspectos fundamentales relacionados con la producci\u00f3n y control de materiales en la industria farmac\u00e9utica, as\u00ed como los procedimientos de validaci\u00f3n y documentaci\u00f3n necesarios para garantizar la calidad de los productos medicinales.", "excerpt_keywords": "Keywords: finished products, quality control, stability studies, batch record review, retention samples"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "776d97f0-360c-427d-9a08-f443ae2a5d02", "node_type": "4", "metadata": {"page_label": "158", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n17.18 For each batch of medicines product, there should be an appropriate laboratory determination of satisfactory conformity to its finished product specification prior to release.\n\n17.19 Products failing to meet the established specifications or any other relevant quality criteria should be rejected.\n\n## Batch Record Review\n\n17.20 QC records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet its specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n17.21 Retention samples from each batch of finished product should be kept for at least one year after the expiry date. Finished products should usually be kept in their final packaging and stored under the recommended conditions. If exceptionally large packages are produced, smaller samples might be stored in appropriate containers. Samples of active starting materials should be retained for at least one year beyond the expiry date of the corresponding finished product. Other starting materials (other than solvents, gases and water) should be retained for a minimum of two years if their stability allows. Retention samples of materials and products should be of a size sufficient to permit at least two full re-examinations.\n\n## Stability Studies\n\n17.22 QC should evaluate the quality and stability of finished pharmaceutical products and, when necessary, of starting materials and intermediate products.\n\n17.23 QC should establish expiry dates and shelf-life specifications on the basis of stability tests related to storage conditions.\n\n17.24 A written programme for ongoing stability determination should be developed and implemented to include elements such as:\n\n- (a) a complete description of the medicine involved in the study;\n- (b) the complete set of testing parameters and methods, describing all tests for potency, purity, and physical characteristics and documented evidence that these tests indicate stability;\n- (c) provision for the inclusion of a sufficient number of batches;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fcc877db3ff53c36540543a0aef97f545a74860cb247b10d3156501f9f140105", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Finished Products\n\n17.18 For each batch of medicines product, there should be an appropriate laboratory determination of satisfactory conformity to its finished product specification prior to release.\n\n17.19 Products failing to meet the established specifications or any other relevant quality criteria should be rejected.\n\n## Batch Record Review\n\n17.20 QC records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet its specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n17.21 Retention samples from each batch of finished product should be kept for at least one year after the expiry date. Finished products should usually be kept in their final packaging and stored under the recommended conditions. If exceptionally large packages are produced, smaller samples might be stored in appropriate containers. Samples of active starting materials should be retained for at least one year beyond the expiry date of the corresponding finished product. Other starting materials (other than solvents, gases and water) should be retained for a minimum of two years if their stability allows. Retention samples of materials and products should be of a size sufficient to permit at least two full re-examinations.\n\n## Stability Studies\n\n17.22 QC should evaluate the quality and stability of finished pharmaceutical products and, when necessary, of starting materials and intermediate products.\n\n17.23 QC should establish expiry dates and shelf-life specifications on the basis of stability tests related to storage conditions.\n\n17.24 A written programme for ongoing stability determination should be developed and implemented to include elements such as:\n\n- (a) a complete description of the medicine involved in the study;\n- (b) the complete set of testing parameters and methods, describing all tests for potency, purity, and physical characteristics and documented evidence that these tests indicate stability;\n- (c) provision for the inclusion of a sufficient number of batches;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2362, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e4a2c318-254b-4764-8456-bfab5a5ec9ad": {"__data__": {"id_": "e4a2c318-254b-4764-8456-bfab5a5ec9ad", "embedding": null, "metadata": {"page_label": "159", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) the testing schedule for each medicine;  \n(e) provision for special storage conditions;  \n(f) provision for adequate sample retention;  \n(g) a summary of all the data generated, including the evaluation and the conclusions of the study.\n\n17.25 Stability should be determined prior to marketing and following any significant changes in processes, equipment, packaging materials, etc.\n\n# References\n\n1. Good manufacturing practices for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\n2. Validation of analytical procedures used in the examination of pharmaceutical materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 5 (WHO Technical Report Series, No. 823).\n\n3. EudraLex \u2014 Volume 4. Good manufacturing practice (GMP) Guidelines. European Commission. (http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm).\n\n4. Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme (PIC/S). In: Guide to good manufacturing practice for medicinal plants, Geneva, PIC/S Secretariat, 2000.\n\n5. *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n6. Good manufacturing practices for pharmaceutical products, Part one. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).\n\n7. Model certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 aspectos se deben considerar en el programa de pruebas para cada medicamento seg\u00fan el documento?**\n   - **Respuesta:** El programa de pruebas debe incluir un cronograma de pruebas para cada medicamento, provisiones para condiciones de almacenamiento especiales, provisiones para la retenci\u00f3n adecuada de muestras y un resumen de todos los datos generados, incluyendo la evaluaci\u00f3n y las conclusiones del estudio.\n\n2. **\u00bfCu\u00e1ndo debe determinarse la estabilidad de un medicamento seg\u00fan las directrices de la OMS?**\n   - **Respuesta:** La estabilidad debe determinarse antes de la comercializaci\u00f3n y despu\u00e9s de cualquier cambio significativo en los procesos, equipos, materiales de embalaje, etc.\n\n3. **\u00bfCu\u00e1les son algunas de las referencias clave citadas en el documento sobre buenas pr\u00e1cticas de fabricaci\u00f3n?**\n   - **Respuesta:** Algunas referencias clave incluyen el \"Good manufacturing practices for pharmaceutical products\" de la OMS (2003), la \"Validation of analytical procedures\" (1992), y las \"Good manufacturing practice (GMP) Guidelines\" de la Comisi\u00f3n Europea (EudraLex, Volumen 4).\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS, \"Technical Report Series 961\", establece directrices sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos. Se enfatiza la importancia de un programa de pruebas que incluya un cronograma, condiciones de almacenamiento, retenci\u00f3n de muestras y un resumen de datos. Adem\u00e1s, se destaca que la estabilidad de los medicamentos debe evaluarse antes de su comercializaci\u00f3n y tras cambios significativos en los procesos de producci\u00f3n. Se citan varias referencias clave que respaldan estas directrices, incluyendo informes de la OMS y directrices de la Comisi\u00f3n Europea.\n\n### Preguntas Mejoradas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el resumen de datos generados durante el estudio de un medicamento?**\n2. **\u00bfQu\u00e9 cambios en el proceso de fabricaci\u00f3n podr\u00edan requerir una nueva evaluaci\u00f3n de estabilidad seg\u00fan las directrices de la OMS?**\n3. **\u00bfCu\u00e1les son las implicaciones de no seguir las provisiones para condiciones de almacenamiento especiales en la fabricaci\u00f3n de medicamentos?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Determinaci\u00f3n de Conformidad**:\n   - Cada lote de productos farmac\u00e9uticos debe someterse a una evaluaci\u00f3n de conformidad en laboratorio antes de su liberaci\u00f3n.\n\n2. **Rechazo de Productos**:\n   - Los productos que no cumplan con las especificaciones establecidas o criterios de calidad relevantes deben ser rechazados.\n\n3. **Revisi\u00f3n de Registros de Control de Calidad (QC)**:\n   - Los registros de QC deben ser revisados como parte del proceso de aprobaci\u00f3n para la liberaci\u00f3n de lotes. Cualquier divergencia o fallo debe ser investigado exhaustivamente.\n\n4. **Muestras de Retenci\u00f3n**:\n   - Las muestras de cada lote de producto terminado deben conservarse durante al menos un a\u00f1o despu\u00e9s de la fecha de caducidad. Las muestras de materiales de partida activos deben conservarse por un a\u00f1o adicional.\n\n5. **Estudios de Estabilidad**:\n   - Se debe evaluar la calidad y estabilidad de los productos farmac\u00e9uticos terminados, as\u00ed como de los materiales de partida e intermedios, cuando sea necesario.\n\n6. **Programa de Determinaci\u00f3n de Estabilidad**:\n   - Se debe desarrollar un programa escrito que incluya:\n     - Descripci\u00f3n completa del medicamento.\n     - Conjunto completo de par\u00e1metros y m\u00e9todos de prueba.\n     - Provisi\u00f3n para incluir un n\u00famero suficiente de lotes en el estudio.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las normas y procedimientos.\n- **Control de Calidad (QC)**: Proceso que asegura la conformidad y calidad de los productos farmac\u00e9uticos.\n- **Lotes de Productos Farmac\u00e9uticos**: Unidades de producci\u00f3n que deben cumplir con especificaciones de calidad.\n- **Muestras de Retenci\u00f3n**: Muestras conservadas para futuras pruebas y verificaci\u00f3n de calidad.\n- **Estudios de Estabilidad**: Evaluaciones que determinan la duraci\u00f3n y condiciones de almacenamiento de los productos.", "excerpt_keywords": "Keywords: pharmaceutical stability, good manufacturing practices, quality assurance, testing schedule, sample retention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "495b6b00-0501-45ac-bb1c-45fb284f11b2", "node_type": "4", "metadata": {"page_label": "159", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) the testing schedule for each medicine;  \n(e) provision for special storage conditions;  \n(f) provision for adequate sample retention;  \n(g) a summary of all the data generated, including the evaluation and the conclusions of the study.\n\n17.25 Stability should be determined prior to marketing and following any significant changes in processes, equipment, packaging materials, etc.\n\n# References\n\n1. Good manufacturing practices for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\n2. Validation of analytical procedures used in the examination of pharmaceutical materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 5 (WHO Technical Report Series, No. 823).\n\n3. EudraLex \u2014 Volume 4. Good manufacturing practice (GMP) Guidelines. European Commission. (http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm).\n\n4. Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme (PIC/S). In: Guide to good manufacturing practice for medicinal plants, Geneva, PIC/S Secretariat, 2000.\n\n5. *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n6. Good manufacturing practices for pharmaceutical products, Part one. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).\n\n7. Model certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fcf04e94f75caba038bd61739da11d92d284bbcbacb29ce5062a96374047b711", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(d) the testing schedule for each medicine;  \n(e) provision for special storage conditions;  \n(f) provision for adequate sample retention;  \n(g) a summary of all the data generated, including the evaluation and the conclusions of the study.\n\n17.25 Stability should be determined prior to marketing and following any significant changes in processes, equipment, packaging materials, etc.\n\n# References\n\n1. Good manufacturing practices for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\n2. Validation of analytical procedures used in the examination of pharmaceutical materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 5 (WHO Technical Report Series, No. 823).\n\n3. EudraLex \u2014 Volume 4. Good manufacturing practice (GMP) Guidelines. European Commission. (http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm).\n\n4. Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme (PIC/S). In: Guide to good manufacturing practice for medicinal plants, Geneva, PIC/S Secretariat, 2000.\n\n5. *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n6. Good manufacturing practices for pharmaceutical products, Part one. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).\n\n7. Model certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2352, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c31cf40e-8729-42f2-a82f-085214cb03f8": {"__data__": {"id_": "c31cf40e-8729-42f2-a82f-085214cb03f8", "embedding": null, "metadata": {"page_label": "160", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO guidelines on good manufacturing practices for blood establishments\n\n1. Introduction\n\n2. Glossary and abbreviations\n\n3. Quality management  \n   3.1 Principles  \n   3.2 Quality assurance  \n       3.2.1 Good manufacturing practice in blood establishments  \n       3.2.2 Quality control  \n   3.3 Product quality review  \n   3.4 Quality risk management  \n   3.5 Change control  \n   3.6 Deviation evaluation and reporting  \n   3.7 Corrective and preventive actions  \n   3.8 Internal audits  \n   3.9 Complaints and product recall  \n       3.9.1 Complaints  \n       3.9.2 Recalls  \n   3.10 Process improvement  \n   3.11 Look-back  \n\n4. Personnel  \n   4.1 Organization and responsibilities  \n   4.2 Training  \n       4.2.1 Initial training  \n       4.2.2 Continuous training  \n       4.2.3 Competency  \n   4.3 Personal hygiene  \n\n5. Documentation  \n   5.1 Standard operating procedures and records  \n       5.1.1 Standard operating procedures  \n       5.1.2 Records  \n   5.2 Document control  \n       5.2.1 Document management  \n       5.2.2 Record retention and archiving  \n\n6. Premises and equipment  \n   6.1 Premises  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que el contexto proporcionado puede responder, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un anexo de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre. Incluye secciones sobre gesti\u00f3n de calidad, personal, documentaci\u00f3n, y premisas y equipos. Se abordan aspectos como la garant\u00eda de calidad, el control de calidad, la formaci\u00f3n del personal, la gesti\u00f3n de documentos y el mantenimiento de las instalaciones.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los principios fundamentales de la gesti\u00f3n de calidad seg\u00fan las directrices de la OMS para los establecimientos de sangre?**\n   - Esta pregunta busca detalles sobre los principios espec\u00edficos que gu\u00edan la gesti\u00f3n de calidad en el contexto de la fabricaci\u00f3n de productos sangu\u00edneos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la evaluaci\u00f3n y el informe de desviaciones en los procesos de fabricaci\u00f3n de sangre?**\n   - Esta pregunta se centra en los pasos y protocolos que deben implementarse cuando se producen desviaciones en los procesos, lo que es crucial para mantener la calidad y la seguridad.\n\n3. **\u00bfQu\u00e9 requisitos de formaci\u00f3n continua se establecen para el personal en los establecimientos de sangre?**\n   - Esta pregunta indaga sobre las expectativas y requisitos espec\u00edficos para la formaci\u00f3n continua del personal, lo que es esencial para asegurar que el personal est\u00e9 actualizado en las mejores pr\u00e1cticas y procedimientos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Programa de Pruebas para Medicamentos:**\n   - Importancia de un cronograma de pruebas.\n   - Necesidad de provisiones para condiciones de almacenamiento especiales.\n   - Requisitos para la retenci\u00f3n adecuada de muestras.\n   - Inclusi\u00f3n de un resumen de datos generados, evaluaciones y conclusiones del estudio.\n\n2. **Estabilidad de Medicamentos:**\n   - Evaluaci\u00f3n de la estabilidad antes de la comercializaci\u00f3n.\n   - Reevaluaci\u00f3n de la estabilidad tras cambios significativos en procesos, equipos o materiales de embalaje.\n\n3. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP):**\n   - Directrices y referencias sobre GMP proporcionadas por la OMS y la Comisi\u00f3n Europea.\n   - Importancia de seguir estas directrices para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n y calidad de productos farmac\u00e9uticos.\n- **EudraLex:** Conjunto de directrices de la Comisi\u00f3n Europea sobre buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Pharmaceutical Inspection Convention (PIC/S):** Organizaci\u00f3n que proporciona gu\u00edas sobre buenas pr\u00e1cticas de fabricaci\u00f3n para plantas medicinales.\n- **Referencias Citadas:**\n  - WHO Technical Report Series (varios n\u00fameros).\n  - Informes de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n\nEste resumen destaca la importancia de seguir directrices rigurosas en la fabricaci\u00f3n y evaluaci\u00f3n de medicamentos para garantizar su calidad y eficacia.", "excerpt_keywords": "Keywords: blood establishments, good manufacturing practices, quality management, personnel training, documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6c79e4ea-1009-489d-aa64-4f60c40339bd", "node_type": "4", "metadata": {"page_label": "160", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO guidelines on good manufacturing practices for blood establishments\n\n1. Introduction\n\n2. Glossary and abbreviations\n\n3. Quality management  \n   3.1 Principles  \n   3.2 Quality assurance  \n       3.2.1 Good manufacturing practice in blood establishments  \n       3.2.2 Quality control  \n   3.3 Product quality review  \n   3.4 Quality risk management  \n   3.5 Change control  \n   3.6 Deviation evaluation and reporting  \n   3.7 Corrective and preventive actions  \n   3.8 Internal audits  \n   3.9 Complaints and product recall  \n       3.9.1 Complaints  \n       3.9.2 Recalls  \n   3.10 Process improvement  \n   3.11 Look-back  \n\n4. Personnel  \n   4.1 Organization and responsibilities  \n   4.2 Training  \n       4.2.1 Initial training  \n       4.2.2 Continuous training  \n       4.2.3 Competency  \n   4.3 Personal hygiene  \n\n5. Documentation  \n   5.1 Standard operating procedures and records  \n       5.1.1 Standard operating procedures  \n       5.1.2 Records  \n   5.2 Document control  \n       5.2.1 Document management  \n       5.2.2 Record retention and archiving  \n\n6. Premises and equipment  \n   6.1 Premises  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "60c577c5585bcd60ad16e0e2757209ca32a90792c6dd4114bc7ed12790a94e47", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 4\n\n## WHO guidelines on good manufacturing practices for blood establishments\n\n1. Introduction\n\n2. Glossary and abbreviations\n\n3. Quality management  \n   3.1 Principles  \n   3.2 Quality assurance  \n       3.2.1 Good manufacturing practice in blood establishments  \n       3.2.2 Quality control  \n   3.3 Product quality review  \n   3.4 Quality risk management  \n   3.5 Change control  \n   3.6 Deviation evaluation and reporting  \n   3.7 Corrective and preventive actions  \n   3.8 Internal audits  \n   3.9 Complaints and product recall  \n       3.9.1 Complaints  \n       3.9.2 Recalls  \n   3.10 Process improvement  \n   3.11 Look-back  \n\n4. Personnel  \n   4.1 Organization and responsibilities  \n   4.2 Training  \n       4.2.1 Initial training  \n       4.2.2 Continuous training  \n       4.2.3 Competency  \n   4.3 Personal hygiene  \n\n5. Documentation  \n   5.1 Standard operating procedures and records  \n       5.1.1 Standard operating procedures  \n       5.1.2 Records  \n   5.2 Document control  \n       5.2.1 Document management  \n       5.2.2 Record retention and archiving  \n\n6. Premises and equipment  \n   6.1 Premises", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1129, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4b0dcfcc-3205-4f86-bf26-7b4efb411e9c": {"__data__": {"id_": "4b0dcfcc-3205-4f86-bf26-7b4efb411e9c", "embedding": null, "metadata": {"page_label": "161", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6.1.1 Design and construction  \n6.1.2 Donor areas  \n6.1.3 Production areas  \n6.1.4 Storage areas  \n6.1.5 Laboratories  \n6.1.6 Mobile collection sites  \n\n6.2 Equipment  \n6.2.1 Design and construction  \n6.2.2 Maintenance  \n6.2.3 Cleaning  \n6.2.4 Calibration  \n\n6.3 Computerized systems  \n\n7. Qualification and validation  \n7.1 Qualification of equipment  \n7.2 Validation of manufacturing processes  \n7.3 Choosing an appropriate test system to screen for infectious disease  \n7.4 Assay performance validation  \n\n8. Management of materials and reagents  \n8.1 Materials and reagents  \n8.2 Receipt and quarantine  \n8.3 Release of incoming production material and test reagents  \n8.4 Storage  \n8.5 Traceability of materials and reagents  \n8.6 Supplier/vendor management  \n\n9. Manufacturing  \n9.1 Donor registration  \n9.2 Donor selection  \n9.2.1 Epidemiological surveillance of the donor population  \n9.2.2 Information to donors  \n9.2.3 Questionnaire and interview  \n9.2.4 Deferral policy and deferral criteria  \n9.2.5 Physical examination, donor health criteria and donor acceptance  \n\n9.3 Collection  \n9.3.1 Whole blood collection  \n9.3.2 Collection by apheresis  \n9.3.3 Safety of donors  \n\n9.4 Component preparation  \n9.4.1 Starting material  \n9.4.2 Methods of production  \n9.4.2.1 Centrifugation  \n9.4.2.2 Separation  \n9.4.2.3 Freezing  \n9.4.2.4 Leukocyte reduction  \n9.4.2.5 Irradiation  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a entender mejor el contenido:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos t\u00e9cnicos relacionados con la recolecci\u00f3n, procesamiento y gesti\u00f3n de materiales en el \u00e1mbito de la salud, espec\u00edficamente en la donaci\u00f3n de sangre y la producci\u00f3n de componentes sangu\u00edneos. Se detallan las instalaciones necesarias, el equipo, la calificaci\u00f3n y validaci\u00f3n de procesos, as\u00ed como la gesti\u00f3n de materiales y la manufactura de productos derivados de la sangre.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos para la selecci\u00f3n de donantes seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los criterios y procedimientos que se deben seguir para seleccionar donantes, incluyendo aspectos como la vigilancia epidemiol\u00f3gica y la salud del donante.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de producci\u00f3n se describen para la preparaci\u00f3n de componentes sangu\u00edneos y cu\u00e1les son sus prop\u00f3sitos?**\n   - Esta pregunta se centra en los m\u00e9todos espec\u00edficos mencionados en el documento, como la centrifugaci\u00f3n y la irradiaci\u00f3n, y su relevancia en el proceso de producci\u00f3n de componentes sangu\u00edneos.\n\n3. **\u00bfC\u00f3mo se gestiona la trazabilidad de los materiales y reactivos en el contexto de la manufactura de productos sangu\u00edneos?**\n   - Esta pregunta busca entender los procedimientos y sistemas implementados para asegurar la trazabilidad de los materiales y reactivos, lo cual es crucial para la seguridad y eficacia en la producci\u00f3n de componentes sangu\u00edneos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido t\u00e9cnico y detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un anexo de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre. A continuaci\u00f3n se presentan los temas clave y entidades mencionados en la secci\u00f3n:\n\n1. **Gesti\u00f3n de Calidad**:\n   - **Principios**: Fundamentos que gu\u00edan la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos sangu\u00edneos.\n   - **Aseguramiento de Calidad**: Incluye buenas pr\u00e1cticas de fabricaci\u00f3n y control de calidad.\n   - **Revisi\u00f3n de Calidad del Producto**: Evaluaci\u00f3n sistem\u00e1tica de la calidad de los productos.\n   - **Gesti\u00f3n de Riesgos de Calidad**: Identificaci\u00f3n y mitigaci\u00f3n de riesgos asociados a la calidad.\n   - **Control de Cambios**: Procedimientos para gestionar cambios en los procesos.\n   - **Evaluaci\u00f3n y Reporte de Desviaciones**: Protocolos para manejar desviaciones en los procesos de fabricaci\u00f3n.\n   - **Acciones Correctivas y Preventivas**: Estrategias para abordar y prevenir problemas de calidad.\n   - **Auditor\u00edas Internas**: Evaluaciones peri\u00f3dicas para asegurar el cumplimiento de las normas.\n   - **Quejas y Retiro de Productos**: Manejo de quejas y procedimientos para el retiro de productos defectuosos.\n   - **Mejora de Procesos**: Estrategias para optimizar los procesos de fabricaci\u00f3n.\n   - **Look-back**: Revisi\u00f3n de procesos y productos anteriores para asegurar la calidad.\n\n2. **Personal**:\n   - **Organizaci\u00f3n y Responsabilidades**: Estructura organizativa y roles del personal.\n   - **Formaci\u00f3n**: Incluye formaci\u00f3n inicial, continua y evaluaci\u00f3n de competencias.\n   - **Higiene Personal**: Normas de higiene que el personal debe seguir.\n\n3. **Documentaci\u00f3n**:\n   - **Procedimientos Operativos Est\u00e1ndar y Registros**: Importancia de tener procedimientos claros y registros precisos.\n   - **Control de Documentos**: Gesti\u00f3n de documentos y retenci\u00f3n de registros.\n\n4. **Instalaciones y Equipos**:\n   - **Premisas**: Requisitos y est\u00e1ndares para las instalaciones donde se lleva a cabo la fabricaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades que producen y gestionan productos sangu\u00edneos.\n- **Calidad**: Concepto central en la fabricaci\u00f3n y gesti\u00f3n de productos sangu\u00edneos.\n\nEste resumen abarca los aspectos fundamentales de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de los establecimientos de sangre.", "excerpt_keywords": "Keywords: donaci\u00f3n de sangre, fabricaci\u00f3n, calidad, gesti\u00f3n de materiales, validaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3d2ffa7a-377d-43f4-8ed3-e56c2499ea1e", "node_type": "4", "metadata": {"page_label": "161", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6.1.1 Design and construction  \n6.1.2 Donor areas  \n6.1.3 Production areas  \n6.1.4 Storage areas  \n6.1.5 Laboratories  \n6.1.6 Mobile collection sites  \n\n6.2 Equipment  \n6.2.1 Design and construction  \n6.2.2 Maintenance  \n6.2.3 Cleaning  \n6.2.4 Calibration  \n\n6.3 Computerized systems  \n\n7. Qualification and validation  \n7.1 Qualification of equipment  \n7.2 Validation of manufacturing processes  \n7.3 Choosing an appropriate test system to screen for infectious disease  \n7.4 Assay performance validation  \n\n8. Management of materials and reagents  \n8.1 Materials and reagents  \n8.2 Receipt and quarantine  \n8.3 Release of incoming production material and test reagents  \n8.4 Storage  \n8.5 Traceability of materials and reagents  \n8.6 Supplier/vendor management  \n\n9. Manufacturing  \n9.1 Donor registration  \n9.2 Donor selection  \n9.2.1 Epidemiological surveillance of the donor population  \n9.2.2 Information to donors  \n9.2.3 Questionnaire and interview  \n9.2.4 Deferral policy and deferral criteria  \n9.2.5 Physical examination, donor health criteria and donor acceptance  \n\n9.3 Collection  \n9.3.1 Whole blood collection  \n9.3.2 Collection by apheresis  \n9.3.3 Safety of donors  \n\n9.4 Component preparation  \n9.4.1 Starting material  \n9.4.2 Methods of production  \n9.4.2.1 Centrifugation  \n9.4.2.2 Separation  \n9.4.2.3 Freezing  \n9.4.2.4 Leukocyte reduction  \n9.4.2.5 Irradiation  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8294ccbbc55e716001fea0536bbdbaa6b5d8d11349fb3be3d2342fe695dd859e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6.1.1 Design and construction  \n6.1.2 Donor areas  \n6.1.3 Production areas  \n6.1.4 Storage areas  \n6.1.5 Laboratories  \n6.1.6 Mobile collection sites  \n\n6.2 Equipment  \n6.2.1 Design and construction  \n6.2.2 Maintenance  \n6.2.3 Cleaning  \n6.2.4 Calibration  \n\n6.3 Computerized systems  \n\n7. Qualification and validation  \n7.1 Qualification of equipment  \n7.2 Validation of manufacturing processes  \n7.3 Choosing an appropriate test system to screen for infectious disease  \n7.4 Assay performance validation  \n\n8. Management of materials and reagents  \n8.1 Materials and reagents  \n8.2 Receipt and quarantine  \n8.3 Release of incoming production material and test reagents  \n8.4 Storage  \n8.5 Traceability of materials and reagents  \n8.6 Supplier/vendor management  \n\n9. Manufacturing  \n9.1 Donor registration  \n9.2 Donor selection  \n9.2.1 Epidemiological surveillance of the donor population  \n9.2.2 Information to donors  \n9.2.3 Questionnaire and interview  \n9.2.4 Deferral policy and deferral criteria  \n9.2.5 Physical examination, donor health criteria and donor acceptance  \n\n9.3 Collection  \n9.3.1 Whole blood collection  \n9.3.2 Collection by apheresis  \n9.3.3 Safety of donors  \n\n9.4 Component preparation  \n9.4.1 Starting material  \n9.4.2 Methods of production  \n9.4.2.1 Centrifugation  \n9.4.2.2 Separation  \n9.4.2.3 Freezing  \n9.4.2.4 Leukocyte reduction  \n9.4.2.5 Irradiation", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1384, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ea249425-34f3-41dc-b8e5-41e7ae7c7c8a": {"__data__": {"id_": "ea249425-34f3-41dc-b8e5-41e7ae7c7c8a", "embedding": null, "metadata": {"page_label": "162", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n- 9.4.3.1 Whole blood\n- 9.4.3.2 Red-cell concentrate\n- 9.4.3.3 Platelet concentrate\n- 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n- 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\n## 9.5 Laboratory testing\n### 9.5.1 Screening tests for infectious disease markers\n- 9.5.1.1 Testing requirements\n- 9.5.1.2 Handling of samples and data\n- 9.5.1.3 Testing and post-analytical procedures\n- 9.5.1.4 Test interpretation and follow-up of reactive results\n\n### 9.5.2 Blood group typing\n### 9.5.3 Retention samples\n\n## 9.6 Quality monitoring of blood and blood components\n\n## 9.7 Labelling\n- 9.7.1 Label information\n- 9.7.2 Product name\n- 9.7.3 Expiry date\n\n## 9.8 Release of product\n## 9.9 Storage\n## 9.10 Distribution\n## 9.11 Shipping\n## 9.12 Returns\n\n# 10. Contract manufacturing, analysis and services\n\n# 11. Authors and acknowledgements\n\n# 12. References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la sangre y los componentes sangu\u00edneos, incluyendo su recolecci\u00f3n, pruebas de laboratorio, etiquetado, almacenamiento, distribuci\u00f3n y otros procesos relacionados. Se detallan los tipos de sangre y componentes, as\u00ed como los procedimientos de prueba para detectar marcadores de enfermedades infecciosas, la tipificaci\u00f3n de grupos sangu\u00edneos y el monitoreo de calidad. Tambi\u00e9n se mencionan aspectos log\u00edsticos como el env\u00edo y la gesti\u00f3n de devoluciones.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los requisitos de prueba para los marcadores de enfermedades infecciosas en la sangre, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los procedimientos y est\u00e1ndares espec\u00edficos que deben seguirse para realizar pruebas de enfermedades infecciosas en muestras de sangre.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los productos sangu\u00edneos, seg\u00fan las directrices del informe?**\n   - Esta pregunta se centra en los requisitos de etiquetado, que son cruciales para la identificaci\u00f3n y el manejo seguro de los productos sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 procedimientos se deben seguir para la liberaci\u00f3n y distribuci\u00f3n de productos sangu\u00edneos?**\n   - Esta pregunta busca entender los pasos y protocolos necesarios para asegurar que los productos sangu\u00edneos sean liberados y distribuidos de manera segura y eficiente, lo cual es vital para la salud p\u00fablica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" se centra en la recolecci\u00f3n, procesamiento y gesti\u00f3n de materiales en el contexto de la donaci\u00f3n de sangre y la producci\u00f3n de componentes sangu\u00edneos. A continuaci\u00f3n se presentan los temas clave y entidades relevantes de la secci\u00f3n:\n\n#### 1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**\n   - **\u00c1reas de Donantes**: Espacios destinados a la recepci\u00f3n y atenci\u00f3n de donantes.\n   - **\u00c1reas de Producci\u00f3n**: Zonas donde se procesan los componentes sangu\u00edneos.\n   - **\u00c1reas de Almacenamiento**: Espacios para guardar materiales y productos.\n   - **Laboratorios**: Instalaciones para realizar pruebas y an\u00e1lisis.\n   - **Sitios de Recolecci\u00f3n M\u00f3vil**: Lugares temporales para la recolecci\u00f3n de sangre.\n\n#### 2. **Equipamiento**\n   - **Dise\u00f1o y Construcci\u00f3n**: Normas para la creaci\u00f3n de equipos adecuados.\n   - **Mantenimiento**: Procedimientos para asegurar el funcionamiento \u00f3ptimo del equipo.\n   - **Limpieza y Calibraci\u00f3n**: Protocolos para mantener la higiene y precisi\u00f3n de los equipos.\n\n#### 3. **Sistemas Computarizados**\n   - Implementaci\u00f3n de tecnolog\u00eda para la gesti\u00f3n de datos y procesos.\n\n#### 4. **Calificaci\u00f3n y Validaci\u00f3n**\n   - **Calificaci\u00f3n de Equipos**: Aseguramiento de que los equipos cumplen con los est\u00e1ndares requeridos.\n   - **Validaci\u00f3n de Procesos de Manufactura**: Confirmaci\u00f3n de que los procesos de producci\u00f3n son efectivos y seguros.\n   - **Selecci\u00f3n de Sistemas de Pruebas**: Elecci\u00f3n de m\u00e9todos adecuados para detectar enfermedades infecciosas.\n   - **Validaci\u00f3n del Rendimiento de Ensayos**: Evaluaci\u00f3n de la eficacia de los ensayos realizados.\n\n#### 5. **Gesti\u00f3n de Materiales y Reactivos**\n   - **Recepci\u00f3n y Cuarentena**: Proceso de manejo de materiales entrantes.\n   - **Liberaci\u00f3n de Materiales**: Procedimientos para autorizar el uso de materiales y reactivos.\n   - **Trazabilidad**: Mecanismos para rastrear el origen y uso de materiales.\n   - **Gesti\u00f3n de Proveedores**: Control y evaluaci\u00f3n de los proveedores de materiales.\n\n#### 6. **Manufactura**\n   - **Registro de Donantes**: Proceso de documentaci\u00f3n de donantes.\n   - **Selecci\u00f3n de Donantes**: Criterios y procedimientos para elegir donantes adecuados.\n   - **Recolecci\u00f3n de Sangre**: M\u00e9todos de recolecci\u00f3n, incluyendo sangre total y a trav\u00e9s de af\u00e9resis.\n   - **Preparaci\u00f3n de Componentes**: M\u00e9todos de producci\u00f3n como centrifugaci\u00f3n, separaci\u00f3n, congelaci\u00f3n, reducci\u00f3n de leucocitos e irradiaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Donantes**: Personas que ofrecen su sangre.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, como plaquetas y plasma.\n- **Equipos y Sistemas**: Herramientas y tecnolog\u00edas utilizadas en el proceso de donaci\u00f3n y manufactura.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos t\u00e9cnicos y organizativos tratados en el documento, destacando la importancia de cada secci\u00f3n en el contexto de la salud p\u00fablica y la seguridad en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood components, laboratory testing, infectious disease markers, quality monitoring, product labeling"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f0229e8-424c-48ed-8c2f-e256249407fb", "node_type": "4", "metadata": {"page_label": "162", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n- 9.4.3.1 Whole blood\n- 9.4.3.2 Red-cell concentrate\n- 9.4.3.3 Platelet concentrate\n- 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n- 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\n## 9.5 Laboratory testing\n### 9.5.1 Screening tests for infectious disease markers\n- 9.5.1.1 Testing requirements\n- 9.5.1.2 Handling of samples and data\n- 9.5.1.3 Testing and post-analytical procedures\n- 9.5.1.4 Test interpretation and follow-up of reactive results\n\n### 9.5.2 Blood group typing\n### 9.5.3 Retention samples\n\n## 9.6 Quality monitoring of blood and blood components\n\n## 9.7 Labelling\n- 9.7.1 Label information\n- 9.7.2 Product name\n- 9.7.3 Expiry date\n\n## 9.8 Release of product\n## 9.9 Storage\n## 9.10 Distribution\n## 9.11 Shipping\n## 9.12 Returns\n\n# 10. Contract manufacturing, analysis and services\n\n# 11. Authors and acknowledgements\n\n# 12. References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "11a4979656c3d5d51c21b708c0e38e33ae0aa4bdcd1d2b7361498308d1819949", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.3 Blood and blood components\n- 9.4.3.1 Whole blood\n- 9.4.3.2 Red-cell concentrate\n- 9.4.3.3 Platelet concentrate\n- 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n- 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\n## 9.5 Laboratory testing\n### 9.5.1 Screening tests for infectious disease markers\n- 9.5.1.1 Testing requirements\n- 9.5.1.2 Handling of samples and data\n- 9.5.1.3 Testing and post-analytical procedures\n- 9.5.1.4 Test interpretation and follow-up of reactive results\n\n### 9.5.2 Blood group typing\n### 9.5.3 Retention samples\n\n## 9.6 Quality monitoring of blood and blood components\n\n## 9.7 Labelling\n- 9.7.1 Label information\n- 9.7.2 Product name\n- 9.7.3 Expiry date\n\n## 9.8 Release of product\n## 9.9 Storage\n## 9.10 Distribution\n## 9.11 Shipping\n## 9.12 Returns\n\n# 10. Contract manufacturing, analysis and services\n\n# 11. Authors and acknowledgements\n\n# 12. References", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 897, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7315bb40-2807-462f-914e-2ac95901dec4": {"__data__": {"id_": "7315bb40-2807-462f-914e-2ac95901dec4", "embedding": null, "metadata": {"page_label": "163", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (1) define a quality assurance system based on (i) the existence of a national structure that is independent of manufacturers, (ii) compliance with the process of quality assurance for biological products \u2014 i.e. control of starting material(s), production processes and final product(s) \u2014 and (iii) strict adherence to the principles of good manufacturing practice (GMP). Since the last revision of these requirements in 1992, two relevant items have been reviewed and new recommendations adopted, namely on virus inactivation and removal of plasma derivatives (2004) (2) and human plasma for fractionation (2007) (3). However, a number of issues, such as the requirement for a quality assurance system in blood establishments, have not yet been addressed. The WHO Expert Committee on Biological Standardization (ECBS), therefore, considered that the development of WHO guidelines on GMP for blood establishments is of highest priority in assisting Member States to meet their needs in this area, as requested by the International Conference of Drug Regulatory Authorities in 2008 (4).\n\nThe importance of establishing reliable quality assurance systems for the whole chain of blood collection, processing and distribution of blood components in blood establishments was also emphasized by the Sixty-third World Health Assembly in resolution WHA63.12 on the availability, safety and quality of blood products (5). In that resolution, quality assurance was seen as a necessary measure that would contribute to increased global availability of plasma that meets internationally recognized standards.\n\nResolution WHA63.12 recognized that a special effort is needed to strengthen globally the technical capacity of national regulatory authorities (NRAs) to assure the appropriate control of blood products. The resolution recalls earlier related resolutions which urged Member States to promote the full implementation of well organized, nationally coordinated and sustainable blood programmes stressing the role of voluntary, non-remunerated blood donations from low-risk populations.\n\nIn recent years, safety and quality in the transfusion chain has become an important topic in many countries and regions (6). Blood establishments should establish and maintain quality systems, based on GMP principles, involving all activities that determine quality policy objectives and responsibilities, and should implement them by such means as quality planning, quality control, quality assurance and quality improvement. A GMP approach to manufacturing safe blood components that consistently meet predefined specifications and customers\u2019 expectations provides a model that allows for a documented system of incorporating quality into", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) establece requisitos para la recolecci\u00f3n, procesamiento y control de calidad de sangre y derivados. Se enfatiza la necesidad de un sistema de aseguramiento de calidad que incluya una estructura nacional independiente de los fabricantes, el cumplimiento de procesos de calidad para productos biol\u00f3gicos y la adherencia a las buenas pr\u00e1cticas de manufactura (GMP). Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado nuevas recomendaciones sobre inactivaci\u00f3n de virus y plasma humano para fraccionamiento, pero a\u00fan quedan temas por abordar, como la necesidad de un sistema de aseguramiento de calidad en los establecimientos de sangre. La resoluci\u00f3n WHA63.12 de la Asamblea Mundial de la Salud subraya la importancia de fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales para asegurar el control adecuado de los productos sangu\u00edneos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres componentes clave que definen el sistema de aseguramiento de calidad seg\u00fan la OMS para los productos sangu\u00edneos?**\n   - Respuesta: Los tres componentes clave son: (i) la existencia de una estructura nacional independiente de los fabricantes, (ii) el cumplimiento del proceso de aseguramiento de calidad para productos biol\u00f3gicos, y (iii) la estricta adherencia a los principios de buenas pr\u00e1cticas de manufactura (GMP).\n\n2. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se han adoptado desde la \u00faltima revisi\u00f3n de los requisitos de la OMS en 1992?**\n   - Respuesta: Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado recomendaciones sobre la inactivaci\u00f3n de virus y la eliminaci\u00f3n de derivados plasm\u00e1ticos en 2004, as\u00ed como sobre el plasma humano para fraccionamiento en 2007.\n\n3. **\u00bfQu\u00e9 papel juega la resoluci\u00f3n WHA63.12 en el contexto de la calidad y seguridad de los productos sangu\u00edneos?**\n   - Respuesta: La resoluci\u00f3n WHA63.12 enfatiza la necesidad de establecer sistemas de aseguramiento de calidad confiables en toda la cadena de recolecci\u00f3n, procesamiento y distribuci\u00f3n de componentes sangu\u00edneos, y reconoce la importancia de fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales para asegurar el control adecuado de los productos sangu\u00edneos. Tambi\u00e9n promueve la implementaci\u00f3n de programas de sangre bien organizados y coordinados a nivel nacional, destacando la importancia de las donaciones de sangre voluntarias y no remuneradas de poblaciones de bajo riesgo.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Componentes de la sangre**:\n   - **Sangre total**: Se refiere a la sangre en su forma completa.\n   - **Concentrado de gl\u00f3bulos rojos**: Producto derivado de la sangre que contiene una alta concentraci\u00f3n de gl\u00f3bulos rojos.\n   - **Concentrado de plaquetas**: Producto que contiene plaquetas, esencial para la coagulaci\u00f3n.\n   - **Plasma**: Se menciona tanto para transfusi\u00f3n como para fraccionamiento, indicando su uso en tratamientos y producci\u00f3n de derivados.\n   - **Crioprecipitado y plasma pobre en crioprecipitado**: Productos derivados del plasma que tienen aplicaciones espec\u00edficas en medicina.\n\n2. **Pruebas de laboratorio**:\n   - **Pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas**: Incluye requisitos de prueba, manejo de muestras, procedimientos anal\u00edticos y seguimiento de resultados reactivos.\n   - **Tipificaci\u00f3n de grupos sangu\u00edneos**: Proceso para determinar el tipo de sangre de un donante o receptor.\n   - **Muestras de retenci\u00f3n**: Muestras que se conservan para futuras pruebas o verificaciones.\n\n3. **Monitoreo de calidad**: Se refiere a los procedimientos y est\u00e1ndares para asegurar la calidad de la sangre y sus componentes.\n\n4. **Etiquetado**:\n   - **Informaci\u00f3n de la etiqueta**: Detalles que deben incluirse en las etiquetas de los productos sangu\u00edneos, como el nombre del producto y la fecha de caducidad.\n\n5. **Log\u00edstica de productos sangu\u00edneos**:\n   - **Liberaci\u00f3n de productos**: Procedimientos para autorizar la distribuci\u00f3n de productos sangu\u00edneos.\n   - **Almacenamiento, distribuci\u00f3n, env\u00edo y devoluciones**: Aspectos log\u00edsticos que aseguran que los productos sangu\u00edneos se manejen de manera segura y eficiente.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Componentes sangu\u00edneos**: Sangre total, gl\u00f3bulos rojos, plaquetas, plasma, crioprecipitado.\n- **Pruebas de laboratorio**: Detecci\u00f3n de enfermedades, tipificaci\u00f3n sangu\u00ednea.\n- **Calidad y seguridad**: Monitoreo de calidad, etiquetado, procedimientos de liberaci\u00f3n y distribuci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando los componentes de la sangre, los procedimientos de prueba y los aspectos log\u00edsticos relacionados con la gesti\u00f3n de productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood safety, quality assurance, good manufacturing practice, WHO guidelines, plasma derivatives"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0598e74c-934b-4034-9876-cf51a2e35cc2", "node_type": "4", "metadata": {"page_label": "163", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (1) define a quality assurance system based on (i) the existence of a national structure that is independent of manufacturers, (ii) compliance with the process of quality assurance for biological products \u2014 i.e. control of starting material(s), production processes and final product(s) \u2014 and (iii) strict adherence to the principles of good manufacturing practice (GMP). Since the last revision of these requirements in 1992, two relevant items have been reviewed and new recommendations adopted, namely on virus inactivation and removal of plasma derivatives (2004) (2) and human plasma for fractionation (2007) (3). However, a number of issues, such as the requirement for a quality assurance system in blood establishments, have not yet been addressed. The WHO Expert Committee on Biological Standardization (ECBS), therefore, considered that the development of WHO guidelines on GMP for blood establishments is of highest priority in assisting Member States to meet their needs in this area, as requested by the International Conference of Drug Regulatory Authorities in 2008 (4).\n\nThe importance of establishing reliable quality assurance systems for the whole chain of blood collection, processing and distribution of blood components in blood establishments was also emphasized by the Sixty-third World Health Assembly in resolution WHA63.12 on the availability, safety and quality of blood products (5). In that resolution, quality assurance was seen as a necessary measure that would contribute to increased global availability of plasma that meets internationally recognized standards.\n\nResolution WHA63.12 recognized that a special effort is needed to strengthen globally the technical capacity of national regulatory authorities (NRAs) to assure the appropriate control of blood products. The resolution recalls earlier related resolutions which urged Member States to promote the full implementation of well organized, nationally coordinated and sustainable blood programmes stressing the role of voluntary, non-remunerated blood donations from low-risk populations.\n\nIn recent years, safety and quality in the transfusion chain has become an important topic in many countries and regions (6). Blood establishments should establish and maintain quality systems, based on GMP principles, involving all activities that determine quality policy objectives and responsibilities, and should implement them by such means as quality planning, quality control, quality assurance and quality improvement. A GMP approach to manufacturing safe blood components that consistently meet predefined specifications and customers\u2019 expectations provides a model that allows for a documented system of incorporating quality into", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "be53f2dfd3a4796bd154a1c841d903161edc78c250692672b65d39f9f025803b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe World Health Organization (WHO) requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (1) define a quality assurance system based on (i) the existence of a national structure that is independent of manufacturers, (ii) compliance with the process of quality assurance for biological products \u2014 i.e. control of starting material(s), production processes and final product(s) \u2014 and (iii) strict adherence to the principles of good manufacturing practice (GMP). Since the last revision of these requirements in 1992, two relevant items have been reviewed and new recommendations adopted, namely on virus inactivation and removal of plasma derivatives (2004) (2) and human plasma for fractionation (2007) (3). However, a number of issues, such as the requirement for a quality assurance system in blood establishments, have not yet been addressed. The WHO Expert Committee on Biological Standardization (ECBS), therefore, considered that the development of WHO guidelines on GMP for blood establishments is of highest priority in assisting Member States to meet their needs in this area, as requested by the International Conference of Drug Regulatory Authorities in 2008 (4).\n\nThe importance of establishing reliable quality assurance systems for the whole chain of blood collection, processing and distribution of blood components in blood establishments was also emphasized by the Sixty-third World Health Assembly in resolution WHA63.12 on the availability, safety and quality of blood products (5). In that resolution, quality assurance was seen as a necessary measure that would contribute to increased global availability of plasma that meets internationally recognized standards.\n\nResolution WHA63.12 recognized that a special effort is needed to strengthen globally the technical capacity of national regulatory authorities (NRAs) to assure the appropriate control of blood products. The resolution recalls earlier related resolutions which urged Member States to promote the full implementation of well organized, nationally coordinated and sustainable blood programmes stressing the role of voluntary, non-remunerated blood donations from low-risk populations.\n\nIn recent years, safety and quality in the transfusion chain has become an important topic in many countries and regions (6). Blood establishments should establish and maintain quality systems, based on GMP principles, involving all activities that determine quality policy objectives and responsibilities, and should implement them by such means as quality planning, quality control, quality assurance and quality improvement. A GMP approach to manufacturing safe blood components that consistently meet predefined specifications and customers\u2019 expectations provides a model that allows for a documented system of incorporating quality into", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2889, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8d9b221d-13f3-4e45-96ff-207125d31a7f": {"__data__": {"id_": "8d9b221d-13f3-4e45-96ff-207125d31a7f", "embedding": null, "metadata": {"page_label": "164", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the entire process. When collecting and processing blood and plasma from human donors, GMP considerations should be addressed in a biological context due to the specific characteristics of materials of human origin.\n\nThe guidelines in this document include:\n\n\u2014 general GMP topics such as quality management, personnel, documentation, premises and equipment, qualification and validation, materials management, contract manufacturing, and complaints and recalls;\n\n\u2014 GMP concepts such as quality risk management and product quality reviews;\n\n\u2014 topics specific to the manufacturing of blood components from donor selection to distribution of the final product.\n\nThey address current and widely accepted GMP principles that are relevant to the consistent production of safe and assured quality blood components in blood establishments, including related donor safety concerns. The document is intended to serve as guidance for both blood establishments and NRAs when implementing and enforcing these principles. It does not address the practice of transfusion medicine or management of emergencies or crises where specific policies defined by the NRA apply. Aspects of personnel and environmental protection are also not within the scope of this document.\n\nComplementary guidance, especially with respect to the production of plasma for fractionation, is available in the *WHO recommendations for the production, control and regulation of human plasma for fractionation* (3).\n\n## 2. Glossary and abbreviations\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**apheresis**  \nThe process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and/or filtration into its components, and returning those not required to the donor.\n\n**blood collection**  \nThe procedure whereby a single donation of blood is collected in an anticoagulant and/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and/or coagulation activation of the resulting blood donation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) en la recolecci\u00f3n y procesamiento de sangre y plasma de donantes humanos. Se enfoca en la calidad y seguridad de los componentes sangu\u00edneos, abarcando temas como gesti\u00f3n de calidad, documentaci\u00f3n, y gesti\u00f3n de riesgos. Adem\u00e1s, proporciona definiciones clave relacionadas con la recolecci\u00f3n de sangre y el proceso de af\u00e9resis, y aclara que no cubre la pr\u00e1ctica de la medicina transfusional ni la gesti\u00f3n de emergencias.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los temas generales de GMP que se abordan en el documento y por qu\u00e9 son relevantes para la producci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: El documento incluye temas como gesti\u00f3n de calidad, personal, documentaci\u00f3n, instalaciones y equipos, calificaci\u00f3n y validaci\u00f3n, gesti\u00f3n de materiales, fabricaci\u00f3n por contrato, y manejo de quejas y retiradas. Estos son relevantes para asegurar la producci\u00f3n consistente de componentes sangu\u00edneos seguros y de calidad.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos de la manufactura de componentes sangu\u00edneos se tratan en las directrices de la OMS?**\n   - Respuesta: Las directrices abordan desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final, asegurando que se sigan principios de GMP que garanticen la seguridad del donante y la calidad del producto.\n\n3. **\u00bfQu\u00e9 tipo de orientaci\u00f3n complementaria se menciona en el documento respecto a la producci\u00f3n de plasma para fraccionamiento?**\n   - Respuesta: Se menciona que hay orientaci\u00f3n complementaria disponible en las \"recomendaciones de la OMS para la producci\u00f3n, control y regulaci\u00f3n de plasma humano para fraccionamiento\", lo que sugiere que hay directrices espec\u00edficas para este proceso que no se detallan en el documento principal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS establece requisitos para la recolecci\u00f3n, procesamiento y control de calidad de sangre y derivados, enfatizando la importancia de un sistema de aseguramiento de calidad.\n\n2. **Sistema de Aseguramiento de Calidad**: Se basa en tres componentes clave:\n   - Existencia de una estructura nacional independiente de los fabricantes.\n   - Cumplimiento del proceso de aseguramiento de calidad para productos biol\u00f3gicos.\n   - Adherencia a las buenas pr\u00e1cticas de manufactura (GMP).\n\n3. **Revisiones y Recomendaciones**: Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado nuevas recomendaciones sobre:\n   - Inactivaci\u00f3n de virus (2004).\n   - Plasma humano para fraccionamiento (2007).\n\n4. **Resoluci\u00f3n WHA63.12**: Esta resoluci\u00f3n de la Sixty-third World Health Assembly subraya la necesidad de:\n   - Establecer sistemas de aseguramiento de calidad en la cadena de recolecci\u00f3n, procesamiento y distribuci\u00f3n de componentes sangu\u00edneos.\n   - Fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales (NRAs).\n   - Promover programas de sangre organizados y donaciones voluntarias de poblaciones de bajo riesgo.\n\n5. **Importancia de la Calidad y Seguridad**: La calidad y seguridad en la cadena de transfusi\u00f3n se han convertido en temas cruciales, y se recomienda que los establecimientos de sangre mantengan sistemas de calidad basados en principios GMP, que incluyan planificaci\u00f3n, control, aseguramiento y mejora de la calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece los requisitos y recomendaciones.\n- **NRAs (National Regulatory Authorities)**: Autoridades regulatorias nacionales que deben fortalecer su capacidad t\u00e9cnica.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre y sus componentes.", "excerpt_keywords": "Keywords: GMP, blood components, donor safety, apheresis, quality management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "324df83e-586e-489a-b9d3-0030ca3f5322", "node_type": "4", "metadata": {"page_label": "164", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the entire process. When collecting and processing blood and plasma from human donors, GMP considerations should be addressed in a biological context due to the specific characteristics of materials of human origin.\n\nThe guidelines in this document include:\n\n\u2014 general GMP topics such as quality management, personnel, documentation, premises and equipment, qualification and validation, materials management, contract manufacturing, and complaints and recalls;\n\n\u2014 GMP concepts such as quality risk management and product quality reviews;\n\n\u2014 topics specific to the manufacturing of blood components from donor selection to distribution of the final product.\n\nThey address current and widely accepted GMP principles that are relevant to the consistent production of safe and assured quality blood components in blood establishments, including related donor safety concerns. The document is intended to serve as guidance for both blood establishments and NRAs when implementing and enforcing these principles. It does not address the practice of transfusion medicine or management of emergencies or crises where specific policies defined by the NRA apply. Aspects of personnel and environmental protection are also not within the scope of this document.\n\nComplementary guidance, especially with respect to the production of plasma for fractionation, is available in the *WHO recommendations for the production, control and regulation of human plasma for fractionation* (3).\n\n## 2. Glossary and abbreviations\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**apheresis**  \nThe process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and/or filtration into its components, and returning those not required to the donor.\n\n**blood collection**  \nThe procedure whereby a single donation of blood is collected in an anticoagulant and/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and/or coagulation activation of the resulting blood donation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c0b33044ac0a92e2140c50fc8b742c04acbdf465062a8f6eb32bfeb2d0ed8cda", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the entire process. When collecting and processing blood and plasma from human donors, GMP considerations should be addressed in a biological context due to the specific characteristics of materials of human origin.\n\nThe guidelines in this document include:\n\n\u2014 general GMP topics such as quality management, personnel, documentation, premises and equipment, qualification and validation, materials management, contract manufacturing, and complaints and recalls;\n\n\u2014 GMP concepts such as quality risk management and product quality reviews;\n\n\u2014 topics specific to the manufacturing of blood components from donor selection to distribution of the final product.\n\nThey address current and widely accepted GMP principles that are relevant to the consistent production of safe and assured quality blood components in blood establishments, including related donor safety concerns. The document is intended to serve as guidance for both blood establishments and NRAs when implementing and enforcing these principles. It does not address the practice of transfusion medicine or management of emergencies or crises where specific policies defined by the NRA apply. Aspects of personnel and environmental protection are also not within the scope of this document.\n\nComplementary guidance, especially with respect to the production of plasma for fractionation, is available in the *WHO recommendations for the production, control and regulation of human plasma for fractionation* (3).\n\n## 2. Glossary and abbreviations\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**apheresis**  \nThe process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and/or filtration into its components, and returning those not required to the donor.\n\n**blood collection**  \nThe procedure whereby a single donation of blood is collected in an anticoagulant and/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and/or coagulation activation of the resulting blood donation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2159, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "56c8b348-48d2-473a-8b98-a6f4850d09da": {"__data__": {"id_": "56c8b348-48d2-473a-8b98-a6f4850d09da", "embedding": null, "metadata": {"page_label": "165", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# blood component\n\nA constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing/manufacturing.\n\n# blood establishment\n\nAny structure, facility or body that is responsible for any aspect of the collection, testing, processing, storage, release and/or distribution of human blood or blood components when intended for transfusion or further industrial manufacturing.\n\n# blood products\n\nAny therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.\n\n# calibration\n\nThe set of operations which establish, under specified conditions, the relationship between values indicated by a measuring instrument or measuring system, or values represented by a material measure, and the corresponding known values of a reference standard.\n\n# CJD/vCJD\n\nCreutzfeld-Jakob-Disease/variant Creutzfeld-Jakob-Disease.\n\n# closed system\n\nA system developed for aseptic collection and separation of blood and blood components, manufactured under clean conditions, sealed to the external environment and sterilized by a validated and approved method.\n\n# computerized system\n\nA system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n\n# contract acceptor\n\nAn establishment or institution that performs particular work or services under a contract for a different institution.\n\n# contract giver\n\nAn establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.\n\n# donor\n\nA person in defined good health conditions who voluntarily donates blood or blood components, including plasma for fractionation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas debe tener un donante de sangre seg\u00fan el documento?**\n   - Respuesta: Un donante debe ser una persona en condiciones de buena salud definidas que voluntariamente dona sangre o componentes sangu\u00edneos, incluyendo plasma para fraccionamiento.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un 'contract giver' y un 'contract acceptor' en el contexto de los establecimientos de sangre?**\n   - Respuesta: Un 'contract giver' es la instituci\u00f3n que subcontrata trabajos o servicios a otra instituci\u00f3n y establece un contrato que define las responsabilidades de cada parte. Por otro lado, un 'contract acceptor' es la instituci\u00f3n que realiza el trabajo o servicio espec\u00edfico bajo ese contrato.\n\n3. **\u00bfQu\u00e9 implica un 'sistema cerrado' en la recolecci\u00f3n y separaci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: Un 'sistema cerrado' es un sistema desarrollado para la recolecci\u00f3n y separaci\u00f3n as\u00e9ptica de sangre y componentes sangu\u00edneos, fabricado en condiciones limpias, sellado al medio ambiente externo y esterilizado mediante un m\u00e9todo validado y aprobado.\n\n### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Definici\u00f3n de componentes sangu\u00edneos y su uso:**\n   - Los componentes sangu\u00edneos son constituyentes de la sangre que pueden ser preparados mediante m\u00e9todos de separaci\u00f3n y utilizados directamente para fines terap\u00e9uticos o para procesamiento adicional.\n\n2. **Funciones de un establecimiento de sangre:**\n   - Un establecimiento de sangre es responsable de la recolecci\u00f3n, prueba, procesamiento, almacenamiento, liberaci\u00f3n y distribuci\u00f3n de sangre humana o componentes sangu\u00edneos destinados a transfusiones o manufactura industrial.\n\n3. **Importancia de los sistemas en la gesti\u00f3n de sangre:**\n   - Los sistemas, tanto cerrados como computarizados, son esenciales para asegurar la recolecci\u00f3n as\u00e9ptica y el manejo eficiente de datos en el proceso de donaci\u00f3n y distribuci\u00f3n de sangre.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, titulado \"WHO - Technical Report Series 961\", se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) aplicadas a la recolecci\u00f3n y procesamiento de sangre y plasma de donantes humanos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Importancia de las GMP en el contexto biol\u00f3gico de los materiales de origen humano.\n   - Temas generales de GMP: gesti\u00f3n de calidad, personal, documentaci\u00f3n, instalaciones y equipos, calificaci\u00f3n y validaci\u00f3n, gesti\u00f3n de materiales, fabricaci\u00f3n por contrato, y manejo de quejas y retiradas.\n   - Conceptos de GMP: gesti\u00f3n de riesgos de calidad y revisiones de calidad del producto.\n\n2. **Manufactura de Componentes Sangu\u00edneos**:\n   - Proceso desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final.\n   - Enfoque en la producci\u00f3n consistente de componentes sangu\u00edneos seguros y de calidad, as\u00ed como en la seguridad del donante.\n\n3. **Orientaci\u00f3n Complementaria**:\n   - Referencia a las recomendaciones de la OMS para la producci\u00f3n, control y regulaci\u00f3n de plasma humano para fraccionamiento.\n\n4. **Definiciones Clave**:\n   - **Af\u00e9resis**: Proceso de obtenci\u00f3n selectiva de componentes sangu\u00edneos de un donante.\n   - **Recolecci\u00f3n de Sangre**: Procedimiento para recolectar una donaci\u00f3n de sangre en condiciones que minimizan la contaminaci\u00f3n microbiana y el da\u00f1o celular.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n y procesamiento de sangre.\n- **Autoridades Reguladoras Nacionales (NRA)**: Organismos que implementan y hacen cumplir las GMP.\n\nEste resumen destaca la importancia de las GMP en la producci\u00f3n de componentes sangu\u00edneos y proporciona un marco para garantizar la calidad y seguridad en el manejo de materiales de origen humano.", "excerpt_keywords": "Keywords: blood components, blood establishment, blood products, donor, closed system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5d0756e1-9162-41fb-8455-9a451eae6330", "node_type": "4", "metadata": {"page_label": "165", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# blood component\n\nA constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing/manufacturing.\n\n# blood establishment\n\nAny structure, facility or body that is responsible for any aspect of the collection, testing, processing, storage, release and/or distribution of human blood or blood components when intended for transfusion or further industrial manufacturing.\n\n# blood products\n\nAny therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.\n\n# calibration\n\nThe set of operations which establish, under specified conditions, the relationship between values indicated by a measuring instrument or measuring system, or values represented by a material measure, and the corresponding known values of a reference standard.\n\n# CJD/vCJD\n\nCreutzfeld-Jakob-Disease/variant Creutzfeld-Jakob-Disease.\n\n# closed system\n\nA system developed for aseptic collection and separation of blood and blood components, manufactured under clean conditions, sealed to the external environment and sterilized by a validated and approved method.\n\n# computerized system\n\nA system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n\n# contract acceptor\n\nAn establishment or institution that performs particular work or services under a contract for a different institution.\n\n# contract giver\n\nAn establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.\n\n# donor\n\nA person in defined good health conditions who voluntarily donates blood or blood components, including plasma for fractionation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6a1c461d4494862cd26d5622acd61103574a993c36a864e294a66a3bf379a897", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# blood component\n\nA constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing/manufacturing.\n\n# blood establishment\n\nAny structure, facility or body that is responsible for any aspect of the collection, testing, processing, storage, release and/or distribution of human blood or blood components when intended for transfusion or further industrial manufacturing.\n\n# blood products\n\nAny therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.\n\n# calibration\n\nThe set of operations which establish, under specified conditions, the relationship between values indicated by a measuring instrument or measuring system, or values represented by a material measure, and the corresponding known values of a reference standard.\n\n# CJD/vCJD\n\nCreutzfeld-Jakob-Disease/variant Creutzfeld-Jakob-Disease.\n\n# closed system\n\nA system developed for aseptic collection and separation of blood and blood components, manufactured under clean conditions, sealed to the external environment and sterilized by a validated and approved method.\n\n# computerized system\n\nA system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n\n# contract acceptor\n\nAn establishment or institution that performs particular work or services under a contract for a different institution.\n\n# contract giver\n\nAn establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.\n\n# donor\n\nA person in defined good health conditions who voluntarily donates blood or blood components, including plasma for fractionation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1946, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "85c96ee5-597a-4573-9499-d05aca352d72": {"__data__": {"id_": "85c96ee5-597a-4573-9499-d05aca352d72", "embedding": null, "metadata": {"page_label": "166", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Distribution\n\nThe act of delivery of blood and blood components to other blood establishments, hospital blood banks or manufacturers of blood- and plasma-derived medicinal products. It does not include the issuing of blood or blood components for transfusion.\n\n# First-time (tested) Donor\n\nA donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.\n\n# Good Manufacturing Practice (GMP)\n\nAll elements in the established practice that will collectively lead to final products or services that consistently meet appropriate specifications and compliance with defined regulations.\n\n# HAV, Hepatitis A Virus\n\nA non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.\n\n# HBsAg, Hepatitis B Surface Antigen\n\nThe antigen on the periphery of the hepatitis B virus.\n\n# HBV, Hepatitis B Virus\n\nAn enveloped double-stranded DNA virus that is the causative agent of hepatitis B.\n\n# HCV, Hepatitis C Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of hepatitis C.\n\n# HIV, Human Immunodeficiency Virus\n\nAn enveloped, single-stranded RNA virus that is the causative agent of the acquired immunodeficiency syndrome (AIDS).\n\n# HTLV 1 and 2, Human T-cell Lymphotropic Virus, Types 1 and 2\n\nEnveloped, single stranded RNA viruses that are typically cell-associated.\n\n# Manufacture\n\nAll operational processes or steps \u2014 including purchase or selection of materials and products, production, quality control, release, storage and distribution of products and the related controls \u2014 used to produce a blood product. This includes also the donation process.\n\n# Mobile Site\n\nA unit or site used for the collection of blood and/or blood components, operating temporarily or at movable locations off-site from a permanent collection site, under the responsibility of a blood establishment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave relacionados con la donaci\u00f3n y el manejo de sangre y componentes sangu\u00edneos. Se definen t\u00e9rminos importantes como \"donante de primera vez\", \"buenas pr\u00e1cticas de manufactura\" (GMP), y se describen virus relevantes como el VIH, HBV, HCV, y otros. Tambi\u00e9n se menciona el proceso de distribuci\u00f3n de sangre y la operaci\u00f3n de sitios m\u00f3viles para la recolecci\u00f3n de sangre.\n\n### Preguntas\n1. **\u00bfQu\u00e9 se entiende por \"donante de primera vez\" en el contexto de la donaci\u00f3n de sangre?**\n   - Respuesta: Un donante de primera vez es aquel cuya sangre o plasma es probado por primera vez para marcadores de enfermedades infecciosas en un establecimiento de sangre.\n\n2. **\u00bfCu\u00e1les son los elementos que constituyen las Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de productos sangu\u00edneos?**\n   - Respuesta: Las GMP incluyen todos los elementos en la pr\u00e1ctica establecida que llevan a productos o servicios finales que cumplen consistentemente con especificaciones apropiadas y regulaciones definidas, abarcando desde la selecci\u00f3n de materiales hasta el control de calidad y distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 es un \"sitio m\u00f3vil\" y cu\u00e1l es su funci\u00f3n en la recolecci\u00f3n de sangre?**\n   - Respuesta: Un sitio m\u00f3vil es una unidad o lugar utilizado para la recolecci\u00f3n de sangre y/o componentes sangu\u00edneos, que opera temporalmente o en ubicaciones m\u00f3viles fuera de un sitio de recolecci\u00f3n permanente, bajo la responsabilidad de un establecimiento de sangre.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Componentes Sangu\u00edneos:**\n   - Definici\u00f3n: Constituyentes de la sangre (eritrocitos, leucocitos, plaquetas, crioprecipitado y plasma) que pueden ser preparados para uso terap\u00e9utico o procesamiento adicional.\n\n2. **Establecimiento de Sangre:**\n   - Funci\u00f3n: Estructura o entidad responsable de la recolecci\u00f3n, prueba, procesamiento, almacenamiento, liberaci\u00f3n y distribuci\u00f3n de sangre humana o componentes sangu\u00edneos para transfusiones o manufactura industrial.\n\n3. **Productos Sangu\u00edneos:**\n   - Definici\u00f3n: Sustancias terap\u00e9uticas derivadas de la sangre humana, incluyendo sangre total, componentes sangu\u00edneos y productos medicinales derivados del plasma.\n\n4. **Calibraci\u00f3n:**\n   - Proceso: Operaciones que establecen la relaci\u00f3n entre los valores indicados por un instrumento de medici\u00f3n y los valores conocidos de un est\u00e1ndar de referencia.\n\n5. **Enfermedades:**\n   - CJD/vCJD: Enfermedades relacionadas con la enfermedad de Creutzfeldt-Jakob y su variante.\n\n6. **Sistema Cerrado:**\n   - Definici\u00f3n: Sistema dise\u00f1ado para la recolecci\u00f3n y separaci\u00f3n as\u00e9ptica de sangre, fabricado en condiciones limpias y sellado al medio ambiente externo.\n\n7. **Sistema Computarizado:**\n   - Definici\u00f3n: Sistema que incluye la entrada de datos, procesamiento electr\u00f3nico y salida de informaci\u00f3n para reportes o control autom\u00e1tico.\n\n8. **Relaciones Contractuales:**\n   - **Contract Giver:** Instituci\u00f3n que subcontrata servicios y establece un contrato con otra instituci\u00f3n.\n   - **Contract Acceptor:** Instituci\u00f3n que realiza el trabajo o servicio bajo un contrato establecido.\n\n9. **Donante:**\n   - Definici\u00f3n: Persona en buenas condiciones de salud que dona sangre o componentes sangu\u00edneos de manera voluntaria.\n\n### Entidades Clave:\n- **Componentes Sangu\u00edneos**\n- **Establecimientos de Sangre**\n- **Productos Sangu\u00edneos**\n- **Sistemas (Cerrado y Computarizado)**\n- **Donantes**\n- **Relaciones Contractuales (Contract Giver y Contract Acceptor)**\n\nEste resumen abarca los conceptos y definiciones esenciales relacionados con la sangre y su manejo, as\u00ed como las entidades involucradas en el proceso de donaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: blood donation, Good Manufacturing Practice, infectious diseases, mobile collection site, blood components"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "59dabd56-7c3f-41fa-859b-b3d7dc7a021f", "node_type": "4", "metadata": {"page_label": "166", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Distribution\n\nThe act of delivery of blood and blood components to other blood establishments, hospital blood banks or manufacturers of blood- and plasma-derived medicinal products. It does not include the issuing of blood or blood components for transfusion.\n\n# First-time (tested) Donor\n\nA donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.\n\n# Good Manufacturing Practice (GMP)\n\nAll elements in the established practice that will collectively lead to final products or services that consistently meet appropriate specifications and compliance with defined regulations.\n\n# HAV, Hepatitis A Virus\n\nA non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.\n\n# HBsAg, Hepatitis B Surface Antigen\n\nThe antigen on the periphery of the hepatitis B virus.\n\n# HBV, Hepatitis B Virus\n\nAn enveloped double-stranded DNA virus that is the causative agent of hepatitis B.\n\n# HCV, Hepatitis C Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of hepatitis C.\n\n# HIV, Human Immunodeficiency Virus\n\nAn enveloped, single-stranded RNA virus that is the causative agent of the acquired immunodeficiency syndrome (AIDS).\n\n# HTLV 1 and 2, Human T-cell Lymphotropic Virus, Types 1 and 2\n\nEnveloped, single stranded RNA viruses that are typically cell-associated.\n\n# Manufacture\n\nAll operational processes or steps \u2014 including purchase or selection of materials and products, production, quality control, release, storage and distribution of products and the related controls \u2014 used to produce a blood product. This includes also the donation process.\n\n# Mobile Site\n\nA unit or site used for the collection of blood and/or blood components, operating temporarily or at movable locations off-site from a permanent collection site, under the responsibility of a blood establishment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "47680c6f4fb81623a73298c41377780d9ae50655b90c1cbc08e09dc1097b84a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Distribution\n\nThe act of delivery of blood and blood components to other blood establishments, hospital blood banks or manufacturers of blood- and plasma-derived medicinal products. It does not include the issuing of blood or blood components for transfusion.\n\n# First-time (tested) Donor\n\nA donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.\n\n# Good Manufacturing Practice (GMP)\n\nAll elements in the established practice that will collectively lead to final products or services that consistently meet appropriate specifications and compliance with defined regulations.\n\n# HAV, Hepatitis A Virus\n\nA non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.\n\n# HBsAg, Hepatitis B Surface Antigen\n\nThe antigen on the periphery of the hepatitis B virus.\n\n# HBV, Hepatitis B Virus\n\nAn enveloped double-stranded DNA virus that is the causative agent of hepatitis B.\n\n# HCV, Hepatitis C Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of hepatitis C.\n\n# HIV, Human Immunodeficiency Virus\n\nAn enveloped, single-stranded RNA virus that is the causative agent of the acquired immunodeficiency syndrome (AIDS).\n\n# HTLV 1 and 2, Human T-cell Lymphotropic Virus, Types 1 and 2\n\nEnveloped, single stranded RNA viruses that are typically cell-associated.\n\n# Manufacture\n\nAll operational processes or steps \u2014 including purchase or selection of materials and products, production, quality control, release, storage and distribution of products and the related controls \u2014 used to produce a blood product. This includes also the donation process.\n\n# Mobile Site\n\nA unit or site used for the collection of blood and/or blood components, operating temporarily or at movable locations off-site from a permanent collection site, under the responsibility of a blood establishment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1875, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fc389e87-1d90-4dbf-a300-bdd54ba928ff": {"__data__": {"id_": "fc389e87-1d90-4dbf-a300-bdd54ba928ff", "embedding": null, "metadata": {"page_label": "167", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# nucleic acid amplification techniques (NAT)\n\nA testing method to detect the presence of a targeted area of a defined microbial genome that uses amplification techniques such as polymerase chain reaction (PCR).\n\n# near-miss event\n\nAn incident that, if not detected in a timely manner, would have affected the safety of the recipients or donors.\n\n# national regulatory authority (NRA)\n\nWHO terminology for national medicines regulatory authorities. NRAs should promulgate and enforce medicines regulations.\n\n# plasma for fractionation\n\nThe liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.\n\n# production\n\nAll operations involved in the preparation of blood components, from collection through processing to completion as a finished product (blood component).\n\n# qualification\n\nA set of actions used to provide documented evidence that any piece of equipment, critical material or reagent used to produce the final product and that might affect the quality or safety of a product works reliably as intended or specified and leads to the expected results.\n\n# quality\n\nThe total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n\n# quality assurance\n\nA part of quality management focused on providing confidence that quality requirements will be met.\n\n# quality management\n\nThe coordinated activities that direct and control an organization with regard to quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas definiciones y conceptos clave relacionados con la regulaci\u00f3n y la calidad en la producci\u00f3n de componentes sangu\u00edneos. Se destacan t\u00e9cnicas de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT) para la detecci\u00f3n de microorganismos, la importancia de las autoridades regulatorias nacionales (NRA), y los procesos de producci\u00f3n y aseguramiento de calidad en la fabricaci\u00f3n de productos sangu\u00edneos. Se enfatiza la necesidad de cumplir con requisitos de calidad y seguridad en todos los aspectos de la producci\u00f3n.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 papel desempe\u00f1an las autoridades regulatorias nacionales (NRA) en la producci\u00f3n de componentes sangu\u00edneos seg\u00fan la OMS?**\n   - Esta pregunta busca entender la funci\u00f3n espec\u00edfica de las NRA en la regulaci\u00f3n y supervisi\u00f3n de la calidad de los productos sangu\u00edneos, algo que puede no estar claramente definido en otros documentos.\n\n2. **\u00bfCu\u00e1les son los pasos involucrados en el proceso de calificaci\u00f3n de equipos y materiales en la producci\u00f3n de productos sangu\u00edneos?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que garantizan que los equipos y materiales utilizados en la producci\u00f3n cumplen con los est\u00e1ndares de calidad y seguridad.\n\n3. **\u00bfC\u00f3mo se define un evento de \"casi accidente\" en el contexto de la seguridad de los donantes y receptores de sangre?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de lo que constituye un \"casi accidente\" y su relevancia en la gesti\u00f3n de riesgos en la transfusi\u00f3n de sangre, un aspecto que puede no estar ampliamente discutido en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n del documento de la OMS aborda varios conceptos fundamentales relacionados con la donaci\u00f3n y manejo de sangre y sus componentes. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Distribuci\u00f3n**: Se refiere al proceso de entrega de sangre y componentes sangu\u00edneos a otros establecimientos de sangre, bancos de sangre hospitalarios o fabricantes de productos medicinales derivados de sangre y plasma. No incluye la emisi\u00f3n de sangre para transfusiones.\n\n2. **Donante de Primera Vez**: Se define como un donante cuya sangre o plasma es sometido a pruebas por primera vez para detectar marcadores de enfermedades infecciosas en un establecimiento de sangre.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se describen como todos los elementos en la pr\u00e1ctica establecida que aseguran que los productos o servicios finales cumplan con especificaciones apropiadas y regulaciones definidas. Esto incluye procesos desde la selecci\u00f3n de materiales hasta el control de calidad y distribuci\u00f3n.\n\n4. **Virus Relacionados con Enfermedades**:\n   - **HAV (Virus de la Hepatitis A)**: Un virus ARN de cadena sencilla no envuelto, causante de hepatitis A.\n   - **HBsAg (Ant\u00edgeno de Superficie de Hepatitis B)**: Ant\u00edgeno presente en la periferia del virus de hepatitis B.\n   - **HBV (Virus de Hepatitis B)**: Un virus ADN de doble cadena envuelto, causante de hepatitis B.\n   - **HCV (Virus de Hepatitis C)**: Un virus ARN de cadena sencilla envuelto, causante de hepatitis C.\n   - **HIV (Virus de Inmunodeficiencia Humana)**: Un virus ARN de cadena sencilla envuelto, causante del s\u00edndrome de inmunodeficiencia adquirida (SIDA).\n   - **HTLV 1 y 2 (Virus Linfotr\u00f3pico Humano de C\u00e9lulas T, Tipos 1 y 2)**: Virus ARN de cadena sencilla envueltos, t\u00edpicamente asociados a c\u00e9lulas.\n\n5. **Manufactura**: Se refiere a todos los procesos operativos involucrados en la producci\u00f3n de productos sangu\u00edneos, incluyendo la selecci\u00f3n de materiales, producci\u00f3n, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n.\n\n6. **Sitio M\u00f3vil**: Se define como una unidad o lugar utilizado temporalmente para la recolecci\u00f3n de sangre y/o componentes sangu\u00edneos, que opera en ubicaciones m\u00f3viles fuera de un sitio de recolecci\u00f3n permanente, bajo la responsabilidad de un establecimiento de sangre.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave relacionados con la donaci\u00f3n y manejo de sangre, as\u00ed como los virus relevantes en este contexto.", "excerpt_keywords": "Keywords: nucleic acid amplification, near-miss event, national regulatory authority, plasma fractionation, quality management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b3a2734-eb46-4005-ab47-4f286ff513ed", "node_type": "4", "metadata": {"page_label": "167", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# nucleic acid amplification techniques (NAT)\n\nA testing method to detect the presence of a targeted area of a defined microbial genome that uses amplification techniques such as polymerase chain reaction (PCR).\n\n# near-miss event\n\nAn incident that, if not detected in a timely manner, would have affected the safety of the recipients or donors.\n\n# national regulatory authority (NRA)\n\nWHO terminology for national medicines regulatory authorities. NRAs should promulgate and enforce medicines regulations.\n\n# plasma for fractionation\n\nThe liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.\n\n# production\n\nAll operations involved in the preparation of blood components, from collection through processing to completion as a finished product (blood component).\n\n# qualification\n\nA set of actions used to provide documented evidence that any piece of equipment, critical material or reagent used to produce the final product and that might affect the quality or safety of a product works reliably as intended or specified and leads to the expected results.\n\n# quality\n\nThe total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n\n# quality assurance\n\nA part of quality management focused on providing confidence that quality requirements will be met.\n\n# quality management\n\nThe coordinated activities that direct and control an organization with regard to quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "eeb96f322c3c6a0d4d3c38e70123c2e86e5199e0d9a2d241726c554ee5e00ee2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# nucleic acid amplification techniques (NAT)\n\nA testing method to detect the presence of a targeted area of a defined microbial genome that uses amplification techniques such as polymerase chain reaction (PCR).\n\n# near-miss event\n\nAn incident that, if not detected in a timely manner, would have affected the safety of the recipients or donors.\n\n# national regulatory authority (NRA)\n\nWHO terminology for national medicines regulatory authorities. NRAs should promulgate and enforce medicines regulations.\n\n# plasma for fractionation\n\nThe liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.\n\n# production\n\nAll operations involved in the preparation of blood components, from collection through processing to completion as a finished product (blood component).\n\n# qualification\n\nA set of actions used to provide documented evidence that any piece of equipment, critical material or reagent used to produce the final product and that might affect the quality or safety of a product works reliably as intended or specified and leads to the expected results.\n\n# quality\n\nThe total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n\n# quality assurance\n\nA part of quality management focused on providing confidence that quality requirements will be met.\n\n# quality management\n\nThe coordinated activities that direct and control an organization with regard to quality.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1911, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4205fdaf-3bb3-403a-8462-aa5a645ed67e": {"__data__": {"id_": "4205fdaf-3bb3-403a-8462-aa5a645ed67e", "embedding": null, "metadata": {"page_label": "168", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\nA management system that directs and controls an organization with respect to quality and that ensures that steps, processes, procedures and policies related to quality activities are being followed.\n\n# Quality Risk Management (QRM)\n\nA systematic process for the assessment, control, communication and review of risks to the quality of the product across the product\u2019s life cycle.\n\n# Quarantine\n\nThe status of starting or packaging materials, intermediate, bulk or finished products that are isolated physically or by other means while a decision is awaited on their release for use or rejection.\n\n# Regular Donor\n\nA person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.\n\n# Repeat Donor\n\nA person who has donated before in the same establishment but not within the period of time considered as regular donation.\n\n# Repeatedly Reactive\n\nA donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.\n\n# Validation\n\nActions for proving that any operational procedure, process, activity or system leads to the expected results. Validation work is normally performed in advance according to a defined and approved protocol that describes tests and acceptance criteria.\n\n# WNV, West Nile Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of West Nile fever.\n\n## 3. Quality Management\n\n### 3.1 Principles\n\nQuality is the responsibility of all persons involved in the various processes of the blood establishment. The management of the blood establishment is responsible for a systematic approach to quality and the implementation and maintenance of a quality management system. A quality programme", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la gesti\u00f3n de calidad en los establecimientos de sangre, destacando la importancia de un sistema de gesti\u00f3n de calidad y la gesti\u00f3n de riesgos de calidad (QRM). Se definen t\u00e9rminos clave como \"donante regular\", \"donante repetido\" y \"reactivo repetido\", as\u00ed como la importancia de la validaci\u00f3n de procedimientos y la gesti\u00f3n de riesgos a lo largo del ciclo de vida del producto. Se enfatiza que la calidad es responsabilidad de todos los involucrados en los procesos del establecimiento de sangre.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre un donante regular y un donante repetido seg\u00fan el documento?**\n   - Respuesta: Un donante regular es una persona que dona sangre, componentes sangu\u00edneos o plasma de manera rutinaria en el mismo establecimiento de sangre, cumpliendo con los intervalos de tiempo m\u00ednimos. En cambio, un donante repetido es alguien que ha donado anteriormente en el mismo establecimiento, pero no dentro del per\u00edodo considerado para una donaci\u00f3n regular.\n\n2. **\u00bfQu\u00e9 implica el proceso de validaci\u00f3n mencionado en el contexto y por qu\u00e9 es importante?**\n   - Respuesta: La validaci\u00f3n implica acciones para demostrar que cualquier procedimiento operativo, proceso, actividad o sistema produce los resultados esperados. Es importante porque asegura que los procedimientos cumplen con los criterios de aceptaci\u00f3n definidos y aprobados, lo que contribuye a la calidad y seguridad de los productos sangu\u00edneos.\n\n3. **\u00bfC\u00f3mo se define la gesti\u00f3n de riesgos de calidad (QRM) en el contexto del ciclo de vida del producto?**\n   - Respuesta: La gesti\u00f3n de riesgos de calidad (QRM) se define como un proceso sistem\u00e1tico para la evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de los riesgos que afectan la calidad del producto a lo largo de su ciclo de vida, asegurando que se tomen medidas adecuadas para mitigar esos riesgos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en definiciones y conceptos fundamentales relacionados con la regulaci\u00f3n, producci\u00f3n y calidad de los componentes sangu\u00edneos, seg\u00fan la OMS. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **T\u00e9cnicas de Amplificaci\u00f3n de \u00c1cidos Nucleicos (NAT)**: M\u00e9todos de prueba que utilizan t\u00e9cnicas como la reacci\u00f3n en cadena de la polimerasa (PCR) para detectar microorganismos en el genoma.\n\n2. **Evento de \"Casi Accidente\"**: Incidentes que, si no se detectan a tiempo, podr\u00edan comprometer la seguridad de los donantes o receptores de sangre.\n\n3. **Autoridad Reguladora Nacional (NRA)**: Entidades responsables de promulgar y hacer cumplir las regulaciones sobre medicamentos a nivel nacional, seg\u00fan la terminolog\u00eda de la OMS.\n\n4. **Plasma para Fraccionamiento**: Parte l\u00edquida de la sangre humana que se utiliza para la fabricaci\u00f3n de productos sangu\u00edneos, obtenida tras la separaci\u00f3n de los elementos celulares.\n\n5. **Producci\u00f3n**: Conjunto de operaciones que abarcan desde la recolecci\u00f3n de sangre hasta la finalizaci\u00f3n de los componentes sangu\u00edneos.\n\n6. **Calificaci\u00f3n**: Proceso que proporciona evidencia documentada de que los equipos y materiales utilizados en la producci\u00f3n funcionan de manera confiable y cumplen con los est\u00e1ndares de calidad.\n\n7. **Calidad**: Conjunto de caracter\u00edsticas que determinan la capacidad de un producto o servicio para satisfacer necesidades espec\u00edficas, incluyendo atributos de seguridad y calidad.\n\n8. **Aseguramiento de la Calidad**: Parte de la gesti\u00f3n de calidad que se enfoca en garantizar que se cumplan los requisitos de calidad.\n\n9. **Gesti\u00f3n de Calidad**: Actividades coordinadas que dirigen y controlan una organizaci\u00f3n en relaci\u00f3n con la calidad.\n\n### Conclusi\u00f3n\nLa secci\u00f3n destaca la importancia de la regulaci\u00f3n, la calidad y la seguridad en la producci\u00f3n de componentes sangu\u00edneos, enfatizando la necesidad de cumplir con est\u00e1ndares rigurosos para proteger la salud de los donantes y receptores.", "excerpt_keywords": "Keywords: Quality Management, Quality Risk Management, Blood Donation, Validation, West Nile Virus"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ecae8993-3ae8-4217-b48d-d6bb1114a11b", "node_type": "4", "metadata": {"page_label": "168", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\nA management system that directs and controls an organization with respect to quality and that ensures that steps, processes, procedures and policies related to quality activities are being followed.\n\n# Quality Risk Management (QRM)\n\nA systematic process for the assessment, control, communication and review of risks to the quality of the product across the product\u2019s life cycle.\n\n# Quarantine\n\nThe status of starting or packaging materials, intermediate, bulk or finished products that are isolated physically or by other means while a decision is awaited on their release for use or rejection.\n\n# Regular Donor\n\nA person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.\n\n# Repeat Donor\n\nA person who has donated before in the same establishment but not within the period of time considered as regular donation.\n\n# Repeatedly Reactive\n\nA donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.\n\n# Validation\n\nActions for proving that any operational procedure, process, activity or system leads to the expected results. Validation work is normally performed in advance according to a defined and approved protocol that describes tests and acceptance criteria.\n\n# WNV, West Nile Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of West Nile fever.\n\n## 3. Quality Management\n\n### 3.1 Principles\n\nQuality is the responsibility of all persons involved in the various processes of the blood establishment. The management of the blood establishment is responsible for a systematic approach to quality and the implementation and maintenance of a quality management system. A quality programme", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e2e8bcc207edcfa1ee90a92c8b603d34cc35557fdffed0016dab220cb959c025", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Management System\n\nA management system that directs and controls an organization with respect to quality and that ensures that steps, processes, procedures and policies related to quality activities are being followed.\n\n# Quality Risk Management (QRM)\n\nA systematic process for the assessment, control, communication and review of risks to the quality of the product across the product\u2019s life cycle.\n\n# Quarantine\n\nThe status of starting or packaging materials, intermediate, bulk or finished products that are isolated physically or by other means while a decision is awaited on their release for use or rejection.\n\n# Regular Donor\n\nA person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.\n\n# Repeat Donor\n\nA person who has donated before in the same establishment but not within the period of time considered as regular donation.\n\n# Repeatedly Reactive\n\nA donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.\n\n# Validation\n\nActions for proving that any operational procedure, process, activity or system leads to the expected results. Validation work is normally performed in advance according to a defined and approved protocol that describes tests and acceptance criteria.\n\n# WNV, West Nile Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of West Nile fever.\n\n## 3. Quality Management\n\n### 3.1 Principles\n\nQuality is the responsibility of all persons involved in the various processes of the blood establishment. The management of the blood establishment is responsible for a systematic approach to quality and the implementation and maintenance of a quality management system. A quality programme", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1867, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4628ed41-9fc9-4b62-9ffe-98ad1080ba36": {"__data__": {"id_": "4628ed41-9fc9-4b62-9ffe-98ad1080ba36", "embedding": null, "metadata": {"page_label": "169", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be designed to ensure that each product (including plasma for fractionation) is manufactured in the same manner from donor selection through to distribution of the final product.\n\nQuality management involves all activities that determine the quality policy, objectives and responsibilities, and their implementation through quality planning, quality control, quality assurance and quality improvement in order to assure the quality and safety of blood and blood components.\n\nThe attainment of the quality policy and objectives is the responsibility of the senior management of the blood establishment and requires the participation and commitment of all staff throughout the entire blood establishment. Senior management should review the quality system at regular intervals to verify its effectiveness and to introduce corrective measures if they are considered necessary.\n\nWithin the organizational structure of the blood establishment there should be a quality management unit comprising one or more persons. The quality management personnel should be responsible for ensuring that there is documented evidence that the quality policies, procedures and practices are being fulfilled. Senior management, in coordination with the quality management unit, should develop and implement quality assurance policies and objectives in a manner that provides clear direction to all staff. The quality assurance policies and objectives should be designed to ensure the highest levels of safety and quality in the blood components that are produced from each collection. The policies and procedures should comply with all national and, where appropriate, international regulations and requirements.\n\nStaff should be able to understand the intent of the quality objectives and their own role in accomplishing the objectives. The performance of the quality management system should be evaluated periodically by determining whether the objectives have been or are continuously being met. If there are shortcomings in the quality system, corrections should be made and the quality management unit should be held responsible for monitoring corrective action and continued compliance.\n\nWithin any blood establishment there should be independent functions for fulfilling quality assurance and quality control responsibilities. The quality assurance function should be independent of manufacturing operations and should assure that all processes are performed and documented. The quality assurance function should be involved in all quality-related matters and in the review and approval of all quality-related documents.\n\n### 3.2 Quality assurance\n\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of the product. It is the", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la importancia de un sistema de gesti\u00f3n de calidad en los establecimientos de sangre, que abarca desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final. Se enfatiza la responsabilidad de la alta direcci\u00f3n en la implementaci\u00f3n y revisi\u00f3n de pol\u00edticas de calidad, as\u00ed como la necesidad de un equipo de gesti\u00f3n de calidad independiente que asegure el cumplimiento de las normativas y la mejora continua. La calidad y seguridad de los componentes sangu\u00edneos son fundamentales y deben ser entendidas por todo el personal involucrado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de la alta direcci\u00f3n en el sistema de gesti\u00f3n de calidad de un establecimiento de sangre?**\n   - Respuesta: La alta direcci\u00f3n es responsable de la implementaci\u00f3n y revisi\u00f3n de la pol\u00edtica de calidad y objetivos, asegurando la participaci\u00f3n y compromiso de todo el personal. Debe revisar el sistema de calidad peri\u00f3dicamente para verificar su efectividad y tomar medidas correctivas si es necesario.\n\n2. **\u00bfQu\u00e9 funciones debe cumplir la unidad de gesti\u00f3n de calidad dentro de un establecimiento de sangre?**\n   - Respuesta: La unidad de gesti\u00f3n de calidad debe asegurarse de que haya evidencia documentada del cumplimiento de las pol\u00edticas, procedimientos y pr\u00e1cticas de calidad. Tambi\u00e9n es responsable de desarrollar e implementar pol\u00edticas y objetivos de aseguramiento de calidad que proporcionen direcci\u00f3n clara a todo el personal.\n\n3. **\u00bfPor qu\u00e9 es importante que la funci\u00f3n de aseguramiento de calidad sea independiente de las operaciones de fabricaci\u00f3n?**\n   - Respuesta: La funci\u00f3n de aseguramiento de calidad debe ser independiente para garantizar que todos los procesos se realicen y documenten adecuadamente, lo que permite una revisi\u00f3n objetiva de todos los asuntos relacionados con la calidad y la aprobaci\u00f3n de documentos relacionados con la calidad sin conflictos de inter\u00e9s.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Gesti\u00f3n de Calidad**: Se refiere a un sistema que dirige y controla una organizaci\u00f3n en relaci\u00f3n con la calidad, asegurando que se sigan los pasos, procesos, procedimientos y pol\u00edticas relacionados con las actividades de calidad.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**: Es un proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar los riesgos que afectan la calidad del producto a lo largo de su ciclo de vida.\n\n3. **Cuarentena**: Estado de materiales o productos que est\u00e1n aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n\n4. **Donante Regular**: Persona que dona sangre, componentes sangu\u00edneos o plasma de manera rutinaria en el mismo establecimiento, cumpliendo con intervalos de tiempo m\u00ednimos.\n\n5. **Donante Repetido**: Persona que ha donado anteriormente en el mismo establecimiento, pero no dentro del per\u00edodo considerado para una donaci\u00f3n regular.\n\n6. **Reactivo Repetido**: Una donaci\u00f3n que es considerada reactiva si se encuentra reactiva en una prueba de detecci\u00f3n y al menos una de las pruebas repetidas tambi\u00e9n es reactiva.\n\n7. **Validaci\u00f3n**: Acciones destinadas a demostrar que un procedimiento, proceso, actividad o sistema produce los resultados esperados, normalmente realizadas de acuerdo con un protocolo definido y aprobado.\n\n8. **Virus del Oeste del Nilo (WNV)**: Un virus de ARN de cadena simple que causa fiebre del Nilo Occidental.\n\n9. **Responsabilidad de la Calidad**: La calidad es responsabilidad de todas las personas involucradas en los procesos del establecimiento de sangre, y la gesti\u00f3n debe adoptar un enfoque sistem\u00e1tico para implementar y mantener un sistema de gesti\u00f3n de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Establecimiento de sangre.\n- **Productos**: Sangre, componentes sangu\u00edneos, plasma.\n- **Personas**: Donantes (regulares y repetidos), personal del establecimiento.\n- **Procesos**: Evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de riesgos de calidad.\n- **Protocolos**: Documentos que describen pruebas y criterios de aceptaci\u00f3n para la validaci\u00f3n. \n\nEste resumen destaca la importancia de la gesti\u00f3n de calidad y los procesos asociados en el contexto de los establecimientos de sangre, as\u00ed como la responsabilidad compartida de todos los involucrados en asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: quality management, blood establishment, quality assurance, donor selection, safety and quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5c7146bf-73e2-42d7-befc-549a2c20a406", "node_type": "4", "metadata": {"page_label": "169", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be designed to ensure that each product (including plasma for fractionation) is manufactured in the same manner from donor selection through to distribution of the final product.\n\nQuality management involves all activities that determine the quality policy, objectives and responsibilities, and their implementation through quality planning, quality control, quality assurance and quality improvement in order to assure the quality and safety of blood and blood components.\n\nThe attainment of the quality policy and objectives is the responsibility of the senior management of the blood establishment and requires the participation and commitment of all staff throughout the entire blood establishment. Senior management should review the quality system at regular intervals to verify its effectiveness and to introduce corrective measures if they are considered necessary.\n\nWithin the organizational structure of the blood establishment there should be a quality management unit comprising one or more persons. The quality management personnel should be responsible for ensuring that there is documented evidence that the quality policies, procedures and practices are being fulfilled. Senior management, in coordination with the quality management unit, should develop and implement quality assurance policies and objectives in a manner that provides clear direction to all staff. The quality assurance policies and objectives should be designed to ensure the highest levels of safety and quality in the blood components that are produced from each collection. The policies and procedures should comply with all national and, where appropriate, international regulations and requirements.\n\nStaff should be able to understand the intent of the quality objectives and their own role in accomplishing the objectives. The performance of the quality management system should be evaluated periodically by determining whether the objectives have been or are continuously being met. If there are shortcomings in the quality system, corrections should be made and the quality management unit should be held responsible for monitoring corrective action and continued compliance.\n\nWithin any blood establishment there should be independent functions for fulfilling quality assurance and quality control responsibilities. The quality assurance function should be independent of manufacturing operations and should assure that all processes are performed and documented. The quality assurance function should be involved in all quality-related matters and in the review and approval of all quality-related documents.\n\n### 3.2 Quality assurance\n\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of the product. It is the", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d8f71a5189d0cbe2d04a2720911fc7551f5298b76913cce08315d0a765f6036e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "should be designed to ensure that each product (including plasma for fractionation) is manufactured in the same manner from donor selection through to distribution of the final product.\n\nQuality management involves all activities that determine the quality policy, objectives and responsibilities, and their implementation through quality planning, quality control, quality assurance and quality improvement in order to assure the quality and safety of blood and blood components.\n\nThe attainment of the quality policy and objectives is the responsibility of the senior management of the blood establishment and requires the participation and commitment of all staff throughout the entire blood establishment. Senior management should review the quality system at regular intervals to verify its effectiveness and to introduce corrective measures if they are considered necessary.\n\nWithin the organizational structure of the blood establishment there should be a quality management unit comprising one or more persons. The quality management personnel should be responsible for ensuring that there is documented evidence that the quality policies, procedures and practices are being fulfilled. Senior management, in coordination with the quality management unit, should develop and implement quality assurance policies and objectives in a manner that provides clear direction to all staff. The quality assurance policies and objectives should be designed to ensure the highest levels of safety and quality in the blood components that are produced from each collection. The policies and procedures should comply with all national and, where appropriate, international regulations and requirements.\n\nStaff should be able to understand the intent of the quality objectives and their own role in accomplishing the objectives. The performance of the quality management system should be evaluated periodically by determining whether the objectives have been or are continuously being met. If there are shortcomings in the quality system, corrections should be made and the quality management unit should be held responsible for monitoring corrective action and continued compliance.\n\nWithin any blood establishment there should be independent functions for fulfilling quality assurance and quality control responsibilities. The quality assurance function should be independent of manufacturing operations and should assure that all processes are performed and documented. The quality assurance function should be involved in all quality-related matters and in the review and approval of all quality-related documents.\n\n### 3.2 Quality assurance\n\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of the product. It is the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2787, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "87d15081-3f3a-45ff-a397-0fa275df7566": {"__data__": {"id_": "87d15081-3f3a-45ff-a397-0fa275df7566", "embedding": null, "metadata": {"page_label": "170", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "totality of arrangements that are made with the purpose of ensuring that products are of the quality required for their intended use. Quality assurance therefore incorporates GMP, and other elements, including those outside the scope of this guideline \u2014 such as product design and development (7).\n\nQuality assurance is that part of quality management that ensures that all critical processes are appropriately described in written instructions (see chapter 5), are performed in accordance with the principles of GMP and comply with the appropriate regulations. The quality assurance system should be fully documented, distributed and explained to everyone involved in the manufacturing processes.\n\nAll parts of the quality assurance system should be adequately resourced with competent personnel, suitable premises, and suitable and sufficient equipment and facilities to enable the manufacturing steps to be completed in a safe and quality-compliant manner.\n\n### 3.2.1 Good manufacturing practice in blood establishments\n\nGMP is the part of quality assurance that ensures that blood products are consistently produced and controlled to the quality standards appropriate to their intended use, as required by predefined specifications and, if applicable, by the marketing authorization. GMP is aimed primarily at diminishing the risks inherent in any blood establishment operation \u2014 such as contamination (including cross-contamination), mix-ups, disease transmission or other unexpected adverse outcomes resulting from the use of blood products. GMP is concerned with both production and quality control.\n\nThe basic requirements of GMP are the following:\n\n- All manufacturing processes are clearly defined by policies and standard operating procedures, are systematically reviewed in the light of experience, and are shown to be capable of consistently manufacturing products of the required quality that comply with their specifications.\n- Qualification of equipment and reagents and validation of processes and methods are performed prior to use in the manufacture of products intended for transfusion or further manufacturing.\n- All necessary resources are provided \u2014 including appropriately qualified and trained personnel, adequate premises, suitable equipment, appropriate materials, approved procedures and instructions, suitable storage and transport.\n- A system is available to maintain traceability of all released products in order to facilitate recall, if necessary, of any product suspected of not conforming to standards, and there is also a system to handle complaints.\n- A system is available that addresses process and quality improvement functions and activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla la importancia de la garant\u00eda de calidad en la producci\u00f3n de productos sangu\u00edneos, enfatizando la pr\u00e1ctica de fabricaci\u00f3n adecuada (GMP) como un componente esencial del sistema de garant\u00eda de calidad. Se describen los requisitos b\u00e1sicos de GMP, que incluyen la definici\u00f3n clara de procesos, la calificaci\u00f3n de equipos, la provisi\u00f3n de recursos adecuados y la implementaci\u00f3n de sistemas para el seguimiento y mejora de la calidad. El objetivo principal de GMP es minimizar los riesgos asociados con la producci\u00f3n y el uso de productos sangu\u00edneos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los elementos clave que deben estar documentados en un sistema de garant\u00eda de calidad seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca respuestas sobre la documentaci\u00f3n y los procesos espec\u00edficos que deben estar presentes en un sistema de garant\u00eda de calidad, que no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para garantizar la trazabilidad de los productos sangu\u00edneos liberados?**\n   - Esta pregunta se centra en las pr\u00e1cticas de trazabilidad y los sistemas necesarios para gestionar la retirada de productos, lo cual es crucial para la seguridad del paciente.\n\n3. **\u00bfC\u00f3mo se aborda la capacitaci\u00f3n del personal en el contexto de las buenas pr\u00e1cticas de fabricaci\u00f3n en los establecimientos de sangre?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos de formaci\u00f3n y calificaci\u00f3n del personal involucrado en la producci\u00f3n de productos sangu\u00edneos, un aspecto que puede no estar ampliamente cubierto en otras directrices.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistema de Gesti\u00f3n de Calidad**: Se enfatiza la necesidad de un sistema de gesti\u00f3n de calidad en los establecimientos de sangre, que abarca desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final.\n\n2. **Responsabilidad de la Alta Direcci\u00f3n**: La alta direcci\u00f3n es responsable de establecer y revisar la pol\u00edtica de calidad y los objetivos, asegurando la participaci\u00f3n de todo el personal y la efectividad del sistema de calidad.\n\n3. **Unidad de Gesti\u00f3n de Calidad**: Debe existir una unidad de gesti\u00f3n de calidad compuesta por uno o m\u00e1s miembros, encargada de garantizar el cumplimiento de las pol\u00edticas y procedimientos de calidad, as\u00ed como de documentar la evidencia de su implementaci\u00f3n.\n\n4. **Pol\u00edticas y Objetivos de Aseguramiento de Calidad**: Estas deben ser desarrolladas en coordinaci\u00f3n con la alta direcci\u00f3n y deben cumplir con las regulaciones nacionales e internacionales, asegurando la m\u00e1xima calidad y seguridad de los componentes sangu\u00edneos.\n\n5. **Evaluaci\u00f3n del Sistema de Calidad**: Se debe evaluar peri\u00f3dicamente el desempe\u00f1o del sistema de gesti\u00f3n de calidad para identificar y corregir deficiencias.\n\n6. **Independencia de la Funci\u00f3n de Aseguramiento de Calidad**: La funci\u00f3n de aseguramiento de calidad debe ser independiente de las operaciones de fabricaci\u00f3n para garantizar la objetividad en la revisi\u00f3n y aprobaci\u00f3n de documentos relacionados con la calidad.\n\n7. **Compromiso del Personal**: Todo el personal debe comprender los objetivos de calidad y su papel en su cumplimiento, lo que es fundamental para el \u00e9xito del sistema de gesti\u00f3n de calidad.\n\n### Entidades Clave:\n- **Establecimientos de Sangre**: Organizaciones encargadas de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre y componentes sangu\u00edneos.\n- **Alta Direcci\u00f3n**: Equipo de liderazgo responsable de la gesti\u00f3n y supervisi\u00f3n del establecimiento de sangre.\n- **Unidad de Gesti\u00f3n de Calidad**: Grupo encargado de implementar y monitorear las pol\u00edticas de calidad.\n- **Pol\u00edticas de Calidad**: Directrices que establecen los est\u00e1ndares de calidad y seguridad para los productos sangu\u00edneos.\n- **Regulaciones Nacionales e Internacionales**: Normativas que deben cumplirse para asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: quality assurance, good manufacturing practice, blood products, traceability, quality management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2fb7de1d-6242-4a98-bf57-066880b58888", "node_type": "4", "metadata": {"page_label": "170", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "totality of arrangements that are made with the purpose of ensuring that products are of the quality required for their intended use. Quality assurance therefore incorporates GMP, and other elements, including those outside the scope of this guideline \u2014 such as product design and development (7).\n\nQuality assurance is that part of quality management that ensures that all critical processes are appropriately described in written instructions (see chapter 5), are performed in accordance with the principles of GMP and comply with the appropriate regulations. The quality assurance system should be fully documented, distributed and explained to everyone involved in the manufacturing processes.\n\nAll parts of the quality assurance system should be adequately resourced with competent personnel, suitable premises, and suitable and sufficient equipment and facilities to enable the manufacturing steps to be completed in a safe and quality-compliant manner.\n\n### 3.2.1 Good manufacturing practice in blood establishments\n\nGMP is the part of quality assurance that ensures that blood products are consistently produced and controlled to the quality standards appropriate to their intended use, as required by predefined specifications and, if applicable, by the marketing authorization. GMP is aimed primarily at diminishing the risks inherent in any blood establishment operation \u2014 such as contamination (including cross-contamination), mix-ups, disease transmission or other unexpected adverse outcomes resulting from the use of blood products. GMP is concerned with both production and quality control.\n\nThe basic requirements of GMP are the following:\n\n- All manufacturing processes are clearly defined by policies and standard operating procedures, are systematically reviewed in the light of experience, and are shown to be capable of consistently manufacturing products of the required quality that comply with their specifications.\n- Qualification of equipment and reagents and validation of processes and methods are performed prior to use in the manufacture of products intended for transfusion or further manufacturing.\n- All necessary resources are provided \u2014 including appropriately qualified and trained personnel, adequate premises, suitable equipment, appropriate materials, approved procedures and instructions, suitable storage and transport.\n- A system is available to maintain traceability of all released products in order to facilitate recall, if necessary, of any product suspected of not conforming to standards, and there is also a system to handle complaints.\n- A system is available that addresses process and quality improvement functions and activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0993517e3b75a0f98ea8ec7090fd1f42d40ee808da484a9e39e81608ecd6b982", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "totality of arrangements that are made with the purpose of ensuring that products are of the quality required for their intended use. Quality assurance therefore incorporates GMP, and other elements, including those outside the scope of this guideline \u2014 such as product design and development (7).\n\nQuality assurance is that part of quality management that ensures that all critical processes are appropriately described in written instructions (see chapter 5), are performed in accordance with the principles of GMP and comply with the appropriate regulations. The quality assurance system should be fully documented, distributed and explained to everyone involved in the manufacturing processes.\n\nAll parts of the quality assurance system should be adequately resourced with competent personnel, suitable premises, and suitable and sufficient equipment and facilities to enable the manufacturing steps to be completed in a safe and quality-compliant manner.\n\n### 3.2.1 Good manufacturing practice in blood establishments\n\nGMP is the part of quality assurance that ensures that blood products are consistently produced and controlled to the quality standards appropriate to their intended use, as required by predefined specifications and, if applicable, by the marketing authorization. GMP is aimed primarily at diminishing the risks inherent in any blood establishment operation \u2014 such as contamination (including cross-contamination), mix-ups, disease transmission or other unexpected adverse outcomes resulting from the use of blood products. GMP is concerned with both production and quality control.\n\nThe basic requirements of GMP are the following:\n\n- All manufacturing processes are clearly defined by policies and standard operating procedures, are systematically reviewed in the light of experience, and are shown to be capable of consistently manufacturing products of the required quality that comply with their specifications.\n- Qualification of equipment and reagents and validation of processes and methods are performed prior to use in the manufacture of products intended for transfusion or further manufacturing.\n- All necessary resources are provided \u2014 including appropriately qualified and trained personnel, adequate premises, suitable equipment, appropriate materials, approved procedures and instructions, suitable storage and transport.\n- A system is available to maintain traceability of all released products in order to facilitate recall, if necessary, of any product suspected of not conforming to standards, and there is also a system to handle complaints.\n- A system is available that addresses process and quality improvement functions and activities.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2683, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d6e72dbe-6273-4322-8d55-a12a4a4c58ba": {"__data__": {"id_": "d6e72dbe-6273-4322-8d55-a12a4a4c58ba", "embedding": null, "metadata": {"page_label": "171", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.2.2 Quality control\n\nQuality control is that part of GMP which is concerned with specifications, sampling and testing. Quality control is also concerned with the organization, documentation and release procedures which ensure that the necessary and relevant tests are carried out and that neither materials are released for use nor products released for supply until their quality has been judged to be satisfactory (7). For quality control programmes in blood establishments, refer to sections 9.5 and 9.6.\n\n# 3.3 Product quality review\n\nRegular periodic or rolling quality reviews should be conducted with the objective of verifying the consistency of the existing process and the appropriateness of current specifications in order to highlight trends and to identify improvements in both product and process.\n\nA product quality review may also be considered as an instrument for surveying the overall quality status of a blood component and its manufacturing processes, including the collection of starting materials. Such a review should normally be conducted annually and should be documented. In accordance with international and/or NRA requirements and recommendations it may include:\n\n- review of starting materials;\n- review of critical in-process controls;\n- review of results of quality control and quality monitoring;\n- review of all changes;\n- review of the qualification status of equipment;\n- review of technical agreements and contracts;\n- review of all significant deviations, errors and non-conformances, and the corrective actions implemented;\n- review of the findings of internal audits and other inspections, and the corrective actions implemented;\n- review of complaints and recalls;\n- review of donor acceptance criteria;\n- review of donor deferrals;\n- review of look-back cases.\n\n# 3.4 Quality risk management\n\nBlood establishments should ensure that blood components manufactured in their facilities are of the quality required for their intended use, comply with quality standard requirements, and do not place recipients at risk due to inadequate safety, quality or efficacy throughout the life-cycle of the product. In order to reliably achieve the quality objective, there should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda aspectos clave de la gesti\u00f3n de calidad en los establecimientos de sangre, centr\u00e1ndose en el control de calidad, la revisi\u00f3n de la calidad del producto y la gesti\u00f3n de riesgos de calidad. Se enfatiza la importancia de realizar revisiones peri\u00f3dicas para asegurar la consistencia de los procesos y la adecuaci\u00f3n de las especificaciones, as\u00ed como la necesidad de cumplir con los est\u00e1ndares de calidad para garantizar la seguridad y eficacia de los componentes sangu\u00edneos a lo largo de su ciclo de vida.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en una revisi\u00f3n de calidad del producto en un establecimiento de sangre?**\n   - La revisi\u00f3n de calidad del producto debe incluir la evaluaci\u00f3n de materiales de partida, controles cr\u00edticos en proceso, resultados de control de calidad, cambios significativos, estado de calificaci\u00f3n del equipo, acuerdos t\u00e9cnicos, desviaciones y no conformidades, hallazgos de auditor\u00edas internas, quejas y retiradas de productos, criterios de aceptaci\u00f3n de donantes, y casos de retroceso.\n\n2. **\u00bfCon qu\u00e9 frecuencia se deben realizar las revisiones de calidad del producto y qu\u00e9 documentaci\u00f3n se requiere?**\n   - Las revisiones de calidad del producto deben realizarse normalmente de manera anual y deben ser documentadas para cumplir con los requisitos internacionales y/o de la autoridad reguladora nacional (NRA).\n\n3. **\u00bfQu\u00e9 medidas deben tomar los establecimientos de sangre para garantizar que los componentes sangu\u00edneos no representen un riesgo para los receptores?**\n   - Los establecimientos de sangre deben asegurarse de que los componentes sangu\u00edneos fabricados cumplan con los requisitos de calidad necesarios para su uso previsto, y que no pongan en riesgo a los receptores debido a una seguridad, calidad o eficacia inadecuadas a lo largo del ciclo de vida del producto. Esto implica implementar un sistema de gesti\u00f3n de riesgos de calidad efectivo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Garant\u00eda de Calidad (Quality Assurance)**: Se refiere a los arreglos totales realizados para asegurar que los productos cumplan con los est\u00e1ndares de calidad requeridos para su uso previsto. Incluye pr\u00e1cticas de fabricaci\u00f3n adecuadas (GMP) y otros elementos como el dise\u00f1o y desarrollo de productos.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Parte fundamental de la garant\u00eda de calidad que asegura que los productos sangu\u00edneos se produzcan y controlen consistentemente seg\u00fan est\u00e1ndares de calidad. Su objetivo es minimizar riesgos como contaminaci\u00f3n, errores de mezcla y transmisi\u00f3n de enfermedades.\n\n3. **Documentaci\u00f3n y Procedimientos**: Es esencial que todos los procesos cr\u00edticos est\u00e9n claramente descritos en instrucciones escritas y que el sistema de garant\u00eda de calidad est\u00e9 completamente documentado y distribuido entre el personal involucrado.\n\n4. **Recursos Adecuados**: Se requiere personal competente, instalaciones adecuadas y equipos suficientes para completar los pasos de fabricaci\u00f3n de manera segura y conforme a la calidad.\n\n5. **Trazabilidad y Gesti\u00f3n de Quejas**: Es necesario contar con un sistema que mantenga la trazabilidad de los productos liberados para facilitar retiradas si es necesario, as\u00ed como un sistema para manejar quejas.\n\n6. **Mejora Continua**: Se debe implementar un sistema que aborde funciones y actividades de mejora de procesos y calidad.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre la garant\u00eda de calidad en la producci\u00f3n de productos sangu\u00edneos.\n- **Productos Sangu\u00edneos**: Productos que requieren est\u00e1ndares espec\u00edficos de calidad y control en su fabricaci\u00f3n.\n- **Personal Calificado**: Individuos que deben estar adecuadamente formados y capacitados para llevar a cabo procesos de fabricaci\u00f3n y control de calidad.\n- **Instalaciones y Equipos**: Infraestructura y herramientas necesarias para la producci\u00f3n segura y conforme a est\u00e1ndares de calidad.\n\nEste resumen destaca la importancia de la garant\u00eda de calidad y las buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de los establecimientos de sangre, as\u00ed como los requisitos y sistemas necesarios para asegurar la seguridad y eficacia de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: quality control, product quality review, blood establishments, quality risk management, good manufacturing practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9c4adfa4-2229-436c-913c-0cf7a3a24501", "node_type": "4", "metadata": {"page_label": "171", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.2.2 Quality control\n\nQuality control is that part of GMP which is concerned with specifications, sampling and testing. Quality control is also concerned with the organization, documentation and release procedures which ensure that the necessary and relevant tests are carried out and that neither materials are released for use nor products released for supply until their quality has been judged to be satisfactory (7). For quality control programmes in blood establishments, refer to sections 9.5 and 9.6.\n\n# 3.3 Product quality review\n\nRegular periodic or rolling quality reviews should be conducted with the objective of verifying the consistency of the existing process and the appropriateness of current specifications in order to highlight trends and to identify improvements in both product and process.\n\nA product quality review may also be considered as an instrument for surveying the overall quality status of a blood component and its manufacturing processes, including the collection of starting materials. Such a review should normally be conducted annually and should be documented. In accordance with international and/or NRA requirements and recommendations it may include:\n\n- review of starting materials;\n- review of critical in-process controls;\n- review of results of quality control and quality monitoring;\n- review of all changes;\n- review of the qualification status of equipment;\n- review of technical agreements and contracts;\n- review of all significant deviations, errors and non-conformances, and the corrective actions implemented;\n- review of the findings of internal audits and other inspections, and the corrective actions implemented;\n- review of complaints and recalls;\n- review of donor acceptance criteria;\n- review of donor deferrals;\n- review of look-back cases.\n\n# 3.4 Quality risk management\n\nBlood establishments should ensure that blood components manufactured in their facilities are of the quality required for their intended use, comply with quality standard requirements, and do not place recipients at risk due to inadequate safety, quality or efficacy throughout the life-cycle of the product. In order to reliably achieve the quality objective, there should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "743e9f55b004af9735c58b5a5e5f7f7688b07315b2ebe4247e8b4101f9c3a7e6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.2.2 Quality control\n\nQuality control is that part of GMP which is concerned with specifications, sampling and testing. Quality control is also concerned with the organization, documentation and release procedures which ensure that the necessary and relevant tests are carried out and that neither materials are released for use nor products released for supply until their quality has been judged to be satisfactory (7). For quality control programmes in blood establishments, refer to sections 9.5 and 9.6.\n\n# 3.3 Product quality review\n\nRegular periodic or rolling quality reviews should be conducted with the objective of verifying the consistency of the existing process and the appropriateness of current specifications in order to highlight trends and to identify improvements in both product and process.\n\nA product quality review may also be considered as an instrument for surveying the overall quality status of a blood component and its manufacturing processes, including the collection of starting materials. Such a review should normally be conducted annually and should be documented. In accordance with international and/or NRA requirements and recommendations it may include:\n\n- review of starting materials;\n- review of critical in-process controls;\n- review of results of quality control and quality monitoring;\n- review of all changes;\n- review of the qualification status of equipment;\n- review of technical agreements and contracts;\n- review of all significant deviations, errors and non-conformances, and the corrective actions implemented;\n- review of the findings of internal audits and other inspections, and the corrective actions implemented;\n- review of complaints and recalls;\n- review of donor acceptance criteria;\n- review of donor deferrals;\n- review of look-back cases.\n\n# 3.4 Quality risk management\n\nBlood establishments should ensure that blood components manufactured in their facilities are of the quality required for their intended use, comply with quality standard requirements, and do not place recipients at risk due to inadequate safety, quality or efficacy throughout the life-cycle of the product. In order to reliably achieve the quality objective, there should", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2212, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4d7f8905-5915-4e87-9736-9c99ae8bbef4": {"__data__": {"id_": "4d7f8905-5915-4e87-9736-9c99ae8bbef4", "embedding": null, "metadata": {"page_label": "172", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be a comprehensively designed and correctly implemented system of quality assurance that incorporates GMP, quality control and quality risk management (QRM).\n\nAn effective QRM approach can ensure the quality of a product by providing proactive means to identify and control potential quality issues. It can also facilitate and improve the decision-making process in cases when quality problems or deviations from standard processes and specifications have to be assessed or planned changes need to be evaluated.\n\nThe two primary principles of QRM are:\n\n- The evaluation of the risk to quality and safety should be based on scientific knowledge and ultimately linked to the protection of the donor and/or recipient.\n- The level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.\n\nExamples of the QRM processes and applications can be found in guidelines on QRM, such as the Q9 guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (8). This describes processes and offers a selection of methods and tools for applying the QRM principles.\n\n### 3.5 Change control\n\nA formal change control system should be in place to plan, evaluate and document all changes that may affect the quality, traceability and availability of blood or blood components or that might have an impact on the safety of blood, blood components, donors or recipients. The change control system should guarantee a formal approval of a change before it is implemented. Furthermore, it should ensure that the impact of the proposed change is assessed and that all necessary measures \u2014 such as qualification and validation, training of personnel, adoption of working instructions, revision of contracts, definition of maintenance tasks, information for third parties and authorities \u2014 are defined and completed at the time the change is put into force. The need for additional testing and validation should be determined on a scientific basis. A risk analysis may be appropriate as part of the QRM.\n\nAfter the implementation of a change, a post-implementation evaluation should be carried out in order to determine whether the introduction of the change has been successful and effective.\n\nThe introduction of new equipment, processes and methods should be treated as a change.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Sistema de Aseguramiento de Calidad**: El texto enfatiza la importancia de un sistema de aseguramiento de calidad bien dise\u00f1ado que integre Buenas Pr\u00e1cticas de Manufactura (GMP), control de calidad y gesti\u00f3n de riesgos de calidad (QRM). Se destaca que un enfoque efectivo de QRM puede identificar y controlar proactivamente problemas de calidad, mejorando as\u00ed la toma de decisiones en situaciones de desviaciones de procesos est\u00e1ndar.\n\n2. **Principios de la Gesti\u00f3n de Riesgos de Calidad (QRM)**: Se presentan dos principios fundamentales de QRM: la evaluaci\u00f3n del riesgo debe basarse en el conocimiento cient\u00edfico y estar vinculada a la protecci\u00f3n de donantes y receptores, y el nivel de formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo.\n\n3. **Control de Cambios**: Se describe la necesidad de un sistema formal de control de cambios que planifique, eval\u00fae y documente todos los cambios que puedan afectar la calidad y seguridad de la sangre y sus componentes. Este sistema debe garantizar la aprobaci\u00f3n formal de los cambios antes de su implementaci\u00f3n y realizar una evaluaci\u00f3n posterior para verificar la efectividad de los cambios introducidos.\n\n### Preguntas espec\u00edficas que el contexto puede responder\n\n1. **\u00bfCu\u00e1les son los pasos necesarios para implementar un sistema de control de cambios en la gesti\u00f3n de calidad de sangre y componentes sangu\u00edneos?**\n   - El contexto detalla que un sistema de control de cambios debe incluir la planificaci\u00f3n, evaluaci\u00f3n y documentaci\u00f3n de cambios, asegurando la aprobaci\u00f3n formal antes de la implementaci\u00f3n y la evaluaci\u00f3n posterior para verificar la efectividad del cambio.\n\n2. **\u00bfC\u00f3mo se determina el nivel de esfuerzo y documentaci\u00f3n necesarios en el proceso de gesti\u00f3n de riesgos de calidad (QRM)?**\n   - Seg\u00fan el texto, el nivel de esfuerzo, formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo asociado, lo que implica que se debe realizar una evaluaci\u00f3n del riesgo basada en el conocimiento cient\u00edfico.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse antes de implementar un cambio en los procesos relacionados con la sangre y sus componentes?**\n   - El contexto menciona que antes de implementar un cambio, se deben definir y completar medidas como la calificaci\u00f3n y validaci\u00f3n, capacitaci\u00f3n del personal, adopci\u00f3n de instrucciones de trabajo, revisi\u00f3n de contratos y definici\u00f3n de tareas de mantenimiento, adem\u00e1s de realizar un an\u00e1lisis de riesgo como parte del QRM.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de Calidad**: Parte de las Buenas Pr\u00e1cticas de Manufactura (GMP) que se ocupa de especificaciones, muestreo y pruebas. Asegura que los materiales y productos no se liberen hasta que su calidad sea considerada satisfactoria.\n\n2. **Revisi\u00f3n de Calidad del Producto**: Se deben realizar revisiones peri\u00f3dicas (normalmente anuales) para verificar la consistencia de los procesos y la adecuaci\u00f3n de las especificaciones. Estas revisiones deben documentarse y pueden incluir la evaluaci\u00f3n de materiales de partida, controles en proceso, resultados de calidad, cambios significativos, y m\u00e1s.\n\n3. **Gesti\u00f3n de Riesgos de Calidad**: Los establecimientos de sangre deben garantizar que los componentes sangu\u00edneos cumplan con los est\u00e1ndares de calidad y no representen un riesgo para los receptores a lo largo de su ciclo de vida. Esto implica implementar un sistema efectivo de gesti\u00f3n de riesgos.\n\n### Entidades:\n\n- **Establecimientos de Sangre**: Organizaciones que fabrican componentes sangu\u00edneos.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre que se utilizan para transfusiones y otros tratamientos m\u00e9dicos.\n- **Autoridad Reguladora Nacional (NRA)**: Entidad que establece y supervisa los est\u00e1ndares de calidad y seguridad en la fabricaci\u00f3n de productos de salud.\n- **Documentaci\u00f3n**: Registros necesarios para cumplir con los requisitos de calidad y auditor\u00eda.\n\n### Resumen:\nLa secci\u00f3n aborda la importancia del control de calidad, la revisi\u00f3n peri\u00f3dica de la calidad del producto y la gesti\u00f3n de riesgos en los establecimientos de sangre. Se enfatiza la necesidad de realizar revisiones anuales documentadas para asegurar la calidad y seguridad de los componentes sangu\u00edneos, cumpliendo con los est\u00e1ndares internacionales y regulaciones nacionales.", "excerpt_keywords": "Keywords: quality assurance, quality risk management, change control, blood components, GMP"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cd32915-ddf5-48bc-95d3-5c5d5c7acd92", "node_type": "4", "metadata": {"page_label": "172", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be a comprehensively designed and correctly implemented system of quality assurance that incorporates GMP, quality control and quality risk management (QRM).\n\nAn effective QRM approach can ensure the quality of a product by providing proactive means to identify and control potential quality issues. It can also facilitate and improve the decision-making process in cases when quality problems or deviations from standard processes and specifications have to be assessed or planned changes need to be evaluated.\n\nThe two primary principles of QRM are:\n\n- The evaluation of the risk to quality and safety should be based on scientific knowledge and ultimately linked to the protection of the donor and/or recipient.\n- The level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.\n\nExamples of the QRM processes and applications can be found in guidelines on QRM, such as the Q9 guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (8). This describes processes and offers a selection of methods and tools for applying the QRM principles.\n\n### 3.5 Change control\n\nA formal change control system should be in place to plan, evaluate and document all changes that may affect the quality, traceability and availability of blood or blood components or that might have an impact on the safety of blood, blood components, donors or recipients. The change control system should guarantee a formal approval of a change before it is implemented. Furthermore, it should ensure that the impact of the proposed change is assessed and that all necessary measures \u2014 such as qualification and validation, training of personnel, adoption of working instructions, revision of contracts, definition of maintenance tasks, information for third parties and authorities \u2014 are defined and completed at the time the change is put into force. The need for additional testing and validation should be determined on a scientific basis. A risk analysis may be appropriate as part of the QRM.\n\nAfter the implementation of a change, a post-implementation evaluation should be carried out in order to determine whether the introduction of the change has been successful and effective.\n\nThe introduction of new equipment, processes and methods should be treated as a change.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "91f3ac073d26aa8e46ac4c15d441bf653ca14c61fd26d2bc1b36746cf5a0da35", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "be a comprehensively designed and correctly implemented system of quality assurance that incorporates GMP, quality control and quality risk management (QRM).\n\nAn effective QRM approach can ensure the quality of a product by providing proactive means to identify and control potential quality issues. It can also facilitate and improve the decision-making process in cases when quality problems or deviations from standard processes and specifications have to be assessed or planned changes need to be evaluated.\n\nThe two primary principles of QRM are:\n\n- The evaluation of the risk to quality and safety should be based on scientific knowledge and ultimately linked to the protection of the donor and/or recipient.\n- The level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.\n\nExamples of the QRM processes and applications can be found in guidelines on QRM, such as the Q9 guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (8). This describes processes and offers a selection of methods and tools for applying the QRM principles.\n\n### 3.5 Change control\n\nA formal change control system should be in place to plan, evaluate and document all changes that may affect the quality, traceability and availability of blood or blood components or that might have an impact on the safety of blood, blood components, donors or recipients. The change control system should guarantee a formal approval of a change before it is implemented. Furthermore, it should ensure that the impact of the proposed change is assessed and that all necessary measures \u2014 such as qualification and validation, training of personnel, adoption of working instructions, revision of contracts, definition of maintenance tasks, information for third parties and authorities \u2014 are defined and completed at the time the change is put into force. The need for additional testing and validation should be determined on a scientific basis. A risk analysis may be appropriate as part of the QRM.\n\nAfter the implementation of a change, a post-implementation evaluation should be carried out in order to determine whether the introduction of the change has been successful and effective.\n\nThe introduction of new equipment, processes and methods should be treated as a change.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2382, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7303c467-b822-496f-b8aa-1185312b39da": {"__data__": {"id_": "7303c467-b822-496f-b8aa-1185312b39da", "embedding": null, "metadata": {"page_label": "173", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 Deviation evaluation and reporting\n\nAny deviation from standard operating procedures, validated processes, or non-conformances with specifications or other quality-related requirements should be recorded and investigated. The potential impact on the quality of the product in question, or on other products, should be evaluated.\n\nThe evaluation of the cause of the deviation and of related processes that may also be implicated in the deviation should be documented. Review and approval of the investigation as completed should be documented by the quality assurance and/or quality control department as appropriate.\n\nAll deviations and non-conformances should be logged in a system that allows for appropriate data review. A data review should be carried out periodically in a manner that allows for tracking and trending of data and that facilitates process improvement.\n\nThe handling of deviations and non-conformances should be defined in writing. Actions should be taken within a reasonable time frame in order to avoid any impact on other products manufactured within the same establishment.\n\nUnder certain circumstances a product may be accepted after evaluation of a deviation. The documentation should include the justification or rationale for accepting a product manufactured in deviation from a specified requirement, and should be signed by the responsible person.\n\n# 3.7 Corrective and preventive actions\n\nA corrective and preventive action system should be established, implemented and maintained to ensure that there is continuous improvement at the blood establishment. The procedures should include the management of deviations and non-conformances, complaints, events and findings of the quality system management review, inspections and audits, and should ensure the proper recording of all corrective and preventive actions taken.\n\nThe corrective and preventive action system should ensure that each quality problem is addressed and corrected and that recurrence of the problem is prevented. Actions should be carried out within a reasonable predefined time frame. The management of the blood establishment should be involved in the review of corrective and preventive actions.\n\nThe blood establishment should have methods and procedures in place to collect, document and evaluate data on quality. Product or quality problems should be entered into the corrective and preventive action system. Quality data include all errors, deviations, non-conformances, accidents, near-miss events and complaints. Quality data also include the results of quality control tests.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la evaluaci\u00f3n y el reporte de desviaciones en procedimientos operativos est\u00e1ndar y la gesti\u00f3n de acciones correctivas y preventivas en establecimientos de sangre. Se enfatiza la importancia de registrar y evaluar cualquier desviaci\u00f3n o no conformidad, as\u00ed como la necesidad de un sistema que permita la revisi\u00f3n de datos para facilitar la mejora continua. Adem\u00e1s, se establece que las acciones correctivas deben ser documentadas y revisadas por la direcci\u00f3n del establecimiento, asegurando que se tomen dentro de un marco de tiempo razonable.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para aceptar un producto que ha sido fabricado en desviaci\u00f3n de un requisito especificado?**\n   - Esta pregunta busca detalles sobre los criterios espec\u00edficos que justifican la aceptaci\u00f3n de un producto a pesar de las desviaciones, que no se encuentran expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de datos deben ser ingresados en el sistema de acciones correctivas y preventivas, y c\u00f3mo se deben clasificar?**\n   - Esta pregunta se centra en la clasificaci\u00f3n y el tipo de datos que deben ser documentados en el sistema, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfCu\u00e1l es el papel espec\u00edfico del departamento de aseguramiento de calidad en la revisi\u00f3n y aprobaci\u00f3n de las investigaciones de desviaciones?**\n   - Esta pregunta busca aclarar las responsabilidades y el proceso que sigue el departamento de calidad en la gesti\u00f3n de desviaciones, un aspecto que puede no estar detallado en otros documentos.\n\n### Resumen adicional\n\nEl documento tambi\u00e9n menciona que la gesti\u00f3n de desviaciones y no conformidades debe estar claramente definida por escrito, y que se deben tomar acciones en un tiempo razonable para evitar impactos en otros productos. Adem\u00e1s, se destaca la importancia de involucrar a la direcci\u00f3n del establecimiento en la revisi\u00f3n de acciones correctivas y preventivas, lo que sugiere un enfoque colaborativo en la mejora de la calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Aseguramiento de Calidad**:\n   - Importancia de un sistema integral que incluya Buenas Pr\u00e1cticas de Manufactura (GMP), control de calidad y gesti\u00f3n de riesgos de calidad (QRM).\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**:\n   - **Principios Fundamentales**:\n     - Evaluaci\u00f3n del riesgo basada en conocimiento cient\u00edfico, vinculada a la protecci\u00f3n de donantes y receptores.\n     - Proporcionalidad entre el nivel de esfuerzo/documentaci\u00f3n y el nivel de riesgo.\n   - Referencia a la gu\u00eda Q9 de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) como fuente de procesos y herramientas para aplicar QRM.\n\n3. **Control de Cambios**:\n   - Necesidad de un sistema formal para planificar, evaluar y documentar cambios que afecten la calidad y seguridad de la sangre y sus componentes.\n   - Requisitos para la aprobaci\u00f3n formal de cambios antes de su implementaci\u00f3n.\n   - Evaluaci\u00f3n del impacto del cambio y definici\u00f3n de medidas necesarias (calificaci\u00f3n, validaci\u00f3n, capacitaci\u00f3n, etc.) antes de la implementaci\u00f3n.\n   - Importancia de realizar una evaluaci\u00f3n post-implementaci\u00f3n para verificar la efectividad del cambio.\n\n### Entidades Clave\n- **GMP**: Buenas Pr\u00e1cticas de Manufactura.\n- **QRM**: Gesti\u00f3n de Riesgos de Calidad.\n- **ICH**: Conferencia Internacional sobre Armonizaci\u00f3n de Requisitos T\u00e9cnicos para el Registro de Productos Farmac\u00e9uticos para Uso Humano.\n- **Sistema de Control de Cambios**: Proceso formal para gestionar cambios en la calidad de sangre y componentes sangu\u00edneos. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y basado en riesgos para garantizar la calidad y seguridad en la gesti\u00f3n de sangre y sus componentes.", "excerpt_keywords": "Keywords: deviations, quality assurance, corrective actions, blood establishment, non-conformances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6be07ce3-4a5f-49c6-bf1d-49da587b6c1a", "node_type": "4", "metadata": {"page_label": "173", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 Deviation evaluation and reporting\n\nAny deviation from standard operating procedures, validated processes, or non-conformances with specifications or other quality-related requirements should be recorded and investigated. The potential impact on the quality of the product in question, or on other products, should be evaluated.\n\nThe evaluation of the cause of the deviation and of related processes that may also be implicated in the deviation should be documented. Review and approval of the investigation as completed should be documented by the quality assurance and/or quality control department as appropriate.\n\nAll deviations and non-conformances should be logged in a system that allows for appropriate data review. A data review should be carried out periodically in a manner that allows for tracking and trending of data and that facilitates process improvement.\n\nThe handling of deviations and non-conformances should be defined in writing. Actions should be taken within a reasonable time frame in order to avoid any impact on other products manufactured within the same establishment.\n\nUnder certain circumstances a product may be accepted after evaluation of a deviation. The documentation should include the justification or rationale for accepting a product manufactured in deviation from a specified requirement, and should be signed by the responsible person.\n\n# 3.7 Corrective and preventive actions\n\nA corrective and preventive action system should be established, implemented and maintained to ensure that there is continuous improvement at the blood establishment. The procedures should include the management of deviations and non-conformances, complaints, events and findings of the quality system management review, inspections and audits, and should ensure the proper recording of all corrective and preventive actions taken.\n\nThe corrective and preventive action system should ensure that each quality problem is addressed and corrected and that recurrence of the problem is prevented. Actions should be carried out within a reasonable predefined time frame. The management of the blood establishment should be involved in the review of corrective and preventive actions.\n\nThe blood establishment should have methods and procedures in place to collect, document and evaluate data on quality. Product or quality problems should be entered into the corrective and preventive action system. Quality data include all errors, deviations, non-conformances, accidents, near-miss events and complaints. Quality data also include the results of quality control tests.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f065280788643ba9af802a69dd7f2356773b330ff7e5dd6e77280e9900ffeb80", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.6 Deviation evaluation and reporting\n\nAny deviation from standard operating procedures, validated processes, or non-conformances with specifications or other quality-related requirements should be recorded and investigated. The potential impact on the quality of the product in question, or on other products, should be evaluated.\n\nThe evaluation of the cause of the deviation and of related processes that may also be implicated in the deviation should be documented. Review and approval of the investigation as completed should be documented by the quality assurance and/or quality control department as appropriate.\n\nAll deviations and non-conformances should be logged in a system that allows for appropriate data review. A data review should be carried out periodically in a manner that allows for tracking and trending of data and that facilitates process improvement.\n\nThe handling of deviations and non-conformances should be defined in writing. Actions should be taken within a reasonable time frame in order to avoid any impact on other products manufactured within the same establishment.\n\nUnder certain circumstances a product may be accepted after evaluation of a deviation. The documentation should include the justification or rationale for accepting a product manufactured in deviation from a specified requirement, and should be signed by the responsible person.\n\n# 3.7 Corrective and preventive actions\n\nA corrective and preventive action system should be established, implemented and maintained to ensure that there is continuous improvement at the blood establishment. The procedures should include the management of deviations and non-conformances, complaints, events and findings of the quality system management review, inspections and audits, and should ensure the proper recording of all corrective and preventive actions taken.\n\nThe corrective and preventive action system should ensure that each quality problem is addressed and corrected and that recurrence of the problem is prevented. Actions should be carried out within a reasonable predefined time frame. The management of the blood establishment should be involved in the review of corrective and preventive actions.\n\nThe blood establishment should have methods and procedures in place to collect, document and evaluate data on quality. Product or quality problems should be entered into the corrective and preventive action system. Quality data include all errors, deviations, non-conformances, accidents, near-miss events and complaints. Quality data also include the results of quality control tests.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2591, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "35577413-a7da-4ece-b177-f597aec8c67d": {"__data__": {"id_": "35577413-a7da-4ece-b177-f597aec8c67d", "embedding": null, "metadata": {"page_label": "174", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Internal audits\n\nIn order to monitor implementation and compliance with the quality management system, regular internal audits should be performed according to an established procedure. Internal audits should be conducted by trained, independent and competent persons under the responsibility of the organization\u2019s quality assurance unit.\n\nInternal audits should be arranged according to a schedule and should cover all parts of the operations, including data processing systems. Each audit should be carried out according to an approved audit plan that assesses compliance with internal requirements and applicable national and/or international regulations.\n\nAll audit results should be documented and reported to the management. Appropriate corrective and preventive actions should be taken in a timely and effective manner and should be assessed for effectiveness after implementation.\n\nThe quality assurance department, where the internal audit function resides, should not audit itself but should be subject to an independent audit.\n\nInternal audits are not a substitute for official inspections performed by the competent national authorities who check compliance with national regulations.\n\n# Complaints and product recall\n\n## Complaints\n\nThere should be a system in place to ensure that all complaints are handled according to written \u2014 and approved \u2014 standard operating procedures. The review of the complaint should take account of whether the complaint relates to a quality defect in a blood component. The blood establishment should determine whether a recall should be initiated. The process should be defined in a standard operating procedure. Complaints, adverse events or reactions, as well as any information concerning potentially defective products, should be carefully reviewed and thoroughly investigated in order to find the root cause of the problem. Consideration should be given to determining whether other products are also affected. All investigations and actions should be carried out in a timely manner to ensure that the safety of the recipient is not compromised and that other products manufactured within the same establishment are not affected.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de realizar auditor\u00edas internas y gestionar quejas y retiradas de productos en el contexto de un sistema de gesti\u00f3n de calidad. Se establece que las auditor\u00edas internas deben ser realizadas por personas capacitadas e independientes, y deben seguir un plan de auditor\u00eda aprobado. Los resultados de las auditor\u00edas deben ser documentados y comunicados a la direcci\u00f3n, y se deben tomar acciones correctivas y preventivas de manera oportuna. Adem\u00e1s, se menciona que debe existir un sistema para manejar quejas, especialmente aquellas relacionadas con defectos de calidad en componentes sangu\u00edneos, y que las investigaciones deben llevarse a cabo de manera r\u00e1pida para garantizar la seguridad del receptor.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben considerarse al revisar una queja relacionada con un componente sangu\u00edneo?**\n   - La revisi\u00f3n de la queja debe tener en cuenta si est\u00e1 relacionada con un defecto de calidad en el componente sangu\u00edneo y determinar si es necesario iniciar un retiro del producto.\n\n2. **\u00bfCu\u00e1l es el papel de la unidad de aseguramiento de calidad en el proceso de auditor\u00eda interna?**\n   - La unidad de aseguramiento de calidad es responsable de llevar a cabo las auditor\u00edas internas, pero no debe auditarse a s\u00ed misma; debe estar sujeta a una auditor\u00eda independiente.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse despu\u00e9s de que se documentan los resultados de una auditor\u00eda interna?**\n   - Despu\u00e9s de documentar los resultados, se deben tomar acciones correctivas y preventivas de manera oportuna y efectiva, y estas acciones deben ser evaluadas para determinar su efectividad tras su implementaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n y Reporte de Desviaciones**:\n   - Importancia de registrar y investigar desviaciones de procedimientos operativos est\u00e1ndar y no conformidades.\n   - Evaluaci\u00f3n del impacto potencial en la calidad del producto afectado y otros productos.\n   - Documentaci\u00f3n de la causa de la desviaci\u00f3n y procesos relacionados.\n   - Necesidad de un sistema para registrar desviaciones y no conformidades, permitiendo la revisi\u00f3n de datos y mejora continua.\n   - Definici\u00f3n escrita del manejo de desviaciones y no conformidades, con acciones a tomar en un tiempo razonable.\n   - Posibilidad de aceptar productos fabricados en desviaci\u00f3n, con justificaci\u00f3n documentada y firma del responsable.\n\n2. **Acciones Correctivas y Preventivas**:\n   - Establecimiento y mantenimiento de un sistema de acciones correctivas y preventivas para la mejora continua en establecimientos de sangre.\n   - Inclusi\u00f3n de la gesti\u00f3n de desviaciones, quejas, eventos y hallazgos en el sistema de calidad.\n   - Documentaci\u00f3n y revisi\u00f3n de todas las acciones correctivas y preventivas.\n   - Involucramiento de la direcci\u00f3n en la revisi\u00f3n de acciones correctivas y preventivas.\n   - M\u00e9todos para recopilar, documentar y evaluar datos de calidad, incluyendo errores, desviaciones, no conformidades y resultados de pruebas de control de calidad.\n\n### Entidades\n\n- **Establecimientos de Sangre**: Organizaciones responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre.\n- **Departamento de Aseguramiento de Calidad**: Entidad encargada de revisar y aprobar investigaciones de desviaciones.\n- **Sistema de Acciones Correctivas y Preventivas**: Herramienta para gestionar problemas de calidad y asegurar la mejora continua.\n- **Documentaci\u00f3n**: Registros que justifican la aceptaci\u00f3n de productos en desviaci\u00f3n y acciones tomadas.\n\nEste resumen destaca la importancia de la gesti\u00f3n de desviaciones y acciones correctivas en el contexto de la calidad en los establecimientos de sangre, enfatizando la necesidad de documentaci\u00f3n y revisi\u00f3n sistem\u00e1tica para garantizar la mejora continua.", "excerpt_keywords": "Keywords: internal audits, quality management, complaints handling, blood components, corrective actions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f90085d3-510a-414c-9298-e6ed720bdb91", "node_type": "4", "metadata": {"page_label": "174", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Internal audits\n\nIn order to monitor implementation and compliance with the quality management system, regular internal audits should be performed according to an established procedure. Internal audits should be conducted by trained, independent and competent persons under the responsibility of the organization\u2019s quality assurance unit.\n\nInternal audits should be arranged according to a schedule and should cover all parts of the operations, including data processing systems. Each audit should be carried out according to an approved audit plan that assesses compliance with internal requirements and applicable national and/or international regulations.\n\nAll audit results should be documented and reported to the management. Appropriate corrective and preventive actions should be taken in a timely and effective manner and should be assessed for effectiveness after implementation.\n\nThe quality assurance department, where the internal audit function resides, should not audit itself but should be subject to an independent audit.\n\nInternal audits are not a substitute for official inspections performed by the competent national authorities who check compliance with national regulations.\n\n# Complaints and product recall\n\n## Complaints\n\nThere should be a system in place to ensure that all complaints are handled according to written \u2014 and approved \u2014 standard operating procedures. The review of the complaint should take account of whether the complaint relates to a quality defect in a blood component. The blood establishment should determine whether a recall should be initiated. The process should be defined in a standard operating procedure. Complaints, adverse events or reactions, as well as any information concerning potentially defective products, should be carefully reviewed and thoroughly investigated in order to find the root cause of the problem. Consideration should be given to determining whether other products are also affected. All investigations and actions should be carried out in a timely manner to ensure that the safety of the recipient is not compromised and that other products manufactured within the same establishment are not affected.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7d418100df63d263ce57386e8cc81e6c203c3562315c5889a7197f7a31d4ffa2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Internal audits\n\nIn order to monitor implementation and compliance with the quality management system, regular internal audits should be performed according to an established procedure. Internal audits should be conducted by trained, independent and competent persons under the responsibility of the organization\u2019s quality assurance unit.\n\nInternal audits should be arranged according to a schedule and should cover all parts of the operations, including data processing systems. Each audit should be carried out according to an approved audit plan that assesses compliance with internal requirements and applicable national and/or international regulations.\n\nAll audit results should be documented and reported to the management. Appropriate corrective and preventive actions should be taken in a timely and effective manner and should be assessed for effectiveness after implementation.\n\nThe quality assurance department, where the internal audit function resides, should not audit itself but should be subject to an independent audit.\n\nInternal audits are not a substitute for official inspections performed by the competent national authorities who check compliance with national regulations.\n\n# Complaints and product recall\n\n## Complaints\n\nThere should be a system in place to ensure that all complaints are handled according to written \u2014 and approved \u2014 standard operating procedures. The review of the complaint should take account of whether the complaint relates to a quality defect in a blood component. The blood establishment should determine whether a recall should be initiated. The process should be defined in a standard operating procedure. Complaints, adverse events or reactions, as well as any information concerning potentially defective products, should be carefully reviewed and thoroughly investigated in order to find the root cause of the problem. Consideration should be given to determining whether other products are also affected. All investigations and actions should be carried out in a timely manner to ensure that the safety of the recipient is not compromised and that other products manufactured within the same establishment are not affected.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2181, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "02486149-6e2f-4aa5-9cf9-1684e888f0d3": {"__data__": {"id_": "02486149-6e2f-4aa5-9cf9-1684e888f0d3", "embedding": null, "metadata": {"page_label": "175", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Immediate corrective actions should be taken to address the root cause of the problem, and actions should be taken to prevent it from recurring. There should be active follow-up of the implementation of corrective actions (see section 3.7).\n\nDesignated personnel should be responsible for managing complaints and coordinating investigations, actions and measures to be taken within a defined time frame. The unit responsible for quality should be included in this process.\n\nAll complaints, with the original details, should be recorded. Records should be retained of all the decisions, investigations and measures taken as a result of a complaint. Complaint records should be reviewed regularly in order to check for unfavourable trends or recurring problems and to ensure continuous quality improvement.\n\nDepending on the national requirements the NRA should be informed.\n\n### 3.9.2 Recalls\n\nAn effective written recall procedure should be in place, including a description of the responsibilities and actions to be taken. A recall should always be initiated whenever it is discovered that a product does not meet the release criteria of the blood establishment and NRA. This may happen when information is obtained subsequent to the release of a product and, had this information been known in advance, it would have prevented the blood component from being released. A recall may also be indicated when it is discovered that personnel did not follow standard operating procedures. Corrective actions should take place within predefined time periods and should include the traceability of all relevant components and, where applicable, look-back procedures (see section 3.11).\n\nA qualified person within the blood establishment should be nominated to assess the need for product recall and to initiate, coordinate and document the necessary actions.\n\nRecall operations should be initiated promptly and at any time. Therefore the standard operating procedures should include emergency and \u201cout of hours\u201d contact details. Depending on the national requirements the NRA should be informed.\n\nRecalled products should be destroyed. If recalled products are not destroyed, they should be clearly identified and stored separately in a secure area.\n\n### 3.10 Process improvement\n\nIdeas for potential improvements to any of the systems may come from research, development, brainstorming, or from the management of non-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de quejas y la implementaci\u00f3n de acciones correctivas en el contexto de los establecimientos de sangre. Se enfatiza la importancia de registrar todas las quejas, realizar un seguimiento de las acciones correctivas y mantener un procedimiento de retiro efectivo para productos que no cumplen con los criterios de liberaci\u00f3n. Tambi\u00e9n se menciona la necesidad de mejorar continuamente los procesos a trav\u00e9s de la recopilaci\u00f3n de ideas y la gesti\u00f3n de no conformidades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para gestionar adecuadamente una queja en un establecimiento de sangre?**\n   - El contexto detalla que se deben tomar acciones correctivas inmediatas, designar personal responsable, registrar todas las quejas y revisar regularmente los registros para identificar tendencias desfavorables.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se debe iniciar un procedimiento de retiro de productos en un establecimiento de sangre?**\n   - Un retiro debe iniciarse si se descubre que un producto no cumple con los criterios de liberaci\u00f3n, ya sea por nueva informaci\u00f3n obtenida despu\u00e9s de la liberaci\u00f3n o por incumplimiento de los procedimientos operativos est\u00e1ndar.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse con respecto a los productos que han sido retirados del mercado?**\n   - Los productos retirados deben ser destruidos o, si no se destruyen, deben ser claramente identificados y almacenados en un \u00e1rea segura, adem\u00e1s de que se debe informar a la autoridad nacional reguladora seg\u00fan los requisitos nacionales.", "prev_section_summary": "### Temas Clave\n\n1. **Auditor\u00edas Internas**:\n   - Importancia de realizar auditor\u00edas internas regulares para monitorear la implementaci\u00f3n y cumplimiento del sistema de gesti\u00f3n de calidad.\n   - Deben ser realizadas por personas capacitadas, independientes y competentes, bajo la responsabilidad de la unidad de aseguramiento de calidad.\n   - Las auditor\u00edas deben seguir un plan aprobado y cubrir todas las operaciones, incluyendo sistemas de procesamiento de datos.\n   - Los resultados de las auditor\u00edas deben ser documentados y reportados a la direcci\u00f3n, con acciones correctivas y preventivas implementadas de manera oportuna.\n   - La unidad de aseguramiento de calidad no debe auditarse a s\u00ed misma, sino que debe estar sujeta a auditor\u00edas independientes.\n   - Las auditor\u00edas internas no sustituyen las inspecciones oficiales de las autoridades nacionales competentes.\n\n2. **Gesti\u00f3n de Quejas y Retiradas de Productos**:\n   - Debe existir un sistema para manejar quejas, siguiendo procedimientos operativos est\u00e1ndar aprobados.\n   - La revisi\u00f3n de quejas debe considerar si est\u00e1n relacionadas con defectos de calidad en componentes sangu\u00edneos y determinar si es necesario iniciar un retiro del producto.\n   - Las quejas, eventos adversos y reacciones deben ser investigados a fondo para identificar la causa ra\u00edz del problema.\n   - Es importante evaluar si otros productos tambi\u00e9n pueden estar afectados y llevar a cabo investigaciones de manera oportuna para garantizar la seguridad del receptor.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Establecimiento de sangre (Blood establishment).\n- **Unidad de Aseguramiento de Calidad**: Responsable de las auditor\u00edas internas.\n- **Autoridades Nacionales Competentes**: Encargadas de realizar inspecciones oficiales.\n- **Productos**: Componentes sangu\u00edneos y otros productos fabricados en el establecimiento. \n\nEste resumen destaca la importancia de las auditor\u00edas internas y la gesti\u00f3n de quejas en el contexto de un sistema de gesti\u00f3n de calidad, enfatizando la necesidad de procedimientos claros y la responsabilidad de las entidades involucradas.", "excerpt_keywords": "Keywords: quejas, retiradas, acciones correctivas, mejora continua, establecimiento de sangre"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2a9afb3-0e0a-46ec-8bf7-821cfbe7c1a8", "node_type": "4", "metadata": {"page_label": "175", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Immediate corrective actions should be taken to address the root cause of the problem, and actions should be taken to prevent it from recurring. There should be active follow-up of the implementation of corrective actions (see section 3.7).\n\nDesignated personnel should be responsible for managing complaints and coordinating investigations, actions and measures to be taken within a defined time frame. The unit responsible for quality should be included in this process.\n\nAll complaints, with the original details, should be recorded. Records should be retained of all the decisions, investigations and measures taken as a result of a complaint. Complaint records should be reviewed regularly in order to check for unfavourable trends or recurring problems and to ensure continuous quality improvement.\n\nDepending on the national requirements the NRA should be informed.\n\n### 3.9.2 Recalls\n\nAn effective written recall procedure should be in place, including a description of the responsibilities and actions to be taken. A recall should always be initiated whenever it is discovered that a product does not meet the release criteria of the blood establishment and NRA. This may happen when information is obtained subsequent to the release of a product and, had this information been known in advance, it would have prevented the blood component from being released. A recall may also be indicated when it is discovered that personnel did not follow standard operating procedures. Corrective actions should take place within predefined time periods and should include the traceability of all relevant components and, where applicable, look-back procedures (see section 3.11).\n\nA qualified person within the blood establishment should be nominated to assess the need for product recall and to initiate, coordinate and document the necessary actions.\n\nRecall operations should be initiated promptly and at any time. Therefore the standard operating procedures should include emergency and \u201cout of hours\u201d contact details. Depending on the national requirements the NRA should be informed.\n\nRecalled products should be destroyed. If recalled products are not destroyed, they should be clearly identified and stored separately in a secure area.\n\n### 3.10 Process improvement\n\nIdeas for potential improvements to any of the systems may come from research, development, brainstorming, or from the management of non-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e0ba99300ecf5ba043e546cdd4823d3c2ed50757e9f9dd38020cb3b6b9367cd3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Immediate corrective actions should be taken to address the root cause of the problem, and actions should be taken to prevent it from recurring. There should be active follow-up of the implementation of corrective actions (see section 3.7).\n\nDesignated personnel should be responsible for managing complaints and coordinating investigations, actions and measures to be taken within a defined time frame. The unit responsible for quality should be included in this process.\n\nAll complaints, with the original details, should be recorded. Records should be retained of all the decisions, investigations and measures taken as a result of a complaint. Complaint records should be reviewed regularly in order to check for unfavourable trends or recurring problems and to ensure continuous quality improvement.\n\nDepending on the national requirements the NRA should be informed.\n\n### 3.9.2 Recalls\n\nAn effective written recall procedure should be in place, including a description of the responsibilities and actions to be taken. A recall should always be initiated whenever it is discovered that a product does not meet the release criteria of the blood establishment and NRA. This may happen when information is obtained subsequent to the release of a product and, had this information been known in advance, it would have prevented the blood component from being released. A recall may also be indicated when it is discovered that personnel did not follow standard operating procedures. Corrective actions should take place within predefined time periods and should include the traceability of all relevant components and, where applicable, look-back procedures (see section 3.11).\n\nA qualified person within the blood establishment should be nominated to assess the need for product recall and to initiate, coordinate and document the necessary actions.\n\nRecall operations should be initiated promptly and at any time. Therefore the standard operating procedures should include emergency and \u201cout of hours\u201d contact details. Depending on the national requirements the NRA should be informed.\n\nRecalled products should be destroyed. If recalled products are not destroyed, they should be clearly identified and stored separately in a secure area.\n\n### 3.10 Process improvement\n\nIdeas for potential improvements to any of the systems may come from research, development, brainstorming, or from the management of non-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2411, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "419afb36-9875-4d41-a40b-27c62ae952ae": {"__data__": {"id_": "419afb36-9875-4d41-a40b-27c62ae952ae", "embedding": null, "metadata": {"page_label": "176", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.11 Look-back\n\nA written system should be in place for carrying out a look-back procedure. This process should be able to trace the products collected from a donor to the final recipients and from the recipient back to the donor, preferably by means of a computer database.\n\nThis standard operating procedure should be followed when it is determined retrospectively that a blood or plasma donation should have been excluded from processing \u2014 for instance, because the unit was collected from a donor who was subsequently rejected for reactive viral marker, high-risk behaviour, exposure to CJD/vCJD or other risks related to infectious diseases (*donor look-back*) (3).\n\nIf a donor is confirmed to have a disease that is transmissible by blood products or has high-risk behaviour, the donor should be permanently excluded from further donation. All donations from such a donor should be traced and prevented from being used or further manufactured unless they have expired and therefore have already been destroyed. If donations have been used or further processed, procedures should be in place to define appropriate actions. Donor notification and counselling is recommended for purposes of donor health and for the safety of the blood supply.\n\nThere should be a process in place for investigating a report of a suspected transfusion-associated reaction in a recipient, in order to identify a potentially implicated donor (*recipient look-back*). The donor of products implicated in transmitting disease or causing recipient harm should be excluded from further donations. All other donations from the implicated donor should be traced and blood components removed from the inventory and recalled, if within the expiry date.\n\nAll post-donation information should be recorded and maintained. There should be a system in place to react accordingly and in time to remove unexpired products from distribution in order to assure the safety of recipients.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece la importancia de implementar un sistema de \"look-back\" para rastrear donaciones de sangre y plasma desde el donante hasta el receptor y viceversa. Este procedimiento es crucial para garantizar la seguridad de la transfusi\u00f3n, especialmente en casos donde se determina que una donaci\u00f3n deber\u00eda haber sido excluida debido a riesgos de enfermedades transmisibles. Se enfatiza la necesidad de excluir permanentemente a donantes con comportamientos de alto riesgo o enfermedades transmisibles, as\u00ed como la importancia de investigar reacciones adversas en receptores para identificar donantes potencialmente implicados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se determina que una donaci\u00f3n de sangre deber\u00eda haber sido excluida debido a un marcador viral reactivo?**\n   - El procedimiento implica rastrear todas las donaciones del donante, excluirlo de futuras donaciones y notificarlo, adem\u00e1s de tomar medidas para asegurar que las donaciones no sean utilizadas.\n\n2. **\u00bfQu\u00e9 acciones se deben tomar si se reporta una reacci\u00f3n transfusional en un receptor?**\n   - Se debe investigar el caso para identificar al donante potencialmente implicado, excluirlo de futuras donaciones y rastrear todas las donaciones realizadas por ese donante, retirando los componentes sangu\u00edneos del inventario si est\u00e1n dentro de la fecha de caducidad.\n\n3. **\u00bfCu\u00e1l es la importancia de mantener un registro de la informaci\u00f3n posterior a la donaci\u00f3n?**\n   - Mantener un registro es crucial para poder reaccionar de manera oportuna y retirar productos no caducados de la distribuci\u00f3n, asegurando as\u00ed la seguridad de los receptores de transfusiones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Acciones Correctivas Inmediatas**: Se deben tomar medidas inmediatas para abordar la causa ra\u00edz de los problemas identificados y prevenir su recurrencia. Es esencial realizar un seguimiento activo de la implementaci\u00f3n de estas acciones.\n\n2. **Gesti\u00f3n de Quejas**: Se designar\u00e1 personal responsable para gestionar las quejas y coordinar investigaciones y acciones dentro de un marco de tiempo definido. Todas las quejas deben ser registradas y los registros revisados regularmente para identificar tendencias desfavorables y asegurar la mejora continua de la calidad.\n\n3. **Procedimiento de Retiro**: Debe existir un procedimiento de retiro escrito y efectivo que describa las responsabilidades y acciones a seguir. Un retiro debe iniciarse si un producto no cumple con los criterios de liberaci\u00f3n, ya sea por nueva informaci\u00f3n o por incumplimiento de procedimientos operativos est\u00e1ndar.\n\n4. **Responsabilidad de Retiro**: Se debe nombrar a una persona calificada dentro del establecimiento de sangre para evaluar la necesidad de un retiro de producto y coordinar las acciones necesarias.\n\n5. **Destrucci\u00f3n de Productos Retirados**: Los productos retirados deben ser destruidos o, si no se destruyen, deben ser claramente identificados y almacenados en un \u00e1rea segura.\n\n6. **Mejora de Procesos**: Se fomenta la recopilaci\u00f3n de ideas para mejorar los sistemas a trav\u00e9s de la investigaci\u00f3n, el desarrollo y la gesti\u00f3n de no conformidades.\n\n### Entidades Clave\n\n- **Establecimientos de Sangre**: Organizaciones responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de productos sangu\u00edneos.\n- **Autoridad Nacional Reguladora (NRA)**: Entidad que debe ser informada seg\u00fan los requisitos nacionales sobre quejas y retiros de productos.\n- **Personal Designado**: Individuos responsables de la gesti\u00f3n de quejas y la implementaci\u00f3n de acciones correctivas.\n- **Productos Sangu\u00edneos**: Componentes que pueden ser objeto de quejas o retiros si no cumplen con los est\u00e1ndares establecidos. \n\nEste resumen destaca la importancia de la gesti\u00f3n de quejas y la implementaci\u00f3n de procedimientos de retiro para garantizar la calidad y seguridad en los establecimientos de sangre.", "excerpt_keywords": "Keywords: look-back procedure, blood donation, infectious diseases, donor exclusion, transfusion safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8811a34-1223-436e-b383-97a8e5afb083", "node_type": "4", "metadata": {"page_label": "176", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.11 Look-back\n\nA written system should be in place for carrying out a look-back procedure. This process should be able to trace the products collected from a donor to the final recipients and from the recipient back to the donor, preferably by means of a computer database.\n\nThis standard operating procedure should be followed when it is determined retrospectively that a blood or plasma donation should have been excluded from processing \u2014 for instance, because the unit was collected from a donor who was subsequently rejected for reactive viral marker, high-risk behaviour, exposure to CJD/vCJD or other risks related to infectious diseases (*donor look-back*) (3).\n\nIf a donor is confirmed to have a disease that is transmissible by blood products or has high-risk behaviour, the donor should be permanently excluded from further donation. All donations from such a donor should be traced and prevented from being used or further manufactured unless they have expired and therefore have already been destroyed. If donations have been used or further processed, procedures should be in place to define appropriate actions. Donor notification and counselling is recommended for purposes of donor health and for the safety of the blood supply.\n\nThere should be a process in place for investigating a report of a suspected transfusion-associated reaction in a recipient, in order to identify a potentially implicated donor (*recipient look-back*). The donor of products implicated in transmitting disease or causing recipient harm should be excluded from further donations. All other donations from the implicated donor should be traced and blood components removed from the inventory and recalled, if within the expiry date.\n\nAll post-donation information should be recorded and maintained. There should be a system in place to react accordingly and in time to remove unexpired products from distribution in order to assure the safety of recipients.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c0794fa42a26a2b0ad372b2f03429dae198a482a15a6713d79e690a48d4c1139", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.11 Look-back\n\nA written system should be in place for carrying out a look-back procedure. This process should be able to trace the products collected from a donor to the final recipients and from the recipient back to the donor, preferably by means of a computer database.\n\nThis standard operating procedure should be followed when it is determined retrospectively that a blood or plasma donation should have been excluded from processing \u2014 for instance, because the unit was collected from a donor who was subsequently rejected for reactive viral marker, high-risk behaviour, exposure to CJD/vCJD or other risks related to infectious diseases (*donor look-back*) (3).\n\nIf a donor is confirmed to have a disease that is transmissible by blood products or has high-risk behaviour, the donor should be permanently excluded from further donation. All donations from such a donor should be traced and prevented from being used or further manufactured unless they have expired and therefore have already been destroyed. If donations have been used or further processed, procedures should be in place to define appropriate actions. Donor notification and counselling is recommended for purposes of donor health and for the safety of the blood supply.\n\nThere should be a process in place for investigating a report of a suspected transfusion-associated reaction in a recipient, in order to identify a potentially implicated donor (*recipient look-back*). The donor of products implicated in transmitting disease or causing recipient harm should be excluded from further donations. All other donations from the implicated donor should be traced and blood components removed from the inventory and recalled, if within the expiry date.\n\nAll post-donation information should be recorded and maintained. There should be a system in place to react accordingly and in time to remove unexpired products from distribution in order to assure the safety of recipients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1954, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "69777f40-adaa-4a72-a751-1f1d2f3c633e": {"__data__": {"id_": "69777f40-adaa-4a72-a751-1f1d2f3c633e", "embedding": null, "metadata": {"page_label": "177", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The recipients of any products identified in the look-back process should be counselled about the risk of having contracted a disease from the potentially contaminated products and should be offered disease marker testing, consultation and medical treatment if indicated. For plasma used for fractionation, the manufacturer of the medicinal product should be notified in case of a look-back (3).\n\n## 4. Personnel\n\nSufficient personnel should be available and should be qualified to perform their tasks. They should have the appropriate qualifications and experience and should be given initial and continuous training in order to assure the quality and safety of blood and blood components.\n\nOnly persons who are competent in the manufacturing process and have read and understood all relevant standard operating procedures should be involved in the manufacturing and distribution processes, including collection, quality control and quality assurance.\n\n### 4.1 Organization and responsibilities\n\nTasks and responsibilities should be clearly documented and understood. Personnel should have clear, current and written job descriptions. There should be an organizational chart showing the hierarchical structure of the blood establishment with clear delineation of lines of responsibility and reporting.\n\nKey personnel include the following functions and their substitutes:\n\n- a \u201cresponsible person\u201d (see functions and qualifications below);\n- a processing or operations manager, responsible for all processing and operations activities;\n- a quality control manager, responsible for all quality control activities;\n- a quality assurance manager, reporting findings or quality issues directly to the responsible person and empowered to discontinue operations if quality and safety expectations are not being fulfilled;\n- a physician with the responsibility to ensure the safety of donors and the safety of the distributed blood components.\n\nThe blood establishment should nominate a \u201cresponsible person\u201d who will be responsible for:\n\n- ensuring that approved donor selection criteria are followed;\n- ensuring that every unit of blood or blood components has been collected, tested, processed, stored and distributed in compliance with the national regulations in force;\n- providing information to the competent national authority;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de productos sangu\u00edneos, enfatizando la importancia de la capacitaci\u00f3n y la organizaci\u00f3n del personal en los establecimientos de sangre. Se destaca la necesidad de un \"responsable\" que garantice el cumplimiento de los criterios de selecci\u00f3n de donantes y la conformidad con las regulaciones nacionales. Adem\u00e1s, se menciona la importancia de informar a los receptores de productos potencialmente contaminados sobre los riesgos asociados y ofrecerles pruebas de marcadores de enfermedades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del \"responsable\" en un establecimiento de sangre seg\u00fan el documento?**\n   - Respuesta: El \"responsable\" debe asegurarse de que se sigan los criterios de selecci\u00f3n de donantes aprobados, que cada unidad de sangre o componentes sangu\u00edneos se recojan, prueben, procesen, almacenen y distribuyan de acuerdo con las regulaciones nacionales vigentes, y proporcionar informaci\u00f3n a la autoridad nacional competente.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n se requiere para el personal involucrado en la fabricaci\u00f3n y distribuci\u00f3n de productos sangu\u00edneos?**\n   - Respuesta: El personal debe recibir formaci\u00f3n inicial y continua para asegurar la calidad y seguridad de la sangre y los componentes sangu\u00edneos. Solo deben participar en los procesos aquellos que sean competentes y que hayan le\u00eddo y comprendido todos los procedimientos operativos est\u00e1ndar relevantes.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en caso de un \"look-back\" relacionado con productos sangu\u00edneos?**\n   - Respuesta: Los receptores de productos identificados en el proceso de \"look-back\" deben ser asesorados sobre el riesgo de haber contra\u00eddo una enfermedad a partir de productos potencialmente contaminados y se les debe ofrecer pruebas de marcadores de enfermedades, consulta y tratamiento m\u00e9dico si es necesario. Adem\u00e1s, el fabricante del producto medicinal debe ser notificado en caso de un \"look-back\" relacionado con plasma utilizado para fraccionamiento.", "prev_section_summary": "### Temas Clave:\n1. **Sistema de Look-back**: Importancia de implementar un procedimiento escrito para rastrear donaciones de sangre y plasma desde el donante hasta el receptor y viceversa.\n2. **Exclusi\u00f3n de Donantes**: Protocolo para excluir permanentemente a donantes que presenten enfermedades transmisibles o comportamientos de alto riesgo.\n3. **Investigaci\u00f3n de Reacciones Transfusionales**: Proceso para investigar reacciones adversas en receptores y rastrear donantes potencialmente implicados.\n4. **Registro de Informaci\u00f3n Post-Donaci\u00f3n**: Necesidad de mantener un registro detallado de la informaci\u00f3n posterior a la donaci\u00f3n para asegurar la seguridad de los receptores.\n\n### Entidades:\n- **Donante**: Persona que proporciona sangre o plasma.\n- **Receptor**: Persona que recibe transfusiones de sangre o componentes sangu\u00edneos.\n- **Enfermedades Transmisibles**: Enfermedades que pueden ser transmitidas a trav\u00e9s de productos sangu\u00edneos.\n- **Comportamientos de Alto Riesgo**: Conductas que aumentan el riesgo de transmisi\u00f3n de enfermedades a trav\u00e9s de donaciones.\n- **CJD/vCJD**: Enfermedades relacionadas con la transmisi\u00f3n de priones que pueden ser un riesgo en donaciones de sangre.\n- **Base de Datos**: Herramienta recomendada para el seguimiento y rastreo de donaciones.\n\n### Resumen:\nEl documento de la OMS enfatiza la necesidad de un sistema de \"look-back\" para rastrear donaciones de sangre y plasma, asegurando la seguridad de las transfusiones. Se establece que los donantes con enfermedades transmisibles o comportamientos de alto riesgo deben ser excluidos permanentemente, y se deben tomar medidas para rastrear y retirar sus donaciones. Adem\u00e1s, se destaca la importancia de investigar reacciones adversas en receptores para identificar donantes implicados y mantener un registro de la informaci\u00f3n post-donaci\u00f3n para garantizar la seguridad de los receptores.", "excerpt_keywords": "Keywords: blood safety, look-back process, personnel qualifications, donor selection, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "656f6374-5534-4ee9-8da9-328cddd6b575", "node_type": "4", "metadata": {"page_label": "177", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The recipients of any products identified in the look-back process should be counselled about the risk of having contracted a disease from the potentially contaminated products and should be offered disease marker testing, consultation and medical treatment if indicated. For plasma used for fractionation, the manufacturer of the medicinal product should be notified in case of a look-back (3).\n\n## 4. Personnel\n\nSufficient personnel should be available and should be qualified to perform their tasks. They should have the appropriate qualifications and experience and should be given initial and continuous training in order to assure the quality and safety of blood and blood components.\n\nOnly persons who are competent in the manufacturing process and have read and understood all relevant standard operating procedures should be involved in the manufacturing and distribution processes, including collection, quality control and quality assurance.\n\n### 4.1 Organization and responsibilities\n\nTasks and responsibilities should be clearly documented and understood. Personnel should have clear, current and written job descriptions. There should be an organizational chart showing the hierarchical structure of the blood establishment with clear delineation of lines of responsibility and reporting.\n\nKey personnel include the following functions and their substitutes:\n\n- a \u201cresponsible person\u201d (see functions and qualifications below);\n- a processing or operations manager, responsible for all processing and operations activities;\n- a quality control manager, responsible for all quality control activities;\n- a quality assurance manager, reporting findings or quality issues directly to the responsible person and empowered to discontinue operations if quality and safety expectations are not being fulfilled;\n- a physician with the responsibility to ensure the safety of donors and the safety of the distributed blood components.\n\nThe blood establishment should nominate a \u201cresponsible person\u201d who will be responsible for:\n\n- ensuring that approved donor selection criteria are followed;\n- ensuring that every unit of blood or blood components has been collected, tested, processed, stored and distributed in compliance with the national regulations in force;\n- providing information to the competent national authority;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2878b10382792ebab9581df70701c5aa8d10f5cefc314ee421778c934aa57f56", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The recipients of any products identified in the look-back process should be counselled about the risk of having contracted a disease from the potentially contaminated products and should be offered disease marker testing, consultation and medical treatment if indicated. For plasma used for fractionation, the manufacturer of the medicinal product should be notified in case of a look-back (3).\n\n## 4. Personnel\n\nSufficient personnel should be available and should be qualified to perform their tasks. They should have the appropriate qualifications and experience and should be given initial and continuous training in order to assure the quality and safety of blood and blood components.\n\nOnly persons who are competent in the manufacturing process and have read and understood all relevant standard operating procedures should be involved in the manufacturing and distribution processes, including collection, quality control and quality assurance.\n\n### 4.1 Organization and responsibilities\n\nTasks and responsibilities should be clearly documented and understood. Personnel should have clear, current and written job descriptions. There should be an organizational chart showing the hierarchical structure of the blood establishment with clear delineation of lines of responsibility and reporting.\n\nKey personnel include the following functions and their substitutes:\n\n- a \u201cresponsible person\u201d (see functions and qualifications below);\n- a processing or operations manager, responsible for all processing and operations activities;\n- a quality control manager, responsible for all quality control activities;\n- a quality assurance manager, reporting findings or quality issues directly to the responsible person and empowered to discontinue operations if quality and safety expectations are not being fulfilled;\n- a physician with the responsibility to ensure the safety of donors and the safety of the distributed blood components.\n\nThe blood establishment should nominate a \u201cresponsible person\u201d who will be responsible for:\n\n- ensuring that approved donor selection criteria are followed;\n- ensuring that every unit of blood or blood components has been collected, tested, processed, stored and distributed in compliance with the national regulations in force;\n- providing information to the competent national authority;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2328, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cf33c91c-93b4-4f85-aa36-9e3482c93466": {"__data__": {"id_": "cf33c91c-93b4-4f85-aa36-9e3482c93466", "embedding": null, "metadata": {"page_label": "178", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 ensuring that the required initial and ongoing training of personnel is carried out;  \n\u2014 ensuring that a quality management system and a haemovigilance system (ensuring traceability as well as notification of serious adverse events and reactions) is in place in the blood establishment.\n\nThe responsible person should fulfil the qualification requirements according to the national regulations, or should fulfil the following minimum conditions of qualification:\n\n- He/she should hold a diploma, certificate or other evidence of formal qualification in the field of medical or biological sciences awarded on completion of a university course of study or a course recognized as equivalent.\n- He/she should have practical experience in relevant areas, preferably for at least two years, in one or more establishments which are authorized to undertake activities related to collection, testing, preparation, storage and distribution of blood and blood components.\n\nDepending on the national legislation, the name of the responsible person may need to be communicated to the NRA.\n\nThe quality assurance manager and the processing or operations manager should be different persons, functioning independently. The quality assurance manager is responsible for ensuring that there are appropriate quality systems and protocols in place for the safe and secure release of all materials, equipment, reagents and blood and blood components.\n\nThe processing or operations manager is responsible for ensuring that there are appropriate manufacturing and technical processes and procedures in place for the production of blood or blood components.\n\nThe physician should hold a relevant medical degree awarded on completion of a university course of study and should hold any registration or licensure that is required by the national authority.\n\nResponsibilities should be delegated only to individuals who have been trained for the task. Delegation should be in written form and should be reviewed regularly.\n\n## 4.2 Training\n\nPersonnel should receive initial and continuous training that is appropriate to their specific tasks. This training should be carried out by qualified personnel or trainers and should follow prearranged written programmes. Approved training programmes should be in place and should also include:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece requisitos y responsabilidades para el personal en establecimientos de sangre, enfatizando la importancia de la formaci\u00f3n inicial y continua, as\u00ed como la implementaci\u00f3n de sistemas de gesti\u00f3n de calidad y hemovigilancia. Se detallan las calificaciones necesarias para el responsable del establecimiento, el gerente de calidad y el gerente de operaciones, as\u00ed como la necesidad de que las responsabilidades se deleguen solo a personal capacitado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las calificaciones m\u00ednimas requeridas para la persona responsable en un establecimiento de sangre seg\u00fan el documento?**\n   - La persona responsable debe tener un diploma o certificado en ciencias m\u00e9dicas o biol\u00f3gicas y al menos dos a\u00f1os de experiencia pr\u00e1ctica en establecimientos autorizados para actividades relacionadas con la sangre.\n\n2. **\u00bfQu\u00e9 diferencias existen entre las responsabilidades del gerente de calidad y el gerente de operaciones en un establecimiento de sangre?**\n   - El gerente de calidad se encarga de asegurar que existan sistemas y protocolos de calidad adecuados para la liberaci\u00f3n segura de materiales y componentes sangu\u00edneos, mientras que el gerente de operaciones es responsable de los procesos t\u00e9cnicos y de fabricaci\u00f3n para la producci\u00f3n de sangre o componentes sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la formaci\u00f3n del personal en los establecimientos de sangre?**\n   - El personal debe recibir formaci\u00f3n inicial y continua adecuada a sus tareas espec\u00edficas, impartida por personal calificado, siguiendo programas escritos preestablecidos que deben estar aprobados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Productos Sangu\u00edneos**:\n   - Importancia de la capacitaci\u00f3n y organizaci\u00f3n del personal en los establecimientos de sangre.\n   - Necesidad de un \"responsable\" que garantice el cumplimiento de criterios de selecci\u00f3n de donantes y regulaciones nacionales.\n\n2. **Responsabilidades del Personal**:\n   - El personal debe estar calificado y recibir formaci\u00f3n inicial y continua.\n   - Solo personal competente y que haya comprendido los procedimientos operativos est\u00e1ndar debe participar en la fabricaci\u00f3n y distribuci\u00f3n.\n\n3. **Organizaci\u00f3n y Estructura**:\n   - Documentaci\u00f3n clara de tareas y responsabilidades.\n   - Descripciones de trabajo escritas y un organigrama que muestre la estructura jer\u00e1rquica del establecimiento de sangre.\n\n4. **Funciones Clave**:\n   - \"Responsable\" del establecimiento.\n   - Gerente de procesamiento u operaciones.\n   - Gerente de control de calidad.\n   - Gerente de aseguramiento de calidad.\n   - M\u00e9dico responsable de la seguridad de donantes y componentes sangu\u00edneos.\n\n5. **Proceso de \"Look-Back\"**:\n   - Asesoramiento a receptores sobre riesgos de enfermedades por productos potencialmente contaminados.\n   - Ofrecimiento de pruebas de marcadores de enfermedades y tratamiento m\u00e9dico si es necesario.\n   - Notificaci\u00f3n al fabricante del producto medicinal en caso de \"look-back\" relacionado con plasma utilizado para fraccionamiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre.\n- **Personal Clave**: Incluye al \"responsable\", gerentes de operaciones, control de calidad, aseguramiento de calidad y m\u00e9dicos.", "excerpt_keywords": "Keywords: formaci\u00f3n, gesti\u00f3n de calidad, hemovigilancia, establecimiento de sangre, calificaciones del personal"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e5c7cb16-708c-44f1-8d1a-8d1a66077c24", "node_type": "4", "metadata": {"page_label": "178", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 ensuring that the required initial and ongoing training of personnel is carried out;  \n\u2014 ensuring that a quality management system and a haemovigilance system (ensuring traceability as well as notification of serious adverse events and reactions) is in place in the blood establishment.\n\nThe responsible person should fulfil the qualification requirements according to the national regulations, or should fulfil the following minimum conditions of qualification:\n\n- He/she should hold a diploma, certificate or other evidence of formal qualification in the field of medical or biological sciences awarded on completion of a university course of study or a course recognized as equivalent.\n- He/she should have practical experience in relevant areas, preferably for at least two years, in one or more establishments which are authorized to undertake activities related to collection, testing, preparation, storage and distribution of blood and blood components.\n\nDepending on the national legislation, the name of the responsible person may need to be communicated to the NRA.\n\nThe quality assurance manager and the processing or operations manager should be different persons, functioning independently. The quality assurance manager is responsible for ensuring that there are appropriate quality systems and protocols in place for the safe and secure release of all materials, equipment, reagents and blood and blood components.\n\nThe processing or operations manager is responsible for ensuring that there are appropriate manufacturing and technical processes and procedures in place for the production of blood or blood components.\n\nThe physician should hold a relevant medical degree awarded on completion of a university course of study and should hold any registration or licensure that is required by the national authority.\n\nResponsibilities should be delegated only to individuals who have been trained for the task. Delegation should be in written form and should be reviewed regularly.\n\n## 4.2 Training\n\nPersonnel should receive initial and continuous training that is appropriate to their specific tasks. This training should be carried out by qualified personnel or trainers and should follow prearranged written programmes. Approved training programmes should be in place and should also include:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "aa4bd1eb843d5750d447ec202c400a1bbd7b5ca08a91fe6daac57f703a62b123", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 ensuring that the required initial and ongoing training of personnel is carried out;  \n\u2014 ensuring that a quality management system and a haemovigilance system (ensuring traceability as well as notification of serious adverse events and reactions) is in place in the blood establishment.\n\nThe responsible person should fulfil the qualification requirements according to the national regulations, or should fulfil the following minimum conditions of qualification:\n\n- He/she should hold a diploma, certificate or other evidence of formal qualification in the field of medical or biological sciences awarded on completion of a university course of study or a course recognized as equivalent.\n- He/she should have practical experience in relevant areas, preferably for at least two years, in one or more establishments which are authorized to undertake activities related to collection, testing, preparation, storage and distribution of blood and blood components.\n\nDepending on the national legislation, the name of the responsible person may need to be communicated to the NRA.\n\nThe quality assurance manager and the processing or operations manager should be different persons, functioning independently. The quality assurance manager is responsible for ensuring that there are appropriate quality systems and protocols in place for the safe and secure release of all materials, equipment, reagents and blood and blood components.\n\nThe processing or operations manager is responsible for ensuring that there are appropriate manufacturing and technical processes and procedures in place for the production of blood or blood components.\n\nThe physician should hold a relevant medical degree awarded on completion of a university course of study and should hold any registration or licensure that is required by the national authority.\n\nResponsibilities should be delegated only to individuals who have been trained for the task. Delegation should be in written form and should be reviewed regularly.\n\n## 4.2 Training\n\nPersonnel should receive initial and continuous training that is appropriate to their specific tasks. This training should be carried out by qualified personnel or trainers and should follow prearranged written programmes. Approved training programmes should be in place and should also include:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2311, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a26a1888-c7e3-42d2-aa26-cc4ddc89315b": {"__data__": {"id_": "a26a1888-c7e3-42d2-aa26-cc4ddc89315b", "embedding": null, "metadata": {"page_label": "179", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 relevant principles of transfusion medicine;\n# \u2014 GMP;\n# \u2014 relevant knowledge in microbiology and hygiene.\n\nTraining should be documented and training records should be retained.\n\n## 4.2.1 Initial training\n\nProgrammes for the initial training of newly recruited personnel or personnel taking over new functions should take into account all relevant tasks and procedures, including general topics such as quality assurance, GMP and computerized systems. The same topics and principles apply to training aimed to reintroduce personnel after a longer absence from the workplace. The time frames should be defined.\n\nThe training records should identify at least the trainer, all the specified tasks (including the relevant standard operating procedures) and when the training was completed. The records should be signed by both the trainee and the trainer. Upon completing the training, the personnel should be competent in the tasks in which they have been trained. If a database is used the personnel training profile should be updated annually.\n\n## 4.2.2 Continuous training\n\nContinuous training programmes (theoretical and/or practical training) should be in place to ensure that personnel keep up the skills to carry out their assigned tasks. Such training programmes should take technical and scientific developments into account. Training should also include any changes to standard operating procedures and personnel requirements. Both internal and external training courses may be useful here.\n\n## 4.2.3 Competency\n\nThe overall competency of personnel is a result of education, experience and training. As a key factor for the quality and safety of blood and blood products, competency has to be carefully evaluated and continuously monitored.\n\nUpon completion of the initial training, the competency of the personnel should be evaluated and documented. After the initial competency is determined, there should be periodic assessment of competency. The contents of training programmes and their effectiveness should be periodically reviewed and assessed.\n\n## 4.3 Personal hygiene\n\nAll personnel, prior to being hired and during employment, as appropriate, should undergo health examinations. Any person shown at any time to", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda principios relevantes de la medicina transfusional, buenas pr\u00e1cticas de manufactura (GMP) y conocimientos en microbiolog\u00eda e higiene. Se enfatiza la importancia de la formaci\u00f3n del personal en estos temas, tanto en la capacitaci\u00f3n inicial como en la continua. Se requiere que los registros de formaci\u00f3n sean documentados y que se mantenga un seguimiento de la competencia del personal. Adem\u00e1s, se menciona la necesidad de ex\u00e1menes de salud para el personal antes de ser contratado y durante su empleo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en los registros de formaci\u00f3n del personal seg\u00fan el documento?**\n   - Los registros de formaci\u00f3n deben identificar al menos al formador, todas las tareas especificadas (incluyendo los procedimientos operativos est\u00e1ndar relevantes) y la fecha en que se complet\u00f3 la formaci\u00f3n. Adem\u00e1s, deben ser firmados por el trainee y el trainer.\n\n2. **\u00bfC\u00f3mo se eval\u00faa la competencia del personal despu\u00e9s de la formaci\u00f3n inicial?**\n   - La competencia del personal debe ser evaluada y documentada tras la finalizaci\u00f3n de la formaci\u00f3n inicial. Despu\u00e9s de determinar la competencia inicial, se deben realizar evaluaciones peri\u00f3dicas de la competencia.\n\n3. **\u00bfQu\u00e9 tipo de formaci\u00f3n continua se recomienda para el personal en el contexto de la medicina transfusional?**\n   - Se recomienda que existan programas de formaci\u00f3n continua (te\u00f3ricos y/o pr\u00e1cticos) que aseguren que el personal mantenga las habilidades necesarias para llevar a cabo sus tareas asignadas, teniendo en cuenta los desarrollos t\u00e9cnicos y cient\u00edficos, as\u00ed como cualquier cambio en los procedimientos operativos est\u00e1ndar y los requisitos del personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda varios aspectos fundamentales relacionados con la gesti\u00f3n y operaci\u00f3n de los establecimientos de sangre, destacando la importancia de la formaci\u00f3n del personal y la implementaci\u00f3n de sistemas de calidad. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n\n1. **Formaci\u00f3n del Personal**:\n   - Se requiere formaci\u00f3n inicial y continua para el personal, adecuada a sus tareas espec\u00edficas.\n   - La formaci\u00f3n debe ser impartida por personal calificado y seguir programas escritos aprobados.\n\n2. **Calificaciones del Personal Responsable**:\n   - La persona responsable debe tener un diploma en ciencias m\u00e9dicas o biol\u00f3gicas y al menos dos a\u00f1os de experiencia pr\u00e1ctica en establecimientos autorizados.\n\n3. **Roles y Responsabilidades**:\n   - **Gerente de Calidad**: Asegura la existencia de sistemas y protocolos de calidad para la liberaci\u00f3n segura de materiales y componentes sangu\u00edneos.\n   - **Gerente de Operaciones**: Responsable de los procesos t\u00e9cnicos y de fabricaci\u00f3n para la producci\u00f3n de sangre o componentes sangu\u00edneos.\n   - **M\u00e9dico**: Debe tener un t\u00edtulo m\u00e9dico relevante y cumplir con los requisitos de registro o licencia establecidos por la autoridad nacional.\n\n4. **Delegaci\u00f3n de Responsabilidades**:\n   - Las responsabilidades deben delegarse solo a personal capacitado, y la delegaci\u00f3n debe ser documentada y revisada regularmente.\n\n5. **Sistemas de Gesti\u00f3n de Calidad y Hemovigilancia**:\n   - Es esencial contar con un sistema de gesti\u00f3n de calidad y un sistema de hemovigilancia para garantizar la trazabilidad y la notificaci\u00f3n de eventos adversos graves.\n\n#### Entidades Mencionadas:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **NRA (Autoridad Reguladora Nacional)**: Puede requerir la comunicaci\u00f3n del nombre de la persona responsable seg\u00fan la legislaci\u00f3n nacional.\n\nEste resumen destaca la importancia de la formaci\u00f3n, las calificaciones necesarias y la clara divisi\u00f3n de responsabilidades en los establecimientos de sangre, asegurando as\u00ed la calidad y seguridad en la gesti\u00f3n de la sangre y sus componentes.", "excerpt_keywords": "Keywords: transfusion medicine, training, competency, quality assurance, personal hygiene"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b094b263-565b-4f08-8136-97227814a88e", "node_type": "4", "metadata": {"page_label": "179", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 relevant principles of transfusion medicine;\n# \u2014 GMP;\n# \u2014 relevant knowledge in microbiology and hygiene.\n\nTraining should be documented and training records should be retained.\n\n## 4.2.1 Initial training\n\nProgrammes for the initial training of newly recruited personnel or personnel taking over new functions should take into account all relevant tasks and procedures, including general topics such as quality assurance, GMP and computerized systems. The same topics and principles apply to training aimed to reintroduce personnel after a longer absence from the workplace. The time frames should be defined.\n\nThe training records should identify at least the trainer, all the specified tasks (including the relevant standard operating procedures) and when the training was completed. The records should be signed by both the trainee and the trainer. Upon completing the training, the personnel should be competent in the tasks in which they have been trained. If a database is used the personnel training profile should be updated annually.\n\n## 4.2.2 Continuous training\n\nContinuous training programmes (theoretical and/or practical training) should be in place to ensure that personnel keep up the skills to carry out their assigned tasks. Such training programmes should take technical and scientific developments into account. Training should also include any changes to standard operating procedures and personnel requirements. Both internal and external training courses may be useful here.\n\n## 4.2.3 Competency\n\nThe overall competency of personnel is a result of education, experience and training. As a key factor for the quality and safety of blood and blood products, competency has to be carefully evaluated and continuously monitored.\n\nUpon completion of the initial training, the competency of the personnel should be evaluated and documented. After the initial competency is determined, there should be periodic assessment of competency. The contents of training programmes and their effectiveness should be periodically reviewed and assessed.\n\n## 4.3 Personal hygiene\n\nAll personnel, prior to being hired and during employment, as appropriate, should undergo health examinations. Any person shown at any time to", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c927914478abe782d8560aa391cd1f20cf8b3701af8a431eaa4a9f0583cf2d1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# \u2014 relevant principles of transfusion medicine;\n# \u2014 GMP;\n# \u2014 relevant knowledge in microbiology and hygiene.\n\nTraining should be documented and training records should be retained.\n\n## 4.2.1 Initial training\n\nProgrammes for the initial training of newly recruited personnel or personnel taking over new functions should take into account all relevant tasks and procedures, including general topics such as quality assurance, GMP and computerized systems. The same topics and principles apply to training aimed to reintroduce personnel after a longer absence from the workplace. The time frames should be defined.\n\nThe training records should identify at least the trainer, all the specified tasks (including the relevant standard operating procedures) and when the training was completed. The records should be signed by both the trainee and the trainer. Upon completing the training, the personnel should be competent in the tasks in which they have been trained. If a database is used the personnel training profile should be updated annually.\n\n## 4.2.2 Continuous training\n\nContinuous training programmes (theoretical and/or practical training) should be in place to ensure that personnel keep up the skills to carry out their assigned tasks. Such training programmes should take technical and scientific developments into account. Training should also include any changes to standard operating procedures and personnel requirements. Both internal and external training courses may be useful here.\n\n## 4.2.3 Competency\n\nThe overall competency of personnel is a result of education, experience and training. As a key factor for the quality and safety of blood and blood products, competency has to be carefully evaluated and continuously monitored.\n\nUpon completion of the initial training, the competency of the personnel should be evaluated and documented. After the initial competency is determined, there should be periodic assessment of competency. The contents of training programmes and their effectiveness should be periodically reviewed and assessed.\n\n## 4.3 Personal hygiene\n\nAll personnel, prior to being hired and during employment, as appropriate, should undergo health examinations. Any person shown at any time to", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2231, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dc98f17c-9017-4569-84f5-3a09f7c59549": {"__data__": {"id_": "dc98f17c-9017-4569-84f5-3a09f7c59549", "embedding": null, "metadata": {"page_label": "180", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have an illness or open lesions that may adversely affect the quality of the products and/or the safety of the donors should be excluded from the establishment\u2019s manufacturing processes until that person\u2019s condition is no longer judged to be a risk.\n\nAll personnel should be trained in personal hygiene. In particular, personnel should be instructed to wash and disinfect their hands before, during and after activities such as blood collection and production.\n\nSpecial attention should be drawn to the need to protect donors, employees and products from contamination \u2014 especially with blood and any other material of human origin.\n\nTo ensure protection of products, donors and employees from contamination, personnel should wear clean protective clothing appropriate for the duties they perform. Soiled protective clothing, if reusable, should be stored in a separate closed container until properly laundered and, if necessary, disinfected or sterilized. Where appropriate, disposable or sterile gloves should be worn when handling items that may come in contact with any blood or blood components.\n\nSmoking, eating, drinking, chewing, and keeping plants, food, drinks, smoking material and personal medicines should not be permitted in areas used for production, testing, storage or distribution, or in other areas where they might adversely affect product quality. Personal hygiene procedures, including the use of appropriate protective clothing and equipment, should apply to all persons entering production areas.\n\n# 5. Documentation\n\nThe documentation of procedures and records is essential to the quality assurance system. It ensures that work is performed in a standardized and uniform manner and ensures the traceability of all steps. Written instructions should include all applicable methods and procedures and should be accessible to all authorized personnel.\n\n## 5.1 Standard operating procedures and records\n\n### 5.1.1 Standard operating procedures\n\nAll critical procedures \u2014 such as purchase and receipt of starting materials, selection of donors, collection of blood, preparation of blood components, laboratory testing and associated quality control testing, product labelling, storage, release, dispatch, shipping, and recall of final products \u2014 should be specified in appropriate written instructions in accordance with the principles of GMP and relevant national regulations. Quality assurance", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las pr\u00e1cticas de higiene y documentaci\u00f3n necesarias en los procesos de manufactura relacionados con la recolecci\u00f3n y producci\u00f3n de sangre y componentes sangu\u00edneos. Se enfatiza la importancia de la higiene personal del personal, el uso de ropa protectora adecuada, y la prohibici\u00f3n de actividades que puedan contaminar el entorno de producci\u00f3n. Adem\u00e1s, se destaca la necesidad de documentaci\u00f3n rigurosa de los procedimientos para asegurar la calidad y trazabilidad de los productos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si un miembro del personal presenta una enfermedad o lesiones abiertas?**\n   - El personal que tenga una enfermedad o lesiones abiertas que puedan afectar la calidad de los productos o la seguridad de los donantes debe ser excluido de los procesos de manufactura hasta que su condici\u00f3n ya no se considere un riesgo.\n\n2. **\u00bfCu\u00e1les son las pr\u00e1cticas de higiene personal que deben seguir los empleados durante la recolecci\u00f3n de sangre?**\n   - Todos los empleados deben ser capacitados en higiene personal, lo que incluye lavarse y desinfectarse las manos antes, durante y despu\u00e9s de actividades como la recolecci\u00f3n y producci\u00f3n de sangre.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para asegurar la calidad en los procesos de manufactura de sangre?**\n   - Se requiere que todos los procedimientos cr\u00edticos, como la compra y recepci\u00f3n de materiales, selecci\u00f3n de donantes, recolecci\u00f3n de sangre, y pruebas de laboratorio, est\u00e9n especificados en instrucciones escritas apropiadas que cumplan con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP) y regulaciones nacionales relevantes.", "prev_section_summary": "### Temas Clave\n\n1. **Principios de Medicina Transfusional**: Se enfatiza la importancia de la formaci\u00f3n en principios relevantes de la medicina transfusional, buenas pr\u00e1cticas de manufactura (GMP) y conocimientos en microbiolog\u00eda e higiene.\n\n2. **Formaci\u00f3n del Personal**:\n   - **Formaci\u00f3n Inicial**: Programas dise\u00f1ados para el personal reci\u00e9n contratado o que asume nuevas funciones, que deben incluir temas como aseguramiento de calidad, GMP y sistemas computarizados. Los registros de formaci\u00f3n deben documentar al formador, las tareas especificadas y la fecha de finalizaci\u00f3n, firmados por el trainee y el trainer.\n   - **Formaci\u00f3n Continua**: Programas de formaci\u00f3n te\u00f3rica y pr\u00e1ctica para mantener las habilidades del personal, considerando desarrollos t\u00e9cnicos y cambios en procedimientos operativos est\u00e1ndar.\n\n3. **Competencia del Personal**: La competencia se eval\u00faa a trav\u00e9s de la educaci\u00f3n, experiencia y formaci\u00f3n. Se requiere una evaluaci\u00f3n inicial de competencia y evaluaciones peri\u00f3dicas posteriores para asegurar la calidad y seguridad de los productos sangu\u00edneos.\n\n4. **Higiene Personal**: Se deben realizar ex\u00e1menes de salud a todo el personal antes de ser contratado y durante su empleo, seg\u00fan sea necesario.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa relevante para la formaci\u00f3n y operaci\u00f3n en medicina transfusional.\n- **Personal de Medicina Transfusional**: Grupo objetivo de la formaci\u00f3n y evaluaci\u00f3n de competencia.\n- **Registros de Formaci\u00f3n**: Documentaci\u00f3n necesaria para el seguimiento de la formaci\u00f3n del personal.\n- **Procedimientos Operativos Est\u00e1ndar (SOP)**: Documentos que gu\u00edan las tareas y procesos en el \u00e1mbito transfusional. \n\nEste resumen destaca la importancia de la formaci\u00f3n y evaluaci\u00f3n continua del personal en el contexto de la medicina transfusional, as\u00ed como la necesidad de mantener est\u00e1ndares de higiene y salud.", "excerpt_keywords": "Keywords: hygiene, blood collection, quality assurance, documentation, standard operating procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "879717b8-6191-4454-a0ee-01d5fdee4f0b", "node_type": "4", "metadata": {"page_label": "180", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have an illness or open lesions that may adversely affect the quality of the products and/or the safety of the donors should be excluded from the establishment\u2019s manufacturing processes until that person\u2019s condition is no longer judged to be a risk.\n\nAll personnel should be trained in personal hygiene. In particular, personnel should be instructed to wash and disinfect their hands before, during and after activities such as blood collection and production.\n\nSpecial attention should be drawn to the need to protect donors, employees and products from contamination \u2014 especially with blood and any other material of human origin.\n\nTo ensure protection of products, donors and employees from contamination, personnel should wear clean protective clothing appropriate for the duties they perform. Soiled protective clothing, if reusable, should be stored in a separate closed container until properly laundered and, if necessary, disinfected or sterilized. Where appropriate, disposable or sterile gloves should be worn when handling items that may come in contact with any blood or blood components.\n\nSmoking, eating, drinking, chewing, and keeping plants, food, drinks, smoking material and personal medicines should not be permitted in areas used for production, testing, storage or distribution, or in other areas where they might adversely affect product quality. Personal hygiene procedures, including the use of appropriate protective clothing and equipment, should apply to all persons entering production areas.\n\n# 5. Documentation\n\nThe documentation of procedures and records is essential to the quality assurance system. It ensures that work is performed in a standardized and uniform manner and ensures the traceability of all steps. Written instructions should include all applicable methods and procedures and should be accessible to all authorized personnel.\n\n## 5.1 Standard operating procedures and records\n\n### 5.1.1 Standard operating procedures\n\nAll critical procedures \u2014 such as purchase and receipt of starting materials, selection of donors, collection of blood, preparation of blood components, laboratory testing and associated quality control testing, product labelling, storage, release, dispatch, shipping, and recall of final products \u2014 should be specified in appropriate written instructions in accordance with the principles of GMP and relevant national regulations. Quality assurance", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "69bca3dc3c50ccea87ff9ec832db8ed63fb5d0274c1a3ac2062df9179228e143", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "have an illness or open lesions that may adversely affect the quality of the products and/or the safety of the donors should be excluded from the establishment\u2019s manufacturing processes until that person\u2019s condition is no longer judged to be a risk.\n\nAll personnel should be trained in personal hygiene. In particular, personnel should be instructed to wash and disinfect their hands before, during and after activities such as blood collection and production.\n\nSpecial attention should be drawn to the need to protect donors, employees and products from contamination \u2014 especially with blood and any other material of human origin.\n\nTo ensure protection of products, donors and employees from contamination, personnel should wear clean protective clothing appropriate for the duties they perform. Soiled protective clothing, if reusable, should be stored in a separate closed container until properly laundered and, if necessary, disinfected or sterilized. Where appropriate, disposable or sterile gloves should be worn when handling items that may come in contact with any blood or blood components.\n\nSmoking, eating, drinking, chewing, and keeping plants, food, drinks, smoking material and personal medicines should not be permitted in areas used for production, testing, storage or distribution, or in other areas where they might adversely affect product quality. Personal hygiene procedures, including the use of appropriate protective clothing and equipment, should apply to all persons entering production areas.\n\n# 5. Documentation\n\nThe documentation of procedures and records is essential to the quality assurance system. It ensures that work is performed in a standardized and uniform manner and ensures the traceability of all steps. Written instructions should include all applicable methods and procedures and should be accessible to all authorized personnel.\n\n## 5.1 Standard operating procedures and records\n\n### 5.1.1 Standard operating procedures\n\nAll critical procedures \u2014 such as purchase and receipt of starting materials, selection of donors, collection of blood, preparation of blood components, laboratory testing and associated quality control testing, product labelling, storage, release, dispatch, shipping, and recall of final products \u2014 should be specified in appropriate written instructions in accordance with the principles of GMP and relevant national regulations. Quality assurance", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2416, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9fd0b9ec-01f2-401d-8473-3b76d182180f": {"__data__": {"id_": "9fd0b9ec-01f2-401d-8473-3b76d182180f", "embedding": null, "metadata": {"page_label": "181", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.1.2 Records\n\nEach activity that may affect the quality of blood and blood components should be documented and recorded at the time it takes place. Critical activities should be double-checked, either by a second person or electronically. There should be documentation to ensure that work is performed in a standardized manner according to standard operating procedures and that all critical steps in the process are traceable \u2014 especially those that have the potential to affect the quality of the product. The documentation should allow all steps and all data to be confirmed by independent review. All documentation should indicate the person performing the action, the date of the action and the equipment used in the action, where applicable.\n\nRecords should be legible, accurate, reliable and a true representation of the results and entries. The legibility of records is of great importance. Handwritten entry of data should be clear. Corrections to any records should be made in a manner that permits the reading and review of the previous entry, the correction, the date of correction and the person responsible for the correction.\n\nCritical manufacturing and laboratory testing records should be reviewed frequently for completeness, legibility and, when appropriate, accuracy by the manager or other designated person.\n\n# 5.2 Document control\n\nAll documents should be laid out in an orderly manner with a unique title and reference number, and should indicate the version and the effective date. The content of the document should be clear and should not include superfluous information. Title, nature, purpose and scope should be clearly outlined. Documents should be reviewed, approved, signed and dated by authorized persons. An audit trail should indicate the person responsible for each step of document control.\n\n## 5.2.1 Document management\n\nA document management system should be in place. Documents that outline specific manufacturing steps or other critical steps should be readily", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la documentaci\u00f3n y el control de documentos en actividades relacionadas con la calidad de la sangre y sus componentes. Se enfatiza la necesidad de registrar cada actividad cr\u00edtica, asegurando que sean legibles, precisas y revisadas regularmente. Adem\u00e1s, se establece que todos los documentos deben estar organizados, ser claros y contar con un sistema de gesti\u00f3n de documentos que garantice la trazabilidad y la responsabilidad en cada paso del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en la documentaci\u00f3n de actividades cr\u00edticas relacionadas con la calidad de la sangre?**\n   - La documentaci\u00f3n debe incluir el nombre de la persona que realiza la acci\u00f3n, la fecha de la acci\u00f3n y el equipo utilizado, donde sea aplicable. Adem\u00e1s, debe ser legible, precisa y permitir la revisi\u00f3n independiente de todos los pasos y datos.\n\n2. **\u00bfC\u00f3mo deben manejarse las correcciones en los registros de datos?**\n   - Las correcciones deben hacerse de manera que se pueda leer y revisar la entrada anterior, la correcci\u00f3n, la fecha de la correcci\u00f3n y la persona responsable de la misma. Esto asegura la trazabilidad y la claridad en los registros.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para el control de documentos en el contexto de la calidad de la sangre?**\n   - Los documentos deben tener un t\u00edtulo \u00fanico y un n\u00famero de referencia, indicar la versi\u00f3n y la fecha de vigencia, y su contenido debe ser claro y sin informaci\u00f3n superflua. Adem\u00e1s, deben ser revisados, aprobados, firmados y fechados por personas autorizadas, y debe existir un rastro de auditor\u00eda que indique la responsabilidad en cada paso del control de documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Higiene Personal del Personal**:\n   - Importancia de la higiene personal en el proceso de recolecci\u00f3n y producci\u00f3n de sangre.\n   - Capacitaci\u00f3n del personal en pr\u00e1cticas de higiene, incluyendo el lavado y desinfecci\u00f3n de manos.\n\n2. **Contaminaci\u00f3n y Protecci\u00f3n**:\n   - Necesidad de proteger a donantes, empleados y productos de la contaminaci\u00f3n, especialmente con sangre y materiales de origen humano.\n   - Uso de ropa protectora limpia y adecuada para las tareas realizadas.\n   - Prohibici\u00f3n de actividades que puedan contaminar el entorno de producci\u00f3n (fumar, comer, beber, etc.).\n\n3. **Documentaci\u00f3n y Procedimientos**:\n   - La documentaci\u00f3n de procedimientos y registros es esencial para el sistema de aseguramiento de calidad.\n   - Instrucciones escritas deben incluir m\u00e9todos y procedimientos aplicables y ser accesibles al personal autorizado.\n   - Especificaci\u00f3n de procedimientos cr\u00edticos en conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP) y regulaciones nacionales.\n\n4. **Procedimientos Operativos Est\u00e1ndar (POE)**:\n   - Detalle de procedimientos cr\u00edticos como la compra de materiales, selecci\u00f3n de donantes, recolecci\u00f3n de sangre, pruebas de laboratorio, etiquetado de productos, almacenamiento y distribuci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Principios que gu\u00edan la documentaci\u00f3n y procedimientos.\n- **Personal de Salud**: Empleados involucrados en la recolecci\u00f3n y producci\u00f3n de sangre.\n- **Donantes**: Personas que contribuyen con sangre y componentes sangu\u00edneos.\n- **Productos Sangu\u00edneos**: Componentes que se producen y distribuyen a partir de la sangre recolectada. \n\nEste resumen destaca la importancia de la higiene, la protecci\u00f3n contra la contaminaci\u00f3n y la documentaci\u00f3n rigurosa en los procesos de manufactura de sangre, asegurando as\u00ed la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: documentation, blood quality, record keeping, document control, standard operating procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a9a643c2-a51c-479c-9c93-18c16195f0fe", "node_type": "4", "metadata": {"page_label": "181", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.1.2 Records\n\nEach activity that may affect the quality of blood and blood components should be documented and recorded at the time it takes place. Critical activities should be double-checked, either by a second person or electronically. There should be documentation to ensure that work is performed in a standardized manner according to standard operating procedures and that all critical steps in the process are traceable \u2014 especially those that have the potential to affect the quality of the product. The documentation should allow all steps and all data to be confirmed by independent review. All documentation should indicate the person performing the action, the date of the action and the equipment used in the action, where applicable.\n\nRecords should be legible, accurate, reliable and a true representation of the results and entries. The legibility of records is of great importance. Handwritten entry of data should be clear. Corrections to any records should be made in a manner that permits the reading and review of the previous entry, the correction, the date of correction and the person responsible for the correction.\n\nCritical manufacturing and laboratory testing records should be reviewed frequently for completeness, legibility and, when appropriate, accuracy by the manager or other designated person.\n\n# 5.2 Document control\n\nAll documents should be laid out in an orderly manner with a unique title and reference number, and should indicate the version and the effective date. The content of the document should be clear and should not include superfluous information. Title, nature, purpose and scope should be clearly outlined. Documents should be reviewed, approved, signed and dated by authorized persons. An audit trail should indicate the person responsible for each step of document control.\n\n## 5.2.1 Document management\n\nA document management system should be in place. Documents that outline specific manufacturing steps or other critical steps should be readily", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "70d863f1764efe5f9fcaeea6b24c77914da470e2dbb96eb0af60b3d520a17a77", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.1.2 Records\n\nEach activity that may affect the quality of blood and blood components should be documented and recorded at the time it takes place. Critical activities should be double-checked, either by a second person or electronically. There should be documentation to ensure that work is performed in a standardized manner according to standard operating procedures and that all critical steps in the process are traceable \u2014 especially those that have the potential to affect the quality of the product. The documentation should allow all steps and all data to be confirmed by independent review. All documentation should indicate the person performing the action, the date of the action and the equipment used in the action, where applicable.\n\nRecords should be legible, accurate, reliable and a true representation of the results and entries. The legibility of records is of great importance. Handwritten entry of data should be clear. Corrections to any records should be made in a manner that permits the reading and review of the previous entry, the correction, the date of correction and the person responsible for the correction.\n\nCritical manufacturing and laboratory testing records should be reviewed frequently for completeness, legibility and, when appropriate, accuracy by the manager or other designated person.\n\n# 5.2 Document control\n\nAll documents should be laid out in an orderly manner with a unique title and reference number, and should indicate the version and the effective date. The content of the document should be clear and should not include superfluous information. Title, nature, purpose and scope should be clearly outlined. Documents should be reviewed, approved, signed and dated by authorized persons. An audit trail should indicate the person responsible for each step of document control.\n\n## 5.2.1 Document management\n\nA document management system should be in place. Documents that outline specific manufacturing steps or other critical steps should be readily", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2005, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf8a8df-5e70-428d-85e2-f6a9bdf869b5": {"__data__": {"id_": "ccf8a8df-5e70-428d-85e2-f6a9bdf869b5", "embedding": null, "metadata": {"page_label": "182", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Record retention and archiving\n\nAll records, including raw data, which are critical to the safety and quality of blood or blood components, should be kept in a secured storage area according to national regulations, or preferably for at least 10 years. A longer period for retention of records may be required by NRAs, international requirements or by specific contractual agreements. Records of permanently deferred donors should be kept indefinitely.\n\nOutdated standard operating procedures should also be kept in a historic file system. Documents should be archived in a secured area and should be readily accessible for retrieval by authorized personnel if required. The archival and retrieval process, especially if computerized systems are used, should be validated to ensure that all information can be retrieved and read at any time until the end of the required period of retention.\n\n# Premises and equipment\n\n## Premises\n\n### Design and construction\n\nPremises should be located, constructed, adapted and maintained to suit the operations that are to be carried out in them. Premises should be designed to permit effective cleaning and maintenance to minimize risk of contamination. The workflow should be designed and arranged to allow for a logical flow of staff, donors and products in order to minimize the risk of errors. Working areas should not be used as passageways or storage areas.\n\nAncillary areas should be separated from the donor evaluation area, and from the screening, collection and manufacturing areas. Washing and toilet facilities and, if required, facilities for changing or eating should be maintained in a hygienic and tidy condition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la retenci\u00f3n y archivo de registros relacionados con la seguridad y calidad de la sangre y sus componentes. Se establece que todos los registros cr\u00edticos deben ser almacenados de manera segura durante al menos 10 a\u00f1os, aunque pueden requerirse per\u00edodos m\u00e1s largos seg\u00fan regulaciones nacionales o acuerdos espec\u00edficos. Adem\u00e1s, se menciona la importancia de mantener procedimientos operativos est\u00e1ndar obsoletos en un sistema de archivo hist\u00f3rico. Tambi\u00e9n se discuten las caracter\u00edsticas de dise\u00f1o y construcci\u00f3n de las instalaciones donde se llevan a cabo estas operaciones, enfatizando la necesidad de un flujo de trabajo l\u00f3gico y la separaci\u00f3n de \u00e1reas para minimizar riesgos de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de no cumplir con el per\u00edodo m\u00ednimo de retenci\u00f3n de registros de sangre seg\u00fan las regulaciones nacionales?**\n   - Esta pregunta busca explorar las consecuencias legales y de seguridad que pueden surgir si no se siguen las pautas de retenci\u00f3n de registros.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para validar el proceso de archivo y recuperaci\u00f3n de documentos en sistemas computarizados?**\n   - Aqu\u00ed se indaga sobre los procedimientos espec\u00edficos que deben implementarse para garantizar que la informaci\u00f3n archivada sea accesible y legible durante el per\u00edodo requerido.\n\n3. **\u00bfQu\u00e9 consideraciones de dise\u00f1o son esenciales para minimizar el riesgo de contaminaci\u00f3n en las instalaciones de recolecci\u00f3n de sangre?**\n   - Esta pregunta se centra en los aspectos pr\u00e1cticos del dise\u00f1o de instalaciones que son cruciales para mantener la seguridad y calidad en la recolecci\u00f3n y manejo de sangre. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n detallada que no se encuentra expl\u00edcitamente en el texto, pero que es relevante para la comprensi\u00f3n de las normativas y pr\u00e1cticas en la gesti\u00f3n de registros y dise\u00f1o de instalaciones en el contexto de la salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Documentaci\u00f3n de Actividades Cr\u00edticas**:\n   - Es esencial documentar cada actividad que pueda afectar la calidad de la sangre y sus componentes en el momento en que se realiza.\n   - Las actividades cr\u00edticas deben ser verificadas por una segunda persona o electr\u00f3nicamente.\n   - La documentaci\u00f3n debe ser estandarizada y permitir la trazabilidad de todos los pasos del proceso.\n\n2. **Requisitos de los Registros**:\n   - Los registros deben ser legibles, precisos, confiables y representar fielmente los resultados.\n   - Las correcciones en los registros deben ser claras y permitir la revisi\u00f3n de entradas anteriores, incluyendo la fecha y la persona responsable de la correcci\u00f3n.\n\n3. **Revisi\u00f3n de Registros**:\n   - Los registros de fabricaci\u00f3n y pruebas de laboratorio deben ser revisados frecuentemente por un gerente o persona designada para asegurar su integridad y legibilidad.\n\n4. **Control de Documentos**:\n   - Todos los documentos deben tener un t\u00edtulo \u00fanico, un n\u00famero de referencia, versi\u00f3n y fecha de vigencia.\n   - El contenido debe ser claro y conciso, sin informaci\u00f3n superflua.\n   - Los documentos deben ser revisados, aprobados, firmados y fechados por personas autorizadas, y debe existir un rastro de auditor\u00eda.\n\n5. **Sistema de Gesti\u00f3n de Documentos**:\n   - Se debe implementar un sistema de gesti\u00f3n de documentos que facilite la organizaci\u00f3n y el acceso a documentos cr\u00edticos relacionados con los pasos de fabricaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Calidad de la Sangre**: Tema central de la documentaci\u00f3n y control.\n- **Registros**: Documentos que deben ser precisos y legibles.\n- **Documentos**: Deben ser controlados y gestionados adecuadamente.\n- **Auditor\u00eda**: Proceso para asegurar la responsabilidad y trazabilidad en el control de documentos. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control de documentos en la gesti\u00f3n de la calidad de la sangre, asegurando que todas las actividades cr\u00edticas sean registradas y revisadas adecuadamente.", "excerpt_keywords": "Keywords: record retention, blood safety, archiving, premises design, contamination prevention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9ae82005-3760-4cad-8c67-37178410eff0", "node_type": "4", "metadata": {"page_label": "182", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Record retention and archiving\n\nAll records, including raw data, which are critical to the safety and quality of blood or blood components, should be kept in a secured storage area according to national regulations, or preferably for at least 10 years. A longer period for retention of records may be required by NRAs, international requirements or by specific contractual agreements. Records of permanently deferred donors should be kept indefinitely.\n\nOutdated standard operating procedures should also be kept in a historic file system. Documents should be archived in a secured area and should be readily accessible for retrieval by authorized personnel if required. The archival and retrieval process, especially if computerized systems are used, should be validated to ensure that all information can be retrieved and read at any time until the end of the required period of retention.\n\n# Premises and equipment\n\n## Premises\n\n### Design and construction\n\nPremises should be located, constructed, adapted and maintained to suit the operations that are to be carried out in them. Premises should be designed to permit effective cleaning and maintenance to minimize risk of contamination. The workflow should be designed and arranged to allow for a logical flow of staff, donors and products in order to minimize the risk of errors. Working areas should not be used as passageways or storage areas.\n\nAncillary areas should be separated from the donor evaluation area, and from the screening, collection and manufacturing areas. Washing and toilet facilities and, if required, facilities for changing or eating should be maintained in a hygienic and tidy condition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "327452effd1a1effa1836b1625bf10241260c738b28a434789823b6acc5cbbd1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Record retention and archiving\n\nAll records, including raw data, which are critical to the safety and quality of blood or blood components, should be kept in a secured storage area according to national regulations, or preferably for at least 10 years. A longer period for retention of records may be required by NRAs, international requirements or by specific contractual agreements. Records of permanently deferred donors should be kept indefinitely.\n\nOutdated standard operating procedures should also be kept in a historic file system. Documents should be archived in a secured area and should be readily accessible for retrieval by authorized personnel if required. The archival and retrieval process, especially if computerized systems are used, should be validated to ensure that all information can be retrieved and read at any time until the end of the required period of retention.\n\n# Premises and equipment\n\n## Premises\n\n### Design and construction\n\nPremises should be located, constructed, adapted and maintained to suit the operations that are to be carried out in them. Premises should be designed to permit effective cleaning and maintenance to minimize risk of contamination. The workflow should be designed and arranged to allow for a logical flow of staff, donors and products in order to minimize the risk of errors. Working areas should not be used as passageways or storage areas.\n\nAncillary areas should be separated from the donor evaluation area, and from the screening, collection and manufacturing areas. Washing and toilet facilities and, if required, facilities for changing or eating should be maintained in a hygienic and tidy condition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1669, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "89166a3f-0249-48e4-a48c-7db3bcf22dba": {"__data__": {"id_": "89166a3f-0249-48e4-a48c-7db3bcf22dba", "embedding": null, "metadata": {"page_label": "183", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production, Testing, and Storage Areas\n\nProduction, testing, and storage areas should be secured against entry by unauthorized persons.\n\nLighting, temperature, humidity, and ventilation should be appropriate and should not adversely affect production or storage. Premises should be designed and equipped to afford maximum protection against the entry of animals, including insects.\n\nPremises should be carefully maintained and cleaned (see sections 6.2.2 and 6.2.3) and where appropriate disinfected according to detailed written standard operating procedures. Cleaning records should be retained.\n\n## 6.1.2 Donor Areas\n\nThe area for blood donors should be separated from all production and testing areas.\n\nThe design of premises should be adequate for the conduct of operations and should allow for the logical flow of donors, in one direction if possible, so that donors who have passed reception, screening, and donation do not have to return to a previous area.\n\nThe area for donor selection should permit confidential personal interviews to take place with due consideration for the safety of donors and personnel.\n\nRest and refreshment rooms for donors should be separated from donation or storage areas.\n\n## 6.1.3 Production Areas\n\nBlood processing should be carried out in adequate facilities that are suitable for the purpose. The donor area, and production and testing areas should be separated from each other.\n\nWhenever possible, closed systems should be used. Using a validated sterile connecting device creates a functionally closed system.\n\nWhen the use of a closed system is not possible or not appropriate, the risk of contamination or cross-contamination needs to be minimized. Therefore, the premises used for the processing of blood components in an open process should be designed and qualified as a grade A environment with a grade B background, as defined in the WHO GMP for sterile pharmaceutical products. A less stringent environment may be acceptable if the preparation of the product is directly combined with additional safety measures \u2014 such as immediate transfusion within a defined and limited time period after processing, or placing the product immediately into storage conditions that prohibit microbial growth. Personnel performing open processing should wear appropriate clothing (i.e., suitable coats, masks, or gloves) and should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS detalla las normas y directrices para las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de componentes sangu\u00edneos. Se enfatiza la importancia de la seguridad, la separaci\u00f3n de \u00e1reas, el control ambiental (iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n), y la limpieza y desinfecci\u00f3n de las instalaciones. Tambi\u00e9n se abordan las \u00e1reas destinadas a donantes, destacando la necesidad de privacidad y seguridad, as\u00ed como las condiciones adecuadas para el procesamiento de sangre, incluyendo el uso de sistemas cerrados y medidas de seguridad adicionales en caso de utilizar sistemas abiertos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las \u00e1reas de donantes para garantizar la privacidad y seguridad durante el proceso de selecci\u00f3n?**\n   - Respuesta: Las \u00e1reas de donantes deben permitir entrevistas personales confidenciales y estar dise\u00f1adas para garantizar la seguridad tanto de los donantes como del personal. Adem\u00e1s, deben estar separadas de las \u00e1reas de producci\u00f3n y almacenamiento.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si no es posible utilizar un sistema cerrado durante el procesamiento de componentes sangu\u00edneos?**\n   - Respuesta: Si no se puede utilizar un sistema cerrado, se debe minimizar el riesgo de contaminaci\u00f3n o contaminaci\u00f3n cruzada. Las instalaciones deben estar dise\u00f1adas y calificadas como un entorno de grado A con un fondo de grado B, y se deben implementar medidas de seguridad adicionales, como transfusiones inmediatas o almacenamiento en condiciones que proh\u00edban el crecimiento microbiano.\n\n3. **\u00bfQu\u00e9 tipo de registros deben mantenerse en relaci\u00f3n con la limpieza y desinfecci\u00f3n de las instalaciones?**\n   - Respuesta: Se deben retener registros de limpieza que documenten las actividades de mantenimiento y desinfecci\u00f3n de las instalaciones, de acuerdo con procedimientos operativos est\u00e1ndar escritos y detallados.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS establece directrices para asegurar que las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de sangre sean seguras y eficaces. Se enfatiza la separaci\u00f3n de \u00e1reas, el control ambiental y la limpieza rigurosa. Tambi\u00e9n se abordan las consideraciones espec\u00edficas para las \u00e1reas de donantes, asegurando la privacidad y la seguridad, as\u00ed como las mejores pr\u00e1cticas para el procesamiento de sangre, incluyendo el uso de sistemas cerrados y medidas de mitigaci\u00f3n en caso de utilizar sistemas abiertos.", "prev_section_summary": "### Temas Clave\n\n1. **Retenci\u00f3n y Archivo de Registros**:\n   - Importancia de mantener registros cr\u00edticos relacionados con la seguridad y calidad de la sangre.\n   - Per\u00edodo m\u00ednimo de retenci\u00f3n de 10 a\u00f1os, con posibles extensiones seg\u00fan regulaciones nacionales o acuerdos espec\u00edficos.\n   - Archivar procedimientos operativos est\u00e1ndar obsoletos en un sistema hist\u00f3rico.\n   - Validaci\u00f3n del proceso de archivo y recuperaci\u00f3n, especialmente en sistemas computarizados.\n\n2. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Ubicaci\u00f3n y construcci\u00f3n de las instalaciones deben adaptarse a las operaciones realizadas.\n   - Necesidad de un dise\u00f1o que permita limpieza efectiva y minimice el riesgo de contaminaci\u00f3n.\n   - Organizaci\u00f3n del flujo de trabajo para reducir errores, evitando el uso de \u00e1reas de trabajo como pasillos o zonas de almacenamiento.\n   - Separaci\u00f3n de \u00e1reas auxiliares de las zonas de evaluaci\u00f3n de donantes y recolecci\u00f3n.\n\n3. **Condiciones Higi\u00e9nicas**:\n   - Mantenimiento de instalaciones de lavado, aseo y \u00e1reas de descanso en condiciones higi\u00e9nicas y ordenadas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Regulaciones Nacionales (NRAs)**: Normativas que pueden influir en los per\u00edodos de retenci\u00f3n de registros.\n- **Donantes**: Individuos cuya informaci\u00f3n y registros deben ser gestionados adecuadamente.\n- **Procedimientos Operativos Est\u00e1ndar**: Documentos que gu\u00edan las pr\u00e1cticas en la recolecci\u00f3n y manejo de sangre.\n- **Instalaciones de Recolecci\u00f3n de Sangre**: Espacios f\u00edsicos donde se llevan a cabo las operaciones relacionadas con la sangre.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de registros y el dise\u00f1o de instalaciones para garantizar la seguridad y calidad en el manejo de sangre y sus componentes.", "excerpt_keywords": "Keywords: blood donation, production areas, contamination control, donor privacy, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8af85296-e848-4a28-bb9d-b14a938c6300", "node_type": "4", "metadata": {"page_label": "183", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production, Testing, and Storage Areas\n\nProduction, testing, and storage areas should be secured against entry by unauthorized persons.\n\nLighting, temperature, humidity, and ventilation should be appropriate and should not adversely affect production or storage. Premises should be designed and equipped to afford maximum protection against the entry of animals, including insects.\n\nPremises should be carefully maintained and cleaned (see sections 6.2.2 and 6.2.3) and where appropriate disinfected according to detailed written standard operating procedures. Cleaning records should be retained.\n\n## 6.1.2 Donor Areas\n\nThe area for blood donors should be separated from all production and testing areas.\n\nThe design of premises should be adequate for the conduct of operations and should allow for the logical flow of donors, in one direction if possible, so that donors who have passed reception, screening, and donation do not have to return to a previous area.\n\nThe area for donor selection should permit confidential personal interviews to take place with due consideration for the safety of donors and personnel.\n\nRest and refreshment rooms for donors should be separated from donation or storage areas.\n\n## 6.1.3 Production Areas\n\nBlood processing should be carried out in adequate facilities that are suitable for the purpose. The donor area, and production and testing areas should be separated from each other.\n\nWhenever possible, closed systems should be used. Using a validated sterile connecting device creates a functionally closed system.\n\nWhen the use of a closed system is not possible or not appropriate, the risk of contamination or cross-contamination needs to be minimized. Therefore, the premises used for the processing of blood components in an open process should be designed and qualified as a grade A environment with a grade B background, as defined in the WHO GMP for sterile pharmaceutical products. A less stringent environment may be acceptable if the preparation of the product is directly combined with additional safety measures \u2014 such as immediate transfusion within a defined and limited time period after processing, or placing the product immediately into storage conditions that prohibit microbial growth. Personnel performing open processing should wear appropriate clothing (i.e., suitable coats, masks, or gloves) and should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "75b16ad360e5132d0cf48d9d734d133bab247355b4223ff691d4b32f243cb84b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Production, Testing, and Storage Areas\n\nProduction, testing, and storage areas should be secured against entry by unauthorized persons.\n\nLighting, temperature, humidity, and ventilation should be appropriate and should not adversely affect production or storage. Premises should be designed and equipped to afford maximum protection against the entry of animals, including insects.\n\nPremises should be carefully maintained and cleaned (see sections 6.2.2 and 6.2.3) and where appropriate disinfected according to detailed written standard operating procedures. Cleaning records should be retained.\n\n## 6.1.2 Donor Areas\n\nThe area for blood donors should be separated from all production and testing areas.\n\nThe design of premises should be adequate for the conduct of operations and should allow for the logical flow of donors, in one direction if possible, so that donors who have passed reception, screening, and donation do not have to return to a previous area.\n\nThe area for donor selection should permit confidential personal interviews to take place with due consideration for the safety of donors and personnel.\n\nRest and refreshment rooms for donors should be separated from donation or storage areas.\n\n## 6.1.3 Production Areas\n\nBlood processing should be carried out in adequate facilities that are suitable for the purpose. The donor area, and production and testing areas should be separated from each other.\n\nWhenever possible, closed systems should be used. Using a validated sterile connecting device creates a functionally closed system.\n\nWhen the use of a closed system is not possible or not appropriate, the risk of contamination or cross-contamination needs to be minimized. Therefore, the premises used for the processing of blood components in an open process should be designed and qualified as a grade A environment with a grade B background, as defined in the WHO GMP for sterile pharmaceutical products. A less stringent environment may be acceptable if the preparation of the product is directly combined with additional safety measures \u2014 such as immediate transfusion within a defined and limited time period after processing, or placing the product immediately into storage conditions that prohibit microbial growth. Personnel performing open processing should wear appropriate clothing (i.e., suitable coats, masks, or gloves) and should", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2370, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "36c1df59-776b-4ef7-9ccc-cacf13ccaf9d": {"__data__": {"id_": "36c1df59-776b-4ef7-9ccc-cacf13ccaf9d", "embedding": null, "metadata": {"page_label": "184", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "receive regular training in aseptic manipulations. Aseptic processing should be validated. Environmental monitoring protocols should be applied and evaluated by the quality assurance unit.\n\nThe premises used for processing blood components should be kept in a clean and hygienic condition. Monitoring of the microbiological contamination load should be considered for critical equipment surfaces and environments where appropriate, according to a risk-based assessment of the process. Records should be available.\n\nEach area of processing and storage should be secured against entry by unauthorized persons and should be used only for the intended purpose.\n\n### 6.1.4 Storage areas\n\nStorage areas should provide adequate space and should be arranged in a way that allows for dry and orderly placement of stored materials.\n\nStorage conditions should be controlled, monitored and documented to show compliance with the specifications. Equal distribution of temperature throughout the storage facility should be guaranteed and documented. This is particularly important for the critical materials used in processing blood and blood components. Temperature checks should be carried out and recorded at least daily. Appropriate alarms at upper and lower temperature limits should be present and should be regularly checked; the checks should be recorded. Appropriate actions to be taken when there is an alarm should be defined in writing.\n\nIntermediate storage and transport should be carried out under defined conditions to ensure that specifications are met.\n\nStorage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and materials.\n\n### 6.1.5 Laboratories\n\nTesting laboratories should be designed and constructed so as to minimize the risk of errors and contamination. Laboratory areas should be separated from the processing and final product storage areas. Where nucleic acid amplification testing (NAT) technology warrants, separate premises (rooms) and air handling systems should be considered for performing NAT. Consideration should be given to constructing a separate room for specimen sampling and another room for amplification and nucleic acid detection in order to minimize the risk of contamination or false-positive test results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Capacitaci\u00f3n y Validaci\u00f3n en Procesos Asepticos**: Se enfatiza la importancia de la capacitaci\u00f3n regular en manipulaciones as\u00e9pticas y la validaci\u00f3n de los procesos as\u00e9pticos. Adem\u00e1s, se menciona que los protocolos de monitoreo ambiental deben ser aplicados y evaluados por la unidad de aseguramiento de calidad.\n\n2. **Condiciones de Almacenamiento**: Se describen las condiciones necesarias para las \u00e1reas de almacenamiento, incluyendo la necesidad de un espacio adecuado, control y documentaci\u00f3n de las condiciones de almacenamiento, y la importancia de la segregaci\u00f3n de materiales en cuarentena y rechazados.\n\n3. **Dise\u00f1o de Laboratorios**: Se establece que los laboratorios de pruebas deben ser dise\u00f1ados para minimizar errores y contaminaci\u00f3n, con \u00e1reas separadas para el procesamiento y almacenamiento de productos finales, as\u00ed como consideraciones espec\u00edficas para la tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT).\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se requiere para el personal que manipula componentes sangu\u00edneos y c\u00f3mo se valida el proceso de manipulaci\u00f3n as\u00e9ptica?**\n   - La capacitaci\u00f3n regular en manipulaciones as\u00e9pticas es esencial, y el proceso de manipulaci\u00f3n debe ser validado para asegurar su eficacia y seguridad.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que deben seguirse cuando se activa una alarma de temperatura en las \u00e1reas de almacenamiento de componentes sangu\u00edneos?**\n   - Se deben definir por escrito las acciones apropiadas a tomar cuando se activa una alarma, asegurando que se sigan los protocolos establecidos para mantener la integridad de los materiales almacenados.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar laboratorios que utilizan tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT)?**\n   - Los laboratorios deben tener \u00e1reas separadas para la toma de muestras y para la amplificaci\u00f3n y detecci\u00f3n de \u00e1cidos nucleicos, as\u00ed como sistemas de manejo de aire independientes para minimizar el riesgo de contaminaci\u00f3n y resultados falsos positivos.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad de las \u00c1reas**: Las \u00e1reas de producci\u00f3n, pruebas y almacenamiento deben estar aseguradas contra el acceso de personas no autorizadas.\n  \n2. **Control Ambiental**: Es fundamental mantener condiciones adecuadas de iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n para no afectar negativamente la producci\u00f3n o el almacenamiento.\n\n3. **Mantenimiento y Limpieza**: Las instalaciones deben ser mantenidas y limpiadas rigurosamente, siguiendo procedimientos operativos est\u00e1ndar escritos, y se deben conservar registros de limpieza.\n\n4. **\u00c1reas para Donantes**: Deben estar separadas de las \u00e1reas de producci\u00f3n y pruebas, permitiendo entrevistas personales confidenciales y garantizando la seguridad de donantes y personal.\n\n5. **Procesamiento de Sangre**: Se debe realizar en instalaciones adecuadas, separando las \u00e1reas de donantes, producci\u00f3n y pruebas. Se recomienda el uso de sistemas cerrados para minimizar el riesgo de contaminaci\u00f3n.\n\n6. **Medidas de Seguridad en Sistemas Abiertos**: Si no se puede usar un sistema cerrado, se deben implementar medidas adicionales para minimizar el riesgo de contaminaci\u00f3n, como transfusiones inmediatas o almacenamiento en condiciones que impidan el crecimiento microbiano.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **\u00c1reas de Producci\u00f3n, Pruebas y Almacenamiento**: Espacios cr\u00edticos en el proceso de manejo de sangre.\n- **\u00c1reas de Donantes**: Espacios dise\u00f1ados para la selecci\u00f3n y donaci\u00f3n de sangre.\n- **Sistemas Cerrados y Abiertos**: M\u00e9todos de procesamiento de sangre que afectan el riesgo de contaminaci\u00f3n.\n- **Registros de Limpieza**: Documentaci\u00f3n necesaria para asegurar el cumplimiento de las normas de limpieza y desinfecci\u00f3n.\n\n### Resumen\n\nEl documento de la OMS establece directrices para asegurar la seguridad y eficacia en las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de componentes sangu\u00edneos. Se enfatiza la importancia de la seguridad, el control ambiental, la limpieza rigurosa y la separaci\u00f3n de \u00e1reas, as\u00ed como la privacidad y seguridad en las \u00e1reas de donantes. Adem\u00e1s, se abordan las mejores pr\u00e1cticas para el procesamiento de sangre, destacando el uso de sistemas cerrados y las medidas de mitigaci\u00f3n necesarias en caso de utilizar sistemas abiertos.", "excerpt_keywords": "Keywords: aseptic processing, blood components, storage conditions, environmental monitoring, laboratory design"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d9f9fbc9-784f-4996-932d-83f1e2a78153", "node_type": "4", "metadata": {"page_label": "184", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "receive regular training in aseptic manipulations. Aseptic processing should be validated. Environmental monitoring protocols should be applied and evaluated by the quality assurance unit.\n\nThe premises used for processing blood components should be kept in a clean and hygienic condition. Monitoring of the microbiological contamination load should be considered for critical equipment surfaces and environments where appropriate, according to a risk-based assessment of the process. Records should be available.\n\nEach area of processing and storage should be secured against entry by unauthorized persons and should be used only for the intended purpose.\n\n### 6.1.4 Storage areas\n\nStorage areas should provide adequate space and should be arranged in a way that allows for dry and orderly placement of stored materials.\n\nStorage conditions should be controlled, monitored and documented to show compliance with the specifications. Equal distribution of temperature throughout the storage facility should be guaranteed and documented. This is particularly important for the critical materials used in processing blood and blood components. Temperature checks should be carried out and recorded at least daily. Appropriate alarms at upper and lower temperature limits should be present and should be regularly checked; the checks should be recorded. Appropriate actions to be taken when there is an alarm should be defined in writing.\n\nIntermediate storage and transport should be carried out under defined conditions to ensure that specifications are met.\n\nStorage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and materials.\n\n### 6.1.5 Laboratories\n\nTesting laboratories should be designed and constructed so as to minimize the risk of errors and contamination. Laboratory areas should be separated from the processing and final product storage areas. Where nucleic acid amplification testing (NAT) technology warrants, separate premises (rooms) and air handling systems should be considered for performing NAT. Consideration should be given to constructing a separate room for specimen sampling and another room for amplification and nucleic acid detection in order to minimize the risk of contamination or false-positive test results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "74c49b078dbf433ce0849561087e2f0a886933f44b54d2260afb10137f40a582", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "receive regular training in aseptic manipulations. Aseptic processing should be validated. Environmental monitoring protocols should be applied and evaluated by the quality assurance unit.\n\nThe premises used for processing blood components should be kept in a clean and hygienic condition. Monitoring of the microbiological contamination load should be considered for critical equipment surfaces and environments where appropriate, according to a risk-based assessment of the process. Records should be available.\n\nEach area of processing and storage should be secured against entry by unauthorized persons and should be used only for the intended purpose.\n\n### 6.1.4 Storage areas\n\nStorage areas should provide adequate space and should be arranged in a way that allows for dry and orderly placement of stored materials.\n\nStorage conditions should be controlled, monitored and documented to show compliance with the specifications. Equal distribution of temperature throughout the storage facility should be guaranteed and documented. This is particularly important for the critical materials used in processing blood and blood components. Temperature checks should be carried out and recorded at least daily. Appropriate alarms at upper and lower temperature limits should be present and should be regularly checked; the checks should be recorded. Appropriate actions to be taken when there is an alarm should be defined in writing.\n\nIntermediate storage and transport should be carried out under defined conditions to ensure that specifications are met.\n\nStorage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and materials.\n\n### 6.1.5 Laboratories\n\nTesting laboratories should be designed and constructed so as to minimize the risk of errors and contamination. Laboratory areas should be separated from the processing and final product storage areas. Where nucleic acid amplification testing (NAT) technology warrants, separate premises (rooms) and air handling systems should be considered for performing NAT. Consideration should be given to constructing a separate room for specimen sampling and another room for amplification and nucleic acid detection in order to minimize the risk of contamination or false-positive test results.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2344, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3e5eeb5a-4909-44e1-8d87-57358e86f236": {"__data__": {"id_": "3e5eeb5a-4909-44e1-8d87-57358e86f236", "embedding": null, "metadata": {"page_label": "185", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.1.6 Mobile collection sites\n\nPremises for mobile collection sites should be adequate in design for the conduct of operations and should allow for the logical flow of staff, donors, and products in order to minimize the risk of errors. The blood collection at mobile sites should be planned thoroughly. Ancillary areas (rest and refreshment rooms) should be separated from donation or storage areas, but observation of donors during post-donation refreshment should still be ensured.\n\nBefore premises are accepted for mobile donor sessions their suitability should be assessed against the following criteria:\n\n- Sufficient size to allow proper operation and ensure donor privacy;\n- Safety for staff and donors;\n- Ventilation, electrical supply, lighting, hand-washing facilities, reliable communication, sufficient space for blood storage and transport, and suitable temperature conditions.\n\nEach site should have an approved plan that details the site layout. The set-up of the mobile collection site should be carried out according to the approved plan.\n\n# 6.2 Equipment\n\n## 6.2.1 Design and construction\n\nAll equipment should be designed and installed to suit its intended purpose and should not present any hazard to donors, personnel or blood components. It should allow for effective cleaning, and disinfection is recommended for all surfaces in direct contact with the bag system.\n\nEquipment should be located in a suitable position (e.g. a balance should be positioned on a suitable even surface) where there is no negative impact from the surrounding environment (e.g. direct sunlight may have an impact on optical instruments such as apheresis systems or balances).\n\n## 6.2.2 Maintenance\n\nMaintenance, cleaning and calibration should be performed regularly and should be recorded. Maintenance of equipment should be carried out at intervals according to a documented schedule.\n\nThe maintenance programmes should be established on the basis of qualification activities. The intervals should be defined according to the instructions of the manufacturer of the equipment. Where intervals are not defined by the equipment manufacturer, maintenance should be carried out at least annually. Different intervals may be defined on the basis of a risk.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las directrices para la operaci\u00f3n de sitios de recolecci\u00f3n m\u00f3vil de sangre, enfatizando la importancia de un dise\u00f1o adecuado de las instalaciones y el equipo. Se establecen criterios para la aceptaci\u00f3n de los locales, incluyendo tama\u00f1o, seguridad y condiciones ambientales. Adem\u00e1s, se subraya la necesidad de un mantenimiento regular y un dise\u00f1o seguro del equipo para proteger a donantes y personal.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para aceptar un local destinado a sesiones de donaci\u00f3n de sangre m\u00f3vil?**\n   - El local debe ser de tama\u00f1o suficiente para permitir una operaci\u00f3n adecuada y garantizar la privacidad del donante, ser seguro para el personal y los donantes, y contar con ventilaci\u00f3n, suministro el\u00e9ctrico, iluminaci\u00f3n, instalaciones para lavado de manos, comunicaci\u00f3n confiable, espacio suficiente para el almacenamiento y transporte de sangre, y condiciones de temperatura adecuadas.\n\n2. **\u00bfQu\u00e9 recomendaciones se hacen respecto al mantenimiento del equipo utilizado en los sitios de recolecci\u00f3n m\u00f3vil?**\n   - El mantenimiento, limpieza y calibraci\u00f3n del equipo deben realizarse regularmente y registrarse. Debe llevarse a cabo de acuerdo con un programa documentado, con intervalos definidos seg\u00fan las instrucciones del fabricante. Si no hay intervalos definidos, el mantenimiento debe realizarse al menos una vez al a\u00f1o, y se pueden establecer diferentes intervalos basados en el riesgo.\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al dise\u00f1ar y ubicar el equipo en un sitio de recolecci\u00f3n m\u00f3vil?**\n   - Todo el equipo debe ser dise\u00f1ado e instalado para su prop\u00f3sito espec\u00edfico, sin presentar riesgos para donantes, personal o componentes sangu\u00edneos. Debe permitir una limpieza efectiva y estar ubicado en un lugar adecuado, evitando impactos negativos del entorno, como la luz solar directa que puede afectar instrumentos \u00f3pticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Capacitaci\u00f3n en Procesos Asepticos**:\n   - Importancia de la capacitaci\u00f3n regular en manipulaciones as\u00e9pticas.\n   - Validaci\u00f3n de los procesos as\u00e9pticos.\n   - Aplicaci\u00f3n y evaluaci\u00f3n de protocolos de monitoreo ambiental por la unidad de aseguramiento de calidad.\n\n2. **Condiciones de Almacenamiento**:\n   - Necesidad de espacios adecuados y ordenados para el almacenamiento de materiales.\n   - Control, monitoreo y documentaci\u00f3n de las condiciones de almacenamiento.\n   - Garant\u00eda de distribuci\u00f3n uniforme de temperatura y registro de controles diarios.\n   - Definici\u00f3n escrita de acciones a seguir ante alarmas de temperatura.\n   - Segregaci\u00f3n efectiva de materiales en cuarentena, liberados y rechazados.\n\n3. **Dise\u00f1o de Laboratorios**:\n   - Dise\u00f1o y construcci\u00f3n de laboratorios para minimizar errores y contaminaci\u00f3n.\n   - Separaci\u00f3n de \u00e1reas de laboratorio de las \u00e1reas de procesamiento y almacenamiento de productos finales.\n   - Consideraciones para la tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT), incluyendo la creaci\u00f3n de habitaciones separadas para muestreo y amplificaci\u00f3n/detecci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Aseptic Processing**: Proceso cr\u00edtico en la manipulaci\u00f3n de componentes sangu\u00edneos.\n- **Environmental Monitoring**: Protocolos necesarios para asegurar la calidad.\n- **Laboratorios de Pruebas**: Espacios dise\u00f1ados para realizar an\u00e1lisis de manera segura y efectiva.\n- **NAT (Nucleic Acid Amplification Testing)**: Tecnolog\u00eda que requiere consideraciones especiales en el dise\u00f1o de laboratorios. \n\nEste resumen destaca la importancia de la capacitaci\u00f3n, las condiciones de almacenamiento y el dise\u00f1o de laboratorios en el contexto del procesamiento de componentes sangu\u00edneos, asegurando la calidad y seguridad en estos procesos.", "excerpt_keywords": "Keywords: mobile collection sites, blood donation, equipment maintenance, safety standards, donor privacy"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "164c8882-b418-46dc-b721-92cbd3efb461", "node_type": "4", "metadata": {"page_label": "185", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.1.6 Mobile collection sites\n\nPremises for mobile collection sites should be adequate in design for the conduct of operations and should allow for the logical flow of staff, donors, and products in order to minimize the risk of errors. The blood collection at mobile sites should be planned thoroughly. Ancillary areas (rest and refreshment rooms) should be separated from donation or storage areas, but observation of donors during post-donation refreshment should still be ensured.\n\nBefore premises are accepted for mobile donor sessions their suitability should be assessed against the following criteria:\n\n- Sufficient size to allow proper operation and ensure donor privacy;\n- Safety for staff and donors;\n- Ventilation, electrical supply, lighting, hand-washing facilities, reliable communication, sufficient space for blood storage and transport, and suitable temperature conditions.\n\nEach site should have an approved plan that details the site layout. The set-up of the mobile collection site should be carried out according to the approved plan.\n\n# 6.2 Equipment\n\n## 6.2.1 Design and construction\n\nAll equipment should be designed and installed to suit its intended purpose and should not present any hazard to donors, personnel or blood components. It should allow for effective cleaning, and disinfection is recommended for all surfaces in direct contact with the bag system.\n\nEquipment should be located in a suitable position (e.g. a balance should be positioned on a suitable even surface) where there is no negative impact from the surrounding environment (e.g. direct sunlight may have an impact on optical instruments such as apheresis systems or balances).\n\n## 6.2.2 Maintenance\n\nMaintenance, cleaning and calibration should be performed regularly and should be recorded. Maintenance of equipment should be carried out at intervals according to a documented schedule.\n\nThe maintenance programmes should be established on the basis of qualification activities. The intervals should be defined according to the instructions of the manufacturer of the equipment. Where intervals are not defined by the equipment manufacturer, maintenance should be carried out at least annually. Different intervals may be defined on the basis of a risk.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8b02e23266c8a9c160f8287bf25a6b19b2ad8f8f03be7aaad4ed81d6502fb0d0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.1.6 Mobile collection sites\n\nPremises for mobile collection sites should be adequate in design for the conduct of operations and should allow for the logical flow of staff, donors, and products in order to minimize the risk of errors. The blood collection at mobile sites should be planned thoroughly. Ancillary areas (rest and refreshment rooms) should be separated from donation or storage areas, but observation of donors during post-donation refreshment should still be ensured.\n\nBefore premises are accepted for mobile donor sessions their suitability should be assessed against the following criteria:\n\n- Sufficient size to allow proper operation and ensure donor privacy;\n- Safety for staff and donors;\n- Ventilation, electrical supply, lighting, hand-washing facilities, reliable communication, sufficient space for blood storage and transport, and suitable temperature conditions.\n\nEach site should have an approved plan that details the site layout. The set-up of the mobile collection site should be carried out according to the approved plan.\n\n# 6.2 Equipment\n\n## 6.2.1 Design and construction\n\nAll equipment should be designed and installed to suit its intended purpose and should not present any hazard to donors, personnel or blood components. It should allow for effective cleaning, and disinfection is recommended for all surfaces in direct contact with the bag system.\n\nEquipment should be located in a suitable position (e.g. a balance should be positioned on a suitable even surface) where there is no negative impact from the surrounding environment (e.g. direct sunlight may have an impact on optical instruments such as apheresis systems or balances).\n\n## 6.2.2 Maintenance\n\nMaintenance, cleaning and calibration should be performed regularly and should be recorded. Maintenance of equipment should be carried out at intervals according to a documented schedule.\n\nThe maintenance programmes should be established on the basis of qualification activities. The intervals should be defined according to the instructions of the manufacturer of the equipment. Where intervals are not defined by the equipment manufacturer, maintenance should be carried out at least annually. Different intervals may be defined on the basis of a risk.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2256, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a09e834a-3f48-42bb-a8b4-20b0fc211d65": {"__data__": {"id_": "a09e834a-3f48-42bb-a8b4-20b0fc211d65", "embedding": null, "metadata": {"page_label": "186", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "If no regular maintenance activities are recommended by the manufacturer, at least a functional control should be performed according to documented procedures. All maintenance activities should be documented. The maintenance reports of external technical services should be checked and countersigned by the staff of the blood establishment in order to decide if action needs to be taken as a result of the maintenance outcome. The maintenance documents should include sufficient information to determine what types of checks have been performed.\n\nMaintenance should also be carried out on equipment that is not in regular use, including back-up systems.\n\nInstructions for use, maintenance, service, cleaning and sanitization should be available in a language that is understood by the user. There should be written procedures for each type of equipment, detailing the actions to be taken when malfunctions or failures occur. Defective equipment, or equipment that is not in service, should be clearly labelled and if possible removed from the working area.\n\nThe maintenance of sterile connecting devices should include a check of the tensile strength. Furthermore, as it is a very critical piece of equipment, there should be regular functional checks of the integrity of the tubing weld.\n\nIn general, functional tests should also be considered for other pieces of equipment \u2014 such as balances before use after they have been moved or transported to a mobile site.\n\nA regular maintenance programme, including appropriate intervals, should be in place for all critical laboratory equipment or systems. A procedure should be implemented for releasing equipment after maintenance or intervention.\n\nIf the maintenance is contracted out (e.g. to the supplier) the work should be documented. Equipment should be evaluated to determine if it is still capable of expected performance prior to returning it to service for manufacturing blood components.\n\n### 6.2.3 Cleaning\n\nCleaning procedures should be established and described in a standard operating procedure. Cleaning of equipment should take into consideration the instructions of the manufacturer. A schedule for regular cleaning and disinfection, if necessary, is recommended for all surfaces with direct contact with the bag system (e.g. centrifuge, separator, storage shelves).\n\nDisinfectant solutions with sufficient and approved antimicrobial activity should be used. A cleaning plan should be established that specifies the cleaning intervals and methods to be used for the different equipment and surfaces.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mantenimiento de Equipos**: El documento establece la importancia de realizar controles funcionales y documentar todas las actividades de mantenimiento en equipos de laboratorio, especialmente en aquellos utilizados en la recolecci\u00f3n y procesamiento de componentes sangu\u00edneos. Se enfatiza la necesidad de mantener un programa de mantenimiento regular y de evaluar el rendimiento del equipo antes de su reingreso al servicio.\n\n2. **Limpieza y Desinfecci\u00f3n**: Se subraya la necesidad de establecer procedimientos de limpieza claros y programados para equipos que entran en contacto directo con sistemas de bolsas. Se recomienda el uso de soluciones desinfectantes aprobadas y un plan de limpieza que detalle los intervalos y m\u00e9todos a seguir.\n\n3. **Instrucciones y Procedimientos**: El documento destaca la importancia de tener instrucciones de uso y mantenimiento disponibles en un idioma comprensible para los usuarios, as\u00ed como la necesidad de etiquetar claramente el equipo defectuoso y establecer procedimientos para abordar fallas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para las actividades de mantenimiento de equipos en un establecimiento de sangre?**\n   - Se requiere que todas las actividades de mantenimiento est\u00e9n documentadas, incluyendo informes de servicios t\u00e9cnicos externos que deben ser revisados y contrasignados por el personal del establecimiento de sangre. Adem\u00e1s, los documentos de mantenimiento deben incluir informaci\u00f3n suficiente sobre los tipos de controles realizados.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el mantenimiento de dispositivos de conexi\u00f3n est\u00e9riles?**\n   - El mantenimiento de dispositivos de conexi\u00f3n est\u00e9riles debe incluir una verificaci\u00f3n de la resistencia a la tracci\u00f3n y realizar controles funcionales regulares de la integridad de la soldadura de los tubos, dado que son equipos cr\u00edticos.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un plan de limpieza para equipos en contacto con sistemas de bolsas?**\n   - Un plan de limpieza debe especificar los intervalos y m\u00e9todos de limpieza para los diferentes equipos y superficies, asegurando que se utilicen soluciones desinfectantes con actividad antimicrobiana suficiente y aprobada, y que se sigan las instrucciones del fabricante para la limpieza y desinfecci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Dise\u00f1o de Sitios de Recolecci\u00f3n M\u00f3vil**:\n   - Importancia de un dise\u00f1o adecuado para facilitar operaciones y minimizar errores.\n   - Separaci\u00f3n de \u00e1reas auxiliares (descanso y refrigerio) de las \u00e1reas de donaci\u00f3n y almacenamiento.\n\n2. **Criterios de Aceptaci\u00f3n de Locales**:\n   - Tama\u00f1o suficiente para operaci\u00f3n y privacidad del donante.\n   - Seguridad para el personal y donantes.\n   - Condiciones ambientales adecuadas: ventilaci\u00f3n, suministro el\u00e9ctrico, iluminaci\u00f3n, instalaciones de lavado de manos, comunicaci\u00f3n confiable, espacio para almacenamiento y transporte de sangre, y temperatura adecuada.\n\n3. **Planificaci\u00f3n y Configuraci\u00f3n**:\n   - Cada sitio debe tener un plan aprobado que detalle la disposici\u00f3n del lugar.\n   - La configuraci\u00f3n debe seguir el plan aprobado.\n\n4. **Equipamiento**:\n   - Dise\u00f1o y construcci\u00f3n del equipo para su prop\u00f3sito espec\u00edfico, sin riesgos para donantes o personal.\n   - Necesidad de limpieza efectiva y desinfecci\u00f3n de superficies en contacto con el sistema de bolsas.\n\n5. **Mantenimiento del Equipo**:\n   - Mantenimiento, limpieza y calibraci\u00f3n deben realizarse regularmente y registrarse.\n   - Programas de mantenimiento basados en actividades de calificaci\u00f3n y seg\u00fan instrucciones del fabricante.\n   - Mantenimiento al menos una vez al a\u00f1o si no hay intervalos definidos, con posibilidad de establecer diferentes intervalos seg\u00fan el riesgo.\n\n### Entidades:\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Componentes**: Donantes, personal, equipos de recolecci\u00f3n de sangre, \u00e1reas de descanso y refrigerio, instalaciones de lavado de manos.\n- **Condiciones**: Tama\u00f1o, seguridad, ventilaci\u00f3n, iluminaci\u00f3n, comunicaci\u00f3n, almacenamiento y transporte de sangre, temperatura. \n\nEste resumen abarca los aspectos esenciales sobre la operaci\u00f3n y mantenimiento de sitios de recolecci\u00f3n m\u00f3vil de sangre, as\u00ed como las consideraciones de dise\u00f1o y seguridad necesarias para proteger a donantes y personal.", "excerpt_keywords": "Keywords: maintenance, cleaning, blood establishment, equipment, procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3e41021e-cd49-4fed-840e-5589c34d2645", "node_type": "4", "metadata": {"page_label": "186", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "If no regular maintenance activities are recommended by the manufacturer, at least a functional control should be performed according to documented procedures. All maintenance activities should be documented. The maintenance reports of external technical services should be checked and countersigned by the staff of the blood establishment in order to decide if action needs to be taken as a result of the maintenance outcome. The maintenance documents should include sufficient information to determine what types of checks have been performed.\n\nMaintenance should also be carried out on equipment that is not in regular use, including back-up systems.\n\nInstructions for use, maintenance, service, cleaning and sanitization should be available in a language that is understood by the user. There should be written procedures for each type of equipment, detailing the actions to be taken when malfunctions or failures occur. Defective equipment, or equipment that is not in service, should be clearly labelled and if possible removed from the working area.\n\nThe maintenance of sterile connecting devices should include a check of the tensile strength. Furthermore, as it is a very critical piece of equipment, there should be regular functional checks of the integrity of the tubing weld.\n\nIn general, functional tests should also be considered for other pieces of equipment \u2014 such as balances before use after they have been moved or transported to a mobile site.\n\nA regular maintenance programme, including appropriate intervals, should be in place for all critical laboratory equipment or systems. A procedure should be implemented for releasing equipment after maintenance or intervention.\n\nIf the maintenance is contracted out (e.g. to the supplier) the work should be documented. Equipment should be evaluated to determine if it is still capable of expected performance prior to returning it to service for manufacturing blood components.\n\n### 6.2.3 Cleaning\n\nCleaning procedures should be established and described in a standard operating procedure. Cleaning of equipment should take into consideration the instructions of the manufacturer. A schedule for regular cleaning and disinfection, if necessary, is recommended for all surfaces with direct contact with the bag system (e.g. centrifuge, separator, storage shelves).\n\nDisinfectant solutions with sufficient and approved antimicrobial activity should be used. A cleaning plan should be established that specifies the cleaning intervals and methods to be used for the different equipment and surfaces.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f25d4681e409d062aa5184fff89757262aabd5b6513242c16683a79da3c256a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "If no regular maintenance activities are recommended by the manufacturer, at least a functional control should be performed according to documented procedures. All maintenance activities should be documented. The maintenance reports of external technical services should be checked and countersigned by the staff of the blood establishment in order to decide if action needs to be taken as a result of the maintenance outcome. The maintenance documents should include sufficient information to determine what types of checks have been performed.\n\nMaintenance should also be carried out on equipment that is not in regular use, including back-up systems.\n\nInstructions for use, maintenance, service, cleaning and sanitization should be available in a language that is understood by the user. There should be written procedures for each type of equipment, detailing the actions to be taken when malfunctions or failures occur. Defective equipment, or equipment that is not in service, should be clearly labelled and if possible removed from the working area.\n\nThe maintenance of sterile connecting devices should include a check of the tensile strength. Furthermore, as it is a very critical piece of equipment, there should be regular functional checks of the integrity of the tubing weld.\n\nIn general, functional tests should also be considered for other pieces of equipment \u2014 such as balances before use after they have been moved or transported to a mobile site.\n\nA regular maintenance programme, including appropriate intervals, should be in place for all critical laboratory equipment or systems. A procedure should be implemented for releasing equipment after maintenance or intervention.\n\nIf the maintenance is contracted out (e.g. to the supplier) the work should be documented. Equipment should be evaluated to determine if it is still capable of expected performance prior to returning it to service for manufacturing blood components.\n\n### 6.2.3 Cleaning\n\nCleaning procedures should be established and described in a standard operating procedure. Cleaning of equipment should take into consideration the instructions of the manufacturer. A schedule for regular cleaning and disinfection, if necessary, is recommended for all surfaces with direct contact with the bag system (e.g. centrifuge, separator, storage shelves).\n\nDisinfectant solutions with sufficient and approved antimicrobial activity should be used. A cleaning plan should be established that specifies the cleaning intervals and methods to be used for the different equipment and surfaces.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2563, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1878db4f-8044-44a1-94df-fc895e491433": {"__data__": {"id_": "1878db4f-8044-44a1-94df-fc895e491433", "embedding": null, "metadata": {"page_label": "187", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.2.4 Calibration\n\nMeasuring instruments and measuring systems used for the collection and further separation of blood and for quality control testing should be calibrated regularly according to the instructions of the manufacturer. Calibration should be carried out and documented according to established standard operating procedures and national regulations. Regular calibration is necessary for temperature probes (e.g. in refrigerators), pipettes, balances, timing devices and haemoglobinometer devices (using control blood and/or cuvettes from the manufacturer). The devices used for calibration, such as the control weight used for the calibration of balances, should be certified for accuracy (by testing against a known standard). If the calibration consists of using a comparison measurement approach with a second device, then the maximum allowed deviation between the two measurements should be defined.\n\n# 6.3 Computerized systems\n\nA computerized system may be described as a functional unit consisting of one or more computers and associated peripheral input and output devices, and associated software that uses common storage for all or part of a programme and for all parts of the data necessary for the execution of the programme (9). A computerized system executes user-written or user-designated programmes, performs user-designated data manipulation (including arithmetic operations and logic operations), and it can execute programmes that modify themselves during their execution. A computer system may be a stand-alone unit or may consist of several interconnected units.\n\nHardware and software should be protected against unauthorized use or changes.\n\nCritical computerized systems should be validated before use. The system is considered critical if:\n\n\u2014 it is directly linked to the decision-making process for blood product manufacturing, blood or blood product testing (donor/recipient), labelling and release;\n\u2014 it is used to handle or manipulate the related information;\n\u2014 it has an impact on product quality, information management, storage, or tools for operational decision-making and control.\n\nPeriodic revalidation or annual checks to ensure reliability should be performed on the basis of a risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Calibraci\u00f3n de Instrumentos**: La calibraci\u00f3n regular de instrumentos y sistemas de medici\u00f3n utilizados en la recolecci\u00f3n y separaci\u00f3n de sangre, as\u00ed como en pruebas de control de calidad, es esencial para garantizar la precisi\u00f3n y fiabilidad de los resultados. Esto incluye la calibraci\u00f3n de dispositivos como sondas de temperatura, pipetas y balances, siguiendo procedimientos operativos est\u00e1ndar y regulaciones nacionales.\n\n2. **Sistemas Computarizados**: Los sistemas computarizados son unidades funcionales que incluyen computadoras y dispositivos perif\u00e9ricos, junto con software que gestiona datos y programas. Es crucial validar estos sistemas, especialmente aquellos que impactan en la calidad del producto y en la toma de decisiones operativas relacionadas con la sangre y productos sangu\u00edneos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de dispositivos requieren calibraci\u00f3n regular seg\u00fan el documento y cu\u00e1les son los procedimientos recomendados para llevar a cabo esta calibraci\u00f3n?**\n   - Respuesta: Los dispositivos que requieren calibraci\u00f3n regular incluyen sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n y hemoglobinom\u00e9tricos. La calibraci\u00f3n debe realizarse y documentarse de acuerdo con procedimientos operativos est\u00e1ndar establecidos y regulaciones nacionales.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas que definen un sistema computarizado cr\u00edtico en el contexto de la fabricaci\u00f3n y prueba de productos sangu\u00edneos?**\n   - Respuesta: Un sistema computarizado se considera cr\u00edtico si est\u00e1 directamente vinculado al proceso de toma de decisiones para la fabricaci\u00f3n de productos sangu\u00edneos, pruebas de sangre o productos sangu\u00edneos (donante/receptor), etiquetado y liberaci\u00f3n; si se utiliza para manejar o manipular informaci\u00f3n relacionada; o si tiene un impacto en la calidad del producto, gesti\u00f3n de informaci\u00f3n, almacenamiento o herramientas para la toma de decisiones operativas y control.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para proteger el hardware y software de un sistema computarizado en el contexto de la recolecci\u00f3n y prueba de sangre?**\n   - Respuesta: El hardware y software deben ser protegidos contra el uso no autorizado o cambios. Adem\u00e1s, los sistemas computarizados cr\u00edticos deben ser validados antes de su uso y deben someterse a revalidaciones peri\u00f3dicas o chequeos anuales basados en una evaluaci\u00f3n de riesgos para asegurar su fiabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Equipos**:\n   - Importancia de realizar controles funcionales y documentar todas las actividades de mantenimiento.\n   - Evaluaci\u00f3n del rendimiento del equipo antes de su reingreso al servicio.\n   - Mantenimiento de equipos no utilizados y sistemas de respaldo.\n   - Documentaci\u00f3n de informes de servicios t\u00e9cnicos externos, que deben ser revisados y contrasignados por el personal del establecimiento de sangre.\n\n2. **Limpieza y Desinfecci\u00f3n**:\n   - Establecimiento de procedimientos de limpieza claros en un documento de procedimientos operativos est\u00e1ndar.\n   - Programaci\u00f3n de limpieza y desinfecci\u00f3n para superficies en contacto con sistemas de bolsas.\n   - Uso de soluciones desinfectantes aprobadas con actividad antimicrobiana suficiente.\n\n3. **Instrucciones y Procedimientos**:\n   - Disponibilidad de instrucciones de uso y mantenimiento en un idioma comprensible para los usuarios.\n   - Etiquetado claro de equipos defectuosos y procedimientos para abordar fallas.\n\n4. **Dispositivos de Conexi\u00f3n Est\u00e9riles**:\n   - Verificaci\u00f3n de la resistencia a la tracci\u00f3n y controles funcionales regulares de la integridad de la soldadura de los tubos.\n\n5. **Plan de Limpieza**:\n   - Especificaci\u00f3n de intervalos y m\u00e9todos de limpieza para diferentes equipos y superficies.\n\n### Entidades Clave\n- **Equipos de Laboratorio**: Incluye dispositivos de conexi\u00f3n est\u00e9riles, balances, centrifugadoras, separadores, estantes de almacenamiento.\n- **Establecimientos de Sangre**: Personal responsable de la revisi\u00f3n y contrasignaci\u00f3n de informes de mantenimiento.\n- **Soluciones Desinfectantes**: Deben tener actividad antimicrobiana aprobada.\n- **Documentaci\u00f3n**: Informes de mantenimiento, procedimientos operativos est\u00e1ndar, planes de limpieza. \n\nEste resumen destaca la importancia de un mantenimiento adecuado y documentado, as\u00ed como la limpieza y desinfecci\u00f3n de equipos cr\u00edticos en el contexto de la recolecci\u00f3n y procesamiento de componentes sangu\u00edneos.", "excerpt_keywords": "Keywords: calibration, computerized systems, blood collection, quality control, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d5133d2-49e4-46d9-8302-26ecc58bb2a4", "node_type": "4", "metadata": {"page_label": "187", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.2.4 Calibration\n\nMeasuring instruments and measuring systems used for the collection and further separation of blood and for quality control testing should be calibrated regularly according to the instructions of the manufacturer. Calibration should be carried out and documented according to established standard operating procedures and national regulations. Regular calibration is necessary for temperature probes (e.g. in refrigerators), pipettes, balances, timing devices and haemoglobinometer devices (using control blood and/or cuvettes from the manufacturer). The devices used for calibration, such as the control weight used for the calibration of balances, should be certified for accuracy (by testing against a known standard). If the calibration consists of using a comparison measurement approach with a second device, then the maximum allowed deviation between the two measurements should be defined.\n\n# 6.3 Computerized systems\n\nA computerized system may be described as a functional unit consisting of one or more computers and associated peripheral input and output devices, and associated software that uses common storage for all or part of a programme and for all parts of the data necessary for the execution of the programme (9). A computerized system executes user-written or user-designated programmes, performs user-designated data manipulation (including arithmetic operations and logic operations), and it can execute programmes that modify themselves during their execution. A computer system may be a stand-alone unit or may consist of several interconnected units.\n\nHardware and software should be protected against unauthorized use or changes.\n\nCritical computerized systems should be validated before use. The system is considered critical if:\n\n\u2014 it is directly linked to the decision-making process for blood product manufacturing, blood or blood product testing (donor/recipient), labelling and release;\n\u2014 it is used to handle or manipulate the related information;\n\u2014 it has an impact on product quality, information management, storage, or tools for operational decision-making and control.\n\nPeriodic revalidation or annual checks to ensure reliability should be performed on the basis of a risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3e5306850d156e20caca17877de7f9df6835b6eb3c3281875e1cb96df4359a07", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.2.4 Calibration\n\nMeasuring instruments and measuring systems used for the collection and further separation of blood and for quality control testing should be calibrated regularly according to the instructions of the manufacturer. Calibration should be carried out and documented according to established standard operating procedures and national regulations. Regular calibration is necessary for temperature probes (e.g. in refrigerators), pipettes, balances, timing devices and haemoglobinometer devices (using control blood and/or cuvettes from the manufacturer). The devices used for calibration, such as the control weight used for the calibration of balances, should be certified for accuracy (by testing against a known standard). If the calibration consists of using a comparison measurement approach with a second device, then the maximum allowed deviation between the two measurements should be defined.\n\n# 6.3 Computerized systems\n\nA computerized system may be described as a functional unit consisting of one or more computers and associated peripheral input and output devices, and associated software that uses common storage for all or part of a programme and for all parts of the data necessary for the execution of the programme (9). A computerized system executes user-written or user-designated programmes, performs user-designated data manipulation (including arithmetic operations and logic operations), and it can execute programmes that modify themselves during their execution. A computer system may be a stand-alone unit or may consist of several interconnected units.\n\nHardware and software should be protected against unauthorized use or changes.\n\nCritical computerized systems should be validated before use. The system is considered critical if:\n\n\u2014 it is directly linked to the decision-making process for blood product manufacturing, blood or blood product testing (donor/recipient), labelling and release;\n\u2014 it is used to handle or manipulate the related information;\n\u2014 it has an impact on product quality, information management, storage, or tools for operational decision-making and control.\n\nPeriodic revalidation or annual checks to ensure reliability should be performed on the basis of a risk assessment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2246, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f5d1f4cc-f430-468b-9eb2-e7ed7be228f1": {"__data__": {"id_": "f5d1f4cc-f430-468b-9eb2-e7ed7be228f1", "embedding": null, "metadata": {"page_label": "188", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "There should be procedures for each type of software and hardware, detailing the action to be taken when malfunctions or failures occur. A back-up procedure should be in place to prevent loss of records in case of expected or unexpected downtime or function failures. The archival and retrieval process should be validated to ensure the accuracy of the stored and retrieved data.\n\nOnce in routine operation, critical computer systems should be maintained in a validated state. Any change should be handled through the formal change control system which includes qualification and/or validation activities. Applicable documentation should be revised and personnel should be trained before the change is introduced into routine use. Any software updates should be evaluated in advance and there should be procedures to validate or verify the acceptability of the update installation.\n\nThe manual entry of critical data, such as laboratory test results, should require independent verification and release by a second person. When a computerized system is used, an audit trail should be guaranteed.\n\n# 7. Qualification and validation\n\n## 7.1 Qualification of equipment\n\nAll equipment should be qualified and used in accordance with validated procedures.\n\nNew and repaired equipment should meet qualification requirements when installed and should be authorized before use. Qualification results should be documented.\n\nThe extent of qualification depends on the critical nature and complexity of the equipment. For some equipment, installation qualification and calibration may be sufficient. More complex equipment may need a more thorough approach to qualification and validation and should include the instruments, the associated operation(s) and the software involved.\n\nFurther guidance on qualification and validation is given in the WHO guidelines on validation (10) and in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) *Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation* (11).\n\n## 7.2 Validation of manufacturing processes\n\nAll critical processes in the manufacture of blood and blood components should be validated before implementation according to a predefined protocol of tests and acceptance criteria. Critical processes include donor", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre la calificaci\u00f3n y validaci\u00f3n de equipos y procesos cr\u00edticos en la fabricaci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de tener procedimientos establecidos para el manejo de fallos en software y hardware, as\u00ed como la necesidad de mantener sistemas inform\u00e1ticos en un estado validado. Se requiere que todos los equipos sean calificados y que los procesos cr\u00edticos sean validados antes de su implementaci\u00f3n, siguiendo protocolos espec\u00edficos. Adem\u00e1s, se menciona la importancia de la verificaci\u00f3n independiente de datos cr\u00edticos y la existencia de un rastro de auditor\u00eda en sistemas computarizados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar fallos en software y hardware seg\u00fan el documento?**\n   - El documento indica que deben existir procedimientos detallados para cada tipo de software y hardware, que incluyan acciones a tomar en caso de malfunciones o fallos. Tambi\u00e9n se debe tener un procedimiento de respaldo para prevenir la p\u00e9rdida de registros.\n\n2. **\u00bfC\u00f3mo se determina la extensi\u00f3n de la calificaci\u00f3n de un equipo?**\n   - La extensi\u00f3n de la calificaci\u00f3n depende de la naturaleza cr\u00edtica y la complejidad del equipo. Para algunos equipos, puede ser suficiente la calificaci\u00f3n de instalaci\u00f3n y calibraci\u00f3n, mientras que equipos m\u00e1s complejos requieren un enfoque m\u00e1s exhaustivo que incluya instrumentos, operaciones asociadas y el software involucrado.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la validaci\u00f3n de procesos cr\u00edticos en la fabricaci\u00f3n de componentes sangu\u00edneos?**\n   - Todos los procesos cr\u00edticos en la fabricaci\u00f3n de sangre y componentes sangu\u00edneos deben ser validados antes de su implementaci\u00f3n, siguiendo un protocolo predefinido de pruebas y criterios de aceptaci\u00f3n. Esto asegura que los procesos cumplan con los est\u00e1ndares necesarios para garantizar la calidad y seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calibraci\u00f3n de Instrumentos**:\n   - **Importancia**: La calibraci\u00f3n regular de instrumentos y sistemas de medici\u00f3n es esencial para asegurar la precisi\u00f3n y fiabilidad en la recolecci\u00f3n y separaci\u00f3n de sangre, as\u00ed como en las pruebas de control de calidad.\n   - **Dispositivos que requieren calibraci\u00f3n**: Sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n y hemoglobinom\u00e9tricos.\n   - **Procedimientos**: La calibraci\u00f3n debe seguir las instrucciones del fabricante y documentarse conforme a procedimientos operativos est\u00e1ndar y regulaciones nacionales. Se deben utilizar dispositivos certificados para la calibraci\u00f3n.\n\n2. **Sistemas Computarizados**:\n   - **Definici\u00f3n**: Un sistema computarizado es una unidad funcional que incluye computadoras, dispositivos perif\u00e9ricos y software que gestiona datos y programas.\n   - **Caracter\u00edsticas de sistemas cr\u00edticos**: Se consideran cr\u00edticos aquellos sistemas que impactan en la toma de decisiones sobre la fabricaci\u00f3n de productos sangu\u00edneos, pruebas de sangre, etiquetado y liberaci\u00f3n, as\u00ed como en la gesti\u00f3n de informaci\u00f3n y calidad del producto.\n   - **Protecci\u00f3n y validaci\u00f3n**: El hardware y software deben estar protegidos contra el uso no autorizado. Los sistemas cr\u00edticos deben ser validados antes de su uso y revalidados peri\u00f3dicamente bas\u00e1ndose en evaluaciones de riesgo.\n\n### Entidades Clave\n- **Instrumentos de Medici\u00f3n**: Sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n, hemoglobinom\u00e9tricos.\n- **Sistemas Computarizados**: Unidades funcionales que incluyen hardware y software para la gesti\u00f3n de datos.\n- **Regulaciones**: Procedimientos operativos est\u00e1ndar y regulaciones nacionales que gu\u00edan la calibraci\u00f3n y validaci\u00f3n de sistemas.", "excerpt_keywords": "Keywords: qualification, validation, critical processes, software procedures, blood components"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6e339d98-3710-45ca-b1f2-297c69024dd0", "node_type": "4", "metadata": {"page_label": "188", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "There should be procedures for each type of software and hardware, detailing the action to be taken when malfunctions or failures occur. A back-up procedure should be in place to prevent loss of records in case of expected or unexpected downtime or function failures. The archival and retrieval process should be validated to ensure the accuracy of the stored and retrieved data.\n\nOnce in routine operation, critical computer systems should be maintained in a validated state. Any change should be handled through the formal change control system which includes qualification and/or validation activities. Applicable documentation should be revised and personnel should be trained before the change is introduced into routine use. Any software updates should be evaluated in advance and there should be procedures to validate or verify the acceptability of the update installation.\n\nThe manual entry of critical data, such as laboratory test results, should require independent verification and release by a second person. When a computerized system is used, an audit trail should be guaranteed.\n\n# 7. Qualification and validation\n\n## 7.1 Qualification of equipment\n\nAll equipment should be qualified and used in accordance with validated procedures.\n\nNew and repaired equipment should meet qualification requirements when installed and should be authorized before use. Qualification results should be documented.\n\nThe extent of qualification depends on the critical nature and complexity of the equipment. For some equipment, installation qualification and calibration may be sufficient. More complex equipment may need a more thorough approach to qualification and validation and should include the instruments, the associated operation(s) and the software involved.\n\nFurther guidance on qualification and validation is given in the WHO guidelines on validation (10) and in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) *Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation* (11).\n\n## 7.2 Validation of manufacturing processes\n\nAll critical processes in the manufacture of blood and blood components should be validated before implementation according to a predefined protocol of tests and acceptance criteria. Critical processes include donor", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a818338bbfd36b0422b80051874ecafd611bc7d996e787b63b29f7c506f3714e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "There should be procedures for each type of software and hardware, detailing the action to be taken when malfunctions or failures occur. A back-up procedure should be in place to prevent loss of records in case of expected or unexpected downtime or function failures. The archival and retrieval process should be validated to ensure the accuracy of the stored and retrieved data.\n\nOnce in routine operation, critical computer systems should be maintained in a validated state. Any change should be handled through the formal change control system which includes qualification and/or validation activities. Applicable documentation should be revised and personnel should be trained before the change is introduced into routine use. Any software updates should be evaluated in advance and there should be procedures to validate or verify the acceptability of the update installation.\n\nThe manual entry of critical data, such as laboratory test results, should require independent verification and release by a second person. When a computerized system is used, an audit trail should be guaranteed.\n\n# 7. Qualification and validation\n\n## 7.1 Qualification of equipment\n\nAll equipment should be qualified and used in accordance with validated procedures.\n\nNew and repaired equipment should meet qualification requirements when installed and should be authorized before use. Qualification results should be documented.\n\nThe extent of qualification depends on the critical nature and complexity of the equipment. For some equipment, installation qualification and calibration may be sufficient. More complex equipment may need a more thorough approach to qualification and validation and should include the instruments, the associated operation(s) and the software involved.\n\nFurther guidance on qualification and validation is given in the WHO guidelines on validation (10) and in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) *Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation* (11).\n\n## 7.2 Validation of manufacturing processes\n\nAll critical processes in the manufacture of blood and blood components should be validated before implementation according to a predefined protocol of tests and acceptance criteria. Critical processes include donor", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2343, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7be22bce-e32c-4142-80bd-d05291c6fa24": {"__data__": {"id_": "7be22bce-e32c-4142-80bd-d05291c6fa24", "embedding": null, "metadata": {"page_label": "189", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Validation Studies and Test Systems\n\nValidation studies, including statistically based sampling where feasible, should be conducted to ensure that products are produced with consistent quality characteristics. Acceptance criteria should be based on a defined set of specifications for each blood component, including a set of quality control tests \u2014 such as measurement of weight respective to volume, residual blood cells (depending on product specifications), haemoglobin, and relevant coagulation factors (e.g. Factor VIII) and/or total protein/IgG content where applicable \u2014 established by the blood establishment or the NRA (see also sections 9.4.3 and 9.6). Data should be available to ensure that the final product is able to meet specifications.\n\nLikewise, apheresis systems, including software, should be qualified and maintained. Apheresis procedures should be validated. Validation criteria with regard to the quality of blood components may, depending on the product, include weight, yield, content of residual white blood cells, haemoglobin and relevant coagulation factors. Validation studies of new apheresis procedures should also evaluate possible risks of activation of the coagulation, fibrinolysis, and complement systems potentially induced by the material in contact with blood. Such studies are usually performed by the manufacturer of the apheresis systems to support the licensing by the regulatory authorities.\n\n## 7.3 Choosing an Appropriate Test System to Screen for Infectious Disease\n\nThe quality of the screening of blood donations for markers of infection depends on a number of conditions being fulfilled:\n\n- Only test systems designed and validated for blood donor screening should be used. Other systems, such as tests validated for diagnostic purposes only, should not be used.\n- All test systems should be validated by the manufacturer.\n- Before implementing a test system for routine analysis, the laboratory should prove by validation that the manufacturer\u2019s specifications are met (in principle this also applies if in-house tests are used).\n- The laboratory should show that, on routine application of test systems, specified performance is reached and is consistently maintained.\n\nScreening of blood donations generally requires such test systems to aim for high sensitivity even though this may be achieved at the expense of specificity. Although this may result in an increased proportion of false-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior del Contexto\n\n1. **Importancia de los Estudios de Validaci\u00f3n**: Los estudios de validaci\u00f3n son esenciales para garantizar que los productos sangu\u00edneos se produzcan con caracter\u00edsticas de calidad consistentes. Esto incluye la realizaci\u00f3n de pruebas de control de calidad y la evaluaci\u00f3n de sistemas de af\u00e9resis.\n\n2. **Criterios de Aceptaci\u00f3n y Especificaciones**: Los criterios de aceptaci\u00f3n para los componentes sangu\u00edneos deben basarse en especificaciones definidas, que incluyen pruebas de calidad como el peso, los niveles de hemoglobina y factores de coagulaci\u00f3n.\n\n3. **Selecci\u00f3n de Sistemas de Prueba para Enfermedades Infecciosas**: La calidad del cribado de donaciones de sangre para marcadores de infecci\u00f3n depende de la utilizaci\u00f3n de sistemas de prueba dise\u00f1ados y validados espec\u00edficamente para este prop\u00f3sito, asegurando que se cumplan las especificaciones del fabricante.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas de control de calidad se deben realizar para cada componente sangu\u00edneo y qui\u00e9n establece estas especificaciones?**\n   - Las pruebas de control de calidad incluyen la medici\u00f3n del peso en relaci\u00f3n con el volumen, la cantidad de c\u00e9lulas sangu\u00edneas residuales, los niveles de hemoglobina y factores de coagulaci\u00f3n relevantes. Estas especificaciones son establecidas por el establecimiento de sangre o la autoridad reguladora nacional (NRA).\n\n2. **\u00bfCu\u00e1les son los riesgos potenciales que deben evaluarse durante los estudios de validaci\u00f3n de nuevos procedimientos de af\u00e9resis?**\n   - Los estudios de validaci\u00f3n deben evaluar los riesgos de activaci\u00f3n de la coagulaci\u00f3n, fibrinolisis y sistemas de complemento que pueden ser inducidos por el material en contacto con la sangre.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un sistema de prueba sea considerado adecuado para el cribado de donaciones de sangre?**\n   - Solo se deben utilizar sistemas de prueba dise\u00f1ados y validados para el cribado de donantes de sangre. Adem\u00e1s, todos los sistemas deben ser validados por el fabricante, y el laboratorio debe demostrar que se cumplen las especificaciones del fabricante antes de implementar el sistema para an\u00e1lisis rutinarios.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Procedimientos para Software y Hardware**:\n   - Se deben establecer procedimientos espec\u00edficos para cada tipo de software y hardware que detallen las acciones a tomar en caso de malfunciones o fallos.\n   - Es necesario contar con un procedimiento de respaldo para evitar la p\u00e9rdida de registros durante tiempos de inactividad.\n\n2. **Mantenimiento de Sistemas Cr\u00edticos**:\n   - Los sistemas inform\u00e1ticos cr\u00edticos deben mantenerse en un estado validado una vez que est\u00e9n en operaci\u00f3n rutinaria.\n   - Cualquier cambio en el sistema debe gestionarse a trav\u00e9s de un sistema formal de control de cambios que incluya actividades de calificaci\u00f3n y/o validaci\u00f3n.\n\n3. **Calificaci\u00f3n de Equipos**:\n   - Todos los equipos deben ser calificados y utilizados de acuerdo con procedimientos validados.\n   - La extensi\u00f3n de la calificaci\u00f3n depende de la naturaleza cr\u00edtica y complejidad del equipo, pudiendo requerir desde calificaci\u00f3n de instalaci\u00f3n y calibraci\u00f3n hasta un enfoque m\u00e1s exhaustivo.\n\n4. **Validaci\u00f3n de Procesos Cr\u00edticos**:\n   - Todos los procesos cr\u00edticos en la fabricaci\u00f3n de sangre y componentes sangu\u00edneos deben ser validados antes de su implementaci\u00f3n, siguiendo un protocolo predefinido de pruebas y criterios de aceptaci\u00f3n.\n\n5. **Verificaci\u00f3n Independiente de Datos**:\n   - La entrada manual de datos cr\u00edticos, como resultados de pruebas de laboratorio, debe ser verificada y liberada por una segunda persona.\n   - En sistemas computarizados, se debe garantizar un rastro de auditor\u00eda.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de las directrices.\n- **Pharmaceutical Inspection Co-operation Scheme (PIC/S)**: Proporciona recomendaciones sobre calificaci\u00f3n y validaci\u00f3n.\n- **Equipos Cr\u00edticos**: Equipos que requieren calificaci\u00f3n y validaci\u00f3n.\n- **Procesos de Fabricaci\u00f3n de Componentes Sangu\u00edneos**: Procesos que deben ser validados antes de su implementaci\u00f3n.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la fabricaci\u00f3n de componentes sangu\u00edneos y el manejo de sistemas inform\u00e1ticos cr\u00edticos.", "excerpt_keywords": "Keywords: validation studies, blood components, quality control, apheresis systems, infectious disease screening"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "caf6c1ed-369a-41e1-83b9-f67d1d0dcf44", "node_type": "4", "metadata": {"page_label": "189", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Validation Studies and Test Systems\n\nValidation studies, including statistically based sampling where feasible, should be conducted to ensure that products are produced with consistent quality characteristics. Acceptance criteria should be based on a defined set of specifications for each blood component, including a set of quality control tests \u2014 such as measurement of weight respective to volume, residual blood cells (depending on product specifications), haemoglobin, and relevant coagulation factors (e.g. Factor VIII) and/or total protein/IgG content where applicable \u2014 established by the blood establishment or the NRA (see also sections 9.4.3 and 9.6). Data should be available to ensure that the final product is able to meet specifications.\n\nLikewise, apheresis systems, including software, should be qualified and maintained. Apheresis procedures should be validated. Validation criteria with regard to the quality of blood components may, depending on the product, include weight, yield, content of residual white blood cells, haemoglobin and relevant coagulation factors. Validation studies of new apheresis procedures should also evaluate possible risks of activation of the coagulation, fibrinolysis, and complement systems potentially induced by the material in contact with blood. Such studies are usually performed by the manufacturer of the apheresis systems to support the licensing by the regulatory authorities.\n\n## 7.3 Choosing an Appropriate Test System to Screen for Infectious Disease\n\nThe quality of the screening of blood donations for markers of infection depends on a number of conditions being fulfilled:\n\n- Only test systems designed and validated for blood donor screening should be used. Other systems, such as tests validated for diagnostic purposes only, should not be used.\n- All test systems should be validated by the manufacturer.\n- Before implementing a test system for routine analysis, the laboratory should prove by validation that the manufacturer\u2019s specifications are met (in principle this also applies if in-house tests are used).\n- The laboratory should show that, on routine application of test systems, specified performance is reached and is consistently maintained.\n\nScreening of blood donations generally requires such test systems to aim for high sensitivity even though this may be achieved at the expense of specificity. Although this may result in an increased proportion of false-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2e119976e5c6554fcb2dedba9db021ce0f6430e73eaf6f5864198c365798c896", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Validation Studies and Test Systems\n\nValidation studies, including statistically based sampling where feasible, should be conducted to ensure that products are produced with consistent quality characteristics. Acceptance criteria should be based on a defined set of specifications for each blood component, including a set of quality control tests \u2014 such as measurement of weight respective to volume, residual blood cells (depending on product specifications), haemoglobin, and relevant coagulation factors (e.g. Factor VIII) and/or total protein/IgG content where applicable \u2014 established by the blood establishment or the NRA (see also sections 9.4.3 and 9.6). Data should be available to ensure that the final product is able to meet specifications.\n\nLikewise, apheresis systems, including software, should be qualified and maintained. Apheresis procedures should be validated. Validation criteria with regard to the quality of blood components may, depending on the product, include weight, yield, content of residual white blood cells, haemoglobin and relevant coagulation factors. Validation studies of new apheresis procedures should also evaluate possible risks of activation of the coagulation, fibrinolysis, and complement systems potentially induced by the material in contact with blood. Such studies are usually performed by the manufacturer of the apheresis systems to support the licensing by the regulatory authorities.\n\n## 7.3 Choosing an Appropriate Test System to Screen for Infectious Disease\n\nThe quality of the screening of blood donations for markers of infection depends on a number of conditions being fulfilled:\n\n- Only test systems designed and validated for blood donor screening should be used. Other systems, such as tests validated for diagnostic purposes only, should not be used.\n- All test systems should be validated by the manufacturer.\n- Before implementing a test system for routine analysis, the laboratory should prove by validation that the manufacturer\u2019s specifications are met (in principle this also applies if in-house tests are used).\n- The laboratory should show that, on routine application of test systems, specified performance is reached and is consistently maintained.\n\nScreening of blood donations generally requires such test systems to aim for high sensitivity even though this may be achieved at the expense of specificity. Although this may result in an increased proportion of false-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2444, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6a2b970e-3b22-487f-acd6-6c52437eb955": {"__data__": {"id_": "6a2b970e-3b22-487f-acd6-6c52437eb955", "embedding": null, "metadata": {"page_label": "190", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "positive results, it is important in ensuring that all components with true-positive test results are detected and not released. In case of new assays or techniques, precise specifications must be established by testing samples of appropriate populations (e.g. donors, recipients, seroconverted recipients) and by comparing the results generated by the existing test system and by the new one.\n\nValidation of a test system involves four main elements:\n\n\u2014 assay reagents which should include quality control material (e.g. positive quality control sample, negative quality control sample, calibrators);\n\u2014 equipment;\n\u2014 software, if applicable;\n\u2014 procedure and handling (test method).\n\nValidation records should not only present proof that the scope and desired specifications are met, but should also provide precise descriptions of all key material, key equipment and conditions of processing (e.g. temperature and time of incubation, rounds per minute in centrifugation). In addition, instructions for handling and processing, by which assay specifications are met, should be put in writing and should be provided with the test system.\n\nTest system specifications that need to be established and/or met by the manufacturer are:\n\n\u2014 specificity;\n\u2014 sensitivity;\n\u2014 accuracy (degree of closeness of measurements to the true value);\n\u2014 repeatability (replicates of series);\n\u2014 reproducibility (replicates of series, variation by operator, by day or by lot of reagents);\n\u2014 known interferences (e.g. haemolytic sera, lipemic sera);\n\u2014 lower and upper limits of detection (serial dilution).\n\nApart from testing appropriate donor/recipient populations, appropriate reference materials should be used to define the performance specifications of a test system. These reference materials should be traceable to the WHO international standard or reference reagents, when available for a specific marker.\n\nThe necessary documentation should be available for each test system and should include at least the following information:\n\n\u2014 a description of the test system (reagents, controls, devices etc.), equipment and diluents (if applicable);\n\u2014 safety instructions;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la validaci\u00f3n de sistemas de pruebas diagn\u00f3sticas, enfatizando la importancia de establecer especificaciones precisas para nuevos ensayos y t\u00e9cnicas. La validaci\u00f3n implica cuatro elementos principales: reactivos de ensayo, equipo, software (si aplica) y procedimientos de manejo. Se requiere documentaci\u00f3n exhaustiva que incluya descripciones del sistema de prueba, instrucciones de seguridad y especificaciones de rendimiento como especificidad, sensibilidad y l\u00edmites de detecci\u00f3n.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los cuatro elementos principales involucrados en la validaci\u00f3n de un sistema de pruebas seg\u00fan el documento de la OMS?**\n   - Respuesta: Los cuatro elementos principales son: reactivos de ensayo (incluyendo material de control de calidad), equipo, software (si aplica) y procedimiento y manejo (m\u00e9todo de prueba).\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para cada sistema de prueba y qu\u00e9 informaci\u00f3n debe incluir?**\n   - Respuesta: La documentaci\u00f3n necesaria debe incluir al menos una descripci\u00f3n del sistema de prueba (reactivos, controles, dispositivos, etc.), equipo y diluyentes (si aplica), as\u00ed como instrucciones de seguridad.\n\n3. **\u00bfQu\u00e9 especificaciones de rendimiento deben establecerse y/o cumplirse por el fabricante de un sistema de prueba?**\n   - Respuesta: Las especificaciones de rendimiento que deben establecerse incluyen: especificidad, sensibilidad, precisi\u00f3n, repetibilidad, reproducibilidad, interferencias conocidas y l\u00edmites inferior y superior de detecci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia de los Estudios de Validaci\u00f3n**: Los estudios de validaci\u00f3n son cruciales para asegurar que los productos sangu\u00edneos mantengan caracter\u00edsticas de calidad consistentes. Esto incluye la realizaci\u00f3n de pruebas de control de calidad y la validaci\u00f3n de procedimientos de af\u00e9resis.\n\n2. **Criterios de Aceptaci\u00f3n y Especificaciones**: Los criterios de aceptaci\u00f3n para los componentes sangu\u00edneos deben basarse en especificaciones definidas, que incluyen pruebas de calidad como el peso, los niveles de hemoglobina y factores de coagulaci\u00f3n.\n\n3. **Selecci\u00f3n de Sistemas de Prueba para Enfermedades Infecciosas**: La calidad del cribado de donaciones de sangre para marcadores de infecci\u00f3n depende de la utilizaci\u00f3n de sistemas de prueba dise\u00f1ados y validados espec\u00edficamente para este prop\u00f3sito, asegurando que se cumplan las especificaciones del fabricante.\n\n### Entidades\n\n- **Establecimiento de Sangre**: Entidad responsable de establecer especificaciones para los componentes sangu\u00edneos.\n- **Autoridad Reguladora Nacional (NRA)**: Entidad que puede establecer criterios de aceptaci\u00f3n y supervisar la calidad de los productos sangu\u00edneos.\n- **Sistemas de Af\u00e9resis**: Equipos y procedimientos utilizados para la recolecci\u00f3n de componentes sangu\u00edneos, que deben ser validados y mantenidos.\n- **Sistemas de Prueba**: Herramientas utilizadas para el cribado de donaciones de sangre, que deben ser dise\u00f1adas y validadas espec\u00edficamente para este fin.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de realizar estudios de validaci\u00f3n para garantizar la calidad de los productos sangu\u00edneos y la importancia de establecer criterios de aceptaci\u00f3n basados en especificaciones definidas. Tambi\u00e9n se enfatiza la validaci\u00f3n de sistemas de af\u00e9resis y la selecci\u00f3n de sistemas de prueba adecuados para el cribado de donaciones de sangre, asegurando que estos sistemas sean dise\u00f1ados y validados espec\u00edficamente para su uso en este contexto.", "excerpt_keywords": "Keywords: validation, test system, specifications, quality control, performance standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b57526c7-0e92-41bc-95e7-360a47327ef1", "node_type": "4", "metadata": {"page_label": "190", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "positive results, it is important in ensuring that all components with true-positive test results are detected and not released. In case of new assays or techniques, precise specifications must be established by testing samples of appropriate populations (e.g. donors, recipients, seroconverted recipients) and by comparing the results generated by the existing test system and by the new one.\n\nValidation of a test system involves four main elements:\n\n\u2014 assay reagents which should include quality control material (e.g. positive quality control sample, negative quality control sample, calibrators);\n\u2014 equipment;\n\u2014 software, if applicable;\n\u2014 procedure and handling (test method).\n\nValidation records should not only present proof that the scope and desired specifications are met, but should also provide precise descriptions of all key material, key equipment and conditions of processing (e.g. temperature and time of incubation, rounds per minute in centrifugation). In addition, instructions for handling and processing, by which assay specifications are met, should be put in writing and should be provided with the test system.\n\nTest system specifications that need to be established and/or met by the manufacturer are:\n\n\u2014 specificity;\n\u2014 sensitivity;\n\u2014 accuracy (degree of closeness of measurements to the true value);\n\u2014 repeatability (replicates of series);\n\u2014 reproducibility (replicates of series, variation by operator, by day or by lot of reagents);\n\u2014 known interferences (e.g. haemolytic sera, lipemic sera);\n\u2014 lower and upper limits of detection (serial dilution).\n\nApart from testing appropriate donor/recipient populations, appropriate reference materials should be used to define the performance specifications of a test system. These reference materials should be traceable to the WHO international standard or reference reagents, when available for a specific marker.\n\nThe necessary documentation should be available for each test system and should include at least the following information:\n\n\u2014 a description of the test system (reagents, controls, devices etc.), equipment and diluents (if applicable);\n\u2014 safety instructions;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2c4c47fcd28eb1c62b700141945035ed19ce55c664481dfe65c0a32e82febc56", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "positive results, it is important in ensuring that all components with true-positive test results are detected and not released. In case of new assays or techniques, precise specifications must be established by testing samples of appropriate populations (e.g. donors, recipients, seroconverted recipients) and by comparing the results generated by the existing test system and by the new one.\n\nValidation of a test system involves four main elements:\n\n\u2014 assay reagents which should include quality control material (e.g. positive quality control sample, negative quality control sample, calibrators);\n\u2014 equipment;\n\u2014 software, if applicable;\n\u2014 procedure and handling (test method).\n\nValidation records should not only present proof that the scope and desired specifications are met, but should also provide precise descriptions of all key material, key equipment and conditions of processing (e.g. temperature and time of incubation, rounds per minute in centrifugation). In addition, instructions for handling and processing, by which assay specifications are met, should be put in writing and should be provided with the test system.\n\nTest system specifications that need to be established and/or met by the manufacturer are:\n\n\u2014 specificity;\n\u2014 sensitivity;\n\u2014 accuracy (degree of closeness of measurements to the true value);\n\u2014 repeatability (replicates of series);\n\u2014 reproducibility (replicates of series, variation by operator, by day or by lot of reagents);\n\u2014 known interferences (e.g. haemolytic sera, lipemic sera);\n\u2014 lower and upper limits of detection (serial dilution).\n\nApart from testing appropriate donor/recipient populations, appropriate reference materials should be used to define the performance specifications of a test system. These reference materials should be traceable to the WHO international standard or reference reagents, when available for a specific marker.\n\nThe necessary documentation should be available for each test system and should include at least the following information:\n\n\u2014 a description of the test system (reagents, controls, devices etc.), equipment and diluents (if applicable);\n\u2014 safety instructions;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2146, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e0ac89-856f-4809-8cb9-0087f2dc5bf1": {"__data__": {"id_": "c2e0ac89-856f-4809-8cb9-0087f2dc5bf1", "embedding": null, "metadata": {"page_label": "191", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a description of the assay principle;\n- specifications;\n- a description of the sampling procedure, sampling plan, sample handling and test procedure;\n- internal quality controls (positive and negative), run with every series of donor samples;\n- recommended calibration material and calibration frequency (e.g. change of reagent lot);\n- primary reading of measurement (format e.g. optical density);\n- interpretation of the measurement and/or conversion to result;\n- acceptance criteria, cut-off, reference values, limits, pro-zone, grey zone.\n\nWhere feasible, the test system should be approved for blood screening by the NRA.\n\n## 7.4 Assay performance validation\n\nIn addition to the validation of the test system by the manufacturer, an on-site validation of the test system in the laboratory is required prior to its use in routine testing. This validation should demonstrate, that:\n\n- the performance specifications of the system established by the kit manufacturer are met by the laboratory;\n- laboratory personnel are thoroughly instructed, trained and competent to operate the test system.\n\nPrior to first-time use, critical equipment, including related computer systems, should be thoroughly qualified. Installation qualification, operational qualification and performance qualification should be carried out and fully documented. This work may involve suppliers and/or third parties. It is strongly recommended that any performance qualification should be performed by the end-user (and not by a third party) since this is intended to demonstrate that the process works as designed.\n\nIn addition, a demonstration showing that the test system performance specifications are constantly met in routine donor testing is required. The means by which this may be achieved are:\n\n- inclusion of internal and external quality control materials with every test series;\n- previously tested samples collected for use as an internal panel for periodical in-process quality control;\n- monitoring measurements of controls (for instance, graphically by using a Levi-Jennings diagram);\n- statistically establishing the standard deviation of control measurements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los pasos necesarios para validar un sistema de ensayo en un laboratorio antes de su uso en pruebas rutinarias?**\n   - Respuesta: La validaci\u00f3n en el laboratorio debe demostrar que las especificaciones de rendimiento del sistema establecidas por el fabricante del kit son cumplidas por el laboratorio, y que el personal del laboratorio est\u00e1 debidamente instruido, capacitado y es competente para operar el sistema de ensayo. Adem\u00e1s, se debe realizar una calificaci\u00f3n exhaustiva del equipo cr\u00edtico, incluyendo sistemas inform\u00e1ticos relacionados, y llevar a cabo la calificaci\u00f3n de instalaci\u00f3n, operaci\u00f3n y rendimiento, documentando todo el proceso.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para asegurar que las especificaciones de rendimiento del sistema de ensayo se mantengan durante las pruebas rutinarias de donantes?**\n   - Respuesta: Para asegurar que las especificaciones de rendimiento se mantengan, se pueden incluir materiales de control de calidad internos y externos con cada serie de pruebas, utilizar muestras previamente analizadas como un panel interno para el control de calidad en proceso, monitorear las mediciones de los controles (por ejemplo, utilizando un diagrama de Levi-Jennings) y establecer estad\u00edsticamente la desviaci\u00f3n est\u00e1ndar de las mediciones de control.\n\n3. **\u00bfQu\u00e9 tipo de controles de calidad se deben implementar en cada serie de muestras de donantes?**\n   - Respuesta: Se deben implementar controles de calidad internos, tanto positivos como negativos, que se ejecuten con cada serie de muestras de donantes. Esto asegura que el sistema de ensayo est\u00e9 funcionando correctamente y que los resultados sean confiables.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre la validaci\u00f3n y el control de calidad de los sistemas de ensayo utilizados en pruebas de sangre. Se enfatiza la importancia de la validaci\u00f3n tanto por parte del fabricante como en el laboratorio donde se utilizar\u00e1 el sistema. Se detallan los requisitos para la calificaci\u00f3n del equipo y la capacitaci\u00f3n del personal, as\u00ed como las medidas necesarias para garantizar que las especificaciones de rendimiento se mantengan durante las pruebas rutinarias. Adem\u00e1s, se menciona la necesidad de incluir controles de calidad en cada serie de pruebas para asegurar la fiabilidad de los resultados.", "prev_section_summary": "### Temas Clave:\n1. **Validaci\u00f3n de Sistemas de Pruebas**: Proceso esencial para asegurar que los resultados de las pruebas diagn\u00f3sticas sean precisos y confiables.\n2. **Elementos de Validaci\u00f3n**: Incluye reactivos de ensayo, equipo, software (si aplica) y procedimientos de manejo.\n3. **Documentaci\u00f3n Requerida**: Es fundamental tener registros que demuestren que se cumplen las especificaciones y que incluyan descripciones detalladas de materiales, equipos y condiciones de procesamiento.\n4. **Especificaciones de Rendimiento**: Deben establecerse y cumplirse especificaciones como especificidad, sensibilidad, precisi\u00f3n, repetibilidad, reproducibilidad, interferencias conocidas y l\u00edmites de detecci\u00f3n.\n5. **Materiales de Referencia**: Uso de materiales de referencia apropiados que sean trazables a est\u00e1ndares internacionales de la OMS para definir las especificaciones de rendimiento.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que proporciona directrices sobre la validaci\u00f3n de sistemas de pruebas.\n- **Reactivos de Ensayo**: Materiales utilizados en las pruebas diagn\u00f3sticas.\n- **Equipos y Software**: Herramientas necesarias para realizar las pruebas.\n- **Poblaciones de Donantes/Receptores**: Grupos de personas de los cuales se toman muestras para validar los ensayos.\n- **Especificaciones de Rendimiento**: Par\u00e1metros que definen la efectividad de un sistema de prueba.\n\n### Resumen:\nEl documento de la OMS aborda la validaci\u00f3n de sistemas de pruebas diagn\u00f3sticas, destacando la importancia de establecer especificaciones precisas y documentar todos los aspectos del proceso. La validaci\u00f3n incluye cuatro elementos clave: reactivos, equipo, software y procedimientos. Adem\u00e1s, se requiere documentaci\u00f3n que detalle el sistema de prueba y las especificaciones de rendimiento que deben cumplirse, como especificidad y sensibilidad. Tambi\u00e9n se enfatiza el uso de materiales de referencia trazables a est\u00e1ndares internacionales para asegurar la calidad de las pruebas.", "excerpt_keywords": "Keywords: assay validation, quality control, blood screening, performance specifications, laboratory training"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9cca0e5b-d88c-4b61-8dba-1597582a0be4", "node_type": "4", "metadata": {"page_label": "191", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a description of the assay principle;\n- specifications;\n- a description of the sampling procedure, sampling plan, sample handling and test procedure;\n- internal quality controls (positive and negative), run with every series of donor samples;\n- recommended calibration material and calibration frequency (e.g. change of reagent lot);\n- primary reading of measurement (format e.g. optical density);\n- interpretation of the measurement and/or conversion to result;\n- acceptance criteria, cut-off, reference values, limits, pro-zone, grey zone.\n\nWhere feasible, the test system should be approved for blood screening by the NRA.\n\n## 7.4 Assay performance validation\n\nIn addition to the validation of the test system by the manufacturer, an on-site validation of the test system in the laboratory is required prior to its use in routine testing. This validation should demonstrate, that:\n\n- the performance specifications of the system established by the kit manufacturer are met by the laboratory;\n- laboratory personnel are thoroughly instructed, trained and competent to operate the test system.\n\nPrior to first-time use, critical equipment, including related computer systems, should be thoroughly qualified. Installation qualification, operational qualification and performance qualification should be carried out and fully documented. This work may involve suppliers and/or third parties. It is strongly recommended that any performance qualification should be performed by the end-user (and not by a third party) since this is intended to demonstrate that the process works as designed.\n\nIn addition, a demonstration showing that the test system performance specifications are constantly met in routine donor testing is required. The means by which this may be achieved are:\n\n- inclusion of internal and external quality control materials with every test series;\n- previously tested samples collected for use as an internal panel for periodical in-process quality control;\n- monitoring measurements of controls (for instance, graphically by using a Levi-Jennings diagram);\n- statistically establishing the standard deviation of control measurements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "04da0cab40f0377806b3d3fd8c71a2647db0f21ef12e9d14202b21de0997a7d0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- a description of the assay principle;\n- specifications;\n- a description of the sampling procedure, sampling plan, sample handling and test procedure;\n- internal quality controls (positive and negative), run with every series of donor samples;\n- recommended calibration material and calibration frequency (e.g. change of reagent lot);\n- primary reading of measurement (format e.g. optical density);\n- interpretation of the measurement and/or conversion to result;\n- acceptance criteria, cut-off, reference values, limits, pro-zone, grey zone.\n\nWhere feasible, the test system should be approved for blood screening by the NRA.\n\n## 7.4 Assay performance validation\n\nIn addition to the validation of the test system by the manufacturer, an on-site validation of the test system in the laboratory is required prior to its use in routine testing. This validation should demonstrate, that:\n\n- the performance specifications of the system established by the kit manufacturer are met by the laboratory;\n- laboratory personnel are thoroughly instructed, trained and competent to operate the test system.\n\nPrior to first-time use, critical equipment, including related computer systems, should be thoroughly qualified. Installation qualification, operational qualification and performance qualification should be carried out and fully documented. This work may involve suppliers and/or third parties. It is strongly recommended that any performance qualification should be performed by the end-user (and not by a third party) since this is intended to demonstrate that the process works as designed.\n\nIn addition, a demonstration showing that the test system performance specifications are constantly met in routine donor testing is required. The means by which this may be achieved are:\n\n- inclusion of internal and external quality control materials with every test series;\n- previously tested samples collected for use as an internal panel for periodical in-process quality control;\n- monitoring measurements of controls (for instance, graphically by using a Levi-Jennings diagram);\n- statistically establishing the standard deviation of control measurements;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2154, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cb12c49e-d315-4601-9d48-67b515892934": {"__data__": {"id_": "cb12c49e-d315-4601-9d48-67b515892934", "embedding": null, "metadata": {"page_label": "192", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Management of materials and reagents\n\n## 8.1 Materials and reagents\n\nOnly reagents and materials from approved suppliers that meet documented requirements and specifications should be used. Materials and reagents should meet the legal requirements for medical devices. The management procedures for materials, reagents and supplies should define the specifications for acceptance of any elements that may influence the quality of the final blood component. Receipt logs or records for these critical materials should indicate their acceptability on the basis of the defined specifications and should identify the person accepting them.\n\n## 8.2 Receipt and quarantine\n\nAppropriate checks (e.g. attached certificates, expiry date, lot number, defects) should be performed on received goods in order to confirm that they correspond to the order and meet the specifications. Damaged containers should be carefully checked to detect possibly affected materials. Incoming critical materials (such as sterile solutions, blood bag systems and testing reagents) should be physically or administratively quarantined immediately after receipt and until they are released for use. Where the quarantine status is ensured by storage in separate areas, these areas should be clearly marked and their access restricted to authorized personnel. When labels are applied to the containers to indicate their status, the use of different colours may be helpful. Any system replacing physical quarantine (e.g. a computerized system) should provide equivalent security.\n\n## 8.3 Release of incoming production material and test reagents\n\nCritical material should be received under quarantine and then evaluated for acceptability. After acceptability has been determined, the materials should be released by an authorized person for use in manufacture. The actual release may be performed by an authorized person or under the guidance of a validated computer system. The minimum criteria for the release should be the availability \u2014 and check of \u2014 certificates or other acceptability records generated by the manufacturer and containing sufficient information to determine product acceptance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de materiales y reactivos en el contexto de la producci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de utilizar solo materiales de proveedores aprobados que cumplan con requisitos documentados y especificaciones legales. Se describen procedimientos para la recepci\u00f3n, cuarentena y liberaci\u00f3n de materiales cr\u00edticos, asegurando que se realicen verificaciones adecuadas y que solo se utilicen materiales aceptables en la fabricaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de materiales y reactivos deben ser utilizados en la producci\u00f3n de componentes sangu\u00edneos seg\u00fan el documento?**\n   - Solo se deben utilizar reactivos y materiales de proveedores aprobados que cumplan con requisitos documentados y especificaciones legales para dispositivos m\u00e9dicos.\n\n2. **\u00bfCu\u00e1les son los pasos que deben seguirse al recibir materiales cr\u00edticos para asegurar su calidad?**\n   - Se deben realizar verificaciones adecuadas, como comprobar certificados, fechas de caducidad, n\u00fameros de lote y defectos. Adem\u00e1s, los materiales cr\u00edticos deben ser puestos en cuarentena inmediatamente despu\u00e9s de su recepci\u00f3n hasta que sean liberados para su uso.\n\n3. **\u00bfQui\u00e9n es responsable de liberar los materiales cr\u00edticos para su uso en la fabricaci\u00f3n?**\n   - La liberaci\u00f3n de los materiales debe ser realizada por una persona autorizada, y puede llevarse a cabo directamente por esta persona o bajo la gu\u00eda de un sistema inform\u00e1tico validado. Se requiere que existan certificados o registros de aceptaci\u00f3n generados por el fabricante para determinar la aceptaci\u00f3n del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n del Sistema de Ensayo**:\n   - Es necesario realizar una validaci\u00f3n en el laboratorio antes de usar el sistema de ensayo en pruebas rutinarias.\n   - La validaci\u00f3n debe demostrar que:\n     - Las especificaciones de rendimiento del fabricante son cumplidas por el laboratorio.\n     - El personal del laboratorio est\u00e1 capacitado y es competente para operar el sistema.\n\n2. **Calificaci\u00f3n del Equipo**:\n   - Antes del primer uso, el equipo cr\u00edtico y los sistemas inform\u00e1ticos relacionados deben ser calificados exhaustivamente.\n   - Se deben llevar a cabo y documentar la calificaci\u00f3n de instalaci\u00f3n, operaci\u00f3n y rendimiento.\n\n3. **Control de Calidad**:\n   - Se deben incluir controles de calidad internos (positivos y negativos) en cada serie de muestras de donantes.\n   - Se recomienda el uso de materiales de control de calidad internos y externos, as\u00ed como muestras previamente analizadas para el control de calidad en proceso.\n\n4. **Monitoreo y Estad\u00edsticas**:\n   - Es importante monitorear las mediciones de los controles, por ejemplo, utilizando un diagrama de Levi-Jennings.\n   - Se debe establecer estad\u00edsticamente la desviaci\u00f3n est\u00e1ndar de las mediciones de control.\n\n5. **Aprobaci\u00f3n del Sistema de Ensayo**:\n   - El sistema de ensayo debe estar aprobado para el tamizaje de sangre por la NRA (Autoridad Reguladora Nacional).\n\n### Entidades Clave:\n- **NRA**: Autoridad Reguladora Nacional.\n- **Levi-Jennings**: Diagrama utilizado para el monitoreo de controles de calidad.\n- **Personal del laboratorio**: Debe estar capacitado y competente.\n- **Equipo cr\u00edtico**: Incluye sistemas inform\u00e1ticos y otros equipos necesarios para el ensayo.\n\nEste resumen destaca la importancia de la validaci\u00f3n, el control de calidad y la capacitaci\u00f3n del personal en el contexto de los sistemas de ensayo utilizados en pruebas de sangre.", "excerpt_keywords": "Keywords: materials management, reagents, quality control, quarantine procedures, blood component production"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "777726ca-6a5a-4a02-992a-df367979d933", "node_type": "4", "metadata": {"page_label": "192", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Management of materials and reagents\n\n## 8.1 Materials and reagents\n\nOnly reagents and materials from approved suppliers that meet documented requirements and specifications should be used. Materials and reagents should meet the legal requirements for medical devices. The management procedures for materials, reagents and supplies should define the specifications for acceptance of any elements that may influence the quality of the final blood component. Receipt logs or records for these critical materials should indicate their acceptability on the basis of the defined specifications and should identify the person accepting them.\n\n## 8.2 Receipt and quarantine\n\nAppropriate checks (e.g. attached certificates, expiry date, lot number, defects) should be performed on received goods in order to confirm that they correspond to the order and meet the specifications. Damaged containers should be carefully checked to detect possibly affected materials. Incoming critical materials (such as sterile solutions, blood bag systems and testing reagents) should be physically or administratively quarantined immediately after receipt and until they are released for use. Where the quarantine status is ensured by storage in separate areas, these areas should be clearly marked and their access restricted to authorized personnel. When labels are applied to the containers to indicate their status, the use of different colours may be helpful. Any system replacing physical quarantine (e.g. a computerized system) should provide equivalent security.\n\n## 8.3 Release of incoming production material and test reagents\n\nCritical material should be received under quarantine and then evaluated for acceptability. After acceptability has been determined, the materials should be released by an authorized person for use in manufacture. The actual release may be performed by an authorized person or under the guidance of a validated computer system. The minimum criteria for the release should be the availability \u2014 and check of \u2014 certificates or other acceptability records generated by the manufacturer and containing sufficient information to determine product acceptance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "58dfe120c82aeb9b59214860e4ce6ede0bf5b449a66e02c47eecd85c001b34be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Management of materials and reagents\n\n## 8.1 Materials and reagents\n\nOnly reagents and materials from approved suppliers that meet documented requirements and specifications should be used. Materials and reagents should meet the legal requirements for medical devices. The management procedures for materials, reagents and supplies should define the specifications for acceptance of any elements that may influence the quality of the final blood component. Receipt logs or records for these critical materials should indicate their acceptability on the basis of the defined specifications and should identify the person accepting them.\n\n## 8.2 Receipt and quarantine\n\nAppropriate checks (e.g. attached certificates, expiry date, lot number, defects) should be performed on received goods in order to confirm that they correspond to the order and meet the specifications. Damaged containers should be carefully checked to detect possibly affected materials. Incoming critical materials (such as sterile solutions, blood bag systems and testing reagents) should be physically or administratively quarantined immediately after receipt and until they are released for use. Where the quarantine status is ensured by storage in separate areas, these areas should be clearly marked and their access restricted to authorized personnel. When labels are applied to the containers to indicate their status, the use of different colours may be helpful. Any system replacing physical quarantine (e.g. a computerized system) should provide equivalent security.\n\n## 8.3 Release of incoming production material and test reagents\n\nCritical material should be received under quarantine and then evaluated for acceptability. After acceptability has been determined, the materials should be released by an authorized person for use in manufacture. The actual release may be performed by an authorized person or under the guidance of a validated computer system. The minimum criteria for the release should be the availability \u2014 and check of \u2014 certificates or other acceptability records generated by the manufacturer and containing sufficient information to determine product acceptance.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2169, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8567b9ff-c95c-47bc-8b2c-d19c8b3dd008": {"__data__": {"id_": "8567b9ff-c95c-47bc-8b2c-d19c8b3dd008", "embedding": null, "metadata": {"page_label": "193", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Similarly, each new lot of testing kits should be evaluated by the laboratory to check compliance with predetermined performance standards before release for routine analysis.\n\nThe manufacturers of sterile materials (e.g. blood bag systems, anticoagulant solutions) should provide a certificate of release for each batch. The blood establishment should define acceptance criteria for such certificates in writing, and should include at least the name of the material, the manufacturer, compliance with the relevant requirements (e.g. pharmacopoeia or medical device regulations) and confirmation that the materials are sterile and pyrogen-free.\n\n### 8.4 Storage\n\nMaterials and reagents should be stored under the conditions established by the manufacturer and in an orderly manner that permits segregation by batch or lot and stock rotation. Storage and use should follow the \u201cfirst-expiring first-out\u201d principle (i.e. the material that entered storage first should be used first). The use of the expiry date as an alternative inventory management technique is also acceptable.\n\nWhere special storage temperature conditions are required, these should be provided, checked and regularly monitored.\n\n### 8.5 Traceability of materials and reagents\n\nInventory records should be kept for traceability. The records should document which batch or lot of materials or reagents have been used for the collection, processing or testing of the blood units or blood components. Inventory of critical supplies such as donation labels with serial numbers should be strictly controlled to avoid mix-ups or mislabelling due to uncontrolled excess labels.\n\n### 8.6 Supplier/vendor management\n\nAll materials and reagents relevant for the quality of the products should be purchased or obtained only from qualified suppliers. The relationship between the two parties (i.e. contract giver and contract acceptor) should be defined in a contract. The blood establishment as contract giver is responsible for assessing the competence of the supplier (contract acceptor).\n\nThe contracting process should include:\n\n- a qualification review prior to awarding the contract to ensure that the supplier meets the organizational needs and complies with GMP requirements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evaluaci\u00f3n de kits de prueba**: Cada nuevo lote de kits de prueba debe ser evaluado por el laboratorio para asegurar que cumpla con los est\u00e1ndares de rendimiento predeterminados antes de su liberaci\u00f3n para an\u00e1lisis rutinarios.\n\n2. **Certificaci\u00f3n de materiales est\u00e9riles**: Los fabricantes de materiales est\u00e9riles deben proporcionar un certificado de liberaci\u00f3n para cada lote, que debe incluir informaci\u00f3n sobre el material, el fabricante, y la confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n3. **Almacenamiento y trazabilidad**: Los materiales y reactivos deben ser almacenados bajo condiciones espec\u00edficas y de manera ordenada, permitiendo la segregaci\u00f3n por lote y la rotaci\u00f3n de stock. Adem\u00e1s, se deben mantener registros de inventario para asegurar la trazabilidad de los materiales utilizados.\n\n4. **Gesti\u00f3n de proveedores**: Todos los materiales y reactivos deben ser adquiridos solo de proveedores calificados, y la relaci\u00f3n entre el establecimiento de sangre y el proveedor debe estar definida en un contrato que incluya una revisi\u00f3n de calificaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben incluirse en el certificado de liberaci\u00f3n proporcionado por los fabricantes de materiales est\u00e9riles?**\n   - El certificado debe incluir el nombre del material, el fabricante, el cumplimiento con los requisitos relevantes (como la farmacopoeia o regulaciones de dispositivos m\u00e9dicos) y la confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n2. **\u00bfCu\u00e1l es el principio de gesti\u00f3n de inventario que se debe seguir para el almacenamiento de materiales y reactivos?**\n   - Se debe seguir el principio de \"primero en expirar, primero en salir\" (first-expiring first-out), lo que significa que el material que ingres\u00f3 al almacenamiento primero debe ser utilizado primero.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse en el proceso de contrataci\u00f3n para asegurar que un proveedor cumpla con los requisitos de GMP?**\n   - El proceso de contrataci\u00f3n debe incluir una revisi\u00f3n de calificaci\u00f3n antes de otorgar el contrato, para asegurar que el proveedor cumpla con las necesidades organizacionales y los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Materiales y Reactivos**:\n   - Solo se deben utilizar reactivos y materiales de proveedores aprobados.\n   - Deben cumplir con requisitos documentados y especificaciones legales para dispositivos m\u00e9dicos.\n\n2. **Gesti\u00f3n de Materiales**:\n   - Los procedimientos de gesti\u00f3n deben definir especificaciones para la aceptaci\u00f3n de materiales que influyan en la calidad del componente sangu\u00edneo final.\n   - Se deben llevar registros de recepci\u00f3n que indiquen la aceptabilidad de los materiales y la persona que los acepta.\n\n3. **Recepci\u00f3n y Cuarentena**:\n   - Se deben realizar verificaciones adecuadas al recibir materiales cr\u00edticos (certificados, fechas de caducidad, n\u00fameros de lote, defectos).\n   - Los materiales cr\u00edticos deben ser puestos en cuarentena inmediatamente tras su recepci\u00f3n.\n   - Las \u00e1reas de cuarentena deben estar claramente marcadas y restringidas a personal autorizado.\n\n4. **Liberaci\u00f3n de Materiales**:\n   - Los materiales cr\u00edticos deben ser evaluados para determinar su aceptabilidad antes de ser liberados para su uso.\n   - La liberaci\u00f3n debe ser realizada por una persona autorizada o bajo la gu\u00eda de un sistema inform\u00e1tico validado.\n   - Se requiere la disponibilidad de certificados o registros de aceptaci\u00f3n generados por el fabricante para determinar la aceptaci\u00f3n del producto.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Proveedores Aprobados**: Entidades que suministran materiales y reactivos.\n- **Materiales Cr\u00edticos**: Incluyen soluciones est\u00e9riles, sistemas de bolsas de sangre y reactivos de prueba.\n- **Personal Autorizado**: Individuos responsables de la aceptaci\u00f3n y liberaci\u00f3n de materiales.", "excerpt_keywords": "Keywords: testing kits, sterile materials, storage conditions, traceability, supplier management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f682a4b3-8dbe-435b-9e4a-273d2e5f89b9", "node_type": "4", "metadata": {"page_label": "193", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Similarly, each new lot of testing kits should be evaluated by the laboratory to check compliance with predetermined performance standards before release for routine analysis.\n\nThe manufacturers of sterile materials (e.g. blood bag systems, anticoagulant solutions) should provide a certificate of release for each batch. The blood establishment should define acceptance criteria for such certificates in writing, and should include at least the name of the material, the manufacturer, compliance with the relevant requirements (e.g. pharmacopoeia or medical device regulations) and confirmation that the materials are sterile and pyrogen-free.\n\n### 8.4 Storage\n\nMaterials and reagents should be stored under the conditions established by the manufacturer and in an orderly manner that permits segregation by batch or lot and stock rotation. Storage and use should follow the \u201cfirst-expiring first-out\u201d principle (i.e. the material that entered storage first should be used first). The use of the expiry date as an alternative inventory management technique is also acceptable.\n\nWhere special storage temperature conditions are required, these should be provided, checked and regularly monitored.\n\n### 8.5 Traceability of materials and reagents\n\nInventory records should be kept for traceability. The records should document which batch or lot of materials or reagents have been used for the collection, processing or testing of the blood units or blood components. Inventory of critical supplies such as donation labels with serial numbers should be strictly controlled to avoid mix-ups or mislabelling due to uncontrolled excess labels.\n\n### 8.6 Supplier/vendor management\n\nAll materials and reagents relevant for the quality of the products should be purchased or obtained only from qualified suppliers. The relationship between the two parties (i.e. contract giver and contract acceptor) should be defined in a contract. The blood establishment as contract giver is responsible for assessing the competence of the supplier (contract acceptor).\n\nThe contracting process should include:\n\n- a qualification review prior to awarding the contract to ensure that the supplier meets the organizational needs and complies with GMP requirements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f758a23382d2a8c9a749a9cfdb5a325d1fcc2d1732730f344edc1d25783e6d5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Similarly, each new lot of testing kits should be evaluated by the laboratory to check compliance with predetermined performance standards before release for routine analysis.\n\nThe manufacturers of sterile materials (e.g. blood bag systems, anticoagulant solutions) should provide a certificate of release for each batch. The blood establishment should define acceptance criteria for such certificates in writing, and should include at least the name of the material, the manufacturer, compliance with the relevant requirements (e.g. pharmacopoeia or medical device regulations) and confirmation that the materials are sterile and pyrogen-free.\n\n### 8.4 Storage\n\nMaterials and reagents should be stored under the conditions established by the manufacturer and in an orderly manner that permits segregation by batch or lot and stock rotation. Storage and use should follow the \u201cfirst-expiring first-out\u201d principle (i.e. the material that entered storage first should be used first). The use of the expiry date as an alternative inventory management technique is also acceptable.\n\nWhere special storage temperature conditions are required, these should be provided, checked and regularly monitored.\n\n### 8.5 Traceability of materials and reagents\n\nInventory records should be kept for traceability. The records should document which batch or lot of materials or reagents have been used for the collection, processing or testing of the blood units or blood components. Inventory of critical supplies such as donation labels with serial numbers should be strictly controlled to avoid mix-ups or mislabelling due to uncontrolled excess labels.\n\n### 8.6 Supplier/vendor management\n\nAll materials and reagents relevant for the quality of the products should be purchased or obtained only from qualified suppliers. The relationship between the two parties (i.e. contract giver and contract acceptor) should be defined in a contract. The blood establishment as contract giver is responsible for assessing the competence of the supplier (contract acceptor).\n\nThe contracting process should include:\n\n- a qualification review prior to awarding the contract to ensure that the supplier meets the organizational needs and complies with GMP requirements;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2240, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9ab04849-237e-4c56-9fbd-f47b7c187ac2": {"__data__": {"id_": "9ab04849-237e-4c56-9fbd-f47b7c187ac2", "embedding": null, "metadata": {"page_label": "194", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Manufacturing\n\n## 9.1 Donor registration\n\nUpon presentation at the blood establishment, donors should positively identify themselves by stating their full name, address and date of birth. Each donor should also provide proof of a permanent place of residence, including a telephone number where appropriate, so that they can be contacted after donation, if necessary.\n\nProof of identity with a photograph \u2014 such as an identity card, passport or driver\u2019s licence \u2014 should be provided, especially in the case of first-time donors. A careful check of the identity of the donor should be repeated prior to each step that is relevant to the quality of the products and the safety of donors, but at least before donor selection and venipuncture.\n\nIf electronic databases are used to maintain donor information, double checks or another validated method to confirm accuracy of information entered manually should be implemented.\n\n## 9.2 Donor selection\n\nBlood and blood components should be obtained from healthy donors who are carefully selected using a systematic and validated process consisting of review of the donor\u2019s health assessment, social behaviour history (the donor questionnaire) and medical examination. This evaluation, along with a review of the results of the infectious disease screening laboratory test, should be used to make sure, prior to the release of any blood component, that the donor presents no increased risk for transmission of infectious agents. NRAs are pivotal in establishing a harmonized framework for donor selection criteria, taking into consideration the types of products, the relevant infectious risks, and the epidemiological data for disease prevalence in the country. The review of these combined data may be used in developing donor selection criteria. The NRA should also be part of", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los procedimientos para el registro y selecci\u00f3n de donantes de sangre. Se enfatiza la importancia de la identificaci\u00f3n adecuada de los donantes, la verificaci\u00f3n de su salud y comportamiento social, as\u00ed como la implementaci\u00f3n de procesos sistem\u00e1ticos y validados para garantizar la seguridad de la sangre donada. Tambi\u00e9n se menciona el papel crucial de las Autoridades Reguladoras Nacionales (NRAs) en el establecimiento de criterios de selecci\u00f3n de donantes, considerando los riesgos infecciosos y la prevalencia de enfermedades en el pa\u00eds.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para que un donante se registre en un establecimiento de sangre?**\n   - El donante debe presentar su nombre completo, direcci\u00f3n, fecha de nacimiento y prueba de identidad con fotograf\u00eda, como una tarjeta de identidad, pasaporte o licencia de conducir.\n\n2. **\u00bfCu\u00e1l es el proceso que se sigue para asegurar que un donante no represente un riesgo de transmisi\u00f3n de agentes infecciosos?**\n   - Se realiza una evaluaci\u00f3n sistem\u00e1tica que incluye la revisi\u00f3n de la salud del donante, su historial de comportamiento social a trav\u00e9s de un cuestionario, un examen m\u00e9dico y la revisi\u00f3n de los resultados de pruebas de laboratorio para detectar enfermedades infecciosas.\n\n3. **\u00bfQu\u00e9 papel juegan las Autoridades Reguladoras Nacionales (NRAs) en la selecci\u00f3n de donantes de sangre?**\n   - Las NRAs son fundamentales para establecer un marco armonizado de criterios de selecci\u00f3n de donantes, considerando los tipos de productos, los riesgos infecciosos relevantes y los datos epidemiol\u00f3gicos sobre la prevalencia de enfermedades en el pa\u00eds.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n de Kits de Prueba**:\n   - Cada nuevo lote de kits de prueba debe ser evaluado por el laboratorio para asegurar el cumplimiento de los est\u00e1ndares de rendimiento antes de su liberaci\u00f3n para an\u00e1lisis rutinarios.\n\n2. **Certificaci\u00f3n de Materiales Est\u00e9riles**:\n   - Los fabricantes de materiales est\u00e9riles, como sistemas de bolsas de sangre y soluciones anticoagulantes, deben proporcionar un certificado de liberaci\u00f3n para cada lote. Este certificado debe incluir:\n     - Nombre del material\n     - Fabricante\n     - Cumplimiento con requisitos relevantes (ej. farmacopoeia, regulaciones de dispositivos m\u00e9dicos)\n     - Confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n3. **Almacenamiento**:\n   - Los materiales y reactivos deben ser almacenados seg\u00fan las condiciones establecidas por el fabricante, permitiendo la segregaci\u00f3n por lote y la rotaci\u00f3n de stock. Se debe seguir el principio de \"primero en expirar, primero en salir\" (first-expiring first-out) para la gesti\u00f3n de inventario.\n\n4. **Trazabilidad de Materiales y Reactivos**:\n   - Se deben mantener registros de inventario para asegurar la trazabilidad de los materiales utilizados en la recolecci\u00f3n, procesamiento o prueba de unidades de sangre. El inventario de suministros cr\u00edticos, como etiquetas de donaci\u00f3n con n\u00fameros de serie, debe ser controlado estrictamente.\n\n5. **Gesti\u00f3n de Proveedores**:\n   - Todos los materiales y reactivos deben ser adquiridos solo de proveedores calificados. La relaci\u00f3n entre el establecimiento de sangre y el proveedor debe estar definida en un contrato que incluya una revisi\u00f3n de calificaci\u00f3n para asegurar que el proveedor cumpla con las necesidades organizacionales y los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades Clave\n- **Kits de prueba**\n- **Materiales est\u00e9riles** (ej. sistemas de bolsas de sangre, soluciones anticoagulantes)\n- **Certificado de liberaci\u00f3n**\n- **Almacenamiento**\n- **Trazabilidad**\n- **Proveedores calificados**\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la evaluaci\u00f3n, certificaci\u00f3n, almacenamiento, trazabilidad y gesti\u00f3n de proveedores en el contexto de la calidad de los productos relacionados con la sangre.", "excerpt_keywords": "Keywords: donor registration, blood safety, infectious disease screening, regulatory authorities, donor selection criteria"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25eae283-4f8c-4ea5-8de2-f69a343d349c", "node_type": "4", "metadata": {"page_label": "194", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Manufacturing\n\n## 9.1 Donor registration\n\nUpon presentation at the blood establishment, donors should positively identify themselves by stating their full name, address and date of birth. Each donor should also provide proof of a permanent place of residence, including a telephone number where appropriate, so that they can be contacted after donation, if necessary.\n\nProof of identity with a photograph \u2014 such as an identity card, passport or driver\u2019s licence \u2014 should be provided, especially in the case of first-time donors. A careful check of the identity of the donor should be repeated prior to each step that is relevant to the quality of the products and the safety of donors, but at least before donor selection and venipuncture.\n\nIf electronic databases are used to maintain donor information, double checks or another validated method to confirm accuracy of information entered manually should be implemented.\n\n## 9.2 Donor selection\n\nBlood and blood components should be obtained from healthy donors who are carefully selected using a systematic and validated process consisting of review of the donor\u2019s health assessment, social behaviour history (the donor questionnaire) and medical examination. This evaluation, along with a review of the results of the infectious disease screening laboratory test, should be used to make sure, prior to the release of any blood component, that the donor presents no increased risk for transmission of infectious agents. NRAs are pivotal in establishing a harmonized framework for donor selection criteria, taking into consideration the types of products, the relevant infectious risks, and the epidemiological data for disease prevalence in the country. The review of these combined data may be used in developing donor selection criteria. The NRA should also be part of", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4635e6ad38800fc71f29bdba544bd14dd5b20313b3fb88b1a2e76473d70cb113", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Manufacturing\n\n## 9.1 Donor registration\n\nUpon presentation at the blood establishment, donors should positively identify themselves by stating their full name, address and date of birth. Each donor should also provide proof of a permanent place of residence, including a telephone number where appropriate, so that they can be contacted after donation, if necessary.\n\nProof of identity with a photograph \u2014 such as an identity card, passport or driver\u2019s licence \u2014 should be provided, especially in the case of first-time donors. A careful check of the identity of the donor should be repeated prior to each step that is relevant to the quality of the products and the safety of donors, but at least before donor selection and venipuncture.\n\nIf electronic databases are used to maintain donor information, double checks or another validated method to confirm accuracy of information entered manually should be implemented.\n\n## 9.2 Donor selection\n\nBlood and blood components should be obtained from healthy donors who are carefully selected using a systematic and validated process consisting of review of the donor\u2019s health assessment, social behaviour history (the donor questionnaire) and medical examination. This evaluation, along with a review of the results of the infectious disease screening laboratory test, should be used to make sure, prior to the release of any blood component, that the donor presents no increased risk for transmission of infectious agents. NRAs are pivotal in establishing a harmonized framework for donor selection criteria, taking into consideration the types of products, the relevant infectious risks, and the epidemiological data for disease prevalence in the country. The review of these combined data may be used in developing donor selection criteria. The NRA should also be part of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1824, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f1cefe0e-d02f-4cae-811d-c1e30ff9e37c": {"__data__": {"id_": "f1cefe0e-d02f-4cae-811d-c1e30ff9e37c", "embedding": null, "metadata": {"page_label": "195", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "any decision-making process intended to modify the donor selection and donation-testing procedures.\n\nRegulatory agencies and professional organizations have respectively published regulations and recommendations on the criteria for the selection of donors of whole blood and blood components (see, for instance, the Council of Europe\u2019s *Guide to the preparation, use and quality assurance of blood components*) that can be used as a reference (13). Such guidance documents also explain critical points that should be considered when processing blood and blood components.\n\nWhenever possible, blood donations should be collected through a donation system involving regular and repeat donors. Obtaining blood from regular and repeat donors is a major contribution to ensuring optimal historical medical information about the donors, and therefore to detecting potential risk factors.\n\n### 9.2.1 Epidemiological surveillance of the donor population\n\nTo ensure optimal long-term safety of blood components, blood establishments should maintain continuous epidemiological surveillance of the donor population. The objective of this surveillance is to know, as precisely as possible, the prevalence and incidence, and their respective trends, of infectious markers that are relevant to the safety of blood components. This enables countermeasures to be taken in a timely manner. The system should be able to gather epidemiological data not only at national/regional levels but also among donor populations that provide blood at individual blood establishments within a country or region. Consideration should be given to the travelling patterns of the donor population with respect to possible transmission of infectious diseases (i.e. malaria, Chagas disease, vCJD, etc.).\n\nThe information from epidemiological surveillance can furthermore be used:\n\n- to detect, among donor populations of various collection centres, differences that may be associated with objective differences in viral markers within donor populations;\n- to detect differences in the donor selection and screening processes at collection centres;\n- to detect trends in infectious markers which may reflect either a change in the rate of viral markers in the population or a possible deviation in the donor selection or screening process at specific collection sites;\n- to assess the relevance of any preventive measures such as a strengthened donor selection process, additional deferral criteria, or implementation of additional screening tests to avoid contamination of blood components.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto aborda la importancia de la selecci\u00f3n de donantes de sangre y la vigilancia epidemiol\u00f3gica de la poblaci\u00f3n donante para garantizar la seguridad de los componentes sangu\u00edneos. Se menciona que las agencias regulatorias y organizaciones profesionales han establecido regulaciones y recomendaciones sobre los criterios de selecci\u00f3n de donantes. Se enfatiza la necesidad de recolectar sangre de donantes regulares y repetidos para asegurar informaci\u00f3n m\u00e9dica hist\u00f3rica \u00f3ptima. Adem\u00e1s, se destaca la importancia de mantener una vigilancia epidemiol\u00f3gica continua para conocer la prevalencia e incidencia de marcadores infecciosos relevantes, lo que permite tomar medidas preventivas adecuadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los beneficios espec\u00edficos de recolectar sangre de donantes regulares y repetidos en comparaci\u00f3n con donantes ocasionales?**\n   - Esta pregunta busca profundizar en las ventajas concretas que ofrecen los donantes regulares en t\u00e9rminos de informaci\u00f3n m\u00e9dica y detecci\u00f3n de riesgos.\n\n2. **\u00bfQu\u00e9 tipo de datos epidemiol\u00f3gicos se deben recopilar para evaluar la seguridad de los componentes sangu\u00edneos y c\u00f3mo se pueden utilizar esos datos en la pr\u00e1ctica?**\n   - Esta pregunta se centra en los tipos de datos que son cruciales para la vigilancia epidemiol\u00f3gica y su aplicaci\u00f3n en la mejora de los procesos de selecci\u00f3n y pruebas de donantes.\n\n3. **\u00bfQu\u00e9 medidas preventivas se pueden implementar si se detectan tendencias preocupantes en los marcadores infecciosos dentro de una poblaci\u00f3n donante espec\u00edfica?**\n   - Esta pregunta busca explorar las acciones concretas que se pueden tomar en respuesta a hallazgos epidemiol\u00f3gicos que indiquen un aumento en los riesgos de transmisi\u00f3n de enfermedades infecciosas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Registro de Donantes**:\n   - **Identificaci\u00f3n**: Los donantes deben identificarse proporcionando su nombre completo, direcci\u00f3n, fecha de nacimiento y prueba de residencia permanente.\n   - **Documentaci\u00f3n**: Se requiere una prueba de identidad con fotograf\u00eda (tarjeta de identidad, pasaporte, licencia de conducir), especialmente para donantes primerizos.\n   - **Verificaci\u00f3n**: Se debe realizar una verificaci\u00f3n cuidadosa de la identidad del donante antes de cada paso relevante para la calidad de los productos y la seguridad de los donantes.\n\n2. **Selecci\u00f3n de Donantes**:\n   - **Proceso Sistem\u00e1tico**: La selecci\u00f3n de donantes se basa en una evaluaci\u00f3n sistem\u00e1tica que incluye la revisi\u00f3n de la salud del donante, su historial de comportamiento social y un examen m\u00e9dico.\n   - **Pruebas de Enfermedades Infecciosas**: Se revisan los resultados de las pruebas de laboratorio para asegurar que el donante no represente un riesgo aumentado de transmisi\u00f3n de agentes infecciosos.\n\n3. **Autoridades Reguladoras Nacionales (NRAs)**:\n   - **Marco Armonizado**: Las NRAs son fundamentales para establecer criterios de selecci\u00f3n de donantes, considerando los tipos de productos, los riesgos infecciosos y los datos epidemiol\u00f3gicos sobre la prevalencia de enfermedades en el pa\u00eds.\n\n### Entidades Clave:\n- **Donantes de Sangre**: Individuos que ofrecen su sangre para transfusiones.\n- **Establecimientos de Sangre**: Instituciones donde se lleva a cabo la recolecci\u00f3n y procesamiento de sangre.\n- **Autoridades Reguladoras Nacionales (NRAs)**: Organismos responsables de establecer y supervisar los criterios de selecci\u00f3n de donantes y la seguridad de la sangre.", "excerpt_keywords": "Keywords: blood donation, donor selection, epidemiological surveillance, infectious markers, safety of blood components"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d4026735-ef8b-4edc-81f6-fd111a0096cf", "node_type": "4", "metadata": {"page_label": "195", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "any decision-making process intended to modify the donor selection and donation-testing procedures.\n\nRegulatory agencies and professional organizations have respectively published regulations and recommendations on the criteria for the selection of donors of whole blood and blood components (see, for instance, the Council of Europe\u2019s *Guide to the preparation, use and quality assurance of blood components*) that can be used as a reference (13). Such guidance documents also explain critical points that should be considered when processing blood and blood components.\n\nWhenever possible, blood donations should be collected through a donation system involving regular and repeat donors. Obtaining blood from regular and repeat donors is a major contribution to ensuring optimal historical medical information about the donors, and therefore to detecting potential risk factors.\n\n### 9.2.1 Epidemiological surveillance of the donor population\n\nTo ensure optimal long-term safety of blood components, blood establishments should maintain continuous epidemiological surveillance of the donor population. The objective of this surveillance is to know, as precisely as possible, the prevalence and incidence, and their respective trends, of infectious markers that are relevant to the safety of blood components. This enables countermeasures to be taken in a timely manner. The system should be able to gather epidemiological data not only at national/regional levels but also among donor populations that provide blood at individual blood establishments within a country or region. Consideration should be given to the travelling patterns of the donor population with respect to possible transmission of infectious diseases (i.e. malaria, Chagas disease, vCJD, etc.).\n\nThe information from epidemiological surveillance can furthermore be used:\n\n- to detect, among donor populations of various collection centres, differences that may be associated with objective differences in viral markers within donor populations;\n- to detect differences in the donor selection and screening processes at collection centres;\n- to detect trends in infectious markers which may reflect either a change in the rate of viral markers in the population or a possible deviation in the donor selection or screening process at specific collection sites;\n- to assess the relevance of any preventive measures such as a strengthened donor selection process, additional deferral criteria, or implementation of additional screening tests to avoid contamination of blood components.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "737b3fc6ddee0d981047ea80f2bc6cc9b92d2195e7c6baf5581178646c3bef40", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "any decision-making process intended to modify the donor selection and donation-testing procedures.\n\nRegulatory agencies and professional organizations have respectively published regulations and recommendations on the criteria for the selection of donors of whole blood and blood components (see, for instance, the Council of Europe\u2019s *Guide to the preparation, use and quality assurance of blood components*) that can be used as a reference (13). Such guidance documents also explain critical points that should be considered when processing blood and blood components.\n\nWhenever possible, blood donations should be collected through a donation system involving regular and repeat donors. Obtaining blood from regular and repeat donors is a major contribution to ensuring optimal historical medical information about the donors, and therefore to detecting potential risk factors.\n\n### 9.2.1 Epidemiological surveillance of the donor population\n\nTo ensure optimal long-term safety of blood components, blood establishments should maintain continuous epidemiological surveillance of the donor population. The objective of this surveillance is to know, as precisely as possible, the prevalence and incidence, and their respective trends, of infectious markers that are relevant to the safety of blood components. This enables countermeasures to be taken in a timely manner. The system should be able to gather epidemiological data not only at national/regional levels but also among donor populations that provide blood at individual blood establishments within a country or region. Consideration should be given to the travelling patterns of the donor population with respect to possible transmission of infectious diseases (i.e. malaria, Chagas disease, vCJD, etc.).\n\nThe information from epidemiological surveillance can furthermore be used:\n\n- to detect, among donor populations of various collection centres, differences that may be associated with objective differences in viral markers within donor populations;\n- to detect differences in the donor selection and screening processes at collection centres;\n- to detect trends in infectious markers which may reflect either a change in the rate of viral markers in the population or a possible deviation in the donor selection or screening process at specific collection sites;\n- to assess the relevance of any preventive measures such as a strengthened donor selection process, additional deferral criteria, or implementation of additional screening tests to avoid contamination of blood components.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2554, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "22010588-d73b-4a1a-ace3-35d2eebcf8ac": {"__data__": {"id_": "22010588-d73b-4a1a-ace3-35d2eebcf8ac", "embedding": null, "metadata": {"page_label": "196", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When donations from first-time donors are used to prepare blood components, epidemiological data on this specific donor group should be included in the estimate of the risk for infectious diseases transmitted by blood. It has been shown that first-time donors, who may occasionally include test-seeking persons, constitute a group that in some situations is more likely to have bloodborne viral markers than regular donors who have already gone through a selection/deferral process.\n\nIt is currently advisable to collect and analyse epidemiological data at the collection sites for HIV1/HIV2, hepatitis C virus (HCV) and hepatitis B virus (HBV) since they historically represent the major pathogenic risks associated with blood components. It is the responsibility of the NRA to define whether this list should be modified or should include additional criteria such as emerging infectious agents, on the basis of local or regional epidemiology. For the current three recommended markers, only confirmed positive tests (i.e. tests which are repeatedly reactive in a screening test and positive in at least one confirmatory test) should be recorded, reported and analysed.\n\n### 9.2.2 Information to donors\n\nPotential new donors should be informed (ideally both verbally and in writing) that it is necessary to respond to questions about their medical history and personal behaviour so that it can be determined whether they are eligible for blood donation. Written information can be a leaflet explaining infectious risks associated with blood products, and the impact of social behaviour on infectious risks or infectious risk factors. This information is usually provided by a licensed physician, or by a designated qualified person under the direct supervision of a licensed physician. The information should clearly explain the deferral criteria that exclude a donor from donating blood or plasma. It is important to ensure that the reasons for deferral are well understood by the candidate donor.\n\nThe candidate donor should be asked to sign a form of informed consent to give blood in which he/she acknowledges understanding the moral and legal responsibilities and possible risks associated with donating blood, as well as the occasional complications that may occur. The declaration of consent should also include a statement that the donor authorizes the release of his/her blood and blood components for transfusion or further manufacturing.\n\nDonors should be informed to contact the blood establishment if there is an unexpected event after the donation, such as illness or the discovery of new information not disclosed during the health screening.\n\n### 9.2.3 Questionnaire and interview\n\nThe interview assessment of each donor should be carried out by a qualified person who is trained in the use of donor selection criteria using a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de recopilar y analizar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente aquellos que son donantes por primera vez. Se destaca que este grupo puede tener un mayor riesgo de transmitir enfermedades infecciosas, como el VIH y los virus de hepatitis. Adem\u00e1s, se enfatiza la necesidad de informar a los donantes sobre los riesgos asociados con la donaci\u00f3n de sangre, los criterios de exclusi\u00f3n y la importancia de dar su consentimiento informado. Tambi\u00e9n se menciona que la evaluaci\u00f3n de los donantes debe ser realizada por personal calificado.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfPor qu\u00e9 es importante recopilar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente los de primera vez?**\n   - La recopilaci\u00f3n de datos epidemiol\u00f3gicos es crucial porque los donantes de primera vez pueden tener un mayor riesgo de portar marcadores virales transmitidos por la sangre, lo que puede aumentar el riesgo de infecciones en los componentes sangu\u00edneos. Esto permite a las autoridades de regulaci\u00f3n ajustar sus criterios de selecci\u00f3n y deferral bas\u00e1ndose en la epidemiolog\u00eda local.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se debe proporcionar a los donantes potenciales antes de la donaci\u00f3n de sangre?**\n   - Los donantes potenciales deben recibir informaci\u00f3n verbal y escrita sobre la importancia de responder preguntas sobre su historial m\u00e9dico y comportamiento personal. Tambi\u00e9n deben ser informados sobre los riesgos infecciosos asociados con los productos sangu\u00edneos, los criterios de exclusi\u00f3n y la necesidad de firmar un consentimiento informado que reconozca los riesgos y responsabilidades de la donaci\u00f3n.\n\n3. **\u00bfQui\u00e9n es responsable de llevar a cabo la evaluaci\u00f3n de los donantes y qu\u00e9 criterios deben seguir?**\n   - La evaluaci\u00f3n de los donantes debe ser realizada por una persona calificada que est\u00e9 entrenada en el uso de criterios de selecci\u00f3n de donantes. Esta persona debe utilizar un cuestionario validado para garantizar que se sigan los procedimientos adecuados y se eval\u00fae correctamente la elegibilidad del donante.", "prev_section_summary": "### Temas Clave\n\n1. **Selecci\u00f3n de Donantes de Sangre**: La importancia de establecer criterios adecuados para la selecci\u00f3n de donantes de sangre y componentes sangu\u00edneos, basados en regulaciones y recomendaciones de agencias regulatorias y organizaciones profesionales.\n\n2. **Donantes Regulares y Repetidos**: Se enfatiza la necesidad de recolectar sangre de donantes regulares y repetidos para asegurar una mejor informaci\u00f3n m\u00e9dica hist\u00f3rica, lo que facilita la detecci\u00f3n de factores de riesgo.\n\n3. **Vigilancia Epidemiol\u00f3gica**: La necesidad de mantener una vigilancia epidemiol\u00f3gica continua de la poblaci\u00f3n donante para conocer la prevalencia e incidencia de marcadores infecciosos relevantes, permitiendo la implementaci\u00f3n de medidas preventivas oportunas.\n\n4. **Datos Epidemiol\u00f3gicos**: La recopilaci\u00f3n de datos epidemiol\u00f3gicos a nivel nacional y regional, as\u00ed como en centros de donaci\u00f3n individuales, es crucial para evaluar la seguridad de los componentes sangu\u00edneos.\n\n5. **Medidas Preventivas**: La vigilancia epidemiol\u00f3gica puede ayudar a detectar diferencias en los procesos de selecci\u00f3n y cribado de donantes, as\u00ed como a identificar tendencias en marcadores infecciosos que requieran acciones preventivas.\n\n### Entidades\n\n- **Agencias Regulatorias**: Organismos que establecen regulaciones sobre la selecci\u00f3n de donantes.\n- **Organizaciones Profesionales**: Entidades que proporcionan recomendaciones sobre criterios de selecci\u00f3n de donantes.\n- **Consejo de Europa**: Referencia citada en el contexto de gu\u00edas sobre la preparaci\u00f3n y calidad de componentes sangu\u00edneos.\n- **Enfermedades Infecciosas**: Ejemplos como malaria, enfermedad de Chagas y vCJD, que son relevantes para la vigilancia epidemiol\u00f3gica.\n- **Centros de Donaci\u00f3n**: Lugares donde se recolecta sangre y se realizan procesos de selecci\u00f3n y cribado de donantes. \n\nEste resumen destaca la importancia de la selecci\u00f3n adecuada de donantes y la vigilancia epidemiol\u00f3gica para garantizar la seguridad de los componentes sangu\u00edneos.", "excerpt_keywords": "Keywords: blood donation, epidemiological data, infectious diseases, donor information, informed consent"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3aa21772-8d1d-4dd9-8633-83e24e17c5f8", "node_type": "4", "metadata": {"page_label": "196", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When donations from first-time donors are used to prepare blood components, epidemiological data on this specific donor group should be included in the estimate of the risk for infectious diseases transmitted by blood. It has been shown that first-time donors, who may occasionally include test-seeking persons, constitute a group that in some situations is more likely to have bloodborne viral markers than regular donors who have already gone through a selection/deferral process.\n\nIt is currently advisable to collect and analyse epidemiological data at the collection sites for HIV1/HIV2, hepatitis C virus (HCV) and hepatitis B virus (HBV) since they historically represent the major pathogenic risks associated with blood components. It is the responsibility of the NRA to define whether this list should be modified or should include additional criteria such as emerging infectious agents, on the basis of local or regional epidemiology. For the current three recommended markers, only confirmed positive tests (i.e. tests which are repeatedly reactive in a screening test and positive in at least one confirmatory test) should be recorded, reported and analysed.\n\n### 9.2.2 Information to donors\n\nPotential new donors should be informed (ideally both verbally and in writing) that it is necessary to respond to questions about their medical history and personal behaviour so that it can be determined whether they are eligible for blood donation. Written information can be a leaflet explaining infectious risks associated with blood products, and the impact of social behaviour on infectious risks or infectious risk factors. This information is usually provided by a licensed physician, or by a designated qualified person under the direct supervision of a licensed physician. The information should clearly explain the deferral criteria that exclude a donor from donating blood or plasma. It is important to ensure that the reasons for deferral are well understood by the candidate donor.\n\nThe candidate donor should be asked to sign a form of informed consent to give blood in which he/she acknowledges understanding the moral and legal responsibilities and possible risks associated with donating blood, as well as the occasional complications that may occur. The declaration of consent should also include a statement that the donor authorizes the release of his/her blood and blood components for transfusion or further manufacturing.\n\nDonors should be informed to contact the blood establishment if there is an unexpected event after the donation, such as illness or the discovery of new information not disclosed during the health screening.\n\n### 9.2.3 Questionnaire and interview\n\nThe interview assessment of each donor should be carried out by a qualified person who is trained in the use of donor selection criteria using a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7ad7aecd33a2159c27f79bbd8ac33f2d9a277b806cb2df4f0a550738dc9113d2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "When donations from first-time donors are used to prepare blood components, epidemiological data on this specific donor group should be included in the estimate of the risk for infectious diseases transmitted by blood. It has been shown that first-time donors, who may occasionally include test-seeking persons, constitute a group that in some situations is more likely to have bloodborne viral markers than regular donors who have already gone through a selection/deferral process.\n\nIt is currently advisable to collect and analyse epidemiological data at the collection sites for HIV1/HIV2, hepatitis C virus (HCV) and hepatitis B virus (HBV) since they historically represent the major pathogenic risks associated with blood components. It is the responsibility of the NRA to define whether this list should be modified or should include additional criteria such as emerging infectious agents, on the basis of local or regional epidemiology. For the current three recommended markers, only confirmed positive tests (i.e. tests which are repeatedly reactive in a screening test and positive in at least one confirmatory test) should be recorded, reported and analysed.\n\n### 9.2.2 Information to donors\n\nPotential new donors should be informed (ideally both verbally and in writing) that it is necessary to respond to questions about their medical history and personal behaviour so that it can be determined whether they are eligible for blood donation. Written information can be a leaflet explaining infectious risks associated with blood products, and the impact of social behaviour on infectious risks or infectious risk factors. This information is usually provided by a licensed physician, or by a designated qualified person under the direct supervision of a licensed physician. The information should clearly explain the deferral criteria that exclude a donor from donating blood or plasma. It is important to ensure that the reasons for deferral are well understood by the candidate donor.\n\nThe candidate donor should be asked to sign a form of informed consent to give blood in which he/she acknowledges understanding the moral and legal responsibilities and possible risks associated with donating blood, as well as the occasional complications that may occur. The declaration of consent should also include a statement that the donor authorizes the release of his/her blood and blood components for transfusion or further manufacturing.\n\nDonors should be informed to contact the blood establishment if there is an unexpected event after the donation, such as illness or the discovery of new information not disclosed during the health screening.\n\n### 9.2.3 Questionnaire and interview\n\nThe interview assessment of each donor should be carried out by a qualified person who is trained in the use of donor selection criteria using a validated", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2853, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5a5b60d0-47ec-4386-b8de-637bda2b9d68": {"__data__": {"id_": "5a5b60d0-47ec-4386-b8de-637bda2b9d68", "embedding": null, "metadata": {"page_label": "197", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 961\", aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el Informe 45 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre el contenido del informe que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en la elaboraci\u00f3n del Informe 45 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques utilizados para recopilar y analizar datos en el informe, lo cual es crucial para entender la validez de los hallazgos.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 45 con otros informes anteriores de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca establecer conexiones entre diferentes informes, lo que puede proporcionar un contexto m\u00e1s amplio sobre la evoluci\u00f3n de las recomendaciones y hallazgos de la OMS.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pol\u00edticas de salud. El Informe 45 en particular podr\u00eda contener informaci\u00f3n relevante sobre un tema espec\u00edfico de salud, as\u00ed como recomendaciones basadas en evidencia para mejorar la pr\u00e1ctica y la pol\u00edtica en el \u00e1mbito de la salud.", "prev_section_summary": "### Temas Clave:\n\n1. **Importancia de los Datos Epidemiol\u00f3gicos**: Se enfatiza la necesidad de recopilar y analizar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente aquellos que son donantes por primera vez, debido a su mayor riesgo de transmitir enfermedades infecciosas.\n\n2. **Riesgos Asociados con la Donaci\u00f3n de Sangre**: Se identifican los principales riesgos patog\u00e9nicos asociados con los componentes sangu\u00edneos, como el VIH y los virus de hepatitis (HCV y HBV).\n\n3. **Informaci\u00f3n a los Donantes**: Se debe proporcionar informaci\u00f3n clara y comprensible a los donantes potenciales sobre su elegibilidad, riesgos de infecci\u00f3n, criterios de exclusi\u00f3n y la importancia del consentimiento informado.\n\n4. **Consentimiento Informado**: Los donantes deben firmar un formulario de consentimiento que reconozca los riesgos y responsabilidades de la donaci\u00f3n de sangre.\n\n5. **Evaluaci\u00f3n de Donantes**: La evaluaci\u00f3n de los donantes debe ser realizada por personal calificado que utilice criterios de selecci\u00f3n validados.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones sobre la donaci\u00f3n de sangre.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad responsable de definir los criterios de selecci\u00f3n y deferral de donantes basados en la epidemiolog\u00eda local.\n- **Virus**: VIH1, VIH2, HCV, HBV (virus asociados con riesgos patog\u00e9nicos en la donaci\u00f3n de sangre).\n- **Donantes de Sangre**: Incluye donantes por primera vez y donantes regulares.\n- **Personal Calificado**: Individuos entrenados para llevar a cabo la evaluaci\u00f3n de donantes.\n\n### Resumen:\nEl documento de la OMS subraya la importancia de recopilar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente los de primera vez, debido a su mayor riesgo de transmitir enfermedades infecciosas. Se recomienda informar a los donantes sobre los riesgos asociados con la donaci\u00f3n, los criterios de exclusi\u00f3n y la necesidad de dar su consentimiento informado. La evaluaci\u00f3n de los donantes debe ser realizada por personal calificado utilizando criterios de selecci\u00f3n validados.", "excerpt_keywords": "Keywords: donaci\u00f3n de sangre, epidemiolog\u00eda, consentimiento informado, riesgos patog\u00e9nicos, evaluaci\u00f3n de donantes"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d0dea423-358c-4495-89b6-a7bf51ba2238", "node_type": "4", "metadata": {"page_label": "197", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "43b396f1-92cf-45eb-bd41-7eab82f240e5": {"__data__": {"id_": "43b396f1-92cf-45eb-bd41-7eab82f240e5", "embedding": null, "metadata": {"page_label": "198", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and layout of the blood establishment (or the mobile collection unit) should allow for adequate confidentiality during the donor interview and selection process so as not to discourage the candidate donor from answering questions about personal or private behaviour; otherwise the safety of the blood donation could be compromised.\n\nThe minimum intervals between two donations should be defined and should then be audited or reviewed for compliance with the waiting period prior to each donation.\n\n### 9.2.4 Deferral policy and deferral criteria\n\nAs part of the blood establishment\u2019s deferral policy, a list of permanent or temporary deferral criteria used for potential donors should be clearly defined, made public, and incorporated in the educational material for donors and the establishment\u2019s procedures. It should also be determined whether the donor has previously been deferred, and reasons for any deferral should be reviewed so that a decision may be made on whether to accept the donor for current donation. A donor who is deferred should be informed of the reason for deferral, encouraged not to donate at other facilities while deferred and informed that the reason for the deferral may be shared with other health professionals or government agencies according to NRA recommendations or other legal requirements.\n\nBoth acceptance and deferral criteria for the donation of blood should be formulated by the NRA and should be national requirements that are applied nationwide. Within the scope of their role of establishing and implementing effective national regulations, NRAs should enforce such criteria.\n\nExamples of the major permanent deferral criteria found in international guidelines include:\n\n- clinical or laboratory evidence of bloodborne infectious diseases such as acute or chronic infection with HIV, HCV or HBV (in certain jurisdictions donors with elevated titres of anti-HBs may be acceptable);\n- past or present intravenous drug use;\n- persistent bacterial or protozoal infections.\n\nOther deferral criteria, either permanent or temporary, may include:\n\n- a sexual relationship between men;\n- men or women who are engaged in prostitution;\n- subjects with haemophilia or other clotting-factor defects;\n- sexual partners of any of the above or of someone the donor suspects may carry the above risk factors;\n- jaundice within the 12 months prior to donation, since this may be a clinical sign of hepatitis A, B or C;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Confidencialidad en el proceso de donaci\u00f3n**: Es fundamental que el dise\u00f1o y la disposici\u00f3n de los establecimientos de sangre o unidades m\u00f3viles de recolecci\u00f3n permitan la confidencialidad durante las entrevistas y el proceso de selecci\u00f3n de donantes. Esto es crucial para fomentar la honestidad de los donantes sobre su comportamiento personal y privado, lo que a su vez garantiza la seguridad de la donaci\u00f3n de sangre.\n\n2. **Pol\u00edtica de aplazamiento y criterios de aplazamiento**: Las pol\u00edticas de aplazamiento deben incluir criterios claros y p\u00fablicos para la aceptaci\u00f3n o rechazo de donantes potenciales. Estos criterios deben ser formulados por la Autoridad Reguladora Nacional (NRA) y aplicarse a nivel nacional. Los donantes que sean aplazados deben ser informados de las razones de su aplazamiento y se les debe aconsejar no donar en otras instalaciones durante este periodo.\n\n3. **Criterios de aplazamiento permanentes y temporales**: Existen criterios espec\u00edficos que pueden llevar a un aplazamiento permanente o temporal de la donaci\u00f3n de sangre, que incluyen enfermedades infecciosas, uso de drogas intravenosas, y ciertas relaciones sexuales de riesgo. Estos criterios son importantes para proteger la salud p\u00fablica y la seguridad de la sangre donada.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las implicaciones de no garantizar la confidencialidad durante el proceso de selecci\u00f3n de donantes?**\n   - Esta pregunta busca explorar c\u00f3mo la falta de confidencialidad puede afectar la disposici\u00f3n de los donantes a ser honestos sobre su historial m\u00e9dico y comportamientos, lo que podr\u00eda comprometer la seguridad de la sangre donada.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si un donante es aplazado y cu\u00e1les son sus derechos en este proceso?**\n   - Esta pregunta se centra en los derechos del donante aplazado, incluyendo la informaci\u00f3n que debe recibir sobre las razones de su aplazamiento y las recomendaciones sobre la donaci\u00f3n en otras instalaciones.\n\n3. **\u00bfC\u00f3mo se determinan y actualizan los criterios de aplazamiento para la donaci\u00f3n de sangre a nivel nacional?**\n   - Esta pregunta indaga sobre el proceso mediante el cual la NRA establece y revisa los criterios de aplazamiento, as\u00ed como la frecuencia con la que se actualizan en funci\u00f3n de nuevas evidencias cient\u00edficas o cambios en la salud p\u00fablica.", "prev_section_summary": "El contenido proporcionado se refiere al documento titulado \"WHO - Technical Report Series 961\", espec\u00edficamente al Informe 45 de esta serie. A continuaci\u00f3n se presenta un resumen de los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Hallazgos y Recomendaciones**: Se busca informaci\u00f3n sobre los principales hallazgos y recomendaciones del Informe 45, que son fundamentales para entender su impacto en la salud p\u00fablica.\n2. **Metodolog\u00edas**: Se hace \u00e9nfasis en las metodolog\u00edas utilizadas para la elaboraci\u00f3n del informe, lo que es crucial para evaluar la validez y confiabilidad de los resultados presentados.\n3. **Relaci\u00f3n con Informes Anteriores**: Se plantea la importancia de entender c\u00f3mo el Informe 45 se relaciona con otros informes previos de la OMS, lo que puede ofrecer un contexto sobre la evoluci\u00f3n de las recomendaciones en salud.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de la serie de informes t\u00e9cnicos.\n- **Informe 45**: Espec\u00edfico documento dentro de la Serie de Informes T\u00e9cnicos que aborda un tema particular de salud p\u00fablica.\n\n### Contexto General:\nEl documento forma parte de una serie que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica y proporciona recomendaciones basadas en evidencia para mejorar pol\u00edticas y pr\u00e1cticas en este campo.", "excerpt_keywords": "Keywords: blood donation, deferral criteria, confidentiality, health regulations, infectious diseases"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53007525-d566-4d96-81d6-63792e658921", "node_type": "4", "metadata": {"page_label": "198", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and layout of the blood establishment (or the mobile collection unit) should allow for adequate confidentiality during the donor interview and selection process so as not to discourage the candidate donor from answering questions about personal or private behaviour; otherwise the safety of the blood donation could be compromised.\n\nThe minimum intervals between two donations should be defined and should then be audited or reviewed for compliance with the waiting period prior to each donation.\n\n### 9.2.4 Deferral policy and deferral criteria\n\nAs part of the blood establishment\u2019s deferral policy, a list of permanent or temporary deferral criteria used for potential donors should be clearly defined, made public, and incorporated in the educational material for donors and the establishment\u2019s procedures. It should also be determined whether the donor has previously been deferred, and reasons for any deferral should be reviewed so that a decision may be made on whether to accept the donor for current donation. A donor who is deferred should be informed of the reason for deferral, encouraged not to donate at other facilities while deferred and informed that the reason for the deferral may be shared with other health professionals or government agencies according to NRA recommendations or other legal requirements.\n\nBoth acceptance and deferral criteria for the donation of blood should be formulated by the NRA and should be national requirements that are applied nationwide. Within the scope of their role of establishing and implementing effective national regulations, NRAs should enforce such criteria.\n\nExamples of the major permanent deferral criteria found in international guidelines include:\n\n- clinical or laboratory evidence of bloodborne infectious diseases such as acute or chronic infection with HIV, HCV or HBV (in certain jurisdictions donors with elevated titres of anti-HBs may be acceptable);\n- past or present intravenous drug use;\n- persistent bacterial or protozoal infections.\n\nOther deferral criteria, either permanent or temporary, may include:\n\n- a sexual relationship between men;\n- men or women who are engaged in prostitution;\n- subjects with haemophilia or other clotting-factor defects;\n- sexual partners of any of the above or of someone the donor suspects may carry the above risk factors;\n- jaundice within the 12 months prior to donation, since this may be a clinical sign of hepatitis A, B or C;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bf943097ef1da48d8d873e072fb82e8f404e799bac3d2a87a8cbbb01a5a37f93", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and layout of the blood establishment (or the mobile collection unit) should allow for adequate confidentiality during the donor interview and selection process so as not to discourage the candidate donor from answering questions about personal or private behaviour; otherwise the safety of the blood donation could be compromised.\n\nThe minimum intervals between two donations should be defined and should then be audited or reviewed for compliance with the waiting period prior to each donation.\n\n### 9.2.4 Deferral policy and deferral criteria\n\nAs part of the blood establishment\u2019s deferral policy, a list of permanent or temporary deferral criteria used for potential donors should be clearly defined, made public, and incorporated in the educational material for donors and the establishment\u2019s procedures. It should also be determined whether the donor has previously been deferred, and reasons for any deferral should be reviewed so that a decision may be made on whether to accept the donor for current donation. A donor who is deferred should be informed of the reason for deferral, encouraged not to donate at other facilities while deferred and informed that the reason for the deferral may be shared with other health professionals or government agencies according to NRA recommendations or other legal requirements.\n\nBoth acceptance and deferral criteria for the donation of blood should be formulated by the NRA and should be national requirements that are applied nationwide. Within the scope of their role of establishing and implementing effective national regulations, NRAs should enforce such criteria.\n\nExamples of the major permanent deferral criteria found in international guidelines include:\n\n- clinical or laboratory evidence of bloodborne infectious diseases such as acute or chronic infection with HIV, HCV or HBV (in certain jurisdictions donors with elevated titres of anti-HBs may be acceptable);\n- past or present intravenous drug use;\n- persistent bacterial or protozoal infections.\n\nOther deferral criteria, either permanent or temporary, may include:\n\n- a sexual relationship between men;\n- men or women who are engaged in prostitution;\n- subjects with haemophilia or other clotting-factor defects;\n- sexual partners of any of the above or of someone the donor suspects may carry the above risk factors;\n- jaundice within the 12 months prior to donation, since this may be a clinical sign of hepatitis A, B or C;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2444, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ccb511ca-6a2f-4f69-b5f0-44e274e6939b": {"__data__": {"id_": "ccb511ca-6a2f-4f69-b5f0-44e274e6939b", "embedding": null, "metadata": {"page_label": "199", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 transfusion with blood, blood components, plasma products, cellular therapy products or vascularized tissue transplant in the 12 months prior to donation, as blood transfusion and transplantations are risk factors for all bloodborne infections;\n\n\u2014 exposure to someone else\u2019s blood, including an accidental needle stick in the 12 months prior to donation;\n\n\u2014 tattooing, scarification, ear-piercing or acupuncture in the 12 months prior to donation (since these practices may be vehicles for transmission of viral diseases) unless clear evidence is provided that it was carried out under sterile conditions;\n\n\u2014 risk factors for Human T-cell lymphotropic virus (HTLV) infection;\n\n\u2014 risk factors for malaria infection (e.g. travel in countries where the prevalence is high);\n\n\u2014 a confirmed family history of CJD;\n\n\u2014 imprisonment longer than three days within the 12 months prior to donation.\n\nWhen temporary deferral criteria are used, a specific procedure involving trained personnel should be in place for the reinstatement of donors. There are deferral criteria that are temporary (as long as a risk factor has been identified) but that can be waived after additional controls have been carried out on the donor or the period of deferral has passed. NRAs may recommend or define different deferral criteria and timelines, e.g. when implementing NAT testing for the relevant viruses.\n\n## 9.2.5 Physical examination, donor health criteria and donor acceptance\n\nA targeted physical examination should be carried out by a licensed physician according to an established procedure prior to the first donation and thereafter before subsequent blood donations, and in case of special apheresis programmes at regular intervals. Depending on national regulations established by the NRA, the physical examination may be performed by a suitably educated and trained physician substitute under the supervision of a licensed physician. NRAs should, usually after consultation with the blood establishment, determine the health criteria and the acceptable limits taken into account during the physical examination \u2014 such as measurement of haemoglobin, blood pressure, weight, age, pulse rate and temperature, or any other criteria considered to be of concern for the safety of blood components or donors.\n\nA written standard operating procedure based on the relevant acceptance/deferral criteria should be in place at the blood establishment to control donor acceptance and deferral criteria, in compliance with the NRA. Abnormal donor findings should be referred to the physician who has the authority.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Criterios de exclusi\u00f3n temporal para donantes de sangre**: El texto detalla varios factores que pueden llevar a la exclusi\u00f3n temporal de un donante de sangre, como transfusiones recientes, exposici\u00f3n a sangre ajena, pr\u00e1cticas de tatuaje o acupuntura, y ciertos antecedentes m\u00e9dicos. Tambi\u00e9n se menciona la importancia de un procedimiento espec\u00edfico para la reinstauraci\u00f3n de donantes tras un per\u00edodo de exclusi\u00f3n.\n\n2. **Examen f\u00edsico y criterios de salud del donante**: Se establece que un examen f\u00edsico dirigido debe ser realizado por un m\u00e9dico licenciado antes de la primera donaci\u00f3n y en donaciones posteriores. Los criterios de salud y l\u00edmites aceptables deben ser determinados por las autoridades nacionales reguladoras (NRA) en consulta con el establecimiento de sangre, y se deben seguir procedimientos operativos est\u00e1ndar para la aceptaci\u00f3n y exclusi\u00f3n de donantes.\n\n3. **Procedimientos de control y seguimiento de donantes**: El texto enfatiza la necesidad de un procedimiento escrito que controle la aceptaci\u00f3n y exclusi\u00f3n de donantes, as\u00ed como la referencia de hallazgos anormales a un m\u00e9dico autorizado, asegurando as\u00ed la seguridad tanto de los donantes como de los componentes sangu\u00edneos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que deben seguirse para la reinstauraci\u00f3n de donantes que han sido temporalmente excluidos?**\n   - Esta pregunta busca informaci\u00f3n sobre los pasos y protocolos que deben implementarse para permitir que un donante que ha sido excluido temporalmente pueda volver a donar sangre.\n\n2. **\u00bfQu\u00e9 criterios de salud se consideran durante el examen f\u00edsico de un donante de sangre y c\u00f3mo se determinan?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que se eval\u00faan durante el examen f\u00edsico y qui\u00e9n es responsable de establecer esos criterios.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se encuentran hallazgos anormales durante el examen f\u00edsico de un donante?**\n   - Esta pregunta busca aclarar el procedimiento a seguir en caso de que un donante presente resultados anormales en su evaluaci\u00f3n m\u00e9dica, asegurando que se tomen las medidas adecuadas para proteger la salud del donante y la seguridad de la sangre donada.", "prev_section_summary": "### Temas Clave:\n\n1. **Confidencialidad en el Proceso de Donaci\u00f3n**: La importancia de garantizar la confidencialidad durante las entrevistas y el proceso de selecci\u00f3n de donantes para fomentar la honestidad y la seguridad en la donaci\u00f3n de sangre.\n\n2. **Pol\u00edtica de Aplazamiento y Criterios de Aplazamiento**: Necesidad de definir y hacer p\u00fablicos los criterios de aplazamiento para donantes potenciales, los cuales deben ser formulados por la Autoridad Reguladora Nacional (NRA) y aplicarse a nivel nacional.\n\n3. **Criterios de Aplazamiento**: Existen criterios permanentes y temporales que pueden llevar a un aplazamiento de la donaci\u00f3n, incluyendo enfermedades infecciosas, uso de drogas intravenosas y relaciones sexuales de riesgo.\n\n4. **Derechos del Donante Aplazado**: Los donantes que son aplazados deben ser informados de las razones de su aplazamiento y se les debe aconsejar no donar en otras instalaciones durante este periodo.\n\n5. **Revisi\u00f3n y Actualizaci\u00f3n de Criterios**: La NRA es responsable de establecer, revisar y actualizar los criterios de aplazamiento bas\u00e1ndose en evidencias cient\u00edficas y cambios en la salud p\u00fablica.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre la donaci\u00f3n de sangre.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad responsable de formular y aplicar criterios de aceptaci\u00f3n y aplazamiento para donantes de sangre.\n- **Donantes de Sangre**: Individuos que se presentan para donar sangre y que deben ser evaluados seg\u00fan los criterios establecidos.\n- **Establecimientos de Sangre**: Instituciones donde se lleva a cabo la recolecci\u00f3n y procesamiento de sangre.\n\nEste resumen destaca la importancia de la confidencialidad, la claridad en las pol\u00edticas de aplazamiento y la responsabilidad de las autoridades reguladoras en la gesti\u00f3n de la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, deferral criteria, physical examination, donor health, bloodborne infections"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa59ff74-9d9b-41eb-a800-38a1acc6da7e", "node_type": "4", "metadata": {"page_label": "199", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 transfusion with blood, blood components, plasma products, cellular therapy products or vascularized tissue transplant in the 12 months prior to donation, as blood transfusion and transplantations are risk factors for all bloodborne infections;\n\n\u2014 exposure to someone else\u2019s blood, including an accidental needle stick in the 12 months prior to donation;\n\n\u2014 tattooing, scarification, ear-piercing or acupuncture in the 12 months prior to donation (since these practices may be vehicles for transmission of viral diseases) unless clear evidence is provided that it was carried out under sterile conditions;\n\n\u2014 risk factors for Human T-cell lymphotropic virus (HTLV) infection;\n\n\u2014 risk factors for malaria infection (e.g. travel in countries where the prevalence is high);\n\n\u2014 a confirmed family history of CJD;\n\n\u2014 imprisonment longer than three days within the 12 months prior to donation.\n\nWhen temporary deferral criteria are used, a specific procedure involving trained personnel should be in place for the reinstatement of donors. There are deferral criteria that are temporary (as long as a risk factor has been identified) but that can be waived after additional controls have been carried out on the donor or the period of deferral has passed. NRAs may recommend or define different deferral criteria and timelines, e.g. when implementing NAT testing for the relevant viruses.\n\n## 9.2.5 Physical examination, donor health criteria and donor acceptance\n\nA targeted physical examination should be carried out by a licensed physician according to an established procedure prior to the first donation and thereafter before subsequent blood donations, and in case of special apheresis programmes at regular intervals. Depending on national regulations established by the NRA, the physical examination may be performed by a suitably educated and trained physician substitute under the supervision of a licensed physician. NRAs should, usually after consultation with the blood establishment, determine the health criteria and the acceptable limits taken into account during the physical examination \u2014 such as measurement of haemoglobin, blood pressure, weight, age, pulse rate and temperature, or any other criteria considered to be of concern for the safety of blood components or donors.\n\nA written standard operating procedure based on the relevant acceptance/deferral criteria should be in place at the blood establishment to control donor acceptance and deferral criteria, in compliance with the NRA. Abnormal donor findings should be referred to the physician who has the authority.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4726d22049969906cfdc3d84dfeb4599637de921d8ee68273de5ead5105593b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 transfusion with blood, blood components, plasma products, cellular therapy products or vascularized tissue transplant in the 12 months prior to donation, as blood transfusion and transplantations are risk factors for all bloodborne infections;\n\n\u2014 exposure to someone else\u2019s blood, including an accidental needle stick in the 12 months prior to donation;\n\n\u2014 tattooing, scarification, ear-piercing or acupuncture in the 12 months prior to donation (since these practices may be vehicles for transmission of viral diseases) unless clear evidence is provided that it was carried out under sterile conditions;\n\n\u2014 risk factors for Human T-cell lymphotropic virus (HTLV) infection;\n\n\u2014 risk factors for malaria infection (e.g. travel in countries where the prevalence is high);\n\n\u2014 a confirmed family history of CJD;\n\n\u2014 imprisonment longer than three days within the 12 months prior to donation.\n\nWhen temporary deferral criteria are used, a specific procedure involving trained personnel should be in place for the reinstatement of donors. There are deferral criteria that are temporary (as long as a risk factor has been identified) but that can be waived after additional controls have been carried out on the donor or the period of deferral has passed. NRAs may recommend or define different deferral criteria and timelines, e.g. when implementing NAT testing for the relevant viruses.\n\n## 9.2.5 Physical examination, donor health criteria and donor acceptance\n\nA targeted physical examination should be carried out by a licensed physician according to an established procedure prior to the first donation and thereafter before subsequent blood donations, and in case of special apheresis programmes at regular intervals. Depending on national regulations established by the NRA, the physical examination may be performed by a suitably educated and trained physician substitute under the supervision of a licensed physician. NRAs should, usually after consultation with the blood establishment, determine the health criteria and the acceptable limits taken into account during the physical examination \u2014 such as measurement of haemoglobin, blood pressure, weight, age, pulse rate and temperature, or any other criteria considered to be of concern for the safety of blood components or donors.\n\nA written standard operating procedure based on the relevant acceptance/deferral criteria should be in place at the blood establishment to control donor acceptance and deferral criteria, in compliance with the NRA. Abnormal donor findings should be referred to the physician who has the authority.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2589, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c408557f-560e-4ba0-b6e0-9e5a598239f8": {"__data__": {"id_": "c408557f-560e-4ba0-b6e0-9e5a598239f8", "embedding": null, "metadata": {"page_label": "200", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Collection\n\n## Whole blood collection\n\nDonors should confirm their identity (by a method such as stating name and date of birth) immediately prior to venipuncture. Also prior to venipuncture, a check should be made to ensure that the collection system to be used is not damaged or contaminated, and that it is appropriate for the intended collection. Any abnormal moisture or discoloration suggests a defect and in such a case the collection system should be discarded. An investigation should be conducted to evaluate the extent of the problem and appropriate corrective actions should be taken. The collection systems should be used in accordance with the instructions of the manufacturer. Appropriate hand disinfection and personal hygiene procedures should be in place and should be performed by the personnel before each donation.\n\nA standardized and validated procedure for the preparation of the phlebotomy site should be followed using a suitable disinfection solution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Identificaci\u00f3n del Donante**: Antes de la venopunci\u00f3n, es crucial que los donantes confirmen su identidad mediante un m\u00e9todo espec\u00edfico, como mencionar su nombre y fecha de nacimiento.\n\n2. **Verificaci\u00f3n del Sistema de Recolecci\u00f3n**: Se debe realizar una inspecci\u00f3n del sistema de recolecci\u00f3n para asegurarse de que no est\u00e9 da\u00f1ado o contaminado, y que sea adecuado para la recolecci\u00f3n de sangre. Cualquier anomal\u00eda debe llevar al descarte del sistema y a una investigaci\u00f3n del problema.\n\n3. **Procedimientos de Higiene y Desinfecci\u00f3n**: Es esencial que se sigan procedimientos estandarizados y validados para la desinfecci\u00f3n del sitio de flebotom\u00eda, as\u00ed como que el personal mantenga pr\u00e1cticas adecuadas de higiene de manos antes de cada donaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 m\u00e9todo se recomienda para que los donantes confirmen su identidad antes de la venopunci\u00f3n?**\n   - Respuesta: Se recomienda que los donantes confirmen su identidad mencionando su nombre y fecha de nacimiento.\n\n2. **\u00bfQu\u00e9 acciones deben tomarse si se encuentra un defecto en el sistema de recolecci\u00f3n de sangre?**\n   - Respuesta: Si se encuentra un defecto, el sistema de recolecci\u00f3n debe ser descartado, y se debe llevar a cabo una investigaci\u00f3n para evaluar la extensi\u00f3n del problema y tomar las acciones correctivas apropiadas.\n\n3. **\u00bfCu\u00e1l es la importancia de seguir un procedimiento estandarizado para la preparaci\u00f3n del sitio de flebotom\u00eda?**\n   - Respuesta: Seguir un procedimiento estandarizado y validado para la preparaci\u00f3n del sitio de flebotom\u00eda es crucial para asegurar una adecuada desinfecci\u00f3n, lo que ayuda a prevenir infecciones y garantiza la seguridad del proceso de donaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Criterios de Exclusi\u00f3n Temporal para Donantes de Sangre**:\n   - Factores que pueden llevar a la exclusi\u00f3n temporal de donantes, como transfusiones recientes, exposici\u00f3n a sangre ajena, pr\u00e1cticas de tatuaje o acupuntura, antecedentes m\u00e9dicos espec\u00edficos, y encarcelamiento prolongado.\n\n2. **Reinstauraci\u00f3n de Donantes**:\n   - Importancia de un procedimiento espec\u00edfico para la reinstauraci\u00f3n de donantes que han sido temporalmente excluidos, con la posibilidad de levantar la exclusi\u00f3n tras controles adicionales o el paso del tiempo.\n\n3. **Examen F\u00edsico y Criterios de Salud**:\n   - Necesidad de un examen f\u00edsico dirigido realizado por un m\u00e9dico licenciado antes de la primera donaci\u00f3n y en donaciones posteriores, con criterios de salud determinados por las autoridades nacionales reguladoras (NRA).\n\n4. **Procedimientos Operativos Est\u00e1ndar**:\n   - Establecimiento de procedimientos escritos para controlar la aceptaci\u00f3n y exclusi\u00f3n de donantes, as\u00ed como la referencia de hallazgos anormales a un m\u00e9dico autorizado.\n\n### Entidades:\n\n- **NRA (Autoridades Nacionales Reguladoras)**: Organismos responsables de establecer regulaciones y criterios de salud para la donaci\u00f3n de sangre.\n- **CJD (Enfermedad de Creutzfeldt-Jakob)**: Enfermedad que puede ser un factor de riesgo en la donaci\u00f3n de sangre.\n- **HTLV (Virus Linfotr\u00f3pico Humano de C\u00e9lulas T)**: Virus que representa un riesgo para la salud de los donantes.\n- **Malaria**: Enfermedad infecciosa que puede influir en la elegibilidad de los donantes seg\u00fan su historial de viajes.\n- **Pr\u00e1cticas de Tatuaje, Acupuntura y Piercing**: Actividades que pueden ser veh\u00edculos de transmisi\u00f3n de enfermedades virales si no se realizan en condiciones est\u00e9riles.\n\nEste resumen abarca los aspectos esenciales de la secci\u00f3n, destacando los criterios de exclusi\u00f3n, la importancia de los ex\u00e1menes m\u00e9dicos y los procedimientos necesarios para garantizar la seguridad en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, venipuncture, donor identification, collection system, hygiene procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6daaa8ba-0694-46df-8e8e-9c83d1dafb58", "node_type": "4", "metadata": {"page_label": "200", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Collection\n\n## Whole blood collection\n\nDonors should confirm their identity (by a method such as stating name and date of birth) immediately prior to venipuncture. Also prior to venipuncture, a check should be made to ensure that the collection system to be used is not damaged or contaminated, and that it is appropriate for the intended collection. Any abnormal moisture or discoloration suggests a defect and in such a case the collection system should be discarded. An investigation should be conducted to evaluate the extent of the problem and appropriate corrective actions should be taken. The collection systems should be used in accordance with the instructions of the manufacturer. Appropriate hand disinfection and personal hygiene procedures should be in place and should be performed by the personnel before each donation.\n\nA standardized and validated procedure for the preparation of the phlebotomy site should be followed using a suitable disinfection solution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "52f865b829c56abf35a1e8dbd5d4bee3e87a9d30cd752380e6a7bbe1603ac67e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Collection\n\n## Whole blood collection\n\nDonors should confirm their identity (by a method such as stating name and date of birth) immediately prior to venipuncture. Also prior to venipuncture, a check should be made to ensure that the collection system to be used is not damaged or contaminated, and that it is appropriate for the intended collection. Any abnormal moisture or discoloration suggests a defect and in such a case the collection system should be discarded. An investigation should be conducted to evaluate the extent of the problem and appropriate corrective actions should be taken. The collection systems should be used in accordance with the instructions of the manufacturer. Appropriate hand disinfection and personal hygiene procedures should be in place and should be performed by the personnel before each donation.\n\nA standardized and validated procedure for the preparation of the phlebotomy site should be followed using a suitable disinfection solution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 979, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "86c6eab2-3614-491d-8f28-0ed9e1838b74": {"__data__": {"id_": "86c6eab2-3614-491d-8f28-0ed9e1838b74", "embedding": null, "metadata": {"page_label": "201", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which should be allowed to dry depending on the type of disinfectant. The expiry date of the disinfectant should be checked. If refillable bottles are used, they should be cleaned before being refilled. The date of manufacture and the date of opening of in-house disinfectants should be stated on the label. The prepared skin area should not be touched after the disinfection and before the needle has been inserted. Care should be taken not to lean over or speak over the disinfected skin.\n\nFor blood donations, laboratory samples should be taken at the time of donation. Procedures should be designed to minimize the risk of microbial contamination to the unit, such as diverting at least the first 10 ml collected in the tubing into test tubes for testing. Methods should be implemented to minimize the deterioration of the sample, such as refrigeration of the sample if required by the manufacturer\u2019s instructions for the sample tube or test kit. The sample labelling process should include steps (such as labelling the tubes immediately at the chair side) to prevent the misidentification of samples. The test samples should be labelled immediately in a manner that links the donor, the samples and the blood component without breaching the confidentiality of the donor.\n\nAs soon as the collection process starts, good mixing of the blood with the anticoagulant solution should be ensured to avoid risks of activation of the coagulation cascade. The collection bag should be mixed gently at regular intervals thereafter. The mixing can be done by using a continuously running automatic mixing balance or by periodic manual mixing of the unit at least every 90 seconds. Collection of one standard unit of whole blood should be achieved within 12\u201315 minutes (depending on the component to be prepared later on), as longer durations may result in activation of the coagulation factors and cellular components.\n\nRecords should be kept for each activity associated with the donation, including identification of the person who performed the venipuncture. Records should also show any unsuccessful donation, adverse reactions or adverse events.\n\nThe maximum collection time for acceptance of the donation for component processing should be specified and controlled. Donations that exceed the maximum time period should be recorded and discarded.\n\nThe integral blood bag collection tubing should be sealed off at the end as close as possible to the blood bag and then removed.\n\nA system of unique donation numbers should be used to identify each donor and the related donation, all associated components, samples and records, and to link each one to the others.\n\nWhen the donation is completed, all records, blood bags and laboratory samples should be checked for the donation number issued. Donation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para la recolecci\u00f3n de sangre y el manejo de muestras en donaciones. Se enfatiza la importancia de la desinfecci\u00f3n adecuada, el etiquetado correcto de las muestras, la mezcla de sangre con anticoagulantes, y el mantenimiento de registros precisos para garantizar la seguridad y la trazabilidad de las donaciones. Tambi\u00e9n se menciona la necesidad de minimizar la contaminaci\u00f3n microbiana y de seguir procedimientos espec\u00edficos para el manejo de las muestras y la documentaci\u00f3n asociada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas recomendadas para evitar la contaminaci\u00f3n microbiana durante la recolecci\u00f3n de sangre?**\n   - El documento sugiere desviar al menos los primeros 10 ml de sangre recolectada en el tubo de recolecci\u00f3n hacia tubos de ensayo para pruebas, as\u00ed como implementar m\u00e9todos para minimizar la deterioraci\u00f3n de la muestra, como la refrigeraci\u00f3n, si es necesario.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para el etiquetado de muestras de sangre y c\u00f3mo se asegura la confidencialidad del donante?**\n   - Se recomienda etiquetar las muestras inmediatamente en el lugar de la donaci\u00f3n de manera que se vincule al donante, las muestras y el componente sangu\u00edneo, sin comprometer la confidencialidad del donante.\n\n3. **\u00bfQu\u00e9 registros deben mantenerse durante el proceso de donaci\u00f3n de sangre y qu\u00e9 informaci\u00f3n deben contener?**\n   - Se deben mantener registros de cada actividad asociada con la donaci\u00f3n, incluyendo la identificaci\u00f3n de la persona que realiz\u00f3 la venopunci\u00f3n, as\u00ed como cualquier donaci\u00f3n fallida, reacciones adversas o eventos adversos. Adem\u00e1s, se debe especificar y controlar el tiempo m\u00e1ximo de recolecci\u00f3n para la aceptaci\u00f3n de la donaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Identificaci\u00f3n del Donante**:\n   - M\u00e9todo recomendado: Confirmaci\u00f3n de identidad mediante nombre y fecha de nacimiento.\n\n2. **Verificaci\u00f3n del Sistema de Recolecci\u00f3n**:\n   - Inspecci\u00f3n del sistema: Asegurarse de que no est\u00e9 da\u00f1ado o contaminado.\n   - Acciones ante defectos: Descartar el sistema defectuoso y realizar una investigaci\u00f3n para evaluar el problema.\n\n3. **Higiene y Desinfecci\u00f3n**:\n   - Procedimientos de higiene: Importancia de la desinfecci\u00f3n de manos y pr\u00e1cticas de higiene personal por parte del personal antes de cada donaci\u00f3n.\n   - Preparaci\u00f3n del sitio de flebotom\u00eda: Seguir un procedimiento estandarizado y validado con una soluci\u00f3n de desinfecci\u00f3n adecuada.\n\n### Entidades Clave\n- **Donantes**: Personas que realizan la donaci\u00f3n de sangre.\n- **Sistema de Recolecci\u00f3n**: Equipamiento utilizado para la recolecci\u00f3n de sangre.\n- **Flebotom\u00eda**: Proceso de extracci\u00f3n de sangre.\n- **Personal**: Profesionales encargados de realizar la donaci\u00f3n y asegurar la higiene y seguridad del proceso.", "excerpt_keywords": "Keywords: blood donation, microbial contamination, sample labeling, anticoagulant mixing, record keeping"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8bea4c23-f9ac-4054-8055-99ad20e43e45", "node_type": "4", "metadata": {"page_label": "201", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which should be allowed to dry depending on the type of disinfectant. The expiry date of the disinfectant should be checked. If refillable bottles are used, they should be cleaned before being refilled. The date of manufacture and the date of opening of in-house disinfectants should be stated on the label. The prepared skin area should not be touched after the disinfection and before the needle has been inserted. Care should be taken not to lean over or speak over the disinfected skin.\n\nFor blood donations, laboratory samples should be taken at the time of donation. Procedures should be designed to minimize the risk of microbial contamination to the unit, such as diverting at least the first 10 ml collected in the tubing into test tubes for testing. Methods should be implemented to minimize the deterioration of the sample, such as refrigeration of the sample if required by the manufacturer\u2019s instructions for the sample tube or test kit. The sample labelling process should include steps (such as labelling the tubes immediately at the chair side) to prevent the misidentification of samples. The test samples should be labelled immediately in a manner that links the donor, the samples and the blood component without breaching the confidentiality of the donor.\n\nAs soon as the collection process starts, good mixing of the blood with the anticoagulant solution should be ensured to avoid risks of activation of the coagulation cascade. The collection bag should be mixed gently at regular intervals thereafter. The mixing can be done by using a continuously running automatic mixing balance or by periodic manual mixing of the unit at least every 90 seconds. Collection of one standard unit of whole blood should be achieved within 12\u201315 minutes (depending on the component to be prepared later on), as longer durations may result in activation of the coagulation factors and cellular components.\n\nRecords should be kept for each activity associated with the donation, including identification of the person who performed the venipuncture. Records should also show any unsuccessful donation, adverse reactions or adverse events.\n\nThe maximum collection time for acceptance of the donation for component processing should be specified and controlled. Donations that exceed the maximum time period should be recorded and discarded.\n\nThe integral blood bag collection tubing should be sealed off at the end as close as possible to the blood bag and then removed.\n\nA system of unique donation numbers should be used to identify each donor and the related donation, all associated components, samples and records, and to link each one to the others.\n\nWhen the donation is completed, all records, blood bags and laboratory samples should be checked for the donation number issued. Donation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a466491bac8a01c2463bd3c912e00a58066bd8c5f1f51e8cd341bd4c972e0ead", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "which should be allowed to dry depending on the type of disinfectant. The expiry date of the disinfectant should be checked. If refillable bottles are used, they should be cleaned before being refilled. The date of manufacture and the date of opening of in-house disinfectants should be stated on the label. The prepared skin area should not be touched after the disinfection and before the needle has been inserted. Care should be taken not to lean over or speak over the disinfected skin.\n\nFor blood donations, laboratory samples should be taken at the time of donation. Procedures should be designed to minimize the risk of microbial contamination to the unit, such as diverting at least the first 10 ml collected in the tubing into test tubes for testing. Methods should be implemented to minimize the deterioration of the sample, such as refrigeration of the sample if required by the manufacturer\u2019s instructions for the sample tube or test kit. The sample labelling process should include steps (such as labelling the tubes immediately at the chair side) to prevent the misidentification of samples. The test samples should be labelled immediately in a manner that links the donor, the samples and the blood component without breaching the confidentiality of the donor.\n\nAs soon as the collection process starts, good mixing of the blood with the anticoagulant solution should be ensured to avoid risks of activation of the coagulation cascade. The collection bag should be mixed gently at regular intervals thereafter. The mixing can be done by using a continuously running automatic mixing balance or by periodic manual mixing of the unit at least every 90 seconds. Collection of one standard unit of whole blood should be achieved within 12\u201315 minutes (depending on the component to be prepared later on), as longer durations may result in activation of the coagulation factors and cellular components.\n\nRecords should be kept for each activity associated with the donation, including identification of the person who performed the venipuncture. Records should also show any unsuccessful donation, adverse reactions or adverse events.\n\nThe maximum collection time for acceptance of the donation for component processing should be specified and controlled. Donations that exceed the maximum time period should be recorded and discarded.\n\nThe integral blood bag collection tubing should be sealed off at the end as close as possible to the blood bag and then removed.\n\nA system of unique donation numbers should be used to identify each donor and the related donation, all associated components, samples and records, and to link each one to the others.\n\nWhen the donation is completed, all records, blood bags and laboratory samples should be checked for the donation number issued. Donation", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2798, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7b7f59f6-8193-4713-afbf-405a61ae80c5": {"__data__": {"id_": "7b7f59f6-8193-4713-afbf-405a61ae80c5", "embedding": null, "metadata": {"page_label": "202", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "number labels that have not been used should be discarded using a controlled procedure. Procedures to exclude misidentification should be in place. After blood collection, the blood bags should be handled in a way that maintains the quality of the blood (see section 9.4.3.1).\n\nA standard operating procedure should be in place describing the actions to be taken following an unsuccessful donation. It should specify how to handle already labelled material and the circumstances under which a second venipuncture might be possible.\n\nAs with other GMP manufacturing steps, the donor product collection process should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and therefore such products should be considered non-conforming products and should not be released for distribution.\n\n### 9.3.2 Collection by apheresis\n\nIn automated procedures, whole blood is collected from the donor, mixed with anticoagulant, and passed through an automated apheresis device. The blood component of choice is separated from the other blood components which are returned to the donor in a series of collection/separation and return cycles. The operational parameters of the apheresis system should be implemented in compliance with the instructions of the equipment manufacturer and in compliance with any specified safety requirements of the NRA. In general, the anticoagulant \u2014 often 4% sodium citrate or anticoagulant citrate dextrose solution A (ACD-A) \u2014 is delivered at a rate that will yield a specified ratio of anticoagulant to blood. The volume of the component collected from the donor during one procedure and over a period of time should be regulated by internal policies based on current medical knowledge and on national regulations set by the NRA. The number of collection/separation and return cycles for each donor depends on the total volume of the component that is to be harvested. To determine the number of cycles to be employed, the equipment requires programming with data inputs such as donor weight, height and haemoglobin values, and the pre-donation platelet count if platelets are to be collected. The amount of time required for the donation procedure depends on the number of cycles. An adequately trained physician should be available during apheresis sessions.\n\nThe donor apheresis collection process should be followed at all times using validated methods. Any deviations from the established procedures and processes may result in products not meeting specifications and therefore they should be considered non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos de manejo de sangre**: El texto describe la importancia de seguir procedimientos controlados para el manejo de etiquetas de sangre no utilizadas y la manipulaci\u00f3n adecuada de las bolsas de sangre despu\u00e9s de la recolecci\u00f3n para mantener su calidad. Tambi\u00e9n se menciona la necesidad de un procedimiento operativo est\u00e1ndar para manejar donaciones fallidas.\n\n2. **Proceso de recolecci\u00f3n por af\u00e9resis**: Se detalla el proceso de recolecci\u00f3n de sangre mediante af\u00e9resis, que implica la separaci\u00f3n de componentes sangu\u00edneos utilizando un dispositivo automatizado. Se enfatiza la importancia de seguir las instrucciones del fabricante y las regulaciones nacionales, as\u00ed como la necesidad de contar con un m\u00e9dico capacitado durante el procedimiento.\n\n3. **Cumplimiento de normas de calidad**: Se subraya que cualquier desviaci\u00f3n de los procedimientos establecidos puede resultar en productos no conformes, los cuales no deben ser liberados para distribuci\u00f3n. Esto resalta la importancia de la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP) en la recolecci\u00f3n de productos de donantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar etiquetas de sangre no utilizadas y qu\u00e9 acciones se deben tomar en caso de una donaci\u00f3n fallida?**\n   - El contexto menciona que las etiquetas no utilizadas deben ser desechadas mediante un procedimiento controlado y que debe existir un procedimiento operativo est\u00e1ndar que describa las acciones a seguir tras una donaci\u00f3n fallida, incluyendo el manejo de material ya etiquetado.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros operativos que deben cumplirse durante el proceso de af\u00e9resis y qu\u00e9 datos son necesarios para programar el equipo?**\n   - Se indica que los par\u00e1metros operativos del sistema de af\u00e9resis deben seguir las instrucciones del fabricante y las regulaciones de la NRA. Para programar el equipo, se requieren datos como el peso, la altura, los valores de hemoglobina del donante y el conteo de plaquetas previo a la donaci\u00f3n si se van a recolectar plaquetas.\n\n3. **\u00bfQu\u00e9 consecuencias pueden surgir de las desviaciones en los procedimientos de recolecci\u00f3n de sangre y c\u00f3mo se deben clasificar los productos resultantes?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos puede resultar en productos que no cumplan con las especificaciones, los cuales deben ser considerados productos no conformes y no deben ser liberados para distribuci\u00f3n. Esto enfatiza la necesidad de adherirse a las Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Temas Clave\n\n1. **Desinfecci\u00f3n**: Importancia de permitir que el desinfectante se seque adecuadamente y verificar la fecha de caducidad. Se deben limpiar las botellas recargables antes de rellenarlas y etiquetar las fechas de fabricaci\u00f3n y apertura.\n\n2. **Recolecci\u00f3n de Sangre**: Se deben tomar muestras de laboratorio en el momento de la donaci\u00f3n, desviando al menos los primeros 10 ml para minimizar la contaminaci\u00f3n microbiana. Es esencial refrigerar las muestras si lo indican las instrucciones del fabricante.\n\n3. **Etiquetado de Muestras**: Las muestras deben etiquetarse inmediatamente en el lugar de la donaci\u00f3n para evitar la identificaci\u00f3n err\u00f3nea, asegurando la confidencialidad del donante.\n\n4. **Mezcla de Sangre y Anticoagulante**: Se debe garantizar una buena mezcla de la sangre con la soluci\u00f3n anticoagulante para evitar la activaci\u00f3n de la cascada de coagulaci\u00f3n. La recolecci\u00f3n debe completarse en un tiempo espec\u00edfico (12-15 minutos) para evitar la activaci\u00f3n de factores de coagulaci\u00f3n.\n\n5. **Mantenimiento de Registros**: Es necesario llevar un registro de todas las actividades relacionadas con la donaci\u00f3n, incluyendo la identificaci\u00f3n del personal, donaciones fallidas y reacciones adversas.\n\n6. **Control de Tiempo de Recolecci\u00f3n**: Se debe especificar y controlar el tiempo m\u00e1ximo de recolecci\u00f3n para la aceptaci\u00f3n de donaciones, registrando y descartando aquellas que excedan este tiempo.\n\n7. **Sistema de Identificaci\u00f3n**: Implementaci\u00f3n de un sistema de n\u00fameros de donaci\u00f3n \u00fanicos para vincular donantes, donaciones, componentes, muestras y registros.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Donantes de Sangre**: Personas que realizan la donaci\u00f3n.\n- **Muestras de Sangre**: Elementos recolectados para pruebas de laboratorio.\n- **Anticoagulantes**: Soluciones utilizadas para prevenir la coagulaci\u00f3n de la sangre.\n- **Registros de Donaci\u00f3n**: Documentaci\u00f3n que incluye detalles sobre el proceso de donaci\u00f3n y el personal involucrado. \n\nEste resumen destaca la importancia de seguir procedimientos rigurosos para garantizar la seguridad y la trazabilidad en el proceso de donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood collection, apheresis, standard operating procedure, quality control, non-conforming products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8b33015-a1b5-4982-ac37-de56aef322c0", "node_type": "4", "metadata": {"page_label": "202", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "number labels that have not been used should be discarded using a controlled procedure. Procedures to exclude misidentification should be in place. After blood collection, the blood bags should be handled in a way that maintains the quality of the blood (see section 9.4.3.1).\n\nA standard operating procedure should be in place describing the actions to be taken following an unsuccessful donation. It should specify how to handle already labelled material and the circumstances under which a second venipuncture might be possible.\n\nAs with other GMP manufacturing steps, the donor product collection process should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and therefore such products should be considered non-conforming products and should not be released for distribution.\n\n### 9.3.2 Collection by apheresis\n\nIn automated procedures, whole blood is collected from the donor, mixed with anticoagulant, and passed through an automated apheresis device. The blood component of choice is separated from the other blood components which are returned to the donor in a series of collection/separation and return cycles. The operational parameters of the apheresis system should be implemented in compliance with the instructions of the equipment manufacturer and in compliance with any specified safety requirements of the NRA. In general, the anticoagulant \u2014 often 4% sodium citrate or anticoagulant citrate dextrose solution A (ACD-A) \u2014 is delivered at a rate that will yield a specified ratio of anticoagulant to blood. The volume of the component collected from the donor during one procedure and over a period of time should be regulated by internal policies based on current medical knowledge and on national regulations set by the NRA. The number of collection/separation and return cycles for each donor depends on the total volume of the component that is to be harvested. To determine the number of cycles to be employed, the equipment requires programming with data inputs such as donor weight, height and haemoglobin values, and the pre-donation platelet count if platelets are to be collected. The amount of time required for the donation procedure depends on the number of cycles. An adequately trained physician should be available during apheresis sessions.\n\nThe donor apheresis collection process should be followed at all times using validated methods. Any deviations from the established procedures and processes may result in products not meeting specifications and therefore they should be considered non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bde9280f6f9446d4c947017d22dda3b16d9b9a0bd1c7f1207295a5d77bbafe7b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "number labels that have not been used should be discarded using a controlled procedure. Procedures to exclude misidentification should be in place. After blood collection, the blood bags should be handled in a way that maintains the quality of the blood (see section 9.4.3.1).\n\nA standard operating procedure should be in place describing the actions to be taken following an unsuccessful donation. It should specify how to handle already labelled material and the circumstances under which a second venipuncture might be possible.\n\nAs with other GMP manufacturing steps, the donor product collection process should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and therefore such products should be considered non-conforming products and should not be released for distribution.\n\n### 9.3.2 Collection by apheresis\n\nIn automated procedures, whole blood is collected from the donor, mixed with anticoagulant, and passed through an automated apheresis device. The blood component of choice is separated from the other blood components which are returned to the donor in a series of collection/separation and return cycles. The operational parameters of the apheresis system should be implemented in compliance with the instructions of the equipment manufacturer and in compliance with any specified safety requirements of the NRA. In general, the anticoagulant \u2014 often 4% sodium citrate or anticoagulant citrate dextrose solution A (ACD-A) \u2014 is delivered at a rate that will yield a specified ratio of anticoagulant to blood. The volume of the component collected from the donor during one procedure and over a period of time should be regulated by internal policies based on current medical knowledge and on national regulations set by the NRA. The number of collection/separation and return cycles for each donor depends on the total volume of the component that is to be harvested. To determine the number of cycles to be employed, the equipment requires programming with data inputs such as donor weight, height and haemoglobin values, and the pre-donation platelet count if platelets are to be collected. The amount of time required for the donation procedure depends on the number of cycles. An adequately trained physician should be available during apheresis sessions.\n\nThe donor apheresis collection process should be followed at all times using validated methods. Any deviations from the established procedures and processes may result in products not meeting specifications and therefore they should be considered non-conforming products and must not be released for distribution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2710, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2b122bea-1e58-43e5-b16f-9938592c96b7": {"__data__": {"id_": "2b122bea-1e58-43e5-b16f-9938592c96b7", "embedding": null, "metadata": {"page_label": "203", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3.3 Safety of donors\n\nAll measures should be taken to avoid anything that could adversely affect the donor before, during and after the donation. Special attention should be drawn to the potential risk of transmission of diseases or infections during the collection and sampling processes.\n\nDonors should be given post-donation instructions regarding a period of recovery, such as refraining from certain activities for a while, drinking more fluids than usual and making sure to eat appropriately after the donation. Donors should be advised to refrain from activities such as heavy lifting, operating large items of equipment and other strenuous activities for a period of time until their blood volume has recovered. Donors should also be provided with information on how to obtain medical advice if they experience an adverse donor reaction after leaving the blood establishment.\n\nThroughout the procedure of withdrawal of blood or blood components, the donor should be monitored. Personnel should be educated to provide appropriate aid in case of any adverse reaction. Donors should be kept under post-donation observation (e.g. for 15 minutes or more) prior to leaving the blood establishment and should be offered refreshment to replace fluid loss. If medically required, drinks may be provided to donors during collection (e.g. apheresis). In these circumstances, a suitable container for the drink is required. Donors should remain under observation for anticipated reactions to donation until they are able to articulate that they feel well enough to leave and be unattended. Immediate care should be given to the donor if there is a donor reaction. Information regarding donor reactions and a process to track and trend reactions should be in place in order to evaluate the number, type and severity of reactions. This information should be used to improve donor safety.\n\n# 9.4 Component preparation\n\nThe quality of the components is assured by control of all stages of manufacture, including donor identification, collection, separation of components, labelling, storage, packaging and dispatch. The standard operating procedures should describe the specifications for materials that will influence the quality of the final blood component. In particular, specifications should be in place for blood and blood components (intermediate and final components), starting materials, additive solutions, primary package material (bags) and equipment.\n\nThe standard operating procedures for component preparation should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and such products should be considered as non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Seguridad de los donantes**: Se enfatiza la importancia de proteger la salud de los donantes antes, durante y despu\u00e9s de la donaci\u00f3n de sangre. Se deben proporcionar instrucciones post-donaci\u00f3n y monitorear a los donantes para detectar reacciones adversas, asegurando que reciban atenci\u00f3n adecuada si es necesario.\n\n2. **Preparaci\u00f3n de componentes**: La calidad de los componentes sangu\u00edneos se garantiza mediante el control de todas las etapas de fabricaci\u00f3n, desde la identificaci\u00f3n del donante hasta el despacho del producto final. Se deben seguir procedimientos operativos est\u00e1ndar para asegurar que los productos cumplan con las especificaciones requeridas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de instrucciones post-donaci\u00f3n se deben proporcionar a los donantes para asegurar su recuperaci\u00f3n adecuada?**\n   - Las instrucciones incluyen refrendarse de actividades extenuantes, aumentar la ingesta de l\u00edquidos y asegurarse de comer adecuadamente despu\u00e9s de la donaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para monitorear a los donantes despu\u00e9s de la donaci\u00f3n y qu\u00e9 acciones deben tomarse en caso de reacciones adversas?**\n   - Los donantes deben ser monitoreados durante al menos 15 minutos despu\u00e9s de la donaci\u00f3n, y se les debe ofrecer refrigerios para reponer la p\u00e9rdida de l\u00edquidos. Si se presenta una reacci\u00f3n adversa, se debe proporcionar atenci\u00f3n inmediata.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si se producen desviaciones de los procedimientos operativos est\u00e1ndar durante la preparaci\u00f3n de componentes sangu\u00edneos?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos debe considerarse como un producto no conforme y no debe ser liberado para distribuci\u00f3n, asegurando as\u00ed que solo se distribuyan productos que cumplan con las especificaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Etiquetas de Sangre**:\n   - Importancia de desechar etiquetas no utilizadas mediante un procedimiento controlado.\n   - Necesidad de procedimientos para evitar la mala identificaci\u00f3n de muestras.\n\n2. **Calidad de la Sangre**:\n   - Las bolsas de sangre deben ser manipuladas adecuadamente despu\u00e9s de la recolecci\u00f3n para mantener su calidad.\n\n3. **Procedimientos Operativos Est\u00e1ndar**:\n   - Se requiere un procedimiento operativo est\u00e1ndar para manejar donaciones fallidas, incluyendo el manejo de material ya etiquetado y las condiciones para una segunda venopunci\u00f3n.\n\n4. **Recolecci\u00f3n de Sangre por Af\u00e9resis**:\n   - Proceso automatizado que implica la recolecci\u00f3n de sangre, mezcla con anticoagulante y separaci\u00f3n de componentes sangu\u00edneos.\n   - Cumplimiento de las instrucciones del fabricante y regulaciones de la NRA (Autoridad Nacional Reguladora).\n   - Uso de anticoagulantes como citrato de sodio al 4% o soluci\u00f3n A de citrato de dextrosa (ACD-A).\n\n5. **Par\u00e1metros Operativos**:\n   - Regulaci\u00f3n del volumen de componente recolectado y n\u00famero de ciclos de recolecci\u00f3n/separaci\u00f3n basados en pol\u00edticas internas y regulaciones nacionales.\n   - Datos necesarios para programar el equipo: peso, altura, valores de hemoglobina y conteo de plaquetas del donante.\n\n6. **Cumplimiento de Normas de Calidad**:\n   - Desviaciones de los procedimientos establecidos pueden resultar en productos no conformes, que no deben ser liberados para distribuci\u00f3n.\n   - Importancia de seguir las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los pasos del proceso de recolecci\u00f3n.\n\n### Entidades Clave\n- **NRA**: Autoridad Nacional Reguladora.\n- **Anticoagulantes**: Citrato de sodio, ACD-A.\n- **M\u00e9todos Validados**: Procedimientos que deben seguirse para asegurar la calidad y conformidad de los productos recolectados.", "excerpt_keywords": "Keywords: donor safety, post-donation instructions, component preparation, standard operating procedures, adverse reactions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2ccdb7fb-bb57-41f1-a382-e304154d9101", "node_type": "4", "metadata": {"page_label": "203", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3.3 Safety of donors\n\nAll measures should be taken to avoid anything that could adversely affect the donor before, during and after the donation. Special attention should be drawn to the potential risk of transmission of diseases or infections during the collection and sampling processes.\n\nDonors should be given post-donation instructions regarding a period of recovery, such as refraining from certain activities for a while, drinking more fluids than usual and making sure to eat appropriately after the donation. Donors should be advised to refrain from activities such as heavy lifting, operating large items of equipment and other strenuous activities for a period of time until their blood volume has recovered. Donors should also be provided with information on how to obtain medical advice if they experience an adverse donor reaction after leaving the blood establishment.\n\nThroughout the procedure of withdrawal of blood or blood components, the donor should be monitored. Personnel should be educated to provide appropriate aid in case of any adverse reaction. Donors should be kept under post-donation observation (e.g. for 15 minutes or more) prior to leaving the blood establishment and should be offered refreshment to replace fluid loss. If medically required, drinks may be provided to donors during collection (e.g. apheresis). In these circumstances, a suitable container for the drink is required. Donors should remain under observation for anticipated reactions to donation until they are able to articulate that they feel well enough to leave and be unattended. Immediate care should be given to the donor if there is a donor reaction. Information regarding donor reactions and a process to track and trend reactions should be in place in order to evaluate the number, type and severity of reactions. This information should be used to improve donor safety.\n\n# 9.4 Component preparation\n\nThe quality of the components is assured by control of all stages of manufacture, including donor identification, collection, separation of components, labelling, storage, packaging and dispatch. The standard operating procedures should describe the specifications for materials that will influence the quality of the final blood component. In particular, specifications should be in place for blood and blood components (intermediate and final components), starting materials, additive solutions, primary package material (bags) and equipment.\n\nThe standard operating procedures for component preparation should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and such products should be considered as non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3084777cf961c993bb84439a8b692737a7d19fa84bd66a4957ddc1a66c064544", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.3.3 Safety of donors\n\nAll measures should be taken to avoid anything that could adversely affect the donor before, during and after the donation. Special attention should be drawn to the potential risk of transmission of diseases or infections during the collection and sampling processes.\n\nDonors should be given post-donation instructions regarding a period of recovery, such as refraining from certain activities for a while, drinking more fluids than usual and making sure to eat appropriately after the donation. Donors should be advised to refrain from activities such as heavy lifting, operating large items of equipment and other strenuous activities for a period of time until their blood volume has recovered. Donors should also be provided with information on how to obtain medical advice if they experience an adverse donor reaction after leaving the blood establishment.\n\nThroughout the procedure of withdrawal of blood or blood components, the donor should be monitored. Personnel should be educated to provide appropriate aid in case of any adverse reaction. Donors should be kept under post-donation observation (e.g. for 15 minutes or more) prior to leaving the blood establishment and should be offered refreshment to replace fluid loss. If medically required, drinks may be provided to donors during collection (e.g. apheresis). In these circumstances, a suitable container for the drink is required. Donors should remain under observation for anticipated reactions to donation until they are able to articulate that they feel well enough to leave and be unattended. Immediate care should be given to the donor if there is a donor reaction. Information regarding donor reactions and a process to track and trend reactions should be in place in order to evaluate the number, type and severity of reactions. This information should be used to improve donor safety.\n\n# 9.4 Component preparation\n\nThe quality of the components is assured by control of all stages of manufacture, including donor identification, collection, separation of components, labelling, storage, packaging and dispatch. The standard operating procedures should describe the specifications for materials that will influence the quality of the final blood component. In particular, specifications should be in place for blood and blood components (intermediate and final components), starting materials, additive solutions, primary package material (bags) and equipment.\n\nThe standard operating procedures for component preparation should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and such products should be considered as non-conforming products and must not be released for distribution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2804, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "45e76eda-b3e6-43e0-97dd-61603016641f": {"__data__": {"id_": "45e76eda-b3e6-43e0-97dd-61603016641f", "embedding": null, "metadata": {"page_label": "204", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.1 Starting material\n\nThe starting materials for preparation of blood components are blood donations collected from suitable donors. Conditions of storage or transport, and the time prior to processing, are contributing factors to the quality of the product. Delays in preparation or unsuitable conditions of storage or transport may adversely affect the quality of the final product. Blood and blood components should be placed in controlled and validated conditions as soon as possible after venipuncture.\n\nDonations and samples should be transported to the processing site in accordance with procedures that ensure both a constant approved temperature and secure confinement. This is especially important when blood is transported from distant collection sites.\n\nProduct transport or shipping at appropriate temperatures and temperature monitoring are important to ensure optimal quality. One way to ensure the temperature of products is to use packaging methods validated to keep the blood within the required temperature limits. There should be validation data to demonstrate that the method of transport maintains the blood within the specified temperature range throughout the period of transportation. Alternatively, portable temperature loggers may be used to record the temperature during the transportation of blood to the processing site. Where the blood is not transported by the processing establishment itself, the responsibilities of the transport company should be clearly defined and periodic audits should be conducted to ensure compliance.\n\n# 9.4.2 Methods of production\n\nBlood components may be prepared by using a centrifugation step with subsequent separation, by using another validated preparation method, or by apheresis technology during collection.\n\nAlthough the use of closed systems is strongly recommended for all steps in component processing, open systems may exceptionally be necessary due to local constraints in an environment specifically designed to minimize the risk of bacterial contamination. When open systems are used, careful attention should be given to the use of aseptic procedures (12).\n\nWhere sterile connecting devices are used to maintain a functionally closed system they should be correctly used in accordance with a validated procedure. The resulting weld should be checked for satisfactory alignment and for validated integrity.\n\nThe critical equipment used for the preparation of blood components should be traceable to the corresponding manufacturing records.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la preparaci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de las condiciones de almacenamiento y transporte de las donaciones de sangre. Se destaca que las donaciones deben ser procesadas lo m\u00e1s pronto posible despu\u00e9s de la venopunci\u00f3n y que el transporte debe realizarse bajo condiciones controladas para mantener la calidad del producto. Adem\u00e1s, se describen los m\u00e9todos de producci\u00f3n de componentes sangu\u00edneos, recomendando el uso de sistemas cerrados y procedimientos as\u00e9pticos para minimizar el riesgo de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse durante el transporte de donaciones de sangre para asegurar su calidad?**\n   - Respuesta: Las donaciones y muestras deben ser transportadas en condiciones que aseguren una temperatura constante aprobada y un confinamiento seguro. Esto incluye el uso de m\u00e9todos de embalaje validados para mantener la sangre dentro de los l\u00edmites de temperatura requeridos y el uso de registradores de temperatura port\u00e1tiles para monitorear la temperatura durante el transporte.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si se utilizan sistemas abiertos en la preparaci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: Si se utilizan sistemas abiertos, se debe prestar especial atenci\u00f3n a la implementaci\u00f3n de procedimientos as\u00e9pticos. Adem\u00e1s, se deben utilizar dispositivos de conexi\u00f3n est\u00e9riles de manera correcta, siguiendo un procedimiento validado, y verificar la alineaci\u00f3n y la integridad de las soldaduras resultantes.\n\n3. **\u00bfQu\u00e9 tipo de validaci\u00f3n se requiere para los m\u00e9todos de transporte de sangre y por qu\u00e9 es importante?**\n   - Respuesta: Se requiere que existan datos de validaci\u00f3n que demuestren que el m\u00e9todo de transporte mantiene la sangre dentro del rango de temperatura especificado durante todo el per\u00edodo de transporte. Esto es importante para asegurar la calidad \u00f3ptima del producto final y minimizar el riesgo de deterioro de la sangre y sus componentes.", "prev_section_summary": "### Temas Clave:\n\n1. **Seguridad de los Donantes**:\n   - Importancia de proteger la salud de los donantes antes, durante y despu\u00e9s de la donaci\u00f3n.\n   - Riesgo de transmisi\u00f3n de enfermedades durante la recolecci\u00f3n.\n   - Instrucciones post-donaci\u00f3n para la recuperaci\u00f3n, incluyendo la restricci\u00f3n de actividades extenuantes y la recomendaci\u00f3n de aumentar la ingesta de l\u00edquidos y alimentaci\u00f3n adecuada.\n   - Monitoreo de donantes durante y despu\u00e9s de la donaci\u00f3n, con un per\u00edodo de observaci\u00f3n de al menos 15 minutos.\n   - Provisi\u00f3n de atenci\u00f3n inmediata en caso de reacciones adversas y establecimiento de un sistema para rastrear y evaluar estas reacciones.\n\n2. **Preparaci\u00f3n de Componentes Sangu\u00edneos**:\n   - Control de calidad en todas las etapas de fabricaci\u00f3n de componentes sangu\u00edneos.\n   - Procedimientos operativos est\u00e1ndar (POE) que deben seguirse para asegurar que los productos cumplan con las especificaciones.\n   - Manejo de desviaciones de los POE, consider\u00e1ndolas como productos no conformes que no deben ser distribuidos.\n\n### Entidades:\n\n- **Donantes**: Personas que realizan la donaci\u00f3n de sangre.\n- **Personal de Salud**: Personal encargado de monitorear y asistir a los donantes durante el proceso de donaci\u00f3n.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, que incluyen sangre entera y sus componentes separados.\n- **Procedimientos Operativos Est\u00e1ndar (POE)**: Documentos que describen los m\u00e9todos y especificaciones para la preparaci\u00f3n y manejo de componentes sangu\u00edneos.\n- **Reacciones Adversas**: Efectos no deseados que pueden ocurrir en los donantes tras la donaci\u00f3n de sangre. \n\nEste resumen destaca la importancia de la seguridad del donante y la calidad en la preparaci\u00f3n de componentes sangu\u00edneos, as\u00ed como los procedimientos necesarios para garantizar ambos aspectos.", "excerpt_keywords": "Keywords: blood components, transportation, quality assurance, aseptic procedures, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7af0b18f-1a4a-4e40-bf5d-2b96f2154d60", "node_type": "4", "metadata": {"page_label": "204", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.1 Starting material\n\nThe starting materials for preparation of blood components are blood donations collected from suitable donors. Conditions of storage or transport, and the time prior to processing, are contributing factors to the quality of the product. Delays in preparation or unsuitable conditions of storage or transport may adversely affect the quality of the final product. Blood and blood components should be placed in controlled and validated conditions as soon as possible after venipuncture.\n\nDonations and samples should be transported to the processing site in accordance with procedures that ensure both a constant approved temperature and secure confinement. This is especially important when blood is transported from distant collection sites.\n\nProduct transport or shipping at appropriate temperatures and temperature monitoring are important to ensure optimal quality. One way to ensure the temperature of products is to use packaging methods validated to keep the blood within the required temperature limits. There should be validation data to demonstrate that the method of transport maintains the blood within the specified temperature range throughout the period of transportation. Alternatively, portable temperature loggers may be used to record the temperature during the transportation of blood to the processing site. Where the blood is not transported by the processing establishment itself, the responsibilities of the transport company should be clearly defined and periodic audits should be conducted to ensure compliance.\n\n# 9.4.2 Methods of production\n\nBlood components may be prepared by using a centrifugation step with subsequent separation, by using another validated preparation method, or by apheresis technology during collection.\n\nAlthough the use of closed systems is strongly recommended for all steps in component processing, open systems may exceptionally be necessary due to local constraints in an environment specifically designed to minimize the risk of bacterial contamination. When open systems are used, careful attention should be given to the use of aseptic procedures (12).\n\nWhere sterile connecting devices are used to maintain a functionally closed system they should be correctly used in accordance with a validated procedure. The resulting weld should be checked for satisfactory alignment and for validated integrity.\n\nThe critical equipment used for the preparation of blood components should be traceable to the corresponding manufacturing records.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "db38d89e4770a0f85c8cf8081cbad170b964eb61573ac15e6b45ede83910b1a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.1 Starting material\n\nThe starting materials for preparation of blood components are blood donations collected from suitable donors. Conditions of storage or transport, and the time prior to processing, are contributing factors to the quality of the product. Delays in preparation or unsuitable conditions of storage or transport may adversely affect the quality of the final product. Blood and blood components should be placed in controlled and validated conditions as soon as possible after venipuncture.\n\nDonations and samples should be transported to the processing site in accordance with procedures that ensure both a constant approved temperature and secure confinement. This is especially important when blood is transported from distant collection sites.\n\nProduct transport or shipping at appropriate temperatures and temperature monitoring are important to ensure optimal quality. One way to ensure the temperature of products is to use packaging methods validated to keep the blood within the required temperature limits. There should be validation data to demonstrate that the method of transport maintains the blood within the specified temperature range throughout the period of transportation. Alternatively, portable temperature loggers may be used to record the temperature during the transportation of blood to the processing site. Where the blood is not transported by the processing establishment itself, the responsibilities of the transport company should be clearly defined and periodic audits should be conducted to ensure compliance.\n\n# 9.4.2 Methods of production\n\nBlood components may be prepared by using a centrifugation step with subsequent separation, by using another validated preparation method, or by apheresis technology during collection.\n\nAlthough the use of closed systems is strongly recommended for all steps in component processing, open systems may exceptionally be necessary due to local constraints in an environment specifically designed to minimize the risk of bacterial contamination. When open systems are used, careful attention should be given to the use of aseptic procedures (12).\n\nWhere sterile connecting devices are used to maintain a functionally closed system they should be correctly used in accordance with a validated procedure. The resulting weld should be checked for satisfactory alignment and for validated integrity.\n\nThe critical equipment used for the preparation of blood components should be traceable to the corresponding manufacturing records.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2521, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1897280d-5a38-4ad4-a92d-cb19c33e0e9d": {"__data__": {"id_": "1897280d-5a38-4ad4-a92d-cb19c33e0e9d", "embedding": null, "metadata": {"page_label": "205", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.1 Centrifugation\n\nThe centrifugation parameters (revolutions per minute, temperature, time, acceleration, deceleration) are important for the composition and characteristics of the specific components. These critical parameters should be defined on the basis of validation data that demonstrate a process that consistently produces quality products. For each run, the centrifugation records should identify the operator and confirm that the centrifugation process was performed according to specifications.\n\n# 9.4.2.2 Separation\n\nAfter centrifugation, the bag system should be carefully removed from the centrifuge and placed into a plasma expressor or blood separation system. The different layers of the components (red cells, platelets, plasma) should be transferred to the satellite bags within the closed systems, in a manner designed to optimize the harvest of the intended component while minimizing the carry-over of other component fractions.\n\nAlternatively, blood components can be separated during collection by apheresis technology (see section 9.3.2.).\n\n# 9.4.2.3 Freezing\n\nFreezing is an important processing step that has an impact on quality, especially of plasma. The rate at which freezing proceeds and the core temperature are both considered to be important parameters. Rapid plasma freezing prevents or reduces the loss of critical constituents such as Factor VIII in frozen plasma that is either recovered or obtained by apheresis.\n\nA system should be in place for ensuring that plasma is frozen to the specified core temperature within the time limit, keeping in mind that the freezing speed will be influenced by the type of plasma container, the freezing equipment and the loading pattern, as well as by the volume of plasma. The validation of the freezing process should consider worst-case scenarios that take into account both minimum and maximum loads and positions in the freezer. Recording the temperature of plasma units and the freezing time during a freezing process allows one to evaluate the freezing capacity of the equipment and ensures a standardized freezing process. Validation studies should be available and should demonstrate that the temperature of a frozen pack reaches the proposed storage temperature following the specifications. As indicated above, the aim is to achieve rapid freezing and thereafter to minimize temperature changes to the frozen plasma.\n\nFreezing of cellular components such as red cells or cellular therapy should follow a well defined, validated procedure that ensures the recovery.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre tres etapas cr\u00edticas en el procesamiento de componentes sangu\u00edneos: centrifugaci\u00f3n, separaci\u00f3n y congelaci\u00f3n. Se enfatiza la importancia de los par\u00e1metros de centrifugaci\u00f3n, la correcta separaci\u00f3n de los componentes sangu\u00edneos y la congelaci\u00f3n adecuada del plasma para mantener la calidad de los productos. Se menciona la necesidad de validar estos procesos y registrar datos relevantes para asegurar que se cumplan las especificaciones y se optimice la recuperaci\u00f3n de los componentes deseados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben definirse para el proceso de centrifugaci\u00f3n y por qu\u00e9 son importantes?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n y deceleraci\u00f3n. Son importantes porque afectan la composici\u00f3n y caracter\u00edsticas de los componentes espec\u00edficos, y deben basarse en datos de validaci\u00f3n que demuestren un proceso que produzca consistentemente productos de calidad.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que el plasma se congele adecuadamente y cu\u00e1les son los factores que influyen en la velocidad de congelaci\u00f3n?**\n   - Respuesta: Se debe tener un sistema para asegurar que el plasma se congele a la temperatura central especificada dentro del l\u00edmite de tiempo. Los factores que influyen en la velocidad de congelaci\u00f3n incluyen el tipo de contenedor de plasma, el equipo de congelaci\u00f3n, el patr\u00f3n de carga y el volumen de plasma.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la separaci\u00f3n de componentes sangu\u00edneos y c\u00f3mo se minimiza la transferencia de fracciones no deseadas?**\n   - Respuesta: Despu\u00e9s de la centrifugaci\u00f3n, el sistema de bolsas debe ser retirado cuidadosamente y colocado en un sistema de separaci\u00f3n de sangre. Las diferentes capas de componentes deben transferirse a bolsas sat\u00e9lites dentro de sistemas cerrados, optimizando la cosecha del componente deseado y minimizando la transferencia de otras fracciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Materiales de Inicio**:\n   - Las donaciones de sangre son el material inicial para la preparaci\u00f3n de componentes sangu\u00edneos.\n   - La calidad del producto final depende de las condiciones de almacenamiento, transporte y el tiempo antes del procesamiento.\n\n2. **Condiciones de Transporte**:\n   - Las donaciones deben ser transportadas en condiciones que aseguren una temperatura constante y un confinamiento seguro.\n   - Es crucial mantener la sangre en condiciones controladas, especialmente cuando se transporta desde sitios de recolecci\u00f3n lejanos.\n   - Se recomienda el uso de m\u00e9todos de embalaje validados y registradores de temperatura port\u00e1tiles para monitorear las condiciones durante el transporte.\n\n3. **M\u00e9todos de Producci\u00f3n**:\n   - Los componentes sangu\u00edneos pueden ser preparados mediante centrifugaci\u00f3n, otros m\u00e9todos validados o tecnolog\u00eda de af\u00e9resis.\n   - Se recomienda el uso de sistemas cerrados para minimizar el riesgo de contaminaci\u00f3n, aunque en situaciones excepcionales se pueden utilizar sistemas abiertos.\n\n4. **Procedimientos Asepticos**:\n   - En el uso de sistemas abiertos, se debe prestar especial atenci\u00f3n a los procedimientos as\u00e9pticos.\n   - Los dispositivos de conexi\u00f3n est\u00e9riles deben ser utilizados correctamente y se debe verificar la alineaci\u00f3n y la integridad de las soldaduras.\n\n5. **Validaci\u00f3n y Trazabilidad**:\n   - Es necesario contar con datos de validaci\u00f3n que demuestren que los m\u00e9todos de transporte mantienen la sangre dentro de los rangos de temperatura especificados.\n   - El equipo cr\u00edtico utilizado en la preparaci\u00f3n de componentes sangu\u00edneos debe ser trazable a los registros de fabricaci\u00f3n correspondientes.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, como plaquetas, plasma y gl\u00f3bulos rojos.\n- **Sistemas Cerrados y Abiertos**: M\u00e9todos de procesamiento de sangre que afectan la calidad y seguridad del producto.\n- **Temperatura Controlada**: Factor cr\u00edtico para mantener la calidad de las donaciones de sangre durante el transporte.", "excerpt_keywords": "Centrifugation, Separation, Freezing, Plasma, Validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6343f713-47ff-4663-a284-830d9acfc825", "node_type": "4", "metadata": {"page_label": "205", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.1 Centrifugation\n\nThe centrifugation parameters (revolutions per minute, temperature, time, acceleration, deceleration) are important for the composition and characteristics of the specific components. These critical parameters should be defined on the basis of validation data that demonstrate a process that consistently produces quality products. For each run, the centrifugation records should identify the operator and confirm that the centrifugation process was performed according to specifications.\n\n# 9.4.2.2 Separation\n\nAfter centrifugation, the bag system should be carefully removed from the centrifuge and placed into a plasma expressor or blood separation system. The different layers of the components (red cells, platelets, plasma) should be transferred to the satellite bags within the closed systems, in a manner designed to optimize the harvest of the intended component while minimizing the carry-over of other component fractions.\n\nAlternatively, blood components can be separated during collection by apheresis technology (see section 9.3.2.).\n\n# 9.4.2.3 Freezing\n\nFreezing is an important processing step that has an impact on quality, especially of plasma. The rate at which freezing proceeds and the core temperature are both considered to be important parameters. Rapid plasma freezing prevents or reduces the loss of critical constituents such as Factor VIII in frozen plasma that is either recovered or obtained by apheresis.\n\nA system should be in place for ensuring that plasma is frozen to the specified core temperature within the time limit, keeping in mind that the freezing speed will be influenced by the type of plasma container, the freezing equipment and the loading pattern, as well as by the volume of plasma. The validation of the freezing process should consider worst-case scenarios that take into account both minimum and maximum loads and positions in the freezer. Recording the temperature of plasma units and the freezing time during a freezing process allows one to evaluate the freezing capacity of the equipment and ensures a standardized freezing process. Validation studies should be available and should demonstrate that the temperature of a frozen pack reaches the proposed storage temperature following the specifications. As indicated above, the aim is to achieve rapid freezing and thereafter to minimize temperature changes to the frozen plasma.\n\nFreezing of cellular components such as red cells or cellular therapy should follow a well defined, validated procedure that ensures the recovery.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fe1651056e46c181040f47df5996fdfd13ff7ca86655ee5611d92b20b57a2be1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.2.1 Centrifugation\n\nThe centrifugation parameters (revolutions per minute, temperature, time, acceleration, deceleration) are important for the composition and characteristics of the specific components. These critical parameters should be defined on the basis of validation data that demonstrate a process that consistently produces quality products. For each run, the centrifugation records should identify the operator and confirm that the centrifugation process was performed according to specifications.\n\n# 9.4.2.2 Separation\n\nAfter centrifugation, the bag system should be carefully removed from the centrifuge and placed into a plasma expressor or blood separation system. The different layers of the components (red cells, platelets, plasma) should be transferred to the satellite bags within the closed systems, in a manner designed to optimize the harvest of the intended component while minimizing the carry-over of other component fractions.\n\nAlternatively, blood components can be separated during collection by apheresis technology (see section 9.3.2.).\n\n# 9.4.2.3 Freezing\n\nFreezing is an important processing step that has an impact on quality, especially of plasma. The rate at which freezing proceeds and the core temperature are both considered to be important parameters. Rapid plasma freezing prevents or reduces the loss of critical constituents such as Factor VIII in frozen plasma that is either recovered or obtained by apheresis.\n\nA system should be in place for ensuring that plasma is frozen to the specified core temperature within the time limit, keeping in mind that the freezing speed will be influenced by the type of plasma container, the freezing equipment and the loading pattern, as well as by the volume of plasma. The validation of the freezing process should consider worst-case scenarios that take into account both minimum and maximum loads and positions in the freezer. Recording the temperature of plasma units and the freezing time during a freezing process allows one to evaluate the freezing capacity of the equipment and ensures a standardized freezing process. Validation studies should be available and should demonstrate that the temperature of a frozen pack reaches the proposed storage temperature following the specifications. As indicated above, the aim is to achieve rapid freezing and thereafter to minimize temperature changes to the frozen plasma.\n\nFreezing of cellular components such as red cells or cellular therapy should follow a well defined, validated procedure that ensures the recovery.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2560, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e88a6390-e6e0-4ec3-b001-c20c4c55427c": {"__data__": {"id_": "e88a6390-e6e0-4ec3-b001-c20c4c55427c", "embedding": null, "metadata": {"page_label": "206", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.4 Leukocyte reduction\n\nWhole blood may be filtered for leukocyte reduction prior to centrifugation. Filtration of whole blood reduces the level of platelet and leukocyte contamination in plasma and red-cell concentrate preparations. Alternatively, components (e.g. red cells, platelets) may be filtered after separation. The introduction of any leukocyte reduction process either by filtration or special centrifugation technique requires careful validation that takes national requirements into account.\n\nIn addition to filter properties, the final result of filtration is influenced by several process parameters (e.g. flow rate, temperature, priming and rinsing) and by the properties of the component to be filtered (e.g. storage history of the component, number of leukocytes and number of platelets). The filtration procedure should incorporate manufacturing specifications such as height and temperature. The method should be fully validated under the conditions to be used. Careful attention should be given to the rate of filtration. Rapid or slow filtration may indicate process failures.\n\nSpecial centrifugation or filtration techniques of leukocyte reduction are used in several apheresis systems. When a standardized procedure is established on the apheresis system, the method should be validated under the conditions to be used.\n\nAn appropriate method should be used for leukocyte counting after leukocyte reduction. The method should be validated to ensure linearity, accuracy and reproducibility.\n\n# 9.4.2.5 Irradiation\n\nRegular dose-mapping of irradiation equipment should be performed. The exposure time should be set to ensure that all blood and blood components receive the specified recommended minimum dose, with no part receiving more than the maximum recommended dose. The common recommended minimum dose is 25 Gy (2500 cGy).\n\nCare should be taken regarding the increased potassium leakage from red cells after their irradiation, either by limiting the shelf-life of the red-cell concentrate or by further manufacturing steps such as washing.\n\nFor the radioactive source, allowance should be made at least annually for source decay. A second independent timing device should be used to monitor exposure time.\n\nRadiation indicators should be used as aids to differentiating between irradiated and non-irradiated blood and blood components. A defined", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda dos procedimientos importantes en la manipulaci\u00f3n de componentes sangu\u00edneos: la reducci\u00f3n de leucocitos y la irradiaci\u00f3n. La reducci\u00f3n de leucocitos se puede realizar mediante filtraci\u00f3n antes o despu\u00e9s de la centrifugaci\u00f3n, y requiere una validaci\u00f3n cuidadosa de los m\u00e9todos utilizados, considerando par\u00e1metros como el flujo, la temperatura y las caracter\u00edsticas del componente. Por otro lado, la irradiaci\u00f3n de componentes sangu\u00edneos debe seguir un mapeo regular de dosis para asegurar que todos los componentes reciban la dosis m\u00ednima recomendada, y se deben tomar precauciones para manejar el aumento de la fuga de potasio en los gl\u00f3bulos rojos irradiados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los par\u00e1metros de proceso que pueden influir en el resultado de la filtraci\u00f3n para la reducci\u00f3n de leucocitos?**\n   - Respuesta: Los par\u00e1metros de proceso que pueden influir en el resultado de la filtraci\u00f3n incluyen el flujo, la temperatura, el primado y el enjuague, as\u00ed como las propiedades del componente a filtrar, como la historia de almacenamiento, el n\u00famero de leucocitos y el n\u00famero de plaquetas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que todos los componentes sangu\u00edneos reciban la dosis m\u00ednima recomendada durante la irradiaci\u00f3n?**\n   - Respuesta: Se debe establecer un tiempo de exposici\u00f3n que garantice que todos los componentes sangu\u00edneos reciban la dosis m\u00ednima recomendada de 25 Gy (2500 cGy), y se debe realizar un mapeo regular de dosis del equipo de irradiaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta respecto a la fuga de potasio en los gl\u00f3bulos rojos despu\u00e9s de la irradiaci\u00f3n?**\n   - Respuesta: Se debe tener cuidado con el aumento de la fuga de potasio de los gl\u00f3bulos rojos irradiados, lo que puede manejarse limitando la vida \u00fatil del concentrado de gl\u00f3bulos rojos o mediante pasos adicionales de fabricaci\u00f3n, como el lavado.", "prev_section_summary": "### Temas Clave\n\n1. **Centrifugaci\u00f3n**:\n   - Importancia de los par\u00e1metros cr\u00edticos: revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n y deceleraci\u00f3n.\n   - Necesidad de definir estos par\u00e1metros bas\u00e1ndose en datos de validaci\u00f3n para asegurar la calidad del producto.\n   - Registro de datos de centrifugaci\u00f3n, incluyendo la identificaci\u00f3n del operador y la confirmaci\u00f3n del cumplimiento de especificaciones.\n\n2. **Separaci\u00f3n**:\n   - Proceso de extracci\u00f3n cuidadosa del sistema de bolsas despu\u00e9s de la centrifugaci\u00f3n.\n   - Transferencia de capas de componentes sangu\u00edneos (gl\u00f3bulos rojos, plaquetas, plasma) a bolsas sat\u00e9lites en sistemas cerrados.\n   - Optimizaci\u00f3n de la cosecha del componente deseado y minimizaci\u00f3n de la transferencia de fracciones no deseadas.\n   - Posibilidad de separaci\u00f3n de componentes sangu\u00edneos durante la recolecci\u00f3n mediante tecnolog\u00eda de af\u00e9resis.\n\n3. **Congelaci\u00f3n**:\n   - Importancia de la congelaci\u00f3n en la calidad del plasma, especialmente en la preservaci\u00f3n de factores cr\u00edticos como el Factor VIII.\n   - Par\u00e1metros cr\u00edticos: velocidad de congelaci\u00f3n y temperatura central.\n   - Necesidad de un sistema para asegurar la congelaci\u00f3n a la temperatura especificada dentro de un tiempo l\u00edmite.\n   - Influencia de factores como el tipo de contenedor, equipo de congelaci\u00f3n, patr\u00f3n de carga y volumen de plasma en la velocidad de congelaci\u00f3n.\n   - Validaci\u00f3n del proceso de congelaci\u00f3n considerando escenarios de carga m\u00ednima y m\u00e1xima.\n   - Registro de temperatura y tiempo de congelaci\u00f3n para evaluar la capacidad del equipo y asegurar un proceso estandarizado.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: gl\u00f3bulos rojos, plaquetas, plasma.\n- **Par\u00e1metros de Procesamiento**: revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n, deceleraci\u00f3n.\n- **Tecnolog\u00eda de Af\u00e9resis**: m\u00e9todo alternativo para la separaci\u00f3n de componentes sangu\u00edneos.\n- **Factor VIII**: componente cr\u00edtico en el plasma que debe preservarse durante la congelaci\u00f3n.\n- **Sistemas de Bolsas y Equipos de Congelaci\u00f3n**: utilizados en el procesamiento y almacenamiento de componentes sangu\u00edneos. \n\nEste resumen destaca la importancia de seguir procedimientos validados y registrar datos relevantes en cada etapa del procesamiento de componentes sangu\u00edneos para garantizar la calidad y eficacia del producto final.", "excerpt_keywords": "Keywords: leukocyte reduction, irradiation, blood components, filtration, apheresis"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd3d20e7-5d8a-4247-b8bc-ea74dec650bf", "node_type": "4", "metadata": {"page_label": "206", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.4 Leukocyte reduction\n\nWhole blood may be filtered for leukocyte reduction prior to centrifugation. Filtration of whole blood reduces the level of platelet and leukocyte contamination in plasma and red-cell concentrate preparations. Alternatively, components (e.g. red cells, platelets) may be filtered after separation. The introduction of any leukocyte reduction process either by filtration or special centrifugation technique requires careful validation that takes national requirements into account.\n\nIn addition to filter properties, the final result of filtration is influenced by several process parameters (e.g. flow rate, temperature, priming and rinsing) and by the properties of the component to be filtered (e.g. storage history of the component, number of leukocytes and number of platelets). The filtration procedure should incorporate manufacturing specifications such as height and temperature. The method should be fully validated under the conditions to be used. Careful attention should be given to the rate of filtration. Rapid or slow filtration may indicate process failures.\n\nSpecial centrifugation or filtration techniques of leukocyte reduction are used in several apheresis systems. When a standardized procedure is established on the apheresis system, the method should be validated under the conditions to be used.\n\nAn appropriate method should be used for leukocyte counting after leukocyte reduction. The method should be validated to ensure linearity, accuracy and reproducibility.\n\n# 9.4.2.5 Irradiation\n\nRegular dose-mapping of irradiation equipment should be performed. The exposure time should be set to ensure that all blood and blood components receive the specified recommended minimum dose, with no part receiving more than the maximum recommended dose. The common recommended minimum dose is 25 Gy (2500 cGy).\n\nCare should be taken regarding the increased potassium leakage from red cells after their irradiation, either by limiting the shelf-life of the red-cell concentrate or by further manufacturing steps such as washing.\n\nFor the radioactive source, allowance should be made at least annually for source decay. A second independent timing device should be used to monitor exposure time.\n\nRadiation indicators should be used as aids to differentiating between irradiated and non-irradiated blood and blood components. A defined", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d1d319bc001b0ed14df92c40f4c0800859de84ab87356fa5e77524895018f50c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.2.4 Leukocyte reduction\n\nWhole blood may be filtered for leukocyte reduction prior to centrifugation. Filtration of whole blood reduces the level of platelet and leukocyte contamination in plasma and red-cell concentrate preparations. Alternatively, components (e.g. red cells, platelets) may be filtered after separation. The introduction of any leukocyte reduction process either by filtration or special centrifugation technique requires careful validation that takes national requirements into account.\n\nIn addition to filter properties, the final result of filtration is influenced by several process parameters (e.g. flow rate, temperature, priming and rinsing) and by the properties of the component to be filtered (e.g. storage history of the component, number of leukocytes and number of platelets). The filtration procedure should incorporate manufacturing specifications such as height and temperature. The method should be fully validated under the conditions to be used. Careful attention should be given to the rate of filtration. Rapid or slow filtration may indicate process failures.\n\nSpecial centrifugation or filtration techniques of leukocyte reduction are used in several apheresis systems. When a standardized procedure is established on the apheresis system, the method should be validated under the conditions to be used.\n\nAn appropriate method should be used for leukocyte counting after leukocyte reduction. The method should be validated to ensure linearity, accuracy and reproducibility.\n\n# 9.4.2.5 Irradiation\n\nRegular dose-mapping of irradiation equipment should be performed. The exposure time should be set to ensure that all blood and blood components receive the specified recommended minimum dose, with no part receiving more than the maximum recommended dose. The common recommended minimum dose is 25 Gy (2500 cGy).\n\nCare should be taken regarding the increased potassium leakage from red cells after their irradiation, either by limiting the shelf-life of the red-cell concentrate or by further manufacturing steps such as washing.\n\nFor the radioactive source, allowance should be made at least annually for source decay. A second independent timing device should be used to monitor exposure time.\n\nRadiation indicators should be used as aids to differentiating between irradiated and non-irradiated blood and blood components. A defined", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2381, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "738cd72e-7cae-4408-adeb-cc1f16412a00": {"__data__": {"id_": "738cd72e-7cae-4408-adeb-cc1f16412a00", "embedding": null, "metadata": {"page_label": "207", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n\nBlood components may be obtained using the methods described in section 9.4.2. However, the sequence and the combination of the methods used in the production of blood components may vary from one product to another.\n\nThe collection process itself is already crucial for the quality of blood components. Measures such as a reliable arm-cleaning and disinfection procedure, the use of closed and sterile collection systems, and appropriate microbiological controls should be implemented. Time limits should be defined for the processing of blood components.\n\nThere are detailed recommendations concerning the preparation and quality assurance of blood components. See for instance *Guide to the preparation, use and quality assurance of blood components* of the Council of Europe (13). In the following sections, examples of the most important blood components are described. Where NRA requirements exist, they should be followed. Specifications of a number of products are described below.\n\n## 9.4.3.1 Whole blood\n\nWhole blood for transfusion is blood that is taken from a donor who has been assessed and found suitable as meeting the blood establishment and NRA acceptance criteria. Whole blood is collected in sterile and pyrogen-free containers with a suitable anticoagulant. It may be used without further processing. In some cases, whole blood for transfusion may also be used after leukocyte reduction.\n\nThe temperature of whole blood stored for transfusion should remain controlled between 1\u00b0 and 6\u00b0C or in a more stringent range defined by the NRA. The storage time depends on the anticoagulant/preservative solution used.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage.\n\nThe primary use of whole blood is as a source material for the preparation of blood components. Transportation and further manufacturing processes", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, destacando la importancia del proceso de recolecci\u00f3n y las medidas necesarias para garantizar la calidad de estos componentes. Se menciona que la sangre total puede ser utilizada sin procesamiento adicional o despu\u00e9s de una reducci\u00f3n de leucocitos, y se establecen par\u00e1metros cr\u00edticos para el control de calidad, como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis al final del almacenamiento. Adem\u00e1s, se hace referencia a la necesidad de cumplir con los requisitos de las autoridades reguladoras nacionales (NRA) y se mencionan recomendaciones espec\u00edficas para la preparaci\u00f3n y aseguramiento de la calidad de los componentes sangu\u00edneos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben implementarse durante el proceso de recolecci\u00f3n de sangre para garantizar la calidad de los componentes sangu\u00edneos?**\n   - Esta pregunta busca detalles sobre los procedimientos de limpieza, desinfecci\u00f3n y control microbiol\u00f3gico que son cruciales para la calidad de la sangre recolectada.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos se deben verificar durante el control de calidad de la sangre total y por qu\u00e9 son importantes?**\n   - Esta pregunta se enfoca en la importancia de los par\u00e1metros como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis, y c\u00f3mo estos afectan la seguridad y eficacia de la sangre para transfusiones.\n\n3. **\u00bfQu\u00e9 condiciones de almacenamiento son necesarias para la sangre total destinada a transfusiones y c\u00f3mo var\u00edan seg\u00fan el anticoagulante utilizado?**\n   - Esta pregunta busca informaci\u00f3n sobre las especificaciones de temperatura y tiempo de almacenamiento, as\u00ed como la influencia del tipo de anticoagulante en la duraci\u00f3n de la sangre total.\n\n### Resumen de nivel superior\n\nEl documento proporciona directrices sobre la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, enfatizando la importancia de un proceso de recolecci\u00f3n adecuado y el cumplimiento de normativas. Se describen las caracter\u00edsticas de la sangre total, su almacenamiento y los controles de calidad necesarios para asegurar su idoneidad para transfusiones. Adem\u00e1s, se menciona la variabilidad en los m\u00e9todos de producci\u00f3n de componentes sangu\u00edneos y la necesidad de seguir las recomendaciones de las autoridades reguladoras.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reducci\u00f3n de Leucocitos**:\n   - **M\u00e9todos**: Filtraci\u00f3n de sangre entera antes o despu\u00e9s de la centrifugaci\u00f3n.\n   - **Objetivo**: Reducir la contaminaci\u00f3n por plaquetas y leucocitos en preparaciones de plasma y concentrados de gl\u00f3bulos rojos.\n   - **Validaci\u00f3n**: Es esencial validar los procesos de reducci\u00f3n de leucocitos, considerando requisitos nacionales y par\u00e1metros como flujo, temperatura, primado y enjuague.\n   - **Par\u00e1metros de Proceso**: Incluyen la historia de almacenamiento del componente, n\u00famero de leucocitos y plaquetas.\n   - **Contaje de Leucocitos**: Se debe utilizar un m\u00e9todo validado para asegurar linealidad, precisi\u00f3n y reproducibilidad.\n\n2. **Irradiaci\u00f3n**:\n   - **Dosis M\u00ednima Recomendada**: Se recomienda una dosis m\u00ednima de 25 Gy (2500 cGy) para todos los componentes sangu\u00edneos.\n   - **Mapeo de Dosis**: Se debe realizar un mapeo regular del equipo de irradiaci\u00f3n para asegurar la correcta exposici\u00f3n.\n   - **Fugas de Potasio**: Se debe tener cuidado con el aumento de la fuga de potasio en gl\u00f3bulos rojos irradiados, limitando su vida \u00fatil o mediante pasos adicionales como el lavado.\n   - **Monitoreo**: Uso de un dispositivo de temporizaci\u00f3n independiente para controlar el tiempo de exposici\u00f3n y considerar la descomposici\u00f3n del fuente radiactiva al menos anualmente.\n\n3. **Indicadores de Radiaci\u00f3n**: Se deben utilizar para diferenciar entre sangre y componentes sangu\u00edneos irradiados y no irradiados.\n\n### Entidades Clave\n- **Componentes Sangu\u00edneos**: Sangre entera, plasma, concentrados de gl\u00f3bulos rojos, plaquetas.\n- **Par\u00e1metros de Proceso**: Flujo, temperatura, primado, enjuague.\n- **Dosis de Irradiaci\u00f3n**: 25 Gy (2500 cGy).\n- **Equipos**: Equipos de filtraci\u00f3n y de irradiaci\u00f3n.\n- **M\u00e9todos de Validaci\u00f3n**: M\u00e9todos para el conteo de leucocitos y procedimientos de irradiaci\u00f3n.", "excerpt_keywords": "Keywords: blood components, quality assurance, whole blood, storage conditions, leukocyte reduction"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e5c0a73a-0587-47f6-b40b-ee276295ae61", "node_type": "4", "metadata": {"page_label": "207", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n\nBlood components may be obtained using the methods described in section 9.4.2. However, the sequence and the combination of the methods used in the production of blood components may vary from one product to another.\n\nThe collection process itself is already crucial for the quality of blood components. Measures such as a reliable arm-cleaning and disinfection procedure, the use of closed and sterile collection systems, and appropriate microbiological controls should be implemented. Time limits should be defined for the processing of blood components.\n\nThere are detailed recommendations concerning the preparation and quality assurance of blood components. See for instance *Guide to the preparation, use and quality assurance of blood components* of the Council of Europe (13). In the following sections, examples of the most important blood components are described. Where NRA requirements exist, they should be followed. Specifications of a number of products are described below.\n\n## 9.4.3.1 Whole blood\n\nWhole blood for transfusion is blood that is taken from a donor who has been assessed and found suitable as meeting the blood establishment and NRA acceptance criteria. Whole blood is collected in sterile and pyrogen-free containers with a suitable anticoagulant. It may be used without further processing. In some cases, whole blood for transfusion may also be used after leukocyte reduction.\n\nThe temperature of whole blood stored for transfusion should remain controlled between 1\u00b0 and 6\u00b0C or in a more stringent range defined by the NRA. The storage time depends on the anticoagulant/preservative solution used.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage.\n\nThe primary use of whole blood is as a source material for the preparation of blood components. Transportation and further manufacturing processes", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "256158788fa6bd98d5cf4c39bece2e4eca0708f6d42cfb2fe616e1b152a56c95", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.3 Blood and blood components\n\nBlood components may be obtained using the methods described in section 9.4.2. However, the sequence and the combination of the methods used in the production of blood components may vary from one product to another.\n\nThe collection process itself is already crucial for the quality of blood components. Measures such as a reliable arm-cleaning and disinfection procedure, the use of closed and sterile collection systems, and appropriate microbiological controls should be implemented. Time limits should be defined for the processing of blood components.\n\nThere are detailed recommendations concerning the preparation and quality assurance of blood components. See for instance *Guide to the preparation, use and quality assurance of blood components* of the Council of Europe (13). In the following sections, examples of the most important blood components are described. Where NRA requirements exist, they should be followed. Specifications of a number of products are described below.\n\n## 9.4.3.1 Whole blood\n\nWhole blood for transfusion is blood that is taken from a donor who has been assessed and found suitable as meeting the blood establishment and NRA acceptance criteria. Whole blood is collected in sterile and pyrogen-free containers with a suitable anticoagulant. It may be used without further processing. In some cases, whole blood for transfusion may also be used after leukocyte reduction.\n\nThe temperature of whole blood stored for transfusion should remain controlled between 1\u00b0 and 6\u00b0C or in a more stringent range defined by the NRA. The storage time depends on the anticoagulant/preservative solution used.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage.\n\nThe primary use of whole blood is as a source material for the preparation of blood components. Transportation and further manufacturing processes", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2125, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c94d4fdd-433b-4588-92b8-2a8fc14e23a4": {"__data__": {"id_": "c94d4fdd-433b-4588-92b8-2a8fc14e23a4", "embedding": null, "metadata": {"page_label": "208", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be developed to maximize the number of components that may be produced from a whole blood donation. After collection, whole blood should be kept at a controlled temperature appropriate to the intended component manufacture and should be delivered to the production site as quickly as possible. If whole blood is collected away from the production site, the validated transport systems should ensure that correct temperatures are maintained throughout the process and that the product is delivered within 24 hours. The period between collection and further processing depends on the product but should not exceed 24 hours.\n\nThe whole blood may also be filtrated to reduce leukocyte content prior to further processing.\n\nComponents should be manufactured by a method validated as meeting the predefined product specifications.\n\n### 9.4.3.2 Red-cell concentrate\n\nRed-cell concentrates are obtained from whole blood by centrifugation and removal of plasma with or without buffy coat, depending on the centrifugation parameters. After subsequent addition of an appropriate nutrient solution, the red cells should be stored at 1\u20136\u00b0C as soon as possible. Alternatively, red-cell concentrates may be obtained using an apheresis system and likewise stored at 1\u20136\u00b0C. Red-cell units that exceed 10\u00b0C after reaching the storage temperature should be discarded. The red-cell concentrate may be used for transfusion without further processing.\n\nTo obtain leukocyte-reduced red-cell concentrates, either whole blood filtration can be applied prior to separation or there can be a post-separation filtration of the red-cell concentrate. A fully validated procedure should be established to determine optimum conditions for use of a leukocyte reduction method.\n\nRed-cell concentrates are stored under the same storage conditions as whole blood. The storage time depends on the anticoagulant/preservative solution used.\n\nFurther methods of preparation, such as irradiation or washing, are applied to obtain specific red-cell products, depending on the clinical indication.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). Parameters measured depend on the type of red-cell concentrate product obtained. At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage;\n- residual leukocytes, if leukocyte reduction is performed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre la recolecci\u00f3n, procesamiento y almacenamiento de componentes sangu\u00edneos, espec\u00edficamente concentrados de gl\u00f3bulos rojos. Se enfatiza la importancia de mantener la sangre entera a temperaturas controladas y de transportarla r\u00e1pidamente al sitio de producci\u00f3n. Se describen los m\u00e9todos de obtenci\u00f3n de concentrados de gl\u00f3bulos rojos, incluyendo la centrifugaci\u00f3n y la aferesis, as\u00ed como la necesidad de realizar controles de calidad peri\u00f3dicos para asegurar que los productos cumplan con las especificaciones predefinidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los concentrados de gl\u00f3bulos rojos y qu\u00e9 sucede si se excede la temperatura m\u00e1xima permitida?**\n   - Respuesta: Los concentrados de gl\u00f3bulos rojos deben ser almacenados a una temperatura de 1\u20136\u00b0C. Si las unidades de gl\u00f3bulos rojos superan los 10\u00b0C despu\u00e9s de alcanzar la temperatura de almacenamiento, deben ser descartadas.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se pueden utilizar para reducir el contenido de leucocitos en los concentrados de gl\u00f3bulos rojos y cu\u00e1l es la importancia de validar estos m\u00e9todos?**\n   - Respuesta: Se pueden aplicar filtraciones de sangre entera antes de la separaci\u00f3n o filtraciones post-separaci\u00f3n del concentrado de gl\u00f3bulos rojos para reducir el contenido de leucocitos. Es crucial establecer un procedimiento completamente validado para determinar las condiciones \u00f3ptimas para el uso de un m\u00e9todo de reducci\u00f3n de leucocitos.\n\n3. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos deben ser verificados durante los ensayos de control de calidad de los concentrados de gl\u00f3bulos rojos?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos que deben ser verificados incluyen el volumen, la hemoglobina o hematocrito, la hem\u00f3lisis al final del almacenamiento y los leucocitos residuales, si se ha realizado una reducci\u00f3n de leucocitos.", "prev_section_summary": "### Temas Clave\n\n1. **Obtenci\u00f3n de Componentes Sangu\u00edneos**: Se describen los m\u00e9todos para obtener componentes sangu\u00edneos, destacando que la secuencia y combinaci\u00f3n de estos m\u00e9todos pueden variar seg\u00fan el producto.\n\n2. **Importancia del Proceso de Recolecci\u00f3n**: Se enfatiza que el proceso de recolecci\u00f3n es crucial para la calidad de los componentes sangu\u00edneos, incluyendo medidas de limpieza, desinfecci\u00f3n y controles microbiol\u00f3gicos.\n\n3. **Recomendaciones y Normativas**: Se mencionan recomendaciones detalladas para la preparaci\u00f3n y aseguramiento de la calidad de los componentes sangu\u00edneos, as\u00ed como la necesidad de cumplir con los requisitos de las autoridades reguladoras nacionales (NRA).\n\n4. **Sangre Total**: Se define la sangre total para transfusi\u00f3n, su recolecci\u00f3n en condiciones est\u00e9riles y su uso potencial sin procesamiento adicional o tras reducci\u00f3n de leucocitos.\n\n5. **Condiciones de Almacenamiento**: Se especifican las condiciones de temperatura (1\u00b0 a 6\u00b0C) para el almacenamiento de sangre total y c\u00f3mo estas pueden variar seg\u00fan el anticoagulante utilizado.\n\n6. **Control de Calidad**: Se establecen par\u00e1metros cr\u00edticos que deben verificarse durante el control de calidad, como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis al final del almacenamiento.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: Sangre total y sus derivados.\n- **Autoridades Reguladoras Nacionales (NRA)**: Organismos que establecen criterios de aceptaci\u00f3n para la sangre y sus componentes.\n- **Anticoagulantes**: Sustancias utilizadas para prevenir la coagulaci\u00f3n de la sangre durante su almacenamiento.\n- **Contenedores Est\u00e9riles**: Recipientes utilizados para la recolecci\u00f3n y almacenamiento de sangre.\n- **Controles Microbiol\u00f3gicos**: Medidas implementadas para asegurar la ausencia de contaminantes en la sangre recolectada.\n\n### Resumen\n\nLa secci\u00f3n aborda la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, subrayando la importancia del proceso de recolecci\u00f3n y las medidas necesarias para garantizar su calidad. Se define la sangre total y se establecen condiciones de almacenamiento y par\u00e1metros de control de calidad que deben cumplirse para asegurar su idoneidad para transfusiones. Adem\u00e1s, se hace hincapi\u00e9 en la necesidad de seguir las recomendaciones de las autoridades reguladoras.", "excerpt_keywords": "Keywords: blood components, red-cell concentrate, leukocyte reduction, quality control, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a7ab810a-10ff-42a5-86f8-a8cde489b2be", "node_type": "4", "metadata": {"page_label": "208", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be developed to maximize the number of components that may be produced from a whole blood donation. After collection, whole blood should be kept at a controlled temperature appropriate to the intended component manufacture and should be delivered to the production site as quickly as possible. If whole blood is collected away from the production site, the validated transport systems should ensure that correct temperatures are maintained throughout the process and that the product is delivered within 24 hours. The period between collection and further processing depends on the product but should not exceed 24 hours.\n\nThe whole blood may also be filtrated to reduce leukocyte content prior to further processing.\n\nComponents should be manufactured by a method validated as meeting the predefined product specifications.\n\n### 9.4.3.2 Red-cell concentrate\n\nRed-cell concentrates are obtained from whole blood by centrifugation and removal of plasma with or without buffy coat, depending on the centrifugation parameters. After subsequent addition of an appropriate nutrient solution, the red cells should be stored at 1\u20136\u00b0C as soon as possible. Alternatively, red-cell concentrates may be obtained using an apheresis system and likewise stored at 1\u20136\u00b0C. Red-cell units that exceed 10\u00b0C after reaching the storage temperature should be discarded. The red-cell concentrate may be used for transfusion without further processing.\n\nTo obtain leukocyte-reduced red-cell concentrates, either whole blood filtration can be applied prior to separation or there can be a post-separation filtration of the red-cell concentrate. A fully validated procedure should be established to determine optimum conditions for use of a leukocyte reduction method.\n\nRed-cell concentrates are stored under the same storage conditions as whole blood. The storage time depends on the anticoagulant/preservative solution used.\n\nFurther methods of preparation, such as irradiation or washing, are applied to obtain specific red-cell products, depending on the clinical indication.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). Parameters measured depend on the type of red-cell concentrate product obtained. At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage;\n- residual leukocytes, if leukocyte reduction is performed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0904e7afa018ba2aeb152de9a6dadc1c07a1b11328e3a4f713188d48e414fd1f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "should be developed to maximize the number of components that may be produced from a whole blood donation. After collection, whole blood should be kept at a controlled temperature appropriate to the intended component manufacture and should be delivered to the production site as quickly as possible. If whole blood is collected away from the production site, the validated transport systems should ensure that correct temperatures are maintained throughout the process and that the product is delivered within 24 hours. The period between collection and further processing depends on the product but should not exceed 24 hours.\n\nThe whole blood may also be filtrated to reduce leukocyte content prior to further processing.\n\nComponents should be manufactured by a method validated as meeting the predefined product specifications.\n\n### 9.4.3.2 Red-cell concentrate\n\nRed-cell concentrates are obtained from whole blood by centrifugation and removal of plasma with or without buffy coat, depending on the centrifugation parameters. After subsequent addition of an appropriate nutrient solution, the red cells should be stored at 1\u20136\u00b0C as soon as possible. Alternatively, red-cell concentrates may be obtained using an apheresis system and likewise stored at 1\u20136\u00b0C. Red-cell units that exceed 10\u00b0C after reaching the storage temperature should be discarded. The red-cell concentrate may be used for transfusion without further processing.\n\nTo obtain leukocyte-reduced red-cell concentrates, either whole blood filtration can be applied prior to separation or there can be a post-separation filtration of the red-cell concentrate. A fully validated procedure should be established to determine optimum conditions for use of a leukocyte reduction method.\n\nRed-cell concentrates are stored under the same storage conditions as whole blood. The storage time depends on the anticoagulant/preservative solution used.\n\nFurther methods of preparation, such as irradiation or washing, are applied to obtain specific red-cell products, depending on the clinical indication.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). Parameters measured depend on the type of red-cell concentrate product obtained. At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage;\n- residual leukocytes, if leukocyte reduction is performed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2513, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "87e3ed6f-2352-4f9f-8e58-2cd116a10a4d": {"__data__": {"id_": "87e3ed6f-2352-4f9f-8e58-2cd116a10a4d", "embedding": null, "metadata": {"page_label": "209", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.3 Platelet concentrate\n\nPlatelet concentrates are derived from whole blood or are obtained by apheresis.\n\nAfter collection, whole blood can be kept for up to 24 hours in conditions that are consistent with the preparation of plasma (see section 9.4.3.4.) and validated to maintain a temperature between 20\u00b0C and 24\u00b0C, following international or NRA recommendations. The whole blood unit is centrifuged so that an optimal number of platelets remain in plasma (platelet-rich plasma, or PRP). Platelet concentrates are then obtained by hard-spin centrifugation of PRP and are then resuspended.\n\nHowever, if whole blood is centrifuged so that the blood platelets are primarily sedimented to the buffy coat layer, the buffy coat is separated and further processed to obtain a platelet concentrate. Either a single buffy coat or a pool of buffy coats is diluted with plasma or an appropriate nutrient solution, and platelets are concentrated by further centrifugation. The platelet content per unit depends on the method of preparation. Similarly, the residual leukocyte content will vary according to the centrifugation parameters.\n\nPlatelet concentrates (both from whole blood and apheresis) should be stored in conditions that guarantee that viability and haemostatic activities are optimally preserved. The storage temperature should be 20\u201324\u00b0C. Continuous gentle agitation of platelets during storage should be sufficient to guarantee the availability of oxygen to the platelets (but should be as gentle as possible). A storage time should be defined in accordance with national regulations set by the NRA; it should normally not exceed five days in the absence of additional measures.\n\nIn special circumstances, volume-reduced, split, washed or irradiated platelet concentrates can be prepared for specific treatments.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- platelet content;\n- residual leukocytes, if leukocyte reduction is performed;\n- pH, measured at the end of the recommended shelf-life.\n\n# 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n\nPlasma for transfusion is prepared either from whole blood or from plasma collected by apheresis, and is frozen within a defined period of time to a temperature that should adequately maintain the labile coagulation factors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona informaci\u00f3n detallada sobre la obtenci\u00f3n, almacenamiento y control de calidad de los concentrados de plaquetas, que pueden derivarse de sangre total o ser obtenidos por af\u00e9resis. Se describen los procedimientos de centrifugaci\u00f3n para obtener plaquetas ricas en plasma y se enfatiza la importancia de mantener condiciones \u00f3ptimas de almacenamiento (20-24\u00b0C) para preservar la viabilidad y actividad hemost\u00e1tica de las plaquetas. Tambi\u00e9n se menciona la necesidad de realizar controles de calidad peri\u00f3dicos sobre el producto final, verificando par\u00e1metros cr\u00edticos como el volumen, contenido de plaquetas, leucocitos residuales y pH.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los concentrados de plaquetas y por qu\u00e9 son importantes?**\n   - Las condiciones de almacenamiento recomendadas para los concentrados de plaquetas son mantener una temperatura entre 20\u00b0C y 24\u00b0C, con agitaci\u00f3n continua y suave. Estas condiciones son importantes para garantizar la viabilidad y las actividades hemost\u00e1ticas \u00f3ptimas de las plaquetas.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos deben ser verificados durante el control de calidad de los concentrados de plaquetas?**\n   - Durante el control de calidad de los concentrados de plaquetas, se deben verificar al menos los siguientes par\u00e1metros cr\u00edticos: volumen, contenido de plaquetas, leucocitos residuales (si se realiza reducci\u00f3n de leucocitos) y pH, medido al final de la vida \u00fatil recomendada.\n\n3. **\u00bfQu\u00e9 m\u00e9todos se pueden utilizar para obtener concentrados de plaquetas a partir de sangre total y c\u00f3mo afecta esto al contenido de plaquetas?**\n   - Los concentrados de plaquetas se pueden obtener a partir de sangre total mediante centrifugaci\u00f3n para separar el plasma rico en plaquetas (PRP) o mediante la sedimentaci\u00f3n de plaquetas en la capa de buffy coat. El contenido de plaquetas por unidad depende del m\u00e9todo de preparaci\u00f3n utilizado, as\u00ed como de los par\u00e1metros de centrifugaci\u00f3n aplicados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recolecci\u00f3n y Transporte de Sangre Entera**:\n   - La sangre entera debe ser recolectada y mantenida a temperaturas controladas para maximizar la producci\u00f3n de componentes sangu\u00edneos.\n   - Debe ser transportada al sitio de producci\u00f3n r\u00e1pidamente, preferiblemente dentro de las 24 horas posteriores a la recolecci\u00f3n.\n\n2. **Filtraci\u00f3n de Sangre**:\n   - Se puede filtrar la sangre entera para reducir el contenido de leucocitos antes del procesamiento adicional.\n\n3. **Concentrados de Gl\u00f3bulos Rojos**:\n   - Se obtienen mediante centrifugaci\u00f3n y eliminaci\u00f3n del plasma, con o sin el buffy coat.\n   - Deben ser almacenados a temperaturas de 1\u20136\u00b0C. Las unidades que superen los 10\u00b0C deben ser descartadas.\n   - Pueden ser utilizados para transfusiones sin procesamiento adicional.\n\n4. **Reducci\u00f3n de Leucocitos**:\n   - Se pueden aplicar m\u00e9todos de filtraci\u00f3n antes o despu\u00e9s de la separaci\u00f3n para obtener concentrados de gl\u00f3bulos rojos con bajo contenido de leucocitos.\n   - Es esencial validar estos m\u00e9todos para asegurar su eficacia.\n\n5. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el producto final para asegurar la consistencia del proceso de fabricaci\u00f3n.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen:\n     - Volumen\n     - Hemoglobina o hematocrito\n     - Hem\u00f3lisis al final del almacenamiento\n     - Leucocitos residuales (si se realiz\u00f3 reducci\u00f3n de leucocitos)\n\n### Entidades Clave\n- **Sangre Entera**\n- **Concentrados de Gl\u00f3bulos Rojos**\n- **Leucocitos**\n- **Temperaturas de Almacenamiento (1\u20136\u00b0C, 10\u00b0C)**\n- **M\u00e9todos de Filtraci\u00f3n**\n- **Control de Calidad**\n- **Par\u00e1metros Cr\u00edticos (volumen, hemoglobina, hem\u00f3lisis, leucocitos residuales)**\n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas en la recolecci\u00f3n, procesamiento y almacenamiento de componentes sangu\u00edneos, as\u00ed como la necesidad de controles de calidad rigurosos para garantizar la seguridad y eficacia de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: platelet concentrates, whole blood, apheresis, quality control, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "513e3499-a3d9-41c2-8dea-ada5884b6527", "node_type": "4", "metadata": {"page_label": "209", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.3 Platelet concentrate\n\nPlatelet concentrates are derived from whole blood or are obtained by apheresis.\n\nAfter collection, whole blood can be kept for up to 24 hours in conditions that are consistent with the preparation of plasma (see section 9.4.3.4.) and validated to maintain a temperature between 20\u00b0C and 24\u00b0C, following international or NRA recommendations. The whole blood unit is centrifuged so that an optimal number of platelets remain in plasma (platelet-rich plasma, or PRP). Platelet concentrates are then obtained by hard-spin centrifugation of PRP and are then resuspended.\n\nHowever, if whole blood is centrifuged so that the blood platelets are primarily sedimented to the buffy coat layer, the buffy coat is separated and further processed to obtain a platelet concentrate. Either a single buffy coat or a pool of buffy coats is diluted with plasma or an appropriate nutrient solution, and platelets are concentrated by further centrifugation. The platelet content per unit depends on the method of preparation. Similarly, the residual leukocyte content will vary according to the centrifugation parameters.\n\nPlatelet concentrates (both from whole blood and apheresis) should be stored in conditions that guarantee that viability and haemostatic activities are optimally preserved. The storage temperature should be 20\u201324\u00b0C. Continuous gentle agitation of platelets during storage should be sufficient to guarantee the availability of oxygen to the platelets (but should be as gentle as possible). A storage time should be defined in accordance with national regulations set by the NRA; it should normally not exceed five days in the absence of additional measures.\n\nIn special circumstances, volume-reduced, split, washed or irradiated platelet concentrates can be prepared for specific treatments.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- platelet content;\n- residual leukocytes, if leukocyte reduction is performed;\n- pH, measured at the end of the recommended shelf-life.\n\n# 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n\nPlasma for transfusion is prepared either from whole blood or from plasma collected by apheresis, and is frozen within a defined period of time to a temperature that should adequately maintain the labile coagulation factors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ee40bd8262cd0dae77a0feed30665782ba5f52513d9a2326cb932b0ba138d656", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.3.3 Platelet concentrate\n\nPlatelet concentrates are derived from whole blood or are obtained by apheresis.\n\nAfter collection, whole blood can be kept for up to 24 hours in conditions that are consistent with the preparation of plasma (see section 9.4.3.4.) and validated to maintain a temperature between 20\u00b0C and 24\u00b0C, following international or NRA recommendations. The whole blood unit is centrifuged so that an optimal number of platelets remain in plasma (platelet-rich plasma, or PRP). Platelet concentrates are then obtained by hard-spin centrifugation of PRP and are then resuspended.\n\nHowever, if whole blood is centrifuged so that the blood platelets are primarily sedimented to the buffy coat layer, the buffy coat is separated and further processed to obtain a platelet concentrate. Either a single buffy coat or a pool of buffy coats is diluted with plasma or an appropriate nutrient solution, and platelets are concentrated by further centrifugation. The platelet content per unit depends on the method of preparation. Similarly, the residual leukocyte content will vary according to the centrifugation parameters.\n\nPlatelet concentrates (both from whole blood and apheresis) should be stored in conditions that guarantee that viability and haemostatic activities are optimally preserved. The storage temperature should be 20\u201324\u00b0C. Continuous gentle agitation of platelets during storage should be sufficient to guarantee the availability of oxygen to the platelets (but should be as gentle as possible). A storage time should be defined in accordance with national regulations set by the NRA; it should normally not exceed five days in the absence of additional measures.\n\nIn special circumstances, volume-reduced, split, washed or irradiated platelet concentrates can be prepared for specific treatments.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- platelet content;\n- residual leukocytes, if leukocyte reduction is performed;\n- pH, measured at the end of the recommended shelf-life.\n\n# 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n\nPlasma for transfusion is prepared either from whole blood or from plasma collected by apheresis, and is frozen within a defined period of time to a temperature that should adequately maintain the labile coagulation factors.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2497, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4c254fd3-695b-4356-b554-349e1610809e": {"__data__": {"id_": "4c254fd3-695b-4356-b554-349e1610809e", "embedding": null, "metadata": {"page_label": "210", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in a functional state, consistent with the intended use of the plasma. In particular, Factor VIII content is critical both as a quality indicator and to assure the efficacy of cryoprecipitate.\n\nIf plasma is separated from a unit of whole blood that is refrigerated to 4\u00b0C, centrifugation should preferably take place within eight hours of collection (14,15,16).\n\nIf the whole blood unit is rapidly cooled to 20\u201324\u00b0C and maintained at this constant temperature after collection, separation can take place within 18\u201320 hours because such conditions have been found to protect Factor VIII (17).\n\nIf plasma is collected by apheresis, the freezing process should begin as soon as possible, and ideally not later than six hours after the completion of the apheresis process. In compliance with NRA requirements, consideration should be given to the time frames of processing with respect to the anticoagulant and device used and the product to be manufactured.\n\nThe freezing process should be validated and should take place in a system that will allow complete freezing to a predefined core temperature in a predefined time (see section 9.4.2.3).\n\nProduct stability is dependent on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (more than one year) the optimal storage temperature is minus 25\u00b0C or colder (18).\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- Factor VIII activity (especially if plasma is used to treat Factor VIII deficiencies);\n- residual leukocytes, if leukocyte reduction is performed;\n- leakage;\n- visual changes.\n\nVirus inactivation and/or quarantine of plasma for transfusion are applied in some countries. Further complementary guidance with respect to virus inactivation is available in *WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products* (2), and in other publications (19,20).\n\nPlasma for transfusion is suitable as source material for the production of fractionated products, and particularly Factor VIII concentrates or other labile factors. Plasma prepared in other ways should meet the specifications of the plasma fractionators and the requirements of the pharmacopoeia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Proceso de separaci\u00f3n y congelaci\u00f3n del plasma**: El plasma debe ser separado de la sangre entera bajo condiciones espec\u00edficas de temperatura y tiempo para preservar su calidad, especialmente el contenido de Factor VIII. La congelaci\u00f3n debe iniciarse r\u00e1pidamente despu\u00e9s de la recolecci\u00f3n, y se deben seguir protocolos validados para asegurar la estabilidad del producto.\n\n2. **Control de calidad del plasma**: Se deben realizar controles de calidad peri\u00f3dicos en el plasma final para garantizar la consistencia del proceso de fabricaci\u00f3n. Los par\u00e1metros cr\u00edticos incluyen el volumen, la actividad del Factor VIII, la reducci\u00f3n de leucocitos, y la detecci\u00f3n de cambios visuales.\n\n3. **Seguridad viral del plasma**: Existen directrices sobre la inactivaci\u00f3n de virus y el manejo del plasma para transfusiones, que son esenciales para asegurar la seguridad del producto. Estas directrices son complementarias a las especificaciones de los fraccionadores de plasma y los requisitos de la farmacopea.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones \u00f3ptimas de temperatura y tiempo para la separaci\u00f3n del plasma de la sangre entera, y c\u00f3mo afectan estas condiciones al contenido de Factor VIII?**\n   - Respuesta: Si el plasma se separa de una unidad de sangre entera refrigerada a 4\u00b0C, la centrifugaci\u00f3n debe realizarse preferiblemente dentro de las ocho horas posteriores a la recolecci\u00f3n. Si la sangre se enfr\u00eda r\u00e1pidamente a 20-24\u00b0C, la separaci\u00f3n puede realizarse dentro de 18-20 horas, lo que ayuda a proteger el Factor VIII.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos se deben verificar durante el control de calidad del plasma, y por qu\u00e9 son importantes?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen el volumen, la actividad del Factor VIII, los leucocitos residuales (si se realiza reducci\u00f3n de leucocitos), la fuga y los cambios visuales. Estos son importantes para asegurar que el plasma cumpla con los est\u00e1ndares de calidad y eficacia, especialmente en el tratamiento de deficiencias de Factor VIII.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad viral del plasma destinado a transfusiones?**\n   - Respuesta: En algunos pa\u00edses, se aplican procedimientos de inactivaci\u00f3n de virus y/o cuarentena del plasma. Se recomienda seguir las directrices de la OMS sobre la inactivaci\u00f3n y eliminaci\u00f3n de virus para asegurar la seguridad viral de los productos de plasma humano.", "prev_section_summary": "### Temas Clave\n\n1. **Obtenci\u00f3n de Concentrados de Plaquetas**:\n   - Derivados de sangre total o obtenidos por af\u00e9resis.\n   - M\u00e9todos de centrifugaci\u00f3n para separar plasma rico en plaquetas (PRP) y concentrados de plaquetas.\n\n2. **Condiciones de Almacenamiento**:\n   - Temperatura recomendada: 20\u00b0C a 24\u00b0C.\n   - Agitaci\u00f3n continua y suave para mantener la viabilidad y actividad hemost\u00e1tica de las plaquetas.\n   - Tiempo de almacenamiento no debe exceder cinco d\u00edas sin medidas adicionales.\n\n3. **Control de Calidad**:\n   - Importancia de realizar controles peri\u00f3dicos sobre el producto final.\n   - Par\u00e1metros cr\u00edticos a verificar: volumen, contenido de plaquetas, leucocitos residuales (si se realiza reducci\u00f3n de leucocitos) y pH.\n\n4. **Preparaciones Especiales**:\n   - Posibilidad de preparar concentrados de plaquetas reducidos en volumen, divididos, lavados o irradiados para tratamientos espec\u00edficos.\n\n### Entidades\n\n- **Concentrados de Plaquetas**: Producto derivado de la sangre utilizado en transfusiones.\n- **Sangre Total**: Fuente de donde se obtienen los concentrados de plaquetas.\n- **Af\u00e9resis**: M\u00e9todo de recolecci\u00f3n de componentes sangu\u00edneos.\n- **Plasma Rico en Plaquetas (PRP)**: Producto intermedio en la obtenci\u00f3n de concentrados de plaquetas.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad que establece regulaciones sobre el almacenamiento y manejo de productos sangu\u00edneos.\n- **Controles de Calidad**: Proceso para asegurar la consistencia y seguridad del producto final.", "excerpt_keywords": "Keywords: plasma separation, Factor VIII, quality control, virus inactivation, storage temperature"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e34f0a79-d386-4433-807d-460c1883d25b", "node_type": "4", "metadata": {"page_label": "210", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in a functional state, consistent with the intended use of the plasma. In particular, Factor VIII content is critical both as a quality indicator and to assure the efficacy of cryoprecipitate.\n\nIf plasma is separated from a unit of whole blood that is refrigerated to 4\u00b0C, centrifugation should preferably take place within eight hours of collection (14,15,16).\n\nIf the whole blood unit is rapidly cooled to 20\u201324\u00b0C and maintained at this constant temperature after collection, separation can take place within 18\u201320 hours because such conditions have been found to protect Factor VIII (17).\n\nIf plasma is collected by apheresis, the freezing process should begin as soon as possible, and ideally not later than six hours after the completion of the apheresis process. In compliance with NRA requirements, consideration should be given to the time frames of processing with respect to the anticoagulant and device used and the product to be manufactured.\n\nThe freezing process should be validated and should take place in a system that will allow complete freezing to a predefined core temperature in a predefined time (see section 9.4.2.3).\n\nProduct stability is dependent on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (more than one year) the optimal storage temperature is minus 25\u00b0C or colder (18).\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- Factor VIII activity (especially if plasma is used to treat Factor VIII deficiencies);\n- residual leukocytes, if leukocyte reduction is performed;\n- leakage;\n- visual changes.\n\nVirus inactivation and/or quarantine of plasma for transfusion are applied in some countries. Further complementary guidance with respect to virus inactivation is available in *WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products* (2), and in other publications (19,20).\n\nPlasma for transfusion is suitable as source material for the production of fractionated products, and particularly Factor VIII concentrates or other labile factors. Plasma prepared in other ways should meet the specifications of the plasma fractionators and the requirements of the pharmacopoeia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "896529ee3f7cdf7b978cb1eb93127efa128dc026fc3b30cee6ec098ab5c96aa5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in a functional state, consistent with the intended use of the plasma. In particular, Factor VIII content is critical both as a quality indicator and to assure the efficacy of cryoprecipitate.\n\nIf plasma is separated from a unit of whole blood that is refrigerated to 4\u00b0C, centrifugation should preferably take place within eight hours of collection (14,15,16).\n\nIf the whole blood unit is rapidly cooled to 20\u201324\u00b0C and maintained at this constant temperature after collection, separation can take place within 18\u201320 hours because such conditions have been found to protect Factor VIII (17).\n\nIf plasma is collected by apheresis, the freezing process should begin as soon as possible, and ideally not later than six hours after the completion of the apheresis process. In compliance with NRA requirements, consideration should be given to the time frames of processing with respect to the anticoagulant and device used and the product to be manufactured.\n\nThe freezing process should be validated and should take place in a system that will allow complete freezing to a predefined core temperature in a predefined time (see section 9.4.2.3).\n\nProduct stability is dependent on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (more than one year) the optimal storage temperature is minus 25\u00b0C or colder (18).\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- Factor VIII activity (especially if plasma is used to treat Factor VIII deficiencies);\n- residual leukocytes, if leukocyte reduction is performed;\n- leakage;\n- visual changes.\n\nVirus inactivation and/or quarantine of plasma for transfusion are applied in some countries. Further complementary guidance with respect to virus inactivation is available in *WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products* (2), and in other publications (19,20).\n\nPlasma for transfusion is suitable as source material for the production of fractionated products, and particularly Factor VIII concentrates or other labile factors. Plasma prepared in other ways should meet the specifications of the plasma fractionators and the requirements of the pharmacopoeia.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2452, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "05b078ba-9f7d-475e-b691-6d5abcb01b4a": {"__data__": {"id_": "05b078ba-9f7d-475e-b691-6d5abcb01b4a", "embedding": null, "metadata": {"page_label": "211", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\nCryoprecipitate is the cryoglobulin fraction of plasma and contains a major portion of the Factor VIII, von Willebrand factor, fibrinogen, Factor XIII and fibronectin present in plasma. Cryoprecipitate is obtained from fresh frozen plasma that is prepared in a way that protects Factor VIII stability. Plasma is allowed to thaw either overnight at 2\u20136\u00b0C or by a rapid-thaw technique. Following thawing, the supernatant cryo-poor plasma and the cryoprecipitate are separated by hard-spin centrifugation. The cryo-poor plasma is then expressed into a transfer bag. The two components are refrozen to the appropriate core temperature.\n\nStability during storage depends on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (for two years or longer) the optimal storage temperature is minus 25\u00b0C or colder.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays of cryoprecipitate:\n\n- volume;\n- Factor VIII activity;\n- clottable fibrinogen;\n- von Willebrand factor activity (if applicable).\n\nVirus inactivation and/or quarantine are applied in some countries.\n\nUnder certain circumstances the use of small pool preparations of cryoprecipitate (by pooling single-donor cryoprecipitate units) may be desired.\n\n# 9.5 Laboratory testing\n\n## 9.5.1 Screening tests for infectious disease markers\n\n### 9.5.1.1 Testing requirements\n\nThe following tests, which are considered mandatory by all regulatory agencies, are relevant to the preparation of blood components and should be performed on each individual blood donation:\n\n- an approved test for Hepatitis B surface antigen (HBsAg);\n- an approved test for anti-HIV1/HIV2;\n- an approved test for anti-HCV.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la preparaci\u00f3n y almacenamiento de crioprecipitados y plasma pobre en crioprecipitados, destacando la importancia de la estabilidad de Factor VIII y otros componentes durante el proceso. Se menciona que el crioprecipitado se obtiene de plasma fresco congelado y que su almacenamiento a largo plazo debe ser a temperaturas de -25\u00b0C o m\u00e1s fr\u00edas. Tambi\u00e9n se enfatiza la necesidad de controles de calidad peri\u00f3dicos y la realizaci\u00f3n de pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas en cada donaci\u00f3n de sangre.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben ser verificados durante los ensayos de control de calidad del crioprecipitado?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos que deben ser verificados incluyen el volumen, la actividad del Factor VIII, el fibrin\u00f3geno coagulable y la actividad del factor von Willebrand (si es aplicable).\n\n2. **\u00bfQu\u00e9 condiciones de almacenamiento son \u00f3ptimas para el crioprecipitado destinado a almacenamiento a largo plazo?**\n   - Respuesta: Para el almacenamiento a largo plazo (por dos a\u00f1os o m\u00e1s), la temperatura \u00f3ptima de almacenamiento es de -25\u00b0C o m\u00e1s fr\u00eda.\n\n3. **\u00bfQu\u00e9 pruebas son obligatorias para cada donaci\u00f3n de sangre seg\u00fan las agencias regulatorias?**\n   - Respuesta: Las pruebas obligatorias incluyen una prueba aprobada para el ant\u00edgeno de superficie de Hepatitis B (HBsAg), una prueba aprobada para anti-HIV1/HIV2 y una prueba aprobada para anti-HCV.", "prev_section_summary": "### Temas Clave\n\n1. **Separaci\u00f3n y Congelaci\u00f3n del Plasma**: \n   - La separaci\u00f3n del plasma de la sangre entera debe realizarse bajo condiciones espec\u00edficas de temperatura y tiempo para preservar la calidad, especialmente el contenido de Factor VIII.\n   - La centrifugaci\u00f3n debe realizarse preferiblemente dentro de las ocho horas si la sangre se mantiene a 4\u00b0C, o dentro de 18-20 horas si se enfr\u00eda r\u00e1pidamente a 20-24\u00b0C.\n   - En el caso de la recolecci\u00f3n por af\u00e9resis, la congelaci\u00f3n debe comenzar idealmente dentro de seis horas despu\u00e9s de completar el proceso.\n\n2. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el plasma final para asegurar la consistencia del proceso de fabricaci\u00f3n.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen el volumen, la actividad del Factor VIII, la reducci\u00f3n de leucocitos, la fuga y los cambios visuales.\n\n3. **Seguridad Viral**:\n   - Se aplican procedimientos de inactivaci\u00f3n de virus y/o cuarentena del plasma en algunos pa\u00edses para garantizar la seguridad del producto.\n   - Existen directrices de la OMS sobre la inactivaci\u00f3n y eliminaci\u00f3n de virus que son esenciales para la seguridad del plasma destinado a transfusiones.\n\n4. **Estabilidad del Producto**:\n   - La estabilidad del plasma depende de la temperatura de almacenamiento, siendo \u00f3ptima para almacenamiento a largo plazo (m\u00e1s de un a\u00f1o) a -25\u00b0C o m\u00e1s fr\u00edo.\n\n### Entidades\n\n- **Factor VIII**: Un componente cr\u00edtico del plasma que act\u00faa como indicador de calidad y eficacia en tratamientos.\n- **Plasma**: Material biol\u00f3gico utilizado para transfusiones y producci\u00f3n de productos fraccionados.\n- **Af\u00e9resis**: Proceso de recolecci\u00f3n de plasma que requiere atenci\u00f3n especial en el tiempo de congelaci\u00f3n.\n- **Control de Calidad**: Proceso que asegura que el plasma cumpla con los est\u00e1ndares necesarios para su uso.\n- **Inactivaci\u00f3n Viral**: Procedimientos aplicados para asegurar la seguridad del plasma frente a virus.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de directrices sobre la seguridad viral del plasma.\n\nEste resumen abarca los aspectos esenciales del manejo del plasma, desde su recolecci\u00f3n hasta su control de calidad y seguridad.", "excerpt_keywords": "Keywords: Cryoprecipitate, Factor VIII, Quality Control, Blood Donation, Virus Inactivation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "50124653-f4a5-4093-b81d-ece57fe9d2e3", "node_type": "4", "metadata": {"page_label": "211", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\nCryoprecipitate is the cryoglobulin fraction of plasma and contains a major portion of the Factor VIII, von Willebrand factor, fibrinogen, Factor XIII and fibronectin present in plasma. Cryoprecipitate is obtained from fresh frozen plasma that is prepared in a way that protects Factor VIII stability. Plasma is allowed to thaw either overnight at 2\u20136\u00b0C or by a rapid-thaw technique. Following thawing, the supernatant cryo-poor plasma and the cryoprecipitate are separated by hard-spin centrifugation. The cryo-poor plasma is then expressed into a transfer bag. The two components are refrozen to the appropriate core temperature.\n\nStability during storage depends on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (for two years or longer) the optimal storage temperature is minus 25\u00b0C or colder.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays of cryoprecipitate:\n\n- volume;\n- Factor VIII activity;\n- clottable fibrinogen;\n- von Willebrand factor activity (if applicable).\n\nVirus inactivation and/or quarantine are applied in some countries.\n\nUnder certain circumstances the use of small pool preparations of cryoprecipitate (by pooling single-donor cryoprecipitate units) may be desired.\n\n# 9.5 Laboratory testing\n\n## 9.5.1 Screening tests for infectious disease markers\n\n### 9.5.1.1 Testing requirements\n\nThe following tests, which are considered mandatory by all regulatory agencies, are relevant to the preparation of blood components and should be performed on each individual blood donation:\n\n- an approved test for Hepatitis B surface antigen (HBsAg);\n- an approved test for anti-HIV1/HIV2;\n- an approved test for anti-HCV.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "25b5be141522c003637d5f1952c8de9c60caaf71b2cff16fecfe01f25af5ea14", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\nCryoprecipitate is the cryoglobulin fraction of plasma and contains a major portion of the Factor VIII, von Willebrand factor, fibrinogen, Factor XIII and fibronectin present in plasma. Cryoprecipitate is obtained from fresh frozen plasma that is prepared in a way that protects Factor VIII stability. Plasma is allowed to thaw either overnight at 2\u20136\u00b0C or by a rapid-thaw technique. Following thawing, the supernatant cryo-poor plasma and the cryoprecipitate are separated by hard-spin centrifugation. The cryo-poor plasma is then expressed into a transfer bag. The two components are refrozen to the appropriate core temperature.\n\nStability during storage depends on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (for two years or longer) the optimal storage temperature is minus 25\u00b0C or colder.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays of cryoprecipitate:\n\n- volume;\n- Factor VIII activity;\n- clottable fibrinogen;\n- von Willebrand factor activity (if applicable).\n\nVirus inactivation and/or quarantine are applied in some countries.\n\nUnder certain circumstances the use of small pool preparations of cryoprecipitate (by pooling single-donor cryoprecipitate units) may be desired.\n\n# 9.5 Laboratory testing\n\n## 9.5.1 Screening tests for infectious disease markers\n\n### 9.5.1.1 Testing requirements\n\nThe following tests, which are considered mandatory by all regulatory agencies, are relevant to the preparation of blood components and should be performed on each individual blood donation:\n\n- an approved test for Hepatitis B surface antigen (HBsAg);\n- an approved test for anti-HIV1/HIV2;\n- an approved test for anti-HCV.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1944, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f62791f0-9b6c-4155-adce-c20748b7a87f": {"__data__": {"id_": "f62791f0-9b6c-4155-adce-c20748b7a87f", "embedding": null, "metadata": {"page_label": "212", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All three tests have to be negative. Initially reactive donations should be retested in duplicate by the same assay. Products from a repeatedly reactive donation should not be used for therapeutic applications and should normally be destroyed unless useful for non-therapeutic purposes or investigations. A sample of the donation should be evaluated by a confirmatory test. There should be a system for notifying and counselling the donor if confirmation is positive. It is recommended that national algorithms should be developed and used to enable consistent resolution of discordant/indeterminate or unconfirmed results.\n\nIn some countries, additional serological testing is required \u2014 for instance, anti-HBc testing may be performed on whole blood donations in order to further reduce the risk of exposure of recipients to HBV by contaminated blood or blood components (3). Additional testing for other agents or markers \u2014 such as anti-HTLV I/II, anti-T.cruzi or West Nile Virus (WNV) \u2014 may be required by the NRA, taking into account the epidemiological situation in any given region or country or the frequency of donating blood. In addition to testing for immunochemical-serological infectious disease markers, NAT testing of blood donations for the virus genomes has been introduced in some countries to increase the chance of identifying infected donors.\n\nDuring the natural course of infection, viraemia usually occurs significantly at a point earlier than that at which immunochemical markers (antibodies) can be detected in the infected serum. Thus, infection may be detected by NAT up to 50\u201360 days before seroconversion (i.e. to HCV) occurs. Testing for the presence of nucleic acid may be performed for viruses such as HCV, HBV, HIV, HAV, WNV (where appropriate) and/or Parvovirus B19, and the application of this technology may be extended to other transmissible microbes. NATs require a particularly sophisticated laboratory environment, special equipment and specially trained laboratory personnel. Mainly because of an extraordinary risk of false-positive results due to the so-called \u201ccarry-over\u201d (inadvertent transfer of the amplification product DNA to neat donor samples), very stringent handling and logistics are mandatory.\n\nIn contrast to testing for the serological markers of individual donor specimens, NAT testing may be performed following current practices by assembling various samples in mini-pools. However, this requires a thoroughly validated system of sample labelling/identification, a validated strategy and pooling process, and a validated algorithm to resolve pool results to individual donors. Hence, a specific logistics system may have to be established not only in the laboratory but also at the blood establishment in order to collect and suitably label samples. Contiguously tracing samples through the whole process from the donor, through pooling (if applicable), testing and release of the donation may present a particularly demanding challenge.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Pruebas de donaciones de sangre**: Se requiere que todas las pruebas de donaciones de sangre sean negativas. Las donaciones inicialmente reactivas deben ser retestadas y, si son repetidamente reactivas, no deben ser utilizadas para aplicaciones terap\u00e9uticas. Se recomienda el desarrollo de algoritmos nacionales para manejar resultados discordantes o indeterminados.\n\n2. **Pruebas serol\u00f3gicas adicionales**: En algunos pa\u00edses, se requieren pruebas serol\u00f3gicas adicionales, como la prueba anti-HBc, para reducir el riesgo de exposici\u00f3n a virus como el HBV. Tambi\u00e9n se pueden requerir pruebas para otros agentes infecciosos, dependiendo de la situaci\u00f3n epidemiol\u00f3gica.\n\n3. **Pruebas de NAT**: La prueba de \u00e1cidos nucleicos (NAT) se utiliza para detectar infecciones antes de que se produzcan anticuerpos. Esta t\u00e9cnica requiere un entorno de laboratorio sofisticado y un manejo riguroso para evitar resultados falsos positivos. La log\u00edstica de la recolecci\u00f3n y etiquetado de muestras es crucial para el \u00e9xito de estas pruebas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si una donaci\u00f3n de sangre resulta repetidamente reactiva?**\n   - Las donaciones que resultan repetidamente reactivas no deben ser utilizadas para aplicaciones terap\u00e9uticas y deben ser destruidas, a menos que sean \u00fatiles para prop\u00f3sitos no terap\u00e9uticos o investigaciones. Adem\u00e1s, se debe realizar una prueba confirmatoria y notificar al donante si la confirmaci\u00f3n es positiva.\n\n2. **\u00bfCu\u00e1l es la importancia de las pruebas de NAT en comparaci\u00f3n con las pruebas serol\u00f3gicas tradicionales?**\n   - Las pruebas de NAT son importantes porque pueden detectar infecciones hasta 50-60 d\u00edas antes de que se produzca la seroconversi\u00f3n, lo que permite identificar a donantes infectados m\u00e1s r\u00e1pidamente. Esto es crucial para reducir el riesgo de transmisi\u00f3n de infecciones a los receptores de sangre.\n\n3. **\u00bfQu\u00e9 desaf\u00edos log\u00edsticos se presentan al implementar pruebas de NAT en donaciones de sangre?**\n   - Los desaf\u00edos log\u00edsticos incluyen la necesidad de un sistema validado para el etiquetado e identificaci\u00f3n de muestras, un proceso de agrupamiento validado y un algoritmo para resolver los resultados de los grupos a donantes individuales. Adem\u00e1s, se requiere un seguimiento continuo de las muestras a lo largo de todo el proceso, desde la donaci\u00f3n hasta la liberaci\u00f3n de la sangre.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Crioprecipitado y Plasma Pobre en Crioprecipitados**:\n   - El crioprecipitado es la fracci\u00f3n de crioglobulina del plasma que contiene factores importantes como el Factor VIII, el factor von Willebrand, el fibrin\u00f3geno, el Factor XIII y la fibronectina.\n   - Se obtiene de plasma fresco congelado, el cual se prepara para mantener la estabilidad del Factor VIII.\n\n2. **Proceso de Preparaci\u00f3n**:\n   - El plasma se descongela a temperaturas controladas (2\u20136\u00b0C o mediante t\u00e9cnicas de descongelaci\u00f3n r\u00e1pida).\n   - Despu\u00e9s de la descongelaci\u00f3n, se separan el plasma pobre en crioprecipitados y el crioprecipitado mediante centrifugaci\u00f3n.\n\n3. **Condiciones de Almacenamiento**:\n   - La estabilidad del crioprecipitado depende de la temperatura de almacenamiento.\n   - Para almacenamiento a largo plazo (dos a\u00f1os o m\u00e1s), la temperatura \u00f3ptima es de -25\u00b0C o m\u00e1s fr\u00eda.\n\n4. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el producto final.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen: volumen, actividad del Factor VIII, fibrin\u00f3geno coagulable y actividad del factor von Willebrand (si aplica).\n\n5. **Pruebas de Detecci\u00f3n de Enfermedades Infecciosas**:\n   - Se requieren pruebas obligatorias para cada donaci\u00f3n de sangre, que incluyen:\n     - Prueba para el ant\u00edgeno de superficie de Hepatitis B (HBsAg).\n     - Prueba para anti-HIV1/HIV2.\n     - Prueba para anti-HCV.\n\n6. **Consideraciones Adicionales**:\n   - En algunos pa\u00edses se aplican medidas de inactivaci\u00f3n de virus y/o cuarentena.\n   - Puede ser deseable el uso de preparaciones de crioprecipitado de peque\u00f1os grupos mediante la agrupaci\u00f3n de unidades de crioprecipitado de donantes individuales.\n\n### Entidades Clave:\n- **Crioprecipitado**\n- **Plasma Fresco Congelado**\n- **Factor VIII**\n- **Factor von Willebrand**\n- **Fibrin\u00f3geno**\n- **Factor XIII**\n- **Fibronectina**\n- **Controles de Calidad**\n- **Pruebas de Detecci\u00f3n de Enfermedades Infecciosas** (HBsAg, anti-HIV1/HIV2, anti-HCV)", "excerpt_keywords": "Keywords: blood donation, serological testing, NAT testing, infectious diseases, donor screening"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d4916332-91ac-4d2b-99e2-19e058b2269d", "node_type": "4", "metadata": {"page_label": "212", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All three tests have to be negative. Initially reactive donations should be retested in duplicate by the same assay. Products from a repeatedly reactive donation should not be used for therapeutic applications and should normally be destroyed unless useful for non-therapeutic purposes or investigations. A sample of the donation should be evaluated by a confirmatory test. There should be a system for notifying and counselling the donor if confirmation is positive. It is recommended that national algorithms should be developed and used to enable consistent resolution of discordant/indeterminate or unconfirmed results.\n\nIn some countries, additional serological testing is required \u2014 for instance, anti-HBc testing may be performed on whole blood donations in order to further reduce the risk of exposure of recipients to HBV by contaminated blood or blood components (3). Additional testing for other agents or markers \u2014 such as anti-HTLV I/II, anti-T.cruzi or West Nile Virus (WNV) \u2014 may be required by the NRA, taking into account the epidemiological situation in any given region or country or the frequency of donating blood. In addition to testing for immunochemical-serological infectious disease markers, NAT testing of blood donations for the virus genomes has been introduced in some countries to increase the chance of identifying infected donors.\n\nDuring the natural course of infection, viraemia usually occurs significantly at a point earlier than that at which immunochemical markers (antibodies) can be detected in the infected serum. Thus, infection may be detected by NAT up to 50\u201360 days before seroconversion (i.e. to HCV) occurs. Testing for the presence of nucleic acid may be performed for viruses such as HCV, HBV, HIV, HAV, WNV (where appropriate) and/or Parvovirus B19, and the application of this technology may be extended to other transmissible microbes. NATs require a particularly sophisticated laboratory environment, special equipment and specially trained laboratory personnel. Mainly because of an extraordinary risk of false-positive results due to the so-called \u201ccarry-over\u201d (inadvertent transfer of the amplification product DNA to neat donor samples), very stringent handling and logistics are mandatory.\n\nIn contrast to testing for the serological markers of individual donor specimens, NAT testing may be performed following current practices by assembling various samples in mini-pools. However, this requires a thoroughly validated system of sample labelling/identification, a validated strategy and pooling process, and a validated algorithm to resolve pool results to individual donors. Hence, a specific logistics system may have to be established not only in the laboratory but also at the blood establishment in order to collect and suitably label samples. Contiguously tracing samples through the whole process from the donor, through pooling (if applicable), testing and release of the donation may present a particularly demanding challenge.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7219d5487ac99e1efebf7213a7fee936da0b285eb9d68f70a482b76707cb70c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "All three tests have to be negative. Initially reactive donations should be retested in duplicate by the same assay. Products from a repeatedly reactive donation should not be used for therapeutic applications and should normally be destroyed unless useful for non-therapeutic purposes or investigations. A sample of the donation should be evaluated by a confirmatory test. There should be a system for notifying and counselling the donor if confirmation is positive. It is recommended that national algorithms should be developed and used to enable consistent resolution of discordant/indeterminate or unconfirmed results.\n\nIn some countries, additional serological testing is required \u2014 for instance, anti-HBc testing may be performed on whole blood donations in order to further reduce the risk of exposure of recipients to HBV by contaminated blood or blood components (3). Additional testing for other agents or markers \u2014 such as anti-HTLV I/II, anti-T.cruzi or West Nile Virus (WNV) \u2014 may be required by the NRA, taking into account the epidemiological situation in any given region or country or the frequency of donating blood. In addition to testing for immunochemical-serological infectious disease markers, NAT testing of blood donations for the virus genomes has been introduced in some countries to increase the chance of identifying infected donors.\n\nDuring the natural course of infection, viraemia usually occurs significantly at a point earlier than that at which immunochemical markers (antibodies) can be detected in the infected serum. Thus, infection may be detected by NAT up to 50\u201360 days before seroconversion (i.e. to HCV) occurs. Testing for the presence of nucleic acid may be performed for viruses such as HCV, HBV, HIV, HAV, WNV (where appropriate) and/or Parvovirus B19, and the application of this technology may be extended to other transmissible microbes. NATs require a particularly sophisticated laboratory environment, special equipment and specially trained laboratory personnel. Mainly because of an extraordinary risk of false-positive results due to the so-called \u201ccarry-over\u201d (inadvertent transfer of the amplification product DNA to neat donor samples), very stringent handling and logistics are mandatory.\n\nIn contrast to testing for the serological markers of individual donor specimens, NAT testing may be performed following current practices by assembling various samples in mini-pools. However, this requires a thoroughly validated system of sample labelling/identification, a validated strategy and pooling process, and a validated algorithm to resolve pool results to individual donors. Hence, a specific logistics system may have to be established not only in the laboratory but also at the blood establishment in order to collect and suitably label samples. Contiguously tracing samples through the whole process from the donor, through pooling (if applicable), testing and release of the donation may present a particularly demanding challenge.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2997, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a8f1f58a-9fdc-4d8e-9e95-13836736081a": {"__data__": {"id_": "a8f1f58a-9fdc-4d8e-9e95-13836736081a", "embedding": null, "metadata": {"page_label": "213", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A system should exist in the country or region for approval of test systems, such as an official approval system by the NRA or a delegated laboratory. The required minimal sensitivity of tests for the different antigens/antibodies or nucleic acids should be defined by the NRA.\n\n### 9.5.1.2 Handling of samples and data\n\nMultiple specimens may be collected from a donor in order to meet all testing requirements (i.e. ABO typing, viral markers, NAT testing). There should be written standard operating procedures that clearly describe the collection, transportation and labelling of donor samples (i.e. whole blood, sera, anti-coagulant, container tubes etc.) and which define the sampling procedure performed on material for analysis (e.g. how and by whom it is done, transfer of samples, accountability of samples). All screening activities, handling of donor specimens, sampling, analysis and data processing should be separated from patient diagnostic testing (21).\n\nSample labelling at the site of collection and identification during all subsequent processing is critical and should be under control at all times. Each step of handling and processing should be described, as should the conditions of pre-analytical treatment of specimens (e.g. centrifugation), storage and transportation (duration, temperature, type of container, storage after testing).\n\nSerological testing should be performed on samples transferred directly into the analyser from the original sample tube.\n\nSecondary aliquot samples may be used for NAT testing of mini-pools of individual samples.\n\nThe following practical points should be considered in order to ensure the traceability and integrity of samples and data:\n\n- At receipt of specimens at the laboratory, positive identification of those received versus those expected should be performed. The integrity of the sample should be checked for compliance with the recommendations made by the manufacturer of the test kit.\n- Aliquot samples for analysis should be withdrawn from the donor sample preferably by automated pipetting equipment.\n- To provide for positive identification of all aspects (donation, donor specimen, aliquot samples etc.) it may be advisable to use a barcode system. Hence, starting with the donation, barcodes should be used for labelling. In case of failure of the automatic barcode reader system and/or data processors, an appropriate system should be available for manual entry and tracing of data throughout the whole process until release of donations for transfusion. Manual handling of data should include independent repeat entry into the database; the data format should include a check-digit algorithm or an automated test for identity of the two sets of data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Aprobaci\u00f3n de sistemas de prueba**: Se establece la necesidad de un sistema oficial en el pa\u00eds o regi\u00f3n para la aprobaci\u00f3n de sistemas de prueba, que debe ser definido por la Autoridad Reguladora Nacional (NRA). Esto incluye la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos.\n\n2. **Manejo de muestras y datos**: Se enfatiza la importancia de procedimientos operativos est\u00e1ndar escritos para la recolecci\u00f3n, transporte y etiquetado de muestras de donantes. Se debe garantizar la separaci\u00f3n de las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes, as\u00ed como la trazabilidad y la integridad de las muestras y datos a trav\u00e9s de un sistema de etiquetado, preferiblemente utilizando c\u00f3digos de barras.\n\n3. **Pr\u00e1cticas recomendadas para la integridad de las muestras**: Se sugieren pr\u00e1cticas espec\u00edficas para asegurar la identificaci\u00f3n positiva de las muestras y su integridad, incluyendo el uso de equipos automatizados para la toma de al\u00edcuotas y la implementaci\u00f3n de un sistema de entrada manual de datos en caso de fallos en el sistema automatizado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar la integridad de las muestras desde su recolecci\u00f3n hasta su an\u00e1lisis?**\n   - El contexto detalla que deben existir procedimientos operativos est\u00e1ndar que describan la recolecci\u00f3n, transporte y etiquetado de las muestras, as\u00ed como la separaci\u00f3n de las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes. Tambi\u00e9n se menciona la importancia de la identificaci\u00f3n positiva y el control de la integridad de las muestras.\n\n2. **\u00bfC\u00f3mo se debe manejar la identificaci\u00f3n de muestras en caso de fallos en el sistema automatizado de c\u00f3digos de barras?**\n   - En caso de fallos en el sistema automatizado, se debe contar con un sistema adecuado para la entrada manual y el rastreo de datos a lo largo de todo el proceso, incluyendo la entrada independiente y repetida en la base de datos, as\u00ed como un algoritmo de verificaci\u00f3n de d\u00edgitos o una prueba automatizada para asegurar la identidad de los conjuntos de datos.\n\n3. **\u00bfQu\u00e9 papel juega la NRA en la aprobaci\u00f3n de sistemas de prueba y qu\u00e9 criterios se deben considerar?**\n   - La NRA debe definir un sistema oficial de aprobaci\u00f3n de pruebas que incluya la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos. Esto asegura que los sistemas de prueba cumplan con los est\u00e1ndares necesarios para su uso en el pa\u00eds o regi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Pruebas de donaciones de sangre**:\n   - Todas las donaciones deben ser negativas en tres pruebas.\n   - Donaciones inicialmente reactivas deben ser retestadas y, si son repetidamente reactivas, no deben ser utilizadas para aplicaciones terap\u00e9uticas y deben ser destruidas, salvo para prop\u00f3sitos no terap\u00e9uticos o investigaciones.\n   - Se debe realizar una prueba confirmatoria y notificar al donante si la confirmaci\u00f3n es positiva.\n   - Se recomienda el desarrollo de algoritmos nacionales para manejar resultados discordantes o indeterminados.\n\n2. **Pruebas serol\u00f3gicas adicionales**:\n   - En algunos pa\u00edses, se requieren pruebas adicionales como la prueba anti-HBc para reducir el riesgo de exposici\u00f3n al virus de la hepatitis B (HBV).\n   - Otras pruebas pueden incluir anti-HTLV I/II, anti-T.cruzi y virus del Nilo Occidental (WNV), dependiendo de la situaci\u00f3n epidemiol\u00f3gica.\n\n3. **Pruebas de \u00e1cidos nucleicos (NAT)**:\n   - Las pruebas NAT permiten detectar infecciones antes de que se produzcan anticuerpos, hasta 50-60 d\u00edas antes de la seroconversi\u00f3n.\n   - Se pueden realizar pruebas para virus como HCV, HBV, HIV, HAV, WNV y Parvovirus B19.\n   - Requieren un entorno de laboratorio sofisticado, equipo especial y personal capacitado.\n   - Se deben seguir estrictos protocolos para evitar resultados falsos positivos debido a la transferencia inadvertida de productos de amplificaci\u00f3n.\n\n4. **Desaf\u00edos log\u00edsticos**:\n   - Implementar pruebas NAT requiere un sistema validado para el etiquetado e identificaci\u00f3n de muestras, un proceso de agrupamiento validado y un algoritmo para resolver resultados de grupos a donantes individuales.\n   - Es crucial el seguimiento continuo de las muestras desde la donaci\u00f3n hasta la liberaci\u00f3n de la sangre, lo que presenta un desaf\u00edo log\u00edstico significativo.\n\n### Entidades mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referencia impl\u00edcita en el documento.\n- **Virus**: HBV, HCV, HIV, HAV, WNV, Parvovirus B19.\n- **Pruebas**: Pruebas serol\u00f3gicas, pruebas NAT, pruebas anti-HBc.\n- **Donantes de sangre**: Sujetos a pruebas y notificaciones.\n- **Agencias reguladoras nacionales (NRA)**: Responsables de establecer requisitos de pruebas adicionales.", "excerpt_keywords": "Keywords: test systems, sample handling, data integrity, NRA approval, serological testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f9043b08-a6e0-45b1-a69d-a1ce6103efa5", "node_type": "4", "metadata": {"page_label": "213", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A system should exist in the country or region for approval of test systems, such as an official approval system by the NRA or a delegated laboratory. The required minimal sensitivity of tests for the different antigens/antibodies or nucleic acids should be defined by the NRA.\n\n### 9.5.1.2 Handling of samples and data\n\nMultiple specimens may be collected from a donor in order to meet all testing requirements (i.e. ABO typing, viral markers, NAT testing). There should be written standard operating procedures that clearly describe the collection, transportation and labelling of donor samples (i.e. whole blood, sera, anti-coagulant, container tubes etc.) and which define the sampling procedure performed on material for analysis (e.g. how and by whom it is done, transfer of samples, accountability of samples). All screening activities, handling of donor specimens, sampling, analysis and data processing should be separated from patient diagnostic testing (21).\n\nSample labelling at the site of collection and identification during all subsequent processing is critical and should be under control at all times. Each step of handling and processing should be described, as should the conditions of pre-analytical treatment of specimens (e.g. centrifugation), storage and transportation (duration, temperature, type of container, storage after testing).\n\nSerological testing should be performed on samples transferred directly into the analyser from the original sample tube.\n\nSecondary aliquot samples may be used for NAT testing of mini-pools of individual samples.\n\nThe following practical points should be considered in order to ensure the traceability and integrity of samples and data:\n\n- At receipt of specimens at the laboratory, positive identification of those received versus those expected should be performed. The integrity of the sample should be checked for compliance with the recommendations made by the manufacturer of the test kit.\n- Aliquot samples for analysis should be withdrawn from the donor sample preferably by automated pipetting equipment.\n- To provide for positive identification of all aspects (donation, donor specimen, aliquot samples etc.) it may be advisable to use a barcode system. Hence, starting with the donation, barcodes should be used for labelling. In case of failure of the automatic barcode reader system and/or data processors, an appropriate system should be available for manual entry and tracing of data throughout the whole process until release of donations for transfusion. Manual handling of data should include independent repeat entry into the database; the data format should include a check-digit algorithm or an automated test for identity of the two sets of data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "af09900f7e4cd2642e202d2c4cb2569a881126ae2e022b2c754947986e03b66f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A system should exist in the country or region for approval of test systems, such as an official approval system by the NRA or a delegated laboratory. The required minimal sensitivity of tests for the different antigens/antibodies or nucleic acids should be defined by the NRA.\n\n### 9.5.1.2 Handling of samples and data\n\nMultiple specimens may be collected from a donor in order to meet all testing requirements (i.e. ABO typing, viral markers, NAT testing). There should be written standard operating procedures that clearly describe the collection, transportation and labelling of donor samples (i.e. whole blood, sera, anti-coagulant, container tubes etc.) and which define the sampling procedure performed on material for analysis (e.g. how and by whom it is done, transfer of samples, accountability of samples). All screening activities, handling of donor specimens, sampling, analysis and data processing should be separated from patient diagnostic testing (21).\n\nSample labelling at the site of collection and identification during all subsequent processing is critical and should be under control at all times. Each step of handling and processing should be described, as should the conditions of pre-analytical treatment of specimens (e.g. centrifugation), storage and transportation (duration, temperature, type of container, storage after testing).\n\nSerological testing should be performed on samples transferred directly into the analyser from the original sample tube.\n\nSecondary aliquot samples may be used for NAT testing of mini-pools of individual samples.\n\nThe following practical points should be considered in order to ensure the traceability and integrity of samples and data:\n\n- At receipt of specimens at the laboratory, positive identification of those received versus those expected should be performed. The integrity of the sample should be checked for compliance with the recommendations made by the manufacturer of the test kit.\n- Aliquot samples for analysis should be withdrawn from the donor sample preferably by automated pipetting equipment.\n- To provide for positive identification of all aspects (donation, donor specimen, aliquot samples etc.) it may be advisable to use a barcode system. Hence, starting with the donation, barcodes should be used for labelling. In case of failure of the automatic barcode reader system and/or data processors, an appropriate system should be available for manual entry and tracing of data throughout the whole process until release of donations for transfusion. Manual handling of data should include independent repeat entry into the database; the data format should include a check-digit algorithm or an automated test for identity of the two sets of data.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2730, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3c016e80-aa13-450c-9350-6551c27afd58": {"__data__": {"id_": "3c016e80-aa13-450c-9350-6551c27afd58", "embedding": null, "metadata": {"page_label": "214", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Pipetting devices and machines should be validated before routine use, and validation reports should be available.\n- Calibration of the pipetting devices should be performed periodically and should be documented.\n\n### 9.5.1.3 Testing and post-analytical procedures\n\nTesting of blood components should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Modifications to the manufacturer\u2019s instructions or reagents for donor screening tests should be validated. Where required, prior approval of the NRA should be obtained before the modified method is used for release of a blood component. Laboratory reagents intended for prolonged use should be marked with the preparation date, expiry date, specific storage conditions and signature of the person who prepared them. Instructions for use and storage should be followed.\n\nScreening algorithms should be precisely defined in writing (i.e. standard operating procedures) to deal with initially reactive specimens and to resolve discrepancies in results after retesting. All available measures should be taken to ensure that blood and blood components that are repeat reactive upon screening for an infectious disease marker are excluded from therapeutic use. Repeat reactive material should be stored away from all other blood components in a separate dedicated storage area. Such material should eventually be destroyed to prevent inadvertent re-entry into the transfusion chain.\n\nTest algorithms should provide details for appropriate confirmatory testing. In the case of repeatedly reactive results, clearly defined follow-up instructions should be followed. Actions include:\n\n- notification and deferral of the donor;\n- disposal of the indicated donation and of concurrent products;\n- tracing and destruction of products which have not yet expired.\n\nIf products from the donor have been processed for further manufacture, there should be a procedure in place to assess both the safety of the manufactured products and whether a recall is needed.\n\nProcedures for donor- and/or recipient-initiated look-backs should also be defined. Look-backs should be designed in such a way that the transfusion chain of donor\u2013blood (or blood product)\u2013recipient can be unequivocally reconstructed. The procedure should comprise notification and counselling action where indicated.\n\nThe following practical points should be considered in order to ensure that the equipment used for virology testing performs appropriately:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS establece directrices sobre la validaci\u00f3n y calibraci\u00f3n de dispositivos de pipeteo, as\u00ed como sobre los procedimientos de prueba y post-anal\u00edticos para componentes sangu\u00edneos. Se enfatiza la importancia de seguir las recomendaciones del fabricante para los reactivos y kits de prueba, y se requiere la validaci\u00f3n de cualquier modificaci\u00f3n a estas instrucciones. Se deben definir algoritmos de cribado y procedimientos para manejar resultados reactivos, asegurando que los materiales repetidamente reactivos se excluyan del uso terap\u00e9utico. Adem\u00e1s, se deben establecer procedimientos para el seguimiento de donantes y receptores, as\u00ed como para la evaluaci\u00f3n de la seguridad de los productos manufacturados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si un donante presenta resultados repetidamente reactivos en las pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas?**\n   - La respuesta debe incluir la notificaci\u00f3n y la suspensi\u00f3n del donante, la eliminaci\u00f3n de la donaci\u00f3n indicada y de los productos concurrentes, y el rastreo y destrucci\u00f3n de productos que no hayan expirado.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los reactivos de laboratorio destinados a un uso prolongado?**\n   - Las etiquetas deben incluir la fecha de preparaci\u00f3n, la fecha de caducidad, las condiciones espec\u00edficas de almacenamiento y la firma de la persona que los prepar\u00f3.\n\n3. **\u00bfCu\u00e1les son las consideraciones pr\u00e1cticas para asegurar que el equipo utilizado en las pruebas de virolog\u00eda funcione adecuadamente?**\n   - Aunque el contexto no proporciona detalles espec\u00edficos sobre estas consideraciones, se puede inferir que se deben seguir protocolos de mantenimiento y calibraci\u00f3n, as\u00ed como asegurar que el equipo est\u00e9 validado y documentado adecuadamente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Aprobaci\u00f3n de Sistemas de Prueba**:\n   - Es necesario un sistema oficial en el pa\u00eds o regi\u00f3n para la aprobaci\u00f3n de sistemas de prueba, definido por la Autoridad Reguladora Nacional (NRA).\n   - La NRA debe establecer la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos.\n\n2. **Manejo de Muestras y Datos**:\n   - Se deben seguir procedimientos operativos est\u00e1ndar escritos para la recolecci\u00f3n, transporte y etiquetado de muestras de donantes.\n   - Es crucial separar las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes.\n\n3. **Trazabilidad e Integridad de Muestras**:\n   - La identificaci\u00f3n positiva de las muestras y su integridad debe ser controlada en todo momento.\n   - Se recomienda el uso de un sistema de c\u00f3digos de barras para el etiquetado de muestras, con un plan de contingencia para la entrada manual de datos en caso de fallos en el sistema automatizado.\n\n4. **Pr\u00e1cticas Recomendadas**:\n   - Verificaci\u00f3n de la identidad de las muestras al recibirlas en el laboratorio.\n   - Preferencia por el uso de equipos automatizados para la toma de al\u00edcuotas.\n   - Implementaci\u00f3n de un sistema de entrada manual de datos que incluya verificaci\u00f3n de identidad.\n\n### Entidades Clave\n- **Autoridad Reguladora Nacional (NRA)**: Entidad responsable de la aprobaci\u00f3n de sistemas de prueba.\n- **Muestras de Donantes**: Incluyen sangre total, sueros y otros materiales biol\u00f3gicos.\n- **C\u00f3digos de Barras**: Sistema recomendado para la identificaci\u00f3n y trazabilidad de muestras.\n- **Procedimientos Operativos Est\u00e1ndar**: Documentaci\u00f3n necesaria para asegurar la correcta manipulaci\u00f3n de muestras.\n\nEste resumen destaca la importancia de la regulaci\u00f3n, el manejo adecuado de muestras y la implementaci\u00f3n de sistemas de trazabilidad para garantizar la integridad y la calidad en los procesos de an\u00e1lisis.", "excerpt_keywords": "Keywords: validation, pipetting, blood components, screening algorithms, donor safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "daa84405-4dc6-4745-a741-5e208e91c2da", "node_type": "4", "metadata": {"page_label": "214", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Pipetting devices and machines should be validated before routine use, and validation reports should be available.\n- Calibration of the pipetting devices should be performed periodically and should be documented.\n\n### 9.5.1.3 Testing and post-analytical procedures\n\nTesting of blood components should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Modifications to the manufacturer\u2019s instructions or reagents for donor screening tests should be validated. Where required, prior approval of the NRA should be obtained before the modified method is used for release of a blood component. Laboratory reagents intended for prolonged use should be marked with the preparation date, expiry date, specific storage conditions and signature of the person who prepared them. Instructions for use and storage should be followed.\n\nScreening algorithms should be precisely defined in writing (i.e. standard operating procedures) to deal with initially reactive specimens and to resolve discrepancies in results after retesting. All available measures should be taken to ensure that blood and blood components that are repeat reactive upon screening for an infectious disease marker are excluded from therapeutic use. Repeat reactive material should be stored away from all other blood components in a separate dedicated storage area. Such material should eventually be destroyed to prevent inadvertent re-entry into the transfusion chain.\n\nTest algorithms should provide details for appropriate confirmatory testing. In the case of repeatedly reactive results, clearly defined follow-up instructions should be followed. Actions include:\n\n- notification and deferral of the donor;\n- disposal of the indicated donation and of concurrent products;\n- tracing and destruction of products which have not yet expired.\n\nIf products from the donor have been processed for further manufacture, there should be a procedure in place to assess both the safety of the manufactured products and whether a recall is needed.\n\nProcedures for donor- and/or recipient-initiated look-backs should also be defined. Look-backs should be designed in such a way that the transfusion chain of donor\u2013blood (or blood product)\u2013recipient can be unequivocally reconstructed. The procedure should comprise notification and counselling action where indicated.\n\nThe following practical points should be considered in order to ensure that the equipment used for virology testing performs appropriately:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "04f077b86ef6e9c42a3ae6304e53db7f19467434326d762843ef3ff83f8603e2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Pipetting devices and machines should be validated before routine use, and validation reports should be available.\n- Calibration of the pipetting devices should be performed periodically and should be documented.\n\n### 9.5.1.3 Testing and post-analytical procedures\n\nTesting of blood components should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Modifications to the manufacturer\u2019s instructions or reagents for donor screening tests should be validated. Where required, prior approval of the NRA should be obtained before the modified method is used for release of a blood component. Laboratory reagents intended for prolonged use should be marked with the preparation date, expiry date, specific storage conditions and signature of the person who prepared them. Instructions for use and storage should be followed.\n\nScreening algorithms should be precisely defined in writing (i.e. standard operating procedures) to deal with initially reactive specimens and to resolve discrepancies in results after retesting. All available measures should be taken to ensure that blood and blood components that are repeat reactive upon screening for an infectious disease marker are excluded from therapeutic use. Repeat reactive material should be stored away from all other blood components in a separate dedicated storage area. Such material should eventually be destroyed to prevent inadvertent re-entry into the transfusion chain.\n\nTest algorithms should provide details for appropriate confirmatory testing. In the case of repeatedly reactive results, clearly defined follow-up instructions should be followed. Actions include:\n\n- notification and deferral of the donor;\n- disposal of the indicated donation and of concurrent products;\n- tracing and destruction of products which have not yet expired.\n\nIf products from the donor have been processed for further manufacture, there should be a procedure in place to assess both the safety of the manufactured products and whether a recall is needed.\n\nProcedures for donor- and/or recipient-initiated look-backs should also be defined. Look-backs should be designed in such a way that the transfusion chain of donor\u2013blood (or blood product)\u2013recipient can be unequivocally reconstructed. The procedure should comprise notification and counselling action where indicated.\n\nThe following practical points should be considered in order to ensure that the equipment used for virology testing performs appropriately:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2510, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "33bf4b0d-90b1-495d-9608-9988250a6d4c": {"__data__": {"id_": "33bf4b0d-90b1-495d-9608-9988250a6d4c", "embedding": null, "metadata": {"page_label": "215", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- There should be a mechanism to ensure positive sample identification and linkage to the donor. The preferred method is by sample tubes with barcodes.\n- Ideally, the addition of reagent and samples and the testing process should be automated, in order to minimize risk of human errors and to ensure full traceability of the testing process.\n- If addition of reagents and samples or preparation of test plates are done manually, full documentation of each addition step should be kept, ensuring identification of the test plate and the location of the reaction well.\n\n### 9.5.1.4 Test interpretation and follow-up of reactive results\n\nThe transfer and interpretation of raw data is a critical step and should therefore be documented and reviewed by a responsible person, as should the test parameters. Traceability and archiving of raw data should be guaranteed (see section 5.2).\n\nThe data should be examined by the supervisor, or by another person authorized to do so, before being officially accepted. If computerized systems are used, accepted data should be downloaded directly to the server, or there should be a secure system for manual download which ensures positive release. Manual transcription of results is discouraged as mistakes may be introduced. Acceptance and rejection criteria should be specified.\n\nThe following should be given special attention:\n\n- Initial reactive results should be identified by means of a secure and validated system.\n- An acceptable system should be in place to confirm repeat reactive results, including sampling, labelling, testing and entry of results.\n- Computer algorithms should edit reactive status to repeat reactive, or the editing should be performed by two authorized staff members.\n- An appropriate deferral system should exist for repeat reactive results.\n- There should be appropriate documentation justifying the re-entry of deferred donors.\n- Donors should be informed of the reason for deferral and should be counselled about social behaviours and their status as a future donor.\n\n### 9.5.2 Blood group typing\n\nEach donation should be tested for ABO and RhD blood groups and at least all first-time donors should be tested for clinically significant irregular red-cell antibodies. When plasma is used for fractionation it should be tested in compliance with the specifications of the fractionator as agreed by the relevant NRA (3).\n\nTesting should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Molecular methods may be used to determine blood groups, as necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mecanismos de Identificaci\u00f3n y Trazabilidad**: Se enfatiza la importancia de un sistema seguro para la identificaci\u00f3n de muestras y su vinculaci\u00f3n con los donantes, preferiblemente mediante el uso de tubos de muestra con c\u00f3digos de barras. Se sugiere la automatizaci\u00f3n de procesos para minimizar errores humanos y asegurar la trazabilidad.\n\n2. **Interpretaci\u00f3n de Resultados y Seguimiento**: La transferencia e interpretaci\u00f3n de datos crudos son pasos cr\u00edticos que deben ser documentados y revisados por personal responsable. Se deben establecer criterios de aceptaci\u00f3n y rechazo, y se debe evitar la transcripci\u00f3n manual de resultados para prevenir errores.\n\n3. **Tipificaci\u00f3n de Grupos Sangu\u00edneos**: Cada donaci\u00f3n debe ser analizada para determinar los grupos sangu\u00edneos ABO y RhD, y se deben realizar pruebas adicionales para detectar anticuerpos irregulares en donantes primerizos. Las pruebas deben seguir las recomendaciones del fabricante de reactivos y kits de prueba.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la trazabilidad de las muestras en el proceso de donaci\u00f3n de sangre?**\n   - El contexto menciona que se debe implementar un mecanismo de identificaci\u00f3n positiva de muestras, preferiblemente mediante tubos de muestra con c\u00f3digos de barras, y que la automatizaci\u00f3n del proceso puede ayudar a minimizar errores y asegurar la trazabilidad.\n\n2. **\u00bfCu\u00e1les son los pasos recomendados para la interpretaci\u00f3n de resultados reactivos en pruebas de sangre?**\n   - Se debe documentar y revisar la transferencia e interpretaci\u00f3n de datos crudos por una persona responsable. Adem\u00e1s, los resultados iniciales reactivos deben ser identificados mediante un sistema seguro, y se debe contar con un sistema aceptable para confirmar resultados reactivos repetidos.\n\n3. **\u00bfQu\u00e9 pruebas deben realizarse en cada donaci\u00f3n de sangre y cu\u00e1les son las recomendaciones para su ejecuci\u00f3n?**\n   - Cada donaci\u00f3n debe ser probada para los grupos sangu\u00edneos ABO y RhD, y todos los donantes primerizos deben ser evaluados para anticuerpos irregulares cl\u00ednicamente significativos. Las pruebas deben llevarse a cabo de acuerdo con las recomendaciones del fabricante de reactivos y kits de prueba, y se pueden utilizar m\u00e9todos moleculares seg\u00fan sea necesario.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Validaci\u00f3n y Calibraci\u00f3n de Dispositivos de Pipeteo**:\n   - Los dispositivos y m\u00e1quinas de pipeteo deben ser validados antes de su uso rutinario, y los informes de validaci\u00f3n deben estar disponibles.\n   - La calibraci\u00f3n de estos dispositivos debe realizarse peri\u00f3dicamente y documentarse.\n\n2. **Procedimientos de Prueba y Post-Anal\u00edticos**:\n   - Las pruebas de componentes sangu\u00edneos deben seguir las recomendaciones del fabricante de reactivos y kits de prueba.\n   - Cualquier modificaci\u00f3n a las instrucciones del fabricante debe ser validada y, si es necesario, aprobada por la Autoridad Reguladora Nacional (NRA) antes de su uso.\n\n3. **Etiquetado de Reactivos de Laboratorio**:\n   - Los reactivos destinados a un uso prolongado deben incluir la fecha de preparaci\u00f3n, fecha de caducidad, condiciones de almacenamiento espec\u00edficas y la firma de la persona que los prepar\u00f3.\n\n4. **Algoritmos de Cribado**:\n   - Deben definirse por escrito para manejar muestras inicialmente reactivas y resolver discrepancias en los resultados.\n   - Se deben tomar medidas para excluir del uso terap\u00e9utico los componentes sangu\u00edneos que sean repetidamente reactivos.\n\n5. **Manejo de Resultados Repetidamente Reactivos**:\n   - Acciones a seguir incluyen la notificaci\u00f3n y suspensi\u00f3n del donante, eliminaci\u00f3n de la donaci\u00f3n y productos concurrentes, y rastreo y destrucci\u00f3n de productos no expirados.\n\n6. **Procedimientos de Seguimiento (Look-Backs)**:\n   - Deben establecerse procedimientos para el seguimiento de donantes y/o receptores, asegurando que la cadena de transfusi\u00f3n pueda reconstruirse claramente.\n\n7. **Consideraciones Pr\u00e1cticas para Pruebas de Virolog\u00eda**:\n   - Aunque no se detallan en el texto, se infiere que se deben seguir protocolos de mantenimiento y calibraci\u00f3n para asegurar el correcto funcionamiento del equipo.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad que debe aprobar modificaciones a los m\u00e9todos de prueba.\n- **Donantes y Receptores**: Sujetos involucrados en el proceso de donaci\u00f3n y transfusi\u00f3n de sangre.\n- **Componentes Sangu\u00edneos**: Elementos que se prueban y transfunden, como sangre y productos derivados.", "excerpt_keywords": "Keywords: sample identification, test interpretation, blood group typing, traceability, reactive results"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de4346e7-75de-4411-9bc6-d73ebf038597", "node_type": "4", "metadata": {"page_label": "215", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- There should be a mechanism to ensure positive sample identification and linkage to the donor. The preferred method is by sample tubes with barcodes.\n- Ideally, the addition of reagent and samples and the testing process should be automated, in order to minimize risk of human errors and to ensure full traceability of the testing process.\n- If addition of reagents and samples or preparation of test plates are done manually, full documentation of each addition step should be kept, ensuring identification of the test plate and the location of the reaction well.\n\n### 9.5.1.4 Test interpretation and follow-up of reactive results\n\nThe transfer and interpretation of raw data is a critical step and should therefore be documented and reviewed by a responsible person, as should the test parameters. Traceability and archiving of raw data should be guaranteed (see section 5.2).\n\nThe data should be examined by the supervisor, or by another person authorized to do so, before being officially accepted. If computerized systems are used, accepted data should be downloaded directly to the server, or there should be a secure system for manual download which ensures positive release. Manual transcription of results is discouraged as mistakes may be introduced. Acceptance and rejection criteria should be specified.\n\nThe following should be given special attention:\n\n- Initial reactive results should be identified by means of a secure and validated system.\n- An acceptable system should be in place to confirm repeat reactive results, including sampling, labelling, testing and entry of results.\n- Computer algorithms should edit reactive status to repeat reactive, or the editing should be performed by two authorized staff members.\n- An appropriate deferral system should exist for repeat reactive results.\n- There should be appropriate documentation justifying the re-entry of deferred donors.\n- Donors should be informed of the reason for deferral and should be counselled about social behaviours and their status as a future donor.\n\n### 9.5.2 Blood group typing\n\nEach donation should be tested for ABO and RhD blood groups and at least all first-time donors should be tested for clinically significant irregular red-cell antibodies. When plasma is used for fractionation it should be tested in compliance with the specifications of the fractionator as agreed by the relevant NRA (3).\n\nTesting should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Molecular methods may be used to determine blood groups, as necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "16e55134b9e5a6d6524a587819cab69d5a59d551bc14f2d3c0230883ebb91f09", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- There should be a mechanism to ensure positive sample identification and linkage to the donor. The preferred method is by sample tubes with barcodes.\n- Ideally, the addition of reagent and samples and the testing process should be automated, in order to minimize risk of human errors and to ensure full traceability of the testing process.\n- If addition of reagents and samples or preparation of test plates are done manually, full documentation of each addition step should be kept, ensuring identification of the test plate and the location of the reaction well.\n\n### 9.5.1.4 Test interpretation and follow-up of reactive results\n\nThe transfer and interpretation of raw data is a critical step and should therefore be documented and reviewed by a responsible person, as should the test parameters. Traceability and archiving of raw data should be guaranteed (see section 5.2).\n\nThe data should be examined by the supervisor, or by another person authorized to do so, before being officially accepted. If computerized systems are used, accepted data should be downloaded directly to the server, or there should be a secure system for manual download which ensures positive release. Manual transcription of results is discouraged as mistakes may be introduced. Acceptance and rejection criteria should be specified.\n\nThe following should be given special attention:\n\n- Initial reactive results should be identified by means of a secure and validated system.\n- An acceptable system should be in place to confirm repeat reactive results, including sampling, labelling, testing and entry of results.\n- Computer algorithms should edit reactive status to repeat reactive, or the editing should be performed by two authorized staff members.\n- An appropriate deferral system should exist for repeat reactive results.\n- There should be appropriate documentation justifying the re-entry of deferred donors.\n- Donors should be informed of the reason for deferral and should be counselled about social behaviours and their status as a future donor.\n\n### 9.5.2 Blood group typing\n\nEach donation should be tested for ABO and RhD blood groups and at least all first-time donors should be tested for clinically significant irregular red-cell antibodies. When plasma is used for fractionation it should be tested in compliance with the specifications of the fractionator as agreed by the relevant NRA (3).\n\nTesting should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Molecular methods may be used to determine blood groups, as necessary.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2579, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f2629072-ea90-41ff-8292-188a93735ac8": {"__data__": {"id_": "f2629072-ea90-41ff-8292-188a93735ac8", "embedding": null, "metadata": {"page_label": "216", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The ABO and RhD blood group should be verified on each subsequent donation. A comparison should be made with the historically determined blood group. If a discrepancy is found, the applicable blood components should not be released until the discrepancy has been unequivocally resolved.\n\nDonors with a history of transfusions or pregnancy since the last donation should be tested for clinically significant irregular red-cell antibodies. If clinically significant red-cell antibodies are detected, and where applicable, the blood or blood component should be labelled accordingly.\n\nNRAs may set different (stronger) requirements.\n\nThe ABO/RhD labelling of the red-cell concentrates of all first-time donations should be based on two independent ABO/RhD tests.\n\n### 9.5.3 Retention samples\n\nAs specified by the NRA, an aliquot of the original testing sample should be retained from each donation and stored under conditions recommended by the test manufacturer that would permit retesting if indicated. The procedure for additional testing should be validated to ensure the integrity of the sample (including storage conditions) and the test results. The sample volume, the retention vial, the kind of specimen (serum or plasma), the storage conditions and length of storage should each be defined and should be included in the validation to ensure the integrity of test results.\n\n### 9.6 Quality monitoring of blood and blood components\n\nQuality control data should demonstrate that critical manufacturing processes are under control. Blood and blood components should comply with specifications and their testing should be performed using test methods approved by the NRA.\n\nAll processes \u2014 including data transfers and computerized systems \u2014 that have an influence on the quality of the products in the area of collection, preparation or testing of blood and blood components should be validated. For critical processes such as rapid freezing of plasma, the need for revalidation should be defined.\n\nQuality control of blood and blood components should be carried out according to a defined sampling plan based on statistical methods. The sampling plan should take into account different collection and production sites, transport, methods of preparation and equipment used. Acceptance criteria should be based on a defined specification for each type of blood component. As an example for fresh frozen plasma, these data may include monitoring of weight/volume, sterility, Factor VIII activity and residual cell", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS establece directrices sobre la verificaci\u00f3n de grupos sangu\u00edneos ABO y RhD en donaciones de sangre, la importancia de realizar pruebas para detectar anticuerpos irregulares en donantes con antecedentes de transfusiones o embarazo, y la necesidad de etiquetar adecuadamente los componentes sangu\u00edneos. Tambi\u00e9n se menciona la retenci\u00f3n de muestras para pruebas adicionales y la importancia del control de calidad en la fabricaci\u00f3n y prueba de componentes sangu\u00edneos, incluyendo la validaci\u00f3n de procesos cr\u00edticos y la implementaci\u00f3n de planes de muestreo basados en m\u00e9todos estad\u00edsticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se encuentra una discrepancia en el grupo sangu\u00edneo ABO/RhD durante una donaci\u00f3n?**\n   - Respuesta: Si se encuentra una discrepancia en el grupo sangu\u00edneo ABO/RhD, los componentes sangu\u00edneos aplicables no deben ser liberados hasta que la discrepancia haya sido resuelta de manera inequ\u00edvoca.\n\n2. **\u00bfCu\u00e1les son los requisitos para la retenci\u00f3n de muestras de donaciones de sangre seg\u00fan la NRA?**\n   - Respuesta: Seg\u00fan la NRA, se debe retener un al\u00edcuota de la muestra de prueba original de cada donaci\u00f3n, almacenada bajo condiciones recomendadas por el fabricante del test que permitan la re-prueba si es necesario. Adem\u00e1s, se deben definir el volumen de la muestra, el vial de retenci\u00f3n, el tipo de muestra (suero o plasma), las condiciones de almacenamiento y la duraci\u00f3n del almacenamiento.\n\n3. **\u00bfC\u00f3mo se debe llevar a cabo el control de calidad de los componentes sangu\u00edneos y qu\u00e9 factores deben considerarse en el plan de muestreo?**\n   - Respuesta: El control de calidad de los componentes sangu\u00edneos debe realizarse de acuerdo con un plan de muestreo definido basado en m\u00e9todos estad\u00edsticos. Este plan debe tener en cuenta diferentes sitios de recolecci\u00f3n y producci\u00f3n, transporte, m\u00e9todos de preparaci\u00f3n y equipos utilizados. Los criterios de aceptaci\u00f3n deben basarse en especificaciones definidas para cada tipo de componente sangu\u00edneo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mecanismos de Identificaci\u00f3n y Trazabilidad**:\n   - Importancia de un sistema seguro para la identificaci\u00f3n de muestras y su vinculaci\u00f3n con los donantes.\n   - Uso preferido de tubos de muestra con c\u00f3digos de barras.\n   - Automatizaci\u00f3n del proceso de adici\u00f3n de reactivos y muestras para minimizar errores humanos y asegurar trazabilidad.\n\n2. **Interpretaci\u00f3n de Resultados y Seguimiento**:\n   - Documentaci\u00f3n y revisi\u00f3n de la transferencia e interpretaci\u00f3n de datos crudos por personal responsable.\n   - Establecimiento de criterios de aceptaci\u00f3n y rechazo.\n   - Evitar la transcripci\u00f3n manual de resultados para prevenir errores.\n   - Identificaci\u00f3n de resultados reactivos iniciales mediante un sistema seguro.\n   - Confirmaci\u00f3n de resultados reactivos repetidos con un sistema adecuado.\n\n3. **Tipificaci\u00f3n de Grupos Sangu\u00edneos**:\n   - Pruebas obligatorias para determinar los grupos sangu\u00edneos ABO y RhD en cada donaci\u00f3n.\n   - Evaluaci\u00f3n de anticuerpos irregulares en donantes primerizos.\n   - Cumplimiento de las recomendaciones del fabricante de reactivos y kits de prueba.\n   - Posibilidad de utilizar m\u00e9todos moleculares para determinar grupos sangu\u00edneos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Donantes de Sangre**: Sujetos de las pruebas y procesos descritos.\n- **Muestras de Sangre**: Elemento central del proceso de donaci\u00f3n y an\u00e1lisis.\n- **Reactivos y Kits de Prueba**: Herramientas necesarias para la tipificaci\u00f3n y an\u00e1lisis de sangre.\n- **Datos Crudos**: Informaci\u00f3n que debe ser documentada y revisada durante el proceso de pruebas. \n\nEste resumen destaca la importancia de la trazabilidad, la correcta interpretaci\u00f3n de resultados y las pruebas necesarias para garantizar la seguridad y eficacia en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, ABO/RhD testing, quality control, retention samples, irregular antibodies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ac32a1bb-976b-42c1-8fae-c0b9068b583d", "node_type": "4", "metadata": {"page_label": "216", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The ABO and RhD blood group should be verified on each subsequent donation. A comparison should be made with the historically determined blood group. If a discrepancy is found, the applicable blood components should not be released until the discrepancy has been unequivocally resolved.\n\nDonors with a history of transfusions or pregnancy since the last donation should be tested for clinically significant irregular red-cell antibodies. If clinically significant red-cell antibodies are detected, and where applicable, the blood or blood component should be labelled accordingly.\n\nNRAs may set different (stronger) requirements.\n\nThe ABO/RhD labelling of the red-cell concentrates of all first-time donations should be based on two independent ABO/RhD tests.\n\n### 9.5.3 Retention samples\n\nAs specified by the NRA, an aliquot of the original testing sample should be retained from each donation and stored under conditions recommended by the test manufacturer that would permit retesting if indicated. The procedure for additional testing should be validated to ensure the integrity of the sample (including storage conditions) and the test results. The sample volume, the retention vial, the kind of specimen (serum or plasma), the storage conditions and length of storage should each be defined and should be included in the validation to ensure the integrity of test results.\n\n### 9.6 Quality monitoring of blood and blood components\n\nQuality control data should demonstrate that critical manufacturing processes are under control. Blood and blood components should comply with specifications and their testing should be performed using test methods approved by the NRA.\n\nAll processes \u2014 including data transfers and computerized systems \u2014 that have an influence on the quality of the products in the area of collection, preparation or testing of blood and blood components should be validated. For critical processes such as rapid freezing of plasma, the need for revalidation should be defined.\n\nQuality control of blood and blood components should be carried out according to a defined sampling plan based on statistical methods. The sampling plan should take into account different collection and production sites, transport, methods of preparation and equipment used. Acceptance criteria should be based on a defined specification for each type of blood component. As an example for fresh frozen plasma, these data may include monitoring of weight/volume, sterility, Factor VIII activity and residual cell", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5ec70568a9cd62acab43b6d38fce470e2b9cffbbed3388ded6a18cd60970d60d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The ABO and RhD blood group should be verified on each subsequent donation. A comparison should be made with the historically determined blood group. If a discrepancy is found, the applicable blood components should not be released until the discrepancy has been unequivocally resolved.\n\nDonors with a history of transfusions or pregnancy since the last donation should be tested for clinically significant irregular red-cell antibodies. If clinically significant red-cell antibodies are detected, and where applicable, the blood or blood component should be labelled accordingly.\n\nNRAs may set different (stronger) requirements.\n\nThe ABO/RhD labelling of the red-cell concentrates of all first-time donations should be based on two independent ABO/RhD tests.\n\n### 9.5.3 Retention samples\n\nAs specified by the NRA, an aliquot of the original testing sample should be retained from each donation and stored under conditions recommended by the test manufacturer that would permit retesting if indicated. The procedure for additional testing should be validated to ensure the integrity of the sample (including storage conditions) and the test results. The sample volume, the retention vial, the kind of specimen (serum or plasma), the storage conditions and length of storage should each be defined and should be included in the validation to ensure the integrity of test results.\n\n### 9.6 Quality monitoring of blood and blood components\n\nQuality control data should demonstrate that critical manufacturing processes are under control. Blood and blood components should comply with specifications and their testing should be performed using test methods approved by the NRA.\n\nAll processes \u2014 including data transfers and computerized systems \u2014 that have an influence on the quality of the products in the area of collection, preparation or testing of blood and blood components should be validated. For critical processes such as rapid freezing of plasma, the need for revalidation should be defined.\n\nQuality control of blood and blood components should be carried out according to a defined sampling plan based on statistical methods. The sampling plan should take into account different collection and production sites, transport, methods of preparation and equipment used. Acceptance criteria should be based on a defined specification for each type of blood component. As an example for fresh frozen plasma, these data may include monitoring of weight/volume, sterility, Factor VIII activity and residual cell", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2513, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9286d6c9-2277-42d0-9cb6-5e1c5c691985": {"__data__": {"id_": "9286d6c9-2277-42d0-9cb6-5e1c5c691985", "embedding": null, "metadata": {"page_label": "217", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Labelling\n\n## 9.7.1 Label Information\n\nThe collected blood, as well as intermediate and finished blood components, should be labelled with relevant information regarding their identity and release status. The type of label to be used, as well as the labelling methodology, should be established in written standard operating procedures. Whenever possible, machine-readable labels (barcodes) should be used.\n\nThe label for a finished blood component should comply with the requirements of the NRA or contain at least the following information:\n\n- The unique donation number (through the use of this number there should be traceability to the donor and all records of the manufacturing steps through to the final product);\n- The product name (see section 9.7.2.);\n\nCounts (platelets, leukocytes, erythrocytes). The sampling plan for testing of blood or blood components should take into account that most components are derived from one donor, and should be considered as a single batch.\n\nWhole blood or blood components should not be released for use if the quality control test indicates that the integrity of the product has been compromised.\n\nThe work record should identify the test(s) employed so as to ensure that entries, such as the calculation of results, are available for review.\n\nTest results that do not meet the acceptance criteria should be clearly identified to ensure that blood components of that donation remain in quarantine and that relevant samples are selected for further testing. An investigation should be conducted into the cause of failure prior to additional or repeat testing. Where possible, the performance of the test procedures should be regularly assessed by participation in a formal system of proficiency testing.\n\nWhere applicable, the practice of pooling samples before testing should be clearly stated and the donations used in the pooled sample should be recorded. Pooling of samples, such as for the measurement of Factor VIII activity in plasma, is acceptable only where comparative data of pooled samples and individual samples have demonstrated assurance of equivalence.\n\nThe results of quality monitoring testing should be subject to periodic review and trend analysis. If the results of quality monitoring suggest that the process is not meeting validated parameters and specifications, then corrective and preventive actions should be taken to correct identified problems before product manufacturing and distribution is continued.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece directrices sobre el etiquetado de sangre y componentes sangu\u00edneos, enfatizando la importancia de la trazabilidad, la calidad y la seguridad en el proceso de donaci\u00f3n y fabricaci\u00f3n. Se especifica que las etiquetas deben contener informaci\u00f3n clave como el n\u00famero de donaci\u00f3n \u00fanico, el nombre del producto y los recuentos celulares. Adem\u00e1s, se menciona la necesidad de procedimientos operativos est\u00e1ndar para el etiquetado y la importancia de realizar pruebas de control de calidad antes de liberar los productos para su uso. Tambi\u00e9n se aborda la pr\u00e1ctica de agrupar muestras para pruebas y la necesidad de revisar peri\u00f3dicamente los resultados de las pruebas de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de un componente sangu\u00edneo terminado para garantizar la trazabilidad y la conformidad con las regulaciones?**\n   - La etiqueta debe incluir el n\u00famero de donaci\u00f3n \u00fanico, el nombre del producto y los recuentos de plaquetas, leucocitos y eritrocitos.\n\n2. **\u00bfQu\u00e9 acciones deben tomarse si los resultados de las pruebas de control de calidad no cumplen con los criterios de aceptaci\u00f3n?**\n   - Los resultados que no cumplen deben ser claramente identificados, los componentes de esa donaci\u00f3n deben permanecer en cuarentena, y se debe investigar la causa de la falla antes de realizar pruebas adicionales.\n\n3. **\u00bfCu\u00e1l es la importancia de la pr\u00e1ctica de agrupar muestras antes de las pruebas y qu\u00e9 condiciones deben cumplirse para que sea aceptable?**\n   - La agrupaci\u00f3n de muestras es aceptable solo si hay datos comparativos que demuestren la equivalencia entre muestras agrupadas e individuales, y debe registrarse qu\u00e9 donaciones se utilizaron en la muestra agrupada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Verificaci\u00f3n de Grupos Sangu\u00edneos**:\n   - Se debe verificar el grupo sangu\u00edneo ABO y RhD en cada donaci\u00f3n subsiguiente.\n   - Comparar con el grupo sangu\u00edneo hist\u00f3ricamente determinado.\n   - Si hay discrepancias, no se deben liberar los componentes sangu\u00edneos hasta resolver la discrepancia.\n\n2. **Pruebas para Anticuerpos Irregulares**:\n   - Donantes con antecedentes de transfusiones o embarazo deben ser evaluados para detectar anticuerpos irregulares cl\u00ednicamente significativos.\n   - Si se detectan, los componentes sangu\u00edneos deben etiquetarse adecuadamente.\n\n3. **Requisitos de la NRA**:\n   - Las Autoridades Reguladoras Nacionales (NRA) pueden establecer requisitos m\u00e1s estrictos.\n\n4. **Etiquetado de Donaciones de Primeras Veces**:\n   - El etiquetado de concentrados de gl\u00f3bulos rojos de donaciones de primer vez debe basarse en dos pruebas independientes de ABO/RhD.\n\n5. **Retenci\u00f3n de Muestras**:\n   - Se debe retener una al\u00edcuota de la muestra de prueba original de cada donaci\u00f3n.\n   - Almacenamiento bajo condiciones recomendadas por el fabricante del test para permitir re-pruebas si es necesario.\n   - Definici\u00f3n de volumen de muestra, vial de retenci\u00f3n, tipo de muestra (suero o plasma), condiciones y duraci\u00f3n de almacenamiento.\n\n6. **Control de Calidad**:\n   - Los datos de control de calidad deben demostrar que los procesos de fabricaci\u00f3n cr\u00edticos est\u00e1n bajo control.\n   - Los componentes sangu\u00edneos deben cumplir con especificaciones y utilizar m\u00e9todos de prueba aprobados por la NRA.\n   - Validaci\u00f3n de todos los procesos que influyen en la calidad de los productos.\n   - Implementaci\u00f3n de un plan de muestreo basado en m\u00e9todos estad\u00edsticos que considere diferentes sitios de recolecci\u00f3n, producci\u00f3n, transporte y m\u00e9todos de preparaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **NRA (Autoridades Reguladoras Nacionales)**: Entidades que pueden establecer requisitos adicionales.\n- **Componentes Sangu\u00edneos**: Incluyen gl\u00f3bulos rojos, plasma, etc.\n- **Anticuerpos Irregulares**: Anticuerpos que pueden afectar la compatibilidad sangu\u00ednea.\n- **Muestras de Prueba**: Muestras retenidas para pruebas adicionales. \n\nEste resumen destaca la importancia de la verificaci\u00f3n, el control de calidad y la gesti\u00f3n de muestras en el contexto de la donaci\u00f3n de sangre y la seguridad transfusional.", "excerpt_keywords": "Keywords: labelling, blood components, quality control, traceability, standard operating procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d289599-0bdd-4cf7-b527-905dce8edd64", "node_type": "4", "metadata": {"page_label": "217", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Labelling\n\n## 9.7.1 Label Information\n\nThe collected blood, as well as intermediate and finished blood components, should be labelled with relevant information regarding their identity and release status. The type of label to be used, as well as the labelling methodology, should be established in written standard operating procedures. Whenever possible, machine-readable labels (barcodes) should be used.\n\nThe label for a finished blood component should comply with the requirements of the NRA or contain at least the following information:\n\n- The unique donation number (through the use of this number there should be traceability to the donor and all records of the manufacturing steps through to the final product);\n- The product name (see section 9.7.2.);\n\nCounts (platelets, leukocytes, erythrocytes). The sampling plan for testing of blood or blood components should take into account that most components are derived from one donor, and should be considered as a single batch.\n\nWhole blood or blood components should not be released for use if the quality control test indicates that the integrity of the product has been compromised.\n\nThe work record should identify the test(s) employed so as to ensure that entries, such as the calculation of results, are available for review.\n\nTest results that do not meet the acceptance criteria should be clearly identified to ensure that blood components of that donation remain in quarantine and that relevant samples are selected for further testing. An investigation should be conducted into the cause of failure prior to additional or repeat testing. Where possible, the performance of the test procedures should be regularly assessed by participation in a formal system of proficiency testing.\n\nWhere applicable, the practice of pooling samples before testing should be clearly stated and the donations used in the pooled sample should be recorded. Pooling of samples, such as for the measurement of Factor VIII activity in plasma, is acceptable only where comparative data of pooled samples and individual samples have demonstrated assurance of equivalence.\n\nThe results of quality monitoring testing should be subject to periodic review and trend analysis. If the results of quality monitoring suggest that the process is not meeting validated parameters and specifications, then corrective and preventive actions should be taken to correct identified problems before product manufacturing and distribution is continued.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ccf152c75d28801c0ed2cff554c146135a13c191f85b55a547b0b798346dfc1a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Labelling\n\n## 9.7.1 Label Information\n\nThe collected blood, as well as intermediate and finished blood components, should be labelled with relevant information regarding their identity and release status. The type of label to be used, as well as the labelling methodology, should be established in written standard operating procedures. Whenever possible, machine-readable labels (barcodes) should be used.\n\nThe label for a finished blood component should comply with the requirements of the NRA or contain at least the following information:\n\n- The unique donation number (through the use of this number there should be traceability to the donor and all records of the manufacturing steps through to the final product);\n- The product name (see section 9.7.2.);\n\nCounts (platelets, leukocytes, erythrocytes). The sampling plan for testing of blood or blood components should take into account that most components are derived from one donor, and should be considered as a single batch.\n\nWhole blood or blood components should not be released for use if the quality control test indicates that the integrity of the product has been compromised.\n\nThe work record should identify the test(s) employed so as to ensure that entries, such as the calculation of results, are available for review.\n\nTest results that do not meet the acceptance criteria should be clearly identified to ensure that blood components of that donation remain in quarantine and that relevant samples are selected for further testing. An investigation should be conducted into the cause of failure prior to additional or repeat testing. Where possible, the performance of the test procedures should be regularly assessed by participation in a formal system of proficiency testing.\n\nWhere applicable, the practice of pooling samples before testing should be clearly stated and the donations used in the pooled sample should be recorded. Pooling of samples, such as for the measurement of Factor VIII activity in plasma, is acceptable only where comparative data of pooled samples and individual samples have demonstrated assurance of equivalence.\n\nThe results of quality monitoring testing should be subject to periodic review and trend analysis. If the results of quality monitoring suggest that the process is not meeting validated parameters and specifications, then corrective and preventive actions should be taken to correct identified problems before product manufacturing and distribution is continued.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2480, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f30cfd36-b3fa-431e-9881-e1524fc927e8": {"__data__": {"id_": "f30cfd36-b3fa-431e-9881-e1524fc927e8", "embedding": null, "metadata": {"page_label": "218", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the required storage conditions;\n- the expiry date and, where appropriate, time (see section 9.7.3.);\n- the date of collection of the donation(s) from which the blood component was prepared and/or the production date and time (where appropriate);\n- the date and time of irradiation (where applicable);\n- the ABO and RhD blood group (where appropriate);\n- the name or other identification of the component preparation site.\n\nInformation regarding the use of the blood product may also be applicable.\n\nFor autologous blood components, the label should additionally contain the name and unique identification of the patient as well as the statement \u201cAutologous donation\u201d. In some countries the signature of the donor is also required.\n\n### 9.7.2 Product name\n\nThe name of the blood component should be clearly stated on the label and should indicate any further processing such as leukocyte reduction or irradiation.\n\nIn addition, the anticoagulant and/or any nutrient or preservative solution should be mentioned on the label.\n\n### 9.7.3 Expiry date\n\nAny final blood product should have its expiry date on its label. It should be also kept in mind that certain processing steps, such as irradiation, have an influence on the expiry date so that relabelling becomes necessary.\n\nThe definition of an expiry date should be validated and based on scientific data according to the processing steps applied and the storage conditions, or should be the subject of stability studies.\n\n### 9.8 Release of product\n\nEach blood establishment should be able to demonstrate that a blood component has been evaluated and approved for release by an authorized person, preferably assisted by validated computerized systems. The release criteria and specifications of blood components should be defined, validated, documented and approved by quality assurance. There should be a standard operating procedure that details the actions and criteria that determine whether the blood or blood component can be released. The decision to release the blood components should be made by the responsible person of the establishment; it should be clearly documented and traceability should be ensured. Electronic release of products should be fully validated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los requisitos para el etiquetado y liberaci\u00f3n de componentes sangu\u00edneos. Se especifican las condiciones de almacenamiento, la fecha de caducidad, la identificaci\u00f3n del donante y del sitio de preparaci\u00f3n, as\u00ed como la necesidad de un procedimiento estandarizado para la liberaci\u00f3n de productos sangu\u00edneos. Tambi\u00e9n se menciona la importancia de la validaci\u00f3n de los procesos y la documentaci\u00f3n adecuada para garantizar la trazabilidad y la calidad de los componentes sangu\u00edneos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la etiqueta de un componente sangu\u00edneo aut\u00f3logo?**\n   - La etiqueta debe incluir el nombre y la identificaci\u00f3n \u00fanica del paciente, as\u00ed como la declaraci\u00f3n \"Donaci\u00f3n aut\u00f3loga\". En algunos pa\u00edses, tambi\u00e9n se requiere la firma del donante.\n\n2. **\u00bfC\u00f3mo se determina la fecha de caducidad de un producto sangu\u00edneo y qu\u00e9 factores pueden influir en ella?**\n   - La fecha de caducidad debe estar validada y basada en datos cient\u00edficos que consideren los pasos de procesamiento aplicados y las condiciones de almacenamiento. Procesos como la irradiaci\u00f3n pueden influir en la fecha de caducidad, lo que puede requerir un nuevo etiquetado.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la liberaci\u00f3n de un componente sangu\u00edneo en un establecimiento de sangre?**\n   - Cada establecimiento debe demostrar que un componente sangu\u00edneo ha sido evaluado y aprobado para su liberaci\u00f3n por una persona autorizada. Deben existir criterios de liberaci\u00f3n definidos, validados y documentados, y la decisi\u00f3n de liberar los componentes debe ser claramente documentada y asegurar la trazabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Sangre y Componentes Sangu\u00edneos**:\n   - Importancia de etiquetar adecuadamente la sangre y sus componentes para asegurar la trazabilidad y la conformidad con las regulaciones.\n\n2. **Informaci\u00f3n Requerida en las Etiquetas**:\n   - N\u00famero de donaci\u00f3n \u00fanico: Permite la trazabilidad al donante y a los registros de fabricaci\u00f3n.\n   - Nombre del producto: Identificaci\u00f3n del tipo de componente sangu\u00edneo.\n   - Recuentos celulares: Incluye plaquetas, leucocitos y eritrocitos.\n\n3. **Procedimientos Operativos Est\u00e1ndar**:\n   - Se deben establecer procedimientos escritos para el etiquetado y la metodolog\u00eda de etiquetado, preferiblemente utilizando etiquetas legibles por m\u00e1quina (c\u00f3digos de barras).\n\n4. **Control de Calidad**:\n   - Los componentes sangu\u00edneos no deben liberarse si las pruebas de control de calidad indican que la integridad del producto est\u00e1 comprometida.\n   - Los resultados de las pruebas que no cumplen con los criterios de aceptaci\u00f3n deben ser identificados y los componentes deben permanecer en cuarentena.\n\n5. **Agrupaci\u00f3n de Muestras**:\n   - La pr\u00e1ctica de agrupar muestras antes de las pruebas debe estar claramente documentada y solo es aceptable si hay datos que demuestren la equivalencia entre muestras agrupadas e individuales.\n\n6. **Revisi\u00f3n y An\u00e1lisis de Tendencias**:\n   - Los resultados de las pruebas de monitoreo de calidad deben revisarse peri\u00f3dicamente. Si se identifican problemas, se deben tomar acciones correctivas y preventivas antes de continuar con la fabricaci\u00f3n y distribuci\u00f3n del producto.\n\n### Entidades Clave\n- **NRA**: Autoridad Reguladora Nacional (National Regulatory Authority).\n- **Factor VIII**: Componente de la coagulaci\u00f3n que puede medirse en plasma.\n- **Componentes Sangu\u00edneos**: Incluyen sangre total, plaquetas, leucocitos y eritrocitos. \n\nEste resumen destaca la importancia del etiquetado, la trazabilidad, el control de calidad y la documentaci\u00f3n en el proceso de manejo de sangre y sus componentes.", "excerpt_keywords": "Keywords: blood components, labeling requirements, expiry date, quality assurance, autologous donation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "37d81d42-e015-4bbe-ad11-d621aabb7b70", "node_type": "4", "metadata": {"page_label": "218", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the required storage conditions;\n- the expiry date and, where appropriate, time (see section 9.7.3.);\n- the date of collection of the donation(s) from which the blood component was prepared and/or the production date and time (where appropriate);\n- the date and time of irradiation (where applicable);\n- the ABO and RhD blood group (where appropriate);\n- the name or other identification of the component preparation site.\n\nInformation regarding the use of the blood product may also be applicable.\n\nFor autologous blood components, the label should additionally contain the name and unique identification of the patient as well as the statement \u201cAutologous donation\u201d. In some countries the signature of the donor is also required.\n\n### 9.7.2 Product name\n\nThe name of the blood component should be clearly stated on the label and should indicate any further processing such as leukocyte reduction or irradiation.\n\nIn addition, the anticoagulant and/or any nutrient or preservative solution should be mentioned on the label.\n\n### 9.7.3 Expiry date\n\nAny final blood product should have its expiry date on its label. It should be also kept in mind that certain processing steps, such as irradiation, have an influence on the expiry date so that relabelling becomes necessary.\n\nThe definition of an expiry date should be validated and based on scientific data according to the processing steps applied and the storage conditions, or should be the subject of stability studies.\n\n### 9.8 Release of product\n\nEach blood establishment should be able to demonstrate that a blood component has been evaluated and approved for release by an authorized person, preferably assisted by validated computerized systems. The release criteria and specifications of blood components should be defined, validated, documented and approved by quality assurance. There should be a standard operating procedure that details the actions and criteria that determine whether the blood or blood component can be released. The decision to release the blood components should be made by the responsible person of the establishment; it should be clearly documented and traceability should be ensured. Electronic release of products should be fully validated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e73284509a21a112600b24c635f57922de4d524872ba93dd14837ee6f92aa7ea", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- the required storage conditions;\n- the expiry date and, where appropriate, time (see section 9.7.3.);\n- the date of collection of the donation(s) from which the blood component was prepared and/or the production date and time (where appropriate);\n- the date and time of irradiation (where applicable);\n- the ABO and RhD blood group (where appropriate);\n- the name or other identification of the component preparation site.\n\nInformation regarding the use of the blood product may also be applicable.\n\nFor autologous blood components, the label should additionally contain the name and unique identification of the patient as well as the statement \u201cAutologous donation\u201d. In some countries the signature of the donor is also required.\n\n### 9.7.2 Product name\n\nThe name of the blood component should be clearly stated on the label and should indicate any further processing such as leukocyte reduction or irradiation.\n\nIn addition, the anticoagulant and/or any nutrient or preservative solution should be mentioned on the label.\n\n### 9.7.3 Expiry date\n\nAny final blood product should have its expiry date on its label. It should be also kept in mind that certain processing steps, such as irradiation, have an influence on the expiry date so that relabelling becomes necessary.\n\nThe definition of an expiry date should be validated and based on scientific data according to the processing steps applied and the storage conditions, or should be the subject of stability studies.\n\n### 9.8 Release of product\n\nEach blood establishment should be able to demonstrate that a blood component has been evaluated and approved for release by an authorized person, preferably assisted by validated computerized systems. The release criteria and specifications of blood components should be defined, validated, documented and approved by quality assurance. There should be a standard operating procedure that details the actions and criteria that determine whether the blood or blood component can be released. The decision to release the blood components should be made by the responsible person of the establishment; it should be clearly documented and traceability should be ensured. Electronic release of products should be fully validated.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2230, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ce1fa88e-0f1c-4b3f-9b8b-10cb852626b3": {"__data__": {"id_": "ce1fa88e-0f1c-4b3f-9b8b-10cb852626b3", "embedding": null, "metadata": {"page_label": "219", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The documented manufacturing processes should be followed at all times using validated methods and procedures. Any deviations from these established procedures and processes may result in products not meeting specifications, in which case they should be considered non-conforming products and must not be released for distribution.\n\nA review of the donor health record, collection and phlebotomy records, consent forms, records of production and test results should be performed and accepted (and should be recorded) prior to the release of the components. The release of products should be arranged in such a way that each component from the donation has been evaluated to ensure conformance with product specifications \u2014 such as platelet content in apheresis units, volume in plasma products or appearance for red blood cells \u2014 prior to release for distribution. The decision to release the component should not be made on the basis of a review of the collection processes alone.\n\nThere should be a system of administrative and physical quarantine for blood and blood components to ensure that components cannot be released until all mandatory requirements have been met.\n\nIn the absence of a computerized system for product status control:\n\n- the label of a blood component should identify the product status and should clearly distinguish released products from non-released (quarantined) ones;\n- records should demonstrate that, before a component is released, all current donor health records, collection and phlebotomy records, consent forms and test results have been verified and accepted by an authorized person.\n\nIf blood or blood components have been prepared from a donor who has donated on previous occasions, a comparison with previous records \u2014 specifically the ABO/RhD and infectious disease marker test results \u2014 should be made before final product release to ensure that current records accurately reflect the donor history.\n\nWhere release is subject to computer-derived information, the following points should be checked:\n\n- Computer systems should be validated so that they are fully secure against the possibility of blood and blood components which do not fulfil all test or donor selection criteria being released.\n- The manual entry of critical data, such as laboratory test results, should require independent verification by a second authorized person.\n- There should be a hierarchy of permitted access to enter, amend, read or print data. Methods of preventing unauthorized entry should be in place, such as personal identity codes or passwords which are changed on a regular basis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto se centra en los procedimientos y requisitos necesarios para la liberaci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de seguir procesos de fabricaci\u00f3n documentados y validados, as\u00ed como la revisi\u00f3n exhaustiva de los registros de salud del donante, los registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas antes de liberar cualquier componente. Tambi\u00e9n se menciona la necesidad de un sistema de cuarentena administrativa y f\u00edsica para asegurar que los componentes no se liberen hasta que se cumplan todos los requisitos obligatorios. En caso de no contar con un sistema computarizado, se establecen directrices sobre el etiquetado y la verificaci\u00f3n de registros. Adem\u00e1s, se abordan las medidas de seguridad necesarias para sistemas inform\u00e1ticos que gestionan la liberaci\u00f3n de productos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que un componente sangu\u00edneo no se libere si no cumple con las especificaciones?**\n   - La liberaci\u00f3n de un componente sangu\u00edneo debe basarse en una revisi\u00f3n completa de los registros de salud del donante, los registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas. Si hay alguna desviaci\u00f3n de los procedimientos establecidos, el producto debe considerarse no conforme y no debe liberarse.\n\n2. **\u00bfCu\u00e1les son las medidas que deben implementarse en un sistema computarizado para garantizar la seguridad en la liberaci\u00f3n de componentes sangu\u00edneos?**\n   - Los sistemas computarizados deben ser validados para asegurar que no se liberen componentes que no cumplan con todos los criterios de prueba o selecci\u00f3n del donante. Adem\u00e1s, la entrada manual de datos cr\u00edticos debe requerir verificaci\u00f3n independiente, y debe existir una jerarqu\u00eda de acceso para modificar o consultar datos.\n\n3. **\u00bfQu\u00e9 pasos se deben seguir si un donante ha donado en ocasiones anteriores antes de liberar un nuevo componente sangu\u00edneo?**\n   - Se debe realizar una comparaci\u00f3n con los registros anteriores del donante, espec\u00edficamente los resultados de las pruebas de ABO/RhD y marcadores de enfermedades infecciosas, para asegurarse de que los registros actuales reflejen con precisi\u00f3n la historia del donante antes de la liberaci\u00f3n del producto.", "prev_section_summary": "### Temas Clave:\n\n1. **Etiquetado de Componentes Sangu\u00edneos**:\n   - Informaci\u00f3n esencial que debe incluirse en la etiqueta, como condiciones de almacenamiento, fecha de caducidad, fecha de recolecci\u00f3n, grupo sangu\u00edneo ABO y RhD, y la identificaci\u00f3n del sitio de preparaci\u00f3n.\n\n2. **Componentes Sangu\u00edneos Aut\u00f3logos**:\n   - Requisitos espec\u00edficos para la etiqueta, que deben incluir el nombre y la identificaci\u00f3n \u00fanica del paciente, as\u00ed como la declaraci\u00f3n \"Donaci\u00f3n aut\u00f3loga\".\n\n3. **Nombre del Producto**:\n   - El nombre del componente sangu\u00edneo debe ser claro e indicar cualquier procesamiento adicional, como reducci\u00f3n de leucocitos o irradiaci\u00f3n, adem\u00e1s de mencionar soluciones anticoagulantes o preservativas.\n\n4. **Fecha de Caducidad**:\n   - Importancia de tener una fecha de caducidad validada, influenciada por procesos de tratamiento como la irradiaci\u00f3n, que puede requerir un nuevo etiquetado.\n\n5. **Liberaci\u00f3n de Productos Sangu\u00edneos**:\n   - Procedimientos que deben seguirse para la liberaci\u00f3n de componentes sangu\u00edneos, incluyendo la evaluaci\u00f3n y aprobaci\u00f3n por una persona autorizada, criterios de liberaci\u00f3n documentados y la necesidad de asegurar la trazabilidad.\n\n### Entidades:\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Componentes Sangu\u00edneos**: Sangre, componentes sangu\u00edneos aut\u00f3logos\n- **Procesos**: Recolecci\u00f3n, procesamiento, irradiaci\u00f3n, liberaci\u00f3n\n- **Identificaci\u00f3n**: Nombre del paciente, identificaci\u00f3n del sitio de preparaci\u00f3n, firma del donante (en algunos pa\u00edses)\n- **Criterios de Calidad**: Validaci\u00f3n, documentaci\u00f3n, trazabilidad, sistemas computarizados validados\n\nEste resumen destaca los aspectos fundamentales relacionados con el etiquetado y la liberaci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de la calidad y la trazabilidad en el manejo de productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood components, release procedures, donor health records, quality control, validation systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a441866f-17cf-4d44-b960-f40be2e47565", "node_type": "4", "metadata": {"page_label": "219", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The documented manufacturing processes should be followed at all times using validated methods and procedures. Any deviations from these established procedures and processes may result in products not meeting specifications, in which case they should be considered non-conforming products and must not be released for distribution.\n\nA review of the donor health record, collection and phlebotomy records, consent forms, records of production and test results should be performed and accepted (and should be recorded) prior to the release of the components. The release of products should be arranged in such a way that each component from the donation has been evaluated to ensure conformance with product specifications \u2014 such as platelet content in apheresis units, volume in plasma products or appearance for red blood cells \u2014 prior to release for distribution. The decision to release the component should not be made on the basis of a review of the collection processes alone.\n\nThere should be a system of administrative and physical quarantine for blood and blood components to ensure that components cannot be released until all mandatory requirements have been met.\n\nIn the absence of a computerized system for product status control:\n\n- the label of a blood component should identify the product status and should clearly distinguish released products from non-released (quarantined) ones;\n- records should demonstrate that, before a component is released, all current donor health records, collection and phlebotomy records, consent forms and test results have been verified and accepted by an authorized person.\n\nIf blood or blood components have been prepared from a donor who has donated on previous occasions, a comparison with previous records \u2014 specifically the ABO/RhD and infectious disease marker test results \u2014 should be made before final product release to ensure that current records accurately reflect the donor history.\n\nWhere release is subject to computer-derived information, the following points should be checked:\n\n- Computer systems should be validated so that they are fully secure against the possibility of blood and blood components which do not fulfil all test or donor selection criteria being released.\n- The manual entry of critical data, such as laboratory test results, should require independent verification by a second authorized person.\n- There should be a hierarchy of permitted access to enter, amend, read or print data. Methods of preventing unauthorized entry should be in place, such as personal identity codes or passwords which are changed on a regular basis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a96a8601baed1335647d659f74407864f2054009e4b6530a904d85d38fd8bec6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The documented manufacturing processes should be followed at all times using validated methods and procedures. Any deviations from these established procedures and processes may result in products not meeting specifications, in which case they should be considered non-conforming products and must not be released for distribution.\n\nA review of the donor health record, collection and phlebotomy records, consent forms, records of production and test results should be performed and accepted (and should be recorded) prior to the release of the components. The release of products should be arranged in such a way that each component from the donation has been evaluated to ensure conformance with product specifications \u2014 such as platelet content in apheresis units, volume in plasma products or appearance for red blood cells \u2014 prior to release for distribution. The decision to release the component should not be made on the basis of a review of the collection processes alone.\n\nThere should be a system of administrative and physical quarantine for blood and blood components to ensure that components cannot be released until all mandatory requirements have been met.\n\nIn the absence of a computerized system for product status control:\n\n- the label of a blood component should identify the product status and should clearly distinguish released products from non-released (quarantined) ones;\n- records should demonstrate that, before a component is released, all current donor health records, collection and phlebotomy records, consent forms and test results have been verified and accepted by an authorized person.\n\nIf blood or blood components have been prepared from a donor who has donated on previous occasions, a comparison with previous records \u2014 specifically the ABO/RhD and infectious disease marker test results \u2014 should be made before final product release to ensure that current records accurately reflect the donor history.\n\nWhere release is subject to computer-derived information, the following points should be checked:\n\n- Computer systems should be validated so that they are fully secure against the possibility of blood and blood components which do not fulfil all test or donor selection criteria being released.\n- The manual entry of critical data, such as laboratory test results, should require independent verification by a second authorized person.\n- There should be a hierarchy of permitted access to enter, amend, read or print data. Methods of preventing unauthorized entry should be in place, such as personal identity codes or passwords which are changed on a regular basis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2611, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "69798271-cc9b-4c52-94dd-48153ebee1e0": {"__data__": {"id_": "69798271-cc9b-4c52-94dd-48153ebee1e0", "embedding": null, "metadata": {"page_label": "220", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Computer systems should prevent the release of all blood or blood components considered not acceptable for release. It should be possible to prevent the release of any future donation from a donor.\n\nIn the event that the final product fails release due to noncompliance with the specified requirements and therefore due to potential impact on recipient safety, all other implicated components should be identified and appropriate action should be taken. A check should be made to ensure that (if relevant) other components from the same donation(s) and components prepared from previous donations given by the donor(s) are identified. There should be an immediate updating of the donor record(s) to ensure that the donor(s) cannot make any further donation, if appropriate.\n\nThere should be a defined procedure for the exceptional release of nonstandard blood and blood components under a planned non-conformance system. The decision to allow such a release should be made by the responsible person; the decision should be clearly documented and traceability should be ensured. Products that cannot be released should be destroyed and the record of destruction should be retained.\n\n### 9.9 Storage\n\nStandard operating procedures should describe the receipt, handling and storage of material, blood and blood components. There should be a system in place to maintain and control storage conditions, including any transportation that may be required. Autologous blood and blood components should be stored separately. Storage areas for blood components to be dispatched should be located near an entrance or exit to facilitate dispatch and to limit the number of persons entering the main working areas. Only authorized persons should have access to storage areas.\n\nStorage conditions should be controlled, monitored and checked. The personnel authorized should be trained to be aware of the correct storage temperature ranges and alarm settings. Temperature records should be available to demonstrate that the blood components are stored at the required temperature throughout the storage area. A temperature monitoring and recording system that is independent from the temperature regulation system should be in place. Appropriate alarms should be present (upper and lower limits) and regularly checked; the checks should be recorded. Depending on the method of measuring the temperature, a delay of the alarm may be acceptable in order to avoid an alarm being triggered by opening a door or taking out a product, but any such delay should be reasonably justified. If the temperature sensor is placed in a reference solution, no delay of the alarm should be accepted. Appropriate actions on alarms should be defined, and a person should be authorized to decide on the use or rejection of affected", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Prevenci\u00f3n de liberaci\u00f3n de componentes sangu\u00edneos**: El documento establece que los sistemas inform\u00e1ticos deben evitar la liberaci\u00f3n de sangre o componentes sangu\u00edneos que no sean aceptables, y se deben tomar medidas para identificar y actuar sobre donaciones implicadas en caso de que un producto final no cumpla con los requisitos de seguridad.\n\n2. **Procedimientos de almacenamiento**: Se detallan los procedimientos est\u00e1ndar para la recepci\u00f3n, manejo y almacenamiento de sangre y componentes sangu\u00edneos, enfatizando la importancia de mantener condiciones de almacenamiento controladas y monitoreadas, as\u00ed como la capacitaci\u00f3n del personal en el manejo de temperaturas y alarmas.\n\n3. **Manejo de no conformidades**: Se menciona la necesidad de un procedimiento definido para la liberaci\u00f3n excepcional de componentes sangu\u00edneos no est\u00e1ndar, que debe ser documentado y autorizado por una persona responsable, asegurando la trazabilidad y el manejo adecuado de productos que no pueden ser liberados.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si un producto sangu\u00edneo no cumple con los requisitos de liberaci\u00f3n?**\n   - En caso de que un producto final falle en su liberaci\u00f3n, se deben identificar todos los componentes implicados, actualizar inmediatamente los registros del donante para evitar futuras donaciones y tomar las acciones apropiadas para garantizar la seguridad del receptor.\n\n2. **\u00bfCu\u00e1les son los requisitos para el almacenamiento de componentes sangu\u00edneos aut\u00f3logos?**\n   - Los componentes sangu\u00edneos aut\u00f3logos deben almacenarse por separado, y las \u00e1reas de almacenamiento deben estar ubicadas cerca de las entradas o salidas para facilitar el despacho y limitar el acceso a personas no autorizadas.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para el monitoreo de la temperatura en las \u00e1reas de almacenamiento de sangre?**\n   - Debe existir un sistema de monitoreo y registro de temperatura independiente del sistema de regulaci\u00f3n, con alarmas adecuadas que se revisen regularmente. Adem\u00e1s, el personal autorizado debe estar capacitado en los rangos de temperatura correctos y en la respuesta a las alarmas, asegurando que se tomen decisiones informadas sobre el uso o rechazo de productos afectados.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos de Fabricaci\u00f3n**: Se enfatiza la importancia de seguir procesos documentados y validados para la fabricaci\u00f3n de componentes sangu\u00edneos. Cualquier desviaci\u00f3n de estos procedimientos puede resultar en productos no conformes.\n\n2. **Revisi\u00f3n de Registros**: Antes de liberar componentes sangu\u00edneos, es necesario realizar una revisi\u00f3n exhaustiva de los registros de salud del donante, registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas.\n\n3. **Cuarentena Administrativa y F\u00edsica**: Se debe implementar un sistema de cuarentena para asegurar que los componentes no se liberen hasta que se cumplan todos los requisitos obligatorios.\n\n4. **Etiquetado y Verificaci\u00f3n**: En ausencia de un sistema computarizado, los componentes deben estar etiquetados para identificar su estado (liberados o en cuarentena) y los registros deben demostrar que se han verificado todos los documentos necesarios.\n\n5. **Comparaci\u00f3n de Registros de Donantes**: Si un donante ha donado anteriormente, se debe comparar su historial con los registros actuales, especialmente en lo que respecta a pruebas de ABO/RhD y marcadores de enfermedades infecciosas.\n\n6. **Seguridad en Sistemas Computarizados**: Los sistemas inform\u00e1ticos deben ser validados para prevenir la liberaci\u00f3n de componentes no conformes. La entrada manual de datos cr\u00edticos debe ser verificada independientemente, y debe existir una jerarqu\u00eda de acceso para proteger la informaci\u00f3n.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre que deben cumplir con especificaciones antes de su liberaci\u00f3n.\n- **Registros de Salud del Donante**: Documentaci\u00f3n que contiene informaci\u00f3n sobre la salud del donante.\n- **Registros de Recolecci\u00f3n y Flebotom\u00eda**: Documentos que registran el proceso de recolecci\u00f3n de sangre.\n- **Formularios de Consentimiento**: Documentos que confirman que el donante ha dado su consentimiento para la donaci\u00f3n.\n- **Resultados de Pruebas**: Informaci\u00f3n sobre las pruebas realizadas a los componentes sangu\u00edneos.\n- **Sistema de Cuarentena**: Proceso administrativo y f\u00edsico para asegurar que los productos no se liberen hasta cumplir con todos los requisitos.\n- **Sistemas Computarizados**: Herramientas tecnol\u00f3gicas utilizadas para gestionar la informaci\u00f3n y el estado de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood safety, storage procedures, donor records, nonconformance, temperature monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "da9e8f1c-ba83-4ead-b0e0-1dc12ba39f04", "node_type": "4", "metadata": {"page_label": "220", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Computer systems should prevent the release of all blood or blood components considered not acceptable for release. It should be possible to prevent the release of any future donation from a donor.\n\nIn the event that the final product fails release due to noncompliance with the specified requirements and therefore due to potential impact on recipient safety, all other implicated components should be identified and appropriate action should be taken. A check should be made to ensure that (if relevant) other components from the same donation(s) and components prepared from previous donations given by the donor(s) are identified. There should be an immediate updating of the donor record(s) to ensure that the donor(s) cannot make any further donation, if appropriate.\n\nThere should be a defined procedure for the exceptional release of nonstandard blood and blood components under a planned non-conformance system. The decision to allow such a release should be made by the responsible person; the decision should be clearly documented and traceability should be ensured. Products that cannot be released should be destroyed and the record of destruction should be retained.\n\n### 9.9 Storage\n\nStandard operating procedures should describe the receipt, handling and storage of material, blood and blood components. There should be a system in place to maintain and control storage conditions, including any transportation that may be required. Autologous blood and blood components should be stored separately. Storage areas for blood components to be dispatched should be located near an entrance or exit to facilitate dispatch and to limit the number of persons entering the main working areas. Only authorized persons should have access to storage areas.\n\nStorage conditions should be controlled, monitored and checked. The personnel authorized should be trained to be aware of the correct storage temperature ranges and alarm settings. Temperature records should be available to demonstrate that the blood components are stored at the required temperature throughout the storage area. A temperature monitoring and recording system that is independent from the temperature regulation system should be in place. Appropriate alarms should be present (upper and lower limits) and regularly checked; the checks should be recorded. Depending on the method of measuring the temperature, a delay of the alarm may be acceptable in order to avoid an alarm being triggered by opening a door or taking out a product, but any such delay should be reasonably justified. If the temperature sensor is placed in a reference solution, no delay of the alarm should be accepted. Appropriate actions on alarms should be defined, and a person should be authorized to decide on the use or rejection of affected", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b749d3ecae3879cbf2b15004756cf52555b9e79e635d56eee333c3e7220dc7ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Computer systems should prevent the release of all blood or blood components considered not acceptable for release. It should be possible to prevent the release of any future donation from a donor.\n\nIn the event that the final product fails release due to noncompliance with the specified requirements and therefore due to potential impact on recipient safety, all other implicated components should be identified and appropriate action should be taken. A check should be made to ensure that (if relevant) other components from the same donation(s) and components prepared from previous donations given by the donor(s) are identified. There should be an immediate updating of the donor record(s) to ensure that the donor(s) cannot make any further donation, if appropriate.\n\nThere should be a defined procedure for the exceptional release of nonstandard blood and blood components under a planned non-conformance system. The decision to allow such a release should be made by the responsible person; the decision should be clearly documented and traceability should be ensured. Products that cannot be released should be destroyed and the record of destruction should be retained.\n\n### 9.9 Storage\n\nStandard operating procedures should describe the receipt, handling and storage of material, blood and blood components. There should be a system in place to maintain and control storage conditions, including any transportation that may be required. Autologous blood and blood components should be stored separately. Storage areas for blood components to be dispatched should be located near an entrance or exit to facilitate dispatch and to limit the number of persons entering the main working areas. Only authorized persons should have access to storage areas.\n\nStorage conditions should be controlled, monitored and checked. The personnel authorized should be trained to be aware of the correct storage temperature ranges and alarm settings. Temperature records should be available to demonstrate that the blood components are stored at the required temperature throughout the storage area. A temperature monitoring and recording system that is independent from the temperature regulation system should be in place. Appropriate alarms should be present (upper and lower limits) and regularly checked; the checks should be recorded. Depending on the method of measuring the temperature, a delay of the alarm may be acceptable in order to avoid an alarm being triggered by opening a door or taking out a product, but any such delay should be reasonably justified. If the temperature sensor is placed in a reference solution, no delay of the alarm should be accepted. Appropriate actions on alarms should be defined, and a person should be authorized to decide on the use or rejection of affected", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2798, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "01e6b08d-df45-44ba-a332-79b1f1966828": {"__data__": {"id_": "01e6b08d-df45-44ba-a332-79b1f1966828", "embedding": null, "metadata": {"page_label": "221", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "products. Temperature excursions may occur and each event should be evaluated using the deviation management system (see section 3.5).\n\nAn alternative storage area of appropriate temperature is recommended for recovery in case of temperature control failure of the primary system. Areas for storage should be secured against the entry of unauthorized persons and should be used only for the intended purpose. Storage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and material. If a temporary mechanical or electrical failure affects control of storage temperatures, an examination of the records should be made to evaluate the impact on plasma or blood component quality.\n\nFor the main blood components, the common storage temperatures are as follows:\n\n- red-cell concentrate: 1\u20136\u00b0C;\n- plasma for transfusion: minus 25\u00b0C or colder;\n- platelets: 20\u201324\u00b0C;\n\nor in a more stringent range defined by the NRA.\n\nHigher storage temperatures (e.g. minus 20\u00b0C) might be acceptable for plasma for transfusion but may result in a significantly shorter shelf-life.\n\nStorage of platelets should also be controlled. Besides the temperature, the continuous agitation is very important. Based on the manufacturer\u2019s instructions, the moving velocity should be set in a way that obtains an optimal quality of the product. The moving velocity should be part of the qualification of the equipment.\n\nDuring the whole collection and manufacturing process it should be ensured that blood or blood components are never placed in direct sunlight or near a heating source.\n\nAll storage equipment should be subject to qualification, cleaning and preventive maintenance. Thermometers or temperature sensors should be calibrated annually. The temperature deviation to the standard measuring device should not exceed 1\u00b0C.\n\n## 9.10 Distribution\n\nPrior to distribution, blood components should be visually inspected. There should be a record that identifies the person distributing and the customer receiving the components. Dispatch of blood components should be made by authorized personnel.\n\nAt the time of dispatch, there should be a procedure in place to ensure that all blood components being issued have been formally released for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre el almacenamiento y distribuci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de mantener temperaturas adecuadas y seguras para preservar la calidad de los productos. Se mencionan las temperaturas de almacenamiento recomendadas para diferentes componentes sangu\u00edneos, la necesidad de un \u00e1rea de almacenamiento alternativa en caso de fallos en el control de temperatura, y la importancia de la inspecci\u00f3n visual y el registro de distribuci\u00f3n antes de enviar los componentes. Tambi\u00e9n se destaca la necesidad de mantenimiento y calibraci\u00f3n de los equipos de almacenamiento.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las temperaturas de almacenamiento recomendadas para los diferentes componentes sangu\u00edneos y qu\u00e9 impacto puede tener un almacenamiento a temperaturas m\u00e1s altas?**\n   - Respuesta: Las temperaturas recomendadas son: concentrado de gl\u00f3bulos rojos a 1\u20136\u00b0C, plasma para transfusi\u00f3n a menos 25\u00b0C o m\u00e1s fr\u00edo, y plaquetas a 20\u201324\u00b0C. Almacenar plasma a temperaturas m\u00e1s altas, como menos 20\u00b0C, puede resultar en una vida \u00fatil significativamente m\u00e1s corta.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de un fallo temporal en el control de temperatura de los equipos de almacenamiento?**\n   - Respuesta: En caso de un fallo temporal, se debe realizar un examen de los registros para evaluar el impacto en la calidad de los componentes sangu\u00edneos, y se recomienda tener un \u00e1rea de almacenamiento alternativa de temperatura adecuada para la recuperaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en las \u00e1reas de almacenamiento de componentes sangu\u00edneos?**\n   - Respuesta: Las \u00e1reas de almacenamiento deben estar aseguradas contra la entrada de personas no autorizadas, y debe haber una efectiva segregaci\u00f3n entre materiales en cuarentena y aquellos liberados, as\u00ed como un \u00e1rea separada para componentes rechazados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prevenci\u00f3n de Liberaci\u00f3n de Componentes Sangu\u00edneos**:\n   - Los sistemas inform\u00e1ticos deben impedir la liberaci\u00f3n de sangre o componentes sangu\u00edneos no aceptables.\n   - Se deben identificar todos los componentes implicados si un producto final no cumple con los requisitos de seguridad.\n   - Actualizaci\u00f3n inmediata de los registros del donante para evitar futuras donaciones.\n\n2. **Procedimientos de Manejo de No Conformidades**:\n   - Se requiere un procedimiento definido para la liberaci\u00f3n excepcional de componentes sangu\u00edneos no est\u00e1ndar.\n   - La decisi\u00f3n de liberar productos no conformes debe ser documentada y autorizada por una persona responsable.\n   - Los productos que no pueden ser liberados deben ser destruidos, y se debe mantener un registro de destrucci\u00f3n.\n\n3. **Almacenamiento de Componentes Sangu\u00edneos**:\n   - Se deben establecer procedimientos est\u00e1ndar para la recepci\u00f3n, manejo y almacenamiento de sangre y componentes sangu\u00edneos.\n   - Los componentes sangu\u00edneos aut\u00f3logos deben almacenarse por separado.\n   - Las \u00e1reas de almacenamiento deben estar ubicadas estrat\u00e9gicamente para facilitar el despacho y limitar el acceso a personal no autorizado.\n\n4. **Monitoreo de Condiciones de Almacenamiento**:\n   - Las condiciones de almacenamiento deben ser controladas y monitoreadas.\n   - El personal debe estar capacitado en los rangos de temperatura y configuraciones de alarma.\n   - Se debe implementar un sistema de monitoreo de temperatura independiente del sistema de regulaci\u00f3n, con alarmas adecuadas y registros de verificaci\u00f3n.\n\n### Entidades Clave\n- **Sistemas Inform\u00e1ticos**: Herramientas para prevenir la liberaci\u00f3n de componentes no aceptables.\n- **Donantes**: Personas que proporcionan sangre; sus registros deben actualizarse en caso de no conformidades.\n- **Productos Sangu\u00edneos**: Componentes que pueden ser liberados o destruidos seg\u00fan su conformidad con los requisitos de seguridad.\n- **Personal Autorizado**: Empleados capacitados para manejar y monitorear las condiciones de almacenamiento de sangre.\n- **Alarmas de Temperatura**: Dispositivos que alertan sobre condiciones de almacenamiento inadecuadas. \n\nEste resumen destaca la importancia de la seguridad en la gesti\u00f3n de sangre y componentes sangu\u00edneos, as\u00ed como la necesidad de procedimientos claros y capacitaci\u00f3n del personal.", "excerpt_keywords": "Keywords: blood components, storage temperatures, distribution procedures, temperature control, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d3b0664-6556-42df-bb07-ec3b69427855", "node_type": "4", "metadata": {"page_label": "221", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "products. Temperature excursions may occur and each event should be evaluated using the deviation management system (see section 3.5).\n\nAn alternative storage area of appropriate temperature is recommended for recovery in case of temperature control failure of the primary system. Areas for storage should be secured against the entry of unauthorized persons and should be used only for the intended purpose. Storage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and material. If a temporary mechanical or electrical failure affects control of storage temperatures, an examination of the records should be made to evaluate the impact on plasma or blood component quality.\n\nFor the main blood components, the common storage temperatures are as follows:\n\n- red-cell concentrate: 1\u20136\u00b0C;\n- plasma for transfusion: minus 25\u00b0C or colder;\n- platelets: 20\u201324\u00b0C;\n\nor in a more stringent range defined by the NRA.\n\nHigher storage temperatures (e.g. minus 20\u00b0C) might be acceptable for plasma for transfusion but may result in a significantly shorter shelf-life.\n\nStorage of platelets should also be controlled. Besides the temperature, the continuous agitation is very important. Based on the manufacturer\u2019s instructions, the moving velocity should be set in a way that obtains an optimal quality of the product. The moving velocity should be part of the qualification of the equipment.\n\nDuring the whole collection and manufacturing process it should be ensured that blood or blood components are never placed in direct sunlight or near a heating source.\n\nAll storage equipment should be subject to qualification, cleaning and preventive maintenance. Thermometers or temperature sensors should be calibrated annually. The temperature deviation to the standard measuring device should not exceed 1\u00b0C.\n\n## 9.10 Distribution\n\nPrior to distribution, blood components should be visually inspected. There should be a record that identifies the person distributing and the customer receiving the components. Dispatch of blood components should be made by authorized personnel.\n\nAt the time of dispatch, there should be a procedure in place to ensure that all blood components being issued have been formally released for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a1b593e4bb0d844486db5dd64cea83d4ba129bfd277e8fee8e4516113721aaaa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "products. Temperature excursions may occur and each event should be evaluated using the deviation management system (see section 3.5).\n\nAn alternative storage area of appropriate temperature is recommended for recovery in case of temperature control failure of the primary system. Areas for storage should be secured against the entry of unauthorized persons and should be used only for the intended purpose. Storage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and material. If a temporary mechanical or electrical failure affects control of storage temperatures, an examination of the records should be made to evaluate the impact on plasma or blood component quality.\n\nFor the main blood components, the common storage temperatures are as follows:\n\n- red-cell concentrate: 1\u20136\u00b0C;\n- plasma for transfusion: minus 25\u00b0C or colder;\n- platelets: 20\u201324\u00b0C;\n\nor in a more stringent range defined by the NRA.\n\nHigher storage temperatures (e.g. minus 20\u00b0C) might be acceptable for plasma for transfusion but may result in a significantly shorter shelf-life.\n\nStorage of platelets should also be controlled. Besides the temperature, the continuous agitation is very important. Based on the manufacturer\u2019s instructions, the moving velocity should be set in a way that obtains an optimal quality of the product. The moving velocity should be part of the qualification of the equipment.\n\nDuring the whole collection and manufacturing process it should be ensured that blood or blood components are never placed in direct sunlight or near a heating source.\n\nAll storage equipment should be subject to qualification, cleaning and preventive maintenance. Thermometers or temperature sensors should be calibrated annually. The temperature deviation to the standard measuring device should not exceed 1\u00b0C.\n\n## 9.10 Distribution\n\nPrior to distribution, blood components should be visually inspected. There should be a record that identifies the person distributing and the customer receiving the components. Dispatch of blood components should be made by authorized personnel.\n\nAt the time of dispatch, there should be a procedure in place to ensure that all blood components being issued have been formally released for", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2310, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "84d8155e-b19f-4da9-a9e5-bc5a7ef54060": {"__data__": {"id_": "84d8155e-b19f-4da9-a9e5-bc5a7ef54060", "embedding": null, "metadata": {"page_label": "222", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.11 Shipping\n\nDistribution should take place in a safe and controlled way in order to assure product quality during transport. All transportation and intermediate storage actions, including receipt and distribution, should be defined by written standard operating procedures and specifications.\n\nThe shipping containers should be of sturdy construction in order to resist damage and should be validated to maintain acceptable storage conditions for the blood and blood components (e.g. by using appropriate cooling elements or insulation during transport). The transportation and storage conditions for blood components, the packaging format and the responsibilities of the persons involved should be in accordance with standard operating procedures agreed between the sites in question.\n\n# 9.12 Returns\n\nBlood components should not be returned to stock for subsequent distribution, unless:\n\n- the procedure for return of a blood component is regulated by contract;\n- for each returned blood component, it is proven that the agreed storage conditions have consistently been met;\n- the integrity of the container has been maintained (i.e. unopened);\n- sufficient material is available for compatibility testing.\n\nIn case of medical urgency, components may be returned and subsequently distributed using a defined procedure.\n\nThe records should indicate that the blood component has been inspected and found to be acceptable before re-issue.\n\n# 10. Contract manufacturing, analysis and services\n\nIn blood establishments, all tasks that have an influence on the quality of collected blood and the manufacture of blood components \u2014 such as component processing, testing or information technology support \u2014 and which are performed externally by another party, should be subject to a specific written contract. The contract should ensure that the contract acceptor meets GMP requirements in all disciplines relevant to the contract giver\u2019s activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda las directrices sobre el transporte y la gesti\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de mantener la calidad del producto durante el transporte mediante procedimientos operativos est\u00e1ndar. Tambi\u00e9n se establecen condiciones espec\u00edficas para la devoluci\u00f3n de componentes sangu\u00edneos y la necesidad de contratos escritos para cualquier tarea externa que afecte la calidad de la sangre y sus componentes.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para que un componente sangu\u00edneo pueda ser devuelto a stock para su posterior distribuci\u00f3n?**\n   - La respuesta se encuentra en la secci\u00f3n sobre devoluciones, donde se especifican las condiciones que deben cumplirse, como la regulaci\u00f3n por contrato, el mantenimiento de las condiciones de almacenamiento, la integridad del contenedor y la disponibilidad de material para pruebas de compatibilidad.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los contenedores de env\u00edo para asegurar la calidad de los componentes sangu\u00edneos durante el transporte?**\n   - El contexto menciona que los contenedores deben ser de construcci\u00f3n robusta y validados para mantener condiciones de almacenamiento aceptables, utilizando elementos de enfriamiento o aislamiento durante el transporte.\n\n3. **\u00bfQu\u00e9 tipo de acuerdos deben establecerse cuando se externalizan tareas que afectan la calidad de la sangre en los establecimientos de sangre?**\n   - Se requiere un contrato escrito que asegure que el aceptador del contrato cumpla con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) en todas las disciplinas relevantes para las actividades del otorgante del contrato.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento de Componentes Sangu\u00edneos**:\n   - Importancia de mantener temperaturas adecuadas para preservar la calidad de los productos sangu\u00edneos.\n   - Temperaturas de almacenamiento recomendadas:\n     - **Concentrado de gl\u00f3bulos rojos**: 1\u20136\u00b0C\n     - **Plasma para transfusi\u00f3n**: menos 25\u00b0C o m\u00e1s fr\u00edo\n     - **Plaquetas**: 20\u201324\u00b0C\n   - Almacenamiento a temperaturas m\u00e1s altas (ej. menos 20\u00b0C para plasma) puede reducir significativamente la vida \u00fatil.\n\n2. **Gesti\u00f3n de Fallos en el Control de Temperatura**:\n   - Se recomienda tener un \u00e1rea de almacenamiento alternativa para recuperaci\u00f3n en caso de fallos en el sistema principal.\n   - Evaluaci\u00f3n del impacto en la calidad de los componentes sangu\u00edneos tras un fallo temporal.\n\n3. **Seguridad en \u00c1reas de Almacenamiento**:\n   - Las \u00e1reas deben estar aseguradas contra el acceso no autorizado.\n   - Segregaci\u00f3n efectiva entre materiales en cuarentena, liberados y rechazados.\n\n4. **Control de Almacenamiento de Plaquetas**:\n   - Importancia de la agitaci\u00f3n continua y la velocidad de movimiento seg\u00fan las instrucciones del fabricante.\n\n5. **Mantenimiento y Calibraci\u00f3n de Equipos**:\n   - Equipos de almacenamiento deben ser calificados, limpiados y mantenidos preventivamente.\n   - Term\u00f3metros y sensores de temperatura deben calibrarse anualmente, con una desviaci\u00f3n m\u00e1xima de 1\u00b0C respecto al dispositivo de medici\u00f3n est\u00e1ndar.\n\n6. **Distribuci\u00f3n de Componentes Sangu\u00edneos**:\n   - Inspecci\u00f3n visual de componentes antes de la distribuci\u00f3n.\n   - Registro de la persona que distribuye y del cliente que recibe los componentes.\n   - Procedimientos para asegurar que todos los componentes han sido formalmente liberados antes del despacho.\n\n### Entidades Clave\n- **Componentes Sangu\u00edneos**: concentrado de gl\u00f3bulos rojos, plasma, plaquetas.\n- **Temperaturas de Almacenamiento**: 1\u20136\u00b0C, menos 25\u00b0C, 20\u201324\u00b0C.\n- **Procedimientos de Seguridad**: acceso no autorizado, segregaci\u00f3n de materiales.\n- **Mantenimiento de Equipos**: calificaci\u00f3n, limpieza, calibraci\u00f3n.\n- **Distribuci\u00f3n**: inspecci\u00f3n visual, registro de distribuci\u00f3n, autorizaci\u00f3n.", "excerpt_keywords": "Keywords: shipping, blood components, returns, standard operating procedures, contract manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e58dd580-7d8c-4044-ac40-0fa6307d8153", "node_type": "4", "metadata": {"page_label": "222", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.11 Shipping\n\nDistribution should take place in a safe and controlled way in order to assure product quality during transport. All transportation and intermediate storage actions, including receipt and distribution, should be defined by written standard operating procedures and specifications.\n\nThe shipping containers should be of sturdy construction in order to resist damage and should be validated to maintain acceptable storage conditions for the blood and blood components (e.g. by using appropriate cooling elements or insulation during transport). The transportation and storage conditions for blood components, the packaging format and the responsibilities of the persons involved should be in accordance with standard operating procedures agreed between the sites in question.\n\n# 9.12 Returns\n\nBlood components should not be returned to stock for subsequent distribution, unless:\n\n- the procedure for return of a blood component is regulated by contract;\n- for each returned blood component, it is proven that the agreed storage conditions have consistently been met;\n- the integrity of the container has been maintained (i.e. unopened);\n- sufficient material is available for compatibility testing.\n\nIn case of medical urgency, components may be returned and subsequently distributed using a defined procedure.\n\nThe records should indicate that the blood component has been inspected and found to be acceptable before re-issue.\n\n# 10. Contract manufacturing, analysis and services\n\nIn blood establishments, all tasks that have an influence on the quality of collected blood and the manufacture of blood components \u2014 such as component processing, testing or information technology support \u2014 and which are performed externally by another party, should be subject to a specific written contract. The contract should ensure that the contract acceptor meets GMP requirements in all disciplines relevant to the contract giver\u2019s activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d7ceeea42f03112e8e61022e66fddaa9fce75e8a1caa79cad38819b90e156264", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.11 Shipping\n\nDistribution should take place in a safe and controlled way in order to assure product quality during transport. All transportation and intermediate storage actions, including receipt and distribution, should be defined by written standard operating procedures and specifications.\n\nThe shipping containers should be of sturdy construction in order to resist damage and should be validated to maintain acceptable storage conditions for the blood and blood components (e.g. by using appropriate cooling elements or insulation during transport). The transportation and storage conditions for blood components, the packaging format and the responsibilities of the persons involved should be in accordance with standard operating procedures agreed between the sites in question.\n\n# 9.12 Returns\n\nBlood components should not be returned to stock for subsequent distribution, unless:\n\n- the procedure for return of a blood component is regulated by contract;\n- for each returned blood component, it is proven that the agreed storage conditions have consistently been met;\n- the integrity of the container has been maintained (i.e. unopened);\n- sufficient material is available for compatibility testing.\n\nIn case of medical urgency, components may be returned and subsequently distributed using a defined procedure.\n\nThe records should indicate that the blood component has been inspected and found to be acceptable before re-issue.\n\n# 10. Contract manufacturing, analysis and services\n\nIn blood establishments, all tasks that have an influence on the quality of collected blood and the manufacture of blood components \u2014 such as component processing, testing or information technology support \u2014 and which are performed externally by another party, should be subject to a specific written contract. The contract should ensure that the contract acceptor meets GMP requirements in all disciplines relevant to the contract giver\u2019s activities.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1948, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b94f7827-9774-406a-9696-e254171e331a": {"__data__": {"id_": "b94f7827-9774-406a-9696-e254171e331a", "embedding": null, "metadata": {"page_label": "223", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The contract giver is ultimately responsible for ensuring that processes are in place to assure the control of outsourced activities and the quality of purchased materials. These processes should incorporate QRM and should include:\n\n- assessing (prior to outsourcing operations or selecting material suppliers) the suitability and competence of the other party to carry out the activity or provide the material using a defined supply chain (e.g. audits, material evaluations, qualification);\n- defining the responsibilities and communication processes for quality-related activities of the parties concerned;\n- monitoring and review of the performance of the contract acceptor or the quality of the material from the provider, and identification and implementation of any improvements needed;\n- monitoring of incoming ingredients and materials to ensure that they are from approved sources using the agreed supply chain.\n\nDetails should be specified in a technical quality agreement or contract.\n\nThe contract or agreement should:\n\n- clearly establish the duties of each party;\n- state the responsibilities of each party;\n- mention any technical arrangements;\n- define the flow of information, especially regarding deviations and changes;\n- define the handling and archiving of documents, samples and other relevant materials and information;\n- state that any of the duties given to the contract acceptor should not be passed to a third party without evaluation and approval of the contract giver;\n- permit the contract giver and competent authorities to visit and inspect the facilities of the contract acceptor.\n\nThe contract giver should provide the contract acceptor with all necessary information to enable compliance with expectations regarding services or goods. This assures that the work or service is performed in compliance with existing regulations. The overall responsibility for the work and duties carried out externally lies always with the contracting company.\n\nThe contract should be agreed and signed by quality assurance representatives from both parties and should be kept up to date.\n\n## 11. Authors and acknowledgements\n\nThese guidelines were developed under the coordination of Dr A Padilla, Scientist, Quality Assurance and Safety of Medicines (Blood Products and Related Biologicals), World Health Organization, Geneva, Switzerland.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Responsabilidad del contratante**: El contratante es responsable de asegurar que existan procesos adecuados para controlar las actividades externalizadas y la calidad de los materiales adquiridos. Esto incluye la evaluaci\u00f3n de la competencia de los proveedores, la definici\u00f3n de responsabilidades y la supervisi\u00f3n del rendimiento.\n\n2. **Acuerdo de calidad t\u00e9cnica**: Se debe formalizar un acuerdo t\u00e9cnico que detalle las obligaciones y responsabilidades de ambas partes, as\u00ed como los procedimientos de comunicaci\u00f3n y manejo de documentos. Este acuerdo debe ser firmado por representantes de aseguramiento de calidad de ambas partes y mantenerse actualizado.\n\n3. **Cumplimiento normativo**: El contratante debe proporcionar toda la informaci\u00f3n necesaria al contratista para garantizar que se cumplan las expectativas y regulaciones pertinentes. La responsabilidad final de las actividades externalizadas recae siempre en la empresa contratante.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que debe seguir el contratante para evaluar la competencia de un proveedor antes de externalizar operaciones?**\n   - El contratante debe realizar auditor\u00edas, evaluaciones de materiales y calificaciones para determinar la idoneidad y competencia del proveedor.\n\n2. **\u00bfQu\u00e9 elementos deben incluirse en un acuerdo t\u00e9cnico de calidad para asegurar una comunicaci\u00f3n efectiva entre las partes?**\n   - El acuerdo debe definir el flujo de informaci\u00f3n, especialmente en relaci\u00f3n con desviaciones y cambios, as\u00ed como el manejo y archivo de documentos y muestras relevantes.\n\n3. **\u00bfQu\u00e9 derechos tiene el contratante en relaci\u00f3n con la supervisi\u00f3n de las instalaciones del contratista?**\n   - El contratante tiene el derecho de visitar e inspeccionar las instalaciones del contratista, as\u00ed como de asegurarse de que las responsabilidades no sean transferidas a un tercero sin su evaluaci\u00f3n y aprobaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Transporte de Componentes Sangu\u00edneos**:\n   - La distribuci\u00f3n debe realizarse de manera segura y controlada para asegurar la calidad del producto durante el transporte.\n   - Se requiere que todas las acciones de transporte y almacenamiento intermedio est\u00e9n definidas por procedimientos operativos est\u00e1ndar escritos.\n\n2. **Condiciones de Env\u00edo**:\n   - Los contenedores de env\u00edo deben ser robustos y validados para mantener condiciones de almacenamiento aceptables, utilizando elementos de enfriamiento o aislamiento.\n\n3. **Devoluciones de Componentes Sangu\u00edneos**:\n   - Existen condiciones espec\u00edficas bajo las cuales los componentes sangu\u00edneos pueden ser devueltos a stock, incluyendo regulaciones contractuales, mantenimiento de condiciones de almacenamiento, integridad del contenedor y disponibilidad para pruebas de compatibilidad.\n   - En situaciones de urgencia m\u00e9dica, se permite la devoluci\u00f3n y redistribuci\u00f3n bajo un procedimiento definido.\n\n4. **Contrataci\u00f3n Externa**:\n   - Todas las tareas que afectan la calidad de la sangre y sus componentes, realizadas externamente, deben estar sujetas a un contrato escrito que garantice el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Componentes Sangu\u00edneos**: Elementos que se transportan y gestionan seg\u00fan las directrices.\n- **Contenedores de Env\u00edo**: Estructuras utilizadas para el transporte de componentes sangu\u00edneos.\n- **Procedimientos Operativos Est\u00e1ndar (SOP)**: Documentos que definen las acciones de transporte y almacenamiento.\n- **Contratos**: Acuerdos escritos necesarios para la externalizaci\u00f3n de tareas relacionadas con la calidad de la sangre.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada del transporte y la devoluci\u00f3n de componentes sangu\u00edneos, as\u00ed como la necesidad de contratos claros para asegurar la calidad en las operaciones externas.", "excerpt_keywords": "Keywords: outsourcing, quality assurance, technical agreement, contract management, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ac23648e-ee1f-455b-ab7f-0b11da796559", "node_type": "4", "metadata": {"page_label": "223", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The contract giver is ultimately responsible for ensuring that processes are in place to assure the control of outsourced activities and the quality of purchased materials. These processes should incorporate QRM and should include:\n\n- assessing (prior to outsourcing operations or selecting material suppliers) the suitability and competence of the other party to carry out the activity or provide the material using a defined supply chain (e.g. audits, material evaluations, qualification);\n- defining the responsibilities and communication processes for quality-related activities of the parties concerned;\n- monitoring and review of the performance of the contract acceptor or the quality of the material from the provider, and identification and implementation of any improvements needed;\n- monitoring of incoming ingredients and materials to ensure that they are from approved sources using the agreed supply chain.\n\nDetails should be specified in a technical quality agreement or contract.\n\nThe contract or agreement should:\n\n- clearly establish the duties of each party;\n- state the responsibilities of each party;\n- mention any technical arrangements;\n- define the flow of information, especially regarding deviations and changes;\n- define the handling and archiving of documents, samples and other relevant materials and information;\n- state that any of the duties given to the contract acceptor should not be passed to a third party without evaluation and approval of the contract giver;\n- permit the contract giver and competent authorities to visit and inspect the facilities of the contract acceptor.\n\nThe contract giver should provide the contract acceptor with all necessary information to enable compliance with expectations regarding services or goods. This assures that the work or service is performed in compliance with existing regulations. The overall responsibility for the work and duties carried out externally lies always with the contracting company.\n\nThe contract should be agreed and signed by quality assurance representatives from both parties and should be kept up to date.\n\n## 11. Authors and acknowledgements\n\nThese guidelines were developed under the coordination of Dr A Padilla, Scientist, Quality Assurance and Safety of Medicines (Blood Products and Related Biologicals), World Health Organization, Geneva, Switzerland.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3142f29ad9dfd8b55bde4f6dc229888aafe8bb59ace40b0452b76cca199902c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The contract giver is ultimately responsible for ensuring that processes are in place to assure the control of outsourced activities and the quality of purchased materials. These processes should incorporate QRM and should include:\n\n- assessing (prior to outsourcing operations or selecting material suppliers) the suitability and competence of the other party to carry out the activity or provide the material using a defined supply chain (e.g. audits, material evaluations, qualification);\n- defining the responsibilities and communication processes for quality-related activities of the parties concerned;\n- monitoring and review of the performance of the contract acceptor or the quality of the material from the provider, and identification and implementation of any improvements needed;\n- monitoring of incoming ingredients and materials to ensure that they are from approved sources using the agreed supply chain.\n\nDetails should be specified in a technical quality agreement or contract.\n\nThe contract or agreement should:\n\n- clearly establish the duties of each party;\n- state the responsibilities of each party;\n- mention any technical arrangements;\n- define the flow of information, especially regarding deviations and changes;\n- define the handling and archiving of documents, samples and other relevant materials and information;\n- state that any of the duties given to the contract acceptor should not be passed to a third party without evaluation and approval of the contract giver;\n- permit the contract giver and competent authorities to visit and inspect the facilities of the contract acceptor.\n\nThe contract giver should provide the contract acceptor with all necessary information to enable compliance with expectations regarding services or goods. This assures that the work or service is performed in compliance with existing regulations. The overall responsibility for the work and duties carried out externally lies always with the contracting company.\n\nThe contract should be agreed and signed by quality assurance representatives from both parties and should be kept up to date.\n\n## 11. Authors and acknowledgements\n\nThese guidelines were developed under the coordination of Dr A Padilla, Scientist, Quality Assurance and Safety of Medicines (Blood Products and Related Biologicals), World Health Organization, Geneva, Switzerland.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2358, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "926dbb25-fc22-4d50-b08e-1901893ad282": {"__data__": {"id_": "926dbb25-fc22-4d50-b08e-1901893ad282", "embedding": null, "metadata": {"page_label": "224", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The drafting group was formed of:  \nMr JW Atkins, National Institutes of Health (NIH), Bethesda, MD, USA; Dr A Padilla, World Health Organization, Geneva, Switzerland; Dr C Sch\u00e4rer, Swissmedic, Bern, Switzerland; Mrs D Schmidkunz Eggler, Swissmedic, Bern, Switzerland; Dr G Werner, Paul-Ehrlich-Institut (PEI), Langen, Germany.\n\nContributions were also solicited from:  \nMs S Douglas, Therapeutic Goods Administration (TGA), Melbourne, Australia; Mr L Fields, Food and Drug Administration (FDA), Rockville, MD, USA; Dr D Kaesermann, Swissmedic, Switzerland; Dr J Morenas and Dr F Teskrat, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS), Saint-Denis, France; Dr W Schwarz, PEI, Germany; Dr U Unkelbach, PEI, Germany; Dr L van Loosbroek, GMP Consultant, Netherlands; Mr L Young, Health Canada, Ottawa, Canada.\n\nComments, advice and information given during the preparation and consultation process for developing these guidelines were received from the following experts:\n\n- Dr F Agbanyo, Health Canada, Ottawa, Canada; Dr M Farag Ahmed, National Organization for Drug Control & Research (NODCAR), Agousa, Egypt; Lic. MP \u00c1lvarez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), La Habana, Cuba; Dr J Ansah, National Centre of Blood Transfusion, Accra, Ghana; Dr C Bianco, America\u2019s Blood Centers, Washington DC, USA; Dr V Bogdanova, Federal Medical and Biological Agency (FMBA), Moscow, Russian Federation; Dr T Burnouf, Human Protein Process Sciences, France; Dr M Cheraghali, Dr Amini and Dr Maqsoudloo, Iranian Blood Transfusion Organization, Tehran, Islamic Republic of Iran; Dr JR Cruz, Regional Advisor, WHO, AMRO/PAHO, Washington, USA; Dr F Darwish, Central Blood Bank, Manama, Kingdom of Bahrain; Dr R Davey, FDA, Rockville, MD, USA; Professor S Diop, National Centre of Blood Transfusion, Dakar, Senegal; Dr D El Sherif, Central Administration of Pharmaceutical Affairs (CAPA), Cairo, Egypt; Dr J Epstein, FDA, Rockville, MD, USA; Dr P Ganz, Health Canada, Ottawa, Canada; Mr A Gould, Medicines Prequalification Programme, WHO, Geneva, Switzerland; Dr I Hamaguchi, National Institute of Infectious Diseases (NIID), Tokyo, Japan; Dr M Heiden, PEI, Langen, Germany; Dr S Hindawi, Blood Transfusion Service, Jeddah, Saudi Arabia; Dr Ho Jung Oh, Korea Food and Drug Administration (KFDA), Seoul, Republic of Korea; Dr M Jutzi, Swissmedic, Bern, Switzerland; Dr H Klein, NIH, Bethesda, MD, USA; Mrs AC Madukwe, National Agency for Food and Drug Administration and Control (NAFDAC), Lagos, Nigeria; Ms GM Mahlangu, Medicines Control Authority, Harare, Zimbabwe; Dr G Michaud, FDA, Rockville, MD, USA; Dr F Moftah, Blood Transfusion Service, Ministry of Health and Population, Agousa, Egypt; Dr Z Mukhtar, National Institute of Health, Islamabad, Pakistan; Dr C Munk and Dr P Strengers, International Society of Blood Transfusion (ISBT), Amsterdam, Netherlands; Dr P Murray, NIH, Bethesda, MD, USA; Dr K Nabae, Ministry of Health, Labour and Welfare, Tokyo, Japan; Dr L Oliva, Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (ANMAT), Buenos Aires, Argentina; Dr R Perry, International Plasma Fractionation Association (IPFA), Amsterdam, Netherlands; Dr I Prosser, TGA, Canberra, Australia; Dr I Sainte-Marie, AFSSAPS, Paris, France; Professor R Seitz, PEI, Langen, Germany; Dr G Silvester, European Medicines Agency (EMA), London, UK; Dr G Smith, TGA, Canberra, Australia; Dr D Teo, Blood Services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Composici\u00f3n del grupo de redacci\u00f3n**: El grupo de redacci\u00f3n del informe est\u00e1 compuesto por expertos de diversas organizaciones de salud y reguladoras de medicamentos de diferentes pa\u00edses, incluyendo la OMS, el NIH, y Swissmedic, entre otros.\n\n2. **Contribuciones de expertos**: Se solicit\u00f3 la colaboraci\u00f3n de numerosos expertos de distintas instituciones y pa\u00edses para proporcionar comentarios, asesor\u00eda e informaci\u00f3n durante el proceso de preparaci\u00f3n de las directrices.\n\n3. **Diversidad geogr\u00e1fica y de especializaci\u00f3n**: Los expertos que contribuyeron provienen de una amplia gama de pa\u00edses y especialidades, lo que refleja un enfoque global y multidisciplinario en el desarrollo de las directrices.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQui\u00e9nes son los miembros clave del grupo de redacci\u00f3n y qu\u00e9 organizaciones representan?**\n   - Respuesta: El grupo de redacci\u00f3n incluye a Mr. JW Atkins (NIH, EE. UU.), Dr. A Padilla (OMS, Suiza), Dr. C Sch\u00e4rer (Swissmedic, Suiza), Mrs. D Schmidkunz Eggler (Swissmedic, Suiza) y Dr. G Werner (PEI, Alemania).\n\n2. **\u00bfQu\u00e9 tipo de contribuciones se recibieron de los expertos durante el proceso de desarrollo de las directrices?**\n   - Respuesta: Se recibieron comentarios, asesor\u00eda e informaci\u00f3n de expertos en diversas \u00e1reas relacionadas con la transfusi\u00f3n de sangre y la regulaci\u00f3n de medicamentos, provenientes de instituciones como Health Canada, FDA, y varias organizaciones internacionales.\n\n3. **\u00bfCu\u00e1l es la importancia de la diversidad geogr\u00e1fica en la composici\u00f3n del grupo de expertos?**\n   - Respuesta: La diversidad geogr\u00e1fica permite incorporar diferentes perspectivas y experiencias en la elaboraci\u00f3n de las directrices, asegurando que sean relevantes y aplicables a un contexto global, lo que es crucial para abordar problemas de salud p\u00fablica de manera efectiva.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad del Contratante**: El contratante debe asegurar procesos para controlar actividades externalizadas y la calidad de los materiales adquiridos, incorporando la Gesti\u00f3n de Riesgos de Calidad (QRM).\n\n2. **Evaluaci\u00f3n de Proveedores**: Antes de externalizar operaciones o seleccionar proveedores, se debe evaluar la idoneidad y competencia de la otra parte mediante auditor\u00edas y evaluaciones de materiales.\n\n3. **Acuerdo T\u00e9cnico de Calidad**: Es esencial formalizar un acuerdo que detalle las obligaciones, responsabilidades y procedimientos de comunicaci\u00f3n entre las partes, as\u00ed como el manejo de documentos y muestras.\n\n4. **Supervisi\u00f3n y Monitoreo**: El contratante debe monitorear el rendimiento del contratista y la calidad de los materiales, asegurando que provengan de fuentes aprobadas.\n\n5. **Derechos del Contratante**: El contratante tiene derecho a visitar e inspeccionar las instalaciones del contratista y a asegurarse de que las responsabilidades no se transfieran a terceros sin su aprobaci\u00f3n.\n\n6. **Cumplimiento Normativo**: El contratante debe proporcionar informaci\u00f3n necesaria para garantizar el cumplimiento de regulaciones y expectativas.\n\n### Entidades\n\n- **Contratante**: Parte responsable de asegurar el control de actividades externalizadas.\n- **Contratista**: Parte que realiza las actividades externalizadas o proporciona materiales.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que coordina el desarrollo de estas directrices.\n- **Dr. A. Padilla**: Cient\u00edfico que coordin\u00f3 el desarrollo de las directrices sobre Aseguramiento de Calidad y Seguridad de Medicamentos.\n\n### Resumen\n\nEl contratante es responsable de establecer procesos para controlar las actividades externalizadas y la calidad de los materiales, evaluando la competencia de los proveedores y formalizando un acuerdo t\u00e9cnico de calidad que detalle las responsabilidades y procedimientos de comunicaci\u00f3n. Adem\u00e1s, debe monitorear el rendimiento del contratista y garantizar el cumplimiento normativo, manteniendo el derecho de inspeccionar las instalaciones del contratista. Estas directrices fueron desarrolladas por la OMS bajo la coordinaci\u00f3n del Dr. A. Padilla.", "excerpt_keywords": "Keywords: drafting group, health organizations, expert contributions, global guidelines, regulatory affairs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "30494564-ff06-4f01-b4e5-c24c15f32ca0", "node_type": "4", "metadata": {"page_label": "224", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The drafting group was formed of:  \nMr JW Atkins, National Institutes of Health (NIH), Bethesda, MD, USA; Dr A Padilla, World Health Organization, Geneva, Switzerland; Dr C Sch\u00e4rer, Swissmedic, Bern, Switzerland; Mrs D Schmidkunz Eggler, Swissmedic, Bern, Switzerland; Dr G Werner, Paul-Ehrlich-Institut (PEI), Langen, Germany.\n\nContributions were also solicited from:  \nMs S Douglas, Therapeutic Goods Administration (TGA), Melbourne, Australia; Mr L Fields, Food and Drug Administration (FDA), Rockville, MD, USA; Dr D Kaesermann, Swissmedic, Switzerland; Dr J Morenas and Dr F Teskrat, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS), Saint-Denis, France; Dr W Schwarz, PEI, Germany; Dr U Unkelbach, PEI, Germany; Dr L van Loosbroek, GMP Consultant, Netherlands; Mr L Young, Health Canada, Ottawa, Canada.\n\nComments, advice and information given during the preparation and consultation process for developing these guidelines were received from the following experts:\n\n- Dr F Agbanyo, Health Canada, Ottawa, Canada; Dr M Farag Ahmed, National Organization for Drug Control & Research (NODCAR), Agousa, Egypt; Lic. MP \u00c1lvarez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), La Habana, Cuba; Dr J Ansah, National Centre of Blood Transfusion, Accra, Ghana; Dr C Bianco, America\u2019s Blood Centers, Washington DC, USA; Dr V Bogdanova, Federal Medical and Biological Agency (FMBA), Moscow, Russian Federation; Dr T Burnouf, Human Protein Process Sciences, France; Dr M Cheraghali, Dr Amini and Dr Maqsoudloo, Iranian Blood Transfusion Organization, Tehran, Islamic Republic of Iran; Dr JR Cruz, Regional Advisor, WHO, AMRO/PAHO, Washington, USA; Dr F Darwish, Central Blood Bank, Manama, Kingdom of Bahrain; Dr R Davey, FDA, Rockville, MD, USA; Professor S Diop, National Centre of Blood Transfusion, Dakar, Senegal; Dr D El Sherif, Central Administration of Pharmaceutical Affairs (CAPA), Cairo, Egypt; Dr J Epstein, FDA, Rockville, MD, USA; Dr P Ganz, Health Canada, Ottawa, Canada; Mr A Gould, Medicines Prequalification Programme, WHO, Geneva, Switzerland; Dr I Hamaguchi, National Institute of Infectious Diseases (NIID), Tokyo, Japan; Dr M Heiden, PEI, Langen, Germany; Dr S Hindawi, Blood Transfusion Service, Jeddah, Saudi Arabia; Dr Ho Jung Oh, Korea Food and Drug Administration (KFDA), Seoul, Republic of Korea; Dr M Jutzi, Swissmedic, Bern, Switzerland; Dr H Klein, NIH, Bethesda, MD, USA; Mrs AC Madukwe, National Agency for Food and Drug Administration and Control (NAFDAC), Lagos, Nigeria; Ms GM Mahlangu, Medicines Control Authority, Harare, Zimbabwe; Dr G Michaud, FDA, Rockville, MD, USA; Dr F Moftah, Blood Transfusion Service, Ministry of Health and Population, Agousa, Egypt; Dr Z Mukhtar, National Institute of Health, Islamabad, Pakistan; Dr C Munk and Dr P Strengers, International Society of Blood Transfusion (ISBT), Amsterdam, Netherlands; Dr P Murray, NIH, Bethesda, MD, USA; Dr K Nabae, Ministry of Health, Labour and Welfare, Tokyo, Japan; Dr L Oliva, Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (ANMAT), Buenos Aires, Argentina; Dr R Perry, International Plasma Fractionation Association (IPFA), Amsterdam, Netherlands; Dr I Prosser, TGA, Canberra, Australia; Dr I Sainte-Marie, AFSSAPS, Paris, France; Professor R Seitz, PEI, Langen, Germany; Dr G Silvester, European Medicines Agency (EMA), London, UK; Dr G Smith, TGA, Canberra, Australia; Dr D Teo, Blood Services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "106f6acb2bf9a047f75271bafef87550bd776c3ff7f39e8f626d3d5b5a9f2f33", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The drafting group was formed of:  \nMr JW Atkins, National Institutes of Health (NIH), Bethesda, MD, USA; Dr A Padilla, World Health Organization, Geneva, Switzerland; Dr C Sch\u00e4rer, Swissmedic, Bern, Switzerland; Mrs D Schmidkunz Eggler, Swissmedic, Bern, Switzerland; Dr G Werner, Paul-Ehrlich-Institut (PEI), Langen, Germany.\n\nContributions were also solicited from:  \nMs S Douglas, Therapeutic Goods Administration (TGA), Melbourne, Australia; Mr L Fields, Food and Drug Administration (FDA), Rockville, MD, USA; Dr D Kaesermann, Swissmedic, Switzerland; Dr J Morenas and Dr F Teskrat, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS), Saint-Denis, France; Dr W Schwarz, PEI, Germany; Dr U Unkelbach, PEI, Germany; Dr L van Loosbroek, GMP Consultant, Netherlands; Mr L Young, Health Canada, Ottawa, Canada.\n\nComments, advice and information given during the preparation and consultation process for developing these guidelines were received from the following experts:\n\n- Dr F Agbanyo, Health Canada, Ottawa, Canada; Dr M Farag Ahmed, National Organization for Drug Control & Research (NODCAR), Agousa, Egypt; Lic. MP \u00c1lvarez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), La Habana, Cuba; Dr J Ansah, National Centre of Blood Transfusion, Accra, Ghana; Dr C Bianco, America\u2019s Blood Centers, Washington DC, USA; Dr V Bogdanova, Federal Medical and Biological Agency (FMBA), Moscow, Russian Federation; Dr T Burnouf, Human Protein Process Sciences, France; Dr M Cheraghali, Dr Amini and Dr Maqsoudloo, Iranian Blood Transfusion Organization, Tehran, Islamic Republic of Iran; Dr JR Cruz, Regional Advisor, WHO, AMRO/PAHO, Washington, USA; Dr F Darwish, Central Blood Bank, Manama, Kingdom of Bahrain; Dr R Davey, FDA, Rockville, MD, USA; Professor S Diop, National Centre of Blood Transfusion, Dakar, Senegal; Dr D El Sherif, Central Administration of Pharmaceutical Affairs (CAPA), Cairo, Egypt; Dr J Epstein, FDA, Rockville, MD, USA; Dr P Ganz, Health Canada, Ottawa, Canada; Mr A Gould, Medicines Prequalification Programme, WHO, Geneva, Switzerland; Dr I Hamaguchi, National Institute of Infectious Diseases (NIID), Tokyo, Japan; Dr M Heiden, PEI, Langen, Germany; Dr S Hindawi, Blood Transfusion Service, Jeddah, Saudi Arabia; Dr Ho Jung Oh, Korea Food and Drug Administration (KFDA), Seoul, Republic of Korea; Dr M Jutzi, Swissmedic, Bern, Switzerland; Dr H Klein, NIH, Bethesda, MD, USA; Mrs AC Madukwe, National Agency for Food and Drug Administration and Control (NAFDAC), Lagos, Nigeria; Ms GM Mahlangu, Medicines Control Authority, Harare, Zimbabwe; Dr G Michaud, FDA, Rockville, MD, USA; Dr F Moftah, Blood Transfusion Service, Ministry of Health and Population, Agousa, Egypt; Dr Z Mukhtar, National Institute of Health, Islamabad, Pakistan; Dr C Munk and Dr P Strengers, International Society of Blood Transfusion (ISBT), Amsterdam, Netherlands; Dr P Murray, NIH, Bethesda, MD, USA; Dr K Nabae, Ministry of Health, Labour and Welfare, Tokyo, Japan; Dr L Oliva, Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (ANMAT), Buenos Aires, Argentina; Dr R Perry, International Plasma Fractionation Association (IPFA), Amsterdam, Netherlands; Dr I Prosser, TGA, Canberra, Australia; Dr I Sainte-Marie, AFSSAPS, Paris, France; Professor R Seitz, PEI, Langen, Germany; Dr G Silvester, European Medicines Agency (EMA), London, UK; Dr G Smith, TGA, Canberra, Australia; Dr D Teo, Blood Services.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3472, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "38011d52-b428-4bb5-b796-e75a35c75644": {"__data__": {"id_": "38011d52-b428-4bb5-b796-e75a35c75644", "embedding": null, "metadata": {"page_label": "225", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. In: *WHO Expert Committee on Biological Standardization. Forty-third report*. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840, Annex 2).\n\n2. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. In: *WHO Expert Committee on Biological Standardization. Fifty-second report*. Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 924, Annex 4).\n\n3. WHO Recommendations for the production, control and regulation of human plasma for fractionation. In: *WHO Expert Committee on Biological Standardization. Fifty-sixth report*. Geneva, World Health Organization, 2007 (WHO Technical Report Series, No. 941, Annex 4).\n\n4. Recommendations of the 13th International Conference of Drug Regulatory Authorities (ICDRA), Bern, 16-19 September 2008. *WHO Drug Information*, 2008, 33(4) (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/Recommendations_13ICDRA.pdf, accessed 11 January 2011).\n\n5. Resolution WHA63.12. Availability, safety and quality of blood products. In: *Sixty-third World Health Assembly, Geneva, 17-21 May 2010, Volume 1, Resolutions*. Geneva, World Health Organization, 2010 (WHA63/2010/REC/1).\n\n6. *Estandares de trabajo para servicios de sangre*. Washington, DC, Organizacion Panamericana de la Salud/Pan American Health Organization, Area de Tecnologia y Prestacion de Servicios de Salud, 2005.\n\n7. Good manufacturing practices for pharmaceutical products: main principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908, Annex 4).\n\n8. *ICH Q9: Guideline on quality risk management*. Geneva, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.\n\n9. ISBT guidelines for validation of automated systems in blood establishments. *Vox Sanguinis*, 2010, 98(1):1\u201319.\n\n10. Supplementary guidelines on good manufacturing practices: validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937, Annex 4).\n\n11. *PIC/S recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en los requisitos y directrices para la recolecci\u00f3n, procesamiento y control de calidad de la sangre y sus derivados. Incluye referencias a varios informes y resoluciones de la OMS y otras organizaciones relacionadas con la seguridad y calidad de los productos sangu\u00edneos, as\u00ed como buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de riesgos. Se mencionan directrices espec\u00edficas sobre la inactivaci\u00f3n viral, la producci\u00f3n de plasma humano y la validaci\u00f3n de sistemas automatizados en establecimientos de sangre.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales principios de las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan el informe de la OMS?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los principios que rigen las buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de productos farmac\u00e9uticos, que se mencionan en el documento.\n\n2. **\u00bfQu\u00e9 recomendaciones se hicieron en la 13\u00aa Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA) en 2008?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que se derivaron de esta conferencia, que pueden no estar ampliamente disponibles en otros documentos.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de sistemas automatizados en los establecimientos de sangre seg\u00fan las directrices de ISBT?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los criterios y procesos de validaci\u00f3n que se deben seguir en los sistemas automatizados, un tema t\u00e9cnico que puede no estar ampliamente cubierto en otras fuentes.\n\n### Resumen de Nivel Superior\n\nEl informe de la OMS proporciona un marco integral para garantizar la seguridad y calidad de la sangre y sus derivados. Incluye directrices sobre la recolecci\u00f3n y procesamiento de sangre, la inactivaci\u00f3n de virus, y la producci\u00f3n de plasma, as\u00ed como recomendaciones sobre buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de riesgos. Adem\u00e1s, se hace referencia a resoluciones y recomendaciones de conferencias internacionales que abordan la regulaci\u00f3n y calidad de los productos sangu\u00edneos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Composici\u00f3n del Grupo de Redacci\u00f3n**:\n   - El grupo de redacci\u00f3n est\u00e1 formado por expertos de diversas organizaciones de salud y reguladoras de medicamentos, incluyendo:\n     - **Mr. JW Atkins** (NIH, EE. UU.)\n     - **Dr. A Padilla** (OMS, Suiza)\n     - **Dr. C Sch\u00e4rer** (Swissmedic, Suiza)\n     - **Mrs. D Schmidkunz Eggler** (Swissmedic, Suiza)\n     - **Dr. G Werner** (Paul-Ehrlich-Institut, Alemania)\n\n2. **Contribuciones de Expertos**:\n   - Se solicit\u00f3 la colaboraci\u00f3n de expertos de varias instituciones y pa\u00edses, tales como:\n     - **Ms. S Douglas** (TGA, Australia)\n     - **Mr. L Fields** (FDA, EE. UU.)\n     - **Dr. D Kaesermann** (Swissmedic, Suiza)\n     - **Dr. J Morenas** y **Dr. F Teskrat** (AFSSAPS, Francia)\n     - **Dr. W Schwarz** y **Dr. U Unkelbach** (PEI, Alemania)\n     - **Dr. L van Loosbroek** (Consultor GMP, Pa\u00edses Bajos)\n     - **Mr. L Young** (Health Canada, Canad\u00e1)\n\n3. **Comentarios y Asesor\u00eda**:\n   - Se recibieron comentarios y asesor\u00eda de un amplio grupo de expertos, incluyendo:\n     - **Dr. F Agbanyo** (Health Canada, Canad\u00e1)\n     - **Dr. M Farag Ahmed** (NODCAR, Egipto)\n     - **Lic. MP \u00c1lvarez** (CECMED, Cuba)\n     - **Dr. J Ansah** (Centro Nacional de Transfusi\u00f3n de Sangre, Ghana)\n     - **Dr. C Bianco** (America\u2019s Blood Centers, EE. UU.)\n     - **Dr. V Bogdanova** (FMBA, Rusia)\n     - **Dr. T Burnouf** (Human Protein Process Sciences, Francia)\n     - **Dr. JR Cruz** (OMS, AMRO/PAHO, EE. UU.)\n     - **Dr. R Perry** (IPFA, Pa\u00edses Bajos)\n     - **Dr. G Silvester** (EMA, Reino Unido)\n\n4. **Diversidad Geogr\u00e1fica y Especializaci\u00f3n**:\n   - La participaci\u00f3n de expertos de diferentes pa\u00edses y especialidades refleja un enfoque global y multidisciplinario en el desarrollo de las directrices, asegurando su relevancia y aplicabilidad en contextos diversos.\n\nEste resumen destaca la colaboraci\u00f3n internacional y la diversidad de expertos involucrados en la elaboraci\u00f3n de las directrices, lo que es fundamental para abordar los desaf\u00edos en la salud p\u00fablica y la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: blood safety, WHO guidelines, viral inactivation, good manufacturing practices, plasma production"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b9866aa-ad9a-4d06-9886-38c436f576ea", "node_type": "4", "metadata": {"page_label": "225", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. In: *WHO Expert Committee on Biological Standardization. Forty-third report*. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840, Annex 2).\n\n2. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. In: *WHO Expert Committee on Biological Standardization. Fifty-second report*. Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 924, Annex 4).\n\n3. WHO Recommendations for the production, control and regulation of human plasma for fractionation. In: *WHO Expert Committee on Biological Standardization. Fifty-sixth report*. Geneva, World Health Organization, 2007 (WHO Technical Report Series, No. 941, Annex 4).\n\n4. Recommendations of the 13th International Conference of Drug Regulatory Authorities (ICDRA), Bern, 16-19 September 2008. *WHO Drug Information*, 2008, 33(4) (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/Recommendations_13ICDRA.pdf, accessed 11 January 2011).\n\n5. Resolution WHA63.12. Availability, safety and quality of blood products. In: *Sixty-third World Health Assembly, Geneva, 17-21 May 2010, Volume 1, Resolutions*. Geneva, World Health Organization, 2010 (WHA63/2010/REC/1).\n\n6. *Estandares de trabajo para servicios de sangre*. Washington, DC, Organizacion Panamericana de la Salud/Pan American Health Organization, Area de Tecnologia y Prestacion de Servicios de Salud, 2005.\n\n7. Good manufacturing practices for pharmaceutical products: main principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908, Annex 4).\n\n8. *ICH Q9: Guideline on quality risk management*. Geneva, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.\n\n9. ISBT guidelines for validation of automated systems in blood establishments. *Vox Sanguinis*, 2010, 98(1):1\u201319.\n\n10. Supplementary guidelines on good manufacturing practices: validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937, Annex 4).\n\n11. *PIC/S recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "62c7b3031fb6509f9e53a6a98a48bb517878fa3b59f42abd7bde8bf1739e70ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. WHO Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. In: *WHO Expert Committee on Biological Standardization. Forty-third report*. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840, Annex 2).\n\n2. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. In: *WHO Expert Committee on Biological Standardization. Fifty-second report*. Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 924, Annex 4).\n\n3. WHO Recommendations for the production, control and regulation of human plasma for fractionation. In: *WHO Expert Committee on Biological Standardization. Fifty-sixth report*. Geneva, World Health Organization, 2007 (WHO Technical Report Series, No. 941, Annex 4).\n\n4. Recommendations of the 13th International Conference of Drug Regulatory Authorities (ICDRA), Bern, 16-19 September 2008. *WHO Drug Information*, 2008, 33(4) (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/Recommendations_13ICDRA.pdf, accessed 11 January 2011).\n\n5. Resolution WHA63.12. Availability, safety and quality of blood products. In: *Sixty-third World Health Assembly, Geneva, 17-21 May 2010, Volume 1, Resolutions*. Geneva, World Health Organization, 2010 (WHA63/2010/REC/1).\n\n6. *Estandares de trabajo para servicios de sangre*. Washington, DC, Organizacion Panamericana de la Salud/Pan American Health Organization, Area de Tecnologia y Prestacion de Servicios de Salud, 2005.\n\n7. Good manufacturing practices for pharmaceutical products: main principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908, Annex 4).\n\n8. *ICH Q9: Guideline on quality risk management*. Geneva, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.\n\n9. ISBT guidelines for validation of automated systems in blood establishments. *Vox Sanguinis*, 2010, 98(1):1\u201319.\n\n10. Supplementary guidelines on good manufacturing practices: validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937, Annex 4).\n\n11. *PIC/S recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation*.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2578, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1f61e206-b0c6-4ff2-9336-24e054f0af4d": {"__data__": {"id_": "1f61e206-b0c6-4ff2-9336-24e054f0af4d", "embedding": null, "metadata": {"page_label": "226", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Geneva, Pharmaceutical Inspection Cooperation Scheme, 2007 (Document PI 006-3).\n\n12. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902, Annex 6).\n\n13. *Guide to the preparation, use and quality assurance of blood components*, 14th edition. Technical annex to Council of Europe Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components. Strasbourg, European Directorate for the Quality of Medicines and HealthCare (EDQM), 2008.\n\n14. Hughes C et al. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. *Transfusion*, 1988, 28:566.\n\n15. Carlebjork G, Blomback M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. *Vox Sanguinis*, 1983, 45:233.\n\n16. Nilsson L et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. *Transfusion*, 1983, 23:377.\n\n17. Pietersz RN et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. *Vox Sanguinis*, 1989, 56:145.\n\n18. Kottischke R et al. Stability of fresh frozen plasma: results of 36-month storage at -20\u00b0C, -25\u00b0C, -30\u00b0C and -40\u00b0C. *Infusionstherapie und Transfusionsmedizin*, 2000, 27:174.\n\n19. Klein HG. Pathogen inactivation technology: cleansing the blood supply. *Journal of Internal Medicine*, 2005, 257:224\u2013237.\n\n20. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. *Archives of pathology & laboratory medicine*, 2007, 131:719\u2013733.\n\n21. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929, Annex 4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las pr\u00e1cticas de fabricaci\u00f3n y calidad de productos farmac\u00e9uticos, especialmente en relaci\u00f3n con componentes sangu\u00edneos y su procesamiento. Incluye referencias a buenas pr\u00e1cticas de fabricaci\u00f3n, gu\u00edas sobre la preparaci\u00f3n y uso de componentes sangu\u00edneos, y estudios sobre la estabilidad y calidad de la sangre y sus derivados. Tambi\u00e9n se mencionan tecnolog\u00edas de inactivaci\u00f3n de pat\u00f3genos como medidas de seguridad para el suministro de sangre.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las buenas pr\u00e1cticas de fabricaci\u00f3n recomendadas para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el informe de la OMS?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las normas y procedimientos que deben seguirse para garantizar la calidad y seguridad de los productos farmac\u00e9uticos est\u00e9riles.\n\n2. **\u00bfQu\u00e9 impacto tiene el retraso en el procesamiento de sangre en el rendimiento del factor VIII en los concentrados de crioprecipitado?**\n   - Esta pregunta se centra en un estudio espec\u00edfico mencionado en el documento que analiza c\u00f3mo el tiempo de procesamiento afecta la calidad de un componente sangu\u00edneo crucial.\n\n3. **\u00bfQu\u00e9 recomendaciones proporciona la OMS sobre la duraci\u00f3n de almacenamiento de sangre y plasma en relaci\u00f3n con los factores de coagulaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las pautas de almacenamiento y su relaci\u00f3n con la estabilidad de los factores de coagulaci\u00f3n, un aspecto cr\u00edtico para la seguridad del suministro de sangre.\n\n### Resumen de Nivel Superior\nEl informe de la OMS proporciona directrices y estudios sobre la fabricaci\u00f3n y calidad de productos farmac\u00e9uticos, con un enfoque particular en componentes sangu\u00edneos. Se discuten las buenas pr\u00e1cticas de fabricaci\u00f3n, la preparaci\u00f3n y uso de componentes sangu\u00edneos, y se presentan investigaciones sobre la estabilidad y calidad de la sangre y sus derivados. Adem\u00e1s, se abordan tecnolog\u00edas para la inactivaci\u00f3n de pat\u00f3genos, destacando su importancia para la seguridad del suministro de sangre.\n\n### Preguntas Adicionales Basadas en el Resumen\n1. **\u00bfQu\u00e9 tecnolog\u00edas se mencionan en el informe como medidas para la inactivaci\u00f3n de pat\u00f3genos en el suministro de sangre?**\n   - Esta pregunta busca informaci\u00f3n sobre las innovaciones y m\u00e9todos espec\u00edficos que se utilizan para garantizar la seguridad de la sangre.\n\n2. **\u00bfC\u00f3mo se relacionan las pautas de la OMS sobre la calidad de los componentes sangu\u00edneos con las recomendaciones del Consejo de Europa?**\n   - Esta pregunta investiga la conexi\u00f3n y coherencia entre las directrices de diferentes organizaciones sobre la calidad y uso de componentes sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 estudios se citan en el informe sobre la estabilidad del plasma fresco congelado y sus condiciones de almacenamiento?**\n   - Esta pregunta busca detalles sobre la investigaci\u00f3n espec\u00edfica que aborda la estabilidad del plasma y las condiciones \u00f3ptimas para su almacenamiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Requisitos y Directrices de la OMS:**\n   - Recolecci\u00f3n, procesamiento y control de calidad de sangre y sus derivados.\n   - Inactivaci\u00f3n y eliminaci\u00f3n de virus en productos de plasma humano.\n   - Producci\u00f3n y regulaci\u00f3n del plasma humano para fraccionamiento.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF):**\n   - Principios fundamentales de las BPF en productos farmac\u00e9uticos.\n   - Validaci\u00f3n de sistemas automatizados en establecimientos de sangre.\n\n3. **Regulaci\u00f3n y Seguridad:**\n   - Resoluciones de la Asamblea Mundial de la Salud sobre la disponibilidad, seguridad y calidad de productos sangu\u00edneos.\n   - Recomendaciones de conferencias internacionales sobre regulaci\u00f3n de medicamentos.\n\n4. **Gesti\u00f3n de Riesgos:**\n   - Directrices sobre gesti\u00f3n de riesgos en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad responsable de establecer directrices y recomendaciones.\n- **Organizaci\u00f3n Panamericana de la Salud (OPS):** Involucrada en la estandarizaci\u00f3n de servicios de sangre.\n- **International Conference on Harmonisation (ICH):** Proporciona directrices sobre gesti\u00f3n de calidad y riesgos.\n- **International Society of Blood Transfusion (ISBT):** Establece directrices para la validaci\u00f3n de sistemas en establecimientos de sangre.\n- **Conferencias Internacionales de Autoridades Reguladoras de Medicamentos (ICDRA):** Proporcionan recomendaciones sobre regulaci\u00f3n de medicamentos.\n\nEste resumen destaca la importancia de las directrices y regulaciones en la seguridad y calidad de los productos sangu\u00edneos, as\u00ed como la necesidad de buenas pr\u00e1cticas y gesti\u00f3n de riesgos en su producci\u00f3n y control.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, Blood Components, Pathogen Inactivation, Coagulation Factors, Pharmaceutical Quality Assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5a3c4e9f-e84d-4080-98cc-3367f01251d0", "node_type": "4", "metadata": {"page_label": "226", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Geneva, Pharmaceutical Inspection Cooperation Scheme, 2007 (Document PI 006-3).\n\n12. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902, Annex 6).\n\n13. *Guide to the preparation, use and quality assurance of blood components*, 14th edition. Technical annex to Council of Europe Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components. Strasbourg, European Directorate for the Quality of Medicines and HealthCare (EDQM), 2008.\n\n14. Hughes C et al. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. *Transfusion*, 1988, 28:566.\n\n15. Carlebjork G, Blomback M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. *Vox Sanguinis*, 1983, 45:233.\n\n16. Nilsson L et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. *Transfusion*, 1983, 23:377.\n\n17. Pietersz RN et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. *Vox Sanguinis*, 1989, 56:145.\n\n18. Kottischke R et al. Stability of fresh frozen plasma: results of 36-month storage at -20\u00b0C, -25\u00b0C, -30\u00b0C and -40\u00b0C. *Infusionstherapie und Transfusionsmedizin*, 2000, 27:174.\n\n19. Klein HG. Pathogen inactivation technology: cleansing the blood supply. *Journal of Internal Medicine*, 2005, 257:224\u2013237.\n\n20. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. *Archives of pathology & laboratory medicine*, 2007, 131:719\u2013733.\n\n21. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929, Annex 4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b6e1f1a23af81f2007b12a7801626013516aa2c2ac77e859dee5d9a096b49a11", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Geneva, Pharmaceutical Inspection Cooperation Scheme, 2007 (Document PI 006-3).\n\n12. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902, Annex 6).\n\n13. *Guide to the preparation, use and quality assurance of blood components*, 14th edition. Technical annex to Council of Europe Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components. Strasbourg, European Directorate for the Quality of Medicines and HealthCare (EDQM), 2008.\n\n14. Hughes C et al. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. *Transfusion*, 1988, 28:566.\n\n15. Carlebjork G, Blomback M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. *Vox Sanguinis*, 1983, 45:233.\n\n16. Nilsson L et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. *Transfusion*, 1983, 23:377.\n\n17. Pietersz RN et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. *Vox Sanguinis*, 1989, 56:145.\n\n18. Kottischke R et al. Stability of fresh frozen plasma: results of 36-month storage at -20\u00b0C, -25\u00b0C, -30\u00b0C and -40\u00b0C. *Infusionstherapie und Transfusionsmedizin*, 2000, 27:174.\n\n19. Klein HG. Pathogen inactivation technology: cleansing the blood supply. *Journal of Internal Medicine*, 2005, 257:224\u2013237.\n\n20. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. *Archives of pathology & laboratory medicine*, 2007, 131:719\u2013733.\n\n21. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929, Annex 4).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2092, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff45878-fc55-44db-afaa-8e475332184b": {"__data__": {"id_": "0ff45878-fc55-44db-afaa-8e475332184b", "embedding": null, "metadata": {"page_label": "227", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms\n\n1. Introduction\n\n2. Scope of document\n\n3. Glossary\n\n4. Protection  \n   4.1 Products and personnel  \n   4.2 Air filtration  \n   4.3 Unidirectional airflow  \n   4.4 Infiltration  \n   4.5 Cross-contamination  \n   4.6 Displacement concept (low pressure differential, high airflow)  \n   4.7 Pressure differential concept (high pressure differential, low airflow)  \n   4.8 Physical barrier concept  \n   4.9 Temperature and relative humidity  \n\n5. Dust control\n\n6. Protection of the environment  \n   6.1 General  \n   6.2 Dust in exhaust air  \n   6.3 Vapour and fume removal  \n\n7. Design of HVAC systems and components  \n   7.1 General  \n   7.2 Air distribution  \n   7.3 Recirculation system  \n   7.4 Full fresh-air systems  \n   7.5 Additional system components  \n\n8. Commissioning, qualification and maintenance  \n   8.1 Commissioning  \n   8.2 Qualification  \n   8.3 Maintenance  \n\n9. Premises\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es una gu\u00eda suplementaria sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la producci\u00f3n de formas farmac\u00e9uticas no est\u00e9riles. Se abordan aspectos clave como la protecci\u00f3n de productos y personal, el control de polvo, el dise\u00f1o de sistemas HVAC, y los procedimientos de puesta en marcha, calificaci\u00f3n y mantenimiento. Tambi\u00e9n se discuten conceptos de flujo de aire y control de contaminaci\u00f3n, as\u00ed como la importancia de la temperatura y la humedad relativa en el entorno de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los conceptos de flujo de aire que se deben considerar en el dise\u00f1o de sistemas HVAC para productos farmac\u00e9uticos no est\u00e9riles?**\n   - Esta pregunta se centra en los conceptos espec\u00edficos mencionados en la secci\u00f3n 4, como el flujo unidireccional, la infiltraci\u00f3n y los conceptos de presi\u00f3n diferencial.\n\n2. **\u00bfQu\u00e9 medidas se recomiendan para el control de polvo en las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos no est\u00e9riles?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las pr\u00e1cticas de control de polvo que se deben implementar, como se menciona en la secci\u00f3n 5 del documento.\n\n3. **\u00bfQu\u00e9 aspectos se deben tener en cuenta durante la fase de calificaci\u00f3n y mantenimiento de los sistemas HVAC en la producci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta se dirige a la secci\u00f3n 8, donde se discuten los procedimientos de calificaci\u00f3n y mantenimiento, proporcionando informaci\u00f3n sobre c\u00f3mo asegurar que los sistemas HVAC funcionen de manera efectiva y cumplan con las normativas de BPF.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**:\n   - Se mencionan las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir normas y procedimientos para garantizar la calidad y seguridad.\n\n2. **Componentes Sangu\u00edneos**:\n   - Se hace referencia a gu\u00edas sobre la preparaci\u00f3n, uso y aseguramiento de la calidad de componentes sangu\u00edneos, incluyendo un anexo t\u00e9cnico del Consejo de Europa.\n\n3. **Investigaciones sobre Factor VIII**:\n   - Se citan estudios que analizan el impacto del retraso en el procesamiento de sangre sobre el rendimiento del factor VIII en crioprecipitados y concentrados.\n\n4. **Estabilidad y Almacenamiento de Sangre y Plasma**:\n   - Se discuten investigaciones sobre la vida \u00fatil de la sangre y el plasma almacenado, as\u00ed como su relaci\u00f3n con los factores de coagulaci\u00f3n.\n\n5. **Tecnolog\u00edas de Inactivaci\u00f3n de Pat\u00f3genos**:\n   - Se mencionan tecnolog\u00edas para la inactivaci\u00f3n de pat\u00f3genos como medidas de seguridad para el suministro de sangre.\n\n6. **Directrices de la OMS**:\n   - Se citan directrices de la OMS sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados, as\u00ed como informes t\u00e9cnicos sobre especificaciones para preparaciones farmac\u00e9uticas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices y recomendaciones sobre pr\u00e1cticas farmac\u00e9uticas y de salud.\n- **Consejo de Europa**: Organizaci\u00f3n que proporciona recomendaciones sobre la calidad y uso de componentes sangu\u00edneos.\n- **European Directorate for the Quality of Medicines and HealthCare (EDQM)**: Entidad que contribuye a la calidad de los medicamentos y componentes sangu\u00edneos en Europa.\n- **Revistas Cient\u00edficas**: Se citan varias publicaciones como *Transfusion*, *Vox Sanguinis*, y *Journal of Internal Medicine*, que presentan investigaciones relevantes sobre la sangre y sus derivados.\n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos, especialmente en el contexto de componentes sangu\u00edneos, as\u00ed como la relevancia de la investigaci\u00f3n cient\u00edfica en este campo.", "excerpt_keywords": "Keywords: good manufacturing practices, HVAC systems, non-sterile pharmaceuticals, air filtration, dust control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4853fcfb-31f6-41e7-93c2-ceadefae913c", "node_type": "4", "metadata": {"page_label": "227", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms\n\n1. Introduction\n\n2. Scope of document\n\n3. Glossary\n\n4. Protection  \n   4.1 Products and personnel  \n   4.2 Air filtration  \n   4.3 Unidirectional airflow  \n   4.4 Infiltration  \n   4.5 Cross-contamination  \n   4.6 Displacement concept (low pressure differential, high airflow)  \n   4.7 Pressure differential concept (high pressure differential, low airflow)  \n   4.8 Physical barrier concept  \n   4.9 Temperature and relative humidity  \n\n5. Dust control\n\n6. Protection of the environment  \n   6.1 General  \n   6.2 Dust in exhaust air  \n   6.3 Vapour and fume removal  \n\n7. Design of HVAC systems and components  \n   7.1 General  \n   7.2 Air distribution  \n   7.3 Recirculation system  \n   7.4 Full fresh-air systems  \n   7.5 Additional system components  \n\n8. Commissioning, qualification and maintenance  \n   8.1 Commissioning  \n   8.2 Qualification  \n   8.3 Maintenance  \n\n9. Premises\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "62e79bce574c40752f57682d508362b8b4f722f55ba1ef2ee97c8a91865bfc6f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 5\n\n## Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms\n\n1. Introduction\n\n2. Scope of document\n\n3. Glossary\n\n4. Protection  \n   4.1 Products and personnel  \n   4.2 Air filtration  \n   4.3 Unidirectional airflow  \n   4.4 Infiltration  \n   4.5 Cross-contamination  \n   4.6 Displacement concept (low pressure differential, high airflow)  \n   4.7 Pressure differential concept (high pressure differential, low airflow)  \n   4.8 Physical barrier concept  \n   4.9 Temperature and relative humidity  \n\n5. Dust control\n\n6. Protection of the environment  \n   6.1 General  \n   6.2 Dust in exhaust air  \n   6.3 Vapour and fume removal  \n\n7. Design of HVAC systems and components  \n   7.1 General  \n   7.2 Air distribution  \n   7.3 Recirculation system  \n   7.4 Full fresh-air systems  \n   7.5 Additional system components  \n\n8. Commissioning, qualification and maintenance  \n   8.1 Commissioning  \n   8.2 Qualification  \n   8.3 Maintenance  \n\n9. Premises\n\nReferences\n\nFurther reading", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1085, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9fa36202-33d7-4cc3-97c7-e163966777e4": {"__data__": {"id_": "9fa36202-33d7-4cc3-97c7-e163966777e4", "embedding": null, "metadata": {"page_label": "228", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nHeating, ventilation and air-conditioning (HVAC) play an important role in ensuring the manufacture of quality pharmaceutical products. A well designed HVAC system will also provide comfortable conditions for operators.\n\nThese guidelines mainly focus on recommendations for systems for manufacturers of solid dosage forms. The guidelines also refer to other systems or components which are not relevant to solid dosage form manufacturing plants, but which may assist in providing a comparison between the requirements for solid dosage-form plants and other systems.\n\nHVAC system design influences architectural layouts with regard to items such as airlock positions, doorways and lobbies. The architectural components have an effect on room pressure differential cascades and cross-contamination control. The prevention of contamination and cross-contamination is an essential design consideration of the HVAC system. In view of these critical aspects, the design of the HVAC system should be considered at the concept design stage of a pharmaceutical manufacturing plant.\n\nTemperature, relative humidity and ventilation should be appropriate and should not adversely affect the quality of pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\nThis document aims to give guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems. These guidelines are intended to complement those provided in *Good manufacturing practices for pharmaceutical products* (1) and should be read in conjunction with the parent guide. The additional standards addressed by the present guidelines should, therefore, be considered supplementary to the general requirements set out in the parent guide.\n\n# 2. Scope of document\n\nThese guidelines focus primarily on the design and good manufacturing practices (GMP) requirements for HVAC systems for facilities for the manufacture of solid dosage forms. Most of the system design principles for facilities manufacturing solid dosage forms also apply to other facilities such as those manufacturing liquids, creams and ointments. These guidelines do not cover requirements for manufacturing sites for the production of sterile pharmaceutical products. These guidelines do not cover the specific requirements relating to facilities handling hazardous products. Guidelines for hazardous product facilities are covered in a separate WHO guideline.\n\nThese guidelines are intended as a basic guide for use by pharmaceutical manufacturers and GMP inspectors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 961, se centra en las directrices para el dise\u00f1o, instalaci\u00f3n, calificaci\u00f3n y mantenimiento de sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la fabricaci\u00f3n de productos farmac\u00e9uticos, especialmente formas s\u00f3lidas. Se enfatiza la importancia de un sistema HVAC bien dise\u00f1ado para garantizar la calidad del producto y la comodidad de los operadores. Las directrices tambi\u00e9n abordan la influencia del dise\u00f1o del sistema HVAC en la arquitectura de las instalaciones y la prevenci\u00f3n de la contaminaci\u00f3n. Sin embargo, no cubren requisitos para productos est\u00e9riles o peligrosos, que est\u00e1n tratados en gu\u00edas separadas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los aspectos cr\u00edticos que deben considerarse en el dise\u00f1o de un sistema HVAC para la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: El dise\u00f1o del sistema HVAC debe considerar la prevenci\u00f3n de la contaminaci\u00f3n y la contaminaci\u00f3n cruzada, la influencia en la disposici\u00f3n arquitect\u00f3nica (como posiciones de airelock, puertas y vest\u00edbulos), y asegurar que la temperatura, la humedad relativa y la ventilaci\u00f3n sean apropiadas para no afectar negativamente la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 tipo de instalaciones no est\u00e1n cubiertas por estas directrices de HVAC seg\u00fan el documento?**\n   - Respuesta: Las directrices no cubren los requisitos para sitios de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles ni para instalaciones que manejan productos peligrosos. Estas \u00e1reas est\u00e1n abordadas en gu\u00edas separadas de la OMS.\n\n3. **\u00bfC\u00f3mo se relacionan estas directrices con las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos?**\n   - Respuesta: Estas directrices est\u00e1n destinadas a complementar las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos y deben leerse en conjunto con la gu\u00eda principal de GMP, considerando los est\u00e1ndares adicionales como suplementarios a los requisitos generales establecidos en la gu\u00eda principal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento proporciona directrices suplementarias sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) espec\u00edficamente para los sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la producci\u00f3n de formas farmac\u00e9uticas no est\u00e9riles. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n1. **Introducci\u00f3n y Alcance**: Se establece el prop\u00f3sito del documento y su aplicabilidad en la industria farmac\u00e9utica.\n\n2. **Protecci\u00f3n**: \n   - **Productos y Personal**: Medidas para proteger tanto los productos farmac\u00e9uticos como al personal que trabaja en su fabricaci\u00f3n.\n   - **Filtraci\u00f3n de Aire**: Importancia de los sistemas de filtraci\u00f3n para mantener la calidad del aire.\n   - **Flujo Unidireccional**: Concepto de flujo de aire controlado para minimizar la contaminaci\u00f3n.\n   - **Infiltraci\u00f3n y Contaminaci\u00f3n Cruzada**: Estrategias para evitar la entrada de contaminantes externos.\n   - **Conceptos de Presi\u00f3n Diferencial**: Diferencias entre sistemas de baja y alta presi\u00f3n en relaci\u00f3n con el flujo de aire.\n   - **Barreras F\u00edsicas**: Uso de barreras para proteger \u00e1reas cr\u00edticas.\n   - **Temperatura y Humedad Relativa**: Control de estos par\u00e1metros para asegurar condiciones \u00f3ptimas de fabricaci\u00f3n.\n\n3. **Control de Polvo**: Estrategias y pr\u00e1cticas recomendadas para minimizar la acumulaci\u00f3n de polvo en las instalaciones.\n\n4. **Protecci\u00f3n del Medio Ambiente**: \n   - **Control de Polvo en Aire de Escape**: Medidas para gestionar el polvo que se libera al medio ambiente.\n   - **Eliminaci\u00f3n de Vapores y Humos**: M\u00e9todos para manejar emisiones nocivas.\n\n5. **Dise\u00f1o de Sistemas HVAC**: \n   - **Distribuci\u00f3n de Aire**: Consideraciones sobre c\u00f3mo se distribuye el aire en las instalaciones.\n   - **Sistemas de Recirculaci\u00f3n y Aire Fresco**: Diferencias y aplicaciones de cada tipo de sistema.\n   - **Componentes Adicionales**: Elementos que pueden ser necesarios para un funcionamiento eficiente.\n\n6. **Puesta en Marcha, Calificaci\u00f3n y Mantenimiento**: \n   - **Puesta en Marcha**: Procedimientos iniciales para asegurar que los sistemas funcionen correctamente.\n   - **Calificaci\u00f3n**: Validaci\u00f3n de que los sistemas cumplen con los est\u00e1ndares requeridos.\n   - **Mantenimiento**: Pr\u00e1cticas para asegurar el funcionamiento continuo y eficiente de los sistemas HVAC.\n\n7. **Premisas**: Consideraciones sobre las instalaciones donde se implementan estos sistemas.\n\n### Entidades Clave\n- **BPF (Buenas Pr\u00e1cticas de Fabricaci\u00f3n)**: Normativas que aseguran la calidad en la producci\u00f3n farmac\u00e9utica.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistemas cr\u00edticos para el control ambiental en la fabricaci\u00f3n.\n- **Contaminaci\u00f3n Cruzada**: Riesgo que se busca minimizar en el entorno de fabricaci\u00f3n.\n- **Temperatura y Humedad Relativa**: Factores ambientales que afectan la calidad del producto.\n\nEste resumen abarca los aspectos fundamentales del documento, proporcionando una visi\u00f3n general de las directrices para la implementaci\u00f3n de sistemas HVAC en la producci\u00f3n farmac\u00e9utica no est\u00e9ril.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical manufacturing, contamination control, good manufacturing practices, solid dosage forms"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "294fb64f-8272-4854-ac81-abbbd16833d8", "node_type": "4", "metadata": {"page_label": "228", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nHeating, ventilation and air-conditioning (HVAC) play an important role in ensuring the manufacture of quality pharmaceutical products. A well designed HVAC system will also provide comfortable conditions for operators.\n\nThese guidelines mainly focus on recommendations for systems for manufacturers of solid dosage forms. The guidelines also refer to other systems or components which are not relevant to solid dosage form manufacturing plants, but which may assist in providing a comparison between the requirements for solid dosage-form plants and other systems.\n\nHVAC system design influences architectural layouts with regard to items such as airlock positions, doorways and lobbies. The architectural components have an effect on room pressure differential cascades and cross-contamination control. The prevention of contamination and cross-contamination is an essential design consideration of the HVAC system. In view of these critical aspects, the design of the HVAC system should be considered at the concept design stage of a pharmaceutical manufacturing plant.\n\nTemperature, relative humidity and ventilation should be appropriate and should not adversely affect the quality of pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\nThis document aims to give guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems. These guidelines are intended to complement those provided in *Good manufacturing practices for pharmaceutical products* (1) and should be read in conjunction with the parent guide. The additional standards addressed by the present guidelines should, therefore, be considered supplementary to the general requirements set out in the parent guide.\n\n# 2. Scope of document\n\nThese guidelines focus primarily on the design and good manufacturing practices (GMP) requirements for HVAC systems for facilities for the manufacture of solid dosage forms. Most of the system design principles for facilities manufacturing solid dosage forms also apply to other facilities such as those manufacturing liquids, creams and ointments. These guidelines do not cover requirements for manufacturing sites for the production of sterile pharmaceutical products. These guidelines do not cover the specific requirements relating to facilities handling hazardous products. Guidelines for hazardous product facilities are covered in a separate WHO guideline.\n\nThese guidelines are intended as a basic guide for use by pharmaceutical manufacturers and GMP inspectors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "283d562fe978081afd17b3b511b09c67438aa7f3fd2e3a03228e486e67d47f2a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. Introduction\n\nHeating, ventilation and air-conditioning (HVAC) play an important role in ensuring the manufacture of quality pharmaceutical products. A well designed HVAC system will also provide comfortable conditions for operators.\n\nThese guidelines mainly focus on recommendations for systems for manufacturers of solid dosage forms. The guidelines also refer to other systems or components which are not relevant to solid dosage form manufacturing plants, but which may assist in providing a comparison between the requirements for solid dosage-form plants and other systems.\n\nHVAC system design influences architectural layouts with regard to items such as airlock positions, doorways and lobbies. The architectural components have an effect on room pressure differential cascades and cross-contamination control. The prevention of contamination and cross-contamination is an essential design consideration of the HVAC system. In view of these critical aspects, the design of the HVAC system should be considered at the concept design stage of a pharmaceutical manufacturing plant.\n\nTemperature, relative humidity and ventilation should be appropriate and should not adversely affect the quality of pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\nThis document aims to give guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems. These guidelines are intended to complement those provided in *Good manufacturing practices for pharmaceutical products* (1) and should be read in conjunction with the parent guide. The additional standards addressed by the present guidelines should, therefore, be considered supplementary to the general requirements set out in the parent guide.\n\n# 2. Scope of document\n\nThese guidelines focus primarily on the design and good manufacturing practices (GMP) requirements for HVAC systems for facilities for the manufacture of solid dosage forms. Most of the system design principles for facilities manufacturing solid dosage forms also apply to other facilities such as those manufacturing liquids, creams and ointments. These guidelines do not cover requirements for manufacturing sites for the production of sterile pharmaceutical products. These guidelines do not cover the specific requirements relating to facilities handling hazardous products. Guidelines for hazardous product facilities are covered in a separate WHO guideline.\n\nThese guidelines are intended as a basic guide for use by pharmaceutical manufacturers and GMP inspectors.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2663, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f29dcee4-839a-44ec-93ca-5bcbd487fc9f": {"__data__": {"id_": "f29dcee4-839a-44ec-93ca-5bcbd487fc9f", "embedding": null, "metadata": {"page_label": "229", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "They are not intended to be prescriptive in specifying requirements and design parameters. There are many parameters affecting a clean area condition and it is, therefore, difficult to lay down the specific requirements for one particular parameter in isolation.\n\nMany pharmaceutical manufacturers have their own engineering design and qualification standards and requirements may vary from one manufacturer to the next. Design parameters and user requirements should, therefore, be set realistically for each project, with a view to creating a cost-effective design, yet still complying with all regulatory standards and ensuring that product quality and safety are not compromised. The three primary aspects addressed in this manual are the roles that the HVAC system plays in product protection, personnel protection and environmental protection (Figure 1).\n\nCognisance should be taken of the products to be manufactured when establishing system design parameters. A facility manufacturing multiple different products may have more stringent design parameters with respect to cross-contamination control, compared with a single product facility.\n\n**Figure 1**\n\n**The guidelines address the various system criteria according to the sequence set out in this diagram**\n\n```\nGMP MANUFACTURING ENVIRONMENT\n    \u251c\u2500\u2500 PRODUCT PROTECTION\n    \u2502   \u251c\u2500\u2500 Contamination (Product & Staff)\n    \u2502   \u251c\u2500\u2500 Protect from Product Contamination\n    \u2502   \u2514\u2500\u2500 Correct Temperature & Humidity\n    \u251c\u2500\u2500 PERSONNEL PROTECTION\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Dust\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Fumes\n    \u2502   \u2514\u2500\u2500 Acceptable Comfort Conditions\n    \u2514\u2500\u2500 PROTECTION OF EXTERNAL ENVIRONMENT\n        \u251c\u2500\u2500 Avoid Dust Discharge\n        \u251c\u2500\u2500 Avoid Fume Discharge\n        \u2514\u2500\u2500 Avoid Effluent Discharge\n\nSYSTEMS\n\nSYSTEM VALIDATION\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las consideraciones de dise\u00f1o y requisitos para sistemas de HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en entornos de fabricaci\u00f3n farmac\u00e9utica. Se enfatiza que no existen requisitos prescriptivos \u00fanicos, ya que las necesidades pueden variar entre fabricantes y proyectos. Se identifican tres \u00e1reas clave de protecci\u00f3n: la protecci\u00f3n del producto, la protecci\u00f3n del personal y la protecci\u00f3n del medio ambiente externo. Adem\u00e1s, se menciona la importancia de establecer par\u00e1metros de dise\u00f1o teniendo en cuenta los productos a fabricar y el riesgo de contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los tres aspectos principales que aborda el manual en relaci\u00f3n con el sistema HVAC en un entorno de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los tres aspectos principales son la protecci\u00f3n del producto, la protecci\u00f3n del personal y la protecci\u00f3n del medio ambiente externo.\n\n2. **\u00bfPor qu\u00e9 es importante considerar los productos a fabricar al establecer los par\u00e1metros de dise\u00f1o del sistema HVAC?**\n   - Respuesta: Es importante considerar los productos a fabricar porque una instalaci\u00f3n que produce m\u00faltiples productos puede requerir par\u00e1metros de dise\u00f1o m\u00e1s estrictos en cuanto al control de la contaminaci\u00f3n cruzada, en comparaci\u00f3n con una instalaci\u00f3n que fabrica un solo producto.\n\n3. **\u00bfQu\u00e9 se debe tener en cuenta al establecer requisitos de dise\u00f1o y par\u00e1metros para un proyecto de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Se deben establecer de manera realista los par\u00e1metros de dise\u00f1o y los requisitos del usuario para cada proyecto, buscando un dise\u00f1o rentable que cumpla con todos los est\u00e1ndares regulatorios y garantice que la calidad y seguridad del producto no se vean comprometidas.", "prev_section_summary": "### Temas Clave:\n1. **Importancia del HVAC**: El sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) es crucial para la fabricaci\u00f3n de productos farmac\u00e9uticos de calidad y para proporcionar condiciones c\u00f3modas a los operadores.\n2. **Dise\u00f1o del Sistema HVAC**: El dise\u00f1o debe considerar la prevenci\u00f3n de la contaminaci\u00f3n y la contaminaci\u00f3n cruzada, as\u00ed como influir en la disposici\u00f3n arquitect\u00f3nica de las instalaciones.\n3. **Condiciones Ambientales**: La temperatura, la humedad relativa y la ventilaci\u00f3n deben ser adecuadas para no afectar la calidad de los productos farmac\u00e9uticos ni el funcionamiento del equipo.\n4. **Gu\u00edas y Buenas Pr\u00e1cticas de Manufactura (GMP)**: Las directrices est\u00e1n destinadas a complementar las GMP y deben leerse junto con la gu\u00eda principal.\n5. **Alcance de las Directrices**: Se centran en la fabricaci\u00f3n de formas s\u00f3lidas y no cubren productos est\u00e9riles ni instalaciones que manejen productos peligrosos.\n\n### Entidades:\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud, que emite las directrices.\n- **Productos farmac\u00e9uticos**: Incluye formas s\u00f3lidas, l\u00edquidas, cremas y ung\u00fcentos.\n- **Contaminaci\u00f3n y contaminaci\u00f3n cruzada**: Aspectos cr\u00edticos en el dise\u00f1o de sistemas HVAC.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que complementan las directrices de HVAC.\n\n### Resumen:\nEl documento de la OMS proporciona directrices sobre el dise\u00f1o, instalaci\u00f3n, calificaci\u00f3n y mantenimiento de sistemas HVAC en la fabricaci\u00f3n de productos farmac\u00e9uticos, con un enfoque en las formas s\u00f3lidas. Se destaca la importancia de un dise\u00f1o adecuado para prevenir la contaminaci\u00f3n y asegurar condiciones ambientales \u00f3ptimas. Las directrices son complementarias a las Buenas Pr\u00e1cticas de Manufactura y no abordan requisitos para productos est\u00e9riles o peligrosos.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical manufacturing, product protection, contamination control, regulatory standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "812b1ab3-5fb3-46ff-8154-033bfa006c7c", "node_type": "4", "metadata": {"page_label": "229", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "They are not intended to be prescriptive in specifying requirements and design parameters. There are many parameters affecting a clean area condition and it is, therefore, difficult to lay down the specific requirements for one particular parameter in isolation.\n\nMany pharmaceutical manufacturers have their own engineering design and qualification standards and requirements may vary from one manufacturer to the next. Design parameters and user requirements should, therefore, be set realistically for each project, with a view to creating a cost-effective design, yet still complying with all regulatory standards and ensuring that product quality and safety are not compromised. The three primary aspects addressed in this manual are the roles that the HVAC system plays in product protection, personnel protection and environmental protection (Figure 1).\n\nCognisance should be taken of the products to be manufactured when establishing system design parameters. A facility manufacturing multiple different products may have more stringent design parameters with respect to cross-contamination control, compared with a single product facility.\n\n**Figure 1**\n\n**The guidelines address the various system criteria according to the sequence set out in this diagram**\n\n```\nGMP MANUFACTURING ENVIRONMENT\n    \u251c\u2500\u2500 PRODUCT PROTECTION\n    \u2502   \u251c\u2500\u2500 Contamination (Product & Staff)\n    \u2502   \u251c\u2500\u2500 Protect from Product Contamination\n    \u2502   \u2514\u2500\u2500 Correct Temperature & Humidity\n    \u251c\u2500\u2500 PERSONNEL PROTECTION\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Dust\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Fumes\n    \u2502   \u2514\u2500\u2500 Acceptable Comfort Conditions\n    \u2514\u2500\u2500 PROTECTION OF EXTERNAL ENVIRONMENT\n        \u251c\u2500\u2500 Avoid Dust Discharge\n        \u251c\u2500\u2500 Avoid Fume Discharge\n        \u2514\u2500\u2500 Avoid Effluent Discharge\n\nSYSTEMS\n\nSYSTEM VALIDATION\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9d0aaf54b62c999b1defe9912afad709c4a453ddfadef839d80e17fa7a4f305d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "They are not intended to be prescriptive in specifying requirements and design parameters. There are many parameters affecting a clean area condition and it is, therefore, difficult to lay down the specific requirements for one particular parameter in isolation.\n\nMany pharmaceutical manufacturers have their own engineering design and qualification standards and requirements may vary from one manufacturer to the next. Design parameters and user requirements should, therefore, be set realistically for each project, with a view to creating a cost-effective design, yet still complying with all regulatory standards and ensuring that product quality and safety are not compromised. The three primary aspects addressed in this manual are the roles that the HVAC system plays in product protection, personnel protection and environmental protection (Figure 1).\n\nCognisance should be taken of the products to be manufactured when establishing system design parameters. A facility manufacturing multiple different products may have more stringent design parameters with respect to cross-contamination control, compared with a single product facility.\n\n**Figure 1**\n\n**The guidelines address the various system criteria according to the sequence set out in this diagram**\n\n```\nGMP MANUFACTURING ENVIRONMENT\n    \u251c\u2500\u2500 PRODUCT PROTECTION\n    \u2502   \u251c\u2500\u2500 Contamination (Product & Staff)\n    \u2502   \u251c\u2500\u2500 Protect from Product Contamination\n    \u2502   \u2514\u2500\u2500 Correct Temperature & Humidity\n    \u251c\u2500\u2500 PERSONNEL PROTECTION\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Dust\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Fumes\n    \u2502   \u2514\u2500\u2500 Acceptable Comfort Conditions\n    \u2514\u2500\u2500 PROTECTION OF EXTERNAL ENVIRONMENT\n        \u251c\u2500\u2500 Avoid Dust Discharge\n        \u251c\u2500\u2500 Avoid Fume Discharge\n        \u2514\u2500\u2500 Avoid Effluent Discharge\n\nSYSTEMS\n\nSYSTEM VALIDATION\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1790, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e538b7b3-9b0e-4908-99a0-d351cc532480": {"__data__": {"id_": "e538b7b3-9b0e-4908-99a0-d351cc532480", "embedding": null, "metadata": {"page_label": "230", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**  \nMeasurable terms under which a test result will be considered acceptable.\n\n**action limit**  \nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n**air changes per hour (ACPH)**  \nThe volume of air supplied to a room, in m\u00b3/hr, divided by the room volume, in m\u00b3.\n\n**air-handling unit (AHU)**  \nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (PAL, personnel airlock; MAL, material airlock).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**as-built**  \nCondition where the installation is complete with all services connected and functioning but with no production equipment, materials or personnel present.\n\n**at-rest**  \nCondition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n**central air-conditioning unit (see air-handling unit)**\n\n**change control**  \nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 es un \"airlock\" y cu\u00e1l es su prop\u00f3sito en un entorno controlado?**\n   - Un \"airlock\" es un espacio cerrado con dos o m\u00e1s puertas que se encuentra entre dos o m\u00e1s habitaciones de diferentes clases de limpieza. Su prop\u00f3sito es controlar el flujo de aire entre esas habitaciones cuando se necesita acceder a ellas, minimizando la contaminaci\u00f3n cruzada. Existen dos tipos de airlocks: el airlock de personal (PAL) y el airlock de material (MAL).\n\n2. **\u00bfC\u00f3mo se determina si un resultado de prueba es aceptable seg\u00fan los criterios de aceptaci\u00f3n?**\n   - Los criterios de aceptaci\u00f3n son t\u00e9rminos medibles que definen las condiciones bajo las cuales un resultado de prueba se considerar\u00e1 aceptable. Si un resultado cumple con estos criterios, se considera que est\u00e1 dentro de los l\u00edmites aceptables.\n\n3. **\u00bfQu\u00e9 implica el t\u00e9rmino \"as-built\" en el contexto de instalaciones?**\n   - El t\u00e9rmino \"as-built\" se refiere a la condici\u00f3n en la que la instalaci\u00f3n est\u00e1 completa, con todos los servicios conectados y funcionando, pero sin la presencia de equipos de producci\u00f3n, materiales o personal. Esto indica que la infraestructura est\u00e1 lista para su uso, aunque no se est\u00e9 llevando a cabo ninguna operaci\u00f3n activa.\n\n### Resumen de nivel superior del contexto:\nEl contexto proporciona un glosario de t\u00e9rminos t\u00e9cnicos utilizados en directrices relacionadas con la calidad del aire y el control ambiental en instalaciones. Incluye definiciones clave que son esenciales para entender los par\u00e1metros cr\u00edticos en la operaci\u00f3n de sistemas de aire acondicionado y control de contaminaci\u00f3n, as\u00ed como los procedimientos de validaci\u00f3n y control de cambios en entornos regulados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las consideraciones de dise\u00f1o y requisitos para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en entornos de fabricaci\u00f3n farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **No Prescriptividad**: Los requisitos y par\u00e1metros de dise\u00f1o no son \u00fanicos ni prescriptivos, ya que var\u00edan entre diferentes fabricantes y proyectos.\n2. **Variabilidad de Requisitos**: Cada fabricante puede tener sus propios est\u00e1ndares de dise\u00f1o e ingenier\u00eda, lo que implica que los requisitos pueden diferir significativamente.\n3. **Tres \u00c1reas de Protecci\u00f3n**:\n   - **Protecci\u00f3n del Producto**: Incluye el control de la contaminaci\u00f3n, la protecci\u00f3n contra la contaminaci\u00f3n del producto y el mantenimiento de condiciones adecuadas de temperatura y humedad.\n   - **Protecci\u00f3n del Personal**: Se enfoca en prevenir el contacto con polvo y vapores, as\u00ed como en garantizar condiciones de confort aceptables.\n   - **Protecci\u00f3n del Medio Ambiente Externo**: Busca evitar la descarga de polvo, vapores y efluentes al entorno exterior.\n4. **Par\u00e1metros de Dise\u00f1o**: La importancia de establecer par\u00e1metros de dise\u00f1o realistas, considerando los productos a fabricar y el riesgo de contaminaci\u00f3n cruzada, especialmente en instalaciones que producen m\u00faltiples productos.\n\n#### Entidades:\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Fabricantes Farmac\u00e9uticos**: Empresas que producen productos farmac\u00e9uticos y que pueden tener diferentes est\u00e1ndares de dise\u00f1o.\n- **Contaminaci\u00f3n Cruzada**: Riesgo asociado a la producci\u00f3n de m\u00faltiples productos en una misma instalaci\u00f3n.\n- **Regulaciones**: Normativas que deben cumplirse para garantizar la calidad y seguridad del producto.\n\nEste resumen destaca la importancia de un enfoque flexible y adaptado a las necesidades espec\u00edficas de cada proyecto en el dise\u00f1o de sistemas HVAC en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: acceptance criteria, airlock, air-handling unit, change control, alert limit"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d2dc39a2-a25d-4cc2-9ee3-cfb11aa4bd07", "node_type": "4", "metadata": {"page_label": "230", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**  \nMeasurable terms under which a test result will be considered acceptable.\n\n**action limit**  \nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n**air changes per hour (ACPH)**  \nThe volume of air supplied to a room, in m\u00b3/hr, divided by the room volume, in m\u00b3.\n\n**air-handling unit (AHU)**  \nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (PAL, personnel airlock; MAL, material airlock).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**as-built**  \nCondition where the installation is complete with all services connected and functioning but with no production equipment, materials or personnel present.\n\n**at-rest**  \nCondition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n**central air-conditioning unit (see air-handling unit)**\n\n**change control**  \nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "470b7b23814752af49eafe0732715ef5c0558f73673b3dd2e809302e2a39fc48", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**  \nMeasurable terms under which a test result will be considered acceptable.\n\n**action limit**  \nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n**air changes per hour (ACPH)**  \nThe volume of air supplied to a room, in m\u00b3/hr, divided by the room volume, in m\u00b3.\n\n**air-handling unit (AHU)**  \nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (PAL, personnel airlock; MAL, material airlock).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**as-built**  \nCondition where the installation is complete with all services connected and functioning but with no production equipment, materials or personnel present.\n\n**at-rest**  \nCondition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n**central air-conditioning unit (see air-handling unit)**\n\n**change control**  \nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1837, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e5fa9463-f759-4cd6-ba07-7e94f10afb71": {"__data__": {"id_": "e5fa9463-f759-4cd6-ba07-7e94f10afb71", "embedding": null, "metadata": {"page_label": "231", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n**clean area (cleanroom)**\u00b9  \nAn area (or room or zone) with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**closed system**  \nA system where the product or material is not exposed to the manufacturing environment.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**controlled area**  \nAn area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n\n**critical parameter or component**  \nA processing parameter (such as temperature or relative humidity) that affects the quality of a product, or a component that may have a direct impact on the quality of the product.\n\n**critical quality attribute (CQA)**  \nA physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.\n\n----\n\n\u00b9 Note: Clean area standards, such as ISO 14644-1, provide details on how to classify air cleanliness by means of particle concentrations, whereas the GMP standards provide a grading for air cleanliness in terms of the condition (at-rest or operational), the permissible microbial concentrations, as well as other factors such as gowning requirements. GMP and clean area standards should be used in conjunction with each other to define and classify the different manufacturing environments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia entre un \"clean area\" y un \"controlled area\" seg\u00fan el documento?**\n   - **Respuesta:** Un \"clean area\" (cleanroom) es un espacio con control ambiental definido para minimizar la contaminaci\u00f3n particulada y microbiana, dise\u00f1ado para reducir la introducci\u00f3n y retenci\u00f3n de contaminantes. En cambio, un \"controlled area\" es un \u00e1rea dentro de la instalaci\u00f3n donde se definen, controlan y monitorean condiciones y procedimientos ambientales espec\u00edficos para prevenir la degradaci\u00f3n o la contaminaci\u00f3n cruzada del producto.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"commissioning\" y en qu\u00e9 etapa se lleva a cabo?**\n   - **Respuesta:** El \"commissioning\" es el proceso documentado de verificar que el equipo y los sistemas est\u00e1n instalados de acuerdo con las especificaciones, poner el equipo en servicio activo y verificar su correcto funcionamiento. Este proceso se lleva a cabo al final de la construcci\u00f3n del proyecto, pero antes de la validaci\u00f3n.\n\n3. **\u00bfQu\u00e9 son los \"critical quality attributes\" (CQA) y por qu\u00e9 son importantes en la producci\u00f3n?**\n   - **Respuesta:** Los \"critical quality attributes\" (CQA) son propiedades o caracter\u00edsticas f\u00edsicas, qu\u00edmicas, biol\u00f3gicas o microbiol\u00f3gicas que deben estar dentro de un l\u00edmite, rango o distribuci\u00f3n apropiados para asegurar la calidad deseada del producto. Son importantes porque afectan directamente la calidad del producto final y, por lo tanto, su seguridad y eficacia.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones clave relacionadas con la producci\u00f3n y el control de calidad en entornos regulados, como las \u00e1reas limpias y controladas, as\u00ed como procesos cr\u00edticos como el \"commissioning\". Se enfatiza la importancia de mantener condiciones ambientales espec\u00edficas para prevenir la contaminaci\u00f3n y asegurar que los atributos de calidad del producto se mantengan dentro de los l\u00edmites aceptables. Adem\u00e1s, se menciona la necesidad de utilizar est\u00e1ndares como ISO 14644-1 y GMP en conjunto para clasificar y definir los diferentes entornos de fabricaci\u00f3n.", "prev_section_summary": "La secci\u00f3n proporcionada es un glosario que define t\u00e9rminos t\u00e9cnicos relevantes para las directrices sobre calidad del aire y control ambiental en instalaciones. A continuaci\u00f3n se resumen los temas clave y entidades:\n\n### Temas Clave:\n1. **Criterios de Aceptaci\u00f3n**: Definiciones medibles que determinan si un resultado de prueba es aceptable.\n2. **L\u00edmites de Acci\u00f3n**: Umbrales que, al ser superados, requieren acciones espec\u00edficas e investigaciones.\n3. **Cambios de Aire por Hora (ACPH)**: Medida del volumen de aire suministrado a una habitaci\u00f3n en relaci\u00f3n con su volumen.\n4. **Unidad de Manejo de Aire (AHU)**: Equipos que acondicionan el aire y facilitan el movimiento del aire en una instalaci\u00f3n.\n5. **Airlock**: Espacio cerrado entre habitaciones de diferentes niveles de limpieza, dise\u00f1ado para controlar el flujo de aire y minimizar la contaminaci\u00f3n.\n6. **L\u00edmite de Alerta**: Umbral que, al ser superado, indica la necesidad de medidas correctivas para evitar alcanzar el l\u00edmite de acci\u00f3n.\n7. **Condici\u00f3n \"As-Built\"**: Estado en el que la instalaci\u00f3n est\u00e1 completa y funcional, pero sin equipos de producci\u00f3n ni personal presente.\n8. **Condici\u00f3n \"At-Rest\"**: Estado en el que la instalaci\u00f3n est\u00e1 operativa seg\u00fan lo acordado, pero sin personal presente.\n9. **Control de Cambios**: Sistema formal para revisar cambios propuestos que puedan afectar la validaci\u00f3n de procesos.\n\n### Entidades:\n- **PAL (Personnel Airlock)**: Airlock dise\u00f1ado para el paso de personas.\n- **MAL (Material Airlock)**: Airlock dise\u00f1ado para el paso de materiales.\n\nEste glosario es esencial para entender los par\u00e1metros cr\u00edticos en la operaci\u00f3n de sistemas de aire acondicionado y control de contaminaci\u00f3n, as\u00ed como los procedimientos de validaci\u00f3n y control de cambios en entornos regulados.", "excerpt_keywords": "Keywords: cleanroom, contamination, commissioning, critical quality attribute, controlled area"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5ac418bc-2647-4ea9-b129-59e534642a12", "node_type": "4", "metadata": {"page_label": "231", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n**clean area (cleanroom)**\u00b9  \nAn area (or room or zone) with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**closed system**  \nA system where the product or material is not exposed to the manufacturing environment.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**controlled area**  \nAn area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n\n**critical parameter or component**  \nA processing parameter (such as temperature or relative humidity) that affects the quality of a product, or a component that may have a direct impact on the quality of the product.\n\n**critical quality attribute (CQA)**  \nA physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.\n\n----\n\n\u00b9 Note: Clean area standards, such as ISO 14644-1, provide details on how to classify air cleanliness by means of particle concentrations, whereas the GMP standards provide a grading for air cleanliness in terms of the condition (at-rest or operational), the permissible microbial concentrations, as well as other factors such as gowning requirements. GMP and clean area standards should be used in conjunction with each other to define and classify the different manufacturing environments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "363376ef33af0911919a81b45b6a57733e780fd75b7ff5af14b8e38d0a3a8a0f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n**clean area (cleanroom)**\u00b9  \nAn area (or room or zone) with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**closed system**  \nA system where the product or material is not exposed to the manufacturing environment.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**controlled area**  \nAn area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n\n**critical parameter or component**  \nA processing parameter (such as temperature or relative humidity) that affects the quality of a product, or a component that may have a direct impact on the quality of the product.\n\n**critical quality attribute (CQA)**  \nA physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.\n\n----\n\n\u00b9 Note: Clean area standards, such as ISO 14644-1, provide details on how to classify air cleanliness by means of particle concentrations, whereas the GMP standards provide a grading for air cleanliness in terms of the condition (at-rest or operational), the permissible microbial concentrations, as well as other factors such as gowning requirements. GMP and clean area standards should be used in conjunction with each other to define and classify the different manufacturing environments.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2356, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1fbe2aec-c438-435c-bcfd-0118e979ddc8": {"__data__": {"id_": "1fbe2aec-c438-435c-bcfd-0118e979ddc8", "embedding": null, "metadata": {"page_label": "232", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# design qualification (DQ)\n\nDesign qualification is the documented check of planning documents and technical specifications for conformity of the design with the process, manufacturing, GMP and regulatory requirements.\n\n# direct impact system\n\nA system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.\n\n# exfiltration\n\nExfiltration is the egress of air from a controlled area to an external zone.\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# good engineering practice (GEP)\n\nEstablished engineering methods and standards that are applied throughout the project life-cycle to deliver appropriate, cost-effective solutions.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury to health or to the environment.\n\n# indirect impact system\n\nThis is a system that is not expected to have a direct impact on product quality, but typically will support a direct impact system. These systems are designed and commissioned according to GEP only.\n\n# infiltration\n\nInfiltration is the ingress of air from an external zone into a controlled area.\n\n# installation qualification (IQ)\n\nInstallation qualification is documented verification that the premises, HVAC system, supporting utilities and equipment have been built and installed in compliance with their approved design specification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 se entiende por \"sistema de impacto directo\" y c\u00f3mo se diferencia de un \"sistema de impacto indirecto\"?**\n   - **Respuesta:** Un \"sistema de impacto directo\" es aquel que se espera que tenga un impacto directo en la calidad del producto y se dise\u00f1a y comisiona de acuerdo con buenas pr\u00e1cticas de ingenier\u00eda (GEP), adem\u00e1s de estar sujeto a pr\u00e1cticas de calificaci\u00f3n. En contraste, un \"sistema de impacto indirecto\" no se espera que afecte directamente la calidad del producto, pero generalmente apoya a un sistema de impacto directo y se dise\u00f1a y comisiona solo seg\u00fan GEP.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de la \"calificaci\u00f3n de dise\u00f1o\" (DQ) en el contexto de la producci\u00f3n?**\n   - **Respuesta:** La \"calificaci\u00f3n de dise\u00f1o\" (DQ) es un proceso documentado que verifica que los documentos de planificaci\u00f3n y las especificaciones t\u00e9cnicas cumplen con los requisitos del dise\u00f1o en relaci\u00f3n con el proceso, la fabricaci\u00f3n, las buenas pr\u00e1cticas de manufactura (GMP) y los requisitos regulatorios.\n\n3. **\u00bfQu\u00e9 implica la \"calificaci\u00f3n de instalaci\u00f3n\" (IQ) y por qu\u00e9 es importante en la construcci\u00f3n de instalaciones controladas?**\n   - **Respuesta:** La \"calificaci\u00f3n de instalaci\u00f3n\" (IQ) implica la verificaci\u00f3n documentada de que las instalaciones, el sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), los servicios de apoyo y el equipo han sido construidos e instalados de acuerdo con las especificaciones de dise\u00f1o aprobadas. Es importante porque asegura que todos los componentes de la instalaci\u00f3n cumplen con los est\u00e1ndares requeridos para operar de manera segura y efectiva en un entorno controlado.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en t\u00e9rminos y definiciones clave relacionados con la producci\u00f3n en entornos controlados, especialmente en el \u00e1mbito de la calidad del producto y las buenas pr\u00e1cticas de ingenier\u00eda. Se abordan conceptos como la contaminaci\u00f3n cruzada, las condiciones de dise\u00f1o, la calificaci\u00f3n de dise\u00f1o e instalaci\u00f3n, y la diferencia entre sistemas de impacto directo e indirecto. Estos t\u00e9rminos son fundamentales para garantizar que los procesos de producci\u00f3n cumplan con los est\u00e1ndares de calidad y regulaciones necesarias para la seguridad y eficacia de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Definiciones de t\u00e9rminos clave**:\n   - **Clean Area (Cleanroom)**: Espacio con control ambiental para minimizar la contaminaci\u00f3n particulada y microbiana.\n   - **Closed System**: Sistema donde el producto no est\u00e1 expuesto al entorno de fabricaci\u00f3n.\n   - **Commissioning**: Proceso documentado para verificar la instalaci\u00f3n y funcionamiento adecuado de equipos y sistemas.\n   - **Containment**: Proceso o dispositivo que evita la fuga de productos o contaminantes a otras zonas.\n   - **Contamination**: Introducci\u00f3n no deseada de impurezas durante la producci\u00f3n o transporte.\n   - **Controlled Area**: \u00c1rea donde se controlan y monitorean condiciones ambientales espec\u00edficas para prevenir contaminaci\u00f3n.\n   - **Critical Parameter or Component**: Par\u00e1metro de procesamiento que afecta la calidad del producto.\n   - **Critical Quality Attribute (CQA)**: Propiedad que debe estar dentro de l\u00edmites adecuados para asegurar la calidad del producto.\n\n2. **Importancia de los est\u00e1ndares**:\n   - Se menciona la necesidad de utilizar est\u00e1ndares como **ISO 14644-1** y **GMP** en conjunto para clasificar y definir entornos de fabricaci\u00f3n, asegurando la calidad y seguridad del producto.\n\n3. **Enfoque en la calidad y control**:\n   - El documento enfatiza la importancia de mantener condiciones ambientales espec\u00edficas y de realizar procesos como el commissioning para asegurar que los atributos de calidad del producto se mantengan dentro de l\u00edmites aceptables.\n\n### Entidades:\n- **ISO 14644-1**: Est\u00e1ndar para clasificar la limpieza del aire.\n- **GMP (Good Manufacturing Practices)**: Buenas pr\u00e1cticas de manufactura que regulan la calidad en la producci\u00f3n. \n\nEste resumen destaca los conceptos fundamentales relacionados con la producci\u00f3n y control de calidad en entornos regulados, as\u00ed como la importancia de los est\u00e1ndares para garantizar la calidad del producto final.", "excerpt_keywords": "Keywords: cross-contamination, design qualification, good engineering practice, controlled area, installation qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "890be5fc-cea5-495f-b880-ffc6f70b7083", "node_type": "4", "metadata": {"page_label": "232", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# design qualification (DQ)\n\nDesign qualification is the documented check of planning documents and technical specifications for conformity of the design with the process, manufacturing, GMP and regulatory requirements.\n\n# direct impact system\n\nA system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.\n\n# exfiltration\n\nExfiltration is the egress of air from a controlled area to an external zone.\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# good engineering practice (GEP)\n\nEstablished engineering methods and standards that are applied throughout the project life-cycle to deliver appropriate, cost-effective solutions.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury to health or to the environment.\n\n# indirect impact system\n\nThis is a system that is not expected to have a direct impact on product quality, but typically will support a direct impact system. These systems are designed and commissioned according to GEP only.\n\n# infiltration\n\nInfiltration is the ingress of air from an external zone into a controlled area.\n\n# installation qualification (IQ)\n\nInstallation qualification is documented verification that the premises, HVAC system, supporting utilities and equipment have been built and installed in compliance with their approved design specification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b9a05ce10adf51dc83682cb1045f525cc2e7ae920431e5e0a3c96e9e314035e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# design qualification (DQ)\n\nDesign qualification is the documented check of planning documents and technical specifications for conformity of the design with the process, manufacturing, GMP and regulatory requirements.\n\n# direct impact system\n\nA system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.\n\n# exfiltration\n\nExfiltration is the egress of air from a controlled area to an external zone.\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# good engineering practice (GEP)\n\nEstablished engineering methods and standards that are applied throughout the project life-cycle to deliver appropriate, cost-effective solutions.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury to health or to the environment.\n\n# indirect impact system\n\nThis is a system that is not expected to have a direct impact on product quality, but typically will support a direct impact system. These systems are designed and commissioned according to GEP only.\n\n# infiltration\n\nInfiltration is the ingress of air from an external zone into a controlled area.\n\n# installation qualification (IQ)\n\nInstallation qualification is documented verification that the premises, HVAC system, supporting utilities and equipment have been built and installed in compliance with their approved design specification.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1986, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8da5f3cb-3b8b-473b-a41c-e4aec900272d": {"__data__": {"id_": "8da5f3cb-3b8b-473b-a41c-e4aec900272d", "embedding": null, "metadata": {"page_label": "233", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# no-impact system\nThis is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n\n# non-critical parameter or component\nA processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product.\n\n# normal operating range\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# operating limits\nThe minimum and/or maximum values that will ensure that product and safety requirements are met.\n\n# operating range\nOperating range is the range of validated critical parameters within which acceptable products can be manufactured.\n\n# operational condition\nThis condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n\n# operational qualification (OQ)\nOperational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.\n\n# oral solid dosage (OSD)\nUsually refers to an OSD plant that manufactures medicinal products such as tablets, capsules and powders to be taken orally.\n\n# pass-through-hatch (PTH) or pass box (PB)\nA cabinet with two or more doors for passing equipment or product, whilst maintaining the pressure cascade and segregation between two controlled zones. A passive PTH has no air supply or extract. A dynamic PTH has an air supply into the chamber.\n\n# performance qualification (PQ)\nPerformance qualification is the documented verification that the process and/or the total process related to the system performs as intended throughout all anticipated operating ranges.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 961, aborda conceptos clave relacionados con la calidad y el control en la producci\u00f3n de medicamentos, especialmente en plantas de dosificaci\u00f3n s\u00f3lida oral (OSD). Se definen t\u00e9rminos como \"sistema sin impacto\", \"par\u00e1metro no cr\u00edtico\", \"rango operativo\" y \"calificaci\u00f3n operativa\", que son esenciales para garantizar que los procesos de fabricaci\u00f3n cumplan con los est\u00e1ndares de calidad y seguridad. Adem\u00e1s, se discuten las condiciones operativas y la calificaci\u00f3n del rendimiento, que son fundamentales para validar que los equipos y procesos funcionen seg\u00fan lo previsto.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 criterios se utilizan para clasificar un sistema como \"sin impacto\" en la calidad del producto?**\n   - Esta pregunta busca entender los criterios espec\u00edficos que determinan que un sistema no afecte la calidad del producto, lo cual no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las diferencias clave entre una \"calificaci\u00f3n operativa\" (OQ) y una \"calificaci\u00f3n de rendimiento\" (PQ) en el contexto de la producci\u00f3n de medicamentos?**\n   - Esta pregunta se centra en las diferencias entre dos tipos de calificaciones que son cruciales para la validaci\u00f3n de procesos, proporcionando claridad sobre sus objetivos y procedimientos.\n\n3. **\u00bfC\u00f3mo se define el \"rango operativo\" y por qu\u00e9 es importante para la fabricaci\u00f3n de productos aceptables?**\n   - Esta pregunta busca una explicaci\u00f3n detallada sobre el concepto de rango operativo y su relevancia en el contexto de la producci\u00f3n de medicamentos, lo que puede no estar claramente expuesto en otras secciones del documento. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del contenido que podr\u00edan no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "El contenido de la secci\u00f3n aborda conceptos fundamentales relacionados con la producci\u00f3n en entornos controlados, especialmente en el contexto de la calidad del producto y las buenas pr\u00e1cticas de ingenier\u00eda. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave\n\n1. **Contaminaci\u00f3n Cruzada**: Se refiere a la contaminaci\u00f3n de materiales o productos durante el proceso de producci\u00f3n.\n  \n2. **Condiciones de Dise\u00f1o**: Rango o precisi\u00f3n de una variable controlada que gu\u00eda el dise\u00f1o de un sistema ingenieril.\n\n3. **Calificaci\u00f3n de Dise\u00f1o (DQ)**: Verificaci\u00f3n documentada de que los documentos de planificaci\u00f3n y especificaciones t\u00e9cnicas cumplen con los requisitos de dise\u00f1o, fabricaci\u00f3n, buenas pr\u00e1cticas de manufactura (GMP) y regulaciones.\n\n4. **Sistemas de Impacto Directo**: Sistemas que afectan directamente la calidad del producto, dise\u00f1ados y comisionados seg\u00fan buenas pr\u00e1cticas de ingenier\u00eda (GEP) y sujetos a calificaci\u00f3n.\n\n5. **Sistemas de Impacto Indirecto**: Sistemas que no afectan directamente la calidad del producto, pero que apoyan a los sistemas de impacto directo, dise\u00f1ados solo seg\u00fan GEP.\n\n6. **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Verificaci\u00f3n documentada de que las instalaciones y equipos cumplen con las especificaciones de dise\u00f1o aprobadas.\n\n7. **Exfiltraci\u00f3n e Infiltraci\u00f3n**: Procesos de salida y entrada de aire entre \u00e1reas controladas y zonas externas, respectivamente.\n\n8. **Instalaciones**: Entorno construido donde operan las instalaciones de \u00e1reas limpias y sus infraestructuras de soporte.\n\n9. **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**: M\u00e9todos y est\u00e1ndares de ingenier\u00eda establecidos aplicados a lo largo del ciclo de vida del proyecto.\n\n10. **Sustancias o Productos Peligrosos**: Productos que pueden representar un riesgo significativo para la salud o el medio ambiente.\n\n### Entidades\n\n- **Sistemas de Impacto Directo e Indirecto**\n- **Calificaci\u00f3n de Dise\u00f1o (DQ)**\n- **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**\n- **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**\n- **Contaminaci\u00f3n Cruzada**\n- **Exfiltraci\u00f3n e Infiltraci\u00f3n**\n- **Instalaciones Controladas**\n\nEste resumen destaca la importancia de estos conceptos en la garant\u00eda de calidad y cumplimiento normativo en la producci\u00f3n de productos en entornos controlados.", "excerpt_keywords": "Keywords: no-impact system, operational qualification, performance qualification, oral solid dosage, operating range"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "101cd49b-3261-46e2-9745-4a3639211afd", "node_type": "4", "metadata": {"page_label": "233", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# no-impact system\nThis is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n\n# non-critical parameter or component\nA processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product.\n\n# normal operating range\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# operating limits\nThe minimum and/or maximum values that will ensure that product and safety requirements are met.\n\n# operating range\nOperating range is the range of validated critical parameters within which acceptable products can be manufactured.\n\n# operational condition\nThis condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n\n# operational qualification (OQ)\nOperational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.\n\n# oral solid dosage (OSD)\nUsually refers to an OSD plant that manufactures medicinal products such as tablets, capsules and powders to be taken orally.\n\n# pass-through-hatch (PTH) or pass box (PB)\nA cabinet with two or more doors for passing equipment or product, whilst maintaining the pressure cascade and segregation between two controlled zones. A passive PTH has no air supply or extract. A dynamic PTH has an air supply into the chamber.\n\n# performance qualification (PQ)\nPerformance qualification is the documented verification that the process and/or the total process related to the system performs as intended throughout all anticipated operating ranges.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b6136bbda41f248b4e149f35c53c1faeb2876cd8b2690d0d110cbcb20271d203", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# no-impact system\nThis is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n\n# non-critical parameter or component\nA processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product.\n\n# normal operating range\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# operating limits\nThe minimum and/or maximum values that will ensure that product and safety requirements are met.\n\n# operating range\nOperating range is the range of validated critical parameters within which acceptable products can be manufactured.\n\n# operational condition\nThis condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n\n# operational qualification (OQ)\nOperational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.\n\n# oral solid dosage (OSD)\nUsually refers to an OSD plant that manufactures medicinal products such as tablets, capsules and powders to be taken orally.\n\n# pass-through-hatch (PTH) or pass box (PB)\nA cabinet with two or more doors for passing equipment or product, whilst maintaining the pressure cascade and segregation between two controlled zones. A passive PTH has no air supply or extract. A dynamic PTH has an air supply into the chamber.\n\n# performance qualification (PQ)\nPerformance qualification is the documented verification that the process and/or the total process related to the system performs as intended throughout all anticipated operating ranges.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1974, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aeba0ab0-52a8-4d5e-b7cf-3fd799f35fd7": {"__data__": {"id_": "aeba0ab0-52a8-4d5e-b7cf-3fd799f35fd7", "embedding": null, "metadata": {"page_label": "234", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# point extraction\n\nAir extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n\n# pressure cascade\n\nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\n# qualification\n\nQualification is the planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\n# quality critical process parameter (CPP)\n\nA process parameter which could have an impact on the critical quality attribute.\n\n# relative humidity\n\nThe ratio of the actual water vapour pressure of the air to the saturated water vapour pressure of the air at the same temperature expressed as a percentage. More simply put, it is the ratio of the mass of moisture in the air, relative to the mass at 100% moisture saturation, at a given temperature.\n\n# standard operating procedure (SOP)\n\nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n# turbulent flow\n\nTurbulent flow, or non-unidirectional airflow, is air distribution that is introduced into the controlled space and then mixes with room air by means of induction.\n\n# unidirectional airflow (UDAF)\n\nUnidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).\n\n# validation\n\nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda varios conceptos clave relacionados con la calidad del aire y los procesos de validaci\u00f3n en entornos controlados. Se definen t\u00e9rminos como extracci\u00f3n de aire, cascada de presi\u00f3n, calificaci\u00f3n, par\u00e1metros cr\u00edticos de calidad del proceso, humedad relativa, procedimientos operativos est\u00e1ndar, flujo turbulento y flujo unidireccional. Estos conceptos son fundamentales para garantizar que los procesos y equipos en entornos regulados funcionen de manera efectiva y cumplan con los est\u00e1ndares de calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la importancia de la ubicaci\u00f3n del punto de extracci\u00f3n de aire en la eliminaci\u00f3n de polvo y c\u00f3mo se relaciona con la calidad del aire en entornos controlados?**\n   - Esta pregunta se centra en el concepto de \"punto de extracci\u00f3n\" y su impacto en la calidad del aire, lo cual no se detalla ampliamente en otras fuentes.\n\n2. **\u00bfC\u00f3mo se determina un par\u00e1metro cr\u00edtico de calidad (CPP) y qu\u00e9 implicaciones tiene en el proceso de validaci\u00f3n de un sistema?**\n   - Esta pregunta busca profundizar en la relaci\u00f3n entre los CPP y la validaci\u00f3n, un aspecto que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias existen entre el flujo turbulento y el flujo unidireccional (UDAF) en t\u00e9rminos de su aplicaci\u00f3n en entornos controlados?**\n   - Esta pregunta invita a explorar las caracter\u00edsticas y aplicaciones espec\u00edficas de ambos tipos de flujo, lo que puede no estar ampliamente discutido en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otras referencias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema Sin Impacto (No-Impact System)**:\n   - Definici\u00f3n: Un sistema que no afecta la calidad del producto, dise\u00f1ado y comisionado seg\u00fan Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP).\n\n2. **Par\u00e1metro o Componente No Cr\u00edtico (Non-Critical Parameter or Component)**:\n   - Descripci\u00f3n: Par\u00e1metros o componentes cuyo funcionamiento tiene un impacto indirecto o nulo en la calidad del producto.\n\n3. **Rango Operativo Normal (Normal Operating Range)**:\n   - Definici\u00f3n: Valores aceptables seleccionados por el fabricante para un par\u00e1metro durante operaciones normales, dentro del rango operativo.\n\n4. **L\u00edmites Operativos (Operating Limits)**:\n   - Descripci\u00f3n: Valores m\u00ednimos y/o m\u00e1ximos que aseguran el cumplimiento de los requisitos de producto y seguridad.\n\n5. **Rango Operativo (Operating Range)**:\n   - Definici\u00f3n: Rango de par\u00e1metros cr\u00edticos validados dentro del cual se pueden fabricar productos aceptables.\n\n6. **Condici\u00f3n Operativa (Operational Condition)**:\n   - Descripci\u00f3n: Relacionada con pruebas de clasificaci\u00f3n de salas durante el proceso de producci\u00f3n normal, con equipos y personal en operaci\u00f3n.\n\n7. **Calificaci\u00f3n Operativa (Operational Qualification - OQ)**:\n   - Definici\u00f3n: Evidencia documental que verifica que el equipo opera seg\u00fan especificaciones de dise\u00f1o en su rango operativo normal.\n\n8. **Dosificaci\u00f3n S\u00f3lida Oral (Oral Solid Dosage - OSD)**:\n   - Descripci\u00f3n: Planta que fabrica productos medicinales como tabletas, c\u00e1psulas y polvos para administraci\u00f3n oral.\n\n9. **Cabina de Pasaje (Pass-Through Hatch - PTH) o Caja de Pasaje (Pass Box - PB)**:\n   - Definici\u00f3n: Mueble con dos o m\u00e1s puertas para pasar equipos o productos, manteniendo la segregaci\u00f3n entre zonas controladas.\n\n10. **Calificaci\u00f3n de Rendimiento (Performance Qualification - PQ)**:\n    - Descripci\u00f3n: Verificaci\u00f3n documentada de que el proceso relacionado con el sistema funciona como se espera en todos los rangos operativos anticipados.\n\n### Conclusi\u00f3n\nLa secci\u00f3n proporciona definiciones y descripciones de t\u00e9rminos clave relacionados con la calidad y control en la producci\u00f3n de medicamentos, enfatizando la importancia de los sistemas, par\u00e1metros y calificaciones en el proceso de fabricaci\u00f3n para asegurar la calidad y seguridad del producto.", "excerpt_keywords": "Keywords: air extraction, pressure cascade, qualification, quality critical process parameter, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e8de84f5-c3e2-4d92-b11a-28d545eb5a61", "node_type": "4", "metadata": {"page_label": "234", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# point extraction\n\nAir extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n\n# pressure cascade\n\nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\n# qualification\n\nQualification is the planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\n# quality critical process parameter (CPP)\n\nA process parameter which could have an impact on the critical quality attribute.\n\n# relative humidity\n\nThe ratio of the actual water vapour pressure of the air to the saturated water vapour pressure of the air at the same temperature expressed as a percentage. More simply put, it is the ratio of the mass of moisture in the air, relative to the mass at 100% moisture saturation, at a given temperature.\n\n# standard operating procedure (SOP)\n\nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n# turbulent flow\n\nTurbulent flow, or non-unidirectional airflow, is air distribution that is introduced into the controlled space and then mixes with room air by means of induction.\n\n# unidirectional airflow (UDAF)\n\nUnidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).\n\n# validation\n\nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "06dc38538813ad87dd8ce97dc6be01340b060620d372cae852ce94a915e6f7f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# point extraction\n\nAir extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n\n# pressure cascade\n\nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\n# qualification\n\nQualification is the planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\n# quality critical process parameter (CPP)\n\nA process parameter which could have an impact on the critical quality attribute.\n\n# relative humidity\n\nThe ratio of the actual water vapour pressure of the air to the saturated water vapour pressure of the air at the same temperature expressed as a percentage. More simply put, it is the ratio of the mass of moisture in the air, relative to the mass at 100% moisture saturation, at a given temperature.\n\n# standard operating procedure (SOP)\n\nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n# turbulent flow\n\nTurbulent flow, or non-unidirectional airflow, is air distribution that is introduced into the controlled space and then mixes with room air by means of induction.\n\n# unidirectional airflow (UDAF)\n\nUnidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).\n\n# validation\n\nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1933, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e356085d-3770-45ab-bfea-b8e38625f372": {"__data__": {"id_": "e356085d-3770-45ab-bfea-b8e38625f372", "embedding": null, "metadata": {"page_label": "235", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Protection\n\n## 4.1 Products and personnel\n\n4.1.1 Areas for the manufacture of pharmaceuticals, where pharmaceutical starting materials and products, utensils, primary packing materials and equipment are exposed to the environment, should be defined as \u201cclean areas\u201d, \u201cclean zones\u201d, \u201ccontrolled areas\u201d or \u201ccleanrooms\u201d.\n\n4.1.2 The achievement of a particular clean area condition depends on a number of criteria that should be addressed at the design and qualification stages. A suitable balance between the different criteria will be required in order to create an efficient clean area.\n\n4.1.3 Some of the basic criteria to be considered which affects room cleanliness should include:\n\n- building finishes and structure\n- air filtration\n- air change rate or flushing rate\n- room pressure\n- location of air terminals and directional airflow\n- temperature\n- relative humidity\n- material flow\n- personnel flow\n- gowning procedures\n- equipment movement\n- process being carried out (open or closed system)\n- outside air conditions\n- occupancy\n- type of product\n- cleaning standard operating procedures (SOPs).\n\n4.1.4 Air filtration and air change rates should be set to ensure that the defined clean area condition is attained.\n\n4.1.5 The air change rates should be determined by the manufacturer and designer, taking into account the various critical parameters using a risk-based approach with due consideration of capital and running costs and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de las \u00e1reas limpias en la fabricaci\u00f3n de productos farmac\u00e9uticos. Define las condiciones necesarias para mantener la limpieza en estas \u00e1reas, considerando diversos criterios como la estructura del edificio, la filtraci\u00f3n de aire, la presi\u00f3n de la sala, y los procedimientos de limpieza. Se enfatiza la necesidad de un enfoque basado en riesgos para determinar las tasas de cambio de aire y otros par\u00e1metros cr\u00edticos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios b\u00e1sicos que deben considerarse para mantener la limpieza en las \u00e1reas de fabricaci\u00f3n farmac\u00e9utica?**\n   - El contexto menciona criterios como acabados y estructura del edificio, filtraci\u00f3n de aire, tasa de cambio de aire, presi\u00f3n de la sala, y procedimientos de limpieza, entre otros.\n\n2. **\u00bfQu\u00e9 enfoque se sugiere para determinar las tasas de cambio de aire en las \u00e1reas limpias?**\n   - Se sugiere un enfoque basado en riesgos que considere par\u00e1metros cr\u00edticos, as\u00ed como los costos de capital y operativos.\n\n3. **\u00bfQu\u00e9 factores pueden influir en la condici\u00f3n de limpieza de un \u00e1rea controlada durante el dise\u00f1o y la calificaci\u00f3n?**\n   - Factores como el flujo de materiales y personal, las condiciones del aire exterior, la ocupaci\u00f3n, y el tipo de producto son mencionados como influyentes en la limpieza del \u00e1rea.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda conceptos fundamentales relacionados con la calidad del aire y los procesos de validaci\u00f3n en entornos controlados. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Extracci\u00f3n de Aire**:\n   - **Definici\u00f3n**: Proceso de eliminaci\u00f3n de polvo mediante un punto de extracci\u00f3n ubicado lo m\u00e1s cerca posible de la fuente de polvo.\n   - **Importancia**: Asegura la calidad del aire en entornos controlados.\n\n2. **Cascada de Presi\u00f3n**:\n   - **Definici\u00f3n**: Flujo de aire desde un \u00e1rea de mayor presi\u00f3n a otra de menor presi\u00f3n.\n   - **Aplicaci\u00f3n**: Utilizada para mantener condiciones controladas en espacios espec\u00edficos.\n\n3. **Calificaci\u00f3n**:\n   - **Definici\u00f3n**: Planificaci\u00f3n, ejecuci\u00f3n y registro de pruebas en equipos y sistemas para demostrar su funcionamiento adecuado dentro de un proceso validado.\n\n4. **Par\u00e1metro Cr\u00edtico de Calidad (CPP)**:\n   - **Definici\u00f3n**: Par\u00e1metro del proceso que puede impactar en la calidad cr\u00edtica del producto.\n   - **Relevancia**: Fundamental para la validaci\u00f3n de sistemas y procesos.\n\n5. **Humedad Relativa**:\n   - **Definici\u00f3n**: Relaci\u00f3n entre la presi\u00f3n de vapor de agua actual en el aire y la presi\u00f3n de vapor de saturaci\u00f3n a la misma temperatura, expresada como un porcentaje.\n\n6. **Procedimiento Operativo Est\u00e1ndar (SOP)**:\n   - **Definici\u00f3n**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones generales, no necesariamente espec\u00edficas de un producto.\n\n7. **Flujo Turbulento**:\n   - **Definici\u00f3n**: Distribuci\u00f3n de aire que se mezcla con el aire de la habitaci\u00f3n mediante inducci\u00f3n, caracterizada por un flujo no unidireccional.\n\n8. **Flujo Unidireccional (UDAF)**:\n   - **Definici\u00f3n**: Flujo de aire rectificado que mantiene una velocidad constante y l\u00edneas de corriente aproximadamente paralelas en una zona limpia.\n\n9. **Validaci\u00f3n**:\n   - **Definici\u00f3n**: Acto documentado de demostrar que un procedimiento, proceso, equipo o sistema produce los resultados esperados.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los procesos y equipos en entornos regulados funcionen de manera efectiva y cumplan con los est\u00e1ndares de calidad, lo que es crucial en industrias como la farmac\u00e9utica y la biotecnol\u00f3gica.", "excerpt_keywords": "Keywords: clean areas, air filtration, pharmaceutical manufacturing, risk-based approach, standard operating procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e10cb40c-d0a9-41a3-bdb7-15575210f16c", "node_type": "4", "metadata": {"page_label": "235", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Protection\n\n## 4.1 Products and personnel\n\n4.1.1 Areas for the manufacture of pharmaceuticals, where pharmaceutical starting materials and products, utensils, primary packing materials and equipment are exposed to the environment, should be defined as \u201cclean areas\u201d, \u201cclean zones\u201d, \u201ccontrolled areas\u201d or \u201ccleanrooms\u201d.\n\n4.1.2 The achievement of a particular clean area condition depends on a number of criteria that should be addressed at the design and qualification stages. A suitable balance between the different criteria will be required in order to create an efficient clean area.\n\n4.1.3 Some of the basic criteria to be considered which affects room cleanliness should include:\n\n- building finishes and structure\n- air filtration\n- air change rate or flushing rate\n- room pressure\n- location of air terminals and directional airflow\n- temperature\n- relative humidity\n- material flow\n- personnel flow\n- gowning procedures\n- equipment movement\n- process being carried out (open or closed system)\n- outside air conditions\n- occupancy\n- type of product\n- cleaning standard operating procedures (SOPs).\n\n4.1.4 Air filtration and air change rates should be set to ensure that the defined clean area condition is attained.\n\n4.1.5 The air change rates should be determined by the manufacturer and designer, taking into account the various critical parameters using a risk-based approach with due consideration of capital and running costs and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1ccf91116e666dc9b92550a3516b9c068aef0d3ccddf6a7312903955af06e0a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Protection\n\n## 4.1 Products and personnel\n\n4.1.1 Areas for the manufacture of pharmaceuticals, where pharmaceutical starting materials and products, utensils, primary packing materials and equipment are exposed to the environment, should be defined as \u201cclean areas\u201d, \u201cclean zones\u201d, \u201ccontrolled areas\u201d or \u201ccleanrooms\u201d.\n\n4.1.2 The achievement of a particular clean area condition depends on a number of criteria that should be addressed at the design and qualification stages. A suitable balance between the different criteria will be required in order to create an efficient clean area.\n\n4.1.3 Some of the basic criteria to be considered which affects room cleanliness should include:\n\n- building finishes and structure\n- air filtration\n- air change rate or flushing rate\n- room pressure\n- location of air terminals and directional airflow\n- temperature\n- relative humidity\n- material flow\n- personnel flow\n- gowning procedures\n- equipment movement\n- process being carried out (open or closed system)\n- outside air conditions\n- occupancy\n- type of product\n- cleaning standard operating procedures (SOPs).\n\n4.1.4 Air filtration and air change rates should be set to ensure that the defined clean area condition is attained.\n\n4.1.5 The air change rates should be determined by the manufacturer and designer, taking into account the various critical parameters using a risk-based approach with due consideration of capital and running costs and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1442, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9ef35ea5-48d4-4dfa-a5a4-afe5a77f4fa5": {"__data__": {"id_": "9ef35ea5-48d4-4dfa-a5a4-afe5a77f4fa5", "embedding": null, "metadata": {"page_label": "236", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.6 Air Change Rates\n\nAir change rates are normally determined by the following considerations (could normally vary between 6 and 20 air changes per hour):\n\n- Area condition required: whether a specific room cleanliness condition is in fact required and whether the room condition is rated for an \u201cat rest\u201d condition or an \u201coperational\u201d condition (air change rate should be selected on need rather than tradition)\n- The product characteristics (e.g. odours, hygroscopicity, etc)\n- The quality and filtration of the supply air\n- Particulates generated by the manufacturing process\n- Particulates generated by the operators\n- Configuration of the room and air supply and extract locations\n- Sufficient air to achieve containment effect and to clean up the area\n- Sufficient air to cope with the room heat load\n- Sufficient air to balance extract rates\n- Sufficient air to maintain the required room pressure.\n\n# 4.1.7 Cleanroom Classification\n\nIf a cleanroom classification is specified the manufacturer should state whether this is achieved under \u201cas-built\u201d (Figure 2), \u201cat-rest\u201d (Figure 3) or \u201coperational\u201d (Figure 4) conditions.\n\n# 4.1.8 Room Classification Tests in the \u201cAs-Built\u201d Condition\n\nRoom classification tests in the \u201cas-built\u201d condition should be carried out on the bare room, in the absence of any equipment or personnel.\n\n# 4.1.9 Room Classification Tests in the \u201cAt-Rest\u201d Condition\n\nRoom classification tests in the \u201cat-rest\u201d condition should be carried out with the equipment operating where relevant, but without any operators. Because of the amounts of dust usually generated in a solid dosage facility, the clean area classifications would be rated for the \u201cat-rest\u201d condition.\n\n# 4.1.10 Room Classification Tests in the \u201cOperational\u201d Condition\n\nRoom classification tests in the \u201coperational\u201d condition are normally carried out during the normal production process with equipment operating, and the normal number of personnel present in the room. Generally a room that is tested for an \u201coperational\u201d condition should be able to be cleaned up to the \u201cat-rest\u201d clean area classification after a short clean-up time. The clean-up time should be determined through validation and is generally of the order of 20 minutes.\n\n# 4.1.11 Protection from Contamination\n\nMaterials and products should be protected from contamination and cross-contamination during all stages of manufacture (see also section 4.5 for cross-contamination control).\n\n*Note: contaminants may result from inappropriate premises (e.g. poor design, layout or finishing), poor cleaning procedures, contaminants brought in by personnel, poor manufacturing process and a poor HVAC system.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda aspectos cr\u00edticos relacionados con las tasas de cambio de aire y la clasificaci\u00f3n de salas limpias en entornos de fabricaci\u00f3n. Se discuten las condiciones bajo las cuales se deben realizar las pruebas de clasificaci\u00f3n de salas limpias, incluyendo las condiciones \"as-built\", \"at-rest\" y \"operational\". Adem\u00e1s, se enfatiza la importancia de proteger los materiales y productos de la contaminaci\u00f3n durante todas las etapas de fabricaci\u00f3n, destacando factores que pueden contribuir a la contaminaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los factores que determinan la tasa de cambio de aire en una sala limpia?**\n   - La tasa de cambio de aire se determina por consideraciones como la condici\u00f3n del \u00e1rea requerida, las caracter\u00edsticas del producto, la calidad y filtraci\u00f3n del aire de suministro, los particulados generados por el proceso de fabricaci\u00f3n y los operadores, la configuraci\u00f3n de la sala, y la necesidad de mantener la presi\u00f3n y el equilibrio de extracci\u00f3n.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para que una sala limpia sea clasificada como \"operational\"?**\n   - Una sala limpia se clasifica como \"operational\" cuando se realizan pruebas durante el proceso de producci\u00f3n normal, con el equipo en funcionamiento y el n\u00famero habitual de personal presente. Adem\u00e1s, debe ser capaz de limpiarse hasta alcanzar la clasificaci\u00f3n de \"at-rest\" en un tiempo de limpieza validado, generalmente alrededor de 20 minutos.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para proteger los materiales y productos de la contaminaci\u00f3n durante la fabricaci\u00f3n?**\n   - Se deben implementar procedimientos adecuados de dise\u00f1o, limpieza y control de procesos, as\u00ed como asegurar que el sistema HVAC sea eficiente. Tambi\u00e9n es crucial controlar la entrada de contaminantes por parte del personal y mantener un ambiente de trabajo que minimice la generaci\u00f3n de polvo y otros contaminantes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **\u00c1reas Limpias**: Se definen como espacios en la fabricaci\u00f3n de productos farmac\u00e9uticos donde los materiales y productos est\u00e1n expuestos al medio ambiente. Estos espacios pueden ser denominados \"\u00e1reas limpias\", \"zonas limpias\", \"\u00e1reas controladas\" o \"salas limpias\".\n\n2. **Criterios para la Limpieza**: Se enumeran varios criterios que afectan la limpieza de las \u00e1reas, que incluyen:\n   - Acabados y estructura del edificio\n   - Filtraci\u00f3n de aire\n   - Tasa de cambio de aire\n   - Presi\u00f3n de la sala\n   - Ubicaci\u00f3n de terminales de aire y flujo de aire direccional\n   - Temperatura y humedad relativa\n   - Flujo de materiales y personal\n   - Procedimientos de vestimenta\n   - Movimiento de equipos\n   - Tipo de proceso (sistema abierto o cerrado)\n   - Condiciones del aire exterior\n   - Ocupaci\u00f3n y tipo de producto\n   - Procedimientos operativos est\u00e1ndar de limpieza (SOPs)\n\n3. **Filtraci\u00f3n de Aire y Tasas de Cambio**: Se establece que la filtraci\u00f3n de aire y las tasas de cambio deben ser configuradas para alcanzar las condiciones definidas de limpieza en el \u00e1rea.\n\n4. **Enfoque Basado en Riesgos**: Se sugiere que las tasas de cambio de aire sean determinadas por el fabricante y el dise\u00f1ador, considerando par\u00e1metros cr\u00edticos y utilizando un enfoque basado en riesgos, as\u00ed como los costos de capital y operativos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos Farmac\u00e9uticos**: Materias primas y productos que requieren condiciones de limpieza espec\u00edficas.\n- **\u00c1reas Limpias**: Espacios cr\u00edticos en la fabricaci\u00f3n farmac\u00e9utica.\n- **Criterios de Limpieza**: Factores que afectan la eficacia de las \u00e1reas limpias.\n\nEste resumen destaca la importancia de las \u00e1reas limpias en la industria farmac\u00e9utica y los criterios necesarios para mantener su eficacia y seguridad.", "excerpt_keywords": "Keywords: air change rates, cleanroom classification, contamination control, operational conditions, manufacturing processes"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97818a69-4b47-421d-9ec2-c6d036cccab0", "node_type": "4", "metadata": {"page_label": "236", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.6 Air Change Rates\n\nAir change rates are normally determined by the following considerations (could normally vary between 6 and 20 air changes per hour):\n\n- Area condition required: whether a specific room cleanliness condition is in fact required and whether the room condition is rated for an \u201cat rest\u201d condition or an \u201coperational\u201d condition (air change rate should be selected on need rather than tradition)\n- The product characteristics (e.g. odours, hygroscopicity, etc)\n- The quality and filtration of the supply air\n- Particulates generated by the manufacturing process\n- Particulates generated by the operators\n- Configuration of the room and air supply and extract locations\n- Sufficient air to achieve containment effect and to clean up the area\n- Sufficient air to cope with the room heat load\n- Sufficient air to balance extract rates\n- Sufficient air to maintain the required room pressure.\n\n# 4.1.7 Cleanroom Classification\n\nIf a cleanroom classification is specified the manufacturer should state whether this is achieved under \u201cas-built\u201d (Figure 2), \u201cat-rest\u201d (Figure 3) or \u201coperational\u201d (Figure 4) conditions.\n\n# 4.1.8 Room Classification Tests in the \u201cAs-Built\u201d Condition\n\nRoom classification tests in the \u201cas-built\u201d condition should be carried out on the bare room, in the absence of any equipment or personnel.\n\n# 4.1.9 Room Classification Tests in the \u201cAt-Rest\u201d Condition\n\nRoom classification tests in the \u201cat-rest\u201d condition should be carried out with the equipment operating where relevant, but without any operators. Because of the amounts of dust usually generated in a solid dosage facility, the clean area classifications would be rated for the \u201cat-rest\u201d condition.\n\n# 4.1.10 Room Classification Tests in the \u201cOperational\u201d Condition\n\nRoom classification tests in the \u201coperational\u201d condition are normally carried out during the normal production process with equipment operating, and the normal number of personnel present in the room. Generally a room that is tested for an \u201coperational\u201d condition should be able to be cleaned up to the \u201cat-rest\u201d clean area classification after a short clean-up time. The clean-up time should be determined through validation and is generally of the order of 20 minutes.\n\n# 4.1.11 Protection from Contamination\n\nMaterials and products should be protected from contamination and cross-contamination during all stages of manufacture (see also section 4.5 for cross-contamination control).\n\n*Note: contaminants may result from inappropriate premises (e.g. poor design, layout or finishing), poor cleaning procedures, contaminants brought in by personnel, poor manufacturing process and a poor HVAC system.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a5180842cf13db4a072adb391f5dc2c0555d85799c724a08e810bba5b1d7d76b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.1.6 Air Change Rates\n\nAir change rates are normally determined by the following considerations (could normally vary between 6 and 20 air changes per hour):\n\n- Area condition required: whether a specific room cleanliness condition is in fact required and whether the room condition is rated for an \u201cat rest\u201d condition or an \u201coperational\u201d condition (air change rate should be selected on need rather than tradition)\n- The product characteristics (e.g. odours, hygroscopicity, etc)\n- The quality and filtration of the supply air\n- Particulates generated by the manufacturing process\n- Particulates generated by the operators\n- Configuration of the room and air supply and extract locations\n- Sufficient air to achieve containment effect and to clean up the area\n- Sufficient air to cope with the room heat load\n- Sufficient air to balance extract rates\n- Sufficient air to maintain the required room pressure.\n\n# 4.1.7 Cleanroom Classification\n\nIf a cleanroom classification is specified the manufacturer should state whether this is achieved under \u201cas-built\u201d (Figure 2), \u201cat-rest\u201d (Figure 3) or \u201coperational\u201d (Figure 4) conditions.\n\n# 4.1.8 Room Classification Tests in the \u201cAs-Built\u201d Condition\n\nRoom classification tests in the \u201cas-built\u201d condition should be carried out on the bare room, in the absence of any equipment or personnel.\n\n# 4.1.9 Room Classification Tests in the \u201cAt-Rest\u201d Condition\n\nRoom classification tests in the \u201cat-rest\u201d condition should be carried out with the equipment operating where relevant, but without any operators. Because of the amounts of dust usually generated in a solid dosage facility, the clean area classifications would be rated for the \u201cat-rest\u201d condition.\n\n# 4.1.10 Room Classification Tests in the \u201cOperational\u201d Condition\n\nRoom classification tests in the \u201coperational\u201d condition are normally carried out during the normal production process with equipment operating, and the normal number of personnel present in the room. Generally a room that is tested for an \u201coperational\u201d condition should be able to be cleaned up to the \u201cat-rest\u201d clean area classification after a short clean-up time. The clean-up time should be determined through validation and is generally of the order of 20 minutes.\n\n# 4.1.11 Protection from Contamination\n\nMaterials and products should be protected from contamination and cross-contamination during all stages of manufacture (see also section 4.5 for cross-contamination control).\n\n*Note: contaminants may result from inappropriate premises (e.g. poor design, layout or finishing), poor cleaning procedures, contaminants brought in by personnel, poor manufacturing process and a poor HVAC system.*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2671, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e8b9607b-e8f2-4a10-a672-3eee7306b2b7": {"__data__": {"id_": "e8b9607b-e8f2-4a10-a672-3eee7306b2b7", "embedding": null, "metadata": {"page_label": "237", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del contexto:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que probablemente contiene informaci\u00f3n t\u00e9cnica y recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre un tema espec\u00edfico relacionado con la salud p\u00fablica. Sin embargo, el contenido espec\u00edfico no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe T\u00e9cnico 961 sobre la salud p\u00fablica?**\n   - Esta pregunta busca obtener detalles sobre las directrices o recomendaciones espec\u00edficas que la OMS ha emitido en este informe, que podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en el documento \"WHO - Technical Report Series 961\"?**\n   - Esta pregunta se centra en identificar los temas o \u00e1reas de enfoque que se discuten en el informe, lo que podr\u00eda incluir enfermedades, tratamientos, pol\u00edticas de salud, etc.\n\n3. **\u00bfC\u00f3mo se estructura el contenido del \"WHO - Technical Report Series 961\" y qu\u00e9 secciones son m\u00e1s relevantes para los investigadores en salud p\u00fablica?**\n   - Esta pregunta busca entender la organizaci\u00f3n del documento y qu\u00e9 partes podr\u00edan ser m\u00e1s \u00fatiles para aquellos que investigan o trabajan en el campo de la salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otras fuentes, bas\u00e1ndose en el contexto del documento de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Tasas de Cambio de Aire**: Se discuten los factores que determinan las tasas de cambio de aire en salas limpias, que pueden variar entre 6 y 20 cambios de aire por hora. Estos factores incluyen la condici\u00f3n del \u00e1rea, las caracter\u00edsticas del producto, la calidad del aire de suministro, y la configuraci\u00f3n de la sala.\n\n2. **Clasificaci\u00f3n de Salas Limpias**: Se especifican las condiciones bajo las cuales se debe clasificar una sala limpia: \"as-built\", \"at-rest\" y \"operational\". Cada una de estas condiciones tiene requisitos espec\u00edficos para las pruebas de clasificaci\u00f3n.\n\n3. **Pruebas de Clasificaci\u00f3n**: Se describen los procedimientos para realizar pruebas de clasificaci\u00f3n en las diferentes condiciones. Las pruebas \"as-built\" se realizan en una sala vac\u00eda, las \"at-rest\" con el equipo en funcionamiento pero sin personal, y las \"operational\" durante el proceso de producci\u00f3n normal.\n\n4. **Protecci\u00f3n contra Contaminaci\u00f3n**: Se enfatiza la importancia de proteger los materiales y productos de la contaminaci\u00f3n en todas las etapas de fabricaci\u00f3n, mencionando factores que pueden contribuir a la contaminaci\u00f3n, como el dise\u00f1o inadecuado, procedimientos de limpieza deficientes y un sistema HVAC ineficiente.\n\n### Entidades\n\n- **Tasas de Cambio de Aire**: 6 a 20 cambios por hora.\n- **Condiciones de Clasificaci\u00f3n**: \"as-built\", \"at-rest\", \"operational\".\n- **Tiempo de Limpieza**: Generalmente alrededor de 20 minutos para alcanzar la clasificaci\u00f3n \"at-rest\".\n- **Factores de Contaminaci\u00f3n**: Dise\u00f1o de instalaciones, limpieza, entrada de contaminantes por personal, procesos de fabricaci\u00f3n, sistema HVAC.\n\nEste resumen destaca los aspectos fundamentales relacionados con la ventilaci\u00f3n y la clasificaci\u00f3n de salas limpias, as\u00ed como la necesidad de mantener un ambiente controlado para evitar la contaminaci\u00f3n durante la fabricaci\u00f3n.", "excerpt_keywords": "Keywords: salud p\u00fablica, OMS, salas limpias, clasificaci\u00f3n, contaminaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3531999e-5301-4cbf-b355-cc73b510a9e8", "node_type": "4", "metadata": {"page_label": "237", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "88f68d68-1985-4b74-8e80-1e661785585a": {"__data__": {"id_": "88f68d68-1985-4b74-8e80-1e661785585a", "embedding": null, "metadata": {"page_label": "238", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 4\n**\u201cOperational\u201d condition**\n\n4.1.12 Airborne contaminants should be controlled through effective ventilation and filtration.\n\n4.1.13 External contaminants should be removed by effective filtration of the supply air (see Figure 5 for an example of a shell-like building layout to enhance containment and protection from external contaminants).\n\n4.1.14 Internal contaminants should be controlled by dilution and flushing of contaminants in the room, or by displacement airflow (See Figures 6 and 7 for examples of methods for the flushing of airborne contaminants).\n\n4.1.15 Airborne particulates and the degree of filtration should be considered critical parameters with reference to the level of product protection required.\n\n4.1.16 Personnel should not be a source of contamination.\n\n4.1.17 The level of protection and air cleanliness for different areas should be determined according to the product being manufactured, the process being used and the product\u2019s susceptibility to degradation (Table 1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las condiciones operativas necesarias para controlar contaminantes en el aire en entornos de fabricaci\u00f3n. Se enfatiza la importancia de la ventilaci\u00f3n y filtraci\u00f3n efectivas para eliminar contaminantes externos e internos, as\u00ed como la necesidad de mantener la limpieza del aire y la protecci\u00f3n del producto. Tambi\u00e9n se menciona que el nivel de protecci\u00f3n debe adaptarse al tipo de producto y proceso, y que el personal no debe ser una fuente de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las estrategias recomendadas para controlar los contaminantes internos en un entorno de fabricaci\u00f3n?**\n   - Respuesta: Los contaminantes internos deben ser controlados mediante la diluci\u00f3n y el lavado de contaminantes en la habitaci\u00f3n, o mediante el uso de flujo de desplazamiento de aire.\n\n2. **\u00bfQu\u00e9 factores deben considerarse al determinar el nivel de protecci\u00f3n y limpieza del aire en diferentes \u00e1reas de producci\u00f3n?**\n   - Respuesta: El nivel de protecci\u00f3n y la limpieza del aire deben determinarse seg\u00fan el producto que se est\u00e1 fabricando, el proceso que se est\u00e1 utilizando y la susceptibilidad del producto a la degradaci\u00f3n.\n\n3. **\u00bfPor qu\u00e9 es importante que el personal no sea una fuente de contaminaci\u00f3n en el entorno de fabricaci\u00f3n?**\n   - Respuesta: Es crucial que el personal no sea una fuente de contaminaci\u00f3n para asegurar que la calidad del producto no se vea comprometida y se mantenga un ambiente controlado que minimice el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de la secci\u00f3n:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un documento de la Organizaci\u00f3n Mundial de la Salud (OMS) que probablemente aborda temas t\u00e9cnicos y recomendaciones relacionadas con la salud p\u00fablica. Sin embargo, no se incluye informaci\u00f3n espec\u00edfica sobre el contenido del informe, ya que se indica \"NO_CONTENT_HERE\".\n\n### Temas clave:\n- **Salud P\u00fablica**: El informe est\u00e1 relacionado con directrices y recomendaciones en este \u00e1mbito.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n\n### Entidades:\n- **WHO (OMS)**: Organizaci\u00f3n que emite el informe.\n- **Technical Report Series 961**: T\u00edtulo del documento espec\u00edfico que se est\u00e1 analizando.\n\n### Preguntas derivadas:\n1. Principales recomendaciones de la OMS en el informe.\n2. Temas espec\u00edficos abordados en el documento.\n3. Estructura del contenido y secciones relevantes para investigadores en salud p\u00fablica.\n\nEste resumen destaca la falta de contenido espec\u00edfico en la secci\u00f3n, pero proporciona un marco para entender el contexto y la relevancia del documento en el \u00e1mbito de la salud p\u00fablica.", "excerpt_keywords": "Keywords: airborne contaminants, ventilation, filtration, product protection, contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "60ff69b6-debd-4d10-aa26-99b08eb55620", "node_type": "4", "metadata": {"page_label": "238", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 4\n**\u201cOperational\u201d condition**\n\n4.1.12 Airborne contaminants should be controlled through effective ventilation and filtration.\n\n4.1.13 External contaminants should be removed by effective filtration of the supply air (see Figure 5 for an example of a shell-like building layout to enhance containment and protection from external contaminants).\n\n4.1.14 Internal contaminants should be controlled by dilution and flushing of contaminants in the room, or by displacement airflow (See Figures 6 and 7 for examples of methods for the flushing of airborne contaminants).\n\n4.1.15 Airborne particulates and the degree of filtration should be considered critical parameters with reference to the level of product protection required.\n\n4.1.16 Personnel should not be a source of contamination.\n\n4.1.17 The level of protection and air cleanliness for different areas should be determined according to the product being manufactured, the process being used and the product\u2019s susceptibility to degradation (Table 1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "eb9d654f690025685d6560fe25a2c565647293d1b129946db80a35c82a60f3ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 4\n**\u201cOperational\u201d condition**\n\n4.1.12 Airborne contaminants should be controlled through effective ventilation and filtration.\n\n4.1.13 External contaminants should be removed by effective filtration of the supply air (see Figure 5 for an example of a shell-like building layout to enhance containment and protection from external contaminants).\n\n4.1.14 Internal contaminants should be controlled by dilution and flushing of contaminants in the room, or by displacement airflow (See Figures 6 and 7 for examples of methods for the flushing of airborne contaminants).\n\n4.1.15 Airborne particulates and the degree of filtration should be considered critical parameters with reference to the level of product protection required.\n\n4.1.16 Personnel should not be a source of contamination.\n\n4.1.17 The level of protection and air cleanliness for different areas should be determined according to the product being manufactured, the process being used and the product\u2019s susceptibility to degradation (Table 1).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1013, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "730fa726-ef69-4ccc-9fa5-d7d92963bb90": {"__data__": {"id_": "730fa726-ef69-4ccc-9fa5-d7d92963bb90", "embedding": null, "metadata": {"page_label": "239", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Shell-like containment control concept\n\n!Shell-like containment control concept\n\n## 4.2 Air filtration\n\n*Note: The degree to which air is filtered plays an important role in the prevention of contamination and the control of cross-contamination.*\n\n### 4.2.1\n\nThe type of filters required for different applications depends on the quality of the ambient air and the return air (where applicable) and also on the air change rates. Table 2 gives the recommended filtration levels for different levels of protection in a pharmaceutical facility. Manufacturers should determine and prove the appropriate use of filters.\n\n### 4.2.2\n\nFilter classes should always be linked to the standard test method because referring to actual filter efficiencies can be very misleading (as different test methods each result in a different value for the same filter). (Referring to filter classifications such as an 85% filter or a 5 \u00b5m filter are not valid classifications and should not be used, as this can lead to the incorrect filter being installed. Only the EN 779 and EN 1822 classifications, as per the table below, should be used.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Importancia de la filtraci\u00f3n de aire en instalaciones farmac\u00e9uticas**: La filtraci\u00f3n de aire es crucial para prevenir la contaminaci\u00f3n y controlar la contaminaci\u00f3n cruzada en entornos farmac\u00e9uticos. La calidad del aire ambiental y el aire de retorno, as\u00ed como las tasas de renovaci\u00f3n del aire, son factores determinantes en la selecci\u00f3n de filtros adecuados.\n\n2. **Clasificaci\u00f3n de filtros y su relevancia**: Es esencial que las clases de filtros se vinculen a m\u00e9todos de prueba est\u00e1ndar, ya que las eficiencias de los filtros pueden variar seg\u00fan el m\u00e9todo utilizado. Las clasificaciones incorrectas pueden llevar a la instalaci\u00f3n de filtros inapropiados, lo que podr\u00eda comprometer la seguridad y la eficacia de las instalaciones.\n\n3. **Recomendaciones para fabricantes**: Los fabricantes de filtros deben determinar y demostrar el uso apropiado de los filtros en funci\u00f3n de las necesidades espec\u00edficas de cada aplicaci\u00f3n en instalaciones farmac\u00e9uticas, siguiendo las clasificaciones estandarizadas como EN 779 y EN 1822.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los factores que determinan el tipo de filtro necesario para una instalaci\u00f3n farmac\u00e9utica?**\n   - La selecci\u00f3n del filtro depende de la calidad del aire ambiental, la calidad del aire de retorno (si aplica) y las tasas de renovaci\u00f3n del aire.\n\n2. **\u00bfPor qu\u00e9 es importante utilizar clasificaciones de filtros estandarizadas como EN 779 y EN 1822?**\n   - Estas clasificaciones son importantes porque proporcionan un m\u00e9todo de prueba est\u00e1ndar que asegura que las eficiencias de los filtros sean comparables y precisas, evitando confusiones que pueden surgir de clasificaciones no v\u00e1lidas.\n\n3. **\u00bfQu\u00e9 consecuencias puede tener la instalaci\u00f3n de un filtro incorrecto en una instalaci\u00f3n farmac\u00e9utica?**\n   - La instalaci\u00f3n de un filtro incorrecto puede llevar a una inadecuada filtraci\u00f3n del aire, lo que aumenta el riesgo de contaminaci\u00f3n y contaminaci\u00f3n cruzada, comprometiendo la seguridad y la calidad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Control de Contaminantes A\u00e9reos**:\n   - Se enfatiza la necesidad de controlar los contaminantes en el aire mediante ventilaci\u00f3n y filtraci\u00f3n efectivas.\n\n2. **Contaminantes Externos**:\n   - Se recomienda la filtraci\u00f3n efectiva del aire de suministro para eliminar contaminantes externos.\n\n3. **Contaminantes Internos**:\n   - Se sugiere el uso de diluci\u00f3n y lavado de contaminantes en el ambiente, as\u00ed como el flujo de desplazamiento de aire para su control.\n\n4. **Part\u00edculas A\u00e9reas**:\n   - Se considera cr\u00edtico el nivel de filtraci\u00f3n de part\u00edculas en relaci\u00f3n con la protecci\u00f3n del producto.\n\n5. **Personal y Contaminaci\u00f3n**:\n   - Se establece que el personal no debe ser una fuente de contaminaci\u00f3n para mantener la calidad del producto.\n\n6. **Determinaci\u00f3n del Nivel de Protecci\u00f3n**:\n   - El nivel de protecci\u00f3n y limpieza del aire debe adaptarse al tipo de producto, el proceso de fabricaci\u00f3n y la susceptibilidad del producto a la degradaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Contaminantes A\u00e9reos**: Elementos a controlar en el entorno de fabricaci\u00f3n.\n- **Ventilaci\u00f3n y Filtraci\u00f3n**: M\u00e9todos recomendados para el control de contaminantes.\n- **Productos Fabricados**: Sujeto a las condiciones de protecci\u00f3n y limpieza del aire.\n- **Personal**: Factor a considerar en la prevenci\u00f3n de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: air filtration, contamination control, pharmaceutical facilities, filter classifications, EN 779 EN 1822"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d49a497d-093b-46dc-ac75-15f52dc73552", "node_type": "4", "metadata": {"page_label": "239", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Shell-like containment control concept\n\n!Shell-like containment control concept\n\n## 4.2 Air filtration\n\n*Note: The degree to which air is filtered plays an important role in the prevention of contamination and the control of cross-contamination.*\n\n### 4.2.1\n\nThe type of filters required for different applications depends on the quality of the ambient air and the return air (where applicable) and also on the air change rates. Table 2 gives the recommended filtration levels for different levels of protection in a pharmaceutical facility. Manufacturers should determine and prove the appropriate use of filters.\n\n### 4.2.2\n\nFilter classes should always be linked to the standard test method because referring to actual filter efficiencies can be very misleading (as different test methods each result in a different value for the same filter). (Referring to filter classifications such as an 85% filter or a 5 \u00b5m filter are not valid classifications and should not be used, as this can lead to the incorrect filter being installed. Only the EN 779 and EN 1822 classifications, as per the table below, should be used.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "681c2a19e976b55a2d00560b0bc7cb6cbbc5836fb4f028ed237d26bc2f1083ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Shell-like containment control concept\n\n!Shell-like containment control concept\n\n## 4.2 Air filtration\n\n*Note: The degree to which air is filtered plays an important role in the prevention of contamination and the control of cross-contamination.*\n\n### 4.2.1\n\nThe type of filters required for different applications depends on the quality of the ambient air and the return air (where applicable) and also on the air change rates. Table 2 gives the recommended filtration levels for different levels of protection in a pharmaceutical facility. Manufacturers should determine and prove the appropriate use of filters.\n\n### 4.2.2\n\nFilter classes should always be linked to the standard test method because referring to actual filter efficiencies can be very misleading (as different test methods each result in a different value for the same filter). (Referring to filter classifications such as an 85% filter or a 5 \u00b5m filter are not valid classifications and should not be used, as this can lead to the incorrect filter being installed. Only the EN 779 and EN 1822 classifications, as per the table below, should be used.)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1122, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ca4c1f6f-ef3f-4e3f-8460-deb7a3a0ac9f": {"__data__": {"id_": "ca4c1f6f-ef3f-4e3f-8460-deb7a3a0ac9f", "embedding": null, "metadata": {"page_label": "240", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 6  \n**Turbulent dilution of dirty air**\n\n!Turbulent dilution of dirty air\n\nLow-level extract is ideal for dust suppression purposes, but is not essential. (Low-level extract is essential for Grade A, B & C areas.)\n\n# Figure 7  \n**Unidirectional displacement of dirty air**\n\n!Unidirectional displacement of dirty air", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que incluye figuras relacionadas con la ventilaci\u00f3n y el control de la calidad del aire en entornos espec\u00edficos. En particular, se mencionan dos tipos de m\u00e9todos de ventilaci\u00f3n: la diluci\u00f3n turbulenta del aire sucio y el desplazamiento unidireccional del aire sucio. Se destaca que el extracto de bajo nivel es ideal para la supresi\u00f3n de polvo, aunque no es esencial, mientras que es esencial para \u00e1reas de Grado A, B y C.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las diferencias clave entre la diluci\u00f3n turbulenta y el desplazamiento unidireccional del aire en t\u00e9rminos de eficacia para el control de la calidad del aire?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre los dos m\u00e9todos mencionados, que no se aborda expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para clasificar las \u00e1reas como Grado A, B y C en relaci\u00f3n con la necesidad de extracto de bajo nivel?**\n   - La pregunta se centra en los criterios de clasificaci\u00f3n que determinan la necesidad de un sistema de ventilaci\u00f3n espec\u00edfico, lo cual no se detalla en el contexto proporcionado.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la falta de extracto de bajo nivel en \u00e1reas que no son de Grado A, B o C en t\u00e9rminos de salud y seguridad?**\n   - Esta pregunta explora las posibles consecuencias de no contar con un sistema de ventilaci\u00f3n adecuado en \u00e1reas que no requieren extracto de bajo nivel, lo que podr\u00eda no estar expl\u00edcitamente mencionado en el documento.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n1. **Filtraci\u00f3n de aire en instalaciones farmac\u00e9uticas**:\n   - La filtraci\u00f3n de aire es fundamental para prevenir la contaminaci\u00f3n y controlar la contaminaci\u00f3n cruzada en entornos farmac\u00e9uticos.\n\n2. **Factores determinantes para la selecci\u00f3n de filtros**:\n   - La elecci\u00f3n del tipo de filtro depende de:\n     - Calidad del aire ambiental.\n     - Calidad del aire de retorno (si aplica).\n     - Tasas de renovaci\u00f3n del aire.\n\n3. **Clasificaci\u00f3n de filtros**:\n   - Es crucial vincular las clases de filtros a m\u00e9todos de prueba est\u00e1ndar para evitar confusiones.\n   - Clasificaciones como \"filtro del 85%\" o \"filtro de 5 \u00b5m\" son consideradas inv\u00e1lidas.\n   - Se deben utilizar las clasificaciones estandarizadas **EN 779** y **EN 1822**.\n\n4. **Recomendaciones para fabricantes**:\n   - Los fabricantes deben determinar y demostrar el uso adecuado de los filtros seg\u00fan las necesidades espec\u00edficas de cada aplicaci\u00f3n en instalaciones farmac\u00e9uticas.\n\n5. **Consecuencias de la instalaci\u00f3n incorrecta de filtros**:\n   - La instalaci\u00f3n de un filtro inapropiado puede resultar en una filtraci\u00f3n inadecuada, aumentando el riesgo de contaminaci\u00f3n y comprometiendo la seguridad y calidad de los productos farmac\u00e9uticos.\n\n### Entidades clave:\n- **Filtraci\u00f3n de aire**\n- **Contaminaci\u00f3n**\n- **Contaminaci\u00f3n cruzada**\n- **Filtros**\n- **Calidad del aire**\n- **Tasas de renovaci\u00f3n del aire**\n- **Clasificaciones de filtros**: EN 779, EN 1822\n- **Fabricantes de filtros**", "excerpt_keywords": "Keywords: ventilation, air quality, dust suppression, WHO report, pharmaceutical facilities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fcdb506d-6edd-4cf9-bfb3-5f1fba46da33", "node_type": "4", "metadata": {"page_label": "240", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 6  \n**Turbulent dilution of dirty air**\n\n!Turbulent dilution of dirty air\n\nLow-level extract is ideal for dust suppression purposes, but is not essential. (Low-level extract is essential for Grade A, B & C areas.)\n\n# Figure 7  \n**Unidirectional displacement of dirty air**\n\n!Unidirectional displacement of dirty air", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "28b74f6362784321e682dd75ff71cbebb0e9ce40a181d139f8b09dfb7228d5f0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 6  \n**Turbulent dilution of dirty air**\n\n!Turbulent dilution of dirty air\n\nLow-level extract is ideal for dust suppression purposes, but is not essential. (Low-level extract is essential for Grade A, B & C areas.)\n\n# Figure 7  \n**Unidirectional displacement of dirty air**\n\n!Unidirectional displacement of dirty air", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 324, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "98974cca-b28a-425c-af36-34c528d645d8": {"__data__": {"id_": "98974cca-b28a-425c-af36-34c528d645d8", "embedding": null, "metadata": {"page_label": "241", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Table 1\n**Examples of levels of protection (based on ISPE oral solid dosage (OSD) Guideline criteria)**\n\n| Level   | Condition | Example of area                                                                                                                                                                                                 |\n|---------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 | General   | Area with normal housekeeping and maintenance where there is no potential for product contamination, e.g. warehousing.                                                                                          |\n| Level 2 | Protected | Area in which steps are taken to protect the pharmaceutical starting material or product from direct or indirect contamination or degradation, e.g. secondary packing, warehousing, first stage change rooms. |\n| Level 3 | Controlled| Area in which specific environmental conditions are defined, controlled and monitored to prevent contamination or degradation of the pharmaceutical starting material or product, e.g. where product, starting materials and components are exposed to the room environment; plus equipment wash and storage areas for equipment product contact parts. |\n\n# Table 2\n**Levels of protection and recommended filtration**\n\n| Level of protection | Recommended filtration                                                                                                                                                                                                 |\n|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1             | Primary filters only (e.g. EN 779 G4 filters)                                                                                                                                                                          |\n| Level 2             | Protected areas operating on 100% outside air: primary plus secondary filters (e.g. EN 779 G4 plus F8 or F9 filters)                                                                                                   |\n| Level 3             | Production facility operating on recirculated plus ambient air, where potential for cross-contamination exists: Primary plus secondary plus tertiary filters (e.g. EN 779 G4 plus F8 plus EN 1822 H13 filters) (for full fresh air system, without recirculation, G4 and F8 or F9 filters are acceptable) |\n\n**Note:** The filter classifications referred to above relate to the EN 1822 and EN 779 test standards (EN 779 relates to filter classes G1 to F9 and EN 1822 relates to filter classes E10 to U17). Refer to Figure 8 for comparative classifications of other filter standards.\n\n4.2.3 In selecting filters, the manufacturer should have considered other factors, such as particularly contaminated ambient conditions, local regulations and specific product requirements. Good pre-filtration extends the life of the more expensive filters downstream.\n\n4.2.4 Materials for components of an HVAC system should be selected with care so that they do not become a source of contamination. Any component with the potential for liberating particulate or microbial contamination into the air stream should be located upstream of the final filters.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se recomiendan para un \u00e1rea de protecci\u00f3n de Nivel 2 que opera con aire 100% exterior?**\n   - **Respuesta:** Para un \u00e1rea de protecci\u00f3n de Nivel 2 que opera con aire 100% exterior, se recomiendan filtros primarios m\u00e1s filtros secundarios, espec\u00edficamente filtros de clase EN 779 G4 m\u00e1s filtros de clase F8 o F9.\n\n2. **\u00bfCu\u00e1les son las consideraciones que un fabricante debe tener en cuenta al seleccionar filtros para un sistema HVAC?**\n   - **Respuesta:** Al seleccionar filtros, el fabricante debe considerar factores como las condiciones ambientales particularmente contaminadas, las regulaciones locales y los requisitos espec\u00edficos del producto. Adem\u00e1s, una buena pre-filtraci\u00f3n puede extender la vida \u00fatil de los filtros m\u00e1s costosos que se encuentran aguas abajo.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas definen un \u00e1rea de protecci\u00f3n de Nivel 3 seg\u00fan las pautas de ISPE?**\n   - **Respuesta:** Un \u00e1rea de protecci\u00f3n de Nivel 3 se define como aquella en la que se establecen, controlan y monitorean condiciones ambientales espec\u00edficas para prevenir la contaminaci\u00f3n o degradaci\u00f3n del material o producto farmac\u00e9utico. Esto incluye \u00e1reas donde los productos, materiales de partida y componentes est\u00e1n expuestos al ambiente de la sala, as\u00ed como \u00e1reas de lavado y almacenamiento de equipos que tienen contacto con el producto.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre los niveles de protecci\u00f3n en entornos de fabricaci\u00f3n farmac\u00e9utica, espec\u00edficamente en relaci\u00f3n con la contaminaci\u00f3n de productos. Se describen tres niveles de protecci\u00f3n, cada uno con ejemplos de \u00e1reas y condiciones espec\u00edficas. Adem\u00e1s, se detallan las recomendaciones de filtraci\u00f3n para cada nivel, basadas en est\u00e1ndares de filtraci\u00f3n europeos. Tambi\u00e9n se enfatiza la importancia de seleccionar cuidadosamente los materiales de los componentes de los sistemas HVAC para evitar la contaminaci\u00f3n.\n\n### Preguntas adicionales basadas en el resumen:\n1. **\u00bfQu\u00e9 ejemplos de \u00e1reas se consideran para cada nivel de protecci\u00f3n en la fabricaci\u00f3n farmac\u00e9utica?**\n2. **\u00bfC\u00f3mo se relacionan las clasificaciones de filtros EN 1822 y EN 779 con los niveles de protecci\u00f3n?**\n3. **\u00bfPor qu\u00e9 es importante la selecci\u00f3n cuidadosa de materiales en un sistema HVAC en entornos farmac\u00e9uticos?**", "prev_section_summary": "La secci\u00f3n del documento de la OMS se centra en m\u00e9todos de ventilaci\u00f3n y control de la calidad del aire, destacando dos enfoques principales: la diluci\u00f3n turbulenta del aire sucio y el desplazamiento unidireccional del aire sucio. Se menciona que el extracto de bajo nivel es ideal para la supresi\u00f3n de polvo, aunque no es esencial en todos los contextos, siendo su uso obligatorio en \u00e1reas clasificadas como Grado A, B y C. \n\n### Temas clave:\n1. **M\u00e9todos de ventilaci\u00f3n**:\n   - Diluci\u00f3n turbulenta del aire sucio.\n   - Desplazamiento unidireccional del aire sucio.\n\n2. **Importancia del extracto de bajo nivel**:\n   - Ideal para la supresi\u00f3n de polvo.\n   - Esencial para \u00e1reas de Grado A, B y C.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Grados de \u00e1reas**: Clasificaci\u00f3n que determina la necesidad de sistemas de ventilaci\u00f3n espec\u00edficos (Grado A, B y C). \n\nEste resumen proporciona una visi\u00f3n general de los conceptos tratados en la secci\u00f3n, as\u00ed como de las entidades relevantes.", "excerpt_keywords": "Keywords: protection levels, pharmaceutical manufacturing, air filtration, HVAC systems, contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3690a798-f7c6-4544-a17c-60ba973af53d", "node_type": "4", "metadata": {"page_label": "241", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Table 1\n**Examples of levels of protection (based on ISPE oral solid dosage (OSD) Guideline criteria)**\n\n| Level   | Condition | Example of area                                                                                                                                                                                                 |\n|---------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 | General   | Area with normal housekeeping and maintenance where there is no potential for product contamination, e.g. warehousing.                                                                                          |\n| Level 2 | Protected | Area in which steps are taken to protect the pharmaceutical starting material or product from direct or indirect contamination or degradation, e.g. secondary packing, warehousing, first stage change rooms. |\n| Level 3 | Controlled| Area in which specific environmental conditions are defined, controlled and monitored to prevent contamination or degradation of the pharmaceutical starting material or product, e.g. where product, starting materials and components are exposed to the room environment; plus equipment wash and storage areas for equipment product contact parts. |\n\n# Table 2\n**Levels of protection and recommended filtration**\n\n| Level of protection | Recommended filtration                                                                                                                                                                                                 |\n|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1             | Primary filters only (e.g. EN 779 G4 filters)                                                                                                                                                                          |\n| Level 2             | Protected areas operating on 100% outside air: primary plus secondary filters (e.g. EN 779 G4 plus F8 or F9 filters)                                                                                                   |\n| Level 3             | Production facility operating on recirculated plus ambient air, where potential for cross-contamination exists: Primary plus secondary plus tertiary filters (e.g. EN 779 G4 plus F8 plus EN 1822 H13 filters) (for full fresh air system, without recirculation, G4 and F8 or F9 filters are acceptable) |\n\n**Note:** The filter classifications referred to above relate to the EN 1822 and EN 779 test standards (EN 779 relates to filter classes G1 to F9 and EN 1822 relates to filter classes E10 to U17). Refer to Figure 8 for comparative classifications of other filter standards.\n\n4.2.3 In selecting filters, the manufacturer should have considered other factors, such as particularly contaminated ambient conditions, local regulations and specific product requirements. Good pre-filtration extends the life of the more expensive filters downstream.\n\n4.2.4 Materials for components of an HVAC system should be selected with care so that they do not become a source of contamination. Any component with the potential for liberating particulate or microbial contamination into the air stream should be located upstream of the final filters.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6edf72e0b39366b6320bce5a85bafd28a40ab5f38e2f3a03e09dc5c7a2c31101", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Table 1\n**Examples of levels of protection (based on ISPE oral solid dosage (OSD) Guideline criteria)**\n\n| Level   | Condition | Example of area                                                                                                                                                                                                 |\n|---------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 | General   | Area with normal housekeeping and maintenance where there is no potential for product contamination, e.g. warehousing.                                                                                          |\n| Level 2 | Protected | Area in which steps are taken to protect the pharmaceutical starting material or product from direct or indirect contamination or degradation, e.g. secondary packing, warehousing, first stage change rooms. |\n| Level 3 | Controlled| Area in which specific environmental conditions are defined, controlled and monitored to prevent contamination or degradation of the pharmaceutical starting material or product, e.g. where product, starting materials and components are exposed to the room environment; plus equipment wash and storage areas for equipment product contact parts. |\n\n# Table 2\n**Levels of protection and recommended filtration**\n\n| Level of protection | Recommended filtration                                                                                                                                                                                                 |\n|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1             | Primary filters only (e.g. EN 779 G4 filters)                                                                                                                                                                          |\n| Level 2             | Protected areas operating on 100% outside air: primary plus secondary filters (e.g. EN 779 G4 plus F8 or F9 filters)                                                                                                   |\n| Level 3             | Production facility operating on recirculated plus ambient air, where potential for cross-contamination exists: Primary plus secondary plus tertiary filters (e.g. EN 779 G4 plus F8 plus EN 1822 H13 filters) (for full fresh air system, without recirculation, G4 and F8 or F9 filters are acceptable) |\n\n**Note:** The filter classifications referred to above relate to the EN 1822 and EN 779 test standards (EN 779 relates to filter classes G1 to F9 and EN 1822 relates to filter classes E10 to U17). Refer to Figure 8 for comparative classifications of other filter standards.\n\n4.2.3 In selecting filters, the manufacturer should have considered other factors, such as particularly contaminated ambient conditions, local regulations and specific product requirements. Good pre-filtration extends the life of the more expensive filters downstream.\n\n4.2.4 Materials for components of an HVAC system should be selected with care so that they do not become a source of contamination. Any component with the potential for liberating particulate or microbial contamination into the air stream should be located upstream of the final filters.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3596, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2589ffd6-17cd-432c-a386-a829e451fbe9": {"__data__": {"id_": "2589ffd6-17cd-432c-a386-a829e451fbe9", "embedding": null, "metadata": {"page_label": "242", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 8\n## Comparison of filter test standards\n\n| Eurovent 4/5 Rating (superseded)\\<br/>Average Arrestance A (%) | ASHRAE 52.2 Merv Rating\\<br/>Average Dust Spot Efficiency E (%) | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1 | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1\\<br/>EN 779 & EN 1822 | |\n| - | - | - | - | - |\n| EU 14 | Merv 18 | | | U17 |\n| EU 13 | Merv 17 | | | U16 |\n| EU 12 | Merv 16 | | | U15 |\n| EU 11 | Merv 15 | | | H14 |\n| EU 10 | Merv 14 | | | H13 |\n| EU 9 | Merv 13 | | | E12 |\n| EU 8 | Merv 12 | | | E11 |\n| EU 7 | Merv 11 | | | E10 |\n| EU 6 | Merv 10 | | | F9 |\n| EU 5 | Merv 9 | | | F8 |\n| EU 4 | Merv 8 | | | F7 |\n| EU 3 | Merv 7 | | | F6 |\n| EU 2 | Merv 6 | | | F5 |\n| EU 1 | Merv 5 | | | G4 |\n| | Merv 4 | | | G3 |\n| | Merv 3 | | | G2 |\n| | Merv 2 | | | G1 |\n| | Merv 1 | | | |\n\n\n<p>MPPS = Most Penetrating Particle Size</p>", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una figura que compara diferentes est\u00e1ndares de pruebas de filtros de aire. La tabla presenta las clasificaciones de Eurovent y ASHRAE, mostrando la relaci\u00f3n entre la eficiencia de los filtros y su capacidad de retenci\u00f3n de part\u00edculas. Se mencionan las clasificaciones de Eurovent 4/5, el Merv de ASHRAE y otros est\u00e1ndares relacionados, as\u00ed como la eficiencia de captura de polvo.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es la relaci\u00f3n entre la clasificaci\u00f3n Eurovent 4/5 y el Merv de ASHRAE en t\u00e9rminos de eficiencia de filtraci\u00f3n?**\n   - La tabla muestra c\u00f3mo las clasificaciones Eurovent 4/5 se correlacionan con las clasificaciones Merv de ASHRAE, indicando que a medida que aumenta la clasificaci\u00f3n Eurovent, tambi\u00e9n lo hace la clasificaci\u00f3n Merv.\n\n2. **\u00bfQu\u00e9 clasificaci\u00f3n Eurovent 4/5 corresponde a un Merv 18 y qu\u00e9 nivel de eficiencia de captura de polvo se asocia con esta clasificaci\u00f3n?**\n   - Seg\u00fan la tabla, la clasificaci\u00f3n Eurovent 4/5 EU 14 corresponde a un Merv 18, aunque no se proporciona un valor espec\u00edfico de eficiencia de captura de polvo en la tabla.\n\n3. **\u00bfQu\u00e9 significa MPPS en el contexto de la filtraci\u00f3n de aire y c\u00f3mo se relaciona con los est\u00e1ndares de filtraci\u00f3n mencionados?**\n   - MPPS significa \"Most Penetrating Particle Size\" (Tama\u00f1o de Part\u00edcula M\u00e1s Penetrante), y se refiere al tama\u00f1o de part\u00edcula que es m\u00e1s dif\u00edcil de capturar por los filtros. Este concepto es relevante para entender la eficacia de los filtros en diferentes clasificaciones y est\u00e1ndares.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Niveles de Protecci\u00f3n**:\n   - **Nivel 1 (General)**: \u00c1reas con mantenimiento normal sin potencial de contaminaci\u00f3n del producto (ej. almacenamiento).\n   - **Nivel 2 (Protegido)**: \u00c1reas protegidas contra contaminaci\u00f3n directa o indirecta (ej. empaquetado secundario, vestuarios).\n   - **Nivel 3 (Controlado)**: \u00c1reas con condiciones ambientales definidas y controladas para prevenir contaminaci\u00f3n (ej. \u00e1reas de lavado de equipos, almacenamiento de partes en contacto con el producto).\n\n2. **Filtraci\u00f3n Recomendada**:\n   - **Nivel 1**: Filtros primarios (ej. filtros EN 779 G4).\n   - **Nivel 2**: Filtros primarios m\u00e1s secundarios (ej. filtros EN 779 G4 m\u00e1s F8 o F9).\n   - **Nivel 3**: Filtros primarios, secundarios y terciarios (ej. filtros EN 779 G4, F8 y EN 1822 H13). Para sistemas de aire fresco sin recirculaci\u00f3n, se aceptan filtros G4 y F8 o F9.\n\n3. **Normativas de Filtraci\u00f3n**:\n   - Clasificaciones de filtros seg\u00fan est\u00e1ndares europeos EN 1822 (clases E10 a U17) y EN 779 (clases G1 a F9).\n\n4. **Consideraciones para Selecci\u00f3n de Filtros**:\n   - Factores a considerar incluyen condiciones ambientales contaminadas, regulaciones locales y requisitos espec\u00edficos del producto. La pre-filtraci\u00f3n adecuada extiende la vida \u00fatil de filtros m\u00e1s costosos.\n\n5. **Materiales de Sistemas HVAC**:\n   - Importancia de seleccionar materiales que no liberen contaminaci\u00f3n en el aire. Componentes que puedan liberar part\u00edculas o contaminaci\u00f3n microbiana deben estar ubicados antes de los filtros finales.\n\n### Entidades Clave:\n- **ISPE**: Organizaci\u00f3n que proporciona directrices sobre la fabricaci\u00f3n farmac\u00e9utica.\n- **Filtros**: Clasificados seg\u00fan est\u00e1ndares EN 1822 y EN 779.\n- **\u00c1reas de Protecci\u00f3n**: Clasificadas en niveles 1, 2 y 3, cada uno con ejemplos espec\u00edficos.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en entornos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la protecci\u00f3n y filtraci\u00f3n en la fabricaci\u00f3n farmac\u00e9utica, as\u00ed como las consideraciones necesarias para mantener la calidad del producto y la seguridad en el ambiente de trabajo.", "excerpt_keywords": "Keywords: filtraci\u00f3n, Eurovent, ASHRAE, est\u00e1ndares, eficiencia"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25268c96-b926-4075-9bf7-ee6789f0b550", "node_type": "4", "metadata": {"page_label": "242", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 8\n## Comparison of filter test standards\n\n| Eurovent 4/5 Rating (superseded)\\<br/>Average Arrestance A (%) | ASHRAE 52.2 Merv Rating\\<br/>Average Dust Spot Efficiency E (%) | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1 | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1\\<br/>EN 779 & EN 1822 | |\n| - | - | - | - | - |\n| EU 14 | Merv 18 | | | U17 |\n| EU 13 | Merv 17 | | | U16 |\n| EU 12 | Merv 16 | | | U15 |\n| EU 11 | Merv 15 | | | H14 |\n| EU 10 | Merv 14 | | | H13 |\n| EU 9 | Merv 13 | | | E12 |\n| EU 8 | Merv 12 | | | E11 |\n| EU 7 | Merv 11 | | | E10 |\n| EU 6 | Merv 10 | | | F9 |\n| EU 5 | Merv 9 | | | F8 |\n| EU 4 | Merv 8 | | | F7 |\n| EU 3 | Merv 7 | | | F6 |\n| EU 2 | Merv 6 | | | F5 |\n| EU 1 | Merv 5 | | | G4 |\n| | Merv 4 | | | G3 |\n| | Merv 3 | | | G2 |\n| | Merv 2 | | | G1 |\n| | Merv 1 | | | |\n\n\n<p>MPPS = Most Penetrating Particle Size</p>", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ec0dc64b1c1d5d8802a7de8d33acfe623181ef828e1bce7b2b8c6cd70aa88cdf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 8\n## Comparison of filter test standards\n\n| Eurovent 4/5 Rating (superseded)\\<br/>Average Arrestance A (%) | ASHRAE 52.2 Merv Rating\\<br/>Average Dust Spot Efficiency E (%) | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1 | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1\\<br/>EN 779 & EN 1822 | |\n| - | - | - | - | - |\n| EU 14 | Merv 18 | | | U17 |\n| EU 13 | Merv 17 | | | U16 |\n| EU 12 | Merv 16 | | | U15 |\n| EU 11 | Merv 15 | | | H14 |\n| EU 10 | Merv 14 | | | H13 |\n| EU 9 | Merv 13 | | | E12 |\n| EU 8 | Merv 12 | | | E11 |\n| EU 7 | Merv 11 | | | E10 |\n| EU 6 | Merv 10 | | | F9 |\n| EU 5 | Merv 9 | | | F8 |\n| EU 4 | Merv 8 | | | F7 |\n| EU 3 | Merv 7 | | | F6 |\n| EU 2 | Merv 6 | | | F5 |\n| EU 1 | Merv 5 | | | G4 |\n| | Merv 4 | | | G3 |\n| | Merv 3 | | | G2 |\n| | Merv 2 | | | G1 |\n| | Merv 1 | | | |\n\n\n<p>MPPS = Most Penetrating Particle Size</p>", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 843, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "15a3d6df-c9ab-4f17-acdd-abe6cb4ba82c": {"__data__": {"id_": "15a3d6df-c9ab-4f17-acdd-abe6cb4ba82c", "embedding": null, "metadata": {"page_label": "243", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2.5\n\nWhere possible ventilation dampers, filters and other services should be designed and positioned so that they are accessible from outside the manufacturing areas (service voids or service corridors) for maintenance purposes.\n\n# 4.2.6\n\nDirectional airflow within production or primary packing areas should assist in preventing contamination. Airflows should be planned in conjunction with operator locations, so as to minimize contamination of the product by the operator and also to protect the operator from dust inhalation.\n\n# 4.2.7\n\nHVAC air distribution components should be designed, installed and located to prevent contaminants generated within the room from being spread.\n\n# 4.2.8\n\nSupply air diffusers should be selected with care taking consideration of, e.g. room requirements and positions of equipment and operators in the room. Supply air diffusers of the high induction type (e.g. those typically used for office-type air-conditioning) should where possible not be used in clean areas where dust is liberated. Air diffusers should be of the non-induction type, introducing air with the least amount of induction so as to maximize the flushing effect. In rooms where the process results in high dust liberation; perforated plates or low induction swirl diffusers with low level extract or return should be used (to contain the dust at the lower level of the room) (see Figures 9\u201311 for illustrations of the three types of diffuser). In cases where dust liberation is low, ceiling return air grilles may be acceptable.\n\n# 4.2.9\n\nInduction and certain swirl diffusers induce room air vertically up to the diffuser to mix with the supply air. These diffusers create good dilution of contaminants in the room and may be used in rooms where there is low dust liberation. However, if used in rooms where excessive dust is generated, the distribution of dust in the room could be hazardous for the operators in the room.\n\n# 4.3 Unidirectional airflow\n\n## 4.3.1\n\nUnidirectional airflow (UDAF) should be used for weighing booths or sampling booths to provide operator and product protection and should also have a slight air in-flow from the room to enhance containment. Dust containment at the weigh booth should be demonstrated by smoke airflow pattern tests, or other appropriate tests. UDAF can also be used to provide protection of other dusty processes.\n\n## 4.3.2\n\nSampling of materials such as starting materials, primary packaging materials and products, should be carried out in the same environmental conditions that are required for the further processing of the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las mejores pr\u00e1cticas para el dise\u00f1o y la instalaci\u00f3n de sistemas de ventilaci\u00f3n y distribuci\u00f3n de aire en \u00e1reas de producci\u00f3n y empaque. Se enfatiza la importancia de la accesibilidad de los componentes de ventilaci\u00f3n para el mantenimiento, la planificaci\u00f3n del flujo de aire para minimizar la contaminaci\u00f3n, y la selecci\u00f3n adecuada de difusores de aire para controlar la liberaci\u00f3n de polvo. Adem\u00e1s, se menciona el uso de flujo de aire unidireccional en cabinas de pesaje y muestreo para proteger tanto a los operadores como a los productos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de difusores de aire se recomienda evitar en \u00e1reas limpias donde se libera polvo, y cu\u00e1l es la raz\u00f3n detr\u00e1s de esta recomendaci\u00f3n?**\n   - Se recomienda evitar los difusores de aire de alta inducci\u00f3n, t\u00edpicamente utilizados en sistemas de aire acondicionado de oficina, en \u00e1reas limpias donde se libera polvo, ya que pueden contribuir a la dispersi\u00f3n de contaminantes en el ambiente.\n\n2. **\u00bfC\u00f3mo se debe demostrar la contenci\u00f3n de polvo en una cabina de pesaje seg\u00fan el documento?**\n   - La contenci\u00f3n de polvo en una cabina de pesaje debe ser demostrada mediante pruebas de patrones de flujo de aire con humo u otras pruebas apropiadas que verifiquen la efectividad del flujo de aire unidireccional.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar difusores de aire en funci\u00f3n de la liberaci\u00f3n de polvo en una sala?**\n   - Al seleccionar difusores de aire, se debe considerar el nivel de liberaci\u00f3n de polvo en la sala. En \u00e1reas con alta liberaci\u00f3n de polvo, se deben usar placas perforadas o difusores de remolino de baja inducci\u00f3n con extracci\u00f3n o retorno a nivel bajo, mientras que en \u00e1reas con baja liberaci\u00f3n de polvo, pueden ser aceptables las rejillas de retorno de aire en el techo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en la comparaci\u00f3n de est\u00e1ndares de pruebas de filtros de aire, espec\u00edficamente entre las clasificaciones Eurovent 4/5 y el Merv de ASHRAE. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n1. **Clasificaciones de Filtros**:\n   - **Eurovent 4/5**: Un sistema de clasificaci\u00f3n que eval\u00faa la eficiencia de los filtros de aire en t\u00e9rminos de su capacidad de retenci\u00f3n de part\u00edculas.\n   - **ASHRAE 52.2 Merv**: Un sistema de clasificaci\u00f3n que mide la eficiencia de los filtros en la captura de polvo, donde \"Merv\" significa \"Minimum Efficiency Reporting Value\".\n\n2. **Relaci\u00f3n entre Clasificaciones**:\n   - La tabla muestra c\u00f3mo las clasificaciones Eurovent se correlacionan con las clasificaciones Merv, indicando que a mayor clasificaci\u00f3n Eurovent, mayor es la clasificaci\u00f3n Merv.\n\n3. **Eficiencia de Captura de Polvo**:\n   - La tabla incluye clasificaciones espec\u00edficas y su correspondiente eficiencia de captura de polvo, aunque no se proporcionan valores exactos en todos los casos.\n\n4. **MPPS (Most Penetrating Particle Size)**:\n   - Se define como el tama\u00f1o de part\u00edcula m\u00e1s dif\u00edcil de capturar por los filtros, un concepto importante para evaluar la eficacia de los filtros en diferentes clasificaciones.\n\n### Entidades Clave\n- **Eurovent 4/5**: Sistema de clasificaci\u00f3n de filtros.\n- **ASHRAE 52.2**: Est\u00e1ndar de eficiencia de filtros.\n- **Merv**: Valor de eficiencia m\u00ednima.\n- **MPPS**: Tama\u00f1o de part\u00edcula m\u00e1s penetrante.\n\nEste resumen destaca la importancia de los est\u00e1ndares de filtraci\u00f3n en la evaluaci\u00f3n de la eficacia de los filtros de aire y su relaci\u00f3n con la calidad del aire interior.", "excerpt_keywords": "Keywords: ventilation, airflow, contamination, dust control, unidirectional airflow"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c7314169-b847-4aed-910b-2dda789ef23f", "node_type": "4", "metadata": {"page_label": "243", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2.5\n\nWhere possible ventilation dampers, filters and other services should be designed and positioned so that they are accessible from outside the manufacturing areas (service voids or service corridors) for maintenance purposes.\n\n# 4.2.6\n\nDirectional airflow within production or primary packing areas should assist in preventing contamination. Airflows should be planned in conjunction with operator locations, so as to minimize contamination of the product by the operator and also to protect the operator from dust inhalation.\n\n# 4.2.7\n\nHVAC air distribution components should be designed, installed and located to prevent contaminants generated within the room from being spread.\n\n# 4.2.8\n\nSupply air diffusers should be selected with care taking consideration of, e.g. room requirements and positions of equipment and operators in the room. Supply air diffusers of the high induction type (e.g. those typically used for office-type air-conditioning) should where possible not be used in clean areas where dust is liberated. Air diffusers should be of the non-induction type, introducing air with the least amount of induction so as to maximize the flushing effect. In rooms where the process results in high dust liberation; perforated plates or low induction swirl diffusers with low level extract or return should be used (to contain the dust at the lower level of the room) (see Figures 9\u201311 for illustrations of the three types of diffuser). In cases where dust liberation is low, ceiling return air grilles may be acceptable.\n\n# 4.2.9\n\nInduction and certain swirl diffusers induce room air vertically up to the diffuser to mix with the supply air. These diffusers create good dilution of contaminants in the room and may be used in rooms where there is low dust liberation. However, if used in rooms where excessive dust is generated, the distribution of dust in the room could be hazardous for the operators in the room.\n\n# 4.3 Unidirectional airflow\n\n## 4.3.1\n\nUnidirectional airflow (UDAF) should be used for weighing booths or sampling booths to provide operator and product protection and should also have a slight air in-flow from the room to enhance containment. Dust containment at the weigh booth should be demonstrated by smoke airflow pattern tests, or other appropriate tests. UDAF can also be used to provide protection of other dusty processes.\n\n## 4.3.2\n\nSampling of materials such as starting materials, primary packaging materials and products, should be carried out in the same environmental conditions that are required for the further processing of the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d9a24796efec8e8d2ffea7aff827d48f9f603a81bb2aab5718aa4e3cba13b1d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.2.5\n\nWhere possible ventilation dampers, filters and other services should be designed and positioned so that they are accessible from outside the manufacturing areas (service voids or service corridors) for maintenance purposes.\n\n# 4.2.6\n\nDirectional airflow within production or primary packing areas should assist in preventing contamination. Airflows should be planned in conjunction with operator locations, so as to minimize contamination of the product by the operator and also to protect the operator from dust inhalation.\n\n# 4.2.7\n\nHVAC air distribution components should be designed, installed and located to prevent contaminants generated within the room from being spread.\n\n# 4.2.8\n\nSupply air diffusers should be selected with care taking consideration of, e.g. room requirements and positions of equipment and operators in the room. Supply air diffusers of the high induction type (e.g. those typically used for office-type air-conditioning) should where possible not be used in clean areas where dust is liberated. Air diffusers should be of the non-induction type, introducing air with the least amount of induction so as to maximize the flushing effect. In rooms where the process results in high dust liberation; perforated plates or low induction swirl diffusers with low level extract or return should be used (to contain the dust at the lower level of the room) (see Figures 9\u201311 for illustrations of the three types of diffuser). In cases where dust liberation is low, ceiling return air grilles may be acceptable.\n\n# 4.2.9\n\nInduction and certain swirl diffusers induce room air vertically up to the diffuser to mix with the supply air. These diffusers create good dilution of contaminants in the room and may be used in rooms where there is low dust liberation. However, if used in rooms where excessive dust is generated, the distribution of dust in the room could be hazardous for the operators in the room.\n\n# 4.3 Unidirectional airflow\n\n## 4.3.1\n\nUnidirectional airflow (UDAF) should be used for weighing booths or sampling booths to provide operator and product protection and should also have a slight air in-flow from the room to enhance containment. Dust containment at the weigh booth should be demonstrated by smoke airflow pattern tests, or other appropriate tests. UDAF can also be used to provide protection of other dusty processes.\n\n## 4.3.2\n\nSampling of materials such as starting materials, primary packaging materials and products, should be carried out in the same environmental conditions that are required for the further processing of the product.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2596, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "03f46bcd-d627-475f-b6f8-f2e3ebc1474d": {"__data__": {"id_": "03f46bcd-d627-475f-b6f8-f2e3ebc1474d", "embedding": null, "metadata": {"page_label": "244", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 9\n**Induction diffuser**\n\n!Induction diffuser\n\n*Enlarged View of Diffuser*\n\n----\n\n# Figure 10\n**Perforated plate diffuser**\n\n!Perforated plate diffuser\n\n*Enlarged Views of Diffusers*\n\n----\n\n232", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye figuras que ilustran diferentes tipos de difusores utilizados en aplicaciones t\u00e9cnicas. En particular, se presentan dos tipos de difusores: el difusor de inducci\u00f3n y el difusor de placa perforada, cada uno con una vista ampliada para facilitar su comprensi\u00f3n.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas principales del difusor de inducci\u00f3n seg\u00fan la figura 9 del informe?**\n   - Esta pregunta busca detalles espec\u00edficos sobre el dise\u00f1o y funcionamiento del difusor de inducci\u00f3n que podr\u00edan no estar disponibles en otras fuentes.\n\n2. **\u00bfEn qu\u00e9 aplicaciones se recomienda el uso del difusor de placa perforada, seg\u00fan la informaci\u00f3n presentada en la figura 10?**\n   - Esta pregunta se centra en las aplicaciones pr\u00e1cticas del difusor de placa perforada, lo que puede no estar claramente especificado en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias clave existen entre el difusor de inducci\u00f3n y el difusor de placa perforada en t\u00e9rminos de eficiencia y dise\u00f1o?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre los dos tipos de difusores, lo que puede proporcionar informaci\u00f3n valiosa para la selecci\u00f3n de tecnolog\u00eda en aplicaciones espec\u00edficas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o y Mantenimiento de Sistemas de Ventilaci\u00f3n**:\n   - Los componentes de ventilaci\u00f3n, como compuertas y filtros, deben ser accesibles desde \u00e1reas externas para facilitar el mantenimiento.\n\n2. **Flujo de Aire Direccional**:\n   - Se debe planificar el flujo de aire en \u00e1reas de producci\u00f3n y empaque para prevenir la contaminaci\u00f3n, considerando la ubicaci\u00f3n de los operadores para proteger tanto al producto como a los trabajadores.\n\n3. **Componentes de Distribuci\u00f3n de Aire HVAC**:\n   - Deben ser dise\u00f1ados e instalados para evitar la propagaci\u00f3n de contaminantes generados en la sala.\n\n4. **Selecci\u00f3n de Difusores de Aire**:\n   - Se deben evitar difusores de alta inducci\u00f3n en \u00e1reas limpias donde se libera polvo. Se prefieren difusores de tipo no inducci\u00f3n para maximizar el efecto de limpieza.\n   - En \u00e1reas con alta liberaci\u00f3n de polvo, se recomiendan placas perforadas o difusores de remolino de baja inducci\u00f3n.\n\n5. **Flujo de Aire Unidireccional (UDAF)**:\n   - Se debe utilizar en cabinas de pesaje y muestreo para proteger a los operadores y productos, con pruebas de contenci\u00f3n de polvo necesarias para validar su efectividad.\n\n6. **Condiciones de Muestreo**:\n   - El muestreo de materiales debe realizarse en condiciones ambientales que coincidan con las requeridas para el procesamiento posterior del producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Sistemas de Ventilaci\u00f3n**: Incluye compuertas, filtros y difusores.\n- **Flujo de Aire**: Direccional y unidireccional, con \u00e9nfasis en la prevenci\u00f3n de contaminaci\u00f3n.\n- **Cabinas de Pesaje y Muestreo**: Espacios donde se aplica el flujo de aire unidireccional.\n- **Contaminantes**: Elementos que deben ser controlados para proteger la salud de los operadores y la calidad del producto. \n\nEste resumen destaca la importancia de un dise\u00f1o cuidadoso de los sistemas de ventilaci\u00f3n y el flujo de aire en entornos de producci\u00f3n para garantizar la seguridad y la calidad.", "excerpt_keywords": "Keywords: difusores, inducci\u00f3n, placa perforada, ventilaci\u00f3n, contaminaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ddf7c2ce-f6c9-4029-ada0-553705c31d5f", "node_type": "4", "metadata": {"page_label": "244", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 9\n**Induction diffuser**\n\n!Induction diffuser\n\n*Enlarged View of Diffuser*\n\n----\n\n# Figure 10\n**Perforated plate diffuser**\n\n!Perforated plate diffuser\n\n*Enlarged Views of Diffusers*\n\n----\n\n232", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "371d84546695bfe9f70d54b51ffb6e6bdd5c3cb309032b8890718e3fe9b86f75", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 9\n**Induction diffuser**\n\n!Induction diffuser\n\n*Enlarged View of Diffuser*\n\n----\n\n# Figure 10\n**Perforated plate diffuser**\n\n!Perforated plate diffuser\n\n*Enlarged Views of Diffusers*\n\n----\n\n232", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 202, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7c4592f1-0f56-411a-b101-eca8b0240535": {"__data__": {"id_": "7c4592f1-0f56-411a-b101-eca8b0240535", "embedding": null, "metadata": {"page_label": "245", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.3\n\nIn a weighing booth situation, the aim of the UDAF is to provide dust containment and operator protection.\n\n*Example:* In Figure 12 the dust generated at the weighing station is immediately extracted through the perforated worktop, thus protecting the operator from dust inhalation, but at the same time protecting the product from contamination by the operator by means of the vertical unidirectional airflow stream.\n\n# 4.3.4\n\nThe unidirectional flow velocity should be such that it does not disrupt the sensitivity of balances in weighing areas. Where necessary the velocity may be reduced to prevent inaccuracies during weighing, provided that sufficient airflow is maintained to provide containment. Conventional unidirectional airflow systems, where a Grade A condition is required, have a guidance airflow velocity of 0.36 to 0.54 m/s. However, in a weigh booth or sampling booth a lower velocity can be used as a Grade A condition is not required. It is often necessary to reduce velocities to a lower level in order not to influence balance readings. The airflow velocity and directional flow should still ensure product containment. For this type of application it is sometimes better to refer to the unit as an airflow protection booth (APB) rather than a UDAF, in order to avoid confusion, with a Grade A requirement.\n\n# 4.3.5\n\nThe position in which the operator stands relative to the source of dust liberation and airflow should be determined to ensure that the operator is not in the path of an airflow that could lead to contamination of the product (Figure 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las especificaciones y recomendaciones para el uso de cabinas de pesaje, espec\u00edficamente en relaci\u00f3n con el flujo de aire unidireccional (UDAF) y su funci\u00f3n en la contenci\u00f3n de polvo y protecci\u00f3n del operador. Se discuten aspectos como la velocidad del flujo de aire, la importancia de no interferir con la sensibilidad de las balanzas, y la posici\u00f3n del operador para evitar la contaminaci\u00f3n del producto.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es la velocidad de flujo de aire recomendada para sistemas de flujo unidireccional en cabinas de pesaje, y c\u00f3mo se ajusta esta velocidad en funci\u00f3n de la sensibilidad de las balanzas?**\n   - Respuesta: La velocidad de flujo de aire recomendada para sistemas de flujo unidireccional en condiciones de Grado A es de 0.36 a 0.54 m/s. Sin embargo, en cabinas de pesaje o muestreo, se puede utilizar una velocidad m\u00e1s baja para no influir en las lecturas de las balanzas, siempre que se mantenga un flujo de aire suficiente para garantizar la contenci\u00f3n del producto.\n\n2. **\u00bfPor qu\u00e9 se sugiere referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF en ciertas aplicaciones?**\n   - Respuesta: Se sugiere referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF para evitar confusiones, ya que en estas aplicaciones no se requiere una condici\u00f3n de Grado A.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta respecto a la posici\u00f3n del operador en relaci\u00f3n con la fuente de liberaci\u00f3n de polvo y el flujo de aire?**\n   - Respuesta: La posici\u00f3n del operador debe ser determinada de manera que no est\u00e9 en el camino de un flujo de aire que podr\u00eda llevar a la contaminaci\u00f3n del producto. Esto implica una planificaci\u00f3n cuidadosa del dise\u00f1o del espacio de trabajo para asegurar la protecci\u00f3n tanto del operador como del producto.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido de la secci\u00f3n se centra en la presentaci\u00f3n de dos tipos de difusores utilizados en aplicaciones t\u00e9cnicas, espec\u00edficamente:\n\n1. **Difusor de Inducci\u00f3n**:\n   - Se menciona en la Figura 9, donde se proporciona una vista ampliada para ilustrar sus caracter\u00edsticas y funcionamiento.\n\n2. **Difusor de Placa Perforada**:\n   - Se presenta en la Figura 10, tambi\u00e9n con una vista ampliada, lo que permite una mejor comprensi\u00f3n de su dise\u00f1o y aplicaciones.\n\n### Entidades:\n- **WHO - Technical Report Series 961**: T\u00edtulo del documento que contiene la informaci\u00f3n.\n- **Difusor de Inducci\u00f3n**: Tipo de difusor destacado en la figura 9.\n- **Difusor de Placa Perforada**: Tipo de difusor destacado en la figura 10.\n\n### Temas Clave:\n- Comparaci\u00f3n y caracter\u00edsticas de diferentes tipos de difusores.\n- Aplicaciones t\u00e9cnicas de los difusores presentados.\n- Importancia de la visualizaci\u00f3n ampliada para entender el dise\u00f1o de los difusores. \n\nEste resumen proporciona una visi\u00f3n general de los elementos discutidos en la secci\u00f3n, destacando la relevancia de los difusores en contextos t\u00e9cnicos.", "excerpt_keywords": "Keywords: UDAF, dust containment, operator protection, airflow velocity, weighing booth"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b60474a-b1d1-4057-b813-f615d6b16c79", "node_type": "4", "metadata": {"page_label": "245", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.3\n\nIn a weighing booth situation, the aim of the UDAF is to provide dust containment and operator protection.\n\n*Example:* In Figure 12 the dust generated at the weighing station is immediately extracted through the perforated worktop, thus protecting the operator from dust inhalation, but at the same time protecting the product from contamination by the operator by means of the vertical unidirectional airflow stream.\n\n# 4.3.4\n\nThe unidirectional flow velocity should be such that it does not disrupt the sensitivity of balances in weighing areas. Where necessary the velocity may be reduced to prevent inaccuracies during weighing, provided that sufficient airflow is maintained to provide containment. Conventional unidirectional airflow systems, where a Grade A condition is required, have a guidance airflow velocity of 0.36 to 0.54 m/s. However, in a weigh booth or sampling booth a lower velocity can be used as a Grade A condition is not required. It is often necessary to reduce velocities to a lower level in order not to influence balance readings. The airflow velocity and directional flow should still ensure product containment. For this type of application it is sometimes better to refer to the unit as an airflow protection booth (APB) rather than a UDAF, in order to avoid confusion, with a Grade A requirement.\n\n# 4.3.5\n\nThe position in which the operator stands relative to the source of dust liberation and airflow should be determined to ensure that the operator is not in the path of an airflow that could lead to contamination of the product (Figure 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fa2d871af0de33d17a0eaa2085c7ca8dfd9accbdd983130b25e00dfba263db70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.3.3\n\nIn a weighing booth situation, the aim of the UDAF is to provide dust containment and operator protection.\n\n*Example:* In Figure 12 the dust generated at the weighing station is immediately extracted through the perforated worktop, thus protecting the operator from dust inhalation, but at the same time protecting the product from contamination by the operator by means of the vertical unidirectional airflow stream.\n\n# 4.3.4\n\nThe unidirectional flow velocity should be such that it does not disrupt the sensitivity of balances in weighing areas. Where necessary the velocity may be reduced to prevent inaccuracies during weighing, provided that sufficient airflow is maintained to provide containment. Conventional unidirectional airflow systems, where a Grade A condition is required, have a guidance airflow velocity of 0.36 to 0.54 m/s. However, in a weigh booth or sampling booth a lower velocity can be used as a Grade A condition is not required. It is often necessary to reduce velocities to a lower level in order not to influence balance readings. The airflow velocity and directional flow should still ensure product containment. For this type of application it is sometimes better to refer to the unit as an airflow protection booth (APB) rather than a UDAF, in order to avoid confusion, with a Grade A requirement.\n\n# 4.3.5\n\nThe position in which the operator stands relative to the source of dust liberation and airflow should be determined to ensure that the operator is not in the path of an airflow that could lead to contamination of the product (Figure 13).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1586, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cec580f3-b046-4bd5-81ef-4fc658deda1c": {"__data__": {"id_": "cec580f3-b046-4bd5-81ef-4fc658deda1c", "embedding": null, "metadata": {"page_label": "246", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator Protection at Weighing Station\n\n4.3.6 Once the system has been designed and qualified with a specific layout for operators and processes, this should be maintained in accordance with an SOP.\n\n4.3.7 There should be no obstructions in the path of a unidirectional flow air stream that may cause the operator to be exposed to dust.\n\nFigure 14 illustrates the incorrect use of a weighing scale which has a solid back. The back of the weighing scale should not block the return air path as this causes air to rise vertically, resulting in a hazardous situation for the operator.\n\nFigure 15 illustrates a situation where an open bin is placed below a vertical unidirectional flow distributor. The downward airflow should be prevented from entering the bin, and then being forced to rise again, as this would carry dust up towards the operator\u2019s face. In such an occurrence it may be necessary to add a partial cover over the bin to limit the entry of air. Point extraction could also be used but this can result in the excessive loss of product.\n\nFigure 16 shows that a solid worktop can sometimes cause deflection of the vertical unidirectional airflow resulting in a flow reversal. A possible solution would be to have a 100 mm gap between the back of the table and the wall, with the air being extracted here.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS aborda la protecci\u00f3n de los operadores en estaciones de pesaje, enfatizando la importancia de un dise\u00f1o adecuado del sistema de flujo de aire unidireccional para minimizar la exposici\u00f3n al polvo. Se destacan varios errores comunes en la disposici\u00f3n de equipos, como el uso de balanzas con respaldos s\u00f3lidos que obstruyen el flujo de aire, la colocaci\u00f3n de contenedores abiertos que permiten la entrada de aire y la deflexi\u00f3n del flujo de aire causada por superficies de trabajo s\u00f3lidas. Se sugieren soluciones pr\u00e1cticas, como mantener espacios adecuados entre los equipos y las paredes, as\u00ed como la implementaci\u00f3n de cubiertas parciales para limitar la entrada de aire.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consecuencias de tener un respaldo s\u00f3lido en una balanza en t\u00e9rminos de flujo de aire y seguridad del operador?**\n   - La presencia de un respaldo s\u00f3lido en una balanza puede bloquear el camino del aire de retorno, causando que el aire se eleve verticalmente, lo que resulta en una situaci\u00f3n peligrosa para el operador al aumentar la exposici\u00f3n al polvo.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para evitar que el flujo de aire descendente entre en un contenedor abierto y cause problemas de seguridad?**\n   - Para prevenir que el flujo de aire descendente ingrese a un contenedor abierto, se puede agregar una cubierta parcial sobre el contenedor o considerar la extracci\u00f3n puntual, aunque esta \u00faltima opci\u00f3n puede resultar en una p\u00e9rdida excesiva de producto.\n\n3. **\u00bfC\u00f3mo puede la disposici\u00f3n de un \u00e1rea de trabajo afectar el flujo de aire unidireccional y qu\u00e9 soluci\u00f3n se propone para mitigar este problema?**\n   - Una superficie de trabajo s\u00f3lida puede desviar el flujo de aire unidireccional, provocando una reversi\u00f3n del flujo. Se sugiere mantener un espacio de 100 mm entre la parte posterior de la mesa y la pared para permitir la extracci\u00f3n adecuada del aire y evitar problemas de seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo de la Cabina de Pesaje (UDAF)**:\n   - Proporcionar contenci\u00f3n de polvo y protecci\u00f3n al operador en situaciones de pesaje.\n\n2. **Extracci\u00f3n de Polvo**:\n   - Ejemplo de funcionamiento: el polvo generado en la estaci\u00f3n de pesaje es extra\u00eddo a trav\u00e9s de una superficie de trabajo perforada, protegiendo al operador de la inhalaci\u00f3n de polvo y evitando la contaminaci\u00f3n del producto mediante un flujo de aire unidireccional vertical.\n\n3. **Velocidad de Flujo de Aire**:\n   - La velocidad del flujo de aire unidireccional debe ser suficiente para no afectar la sensibilidad de las balanzas. \n   - Para condiciones de Grado A, la velocidad recomendada es de 0.36 a 0.54 m/s, pero en cabinas de pesaje o muestreo se puede utilizar una velocidad m\u00e1s baja para evitar influencias en las lecturas de las balanzas, siempre que se mantenga una contenci\u00f3n adecuada.\n\n4. **Terminolog\u00eda**:\n   - En ciertas aplicaciones, es preferible referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF para evitar confusiones relacionadas con los requisitos de Grado A.\n\n5. **Posici\u00f3n del Operador**:\n   - La ubicaci\u00f3n del operador debe ser cuidadosamente determinada para evitar que est\u00e9 en el camino de un flujo de aire que pueda contaminar el producto, lo que requiere una planificaci\u00f3n adecuada del espacio de trabajo.\n\n### Entidades Clave\n- **UDAF**: Unidad de flujo de aire unidireccional.\n- **APB**: Cabina de protecci\u00f3n de flujo de aire.\n- **Grado A**: Condici\u00f3n de calidad del aire en entornos controlados.\n- **Balances**: Instrumentos de medici\u00f3n de peso que requieren condiciones espec\u00edficas para su funcionamiento preciso.", "excerpt_keywords": "Keywords: operator protection, unidirectional airflow, weighing station, dust exposure, airflow design"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25b0c416-f3fe-4e67-82b3-934db0e96d2b", "node_type": "4", "metadata": {"page_label": "246", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator Protection at Weighing Station\n\n4.3.6 Once the system has been designed and qualified with a specific layout for operators and processes, this should be maintained in accordance with an SOP.\n\n4.3.7 There should be no obstructions in the path of a unidirectional flow air stream that may cause the operator to be exposed to dust.\n\nFigure 14 illustrates the incorrect use of a weighing scale which has a solid back. The back of the weighing scale should not block the return air path as this causes air to rise vertically, resulting in a hazardous situation for the operator.\n\nFigure 15 illustrates a situation where an open bin is placed below a vertical unidirectional flow distributor. The downward airflow should be prevented from entering the bin, and then being forced to rise again, as this would carry dust up towards the operator\u2019s face. In such an occurrence it may be necessary to add a partial cover over the bin to limit the entry of air. Point extraction could also be used but this can result in the excessive loss of product.\n\nFigure 16 shows that a solid worktop can sometimes cause deflection of the vertical unidirectional airflow resulting in a flow reversal. A possible solution would be to have a 100 mm gap between the back of the table and the wall, with the air being extracted here.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "598a7db0352aeaf83e183a1087fedc26462e4ec223fe0f7cf33d37582889d58e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Operator Protection at Weighing Station\n\n4.3.6 Once the system has been designed and qualified with a specific layout for operators and processes, this should be maintained in accordance with an SOP.\n\n4.3.7 There should be no obstructions in the path of a unidirectional flow air stream that may cause the operator to be exposed to dust.\n\nFigure 14 illustrates the incorrect use of a weighing scale which has a solid back. The back of the weighing scale should not block the return air path as this causes air to rise vertically, resulting in a hazardous situation for the operator.\n\nFigure 15 illustrates a situation where an open bin is placed below a vertical unidirectional flow distributor. The downward airflow should be prevented from entering the bin, and then being forced to rise again, as this would carry dust up towards the operator\u2019s face. In such an occurrence it may be necessary to add a partial cover over the bin to limit the entry of air. Point extraction could also be used but this can result in the excessive loss of product.\n\nFigure 16 shows that a solid worktop can sometimes cause deflection of the vertical unidirectional airflow resulting in a flow reversal. A possible solution would be to have a 100 mm gap between the back of the table and the wall, with the air being extracted here.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1317, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3536364c-71c6-4b1e-813a-b43f99fa7a1b": {"__data__": {"id_": "3536364c-71c6-4b1e-813a-b43f99fa7a1b", "embedding": null, "metadata": {"page_label": "247", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator protection by horizontal airflow\n\n4.3.8 The manufacturer should select either vertical or horizontal unidirectional flow (Figure 17) and an appropriate airflow pattern to provide the best protection for the particular application.\n\n4.3.9 Return or exhaust air grilles in rooms or at weigh or sampling booths should preferably be of the perforated grille types, which are easy to clean. Return/exhaust air filters can either be installed at the room terminal or in the air-handling unit. Maintenance and cleaning of filters and ducts should be addressed to ensure constant airflow.\n\n## 4.4 Infiltration\n\n4.4.1 Air infiltration of unfiltered air into a pharmaceutical plant should not be a source of contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la protecci\u00f3n de los operadores en entornos farmac\u00e9uticos mediante el uso de flujos de aire unidireccionales, ya sea vertical u horizontal. Se enfatiza la importancia de seleccionar el patr\u00f3n de flujo de aire adecuado para garantizar la protecci\u00f3n en aplicaciones espec\u00edficas. Adem\u00e1s, se menciona la necesidad de utilizar rejillas de aire de tipo perforado en \u00e1reas de pesaje o muestreo, as\u00ed como la importancia del mantenimiento regular de filtros y conductos para asegurar un flujo de aire constante. Por \u00faltimo, se establece que la infiltraci\u00f3n de aire no filtrado en una planta farmac\u00e9utica no debe ser una fuente de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones que un fabricante debe tener en cuenta al seleccionar entre flujo de aire vertical u horizontal en un entorno farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre los criterios espec\u00edficos que gu\u00edan la elecci\u00f3n del tipo de flujo de aire, que no se abordan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de rejillas de aire se recomienda para las \u00e1reas de pesaje o muestreo y por qu\u00e9?**\n   - Esta pregunta se centra en las caracter\u00edsticas de las rejillas de aire recomendadas y su facilidad de limpieza, lo que podr\u00eda no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para garantizar que la infiltraci\u00f3n de aire no filtrado no contamine una planta farmac\u00e9utica?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas o protocolos que se deben implementar para prevenir la contaminaci\u00f3n por aire no filtrado, que podr\u00eda no estar detallada en otros documentos.\n\n### Resumen adicional\n\nEl documento tambi\u00e9n aborda la importancia de mantener un ambiente controlado en las instalaciones farmac\u00e9uticas, donde el flujo de aire y la calidad del aire son cruciales para prevenir la contaminaci\u00f3n. Se subraya la necesidad de un mantenimiento regular de los sistemas de ventilaci\u00f3n y filtraci\u00f3n para asegurar que el aire que circula en estas \u00e1reas cumpla con los est\u00e1ndares de calidad requeridos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Protecci\u00f3n del Operador**: La secci\u00f3n se centra en la protecci\u00f3n de los operadores en estaciones de pesaje, destacando la importancia de un dise\u00f1o adecuado del sistema de flujo de aire unidireccional para minimizar la exposici\u00f3n al polvo.\n\n2. **Dise\u00f1o del Sistema**: Se enfatiza que una vez que el sistema ha sido dise\u00f1ado y calificado, debe mantenerse de acuerdo con un Procedimiento Operativo Est\u00e1ndar (SOP).\n\n3. **Flujo de Aire Unidireccional**: Se menciona la necesidad de evitar obstrucciones en el camino del flujo de aire unidireccional para proteger al operador de la exposici\u00f3n al polvo.\n\n4. **Errores Comunes**:\n   - **Respaldo S\u00f3lido en Balanzas**: Se ilustra que un respaldo s\u00f3lido en una balanza puede bloquear el flujo de aire de retorno, causando que el aire se eleve verticalmente y genere un riesgo para el operador.\n   - **Contenedores Abiertos**: La colocaci\u00f3n de un contenedor abierto debajo de un distribuidor de flujo vertical puede permitir que el aire descendente ingrese al contenedor, forzando el polvo hacia el rostro del operador.\n   - **Superficies de Trabajo S\u00f3lidas**: Estas pueden desviar el flujo de aire unidireccional, provocando una reversi\u00f3n del flujo.\n\n5. **Soluciones Propuestas**:\n   - **Cubiertas Parciales**: Se sugiere agregar cubiertas parciales sobre los contenedores abiertos para limitar la entrada de aire.\n   - **Extracci\u00f3n Puntual**: Aunque puede ser efectiva, esta opci\u00f3n puede resultar en una p\u00e9rdida excesiva de producto.\n   - **Espacio entre Mesa y Pared**: Se recomienda mantener un espacio de 100 mm entre la parte posterior de la mesa y la pared para facilitar la extracci\u00f3n adecuada del aire.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Estaciones de Pesaje**: Contexto espec\u00edfico donde se aplican las recomendaciones.\n- **SOP (Procedimiento Operativo Est\u00e1ndar)**: Protocolo para el mantenimiento del sistema.\n- **Flujo de Aire Unidireccional**: Concepto central en la protecci\u00f3n del operador.\n- **Contenedores y Balanzas**: Equipos mencionados en relaci\u00f3n con el flujo de aire y la seguridad del operador.", "excerpt_keywords": "Keywords: operator protection, unidirectional airflow, pharmaceutical plant, air filtration, contamination prevention"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d05d909d-1d1b-4f1b-8e50-4dd9b8e4ec67", "node_type": "4", "metadata": {"page_label": "247", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator protection by horizontal airflow\n\n4.3.8 The manufacturer should select either vertical or horizontal unidirectional flow (Figure 17) and an appropriate airflow pattern to provide the best protection for the particular application.\n\n4.3.9 Return or exhaust air grilles in rooms or at weigh or sampling booths should preferably be of the perforated grille types, which are easy to clean. Return/exhaust air filters can either be installed at the room terminal or in the air-handling unit. Maintenance and cleaning of filters and ducts should be addressed to ensure constant airflow.\n\n## 4.4 Infiltration\n\n4.4.1 Air infiltration of unfiltered air into a pharmaceutical plant should not be a source of contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1cd82fbbbfb555520fa37de5364902e1ce1fb0ee404c12e0f6be37d874368742", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Operator protection by horizontal airflow\n\n4.3.8 The manufacturer should select either vertical or horizontal unidirectional flow (Figure 17) and an appropriate airflow pattern to provide the best protection for the particular application.\n\n4.3.9 Return or exhaust air grilles in rooms or at weigh or sampling booths should preferably be of the perforated grille types, which are easy to clean. Return/exhaust air filters can either be installed at the room terminal or in the air-handling unit. Maintenance and cleaning of filters and ducts should be addressed to ensure constant airflow.\n\n## 4.4 Infiltration\n\n4.4.1 Air infiltration of unfiltered air into a pharmaceutical plant should not be a source of contamination.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 723, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e093f4b6-8e36-4d62-b775-40e9795a8306": {"__data__": {"id_": "e093f4b6-8e36-4d62-b775-40e9795a8306", "embedding": null, "metadata": {"page_label": "248", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1l es el enfoque principal del Informe T\u00e9cnico de la OMS en la Serie 961?**\n   - Esta pregunta busca obtener informaci\u00f3n sobre los temas o \u00e1reas espec\u00edficas que se abordan en el informe, lo que podr\u00eda incluir aspectos de salud p\u00fablica, investigaci\u00f3n m\u00e9dica o recomendaciones de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 tipo de datos o hallazgos se presentan en la p\u00e1gina 248 del Informe T\u00e9cnico de la OMS?**\n   - Dado que se menciona una p\u00e1gina espec\u00edfica, esta pregunta se centra en los contenidos que podr\u00edan estar disponibles en esa p\u00e1gina, como estad\u00edsticas, estudios de caso o conclusiones relevantes.\n\n3. **\u00bfQu\u00e9 recomendaciones o directrices se ofrecen en el Informe T\u00e9cnico de la OMS para abordar problemas de salud global?**\n   - Esta pregunta busca identificar las sugerencias pr\u00e1cticas o pol\u00edticas que la OMS podr\u00eda proponer en el informe, lo que podr\u00eda ser \u00fatil para profesionales de la salud, investigadores o responsables de pol\u00edticas.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento mencionado es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el n\u00famero 961 de la Serie de Informes T\u00e9cnicos. Estos informes suelen abordar temas cr\u00edticos en el \u00e1mbito de la salud global, proporcionando an\u00e1lisis, recomendaciones y directrices basadas en la evidencia. Aunque no se proporciona contenido espec\u00edfico en el contexto, es probable que el informe contenga informaci\u00f3n valiosa sobre la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Protecci\u00f3n de operadores**: Se enfatiza la importancia de seleccionar un flujo de aire unidireccional (vertical u horizontal) para proporcionar la mejor protecci\u00f3n en entornos farmac\u00e9uticos.\n\n2. **Selecci\u00f3n de flujo de aire**: Los fabricantes deben considerar el tipo de flujo de aire adecuado para la aplicaci\u00f3n espec\u00edfica, aunque no se detallan los criterios espec\u00edficos en el texto.\n\n3. **Rejillas de aire**: Se recomienda el uso de rejillas de aire perforadas en \u00e1reas de pesaje o muestreo debido a su facilidad de limpieza.\n\n4. **Filtros de aire**: Los filtros de retorno/exhaustaci\u00f3n pueden instalarse en la terminal de la habitaci\u00f3n o en la unidad de manejo de aire, y se destaca la necesidad de mantenimiento regular para asegurar un flujo de aire constante.\n\n5. **Infiltraci\u00f3n de aire**: Se establece que la infiltraci\u00f3n de aire no filtrado en una planta farmac\u00e9utica no debe ser una fuente de contaminaci\u00f3n, aunque no se especifican medidas concretas para prevenirla.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona las recomendaciones.\n- **Flujo de aire unidireccional**: Concepto clave en la protecci\u00f3n de operadores.\n- **Rejillas de aire perforadas**: Tipo de rejilla recomendado para \u00e1reas espec\u00edficas.\n- **Filtros de aire**: Elementos esenciales para el mantenimiento de la calidad del aire.\n- **Planta farmac\u00e9utica**: Entorno donde se aplican estas recomendaciones. \n\nEste resumen destaca la importancia de un manejo adecuado del flujo de aire y la limpieza en entornos farmac\u00e9uticos para prevenir la contaminaci\u00f3n y proteger a los operadores.", "excerpt_keywords": "Keywords: OMS, Informe T\u00e9cnico, salud p\u00fablica, flujo de aire, contaminaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8edf9028-6288-416a-a610-605caa51533f", "node_type": "4", "metadata": {"page_label": "248", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d56d77a8-6a4f-4297-87e9-6325aea8d4a6": {"__data__": {"id_": "d56d77a8-6a4f-4297-87e9-6325aea8d4a6", "embedding": null, "metadata": {"page_label": "249", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4.2\n\nManufacturing facilities should normally be maintained at a positive pressure relative to the outside, to limit the ingress of contaminants. Where facilities are to be maintained at negative pressures relative to the ambient pressure, special precautions should be taken. Refer to the WHO guideline for hazardous products, for further guidance on negative pressure facilities.\n\n4.4.3 The location of the negative pressure facility should be carefully considered with reference to the areas surrounding it, particular attention being given to ensuring that the building structure is well sealed.\n\n4.4.4 Negative pressure zones should, as far as possible, be encapsulated by surrounding areas with clean air supplies, so that only clean air can infiltrate into the controlled zone.\n\n# 4.5 Cross-contamination\n\n4.5.1 Where different products are manufactured at the same time, in different areas or cubicles, in a multiproduct OSD manufacturing site, measures should be taken to ensure that dust cannot move from one cubicle to another.\n\n4.5.2 Correct directional air movement and a pressure cascade system can assist in preventing cross-contamination. The pressure cascade should be such that the direction of airflow is from the clean corridor into the cubicles, resulting in dust containment.\n\n4.5.3 The corridor should be maintained at a higher pressure than the cubicles, and the cubicles at a higher pressure than atmospheric pressure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para el mantenimiento de instalaciones de fabricaci\u00f3n, especialmente en lo que respecta a la presi\u00f3n del aire y la prevenci\u00f3n de la contaminaci\u00f3n cruzada en sitios de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener presiones positivas en las instalaciones para limitar la entrada de contaminantes y se ofrecen directrices sobre el manejo de instalaciones de presi\u00f3n negativa. Adem\u00e1s, se discuten medidas para evitar la contaminaci\u00f3n cruzada entre diferentes productos fabricados simult\u00e1neamente, destacando la importancia de la direcci\u00f3n del flujo de aire y la presi\u00f3n en los corredores y cub\u00edculos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las precauciones especiales que se deben tomar al mantener instalaciones a presi\u00f3n negativa, seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las medidas que deben implementarse en instalaciones de presi\u00f3n negativa, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 caracter\u00edsticas debe tener la ubicaci\u00f3n de una instalaci\u00f3n de presi\u00f3n negativa para garantizar su eficacia en la contenci\u00f3n de contaminantes?**\n   - Esta pregunta se centra en los aspectos de dise\u00f1o y ubicaci\u00f3n de las instalaciones, que son cruciales para su funcionamiento seguro y que pueden no estar ampliamente discutidos en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe gestionar el flujo de aire y la presi\u00f3n en un entorno de fabricaci\u00f3n multiproducto para prevenir la contaminaci\u00f3n cruzada?**\n   - Esta pregunta busca detalles sobre la gesti\u00f3n del flujo de aire y la presi\u00f3n en un entorno espec\u00edfico de fabricaci\u00f3n, lo que puede no estar claramente definido en otras normativas o gu\u00edas.", "prev_section_summary": "El contenido proporcionado se refiere al Informe T\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el n\u00famero 961 de la Serie de Informes T\u00e9cnicos. Aunque no se incluye contenido espec\u00edfico, se pueden identificar algunos temas clave y entidades relevantes:\n\n### Temas Clave:\n1. **Salud P\u00fablica**: El informe aborda cuestiones cr\u00edticas relacionadas con la salud global.\n2. **Investigaci\u00f3n M\u00e9dica**: Se espera que el documento incluya an\u00e1lisis y hallazgos relevantes en el \u00e1mbito de la investigaci\u00f3n.\n3. **Recomendaciones de Pol\u00edticas**: El informe probablemente ofrezca directrices y sugerencias para abordar problemas de salud a nivel global.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico de la OMS**: El tipo de documento que se est\u00e1 analizando, que proporciona informaci\u00f3n basada en evidencia sobre temas de salud.\n\n### Preguntas Potenciales:\n1. Enfoque principal del Informe T\u00e9cnico de la OMS en la Serie 961.\n2. Datos o hallazgos presentados en la p\u00e1gina 248 del informe.\n3. Recomendaciones o directrices ofrecidas para abordar problemas de salud global.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica, as\u00ed como su relevancia para profesionales y responsables de pol\u00edticas en el \u00e1mbito de la salud.", "excerpt_keywords": "Keywords: manufacturing facilities, positive pressure, negative pressure, cross-contamination, air flow management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "edd88bd1-d9fc-47e4-bdb2-d1802eb17148", "node_type": "4", "metadata": {"page_label": "249", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4.2\n\nManufacturing facilities should normally be maintained at a positive pressure relative to the outside, to limit the ingress of contaminants. Where facilities are to be maintained at negative pressures relative to the ambient pressure, special precautions should be taken. Refer to the WHO guideline for hazardous products, for further guidance on negative pressure facilities.\n\n4.4.3 The location of the negative pressure facility should be carefully considered with reference to the areas surrounding it, particular attention being given to ensuring that the building structure is well sealed.\n\n4.4.4 Negative pressure zones should, as far as possible, be encapsulated by surrounding areas with clean air supplies, so that only clean air can infiltrate into the controlled zone.\n\n# 4.5 Cross-contamination\n\n4.5.1 Where different products are manufactured at the same time, in different areas or cubicles, in a multiproduct OSD manufacturing site, measures should be taken to ensure that dust cannot move from one cubicle to another.\n\n4.5.2 Correct directional air movement and a pressure cascade system can assist in preventing cross-contamination. The pressure cascade should be such that the direction of airflow is from the clean corridor into the cubicles, resulting in dust containment.\n\n4.5.3 The corridor should be maintained at a higher pressure than the cubicles, and the cubicles at a higher pressure than atmospheric pressure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "af65abd7dbab6cb99a8cbd24f1a4c70b81081a906969dd44b9c6581b98065c7f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.4.2\n\nManufacturing facilities should normally be maintained at a positive pressure relative to the outside, to limit the ingress of contaminants. Where facilities are to be maintained at negative pressures relative to the ambient pressure, special precautions should be taken. Refer to the WHO guideline for hazardous products, for further guidance on negative pressure facilities.\n\n4.4.3 The location of the negative pressure facility should be carefully considered with reference to the areas surrounding it, particular attention being given to ensuring that the building structure is well sealed.\n\n4.4.4 Negative pressure zones should, as far as possible, be encapsulated by surrounding areas with clean air supplies, so that only clean air can infiltrate into the controlled zone.\n\n# 4.5 Cross-contamination\n\n4.5.1 Where different products are manufactured at the same time, in different areas or cubicles, in a multiproduct OSD manufacturing site, measures should be taken to ensure that dust cannot move from one cubicle to another.\n\n4.5.2 Correct directional air movement and a pressure cascade system can assist in preventing cross-contamination. The pressure cascade should be such that the direction of airflow is from the clean corridor into the cubicles, resulting in dust containment.\n\n4.5.3 The corridor should be maintained at a higher pressure than the cubicles, and the cubicles at a higher pressure than atmospheric pressure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1447, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "249f01ba-f67d-480b-a9f2-3f53f29135b8": {"__data__": {"id_": "249f01ba-f67d-480b-a9f2-3f53f29135b8", "embedding": null, "metadata": {"page_label": "250", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 17\n\n**Diagram indicating horizontal and vertical unidirectional flow**\n\n----\n\n4.5.4 Containment can normally be achieved by application of the displacement concept (low pressure differential, high airflow), or the pressure differential concept (high pressure differential, low airflow), or the physical barrier concept.\n\n4.5.5 The pressure cascade regime and the direction of airflow should be appropriate to the product and processing method used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos relacionados con el flujo unidireccional en entornos controlados, destacando la importancia de la contenci\u00f3n en procesos de manipulaci\u00f3n de productos. Se mencionan tres conceptos clave para lograr la contenci\u00f3n: el concepto de desplazamiento, el concepto de diferencial de presi\u00f3n y el concepto de barrera f\u00edsica. Adem\u00e1s, se enfatiza que el r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser adecuados para el producto y el m\u00e9todo de procesamiento utilizados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los tres conceptos clave mencionados para lograr la contenci\u00f3n en entornos controlados?**\n   - Respuesta: Los tres conceptos clave son el concepto de desplazamiento (bajo diferencial de presi\u00f3n, alto flujo de aire), el concepto de diferencial de presi\u00f3n (alto diferencial de presi\u00f3n, bajo flujo de aire) y el concepto de barrera f\u00edsica.\n\n2. **\u00bfC\u00f3mo debe ser el r\u00e9gimen de presi\u00f3n y la direcci\u00f3n del flujo de aire en relaci\u00f3n con el producto y el m\u00e9todo de procesamiento?**\n   - Respuesta: El r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser apropiados para el producto y el m\u00e9todo de procesamiento utilizados.\n\n3. **\u00bfQu\u00e9 se entiende por el concepto de desplazamiento en el contexto de la contenci\u00f3n?**\n   - Respuesta: El concepto de desplazamiento se refiere a la creaci\u00f3n de un bajo diferencial de presi\u00f3n y un alto flujo de aire para lograr la contenci\u00f3n en entornos controlados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Presi\u00f3n en Instalaciones de Fabricaci\u00f3n**:\n   - Las instalaciones deben mantenerse normalmente a presi\u00f3n positiva para limitar la entrada de contaminantes.\n   - En caso de mantener presi\u00f3n negativa, se deben tomar precauciones especiales, referenciando las directrices de la OMS para productos peligrosos.\n\n2. **Ubicaci\u00f3n de Instalaciones de Presi\u00f3n Negativa**:\n   - La ubicaci\u00f3n debe ser cuidadosamente considerada, asegurando que la estructura del edificio est\u00e9 bien sellada.\n   - Las zonas de presi\u00f3n negativa deben estar rodeadas de \u00e1reas con suministro de aire limpio para evitar la infiltraci\u00f3n de contaminantes.\n\n3. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**:\n   - En entornos de fabricaci\u00f3n multiproducto, se deben implementar medidas para evitar que el polvo se mueva entre cub\u00edculos.\n   - Se debe gestionar el flujo de aire y establecer un sistema de cascada de presi\u00f3n, donde el aire fluya desde un corredor limpio hacia los cub\u00edculos, manteniendo as\u00ed la contenci\u00f3n del polvo.\n   - Los corredores deben estar a una presi\u00f3n m\u00e1s alta que los cub\u00edculos, y estos a una presi\u00f3n superior a la atmosf\u00e9rica.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre pr\u00e1cticas de fabricaci\u00f3n.\n- **Instalaciones de fabricaci\u00f3n**: Espacios donde se producen productos farmac\u00e9uticos.\n- **Presi\u00f3n positiva y negativa**: Conceptos clave en el control de la contaminaci\u00f3n en entornos de fabricaci\u00f3n.\n- **Contaminaci\u00f3n cruzada**: Riesgo asociado a la fabricaci\u00f3n de m\u00faltiples productos simult\u00e1neamente. \n\nEste resumen destaca la importancia de la presi\u00f3n del aire y el dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: contenci\u00f3n, flujo unidireccional, presi\u00f3n diferencial, barrera f\u00edsica, procesamiento de productos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "efd474a7-c291-496f-a23d-04d0747f29b7", "node_type": "4", "metadata": {"page_label": "250", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 17\n\n**Diagram indicating horizontal and vertical unidirectional flow**\n\n----\n\n4.5.4 Containment can normally be achieved by application of the displacement concept (low pressure differential, high airflow), or the pressure differential concept (high pressure differential, low airflow), or the physical barrier concept.\n\n4.5.5 The pressure cascade regime and the direction of airflow should be appropriate to the product and processing method used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cf1caefa5639e85e6cf4968812118cb57b3e89f9f74263d51494b0970ad660f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 17\n\n**Diagram indicating horizontal and vertical unidirectional flow**\n\n----\n\n4.5.4 Containment can normally be achieved by application of the displacement concept (low pressure differential, high airflow), or the pressure differential concept (high pressure differential, low airflow), or the physical barrier concept.\n\n4.5.5 The pressure cascade regime and the direction of airflow should be appropriate to the product and processing method used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 457, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "624a286a-20fa-4c59-a601-11b20f05b9f2": {"__data__": {"id_": "624a286a-20fa-4c59-a601-11b20f05b9f2", "embedding": null, "metadata": {"page_label": "251", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "4.5.6 Highly potent products should be manufactured under a pressure cascade regime that is negative relative to atmospheric pressure.\n\n4.5.7 The pressure cascade for each facility should be individually assessed according to the product handled and level of protection required.\n\n4.5.8 Building structure should be given special attention to accommodate the pressure cascade design.\n\n4.5.9 Ceilings and walls, close fitting doors and sealed light fittings should be in place, to limit ingress or egress of air.\n\n## 4.6 Displacement concept (low pressure differential, high airflow)\n\n*Note: This method of containment is not the preferred method, as the measurement and monitoring of airflow velocities in doorways is difficult. This concept is commonly found in production processes where large amounts of dust are generated.*\n\n4.6.1 Under this concept the air should be supplied to the corridor, flow through the doorway, and be extracted from the back of the cubicle. Normally the cubicle door should be closed and the air should enter the cubicle through a door grille, although the concept can be applied to an opening without a door.\n\n4.6.2 The velocity should be high enough to prevent turbulence within the doorway resulting in dust escaping.\n\n4.6.3 This displacement airflow should be calculated as the product of the door area and the velocity, which generally results in fairly large air quantities.\n\n*Note: Although this method of containment may still exist on older facilities, it is not the preferred method, as the measurement and monitoring of doorway velocities is difficult. In addition, simultaneously maintaining the correct room pressure and the correct room air change rate is often not achieved.*\n\n## 4.7 Pressure differential concept (high pressure differential, low airflow)\n\n*Note: The pressure differential concept may normally be used in zones where little or no dust is being generated. It may be used alone or in combination with other containment control techniques and concepts, such as a double door airlock.*\n\n4.7.1 The high pressure differential between the clean and less clean zones should be generated by leakage through the gaps of the closed doors to the cubicle.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las pr\u00e1cticas de contenci\u00f3n y dise\u00f1o de instalaciones para la fabricaci\u00f3n de productos altamente potentes. Se discuten dos conceptos principales de contenci\u00f3n: el concepto de desplazamiento (bajo diferencial de presi\u00f3n y alto flujo de aire) y el concepto de diferencial de presi\u00f3n (alto diferencial de presi\u00f3n y bajo flujo de aire). Se enfatiza la importancia de mantener un r\u00e9gimen de cascada de presi\u00f3n negativo, as\u00ed como la necesidad de evaluar individualmente cada instalaci\u00f3n seg\u00fan el producto manejado y el nivel de protecci\u00f3n requerido. Tambi\u00e9n se menciona la importancia de la estructura del edificio y los elementos de dise\u00f1o que limitan la entrada y salida de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de la estructura de un edificio que alberga productos altamente potentes?**\n   - La estructura del edificio debe ser dise\u00f1ada para acomodar el r\u00e9gimen de cascada de presi\u00f3n, lo que incluye prestar especial atenci\u00f3n a los techos y paredes, as\u00ed como asegurar que las puertas cierren adecuadamente y que las luminarias est\u00e9n selladas para limitar la entrada o salida de aire.\n\n2. **\u00bfPor qu\u00e9 el concepto de desplazamiento no es el m\u00e9todo preferido para la contenci\u00f3n en instalaciones de producci\u00f3n?**\n   - Este m\u00e9todo no es preferido porque la medici\u00f3n y el monitoreo de las velocidades de flujo de aire en las puertas son dif\u00edciles. Adem\u00e1s, mantener simult\u00e1neamente la presi\u00f3n correcta de la habitaci\u00f3n y la tasa de cambio de aire adecuada es a menudo complicado.\n\n3. **\u00bfC\u00f3mo se genera el diferencial de presi\u00f3n en el concepto de diferencial de presi\u00f3n y en qu\u00e9 situaciones se recomienda su uso?**\n   - El alto diferencial de presi\u00f3n entre las zonas limpias y menos limpias se genera por la fuga a trav\u00e9s de las rendijas de las puertas cerradas del cub\u00edculo. Este concepto se recomienda en zonas donde se genera poco o ning\u00fan polvo y puede usarse solo o en combinaci\u00f3n con otras t\u00e9cnicas de control de contenci\u00f3n, como un vest\u00edbulo de doble puerta.\n\n### Resumen de nivel superior\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de productos altamente potentes, destacando la importancia de un dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la contenci\u00f3n. Se presentan dos enfoques para la contenci\u00f3n: el desplazamiento y el diferencial de presi\u00f3n, cada uno con sus propias caracter\u00edsticas y aplicaciones. Se enfatiza la necesidad de un an\u00e1lisis individualizado de cada instalaci\u00f3n y la atenci\u00f3n a los detalles estructurales para mantener un ambiente controlado y seguro.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Contenci\u00f3n en entornos controlados**: La secci\u00f3n aborda la importancia de la contenci\u00f3n en procesos de manipulaci\u00f3n de productos en entornos controlados, como laboratorios o instalaciones de producci\u00f3n.\n\n2. **Conceptos de contenci\u00f3n**:\n   - **Concepto de desplazamiento**: Se refiere a la creaci\u00f3n de un bajo diferencial de presi\u00f3n y un alto flujo de aire para lograr la contenci\u00f3n.\n   - **Concepto de diferencial de presi\u00f3n**: Implica un alto diferencial de presi\u00f3n y un bajo flujo de aire para mantener la contenci\u00f3n.\n   - **Concepto de barrera f\u00edsica**: Utiliza barreras f\u00edsicas para prevenir la contaminaci\u00f3n y asegurar la contenci\u00f3n.\n\n3. **R\u00e9gimen de presi\u00f3n y flujo de aire**: Se enfatiza que el r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser adecuados y espec\u00edficos para el tipo de producto y el m\u00e9todo de procesamiento utilizado.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Documentos t\u00e9cnicos**: Referencia a la serie de informes t\u00e9cnicos de la OMS, espec\u00edficamente el informe 961.\n- **Flujo unidireccional**: Concepto clave en el manejo de aire en entornos controlados.\n- **Diferencial de presi\u00f3n**: Par\u00e1metro f\u00edsico importante en la contenci\u00f3n. \n\nEste resumen destaca los conceptos fundamentales y las entidades relevantes en la secci\u00f3n proporcionada, centr\u00e1ndose en la contenci\u00f3n y el manejo del flujo de aire en entornos controlados.", "excerpt_keywords": "Keywords: containment, pressure cascade, airflow, differential pressure, facility design"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3c157e6-e0ae-486c-a4c6-d05a707563ec", "node_type": "4", "metadata": {"page_label": "251", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "4.5.6 Highly potent products should be manufactured under a pressure cascade regime that is negative relative to atmospheric pressure.\n\n4.5.7 The pressure cascade for each facility should be individually assessed according to the product handled and level of protection required.\n\n4.5.8 Building structure should be given special attention to accommodate the pressure cascade design.\n\n4.5.9 Ceilings and walls, close fitting doors and sealed light fittings should be in place, to limit ingress or egress of air.\n\n## 4.6 Displacement concept (low pressure differential, high airflow)\n\n*Note: This method of containment is not the preferred method, as the measurement and monitoring of airflow velocities in doorways is difficult. This concept is commonly found in production processes where large amounts of dust are generated.*\n\n4.6.1 Under this concept the air should be supplied to the corridor, flow through the doorway, and be extracted from the back of the cubicle. Normally the cubicle door should be closed and the air should enter the cubicle through a door grille, although the concept can be applied to an opening without a door.\n\n4.6.2 The velocity should be high enough to prevent turbulence within the doorway resulting in dust escaping.\n\n4.6.3 This displacement airflow should be calculated as the product of the door area and the velocity, which generally results in fairly large air quantities.\n\n*Note: Although this method of containment may still exist on older facilities, it is not the preferred method, as the measurement and monitoring of doorway velocities is difficult. In addition, simultaneously maintaining the correct room pressure and the correct room air change rate is often not achieved.*\n\n## 4.7 Pressure differential concept (high pressure differential, low airflow)\n\n*Note: The pressure differential concept may normally be used in zones where little or no dust is being generated. It may be used alone or in combination with other containment control techniques and concepts, such as a double door airlock.*\n\n4.7.1 The high pressure differential between the clean and less clean zones should be generated by leakage through the gaps of the closed doors to the cubicle.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "93b72a9161bd1979812916e8fb78f1de734d7e8727f901d81c9fd1880874c1d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4.5.6 Highly potent products should be manufactured under a pressure cascade regime that is negative relative to atmospheric pressure.\n\n4.5.7 The pressure cascade for each facility should be individually assessed according to the product handled and level of protection required.\n\n4.5.8 Building structure should be given special attention to accommodate the pressure cascade design.\n\n4.5.9 Ceilings and walls, close fitting doors and sealed light fittings should be in place, to limit ingress or egress of air.\n\n## 4.6 Displacement concept (low pressure differential, high airflow)\n\n*Note: This method of containment is not the preferred method, as the measurement and monitoring of airflow velocities in doorways is difficult. This concept is commonly found in production processes where large amounts of dust are generated.*\n\n4.6.1 Under this concept the air should be supplied to the corridor, flow through the doorway, and be extracted from the back of the cubicle. Normally the cubicle door should be closed and the air should enter the cubicle through a door grille, although the concept can be applied to an opening without a door.\n\n4.6.2 The velocity should be high enough to prevent turbulence within the doorway resulting in dust escaping.\n\n4.6.3 This displacement airflow should be calculated as the product of the door area and the velocity, which generally results in fairly large air quantities.\n\n*Note: Although this method of containment may still exist on older facilities, it is not the preferred method, as the measurement and monitoring of doorway velocities is difficult. In addition, simultaneously maintaining the correct room pressure and the correct room air change rate is often not achieved.*\n\n## 4.7 Pressure differential concept (high pressure differential, low airflow)\n\n*Note: The pressure differential concept may normally be used in zones where little or no dust is being generated. It may be used alone or in combination with other containment control techniques and concepts, such as a double door airlock.*\n\n4.7.1 The high pressure differential between the clean and less clean zones should be generated by leakage through the gaps of the closed doors to the cubicle.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2204, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0281fcd1-728d-4d6c-8bf5-83ce8adffdf0": {"__data__": {"id_": "0281fcd1-728d-4d6c-8bf5-83ce8adffdf0", "embedding": null, "metadata": {"page_label": "252", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.7.2\n\nThe pressure differential should be of sufficient magnitude to ensure containment and prevention of flow reversal, but should not be so high as to create turbulence problems.\n\n# 4.7.3\n\nIn considering room pressure differentials, transient variations, such as machine extract systems, should be taken into consideration.\n\n# 4.7.4\n\nA pressure differential of 15 Pa is often used for achieving containment between two adjacent zones, but pressure differentials of between 5 Pa and 20 Pa may be acceptable. Where the design pressure differential is too low and tolerances are at opposite extremities, a flow reversal can take place. For example, where a control tolerance of \u00b1 3 Pa is specified, the implications of rooms being operated at the upper and lower tolerances should be evaluated. It is important to select pressures and tolerances such that a flow reversal is unlikely to occur.\n\n# 4.7.5\n\nThe pressure differential between adjacent rooms could be considered a critical parameter, depending on the outcome of risk analysis. The limits for the pressure differential between adjacent areas should be such that there is no risk of overlap in the acceptable operating range, e.g. 5 Pa to 15 Pa in one room and 15 Pa to 30 Pa in an adjacent room, resulting in the failure of the pressure cascade, where the first room is at the maximum pressure limit and the second room is at its minimum pressure limit.\n\n# 4.7.6\n\nLow pressure differentials may be acceptable when airlocks (pressure sinks or pressure bubbles) are used to segregate areas.\n\n# 4.7.7\n\nThe effect of room pressure tolerances are illustrated in Figure 18.\n\n# 4.7.8\n\nThe pressure control and monitoring devices used should be calibrated and qualified. Compliance with specifications should be regularly verified and the results recorded. Pressure control devices should be linked to an alarm system set according to the levels determined by a risk analysis.\n\n# 4.7.9\n\nManual control systems, where used, should be set up during commissioning, with set point marked, and should not change unless other system conditions change.\n\n# 4.7.10\n\nAirlocks can be important components in setting up and maintaining pressure cascade systems and also to limit cross-contamination.\n\n# 4.7.11\n\nAirlocks with different pressure cascade regimes include the cascade airlock, sink airlock and bubble airlock (Figures 19\u201321):\n\n- **Cascade airlock:** higher pressure on one side of the airlock and lower pressure on the other;\n- **Sink airlock:** lower pressure inside the airlock and higher pressure on both outer sides;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto aborda la importancia de los diferenciales de presi\u00f3n en entornos controlados, como laboratorios o instalaciones de bioseguridad. Se discuten los niveles de presi\u00f3n recomendados (entre 5 Pa y 20 Pa) para evitar el flujo inverso y garantizar la contenci\u00f3n. Tambi\u00e9n se menciona la necesidad de considerar variaciones transitorias y la calibraci\u00f3n de dispositivos de control de presi\u00f3n. Se destacan los sistemas de aire de presi\u00f3n, como los airlocks, que ayudan a mantener la segregaci\u00f3n de \u00e1reas y prevenir la contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el rango de presi\u00f3n diferencial recomendado para evitar el flujo inverso entre dos zonas adyacentes, y qu\u00e9 implicaciones tiene un dise\u00f1o de presi\u00f3n demasiado bajo?**\n   - Respuesta: Se recomienda un diferencial de presi\u00f3n de 15 Pa, aunque se aceptan rangos entre 5 Pa y 20 Pa. Un dise\u00f1o de presi\u00f3n demasiado bajo puede resultar en un flujo inverso si las tolerancias est\u00e1n en extremos opuestos.\n\n2. **\u00bfQu\u00e9 papel juegan los airlocks en la gesti\u00f3n de los diferenciales de presi\u00f3n y c\u00f3mo se clasifican?**\n   - Respuesta: Los airlocks son componentes clave para establecer y mantener sistemas de cascada de presi\u00f3n y limitar la contaminaci\u00f3n cruzada. Se clasifican en tres tipos: airlock de cascada, airlock de hundimiento y airlock de burbuja.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para asegurar la efectividad de los dispositivos de control y monitoreo de presi\u00f3n?**\n   - Respuesta: Los dispositivos de control y monitoreo de presi\u00f3n deben ser calibrados y calificados, y su cumplimiento con las especificaciones debe ser verificado regularmente. Adem\u00e1s, deben estar vinculados a un sistema de alarma basado en un an\u00e1lisis de riesgo.", "prev_section_summary": "### Temas Clave\n\n1. **Contenci\u00f3n de Productos Altamente Potentes**: Se enfatiza la necesidad de un r\u00e9gimen de cascada de presi\u00f3n negativa para la fabricaci\u00f3n de productos altamente potentes, asegurando que las instalaciones est\u00e9n dise\u00f1adas para mantener un ambiente controlado.\n\n2. **Evaluaci\u00f3n Individual de Instalaciones**: Cada instalaci\u00f3n debe ser evaluada de manera individual seg\u00fan el producto manejado y el nivel de protecci\u00f3n requerido, lo que implica un an\u00e1lisis detallado de las caracter\u00edsticas espec\u00edficas de cada entorno.\n\n3. **Dise\u00f1o Estructural**: La estructura del edificio debe ser dise\u00f1ada para facilitar el r\u00e9gimen de cascada de presi\u00f3n, incluyendo techos, paredes, puertas ajustadas y luminarias selladas para limitar la entrada y salida de aire.\n\n4. **M\u00e9todos de Contenci\u00f3n**:\n   - **Concepto de Desplazamiento**: Este m\u00e9todo implica un bajo diferencial de presi\u00f3n y un alto flujo de aire, pero no es el preferido debido a la dificultad de medir y monitorear las velocidades de flujo de aire en las puertas.\n   - **Concepto de Diferencial de Presi\u00f3n**: Este m\u00e9todo se utiliza en zonas donde se genera poco o ning\u00fan polvo, generando un alto diferencial de presi\u00f3n a trav\u00e9s de fugas en las puertas cerradas.\n\n### Entidades\n\n- **Productos Altamente Potentes**: Productos que requieren un manejo cuidadoso debido a su potencia.\n- **R\u00e9gimen de Cascada de Presi\u00f3n**: Sistema de control de presi\u00f3n que debe ser negativo en relaci\u00f3n con la presi\u00f3n atmosf\u00e9rica.\n- **Zonas Limpias y Menos Limpias**: \u00c1reas dentro de la instalaci\u00f3n que requieren diferentes niveles de contenci\u00f3n y control de contaminaci\u00f3n.\n- **Vest\u00edbulo de Doble Puerta**: T\u00e9cnica de control de contenci\u00f3n que puede combinarse con el concepto de diferencial de presi\u00f3n.\n\n### Resumen General\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de productos altamente potentes, destacando la importancia de un dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la contenci\u00f3n. Se presentan dos enfoques para la contenci\u00f3n: el desplazamiento y el diferencial de presi\u00f3n, cada uno con sus propias caracter\u00edsticas y aplicaciones. Se enfatiza la necesidad de un an\u00e1lisis individualizado de cada instalaci\u00f3n y la atenci\u00f3n a los detalles estructurales para mantener un ambiente controlado y seguro.", "excerpt_keywords": "Keywords: pressure differential, containment, airlocks, risk analysis, monitoring devices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6deff116-2930-4a27-83e7-9a596b4e2365", "node_type": "4", "metadata": {"page_label": "252", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.7.2\n\nThe pressure differential should be of sufficient magnitude to ensure containment and prevention of flow reversal, but should not be so high as to create turbulence problems.\n\n# 4.7.3\n\nIn considering room pressure differentials, transient variations, such as machine extract systems, should be taken into consideration.\n\n# 4.7.4\n\nA pressure differential of 15 Pa is often used for achieving containment between two adjacent zones, but pressure differentials of between 5 Pa and 20 Pa may be acceptable. Where the design pressure differential is too low and tolerances are at opposite extremities, a flow reversal can take place. For example, where a control tolerance of \u00b1 3 Pa is specified, the implications of rooms being operated at the upper and lower tolerances should be evaluated. It is important to select pressures and tolerances such that a flow reversal is unlikely to occur.\n\n# 4.7.5\n\nThe pressure differential between adjacent rooms could be considered a critical parameter, depending on the outcome of risk analysis. The limits for the pressure differential between adjacent areas should be such that there is no risk of overlap in the acceptable operating range, e.g. 5 Pa to 15 Pa in one room and 15 Pa to 30 Pa in an adjacent room, resulting in the failure of the pressure cascade, where the first room is at the maximum pressure limit and the second room is at its minimum pressure limit.\n\n# 4.7.6\n\nLow pressure differentials may be acceptable when airlocks (pressure sinks or pressure bubbles) are used to segregate areas.\n\n# 4.7.7\n\nThe effect of room pressure tolerances are illustrated in Figure 18.\n\n# 4.7.8\n\nThe pressure control and monitoring devices used should be calibrated and qualified. Compliance with specifications should be regularly verified and the results recorded. Pressure control devices should be linked to an alarm system set according to the levels determined by a risk analysis.\n\n# 4.7.9\n\nManual control systems, where used, should be set up during commissioning, with set point marked, and should not change unless other system conditions change.\n\n# 4.7.10\n\nAirlocks can be important components in setting up and maintaining pressure cascade systems and also to limit cross-contamination.\n\n# 4.7.11\n\nAirlocks with different pressure cascade regimes include the cascade airlock, sink airlock and bubble airlock (Figures 19\u201321):\n\n- **Cascade airlock:** higher pressure on one side of the airlock and lower pressure on the other;\n- **Sink airlock:** lower pressure inside the airlock and higher pressure on both outer sides;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "216a7820ee9a0ae8e894ed6f962d89f21a7d72dde06274bc77920f11189ba205", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.7.2\n\nThe pressure differential should be of sufficient magnitude to ensure containment and prevention of flow reversal, but should not be so high as to create turbulence problems.\n\n# 4.7.3\n\nIn considering room pressure differentials, transient variations, such as machine extract systems, should be taken into consideration.\n\n# 4.7.4\n\nA pressure differential of 15 Pa is often used for achieving containment between two adjacent zones, but pressure differentials of between 5 Pa and 20 Pa may be acceptable. Where the design pressure differential is too low and tolerances are at opposite extremities, a flow reversal can take place. For example, where a control tolerance of \u00b1 3 Pa is specified, the implications of rooms being operated at the upper and lower tolerances should be evaluated. It is important to select pressures and tolerances such that a flow reversal is unlikely to occur.\n\n# 4.7.5\n\nThe pressure differential between adjacent rooms could be considered a critical parameter, depending on the outcome of risk analysis. The limits for the pressure differential between adjacent areas should be such that there is no risk of overlap in the acceptable operating range, e.g. 5 Pa to 15 Pa in one room and 15 Pa to 30 Pa in an adjacent room, resulting in the failure of the pressure cascade, where the first room is at the maximum pressure limit and the second room is at its minimum pressure limit.\n\n# 4.7.6\n\nLow pressure differentials may be acceptable when airlocks (pressure sinks or pressure bubbles) are used to segregate areas.\n\n# 4.7.7\n\nThe effect of room pressure tolerances are illustrated in Figure 18.\n\n# 4.7.8\n\nThe pressure control and monitoring devices used should be calibrated and qualified. Compliance with specifications should be regularly verified and the results recorded. Pressure control devices should be linked to an alarm system set according to the levels determined by a risk analysis.\n\n# 4.7.9\n\nManual control systems, where used, should be set up during commissioning, with set point marked, and should not change unless other system conditions change.\n\n# 4.7.10\n\nAirlocks can be important components in setting up and maintaining pressure cascade systems and also to limit cross-contamination.\n\n# 4.7.11\n\nAirlocks with different pressure cascade regimes include the cascade airlock, sink airlock and bubble airlock (Figures 19\u201321):\n\n- **Cascade airlock:** higher pressure on one side of the airlock and lower pressure on the other;\n- **Sink airlock:** lower pressure inside the airlock and higher pressure on both outer sides;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2574, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1c7048a8-cf00-45b8-99f3-10ec1efcd1b5": {"__data__": {"id_": "1c7048a8-cf00-45b8-99f3-10ec1efcd1b5", "embedding": null, "metadata": {"page_label": "253", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 18\n## Examples of pressure cascades\n\n!Image of room pressure gauge indicating colour coded normal, alert & action parameters\n\n### Diagram 1\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n### Diagram 2\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n# Figure 19\n## Example of cascade airlock\n\n*(In most cases the internal pressure of the airlock is not critical. The pressure differential between the two outer sides is the important criteria.)*\n\n### Diagram\n- **Air Leakage**: \n  - Left: 15 Pa\n  - Right: 30 Pa\n- **Material Airlock**: 22.5 Pa\n- **Cascade Airlock**: \n\n**Pressure Differential**: Between 15 Pa and 30 Pa.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta informaci\u00f3n sobre la presi\u00f3n en compartimentos y sistemas de aire, espec\u00edficamente en relaci\u00f3n con las cascadas de presi\u00f3n y los airlocks (puertas de aire). Se describen dos diagramas que ilustran los niveles de presi\u00f3n t\u00edpicos en diferentes compartimentos, as\u00ed como un ejemplo de un airlock en cascada. Se enfatiza la importancia del diferencial de presi\u00f3n entre los lados exteriores de un airlock, en lugar de la presi\u00f3n interna.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la presi\u00f3n t\u00edpica recomendada para un compartimento de decontaminaci\u00f3n seg\u00fan los diagramas presentados?**\n   - Respuesta: La presi\u00f3n t\u00edpica recomendada para un compartimento de decontaminaci\u00f3n es de 15 Pa \u00b1 5 Pa.\n\n2. **En el contexto de un airlock, \u00bfcu\u00e1l es el rango de presi\u00f3n diferencial que se establece entre los dos lados exteriores seg\u00fan el ejemplo proporcionado?**\n   - Respuesta: El rango de presi\u00f3n diferencial establecido entre los dos lados exteriores del airlock es entre 15 Pa y 30 Pa.\n\n3. **\u00bfQu\u00e9 se considera m\u00e1s cr\u00edtico en el dise\u00f1o de un airlock, la presi\u00f3n interna o el diferencial de presi\u00f3n entre los lados exteriores?**\n   - Respuesta: En la mayor\u00eda de los casos, el diferencial de presi\u00f3n entre los dos lados exteriores es el criterio m\u00e1s importante, no la presi\u00f3n interna del airlock.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre la gesti\u00f3n de la presi\u00f3n en entornos controlados, destacando la importancia de mantener diferencias de presi\u00f3n adecuadas para prevenir la contaminaci\u00f3n y asegurar la seguridad en \u00e1reas de decontaminaci\u00f3n y en el uso de airlocks. Se presentan valores espec\u00edficos de presi\u00f3n para diferentes compartimentos y se discute la relevancia del diferencial de presi\u00f3n en el dise\u00f1o de sistemas de aire.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Diferenciales de Presi\u00f3n**: Se enfatiza la importancia de mantener un diferencial de presi\u00f3n adecuado para asegurar la contenci\u00f3n y prevenir el flujo inverso entre zonas adyacentes. Se recomienda un diferencial de 15 Pa, con un rango aceptable entre 5 Pa y 20 Pa.\n\n2. **Variaciones Transitorias**: Se deben considerar las variaciones transitorias en los sistemas de extracci\u00f3n de m\u00e1quinas al evaluar los diferenciales de presi\u00f3n en las habitaciones.\n\n3. **Riesgo de Flujo Inverso**: Un dise\u00f1o de presi\u00f3n demasiado bajo, combinado con tolerancias en extremos opuestos, puede resultar en un flujo inverso. Es crucial seleccionar presiones y tolerancias que minimicen este riesgo.\n\n4. **An\u00e1lisis de Riesgo**: El diferencial de presi\u00f3n entre habitaciones adyacentes es un par\u00e1metro cr\u00edtico que debe evaluarse mediante un an\u00e1lisis de riesgo para evitar la superposici\u00f3n en los rangos operativos aceptables.\n\n5. **Airlocks**: Los airlocks son componentes esenciales para mantener sistemas de cascada de presi\u00f3n y prevenir la contaminaci\u00f3n cruzada. Se clasifican en:\n   - **Airlock de Cascada**: Mayor presi\u00f3n en un lado y menor en el otro.\n   - **Airlock de Hundimiento**: Menor presi\u00f3n dentro del airlock y mayor presi\u00f3n en ambos lados exteriores.\n   - **Airlock de Burbuja**: (no se detalla en el texto, pero se menciona).\n\n6. **Control y Monitoreo de Presi\u00f3n**: Los dispositivos de control y monitoreo de presi\u00f3n deben ser calibrados y calificados, y su cumplimiento debe ser verificado regularmente. Deben estar conectados a un sistema de alarma basado en un an\u00e1lisis de riesgo.\n\n7. **Sistemas de Control Manual**: Los sistemas de control manual deben establecerse durante la puesta en marcha y no deben cambiar a menos que cambien otras condiciones del sistema.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Pa (Pascal)**: Unidad de medida utilizada para los diferenciales de presi\u00f3n.\n- **Airlocks**: Dispositivos utilizados para mantener la presi\u00f3n y prevenir la contaminaci\u00f3n cruzada.\n- **Riesgo**: Concepto clave en la evaluaci\u00f3n de los diferenciales de presi\u00f3n y su gesti\u00f3n. \n\nEste resumen destaca la importancia de los diferenciales de presi\u00f3n en entornos controlados y las medidas necesarias para garantizar su efectividad y seguridad.", "excerpt_keywords": "Keywords: presi\u00f3n, airlock, decontaminaci\u00f3n, diferencial, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2144fde-ac86-4cde-8816-217f34d49dd2", "node_type": "4", "metadata": {"page_label": "253", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 18\n## Examples of pressure cascades\n\n!Image of room pressure gauge indicating colour coded normal, alert & action parameters\n\n### Diagram 1\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n### Diagram 2\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n# Figure 19\n## Example of cascade airlock\n\n*(In most cases the internal pressure of the airlock is not critical. The pressure differential between the two outer sides is the important criteria.)*\n\n### Diagram\n- **Air Leakage**: \n  - Left: 15 Pa\n  - Right: 30 Pa\n- **Material Airlock**: 22.5 Pa\n- **Cascade Airlock**: \n\n**Pressure Differential**: Between 15 Pa and 30 Pa.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "edaa94f3a4079a109aeb7723cba0d286275967800091b48f895ac1f54767949b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 18\n## Examples of pressure cascades\n\n!Image of room pressure gauge indicating colour coded normal, alert & action parameters\n\n### Diagram 1\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n### Diagram 2\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n# Figure 19\n## Example of cascade airlock\n\n*(In most cases the internal pressure of the airlock is not critical. The pressure differential between the two outer sides is the important criteria.)*\n\n### Diagram\n- **Air Leakage**: \n  - Left: 15 Pa\n  - Right: 30 Pa\n- **Material Airlock**: 22.5 Pa\n- **Cascade Airlock**: \n\n**Pressure Differential**: Between 15 Pa and 30 Pa.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 845, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0c6dc04a-f7bf-4a9d-8df8-aeb08491250d": {"__data__": {"id_": "0c6dc04a-f7bf-4a9d-8df8-aeb08491250d", "embedding": null, "metadata": {"page_label": "254", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 20\n**Example of sink airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      30 Pa        |      30 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   15 Pa               |\n+---------------------------------------+\n|                   Sink Airlock        |\n+---------------------------------------+\n```\n\n# Figure 21\n**Example of bubble airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      15 Pa        |      15 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   30 Pa               |\n+---------------------------------------+\n|                   Bubble Airlock      |\n+---------------------------------------+\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye ejemplos de diferentes tipos de \"airlocks\" (compuertas de aire) utilizados en entornos controlados. Se presentan dos tipos espec\u00edficos: el \"sink airlock\" y el \"bubble airlock\", cada uno con sus respectivas caracter\u00edsticas de presi\u00f3n y manejo de fugas de aire. El \"sink airlock\" tiene una presi\u00f3n de 15 Pa en su interior y 30 Pa en el exterior, mientras que el \"bubble airlock\" tiene 30 Pa en su interior y 15 Pa en el exterior. Ambos dise\u00f1os est\u00e1n destinados a minimizar la fuga de aire entre diferentes \u00e1reas.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la diferencia en la presi\u00f3n entre el interior y el exterior del \"sink airlock\" y el \"bubble airlock\"?**\n   - Respuesta: El \"sink airlock\" tiene una presi\u00f3n de 15 Pa en su interior y 30 Pa en el exterior, mientras que el \"bubble airlock\" tiene 30 Pa en su interior y 15 Pa en el exterior.\n\n2. **\u00bfQu\u00e9 funci\u00f3n tienen las fugas de aire en el dise\u00f1o de los \"airlocks\" mencionados en el documento?**\n   - Respuesta: Las fugas de aire en el dise\u00f1o de los \"airlocks\" est\u00e1n destinadas a controlar el flujo de aire entre diferentes \u00e1reas, asegurando que la presi\u00f3n se mantenga adecuada y minimizando la contaminaci\u00f3n cruzada.\n\n3. **\u00bfC\u00f3mo se representan las fugas de aire en los diagramas de los \"airlocks\"?**\n   - Respuesta: En los diagramas, las fugas de aire se representan con flechas que indican la direcci\u00f3n del flujo de aire, mostrando que hay aire que se escapa hacia el exterior o que entra desde el exterior, dependiendo del tipo de \"airlock\".", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Cascadas de Presi\u00f3n**:\n   - Se presentan ejemplos de cascadas de presi\u00f3n en compartimentos, destacando la importancia de mantener niveles de presi\u00f3n adecuados para la seguridad y la prevenci\u00f3n de contaminaci\u00f3n.\n\n2. **Presiones T\u00edpicas en Compartimentos**:\n   - **Compartimento T\u00edpico**: 50 Pa \u00b1 5 Pa\n   - **Compartimento T\u00edpico**: 35 Pa \u00b1 5 Pa\n   - **Compartimento de Decontaminaci\u00f3n**: 15 Pa \u00b1 5 Pa\n   - Se establece un gradiente de presi\u00f3n de 15 Pa (\u00b1 5 Pa) entre los compartimentos.\n\n3. **Airlocks (Puertas de Aire)**:\n   - Se discute un ejemplo de un airlock en cascada, donde la presi\u00f3n interna no es cr\u00edtica, sino que el diferencial de presi\u00f3n entre los lados exteriores es el criterio m\u00e1s importante.\n   - **Diferencial de Presi\u00f3n**: Entre 15 Pa (lado izquierdo) y 30 Pa (lado derecho).\n   - **Material Airlock**: 22.5 Pa.\n\n4. **Importancia del Diferencial de Presi\u00f3n**:\n   - Se enfatiza que el diferencial de presi\u00f3n entre los lados exteriores de un airlock es fundamental para el dise\u00f1o y funcionamiento efectivo de estos sistemas, m\u00e1s que la presi\u00f3n interna.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la gesti\u00f3n de la presi\u00f3n en entornos controlados.\n- **Pa (Pascal)**: Unidad de medida utilizada para expresar la presi\u00f3n en los compartimentos y airlocks.\n- **Compartimentos**: Espacios controlados donde se gestionan las presiones para asegurar la seguridad y la decontaminaci\u00f3n.\n- **Airlock (Puerta de Aire)**: Sistema dise\u00f1ado para controlar el flujo de aire y la presi\u00f3n entre diferentes \u00e1reas, crucial en entornos de decontaminaci\u00f3n. \n\nEste resumen destaca la relevancia de mantener presiones adecuadas y el dise\u00f1o de sistemas de aire para garantizar la seguridad en entornos controlados.", "excerpt_keywords": "Keywords: airlock, pressure differential, contamination control, WHO, technical report"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d7c517a-dee7-4fc3-a7f9-a3d1f8552ee7", "node_type": "4", "metadata": {"page_label": "254", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 20\n**Example of sink airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      30 Pa        |      30 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   15 Pa               |\n+---------------------------------------+\n|                   Sink Airlock        |\n+---------------------------------------+\n```\n\n# Figure 21\n**Example of bubble airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      15 Pa        |      15 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   30 Pa               |\n+---------------------------------------+\n|                   Bubble Airlock      |\n+---------------------------------------+\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6e67e87a2dd9d8a2e6c4b120b9d1d670f9aaaf4979611607c2e6110caab89dda", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 20\n**Example of sink airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      30 Pa        |      30 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   15 Pa               |\n+---------------------------------------+\n|                   Sink Airlock        |\n+---------------------------------------+\n```\n\n# Figure 21\n**Example of bubble airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      15 Pa        |      15 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   30 Pa               |\n+---------------------------------------+\n|                   Bubble Airlock      |\n+---------------------------------------+\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1108, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "22282cf5-bb37-4382-bddb-de17e1509c45": {"__data__": {"id_": "22282cf5-bb37-4382-bddb-de17e1509c45", "embedding": null, "metadata": {"page_label": "255", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- bubble airlock: higher pressure inside the airlock and lower pressure on both outer sides.\n\n*Note: The diagrams above and the differential pressures shown here are for illustration purposes only. Pressures indicated in these examples are absolute pressures, whereas the local pressure indication would most likely be pressure differential from room to room.*\n\n### 4.7.12\nDoors should open to the high pressure side, so that room pressure assists in holding the door closed and in addition be provided with self-closers. Should the doors open to the low pressure side, the door closer springs should be sufficient to hold the door closed and prevent the pressure differential from pushing the door open. There should be a method to indicate if both doors to airlocks are open at the same time, or alternatively these should be interlocked. The determination of which doors should be interlocked should be the subject of a risk assessment study.\n\n### 4.7.13\nCentral dust extraction systems should be interlocked with the appropriate air-handling systems, to ensure that they operate simultaneously.\n\n### 4.7.14\nRoom pressure differential between adjacent cubicles, which are linked by common dust extraction ducting, should be avoided.\n\n### 4.7.15\nAir should not flow through the dust extraction ducting or return air ducting from the room with the higher pressure to the room with the lower pressure (this would normally occur only if extract or return systems were inoperative). Systems should be designed to prevent dust flowing back in the opposite direction in the event of component failure or airflow failure.\n\n### 4.7.16\nAdequate room pressure differential indication should be provided so that each critical room pressure can be traced back to ambient pressure (by summation of the room pressure differentials), in order to determine the room actual absolute pressure. Room pressure indication gauges should have a range and graduation scale which enables the reading to an accuracy, as appropriate; normal operating range, alert and action limits should be defined and displayed at the point of indication. A colour coding gauge may be helpful.\n\nRoom pressure indication may be either analogue or digital, and may be represented as either pressure differentials or absolute pressures. Whichever system is used any out-of-specification condition should be easily identifiable.\n\n### 4.7.17\nMaterial pass-through-hatches (PTH) or pass boxes (PB) can also be used for separating two different zones. PTHs fall into two categories, namely a dynamic PTH or a passive PTH. Dynamic PTHs have an air supply to or extraction from them, and can then be used as bubble, sink or cascade PTHs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de las puertas en un sistema de burbuja de aire (bubble airlock) seg\u00fan el documento?**\n   - **Respuesta:** Las puertas deben abrirse hacia el lado de alta presi\u00f3n para que la presi\u00f3n de la habitaci\u00f3n ayude a mantener la puerta cerrada. Adem\u00e1s, deben estar equipadas con mecanismos de cierre autom\u00e1tico. Si las puertas abren hacia el lado de baja presi\u00f3n, los resortes de cierre deben ser suficientes para mantener la puerta cerrada y evitar que la diferencia de presi\u00f3n la empuje hacia afuera.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para evitar el flujo de aire no deseado entre habitaciones de diferentes presiones?**\n   - **Respuesta:** Se debe evitar que el aire fluya a trav\u00e9s de los ductos de extracci\u00f3n de polvo o de retorno desde la habitaci\u00f3n de mayor presi\u00f3n hacia la de menor presi\u00f3n. Los sistemas deben estar dise\u00f1ados para prevenir el retroceso de polvo en caso de fallos en los componentes o en el flujo de aire.\n\n3. **\u00bfC\u00f3mo se debe indicar la presi\u00f3n diferencial de las habitaciones cr\u00edticas y qu\u00e9 caracter\u00edsticas deben tener los man\u00f3metros de presi\u00f3n?**\n   - **Respuesta:** Se debe proporcionar una indicaci\u00f3n adecuada de la presi\u00f3n diferencial de las habitaciones para que cada presi\u00f3n cr\u00edtica pueda rastrearse hasta la presi\u00f3n ambiente. Los man\u00f3metros deben tener un rango y una escala de graduaci\u00f3n que permitan lecturas precisas, y deben definirse y mostrarse los l\u00edmites de operaci\u00f3n normal, alerta y acci\u00f3n en el punto de indicaci\u00f3n. Un man\u00f3metro con codificaci\u00f3n por colores puede ser \u00fatil para identificar condiciones fuera de especificaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS detalla las mejores pr\u00e1cticas para el dise\u00f1o y funcionamiento de sistemas de control de presi\u00f3n en entornos cr\u00edticos, como laboratorios o instalaciones de bioseguridad. Se enfatiza la importancia de mantener diferencias de presi\u00f3n adecuadas entre habitaciones, el uso de puertas y sistemas de extracci\u00f3n de polvo interconectados, y la necesidad de indicadores precisos de presi\u00f3n para garantizar la seguridad y la eficacia operativa. Adem\u00e1s, se discuten las caracter\u00edsticas de los pasajes de materiales que pueden ayudar a separar diferentes zonas dentro de estas instalaciones.\n\n### Preguntas Generadas a Partir del Resumen\n\n1. **\u00bfPor qu\u00e9 es crucial mantener diferencias de presi\u00f3n adecuadas en entornos cr\u00edticos seg\u00fan el documento?**\n2. **\u00bfQu\u00e9 papel juegan los sistemas de extracci\u00f3n de polvo en la seguridad de las instalaciones descritas?**\n3. **\u00bfCu\u00e1les son las caracter\u00edsticas recomendadas para los pasajes de materiales en el contexto de separaci\u00f3n de zonas?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado se centra en dos tipos de compuertas de aire (airlocks) utilizados en entornos controlados, espec\u00edficamente el \"sink airlock\" y el \"bubble airlock\". A continuaci\u00f3n se detallan los temas clave y las entidades relevantes:\n\n#### Temas Clave:\n1. **Tipos de Airlocks**:\n   - **Sink Airlock**: Dise\u00f1ado con una presi\u00f3n interna de 15 Pa y externa de 30 Pa, lo que permite un control espec\u00edfico de la fuga de aire hacia el exterior.\n   - **Bubble Airlock**: Presenta una presi\u00f3n interna de 30 Pa y externa de 15 Pa, lo que tambi\u00e9n facilita el manejo de la fuga de aire, pero en direcci\u00f3n opuesta al sink airlock.\n\n2. **Manejo de la Presi\u00f3n**:\n   - La diferencia de presi\u00f3n entre el interior y el exterior de cada tipo de airlock es fundamental para su funcionamiento, ayudando a prevenir la contaminaci\u00f3n cruzada y a mantener un ambiente controlado.\n\n3. **Fugas de Aire**:\n   - Las fugas de aire son representadas en los diagramas mediante flechas que indican la direcci\u00f3n del flujo, lo que es crucial para entender c\u00f3mo cada tipo de airlock gestiona el aire entre diferentes \u00e1reas.\n\n#### Entidades:\n- **Airlocks**: Compuertas de aire utilizadas en entornos controlados.\n- **Sink Airlock**: Un tipo espec\u00edfico de airlock con caracter\u00edsticas de presi\u00f3n definidas.\n- **Bubble Airlock**: Otro tipo de airlock, tambi\u00e9n con caracter\u00edsticas de presi\u00f3n espec\u00edficas.\n- **Presi\u00f3n (Pa)**: Unidad de medida utilizada para describir la presi\u00f3n en el interior y exterior de los airlocks.\n\nEste resumen destaca la importancia de los airlocks en el control de la contaminaci\u00f3n y la gesti\u00f3n del aire en entornos sensibles, as\u00ed como las diferencias clave entre los dos tipos presentados.", "excerpt_keywords": "Keywords: airlock, pressure differential, dust extraction, room pressure indication, pass-through-hatch"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e79ad889-4c4a-41b4-8cd0-589cc62d579b", "node_type": "4", "metadata": {"page_label": "255", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- bubble airlock: higher pressure inside the airlock and lower pressure on both outer sides.\n\n*Note: The diagrams above and the differential pressures shown here are for illustration purposes only. Pressures indicated in these examples are absolute pressures, whereas the local pressure indication would most likely be pressure differential from room to room.*\n\n### 4.7.12\nDoors should open to the high pressure side, so that room pressure assists in holding the door closed and in addition be provided with self-closers. Should the doors open to the low pressure side, the door closer springs should be sufficient to hold the door closed and prevent the pressure differential from pushing the door open. There should be a method to indicate if both doors to airlocks are open at the same time, or alternatively these should be interlocked. The determination of which doors should be interlocked should be the subject of a risk assessment study.\n\n### 4.7.13\nCentral dust extraction systems should be interlocked with the appropriate air-handling systems, to ensure that they operate simultaneously.\n\n### 4.7.14\nRoom pressure differential between adjacent cubicles, which are linked by common dust extraction ducting, should be avoided.\n\n### 4.7.15\nAir should not flow through the dust extraction ducting or return air ducting from the room with the higher pressure to the room with the lower pressure (this would normally occur only if extract or return systems were inoperative). Systems should be designed to prevent dust flowing back in the opposite direction in the event of component failure or airflow failure.\n\n### 4.7.16\nAdequate room pressure differential indication should be provided so that each critical room pressure can be traced back to ambient pressure (by summation of the room pressure differentials), in order to determine the room actual absolute pressure. Room pressure indication gauges should have a range and graduation scale which enables the reading to an accuracy, as appropriate; normal operating range, alert and action limits should be defined and displayed at the point of indication. A colour coding gauge may be helpful.\n\nRoom pressure indication may be either analogue or digital, and may be represented as either pressure differentials or absolute pressures. Whichever system is used any out-of-specification condition should be easily identifiable.\n\n### 4.7.17\nMaterial pass-through-hatches (PTH) or pass boxes (PB) can also be used for separating two different zones. PTHs fall into two categories, namely a dynamic PTH or a passive PTH. Dynamic PTHs have an air supply to or extraction from them, and can then be used as bubble, sink or cascade PTHs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "319f36d3475e943387167f19ce0f6677ca545e664630c008dca8915f61a1bc86", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- bubble airlock: higher pressure inside the airlock and lower pressure on both outer sides.\n\n*Note: The diagrams above and the differential pressures shown here are for illustration purposes only. Pressures indicated in these examples are absolute pressures, whereas the local pressure indication would most likely be pressure differential from room to room.*\n\n### 4.7.12\nDoors should open to the high pressure side, so that room pressure assists in holding the door closed and in addition be provided with self-closers. Should the doors open to the low pressure side, the door closer springs should be sufficient to hold the door closed and prevent the pressure differential from pushing the door open. There should be a method to indicate if both doors to airlocks are open at the same time, or alternatively these should be interlocked. The determination of which doors should be interlocked should be the subject of a risk assessment study.\n\n### 4.7.13\nCentral dust extraction systems should be interlocked with the appropriate air-handling systems, to ensure that they operate simultaneously.\n\n### 4.7.14\nRoom pressure differential between adjacent cubicles, which are linked by common dust extraction ducting, should be avoided.\n\n### 4.7.15\nAir should not flow through the dust extraction ducting or return air ducting from the room with the higher pressure to the room with the lower pressure (this would normally occur only if extract or return systems were inoperative). Systems should be designed to prevent dust flowing back in the opposite direction in the event of component failure or airflow failure.\n\n### 4.7.16\nAdequate room pressure differential indication should be provided so that each critical room pressure can be traced back to ambient pressure (by summation of the room pressure differentials), in order to determine the room actual absolute pressure. Room pressure indication gauges should have a range and graduation scale which enables the reading to an accuracy, as appropriate; normal operating range, alert and action limits should be defined and displayed at the point of indication. A colour coding gauge may be helpful.\n\nRoom pressure indication may be either analogue or digital, and may be represented as either pressure differentials or absolute pressures. Whichever system is used any out-of-specification condition should be easily identifiable.\n\n### 4.7.17\nMaterial pass-through-hatches (PTH) or pass boxes (PB) can also be used for separating two different zones. PTHs fall into two categories, namely a dynamic PTH or a passive PTH. Dynamic PTHs have an air supply to or extraction from them, and can then be used as bubble, sink or cascade PTHs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2689, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e650108a-0745-4f56-bd8f-2db170cda741": {"__data__": {"id_": "e650108a-0745-4f56-bd8f-2db170cda741", "embedding": null, "metadata": {"page_label": "256", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 Physical barrier concept\n\n4.8.1 Where appropriate, an impervious barrier to prevent cross-contamination between two zones, such as closed systems, pumped or vacuum transfer of materials, should be used.\n\n# 4.9 Temperature and relative humidity\n\n4.9.1 Where appropriate, temperature and relative humidity should be controlled, monitored and recorded, where relevant, to ensure compliance with requirements pertinent to the materials and products and provide a comfortable environment for the operator where necessary.\n\n4.9.2 Maximum and minimum room temperatures and relative humidity should be appropriate. Alert and action limits on temperatures and humidities should be set, as appropriate.\n\n4.9.3 The operating band, or tolerance, between the acceptable minimum and maximum temperatures should not be made too close. Tight control tolerances may be difficult to achieve and can also add unnecessary installation and running costs.\n\n4.9.4 Cubicles, or suites, in which products requiring low relative humidity are processed, should have well-sealed walls and ceilings and should also be separated from adjacent areas with higher relative humidity by means of suitable airlocks.\n\n4.9.5 Precautions should be taken to prevent moisture migration that increases the load on the HVAC system.\n\n4.9.6 Humidity control should be achieved by removing moisture from the air, or adding moisture to the air, as relevant.\n\n4.9.7 Dehumidification (moisture removal) may be achieved by means of either refrigerated dehumidifiers or chemical dehumidifiers.\n\n4.9.8 Appropriate cooling media for dehumidification such as low temperature chilled water/glycol mixture or refrigerant should be used.\n\n4.9.9 Humidifiers should be avoided if possible as they may become a source of contamination (e.g. microbiological growth). Where humidification is required, this should be achieved by appropriate means such as the injection of steam into the air stream. A product-contamination assessment should be done to determine whether pure or clean steam is required for the purposes of humidification.\n\n4.9.10 Where steam humidifiers are used, chemicals such as corrosion inhibitors or chelating agents, which could have a detrimental effect on", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos cr\u00edticos de control ambiental en la producci\u00f3n y manejo de materiales y productos, centr\u00e1ndose en la importancia de barreras f\u00edsicas para prevenir la contaminaci\u00f3n cruzada y el control de temperatura y humedad. Se enfatiza la necesidad de mantener condiciones adecuadas para garantizar la calidad de los productos y la comodidad de los operadores, as\u00ed como las precauciones necesarias para evitar la migraci\u00f3n de humedad y la contaminaci\u00f3n microbiol\u00f3gica.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el control de la humedad en \u00e1reas donde se procesan productos que requieren baja humedad relativa?**\n   - El documento sugiere que estas \u00e1reas deben tener paredes y techos bien sellados y estar separadas de zonas adyacentes con mayor humedad relativa mediante airlocks adecuados. Adem\u00e1s, se deben tomar precauciones para prevenir la migraci\u00f3n de humedad que aumente la carga en el sistema HVAC.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para la deshumidificaci\u00f3n y cu\u00e1les son los medios de enfriamiento apropiados para este proceso?**\n   - La deshumidificaci\u00f3n puede lograrse mediante deshumidificadores refrigerados o qu\u00edmicos. Se recomienda el uso de medios de enfriamiento apropiados, como una mezcla de agua/glicol enfriada a baja temperatura o refrigerantes.\n\n3. **\u00bfPor qu\u00e9 se deben evitar los humidificadores y qu\u00e9 alternativas se sugieren si la humidificaci\u00f3n es necesaria?**\n   - Los humidificadores deben evitarse porque pueden convertirse en una fuente de contaminaci\u00f3n, como el crecimiento microbiol\u00f3gico. Si se requiere humidificaci\u00f3n, se sugiere utilizar m\u00e9todos apropiados, como la inyecci\u00f3n de vapor en la corriente de aire, y realizar una evaluaci\u00f3n de contaminaci\u00f3n del producto para determinar si se necesita vapor puro o limpio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Presi\u00f3n Diferencial:**\n   - Importancia de mantener diferencias de presi\u00f3n adecuadas entre habitaciones para garantizar la seguridad y el control de contaminantes.\n\n2. **Puertas de Aire (Bubble Airlock):**\n   - Deben abrirse hacia el lado de alta presi\u00f3n para facilitar el cierre mediante la presi\u00f3n de la habitaci\u00f3n.\n   - Necesidad de mecanismos de cierre autom\u00e1tico y sistemas de interbloqueo para evitar la apertura simult\u00e1nea de puertas.\n\n3. **Sistemas de Extracci\u00f3n de Polvo:**\n   - Deben estar interconectados con sistemas de manejo de aire para asegurar su funcionamiento simult\u00e1neo.\n   - Se debe evitar el flujo de aire no deseado entre habitaciones de diferentes presiones.\n\n4. **Indicadores de Presi\u00f3n:**\n   - Se requiere una indicaci\u00f3n adecuada de la presi\u00f3n diferencial para rastrear la presi\u00f3n cr\u00edtica hasta la presi\u00f3n ambiente.\n   - Los man\u00f3metros deben tener escalas precisas y l\u00edmites de operaci\u00f3n claramente definidos, con opciones de codificaci\u00f3n por colores para facilitar la identificaci\u00f3n de condiciones fuera de especificaci\u00f3n.\n\n5. **Pasajes de Materiales:**\n   - Uso de pasajes de transferencia (PTH) o cajas de paso (PB) para separar zonas diferentes.\n   - Clasificaci\u00f3n de PTH en din\u00e1micos (con suministro o extracci\u00f3n de aire) y pasivos.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Fuente del documento.\n- **Sistemas de Control de Presi\u00f3n:** Elementos cr\u00edticos en entornos de bioseguridad.\n- **Puertas de Aire:** Componentes esenciales para el control de presi\u00f3n.\n- **Sistemas de Extracci\u00f3n de Polvo:** Elementos de seguridad en el manejo de contaminantes.\n- **Man\u00f3metros de Presi\u00f3n:** Dispositivos para medir y mostrar la presi\u00f3n diferencial.\n- **Pasajes de Transferencia (PTH):** Estructuras para la separaci\u00f3n de zonas en instalaciones cr\u00edticas. \n\nEste resumen destaca la importancia de los sistemas de control de presi\u00f3n y las medidas de seguridad necesarias en entornos cr\u00edticos, as\u00ed como las especificaciones t\u00e9cnicas para su implementaci\u00f3n.", "excerpt_keywords": "Keywords: cross-contamination, humidity control, dehumidification, airlocks, environmental monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "796f4878-e7f9-4ad3-8df4-f3c0e0266af8", "node_type": "4", "metadata": {"page_label": "256", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 Physical barrier concept\n\n4.8.1 Where appropriate, an impervious barrier to prevent cross-contamination between two zones, such as closed systems, pumped or vacuum transfer of materials, should be used.\n\n# 4.9 Temperature and relative humidity\n\n4.9.1 Where appropriate, temperature and relative humidity should be controlled, monitored and recorded, where relevant, to ensure compliance with requirements pertinent to the materials and products and provide a comfortable environment for the operator where necessary.\n\n4.9.2 Maximum and minimum room temperatures and relative humidity should be appropriate. Alert and action limits on temperatures and humidities should be set, as appropriate.\n\n4.9.3 The operating band, or tolerance, between the acceptable minimum and maximum temperatures should not be made too close. Tight control tolerances may be difficult to achieve and can also add unnecessary installation and running costs.\n\n4.9.4 Cubicles, or suites, in which products requiring low relative humidity are processed, should have well-sealed walls and ceilings and should also be separated from adjacent areas with higher relative humidity by means of suitable airlocks.\n\n4.9.5 Precautions should be taken to prevent moisture migration that increases the load on the HVAC system.\n\n4.9.6 Humidity control should be achieved by removing moisture from the air, or adding moisture to the air, as relevant.\n\n4.9.7 Dehumidification (moisture removal) may be achieved by means of either refrigerated dehumidifiers or chemical dehumidifiers.\n\n4.9.8 Appropriate cooling media for dehumidification such as low temperature chilled water/glycol mixture or refrigerant should be used.\n\n4.9.9 Humidifiers should be avoided if possible as they may become a source of contamination (e.g. microbiological growth). Where humidification is required, this should be achieved by appropriate means such as the injection of steam into the air stream. A product-contamination assessment should be done to determine whether pure or clean steam is required for the purposes of humidification.\n\n4.9.10 Where steam humidifiers are used, chemicals such as corrosion inhibitors or chelating agents, which could have a detrimental effect on", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cf9d2682569d075cd9326f392a9d9156abde9d761a0ee5eef238fb1efc448216", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.8 Physical barrier concept\n\n4.8.1 Where appropriate, an impervious barrier to prevent cross-contamination between two zones, such as closed systems, pumped or vacuum transfer of materials, should be used.\n\n# 4.9 Temperature and relative humidity\n\n4.9.1 Where appropriate, temperature and relative humidity should be controlled, monitored and recorded, where relevant, to ensure compliance with requirements pertinent to the materials and products and provide a comfortable environment for the operator where necessary.\n\n4.9.2 Maximum and minimum room temperatures and relative humidity should be appropriate. Alert and action limits on temperatures and humidities should be set, as appropriate.\n\n4.9.3 The operating band, or tolerance, between the acceptable minimum and maximum temperatures should not be made too close. Tight control tolerances may be difficult to achieve and can also add unnecessary installation and running costs.\n\n4.9.4 Cubicles, or suites, in which products requiring low relative humidity are processed, should have well-sealed walls and ceilings and should also be separated from adjacent areas with higher relative humidity by means of suitable airlocks.\n\n4.9.5 Precautions should be taken to prevent moisture migration that increases the load on the HVAC system.\n\n4.9.6 Humidity control should be achieved by removing moisture from the air, or adding moisture to the air, as relevant.\n\n4.9.7 Dehumidification (moisture removal) may be achieved by means of either refrigerated dehumidifiers or chemical dehumidifiers.\n\n4.9.8 Appropriate cooling media for dehumidification such as low temperature chilled water/glycol mixture or refrigerant should be used.\n\n4.9.9 Humidifiers should be avoided if possible as they may become a source of contamination (e.g. microbiological growth). Where humidification is required, this should be achieved by appropriate means such as the injection of steam into the air stream. A product-contamination assessment should be done to determine whether pure or clean steam is required for the purposes of humidification.\n\n4.9.10 Where steam humidifiers are used, chemicals such as corrosion inhibitors or chelating agents, which could have a detrimental effect on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2224, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d21c7f4b-1b77-4276-98e1-bec3a161e481": {"__data__": {"id_": "d21c7f4b-1b77-4276-98e1-bec3a161e481", "embedding": null, "metadata": {"page_label": "257", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Dust Control\n\n4.9.11 Humidification systems should be well drained. No condensate should accumulate in air-handling systems.\n\n4.9.12 Other humidification appliances such as evaporative systems, atomizers and water mist sprays, should not be used because of the potential risk of microbial contamination.\n\n4.9.13 Duct material in the vicinity of the humidifier should not add contaminants to air that will not be removed by filtration further downstream.\n\n4.6.14 Air filters should not be installed immediately downstream of humidifiers, as moisture on the filters could lead to bacterial growth.\n\n4.9.15 Cold surfaces should be insulated to prevent condensation within the clean area or on air-handling components.\n\n4.9.16 When specifying relative humidity, the associated temperature should also be specified.\n\n4.9.17 Chemical driers using silica gel or lithium chloride are acceptable, provided that they do not become sources of contamination.\n\n## 5. Dust Control\n\n5.1 Wherever possible, dust or vapour contamination should be removed at source. Point-of-use extraction, i.e. as close as possible to the point where the dust is generated, should be employed. Spot ventilation or capture hoods may be used as appropriate.\n\n5.2 Point-of-use extraction should be either in the form of a fixed high velocity extraction point or an articulated arm with movable hood or a fixed extraction hood.\n\n5.3 Dust extraction ducting should be designed with sufficient transfer velocity to ensure that dust is carried away, and does not settle in the ducting. Periodic checks should be performed to ensure that there is no build up of the dust in the ducting.\n\n5.4 The required transfer velocity should be determined: it is dependent on the density of the dust (the denser the dust, the higher the transfer velocity should be, e.g. 15\u201320 m/s).\n\n5.5 Airflow direction should be carefully chosen, to ensure that the operator does not contaminate the product, and also so that the operator is not put at risk by the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para el control de la humedad y el polvo en entornos limpios. Se enfatiza la importancia de sistemas de humidificaci\u00f3n bien drenados y la eliminaci\u00f3n de contaminantes en el origen, utilizando extracci\u00f3n puntual. Tambi\u00e9n se discuten las especificaciones de dise\u00f1o para ductos de extracci\u00f3n de polvo y la direcci\u00f3n del flujo de aire para proteger tanto el producto como al operador.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el dise\u00f1o de ductos de extracci\u00f3n de polvo en relaci\u00f3n con la velocidad de transferencia?**\n   - La velocidad de transferencia debe ser suficiente para asegurar que el polvo sea transportado y no se asiente en los ductos. Se menciona que la velocidad requerida depende de la densidad del polvo, siendo recomendable una velocidad de 15\u201320 m/s para polvos m\u00e1s densos.\n\n2. **\u00bfQu\u00e9 precauciones se deben tomar al instalar filtros de aire en sistemas de humidificaci\u00f3n?**\n   - Los filtros de aire no deben instalarse inmediatamente despu\u00e9s de los humidificadores, ya que la humedad en los filtros puede favorecer el crecimiento bacteriano.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de extracci\u00f3n se recomiendan para la eliminaci\u00f3n de polvo en el lugar de generaci\u00f3n?**\n   - Se recomienda el uso de extracci\u00f3n puntual, que puede ser en forma de un punto de extracci\u00f3n de alta velocidad fijo, un brazo articulado con capucha m\u00f3vil o una capucha de extracci\u00f3n fija, para asegurar que el polvo se elimine lo m\u00e1s cerca posible de su fuente.", "prev_section_summary": "### Temas Clave:\n\n1. **Barreras F\u00edsicas**: Se enfatiza la importancia de utilizar barreras impermeables para prevenir la contaminaci\u00f3n cruzada entre diferentes zonas, especialmente en sistemas cerrados y en el transporte de materiales mediante bombeo o vac\u00edo.\n\n2. **Control de Temperatura y Humedad**: Se establece la necesidad de controlar, monitorear y registrar la temperatura y la humedad relativa en \u00e1reas relevantes para asegurar el cumplimiento de los requisitos de los materiales y productos, as\u00ed como para proporcionar un ambiente c\u00f3modo para los operadores.\n\n3. **Condiciones Ambientales**: Se deben establecer l\u00edmites de alerta y acci\u00f3n para las temperaturas y humedades, y se recomienda no tener tolerancias demasiado ajustadas para evitar costos innecesarios en la instalaci\u00f3n y operaci\u00f3n.\n\n4. **Dise\u00f1o de Espacios**: Las \u00e1reas donde se procesan productos que requieren baja humedad relativa deben tener paredes y techos bien sellados y estar separadas de \u00e1reas con mayor humedad mediante airlocks.\n\n5. **Prevenci\u00f3n de Migraci\u00f3n de Humedad**: Se deben tomar precauciones para evitar la migraci\u00f3n de humedad que pueda aumentar la carga en el sistema de HVAC.\n\n6. **M\u00e9todos de Deshumidificaci\u00f3n**: Se pueden utilizar deshumidificadores refrigerados o qu\u00edmicos, y se deben emplear medios de enfriamiento adecuados, como mezclas de agua/glicol enfriadas o refrigerantes.\n\n7. **Uso de Humidificadores**: Se recomienda evitar los humidificadores debido a su potencial de contaminaci\u00f3n, sugiriendo en su lugar la inyecci\u00f3n de vapor en la corriente de aire, con una evaluaci\u00f3n de contaminaci\u00f3n del producto para determinar la necesidad de vapor puro o limpio.\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las recomendaciones.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistema mencionado en relaci\u00f3n con el control de humedad.\n- **Deshumidificadores**: Equipos recomendados para el control de humedad.\n- **Airlocks**: Dispositivos para separar \u00e1reas con diferentes niveles de humedad.\n- **Vapor**: M\u00e9todo sugerido para la humidificaci\u00f3n controlada.\n\nEste resumen destaca los aspectos fundamentales del control ambiental en la producci\u00f3n y manejo de materiales, enfatizando la importancia de mantener condiciones adecuadas para la calidad del producto y la seguridad del operador.", "excerpt_keywords": "Keywords: dust control, humidification systems, point-of-use extraction, air filters, transfer velocity"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "95b79d7b-cf4c-45fb-94ab-de9e28d1934c", "node_type": "4", "metadata": {"page_label": "257", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Dust Control\n\n4.9.11 Humidification systems should be well drained. No condensate should accumulate in air-handling systems.\n\n4.9.12 Other humidification appliances such as evaporative systems, atomizers and water mist sprays, should not be used because of the potential risk of microbial contamination.\n\n4.9.13 Duct material in the vicinity of the humidifier should not add contaminants to air that will not be removed by filtration further downstream.\n\n4.6.14 Air filters should not be installed immediately downstream of humidifiers, as moisture on the filters could lead to bacterial growth.\n\n4.9.15 Cold surfaces should be insulated to prevent condensation within the clean area or on air-handling components.\n\n4.9.16 When specifying relative humidity, the associated temperature should also be specified.\n\n4.9.17 Chemical driers using silica gel or lithium chloride are acceptable, provided that they do not become sources of contamination.\n\n## 5. Dust Control\n\n5.1 Wherever possible, dust or vapour contamination should be removed at source. Point-of-use extraction, i.e. as close as possible to the point where the dust is generated, should be employed. Spot ventilation or capture hoods may be used as appropriate.\n\n5.2 Point-of-use extraction should be either in the form of a fixed high velocity extraction point or an articulated arm with movable hood or a fixed extraction hood.\n\n5.3 Dust extraction ducting should be designed with sufficient transfer velocity to ensure that dust is carried away, and does not settle in the ducting. Periodic checks should be performed to ensure that there is no build up of the dust in the ducting.\n\n5.4 The required transfer velocity should be determined: it is dependent on the density of the dust (the denser the dust, the higher the transfer velocity should be, e.g. 15\u201320 m/s).\n\n5.5 Airflow direction should be carefully chosen, to ensure that the operator does not contaminate the product, and also so that the operator is not put at risk by the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9a6cf0a8682ea45b2e907f8ff444e7a07e93a8ef907faff8a6461c4c56b9b263", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Dust Control\n\n4.9.11 Humidification systems should be well drained. No condensate should accumulate in air-handling systems.\n\n4.9.12 Other humidification appliances such as evaporative systems, atomizers and water mist sprays, should not be used because of the potential risk of microbial contamination.\n\n4.9.13 Duct material in the vicinity of the humidifier should not add contaminants to air that will not be removed by filtration further downstream.\n\n4.6.14 Air filters should not be installed immediately downstream of humidifiers, as moisture on the filters could lead to bacterial growth.\n\n4.9.15 Cold surfaces should be insulated to prevent condensation within the clean area or on air-handling components.\n\n4.9.16 When specifying relative humidity, the associated temperature should also be specified.\n\n4.9.17 Chemical driers using silica gel or lithium chloride are acceptable, provided that they do not become sources of contamination.\n\n## 5. Dust Control\n\n5.1 Wherever possible, dust or vapour contamination should be removed at source. Point-of-use extraction, i.e. as close as possible to the point where the dust is generated, should be employed. Spot ventilation or capture hoods may be used as appropriate.\n\n5.2 Point-of-use extraction should be either in the form of a fixed high velocity extraction point or an articulated arm with movable hood or a fixed extraction hood.\n\n5.3 Dust extraction ducting should be designed with sufficient transfer velocity to ensure that dust is carried away, and does not settle in the ducting. Periodic checks should be performed to ensure that there is no build up of the dust in the ducting.\n\n5.4 The required transfer velocity should be determined: it is dependent on the density of the dust (the denser the dust, the higher the transfer velocity should be, e.g. 15\u201320 m/s).\n\n5.5 Airflow direction should be carefully chosen, to ensure that the operator does not contaminate the product, and also so that the operator is not put at risk by the product.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2010, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "039ac4c7-d9f9-4d71-8167-5a63d8718e84": {"__data__": {"id_": "039ac4c7-d9f9-4d71-8167-5a63d8718e84", "embedding": null, "metadata": {"page_label": "258", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.6 \nPoint extraction alone is usually not sufficient to capture all of the contaminants, and general directional airflow should be used to assist in removing dust and vapours from the room.\n\n5.7 \nTypically, in a room operating with turbulent airflow, the air should be introduced from ceiling diffusers, located at the door entry side of the room and extracted from the rear of the room at low level to help give a flushing effect in the room. Correct flushing of the rooms may be verified by airflow visualization smoke tests.\n\n5.8 \nWhen dealing with particularly harmful products, additional steps, such as handling the products in glove boxes or using barrier isolator technology, should be used.\n\n# 6. Protection of the environment\n\n## 6.1 General\n\n6.1.1 \nIt should be noted that protection of the environment is not addressed in this guideline, and discharges into the atmosphere should be compliant with relevant local and national environmental legislation and standards.\n\n6.1.2 \nDust, vapours and fumes could be possible sources of contamination; therefore, care should be taken when deciding on the location of the inlet and exhaust points relative to one other.\n\n## 6.2 Dust in exhaust air\n\n6.2.1 \nExhaust air discharge points on pharmaceutical equipment and facilities, such as from fluid bed driers and tablet-coating equipment, and exhaust air from dust extraction systems, carry heavy dust loads and should be provided with adequate filtration to prevent contamination of the ambient air.\n\n6.2.2 \nWhere the powders are not highly potent, final filters on a dust exhaust system should be fine dust filters with a filter classification of F9 according to EN 779 filter standards.\n\n6.2.3 \nWhere reverse-pulse dust collectors are used for removing dust from dust extraction systems, they should usually be equipped with cartridge filters containing a compressed air lance, and be capable of continuous operation without interrupting the airflow.\n\n6.2.4 \nAlternative types of dust collectors (such as those operating with a mechanical shaker, requiring that the fan be switched off when the mechanical shaker is activated) should be used in such a manner that there is no risk of cross-contamination. There should be no disruption of airflow during a production run as the loss of airflow could disrupt the pressure cascade.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de la extracci\u00f3n de contaminantes en entornos farmac\u00e9uticos, destacando que la extracci\u00f3n puntual no es suficiente y que se debe utilizar un flujo de aire direccional para eliminar polvo y vapores. Se recomienda la introducci\u00f3n de aire desde difusores en el techo y su extracci\u00f3n desde la parte trasera del cuarto para lograr un efecto de \"flushing\". Adem\u00e1s, se enfatiza la necesidad de cumplir con las normativas ambientales locales y nacionales, y se discuten las medidas para manejar el polvo en el aire de escape, incluyendo el uso de filtros adecuados y sistemas de recolecci\u00f3n de polvo que no interrumpan el flujo de aire.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se deben tomar al manejar productos particularmente da\u00f1inos en un entorno farmac\u00e9utico?**\n   - Respuesta: Se deben utilizar pasos adicionales como manejar los productos en cajas de guantes o emplear tecnolog\u00eda de aisladores de barrera.\n\n2. **\u00bfCu\u00e1l es la clasificaci\u00f3n de filtro recomendada para sistemas de extracci\u00f3n de polvo donde los polvos no son altamente potentes?**\n   - Respuesta: Se recomienda utilizar filtros de polvo fino con una clasificaci\u00f3n de filtro F9 seg\u00fan las normas de filtro EN 779.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de recolecci\u00f3n de polvo se deben evitar para prevenir la contaminaci\u00f3n cruzada durante la producci\u00f3n?**\n   - Respuesta: Se deben evitar los sistemas de recolecci\u00f3n de polvo que operan con un agitador mec\u00e1nico que requiera que el ventilador se apague cuando se activa el agitador, ya que esto puede interrumpir el flujo de aire y causar contaminaci\u00f3n cruzada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Sistemas de Humidificaci\u00f3n**:\n   - Importancia de un buen drenaje para evitar la acumulaci\u00f3n de condensado.\n   - Prohibici\u00f3n de ciertos dispositivos de humidificaci\u00f3n (sistemas evaporativos, atomizadores, sprays de agua) debido al riesgo de contaminaci\u00f3n microbiana.\n   - Materiales de ducto deben ser seleccionados para no introducir contaminantes en el aire.\n\n2. **Filtros de Aire**:\n   - No deben instalarse inmediatamente despu\u00e9s de los humidificadores para evitar el crecimiento bacteriano por la humedad.\n\n3. **Control de Polvo**:\n   - Se debe eliminar la contaminaci\u00f3n por polvo o vapor en la fuente, utilizando extracci\u00f3n puntual.\n   - Tipos de extracci\u00f3n recomendados: puntos de extracci\u00f3n de alta velocidad fijos, brazos articulados con capuchas m\u00f3viles o capuchas de extracci\u00f3n fijas.\n   - Dise\u00f1o de ductos de extracci\u00f3n de polvo debe asegurar una velocidad de transferencia adecuada para evitar la acumulaci\u00f3n de polvo.\n\n4. **Velocidad de Transferencia**:\n   - La velocidad de transferencia necesaria depende de la densidad del polvo, con recomendaciones de 15\u201320 m/s para polvos m\u00e1s densos.\n\n5. **Direcci\u00f3n del Flujo de Aire**:\n   - Debe ser cuidadosamente seleccionada para proteger tanto al operador como al producto de la contaminaci\u00f3n.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Sistemas de Humidificaci\u00f3n**: Equipos y tecnolog\u00edas discutidos.\n- **Contaminaci\u00f3n Microbiana**: Riesgo asociado a ciertos m\u00e9todos de humidificaci\u00f3n.\n- **Extracci\u00f3n Puntual**: M\u00e9todo recomendado para el control de polvo.\n- **Ductos de Extracci\u00f3n**: Componentes cr\u00edticos en el manejo de polvo.\n- **Velocidad de Transferencia**: Par\u00e1metro clave en el dise\u00f1o de sistemas de extracci\u00f3n de polvo. \n\nEste resumen destaca las mejores pr\u00e1cticas y consideraciones t\u00e9cnicas para el control de la humedad y el polvo en entornos limpios, enfatizando la importancia de la prevenci\u00f3n de la contaminaci\u00f3n y la seguridad del operador.", "excerpt_keywords": "Keywords: extraction, airflow, contamination, filtration, pharmaceutical"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3372f70f-eb5e-481d-b4d1-dce9e6b9a5ad", "node_type": "4", "metadata": {"page_label": "258", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.6 \nPoint extraction alone is usually not sufficient to capture all of the contaminants, and general directional airflow should be used to assist in removing dust and vapours from the room.\n\n5.7 \nTypically, in a room operating with turbulent airflow, the air should be introduced from ceiling diffusers, located at the door entry side of the room and extracted from the rear of the room at low level to help give a flushing effect in the room. Correct flushing of the rooms may be verified by airflow visualization smoke tests.\n\n5.8 \nWhen dealing with particularly harmful products, additional steps, such as handling the products in glove boxes or using barrier isolator technology, should be used.\n\n# 6. Protection of the environment\n\n## 6.1 General\n\n6.1.1 \nIt should be noted that protection of the environment is not addressed in this guideline, and discharges into the atmosphere should be compliant with relevant local and national environmental legislation and standards.\n\n6.1.2 \nDust, vapours and fumes could be possible sources of contamination; therefore, care should be taken when deciding on the location of the inlet and exhaust points relative to one other.\n\n## 6.2 Dust in exhaust air\n\n6.2.1 \nExhaust air discharge points on pharmaceutical equipment and facilities, such as from fluid bed driers and tablet-coating equipment, and exhaust air from dust extraction systems, carry heavy dust loads and should be provided with adequate filtration to prevent contamination of the ambient air.\n\n6.2.2 \nWhere the powders are not highly potent, final filters on a dust exhaust system should be fine dust filters with a filter classification of F9 according to EN 779 filter standards.\n\n6.2.3 \nWhere reverse-pulse dust collectors are used for removing dust from dust extraction systems, they should usually be equipped with cartridge filters containing a compressed air lance, and be capable of continuous operation without interrupting the airflow.\n\n6.2.4 \nAlternative types of dust collectors (such as those operating with a mechanical shaker, requiring that the fan be switched off when the mechanical shaker is activated) should be used in such a manner that there is no risk of cross-contamination. There should be no disruption of airflow during a production run as the loss of airflow could disrupt the pressure cascade.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "af68f31bb328fff7ca2bd1be975a33b236d28b4d2f2f0ab1ee6b3774df7fa397", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.6 \nPoint extraction alone is usually not sufficient to capture all of the contaminants, and general directional airflow should be used to assist in removing dust and vapours from the room.\n\n5.7 \nTypically, in a room operating with turbulent airflow, the air should be introduced from ceiling diffusers, located at the door entry side of the room and extracted from the rear of the room at low level to help give a flushing effect in the room. Correct flushing of the rooms may be verified by airflow visualization smoke tests.\n\n5.8 \nWhen dealing with particularly harmful products, additional steps, such as handling the products in glove boxes or using barrier isolator technology, should be used.\n\n# 6. Protection of the environment\n\n## 6.1 General\n\n6.1.1 \nIt should be noted that protection of the environment is not addressed in this guideline, and discharges into the atmosphere should be compliant with relevant local and national environmental legislation and standards.\n\n6.1.2 \nDust, vapours and fumes could be possible sources of contamination; therefore, care should be taken when deciding on the location of the inlet and exhaust points relative to one other.\n\n## 6.2 Dust in exhaust air\n\n6.2.1 \nExhaust air discharge points on pharmaceutical equipment and facilities, such as from fluid bed driers and tablet-coating equipment, and exhaust air from dust extraction systems, carry heavy dust loads and should be provided with adequate filtration to prevent contamination of the ambient air.\n\n6.2.2 \nWhere the powders are not highly potent, final filters on a dust exhaust system should be fine dust filters with a filter classification of F9 according to EN 779 filter standards.\n\n6.2.3 \nWhere reverse-pulse dust collectors are used for removing dust from dust extraction systems, they should usually be equipped with cartridge filters containing a compressed air lance, and be capable of continuous operation without interrupting the airflow.\n\n6.2.4 \nAlternative types of dust collectors (such as those operating with a mechanical shaker, requiring that the fan be switched off when the mechanical shaker is activated) should be used in such a manner that there is no risk of cross-contamination. There should be no disruption of airflow during a production run as the loss of airflow could disrupt the pressure cascade.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2336, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "93184b82-c88f-4f1c-b385-9f845ee3fe56": {"__data__": {"id_": "93184b82-c88f-4f1c-b385-9f845ee3fe56", "embedding": null, "metadata": {"page_label": "259", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.2.5\nMechanical-shaker dust collectors should not be used for applications where continuous airflow is required, in order to avoid unacceptable fluctuations in room pressures, except in the case where room pressures are automatically controlled.\n\n## 6.2.6\nWhen wet scrubbers are used, the dust-slurry should be removed by a suitable means, e.g. a drainage system or waste removal contractor.\n\n## 6.2.7\nThe quality of the exhaust air should be determined to see whether the filtration efficiency is adequate with all types of dust collectors and wet scrubbers.\n\n## 6.2.8\nWhere necessary, additional filtration may be provided downstream of the dust collector.\n\n## 6.3 Vapour and fume removal\n\n### 6.3.1\nVapour should be extracted at the point of generation. When planning the system for the extraction of residual vapours, the density of the vapour should be taken into account. If the vapour is lighter than air, the extract grilles should be at a high level, or possibly at both high and low levels.\n\n### 6.3.2\nThe systems for fume, dust and effluent control should be designed, installed and operated in such a manner that they do not become possible sources of contamination or cross-contamination, e.g. an exhaust-air discharge point located close to the HVAC system fresh air inlet.\n\n### 6.3.3\nFumes should be removed by means of wet scrubbers or dry chemical scrubbers (deep-bed scrubbers).\n\n### 6.3.4\nWet scrubbers for fume removal normally require the addition of various chemicals to the water to increase the adsorption efficiency.\n\n### 6.3.5\nDeep-bed scrubbers should be designed with activated carbon filters or granular chemical adsorption media. The chemical media for deep-bed scrubbers should be specific to the effluent being treated.\n\n### 6.3.6\nThe type and quantity of the vapours to be removed should be known to enable the appropriate filter media, as well as the volume of media required to be determined.\n\n## 7. Design of HVAC systems and components\n\n### 7.1 General\n\n#### 7.1.1\nThe required degree of air cleanliness in most OSD manufacturing facilities can normally be achieved without the use of high-efficiency particulate air (HEPA) filters, provided the air is not recirculated or", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento aborda las directrices para el control de polvo, vapores y humos en instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la extracci\u00f3n adecuada de polvo y vapores, as\u00ed como el dise\u00f1o de sistemas de ventilaci\u00f3n y filtraci\u00f3n para evitar la contaminaci\u00f3n cruzada. Se mencionan diferentes m\u00e9todos de recolecci\u00f3n de polvo, como los colectores de polvo mec\u00e1nicos y los scrubbers h\u00famedos, y se discuten consideraciones sobre la calidad del aire de escape y la selecci\u00f3n de medios filtrantes.\n\n### Preguntas:\n1. **\u00bfPor qu\u00e9 no se deben utilizar colectores de polvo mec\u00e1nicos en aplicaciones que requieren un flujo de aire continuo?**\n   - Respuesta: Los colectores de polvo mec\u00e1nicos no deben usarse en aplicaciones con flujo de aire continuo debido a que pueden causar fluctuaciones inaceptables en las presiones de la sala, a menos que las presiones de la sala est\u00e9n controladas autom\u00e1ticamente.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los sistemas de control de humos y vapores no se conviertan en fuentes de contaminaci\u00f3n?**\n   - Respuesta: Los sistemas de control de humos, polvo y efluentes deben ser dise\u00f1ados, instalados y operados de manera que no se conviertan en fuentes de contaminaci\u00f3n o contaminaci\u00f3n cruzada, como evitar que los puntos de descarga de aire de escape est\u00e9n cerca de la entrada de aire fresco del sistema HVAC.\n\n3. **\u00bfQu\u00e9 factores deben considerarse al planificar un sistema de extracci\u00f3n de vapores residuales?**\n   - Respuesta: Al planificar un sistema de extracci\u00f3n de vapores residuales, se debe tener en cuenta la densidad del vapor. Si el vapor es m\u00e1s ligero que el aire, las rejillas de extracci\u00f3n deben estar ubicadas en un nivel alto, o posiblemente en niveles altos y bajos.", "prev_section_summary": "### Temas Clave:\n1. **Extracci\u00f3n de Contaminantes**: La extracci\u00f3n puntual no es suficiente para capturar todos los contaminantes; se debe utilizar un flujo de aire direccional para eliminar polvo y vapores.\n2. **Flujo de Aire en Habitaciones**: Se recomienda introducir aire desde difusores en el techo y extraerlo desde la parte trasera a nivel bajo para lograr un efecto de \"flushing\".\n3. **Manejo de Productos Peligrosos**: Para productos particularmente da\u00f1inos, se deben implementar medidas adicionales como el uso de cajas de guantes o tecnolog\u00eda de aisladores de barrera.\n4. **Protecci\u00f3n del Medio Ambiente**: Las descargas al ambiente deben cumplir con la legislaci\u00f3n y normativas ambientales locales y nacionales.\n5. **Filtraci\u00f3n de Aire de Escape**: Los sistemas de extracci\u00f3n de polvo deben contar con filtraci\u00f3n adecuada para evitar la contaminaci\u00f3n del aire ambiente, utilizando filtros de clasificaci\u00f3n F9 para polvos no altamente potentes.\n6. **Sistemas de Recolecci\u00f3n de Polvo**: Se deben evitar sistemas que interrumpan el flujo de aire durante la producci\u00f3n para prevenir la contaminaci\u00f3n cruzada.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Normas EN 779**: Est\u00e1ndares de clasificaci\u00f3n de filtros.\n- **Cajas de Guantes**: Equipamiento recomendado para el manejo de productos peligrosos.\n- **Tecnolog\u00eda de Aisladores de Barrera**: M\u00e9todo adicional para manejar productos da\u00f1inos.\n- **Filtros de Polvo Fino**: Clasificaci\u00f3n recomendada para sistemas de extracci\u00f3n de polvo.\n- **Sistemas de Recolecci\u00f3n de Polvo**: Equipos utilizados para la extracci\u00f3n de polvo en entornos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de un manejo adecuado del aire y la filtraci\u00f3n en entornos farmac\u00e9uticos para garantizar la seguridad y la protecci\u00f3n del medio ambiente.", "excerpt_keywords": "Keywords: dust collection, vapour extraction, air quality, filtration systems, contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b5b2caf2-2fc0-485c-95ca-88723c4fcb25", "node_type": "4", "metadata": {"page_label": "259", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.2.5\nMechanical-shaker dust collectors should not be used for applications where continuous airflow is required, in order to avoid unacceptable fluctuations in room pressures, except in the case where room pressures are automatically controlled.\n\n## 6.2.6\nWhen wet scrubbers are used, the dust-slurry should be removed by a suitable means, e.g. a drainage system or waste removal contractor.\n\n## 6.2.7\nThe quality of the exhaust air should be determined to see whether the filtration efficiency is adequate with all types of dust collectors and wet scrubbers.\n\n## 6.2.8\nWhere necessary, additional filtration may be provided downstream of the dust collector.\n\n## 6.3 Vapour and fume removal\n\n### 6.3.1\nVapour should be extracted at the point of generation. When planning the system for the extraction of residual vapours, the density of the vapour should be taken into account. If the vapour is lighter than air, the extract grilles should be at a high level, or possibly at both high and low levels.\n\n### 6.3.2\nThe systems for fume, dust and effluent control should be designed, installed and operated in such a manner that they do not become possible sources of contamination or cross-contamination, e.g. an exhaust-air discharge point located close to the HVAC system fresh air inlet.\n\n### 6.3.3\nFumes should be removed by means of wet scrubbers or dry chemical scrubbers (deep-bed scrubbers).\n\n### 6.3.4\nWet scrubbers for fume removal normally require the addition of various chemicals to the water to increase the adsorption efficiency.\n\n### 6.3.5\nDeep-bed scrubbers should be designed with activated carbon filters or granular chemical adsorption media. The chemical media for deep-bed scrubbers should be specific to the effluent being treated.\n\n### 6.3.6\nThe type and quantity of the vapours to be removed should be known to enable the appropriate filter media, as well as the volume of media required to be determined.\n\n## 7. Design of HVAC systems and components\n\n### 7.1 General\n\n#### 7.1.1\nThe required degree of air cleanliness in most OSD manufacturing facilities can normally be achieved without the use of high-efficiency particulate air (HEPA) filters, provided the air is not recirculated or", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "86f17bbaaae95c0e9e17dab9a9e5dc158135627c51c0be4140df3cddac51a784", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 6.2.5\nMechanical-shaker dust collectors should not be used for applications where continuous airflow is required, in order to avoid unacceptable fluctuations in room pressures, except in the case where room pressures are automatically controlled.\n\n## 6.2.6\nWhen wet scrubbers are used, the dust-slurry should be removed by a suitable means, e.g. a drainage system or waste removal contractor.\n\n## 6.2.7\nThe quality of the exhaust air should be determined to see whether the filtration efficiency is adequate with all types of dust collectors and wet scrubbers.\n\n## 6.2.8\nWhere necessary, additional filtration may be provided downstream of the dust collector.\n\n## 6.3 Vapour and fume removal\n\n### 6.3.1\nVapour should be extracted at the point of generation. When planning the system for the extraction of residual vapours, the density of the vapour should be taken into account. If the vapour is lighter than air, the extract grilles should be at a high level, or possibly at both high and low levels.\n\n### 6.3.2\nThe systems for fume, dust and effluent control should be designed, installed and operated in such a manner that they do not become possible sources of contamination or cross-contamination, e.g. an exhaust-air discharge point located close to the HVAC system fresh air inlet.\n\n### 6.3.3\nFumes should be removed by means of wet scrubbers or dry chemical scrubbers (deep-bed scrubbers).\n\n### 6.3.4\nWet scrubbers for fume removal normally require the addition of various chemicals to the water to increase the adsorption efficiency.\n\n### 6.3.5\nDeep-bed scrubbers should be designed with activated carbon filters or granular chemical adsorption media. The chemical media for deep-bed scrubbers should be specific to the effluent being treated.\n\n### 6.3.6\nThe type and quantity of the vapours to be removed should be known to enable the appropriate filter media, as well as the volume of media required to be determined.\n\n## 7. Design of HVAC systems and components\n\n### 7.1 General\n\n#### 7.1.1\nThe required degree of air cleanliness in most OSD manufacturing facilities can normally be achieved without the use of high-efficiency particulate air (HEPA) filters, provided the air is not recirculated or", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2213, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b3f8d196-fd27-446c-9a39-e53533711163": {"__data__": {"id_": "b3f8d196-fd27-446c-9a39-e53533711163", "embedding": null, "metadata": {"page_label": "260", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in the case of a single-product facility. Many open product zones of OSD form facilities are capable of meeting ISO 14644-1 Class 8 or Grade D, \"at-rest\" condition, measured against particle sizes of 0.5 \u00b5m and 5 \u00b5m, but cleanliness may not necessarily be classified as such by manufacturers.\n\nA risk assessment should be carried out to determine the cleanroom conditions required and the extent of validation required.\n\n7.1.2 There are two basic concepts of air delivery to pharmaceutical production facilities: a recirculation system, and a full fresh air system (100% outside air supply). For recirculation systems the amount of fresh air should not be determined arbitrarily on a percentage basis, but, for example, by the following criteria:\n\n- sufficient fresh air to compensate for leakage from the facility and loss through exhaust air systems;\n- sufficient fresh air to comply with national building regulations; and[^2]\n- sufficient fresh air for odour control.\n\n7.1.3 Where automated monitoring systems are used, these should be capable of indicating any out-of-specification condition without delay by means of an alarm or similar system. Sophisticated computer-based data monitoring systems may be installed, which can aid with planning of preventive maintenance and can also provide trend logging.\n\n(This type of system is commonly referred to as a building management system (BMS), building automation system (BAS) or system control and data acquisition (SCADA) system.) If these systems are used for critical decision-making, they should be validated.\n\n7.1.4 Failure of a supply air fan, return air fan, exhaust air fan or dust extract system fan can cause a system imbalance, resulting in a pressure cascade malfunction with a resultant airflow reversal.\n\n7.1.5 All critical alarms should be easily identifiable and visible and/or audible to relevant personnel.\n\n7.1.6 Appropriate alarm systems should be in place to alert personnel if a critical fan fails. A fan interlock failure matrix should be set up, such that if a fan serving a high pressure zone fails, then any fans serving surrounding lower pressure areas should automatically stop, to prevent an airflow reversal and possible cross-contamination.\n\n[^2]: Depending on occupant density, between 1 and ACPH will often satisfy occupancy requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS aborda las condiciones de limpieza y los sistemas de entrega de aire en instalaciones de producci\u00f3n farmac\u00e9utica. Se discuten los requisitos de aire fresco, la importancia de los sistemas de monitoreo automatizados, y la gesti\u00f3n de fallos en los ventiladores para evitar problemas de contaminaci\u00f3n cruzada. Se enfatiza la necesidad de realizar evaluaciones de riesgo y de validar los sistemas utilizados para la toma de decisiones cr\u00edticas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben considerarse al determinar la cantidad de aire fresco en un sistema de recirculaci\u00f3n en instalaciones farmac\u00e9uticas?**\n   - Esta pregunta se centra en los criterios mencionados en el contexto, que no son comunes en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de sistemas de monitoreo automatizados se recomienda para las instalaciones de producci\u00f3n farmac\u00e9utica y qu\u00e9 funciones deben cumplir?**\n   - Esta pregunta busca detalles sobre los sistemas de monitoreo y su validaci\u00f3n, que son aspectos t\u00e9cnicos espec\u00edficos del contexto.\n\n3. **\u00bfC\u00f3mo se debe gestionar la falla de un ventilador en una instalaci\u00f3n de producci\u00f3n farmac\u00e9utica para prevenir la contaminaci\u00f3n cruzada?**\n   - Esta pregunta se enfoca en las medidas espec\u00edficas que deben implementarse en caso de fallos en los ventiladores, un tema que puede no estar ampliamente cubierto en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de Polvo**:\n   - **Colectores de Polvo Mec\u00e1nicos**: No son adecuados para aplicaciones con flujo de aire continuo debido a fluctuaciones en la presi\u00f3n de la sala, a menos que haya control autom\u00e1tico de presi\u00f3n.\n   - **Scrubbers H\u00famedos**: Deben tener un sistema adecuado para la eliminaci\u00f3n de lodos de polvo, como un sistema de drenaje.\n\n2. **Calidad del Aire de Escape**:\n   - Es esencial evaluar la eficiencia de filtraci\u00f3n de los colectores de polvo y scrubbers h\u00famedos.\n   - Puede ser necesaria filtraci\u00f3n adicional despu\u00e9s del colector de polvo.\n\n3. **Extracci\u00f3n de Vapores y Humos**:\n   - **Extracci\u00f3n en el Punto de Generaci\u00f3n**: Los vapores deben ser extra\u00eddos donde se generan, considerando su densidad para la ubicaci\u00f3n de las rejillas de extracci\u00f3n.\n   - **Dise\u00f1o de Sistemas**: Los sistemas de control de humos, polvo y efluentes deben evitar la contaminaci\u00f3n cruzada, evitando la proximidad de puntos de descarga de aire de escape a entradas de aire fresco.\n\n4. **M\u00e9todos de Eliminaci\u00f3n de Humos**:\n   - Uso de scrubbers h\u00famedos o scrubbers qu\u00edmicos secos (scrubbers de lecho profundo).\n   - Los scrubbers h\u00famedos requieren la adici\u00f3n de qu\u00edmicos para mejorar la eficiencia de adsorci\u00f3n.\n\n5. **Dise\u00f1o de Sistemas HVAC**:\n   - La limpieza del aire en instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos puede lograrse sin filtros HEPA, siempre que no haya recirculaci\u00f3n de aire.\n\n### Entidades Clave:\n- **Colectores de Polvo Mec\u00e1nicos**\n- **Scrubbers H\u00famedos**\n- **Scrubbers de Lecho Profundo**\n- **Filtros de Carb\u00f3n Activado**\n- **Sistemas HVAC**\n- **Vapores y Humos**\n- **Contaminaci\u00f3n Cruzada**\n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y la operaci\u00f3n de sistemas de control de polvo y vapores en entornos de fabricaci\u00f3n, as\u00ed como la necesidad de mantener la calidad del aire y evitar la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: cleanroom conditions, air delivery systems, automated monitoring, contamination control, pharmaceutical production"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4c6cbcaf-3e8f-4366-a260-5e9e56052bf2", "node_type": "4", "metadata": {"page_label": "260", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in the case of a single-product facility. Many open product zones of OSD form facilities are capable of meeting ISO 14644-1 Class 8 or Grade D, \"at-rest\" condition, measured against particle sizes of 0.5 \u00b5m and 5 \u00b5m, but cleanliness may not necessarily be classified as such by manufacturers.\n\nA risk assessment should be carried out to determine the cleanroom conditions required and the extent of validation required.\n\n7.1.2 There are two basic concepts of air delivery to pharmaceutical production facilities: a recirculation system, and a full fresh air system (100% outside air supply). For recirculation systems the amount of fresh air should not be determined arbitrarily on a percentage basis, but, for example, by the following criteria:\n\n- sufficient fresh air to compensate for leakage from the facility and loss through exhaust air systems;\n- sufficient fresh air to comply with national building regulations; and[^2]\n- sufficient fresh air for odour control.\n\n7.1.3 Where automated monitoring systems are used, these should be capable of indicating any out-of-specification condition without delay by means of an alarm or similar system. Sophisticated computer-based data monitoring systems may be installed, which can aid with planning of preventive maintenance and can also provide trend logging.\n\n(This type of system is commonly referred to as a building management system (BMS), building automation system (BAS) or system control and data acquisition (SCADA) system.) If these systems are used for critical decision-making, they should be validated.\n\n7.1.4 Failure of a supply air fan, return air fan, exhaust air fan or dust extract system fan can cause a system imbalance, resulting in a pressure cascade malfunction with a resultant airflow reversal.\n\n7.1.5 All critical alarms should be easily identifiable and visible and/or audible to relevant personnel.\n\n7.1.6 Appropriate alarm systems should be in place to alert personnel if a critical fan fails. A fan interlock failure matrix should be set up, such that if a fan serving a high pressure zone fails, then any fans serving surrounding lower pressure areas should automatically stop, to prevent an airflow reversal and possible cross-contamination.\n\n[^2]: Depending on occupant density, between 1 and ACPH will often satisfy occupancy requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "18df0d6f59b4ec558161b81f539c246d06d288f0c90820407ddc12ab392c55e7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in the case of a single-product facility. Many open product zones of OSD form facilities are capable of meeting ISO 14644-1 Class 8 or Grade D, \"at-rest\" condition, measured against particle sizes of 0.5 \u00b5m and 5 \u00b5m, but cleanliness may not necessarily be classified as such by manufacturers.\n\nA risk assessment should be carried out to determine the cleanroom conditions required and the extent of validation required.\n\n7.1.2 There are two basic concepts of air delivery to pharmaceutical production facilities: a recirculation system, and a full fresh air system (100% outside air supply). For recirculation systems the amount of fresh air should not be determined arbitrarily on a percentage basis, but, for example, by the following criteria:\n\n- sufficient fresh air to compensate for leakage from the facility and loss through exhaust air systems;\n- sufficient fresh air to comply with national building regulations; and[^2]\n- sufficient fresh air for odour control.\n\n7.1.3 Where automated monitoring systems are used, these should be capable of indicating any out-of-specification condition without delay by means of an alarm or similar system. Sophisticated computer-based data monitoring systems may be installed, which can aid with planning of preventive maintenance and can also provide trend logging.\n\n(This type of system is commonly referred to as a building management system (BMS), building automation system (BAS) or system control and data acquisition (SCADA) system.) If these systems are used for critical decision-making, they should be validated.\n\n7.1.4 Failure of a supply air fan, return air fan, exhaust air fan or dust extract system fan can cause a system imbalance, resulting in a pressure cascade malfunction with a resultant airflow reversal.\n\n7.1.5 All critical alarms should be easily identifiable and visible and/or audible to relevant personnel.\n\n7.1.6 Appropriate alarm systems should be in place to alert personnel if a critical fan fails. A fan interlock failure matrix should be set up, such that if a fan serving a high pressure zone fails, then any fans serving surrounding lower pressure areas should automatically stop, to prevent an airflow reversal and possible cross-contamination.\n\n[^2]: Depending on occupant density, between 1 and ACPH will often satisfy occupancy requirements.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2325, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "25acc001-0e15-45bb-8675-a065758397b9": {"__data__": {"id_": "25acc001-0e15-45bb-8675-a065758397b9", "embedding": null, "metadata": {"page_label": "261", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Air distribution\n\n7.2.1 The positioning of supply and extract grilles should be such as to provide effective room flushing. Low-level return or exhaust air grilles are usually preferred. However, where this is not possible, a higher air change rate may be needed to achieve a specified clean area condition, e.g. where ceiling return air grilles are used.\n\n7.2.2 There may be alternative locations for return air. For example, referring to Figure 22, Room 1 (low-level return air) and Room 2 (ceiling return air). The airflow diagram in Figure 22 is an example of a typical system with a lower clean area condition.\n\n**Figure 22**  \n*Air-handling system with high-efficiency particulate air filters in air-handling unit*\n\n!Air-handling system diagram\n\nThe airflow schematics of the two systems (Figures 22 and 23) indicate air-handling units with return air or recirculated air, having a percentage of fresh air added. Depending on product characteristics and dust loading it is sometimes preferable to fit filters on return air outlets or in return air ducting.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la distribuci\u00f3n del aire en sistemas de manejo de aire, enfatizando la importancia de la ubicaci\u00f3n de las rejillas de suministro y extracci\u00f3n para lograr una adecuada renovaci\u00f3n del aire en espacios limpios. Se discuten las preferencias por rejillas de retorno de aire a nivel bajo y las alternativas disponibles, como las rejillas de retorno en el techo. Adem\u00e1s, se menciona la incorporaci\u00f3n de filtros de alta eficiencia en las unidades de manejo de aire y la consideraci\u00f3n de la carga de polvo y caracter\u00edsticas del producto al decidir la ubicaci\u00f3n de los filtros.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las ventajas de utilizar rejillas de retorno de aire a nivel bajo en comparaci\u00f3n con las rejillas de retorno en el techo en sistemas de manejo de aire?**\n   - Esta pregunta busca una comparaci\u00f3n espec\u00edfica que no se aborda de manera general en otros documentos.\n\n2. **En el contexto de la carga de polvo, \u00bfqu\u00e9 factores deben considerarse al decidir la ubicaci\u00f3n de los filtros en un sistema de manejo de aire?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos que afectan la eficiencia del sistema, lo cual puede no estar ampliamente discutido en otras fuentes.\n\n3. **\u00bfQu\u00e9 implicaciones tiene un mayor \u00edndice de renovaci\u00f3n de aire en la calidad del aire en \u00e1reas limpias cuando se utilizan rejillas de retorno en el techo?**\n   - Esta pregunta explora las consecuencias de las decisiones de dise\u00f1o en la calidad del aire, un tema que puede no ser tratado en profundidad en otros documentos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se encuentra en el contexto proporcionado, lo que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Condiciones de Limpieza en Instalaciones Farmac\u00e9uticas**:\n   - Se menciona que muchas zonas de productos abiertos en instalaciones de OSD pueden cumplir con la norma ISO 14644-1 Clase 8 o Grado D en condiciones \"en reposo\", aunque la limpieza puede no ser clasificada de esta manera por los fabricantes.\n\n2. **Evaluaci\u00f3n de Riesgos**:\n   - Se enfatiza la necesidad de realizar una evaluaci\u00f3n de riesgos para determinar las condiciones de limpieza requeridas y el alcance de la validaci\u00f3n necesaria.\n\n3. **Sistemas de Entrega de Aire**:\n   - Se describen dos conceptos b\u00e1sicos: sistemas de recirculaci\u00f3n y sistemas de aire fresco (100% aire exterior). \n   - Los criterios para determinar la cantidad de aire fresco en sistemas de recirculaci\u00f3n incluyen compensar p\u00e9rdidas por fugas, cumplir con regulaciones de construcci\u00f3n nacionales y controlar olores.\n\n4. **Sistemas de Monitoreo Automatizados**:\n   - Se recomienda el uso de sistemas de monitoreo automatizados que puedan indicar condiciones fuera de especificaci\u00f3n de inmediato mediante alarmas.\n   - Se mencionan sistemas avanzados como BMS, BAS o SCADA, que deben ser validados si se utilizan para decisiones cr\u00edticas.\n\n5. **Gesti\u00f3n de Fallos en Ventiladores**:\n   - Se discute c\u00f3mo la falla de ventiladores (suministro, retorno, extracci\u00f3n de aire) puede causar un desequilibrio en el sistema, resultando en un mal funcionamiento de la presi\u00f3n y reversi\u00f3n del flujo de aire.\n   - Se deben implementar sistemas de alarma adecuados para alertar al personal sobre fallos cr\u00edticos de ventiladores y establecer una matriz de interbloqueo para prevenir la contaminaci\u00f3n cruzada.\n\n### Entidades Clave:\n- **ISO 14644-1**: Norma que establece los requisitos de limpieza del aire en salas limpias.\n- **Sistemas de Monitoreo**: BMS (Building Management System), BAS (Building Automation System), SCADA (System Control and Data Acquisition).\n- **Condiciones de Limpieza**: Clase 8, Grado D.\n- **Criterios de Aire Fresco**: Compensaci\u00f3n de fugas, regulaciones de construcci\u00f3n, control de olores.\n- **Alarmas Cr\u00edticas**: Sistemas de alarma para ventiladores y gesti\u00f3n de fallos. \n\nEste resumen destaca los aspectos fundamentales relacionados con la limpieza, la entrega de aire, el monitoreo y la gesti\u00f3n de fallos en instalaciones de producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: air distribution, clean area condition, return air grilles, air-handling system, high-efficiency filters"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "674d7cdc-814c-455c-b346-9e9a6b6a629e", "node_type": "4", "metadata": {"page_label": "261", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Air distribution\n\n7.2.1 The positioning of supply and extract grilles should be such as to provide effective room flushing. Low-level return or exhaust air grilles are usually preferred. However, where this is not possible, a higher air change rate may be needed to achieve a specified clean area condition, e.g. where ceiling return air grilles are used.\n\n7.2.2 There may be alternative locations for return air. For example, referring to Figure 22, Room 1 (low-level return air) and Room 2 (ceiling return air). The airflow diagram in Figure 22 is an example of a typical system with a lower clean area condition.\n\n**Figure 22**  \n*Air-handling system with high-efficiency particulate air filters in air-handling unit*\n\n!Air-handling system diagram\n\nThe airflow schematics of the two systems (Figures 22 and 23) indicate air-handling units with return air or recirculated air, having a percentage of fresh air added. Depending on product characteristics and dust loading it is sometimes preferable to fit filters on return air outlets or in return air ducting.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e8651f4645adcf9bfbd7fbd0add6547cdaac4c9a705e819513cf2d75f50f07f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.2 Air distribution\n\n7.2.1 The positioning of supply and extract grilles should be such as to provide effective room flushing. Low-level return or exhaust air grilles are usually preferred. However, where this is not possible, a higher air change rate may be needed to achieve a specified clean area condition, e.g. where ceiling return air grilles are used.\n\n7.2.2 There may be alternative locations for return air. For example, referring to Figure 22, Room 1 (low-level return air) and Room 2 (ceiling return air). The airflow diagram in Figure 22 is an example of a typical system with a lower clean area condition.\n\n**Figure 22**  \n*Air-handling system with high-efficiency particulate air filters in air-handling unit*\n\n!Air-handling system diagram\n\nThe airflow schematics of the two systems (Figures 22 and 23) indicate air-handling units with return air or recirculated air, having a percentage of fresh air added. Depending on product characteristics and dust loading it is sometimes preferable to fit filters on return air outlets or in return air ducting.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1068, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "901a3fcd-606f-4d27-b4de-a098db0a466f": {"__data__": {"id_": "901a3fcd-606f-4d27-b4de-a098db0a466f", "embedding": null, "metadata": {"page_label": "262", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Figure 23 is a schematic diagram of an air-handling system serving rooms with horizontal unidirectional flow, vertical unidirectional flow and turbulent flow, for rooms 3, 4 and 5, respectively.\n\n### Figure 23\n**Horizontal unidirectional flow, vertical unidirectional flow and turbulent flow**\n\n----\n\n## 7.3 Recirculation system\n\n7.3.1 There should be no risk of contamination or cross-contamination (including by fumes and volatiles) due to recirculation of air.\n\n7.3.2 Depending on the airborne contaminants in the return-air system it may be acceptable to use recirculated air, provided that HEPA filters are installed in the supply air stream (or return air stream) to remove contaminants and thus prevent cross-contamination. The HEPA filters for this application should have an EN 1822 classification of H13.\n\n7.3.3 HEPA filters may not be required where the air-handling system is serving a single product facility and there is evidence that cross-contamination would not be possible.\n\n7.3.4 Recirculation of air from areas where pharmaceutical dust is not generated such as secondary packing, may not require HEPA filters in the system.\n\n7.3.5 HEPA filters may be located in the air-handling unit or placed terminally. Where HEPA filters are terminally mounted they should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Sistema de manejo de aire**: El documento describe un sistema de manejo de aire que incluye diferentes tipos de flujos (horizontal unidireccional, vertical unidireccional y turbulento) para diversas salas, lo que es crucial para mantener la calidad del aire en entornos farmac\u00e9uticos.\n\n2. **Recirculaci\u00f3n de aire**: Se establecen directrices sobre la recirculaci\u00f3n de aire en instalaciones farmac\u00e9uticas, enfatizando la importancia de evitar la contaminaci\u00f3n cruzada y el uso de filtros HEPA para garantizar la pureza del aire.\n\n3. **Filtros HEPA**: Se discute el uso de filtros HEPA en sistemas de manejo de aire, especificando su clasificaci\u00f3n y las condiciones bajo las cuales pueden ser necesarios o no, dependiendo del tipo de instalaci\u00f3n y la generaci\u00f3n de contaminantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede utilizar aire recirculado en un sistema de manejo de aire en instalaciones farmac\u00e9uticas?**\n   - Respuesta: Se puede utilizar aire recirculado siempre que se instalen filtros HEPA en el flujo de aire de suministro o en el flujo de aire de retorno para eliminar contaminantes y prevenir la contaminaci\u00f3n cruzada.\n\n2. **\u00bfQu\u00e9 clasificaci\u00f3n deben tener los filtros HEPA utilizados en sistemas de manejo de aire seg\u00fan el documento?**\n   - Respuesta: Los filtros HEPA para esta aplicaci\u00f3n deben tener una clasificaci\u00f3n EN 1822 de H13.\n\n3. **\u00bfEn qu\u00e9 situaciones no se requieren filtros HEPA en un sistema de manejo de aire?**\n   - Respuesta: Los filtros HEPA pueden no ser necesarios en sistemas que sirven a instalaciones de un solo producto donde hay evidencia de que no ser\u00eda posible la contaminaci\u00f3n cruzada, o en \u00e1reas donde no se genera polvo farmac\u00e9utico, como en el empaque secundario.", "prev_section_summary": "### Resumen de la Secci\u00f3n 7.2: Distribuci\u00f3n del Aire\n\nLa secci\u00f3n 7.2 del documento de la OMS se centra en la distribuci\u00f3n del aire en sistemas de manejo de aire, destacando la importancia de la ubicaci\u00f3n de las rejillas de suministro y extracci\u00f3n para asegurar una adecuada renovaci\u00f3n del aire en \u00e1reas limpias. \n\n#### Temas Clave:\n1. **Posicionamiento de Rejillas**: Se enfatiza que las rejillas de retorno o extracci\u00f3n de aire deben estar posicionadas para proporcionar una efectiva renovaci\u00f3n del aire en la habitaci\u00f3n. Se prefieren las rejillas de retorno a nivel bajo, aunque en situaciones donde esto no es posible, se puede requerir un mayor \u00edndice de renovaci\u00f3n de aire.\n\n2. **Alternativas de Ubicaci\u00f3n**: Se presentan alternativas para la ubicaci\u00f3n de las rejillas de retorno, como las rejillas en el techo, y se ilustran en un diagrama (Figura 22) que compara dos habitaciones con diferentes configuraciones de retorno de aire.\n\n3. **Filtros de Alta Eficiencia**: Se menciona la instalaci\u00f3n de filtros de alta eficiencia en las unidades de manejo de aire, as\u00ed como la consideraci\u00f3n de las caracter\u00edsticas del producto y la carga de polvo al decidir la ubicaci\u00f3n de los filtros, ya sea en las salidas de aire de retorno o en el conducto de retorno.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Rejillas de Suministro y Extracci\u00f3n**: Elementos clave en la distribuci\u00f3n del aire.\n- **Aire Limpio**: Condici\u00f3n deseada en los espacios tratados.\n- **Filtros de Alta Eficiencia**: Dispositivos utilizados para mejorar la calidad del aire.\n- **Diagrama de Flujo de Aire**: Herramienta visual utilizada para ilustrar los sistemas de manejo de aire.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos t\u00e9cnicos y consideraciones de dise\u00f1o en la distribuci\u00f3n del aire, esenciales para mantener condiciones adecuadas en \u00e1reas limpias.", "excerpt_keywords": "Keywords: air-handling system, HEPA filters, recirculation, contamination prevention, pharmaceutical environments"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "90915b08-a8b6-40ee-9cf1-4819db141d87", "node_type": "4", "metadata": {"page_label": "262", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Figure 23 is a schematic diagram of an air-handling system serving rooms with horizontal unidirectional flow, vertical unidirectional flow and turbulent flow, for rooms 3, 4 and 5, respectively.\n\n### Figure 23\n**Horizontal unidirectional flow, vertical unidirectional flow and turbulent flow**\n\n----\n\n## 7.3 Recirculation system\n\n7.3.1 There should be no risk of contamination or cross-contamination (including by fumes and volatiles) due to recirculation of air.\n\n7.3.2 Depending on the airborne contaminants in the return-air system it may be acceptable to use recirculated air, provided that HEPA filters are installed in the supply air stream (or return air stream) to remove contaminants and thus prevent cross-contamination. The HEPA filters for this application should have an EN 1822 classification of H13.\n\n7.3.3 HEPA filters may not be required where the air-handling system is serving a single product facility and there is evidence that cross-contamination would not be possible.\n\n7.3.4 Recirculation of air from areas where pharmaceutical dust is not generated such as secondary packing, may not require HEPA filters in the system.\n\n7.3.5 HEPA filters may be located in the air-handling unit or placed terminally. Where HEPA filters are terminally mounted they should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "89835b0fe7d63d52bc70ebedd52210cf49e638ee915d30264fd15ca0851395b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Figure 23 is a schematic diagram of an air-handling system serving rooms with horizontal unidirectional flow, vertical unidirectional flow and turbulent flow, for rooms 3, 4 and 5, respectively.\n\n### Figure 23\n**Horizontal unidirectional flow, vertical unidirectional flow and turbulent flow**\n\n----\n\n## 7.3 Recirculation system\n\n7.3.1 There should be no risk of contamination or cross-contamination (including by fumes and volatiles) due to recirculation of air.\n\n7.3.2 Depending on the airborne contaminants in the return-air system it may be acceptable to use recirculated air, provided that HEPA filters are installed in the supply air stream (or return air stream) to remove contaminants and thus prevent cross-contamination. The HEPA filters for this application should have an EN 1822 classification of H13.\n\n7.3.3 HEPA filters may not be required where the air-handling system is serving a single product facility and there is evidence that cross-contamination would not be possible.\n\n7.3.4 Recirculation of air from areas where pharmaceutical dust is not generated such as secondary packing, may not require HEPA filters in the system.\n\n7.3.5 HEPA filters may be located in the air-handling unit or placed terminally. Where HEPA filters are terminally mounted they should", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1280, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ca3468fa-2780-43d2-a01d-02f37cba594e": {"__data__": {"id_": "ca3468fa-2780-43d2-a01d-02f37cba594e", "embedding": null, "metadata": {"page_label": "263", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "preferably not be connected to the ducting by means of flexible ducting. Due to the high air pressure required for the terminal filter, this connection should preferably be a rigid duct connection. Where flexible ducting is used, it should be as short as possible and properly fixed to withstand duct pressure.\n\n7.3.6 Air containing dust from highly toxic processes and/or solvents or flammable vapours should never be recirculated to the HVAC system.\n\n## 7.4 Full fresh-air systems\n\nFigure 24 indicates a system operating on 100% fresh air and would normally be used in a facility dealing with toxic products or solvents, where recirculation of air with contaminants should be avoided.\n\n7.4.1 The required degree of filtration of the exhaust air depends on the exhaust air contaminants and local environmental regulations. HEPA filters in the exhaust system would normally only be required when handling hazardous materials.\n\n**Figure 24**  \n**Full fresh-air system**\n\n!Full fresh-air system diagram", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de los sistemas de ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos o solventes. Se enfatiza que las conexiones de ductos deben ser r\u00edgidas para soportar la alta presi\u00f3n de aire y que el aire contaminado no debe ser recirculado al sistema HVAC. Adem\u00e1s, se menciona que los sistemas de aire fresco completo son preferibles en estas situaciones, y que el grado de filtraci\u00f3n del aire de escape depende de los contaminantes presentes y de las regulaciones ambientales locales.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfPor qu\u00e9 se recomienda el uso de conexiones de ductos r\u00edgidos en lugar de ductos flexibles en sistemas de ventilaci\u00f3n para productos t\u00f3xicos?**\n   - Respuesta: Se recomienda el uso de conexiones de ductos r\u00edgidos debido a la alta presi\u00f3n de aire requerida para el filtro terminal, lo que asegura una mejor integridad estructural y resistencia a la presi\u00f3n del ducto.\n\n2. **\u00bfQu\u00e9 tipo de filtros se consideran necesarios en el sistema de escape cuando se manejan materiales peligrosos?**\n   - Respuesta: Normalmente, se requieren filtros HEPA en el sistema de escape cuando se manejan materiales peligrosos, ya que estos filtros son capaces de capturar part\u00edculas finas y contaminantes peligrosos.\n\n3. **\u00bfCu\u00e1les son las implicaciones de recircular aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables en un sistema HVAC?**\n   - Respuesta: Recircular aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables puede resultar en la contaminaci\u00f3n del ambiente de trabajo, poniendo en riesgo la salud de los trabajadores y violando regulaciones ambientales, por lo que nunca debe hacerse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Manejo de Aire**:\n   - Se describe un sistema que incluye flujos de aire horizontal unidireccional, vertical unidireccional y turbulento, dise\u00f1ado para diferentes salas en entornos farmac\u00e9uticos.\n\n2. **Recirculaci\u00f3n de Aire**:\n   - Se establecen directrices para la recirculaci\u00f3n de aire, enfatizando la necesidad de evitar la contaminaci\u00f3n cruzada y el riesgo de contaminaci\u00f3n por vapores y vol\u00e1tiles.\n\n3. **Filtros HEPA**:\n   - Se discute la instalaci\u00f3n de filtros HEPA en sistemas de manejo de aire, especificando que deben tener una clasificaci\u00f3n EN 1822 de H13 para eliminar contaminantes y prevenir la contaminaci\u00f3n cruzada.\n\n4. **Excepciones para el Uso de Filtros HEPA**:\n   - Los filtros HEPA pueden no ser necesarios en instalaciones de un solo producto donde no se genere riesgo de contaminaci\u00f3n cruzada, o en \u00e1reas como el empaque secundario donde no se produzca polvo farmac\u00e9utico.\n\n### Entidades Clave\n\n- **Tipos de Flujo de Aire**: Horizontal unidireccional, vertical unidireccional, turbulento.\n- **Clasificaci\u00f3n de Filtros**: EN 1822 H13.\n- **Condiciones de Uso de Aire Recirculado**: Instalaci\u00f3n de filtros HEPA, ausencia de contaminaci\u00f3n cruzada.\n- **\u00c1reas de Excepci\u00f3n**: Instalaciones de un solo producto, \u00e1reas sin generaci\u00f3n de polvo farmac\u00e9utico. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos cr\u00edticos relacionados con el manejo de aire y la recirculaci\u00f3n en entornos farmac\u00e9uticos, as\u00ed como las especificaciones sobre el uso de filtros HEPA.", "excerpt_keywords": "Keywords: ventilation, toxic materials, HEPA filters, fresh-air systems, HVAC system"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "202361ba-37f0-4f28-83e7-e884864bda45", "node_type": "4", "metadata": {"page_label": "263", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "preferably not be connected to the ducting by means of flexible ducting. Due to the high air pressure required for the terminal filter, this connection should preferably be a rigid duct connection. Where flexible ducting is used, it should be as short as possible and properly fixed to withstand duct pressure.\n\n7.3.6 Air containing dust from highly toxic processes and/or solvents or flammable vapours should never be recirculated to the HVAC system.\n\n## 7.4 Full fresh-air systems\n\nFigure 24 indicates a system operating on 100% fresh air and would normally be used in a facility dealing with toxic products or solvents, where recirculation of air with contaminants should be avoided.\n\n7.4.1 The required degree of filtration of the exhaust air depends on the exhaust air contaminants and local environmental regulations. HEPA filters in the exhaust system would normally only be required when handling hazardous materials.\n\n**Figure 24**  \n**Full fresh-air system**\n\n!Full fresh-air system diagram", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e06c44a44255eaae39d8e6892242fcbb34cfdffb7e9b519e4ef89ded55fa35cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "preferably not be connected to the ducting by means of flexible ducting. Due to the high air pressure required for the terminal filter, this connection should preferably be a rigid duct connection. Where flexible ducting is used, it should be as short as possible and properly fixed to withstand duct pressure.\n\n7.3.6 Air containing dust from highly toxic processes and/or solvents or flammable vapours should never be recirculated to the HVAC system.\n\n## 7.4 Full fresh-air systems\n\nFigure 24 indicates a system operating on 100% fresh air and would normally be used in a facility dealing with toxic products or solvents, where recirculation of air with contaminants should be avoided.\n\n7.4.1 The required degree of filtration of the exhaust air depends on the exhaust air contaminants and local environmental regulations. HEPA filters in the exhaust system would normally only be required when handling hazardous materials.\n\n**Figure 24**  \n**Full fresh-air system**\n\n!Full fresh-air system diagram", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1000, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c622ac40-029f-4e66-9d85-0a7f4fce6ffd": {"__data__": {"id_": "c622ac40-029f-4e66-9d85-0a7f4fce6ffd", "embedding": null, "metadata": {"page_label": "264", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 25  \n**Full fresh-air system with energy recovery**\n\n!Full fresh-air system with energy recovery\n\n7.4.2 Energy-recovery wheels if used in multiproduct facilities should have been subjected to a risk assessment to determine if there is any risk of cross-contamination. When such wheels are used they should not become a source of possible contamination (see Figure 25). *Note: Alternatives to the energy-recovery wheels, such as crossover plate heat exchangers and water-coil heat exchangers, may be used in multiproduct facilities.*\n\n7.4.3 The potential for air leakage between the supply air and exhaust air as it passes through the wheel should be prevented. The relative pressures between supply and exhaust air systems should be such that the exhaust air system operates at a lower pressure than the supply system.\n\n## 7.5 Additional system components\n\n7.5.1 A schematic diagram of the airflow for a typical system serving a low relative humidity suite is represented in Figure 26. Air can be dried with a chemical drier (e.g. a rotating desiccant wheel which is continuously regenerated by means of passing hot air through one segment of the wheel). Alternative methods of drying air are also available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de los sistemas de aire fresco con recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto. Se enfatiza la necesidad de realizar evaluaciones de riesgo para evitar la contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda. Adem\u00e1s, se menciona la importancia de mantener diferencias de presi\u00f3n adecuadas entre los sistemas de aire de suministro y de escape para prevenir fugas de aire. Tambi\u00e9n se discuten m\u00e9todos alternativos para el secado del aire en sistemas de baja humedad.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se deben tomar para evaluar el riesgo de contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto?**\n   - Respuesta: Se debe realizar una evaluaci\u00f3n de riesgo para determinar si hay alg\u00fan riesgo de contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto.\n\n2. **\u00bfCu\u00e1l es la presi\u00f3n relativa que debe mantenerse entre los sistemas de aire de suministro y de escape para evitar la fuga de aire?**\n   - Respuesta: La presi\u00f3n del sistema de escape debe ser inferior a la del sistema de suministro para prevenir la fuga de aire entre ambos.\n\n3. **\u00bfQu\u00e9 alternativas a las ruedas de recuperaci\u00f3n de energ\u00eda se pueden considerar en instalaciones multiproducto?**\n   - Respuesta: Se pueden considerar alternativas como intercambiadores de calor de placa cruzada y intercambiadores de calor de bobina de agua en instalaciones multiproducto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Ventilaci\u00f3n**: Se discute la importancia de los sistemas de ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos o solventes, enfatizando la necesidad de evitar la recirculaci\u00f3n de aire contaminado.\n\n2. **Conexiones de Ductos**: Se recomienda el uso de conexiones de ductos r\u00edgidos en lugar de flexibles debido a la alta presi\u00f3n de aire requerida para los filtros terminales. Las conexiones r\u00edgidas son m\u00e1s adecuadas para soportar esta presi\u00f3n.\n\n3. **Aire Contaminado**: Se establece que el aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables no debe ser recirculado al sistema HVAC, ya que esto puede comprometer la seguridad y la salud en el ambiente de trabajo.\n\n4. **Sistemas de Aire Fresco Completo**: Se menciona que los sistemas que operan con 100% de aire fresco son preferibles en instalaciones que manejan productos t\u00f3xicos, ya que evitan la recirculaci\u00f3n de aire contaminado.\n\n5. **Filtraci\u00f3n del Aire de Escape**: El grado de filtraci\u00f3n del aire de escape depende de los contaminantes presentes y de las regulaciones ambientales locales. Se indica que los filtros HEPA son necesarios cuando se manejan materiales peligrosos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre la ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos.\n- **Filtros HEPA**: Tipo de filtro mencionado como necesario para la captura de part\u00edculas finas en sistemas de escape que manejan materiales peligrosos.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado que deben ser dise\u00f1ados para evitar la recirculaci\u00f3n de aire contaminado.\n\nEste resumen destaca la importancia de la ventilaci\u00f3n adecuada y el manejo seguro de aire en entornos donde se manipulan sustancias peligrosas.", "excerpt_keywords": "Keywords: energy recovery, cross-contamination, air leakage, multiproduct facilities, ventilation systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ffa23a9f-2520-401b-809a-a417c0db493c", "node_type": "4", "metadata": {"page_label": "264", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 25  \n**Full fresh-air system with energy recovery**\n\n!Full fresh-air system with energy recovery\n\n7.4.2 Energy-recovery wheels if used in multiproduct facilities should have been subjected to a risk assessment to determine if there is any risk of cross-contamination. When such wheels are used they should not become a source of possible contamination (see Figure 25). *Note: Alternatives to the energy-recovery wheels, such as crossover plate heat exchangers and water-coil heat exchangers, may be used in multiproduct facilities.*\n\n7.4.3 The potential for air leakage between the supply air and exhaust air as it passes through the wheel should be prevented. The relative pressures between supply and exhaust air systems should be such that the exhaust air system operates at a lower pressure than the supply system.\n\n## 7.5 Additional system components\n\n7.5.1 A schematic diagram of the airflow for a typical system serving a low relative humidity suite is represented in Figure 26. Air can be dried with a chemical drier (e.g. a rotating desiccant wheel which is continuously regenerated by means of passing hot air through one segment of the wheel). Alternative methods of drying air are also available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e6804d3d0d92f68e4842bb6e2212cd704ebcab5001dd0e02a9aa60d43a5d0918", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 25  \n**Full fresh-air system with energy recovery**\n\n!Full fresh-air system with energy recovery\n\n7.4.2 Energy-recovery wheels if used in multiproduct facilities should have been subjected to a risk assessment to determine if there is any risk of cross-contamination. When such wheels are used they should not become a source of possible contamination (see Figure 25). *Note: Alternatives to the energy-recovery wheels, such as crossover plate heat exchangers and water-coil heat exchangers, may be used in multiproduct facilities.*\n\n7.4.3 The potential for air leakage between the supply air and exhaust air as it passes through the wheel should be prevented. The relative pressures between supply and exhaust air systems should be such that the exhaust air system operates at a lower pressure than the supply system.\n\n## 7.5 Additional system components\n\n7.5.1 A schematic diagram of the airflow for a typical system serving a low relative humidity suite is represented in Figure 26. Air can be dried with a chemical drier (e.g. a rotating desiccant wheel which is continuously regenerated by means of passing hot air through one segment of the wheel). Alternative methods of drying air are also available.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1217, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0199facb-18cd-4c05-b6ba-38f7a0805a82": {"__data__": {"id_": "0199facb-18cd-4c05-b6ba-38f7a0805a82", "embedding": null, "metadata": {"page_label": "265", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 26  \nAir-handling system with chemical drying\n\n7.5.2 The figure illustrates the chemical drier handling part of the fresh air/return air mixture on a bypass flow. The location of the chemical drier should be considered in the design phase. The practice of locating the complete chemical drier unit in the production cubicle is not recommended as this could be a source of contamination or cross-contamination. Examples of appropriate locations for the drying wheel could include:\n\n- full flow of fresh/return air;\n- partial handling of fresh/return air (bypass airflow);\n- return air only;\n- fresh air only; or\n- pre-cooled air with any of the above alternatives.\n\n7.5.3 Possible additional components that may be required in air handling should be considered depending on the climatic conditions and locations. These may include items such as:\n\n- frost coils on fresh air inlets in very cold climates to preheat the air;\n- reheaters for humidity control\n- automatic air volume control devices\n- sound attenuators", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Dise\u00f1o del sistema de manejo de aire**: El dise\u00f1o de un sistema de manejo de aire con secado qu\u00edmico es crucial para evitar la contaminaci\u00f3n en entornos de producci\u00f3n. La ubicaci\u00f3n del secador qu\u00edmico debe ser cuidadosamente considerada para garantizar la calidad del aire.\n\n2. **Componentes adicionales en el manejo de aire**: Dependiendo de las condiciones clim\u00e1ticas, pueden ser necesarios componentes adicionales en el sistema de manejo de aire, como bobinas de escarcha, reheaters y dispositivos de control de volumen de aire.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las implicaciones de ubicar el secador qu\u00edmico en la cub\u00edcula de producci\u00f3n?**\n   - La ubicaci\u00f3n del secador qu\u00edmico en la cub\u00edcula de producci\u00f3n puede ser una fuente de contaminaci\u00f3n o contaminaci\u00f3n cruzada, lo que podr\u00eda comprometer la calidad del producto y la seguridad del ambiente de trabajo.\n\n2. **\u00bfQu\u00e9 consideraciones clim\u00e1ticas deben tenerse en cuenta al dise\u00f1ar un sistema de manejo de aire?**\n   - Las condiciones clim\u00e1ticas pueden requerir la inclusi\u00f3n de componentes como bobinas de escarcha para precalentar el aire en climas muy fr\u00edos, as\u00ed como reheaters para el control de la humedad y dispositivos autom\u00e1ticos de control de volumen de aire.\n\n3. **\u00bfQu\u00e9 alternativas existen para el flujo de aire en el sistema de secado qu\u00edmico?**\n   - Las alternativas para el flujo de aire en el sistema de secado qu\u00edmico incluyen el manejo de aire fresco y de retorno en flujo completo, manejo parcial de aire fresco/retorno (flujo de bypass), manejo solo de aire de retorno, manejo solo de aire fresco, o aire precocido con cualquiera de las alternativas mencionadas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistemas de aire fresco con recuperaci\u00f3n de energ\u00eda**: Se discute la importancia de estos sistemas en instalaciones multiproducto, destacando su funci\u00f3n en la ventilaci\u00f3n y el control de la calidad del aire.\n\n2. **Evaluaci\u00f3n de riesgo**: Se enfatiza la necesidad de realizar una evaluaci\u00f3n de riesgo para identificar posibles contaminaciones cruzadas al utilizar ruedas de recuperaci\u00f3n de energ\u00eda.\n\n3. **Prevenci\u00f3n de contaminaci\u00f3n**: Se menciona que las ruedas de recuperaci\u00f3n de energ\u00eda no deben convertirse en fuentes de contaminaci\u00f3n.\n\n4. **Presiones relativas**: Se establece que la presi\u00f3n del sistema de escape debe ser inferior a la del sistema de suministro para evitar fugas de aire entre ambos.\n\n5. **Alternativas a las ruedas de recuperaci\u00f3n de energ\u00eda**: Se sugieren opciones como intercambiadores de calor de placa cruzada y intercambiadores de calor de bobina de agua para su uso en instalaciones multiproducto.\n\n6. **Secado del aire**: Se menciona el uso de deshidratadores qu\u00edmicos, como ruedas deshidratantes rotativas, y se indican m\u00e9todos alternativos para el secado del aire en sistemas de baja humedad.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Ruedas de recuperaci\u00f3n de energ\u00eda**: Componente clave en el sistema de ventilaci\u00f3n.\n- **Intercambiadores de calor**: Alternativas mencionadas para la recuperaci\u00f3n de energ\u00eda.\n- **Sistemas de aire de suministro y de escape**: Elementos cr\u00edticos en la gesti\u00f3n de la calidad del aire.\n- **Deshidratadores qu\u00edmicos**: M\u00e9todos utilizados para controlar la humedad del aire.", "excerpt_keywords": "Keywords: air-handling system, chemical drying, contamination prevention, climatic conditions, humidity control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fc6e2cd0-c24f-48b0-b795-4eda9ec3d3f7", "node_type": "4", "metadata": {"page_label": "265", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 26  \nAir-handling system with chemical drying\n\n7.5.2 The figure illustrates the chemical drier handling part of the fresh air/return air mixture on a bypass flow. The location of the chemical drier should be considered in the design phase. The practice of locating the complete chemical drier unit in the production cubicle is not recommended as this could be a source of contamination or cross-contamination. Examples of appropriate locations for the drying wheel could include:\n\n- full flow of fresh/return air;\n- partial handling of fresh/return air (bypass airflow);\n- return air only;\n- fresh air only; or\n- pre-cooled air with any of the above alternatives.\n\n7.5.3 Possible additional components that may be required in air handling should be considered depending on the climatic conditions and locations. These may include items such as:\n\n- frost coils on fresh air inlets in very cold climates to preheat the air;\n- reheaters for humidity control\n- automatic air volume control devices\n- sound attenuators", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7074e34beb1462c597601fbc90faf2b5a8ff3f3e84b99015d0bbd5af88c7e999", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Figure 26  \nAir-handling system with chemical drying\n\n7.5.2 The figure illustrates the chemical drier handling part of the fresh air/return air mixture on a bypass flow. The location of the chemical drier should be considered in the design phase. The practice of locating the complete chemical drier unit in the production cubicle is not recommended as this could be a source of contamination or cross-contamination. Examples of appropriate locations for the drying wheel could include:\n\n- full flow of fresh/return air;\n- partial handling of fresh/return air (bypass airflow);\n- return air only;\n- fresh air only; or\n- pre-cooled air with any of the above alternatives.\n\n7.5.3 Possible additional components that may be required in air handling should be considered depending on the climatic conditions and locations. These may include items such as:\n\n- frost coils on fresh air inlets in very cold climates to preheat the air;\n- reheaters for humidity control\n- automatic air volume control devices\n- sound attenuators", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1022, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cf3a5a2e-a4ae-4fcd-bbb9-704f652c5467": {"__data__": {"id_": "cf3a5a2e-a4ae-4fcd-bbb9-704f652c5467", "embedding": null, "metadata": {"page_label": "266", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Commissioning, qualification and maintenance\n\n## 8.1 Commissioning\n\n8.1.1 Commissioning should include the setting up, balancing, adjustment and testing of the entire HVAC system, to ensure that it meets all the requirements, as specified in the user requirement specification (URS), and capacities as specified by the designer or developer. The commissioning plan should start at the early stages of a project so that it can be integrated with qualification and verification procedures.\n\n8.1.2 The installation records of the system should provide documented evidence of all measured capacities of the system.\n\n8.1.3 Acceptance criteria should be set for all system parameters. The measured data should fall within the acceptance criteria.\n\n8.1.4 Acceptable tolerances for all system parameters should be specified prior to commencing the physical installation.\n\n8.1.5 Training should be provided to personnel after installation of the system, and should include operation and maintenance.\n\n8.1.6 Commissioning should be a precursor to system qualification and process validation.\n\n## 8.2 Qualification\n\n8.2.1 Validation is a many-faceted and extensive activity and is beyond the scope of these guidelines (2) (see also Figure 27).\n\nA risk-based approach should be used to identify the extent to which the HVAC system requires qualification and verification. The basic concepts of qualification of HVAC systems are set out below.\n\n8.2.2 The qualification of the HVAC system should be described in a validation master plan (VMP).\n\n8.2.3 It should define the nature and extent of testing and the test procedures and protocols to be followed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda la importancia de la **comisionamiento**, **calificaci\u00f3n** y **mantenimiento** de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado). Se enfatiza que el comisionamiento debe incluir la configuraci\u00f3n, ajuste y prueba del sistema para cumplir con los requisitos especificados. Adem\u00e1s, se menciona que la calificaci\u00f3n del sistema debe ser parte de un plan maestro de validaci\u00f3n y que se debe adoptar un enfoque basado en riesgos para determinar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos clave que deben incluirse en un plan de comisionamiento para un sistema HVAC?**\n   - El plan de comisionamiento debe incluir la configuraci\u00f3n, balanceo, ajuste y prueba del sistema HVAC, asegurando que cumpla con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario (URS) y las capacidades definidas por el dise\u00f1ador.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para evidenciar la instalaci\u00f3n de un sistema HVAC?**\n   - Se deben mantener registros de instalaci\u00f3n que proporcionen evidencia documentada de todas las capacidades medidas del sistema.\n\n3. **\u00bfC\u00f3mo se debe abordar la calificaci\u00f3n de un sistema HVAC seg\u00fan el documento?**\n   - La calificaci\u00f3n del sistema HVAC debe ser descrita en un plan maestro de validaci\u00f3n (VMP) y debe definir la naturaleza y extensi\u00f3n de las pruebas, as\u00ed como los procedimientos y protocolos a seguir. Adem\u00e1s, se debe utilizar un enfoque basado en riesgos para identificar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Manejo de Aire**: Se discute el dise\u00f1o de un sistema de manejo de aire que incluye un secador qu\u00edmico, enfatizando la importancia de su ubicaci\u00f3n para evitar la contaminaci\u00f3n en entornos de producci\u00f3n.\n\n2. **Ubicaci\u00f3n del Secador Qu\u00edmico**: Se desaconseja la colocaci\u00f3n del secador qu\u00edmico en la cub\u00edcula de producci\u00f3n debido al riesgo de contaminaci\u00f3n cruzada. Se sugieren ubicaciones alternativas, como:\n   - Flujo completo de aire fresco/retorno.\n   - Manejo parcial de aire fresco/retorno (flujo de bypass).\n   - Solo aire de retorno.\n   - Solo aire fresco.\n   - Aire precocido con cualquiera de las alternativas mencionadas.\n\n3. **Componentes Adicionales**: Se mencionan componentes que pueden ser necesarios en el sistema de manejo de aire, dependiendo de las condiciones clim\u00e1ticas, tales como:\n   - Bobinas de escarcha para precalentar el aire en climas fr\u00edos.\n   - Recalentadores para el control de la humedad.\n   - Dispositivos autom\u00e1ticos de control de volumen de aire.\n   - Atenuadores de sonido.\n\n### Entidades Clave\n- **Secador Qu\u00edmico**: Dispositivo utilizado para el manejo del aire en el sistema.\n- **Cub\u00edcula de Producci\u00f3n**: \u00c1rea donde se lleva a cabo la producci\u00f3n y que debe estar libre de contaminantes.\n- **Condiciones Clim\u00e1ticas**: Factores ambientales que influyen en el dise\u00f1o del sistema de manejo de aire.\n- **Componentes del Sistema**: Elementos adicionales que pueden ser necesarios para optimizar el manejo del aire, como bobinas de escarcha y reheaters.", "excerpt_keywords": "Keywords: commissioning, qualification, HVAC system, validation master plan, acceptance criteria"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93632837-eab3-4f7b-ba24-094995b3ef23", "node_type": "4", "metadata": {"page_label": "266", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Commissioning, qualification and maintenance\n\n## 8.1 Commissioning\n\n8.1.1 Commissioning should include the setting up, balancing, adjustment and testing of the entire HVAC system, to ensure that it meets all the requirements, as specified in the user requirement specification (URS), and capacities as specified by the designer or developer. The commissioning plan should start at the early stages of a project so that it can be integrated with qualification and verification procedures.\n\n8.1.2 The installation records of the system should provide documented evidence of all measured capacities of the system.\n\n8.1.3 Acceptance criteria should be set for all system parameters. The measured data should fall within the acceptance criteria.\n\n8.1.4 Acceptable tolerances for all system parameters should be specified prior to commencing the physical installation.\n\n8.1.5 Training should be provided to personnel after installation of the system, and should include operation and maintenance.\n\n8.1.6 Commissioning should be a precursor to system qualification and process validation.\n\n## 8.2 Qualification\n\n8.2.1 Validation is a many-faceted and extensive activity and is beyond the scope of these guidelines (2) (see also Figure 27).\n\nA risk-based approach should be used to identify the extent to which the HVAC system requires qualification and verification. The basic concepts of qualification of HVAC systems are set out below.\n\n8.2.2 The qualification of the HVAC system should be described in a validation master plan (VMP).\n\n8.2.3 It should define the nature and extent of testing and the test procedures and protocols to be followed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b5c21bb44cf64d621a67f6dccd42d1553840efc5f432569fad7c5b9498cce5fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Commissioning, qualification and maintenance\n\n## 8.1 Commissioning\n\n8.1.1 Commissioning should include the setting up, balancing, adjustment and testing of the entire HVAC system, to ensure that it meets all the requirements, as specified in the user requirement specification (URS), and capacities as specified by the designer or developer. The commissioning plan should start at the early stages of a project so that it can be integrated with qualification and verification procedures.\n\n8.1.2 The installation records of the system should provide documented evidence of all measured capacities of the system.\n\n8.1.3 Acceptance criteria should be set for all system parameters. The measured data should fall within the acceptance criteria.\n\n8.1.4 Acceptable tolerances for all system parameters should be specified prior to commencing the physical installation.\n\n8.1.5 Training should be provided to personnel after installation of the system, and should include operation and maintenance.\n\n8.1.6 Commissioning should be a precursor to system qualification and process validation.\n\n## 8.2 Qualification\n\n8.2.1 Validation is a many-faceted and extensive activity and is beyond the scope of these guidelines (2) (see also Figure 27).\n\nA risk-based approach should be used to identify the extent to which the HVAC system requires qualification and verification. The basic concepts of qualification of HVAC systems are set out below.\n\n8.2.2 The qualification of the HVAC system should be described in a validation master plan (VMP).\n\n8.2.3 It should define the nature and extent of testing and the test procedures and protocols to be followed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1642, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ff4a8ef2-a926-4e12-a790-8ad10385dc56": {"__data__": {"id_": "ff4a8ef2-a926-4e12-a790-8ad10385dc56", "embedding": null, "metadata": {"page_label": "267", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification is a part of validation\n\n```\nEquipment 1  Equipment 2  Equipment 3  Equipment 4  Equipment 5  Equipment 6  Equipment 7\n     |            |            |            |            |            |            |\n     --------------------------------------------------------------\n                             |                                      |\n                          System 1                               System 2\n                             |                                      |\n                             ---------------------------------------\n                                         |\n                                       Process\n```\n\n8.2.4 Stages of the qualification of the HVAC system should include DQ, IQ, OQ and PQ.\n\n8.2.5 Critical and non-critical parameters should be determined by means of a risk analysis for all HVAC installation components, subsystems and controls.\n\n8.2.6 Any parameter that may affect the quality of the pharmaceutical product, or a direct impact component, should be considered a critical parameter.\n\n8.2.7 All critical parameters should be included in the qualification process. *Note: A realistic approach to differentiating between critical and noncritical parameters is required, to avoid making the validation process unnecessarily complex.*\n\n**Example:**\n\n- *The relative humidity of the room where the product is exposed should be considered a critical parameter when a humidity-sensitive product is being manufactured. The humidity sensors and the humidity monitoring system should, therefore, be qualified. The heat transfer system, chemical drier or steam humidifier, which is producing the humidity controlled air, is further removed from the product and may not require operational qualification.*\n\n- *A room cleanliness condition is a critical parameter and, therefore, the room air change rates and HEPA filters should be critical parameters and require qualification. Items such as the fan generating the airflow and the primary and secondary filters are non-critical parameters, and may not require operational qualification.*\n\n8.2.8 Non-critical systems and components should be subject to GEP and may not necessarily require qualification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la calificaci\u00f3n de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en el contexto de la fabricaci\u00f3n farmac\u00e9utica. Se describen las etapas de calificaci\u00f3n, que incluyen DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o). Se enfatiza la importancia de realizar un an\u00e1lisis de riesgo para identificar par\u00e1metros cr\u00edticos y no cr\u00edticos que puedan afectar la calidad del producto farmac\u00e9utico. Se proporcionan ejemplos de c\u00f3mo determinar qu\u00e9 par\u00e1metros son cr\u00edticos y cu\u00e1les no, as\u00ed como la necesidad de aplicar Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP) a los sistemas no cr\u00edticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las etapas espec\u00edficas de la calificaci\u00f3n de un sistema HVAC seg\u00fan el documento?**\n   - Respuesta: Las etapas de la calificaci\u00f3n del sistema HVAC incluyen DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o).\n\n2. **\u00bfC\u00f3mo se determina si un par\u00e1metro es cr\u00edtico o no cr\u00edtico en el contexto de un sistema HVAC?**\n   - Respuesta: La determinaci\u00f3n de par\u00e1metros cr\u00edticos y no cr\u00edticos se realiza mediante un an\u00e1lisis de riesgo para todos los componentes, subsistemas y controles de la instalaci\u00f3n HVAC. Cualquier par\u00e1metro que pueda afectar la calidad del producto farmac\u00e9utico o que tenga un impacto directo se considera cr\u00edtico.\n\n3. **\u00bfQu\u00e9 ejemplos se proporcionan en el documento para ilustrar la diferencia entre par\u00e1metros cr\u00edticos y no cr\u00edticos?**\n   - Respuesta: Se menciona que la humedad relativa en una sala donde se expone un producto sensible a la humedad es un par\u00e1metro cr\u00edtico y, por lo tanto, los sensores de humedad y el sistema de monitoreo de humedad deben ser calificados. En contraste, el ventilador que genera el flujo de aire y los filtros primarios y secundarios son considerados par\u00e1metros no cr\u00edticos y pueden no requerir calificaci\u00f3n operativa.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Comisionamiento de Sistemas HVAC:**\n   - Incluye la configuraci\u00f3n, balanceo, ajuste y prueba del sistema.\n   - Debe cumplir con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario (URS) y las capacidades definidas por el dise\u00f1ador.\n   - Se deben establecer criterios de aceptaci\u00f3n y tolerancias antes de la instalaci\u00f3n.\n   - Se requiere documentaci\u00f3n de las capacidades medidas del sistema.\n   - Es esencial proporcionar capacitaci\u00f3n al personal sobre operaci\u00f3n y mantenimiento.\n   - El comisionamiento es un precursor de la calificaci\u00f3n del sistema y la validaci\u00f3n del proceso.\n\n2. **Calificaci\u00f3n de Sistemas HVAC:**\n   - La calificaci\u00f3n debe ser parte de un plan maestro de validaci\u00f3n (VMP).\n   - Se debe adoptar un enfoque basado en riesgos para determinar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.\n   - El VMP debe definir la naturaleza y extensi\u00f3n de las pruebas, as\u00ed como los procedimientos y protocolos a seguir.\n\n**Entidades:**\n\n- **Sistemas HVAC:** Calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Especificaci\u00f3n de Requisitos del Usuario (URS):** Documento que detalla los requisitos que debe cumplir el sistema.\n- **Plan Maestro de Validaci\u00f3n (VMP):** Documento que describe la calificaci\u00f3n del sistema HVAC y los procedimientos de prueba.\n- **Criterios de Aceptaci\u00f3n:** Par\u00e1metros establecidos que deben cumplirse para considerar que el sistema est\u00e1 funcionando correctamente.\n- **Tolerancias Aceptables:** L\u00edmites permitidos para los par\u00e1metros del sistema antes de la instalaci\u00f3n.\n\nEste resumen destaca la importancia del comisionamiento y la calificaci\u00f3n en la implementaci\u00f3n y mantenimiento de sistemas HVAC, as\u00ed como la necesidad de documentaci\u00f3n y capacitaci\u00f3n adecuada.", "excerpt_keywords": "Keywords: HVAC, qualification, critical parameters, risk analysis, pharmaceutical manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eac5488b-22bd-489e-afe9-13e7b32affd0", "node_type": "4", "metadata": {"page_label": "267", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification is a part of validation\n\n```\nEquipment 1  Equipment 2  Equipment 3  Equipment 4  Equipment 5  Equipment 6  Equipment 7\n     |            |            |            |            |            |            |\n     --------------------------------------------------------------\n                             |                                      |\n                          System 1                               System 2\n                             |                                      |\n                             ---------------------------------------\n                                         |\n                                       Process\n```\n\n8.2.4 Stages of the qualification of the HVAC system should include DQ, IQ, OQ and PQ.\n\n8.2.5 Critical and non-critical parameters should be determined by means of a risk analysis for all HVAC installation components, subsystems and controls.\n\n8.2.6 Any parameter that may affect the quality of the pharmaceutical product, or a direct impact component, should be considered a critical parameter.\n\n8.2.7 All critical parameters should be included in the qualification process. *Note: A realistic approach to differentiating between critical and noncritical parameters is required, to avoid making the validation process unnecessarily complex.*\n\n**Example:**\n\n- *The relative humidity of the room where the product is exposed should be considered a critical parameter when a humidity-sensitive product is being manufactured. The humidity sensors and the humidity monitoring system should, therefore, be qualified. The heat transfer system, chemical drier or steam humidifier, which is producing the humidity controlled air, is further removed from the product and may not require operational qualification.*\n\n- *A room cleanliness condition is a critical parameter and, therefore, the room air change rates and HEPA filters should be critical parameters and require qualification. Items such as the fan generating the airflow and the primary and secondary filters are non-critical parameters, and may not require operational qualification.*\n\n8.2.8 Non-critical systems and components should be subject to GEP and may not necessarily require qualification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "03062547f3cbc6190ea9a8338b32c3ef3870a83af702b363149936d240e85d9c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Qualification is a part of validation\n\n```\nEquipment 1  Equipment 2  Equipment 3  Equipment 4  Equipment 5  Equipment 6  Equipment 7\n     |            |            |            |            |            |            |\n     --------------------------------------------------------------\n                             |                                      |\n                          System 1                               System 2\n                             |                                      |\n                             ---------------------------------------\n                                         |\n                                       Process\n```\n\n8.2.4 Stages of the qualification of the HVAC system should include DQ, IQ, OQ and PQ.\n\n8.2.5 Critical and non-critical parameters should be determined by means of a risk analysis for all HVAC installation components, subsystems and controls.\n\n8.2.6 Any parameter that may affect the quality of the pharmaceutical product, or a direct impact component, should be considered a critical parameter.\n\n8.2.7 All critical parameters should be included in the qualification process. *Note: A realistic approach to differentiating between critical and noncritical parameters is required, to avoid making the validation process unnecessarily complex.*\n\n**Example:**\n\n- *The relative humidity of the room where the product is exposed should be considered a critical parameter when a humidity-sensitive product is being manufactured. The humidity sensors and the humidity monitoring system should, therefore, be qualified. The heat transfer system, chemical drier or steam humidifier, which is producing the humidity controlled air, is further removed from the product and may not require operational qualification.*\n\n- *A room cleanliness condition is a critical parameter and, therefore, the room air change rates and HEPA filters should be critical parameters and require qualification. Items such as the fan generating the airflow and the primary and secondary filters are non-critical parameters, and may not require operational qualification.*\n\n8.2.8 Non-critical systems and components should be subject to GEP and may not necessarily require qualification.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2219, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "72118518-036f-4ec6-b989-148216b470d0": {"__data__": {"id_": "72118518-036f-4ec6-b989-148216b470d0", "embedding": null, "metadata": {"page_label": "268", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.2.9 A change control procedure should be followed when changes are planned to the direct impact HVAC system, its components and controls that may affect critical parameters.\n\n8.2.10 The design condition, normal operating ranges, operating range and alert and action limits should be defined and be realistic.\n\n8.2.11 Out-of-limit results (e.g. action limit deviations) should be recorded and their impact should be investigated.\n\n8.2.12 The relationships between design conditions, normal operating range and validated acceptance criteria (also known as proven acceptable range) are given in Figure 28.\n\n**Figure 28**  \n**System operating ranges**\n\n| ACTION LIMIT | ALERT LIMIT | DESIGN SET-POINT | DESIGN SET-POINT | ALERT LIMIT | ACTION LIMIT |\n|--------------|-------------|------------------|------------------|-------------|--------------|\n\n- Design Condition\n- Normal Operating Range\n- Operating Range \u2013 Validated Acceptance Criteria\n\n8.2.13 For a pharmaceutical facility, based on a risk assessment, some of the typical HVAC system parameters that should be qualified may include:\n\n- temperature\n- relative humidity\n- supply air quantities for all diffusers\n- return air or exhaust air quantities\n- room air change rates\n- room pressures (pressure differentials)\n- room airflow patterns\n- unidirectional flow velocities\n- containment system velocities\n- HEPA filter penetration tests", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de un procedimiento de control de cambios en los sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en instalaciones farmac\u00e9uticas. Se enfatiza la necesidad de definir condiciones de dise\u00f1o, rangos operativos normales y l\u00edmites de alerta y acci\u00f3n. Tambi\u00e9n se menciona la importancia de registrar resultados fuera de los l\u00edmites y evaluar su impacto. Adem\u00e1s, se enumeran par\u00e1metros t\u00edpicos del sistema HVAC que deben ser calificados, basados en una evaluaci\u00f3n de riesgos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos recomendados en un procedimiento de control de cambios para un sistema HVAC en una instalaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre el proceso espec\u00edfico que se debe seguir al implementar cambios en el sistema HVAC, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al definir los l\u00edmites de alerta y acci\u00f3n para los par\u00e1metros del sistema HVAC?**\n   - Esta pregunta se centra en los factores que influyen en la determinaci\u00f3n de l\u00edmites espec\u00edficos, lo que podr\u00eda no estar claramente definido en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe documentar y evaluar el impacto de los resultados que se encuentran fuera de los l\u00edmites establecidos en un sistema HVAC?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso de documentaci\u00f3n y evaluaci\u00f3n de resultados an\u00f3malos, que podr\u00eda no estar ampliamente cubierto en otros documentos relacionados. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otros contextos, bas\u00e1ndose en el contenido del documento de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n de Sistemas HVAC**: Se detalla el proceso de calificaci\u00f3n de sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en la fabricaci\u00f3n farmac\u00e9utica, que incluye las etapas de DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o).\n\n2. **An\u00e1lisis de Riesgo**: Se enfatiza la importancia de realizar un an\u00e1lisis de riesgo para identificar par\u00e1metros cr\u00edticos y no cr\u00edticos en todos los componentes, subsistemas y controles de la instalaci\u00f3n HVAC.\n\n3. **Par\u00e1metros Cr\u00edticos y No Cr\u00edticos**: Se define que cualquier par\u00e1metro que pueda afectar la calidad del producto farmac\u00e9utico o que tenga un impacto directo debe ser considerado cr\u00edtico. Se proporciona orientaci\u00f3n sobre c\u00f3mo diferenciar entre par\u00e1metros cr\u00edticos y no cr\u00edticos para evitar complicaciones innecesarias en el proceso de validaci\u00f3n.\n\n4. **Ejemplos Pr\u00e1cticos**: Se ofrecen ejemplos espec\u00edficos que ilustran la clasificaci\u00f3n de par\u00e1metros, como la humedad relativa en salas de producci\u00f3n y las condiciones de limpieza del ambiente.\n\n5. **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**: Se menciona que los sistemas y componentes no cr\u00edticos deben estar sujetos a Buenas Pr\u00e1cticas de Ingenier\u00eda y pueden no requerir calificaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en el contexto farmac\u00e9utico.\n- **Par\u00e1metros Cr\u00edticos**: Elementos que afectan directamente la calidad del producto farmac\u00e9utico.\n- **Par\u00e1metros No Cr\u00edticos**: Elementos que no afectan directamente la calidad del producto y pueden no requerir calificaci\u00f3n.\n- **Etapas de Calificaci\u00f3n**: DQ, IQ, OQ, PQ.\n- **Ejemplos de Par\u00e1metros**: Humedad relativa, tasas de cambio de aire, filtros HEPA, ventiladores.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes de la secci\u00f3n sobre la calificaci\u00f3n de sistemas HVAC en la fabricaci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical facility, change control procedure, risk assessment, operating ranges"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8fd1404a-701d-472d-9e7c-eb5736cf0acf", "node_type": "4", "metadata": {"page_label": "268", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.2.9 A change control procedure should be followed when changes are planned to the direct impact HVAC system, its components and controls that may affect critical parameters.\n\n8.2.10 The design condition, normal operating ranges, operating range and alert and action limits should be defined and be realistic.\n\n8.2.11 Out-of-limit results (e.g. action limit deviations) should be recorded and their impact should be investigated.\n\n8.2.12 The relationships between design conditions, normal operating range and validated acceptance criteria (also known as proven acceptable range) are given in Figure 28.\n\n**Figure 28**  \n**System operating ranges**\n\n| ACTION LIMIT | ALERT LIMIT | DESIGN SET-POINT | DESIGN SET-POINT | ALERT LIMIT | ACTION LIMIT |\n|--------------|-------------|------------------|------------------|-------------|--------------|\n\n- Design Condition\n- Normal Operating Range\n- Operating Range \u2013 Validated Acceptance Criteria\n\n8.2.13 For a pharmaceutical facility, based on a risk assessment, some of the typical HVAC system parameters that should be qualified may include:\n\n- temperature\n- relative humidity\n- supply air quantities for all diffusers\n- return air or exhaust air quantities\n- room air change rates\n- room pressures (pressure differentials)\n- room airflow patterns\n- unidirectional flow velocities\n- containment system velocities\n- HEPA filter penetration tests", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1b2579e68d1fedc00d7457c2cf291ddb033ce54cf7848ebc2266f18b574b97c9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8.2.9 A change control procedure should be followed when changes are planned to the direct impact HVAC system, its components and controls that may affect critical parameters.\n\n8.2.10 The design condition, normal operating ranges, operating range and alert and action limits should be defined and be realistic.\n\n8.2.11 Out-of-limit results (e.g. action limit deviations) should be recorded and their impact should be investigated.\n\n8.2.12 The relationships between design conditions, normal operating range and validated acceptance criteria (also known as proven acceptable range) are given in Figure 28.\n\n**Figure 28**  \n**System operating ranges**\n\n| ACTION LIMIT | ALERT LIMIT | DESIGN SET-POINT | DESIGN SET-POINT | ALERT LIMIT | ACTION LIMIT |\n|--------------|-------------|------------------|------------------|-------------|--------------|\n\n- Design Condition\n- Normal Operating Range\n- Operating Range \u2013 Validated Acceptance Criteria\n\n8.2.13 For a pharmaceutical facility, based on a risk assessment, some of the typical HVAC system parameters that should be qualified may include:\n\n- temperature\n- relative humidity\n- supply air quantities for all diffusers\n- return air or exhaust air quantities\n- room air change rates\n- room pressures (pressure differentials)\n- room airflow patterns\n- unidirectional flow velocities\n- containment system velocities\n- HEPA filter penetration tests", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1392, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6dcb2e44-3e00-4ade-867e-0512f5ca66fe": {"__data__": {"id_": "6dcb2e44-3e00-4ade-867e-0512f5ca66fe", "embedding": null, "metadata": {"page_label": "269", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 room particle counts  \n\u2014 room clean-up rates  \n\u2014 microbiological air and surface counts where appropriate  \n\u2014 operation of de-dusting  \n\u2014 warning/alarm systems where applicable.  \n\n8.2.14 The maximum time interval between tests should be defined by the manufacturer. The type of facility under test and the product level of protection should be considered. Table 3 gives various tests that can be carried out. The required tests and intervals between testing should be determined through risk assessment.\n\n### Table 3  \n**Tests to demonstrate compliance**\n\n| Test parameter | Test procedure |\n| - | - |\n| Particle count test (Verification of cleanliness) | Dust particle counts to be carried out and result printouts produced. No. of readings and positions of tests to be in accordance with ISO 14644-1 Annex B5 |\n| Air pressure difference (To verify non cross-contamination) | Log of pressure differential readings to be produced or critical plants should be logged daily, preferably continuously. A 15 Pa pressure differential between different zones is recommended. In accordance with ISO 14644-3 Annex B5 |\n| Airflow volume (To verify air change rates) | Airflow readings for supply air and return air grilles to be measured and air change rates to be calculated. In accordance with ISO 14644-3 Annex B13 |\n| Airflow velocity (To verify unidirectional flow or containment conditions) | Air velocities for containment systems and unidirectional flow protection systems to be measured. In accordance with ISO 14644-3 Annex B4 |\n| Filter leakage tests (To verify filter integrity) | Filter penetration tests to be carried out by a competent person to demonstrate filter media, filter seal and filter frame integrity. Only required on HEPA filters. In accordance with ISO 14644-3 Annex B6 |\n| Containment leakage (To verify absence of cross-contamination) | Demonstrate that contaminant is maintained within a room by means of: \u2022 airflow direction smoke tests \u2022 room air pressures. In accordance with ISO 14644-3 Annex B4 |\n| Recovery (To verify clean-up time) | Test to establish time that a cleanroom takes to recover from a contaminated condition to the specified cleanroom condition. Should not take more than 15 min. In accordance with ISO 14644-3 Annex B13\\* |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las pruebas necesarias para garantizar la conformidad de las instalaciones que requieren un control estricto de la contaminaci\u00f3n, como las salas limpias. Se menciona la importancia de realizar pruebas peri\u00f3dicas, definidas por el fabricante, y se proporciona una tabla con diferentes par\u00e1metros de prueba, procedimientos y normas ISO correspondientes. Las pruebas incluyen conteos de part\u00edculas, diferencias de presi\u00f3n de aire, vol\u00famenes y velocidades de flujo de aire, pruebas de integridad de filtros, y pruebas de recuperaci\u00f3n de la sala limpia.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre la diferencia de presi\u00f3n entre diferentes zonas en una instalaci\u00f3n cr\u00edtica, seg\u00fan el documento?**\n   - La recomendaci\u00f3n es mantener una diferencia de presi\u00f3n de 15 Pa entre diferentes zonas.\n\n2. **\u00bfQu\u00e9 procedimiento se debe seguir para verificar la integridad de los filtros HEPA en una sala limpia?**\n   - Se deben realizar pruebas de penetraci\u00f3n de filtros llevadas a cabo por una persona competente para demostrar la integridad del medio filtrante, el sello del filtro y el marco del filtro.\n\n3. **\u00bfCu\u00e1nto tiempo se considera aceptable para que una sala limpia recupere su condici\u00f3n especificada despu\u00e9s de una contaminaci\u00f3n?**\n   - El tiempo de recuperaci\u00f3n no debe exceder los 15 minutos.\n\n### Resumen de nivel superior\nEl documento de la OMS establece directrices para la evaluaci\u00f3n y el mantenimiento de la calidad del aire en instalaciones cr\u00edticas, como las salas limpias. Se enfatiza la necesidad de realizar pruebas regulares para asegurar que las condiciones de limpieza y la integridad de los sistemas de filtraci\u00f3n se mantengan dentro de los est\u00e1ndares establecidos. Las pruebas deben ser adaptadas a las caracter\u00edsticas espec\u00edficas de cada instalaci\u00f3n y deben ser realizadas por personal competente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimiento de Control de Cambios**:\n   - Importancia de seguir un procedimiento de control de cambios para el sistema HVAC en instalaciones farmac\u00e9uticas.\n   - Cambios que pueden afectar par\u00e1metros cr\u00edticos deben ser gestionados adecuadamente.\n\n2. **Definici\u00f3n de Par\u00e1metros**:\n   - Necesidad de definir condiciones de dise\u00f1o, rangos operativos normales, y l\u00edmites de alerta y acci\u00f3n de manera realista.\n   - Relaci\u00f3n entre condiciones de dise\u00f1o, rangos operativos normales y criterios de aceptaci\u00f3n validados.\n\n3. **Registro y Evaluaci\u00f3n de Resultados Fuera de L\u00edmites**:\n   - Resultados que exceden los l\u00edmites establecidos deben ser documentados y su impacto investigado.\n\n4. **Par\u00e1metros T\u00edpicos del Sistema HVAC**:\n   - Identificaci\u00f3n de par\u00e1metros que deben ser calificados en funci\u00f3n de una evaluaci\u00f3n de riesgos, incluyendo:\n     - Temperatura\n     - Humedad relativa\n     - Cantidades de aire suministrado y retornado\n     - Tasas de cambio de aire en las habitaciones\n     - Presiones de las habitaciones (diferenciales de presi\u00f3n)\n     - Patrones de flujo de aire en las habitaciones\n     - Velocidades de flujo unidireccional\n     - Velocidades de sistemas de contenci\u00f3n\n     - Pruebas de penetraci\u00f3n de filtros HEPA\n\n5. **Figura 28 - Rangos Operativos del Sistema**:\n   - Representaci\u00f3n gr\u00e1fica que ilustra los l\u00edmites de acci\u00f3n, l\u00edmites de alerta, y puntos de ajuste de dise\u00f1o.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado relevante para instalaciones farmac\u00e9uticas.\n- **Par\u00e1metros Cr\u00edticos**: Elementos que afectan la calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n- **Riesgo**: Concepto utilizado para determinar qu\u00e9 par\u00e1metros deben ser calificados en el sistema HVAC.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de los sistemas HVAC en el contexto de la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de procedimientos claros y la evaluaci\u00f3n continua de los par\u00e1metros cr\u00edticos.", "excerpt_keywords": "Keywords: cleanroom, contamination control, ISO standards, air quality testing, HEPA filters"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23622f76-3be0-4fd5-8470-679ecccdd3c0", "node_type": "4", "metadata": {"page_label": "269", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 room particle counts  \n\u2014 room clean-up rates  \n\u2014 microbiological air and surface counts where appropriate  \n\u2014 operation of de-dusting  \n\u2014 warning/alarm systems where applicable.  \n\n8.2.14 The maximum time interval between tests should be defined by the manufacturer. The type of facility under test and the product level of protection should be considered. Table 3 gives various tests that can be carried out. The required tests and intervals between testing should be determined through risk assessment.\n\n### Table 3  \n**Tests to demonstrate compliance**\n\n| Test parameter | Test procedure |\n| - | - |\n| Particle count test (Verification of cleanliness) | Dust particle counts to be carried out and result printouts produced. No. of readings and positions of tests to be in accordance with ISO 14644-1 Annex B5 |\n| Air pressure difference (To verify non cross-contamination) | Log of pressure differential readings to be produced or critical plants should be logged daily, preferably continuously. A 15 Pa pressure differential between different zones is recommended. In accordance with ISO 14644-3 Annex B5 |\n| Airflow volume (To verify air change rates) | Airflow readings for supply air and return air grilles to be measured and air change rates to be calculated. In accordance with ISO 14644-3 Annex B13 |\n| Airflow velocity (To verify unidirectional flow or containment conditions) | Air velocities for containment systems and unidirectional flow protection systems to be measured. In accordance with ISO 14644-3 Annex B4 |\n| Filter leakage tests (To verify filter integrity) | Filter penetration tests to be carried out by a competent person to demonstrate filter media, filter seal and filter frame integrity. Only required on HEPA filters. In accordance with ISO 14644-3 Annex B6 |\n| Containment leakage (To verify absence of cross-contamination) | Demonstrate that contaminant is maintained within a room by means of: \u2022 airflow direction smoke tests \u2022 room air pressures. In accordance with ISO 14644-3 Annex B4 |\n| Recovery (To verify clean-up time) | Test to establish time that a cleanroom takes to recover from a contaminated condition to the specified cleanroom condition. Should not take more than 15 min. In accordance with ISO 14644-3 Annex B13\\* |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0538b53e5c8a2ee960f01efa232929bef5c68d78d7dfea22a5f120beda880ca1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 room particle counts  \n\u2014 room clean-up rates  \n\u2014 microbiological air and surface counts where appropriate  \n\u2014 operation of de-dusting  \n\u2014 warning/alarm systems where applicable.  \n\n8.2.14 The maximum time interval between tests should be defined by the manufacturer. The type of facility under test and the product level of protection should be considered. Table 3 gives various tests that can be carried out. The required tests and intervals between testing should be determined through risk assessment.\n\n### Table 3  \n**Tests to demonstrate compliance**\n\n| Test parameter | Test procedure |\n| - | - |\n| Particle count test (Verification of cleanliness) | Dust particle counts to be carried out and result printouts produced. No. of readings and positions of tests to be in accordance with ISO 14644-1 Annex B5 |\n| Air pressure difference (To verify non cross-contamination) | Log of pressure differential readings to be produced or critical plants should be logged daily, preferably continuously. A 15 Pa pressure differential between different zones is recommended. In accordance with ISO 14644-3 Annex B5 |\n| Airflow volume (To verify air change rates) | Airflow readings for supply air and return air grilles to be measured and air change rates to be calculated. In accordance with ISO 14644-3 Annex B13 |\n| Airflow velocity (To verify unidirectional flow or containment conditions) | Air velocities for containment systems and unidirectional flow protection systems to be measured. In accordance with ISO 14644-3 Annex B4 |\n| Filter leakage tests (To verify filter integrity) | Filter penetration tests to be carried out by a competent person to demonstrate filter media, filter seal and filter frame integrity. Only required on HEPA filters. In accordance with ISO 14644-3 Annex B6 |\n| Containment leakage (To verify absence of cross-contamination) | Demonstrate that contaminant is maintained within a room by means of: \u2022 airflow direction smoke tests \u2022 room air pressures. In accordance with ISO 14644-3 Annex B4 |\n| Recovery (To verify clean-up time) | Test to establish time that a cleanroom takes to recover from a contaminated condition to the specified cleanroom condition. Should not take more than 15 min. In accordance with ISO 14644-3 Annex B13\\* |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2268, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8fd7f768-396a-4481-a9fa-090cc77be9cc": {"__data__": {"id_": "8fd7f768-396a-4481-a9fa-090cc77be9cc", "embedding": null, "metadata": {"page_label": "270", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test parameter | Test procedure |\n| - | - |\n| Airflow visualization (To verify required airflow patterns) | * Tests to demonstrate air flows:\n* from clean to dirty areas\n* do not cause cross-contamination\n* uniformly from unidirectional airflow unitsDemonstrated by actual or video-taped smoke tests. In accordance with ISO 14644-3 Annex B7 |\n\n\n8.2.15 Requalification should also be done when any change, which could affect system performance, takes place.\n\n8.2.16 Clean-up or recovery times normally relate to the time it takes to \u201cclean up\u201d the room from one condition to another, e.g. the relationship between \u201cat-rest\u201d and \u201coperational\u201d conditions in the clean area may be used as the criteria for clean-up tests. Therefore, the clean-up time can be expressed as the time taken to change from an \u201coperational\u201d condition to an \u201cat rest\u201d condition.\n\n8.2.17 If energy-saving procedures such as reducing the airflow during non-production hours are used, precautionary measures should be in place to ensure that the systems are not operated outside the defined relevant environmental conditions.\n\nThese precautionary measures should be based on a risk assessment to ensure that there is no negative impact on the quality of the product.\n\n8.2.18 Documents that should be included in the qualification manuals should include system airflow schematics, room pressure cascade drawings, zone concept drawings, air-handling system allocation drawings, particle count mapping drawings, etc.\n\n# 8.3 Maintenance\n\n8.3.1 There should be a planned preventive maintenance programme, procedures and records for the HVAC system. Records should be kept.\n\n8.3.2 Operating and maintenance (O&M) manuals, schematic drawings, protocols and reports should be maintained as reference documents for any future changes and upgrades to the system. These documents should be kept up to date, containing any system revisions made.\n\n8.3.3 Maintenance personnel should receive appropriate training.\n\n8.3.4 HEPA filters should be changed either by a specialist or a trained person, and then followed by installed filter leakage testing.\n\n8.3.5 Any maintenance activity should be assessed critically to determine any impact on product quality including possible contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de la calificaci\u00f3n y el mantenimiento de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en \u00e1reas limpias. Se enfatiza la necesidad de realizar pruebas de visualizaci\u00f3n del flujo de aire para garantizar que no haya contaminaci\u00f3n cruzada y que el aire fluya de \u00e1reas limpias a sucias. Adem\u00e1s, se discuten los tiempos de limpieza, la importancia de las medidas de precauci\u00f3n durante la reducci\u00f3n del flujo de aire y la necesidad de mantener documentaci\u00f3n adecuada y un programa de mantenimiento preventivo. Tambi\u00e9n se menciona la capacitaci\u00f3n del personal de mantenimiento y la importancia de evaluar el impacto de las actividades de mantenimiento en la calidad del producto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas se deben realizar para verificar los patrones de flujo de aire en \u00e1reas limpias, y qu\u00e9 norma se menciona para estas pruebas?**\n   - Respuesta: Se deben realizar pruebas de visualizaci\u00f3n del flujo de aire, que demuestran que el aire fluye de \u00e1reas limpias a sucias, no causa contaminaci\u00f3n cruzada y es uniforme desde unidades de flujo de aire unidireccional. Estas pruebas deben ser realizadas de acuerdo con la norma ISO 14644-3, Anexo B7.\n\n2. **\u00bfQu\u00e9 documentos son esenciales para incluir en los manuales de calificaci\u00f3n de sistemas HVAC seg\u00fan el contexto?**\n   - Respuesta: Los documentos que deben incluirse en los manuales de calificaci\u00f3n son: esquemas de flujo de aire del sistema, dibujos de cascada de presi\u00f3n de la sala, dibujos del concepto de zonas, dibujos de asignaci\u00f3n del sistema de manejo de aire, y dibujos de mapeo de conteo de part\u00edculas.\n\n3. **\u00bfCu\u00e1les son las consideraciones que deben tenerse en cuenta al realizar actividades de mantenimiento en sistemas HVAC en relaci\u00f3n con la calidad del producto?**\n   - Respuesta: Cualquier actividad de mantenimiento debe ser evaluada cr\u00edticamente para determinar su impacto en la calidad del producto, incluyendo la posibilidad de contaminaci\u00f3n. Adem\u00e1s, se debe asegurar que los filtros HEPA sean cambiados por personal especializado o capacitado, seguido de pruebas de fuga de los filtros instalados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Pruebas de Conformidad:** El documento detalla las pruebas necesarias para asegurar que las instalaciones, como las salas limpias, cumplan con los est\u00e1ndares de calidad del aire y control de contaminaci\u00f3n.\n2. **Intervalos de Prueba:** Se establece que el intervalo m\u00e1ximo entre pruebas debe ser definido por el fabricante, considerando el tipo de instalaci\u00f3n y el nivel de protecci\u00f3n del producto.\n3. **Par\u00e1metros de Prueba:** Se presentan varios par\u00e1metros de prueba en una tabla, incluyendo conteos de part\u00edculas, diferencias de presi\u00f3n de aire, vol\u00famenes y velocidades de flujo de aire, pruebas de integridad de filtros y pruebas de recuperaci\u00f3n.\n4. **Normas ISO:** Las pruebas deben realizarse de acuerdo con las normas ISO pertinentes, como ISO 14644-1 y ISO 14644-3.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite el documento.\n- **ISO 14644-1 y ISO 14644-3:** Normas internacionales que regulan la clasificaci\u00f3n y el control de la contaminaci\u00f3n en salas limpias.\n- **Filtros HEPA:** Filtros de alta eficiencia que requieren pruebas espec\u00edficas de integridad.\n- **Par\u00e1metros de Prueba:**\n  - Conteo de part\u00edculas\n  - Diferencia de presi\u00f3n de aire\n  - Volumen de flujo de aire\n  - Velocidad de flujo de aire\n  - Pruebas de fuga de filtros\n  - Pruebas de contenci\u00f3n\n  - Tiempo de recuperaci\u00f3n\n\n**Recomendaciones Clave:**\n- Mantener una diferencia de presi\u00f3n de 15 Pa entre zonas cr\u00edticas.\n- Realizar pruebas de integridad de filtros HEPA por personal competente.\n- El tiempo de recuperaci\u00f3n de una sala limpia no debe exceder los 15 minutos tras una contaminaci\u00f3n. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes relacionados con el control de la contaminaci\u00f3n en instalaciones cr\u00edticas, as\u00ed como las pruebas necesarias para garantizar su conformidad.", "excerpt_keywords": "Keywords: HVAC, airflow visualization, cleanroom maintenance, HEPA filters, contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0081e52b-fd04-49c6-bc7a-cb0937059387", "node_type": "4", "metadata": {"page_label": "270", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test parameter | Test procedure |\n| - | - |\n| Airflow visualization (To verify required airflow patterns) | * Tests to demonstrate air flows:\n* from clean to dirty areas\n* do not cause cross-contamination\n* uniformly from unidirectional airflow unitsDemonstrated by actual or video-taped smoke tests. In accordance with ISO 14644-3 Annex B7 |\n\n\n8.2.15 Requalification should also be done when any change, which could affect system performance, takes place.\n\n8.2.16 Clean-up or recovery times normally relate to the time it takes to \u201cclean up\u201d the room from one condition to another, e.g. the relationship between \u201cat-rest\u201d and \u201coperational\u201d conditions in the clean area may be used as the criteria for clean-up tests. Therefore, the clean-up time can be expressed as the time taken to change from an \u201coperational\u201d condition to an \u201cat rest\u201d condition.\n\n8.2.17 If energy-saving procedures such as reducing the airflow during non-production hours are used, precautionary measures should be in place to ensure that the systems are not operated outside the defined relevant environmental conditions.\n\nThese precautionary measures should be based on a risk assessment to ensure that there is no negative impact on the quality of the product.\n\n8.2.18 Documents that should be included in the qualification manuals should include system airflow schematics, room pressure cascade drawings, zone concept drawings, air-handling system allocation drawings, particle count mapping drawings, etc.\n\n# 8.3 Maintenance\n\n8.3.1 There should be a planned preventive maintenance programme, procedures and records for the HVAC system. Records should be kept.\n\n8.3.2 Operating and maintenance (O&M) manuals, schematic drawings, protocols and reports should be maintained as reference documents for any future changes and upgrades to the system. These documents should be kept up to date, containing any system revisions made.\n\n8.3.3 Maintenance personnel should receive appropriate training.\n\n8.3.4 HEPA filters should be changed either by a specialist or a trained person, and then followed by installed filter leakage testing.\n\n8.3.5 Any maintenance activity should be assessed critically to determine any impact on product quality including possible contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5d806eabcedd9f97384bd9e9516ab61279b6b1cb8523680b2ea5436d1e961fa8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Test parameter | Test procedure |\n| - | - |\n| Airflow visualization (To verify required airflow patterns) | * Tests to demonstrate air flows:\n* from clean to dirty areas\n* do not cause cross-contamination\n* uniformly from unidirectional airflow unitsDemonstrated by actual or video-taped smoke tests. In accordance with ISO 14644-3 Annex B7 |\n\n\n8.2.15 Requalification should also be done when any change, which could affect system performance, takes place.\n\n8.2.16 Clean-up or recovery times normally relate to the time it takes to \u201cclean up\u201d the room from one condition to another, e.g. the relationship between \u201cat-rest\u201d and \u201coperational\u201d conditions in the clean area may be used as the criteria for clean-up tests. Therefore, the clean-up time can be expressed as the time taken to change from an \u201coperational\u201d condition to an \u201cat rest\u201d condition.\n\n8.2.17 If energy-saving procedures such as reducing the airflow during non-production hours are used, precautionary measures should be in place to ensure that the systems are not operated outside the defined relevant environmental conditions.\n\nThese precautionary measures should be based on a risk assessment to ensure that there is no negative impact on the quality of the product.\n\n8.2.18 Documents that should be included in the qualification manuals should include system airflow schematics, room pressure cascade drawings, zone concept drawings, air-handling system allocation drawings, particle count mapping drawings, etc.\n\n# 8.3 Maintenance\n\n8.3.1 There should be a planned preventive maintenance programme, procedures and records for the HVAC system. Records should be kept.\n\n8.3.2 Operating and maintenance (O&M) manuals, schematic drawings, protocols and reports should be maintained as reference documents for any future changes and upgrades to the system. These documents should be kept up to date, containing any system revisions made.\n\n8.3.3 Maintenance personnel should receive appropriate training.\n\n8.3.4 HEPA filters should be changed either by a specialist or a trained person, and then followed by installed filter leakage testing.\n\n8.3.5 Any maintenance activity should be assessed critically to determine any impact on product quality including possible contamination.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2246, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fe8ee19e-04be-4e37-a6c7-f6f49b741e6b": {"__data__": {"id_": "fe8ee19e-04be-4e37-a6c7-f6f49b741e6b", "embedding": null, "metadata": {"page_label": "271", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.3.6 Maintenance activities should normally be scheduled to take place outside production hours, and any system stoppage should be assessed with a view to the possible need for requalification of an area as a result of an interruption of the service.\n\n## 9. Premises\n\n9.1 As the efficient operation of the air-handling system and cleanliness levels attained are reliant on the correct building layout and building finishes, the following items should be considered:\n\n- adequate airlocks, such as personnel airlocks (PAL) and/or material airlocks (MAL), change rooms and passages should be provided to protect passage between different cleanliness conditions. These should have supply and extract air systems as appropriate;\n- areas such as airlocks, change rooms and passages, should be designed so that the required pressure cascades can be achieved;\n- detailed diagrams depicting pressure cascades, air flow directions and flow routes for personnel and materials should be prepared and maintained;\n- where possible, personnel and materials should not move from a higher cleanliness zone to a lower cleanliness zone and back to a higher cleanliness zone; (if moving from a lower cleanliness zone to a higher cleanliness zone, changing/decontamination procedures should be followed); and\n- the final stage of the changing room should, in the \u201cat rest\u201d state, be the same GMP classification grade as the area into which it leads.\n\n## References\n\n1. Good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908), Annex 4. http://whqlibdoc.who.int/trs/WHO_TRS_908_eng.pdf; *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection.* Geneva, World Health Organization, 2007; and *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials.* Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. *Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 937). http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica, centr\u00e1ndose en la importancia de la planificaci\u00f3n de actividades de mantenimiento y el dise\u00f1o adecuado de las instalaciones. Se enfatiza la necesidad de mantener la limpieza y la presi\u00f3n adecuada en diferentes zonas de producci\u00f3n, as\u00ed como la correcta circulaci\u00f3n de personal y materiales entre \u00e1reas de diferentes niveles de limpieza. Se mencionan procedimientos espec\u00edficos para evitar la contaminaci\u00f3n cruzada y se proporcionan referencias a informes anteriores de la OMS sobre el tema.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de \u00e1reas de cambio y aire en instalaciones farmac\u00e9uticas seg\u00fan el documento?**\n   - Respuesta: El dise\u00f1o debe incluir adecuadas airlocks (tanto para personal como para materiales), asegurar que se logren las cascadas de presi\u00f3n requeridas, y preparar diagramas detallados que muestren las direcciones del flujo de aire y las rutas para el personal y los materiales.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse al mover personal y materiales entre zonas de limpieza diferente?**\n   - Respuesta: Se debe evitar el movimiento de personal y materiales de una zona de limpieza m\u00e1s alta a una m\u00e1s baja y viceversa. Si se debe mover de una zona de limpieza m\u00e1s baja a una m\u00e1s alta, se deben seguir procedimientos de cambio y descontaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 implicaciones tiene una interrupci\u00f3n del servicio en el \u00e1rea de producci\u00f3n seg\u00fan el documento?**\n   - Respuesta: Cualquier interrupci\u00f3n del servicio debe ser evaluada para determinar si es necesaria la revalidaci\u00f3n del \u00e1rea afectada, asegurando que se mantengan los est\u00e1ndares de GMP.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre las buenas pr\u00e1cticas de manufactura en la industria farmac\u00e9utica, destacando la importancia de la planificaci\u00f3n del mantenimiento y el dise\u00f1o de instalaciones para garantizar la limpieza y la calidad del aire. Se enfatiza la necesidad de evitar la contaminaci\u00f3n cruzada y de seguir procedimientos espec\u00edficos al mover personal y materiales entre diferentes zonas de limpieza. Adem\u00e1s, se subraya la importancia de la revalidaci\u00f3n de \u00e1reas tras interrupciones en el servicio.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n de Sistemas HVAC**: Importancia de realizar pruebas de visualizaci\u00f3n del flujo de aire para asegurar que el aire fluya de \u00e1reas limpias a sucias sin causar contaminaci\u00f3n cruzada. Se menciona la norma ISO 14644-3, Anexo B7 como referencia para estas pruebas.\n\n2. **Recalificaci\u00f3n**: Necesidad de realizar recalificaciones cuando ocurren cambios que pueden afectar el rendimiento del sistema.\n\n3. **Tiempos de Limpieza**: Definici\u00f3n de los tiempos de limpieza o recuperaci\u00f3n en funci\u00f3n de la transici\u00f3n entre condiciones \"operativas\" y \"en reposo\" en \u00e1reas limpias.\n\n4. **Medidas de Precauci\u00f3n**: Importancia de implementar medidas de precauci\u00f3n al reducir el flujo de aire durante horas no productivas, basadas en evaluaciones de riesgo para proteger la calidad del producto.\n\n5. **Documentaci\u00f3n**: Necesidad de mantener documentaci\u00f3n adecuada en los manuales de calificaci\u00f3n, incluyendo esquemas de flujo de aire, dibujos de presi\u00f3n, y mapeo de conteo de part\u00edculas.\n\n6. **Mantenimiento Preventivo**: Establecimiento de un programa de mantenimiento preventivo para el sistema HVAC, con registros y manuales de operaci\u00f3n y mantenimiento actualizados.\n\n7. **Capacitaci\u00f3n del Personal**: Importancia de la capacitaci\u00f3n adecuada para el personal de mantenimiento.\n\n8. **Cambio de Filtros HEPA**: Procedimientos para el cambio de filtros HEPA, que deben ser realizados por personal especializado o capacitado, seguido de pruebas de fuga.\n\n9. **Evaluaci\u00f3n de Impacto en la Calidad del Producto**: Evaluaci\u00f3n cr\u00edtica de cualquier actividad de mantenimiento para determinar su impacto en la calidad del producto y la posibilidad de contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **ISO 14644-3**: Norma mencionada para la verificaci\u00f3n de patrones de flujo de aire.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado discutidos en el contexto de \u00e1reas limpias.\n- **Filtros HEPA**: Filtros de alta eficiencia que requieren atenci\u00f3n especial durante el mantenimiento.\n- **Documentaci\u00f3n**: Incluye manuales de operaci\u00f3n, esquemas, y registros de mantenimiento.\n\nEste resumen destaca los aspectos esenciales relacionados con la calificaci\u00f3n y el mantenimiento de sistemas HVAC en \u00e1reas limpias, enfatizando la importancia de las pruebas, la documentaci\u00f3n y la capacitaci\u00f3n del personal para asegurar la calidad del producto.", "excerpt_keywords": "Keywords: GMP, air-handling system, cleanliness zones, maintenance activities, pharmaceutical facilities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92028b1f-4c79-4e65-a705-d7d49f988666", "node_type": "4", "metadata": {"page_label": "271", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.3.6 Maintenance activities should normally be scheduled to take place outside production hours, and any system stoppage should be assessed with a view to the possible need for requalification of an area as a result of an interruption of the service.\n\n## 9. Premises\n\n9.1 As the efficient operation of the air-handling system and cleanliness levels attained are reliant on the correct building layout and building finishes, the following items should be considered:\n\n- adequate airlocks, such as personnel airlocks (PAL) and/or material airlocks (MAL), change rooms and passages should be provided to protect passage between different cleanliness conditions. These should have supply and extract air systems as appropriate;\n- areas such as airlocks, change rooms and passages, should be designed so that the required pressure cascades can be achieved;\n- detailed diagrams depicting pressure cascades, air flow directions and flow routes for personnel and materials should be prepared and maintained;\n- where possible, personnel and materials should not move from a higher cleanliness zone to a lower cleanliness zone and back to a higher cleanliness zone; (if moving from a lower cleanliness zone to a higher cleanliness zone, changing/decontamination procedures should be followed); and\n- the final stage of the changing room should, in the \u201cat rest\u201d state, be the same GMP classification grade as the area into which it leads.\n\n## References\n\n1. Good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908), Annex 4. http://whqlibdoc.who.int/trs/WHO_TRS_908_eng.pdf; *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection.* Geneva, World Health Organization, 2007; and *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials.* Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. *Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 937). http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0fe43858ba5c4a851a269800e47478d0549e484bf1001c9b4e8799e0cd35a703", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "8.3.6 Maintenance activities should normally be scheduled to take place outside production hours, and any system stoppage should be assessed with a view to the possible need for requalification of an area as a result of an interruption of the service.\n\n## 9. Premises\n\n9.1 As the efficient operation of the air-handling system and cleanliness levels attained are reliant on the correct building layout and building finishes, the following items should be considered:\n\n- adequate airlocks, such as personnel airlocks (PAL) and/or material airlocks (MAL), change rooms and passages should be provided to protect passage between different cleanliness conditions. These should have supply and extract air systems as appropriate;\n- areas such as airlocks, change rooms and passages, should be designed so that the required pressure cascades can be achieved;\n- detailed diagrams depicting pressure cascades, air flow directions and flow routes for personnel and materials should be prepared and maintained;\n- where possible, personnel and materials should not move from a higher cleanliness zone to a lower cleanliness zone and back to a higher cleanliness zone; (if moving from a lower cleanliness zone to a higher cleanliness zone, changing/decontamination procedures should be followed); and\n- the final stage of the changing room should, in the \u201cat rest\u201d state, be the same GMP classification grade as the area into which it leads.\n\n## References\n\n1. Good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908), Annex 4. http://whqlibdoc.who.int/trs/WHO_TRS_908_eng.pdf; *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection.* Geneva, World Health Organization, 2007; and *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials.* Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. *Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 937). http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2336, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ae20f725-7154-4e5a-9603-0e539c19534e": {"__data__": {"id_": "ae20f725-7154-4e5a-9603-0e539c19534e", "embedding": null, "metadata": {"page_label": "272", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Further reading\n\n**Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1.** Geneva, World Health Organization, 1997.\n\n**Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, Second updated edition.** Good manufacturing practices and inspection. Geneva, World Health Organization, 2007. http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html; and Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\nWorld Health Organization. Supplements and updates available at: www.who.int/medicines.\n\n**ASHRAE handbook 1999. HVAC Applications, SI edition.** Atlanta, GA, ASHRAE, 2007. http://www.ashrae.org/technology/page/548.\n\n**ASHRAE handbook 2000. HVAC Systems and Equipment.** Atlanta, GA, ASHRAE, 2008. http://www.ashrae.org/technology/page/548.\n\nDaly BB. **Woods practical guide to fan engineering.** Colchester, Woods of Colchester Ltd. Third impression, June 1985. Cambridge, Cambridge University Press. www.flaktwoods.com.\n\nEuropean Commission. **The rules governing medicinal products in the European Community, Volume IV. Good manufacturing practice for medicinal products.** European Commission, Brussels, 2005. http://www.cen.eu/cenorm/sectors/sectors/healthcare/index.asp.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms,** Second Edition / November 2009, International Society for Pharmaceutical Engineering. http://www.ispe.org/.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides for new and renovated facilities, Volume 5. Commissioning and qualification,** 1st ed. Tampa, Fl, International Society for Pharmaceutical Engineering, 2001. http://www.ispe.org/.\n\n**International Cleanroom Standards, ISO 14644.** Geneva, International Organization for Standardization. http://www.iso.org/iso/standards_development.htm.\n\nLuwa. **Introduction to high efficiency filtration.** Bulletin 50.10.10, Sheet 020. Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme. **Guide to Good Manufacturing Practice for Medicinal Products.** PH 1/97 (Rev. 3), 15 January 2002.\n\nPIC/s GMP Guide (PE 009) http://www.picscheme.org/publication.php?id=4\n\nICH Q9: **\u201cQuality Risk Management\u201d**, November 2005 http://www.ich.org.\n\nWorld Health Organization. Draft working document QAS/10.376: **\u201cGuidelines on quality risk management\u201d**, 2010 (in preparation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de recursos y gu\u00edas sobre la garant\u00eda de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se mencionan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) y otras organizaciones relevantes, como la ASHRAE y la Comisi\u00f3n Europea, que abordan buenas pr\u00e1cticas de fabricaci\u00f3n, gesti\u00f3n de riesgos de calidad y est\u00e1ndares de limpieza en entornos de producci\u00f3n farmac\u00e9utica. Tambi\u00e9n se incluyen enlaces a documentos y gu\u00edas que pueden ser \u00fatiles para profesionales en el campo de la ingenier\u00eda farmac\u00e9utica y la calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las dos ediciones de la \"Quality Assurance of Pharmaceuticals\" publicadas por la OMS y en qu\u00e9 a\u00f1os fueron publicadas?**\n   - Respuesta: La primera edici\u00f3n fue publicada en 1997 y la segunda edici\u00f3n, actualizada, fue publicada en 2007.\n\n2. **\u00bfQu\u00e9 gu\u00eda de la ISPE se menciona en el contexto y cu\u00e1l es su enfoque principal?**\n   - Respuesta: Se menciona la \"ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms\", que se centra en las formas de dosificaci\u00f3n s\u00f3lida oral.\n\n3. **\u00bfQu\u00e9 documento de la OMS est\u00e1 en preparaci\u00f3n y qu\u00e9 tema aborda?**\n   - Respuesta: El documento en preparaci\u00f3n es el \"Draft working document QAS/10.376: Guidelines on quality risk management\", que aborda la gesti\u00f3n de riesgos de calidad.", "prev_section_summary": "### Temas Clave\n\n1. **Mantenimiento de Instalaciones**: Las actividades de mantenimiento deben programarse fuera del horario de producci\u00f3n y cualquier interrupci\u00f3n del servicio debe evaluarse para determinar si es necesaria la revalidaci\u00f3n del \u00e1rea afectada.\n\n2. **Dise\u00f1o de Instalaciones**: La eficiencia del sistema de manejo de aire y los niveles de limpieza dependen del dise\u00f1o adecuado de las instalaciones. Se deben considerar elementos como:\n   - Airlocks adecuados (para personal y materiales).\n   - Dise\u00f1o de \u00e1reas para lograr cascadas de presi\u00f3n requeridas.\n   - Diagramas detallados que muestren las direcciones del flujo de aire y las rutas para el personal y materiales.\n\n3. **Movimientos entre Zonas de Limpieza**: Se deben seguir procedimientos espec\u00edficos al mover personal y materiales entre zonas de diferentes niveles de limpieza, evitando movimientos de zonas m\u00e1s limpias a menos limpias sin las debidas precauciones.\n\n4. **Clasificaci\u00f3n de \u00c1reas**: La \u00faltima etapa del vestuario debe tener la misma clasificaci\u00f3n de Buenas Pr\u00e1cticas de Manufactura (GMP) que el \u00e1rea a la que conduce.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre buenas pr\u00e1cticas de manufactura.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que asegura la calidad y limpieza en la producci\u00f3n farmac\u00e9utica.\n- **Airlocks**: Sistemas de entrada/salida que protegen la integridad de las zonas de limpieza.\n- **Cascadas de presi\u00f3n**: Diferencias de presi\u00f3n necesarias para mantener la limpieza en diferentes \u00e1reas.\n- **Zonas de limpieza**: Clasificaciones que determinan el nivel de limpieza requerido en diferentes \u00e1reas de producci\u00f3n.\n\nEste resumen destaca la importancia del mantenimiento, el dise\u00f1o adecuado de las instalaciones y los procedimientos para evitar la contaminaci\u00f3n cruzada en la industria farmac\u00e9utica, seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: quality assurance, pharmaceuticals, good manufacturing practices, risk management, cleanroom standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "66c9f6dc-5f35-4beb-81c5-617a16d8b683", "node_type": "4", "metadata": {"page_label": "272", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Further reading\n\n**Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1.** Geneva, World Health Organization, 1997.\n\n**Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, Second updated edition.** Good manufacturing practices and inspection. Geneva, World Health Organization, 2007. http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html; and Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\nWorld Health Organization. Supplements and updates available at: www.who.int/medicines.\n\n**ASHRAE handbook 1999. HVAC Applications, SI edition.** Atlanta, GA, ASHRAE, 2007. http://www.ashrae.org/technology/page/548.\n\n**ASHRAE handbook 2000. HVAC Systems and Equipment.** Atlanta, GA, ASHRAE, 2008. http://www.ashrae.org/technology/page/548.\n\nDaly BB. **Woods practical guide to fan engineering.** Colchester, Woods of Colchester Ltd. Third impression, June 1985. Cambridge, Cambridge University Press. www.flaktwoods.com.\n\nEuropean Commission. **The rules governing medicinal products in the European Community, Volume IV. Good manufacturing practice for medicinal products.** European Commission, Brussels, 2005. http://www.cen.eu/cenorm/sectors/sectors/healthcare/index.asp.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms,** Second Edition / November 2009, International Society for Pharmaceutical Engineering. http://www.ispe.org/.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides for new and renovated facilities, Volume 5. Commissioning and qualification,** 1st ed. Tampa, Fl, International Society for Pharmaceutical Engineering, 2001. http://www.ispe.org/.\n\n**International Cleanroom Standards, ISO 14644.** Geneva, International Organization for Standardization. http://www.iso.org/iso/standards_development.htm.\n\nLuwa. **Introduction to high efficiency filtration.** Bulletin 50.10.10, Sheet 020. Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme. **Guide to Good Manufacturing Practice for Medicinal Products.** PH 1/97 (Rev. 3), 15 January 2002.\n\nPIC/s GMP Guide (PE 009) http://www.picscheme.org/publication.php?id=4\n\nICH Q9: **\u201cQuality Risk Management\u201d**, November 2005 http://www.ich.org.\n\nWorld Health Organization. Draft working document QAS/10.376: **\u201cGuidelines on quality risk management\u201d**, 2010 (in preparation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bc3d8af41993ebae7171044e3c10a9a8c9442c59a419e61fc831c1b650f434b2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Further reading\n\n**Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1.** Geneva, World Health Organization, 1997.\n\n**Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, Second updated edition.** Good manufacturing practices and inspection. Geneva, World Health Organization, 2007. http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html; and Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\nWorld Health Organization. Supplements and updates available at: www.who.int/medicines.\n\n**ASHRAE handbook 1999. HVAC Applications, SI edition.** Atlanta, GA, ASHRAE, 2007. http://www.ashrae.org/technology/page/548.\n\n**ASHRAE handbook 2000. HVAC Systems and Equipment.** Atlanta, GA, ASHRAE, 2008. http://www.ashrae.org/technology/page/548.\n\nDaly BB. **Woods practical guide to fan engineering.** Colchester, Woods of Colchester Ltd. Third impression, June 1985. Cambridge, Cambridge University Press. www.flaktwoods.com.\n\nEuropean Commission. **The rules governing medicinal products in the European Community, Volume IV. Good manufacturing practice for medicinal products.** European Commission, Brussels, 2005. http://www.cen.eu/cenorm/sectors/sectors/healthcare/index.asp.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms,** Second Edition / November 2009, International Society for Pharmaceutical Engineering. http://www.ispe.org/.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides for new and renovated facilities, Volume 5. Commissioning and qualification,** 1st ed. Tampa, Fl, International Society for Pharmaceutical Engineering, 2001. http://www.ispe.org/.\n\n**International Cleanroom Standards, ISO 14644.** Geneva, International Organization for Standardization. http://www.iso.org/iso/standards_development.htm.\n\nLuwa. **Introduction to high efficiency filtration.** Bulletin 50.10.10, Sheet 020. Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme. **Guide to Good Manufacturing Practice for Medicinal Products.** PH 1/97 (Rev. 3), 15 January 2002.\n\nPIC/s GMP Guide (PE 009) http://www.picscheme.org/publication.php?id=4\n\nICH Q9: **\u201cQuality Risk Management\u201d**, November 2005 http://www.ich.org.\n\nWorld Health Organization. Draft working document QAS/10.376: **\u201cGuidelines on quality risk management\u201d**, 2010 (in preparation).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2523, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ada3baa9-2052-413b-8ca1-88a636fe891d": {"__data__": {"id_": "ada3baa9-2052-413b-8ca1-88a636fe891d", "embedding": null, "metadata": {"page_label": "273", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nFollowing implementation of these WHO good manufacturing practices (GMP) guidelines (1) within the context of the WHO Prequalification of Medicines Programme, clarifying, editorial modifications have been proposed. These changes were adopted for maintenance purposes. In order to ease reading the full guideline has been reproduced again as an Annex to the current report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\n### WHO good manufacturing practices for sterile pharmaceutical products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un anexo del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 961) que presenta las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles. Se menciona que se han realizado modificaciones editoriales para facilitar la lectura y que estas pautas son parte del Programa de Precalificaci\u00f3n de Medicamentos de la OMS. El anexo incluye secciones sobre consideraciones generales, control de calidad, sanidad, fabricaci\u00f3n de preparaciones est\u00e9riles, m\u00e9todos de esterilizaci\u00f3n, tecnolog\u00eda de aislamiento, y otros aspectos relevantes para la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las secciones espec\u00edficas que abordan los m\u00e9todos de esterilizaci\u00f3n en las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles seg\u00fan la OMS?**\n   - Esta pregunta busca detalles sobre los m\u00e9todos de esterilizaci\u00f3n mencionados en el documento, que son cruciales para la producci\u00f3n segura de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 cambios editoriales se han propuesto en las directrices de buenas pr\u00e1cticas de fabricaci\u00f3n y cu\u00e1l es su prop\u00f3sito?**\n   - Esta pregunta se centra en entender las modificaciones realizadas y su objetivo de facilitar la comprensi\u00f3n de las directrices.\n\n3. **\u00bfQu\u00e9 tecnolog\u00edas se mencionan en el documento para el procesamiento as\u00e9ptico y c\u00f3mo se diferencian entre s\u00ed?**\n   - Esta pregunta busca informaci\u00f3n sobre las tecnolog\u00edas espec\u00edficas, como la tecnolog\u00eda de aislamiento y la tecnolog\u00eda de blow/fill/seal, y sus diferencias en el contexto de la fabricaci\u00f3n est\u00e9ril.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nLa secci\u00f3n \"Further reading\" del documento \"WHO - Technical Report Series 961\" proporciona una lista de recursos y gu\u00edas relevantes sobre la garant\u00eda de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Garant\u00eda de Calidad**: Se destacan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) que abordan la calidad y las buenas pr\u00e1cticas en la producci\u00f3n farmac\u00e9utica.\n   - **Publicaciones de la OMS**:\n     - \"Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1\" (1997).\n     - \"Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2\" (2007).\n     - \"Guidelines on quality risk management\" (en preparaci\u00f3n, 2010).\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se mencionan gu\u00edas sobre BPF, incluyendo la publicaci\u00f3n de la Comisi\u00f3n Europea sobre productos medicinales.\n\n3. **Normas y Est\u00e1ndares**: Se hace referencia a est\u00e1ndares internacionales, como ISO 14644 para salas limpias y gu\u00edas de la ISPE sobre ingenier\u00eda farmac\u00e9utica.\n\n4. **Filtraci\u00f3n y Ventilaci\u00f3n**: Se incluye un recurso sobre filtraci\u00f3n de alta eficiencia y gu\u00edas de ingenier\u00eda de ventilaci\u00f3n de ASHRAE.\n\n5. **Gesti\u00f3n de Riesgos**: Se menciona el documento ICH Q9 sobre gesti\u00f3n de riesgos de calidad.\n\n### Entidades mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publicaciones sobre garant\u00eda de calidad y buenas pr\u00e1cticas.\n- **ASHRAE**: Gu\u00edas sobre aplicaciones y sistemas HVAC.\n- **Comisi\u00f3n Europea**: Normativas sobre productos medicinales.\n- **International Society for Pharmaceutical Engineering (ISPE)**: Gu\u00edas sobre ingenier\u00eda farmac\u00e9utica.\n- **International Organization for Standardization (ISO)**: Est\u00e1ndares internacionales.\n- **Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme**: Gu\u00edas sobre buenas pr\u00e1cticas de fabricaci\u00f3n.\n\nEste resumen destaca la importancia de la calidad y las buenas pr\u00e1cticas en la industria farmac\u00e9utica, as\u00ed como los recursos disponibles para profesionales en el campo.", "excerpt_keywords": "Keywords: WHO, good manufacturing practices, sterile pharmaceutical products, sterilization, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7bc36d2a-ab8c-4d8b-99d1-a4d32daef57c", "node_type": "4", "metadata": {"page_label": "273", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nFollowing implementation of these WHO good manufacturing practices (GMP) guidelines (1) within the context of the WHO Prequalification of Medicines Programme, clarifying, editorial modifications have been proposed. These changes were adopted for maintenance purposes. In order to ease reading the full guideline has been reproduced again as an Annex to the current report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\n### WHO good manufacturing practices for sterile pharmaceutical products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "65c594ddff8eb08710fe18b82e622cf70909ed0a419191cc82a9409e50ce4ec2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 6\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nFollowing implementation of these WHO good manufacturing practices (GMP) guidelines (1) within the context of the WHO Prequalification of Medicines Programme, clarifying, editorial modifications have been proposed. These changes were adopted for maintenance purposes. In order to ease reading the full guideline has been reproduced again as an Annex to the current report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\n### WHO good manufacturing practices for sterile pharmaceutical products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences\n\nFurther reading", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 978, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e2acf45d-b1a6-4000-bc5e-6b7104991009": {"__data__": {"id_": "e2acf45d-b1a6-4000-bc5e-6b7104991009", "embedding": null, "metadata": {"page_label": "274", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\n1.3 Manufacturing operations are divided here into two categories:\n\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Producci\u00f3n de Preparaciones Est\u00e9riles**: La producci\u00f3n de productos est\u00e9riles debe realizarse en \u00e1reas limpias que cumplan con est\u00e1ndares de limpieza espec\u00edficos y que est\u00e9n equipadas con sistemas de filtraci\u00f3n de aire. Las operaciones de preparaci\u00f3n de componentes, productos, llenado y esterilizaci\u00f3n deben realizarse en \u00e1reas separadas, clasificadas en cuatro grados.\n\n2. **Control de Calidad**: El control de la esterilidad de los productos terminados se basa en una serie de medidas, siendo la prueba de esterilidad la \u00faltima. Esta prueba debe ser validada y los muestreos deben ser representativos del lote, prestando especial atenci\u00f3n a las partes m\u00e1s susceptibles a la contaminaci\u00f3n. La validaci\u00f3n del ciclo de esterilizaci\u00f3n y los registros de procesamiento son esenciales para asegurar la esterilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios para clasificar las \u00e1reas dentro de la producci\u00f3n de preparaciones est\u00e9riles?**\n   - Este contexto menciona que las \u00e1reas se clasifican en cuatro grados, pero no detalla los criterios espec\u00edficos para cada grado.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para validar la prueba de esterilidad en productos que han sido procesados asepticamente?**\n   - Aunque se menciona que la prueba de esterilidad debe ser validada, no se especifican los pasos o m\u00e9todos exactos que deben seguirse para la validaci\u00f3n en el caso de productos procesados asepticamente.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al tomar muestras para la prueba de esterilidad de productos que han sido llenados asepticamente?**\n   - El contexto proporciona ejemplos de c\u00f3mo tomar muestras, pero no detalla las consideraciones adicionales que podr\u00edan influir en la selecci\u00f3n de muestras para asegurar la representatividad y minimizar el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Tema Principal:** Buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles.\n\n**Contexto:**\n- El documento es un anexo del Informe T\u00e9cnico de la OMS que presenta directrices sobre GMP en el contexto del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n- Se han realizado modificaciones editoriales para facilitar la lectura y comprensi\u00f3n de las directrices.\n\n**Secciones Clave:**\n1. **Consideraciones Generales**\n2. **Control de Calidad**\n3. **Sanidad**\n4. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**\n5. **Esterilizaci\u00f3n**\n6. **Esterilizaci\u00f3n Terminal**\n7. **Procesamiento Aseptic y Esterilizaci\u00f3n por Filtraci\u00f3n**\n8. **Tecnolog\u00eda de Aislamiento**\n9. **Tecnolog\u00eda de Blow/Fill/Seal**\n10. **Personal**\n11. **Instalaciones**\n12. **Equipos**\n13. **Finalizaci\u00f3n de Productos Est\u00e9riles**\n\n**Referencias y Lecturas Adicionales:** Se menciona que hay referencias y lecturas adicionales disponibles, aunque no se detallan en el extracto.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Autoridad que establece las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Fabricaci\u00f3n):** Conjunto de directrices para asegurar la calidad y seguridad en la producci\u00f3n de productos farmac\u00e9uticos.\n- **Programa de Precalificaci\u00f3n de Medicamentos:** Iniciativa de la OMS para evaluar la calidad de los medicamentos.\n\nEste resumen destaca los aspectos fundamentales del documento, incluyendo su prop\u00f3sito, estructura y las secciones que abordan temas cr\u00edticos para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, quality control, sterility testing, aseptic processing, manufacturing standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5e431ff8-1ca7-4e34-8aff-e1a70d84643c", "node_type": "4", "metadata": {"page_label": "274", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\n1.3 Manufacturing operations are divided here into two categories:\n\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a2c3de2f07a0634f33eb28bf881b69b900270edef9c8c5e0bcefd84ae53f46f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\n1.3 Manufacturing operations are divided here into two categories:\n\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2416, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7fde23c2-5965-4646-a4dd-be0439b874ef": {"__data__": {"id_": "7fde23c2-5965-4646-a4dd-be0439b874ef", "embedding": null, "metadata": {"page_label": "275", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4\n\nFor injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins, using an established pharmacopoeial method that has been validated for each type of product. For large-volume infusion solutions, such monitoring of water or intermediates should always be done, in addition to any tests required by an approved monograph for the finished product. When a sample fails a test, the cause of the failure should be investigated and necessary action should be taken. Alternative methods to those in the pharmacopoeias may be used if they are validated, justified and authorized.\n\n2.5 The use of rapid microbiological methods to replace the traditional microbiological methods, and to obtain earlier results on the microbiological quality of, for example, water, the environment or bioburden, could be considered if appropriately validated and if a comparative assessment of the proposed rapid method is performed against the pharmacopoeial method.\n\n# 3. Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in Grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# 4. Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS aborda las directrices para la fabricaci\u00f3n de productos inyectables y la importancia de la calidad microbiol\u00f3gica y la sanitizaci\u00f3n en \u00e1reas limpias. Se enfatiza la necesidad de monitorear el agua para inyecci\u00f3n y los productos intermedios y terminados para endotoxinas, as\u00ed como la implementaci\u00f3n de m\u00e9todos microbiol\u00f3gicos r\u00e1pidos, siempre que est\u00e9n validados. Adem\u00e1s, se discuten las pr\u00e1cticas de limpieza y desinfecci\u00f3n, incluyendo el uso de m\u00faltiples desinfectantes, la validaci\u00f3n de interacciones entre productos de limpieza y la necesidad de un programa de desinfecci\u00f3n que incluya agentes esporicidas. Finalmente, se menciona la clasificaci\u00f3n de \u00e1reas limpias seg\u00fan las caracter\u00edsticas ambientales requeridas para la fabricaci\u00f3n de productos est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si una muestra de agua para inyecci\u00f3n falla en la prueba de endotoxinas?**\n   - La causa de la falla debe ser investigada y se deben tomar las acciones necesarias para corregir el problema.\n\n2. **\u00bfPor qu\u00e9 es importante utilizar m\u00e1s de un tipo de desinfectante en las \u00e1reas limpias?**\n   - Es importante porque diferentes desinfectantes pueden ser efectivos contra diferentes tipos de microorganismos, y el uso de m\u00faltiples desinfectantes ayuda a asegurar una limpieza m\u00e1s completa y efectiva.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al utilizar m\u00e9todos microbiol\u00f3gicos r\u00e1pidos en lugar de m\u00e9todos tradicionales?**\n   - Los m\u00e9todos microbiol\u00f3gicos r\u00e1pidos deben ser apropiadamente validados y se debe realizar una evaluaci\u00f3n comparativa con el m\u00e9todo farmacopoeial para asegurar su eficacia y confiabilidad en la obtenci\u00f3n de resultados microbiol\u00f3gicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Producci\u00f3n de Preparaciones Est\u00e9riles\n- **\u00c1reas Limpias**: La producci\u00f3n debe realizarse en \u00e1reas limpias con acceso a trav\u00e9s de airlocks. Estas \u00e1reas deben mantener un est\u00e1ndar de limpieza y contar con sistemas de filtraci\u00f3n de aire.\n- **Clasificaci\u00f3n de \u00c1reas**: Las operaciones de preparaci\u00f3n de componentes, productos, llenado y esterilizaci\u00f3n se realizan en \u00e1reas separadas, clasificadas en cuatro grados.\n- **Categor\u00edas de Operaciones**: Se dividen en dos tipos: \n  - Productos que son esterilizados terminalmente.\n  - Productos procesados asepticamente en alguna o todas las etapas.\n\n#### 2. Control de Calidad\n- **Prueba de Esterilidad**: Considerada como la \u00faltima medida de control para asegurar la esterilidad. Debe ser validada para los productos espec\u00edficos.\n- **Muestreo para Pruebas de Esterilidad**: Las muestras deben ser representativas del lote, incluyendo partes con mayor riesgo de contaminaci\u00f3n. Ejemplos incluyen:\n  - Para productos llenados asepticamente: muestras de contenedores al inicio y al final del lote, y despu\u00e9s de interrupciones significativas.\n  - Para productos esterilizados por calor: considerar muestras de la parte m\u00e1s fr\u00eda del lote.\n- **Validaci\u00f3n del Ciclo de Esterilizaci\u00f3n**: Es esencial para productos esterilizados terminalmente, y se utilizan simulaciones de medios para productos procesados asepticamente. \n- **Registros de Procesamiento**: Deben ser revisados junto con los resultados de las pruebas de esterilidad. Se deben seguir m\u00e9todos farmacopoeiales para la validaci\u00f3n y ejecuci\u00f3n de la prueba de esterilidad.\n\n### Entidades Clave\n- **\u00c1reas Limpias**: Espacios controlados para la producci\u00f3n est\u00e9ril.\n- **Airlocks**: Sistemas de entrada para mantener la limpieza.\n- **Grados de Clasificaci\u00f3n**: Cuatro niveles de \u00e1reas limpias.\n- **Prueba de Esterilidad**: M\u00e9todo para asegurar la ausencia de microorganismos en productos terminados.\n- **Muestreo**: Proceso de recolecci\u00f3n de muestras representativas para pruebas.\n- **Validaci\u00f3n**: Proceso de asegurar que los m\u00e9todos y ciclos de esterilizaci\u00f3n son efectivos. \n\nEste resumen destaca los aspectos fundamentales de la producci\u00f3n de preparaciones est\u00e9riles y el control de calidad, as\u00ed como las entidades relevantes en el contexto de la normativa de la OMS.", "excerpt_keywords": "Keywords: injectable products, endotoxins, sanitation, microbiological methods, sterile preparations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "48b051a2-6413-46c9-a232-bd916188f036", "node_type": "4", "metadata": {"page_label": "275", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4\n\nFor injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins, using an established pharmacopoeial method that has been validated for each type of product. For large-volume infusion solutions, such monitoring of water or intermediates should always be done, in addition to any tests required by an approved monograph for the finished product. When a sample fails a test, the cause of the failure should be investigated and necessary action should be taken. Alternative methods to those in the pharmacopoeias may be used if they are validated, justified and authorized.\n\n2.5 The use of rapid microbiological methods to replace the traditional microbiological methods, and to obtain earlier results on the microbiological quality of, for example, water, the environment or bioburden, could be considered if appropriately validated and if a comparative assessment of the proposed rapid method is performed against the pharmacopoeial method.\n\n# 3. Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in Grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# 4. Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dfe8f597c8dd59feb8c36fd77718f7639b9ff1f625ee09d1b83a2071844b8a6b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.4\n\nFor injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins, using an established pharmacopoeial method that has been validated for each type of product. For large-volume infusion solutions, such monitoring of water or intermediates should always be done, in addition to any tests required by an approved monograph for the finished product. When a sample fails a test, the cause of the failure should be investigated and necessary action should be taken. Alternative methods to those in the pharmacopoeias may be used if they are validated, justified and authorized.\n\n2.5 The use of rapid microbiological methods to replace the traditional microbiological methods, and to obtain earlier results on the microbiological quality of, for example, water, the environment or bioburden, could be considered if appropriately validated and if a comparative assessment of the proposed rapid method is performed against the pharmacopoeial method.\n\n# 3. Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in Grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# 4. Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2503, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ff43af36-43ed-4497-85b2-c0c5bcba89c3": {"__data__": {"id_": "ff43af36-43ed-4497-85b2-c0c5bcba89c3", "embedding": null, "metadata": {"page_label": "276", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.\n\n4.2 Detailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n4.3 For the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests.\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the Grade A zone.\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n4.4 In order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n4.5 High-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (3) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la limpieza en \u00e1reas operativas para minimizar la contaminaci\u00f3n microbiol\u00f3gica y de part\u00edculas en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se definen cuatro grados de \u00e1reas limpias (A, B, C y D) seg\u00fan el riesgo de contaminaci\u00f3n, y se establecen directrices sobre el flujo de aire, la velocidad del aire, y la frecuencia de pruebas de fugas en filtros HEPA. Se enfatiza la importancia de mantener condiciones controladas para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que debe cumplir un sistema de flujo de aire unidireccional para ser considerado adecuado en un \u00e1rea de grado A?**\n   - Respuesta: Un sistema de flujo de aire unidireccional debe proporcionar una velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s a una posici\u00f3n de prueba definida de 15\u201330 cm por debajo del filtro terminal o sistema distribuidor de aire. La velocidad en el nivel de trabajo no debe ser inferior a 0.36 m/s, y se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para demostrar su uniformidad y efectividad.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar para determinar el n\u00famero de cambios de aire necesarios en \u00e1reas de grado B, C y D?**\n   - Respuesta: El n\u00famero de cambios de aire debe ser apropiado para el tama\u00f1o de la habitaci\u00f3n, as\u00ed como para el equipo y el personal presentes en ella. Esto asegura que se mantengan las condiciones de limpieza necesarias para la fabricaci\u00f3n de productos est\u00e9riles.\n\n3. **\u00bfCon qu\u00e9 frecuencia se deben realizar las pruebas de fugas en los filtros HEPA y cu\u00e1l es el objetivo de estas pruebas?**\n   - Respuesta: Las pruebas de fugas en los filtros HEPA deben realizarse cada 6 meses, pero no deben exceder los 12 meses. El objetivo de estas pruebas es asegurar que el medio del filtro, el marco del filtro y el sello del filtro est\u00e9n libres de fugas, lo que es crucial para mantener la eficacia del sistema de filtraci\u00f3n y la calidad del aire en las \u00e1reas limpias.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo de Endotoxinas**: Es esencial monitorear el agua para inyecci\u00f3n y los productos intermedios y terminados para endotoxinas, utilizando m\u00e9todos farmacopoeiales validados. En caso de que una muestra falle, se debe investigar la causa y tomar las acciones necesarias.\n\n2. **M\u00e9todos Microbiol\u00f3gicos R\u00e1pidos**: Se considera el uso de m\u00e9todos microbiol\u00f3gicos r\u00e1pidos como alternativa a los m\u00e9todos tradicionales, siempre que est\u00e9n validados y se realice una evaluaci\u00f3n comparativa con los m\u00e9todos farmacopoeiales.\n\n3. **Sanitizaci\u00f3n de \u00c1reas Limpias**: La limpieza y desinfecci\u00f3n de \u00e1reas limpias es crucial. Se deben seguir programas de limpieza aprobados, utilizar m\u00faltiples tipos de desinfectantes y validar las interacciones entre productos de limpieza.\n\n4. **Contaminaci\u00f3n Microbiana de Desinfectantes**: Los desinfectantes y detergentes deben ser monitoreados para detectar contaminaci\u00f3n microbiana y deben ser est\u00e9riles antes de su uso en \u00e1reas de Grado A y B.\n\n5. **Agentes Esporicidas**: Un programa de desinfecci\u00f3n debe incluir agentes esporicidas, ya que muchos desinfectantes comunes son ineficaces contra esporas.\n\n6. **Fumigaci\u00f3n**: La fumigaci\u00f3n puede ser \u00fatil para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso.\n\n7. **Clasificaci\u00f3n de \u00c1reas Limpias**: Las \u00e1reas limpias para la fabricaci\u00f3n de productos est\u00e9riles se clasifican seg\u00fan las caracter\u00edsticas ambientales requeridas para cada operaci\u00f3n de fabricaci\u00f3n.\n\n### Entidades\n\n- **Productos Inyectables**: Incluyen agua para inyecci\u00f3n, productos intermedios y productos terminados.\n- **M\u00e9todos Microbiol\u00f3gicos**: M\u00e9todos tradicionales y r\u00e1pidos para evaluar la calidad microbiol\u00f3gica.\n- **Desinfectantes y Detergentes**: Productos utilizados para la limpieza y desinfecci\u00f3n de \u00e1reas limpias.\n- **Agentes Esporicidas**: Tipo espec\u00edfico de desinfectante efectivo contra esporas.\n- **\u00c1reas Limpias**: Espacios clasificados seg\u00fan su nivel de limpieza y requisitos ambientales para la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: cleanliness, sterile pharmaceutical, unidirectional airflow, HEPA filters, contamination control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d0d0a6f-50b6-4c62-83f6-434fff41b09d", "node_type": "4", "metadata": {"page_label": "276", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.\n\n4.2 Detailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n4.3 For the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests.\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the Grade A zone.\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n4.4 In order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n4.5 High-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (3) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9db1783ea0554749370ae3a64bf7088267b88736a14214ff91b1b3d9dcfa1e5a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.\n\n4.2 Detailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n4.3 For the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests.\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the Grade A zone.\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n4.4 In order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n4.5 High-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (3) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (4).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2677, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ee393476-b032-4a7f-b1b4-3e028c246730": {"__data__": {"id_": "ee393476-b032-4a7f-b1b4-3e028c246730", "embedding": null, "metadata": {"page_label": "277", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean room and clean-air device classification\n\n4.6 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2\u20133, 5\u20137).\n\n4.6.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1: Maximum permitted airborne particle concentration**\n\n| Grade\\<br/>0.5 \u00b5m | At rest\\<br/>5.0 \u00b5m | At rest\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0 \u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes in Grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for Grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For Grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For Grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For Grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades (Grade C in operation and Grade D at rest) the sample volume per location should be at least 2 litres and the sample time per location should be not less than 1 minute.\n\n4.6.3 Portable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u00b5m. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n4.6.4 \u201cIn operation\u201d classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento se centra en la clasificaci\u00f3n de salas limpias y dispositivos de aire limpio seg\u00fan la norma ISO 14644. Se detalla la diferencia entre la clasificaci\u00f3n y el monitoreo ambiental operativo, y se proporciona una tabla con las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D). Adem\u00e1s, se especifican los requisitos de muestreo y las condiciones para la clasificaci\u00f3n \"en reposo\" y \"en operaci\u00f3n\".\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para el grado A en estado \"en operaci\u00f3n\" y \"en reposo\"?**\n   - Respuesta: Para el grado A, la concentraci\u00f3n m\u00e1xima permitida es de 3,520 part\u00edculas de 0.5 \u00b5m y 20 part\u00edculas de 5.0 \u00b5m \"en reposo\", y se mantiene la misma concentraci\u00f3n de 3,520 part\u00edculas de 0.5 \u00b5m y 20 part\u00edculas de 5.0 \u00b5m \"en operaci\u00f3n\".\n\n2. **\u00bfQu\u00e9 volumen m\u00ednimo de muestra se debe tomar en las zonas de grado A para la clasificaci\u00f3n y cu\u00e1l es la clasificaci\u00f3n de part\u00edculas en el aire correspondiente?**\n   - Respuesta: En las zonas de grado A, se debe tomar un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra, y la clasificaci\u00f3n de part\u00edculas en el aire es ISO 4.8, dictada por el l\u00edmite para part\u00edculas \u2265 5.0 \u00b5m.\n\n3. **\u00bfQu\u00e9 tipo de equipos se recomienda utilizar para la clasificaci\u00f3n de salas limpias y por qu\u00e9?**\n   - Respuesta: Se recomienda utilizar contadores de part\u00edculas port\u00e1tiles con una longitud corta de tuber\u00eda de muestreo para evitar la p\u00e9rdida de part\u00edculas \u2265 5.0 \u00b5m, y se deben usar cabezales de muestreo isocin\u00e9tico en sistemas de flujo de aire unidireccional.", "prev_section_summary": "### Temas Clave\n\n1. **Limpieza en \u00c1reas Operativas**: Se enfatiza la importancia de mantener la limpieza para minimizar la contaminaci\u00f3n microbiol\u00f3gica y de part\u00edculas en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n2. **Clasificaci\u00f3n de \u00c1reas Limpias**: Se definen cuatro grados de \u00e1reas limpias (A, B, C y D) seg\u00fan el riesgo de contaminaci\u00f3n, con especificaciones sobre el flujo de aire y la velocidad del aire.\n\n3. **Flujo de Aire Unidireccional**: Para el \u00e1rea de grado A, se requiere un sistema de flujo de aire unidireccional que mantenga una velocidad homog\u00e9nea de 0.36\u20130.54 m/s.\n\n4. **Cambios de Aire**: Se establece que el n\u00famero de cambios de aire en las \u00e1reas de grado B, C y D debe ser adecuado al tama\u00f1o de la habitaci\u00f3n y a la cantidad de equipo y personal presente.\n\n5. **Filtros HEPA**: Se requiere realizar pruebas de fugas en los filtros HEPA cada 6 a 12 meses para asegurar su eficacia y evitar contaminaciones.\n\n### Entidades\n\n- **ISO 14644-1**: Norma utilizada para la clasificaci\u00f3n de limpieza seg\u00fan la concentraci\u00f3n de part\u00edculas en el aire.\n- **ISO 14644-3**: Norma que establece los procedimientos para las pruebas de fugas en filtros HEPA.\n- **ISO 1822-4**: Norma que proporciona recomendaciones sobre el parcheo de filtros HEPA.\n- **Grados de Limpieza**: Clasificaci\u00f3n de \u00e1reas limpias en Grado A, B, C y D.\n- **Filtros HEPA**: Filtros de aire de alta eficiencia que son cruciales para mantener la calidad del aire en \u00e1reas limpias.\n\n### Resumen General\nEl documento de la OMS establece directrices sobre la limpieza en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, definiendo grados de limpieza y especificaciones t\u00e9cnicas para asegurar un ambiente controlado y libre de contaminantes. Se subraya la importancia de los sistemas de flujo de aire, la frecuencia de pruebas de filtros HEPA y la adecuada gesti\u00f3n de cambios de aire en las \u00e1reas de producci\u00f3n.", "excerpt_keywords": "Keywords: clean rooms, ISO 14644, airborne particle concentration, classification, environmental monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5b3130d4-c8aa-482d-b53e-837029e266d0", "node_type": "4", "metadata": {"page_label": "277", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean room and clean-air device classification\n\n4.6 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2\u20133, 5\u20137).\n\n4.6.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1: Maximum permitted airborne particle concentration**\n\n| Grade\\<br/>0.5 \u00b5m | At rest\\<br/>5.0 \u00b5m | At rest\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0 \u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes in Grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for Grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For Grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For Grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For Grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades (Grade C in operation and Grade D at rest) the sample volume per location should be at least 2 litres and the sample time per location should be not less than 1 minute.\n\n4.6.3 Portable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u00b5m. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n4.6.4 \u201cIn operation\u201d classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ee896d0b1cc41ddf9eab605660e712204879b6e543512b06e527015a1bd33136", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Clean room and clean-air device classification\n\n4.6 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2\u20133, 5\u20137).\n\n4.6.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1: Maximum permitted airborne particle concentration**\n\n| Grade\\<br/>0.5 \u00b5m | At rest\\<br/>5.0 \u00b5m | At rest\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0 \u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes in Grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for Grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For Grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For Grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For Grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades (Grade C in operation and Grade D at rest) the sample volume per location should be at least 2 litres and the sample time per location should be not less than 1 minute.\n\n4.6.3 Portable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u00b5m. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n4.6.4 \u201cIn operation\u201d classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2672, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c9de14c5-51f9-446d-9095-0e214338c624": {"__data__": {"id_": "c9de14c5-51f9-446d-9095-0e214338c624", "embedding": null, "metadata": {"page_label": "278", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean Room and Clean-Air Device Monitoring\n\n4.7 Clean rooms and clean-air devices should be routinely monitored while in operation. The monitoring locations should be based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.1\n\nFor Grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases, monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The Grade A zone should be monitored at a frequency and sample size such that all interventions, transient events, and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u00b5m particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.2\n\nIt is recommended that a similar system be used for Grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent Grade A and B zones. The Grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.3\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered.\n\nWhere remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n## 4.7.4\n\nThe sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS detalla las pautas para el monitoreo de salas limpias y dispositivos de aire limpio, enfatizando la importancia de realizar un an\u00e1lisis de riesgo formal para determinar los puntos de monitoreo. Se especifican diferentes protocolos para zonas de Grado A y Grado B, incluyendo la frecuencia de monitoreo y el tama\u00f1o de las muestras. Adem\u00e1s, se discuten los sistemas de monitoreo de part\u00edculas en el aire y las consideraciones t\u00e9cnicas para su implementaci\u00f3n, como la longitud de los tubos y el riesgo asociado con los materiales utilizados en las operaciones de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 justificaciones se pueden considerar para no realizar el monitoreo de part\u00edculas en zonas de Grado A durante la configuraci\u00f3n del equipo?**\n   - Respuesta: El monitoreo puede no realizarse si hay contaminantes en el proceso que podr\u00edan da\u00f1ar el contador de part\u00edculas o presentar un riesgo, como organismos vivos o peligros radiol\u00f3gicos. En tales casos, se debe realizar el monitoreo antes de la exposici\u00f3n al riesgo.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia de monitoreo en zonas de Grado B y qu\u00e9 factores influyen en esta decisi\u00f3n?**\n   - Respuesta: La frecuencia de monitoreo en zonas de Grado B puede ser menor que en Grado A, y su importancia se determina por la efectividad de la segregaci\u00f3n entre las zonas adyacentes de Grado A y B. Se debe monitorear a una frecuencia y tama\u00f1o de muestra que capture cambios en los niveles de contaminaci\u00f3n y cualquier deterioro del sistema.\n\n3. **\u00bfQu\u00e9 consideraciones t\u00e9cnicas deben tenerse en cuenta al seleccionar un sistema de monitoreo de part\u00edculas en el aire?**\n   - Respuesta: Al seleccionar un sistema de monitoreo, se deben considerar la longitud de los tubos y los radios de cualquier curva en los tubos en relaci\u00f3n con las p\u00e9rdidas de part\u00edculas. Adem\u00e1s, se debe tener en cuenta el riesgo presentado por los materiales utilizados en la operaci\u00f3n de fabricaci\u00f3n, como aquellos que involucran organismos vivos o productos radiopharmaceuticals.", "prev_section_summary": "### Resumen de los temas clave y entidades de la secci\u00f3n:\n\n1. **Clasificaci\u00f3n de Salas Limpias y Dispositivos de Aire Limpio**:\n   - Las salas limpias y los dispositivos de aire limpio deben clasificarse de acuerdo con la norma ISO 14644.\n\n2. **Diferenciaci\u00f3n de Clasificaci\u00f3n y Monitoreo**:\n   - La clasificaci\u00f3n se distingue claramente del monitoreo ambiental operativo.\n\n3. **Concentraciones M\u00e1ximas Permitidas**:\n   - Se proporciona una tabla (Tabla 1) que detalla las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D) en condiciones \"en reposo\" y \"en operaci\u00f3n\".\n\n4. **Condiciones de Muestreo**:\n   - Para la clasificaci\u00f3n en zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra.\n   - Se especifican las clasificaciones de part\u00edculas en el aire correspondientes a cada grado.\n\n5. **Equipos de Muestreo**:\n   - Se recomienda el uso de contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas.\n   - Se deben utilizar cabezales de muestreo isocin\u00e9tico en sistemas de flujo de aire unidireccional.\n\n6. **Condiciones de \"En Reposo\" y \"En Operaci\u00f3n\"**:\n   - Se definen las condiciones de \"en reposo\" (sin personal presente) y \"en operaci\u00f3n\" (con personal presente) para la clasificaci\u00f3n.\n\n7. **Normativa ISO**:\n   - Se hace referencia a la metodolog\u00eda de la norma ISO 14644-1 para determinar el n\u00famero m\u00ednimo de ubicaciones de muestreo y el tama\u00f1o de la muestra.\n\n### Entidades Clave:\n- **Norma ISO 14644**: Est\u00e1ndar para la clasificaci\u00f3n de salas limpias.\n- **Grados de Limpieza**: A, B, C, D.\n- **Concentraciones de Part\u00edculas**: L\u00edmites establecidos para part\u00edculas de 0.5 \u00b5m y 5.0 \u00b5m.\n- **Contadores de Part\u00edculas**: Equipos recomendados para la clasificaci\u00f3n.\n- **Condiciones de Muestreo**: \"En reposo\" y \"en operaci\u00f3n\". \n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la clasificaci\u00f3n adecuada y los requisitos t\u00e9cnicos necesarios para mantener la calidad del aire en entornos controlados.", "excerpt_keywords": "Keywords: clean rooms, particle monitoring, Grade A zones, risk analysis, airborne particle monitoring systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f9ab6a15-e7dd-46f1-9454-ec9047e93082", "node_type": "4", "metadata": {"page_label": "278", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean Room and Clean-Air Device Monitoring\n\n4.7 Clean rooms and clean-air devices should be routinely monitored while in operation. The monitoring locations should be based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.1\n\nFor Grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases, monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The Grade A zone should be monitored at a frequency and sample size such that all interventions, transient events, and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u00b5m particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.2\n\nIt is recommended that a similar system be used for Grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent Grade A and B zones. The Grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.3\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered.\n\nWhere remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n## 4.7.4\n\nThe sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fc44f3d109809d3c5a7d6762c1e4ca9090fcb5337c14f06555f4e6c5c2b36593", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Clean Room and Clean-Air Device Monitoring\n\n4.7 Clean rooms and clean-air devices should be routinely monitored while in operation. The monitoring locations should be based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.1\n\nFor Grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases, monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The Grade A zone should be monitored at a frequency and sample size such that all interventions, transient events, and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u00b5m particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.2\n\nIt is recommended that a similar system be used for Grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent Grade A and B zones. The Grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.3\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered.\n\nWhere remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n## 4.7.4\n\nThe sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2684, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e56d3bc0-bc8d-4073-8193-c4b5a007a624": {"__data__": {"id_": "e56d3bc0-bc8d-4073-8193-c4b5a007a624", "embedding": null, "metadata": {"page_label": "279", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.5 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for Grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (3).\n\n4.7.6 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.7 The monitoring of Grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.8 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.9 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.12\u20134.20).\n\n**Table 2**\n\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products (see sections 4.12\u20134.15) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations (see sections 4.16\u20134.20) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Technical Report Series 961) aborda las condiciones de limpieza y monitoreo en \u00e1reas clasificadas como limpias, especialmente en relaci\u00f3n con la operaci\u00f3n de productos est\u00e9riles y preparaciones as\u00e9pticas. Se establecen directrices sobre c\u00f3mo lograr y mantener condiciones de part\u00edculas en el aire, as\u00ed como la importancia de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones. Tambi\u00e9n se discuten los m\u00e9todos de monitoreo y los ejemplos de operaciones adecuadas para diferentes grados de limpieza.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" mencionado en el documento y cu\u00e1nto tiempo se recomienda?**\n   - El objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" es alcanzar las condiciones de part\u00edculas en el aire especificadas para el estado \"en reposo\" en ausencia del personal operativo. Se recomienda un per\u00edodo de aproximadamente 15 a 20 minutos.\n\n2. **\u00bfQu\u00e9 factores deben considerarse al determinar los lugares y tama\u00f1os de muestra para el monitoreo de part\u00edculas en \u00e1reas limpias?**\n   - Los lugares y tama\u00f1os de muestra deben determinarse en funci\u00f3n de una evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n, lo que implica considerar la naturaleza de las operaciones realizadas.\n\n3. **\u00bfQu\u00e9 operaciones se recomiendan para el grado A en el contexto de productos est\u00e9riles y preparaciones as\u00e9pticas?**\n   - Para productos est\u00e9riles, se recomienda el llenado de productos cuando est\u00e1n en un riesgo inusualmente alto. Para preparaciones as\u00e9pticas, se recomienda la preparaci\u00f3n y llenado as\u00e9ptico.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo de Salas Limpias y Dispositivos de Aire Limpio**: Se enfatiza la necesidad de un monitoreo rutinario de las salas limpias y dispositivos de aire limpio durante su operaci\u00f3n, basado en un an\u00e1lisis de riesgo formal.\n\n2. **Zonas de Grado A y Grado B**: Se establecen protocolos espec\u00edficos para el monitoreo de part\u00edculas en zonas de Grado A y Grado B, incluyendo la duraci\u00f3n del monitoreo, la frecuencia y el tama\u00f1o de las muestras.\n\n3. **Contaminantes y Riesgos**: Se discuten las justificaciones para no realizar el monitoreo en ciertas situaciones, como la presencia de contaminantes que podr\u00edan da\u00f1ar los equipos de monitoreo o representar un riesgo.\n\n4. **Sistemas de Monitoreo de Part\u00edculas**: Se describen diferentes configuraciones de sistemas de monitoreo de part\u00edculas en el aire, as\u00ed como consideraciones t\u00e9cnicas como la longitud de los tubos y el riesgo asociado con los materiales utilizados en la fabricaci\u00f3n.\n\n5. **Tama\u00f1o de Muestras**: Se menciona que el tama\u00f1o de las muestras para el monitoreo automatizado depende de la tasa de muestreo del sistema utilizado.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las pautas.\n- **Salas Limpias**: Espacios controlados donde se minimiza la contaminaci\u00f3n.\n- **Dispositivos de Aire Limpio**: Equipos dise\u00f1ados para mantener la calidad del aire en entornos controlados.\n- **Zonas de Grado A y Grado B**: Clasificaciones que indican diferentes niveles de control de contaminaci\u00f3n.\n- **Contadores de Part\u00edculas**: Equipos utilizados para medir la cantidad de part\u00edculas en el aire.\n- **Organismos Vivos y Productos Radiopharmaceuticals**: Materiales que presentan riesgos espec\u00edficos en el contexto de monitoreo.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes y las entidades relevantes en la secci\u00f3n sobre el monitoreo de salas limpias y dispositivos de aire limpio.", "excerpt_keywords": "Keywords: clean rooms, airborne particles, monitoring, aseptic preparations, recovery period"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "49aff1be-42d8-41ca-8f5e-43dfc0e26c21", "node_type": "4", "metadata": {"page_label": "279", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.5 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for Grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (3).\n\n4.7.6 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.7 The monitoring of Grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.8 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.9 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.12\u20134.20).\n\n**Table 2**\n\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products (see sections 4.12\u20134.15) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations (see sections 4.16\u20134.20) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9d9f39e8dc610bc20eb4d14d00126024514f7c084494b6eae2125e4210f2479e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.5 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for Grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (3).\n\n4.7.6 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.7 The monitoring of Grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.8 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.9 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.12\u20134.20).\n\n**Table 2**\n\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products (see sections 4.12\u20134.15) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations (see sections 4.16\u20134.20) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2531, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d9274fd1-9dd6-4fcf-a291-b0050ff44d98": {"__data__": {"id_": "d9274fd1-9dd6-4fcf-a291-b0050ff44d98", "embedding": null, "metadata": {"page_label": "280", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 \nTo control the microbiological cleanliness of Grades A\u2013D in operation, the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n# 4.9 \nLevels of detection of microbial contamination should be established for the purpose of setting alert and action limits and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n**Table 3**\n\n### Recommended limits for microbial contamination<sup>a</sup>\n\n| Grade | Air sample (CFU/m) | Settle plates (diameter 90 mm) (CFU/4 hours) | Contact plates (diameter 55 mm) (CFU/plate) | Glove print (5 fingers) (CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.\n\n# 4.10 \nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert limits, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11 \nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para el control de la limpieza microbiol\u00f3gica en \u00e1reas clasificadas de A a D en operaciones de producci\u00f3n. Se enfatiza la importancia de monitorear frecuentemente estas \u00e1reas mediante m\u00e9todos como placas de asentamiento y muestreo de aire y superficies. Se definen l\u00edmites de detecci\u00f3n de contaminaci\u00f3n microbiana en unidades formadoras de colonias (CFU) y se recomienda establecer l\u00edmites de alerta y acci\u00f3n para la monitorizaci\u00f3n de la limpieza ambiental. Adem\u00e1s, se sugiere que los fabricantes seleccionen las clasificaciones de \u00e1rea bas\u00e1ndose en la naturaleza de las operaciones y la contaminaci\u00f3n microbiana encontrada.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 m\u00e9todos de muestreo se recomiendan para el monitoreo de la limpieza microbiol\u00f3gica en \u00e1reas de producci\u00f3n?**\n   - El documento menciona m\u00e9todos como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficies (por ejemplo, hisopos y placas de contacto).\n\n2. **\u00bfCu\u00e1les son los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en las diferentes \u00e1reas clasificadas (A, B, C, D) seg\u00fan el documento?**\n   - Los l\u00edmites son los siguientes:\n     - **A:** < 1 CFU/m (aire), < 1 CFU/4 horas (placas de asentamiento), < 1 CFU/placa (placas de contacto), < 1 CFU/glove (guantes).\n     - **B:** 10 CFU/m, 5 CFU/4 horas, 5 CFU/placa, 5 CFU/glove.\n     - **C:** 100 CFU/m, 50 CFU/4 horas, 25 CFU/placa.\n     - **D:** 200 CFU/m, 100 CFU/4 horas, 50 CFU/placa.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se superan los l\u00edmites de acci\u00f3n establecidos para el monitoreo microbiol\u00f3gico?**\n   - Si se superan los l\u00edmites de acci\u00f3n o se identifica una tendencia en los l\u00edmites de alerta, se debe iniciar una investigaci\u00f3n y tomar las acciones correctivas apropiadas, seg\u00fan lo prescrito en los procedimientos operativos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Technical Report Series 961) se centra en las condiciones de limpieza y monitoreo en \u00e1reas clasificadas como limpias, especialmente en el contexto de productos est\u00e9riles y preparaciones as\u00e9pticas. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Condiciones de Part\u00edculas en el Aire**:\n   - Se establecen condiciones espec\u00edficas para el estado \"en reposo\" y \"en operaci\u00f3n\" de las \u00e1reas limpias.\n   - Se requiere un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" de 15 a 20 minutos despu\u00e9s de las operaciones.\n\n2. **Monitoreo de la Limpieza**:\n   - Es necesario monitorear las \u00e1reas limpias para part\u00edculas en el aire y contaminaci\u00f3n microbiana.\n   - Los planes de muestreo deben basarse en la evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n.\n\n3. **Clasificaci\u00f3n de \u00c1reas**:\n   - Se mencionan diferentes grados de limpieza (A, C, D) y las operaciones adecuadas para cada uno.\n   - Se enfatiza la importancia de mantener las condiciones de limpieza durante las operaciones.\n\n4. **Par\u00e1metros Adicionales**:\n   - Se discuten otros factores como la temperatura y la humedad relativa, que no deben interferir con los est\u00e1ndares de limpieza.\n\n5. **Ejemplos de Operaciones**:\n   - Se proporcionan ejemplos de operaciones espec\u00edficas para productos terminalmente esterilizados y preparaciones as\u00e9pticas seg\u00fan el grado de limpieza.\n\n#### Entidades Relevantes:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **ISO 14644-3**: Norma mencionada que se refiere a la clasificaci\u00f3n de la limpieza del aire.\n- **Grados de Limpieza**: A, C, D, que indican diferentes niveles de control de contaminaci\u00f3n.\n- **Operaciones**: Ejemplos incluyen el llenado de productos, preparaci\u00f3n de soluciones y manejo de componentes.\n\nEste resumen destaca la importancia de mantener condiciones controladas en \u00e1reas limpias y la necesidad de un monitoreo riguroso para asegurar la calidad y seguridad de los productos est\u00e9riles y las preparaciones as\u00e9pticas.", "excerpt_keywords": "Keywords: microbiological cleanliness, contamination limits, aseptic operations, environmental monitoring, clean areas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "762b4ae6-6973-4571-b9c7-5d6d99d0dd68", "node_type": "4", "metadata": {"page_label": "280", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 \nTo control the microbiological cleanliness of Grades A\u2013D in operation, the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n# 4.9 \nLevels of detection of microbial contamination should be established for the purpose of setting alert and action limits and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n**Table 3**\n\n### Recommended limits for microbial contamination<sup>a</sup>\n\n| Grade | Air sample (CFU/m) | Settle plates (diameter 90 mm) (CFU/4 hours) | Contact plates (diameter 55 mm) (CFU/plate) | Glove print (5 fingers) (CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.\n\n# 4.10 \nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert limits, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11 \nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d05f270130e0a94ca768d0893e60dff6c312e4eab412713e2753a8c5f934f81d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.8 \nTo control the microbiological cleanliness of Grades A\u2013D in operation, the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n# 4.9 \nLevels of detection of microbial contamination should be established for the purpose of setting alert and action limits and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n**Table 3**\n\n### Recommended limits for microbial contamination<sup>a</sup>\n\n| Grade | Air sample (CFU/m) | Settle plates (diameter 90 mm) (CFU/4 hours) | Contact plates (diameter 55 mm) (CFU/plate) | Glove print (5 fingers) (CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.\n\n# 4.10 \nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert limits, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11 \nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2496, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "26adbbef-2876-4276-9a93-276724b3ad01": {"__data__": {"id_": "26adbbef-2876-4276-9a93-276724b3ad01", "embedding": null, "metadata": {"page_label": "281", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Terminally Sterilized Products\n\n4.12 Components and most products should be prepared in at least a Grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g., because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a Grade C environment.\n\n4.13 The filling of products for terminal sterilization should generally be done in at least a Grade C environment.\n\n4.14 Where the product is at unusual risk of contamination from the environment (e.g., because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a Grade A zone with at least a Grade C background.\n\n4.15 The preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a Grade C environment before terminal sterilization.\n\n# Aseptic Preparation\n\n4.16 Components after washing should be handled in at least a Grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a Grade A environment with a Grade B background.\n\n4.17 The preparation of solutions which are to be sterile-filtered during the process should be undertaken in a Grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable). If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a Grade A environment with a Grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a Grade A environment with a Grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a Grade A environment with a Grade B background or in sealed transfer trays in a Grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a Grade A environment with a Grade B background when the product is exposed and is not subsequently filtered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las condiciones ambientales necesarias para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, tanto para la esterilizaci\u00f3n terminal como para la preparaci\u00f3n as\u00e9ptica. Se especifican diferentes \"grados\" de ambientes (A, B, C, D) que deben ser utilizados dependiendo del riesgo de contaminaci\u00f3n microbiana y la naturaleza del producto. Por ejemplo, los productos que est\u00e1n en riesgo inusual de contaminaci\u00f3n deben ser preparados en ambientes de mayor calidad (como el Grado C o A), mientras que otros productos pueden ser preparados en ambientes de menor calidad (como el Grado D).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que justifican el uso de un ambiente de Grado C en lugar de un ambiente de Grado D para la preparaci\u00f3n de productos?**\n   - Respuesta: Un ambiente de Grado C debe ser utilizado cuando el producto est\u00e1 en un riesgo inusual de contaminaci\u00f3n microbiana, como cuando apoya activamente el crecimiento microbiano, debe ser mantenido durante un largo per\u00edodo antes de la esterilizaci\u00f3n, o es procesado principalmente en recipientes abiertos.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse durante el llenado de productos que est\u00e1n en riesgo de contaminaci\u00f3n ambiental?**\n   - Respuesta: Para productos en riesgo de contaminaci\u00f3n ambiental, el llenado debe realizarse en una zona de Grado A con al menos un fondo de Grado C, especialmente si la operaci\u00f3n de llenado es lenta, los recipientes son de cuello ancho o est\u00e1n expuestos durante m\u00e1s de unos pocos segundos antes de sellarse.\n\n3. **\u00bfQu\u00e9 tipo de ambiente se recomienda para la preparaci\u00f3n y llenado de productos como ung\u00fcentos y emulsiones antes de la esterilizaci\u00f3n terminal?**\n   - Respuesta: La preparaci\u00f3n y el llenado de ung\u00fcentos, cremas, suspensiones y emulsiones deben realizarse generalmente en un ambiente de Grado C antes de la esterilizaci\u00f3n terminal.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices sobre los ambientes necesarios para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n microbiana. Se clasifican los ambientes en grados (A, B, C, D) y se proporcionan recomendaciones espec\u00edficas seg\u00fan el tipo de producto y el riesgo de contaminaci\u00f3n. Estas directrices son cruciales para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de la Limpieza Microbiol\u00f3gica**: Se enfatiza la importancia de monitorear la limpieza microbiol\u00f3gica en \u00e1reas clasificadas de A a D durante las operaciones de producci\u00f3n.\n\n2. **M\u00e9todos de Monitoreo**: Se recomiendan m\u00e9todos de muestreo como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficies (hisopos y placas de contacto) para asegurar la asepsia.\n\n3. **L\u00edmites de Contaminaci\u00f3n Microbiana**: Se establecen l\u00edmites de detecci\u00f3n de contaminaci\u00f3n microbiana expresados en unidades formadoras de colonias (CFU) para cada grado de \u00e1rea (A, B, C, D).\n\n4. **L\u00edmites de Alerta y Acci\u00f3n**: Se deben establecer l\u00edmites apropiados para alertar y tomar acciones correctivas si se superan los l\u00edmites de acci\u00f3n o se identifican tendencias preocupantes.\n\n5. **Selecci\u00f3n de Grados de \u00c1rea**: Los fabricantes deben seleccionar los grados de \u00e1rea bas\u00e1ndose en la naturaleza de las operaciones y la contaminaci\u00f3n microbiana encontrada, utilizando simulaciones de procesos para establecer tiempos de retenci\u00f3n y duraci\u00f3n m\u00e1xima de llenado.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de \u00c1rea**: Clasificaciones de limpieza microbiol\u00f3gica (A, B, C, D).\n- **M\u00e9todos de Muestreo**: Placas de asentamiento, muestreo de aire, hisopos, placas de contacto.\n- **Unidades Formadoras de Colonias (CFU)**: Unidad de medida para la contaminaci\u00f3n microbiana.\n- **L\u00edmites de Alerta y Acci\u00f3n**: Par\u00e1metros establecidos para la monitorizaci\u00f3n de la limpieza ambiental.\n- **Contaminaci\u00f3n Microbiana (Bioburden)**: Carga microbiana presente en el entorno de producci\u00f3n. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes del control de la limpieza microbiol\u00f3gica en entornos de producci\u00f3n, as\u00ed como las entidades involucradas en el proceso.", "excerpt_keywords": "Keywords: terminal sterilization, aseptic preparation, microbial contamination, Grade A environment, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4900ee81-1cd4-4618-a0d2-7711a6325a19", "node_type": "4", "metadata": {"page_label": "281", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Terminally Sterilized Products\n\n4.12 Components and most products should be prepared in at least a Grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g., because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a Grade C environment.\n\n4.13 The filling of products for terminal sterilization should generally be done in at least a Grade C environment.\n\n4.14 Where the product is at unusual risk of contamination from the environment (e.g., because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a Grade A zone with at least a Grade C background.\n\n4.15 The preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a Grade C environment before terminal sterilization.\n\n# Aseptic Preparation\n\n4.16 Components after washing should be handled in at least a Grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a Grade A environment with a Grade B background.\n\n4.17 The preparation of solutions which are to be sterile-filtered during the process should be undertaken in a Grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable). If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a Grade A environment with a Grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a Grade A environment with a Grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a Grade A environment with a Grade B background or in sealed transfer trays in a Grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a Grade A environment with a Grade B background when the product is exposed and is not subsequently filtered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f7ccb165fc4ce4c1a3dc0646c8723183f1aa92679e9cb142d59a96bcafe54992", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Terminally Sterilized Products\n\n4.12 Components and most products should be prepared in at least a Grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g., because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a Grade C environment.\n\n4.13 The filling of products for terminal sterilization should generally be done in at least a Grade C environment.\n\n4.14 Where the product is at unusual risk of contamination from the environment (e.g., because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a Grade A zone with at least a Grade C background.\n\n4.15 The preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a Grade C environment before terminal sterilization.\n\n# Aseptic Preparation\n\n4.16 Components after washing should be handled in at least a Grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a Grade A environment with a Grade B background.\n\n4.17 The preparation of solutions which are to be sterile-filtered during the process should be undertaken in a Grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable). If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a Grade A environment with a Grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a Grade A environment with a Grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a Grade A environment with a Grade B background or in sealed transfer trays in a Grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a Grade A environment with a Grade B background when the product is exposed and is not subsequently filtered.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2504, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "128aabad-5c09-487c-8166-3b44de5fcbd4": {"__data__": {"id_": "128aabad-5c09-487c-8166-3b44de5fcbd4", "embedding": null, "metadata": {"page_label": "282", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the heating, ventilation and air-conditioning (HVAC) system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- When filling fewer than 5000 units, no contaminated units should be detected.\n- When filling 5000\u201310 000 units:\n  - One contaminated unit should result in an investigation, including consideration of a repeat media fill;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las precauciones y procedimientos necesarios para minimizar la contaminaci\u00f3n durante el procesamiento de productos farmac\u00e9uticos, especialmente aquellos que contienen microorganismos vivos. Se enfatiza la importancia de la validaci\u00f3n de los procesos as\u00e9pticos, incluyendo pruebas de simulaci\u00f3n de procesos (media fill) que imitan los pasos de fabricaci\u00f3n as\u00e9ptica. Se establecen criterios espec\u00edficos para la evaluaci\u00f3n de la contaminaci\u00f3n en lotes peque\u00f1os y se menciona la necesidad de realizar pruebas de simulaci\u00f3n de manera regular y tras modificaciones significativas en el sistema de producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un fabricante pueda justificar el uso de instalaciones multiproducto al procesar microorganismos vivos?**\n   - Respuesta: El fabricante debe demostrar y validar la contenci\u00f3n y decontaminaci\u00f3n efectivas de los microorganismos vivos, adem\u00e1s de tomar precauciones para minimizar la contaminaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los requisitos para la selecci\u00f3n del medio de cultivo utilizado en las pruebas de simulaci\u00f3n de procesos?**\n   - Respuesta: La selecci\u00f3n del medio de cultivo debe basarse en la forma de dosificaci\u00f3n del producto, as\u00ed como en la selectividad, claridad, concentraci\u00f3n y adecuaci\u00f3n para la esterilizaci\u00f3n del medio.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta una unidad contaminada durante el llenado de entre 5000 y 10,000 unidades?**\n   - Respuesta: La detecci\u00f3n de una unidad contaminada debe resultar en una investigaci\u00f3n, que incluir\u00e1 la consideraci\u00f3n de repetir la prueba de media fill.", "prev_section_summary": "### Temas Clave\n\n1. **Ambientes de Preparaci\u00f3n**: Se especifican diferentes grados de ambientes (A, B, C, D) que deben ser utilizados para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, dependiendo del riesgo de contaminaci\u00f3n microbiana.\n\n2. **Esterilizaci\u00f3n Terminal**: \n   - Preparaci\u00f3n de componentes y productos en un ambiente de al menos Grado D.\n   - Uso de Grado C para productos con riesgo inusual de contaminaci\u00f3n.\n   - Llenado de productos en un ambiente de al menos Grado C, y en Grado A con fondo de Grado C para productos en alto riesgo de contaminaci\u00f3n ambiental.\n\n3. **Preparaci\u00f3n Aseptica**:\n   - Manejo de componentes lavados en un ambiente de al menos Grado D.\n   - Preparaci\u00f3n de soluciones que ser\u00e1n filtradas en un ambiente de Grado C, o Grado A con fondo de Grado B si no se filtran.\n   - Manejo y llenado de productos preparados asepticamente en un ambiente de Grado A con fondo de Grado B.\n\n4. **Transferencia de Contenedores**: Transferencia de contenedores parcialmente cerrados en ambientes controlados para evitar contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de Ambiente**: Clasificaci\u00f3n de ambientes (A, B, C, D) seg\u00fan el nivel de control de contaminaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen ung\u00fcentos, cremas, suspensiones y emulsiones que requieren condiciones espec\u00edficas de preparaci\u00f3n y llenado.\n- **Contaminaci\u00f3n Microbiana**: Riesgo asociado a la preparaci\u00f3n y llenado de productos que debe ser minimizado.\n\n### Resumen\n\nEl documento de la OMS establece directrices sobre las condiciones ambientales necesarias para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n microbiana. Se clasifican los ambientes en grados y se proporcionan recomendaciones espec\u00edficas seg\u00fan el tipo de producto y el riesgo de contaminaci\u00f3n, lo cual es crucial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: contamination, aseptic processing, validation, multiproduct facilities, media fill"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f4ffe037-f0db-43c1-9870-d281aa2bd9da", "node_type": "4", "metadata": {"page_label": "282", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the heating, ventilation and air-conditioning (HVAC) system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- When filling fewer than 5000 units, no contaminated units should be detected.\n- When filling 5000\u201310 000 units:\n  - One contaminated unit should result in an investigation, including consideration of a repeat media fill;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "69af14ef90b3f5a405e0c5bfdd0c684ba31dbfa11765e666421c255c8ee4f591", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Processing\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the heating, ventilation and air-conditioning (HVAC) system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- When filling fewer than 5000 units, no contaminated units should be detected.\n- When filling 5000\u201310 000 units:\n  - One contaminated unit should result in an investigation, including consideration of a repeat media fill;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2650, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0e2ebebb-ea02-44ff-a686-c5d28a50e172": {"__data__": {"id_": "0e2ebebb-ea02-44ff-a686-c5d28a50e172", "embedding": null, "metadata": {"page_label": "283", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n\u2014 two contaminated units are considered cause for revalidation \n  following investigation;\n- when filling more than 10 000 units:\n  \u2014 one contaminated unit should result in an investigation;\n  \u2014 two contaminated units are considered cause for revalidation \n    following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination \nmay be indicative of low-level contamination that should be investigated. \nInvestigation of gross failures should include the potential impact on the \nsterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not \ncompromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should \nbe monitored regularly for chemicals, biological contamination and \ncontamination with endotoxins to ensure that the water complies with the \nspecifications appropriate to its use. Records should be maintained of the \nresults of the monitoring and of any action taken (8).\n\n4.30 Activities in clean areas, especially when aseptic operations are in \nprogress, should be kept to a minimum and the movement of personnel should \nbe controlled and methodical, so as to avoid excessive shedding of particles and \norganisms due to over-vigorous activity. As far as possible, personnel should \nbe excluded from Grade A zones. The ambient temperature and humidity \nshould not be uncomfortably high because of the nature of the garments worn \nand to reduce the risk of contamination liberated from the personnel.\n\n4.31 The presence of containers and materials liable to generate fibres \nshould be minimized in clean areas and avoided completely when aseptic \nwork is in progress.\n\n4.32 Components, bulk-product containers and equipment should be \nhandled after the final cleaning process in such a way as to ensure that they \nare not recontaminated. The stage of processing of components as well as \nthe bulk-product containers and equipment should be properly identified.\n\n4.33 The interval between the washing and drying and the sterilization of \ncomponents, bulk-product containers and equipment, as well as between \nsterilization and use, should be as short as possible and subject to a time- \nlimit appropriate to the validated storage conditions.\n\n4.34 The time between the start of the preparation of a solution and its \nsterilization or filtration through a bacteria-retaining filter should be as short \nas possible. A maximum permissible time should be set for each product that \ntakes into account its composition and the prescribed method of storage.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda las pr\u00e1cticas de validaci\u00f3n y control de calidad en la producci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la contaminaci\u00f3n microbiana y la gesti\u00f3n del agua en \u00e1reas limpias. Se establecen directrices sobre c\u00f3mo manejar incidentes de contaminaci\u00f3n, la importancia de la validaci\u00f3n de procesos, y las medidas necesarias para mantener la esterilidad y la calidad del producto durante su fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las acciones recomendadas cuando se detectan unidades contaminadas durante la producci\u00f3n de m\u00e1s de 10,000 unidades?**\n   - Respuesta: Se debe investigar cualquier unidad contaminada, y si se encuentran dos unidades contaminadas, esto se considera motivo para la revalidaci\u00f3n tras la investigaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que el agua utilizada en el proceso de producci\u00f3n cumpla con las especificaciones necesarias?**\n   - Respuesta: Las fuentes de agua, el equipo de tratamiento de agua y el agua tratada deben ser monitoreados regularmente para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, y se deben mantener registros de los resultados del monitoreo y de cualquier acci\u00f3n tomada.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse en \u00e1reas limpias durante operaciones as\u00e9pticas para minimizar el riesgo de contaminaci\u00f3n?**\n   - Respuesta: Las actividades en \u00e1reas limpias deben ser m\u00ednimas, el movimiento del personal debe ser controlado y met\u00f3dico, y se debe evitar la presencia de materiales que generen fibras. Adem\u00e1s, se debe mantener una temperatura y humedad adecuadas para reducir el riesgo de contaminaci\u00f3n liberada por el personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Precauciones contra la Contaminaci\u00f3n**: Se enfatiza la importancia de tomar medidas para minimizar la contaminaci\u00f3n en todas las etapas del procesamiento de productos farmac\u00e9uticos, especialmente antes de la esterilizaci\u00f3n.\n\n2. **Uso de Instalaciones Multiproducto**: Generalmente, no se deben elaborar preparaciones que contengan microorganismos vivos en \u00e1reas donde se procesan otros productos farmac\u00e9uticos. Sin embargo, se permite el uso de instalaciones multiproducto si el fabricante puede demostrar la contenci\u00f3n y decontaminaci\u00f3n efectivas de los microorganismos vivos.\n\n3. **Validaci\u00f3n de Procesos Aseptic\u00f3s**: La validaci\u00f3n del procesamiento as\u00e9ptico debe incluir pruebas de simulaci\u00f3n de procesos (media fill) utilizando un medio de cultivo adecuado, que debe seleccionarse seg\u00fan la forma de dosificaci\u00f3n del producto y otros criterios como claridad y adecuaci\u00f3n para la esterilizaci\u00f3n.\n\n4. **Pruebas de Simulaci\u00f3n de Procesos**: Estas pruebas deben replicar lo m\u00e1s fielmente posible los pasos de fabricaci\u00f3n as\u00e9ptica y realizarse de manera regular, especialmente despu\u00e9s de modificaciones significativas en el sistema de producci\u00f3n.\n\n5. **Evaluaci\u00f3n de Contaminaci\u00f3n en Lotes Peque\u00f1os**: Se establecen criterios espec\u00edficos para la evaluaci\u00f3n de contaminaci\u00f3n en lotes peque\u00f1os, donde se espera que no se detecten unidades contaminadas en lotes de menos de 5000 unidades, y se requiere una investigaci\u00f3n si se encuentra una unidad contaminada en lotes de entre 5000 y 10,000 unidades.\n\n### Entidades Clave\n\n- **Microorganismos Vivos**: Organismos que deben ser manejados con precauciones especiales para evitar la contaminaci\u00f3n.\n- **Instalaciones Multiproducto**: Instalaciones que pueden procesar diferentes productos farmac\u00e9uticos, bajo ciertas condiciones de validaci\u00f3n.\n- **Pruebas de Simulaci\u00f3n de Procesos (Media Fill)**: M\u00e9todos utilizados para validar el procesamiento as\u00e9ptico.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar durante el procesamiento de productos farmac\u00e9uticos.\n- **Lotes Peque\u00f1os**: Referencia a la cantidad de unidades producidas que requieren atenci\u00f3n especial en t\u00e9rminos de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: contaminaci\u00f3n microbiana, validaci\u00f3n de procesos, \u00e1reas limpias, monitoreo de agua, esterilizaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4eed555b-950c-47f1-aba7-ac927a452ddb", "node_type": "4", "metadata": {"page_label": "283", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n\u2014 two contaminated units are considered cause for revalidation \n  following investigation;\n- when filling more than 10 000 units:\n  \u2014 one contaminated unit should result in an investigation;\n  \u2014 two contaminated units are considered cause for revalidation \n    following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination \nmay be indicative of low-level contamination that should be investigated. \nInvestigation of gross failures should include the potential impact on the \nsterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not \ncompromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should \nbe monitored regularly for chemicals, biological contamination and \ncontamination with endotoxins to ensure that the water complies with the \nspecifications appropriate to its use. Records should be maintained of the \nresults of the monitoring and of any action taken (8).\n\n4.30 Activities in clean areas, especially when aseptic operations are in \nprogress, should be kept to a minimum and the movement of personnel should \nbe controlled and methodical, so as to avoid excessive shedding of particles and \norganisms due to over-vigorous activity. As far as possible, personnel should \nbe excluded from Grade A zones. The ambient temperature and humidity \nshould not be uncomfortably high because of the nature of the garments worn \nand to reduce the risk of contamination liberated from the personnel.\n\n4.31 The presence of containers and materials liable to generate fibres \nshould be minimized in clean areas and avoided completely when aseptic \nwork is in progress.\n\n4.32 Components, bulk-product containers and equipment should be \nhandled after the final cleaning process in such a way as to ensure that they \nare not recontaminated. The stage of processing of components as well as \nthe bulk-product containers and equipment should be properly identified.\n\n4.33 The interval between the washing and drying and the sterilization of \ncomponents, bulk-product containers and equipment, as well as between \nsterilization and use, should be as short as possible and subject to a time- \nlimit appropriate to the validated storage conditions.\n\n4.34 The time between the start of the preparation of a solution and its \nsterilization or filtration through a bacteria-retaining filter should be as short \nas possible. A maximum permissible time should be set for each product that \ntakes into account its composition and the prescribed method of storage.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0eed5377d4429d59f2069821c789fe18c97d8695a59c608ca25b5b323b3c653e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "```\n\u2014 two contaminated units are considered cause for revalidation \n  following investigation;\n- when filling more than 10 000 units:\n  \u2014 one contaminated unit should result in an investigation;\n  \u2014 two contaminated units are considered cause for revalidation \n    following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination \nmay be indicative of low-level contamination that should be investigated. \nInvestigation of gross failures should include the potential impact on the \nsterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not \ncompromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should \nbe monitored regularly for chemicals, biological contamination and \ncontamination with endotoxins to ensure that the water complies with the \nspecifications appropriate to its use. Records should be maintained of the \nresults of the monitoring and of any action taken (8).\n\n4.30 Activities in clean areas, especially when aseptic operations are in \nprogress, should be kept to a minimum and the movement of personnel should \nbe controlled and methodical, so as to avoid excessive shedding of particles and \norganisms due to over-vigorous activity. As far as possible, personnel should \nbe excluded from Grade A zones. The ambient temperature and humidity \nshould not be uncomfortably high because of the nature of the garments worn \nand to reduce the risk of contamination liberated from the personnel.\n\n4.31 The presence of containers and materials liable to generate fibres \nshould be minimized in clean areas and avoided completely when aseptic \nwork is in progress.\n\n4.32 Components, bulk-product containers and equipment should be \nhandled after the final cleaning process in such a way as to ensure that they \nare not recontaminated. The stage of processing of components as well as \nthe bulk-product containers and equipment should be properly identified.\n\n4.33 The interval between the washing and drying and the sterilization of \ncomponents, bulk-product containers and equipment, as well as between \nsterilization and use, should be as short as possible and subject to a time- \nlimit appropriate to the validated storage conditions.\n\n4.34 The time between the start of the preparation of a solution and its \nsterilization or filtration through a bacteria-retaining filter should be as short \nas possible. A maximum permissible time should be set for each product that \ntakes into account its composition and the prescribed method of storage.\n```", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2619, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "01d12d1a-36b1-4d6c-bb76-c8ee2ff6015b": {"__data__": {"id_": "01d12d1a-36b1-4d6c-bb76-c8ee2ff6015b", "embedding": null, "metadata": {"page_label": "284", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n4.36 The bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n4.37 Components, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n4.38 The efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.\n\n# 5. Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre el manejo de la biocarga y los procesos de esterilizaci\u00f3n en la producci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de monitorear la biocarga antes de la esterilizaci\u00f3n, el uso de filtros esterilizantes para gases y soluciones, y la necesidad de validar la eficacia de los procedimientos de procesamiento. Adem\u00e1s, se discuten diferentes m\u00e9todos de esterilizaci\u00f3n, como el calor, la irradiaci\u00f3n y el \u00f3xido de etileno, y se establece que, siempre que sea posible, se debe optar por la esterilizaci\u00f3n terminal por calor en el envase final.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los l\u00edmites de trabajo recomendados para la biocarga antes de la esterilizaci\u00f3n y c\u00f3mo se relacionan con la eficiencia del m\u00e9todo de esterilizaci\u00f3n utilizado?**\n   - Respuesta: Los l\u00edmites de trabajo sobre la biocarga deben establecerse en funci\u00f3n de la eficiencia del m\u00e9todo de esterilizaci\u00f3n que se va a utilizar. Esto implica que se deben definir niveles aceptables de contaminaci\u00f3n que no comprometan la eficacia del proceso de esterilizaci\u00f3n.\n\n2. **\u00bfQu\u00e9 procedimientos se pueden implementar para prevenir la introducci\u00f3n de contaminaci\u00f3n en \u00e1reas limpias donde se realiza trabajo as\u00e9ptico?**\n   - Respuesta: Se recomienda que los componentes, contenedores de productos a granel, equipos y otros art\u00edculos necesarios en un \u00e1rea limpia sean esterilizados y, siempre que sea posible, se introduzcan en el \u00e1rea a trav\u00e9s de esterilizadores de doble extremo sellados en la pared. Tambi\u00e9n se pueden aceptar otros procedimientos que minimicen la contaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al elegir un m\u00e9todo de esterilizaci\u00f3n alternativo cuando la esterilizaci\u00f3n terminal por calor no es viable?**\n   - Respuesta: Si la esterilizaci\u00f3n terminal por calor no es posible debido a la inestabilidad de la formulaci\u00f3n o la incompatibilidad del tipo de envase, se debe optar por un m\u00e9todo alternativo de esterilizaci\u00f3n que incluya filtraci\u00f3n y/o procesamiento as\u00e9ptico. Es crucial que cualquier m\u00e9todo alternativo cumpla con las autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Contaminaci\u00f3n Microbiana**:\n   - Se establece que la detecci\u00f3n de unidades contaminadas durante la producci\u00f3n requiere acciones espec\u00edficas. Para lotes de m\u00e1s de 10,000 unidades, una unidad contaminada debe ser investigada y dos unidades contaminadas justifican la revalidaci\u00f3n.\n\n2. **Validaci\u00f3n de Procesos**:\n   - Es crucial que cualquier proceso de validaci\u00f3n no comprometa la calidad y la seguridad del producto. Se enfatiza la importancia de investigar incidentes de contaminaci\u00f3n para asegurar la esterilidad de los lotes producidos.\n\n3. **Monitoreo del Agua**:\n   - Las fuentes de agua y el equipo de tratamiento deben ser monitoreados regularmente para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas. Se requiere mantener registros de los resultados y acciones tomadas.\n\n4. **Pr\u00e1cticas en \u00c1reas Limpias**:\n   - Se deben minimizar las actividades y controlar el movimiento del personal en \u00e1reas limpias, especialmente durante operaciones as\u00e9pticas, para reducir el riesgo de contaminaci\u00f3n. Se recomienda excluir al personal de zonas de Grado A y mantener condiciones ambientales adecuadas.\n\n5. **Manejo de Componentes y Equipos**:\n   - Los componentes y equipos deben ser manipulados adecuadamente despu\u00e9s de la limpieza final para evitar recontaminaci\u00f3n. Se debe reducir al m\u00ednimo el tiempo entre los procesos de lavado, secado, esterilizaci\u00f3n y uso.\n\n6. **Preparaci\u00f3n de Soluciones**:\n   - El tiempo entre la preparaci\u00f3n de una soluci\u00f3n y su esterilizaci\u00f3n o filtraci\u00f3n debe ser lo m\u00e1s corto posible, estableciendo un tiempo m\u00e1ximo permisible basado en la composici\u00f3n del producto y las condiciones de almacenamiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Contaminaci\u00f3n Microbiana**: Problema cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n- **Agua**: Elemento esencial que debe ser monitoreado para asegurar la calidad.\n- **\u00c1reas Limpias**: Espacios donde se llevan a cabo operaciones as\u00e9pticas que requieren estrictas medidas de control.\n- **Componentes y Equipos**: Elementos que deben ser manejados con cuidado para mantener la esterilidad.\n\nEste resumen destaca la importancia de la gesti\u00f3n de la contaminaci\u00f3n y la validaci\u00f3n de procesos en la producci\u00f3n farmac\u00e9utica, as\u00ed como las medidas necesarias para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: bioburden, sterilization, aseptic processing, contamination control, validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "01e722a5-b8de-4775-b4f2-b325f1be6565", "node_type": "4", "metadata": {"page_label": "284", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n4.36 The bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n4.37 Components, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n4.38 The efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.\n\n# 5. Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c29e9500b8bc48d69b5e97ee18b6878124a895f7681741e588b26dd0315d5c70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n4.36 The bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n4.37 Components, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n4.38 The efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.\n\n# 5. Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2747, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "db5a0b0c-34fd-4e26-aadb-22d1cd057f66": {"__data__": {"id_": "db5a0b0c-34fd-4e26-aadb-22d1cd057f66", "embedding": null, "metadata": {"page_label": "285", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nshould include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer's instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.\n\n5.8 There should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9 Validated loading patterns should be established for all sterilization processes.\n\n5.10 Sterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1 Each heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre los procesos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, enfatizando la importancia de validar todos los m\u00e9todos de esterilizaci\u00f3n, asegurando que se cumplan los est\u00e1ndares microbiol\u00f3gicos y que se mantengan registros precisos de cada ciclo de esterilizaci\u00f3n. Se menciona la necesidad de utilizar indicadores biol\u00f3gicos como m\u00e9todo adicional de monitoreo y la importancia de etiquetar claramente los productos esterilizados y no esterilizados. Tambi\u00e9n se destaca la necesidad de establecer patrones de carga validados y de registrar cada ciclo de esterilizaci\u00f3n con equipos precisos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para validar un proceso de esterilizaci\u00f3n que no se alinea con los est\u00e1ndares farmacopoeicos?**\n   - Esta pregunta busca detalles sobre los criterios de validaci\u00f3n que se deben considerar cuando un m\u00e9todo de esterilizaci\u00f3n no sigue las normas establecidas, lo cual no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de registros se deben mantener para cada ciclo de esterilizaci\u00f3n y c\u00f3mo deben ser aprobados en el procedimiento de liberaci\u00f3n de lotes?**\n   - Esta pregunta se centra en la naturaleza espec\u00edfica de los registros requeridos y el proceso de aprobaci\u00f3n, que podr\u00eda no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la transferencia de contaminaci\u00f3n microbiana al utilizar indicadores biol\u00f3gicos en el proceso de esterilizaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las precauciones pr\u00e1cticas que deben implementarse al usar indicadores biol\u00f3gicos, un aspecto que puede no estar ampliamente cubierto en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Biocarga y Monitoreo**:\n   - Importancia de monitorear la biocarga antes de la esterilizaci\u00f3n.\n   - Establecimiento de l\u00edmites de trabajo relacionados con la eficiencia del m\u00e9todo de esterilizaci\u00f3n.\n   - Realizaci\u00f3n de ensayos de biocarga en cada lote de productos llenados as\u00e9pticamente y productos esterilizados terminalmente.\n\n2. **Filtraci\u00f3n y Esterilizaci\u00f3n**:\n   - Uso de filtros esterilizantes para gases y soluciones, especialmente en fluidos de infusi\u00f3n de gran volumen.\n   - Recomendaci\u00f3n de pasar soluciones a trav\u00e9s de filtros que retengan microorganismos antes del llenado.\n\n3. **Esterilizaci\u00f3n de Componentes**:\n   - Necesidad de esterilizar componentes, contenedores y equipos en \u00e1reas limpias.\n   - Uso de esterilizadores de doble extremo para minimizar la contaminaci\u00f3n.\n\n4. **Validaci\u00f3n de Procedimientos**:\n   - Validaci\u00f3n de la eficacia de nuevos procedimientos de procesamiento y repetici\u00f3n de la validaci\u00f3n a intervalos regulares o tras cambios significativos.\n\n5. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - Preferencia por la esterilizaci\u00f3n terminal por calor en el envase final, cuando sea posible.\n   - Alternativas a la esterilizaci\u00f3n por calor incluyen m\u00e9todos como calor h\u00famedo, radiaci\u00f3n ionizante, \u00f3xido de etileno y filtraci\u00f3n.\n   - Consideraciones sobre la estabilidad de formulaciones y compatibilidad de envases al elegir m\u00e9todos alternativos.\n\n6. **Contaminaci\u00f3n Microbiana**:\n   - Necesidad de mantener la contaminaci\u00f3n microbiana de los materiales de partida al m\u00ednimo y monitorear la biocarga antes de la esterilizaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Biocarga**: Concepto relacionado con la carga microbiana en productos antes de la esterilizaci\u00f3n.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Calor, radiaci\u00f3n ionizante, \u00f3xido de etileno, filtraci\u00f3n.\n- **Esterilizadores de Doble Extremo**: Equipos recomendados para introducir materiales en \u00e1reas limpias.\n- **Validaci\u00f3n**: Proceso necesario para asegurar la eficacia de los procedimientos de esterilizaci\u00f3n y procesamiento.", "excerpt_keywords": "Keywords: sterilization, validation, microbiological quality, biological indicators, batch-release procedure"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b371a2ed-a0ea-4ef3-9a4d-e2aaa9fba7d3", "node_type": "4", "metadata": {"page_label": "285", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nshould include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer's instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.\n\n5.8 There should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9 Validated loading patterns should be established for all sterilization processes.\n\n5.10 Sterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1 Each heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5e7a086c7caaad3d0e6a3dd3aa939ae0854c592250fb915089beeb1a7c2ab4da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "should include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer's instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.\n\n5.8 There should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9 Validated loading patterns should be established for all sterilization processes.\n\n5.10 Sterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1 Each heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2505, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c3327aef-df58-4257-8a21-8190ebd5de14": {"__data__": {"id_": "c3327aef-df58-4257-8a21-8190ebd5de14", "embedding": null, "metadata": {"page_label": "286", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2 Sufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3 After the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n**Sterilization by moist heat**\n\n6.4 Both temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator. The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Monitoreo y Control del Proceso de Esterilizaci\u00f3n**: El proceso de esterilizaci\u00f3n debe ser monitoreado utilizando tanto temperatura como presi\u00f3n, con la necesidad de contar con instrumentos de control y monitoreo independientes. Se enfatiza la importancia de validar los sistemas automatizados y realizar pruebas de fugas en las c\u00e1maras de esterilizaci\u00f3n.\n\n2. **Preparaci\u00f3n y Manejo de Cargas Esterilizadas**: Se deben tomar precauciones para evitar la contaminaci\u00f3n de las cargas esterilizadas durante el enfriamiento. Los art\u00edculos a esterilizar deben estar envueltos en materiales que permitan la penetraci\u00f3n del vapor y la eliminaci\u00f3n del aire, y se debe asegurar que el vapor utilizado sea de calidad adecuada.\n\n3. **Requisitos de Calidad del Vapor**: El vapor utilizado para la esterilizaci\u00f3n debe ser analizado para asegurar que cumpla con est\u00e1ndares qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas, y no debe contener aditivos que puedan contaminar los productos o equipos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que la carga alcance la temperatura requerida antes de iniciar la medici\u00f3n del tiempo de esterilizaci\u00f3n?**\n   - Se debe permitir un tiempo suficiente para que toda la carga alcance la temperatura requerida, y este tiempo debe ser determinado para cada tipo de carga a procesar.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas que debe tener el material de envoltura de los art\u00edculos a esterilizar?**\n   - El material debe permitir la eliminaci\u00f3n del aire y la penetraci\u00f3n de vapor, pero debe prevenir la recontaminaci\u00f3n despu\u00e9s de la esterilizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de an\u00e1lisis se debe realizar para asegurar la calidad del vapor utilizado en el proceso de esterilizaci\u00f3n?**\n   - Se debe realizar un an\u00e1lisis qu\u00edmico, microbiol\u00f3gico y de endotoxinas del condensado, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor, que incluya aspectos como sequedad, sobrecalentamiento y gases no condensables.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Procesos de Esterilizaci\u00f3n**: Todos los procesos de esterilizaci\u00f3n deben ser validados, especialmente si no cumplen con los est\u00e1ndares farmacopoeicos o nacionales. Se requiere demostrar la idoneidad del m\u00e9todo para el producto y su eficacia en alcanzar las condiciones de esterilizaci\u00f3n deseadas.\n\n2. **Monitoreo y Registros**: Es esencial mantener registros precisos de cada ciclo de esterilizaci\u00f3n, que deben ser verificados al menos anualmente y cada vez que se realicen modificaciones significativas en el equipo. Estos registros son parte del procedimiento de liberaci\u00f3n de lotes.\n\n3. **Indicadores Biol\u00f3gicos**: Los indicadores biol\u00f3gicos son un m\u00e9todo adicional para monitorear el proceso de esterilizaci\u00f3n. Deben ser utilizados y almacenados seg\u00fan las instrucciones del fabricante, y se deben tomar precauciones estrictas para evitar la transferencia de contaminaci\u00f3n microbiana.\n\n4. **Etiquetado de Productos**: Los productos esterilizados y no esterilizados deben ser claramente diferenciados mediante etiquetado que incluya el nombre del material, el n\u00famero de lote y el estado de esterilizaci\u00f3n. Se pueden usar indicadores como cinta de autoclave, aunque no son una garant\u00eda de esterilidad.\n\n5. **Patrones de Carga Validados**: Se deben establecer patrones de carga validados para todos los procesos de esterilizaci\u00f3n, asegurando que todo el material reciba el tratamiento requerido.\n\n6. **Ciclo de Esterilizaci\u00f3n por Calor**: Cada ciclo de esterilizaci\u00f3n por calor debe ser registrado utilizando equipos precisos, como gr\u00e1ficos de tiempo/temperatura.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Est\u00e1ndares Farmacopoeicos**: Normas que gu\u00edan los procesos de esterilizaci\u00f3n.\n- **Indicadores Biol\u00f3gicos**: Herramientas para monitorear la eficacia de la esterilizaci\u00f3n.\n- **Registros de Esterilizaci\u00f3n**: Documentaci\u00f3n necesaria para cada ciclo de esterilizaci\u00f3n.\n- **Cinta de Autoclave**: Indicador visual utilizado en procesos de esterilizaci\u00f3n. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el monitoreo y el etiquetado en los procesos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad microbiol\u00f3gica.", "excerpt_keywords": "Sterilization, Monitoring, Validation, Steam Quality, Contamination"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "833de9f9-151d-4b36-83ee-8fae5c6ceed7", "node_type": "4", "metadata": {"page_label": "286", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2 Sufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3 After the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n**Sterilization by moist heat**\n\n6.4 Both temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator. The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "664a5101ab41bda5a7a22bce8afec100637e9179f606d9cba03b41f6946e1145", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2 Sufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3 After the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n**Sterilization by moist heat**\n\n6.4 Both temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator. The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2704, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "12897d53-0be0-4c16-9174-ccc133af46b7": {"__data__": {"id_": "12897d53-0be0-4c16-9174-ccc133af46b7", "embedding": null, "metadata": {"page_label": "287", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization by Dry Heat\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n# Sterilization by Radiation\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n# Sterilization by Gases and Fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre diferentes m\u00e9todos de esterilizaci\u00f3n utilizados en la industria farmac\u00e9utica, espec\u00edficamente la esterilizaci\u00f3n por calor seco, radiaci\u00f3n y gases/fumigantes. Se enfatiza la importancia de validar los procesos de esterilizaci\u00f3n, asegurando que se cumplan los requisitos espec\u00edficos para cada m\u00e9todo. Se mencionan aspectos t\u00e9cnicos como la circulaci\u00f3n de aire, el uso de filtros, la medici\u00f3n de dosis de radiaci\u00f3n y la prevenci\u00f3n de confusiones entre materiales irradiados y no irradiados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de productos son m\u00e1s adecuados para la esterilizaci\u00f3n por calor seco y qu\u00e9 condiciones deben cumplirse durante este proceso?**\n   - La esterilizaci\u00f3n por calor seco es adecuada para l\u00edquidos no acuosos o productos en polvo seco. Durante este proceso, es esencial mantener la circulaci\u00f3n de aire dentro de la c\u00e1mara y mantener una presi\u00f3n positiva para evitar la entrada de aire no est\u00e9ril. Si se suministra aire, debe pasar a trav\u00e9s de un filtro que retenga microorganismos, como un filtro HEPA.\n\n2. **\u00bfCu\u00e1les son los requisitos de validaci\u00f3n para la esterilizaci\u00f3n por radiaci\u00f3n, especialmente si se realiza a trav\u00e9s de un contratista externo?**\n   - Si la esterilizaci\u00f3n por radiaci\u00f3n es realizada por un contratista externo, el fabricante es responsable de garantizar que se cumplan los requisitos establecidos en la secci\u00f3n 6.8 y que el proceso de esterilizaci\u00f3n est\u00e9 validado. Esto incluye confirmar experimentalmente que no hay efectos perjudiciales en el producto debido a la radiaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar la confusi\u00f3n entre materiales irradiados y no irradiados durante el manejo de productos?**\n   - Se deben implementar procedimientos de manejo de materiales que prevengan cualquier confusi\u00f3n entre materiales irradiados y no irradiados. Cada paquete debe llevar un indicador sensible a la radiaci\u00f3n que muestre si ha sido sometido a tratamiento de radiaci\u00f3n. Adem\u00e1s, es importante que la dosis total de radiaci\u00f3n se administre dentro de un per\u00edodo predeterminado.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo y Control del Proceso de Esterilizaci\u00f3n**:\n   - Importancia de registrar la temperatura en el punto m\u00e1s fresco de la carga.\n   - Necesidad de contar con registros de esterilizaci\u00f3n aprobados como parte del procedimiento de liberaci\u00f3n de lotes.\n   - Uso de indicadores qu\u00edmicos o biol\u00f3gicos como complemento, pero no como sustituto de controles f\u00edsicos.\n\n2. **Preparaci\u00f3n y Manejo de Cargas Esterilizadas**:\n   - Permitir tiempo suficiente para que toda la carga alcance la temperatura requerida antes de iniciar la medici\u00f3n del tiempo de esterilizaci\u00f3n.\n   - Precauciones contra la contaminaci\u00f3n durante el enfriamiento de cargas esterilizadas.\n\n3. **Esterilizaci\u00f3n por Calor H\u00famedo**:\n   - Monitoreo del proceso mediante temperatura y presi\u00f3n, con instrumentos de control y monitoreo independientes.\n   - Validaci\u00f3n de sistemas automatizados y realizaci\u00f3n de pruebas de fugas en c\u00e1maras de esterilizaci\u00f3n.\n   - Requisitos para el material de envoltura de los art\u00edculos a esterilizar.\n\n4. **Calidad del Vapor**:\n   - An\u00e1lisis qu\u00edmico, microbiol\u00f3gico y de endotoxinas del vapor utilizado para la esterilizaci\u00f3n.\n   - Evaluaci\u00f3n f\u00edsica del vapor, incluyendo sequedad, sobrecalentamiento y gases no condensables.\n\n### Entidades:\n\n- **Instrumentos de Monitoreo**: Probes, chart recorders.\n- **Materiales de Envoltura**: Materiales que permiten la penetraci\u00f3n de vapor y eliminaci\u00f3n de aire.\n- **Contenedores**: Contenedores de acero inoxidable autoclavables.\n- **Calidad del Vapor**: An\u00e1lisis de condensado, caracter\u00edsticas f\u00edsicas del vapor.\n- **Registros de Esterilizaci\u00f3n**: Documentaci\u00f3n de cada ciclo de esterilizaci\u00f3n.\n\nEste resumen abarca los aspectos esenciales del proceso de esterilizaci\u00f3n, enfatizando la importancia del monitoreo, la preparaci\u00f3n adecuada de las cargas y la calidad del vapor utilizado.", "excerpt_keywords": "Keywords: sterilization, dry heat, radiation, validation, pharmaceutical"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a720a272-803d-46e1-bfb3-8446e3cf24fe", "node_type": "4", "metadata": {"page_label": "287", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization by Dry Heat\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n# Sterilization by Radiation\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n# Sterilization by Gases and Fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e875a8653e069ed4acb9ee9a647919b972683985f2d8ab07ec40bccb0b231874", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Sterilization by Dry Heat\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n# Sterilization by Radiation\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n# Sterilization by Gases and Fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2578, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5872b667-0fbf-46a9-87bd-ea6dbe0253e2": {"__data__": {"id_": "5872b667-0fbf-46a9-87bd-ea6dbe0253e2", "embedding": null, "metadata": {"page_label": "288", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.15\nVarious gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n# 6.16\nDirect contact between gas and microorganisms is essential; precautions should, therefore, be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n# 6.17\nBefore exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n# 6.18\nEach sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed throughout the load. The information thus obtained should form part of the batch record.\n\n# 6.19\nBiological indicators should be stored and used according to the manufacturer\u2019s instructions and their performance checked by positive controls.\n\n# 6.20\nFor each sterilization cycle, records should be made of the time taken to complete the cycle, of the pressure, temperature and humidity within the chamber during the process and of the gas concentration. The pressure and temperature should be recorded on a chart throughout the cycle. The records should form part of the batch record.\n\n# 6.21\nAfter sterilization, the load should be stored in a controlled manner in ventilated conditions to allow concentrations of residual gas and reaction products to fall to their prescribed levels. This process should be validated.\n\n# 7. Aseptic processing and sterilization by filtration\n\n## 7.1\nThe objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n## 7.2\nThe operating conditions should be such as to prevent microbial contamination.\n\n## 7.3\nIn order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **M\u00e9todos de esterilizaci\u00f3n**: Se describen varios m\u00e9todos de esterilizaci\u00f3n, incluyendo el uso de gases como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno. Se enfatiza la importancia de validar el proceso para asegurar que no haya efectos da\u00f1inos en el producto y que los niveles de residuos sean aceptables.\n\n2. **Monitoreo y control del proceso**: Se establece la necesidad de monitorear cada ciclo de esterilizaci\u00f3n utilizando indicadores biol\u00f3gicos y de mantener registros detallados de las condiciones del proceso, como presi\u00f3n, temperatura y concentraci\u00f3n de gas.\n\n3. **Procesamiento as\u00e9ptico**: Se aborda el objetivo del procesamiento as\u00e9ptico, que es mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados. Se subraya la importancia de prevenir la contaminaci\u00f3n microbiana durante este proceso.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse durante la validaci\u00f3n del proceso de esterilizaci\u00f3n con \u00f3xido de etileno?**\n   - La validaci\u00f3n del proceso debe demostrar que el gas no tiene efectos da\u00f1inos en el producto y que las condiciones y el tiempo de desgasificaci\u00f3n son adecuados para reducir los residuos de gas y productos de reacci\u00f3n a niveles aceptables, que deben estar especificados.\n\n2. **\u00bfQu\u00e9 precauciones deben tomarse para asegurar el contacto directo entre el gas y los microorganismos durante la esterilizaci\u00f3n?**\n   - Es esencial evitar la presencia de organismos que puedan estar encerrados en materiales como cristales o prote\u00ednas secas, ya que esto puede afectar la eficacia del proceso de esterilizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe registrarse durante cada ciclo de esterilizaci\u00f3n y por qu\u00e9 es importante?**\n   - Se deben registrar el tiempo de ciclo, la presi\u00f3n, la temperatura, la humedad dentro de la c\u00e1mara y la concentraci\u00f3n de gas. Esta informaci\u00f3n es crucial para formar parte del registro del lote y para asegurar que el proceso se ha llevado a cabo de acuerdo con las especificaciones establecidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - **Esterilizaci\u00f3n por Calor Seco**:\n     - Adecuada para l\u00edquidos no acuosos y productos en polvo seco.\n     - Requiere circulaci\u00f3n de aire y presi\u00f3n positiva en la c\u00e1mara.\n     - Uso de filtros (ej. HEPA) para evitar entrada de aire no est\u00e9ril.\n     - Pruebas de desaf\u00edo con endotoxinas necesarias si se busca eliminar pir\u00f3genos.\n\n   - **Esterilizaci\u00f3n por Radiaci\u00f3n**:\n     - Principalmente para materiales y productos sensibles al calor.\n     - Se debe confirmar experimentalmente que no hay efectos perjudiciales en el producto.\n     - No se acepta la irradiaci\u00f3n ultravioleta para esterilizaci\u00f3n terminal.\n     - Responsabilidad del fabricante de validar el proceso si se realiza por un contratista externo.\n     - Medici\u00f3n de la dosis de radiaci\u00f3n con dos\u00edmetros que deben estar en n\u00famero suficiente y calibrados.\n     - Indicadores sensibles a la radiaci\u00f3n deben estar presentes en cada paquete para evitar confusiones.\n\n   - **Esterilizaci\u00f3n por Gases y Fumigantes**:\n     - Solo se debe utilizar para productos terminados cuando no hay alternativas adecuadas.\n\n2. **Validaci\u00f3n y Procedimientos**:\n   - Importancia de la validaci\u00f3n de los procesos de esterilizaci\u00f3n.\n   - Consideraci\u00f3n de variaciones en la densidad de los paquetes durante la validaci\u00f3n.\n   - Procedimientos de manejo de materiales para prevenir confusiones entre materiales irradiados y no irradiados.\n\n3. **Entidades Clave**:\n   - **Filtros HEPA**: Utilizados para mantener la esterilidad del aire.\n   - **Dos\u00edmetros**: Dispositivos para medir la dosis de radiaci\u00f3n recibida por los productos.\n   - **Indicadores Sensibles a la Radiaci\u00f3n**: Se\u00f1alan si un paquete ha sido sometido a tratamiento de radiaci\u00f3n.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para garantizar la eficacia y seguridad de los m\u00e9todos de esterilizaci\u00f3n en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: sterilization, ethylene oxide, biological indicators, aseptic processing, gas concentration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "82b87288-e773-4512-9416-9b1c7bcde0de", "node_type": "4", "metadata": {"page_label": "288", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.15\nVarious gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n# 6.16\nDirect contact between gas and microorganisms is essential; precautions should, therefore, be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n# 6.17\nBefore exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n# 6.18\nEach sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed throughout the load. The information thus obtained should form part of the batch record.\n\n# 6.19\nBiological indicators should be stored and used according to the manufacturer\u2019s instructions and their performance checked by positive controls.\n\n# 6.20\nFor each sterilization cycle, records should be made of the time taken to complete the cycle, of the pressure, temperature and humidity within the chamber during the process and of the gas concentration. The pressure and temperature should be recorded on a chart throughout the cycle. The records should form part of the batch record.\n\n# 6.21\nAfter sterilization, the load should be stored in a controlled manner in ventilated conditions to allow concentrations of residual gas and reaction products to fall to their prescribed levels. This process should be validated.\n\n# 7. Aseptic processing and sterilization by filtration\n\n## 7.1\nThe objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n## 7.2\nThe operating conditions should be such as to prevent microbial contamination.\n\n## 7.3\nIn order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "22f3c731610cc977faaf566b61b535cd3a5e7ec2e9658ff7b999b33676afedeb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.15\nVarious gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n# 6.16\nDirect contact between gas and microorganisms is essential; precautions should, therefore, be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n# 6.17\nBefore exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n# 6.18\nEach sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed throughout the load. The information thus obtained should form part of the batch record.\n\n# 6.19\nBiological indicators should be stored and used according to the manufacturer\u2019s instructions and their performance checked by positive controls.\n\n# 6.20\nFor each sterilization cycle, records should be made of the time taken to complete the cycle, of the pressure, temperature and humidity within the chamber during the process and of the gas concentration. The pressure and temperature should be recorded on a chart throughout the cycle. The records should form part of the batch record.\n\n# 6.21\nAfter sterilization, the load should be stored in a controlled manner in ventilated conditions to allow concentrations of residual gas and reaction products to fall to their prescribed levels. This process should be validated.\n\n# 7. Aseptic processing and sterilization by filtration\n\n## 7.1\nThe objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n## 7.2\nThe operating conditions should be such as to prevent microbial contamination.\n\n## 7.3\nIn order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2538, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f315fa59-f714-4257-9e26-5cee763bcdf6": {"__data__": {"id_": "f315fa59-f714-4257-9e26-5cee763bcdf6", "embedding": null, "metadata": {"page_label": "289", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the environment;  \n\u2014 personnel;  \n\u2014 critical surfaces;  \n\u2014 container/closure sterilization and transfer procedures;  \n\u2014 the maximum holding period of the product before filling into the final container; and  \n\u2014 the sterilizing filter.  \n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is preferred.\n\n7.5 Owing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n7.6 The fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n7.7 The integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n7.8 The same filter should not be used for more than one working day unless such use has been validated.\n\n7.9 The filter should not affect the product either by removing ingredients from it or by releasing substances into it.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl texto proporciona directrices sobre la filtraci\u00f3n y esterilizaci\u00f3n de soluciones y l\u00edquidos en el contexto de la producci\u00f3n farmac\u00e9utica. Se discuten los m\u00e9todos de filtraci\u00f3n, la importancia de la integridad de los filtros, y se enfatiza que la filtraci\u00f3n no debe ser el \u00fanico m\u00e9todo de esterilizaci\u00f3n cuando es posible utilizar la esterilizaci\u00f3n en el contenedor final. Tambi\u00e9n se mencionan las caracter\u00edsticas de los filtros, la verificaci\u00f3n de su integridad y las precauciones necesarias para su uso.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas que deben tener los filtros utilizados en el proceso de filtraci\u00f3n de soluciones y l\u00edquidos?**\n   - Respuesta: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas (pr\u00e1cticamente cero) y no deben contener asbesto bajo ninguna circunstancia.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para verificar la integridad de un filtro esterilizado antes y despu\u00e9s de su uso?**\n   - Respuesta: La integridad del filtro debe ser verificada antes de su uso y confirmada inmediatamente despu\u00e9s mediante m\u00e9todos apropiados como la prueba de punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar en cuenta al utilizar filtros en condiciones de trabajo severas, como la circulaci\u00f3n de aire a alta temperatura?**\n   - Respuesta: Se debe considerar un aumento en la monitorizaci\u00f3n de la integridad del filtro en procesos que involucran condiciones severas, como la circulaci\u00f3n de aire a alta temperatura, para asegurar su eficacia y seguridad.", "prev_section_summary": "### Temas Clave:\n\n1. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - Uso de gases como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno.\n   - Importancia de la validaci\u00f3n del proceso para asegurar que no haya efectos da\u00f1inos en el producto y que los residuos de gas se mantengan dentro de l\u00edmites aceptables.\n\n2. **Monitoreo del Proceso**:\n   - Necesidad de monitorear cada ciclo de esterilizaci\u00f3n con indicadores biol\u00f3gicos.\n   - Registro de condiciones del proceso (tiempo, presi\u00f3n, temperatura, humedad y concentraci\u00f3n de gas) como parte del registro del lote.\n\n3. **Condiciones de Contacto**:\n   - Importancia del contacto directo entre el gas y los microorganismos.\n   - Precauciones para evitar la presencia de organismos encerrados en materiales que puedan afectar la esterilizaci\u00f3n.\n\n4. **Almacenamiento Post-Esterilizaci\u00f3n**:\n   - Carga esterilizada debe ser almacenada en condiciones controladas para permitir que los residuos de gas y productos de reacci\u00f3n caigan a niveles prescritos.\n\n5. **Procesamiento Aseptic**:\n   - Objetivo de mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados.\n   - Prevenci\u00f3n de la contaminaci\u00f3n microbiana durante el procesamiento as\u00e9ptico.\n\n### Entidades:\n\n- **Gases/Fumigantes**: \u00d3xido de etileno, vapor de per\u00f3xido de hidr\u00f3geno.\n- **Indicadores Biol\u00f3gicos**: Herramientas para monitorear la eficacia de la esterilizaci\u00f3n.\n- **Condiciones de Proceso**: Humedad, temperatura, presi\u00f3n, concentraci\u00f3n de gas.\n- **Componentes**: Elementos que se ensamblan en el producto final y que deben ser esterilizados previamente.\n- **Registros**: Documentaci\u00f3n necesaria para validar el proceso de esterilizaci\u00f3n y asegurar su cumplimiento con las especificaciones.", "excerpt_keywords": "filtration, sterilization, integrity, pharmaceutical, microorganisms"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b509ef7d-c8d7-4ee5-a41d-aabd5f2a9290", "node_type": "4", "metadata": {"page_label": "289", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the environment;  \n\u2014 personnel;  \n\u2014 critical surfaces;  \n\u2014 container/closure sterilization and transfer procedures;  \n\u2014 the maximum holding period of the product before filling into the final container; and  \n\u2014 the sterilizing filter.  \n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is preferred.\n\n7.5 Owing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n7.6 The fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n7.7 The integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n7.8 The same filter should not be used for more than one working day unless such use has been validated.\n\n7.9 The filter should not affect the product either by removing ingredients from it or by releasing substances into it.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cef1d55d020500f49d523cffa63202cf828d3f6af7fedabc550767ad573b5f84", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 the environment;  \n\u2014 personnel;  \n\u2014 critical surfaces;  \n\u2014 container/closure sterilization and transfer procedures;  \n\u2014 the maximum holding period of the product before filling into the final container; and  \n\u2014 the sterilizing filter.  \n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is preferred.\n\n7.5 Owing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n7.6 The fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n7.7 The integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n7.8 The same filter should not be used for more than one working day unless such use has been validated.\n\n7.9 The filter should not affect the product either by removing ingredients from it or by releasing substances into it.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2470, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "20c2267b-66d4-4c39-80df-bc61724d8140": {"__data__": {"id_": "20c2267b-66d4-4c39-80df-bc61724d8140", "embedding": null, "metadata": {"page_label": "290", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8. Isolator technology\n\n8.1 The use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n8.2 The transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.\n\n8.3 The air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least Grade D.\n\n8.4 Isolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 Monitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 Blow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective Grade A air shower may be installed in at least a Grade C environment, provided that Grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a Grade D environment.\n\n9.2 Because of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda tecnolog\u00edas de aislamiento y de llenado/sellado, destacando la importancia de minimizar la intervenci\u00f3n humana en \u00e1reas de procesamiento para reducir el riesgo de contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente. Se discuten los dise\u00f1os de los aisladores, la clasificaci\u00f3n del aire necesaria para el entorno de fondo, la validaci\u00f3n de los sistemas de aislamiento y la monitorizaci\u00f3n continua para garantizar la integridad del proceso.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para la validaci\u00f3n de los aisladores en el contexto de la fabricaci\u00f3n as\u00e9ptica?**\n   - Esta pregunta busca detalles sobre los factores cr\u00edticos que se deben considerar durante la validaci\u00f3n de los aisladores, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de dise\u00f1o de transferencias se recomienda para minimizar la contaminaci\u00f3n durante el proceso de transferencia de materiales en un aislador?**\n   - Esta pregunta se centra en los dise\u00f1os espec\u00edficos de dispositivos de transferencia que son m\u00e1s efectivos para reducir el riesgo de contaminaci\u00f3n, un aspecto que puede no estar ampliamente discutido en otros documentos.\n\n3. **\u00bfQu\u00e9 requisitos de calidad del aire son necesarios para el entorno de fondo de un aislador utilizado en procesamiento as\u00e9ptico?**\n   - Esta pregunta busca informaci\u00f3n sobre la clasificaci\u00f3n del aire y los est\u00e1ndares espec\u00edficos que deben cumplirse en el entorno de fondo de un aislador, lo cual es crucial para garantizar la seguridad del proceso de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Filtraci\u00f3n y Esterilizaci\u00f3n**: Se discuten m\u00e9todos de filtraci\u00f3n para soluciones y l\u00edquidos que no pueden ser esterilizados en el contenedor final. Se recomienda el uso de filtros est\u00e9riles con un tama\u00f1o de poro nominal de 0.22 micrones o menos.\n\n2. **Complemento de Procesos**: Se sugiere complementar la filtraci\u00f3n con tratamiento t\u00e9rmico, ya que la filtraci\u00f3n sola no es suficiente cuando la esterilizaci\u00f3n en el contenedor final es posible. La esterilizaci\u00f3n por vapor es el m\u00e9todo preferido.\n\n3. **Integridad de los Filtros**: La integridad de los filtros debe ser verificada antes y despu\u00e9s de su uso mediante m\u00e9todos como pruebas de punto de burbuja, flujo difusivo o pruebas de retenci\u00f3n de presi\u00f3n. Se deben registrar los resultados en el registro de lote.\n\n4. **Caracter\u00edsticas de los Filtros**: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas y no deben contener asbesto. Se recomienda el uso de una doble capa de filtraci\u00f3n o una segunda filtraci\u00f3n antes del llenado para mitigar riesgos adicionales.\n\n5. **Condiciones Severas**: En procesos que involucran condiciones severas, como la circulaci\u00f3n de aire a alta temperatura, se debe aumentar la monitorizaci\u00f3n de la integridad del filtro.\n\n6. **Uso de Filtros**: No se debe utilizar el mismo filtro por m\u00e1s de un d\u00eda laboral a menos que su uso haya sido validado. Adem\u00e1s, los filtros no deben afectar el producto, ya sea eliminando ingredientes o liberando sustancias en \u00e9l.\n\n### Entidades Clave\n- **Filtros**: Est\u00e9riles, con tama\u00f1o de poro de 0.22 micrones o menos, caracter\u00edsticas de desprendimiento de fibras m\u00ednimas, sin asbesto.\n- **M\u00e9todos de Verificaci\u00f3n**: Prueba de punto de burbuja, flujo difusivo, prueba de retenci\u00f3n de presi\u00f3n.\n- **Condiciones de Trabajo**: Circulaci\u00f3n de aire a alta temperatura.\n- **Procesos de Esterilizaci\u00f3n**: Filtraci\u00f3n, esterilizaci\u00f3n en el contenedor final, esterilizaci\u00f3n por vapor.", "excerpt_keywords": "Keywords: isolator technology, aseptic processing, microbial contamination, air quality classification, blow/fill/seal technology"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "04f62060-dd08-4c9d-8476-60cc3659d39f", "node_type": "4", "metadata": {"page_label": "290", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8. Isolator technology\n\n8.1 The use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n8.2 The transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.\n\n8.3 The air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least Grade D.\n\n8.4 Isolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 Monitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 Blow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective Grade A air shower may be installed in at least a Grade C environment, provided that Grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a Grade D environment.\n\n9.2 Because of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2473fd45df3f7f771d71b8b7ffd96eff2dab3e8fa32d7b7102617c3a95d43615", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 8. Isolator technology\n\n8.1 The use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n8.2 The transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.\n\n8.3 The air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least Grade D.\n\n8.4 Isolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 Monitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 Blow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective Grade A air shower may be installed in at least a Grade C environment, provided that Grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a Grade D environment.\n\n9.2 Because of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2488, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "918c61e7-8776-4bf3-a483-6501a1fe6385": {"__data__": {"id_": "918c61e7-8776-4bf3-a483-6501a1fe6385", "embedding": null, "metadata": {"page_label": "291", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n10.1 Only the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 All personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to Grade B and C rooms. For every worker in a Grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS establece directrices sobre el personal que trabaja en \u00e1reas limpias y en la fabricaci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de mantener un n\u00famero m\u00ednimo de personal en estas \u00e1reas, la necesidad de formaci\u00f3n regular en higiene y microbiolog\u00eda, y la implementaci\u00f3n de procedimientos rigurosos de descontaminaci\u00f3n. Tambi\u00e9n se abordan las normas de higiene personal, el uso adecuado de vestimenta y la prohibici\u00f3n de ropa exterior en \u00e1reas cr\u00edticas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n deben recibir los empleados que trabajan en \u00e1reas limpias y cu\u00e1les son los temas clave que deben abarcar?**\n   - Los empleados deben recibir formaci\u00f3n inicial y regular en disciplinas relevantes para la fabricaci\u00f3n correcta de productos est\u00e9riles, incluyendo higiene y los elementos b\u00e1sicos de microbiolog\u00eda.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si se requiere la entrada de personal externo no capacitado en \u00e1reas est\u00e9riles?**\n   - Se debe tener especial cuidado en la instrucci\u00f3n y supervisi\u00f3n de estos trabajadores externos, asegurando que comprendan los procedimientos y riesgos asociados.\n\n3. **\u00bfCu\u00e1les son las recomendaciones sobre la vestimenta y el cambio de ropa para el personal que trabaja en \u00e1reas de grado A/B?**\n   - Se deben proporcionar prendas protectoras limpias y est\u00e9riles para cada sesi\u00f3n de trabajo, y se proh\u00edbe la entrada de ropa exterior en los vestuarios que conducen a las salas de grado B y C. Adem\u00e1s, los guantes deben desinfectarse regularmente durante la producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Tecnolog\u00eda de Aisladores**:\n   - **Objetivo**: Minimizar la intervenci\u00f3n humana en \u00e1reas de procesamiento para reducir el riesgo de contaminaci\u00f3n microbiana en productos as\u00e9pticos.\n   - **Dise\u00f1os**: Existen diversos dise\u00f1os de aisladores y dispositivos de transferencia, que pueden incluir sistemas de una o dos puertas y mecanismos de esterilizaci\u00f3n.\n   - **Contaminaci\u00f3n**: La transferencia de materiales es una de las principales fuentes de contaminaci\u00f3n; el \u00e1rea dentro del aislador es considerada de alto riesgo.\n   - **Clasificaci\u00f3n del aire**: El entorno de fondo debe cumplir con una clasificaci\u00f3n de aire controlada, siendo al menos de Grado D para procesamiento as\u00e9ptico.\n   - **Validaci\u00f3n**: Los aisladores deben ser validados considerando factores cr\u00edticos como la calidad del aire, la sanitizaci\u00f3n, el proceso de transferencia y la integridad del aislador.\n   - **Monitoreo**: Se requiere monitoreo rutinario, incluyendo pruebas de fugas del aislador y del sistema de guantes/mangas.\n\n2. **Tecnolog\u00eda de Blow/Fill/Seal**:\n   - **Descripci\u00f3n**: M\u00e1quinas dise\u00f1adas para formar, llenar y sellar contenedores en una operaci\u00f3n continua.\n   - **Entorno de instalaci\u00f3n**: Equipos para producci\u00f3n as\u00e9ptica deben estar en un entorno de al menos Grado C, con ropa de Grado A o B, y cumplir con l\u00edmites viables y no viables.\n   - **Requisitos para productos esterilizados**: Equipos para productos que se esterilizan terminalmente deben estar en un entorno de al menos Grado D.\n   - **Atenci\u00f3n especial**: Se debe prestar atenci\u00f3n al dise\u00f1o y calificaci\u00f3n del equipo.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Aisladores**: Dispositivos utilizados para crear un entorno controlado.\n- **Dispositivos de transferencia**: Sistemas para mover materiales dentro y fuera de los aisladores.\n- **Clasificaci\u00f3n del aire**: Est\u00e1ndares de calidad del aire (Grado D, Grado C, Grado A, Grado B).\n- **Equipos Blow/Fill/Seal**: M\u00e1quinas espec\u00edficas para el llenado y sellado de productos.", "excerpt_keywords": "Keywords: personnel, sterile products, hygiene training, contamination control, clean areas"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21c4b7c1-2ca2-41f1-839d-a13aa2dea394", "node_type": "4", "metadata": {"page_label": "291", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n10.1 Only the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 All personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to Grade B and C rooms. For every worker in a Grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dc68813f58eb50ad1b8cd6dd04d7d7565b97b533152a545b82f2b947ea3b76ae", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Personnel\n\n10.1 Only the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 All personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to Grade B and C rooms. For every worker in a Grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during production.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2129, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3c394d04-c360-45b5-afe0-d72f9d779f02": {"__data__": {"id_": "3c394d04-c360-45b5-afe0-d72f9d779f02", "embedding": null, "metadata": {"page_label": "292", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10.7\n\nWrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n# 10.8\n\nThe clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n- **Grades A and B.** Entry of personnel into Grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and with a high neck, should be worn. The headgear should be tucked into the neck of the suit. A facemask should be worn to prevent the shedding of droplets. Sterilized, non-powdered gloves of appropriate material and sterilized or disinfected footwear should be worn. Trouser-bottoms should be tucked inside the footwear and garment sleeves into the gloves. The protective clothing should shed virtually no fibres or particulate matter and should retain particles shed by the body.\n\n# 10.9\n\nClothing used in clean areas should be laundered or cleaned in such a way that it does not gather additional particulate contaminants that can later be shed. Separate laundry facilities for such clothing are desirable. If fibres are damaged by inappropriate cleaning or sterilization, there may be an increased risk of shedding particles. Washing and sterilization operations should follow standard operating procedures.\n\n# 11. Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la vestimenta y las condiciones de los locales en \u00e1reas limpias, que son esenciales para minimizar la contaminaci\u00f3n y la acumulaci\u00f3n de part\u00edculas. Se especifican los requisitos de vestimenta para diferentes grados de limpieza (A, B, C y D), as\u00ed como las caracter\u00edsticas de las instalaciones para asegurar un ambiente controlado y limpio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas de la vestimenta requerida para el personal que trabaja en \u00e1reas de Grado A y B, y por qu\u00e9 son importantes estas caracter\u00edsticas?**\n   - Respuesta: El personal en \u00e1reas de Grado A y B debe usar un traje de una sola pieza que se ajuste en las mu\u00f1ecas y el cuello, con un gorro que cubra completamente el cabello y, si es necesario, la barba y el bigote. Tambi\u00e9n deben usar una mascarilla, guantes esterilizados y calzado desinfectado. Estas caracter\u00edsticas son importantes para evitar la liberaci\u00f3n de part\u00edculas y microorganismos al ambiente, manteniendo as\u00ed la integridad del \u00e1rea limpia.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para el lavado y la limpieza de la ropa utilizada en \u00e1reas limpias, y por qu\u00e9 es crucial seguir estas medidas?**\n   - Respuesta: La ropa utilizada en \u00e1reas limpias debe ser lavada o limpiada de manera que no recoja contaminantes adicionales que puedan ser liberados posteriormente. Se recomienda tener instalaciones de lavander\u00eda separadas para esta ropa. Es crucial seguir estas medidas porque si las fibras se da\u00f1an por una limpieza inapropiada, puede aumentar el riesgo de liberaci\u00f3n de part\u00edculas contaminantes.\n\n3. **\u00bfC\u00f3mo deben estar dise\u00f1adas las instalaciones de las \u00e1reas limpias para minimizar la entrada de personal no esencial y facilitar la observaci\u00f3n de las operaciones?**\n   - Respuesta: Las instalaciones deben ser dise\u00f1adas para evitar la entrada innecesaria de personal de supervisi\u00f3n o control. En particular, las \u00e1reas de Grado A y B deben estar configuradas de tal manera que todas las operaciones puedan ser observadas desde el exterior, lo que ayuda a mantener la integridad del ambiente limpio y reduce el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **N\u00famero M\u00ednimo de Personal:** Se debe mantener solo el personal necesario en \u00e1reas limpias, especialmente durante procesos as\u00e9pticos, y las inspecciones deben realizarse desde el exterior cuando sea posible.\n\n2. **Formaci\u00f3n del Personal:** Todos los empleados en \u00e1reas limpias deben recibir formaci\u00f3n inicial y continua en higiene y microbiolog\u00eda. Se debe prestar especial atenci\u00f3n a la instrucci\u00f3n y supervisi\u00f3n de personal externo no capacitado.\n\n3. **Descontaminaci\u00f3n:** El personal que haya trabajado con materiales de tejido animal o microorganismos diferentes a los utilizados en el proceso actual no debe ingresar a \u00e1reas est\u00e9riles sin seguir procedimientos de descontaminaci\u00f3n rigurosos.\n\n4. **Higiene Personal:** Se requieren altos est\u00e1ndares de higiene personal, y el personal debe informar sobre condiciones que puedan causar contaminaci\u00f3n. Se recomiendan chequeos de salud peri\u00f3dicos.\n\n5. **Procedimientos de Cambio y Lavado:** Deben seguirse procedimientos escritos para minimizar la contaminaci\u00f3n de la ropa de \u00e1rea limpia. La vestimenta debe ser adecuada para el proceso y el grado del \u00e1rea de trabajo.\n\n6. **Vestimenta en \u00c1reas Cr\u00edticas:** No se debe permitir la entrada de ropa exterior en vestuarios que conducen a salas de grado B y C. Se deben proporcionar prendas protectoras limpias y est\u00e9riles para cada sesi\u00f3n de trabajo, y los guantes deben desinfectarse regularmente.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **\u00c1reas Limpias:** Espacios donde se fabrican productos est\u00e9riles.\n- **Personal:** Empleados involucrados en la fabricaci\u00f3n, limpieza y mantenimiento en \u00e1reas limpias.\n- **Grados de \u00c1reas:** Clasificaci\u00f3n de \u00e1reas (A, B, C) seg\u00fan su nivel de limpieza y requisitos de control de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: clean areas, protective clothing, contamination control, sterilization procedures, hygiene standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6c1e64b-255c-48f4-85a7-5cc6b741bd50", "node_type": "4", "metadata": {"page_label": "292", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10.7\n\nWrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n# 10.8\n\nThe clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n- **Grades A and B.** Entry of personnel into Grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and with a high neck, should be worn. The headgear should be tucked into the neck of the suit. A facemask should be worn to prevent the shedding of droplets. Sterilized, non-powdered gloves of appropriate material and sterilized or disinfected footwear should be worn. Trouser-bottoms should be tucked inside the footwear and garment sleeves into the gloves. The protective clothing should shed virtually no fibres or particulate matter and should retain particles shed by the body.\n\n# 10.9\n\nClothing used in clean areas should be laundered or cleaned in such a way that it does not gather additional particulate contaminants that can later be shed. Separate laundry facilities for such clothing are desirable. If fibres are damaged by inappropriate cleaning or sterilization, there may be an increased risk of shedding particles. Washing and sterilization operations should follow standard operating procedures.\n\n# 11. Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "524093ad519780fdb7effca261edca99f60503590384b74d7b961e26336040fa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 10.7\n\nWrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n# 10.8\n\nThe clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n- **Grades A and B.** Entry of personnel into Grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and with a high neck, should be worn. The headgear should be tucked into the neck of the suit. A facemask should be worn to prevent the shedding of droplets. Sterilized, non-powdered gloves of appropriate material and sterilized or disinfected footwear should be worn. Trouser-bottoms should be tucked inside the footwear and garment sleeves into the gloves. The protective clothing should shed virtually no fibres or particulate matter and should retain particles shed by the body.\n\n# 10.9\n\nClothing used in clean areas should be laundered or cleaned in such a way that it does not gather additional particulate contaminants that can later be shed. Separate laundry facilities for such clothing are desirable. If fibres are damaged by inappropriate cleaning or sterilization, there may be an increased risk of shedding particles. Washing and sterilization operations should follow standard operating procedures.\n\n# 11. Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2261, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "66a5c9f3-e91f-478c-9d3f-ffa2a9f7c42a": {"__data__": {"id_": "66a5c9f3-e91f-478c-9d3f-ffa2a9f7c42a", "embedding": null, "metadata": {"page_label": "293", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 \nTo reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n# 11.4 \nFalse ceilings should be sealed to prevent contamination from the void space above them.\n\n# 11.5 \nPipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n# 11.6 \nSinks and drains should be avoided wherever possible and should be excluded from Grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n# 11.7 \nChanging rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a Grade D passage can lead to a Grade C airlock, which leads to a Grade B changing room, which leads to a Grade B clean room. Changing rooms should be of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n# 11.8 \nAirlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n# 11.9 \nA filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el dise\u00f1o y mantenimiento de \u00e1reas limpias y entornos controlados, enfatizando la importancia de minimizar la acumulaci\u00f3n de polvo y la contaminaci\u00f3n microbiana. Se abordan aspectos como el dise\u00f1o de puertas, la instalaci\u00f3n de techos falsos, la ubicaci\u00f3n de tuber\u00edas y desag\u00fces, el dise\u00f1o de vestuarios como \u00e1reas de aire de separaci\u00f3n, y la necesidad de un suministro de aire filtrado para mantener la presi\u00f3n positiva. Tambi\u00e9n se menciona la importancia de evitar cambios de grado inadecuados entre \u00e1reas y la implementaci\u00f3n de sistemas de interbloqueo para las puertas de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las puertas en \u00e1reas limpias para evitar la acumulaci\u00f3n de polvo y facilitar la limpieza?**\n   - Respuesta: Las puertas deben estar dise\u00f1adas para evitar recovecos inalcanzables, preferiblemente deben ser puertas oscilantes que abran hacia el lado de alta presi\u00f3n y contar con mecanismos de cierre autom\u00e1tico.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en el dise\u00f1o de los vestuarios para minimizar la contaminaci\u00f3n microbiana y particulada?**\n   - Respuesta: Los vestuarios deben ser dise\u00f1ados como aire de separaci\u00f3n, deben ser eficaces en el flujo de aire filtrado, y no debe haber un cambio de m\u00e1s de un grado entre los pasillos y los vestuarios. Adem\u00e1s, deben ser lo suficientemente amplios y contar con espejos para que el personal pueda verificar el ajuste de la vestimenta.\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al instalar desag\u00fces y fregaderos en \u00e1reas de alta clasificaci\u00f3n?**\n   - Respuesta: Los fregaderos y desag\u00fces deben evitarse en \u00e1reas de Grado A y B, y si se instalan, deben estar dise\u00f1ados y mantenidos para minimizar el riesgo de contaminaci\u00f3n microbiana, incluyendo trampas de f\u00e1cil limpieza y sistemas de ruptura de aire para prevenir el retroceso.", "prev_section_summary": "### Temas Clave\n\n1. **Vestimenta en \u00c1reas Limpias:**\n   - Prohibici\u00f3n de relojes, cosm\u00e9ticos y joyas.\n   - Requisitos espec\u00edficos de vestimenta para diferentes grados de limpieza (A, B, C y D).\n   - Importancia de la vestimenta para minimizar la contaminaci\u00f3n y la liberaci\u00f3n de part\u00edculas.\n\n2. **Limpieza y Mantenimiento de Ropa:**\n   - Procedimientos para el lavado y limpieza de la ropa utilizada en \u00e1reas limpias.\n   - Necesidad de instalaciones de lavander\u00eda separadas.\n   - Riesgos asociados con la limpieza inapropiada que puede da\u00f1ar las fibras.\n\n3. **Dise\u00f1o de Instalaciones:**\n   - Dise\u00f1o de locales para evitar la entrada innecesaria de personal no esencial.\n   - Observaci\u00f3n de operaciones desde el exterior en \u00e1reas de Grado A y B.\n   - Caracter\u00edsticas de las superficies en \u00e1reas limpias para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Grados de Limpieza:** Clasificaci\u00f3n de \u00e1reas (A, B, C, D) con requisitos espec\u00edficos de vestimenta y dise\u00f1o.\n- **Personal:** Trabajadores que deben cumplir con las normativas de vestimenta y limpieza.\n- **Superficies Expuestas:** Elementos del dise\u00f1o de instalaciones que deben ser lisos e impermeables.\n- **Procedimientos Operativos Est\u00e1ndar:** Normas que deben seguirse para el lavado y esterilizaci\u00f3n de la ropa. \n\nEste resumen destaca la importancia de las directrices de vestimenta y dise\u00f1o de instalaciones en la prevenci\u00f3n de la contaminaci\u00f3n en \u00e1reas limpias, as\u00ed como los procedimientos necesarios para mantener la integridad de estas \u00e1reas.", "excerpt_keywords": "Keywords: cleanroom design, contamination control, airlock systems, aseptic operations, filtered air supply"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6646fe25-720d-4a5a-9b1d-df14f4ab3d56", "node_type": "4", "metadata": {"page_label": "293", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 \nTo reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n# 11.4 \nFalse ceilings should be sealed to prevent contamination from the void space above them.\n\n# 11.5 \nPipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n# 11.6 \nSinks and drains should be avoided wherever possible and should be excluded from Grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n# 11.7 \nChanging rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a Grade D passage can lead to a Grade C airlock, which leads to a Grade B changing room, which leads to a Grade B clean room. Changing rooms should be of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n# 11.8 \nAirlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n# 11.9 \nA filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b3985082f0c6473b339db07a8b5a75e6e23eec8d5633a21d58370f9d31b2495e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11.3 \nTo reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n# 11.4 \nFalse ceilings should be sealed to prevent contamination from the void space above them.\n\n# 11.5 \nPipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n# 11.6 \nSinks and drains should be avoided wherever possible and should be excluded from Grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n# 11.7 \nChanging rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a Grade D passage can lead to a Grade C airlock, which leads to a Grade B changing room, which leads to a Grade B clean room. Changing rooms should be of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n# 11.8 \nAirlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n# 11.9 \nA filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2837, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e4d08e75-a422-44df-956e-93d1cb614c66": {"__data__": {"id_": "e4d08e75-a422-44df-956e-93d1cb614c66", "embedding": null, "metadata": {"page_label": "294", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\nof different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas where this difference is important, and the pressure differentials should be regularly recorded and failure alarmed.\n\n11.12 Consideration should be given to restricting unnecessary access to critical filling areas, e.g. Grade A filling zones, by means of a physical barrier.\n\n## 12. Equipment\n\n12.1 A conveyor belt should not pass through a partition between a Grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones sobre el control de la contaminaci\u00f3n en \u00e1reas limpias**: El documento establece directrices sobre c\u00f3mo mantener la calidad del aire y prevenir la contaminaci\u00f3n en \u00e1reas de procesamiento de productos est\u00e9riles. Se enfatiza la importancia de las diferencias de presi\u00f3n, el flujo de aire y la restricci\u00f3n de acceso a zonas cr\u00edticas.\n\n2. **Mantenimiento y esterilizaci\u00f3n de equipos**: Se detallan las mejores pr\u00e1cticas para el mantenimiento de equipos en \u00e1reas limpias, incluyendo la necesidad de esterilizaci\u00f3n de herramientas y equipos, as\u00ed como la importancia de realizar operaciones de mantenimiento fuera de estas \u00e1reas siempre que sea posible.\n\n3. **Equipos y sistemas de soporte**: Se menciona la importancia de seleccionar equipos que puedan ser esterilizados efectivamente y la necesidad de sistemas de manejo de aire y filtraci\u00f3n para mantener la calidad del aire en \u00e1reas de procesamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el mantenimiento de equipos dentro de un \u00e1rea limpia y qu\u00e9 procedimientos deben seguirse para garantizar la limpieza y la asepsia?**\n   - El documento indica que, al realizar mantenimiento dentro de un \u00e1rea limpia, se deben utilizar instrumentos y herramientas limpias, y el \u00e1rea debe ser limpiada y desinfectada nuevamente antes de reanudar el procesamiento, si no se han mantenido los est\u00e1ndares requeridos de limpieza y/o asepsia.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los patrones de flujo de aire no representen un riesgo de contaminaci\u00f3n en \u00e1reas de mayor riesgo de producto?**\n   - Se debe demostrar que los patrones de flujo de aire no presentan un riesgo de contaminaci\u00f3n, asegurando que las part\u00edculas generadas por personas, operaciones o m\u00e1quinas no se transporten a zonas de mayor riesgo de producto.\n\n3. **\u00bfQu\u00e9 tipo de equipos se recomienda utilizar para el procesamiento de productos est\u00e9riles y cu\u00e1les son las consideraciones para su instalaci\u00f3n y mantenimiento?**\n   - Se recomienda elegir equipos que puedan ser esterilizados efectivamente por m\u00e9todos como vapor o calor seco. Adem\u00e1s, los accesorios y servicios del equipo deben ser dise\u00f1ados para permitir operaciones, mantenimiento y reparaciones fuera del \u00e1rea limpia, y cualquier equipo que deba ser desensamblado para mantenimiento debe ser re-esterilizado despu\u00e9s de su reensamblaje.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de \u00c1reas Limpias**:\n   - Importancia de evitar recovecos inalcanzables y superficies dif\u00edciles de limpiar.\n   - Recomendaciones sobre el dise\u00f1o de puertas (puertas oscilantes, cierre autom\u00e1tico).\n\n2. **Techos Falsos**:\n   - Necesidad de sellar techos falsos para prevenir la contaminaci\u00f3n desde el espacio superior.\n\n3. **Instalaci\u00f3n de Tuber\u00edas y Ductos**:\n   - Deben evitarse recovecos y aberturas sin sellar.\n   - Uso de tuber\u00edas sanitarias y evitar conexiones roscadas.\n\n4. **Sistemas de Saneamiento**:\n   - Evitar fregaderos y desag\u00fces en \u00e1reas de Grado A y B.\n   - Si se instalan, deben minimizar el riesgo de contaminaci\u00f3n microbiana.\n\n5. **Dise\u00f1o de Vestuarios**:\n   - Deben funcionar como aire de separaci\u00f3n para minimizar la contaminaci\u00f3n.\n   - Importancia de un flujo de aire filtrado y la correcta clasificaci\u00f3n de \u00e1reas.\n\n6. **Interbloqueo de Puertas**:\n   - Sistemas para evitar la apertura simult\u00e1nea de puertas de aire.\n\n7. **Suministro de Aire Filtrado**:\n   - Mantener presi\u00f3n positiva y flujo de aire adecuado en \u00e1reas controladas.\n\n### Entidades Clave\n- **Grados de Clasificaci\u00f3n**: Grado A, B, C, D.\n- **Elementos de Dise\u00f1o**: Puertas, techos falsos, tuber\u00edas, fregaderos, vestuarios.\n- **Contaminaci\u00f3n Microbiana**: Riesgos asociados y medidas de mitigaci\u00f3n.\n- **Sistemas de Aire**: Filtraci\u00f3n y presi\u00f3n positiva. \n\nEste resumen destaca la importancia de un dise\u00f1o cuidadoso y la implementaci\u00f3n de medidas espec\u00edficas para mantener la limpieza y la seguridad en entornos controlados.", "excerpt_keywords": "Keywords: clean areas, sterilization, air quality, contamination control, equipment maintenance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f87a4bd3-a097-4637-b479-b625edca762c", "node_type": "4", "metadata": {"page_label": "294", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\nof different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas where this difference is important, and the pressure differentials should be regularly recorded and failure alarmed.\n\n11.12 Consideration should be given to restricting unnecessary access to critical filling areas, e.g. Grade A filling zones, by means of a physical barrier.\n\n## 12. Equipment\n\n12.1 A conveyor belt should not pass through a partition between a Grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b11ef29c0a923587d04ec7864df89353a5da6275863707ae4a0d9dc86dd2d69a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Equipment\n\nof different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas where this difference is important, and the pressure differentials should be regularly recorded and failure alarmed.\n\n11.12 Consideration should be given to restricting unnecessary access to critical filling areas, e.g. Grade A filling zones, by means of a physical barrier.\n\n## 12. Equipment\n\n12.1 A conveyor belt should not pass through a partition between a Grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2556, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "05e2c9db-6f03-4415-944c-dea324052c8b": {"__data__": {"id_": "05e2c9db-6f03-4415-944c-dea324052c8b", "embedding": null, "metadata": {"page_label": "295", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finishing of Sterile Products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g., glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.\n\n13.2 The container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n13.3 As the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n13.4 Vial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by Grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a Grade A air supply until the cap has been crimped.\n\n13.5 Vials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n13.6 Restricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n13.7 Containers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n13.8 Filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para el acabado de productos est\u00e9riles, centr\u00e1ndose en la integridad de los envases, el proceso de cierre de viales, y las medidas de control para minimizar la contaminaci\u00f3n microbiana. Se enfatiza la importancia de utilizar m\u00e9todos validados para cerrar los envases, la necesidad de realizar pruebas de integridad, y las condiciones de trabajo adecuadas para asegurar la calidad del producto final.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas de integridad se deben realizar en los envases cerrados por fusi\u00f3n, como ampollas de vidrio o pl\u00e1stico?**\n   - Respuesta: Los envases cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para el cierre de viales despu\u00e9s de la inserci\u00f3n del tap\u00f3n?**\n   - Respuesta: El crimpado de la tapa debe realizarse lo antes posible despu\u00e9s de la inserci\u00f3n del tap\u00f3n para asegurar que el sistema de cierre del envase sea completamente integral.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para minimizar la contaminaci\u00f3n microbiana durante el proceso de capping de viales?**\n   - Respuesta: Se deben utilizar tecnolog\u00edas apropiadas para evitar el contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana, adem\u00e1s de considerar el uso de barreras de acceso restringido y aisladores para asegurar las condiciones requeridas.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre el acabado de productos est\u00e9riles, destacando la importancia de m\u00e9todos validados para el cierre de envases, la realizaci\u00f3n de pruebas de integridad, y el control de la contaminaci\u00f3n microbiana durante el proceso de capping. Se enfatiza la necesidad de proteger los viales en condiciones de calidad adecuadas y de rechazar aquellos con tapones faltantes o desplazados antes del cierre.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Contaminaci\u00f3n en \u00c1reas Limpias**: Se enfatiza la importancia de mantener diferencias de presi\u00f3n y patrones de flujo de aire adecuados para prevenir la contaminaci\u00f3n en zonas de alto riesgo, especialmente en \u00e1reas de procesamiento de productos est\u00e9riles.\n\n2. **Mantenimiento y Esterilizaci\u00f3n de Equipos**: Se establecen directrices sobre el mantenimiento de equipos en \u00e1reas limpias, destacando la necesidad de utilizar herramientas limpias y de desinfectar el \u00e1rea despu\u00e9s de cualquier trabajo de mantenimiento.\n\n3. **Selecci\u00f3n y Dise\u00f1o de Equipos**: Se recomienda elegir equipos que puedan ser esterilizados eficazmente y que est\u00e9n dise\u00f1ados para facilitar el mantenimiento fuera de las \u00e1reas limpias.\n\n4. **Sistemas de Alerta y Monitoreo**: Se sugiere implementar sistemas de advertencia para detectar fallos en el suministro de aire y registrar las diferencias de presi\u00f3n entre \u00e1reas cr\u00edticas.\n\n### Entidades\n\n- **\u00c1reas Limpias**: Clasificadas como Grado A y B, donde se procesan productos est\u00e9riles.\n- **Equipos**: Incluyen cintas transportadoras, esterilizadores, sistemas de manejo de aire y filtraci\u00f3n, y sistemas de tratamiento de agua.\n- **Materiales**: Pat\u00f3genos, t\u00f3xicos, radiactivos, y productos virales o bacterianos vivos.\n- **Procedimientos de Mantenimiento**: Uso de instrumentos limpios, limpieza y desinfecci\u00f3n del \u00e1rea, re-esterilizaci\u00f3n de equipos desensamblados.\n- **Sistemas de Monitoreo**: Indicadores de presi\u00f3n diferencial y sistemas de advertencia para fallos en el suministro de aire.", "excerpt_keywords": "Keywords: sterile products, container integrity, vial capping, microbial contamination, aseptic processing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24880c04-83f7-4990-93d7-fc302649b66d", "node_type": "4", "metadata": {"page_label": "295", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finishing of Sterile Products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g., glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.\n\n13.2 The container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n13.3 As the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n13.4 Vial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by Grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a Grade A air supply until the cap has been crimped.\n\n13.5 Vials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n13.6 Restricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n13.7 Containers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n13.8 Filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a98516853be277aca8d13d0f163a21e18ee3b41bab1acc7121a74cab6cd99f70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Finishing of Sterile Products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g., glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.\n\n13.2 The container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n13.3 As the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n13.4 Vial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by Grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a Grade A air supply until the cap has been crimped.\n\n13.5 Vials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n13.6 Restricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n13.7 Containers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n13.8 Filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1860, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2a1d7c0f-814b-45bb-8c31-cff45bc41183": {"__data__": {"id_": "2a1d7c0f-814b-45bb-8c31-cff45bc41183", "embedding": null, "metadata": {"page_label": "296", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902), Annex 6; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; and in Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. ISO 14644-1. Clean rooms and associated controlled environments. Part 1: Classification of airborne particles. Geneva, International Organization for Standardization.\n\n3. ISO 14644-3. Clean rooms and associated controlled environments. Part 3: Test methods. Geneva, International Organization for Standardization.\n\n4. ISO 1822-4. High efficiency air filters (HEPA and ULPA). Determining leakage of filter elements (scan method).\n\n5. ISO 14644-4. Clean rooms and associated controlled environments. Part 4: Design, construction and start-up. Geneva, International Organization for Standardization.\n\n6. ISO 14644-2. Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1. Geneva, International Organization for Standardization.\n\n7. ISO 14644-5 Clean rooms and associated controlled environments. Part 5: Cleanroom operations. Geneva, International Organization for Standardization.\n\n8. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 3; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n# Further reading\n\n- FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n- Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n- Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos est\u00e9riles. Incluye referencias a normas internacionales, como las de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO), que abordan la clasificaci\u00f3n de part\u00edculas en salas limpias, m\u00e9todos de prueba, dise\u00f1o y operaci\u00f3n de estas instalaciones. Tambi\u00e9n se mencionan directrices adicionales de la FDA y regulaciones de la Uni\u00f3n Europea sobre la fabricaci\u00f3n de productos medicinales est\u00e9riles.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales normas ISO mencionadas en el documento y qu\u00e9 aspectos de las salas limpias abordan?**\n   - Esta pregunta busca respuestas sobre las normas ISO espec\u00edficas y su enfoque en la clasificaci\u00f3n, pruebas y operaci\u00f3n de salas limpias, que son cruciales para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n2. **\u00bfQu\u00e9 se incluye en las buenas pr\u00e1cticas de fabricaci\u00f3n para el agua utilizada en productos farmac\u00e9uticos seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en las directrices espec\u00edficas sobre el uso del agua en la fabricaci\u00f3n de productos farmac\u00e9uticos, un aspecto cr\u00edtico que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 diferencias existen entre las directrices de la FDA y las de la OMS en relaci\u00f3n con la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta busca explorar las variaciones en las regulaciones y directrices entre dos de las principales organizaciones de salud, lo que puede proporcionar una comprensi\u00f3n m\u00e1s profunda de las pr\u00e1cticas de fabricaci\u00f3n en diferentes contextos regulatorios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **M\u00e9todos de Cierre de Envases**:\n   - Importancia de utilizar m\u00e9todos validados para cerrar los envases.\n   - Pruebas de integridad al 100% para envases cerrados por fusi\u00f3n (ampollas de vidrio o pl\u00e1stico).\n\n2. **Cierre de Viales**:\n   - El sistema de cierre de viales no es completamente integral hasta que la tapa de aluminio est\u00e9 crimpada.\n   - El crimpado debe realizarse lo antes posible despu\u00e9s de la inserci\u00f3n del tap\u00f3n.\n\n3. **Control de Contaminaci\u00f3n**:\n   - Equipos de crimpado deben estar en estaciones separadas con adecuada extracci\u00f3n de aire para minimizar part\u00edculas no viables.\n   - Uso de tecnolog\u00edas para evitar contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana.\n\n4. **Condiciones de Protecci\u00f3n**:\n   - Viales deben ser protegidos bajo condiciones de Grado A hasta que se complete el crimpado.\n   - Barreras de acceso restringido y aisladores pueden ayudar a mantener las condiciones requeridas.\n\n5. **Rechazo de Viales**:\n   - Viales con tapones faltantes o desplazados deben ser rechazados antes del cierre.\n\n6. **Pruebas de Vac\u00edo**:\n   - Envases sellados al vac\u00edo deben ser probados para asegurar el mantenimiento del vac\u00edo despu\u00e9s de un per\u00edodo predeterminado.\n\n7. **Inspecci\u00f3n de Productos Parenterales**:\n   - Inspecci\u00f3n individual de envases llenos para detectar contaminaci\u00f3n extr\u00ednseca o defectos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Envases**: Incluyen ampollas de vidrio y pl\u00e1stico, viales.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar durante el proceso de capping.\n- **Grado A**: Clasificaci\u00f3n de condiciones de aire necesarias para la protecci\u00f3n de viales.\n- **Viales**: Contenedores utilizados para productos est\u00e9riles, especialmente parenterales.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, productos farmac\u00e9uticos est\u00e9riles, salas limpias, normas ISO, regulaci\u00f3n sanitaria"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8f43f4f3-fca5-4d79-8bef-c24ebfe0bf33", "node_type": "4", "metadata": {"page_label": "296", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902), Annex 6; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; and in Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. ISO 14644-1. Clean rooms and associated controlled environments. Part 1: Classification of airborne particles. Geneva, International Organization for Standardization.\n\n3. ISO 14644-3. Clean rooms and associated controlled environments. Part 3: Test methods. Geneva, International Organization for Standardization.\n\n4. ISO 1822-4. High efficiency air filters (HEPA and ULPA). Determining leakage of filter elements (scan method).\n\n5. ISO 14644-4. Clean rooms and associated controlled environments. Part 4: Design, construction and start-up. Geneva, International Organization for Standardization.\n\n6. ISO 14644-2. Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1. Geneva, International Organization for Standardization.\n\n7. ISO 14644-5 Clean rooms and associated controlled environments. Part 5: Cleanroom operations. Geneva, International Organization for Standardization.\n\n8. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 3; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n# Further reading\n\n- FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n- Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n- Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "160c16cc87fa45e972b1b227a69e15e514ac2a2627f96d5e8889efc328a4dbff", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902), Annex 6; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; and in Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. ISO 14644-1. Clean rooms and associated controlled environments. Part 1: Classification of airborne particles. Geneva, International Organization for Standardization.\n\n3. ISO 14644-3. Clean rooms and associated controlled environments. Part 3: Test methods. Geneva, International Organization for Standardization.\n\n4. ISO 1822-4. High efficiency air filters (HEPA and ULPA). Determining leakage of filter elements (scan method).\n\n5. ISO 14644-4. Clean rooms and associated controlled environments. Part 4: Design, construction and start-up. Geneva, International Organization for Standardization.\n\n6. ISO 14644-2. Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1. Geneva, International Organization for Standardization.\n\n7. ISO 14644-5 Clean rooms and associated controlled environments. Part 5: Cleanroom operations. Geneva, International Organization for Standardization.\n\n8. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 3; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n# Further reading\n\n- FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n- Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n- Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2529, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "39383a4f-621f-4401-9797-1eb11f33ffa7": {"__data__": {"id_": "39383a4f-621f-4401-9797-1eb11f33ffa7", "embedding": null, "metadata": {"page_label": "297", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## WHO guidelines on transfer of technology in pharmaceutical manufacturing\n\n1. Introduction\n2. Scope\n3. Glossary\n4. Organization and management\n5. Production: transfer (processing, packaging and cleaning)\n6. Quality control: analytical method transfer\n7. Premises and equipment\n8. Documentation\n9. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una secci\u00f3n titulada \"Anexo 7\", que presenta directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica. Este anexo abarca varios aspectos clave, como la introducci\u00f3n al tema, el alcance de las directrices, un glosario de t\u00e9rminos, la organizaci\u00f3n y gesti\u00f3n del proceso, as\u00ed como detalles sobre la producci\u00f3n, control de calidad, instalaciones y equipos, documentaci\u00f3n, y los procesos de calificaci\u00f3n y validaci\u00f3n.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales componentes que se abordan en las directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los principales componentes incluyen la introducci\u00f3n, el alcance, un glosario, organizaci\u00f3n y gesti\u00f3n, producci\u00f3n, control de calidad, instalaciones y equipos, documentaci\u00f3n, y calificaci\u00f3n y validaci\u00f3n.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en la secci\u00f3n de \"Producci\u00f3n\" de las directrices sobre transferencia de tecnolog\u00eda?**\n   - Respuesta: La secci\u00f3n de \"Producci\u00f3n\" aborda el proceso de transferencia, que incluye el procesamiento, el empaquetado y la limpieza.\n\n3. **\u00bfQu\u00e9 importancia tiene la \"calificaci\u00f3n y validaci\u00f3n\" en el contexto de la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica seg\u00fan las directrices de la OMS?**\n   - Respuesta: La \"calificaci\u00f3n y validaci\u00f3n\" son cruciales para asegurar que los procesos y equipos utilizados en la fabricaci\u00f3n farmac\u00e9utica cumplen con los est\u00e1ndares de calidad y eficacia requeridos, garantizando as\u00ed la seguridad y efectividad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**:\n   - El documento se centra en las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir directrices espec\u00edficas para garantizar la calidad y seguridad de estos productos.\n\n2. **Normas ISO**:\n   - Se mencionan varias normas de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO) relacionadas con salas limpias y entornos controlados:\n     - **ISO 14644-1**: Clasificaci\u00f3n de part\u00edculas en el aire.\n     - **ISO 14644-2**: Monitoreo para el cumplimiento continuo.\n     - **ISO 14644-3**: M\u00e9todos de prueba.\n     - **ISO 14644-4**: Dise\u00f1o, construcci\u00f3n y puesta en marcha.\n     - **ISO 14644-5**: Operaciones en salas limpias.\n     - **ISO 1822-4**: Determinaci\u00f3n de fugas en filtros de alta eficiencia (HEPA y ULPA).\n\n3. **Agua para Uso Farmac\u00e9utico**:\n   - Se abordan las BPF espec\u00edficas para el agua utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos, subrayando su relevancia en el proceso de producci\u00f3n.\n\n4. **Referencias Adicionales**:\n   - Se incluyen gu\u00edas de la FDA y regulaciones de la Uni\u00f3n Europea sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, lo que proporciona un contexto m\u00e1s amplio sobre las normativas internacionales.\n\n5. **Entidades Involucradas**:\n   - **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y reportes sobre BPF.\n   - **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Establece normas para la clasificaci\u00f3n y operaci\u00f3n de salas limpias.\n   - **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Ofrece gu\u00edas sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n   - **Uni\u00f3n Europea**: Regula las buenas pr\u00e1cticas de fabricaci\u00f3n para productos medicinales.\n\nEste resumen destaca la importancia de las BPF y las normas ISO en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, as\u00ed como las entidades que contribuyen a establecer y regular estas pr\u00e1cticas.", "excerpt_keywords": "Keywords: transfer of technology, pharmaceutical manufacturing, quality control, qualification and validation, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b94f19d-ceac-4f40-a2ad-ff8e943a4d6a", "node_type": "4", "metadata": {"page_label": "297", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## WHO guidelines on transfer of technology in pharmaceutical manufacturing\n\n1. Introduction\n2. Scope\n3. Glossary\n4. Organization and management\n5. Production: transfer (processing, packaging and cleaning)\n6. Quality control: analytical method transfer\n7. Premises and equipment\n8. Documentation\n9. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2ab6e5688433972efe54d64ecaeb7bf5537674208ea4d45a13994453b7dde1b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 7\n\n## WHO guidelines on transfer of technology in pharmaceutical manufacturing\n\n1. Introduction\n2. Scope\n3. Glossary\n4. Organization and management\n5. Production: transfer (processing, packaging and cleaning)\n6. Quality control: analytical method transfer\n7. Premises and equipment\n8. Documentation\n9. Qualification and validation\n\nReferences", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 350, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ec11e5b2-352a-4546-9394-ef3460de2b5f": {"__data__": {"id_": "ec11e5b2-352a-4546-9394-ef3460de2b5f", "embedding": null, "metadata": {"page_label": "298", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThese guiding principles on transfer of technology are intended to serve as a framework which can be applied in a flexible manner rather than as strict rigid guidance. Focus has been placed on the quality aspects, in line with WHO\u2019s mandate.\n\n1.1 Transfer of processes to an alternative site occurs at some stage in the life-cycle of most products, from development, scale-up, manufacturing, production and launch, to the post-approval phase.\n\n1.2 Transfer of technology is defined as \u201ca logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites\u201d. It is a systematic procedure that is followed in order to pass the documented knowledge and experience gained during development and or commercialization to an appropriate, responsible and authorized party. Technology transfer embodies both the transfer of documentation and the demonstrated ability of the receiving unit (RU) to effectively perform the critical elements of the transferred technology, to the satisfaction of all parties and any applicable regulatory bodies.\n\n1.3 Literature searches revealed little information on the subject originating from national or regional regulatory bodies. Guidance on intracompany transfers was prepared by the International Society for Pharmaceutical Engineering (ISPE) (1).\n\n1.4 The ever changing business strategies of pharmaceutical companies increasingly involve intra- and intercompany transfers of technology for reasons such as the need for additional capacity, relocation of operations or consolidations and mergers. The WHO Expert Committee on Specifications for Pharmaceutical Preparations, therefore, recommended in its forty-second report that WHO address this issue through preparation of WHO guidelines on this matter (2).\n\n1.5 Transfer of technology requires a documented, planned approach using trained and knowledgeable personnel working within a quality system, with documentation of data covering all aspects of development, production and quality control. Usually there is a sending unit (SU), a receiving unit and the unit managing the process, which may or may not be a separate entity. For \u201ccontract manufacturing\u201d please see good manufacturing practices (GMP) (3).\n\n1.6 For the transfer to be successful, the following general principles and requirements should be met:\n\n- the project plan should encompass the quality aspects of the project and be based upon the principles of quality risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece principios orientadores sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica. Se define la transferencia de tecnolog\u00eda como un procedimiento l\u00f3gico que controla el traspaso de procesos, documentaci\u00f3n y experiencia profesional entre el desarrollo y la fabricaci\u00f3n, o entre sitios de fabricaci\u00f3n. Se enfatiza la importancia de un enfoque documentado y planificado, el uso de personal capacitado y la necesidad de cumplir con los aspectos de calidad y gesti\u00f3n de riesgos. Adem\u00e1s, se menciona la creciente tendencia de las empresas farmac\u00e9uticas a realizar transferencias intra- e interempresariales debido a cambios en sus estrategias comerciales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los elementos cr\u00edticos que deben ser transferidos durante el proceso de transferencia de tecnolog\u00eda seg\u00fan la OMS?**\n   - Esta pregunta busca detalles sobre los componentes espec\u00edficos que se consideran esenciales en la transferencia de tecnolog\u00eda, m\u00e1s all\u00e1 de la documentaci\u00f3n y la experiencia.\n\n2. **\u00bfQu\u00e9 papel juega la gesti\u00f3n de riesgos de calidad en la planificaci\u00f3n de un proyecto de transferencia de tecnolog\u00eda?**\n   - Esta pregunta se centra en c\u00f3mo se integran los principios de gesti\u00f3n de riesgos de calidad en el desarrollo del plan del proyecto, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 recomendaciones espec\u00edficas hizo el Comit\u00e9 de Expertos de la OMS sobre la transferencia de tecnolog\u00eda en su cuadrag\u00e9simo segundo informe?**\n   - Esta pregunta busca informaci\u00f3n sobre las recomendaciones concretas que la OMS ha hecho en relaci\u00f3n con la transferencia de tecnolog\u00eda, que podr\u00edan no estar disponibles en otros documentos o gu\u00edas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl \"Anexo 7\" del documento \"WHO - Technical Report Series 961\" presenta directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica. Los temas clave abordados en esta secci\u00f3n incluyen:\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n2. **Alcance**: Define los l\u00edmites y la aplicabilidad de las directrices.\n3. **Glosario**: Proporciona definiciones de t\u00e9rminos relevantes utilizados en el documento.\n4. **Organizaci\u00f3n y gesti\u00f3n**: Describe la estructura organizativa y los procesos de gesti\u00f3n necesarios para implementar la transferencia de tecnolog\u00eda.\n5. **Producci\u00f3n**: Detalla el proceso de transferencia en la producci\u00f3n, que incluye el procesamiento, empaquetado y limpieza de productos farmac\u00e9uticos.\n6. **Control de calidad**: Se centra en la transferencia de m\u00e9todos anal\u00edticos para asegurar la calidad de los productos.\n7. **Instalaciones y equipos**: Aborda los requisitos y est\u00e1ndares para las instalaciones y equipos utilizados en la fabricaci\u00f3n.\n8. **Documentaci\u00f3n**: Enfatiza la importancia de la documentaci\u00f3n adecuada en todos los procesos de transferencia.\n9. **Calificaci\u00f3n y validaci\u00f3n**: Explica los procesos necesarios para asegurar que los sistemas y procesos cumplen con los est\u00e1ndares de calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Fabricaci\u00f3n farmac\u00e9utica**: Sector industrial al que se aplican las directrices.\n- **Transferencia de tecnolog\u00eda**: Proceso central del documento que abarca varios aspectos de la producci\u00f3n y control de calidad.\n\nEste resumen destaca los componentes esenciales y las entidades involucradas en las directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica seg\u00fan la OMS.", "excerpt_keywords": "Keywords: technology transfer, pharmaceutical manufacturing, quality management, regulatory guidelines, process documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2c147a2-7f1b-43d0-bdf1-3461e9891d82", "node_type": "4", "metadata": {"page_label": "298", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThese guiding principles on transfer of technology are intended to serve as a framework which can be applied in a flexible manner rather than as strict rigid guidance. Focus has been placed on the quality aspects, in line with WHO\u2019s mandate.\n\n1.1 Transfer of processes to an alternative site occurs at some stage in the life-cycle of most products, from development, scale-up, manufacturing, production and launch, to the post-approval phase.\n\n1.2 Transfer of technology is defined as \u201ca logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites\u201d. It is a systematic procedure that is followed in order to pass the documented knowledge and experience gained during development and or commercialization to an appropriate, responsible and authorized party. Technology transfer embodies both the transfer of documentation and the demonstrated ability of the receiving unit (RU) to effectively perform the critical elements of the transferred technology, to the satisfaction of all parties and any applicable regulatory bodies.\n\n1.3 Literature searches revealed little information on the subject originating from national or regional regulatory bodies. Guidance on intracompany transfers was prepared by the International Society for Pharmaceutical Engineering (ISPE) (1).\n\n1.4 The ever changing business strategies of pharmaceutical companies increasingly involve intra- and intercompany transfers of technology for reasons such as the need for additional capacity, relocation of operations or consolidations and mergers. The WHO Expert Committee on Specifications for Pharmaceutical Preparations, therefore, recommended in its forty-second report that WHO address this issue through preparation of WHO guidelines on this matter (2).\n\n1.5 Transfer of technology requires a documented, planned approach using trained and knowledgeable personnel working within a quality system, with documentation of data covering all aspects of development, production and quality control. Usually there is a sending unit (SU), a receiving unit and the unit managing the process, which may or may not be a separate entity. For \u201ccontract manufacturing\u201d please see good manufacturing practices (GMP) (3).\n\n1.6 For the transfer to be successful, the following general principles and requirements should be met:\n\n- the project plan should encompass the quality aspects of the project and be based upon the principles of quality risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4f635730f257562aa993f9a939359b97226fc5330826a5d41aa3b87cbfcec196", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThese guiding principles on transfer of technology are intended to serve as a framework which can be applied in a flexible manner rather than as strict rigid guidance. Focus has been placed on the quality aspects, in line with WHO\u2019s mandate.\n\n1.1 Transfer of processes to an alternative site occurs at some stage in the life-cycle of most products, from development, scale-up, manufacturing, production and launch, to the post-approval phase.\n\n1.2 Transfer of technology is defined as \u201ca logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites\u201d. It is a systematic procedure that is followed in order to pass the documented knowledge and experience gained during development and or commercialization to an appropriate, responsible and authorized party. Technology transfer embodies both the transfer of documentation and the demonstrated ability of the receiving unit (RU) to effectively perform the critical elements of the transferred technology, to the satisfaction of all parties and any applicable regulatory bodies.\n\n1.3 Literature searches revealed little information on the subject originating from national or regional regulatory bodies. Guidance on intracompany transfers was prepared by the International Society for Pharmaceutical Engineering (ISPE) (1).\n\n1.4 The ever changing business strategies of pharmaceutical companies increasingly involve intra- and intercompany transfers of technology for reasons such as the need for additional capacity, relocation of operations or consolidations and mergers. The WHO Expert Committee on Specifications for Pharmaceutical Preparations, therefore, recommended in its forty-second report that WHO address this issue through preparation of WHO guidelines on this matter (2).\n\n1.5 Transfer of technology requires a documented, planned approach using trained and knowledgeable personnel working within a quality system, with documentation of data covering all aspects of development, production and quality control. Usually there is a sending unit (SU), a receiving unit and the unit managing the process, which may or may not be a separate entity. For \u201ccontract manufacturing\u201d please see good manufacturing practices (GMP) (3).\n\n1.6 For the transfer to be successful, the following general principles and requirements should be met:\n\n- the project plan should encompass the quality aspects of the project and be based upon the principles of quality risk management;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2562, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "19da3a1e-32ce-43f2-b13b-152455619c80": {"__data__": {"id_": "19da3a1e-32ce-43f2-b13b-152455619c80", "embedding": null, "metadata": {"page_label": "299", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the capabilities of the SU and at the RU should be similar, but not necessarily identical, and facilities and equipment should operate according to similar operating principles;\n- a comprehensive technical gap analysis between the SU and RU including technical risk assessment and potential regulatory gaps, should be performed as needed;\n- adequately trained staff should be available or should be trained at the RU:\n  - regulatory requirements in the countries of the SU and the RU, and in any countries where the product is intended to be supplied, should be taken into account and interpreted consistently throughout any transfer programme project; and\n  - there should be effective process and product knowledge transfer.\n\n1.7 Technology transfer can be considered successful if there is documented evidence that the RU can routinely reproduce the transferred product, process or method against a predefined set of specifications as agreed with the SU.\n\n1.8 In the event that the RU identifies particular problems with the process during the transfer, the RU should communicate them back to the SU to ensure continuing knowledge management.\n\n1.9 Technology transfer projects, particularly those between different companies, have legal and economic implications. If such issues, which may include intellectual property rights, royalties, pricing, conflict of interest and confidentiality, are expected to impact on open communication of technical matters in any way, they should be addressed before and during planning and execution of the transfer.\n\n1.10 Any lack of transparency may lead to ineffective transfer of technology.\n\n1.11 Some of the principles outlined in this document may also be applicable to manufacturing investigational pharmaceutical products for clinical trials as part of research and development, but this is not the main focus of this guidance and has been excluded due to the complexity of the processes.\n\n1.12 Some of the responsibilities outlined in this document for the SU may also be considered to be part of the management unit responsibilities.\n\n## 2. Scope\n\n*Note:* This section specifically provides for transfer of quality control (QC) methods where a technical agreement exists (SU manufacturer to RU manufacturer or SU manufacturer to RU QC laboratory). Where no such technical agreements exist (e.g. testing by national laboratories or testing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la transferencia de tecnolog\u00eda entre unidades de fabricaci\u00f3n (SU) y unidades receptoras (RU) en el contexto de productos farmac\u00e9uticos. Se enfatiza la importancia de que las capacidades de ambas unidades sean similares, la necesidad de realizar un an\u00e1lisis de brechas t\u00e9cnicas, y la formaci\u00f3n adecuada del personal en regulaciones pertinentes. Adem\u00e1s, se destaca que la transferencia de tecnolog\u00eda debe ser transparente y que cualquier problema identificado durante el proceso debe ser comunicado para asegurar una gesti\u00f3n del conocimiento efectiva. Tambi\u00e9n se mencionan las implicaciones legales y econ\u00f3micas que pueden surgir durante estos proyectos de transferencia.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 criterios se deben cumplir para considerar exitosa una transferencia de tecnolog\u00eda entre la SU y la RU?**\n   - La transferencia de tecnolog\u00eda se considera exitosa si hay evidencia documentada de que la RU puede reproducir rutinariamente el producto, proceso o m\u00e9todo transferido de acuerdo con un conjunto de especificaciones predefinidas acordadas con la SU.\n\n2. **\u00bfQu\u00e9 tipo de an\u00e1lisis se recomienda realizar entre la SU y la RU antes de iniciar un proyecto de transferencia de tecnolog\u00eda?**\n   - Se recomienda realizar un an\u00e1lisis t\u00e9cnico exhaustivo que incluya una evaluaci\u00f3n de riesgos t\u00e9cnicos y la identificaci\u00f3n de posibles brechas regulatorias.\n\n3. **\u00bfCu\u00e1les son algunas de las implicaciones legales y econ\u00f3micas que deben considerarse durante la transferencia de tecnolog\u00eda?**\n   - Las implicaciones incluyen derechos de propiedad intelectual, regal\u00edas, precios, conflictos de inter\u00e9s y confidencialidad, que deben ser abordados antes y durante la planificaci\u00f3n y ejecuci\u00f3n de la transferencia para asegurar una comunicaci\u00f3n abierta sobre asuntos t\u00e9cnicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de Tecnolog\u00eda**: Se define como un procedimiento l\u00f3gico que controla el traspaso de procesos, documentaci\u00f3n y experiencia profesional entre el desarrollo y la fabricaci\u00f3n, o entre sitios de fabricaci\u00f3n. Es un proceso sistem\u00e1tico que asegura que el conocimiento documentado y la experiencia se transfieran a una parte responsable y autorizada.\n\n2. **Importancia de la Calidad**: El documento enfatiza la necesidad de un enfoque documentado y planificado que utilice personal capacitado dentro de un sistema de calidad. Se destaca que la transferencia de tecnolog\u00eda debe cumplir con los aspectos de calidad y gesti\u00f3n de riesgos.\n\n3. **Estrategias Empresariales**: Se menciona que las empresas farmac\u00e9uticas est\u00e1n adoptando cada vez m\u00e1s estrategias que implican transferencias intra- e interempresariales debido a la necesidad de aumentar la capacidad, reubicar operaciones o realizar consolidaciones y fusiones.\n\n4. **Recomendaciones de la OMS**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 la elaboraci\u00f3n de directrices sobre la transferencia de tecnolog\u00eda en su cuadrag\u00e9simo segundo informe, reconociendo la falta de informaci\u00f3n en este \u00e1mbito por parte de organismos reguladores nacionales o regionales.\n\n5. **Unidades Involucradas**: En el proceso de transferencia, generalmente hay una unidad de env\u00edo (SU), una unidad receptora (RU) y una unidad que gestiona el proceso, que puede ser una entidad separada.\n\n6. **Principios Generales para el \u00c9xito**: Para que la transferencia sea exitosa, el plan del proyecto debe incluir aspectos de calidad y basarse en principios de gesti\u00f3n de riesgos de calidad.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece las directrices sobre la transferencia de tecnolog\u00eda.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Entidad que ha preparado gu\u00edas sobre transferencias intracompany.\n- **Unidades de Transferencia**: Incluyen la unidad de env\u00edo (SU) y la unidad receptora (RU). \n\nEste resumen destaca los aspectos fundamentales de la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, as\u00ed como las recomendaciones y el marco propuesto por la OMS.", "excerpt_keywords": "Keywords: transferencia de tecnolog\u00eda, unidades de fabricaci\u00f3n, an\u00e1lisis de brechas t\u00e9cnicas, implicaciones legales, gesti\u00f3n del conocimiento"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "13a03394-23fc-4f92-92cb-7c5e59177645", "node_type": "4", "metadata": {"page_label": "299", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the capabilities of the SU and at the RU should be similar, but not necessarily identical, and facilities and equipment should operate according to similar operating principles;\n- a comprehensive technical gap analysis between the SU and RU including technical risk assessment and potential regulatory gaps, should be performed as needed;\n- adequately trained staff should be available or should be trained at the RU:\n  - regulatory requirements in the countries of the SU and the RU, and in any countries where the product is intended to be supplied, should be taken into account and interpreted consistently throughout any transfer programme project; and\n  - there should be effective process and product knowledge transfer.\n\n1.7 Technology transfer can be considered successful if there is documented evidence that the RU can routinely reproduce the transferred product, process or method against a predefined set of specifications as agreed with the SU.\n\n1.8 In the event that the RU identifies particular problems with the process during the transfer, the RU should communicate them back to the SU to ensure continuing knowledge management.\n\n1.9 Technology transfer projects, particularly those between different companies, have legal and economic implications. If such issues, which may include intellectual property rights, royalties, pricing, conflict of interest and confidentiality, are expected to impact on open communication of technical matters in any way, they should be addressed before and during planning and execution of the transfer.\n\n1.10 Any lack of transparency may lead to ineffective transfer of technology.\n\n1.11 Some of the principles outlined in this document may also be applicable to manufacturing investigational pharmaceutical products for clinical trials as part of research and development, but this is not the main focus of this guidance and has been excluded due to the complexity of the processes.\n\n1.12 Some of the responsibilities outlined in this document for the SU may also be considered to be part of the management unit responsibilities.\n\n## 2. Scope\n\n*Note:* This section specifically provides for transfer of quality control (QC) methods where a technical agreement exists (SU manufacturer to RU manufacturer or SU manufacturer to RU QC laboratory). Where no such technical agreements exist (e.g. testing by national laboratories or testing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8c6a2e5a60f57a0e92af2f0a7fa099127f5fd4d68dc9ef6ecb8d43a0bc9f1329", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- the capabilities of the SU and at the RU should be similar, but not necessarily identical, and facilities and equipment should operate according to similar operating principles;\n- a comprehensive technical gap analysis between the SU and RU including technical risk assessment and potential regulatory gaps, should be performed as needed;\n- adequately trained staff should be available or should be trained at the RU:\n  - regulatory requirements in the countries of the SU and the RU, and in any countries where the product is intended to be supplied, should be taken into account and interpreted consistently throughout any transfer programme project; and\n  - there should be effective process and product knowledge transfer.\n\n1.7 Technology transfer can be considered successful if there is documented evidence that the RU can routinely reproduce the transferred product, process or method against a predefined set of specifications as agreed with the SU.\n\n1.8 In the event that the RU identifies particular problems with the process during the transfer, the RU should communicate them back to the SU to ensure continuing knowledge management.\n\n1.9 Technology transfer projects, particularly those between different companies, have legal and economic implications. If such issues, which may include intellectual property rights, royalties, pricing, conflict of interest and confidentiality, are expected to impact on open communication of technical matters in any way, they should be addressed before and during planning and execution of the transfer.\n\n1.10 Any lack of transparency may lead to ineffective transfer of technology.\n\n1.11 Some of the principles outlined in this document may also be applicable to manufacturing investigational pharmaceutical products for clinical trials as part of research and development, but this is not the main focus of this guidance and has been excluded due to the complexity of the processes.\n\n1.12 Some of the responsibilities outlined in this document for the SU may also be considered to be part of the management unit responsibilities.\n\n## 2. Scope\n\n*Note:* This section specifically provides for transfer of quality control (QC) methods where a technical agreement exists (SU manufacturer to RU manufacturer or SU manufacturer to RU QC laboratory). Where no such technical agreements exist (e.g. testing by national laboratories or testing", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2388, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa5a13f-550d-45fb-ac55-41488b9658a1": {"__data__": {"id_": "6fa5a13f-550d-45fb-ac55-41488b9658a1", "embedding": null, "metadata": {"page_label": "300", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.1\n\nThis document gives guidance in principle and provides general recommendations on the activities necessary to conduct a successful intra- or intersite transfer of technology as described in the Introduction to these guidelines. The intention is to address the basic considerations needed for a successful transfer in order to satisfy the regulatory authority defined for the transfer process.\n\n# 2.2\n\nThe guidelines will be applied to manufacturing active pharmaceutical ingredients (APIs), manufacturing and packaging of bulk materials, manufacturing and packaging of finished pharmaceutical products (FPPs) and/or performing analytical testing.\n\n# 2.3\n\nThe recommendations provided in these guidelines apply to all dosage forms but need to be adjusted on a case-by-case basis (e.g. by using risk management principles). Particularly close control of certain aspects will be required for certain formulations such as sterile products, and metered-dose aerosols. WHO guidance on manufacture of specific pharmaceutical products (4,5) will be useful in this regard.\n\n# 2.4\n\nThe guidelines address the following areas at the SU and the RU:\n\n- transfer of development and production (processing, packaging and cleaning);\n- transfer of analytical methods for quality assurance and quality control;\n- skills assessment and training;\n- organization and management of the transfer;\n- assessment of premises and equipment;\n- documentation; and\n- qualification and validation.\n\n# 2.5\n\nBecause each transfer project is unique, the provision of a comprehensive set of guidelines is beyond the scope of this document.\n\n# 2.6\n\nThese guidelines do not provide guidance on any legal, financial or commercial considerations associated with technology transfer projects.\n\n# 3. Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**\n\nMeasurable terms under which a test result will be considered acceptable.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices generales para la transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo ingredientes activos, productos en estado bruto y productos farmac\u00e9uticos terminados. Se abordan aspectos clave como la transferencia de m\u00e9todos anal\u00edticos, la evaluaci\u00f3n de habilidades, la gesti\u00f3n del proceso de transferencia, y la documentaci\u00f3n necesaria. Las recomendaciones son aplicables a todas las formas de dosificaci\u00f3n, pero deben adaptarse a cada caso particular, especialmente para productos est\u00e9riles y aerosoles de dosis medida. El documento no cubre consideraciones legales, financieras o comerciales.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los aspectos espec\u00edficos que requieren un control m\u00e1s cercano durante la transferencia de tecnolog\u00eda para productos est\u00e9riles y aerosoles de dosis medida?**\n   - Esta pregunta busca detalles sobre las consideraciones especiales que deben tenerse en cuenta para ciertas formulaciones, que no se abordan en otras partes del documento.\n\n2. **\u00bfQu\u00e9 \u00e1reas espec\u00edficas se deben evaluar en las instalaciones y equipos durante el proceso de transferencia de tecnolog\u00eda seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los criterios de evaluaci\u00f3n de las instalaciones y equipos, que son cruciales para garantizar el \u00e9xito de la transferencia.\n\n3. **\u00bfC\u00f3mo se deben ajustar las recomendaciones de las directrices de la OMS en funci\u00f3n de los principios de gesti\u00f3n de riesgos para diferentes proyectos de transferencia?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de c\u00f3mo aplicar los principios de gesti\u00f3n de riesgos en la pr\u00e1ctica, lo cual es esencial para adaptar las directrices a situaciones espec\u00edficas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS se centra en la **transferencia de tecnolog\u00eda** entre **unidades de fabricaci\u00f3n (SU)** y **unidades receptoras (RU)** en el \u00e1mbito de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Similitud de Capacidades**: Las capacidades de la SU y la RU deben ser similares, aunque no necesariamente id\u00e9nticas, y los equipos deben operar bajo principios operativos similares.\n   \n2. **An\u00e1lisis de Brechas T\u00e9cnicas**: Se debe realizar un an\u00e1lisis exhaustivo que incluya la evaluaci\u00f3n de riesgos t\u00e9cnicos y la identificaci\u00f3n de brechas regulatorias entre la SU y la RU.\n\n3. **Formaci\u00f3n del Personal**: Es esencial que el personal en la RU est\u00e9 adecuadamente capacitado en los requisitos regulatorios pertinentes y que haya una transferencia efectiva de conocimiento sobre procesos y productos.\n\n4. **\u00c9xito de la Transferencia**: La transferencia se considera exitosa si la RU puede reproducir el producto o proceso transferido de acuerdo con especificaciones predefinidas.\n\n5. **Comunicaci\u00f3n de Problemas**: La RU debe informar a la SU sobre cualquier problema identificado durante el proceso de transferencia para asegurar una gesti\u00f3n del conocimiento continua.\n\n6. **Implicaciones Legales y Econ\u00f3micas**: Los proyectos de transferencia de tecnolog\u00eda pueden tener implicaciones relacionadas con derechos de propiedad intelectual, regal\u00edas, precios, conflictos de inter\u00e9s y confidencialidad, que deben ser abordadas adecuadamente.\n\n7. **Transparencia**: La falta de transparencia puede resultar en una transferencia de tecnolog\u00eda ineficaz.\n\n8. **Aplicabilidad a Ensayos Cl\u00ednicos**: Algunos principios pueden ser aplicables a la fabricaci\u00f3n de productos farmac\u00e9uticos investigacionales para ensayos cl\u00ednicos, aunque este no es el enfoque principal del documento.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices sobre la transferencia de tecnolog\u00eda.\n- **Unidades de Fabricaci\u00f3n (SU)**: Entidades que producen el producto original.\n- **Unidades Receptoras (RU)**: Entidades que reciben y reproducen el producto o proceso.\n- **Regulaciones**: Normativas que deben ser consideradas en el proceso de transferencia.\n- **Proyectos de Transferencia de Tecnolog\u00eda**: Iniciativas que implican la transferencia de conocimientos y procesos entre diferentes entidades.\n\nEste resumen destaca la importancia de la planificaci\u00f3n, la formaci\u00f3n y la comunicaci\u00f3n en la transferencia de tecnolog\u00eda, as\u00ed como las consideraciones legales y regulatorias que deben tenerse en cuenta.", "excerpt_keywords": "Keywords: technology transfer, pharmaceutical manufacturing, regulatory guidelines, risk management, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f437563-b9a1-46e1-ac72-0ba3e714c271", "node_type": "4", "metadata": {"page_label": "300", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.1\n\nThis document gives guidance in principle and provides general recommendations on the activities necessary to conduct a successful intra- or intersite transfer of technology as described in the Introduction to these guidelines. The intention is to address the basic considerations needed for a successful transfer in order to satisfy the regulatory authority defined for the transfer process.\n\n# 2.2\n\nThe guidelines will be applied to manufacturing active pharmaceutical ingredients (APIs), manufacturing and packaging of bulk materials, manufacturing and packaging of finished pharmaceutical products (FPPs) and/or performing analytical testing.\n\n# 2.3\n\nThe recommendations provided in these guidelines apply to all dosage forms but need to be adjusted on a case-by-case basis (e.g. by using risk management principles). Particularly close control of certain aspects will be required for certain formulations such as sterile products, and metered-dose aerosols. WHO guidance on manufacture of specific pharmaceutical products (4,5) will be useful in this regard.\n\n# 2.4\n\nThe guidelines address the following areas at the SU and the RU:\n\n- transfer of development and production (processing, packaging and cleaning);\n- transfer of analytical methods for quality assurance and quality control;\n- skills assessment and training;\n- organization and management of the transfer;\n- assessment of premises and equipment;\n- documentation; and\n- qualification and validation.\n\n# 2.5\n\nBecause each transfer project is unique, the provision of a comprehensive set of guidelines is beyond the scope of this document.\n\n# 2.6\n\nThese guidelines do not provide guidance on any legal, financial or commercial considerations associated with technology transfer projects.\n\n# 3. Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**\n\nMeasurable terms under which a test result will be considered acceptable.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cbeda855fd7484f03ece986fc107ef4c90ec3c56d101a24ad4a505958d6dcd6b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.1\n\nThis document gives guidance in principle and provides general recommendations on the activities necessary to conduct a successful intra- or intersite transfer of technology as described in the Introduction to these guidelines. The intention is to address the basic considerations needed for a successful transfer in order to satisfy the regulatory authority defined for the transfer process.\n\n# 2.2\n\nThe guidelines will be applied to manufacturing active pharmaceutical ingredients (APIs), manufacturing and packaging of bulk materials, manufacturing and packaging of finished pharmaceutical products (FPPs) and/or performing analytical testing.\n\n# 2.3\n\nThe recommendations provided in these guidelines apply to all dosage forms but need to be adjusted on a case-by-case basis (e.g. by using risk management principles). Particularly close control of certain aspects will be required for certain formulations such as sterile products, and metered-dose aerosols. WHO guidance on manufacture of specific pharmaceutical products (4,5) will be useful in this regard.\n\n# 2.4\n\nThe guidelines address the following areas at the SU and the RU:\n\n- transfer of development and production (processing, packaging and cleaning);\n- transfer of analytical methods for quality assurance and quality control;\n- skills assessment and training;\n- organization and management of the transfer;\n- assessment of premises and equipment;\n- documentation; and\n- qualification and validation.\n\n# 2.5\n\nBecause each transfer project is unique, the provision of a comprehensive set of guidelines is beyond the scope of this document.\n\n# 2.6\n\nThese guidelines do not provide guidance on any legal, financial or commercial considerations associated with technology transfer projects.\n\n# 3. Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**\n\nMeasurable terms under which a test result will be considered acceptable.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2000, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb66485-3dc5-41f7-9e3a-83cc7625652b": {"__data__": {"id_": "4cb66485-3dc5-41f7-9e3a-83cc7625652b", "embedding": null, "metadata": {"page_label": "301", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n# bracketing\n\nAn experimental design to test only the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.\n\n# change control (C/C)\n\nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n# commissioning\n\nThe setting up, adjustment and testing of equipment or a system to ensure that it meets all the requirements, as specified in the user requirement specification, and capacities as specified by the designer or developer. Commissioning is carried out before qualification and validation.\n\n# control strategy\n\nA planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to materials and components related to drug substances and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (6).\n\n# corrective action (C/A)\n\nAny action to be taken when the results of monitoring at a critical control point indicate a loss of control.\n\n# critical\n\nHaving the potential to impact on product quality or performance in a significant way.\n\n# critical control point (CCP)\n\nA step at which control can be applied and is essential to prevent or eliminate a pharmaceutical quality hazard or to reduce it to an acceptable level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la fabricaci\u00f3n y control de productos farmac\u00e9uticos. Se definen t\u00e9rminos como \"ingrediente farmac\u00e9utico activo\" (API), \"control cr\u00edtico\" y \"estrategia de control\", que son fundamentales para asegurar la calidad y eficacia de los medicamentos. Adem\u00e1s, se discuten procesos como el \"control de cambios\" y la \"comisionamiento\" de equipos, que son esenciales para mantener la validez y el rendimiento de los sistemas de producci\u00f3n farmac\u00e9utica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la importancia de un \"punto de control cr\u00edtico\" (CCP) en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Un CCP es un paso en el proceso donde se puede aplicar control y es esencial para prevenir o eliminar un peligro de calidad farmac\u00e9utica o reducirlo a un nivel aceptable. Su identificaci\u00f3n y monitoreo son cruciales para garantizar la calidad del producto final.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"comisionamiento\" y por qu\u00e9 es un paso previo a la calificaci\u00f3n y validaci\u00f3n de equipos?**\n   - Respuesta: El comisionamiento implica la configuraci\u00f3n, ajuste y prueba de equipos o sistemas para asegurar que cumplan con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario. Este proceso es fundamental para garantizar que el equipo funcione correctamente antes de ser calificado y validado para su uso en la producci\u00f3n.\n\n3. **\u00bfC\u00f3mo se define una \"estrategia de control\" y qu\u00e9 elementos incluye para asegurar la calidad del producto farmac\u00e9utico?**\n   - Respuesta: Una estrategia de control es un conjunto planificado de controles derivados de la comprensi\u00f3n actual del producto y del proceso, que asegura el rendimiento del proceso y la calidad del producto. Incluye par\u00e1metros y atributos relacionados con materiales, condiciones operativas, controles en proceso, especificaciones del producto terminado y m\u00e9todos de monitoreo y control.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, titulado \"WHO - Technical Report Series 961\", proporciona directrices generales para la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Transferencia de Tecnolog\u00eda**: Directrices para la transferencia intra- e intersitio de tecnolog\u00eda, enfoc\u00e1ndose en la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs), productos en estado bruto y productos farmac\u00e9uticos terminados (FPPs).\n   \n2. **Adaptabilidad de las Recomendaciones**: Las directrices son aplicables a todas las formas de dosificaci\u00f3n, pero deben ajustarse seg\u00fan el contexto y los principios de gesti\u00f3n de riesgos, especialmente para productos est\u00e9riles y aerosoles de dosis medida.\n\n3. **\u00c1reas de Evaluaci\u00f3n**: Se abordan aspectos como:\n   - Transferencia de desarrollo y producci\u00f3n (procesamiento, envasado y limpieza).\n   - Transferencia de m\u00e9todos anal\u00edticos para aseguramiento y control de calidad.\n   - Evaluaci\u00f3n de habilidades y capacitaci\u00f3n.\n   - Organizaci\u00f3n y gesti\u00f3n del proceso de transferencia.\n   - Evaluaci\u00f3n de instalaciones y equipos.\n   - Documentaci\u00f3n necesaria.\n   - Calificaci\u00f3n y validaci\u00f3n.\n\n4. **Limitaciones del Documento**: Se aclara que no se proporcionan directrices sobre consideraciones legales, financieras o comerciales relacionadas con los proyectos de transferencia de tecnolog\u00eda.\n\n5. **Criterios de Aceptaci\u00f3n**: Se define el t\u00e9rmino \"criterios de aceptaci\u00f3n\" como los t\u00e9rminos medibles bajo los cuales un resultado de prueba se considerar\u00e1 aceptable.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos Terminados (FPPs)**: Productos finales listos para la distribuci\u00f3n y uso.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para asegurar la calidad y control de los productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para garantizar una transferencia de tecnolog\u00eda efectiva y conforme a las regulaciones en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: active pharmaceutical ingredient, change control, commissioning, control strategy, critical control point"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18991383-76df-4d26-a806-fb84871e3e00", "node_type": "4", "metadata": {"page_label": "301", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n# bracketing\n\nAn experimental design to test only the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.\n\n# change control (C/C)\n\nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n# commissioning\n\nThe setting up, adjustment and testing of equipment or a system to ensure that it meets all the requirements, as specified in the user requirement specification, and capacities as specified by the designer or developer. Commissioning is carried out before qualification and validation.\n\n# control strategy\n\nA planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to materials and components related to drug substances and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (6).\n\n# corrective action (C/A)\n\nAny action to be taken when the results of monitoring at a critical control point indicate a loss of control.\n\n# critical\n\nHaving the potential to impact on product quality or performance in a significant way.\n\n# critical control point (CCP)\n\nA step at which control can be applied and is essential to prevent or eliminate a pharmaceutical quality hazard or to reduce it to an acceptable level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e7fc59d0965c5c2823cd0ede7efaf2d2add4426d94174f3564a623b2d23833c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n# bracketing\n\nAn experimental design to test only the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.\n\n# change control (C/C)\n\nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n# commissioning\n\nThe setting up, adjustment and testing of equipment or a system to ensure that it meets all the requirements, as specified in the user requirement specification, and capacities as specified by the designer or developer. Commissioning is carried out before qualification and validation.\n\n# control strategy\n\nA planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to materials and components related to drug substances and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (6).\n\n# corrective action (C/A)\n\nAny action to be taken when the results of monitoring at a critical control point indicate a loss of control.\n\n# critical\n\nHaving the potential to impact on product quality or performance in a significant way.\n\n# critical control point (CCP)\n\nA step at which control can be applied and is essential to prevent or eliminate a pharmaceutical quality hazard or to reduce it to an acceptable level.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2157, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e751b12b-9e56-4949-8fcc-38f76ebb8e2e": {"__data__": {"id_": "e751b12b-9e56-4949-8fcc-38f76ebb8e2e", "embedding": null, "metadata": {"page_label": "302", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# design qualification (DQ)\nDocumented evidence that the premises, supporting systems, utilities, equipment and processes have been designed in accordance with the requirements of good manufacturing practices (GMP).\n\n# design space\nThe multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality (7).\n\n# drug master file (DMF)\nDetailed information concerning a specific facility, process or product submitted to the medicines regulatory authority, intended for incorporation into the application for marketing authorization.\n\n# finished pharmaceutical product (FPP)\nA product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# gap analysis\nIdentification of critical elements of a process which are available at the SU but are missing from the RU.\n\n# good manufacturing practices (GMP)\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (3).\n\n# in-process control (IPC)\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# installation qualification (IQ)\nThe performance of tests to ensure that the installations (such as machines, measuring devices, utilities and manufacturing areas) used in a manufacturing process are appropriately selected and correctly installed and operate in accordance with established specifications.\n\n# intercompany transfer\nA transfer of technology between sites of different companies.\n\n# intracompany transfer\nA transfer of technology between sites of the same group of companies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 961\", aborda conceptos clave relacionados con las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica. Se definen t\u00e9rminos esenciales como la calificaci\u00f3n de dise\u00f1o (DQ), el espacio de dise\u00f1o, el archivo maestro de medicamentos (DMF), el producto farmac\u00e9utico terminado (FPP), el an\u00e1lisis de brechas, el control en proceso (IPC), la calificaci\u00f3n de instalaci\u00f3n (IQ), y las transferencias de tecnolog\u00eda tanto interempresariales como intraempresariales. Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con los est\u00e1ndares de calidad requeridos.\n\n### Preguntas\n1. **\u00bfQu\u00e9 evidencia se requiere para demostrar que un proceso de fabricaci\u00f3n cumple con las buenas pr\u00e1cticas de manufactura (GMP)?**\n   - Respuesta: Se requiere documentaci\u00f3n que evidencie que las instalaciones, sistemas de soporte, utilidades, equipos y procesos han sido dise\u00f1ados de acuerdo con los requisitos de GMP, lo que se conoce como calificaci\u00f3n de dise\u00f1o (DQ).\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto farmac\u00e9utico terminado (FPP) y un ingrediente farmac\u00e9utico activo (API)?**\n   - Respuesta: Un producto farmac\u00e9utico terminado (FPP) es aquel que ha pasado por todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado en su contenedor final, y puede contener uno o m\u00e1s ingredientes farmac\u00e9uticos activos (API).\n\n3. **\u00bfQu\u00e9 implica la calificaci\u00f3n de instalaci\u00f3n (IQ) en el contexto de la manufactura farmac\u00e9utica?**\n   - Respuesta: La calificaci\u00f3n de instalaci\u00f3n (IQ) implica la realizaci\u00f3n de pruebas para asegurar que las instalaciones, como m\u00e1quinas y dispositivos de medici\u00f3n, est\u00e9n correctamente seleccionadas, instaladas y operando de acuerdo con las especificaciones establecidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n aborda conceptos fundamentales en la fabricaci\u00f3n y control de productos farmac\u00e9uticos, destacando la importancia de asegurar la calidad y eficacia de los medicamentos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Ingrediente Farmac\u00e9utico Activo (API)**:\n   - Definici\u00f3n: Sustancia o mezcla utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efecto directo en el diagn\u00f3stico, tratamiento o prevenci\u00f3n de enfermedades.\n\n2. **Bracketing**:\n   - Definici\u00f3n: Dise\u00f1o experimental que prueba solo los extremos de una variable (como la fuerza de dosificaci\u00f3n), asumiendo que estos extremos son representativos de todos los valores intermedios.\n\n3. **Control de Cambios (C/C)**:\n   - Definici\u00f3n: Sistema formal para revisar cambios propuestos o reales que puedan afectar el estado validado de un sistema, asegurando que se mantenga en un estado validado.\n\n4. **Comisionamiento**:\n   - Definici\u00f3n: Proceso de configuraci\u00f3n, ajuste y prueba de equipos o sistemas para garantizar que cumplan con los requisitos especificados antes de la calificaci\u00f3n y validaci\u00f3n.\n\n5. **Estrategia de Control**:\n   - Definici\u00f3n: Conjunto planificado de controles que asegura el rendimiento del proceso y la calidad del producto, incluyendo par\u00e1metros relacionados con materiales, condiciones operativas y especificaciones del producto terminado.\n\n6. **Acci\u00f3n Correctiva (C/A)**:\n   - Definici\u00f3n: Medidas a tomar cuando el monitoreo en un punto de control cr\u00edtico indica una p\u00e9rdida de control.\n\n7. **Punto de Control Cr\u00edtico (CCP)**:\n   - Definici\u00f3n: Paso en el proceso donde se puede aplicar control para prevenir o eliminar un peligro de calidad farmac\u00e9utica o reducirlo a un nivel aceptable.\n\n8. **Cr\u00edtico**:\n   - Definici\u00f3n: Cualquier aspecto que tenga el potencial de impactar significativamente en la calidad o rendimiento del producto.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar la calidad y seguridad en la producci\u00f3n de medicamentos, y su comprensi\u00f3n es fundamental para los profesionales del sector farmac\u00e9utico.", "excerpt_keywords": "Keywords: design qualification, good manufacturing practices, drug master file, finished pharmaceutical product, in-process control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f44f7d2-2903-45e8-b515-21b13212f5dd", "node_type": "4", "metadata": {"page_label": "302", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# design qualification (DQ)\nDocumented evidence that the premises, supporting systems, utilities, equipment and processes have been designed in accordance with the requirements of good manufacturing practices (GMP).\n\n# design space\nThe multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality (7).\n\n# drug master file (DMF)\nDetailed information concerning a specific facility, process or product submitted to the medicines regulatory authority, intended for incorporation into the application for marketing authorization.\n\n# finished pharmaceutical product (FPP)\nA product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# gap analysis\nIdentification of critical elements of a process which are available at the SU but are missing from the RU.\n\n# good manufacturing practices (GMP)\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (3).\n\n# in-process control (IPC)\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# installation qualification (IQ)\nThe performance of tests to ensure that the installations (such as machines, measuring devices, utilities and manufacturing areas) used in a manufacturing process are appropriately selected and correctly installed and operate in accordance with established specifications.\n\n# intercompany transfer\nA transfer of technology between sites of different companies.\n\n# intracompany transfer\nA transfer of technology between sites of the same group of companies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "34fab5e551684d0dc3986a319456f4df71111a40fdc05b45d3f0163ed0491d58", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# design qualification (DQ)\nDocumented evidence that the premises, supporting systems, utilities, equipment and processes have been designed in accordance with the requirements of good manufacturing practices (GMP).\n\n# design space\nThe multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality (7).\n\n# drug master file (DMF)\nDetailed information concerning a specific facility, process or product submitted to the medicines regulatory authority, intended for incorporation into the application for marketing authorization.\n\n# finished pharmaceutical product (FPP)\nA product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# gap analysis\nIdentification of critical elements of a process which are available at the SU but are missing from the RU.\n\n# good manufacturing practices (GMP)\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (3).\n\n# in-process control (IPC)\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# installation qualification (IQ)\nThe performance of tests to ensure that the installations (such as machines, measuring devices, utilities and manufacturing areas) used in a manufacturing process are appropriately selected and correctly installed and operate in accordance with established specifications.\n\n# intercompany transfer\nA transfer of technology between sites of different companies.\n\n# intracompany transfer\nA transfer of technology between sites of the same group of companies.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1990, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1d3f3251-8fe7-46d6-ae19-9472374cd5c8": {"__data__": {"id_": "1d3f3251-8fe7-46d6-ae19-9472374cd5c8", "embedding": null, "metadata": {"page_label": "303", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# operational qualification (OQ)\nDocumented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n\n# performance qualification (PQ)\nDocumented verification that the equipment or system operates consistently and gives reproducibility within defined specifications and parameters for prolonged periods. (In the context of systems, the term \u201cprocess validation\u201d may also be used.)\n\n# process validation\nDocumented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets its predetermined specifications and quality characteristics.\n\n# qualification\nAction of proving and documenting that any premises, systems and equipment are properly installed, and/or work correctly and lead to the expected results. Qualification is often a part (the initial stage) of validation, but the individual qualification steps alone do not constitute process validation.\n\n# qualification batches\nThose batches produced by the RU to demonstrate its ability to reproduce the product (1).\n\n# quality assurance (QA)\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the objective of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n# quality control (QC)\nQuality control covers all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\n# quality planning\nPart of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives (6).\n\n# quality policy\nOverall intentions and direction of an organization related to quality as formally expressed by senior management (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la calidad en la industria farmac\u00e9utica. Se definen t\u00e9rminos como calificaci\u00f3n operativa (OQ), calificaci\u00f3n de rendimiento (PQ), validaci\u00f3n de procesos, y se diferencian los conceptos de aseguramiento de calidad (QA) y control de calidad (QC). Adem\u00e1s, se discuten los objetivos de planificaci\u00f3n de calidad y la pol\u00edtica de calidad de una organizaci\u00f3n, enfatizando la importancia de documentar y verificar que los sistemas y procesos cumplan con las especificaciones y caracter\u00edsticas de calidad predeterminadas.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la diferencia entre la calificaci\u00f3n operativa (OQ) y la calificaci\u00f3n de rendimiento (PQ) en el contexto de la validaci\u00f3n de sistemas?**\n   - Esta pregunta se centra en las definiciones espec\u00edficas de OQ y PQ, que son fundamentales para entender c\u00f3mo se verifica el funcionamiento de los sistemas en la industria farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 papel juega la validaci\u00f3n de procesos en la garant\u00eda de que un producto farmac\u00e9utico cumpla con sus especificaciones predeterminadas?**\n   - Esta pregunta busca profundizar en el concepto de validaci\u00f3n de procesos y su importancia en la producci\u00f3n de productos que cumplen con los est\u00e1ndares de calidad.\n\n3. **\u00bfC\u00f3mo se relacionan los conceptos de aseguramiento de calidad (QA) y control de calidad (QC) en el contexto de la gesti\u00f3n de calidad en la industria farmac\u00e9utica?**\n   - Esta pregunta permite explorar la interconexi\u00f3n entre QA y QC, dos aspectos cruciales para garantizar la calidad de los productos farmac\u00e9uticos, y c\u00f3mo cada uno contribuye al objetivo general de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento \"Technical Report Series 961\" de la OMS aborda varios conceptos fundamentales relacionados con las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Calificaci\u00f3n de Dise\u00f1o (DQ)**: Se refiere a la evidencia documentada que asegura que las instalaciones, sistemas de soporte, utilidades, equipos y procesos est\u00e1n dise\u00f1ados conforme a los requisitos de GMP.\n\n2. **Espacio de Dise\u00f1o**: Describe la combinaci\u00f3n multidimensional de variables de entrada y par\u00e1metros de proceso que garantizan la calidad del producto.\n\n3. **Archivo Maestro de Medicamentos (DMF)**: Informaci\u00f3n detallada sobre una instalaci\u00f3n, proceso o producto que se presenta a la autoridad reguladora de medicamentos para su inclusi\u00f3n en la solicitud de autorizaci\u00f3n de comercializaci\u00f3n.\n\n4. **Producto Farmac\u00e9utico Terminado (FPP)**: Un producto que ha completado todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado, y que puede contener uno o m\u00e1s ingredientes farmac\u00e9uticos activos (API).\n\n5. **An\u00e1lisis de Brechas**: Identificaci\u00f3n de elementos cr\u00edticos de un proceso que est\u00e1n disponibles en una unidad de producci\u00f3n (SU) pero que faltan en otra (RU).\n\n6. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Parte de la garant\u00eda de calidad que asegura que los productos farmac\u00e9uticos se producen y controlan consistentemente seg\u00fan los est\u00e1ndares de calidad requeridos.\n\n7. **Control en Proceso (IPC)**: Verificaciones realizadas durante la producci\u00f3n para monitorear y ajustar el proceso, asegurando que el producto cumpla con sus especificaciones.\n\n8. **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Pruebas realizadas para asegurar que las instalaciones utilizadas en el proceso de manufactura est\u00e1n correctamente seleccionadas, instaladas y operan seg\u00fan las especificaciones establecidas.\n\n9. **Transferencia Interempresarial**: Transferencia de tecnolog\u00eda entre diferentes empresas.\n\n10. **Transferencia Intraempresarial**: Transferencia de tecnolog\u00eda entre diferentes sitios de la misma empresa o grupo de empresas.\n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos se desarrollen y mantengan de acuerdo con los est\u00e1ndares de calidad necesarios para su uso previsto.", "excerpt_keywords": "Keywords: operational qualification, performance qualification, process validation, quality assurance, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4f41deae-a3cf-42c5-88b8-36d8ec03ea42", "node_type": "4", "metadata": {"page_label": "303", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# operational qualification (OQ)\nDocumented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n\n# performance qualification (PQ)\nDocumented verification that the equipment or system operates consistently and gives reproducibility within defined specifications and parameters for prolonged periods. (In the context of systems, the term \u201cprocess validation\u201d may also be used.)\n\n# process validation\nDocumented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets its predetermined specifications and quality characteristics.\n\n# qualification\nAction of proving and documenting that any premises, systems and equipment are properly installed, and/or work correctly and lead to the expected results. Qualification is often a part (the initial stage) of validation, but the individual qualification steps alone do not constitute process validation.\n\n# qualification batches\nThose batches produced by the RU to demonstrate its ability to reproduce the product (1).\n\n# quality assurance (QA)\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the objective of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n# quality control (QC)\nQuality control covers all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\n# quality planning\nPart of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives (6).\n\n# quality policy\nOverall intentions and direction of an organization related to quality as formally expressed by senior management (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ec743fb0d58f0eaf014ec98e61a5244aa1f59b5b421b508790ff5593c5f637bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# operational qualification (OQ)\nDocumented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n\n# performance qualification (PQ)\nDocumented verification that the equipment or system operates consistently and gives reproducibility within defined specifications and parameters for prolonged periods. (In the context of systems, the term \u201cprocess validation\u201d may also be used.)\n\n# process validation\nDocumented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets its predetermined specifications and quality characteristics.\n\n# qualification\nAction of proving and documenting that any premises, systems and equipment are properly installed, and/or work correctly and lead to the expected results. Qualification is often a part (the initial stage) of validation, but the individual qualification steps alone do not constitute process validation.\n\n# qualification batches\nThose batches produced by the RU to demonstrate its ability to reproduce the product (1).\n\n# quality assurance (QA)\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the objective of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n# quality control (QC)\nQuality control covers all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\n# quality planning\nPart of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives (6).\n\n# quality policy\nOverall intentions and direction of an organization related to quality as formally expressed by senior management (6).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2082, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "79cb584d-d8d1-49b1-b957-7881620b4364": {"__data__": {"id_": "79cb584d-d8d1-49b1-b957-7881620b4364", "embedding": null, "metadata": {"page_label": "304", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality risk management (QRM)  \nQuality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life-cycle.\n\nreceiving unit (RU)  \nThe involved disciplines at an organization where a designated product, process or method is expected to be transferred.\n\nsending unit (SU)  \nThe involved disciplines at an organization from where a designated product, process or method is expected to be transferred.\n\nspiking  \nThe addition of a known amount of a compound to a standard, sample or placebo, typically for the purpose of confirming the performance of an analytical procedure.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\ntechnology transfer report  \nA documented summary of a specific technology transfer project listing procedures, acceptance criteria, results achieved and conclusions. Any deviation should be discussed and justified.\n\nvalidation  \nAction of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n\nvalidation master plan (VMP)  \nA high-level document that establishes an umbrella validation plan for the entire project and summarizes the manufacturer\u2019s overall philosophy and approach, to be used for establishing performance adequacy. It provides information on the manufacturer\u2019s validation work programme and defines details of and timescales for the validation work to be performed, including a statement of the responsibilities of those implementing the plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal del Quality Risk Management (QRM) en la industria farmac\u00e9utica?**\n   - **Respuesta:** El prop\u00f3sito principal del Quality Risk Management (QRM) es llevar a cabo un proceso sistem\u00e1tico para la evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de los riesgos que pueden afectar la calidad del producto farmac\u00e9utico a lo largo de su ciclo de vida.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en un Technology Transfer Report y por qu\u00e9 es importante?**\n   - **Respuesta:** Un Technology Transfer Report incluye un resumen documentado de un proyecto espec\u00edfico de transferencia de tecnolog\u00eda, que lista los procedimientos, criterios de aceptaci\u00f3n, resultados obtenidos y conclusiones. Es importante porque permite discutir y justificar cualquier desviaci\u00f3n del plan original, asegurando as\u00ed la transparencia y la trazabilidad en el proceso de transferencia.\n\n3. **\u00bfQu\u00e9 rol desempe\u00f1a el Validation Master Plan (VMP) en un proyecto de validaci\u00f3n?**\n   - **Respuesta:** El Validation Master Plan (VMP) desempe\u00f1a un rol crucial al establecer un plan de validaci\u00f3n general para todo el proyecto. Resume la filosof\u00eda y el enfoque del fabricante respecto a la validaci\u00f3n, proporciona informaci\u00f3n sobre el programa de trabajo de validaci\u00f3n y define los detalles y plazos para las actividades de validaci\u00f3n, as\u00ed como las responsabilidades de quienes implementan el plan.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS, \"Technical Report Series 961\", aborda conceptos clave en la gesti\u00f3n de calidad y validaci\u00f3n en la industria farmac\u00e9utica. Se define el Quality Risk Management (QRM) como un proceso sistem\u00e1tico para manejar riesgos a lo largo del ciclo de vida del producto. Tambi\u00e9n se explican t\u00e9rminos como \"receiving unit\" y \"sending unit\", que se refieren a las disciplinas involucradas en la transferencia de productos o procesos. Adem\u00e1s, se discuten procedimientos como el \"spiking\", las \"standard operating procedures\" (SOP), y la importancia de los informes de transferencia de tecnolog\u00eda y los planes de validaci\u00f3n. Estos elementos son fundamentales para asegurar la calidad y la eficacia en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en conceptos fundamentales relacionados con la calidad en la industria farmac\u00e9utica, destacando la importancia de la documentaci\u00f3n y verificaci\u00f3n de procesos y sistemas. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Calificaci\u00f3n Operativa (OQ)**: Verificaci\u00f3n documentada de que un sistema o subsistema funciona como se espera en todos los rangos operativos anticipados.\n\n2. **Calificaci\u00f3n de Rendimiento (PQ)**: Verificaci\u00f3n documentada de que el equipo o sistema opera de manera consistente y reproducible dentro de especificaciones y par\u00e1metros definidos durante per\u00edodos prolongados.\n\n3. **Validaci\u00f3n de Procesos**: Evidencia documentada que asegura que un proceso espec\u00edfico resultar\u00e1 consistentemente en un producto que cumple con especificaciones y caracter\u00edsticas de calidad predeterminadas.\n\n4. **Calificaci\u00f3n**: Proceso de demostrar y documentar que las instalaciones, sistemas y equipos est\u00e1n correctamente instalados y funcionan adecuadamente.\n\n5. **Lotes de Calificaci\u00f3n**: Lotes producidos para demostrar la capacidad de reproducir un producto.\n\n6. **Aseguramiento de Calidad (QA)**: Concepto amplio que abarca todos los aspectos que influyen en la calidad de un producto, asegurando que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares requeridos.\n\n7. **Control de Calidad (QC)**: Medidas tomadas para asegurar que los materiales y productos farmac\u00e9uticos cumplan con especificaciones establecidas en cuanto a identidad, fuerza, pureza y otras caracter\u00edsticas.\n\n8. **Planificaci\u00f3n de Calidad**: Parte de la gesti\u00f3n de calidad que se enfoca en establecer objetivos de calidad y especificar procesos operativos necesarios para cumplir con esos objetivos.\n\n9. **Pol\u00edtica de Calidad**: Intenciones y direcci\u00f3n general de una organizaci\u00f3n en relaci\u00f3n con la calidad, expresadas formalmente por la alta direcci\u00f3n.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos sean seguros y efectivos, cumpliendo con los est\u00e1ndares de calidad requeridos para su uso previsto. La documentaci\u00f3n y la verificaci\u00f3n son componentes cr\u00edticos en cada etapa del proceso de producci\u00f3n y gesti\u00f3n de calidad.", "excerpt_keywords": "Keywords: Quality Risk Management, Technology Transfer, Validation Master Plan, Standard Operating Procedure, Pharmaceutical Quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ea35f195-1c39-4c57-b1af-4c75a97b49a9", "node_type": "4", "metadata": {"page_label": "304", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality risk management (QRM)  \nQuality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life-cycle.\n\nreceiving unit (RU)  \nThe involved disciplines at an organization where a designated product, process or method is expected to be transferred.\n\nsending unit (SU)  \nThe involved disciplines at an organization from where a designated product, process or method is expected to be transferred.\n\nspiking  \nThe addition of a known amount of a compound to a standard, sample or placebo, typically for the purpose of confirming the performance of an analytical procedure.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\ntechnology transfer report  \nA documented summary of a specific technology transfer project listing procedures, acceptance criteria, results achieved and conclusions. Any deviation should be discussed and justified.\n\nvalidation  \nAction of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n\nvalidation master plan (VMP)  \nA high-level document that establishes an umbrella validation plan for the entire project and summarizes the manufacturer\u2019s overall philosophy and approach, to be used for establishing performance adequacy. It provides information on the manufacturer\u2019s validation work programme and defines details of and timescales for the validation work to be performed, including a statement of the responsibilities of those implementing the plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0a080825edbaca548995f094e7bc1a3b4dd4a190677d21f43b6cd69429675c76", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "quality risk management (QRM)  \nQuality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life-cycle.\n\nreceiving unit (RU)  \nThe involved disciplines at an organization where a designated product, process or method is expected to be transferred.\n\nsending unit (SU)  \nThe involved disciplines at an organization from where a designated product, process or method is expected to be transferred.\n\nspiking  \nThe addition of a known amount of a compound to a standard, sample or placebo, typically for the purpose of confirming the performance of an analytical procedure.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\ntechnology transfer report  \nA documented summary of a specific technology transfer project listing procedures, acceptance criteria, results achieved and conclusions. Any deviation should be discussed and justified.\n\nvalidation  \nAction of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n\nvalidation master plan (VMP)  \nA high-level document that establishes an umbrella validation plan for the entire project and summarizes the manufacturer\u2019s overall philosophy and approach, to be used for establishing performance adequacy. It provides information on the manufacturer\u2019s validation work programme and defines details of and timescales for the validation work to be performed, including a statement of the responsibilities of those implementing the plan.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1925, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bd04b1ce-7586-4fbc-a0a1-1a37e199e179": {"__data__": {"id_": "bd04b1ce-7586-4fbc-a0a1-1a37e199e179", "embedding": null, "metadata": {"page_label": "305", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization and Management\n\n**Validation Protocol (or Plan) (VP)**  \nA document describing the activities to be performed in a validation, including the acceptance criteria for the approval of a manufacturing process \u2014 or a part thereof \u2014 for routine use.\n\n**Validation Report (VR)**  \nA document in which the records, results and evaluation of a completed validation programme are assembled and summarized. It may also contain proposals for the improvement of processes and or equipment.\n\n## 4. Organization and Management\n\n4.1 Transfer comprises an SU and an RU. In some circumstances there may be an additional unit which will be responsible for directing, managing and approving the transfer.\n\n4.2 There is a formal agreement between the parties, which specifies the responsibilities before, during and after transfer.\n\n4.3 Organization and management of a successful technology transfer need to ensure that the main steps have been executed and documented as described in section 1.6.\n\n4.4 There should be a project management plan which identifies and controls all the necessary activities identified at the start of the undertaking.\n\n4.5 The transfer protocol should list the intended sequential stages of the transfer. The protocol should include:\n\n- objective;\n- scope;\n- key personnel and their responsibilities;\n- a parallel comparison of materials, methods and equipment;\n- the transfer stages with documented evidence that each critical stage has been satisfactorily accomplished before the next commences;\n- identification of critical control points;\n- experimental design and acceptance criteria for analytical methods;\n- information on trial production batches, qualification batches and process validation;\n- change control for any process deviations encountered;\n- assessment of end-product;\n- arrangements for keeping retention samples of active ingredients, intermediates and finished products, and information on reference substances where applicable; and\n- conclusion, including signed-off approval by project manager.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la organizaci\u00f3n y gesti\u00f3n de la transferencia de tecnolog\u00eda en el \u00e1mbito de la fabricaci\u00f3n. Se define el protocolo de validaci\u00f3n y el informe de validaci\u00f3n, y se describen los elementos clave que deben incluirse en un plan de gesti\u00f3n de proyectos para asegurar una transferencia exitosa. Se enfatiza la importancia de un acuerdo formal entre las partes involucradas y la documentaci\u00f3n de cada etapa del proceso de transferencia.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 elementos espec\u00edficos deben incluirse en un protocolo de transferencia seg\u00fan el documento?**\n   - El protocolo de transferencia debe incluir el objetivo, el alcance, el personal clave y sus responsabilidades, una comparaci\u00f3n paralela de materiales, m\u00e9todos y equipos, las etapas de transferencia con evidencia documentada, identificaci\u00f3n de puntos de control cr\u00edticos, dise\u00f1o experimental y criterios de aceptaci\u00f3n para m\u00e9todos anal\u00edticos, informaci\u00f3n sobre lotes de producci\u00f3n de prueba y validaci\u00f3n de procesos, control de cambios, evaluaci\u00f3n del producto final, y disposiciones para mantener muestras de retenci\u00f3n.\n\n2. **\u00bfCu\u00e1l es la importancia de tener un acuerdo formal entre las partes involucradas en la transferencia de tecnolog\u00eda?**\n   - Un acuerdo formal especifica las responsabilidades de cada parte antes, durante y despu\u00e9s de la transferencia, lo que es crucial para asegurar que todas las actividades se realicen de manera coordinada y que se cumplan los requisitos establecidos para una transferencia exitosa.\n\n3. **\u00bfQu\u00e9 se entiende por \"puntos de control cr\u00edticos\" en el contexto de la transferencia de tecnolog\u00eda?**\n   - Los puntos de control cr\u00edticos son etapas o elementos dentro del proceso de transferencia que deben ser identificados y monitoreados para asegurar que se cumplan los est\u00e1ndares de calidad y que cada fase del proceso se complete satisfactoriamente antes de avanzar a la siguiente. Esto es esencial para garantizar la eficacia y seguridad del proceso de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Quality Risk Management (QRM)**: \n   - Proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar riesgos que afectan la calidad de productos farmac\u00e9uticos a lo largo de su ciclo de vida.\n\n2. **Receiving Unit (RU)**: \n   - Disciplinas involucradas en una organizaci\u00f3n donde se espera que un producto, proceso o m\u00e9todo designado sea transferido.\n\n3. **Sending Unit (SU)**: \n   - Disciplinas involucradas en una organizaci\u00f3n desde donde se espera que un producto, proceso o m\u00e9todo designado sea transferido.\n\n4. **Spiking**: \n   - Adici\u00f3n de una cantidad conocida de un compuesto a un est\u00e1ndar, muestra o placebo para confirmar el rendimiento de un procedimiento anal\u00edtico.\n\n5. **Standard Operating Procedure (SOP)**: \n   - Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones, no necesariamente espec\u00edficas a un producto o material.\n\n6. **Technology Transfer Report**: \n   - Resumen documentado de un proyecto de transferencia de tecnolog\u00eda que incluye procedimientos, criterios de aceptaci\u00f3n, resultados y conclusiones, con discusi\u00f3n de desviaciones.\n\n7. **Validation**: \n   - Acci\u00f3n de demostrar y documentar que un proceso, procedimiento o m\u00e9todo produce consistentemente los resultados esperados.\n\n8. **Validation Master Plan (VMP)**: \n   - Documento de alto nivel que establece un plan de validaci\u00f3n general para un proyecto, resumiendo la filosof\u00eda y enfoque del fabricante, y definiendo detalles y plazos para el trabajo de validaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Entidades que participan en la transferencia de productos, procesos o m\u00e9todos.\n- **Productos Farmac\u00e9uticos**: Objetos de calidad y validaci\u00f3n en el contexto de la industria farmac\u00e9utica.\n- **Procedimientos Anal\u00edticos**: M\u00e9todos utilizados para confirmar la calidad y eficacia de productos farmac\u00e9uticos.\n- **Documentaci\u00f3n**: Informes y planes que aseguran la trazabilidad y transparencia en los procesos de calidad y validaci\u00f3n. \n\nEste resumen destaca los conceptos y t\u00e9rminos esenciales relacionados con la gesti\u00f3n de calidad y validaci\u00f3n en la industria farmac\u00e9utica, tal como se presenta en el documento de la OMS.", "excerpt_keywords": "Keywords: validation protocol, technology transfer, project management, critical control points, pharmaceutical manufacturing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "73a5b4c6-baf3-4703-bb6c-8d2ef7e9dbb9", "node_type": "4", "metadata": {"page_label": "305", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization and Management\n\n**Validation Protocol (or Plan) (VP)**  \nA document describing the activities to be performed in a validation, including the acceptance criteria for the approval of a manufacturing process \u2014 or a part thereof \u2014 for routine use.\n\n**Validation Report (VR)**  \nA document in which the records, results and evaluation of a completed validation programme are assembled and summarized. It may also contain proposals for the improvement of processes and or equipment.\n\n## 4. Organization and Management\n\n4.1 Transfer comprises an SU and an RU. In some circumstances there may be an additional unit which will be responsible for directing, managing and approving the transfer.\n\n4.2 There is a formal agreement between the parties, which specifies the responsibilities before, during and after transfer.\n\n4.3 Organization and management of a successful technology transfer need to ensure that the main steps have been executed and documented as described in section 1.6.\n\n4.4 There should be a project management plan which identifies and controls all the necessary activities identified at the start of the undertaking.\n\n4.5 The transfer protocol should list the intended sequential stages of the transfer. The protocol should include:\n\n- objective;\n- scope;\n- key personnel and their responsibilities;\n- a parallel comparison of materials, methods and equipment;\n- the transfer stages with documented evidence that each critical stage has been satisfactorily accomplished before the next commences;\n- identification of critical control points;\n- experimental design and acceptance criteria for analytical methods;\n- information on trial production batches, qualification batches and process validation;\n- change control for any process deviations encountered;\n- assessment of end-product;\n- arrangements for keeping retention samples of active ingredients, intermediates and finished products, and information on reference substances where applicable; and\n- conclusion, including signed-off approval by project manager.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "43ad7d1007636aeee41ed457471dae86a28dc4a852905b0699326e2a8b182f3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Organization and Management\n\n**Validation Protocol (or Plan) (VP)**  \nA document describing the activities to be performed in a validation, including the acceptance criteria for the approval of a manufacturing process \u2014 or a part thereof \u2014 for routine use.\n\n**Validation Report (VR)**  \nA document in which the records, results and evaluation of a completed validation programme are assembled and summarized. It may also contain proposals for the improvement of processes and or equipment.\n\n## 4. Organization and Management\n\n4.1 Transfer comprises an SU and an RU. In some circumstances there may be an additional unit which will be responsible for directing, managing and approving the transfer.\n\n4.2 There is a formal agreement between the parties, which specifies the responsibilities before, during and after transfer.\n\n4.3 Organization and management of a successful technology transfer need to ensure that the main steps have been executed and documented as described in section 1.6.\n\n4.4 There should be a project management plan which identifies and controls all the necessary activities identified at the start of the undertaking.\n\n4.5 The transfer protocol should list the intended sequential stages of the transfer. The protocol should include:\n\n- objective;\n- scope;\n- key personnel and their responsibilities;\n- a parallel comparison of materials, methods and equipment;\n- the transfer stages with documented evidence that each critical stage has been satisfactorily accomplished before the next commences;\n- identification of critical control points;\n- experimental design and acceptance criteria for analytical methods;\n- information on trial production batches, qualification batches and process validation;\n- change control for any process deviations encountered;\n- assessment of end-product;\n- arrangements for keeping retention samples of active ingredients, intermediates and finished products, and information on reference substances where applicable; and\n- conclusion, including signed-off approval by project manager.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2043, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "01b990a6-d92c-4b39-8952-b1eaf3d060bc": {"__data__": {"id_": "01b990a6-d92c-4b39-8952-b1eaf3d060bc", "embedding": null, "metadata": {"page_label": "306", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 \nThe SU should provide the necessary validation documentation for the process and its support functions. Usually, an established process is transferred, and such documentation is already available.\n\n# 4.7 \nThe SU should provide criteria and information on hazards and critical steps associated with the product, process or method to be transferred, to serve as a basis for a quality risk management (QRM) exercise at the RU (7\u201310).\n\n# 4.8 \nThe SU or third party should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms, quality control (QC) procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).\n\n# 4.9 \nThe SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:\n\n- Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and\n- Qualification of the rooms for both manufacture and packaging at the RU site.\n\n# 4.10 \nThe SU and the RU should jointly implement any training programmes that may be required specific to the product, process or method to be transferred, e.g. on analytical methods or equipment usage, and assess training outcomes.\n\n# 4.11 \nThe SU and the RU should jointly execute the transfer protocol according to a checklist and or flow diagram showing the sequence of steps to be carried out to effect an efficient transfer.\n\n# 4.12 \nAny changes and adaptations made during the course of the technology transfer should be fully documented.\n\n# 4.13 \nThe SU and the RU should jointly document the execution of the transfer protocol in a transfer of technology summary in a report.\n\n## Project team\n\n# 4.14 \nAny transfer project will be managed by a team comprising members with clearly defined key responsibilities. The team should be drawn from members of relevant disciplines from both the SU and RU sites.\n\n# 4.15 \nThe team members should have the necessary qualifications and experience to manage their particular aspect of the transfer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda el proceso de transferencia de tecnolog\u00eda en el \u00e1mbito farmac\u00e9utico. Se enfatiza la importancia de la documentaci\u00f3n de validaci\u00f3n, la evaluaci\u00f3n de la preparaci\u00f3n del sitio receptor (RU), la verificaci\u00f3n conjunta de protocolos de validaci\u00f3n, la implementaci\u00f3n de programas de capacitaci\u00f3n y la gesti\u00f3n del proyecto por un equipo multidisciplinario. Se destaca la necesidad de documentar cualquier cambio durante la transferencia y de llevar un registro detallado del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n de validaci\u00f3n debe proporcionar la SU antes de la transferencia?**\n   - La SU debe proporcionar la documentaci\u00f3n necesaria que valide el proceso y sus funciones de soporte, que generalmente ya est\u00e1 disponible si se trata de un proceso establecido.\n\n2. **\u00bfCu\u00e1les son los criterios que la SU debe proporcionar para la gesti\u00f3n de riesgos de calidad (QRM) en el RU?**\n   - La SU debe proporcionar criterios e informaci\u00f3n sobre los peligros y los pasos cr\u00edticos asociados con el producto, proceso o m\u00e9todo a transferir, que servir\u00e1n como base para un ejercicio de gesti\u00f3n de riesgos de calidad en el RU.\n\n3. **\u00bfQu\u00e9 aspectos deben ser verificados conjuntamente por la SU y el RU antes de la transferencia?**\n   - La SU y el RU deben verificar que est\u00e9n disponibles los protocolos de validaci\u00f3n completados, que incluyen datos de calificaci\u00f3n de instalaci\u00f3n (IQ) y calificaci\u00f3n operativa (OQ) para el equipo de fabricaci\u00f3n y envasado, as\u00ed como la calificaci\u00f3n de las salas de fabricaci\u00f3n y envasado en el sitio del RU.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Protocolo de Validaci\u00f3n (VP)**: Documento que describe las actividades y criterios de aceptaci\u00f3n para la aprobaci\u00f3n de un proceso de fabricaci\u00f3n.\n\n2. **Informe de Validaci\u00f3n (VR)**: Documento que compila y resume los registros, resultados y evaluaciones de un programa de validaci\u00f3n completado, incluyendo propuestas de mejora.\n\n3. **Transferencia de Tecnolog\u00eda**: Implica la colaboraci\u00f3n entre una Unidad de Suministro (SU) y una Unidad Receptora (RU), con la posibilidad de una unidad adicional para la gesti\u00f3n y aprobaci\u00f3n del proceso.\n\n4. **Acuerdo Formal**: Especifica las responsabilidades de las partes involucradas antes, durante y despu\u00e9s de la transferencia, asegurando una coordinaci\u00f3n efectiva.\n\n5. **Plan de Gesti\u00f3n de Proyectos**: Debe identificar y controlar todas las actividades necesarias desde el inicio del proceso de transferencia.\n\n6. **Protocolo de Transferencia**: Debe incluir elementos como objetivos, alcance, personal clave, comparaci\u00f3n de materiales y m\u00e9todos, etapas de transferencia, identificaci\u00f3n de puntos de control cr\u00edticos, dise\u00f1o experimental, informaci\u00f3n sobre lotes de producci\u00f3n y control de cambios.\n\n7. **Puntos de Control Cr\u00edticos**: Elementos clave que deben ser monitoreados para asegurar la calidad y eficacia del proceso de transferencia.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Unidad de Suministro (SU)**: Parte responsable de proporcionar los recursos necesarios para la transferencia.\n- **Unidad Receptora (RU)**: Parte que recibe y utiliza los recursos transferidos.\n- **Personal Clave**: Individuos responsables de las diferentes etapas del proceso de transferencia.\n- **Muestras de Retenci\u00f3n**: Muestras de ingredientes activos, intermedios y productos terminados que deben ser conservadas para referencia futura.\n\nEste resumen destaca la importancia de la organizaci\u00f3n, la documentaci\u00f3n y la gesti\u00f3n en el proceso de transferencia de tecnolog\u00eda en el \u00e1mbito de la fabricaci\u00f3n, seg\u00fan lo establecido por la OMS.", "excerpt_keywords": "Keywords: technology transfer, validation documentation, quality risk management, project team, pharmaceutical production"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "46afcb6d-2b39-47c6-86d1-b0de08358a85", "node_type": "4", "metadata": {"page_label": "306", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 \nThe SU should provide the necessary validation documentation for the process and its support functions. Usually, an established process is transferred, and such documentation is already available.\n\n# 4.7 \nThe SU should provide criteria and information on hazards and critical steps associated with the product, process or method to be transferred, to serve as a basis for a quality risk management (QRM) exercise at the RU (7\u201310).\n\n# 4.8 \nThe SU or third party should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms, quality control (QC) procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).\n\n# 4.9 \nThe SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:\n\n- Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and\n- Qualification of the rooms for both manufacture and packaging at the RU site.\n\n# 4.10 \nThe SU and the RU should jointly implement any training programmes that may be required specific to the product, process or method to be transferred, e.g. on analytical methods or equipment usage, and assess training outcomes.\n\n# 4.11 \nThe SU and the RU should jointly execute the transfer protocol according to a checklist and or flow diagram showing the sequence of steps to be carried out to effect an efficient transfer.\n\n# 4.12 \nAny changes and adaptations made during the course of the technology transfer should be fully documented.\n\n# 4.13 \nThe SU and the RU should jointly document the execution of the transfer protocol in a transfer of technology summary in a report.\n\n## Project team\n\n# 4.14 \nAny transfer project will be managed by a team comprising members with clearly defined key responsibilities. The team should be drawn from members of relevant disciplines from both the SU and RU sites.\n\n# 4.15 \nThe team members should have the necessary qualifications and experience to manage their particular aspect of the transfer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5e5f56659c0267795443ba894e6de15efc88ccb302ca3508e38b3c1d3025e431", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.6 \nThe SU should provide the necessary validation documentation for the process and its support functions. Usually, an established process is transferred, and such documentation is already available.\n\n# 4.7 \nThe SU should provide criteria and information on hazards and critical steps associated with the product, process or method to be transferred, to serve as a basis for a quality risk management (QRM) exercise at the RU (7\u201310).\n\n# 4.8 \nThe SU or third party should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms, quality control (QC) procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).\n\n# 4.9 \nThe SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:\n\n- Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and\n- Qualification of the rooms for both manufacture and packaging at the RU site.\n\n# 4.10 \nThe SU and the RU should jointly implement any training programmes that may be required specific to the product, process or method to be transferred, e.g. on analytical methods or equipment usage, and assess training outcomes.\n\n# 4.11 \nThe SU and the RU should jointly execute the transfer protocol according to a checklist and or flow diagram showing the sequence of steps to be carried out to effect an efficient transfer.\n\n# 4.12 \nAny changes and adaptations made during the course of the technology transfer should be fully documented.\n\n# 4.13 \nThe SU and the RU should jointly document the execution of the transfer protocol in a transfer of technology summary in a report.\n\n## Project team\n\n# 4.14 \nAny transfer project will be managed by a team comprising members with clearly defined key responsibilities. The team should be drawn from members of relevant disciplines from both the SU and RU sites.\n\n# 4.15 \nThe team members should have the necessary qualifications and experience to manage their particular aspect of the transfer.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2249, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c993cbcf-4237-474e-b5a6-32eeedb0530a": {"__data__": {"id_": "c993cbcf-4237-474e-b5a6-32eeedb0530a", "embedding": null, "metadata": {"page_label": "307", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production: transfer (processing, packaging and cleaning)\n\n5.1 The RU should be able to accommodate the intended production capacity. If possible, it should be established at the outset whether the intention is to perform single-batch manufacture, continuous production or campaigns.\n\n5.2 Consideration should be given to the level and depth of detail to be transferred to support production and any further process development and optimization at the RU as intended under the transfer project plan.\n\n5.3 Consideration should be given to the technical expertise, site technology and site capabilities for the RU. It should be identified upfront by the SU of any process robustness issues so that plans may be put in place at the RU.\n\n5.4 The SU and the RU should jointly develop a protocol for the transfer of relevant information related to the process under consideration from the SU to the RU, as well as the development of a comparable process at the RU.\n\n## Starting materials\n\n5.5 The specifications and relevant functional characteristics of the starting materials (APIs and excipients) (I1, I2) to be used at the RU should be consistent with materials used at the SU. Any properties which are likely to influence the process or product should be identified and characterized.\n\n## Active pharmaceutical ingredients (API)\n\n5.6 The SU should provide the RU with the open (applicant\u2019s) part of the API master file (APIMF or drug master file (DMF) or active substance master file (ASMF)), or equivalent information and any relevant additional information on the API of importance for the manufacture of the pharmaceutical product. The following are examples of the information which may typically be provided; however the information needed in each specific case should be assessed using the principles of QRM:\n\n- Manufacturer and associated supply chain;\n- Step of the API to be transferred;\n- Flow chart of synthesis pathway, outlining the process, including entry points for raw materials, critical steps, process controls and intermediates;\n- Where relevant, definitive physical form of the API (including photomicrographs and other relevant data) and any polymorphic and solvate forms;\n- Solubility profile;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de transferencia de producci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en la capacidad de la unidad receptora (RU) para manejar la producci\u00f3n, la importancia de la transferencia de informaci\u00f3n t\u00e9cnica entre la unidad suministradora (SU) y la RU, y la necesidad de que los materiales iniciales y los ingredientes farmac\u00e9uticos activos (API) sean consistentes y bien documentados. Se enfatiza la colaboraci\u00f3n entre la SU y la RU para desarrollar protocolos que aseguren una transferencia efectiva y la optimizaci\u00f3n de procesos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos t\u00e9cnicos deben considerarse al evaluar la capacidad de producci\u00f3n de la unidad receptora (RU) en comparaci\u00f3n con la unidad suministradora (SU)?**\n   - Esta pregunta se centra en los detalles t\u00e9cnicos que pueden no estar expl\u00edcitamente mencionados en otros documentos, como la experiencia t\u00e9cnica y las capacidades del sitio.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n espec\u00edfica sobre el ingrediente farmac\u00e9utico activo (API) debe ser proporcionada por la unidad suministradora (SU) a la unidad receptora (RU) para asegurar una transferencia efectiva?**\n   - Esta pregunta busca detalles sobre la documentaci\u00f3n y la informaci\u00f3n cr\u00edtica que se requiere para la transferencia de API, que puede no estar disponible en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe abordar la identificaci\u00f3n y caracterizaci\u00f3n de propiedades de los materiales iniciales que pueden influir en el proceso de producci\u00f3n?**\n   - Esta pregunta se enfoca en el proceso de identificaci\u00f3n y caracterizaci\u00f3n de propiedades de los materiales iniciales, un aspecto que puede ser espec\u00edfico y no ampliamente discutido en otros contextos.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la transferencia de procesos de producci\u00f3n farmac\u00e9utica, destacando la importancia de la colaboraci\u00f3n entre las unidades suministradoras y receptoras. Se enfatiza la necesidad de que ambas partes desarrollen protocolos claros y compartan informaci\u00f3n t\u00e9cnica relevante, asegurando que los materiales utilizados sean consistentes y que se mantenga la calidad del producto final. La transferencia de informaci\u00f3n sobre los ingredientes farmac\u00e9uticos activos y las especificaciones de los materiales iniciales es crucial para el \u00e9xito del proceso de producci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Validaci\u00f3n**: La SU (Suministrador) debe proporcionar la documentaci\u00f3n necesaria para validar el proceso y sus funciones de soporte, que generalmente ya est\u00e1 disponible si se trata de un proceso establecido.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**: La SU debe ofrecer criterios e informaci\u00f3n sobre peligros y pasos cr\u00edticos asociados con el producto, proceso o m\u00e9todo a transferir, que servir\u00e1n como base para un ejercicio de QRM en el RU (Receptor).\n\n3. **Evaluaci\u00f3n de Preparaci\u00f3n del RU**: Antes de la transferencia, la SU o un tercero debe evaluar la idoneidad y el grado de preparaci\u00f3n del RU en t\u00e9rminos de instalaciones, equipos y servicios de soporte.\n\n4. **Verificaci\u00f3n de Protocolos de Validaci\u00f3n**: La SU y el RU deben verificar conjuntamente que se disponga de protocolos de validaci\u00f3n completados, incluyendo datos de calificaci\u00f3n de instalaci\u00f3n (IQ) y calificaci\u00f3n operativa (OQ) para el equipo de fabricaci\u00f3n y envasado.\n\n5. **Programas de Capacitaci\u00f3n**: Ambas partes deben implementar programas de capacitaci\u00f3n espec\u00edficos para el producto, proceso o m\u00e9todo a transferir y evaluar los resultados de dicha capacitaci\u00f3n.\n\n6. **Ejecuci\u00f3n del Protocolo de Transferencia**: La transferencia debe llevarse a cabo seg\u00fan un protocolo que incluya una lista de verificaci\u00f3n o un diagrama de flujo que muestre la secuencia de pasos a seguir.\n\n7. **Documentaci\u00f3n de Cambios**: Cualquier cambio o adaptaci\u00f3n durante la transferencia debe ser completamente documentado.\n\n8. **Gesti\u00f3n del Proyecto**: El proyecto de transferencia debe ser gestionado por un equipo multidisciplinario con responsabilidades claramente definidas, compuesto por miembros de ambas partes.\n\n### Entidades\n\n- **SU (Suministrador)**: Parte responsable de proporcionar la tecnolog\u00eda y la documentaci\u00f3n necesaria.\n- **RU (Receptor)**: Parte que recibe la tecnolog\u00eda y debe estar preparada para su implementaci\u00f3n.\n- **Protocolos de Validaci\u00f3n**: Documentos que aseguran que los equipos y procesos cumplen con los est\u00e1ndares requeridos.\n- **Equipo de Proyecto**: Grupo de personas con responsabilidades definidas que gestionan el proceso de transferencia.\n- **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Proceso de verificaci\u00f3n de que los equipos est\u00e1n instalados correctamente.\n- **Calificaci\u00f3n Operativa (OQ)**: Proceso de verificaci\u00f3n de que los equipos funcionan seg\u00fan lo previsto.\n\nEste resumen destaca los aspectos esenciales del proceso de transferencia de tecnolog\u00eda en el \u00e1mbito farmac\u00e9utico, enfatizando la importancia de la documentaci\u00f3n, la capacitaci\u00f3n y la gesti\u00f3n adecuada del proyecto.", "excerpt_keywords": "Keywords: production transfer, active pharmaceutical ingredients, process optimization, technical expertise, starting materials"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fc0302f0-c2a1-43ee-aabd-75b7a3be177a", "node_type": "4", "metadata": {"page_label": "307", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production: transfer (processing, packaging and cleaning)\n\n5.1 The RU should be able to accommodate the intended production capacity. If possible, it should be established at the outset whether the intention is to perform single-batch manufacture, continuous production or campaigns.\n\n5.2 Consideration should be given to the level and depth of detail to be transferred to support production and any further process development and optimization at the RU as intended under the transfer project plan.\n\n5.3 Consideration should be given to the technical expertise, site technology and site capabilities for the RU. It should be identified upfront by the SU of any process robustness issues so that plans may be put in place at the RU.\n\n5.4 The SU and the RU should jointly develop a protocol for the transfer of relevant information related to the process under consideration from the SU to the RU, as well as the development of a comparable process at the RU.\n\n## Starting materials\n\n5.5 The specifications and relevant functional characteristics of the starting materials (APIs and excipients) (I1, I2) to be used at the RU should be consistent with materials used at the SU. Any properties which are likely to influence the process or product should be identified and characterized.\n\n## Active pharmaceutical ingredients (API)\n\n5.6 The SU should provide the RU with the open (applicant\u2019s) part of the API master file (APIMF or drug master file (DMF) or active substance master file (ASMF)), or equivalent information and any relevant additional information on the API of importance for the manufacture of the pharmaceutical product. The following are examples of the information which may typically be provided; however the information needed in each specific case should be assessed using the principles of QRM:\n\n- Manufacturer and associated supply chain;\n- Step of the API to be transferred;\n- Flow chart of synthesis pathway, outlining the process, including entry points for raw materials, critical steps, process controls and intermediates;\n- Where relevant, definitive physical form of the API (including photomicrographs and other relevant data) and any polymorphic and solvate forms;\n- Solubility profile;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cd75d1250eac8978344384edeac5539d5a2e034f612695f9588e15e4e4fc09fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Production: transfer (processing, packaging and cleaning)\n\n5.1 The RU should be able to accommodate the intended production capacity. If possible, it should be established at the outset whether the intention is to perform single-batch manufacture, continuous production or campaigns.\n\n5.2 Consideration should be given to the level and depth of detail to be transferred to support production and any further process development and optimization at the RU as intended under the transfer project plan.\n\n5.3 Consideration should be given to the technical expertise, site technology and site capabilities for the RU. It should be identified upfront by the SU of any process robustness issues so that plans may be put in place at the RU.\n\n5.4 The SU and the RU should jointly develop a protocol for the transfer of relevant information related to the process under consideration from the SU to the RU, as well as the development of a comparable process at the RU.\n\n## Starting materials\n\n5.5 The specifications and relevant functional characteristics of the starting materials (APIs and excipients) (I1, I2) to be used at the RU should be consistent with materials used at the SU. Any properties which are likely to influence the process or product should be identified and characterized.\n\n## Active pharmaceutical ingredients (API)\n\n5.6 The SU should provide the RU with the open (applicant\u2019s) part of the API master file (APIMF or drug master file (DMF) or active substance master file (ASMF)), or equivalent information and any relevant additional information on the API of importance for the manufacture of the pharmaceutical product. The following are examples of the information which may typically be provided; however the information needed in each specific case should be assessed using the principles of QRM:\n\n- Manufacturer and associated supply chain;\n- Step of the API to be transferred;\n- Flow chart of synthesis pathway, outlining the process, including entry points for raw materials, critical steps, process controls and intermediates;\n- Where relevant, definitive physical form of the API (including photomicrographs and other relevant data) and any polymorphic and solvate forms;\n- Solubility profile;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2217, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "71137471-68c8-4efe-8f9b-494a73bfe6d2": {"__data__": {"id_": "71137471-68c8-4efe-8f9b-494a73bfe6d2", "embedding": null, "metadata": {"page_label": "308", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- if relevant, pH in solution;\n- partition coefficient, including the method of determination;\n- intrinsic dissolution rate, including the method of determination;\n- particle size and distribution, including the method of determination;\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate;\n- water content and determination of hygroscopicity, including water activity data and special handling requirements;\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the API supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements;\n- specifications and justification for release and end-of-life limits;\n- summary of stability studies conducted in conformity with current guidelines, including conclusions and recommendations on retest date;\n- list of potential and observed synthetic impurities, with data to support proposed specifications and typically observed levels;\n- information on degradants, with a list of potential and observed degradation products and data to support proposed specifications and typically observed levels;\n- potency factor, indicating observed purity and justification for any recommended adjustment to the input quantity of API for product manufacturing, providing example calculations; and\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets) and sensitivity to heat, light or moisture.\n\n# Excipients\n\n5.7 The excipients (I1) to be used have a potential impact on the final product. Their specifications and relevant functional characteristics should, therefore, be made available by the SU for transfer to the RU site. The following are examples of the information which may typically be provided; however, the information needed in each specific case should be assessed using the principles of QRM:\n\n- manufacturer and associated supply chain;\n- description of functionality, with justification for inclusion of any antioxidant, preservative or any excipient;\n- definitive form (particularly for solid and inhaled dosage forms);\n- solubility profile (particularly for inhaled and transdermal dosage forms);\n- partition coefficient, including the method of determination (for transdermal dosage forms);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para determinar el coeficiente de partici\u00f3n y la tasa de disoluci\u00f3n intr\u00ednseca de un API, y por qu\u00e9 son importantes estos par\u00e1metros en el desarrollo de productos farmac\u00e9uticos?**\n\n2. **\u00bfQu\u00e9 consideraciones microbiol\u00f3gicas deben tenerse en cuenta al evaluar un API, y c\u00f3mo se relacionan estas consideraciones con los requisitos de las farmacopeas nacionales, regionales o internacionales?**\n\n3. **\u00bfQu\u00e9 informaci\u00f3n sobre los excipientes es crucial para su transferencia desde el sitio del fabricante (SU) al sitio del usuario (RU), y c\u00f3mo se eval\u00faa la funcionalidad de estos excipientes en el contexto de la calidad del producto final?**\n\n### Res\u00famenes de nivel superior del contexto:\n\n1. **Par\u00e1metros de calidad del API:** El contexto detalla una serie de par\u00e1metros cr\u00edticos que deben evaluarse para un API, incluyendo propiedades fisicoqu\u00edmicas, microbiol\u00f3gicas y de estabilidad, as\u00ed como la necesidad de justificar especificaciones y l\u00edmites de liberaci\u00f3n.\n\n2. **Impacto de los excipientes:** Se enfatiza la importancia de los excipientes en la formulaci\u00f3n final del producto, destacando la necesidad de proporcionar informaci\u00f3n sobre su funcionalidad, cadena de suministro y caracter\u00edsticas espec\u00edficas, especialmente en formas de dosificaci\u00f3n s\u00f3lidas e inhaladas.\n\n3. **Principios de Gesti\u00f3n de Riesgos de Calidad (QRM):** Se menciona que la informaci\u00f3n requerida sobre los excipientes debe ser evaluada utilizando principios de QRM, lo que sugiere un enfoque sistem\u00e1tico para identificar y mitigar riesgos en el desarrollo de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Capacidad de Producci\u00f3n**: La unidad receptora (RU) debe ser capaz de manejar la capacidad de producci\u00f3n prevista, considerando si se realizar\u00e1 una fabricaci\u00f3n por lotes, producci\u00f3n continua o campa\u00f1as.\n\n2. **Transferencia de Informaci\u00f3n**: Es crucial establecer un protocolo conjunto entre la unidad suministradora (SU) y la RU para la transferencia de informaci\u00f3n t\u00e9cnica relevante, as\u00ed como para el desarrollo de un proceso comparable en la RU.\n\n3. **Materiales Iniciales**: Los materiales iniciales, incluidos los ingredientes farmac\u00e9uticos activos (API) y excipientes, deben ser consistentes con los utilizados en la SU. Se deben identificar y caracterizar las propiedades que puedan influir en el proceso o producto.\n\n4. **Ingredientes Farmac\u00e9uticos Activos (API)**: La SU debe proporcionar a la RU informaci\u00f3n detallada sobre el API, incluyendo el archivo maestro del API (APIMF, DMF o ASMF), la cadena de suministro, el flujo del proceso de s\u00edntesis, y las caracter\u00edsticas f\u00edsicas y perfil de solubilidad del API.\n\n5. **Colaboraci\u00f3n y Optimizaci\u00f3n**: Se enfatiza la importancia de la colaboraci\u00f3n entre la SU y la RU para optimizar los procesos y asegurar la calidad del producto final.\n\n### Entidades\n\n- **Unidad Receptora (RU)**: Entidad que recibe la transferencia de producci\u00f3n.\n- **Unidad Suministradora (SU)**: Entidad que proporciona la informaci\u00f3n y los materiales para la producci\u00f3n.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Sustancias que tienen un efecto terap\u00e9utico en los productos farmac\u00e9uticos.\n- **Materiales Iniciales**: Incluyen tanto los API como los excipientes utilizados en la producci\u00f3n.\n- **Protocolos de Transferencia**: Documentos que establecen c\u00f3mo se compartir\u00e1 la informaci\u00f3n t\u00e9cnica entre la SU y la RU.\n\nEste resumen destaca la importancia de la planificaci\u00f3n y la colaboraci\u00f3n en el proceso de transferencia de producci\u00f3n farmac\u00e9utica, asegurando que se mantenga la calidad y la eficacia del producto final.", "excerpt_keywords": "Keywords: API, excipients, microbiological considerations, quality risk management, stability studies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74cac053-556d-4880-bdc8-de6bf3a3470e", "node_type": "4", "metadata": {"page_label": "308", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- if relevant, pH in solution;\n- partition coefficient, including the method of determination;\n- intrinsic dissolution rate, including the method of determination;\n- particle size and distribution, including the method of determination;\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate;\n- water content and determination of hygroscopicity, including water activity data and special handling requirements;\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the API supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements;\n- specifications and justification for release and end-of-life limits;\n- summary of stability studies conducted in conformity with current guidelines, including conclusions and recommendations on retest date;\n- list of potential and observed synthetic impurities, with data to support proposed specifications and typically observed levels;\n- information on degradants, with a list of potential and observed degradation products and data to support proposed specifications and typically observed levels;\n- potency factor, indicating observed purity and justification for any recommended adjustment to the input quantity of API for product manufacturing, providing example calculations; and\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets) and sensitivity to heat, light or moisture.\n\n# Excipients\n\n5.7 The excipients (I1) to be used have a potential impact on the final product. Their specifications and relevant functional characteristics should, therefore, be made available by the SU for transfer to the RU site. The following are examples of the information which may typically be provided; however, the information needed in each specific case should be assessed using the principles of QRM:\n\n- manufacturer and associated supply chain;\n- description of functionality, with justification for inclusion of any antioxidant, preservative or any excipient;\n- definitive form (particularly for solid and inhaled dosage forms);\n- solubility profile (particularly for inhaled and transdermal dosage forms);\n- partition coefficient, including the method of determination (for transdermal dosage forms);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1fed58dbd03904991f30a9483a15e73e28920d4921e0ffb38c6a81d58a95f69c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- if relevant, pH in solution;\n- partition coefficient, including the method of determination;\n- intrinsic dissolution rate, including the method of determination;\n- particle size and distribution, including the method of determination;\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate;\n- water content and determination of hygroscopicity, including water activity data and special handling requirements;\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the API supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements;\n- specifications and justification for release and end-of-life limits;\n- summary of stability studies conducted in conformity with current guidelines, including conclusions and recommendations on retest date;\n- list of potential and observed synthetic impurities, with data to support proposed specifications and typically observed levels;\n- information on degradants, with a list of potential and observed degradation products and data to support proposed specifications and typically observed levels;\n- potency factor, indicating observed purity and justification for any recommended adjustment to the input quantity of API for product manufacturing, providing example calculations; and\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets) and sensitivity to heat, light or moisture.\n\n# Excipients\n\n5.7 The excipients (I1) to be used have a potential impact on the final product. Their specifications and relevant functional characteristics should, therefore, be made available by the SU for transfer to the RU site. The following are examples of the information which may typically be provided; however, the information needed in each specific case should be assessed using the principles of QRM:\n\n- manufacturer and associated supply chain;\n- description of functionality, with justification for inclusion of any antioxidant, preservative or any excipient;\n- definitive form (particularly for solid and inhaled dosage forms);\n- solubility profile (particularly for inhaled and transdermal dosage forms);\n- partition coefficient, including the method of determination (for transdermal dosage forms);", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2427, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7be3f6de-8651-4d41-99ca-1ef9ffcfa64e": {"__data__": {"id_": "7be3f6de-8651-4d41-99ca-1ef9ffcfa64e", "embedding": null, "metadata": {"page_label": "309", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- intrinsic dissolution rate, including the method of determination (for transdermal dosage forms);\n- particle size and distribution, including the method of determination (for solid, inhaled and transdermal dosage forms);\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate (for solid and inhaled dosage forms);\n- compaction properties (for solid dosage forms);\n- melting point range (for semi-solid or topical dosage forms);\n- pH range (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- ionic strength (for parenteral dosage forms);\n- specific density or gravity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- viscosity and or viscoelasticity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- osmolarity (for parenteral dosage forms);\n- water content and determination of hygroscopicity, including water activity data and special handling requirements (for solid and inhaled dosage forms);\n- moisture content range (for parenteral, semisolid or topical, liquid and transdermal dosage forms);\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the excipient supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements, as applicable (for general and specific monographs);\n- specifications and justification for release and end-of-life limits;\n- information on adhesives supporting compliance with peel, sheer and adhesion design criteria (for transdermal dosage forms);\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets (MSDS)) and sensitivity to heat, light or moisture; and\n- regulatory considerations, e.g. documentation to support compliance with transmissible animal spongiform encephalopathy certification requirements (where applicable).\n\n## Information on process and finished pharmaceutical products information\n\n5.8 The SU should provide a detailed characterization of the product, including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la caracterizaci\u00f3n de excipientes y productos farmac\u00e9uticos terminados. Se enfatiza la importancia de proporcionar informaci\u00f3n sobre propiedades f\u00edsicas, m\u00e9todos de fabricaci\u00f3n, controles en proceso, especificaciones y consideraciones microbiol\u00f3gicas, as\u00ed como aspectos regulatorios y de manejo seguro.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para determinar la tasa de disoluci\u00f3n intr\u00ednseca en formas de dosificaci\u00f3n transd\u00e9rmica, y por qu\u00e9 es importante esta medida?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los m\u00e9todos de determinaci\u00f3n de la tasa de disoluci\u00f3n intr\u00ednseca, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 consideraciones microbiol\u00f3gicas deben tenerse en cuenta al evaluar excipientes que pueden soportar el crecimiento microbiol\u00f3gico, y c\u00f3mo se alinean con los requisitos de las farmacopeas?**\n   - Esta pregunta se centra en las consideraciones microbiol\u00f3gicas y su relaci\u00f3n con las normativas, un aspecto que puede no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica sobre la composici\u00f3n cualitativa y cuantitativa de un producto farmac\u00e9utico terminado es esencial para cumplir con los est\u00e1ndares de la OMS, y c\u00f3mo se relaciona esto con la seguridad y el manejo del producto?**\n   - Esta pregunta busca profundizar en los requisitos de caracterizaci\u00f3n de productos farmac\u00e9uticos, un tema que puede no ser tratado en detalle en otras gu\u00edas o documentos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto proporcionado, y que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Par\u00e1metros de Calidad del API:**\n   - Se enumeran par\u00e1metros cr\u00edticos para la evaluaci\u00f3n de un Ingrediente Farmac\u00e9utico Activo (API), que incluyen:\n     - pH en soluci\u00f3n.\n     - Coeficiente de partici\u00f3n y tasa de disoluci\u00f3n intr\u00ednseca, junto con sus m\u00e9todos de determinaci\u00f3n.\n     - Tama\u00f1o y distribuci\u00f3n de part\u00edculas.\n     - Propiedades f\u00edsicas a granel (densidad, \u00e1rea de superficie, porosidad).\n     - Contenido de agua y determinaci\u00f3n de higroscopicidad.\n     - Consideraciones microbiol\u00f3gicas (esterilidad, endotoxinas bacterianas, niveles de biocarga).\n     - Especificaciones y justificaci\u00f3n para l\u00edmites de liberaci\u00f3n y vida \u00fatil.\n     - Resumen de estudios de estabilidad y recomendaciones sobre fechas de rean\u00e1lisis.\n     - Impurezas sint\u00e9ticas potenciales y observadas.\n     - Productos de degradaci\u00f3n y especificaciones asociadas.\n     - Factor de potencia y ajustes recomendados en la cantidad de API para la fabricaci\u00f3n del producto.\n     - Consideraciones especiales para almacenamiento y manejo.\n\n2. **Impacto de los Excipientes:**\n   - Los excipientes tienen un impacto significativo en el producto final. La informaci\u00f3n relevante que debe ser transferida del sitio del fabricante (SU) al sitio del usuario (RU) incluye:\n     - Fabricante y cadena de suministro asociada.\n     - Descripci\u00f3n de la funcionalidad de los excipientes, incluyendo justificaci\u00f3n para antioxidantes y conservantes.\n     - Forma definitiva, especialmente para formas de dosificaci\u00f3n s\u00f3lidas e inhaladas.\n     - Perfil de solubilidad, particularmente para formas de dosificaci\u00f3n inhaladas y transd\u00e9rmicas.\n     - Coeficiente de partici\u00f3n y m\u00e9todo de determinaci\u00f3n para formas transd\u00e9rmicas.\n\n3. **Principios de Gesti\u00f3n de Riesgos de Calidad (QRM):**\n   - La informaci\u00f3n sobre los excipientes debe ser evaluada utilizando principios de QRM, lo que implica un enfoque sistem\u00e1tico para identificar y mitigar riesgos en el desarrollo de productos farmac\u00e9uticos.\n\n### Entidades Clave:\n- **API (Ingrediente Farmac\u00e9utico Activo)**\n- **Excipientes**\n- **Propiedades fisicoqu\u00edmicas**\n- **Estabilidad**\n- **Microbiolog\u00eda**\n- **Gesti\u00f3n de Riesgos de Calidad (QRM)**\n\nEste resumen destaca la importancia de los par\u00e1metros de calidad del API y la funcionalidad de los excipientes en el desarrollo de productos farmac\u00e9uticos, as\u00ed como la necesidad de un enfoque sistem\u00e1tico para la gesti\u00f3n de riesgos.", "excerpt_keywords": "Keywords: dissolution rate, microbiological considerations, excipients, pharmaceutical products, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d8ffe89-0950-4099-b3c0-0c30069f1d6b", "node_type": "4", "metadata": {"page_label": "309", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- intrinsic dissolution rate, including the method of determination (for transdermal dosage forms);\n- particle size and distribution, including the method of determination (for solid, inhaled and transdermal dosage forms);\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate (for solid and inhaled dosage forms);\n- compaction properties (for solid dosage forms);\n- melting point range (for semi-solid or topical dosage forms);\n- pH range (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- ionic strength (for parenteral dosage forms);\n- specific density or gravity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- viscosity and or viscoelasticity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- osmolarity (for parenteral dosage forms);\n- water content and determination of hygroscopicity, including water activity data and special handling requirements (for solid and inhaled dosage forms);\n- moisture content range (for parenteral, semisolid or topical, liquid and transdermal dosage forms);\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the excipient supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements, as applicable (for general and specific monographs);\n- specifications and justification for release and end-of-life limits;\n- information on adhesives supporting compliance with peel, sheer and adhesion design criteria (for transdermal dosage forms);\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets (MSDS)) and sensitivity to heat, light or moisture; and\n- regulatory considerations, e.g. documentation to support compliance with transmissible animal spongiform encephalopathy certification requirements (where applicable).\n\n## Information on process and finished pharmaceutical products information\n\n5.8 The SU should provide a detailed characterization of the product, including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dea2bb9161505aa0ff4b17a1dacedafd7345606cc4160127b6c6a3add85a9e3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- intrinsic dissolution rate, including the method of determination (for transdermal dosage forms);\n- particle size and distribution, including the method of determination (for solid, inhaled and transdermal dosage forms);\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate (for solid and inhaled dosage forms);\n- compaction properties (for solid dosage forms);\n- melting point range (for semi-solid or topical dosage forms);\n- pH range (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- ionic strength (for parenteral dosage forms);\n- specific density or gravity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- viscosity and or viscoelasticity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- osmolarity (for parenteral dosage forms);\n- water content and determination of hygroscopicity, including water activity data and special handling requirements (for solid and inhaled dosage forms);\n- moisture content range (for parenteral, semisolid or topical, liquid and transdermal dosage forms);\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the excipient supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements, as applicable (for general and specific monographs);\n- specifications and justification for release and end-of-life limits;\n- information on adhesives supporting compliance with peel, sheer and adhesion design criteria (for transdermal dosage forms);\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets (MSDS)) and sensitivity to heat, light or moisture; and\n- regulatory considerations, e.g. documentation to support compliance with transmissible animal spongiform encephalopathy certification requirements (where applicable).\n\n## Information on process and finished pharmaceutical products information\n\n5.8 The SU should provide a detailed characterization of the product, including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2425, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "04c53214-34d1-49f9-9386-547d1ff551a9": {"__data__": {"id_": "04c53214-34d1-49f9-9386-547d1ff551a9", "embedding": null, "metadata": {"page_label": "310", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.9\n\nThe SU should provide any information on the history of process development which may be required to enable the RU to perform any further development and or process optimization after successful transfer. Such information may include the following:\n\n- Information on clinical development, e.g. information on the rationale for the synthesis, route and form selection, technology selection, equipment, clinical tests, and product composition;\n- Information on scale-up activities: process optimization, statistical optimization of critical process parameters, critical quality attributes, pilot report and or information on pilot-scale development activities indicating the number and disposition of batches manufactured;\n- Information or report on full-scale development activities, indicating the number and disposition of batches manufactured, and deviation and change control (sometimes referred to as change management) reports which led to the current manufacturing process;\n- The change history and reasons, e.g. a change control log, indicating any changes to the process or primary packaging or analytical methods as a part of process optimization or improvement; and\n- Information on investigations of problems and the outcomes of the investigations.\n\n## 5.10\n\nThe SU should provide to the RU information on any health, safety and environmental issues associated with the manufacturing processes to be transferred, and the implications, e.g. need for gowning or protective clothing.\n\n## 5.11\n\nThe SU should provide to the RU information on current processing and testing, including but not limited to:\n\n- A detailed description of facility requirements and equipment;\n- Information on starting materials, applicable MSDS and storage requirements for raw materials and finished products;\n- Description of manufacturing steps (narrative and process maps or flow charts, and or master batch records), including qualification of in-processing hold times and conditions, order and method of raw material addition and bulk transfers between processing steps;\n- Description of analytical methods;\n- Identification and justification of control strategy (e.g. identification of critical performance aspects for specific dosage forms, identification of process control points, product quality attributes and qualification of critical processing parameter ranges, statistical process control (SPC) charts);\n- Design space, in cases where this has been defined;\n- Validation information, e.g. validation plans and reports;\n- Annual product quality reviews;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n sobre el desarrollo cl\u00ednico debe proporcionar la SU al RU para facilitar la optimizaci\u00f3n del proceso despu\u00e9s de la transferencia?**\n   - Esta pregunta se centra en los detalles espec\u00edficos que la SU debe compartir sobre el desarrollo cl\u00ednico, incluyendo la justificaci\u00f3n para la s\u00edntesis y la selecci\u00f3n de tecnolog\u00eda, que no se detalla en otras secciones del documento.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en el informe de actividades de desarrollo a gran escala que la SU debe proporcionar al RU?**\n   - Esta pregunta busca informaci\u00f3n sobre los aspectos espec\u00edficos que deben ser documentados en el informe de desarrollo a gran escala, como la disposici\u00f3n de lotes fabricados y los informes de control de cambios, que son cruciales para entender el proceso de fabricaci\u00f3n actual.\n\n3. **\u00bfQu\u00e9 consideraciones de salud, seguridad y medio ambiente deben tener en cuenta el RU al recibir informaci\u00f3n sobre los procesos de fabricaci\u00f3n transferidos?**\n   - Esta pregunta se enfoca en los aspectos de salud y seguridad que la SU debe comunicar al RU, lo cual es esencial para garantizar un entorno de trabajo seguro y cumplir con las normativas pertinentes.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento proporciona directrices sobre la informaci\u00f3n que debe ser transferida de una Unidad de Suministro (SU) a una Unidad Receptora (RU) durante el proceso de transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos. Se enfatiza la importancia de compartir informaci\u00f3n sobre el desarrollo del proceso, la optimizaci\u00f3n, la seguridad y los requisitos de instalaci\u00f3n, as\u00ed como los m\u00e9todos anal\u00edticos y las estrategias de control. Esto asegura que el RU pueda continuar el desarrollo y la producci\u00f3n de manera efectiva y segura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Caracterizaci\u00f3n de Excipientes y Productos Farmac\u00e9uticos**:\n   - Importancia de la caracterizaci\u00f3n detallada de excipientes y productos terminados para garantizar la calidad y seguridad.\n\n2. **Propiedades F\u00edsicas**:\n   - Tasa de disoluci\u00f3n intr\u00ednseca, tama\u00f1o y distribuci\u00f3n de part\u00edculas, propiedades f\u00edsicas a granel (densidad, \u00e1rea de superficie, porosidad), propiedades de compactaci\u00f3n, rango de punto de fusi\u00f3n, pH, fuerza i\u00f3nica, densidad espec\u00edfica, viscosidad, osmolaridad, contenido de agua y humedad.\n\n3. **Consideraciones Microbiol\u00f3gicas**:\n   - Evaluaci\u00f3n de la esterilidad, endotoxinas bacterianas y niveles de biocarga, alineadas con requisitos de farmacopeas nacionales, regionales o internacionales.\n\n4. **Especificaciones y Justificaci\u00f3n**:\n   - Necesidad de especificaciones claras y justificaci\u00f3n para l\u00edmites de liberaci\u00f3n y fin de vida \u00fatil de los productos.\n\n5. **Adhesivos y Cumplimiento**:\n   - Informaci\u00f3n sobre adhesivos en formas de dosificaci\u00f3n transd\u00e9rmica y su cumplimiento con criterios de dise\u00f1o.\n\n6. **Consideraciones de Almacenamiento y Manejo**:\n   - Factores de seguridad y ambientales, sensibilidad a calor, luz o humedad, y requisitos de manejo especial.\n\n7. **Aspectos Regulatorios**:\n   - Documentaci\u00f3n necesaria para cumplir con requisitos regulatorios, como certificaciones relacionadas con encefalopat\u00edas espongiformes transmisibles.\n\n8. **Informaci\u00f3n sobre Productos Farmac\u00e9uticos Terminados**:\n   - Requisitos para la composici\u00f3n cualitativa y cuantitativa, descripci\u00f3n f\u00edsica, m\u00e9todo de fabricaci\u00f3n, controles en proceso, m\u00e9todos de control, especificaciones y consideraciones de seguridad y manejo.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece los est\u00e1ndares y requisitos.\n- **Excipientes**: Sustancias inactivas que acompa\u00f1an al principio activo en las formulaciones.\n- **Productos Farmac\u00e9uticos**: Formas de dosificaci\u00f3n que incluyen parenterales, semis\u00f3lidos, t\u00f3picos, l\u00edquidos y transd\u00e9rmicos.\n- **Farmacopeas**: Compendios de est\u00e1ndares de calidad y pruebas para medicamentos.\n- **Material Safety Data Sheets (MSDS)**: Documentos que proporcionan informaci\u00f3n sobre las propiedades de las sustancias qu\u00edmicas y su manejo seguro. \n\nEste resumen destaca los aspectos esenciales y las entidades relevantes en la caracterizaci\u00f3n de excipientes y productos farmac\u00e9uticos, seg\u00fan lo estipulado en el documento de la OMS.", "excerpt_keywords": "Keywords: process development, technology transfer, clinical development, manufacturing processes, quality control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b0c0b44-13af-459b-ba25-c1729e3166a2", "node_type": "4", "metadata": {"page_label": "310", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.9\n\nThe SU should provide any information on the history of process development which may be required to enable the RU to perform any further development and or process optimization after successful transfer. Such information may include the following:\n\n- Information on clinical development, e.g. information on the rationale for the synthesis, route and form selection, technology selection, equipment, clinical tests, and product composition;\n- Information on scale-up activities: process optimization, statistical optimization of critical process parameters, critical quality attributes, pilot report and or information on pilot-scale development activities indicating the number and disposition of batches manufactured;\n- Information or report on full-scale development activities, indicating the number and disposition of batches manufactured, and deviation and change control (sometimes referred to as change management) reports which led to the current manufacturing process;\n- The change history and reasons, e.g. a change control log, indicating any changes to the process or primary packaging or analytical methods as a part of process optimization or improvement; and\n- Information on investigations of problems and the outcomes of the investigations.\n\n## 5.10\n\nThe SU should provide to the RU information on any health, safety and environmental issues associated with the manufacturing processes to be transferred, and the implications, e.g. need for gowning or protective clothing.\n\n## 5.11\n\nThe SU should provide to the RU information on current processing and testing, including but not limited to:\n\n- A detailed description of facility requirements and equipment;\n- Information on starting materials, applicable MSDS and storage requirements for raw materials and finished products;\n- Description of manufacturing steps (narrative and process maps or flow charts, and or master batch records), including qualification of in-processing hold times and conditions, order and method of raw material addition and bulk transfers between processing steps;\n- Description of analytical methods;\n- Identification and justification of control strategy (e.g. identification of critical performance aspects for specific dosage forms, identification of process control points, product quality attributes and qualification of critical processing parameter ranges, statistical process control (SPC) charts);\n- Design space, in cases where this has been defined;\n- Validation information, e.g. validation plans and reports;\n- Annual product quality reviews;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b51fb32c58f1b9b573dea324b11f333a48b82456ed92f370cb864eda6d427ad0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 5.9\n\nThe SU should provide any information on the history of process development which may be required to enable the RU to perform any further development and or process optimization after successful transfer. Such information may include the following:\n\n- Information on clinical development, e.g. information on the rationale for the synthesis, route and form selection, technology selection, equipment, clinical tests, and product composition;\n- Information on scale-up activities: process optimization, statistical optimization of critical process parameters, critical quality attributes, pilot report and or information on pilot-scale development activities indicating the number and disposition of batches manufactured;\n- Information or report on full-scale development activities, indicating the number and disposition of batches manufactured, and deviation and change control (sometimes referred to as change management) reports which led to the current manufacturing process;\n- The change history and reasons, e.g. a change control log, indicating any changes to the process or primary packaging or analytical methods as a part of process optimization or improvement; and\n- Information on investigations of problems and the outcomes of the investigations.\n\n## 5.10\n\nThe SU should provide to the RU information on any health, safety and environmental issues associated with the manufacturing processes to be transferred, and the implications, e.g. need for gowning or protective clothing.\n\n## 5.11\n\nThe SU should provide to the RU information on current processing and testing, including but not limited to:\n\n- A detailed description of facility requirements and equipment;\n- Information on starting materials, applicable MSDS and storage requirements for raw materials and finished products;\n- Description of manufacturing steps (narrative and process maps or flow charts, and or master batch records), including qualification of in-processing hold times and conditions, order and method of raw material addition and bulk transfers between processing steps;\n- Description of analytical methods;\n- Identification and justification of control strategy (e.g. identification of critical performance aspects for specific dosage forms, identification of process control points, product quality attributes and qualification of critical processing parameter ranges, statistical process control (SPC) charts);\n- Design space, in cases where this has been defined;\n- Validation information, e.g. validation plans and reports;\n- Annual product quality reviews;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2561, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "443d8d01-ba6f-4610-be4d-385e3285b4bc": {"__data__": {"id_": "443d8d01-ba6f-4610-be4d-385e3285b4bc", "embedding": null, "metadata": {"page_label": "311", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- stability information;\n- an authorized set of protocols and work instructions for manufacturing; and\n- environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.\n\n5.12 During the transfer process, the RU should identify any differences in facilities, systems and capabilities and communicate with the SU about these differences to understand the potential impact on ability to run the process to deliver good product quality. Differences should be understood and satisfactorily addressed to assure equivalent product quality. Based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop relevant plant operating procedures and documentation before the start of production. Process development at the RU should address the following tasks:\n\n- comparison and assessment of suitability and qualification of facility and equipment;\n- description of manufacturing process and flow of personnel and of materials at the RU (narrative and or process maps or flow charts);\n- determination of critical steps in manufacture, including hold times, end-points, sampling points and sampling techniques (13);\n- writing and approval of SOPs for all production operations (e.g. dispensing, granulation or blending or solution preparation, tablet compression, tablet coating, encapsulation, liquid filling, primary and secondary packaging and in-process quality control), packaging, cleaning, testing and storage;\n- evaluation of stability information, with generation of site-specific stability data if required (14); and\n- compliance with regulatory requirements for any changes made, e.g. in terms of batch size.\n\n# Packaging\n\n5.13 The transfer of packaging operations should follow the same procedural patterns as those of the production transfer.\n\n5.14 Information on packaging to be transferred from the SU to the RU includes specifications for a suitable container or closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti-counterfeiting measures needed for qualification of packaging components at the RU.\n\n5.15 For QC testing of packaging components, specifications should be provided for drawings, artwork and material (for example, glass, card or fibre board).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de transferencia de productos farmac\u00e9uticos entre unidades de producci\u00f3n (RU) y unidades de suministro (SU). Se enfatiza la importancia de identificar y comunicar diferencias en las instalaciones, sistemas y capacidades entre las dos unidades para asegurar la calidad del producto. Se detallan las tareas que deben realizarse en el RU, como la evaluaci\u00f3n de la idoneidad de las instalaciones, la descripci\u00f3n del proceso de fabricaci\u00f3n, la determinaci\u00f3n de pasos cr\u00edticos y la redacci\u00f3n de procedimientos operativos est\u00e1ndar (SOP). Tambi\u00e9n se menciona la transferencia de informaci\u00f3n sobre operaciones de envasado y los requisitos de calidad para los componentes de envasado.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 pasos cr\u00edticos deben determinarse durante el desarrollo del proceso en la RU para asegurar la calidad del producto?**\n   - La RU debe determinar los pasos cr\u00edticos en la fabricaci\u00f3n, que incluyen tiempos de espera, puntos finales, puntos de muestreo y t\u00e9cnicas de muestreo.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n sobre el envasado debe ser transferida del SU al RU?**\n   - La informaci\u00f3n incluye especificaciones para un sistema de contenedor o cierre adecuado, as\u00ed como detalles sobre dise\u00f1o, requisitos de etiquetado, y medidas de seguridad como tamper-evident y anti-counterfeiting.\n\n3. **\u00bfCu\u00e1les son las implicaciones de las diferencias en las capacidades de las instalaciones entre el RU y el SU?**\n   - Las diferencias deben ser entendidas y abordadas satisfactoriamente para asegurar una calidad de producto equivalente. Esto implica que el RU debe evaluar su propia capacidad para fabricar y empaquetar el producto seg\u00fan los est\u00e1ndares requeridos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Transferencia de Informaci\u00f3n**: La Unidad de Suministro (SU) debe proporcionar informaci\u00f3n cr\u00edtica a la Unidad Receptora (RU) para facilitar el desarrollo y la optimizaci\u00f3n de procesos despu\u00e9s de la transferencia.\n\n2. **Desarrollo Cl\u00ednico**: Se requiere informaci\u00f3n sobre el desarrollo cl\u00ednico, incluyendo:\n   - Justificaci\u00f3n para la s\u00edntesis.\n   - Selecci\u00f3n de rutas y formas.\n   - Selecci\u00f3n de tecnolog\u00eda y equipo.\n   - Composici\u00f3n del producto y pruebas cl\u00ednicas.\n\n3. **Actividades de Escalado**: La SU debe incluir detalles sobre:\n   - Optimizaci\u00f3n de procesos.\n   - Par\u00e1metros cr\u00edticos de calidad.\n   - Informes de actividades a escala piloto, incluyendo n\u00famero y disposici\u00f3n de lotes fabricados.\n\n4. **Desarrollo a Gran Escala**: Informaci\u00f3n sobre:\n   - Actividades de desarrollo a gran escala.\n   - Disposici\u00f3n de lotes fabricados.\n   - Informes de control de cambios y desviaciones.\n\n5. **Historial de Cambios**: Se debe proporcionar un registro de cambios que documente:\n   - Cambios en procesos, empaques primarios y m\u00e9todos anal\u00edticos.\n   - Razones detr\u00e1s de estos cambios.\n\n6. **Investigaciones de Problemas**: Informaci\u00f3n sobre problemas encontrados durante el proceso y los resultados de las investigaciones.\n\n7. **Salud, Seguridad y Medio Ambiente**: La SU debe informar sobre:\n   - Problemas de salud y seguridad asociados con los procesos de fabricaci\u00f3n.\n   - Implicaciones como la necesidad de ropa de protecci\u00f3n.\n\n8. **Requisitos de Procesamiento y Pruebas**: Informaci\u00f3n detallada sobre:\n   - Requisitos de instalaciones y equipos.\n   - Materiales iniciales y requisitos de almacenamiento.\n   - Pasos de fabricaci\u00f3n y m\u00e9todos anal\u00edticos.\n   - Estrategias de control y validaci\u00f3n.\n\n### Entidades Clave\n- **Unidad de Suministro (SU)**: Entidad responsable de proporcionar informaci\u00f3n.\n- **Unidad Receptora (RU)**: Entidad que recibe la informaci\u00f3n para continuar el desarrollo.\n- **Documentaci\u00f3n**: Informes sobre desarrollo cl\u00ednico, escalado, control de cambios, y validaci\u00f3n.\n- **Salud y Seguridad**: Consideraciones necesarias para un entorno de trabajo seguro.\n\nEste resumen destaca la importancia de la comunicaci\u00f3n efectiva y la documentaci\u00f3n detallada en el proceso de transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos.", "excerpt_keywords": "Keywords: transfer process, product quality, manufacturing protocols, packaging specifications, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b811555b-b31d-4c84-bfa7-fbbc64503be5", "node_type": "4", "metadata": {"page_label": "311", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- stability information;\n- an authorized set of protocols and work instructions for manufacturing; and\n- environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.\n\n5.12 During the transfer process, the RU should identify any differences in facilities, systems and capabilities and communicate with the SU about these differences to understand the potential impact on ability to run the process to deliver good product quality. Differences should be understood and satisfactorily addressed to assure equivalent product quality. Based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop relevant plant operating procedures and documentation before the start of production. Process development at the RU should address the following tasks:\n\n- comparison and assessment of suitability and qualification of facility and equipment;\n- description of manufacturing process and flow of personnel and of materials at the RU (narrative and or process maps or flow charts);\n- determination of critical steps in manufacture, including hold times, end-points, sampling points and sampling techniques (13);\n- writing and approval of SOPs for all production operations (e.g. dispensing, granulation or blending or solution preparation, tablet compression, tablet coating, encapsulation, liquid filling, primary and secondary packaging and in-process quality control), packaging, cleaning, testing and storage;\n- evaluation of stability information, with generation of site-specific stability data if required (14); and\n- compliance with regulatory requirements for any changes made, e.g. in terms of batch size.\n\n# Packaging\n\n5.13 The transfer of packaging operations should follow the same procedural patterns as those of the production transfer.\n\n5.14 Information on packaging to be transferred from the SU to the RU includes specifications for a suitable container or closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti-counterfeiting measures needed for qualification of packaging components at the RU.\n\n5.15 For QC testing of packaging components, specifications should be provided for drawings, artwork and material (for example, glass, card or fibre board).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "47ec6ef790825c9a094f8e08ec04c0fd37a6c8ba97f64721a1101fcc0f3ff303", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- stability information;\n- an authorized set of protocols and work instructions for manufacturing; and\n- environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.\n\n5.12 During the transfer process, the RU should identify any differences in facilities, systems and capabilities and communicate with the SU about these differences to understand the potential impact on ability to run the process to deliver good product quality. Differences should be understood and satisfactorily addressed to assure equivalent product quality. Based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop relevant plant operating procedures and documentation before the start of production. Process development at the RU should address the following tasks:\n\n- comparison and assessment of suitability and qualification of facility and equipment;\n- description of manufacturing process and flow of personnel and of materials at the RU (narrative and or process maps or flow charts);\n- determination of critical steps in manufacture, including hold times, end-points, sampling points and sampling techniques (13);\n- writing and approval of SOPs for all production operations (e.g. dispensing, granulation or blending or solution preparation, tablet compression, tablet coating, encapsulation, liquid filling, primary and secondary packaging and in-process quality control), packaging, cleaning, testing and storage;\n- evaluation of stability information, with generation of site-specific stability data if required (14); and\n- compliance with regulatory requirements for any changes made, e.g. in terms of batch size.\n\n# Packaging\n\n5.13 The transfer of packaging operations should follow the same procedural patterns as those of the production transfer.\n\n5.14 Information on packaging to be transferred from the SU to the RU includes specifications for a suitable container or closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti-counterfeiting measures needed for qualification of packaging components at the RU.\n\n5.15 For QC testing of packaging components, specifications should be provided for drawings, artwork and material (for example, glass, card or fibre board).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2445, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4c9186f0-4779-4b7e-9b4f-57001dc50d39": {"__data__": {"id_": "4c9186f0-4779-4b7e-9b4f-57001dc50d39", "embedding": null, "metadata": {"page_label": "312", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.16 \nBased on the information provided, the RU should perform a suitability study for initial qualification of the packaging components. Packaging is considered suitable if it provides adequate protection (preventing degradation of the medicine due to environmental influences), safety (absence of undesirable substances released into the product), compatibility (absence of interaction possibly affecting medicine quality) and performance (functionality in terms of drug delivery).\n\n# Cleaning\n\n5.17 During the manufacturing process, pharmaceutical products and APIs can be contaminated by other pharmaceutical products or APIs if the plant is processing different products. To minimize the risk of contamination and cross-contamination, operator exposure and environmental effects, adequate cleaning procedures are essential.\n\n5.18 Cleaning procedures and their validation are site-specific. In order for the RU to define its cleaning strategy the SU should provide information on cleaning at the SU to minimize cross-contamination due to residues from previous manufacturing steps, operator exposure and environmental impact, including:\n\n- information on solubility of active ingredients, excipients and vehicles;\n- minimum therapeutic doses of active ingredients;\n- therapeutic category and toxicological assessment; and\n- existing cleaning procedures.\n\nAdditional information should be provided, as appropriate and where available, e.g.:\n\n- cleaning validation reports (chemical and microbiological);\n- information on cleaning agents used (efficacy, evidence that they do not interfere with analytical testing for residues of APIs, removal of residual cleaning agents); and\n- recovery studies to validate the sampling methodology.\n\n5.19 Before the transfer, the SU should provide information on limits for product residues, and the rationale for limit selection.\n\n5.20 Based on the information provided by the SU, cleaning procedures should be designed at the RU, taking into account relevant characteristics of the starting materials (e.g. potency, toxicity, solubility, corrosiveness and temperature sensitivity), manufacturing equipment design and configuration, cleaning agent and products residue.\n\n# Implementation of processing, packaging and cleaning systems\n\n5.21 Trial batch(es) (\u201cdemonstration batches\u201d) are normally produced to confirm process capability before initiating formal validation. Where trial", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento aborda la importancia de realizar estudios de idoneidad para la calificaci\u00f3n inicial de los componentes de embalaje en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la necesidad de procedimientos de limpieza adecuados para minimizar la contaminaci\u00f3n cruzada durante el proceso de fabricaci\u00f3n. Adem\u00e1s, se detalla la informaci\u00f3n que debe ser proporcionada por la unidad de suministro (SU) para definir estrategias de limpieza en la unidad receptora (RU), as\u00ed como la importancia de realizar lotes de prueba para confirmar la capacidad del proceso antes de la validaci\u00f3n formal.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios se deben considerar para determinar si un componente de embalaje es adecuado para un producto farmac\u00e9utico?**\n   - La idoneidad del embalaje se basa en su capacidad para proporcionar protecci\u00f3n adecuada, seguridad, compatibilidad y rendimiento en t\u00e9rminos de entrega del medicamento.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe proporcionar la unidad de suministro (SU) para ayudar a la unidad receptora (RU) a definir su estrategia de limpieza?**\n   - La SU debe proporcionar informaci\u00f3n sobre la solubilidad de los ingredientes activos, dosis terap\u00e9uticas m\u00ednimas, categor\u00eda terap\u00e9utica, evaluaci\u00f3n toxicol\u00f3gica y procedimientos de limpieza existentes, as\u00ed como informes de validaci\u00f3n de limpieza y detalles sobre los agentes de limpieza utilizados.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de producir lotes de prueba antes de la validaci\u00f3n formal en el proceso de fabricaci\u00f3n?**\n   - Los lotes de prueba, o \"lotes de demostraci\u00f3n\", se producen para confirmar la capacidad del proceso antes de iniciar la validaci\u00f3n formal, asegurando que el proceso es capaz de producir productos de calidad consistente.", "prev_section_summary": "### Temas Clave\n\n1. **Transferencia de Productos Farmac\u00e9uticos**: El documento aborda el proceso de transferencia de productos entre unidades de producci\u00f3n (RU) y unidades de suministro (SU), enfatizando la necesidad de asegurar la calidad del producto durante este proceso.\n\n2. **Identificaci\u00f3n de Diferencias**: Se destaca la importancia de identificar y comunicar las diferencias en instalaciones, sistemas y capacidades entre RU y SU para entender su impacto en la calidad del producto.\n\n3. **Desarrollo de Procesos en la RU**: Se enumeran las tareas que la RU debe realizar, incluyendo la evaluaci\u00f3n de instalaciones, descripci\u00f3n del proceso de fabricaci\u00f3n, determinaci\u00f3n de pasos cr\u00edticos, redacci\u00f3n de procedimientos operativos est\u00e1ndar (SOP) y cumplimiento de requisitos regulatorios.\n\n4. **Transferencia de Informaci\u00f3n de Envasado**: Se menciona que la transferencia de informaci\u00f3n sobre operaciones de envasado debe seguir patrones similares a los de la producci\u00f3n, incluyendo especificaciones para sistemas de contenedores y requisitos de etiquetado.\n\n5. **Control de Calidad (QC)**: Se requiere que se proporcionen especificaciones para la prueba de calidad de los componentes de envasado, incluyendo dibujos y materiales.\n\n### Entidades\n\n- **RU (Unidad de Producci\u00f3n)**: La unidad responsable de la fabricaci\u00f3n y empaquetado del producto.\n- **SU (Unidad de Suministro)**: La unidad que proporciona la informaci\u00f3n y los productos a la RU.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen los procedimientos a seguir en las operaciones de producci\u00f3n.\n- **Estabilidad**: Informaci\u00f3n relacionada con la estabilidad del producto que debe ser evaluada y, si es necesario, generada en el sitio.\n- **Componentes de Envasado**: Elementos utilizados para empaquetar el producto, que deben cumplir con especificaciones de calidad y seguridad.\n\n### Resumen\nEl documento de la OMS detalla el proceso de transferencia de productos farmac\u00e9uticos entre unidades de producci\u00f3n y suministro, subrayando la importancia de identificar diferencias en capacidades y asegurar la calidad del producto. Se describen las tareas que la unidad de producci\u00f3n debe llevar a cabo, incluyendo la evaluaci\u00f3n de instalaciones y la redacci\u00f3n de procedimientos operativos est\u00e1ndar. Tambi\u00e9n se aborda la transferencia de informaci\u00f3n sobre envasado y los requisitos de control de calidad para los componentes de envasado.", "excerpt_keywords": "Keywords: packaging qualification, cleaning procedures, contamination prevention, pharmaceutical manufacturing, trial batches"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5084db76-55e4-47a8-a2f9-cb19cb8555d2", "node_type": "4", "metadata": {"page_label": "312", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.16 \nBased on the information provided, the RU should perform a suitability study for initial qualification of the packaging components. Packaging is considered suitable if it provides adequate protection (preventing degradation of the medicine due to environmental influences), safety (absence of undesirable substances released into the product), compatibility (absence of interaction possibly affecting medicine quality) and performance (functionality in terms of drug delivery).\n\n# Cleaning\n\n5.17 During the manufacturing process, pharmaceutical products and APIs can be contaminated by other pharmaceutical products or APIs if the plant is processing different products. To minimize the risk of contamination and cross-contamination, operator exposure and environmental effects, adequate cleaning procedures are essential.\n\n5.18 Cleaning procedures and their validation are site-specific. In order for the RU to define its cleaning strategy the SU should provide information on cleaning at the SU to minimize cross-contamination due to residues from previous manufacturing steps, operator exposure and environmental impact, including:\n\n- information on solubility of active ingredients, excipients and vehicles;\n- minimum therapeutic doses of active ingredients;\n- therapeutic category and toxicological assessment; and\n- existing cleaning procedures.\n\nAdditional information should be provided, as appropriate and where available, e.g.:\n\n- cleaning validation reports (chemical and microbiological);\n- information on cleaning agents used (efficacy, evidence that they do not interfere with analytical testing for residues of APIs, removal of residual cleaning agents); and\n- recovery studies to validate the sampling methodology.\n\n5.19 Before the transfer, the SU should provide information on limits for product residues, and the rationale for limit selection.\n\n5.20 Based on the information provided by the SU, cleaning procedures should be designed at the RU, taking into account relevant characteristics of the starting materials (e.g. potency, toxicity, solubility, corrosiveness and temperature sensitivity), manufacturing equipment design and configuration, cleaning agent and products residue.\n\n# Implementation of processing, packaging and cleaning systems\n\n5.21 Trial batch(es) (\u201cdemonstration batches\u201d) are normally produced to confirm process capability before initiating formal validation. Where trial", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c2efe457a127b8d11a8b7ec1971b6d9a961bec0e7e56e543f1ff7784e12f65ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.16 \nBased on the information provided, the RU should perform a suitability study for initial qualification of the packaging components. Packaging is considered suitable if it provides adequate protection (preventing degradation of the medicine due to environmental influences), safety (absence of undesirable substances released into the product), compatibility (absence of interaction possibly affecting medicine quality) and performance (functionality in terms of drug delivery).\n\n# Cleaning\n\n5.17 During the manufacturing process, pharmaceutical products and APIs can be contaminated by other pharmaceutical products or APIs if the plant is processing different products. To minimize the risk of contamination and cross-contamination, operator exposure and environmental effects, adequate cleaning procedures are essential.\n\n5.18 Cleaning procedures and their validation are site-specific. In order for the RU to define its cleaning strategy the SU should provide information on cleaning at the SU to minimize cross-contamination due to residues from previous manufacturing steps, operator exposure and environmental impact, including:\n\n- information on solubility of active ingredients, excipients and vehicles;\n- minimum therapeutic doses of active ingredients;\n- therapeutic category and toxicological assessment; and\n- existing cleaning procedures.\n\nAdditional information should be provided, as appropriate and where available, e.g.:\n\n- cleaning validation reports (chemical and microbiological);\n- information on cleaning agents used (efficacy, evidence that they do not interfere with analytical testing for residues of APIs, removal of residual cleaning agents); and\n- recovery studies to validate the sampling methodology.\n\n5.19 Before the transfer, the SU should provide information on limits for product residues, and the rationale for limit selection.\n\n5.20 Based on the information provided by the SU, cleaning procedures should be designed at the RU, taking into account relevant characteristics of the starting materials (e.g. potency, toxicity, solubility, corrosiveness and temperature sensitivity), manufacturing equipment design and configuration, cleaning agent and products residue.\n\n# Implementation of processing, packaging and cleaning systems\n\n5.21 Trial batch(es) (\u201cdemonstration batches\u201d) are normally produced to confirm process capability before initiating formal validation. Where trial", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2423, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8144d89d-0238-4e91-8f37-ef948a021a9e": {"__data__": {"id_": "8144d89d-0238-4e91-8f37-ef948a021a9e", "embedding": null, "metadata": {"page_label": "313", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control: Analytical Method Transfer\n\n6.1 Transfer of analytical methods should accommodate all the analytical testing required to demonstrate compliance of the product to be transferred with the registered specification (15).\n\n6.2 Analytical methods used to test pharmaceutical products, starting materials, packaging components and cleaning (residue) samples, if applicable, should be implemented at the testing laboratory before testing of samples for process validation studies is performed by the RU. Process validation samples may be tested at the RU, the SU or a third laboratory.\n\n6.3 A protocol defining the steps should be prepared for transfer of analytical methods. The analytical methods transfer protocol should include a description of the objective, scope and responsibilities of the SU and the RU; a specification of materials and methods; the experimental design and acceptance criteria; documentation (including information to be supplied with the results, and report forms to be used, if any); procedure for the handling of deviations; references; signed approval; and details of reference samples (starting materials, intermediates and finished products).\n\n6.4 The SU\u2019s responsibilities for the transfer of analytical methods are to:\n\n- provide method-specific training for analysts and other quality control staff, if required;\n- assist in analysis of QC testing results;\n- define all methods to be transferred for testing a given product, starting material or cleaning sample;\n- define experimental design, sampling methods and acceptance criteria;\n- provide any validation reports for methods under transfer and demonstrate their robustness;\n- provide details of the equipment used, as necessary (part of validation report, if available) and any standard reference samples;\n- provide approved procedures used in testing; and\n- review and approve transfer reports.\n\n6.5 The RU\u2019s responsibilities are to:\n\n- review analytical methods provided by the SU, and formally agree on acceptance criteria before execution of the transfer protocol;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda el proceso de transferencia de m\u00e9todos anal\u00edticos en el control de calidad de productos farmac\u00e9uticos. Se detalla la importancia de que los m\u00e9todos anal\u00edticos sean implementados en el laboratorio de pruebas antes de realizar estudios de validaci\u00f3n de procesos. Se establece un protocolo que define las responsabilidades tanto del laboratorio de origen (SU) como del laboratorio receptor (RU), incluyendo la capacitaci\u00f3n, el dise\u00f1o experimental y la revisi\u00f3n de informes de transferencia.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los elementos clave que debe incluir un protocolo de transferencia de m\u00e9todos anal\u00edticos?**\n   - El protocolo debe incluir una descripci\u00f3n del objetivo, el alcance y las responsabilidades de los laboratorios involucrados, especificaciones de materiales y m\u00e9todos, dise\u00f1o experimental y criterios de aceptaci\u00f3n, documentaci\u00f3n necesaria, procedimientos para manejar desviaciones, referencias, aprobaci\u00f3n firmada y detalles de muestras de referencia.\n\n2. **\u00bfQu\u00e9 responsabilidades tiene el laboratorio de origen (SU) en el proceso de transferencia de m\u00e9todos anal\u00edticos?**\n   - El SU es responsable de proporcionar capacitaci\u00f3n espec\u00edfica sobre el m\u00e9todo, asistir en el an\u00e1lisis de resultados de control de calidad, definir los m\u00e9todos a transferir, establecer el dise\u00f1o experimental y los criterios de aceptaci\u00f3n, proporcionar informes de validaci\u00f3n y detalles del equipo utilizado, as\u00ed como revisar y aprobar los informes de transferencia.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse antes de que se realicen pruebas de validaci\u00f3n de procesos en el laboratorio receptor (RU)?**\n   - Antes de realizar pruebas de validaci\u00f3n de procesos, los m\u00e9todos anal\u00edticos deben ser implementados en el laboratorio de pruebas, y el RU debe revisar los m\u00e9todos anal\u00edticos proporcionados por el SU y acordar formalmente los criterios de aceptaci\u00f3n antes de ejecutar el protocolo de transferencia.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Idoneidad del embalaje**:\n   - Se requiere un estudio de idoneidad para la calificaci\u00f3n inicial de los componentes de embalaje.\n   - Criterios de idoneidad: protecci\u00f3n adecuada, seguridad, compatibilidad y rendimiento en la entrega del medicamento.\n\n2. **Procedimientos de limpieza**:\n   - Importancia de procedimientos de limpieza adecuados para minimizar la contaminaci\u00f3n cruzada durante la fabricaci\u00f3n.\n   - La validaci\u00f3n de los procedimientos de limpieza es espec\u00edfica para cada sitio.\n\n3. **Informaci\u00f3n requerida de la unidad de suministro (SU)**:\n   - La SU debe proporcionar datos sobre:\n     - Solubilidad de ingredientes activos, excipientes y veh\u00edculos.\n     - Dosis terap\u00e9uticas m\u00ednimas.\n     - Categor\u00eda terap\u00e9utica y evaluaci\u00f3n toxicol\u00f3gica.\n     - Procedimientos de limpieza existentes.\n   - Informaci\u00f3n adicional puede incluir informes de validaci\u00f3n de limpieza y detalles sobre agentes de limpieza utilizados.\n\n4. **L\u00edmites de residuos**:\n   - La SU debe proporcionar informaci\u00f3n sobre los l\u00edmites de residuos de productos y la justificaci\u00f3n para su selecci\u00f3n.\n\n5. **Dise\u00f1o de procedimientos de limpieza**:\n   - Los procedimientos de limpieza en la unidad receptora (RU) deben considerar caracter\u00edsticas relevantes de los materiales de partida, dise\u00f1o del equipo de fabricaci\u00f3n y residuos de agentes de limpieza.\n\n6. **Lotes de prueba**:\n   - Se producen lotes de prueba (\"lotes de demostraci\u00f3n\") para confirmar la capacidad del proceso antes de la validaci\u00f3n formal.\n\n### Entidades:\n- **RU**: Unidad receptora.\n- **SU**: Unidad de suministro.\n- **API**: Ingrediente farmac\u00e9utico activo.\n- **Procedimientos de limpieza**: M\u00e9todos para evitar la contaminaci\u00f3n cruzada.\n- **Lotes de prueba**: Producci\u00f3n inicial para validar la capacidad del proceso.", "excerpt_keywords": "Keywords: analytical methods, quality control, method transfer, pharmaceutical testing, validation procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9e3955db-8469-4935-8728-4610f5ade1e5", "node_type": "4", "metadata": {"page_label": "313", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control: Analytical Method Transfer\n\n6.1 Transfer of analytical methods should accommodate all the analytical testing required to demonstrate compliance of the product to be transferred with the registered specification (15).\n\n6.2 Analytical methods used to test pharmaceutical products, starting materials, packaging components and cleaning (residue) samples, if applicable, should be implemented at the testing laboratory before testing of samples for process validation studies is performed by the RU. Process validation samples may be tested at the RU, the SU or a third laboratory.\n\n6.3 A protocol defining the steps should be prepared for transfer of analytical methods. The analytical methods transfer protocol should include a description of the objective, scope and responsibilities of the SU and the RU; a specification of materials and methods; the experimental design and acceptance criteria; documentation (including information to be supplied with the results, and report forms to be used, if any); procedure for the handling of deviations; references; signed approval; and details of reference samples (starting materials, intermediates and finished products).\n\n6.4 The SU\u2019s responsibilities for the transfer of analytical methods are to:\n\n- provide method-specific training for analysts and other quality control staff, if required;\n- assist in analysis of QC testing results;\n- define all methods to be transferred for testing a given product, starting material or cleaning sample;\n- define experimental design, sampling methods and acceptance criteria;\n- provide any validation reports for methods under transfer and demonstrate their robustness;\n- provide details of the equipment used, as necessary (part of validation report, if available) and any standard reference samples;\n- provide approved procedures used in testing; and\n- review and approve transfer reports.\n\n6.5 The RU\u2019s responsibilities are to:\n\n- review analytical methods provided by the SU, and formally agree on acceptance criteria before execution of the transfer protocol;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6f0267ea302e1a1b5b5d15bfbf08692252e5dd2e71367a87bb4e4c7ae0f905d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Control: Analytical Method Transfer\n\n6.1 Transfer of analytical methods should accommodate all the analytical testing required to demonstrate compliance of the product to be transferred with the registered specification (15).\n\n6.2 Analytical methods used to test pharmaceutical products, starting materials, packaging components and cleaning (residue) samples, if applicable, should be implemented at the testing laboratory before testing of samples for process validation studies is performed by the RU. Process validation samples may be tested at the RU, the SU or a third laboratory.\n\n6.3 A protocol defining the steps should be prepared for transfer of analytical methods. The analytical methods transfer protocol should include a description of the objective, scope and responsibilities of the SU and the RU; a specification of materials and methods; the experimental design and acceptance criteria; documentation (including information to be supplied with the results, and report forms to be used, if any); procedure for the handling of deviations; references; signed approval; and details of reference samples (starting materials, intermediates and finished products).\n\n6.4 The SU\u2019s responsibilities for the transfer of analytical methods are to:\n\n- provide method-specific training for analysts and other quality control staff, if required;\n- assist in analysis of QC testing results;\n- define all methods to be transferred for testing a given product, starting material or cleaning sample;\n- define experimental design, sampling methods and acceptance criteria;\n- provide any validation reports for methods under transfer and demonstrate their robustness;\n- provide details of the equipment used, as necessary (part of validation report, if available) and any standard reference samples;\n- provide approved procedures used in testing; and\n- review and approve transfer reports.\n\n6.5 The RU\u2019s responsibilities are to:\n\n- review analytical methods provided by the SU, and formally agree on acceptance criteria before execution of the transfer protocol;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2069, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "92171587-7adb-4a2a-bbe5-5bd7f82917cc": {"__data__": {"id_": "92171587-7adb-4a2a-bbe5-5bd7f82917cc", "embedding": null, "metadata": {"page_label": "314", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet appropriate specifications to ensure the requirements of the method or specification are met;\n- ensure that adequately trained and experienced personnel are in place for analytical testing;\n- provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);\n- execute the transfer protocol;\n- perform the appropriate level of validation to support the implementation of the methods; and\n- generate and obtain approval of transfer reports.\n\n6.6 Appropriate training should be provided and all training activities and outcomes should be documented.\n\n6.7 Reference to compendial monographs (e.g. *The International Pharmacopoeia (15), European Pharmacopoeia, British Pharmacopoeia and United States Pharmacopeia*), where available, is expected.\n\n6.8 Possible experimental designs and acceptance criteria for the main analytical testing methods are shown in Table 1. Note that this table represents high-level guidance to apply the general principle that method transfers should account for the variability and sensitivity of the method and the specifications for the quality parameter. Alternative procedures and acceptance criteria may be applied based on science and the characteristics of the analytical method and the analyte.\n\n**Table 1**  \n**Possible experimental designs and acceptance criteria for analytical testing**\n\n| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Identity | Transfer should focus on sample preparation, instruments, data interpretation. Acceptable to include in assay transfer where relevant | One determination usually sufficient to demonstrate equivalence | | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los requisitos clave para el equipo utilizado en la transferencia anal\u00edtica en un sitio de RU (Unidad de Referencia)?**\n   - El equipo utilizado por la RU durante la transferencia anal\u00edtica debe estar disponible y calificado en el sitio, cumpliendo con las especificaciones apropiadas para asegurar que se satisfacen los requisitos del m\u00e9todo o especificaci\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el proceso de transferencia anal\u00edtica?**\n   - Se requiere un sistema de documentaci\u00f3n capaz de registrar la recepci\u00f3n y prueba de muestras seg\u00fan las especificaciones requeridas, utilizando m\u00e9todos de prueba aprobados. Adem\u00e1s, debe incluir la capacidad de reportar, registrar y compilar datos, as\u00ed como designar el estado de las muestras (aprobadas, rechazadas, en cuarentena).\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al dise\u00f1ar un protocolo de transferencia anal\u00edtica?**\n   - Al dise\u00f1ar un protocolo de transferencia anal\u00edtica, se debe considerar la variabilidad y sensibilidad del m\u00e9todo, as\u00ed como las especificaciones para el par\u00e1metro de calidad. Adem\u00e1s, se pueden aplicar procedimientos alternativos y criterios de aceptaci\u00f3n basados en la ciencia y las caracter\u00edsticas del m\u00e9todo anal\u00edtico y el analito.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS proporciona directrices sobre la transferencia anal\u00edtica, enfatizando la importancia de contar con el equipo adecuado, personal capacitado y un sistema de documentaci\u00f3n robusto. Tambi\u00e9n se menciona la necesidad de validar los m\u00e9todos y generar informes de transferencia aprobados. Se hace referencia a monograf\u00edas compendiales y se presentan consideraciones para el dise\u00f1o experimental y criterios de aceptaci\u00f3n en las pruebas anal\u00edticas, destacando que la transferencia debe tener en cuenta la variabilidad del m\u00e9todo y las especificaciones de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Transferencia de M\u00e9todos Anal\u00edticos:** Se enfatiza la necesidad de que la transferencia de m\u00e9todos anal\u00edticos incluya todas las pruebas necesarias para demostrar que el producto cumple con las especificaciones registradas.\n\n2. **Implementaci\u00f3n Previa:** Los m\u00e9todos anal\u00edticos deben ser implementados en el laboratorio de pruebas antes de realizar estudios de validaci\u00f3n de procesos.\n\n3. **Protocolo de Transferencia:** Se requiere un protocolo que defina los pasos para la transferencia, incluyendo objetivos, alcance, responsabilidades, dise\u00f1o experimental, criterios de aceptaci\u00f3n y documentaci\u00f3n necesaria.\n\n4. **Responsabilidades del Laboratorio de Origen (SU):** Incluyen la capacitaci\u00f3n del personal, asistencia en el an\u00e1lisis de resultados, definici\u00f3n de m\u00e9todos a transferir, y revisi\u00f3n de informes de transferencia.\n\n5. **Responsabilidades del Laboratorio Receptor (RU):** Implican la revisi\u00f3n de m\u00e9todos anal\u00edticos y el acuerdo formal sobre los criterios de aceptaci\u00f3n antes de ejecutar el protocolo de transferencia.\n\n**Entidades:**\n\n- **Laboratorio de Origen (SU):** Responsable de proporcionar capacitaci\u00f3n, definir m\u00e9todos y revisar informes.\n- **Laboratorio Receptor (RU):** Encargado de revisar y acordar m\u00e9todos y criterios de aceptaci\u00f3n.\n- **M\u00e9todos Anal\u00edticos:** Herramientas utilizadas para evaluar productos farmac\u00e9uticos, materiales de partida y muestras de limpieza.\n- **Protocolo de Transferencia:** Documento que detalla el proceso de transferencia de m\u00e9todos anal\u00edticos.\n\nEste resumen destaca la importancia de un proceso estructurado y colaborativo en la transferencia de m\u00e9todos anal\u00edticos para asegurar la calidad y conformidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: transferencia anal\u00edtica, equipo de calidad, documentaci\u00f3n, validaci\u00f3n, m\u00e9todos anal\u00edticos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dd987a76-4793-4a4f-9fa8-3eb89c396a3f", "node_type": "4", "metadata": {"page_label": "314", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet appropriate specifications to ensure the requirements of the method or specification are met;\n- ensure that adequately trained and experienced personnel are in place for analytical testing;\n- provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);\n- execute the transfer protocol;\n- perform the appropriate level of validation to support the implementation of the methods; and\n- generate and obtain approval of transfer reports.\n\n6.6 Appropriate training should be provided and all training activities and outcomes should be documented.\n\n6.7 Reference to compendial monographs (e.g. *The International Pharmacopoeia (15), European Pharmacopoeia, British Pharmacopoeia and United States Pharmacopeia*), where available, is expected.\n\n6.8 Possible experimental designs and acceptance criteria for the main analytical testing methods are shown in Table 1. Note that this table represents high-level guidance to apply the general principle that method transfers should account for the variability and sensitivity of the method and the specifications for the quality parameter. Alternative procedures and acceptance criteria may be applied based on science and the characteristics of the analytical method and the analyte.\n\n**Table 1**  \n**Possible experimental designs and acceptance criteria for analytical testing**\n\n| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Identity | Transfer should focus on sample preparation, instruments, data interpretation. Acceptable to include in assay transfer where relevant | One determination usually sufficient to demonstrate equivalence | | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6c1e48830689eb2fe135e4e0ddb4741234cc8a16e48f80bca462f65ff3bef681", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet appropriate specifications to ensure the requirements of the method or specification are met;\n- ensure that adequately trained and experienced personnel are in place for analytical testing;\n- provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);\n- execute the transfer protocol;\n- perform the appropriate level of validation to support the implementation of the methods; and\n- generate and obtain approval of transfer reports.\n\n6.6 Appropriate training should be provided and all training activities and outcomes should be documented.\n\n6.7 Reference to compendial monographs (e.g. *The International Pharmacopoeia (15), European Pharmacopoeia, British Pharmacopoeia and United States Pharmacopeia*), where available, is expected.\n\n6.8 Possible experimental designs and acceptance criteria for the main analytical testing methods are shown in Table 1. Note that this table represents high-level guidance to apply the general principle that method transfers should account for the variability and sensitivity of the method and the specifications for the quality parameter. Alternative procedures and acceptance criteria may be applied based on science and the characteristics of the analytical method and the analyte.\n\n**Table 1**  \n**Possible experimental designs and acceptance criteria for analytical testing**\n\n| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Identity | Transfer should focus on sample preparation, instruments, data interpretation. Acceptable to include in assay transfer where relevant | One determination usually sufficient to demonstrate equivalence | | | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2092, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c0a7d32a-1aa9-45db-8889-332f4b4020e0": {"__data__": {"id_": "c0a7d32a-1aa9-45db-8889-332f4b4020e0", "embedding": null, "metadata": {"page_label": "315", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test | Considerations for transfer | Replication of tests | Set-up | Acceptance criteria | Direct | Statistically derived |\n| - | - | - | - | - | - | - |\n| Assay for potency | * *Non-specific assay should not be used for stability testing.*\n* Bracketing may be appropriate for multiple strengths | At each site: 2 analysts \u00d7 3 lots, in triplicate (= 18 per site) | - Different sets of instruments and columns\n- Independent solution preparation | Comparison of mean and variability | Two one-sided t-tests with intersite differences \u2264 2%, 95% confidence | |\n| Content uniformity | If method is equivalent to assay method, separate transfer is not usually required | At each site: 2 analysts, \u00d7 1 lot (= 2 per site) | * Different sets of instruments and columns\n* Independent solution preparation | Mean at RU within \u00b1 3% of mean at SU; comparison of relative st. dev. | Two one-sided t-tests with intersite differences \u2264 3%, 95% confidence | |\n| Dissolution | Bracketing may be appropriate for multiple strengths | 6 units (12 if not routine at RU, and for extended release products) | | Mean at RU within \u00b1 5% of mean at SU | Compare profile (e.g., F\u2082), or Compare data at Q time points as for assay | |\n| Cleaning verification (recovery of residues from surfaces) | Confirm that same swabbing material is used at sending unit (SU) and receiving unit (RU) | | Use spiked samples, with levels within 3x validated st. dev. or within \u00b1 10% of specification (whichever is the greater) | - All samples spiked above specification should fail\n- 90% of samples spiked below specification should pass | | |\n| Microbiological testing (qualitative and quantitative limit tests) | * Execute common on-site validation protocol: rationale; method identity; validation parameters; data summary; acceptance criteria; methods of compiling and analysing data; handling of out-of-specification results; follow-up requirements\n* Use same materials, techniques, inoculum preparation | Validation in triplicate | Use different lots for each validation exercise | - Qualitative: Demonstrate recovery of microorganisms\n- Quantitative: Recovery levels within acceptance limits specified in protocol | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 961 aborda las consideraciones para la transferencia de m\u00e9todos anal\u00edticos en el contexto de pruebas de calidad de productos farmac\u00e9uticos. Se detallan varios tipos de pruebas, como el ensayo de potencia, la uniformidad de contenido, la disoluci\u00f3n, la verificaci\u00f3n de limpieza y las pruebas microbiol\u00f3gicas. Para cada prueba, se especifican las consideraciones para la transferencia, la replicaci\u00f3n de pruebas, el establecimiento de criterios de aceptaci\u00f3n y los m\u00e9todos estad\u00edsticos aplicables.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para el ensayo de potencia y c\u00f3mo se determina la variabilidad intersitios?**\n   - Respuesta: Para el ensayo de potencia, se compara la media y la variabilidad entre los sitios. Se utilizan dos pruebas t de una sola cola con diferencias intersitios que deben ser \u2264 2% y un nivel de confianza del 95%.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para la verificaci\u00f3n de limpieza en la recuperaci\u00f3n de residuos de superficies?**\n   - Respuesta: Se debe confirmar que se utiliza el mismo material de muestreo en la unidad de env\u00edo (SU) y en la unidad receptora (RU). Adem\u00e1s, se deben usar muestras espaciadas, con niveles dentro de 3 veces la desviaci\u00f3n est\u00e1ndar validada o dentro del \u00b1 10% de la especificaci\u00f3n, siendo el mayor de los dos el que se considere.\n\n3. **\u00bfQu\u00e9 protocolo se debe seguir para las pruebas microbiol\u00f3gicas y qu\u00e9 aspectos deben ser considerados durante la validaci\u00f3n?**\n   - Respuesta: Se debe ejecutar un protocolo de validaci\u00f3n com\u00fan en el sitio que incluya la justificaci\u00f3n, la identidad del m\u00e9todo, los par\u00e1metros de validaci\u00f3n, un resumen de datos, criterios de aceptaci\u00f3n, m\u00e9todos de compilaci\u00f3n y an\u00e1lisis de datos, manejo de resultados fuera de especificaci\u00f3n y requisitos de seguimiento. La validaci\u00f3n debe realizarse en triplicado utilizando diferentes lotes para cada ejercicio de validaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Equipamiento**: \n   - Es esencial que el equipo de control de calidad (QC) est\u00e9 disponible y calificado en el sitio de la Unidad de Referencia (RU). Debe cumplir con especificaciones apropiadas para satisfacer los requisitos del m\u00e9todo anal\u00edtico.\n\n2. **Personal Capacitado**: \n   - Se debe contar con personal adecuadamente entrenado y con experiencia para llevar a cabo las pruebas anal\u00edticas.\n\n3. **Sistema de Documentaci\u00f3n**: \n   - Es necesario un sistema de documentaci\u00f3n que registre la recepci\u00f3n y prueba de muestras, utilizando m\u00e9todos de prueba aprobados. Este sistema debe permitir la reportaci\u00f3n, registro y compilaci\u00f3n de datos, as\u00ed como la designaci\u00f3n del estado de las muestras (aprobadas, rechazadas, en cuarentena).\n\n4. **Ejecuci\u00f3n del Protocolo de Transferencia**: \n   - Se debe ejecutar un protocolo de transferencia que incluya la validaci\u00f3n adecuada para respaldar la implementaci\u00f3n de los m\u00e9todos anal\u00edticos.\n\n5. **Generaci\u00f3n de Informes de Transferencia**: \n   - Es importante generar y obtener la aprobaci\u00f3n de los informes de transferencia.\n\n6. **Capacitaci\u00f3n Documentada**: \n   - Se debe proporcionar capacitaci\u00f3n adecuada y documentar todas las actividades y resultados de la capacitaci\u00f3n.\n\n7. **Referencias a Monograf\u00edas Compendiales**: \n   - Se espera hacer referencia a monograf\u00edas compendiales como *The International Pharmacopoeia*, *European Pharmacopoeia*, *British Pharmacopoeia* y *United States Pharmacopeia*, cuando est\u00e9n disponibles.\n\n8. **Dise\u00f1os Experimentales y Criterios de Aceptaci\u00f3n**: \n   - Se presentan consideraciones para el dise\u00f1o experimental y criterios de aceptaci\u00f3n en las pruebas anal\u00edticas, enfatizando que la transferencia debe considerar la variabilidad y sensibilidad del m\u00e9todo, as\u00ed como las especificaciones del par\u00e1metro de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos de Referencia**: Monograf\u00edas compendiales (International Pharmacopoeia, European Pharmacopoeia, British Pharmacopoeia, United States Pharmacopeia)\n- **Conceptos**: Transferencia anal\u00edtica, control de calidad (QC), validaci\u00f3n de m\u00e9todos, documentaci\u00f3n de procesos, capacitaci\u00f3n del personal. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado en la transferencia anal\u00edtica, asegurando que se cumplan los est\u00e1ndares de calidad y que se minimicen las variaciones en los resultados.", "excerpt_keywords": "Keywords: transfer methods, analytical testing, quality control, validation protocols, microbiological testing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8161264-b91f-4406-a437-5a82f63d0b4e", "node_type": "4", "metadata": {"page_label": "315", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test | Considerations for transfer | Replication of tests | Set-up | Acceptance criteria | Direct | Statistically derived |\n| - | - | - | - | - | - | - |\n| Assay for potency | * *Non-specific assay should not be used for stability testing.*\n* Bracketing may be appropriate for multiple strengths | At each site: 2 analysts \u00d7 3 lots, in triplicate (= 18 per site) | - Different sets of instruments and columns\n- Independent solution preparation | Comparison of mean and variability | Two one-sided t-tests with intersite differences \u2264 2%, 95% confidence | |\n| Content uniformity | If method is equivalent to assay method, separate transfer is not usually required | At each site: 2 analysts, \u00d7 1 lot (= 2 per site) | * Different sets of instruments and columns\n* Independent solution preparation | Mean at RU within \u00b1 3% of mean at SU; comparison of relative st. dev. | Two one-sided t-tests with intersite differences \u2264 3%, 95% confidence | |\n| Dissolution | Bracketing may be appropriate for multiple strengths | 6 units (12 if not routine at RU, and for extended release products) | | Mean at RU within \u00b1 5% of mean at SU | Compare profile (e.g., F\u2082), or Compare data at Q time points as for assay | |\n| Cleaning verification (recovery of residues from surfaces) | Confirm that same swabbing material is used at sending unit (SU) and receiving unit (RU) | | Use spiked samples, with levels within 3x validated st. dev. or within \u00b1 10% of specification (whichever is the greater) | - All samples spiked above specification should fail\n- 90% of samples spiked below specification should pass | | |\n| Microbiological testing (qualitative and quantitative limit tests) | * Execute common on-site validation protocol: rationale; method identity; validation parameters; data summary; acceptance criteria; methods of compiling and analysing data; handling of out-of-specification results; follow-up requirements\n* Use same materials, techniques, inoculum preparation | Validation in triplicate | Use different lots for each validation exercise | - Qualitative: Demonstrate recovery of microorganisms\n- Quantitative: Recovery levels within acceptance limits specified in protocol | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "140d82a9a1b05110a05f487bd373c8c1c6aebce4299c9c2140255b34d4c22cbe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Test | Considerations for transfer | Replication of tests | Set-up | Acceptance criteria | Direct | Statistically derived |\n| - | - | - | - | - | - | - |\n| Assay for potency | * *Non-specific assay should not be used for stability testing.*\n* Bracketing may be appropriate for multiple strengths | At each site: 2 analysts \u00d7 3 lots, in triplicate (= 18 per site) | - Different sets of instruments and columns\n- Independent solution preparation | Comparison of mean and variability | Two one-sided t-tests with intersite differences \u2264 2%, 95% confidence | |\n| Content uniformity | If method is equivalent to assay method, separate transfer is not usually required | At each site: 2 analysts, \u00d7 1 lot (= 2 per site) | * Different sets of instruments and columns\n* Independent solution preparation | Mean at RU within \u00b1 3% of mean at SU; comparison of relative st. dev. | Two one-sided t-tests with intersite differences \u2264 3%, 95% confidence | |\n| Dissolution | Bracketing may be appropriate for multiple strengths | 6 units (12 if not routine at RU, and for extended release products) | | Mean at RU within \u00b1 5% of mean at SU | Compare profile (e.g., F\u2082), or Compare data at Q time points as for assay | |\n| Cleaning verification (recovery of residues from surfaces) | Confirm that same swabbing material is used at sending unit (SU) and receiving unit (RU) | | Use spiked samples, with levels within 3x validated st. dev. or within \u00b1 10% of specification (whichever is the greater) | - All samples spiked above specification should fail\n- 90% of samples spiked below specification should pass | | |\n| Microbiological testing (qualitative and quantitative limit tests) | * Execute common on-site validation protocol: rationale; method identity; validation parameters; data summary; acceptance criteria; methods of compiling and analysing data; handling of out-of-specification results; follow-up requirements\n* Use same materials, techniques, inoculum preparation | Validation in triplicate | Use different lots for each validation exercise | - Qualitative: Demonstrate recovery of microorganisms\n- Quantitative: Recovery levels within acceptance limits specified in protocol | | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2181, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f54b5582-c94f-492d-8425-3644a2456280": {"__data__": {"id_": "f54b5582-c94f-492d-8425-3644a2456280", "embedding": null, "metadata": {"page_label": "316", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Impurity, degradation, residual solvents | \u2013 Confirm response factors for calculation relative to drug peak; \u2013 Confirm limit of quantitation at RU; \u2013 Compare chromatograms \u2013 Compare accuracy and precision for spiking experiments | At each site: 2 analysts x 3 lots, in duplicate (in triplicate if done together with assay) | \u2013 Different days, different sets of instruments and columns \u2013 Use samples of similar age, homogeneity, packaging, storage \u2013 Use spiked samples if necessary | (For low levels) Values at RU within \u00b1 25% of values at SU, or Mean at RU within \u00b1 0.05% of mean at SU (5%) | (For moderately high levels) Two one-sided t-tests, differences \u2264 10%, 95% confidence |\n\n\nst. dev., standard deviation.  \n*Note*: numbers in the table are given as examples only and should not be considered as recommendations.\n\nThe SU and the RU should execute the transfer protocol and jointly prepare a transfer report. The points to be addressed in the analytical methods transfer report are listed in these guidelines.\n\n# 7. Premises and equipment\n\n## Premises\n\n7.1 The SU should provide information to the RU on the layout, construction and finish of buildings and services (16,17) (heating, ventilation and air-conditioning (HVAC), temperature, relative humidity, water, power, and compressed air), which have an impact on the product, process or method to be transferred.\n\n7.2 The SU should provide information on relevant health, safety and environmental issues, including:\n\n- inherent risks of the manufacturing processes (e.g. reactive chemical hazards, exposure limits, fire and explosion risks);\n- health and safety requirements to minimize operator exposure (e.g. atmospheric containment of pharmaceutical dust);\n- emergency planning considerations (e.g. in case of gas or dust release, spillage, fire and firewater run-off); and\n- identification of waste streams and provisions for re-use, recycling and/or disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la transferencia de m\u00e9todos anal\u00edticos en relaci\u00f3n con los niveles bajos y moderadamente altos de impurezas, degradaci\u00f3n y solventes residuales?**\n   - Respuesta: Para niveles bajos, los valores en el RU deben estar dentro de \u00b1 25% de los valores en el SU, o la media en el RU debe estar dentro de \u00b1 0.05% de la media en el SU. Para niveles moderadamente altos, se deben realizar dos pruebas t unilaterales, donde las diferencias deben ser \u2264 10% con un nivel de confianza del 95%.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe proporcionar la SU al RU en relaci\u00f3n con las instalaciones y el equipo antes de la transferencia de m\u00e9todos anal\u00edticos?**\n   - Respuesta: La SU debe proporcionar informaci\u00f3n sobre el dise\u00f1o, construcci\u00f3n y acabado de los edificios y servicios, incluyendo aspectos como calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), temperatura, humedad relativa, agua, energ\u00eda y aire comprimido, que pueden impactar en el producto, proceso o m\u00e9todo a transferir.\n\n3. **\u00bfQu\u00e9 consideraciones de salud, seguridad y medio ambiente deben tener en cuenta la SU y la RU durante la transferencia de m\u00e9todos anal\u00edticos?**\n   - Respuesta: Deben considerar los riesgos inherentes de los procesos de fabricaci\u00f3n, los requisitos de salud y seguridad para minimizar la exposici\u00f3n del operador, la planificaci\u00f3n de emergencias en caso de liberaci\u00f3n de gases o polvo, derrames, incendios y escorrent\u00eda de agua de incendio, as\u00ed como la identificaci\u00f3n de flujos de desechos y las disposiciones para su reutilizaci\u00f3n, reciclaje y/o eliminaci\u00f3n.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre la transferencia de m\u00e9todos anal\u00edticos entre un sitio de origen (SU) y un sitio receptor (RU). Se detallan los criterios de aceptaci\u00f3n para la transferencia de pruebas relacionadas con impurezas y solventes residuales, as\u00ed como la necesidad de un informe de transferencia conjunto. Adem\u00e1s, se enfatiza la importancia de la informaci\u00f3n sobre las instalaciones y los equipos, as\u00ed como las consideraciones de salud, seguridad y medio ambiente que deben ser abordadas durante el proceso de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 961 se centra en las consideraciones para la transferencia de m\u00e9todos anal\u00edticos en la evaluaci\u00f3n de la calidad de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades relevantes:\n\n#### Temas Clave:\n1. **Transferencia de M\u00e9todos Anal\u00edticos**: Se discuten las consideraciones necesarias para transferir m\u00e9todos anal\u00edticos entre diferentes unidades de producci\u00f3n.\n2. **Tipos de Pruebas**:\n   - **Ensayo de Potencia**: Importancia de no utilizar ensayos no espec\u00edficos para pruebas de estabilidad.\n   - **Uniformidad de Contenido**: Condiciones bajo las cuales no se requiere una transferencia separada si el m\u00e9todo es equivalente.\n   - **Dissoluci\u00f3n**: Uso de bracketing para m\u00faltiples fortalezas y criterios de aceptaci\u00f3n.\n   - **Verificaci\u00f3n de Limpieza**: Protocolo para la recuperaci\u00f3n de residuos de superficies.\n   - **Pruebas Microbiol\u00f3gicas**: Protocolo de validaci\u00f3n com\u00fan y requisitos para la validaci\u00f3n.\n\n3. **Criterios de Aceptaci\u00f3n**: Se establecen criterios espec\u00edficos para cada tipo de prueba, incluyendo l\u00edmites de variabilidad y m\u00e9todos estad\u00edsticos para la comparaci\u00f3n de resultados.\n\n4. **Replicaci\u00f3n de Pruebas**: Se especifican los requisitos de replicaci\u00f3n para asegurar la validez de los resultados obtenidos en diferentes sitios.\n\n5. **M\u00e9todos Estad\u00edsticos**: Se mencionan pruebas estad\u00edsticas espec\u00edficas, como las pruebas t de una sola cola, para evaluar la variabilidad y la aceptaci\u00f3n de los resultados.\n\n#### Entidades Relevantes:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para evaluar la calidad de los productos farmac\u00e9uticos.\n- **Unidades de Producci\u00f3n**: Referencia a las instalaciones donde se realizan las pruebas.\n- **Analistas**: Personal encargado de realizar las pruebas en los diferentes sitios.\n- **Lotes**: Cantidades espec\u00edficas de productos farmac\u00e9uticos sometidos a prueba.\n- **Criterios de Aceptaci\u00f3n**: Par\u00e1metros establecidos para determinar si los resultados de las pruebas son satisfactorios.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes tratados en la secci\u00f3n, destacando la importancia de la transferencia de m\u00e9todos anal\u00edticos y los criterios necesarios para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: transferencia de m\u00e9todos anal\u00edticos, criterios de aceptaci\u00f3n, salud y seguridad, instalaciones y equipos, impurezas y solventes residuales"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "05ccd945-9223-4c79-b45c-02c20166a010", "node_type": "4", "metadata": {"page_label": "316", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Impurity, degradation, residual solvents | \u2013 Confirm response factors for calculation relative to drug peak; \u2013 Confirm limit of quantitation at RU; \u2013 Compare chromatograms \u2013 Compare accuracy and precision for spiking experiments | At each site: 2 analysts x 3 lots, in duplicate (in triplicate if done together with assay) | \u2013 Different days, different sets of instruments and columns \u2013 Use samples of similar age, homogeneity, packaging, storage \u2013 Use spiked samples if necessary | (For low levels) Values at RU within \u00b1 25% of values at SU, or Mean at RU within \u00b1 0.05% of mean at SU (5%) | (For moderately high levels) Two one-sided t-tests, differences \u2264 10%, 95% confidence |\n\n\nst. dev., standard deviation.  \n*Note*: numbers in the table are given as examples only and should not be considered as recommendations.\n\nThe SU and the RU should execute the transfer protocol and jointly prepare a transfer report. The points to be addressed in the analytical methods transfer report are listed in these guidelines.\n\n# 7. Premises and equipment\n\n## Premises\n\n7.1 The SU should provide information to the RU on the layout, construction and finish of buildings and services (16,17) (heating, ventilation and air-conditioning (HVAC), temperature, relative humidity, water, power, and compressed air), which have an impact on the product, process or method to be transferred.\n\n7.2 The SU should provide information on relevant health, safety and environmental issues, including:\n\n- inherent risks of the manufacturing processes (e.g. reactive chemical hazards, exposure limits, fire and explosion risks);\n- health and safety requirements to minimize operator exposure (e.g. atmospheric containment of pharmaceutical dust);\n- emergency planning considerations (e.g. in case of gas or dust release, spillage, fire and firewater run-off); and\n- identification of waste streams and provisions for re-use, recycling and/or disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f3fcfaaa99bf0fc4c37627f7d23f1e023dd21acf44999e2376eab8f4a87b3d18", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Impurity, degradation, residual solvents | \u2013 Confirm response factors for calculation relative to drug peak; \u2013 Confirm limit of quantitation at RU; \u2013 Compare chromatograms \u2013 Compare accuracy and precision for spiking experiments | At each site: 2 analysts x 3 lots, in duplicate (in triplicate if done together with assay) | \u2013 Different days, different sets of instruments and columns \u2013 Use samples of similar age, homogeneity, packaging, storage \u2013 Use spiked samples if necessary | (For low levels) Values at RU within \u00b1 25% of values at SU, or Mean at RU within \u00b1 0.05% of mean at SU (5%) | (For moderately high levels) Two one-sided t-tests, differences \u2264 10%, 95% confidence |\n\n\nst. dev., standard deviation.  \n*Note*: numbers in the table are given as examples only and should not be considered as recommendations.\n\nThe SU and the RU should execute the transfer protocol and jointly prepare a transfer report. The points to be addressed in the analytical methods transfer report are listed in these guidelines.\n\n# 7. Premises and equipment\n\n## Premises\n\n7.1 The SU should provide information to the RU on the layout, construction and finish of buildings and services (16,17) (heating, ventilation and air-conditioning (HVAC), temperature, relative humidity, water, power, and compressed air), which have an impact on the product, process or method to be transferred.\n\n7.2 The SU should provide information on relevant health, safety and environmental issues, including:\n\n- inherent risks of the manufacturing processes (e.g. reactive chemical hazards, exposure limits, fire and explosion risks);\n- health and safety requirements to minimize operator exposure (e.g. atmospheric containment of pharmaceutical dust);\n- emergency planning considerations (e.g. in case of gas or dust release, spillage, fire and firewater run-off); and\n- identification of waste streams and provisions for re-use, recycling and/or disposal.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2129, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "67905ef3-4462-48b2-851d-ddeb37cc2a6a": {"__data__": {"id_": "67905ef3-4462-48b2-851d-ddeb37cc2a6a", "embedding": null, "metadata": {"page_label": "317", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n7.3 The SU should provide a list of equipment, makes and models involved in the manufacture, filling, packing and or control of the product, process or method to be transferred, together with existing qualification and validation documentation. Relevant documentation may include:\n\n- drawings;\n- manuals;\n- maintenance logs;\n- calibration logs; and\n- procedures (e.g. regarding equipment set-up, operation, cleaning, maintenance, calibration and storage).\n\n7.4 The RU should review the information provided by the SU together with its own inventory list including the qualification status (IQ, OQ, PQ) of all equipment and systems, and perform a side-by-side comparison of equipment at the two sites in terms of their functionality, makes, models and qualification status.\n\n7.5 The RU should perform a gap analysis to identify requirements for adaptation of existing equipment, or acquisition of new equipment, or a change in the process, to enable the RU to reproduce the process being transferred. GMP requirements should be satisfied and intended production volumes and batch sizes (e.g. same, scaled-up or campaign) should be considered. Factors to be compared include:\n\n- minimum and maximum capacity;\n- material of construction;\n- critical operating parameters;\n- critical equipment components (e.g. filters, screens, and temperature/pressure sensors);\n- critical quality attribute; and\n- range of intended use.\n\n7.6 The facility- and building-specific location of all equipment at the RU should be considered at the time of drawing up process maps or flow charts of the manufacturing process to be transferred, including flows of personnel and material.\n\n7.7 The impact of manufacturing new products on products currently manufactured with the same equipment should be determined.\n\n7.8 Any modification of existing equipment that needs to be adapted to become capable of reproducing the process being transferred should be documented in the transfer project plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS detalla los procedimientos y requisitos para la transferencia de procesos de fabricaci\u00f3n, enfatizando la importancia de la documentaci\u00f3n y la comparaci\u00f3n de equipos entre el sitio de origen (SU) y el sitio receptor (RU). Se abordan aspectos como la revisi\u00f3n de la calificaci\u00f3n del equipo, la realizaci\u00f3n de un an\u00e1lisis de brechas para identificar necesidades de adaptaci\u00f3n o adquisici\u00f3n de nuevos equipos, y la consideraci\u00f3n de la ubicaci\u00f3n espec\u00edfica de los equipos en el RU. Tambi\u00e9n se menciona la necesidad de evaluar el impacto de la fabricaci\u00f3n de nuevos productos en los productos existentes y la documentaci\u00f3n de cualquier modificaci\u00f3n necesaria en el equipo.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se considera relevante para la transferencia de procesos y qu\u00e9 ejemplos se proporcionan?**\n   - El contexto menciona que la documentaci\u00f3n relevante puede incluir dibujos, manuales, registros de mantenimiento, registros de calibraci\u00f3n y procedimientos relacionados con la configuraci\u00f3n, operaci\u00f3n, limpieza, mantenimiento, calibraci\u00f3n y almacenamiento del equipo.\n\n2. **\u00bfCu\u00e1les son los factores clave que el RU debe comparar al realizar un an\u00e1lisis de brechas entre el equipo del SU y el RU?**\n   - Los factores a comparar incluyen la capacidad m\u00ednima y m\u00e1xima, el material de construcci\u00f3n, los par\u00e1metros operativos cr\u00edticos, los componentes cr\u00edticos del equipo (como filtros y sensores), los atributos de calidad cr\u00edticos y el rango de uso previsto.\n\n3. **\u00bfQu\u00e9 se debe documentar en el plan del proyecto de transferencia si se requieren modificaciones en el equipo existente?**\n   - Cualquier modificaci\u00f3n del equipo existente que sea necesaria para reproducir el proceso transferido debe ser documentada en el plan del proyecto de transferencia, asegurando que se mantenga la conformidad con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de M\u00e9todos Anal\u00edticos**:\n   - Se establece un protocolo de transferencia que debe ser ejecutado conjuntamente por el sitio de origen (SU) y el sitio receptor (RU).\n   - Se requiere la elaboraci\u00f3n de un informe de transferencia que aborde puntos espec\u00edficos.\n\n2. **Criterios de Aceptaci\u00f3n**:\n   - Para impurezas, degradaci\u00f3n y solventes residuales, se definen criterios de aceptaci\u00f3n:\n     - **Niveles bajos**: Valores en el RU deben estar dentro de \u00b1 25% de los valores en el SU, o la media en el RU dentro de \u00b1 0.05% de la media en el SU.\n     - **Niveles moderadamente altos**: Se deben realizar dos pruebas t unilaterales, donde las diferencias deben ser \u2264 10% con un nivel de confianza del 95%.\n\n3. **Premisas y Equipos**:\n   - La SU debe proporcionar informaci\u00f3n sobre el dise\u00f1o, construcci\u00f3n y acabados de las instalaciones, as\u00ed como sobre servicios como HVAC, temperatura, humedad, agua, energ\u00eda y aire comprimido.\n   - Se enfatiza la importancia de la salud, seguridad y consideraciones ambientales durante la transferencia.\n\n4. **Consideraciones de Salud y Seguridad**:\n   - Identificaci\u00f3n de riesgos inherentes a los procesos de fabricaci\u00f3n (ej. peligros qu\u00edmicos, l\u00edmites de exposici\u00f3n, riesgos de incendio).\n   - Requisitos para minimizar la exposici\u00f3n del operador y planificaci\u00f3n de emergencias.\n   - Identificaci\u00f3n de flujos de desechos y disposiciones para su manejo.\n\n### Entidades Clave:\n- **SU (Sitio de Origen)**: Entidad que proporciona informaci\u00f3n y realiza la transferencia.\n- **RU (Sitio Receptor)**: Entidad que recibe la transferencia y debe cumplir con los criterios establecidos.\n- **M\u00e9todos Anal\u00edticos**: Procesos que se transfieren entre SU y RU.\n- **Criterios de Aceptaci\u00f3n**: Est\u00e1ndares que deben cumplirse para validar la transferencia.\n- **Salud y Seguridad**: Consideraciones cr\u00edticas para la operaci\u00f3n segura durante la transferencia. \n\nEste resumen destaca los aspectos fundamentales y las entidades involucradas en el proceso de transferencia de m\u00e9todos anal\u00edticos seg\u00fan las directrices del documento de la OMS.", "excerpt_keywords": "Keywords: equipment transfer, gap analysis, qualification documentation, manufacturing process, GMP compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0e1e6011-65d7-4925-ac6b-7f5d37bffcb6", "node_type": "4", "metadata": {"page_label": "317", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n7.3 The SU should provide a list of equipment, makes and models involved in the manufacture, filling, packing and or control of the product, process or method to be transferred, together with existing qualification and validation documentation. Relevant documentation may include:\n\n- drawings;\n- manuals;\n- maintenance logs;\n- calibration logs; and\n- procedures (e.g. regarding equipment set-up, operation, cleaning, maintenance, calibration and storage).\n\n7.4 The RU should review the information provided by the SU together with its own inventory list including the qualification status (IQ, OQ, PQ) of all equipment and systems, and perform a side-by-side comparison of equipment at the two sites in terms of their functionality, makes, models and qualification status.\n\n7.5 The RU should perform a gap analysis to identify requirements for adaptation of existing equipment, or acquisition of new equipment, or a change in the process, to enable the RU to reproduce the process being transferred. GMP requirements should be satisfied and intended production volumes and batch sizes (e.g. same, scaled-up or campaign) should be considered. Factors to be compared include:\n\n- minimum and maximum capacity;\n- material of construction;\n- critical operating parameters;\n- critical equipment components (e.g. filters, screens, and temperature/pressure sensors);\n- critical quality attribute; and\n- range of intended use.\n\n7.6 The facility- and building-specific location of all equipment at the RU should be considered at the time of drawing up process maps or flow charts of the manufacturing process to be transferred, including flows of personnel and material.\n\n7.7 The impact of manufacturing new products on products currently manufactured with the same equipment should be determined.\n\n7.8 Any modification of existing equipment that needs to be adapted to become capable of reproducing the process being transferred should be documented in the transfer project plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "812f33210aad9e15b5163ca3f51f56fac39539be92342f4a4bd4e64a50ac1aa3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Equipment\n\n7.3 The SU should provide a list of equipment, makes and models involved in the manufacture, filling, packing and or control of the product, process or method to be transferred, together with existing qualification and validation documentation. Relevant documentation may include:\n\n- drawings;\n- manuals;\n- maintenance logs;\n- calibration logs; and\n- procedures (e.g. regarding equipment set-up, operation, cleaning, maintenance, calibration and storage).\n\n7.4 The RU should review the information provided by the SU together with its own inventory list including the qualification status (IQ, OQ, PQ) of all equipment and systems, and perform a side-by-side comparison of equipment at the two sites in terms of their functionality, makes, models and qualification status.\n\n7.5 The RU should perform a gap analysis to identify requirements for adaptation of existing equipment, or acquisition of new equipment, or a change in the process, to enable the RU to reproduce the process being transferred. GMP requirements should be satisfied and intended production volumes and batch sizes (e.g. same, scaled-up or campaign) should be considered. Factors to be compared include:\n\n- minimum and maximum capacity;\n- material of construction;\n- critical operating parameters;\n- critical equipment components (e.g. filters, screens, and temperature/pressure sensors);\n- critical quality attribute; and\n- range of intended use.\n\n7.6 The facility- and building-specific location of all equipment at the RU should be considered at the time of drawing up process maps or flow charts of the manufacturing process to be transferred, including flows of personnel and material.\n\n7.7 The impact of manufacturing new products on products currently manufactured with the same equipment should be determined.\n\n7.8 Any modification of existing equipment that needs to be adapted to become capable of reproducing the process being transferred should be documented in the transfer project plan.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1983, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "02e54b8b-aa10-40f5-8cba-ccf7249561b2": {"__data__": {"id_": "02e54b8b-aa10-40f5-8cba-ccf7249561b2", "embedding": null, "metadata": {"page_label": "318", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n8.1 The documentation required for the transfer project itself is wide-ranging. Examples of documentation commonly required are summarized in Table 2.\n\n8.2 The documented evidence that the transfer of technology has been considered successful should be formalized and stated in a technology transfer summary report. That report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU (preferably in a tabulated format) and the final conclusions of the transfer. Possible discrepancies should be listed and appropriate actions, where needed, taken to resolve them.\n\n**Table 2**  \nExamples of documentation for transfer of technology (TOT)\n\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Project definition | Project plan and quality plan (where separate documents), protocol, risk assessments, gap analysis | Project implementation plan TOT protocol |\n| Quality agreement | | |\n| Facility assessment | Plans and layout of facility, buildings (construction, finish) Qualification status (DQ, IQ, OQ) and reports | Side-by-side comparison with RU facility and buildings; gap analysis Qualification protocol and report |\n| Health & Safety assessment | Product-specific waste management plans Contingency plans | |\n| Skill set analysis and training | SOPs and training documentation (product-specific operations, analysis, testing) | Training protocols, assessment results |\n| Analytical method transfer | Analytical method specifications and validation, including in-process quality control | Analytical methods transfer protocol and report |\n| Starting material evaluation | Specifications and additional information on APIs, excipients | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la evaluaci\u00f3n de las instalaciones en un proyecto de transferencia de tecnolog\u00eda?**\n   - La documentaci\u00f3n requerida para la evaluaci\u00f3n de las instalaciones incluye los planos y el dise\u00f1o de la instalaci\u00f3n y los edificios (construcci\u00f3n y acabado), as\u00ed como el estado de calificaci\u00f3n (DQ, IQ, OQ) y los informes correspondientes. Adem\u00e1s, se debe realizar una comparaci\u00f3n lado a lado con la instalaci\u00f3n y los edificios de la unidad receptora (RU) y llevar a cabo un an\u00e1lisis de brechas, junto con un protocolo y un informe de calificaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de un informe de resumen de transferencia de tecnolog\u00eda?**\n   - El informe de resumen de transferencia de tecnolog\u00eda tiene como prop\u00f3sito formalizar y documentar que la transferencia ha sido considerada exitosa. Debe resumir el alcance de la transferencia, los par\u00e1metros cr\u00edticos obtenidos en la unidad de origen (SU) y la unidad receptora (RU), preferiblemente en un formato tabulado, as\u00ed como las conclusiones finales de la transferencia. Tambi\u00e9n debe listar posibles discrepancias y las acciones apropiadas que se han tomado para resolverlas.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se debe proporcionar en relaci\u00f3n con el an\u00e1lisis de habilidades y la capacitaci\u00f3n durante la transferencia de tecnolog\u00eda?**\n   - En relaci\u00f3n con el an\u00e1lisis de habilidades y la capacitaci\u00f3n, se debe proporcionar documentaci\u00f3n de Procedimientos Operativos Est\u00e1ndar (SOPs) y documentaci\u00f3n de capacitaci\u00f3n que aborde operaciones espec\u00edficas del producto, an\u00e1lisis y pruebas. Adem\u00e1s, se deben incluir protocolos de capacitaci\u00f3n y resultados de evaluaci\u00f3n.\n\n### Resumen de nivel superior del contexto:\nEl contexto se centra en la documentaci\u00f3n necesaria para un proyecto de transferencia de tecnolog\u00eda, destacando la importancia de formalizar el \u00e9xito de la transferencia a trav\u00e9s de un informe de resumen. Se presenta una tabla que enumera ejemplos de documentaci\u00f3n requerida para diversas tareas clave, como la definici\u00f3n del proyecto, la evaluaci\u00f3n de instalaciones, la evaluaci\u00f3n de salud y seguridad, el an\u00e1lisis de habilidades y la transferencia de m\u00e9todos anal\u00edticos. Este enfoque sistem\u00e1tico asegura que todos los aspectos cr\u00edticos de la transferencia sean considerados y documentados adecuadamente.", "prev_section_summary": "### Temas Clave:\n\n1. **Documentaci\u00f3n Requerida**: Se enfatiza la importancia de proporcionar una lista detallada de equipos, incluyendo marcas y modelos, as\u00ed como la documentaci\u00f3n de calificaci\u00f3n y validaci\u00f3n existente. Ejemplos de documentaci\u00f3n relevante incluyen dibujos, manuales, registros de mantenimiento y procedimientos operativos.\n\n2. **Revisi\u00f3n y Comparaci\u00f3n de Equipos**: El sitio receptor (RU) debe revisar la informaci\u00f3n proporcionada por el sitio de origen (SU) y realizar una comparaci\u00f3n detallada de los equipos en t\u00e9rminos de funcionalidad, marcas, modelos y estado de calificaci\u00f3n.\n\n3. **An\u00e1lisis de Brechas**: Se debe llevar a cabo un an\u00e1lisis de brechas para identificar las necesidades de adaptaci\u00f3n de equipos existentes, adquisici\u00f3n de nuevos equipos o cambios en el proceso, asegurando que se cumplan los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n4. **Factores de Comparaci\u00f3n**: Se deben considerar varios factores al realizar el an\u00e1lisis de brechas, como la capacidad de producci\u00f3n, el material de construcci\u00f3n, los par\u00e1metros operativos cr\u00edticos y los atributos de calidad.\n\n5. **Ubicaci\u00f3n del Equipo**: La ubicaci\u00f3n espec\u00edfica de los equipos en el RU debe ser considerada al elaborar mapas de procesos o diagramas de flujo, incluyendo el flujo de personal y material.\n\n6. **Impacto en Productos Existentes**: Es necesario evaluar c\u00f3mo la fabricaci\u00f3n de nuevos productos afectar\u00e1 a los productos que actualmente se fabrican con el mismo equipo.\n\n7. **Documentaci\u00f3n de Modificaciones**: Cualquier modificaci\u00f3n necesaria en el equipo existente para reproducir el proceso transferido debe ser documentada en el plan del proyecto de transferencia.\n\n### Entidades:\n\n- **SU (Sitio de Origen)**: El lugar donde se encuentra el proceso de fabricaci\u00f3n original.\n- **RU (Sitio Receptor)**: El lugar donde se transferir\u00e1 el proceso de fabricaci\u00f3n.\n- **Equipos**: Herramientas y maquinaria involucradas en la fabricaci\u00f3n, llenado, empaque y control del producto.\n- **Documentaci\u00f3n**: Incluye dibujos, manuales, registros de mantenimiento, registros de calibraci\u00f3n y procedimientos operativos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que deben cumplirse durante el proceso de transferencia.\n- **Capacidad de Producci\u00f3n**: M\u00ednima y m\u00e1xima capacidad de los equipos.\n- **Par\u00e1metros Cr\u00edticos**: Elementos esenciales que afectan la calidad y funcionamiento del proceso de fabricaci\u00f3n. \n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en el contexto de la transferencia de procesos de fabricaci\u00f3n seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: technology transfer, documentation, quality agreement, facility assessment, analytical methods"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7617f773-ade7-4cc4-8bc3-f191c64faf7a", "node_type": "4", "metadata": {"page_label": "318", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n8.1 The documentation required for the transfer project itself is wide-ranging. Examples of documentation commonly required are summarized in Table 2.\n\n8.2 The documented evidence that the transfer of technology has been considered successful should be formalized and stated in a technology transfer summary report. That report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU (preferably in a tabulated format) and the final conclusions of the transfer. Possible discrepancies should be listed and appropriate actions, where needed, taken to resolve them.\n\n**Table 2**  \nExamples of documentation for transfer of technology (TOT)\n\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Project definition | Project plan and quality plan (where separate documents), protocol, risk assessments, gap analysis | Project implementation plan TOT protocol |\n| Quality agreement | | |\n| Facility assessment | Plans and layout of facility, buildings (construction, finish) Qualification status (DQ, IQ, OQ) and reports | Side-by-side comparison with RU facility and buildings; gap analysis Qualification protocol and report |\n| Health & Safety assessment | Product-specific waste management plans Contingency plans | |\n| Skill set analysis and training | SOPs and training documentation (product-specific operations, analysis, testing) | Training protocols, assessment results |\n| Analytical method transfer | Analytical method specifications and validation, including in-process quality control | Analytical methods transfer protocol and report |\n| Starting material evaluation | Specifications and additional information on APIs, excipients | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "00c63d7e758d5171bcbe94db3fae513b4b241ac23b6d80c24cc4847e5b223ac6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Documentation\n\n8.1 The documentation required for the transfer project itself is wide-ranging. Examples of documentation commonly required are summarized in Table 2.\n\n8.2 The documented evidence that the transfer of technology has been considered successful should be formalized and stated in a technology transfer summary report. That report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU (preferably in a tabulated format) and the final conclusions of the transfer. Possible discrepancies should be listed and appropriate actions, where needed, taken to resolve them.\n\n**Table 2**  \nExamples of documentation for transfer of technology (TOT)\n\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Project definition | Project plan and quality plan (where separate documents), protocol, risk assessments, gap analysis | Project implementation plan TOT protocol |\n| Quality agreement | | |\n| Facility assessment | Plans and layout of facility, buildings (construction, finish) Qualification status (DQ, IQ, OQ) and reports | Side-by-side comparison with RU facility and buildings; gap analysis Qualification protocol and report |\n| Health & Safety assessment | Product-specific waste management plans Contingency plans | |\n| Skill set analysis and training | SOPs and training documentation (product-specific operations, analysis, testing) | Training protocols, assessment results |\n| Analytical method transfer | Analytical method specifications and validation, including in-process quality control | Analytical methods transfer protocol and report |\n| Starting material evaluation | Specifications and additional information on APIs, excipients | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1733, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d4530800-75bd-4c1b-9588-0837c4d290c7": {"__data__": {"id_": "d4530800-75bd-4c1b-9588-0837c4d290c7", "embedding": null, "metadata": {"page_label": "319", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Equipment selection and transfer | Inventory list of all equipment and systems, including makes, models, qualification status (IQ, OQ, PQ) Drawings, manuals, logs, SOPs (e.g. set-up, operation, cleaning, maintenance, calibration, storage) | Side-by-side comparison with RU equipment (makes, models, qualification status) Gap analysis **Qualification and validation protocol and report** |\n| Process transfer: manufacturing and packaging | Reference batches (clinical, dossier, biobatches) Development report (manufacturing process rationale) History of critical analytical data Rationale for specifications Change control documentation Critical manufacturing process parameters Process validation reports Drug master file API validation status and report(s) Product stability data Current master batch manufacturing and packaging records List of all batches produced Deviation reports Investigations, complaints, recalls Annual product review | History of process development at RU Experiences at RU should be recorded for future reference Provisional batch manufacturing document (RU to develop) Provisional batch packaging document (RU to develop) Description of process at RU (narrative, process map, flow chart) **Process validation protocol and report** |\n| Cleaning | Cleaning validation, including: Solubility information; therapeutic doses; category (toxicology); existing cleaning SOPs; validation reports \u2014 chemical and micro; agents used; recovery study | Product- and site-specific cleaning SOPs at RU **Cleaning validation protocol and report** |\n\n\nDQ, design qualification; IQ, installation qualification; OQ, operational qualification; API, active pharmaceutical ingredient; SOPs, standard operating procedures; RU, receiving unit.\n\n## 9. Qualification and validation\n\n### General\n\n9.1 The extent of qualification and or validation (18) to be performed should be determined on the basis of risk management principles.\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Technical Report Series 961) aborda la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, centr\u00e1ndose en la calificaci\u00f3n y validaci\u00f3n de equipos y procesos. Se detallan las tareas clave, la documentaci\u00f3n necesaria proporcionada por la unidad de suministro (SU) y la documentaci\u00f3n de transferencia requerida por la unidad receptora (RU). Se enfatiza la importancia de la gesti\u00f3n de riesgos en la determinaci\u00f3n del alcance de la calificaci\u00f3n y validaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la transferencia de equipos y sistemas desde la unidad de suministro (SU) a la unidad receptora (RU)?**\n   - La documentaci\u00f3n requerida incluye una lista de inventario de todos los equipos y sistemas, que abarca marcas, modelos y estado de calificaci\u00f3n (IQ, OQ, PQ), as\u00ed como dibujos, manuales, registros y procedimientos operativos est\u00e1ndar (SOPs).\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en el protocolo y el informe de validaci\u00f3n del proceso durante la transferencia de fabricaci\u00f3n y empaquetado?**\n   - El protocolo y el informe de validaci\u00f3n del proceso deben incluir la historia del desarrollo del proceso en la RU, un documento provisional de fabricaci\u00f3n de lotes, un documento provisional de empaquetado, y una descripci\u00f3n del proceso en la RU, que puede ser en forma de narrativa, mapa de procesos o diagrama de flujo.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de limpieza y qu\u00e9 documentaci\u00f3n espec\u00edfica se requiere para la RU?**\n   - La validaci\u00f3n de limpieza debe incluir informaci\u00f3n sobre solubilidad, dosis terap\u00e9uticas, categor\u00eda (toxicolog\u00eda), SOPs de limpieza existentes y estudios de recuperaci\u00f3n. La RU debe proporcionar SOPs de limpieza espec\u00edficas para el producto y el sitio, as\u00ed como un protocolo y un informe de validaci\u00f3n de limpieza.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Documentaci\u00f3n para la Transferencia de Tecnolog\u00eda (TOT):** Se destaca la variedad de documentaci\u00f3n necesaria para llevar a cabo un proyecto de transferencia de tecnolog\u00eda, que incluye planes de proyecto, evaluaciones de riesgos, y an\u00e1lisis de brechas.\n  \n2. **Informe de Resumen de Transferencia de Tecnolog\u00eda:** Se enfatiza la importancia de formalizar el \u00e9xito de la transferencia mediante un informe que resuma el alcance, par\u00e1metros cr\u00edticos y conclusiones, as\u00ed como las discrepancias y acciones correctivas.\n\n3. **Evaluaci\u00f3n de Instalaciones:** Se requiere documentaci\u00f3n espec\u00edfica sobre la evaluaci\u00f3n de las instalaciones, incluyendo planos, estado de calificaci\u00f3n y comparaciones con la unidad receptora.\n\n4. **An\u00e1lisis de Habilidades y Capacitaci\u00f3n:** Se menciona la necesidad de documentaci\u00f3n sobre procedimientos operativos est\u00e1ndar y capacitaci\u00f3n relacionada con operaciones espec\u00edficas del producto.\n\n5. **Transferencia de M\u00e9todos Anal\u00edticos:** Se requiere documentaci\u00f3n sobre especificaciones y validaci\u00f3n de m\u00e9todos anal\u00edticos, as\u00ed como protocolos de transferencia.\n\n**Entidades:**\n- **SU (Unidad de Origen):** La unidad de donde se transfiere la tecnolog\u00eda.\n- **RU (Unidad Receptora):** La unidad que recibe la tecnolog\u00eda.\n- **Documentaci\u00f3n:** Incluye planes de proyecto, protocolos, informes de calificaci\u00f3n, SOPs, y resultados de evaluaci\u00f3n.\n- **Par\u00e1metros Cr\u00edticos:** Elementos esenciales que deben ser documentados y evaluados durante la transferencia.\n- **Calificaci\u00f3n (DQ, IQ, OQ):** Estado de calificaci\u00f3n de las instalaciones y procesos involucrados en la transferencia.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos fundamentales relacionados con la documentaci\u00f3n y los procesos necesarios para una transferencia de tecnolog\u00eda exitosa.", "excerpt_keywords": "Keywords: transferencia de tecnolog\u00eda, calificaci\u00f3n, validaci\u00f3n, documentaci\u00f3n, industria farmac\u00e9utica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8aa848ba-e5fb-483d-a766-308e55eb1394", "node_type": "4", "metadata": {"page_label": "319", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Equipment selection and transfer | Inventory list of all equipment and systems, including makes, models, qualification status (IQ, OQ, PQ) Drawings, manuals, logs, SOPs (e.g. set-up, operation, cleaning, maintenance, calibration, storage) | Side-by-side comparison with RU equipment (makes, models, qualification status) Gap analysis **Qualification and validation protocol and report** |\n| Process transfer: manufacturing and packaging | Reference batches (clinical, dossier, biobatches) Development report (manufacturing process rationale) History of critical analytical data Rationale for specifications Change control documentation Critical manufacturing process parameters Process validation reports Drug master file API validation status and report(s) Product stability data Current master batch manufacturing and packaging records List of all batches produced Deviation reports Investigations, complaints, recalls Annual product review | History of process development at RU Experiences at RU should be recorded for future reference Provisional batch manufacturing document (RU to develop) Provisional batch packaging document (RU to develop) Description of process at RU (narrative, process map, flow chart) **Process validation protocol and report** |\n| Cleaning | Cleaning validation, including: Solubility information; therapeutic doses; category (toxicology); existing cleaning SOPs; validation reports \u2014 chemical and micro; agents used; recovery study | Product- and site-specific cleaning SOPs at RU **Cleaning validation protocol and report** |\n\n\nDQ, design qualification; IQ, installation qualification; OQ, operational qualification; API, active pharmaceutical ingredient; SOPs, standard operating procedures; RU, receiving unit.\n\n## 9. Qualification and validation\n\n### General\n\n9.1 The extent of qualification and or validation (18) to be performed should be determined on the basis of risk management principles.\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f6db16125df48d2f1ab18b460276833a8906ff5896e70147ebe10fd407cf5558", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Equipment selection and transfer | Inventory list of all equipment and systems, including makes, models, qualification status (IQ, OQ, PQ) Drawings, manuals, logs, SOPs (e.g. set-up, operation, cleaning, maintenance, calibration, storage) | Side-by-side comparison with RU equipment (makes, models, qualification status) Gap analysis **Qualification and validation protocol and report** |\n| Process transfer: manufacturing and packaging | Reference batches (clinical, dossier, biobatches) Development report (manufacturing process rationale) History of critical analytical data Rationale for specifications Change control documentation Critical manufacturing process parameters Process validation reports Drug master file API validation status and report(s) Product stability data Current master batch manufacturing and packaging records List of all batches produced Deviation reports Investigations, complaints, recalls Annual product review | History of process development at RU Experiences at RU should be recorded for future reference Provisional batch manufacturing document (RU to develop) Provisional batch packaging document (RU to develop) Description of process at RU (narrative, process map, flow chart) **Process validation protocol and report** |\n| Cleaning | Cleaning validation, including: Solubility information; therapeutic doses; category (toxicology); existing cleaning SOPs; validation reports \u2014 chemical and micro; agents used; recovery study | Product- and site-specific cleaning SOPs at RU **Cleaning validation protocol and report** |\n\n\nDQ, design qualification; IQ, installation qualification; OQ, operational qualification; API, active pharmaceutical ingredient; SOPs, standard operating procedures; RU, receiving unit.\n\n## 9. Qualification and validation\n\n### General\n\n9.1 The extent of qualification and or validation (18) to be performed should be determined on the basis of risk management principles.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2018, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "35066ccf-6258-40de-b778-08dbb233a492": {"__data__": {"id_": "35066ccf-6258-40de-b778-08dbb233a492", "embedding": null, "metadata": {"page_label": "320", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.2 Qualification and validation should be documented.\n\n## References\n\n1. **ISPE Good practice guide. Technology transfer.** Tampa, FL, International Society for Pharmaceutical Engineering, 2003.\n\n2. **WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report.** Geneva, World Health Organization, 2008 (WHO Technical Report Series, No. 948).\n\n3. **Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2,** second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007 and related updates; Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n4. **Good manufacturing practices for sterile pharmaceutical products** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 957, 2010), Annex 4; WHO Technical Report Series, No. 961, 2011) Annex 6.\n\n5. **WHO good manufacturing practices: supplementary guidelines for the manufacture of investigational pharmaceutical products for clinical trials in humans.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization (WHO Technical Report Series, No. 863, 1996), Annex 7.\n\n6. **ISO 9000:2005, Quality management systems \u2014 Fundamentals and vocabulary.**\n\n7. **ICH Draft Consensus Guideline. Pharmaceutical Quality System. Q10.** Geneva, ICH Secretariat, 2008 (http://www.ich.org/LOB/media/MEDIA3917.pdf, last accessed 27 July 2010).\n\n8. **ICH Harmonized Tripartite Guideline. Pharmaceutical development. Q8 (2R). As revised in August 2009.** Geneva, ICH Secretariat, 2009 (http://www.ich.org/LOB/media/MEDIA4986.pdf last accessed 27 July 2010).\n\n9. **ICH Harmonized Tripartite Guideline. Quality Risk Management. Q9. November 2005.** Geneva, ICH Secretariat, 2005 (http://www.ich.org/LOB/media/MEDIA1957.pdf, last accessed 27 July 2010).\n\n10. **Application of hazard analysis and critical control point (HACCP) methodology to pharmaceuticals.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization (WHO Technical Report Series, No. 908, 2003), Annex 7.\n\n11. **WHO good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization (WHO Technical Report Series, No. 885, 1999), Annex 5.\n\n12. **WHO good manufacturing practices: Active pharmaceutical ingredients (bulk drug substances)** In: WHO Expert Committee on Specifications for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS y se centra en la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza que estos procesos deben ser documentados adecuadamente. Adem\u00e1s, se incluyen referencias a diversas gu\u00edas y normativas relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n, la gesti\u00f3n de calidad y el desarrollo farmac\u00e9utico, que son esenciales para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de no documentar adecuadamente la calificaci\u00f3n y validaci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca explorar las consecuencias potenciales, como problemas de calidad, riesgos para la salud p\u00fablica y repercusiones legales.\n\n2. **\u00bfQu\u00e9 documentos o gu\u00edas espec\u00edficas se mencionan en el contexto que son fundamentales para la calificaci\u00f3n y validaci\u00f3n en la industria farmac\u00e9utica?**\n   - Esta pregunta se centra en identificar las referencias clave que pueden servir como recursos para los profesionales en el campo.\n\n3. **\u00bfC\u00f3mo se relacionan las gu\u00edas de la OMS y de la ICH en t\u00e9rminos de requisitos de calidad y gesti\u00f3n de riesgos en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca entender la interconexi\u00f3n entre diferentes normativas y c\u00f3mo se complementan para asegurar la calidad en la industria farmac\u00e9utica.\n\n### Resumen de Nivel Superior\n\nEl documento subraya la importancia de la calificaci\u00f3n y validaci\u00f3n en la producci\u00f3n farmac\u00e9utica, destacando que estos procesos deben ser documentados para garantizar la calidad y seguridad de los productos. Se citan m\u00faltiples referencias que ofrecen directrices y est\u00e1ndares sobre buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de calidad, lo que es crucial para los profesionales del sector farmac\u00e9utico.", "prev_section_summary": "### Temas Clave:\n\n1. **Transferencia de Tecnolog\u00eda**: El documento se centra en la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, espec\u00edficamente en la calificaci\u00f3n y validaci\u00f3n de equipos y procesos.\n\n2. **Documentaci\u00f3n Requerida**: Se detallan las diferentes categor\u00edas de documentaci\u00f3n que deben ser proporcionadas por la unidad de suministro (SU) y la unidad receptora (RU) para asegurar una transferencia efectiva.\n\n3. **Gesti\u00f3n de Riesgos**: Se enfatiza la importancia de aplicar principios de gesti\u00f3n de riesgos para determinar el alcance de la calificaci\u00f3n y validaci\u00f3n.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n**: Se describen los procesos de calificaci\u00f3n (DQ, IQ, OQ) y validaci\u00f3n necesarios para equipos, procesos de fabricaci\u00f3n y limpieza.\n\n### Entidades:\n\n- **SU (Unidad de Suministro)**: Entidad que proporciona la documentaci\u00f3n y equipos.\n- **RU (Unidad Receptora)**: Entidad que recibe la documentaci\u00f3n y equipos, y que debe desarrollar ciertos documentos provisionales.\n- **Documentaci\u00f3n**: Incluye listas de inventario, informes de desarrollo, protocolos de validaci\u00f3n, SOPs, y m\u00e1s.\n- **Equipos y Sistemas**: Se refiere a los equipos utilizados en la fabricaci\u00f3n y empaquetado de productos farmac\u00e9uticos.\n- **Proceso de Fabricaci\u00f3n y Empaque**: Incluye la transferencia de procesos cr\u00edticos y la documentaci\u00f3n asociada.\n- **Validaci\u00f3n de Limpieza**: Proceso que asegura que los procedimientos de limpieza son efectivos y seguros.\n\n### Resumen General:\nEl documento de la OMS (Technical Report Series 961) aborda la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, destacando la importancia de la calificaci\u00f3n y validaci\u00f3n de equipos y procesos. Se especifica la documentaci\u00f3n necesaria para la transferencia, la cual debe ser proporcionada por la unidad de suministro y adaptada por la unidad receptora, todo bajo un enfoque de gesti\u00f3n de riesgos.", "excerpt_keywords": "Keywords: calificaci\u00f3n, validaci\u00f3n, buenas pr\u00e1cticas, farmac\u00e9uticos, gesti\u00f3n de calidad"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8032ae35-979a-40bf-97a6-8c412d97d675", "node_type": "4", "metadata": {"page_label": "320", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.2 Qualification and validation should be documented.\n\n## References\n\n1. **ISPE Good practice guide. Technology transfer.** Tampa, FL, International Society for Pharmaceutical Engineering, 2003.\n\n2. **WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report.** Geneva, World Health Organization, 2008 (WHO Technical Report Series, No. 948).\n\n3. **Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2,** second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007 and related updates; Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n4. **Good manufacturing practices for sterile pharmaceutical products** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 957, 2010), Annex 4; WHO Technical Report Series, No. 961, 2011) Annex 6.\n\n5. **WHO good manufacturing practices: supplementary guidelines for the manufacture of investigational pharmaceutical products for clinical trials in humans.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization (WHO Technical Report Series, No. 863, 1996), Annex 7.\n\n6. **ISO 9000:2005, Quality management systems \u2014 Fundamentals and vocabulary.**\n\n7. **ICH Draft Consensus Guideline. Pharmaceutical Quality System. Q10.** Geneva, ICH Secretariat, 2008 (http://www.ich.org/LOB/media/MEDIA3917.pdf, last accessed 27 July 2010).\n\n8. **ICH Harmonized Tripartite Guideline. Pharmaceutical development. Q8 (2R). As revised in August 2009.** Geneva, ICH Secretariat, 2009 (http://www.ich.org/LOB/media/MEDIA4986.pdf last accessed 27 July 2010).\n\n9. **ICH Harmonized Tripartite Guideline. Quality Risk Management. Q9. November 2005.** Geneva, ICH Secretariat, 2005 (http://www.ich.org/LOB/media/MEDIA1957.pdf, last accessed 27 July 2010).\n\n10. **Application of hazard analysis and critical control point (HACCP) methodology to pharmaceuticals.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization (WHO Technical Report Series, No. 908, 2003), Annex 7.\n\n11. **WHO good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization (WHO Technical Report Series, No. 885, 1999), Annex 5.\n\n12. **WHO good manufacturing practices: Active pharmaceutical ingredients (bulk drug substances)** In: WHO Expert Committee on Specifications for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5a3dc9f2c2ab8e6e7f83ac9f08b7d26cf1bbe7c3f45352013088b47fd6c1f502", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.2 Qualification and validation should be documented.\n\n## References\n\n1. **ISPE Good practice guide. Technology transfer.** Tampa, FL, International Society for Pharmaceutical Engineering, 2003.\n\n2. **WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report.** Geneva, World Health Organization, 2008 (WHO Technical Report Series, No. 948).\n\n3. **Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2,** second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007 and related updates; Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n4. **Good manufacturing practices for sterile pharmaceutical products** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 957, 2010), Annex 4; WHO Technical Report Series, No. 961, 2011) Annex 6.\n\n5. **WHO good manufacturing practices: supplementary guidelines for the manufacture of investigational pharmaceutical products for clinical trials in humans.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization (WHO Technical Report Series, No. 863, 1996), Annex 7.\n\n6. **ISO 9000:2005, Quality management systems \u2014 Fundamentals and vocabulary.**\n\n7. **ICH Draft Consensus Guideline. Pharmaceutical Quality System. Q10.** Geneva, ICH Secretariat, 2008 (http://www.ich.org/LOB/media/MEDIA3917.pdf, last accessed 27 July 2010).\n\n8. **ICH Harmonized Tripartite Guideline. Pharmaceutical development. Q8 (2R). As revised in August 2009.** Geneva, ICH Secretariat, 2009 (http://www.ich.org/LOB/media/MEDIA4986.pdf last accessed 27 July 2010).\n\n9. **ICH Harmonized Tripartite Guideline. Quality Risk Management. Q9. November 2005.** Geneva, ICH Secretariat, 2005 (http://www.ich.org/LOB/media/MEDIA1957.pdf, last accessed 27 July 2010).\n\n10. **Application of hazard analysis and critical control point (HACCP) methodology to pharmaceuticals.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization (WHO Technical Report Series, No. 908, 2003), Annex 7.\n\n11. **WHO good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization (WHO Technical Report Series, No. 885, 1999), Annex 5.\n\n12. **WHO good manufacturing practices: Active pharmaceutical ingredients (bulk drug substances)** In: WHO Expert Committee on Specifications for", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2862, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8a91e37a-4440-49fd-833a-96078a718fda": {"__data__": {"id_": "8a91e37a-4440-49fd-833a-96078a718fda", "embedding": null, "metadata": {"page_label": "321", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido circundante:\n\n### Resumen del contexto:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 961?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir descubrimientos clave o directrices de salud p\u00fablica.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 961 con esos temas?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio de la serie de informes, permitiendo entender la relevancia del informe 961 dentro de la colecci\u00f3n.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 961 para abordar los problemas de salud discutidos?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos espec\u00edficos que el informe podr\u00eda emplear para analizar y presentar sus hallazgos, lo que puede ser crucial para la interpretaci\u00f3n de los resultados.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido espec\u00edfico del informe y su contexto dentro de la serie de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de documentar adecuadamente los procesos de calificaci\u00f3n y validaci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos para garantizar su calidad y seguridad.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se mencionan diversas gu\u00edas y normativas que establecen est\u00e1ndares para la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo la gesti\u00f3n de calidad y el desarrollo farmac\u00e9utico.\n\n3. **Gesti\u00f3n de Calidad y Riesgos**: Se hace referencia a la interconexi\u00f3n entre diferentes normativas, como las de la OMS y la ICH, que abordan los requisitos de calidad y la gesti\u00f3n de riesgos en la industria farmac\u00e9utica.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y est\u00e1ndares sobre buenas pr\u00e1cticas de fabricaci\u00f3n y calidad en productos farmac\u00e9uticos.\n  \n- **International Society for Pharmaceutical Engineering (ISPE)**: Ofrece gu\u00edas sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n\n- **International Conference on Harmonisation (ICH)**: Desarrolla directrices sobre sistemas de calidad, desarrollo farmac\u00e9utico y gesti\u00f3n de riesgos.\n\n### Referencias Clave\n\n1. **ISPE Good Practice Guide**: Gu\u00eda sobre la transferencia de tecnolog\u00eda.\n2. **WHO Technical Report Series**: Incluye m\u00faltiples informes sobre especificaciones y buenas pr\u00e1cticas de fabricaci\u00f3n.\n3. **ISO 9000:2005**: Normativa sobre sistemas de gesti\u00f3n de calidad.\n4. **ICH Guidelines (Q8, Q9, Q10)**: Directrices sobre desarrollo farmac\u00e9utico, gesti\u00f3n de riesgos y sistemas de calidad.\n\nEste resumen destaca la relevancia de la documentaci\u00f3n en los procesos de calificaci\u00f3n y validaci\u00f3n, as\u00ed como la importancia de seguir las gu\u00edas y normativas establecidas para asegurar la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: OMS, calidad, farmac\u00e9utica, buenas pr\u00e1cticas, validaci\u00f3n"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fbabd06b-d065-4db2-be9d-76f63ff6ee24", "node_type": "4", "metadata": {"page_label": "321", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b3ccef19-6656-46ab-92b1-ebb984cf7a12": {"__data__": {"id_": "b3ccef19-6656-46ab-92b1-ebb984cf7a12", "embedding": null, "metadata": {"page_label": "322", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 8\n\n## Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services\n\n### Background\n\n1. Introduction\n2. Underlying philosophy\n3. Definition of good pharmacy practice\n4. Requirements of good pharmacy practice\n5. Setting standards for good pharmacy practice\n6. Conclusions\n\n\u00a9 World Health Organization  \nWHO Technical Report Series, No. 961, 2011", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los principios fundamentales que sustentan las directrices conjuntas de la FIP/OMS sobre la buena pr\u00e1ctica farmac\u00e9utica?**\n   - Esta pregunta busca explorar la \"filosof\u00eda subyacente\" mencionada en el documento, que puede ofrecer una comprensi\u00f3n m\u00e1s profunda de los valores y principios que gu\u00edan la pr\u00e1ctica farmac\u00e9utica de calidad.\n\n2. **\u00bfQu\u00e9 requisitos espec\u00edficos se establecen para garantizar una buena pr\u00e1ctica farmac\u00e9utica seg\u00fan las directrices de la FIP/OMS?**\n   - Esta pregunta se centra en la secci\u00f3n que detalla los \"requisitos de buena pr\u00e1ctica farmac\u00e9utica\", lo que puede proporcionar informaci\u00f3n sobre las expectativas y est\u00e1ndares que deben cumplirse en el \u00e1mbito farmac\u00e9utico.\n\n3. **\u00bfC\u00f3mo se proponen establecer est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica en el contexto de los servicios de farmacia?**\n   - Esta pregunta indaga en la secci\u00f3n sobre \"establecimiento de est\u00e1ndares\", lo que puede revelar los m\u00e9todos y enfoques sugeridos para implementar y mantener est\u00e1ndares de calidad en los servicios farmac\u00e9uticos.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento es un informe t\u00e9cnico de la OMS que presenta directrices conjuntas con la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) sobre la buena pr\u00e1ctica farmac\u00e9utica. Estas directrices est\u00e1n dise\u00f1adas para establecer est\u00e1ndares de calidad en los servicios de farmacia, abordando aspectos como la definici\u00f3n de buena pr\u00e1ctica, los requisitos necesarios y la filosof\u00eda que gu\u00eda estas pr\u00e1cticas. El informe busca mejorar la calidad de los servicios farmac\u00e9uticos a nivel global, asegurando que se cumplan ciertos criterios y est\u00e1ndares en la atenci\u00f3n al paciente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 961\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - Entidad responsable de la publicaci\u00f3n del informe, enfocada en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica a nivel global.\n\n2. **Informe T\u00e9cnico**:\n   - Parte de una serie que aborda diversos temas de salud p\u00fablica, proporcionando recomendaciones y hallazgos basados en investigaciones.\n\n3. **Salud P\u00fablica**:\n   - Tema central del informe, que podr\u00eda incluir aspectos como prevenci\u00f3n de enfermedades, pol\u00edticas de salud, y estrategias de intervenci\u00f3n.\n\n4. **Investigaci\u00f3n M\u00e9dica**:\n   - Posible enfoque del informe, que podr\u00eda presentar estudios, an\u00e1lisis de datos y metodolog\u00edas relacionadas con la salud.\n\n5. **Recomendaciones de Pol\u00edticas de Salud**:\n   - Es probable que el informe contenga directrices o sugerencias para mejorar la salud p\u00fablica y la atenci\u00f3n m\u00e9dica.\n\n### Temas Clave Potenciales:\n- Hallazgos sobre enfermedades espec\u00edficas o condiciones de salud.\n- Estrategias de prevenci\u00f3n y control de enfermedades.\n- Evaluaci\u00f3n de programas de salud p\u00fablica.\n- An\u00e1lisis de datos epidemiol\u00f3gicos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: pharmacy practice, quality standards, WHO guidelines, FIP collaboration, healthcare services"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3a20e2c8-d6dc-4b6c-a08f-3e5bf7c525a2", "node_type": "4", "metadata": {"page_label": "322", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 8\n\n## Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services\n\n### Background\n\n1. Introduction\n2. Underlying philosophy\n3. Definition of good pharmacy practice\n4. Requirements of good pharmacy practice\n5. Setting standards for good pharmacy practice\n6. Conclusions\n\n\u00a9 World Health Organization  \nWHO Technical Report Series, No. 961, 2011", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "443473fb69d928bf6bedf146102ca58ac6d774240c7e24e1e2b6ca2e548f3acf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 8\n\n## Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services\n\n### Background\n\n1. Introduction\n2. Underlying philosophy\n3. Definition of good pharmacy practice\n4. Requirements of good pharmacy practice\n5. Setting standards for good pharmacy practice\n6. Conclusions\n\n\u00a9 World Health Organization  \nWHO Technical Report Series, No. 961, 2011", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 385, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fcf69961-d6b9-4cdb-8477-35c00c2d223d": {"__data__": {"id_": "fcf69961-d6b9-4cdb-8477-35c00c2d223d", "embedding": null, "metadata": {"page_label": "323", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nUnder the World Health Organization (WHO)\u2019s Revised Drug Strategy adopted by the World Health Assembly in 1986, WHO organized two meetings on the role of the pharmacist, in Delhi, India in 1988 and in Tokyo, Japan in 1993. This was followed by the adoption, in May 1994, of the World Health Assembly Resolution WHA47.12 on the role of the pharmacist, in support of the WHO Revised Drug Strategy.\n\nIn 1992 the International Pharmaceutical Federation (FIP) developed standards for pharmacy services under the heading \u201cGood pharmacy practice in community and hospital pharmacy settings\u201d. The text on good pharmacy practice was also submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on good pharmacy practice (GPP) was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nSubsequently WHO organized two more meetings on the role of the pharmacist, in Vancouver, Canada in 1997 and in the Hague, the Netherlands in 1998. These meetings reinforced the need for pharmacy curricular reform and the added value of the pharmacist in self-care and self-medication.\n\nIn collaboration with WHO, the first edition of a practical handbook *Developing pharmacy practice \u2014 a focus on patient care* was launched in 2006. This handbook is designed to meet the changing needs of pharmacists, setting out a new paradigm for pharmacy practice and presenting a step-by-step approach to pharmaceutical care.\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out the commitment of its Member Associations towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evoluci\u00f3n de la pr\u00e1ctica farmac\u00e9utica**: Desde la adopci\u00f3n de la Estrategia de Medicamentos Revisada de la OMS en 1986, ha habido un enfoque continuo en el papel del farmac\u00e9utico, con m\u00faltiples reuniones y la creaci\u00f3n de documentos clave que establecen est\u00e1ndares para la pr\u00e1ctica farmac\u00e9utica, como las directrices de Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP).\n\n2. **Colaboraci\u00f3n entre organizaciones**: La colaboraci\u00f3n entre la OMS y la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) ha sido fundamental para desarrollar y promover est\u00e1ndares de pr\u00e1ctica farmac\u00e9utica, incluyendo la creaci\u00f3n de manuales pr\u00e1cticos y la implementaci\u00f3n de estudios piloto en varios pa\u00edses para mejorar la calidad de los servicios farmac\u00e9uticos.\n\n3. **Impacto de las resoluciones de la OMS**: Las resoluciones de la Asamblea Mundial de la Salud han influido en la evoluci\u00f3n de la pr\u00e1ctica farmac\u00e9utica, destacando la importancia de la reforma curricular y el papel del farmac\u00e9utico en el autocuidado y la automedicaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales resultados de las reuniones organizadas por la OMS en Delhi y Tokio sobre el papel del farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre las conclusiones y recomendaciones espec\u00edficas que surgieron de estas reuniones, que pueden no estar documentadas en otros lugares.\n\n2. **\u00bfQu\u00e9 cambios significativos en la pr\u00e1ctica farmac\u00e9utica se han observado desde la adopci\u00f3n de las directrices de GPP en 1999?**\n   - Esta pregunta se centra en los cambios concretos en la pr\u00e1ctica y la pol\u00edtica farmac\u00e9utica que han ocurrido desde la publicaci\u00f3n de las directrices, proporcionando una perspectiva sobre la evoluci\u00f3n del campo.\n\n3. **\u00bfC\u00f3mo se implementaron las directrices de GPP en los pa\u00edses que participaron en el estudio piloto de 2005 a 2007?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el proceso y los resultados de la implementaci\u00f3n de las directrices de GPP en los pa\u00edses mencionados, lo que puede ofrecer ejemplos pr\u00e1cticos de su aplicaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Secci\u00f3n:** Anexo 8 - Directrices conjuntas de la FIP/OMS sobre buena pr\u00e1ctica farmac\u00e9utica: est\u00e1ndares para la calidad de los servicios de farmacia.\n\n**Temas Clave:**\n1. **Introducci\u00f3n:** Presentaci\u00f3n del contexto y la importancia de la buena pr\u00e1ctica farmac\u00e9utica.\n2. **Filosof\u00eda Subyacente:** Principios y valores que gu\u00edan la pr\u00e1ctica farmac\u00e9utica de calidad.\n3. **Definici\u00f3n de Buena Pr\u00e1ctica Farmac\u00e9utica:** Concepto y caracter\u00edsticas que definen lo que se considera buena pr\u00e1ctica en el \u00e1mbito farmac\u00e9utico.\n4. **Requisitos de Buena Pr\u00e1ctica Farmac\u00e9utica:** Expectativas y criterios espec\u00edficos que deben cumplirse para asegurar la calidad en los servicios farmac\u00e9uticos.\n5. **Establecimiento de Est\u00e1ndares:** M\u00e9todos y enfoques propuestos para implementar y mantener est\u00e1ndares de calidad en los servicios de farmacia.\n6. **Conclusiones:** Reflexiones finales sobre la importancia de seguir estas directrices para mejorar la atenci\u00f3n al paciente.\n\n**Entidades:**\n- **Organizaciones:** Organizaci\u00f3n Mundial de la Salud (OMS), Federaci\u00f3n Internacional Farmac\u00e9utica (FIP).\n- **A\u00f1o de Publicaci\u00f3n:** 2011.\n- **N\u00famero de Informe:** WHO Technical Report Series, No. 961.\n\nEste resumen destaca los elementos esenciales del documento, que busca mejorar la calidad de los servicios farmac\u00e9uticos a nivel global mediante la implementaci\u00f3n de est\u00e1ndares y buenas pr\u00e1cticas.", "excerpt_keywords": "Keywords: pharmacy practice, WHO, good pharmacy practice, pharmaceutical standards, healthcare reform"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4dc16ac7-5306-4f5f-a055-f7ac2e16621b", "node_type": "4", "metadata": {"page_label": "323", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nUnder the World Health Organization (WHO)\u2019s Revised Drug Strategy adopted by the World Health Assembly in 1986, WHO organized two meetings on the role of the pharmacist, in Delhi, India in 1988 and in Tokyo, Japan in 1993. This was followed by the adoption, in May 1994, of the World Health Assembly Resolution WHA47.12 on the role of the pharmacist, in support of the WHO Revised Drug Strategy.\n\nIn 1992 the International Pharmaceutical Federation (FIP) developed standards for pharmacy services under the heading \u201cGood pharmacy practice in community and hospital pharmacy settings\u201d. The text on good pharmacy practice was also submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on good pharmacy practice (GPP) was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nSubsequently WHO organized two more meetings on the role of the pharmacist, in Vancouver, Canada in 1997 and in the Hague, the Netherlands in 1998. These meetings reinforced the need for pharmacy curricular reform and the added value of the pharmacist in self-care and self-medication.\n\nIn collaboration with WHO, the first edition of a practical handbook *Developing pharmacy practice \u2014 a focus on patient care* was launched in 2006. This handbook is designed to meet the changing needs of pharmacists, setting out a new paradigm for pharmacy practice and presenting a step-by-step approach to pharmaceutical care.\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out the commitment of its Member Associations towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1730d870495581cf89f4f4b4d8382fdd644003977bcc942574cc4bafcef9f59f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Background\n\nUnder the World Health Organization (WHO)\u2019s Revised Drug Strategy adopted by the World Health Assembly in 1986, WHO organized two meetings on the role of the pharmacist, in Delhi, India in 1988 and in Tokyo, Japan in 1993. This was followed by the adoption, in May 1994, of the World Health Assembly Resolution WHA47.12 on the role of the pharmacist, in support of the WHO Revised Drug Strategy.\n\nIn 1992 the International Pharmaceutical Federation (FIP) developed standards for pharmacy services under the heading \u201cGood pharmacy practice in community and hospital pharmacy settings\u201d. The text on good pharmacy practice was also submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on good pharmacy practice (GPP) was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nSubsequently WHO organized two more meetings on the role of the pharmacist, in Vancouver, Canada in 1997 and in the Hague, the Netherlands in 1998. These meetings reinforced the need for pharmacy curricular reform and the added value of the pharmacist in self-care and self-medication.\n\nIn collaboration with WHO, the first edition of a practical handbook *Developing pharmacy practice \u2014 a focus on patient care* was launched in 2006. This handbook is designed to meet the changing needs of pharmacists, setting out a new paradigm for pharmacy practice and presenting a step-by-step approach to pharmaceutical care.\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out the commitment of its Member Associations towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2700, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c8b20f1a-f70a-4bb1-bf4b-4f24c238dddd": {"__data__": {"id_": "c8b20f1a-f70a-4bb1-bf4b-4f24c238dddd", "embedding": null, "metadata": {"page_label": "324", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe health of the public is fundamental to the happiness and welfare of all people. Barriers to good health include poor access to quality medical products, lack of access to trained health professionals and care, an inadequate health workforce, unaffordable cost of care and poor standards of education of health-care professionals.\n\nMedicines are an essential and critical part of health-care services in all cultures and societies. When accessed, medicines are often an essential component of many disease prevention programmes and virtually all disease treatment plans. The potential benefit of medicines is often not realized \u2014 there is a gap between the proven efficacy of medicines demonstrated in clinical trials and their actual effectiveness in practice. The reasons for this gap include problems with medicine selection and dosages, improper administration of medicines and lack of adherence by patients to prescribed treatment, medicine\u2013medicine and medicine\u2013food interactions, and adverse medicine events. Besides clinical problems associated with medicine-related problems, there are cost\n\n----\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation, the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 120 national Member Associations, relevant experts and WHO. A proposal for this initiative was presented to the forty-third meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Importancia de la salud p\u00fablica**: La salud p\u00fablica es esencial para el bienestar de las personas, y existen m\u00faltiples barreras que impiden el acceso a una atenci\u00f3n m\u00e9dica de calidad, incluyendo la falta de productos m\u00e9dicos adecuados, profesionales de salud capacitados y costos asequibles.\n\n2. **Medicamentos y su efectividad**: Los medicamentos son cruciales en los servicios de salud y en los programas de prevenci\u00f3n y tratamiento de enfermedades. Sin embargo, existe una brecha entre la eficacia demostrada en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica, debido a problemas como la selecci\u00f3n y dosificaci\u00f3n incorrectas, la administraci\u00f3n inapropiada y la falta de adherencia de los pacientes.\n\n3. **Iniciativa de la FIP para actualizar las gu\u00edas de buenas pr\u00e1cticas farmac\u00e9uticas (GPP)**: En 2007, la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 un esfuerzo para actualizar las gu\u00edas de GPP, llevando a cabo consultas y revisiones de est\u00e1ndares nacionales en varios pa\u00edses, con el objetivo de reflejar las pr\u00e1cticas contempor\u00e1neas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las principales barreras identificadas que afectan el acceso a medicamentos de calidad en la atenci\u00f3n m\u00e9dica?**\n   - Esta pregunta busca respuestas sobre los obst\u00e1culos espec\u00edficos que enfrentan las personas para acceder a medicamentos, que no se detallan exhaustivamente en otros documentos.\n\n2. **\u00bfQu\u00e9 factores contribuyen a la brecha entre la eficacia de los medicamentos en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica cl\u00ednica?**\n   - Esta pregunta se centra en los problemas espec\u00edficos que afectan la implementaci\u00f3n de tratamientos efectivos, proporcionando una visi\u00f3n m\u00e1s profunda de los desaf\u00edos en la adherencia y administraci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 pasos se han tomado desde la consulta de 2008 para revisar las gu\u00edas de GPP y cu\u00e1les son los resultados esperados de esta revisi\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso y los resultados de la revisi\u00f3n de las gu\u00edas de GPP, as\u00ed como las expectativas de la FIP y la OMS en relaci\u00f3n con la mejora de las pr\u00e1cticas farmac\u00e9uticas a nivel global.", "prev_section_summary": "### Temas Clave\n\n1. **Estrategia de Medicamentos de la OMS**: La adopci\u00f3n de la Estrategia de Medicamentos Revisada en 1986 marc\u00f3 el inicio de un enfoque sistem\u00e1tico sobre el papel del farmac\u00e9utico, con reuniones clave en Delhi y Tokio.\n\n2. **Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP)**: La Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) desarroll\u00f3 est\u00e1ndares para la pr\u00e1ctica farmac\u00e9utica, culminando en la publicaci\u00f3n de un documento conjunto con la OMS en 1999 que establece directrices para la pr\u00e1ctica en entornos comunitarios y hospitalarios.\n\n3. **Reforma Curricular y Autocuidado**: Las reuniones posteriores en Vancouver y La Haya subrayaron la necesidad de reformar los planes de estudio de farmacia y el papel del farmac\u00e9utico en el autocuidado y la automedicaci\u00f3n.\n\n4. **Manual Pr\u00e1ctico de Pr\u00e1ctica Farmac\u00e9utica**: En 2006, se lanz\u00f3 un manual pr\u00e1ctico que establece un nuevo paradigma para la pr\u00e1ctica farmac\u00e9utica, enfocado en el cuidado del paciente.\n\n5. **Asistencia T\u00e9cnica y Estudio Piloto**: La FIP, en colaboraci\u00f3n con la OMS, llev\u00f3 a cabo un estudio piloto entre 2005 y 2007 en varios pa\u00edses para desarrollar est\u00e1ndares nacionales de GPP.\n\n6. **Declaraci\u00f3n de Bangkok**: En 2007, se adopt\u00f3 la Declaraci\u00f3n de Bangkok, que reafirma el compromiso de las asociaciones farmac\u00e9uticas en la regi\u00f3n de Asia Sudoriental para elevar los est\u00e1ndares de los servicios farmac\u00e9uticos.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n que lidera la estrategia y las reuniones sobre el papel del farmac\u00e9utico.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que desarroll\u00f3 est\u00e1ndares de pr\u00e1ctica y colabor\u00f3 con la OMS en la creaci\u00f3n de directrices.\n- **Asamblea Mundial de la Salud**: \u00d3rgano que adopt\u00f3 resoluciones relevantes para la pr\u00e1ctica farmac\u00e9utica, incluyendo la WHA47.12 y WHA54.11.\n- **Pa\u00edses Participantes**: Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam, que participaron en el estudio piloto para el desarrollo de est\u00e1ndares de GPP. \n\nEste resumen destaca la evoluci\u00f3n y el impacto de la pr\u00e1ctica farmac\u00e9utica a trav\u00e9s de la colaboraci\u00f3n internacional y el establecimiento de est\u00e1ndares.", "excerpt_keywords": "Keywords: public health, medicines, guidelines, FIP, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e93e1446-0faa-4853-96e4-69abba33e17a", "node_type": "4", "metadata": {"page_label": "324", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe health of the public is fundamental to the happiness and welfare of all people. Barriers to good health include poor access to quality medical products, lack of access to trained health professionals and care, an inadequate health workforce, unaffordable cost of care and poor standards of education of health-care professionals.\n\nMedicines are an essential and critical part of health-care services in all cultures and societies. When accessed, medicines are often an essential component of many disease prevention programmes and virtually all disease treatment plans. The potential benefit of medicines is often not realized \u2014 there is a gap between the proven efficacy of medicines demonstrated in clinical trials and their actual effectiveness in practice. The reasons for this gap include problems with medicine selection and dosages, improper administration of medicines and lack of adherence by patients to prescribed treatment, medicine\u2013medicine and medicine\u2013food interactions, and adverse medicine events. Besides clinical problems associated with medicine-related problems, there are cost\n\n----\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation, the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 120 national Member Associations, relevant experts and WHO. A proposal for this initiative was presented to the forty-third meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2bd6bbcb25e91469c7d2ee2e2d6dcb9ff252047940998d58b67f4f48cb4768ed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe health of the public is fundamental to the happiness and welfare of all people. Barriers to good health include poor access to quality medical products, lack of access to trained health professionals and care, an inadequate health workforce, unaffordable cost of care and poor standards of education of health-care professionals.\n\nMedicines are an essential and critical part of health-care services in all cultures and societies. When accessed, medicines are often an essential component of many disease prevention programmes and virtually all disease treatment plans. The potential benefit of medicines is often not realized \u2014 there is a gap between the proven efficacy of medicines demonstrated in clinical trials and their actual effectiveness in practice. The reasons for this gap include problems with medicine selection and dosages, improper administration of medicines and lack of adherence by patients to prescribed treatment, medicine\u2013medicine and medicine\u2013food interactions, and adverse medicine events. Besides clinical problems associated with medicine-related problems, there are cost\n\n----\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation, the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 120 national Member Associations, relevant experts and WHO. A proposal for this initiative was presented to the forty-third meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2502, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ee14ac38-b760-41b0-854c-8519d2bcf1f0": {"__data__": {"id_": "ee14ac38-b760-41b0-854c-8519d2bcf1f0", "embedding": null, "metadata": {"page_label": "325", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "implications. It has been estimated that the cost of problems with the use of medicines is equal to or greater than the cost of the medicines themselves.\n\nMedicines are also increasingly expensive and their cost is compromising the affordability of health care. Managing the costs of medicines is critical to making the best use of limited resources to maximize health care for as many people as possible.\n\nSubstandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/ counterfeit medicines are a growing problem that compromise health. There is a need for a system of assuring the integrity of the medicine supply chain to assure the value of medicines used for the prevention of disease and the treatment of patients.\n\nPharmacists[^1] are specifically educated and trained health professionals who are charged by their national or other appropriate (e.g. state or provincial) authorities with the management of the distribution of medicines to consumers and to engage in appropriate efforts to assure their safe and efficacious use. There is also increasing recognition that providing consumers with medicines alone is not sufficient to achieve the treatment goals. To address these medication-related needs, pharmacists are accepting greater responsibility for the outcomes of medicines use and are evolving their practices to provide patients with enhanced medicines-use services.\n\nAs health-care professionals, pharmacists play an important role in improving access to health care and in closing the gap between the potential benefit of medicines and the actual value realized and should be part of any comprehensive health system. In addition, the increasingly complex and diverse nature of pharmacists\u2019 roles in the health-care system and public health demands a continuous maintenance of the competence of pharmacists as health-care professionals who have up-to-date skills and expertise.\n\nNational pharmacy professional associations need to work together with their governing bodies and other health-care professional associations to support pharmacists in their countries through provision of continuing professional development activities, including distance-learning programmes, and establishing national standards of pharmacy services and practice objectives.\n\nThese guidelines are intended to provide a description of ways in which pharmacists can improve access to health care, health promotion and the use of medicines on behalf of the patients they serve. The role of FIP is to provide leadership for national pharmacy professional organizations,\n\n[^1]: Pharmacists are health-care professionals whose professional responsibilities and accountabilities include seeking to ensure that people derive maximum therapeutic benefit from their treatments with medicines. This requires them to keep abreast of developments in pharmacy practice and the pharmaceutical sciences, professional standards and requirements, the laws governing pharmacy and medicines and advances in knowledge and technology relating to use of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Costo y Accesibilidad de Medicamentos**: El aumento en el costo de los medicamentos est\u00e1 afectando la accesibilidad a la atenci\u00f3n m\u00e9dica. Se estima que los problemas relacionados con el uso de medicamentos pueden tener costos iguales o superiores a los de los propios medicamentos, lo que resalta la necesidad de gestionar estos costos de manera efectiva.\n\n2. **Problemas con Medicamentos**: Existe un creciente problema con medicamentos subest\u00e1ndar, adulterados y falsificados, lo que compromete la salud p\u00fablica. Se requiere un sistema que garantice la integridad de la cadena de suministro de medicamentos para asegurar su valor en la prevenci\u00f3n y tratamiento de enfermedades.\n\n3. **Rol de los Farmac\u00e9uticos**: Los farmac\u00e9uticos son profesionales de la salud capacitados que no solo distribuyen medicamentos, sino que tambi\u00e9n asumen una mayor responsabilidad en los resultados del uso de medicamentos. Su papel es crucial para mejorar el acceso a la atenci\u00f3n m\u00e9dica y cerrar la brecha entre el beneficio potencial de los medicamentos y su valor real.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1les son las implicaciones econ\u00f3micas de los problemas relacionados con el uso de medicamentos en comparaci\u00f3n con su costo?**\n   - El contexto menciona que el costo de los problemas con el uso de medicamentos es igual o mayor que el costo de los propios medicamentos, lo que implica una carga econ\u00f3mica significativa en el sistema de salud.\n\n2. **\u00bfQu\u00e9 medidas se sugieren para asegurar la integridad de la cadena de suministro de medicamentos?**\n   - Se destaca la necesidad de un sistema que garantice la integridad de la cadena de suministro de medicamentos, aunque el texto no detalla las medidas espec\u00edficas, se puede inferir que se requiere una regulaci\u00f3n m\u00e1s estricta y mecanismos de control.\n\n3. **\u00bfC\u00f3mo est\u00e1n evolucionando las responsabilidades de los farmac\u00e9uticos en el sistema de salud?**\n   - Los farmac\u00e9uticos est\u00e1n asumiendo una mayor responsabilidad en los resultados del uso de medicamentos y est\u00e1n evolucionando sus pr\u00e1cticas para ofrecer servicios mejorados relacionados con el uso de medicamentos, lo que refleja un cambio hacia un enfoque m\u00e1s integral en la atenci\u00f3n al paciente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Salud P\u00fablica**: La salud p\u00fablica es esencial para el bienestar general de las personas. Existen barreras significativas que afectan el acceso a atenci\u00f3n m\u00e9dica de calidad, incluyendo:\n   - Acceso limitado a productos m\u00e9dicos de calidad.\n   - Falta de profesionales de salud capacitados.\n   - Costos de atenci\u00f3n m\u00e9dica inasequibles.\n   - Est\u00e1ndares educativos deficientes para los profesionales de la salud.\n\n2. **Medicamentos**: Los medicamentos son fundamentales en los servicios de salud y en programas de prevenci\u00f3n y tratamiento de enfermedades. Sin embargo, hay una brecha entre la eficacia demostrada en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica cl\u00ednica. Las razones de esta brecha incluyen:\n   - Problemas en la selecci\u00f3n y dosificaci\u00f3n de medicamentos.\n   - Administraci\u00f3n inapropiada de medicamentos.\n   - Falta de adherencia de los pacientes a los tratamientos prescritos.\n   - Interacciones entre medicamentos y alimentos, as\u00ed como eventos adversos relacionados con los medicamentos.\n\n3. **Iniciativa de la FIP sobre Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP)**: En 2007, la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 una iniciativa para actualizar las gu\u00edas de GPP. Los pasos clave incluyen:\n   - Formaci\u00f3n de un grupo de trabajo de la FIP sobre GPP.\n   - Consulta de expertos en 2008 en Basilea, Suiza, con la participaci\u00f3n de representantes de la OMS y asesores de medicamentos de varios pa\u00edses.\n   - Revisi\u00f3n exhaustiva de est\u00e1ndares nacionales de GPP en al menos 37 pa\u00edses.\n   - Presentaci\u00f3n de propuestas a la OMS en reuniones de expertos en 2008 y 2009.\n\n### Entidades Clave\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que lidera la iniciativa para actualizar las gu\u00edas de GPP.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Colabora con la FIP en la revisi\u00f3n de est\u00e1ndares y gu\u00edas de pr\u00e1cticas farmac\u00e9uticas.\n- **Participantes de la Consulta de Expertos**: Incluyen representantes de la OMS, asesores de medicamentos de varios pa\u00edses y expertos en farmacolog\u00eda.", "excerpt_keywords": "Keywords: medicines, pharmacists, health care, supply chain integrity, professional development"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65332d51-d814-4342-a93d-7086fec28e32", "node_type": "4", "metadata": {"page_label": "325", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "implications. It has been estimated that the cost of problems with the use of medicines is equal to or greater than the cost of the medicines themselves.\n\nMedicines are also increasingly expensive and their cost is compromising the affordability of health care. Managing the costs of medicines is critical to making the best use of limited resources to maximize health care for as many people as possible.\n\nSubstandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/ counterfeit medicines are a growing problem that compromise health. There is a need for a system of assuring the integrity of the medicine supply chain to assure the value of medicines used for the prevention of disease and the treatment of patients.\n\nPharmacists[^1] are specifically educated and trained health professionals who are charged by their national or other appropriate (e.g. state or provincial) authorities with the management of the distribution of medicines to consumers and to engage in appropriate efforts to assure their safe and efficacious use. There is also increasing recognition that providing consumers with medicines alone is not sufficient to achieve the treatment goals. To address these medication-related needs, pharmacists are accepting greater responsibility for the outcomes of medicines use and are evolving their practices to provide patients with enhanced medicines-use services.\n\nAs health-care professionals, pharmacists play an important role in improving access to health care and in closing the gap between the potential benefit of medicines and the actual value realized and should be part of any comprehensive health system. In addition, the increasingly complex and diverse nature of pharmacists\u2019 roles in the health-care system and public health demands a continuous maintenance of the competence of pharmacists as health-care professionals who have up-to-date skills and expertise.\n\nNational pharmacy professional associations need to work together with their governing bodies and other health-care professional associations to support pharmacists in their countries through provision of continuing professional development activities, including distance-learning programmes, and establishing national standards of pharmacy services and practice objectives.\n\nThese guidelines are intended to provide a description of ways in which pharmacists can improve access to health care, health promotion and the use of medicines on behalf of the patients they serve. The role of FIP is to provide leadership for national pharmacy professional organizations,\n\n[^1]: Pharmacists are health-care professionals whose professional responsibilities and accountabilities include seeking to ensure that people derive maximum therapeutic benefit from their treatments with medicines. This requires them to keep abreast of developments in pharmacy practice and the pharmaceutical sciences, professional standards and requirements, the laws governing pharmacy and medicines and advances in knowledge and technology relating to use of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c1d0c37e7d621b11ba928f22761a93a97bbcbe33de9d211fb3c9d5b505e90d3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "implications. It has been estimated that the cost of problems with the use of medicines is equal to or greater than the cost of the medicines themselves.\n\nMedicines are also increasingly expensive and their cost is compromising the affordability of health care. Managing the costs of medicines is critical to making the best use of limited resources to maximize health care for as many people as possible.\n\nSubstandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/ counterfeit medicines are a growing problem that compromise health. There is a need for a system of assuring the integrity of the medicine supply chain to assure the value of medicines used for the prevention of disease and the treatment of patients.\n\nPharmacists[^1] are specifically educated and trained health professionals who are charged by their national or other appropriate (e.g. state or provincial) authorities with the management of the distribution of medicines to consumers and to engage in appropriate efforts to assure their safe and efficacious use. There is also increasing recognition that providing consumers with medicines alone is not sufficient to achieve the treatment goals. To address these medication-related needs, pharmacists are accepting greater responsibility for the outcomes of medicines use and are evolving their practices to provide patients with enhanced medicines-use services.\n\nAs health-care professionals, pharmacists play an important role in improving access to health care and in closing the gap between the potential benefit of medicines and the actual value realized and should be part of any comprehensive health system. In addition, the increasingly complex and diverse nature of pharmacists\u2019 roles in the health-care system and public health demands a continuous maintenance of the competence of pharmacists as health-care professionals who have up-to-date skills and expertise.\n\nNational pharmacy professional associations need to work together with their governing bodies and other health-care professional associations to support pharmacists in their countries through provision of continuing professional development activities, including distance-learning programmes, and establishing national standards of pharmacy services and practice objectives.\n\nThese guidelines are intended to provide a description of ways in which pharmacists can improve access to health care, health promotion and the use of medicines on behalf of the patients they serve. The role of FIP is to provide leadership for national pharmacy professional organizations,\n\n[^1]: Pharmacists are health-care professionals whose professional responsibilities and accountabilities include seeking to ensure that people derive maximum therapeutic benefit from their treatments with medicines. This requires them to keep abreast of developments in pharmacy practice and the pharmaceutical sciences, professional standards and requirements, the laws governing pharmacy and medicines and advances in knowledge and technology relating to use of medicines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3055, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7eff5369-7e46-48a3-8625-1f43a3e01375": {"__data__": {"id_": "7eff5369-7e46-48a3-8625-1f43a3e01375", "embedding": null, "metadata": {"page_label": "326", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which in turn provide the impetus for setting national standards. The vital element is the commitment of the pharmacy profession worldwide to promoting excellence in practice for the benefit of those served. The public and other professions will judge the pharmacy profession on how its members translate that commitment into practice in all settings, especially community and hospital pharmacy settings.\n\nIt is the policy of FIP and WHO to provide guidance to national pharmacy professional organizations regarding the development of their national GPP guidelines. The conditions of practice vary widely from country to country and each national pharmacy professional organization is best able to decide what can be achieved and within what time-scale.\n\n## 2. Underlying philosophy\n\nThe mission of pharmacy practice is to contribute to health improvement and to help patients with health problems to make the best use of their medicines.\n\nThere are six components to this mission:\n\n- being readily available to patients with or without an appointment;\n- identifying and managing or triaging health-related problems;\n- health promotion;\n- assuring effectiveness of medicines;\n- preventing harm from medicines; and\n- making responsible use of limited health-care resources.\n\nIn the community setting, pharmacists should be acknowledged as health-care professionals whom patients can consult for health-related problems. Because health-care products and services are available from the pharmacist, some problems can be managed at this point of care. Problems that require additional diagnostic skill or treatments not available from a pharmacist can be referred to an appropriate health-care professional or site of care, such as a hospital. This should be done in good collaboration between the health-care providers.\n\nTo improve the use of medicines, pharmacists have responsibilities for many aspects of the process of medicines use, each of which is important to achieve good outcomes from treatment. This begins with assuring the integrity of the medicine supply chain, including detecting spurious/falsely-labelled/falsified/counterfeit medicines, ensuring proper storage of medicines and quality preparation of medicines when needed. It also includes assuring the proper prescribing of medicines so that dose regimens and dosage forms\n\n----\n\n2 Throughout this document, the term \u201cnational standards\u201d includes laws, regulations, standards, ordinances or other requirements enacted or promulgated by an official body at any level of government, as well as guidelines, recommendations or other pronouncements of professional organizations of pharmacy.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Compromiso de la profesi\u00f3n farmac\u00e9utica**: La profesi\u00f3n farmac\u00e9utica a nivel mundial se compromete a promover la excelencia en la pr\u00e1ctica para beneficiar a la comunidad. Este compromiso se traduce en la implementaci\u00f3n de est\u00e1ndares nacionales que var\u00edan seg\u00fan las condiciones de pr\u00e1ctica en cada pa\u00eds.\n\n2. **Misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica**: La misi\u00f3n principal de la pr\u00e1ctica farmac\u00e9utica es contribuir a la mejora de la salud y ayudar a los pacientes a utilizar sus medicamentos de manera efectiva. Esto implica una serie de responsabilidades que incluyen la disponibilidad para los pacientes, la gesti\u00f3n de problemas de salud, la promoci\u00f3n de la salud y la prevenci\u00f3n de da\u00f1os relacionados con los medicamentos.\n\n3. **Responsabilidades del farmac\u00e9utico**: Los farmac\u00e9uticos tienen un papel crucial en el proceso de uso de medicamentos, que abarca desde asegurar la integridad de la cadena de suministro de medicamentos hasta garantizar la prescripci\u00f3n adecuada. Esto incluye la detecci\u00f3n de medicamentos falsificados y la colaboraci\u00f3n con otros profesionales de la salud.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los seis componentes de la misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica y c\u00f3mo se relacionan con la atenci\u00f3n al paciente?**\n   - Esta pregunta busca una respuesta detallada sobre los componentes espec\u00edficos que definen la misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica y su impacto en la atenci\u00f3n al paciente.\n\n2. **\u00bfC\u00f3mo se determina el desarrollo de las gu\u00edas nacionales de buenas pr\u00e1cticas farmac\u00e9uticas (GPP) en diferentes pa\u00edses?**\n   - Esta pregunta se centra en el proceso y los criterios que utilizan las organizaciones profesionales farmac\u00e9uticas nacionales para establecer sus gu\u00edas de GPP, considerando las variaciones en las condiciones de pr\u00e1ctica.\n\n3. **\u00bfQu\u00e9 medidas deben tomar los farmac\u00e9uticos para asegurar la integridad de la cadena de suministro de medicamentos y prevenir el da\u00f1o a los pacientes?**\n   - Esta pregunta busca una respuesta espec\u00edfica sobre las acciones y responsabilidades que tienen los farmac\u00e9uticos en la gesti\u00f3n de la cadena de suministro de medicamentos y la prevenci\u00f3n de problemas relacionados con su uso.", "prev_section_summary": "### Temas Clave:\n\n1. **Costo y Accesibilidad de Medicamentos**: \n   - El aumento en el costo de los medicamentos est\u00e1 afectando la accesibilidad a la atenci\u00f3n m\u00e9dica. Los problemas relacionados con el uso de medicamentos pueden tener costos iguales o superiores a los de los propios medicamentos.\n\n2. **Problemas con Medicamentos**: \n   - La existencia de medicamentos subest\u00e1ndar, adulterados y falsificados representa un riesgo creciente para la salud p\u00fablica. Se requiere un sistema que garantice la integridad de la cadena de suministro de medicamentos.\n\n3. **Rol de los Farmac\u00e9uticos**: \n   - Los farmac\u00e9uticos son profesionales de la salud capacitados que no solo distribuyen medicamentos, sino que tambi\u00e9n asumen una mayor responsabilidad en los resultados del uso de medicamentos. Su papel es crucial para mejorar el acceso a la atenci\u00f3n m\u00e9dica y maximizar el beneficio de los tratamientos.\n\n4. **Desarrollo Profesional Continuo**: \n   - Es esencial que las asociaciones profesionales de farmac\u00e9uticos colaboren con organismos gubernamentales y otras asociaciones de salud para apoyar el desarrollo profesional continuo y establecer est\u00e1ndares nacionales de servicios farmac\u00e9uticos.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referenciada en el documento como la fuente del informe.\n- **Farmac\u00e9uticos**: Profesionales de la salud responsables de la gesti\u00f3n y distribuci\u00f3n de medicamentos.\n- **Asociaciones Profesionales de Farmac\u00e9uticos**: Organizaciones que deben trabajar en conjunto para el desarrollo profesional y la mejora de los servicios farmac\u00e9uticos.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Organizaci\u00f3n que proporciona liderazgo a las asociaciones nacionales de farmac\u00e9uticos.\n\nEste resumen destaca la importancia de gestionar los costos de los medicamentos, la necesidad de asegurar la calidad de los mismos y el papel fundamental de los farmac\u00e9uticos en el sistema de salud.", "excerpt_keywords": "Keywords: pharmacy practice, health improvement, national standards, medication management, professional guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ea34979e-ddff-4647-bf0c-4b09bdfaf008", "node_type": "4", "metadata": {"page_label": "326", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which in turn provide the impetus for setting national standards. The vital element is the commitment of the pharmacy profession worldwide to promoting excellence in practice for the benefit of those served. The public and other professions will judge the pharmacy profession on how its members translate that commitment into practice in all settings, especially community and hospital pharmacy settings.\n\nIt is the policy of FIP and WHO to provide guidance to national pharmacy professional organizations regarding the development of their national GPP guidelines. The conditions of practice vary widely from country to country and each national pharmacy professional organization is best able to decide what can be achieved and within what time-scale.\n\n## 2. Underlying philosophy\n\nThe mission of pharmacy practice is to contribute to health improvement and to help patients with health problems to make the best use of their medicines.\n\nThere are six components to this mission:\n\n- being readily available to patients with or without an appointment;\n- identifying and managing or triaging health-related problems;\n- health promotion;\n- assuring effectiveness of medicines;\n- preventing harm from medicines; and\n- making responsible use of limited health-care resources.\n\nIn the community setting, pharmacists should be acknowledged as health-care professionals whom patients can consult for health-related problems. Because health-care products and services are available from the pharmacist, some problems can be managed at this point of care. Problems that require additional diagnostic skill or treatments not available from a pharmacist can be referred to an appropriate health-care professional or site of care, such as a hospital. This should be done in good collaboration between the health-care providers.\n\nTo improve the use of medicines, pharmacists have responsibilities for many aspects of the process of medicines use, each of which is important to achieve good outcomes from treatment. This begins with assuring the integrity of the medicine supply chain, including detecting spurious/falsely-labelled/falsified/counterfeit medicines, ensuring proper storage of medicines and quality preparation of medicines when needed. It also includes assuring the proper prescribing of medicines so that dose regimens and dosage forms\n\n----\n\n2 Throughout this document, the term \u201cnational standards\u201d includes laws, regulations, standards, ordinances or other requirements enacted or promulgated by an official body at any level of government, as well as guidelines, recommendations or other pronouncements of professional organizations of pharmacy.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5bfcc77e625ff8c6db93c39a6366caaf805759d406c04cfafe7d1b62ce03e3c1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "which in turn provide the impetus for setting national standards. The vital element is the commitment of the pharmacy profession worldwide to promoting excellence in practice for the benefit of those served. The public and other professions will judge the pharmacy profession on how its members translate that commitment into practice in all settings, especially community and hospital pharmacy settings.\n\nIt is the policy of FIP and WHO to provide guidance to national pharmacy professional organizations regarding the development of their national GPP guidelines. The conditions of practice vary widely from country to country and each national pharmacy professional organization is best able to decide what can be achieved and within what time-scale.\n\n## 2. Underlying philosophy\n\nThe mission of pharmacy practice is to contribute to health improvement and to help patients with health problems to make the best use of their medicines.\n\nThere are six components to this mission:\n\n- being readily available to patients with or without an appointment;\n- identifying and managing or triaging health-related problems;\n- health promotion;\n- assuring effectiveness of medicines;\n- preventing harm from medicines; and\n- making responsible use of limited health-care resources.\n\nIn the community setting, pharmacists should be acknowledged as health-care professionals whom patients can consult for health-related problems. Because health-care products and services are available from the pharmacist, some problems can be managed at this point of care. Problems that require additional diagnostic skill or treatments not available from a pharmacist can be referred to an appropriate health-care professional or site of care, such as a hospital. This should be done in good collaboration between the health-care providers.\n\nTo improve the use of medicines, pharmacists have responsibilities for many aspects of the process of medicines use, each of which is important to achieve good outcomes from treatment. This begins with assuring the integrity of the medicine supply chain, including detecting spurious/falsely-labelled/falsified/counterfeit medicines, ensuring proper storage of medicines and quality preparation of medicines when needed. It also includes assuring the proper prescribing of medicines so that dose regimens and dosage forms\n\n----\n\n2 Throughout this document, the term \u201cnational standards\u201d includes laws, regulations, standards, ordinances or other requirements enacted or promulgated by an official body at any level of government, as well as guidelines, recommendations or other pronouncements of professional organizations of pharmacy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2653, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c1903f8b-156d-4812-8c41-dc28cbc6de33": {"__data__": {"id_": "c1903f8b-156d-4812-8c41-dc28cbc6de33", "embedding": null, "metadata": {"page_label": "327", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Definition of Good Pharmacy Practice\n\nGPP is the practice of pharmacy that responds to the needs of the people who use the pharmacists\u2019 services to provide optimal, evidence-based care. To support this practice it is essential that there be an established national framework of quality standards and guidelines.\n\n# Requirements of Good Pharmacy Practice\n\n- GPP requires that a pharmacist's first concern in all settings is the welfare of patients.\n- GPP requires that the core of the pharmacy activity is to help patients make the best use of medicines. Fundamental functions include the supply of medication and other health-care products of assured quality, the provision of appropriate information and advice to the patient, administration of medication, when required, and the monitoring of the effects of medication use.\n- GPP requires that an integral part of the pharmacist's contribution is the promotion of rational and economic prescribing, as well as dispensing.\n- GPP requires that the objective of each element of pharmacy service is relevant to the patient, is clearly defined and is effectively communicated to all those involved. Multidisciplinary collaboration among health-care professionals is the key factor for successfully improving patient safety.\n\nIn satisfying these requirements, the following conditions are necessary:\n\n- The well-being of patients should be the main philosophy underlying practice, even though it is accepted that ethical and economic factors are also important.\n- Pharmacists should have input into decisions about the use of medicines. A system should exist that enables pharmacists to report and to obtain feedback about adverse events, medicine-related problems, medication errors, misuse or medicine abuse, defects in product quality or detection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS define la \"Buena Pr\u00e1ctica Farmac\u00e9utica\" (GPP) como la pr\u00e1ctica que responde a las necesidades de los pacientes, asegurando una atenci\u00f3n \u00f3ptima y basada en evidencia. Se establecen requisitos fundamentales para la GPP, que incluyen la prioridad en el bienestar del paciente, la promoci\u00f3n del uso racional de medicamentos, y la colaboraci\u00f3n multidisciplinaria entre profesionales de la salud. Adem\u00e1s, se enfatiza la importancia de que los farmac\u00e9uticos participen en decisiones sobre el uso de medicamentos y tengan un sistema para reportar problemas relacionados con medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones fundamentales que debe cumplir un farmac\u00e9utico seg\u00fan la GPP?**\n   - Respuesta: Las funciones fundamentales incluyen el suministro de medicamentos y otros productos de salud de calidad asegurada, la provisi\u00f3n de informaci\u00f3n y asesoramiento apropiado al paciente, la administraci\u00f3n de medicamentos cuando sea necesario, y el monitoreo de los efectos del uso de medicamentos.\n\n2. **\u00bfQu\u00e9 papel juega la colaboraci\u00f3n multidisciplinaria en la GPP y por qu\u00e9 es importante?**\n   - Respuesta: La colaboraci\u00f3n multidisciplinaria entre profesionales de la salud es clave para mejorar la seguridad del paciente, ya que permite una comunicaci\u00f3n efectiva y un enfoque integral en la atenci\u00f3n al paciente.\n\n3. **\u00bfQu\u00e9 condiciones son necesarias para satisfacer los requisitos de la GPP?**\n   - Respuesta: Es necesario que el bienestar de los pacientes sea la filosof\u00eda principal de la pr\u00e1ctica, y que los farmac\u00e9uticos tengan la capacidad de participar en decisiones sobre el uso de medicamentos, as\u00ed como un sistema para reportar y recibir retroalimentaci\u00f3n sobre eventos adversos y problemas relacionados con medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Compromiso de la Profesi\u00f3n Farmac\u00e9utica**:\n   - La profesi\u00f3n farmac\u00e9utica a nivel mundial se compromete a promover la excelencia en la pr\u00e1ctica para el beneficio de la comunidad.\n   - Este compromiso se traduce en la creaci\u00f3n de est\u00e1ndares nacionales que var\u00edan seg\u00fan las condiciones de pr\u00e1ctica en cada pa\u00eds.\n\n2. **Misi\u00f3n de la Pr\u00e1ctica Farmac\u00e9utica**:\n   - Contribuir a la mejora de la salud y ayudar a los pacientes a utilizar sus medicamentos de manera efectiva.\n   - Se identifican seis componentes clave de esta misi\u00f3n:\n     - Disponibilidad para los pacientes.\n     - Identificaci\u00f3n y gesti\u00f3n de problemas de salud.\n     - Promoci\u00f3n de la salud.\n     - Aseguramiento de la efectividad de los medicamentos.\n     - Prevenci\u00f3n de da\u00f1os relacionados con los medicamentos.\n     - Uso responsable de los recursos de atenci\u00f3n m\u00e9dica limitados.\n\n3. **Rol del Farmac\u00e9utico en la Atenci\u00f3n al Paciente**:\n   - Los farmac\u00e9uticos son reconocidos como profesionales de la salud a los que los pacientes pueden consultar para problemas de salud.\n   - Pueden gestionar ciertos problemas en el punto de atenci\u00f3n y referir a otros profesionales de salud cuando sea necesario.\n\n4. **Responsabilidades en el Uso de Medicamentos**:\n   - Asegurar la integridad de la cadena de suministro de medicamentos, incluyendo la detecci\u00f3n de medicamentos falsificados.\n   - Garantizar el almacenamiento adecuado y la preparaci\u00f3n de medicamentos.\n   - Asegurar la prescripci\u00f3n correcta de medicamentos.\n\n5. **Pol\u00edtica de FIP y OMS**:\n   - FIP (Federaci\u00f3n Internacional Farmac\u00e9utica) y OMS (Organizaci\u00f3n Mundial de la Salud) proporcionan orientaci\u00f3n a las organizaciones profesionales farmac\u00e9uticas nacionales para el desarrollo de gu\u00edas nacionales de buenas pr\u00e1cticas farmac\u00e9uticas (GPP).\n\n### Entidades Clave\n- **FIP**: Federaci\u00f3n Internacional Farmac\u00e9utica.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **Profesionales de la Salud**: Incluyendo farmac\u00e9uticos y otros proveedores de atenci\u00f3n m\u00e9dica. \n\nEste resumen destaca la importancia del compromiso de la profesi\u00f3n farmac\u00e9utica en la mejora de la salud p\u00fablica y el papel esencial de los farmac\u00e9uticos en la atenci\u00f3n al paciente y la gesti\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: Good Pharmacy Practice, patient welfare, multidisciplinary collaboration, medication management, evidence-based care"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4ccb1c6d-a09f-4ea9-a187-4ef31116cc22", "node_type": "4", "metadata": {"page_label": "327", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Definition of Good Pharmacy Practice\n\nGPP is the practice of pharmacy that responds to the needs of the people who use the pharmacists\u2019 services to provide optimal, evidence-based care. To support this practice it is essential that there be an established national framework of quality standards and guidelines.\n\n# Requirements of Good Pharmacy Practice\n\n- GPP requires that a pharmacist's first concern in all settings is the welfare of patients.\n- GPP requires that the core of the pharmacy activity is to help patients make the best use of medicines. Fundamental functions include the supply of medication and other health-care products of assured quality, the provision of appropriate information and advice to the patient, administration of medication, when required, and the monitoring of the effects of medication use.\n- GPP requires that an integral part of the pharmacist's contribution is the promotion of rational and economic prescribing, as well as dispensing.\n- GPP requires that the objective of each element of pharmacy service is relevant to the patient, is clearly defined and is effectively communicated to all those involved. Multidisciplinary collaboration among health-care professionals is the key factor for successfully improving patient safety.\n\nIn satisfying these requirements, the following conditions are necessary:\n\n- The well-being of patients should be the main philosophy underlying practice, even though it is accepted that ethical and economic factors are also important.\n- Pharmacists should have input into decisions about the use of medicines. A system should exist that enables pharmacists to report and to obtain feedback about adverse events, medicine-related problems, medication errors, misuse or medicine abuse, defects in product quality or detection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "11c9587f362a62797b938b7b68191477eca1c4c89c151aa717b9464768b961e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Definition of Good Pharmacy Practice\n\nGPP is the practice of pharmacy that responds to the needs of the people who use the pharmacists\u2019 services to provide optimal, evidence-based care. To support this practice it is essential that there be an established national framework of quality standards and guidelines.\n\n# Requirements of Good Pharmacy Practice\n\n- GPP requires that a pharmacist's first concern in all settings is the welfare of patients.\n- GPP requires that the core of the pharmacy activity is to help patients make the best use of medicines. Fundamental functions include the supply of medication and other health-care products of assured quality, the provision of appropriate information and advice to the patient, administration of medication, when required, and the monitoring of the effects of medication use.\n- GPP requires that an integral part of the pharmacist's contribution is the promotion of rational and economic prescribing, as well as dispensing.\n- GPP requires that the objective of each element of pharmacy service is relevant to the patient, is clearly defined and is effectively communicated to all those involved. Multidisciplinary collaboration among health-care professionals is the key factor for successfully improving patient safety.\n\nIn satisfying these requirements, the following conditions are necessary:\n\n- The well-being of patients should be the main philosophy underlying practice, even though it is accepted that ethical and economic factors are also important.\n- Pharmacists should have input into decisions about the use of medicines. A system should exist that enables pharmacists to report and to obtain feedback about adverse events, medicine-related problems, medication errors, misuse or medicine abuse, defects in product quality or detection.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1799, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "79ae37b1-921b-456a-ae45-2bb13d5e7cc4": {"__data__": {"id_": "79ae37b1-921b-456a-ae45-2bb13d5e7cc4", "embedding": null, "metadata": {"page_label": "328", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of counterfeit products. This reporting may include information about medicine use supplied by patients or health professionals, either directly or through pharmacists;\n\n- the relationship with other health professionals, particularly physicians, should be established as a therapeutic collaborative partnership that involves mutual trust and confidence in all matters relating to pharmacotherapy;\n\n- the relationship between pharmacists should be one of colleagues seeking to improve pharmacy service, rather than acting as competitors;\n\n- in reality, organizations, group practices and pharmacy managers should accept a share of responsibility for the definition, evaluation and improvement of quality;\n\n- the pharmacist should be aware of essential medical and pharmaceutical information (i.e. diagnosis, laboratory test results and medical history) about each patient. Obtaining such information is made easier if the patient chooses to use only one pharmacy or if the patient's medication profile is available;\n\n- the pharmacist needs evidence-based, unbiased, comprehensive, objective and current information about therapeutics, medicines and other health-care products in use, including potential environmental hazard caused by disposal of medicines\u2019 waste;\n\n- pharmacists in each practice setting should accept personal responsibility for maintaining and assessing their own competence throughout their professional working lives. While self-monitoring is important, an element of assessment and monitoring by the national pharmacy professional organizations would also be relevant in ensuring that pharmacists maintain standards and comply with requirements for continuous professional development;\n\n- educational programmes for entry into the profession should appropriately address both current and foreseeable changes in pharmacy practice; and\n\n- national standards of GPP should be specified and should be adhered to by practitioners.\n\nAt the national or appropriate (e.g. state or provincial) level, it is necessary to establish:\n\n- **A legal framework that:**\n  - defines who can practice pharmacy;\n  - defines the scope of pharmacy practice;\n  - ensures the integrity of the supply chain and the quality of medicines.\n\n- **A workforce framework that:**\n  - ensures the competence of pharmacy staff through continuing professional development (CPD or continuing education (CE)) programmes;\n  - defines the personnel resources needed to provide GPP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de establecer relaciones colaborativas entre farmac\u00e9uticos y otros profesionales de la salud, as\u00ed como la necesidad de que los farmac\u00e9uticos mantengan un alto nivel de competencia y se adhieran a est\u00e1ndares nacionales de buenas pr\u00e1cticas de farmacia (GPP). Tambi\u00e9n se enfatiza la creaci\u00f3n de un marco legal y de fuerza laboral que garantice la calidad y la integridad en la pr\u00e1ctica farmac\u00e9utica.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las responsabilidades compartidas que deben asumir las organizaciones y los gerentes de farmacia en relaci\u00f3n con la calidad de los servicios farmac\u00e9uticos?**\n   - Esta pregunta se centra en la parte del texto que menciona la responsabilidad de las organizaciones y gerentes en la definici\u00f3n, evaluaci\u00f3n y mejora de la calidad en la pr\u00e1ctica farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe tener un farmac\u00e9utico sobre cada paciente para proporcionar un servicio adecuado y seguro?**\n   - Esta pregunta se refiere a la necesidad de que los farmac\u00e9uticos est\u00e9n informados sobre el diagn\u00f3stico, resultados de laboratorio y la historia m\u00e9dica de los pacientes, lo que es crucial para la atenci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un marco legal para la pr\u00e1ctica de la farmacia seg\u00fan el informe?**\n   - Esta pregunta aborda los componentes espec\u00edficos que el documento sugiere que deben definirse en un marco legal, como qui\u00e9n puede practicar farmacia y el alcance de la pr\u00e1ctica farmac\u00e9utica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Principal: Buena Pr\u00e1ctica Farmac\u00e9utica (GPP)**  \nLa GPP se define como la pr\u00e1ctica farmac\u00e9utica que responde a las necesidades de los pacientes, asegurando una atenci\u00f3n \u00f3ptima y basada en evidencia. Es fundamental contar con un marco nacional de est\u00e1ndares de calidad y directrices para respaldar esta pr\u00e1ctica.\n\n**Requisitos de la GPP:**\n1. **Bienestar del Paciente:** La prioridad del farmac\u00e9utico debe ser siempre el bienestar de los pacientes.\n2. **Funciones Fundamentales del Farmac\u00e9utico:**\n   - Suministro de medicamentos y productos de salud de calidad asegurada.\n   - Provisi\u00f3n de informaci\u00f3n y asesoramiento adecuado al paciente.\n   - Administraci\u00f3n de medicamentos cuando sea necesario.\n   - Monitoreo de los efectos del uso de medicamentos.\n3. **Promoci\u00f3n de Prescripci\u00f3n Racional:** Fomentar la prescripci\u00f3n y dispensaci\u00f3n racional y econ\u00f3mica de medicamentos.\n4. **Colaboraci\u00f3n Multidisciplinaria:** La comunicaci\u00f3n efectiva y la colaboraci\u00f3n entre profesionales de la salud son esenciales para mejorar la seguridad del paciente.\n\n**Condiciones Necesarias para la GPP:**\n- El bienestar del paciente debe ser la filosof\u00eda central de la pr\u00e1ctica, considerando tambi\u00e9n factores \u00e9ticos y econ\u00f3micos.\n- Los farmac\u00e9uticos deben participar en decisiones sobre el uso de medicamentos y contar con un sistema para reportar y recibir retroalimentaci\u00f3n sobre eventos adversos y problemas relacionados con medicamentos.\n\n**Entidades Clave:**\n- **Farmac\u00e9uticos:** Profesionales responsables de la atenci\u00f3n y el uso adecuado de medicamentos.\n- **Pacientes:** Usuarios de los servicios farmac\u00e9uticos que requieren atenci\u00f3n y asesoramiento.\n- **Profesionales de la Salud:** Colaboradores en el proceso de atenci\u00f3n al paciente que trabajan en conjunto con farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la GPP en la atenci\u00f3n farmac\u00e9utica y la necesidad de un enfoque colaborativo y centrado en el paciente.", "excerpt_keywords": "Keywords: pharmacy practice, good pharmacy practice, collaborative healthcare, professional development, legal framework"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5e75454-5341-48d9-bd7f-78661e3ef08e", "node_type": "4", "metadata": {"page_label": "328", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of counterfeit products. This reporting may include information about medicine use supplied by patients or health professionals, either directly or through pharmacists;\n\n- the relationship with other health professionals, particularly physicians, should be established as a therapeutic collaborative partnership that involves mutual trust and confidence in all matters relating to pharmacotherapy;\n\n- the relationship between pharmacists should be one of colleagues seeking to improve pharmacy service, rather than acting as competitors;\n\n- in reality, organizations, group practices and pharmacy managers should accept a share of responsibility for the definition, evaluation and improvement of quality;\n\n- the pharmacist should be aware of essential medical and pharmaceutical information (i.e. diagnosis, laboratory test results and medical history) about each patient. Obtaining such information is made easier if the patient chooses to use only one pharmacy or if the patient's medication profile is available;\n\n- the pharmacist needs evidence-based, unbiased, comprehensive, objective and current information about therapeutics, medicines and other health-care products in use, including potential environmental hazard caused by disposal of medicines\u2019 waste;\n\n- pharmacists in each practice setting should accept personal responsibility for maintaining and assessing their own competence throughout their professional working lives. While self-monitoring is important, an element of assessment and monitoring by the national pharmacy professional organizations would also be relevant in ensuring that pharmacists maintain standards and comply with requirements for continuous professional development;\n\n- educational programmes for entry into the profession should appropriately address both current and foreseeable changes in pharmacy practice; and\n\n- national standards of GPP should be specified and should be adhered to by practitioners.\n\nAt the national or appropriate (e.g. state or provincial) level, it is necessary to establish:\n\n- **A legal framework that:**\n  - defines who can practice pharmacy;\n  - defines the scope of pharmacy practice;\n  - ensures the integrity of the supply chain and the quality of medicines.\n\n- **A workforce framework that:**\n  - ensures the competence of pharmacy staff through continuing professional development (CPD or continuing education (CE)) programmes;\n  - defines the personnel resources needed to provide GPP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f3ec0a1e3cb60cd2c57103a75d4725b2605f8e68bc4cc0b9758d577ebcf9fcd9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "of counterfeit products. This reporting may include information about medicine use supplied by patients or health professionals, either directly or through pharmacists;\n\n- the relationship with other health professionals, particularly physicians, should be established as a therapeutic collaborative partnership that involves mutual trust and confidence in all matters relating to pharmacotherapy;\n\n- the relationship between pharmacists should be one of colleagues seeking to improve pharmacy service, rather than acting as competitors;\n\n- in reality, organizations, group practices and pharmacy managers should accept a share of responsibility for the definition, evaluation and improvement of quality;\n\n- the pharmacist should be aware of essential medical and pharmaceutical information (i.e. diagnosis, laboratory test results and medical history) about each patient. Obtaining such information is made easier if the patient chooses to use only one pharmacy or if the patient's medication profile is available;\n\n- the pharmacist needs evidence-based, unbiased, comprehensive, objective and current information about therapeutics, medicines and other health-care products in use, including potential environmental hazard caused by disposal of medicines\u2019 waste;\n\n- pharmacists in each practice setting should accept personal responsibility for maintaining and assessing their own competence throughout their professional working lives. While self-monitoring is important, an element of assessment and monitoring by the national pharmacy professional organizations would also be relevant in ensuring that pharmacists maintain standards and comply with requirements for continuous professional development;\n\n- educational programmes for entry into the profession should appropriately address both current and foreseeable changes in pharmacy practice; and\n\n- national standards of GPP should be specified and should be adhered to by practitioners.\n\nAt the national or appropriate (e.g. state or provincial) level, it is necessary to establish:\n\n- **A legal framework that:**\n  - defines who can practice pharmacy;\n  - defines the scope of pharmacy practice;\n  - ensures the integrity of the supply chain and the quality of medicines.\n\n- **A workforce framework that:**\n  - ensures the competence of pharmacy staff through continuing professional development (CPD or continuing education (CE)) programmes;\n  - defines the personnel resources needed to provide GPP.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2463, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5c729dc2-f44e-40c0-b443-83348b6c93b6": {"__data__": {"id_": "5c729dc2-f44e-40c0-b443-83348b6c93b6", "embedding": null, "metadata": {"page_label": "329", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- An economic framework that:\n  - provides sufficient resources and incentives that are effectively used to ensure the activities undertaken in GPP.\n\n## 5. Setting standards for good pharmacy practice\n\nGPP includes standards that often exceed those laid down by national legislation. Furthermore, legislation seldom gives precise instructions about how the services should be produced to meet the requirements. Therefore, national pharmacy professional associations have a role in setting standards required for GPP, which includes a quality management framework and a strategic plan for developing services. It is also recognized that in developing national standards for GPP, attention must be paid to both the needs of the users of health-care services and the capacity of national health-care systems to support these services.\n\nJust as pharmacy practice will vary among nations, it will also vary among practice locations. Therefore, standards should recognize the uniqueness of different pharmacy practice settings (e.g. community and hospital pharmacy). In addition, as medicines and needs change, the standards should acknowledge evolving practice settings and provide these developing services with guidance without negatively affecting the evolutionary nature of practice. At the same time, a baseline should be established for practice below which the activity cannot be considered \u201cpharmacy practice\u201d at all and, therefore, should not be condoned.\n\nWhen establishing minimum standards on GPP, FIP emphasizes the importance of first defining the roles played by pharmacists, as expected by patients and society. Secondly, relevant functions for which pharmacists have direct responsibility and accountability need to be determined within each role. Thirdly, minimum national standards should then be established, based upon the need to demonstrate competency in a set of activities supporting each function and role.\n\nThe minimum national standards for each activity are based on processes that need to be relevant and defined appropriately according to the local needs of the pharmacy practice environment and national profession aspirations. All national pharmacy professional associations should also adapt these roles and functions in accordance to their own requirements. The activities listed below can be further defined and measured by setting indicators of good practice within a national context and can be weighted by actual practice-setting priorities.\n\nIt is recommended that national pharmacy professional associations consider the following roles, functions and activities for pharmacists, where appropriate:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece un marco econ\u00f3mico para la pr\u00e1ctica farmac\u00e9utica, enfatizando la importancia de establecer est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica (GPP). Estos est\u00e1ndares deben ir m\u00e1s all\u00e1 de la legislaci\u00f3n nacional y adaptarse a las necesidades de los usuarios de servicios de salud y a la capacidad de los sistemas de salud nacionales. Se reconoce que la pr\u00e1ctica farmac\u00e9utica var\u00eda entre pa\u00edses y entornos, por lo que es crucial definir roles y funciones claras para los farmac\u00e9uticos, as\u00ed como establecer est\u00e1ndares m\u00ednimos que demuestren competencia en actividades espec\u00edficas.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los elementos clave que deben considerarse al establecer est\u00e1ndares m\u00ednimos para la buena pr\u00e1ctica farmac\u00e9utica (GPP) en un pa\u00eds?**\n   - Respuesta: Los elementos clave incluyen la definici\u00f3n de los roles de los farmac\u00e9uticos, la determinaci\u00f3n de funciones relevantes con responsabilidad y rendici\u00f3n de cuentas, y el establecimiento de est\u00e1ndares nacionales m\u00ednimos basados en la competencia en actividades espec\u00edficas.\n\n2. **\u00bfC\u00f3mo deben adaptarse los est\u00e1ndares de GPP a las diferentes configuraciones de pr\u00e1ctica farmac\u00e9utica, como la farmacia comunitaria y la hospitalaria?**\n   - Respuesta: Los est\u00e1ndares deben reconocer la singularidad de cada entorno de pr\u00e1ctica, proporcionando orientaci\u00f3n que se ajuste a las necesidades cambiantes de los medicamentos y de los servicios, sin comprometer la naturaleza evolutiva de la pr\u00e1ctica farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las asociaciones profesionales farmac\u00e9uticas nacionales en el desarrollo de est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica?**\n   - Respuesta: Las asociaciones profesionales tienen la responsabilidad de establecer los est\u00e1ndares necesarios para GPP, que incluyen un marco de gesti\u00f3n de calidad y un plan estrat\u00e9gico para el desarrollo de servicios, adaptando roles y funciones seg\u00fan las necesidades locales y aspiraciones profesionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda varios temas fundamentales relacionados con la pr\u00e1ctica farmac\u00e9utica y la colaboraci\u00f3n entre profesionales de la salud. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Colaboraci\u00f3n Profesional**: Se enfatiza la importancia de establecer relaciones de confianza y colaboraci\u00f3n entre farmac\u00e9uticos y otros profesionales de la salud, especialmente m\u00e9dicos, para mejorar la atenci\u00f3n farmac\u00e9utica.\n   \n2. **Responsabilidad Compartida**: Las organizaciones y gerentes de farmacia deben asumir la responsabilidad en la definici\u00f3n, evaluaci\u00f3n y mejora de la calidad de los servicios farmac\u00e9uticos.\n\n3. **Informaci\u00f3n del Paciente**: Los farmac\u00e9uticos deben estar informados sobre el diagn\u00f3stico, resultados de laboratorio y la historia m\u00e9dica de los pacientes para proporcionar un servicio seguro y adecuado.\n\n4. **Competencia Profesional**: Se requiere que los farmac\u00e9uticos mantengan y eval\u00faen su competencia a lo largo de su vida profesional, con un enfoque en el desarrollo profesional continuo.\n\n5. **Educaci\u00f3n y Formaci\u00f3n**: Los programas educativos para la entrada en la profesi\u00f3n deben abordar los cambios actuales y futuros en la pr\u00e1ctica farmac\u00e9utica.\n\n6. **Normas de Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se deben especificar y adherir a est\u00e1ndares nacionales de GPP para asegurar la calidad en la pr\u00e1ctica farmac\u00e9utica.\n\n7. **Marco Legal y de Fuerza Laboral**: Es necesario establecer un marco legal que defina qui\u00e9n puede practicar farmacia, el alcance de la pr\u00e1ctica y garantice la integridad de la cadena de suministro y la calidad de los medicamentos. Tambi\u00e9n se debe definir un marco de fuerza laboral que asegure la competencia del personal farmac\u00e9utico.\n\n#### Entidades Mencionadas:\n- **Organizaciones de Farmacia**: Se refiere a las entidades que regulan y supervisan la pr\u00e1ctica farmac\u00e9utica a nivel nacional.\n- **Profesionales de la Salud**: Incluye farmac\u00e9uticos, m\u00e9dicos y otros profesionales que colaboran en la atenci\u00f3n al paciente.\n- **Pacientes**: Los individuos que reciben atenci\u00f3n farmac\u00e9utica y cuyos datos m\u00e9dicos son relevantes para el farmac\u00e9utico.\n- **Medicamentos**: Productos farmac\u00e9uticos cuya calidad y uso deben ser monitoreados y regulados.\n\nEste resumen destaca la importancia de la colaboraci\u00f3n, la responsabilidad compartida y la necesidad de un marco legal y educativo s\u00f3lido para garantizar la calidad en la pr\u00e1ctica farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmacy practice, good pharmacy practice, standards, national associations, competency"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef8b9609-f356-4b98-a91f-201b2a1025c0", "node_type": "4", "metadata": {"page_label": "329", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- An economic framework that:\n  - provides sufficient resources and incentives that are effectively used to ensure the activities undertaken in GPP.\n\n## 5. Setting standards for good pharmacy practice\n\nGPP includes standards that often exceed those laid down by national legislation. Furthermore, legislation seldom gives precise instructions about how the services should be produced to meet the requirements. Therefore, national pharmacy professional associations have a role in setting standards required for GPP, which includes a quality management framework and a strategic plan for developing services. It is also recognized that in developing national standards for GPP, attention must be paid to both the needs of the users of health-care services and the capacity of national health-care systems to support these services.\n\nJust as pharmacy practice will vary among nations, it will also vary among practice locations. Therefore, standards should recognize the uniqueness of different pharmacy practice settings (e.g. community and hospital pharmacy). In addition, as medicines and needs change, the standards should acknowledge evolving practice settings and provide these developing services with guidance without negatively affecting the evolutionary nature of practice. At the same time, a baseline should be established for practice below which the activity cannot be considered \u201cpharmacy practice\u201d at all and, therefore, should not be condoned.\n\nWhen establishing minimum standards on GPP, FIP emphasizes the importance of first defining the roles played by pharmacists, as expected by patients and society. Secondly, relevant functions for which pharmacists have direct responsibility and accountability need to be determined within each role. Thirdly, minimum national standards should then be established, based upon the need to demonstrate competency in a set of activities supporting each function and role.\n\nThe minimum national standards for each activity are based on processes that need to be relevant and defined appropriately according to the local needs of the pharmacy practice environment and national profession aspirations. All national pharmacy professional associations should also adapt these roles and functions in accordance to their own requirements. The activities listed below can be further defined and measured by setting indicators of good practice within a national context and can be weighted by actual practice-setting priorities.\n\nIt is recommended that national pharmacy professional associations consider the following roles, functions and activities for pharmacists, where appropriate:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "391731a5e62c92387f2e8745c3f5e99711c6d765d4fd6b9ea6368c13e6596c0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- An economic framework that:\n  - provides sufficient resources and incentives that are effectively used to ensure the activities undertaken in GPP.\n\n## 5. Setting standards for good pharmacy practice\n\nGPP includes standards that often exceed those laid down by national legislation. Furthermore, legislation seldom gives precise instructions about how the services should be produced to meet the requirements. Therefore, national pharmacy professional associations have a role in setting standards required for GPP, which includes a quality management framework and a strategic plan for developing services. It is also recognized that in developing national standards for GPP, attention must be paid to both the needs of the users of health-care services and the capacity of national health-care systems to support these services.\n\nJust as pharmacy practice will vary among nations, it will also vary among practice locations. Therefore, standards should recognize the uniqueness of different pharmacy practice settings (e.g. community and hospital pharmacy). In addition, as medicines and needs change, the standards should acknowledge evolving practice settings and provide these developing services with guidance without negatively affecting the evolutionary nature of practice. At the same time, a baseline should be established for practice below which the activity cannot be considered \u201cpharmacy practice\u201d at all and, therefore, should not be condoned.\n\nWhen establishing minimum standards on GPP, FIP emphasizes the importance of first defining the roles played by pharmacists, as expected by patients and society. Secondly, relevant functions for which pharmacists have direct responsibility and accountability need to be determined within each role. Thirdly, minimum national standards should then be established, based upon the need to demonstrate competency in a set of activities supporting each function and role.\n\nThe minimum national standards for each activity are based on processes that need to be relevant and defined appropriately according to the local needs of the pharmacy practice environment and national profession aspirations. All national pharmacy professional associations should also adapt these roles and functions in accordance to their own requirements. The activities listed below can be further defined and measured by setting indicators of good practice within a national context and can be weighted by actual practice-setting priorities.\n\nIt is recommended that national pharmacy professional associations consider the following roles, functions and activities for pharmacists, where appropriate:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2634, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f52e2a4c-c188-4ac8-b34b-796a2d2304ff": {"__data__": {"id_": "f52e2a4c-c188-4ac8-b34b-796a2d2304ff", "embedding": null, "metadata": {"page_label": "330", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Role 1: Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products\n\n- **Function A: Prepare extemporaneous medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that medicine preparation areas are appropriately designed to permit ease of extemporaneous preparations and are maintained in a manner that minimizes the potential for medication errors and assures the cleanliness and safety of medical products.\n  - Pharmacists should ensure that compounded medicines are consistently prepared to comply with written formulas and quality standards for raw materials, equipment and preparation processes, including sterility where appropriate.\n\n- **Function B: Obtain, store and secure medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists who are responsible for procurement should ensure that the procurement process is transparent, professional and ethical so as to promote equity and access and to ensure accountability to relevant governing and legal entities.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by strong quality assurance principles to assure that substandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/counterfeit medicines are not procured or allowed into the system.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by a reliable information system which provides accurate, timely and accessible information.\n  - Pharmacists should establish contingency plans for shortages of medicines and for purchases in emergencies.\n  - Pharmacists should assure that proper storage conditions are provided for all medicines, especially for controlled substances, used in the pharmacy or health-care facility.\n\n- **Function C: Distribute medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that all medical products, including medicine samples, are handled and distributed in a manner that assures reliability and safety of the medicine supply.\n  - Pharmacists should establish an effective distribution system which includes a written procedure, to recall promptly and effectively.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre el papel de los farmac\u00e9uticos en la preparaci\u00f3n, obtenci\u00f3n, almacenamiento, seguridad, distribuci\u00f3n, administraci\u00f3n, dispensaci\u00f3n y eliminaci\u00f3n de productos m\u00e9dicos. Se enfatiza la necesidad de establecer est\u00e1ndares nacionales m\u00ednimos para estas actividades, asegurando la calidad, seguridad y accesibilidad de los medicamentos. Las funciones se dividen en tres \u00e1reas principales: preparaci\u00f3n de medicamentos, obtenci\u00f3n y almacenamiento, y distribuci\u00f3n de productos m\u00e9dicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas que deben tener las \u00e1reas de preparaci\u00f3n de medicamentos para minimizar errores y asegurar la limpieza?**\n   - El contexto menciona que las \u00e1reas de preparaci\u00f3n deben estar dise\u00f1adas adecuadamente para facilitar las preparaciones extempor\u00e1neas y mantenerse de manera que minimicen el potencial de errores de medicaci\u00f3n, asegurando la limpieza y seguridad de los productos m\u00e9dicos.\n\n2. **\u00bfQu\u00e9 principios deben seguir los farmac\u00e9uticos en el proceso de adquisici\u00f3n de medicamentos para garantizar la calidad y la \u00e9tica?**\n   - Los farmac\u00e9uticos responsables de la adquisici\u00f3n deben asegurar que el proceso sea transparente, profesional y \u00e9tico, promoviendo la equidad y el acceso, y garantizando la rendici\u00f3n de cuentas a las entidades gubernamentales y legales pertinentes. Adem\u00e1s, deben aplicar principios s\u00f3lidos de aseguramiento de la calidad para evitar la adquisici\u00f3n de medicamentos subest\u00e1ndar o falsificados.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para manejar la distribuci\u00f3n de productos m\u00e9dicos y asegurar su seguridad?**\n   - Los farmac\u00e9uticos deben garantizar que todos los productos m\u00e9dicos se manejen y distribuyan de manera que se asegure la fiabilidad y seguridad del suministro de medicamentos. Tambi\u00e9n deben establecer un sistema de distribuci\u00f3n efectivo que incluya procedimientos escritos para la recuperaci\u00f3n r\u00e1pida y efectiva de productos cuando sea necesario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Marco Econ\u00f3mico para la Pr\u00e1ctica Farmac\u00e9utica**: Se establece la necesidad de un marco que proporcione recursos e incentivos adecuados para asegurar que las actividades de buena pr\u00e1ctica farmac\u00e9utica (GPP) se realicen de manera efectiva.\n\n2. **Establecimiento de Est\u00e1ndares para la Buena Pr\u00e1ctica Farmac\u00e9utica (GPP)**:\n   - **Superaci\u00f3n de la Legislaci\u00f3n Nacional**: Los est\u00e1ndares de GPP deben ir m\u00e1s all\u00e1 de lo que establece la legislaci\u00f3n nacional, que a menudo no proporciona instrucciones precisas sobre la producci\u00f3n de servicios.\n   - **Rol de las Asociaciones Profesionales**: Las asociaciones profesionales farmac\u00e9uticas nacionales son responsables de establecer los est\u00e1ndares necesarios para GPP, incluyendo un marco de gesti\u00f3n de calidad y un plan estrat\u00e9gico para el desarrollo de servicios.\n\n3. **Adaptaci\u00f3n a Diferentes Entornos de Pr\u00e1ctica**: Se reconoce que la pr\u00e1ctica farmac\u00e9utica var\u00eda entre pa\u00edses y entornos (como farmacias comunitarias y hospitalarias), por lo que los est\u00e1ndares deben ser flexibles y adaptarse a estas diferencias.\n\n4. **Evoluci\u00f3n de la Pr\u00e1ctica Farmac\u00e9utica**: Los est\u00e1ndares deben reconocer y guiar el desarrollo de servicios en un contexto de cambios en medicamentos y necesidades, sin comprometer la naturaleza evolutiva de la pr\u00e1ctica.\n\n5. **Definici\u00f3n de Roles y Funciones**:\n   - **Roles de los Farmac\u00e9uticos**: Es fundamental definir los roles que desempe\u00f1an los farmac\u00e9uticos seg\u00fan las expectativas de los pacientes y la sociedad.\n   - **Responsabilidad y Rendici\u00f3n de Cuentas**: Se deben determinar las funciones relevantes para las cuales los farmac\u00e9uticos tienen responsabilidad directa.\n\n6. **Establecimiento de Est\u00e1ndares M\u00ednimos**: Los est\u00e1ndares nacionales m\u00ednimos deben basarse en la competencia en actividades espec\u00edficas, adapt\u00e1ndose a las necesidades locales y aspiraciones profesionales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe y establece directrices sobre GPP.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que enfatiza la importancia de definir roles y establecer est\u00e1ndares m\u00ednimos para la pr\u00e1ctica farmac\u00e9utica.\n- **Asociaciones Profesionales Farmac\u00e9uticas Nacionales**: Entidades responsables de adaptar y establecer est\u00e1ndares de GPP en sus respectivos pa\u00edses. \n\nEste resumen destaca la importancia de un enfoque estructurado y adaptativo para la buena pr\u00e1ctica farmac\u00e9utica, asegurando que se satisfagan las necesidades de los usuarios de servicios de salud y se mantenga la calidad en la atenci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmacists, medical products, procurement, distribution, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aa26da2e-2915-420e-9f94-8b22bfc5767a", "node_type": "4", "metadata": {"page_label": "330", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Role 1: Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products\n\n- **Function A: Prepare extemporaneous medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that medicine preparation areas are appropriately designed to permit ease of extemporaneous preparations and are maintained in a manner that minimizes the potential for medication errors and assures the cleanliness and safety of medical products.\n  - Pharmacists should ensure that compounded medicines are consistently prepared to comply with written formulas and quality standards for raw materials, equipment and preparation processes, including sterility where appropriate.\n\n- **Function B: Obtain, store and secure medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists who are responsible for procurement should ensure that the procurement process is transparent, professional and ethical so as to promote equity and access and to ensure accountability to relevant governing and legal entities.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by strong quality assurance principles to assure that substandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/counterfeit medicines are not procured or allowed into the system.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by a reliable information system which provides accurate, timely and accessible information.\n  - Pharmacists should establish contingency plans for shortages of medicines and for purchases in emergencies.\n  - Pharmacists should assure that proper storage conditions are provided for all medicines, especially for controlled substances, used in the pharmacy or health-care facility.\n\n- **Function C: Distribute medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that all medical products, including medicine samples, are handled and distributed in a manner that assures reliability and safety of the medicine supply.\n  - Pharmacists should establish an effective distribution system which includes a written procedure, to recall promptly and effectively.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "07174ed0bf429cbb3985f2838809be863ac75f4ccd92b1cbf3ad6793160f36b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Role 1: Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products\n\n- **Function A: Prepare extemporaneous medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that medicine preparation areas are appropriately designed to permit ease of extemporaneous preparations and are maintained in a manner that minimizes the potential for medication errors and assures the cleanliness and safety of medical products.\n  - Pharmacists should ensure that compounded medicines are consistently prepared to comply with written formulas and quality standards for raw materials, equipment and preparation processes, including sterility where appropriate.\n\n- **Function B: Obtain, store and secure medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists who are responsible for procurement should ensure that the procurement process is transparent, professional and ethical so as to promote equity and access and to ensure accountability to relevant governing and legal entities.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by strong quality assurance principles to assure that substandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/counterfeit medicines are not procured or allowed into the system.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by a reliable information system which provides accurate, timely and accessible information.\n  - Pharmacists should establish contingency plans for shortages of medicines and for purchases in emergencies.\n  - Pharmacists should assure that proper storage conditions are provided for all medicines, especially for controlled substances, used in the pharmacy or health-care facility.\n\n- **Function C: Distribute medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that all medical products, including medicine samples, are handled and distributed in a manner that assures reliability and safety of the medicine supply.\n  - Pharmacists should establish an effective distribution system which includes a written procedure, to recall promptly and effectively.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2427, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "68374f1d-8116-4e7c-bb16-2893dabb99ce": {"__data__": {"id_": "68374f1d-8116-4e7c-bb16-2893dabb99ce", "embedding": null, "metadata": {"page_label": "331", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medical products known or suspected to be defective or spurious/ falsely-labelled/falsified/counterfeit, with a designated person(s) responsible for recalls.\n\n\u2014 Pharmacists should develop with manufacturers, wholesalers and government agencies (where appropriate) an access plan for uninterrupted supply of essential medicines as part of a disaster or pandemic preparedness strategy.\n\n\u2014 As part of a disaster or pandemic preparedness strategy, national medicines regulatory agencies may introduce new medicines which are authorized for marketing with limited safety data; pharmacists have a responsibility to be aware of the safety issues and to institute necessary mechanisms for monitoring occurrence of adverse events.\n\n- **Function D: Administration of medicines, vaccines and other injectable medications**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should have a role in the preparation and administration of medicines, in establishing procedures in their work settings with respect to the administration, and in monitoring the outcomes of medication administration.\n\n  \u2014 Pharmacists should have an educator, facilitator and immunizer role, thus contributing to the prevention of diseases through participation in vaccination programmes, by ensuring vaccination coverage and by also ensuring vaccine safety.\n\n  \u2014 Pharmacists should participate in directly observed therapy (DOT) programmes in areas such as the management of drug addiction, HIV/ AIDS, tuberculosis and sexually transmitted diseases, where applicable.\n\n- **Function E: Dispensing of medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that appropriate facilities, trained personnel, standard dispensing practices and documentation procedures are in place in the pharmacy for the supply and dispensing of prescribed medicines and other health-care products.\n\n  \u2014 Pharmacists should assess and evaluate all paper or electronic prescriptions received, considering the therapeutic, social, economic and legal aspects of the prescribed indication(s) before supplying medical products to the patient. Where possible, generic substitution is recommended.\n\n  \u2014 Pharmacists should ensure patient confidentiality at the point of dispensing medical products and should provide advice to ensure that the patient receives and understands sufficient written and oral information to derive maximum benefit for the treatment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Responsabilidades de los farmac\u00e9uticos en situaciones de emergencia**: Los farmac\u00e9uticos deben colaborar con fabricantes, mayoristas y agencias gubernamentales para garantizar un suministro ininterrumpido de medicamentos esenciales durante desastres o pandemias. Tambi\u00e9n deben estar al tanto de los problemas de seguridad relacionados con nuevos medicamentos autorizados con datos de seguridad limitados.\n\n2. **Normas m\u00ednimas para la administraci\u00f3n y dispensaci\u00f3n de medicamentos**: Se deben establecer est\u00e1ndares nacionales m\u00ednimos para la administraci\u00f3n de medicamentos, vacunas y otros productos inyectables. Los farmac\u00e9uticos tienen un papel crucial en la preparaci\u00f3n, administraci\u00f3n y monitoreo de medicamentos, as\u00ed como en la dispensaci\u00f3n de productos m\u00e9dicos, asegurando la confidencialidad del paciente y la correcta informaci\u00f3n sobre el tratamiento.\n\n3. **Participaci\u00f3n en programas de salud p\u00fablica**: Los farmac\u00e9uticos deben desempe\u00f1ar roles educativos y de facilitaci\u00f3n en programas de vacunaci\u00f3n y terapia observada directamente (DOT) para el manejo de enfermedades como el VIH/SIDA y la tuberculosis, contribuyendo as\u00ed a la prevenci\u00f3n de enfermedades.\n\n### Preguntas espec\u00edficas que este contexto puede responder:\n\n1. **\u00bfQu\u00e9 papel deben desempe\u00f1ar los farmac\u00e9uticos en la preparaci\u00f3n y respuesta ante pandemias en relaci\u00f3n con el suministro de medicamentos?**\n   - Respuesta: Los farmac\u00e9uticos deben desarrollar un plan de acceso con fabricantes, mayoristas y agencias gubernamentales para garantizar un suministro ininterrumpido de medicamentos esenciales y estar al tanto de los problemas de seguridad de nuevos medicamentos autorizados con datos limitados.\n\n2. **\u00bfCu\u00e1les son las responsabilidades de los farmac\u00e9uticos en la administraci\u00f3n de medicamentos y vacunas?**\n   - Respuesta: Los farmac\u00e9uticos deben participar en la preparaci\u00f3n y administraci\u00f3n de medicamentos, establecer procedimientos en sus entornos de trabajo, monitorear los resultados de la administraci\u00f3n de medicamentos y contribuir a la prevenci\u00f3n de enfermedades a trav\u00e9s de programas de vacunaci\u00f3n.\n\n3. **\u00bfQu\u00e9 est\u00e1ndares deben cumplirse en la dispensaci\u00f3n de productos m\u00e9dicos por parte de los farmac\u00e9uticos?**\n   - Respuesta: Se deben establecer est\u00e1ndares m\u00ednimos que incluyan la disponibilidad de instalaciones adecuadas, personal capacitado, pr\u00e1cticas de dispensaci\u00f3n est\u00e1ndar y procedimientos de documentaci\u00f3n, as\u00ed como la evaluaci\u00f3n de las recetas considerando aspectos terap\u00e9uticos, sociales, econ\u00f3micos y legales. Adem\u00e1s, deben garantizar la confidencialidad del paciente y proporcionar informaci\u00f3n adecuada sobre el tratamiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda el papel fundamental de los farmac\u00e9uticos en la gesti\u00f3n de productos m\u00e9dicos, dividiendo sus responsabilidades en tres funciones principales:\n\n1. **Preparaci\u00f3n de Medicamentos**:\n   - Establecimiento de est\u00e1ndares nacionales m\u00ednimos para la preparaci\u00f3n de medicamentos extempor\u00e1neos.\n   - Dise\u00f1o adecuado de \u00e1reas de preparaci\u00f3n para minimizar errores y asegurar la limpieza.\n   - Cumplimiento de f\u00f3rmulas y est\u00e1ndares de calidad en la preparaci\u00f3n de medicamentos compuestos.\n\n2. **Obtenci\u00f3n, Almacenamiento y Seguridad**:\n   - Proceso de adquisici\u00f3n transparente, profesional y \u00e9tico para promover la equidad y el acceso a medicamentos.\n   - Aplicaci\u00f3n de principios de aseguramiento de calidad para evitar la adquisici\u00f3n de medicamentos subest\u00e1ndar o falsificados.\n   - Establecimiento de planes de contingencia para escasez de medicamentos y condiciones de almacenamiento adecuadas, especialmente para sustancias controladas.\n\n3. **Distribuci\u00f3n de Productos M\u00e9dicos**:\n   - Manejo y distribuci\u00f3n de productos m\u00e9dicos de manera que se garantice la fiabilidad y seguridad del suministro.\n   - Creaci\u00f3n de un sistema de distribuci\u00f3n efectivo con procedimientos escritos para la recuperaci\u00f3n de productos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **Farmac\u00e9uticos**: Profesionales responsables de la preparaci\u00f3n, obtenci\u00f3n, almacenamiento, distribuci\u00f3n y administraci\u00f3n de productos m\u00e9dicos.\n- **Medicamentos**: Productos m\u00e9dicos que deben ser preparados, almacenados y distribuidos de acuerdo con est\u00e1ndares de calidad y seguridad.\n- **Sistemas de Informaci\u00f3n**: Herramientas necesarias para asegurar la transparencia y la calidad en el proceso de adquisici\u00f3n de medicamentos. \n\nEste resumen destaca la importancia de establecer est\u00e1ndares y procedimientos claros para garantizar la calidad y seguridad en la gesti\u00f3n de productos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmacists, disaster preparedness, medication administration, vaccine safety, medical product dispensing"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9724ea0b-82de-4a4d-a81a-bcf136655a29", "node_type": "4", "metadata": {"page_label": "331", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medical products known or suspected to be defective or spurious/ falsely-labelled/falsified/counterfeit, with a designated person(s) responsible for recalls.\n\n\u2014 Pharmacists should develop with manufacturers, wholesalers and government agencies (where appropriate) an access plan for uninterrupted supply of essential medicines as part of a disaster or pandemic preparedness strategy.\n\n\u2014 As part of a disaster or pandemic preparedness strategy, national medicines regulatory agencies may introduce new medicines which are authorized for marketing with limited safety data; pharmacists have a responsibility to be aware of the safety issues and to institute necessary mechanisms for monitoring occurrence of adverse events.\n\n- **Function D: Administration of medicines, vaccines and other injectable medications**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should have a role in the preparation and administration of medicines, in establishing procedures in their work settings with respect to the administration, and in monitoring the outcomes of medication administration.\n\n  \u2014 Pharmacists should have an educator, facilitator and immunizer role, thus contributing to the prevention of diseases through participation in vaccination programmes, by ensuring vaccination coverage and by also ensuring vaccine safety.\n\n  \u2014 Pharmacists should participate in directly observed therapy (DOT) programmes in areas such as the management of drug addiction, HIV/ AIDS, tuberculosis and sexually transmitted diseases, where applicable.\n\n- **Function E: Dispensing of medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that appropriate facilities, trained personnel, standard dispensing practices and documentation procedures are in place in the pharmacy for the supply and dispensing of prescribed medicines and other health-care products.\n\n  \u2014 Pharmacists should assess and evaluate all paper or electronic prescriptions received, considering the therapeutic, social, economic and legal aspects of the prescribed indication(s) before supplying medical products to the patient. Where possible, generic substitution is recommended.\n\n  \u2014 Pharmacists should ensure patient confidentiality at the point of dispensing medical products and should provide advice to ensure that the patient receives and understands sufficient written and oral information to derive maximum benefit for the treatment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "790e6898fcf6642a1d70a0cc4f55b1c77550c1f80feb6a11fbd5aa3e71e02286", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "medical products known or suspected to be defective or spurious/ falsely-labelled/falsified/counterfeit, with a designated person(s) responsible for recalls.\n\n\u2014 Pharmacists should develop with manufacturers, wholesalers and government agencies (where appropriate) an access plan for uninterrupted supply of essential medicines as part of a disaster or pandemic preparedness strategy.\n\n\u2014 As part of a disaster or pandemic preparedness strategy, national medicines regulatory agencies may introduce new medicines which are authorized for marketing with limited safety data; pharmacists have a responsibility to be aware of the safety issues and to institute necessary mechanisms for monitoring occurrence of adverse events.\n\n- **Function D: Administration of medicines, vaccines and other injectable medications**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should have a role in the preparation and administration of medicines, in establishing procedures in their work settings with respect to the administration, and in monitoring the outcomes of medication administration.\n\n  \u2014 Pharmacists should have an educator, facilitator and immunizer role, thus contributing to the prevention of diseases through participation in vaccination programmes, by ensuring vaccination coverage and by also ensuring vaccine safety.\n\n  \u2014 Pharmacists should participate in directly observed therapy (DOT) programmes in areas such as the management of drug addiction, HIV/ AIDS, tuberculosis and sexually transmitted diseases, where applicable.\n\n- **Function E: Dispensing of medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that appropriate facilities, trained personnel, standard dispensing practices and documentation procedures are in place in the pharmacy for the supply and dispensing of prescribed medicines and other health-care products.\n\n  \u2014 Pharmacists should assess and evaluate all paper or electronic prescriptions received, considering the therapeutic, social, economic and legal aspects of the prescribed indication(s) before supplying medical products to the patient. Where possible, generic substitution is recommended.\n\n  \u2014 Pharmacists should ensure patient confidentiality at the point of dispensing medical products and should provide advice to ensure that the patient receives and understands sufficient written and oral information to derive maximum benefit for the treatment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2505, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "804272a5-1dd2-4cc7-94f7-c7f69f05420b": {"__data__": {"id_": "804272a5-1dd2-4cc7-94f7-c7f69f05420b", "embedding": null, "metadata": {"page_label": "332", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- **Function F: Dispose of medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that regular monitoring of the medicines inventory is conducted and should always include medicines samples in the process of periodic inspection for expiration dates and removal of outdated stock.\n  \n  \u2014 Pharmacists should ensure that recalled medical products, including medicines samples, are immediately stored separately for subsequent disposal and prevented from being available for further dispensing or distribution.\n  \n  \u2014 Pharmacists should establish a safe way of medicines waste disposal at the hospital and/or community pharmacy so that patients and the public can be encouraged to return their expired or unwanted medicines and medical devices. Alternatively, pharmacists should provide appropriate information to patients on how to safely dispose of expired or unwanted medicines.\n\n# Role 2: Provide effective medication therapy management\n\n- **Function A: Assess patient health status and needs**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that health management, disease prevention and healthy lifestyle behaviour are incorporated into the patient assessment and care process.\n  \n  \u2014 Pharmacists should acknowledge unique patient considerations such as education level, cultural beliefs, literacy, native language and physical and mental capacity in all individual patient assessments.\n\n- **Function B: Manage patient medication therapy**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should maintain access to an appropriate evidence base relating to the safe, rational and cost-effective use of medicines such as reference books on medicines, journals, national essential medicines lists and standard treatment guidelines.\n  \n  \u2014 Pharmacists should ensure that medicine formulary system(s) (local, regional and/or national) are linked to standard treatment guidelines, protocols and treatment pathways based on the best available evidence.\n  \n  \u2014 Pharmacists should have a key role in educating prescribers on the access to and evidence for optimal and appropriate use of medicines including the required monitoring parameters and prescribing adjustments. Where appropriate, pharmacists should provide advice.\n\n----\n\n3. Medication therapy management is a distinct service or group of services that optimize therapeutic outcomes for individual patients. Medication therapy management services are independent of, but can occur in conjunction with, the provision of a medication product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de los farmac\u00e9uticos en la gesti\u00f3n de productos m\u00e9dicos retirados del mercado?**\n   - Los farmac\u00e9uticos deben asegurarse de que los productos m\u00e9dicos retirados, incluidas las muestras de medicamentos, se almacenen de inmediato por separado para su posterior eliminaci\u00f3n y que no est\u00e9n disponibles para su dispensaci\u00f3n o distribuci\u00f3n. Esto implica un manejo cuidadoso y responsable de los productos que han sido objeto de un retiro.\n\n2. **\u00bfQu\u00e9 consideraciones deben tener en cuenta los farmac\u00e9uticos al evaluar la salud y las necesidades de los pacientes?**\n   - Los farmac\u00e9uticos deben incorporar la gesti\u00f3n de la salud, la prevenci\u00f3n de enfermedades y comportamientos de vida saludable en el proceso de evaluaci\u00f3n y atenci\u00f3n del paciente. Adem\u00e1s, deben reconocer consideraciones \u00fanicas del paciente, como el nivel educativo, creencias culturales, alfabetizaci\u00f3n, lengua nativa y capacidades f\u00edsicas y mentales en todas las evaluaciones individuales.\n\n3. **\u00bfQu\u00e9 tipo de recursos deben mantener los farmac\u00e9uticos para gestionar la terapia medicamentosa de los pacientes de manera efectiva?**\n   - Los farmac\u00e9uticos deben tener acceso a una base de evidencia adecuada relacionada con el uso seguro, racional y costo-efectivo de los medicamentos, que incluya libros de referencia sobre medicamentos, revistas, listas nacionales de medicamentos esenciales y gu\u00edas de tratamiento est\u00e1ndar. Esto les permite tomar decisiones informadas y basadas en la evidencia al gestionar la terapia medicamentosa.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en las funciones y responsabilidades de los farmac\u00e9uticos en la gesti\u00f3n de medicamentos y productos m\u00e9dicos, destacando la importancia de establecer est\u00e1ndares nacionales m\u00ednimos para estas actividades. Se enfatiza la necesidad de un manejo adecuado de los productos m\u00e9dicos retirados, la evaluaci\u00f3n integral de la salud del paciente y la gesti\u00f3n efectiva de la terapia medicamentosa. Los farmac\u00e9uticos juegan un papel crucial en la educaci\u00f3n de los prescriptores y en la promoci\u00f3n de pr\u00e1cticas seguras y efectivas en el uso de medicamentos.", "prev_section_summary": "### Temas Clave:\n\n1. **Responsabilidades de los farmac\u00e9uticos en emergencias**:\n   - Colaboraci\u00f3n con fabricantes, mayoristas y agencias gubernamentales para asegurar el suministro de medicamentos esenciales durante desastres o pandemias.\n   - Vigilancia de la seguridad de nuevos medicamentos autorizados con datos limitados.\n\n2. **Normas m\u00ednimas para la administraci\u00f3n de medicamentos**:\n   - Establecimiento de est\u00e1ndares nacionales para la preparaci\u00f3n, administraci\u00f3n y monitoreo de medicamentos y vacunas.\n   - Rol de los farmac\u00e9uticos como educadores y facilitadores en programas de vacunaci\u00f3n y terapia observada directamente (DOT).\n\n3. **Dispensaci\u00f3n de productos m\u00e9dicos**:\n   - Necesidad de instalaciones adecuadas, personal capacitado y pr\u00e1cticas de dispensaci\u00f3n est\u00e1ndar.\n   - Evaluaci\u00f3n de recetas considerando aspectos terap\u00e9uticos, sociales, econ\u00f3micos y legales.\n   - Garant\u00eda de la confidencialidad del paciente y provisi\u00f3n de informaci\u00f3n adecuada sobre el tratamiento.\n\n### Entidades:\n\n- **Farmac\u00e9uticos**: Profesionales responsables de la administraci\u00f3n y dispensaci\u00f3n de medicamentos, as\u00ed como de la educaci\u00f3n y prevenci\u00f3n de enfermedades.\n- **Fabricantes y mayoristas**: Entidades con las que los farmac\u00e9uticos deben colaborar para asegurar el suministro de medicamentos.\n- **Agencias gubernamentales y reguladoras**: Organismos que pueden introducir nuevos medicamentos y establecer normas para la pr\u00e1ctica farmac\u00e9utica.\n- **Medicamentos**: Productos m\u00e9dicos que deben ser administrados y dispensados de manera segura y efectiva.\n- **Programas de salud p\u00fablica**: Iniciativas en las que los farmac\u00e9uticos participan para promover la salud y prevenir enfermedades.", "excerpt_keywords": "Keywords: pharmacists, medication therapy management, medicine disposal, patient assessment, health standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53a19ddc-c125-4f93-a410-f84c9aca8637", "node_type": "4", "metadata": {"page_label": "332", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- **Function F: Dispose of medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that regular monitoring of the medicines inventory is conducted and should always include medicines samples in the process of periodic inspection for expiration dates and removal of outdated stock.\n  \n  \u2014 Pharmacists should ensure that recalled medical products, including medicines samples, are immediately stored separately for subsequent disposal and prevented from being available for further dispensing or distribution.\n  \n  \u2014 Pharmacists should establish a safe way of medicines waste disposal at the hospital and/or community pharmacy so that patients and the public can be encouraged to return their expired or unwanted medicines and medical devices. Alternatively, pharmacists should provide appropriate information to patients on how to safely dispose of expired or unwanted medicines.\n\n# Role 2: Provide effective medication therapy management\n\n- **Function A: Assess patient health status and needs**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that health management, disease prevention and healthy lifestyle behaviour are incorporated into the patient assessment and care process.\n  \n  \u2014 Pharmacists should acknowledge unique patient considerations such as education level, cultural beliefs, literacy, native language and physical and mental capacity in all individual patient assessments.\n\n- **Function B: Manage patient medication therapy**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should maintain access to an appropriate evidence base relating to the safe, rational and cost-effective use of medicines such as reference books on medicines, journals, national essential medicines lists and standard treatment guidelines.\n  \n  \u2014 Pharmacists should ensure that medicine formulary system(s) (local, regional and/or national) are linked to standard treatment guidelines, protocols and treatment pathways based on the best available evidence.\n  \n  \u2014 Pharmacists should have a key role in educating prescribers on the access to and evidence for optimal and appropriate use of medicines including the required monitoring parameters and prescribing adjustments. Where appropriate, pharmacists should provide advice.\n\n----\n\n3. Medication therapy management is a distinct service or group of services that optimize therapeutic outcomes for individual patients. Medication therapy management services are independent of, but can occur in conjunction with, the provision of a medication product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ab2d2b7b1419ed0e979cedf2ce466ea64f2e45ed2a13211d00235ae3eb121308", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- **Function F: Dispose of medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that regular monitoring of the medicines inventory is conducted and should always include medicines samples in the process of periodic inspection for expiration dates and removal of outdated stock.\n  \n  \u2014 Pharmacists should ensure that recalled medical products, including medicines samples, are immediately stored separately for subsequent disposal and prevented from being available for further dispensing or distribution.\n  \n  \u2014 Pharmacists should establish a safe way of medicines waste disposal at the hospital and/or community pharmacy so that patients and the public can be encouraged to return their expired or unwanted medicines and medical devices. Alternatively, pharmacists should provide appropriate information to patients on how to safely dispose of expired or unwanted medicines.\n\n# Role 2: Provide effective medication therapy management\n\n- **Function A: Assess patient health status and needs**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that health management, disease prevention and healthy lifestyle behaviour are incorporated into the patient assessment and care process.\n  \n  \u2014 Pharmacists should acknowledge unique patient considerations such as education level, cultural beliefs, literacy, native language and physical and mental capacity in all individual patient assessments.\n\n- **Function B: Manage patient medication therapy**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should maintain access to an appropriate evidence base relating to the safe, rational and cost-effective use of medicines such as reference books on medicines, journals, national essential medicines lists and standard treatment guidelines.\n  \n  \u2014 Pharmacists should ensure that medicine formulary system(s) (local, regional and/or national) are linked to standard treatment guidelines, protocols and treatment pathways based on the best available evidence.\n  \n  \u2014 Pharmacists should have a key role in educating prescribers on the access to and evidence for optimal and appropriate use of medicines including the required monitoring parameters and prescribing adjustments. Where appropriate, pharmacists should provide advice.\n\n----\n\n3. Medication therapy management is a distinct service or group of services that optimize therapeutic outcomes for individual patients. Medication therapy management services are independent of, but can occur in conjunction with, the provision of a medication product.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2700, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3bb7142d-1463-4a32-af87-88cbcf8bb6dc": {"__data__": {"id_": "3bb7142d-1463-4a32-af87-88cbcf8bb6dc", "embedding": null, "metadata": {"page_label": "333", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Monitor patient progress and outcomes\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should consider patient diagnosis and patient-specific needs when assessing patient response to medicine therapy and intervene if necessary.\n- Pharmacists should document necessary clinical and patient data to assess and monitor medication therapy and to track patients\u2019 therapeutic outcomes.\n- Pharmacists should perform point-of-care testing for patients in order to monitor and adjust therapy, when needed.\n\n# Function D: Provide information about medicines and health-related issues\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should ensure that in every pharmacy there is a suitable place for discussing confidential information with the customers and patients.\n- Pharmacists should provide sufficient health, disease and medicine-specific information to patients for their participation in their decision-making process regarding a comprehensive care management plan. This information should aim at supporting adherence to treatment and empowerment of the patient.\n- Pharmacists should be proactive in reducing antimicrobial resistance by providing information about the appropriate use of antimicrobials to consumers and prescribers.\n\n# Role 3: Maintain and improve professional performance\n\n- **Function A: Plan and implement continuing professional development**[^4] strategies to improve current and future performance\n\n[^4]: The concept of continuing professional development (CPD) can be defined as \"the responsibility of individual pharmacists for systematic maintenance, development and broadening of knowledge, skills and attitudes, to ensure continuing competence as a professional, throughout their careers.\"", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece est\u00e1ndares m\u00ednimos para las funciones de los farmac\u00e9uticos en la monitorizaci\u00f3n del progreso y resultados de los pacientes, la provisi\u00f3n de informaci\u00f3n sobre medicamentos y temas de salud, y la mejora del rendimiento profesional. Se enfatiza la importancia de considerar las necesidades espec\u00edficas del paciente, documentar datos cl\u00ednicos, realizar pruebas en el punto de atenci\u00f3n, y fomentar la educaci\u00f3n sobre el uso adecuado de antimicrobianos. Adem\u00e1s, se menciona la responsabilidad de los farmac\u00e9uticos en su desarrollo profesional continuo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de los farmac\u00e9uticos al monitorizar la terapia de medicamentos en los pacientes?**\n   - Respuesta: Los farmac\u00e9uticos deben considerar el diagn\u00f3stico del paciente y sus necesidades espec\u00edficas al evaluar la respuesta a la terapia, documentar datos cl\u00ednicos y del paciente, y realizar pruebas en el punto de atenci\u00f3n para ajustar la terapia seg\u00fan sea necesario.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los farmac\u00e9uticos para garantizar la confidencialidad al proporcionar informaci\u00f3n a los pacientes?**\n   - Respuesta: Los farmac\u00e9uticos deben asegurarse de que en cada farmacia haya un lugar adecuado para discutir informaci\u00f3n confidencial con los clientes y pacientes.\n\n3. **\u00bfC\u00f3mo pueden los farmac\u00e9uticos contribuir a la reducci\u00f3n de la resistencia a los antimicrobianos?**\n   - Respuesta: Los farmac\u00e9uticos deben ser proactivos en proporcionar informaci\u00f3n sobre el uso adecuado de antimicrobianos tanto a los consumidores como a los prescriptores, con el fin de reducir la resistencia a estos medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Funciones de los Farmac\u00e9uticos**:\n   - **Eliminaci\u00f3n de Preparaciones Medicinales y Productos M\u00e9dicos**:\n     - Establecimiento de est\u00e1ndares nacionales m\u00ednimos para la gesti\u00f3n de medicamentos.\n     - Monitoreo regular del inventario de medicamentos, incluyendo la inspecci\u00f3n de fechas de caducidad.\n     - Almacenamiento separado de productos m\u00e9dicos retirados para su eliminaci\u00f3n segura.\n     - Promoci\u00f3n de la devoluci\u00f3n de medicamentos caducados o no deseados por parte de pacientes y el p\u00fablico.\n\n2. **Gesti\u00f3n Efectiva de la Terapia Medicamentosa**:\n   - **Evaluaci\u00f3n del Estado de Salud y Necesidades del Paciente**:\n     - Incorporaci\u00f3n de la gesti\u00f3n de salud, prevenci\u00f3n de enfermedades y promoci\u00f3n de estilos de vida saludables en la evaluaci\u00f3n del paciente.\n     - Consideraci\u00f3n de factores \u00fanicos del paciente como educaci\u00f3n, creencias culturales y capacidades f\u00edsicas y mentales.\n\n   - **Manejo de la Terapia Medicamentosa**:\n     - Acceso a una base de evidencia sobre el uso seguro y efectivo de medicamentos.\n     - Aseguramiento de que los sistemas de formularios de medicamentos est\u00e9n alineados con gu\u00edas de tratamiento basadas en evidencia.\n     - Educaci\u00f3n a los prescriptores sobre el uso \u00f3ptimo de medicamentos y ajustes necesarios en la prescripci\u00f3n.\n\n3. **Definici\u00f3n de Gesti\u00f3n de Terapia Medicamentosa**:\n   - Se describe como un servicio que optimiza los resultados terap\u00e9uticos para pacientes individuales, independiente pero complementario a la provisi\u00f3n de productos medicinales.\n\n### Entidades Clave\n- **Farmac\u00e9uticos**: Profesionales responsables de la gesti\u00f3n de medicamentos y productos m\u00e9dicos.\n- **Medicamentos**: Sustancias utilizadas para tratar enfermedades y condiciones de salud.\n- **Productos M\u00e9dicos**: Incluyen dispositivos y otros productos relacionados con la salud.\n- **Pacientes**: Personas que reciben atenci\u00f3n m\u00e9dica y cuyos medicamentos deben ser gestionados adecuadamente.\n- **Est\u00e1ndares Nacionales**: Normativas que deben establecerse para asegurar la calidad y seguridad en la gesti\u00f3n de medicamentos. \n\nEste resumen destaca la importancia de las funciones de los farmac\u00e9uticos en la gesti\u00f3n de medicamentos y la atenci\u00f3n al paciente, enfatizando la necesidad de est\u00e1ndares y pr\u00e1cticas seguras en el manejo de productos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmacists, medication therapy, patient outcomes, antimicrobial resistance, professional development"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ee4a1e10-76fb-406c-a24e-3f3bdd66d064", "node_type": "4", "metadata": {"page_label": "333", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Monitor patient progress and outcomes\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should consider patient diagnosis and patient-specific needs when assessing patient response to medicine therapy and intervene if necessary.\n- Pharmacists should document necessary clinical and patient data to assess and monitor medication therapy and to track patients\u2019 therapeutic outcomes.\n- Pharmacists should perform point-of-care testing for patients in order to monitor and adjust therapy, when needed.\n\n# Function D: Provide information about medicines and health-related issues\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should ensure that in every pharmacy there is a suitable place for discussing confidential information with the customers and patients.\n- Pharmacists should provide sufficient health, disease and medicine-specific information to patients for their participation in their decision-making process regarding a comprehensive care management plan. This information should aim at supporting adherence to treatment and empowerment of the patient.\n- Pharmacists should be proactive in reducing antimicrobial resistance by providing information about the appropriate use of antimicrobials to consumers and prescribers.\n\n# Role 3: Maintain and improve professional performance\n\n- **Function A: Plan and implement continuing professional development**[^4] strategies to improve current and future performance\n\n[^4]: The concept of continuing professional development (CPD) can be defined as \"the responsibility of individual pharmacists for systematic maintenance, development and broadening of knowledge, skills and attitudes, to ensure continuing competence as a professional, throughout their careers.\"", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ae8b7493a738d30f4bdd4e2a3305ec60000a49c0dc1c3d9a9ff90bcc9b20a177", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Function C: Monitor patient progress and outcomes\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should consider patient diagnosis and patient-specific needs when assessing patient response to medicine therapy and intervene if necessary.\n- Pharmacists should document necessary clinical and patient data to assess and monitor medication therapy and to track patients\u2019 therapeutic outcomes.\n- Pharmacists should perform point-of-care testing for patients in order to monitor and adjust therapy, when needed.\n\n# Function D: Provide information about medicines and health-related issues\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should ensure that in every pharmacy there is a suitable place for discussing confidential information with the customers and patients.\n- Pharmacists should provide sufficient health, disease and medicine-specific information to patients for their participation in their decision-making process regarding a comprehensive care management plan. This information should aim at supporting adherence to treatment and empowerment of the patient.\n- Pharmacists should be proactive in reducing antimicrobial resistance by providing information about the appropriate use of antimicrobials to consumers and prescribers.\n\n# Role 3: Maintain and improve professional performance\n\n- **Function A: Plan and implement continuing professional development**[^4] strategies to improve current and future performance\n\n[^4]: The concept of continuing professional development (CPD) can be defined as \"the responsibility of individual pharmacists for systematic maintenance, development and broadening of knowledge, skills and attitudes, to ensure continuing competence as a professional, throughout their careers.\"", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1815, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb0bec4-3af4-4ba1-8069-eebeccc5609e": {"__data__": {"id_": "7eb0bec4-3af4-4ba1-8069-eebeccc5609e", "embedding": null, "metadata": {"page_label": "334", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Minimum national standards should be established for these activities.\n\n\u2014 Pharmacists should perceive continuing education as being lifelong and be able to demonstrate evidence of continuing education or continuing professional development to improve clinical knowledge, skills and performance.\n\n\u2014 Pharmacists should take steps to update their knowledge and skills about complementary and alternative therapies such as traditional Chinese medicines, health supplements, acupuncture, homeopathy and naturopathy.\n\n\u2014 Pharmacists should take steps to update their knowledge and be engaged in implementation of new technology and automation in pharmacy practice, where feasible.\n\n\u2014 Pharmacists should take steps to become informed and update their knowledge on changes to information on medical products.\n\n# Role 4: Contribute to improve effectiveness of the health-care system and public health\n\n- **Function A:** Disseminate evaluated information about medicines and various aspects of self-care\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that the information provided to patients, other health-care professionals and the public is evidence-based, objective, understandable, non-promotional, accurate and appropriate.\n\n  \u2014 Pharmacists should develop and/or use educational materials for health management, health promotion and disease prevention programmes that are applicable to a wide range of patient populations, age groups and health literacy levels.\n\n  \u2014 Pharmacists should educate patients on how to evaluate and use web-based or other forms of health-care information (including medicines information) and strongly encourage them to be advised by a pharmacist regarding the information they find, particularly if obtained from the Internet.\n\n  \u2014 Pharmacists should assist patients and their care providers to obtain and critically analyse information to meet their individual needs.\n\n- **Function B:** Engage in preventive care activities and services\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should engage in preventive care activities that promote public health and prevent disease, i.e. in areas such as smoking cessation, infectious and sexually transmitted diseases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS establece est\u00e1ndares m\u00ednimos para la educaci\u00f3n continua de los farmac\u00e9uticos y su papel en la mejora del sistema de salud y la salud p\u00fablica. Se enfatiza la importancia de que los farmac\u00e9uticos mantengan actualizados sus conocimientos sobre terapias complementarias, nuevas tecnolog\u00edas y cambios en la informaci\u00f3n de productos m\u00e9dicos. Adem\u00e1s, se destacan dos funciones clave: la difusi\u00f3n de informaci\u00f3n evaluada sobre medicamentos y la participaci\u00f3n en actividades de atenci\u00f3n preventiva.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de educaci\u00f3n continua se espera que los farmac\u00e9uticos realicen para mejorar su desempe\u00f1o cl\u00ednico?**\n   - Los farmac\u00e9uticos deben percibir la educaci\u00f3n continua como un proceso de por vida y demostrar evidencia de su desarrollo profesional continuo para mejorar sus conocimientos, habilidades y desempe\u00f1o cl\u00ednico.\n\n2. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas en las que los farmac\u00e9uticos deben actualizar sus conocimientos seg\u00fan el documento?**\n   - Los farmac\u00e9uticos deben actualizar sus conocimientos sobre terapias complementarias y alternativas, como la medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda y naturopat\u00eda, as\u00ed como sobre la implementaci\u00f3n de nuevas tecnolog\u00edas y automatizaci\u00f3n en la pr\u00e1ctica farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an los farmac\u00e9uticos en la promoci\u00f3n de la salud p\u00fablica y la prevenci\u00f3n de enfermedades?**\n   - Los farmac\u00e9uticos deben participar en actividades de atenci\u00f3n preventiva que promuevan la salud p\u00fablica y prevengan enfermedades, incluyendo \u00e1reas como la cesaci\u00f3n del tabaquismo y la prevenci\u00f3n de enfermedades infecciosas y de transmisi\u00f3n sexual.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Monitorizaci\u00f3n del Progreso y Resultados de los Pacientes:**\n   - Establecimiento de est\u00e1ndares nacionales m\u00ednimos.\n   - Evaluaci\u00f3n de la respuesta a la terapia considerando el diagn\u00f3stico y necesidades del paciente.\n   - Documentaci\u00f3n de datos cl\u00ednicos y seguimiento de resultados terap\u00e9uticos.\n   - Realizaci\u00f3n de pruebas en el punto de atenci\u00f3n para ajustar la terapia.\n\n2. **Provisi\u00f3n de Informaci\u00f3n sobre Medicamentos y Temas de Salud:**\n   - Creaci\u00f3n de espacios adecuados para discutir informaci\u00f3n confidencial en farmacias.\n   - Suministro de informaci\u00f3n espec\u00edfica sobre salud, enfermedades y medicamentos para la toma de decisiones del paciente.\n   - Promoci\u00f3n del uso adecuado de antimicrobianos para reducir la resistencia.\n\n3. **Mejora del Rendimiento Profesional:**\n   - Planificaci\u00f3n e implementaci\u00f3n de estrategias de desarrollo profesional continuo (CPD).\n   - Responsabilidad de los farmac\u00e9uticos en el mantenimiento y desarrollo de sus competencias profesionales.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que establece los est\u00e1ndares y directrices.\n- **Farmac\u00e9uticos:** Profesionales responsables de la monitorizaci\u00f3n de la terapia, provisi\u00f3n de informaci\u00f3n y desarrollo profesional.\n- **Pacientes:** Sujetos de la atenci\u00f3n farmac\u00e9utica que requieren seguimiento y educaci\u00f3n sobre su tratamiento.\n- **Antimicrobianos:** Medicamentos cuyo uso adecuado es crucial para prevenir la resistencia.\n\nEste resumen destaca la importancia de la funci\u00f3n de los farmac\u00e9uticos en la atenci\u00f3n al paciente, la confidencialidad y el desarrollo profesional continuo, as\u00ed como su papel en la lucha contra la resistencia a los antimicrobianos.", "excerpt_keywords": "Keywords: pharmacists, continuing education, public health, preventive care, complementary therapies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7975bd48-7abc-4e9a-801e-3624e4da99ca", "node_type": "4", "metadata": {"page_label": "334", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Minimum national standards should be established for these activities.\n\n\u2014 Pharmacists should perceive continuing education as being lifelong and be able to demonstrate evidence of continuing education or continuing professional development to improve clinical knowledge, skills and performance.\n\n\u2014 Pharmacists should take steps to update their knowledge and skills about complementary and alternative therapies such as traditional Chinese medicines, health supplements, acupuncture, homeopathy and naturopathy.\n\n\u2014 Pharmacists should take steps to update their knowledge and be engaged in implementation of new technology and automation in pharmacy practice, where feasible.\n\n\u2014 Pharmacists should take steps to become informed and update their knowledge on changes to information on medical products.\n\n# Role 4: Contribute to improve effectiveness of the health-care system and public health\n\n- **Function A:** Disseminate evaluated information about medicines and various aspects of self-care\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that the information provided to patients, other health-care professionals and the public is evidence-based, objective, understandable, non-promotional, accurate and appropriate.\n\n  \u2014 Pharmacists should develop and/or use educational materials for health management, health promotion and disease prevention programmes that are applicable to a wide range of patient populations, age groups and health literacy levels.\n\n  \u2014 Pharmacists should educate patients on how to evaluate and use web-based or other forms of health-care information (including medicines information) and strongly encourage them to be advised by a pharmacist regarding the information they find, particularly if obtained from the Internet.\n\n  \u2014 Pharmacists should assist patients and their care providers to obtain and critically analyse information to meet their individual needs.\n\n- **Function B:** Engage in preventive care activities and services\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should engage in preventive care activities that promote public health and prevent disease, i.e. in areas such as smoking cessation, infectious and sexually transmitted diseases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "067514c601fac82ed9d330237ca15e0813749780b39a2ceab627bdff082798d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Minimum national standards should be established for these activities.\n\n\u2014 Pharmacists should perceive continuing education as being lifelong and be able to demonstrate evidence of continuing education or continuing professional development to improve clinical knowledge, skills and performance.\n\n\u2014 Pharmacists should take steps to update their knowledge and skills about complementary and alternative therapies such as traditional Chinese medicines, health supplements, acupuncture, homeopathy and naturopathy.\n\n\u2014 Pharmacists should take steps to update their knowledge and be engaged in implementation of new technology and automation in pharmacy practice, where feasible.\n\n\u2014 Pharmacists should take steps to become informed and update their knowledge on changes to information on medical products.\n\n# Role 4: Contribute to improve effectiveness of the health-care system and public health\n\n- **Function A:** Disseminate evaluated information about medicines and various aspects of self-care\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that the information provided to patients, other health-care professionals and the public is evidence-based, objective, understandable, non-promotional, accurate and appropriate.\n\n  \u2014 Pharmacists should develop and/or use educational materials for health management, health promotion and disease prevention programmes that are applicable to a wide range of patient populations, age groups and health literacy levels.\n\n  \u2014 Pharmacists should educate patients on how to evaluate and use web-based or other forms of health-care information (including medicines information) and strongly encourage them to be advised by a pharmacist regarding the information they find, particularly if obtained from the Internet.\n\n  \u2014 Pharmacists should assist patients and their care providers to obtain and critically analyse information to meet their individual needs.\n\n- **Function B:** Engage in preventive care activities and services\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should engage in preventive care activities that promote public health and prevent disease, i.e. in areas such as smoking cessation, infectious and sexually transmitted diseases.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2292, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b8c4581a-0858-4299-8e48-71f9c05b4f37": {"__data__": {"id_": "b8c4581a-0858-4299-8e48-71f9c05b4f37", "embedding": null, "metadata": {"page_label": "335", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Comply with national professional obligations, guidelines and legislations\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should take steps to ensure that they comply with the provisions of a national code of ethics for pharmacists.\n\n# Function D: Advocate and support national policies that promote improved health outcomes\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should contribute to public and professional groups to promote, evaluate and improve health in the community.\n- Pharmacists should collaborate with other health-care professionals in their efforts to improve health outcomes.\n\n## Conclusions\n\nThere are four main roles where pharmacists\u2019 involvement or supervision is expected by society and the individuals they serve:\n\n1. Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products.\n2. Provide effective medication therapy management.\n3. Maintain and improve professional performance.\n4. Contribute to improve effectiveness of the health-care system and public health.\n\nThese roles may vary for each individual pharmacist depending on their practice responsibilities.\n\nSpecific standards of GPP can be developed only within a national pharmacy professional organization framework.\n\nThis guidance is recommended as a set of professional goals to be met in the interest of the patients and other key stakeholders in the pharmaceutical sector. Responsibility for moving the project forward will rest with each national pharmacy professional association. Achieving specific standards of GPP for each nation within these recommendations may require considerable time and effort. As health professionals, pharmacists have a duty to begin the process without delay.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre las funciones y responsabilidades de los farmac\u00e9uticos en el contexto de la atenci\u00f3n sanitaria. Se destacan dos funciones principales: cumplir con las obligaciones profesionales y abogar por pol\u00edticas nacionales que mejoren los resultados de salud. Se enfatiza la necesidad de establecer est\u00e1ndares nacionales m\u00ednimos y la importancia de la colaboraci\u00f3n entre farmac\u00e9uticos y otros profesionales de la salud. Adem\u00e1s, se identifican cuatro roles clave de los farmac\u00e9uticos en la sociedad, que incluyen la gesti\u00f3n de productos m\u00e9dicos, la terapia farmacol\u00f3gica, el mantenimiento del rendimiento profesional y la mejora del sistema de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguir los farmac\u00e9uticos para cumplir con el c\u00f3digo de \u00e9tica nacional, y c\u00f3mo se pueden medir estos pasos?**\n   - Esta pregunta busca detalles sobre la implementaci\u00f3n pr\u00e1ctica del c\u00f3digo de \u00e9tica y los criterios de evaluaci\u00f3n que podr\u00edan no estar claramente definidos en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de colaboraci\u00f3n se espera entre los farmac\u00e9uticos y otros profesionales de la salud para mejorar los resultados de salud, y qu\u00e9 ejemplos concretos se pueden dar?**\n   - Esta pregunta se centra en ejemplos espec\u00edficos de colaboraci\u00f3n interprofesional que podr\u00edan no estar documentados en otras fuentes.\n\n3. **\u00bfQu\u00e9 desaf\u00edos espec\u00edficos enfrentan las asociaciones profesionales de farmac\u00e9uticos al intentar establecer est\u00e1ndares de Buenas Pr\u00e1cticas de Farmacia (GPP) en sus respectivos pa\u00edses?**\n   - Esta pregunta busca explorar los obst\u00e1culos \u00fanicos que pueden surgir en el proceso de establecimiento de est\u00e1ndares, que pueden no ser evidentes en otros contextos o documentos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del rol de los farmac\u00e9uticos y los est\u00e1ndares profesionales, proporcionando informaci\u00f3n que puede no estar disponible en otros lugares.", "prev_section_summary": "### Temas Clave:\n\n1. **Educaci\u00f3n Continua de los Farmac\u00e9uticos:**\n   - Importancia de la educaci\u00f3n continua como un proceso de por vida.\n   - Necesidad de demostrar evidencia de desarrollo profesional continuo para mejorar conocimientos, habilidades y desempe\u00f1o cl\u00ednico.\n\n2. **Actualizaci\u00f3n de Conocimientos:**\n   - Necesidad de actualizar conocimientos sobre terapias complementarias y alternativas (medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda, naturopat\u00eda).\n   - Importancia de estar al tanto de nuevas tecnolog\u00edas y automatizaci\u00f3n en la pr\u00e1ctica farmac\u00e9utica.\n   - Mantenerse informado sobre cambios en la informaci\u00f3n de productos m\u00e9dicos.\n\n3. **Contribuci\u00f3n a la Salud P\u00fablica:**\n   - Rol de los farmac\u00e9uticos en la mejora de la efectividad del sistema de salud y la salud p\u00fablica.\n   - Funci\u00f3n de diseminar informaci\u00f3n evaluada sobre medicamentos y autocuidado.\n   - Participaci\u00f3n en actividades de atenci\u00f3n preventiva para promover la salud p\u00fablica y prevenir enfermedades (ej. cesaci\u00f3n del tabaquismo, prevenci\u00f3n de enfermedades infecciosas y de transmisi\u00f3n sexual).\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Emisora del documento y responsable de establecer est\u00e1ndares.\n- **Farmac\u00e9uticos:** Profesionales de la salud que deben actualizar sus conocimientos y participar en la educaci\u00f3n continua.\n- **Terapias Complementarias y Alternativas:** Incluyen medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda y naturopat\u00eda.\n- **Tecnolog\u00eda y Automatizaci\u00f3n:** Elementos clave en la pr\u00e1ctica farmac\u00e9utica moderna.\n- **Salud P\u00fablica:** \u00c1rea en la que los farmac\u00e9uticos deben involucrarse activamente a trav\u00e9s de actividades preventivas. \n\nEste resumen destaca la importancia de la educaci\u00f3n continua y la actualizaci\u00f3n de conocimientos en el \u00e1mbito farmac\u00e9utico, as\u00ed como el papel crucial de los farmac\u00e9uticos en la promoci\u00f3n de la salud p\u00fablica.", "excerpt_keywords": "Keywords: pharmacists, national standards, health outcomes, professional ethics, medication management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4896154a-41cf-46f3-ba30-c4219d760818", "node_type": "4", "metadata": {"page_label": "335", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Comply with national professional obligations, guidelines and legislations\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should take steps to ensure that they comply with the provisions of a national code of ethics for pharmacists.\n\n# Function D: Advocate and support national policies that promote improved health outcomes\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should contribute to public and professional groups to promote, evaluate and improve health in the community.\n- Pharmacists should collaborate with other health-care professionals in their efforts to improve health outcomes.\n\n## Conclusions\n\nThere are four main roles where pharmacists\u2019 involvement or supervision is expected by society and the individuals they serve:\n\n1. Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products.\n2. Provide effective medication therapy management.\n3. Maintain and improve professional performance.\n4. Contribute to improve effectiveness of the health-care system and public health.\n\nThese roles may vary for each individual pharmacist depending on their practice responsibilities.\n\nSpecific standards of GPP can be developed only within a national pharmacy professional organization framework.\n\nThis guidance is recommended as a set of professional goals to be met in the interest of the patients and other key stakeholders in the pharmaceutical sector. Responsibility for moving the project forward will rest with each national pharmacy professional association. Achieving specific standards of GPP for each nation within these recommendations may require considerable time and effort. As health professionals, pharmacists have a duty to begin the process without delay.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2643d1c5b2eff48b8a280049bc967eb7ce5ef3258f215564fe930877f01d619b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Function C: Comply with national professional obligations, guidelines and legislations\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should take steps to ensure that they comply with the provisions of a national code of ethics for pharmacists.\n\n# Function D: Advocate and support national policies that promote improved health outcomes\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should contribute to public and professional groups to promote, evaluate and improve health in the community.\n- Pharmacists should collaborate with other health-care professionals in their efforts to improve health outcomes.\n\n## Conclusions\n\nThere are four main roles where pharmacists\u2019 involvement or supervision is expected by society and the individuals they serve:\n\n1. Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products.\n2. Provide effective medication therapy management.\n3. Maintain and improve professional performance.\n4. Contribute to improve effectiveness of the health-care system and public health.\n\nThese roles may vary for each individual pharmacist depending on their practice responsibilities.\n\nSpecific standards of GPP can be developed only within a national pharmacy professional organization framework.\n\nThis guidance is recommended as a set of professional goals to be met in the interest of the patients and other key stakeholders in the pharmaceutical sector. Responsibility for moving the project forward will rest with each national pharmacy professional association. Achieving specific standards of GPP for each nation within these recommendations may require considerable time and effort. As health professionals, pharmacists have a duty to begin the process without delay.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1816, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ebdbacc2-1670-4315-8666-1da19fc441ba": {"__data__": {"id_": "ebdbacc2-1670-4315-8666-1da19fc441ba", "embedding": null, "metadata": {"page_label": "336", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 9\n\n## Model guidance for the storage and transport of time- and temperature\u2013sensitive pharmaceutical products\n\n- Abbreviations\n- Background\n- Key to conventions used\n- Glossary\n- Introduction\n- Key to conventions used\n\n### 1. Importation\n\n1.1 Port handling and customs clearance  \n  1.1.1 Port of entry  \n  1.1.2 Offloading  \n  1.1.3 Temporary storage at port of entry  \n  1.1.4 Customs clearance  \n\n### 2. Warehousing sites\n\n2.1 Site layout  \n  2.1.1 Natural hazards  \n  2.1.2 Site access  \n2.2 Site security  \n2.3 Site cleanliness  \n\n### 3. Storage buildings\n\n3.1 Construction standards  \n3.2 Accommodation and layout  \n3.3 Loading and receiving bays  \n  3.3.1 Loading bays  \n  3.3.2 Receiving bays  \n3.4 Goods assembly and quarantine areas  \n  3.4.1 Goods assembly areas  \n  3.4.2 Holding area for incoming goods  \n  3.4.3 Quarantine area  \n3.5 Environmental control of ancillary areas  \n3.6 Building security  \n  3.6.1 General building security  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que el contexto proporcionado puede responder, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una gu\u00eda modelo para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura. Se abordan aspectos clave como la importaci\u00f3n, el manejo en puertos, la seguridad y limpieza de los sitios de almacenamiento, as\u00ed como los est\u00e1ndares de construcci\u00f3n y control ambiental en los edificios de almacenamiento. La gu\u00eda est\u00e1 dise\u00f1ada para asegurar que estos productos se manejen adecuadamente a lo largo de toda la cadena de suministro.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la limpieza y seguridad de los sitios de almacenamiento de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta se centra en los detalles sobre las pr\u00e1cticas de limpieza y los protocolos de seguridad que deben seguirse en los sitios de almacenamiento, que son cruciales para mantener la integridad de los productos.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar un puerto de entrada para la importaci\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta busca informaci\u00f3n sobre los factores que influyen en la elecci\u00f3n de un puerto, como la infraestructura, la capacidad de manejo y las regulaciones aduaneras.\n\n3. **\u00bfQu\u00e9 \u00e1reas espec\u00edficas se deben establecer en un edificio de almacenamiento para garantizar la correcta gesti\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta se enfoca en las \u00e1reas funcionales dentro de un edificio de almacenamiento, como las zonas de cuarentena, las \u00e1reas de ensamblaje de mercanc\u00edas y las \u00e1reas de recepci\u00f3n, que son esenciales para el manejo adecuado de estos productos.", "prev_section_summary": "### Temas Clave\n\n1. **Cumplimiento de Obligaciones Profesionales**: Se enfatiza la importancia de que los farmac\u00e9uticos cumplan con un c\u00f3digo de \u00e9tica nacional y se establezcan est\u00e1ndares m\u00ednimos para estas actividades.\n\n2. **Abogac\u00eda por Pol\u00edticas de Salud**: Los farmac\u00e9uticos deben contribuir a grupos p\u00fablicos y profesionales para promover y mejorar la salud en la comunidad, as\u00ed como colaborar con otros profesionales de la salud.\n\n3. **Roles de los Farmac\u00e9uticos**: Se identifican cuatro roles principales que los farmac\u00e9uticos deben desempe\u00f1ar:\n   - Gesti\u00f3n de productos m\u00e9dicos (preparaci\u00f3n, obtenci\u00f3n, almacenamiento, distribuci\u00f3n, administraci\u00f3n, dispensaci\u00f3n y eliminaci\u00f3n).\n   - Manejo efectivo de la terapia farmacol\u00f3gica.\n   - Mantenimiento y mejora del rendimiento profesional.\n   - Contribuci\u00f3n a la efectividad del sistema de salud y la salud p\u00fablica.\n\n4. **Desarrollo de Est\u00e1ndares de Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se menciona que los est\u00e1ndares espec\u00edficos de GPP deben desarrollarse dentro del marco de organizaciones profesionales nacionales de farmacia, y que esto puede requerir tiempo y esfuerzo considerable.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento y directrices.\n- **Farmac\u00e9uticos**: Profesionales responsables de cumplir con las obligaciones \u00e9ticas y colaborar en la mejora de la salud p\u00fablica.\n- **Asociaciones Profesionales de Farmac\u00e9uticos**: Entidades responsables de establecer y promover est\u00e1ndares de GPP en sus respectivos pa\u00edses.\n\nEste resumen destaca la importancia del cumplimiento \u00e9tico y la colaboraci\u00f3n interprofesional en el \u00e1mbito farmac\u00e9utico, as\u00ed como la necesidad de establecer est\u00e1ndares claros para mejorar la atenci\u00f3n sanitaria.", "excerpt_keywords": "Keywords: pharmaceutical storage, temperature-sensitive products, importation guidelines, warehousing security, environmental control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d8dd7fbe-8bac-4591-9ace-be8504f6f024", "node_type": "4", "metadata": {"page_label": "336", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 9\n\n## Model guidance for the storage and transport of time- and temperature\u2013sensitive pharmaceutical products\n\n- Abbreviations\n- Background\n- Key to conventions used\n- Glossary\n- Introduction\n- Key to conventions used\n\n### 1. Importation\n\n1.1 Port handling and customs clearance  \n  1.1.1 Port of entry  \n  1.1.2 Offloading  \n  1.1.3 Temporary storage at port of entry  \n  1.1.4 Customs clearance  \n\n### 2. Warehousing sites\n\n2.1 Site layout  \n  2.1.1 Natural hazards  \n  2.1.2 Site access  \n2.2 Site security  \n2.3 Site cleanliness  \n\n### 3. Storage buildings\n\n3.1 Construction standards  \n3.2 Accommodation and layout  \n3.3 Loading and receiving bays  \n  3.3.1 Loading bays  \n  3.3.2 Receiving bays  \n3.4 Goods assembly and quarantine areas  \n  3.4.1 Goods assembly areas  \n  3.4.2 Holding area for incoming goods  \n  3.4.3 Quarantine area  \n3.5 Environmental control of ancillary areas  \n3.6 Building security  \n  3.6.1 General building security  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "44a71840c1837b8f2143a4dd90acb7dda56316213563c84d60f6f26cb91ab1e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 9\n\n## Model guidance for the storage and transport of time- and temperature\u2013sensitive pharmaceutical products\n\n- Abbreviations\n- Background\n- Key to conventions used\n- Glossary\n- Introduction\n- Key to conventions used\n\n### 1. Importation\n\n1.1 Port handling and customs clearance  \n  1.1.1 Port of entry  \n  1.1.2 Offloading  \n  1.1.3 Temporary storage at port of entry  \n  1.1.4 Customs clearance  \n\n### 2. Warehousing sites\n\n2.1 Site layout  \n  2.1.1 Natural hazards  \n  2.1.2 Site access  \n2.2 Site security  \n2.3 Site cleanliness  \n\n### 3. Storage buildings\n\n3.1 Construction standards  \n3.2 Accommodation and layout  \n3.3 Loading and receiving bays  \n  3.3.1 Loading bays  \n  3.3.2 Receiving bays  \n3.4 Goods assembly and quarantine areas  \n  3.4.1 Goods assembly areas  \n  3.4.2 Holding area for incoming goods  \n  3.4.3 Quarantine area  \n3.5 Environmental control of ancillary areas  \n3.6 Building security  \n  3.6.1 General building security", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 956, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "47c1a897-28bf-4b7c-9c95-0fae78c38f66": {"__data__": {"id_": "47c1a897-28bf-4b7c-9c95-0fae78c38f66", "embedding": null, "metadata": {"page_label": "337", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 3.6.2 Controlled and hazardous substances areas\n\n### 3.7 Fire protection\n- **3.7.1** Fire protection equipment\n- **3.7.2** Fire prevention, detection and control procedures\n\n### 3.8 Building hygiene\n- **3.8.1** Building cleanliness\n- **3.8.2** Pest control\n\n### 3.9 Power supply\n- **3.9.1** Uninterrupted power supply\n- **3.9.2** Power failure contingency plan\n\n### 3.10 Building maintenance\n\n## 4. Temperature-controlled storage\n\n### 4.1 Normative references\n\n### 4.2 Storage capacity of temperature-controlled stores\n\n### 4.3 Temperature-controlled storage\n\n### 4.4 Temperature-controlled storage for controlled and hazardous products\n\n### 4.5 Temperature and humidity control and monitoring in storage\n- **4.5.1** Temperature control\n- **4.5.2** Temperature monitoring\n- **4.5.3** Humidity control\n- **4.5.4** Humidity monitoring\n\n### 4.6 Alarm systems\n- **4.6.1** Temperature alarms\n- **4.6.2** Humidity alarms\n\n### 4.7 Qualification of temperature-controlled stores\n\n### 4.8 Cleanliness of temperature-controlled stores\n\n### 4.9 Refrigeration equipment maintenance\n\n### 4.10 Calibration and verification of control and monitoring devices\n- **4.10.1** Calibration of temperature control and monitoring devices\n- **4.10.2** Calibration of humidity control and monitoring devices\n- **4.10.3** Alarm equipment verification\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\n## 6. Transport and delivery\n\n### 6.1 Normative references\n\n### 6.2 Product stability profiles\n\n### 6.3 Transport route profiling and qualification\n\n### 6.4 Temperature-controlled transport\n- **6.4.1** Air and sea transport\n- **6.4.2** Temperature-controlled road vehicles operated by common carriers\n- **6.4.3** Temperature-controlled road vehicles generally\n- **6.4.4** Transport of controlled TTSPPs and TTSPPs with high illicit value", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, \"Technical Report Series 961\", aborda diversas normativas y procedimientos relacionados con la gesti\u00f3n de sustancias controladas y peligrosas, as\u00ed como el almacenamiento y transporte de productos que requieren control de temperatura. Se detallan aspectos como la protecci\u00f3n contra incendios, la higiene de los edificios, el suministro de energ\u00eda, el mantenimiento de equipos de refrigeraci\u00f3n, y la calibraci\u00f3n de dispositivos de control y monitoreo. Tambi\u00e9n se discuten las caracter\u00edsticas del transporte de productos sensibles a la temperatura, incluyendo veh\u00edculos de transporte y rutas de entrega.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la prevenci\u00f3n, detecci\u00f3n y control de incendios en \u00e1reas que manejan sustancias controladas y peligrosas?**\n   - Esta pregunta se centra en los subtemas espec\u00edficos de protecci\u00f3n contra incendios mencionados en el documento, que son cruciales para la seguridad en el manejo de sustancias peligrosas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la limpieza y el control de plagas en instalaciones que almacenan productos controlados y peligrosos?**\n   - Esta pregunta aborda la importancia de la higiene en el almacenamiento de productos sensibles, un aspecto que puede no ser ampliamente discutido en otros documentos.\n\n3. **\u00bfQu\u00e9 requisitos existen para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de control y monitoreo en almacenes de temperatura controlada?**\n   - Esta pregunta se enfoca en los procedimientos t\u00e9cnicos espec\u00edficos que garantizan la eficacia de los sistemas de control de temperatura y humedad, un tema que es fundamental para la integridad de los productos almacenados. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otros contextos o documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl **Anexo 9** del documento \"WHO - Technical Report Series 961\" proporciona una gu\u00eda modelo para el almacenamiento y transporte de productos farmac\u00e9uticos que son sensibles al tiempo y la temperatura. A continuaci\u00f3n se presentan los temas clave y entidades abordados en esta secci\u00f3n:\n\n#### Temas Clave:\n\n1. **Importaci\u00f3n**:\n   - Manejo en puertos y procesos de despacho aduanero.\n   - Consideraciones para la selecci\u00f3n del puerto de entrada, offloading, almacenamiento temporal y procedimientos de aduanas.\n\n2. **Sitios de Almacenamiento**:\n   - Dise\u00f1o y disposici\u00f3n del sitio, incluyendo la evaluaci\u00f3n de riesgos naturales y acceso al sitio.\n   - Protocolos de seguridad y limpieza necesarios para mantener la integridad de los productos.\n\n3. **Edificios de Almacenamiento**:\n   - Est\u00e1ndares de construcci\u00f3n y dise\u00f1o de las instalaciones.\n   - \u00c1reas espec\u00edficas dentro del edificio, como:\n     - **Bays de carga y recepci\u00f3n**: Espacios dedicados para la carga y descarga de productos.\n     - **\u00c1reas de ensamblaje y cuarentena**: Zonas para la preparaci\u00f3n y aislamiento de productos entrantes.\n     - **Control ambiental**: Mantenimiento de condiciones adecuadas en \u00e1reas auxiliares.\n     - **Seguridad del edificio**: Medidas generales para proteger las instalaciones.\n\n#### Entidades:\n\n- **Productos farmac\u00e9uticos**: Enfocados en aquellos sensibles al tiempo y la temperatura.\n- **Puertos de entrada**: Infraestructura cr\u00edtica para la importaci\u00f3n.\n- **Sitios de almacenamiento**: Espacios dise\u00f1ados para la conservaci\u00f3n de productos farmac\u00e9uticos.\n- **Edificios de almacenamiento**: Estructuras que deben cumplir con est\u00e1ndares espec\u00edficos para garantizar la calidad de los productos.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para asegurar que los productos farmac\u00e9uticos sensibles sean manejados adecuadamente a lo largo de toda la cadena de suministro, desde la importaci\u00f3n hasta el almacenamiento.", "excerpt_keywords": "Keywords: controlled substances, fire protection, temperature-controlled storage, building hygiene, materials handling"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a837d3a5-79e3-4cc2-9b51-17ab687b2bd1", "node_type": "4", "metadata": {"page_label": "337", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 3.6.2 Controlled and hazardous substances areas\n\n### 3.7 Fire protection\n- **3.7.1** Fire protection equipment\n- **3.7.2** Fire prevention, detection and control procedures\n\n### 3.8 Building hygiene\n- **3.8.1** Building cleanliness\n- **3.8.2** Pest control\n\n### 3.9 Power supply\n- **3.9.1** Uninterrupted power supply\n- **3.9.2** Power failure contingency plan\n\n### 3.10 Building maintenance\n\n## 4. Temperature-controlled storage\n\n### 4.1 Normative references\n\n### 4.2 Storage capacity of temperature-controlled stores\n\n### 4.3 Temperature-controlled storage\n\n### 4.4 Temperature-controlled storage for controlled and hazardous products\n\n### 4.5 Temperature and humidity control and monitoring in storage\n- **4.5.1** Temperature control\n- **4.5.2** Temperature monitoring\n- **4.5.3** Humidity control\n- **4.5.4** Humidity monitoring\n\n### 4.6 Alarm systems\n- **4.6.1** Temperature alarms\n- **4.6.2** Humidity alarms\n\n### 4.7 Qualification of temperature-controlled stores\n\n### 4.8 Cleanliness of temperature-controlled stores\n\n### 4.9 Refrigeration equipment maintenance\n\n### 4.10 Calibration and verification of control and monitoring devices\n- **4.10.1** Calibration of temperature control and monitoring devices\n- **4.10.2** Calibration of humidity control and monitoring devices\n- **4.10.3** Alarm equipment verification\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\n## 6. Transport and delivery\n\n### 6.1 Normative references\n\n### 6.2 Product stability profiles\n\n### 6.3 Transport route profiling and qualification\n\n### 6.4 Temperature-controlled transport\n- **6.4.1** Air and sea transport\n- **6.4.2** Temperature-controlled road vehicles operated by common carriers\n- **6.4.3** Temperature-controlled road vehicles generally\n- **6.4.4** Transport of controlled TTSPPs and TTSPPs with high illicit value", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "daef69a0b5d421ba84579655afceb41c87a8c4c2faf6ff6caf16d7b14edef4ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 3.6.2 Controlled and hazardous substances areas\n\n### 3.7 Fire protection\n- **3.7.1** Fire protection equipment\n- **3.7.2** Fire prevention, detection and control procedures\n\n### 3.8 Building hygiene\n- **3.8.1** Building cleanliness\n- **3.8.2** Pest control\n\n### 3.9 Power supply\n- **3.9.1** Uninterrupted power supply\n- **3.9.2** Power failure contingency plan\n\n### 3.10 Building maintenance\n\n## 4. Temperature-controlled storage\n\n### 4.1 Normative references\n\n### 4.2 Storage capacity of temperature-controlled stores\n\n### 4.3 Temperature-controlled storage\n\n### 4.4 Temperature-controlled storage for controlled and hazardous products\n\n### 4.5 Temperature and humidity control and monitoring in storage\n- **4.5.1** Temperature control\n- **4.5.2** Temperature monitoring\n- **4.5.3** Humidity control\n- **4.5.4** Humidity monitoring\n\n### 4.6 Alarm systems\n- **4.6.1** Temperature alarms\n- **4.6.2** Humidity alarms\n\n### 4.7 Qualification of temperature-controlled stores\n\n### 4.8 Cleanliness of temperature-controlled stores\n\n### 4.9 Refrigeration equipment maintenance\n\n### 4.10 Calibration and verification of control and monitoring devices\n- **4.10.1** Calibration of temperature control and monitoring devices\n- **4.10.2** Calibration of humidity control and monitoring devices\n- **4.10.3** Alarm equipment verification\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\n## 6. Transport and delivery\n\n### 6.1 Normative references\n\n### 6.2 Product stability profiles\n\n### 6.3 Transport route profiling and qualification\n\n### 6.4 Temperature-controlled transport\n- **6.4.1** Air and sea transport\n- **6.4.2** Temperature-controlled road vehicles operated by common carriers\n- **6.4.3** Temperature-controlled road vehicles generally\n- **6.4.4** Transport of controlled TTSPPs and TTSPPs with high illicit value", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1829, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "81e475a8-8919-4748-9b00-41fcebfc9d1d": {"__data__": {"id_": "81e475a8-8919-4748-9b00-41fcebfc9d1d", "embedding": null, "metadata": {"page_label": "338", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.5 Temperature and humidity control and monitoring during transit\n6.5.1 Temperature control in temperature-controlled road vehicles  \n6.5.2 Temperature monitoring in temperature-controlled road vehicles  \n6.5.3 Humidity monitoring in temperature-controlled road vehicles  \n6.5.4 Temperature monitoring in passive and active shipping containers  \n\n# 6.6 Qualification of temperature-controlled road vehicles\n\n# 6.7 Calibration and verification of transport monitoring devices\n6.7.1 Calibration of transport temperature control devices  \n6.7.2 Calibration of transport temperature monitoring devices  \n6.7.3 Calibration of transport humidity monitoring devices  \n6.7.4 Verification of transport alarm equipment  \n\n# 6.8 Shipping containers\n6.8.1 Container selection generally  \n6.8.2 Uninsulated containers  \n6.8.3 Qualification of insulated passive containers  \n6.8.4 Qualification of active containers  \n\n# 6.9 Shipping container packing\n\n# 6.10 Product handling during packing and transport\n\n# 6.11 Cleaning road vehicles and transport containers\n\n# 6.12 Transport of returned and recalled TTSPPs\n6.12.1 Transport of returned TTSPPs  \n6.12.2 Transport of recalled TTSPPs  \n\n# 7. Labelling\n7.1 Normative references  \n7.2 Labelling  \n  7.2.1 Labelling generally  \n  7.2.2 Labelling air-freighted shipments  \n\n# 8. Stock management\n8.1 Stock control systems  \n  8.1.1 General stock control systems and procedures  \n  8.1.2 Stock control procedures for controlled and hazardous TTSPPs  \n\n8.2 Incoming goods  \n  8.2.1 Product arrival checks  \n  8.2.2 Actions following arrival checks  \n\n8.3 Outgoing goods (external deliveries)  \n  8.3.1 Management of outgoing goods  \n  8.3.2 Actions following dispatch  \n\n8.4 Product complaint procedures  \n\n8.5 Suspect product procedures  \n  8.5.1 Suspect products  \n\n8.6 Product return, recall, withdrawal and disposal procedures  \n  8.6.1 Return procedures  \n  8.6.2 Recall procedures  \n  8.6.3 Disposal procedures  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda las directrices y procedimientos relacionados con el control y monitoreo de temperatura y humedad durante el transporte de productos farmac\u00e9uticos y otros productos sensibles. Se detalla la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo, la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, as\u00ed como la gesti\u00f3n de existencias y procedimientos para el manejo de productos devueltos o retirados. Tambi\u00e9n se incluyen aspectos sobre el etiquetado y la limpieza de veh\u00edculos y contenedores de transporte.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la calibraci\u00f3n de dispositivos de monitoreo de temperatura y humedad en veh\u00edculos de transporte?**\n   - Esta pregunta se centra en la secci\u00f3n 6.7 del documento, que detalla la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar contenedores de env\u00edo para productos que requieren control de temperatura?**\n   - Esta pregunta se relaciona con la secci\u00f3n 6.8, que aborda la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, tanto aislados como no aislados.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse tras la llegada de productos a un almac\u00e9n seg\u00fan las directrices del informe?**\n   - Esta pregunta se refiere a la secci\u00f3n 8.2, que describe los procedimientos de verificaci\u00f3n y acciones a seguir despu\u00e9s de la llegada de productos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"Technical Report Series 961\" de la OMS aborda varios aspectos cr\u00edticos relacionados con la gesti\u00f3n de sustancias controladas y peligrosas, as\u00ed como el almacenamiento y transporte de productos que requieren control de temperatura. A continuaci\u00f3n se presentan los temas clave y las entidades relevantes de la secci\u00f3n:\n\n#### Temas Clave:\n\n1. **\u00c1reas de Sustancias Controladas y Peligrosas**:\n   - Normativas y procedimientos para el manejo seguro de sustancias peligrosas.\n\n2. **Protecci\u00f3n Contra Incendios**:\n   - Equipos de protecci\u00f3n contra incendios.\n   - Procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios.\n\n3. **Higiene de Edificios**:\n   - Limpieza de instalaciones.\n   - Control de plagas.\n\n4. **Suministro de Energ\u00eda**:\n   - Provisi\u00f3n de energ\u00eda ininterrumpida.\n   - Planes de contingencia ante fallos de energ\u00eda.\n\n5. **Mantenimiento de Edificios**:\n   - Estrategias para el mantenimiento adecuado de las instalaciones.\n\n6. **Almacenamiento Controlado por Temperatura**:\n   - Referencias normativas y capacidad de almacenamiento.\n   - Control y monitoreo de temperatura y humedad.\n   - Sistemas de alarma para temperatura y humedad.\n   - Mantenimiento de equipos de refrigeraci\u00f3n.\n   - Calibraci\u00f3n y verificaci\u00f3n de dispositivos de control.\n\n7. **Manejo de Materiales**:\n   - Equipos utilizados para el manejo de materiales.\n\n8. **Transporte y Entrega**:\n   - Referencias normativas y perfiles de estabilidad de productos.\n   - Calificaci\u00f3n de rutas de transporte.\n   - Transporte controlado por temperatura, incluyendo veh\u00edculos y m\u00e9todos de transporte.\n\n#### Entidades Relevantes:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las normativas.\n- **Sustancias Controladas y Peligrosas**: Productos que requieren manejo especial.\n- **Equipos de Protecci\u00f3n Contra Incendios**: Herramientas y dispositivos para la seguridad contra incendios.\n- **Dispositivos de Control y Monitoreo**: Equipos utilizados para asegurar condiciones adecuadas de almacenamiento.\n- **Veh\u00edculos de Transporte Controlado por Temperatura**: Medios de transporte dise\u00f1ados para mantener condiciones espec\u00edficas de temperatura.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes tratados en la secci\u00f3n, destacando la importancia de la seguridad, la higiene y el control en el manejo de sustancias sensibles y peligrosas.", "excerpt_keywords": "Keywords: temperature control, humidity monitoring, shipping containers, stock management, calibration procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dc722788-7530-4bcf-999e-db8ae7c6a668", "node_type": "4", "metadata": {"page_label": "338", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.5 Temperature and humidity control and monitoring during transit\n6.5.1 Temperature control in temperature-controlled road vehicles  \n6.5.2 Temperature monitoring in temperature-controlled road vehicles  \n6.5.3 Humidity monitoring in temperature-controlled road vehicles  \n6.5.4 Temperature monitoring in passive and active shipping containers  \n\n# 6.6 Qualification of temperature-controlled road vehicles\n\n# 6.7 Calibration and verification of transport monitoring devices\n6.7.1 Calibration of transport temperature control devices  \n6.7.2 Calibration of transport temperature monitoring devices  \n6.7.3 Calibration of transport humidity monitoring devices  \n6.7.4 Verification of transport alarm equipment  \n\n# 6.8 Shipping containers\n6.8.1 Container selection generally  \n6.8.2 Uninsulated containers  \n6.8.3 Qualification of insulated passive containers  \n6.8.4 Qualification of active containers  \n\n# 6.9 Shipping container packing\n\n# 6.10 Product handling during packing and transport\n\n# 6.11 Cleaning road vehicles and transport containers\n\n# 6.12 Transport of returned and recalled TTSPPs\n6.12.1 Transport of returned TTSPPs  \n6.12.2 Transport of recalled TTSPPs  \n\n# 7. Labelling\n7.1 Normative references  \n7.2 Labelling  \n  7.2.1 Labelling generally  \n  7.2.2 Labelling air-freighted shipments  \n\n# 8. Stock management\n8.1 Stock control systems  \n  8.1.1 General stock control systems and procedures  \n  8.1.2 Stock control procedures for controlled and hazardous TTSPPs  \n\n8.2 Incoming goods  \n  8.2.1 Product arrival checks  \n  8.2.2 Actions following arrival checks  \n\n8.3 Outgoing goods (external deliveries)  \n  8.3.1 Management of outgoing goods  \n  8.3.2 Actions following dispatch  \n\n8.4 Product complaint procedures  \n\n8.5 Suspect product procedures  \n  8.5.1 Suspect products  \n\n8.6 Product return, recall, withdrawal and disposal procedures  \n  8.6.1 Return procedures  \n  8.6.2 Recall procedures  \n  8.6.3 Disposal procedures  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b27c7f34e2e94239c8eba2e5b4d979d6b7f85d51fae5ef3807da8dcdec904af8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.5 Temperature and humidity control and monitoring during transit\n6.5.1 Temperature control in temperature-controlled road vehicles  \n6.5.2 Temperature monitoring in temperature-controlled road vehicles  \n6.5.3 Humidity monitoring in temperature-controlled road vehicles  \n6.5.4 Temperature monitoring in passive and active shipping containers  \n\n# 6.6 Qualification of temperature-controlled road vehicles\n\n# 6.7 Calibration and verification of transport monitoring devices\n6.7.1 Calibration of transport temperature control devices  \n6.7.2 Calibration of transport temperature monitoring devices  \n6.7.3 Calibration of transport humidity monitoring devices  \n6.7.4 Verification of transport alarm equipment  \n\n# 6.8 Shipping containers\n6.8.1 Container selection generally  \n6.8.2 Uninsulated containers  \n6.8.3 Qualification of insulated passive containers  \n6.8.4 Qualification of active containers  \n\n# 6.9 Shipping container packing\n\n# 6.10 Product handling during packing and transport\n\n# 6.11 Cleaning road vehicles and transport containers\n\n# 6.12 Transport of returned and recalled TTSPPs\n6.12.1 Transport of returned TTSPPs  \n6.12.2 Transport of recalled TTSPPs  \n\n# 7. Labelling\n7.1 Normative references  \n7.2 Labelling  \n  7.2.1 Labelling generally  \n  7.2.2 Labelling air-freighted shipments  \n\n# 8. Stock management\n8.1 Stock control systems  \n  8.1.1 General stock control systems and procedures  \n  8.1.2 Stock control procedures for controlled and hazardous TTSPPs  \n\n8.2 Incoming goods  \n  8.2.1 Product arrival checks  \n  8.2.2 Actions following arrival checks  \n\n8.3 Outgoing goods (external deliveries)  \n  8.3.1 Management of outgoing goods  \n  8.3.2 Actions following dispatch  \n\n8.4 Product complaint procedures  \n\n8.5 Suspect product procedures  \n  8.5.1 Suspect products  \n\n8.6 Product return, recall, withdrawal and disposal procedures  \n  8.6.1 Return procedures  \n  8.6.2 Recall procedures  \n  8.6.3 Disposal procedures", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1951, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "48c37ecc-1564-4833-ac64-47499fe8b50c": {"__data__": {"id_": "48c37ecc-1564-4833-ac64-47499fe8b50c", "embedding": null, "metadata": {"page_label": "339", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. General procedures and record-keeping\n\n9.1 Emergencies and contingency planning  \n9.2 General record-keeping  \n    9.2.1 Record-keeping  \n    9.2.2 Content of records  \n    9.2.3 Record review and retention  \n9.3 Temperature and humidity records  \n    9.3.1 Temperature records  \n    9.3.2 Humidity records  \n\n# 10. Environmental management\n\n10.1 Normative references  \n10.2 Environmental management of refrigeration equipment  \n\n# 11. Quality management\n\n11.1 Normative references  \n11.2 Organizational structure  \n11.3 Quality systems  \n    11.3.1 Quality system  \n    11.3.2 Self inspections  \n    11.3.3 Contractors subject to service level agreements  \n11.4 Management of documents and standard operating procedures  \n    11.4.1 Standard operating procedures  \n11.5 Document control  \n\n# 12. Personnel/training\n\n12.1 Training  \n    12.1.1 General training  \n    12.1.2 Specialist training  \n\nKey references  \n\nFurther reading  \n\nTask force membership  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda procedimientos generales y mantenimiento de registros, gesti\u00f3n ambiental, gesti\u00f3n de calidad y formaci\u00f3n del personal en el contexto de la salud p\u00fablica. Se detallan aspectos como la planificaci\u00f3n de emergencias, el mantenimiento de registros de temperatura y humedad, la gesti\u00f3n de equipos de refrigeraci\u00f3n, y la estructura organizativa necesaria para asegurar la calidad. Tambi\u00e9n se menciona la importancia de la formaci\u00f3n general y especializada del personal involucrado en estos procesos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en los registros de temperatura y humedad seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los requisitos de registro que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos se sugieren para la gesti\u00f3n de documentos y procedimientos operativos est\u00e1ndar en el contexto de la gesti\u00f3n de calidad?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se deben seguir para asegurar la calidad en la documentaci\u00f3n, lo cual es crucial para la implementaci\u00f3n efectiva de sistemas de calidad.\n\n3. **\u00bfQu\u00e9 tipo de formaci\u00f3n se recomienda para el personal involucrado en la gesti\u00f3n ambiental y de calidad, y c\u00f3mo se diferencia entre la formaci\u00f3n general y la especializada?**\n   - Esta pregunta busca informaci\u00f3n sobre los enfoques de formaci\u00f3n que se deben adoptar, lo que puede ser esencial para la capacitaci\u00f3n efectiva del personal en estos \u00e1mbitos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Control y Monitoreo de Temperatura y Humedad**:\n   - Secci\u00f3n 6.5 aborda el control y monitoreo de temperatura y humedad durante el transporte, incluyendo veh\u00edculos de carretera y contenedores de env\u00edo.\n\n2. **Calificaci\u00f3n de Veh\u00edculos de Transporte**:\n   - Secci\u00f3n 6.6 se centra en la calificaci\u00f3n de veh\u00edculos de transporte que mantienen condiciones de temperatura controlada.\n\n3. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos**:\n   - Secci\u00f3n 6.7 detalla los procedimientos para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo de temperatura y humedad, as\u00ed como equipos de alarma.\n\n4. **Contenedores de Env\u00edo**:\n   - Secci\u00f3n 6.8 trata sobre la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, diferenciando entre contenedores aislados y no aislados.\n\n5. **Manejo de Productos**:\n   - Secciones 6.9 a 6.12 abordan el empaquetado de contenedores, manejo de productos durante el transporte, limpieza de veh\u00edculos y contenedores, y el transporte de productos devueltos o retirados.\n\n6. **Etiquetado**:\n   - Secci\u00f3n 7 se refiere a las referencias normativas y procedimientos de etiquetado, incluyendo env\u00edos por aire.\n\n7. **Gesti\u00f3n de Existencias**:\n   - Secci\u00f3n 8 cubre sistemas de control de existencias, procedimientos para la llegada y salida de productos, manejo de quejas y procedimientos para productos sospechosos, as\u00ed como devoluciones y retiradas.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y otros productos sensibles al transporte.\n- **Dispositivos de Monitoreo**: Equipos utilizados para controlar temperatura y humedad.\n- **Contenedores de Env\u00edo**: Estructuras utilizadas para el transporte de productos, que pueden ser activos o pasivos.\n- **Veh\u00edculos de Transporte**: Medios de transporte que requieren control de temperatura.\n- **Procedimientos de Gesti\u00f3n**: Protocolos para el manejo de productos, incluyendo devoluciones y quejas.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de la gesti\u00f3n adecuada de productos sensibles durante el transporte.", "excerpt_keywords": "Keywords: record-keeping, environmental management, quality management, training, emergencies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b41dd8a2-cec6-4dee-b6bf-5e7666b7404b", "node_type": "4", "metadata": {"page_label": "339", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. General procedures and record-keeping\n\n9.1 Emergencies and contingency planning  \n9.2 General record-keeping  \n    9.2.1 Record-keeping  \n    9.2.2 Content of records  \n    9.2.3 Record review and retention  \n9.3 Temperature and humidity records  \n    9.3.1 Temperature records  \n    9.3.2 Humidity records  \n\n# 10. Environmental management\n\n10.1 Normative references  \n10.2 Environmental management of refrigeration equipment  \n\n# 11. Quality management\n\n11.1 Normative references  \n11.2 Organizational structure  \n11.3 Quality systems  \n    11.3.1 Quality system  \n    11.3.2 Self inspections  \n    11.3.3 Contractors subject to service level agreements  \n11.4 Management of documents and standard operating procedures  \n    11.4.1 Standard operating procedures  \n11.5 Document control  \n\n# 12. Personnel/training\n\n12.1 Training  \n    12.1.1 General training  \n    12.1.2 Specialist training  \n\nKey references  \n\nFurther reading  \n\nTask force membership  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3fe414730630b683627661f1e61375e806c4d451f54b239d4c44409f3fcd3961", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9. General procedures and record-keeping\n\n9.1 Emergencies and contingency planning  \n9.2 General record-keeping  \n    9.2.1 Record-keeping  \n    9.2.2 Content of records  \n    9.2.3 Record review and retention  \n9.3 Temperature and humidity records  \n    9.3.1 Temperature records  \n    9.3.2 Humidity records  \n\n# 10. Environmental management\n\n10.1 Normative references  \n10.2 Environmental management of refrigeration equipment  \n\n# 11. Quality management\n\n11.1 Normative references  \n11.2 Organizational structure  \n11.3 Quality systems  \n    11.3.1 Quality system  \n    11.3.2 Self inspections  \n    11.3.3 Contractors subject to service level agreements  \n11.4 Management of documents and standard operating procedures  \n    11.4.1 Standard operating procedures  \n11.5 Document control  \n\n# 12. Personnel/training\n\n12.1 Training  \n    12.1.1 General training  \n    12.1.2 Specialist training  \n\nKey references  \n\nFurther reading  \n\nTask force membership", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 960, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "dadbf5a0-7a85-40bc-831f-34ebe40a71c2": {"__data__": {"id_": "dadbf5a0-7a85-40bc-831f-34ebe40a71c2", "embedding": null, "metadata": {"page_label": "340", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Abbreviations\n\n| Abbreviation | Description |\n|--------------|-------------|\n| CAPA         | corrective and preventive action (procedures) |\n| DCVMN        | Developing Countries Vaccine Manufacturers Network |\n| EEFO         | earliest-expiry-first-out. Used in this document as equivalent to FEFO (first to expire-first-out) |\n| FIFO         | first-in-first-out |\n| GDP          | good distribution practice |\n| GMP          | good manufacturing practice |\n| GPS          | global positioning system |\n| GSP          | good storage practice |\n| HVAC         | heating ventilating and air-conditioning (system) |\n| IATA         | International Air Transport Association |\n| IFPMA        | International Federation of Pharmaceutical Manufacturers and Associations |\n| IQ           | installation qualification |\n| PCCIG        | Pharmaceutical Cold Chain Interest Group |\n| PDA          | Parenteral Drug Association |\n| SKU          | stock-keeping unit |\n| SLA          | service level agreement |\n| SMS          | short message service |\n| SOP          | standard operating procedure |\n| TTSPP        | time- and temperature-sensitive pharmaceutical product |\n| UPS          | uninterrupted power supply |\n| USP          | United States Pharmacopeia |\n\n# Background\n\nThese guidelines set out the principal requirements for the safe storage and distribution of time- and temperature-sensitive pharmaceutical products (TTSPPs). They are based upon existing regulations and best practice guidance from a wide range of international sources (see References), while accepting that local legislation and regulations will continue to take precedence. The target audience includes regulators, logisticians and pharmaceutical professionals in industry, government and the international agencies.\n\nThe document has been prepared in close consultation with the WHO Task Force on Regulatory Oversight on Pharmaceutical Cold Chain Management which has been central to the review process. A full list of members is given at the end of this annex.\n\nThe intention is that the guidance in this document should be directly applicable in less-developed countries as well as in the industrialized world. To this end, supplementary materials will be developed to show", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento \"WHO - Technical Report Series 961\" establece directrices sobre los requisitos principales para el almacenamiento y distribuci\u00f3n seguros de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs). Estas directrices se basan en regulaciones existentes y mejores pr\u00e1cticas de diversas fuentes internacionales, reconociendo que la legislaci\u00f3n local tiene prioridad. Est\u00e1 dirigido a reguladores, logistas y profesionales farmac\u00e9uticos en diferentes sectores. Se ha elaborado en consulta con el Grupo de Trabajo de la OMS sobre Supervisi\u00f3n Regulatoria en la Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica, y se busca que sea aplicable tanto en pa\u00edses en desarrollo como en el mundo industrializado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias en las regulaciones de almacenamiento y distribuci\u00f3n de TTSPPs entre pa\u00edses en desarrollo y pa\u00edses industrializados, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre c\u00f3mo las directrices se adaptan a diferentes contextos regulatorios y log\u00edsticos.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el Grupo de Inter\u00e9s de la Cadena de Fr\u00edo Farmac\u00e9utica (PCCIG) en la elaboraci\u00f3n de estas directrices y cu\u00e1les son sus principales recomendaciones?**\n   - Esta pregunta se centra en el papel de un grupo espec\u00edfico mencionado en el documento y sus contribuciones a las directrices.\n\n3. **\u00bfQu\u00e9 materiales suplementarios se planean desarrollar para facilitar la implementaci\u00f3n de estas directrices en pa\u00edses menos desarrollados?**\n   - Esta pregunta busca detalles sobre los recursos adicionales que se ofrecer\u00e1n para ayudar a la aplicaci\u00f3n de las directrices en contextos espec\u00edficos.\n\n### Resumen de Nivel Superior\n\nEl documento proporciona un marco para la gesti\u00f3n segura de productos farmac\u00e9uticos sensibles a la temperatura, destacando la importancia de seguir regulaciones y mejores pr\u00e1cticas internacionales. Se enfoca en la necesidad de que estas directrices sean aplicables en diversas realidades, desde pa\u00edses en desarrollo hasta naciones industrializadas, y enfatiza la colaboraci\u00f3n con organismos internacionales y grupos de inter\u00e9s en el sector farmac\u00e9utico.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Procedimientos Generales y Mantenimiento de Registros**:\n   - **Planificaci\u00f3n de Emergencias**: Estrategias para manejar situaciones cr\u00edticas.\n   - **Mantenimiento de Registros**: Incluye la creaci\u00f3n, contenido, revisi\u00f3n y retenci\u00f3n de registros.\n   - **Registros de Temperatura y Humedad**: Importancia de llevar un control adecuado de estos par\u00e1metros.\n\n2. **Gesti\u00f3n Ambiental**:\n   - **Referencias Normativas**: Normas y regulaciones que gu\u00edan la gesti\u00f3n ambiental.\n   - **Gesti\u00f3n de Equipos de Refrigeraci\u00f3n**: Pr\u00e1cticas para asegurar el funcionamiento adecuado y sostenible de estos equipos.\n\n3. **Gesti\u00f3n de Calidad**:\n   - **Estructura Organizativa**: Organizaci\u00f3n necesaria para implementar sistemas de calidad.\n   - **Sistemas de Calidad**: Incluye autoinspecciones y acuerdos de nivel de servicio con contratistas.\n   - **Gesti\u00f3n de Documentos y Procedimientos Operativos Est\u00e1ndar**: Importancia de tener procedimientos claros y controlados.\n\n4. **Formaci\u00f3n del Personal**:\n   - **Capacitaci\u00f3n General y Especializada**: Diferenciaci\u00f3n entre los tipos de formaci\u00f3n que se deben proporcionar al personal involucrado en la gesti\u00f3n ambiental y de calidad.\n\n### Entidades Clave:\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Registros de Temperatura y Humedad**: Elementos cr\u00edticos para la gesti\u00f3n de calidad y seguridad.\n- **Equipos de Refrigeraci\u00f3n**: Elementos que requieren gesti\u00f3n ambiental adecuada.\n- **Sistemas de Calidad**: Estructuras y procedimientos que aseguran la calidad en procesos de salud p\u00fablica.\n- **Personal**: Recurso humano que necesita formaci\u00f3n adecuada para cumplir con los est\u00e1ndares establecidos. \n\nEste resumen destaca los componentes esenciales y las entidades relevantes en el contexto de la salud p\u00fablica seg\u00fan el documento \"WHO - Technical Report Series 961\".", "excerpt_keywords": "Keywords: pharmaceutical products, cold chain management, storage guidelines, temperature-sensitive, regulatory oversight"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e7dec974-a9c1-46e0-9321-c694daf0faf3", "node_type": "4", "metadata": {"page_label": "340", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Abbreviations\n\n| Abbreviation | Description |\n|--------------|-------------|\n| CAPA         | corrective and preventive action (procedures) |\n| DCVMN        | Developing Countries Vaccine Manufacturers Network |\n| EEFO         | earliest-expiry-first-out. Used in this document as equivalent to FEFO (first to expire-first-out) |\n| FIFO         | first-in-first-out |\n| GDP          | good distribution practice |\n| GMP          | good manufacturing practice |\n| GPS          | global positioning system |\n| GSP          | good storage practice |\n| HVAC         | heating ventilating and air-conditioning (system) |\n| IATA         | International Air Transport Association |\n| IFPMA        | International Federation of Pharmaceutical Manufacturers and Associations |\n| IQ           | installation qualification |\n| PCCIG        | Pharmaceutical Cold Chain Interest Group |\n| PDA          | Parenteral Drug Association |\n| SKU          | stock-keeping unit |\n| SLA          | service level agreement |\n| SMS          | short message service |\n| SOP          | standard operating procedure |\n| TTSPP        | time- and temperature-sensitive pharmaceutical product |\n| UPS          | uninterrupted power supply |\n| USP          | United States Pharmacopeia |\n\n# Background\n\nThese guidelines set out the principal requirements for the safe storage and distribution of time- and temperature-sensitive pharmaceutical products (TTSPPs). They are based upon existing regulations and best practice guidance from a wide range of international sources (see References), while accepting that local legislation and regulations will continue to take precedence. The target audience includes regulators, logisticians and pharmaceutical professionals in industry, government and the international agencies.\n\nThe document has been prepared in close consultation with the WHO Task Force on Regulatory Oversight on Pharmaceutical Cold Chain Management which has been central to the review process. A full list of members is given at the end of this annex.\n\nThe intention is that the guidance in this document should be directly applicable in less-developed countries as well as in the industrialized world. To this end, supplementary materials will be developed to show", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8c97946e88cc2807bb857b740ef53f0c9021df39759b99c2a4784a9ac46c417d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Abbreviations\n\n| Abbreviation | Description |\n|--------------|-------------|\n| CAPA         | corrective and preventive action (procedures) |\n| DCVMN        | Developing Countries Vaccine Manufacturers Network |\n| EEFO         | earliest-expiry-first-out. Used in this document as equivalent to FEFO (first to expire-first-out) |\n| FIFO         | first-in-first-out |\n| GDP          | good distribution practice |\n| GMP          | good manufacturing practice |\n| GPS          | global positioning system |\n| GSP          | good storage practice |\n| HVAC         | heating ventilating and air-conditioning (system) |\n| IATA         | International Air Transport Association |\n| IFPMA        | International Federation of Pharmaceutical Manufacturers and Associations |\n| IQ           | installation qualification |\n| PCCIG        | Pharmaceutical Cold Chain Interest Group |\n| PDA          | Parenteral Drug Association |\n| SKU          | stock-keeping unit |\n| SLA          | service level agreement |\n| SMS          | short message service |\n| SOP          | standard operating procedure |\n| TTSPP        | time- and temperature-sensitive pharmaceutical product |\n| UPS          | uninterrupted power supply |\n| USP          | United States Pharmacopeia |\n\n# Background\n\nThese guidelines set out the principal requirements for the safe storage and distribution of time- and temperature-sensitive pharmaceutical products (TTSPPs). They are based upon existing regulations and best practice guidance from a wide range of international sources (see References), while accepting that local legislation and regulations will continue to take precedence. The target audience includes regulators, logisticians and pharmaceutical professionals in industry, government and the international agencies.\n\nThe document has been prepared in close consultation with the WHO Task Force on Regulatory Oversight on Pharmaceutical Cold Chain Management which has been central to the review process. A full list of members is given at the end of this annex.\n\nThe intention is that the guidance in this document should be directly applicable in less-developed countries as well as in the industrialized world. To this end, supplementary materials will be developed to show", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2253, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce447c5-e03d-458c-96e5-4fce75c00442": {"__data__": {"id_": "7ce447c5-e03d-458c-96e5-4fce75c00442", "embedding": null, "metadata": {"page_label": "341", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key to conventions used\n\nThe following conventions are used in the requirements clauses:\n\n- The imperative voice is used to denote a mandatory or highly desirable requirement. For example: \u201cEnsure that\u2026\u201d, \u201cProvide\u2026\u201d and the like.\n- The words \u201cwhere possible\u201d or \u201cpreferably\u201d are used to denote an optional but desirable requirement.\n- Many clauses are followed by a brief explanation setting out the underlying reason for including the clause.\n\n# Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**active systems**  \nActively powered systems using electricity or other fuel source to maintain a temperature-controlled environment inside an insulated enclosure under thermostatic regulation (e.g. cold rooms, refrigerators, temperature-controlled trucks, refrigerated ocean and air containers).\n\n**change control**  \nThe processes and procedures to manage system changes.\n\n**common carrier**  \nA seller of distribution services.\n\n**controlled or hazardous time- and temperature-sensitive pharmaceutical products**  \nTime- and temperature-sensitive pharmaceutical products (TTSPPs) with high illicit value: poisons, narcotics, psychotropic products, inflammable or explosive substances and radioactive materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la OMS que establece directrices sobre el manejo de productos farmac\u00e9uticos sensibles al tiempo y la temperatura. Se utilizan convenciones espec\u00edficas para denotar requisitos obligatorios y opcionales, y se proporciona un glosario de t\u00e9rminos clave relacionados con sistemas activos, control de cambios, transportistas comunes y productos farmac\u00e9uticos peligrosos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de sistemas se consideran \"sistemas activos\" seg\u00fan las directrices de la OMS?**\n   - Respuesta: Los \"sistemas activos\" son aquellos que utilizan electricidad u otra fuente de combustible para mantener un ambiente controlado en temperatura dentro de un recinto aislado bajo regulaci\u00f3n termost\u00e1tica, como c\u00e1maras fr\u00edas, refrigeradores y camiones de temperatura controlada.\n\n2. **\u00bfCu\u00e1l es la importancia del \"control de cambios\" en el contexto de la gesti\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Respuesta: El \"control de cambios\" se refiere a los procesos y procedimientos necesarios para gestionar cambios en los sistemas, lo cual es crucial para garantizar la integridad y seguridad de los productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n\n3. **\u00bfQu\u00e9 se entiende por \"productos farmac\u00e9uticos controlados o peligrosos\" en el contexto de este informe?**\n   - Respuesta: Los \"productos farmac\u00e9uticos controlados o peligrosos\" son aquellos productos farmac\u00e9uticos sensibles al tiempo y la temperatura que tienen un alto valor il\u00edcito, incluyendo sustancias como venenos, narc\u00f3ticos, productos psicotr\u00f3picos, sustancias inflamables o explosivas y materiales radiactivos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Directrices para TTSPPs:** El documento establece requisitos para el almacenamiento y distribuci\u00f3n seguros de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs).\n2. **Regulaciones y Mejores Pr\u00e1cticas:** Se basa en regulaciones existentes y mejores pr\u00e1cticas de diversas fuentes internacionales, reconociendo la primac\u00eda de la legislaci\u00f3n local.\n3. **Audiencia Objetivo:** Est\u00e1 dirigido a reguladores, logistas y profesionales farmac\u00e9uticos en la industria, el gobierno y agencias internacionales.\n4. **Colaboraci\u00f3n con la OMS:** Se elabor\u00f3 en consulta con el Grupo de Trabajo de la OMS sobre Supervisi\u00f3n Regulatoria en la Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica.\n5. **Aplicabilidad Global:** Las directrices buscan ser aplicables tanto en pa\u00edses en desarrollo como en el mundo industrializado, con planes para desarrollar materiales suplementarios.\n\n**Entidades Mencionadas:**\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Organismo que proporciona las directrices.\n- **PCCIG (Pharmaceutical Cold Chain Interest Group):** Grupo que ha colaborado en la elaboraci\u00f3n de las directrices.\n- **DCVMN (Developing Countries Vaccine Manufacturers Network):** Red de fabricantes de vacunas en pa\u00edses en desarrollo.\n- **IFPMA (International Federation of Pharmaceutical Manufacturers and Associations):** Federaci\u00f3n internacional de fabricantes de productos farmac\u00e9uticos.\n- **PDA (Parenteral Drug Association):** Asociaci\u00f3n que se enfoca en productos farmac\u00e9uticos parenterales.\n\nEste resumen destaca la importancia de las directrices para la gesti\u00f3n de productos farmac\u00e9uticos sensibles y la colaboraci\u00f3n internacional necesaria para su implementaci\u00f3n efectiva.", "excerpt_keywords": "Keywords: pharmaceutical guidelines, temperature-sensitive products, active systems, change control, hazardous materials"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "681e3c2f-a98e-499d-b892-683be2ab6287", "node_type": "4", "metadata": {"page_label": "341", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key to conventions used\n\nThe following conventions are used in the requirements clauses:\n\n- The imperative voice is used to denote a mandatory or highly desirable requirement. For example: \u201cEnsure that\u2026\u201d, \u201cProvide\u2026\u201d and the like.\n- The words \u201cwhere possible\u201d or \u201cpreferably\u201d are used to denote an optional but desirable requirement.\n- Many clauses are followed by a brief explanation setting out the underlying reason for including the clause.\n\n# Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**active systems**  \nActively powered systems using electricity or other fuel source to maintain a temperature-controlled environment inside an insulated enclosure under thermostatic regulation (e.g. cold rooms, refrigerators, temperature-controlled trucks, refrigerated ocean and air containers).\n\n**change control**  \nThe processes and procedures to manage system changes.\n\n**common carrier**  \nA seller of distribution services.\n\n**controlled or hazardous time- and temperature-sensitive pharmaceutical products**  \nTime- and temperature-sensitive pharmaceutical products (TTSPPs) with high illicit value: poisons, narcotics, psychotropic products, inflammable or explosive substances and radioactive materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1d755f2d7c2d4ce67ae105a68637836ecc069815da3ebe5bac113d221feeaa63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Key to conventions used\n\nThe following conventions are used in the requirements clauses:\n\n- The imperative voice is used to denote a mandatory or highly desirable requirement. For example: \u201cEnsure that\u2026\u201d, \u201cProvide\u2026\u201d and the like.\n- The words \u201cwhere possible\u201d or \u201cpreferably\u201d are used to denote an optional but desirable requirement.\n- Many clauses are followed by a brief explanation setting out the underlying reason for including the clause.\n\n# Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**active systems**  \nActively powered systems using electricity or other fuel source to maintain a temperature-controlled environment inside an insulated enclosure under thermostatic regulation (e.g. cold rooms, refrigerators, temperature-controlled trucks, refrigerated ocean and air containers).\n\n**change control**  \nThe processes and procedures to manage system changes.\n\n**common carrier**  \nA seller of distribution services.\n\n**controlled or hazardous time- and temperature-sensitive pharmaceutical products**  \nTime- and temperature-sensitive pharmaceutical products (TTSPPs) with high illicit value: poisons, narcotics, psychotropic products, inflammable or explosive substances and radioactive materials.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1299, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "22ff7347-4f6d-4bb4-b176-20e7c2a8ee3a": {"__data__": {"id_": "22ff7347-4f6d-4bb4-b176-20e7c2a8ee3a", "embedding": null, "metadata": {"page_label": "342", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dunnage\n\nLoose packing material used to protect TTSPPs from damage during transport.\n\n# external distribution\n\nTransport of TTSPPs through various steps in the customer\u2019s supply chain (i.e. transport from a pharmaceutical manufacturer\u2019s distribution centre to commercial customers (including wholesalers, retailers and buying groups), to clinical facilities or direct to the patient).\n\n# installation qualification\n\nThe process of obtaining and documenting evidence that equipment has been provided and installed in accordance with its specifications and that it functions within predetermined limits when operated in accordance with the operating instructions.\n\n# internal distribution\n\nTransport of a TTSPP within a pharmaceutical manufacturer\u2019s internal supply chain (i.e. all internal transports from manufacturing facility to packaging facility to warehouse to distribution centre).\n\n# net storage capacity\n\nThe total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n\n# passive systems\n\nSystems which maintain a temperature-controlled environment inside an insulated enclosure, with or without thermostatic regulation, using a finite amount of pre-conditioned coolant in the form of chilled or frozen gel packs, phase change materials, dry ice or others.\n\n# pests\n\nIncludes birds, bats, rodents and insects whose uncontrolled presence affects hygiene and cleanliness.\n\n# pharmaceutical product\n\nAny product intended for human use or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, that is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices. \n\n----\n\n1 Definition from *Revision of WHO good distribution practices for pharmaceutical products*. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 5.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda las buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos, definiendo t\u00e9rminos clave relacionados con el transporte y almacenamiento de productos farmac\u00e9uticos. Se discuten conceptos como \"dunnage\" (material de embalaje suelto), \"distribuci\u00f3n externa\" e \"interna\", \"calificaci\u00f3n de instalaci\u00f3n\", \"capacidad de almacenamiento neta\", \"sistemas pasivos\", \"plagas\" y \"producto farmac\u00e9utico\". Estas definiciones son esenciales para garantizar la integridad y seguridad de los productos durante su transporte y almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben cumplir para que un equipo sea considerado instalado correctamente seg\u00fan el proceso de calificaci\u00f3n de instalaci\u00f3n?**\n   - Esta pregunta busca detalles sobre los requisitos espec\u00edficos que deben documentarse para validar la instalaci\u00f3n de equipos en el contexto de la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las implicaciones de la presencia de plagas en el transporte y almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en las consecuencias que pueden derivarse de la presencia de plagas y c\u00f3mo pueden afectar la higiene y la calidad de los productos farmac\u00e9uticos.\n\n3. **\u00bfC\u00f3mo se determina la capacidad de almacenamiento neta en un almac\u00e9n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca una explicaci\u00f3n sobre los factores que se consideran al calcular la capacidad de almacenamiento, incluyendo el tipo de sistema de soporte de carga y el factor de utilizaci\u00f3n.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en las definiciones y conceptos presentados en el documento de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Convenciones de Requisitos**:\n   - Se utilizan diferentes voces para indicar la obligatoriedad o deseabilidad de los requisitos en las directrices.\n   - La voz imperativa se\u00f1ala requisitos obligatorios, mientras que expresiones como \"donde sea posible\" indican requisitos opcionales pero deseables.\n\n2. **Glosario de T\u00e9rminos**:\n   - **Sistemas Activos**: Sistemas que utilizan electricidad o combustibles para mantener un ambiente controlado en temperatura, como c\u00e1maras fr\u00edas y camiones refrigerados.\n   - **Control de Cambios**: Procesos y procedimientos para gestionar cambios en los sistemas, esenciales para la seguridad de los productos farmac\u00e9uticos.\n   - **Transportista Com\u00fan**: Vendedor de servicios de distribuci\u00f3n.\n   - **Productos Farmac\u00e9uticos Controlados o Peligrosos**: Productos farmac\u00e9uticos sensibles al tiempo y la temperatura con alto valor il\u00edcito, incluyendo venenos, narc\u00f3ticos y materiales radiactivos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Incluyen productos sensibles al tiempo y la temperatura.\n- **Sistemas de Refrigeraci\u00f3n**: Ejemplos de sistemas activos mencionados en el documento.\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes que se presentan en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: dunnage, external distribution, installation qualification, net storage capacity, pharmaceutical product"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f7a0ac2e-2396-47b1-a62e-a4aca54ce7aa", "node_type": "4", "metadata": {"page_label": "342", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dunnage\n\nLoose packing material used to protect TTSPPs from damage during transport.\n\n# external distribution\n\nTransport of TTSPPs through various steps in the customer\u2019s supply chain (i.e. transport from a pharmaceutical manufacturer\u2019s distribution centre to commercial customers (including wholesalers, retailers and buying groups), to clinical facilities or direct to the patient).\n\n# installation qualification\n\nThe process of obtaining and documenting evidence that equipment has been provided and installed in accordance with its specifications and that it functions within predetermined limits when operated in accordance with the operating instructions.\n\n# internal distribution\n\nTransport of a TTSPP within a pharmaceutical manufacturer\u2019s internal supply chain (i.e. all internal transports from manufacturing facility to packaging facility to warehouse to distribution centre).\n\n# net storage capacity\n\nThe total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n\n# passive systems\n\nSystems which maintain a temperature-controlled environment inside an insulated enclosure, with or without thermostatic regulation, using a finite amount of pre-conditioned coolant in the form of chilled or frozen gel packs, phase change materials, dry ice or others.\n\n# pests\n\nIncludes birds, bats, rodents and insects whose uncontrolled presence affects hygiene and cleanliness.\n\n# pharmaceutical product\n\nAny product intended for human use or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, that is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices. \n\n----\n\n1 Definition from *Revision of WHO good distribution practices for pharmaceutical products*. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 5.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "82fc9636f825da8895c1857a6d3f2a886d9f5fac8d9c4d391c69e6c83138e9bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# dunnage\n\nLoose packing material used to protect TTSPPs from damage during transport.\n\n# external distribution\n\nTransport of TTSPPs through various steps in the customer\u2019s supply chain (i.e. transport from a pharmaceutical manufacturer\u2019s distribution centre to commercial customers (including wholesalers, retailers and buying groups), to clinical facilities or direct to the patient).\n\n# installation qualification\n\nThe process of obtaining and documenting evidence that equipment has been provided and installed in accordance with its specifications and that it functions within predetermined limits when operated in accordance with the operating instructions.\n\n# internal distribution\n\nTransport of a TTSPP within a pharmaceutical manufacturer\u2019s internal supply chain (i.e. all internal transports from manufacturing facility to packaging facility to warehouse to distribution centre).\n\n# net storage capacity\n\nThe total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n\n# passive systems\n\nSystems which maintain a temperature-controlled environment inside an insulated enclosure, with or without thermostatic regulation, using a finite amount of pre-conditioned coolant in the form of chilled or frozen gel packs, phase change materials, dry ice or others.\n\n# pests\n\nIncludes birds, bats, rodents and insects whose uncontrolled presence affects hygiene and cleanliness.\n\n# pharmaceutical product\n\nAny product intended for human use or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, that is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices. \n\n----\n\n1 Definition from *Revision of WHO good distribution practices for pharmaceutical products*. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 5.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2330, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "25f2ef48-c9bb-4654-997c-9af8fad4f475": {"__data__": {"id_": "25f2ef48-c9bb-4654-997c-9af8fad4f475", "embedding": null, "metadata": {"page_label": "343", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\nDocumented testing that demonstrates, with a high degree of assurance, that a specific process will meet its predetermined acceptance criteria.\u00b2\n\n# Refrigeration Equipment\n\nThe term \u201crefrigeration\u201d or \u201crefrigeration equipment\u201d means any equipment whose purpose is to lower air and product temperatures and/or to control relative humidity.\n\n# Service Level Agreement (SLA)\n\nA service level agreement or contract is a negotiated agreement between the customer and service provider that defines the common understanding about materials or service quality specifications, responsibilities, guarantees and communication mechanisms. It can either be legally binding, or an information agreement. The SLA may also specify the target and minimum level performance, operation or other service attributes.\u00b3\n\n# Standard Operating Procedure (SOP)\n\nA set of instructions having the force of a directive, covering those features of operations that lend themselves to a definite or standardized procedure without loss of effectiveness.\n\n# Storage Temperature\n\nThe temperature range listed on the TTSPP label, and within the regulatory documentation, for long-term storage.\n\n# Storage Unit Temperature/Humidity Distribution\n\nThe range and pattern of temperatures and/or humidity within a temperature-controlled storage unit during normal operation.\n\n# Suspect Product\n\nA TTSPP whose presentation and/or pharmacological formulation indicates that it has not been manufactured by the company named on the packaging. A TTSPP that shows visible or pharmacological evidence of tampering.\n\n# Temperature-Controlled\n\nIncludes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits.\n\n# Temperature Excursion\n\nAn excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and/or transport. Temperature ranges for\n\n----\n\n\u00b2 Definition from the Parenteral Drug Association (PDA) Technical Report No. 39, 2007.  \n\u00b3 Definition from International Air Transport Association (IATA), Chapter 17, 9th ed., June 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 961 aborda diversos t\u00e9rminos y definiciones relacionados con la calificaci\u00f3n de procesos, equipos de refrigeraci\u00f3n, acuerdos de nivel de servicio (SLA), procedimientos operativos est\u00e1ndar (SOP), y aspectos cr\u00edticos del almacenamiento y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener condiciones controladas de temperatura y humedad para asegurar la calidad y seguridad de los productos durante su almacenamiento y transporte.\n\n### Preguntas\n1. **\u00bfQu\u00e9 se entiende por \"calificaci\u00f3n\" en el contexto de los procesos farmac\u00e9uticos y por qu\u00e9 es importante?**\n   - La calificaci\u00f3n se refiere a las pruebas documentadas que demuestran, con un alto grado de certeza, que un proceso espec\u00edfico cumplir\u00e1 con sus criterios de aceptaci\u00f3n predeterminados. Esto es crucial para garantizar que los procesos utilizados en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos sean seguros y efectivos.\n\n2. **\u00bfCu\u00e1l es la definici\u00f3n de un \"producto sospechoso\" seg\u00fan el documento y qu\u00e9 implicaciones tiene para la seguridad del paciente?**\n   - Un producto sospechoso es aquel cuyo etiquetado o formulaci\u00f3n farmacol\u00f3gica indica que no ha sido fabricado por la empresa mencionada en el empaque, o que muestra evidencia visible o farmacol\u00f3gica de manipulaci\u00f3n. Esto tiene implicaciones serias para la seguridad del paciente, ya que puede indicar un riesgo de calidad o efectividad del producto.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar para definir un \"entorno controlado por temperatura\" y por qu\u00e9 es relevante en el almacenamiento de productos farmac\u00e9uticos?**\n   - Un entorno controlado por temperatura es aquel en el que la temperatura se controla activa o pasivamente a un nivel diferente del entorno circundante dentro de l\u00edmites predefinidos. Esto es relevante para el almacenamiento de productos farmac\u00e9uticos, ya que mantener condiciones adecuadas es esencial para preservar la estabilidad y eficacia de los productos a lo largo de su vida \u00fatil.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dunnage**: Material de embalaje suelto utilizado para proteger los productos farmac\u00e9uticos durante el transporte.\n\n2. **Distribuci\u00f3n Externa**: Proceso de transporte de productos farmac\u00e9uticos a trav\u00e9s de la cadena de suministro del cliente, desde el centro de distribuci\u00f3n del fabricante hasta los clientes comerciales, instalaciones cl\u00ednicas o directamente al paciente.\n\n3. **Calificaci\u00f3n de Instalaci\u00f3n**: Proceso de obtenci\u00f3n y documentaci\u00f3n de evidencia que asegura que el equipo ha sido instalado de acuerdo con sus especificaciones y que funciona dentro de l\u00edmites predeterminados.\n\n4. **Distribuci\u00f3n Interna**: Transporte de productos farmac\u00e9uticos dentro de la cadena de suministro interna de un fabricante, abarcando todos los traslados internos desde la instalaci\u00f3n de fabricaci\u00f3n hasta el centro de distribuci\u00f3n.\n\n5. **Capacidad de Almacenamiento Neta**: Volumen total disponible para almacenar productos farmac\u00e9uticos, considerando el tipo de sistema de soporte de carga y el factor de utilizaci\u00f3n.\n\n6. **Sistemas Pasivos**: Sistemas que mantienen un ambiente controlado en temperatura dentro de un recinto aislado, utilizando refrigerantes precondicionados como geles, materiales de cambio de fase o hielo seco.\n\n7. **Plagas**: Incluye aves, murci\u00e9lagos, roedores e insectos cuya presencia incontrolada afecta la higiene y limpieza.\n\n8. **Producto Farmac\u00e9utico**: Cualquier producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a control por legislaci\u00f3n farmac\u00e9utica, excluyendo dispositivos m\u00e9dicos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece las buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n- **TTSPP (Therapeutic and Technical Support Pharmaceutical Products)**: T\u00e9rmino utilizado para referirse a los productos farmac\u00e9uticos en el contexto del documento.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Normativa que regula la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y definiciones esenciales relacionados con la distribuci\u00f3n y almacenamiento de productos farmac\u00e9uticos, tal como se detalla en el documento de la OMS.", "excerpt_keywords": "Keywords: Qualification, Refrigeration Equipment, Service Level Agreement, Standard Operating Procedure, Temperature-Controlled"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b78f7af-17e8-4728-9416-fd528200309f", "node_type": "4", "metadata": {"page_label": "343", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\nDocumented testing that demonstrates, with a high degree of assurance, that a specific process will meet its predetermined acceptance criteria.\u00b2\n\n# Refrigeration Equipment\n\nThe term \u201crefrigeration\u201d or \u201crefrigeration equipment\u201d means any equipment whose purpose is to lower air and product temperatures and/or to control relative humidity.\n\n# Service Level Agreement (SLA)\n\nA service level agreement or contract is a negotiated agreement between the customer and service provider that defines the common understanding about materials or service quality specifications, responsibilities, guarantees and communication mechanisms. It can either be legally binding, or an information agreement. The SLA may also specify the target and minimum level performance, operation or other service attributes.\u00b3\n\n# Standard Operating Procedure (SOP)\n\nA set of instructions having the force of a directive, covering those features of operations that lend themselves to a definite or standardized procedure without loss of effectiveness.\n\n# Storage Temperature\n\nThe temperature range listed on the TTSPP label, and within the regulatory documentation, for long-term storage.\n\n# Storage Unit Temperature/Humidity Distribution\n\nThe range and pattern of temperatures and/or humidity within a temperature-controlled storage unit during normal operation.\n\n# Suspect Product\n\nA TTSPP whose presentation and/or pharmacological formulation indicates that it has not been manufactured by the company named on the packaging. A TTSPP that shows visible or pharmacological evidence of tampering.\n\n# Temperature-Controlled\n\nIncludes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits.\n\n# Temperature Excursion\n\nAn excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and/or transport. Temperature ranges for\n\n----\n\n\u00b2 Definition from the Parenteral Drug Association (PDA) Technical Report No. 39, 2007.  \n\u00b3 Definition from International Air Transport Association (IATA), Chapter 17, 9th ed., June 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b42fb6be9c9a382e6dbde9083f77a405b70b751a0e2d63d9f1bd482bdcd01eaf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Qualification\n\nDocumented testing that demonstrates, with a high degree of assurance, that a specific process will meet its predetermined acceptance criteria.\u00b2\n\n# Refrigeration Equipment\n\nThe term \u201crefrigeration\u201d or \u201crefrigeration equipment\u201d means any equipment whose purpose is to lower air and product temperatures and/or to control relative humidity.\n\n# Service Level Agreement (SLA)\n\nA service level agreement or contract is a negotiated agreement between the customer and service provider that defines the common understanding about materials or service quality specifications, responsibilities, guarantees and communication mechanisms. It can either be legally binding, or an information agreement. The SLA may also specify the target and minimum level performance, operation or other service attributes.\u00b3\n\n# Standard Operating Procedure (SOP)\n\nA set of instructions having the force of a directive, covering those features of operations that lend themselves to a definite or standardized procedure without loss of effectiveness.\n\n# Storage Temperature\n\nThe temperature range listed on the TTSPP label, and within the regulatory documentation, for long-term storage.\n\n# Storage Unit Temperature/Humidity Distribution\n\nThe range and pattern of temperatures and/or humidity within a temperature-controlled storage unit during normal operation.\n\n# Suspect Product\n\nA TTSPP whose presentation and/or pharmacological formulation indicates that it has not been manufactured by the company named on the packaging. A TTSPP that shows visible or pharmacological evidence of tampering.\n\n# Temperature-Controlled\n\nIncludes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits.\n\n# Temperature Excursion\n\nAn excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and/or transport. Temperature ranges for\n\n----\n\n\u00b2 Definition from the Parenteral Drug Association (PDA) Technical Report No. 39, 2007.  \n\u00b3 Definition from International Air Transport Association (IATA), Chapter 17, 9th ed., June 2009.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2160, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "cab84831-2f53-4e2d-a046-e36e389b3368": {"__data__": {"id_": "cab84831-2f53-4e2d-a046-e36e389b3368", "embedding": null, "metadata": {"page_label": "344", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Importation\n\n## Port handling and customs clearance\n\n### Port of entry\n\nImport TTSPPs through a port of entry that is equipped to handle such products. Where this is not possible, ensure that arrangements are in place to provide the necessary level of protection and security.\n\n*Reason:* To minimize the risk of damage.\n\n### Offloading\n\nAs soon as possible after arrival, remove TTSPP shipments from the wharf or airport apron to a safe and suitable temperature-controlled storage location.\n\n----\n\n**temperature-modified**\n\nIncludes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n\n**time- and temperature-sensitive pharmaceutical product (TTSPP)**\n\nAny pharmaceutical good or product which, when not stored or transported within predefined environmental conditions and/or within predefined time limits, is degraded to the extent that it no longer performs as originally intended.\n\n**transport temperature profile**\n\nAnticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.\n\n**utilization factor**\n\nThe percentage of the total volume available for storing TTSPPs that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store.\n\n**validation**\n\nDocumented testing performed under highly controlled conditions, demonstrating that processes, methods, and systems consistently produce results meeting predetermined acceptance criteria. [^4]\n\n[^4]: Definition from PDA Technical Report No. 39, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importaci\u00f3n de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPP). Se enfatiza la importancia de manejar adecuadamente la entrada y el despacho de estos productos en puertos equipados, as\u00ed como la necesidad de trasladarlos r\u00e1pidamente a un almacenamiento controlado en temperatura para evitar su degradaci\u00f3n. Se definen t\u00e9rminos clave relacionados con el manejo y almacenamiento de TTSPP, como \"temperatura modificada\", \"perfil de temperatura de transporte\", \"factor de utilizaci\u00f3n\" y \"validaci\u00f3n\".\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse al importar TTSPPs a un puerto que no est\u00e1 equipado para manejarlos?**\n   - Respuesta: Se deben hacer arreglos para proporcionar el nivel necesario de protecci\u00f3n y seguridad para minimizar el riesgo de da\u00f1o a los productos.\n\n2. **\u00bfQu\u00e9 se debe hacer inmediatamente despu\u00e9s de la llegada de un env\u00edo de TTSPP?**\n   - Respuesta: Los env\u00edos de TTSPP deben ser retirados lo antes posible del muelle o la pista del aeropuerto y trasladados a un lugar de almacenamiento seguro y adecuado que mantenga la temperatura controlada.\n\n3. **\u00bfC\u00f3mo se define el \"factor de utilizaci\u00f3n\" en el contexto del almacenamiento de TTSPPs?**\n   - Respuesta: El \"factor de utilizaci\u00f3n\" se refiere al porcentaje del volumen total disponible para almacenar TTSPPs que se puede lograr de manera confiable en la pr\u00e1ctica, considerando los tipos de unidades de mantenimiento de existencias (SKU), los sistemas de soporte de carga y los sistemas de gesti\u00f3n de existencias utilizados en el almac\u00e9n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n**: Proceso de pruebas documentadas que aseguran que un proceso espec\u00edfico cumple con criterios de aceptaci\u00f3n predeterminados, esencial para la seguridad y efectividad en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Equipos de Refrigeraci\u00f3n**: Equipos dise\u00f1ados para reducir temperaturas y controlar la humedad relativa, fundamentales para el almacenamiento adecuado de productos sensibles.\n\n3. **Acuerdo de Nivel de Servicio (SLA)**: Contrato que define las expectativas entre el cliente y el proveedor de servicios, incluyendo especificaciones de calidad, responsabilidades y niveles de rendimiento.\n\n4. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Conjunto de instrucciones que gu\u00edan operaciones de manera estandarizada, asegurando eficacia sin p\u00e9rdida de calidad.\n\n5. **Temperatura de Almacenamiento**: Rango de temperatura especificado para el almacenamiento a largo plazo de productos, cr\u00edtico para mantener su integridad.\n\n6. **Distribuci\u00f3n de Temperatura/Humedad en la Unidad de Almacenamiento**: Patr\u00f3n de temperaturas y humedad dentro de una unidad de almacenamiento controlada, importante para la estabilidad del producto.\n\n7. **Producto Sospechoso**: Producto que presenta indicios de no haber sido fabricado por la empresa indicada o que muestra evidencia de manipulaci\u00f3n, lo que plantea riesgos para la seguridad del paciente.\n\n8. **Control de Temperatura**: Entorno donde la temperatura se mantiene dentro de l\u00edmites predefinidos, esencial para la conservaci\u00f3n de productos farmac\u00e9uticos.\n\n9. **Excursi\u00f3n de Temperatura**: Evento en el que un producto se expone a temperaturas fuera de los rangos prescritos, lo que puede comprometer su calidad y eficacia.\n\n### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Parenteral Drug Association (PDA)**: Fuente de la definici\u00f3n de calificaci\u00f3n.\n- **International Air Transport Association (IATA)**: Fuente de la definici\u00f3n de SLA. \n\nEste resumen destaca la importancia de mantener est\u00e1ndares rigurosos en la manipulaci\u00f3n y almacenamiento de productos farmac\u00e9uticos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: importation, TTSPP, temperature-controlled storage, validation, customs clearance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa014ee9-f1e6-4f71-a158-0a13c7e7aadb", "node_type": "4", "metadata": {"page_label": "344", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Importation\n\n## Port handling and customs clearance\n\n### Port of entry\n\nImport TTSPPs through a port of entry that is equipped to handle such products. Where this is not possible, ensure that arrangements are in place to provide the necessary level of protection and security.\n\n*Reason:* To minimize the risk of damage.\n\n### Offloading\n\nAs soon as possible after arrival, remove TTSPP shipments from the wharf or airport apron to a safe and suitable temperature-controlled storage location.\n\n----\n\n**temperature-modified**\n\nIncludes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n\n**time- and temperature-sensitive pharmaceutical product (TTSPP)**\n\nAny pharmaceutical good or product which, when not stored or transported within predefined environmental conditions and/or within predefined time limits, is degraded to the extent that it no longer performs as originally intended.\n\n**transport temperature profile**\n\nAnticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.\n\n**utilization factor**\n\nThe percentage of the total volume available for storing TTSPPs that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store.\n\n**validation**\n\nDocumented testing performed under highly controlled conditions, demonstrating that processes, methods, and systems consistently produce results meeting predetermined acceptance criteria. [^4]\n\n[^4]: Definition from PDA Technical Report No. 39, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e6490d23f484cb3caf559c54377af0489e65c3cceaf304a62e4525b66d486bc0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Importation\n\n## Port handling and customs clearance\n\n### Port of entry\n\nImport TTSPPs through a port of entry that is equipped to handle such products. Where this is not possible, ensure that arrangements are in place to provide the necessary level of protection and security.\n\n*Reason:* To minimize the risk of damage.\n\n### Offloading\n\nAs soon as possible after arrival, remove TTSPP shipments from the wharf or airport apron to a safe and suitable temperature-controlled storage location.\n\n----\n\n**temperature-modified**\n\nIncludes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n\n**time- and temperature-sensitive pharmaceutical product (TTSPP)**\n\nAny pharmaceutical good or product which, when not stored or transported within predefined environmental conditions and/or within predefined time limits, is degraded to the extent that it no longer performs as originally intended.\n\n**transport temperature profile**\n\nAnticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.\n\n**utilization factor**\n\nThe percentage of the total volume available for storing TTSPPs that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store.\n\n**validation**\n\nDocumented testing performed under highly controlled conditions, demonstrating that processes, methods, and systems consistently produce results meeting predetermined acceptance criteria. [^4]\n\n[^4]: Definition from PDA Technical Report No. 39, 2007.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1725, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8f4a2c9a-fc33-4b23-8292-dfa8efe897de": {"__data__": {"id_": "8f4a2c9a-fc33-4b23-8292-dfa8efe897de", "embedding": null, "metadata": {"page_label": "345", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.1.3 Temporary storage at port of entry\n\nStore TTSPP shipments in a secure warehouse under the conditions recommended by the product manufacturer, until the shipment has been authorized for removal by customs.\u2075\n\n*Reason:* To avoid risk of theft or damage during temporary storage.\n\n# 1.1.4 Customs clearance\n\nDraw up procedures and memoranda of understanding to ensure that TTSPP shipments are cleared through customs as rapidly as possible. This can be facilitated by a pre-clearance procedure carried out by the local health agency, clearing agent or freight forwarder in collaboration with customs. Alternatively, the clearance process should be conducted by customs staff, supported by personnel with suitable pharmaceutical training, especially when clearance involves the opening and resealing of temperature-controlled packaging.\n\n*Reason:* To avoid delays during customs clearance that may cause temperature excursions and place TTSPPs at risk.\n\n# 2. Warehousing sites\n\n## 2.1 Site layout\n\n### 2.1.1 Natural hazards\n\nSelect and/or develop storage sites to minimize risks from natural hazards such as floods, landslides and earthquakes and extreme weather conditions such as hurricanes and tornadoes.\n\n*Reason:* To protect against loss of valuable pharmaceutical products, to ensure continued supply to patients in the market and to protect personnel working in the store.\n\n### 2.1.2 Site access\n\nProvide vehicular access to storage buildings sufficient to accommodate the largest vehicles visiting the site, including emergency vehicles.\n\n*Reason:* To ensure convenient operation of the facility.\n\n----\n\n\u2075 In some situations, arrangements can be made for formal customs clearance to take place away from the port of entry \u2014 for example, at a national vaccine store. In situations where the port of entry is not equipped with suitable cold storage facilities, this can reduce the risk of temperature excursions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de env\u00edos de productos farmac\u00e9uticos sensibles a la temperatura (TTSPP) en t\u00e9rminos de almacenamiento temporal en puertos de entrada, procedimientos de despacho aduanero y la disposici\u00f3n de sitios de almacenamiento. Se enfatiza la importancia de seguir las recomendaciones del fabricante para el almacenamiento, la rapidez en el proceso de despacho aduanero para evitar riesgos de temperatura, y la selecci\u00f3n de sitios de almacenamiento que minimicen los riesgos de desastres naturales y que permitan un acceso adecuado para veh\u00edculos, incluyendo emergencias.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas del fabricante que deben seguirse para el almacenamiento temporal de env\u00edos TTSPP en un puerto de entrada?**\n   - Esta pregunta busca detalles sobre las condiciones espec\u00edficas que los fabricantes sugieren para el almacenamiento, que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 procedimientos se sugieren para facilitar el proceso de despacho aduanero de los env\u00edos TTSPP y qui\u00e9nes deben estar involucrados en este proceso?**\n   - Esta pregunta se centra en los pasos concretos y las partes interesadas que deben participar en el proceso de despacho aduanero, m\u00e1s all\u00e1 de lo que se menciona en el contexto.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se pueden tomar para mitigar los riesgos de desastres naturales en los sitios de almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre estrategias o pr\u00e1cticas espec\u00edficas que se pueden implementar para proteger los sitios de almacenamiento de desastres naturales, que no se detallan en el texto. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos que pueden no estar completamente cubiertos en el documento, proporcionando as\u00ed un enfoque m\u00e1s detallado sobre la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Importaci\u00f3n de TTSPPs**: El documento se centra en la importaci\u00f3n de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPP), destacando la importancia de un manejo adecuado durante la entrada y el despacho en puertos.\n\n2. **Manejo en puertos**:\n   - **Puerto de entrada**: Se debe importar TTSPPs a trav\u00e9s de puertos equipados para su manejo. Si no es posible, se deben hacer arreglos para garantizar la protecci\u00f3n y seguridad de los productos.\n   - **Descarga**: Es crucial retirar los env\u00edos de TTSPP del muelle o pista del aeropuerto lo antes posible y trasladarlos a un almacenamiento controlado en temperatura.\n\n3. **Definiciones clave**:\n   - **Temperatura modificada**: Entorno donde la temperatura se mantiene a un nivel diferente al del ambiente circundante, sin control preciso.\n   - **TTSPP**: Productos farmac\u00e9uticos que se degradan si no se almacenan o transportan dentro de condiciones ambientales y l\u00edmites de tiempo predefinidos.\n   - **Perfil de temperatura de transporte**: Variaci\u00f3n de temperatura y duraci\u00f3n a la que un TTSPP puede estar expuesto durante el transporte.\n   - **Factor de utilizaci\u00f3n**: Porcentaje del volumen total disponible para almacenar TTSPPs que se puede lograr de manera confiable, considerando diferentes factores log\u00edsticos.\n   - **Validaci\u00f3n**: Pruebas documentadas que demuestran que los procesos y sistemas producen resultados que cumplen con criterios de aceptaci\u00f3n predefinidos.\n\n4. **Objetivo principal**: Minimizar el riesgo de da\u00f1o a los TTSPPs durante su importaci\u00f3n y asegurar su integridad a trav\u00e9s de un manejo y almacenamiento adecuados.", "excerpt_keywords": "Keywords: TTSPP, customs clearance, temporary storage, natural hazards, pharmaceutical logistics"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6fa8416a-de44-43ef-8df7-a215ce99f304", "node_type": "4", "metadata": {"page_label": "345", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.1.3 Temporary storage at port of entry\n\nStore TTSPP shipments in a secure warehouse under the conditions recommended by the product manufacturer, until the shipment has been authorized for removal by customs.\u2075\n\n*Reason:* To avoid risk of theft or damage during temporary storage.\n\n# 1.1.4 Customs clearance\n\nDraw up procedures and memoranda of understanding to ensure that TTSPP shipments are cleared through customs as rapidly as possible. This can be facilitated by a pre-clearance procedure carried out by the local health agency, clearing agent or freight forwarder in collaboration with customs. Alternatively, the clearance process should be conducted by customs staff, supported by personnel with suitable pharmaceutical training, especially when clearance involves the opening and resealing of temperature-controlled packaging.\n\n*Reason:* To avoid delays during customs clearance that may cause temperature excursions and place TTSPPs at risk.\n\n# 2. Warehousing sites\n\n## 2.1 Site layout\n\n### 2.1.1 Natural hazards\n\nSelect and/or develop storage sites to minimize risks from natural hazards such as floods, landslides and earthquakes and extreme weather conditions such as hurricanes and tornadoes.\n\n*Reason:* To protect against loss of valuable pharmaceutical products, to ensure continued supply to patients in the market and to protect personnel working in the store.\n\n### 2.1.2 Site access\n\nProvide vehicular access to storage buildings sufficient to accommodate the largest vehicles visiting the site, including emergency vehicles.\n\n*Reason:* To ensure convenient operation of the facility.\n\n----\n\n\u2075 In some situations, arrangements can be made for formal customs clearance to take place away from the port of entry \u2014 for example, at a national vaccine store. In situations where the port of entry is not equipped with suitable cold storage facilities, this can reduce the risk of temperature excursions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bda773b7df7871e0873c7300ee335577c63609ad0cd363d454fa2efbf1395bc2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1.1.3 Temporary storage at port of entry\n\nStore TTSPP shipments in a secure warehouse under the conditions recommended by the product manufacturer, until the shipment has been authorized for removal by customs.\u2075\n\n*Reason:* To avoid risk of theft or damage during temporary storage.\n\n# 1.1.4 Customs clearance\n\nDraw up procedures and memoranda of understanding to ensure that TTSPP shipments are cleared through customs as rapidly as possible. This can be facilitated by a pre-clearance procedure carried out by the local health agency, clearing agent or freight forwarder in collaboration with customs. Alternatively, the clearance process should be conducted by customs staff, supported by personnel with suitable pharmaceutical training, especially when clearance involves the opening and resealing of temperature-controlled packaging.\n\n*Reason:* To avoid delays during customs clearance that may cause temperature excursions and place TTSPPs at risk.\n\n# 2. Warehousing sites\n\n## 2.1 Site layout\n\n### 2.1.1 Natural hazards\n\nSelect and/or develop storage sites to minimize risks from natural hazards such as floods, landslides and earthquakes and extreme weather conditions such as hurricanes and tornadoes.\n\n*Reason:* To protect against loss of valuable pharmaceutical products, to ensure continued supply to patients in the market and to protect personnel working in the store.\n\n### 2.1.2 Site access\n\nProvide vehicular access to storage buildings sufficient to accommodate the largest vehicles visiting the site, including emergency vehicles.\n\n*Reason:* To ensure convenient operation of the facility.\n\n----\n\n\u2075 In some situations, arrangements can be made for formal customs clearance to take place away from the port of entry \u2014 for example, at a national vaccine store. In situations where the port of entry is not equipped with suitable cold storage facilities, this can reduce the risk of temperature excursions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1921, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3422c813-05f3-478a-8f71-f4dd4e756060": {"__data__": {"id_": "3422c813-05f3-478a-8f71-f4dd4e756060", "embedding": null, "metadata": {"page_label": "346", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Site security\n\nProvide perimeter protection to ensure security of the grounds and storage buildings against anticipated risks.\n\n**Reason:** To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and the value of goods stored there.\n\n## 2.3 Site cleanliness\n\nKeep the site free of accumulated dust, dirt, waste and debris. Ensure that pests are kept under control within the site area. Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\n**Reason:** To help protect storage buildings against ingress by dust, dirt and pests.\n\n# 3. Storage buildings\n\n## 3.1 Construction standards\n\nConstruct or procure storage buildings that are:\n\n- purpose-designed for the storage of TTSPPs, or well-adapted for this purpose;\n- designed to suit the prevailing climate, making maximum use of passive heating, cooling and ventilation;\n- designed and equipped to minimize the consumption of electricity and other fuel sources;\n- constructed using materials and finishes that are robust, easy to clean and which are selected to minimize long-term maintenance;\n- constructed using locally available materials and building technologies; and\n- built to minimize hiding and nesting places for pests.\n\n**Reasons:** Storage in unsuitable and poorly-designed buildings places TTSPPs at risk and increases storage costs. Buildings constructed using inappropriate materials and technologies are difficult to operate and maintain in resource-constrained settings.\n\n## 3.2 Accommodation and layout\n\nEnsure that the storage buildings are well laid out and contain all the necessary storage areas, goods assembly, receiving and dispatch bays and office accommodation needed for efficient operation of the TTSPP store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la seguridad y limpieza de los sitios de almacenamiento, as\u00ed como los est\u00e1ndares de construcci\u00f3n y dise\u00f1o de los edificios de almacenamiento para productos farmac\u00e9uticos y otros productos t\u00e9cnicos. Se enfatiza la importancia de proteger los sitios contra riesgos como el vandalismo y el robo, mantener la limpieza para evitar la acumulaci\u00f3n de desechos y plagas, y asegurar que los edificios de almacenamiento est\u00e9n dise\u00f1ados adecuadamente para su prop\u00f3sito, el clima y la eficiencia energ\u00e9tica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener los edificios de almacenamiento para garantizar la seguridad de los TTSPPs?**\n   - Respuesta: Los edificios deben ser dise\u00f1ados espec\u00edficamente para el almacenamiento de TTSPPs, adaptarse al clima local, minimizar el consumo de energ\u00eda, utilizar materiales robustos y de f\u00e1cil mantenimiento, y construirse con tecnolog\u00edas y materiales disponibles localmente.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para mantener la limpieza del sitio de almacenamiento y por qu\u00e9 es importante?**\n   - Respuesta: Se debe mantener el sitio libre de polvo, suciedad, desechos y escombros, controlar las plagas y recoger los desechos en contenedores cerrados para su disposici\u00f3n segura. Esto es importante para proteger los edificios de almacenamiento contra la entrada de polvo, suciedad y plagas.\n\n3. **\u00bfQu\u00e9 tipo de protecci\u00f3n perimetral se recomienda para los sitios de almacenamiento y cu\u00e1l es su prop\u00f3sito?**\n   - Respuesta: Se recomienda proporcionar protecci\u00f3n perimetral para asegurar la seguridad de los terrenos y edificios de almacenamiento contra riesgos anticipados, como vandalismo y robo. Las medidas de seguridad deben ser apropiadas para la ubicaci\u00f3n del sitio y el valor de los bienes almacenados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento Temporal en Puertos de Entrada**\n   - **Recomendaciones del Fabricante:** Los env\u00edos de productos farmac\u00e9uticos sensibles a la temperatura (TTSPP) deben almacenarse en un almac\u00e9n seguro bajo las condiciones recomendadas por el fabricante hasta que sean autorizados para su remoci\u00f3n por la aduana.\n   - **Raz\u00f3n:** Evitar el riesgo de robo o da\u00f1o durante el almacenamiento temporal.\n\n2. **Despacho Aduanero**\n   - **Procedimientos Sugeridos:** Se deben elaborar procedimientos y memorandos de entendimiento para asegurar que los env\u00edos TTSPP sean despachados aduanalmente lo m\u00e1s r\u00e1pido posible. Esto puede incluir un procedimiento de pre-despeje realizado por agencias de salud locales o agentes de carga en colaboraci\u00f3n con la aduana.\n   - **Personal Involucrado:** El proceso de despacho debe ser realizado por personal aduanero, apoyado por personal con formaci\u00f3n farmac\u00e9utica adecuada, especialmente cuando se requiere abrir y volver a sellar empaques controlados por temperatura.\n   - **Raz\u00f3n:** Evitar retrasos que puedan causar excursiones de temperatura y poner en riesgo los TTSPP.\n\n3. **Sitios de Almacenamiento**\n   - **Dise\u00f1o del Sitio:** Seleccionar y/o desarrollar sitios de almacenamiento para minimizar riesgos de desastres naturales (inundaciones, deslizamientos de tierra, terremotos, huracanes, tornados).\n   - **Raz\u00f3n:** Proteger contra la p\u00e9rdida de productos farmac\u00e9uticos valiosos, asegurar el suministro continuo a los pacientes y proteger al personal.\n   - **Acceso al Sitio:** Proveer acceso vehicular adecuado a los edificios de almacenamiento para acomodar veh\u00edculos grandes, incluyendo veh\u00edculos de emergencia.\n   - **Raz\u00f3n:** Asegurar la operaci\u00f3n conveniente de la instalaci\u00f3n.\n\n### Entidades Clave\n- **TTSPP:** Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Agencias de Salud Locales:** Entidades que pueden facilitar el proceso de despacho aduanero.\n- **Personal Aduanero:** Personal encargado de realizar el despacho aduanero.\n- **Sitios de Almacenamiento:** Instalaciones donde se almacenan los TTSPP, que deben ser seleccionadas cuidadosamente para minimizar riesgos. \n\nEste resumen destaca la importancia de seguir procedimientos adecuados para el almacenamiento y despacho de productos farmac\u00e9uticos sensibles, as\u00ed como la necesidad de considerar factores de seguridad y accesibilidad en los sitios de almacenamiento.", "excerpt_keywords": "Keywords: site security, storage buildings, TTSPPs, cleanliness, construction standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "767d9fd5-1d5e-4816-98f2-a5c9b9afe358", "node_type": "4", "metadata": {"page_label": "346", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Site security\n\nProvide perimeter protection to ensure security of the grounds and storage buildings against anticipated risks.\n\n**Reason:** To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and the value of goods stored there.\n\n## 2.3 Site cleanliness\n\nKeep the site free of accumulated dust, dirt, waste and debris. Ensure that pests are kept under control within the site area. Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\n**Reason:** To help protect storage buildings against ingress by dust, dirt and pests.\n\n# 3. Storage buildings\n\n## 3.1 Construction standards\n\nConstruct or procure storage buildings that are:\n\n- purpose-designed for the storage of TTSPPs, or well-adapted for this purpose;\n- designed to suit the prevailing climate, making maximum use of passive heating, cooling and ventilation;\n- designed and equipped to minimize the consumption of electricity and other fuel sources;\n- constructed using materials and finishes that are robust, easy to clean and which are selected to minimize long-term maintenance;\n- constructed using locally available materials and building technologies; and\n- built to minimize hiding and nesting places for pests.\n\n**Reasons:** Storage in unsuitable and poorly-designed buildings places TTSPPs at risk and increases storage costs. Buildings constructed using inappropriate materials and technologies are difficult to operate and maintain in resource-constrained settings.\n\n## 3.2 Accommodation and layout\n\nEnsure that the storage buildings are well laid out and contain all the necessary storage areas, goods assembly, receiving and dispatch bays and office accommodation needed for efficient operation of the TTSPP store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fbba912f41ebeeda0178165d7e0976154fb1ac7f139f400c018642faeef6812e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 2.2 Site security\n\nProvide perimeter protection to ensure security of the grounds and storage buildings against anticipated risks.\n\n**Reason:** To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and the value of goods stored there.\n\n## 2.3 Site cleanliness\n\nKeep the site free of accumulated dust, dirt, waste and debris. Ensure that pests are kept under control within the site area. Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\n**Reason:** To help protect storage buildings against ingress by dust, dirt and pests.\n\n# 3. Storage buildings\n\n## 3.1 Construction standards\n\nConstruct or procure storage buildings that are:\n\n- purpose-designed for the storage of TTSPPs, or well-adapted for this purpose;\n- designed to suit the prevailing climate, making maximum use of passive heating, cooling and ventilation;\n- designed and equipped to minimize the consumption of electricity and other fuel sources;\n- constructed using materials and finishes that are robust, easy to clean and which are selected to minimize long-term maintenance;\n- constructed using locally available materials and building technologies; and\n- built to minimize hiding and nesting places for pests.\n\n**Reasons:** Storage in unsuitable and poorly-designed buildings places TTSPPs at risk and increases storage costs. Buildings constructed using inappropriate materials and technologies are difficult to operate and maintain in resource-constrained settings.\n\n## 3.2 Accommodation and layout\n\nEnsure that the storage buildings are well laid out and contain all the necessary storage areas, goods assembly, receiving and dispatch bays and office accommodation needed for efficient operation of the TTSPP store.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1815, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e6d91171-4386-46fa-8960-0d5a201ddfeb": {"__data__": {"id_": "e6d91171-4386-46fa-8960-0d5a201ddfeb", "embedding": null, "metadata": {"page_label": "347", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.3 Loading and receiving bays\n\n## 3.3.1 Loading bays\n\nEnsure that receiving and dispatch bays are designed to avoid conflict between incoming and outgoing goods and are protected from direct sunlight, dust, dirt, rain, snow and wind, and from extremes of heat, cold and solar radiation that could damage TTSPPs, and measures are taken to minimize pest activity in these areas.\n\n*Reason:* Protection against damage and maintenance of product quality.\n\n## 3.3.2 Receiving bays\n\nProvide receiving areas with suitable equipment to clean reusable transport containers after their contents have been unloaded, and before the containers are stored for re-use.\n\n*Reason:* Protection against contamination of outgoing TTSPPs.\n\n# 3.4 Goods assembly and quarantine areas\n\n## 3.4.1 Goods assembly areas\n\nProvide sufficient space to receive, assemble and pack TTSPPs for dispatch under temperature-modified conditions. Preferably, these areas should be physically close to the temperature-controlled storage area.\n\n*Reason:* Protection of TTSPPs during arrival, order assembly and dispatch.\n\n## 3.4.2 Holding area for incoming goods\n\nProvide a temperature-controlled holding area for incoming TTSPPs pending their acceptance into the main storage area. The holding area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement. Where goods are held in bond in the warehouse, awaiting customs clearance, they must be physically separated and secured.\n\n*Reason:* Incoming items may need inspection and/or regulatory clearance, including laboratory testing.\n\n## 3.4.3 Quarantine area\n\nProvide a quarantine area for the isolation of returned, faulty, recalled and otherwise withdrawn goods pending a decision on disposal or re-stocking by the qualified person or department. Materials within quarantine areas must be clearly identified with their status.\n\n- with temperature control, for items returned for re-stocking;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las mejores pr\u00e1cticas para el dise\u00f1o y la operaci\u00f3n de \u00e1reas de carga y recepci\u00f3n en instalaciones que manejan productos farmac\u00e9uticos y biol\u00f3gicos. Se enfatiza la importancia de proteger los productos de da\u00f1os y contaminaci\u00f3n, as\u00ed como la necesidad de \u00e1reas espec\u00edficas para la asamblea de bienes, el almacenamiento temporal y la cuarentena de productos devueltos o retirados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener las \u00e1reas de carga y recepci\u00f3n para proteger los TTSPPs?**\n   - El contexto menciona que las \u00e1reas de carga y recepci\u00f3n deben evitar conflictos entre bienes entrantes y salientes, y estar protegidas de la luz solar directa, polvo, suciedad, lluvia, nieve, viento y extremos de temperatura. Esto es crucial para mantener la calidad del producto.\n\n2. **\u00bfQu\u00e9 equipo se recomienda para las \u00e1reas de recepci\u00f3n y cu\u00e1l es su prop\u00f3sito?**\n   - Se sugiere que las \u00e1reas de recepci\u00f3n cuenten con equipos adecuados para limpiar los contenedores de transporte reutilizables despu\u00e9s de descargar su contenido. Esto es esencial para prevenir la contaminaci\u00f3n de los TTSPPs que se enviar\u00e1n posteriormente.\n\n3. **\u00bfC\u00f3mo se debe gestionar el \u00e1rea de cuarentena para productos devueltos o retirados?**\n   - El contexto indica que debe haber un \u00e1rea de cuarentena para aislar productos devueltos, defectuosos o retirados, donde se espera una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento. Adem\u00e1s, los materiales en estas \u00e1reas deben estar claramente identificados con su estado, y se menciona que los art\u00edculos devueltos para reabastecimiento deben estar bajo control de temperatura.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Seguridad del sitio:**\n   - **Protecci\u00f3n perimetral:** Se recomienda implementar medidas de seguridad para proteger los terrenos y edificios de almacenamiento contra riesgos como vandalismo y robo.\n   - **Importancia:** La seguridad debe ser adecuada a la ubicaci\u00f3n del sitio y al valor de los bienes almacenados.\n\n2. **Limpieza del sitio:**\n   - **Mantenimiento:** Es esencial mantener el sitio libre de polvo, suciedad, desechos y plagas.\n   - **Gesti\u00f3n de residuos:** Los desechos deben ser recogidos en contenedores cerrados y desechados de manera segura y frecuente.\n   - **Objetivo:** Proteger los edificios de almacenamiento de la entrada de contaminantes y plagas.\n\n3. **Edificios de almacenamiento:**\n   - **Est\u00e1ndares de construcci\u00f3n:** Los edificios deben ser dise\u00f1ados espec\u00edficamente para el almacenamiento de productos t\u00e9cnicos y farmac\u00e9uticos (TTSPPs), adapt\u00e1ndose al clima local y optimizando el uso de recursos energ\u00e9ticos.\n   - **Materiales y tecnolog\u00eda:** Se deben utilizar materiales robustos y de f\u00e1cil mantenimiento, preferiblemente de origen local, para minimizar costos y facilitar el mantenimiento.\n   - **Dise\u00f1o y distribuci\u00f3n:** Los edificios deben tener una disposici\u00f3n eficiente que incluya \u00e1reas de almacenamiento, recepci\u00f3n, despacho y oficinas.\n\n### Entidades:\n- **TTSPPs:** Productos t\u00e9cnicos y farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento.\n- **OMS:** Organizaci\u00f3n Mundial de la Salud, responsable de establecer directrices para la gesti\u00f3n de la salud p\u00fablica y el almacenamiento seguro de productos.\n- **Riesgos:** Vandalismo, robo, acumulaci\u00f3n de desechos y plagas que pueden afectar la integridad de los productos almacenados. \n\nEste resumen destaca la importancia de la seguridad, limpieza y est\u00e1ndares de construcci\u00f3n en la gesti\u00f3n de sitios de almacenamiento para productos sensibles.", "excerpt_keywords": "Keywords: loading bays, receiving bays, TTSPPs, quarantine area, temperature control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "161142ff-566d-41c8-8691-6d537c8d48a5", "node_type": "4", "metadata": {"page_label": "347", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.3 Loading and receiving bays\n\n## 3.3.1 Loading bays\n\nEnsure that receiving and dispatch bays are designed to avoid conflict between incoming and outgoing goods and are protected from direct sunlight, dust, dirt, rain, snow and wind, and from extremes of heat, cold and solar radiation that could damage TTSPPs, and measures are taken to minimize pest activity in these areas.\n\n*Reason:* Protection against damage and maintenance of product quality.\n\n## 3.3.2 Receiving bays\n\nProvide receiving areas with suitable equipment to clean reusable transport containers after their contents have been unloaded, and before the containers are stored for re-use.\n\n*Reason:* Protection against contamination of outgoing TTSPPs.\n\n# 3.4 Goods assembly and quarantine areas\n\n## 3.4.1 Goods assembly areas\n\nProvide sufficient space to receive, assemble and pack TTSPPs for dispatch under temperature-modified conditions. Preferably, these areas should be physically close to the temperature-controlled storage area.\n\n*Reason:* Protection of TTSPPs during arrival, order assembly and dispatch.\n\n## 3.4.2 Holding area for incoming goods\n\nProvide a temperature-controlled holding area for incoming TTSPPs pending their acceptance into the main storage area. The holding area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement. Where goods are held in bond in the warehouse, awaiting customs clearance, they must be physically separated and secured.\n\n*Reason:* Incoming items may need inspection and/or regulatory clearance, including laboratory testing.\n\n## 3.4.3 Quarantine area\n\nProvide a quarantine area for the isolation of returned, faulty, recalled and otherwise withdrawn goods pending a decision on disposal or re-stocking by the qualified person or department. Materials within quarantine areas must be clearly identified with their status.\n\n- with temperature control, for items returned for re-stocking;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8dee10ad0586c22fb329a8fa7204900cf0a6ecbf24d00f0d892e96232666bd03", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.3 Loading and receiving bays\n\n## 3.3.1 Loading bays\n\nEnsure that receiving and dispatch bays are designed to avoid conflict between incoming and outgoing goods and are protected from direct sunlight, dust, dirt, rain, snow and wind, and from extremes of heat, cold and solar radiation that could damage TTSPPs, and measures are taken to minimize pest activity in these areas.\n\n*Reason:* Protection against damage and maintenance of product quality.\n\n## 3.3.2 Receiving bays\n\nProvide receiving areas with suitable equipment to clean reusable transport containers after their contents have been unloaded, and before the containers are stored for re-use.\n\n*Reason:* Protection against contamination of outgoing TTSPPs.\n\n# 3.4 Goods assembly and quarantine areas\n\n## 3.4.1 Goods assembly areas\n\nProvide sufficient space to receive, assemble and pack TTSPPs for dispatch under temperature-modified conditions. Preferably, these areas should be physically close to the temperature-controlled storage area.\n\n*Reason:* Protection of TTSPPs during arrival, order assembly and dispatch.\n\n## 3.4.2 Holding area for incoming goods\n\nProvide a temperature-controlled holding area for incoming TTSPPs pending their acceptance into the main storage area. The holding area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement. Where goods are held in bond in the warehouse, awaiting customs clearance, they must be physically separated and secured.\n\n*Reason:* Incoming items may need inspection and/or regulatory clearance, including laboratory testing.\n\n## 3.4.3 Quarantine area\n\nProvide a quarantine area for the isolation of returned, faulty, recalled and otherwise withdrawn goods pending a decision on disposal or re-stocking by the qualified person or department. Materials within quarantine areas must be clearly identified with their status.\n\n- with temperature control, for items returned for re-stocking;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1988, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d1b3e2da-7bd2-4018-a237-b2d147d2100b": {"__data__": {"id_": "d1b3e2da-7bd2-4018-a237-b2d147d2100b", "embedding": null, "metadata": {"page_label": "348", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 with temperature control, for items recalled for testing;  \n\u2014 without temperature control, for items awaiting disposal.\n\nThe quarantine area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement.\n\n*Reason:* Items for re-stocking, testing and disposal should be kept separate to avoid the risk of inappropriate use.\n\n## 3.5 Environmental control of ancillary areas\n\nEnsure, where possible, that ancillary areas where TTSPPs are temporarily held during arrival, order assembly or dispatch are:\n\n\u2014 maintained within the temperature range specified for the goods being handled;  \n\u2014 maintained within the humidity range specified for goods that are adversely affected by high relative humidity and are not sufficiently protected by their packaging;[^6]  \n\u2014 protected from undue exposure to direct sunlight;  \n\u2014 protected from the weather;  \n\u2014 protected against dust, dirt and waste accumulation;  \n\u2014 adequately ventilated;  \n\u2014 adequately lit to enable operations to be carried out accurately and safely;  \n\u2014 monitored during the times when TTSPPs are handled; and monitored during the times when TTSPPs are handled (see 4.5.1\u20134.5.4).\n\n*Reason:* Protection of TTSPP quality during arrival, order assembly or dispatch.\n\n## 3.6 Building security\n\n### 3.6.1 General building security\n\nEnsure that buildings used to store TTSPPs have sufficient security to prevent unauthorized access and to prevent misappropriation of goods.\n\n*Reason:* To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and to the value of goods stored there.\n\n### 3.6.2 Controlled and hazardous substances areas\n\nEnsure that all areas that are used to store controlled or hazardous TTSPPs are:\n\n[^6]: Active environmental control of ancillary areas may not be needed if all TTSPPs are kept in temperature-controlled packaging and/or humidity-protective packaging when passing through these areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n y control de productos farmac\u00e9uticos y otros productos relacionados con la salud (TTSPPs) en t\u00e9rminos de su almacenamiento, control ambiental y seguridad. Se enfatiza la importancia de mantener \u00e1reas de cuarentena, controlar las condiciones ambientales en \u00e1reas auxiliares, y asegurar la protecci\u00f3n de los edificios donde se almacenan estos productos. Tambi\u00e9n se menciona la necesidad de separar los productos en cuarentena para evitar su uso inapropiado y la importancia de la seguridad para prevenir el acceso no autorizado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones ambientales espec\u00edficas que deben mantenerse en las \u00e1reas auxiliares donde se manejan TTSPPs?**\n   - Respuesta: Las \u00e1reas auxiliares deben mantenerse dentro del rango de temperatura y humedad especificados para los productos, protegidas de la luz solar directa, el clima, el polvo y la acumulaci\u00f3n de desechos, adem\u00e1s de estar adecuadamente ventiladas y iluminadas.\n\n2. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en los edificios que almacenan TTSPPs?**\n   - Respuesta: Los edificios deben tener suficiente seguridad para prevenir el acceso no autorizado y la apropiaci\u00f3n indebida de bienes, con arreglos de seguridad apropiados seg\u00fan la ubicaci\u00f3n del sitio y el valor de los productos almacenados.\n\n3. **\u00bfPor qu\u00e9 es importante mantener separados los productos en cuarentena y cu\u00e1les son las categor\u00edas de productos mencionadas?**\n   - Respuesta: Es importante mantener separados los productos en cuarentena para evitar el riesgo de uso inapropiado. Las categor\u00edas mencionadas incluyen productos para reabastecimiento, pruebas y disposici\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **\u00c1reas de Carga y Recepci\u00f3n**:\n   - **Dise\u00f1o de \u00c1reas**: Las \u00e1reas de carga y recepci\u00f3n deben estar dise\u00f1adas para evitar conflictos entre bienes entrantes y salientes, y deben estar protegidas de factores ambientales adversos como luz solar, polvo, lluvia, nieve, viento y temperaturas extremas.\n   - **Protecci\u00f3n de TTSPPs**: Se enfatiza la importancia de proteger los productos farmac\u00e9uticos y biol\u00f3gicos (TTSPPs) de da\u00f1os y mantener su calidad.\n\n2. **Equipamiento en \u00c1reas de Recepci\u00f3n**:\n   - **Limpieza de Contenedores**: Se recomienda que las \u00e1reas de recepci\u00f3n cuenten con equipos adecuados para limpiar los contenedores de transporte reutilizables despu\u00e9s de su uso, para prevenir la contaminaci\u00f3n de los TTSPPs.\n\n3. **\u00c1reas de Ensamblaje y Cuarentena**:\n   - **Espacio para Ensamblaje**: Se debe proporcionar suficiente espacio para recibir, ensamblar y empaquetar TTSPPs bajo condiciones de temperatura controlada, preferiblemente cerca de las \u00e1reas de almacenamiento controlado por temperatura.\n   - **\u00c1rea de Sostenimiento**: Se debe contar con un \u00e1rea de sostenimiento controlada por temperatura para los TTSPPs entrantes que esperan aceptaci\u00f3n en el \u00e1rea de almacenamiento principal.\n   - **\u00c1rea de Cuarentena**: Es necesario establecer un \u00e1rea de cuarentena para aislar productos devueltos, defectuosos o retirados, donde se espera una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento. Los materiales en estas \u00e1reas deben estar claramente identificados.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y biol\u00f3gicos que requieren protecci\u00f3n y manejo cuidadoso.\n- **\u00c1reas de Carga y Recepci\u00f3n**: Espacios dise\u00f1ados para la entrada y salida de bienes.\n- **Equipos de Limpieza**: Herramientas necesarias para mantener la higiene de los contenedores reutilizables.\n- **\u00c1reas de Ensamblaje y Cuarentena**: Espacios espec\u00edficos para la preparaci\u00f3n y gesti\u00f3n de productos, incluyendo el manejo de productos devueltos o defectuosos. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y pr\u00e1cticas operativas en la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: TTSPPs, environmental control, quarantine area, building security, temperature management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6371738-eb6f-4bcd-9ecb-cf45a2d10bb3", "node_type": "4", "metadata": {"page_label": "348", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 with temperature control, for items recalled for testing;  \n\u2014 without temperature control, for items awaiting disposal.\n\nThe quarantine area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement.\n\n*Reason:* Items for re-stocking, testing and disposal should be kept separate to avoid the risk of inappropriate use.\n\n## 3.5 Environmental control of ancillary areas\n\nEnsure, where possible, that ancillary areas where TTSPPs are temporarily held during arrival, order assembly or dispatch are:\n\n\u2014 maintained within the temperature range specified for the goods being handled;  \n\u2014 maintained within the humidity range specified for goods that are adversely affected by high relative humidity and are not sufficiently protected by their packaging;[^6]  \n\u2014 protected from undue exposure to direct sunlight;  \n\u2014 protected from the weather;  \n\u2014 protected against dust, dirt and waste accumulation;  \n\u2014 adequately ventilated;  \n\u2014 adequately lit to enable operations to be carried out accurately and safely;  \n\u2014 monitored during the times when TTSPPs are handled; and monitored during the times when TTSPPs are handled (see 4.5.1\u20134.5.4).\n\n*Reason:* Protection of TTSPP quality during arrival, order assembly or dispatch.\n\n## 3.6 Building security\n\n### 3.6.1 General building security\n\nEnsure that buildings used to store TTSPPs have sufficient security to prevent unauthorized access and to prevent misappropriation of goods.\n\n*Reason:* To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and to the value of goods stored there.\n\n### 3.6.2 Controlled and hazardous substances areas\n\nEnsure that all areas that are used to store controlled or hazardous TTSPPs are:\n\n[^6]: Active environmental control of ancillary areas may not be needed if all TTSPPs are kept in temperature-controlled packaging and/or humidity-protective packaging when passing through these areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3a40d0003035ffe2961c1624855157f70425811ab905788ea38306c568f830b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 with temperature control, for items recalled for testing;  \n\u2014 without temperature control, for items awaiting disposal.\n\nThe quarantine area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement.\n\n*Reason:* Items for re-stocking, testing and disposal should be kept separate to avoid the risk of inappropriate use.\n\n## 3.5 Environmental control of ancillary areas\n\nEnsure, where possible, that ancillary areas where TTSPPs are temporarily held during arrival, order assembly or dispatch are:\n\n\u2014 maintained within the temperature range specified for the goods being handled;  \n\u2014 maintained within the humidity range specified for goods that are adversely affected by high relative humidity and are not sufficiently protected by their packaging;[^6]  \n\u2014 protected from undue exposure to direct sunlight;  \n\u2014 protected from the weather;  \n\u2014 protected against dust, dirt and waste accumulation;  \n\u2014 adequately ventilated;  \n\u2014 adequately lit to enable operations to be carried out accurately and safely;  \n\u2014 monitored during the times when TTSPPs are handled; and monitored during the times when TTSPPs are handled (see 4.5.1\u20134.5.4).\n\n*Reason:* Protection of TTSPP quality during arrival, order assembly or dispatch.\n\n## 3.6 Building security\n\n### 3.6.1 General building security\n\nEnsure that buildings used to store TTSPPs have sufficient security to prevent unauthorized access and to prevent misappropriation of goods.\n\n*Reason:* To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and to the value of goods stored there.\n\n### 3.6.2 Controlled and hazardous substances areas\n\nEnsure that all areas that are used to store controlled or hazardous TTSPPs are:\n\n[^6]: Active environmental control of ancillary areas may not be needed if all TTSPPs are kept in temperature-controlled packaging and/or humidity-protective packaging when passing through these areas.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2024, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6f0afbee-f0fb-481b-8792-a90b13c62316": {"__data__": {"id_": "6f0afbee-f0fb-481b-8792-a90b13c62316", "embedding": null, "metadata": {"page_label": "349", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Fire Protection\n\n## 3.7 Fire protection\n\n### 3.7.1 Fire protection equipment\n\nProvide suitable fire detection and fire-fighting equipment, including fire hydrants, in all TTSPP storage areas and ensure that:\n\n- systems and equipment are appropriate for the class of occupancy and product storage arrangements and are approved by the local fire authority; and\n- equipment is regularly serviced in accordance with the equipment manufacturers\u2019 recommendations and local regulations.\n\n*Reason:* Protection of property and life.\n\n### 3.7.2 Fire prevention, detection and control procedures\n\nFollow standard operating procedures (SOPs) for fire prevention, detection and control. Train staff and carry out regular fire drills. Prohibit smoking in all areas.\n\n*Reason:* Protection of property and life.\n\n## 3.8 Building hygiene\n\n### 3.8.1 Building cleanliness\n\nImplement a cleaning programme for all areas:\n\n- do not allow the accumulation of dust, dirt and waste, including packaging waste;\n- take precautions against spillage or breakage, and cross-contamination;\n\n----\n\n7 Zoned sprinkler systems are recommended to control fires and to localize product damage in the event of system activation.\n\n8 Explosion-proof stores must have a blast roof or wall. Preferably, explosive substances should be stored in an independent building, well separated from the main store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la protecci\u00f3n contra incendios en \u00e1reas de almacenamiento de productos, enfatizando la importancia de contar con equipos de detecci\u00f3n y extinci\u00f3n de incendios adecuados, as\u00ed como la implementaci\u00f3n de procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios. Tambi\u00e9n se menciona la necesidad de mantener la limpieza en los edificios para evitar la acumulaci\u00f3n de desechos y la contaminaci\u00f3n cruzada.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de equipos de protecci\u00f3n contra incendios se recomienda instalar en las \u00e1reas de almacenamiento de TTSPP?**\n   - Respuesta: Se recomienda proporcionar equipos de detecci\u00f3n y extinci\u00f3n de incendios adecuados, incluyendo hidrantes, que sean apropiados para la clase de ocupaci\u00f3n y las disposiciones de almacenamiento de productos, y que est\u00e9n aprobados por la autoridad local de incendios.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para prevenir incendios en las instalaciones de almacenamiento?**\n   - Respuesta: Se deben seguir procedimientos operativos est\u00e1ndar (SOP) para la prevenci\u00f3n, detecci\u00f3n y control de incendios, capacitar al personal, realizar simulacros de incendio regularmente y prohibir fumar en todas las \u00e1reas.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar en relaci\u00f3n con la limpieza de las instalaciones de almacenamiento?**\n   - Respuesta: Se debe implementar un programa de limpieza que evite la acumulaci\u00f3n de polvo, suciedad y desechos, incluyendo desechos de embalaje, y tomar precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de Cuarentena:**\n   - Se requiere mantener separados los productos en cuarentena, que incluyen:\n     - Productos con control de temperatura para pruebas.\n     - Productos sin control de temperatura para disposici\u00f3n.\n   - La zona de cuarentena puede ser f\u00edsica o definida por un sistema de control de stock.\n\n2. **Control Ambiental en \u00c1reas Auxiliares:**\n   - Las \u00e1reas donde se manejan productos farmac\u00e9uticos y relacionados (TTSPPs) deben cumplir con condiciones espec\u00edficas:\n     - Rango de temperatura y humedad adecuados.\n     - Protecci\u00f3n contra luz solar directa, clima, polvo y acumulaci\u00f3n de desechos.\n     - Ventilaci\u00f3n y iluminaci\u00f3n adecuadas.\n     - Monitoreo durante el manejo de TTSPPs.\n\n3. **Seguridad de Edificios:**\n   - Los edificios que almacenan TTSPPs deben tener medidas de seguridad suficientes para prevenir el acceso no autorizado y la apropiaci\u00f3n indebida de bienes.\n   - Las medidas de seguridad deben ser apropiadas seg\u00fan la ubicaci\u00f3n y el valor de los productos almacenados.\n\n4. **Sustancias Controladas y Peligrosas:**\n   - Se deben implementar medidas espec\u00edficas para el almacenamiento de TTSPPs controlados o peligrosos.\n\n### Entidades Clave:\n- **TTSPPs (Productos Farmac\u00e9uticos y Relacionados):** Productos que requieren manejo y almacenamiento cuidadoso.\n- **\u00c1reas de Cuarentena:** Espacios designados para productos en espera de pruebas o disposici\u00f3n.\n- **Condiciones Ambientales:** Temperatura, humedad, ventilaci\u00f3n, y protecci\u00f3n contra contaminantes.\n- **Seguridad del Edificio:** Medidas para prevenir vandalismo y robo.\n- **Sustancias Controladas y Peligrosas:** Productos que requieren un manejo y almacenamiento especial debido a su naturaleza. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de TTSPPs en t\u00e9rminos de control ambiental, seguridad y separaci\u00f3n de productos en cuarentena para garantizar su calidad y prevenir el uso inapropiado.", "excerpt_keywords": "Keywords: fire protection, TTSPP storage, fire prevention, building hygiene, safety equipment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eeeb5a3b-b6b5-41b4-ab03-e092921dd207", "node_type": "4", "metadata": {"page_label": "349", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Fire Protection\n\n## 3.7 Fire protection\n\n### 3.7.1 Fire protection equipment\n\nProvide suitable fire detection and fire-fighting equipment, including fire hydrants, in all TTSPP storage areas and ensure that:\n\n- systems and equipment are appropriate for the class of occupancy and product storage arrangements and are approved by the local fire authority; and\n- equipment is regularly serviced in accordance with the equipment manufacturers\u2019 recommendations and local regulations.\n\n*Reason:* Protection of property and life.\n\n### 3.7.2 Fire prevention, detection and control procedures\n\nFollow standard operating procedures (SOPs) for fire prevention, detection and control. Train staff and carry out regular fire drills. Prohibit smoking in all areas.\n\n*Reason:* Protection of property and life.\n\n## 3.8 Building hygiene\n\n### 3.8.1 Building cleanliness\n\nImplement a cleaning programme for all areas:\n\n- do not allow the accumulation of dust, dirt and waste, including packaging waste;\n- take precautions against spillage or breakage, and cross-contamination;\n\n----\n\n7 Zoned sprinkler systems are recommended to control fires and to localize product damage in the event of system activation.\n\n8 Explosion-proof stores must have a blast roof or wall. Preferably, explosive substances should be stored in an independent building, well separated from the main store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "49023864556d94cf082b3376be92e8954a0cb78fc69831cb6f1b6f08020bad3d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Fire Protection\n\n## 3.7 Fire protection\n\n### 3.7.1 Fire protection equipment\n\nProvide suitable fire detection and fire-fighting equipment, including fire hydrants, in all TTSPP storage areas and ensure that:\n\n- systems and equipment are appropriate for the class of occupancy and product storage arrangements and are approved by the local fire authority; and\n- equipment is regularly serviced in accordance with the equipment manufacturers\u2019 recommendations and local regulations.\n\n*Reason:* Protection of property and life.\n\n### 3.7.2 Fire prevention, detection and control procedures\n\nFollow standard operating procedures (SOPs) for fire prevention, detection and control. Train staff and carry out regular fire drills. Prohibit smoking in all areas.\n\n*Reason:* Protection of property and life.\n\n## 3.8 Building hygiene\n\n### 3.8.1 Building cleanliness\n\nImplement a cleaning programme for all areas:\n\n- do not allow the accumulation of dust, dirt and waste, including packaging waste;\n- take precautions against spillage or breakage, and cross-contamination;\n\n----\n\n7 Zoned sprinkler systems are recommended to control fires and to localize product damage in the event of system activation.\n\n8 Explosion-proof stores must have a blast roof or wall. Preferably, explosive substances should be stored in an independent building, well separated from the main store.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1364, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9e89cac9-3bb3-4aa4-9ea1-6e82ad1b406f": {"__data__": {"id_": "9e89cac9-3bb3-4aa4-9ea1-6e82ad1b406f", "embedding": null, "metadata": {"page_label": "350", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- collect waste in designated closed containers and arrange for safe disposal at frequent intervals;\n- do not permit consumption of food or beverages other than in designated areas; and\n- maintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and to minimize the risk of pest infestation.\n\n### 3.8.2 Pest control\n\nImplement a programme to keep all areas free of pests. This should include enclosed receiving and loading bays. Maintain records to demonstrate compliance with a robust pest control programme.\n\n*Reason:* Protection against damage and contamination of TTSPPs.\n\n## 3.9 Power supply\n\n### 3.9.1 Uninterrupted power supply\n\nWhere possible, and where necessary, ensure that all temperature-controlling equipment for TTSPP storage (i.e. refrigerators, freezers, building management systems, heating, ventilation and air-conditioning (HVAC) systems, compressors, air-handling units, monitoring systems, alarms and related computer equipment) are connected to an uninterrupted power supply (UPS) system. Where a generator and associated control equipment is used it should:\n\n- be able to manage the combined start-up load of all connected temperature-controlling and temperature-monitoring equipment;\n- not exceed the defined parameters of the mains power supply;\n- be equipped with automatic mains failure start-up and automatic shutdown when power is restored; and\n- have adequate fuel tank capacity and sufficient fuel to cover a prolonged power outage.\n\nRegularly test and service UPS equipment and generators. Maintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n----\n\n9. UPS systems may be unnecessary in countries with a very reliable electricity supply. In smaller stores in countries where electricity is only available for a limited period each day, or is entirely absent, an alternative approach to UPS is to use refrigeration equipment with extended holdover capacity, for example, ice-lined refrigerators, or gas, kerosene or solar-powered refrigerators.\n\n10. The installed capacity of the UPS system can be minimized by fitting electronic controls which reduce compressor start-up loads.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Manejo de Residuos y Control de Plagas**: Se enfatiza la importancia de recolectar residuos en contenedores cerrados y deshacerse de ellos de manera segura para proteger los productos farmac\u00e9uticos y minimizar el riesgo de infestaci\u00f3n de plagas. Tambi\u00e9n se requiere mantener registros de limpieza y un programa robusto de control de plagas.\n\n2. **Suministro de Energ\u00eda Ininterrumpido**: Se recomienda que todos los equipos de control de temperatura para el almacenamiento de productos farmac\u00e9uticos est\u00e9n conectados a un sistema de suministro de energ\u00eda ininterrumpido (UPS). Se detallan las especificaciones que debe cumplir un generador en caso de ser utilizado, as\u00ed como la necesidad de realizar pruebas y mantenimiento regular.\n\n3. **Alternativas a los Sistemas UPS**: En regiones con un suministro el\u00e9ctrico confiable, los sistemas UPS pueden no ser necesarios. En lugares donde la electricidad es limitada, se sugiere el uso de equipos de refrigeraci\u00f3n con capacidad de retenci\u00f3n prolongada, como refrigeradores con hielo o alimentados por gas, queroseno o energ\u00eda solar.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que debe tener un generador utilizado en un sistema de suministro de energ\u00eda ininterrumpido (UPS) para el almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: El generador debe ser capaz de manejar la carga de arranque combinada de todos los equipos conectados, no exceder los par\u00e1metros definidos del suministro el\u00e9ctrico, estar equipado con un arranque autom\u00e1tico en caso de fallo de la red y tener una capacidad de tanque de combustible adecuada para cubrir cortes prolongados de energ\u00eda.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la limpieza y el control de plagas en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: Se deben recolectar residuos en contenedores cerrados y deshacerse de ellos de manera segura, no permitir el consumo de alimentos o bebidas fuera de \u00e1reas designadas, y mantener registros de limpieza. Adem\u00e1s, se debe implementar un programa de control de plagas que incluya \u00e1reas de recepci\u00f3n y carga cerradas, con registros que demuestren el cumplimiento.\n\n3. **\u00bfQu\u00e9 alternativas existen para los sistemas UPS en lugares donde la electricidad es limitada o intermitente?**\n   - Respuesta: En lugares con suministro el\u00e9ctrico limitado, se pueden utilizar equipos de refrigeraci\u00f3n con capacidad de retenci\u00f3n prolongada, como refrigeradores con hielo, o refrigeradores alimentados por gas, queroseno o energ\u00eda solar, en lugar de depender de un sistema UPS.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Protecci\u00f3n contra incendios**:\n   - Importancia de contar con equipos adecuados de detecci\u00f3n y extinci\u00f3n de incendios en \u00e1reas de almacenamiento de TTSPP.\n   - Equipos deben ser aprobados por la autoridad local de incendios y adecuados para la clase de ocupaci\u00f3n.\n\n2. **Equipos de protecci\u00f3n contra incendios**:\n   - Se recomienda la instalaci\u00f3n de hidrantes y sistemas de rociadores zonificados para controlar incendios y minimizar da\u00f1os a productos.\n\n3. **Procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios**:\n   - Implementaci\u00f3n de procedimientos operativos est\u00e1ndar (SOP).\n   - Capacitaci\u00f3n del personal y realizaci\u00f3n de simulacros de incendio.\n   - Prohibici\u00f3n de fumar en todas las \u00e1reas.\n\n4. **Higiene del edificio**:\n   - Necesidad de un programa de limpieza para evitar la acumulaci\u00f3n de polvo, suciedad y desechos.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n\n5. **Almacenamiento de sustancias explosivas**:\n   - Almacenes a prueba de explosiones deben tener techos o paredes resistentes a explosiones.\n   - Preferencia por almacenar sustancias explosivas en edificios independientes, separados del almac\u00e9n principal.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **TTSPP (Productos Terap\u00e9uticos y de Salud P\u00fablica)**: Tipo de productos mencionados en el contexto de almacenamiento.\n- **Autoridad local de incendios**: Entidad responsable de la aprobaci\u00f3n de equipos de protecci\u00f3n contra incendios.", "excerpt_keywords": "Keywords: waste management, pest control, uninterrupted power supply, temperature control, pharmaceutical storage"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f41c4458-6c59-4417-a034-b6ff4c8334ed", "node_type": "4", "metadata": {"page_label": "350", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- collect waste in designated closed containers and arrange for safe disposal at frequent intervals;\n- do not permit consumption of food or beverages other than in designated areas; and\n- maintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and to minimize the risk of pest infestation.\n\n### 3.8.2 Pest control\n\nImplement a programme to keep all areas free of pests. This should include enclosed receiving and loading bays. Maintain records to demonstrate compliance with a robust pest control programme.\n\n*Reason:* Protection against damage and contamination of TTSPPs.\n\n## 3.9 Power supply\n\n### 3.9.1 Uninterrupted power supply\n\nWhere possible, and where necessary, ensure that all temperature-controlling equipment for TTSPP storage (i.e. refrigerators, freezers, building management systems, heating, ventilation and air-conditioning (HVAC) systems, compressors, air-handling units, monitoring systems, alarms and related computer equipment) are connected to an uninterrupted power supply (UPS) system. Where a generator and associated control equipment is used it should:\n\n- be able to manage the combined start-up load of all connected temperature-controlling and temperature-monitoring equipment;\n- not exceed the defined parameters of the mains power supply;\n- be equipped with automatic mains failure start-up and automatic shutdown when power is restored; and\n- have adequate fuel tank capacity and sufficient fuel to cover a prolonged power outage.\n\nRegularly test and service UPS equipment and generators. Maintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n----\n\n9. UPS systems may be unnecessary in countries with a very reliable electricity supply. In smaller stores in countries where electricity is only available for a limited period each day, or is entirely absent, an alternative approach to UPS is to use refrigeration equipment with extended holdover capacity, for example, ice-lined refrigerators, or gas, kerosene or solar-powered refrigerators.\n\n10. The installed capacity of the UPS system can be minimized by fitting electronic controls which reduce compressor start-up loads.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "feb747598a01ccc450878138ef28054ffde2f2303e8ac42aa737a628494f267e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- collect waste in designated closed containers and arrange for safe disposal at frequent intervals;\n- do not permit consumption of food or beverages other than in designated areas; and\n- maintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and to minimize the risk of pest infestation.\n\n### 3.8.2 Pest control\n\nImplement a programme to keep all areas free of pests. This should include enclosed receiving and loading bays. Maintain records to demonstrate compliance with a robust pest control programme.\n\n*Reason:* Protection against damage and contamination of TTSPPs.\n\n## 3.9 Power supply\n\n### 3.9.1 Uninterrupted power supply\n\nWhere possible, and where necessary, ensure that all temperature-controlling equipment for TTSPP storage (i.e. refrigerators, freezers, building management systems, heating, ventilation and air-conditioning (HVAC) systems, compressors, air-handling units, monitoring systems, alarms and related computer equipment) are connected to an uninterrupted power supply (UPS) system. Where a generator and associated control equipment is used it should:\n\n- be able to manage the combined start-up load of all connected temperature-controlling and temperature-monitoring equipment;\n- not exceed the defined parameters of the mains power supply;\n- be equipped with automatic mains failure start-up and automatic shutdown when power is restored; and\n- have adequate fuel tank capacity and sufficient fuel to cover a prolonged power outage.\n\nRegularly test and service UPS equipment and generators. Maintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n----\n\n9. UPS systems may be unnecessary in countries with a very reliable electricity supply. In smaller stores in countries where electricity is only available for a limited period each day, or is entirely absent, an alternative approach to UPS is to use refrigeration equipment with extended holdover capacity, for example, ice-lined refrigerators, or gas, kerosene or solar-powered refrigerators.\n\n10. The installed capacity of the UPS system can be minimized by fitting electronic controls which reduce compressor start-up loads.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2189, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e270facf-1c08-44b6-90dc-0039cdebdfb7": {"__data__": {"id_": "e270facf-1c08-44b6-90dc-0039cdebdfb7", "embedding": null, "metadata": {"page_label": "351", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.9.2 Power failure contingency plan\n\nDevelop and maintain a contingency plan to protect TTSPPs in the event of power failure which places products at risk. Alternative emergency cooling systems (e.g. liquid nitrogen or dry ice) are acceptable.\n\n*Reason:* Loss prevention.\n\n# 3.10 Building maintenance\n\nImplement a planned preventive maintenance programme to ensure that storage buildings and building utilities are well maintained. Keep records to demonstrate compliance with the programme.\n\n*Reason:* To ensure that storage buildings continue to protect stored products against damage.\n\n# 4. Temperature-controlled storage\n\n## 4.1 Normative references\n\n- EN 60068-3 parts 5, 6, 7 and 11: *Environmental testing. Guidance. Confirmation of the performance of temperature chambers*\n- International Air Transport Association (IATA) *Perishable cargo regulations chapter 17. 10th ed, July 2010*\n- USP <1079> *Good storage and shipping practices*\n- USP <1118> *Monitoring devices \u2014 time, temperature and humidity*\n\n## 4.2 Storage capacity of temperature-controlled stores\n\nEnsure that the net storage capacity of the temperature-controlled stores is sufficient to accommodate peak TTSPP stock levels and their associated transit temperature protection components (i.e. freezer blocks, flexible ice blankets, refrigerated gel packs, phase change materials and insulated packaging, if retained), under correct temperature conditions and in a manner which enables efficient and correct stock management operations to take place.\n\n*Reason:* To avoid the risks associated with overstocking and to ensure that good warehousing practices can be adopted (i.e. first in-first out (FIFO) or earliest expiry-first out (EEFO)). Overstocking makes FIFO or EEFO handling difficult or impossible and hinders accurate physical stock counts.\n\n## 4.3 Temperature-controlled storage\n\nEnsure that TTSPPs are stored in temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers which comply with the following requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Incluye directrices sobre la planificaci\u00f3n de contingencias ante fallos de energ\u00eda, el mantenimiento de edificios de almacenamiento y los requisitos para el almacenamiento controlado de temperatura. Se enfatiza la importancia de mantener condiciones adecuadas para proteger los productos almacenados y evitar riesgos asociados con el manejo inadecuado de inventarios.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas espec\u00edficas se deben implementar en un plan de contingencia para proteger los TTSPPs durante un fallo de energ\u00eda?**\n   - Respuesta: Se debe desarrollar y mantener un plan de contingencia que incluya sistemas de enfriamiento de emergencia alternativos, como nitr\u00f3geno l\u00edquido o hielo seco, para proteger los TTSPPs en caso de un fallo de energ\u00eda.\n\n2. **\u00bfCu\u00e1les son las referencias normativas que se deben considerar al establecer un almacenamiento controlado de temperatura para TTSPPs?**\n   - Respuesta: Las referencias normativas incluyen EN 60068-3 (pruebas ambientales), las regulaciones de carga perecedera de la IATA (cap\u00edtulo 17), y las pr\u00e1cticas de almacenamiento y env\u00edo de la USP, as\u00ed como los dispositivos de monitoreo de tiempo, temperatura y humedad de la USP.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas de gesti\u00f3n de inventario se deben seguir para evitar problemas asociados con el sobrealmacenamiento de TTSPPs?**\n   - Respuesta: Se deben adoptar buenas pr\u00e1cticas de almacenamiento, como el m\u00e9todo de primero en entrar, primero en salir (FIFO) o el de primero en expirar, primero en salir (EEFO), para evitar los riesgos del sobrealmacenamiento y facilitar conteos f\u00edsicos precisos del inventario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Residuos**:\n   - Importancia de recolectar residuos en contenedores cerrados.\n   - Disposici\u00f3n segura de residuos a intervalos frecuentes.\n   - Prohibici\u00f3n de consumo de alimentos y bebidas fuera de \u00e1reas designadas.\n   - Mantenimiento de registros de limpieza para demostrar cumplimiento.\n\n2. **Control de Plagas**:\n   - Implementaci\u00f3n de un programa para mantener \u00e1reas libres de plagas.\n   - Inclusi\u00f3n de \u00e1reas de recepci\u00f3n y carga cerradas en el programa.\n   - Mantenimiento de registros que demuestren el cumplimiento del programa de control de plagas.\n\n3. **Suministro de Energ\u00eda Ininterrumpido (UPS)**:\n   - Conexi\u00f3n de equipos de control de temperatura a un sistema UPS.\n   - Especificaciones para generadores utilizados en sistemas UPS:\n     - Capacidad para manejar la carga de arranque combinada.\n     - No exceder par\u00e1metros del suministro el\u00e9ctrico.\n     - Arranque autom\u00e1tico en caso de fallo de la red.\n     - Capacidad de tanque de combustible adecuada para cortes prolongados.\n   - Importancia de pruebas y mantenimiento regular de equipos UPS y generadores.\n\n4. **Alternativas a los Sistemas UPS**:\n   - En pa\u00edses con suministro el\u00e9ctrico confiable, los sistemas UPS pueden no ser necesarios.\n   - Uso de refrigeradores con capacidad de retenci\u00f3n prolongada (ej. refrigeradores con hielo, alimentados por gas, queroseno o energ\u00eda solar) en lugares con electricidad limitada.\n\n### Entidades Clave\n- **TTSPP**: Productos farmac\u00e9uticos que requieren control de temperatura.\n- **UPS**: Sistema de suministro de energ\u00eda ininterrumpido.\n- **HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Generadores**: Equipos para proporcionar energ\u00eda en caso de fallo del suministro el\u00e9ctrico.\n- **Contenedores cerrados**: Elementos para la recolecci\u00f3n de residuos.\n- **Programa de control de plagas**: Estrategia para mantener \u00e1reas libres de infestaciones. \n\nEste resumen destaca las pr\u00e1cticas recomendadas para el manejo de residuos, control de plagas y suministro de energ\u00eda en el contexto del almacenamiento de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: TTSPPs, temperature-controlled storage, contingency plan, building maintenance, overstocking"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "58ccd3d8-9628-4fef-962d-04433a0035dc", "node_type": "4", "metadata": {"page_label": "351", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.9.2 Power failure contingency plan\n\nDevelop and maintain a contingency plan to protect TTSPPs in the event of power failure which places products at risk. Alternative emergency cooling systems (e.g. liquid nitrogen or dry ice) are acceptable.\n\n*Reason:* Loss prevention.\n\n# 3.10 Building maintenance\n\nImplement a planned preventive maintenance programme to ensure that storage buildings and building utilities are well maintained. Keep records to demonstrate compliance with the programme.\n\n*Reason:* To ensure that storage buildings continue to protect stored products against damage.\n\n# 4. Temperature-controlled storage\n\n## 4.1 Normative references\n\n- EN 60068-3 parts 5, 6, 7 and 11: *Environmental testing. Guidance. Confirmation of the performance of temperature chambers*\n- International Air Transport Association (IATA) *Perishable cargo regulations chapter 17. 10th ed, July 2010*\n- USP <1079> *Good storage and shipping practices*\n- USP <1118> *Monitoring devices \u2014 time, temperature and humidity*\n\n## 4.2 Storage capacity of temperature-controlled stores\n\nEnsure that the net storage capacity of the temperature-controlled stores is sufficient to accommodate peak TTSPP stock levels and their associated transit temperature protection components (i.e. freezer blocks, flexible ice blankets, refrigerated gel packs, phase change materials and insulated packaging, if retained), under correct temperature conditions and in a manner which enables efficient and correct stock management operations to take place.\n\n*Reason:* To avoid the risks associated with overstocking and to ensure that good warehousing practices can be adopted (i.e. first in-first out (FIFO) or earliest expiry-first out (EEFO)). Overstocking makes FIFO or EEFO handling difficult or impossible and hinders accurate physical stock counts.\n\n## 4.3 Temperature-controlled storage\n\nEnsure that TTSPPs are stored in temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers which comply with the following requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "225ba65752cd378e033b71102086acb2dd7693540de8c8b0f58d85b84adaed54", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.9.2 Power failure contingency plan\n\nDevelop and maintain a contingency plan to protect TTSPPs in the event of power failure which places products at risk. Alternative emergency cooling systems (e.g. liquid nitrogen or dry ice) are acceptable.\n\n*Reason:* Loss prevention.\n\n# 3.10 Building maintenance\n\nImplement a planned preventive maintenance programme to ensure that storage buildings and building utilities are well maintained. Keep records to demonstrate compliance with the programme.\n\n*Reason:* To ensure that storage buildings continue to protect stored products against damage.\n\n# 4. Temperature-controlled storage\n\n## 4.1 Normative references\n\n- EN 60068-3 parts 5, 6, 7 and 11: *Environmental testing. Guidance. Confirmation of the performance of temperature chambers*\n- International Air Transport Association (IATA) *Perishable cargo regulations chapter 17. 10th ed, July 2010*\n- USP <1079> *Good storage and shipping practices*\n- USP <1118> *Monitoring devices \u2014 time, temperature and humidity*\n\n## 4.2 Storage capacity of temperature-controlled stores\n\nEnsure that the net storage capacity of the temperature-controlled stores is sufficient to accommodate peak TTSPP stock levels and their associated transit temperature protection components (i.e. freezer blocks, flexible ice blankets, refrigerated gel packs, phase change materials and insulated packaging, if retained), under correct temperature conditions and in a manner which enables efficient and correct stock management operations to take place.\n\n*Reason:* To avoid the risks associated with overstocking and to ensure that good warehousing practices can be adopted (i.e. first in-first out (FIFO) or earliest expiry-first out (EEFO)). Overstocking makes FIFO or EEFO handling difficult or impossible and hinders accurate physical stock counts.\n\n## 4.3 Temperature-controlled storage\n\nEnsure that TTSPPs are stored in temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers which comply with the following requirements.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2025, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9866f1b2-f068-4e7b-ad4b-05b9e059e49e": {"__data__": {"id_": "9866f1b2-f068-4e7b-ad4b-05b9e059e49e", "embedding": null, "metadata": {"page_label": "352", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Temperature-controlled rooms, cold rooms and freezer rooms should be:\n\n- Capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced at the store location;\n- Preferably equipped with an auto-defrost circuit which has a minimal effect on temperature within the unit during the defrost cycle and maintains temperature within specification for this period;\n- Equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- Connected to a UPS as described in clause 3.9.1;\n- Equipped with a calibrated continuous temperature monitoring system with sensors located at points representing greatest temperature variability and temperature extremes;\n- Preferably equipped with continuous humidity monitoring devices with sensors located at points representing humidity extremes;\n- Equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors, or an access control system, as necessary; locks must have a safety device so that doors can be freely opened from the inside; and\n- Qualified as defined in clause 4.7.\n\n# Refrigerators and freezers should be:\n\n- Purpose-designed for the storage of TTSPPs; household-style units are only acceptable if they have been independently tested and found to comply with the temperature control requirements of a recognized standard for pharmaceutical refrigerators and freezers;[^11]\n- Capable of maintaining the temperature range specified by the TTSPP manufacturer over the full annual ambient temperature range experienced at the storage site;\n- Equipped with calibrated temperature monitoring devices appropriate to the level of risk but preferably capable of continuous recording and with sensor(s) located at a point or points within the cabinet which most accurately represents the temperature profile of the equipment during normal operation;\n- Preferably equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors or lids, or access control system, as necessary; and\n- Qualified and/or tested as defined in clause 4.7.\n\n[^11]: For example, WHO PQS standards for refrigerators and freezers are available at: http://www.who.int/immunization_standards/vaccine_quality/pqs_e03_fridges_freezers/en/index.html.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices para el dise\u00f1o y operaci\u00f3n de habitaciones controladas por temperatura, as\u00ed como de refrigeradores y congeladores destinados al almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se detallan requisitos espec\u00edficos que estos equipos deben cumplir, como la capacidad de mantener rangos de temperatura adecuados, la inclusi\u00f3n de sistemas de monitoreo de temperatura y humedad, alarmas para detectar fallos, y la necesidad de que sean dise\u00f1ados espec\u00edficamente para su prop\u00f3sito.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las habitaciones controladas por temperatura para garantizar la seguridad de los TTSPPs?**\n   - Respuesta: Las habitaciones deben ser capaces de mantener el rango de temperatura definido, estar equipadas con un circuito de autodescongelaci\u00f3n, contar con un circuito de protecci\u00f3n contra bajas temperaturas, estar conectadas a un UPS, tener un sistema de monitoreo de temperatura calibrado, y alarmas para indicar excursiones de temperatura, entre otros requisitos.\n\n2. **\u00bfQu\u00e9 tipo de refrigeradores y congeladores son aceptables para el almacenamiento de TTSPPs seg\u00fan la OMS?**\n   - Respuesta: Solo se aceptan unidades dise\u00f1adas espec\u00edficamente para el almacenamiento de TTSPPs. Las unidades de estilo dom\u00e9stico son aceptables solo si han sido probadas de manera independiente y cumplen con los requisitos de control de temperatura de un est\u00e1ndar reconocido para refrigeradores y congeladores farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en los refrigeradores y congeladores para proteger los TTSPPs?**\n   - Respuesta: Los refrigeradores y congeladores deben estar equipados con puertas o tapas que se puedan bloquear, sistemas de control de acceso seg\u00fan sea necesario, y los mecanismos de bloqueo deben tener un dispositivo de seguridad que permita abrir las puertas desde el interior en caso de emergencia.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Plan de contingencia ante fallos de energ\u00eda (3.9.2)**:\n   - Importancia de desarrollar y mantener un plan para proteger los productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs) en caso de interrupciones de energ\u00eda.\n   - Se aceptan sistemas de enfriamiento de emergencia alternativos, como nitr\u00f3geno l\u00edquido o hielo seco.\n   - **Objetivo**: Prevenci\u00f3n de p\u00e9rdidas.\n\n2. **Mantenimiento de edificios (3.10)**:\n   - Implementaci\u00f3n de un programa de mantenimiento preventivo planificado para asegurar que los edificios de almacenamiento y sus utilidades est\u00e9n en buen estado.\n   - Registro de cumplimiento del programa de mantenimiento.\n   - **Objetivo**: Proteger los productos almacenados contra da\u00f1os.\n\n3. **Almacenamiento controlado de temperatura (4)**:\n   - **Referencias normativas (4.1)**: Incluye normas y regulaciones relevantes como EN 60068-3, regulaciones de la IATA y pr\u00e1cticas de la USP.\n   - **Capacidad de almacenamiento (4.2)**: Asegurar que la capacidad neta de los almacenes controlados por temperatura sea suficiente para manejar los niveles m\u00e1ximos de stock de TTSPPs y sus componentes de protecci\u00f3n t\u00e9rmica.\n     - **Objetivo**: Evitar riesgos de sobrealmacenamiento y facilitar buenas pr\u00e1cticas de gesti\u00f3n de inventario (FIFO y EEFO).\n   - **Requisitos de almacenamiento (4.3)**: Asegurar que los TTSPPs se almacenen en habitaciones y equipos controlados por temperatura que cumplan con los requisitos establecidos.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sistemas de enfriamiento**: Nitr\u00f3geno l\u00edquido, hielo seco.\n- **Normas y regulaciones**: EN 60068-3, IATA, USP.\n- **Pr\u00e1cticas de gesti\u00f3n de inventario**: FIFO (primero en entrar, primero en salir), EEFO (primero en expirar, primero en salir). \n\nEste resumen destaca la importancia de la planificaci\u00f3n, el mantenimiento y el cumplimiento normativo en la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura.", "excerpt_keywords": "Keywords: temperature control, pharmaceutical storage, TTSPPs, refrigeration standards, monitoring systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "30587ff2-ef25-48c4-a1d9-04bb06793b35", "node_type": "4", "metadata": {"page_label": "352", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Temperature-controlled rooms, cold rooms and freezer rooms should be:\n\n- Capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced at the store location;\n- Preferably equipped with an auto-defrost circuit which has a minimal effect on temperature within the unit during the defrost cycle and maintains temperature within specification for this period;\n- Equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- Connected to a UPS as described in clause 3.9.1;\n- Equipped with a calibrated continuous temperature monitoring system with sensors located at points representing greatest temperature variability and temperature extremes;\n- Preferably equipped with continuous humidity monitoring devices with sensors located at points representing humidity extremes;\n- Equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors, or an access control system, as necessary; locks must have a safety device so that doors can be freely opened from the inside; and\n- Qualified as defined in clause 4.7.\n\n# Refrigerators and freezers should be:\n\n- Purpose-designed for the storage of TTSPPs; household-style units are only acceptable if they have been independently tested and found to comply with the temperature control requirements of a recognized standard for pharmaceutical refrigerators and freezers;[^11]\n- Capable of maintaining the temperature range specified by the TTSPP manufacturer over the full annual ambient temperature range experienced at the storage site;\n- Equipped with calibrated temperature monitoring devices appropriate to the level of risk but preferably capable of continuous recording and with sensor(s) located at a point or points within the cabinet which most accurately represents the temperature profile of the equipment during normal operation;\n- Preferably equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors or lids, or access control system, as necessary; and\n- Qualified and/or tested as defined in clause 4.7.\n\n[^11]: For example, WHO PQS standards for refrigerators and freezers are available at: http://www.who.int/immunization_standards/vaccine_quality/pqs_e03_fridges_freezers/en/index.html.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3b336a490d18eeba9152982a0b0c2baa0d4d1ea5a903b1372dee1d6ca7905179", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Temperature-controlled rooms, cold rooms and freezer rooms should be:\n\n- Capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced at the store location;\n- Preferably equipped with an auto-defrost circuit which has a minimal effect on temperature within the unit during the defrost cycle and maintains temperature within specification for this period;\n- Equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- Connected to a UPS as described in clause 3.9.1;\n- Equipped with a calibrated continuous temperature monitoring system with sensors located at points representing greatest temperature variability and temperature extremes;\n- Preferably equipped with continuous humidity monitoring devices with sensors located at points representing humidity extremes;\n- Equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors, or an access control system, as necessary; locks must have a safety device so that doors can be freely opened from the inside; and\n- Qualified as defined in clause 4.7.\n\n# Refrigerators and freezers should be:\n\n- Purpose-designed for the storage of TTSPPs; household-style units are only acceptable if they have been independently tested and found to comply with the temperature control requirements of a recognized standard for pharmaceutical refrigerators and freezers;[^11]\n- Capable of maintaining the temperature range specified by the TTSPP manufacturer over the full annual ambient temperature range experienced at the storage site;\n- Equipped with calibrated temperature monitoring devices appropriate to the level of risk but preferably capable of continuous recording and with sensor(s) located at a point or points within the cabinet which most accurately represents the temperature profile of the equipment during normal operation;\n- Preferably equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors or lids, or access control system, as necessary; and\n- Qualified and/or tested as defined in clause 4.7.\n\n[^11]: For example, WHO PQS standards for refrigerators and freezers are available at: http://www.who.int/immunization_standards/vaccine_quality/pqs_e03_fridges_freezers/en/index.html.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2462, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "110fcc70-98f0-4267-bdd6-dd184fcc2f74": {"__data__": {"id_": "110fcc70-98f0-4267-bdd6-dd184fcc2f74", "embedding": null, "metadata": {"page_label": "353", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Temperature-controlled storage for controlled and hazardous products\n\nEnsure that controlled and hazardous TTSPPs are securely stored:\n\n- Provide dedicated temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers for these TTSPPs, in separate secure areas, as described in clause 3.6.2.\n- Alternatively, but only if acceptable to the regulatory authority, bulk stocks of TTSPPs with high illicit-value may be stored in a securely locked section of a general temperature-controlled storage area.\n\n*Reason:* To protect this category of TTSPPs against theft and misuse and to safeguard workers and general storage areas in the event of an accident involving hazardous substances.\n\n# 4.5 Temperature and humidity control and monitoring in storage\n\n## 4.5.1 Temperature control\n\nProvide thermostatic temperature control systems for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n- System able continuously to maintain air temperatures within the set point limits throughout the validated storage volume;\n- Control sensors accurate to \u00b1 0.5 \u00b0C or better;\n- Control sensors calibrated as described in clause 4.10.1;\n- Control sensors located in areas where greatest variability in temperature is expected to occur in order to maximize available safe storage volume;\n- Control sensors positioned at the hot and cold spots determined by temperature mapping, even if affected by door opening, unless recommendations are being made not to store products in such areas; and\n- Control sensors independent of the temperature monitoring system.\n\n## 4.5.2 Temperature monitoring\n\nProvide air temperature monitoring systems and devices for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n**General requirements**\n\n- Monitoring sensors accurate to \u00b1 0.5 \u00b0C or better for electronic devices and \u00b1 1 \u00b0C or better for alcohol, bi-metal gas or vapour pressure thermometers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) establece directrices sobre el almacenamiento controlado de productos farmac\u00e9uticos y peligrosos (TTSPPs). Se enfatiza la necesidad de contar con instalaciones de almacenamiento con control de temperatura y humedad, as\u00ed como sistemas de monitoreo para garantizar la seguridad y eficacia de estos productos. Se detallan requisitos espec\u00edficos para el control y monitoreo de la temperatura, incluyendo la precisi\u00f3n de los sensores y su ubicaci\u00f3n estrat\u00e9gica.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los requisitos m\u00ednimos para los sistemas de control de temperatura en las habitaciones de almacenamiento de TTSPPs?**\n   - Respuesta: Los sistemas deben mantener continuamente las temperaturas del aire dentro de los l\u00edmites establecidos, contar con sensores de control precisos a \u00b1 0.5 \u00b0C o mejor, estar calibrados adecuadamente, ubicarse en \u00e1reas con mayor variabilidad de temperatura y ser independientes del sistema de monitoreo de temperatura.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para proteger los TTSPPs controlados y peligrosos contra el robo y el uso indebido?**\n   - Respuesta: Se deben proporcionar habitaciones de temperatura controlada dedicadas, as\u00ed como \u00e1reas de almacenamiento seguras. Alternativamente, si es aceptable para la autoridad reguladora, se pueden almacenar existencias a granel de TTSPPs de alto valor il\u00edcito en una secci\u00f3n cerrada de un \u00e1rea de almacenamiento general controlada por temperatura.\n\n3. **\u00bfQu\u00e9 precisi\u00f3n deben tener los sensores de monitoreo de temperatura para cumplir con los requisitos establecidos en el documento?**\n   - Respuesta: Los sensores de monitoreo deben ser precisos a \u00b1 0.5 \u00b0C o mejor para dispositivos electr\u00f3nicos, y a \u00b1 1 \u00b0C o mejor para term\u00f3metros de alcohol, bi-metal, gas o de presi\u00f3n de vapor.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Requisitos para Habitaciones Controladas por Temperatura:**\n   - Capacidad para mantener el rango de temperatura definido.\n   - Equipamiento con circuitos de autodescongelaci\u00f3n y protecci\u00f3n contra bajas temperaturas.\n   - Conexi\u00f3n a un sistema de alimentaci\u00f3n ininterrumpida (UPS).\n   - Monitoreo continuo de temperatura y humedad.\n   - Alarmas para detectar excursiones de temperatura y fallos en la refrigeraci\u00f3n.\n   - Seguridad en el acceso mediante puertas bloqueables.\n\n2. **Requisitos para Refrigeradores y Congeladores:**\n   - Dise\u00f1o espec\u00edfico para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - Capacidad para mantener el rango de temperatura especificado por el fabricante de TTSPPs.\n   - Equipamiento con dispositivos de monitoreo de temperatura calibrados.\n   - Alarmas para detectar problemas de temperatura y refrigeraci\u00f3n.\n   - Seguridad en el acceso mediante puertas o tapas bloqueables.\n\n**Entidades:**\n\n- **TTSPPs:** Productos farmac\u00e9uticos sensibles a la temperatura.\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad que establece las directrices.\n- **UPS (Sistema de Alimentaci\u00f3n Ininterrumpida):** Dispositivo para asegurar el suministro el\u00e9ctrico continuo.\n- **PQS (Prequalification of Vaccines):** Est\u00e1ndares de la OMS para refrigeradores y congeladores.\n\nEste resumen destaca la importancia de mantener condiciones adecuadas de temperatura y seguridad para el almacenamiento de productos farmac\u00e9uticos, as\u00ed como los est\u00e1ndares que deben seguir los equipos utilizados en estos procesos.", "excerpt_keywords": "Keywords: temperature control, hazardous products, storage requirements, monitoring systems, TTSPPs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e3baed74-35a3-4267-98d9-b0129c46da3f", "node_type": "4", "metadata": {"page_label": "353", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Temperature-controlled storage for controlled and hazardous products\n\nEnsure that controlled and hazardous TTSPPs are securely stored:\n\n- Provide dedicated temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers for these TTSPPs, in separate secure areas, as described in clause 3.6.2.\n- Alternatively, but only if acceptable to the regulatory authority, bulk stocks of TTSPPs with high illicit-value may be stored in a securely locked section of a general temperature-controlled storage area.\n\n*Reason:* To protect this category of TTSPPs against theft and misuse and to safeguard workers and general storage areas in the event of an accident involving hazardous substances.\n\n# 4.5 Temperature and humidity control and monitoring in storage\n\n## 4.5.1 Temperature control\n\nProvide thermostatic temperature control systems for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n- System able continuously to maintain air temperatures within the set point limits throughout the validated storage volume;\n- Control sensors accurate to \u00b1 0.5 \u00b0C or better;\n- Control sensors calibrated as described in clause 4.10.1;\n- Control sensors located in areas where greatest variability in temperature is expected to occur in order to maximize available safe storage volume;\n- Control sensors positioned at the hot and cold spots determined by temperature mapping, even if affected by door opening, unless recommendations are being made not to store products in such areas; and\n- Control sensors independent of the temperature monitoring system.\n\n## 4.5.2 Temperature monitoring\n\nProvide air temperature monitoring systems and devices for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n**General requirements**\n\n- Monitoring sensors accurate to \u00b1 0.5 \u00b0C or better for electronic devices and \u00b1 1 \u00b0C or better for alcohol, bi-metal gas or vapour pressure thermometers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "72e2e0a4281fcedd6a5b0249990330fc511bc9af07d889eb71ae2a14e0f7db8d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.4 Temperature-controlled storage for controlled and hazardous products\n\nEnsure that controlled and hazardous TTSPPs are securely stored:\n\n- Provide dedicated temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers for these TTSPPs, in separate secure areas, as described in clause 3.6.2.\n- Alternatively, but only if acceptable to the regulatory authority, bulk stocks of TTSPPs with high illicit-value may be stored in a securely locked section of a general temperature-controlled storage area.\n\n*Reason:* To protect this category of TTSPPs against theft and misuse and to safeguard workers and general storage areas in the event of an accident involving hazardous substances.\n\n# 4.5 Temperature and humidity control and monitoring in storage\n\n## 4.5.1 Temperature control\n\nProvide thermostatic temperature control systems for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n- System able continuously to maintain air temperatures within the set point limits throughout the validated storage volume;\n- Control sensors accurate to \u00b1 0.5 \u00b0C or better;\n- Control sensors calibrated as described in clause 4.10.1;\n- Control sensors located in areas where greatest variability in temperature is expected to occur in order to maximize available safe storage volume;\n- Control sensors positioned at the hot and cold spots determined by temperature mapping, even if affected by door opening, unless recommendations are being made not to store products in such areas; and\n- Control sensors independent of the temperature monitoring system.\n\n## 4.5.2 Temperature monitoring\n\nProvide air temperature monitoring systems and devices for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n**General requirements**\n\n- Monitoring sensors accurate to \u00b1 0.5 \u00b0C or better for electronic devices and \u00b1 1 \u00b0C or better for alcohol, bi-metal gas or vapour pressure thermometers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2109, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ef1c1ddc-b372-421d-9596-6d5c9bd64211": {"__data__": {"id_": "ef1c1ddc-b372-421d-9596-6d5c9bd64211", "embedding": null, "metadata": {"page_label": "354", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Monitoring sensors calibrated as described in clause 4.10.1.\n- Monitoring sensors located in areas where greatest variability in temperature is expected to occur within the qualified and/or tested storage volume as defined in clause 4.7.\n- Monitoring sensors positioned so as to be minimally affected by transient events such as door opening.\n- Temperature monitoring devices, temperature traces or electronic temperature records manually checked at least twice a day, in the morning and evening, seven days a week, including public holidays.\n\n**Temperature-controlled rooms, cold rooms and freezer rooms**\n- Provide a temperature record with a minimum recording frequency of six times per hour for each monitoring sensor position.\n- Provide documentation for each monitoring sensor position which can be stored and accessed.\n- Continue to operate independently in the event of a power failure.\u00b9\u00b2\n\n**Refrigerators and freezers**\n- Preferably, connect refrigerators and freezers to a multipoint monitoring system with a minimum recording frequency of six times per hour for each sensor position which can operate independently in the event of a power failure.\n- Alternatively use battery-powered portable temperature monitoring devices with a minimum recording frequency of six times per hour.\n- The least preferred option is a thermometer or maximum/minimum thermometer.\n- Provide documentation for each appliance which can be stored and accessed.\n\n**Reasons:** To maintain labelled TTSPP temperatures during long-term storage. Thermometers provide only limited and discontinuous temperature information. For this reason, continuous recording devices are preferable.\n\n### 4.5.3 Humidity control\n\nProvide humidity control in temperature-controlled rooms that are used to store TTSPPs which are adversely affected by high relative humidity and are not sufficiently protected by their packaging. Such products are typically labelled \u201cstore in a dry place\u201d, or carry similar wording and require a humidity-controlled environment.\n\n----\n\n\u00b9\u00b2 Where there is no UPS, the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para el monitoreo de temperatura y humedad en el almacenamiento de productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la temperatura (TTSPP). Se enfatiza la importancia de utilizar sensores de monitoreo calibrados, ubicados estrat\u00e9gicamente y con un registro continuo de temperatura. Adem\u00e1s, se requiere un control de humedad en entornos donde los productos pueden verse afectados por la humedad relativa alta. Se sugieren diferentes m\u00e9todos de monitoreo, priorizando sistemas que operen de manera independiente en caso de fallos de energ\u00eda.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener los sensores de monitoreo de temperatura en las habitaciones controladas por temperatura?**\n   - Respuesta: Los sensores deben estar calibrados, ubicados en \u00e1reas con mayor variabilidad de temperatura, posicionados para minimizar el impacto de eventos transitorios (como la apertura de puertas) y deben ser verificados manualmente al menos dos veces al d\u00eda.\n\n2. **\u00bfQu\u00e9 se debe hacer en caso de un fallo de energ\u00eda en los refrigeradores y congeladores utilizados para almacenar TTSPP?**\n   - Respuesta: Los refrigeradores y congeladores deben estar conectados a un sistema de monitoreo multipunto que funcione de manera independiente en caso de un fallo de energ\u00eda, o utilizar dispositivos de monitoreo de temperatura port\u00e1tiles con bater\u00eda que registren al menos seis veces por hora.\n\n3. **\u00bfQu\u00e9 tipo de productos requieren un control de humedad en las habitaciones de almacenamiento y c\u00f3mo se identifican?**\n   - Respuesta: Los productos que son adversamente afectados por alta humedad relativa y que no est\u00e1n suficientemente protegidos por su embalaje requieren control de humedad. Estos productos suelen estar etiquetados con instrucciones como \"almacenar en un lugar seco\" o frases similares.", "prev_section_summary": "### Temas Clave:\n\n1. **Almacenamiento Controlado de Productos**: Se enfatiza la importancia de almacenar productos farmac\u00e9uticos y peligrosos (TTSPPs) en condiciones de temperatura controlada para prevenir el robo, el uso indebido y accidentes.\n\n2. **Requisitos de Control de Temperatura**: Se establecen requisitos espec\u00edficos para los sistemas de control de temperatura en habitaciones de almacenamiento, incluyendo la capacidad de mantener temperaturas dentro de l\u00edmites establecidos y la precisi\u00f3n de los sensores.\n\n3. **Monitoreo de Temperatura**: Se detallan las especificaciones para los sistemas de monitoreo de temperatura, incluyendo la precisi\u00f3n de los sensores y su ubicaci\u00f3n estrat\u00e9gica para maximizar la seguridad del almacenamiento.\n\n4. **Seguridad en el Almacenamiento**: Se menciona la necesidad de \u00e1reas de almacenamiento seguras y dedicadas para TTSPPs, as\u00ed como la posibilidad de almacenar productos de alto valor il\u00edcito en secciones cerradas de \u00e1reas de almacenamiento general.\n\n### Entidades:\n\n- **TTSPPs**: Productos farmac\u00e9uticos y peligrosos que requieren almacenamiento controlado.\n- **Sistemas de Control de Temperatura**: Equipos necesarios para mantener condiciones adecuadas en el almacenamiento.\n- **Sensores de Control y Monitoreo**: Dispositivos utilizados para medir y asegurar la temperatura en las \u00e1reas de almacenamiento.\n- **Autoridad Reguladora**: Entidad que puede aceptar alternativas en el almacenamiento de TTSPPs de alto valor il\u00edcito.\n- **Habitaciones de Almacenamiento**: Espacios dedicados para el almacenamiento seguro de TTSPPs, incluyendo habitaciones de temperatura controlada, c\u00e1maras fr\u00edas, y congeladores. \n\n### Resumen:\nEl documento de la OMS establece directrices para el almacenamiento seguro de productos farmac\u00e9uticos y peligrosos, enfatizando la necesidad de control y monitoreo de temperatura. Se especifican requisitos para los sistemas de control y sensores, as\u00ed como medidas de seguridad para proteger estos productos contra el robo y el uso indebido.", "excerpt_keywords": "Keywords: temperature monitoring, humidity control, TTSPPs, storage guidelines, continuous recording devices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f7bc63ee-6b2c-422d-8a81-aa20f18dff20", "node_type": "4", "metadata": {"page_label": "354", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Monitoring sensors calibrated as described in clause 4.10.1.\n- Monitoring sensors located in areas where greatest variability in temperature is expected to occur within the qualified and/or tested storage volume as defined in clause 4.7.\n- Monitoring sensors positioned so as to be minimally affected by transient events such as door opening.\n- Temperature monitoring devices, temperature traces or electronic temperature records manually checked at least twice a day, in the morning and evening, seven days a week, including public holidays.\n\n**Temperature-controlled rooms, cold rooms and freezer rooms**\n- Provide a temperature record with a minimum recording frequency of six times per hour for each monitoring sensor position.\n- Provide documentation for each monitoring sensor position which can be stored and accessed.\n- Continue to operate independently in the event of a power failure.\u00b9\u00b2\n\n**Refrigerators and freezers**\n- Preferably, connect refrigerators and freezers to a multipoint monitoring system with a minimum recording frequency of six times per hour for each sensor position which can operate independently in the event of a power failure.\n- Alternatively use battery-powered portable temperature monitoring devices with a minimum recording frequency of six times per hour.\n- The least preferred option is a thermometer or maximum/minimum thermometer.\n- Provide documentation for each appliance which can be stored and accessed.\n\n**Reasons:** To maintain labelled TTSPP temperatures during long-term storage. Thermometers provide only limited and discontinuous temperature information. For this reason, continuous recording devices are preferable.\n\n### 4.5.3 Humidity control\n\nProvide humidity control in temperature-controlled rooms that are used to store TTSPPs which are adversely affected by high relative humidity and are not sufficiently protected by their packaging. Such products are typically labelled \u201cstore in a dry place\u201d, or carry similar wording and require a humidity-controlled environment.\n\n----\n\n\u00b9\u00b2 Where there is no UPS, the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "73aa0473eaa641d6d1c82ea88ea092d6548cb1b73f36d3c728974b56f843e512", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Monitoring sensors calibrated as described in clause 4.10.1.\n- Monitoring sensors located in areas where greatest variability in temperature is expected to occur within the qualified and/or tested storage volume as defined in clause 4.7.\n- Monitoring sensors positioned so as to be minimally affected by transient events such as door opening.\n- Temperature monitoring devices, temperature traces or electronic temperature records manually checked at least twice a day, in the morning and evening, seven days a week, including public holidays.\n\n**Temperature-controlled rooms, cold rooms and freezer rooms**\n- Provide a temperature record with a minimum recording frequency of six times per hour for each monitoring sensor position.\n- Provide documentation for each monitoring sensor position which can be stored and accessed.\n- Continue to operate independently in the event of a power failure.\u00b9\u00b2\n\n**Refrigerators and freezers**\n- Preferably, connect refrigerators and freezers to a multipoint monitoring system with a minimum recording frequency of six times per hour for each sensor position which can operate independently in the event of a power failure.\n- Alternatively use battery-powered portable temperature monitoring devices with a minimum recording frequency of six times per hour.\n- The least preferred option is a thermometer or maximum/minimum thermometer.\n- Provide documentation for each appliance which can be stored and accessed.\n\n**Reasons:** To maintain labelled TTSPP temperatures during long-term storage. Thermometers provide only limited and discontinuous temperature information. For this reason, continuous recording devices are preferable.\n\n### 4.5.3 Humidity control\n\nProvide humidity control in temperature-controlled rooms that are used to store TTSPPs which are adversely affected by high relative humidity and are not sufficiently protected by their packaging. Such products are typically labelled \u201cstore in a dry place\u201d, or carry similar wording and require a humidity-controlled environment.\n\n----\n\n\u00b9\u00b2 Where there is no UPS, the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2165, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7684478d-1fb9-4f82-8c13-10e3d257660c": {"__data__": {"id_": "7684478d-1fb9-4f82-8c13-10e3d257660c", "embedding": null, "metadata": {"page_label": "355", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.5.4 Humidity monitoring\n\nProvide humidity monitoring systems and devices in temperature-controlled rooms that are used to store TTSPPs which require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% RH;\n- Sensors calibrated as per clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the qualified storage volume defined in clause 4.7;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- Provides a humidity record with a minimum recording frequency of six times per hour for each sensor position;\n- Provides documentation for each sensor position which can be stored and accessed; and\n- Continues to operate independently in the event of a power failure.13\n\n*Reason:* To maintain labelled TTSPP humidity conditions during long-term storage.\n\n# 4.6 Alarm systems\n\n## 4.6.1 Temperature alarms\n\nProvide temperature alarm systems for temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n### General requirements\n\n- Sensors accurate to \u00b1 0.5 \u00b0C.\n- Sensors calibrated as described in clause 4.10.1.\n- Sensors located to monitor worst-case temperatures within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the temperature monitoring system, sensors should be located close to the temperature monitoring sensors.\n- Sensors positioned so as to be minimally affected by transient events such as door opening.\n\n### Temperature-controlled rooms, cold rooms and freezer rooms\n\n- High/low alarms set points to trigger appropriately located visual alarm(s).\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s).\n\n----\n\n13 Where there is no UPS the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece requisitos m\u00ednimos para los sistemas de monitoreo de humedad y alarmas de temperatura en habitaciones controladas por temperatura, donde se almacenan productos farmac\u00e9uticos y terap\u00e9uticos (TTSPPs). Se especifican las caracter\u00edsticas de los sensores, su ubicaci\u00f3n, la frecuencia de registro de datos y la necesidad de operar de manera independiente en caso de fallos de energ\u00eda. Adem\u00e1s, se detallan los requisitos para los sistemas de alarma de temperatura, incluyendo la precisi\u00f3n de los sensores y la necesidad de alarmas visuales y auditivas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las especificaciones de precisi\u00f3n requeridas para los sensores de humedad y temperatura en el almacenamiento de TTSPPs?**\n   - Respuesta: Los sensores de humedad deben ser precisos a \u00b1 5% RH, mientras que los sensores de temperatura deben ser precisos a \u00b1 0.5 \u00b0C.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los sensores de humedad y temperatura no se vean afectados por eventos transitorios como la apertura de puertas?**\n   - Respuesta: Los sensores deben ser posicionados de tal manera que sean m\u00ednimamente afectados por eventos transitorios, como la apertura de puertas.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para cada posici\u00f3n de sensor de humedad y c\u00f3mo debe ser accesible?**\n   - Respuesta: Se debe proporcionar documentaci\u00f3n para cada posici\u00f3n de sensor que pueda ser almacenada y accesible, asegurando que se mantenga un registro adecuado de las condiciones de humedad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Monitoreo de Temperatura:**\n   - Importancia de utilizar sensores de monitoreo calibrados.\n   - Ubicaci\u00f3n estrat\u00e9gica de los sensores en \u00e1reas con mayor variabilidad de temperatura.\n   - Verificaci\u00f3n manual de registros de temperatura al menos dos veces al d\u00eda.\n   - Registro continuo de temperatura con una frecuencia m\u00ednima de seis veces por hora.\n\n2. **Almacenamiento en Habitaciones Controladas por Temperatura:**\n   - Requisitos para el funcionamiento independiente de los dispositivos en caso de fallos de energ\u00eda.\n   - Preferencia por sistemas de monitoreo multipunto o dispositivos port\u00e1tiles de monitoreo de temperatura.\n\n3. **Control de Humedad:**\n   - Necesidad de controlar la humedad en habitaciones que almacenan productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la humedad.\n   - Identificaci\u00f3n de productos que requieren control de humedad a trav\u00e9s de etiquetas que indican \"almacenar en un lugar seco\".\n\n4. **Documentaci\u00f3n:**\n   - Requerimiento de documentaci\u00f3n accesible para cada posici\u00f3n de sensor y cada aparato de almacenamiento.\n\n**Entidades:**\n\n- **Organizaci\u00f3n:** Organizaci\u00f3n Mundial de la Salud (OMS).\n- **Tipos de Productos:** Productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la temperatura (TTSPP).\n- **Dispositivos de Monitoreo:** Sensores de temperatura, dispositivos de monitoreo port\u00e1tiles, term\u00f3metros.\n- **Condiciones de Almacenamiento:** Habitaciones controladas por temperatura, c\u00e1maras fr\u00edas, congeladores.\n- **Frecuencia de Registro:** M\u00ednimo seis veces por hora.\n- **Condiciones de Humedad:** Alta humedad relativa, productos etiquetados para almacenamiento en un lugar seco.\n\nEste resumen destaca la importancia de un monitoreo riguroso y continuo de temperatura y humedad para garantizar la integridad de los productos sensibles, as\u00ed como la necesidad de documentaci\u00f3n adecuada y preparaci\u00f3n para fallos de energ\u00eda.", "excerpt_keywords": "Keywords: humidity monitoring, temperature alarms, TTSPPs, sensor calibration, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "29c12703-2440-47ac-93ff-d413c8b07ed5", "node_type": "4", "metadata": {"page_label": "355", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.5.4 Humidity monitoring\n\nProvide humidity monitoring systems and devices in temperature-controlled rooms that are used to store TTSPPs which require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% RH;\n- Sensors calibrated as per clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the qualified storage volume defined in clause 4.7;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- Provides a humidity record with a minimum recording frequency of six times per hour for each sensor position;\n- Provides documentation for each sensor position which can be stored and accessed; and\n- Continues to operate independently in the event of a power failure.13\n\n*Reason:* To maintain labelled TTSPP humidity conditions during long-term storage.\n\n# 4.6 Alarm systems\n\n## 4.6.1 Temperature alarms\n\nProvide temperature alarm systems for temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n### General requirements\n\n- Sensors accurate to \u00b1 0.5 \u00b0C.\n- Sensors calibrated as described in clause 4.10.1.\n- Sensors located to monitor worst-case temperatures within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the temperature monitoring system, sensors should be located close to the temperature monitoring sensors.\n- Sensors positioned so as to be minimally affected by transient events such as door opening.\n\n### Temperature-controlled rooms, cold rooms and freezer rooms\n\n- High/low alarms set points to trigger appropriately located visual alarm(s).\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s).\n\n----\n\n13 Where there is no UPS the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b77ba7a18352dea4ced5fc2b4fbd7d0a2d5b97733d944db72bdc2acf4b609f1d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.5.4 Humidity monitoring\n\nProvide humidity monitoring systems and devices in temperature-controlled rooms that are used to store TTSPPs which require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% RH;\n- Sensors calibrated as per clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the qualified storage volume defined in clause 4.7;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- Provides a humidity record with a minimum recording frequency of six times per hour for each sensor position;\n- Provides documentation for each sensor position which can be stored and accessed; and\n- Continues to operate independently in the event of a power failure.13\n\n*Reason:* To maintain labelled TTSPP humidity conditions during long-term storage.\n\n# 4.6 Alarm systems\n\n## 4.6.1 Temperature alarms\n\nProvide temperature alarm systems for temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n### General requirements\n\n- Sensors accurate to \u00b1 0.5 \u00b0C.\n- Sensors calibrated as described in clause 4.10.1.\n- Sensors located to monitor worst-case temperatures within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the temperature monitoring system, sensors should be located close to the temperature monitoring sensors.\n- Sensors positioned so as to be minimally affected by transient events such as door opening.\n\n### Temperature-controlled rooms, cold rooms and freezer rooms\n\n- High/low alarms set points to trigger appropriately located visual alarm(s).\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s).\n\n----\n\n13 Where there is no UPS the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1978, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d35e192b-d33a-4aaf-8e5f-2d6e4b0117f1": {"__data__": {"id_": "d35e192b-d33a-4aaf-8e5f-2d6e4b0117f1", "embedding": null, "metadata": {"page_label": "356", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n**Refrigerators and freezers**\n- Preferably there should be a visual and/or audible alarm system; this may be integrated with a portable continuous temperature monitoring device.\n\n*Reason:* Loss prevention.\n\n### 4.6.2 Humidity alarms\n\nProvide humidity alarm systems for temperature-controlled rooms used to store TTSPPs that require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% relative humidity (RH);\n- Sensors calibrated as described in clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the humidity monitoring system, sensors should be located close to the humidity monitoring sensors;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- High/low alarms set points to trigger appropriately located visual alarm(s);\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s); and\n- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n*Reason:* Loss prevention.\n\n### 4.7 Qualification of temperature-controlled stores\n\nQualify new temperature-controlled storage areas and new refrigeration equipment before it becomes operational. The qualification procedure should:\n\n- Demonstrate the air temperature profile throughout the storage area or equipment cabinet, when empty and in a normal loaded condition;\n- Define zones which should not be used for storage of TTSPPs (for example areas in close proximity to cooling coils, cold air streams or heat sources); and\n- Demonstrate the time taken for temperatures to exceed the designated limits in the event of power failure.\n\nFully document the initial qualification. Carry out additional qualification exercises whenever modifications are made to the storage area that may...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece directrices para la gesti\u00f3n de ambientes controlados de temperatura y humedad, especialmente en el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se enfatiza la importancia de sistemas de alarma para la detecci\u00f3n de cambios en la temperatura y la humedad, as\u00ed como la necesidad de calificar adecuadamente las \u00e1reas de almacenamiento antes de su uso. Las recomendaciones incluyen la instalaci\u00f3n de alarmas visuales y audibles, as\u00ed como sistemas de alerta autom\u00e1tica para el personal de guardia.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son las especificaciones m\u00ednimas requeridas para los sensores de humedad en las habitaciones de almacenamiento controladas por temperatura?**\n   - Respuesta: Los sensores deben ser precisos a \u00b1 5% de humedad relativa (RH), calibrados seg\u00fan lo descrito en la cl\u00e1usula 4.10.2, y ubicados para monitorear los niveles de humedad en el volumen de almacenamiento validado.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para calificar nuevas \u00e1reas de almacenamiento controladas por temperatura antes de que se vuelvan operativas?**\n   - Respuesta: La calificaci\u00f3n debe demostrar el perfil de temperatura del aire en el \u00e1rea de almacenamiento, definir zonas que no deben usarse para el almacenamiento de TTSPPs y demostrar el tiempo que tardan las temperaturas en exceder los l\u00edmites designados en caso de fallo de energ\u00eda.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de alarma se recomiendan para los refrigeradores y congeladores utilizados en el almacenamiento de TTSPPs?**\n   - Respuesta: Se recomienda un sistema de alarma visual y/o audible, que puede integrarse con un dispositivo de monitoreo de temperatura continuo port\u00e1til, as\u00ed como un sistema autom\u00e1tico de marcado telef\u00f3nico o de alerta por SMS para notificar al personal de guardia cuando se activa una alarma fuera del horario laboral.", "prev_section_summary": "### Temas clave:\n\n1. **Monitoreo de Humedad**:\n   - Sistemas y dispositivos de monitoreo de humedad en habitaciones controladas por temperatura para almacenar productos farmac\u00e9uticos y terap\u00e9uticos (TTSPPs).\n   - Requisitos de precisi\u00f3n y calibraci\u00f3n de sensores.\n   - Ubicaci\u00f3n de sensores para monitorear niveles de humedad en condiciones desfavorables.\n   - Registro de datos de humedad con frecuencia m\u00ednima.\n   - Documentaci\u00f3n accesible para cada posici\u00f3n de sensor.\n   - Operaci\u00f3n independiente en caso de fallos de energ\u00eda.\n\n2. **Sistemas de Alarmas de Temperatura**:\n   - Sistemas de alarma para habitaciones controladas por temperatura, c\u00e1maras fr\u00edas, congeladores y refrigeradores.\n   - Especificaciones de precisi\u00f3n y calibraci\u00f3n de sensores de temperatura.\n   - Ubicaci\u00f3n de sensores para monitorear temperaturas en condiciones desfavorables.\n   - Alarmas visuales y auditivas para alertar sobre temperaturas fuera de rango.\n\n### Entidades:\n\n- **TTSPPs**: Productos farmac\u00e9uticos y terap\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento.\n- **Sensores**: Dispositivos utilizados para medir humedad y temperatura, con requisitos espec\u00edficos de precisi\u00f3n y ubicaci\u00f3n.\n- **Documentaci\u00f3n**: Registros necesarios para cada sensor que deben ser accesibles.\n- **Alarmas**: Sistemas de alerta que incluyen alarmas visuales y auditivas para condiciones de temperatura inadecuadas.\n\n### Resumen:\nEl documento de la OMS establece requisitos m\u00ednimos para el monitoreo de humedad y sistemas de alarma de temperatura en el almacenamiento de TTSPPs. Se detallan especificaciones sobre la precisi\u00f3n y calibraci\u00f3n de los sensores, su ubicaci\u00f3n para evitar interferencias, la frecuencia de registro de datos y la necesidad de documentaci\u00f3n accesible. Adem\u00e1s, se enfatiza la importancia de que los sistemas contin\u00faen operando de manera independiente durante cortes de energ\u00eda.", "excerpt_keywords": "Keywords: temperature control, humidity monitoring, alarm systems, TTSPPs, storage qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1abcd144-b47a-4196-a137-4f6905fdbcba", "node_type": "4", "metadata": {"page_label": "356", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n**Refrigerators and freezers**\n- Preferably there should be a visual and/or audible alarm system; this may be integrated with a portable continuous temperature monitoring device.\n\n*Reason:* Loss prevention.\n\n### 4.6.2 Humidity alarms\n\nProvide humidity alarm systems for temperature-controlled rooms used to store TTSPPs that require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% relative humidity (RH);\n- Sensors calibrated as described in clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the humidity monitoring system, sensors should be located close to the humidity monitoring sensors;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- High/low alarms set points to trigger appropriately located visual alarm(s);\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s); and\n- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n*Reason:* Loss prevention.\n\n### 4.7 Qualification of temperature-controlled stores\n\nQualify new temperature-controlled storage areas and new refrigeration equipment before it becomes operational. The qualification procedure should:\n\n- Demonstrate the air temperature profile throughout the storage area or equipment cabinet, when empty and in a normal loaded condition;\n- Define zones which should not be used for storage of TTSPPs (for example areas in close proximity to cooling coils, cold air streams or heat sources); and\n- Demonstrate the time taken for temperatures to exceed the designated limits in the event of power failure.\n\nFully document the initial qualification. Carry out additional qualification exercises whenever modifications are made to the storage area that may...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a0edabf55444ed8427d222ad5280ceef91f141afcc43afa40766dcdb45956241", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n**Refrigerators and freezers**\n- Preferably there should be a visual and/or audible alarm system; this may be integrated with a portable continuous temperature monitoring device.\n\n*Reason:* Loss prevention.\n\n### 4.6.2 Humidity alarms\n\nProvide humidity alarm systems for temperature-controlled rooms used to store TTSPPs that require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% relative humidity (RH);\n- Sensors calibrated as described in clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the humidity monitoring system, sensors should be located close to the humidity monitoring sensors;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- High/low alarms set points to trigger appropriately located visual alarm(s);\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s); and\n- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n*Reason:* Loss prevention.\n\n### 4.7 Qualification of temperature-controlled stores\n\nQualify new temperature-controlled storage areas and new refrigeration equipment before it becomes operational. The qualification procedure should:\n\n- Demonstrate the air temperature profile throughout the storage area or equipment cabinet, when empty and in a normal loaded condition;\n- Define zones which should not be used for storage of TTSPPs (for example areas in close proximity to cooling coils, cold air streams or heat sources); and\n- Demonstrate the time taken for temperatures to exceed the designated limits in the event of power failure.\n\nFully document the initial qualification. Carry out additional qualification exercises whenever modifications are made to the storage area that may...", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2184, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9f77e6d9-e8ca-4ab9-8714-cbb068e314ef": {"__data__": {"id_": "9f77e6d9-e8ca-4ab9-8714-cbb068e314ef", "embedding": null, "metadata": {"page_label": "357", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "increase loading or affect air circulation, or when changes are made to the refrigeration equipment, such as a change in the set point. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\nQualification may not be required for equipment which requires little or no site assembly or commissioning, such as vaccine refrigerators and freezers that have been independently tested and found suitable for the storage of TTSPPs. Independent testing must be carried out between the chosen set points and under the ambient temperature conditions to which the equipment will be exposed during operation. Prequalified equipment of this type must be correctly installed in each location in accordance with written guidance.\n\n*Reason:* To ensure that labelled TTSPP temperatures can be maintained during long-term storage and that the facility can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n### 4.8 Cleanliness of temperature-controlled stores\n\nImplement a cleaning and decontamination programme for all temperature-controlled rooms:\n\n- Ensure that floor areas are fully accessible for cleaning. Do not store goods directly on the floor.\n- Do not permit storage of any non-pharmaceutical products except transport-related items such as icepacks, gel packs and the like.\n- Do not allow the accumulation of dust, dirt and waste, including packaging waste.\n- Take precautions against spillage or breakage, and cross-contamination.\n- Do not allow accumulation of frost and ice, particularly ice contaminated by spillages.\n- Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers, arising from spillage or breakage.\n\n### 4.9 Refrigeration equipment maintenance\n\nImplement a maintenance programme for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers:\n\n- Carry out regular planned preventive maintenance on all temperature-controlling equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Calificaci\u00f3n y Recalificaci\u00f3n de Equipos de Refrigeraci\u00f3n**: Se establece que la calificaci\u00f3n de equipos de refrigeraci\u00f3n, como refrigeradores y congeladores de vacunas, puede no ser necesaria si han sido probados de manera independiente y se instalan correctamente. Sin embargo, se debe considerar la recalificaci\u00f3n si hay variaciones inexplicables en la temperatura o humedad.\n\n2. **Limpieza de Almacenes Controlados por Temperatura**: Se requiere un programa de limpieza y descontaminaci\u00f3n para las habitaciones controladas por temperatura, asegurando que no se acumulen residuos, polvo o productos no farmac\u00e9uticos, y que se tomen precauciones contra derrames y contaminaci\u00f3n cruzada.\n\n3. **Mantenimiento de Equipos de Refrigeraci\u00f3n**: Se debe implementar un programa de mantenimiento preventivo regular para todos los equipos de control de temperatura, garantizando su funcionamiento adecuado y la protecci\u00f3n de los productos farmac\u00e9uticos sensibles a la temperatura.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 condiciones espec\u00edficas deben cumplirse para que no sea necesaria la calificaci\u00f3n de los refrigeradores y congeladores de vacunas?**\n   - Respuesta: La calificaci\u00f3n puede no ser necesaria si los equipos requieren poca o ninguna ensambladura o puesta en marcha en el sitio, han sido probados de manera independiente y se consideran adecuados para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para evitar la acumulaci\u00f3n de contaminantes en las habitaciones controladas por temperatura?**\n   - Respuesta: Se deben implementar medidas como asegurar que las \u00e1reas del suelo sean completamente accesibles para la limpieza, no permitir el almacenamiento de productos no farmac\u00e9uticos, evitar la acumulaci\u00f3n de polvo y residuos, y tomar precauciones contra derrames y contaminaci\u00f3n cruzada.\n\n3. **\u00bfQu\u00e9 tipo de mantenimiento se recomienda para los equipos de refrigeraci\u00f3n y con qu\u00e9 frecuencia debe realizarse?**\n   - Respuesta: Se recomienda llevar a cabo un mantenimiento preventivo planificado regularmente en todos los equipos de control de temperatura, incluyendo habitaciones fr\u00edas, congeladores y refrigeradores, para asegurar su correcto funcionamiento y la protecci\u00f3n de los TTSPPs.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistemas de Alarma**:\n   - Se recomienda la instalaci\u00f3n de sistemas de alarma visual y/o audible para refrigeradores y congeladores utilizados en el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - Se sugiere un sistema autom\u00e1tico de marcado telef\u00f3nico o de alerta por SMS para notificar al personal de guardia cuando se activa una alarma fuera del horario laboral.\n\n2. **Alarmas de Humedad**:\n   - Se deben proporcionar sistemas de alarma de humedad en habitaciones controladas por temperatura que almacenan TTSPPs que requieren un ambiente con control de humedad.\n   - Los sensores de humedad deben cumplir con especificaciones m\u00ednimas, incluyendo precisi\u00f3n de \u00b1 5% de humedad relativa, calibraci\u00f3n adecuada y ubicaci\u00f3n estrat\u00e9gica para monitorear los niveles de humedad.\n\n3. **Calificaci\u00f3n de Almacenes Controlados por Temperatura**:\n   - Es necesario calificar nuevas \u00e1reas de almacenamiento controladas por temperatura y nuevos equipos de refrigeraci\u00f3n antes de que se vuelvan operativos.\n   - La calificaci\u00f3n debe incluir la demostraci\u00f3n del perfil de temperatura del aire, la definici\u00f3n de zonas no aptas para el almacenamiento de TTSPPs y la evaluaci\u00f3n del tiempo que tardan las temperaturas en exceder los l\u00edmites designados en caso de fallo de energ\u00eda.\n\n4. **Prevenci\u00f3n de P\u00e9rdidas**:\n   - La implementaci\u00f3n de estos sistemas y procedimientos tiene como objetivo principal la prevenci\u00f3n de p\u00e9rdidas en el almacenamiento de productos sensibles a la temperatura y humedad.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sensores de Humedad**: Dispositivos utilizados para monitorear la humedad en ambientes controlados.\n- **Sistemas de Alarma**: Mecanismos para alertar sobre cambios en las condiciones de almacenamiento.\n- **Calificaci\u00f3n de Almacenes**: Proceso de validaci\u00f3n de \u00e1reas de almacenamiento y equipos de refrigeraci\u00f3n.", "excerpt_keywords": "Keywords: refrigeration, temperature-controlled storage, maintenance, cleanliness, qualification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6d4527f-9ca5-40f7-bacd-c2fb6f4b955f", "node_type": "4", "metadata": {"page_label": "357", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "increase loading or affect air circulation, or when changes are made to the refrigeration equipment, such as a change in the set point. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\nQualification may not be required for equipment which requires little or no site assembly or commissioning, such as vaccine refrigerators and freezers that have been independently tested and found suitable for the storage of TTSPPs. Independent testing must be carried out between the chosen set points and under the ambient temperature conditions to which the equipment will be exposed during operation. Prequalified equipment of this type must be correctly installed in each location in accordance with written guidance.\n\n*Reason:* To ensure that labelled TTSPP temperatures can be maintained during long-term storage and that the facility can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n### 4.8 Cleanliness of temperature-controlled stores\n\nImplement a cleaning and decontamination programme for all temperature-controlled rooms:\n\n- Ensure that floor areas are fully accessible for cleaning. Do not store goods directly on the floor.\n- Do not permit storage of any non-pharmaceutical products except transport-related items such as icepacks, gel packs and the like.\n- Do not allow the accumulation of dust, dirt and waste, including packaging waste.\n- Take precautions against spillage or breakage, and cross-contamination.\n- Do not allow accumulation of frost and ice, particularly ice contaminated by spillages.\n- Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers, arising from spillage or breakage.\n\n### 4.9 Refrigeration equipment maintenance\n\nImplement a maintenance programme for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers:\n\n- Carry out regular planned preventive maintenance on all temperature-controlling equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fc7f514963fe741b755715ffec6a6031a540734d4236f31dbbc095c0322d6e70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "increase loading or affect air circulation, or when changes are made to the refrigeration equipment, such as a change in the set point. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\nQualification may not be required for equipment which requires little or no site assembly or commissioning, such as vaccine refrigerators and freezers that have been independently tested and found suitable for the storage of TTSPPs. Independent testing must be carried out between the chosen set points and under the ambient temperature conditions to which the equipment will be exposed during operation. Prequalified equipment of this type must be correctly installed in each location in accordance with written guidance.\n\n*Reason:* To ensure that labelled TTSPP temperatures can be maintained during long-term storage and that the facility can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n### 4.8 Cleanliness of temperature-controlled stores\n\nImplement a cleaning and decontamination programme for all temperature-controlled rooms:\n\n- Ensure that floor areas are fully accessible for cleaning. Do not store goods directly on the floor.\n- Do not permit storage of any non-pharmaceutical products except transport-related items such as icepacks, gel packs and the like.\n- Do not allow the accumulation of dust, dirt and waste, including packaging waste.\n- Take precautions against spillage or breakage, and cross-contamination.\n- Do not allow accumulation of frost and ice, particularly ice contaminated by spillages.\n- Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers, arising from spillage or breakage.\n\n### 4.9 Refrigeration equipment maintenance\n\nImplement a maintenance programme for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers:\n\n- Carry out regular planned preventive maintenance on all temperature-controlling equipment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2210, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6257a5f0-a145-452e-99b4-ef5978999f7a": {"__data__": {"id_": "6257a5f0-a145-452e-99b4-ef5978999f7a", "embedding": null, "metadata": {"page_label": "358", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Make arrangements to ensure that emergency maintenance is carried out within a time period that does not place TTSPPs at risk of damage.\n- Ensure that there is a contingency plan to move products stored in non-functioning equipment to a safe location before damage to the product occurs in the event that equipment cannot be repaired in a timely manner.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n## 4.10 Calibration and verification of control and monitoring devices\n\n### 4.10.1 Calibration of temperature control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified. Calibration should demonstrate the accuracy of the unit across the entire temperature range over which the device is designed to be used. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.2 Calibration of humidity control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year unless otherwise justified. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.3 Alarm equipment verification\n\nCheck functionality of temperature and humidity alarms at least once every six months at the designated set points.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that labelled TTSPP storage temperatures and humidity control can be maintained during long-term storage and that the store can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\nWhere powered materials handling equipment is used in temperature-controlled rooms, cold rooms or freezer rooms, select equipment which is certified for safe use in confined spaces.\n\n*Reason:* Protection of the workforce.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mantenimiento de Equipos y Planificaci\u00f3n de Contingencias**: Se enfatiza la importancia de realizar mantenimiento de emergencia en equipos que almacenan productos sensibles, asegurando que no se pongan en riesgo. Adem\u00e1s, se requiere un plan de contingencia para mover productos a un lugar seguro si el equipo no puede ser reparado a tiempo.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos de Control**: Se establecen directrices para la calibraci\u00f3n de dispositivos de control de temperatura y humedad, que deben realizarse al menos una vez al a\u00f1o. Tambi\u00e9n se requiere la verificaci\u00f3n de alarmas de temperatura y humedad cada seis meses para garantizar el cumplimiento de las normativas.\n\n3. **Manejo de Materiales**: Se especifica que el equipo de manejo de materiales utilizado en habitaciones controladas por temperatura debe estar certificado para su uso seguro en espacios confinados, priorizando la protecci\u00f3n del personal.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si un equipo de almacenamiento de productos no funciona y no puede ser reparado a tiempo?**\n   - El contexto menciona que se debe tener un plan de contingencia para mover los productos almacenados en equipos no funcionales a una ubicaci\u00f3n segura antes de que ocurra da\u00f1o al producto.\n\n2. **\u00bfCon qu\u00e9 frecuencia deben calibrarse los dispositivos de control de temperatura y humedad, y qu\u00e9 excepciones existen?**\n   - Los dispositivos deben calibrarse al menos una vez al a\u00f1o, a menos que se justifique lo contrario. Los dispositivos de un solo uso que vienen con un certificado de calibraci\u00f3n del fabricante no necesitan ser recalibrados.\n\n3. **\u00bfQu\u00e9 tipo de equipo de manejo de materiales se debe utilizar en habitaciones controladas por temperatura?**\n   - Se debe seleccionar equipo de manejo de materiales que est\u00e9 certificado para su uso seguro en espacios confinados, especialmente en habitaciones controladas por temperatura, c\u00e1maras fr\u00edas o congeladores, para proteger al personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n y Recalificaci\u00f3n de Equipos de Refrigeraci\u00f3n**:\n   - **Condiciones para la no calificaci\u00f3n**: Equipos que requieren poca o ninguna ensambladura, que han sido probados independientemente y son adecuados para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - **Importancia de la recalificaci\u00f3n**: Necesaria si hay variaciones inexplicables en la temperatura o humedad.\n\n2. **Limpieza de Almacenes Controlados por Temperatura**:\n   - **Programa de limpieza y descontaminaci\u00f3n**: Debe incluir la accesibilidad de las \u00e1reas del suelo, prohibici\u00f3n de almacenamiento de productos no farmac\u00e9uticos, y medidas contra la acumulaci\u00f3n de residuos y contaminaci\u00f3n cruzada.\n   - **Precauciones**: Evitar acumulaciones de polvo, derrames y hielo contaminado.\n\n3. **Mantenimiento de Equipos de Refrigeraci\u00f3n**:\n   - **Programa de mantenimiento preventivo**: Debe ser regular y planificado para todos los equipos de control de temperatura, incluyendo habitaciones fr\u00edas, congeladores y refrigeradores.\n   - **Objetivo**: Asegurar el correcto funcionamiento de los equipos y la protecci\u00f3n de los TTSPPs.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Equipos de Refrigeraci\u00f3n**: Refrigeradores y congeladores, especialmente para vacunas.\n- **Regulaciones**: Normativas que deben cumplirse para demostrar el debido cuidado ante autoridades regulatorias.\n\n### Razones Fundamentales\n- **Protecci\u00f3n de TTSPPs**: Asegurar que las temperaturas etiquetadas se mantengan durante el almacenamiento a largo plazo.\n- **Seguridad de los Trabajadores**: Minimizar riesgos de da\u00f1os y contaminaci\u00f3n por derrames o roturas.", "excerpt_keywords": "Keywords: maintenance, calibration, temperature control, materials handling, TTSPPs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4407880f-81c8-44ad-b4f5-4d725cbbb5ca", "node_type": "4", "metadata": {"page_label": "358", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Make arrangements to ensure that emergency maintenance is carried out within a time period that does not place TTSPPs at risk of damage.\n- Ensure that there is a contingency plan to move products stored in non-functioning equipment to a safe location before damage to the product occurs in the event that equipment cannot be repaired in a timely manner.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n## 4.10 Calibration and verification of control and monitoring devices\n\n### 4.10.1 Calibration of temperature control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified. Calibration should demonstrate the accuracy of the unit across the entire temperature range over which the device is designed to be used. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.2 Calibration of humidity control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year unless otherwise justified. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.3 Alarm equipment verification\n\nCheck functionality of temperature and humidity alarms at least once every six months at the designated set points.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that labelled TTSPP storage temperatures and humidity control can be maintained during long-term storage and that the store can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\nWhere powered materials handling equipment is used in temperature-controlled rooms, cold rooms or freezer rooms, select equipment which is certified for safe use in confined spaces.\n\n*Reason:* Protection of the workforce.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "20aa462081477e0fa4e9b783f3b23ce587f7f50d49d7ef50a37f3980b3b06cc9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Make arrangements to ensure that emergency maintenance is carried out within a time period that does not place TTSPPs at risk of damage.\n- Ensure that there is a contingency plan to move products stored in non-functioning equipment to a safe location before damage to the product occurs in the event that equipment cannot be repaired in a timely manner.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n## 4.10 Calibration and verification of control and monitoring devices\n\n### 4.10.1 Calibration of temperature control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified. Calibration should demonstrate the accuracy of the unit across the entire temperature range over which the device is designed to be used. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.2 Calibration of humidity control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year unless otherwise justified. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.3 Alarm equipment verification\n\nCheck functionality of temperature and humidity alarms at least once every six months at the designated set points.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that labelled TTSPP storage temperatures and humidity control can be maintained during long-term storage and that the store can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\nWhere powered materials handling equipment is used in temperature-controlled rooms, cold rooms or freezer rooms, select equipment which is certified for safe use in confined spaces.\n\n*Reason:* Protection of the workforce.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1992, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4a87a2e1-9e07-4e33-a630-d5ab40fe196e": {"__data__": {"id_": "4a87a2e1-9e07-4e33-a630-d5ab40fe196e", "embedding": null, "metadata": {"page_label": "359", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Transport and delivery\n\n## 6.1 Normative references\n\n- Directive 94/62/EC. *European Parliament and Council Directive of 20 December 1994 on packaging and packaging waste*. 1994.\n- EN 13428:2004. *Packaging. Requirements specific to manufacturing and composition. Prevention by source reduction*.\n- EN 13430:2004. *Packaging. Requirements for packaging recoverable by material recycling*.\n- EN 13431:2004. *Packaging. Requirements for packaging recoverable in the form of energy recovery, including specification of minimum inferior calorific value*.\n- EN 13432:2000. *Packaging. Requirements for packaging recoverable through composting and biodegradation. Test scheme and evaluation criteria for the final acceptance of packaging*.\n- IATA Perishable Cargo Regulations Chapter 17, 9th Edition, July 2009. *Isothermal and refrigerating containers for health products \u2014 Thermal performance qualification method*.\n- ISTA \u2014 5B: *Focused Simulation Guide for Thermal Performance Testing of Temperature Controlled Transport Packaging*.\n- ISTA \u2014 7D: *Thermal Controlled Transport Packaging for Parcel Delivery System Shipment. Basic Requirements: atmospheric conditioning, vibration and shock testing*.\n- WHO Technical Report Series, No. 937, 2006. Annex 5: *Good distribution practices for pharmaceutical products*.\n\n## 6.2 Product stability profiles\n\nTransport TTSPPs in such a manner that transport temperatures meet local regulatory requirements at the sending and receiving sites and/or so that temperature excursions above or below the manufacturer\u2019s labelled storage temperature range do not adversely affect product quality. Product stability data must demonstrate the acceptable temperature excursion time during transport.\n\n*Reason*: Protection of TTSPPs against degradation.\n\n## 6.3 Transport route profiling and qualification\n\nProfile and qualify transport routes:\n\n- Select the most suitable methods for protecting TTSPPs against anticipated ambient temperature and humidity conditions throughout the year.\n- Use suitable methods, including published standards, weather data, laboratory tests and field tests to select suitable transport equipment and shipping containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos No. 961 aborda el transporte y la entrega de productos farmac\u00e9uticos, enfatizando la importancia de cumplir con las normativas y est\u00e1ndares para garantizar la estabilidad y calidad de los productos durante el transporte. Se mencionan referencias normativas clave, la necesidad de mantener las temperaturas adecuadas durante el transporte y la importancia de perfilar y calificar las rutas de transporte para proteger los productos farmac\u00e9uticos de condiciones ambientales adversas.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las normativas espec\u00edficas que deben seguirse para el transporte de productos farmac\u00e9uticos seg\u00fan el documento de la OMS?**\n   - Esta pregunta se centra en las referencias normativas mencionadas en la secci\u00f3n 6.1, que incluyen directivas y est\u00e1ndares relevantes para el embalaje y el transporte de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 datos de estabilidad del producto son necesarios para garantizar que los TTSPPs no se degraden durante el transporte?**\n   - Esta pregunta se relaciona con la secci\u00f3n 6.2, donde se discute la importancia de demostrar la aceptabilidad de las excursiones de temperatura durante el transporte y c\u00f3mo esto afecta la calidad del producto.\n\n3. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para perfilar y calificar las rutas de transporte de productos farmac\u00e9uticos?**\n   - Esta pregunta se refiere a la secci\u00f3n 6.3, que detalla los m\u00e9todos adecuados para proteger los productos farmac\u00e9uticos de las condiciones ambientales, incluyendo el uso de datos meteorol\u00f3gicos y pruebas de laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Equipos**:\n   - Importancia de realizar mantenimiento de emergencia para evitar da\u00f1os a productos sensibles.\n   - Necesidad de un plan de contingencia para mover productos a un lugar seguro si el equipo no puede ser reparado a tiempo.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos**:\n   - **Dispositivos de Control de Temperatura**: Deben calibrarse al menos una vez al a\u00f1o, salvo justificaci\u00f3n en contrario. Los dispositivos de un solo uso con certificado de calibraci\u00f3n del fabricante no requieren recalibraci\u00f3n.\n   - **Dispositivos de Control de Humedad**: Igual que los de temperatura, deben calibrarse anualmente, con la misma excepci\u00f3n para dispositivos de un solo uso.\n   - **Verificaci\u00f3n de Alarmas**: Se debe comprobar la funcionalidad de alarmas de temperatura y humedad cada seis meses.\n\n3. **Manejo de Materiales**:\n   - Equipos de manejo de materiales en habitaciones controladas por temperatura deben estar certificados para su uso seguro en espacios confinados, priorizando la protecci\u00f3n del personal.\n\n### Entidades Clave\n- **TTSPPs**: Productos sensibles a la temperatura.\n- **Dispositivos de Control**: Incluyen dispositivos de temperatura y humedad.\n- **Equipos de Manejo de Materiales**: Equipos utilizados en entornos controlados.\n- **Reguladores**: Autoridades que supervisan el cumplimiento normativo.\n\n### Razones Clave\n- **Prevenci\u00f3n de P\u00e9rdidas**: Mantener la integridad de los productos almacenados.\n- **Protecci\u00f3n del Personal**: Asegurar un entorno de trabajo seguro.", "excerpt_keywords": "Keywords: transport, pharmaceutical products, temperature control, regulatory compliance, product stability"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4ce659d3-381d-4df8-aa5f-a829932d760e", "node_type": "4", "metadata": {"page_label": "359", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Transport and delivery\n\n## 6.1 Normative references\n\n- Directive 94/62/EC. *European Parliament and Council Directive of 20 December 1994 on packaging and packaging waste*. 1994.\n- EN 13428:2004. *Packaging. Requirements specific to manufacturing and composition. Prevention by source reduction*.\n- EN 13430:2004. *Packaging. Requirements for packaging recoverable by material recycling*.\n- EN 13431:2004. *Packaging. Requirements for packaging recoverable in the form of energy recovery, including specification of minimum inferior calorific value*.\n- EN 13432:2000. *Packaging. Requirements for packaging recoverable through composting and biodegradation. Test scheme and evaluation criteria for the final acceptance of packaging*.\n- IATA Perishable Cargo Regulations Chapter 17, 9th Edition, July 2009. *Isothermal and refrigerating containers for health products \u2014 Thermal performance qualification method*.\n- ISTA \u2014 5B: *Focused Simulation Guide for Thermal Performance Testing of Temperature Controlled Transport Packaging*.\n- ISTA \u2014 7D: *Thermal Controlled Transport Packaging for Parcel Delivery System Shipment. Basic Requirements: atmospheric conditioning, vibration and shock testing*.\n- WHO Technical Report Series, No. 937, 2006. Annex 5: *Good distribution practices for pharmaceutical products*.\n\n## 6.2 Product stability profiles\n\nTransport TTSPPs in such a manner that transport temperatures meet local regulatory requirements at the sending and receiving sites and/or so that temperature excursions above or below the manufacturer\u2019s labelled storage temperature range do not adversely affect product quality. Product stability data must demonstrate the acceptable temperature excursion time during transport.\n\n*Reason*: Protection of TTSPPs against degradation.\n\n## 6.3 Transport route profiling and qualification\n\nProfile and qualify transport routes:\n\n- Select the most suitable methods for protecting TTSPPs against anticipated ambient temperature and humidity conditions throughout the year.\n- Use suitable methods, including published standards, weather data, laboratory tests and field tests to select suitable transport equipment and shipping containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9898f7529ad83321ac1866beaa08c5e54dab6bc7432a4baf853e188b86785f36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6. Transport and delivery\n\n## 6.1 Normative references\n\n- Directive 94/62/EC. *European Parliament and Council Directive of 20 December 1994 on packaging and packaging waste*. 1994.\n- EN 13428:2004. *Packaging. Requirements specific to manufacturing and composition. Prevention by source reduction*.\n- EN 13430:2004. *Packaging. Requirements for packaging recoverable by material recycling*.\n- EN 13431:2004. *Packaging. Requirements for packaging recoverable in the form of energy recovery, including specification of minimum inferior calorific value*.\n- EN 13432:2000. *Packaging. Requirements for packaging recoverable through composting and biodegradation. Test scheme and evaluation criteria for the final acceptance of packaging*.\n- IATA Perishable Cargo Regulations Chapter 17, 9th Edition, July 2009. *Isothermal and refrigerating containers for health products \u2014 Thermal performance qualification method*.\n- ISTA \u2014 5B: *Focused Simulation Guide for Thermal Performance Testing of Temperature Controlled Transport Packaging*.\n- ISTA \u2014 7D: *Thermal Controlled Transport Packaging for Parcel Delivery System Shipment. Basic Requirements: atmospheric conditioning, vibration and shock testing*.\n- WHO Technical Report Series, No. 937, 2006. Annex 5: *Good distribution practices for pharmaceutical products*.\n\n## 6.2 Product stability profiles\n\nTransport TTSPPs in such a manner that transport temperatures meet local regulatory requirements at the sending and receiving sites and/or so that temperature excursions above or below the manufacturer\u2019s labelled storage temperature range do not adversely affect product quality. Product stability data must demonstrate the acceptable temperature excursion time during transport.\n\n*Reason*: Protection of TTSPPs against degradation.\n\n## 6.3 Transport route profiling and qualification\n\nProfile and qualify transport routes:\n\n- Select the most suitable methods for protecting TTSPPs against anticipated ambient temperature and humidity conditions throughout the year.\n- Use suitable methods, including published standards, weather data, laboratory tests and field tests to select suitable transport equipment and shipping containers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2184, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e237ac85-56f2-43d1-89d4-18a7ffaa893c": {"__data__": {"id_": "e237ac85-56f2-43d1-89d4-18a7ffaa893c", "embedding": null, "metadata": {"page_label": "360", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.4 Temperature-controlled transport\n\n## 6.4.1 Air and sea transport\n\nEnsure that any carrier contracted to transport TTSPPs by air or by sea operates under the terms of a formal service level agreement (SLA) drawn up between the parties. The carrier is to be made responsible for maintaining load temperatures within the transport temperature profile defined for each product.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\nTemperature-controlled road vehicles operated by common carriers\n\nTemperature control in vehicles operated by a common carrier must be qualified and the details and responsibilities for this process should be set out in a formal SLA drawn up between the parties.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\n## 6.4.2 Temperature-controlled road vehicles generally\n\nEnsure that temperature-controlled road vehicles used for the transport of TTSPPs are:\n\n- capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced over known distribution routes and when the vehicle is in motion, or parked with the main engine stopped;\n- equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- equipped with calibrated temperature monitoring devices with sensors located at points representing temperature extremes;\n- equipped with alarms to alert the driver in the event of temperature excursions and/or refrigeration unit failure;\n- fitted with doors with security seals and/or security locks that protect against unauthorized access during transit;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el transporte controlado por temperatura de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se enfatiza la importancia de establecer acuerdos de nivel de servicio (SLA) con los transportistas, ya sea por aire, mar o carretera, para garantizar que se mantengan las temperaturas adecuadas durante el transporte. Adem\u00e1s, se detallan las caracter\u00edsticas que deben tener los veh\u00edculos de transporte por carretera, incluyendo la capacidad de mantener rangos de temperatura, dispositivos de monitoreo, alarmas y medidas de seguridad.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 medidas deben incluirse en un SLA para el transporte de TTSPPs por aire o mar?**\n   - El SLA debe incluir la responsabilidad del transportista de mantener las temperaturas de carga dentro del perfil de temperatura definido para cada producto, as\u00ed como la capacidad de demostrar el cumplimiento a la organizaci\u00f3n contratante y a las autoridades regulatorias.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas esenciales que deben tener los veh\u00edculos de transporte por carretera para TTSPPs?**\n   - Los veh\u00edculos deben ser capaces de mantener el rango de temperatura definido, estar equipados con un circuito de protecci\u00f3n contra bajas temperaturas, tener dispositivos de monitoreo calibrados, alarmas para alertar sobre excursiones de temperatura y contar con medidas de seguridad como sellos y cerraduras en las puertas.\n\n3. **\u00bfPor qu\u00e9 es importante que los transportistas sean responsables de mantener las temperaturas de carga durante el transporte de TTSPPs?**\n   - Es crucial para garantizar la integridad y eficacia de los productos farmac\u00e9uticos, as\u00ed como para cumplir con las regulaciones y demostrar el cumplimiento a las partes interesadas, incluyendo organizaciones contratantes y autoridades regulatorias.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n 6: Transporte y entrega\n\n1. **Normativas y Referencias Normativas**:\n   - Se enumeran diversas directivas y est\u00e1ndares que regulan el embalaje y el transporte de productos farmac\u00e9uticos, incluyendo:\n     - **Directiva 94/62/EC**: Relativa al embalaje y residuos de embalaje.\n     - **Normas EN**: Que abordan requisitos espec\u00edficos para el embalaje, reciclaje y biodegradaci\u00f3n.\n     - **Regulaciones IATA**: Para el transporte de carga perecedera.\n     - **Normas ISTA**: Para pruebas de rendimiento t\u00e9rmico en embalajes controlados por temperatura.\n     - **Informe T\u00e9cnico de la OMS No. 937**: Buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n\n2. **Perfiles de Estabilidad del Producto**:\n   - Se enfatiza la necesidad de transportar productos farmac\u00e9uticos (TTSPPs) manteniendo las temperaturas adecuadas seg\u00fan las regulaciones locales y las especificaciones del fabricante.\n   - Se requiere demostrar que las excursiones de temperatura durante el transporte no afectan negativamente la calidad del producto.\n\n3. **Perfilado y Calificaci\u00f3n de Rutas de Transporte**:\n   - Se deben perfilar y calificar las rutas de transporte para proteger los TTSPPs de condiciones ambientales adversas.\n   - Se recomienda seleccionar m\u00e9todos adecuados basados en est\u00e1ndares publicados, datos meteorol\u00f3gicos, y pruebas de laboratorio y de campo para elegir el equipo de transporte y los contenedores de env\u00edo apropiados.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Directivas y Normas**: Incluyen la Directiva 94/62/EC, normas EN, regulaciones IATA, y normas ISTA.\n- **TTSPPs**: T\u00e9rmino que se refiere a productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de transporte.\n- **Condiciones Ambientales**: Factores como temperatura y humedad que pueden afectar la calidad de los productos durante el transporte. \n\nEste resumen destaca la importancia de seguir normativas espec\u00edficas y de implementar pr\u00e1cticas adecuadas para asegurar la calidad y estabilidad de los productos farmac\u00e9uticos durante su transporte.", "excerpt_keywords": "Keywords: temperature-controlled transport, TTSPPs, service level agreement, temperature monitoring, pharmaceutical logistics"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f1482fd4-de70-4fdb-90be-5cbac8082963", "node_type": "4", "metadata": {"page_label": "360", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.4 Temperature-controlled transport\n\n## 6.4.1 Air and sea transport\n\nEnsure that any carrier contracted to transport TTSPPs by air or by sea operates under the terms of a formal service level agreement (SLA) drawn up between the parties. The carrier is to be made responsible for maintaining load temperatures within the transport temperature profile defined for each product.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\nTemperature-controlled road vehicles operated by common carriers\n\nTemperature control in vehicles operated by a common carrier must be qualified and the details and responsibilities for this process should be set out in a formal SLA drawn up between the parties.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\n## 6.4.2 Temperature-controlled road vehicles generally\n\nEnsure that temperature-controlled road vehicles used for the transport of TTSPPs are:\n\n- capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced over known distribution routes and when the vehicle is in motion, or parked with the main engine stopped;\n- equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- equipped with calibrated temperature monitoring devices with sensors located at points representing temperature extremes;\n- equipped with alarms to alert the driver in the event of temperature excursions and/or refrigeration unit failure;\n- fitted with doors with security seals and/or security locks that protect against unauthorized access during transit;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bc75c9b631fb7bd3dbd21b6badd07376f22c80ab5a27c315af1e03e76b0da174", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.4 Temperature-controlled transport\n\n## 6.4.1 Air and sea transport\n\nEnsure that any carrier contracted to transport TTSPPs by air or by sea operates under the terms of a formal service level agreement (SLA) drawn up between the parties. The carrier is to be made responsible for maintaining load temperatures within the transport temperature profile defined for each product.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\nTemperature-controlled road vehicles operated by common carriers\n\nTemperature control in vehicles operated by a common carrier must be qualified and the details and responsibilities for this process should be set out in a formal SLA drawn up between the parties.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\n## 6.4.2 Temperature-controlled road vehicles generally\n\nEnsure that temperature-controlled road vehicles used for the transport of TTSPPs are:\n\n- capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced over known distribution routes and when the vehicle is in motion, or parked with the main engine stopped;\n- equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- equipped with calibrated temperature monitoring devices with sensors located at points representing temperature extremes;\n- equipped with alarms to alert the driver in the event of temperature excursions and/or refrigeration unit failure;\n- fitted with doors with security seals and/or security locks that protect against unauthorized access during transit;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2166, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b5e365a0-7a8c-4505-83fb-df4d965cb6c3": {"__data__": {"id_": "b5e365a0-7a8c-4505-83fb-df4d965cb6c3", "embedding": null, "metadata": {"page_label": "361", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- qualified as defined in clause 6.6; and\n- regularly calibrated and maintained and records kept to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.4.3 Transport of controlled TTSPPs and TTSPPs with high illicit value\n\nEnsure that controlled TTSPPs and TTSPPs with high illicit value are transported in the following manner:\n\n- Transport practices comply with all relevant local legislation and regulations.\n- Vehicles are equipped with lockable doors and an intruder alarm.\n- Vehicles use unique seal lock indicating devices such as cable seal locks with unique identifiers that are tamper-resistant to protect against unauthorized access during transit. [^14]\n- Security-cleared delivery drivers are employed.\n- All deliveries are documented and tracked.\n- Signed dispatch and arrival records are kept.\n- Shipments are fitted with security equipment appropriate to the product being transported and the assessed security risk, such as global positioning system (GPS) devices located in the vehicle and/or hidden in the product.\n- Drivers are informed about the perishability of the product and the maximum acceptable transport time.\n\n*Reason:* To prevent theft and misappropriation of this category of TTSPP and to ensure the security and safety of the driver.\n\n### 6.5 Temperature and humidity control and monitoring during transit\n\n#### 6.5.1 Temperature control in temperature-controlled road vehicles\n\nProvide thermostatic temperature control systems for all temperature-controlled vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- system able continuously to maintain air temperatures within the set point limits throughout the validated storage volume defined in clause 6.6;\n- control sensors accurate to \u00b1 0.5 \u00b0C;\n- control sensors calibrated as described in clause 6.7.1;\n\n[^14]: Refer to ISO/PAS 17712: *Freight containers \u2014 Mechanical seals.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Transporte de TTSPPs Controlados**: El documento establece directrices espec\u00edficas para el transporte de productos terap\u00e9uticos y de salud (TTSPPs) controlados y de alto valor il\u00edcito, enfatizando la necesidad de cumplir con la legislaci\u00f3n local, asegurar los veh\u00edculos y documentar todas las entregas para prevenir el robo y garantizar la seguridad.\n\n2. **Control de Temperatura y Humedad**: Se requiere que los veh\u00edculos utilizados para el transporte de TTSPPs mantengan un control de temperatura adecuado, con sistemas que aseguren que las temperaturas se mantengan dentro de los l\u00edmites establecidos y que los sensores de control sean precisos y calibrados.\n\n3. **Mantenimiento de Registros y Cumplimiento**: Es fundamental mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura, as\u00ed como documentaci\u00f3n de las entregas, para demostrar el cumplimiento ante las autoridades reguladoras.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos m\u00ednimos para los sistemas de control de temperatura en veh\u00edculos de transporte de TTSPPs?**\n   - Respuesta: Los sistemas deben ser capaces de mantener continuamente las temperaturas del aire dentro de los l\u00edmites establecidos, contar con sensores de control precisos a \u00b1 0.5 \u00b0C y estar calibrados seg\u00fan lo descrito en la cl\u00e1usula 6.7.1.\n\n2. **\u00bfQu\u00e9 medidas de seguridad se deben implementar para el transporte de TTSPPs con alto valor il\u00edcito?**\n   - Respuesta: Se deben utilizar veh\u00edculos con puertas cerradas con llave y alarmas, dispositivos de sellado \u00fanicos y resistentes a manipulaciones, emplear conductores con autorizaci\u00f3n de seguridad, documentar y rastrear todas las entregas, y equipar los env\u00edos con dispositivos de seguridad adecuados, como GPS.\n\n3. **\u00bfPor qu\u00e9 es importante mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura?**\n   - Respuesta: Es crucial para demostrar el cumplimiento de las regulaciones ante las autoridades y otras partes interesadas, asegurando que los TTSPPs se transporten de manera segura dentro de los perfiles de temperatura definidos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Transporte controlado por temperatura**: La secci\u00f3n se centra en el transporte de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs) y la necesidad de mantener condiciones adecuadas durante su transporte.\n\n2. **Acuerdos de nivel de servicio (SLA)**: Se enfatiza la importancia de establecer SLAs formales con los transportistas, tanto para el transporte a\u00e9reo como mar\u00edtimo, donde se detalla la responsabilidad del transportista de mantener las temperaturas de carga dentro de los perfiles definidos para cada producto.\n\n3. **Veh\u00edculos de transporte por carretera**: Se describen las caracter\u00edsticas esenciales que deben tener los veh\u00edculos de transporte por carretera, incluyendo:\n   - Capacidad para mantener el rango de temperatura definido.\n   - Circuito de protecci\u00f3n contra bajas temperaturas.\n   - Dispositivos de monitoreo de temperatura calibrados.\n   - Alarmas para alertar sobre excursiones de temperatura o fallos en la unidad de refrigeraci\u00f3n.\n   - Medidas de seguridad como sellos y cerraduras en las puertas.\n\n4. **Responsabilidad del transportista**: Se subraya la importancia de que los transportistas sean responsables de mantener las temperaturas adecuadas, lo cual es crucial para la integridad y eficacia de los TTSPPs, as\u00ed como para cumplir con las regulaciones y demostrar el cumplimiento a las partes interesadas.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Transportistas**: Empresas o individuos encargados del transporte de TTSPPs.\n- **Organizaci\u00f3n contratante**: Entidad que contrata los servicios de transporte.\n- **Autoridades regulatorias**: Organismos que supervisan el cumplimiento de normativas relacionadas con el transporte de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: TTSPPs, temperature control, transport security, compliance, calibration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "db3bf11d-3918-4f14-a8f6-93e14ff03324", "node_type": "4", "metadata": {"page_label": "361", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- qualified as defined in clause 6.6; and\n- regularly calibrated and maintained and records kept to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.4.3 Transport of controlled TTSPPs and TTSPPs with high illicit value\n\nEnsure that controlled TTSPPs and TTSPPs with high illicit value are transported in the following manner:\n\n- Transport practices comply with all relevant local legislation and regulations.\n- Vehicles are equipped with lockable doors and an intruder alarm.\n- Vehicles use unique seal lock indicating devices such as cable seal locks with unique identifiers that are tamper-resistant to protect against unauthorized access during transit. [^14]\n- Security-cleared delivery drivers are employed.\n- All deliveries are documented and tracked.\n- Signed dispatch and arrival records are kept.\n- Shipments are fitted with security equipment appropriate to the product being transported and the assessed security risk, such as global positioning system (GPS) devices located in the vehicle and/or hidden in the product.\n- Drivers are informed about the perishability of the product and the maximum acceptable transport time.\n\n*Reason:* To prevent theft and misappropriation of this category of TTSPP and to ensure the security and safety of the driver.\n\n### 6.5 Temperature and humidity control and monitoring during transit\n\n#### 6.5.1 Temperature control in temperature-controlled road vehicles\n\nProvide thermostatic temperature control systems for all temperature-controlled vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- system able continuously to maintain air temperatures within the set point limits throughout the validated storage volume defined in clause 6.6;\n- control sensors accurate to \u00b1 0.5 \u00b0C;\n- control sensors calibrated as described in clause 6.7.1;\n\n[^14]: Refer to ISO/PAS 17712: *Freight containers \u2014 Mechanical seals.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0117c93d42764ac13bc0094ad2fe48ed9220c45e4d08078e6c071727f2da28d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- qualified as defined in clause 6.6; and\n- regularly calibrated and maintained and records kept to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.4.3 Transport of controlled TTSPPs and TTSPPs with high illicit value\n\nEnsure that controlled TTSPPs and TTSPPs with high illicit value are transported in the following manner:\n\n- Transport practices comply with all relevant local legislation and regulations.\n- Vehicles are equipped with lockable doors and an intruder alarm.\n- Vehicles use unique seal lock indicating devices such as cable seal locks with unique identifiers that are tamper-resistant to protect against unauthorized access during transit. [^14]\n- Security-cleared delivery drivers are employed.\n- All deliveries are documented and tracked.\n- Signed dispatch and arrival records are kept.\n- Shipments are fitted with security equipment appropriate to the product being transported and the assessed security risk, such as global positioning system (GPS) devices located in the vehicle and/or hidden in the product.\n- Drivers are informed about the perishability of the product and the maximum acceptable transport time.\n\n*Reason:* To prevent theft and misappropriation of this category of TTSPP and to ensure the security and safety of the driver.\n\n### 6.5 Temperature and humidity control and monitoring during transit\n\n#### 6.5.1 Temperature control in temperature-controlled road vehicles\n\nProvide thermostatic temperature control systems for all temperature-controlled vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- system able continuously to maintain air temperatures within the set point limits throughout the validated storage volume defined in clause 6.6;\n- control sensors accurate to \u00b1 0.5 \u00b0C;\n- control sensors calibrated as described in clause 6.7.1;\n\n[^14]: Refer to ISO/PAS 17712: *Freight containers \u2014 Mechanical seals.*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2098, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8c7c56d5-e107-45c6-9e62-83b65a4dcf4c": {"__data__": {"id_": "8c7c56d5-e107-45c6-9e62-83b65a4dcf4c", "embedding": null, "metadata": {"page_label": "362", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- control sensors located to control worst-case temperatures in order to maximize available safe storage volume;\n- control sensors positioned in the return air stream; and\n- control sensors independent of the temperature monitoring system.\n\n### 6.5.2 Temperature monitoring in temperature-controlled road vehicles\n\nProvide air temperature monitoring systems and devices for vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- monitoring sensors accurate to \u00b1 0.5 \u00b0C;\n- monitoring sensors calibrated as described in clause 6.7.2;\n- monitoring sensors located to monitor worst-case temperatures within the qualified storage zone defined in clause 6.6;\n- monitoring sensors positioned so as to monitor worst-case positions;\n- provide a temperature record with a minimum recording frequency of six times per hour for each sensor position;[^15] and\n- provide documentation which can be stored and accessed.\n\nEstablish transit temperature specifications and document transit temperatures for every internal and external shipment.\n\n### 6.5.3 Humidity monitoring in temperature-controlled road vehicles\n\nPreferably provide humidity monitoring systems and devices for temperature-controlled vehicles which are used to transport TTSPPs that require a humidity-controlled environment. Systems and devices should comply with the following minimum requirements:\n\n- sensors accurate to \u00b1 5% RH;\n- sensors calibrated as described in clause 6.7.3;\n- sensors located to monitor worst-case humidity levels within the qualified storage zone defined in clause 6.6;\n- sensors positioned so as to be minimally affected by transient events such as door opening;\n- provide a humidity record with a minimum recording frequency of six times per hour for each sensor position; and\n- provide documentation which can be stored and accessed.\n\nEstablish transit humidity specifications and document transit humidity conditions for internal and external shipments where required.\n\n[^15]: Recording frequency should take account of the storage capacity of the data logger and the expected transport period.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monitoreo de Temperatura en Veh\u00edculos de Transporte**: Se establecen requisitos espec\u00edficos para los sistemas de monitoreo de temperatura en veh\u00edculos que transportan productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Esto incluye la precisi\u00f3n de los sensores, su calibraci\u00f3n, ubicaci\u00f3n y frecuencia de registro de datos.\n\n2. **Monitoreo de Humedad en Veh\u00edculos de Transporte**: Se detallan las especificaciones para los sistemas de monitoreo de humedad en veh\u00edculos que transportan TTSPPs que requieren un ambiente controlado en t\u00e9rminos de humedad. Se especifican los requisitos de precisi\u00f3n, calibraci\u00f3n, ubicaci\u00f3n y frecuencia de registro de los sensores de humedad.\n\n3. **Documentaci\u00f3n y Especificaciones de Tr\u00e1nsito**: Se enfatiza la importancia de establecer especificaciones de temperatura y humedad durante el tr\u00e1nsito, as\u00ed como la necesidad de documentar estas condiciones para cada env\u00edo interno y externo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las ubicaciones recomendadas para instalar los sensores de temperatura en veh\u00edculos de transporte de TTSPPs para garantizar la monitorizaci\u00f3n de las temperaturas m\u00e1s desfavorables?**\n   - Esta pregunta busca informaci\u00f3n sobre la ubicaci\u00f3n estrat\u00e9gica de los sensores, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el registro de las condiciones de temperatura y humedad durante el transporte de TTSPPs, y c\u00f3mo debe ser accesible?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de documentaci\u00f3n que pueden no estar claramente definidos en otras fuentes.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al establecer las especificaciones de temperatura y humedad para el tr\u00e1nsito de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta busca profundizar en los factores que influyen en la definici\u00f3n de las especificaciones de tr\u00e1nsito, que pueden no ser evidentes en otras partes del texto o en documentos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transporte de TTSPPs Controlados y de Alto Valor Il\u00edcito**:\n   - Se establecen directrices para el transporte seguro de productos terap\u00e9uticos y de salud (TTSPPs) que son controlados o tienen un alto valor il\u00edcito.\n   - Se enfatiza la necesidad de cumplir con la legislaci\u00f3n local y de implementar medidas de seguridad adecuadas.\n\n2. **Requisitos de Seguridad para el Transporte**:\n   - Los veh\u00edculos deben tener puertas cerradas con llave, alarmas, y dispositivos de sellado \u00fanicos y resistentes a manipulaciones.\n   - Se requiere que los conductores tengan autorizaci\u00f3n de seguridad y que todas las entregas sean documentadas y rastreadas.\n\n3. **Control de Temperatura y Humedad**:\n   - Los veh\u00edculos de transporte deben contar con sistemas de control de temperatura que mantengan las condiciones adecuadas durante el transporte.\n   - Los sensores de control deben ser precisos (\u00b1 0.5 \u00b0C) y calibrados regularmente.\n\n4. **Mantenimiento de Registros**:\n   - Es fundamental mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura, as\u00ed como documentaci\u00f3n de las entregas, para demostrar el cumplimiento ante las autoridades reguladoras.\n\n### Entidades Clave\n- **TTSPPs**: Productos terap\u00e9uticos y de salud.\n- **Legislaci\u00f3n Local**: Normativas que regulan el transporte de productos controlados.\n- **Dispositivos de Seguridad**: Incluyen alarmas, sellos de seguridad y sistemas GPS.\n- **Conductores**: Personal de entrega que debe estar autorizado y capacitado.\n- **Sensores de Control**: Equipos utilizados para monitorear la temperatura en los veh\u00edculos de transporte. \n\nEste resumen destaca la importancia de la seguridad, el cumplimiento normativo y el control de condiciones durante el transporte de productos sensibles.", "excerpt_keywords": "Keywords: temperature monitoring, humidity monitoring, TTSPPs, transport regulations, sensor calibration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8f3b27ee-2718-4801-a25a-a0ce32d59729", "node_type": "4", "metadata": {"page_label": "362", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- control sensors located to control worst-case temperatures in order to maximize available safe storage volume;\n- control sensors positioned in the return air stream; and\n- control sensors independent of the temperature monitoring system.\n\n### 6.5.2 Temperature monitoring in temperature-controlled road vehicles\n\nProvide air temperature monitoring systems and devices for vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- monitoring sensors accurate to \u00b1 0.5 \u00b0C;\n- monitoring sensors calibrated as described in clause 6.7.2;\n- monitoring sensors located to monitor worst-case temperatures within the qualified storage zone defined in clause 6.6;\n- monitoring sensors positioned so as to monitor worst-case positions;\n- provide a temperature record with a minimum recording frequency of six times per hour for each sensor position;[^15] and\n- provide documentation which can be stored and accessed.\n\nEstablish transit temperature specifications and document transit temperatures for every internal and external shipment.\n\n### 6.5.3 Humidity monitoring in temperature-controlled road vehicles\n\nPreferably provide humidity monitoring systems and devices for temperature-controlled vehicles which are used to transport TTSPPs that require a humidity-controlled environment. Systems and devices should comply with the following minimum requirements:\n\n- sensors accurate to \u00b1 5% RH;\n- sensors calibrated as described in clause 6.7.3;\n- sensors located to monitor worst-case humidity levels within the qualified storage zone defined in clause 6.6;\n- sensors positioned so as to be minimally affected by transient events such as door opening;\n- provide a humidity record with a minimum recording frequency of six times per hour for each sensor position; and\n- provide documentation which can be stored and accessed.\n\nEstablish transit humidity specifications and document transit humidity conditions for internal and external shipments where required.\n\n[^15]: Recording frequency should take account of the storage capacity of the data logger and the expected transport period.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9aeb8427c3ed85209f8e1f61bfab3328c437ae2be8aa76f78e90a4a64930b471", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- control sensors located to control worst-case temperatures in order to maximize available safe storage volume;\n- control sensors positioned in the return air stream; and\n- control sensors independent of the temperature monitoring system.\n\n### 6.5.2 Temperature monitoring in temperature-controlled road vehicles\n\nProvide air temperature monitoring systems and devices for vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- monitoring sensors accurate to \u00b1 0.5 \u00b0C;\n- monitoring sensors calibrated as described in clause 6.7.2;\n- monitoring sensors located to monitor worst-case temperatures within the qualified storage zone defined in clause 6.6;\n- monitoring sensors positioned so as to monitor worst-case positions;\n- provide a temperature record with a minimum recording frequency of six times per hour for each sensor position;[^15] and\n- provide documentation which can be stored and accessed.\n\nEstablish transit temperature specifications and document transit temperatures for every internal and external shipment.\n\n### 6.5.3 Humidity monitoring in temperature-controlled road vehicles\n\nPreferably provide humidity monitoring systems and devices for temperature-controlled vehicles which are used to transport TTSPPs that require a humidity-controlled environment. Systems and devices should comply with the following minimum requirements:\n\n- sensors accurate to \u00b1 5% RH;\n- sensors calibrated as described in clause 6.7.3;\n- sensors located to monitor worst-case humidity levels within the qualified storage zone defined in clause 6.6;\n- sensors positioned so as to be minimally affected by transient events such as door opening;\n- provide a humidity record with a minimum recording frequency of six times per hour for each sensor position; and\n- provide documentation which can be stored and accessed.\n\nEstablish transit humidity specifications and document transit humidity conditions for internal and external shipments where required.\n\n[^15]: Recording frequency should take account of the storage capacity of the data logger and the expected transport period.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2107, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "864e23a5-35f8-4088-b8ea-cd1147bdbc2e": {"__data__": {"id_": "864e23a5-35f8-4088-b8ea-cd1147bdbc2e", "embedding": null, "metadata": {"page_label": "363", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.5.4 Temperature monitoring in passive and active shipping containers\n\nUse chemical or electronic freeze indicators, electronic loggers (with or without alarms) and/or other suitable indicators to monitor temperature and/or humidity exposure during internal distribution. Preferably use these devices for external distribution. Monitor and document indicator status upon arrival.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n## 6.6 Qualification of temperature-controlled road vehicles\n\nWhere temperature-controlled vehicles are directly owned and/or operated, qualify each vehicle before it becomes operational, wherever possible. The qualification procedure should:\n\n- Demonstrate that the air temperature distribution is maintained within the limits specified throughout the temperature-controlled compartment for both air and product temperatures for commonly used load layouts and at the ambient temperature extremes anticipated during normal operation over known routes;\n- Demonstrate the humidity distribution throughout the temperature-controlled compartment for commonly used load layouts, where products are being transported that require a humidity-controlled environment;\n- Define zones within the vehicle\u2019s payload area which should not be packed with TTSPPs (for example areas in close proximity to cooling coils or cold air streams);\n- Demonstrate the time taken for temperatures to exceed the designated maximum in the event that the temperature-controlling unit fails; and\n- Document the qualification exercise.\n\nAn alternative approach is to perform an initial full qualification on each trailer/refrigeration unit type combined with an installation qualification (IQ) for each example when a new vehicle becomes operational.\n\nCarry out additional qualification exercises whenever significant modifications are made to the vehicle. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monitoreo de temperatura en contenedores de env\u00edo**: Se enfatiza la importancia de utilizar indicadores qu\u00edmicos o electr\u00f3nicos para monitorear la temperatura y la humedad durante la distribuci\u00f3n de productos termol\u00e1biles. Esto es crucial para garantizar que los productos se transporten dentro de un perfil de temperatura seguro y que se pueda demostrar el cumplimiento ante las autoridades regulatorias.\n\n2. **Calificaci\u00f3n de veh\u00edculos de transporte controlados por temperatura**: Se detalla un procedimiento de calificaci\u00f3n para veh\u00edculos que transportan productos sensibles a la temperatura. Este procedimiento incluye la evaluaci\u00f3n de la distribuci\u00f3n de temperatura y humedad, la identificaci\u00f3n de zonas prohibidas para el empaquetado de productos, y la documentaci\u00f3n de los resultados de la calificaci\u00f3n. Se menciona la necesidad de requalificaci\u00f3n tras modificaciones significativas o variaciones inexplicables en el monitoreo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de dispositivos se recomienda utilizar para el monitoreo de temperatura y humedad en la distribuci\u00f3n interna y externa de productos termol\u00e1biles?**\n   - Respuesta: Se recomienda el uso de indicadores qu\u00edmicos o electr\u00f3nicos, loggers electr\u00f3nicos (con o sin alarmas) y otros indicadores adecuados para monitorear la temperatura y/o la humedad durante la distribuci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los criterios que deben cumplirse durante la calificaci\u00f3n de un veh\u00edculo de transporte controlado por temperatura?**\n   - Respuesta: La calificaci\u00f3n debe demostrar que la distribuci\u00f3n de temperatura y humedad se mantiene dentro de los l\u00edmites especificados, definir zonas dentro del \u00e1rea de carga que no deben ser empaquetadas con productos termol\u00e1biles, y documentar el ejercicio de calificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones se deben tomar si se observa una variabilidad inexplicable en el monitoreo de temperatura y/o humedad?**\n   - Respuesta: Se debe considerar la necesidad de requalificaci\u00f3n del veh\u00edculo siempre que el monitoreo de temperatura y/o humedad muestre una variabilidad inexplicable que sea mayor de lo normal. Adem\u00e1s, se deben llevar a cabo ejercicios de calificaci\u00f3n adicionales siempre que se realicen modificaciones significativas en el veh\u00edculo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monitoreo de Temperatura en Veh\u00edculos de Transporte**:\n   - **Objetivo**: Asegurar el transporte seguro de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - **Requisitos**:\n     - Sensores de temperatura con precisi\u00f3n de \u00b1 0.5 \u00b0C.\n     - Calibraci\u00f3n de sensores seg\u00fan especificaciones.\n     - Ubicaci\u00f3n estrat\u00e9gica de sensores para monitorear temperaturas m\u00e1s desfavorables.\n     - Frecuencia m\u00ednima de registro de temperatura: seis veces por hora.\n     - Documentaci\u00f3n accesible y almacenable.\n\n2. **Monitoreo de Humedad en Veh\u00edculos de Transporte**:\n   - **Objetivo**: Controlar la humedad en veh\u00edculos que transportan TTSPPs que requieren un ambiente espec\u00edfico.\n   - **Requisitos**:\n     - Sensores de humedad con precisi\u00f3n de \u00b1 5% RH.\n     - Calibraci\u00f3n de sensores seg\u00fan especificaciones.\n     - Ubicaci\u00f3n de sensores para monitorear niveles de humedad m\u00e1s desfavorables.\n     - Frecuencia m\u00ednima de registro de humedad: seis veces por hora.\n     - Documentaci\u00f3n accesible y almacenable.\n\n3. **Especificaciones de Tr\u00e1nsito**:\n   - **Importancia**: Establecer y documentar especificaciones de temperatura y humedad para cada env\u00edo interno y externo.\n   - **Documentaci\u00f3n**: Se requiere un registro claro de las condiciones de temperatura y humedad durante el transporte.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sensores**: Dispositivos utilizados para monitorear temperatura y humedad.\n- **Documentaci\u00f3n**: Registros que deben ser accesibles y almacenables para cumplir con los requisitos de transporte. \n\nEste resumen destaca la importancia de un monitoreo riguroso y la documentaci\u00f3n adecuada para garantizar la integridad de los productos farmac\u00e9uticos durante el transporte.", "excerpt_keywords": "Keywords: temperature monitoring, TTSPPs, qualification, humidity control, transportation compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c0ba0514-3b1d-4937-b612-8adbf59142e5", "node_type": "4", "metadata": {"page_label": "363", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.5.4 Temperature monitoring in passive and active shipping containers\n\nUse chemical or electronic freeze indicators, electronic loggers (with or without alarms) and/or other suitable indicators to monitor temperature and/or humidity exposure during internal distribution. Preferably use these devices for external distribution. Monitor and document indicator status upon arrival.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n## 6.6 Qualification of temperature-controlled road vehicles\n\nWhere temperature-controlled vehicles are directly owned and/or operated, qualify each vehicle before it becomes operational, wherever possible. The qualification procedure should:\n\n- Demonstrate that the air temperature distribution is maintained within the limits specified throughout the temperature-controlled compartment for both air and product temperatures for commonly used load layouts and at the ambient temperature extremes anticipated during normal operation over known routes;\n- Demonstrate the humidity distribution throughout the temperature-controlled compartment for commonly used load layouts, where products are being transported that require a humidity-controlled environment;\n- Define zones within the vehicle\u2019s payload area which should not be packed with TTSPPs (for example areas in close proximity to cooling coils or cold air streams);\n- Demonstrate the time taken for temperatures to exceed the designated maximum in the event that the temperature-controlling unit fails; and\n- Document the qualification exercise.\n\nAn alternative approach is to perform an initial full qualification on each trailer/refrigeration unit type combined with an installation qualification (IQ) for each example when a new vehicle becomes operational.\n\nCarry out additional qualification exercises whenever significant modifications are made to the vehicle. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bb8ce29c65d27426753cc00cae1881bfc30d77a1d5c7d54ddd286b321a67b5da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 6.5.4 Temperature monitoring in passive and active shipping containers\n\nUse chemical or electronic freeze indicators, electronic loggers (with or without alarms) and/or other suitable indicators to monitor temperature and/or humidity exposure during internal distribution. Preferably use these devices for external distribution. Monitor and document indicator status upon arrival.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n## 6.6 Qualification of temperature-controlled road vehicles\n\nWhere temperature-controlled vehicles are directly owned and/or operated, qualify each vehicle before it becomes operational, wherever possible. The qualification procedure should:\n\n- Demonstrate that the air temperature distribution is maintained within the limits specified throughout the temperature-controlled compartment for both air and product temperatures for commonly used load layouts and at the ambient temperature extremes anticipated during normal operation over known routes;\n- Demonstrate the humidity distribution throughout the temperature-controlled compartment for commonly used load layouts, where products are being transported that require a humidity-controlled environment;\n- Define zones within the vehicle\u2019s payload area which should not be packed with TTSPPs (for example areas in close proximity to cooling coils or cold air streams);\n- Demonstrate the time taken for temperatures to exceed the designated maximum in the event that the temperature-controlling unit fails; and\n- Document the qualification exercise.\n\nAn alternative approach is to perform an initial full qualification on each trailer/refrigeration unit type combined with an installation qualification (IQ) for each example when a new vehicle becomes operational.\n\nCarry out additional qualification exercises whenever significant modifications are made to the vehicle. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2408, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f408ff-3f6f-4247-a250-688732341413": {"__data__": {"id_": "c5f408ff-3f6f-4247-a250-688732341413", "embedding": null, "metadata": {"page_label": "364", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Calibration and verification of transport monitoring devices\n\n## 6.7.1 Calibration of transport temperature control devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.2 Calibration of transport temperature monitoring devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.3 Calibration of transport humidity monitoring devices\nCalibrate devices against a certified, traceable, reference standard at least once a year, unless otherwise justified.\n\n## 6.7.4 Verification of transport alarm equipment\nCheck functionality of temperature and humidity alarms at the designated set points. Check functionality of security alarm systems. Carry out these checks at least once a year, unless otherwise justified.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.8 Shipping containers\n\n## 6.8.1 Container selection generally\nSelect shipping containers that:\n\n- comply with applicable national and international standards relevant to the product type and the chosen transport route and mode(s);\n- protect personnel and the general public from hazards arising from spillage, leakage or excessive internal pressure;\n- protect the product being transported against mechanical damage and the anticipated ambient temperature range that will be encountered in transit; and\n- can be closed in a manner that allows the recipient of the consignment to establish that the product has not been tampered with during transport.\n\n*Reason:* Quality assurance and safety.\n\n## 6.8.2 Uninsulated containers\nEnsure that uninsulated containers are correctly used, in a manner which protects their contents:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las directrices para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo de transporte, as\u00ed como la selecci\u00f3n de contenedores de env\u00edo. Se enfatiza la importancia de calibrar dispositivos de control de temperatura y humedad al menos una vez al a\u00f1o y de verificar el funcionamiento de los sistemas de alarma. Adem\u00e1s, se establecen criterios para la selecci\u00f3n de contenedores que garanticen la seguridad y calidad de los productos durante el transporte.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1l es la frecuencia recomendada para la calibraci\u00f3n de dispositivos de monitoreo de temperatura y humedad en el transporte?**\n   - La calibraci\u00f3n de dispositivos de control de temperatura y humedad debe realizarse al menos una vez al a\u00f1o, a menos que se justifique lo contrario.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse al seleccionar contenedores de env\u00edo seg\u00fan las directrices de la OMS?**\n   - Los contenedores de env\u00edo deben cumplir con est\u00e1ndares nacionales e internacionales aplicables, proteger al personal y al p\u00fablico de peligros, resguardar el producto contra da\u00f1os mec\u00e1nicos y temperaturas extremas, y permitir que el destinatario verifique que el producto no ha sido manipulado.\n\n3. **\u00bfQu\u00e9 registros se deben mantener para demostrar el cumplimiento de las directrices de calibraci\u00f3n y verificaci\u00f3n?**\n   - Se deben mantener registros que demuestren la calibraci\u00f3n y verificaci\u00f3n de los dispositivos de monitoreo, as\u00ed como la funcionalidad de los sistemas de alarma, para asegurar que se cumplen las normativas y se puede demostrar la conformidad ante las autoridades reguladoras y otras partes interesadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monitoreo de Temperatura en Contenedores de Env\u00edo**:\n   - **Dispositivos Recomendados**: Indicadores qu\u00edmicos o electr\u00f3nicos, loggers electr\u00f3nicos (con o sin alarmas) y otros indicadores adecuados.\n   - **Objetivo**: Asegurar que los productos termol\u00e1biles (TTSPPs) se transporten dentro de un perfil de temperatura seguro y demostrar cumplimiento ante autoridades regulatorias.\n\n2. **Calificaci\u00f3n de Veh\u00edculos de Transporte Controlados por Temperatura**:\n   - **Procedimiento de Calificaci\u00f3n**:\n     - Evaluar la distribuci\u00f3n de temperatura y humedad en el compartimento controlado por temperatura.\n     - Definir zonas prohibidas para el empaquetado de productos sensibles.\n     - Documentar los resultados de la calificaci\u00f3n.\n   - **Acciones Adicionales**: Realizar ejercicios de calificaci\u00f3n adicionales tras modificaciones significativas o si se observa variabilidad inexplicable en el monitoreo.\n\n3. **Importancia de la Documentaci\u00f3n**:\n   - La documentaci\u00f3n de los procedimientos de calificaci\u00f3n y monitoreo es crucial para demostrar el cumplimiento con las normativas y asegurar la seguridad en el transporte de productos termol\u00e1biles.\n\n### Entidades Clave\n- **TTSPPs**: Productos termol\u00e1biles que requieren un control estricto de temperatura y humedad durante el transporte.\n- **Regulaciones**: Normativas que deben cumplirse para garantizar la seguridad y eficacia en el transporte de productos sensibles.\n- **Veh\u00edculos de Transporte Controlados por Temperatura**: Veh\u00edculos dise\u00f1ados para mantener condiciones espec\u00edficas de temperatura y humedad durante el transporte.", "excerpt_keywords": "Keywords: calibration, transport monitoring, shipping containers, temperature control, compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "04b5bf76-2147-49a9-9637-744810d0cdc2", "node_type": "4", "metadata": {"page_label": "364", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Calibration and verification of transport monitoring devices\n\n## 6.7.1 Calibration of transport temperature control devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.2 Calibration of transport temperature monitoring devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.3 Calibration of transport humidity monitoring devices\nCalibrate devices against a certified, traceable, reference standard at least once a year, unless otherwise justified.\n\n## 6.7.4 Verification of transport alarm equipment\nCheck functionality of temperature and humidity alarms at the designated set points. Check functionality of security alarm systems. Carry out these checks at least once a year, unless otherwise justified.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.8 Shipping containers\n\n## 6.8.1 Container selection generally\nSelect shipping containers that:\n\n- comply with applicable national and international standards relevant to the product type and the chosen transport route and mode(s);\n- protect personnel and the general public from hazards arising from spillage, leakage or excessive internal pressure;\n- protect the product being transported against mechanical damage and the anticipated ambient temperature range that will be encountered in transit; and\n- can be closed in a manner that allows the recipient of the consignment to establish that the product has not been tampered with during transport.\n\n*Reason:* Quality assurance and safety.\n\n## 6.8.2 Uninsulated containers\nEnsure that uninsulated containers are correctly used, in a manner which protects their contents:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "77e7fc0cecf88f2b773fcb769be5cac7094069e8988ef79f269e19e850fcae41", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.7 Calibration and verification of transport monitoring devices\n\n## 6.7.1 Calibration of transport temperature control devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.2 Calibration of transport temperature monitoring devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.3 Calibration of transport humidity monitoring devices\nCalibrate devices against a certified, traceable, reference standard at least once a year, unless otherwise justified.\n\n## 6.7.4 Verification of transport alarm equipment\nCheck functionality of temperature and humidity alarms at the designated set points. Check functionality of security alarm systems. Carry out these checks at least once a year, unless otherwise justified.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.8 Shipping containers\n\n## 6.8.1 Container selection generally\nSelect shipping containers that:\n\n- comply with applicable national and international standards relevant to the product type and the chosen transport route and mode(s);\n- protect personnel and the general public from hazards arising from spillage, leakage or excessive internal pressure;\n- protect the product being transported against mechanical damage and the anticipated ambient temperature range that will be encountered in transit; and\n- can be closed in a manner that allows the recipient of the consignment to establish that the product has not been tampered with during transport.\n\n*Reason:* Quality assurance and safety.\n\n## 6.8.2 Uninsulated containers\nEnsure that uninsulated containers are correctly used, in a manner which protects their contents:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1968, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5d0c05b6-e7bd-4a6d-be3c-fbb8693d6cf5": {"__data__": {"id_": "5d0c05b6-e7bd-4a6d-be3c-fbb8693d6cf5", "embedding": null, "metadata": {"page_label": "365", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- transport uninsulated containers in a qualified temperature-controlled environment such as an actively or passively temperature-controlled vehicle;\n- ensure that the transport system is able to maintain the temperature of the TTSPP within the product\u2019s stability profile as stated by the product manufacturer and/or to maintain the TTSPP within the transit temperature specification requirements specified by the regulatory authorities at both the sending and receiving locations.\n\n*Reason:* Quality assurance and safety.\n\n### 6.8.3 Qualification of insulated passive containers\n\nQualify insulated passive containers, including any and all necessary ancillary packaging such as temperature stabilizing medium, dry ice, ice or gel packs, cool water packs or warm packs, phase change materials, partitions, bubble wrap and dunnage:\n\n- ensure that the qualified packaging system is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer. Container qualification should include full details of the packaging assembly, the thermal conditioning regime and the minimum and maximum shipping volume, weight and thermal mass that can safely be accommodated in the container. Qualification should also include the correct placement of temperature monitors where these are used;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can safely be transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.8.4 Qualification of active containers\n\nQualify active containers:\n\n- ensure that the container is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (WHO - Technical Report Series 961) aborda la importancia de mantener la temperatura adecuada durante el transporte de productos termol\u00e1biles (TTSPP). Se detallan los requisitos para la calificaci\u00f3n de contenedores pasivos e activos, as\u00ed como la necesidad de asegurar que los sistemas de transporte mantengan la temperatura dentro de los perfiles de estabilidad del producto. Se enfatiza la importancia de cumplir con las especificaciones de temperatura establecidas por los fabricantes y las autoridades regulatorias, as\u00ed como la necesidad de documentar y demostrar el cumplimiento de estos requisitos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en la calificaci\u00f3n de contenedores pasivos para garantizar que mantengan la temperatura adecuada durante el transporte?**\n   - La calificaci\u00f3n debe incluir detalles sobre el ensamblaje del empaque, el r\u00e9gimen de acondicionamiento t\u00e9rmico, y el volumen, peso y masa t\u00e9rmica que el contenedor puede acomodar de manera segura. Tambi\u00e9n debe considerar la colocaci\u00f3n correcta de los monitores de temperatura.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave al calificar contenedores activos para el transporte de TTSPP?**\n   - Es fundamental asegurarse de que el contenedor pueda mantener la temperatura dentro del rango necesario para cumplir con el perfil de estabilidad del producto, as\u00ed como tener en cuenta la ruta de transporte y el perfil de temperatura ambiental anticipado durante el transporte.\n\n3. **\u00bfPor qu\u00e9 es crucial demostrar el cumplimiento de los requisitos de temperatura durante el transporte de TTSPP ante las autoridades regulatorias?**\n   - Demostrar el cumplimiento es esencial para garantizar que los TTSPP se transporten de manera segura dentro del perfil de temperatura definido para cada producto, lo que a su vez asegura la calidad y la seguridad del producto, cumpliendo con las expectativas de los reguladores y otras partes interesadas.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Calibraci\u00f3n de dispositivos de monitoreo de transporte**:\n   - **Frecuencia**: Al menos una vez al a\u00f1o para dispositivos de control de temperatura y humedad, a menos que se justifique lo contrario.\n   - **Est\u00e1ndares**: Los dispositivos deben calibrarse contra un est\u00e1ndar de referencia certificado y trazable.\n\n2. **Verificaci\u00f3n de equipos de alarma de transporte**:\n   - **Funcionalidad**: Se debe verificar el funcionamiento de alarmas de temperatura, humedad y sistemas de seguridad al menos una vez al a\u00f1o.\n   - **Registros**: Es necesario mantener registros que demuestren el cumplimiento de estas verificaciones.\n\n3. **Selecci\u00f3n de contenedores de env\u00edo**:\n   - **Criterios**: Los contenedores deben cumplir con est\u00e1ndares nacionales e internacionales, proteger al personal y al p\u00fablico, resguardar el producto de da\u00f1os mec\u00e1nicos y temperaturas extremas, y permitir la verificaci\u00f3n de que no ha habido manipulaci\u00f3n durante el transporte.\n\n4. **Contenedores no aislados**:\n   - **Uso adecuado**: Se debe asegurar que los contenedores no aislados se utilicen correctamente para proteger su contenido.\n\n### Entidades clave:\n- **Dispositivos de monitoreo de temperatura y humedad**: Equipos que requieren calibraci\u00f3n y verificaci\u00f3n.\n- **Alarmas de temperatura y humedad**: Sistemas que deben ser funcionales y verificados.\n- **Contenedores de env\u00edo**: Elementos cr\u00edticos para el transporte seguro de productos.\n- **Normativas nacionales e internacionales**: Est\u00e1ndares que deben cumplirse en la selecci\u00f3n de contenedores.\n\n### Raz\u00f3n de las directrices:\nAsegurar que los productos sensibles a la temperatura y humedad (TTSPPs) sean transportados de manera segura y conforme a las regulaciones, garantizando la calidad y seguridad durante el transporte.", "excerpt_keywords": "Keywords: temperature control, transport qualification, TTSPP, passive containers, active containers"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cf6a336-ea6b-454a-8c69-64330f430667", "node_type": "4", "metadata": {"page_label": "365", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- transport uninsulated containers in a qualified temperature-controlled environment such as an actively or passively temperature-controlled vehicle;\n- ensure that the transport system is able to maintain the temperature of the TTSPP within the product\u2019s stability profile as stated by the product manufacturer and/or to maintain the TTSPP within the transit temperature specification requirements specified by the regulatory authorities at both the sending and receiving locations.\n\n*Reason:* Quality assurance and safety.\n\n### 6.8.3 Qualification of insulated passive containers\n\nQualify insulated passive containers, including any and all necessary ancillary packaging such as temperature stabilizing medium, dry ice, ice or gel packs, cool water packs or warm packs, phase change materials, partitions, bubble wrap and dunnage:\n\n- ensure that the qualified packaging system is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer. Container qualification should include full details of the packaging assembly, the thermal conditioning regime and the minimum and maximum shipping volume, weight and thermal mass that can safely be accommodated in the container. Qualification should also include the correct placement of temperature monitors where these are used;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can safely be transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.8.4 Qualification of active containers\n\nQualify active containers:\n\n- ensure that the container is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d1f591cb273eed31ccf454ca0dbf5a5637ab650ff9a886b0278406be2bffb394", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- transport uninsulated containers in a qualified temperature-controlled environment such as an actively or passively temperature-controlled vehicle;\n- ensure that the transport system is able to maintain the temperature of the TTSPP within the product\u2019s stability profile as stated by the product manufacturer and/or to maintain the TTSPP within the transit temperature specification requirements specified by the regulatory authorities at both the sending and receiving locations.\n\n*Reason:* Quality assurance and safety.\n\n### 6.8.3 Qualification of insulated passive containers\n\nQualify insulated passive containers, including any and all necessary ancillary packaging such as temperature stabilizing medium, dry ice, ice or gel packs, cool water packs or warm packs, phase change materials, partitions, bubble wrap and dunnage:\n\n- ensure that the qualified packaging system is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer. Container qualification should include full details of the packaging assembly, the thermal conditioning regime and the minimum and maximum shipping volume, weight and thermal mass that can safely be accommodated in the container. Qualification should also include the correct placement of temperature monitors where these are used;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can safely be transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.8.4 Qualification of active containers\n\nQualify active containers:\n\n- ensure that the container is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2522, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "a1904806-ba76-4daf-8166-3e64d8f9c5e7": {"__data__": {"id_": "a1904806-ba76-4daf-8166-3e64d8f9c5e7", "embedding": null, "metadata": {"page_label": "366", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.9 Shipping container packing\n\nPack TTSPP shipping containers to:\n\n- the exact specified configuration to ensure that the correct TTSPP temperature range is maintained;\n- minimize the risk of theft and fraud and assure the recipient that the goods have not been tampered with while in transit, for example by using locked containers or shrink-wrapped pallets;\n- minimize the risk of mechanical damage during transport;\n- protect freeze-sensitive products against temperatures below 0 \u00b0C when frozen packs are used;\n- protect products against light, moisture and contamination or attack by microorganisms and pests;\n- protect products against adverse effects when dry ice is used as a coolant;\n- clearly label containers to identify the correct transport temperature range and to show correct orientation for handling; and\n- ensure that packages containing dangerous goods (including dry ice) are labelled in compliance with relevant transport regulations and requirements.\n\n*Reason:* To ensure that shipping containers are systematically used in the manner defined during the container qualification process and that this can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.10 Product handling during packing and transport\n\nHandle TTSPPs correctly during packing and transport:\n\n- pack TTSPPs in an area set aside for the assembly and packaging of these products as specified in clause 3.3.1;\n- take precautions against spillage or breakage, contamination and cross-contamination;\n- deliver TTSPPs to outside recipients by the most suitable mode(s) of transport available in order to minimize delivery time; and\n- ensure that patients receiving TTSPP deliveries are given clear advice on correct storage of the product before use.\n\n*Reason:* To maintain TTSPP quality during transport.\n\n# 6.11 Cleaning road vehicles and transport containers\n\nImplement a cleaning and decontamination programme for all road vehicles and reusable shipping containers used to transport TTSPPs:\n\n- ensure that all internal surfaces of load compartments are regularly cleaned;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las mejores pr\u00e1cticas para el embalaje, manejo y limpieza de veh\u00edculos y contenedores de transporte de productos terap\u00e9uticos sensibles a la temperatura (TTSPP). Se enfatiza la importancia de mantener la temperatura adecuada, prevenir el robo y la contaminaci\u00f3n, y asegurar que los productos sean entregados en condiciones \u00f3ptimas. Tambi\u00e9n se menciona la necesidad de etiquetar correctamente los contenedores y seguir regulaciones espec\u00edficas para el transporte de mercanc\u00edas peligrosas.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para proteger los productos sensibles a la temperatura durante el transporte?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de embalaje y las condiciones necesarias para mantener la calidad de los TTSPP, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de etiquetado es necesario para los contenedores que transportan productos peligrosos, y por qu\u00e9 es importante?**\n   - Esta pregunta se centra en la importancia del etiquetado adecuado y las regulaciones que deben seguirse, lo cual es crucial para la seguridad durante el transporte.\n\n3. **\u00bfQu\u00e9 procedimientos de limpieza se deben implementar para los veh\u00edculos y contenedores que transportan TTSPP, y con qu\u00e9 frecuencia deben realizarse?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el programa de limpieza y desinfecci\u00f3n, que es fundamental para prevenir la contaminaci\u00f3n y asegurar la calidad del producto durante el transporte.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Transporte de Productos Termol\u00e1biles (TTSPP):** La secci\u00f3n se centra en la importancia de mantener la temperatura adecuada durante el transporte de productos que son sensibles a la temperatura.\n\n2. **Calificaci\u00f3n de Contenedores:**\n   - **Contenedores Pasivos:** Se requiere calificaci\u00f3n de contenedores aislados, incluyendo el uso de materiales estabilizadores de temperatura (hielo seco, gel packs, etc.), y la consideraci\u00f3n de factores como el volumen, peso y colocaci\u00f3n de monitores de temperatura.\n   - **Contenedores Activos:** Se enfatiza la necesidad de que estos contenedores mantengan la temperatura adecuada y consideren la ruta de transporte y el perfil de temperatura ambiental.\n\n3. **Cumplimiento Regulatorio:** Es crucial demostrar que se cumplen los requisitos de temperatura establecidos por los fabricantes y las autoridades regulatorias para garantizar la calidad y seguridad de los productos transportados.\n\n4. **Documentaci\u00f3n y Verificaci\u00f3n:** La calificaci\u00f3n de los contenedores debe incluir documentaci\u00f3n detallada que demuestre el cumplimiento de los est\u00e1ndares de temperatura y estabilidad del producto.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre el transporte de productos termol\u00e1biles.\n- **TTSPP (Productos Termol\u00e1biles):** Productos que requieren condiciones espec\u00edficas de temperatura durante el transporte.\n- **Contenedores Pasivos y Activos:** Tipos de contenedores utilizados para el transporte de TTSPP, cada uno con requisitos espec\u00edficos de calificaci\u00f3n.\n- **Reguladores y Autoridades:** Entidades que establecen y supervisan el cumplimiento de las normativas de transporte de productos sensibles a la temperatura.\n\nEste resumen destaca la importancia de la calificaci\u00f3n adecuada de los contenedores y el cumplimiento de las normativas para garantizar la seguridad y calidad de los productos durante su transporte.", "excerpt_keywords": "Keywords: TTSPP, shipping containers, temperature control, product handling, cleaning protocols"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "199872c4-c733-4e4a-85ee-01cf906c2615", "node_type": "4", "metadata": {"page_label": "366", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.9 Shipping container packing\n\nPack TTSPP shipping containers to:\n\n- the exact specified configuration to ensure that the correct TTSPP temperature range is maintained;\n- minimize the risk of theft and fraud and assure the recipient that the goods have not been tampered with while in transit, for example by using locked containers or shrink-wrapped pallets;\n- minimize the risk of mechanical damage during transport;\n- protect freeze-sensitive products against temperatures below 0 \u00b0C when frozen packs are used;\n- protect products against light, moisture and contamination or attack by microorganisms and pests;\n- protect products against adverse effects when dry ice is used as a coolant;\n- clearly label containers to identify the correct transport temperature range and to show correct orientation for handling; and\n- ensure that packages containing dangerous goods (including dry ice) are labelled in compliance with relevant transport regulations and requirements.\n\n*Reason:* To ensure that shipping containers are systematically used in the manner defined during the container qualification process and that this can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.10 Product handling during packing and transport\n\nHandle TTSPPs correctly during packing and transport:\n\n- pack TTSPPs in an area set aside for the assembly and packaging of these products as specified in clause 3.3.1;\n- take precautions against spillage or breakage, contamination and cross-contamination;\n- deliver TTSPPs to outside recipients by the most suitable mode(s) of transport available in order to minimize delivery time; and\n- ensure that patients receiving TTSPP deliveries are given clear advice on correct storage of the product before use.\n\n*Reason:* To maintain TTSPP quality during transport.\n\n# 6.11 Cleaning road vehicles and transport containers\n\nImplement a cleaning and decontamination programme for all road vehicles and reusable shipping containers used to transport TTSPPs:\n\n- ensure that all internal surfaces of load compartments are regularly cleaned;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "67cc55c90a2a541226c60b7ea0d53f5691dd4dfdbc704dc738529ff48ecdb6be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.9 Shipping container packing\n\nPack TTSPP shipping containers to:\n\n- the exact specified configuration to ensure that the correct TTSPP temperature range is maintained;\n- minimize the risk of theft and fraud and assure the recipient that the goods have not been tampered with while in transit, for example by using locked containers or shrink-wrapped pallets;\n- minimize the risk of mechanical damage during transport;\n- protect freeze-sensitive products against temperatures below 0 \u00b0C when frozen packs are used;\n- protect products against light, moisture and contamination or attack by microorganisms and pests;\n- protect products against adverse effects when dry ice is used as a coolant;\n- clearly label containers to identify the correct transport temperature range and to show correct orientation for handling; and\n- ensure that packages containing dangerous goods (including dry ice) are labelled in compliance with relevant transport regulations and requirements.\n\n*Reason:* To ensure that shipping containers are systematically used in the manner defined during the container qualification process and that this can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.10 Product handling during packing and transport\n\nHandle TTSPPs correctly during packing and transport:\n\n- pack TTSPPs in an area set aside for the assembly and packaging of these products as specified in clause 3.3.1;\n- take precautions against spillage or breakage, contamination and cross-contamination;\n- deliver TTSPPs to outside recipients by the most suitable mode(s) of transport available in order to minimize delivery time; and\n- ensure that patients receiving TTSPP deliveries are given clear advice on correct storage of the product before use.\n\n*Reason:* To maintain TTSPP quality during transport.\n\n# 6.11 Cleaning road vehicles and transport containers\n\nImplement a cleaning and decontamination programme for all road vehicles and reusable shipping containers used to transport TTSPPs:\n\n- ensure that all internal surfaces of load compartments are regularly cleaned;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2091, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5db4884c-878d-4a8a-8075-1e05e17f046d": {"__data__": {"id_": "5db4884c-878d-4a8a-8075-1e05e17f046d", "embedding": null, "metadata": {"page_label": "367", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- do not allow the accumulation of dust, dirt and waste, including packaging waste in load compartments, or in reusable shipping containers;\n- take precautions against spillage or breakage, and cross-contamination;\n- do not allow accumulation of frost and ice in refrigerated vehicles, particularly ice contaminated by spillages; and\n- collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records for vehicles and reusable shipping containers to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers arising from spillage or breakage.\n\n## 6.12 Transport of returned and recalled TTSPPs\n\n### 6.12.1 Transport of returned TTSPPs\n\nEnsure that returned TTSPPs are transported under the same conditions as those used for the initial delivery:\n\n- the sender and recipient must work together so that the product is maintained within the temperature range needed to meet the manufacturer\u2019s stated product stability profile;\n- take account of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of return; and\n- quarantine returned TTSPPs in temperature-controlled storage pending a decision by the quality control department or qualified person to dispose of the product or to return it to stock.\n\n*Reason:* To ensure that returned and recalled TTSPPs are maintained within the correct transport temperature profile so that they can safely be re-stocked if a decision to do so is made.\n\n### 6.12.2 Transport of recalled TTSPPs\n\nEnsure that recalled TTSPPs are:\n\n- marked for disposal as either \u201crecalled\u201d or \u201cwithdrawn\u201d;\n- transported back from the recipient and quarantined under secure conditions pending a final decision on disposal as described in clause 8.6.3.\n\n## 7. Labelling\n\n### 7.1 Normative references\n\n- IATA Perishable Cargo Regulations Chapter 17th Edition, July 2009. Clauses 17.10.5 and 17.10.6.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices para el transporte de productos farmac\u00e9uticos y biol\u00f3gicos, espec\u00edficamente los productos terap\u00e9uticos y de salud p\u00fablica (TTSPPs). Se enfatiza la importancia de mantener condiciones adecuadas durante el transporte para evitar la contaminaci\u00f3n, el da\u00f1o y garantizar la seguridad de los trabajadores. Se detallan procedimientos para el transporte de TTSPPs devueltos y retirados, incluyendo la necesidad de mantener la temperatura adecuada y el manejo seguro de productos que han sido retirados del mercado. Tambi\u00e9n se menciona la importancia de la limpieza y el mantenimiento de registros para demostrar el cumplimiento de estas normativas.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para evitar la contaminaci\u00f3n y el da\u00f1o a los TTSPPs durante el transporte?**\n   - Respuesta: Se deben evitar la acumulaci\u00f3n de polvo, suciedad y desechos en los compartimentos de carga y contenedores reutilizables, tomar precauciones contra derrames y roturas, y no permitir la acumulaci\u00f3n de escarcha e hielo en veh\u00edculos refrigerados. Adem\u00e1s, se debe recolectar la basura en contenedores cerrados designados y disponer de ella de manera segura con frecuencia.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para el transporte de TTSPPs devueltos y c\u00f3mo se asegura su correcta conservaci\u00f3n?**\n   - Respuesta: Los TTSPPs devueltos deben transportarse bajo las mismas condiciones que se usaron para la entrega inicial, manteniendo la temperatura adecuada y considerando el perfil de temperatura ambiental durante el transporte. Adem\u00e1s, deben ser puestos en cuarentena en almacenamiento controlado por temperatura hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento.\n\n3. **\u00bfQu\u00e9 etiquetado es necesario para los TTSPPs que han sido retirados del mercado y cu\u00e1les son los pasos a seguir para su transporte?**\n   - Respuesta: Los TTSPPs retirados deben estar marcados para su disposici\u00f3n como \"retirados\" o \"retirados del mercado\". Deben ser transportados de regreso desde el destinatario y puestos en cuarentena bajo condiciones seguras hasta que se tome una decisi\u00f3n final sobre su disposici\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Embalaje de Contenedores de Transporte**:\n   - Importancia de seguir configuraciones espec\u00edficas para mantener la temperatura adecuada de los productos terap\u00e9uticos sensibles a la temperatura (TTSPP).\n   - Medidas para prevenir el robo y la manipulaci\u00f3n de los productos durante el transporte, como el uso de contenedores cerrados y paletas envueltas.\n   - Protecci\u00f3n de los productos contra da\u00f1os mec\u00e1nicos, temperaturas extremas, luz, humedad, contaminaci\u00f3n, microorganismos y plagas.\n   - Etiquetado claro de los contenedores para indicar la temperatura de transporte y la orientaci\u00f3n correcta.\n   - Cumplimiento de regulaciones para el etiquetado de mercanc\u00edas peligrosas, incluyendo el hielo seco.\n\n2. **Manejo de Productos Durante el Embalaje y Transporte**:\n   - Protocolo para el embalaje de TTSPP en \u00e1reas designadas.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n   - Selecci\u00f3n de modos de transporte adecuados para minimizar el tiempo de entrega.\n   - Instrucciones claras para los pacientes sobre el almacenamiento correcto de los productos.\n\n3. **Limpieza de Veh\u00edculos y Contenedores de Transporte**:\n   - Implementaci\u00f3n de un programa de limpieza y desinfecci\u00f3n para veh\u00edculos y contenedores reutilizables.\n   - Mantenimiento regular de las superficies internas de los compartimentos de carga.\n\n### Entidades Clave:\n- **TTSPP**: Productos terap\u00e9uticos sensibles a la temperatura.\n- **Contenedores de Transporte**: Elementos utilizados para el env\u00edo de TTSPP.\n- **Regulaciones de Transporte**: Normativas que rigen el etiquetado y manejo de mercanc\u00edas peligrosas.\n- **Hielo Seco**: Material utilizado como refrigerante que requiere etiquetado espec\u00edfico.\n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas de embalaje, manejo y limpieza para garantizar la calidad y seguridad de los productos durante el transporte.", "excerpt_keywords": "Keywords: transporte, TTSPPs, contaminaci\u00f3n, limpieza, etiquetado"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cecdb73-bdbc-4f7b-b82d-4380b3c903ba", "node_type": "4", "metadata": {"page_label": "367", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- do not allow the accumulation of dust, dirt and waste, including packaging waste in load compartments, or in reusable shipping containers;\n- take precautions against spillage or breakage, and cross-contamination;\n- do not allow accumulation of frost and ice in refrigerated vehicles, particularly ice contaminated by spillages; and\n- collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records for vehicles and reusable shipping containers to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers arising from spillage or breakage.\n\n## 6.12 Transport of returned and recalled TTSPPs\n\n### 6.12.1 Transport of returned TTSPPs\n\nEnsure that returned TTSPPs are transported under the same conditions as those used for the initial delivery:\n\n- the sender and recipient must work together so that the product is maintained within the temperature range needed to meet the manufacturer\u2019s stated product stability profile;\n- take account of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of return; and\n- quarantine returned TTSPPs in temperature-controlled storage pending a decision by the quality control department or qualified person to dispose of the product or to return it to stock.\n\n*Reason:* To ensure that returned and recalled TTSPPs are maintained within the correct transport temperature profile so that they can safely be re-stocked if a decision to do so is made.\n\n### 6.12.2 Transport of recalled TTSPPs\n\nEnsure that recalled TTSPPs are:\n\n- marked for disposal as either \u201crecalled\u201d or \u201cwithdrawn\u201d;\n- transported back from the recipient and quarantined under secure conditions pending a final decision on disposal as described in clause 8.6.3.\n\n## 7. Labelling\n\n### 7.1 Normative references\n\n- IATA Perishable Cargo Regulations Chapter 17th Edition, July 2009. Clauses 17.10.5 and 17.10.6.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "55a35dfd499542799c863aa345b545cbf85d1423b668267e35da53726b6a2254", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- do not allow the accumulation of dust, dirt and waste, including packaging waste in load compartments, or in reusable shipping containers;\n- take precautions against spillage or breakage, and cross-contamination;\n- do not allow accumulation of frost and ice in refrigerated vehicles, particularly ice contaminated by spillages; and\n- collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records for vehicles and reusable shipping containers to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers arising from spillage or breakage.\n\n## 6.12 Transport of returned and recalled TTSPPs\n\n### 6.12.1 Transport of returned TTSPPs\n\nEnsure that returned TTSPPs are transported under the same conditions as those used for the initial delivery:\n\n- the sender and recipient must work together so that the product is maintained within the temperature range needed to meet the manufacturer\u2019s stated product stability profile;\n- take account of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of return; and\n- quarantine returned TTSPPs in temperature-controlled storage pending a decision by the quality control department or qualified person to dispose of the product or to return it to stock.\n\n*Reason:* To ensure that returned and recalled TTSPPs are maintained within the correct transport temperature profile so that they can safely be re-stocked if a decision to do so is made.\n\n### 6.12.2 Transport of recalled TTSPPs\n\nEnsure that recalled TTSPPs are:\n\n- marked for disposal as either \u201crecalled\u201d or \u201cwithdrawn\u201d;\n- transported back from the recipient and quarantined under secure conditions pending a final decision on disposal as described in clause 8.6.3.\n\n## 7. Labelling\n\n### 7.1 Normative references\n\n- IATA Perishable Cargo Regulations Chapter 17th Edition, July 2009. Clauses 17.10.5 and 17.10.6.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2000, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "256d9946-a0b5-4105-8909-8cf623f31d06": {"__data__": {"id_": "256d9946-a0b5-4105-8909-8cf623f31d06", "embedding": null, "metadata": {"page_label": "368", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Labelling\n\n## 7.2.1 Labelling generally\n\nLabel internal shipping and external distribution containers containing TTSPPs as follows:\n\n- Identify the product in accordance with all national and international labelling requirements relevant to the container content, transport route and mode(s);\n- Identify hazardous products in accordance with relevant national and international labelling conventions; and\n- Indicate the appropriate temperature and humidity ranges within which the product is to be transported and/or stored.\n\n## 7.2.2 Labelling air-freighted shipments\n\nIn cases where TTSPPs are to be air-freighted, the package(s) should be labelled using the standard International Air Transport Association (IATA) time and temperature-sensitive symbol, in accordance with the conditions outlined in Chapter 17 of the IATA Perishable Cargo Regulations. Apply the label to the outer surface of individual shipping packages, overpacks or bulk containers.\n\n*Reason:* To ensure that products are correctly and safely handled at all points in the supply chain.\n\n# 8. Stock management\n\n## 8.1 Stock control systems\n\n### 8.1.1 General stock control systems and procedures\n\nTTSPP stock control systems and procedures meet the following minimum requirements:\n\n- Allow access only to authorized persons;\n- Record all receipts and dispatches;\n- Record batch numbers and expiry dates;\n- Record short-dated and expired products;\n- Record product status (i.e. released, quarantined, hold, reject);\n- Record all product returns, recalls, withdrawals, damage and disposals;\n- Manage the issue of products in EEFO order; and\n- Take regular physical inventories and reconcile stock records with the actual physical count. Investigate and report on stock discrepancies in accordance with agreed procedures. Preferably physical counts should be made at least twice a year.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la etiquetaci\u00f3n y gesti\u00f3n de existencias de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs). Se establecen requisitos para la etiquetaci\u00f3n de envases, tanto para el transporte interno como para la distribuci\u00f3n externa, incluyendo la identificaci\u00f3n de productos y condiciones de almacenamiento. Adem\u00e1s, se describen los sistemas de control de existencias necesarios para garantizar la seguridad y la precisi\u00f3n en la gesti\u00f3n de estos productos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la etiquetaci\u00f3n de productos peligrosos seg\u00fan el documento?**\n   - Respuesta: Los productos peligrosos deben ser identificados de acuerdo con las convenciones de etiquetado nacionales e internacionales relevantes.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para el control de existencias de TTSPPs seg\u00fan el documento?**\n   - Respuesta: Los procedimientos deben incluir el acceso restringido a personas autorizadas, el registro de todas las recepciones y despachos, el seguimiento de n\u00fameros de lote y fechas de caducidad, y la gesti\u00f3n de productos en orden EEFO (Primero en Expirar, Primero en Salir).\n\n3. **\u00bfQu\u00e9 s\u00edmbolo debe utilizarse para etiquetar env\u00edos a\u00e9reos de TTSPPs y qu\u00e9 regulaciones se deben seguir?**\n   - Respuesta: Se debe utilizar el s\u00edmbolo est\u00e1ndar de tiempo y temperatura sensible de la Asociaci\u00f3n Internacional de Transporte A\u00e9reo (IATA), siguiendo las condiciones establecidas en el Cap\u00edtulo 17 de las Regulaciones de Carga Perecedera de la IATA.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transporte de Productos Terap\u00e9uticos y de Salud P\u00fablica (TTSPPs)**:\n   - Importancia de mantener condiciones adecuadas durante el transporte para evitar contaminaci\u00f3n y da\u00f1o.\n\n2. **Medidas de Prevenci\u00f3n**:\n   - Evitar acumulaci\u00f3n de polvo, suciedad y desechos en compartimentos de carga y contenedores reutilizables.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n   - No permitir acumulaci\u00f3n de escarcha e hielo en veh\u00edculos refrigerados.\n   - Recolecci\u00f3n de desechos en contenedores cerrados y disposici\u00f3n segura frecuente.\n\n3. **Registros de Limpieza**:\n   - Mantener registros de limpieza para veh\u00edculos y contenedores reutilizables como evidencia de cumplimiento.\n\n4. **Transporte de TTSPPs Devueltos**:\n   - Deben transportarse bajo las mismas condiciones que la entrega inicial.\n   - Colaboraci\u00f3n entre remitente y destinatario para mantener la temperatura adecuada.\n   - Consideraci\u00f3n del perfil de temperatura ambiental durante el transporte.\n   - Cuarentena en almacenamiento controlado por temperatura hasta decisi\u00f3n sobre disposici\u00f3n o reabastecimiento.\n\n5. **Transporte de TTSPPs Retirados**:\n   - Marcado como \"retirados\" o \"retirados del mercado\".\n   - Transporte de regreso bajo condiciones seguras y cuarentena hasta decisi\u00f3n final sobre disposici\u00f3n.\n\n6. **Normativas de Etiquetado**:\n   - Referencias normativas de la IATA sobre el transporte de carga perecedera.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **TTSPPs (Productos Terap\u00e9uticos y de Salud P\u00fablica)**: Productos cuyo transporte se regula.\n- **IATA (Asociaci\u00f3n Internacional de Transporte A\u00e9reo)**: Referencia normativa para el transporte de carga perecedera. \n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas en el transporte de productos sensibles, as\u00ed como las normativas que deben seguirse para garantizar la seguridad y calidad de los TTSPPs.", "excerpt_keywords": "Keywords: labelling, TTSPPs, stock management, IATA, temperature-sensitive"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ff7d50f3-e153-44d6-82d6-25997e2a22b4", "node_type": "4", "metadata": {"page_label": "368", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Labelling\n\n## 7.2.1 Labelling generally\n\nLabel internal shipping and external distribution containers containing TTSPPs as follows:\n\n- Identify the product in accordance with all national and international labelling requirements relevant to the container content, transport route and mode(s);\n- Identify hazardous products in accordance with relevant national and international labelling conventions; and\n- Indicate the appropriate temperature and humidity ranges within which the product is to be transported and/or stored.\n\n## 7.2.2 Labelling air-freighted shipments\n\nIn cases where TTSPPs are to be air-freighted, the package(s) should be labelled using the standard International Air Transport Association (IATA) time and temperature-sensitive symbol, in accordance with the conditions outlined in Chapter 17 of the IATA Perishable Cargo Regulations. Apply the label to the outer surface of individual shipping packages, overpacks or bulk containers.\n\n*Reason:* To ensure that products are correctly and safely handled at all points in the supply chain.\n\n# 8. Stock management\n\n## 8.1 Stock control systems\n\n### 8.1.1 General stock control systems and procedures\n\nTTSPP stock control systems and procedures meet the following minimum requirements:\n\n- Allow access only to authorized persons;\n- Record all receipts and dispatches;\n- Record batch numbers and expiry dates;\n- Record short-dated and expired products;\n- Record product status (i.e. released, quarantined, hold, reject);\n- Record all product returns, recalls, withdrawals, damage and disposals;\n- Manage the issue of products in EEFO order; and\n- Take regular physical inventories and reconcile stock records with the actual physical count. Investigate and report on stock discrepancies in accordance with agreed procedures. Preferably physical counts should be made at least twice a year.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ce6d40552c3ff708ff206e2fcfdef5289719411151f16a531595d1fa83a5a5cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7.2 Labelling\n\n## 7.2.1 Labelling generally\n\nLabel internal shipping and external distribution containers containing TTSPPs as follows:\n\n- Identify the product in accordance with all national and international labelling requirements relevant to the container content, transport route and mode(s);\n- Identify hazardous products in accordance with relevant national and international labelling conventions; and\n- Indicate the appropriate temperature and humidity ranges within which the product is to be transported and/or stored.\n\n## 7.2.2 Labelling air-freighted shipments\n\nIn cases where TTSPPs are to be air-freighted, the package(s) should be labelled using the standard International Air Transport Association (IATA) time and temperature-sensitive symbol, in accordance with the conditions outlined in Chapter 17 of the IATA Perishable Cargo Regulations. Apply the label to the outer surface of individual shipping packages, overpacks or bulk containers.\n\n*Reason:* To ensure that products are correctly and safely handled at all points in the supply chain.\n\n# 8. Stock management\n\n## 8.1 Stock control systems\n\n### 8.1.1 General stock control systems and procedures\n\nTTSPP stock control systems and procedures meet the following minimum requirements:\n\n- Allow access only to authorized persons;\n- Record all receipts and dispatches;\n- Record batch numbers and expiry dates;\n- Record short-dated and expired products;\n- Record product status (i.e. released, quarantined, hold, reject);\n- Record all product returns, recalls, withdrawals, damage and disposals;\n- Manage the issue of products in EEFO order; and\n- Take regular physical inventories and reconcile stock records with the actual physical count. Investigate and report on stock discrepancies in accordance with agreed procedures. Preferably physical counts should be made at least twice a year.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1945, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b292d080-4542-432a-8a36-f101b395aa25": {"__data__": {"id_": "b292d080-4542-432a-8a36-f101b395aa25", "embedding": null, "metadata": {"page_label": "369", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 8.1.2 Stock control procedures for controlled and hazardous TTSPPs\n\nIn addition to the requirements set out in clause 8.1.1, implement the following procedures:\n\n- Institute a customer verification process to ensure that all recipients of these products are authorized to receive them.\n- Maintain stock records which specifically identify products in these categories.\n- Carry out regular audits and make audit reports available to the responsible authorities.\n- Comply with all record-keeping procedures specified in local legislation and regulations. Retain product transaction and delivery records for at least the minimum time period required by local regulations.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times and to satisfy the requirements of the regulatory authorities.\n\n## 8.2 Incoming goods\n\n### 8.2.1 Product arrival checks\n\nCheck and record the following for all incoming TTSPPs:\n\n- product name, item code (identifier), strength, and batch/lot number;\n- quantity received against order;\n- name and address of the supplying site;\n- examine containers for tampering, damage or contamination;\n- examine expiry dates \u2014 accept short-dated products only if prior agreement has been reached with the supplier; do not accept products that have expired or which are so close to their expiry date that this date is likely to occur before use by the consumer;\n- delays encountered during transport;\n- status of any attached temperature recording device(s) and/or time/temperature indicators; and\n- verify that required storage and transport conditions have been maintained.\n\n### 8.2.2 Actions following arrival checks\n\n- Enter product details, including product name/number, strength, batch numbers, quantities received, expiry dates and acceptance status into the stock recording system.\n- Store checked goods under the correct temperature and security regime immediately upon receipt.\n- Quarantine defective or potentially defective products, products with incomplete or missing paperwork, products that experienced unacceptable temperature excursions during transport, or products suspected to be counterfeit. Do not release until checks have been completed satisfactorily.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece procedimientos para el control de existencias de productos farmac\u00e9uticos controlados y peligrosos (TTSPPs). Se enfatiza la importancia de verificar a los clientes, mantener registros precisos, realizar auditor\u00edas regulares y cumplir con la legislaci\u00f3n local. Adem\u00e1s, se detallan los pasos a seguir al recibir productos, incluyendo la verificaci\u00f3n de la informaci\u00f3n del producto, el estado de los envases y las condiciones de transporte. Se requiere que los productos defectuosos o sospechosos sean puestos en cuarentena hasta que se completen las verificaciones necesarias.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos se deben implementar para verificar que los clientes est\u00e1n autorizados a recibir TTSPPs?**\n   - El documento menciona que se debe instituir un proceso de verificaci\u00f3n de clientes para asegurar que todos los destinatarios de estos productos est\u00e9n autorizados para recibirlos.\n\n2. **\u00bfCu\u00e1les son los criterios para aceptar productos con fechas de caducidad cercanas?**\n   - Se deben aceptar productos con fechas de caducidad cercanas solo si se ha llegado a un acuerdo previo con el proveedor; no se deben aceptar productos que ya han expirado o que est\u00e1n tan cerca de su fecha de caducidad que es probable que expiren antes de ser utilizados por el consumidor.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se encuentran productos defectuosos o sospechosos durante la verificaci\u00f3n de llegada?**\n   - Los productos defectuosos o potencialmente defectuosos, aquellos con documentaci\u00f3n incompleta o faltante, productos que experimentaron excursiones de temperatura inaceptables durante el transporte, o productos sospechosos de ser falsificados deben ser puestos en cuarentena y no se deben liberar hasta que se completen las verificaciones de manera satisfactoria.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Etiquetado de Productos Sensibles al Tiempo y Temperatura (TTSPPs)**:\n   - **Requisitos Generales**: \n     - Identificaci\u00f3n del producto seg\u00fan normativas nacionales e internacionales.\n     - Identificaci\u00f3n de productos peligrosos conforme a convenciones de etiquetado.\n     - Indicaci\u00f3n de rangos de temperatura y humedad para transporte y almacenamiento.\n   - **Etiquetado de Env\u00edos A\u00e9reos**: \n     - Uso del s\u00edmbolo de tiempo y temperatura sensible de la IATA.\n     - Cumplimiento de las regulaciones de carga perecedera de la IATA.\n\n2. **Gesti\u00f3n de Existencias**:\n   - **Sistemas de Control de Existencias**:\n     - Acceso restringido a personal autorizado.\n     - Registro de recepciones, despachos, n\u00fameros de lote, fechas de caducidad y estado del producto.\n     - Gesti\u00f3n de productos en orden EEFO (Primero en Expirar, Primero en Salir).\n     - Realizaci\u00f3n de inventarios f\u00edsicos regulares y conciliaci\u00f3n de registros.\n\n3. **Objetivos**:\n   - Asegurar el manejo correcto y seguro de los productos a lo largo de la cadena de suministro.\n   - Mantener registros de existencias precisos y completos.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n- **IATA**: Asociaci\u00f3n Internacional de Transporte A\u00e9reo.\n- **Regulaciones de Carga Perecedera**: Normativas que rigen el transporte de productos perecederos.\n- **EEFO**: M\u00e9todo de gesti\u00f3n de existencias (Primero en Expirar, Primero en Salir). \n\nEste resumen destaca los aspectos esenciales relacionados con la etiquetaci\u00f3n y gesti\u00f3n de existencias de productos sensibles, as\u00ed como las normativas y procedimientos necesarios para su manejo adecuado.", "excerpt_keywords": "Keywords: stock control, TTSPPs, customer verification, product arrival checks, quarantine procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "da6b2abe-804d-4b37-8bc8-6806c5b54a28", "node_type": "4", "metadata": {"page_label": "369", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 8.1.2 Stock control procedures for controlled and hazardous TTSPPs\n\nIn addition to the requirements set out in clause 8.1.1, implement the following procedures:\n\n- Institute a customer verification process to ensure that all recipients of these products are authorized to receive them.\n- Maintain stock records which specifically identify products in these categories.\n- Carry out regular audits and make audit reports available to the responsible authorities.\n- Comply with all record-keeping procedures specified in local legislation and regulations. Retain product transaction and delivery records for at least the minimum time period required by local regulations.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times and to satisfy the requirements of the regulatory authorities.\n\n## 8.2 Incoming goods\n\n### 8.2.1 Product arrival checks\n\nCheck and record the following for all incoming TTSPPs:\n\n- product name, item code (identifier), strength, and batch/lot number;\n- quantity received against order;\n- name and address of the supplying site;\n- examine containers for tampering, damage or contamination;\n- examine expiry dates \u2014 accept short-dated products only if prior agreement has been reached with the supplier; do not accept products that have expired or which are so close to their expiry date that this date is likely to occur before use by the consumer;\n- delays encountered during transport;\n- status of any attached temperature recording device(s) and/or time/temperature indicators; and\n- verify that required storage and transport conditions have been maintained.\n\n### 8.2.2 Actions following arrival checks\n\n- Enter product details, including product name/number, strength, batch numbers, quantities received, expiry dates and acceptance status into the stock recording system.\n- Store checked goods under the correct temperature and security regime immediately upon receipt.\n- Quarantine defective or potentially defective products, products with incomplete or missing paperwork, products that experienced unacceptable temperature excursions during transport, or products suspected to be counterfeit. Do not release until checks have been completed satisfactorily.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "536b3f72001238112b5113cc241e820d7d6b92436b774d55d9e4aecfcac795df", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "## 8.1.2 Stock control procedures for controlled and hazardous TTSPPs\n\nIn addition to the requirements set out in clause 8.1.1, implement the following procedures:\n\n- Institute a customer verification process to ensure that all recipients of these products are authorized to receive them.\n- Maintain stock records which specifically identify products in these categories.\n- Carry out regular audits and make audit reports available to the responsible authorities.\n- Comply with all record-keeping procedures specified in local legislation and regulations. Retain product transaction and delivery records for at least the minimum time period required by local regulations.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times and to satisfy the requirements of the regulatory authorities.\n\n## 8.2 Incoming goods\n\n### 8.2.1 Product arrival checks\n\nCheck and record the following for all incoming TTSPPs:\n\n- product name, item code (identifier), strength, and batch/lot number;\n- quantity received against order;\n- name and address of the supplying site;\n- examine containers for tampering, damage or contamination;\n- examine expiry dates \u2014 accept short-dated products only if prior agreement has been reached with the supplier; do not accept products that have expired or which are so close to their expiry date that this date is likely to occur before use by the consumer;\n- delays encountered during transport;\n- status of any attached temperature recording device(s) and/or time/temperature indicators; and\n- verify that required storage and transport conditions have been maintained.\n\n### 8.2.2 Actions following arrival checks\n\n- Enter product details, including product name/number, strength, batch numbers, quantities received, expiry dates and acceptance status into the stock recording system.\n- Store checked goods under the correct temperature and security regime immediately upon receipt.\n- Quarantine defective or potentially defective products, products with incomplete or missing paperwork, products that experienced unacceptable temperature excursions during transport, or products suspected to be counterfeit. Do not release until checks have been completed satisfactorily.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2219, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6a813e00-31d7-414f-812f-98ba8d15a54e": {"__data__": {"id_": "6a813e00-31d7-414f-812f-98ba8d15a54e", "embedding": null, "metadata": {"page_label": "370", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All unacceptable temperature excursions should be evaluated to determine their effect on the product.\n\n- Report any defects to the supplying store or holder of the marketing authorization.\n- Do not transfer to saleable stock until all relevant disposition procedures have been completed.\n\n*Reason:* To ensure that incoming TTSPPs are in acceptable condition, accurately recorded and correctly stored and that defective and/or incorrect shipments are followed up with the supplier.\n\n## 8.3 Outgoing goods (external deliveries)\n\n### 8.3.1 Management of outgoing goods\n\nImplement outgoing goods procedures to ensure that:\n\n- Transport vehicle conformity, including conformity with SLA or quality assurance (QA) agreements, is checked before loading goods.\n- Expired products are never issued.\n- Products with short expiry dates are not issued unless the recipient accepts that they can be consumed before the expiry date is reached.\n- Products are distributed in strict EEFO order unless a product-based time-temperature exposure indicator, such as a vaccine vial monitor, demonstrates that a batch should be distributed ahead of its EEFO order.\n- Details of any temperature monitoring devices packed with the external distributions are recorded.\n- Details of outgoing products, including product name/number, strength, batch numbers, expiry dates and quantities distributed, are entered into the stock recording system.\n\n### 8.3.2 Actions following dispatch\n\nMonitor TTSPPs following dispatch in order to:\n\n- Trace products to their intended destination;\n- Record and retain records to provide assurance of goods arrival status. A suitable delivery report from the carrier is an acceptable alternative; and\n- Take appropriate action in the event of returns, recalls or complaints.\n\n*Reason:* To ensure that outgoing TTSPPs are in acceptable condition, that short-dated stock does not accumulate in the store and that evidence is kept to demonstrate that correct quantities are distributed and received in good condition.\n\n## 8.4 Product complaint procedures\n\nManage product complaints as follows:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece procedimientos para la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, centr\u00e1ndose en la evaluaci\u00f3n de excursiones de temperatura, la gesti\u00f3n de bienes salientes y la gesti\u00f3n de quejas de productos. Se enfatiza la importancia de asegurar que los productos lleguen en condiciones aceptables, se registren adecuadamente y se manejen de acuerdo con las normativas de calidad y seguridad.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los productos salientes no est\u00e9n caducados y se distribuyan correctamente?**\n   - Respuesta: Los procedimientos incluyen verificar la conformidad del veh\u00edculo de transporte, no emitir productos caducados, no emitir productos con fechas de caducidad cortas a menos que el destinatario acepte su uso, y distribuir productos en estricto orden EEFO, a menos que un indicador de exposici\u00f3n a temperatura demuestre que un lote debe ser distribuido antes de su orden EEFO.\n\n2. **\u00bfQu\u00e9 acciones se deben tomar en caso de que se detecten excursiones de temperatura inaceptables en los productos?**\n   - Respuesta: Se deben evaluar todas las excursiones de temperatura inaceptables para determinar su efecto en el producto, reportar cualquier defecto al almac\u00e9n proveedor o al titular de la autorizaci\u00f3n de comercializaci\u00f3n, y no transferir los productos a stock vendible hasta que se hayan completado todos los procedimientos de disposici\u00f3n relevantes.\n\n3. **\u00bfC\u00f3mo se debe gestionar el seguimiento de los productos despu\u00e9s de su despacho?**\n   - Respuesta: Se debe monitorear los productos para rastrear su destino, registrar y conservar los registros que proporcionen garant\u00eda sobre el estado de llegada de los bienes, y tomar las acciones apropiadas en caso de devoluciones, retiradas o quejas. Un informe de entrega adecuado del transportista es una alternativa aceptable para demostrar la llegada de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de existencias de TTSPPs**:\n   - Se establecen procedimientos espec\u00edficos para el control de productos farmac\u00e9uticos controlados y peligrosos (TTSPPs).\n   - Importancia de la verificaci\u00f3n de clientes para asegurar que solo los autorizados reciban estos productos.\n\n2. **Mantenimiento de registros**:\n   - Se requiere llevar registros de existencias que identifiquen claramente los productos en estas categor\u00edas.\n   - Realizaci\u00f3n de auditor\u00edas regulares y disponibilidad de informes para las autoridades responsables.\n   - Cumplimiento de la legislaci\u00f3n local en cuanto a la conservaci\u00f3n de registros de transacciones y entregas.\n\n3. **Verificaci\u00f3n de llegada de productos**:\n   - Proceso de chequeo al recibir productos, que incluye la verificaci\u00f3n de nombre del producto, c\u00f3digo, fuerza, n\u00famero de lote, cantidad recibida, y estado de los envases.\n   - Examen de fechas de caducidad y condiciones de transporte, con criterios espec\u00edficos para aceptar productos con fechas cercanas a la caducidad.\n\n4. **Acciones tras la verificaci\u00f3n de llegada**:\n   - Registro de detalles del producto en el sistema de control de existencias.\n   - Almacenamiento inmediato de los productos bajo condiciones adecuadas de temperatura y seguridad.\n   - Cuarentena de productos defectuosos, sospechosos o con documentaci\u00f3n incompleta hasta que se completen las verificaciones necesarias.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos controlados y peligrosos.\n- **Regulaciones locales**: Normativas que rigen el manejo y almacenamiento de productos farmac\u00e9uticos.\n- **Autoridades responsables**: Entidades que supervisan el cumplimiento de las normativas y procedimientos establecidos. \n\nEste resumen destaca la importancia de los procedimientos de control y verificaci\u00f3n en la gesti\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de cumplir con las regulaciones locales para garantizar la seguridad y eficacia de estos productos.", "excerpt_keywords": "Keywords: temperature excursions, outgoing goods management, product complaints, TTSPPs, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "71390f54-4539-420e-9c33-20727114f280", "node_type": "4", "metadata": {"page_label": "370", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All unacceptable temperature excursions should be evaluated to determine their effect on the product.\n\n- Report any defects to the supplying store or holder of the marketing authorization.\n- Do not transfer to saleable stock until all relevant disposition procedures have been completed.\n\n*Reason:* To ensure that incoming TTSPPs are in acceptable condition, accurately recorded and correctly stored and that defective and/or incorrect shipments are followed up with the supplier.\n\n## 8.3 Outgoing goods (external deliveries)\n\n### 8.3.1 Management of outgoing goods\n\nImplement outgoing goods procedures to ensure that:\n\n- Transport vehicle conformity, including conformity with SLA or quality assurance (QA) agreements, is checked before loading goods.\n- Expired products are never issued.\n- Products with short expiry dates are not issued unless the recipient accepts that they can be consumed before the expiry date is reached.\n- Products are distributed in strict EEFO order unless a product-based time-temperature exposure indicator, such as a vaccine vial monitor, demonstrates that a batch should be distributed ahead of its EEFO order.\n- Details of any temperature monitoring devices packed with the external distributions are recorded.\n- Details of outgoing products, including product name/number, strength, batch numbers, expiry dates and quantities distributed, are entered into the stock recording system.\n\n### 8.3.2 Actions following dispatch\n\nMonitor TTSPPs following dispatch in order to:\n\n- Trace products to their intended destination;\n- Record and retain records to provide assurance of goods arrival status. A suitable delivery report from the carrier is an acceptable alternative; and\n- Take appropriate action in the event of returns, recalls or complaints.\n\n*Reason:* To ensure that outgoing TTSPPs are in acceptable condition, that short-dated stock does not accumulate in the store and that evidence is kept to demonstrate that correct quantities are distributed and received in good condition.\n\n## 8.4 Product complaint procedures\n\nManage product complaints as follows:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "65b3fb8482587943fd610f34c693948a95d9ed0426cbed17c35961dcb8a38d87", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "All unacceptable temperature excursions should be evaluated to determine their effect on the product.\n\n- Report any defects to the supplying store or holder of the marketing authorization.\n- Do not transfer to saleable stock until all relevant disposition procedures have been completed.\n\n*Reason:* To ensure that incoming TTSPPs are in acceptable condition, accurately recorded and correctly stored and that defective and/or incorrect shipments are followed up with the supplier.\n\n## 8.3 Outgoing goods (external deliveries)\n\n### 8.3.1 Management of outgoing goods\n\nImplement outgoing goods procedures to ensure that:\n\n- Transport vehicle conformity, including conformity with SLA or quality assurance (QA) agreements, is checked before loading goods.\n- Expired products are never issued.\n- Products with short expiry dates are not issued unless the recipient accepts that they can be consumed before the expiry date is reached.\n- Products are distributed in strict EEFO order unless a product-based time-temperature exposure indicator, such as a vaccine vial monitor, demonstrates that a batch should be distributed ahead of its EEFO order.\n- Details of any temperature monitoring devices packed with the external distributions are recorded.\n- Details of outgoing products, including product name/number, strength, batch numbers, expiry dates and quantities distributed, are entered into the stock recording system.\n\n### 8.3.2 Actions following dispatch\n\nMonitor TTSPPs following dispatch in order to:\n\n- Trace products to their intended destination;\n- Record and retain records to provide assurance of goods arrival status. A suitable delivery report from the carrier is an acceptable alternative; and\n- Take appropriate action in the event of returns, recalls or complaints.\n\n*Reason:* To ensure that outgoing TTSPPs are in acceptable condition, that short-dated stock does not accumulate in the store and that evidence is kept to demonstrate that correct quantities are distributed and received in good condition.\n\n## 8.4 Product complaint procedures\n\nManage product complaints as follows:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2094, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4d6aef1d-f58f-49d0-a42e-db2d140b93b0": {"__data__": {"id_": "4d6aef1d-f58f-49d0-a42e-db2d140b93b0", "embedding": null, "metadata": {"page_label": "371", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- If a product defect is discovered or suspected in a batch of TTSPPs, cooperate with the regulatory authority to determine whether other batches are affected and recall products if required to do so by the regulatory authority.\n- Where complaints or defects relate to a product or its packaging, immediately notify the holder of the marketing authorization for the product.\n- Where complaints or defects arise as a result of errors or omissions within the organization, immediately evaluate the causes and take remedial measures to prevent a recurrence.\n- Record all complaints and the remedial actions taken. Monitor and analyse trends in the complaint records.\n\n*Reason:* Protection of the public and of the reputation of the supplying organization.\n\n## 8.5 Suspect product procedures\n\n### 8.5.1 Suspect products\n\nImplement systems for identifying and managing suspect products found in the supply chain as follows:\n\n- Physically segregate any suspect TTSPPs found in the supply chain and store securely until legal investigations are complete.\n- Label them clearly as \u201cNot for use\u201d or other similar phrase;\n- Immediately notify the regulatory authority or authorities and any other relevant authorities, as well as the holder of the marketing authorization of the product.\n- Cooperate with regulatory authorities to assist with investigating the source of suspect products and implement appropriate remedial action(s).\n- Document the decision-making process for disposal or return of condemned or defective TTSPPs and make these records available to the relevant authorities.\n\n*Reason:* Protection of the public, protection of legitimate suppliers and manufacturers and conformity with regulatory requirements.\n\n## 8.6 Product return, recall, withdrawal and disposal procedures\n\n### 8.6.1 Return procedures\n\nManage product returns as follows:\n\n- Quarantine returned TTSPPs in a suitable temperature-controlled area and under the security conditions applicable to the product type.\n- Do not return to saleable stock unless storage and transport temperature conditions after dispatch from the distribution site have been fully verified and documented, including the return leg to the distribution site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos para productos defectuosos**: El documento establece directrices sobre c\u00f3mo manejar productos defectuosos o sospechosos en la cadena de suministro, enfatizando la cooperaci\u00f3n con las autoridades regulatorias y la importancia de documentar todas las quejas y acciones correctivas.\n\n2. **Manejo de productos sospechosos**: Se describen los pasos a seguir para identificar y gestionar productos sospechosos, incluyendo la segregaci\u00f3n f\u00edsica, el etiquetado adecuado y la notificaci\u00f3n a las autoridades pertinentes.\n\n3. **Procedimientos de devoluci\u00f3n y retiro de productos**: Se detallan las medidas que deben tomarse al gestionar devoluciones de productos, incluyendo el almacenamiento en condiciones controladas y la verificaci\u00f3n de las condiciones de temperatura antes de devolver los productos a la venta.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para documentar la decisi\u00f3n de disposici\u00f3n de productos condenados o defectuosos?**\n   - El contexto menciona que se debe documentar el proceso de toma de decisiones para la disposici\u00f3n o retorno de productos condenados o defectuosos, y que estos registros deben estar disponibles para las autoridades relevantes.\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento y transporte que deben verificarse antes de devolver productos a la venta?**\n   - Se indica que no se deben devolver productos a la venta a menos que se hayan verificado y documentado completamente las condiciones de temperatura de almacenamiento y transporte despu\u00e9s del despacho desde el sitio de distribuci\u00f3n, incluyendo el trayecto de retorno.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si se descubre un defecto en un lote de TTSPPs?**\n   - Se debe cooperar con la autoridad regulatoria para determinar si otros lotes est\u00e1n afectados y realizar un retiro de productos si as\u00ed lo requiere la autoridad regulatoria. Adem\u00e1s, se deben notificar inmediatamente las quejas o defectos al titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Excursiones de Temperatura:**\n   - Evaluaci\u00f3n de excursiones de temperatura inaceptables para determinar su impacto en los productos.\n   - Reporte de defectos al almac\u00e9n proveedor o al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n   - Prohibici\u00f3n de transferir productos a stock vendible hasta completar los procedimientos de disposici\u00f3n.\n\n2. **Procedimientos para Bienes Salientes:**\n   - Verificaci\u00f3n de la conformidad del veh\u00edculo de transporte antes de cargar productos.\n   - Prohibici\u00f3n de emitir productos caducados.\n   - Emisi\u00f3n de productos con fechas de caducidad cortas solo con aceptaci\u00f3n del destinatario.\n   - Distribuci\u00f3n de productos en orden EEFO, salvo indicaciones de exposici\u00f3n a temperatura que justifiquen un cambio en el orden.\n   - Registro de detalles de dispositivos de monitoreo de temperatura y productos salientes en el sistema de registro de stock.\n\n3. **Acciones Posteriores al Despacho:**\n   - Monitoreo de productos para rastrear su destino.\n   - Registro y conservaci\u00f3n de documentos que aseguren el estado de llegada de los bienes.\n   - Acciones apropiadas en caso de devoluciones, retiradas o quejas, incluyendo la aceptaci\u00f3n de informes de entrega del transportista.\n\n4. **Procedimientos de Quejas de Productos:**\n   - Gesti\u00f3n de quejas de productos, aunque no se detallan en el extracto proporcionado.\n\n### Entidades Clave:\n- **TTSPPs:** Productos farmac\u00e9uticos y biol\u00f3gicos que requieren seguimiento y gesti\u00f3n.\n- **SLA:** Acuerdos de nivel de servicio relacionados con la calidad y conformidad del transporte.\n- **EEFO:** Estrategia de distribuci\u00f3n que prioriza la salida de productos con fechas de caducidad m\u00e1s cercanas.\n\n### Conclusi\u00f3n:\nEl documento enfatiza la importancia de seguir procedimientos rigurosos para asegurar la calidad y seguridad de los productos farmac\u00e9uticos y biol\u00f3gicos, desde su recepci\u00f3n hasta su distribuci\u00f3n y gesti\u00f3n de quejas.", "excerpt_keywords": "Keywords: product defects, regulatory authority, suspect products, product recall, temperature control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6af8dcfd-c0d8-4fbd-8883-f09d41d4aed7", "node_type": "4", "metadata": {"page_label": "371", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- If a product defect is discovered or suspected in a batch of TTSPPs, cooperate with the regulatory authority to determine whether other batches are affected and recall products if required to do so by the regulatory authority.\n- Where complaints or defects relate to a product or its packaging, immediately notify the holder of the marketing authorization for the product.\n- Where complaints or defects arise as a result of errors or omissions within the organization, immediately evaluate the causes and take remedial measures to prevent a recurrence.\n- Record all complaints and the remedial actions taken. Monitor and analyse trends in the complaint records.\n\n*Reason:* Protection of the public and of the reputation of the supplying organization.\n\n## 8.5 Suspect product procedures\n\n### 8.5.1 Suspect products\n\nImplement systems for identifying and managing suspect products found in the supply chain as follows:\n\n- Physically segregate any suspect TTSPPs found in the supply chain and store securely until legal investigations are complete.\n- Label them clearly as \u201cNot for use\u201d or other similar phrase;\n- Immediately notify the regulatory authority or authorities and any other relevant authorities, as well as the holder of the marketing authorization of the product.\n- Cooperate with regulatory authorities to assist with investigating the source of suspect products and implement appropriate remedial action(s).\n- Document the decision-making process for disposal or return of condemned or defective TTSPPs and make these records available to the relevant authorities.\n\n*Reason:* Protection of the public, protection of legitimate suppliers and manufacturers and conformity with regulatory requirements.\n\n## 8.6 Product return, recall, withdrawal and disposal procedures\n\n### 8.6.1 Return procedures\n\nManage product returns as follows:\n\n- Quarantine returned TTSPPs in a suitable temperature-controlled area and under the security conditions applicable to the product type.\n- Do not return to saleable stock unless storage and transport temperature conditions after dispatch from the distribution site have been fully verified and documented, including the return leg to the distribution site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "2982a5001e1bd37e9084757e222ee3ed72ebe9567663d7f7a4e8c4d5742be015", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- If a product defect is discovered or suspected in a batch of TTSPPs, cooperate with the regulatory authority to determine whether other batches are affected and recall products if required to do so by the regulatory authority.\n- Where complaints or defects relate to a product or its packaging, immediately notify the holder of the marketing authorization for the product.\n- Where complaints or defects arise as a result of errors or omissions within the organization, immediately evaluate the causes and take remedial measures to prevent a recurrence.\n- Record all complaints and the remedial actions taken. Monitor and analyse trends in the complaint records.\n\n*Reason:* Protection of the public and of the reputation of the supplying organization.\n\n## 8.5 Suspect product procedures\n\n### 8.5.1 Suspect products\n\nImplement systems for identifying and managing suspect products found in the supply chain as follows:\n\n- Physically segregate any suspect TTSPPs found in the supply chain and store securely until legal investigations are complete.\n- Label them clearly as \u201cNot for use\u201d or other similar phrase;\n- Immediately notify the regulatory authority or authorities and any other relevant authorities, as well as the holder of the marketing authorization of the product.\n- Cooperate with regulatory authorities to assist with investigating the source of suspect products and implement appropriate remedial action(s).\n- Document the decision-making process for disposal or return of condemned or defective TTSPPs and make these records available to the relevant authorities.\n\n*Reason:* Protection of the public, protection of legitimate suppliers and manufacturers and conformity with regulatory requirements.\n\n## 8.6 Product return, recall, withdrawal and disposal procedures\n\n### 8.6.1 Return procedures\n\nManage product returns as follows:\n\n- Quarantine returned TTSPPs in a suitable temperature-controlled area and under the security conditions applicable to the product type.\n- Do not return to saleable stock unless storage and transport temperature conditions after dispatch from the distribution site have been fully verified and documented, including the return leg to the distribution site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2204, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "21544908-0f1c-4360-b228-12b610aebc39": {"__data__": {"id_": "21544908-0f1c-4360-b228-12b610aebc39", "embedding": null, "metadata": {"page_label": "372", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Where appropriate, obtain written advice from the holder of the marketing authorization regarding handling and/or disposal of the returned TTSPP.\n- If returned stock is re-issued, distribute in EEFO order or in accordance with the exposure status of any product-mounted time-temperature indicator device.\n- Quarantine returned TTSPPs that have been exposed to unacceptable storage and/or transport temperatures and mark for disposal.\n- Maintain records of all returned TTSPPs.\n\n*Reason:* Protection of the public.\n\n### 8.6.2 Recall procedures\n\nManage product recalls as follows:\n\n- Conduct urgent and non-urgent TTSPP recalls in accordance with an agreed emergency plan.\n- Notify the local regulatory authority or authorities.\n- Notify overseas regulatory counterparts where the product has been exported.\n- Notify all affected customers as applicable.\n- Quarantine any remaining inventory of recalled TTSPPs and mark for further investigation before disposal.\n- Maintain records of all TTSPP recalls, including reconciliation of quantity sold, quantity returned, quantity remaining or quantity consumed.\n\n*Reason:* Protection of the public and conformity with regulatory requirements.\n\n### 8.6.3 Disposal procedures\n\nManage product awaiting board of survey or disposal as follows:\n\n- Ensure that rejected and/or recalled or withdrawn TTSPPs cannot be used, released or cause contamination to other products. Store separately from other products, in accordance with local regulations, to await destruction or return to the supplier.\n- Safely dispose of rejected and/or recalled/withdrawn products in accordance with local regulations, including where relevant, regulations covering the disposal of hazardous and controlled drugs.\n- Maintain disposal records.\n\n*Reason:* Protection of the public and the environment.\n\n### 8.7 Traceability or stock tracking\n\nEnsure that stock and distribution records enable traceability, or stock tracking, of TTSPPs from the point of supply to the end-user or patient.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos relacionados con la gesti\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente los productos terap\u00e9uticos y de salud p\u00fablica (TTSPP). Se detallan las pr\u00e1cticas recomendadas para el manejo de devoluciones, retiros de productos, procedimientos de disposici\u00f3n y la importancia de la trazabilidad de los productos desde el punto de suministro hasta el usuario final. Se enfatiza la protecci\u00f3n del p\u00fablico y el cumplimiento de las regulaciones locales en cada uno de estos procesos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para manejar un TTSPP que ha sido devuelto y ha estado expuesto a temperaturas inaceptables?**\n   - Respuesta: Los TTSPP devueltos que han estado expuestos a temperaturas inaceptables deben ser puestos en cuarentena y marcados para su disposici\u00f3n. Adem\u00e1s, se debe mantener un registro de todos los TTSPP devueltos.\n\n2. **\u00bfCu\u00e1les son las obligaciones de notificaci\u00f3n en caso de un retiro de producto no urgente?**\n   - Respuesta: En caso de un retiro de producto no urgente, se debe notificar a la autoridad reguladora local, a los contrapartes regulatorios en el extranjero si el producto ha sido exportado, y a todos los clientes afectados seg\u00fan sea aplicable.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar que los TTSPP rechazados o retirados no causen contaminaci\u00f3n a otros productos?**\n   - Respuesta: Los TTSPP rechazados o retirados deben almacenarse por separado de otros productos, de acuerdo con las regulaciones locales, para evitar su uso o liberaci\u00f3n, y deben estar preparados para su destrucci\u00f3n o devoluci\u00f3n al proveedor. Adem\u00e1s, se deben mantener registros de disposici\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Defectuosos**:\n   - Procedimientos para identificar y gestionar productos defectuosos o sospechosos en la cadena de suministro.\n   - Importancia de la cooperaci\u00f3n con las autoridades regulatorias para determinar el impacto en otros lotes y realizar retiros si es necesario.\n   - Notificaci\u00f3n inmediata al titular de la autorizaci\u00f3n de comercializaci\u00f3n sobre quejas o defectos.\n\n2. **Procedimientos para Productos Sospechosos**:\n   - Implementaci\u00f3n de sistemas para la identificaci\u00f3n y gesti\u00f3n de productos sospechosos.\n   - Segregaci\u00f3n f\u00edsica y almacenamiento seguro de productos sospechosos hasta que se completen las investigaciones legales.\n   - Etiquetado claro de los productos como \"No para uso\" y notificaci\u00f3n a las autoridades pertinentes.\n\n3. **Devoluciones y Retiro de Productos**:\n   - Procedimientos para gestionar devoluciones de productos, incluyendo el almacenamiento en \u00e1reas controladas por temperatura.\n   - Verificaci\u00f3n y documentaci\u00f3n de las condiciones de temperatura de almacenamiento y transporte antes de devolver productos a la venta.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y de salud en la cadena de suministro.\n- **Autoridades Regulatorias**: Entidades responsables de la supervisi\u00f3n y regulaci\u00f3n de productos en el mercado.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad que posee la autorizaci\u00f3n para comercializar un producto espec\u00edfico.\n\n### Razones para los Procedimientos:\n- Protecci\u00f3n del p\u00fablico y de la reputaci\u00f3n de la organizaci\u00f3n proveedora.\n- Protecci\u00f3n de proveedores y fabricantes leg\u00edtimos.\n- Conformidad con los requisitos regulatorios.", "excerpt_keywords": "Keywords: TTSPP, product recall, disposal procedures, traceability, regulatory compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c92f3df4-199d-4d6b-838c-42881f5e3608", "node_type": "4", "metadata": {"page_label": "372", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Where appropriate, obtain written advice from the holder of the marketing authorization regarding handling and/or disposal of the returned TTSPP.\n- If returned stock is re-issued, distribute in EEFO order or in accordance with the exposure status of any product-mounted time-temperature indicator device.\n- Quarantine returned TTSPPs that have been exposed to unacceptable storage and/or transport temperatures and mark for disposal.\n- Maintain records of all returned TTSPPs.\n\n*Reason:* Protection of the public.\n\n### 8.6.2 Recall procedures\n\nManage product recalls as follows:\n\n- Conduct urgent and non-urgent TTSPP recalls in accordance with an agreed emergency plan.\n- Notify the local regulatory authority or authorities.\n- Notify overseas regulatory counterparts where the product has been exported.\n- Notify all affected customers as applicable.\n- Quarantine any remaining inventory of recalled TTSPPs and mark for further investigation before disposal.\n- Maintain records of all TTSPP recalls, including reconciliation of quantity sold, quantity returned, quantity remaining or quantity consumed.\n\n*Reason:* Protection of the public and conformity with regulatory requirements.\n\n### 8.6.3 Disposal procedures\n\nManage product awaiting board of survey or disposal as follows:\n\n- Ensure that rejected and/or recalled or withdrawn TTSPPs cannot be used, released or cause contamination to other products. Store separately from other products, in accordance with local regulations, to await destruction or return to the supplier.\n- Safely dispose of rejected and/or recalled/withdrawn products in accordance with local regulations, including where relevant, regulations covering the disposal of hazardous and controlled drugs.\n- Maintain disposal records.\n\n*Reason:* Protection of the public and the environment.\n\n### 8.7 Traceability or stock tracking\n\nEnsure that stock and distribution records enable traceability, or stock tracking, of TTSPPs from the point of supply to the end-user or patient.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c972ecff33e607fdadbc2bb8c39baf2076217d07c977ffa4c7f8e93c64e9542d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- Where appropriate, obtain written advice from the holder of the marketing authorization regarding handling and/or disposal of the returned TTSPP.\n- If returned stock is re-issued, distribute in EEFO order or in accordance with the exposure status of any product-mounted time-temperature indicator device.\n- Quarantine returned TTSPPs that have been exposed to unacceptable storage and/or transport temperatures and mark for disposal.\n- Maintain records of all returned TTSPPs.\n\n*Reason:* Protection of the public.\n\n### 8.6.2 Recall procedures\n\nManage product recalls as follows:\n\n- Conduct urgent and non-urgent TTSPP recalls in accordance with an agreed emergency plan.\n- Notify the local regulatory authority or authorities.\n- Notify overseas regulatory counterparts where the product has been exported.\n- Notify all affected customers as applicable.\n- Quarantine any remaining inventory of recalled TTSPPs and mark for further investigation before disposal.\n- Maintain records of all TTSPP recalls, including reconciliation of quantity sold, quantity returned, quantity remaining or quantity consumed.\n\n*Reason:* Protection of the public and conformity with regulatory requirements.\n\n### 8.6.3 Disposal procedures\n\nManage product awaiting board of survey or disposal as follows:\n\n- Ensure that rejected and/or recalled or withdrawn TTSPPs cannot be used, released or cause contamination to other products. Store separately from other products, in accordance with local regulations, to await destruction or return to the supplier.\n- Safely dispose of rejected and/or recalled/withdrawn products in accordance with local regulations, including where relevant, regulations covering the disposal of hazardous and controlled drugs.\n- Maintain disposal records.\n\n*Reason:* Protection of the public and the environment.\n\n### 8.7 Traceability or stock tracking\n\nEnsure that stock and distribution records enable traceability, or stock tracking, of TTSPPs from the point of supply to the end-user or patient.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2004, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8909c322-fe28-46c3-8315-959451b24de1": {"__data__": {"id_": "8909c322-fe28-46c3-8315-959451b24de1", "embedding": null, "metadata": {"page_label": "373", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Traceability should include records of the temperature exposure of the product during internal shipping and storage. These records should include:\n\n- for incoming goods: status of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of receipt;\n- for outgoing goods: type of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of dispatch.\n\nMonitor, record, and investigate discrepancies.\n\n*Reason:* To demonstrate that TTSPPs have been correctly distributed and to facilitate product recalls and detect theft and fraud.\n\n## 9. General procedures and record-keeping\n\n### 9.1 Emergencies and contingency planning\n\nMake contingency arrangements for the safe storage of TTSPPs in the event of emergencies, including, but not confined to:\n\n- extended power supply outages;\n- equipment failure; and\n- vehicle breakdown during transport of TTSPPs.\n\nPrepare action plans to deal with products subjected to temperature excursions.\n\nEnsure that the responsible staff know, and have rehearsed, the appropriate actions to be taken in the event of the identified emergency scenarios.\n\n*Reason:* Loss prevention.\n\n### 9.2 General record-keeping\n\n#### 9.2.1 Record-keeping\n\nMaintain comprehensive records and ensure that they are laid out in an orderly fashion and are easy to check.\n\nPaper records must be:\n\n- stored and maintained so that they are accessible and easily retrievable;\n- labelled, dated and filed for easy identification;\n- protected against deterioration and loss due to fire, flood or other hazards;\n- kept secure and protected against unauthorized access; and\n- signed and dated by authorized persons and not changed without due authorization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la trazabilidad y el registro de productos farmac\u00e9uticos, enfatizando la importancia de mantener registros de la exposici\u00f3n a la temperatura durante el transporte y almacenamiento interno. Se detallan procedimientos para manejar emergencias y la planificaci\u00f3n de contingencias, as\u00ed como la necesidad de mantener registros organizados y accesibles. Se subraya la importancia de la monitorizaci\u00f3n y la investigaci\u00f3n de discrepancias para prevenir p\u00e9rdidas y facilitar la recuperaci\u00f3n de productos en caso de problemas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de indicadores de env\u00edo se deben registrar para los productos entrantes y salientes, y por qu\u00e9 es importante esta informaci\u00f3n?**\n   - Esta pregunta se centra en los detalles espec\u00edficos de los indicadores de env\u00edo y su relevancia para la trazabilidad y la seguridad del producto.\n\n2. **\u00bfCu\u00e1les son las acciones espec\u00edficas que el personal debe conocer y ensayar en caso de un corte de energ\u00eda prolongado o falla de equipo?**\n   - Esta pregunta busca informaci\u00f3n sobre los procedimientos de emergencia espec\u00edficos que deben seguirse, lo que no se detalla en el contexto.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para proteger los registros en papel contra la p\u00e9rdida o deterioro, y qui\u00e9n es responsable de su autorizaci\u00f3n?**\n   - Esta pregunta se enfoca en las pr\u00e1cticas de conservaci\u00f3n de registros y la responsabilidad de la autorizaci\u00f3n, aspectos que pueden no estar claramente definidos en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Devueltos (TTSPP)**:\n   - Obtener asesor\u00eda escrita del titular de la autorizaci\u00f3n de comercializaci\u00f3n sobre el manejo y disposici\u00f3n de TTSPP devueltos.\n   - Poner en cuarentena los TTSPP expuestos a temperaturas inaceptables y marcarlos para su disposici\u00f3n.\n   - Mantener registros de todos los TTSPP devueltos.\n\n2. **Procedimientos de Retiro de Productos**:\n   - Realizar retiros de TTSPP (urgentes y no urgentes) seg\u00fan un plan de emergencia acordado.\n   - Notificar a la autoridad reguladora local y a contrapartes regulatorias en el extranjero si el producto ha sido exportado.\n   - Informar a todos los clientes afectados y poner en cuarentena el inventario restante de productos retirados.\n\n3. **Procedimientos de Disposici\u00f3n**:\n   - Asegurar que los TTSPP rechazados o retirados no puedan ser utilizados o causar contaminaci\u00f3n a otros productos.\n   - Almacenar estos productos por separado y disponer de ellos de acuerdo con las regulaciones locales.\n   - Mantener registros de disposici\u00f3n.\n\n4. **Trazabilidad y Seguimiento de Stock**:\n   - Asegurar que los registros de stock y distribuci\u00f3n permitan la trazabilidad de los TTSPP desde el punto de suministro hasta el usuario final.\n\n### Entidades Clave:\n- **TTSPP**: Productos Terap\u00e9uticos y de Salud P\u00fablica.\n- **Autoridades Reguladoras**: Entidades responsables de la regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Clientes Afectados**: Usuarios o entidades que han recibido productos retirados.\n- **Regulaciones Locales**: Normativas que rigen el manejo y disposici\u00f3n de productos farmac\u00e9uticos en cada jurisdicci\u00f3n. \n\n### Razones Fundamentales:\n- Protecci\u00f3n del p\u00fablico.\n- Conformidad con los requisitos regulatorios.\n- Protecci\u00f3n del medio ambiente.", "excerpt_keywords": "Keywords: traceability, temperature exposure, emergency planning, record-keeping, product recalls"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "734e37d3-a592-4ffc-875a-ce92d938e6a1", "node_type": "4", "metadata": {"page_label": "373", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Traceability should include records of the temperature exposure of the product during internal shipping and storage. These records should include:\n\n- for incoming goods: status of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of receipt;\n- for outgoing goods: type of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of dispatch.\n\nMonitor, record, and investigate discrepancies.\n\n*Reason:* To demonstrate that TTSPPs have been correctly distributed and to facilitate product recalls and detect theft and fraud.\n\n## 9. General procedures and record-keeping\n\n### 9.1 Emergencies and contingency planning\n\nMake contingency arrangements for the safe storage of TTSPPs in the event of emergencies, including, but not confined to:\n\n- extended power supply outages;\n- equipment failure; and\n- vehicle breakdown during transport of TTSPPs.\n\nPrepare action plans to deal with products subjected to temperature excursions.\n\nEnsure that the responsible staff know, and have rehearsed, the appropriate actions to be taken in the event of the identified emergency scenarios.\n\n*Reason:* Loss prevention.\n\n### 9.2 General record-keeping\n\n#### 9.2.1 Record-keeping\n\nMaintain comprehensive records and ensure that they are laid out in an orderly fashion and are easy to check.\n\nPaper records must be:\n\n- stored and maintained so that they are accessible and easily retrievable;\n- labelled, dated and filed for easy identification;\n- protected against deterioration and loss due to fire, flood or other hazards;\n- kept secure and protected against unauthorized access; and\n- signed and dated by authorized persons and not changed without due authorization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1f7b83ed26569f615cb7fe2d1e4683e7296bfb41ed8f3945e3317d6efd0428f0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Traceability should include records of the temperature exposure of the product during internal shipping and storage. These records should include:\n\n- for incoming goods: status of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of receipt;\n- for outgoing goods: type of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of dispatch.\n\nMonitor, record, and investigate discrepancies.\n\n*Reason:* To demonstrate that TTSPPs have been correctly distributed and to facilitate product recalls and detect theft and fraud.\n\n## 9. General procedures and record-keeping\n\n### 9.1 Emergencies and contingency planning\n\nMake contingency arrangements for the safe storage of TTSPPs in the event of emergencies, including, but not confined to:\n\n- extended power supply outages;\n- equipment failure; and\n- vehicle breakdown during transport of TTSPPs.\n\nPrepare action plans to deal with products subjected to temperature excursions.\n\nEnsure that the responsible staff know, and have rehearsed, the appropriate actions to be taken in the event of the identified emergency scenarios.\n\n*Reason:* Loss prevention.\n\n### 9.2 General record-keeping\n\n#### 9.2.1 Record-keeping\n\nMaintain comprehensive records and ensure that they are laid out in an orderly fashion and are easy to check.\n\nPaper records must be:\n\n- stored and maintained so that they are accessible and easily retrievable;\n- labelled, dated and filed for easy identification;\n- protected against deterioration and loss due to fire, flood or other hazards;\n- kept secure and protected against unauthorized access; and\n- signed and dated by authorized persons and not changed without due authorization.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1817, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0e170f1e-debe-4b09-b766-725b6a3104ba": {"__data__": {"id_": "0e170f1e-debe-4b09-b766-725b6a3104ba", "embedding": null, "metadata": {"page_label": "374", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Computer records must be:\n\n- logically filed for easy identification and retrieval;\n- kept secure and protected against unauthorized access;\n- where feasible, manually signed, dated and scanned or when electronically archived dated, encrypted and with check-sum;[^16]\n- regularly backed-up and archived on media that are independent of the record-keeping computer system(s). Back-up media may be a separate secure server, a separate hard disc, a flash drive or other digital media appropriate to the scale of the operation.\n\n## 9.2.2 Content of records\n\nEnsure that the following traceability data is recorded for each TTSPP batch number, as applicable:\n\n- status of product on arrival;\n- temperature and humidity records including records of excursions outside labelled storage and/or transit temperature specification conditions;\n- general TTSPP stock transactions, including purchase and sale records;\n- controlled drug audits;\n- audits for products with high illicit value;\n- audits for hazardous products;\n- stock tracking;\n- return, recall, withdrawal and disposal reports, where relevant;\n- product complaint reports, where relevant; and\n- counterfeit product reports, where relevant.\n\nMaintain all records in accordance with local legislation and regulations.\n\n## 9.2.3 Record review and retention\n\nEnsure that records are reviewed and approved on a regular basis by a designated member of the quality management team. Ensure that records are accessible for review by end-users, the regulatory authority and other interested parties. Retain records for the minimum period required under local legislation, but for not less than three years.\n\n**Reason:** Internal quality control, transparency and external inspection by the regulatory authorities and other interested parties.\n\n[^16]: Electronic records from data loggers are usually encrypted and protected by check-sums. This ensures compliance with FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures; Final Rule (1997).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de registros inform\u00e1ticos en el \u00e1mbito de la salud, enfatizando la importancia de la organizaci\u00f3n, seguridad y accesibilidad de los registros. Se detallan los tipos de datos que deben ser registrados para cada lote de productos, as\u00ed como los procedimientos para la revisi\u00f3n y retenci\u00f3n de estos registros. Se subraya la necesidad de cumplir con la legislaci\u00f3n local y se menciona la importancia de la transparencia y el control de calidad interno.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para garantizar la seguridad de los registros inform\u00e1ticos?**\n   - Los registros inform\u00e1ticos deben ser mantenidos de manera segura y protegidos contra accesos no autorizados. Adem\u00e1s, deben ser firmados manualmente, fechados y escaneados cuando sea posible, o, si est\u00e1n archivados electr\u00f3nicamente, deben estar fechados, encriptados y contar con un check-sum.\n\n2. **\u00bfQu\u00e9 tipo de datos de trazabilidad se deben registrar para cada n\u00famero de lote de TTSPP?**\n   - Se deben registrar datos como el estado del producto a la llegada, registros de temperatura y humedad, transacciones de stock, auditor\u00edas de drogas controladas, auditor\u00edas de productos de alto valor il\u00edcito, auditor\u00edas de productos peligrosos, seguimiento de stock, y reportes de devoluciones, retiradas, quejas de productos y productos falsificados.\n\n3. **\u00bfCu\u00e1l es el per\u00edodo m\u00ednimo de retenci\u00f3n de registros seg\u00fan las directrices de la OMS?**\n   - Los registros deben ser retenidos por el per\u00edodo m\u00ednimo requerido por la legislaci\u00f3n local, pero no por menos de tres a\u00f1os. Esto es esencial para el control de calidad interno y para facilitar la inspecci\u00f3n externa por parte de autoridades regulatorias y otras partes interesadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Trazabilidad de Productos**:\n   - Importancia de mantener registros de la exposici\u00f3n a la temperatura durante el transporte y almacenamiento interno de productos farmac\u00e9uticos.\n   - Registros necesarios para productos entrantes y salientes, incluyendo indicadores de env\u00edo y condiciones f\u00edsicas.\n\n2. **Monitoreo y Discrepancias**:\n   - Necesidad de monitorear, registrar e investigar discrepancias en la distribuci\u00f3n de productos para prevenir robos y fraudes, as\u00ed como facilitar recuperaciones de productos.\n\n3. **Procedimientos Generales y Mantenimiento de Registros**:\n   - Planificaci\u00f3n de contingencias para el almacenamiento seguro de productos en caso de emergencias (cortes de energ\u00eda, fallas de equipo, descomposturas de veh\u00edculos).\n   - Preparaci\u00f3n de planes de acci\u00f3n para productos que experimenten excursiones de temperatura.\n\n4. **Mantenimiento de Registros**:\n   - Importancia de mantener registros organizados, accesibles y protegidos contra deterioro y acceso no autorizado.\n   - Requisitos para registros en papel: etiquetado, fecha, archivo, seguridad y autorizaci\u00f3n.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos que requieren trazabilidad.\n- **Indicadores de Env\u00edo**: Herramientas utilizadas para monitorear condiciones durante el transporte.\n- **Emergencias**: Situaciones que requieren planes de contingencia, como cortes de energ\u00eda y fallas de equipo.\n- **Registros**: Documentaci\u00f3n que debe ser mantenida de manera ordenada y segura. \n\nEste resumen destaca la importancia de la trazabilidad, el manejo de emergencias y la adecuada conservaci\u00f3n de registros en el contexto de la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: registros inform\u00e1ticos, trazabilidad, seguridad de datos, auditor\u00edas, retenci\u00f3n de registros"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "777245b2-8aad-40f0-bae7-38559b41654f", "node_type": "4", "metadata": {"page_label": "374", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Computer records must be:\n\n- logically filed for easy identification and retrieval;\n- kept secure and protected against unauthorized access;\n- where feasible, manually signed, dated and scanned or when electronically archived dated, encrypted and with check-sum;[^16]\n- regularly backed-up and archived on media that are independent of the record-keeping computer system(s). Back-up media may be a separate secure server, a separate hard disc, a flash drive or other digital media appropriate to the scale of the operation.\n\n## 9.2.2 Content of records\n\nEnsure that the following traceability data is recorded for each TTSPP batch number, as applicable:\n\n- status of product on arrival;\n- temperature and humidity records including records of excursions outside labelled storage and/or transit temperature specification conditions;\n- general TTSPP stock transactions, including purchase and sale records;\n- controlled drug audits;\n- audits for products with high illicit value;\n- audits for hazardous products;\n- stock tracking;\n- return, recall, withdrawal and disposal reports, where relevant;\n- product complaint reports, where relevant; and\n- counterfeit product reports, where relevant.\n\nMaintain all records in accordance with local legislation and regulations.\n\n## 9.2.3 Record review and retention\n\nEnsure that records are reviewed and approved on a regular basis by a designated member of the quality management team. Ensure that records are accessible for review by end-users, the regulatory authority and other interested parties. Retain records for the minimum period required under local legislation, but for not less than three years.\n\n**Reason:** Internal quality control, transparency and external inspection by the regulatory authorities and other interested parties.\n\n[^16]: Electronic records from data loggers are usually encrypted and protected by check-sums. This ensures compliance with FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures; Final Rule (1997).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3d9d5a0020f4bd2ac06a8d654f5b2fa04537026140f6fd9600921e9619313336", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Computer records must be:\n\n- logically filed for easy identification and retrieval;\n- kept secure and protected against unauthorized access;\n- where feasible, manually signed, dated and scanned or when electronically archived dated, encrypted and with check-sum;[^16]\n- regularly backed-up and archived on media that are independent of the record-keeping computer system(s). Back-up media may be a separate secure server, a separate hard disc, a flash drive or other digital media appropriate to the scale of the operation.\n\n## 9.2.2 Content of records\n\nEnsure that the following traceability data is recorded for each TTSPP batch number, as applicable:\n\n- status of product on arrival;\n- temperature and humidity records including records of excursions outside labelled storage and/or transit temperature specification conditions;\n- general TTSPP stock transactions, including purchase and sale records;\n- controlled drug audits;\n- audits for products with high illicit value;\n- audits for hazardous products;\n- stock tracking;\n- return, recall, withdrawal and disposal reports, where relevant;\n- product complaint reports, where relevant; and\n- counterfeit product reports, where relevant.\n\nMaintain all records in accordance with local legislation and regulations.\n\n## 9.2.3 Record review and retention\n\nEnsure that records are reviewed and approved on a regular basis by a designated member of the quality management team. Ensure that records are accessible for review by end-users, the regulatory authority and other interested parties. Retain records for the minimum period required under local legislation, but for not less than three years.\n\n**Reason:** Internal quality control, transparency and external inspection by the regulatory authorities and other interested parties.\n\n[^16]: Electronic records from data loggers are usually encrypted and protected by check-sums. This ensures compliance with FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures; Final Rule (1997).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1997, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "671c90b1-1f49-49aa-82be-adb24fe18b2b": {"__data__": {"id_": "671c90b1-1f49-49aa-82be-adb24fe18b2b", "embedding": null, "metadata": {"page_label": "375", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Temperature and humidity records\n\n## 9.3.1 Temperature records\n\nMonitor and record storage temperatures in all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, as follows:\n\n- Check and record temperatures at least twice daily \u2014 in the morning and evening \u2014 and preferably continuously.\n- Review temperature records monthly and take action to rectify systematic excursions.\n- Systematically file temperature records for each storage environment or piece of equipment to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n## 9.3.2 Humidity records\n\nWhen storing products which are adversely affected by high relative humidity (see clause 4.5.3), monitor and record humidity levels in all temperature-controlled rooms as follows:\n\n- Record humidity at least twice every 24 hours or preferably continuously.\n- Check humidity records daily.\n- Review humidity records monthly and take action to rectify systematic excursions.\n- Systematically file humidity records for each temperature-controlled room to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n*Reason:* Internal quality assurance and availability of records for review by the regulatory authorities and other interested parties.\n\n# 10. Environmental management\n\n## 10.1 Normative references\n\n- ISO 14001: 2004. *Environmental management systems \u2014 Requirements with guidance for use*.\n- *The Montreal Protocol on Substances that Deplete the Ozone Layer*. UNEP, 2000.\n\n## 10.2 Environmental management of refrigeration equipment\n\nEnsure that all new refrigeration equipment for temperature-controlled storage and transport is specified to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre el monitoreo y registro de temperaturas y niveles de humedad en entornos de almacenamiento controlados, como c\u00e1maras fr\u00edas y congeladores. Se enfatiza la importancia de realizar registros sistem\u00e1ticos para asegurar la trazabilidad y cumplir con las normativas nacionales. Adem\u00e1s, se menciona la gesti\u00f3n ambiental de los equipos de refrigeraci\u00f3n, haciendo referencia a est\u00e1ndares como ISO 14001 y el Protocolo de Montreal.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCon qu\u00e9 frecuencia se deben revisar los registros de temperatura y qu\u00e9 acciones se deben tomar si se detectan excursiones sistem\u00e1ticas?**\n   - Se deben revisar los registros de temperatura mensualmente y tomar medidas para rectificar cualquier excursi\u00f3n sistem\u00e1tica que se haya detectado.\n\n2. **\u00bfQu\u00e9 requisitos se establecen para el almacenamiento de productos que son sensibles a la humedad?**\n   - Para productos que se ven afectados por alta humedad relativa, se deben registrar los niveles de humedad al menos dos veces cada 24 horas, preferiblemente de manera continua, y revisar estos registros diariamente.\n\n3. **\u00bfCu\u00e1nto tiempo deben conservarse los registros de temperatura y humedad despu\u00e9s de que finalice la vida \u00fatil del material almacenado?**\n   - Los registros deben conservarse durante al menos un a\u00f1o despu\u00e9s de que finalice la vida \u00fatil del material o producto almacenado, o por el tiempo que exija la legislaci\u00f3n nacional.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad de Registros Inform\u00e1ticos**: Se enfatiza la necesidad de mantener los registros inform\u00e1ticos organizados, seguros y protegidos contra accesos no autorizados. Se sugiere la firma manual y el escaneo de documentos, as\u00ed como el uso de encriptaci\u00f3n y check-sums para registros electr\u00f3nicos.\n\n2. **Contenido de los Registros**: Se especifican los datos de trazabilidad que deben ser registrados para cada lote de productos, incluyendo el estado del producto, registros de temperatura y humedad, transacciones de stock, auditor\u00edas de drogas controladas y productos peligrosos, as\u00ed como reportes de quejas y productos falsificados.\n\n3. **Revisi\u00f3n y Retenci\u00f3n de Registros**: Se establece la importancia de la revisi\u00f3n regular de los registros por parte del equipo de gesti\u00f3n de calidad y la accesibilidad de estos para las partes interesadas. Se menciona que los registros deben ser retenidos por un m\u00ednimo de tres a\u00f1os, conforme a la legislaci\u00f3n local.\n\n4. **Cumplimiento Normativo**: Se destaca la necesidad de cumplir con la legislaci\u00f3n local y las regulaciones pertinentes, as\u00ed como la importancia de la transparencia y el control de calidad interno.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **TTSPP**: T\u00e9rmino relacionado con los productos que requieren trazabilidad.\n- **FDA**: Referencia a la normativa de la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. sobre registros electr\u00f3nicos y firmas electr\u00f3nicas.\n- **Equipo de Gesti\u00f3n de Calidad**: Grupo responsable de la revisi\u00f3n y aprobaci\u00f3n de registros.\n- **Partes Interesadas**: Incluye usuarios finales y autoridades regulatorias que pueden revisar los registros.\n\nEste resumen abarca los aspectos fundamentales y las entidades relevantes en la gesti\u00f3n de registros inform\u00e1ticos en el contexto de la salud, seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: temperature records, humidity records, environmental management, traceability, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7397c490-5cea-4483-81e9-e9c467c85cd7", "node_type": "4", "metadata": {"page_label": "375", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Temperature and humidity records\n\n## 9.3.1 Temperature records\n\nMonitor and record storage temperatures in all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, as follows:\n\n- Check and record temperatures at least twice daily \u2014 in the morning and evening \u2014 and preferably continuously.\n- Review temperature records monthly and take action to rectify systematic excursions.\n- Systematically file temperature records for each storage environment or piece of equipment to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n## 9.3.2 Humidity records\n\nWhen storing products which are adversely affected by high relative humidity (see clause 4.5.3), monitor and record humidity levels in all temperature-controlled rooms as follows:\n\n- Record humidity at least twice every 24 hours or preferably continuously.\n- Check humidity records daily.\n- Review humidity records monthly and take action to rectify systematic excursions.\n- Systematically file humidity records for each temperature-controlled room to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n*Reason:* Internal quality assurance and availability of records for review by the regulatory authorities and other interested parties.\n\n# 10. Environmental management\n\n## 10.1 Normative references\n\n- ISO 14001: 2004. *Environmental management systems \u2014 Requirements with guidance for use*.\n- *The Montreal Protocol on Substances that Deplete the Ozone Layer*. UNEP, 2000.\n\n## 10.2 Environmental management of refrigeration equipment\n\nEnsure that all new refrigeration equipment for temperature-controlled storage and transport is specified to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7847074294ebc570ba56b2414a253e3178235883272475992166c3eaf4c06f4b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9.3 Temperature and humidity records\n\n## 9.3.1 Temperature records\n\nMonitor and record storage temperatures in all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, as follows:\n\n- Check and record temperatures at least twice daily \u2014 in the morning and evening \u2014 and preferably continuously.\n- Review temperature records monthly and take action to rectify systematic excursions.\n- Systematically file temperature records for each storage environment or piece of equipment to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n## 9.3.2 Humidity records\n\nWhen storing products which are adversely affected by high relative humidity (see clause 4.5.3), monitor and record humidity levels in all temperature-controlled rooms as follows:\n\n- Record humidity at least twice every 24 hours or preferably continuously.\n- Check humidity records daily.\n- Review humidity records monthly and take action to rectify systematic excursions.\n- Systematically file humidity records for each temperature-controlled room to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n*Reason:* Internal quality assurance and availability of records for review by the regulatory authorities and other interested parties.\n\n# 10. Environmental management\n\n## 10.1 Normative references\n\n- ISO 14001: 2004. *Environmental management systems \u2014 Requirements with guidance for use*.\n- *The Montreal Protocol on Substances that Deplete the Ozone Layer*. UNEP, 2000.\n\n## 10.2 Environmental management of refrigeration equipment\n\nEnsure that all new refrigeration equipment for temperature-controlled storage and transport is specified to:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1878, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "179cac5f-1988-4b79-aba6-3e78642c9eda": {"__data__": {"id_": "179cac5f-1988-4b79-aba6-3e78642c9eda", "embedding": null, "metadata": {"page_label": "376", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management\n\n## 11.1 Normative References\n\n- ICH, 2005: *ICH Harmonized Tripartite Guideline: Quality risk management Q9*\n- ISO 9000:2005. *Quality management systems \u2014 Fundamentals and vocabulary*\n- ISO 9001:2008. *Quality management systems \u2014 Requirements*\n- ISO 9004:2000. *Quality management systems \u2014 Guidelines for performance improvements*\n- ISO 10005:2005. *Quality management systems \u2014 Guidelines for quality plans*\n- ISO 19011:2002. *Guidelines for quality and/or environmental management systems auditing*\n\n## 11.2 Organizational Structure\n\nEstablish, document and maintain an organizational structure for the TTSPP storage and shipping and distribution operations which clearly identifies all key management responsibilities, and the personnel who are accountable.\n\n*Reason:* Quality management.\n\n## 11.3 Quality Systems\n\n### 11.3.1 Quality System\n\nEstablish, document and maintain a quality system for the management of TTSPPs including, the following, as applicable:\n\n- standard quality system(s) and associated auditing procedures;\n- written procedures and specifications;\n- record storage, record retention and record destruction programme;\n- risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda la gesti\u00f3n de calidad en el contexto de los productos farmac\u00e9uticos y su distribuci\u00f3n. Se mencionan referencias normativas clave, la importancia de establecer una estructura organizativa clara para las operaciones de almacenamiento y distribuci\u00f3n, y la necesidad de implementar un sistema de calidad que incluya procedimientos, especificaciones y gesti\u00f3n de riesgos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las normas ISO mencionadas en el documento y qu\u00e9 aspectos de la gesti\u00f3n de calidad abordan?**\n   - Respuesta: Las normas ISO mencionadas son ISO 9000:2005 (Fundamentos y vocabulario de sistemas de gesti\u00f3n de calidad), ISO 9001:2008 (Requisitos de sistemas de gesti\u00f3n de calidad), ISO 9004:2000 (Directrices para mejoras del rendimiento), ISO 10005:2005 (Directrices para planes de calidad) e ISO 19011:2002 (Directrices para auditor\u00edas de sistemas de gesti\u00f3n de calidad y/o medioambientales).\n\n2. **\u00bfQu\u00e9 elementos son esenciales para establecer un sistema de calidad para la gesti\u00f3n de TTSPPs seg\u00fan el documento?**\n   - Respuesta: Los elementos esenciales incluyen sistemas de calidad est\u00e1ndar y procedimientos de auditor\u00eda asociados, procedimientos y especificaciones documentadas, un programa de almacenamiento, retenci\u00f3n y destrucci\u00f3n de registros, y gesti\u00f3n de riesgos.\n\n3. **\u00bfCu\u00e1l es la raz\u00f3n principal para establecer y mantener una estructura organizativa en las operaciones de almacenamiento y distribuci\u00f3n de TTSPPs?**\n   - Respuesta: La raz\u00f3n principal es asegurar una gesti\u00f3n de calidad efectiva, lo que implica identificar claramente todas las responsabilidades clave de gesti\u00f3n y el personal responsable en las operaciones.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Monitoreo de Temperatura y Humedad**:\n   - Se establecen directrices para el monitoreo y registro de temperaturas y niveles de humedad en entornos de almacenamiento controlados, como c\u00e1maras fr\u00edas y congeladores.\n   - La frecuencia de registro es al menos dos veces al d\u00eda para temperaturas y al menos dos veces cada 24 horas para humedad.\n\n2. **Acciones Correctivas**:\n   - Se requiere revisar los registros mensualmente y tomar medidas para rectificar cualquier excursi\u00f3n sistem\u00e1tica detectada en los registros de temperatura y humedad.\n\n3. **Conservaci\u00f3n de Registros**:\n   - Los registros de temperatura y humedad deben conservarse durante al menos un a\u00f1o despu\u00e9s de que finalice la vida \u00fatil del material o producto almacenado, o seg\u00fan lo exija la legislaci\u00f3n nacional.\n\n4. **Gesti\u00f3n Ambiental**:\n   - Se menciona la importancia de la gesti\u00f3n ambiental de los equipos de refrigeraci\u00f3n, haciendo referencia a normas como ISO 14001 y el Protocolo de Montreal.\n\n5. **Normativas y Referencias**:\n   - Se citan normativas relevantes que gu\u00edan la gesti\u00f3n ambiental y el manejo de sustancias que afectan la capa de ozono.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **ISO 14001:2004**: Norma sobre sistemas de gesti\u00f3n ambiental.\n- **Protocolo de Montreal**: Acuerdo internacional sobre sustancias que agotan la capa de ozono. \n\nEste resumen destaca la importancia del monitoreo sistem\u00e1tico y la gesti\u00f3n ambiental en el almacenamiento de productos sensibles a la temperatura y humedad.", "excerpt_keywords": "Keywords: Quality Management, ISO Standards, Organizational Structure, Quality Systems, Risk Management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c298ebf1-9fc9-48be-9903-9dd238946b52", "node_type": "4", "metadata": {"page_label": "376", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management\n\n## 11.1 Normative References\n\n- ICH, 2005: *ICH Harmonized Tripartite Guideline: Quality risk management Q9*\n- ISO 9000:2005. *Quality management systems \u2014 Fundamentals and vocabulary*\n- ISO 9001:2008. *Quality management systems \u2014 Requirements*\n- ISO 9004:2000. *Quality management systems \u2014 Guidelines for performance improvements*\n- ISO 10005:2005. *Quality management systems \u2014 Guidelines for quality plans*\n- ISO 19011:2002. *Guidelines for quality and/or environmental management systems auditing*\n\n## 11.2 Organizational Structure\n\nEstablish, document and maintain an organizational structure for the TTSPP storage and shipping and distribution operations which clearly identifies all key management responsibilities, and the personnel who are accountable.\n\n*Reason:* Quality management.\n\n## 11.3 Quality Systems\n\n### 11.3.1 Quality System\n\nEstablish, document and maintain a quality system for the management of TTSPPs including, the following, as applicable:\n\n- standard quality system(s) and associated auditing procedures;\n- written procedures and specifications;\n- record storage, record retention and record destruction programme;\n- risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f266450a5316d3cb85ed0f839821beab250cd552fbf470bec00acd7c3dc1d2b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Management\n\n## 11.1 Normative References\n\n- ICH, 2005: *ICH Harmonized Tripartite Guideline: Quality risk management Q9*\n- ISO 9000:2005. *Quality management systems \u2014 Fundamentals and vocabulary*\n- ISO 9001:2008. *Quality management systems \u2014 Requirements*\n- ISO 9004:2000. *Quality management systems \u2014 Guidelines for performance improvements*\n- ISO 10005:2005. *Quality management systems \u2014 Guidelines for quality plans*\n- ISO 19011:2002. *Guidelines for quality and/or environmental management systems auditing*\n\n## 11.2 Organizational Structure\n\nEstablish, document and maintain an organizational structure for the TTSPP storage and shipping and distribution operations which clearly identifies all key management responsibilities, and the personnel who are accountable.\n\n*Reason:* Quality management.\n\n## 11.3 Quality Systems\n\n### 11.3.1 Quality System\n\nEstablish, document and maintain a quality system for the management of TTSPPs including, the following, as applicable:\n\n- standard quality system(s) and associated auditing procedures;\n- written procedures and specifications;\n- record storage, record retention and record destruction programme;\n- risk management;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1184, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "014cbe89-7a69-46cb-8dba-bd96b8f77cd1": {"__data__": {"id_": "014cbe89-7a69-46cb-8dba-bd96b8f77cd1", "embedding": null, "metadata": {"page_label": "377", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\n- calibration programme;\n- stability programme;\n- qualification and validation programme;\n- deviation and root cause investigation programme;\n- corrective and preventive action (CAPA) procedures;\n- training programme;\n- periodic temperature-controlled process assessment;\n- change control programme;\n- maintenance programme;\n- management controls;\n- product return and recall/withdrawal policies, including emergency recalls;\n- product complaint policies;\n- material destruction programme;\n- warehouse and storage programme;\n- shipping and distribution programme;\n- notification systems for regulatory agencies; boards of health and ministries of health; and\n- self-inspection programme and continuous quality improvement.\n\nCarry out annual reviews of the quality management system to ensure that it remains appropriate, relevant, and effective.\n\n*Reason:* Quality assurance.\n\n## 11.3.2 Self Inspections\n\nConduct regular self-inspections to ensure continuing compliance with quality management standards GSP and GDP; record results, follow-up with the corrective actions needed to rectify areas of non-compliance and document the changes made.\n\n## 11.3.3 Contractors Subject to Service Level Agreements\n\nEnsure that every contractor with whom there is an SLA provides periodic evidence of compliance with the GSP and/or GDP standards incorporated into the SLA.\n\n*Reason:* To demonstrate compliance with applicable quality management standards.\n\n## 11.4 Management of Documents and Standard Operating Procedures\n\n### 11.4.1 Standard Operating Procedures\n\nDevelop and maintain SOPs covering correct storage, internal shipping and external distribution of TTSPPs, including, but not limited to, the following topics:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un breve resumen del contenido:\n\n### Resumen del Contexto\nEl documento se centra en el Sistema de Gesti\u00f3n de Calidad (SGC) y detalla varios programas y procedimientos necesarios para asegurar la calidad en la gesti\u00f3n de productos. Incluye la importancia de realizar revisiones anuales del SGC, llevar a cabo autoinspecciones regulares, y la gesti\u00f3n de documentos y procedimientos operativos est\u00e1ndar (SOP). Tambi\u00e9n se menciona la necesidad de que los contratistas cumplan con los est\u00e1ndares de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Almacenamiento (GSP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos se deben seguir para manejar las desviaciones y las investigaciones de causa ra\u00edz dentro del Sistema de Gesti\u00f3n de Calidad?**\n   - Respuesta: Se debe implementar un programa de desviaci\u00f3n y de investigaci\u00f3n de causa ra\u00edz que permita identificar y documentar las causas de las no conformidades, as\u00ed como las acciones correctivas necesarias para rectificarlas.\n\n2. **\u00bfCu\u00e1l es la importancia de realizar autoinspecciones regulares y qu\u00e9 se debe hacer con los resultados obtenidos?**\n   - Respuesta: Las autoinspecciones son cruciales para asegurar el cumplimiento continuo con los est\u00e1ndares de GSP y GDP. Los resultados deben ser registrados, y se deben seguir las acciones correctivas necesarias para abordar cualquier \u00e1rea de no conformidad, documentando los cambios realizados.\n\n3. **\u00bfQu\u00e9 aspectos deben cubrir los Procedimientos Operativos Est\u00e1ndar (SOP) en relaci\u00f3n con el almacenamiento y distribuci\u00f3n de productos?**\n   - Respuesta: Los SOP deben abordar el almacenamiento correcto, el env\u00edo interno y la distribuci\u00f3n externa de productos, asegurando que se sigan las mejores pr\u00e1cticas para mantener la calidad y la integridad de los productos durante su manejo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Calidad**: La secci\u00f3n se centra en la importancia de establecer un sistema de gesti\u00f3n de calidad para los productos farmac\u00e9uticos, espec\u00edficamente en el contexto de almacenamiento y distribuci\u00f3n de TTSPPs (productos farmac\u00e9uticos de calidad).\n\n2. **Referencias Normativas**: Se mencionan varias normas ISO y directrices del ICH que son fundamentales para la gesti\u00f3n de calidad:\n   - **ICH Q9**: Gesti\u00f3n de riesgos de calidad.\n   - **ISO 9000:2005**: Fundamentos y vocabulario de sistemas de gesti\u00f3n de calidad.\n   - **ISO 9001:2008**: Requisitos de sistemas de gesti\u00f3n de calidad.\n   - **ISO 9004:2000**: Directrices para mejoras del rendimiento.\n   - **ISO 10005:2005**: Directrices para planes de calidad.\n   - **ISO 19011:2002**: Directrices para auditor\u00edas de sistemas de gesti\u00f3n de calidad y medioambientales.\n\n3. **Estructura Organizativa**: Se enfatiza la necesidad de establecer y documentar una estructura organizativa clara que defina las responsabilidades de gesti\u00f3n y el personal responsable en las operaciones de almacenamiento y distribuci\u00f3n.\n\n4. **Sistema de Calidad**: Se requiere la creaci\u00f3n y mantenimiento de un sistema de calidad que incluya:\n   - Sistemas de calidad est\u00e1ndar y procedimientos de auditor\u00eda.\n   - Procedimientos y especificaciones documentadas.\n   - Programa para el almacenamiento, retenci\u00f3n y destrucci\u00f3n de registros.\n   - Gesti\u00f3n de riesgos.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos de calidad.\n- **Normas ISO**: Conjunto de est\u00e1ndares internacionales que gu\u00edan la gesti\u00f3n de calidad.\n- **ICH**: Consejo Internacional de Armonizaci\u00f3n, que proporciona directrices para la gesti\u00f3n de calidad en la industria farmac\u00e9utica. \n\nEste resumen destaca la importancia de la gesti\u00f3n de calidad en la industria farmac\u00e9utica y los elementos necesarios para establecer un sistema efectivo.", "excerpt_keywords": "Keywords: Quality Management System, Self Inspections, Standard Operating Procedures, Good Distribution Practices, Corrective Actions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cb003069-afee-409f-80dc-4563de93186d", "node_type": "4", "metadata": {"page_label": "377", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\n- calibration programme;\n- stability programme;\n- qualification and validation programme;\n- deviation and root cause investigation programme;\n- corrective and preventive action (CAPA) procedures;\n- training programme;\n- periodic temperature-controlled process assessment;\n- change control programme;\n- maintenance programme;\n- management controls;\n- product return and recall/withdrawal policies, including emergency recalls;\n- product complaint policies;\n- material destruction programme;\n- warehouse and storage programme;\n- shipping and distribution programme;\n- notification systems for regulatory agencies; boards of health and ministries of health; and\n- self-inspection programme and continuous quality improvement.\n\nCarry out annual reviews of the quality management system to ensure that it remains appropriate, relevant, and effective.\n\n*Reason:* Quality assurance.\n\n## 11.3.2 Self Inspections\n\nConduct regular self-inspections to ensure continuing compliance with quality management standards GSP and GDP; record results, follow-up with the corrective actions needed to rectify areas of non-compliance and document the changes made.\n\n## 11.3.3 Contractors Subject to Service Level Agreements\n\nEnsure that every contractor with whom there is an SLA provides periodic evidence of compliance with the GSP and/or GDP standards incorporated into the SLA.\n\n*Reason:* To demonstrate compliance with applicable quality management standards.\n\n## 11.4 Management of Documents and Standard Operating Procedures\n\n### 11.4.1 Standard Operating Procedures\n\nDevelop and maintain SOPs covering correct storage, internal shipping and external distribution of TTSPPs, including, but not limited to, the following topics:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0d0aa413602ed614450f58e52b6813c16bb3c8c9b088f4d1c47fe29bbb837004", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Quality Management System\n\n- calibration programme;\n- stability programme;\n- qualification and validation programme;\n- deviation and root cause investigation programme;\n- corrective and preventive action (CAPA) procedures;\n- training programme;\n- periodic temperature-controlled process assessment;\n- change control programme;\n- maintenance programme;\n- management controls;\n- product return and recall/withdrawal policies, including emergency recalls;\n- product complaint policies;\n- material destruction programme;\n- warehouse and storage programme;\n- shipping and distribution programme;\n- notification systems for regulatory agencies; boards of health and ministries of health; and\n- self-inspection programme and continuous quality improvement.\n\nCarry out annual reviews of the quality management system to ensure that it remains appropriate, relevant, and effective.\n\n*Reason:* Quality assurance.\n\n## 11.3.2 Self Inspections\n\nConduct regular self-inspections to ensure continuing compliance with quality management standards GSP and GDP; record results, follow-up with the corrective actions needed to rectify areas of non-compliance and document the changes made.\n\n## 11.3.3 Contractors Subject to Service Level Agreements\n\nEnsure that every contractor with whom there is an SLA provides periodic evidence of compliance with the GSP and/or GDP standards incorporated into the SLA.\n\n*Reason:* To demonstrate compliance with applicable quality management standards.\n\n## 11.4 Management of Documents and Standard Operating Procedures\n\n### 11.4.1 Standard Operating Procedures\n\nDevelop and maintain SOPs covering correct storage, internal shipping and external distribution of TTSPPs, including, but not limited to, the following topics:", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1742, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ba5cbc2e-68a1-4fd6-a7cd-be1ba1d89326": {"__data__": {"id_": "ba5cbc2e-68a1-4fd6-a7cd-be1ba1d89326", "embedding": null, "metadata": {"page_label": "378", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 security, including management of controlled and hazardous TTSPPs;  \n\u2014 safe handling of TTSPPs;  \n\u2014 temperature monitoring;  \n\u2014 calibration of temperature and humidity monitoring devices and alarm systems;  \n\u2014 qualification and validation procedures, including temperature mapping;  \n\u2014 maintenance of controlled-temperature equipment;  \n\u2014 facility cleaning and pest control;  \n\u2014 facility maintenance;  \n\u2014 product arrival (receiving) procedures and records;  \n\u2014 stock storage and warehousing procedures (put away, replenishment, order fulfilment, packing);  \n\u2014 stock control procedures and records;  \n\u2014 distribution procedures and records;  \n\u2014 management of temperature excursions;  \n\u2014 product return and recall/withdrawal procedures and records;  \n\u2014 product complaint procedures and records;  \n\u2014 safe disposal of damaged, expired and quarantined products and records which are no longer required;  \n\u2014 temperature-controlled packaging and route qualification;  \n\u2014 temperature-controlled vehicle operation, including management of security locks and seals;  \n\u2014 emergency response procedures; and  \n\u2014 environmental management.  \n\nEnsure that all documents are clear and unambiguous and that document change control procedures are in place as specified in clause 11.5.  \n\n*Reason:* Quality management and staff training.  \n\n## 11.5 Document control\n\nEnsure that all quality manuals, SOPs and similar documents are:\n\n\u2014 authorized by an appropriate person;  \n\u2014 recorded in a document register;  \n\u2014 regularly reviewed and kept up to date, with all changes recorded and authorized;  \n\u2014 version controlled;  \n\u2014 issued to all relevant personnel; and  \n\u2014 withdrawn when superseded.  \n\nWithdraw superseded documents and retain record copies for document history files and for the minimum period(s) required by the regulatory authorities and for duty-of-care purposes.  \n\n*Reason:* Good quality management practice.  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, centr\u00e1ndose en la seguridad, el manejo adecuado, el monitoreo de temperatura y la gesti\u00f3n de documentos. Se enfatiza la importancia de tener procedimientos claros para el control de calidad, la capacitaci\u00f3n del personal y el mantenimiento de registros. Adem\u00e1s, se establece un protocolo para el control de documentos, asegurando que todos los manuales y procedimientos operativos est\u00e1ndar (SOP) sean autorizados, revisados y actualizados regularmente.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos mencionados para la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos en condiciones controladas?**\n   - Respuesta: Los procedimientos incluyen la gesti\u00f3n de la seguridad de TTSPPs, el manejo seguro de TTSPPs, el monitoreo de temperatura, la calibraci\u00f3n de dispositivos de monitoreo, mantenimiento de equipos de temperatura controlada, y procedimientos de recepci\u00f3n y almacenamiento de productos, entre otros.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar el control de documentos seg\u00fan la cl\u00e1usula 11.5?**\n   - Respuesta: Se deben autorizar los documentos por una persona apropiada, registrarlos en un registro de documentos, revisarlos regularmente, mantener un control de versiones, emitirlos a todo el personal relevante y retirarlos cuando sean superados.\n\n3. **\u00bfCu\u00e1l es la raz\u00f3n principal para implementar procedimientos de control de documentos y gesti\u00f3n de calidad en el manejo de productos farmac\u00e9uticos?**\n   - Respuesta: La raz\u00f3n principal es asegurar una buena pr\u00e1ctica de gesti\u00f3n de calidad y proporcionar capacitaci\u00f3n adecuada al personal, lo que contribuye a la seguridad y eficacia en el manejo de productos farmac\u00e9uticos y biol\u00f3gicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido se centra en el **Sistema de Gesti\u00f3n de Calidad (SGC)** y abarca varios programas y procedimientos esenciales para garantizar la calidad en la gesti\u00f3n de productos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Programas del SGC**:\n   - Programa de calibraci\u00f3n\n   - Programa de estabilidad\n   - Programa de calificaci\u00f3n y validaci\u00f3n\n   - Programa de desviaci\u00f3n e investigaci\u00f3n de causa ra\u00edz\n   - Procedimientos de acci\u00f3n correctiva y preventiva (CAPA)\n   - Programa de formaci\u00f3n\n   - Evaluaci\u00f3n peri\u00f3dica de procesos controlados por temperatura\n   - Programa de control de cambios\n   - Programa de mantenimiento\n   - Controles de gesti\u00f3n\n   - Pol\u00edticas de devoluci\u00f3n y retiro de productos, incluyendo retiros de emergencia\n   - Pol\u00edticas de quejas de productos\n   - Programa de destrucci\u00f3n de materiales\n   - Programa de almacenamiento y almac\u00e9n\n   - Programa de env\u00edo y distribuci\u00f3n\n   - Sistemas de notificaci\u00f3n para agencias regulatorias y ministerios de salud\n   - Programa de autoinspecci\u00f3n y mejora continua de la calidad\n\n2. **Revisiones Anuales**:\n   - Se enfatiza la necesidad de realizar revisiones anuales del SGC para asegurar su relevancia y efectividad.\n\n3. **Autoinspecciones**:\n   - Se deben llevar a cabo autoinspecciones regulares para garantizar el cumplimiento de los est\u00e1ndares de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Almacenamiento (GSP). Los resultados deben ser documentados y seguidos de acciones correctivas.\n\n4. **Contratistas y Acuerdos de Nivel de Servicio (SLA)**:\n   - Se requiere que los contratistas proporcionen evidencia peri\u00f3dica de cumplimiento con los est\u00e1ndares GSP y/o GDP establecidos en los SLA.\n\n5. **Gesti\u00f3n de Documentos y Procedimientos Operativos Est\u00e1ndar (SOP)**:\n   - Se deben desarrollar y mantener SOP que aborden el almacenamiento correcto, el env\u00edo interno y la distribuci\u00f3n externa de productos.\n\n### Entidades Clave\n- **GSP**: Buenas Pr\u00e1cticas de Almacenamiento\n- **GDP**: Buenas Pr\u00e1cticas de Distribuci\u00f3n\n- **SLA**: Acuerdos de Nivel de Servicio\n- **CAPA**: Acci\u00f3n Correctiva y Preventiva\n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para la gesti\u00f3n de la calidad en la distribuci\u00f3n y almacenamiento de productos, asegurando el cumplimiento de normativas y est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: quality management, document control, temperature monitoring, pharmaceutical safety, SOPs"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40e85c16-40a2-448a-a4c3-423625087924", "node_type": "4", "metadata": {"page_label": "378", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 security, including management of controlled and hazardous TTSPPs;  \n\u2014 safe handling of TTSPPs;  \n\u2014 temperature monitoring;  \n\u2014 calibration of temperature and humidity monitoring devices and alarm systems;  \n\u2014 qualification and validation procedures, including temperature mapping;  \n\u2014 maintenance of controlled-temperature equipment;  \n\u2014 facility cleaning and pest control;  \n\u2014 facility maintenance;  \n\u2014 product arrival (receiving) procedures and records;  \n\u2014 stock storage and warehousing procedures (put away, replenishment, order fulfilment, packing);  \n\u2014 stock control procedures and records;  \n\u2014 distribution procedures and records;  \n\u2014 management of temperature excursions;  \n\u2014 product return and recall/withdrawal procedures and records;  \n\u2014 product complaint procedures and records;  \n\u2014 safe disposal of damaged, expired and quarantined products and records which are no longer required;  \n\u2014 temperature-controlled packaging and route qualification;  \n\u2014 temperature-controlled vehicle operation, including management of security locks and seals;  \n\u2014 emergency response procedures; and  \n\u2014 environmental management.  \n\nEnsure that all documents are clear and unambiguous and that document change control procedures are in place as specified in clause 11.5.  \n\n*Reason:* Quality management and staff training.  \n\n## 11.5 Document control\n\nEnsure that all quality manuals, SOPs and similar documents are:\n\n\u2014 authorized by an appropriate person;  \n\u2014 recorded in a document register;  \n\u2014 regularly reviewed and kept up to date, with all changes recorded and authorized;  \n\u2014 version controlled;  \n\u2014 issued to all relevant personnel; and  \n\u2014 withdrawn when superseded.  \n\nWithdraw superseded documents and retain record copies for document history files and for the minimum period(s) required by the regulatory authorities and for duty-of-care purposes.  \n\n*Reason:* Good quality management practice.  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e6f58159259aa89b00cd32e68ccc832b52ed4c3348d52a9f96da32f555782fde", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "\u2014 security, including management of controlled and hazardous TTSPPs;  \n\u2014 safe handling of TTSPPs;  \n\u2014 temperature monitoring;  \n\u2014 calibration of temperature and humidity monitoring devices and alarm systems;  \n\u2014 qualification and validation procedures, including temperature mapping;  \n\u2014 maintenance of controlled-temperature equipment;  \n\u2014 facility cleaning and pest control;  \n\u2014 facility maintenance;  \n\u2014 product arrival (receiving) procedures and records;  \n\u2014 stock storage and warehousing procedures (put away, replenishment, order fulfilment, packing);  \n\u2014 stock control procedures and records;  \n\u2014 distribution procedures and records;  \n\u2014 management of temperature excursions;  \n\u2014 product return and recall/withdrawal procedures and records;  \n\u2014 product complaint procedures and records;  \n\u2014 safe disposal of damaged, expired and quarantined products and records which are no longer required;  \n\u2014 temperature-controlled packaging and route qualification;  \n\u2014 temperature-controlled vehicle operation, including management of security locks and seals;  \n\u2014 emergency response procedures; and  \n\u2014 environmental management.  \n\nEnsure that all documents are clear and unambiguous and that document change control procedures are in place as specified in clause 11.5.  \n\n*Reason:* Quality management and staff training.  \n\n## 11.5 Document control\n\nEnsure that all quality manuals, SOPs and similar documents are:\n\n\u2014 authorized by an appropriate person;  \n\u2014 recorded in a document register;  \n\u2014 regularly reviewed and kept up to date, with all changes recorded and authorized;  \n\u2014 version controlled;  \n\u2014 issued to all relevant personnel; and  \n\u2014 withdrawn when superseded.  \n\nWithdraw superseded documents and retain record copies for document history files and for the minimum period(s) required by the regulatory authorities and for duty-of-care purposes.  \n\n*Reason:* Good quality management practice.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1904, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "43457019-1d65-49b8-9461-ccfd9a35f78f": {"__data__": {"id_": "43457019-1d65-49b8-9461-ccfd9a35f78f", "embedding": null, "metadata": {"page_label": "379", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Personnel/training\n\n## 12.1 Training\n\n### 12.1.1 General training\n\nProvide regular and systematic training for all relevant personnel responsible for storage, loading and unloading areas used for non-hazardous TTSPPs, covering the following:\n\n- applicable pharmaceutical legislation and regulations;\n- SOPs and safety issues; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Provide similar training for drivers who are responsible for transporting these substances. Maintain individual training records to demonstrate compliance and regularly evaluate the effectiveness of training programmes.\n\n*Reason:* To ensure that all relevant personnel are competent to carry out their duties.\n\n### 12.1.2 Specialist training\n\nIn addition to the training described in clause 12.1.1, provide regular and systematic additional training for relevant personnel responsible for storage, loading and unloading of controlled or hazardous TTSPPs. Training should cover the following:\n\n- applicable legislation and regulations;\n- security and safety risks; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Maintain training records to demonstrate compliance and perform effectiveness checks on training. Provide similar training for drivers who are responsible for transporting these substances.\n\n*Reason:* To ensure that all relevant personnel are competent to handle controlled or hazardous TTSPPs.\n\n## Key references\n\nWorld Health Organization/United Nations Children\u2019s Fund/United Nations Development Programme/United Nations Population Fund/World Bank  \n* A model quality assurance system for procurement agencies.* Geneva, World Health Organization, 2007 (WHO/PSM/PAR/2007.3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda la capacitaci\u00f3n del personal involucrado en el almacenamiento, carga y descarga de productos farmac\u00e9uticos no peligrosos y peligrosos. Se enfatiza la importancia de proporcionar formaci\u00f3n regular y sistem\u00e1tica que cubra la legislaci\u00f3n farmac\u00e9utica aplicable, procedimientos operativos est\u00e1ndar (SOPs), cuestiones de seguridad y respuesta a emergencias. Adem\u00e1s, se requiere mantener registros de capacitaci\u00f3n y evaluar la efectividad de los programas de formaci\u00f3n. La capacitaci\u00f3n especializada es necesaria para el manejo de productos farmac\u00e9uticos controlados o peligrosos, asegurando que el personal comprenda sus responsabilidades espec\u00edficas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de legislaci\u00f3n y regulaciones deben conocer los empleados responsables del manejo de TTSPPs no peligrosos?**\n   - La capacitaci\u00f3n debe incluir legislaci\u00f3n y regulaciones farmac\u00e9uticas aplicables, as\u00ed como procedimientos operativos est\u00e1ndar (SOPs) y cuestiones de seguridad.\n\n2. **\u00bfCu\u00e1l es la raz\u00f3n principal para mantener registros individuales de capacitaci\u00f3n para el personal?**\n   - La raz\u00f3n principal es demostrar el cumplimiento de los requisitos de capacitaci\u00f3n y evaluar regularmente la efectividad de los programas de formaci\u00f3n.\n\n3. **\u00bfQu\u00e9 aspectos adicionales se deben cubrir en la capacitaci\u00f3n especializada para el manejo de TTSPPs controlados o peligrosos?**\n   - La capacitaci\u00f3n especializada debe incluir legislaci\u00f3n y regulaciones aplicables, riesgos de seguridad y seguridad, as\u00ed como la respuesta a emergencias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Gesti\u00f3n de Productos Farmac\u00e9uticos y Biol\u00f3gicos:**\n   - Seguridad en el manejo de productos farmac\u00e9uticos y biol\u00f3gicos (TTSPPs).\n   - Procedimientos para el manejo seguro y control de temperatura.\n\n2. **Monitoreo y Mantenimiento:**\n   - Monitoreo de temperatura y calibraci\u00f3n de dispositivos.\n   - Mantenimiento de equipos de temperatura controlada y limpieza de instalaciones.\n\n3. **Procedimientos Operativos:**\n   - Recepci\u00f3n, almacenamiento, control de inventario y distribuci\u00f3n de productos.\n   - Manejo de excursiones de temperatura y procedimientos de devoluci\u00f3n y retiro de productos.\n\n4. **Control de Documentos:**\n   - Importancia de tener procedimientos claros para la gesti\u00f3n de documentos.\n   - Requisitos para la autorizaci\u00f3n, revisi\u00f3n y control de versiones de documentos.\n\n5. **Capacitaci\u00f3n y Buenas Pr\u00e1cticas:**\n   - Necesidad de capacitaci\u00f3n del personal y buenas pr\u00e1cticas de gesti\u00f3n de calidad.\n\n**Entidades:**\n- **TTSPPs:** Productos farmac\u00e9uticos y biol\u00f3gicos controlados y peligrosos.\n- **SOPs:** Procedimientos Operativos Est\u00e1ndar.\n- **Regulatory Authorities:** Autoridades regulatorias que establecen requisitos de retenci\u00f3n de documentos.\n- **Document Register:** Registro donde se registran todos los documentos relevantes.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de productos farmac\u00e9uticos y biol\u00f3gicos, as\u00ed como la necesidad de un control riguroso de documentos y capacitaci\u00f3n del personal para asegurar la calidad y seguridad en su manejo.", "excerpt_keywords": "Keywords: training, pharmaceutical legislation, TTSPPs, safety, compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "227de9f2-0ea6-41fc-950a-ccd00fd2c345", "node_type": "4", "metadata": {"page_label": "379", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Personnel/training\n\n## 12.1 Training\n\n### 12.1.1 General training\n\nProvide regular and systematic training for all relevant personnel responsible for storage, loading and unloading areas used for non-hazardous TTSPPs, covering the following:\n\n- applicable pharmaceutical legislation and regulations;\n- SOPs and safety issues; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Provide similar training for drivers who are responsible for transporting these substances. Maintain individual training records to demonstrate compliance and regularly evaluate the effectiveness of training programmes.\n\n*Reason:* To ensure that all relevant personnel are competent to carry out their duties.\n\n### 12.1.2 Specialist training\n\nIn addition to the training described in clause 12.1.1, provide regular and systematic additional training for relevant personnel responsible for storage, loading and unloading of controlled or hazardous TTSPPs. Training should cover the following:\n\n- applicable legislation and regulations;\n- security and safety risks; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Maintain training records to demonstrate compliance and perform effectiveness checks on training. Provide similar training for drivers who are responsible for transporting these substances.\n\n*Reason:* To ensure that all relevant personnel are competent to handle controlled or hazardous TTSPPs.\n\n## Key references\n\nWorld Health Organization/United Nations Children\u2019s Fund/United Nations Development Programme/United Nations Population Fund/World Bank  \n* A model quality assurance system for procurement agencies.* Geneva, World Health Organization, 2007 (WHO/PSM/PAR/2007.3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "33064fd7d8c659dfc619ec64b915257178b5a2071b41a5f66d139c5ca370cf77", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12. Personnel/training\n\n## 12.1 Training\n\n### 12.1.1 General training\n\nProvide regular and systematic training for all relevant personnel responsible for storage, loading and unloading areas used for non-hazardous TTSPPs, covering the following:\n\n- applicable pharmaceutical legislation and regulations;\n- SOPs and safety issues; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Provide similar training for drivers who are responsible for transporting these substances. Maintain individual training records to demonstrate compliance and regularly evaluate the effectiveness of training programmes.\n\n*Reason:* To ensure that all relevant personnel are competent to carry out their duties.\n\n### 12.1.2 Specialist training\n\nIn addition to the training described in clause 12.1.1, provide regular and systematic additional training for relevant personnel responsible for storage, loading and unloading of controlled or hazardous TTSPPs. Training should cover the following:\n\n- applicable legislation and regulations;\n- security and safety risks; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Maintain training records to demonstrate compliance and perform effectiveness checks on training. Provide similar training for drivers who are responsible for transporting these substances.\n\n*Reason:* To ensure that all relevant personnel are competent to handle controlled or hazardous TTSPPs.\n\n## Key references\n\nWorld Health Organization/United Nations Children\u2019s Fund/United Nations Development Programme/United Nations Population Fund/World Bank  \n* A model quality assurance system for procurement agencies.* Geneva, World Health Organization, 2007 (WHO/PSM/PAR/2007.3).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1788, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bef04473-0a6c-45c3-adb2-541a859d9df2": {"__data__": {"id_": "bef04473-0a6c-45c3-adb2-541a859d9df2", "embedding": null, "metadata": {"page_label": "380", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Therapeutic Goods Administration *Australian code of good wholesaling practice for therapeutic goods for human use*. Commonwealth of Australia, Canberra ACT, Draft Revision \u2014 June 2006.\n\n*Protocol for the control of storage temperatures of medicinal products*. London, British Association of Pharmaceutical Wholesalers, 1999.\n\nThe Council of the European Communities. Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use. *Official Journal L 113 , 30/04/1992 p. 0001 \u2014 0004*.\n\nThe Council of the European Communities. EU Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. *Official Journal L 113 , 30/04/1992 p. 0008 \u2014 0012*.\n\nState Food and Drug Administration of the People's Republic of China. *Drug administration law of the People's Republic of China*. 2001.\n\nEU 94/C 63/03. *Guidelines on good distribution practice of medicinal products for human use*. 1994.\n\nThe European Parliament and the Council of the European Union. EU Directive 2004/27/EC. Community code relating to medicinal products for human use. *Official Journal L 136/34/2004*.\n\nEU Regulation 4/2007. *Good distribution practices for pharmaceutical wholesalers*. 2007.\n\nGUIDE-0069: *Guidelines for temperature control of drug products during storage and transportation*. Ottawa, Ontario, Health Canada. Health Products and Food Branch Inspectorate, 2005.\n\n*IATA Perishable Cargo Regulations Chapter 17*. 9th ed, International Air Transport Association, 2009.\n\nInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: *ICH Harmonised Tripartite Guideline: Quality Risk Management Q9*. November 2005.\n\nIrish Medicines Board. *Guide to control and monitoring of storage and transportation temperature conditions for medicinal products and active substances*. Edition IND-003 Version 1, March 2006.\n\n*Best practices for repositories*. International Society for Biological and Environmental Repositories, 2008.\n\nMedicines and Healthcare products Regulatory Agency. *Rules and guidance for pharmaceutical manufacturers and distributors*. London, Pharmaceutical Press, 2007.\n\nPDA: Technical report 39: *Guidance for Temperature Controlled Medicinal Products: Maintaining the quality of temperature-sensitive medicinal products through the transportation environment*. Parenteral Drug Association, 2007.\n\n*Guidance notes on good distribution practices*. Singapore Health Sciences Authority: 2008.\n\nTaylor, J. *Recommendations on the control and monitoring of storage and transportation temperatures of medicinal products*. London, Medicines and Healthcare products Regulatory Agency, 2001.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales. Incluye referencias a diversas directrices y regulaciones internacionales, como las de la Uni\u00f3n Europea, la Administraci\u00f3n de Alimentos y Medicamentos de China, y otras organizaciones relevantes. Se abordan temas como el control de temperaturas durante el almacenamiento y transporte de productos medicinales, as\u00ed como las normativas que rigen la distribuci\u00f3n y etiquetado de estos productos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las principales directrices mencionadas en el documento para el control de temperaturas de productos medicinales durante su almacenamiento y transporte?**\n   - Respuesta: El documento menciona varias directrices, incluyendo el \"GUIDE-0069\" de Health Canada sobre el control de temperatura, y el \"PDA Technical Report 39\" que proporciona orientaci\u00f3n sobre productos medicinales sensibles a la temperatura.\n\n2. **\u00bfQu\u00e9 regulaciones de la Uni\u00f3n Europea se citan en el documento en relaci\u00f3n con la distribuci\u00f3n y etiquetado de productos medicinales?**\n   - Respuesta: Se citan la Directiva 92/25/EEC sobre la distribuci\u00f3n mayorista y la Directiva 92/27/EEC sobre el etiquetado y prospectos de productos medicinales, as\u00ed como la Directiva 2004/27/EC que establece el c\u00f3digo comunitario para productos medicinales.\n\n3. **\u00bfQu\u00e9 organizaciones han emitido gu\u00edas sobre las buenas pr\u00e1cticas de distribuci\u00f3n de productos medicinales seg\u00fan el documento?**\n   - Respuesta: Entre las organizaciones mencionadas se encuentran la Therapeutic Goods Administration de Australia, la Medicines and Healthcare products Regulatory Agency del Reino Unido, y la International Society for Biological and Environmental Repositories, entre otras.\n\n### Resumen de Nivel Superior\nEl documento proporciona un marco normativo y directrices sobre las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales, enfatizando la importancia del control de temperatura y el cumplimiento de regulaciones internacionales. Se citan m\u00faltiples fuentes y directrices que abordan la calidad y seguridad de los productos durante su transporte y almacenamiento, lo que es crucial para mantener su eficacia y seguridad para el uso humano.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**Temas clave:**\n\n1. **Capacitaci\u00f3n del personal:**\n   - Importancia de la formaci\u00f3n regular y sistem\u00e1tica para el personal involucrado en el almacenamiento, carga y descarga de productos farmac\u00e9uticos (TTSPPs).\n   - Diferenciaci\u00f3n entre capacitaci\u00f3n general para TTSPPs no peligrosos y capacitaci\u00f3n especializada para TTSPPs controlados o peligrosos.\n\n2. **Contenido de la capacitaci\u00f3n:**\n   - **Capacitaci\u00f3n general:**\n     - Legislaci\u00f3n y regulaciones farmac\u00e9uticas aplicables.\n     - Procedimientos operativos est\u00e1ndar (SOPs).\n     - Cuestiones de seguridad y respuesta a emergencias.\n   - **Capacitaci\u00f3n especializada:**\n     - Legislaci\u00f3n y regulaciones espec\u00edficas para productos controlados o peligrosos.\n     - Riesgos de seguridad y medidas de seguridad.\n     - Respuesta a emergencias.\n\n3. **Responsabilidades y registros:**\n   - Asegurar que cada empleado comprenda sus responsabilidades espec\u00edficas.\n   - Mantenimiento de registros individuales de capacitaci\u00f3n para demostrar cumplimiento y evaluar la efectividad de los programas de formaci\u00f3n.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices sobre la capacitaci\u00f3n del personal.\n- **TTSPPs (Productos farmac\u00e9uticos no peligrosos y peligrosos):** Sustancias que requieren manejo especializado y capacitaci\u00f3n.\n- **SOPs (Procedimientos Operativos Est\u00e1ndar):** Documentos que gu\u00edan las pr\u00e1cticas de trabajo seguras y efectivas.\n- **Referencias clave:** \n  - \"A model quality assurance system for procurement agencies.\" (WHO/PSM/PAR/2007.3) - Documento de referencia que respalda las directrices de capacitaci\u00f3n.\n\nEste resumen destaca la importancia de la capacitaci\u00f3n adecuada del personal en el manejo de productos farmac\u00e9uticos, asegurando la competencia y la seguridad en las operaciones.", "excerpt_keywords": "Keywords: medicinal products, temperature control, good distribution practices, regulatory guidelines, pharmaceutical storage"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0b47360d-b606-4a29-9119-c74d91a5b743", "node_type": "4", "metadata": {"page_label": "380", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Therapeutic Goods Administration *Australian code of good wholesaling practice for therapeutic goods for human use*. Commonwealth of Australia, Canberra ACT, Draft Revision \u2014 June 2006.\n\n*Protocol for the control of storage temperatures of medicinal products*. London, British Association of Pharmaceutical Wholesalers, 1999.\n\nThe Council of the European Communities. Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use. *Official Journal L 113 , 30/04/1992 p. 0001 \u2014 0004*.\n\nThe Council of the European Communities. EU Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. *Official Journal L 113 , 30/04/1992 p. 0008 \u2014 0012*.\n\nState Food and Drug Administration of the People's Republic of China. *Drug administration law of the People's Republic of China*. 2001.\n\nEU 94/C 63/03. *Guidelines on good distribution practice of medicinal products for human use*. 1994.\n\nThe European Parliament and the Council of the European Union. EU Directive 2004/27/EC. Community code relating to medicinal products for human use. *Official Journal L 136/34/2004*.\n\nEU Regulation 4/2007. *Good distribution practices for pharmaceutical wholesalers*. 2007.\n\nGUIDE-0069: *Guidelines for temperature control of drug products during storage and transportation*. Ottawa, Ontario, Health Canada. Health Products and Food Branch Inspectorate, 2005.\n\n*IATA Perishable Cargo Regulations Chapter 17*. 9th ed, International Air Transport Association, 2009.\n\nInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: *ICH Harmonised Tripartite Guideline: Quality Risk Management Q9*. November 2005.\n\nIrish Medicines Board. *Guide to control and monitoring of storage and transportation temperature conditions for medicinal products and active substances*. Edition IND-003 Version 1, March 2006.\n\n*Best practices for repositories*. International Society for Biological and Environmental Repositories, 2008.\n\nMedicines and Healthcare products Regulatory Agency. *Rules and guidance for pharmaceutical manufacturers and distributors*. London, Pharmaceutical Press, 2007.\n\nPDA: Technical report 39: *Guidance for Temperature Controlled Medicinal Products: Maintaining the quality of temperature-sensitive medicinal products through the transportation environment*. Parenteral Drug Association, 2007.\n\n*Guidance notes on good distribution practices*. Singapore Health Sciences Authority: 2008.\n\nTaylor, J. *Recommendations on the control and monitoring of storage and transportation temperatures of medicinal products*. London, Medicines and Healthcare products Regulatory Agency, 2001.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0f1cd9ec68bac929df3b6bbdea1c2464faf6b308d3c549672922cee57bfd45fb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Therapeutic Goods Administration *Australian code of good wholesaling practice for therapeutic goods for human use*. Commonwealth of Australia, Canberra ACT, Draft Revision \u2014 June 2006.\n\n*Protocol for the control of storage temperatures of medicinal products*. London, British Association of Pharmaceutical Wholesalers, 1999.\n\nThe Council of the European Communities. Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use. *Official Journal L 113 , 30/04/1992 p. 0001 \u2014 0004*.\n\nThe Council of the European Communities. EU Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. *Official Journal L 113 , 30/04/1992 p. 0008 \u2014 0012*.\n\nState Food and Drug Administration of the People's Republic of China. *Drug administration law of the People's Republic of China*. 2001.\n\nEU 94/C 63/03. *Guidelines on good distribution practice of medicinal products for human use*. 1994.\n\nThe European Parliament and the Council of the European Union. EU Directive 2004/27/EC. Community code relating to medicinal products for human use. *Official Journal L 136/34/2004*.\n\nEU Regulation 4/2007. *Good distribution practices for pharmaceutical wholesalers*. 2007.\n\nGUIDE-0069: *Guidelines for temperature control of drug products during storage and transportation*. Ottawa, Ontario, Health Canada. Health Products and Food Branch Inspectorate, 2005.\n\n*IATA Perishable Cargo Regulations Chapter 17*. 9th ed, International Air Transport Association, 2009.\n\nInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: *ICH Harmonised Tripartite Guideline: Quality Risk Management Q9*. November 2005.\n\nIrish Medicines Board. *Guide to control and monitoring of storage and transportation temperature conditions for medicinal products and active substances*. Edition IND-003 Version 1, March 2006.\n\n*Best practices for repositories*. International Society for Biological and Environmental Repositories, 2008.\n\nMedicines and Healthcare products Regulatory Agency. *Rules and guidance for pharmaceutical manufacturers and distributors*. London, Pharmaceutical Press, 2007.\n\nPDA: Technical report 39: *Guidance for Temperature Controlled Medicinal Products: Maintaining the quality of temperature-sensitive medicinal products through the transportation environment*. Parenteral Drug Association, 2007.\n\n*Guidance notes on good distribution practices*. Singapore Health Sciences Authority: 2008.\n\nTaylor, J. *Recommendations on the control and monitoring of storage and transportation temperatures of medicinal products*. London, Medicines and Healthcare products Regulatory Agency, 2001.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2745, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "85406487-299c-4930-9155-949b1e88e664": {"__data__": {"id_": "85406487-299c-4930-9155-949b1e88e664", "embedding": null, "metadata": {"page_label": "381", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ozone Secretariat United Nations Environment Programme. *The Montreal Protocol on Substances that Deplete the Ozone Layer.* Nairobi, UNEP, 2000.\n\nUSP <1079> *Good storage and shipping practices.* United States Pharmacopeia, 2009.\n\nUSP 32-NF 27, *General Notices and requirements.* United States Pharmacopeia 2009.\n\nUSP <1118> *Monitoring Devices\u2013Time, Temperature, and Humidity.* United States Pharmacopeia, 2007.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report.* Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908).\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report.* Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 917) Annex 2.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957) Annex 5.\n\n# Further reading\n\n**Bishara, R.** A simple answer to cold chain chaos. *World Pharmaceutical Frontiers,* 2008, 5:65\u201366.\n\nEuropean Parliament and Council Directive 94/62/EC of 20 December 1994 on packaging and packaging waste. Official Journal L 365, 31/12/1994 P. 0010 \u2014 0023.\n\n**Falconer P, Drury J.** *Building and planning for industrial storage and distribution.* Architectural Press, London, 2003.\n\nGermanischer Lloyd Certification & Cool Chain Association. *Cool Chain Quality Indicator Standard (CCQI)* 20th June 2007, Version 1.5.\n\n**Kartoglu U, Ganivet S, Guichard S, Aiyar V, Bollen P, Maire D, Altay B.** Use of cool water packs to prevent freezing during vaccine transportation at the country level. *PDA Journal of Pharmaceutical Science and Technology,* 2009, 63:11-26\n\nManagement Sciences for Health. *Managing Drug Supply.* Kumarian Press, pp. 11-26,1997.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las especificaciones para preparaciones farmac\u00e9uticas y buenas pr\u00e1cticas de almacenamiento y distribuci\u00f3n. Incluye referencias a varios informes de la OMS y la Farmacopea de los Estados Unidos, as\u00ed como lecturas adicionales sobre la gesti\u00f3n de la cadena de fr\u00edo y la regulaci\u00f3n de envases. Se abordan temas como la importancia de mantener condiciones adecuadas de temperatura y humedad durante el transporte de productos farmac\u00e9uticos, as\u00ed como la normativa relacionada con el envasado y los residuos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones clave del informe de la OMS sobre las pr\u00e1cticas de almacenamiento y distribuci\u00f3n de materiales farmac\u00e9uticos?**\n   - Esta pregunta busca respuestas espec\u00edficas sobre las directrices y recomendaciones que se mencionan en los informes de la OMS, que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 papel juega el \"Cool Chain Quality Indicator Standard (CCQI)\" en la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en un est\u00e1ndar espec\u00edfico mencionado en el contexto y busca detalles sobre su aplicaci\u00f3n y relevancia en la industria farmac\u00e9utica.\n\n3. **\u00bfC\u00f3mo se utilizan los paquetes de agua fr\u00eda para prevenir el congelamiento durante el transporte de vacunas, seg\u00fan el estudio mencionado en el contexto?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre la metodolog\u00eda y los resultados del estudio citado, que puede no estar ampliamente documentada en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se encuentra en el contexto proporcionado, lo que puede no estar disponible en otras partes de la literatura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales, destacando la importancia del control de temperaturas durante su transporte y almacenamiento. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Control de Temperaturas**: Se enfatiza la necesidad de mantener condiciones adecuadas de temperatura para asegurar la calidad y eficacia de los productos medicinales.\n2. **Regulaciones Internacionales**: Se citan diversas directrices y regulaciones que rigen la distribuci\u00f3n, etiquetado y almacenamiento de productos medicinales.\n3. **Buenas Pr\u00e1cticas de Distribuci\u00f3n**: Se abordan las mejores pr\u00e1cticas que deben seguir los distribuidores y fabricantes para garantizar la seguridad y calidad de los productos.\n\n#### Entidades Mencionadas:\n1. **Therapeutic Goods Administration (Australia)**: Emisora del \"Australian code of good wholesaling practice\".\n2. **British Association of Pharmaceutical Wholesalers**: Autores del \"Protocol for the control of storage temperatures\".\n3. **Consejo de las Comunidades Europeas**: Cita de las Directivas 92/25/EEC y 92/27/EEC sobre distribuci\u00f3n y etiquetado de productos medicinales.\n4. **Administraci\u00f3n Estatal de Alimentos y Medicamentos de China**: Referencia a la \"Drug administration law\".\n5. **Health Canada**: Emisores de las \"GUIDE-0069\" sobre control de temperatura.\n6. **International Air Transport Association (IATA)**: Proveedores de regulaciones para el transporte de carga perecedera.\n7. **International Conference on Harmonisation (ICH)**: Emisores de la gu\u00eda sobre gesti\u00f3n de riesgos de calidad.\n8. **Medicines and Healthcare products Regulatory Agency (MHRA, Reino Unido)**: Autores de varias gu\u00edas y regulaciones sobre pr\u00e1cticas de distribuci\u00f3n.\n9. **Parenteral Drug Association (PDA)**: Autores del \"Technical report 39\" sobre productos medicinales sensibles a la temperatura.\n10. **Singapore Health Sciences Authority**: Emisores de notas de orientaci\u00f3n sobre buenas pr\u00e1cticas de distribuci\u00f3n.\n\nEste resumen destaca la relevancia de las regulaciones y directrices internacionales en la gesti\u00f3n de productos medicinales, as\u00ed como la colaboraci\u00f3n de diversas entidades para establecer est\u00e1ndares de calidad y seguridad.", "excerpt_keywords": "Keywords: pharmaceutical preparations, cold chain management, storage practices, WHO guidelines, temperature control"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd18a2a6-89a0-43c3-9ba2-f6413dd56639", "node_type": "4", "metadata": {"page_label": "381", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ozone Secretariat United Nations Environment Programme. *The Montreal Protocol on Substances that Deplete the Ozone Layer.* Nairobi, UNEP, 2000.\n\nUSP <1079> *Good storage and shipping practices.* United States Pharmacopeia, 2009.\n\nUSP 32-NF 27, *General Notices and requirements.* United States Pharmacopeia 2009.\n\nUSP <1118> *Monitoring Devices\u2013Time, Temperature, and Humidity.* United States Pharmacopeia, 2007.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report.* Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908).\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report.* Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 917) Annex 2.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957) Annex 5.\n\n# Further reading\n\n**Bishara, R.** A simple answer to cold chain chaos. *World Pharmaceutical Frontiers,* 2008, 5:65\u201366.\n\nEuropean Parliament and Council Directive 94/62/EC of 20 December 1994 on packaging and packaging waste. Official Journal L 365, 31/12/1994 P. 0010 \u2014 0023.\n\n**Falconer P, Drury J.** *Building and planning for industrial storage and distribution.* Architectural Press, London, 2003.\n\nGermanischer Lloyd Certification & Cool Chain Association. *Cool Chain Quality Indicator Standard (CCQI)* 20th June 2007, Version 1.5.\n\n**Kartoglu U, Ganivet S, Guichard S, Aiyar V, Bollen P, Maire D, Altay B.** Use of cool water packs to prevent freezing during vaccine transportation at the country level. *PDA Journal of Pharmaceutical Science and Technology,* 2009, 63:11-26\n\nManagement Sciences for Health. *Managing Drug Supply.* Kumarian Press, pp. 11-26,1997.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0f722a365b199139345c7cdab0e0688f48b1317fa9395345beaad8c8879681ba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Ozone Secretariat United Nations Environment Programme. *The Montreal Protocol on Substances that Deplete the Ozone Layer.* Nairobi, UNEP, 2000.\n\nUSP <1079> *Good storage and shipping practices.* United States Pharmacopeia, 2009.\n\nUSP 32-NF 27, *General Notices and requirements.* United States Pharmacopeia 2009.\n\nUSP <1118> *Monitoring Devices\u2013Time, Temperature, and Humidity.* United States Pharmacopeia, 2007.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report.* Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908).\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report.* Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 917) Annex 2.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957) Annex 5.\n\n# Further reading\n\n**Bishara, R.** A simple answer to cold chain chaos. *World Pharmaceutical Frontiers,* 2008, 5:65\u201366.\n\nEuropean Parliament and Council Directive 94/62/EC of 20 December 1994 on packaging and packaging waste. Official Journal L 365, 31/12/1994 P. 0010 \u2014 0023.\n\n**Falconer P, Drury J.** *Building and planning for industrial storage and distribution.* Architectural Press, London, 2003.\n\nGermanischer Lloyd Certification & Cool Chain Association. *Cool Chain Quality Indicator Standard (CCQI)* 20th June 2007, Version 1.5.\n\n**Kartoglu U, Ganivet S, Guichard S, Aiyar V, Bollen P, Maire D, Altay B.** Use of cool water packs to prevent freezing during vaccine transportation at the country level. *PDA Journal of Pharmaceutical Science and Technology,* 2009, 63:11-26\n\nManagement Sciences for Health. *Managing Drug Supply.* Kumarian Press, pp. 11-26,1997.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2263, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "97ca69d7-af96-4826-8b0b-65ca5ae9c3ac": {"__data__": {"id_": "97ca69d7-af96-4826-8b0b-65ca5ae9c3ac", "embedding": null, "metadata": {"page_label": "382", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Task force membership\n\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Henry Ames | Sensitech | Temperature monitoring | United States of America |\n| Claude Ammann | Topotarget | Manufacturer | Switzerland |\n| Erik van Asselt | PDA PCCIG | PDA | Netherlands (the) |\n| Anthony Battersby | FBA Health Systems | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| Rafik Bishara | PDA PCCIG | PDA | United States of America |\n| Richard Brown | TGA | Regulatory | Australia |\n| Linda Carducci | Johnson & Johnson | IFPMA | United States of America |\n| G\u00e9rald Cavalier | Cemafroid | IIR | France |\n| Isabelle Clamou | EFPIA | IFPMA | Belgium |\n| Michael Eakins | USP | Regulatory | United States of America |\n| Chris T Forrest | AstraZenca | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n| Juliman Fuad | BioFarma | Manufacturer | Indonesia |\n| Andreas Giger | Berlinger | Temperature monitoring | Switzerland |\n| Andre Haeusermann | Novartis Pharma | IFPMA | Switzerland |\n| Rodney L Horder | Abbott | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de miembros de un grupo de trabajo que abarca diversas organizaciones y categor\u00edas relacionadas con la salud y la regulaci\u00f3n. Los miembros provienen de diferentes pa\u00edses y representan a fabricantes, consultores, organizaciones regulatorias y asociaciones de la industria farmac\u00e9utica.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas en el grupo de trabajo y qu\u00e9 categor\u00edas de participaci\u00f3n tienen sus miembros?**\n   - Respuesta: Las organizaciones representadas incluyen Sensitech, Topotarget, PDA PCCIG, FBA Health Systems, TGA, Johnson & Johnson, Cemafroid, EFPIA, USP, AstraZeneca, BioFarma, Berlinger, Novartis Pharma y Abbott. Las categor\u00edas de participaci\u00f3n incluyen temperatura monitoreo, fabricante, PDA, consultor, regulador e IFPMA.\n\n2. **\u00bfCu\u00e1les son los pa\u00edses de origen de los miembros del grupo de trabajo y cu\u00e1ntos miembros provienen de cada pa\u00eds?**\n   - Respuesta: Los pa\u00edses de origen de los miembros incluyen Estados Unidos de Am\u00e9rica (5 miembros), Suiza (3 miembros), Reino Unido (4 miembros), Australia (1 miembro), B\u00e9lgica (1 miembro), Francia (1 miembro) e Indonesia (1 miembro).\n\n3. **\u00bfQui\u00e9nes son los miembros del grupo de trabajo que representan a organizaciones reguladoras y cu\u00e1les son sus respectivas organizaciones?**\n   - Respuesta: Los miembros que representan a organizaciones reguladoras son Richard Brown de TGA (Australia) y Michael Eakins de USP (Estados Unidos de Am\u00e9rica).", "prev_section_summary": "La secci\u00f3n proporcionada se centra en las especificaciones y buenas pr\u00e1cticas relacionadas con el almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de mantener condiciones adecuadas durante el transporte. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Regulaciones y Normativas**:\n   - Protocolo de Montreal sobre sustancias que agotan la capa de ozono.\n   - Buenas pr\u00e1cticas de almacenamiento y env\u00edo seg\u00fan la Farmacopea de los Estados Unidos (USP).\n   - Directrices de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n\n2. **Informes de la OMS**:\n   - M\u00faltiples informes de la OMS que abordan especificaciones y buenas pr\u00e1cticas en la industria farmac\u00e9utica, incluyendo los informes 36, 37, 38, 40 y 44.\n\n3. **Cadena de Fr\u00edo**:\n   - Importancia de la temperatura y la humedad en el transporte de productos farmac\u00e9uticos.\n   - Uso de paquetes de agua fr\u00eda para prevenir el congelamiento de vacunas durante el transporte.\n\n4. **Est\u00e1ndares de Calidad**:\n   - Introducci\u00f3n del \"Cool Chain Quality Indicator Standard (CCQI)\" para asegurar la calidad en la cadena de fr\u00edo.\n\n5. **Gesti\u00f3n de Residuos**:\n   - Directiva de la Uni\u00f3n Europea sobre envases y residuos de envases.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad en la regulaci\u00f3n de pr\u00e1cticas farmac\u00e9uticas.\n- **Farmacopea de los Estados Unidos (USP)**: Fuente de est\u00e1ndares y pr\u00e1cticas recomendadas.\n- **Secretar\u00eda del Ozono**: Parte del Programa de las Naciones Unidas para el Medio Ambiente (UNEP).\n- **Publicaciones y Autores**: \n  - R. Bishara, P. Falconer, J. Drury, y otros autores que contribuyen a la literatura sobre gesti\u00f3n de la cadena de fr\u00edo y almacenamiento industrial.\n\nEste resumen destaca la relevancia de las buenas pr\u00e1cticas en la industria farmac\u00e9utica y la necesidad de cumplir con las normativas para garantizar la eficacia y seguridad de los productos.", "excerpt_keywords": "Keywords: task force, membership, regulatory, pharmaceutical, temperature monitoring"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "98716d2f-5b54-4de9-b2df-031fda86dc8f", "node_type": "4", "metadata": {"page_label": "382", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Task force membership\n\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Henry Ames | Sensitech | Temperature monitoring | United States of America |\n| Claude Ammann | Topotarget | Manufacturer | Switzerland |\n| Erik van Asselt | PDA PCCIG | PDA | Netherlands (the) |\n| Anthony Battersby | FBA Health Systems | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| Rafik Bishara | PDA PCCIG | PDA | United States of America |\n| Richard Brown | TGA | Regulatory | Australia |\n| Linda Carducci | Johnson & Johnson | IFPMA | United States of America |\n| G\u00e9rald Cavalier | Cemafroid | IIR | France |\n| Isabelle Clamou | EFPIA | IFPMA | Belgium |\n| Michael Eakins | USP | Regulatory | United States of America |\n| Chris T Forrest | AstraZenca | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n| Juliman Fuad | BioFarma | Manufacturer | Indonesia |\n| Andreas Giger | Berlinger | Temperature monitoring | Switzerland |\n| Andre Haeusermann | Novartis Pharma | IFPMA | Switzerland |\n| Rodney L Horder | Abbott | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d0fad64f2456f9540c6c3acbf7985245c217e7853556573e9abc65bfee1121f7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Task force membership\n\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Henry Ames | Sensitech | Temperature monitoring | United States of America |\n| Claude Ammann | Topotarget | Manufacturer | Switzerland |\n| Erik van Asselt | PDA PCCIG | PDA | Netherlands (the) |\n| Anthony Battersby | FBA Health Systems | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| Rafik Bishara | PDA PCCIG | PDA | United States of America |\n| Richard Brown | TGA | Regulatory | Australia |\n| Linda Carducci | Johnson & Johnson | IFPMA | United States of America |\n| G\u00e9rald Cavalier | Cemafroid | IIR | France |\n| Isabelle Clamou | EFPIA | IFPMA | Belgium |\n| Michael Eakins | USP | Regulatory | United States of America |\n| Chris T Forrest | AstraZenca | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n| Juliman Fuad | BioFarma | Manufacturer | Indonesia |\n| Andreas Giger | Berlinger | Temperature monitoring | Switzerland |\n| Andre Haeusermann | Novartis Pharma | IFPMA | Switzerland |\n| Rodney L Horder | Abbott | IFPMA | United Kingdom of Great Britain and Northern Ireland |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1113, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d73aa760-852c-419e-8925-5abc34efd4c9": {"__data__": {"id_": "d73aa760-852c-419e-8925-5abc34efd4c9", "embedding": null, "metadata": {"page_label": "383", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name                   | Organization                                      | Category               | Country                                           |\n|------------------------|---------------------------------------------------|------------------------|---------------------------------------------------|\n| Laila Jarrar           | Food & Drug Administration                        | Regulatory             | Jordan                                            |\n| Ryoko Krause           | IFPMA                                             | IFPMA                  | Switzerland                                       |\n| Santosh Kutty          | CDL Kasauli                                       | Regulatory             | India                                             |\n| Gilles Labranque       | Sofrigam                                          | IIR                    | France                                            |\n| Adrien Lehideux        | ColdPack                                          | Passive cooling        | France                                            |\n| Zhang Lei              | National Biotec Group (Chengdu Institute)         | DCVMN                  | China                                             |\n| Eric Lindquist         | Organization                                      | Category               | Passive cooling Country United States of America  |\n| K\u00e5re Lindroos          | Huure                                             | Active cooling         | Finland                                           |\n| Gianluca Minestrini    | Hoffmann-La Roche                                 | IFPMA                  | Switzerland                                       |\n| Ali Musa Muhaidat      | Vaccine & Sera Department                         | Ministry of Health     | Jordan                                            |\n| Fernand Muller         | Dometic                                           | Active cooling         | Luxembourg                                        |\n| Kevin O.Donnell        | IATA                                              | IATA                   | United States of America                          |\n| Girolamo Panozzo       | ITC/CNR                                           | IIR                    | Italy                                             |\n| Stefanie Pluschkell    | Pfizer                                            | IFPMA                  | United States of America                          |\n| Fabian De Paoli        | GSK Biologicals                                   | IFPMA                  | Belgium                                           |\n| Cristiane Frensch Pereira | Bio-Manguinhos                                 | DCVMN                  | Brazil                                            |\n| Thadeus Prusik         | TempTime                                          | Temperature monitoring | United States of America                          |\n| Eric Raemdonnck        | IATA                                              | IATA                   | Canada                                            |\n| Joanie Robertson       | PATH                                              | PATH                   | United States of America                          |\n| Isabel Rojas           | CIGB/ Cuba                                        | DCVMN                  | Cuba                                              |\n| Wolfram Schlimme       | Crucell                                           | IFPMA                  | Switzerland                                       |\n| Inder Jit Sharma       | Serum Institute of India Ltd                      | DCVMN                  | India                                             |\n| Sarah Skuce            | Health Canada                                     | Regulatory             | Canada                                            |\n| Engko Sosilaine        | National Agency of Drug and Food Control          | Regulatory             | Indonesia                                         |\n| John Taylor            | MHRA                                              | Regulatory             | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de profesionales y representantes de diversas organizaciones relacionadas con la regulaci\u00f3n y el desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos. La tabla presenta informaci\u00f3n sobre el nombre, la organizaci\u00f3n, la categor\u00eda y el pa\u00eds de cada individuo. Las organizaciones abarcan desde agencias regulatorias hasta empresas farmac\u00e9uticas y de transporte, reflejando una amplia gama de actores en el \u00e1mbito de la salud global.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas por los profesionales que trabajan en el \u00e1mbito de la regulaci\u00f3n de productos biol\u00f3gicos y farmac\u00e9uticos en el contexto del informe?**\n   - Esta pregunta busca identificar las diversas organizaciones mencionadas en la tabla, lo que puede proporcionar una visi\u00f3n sobre la colaboraci\u00f3n internacional en la regulaci\u00f3n de la salud.\n\n2. **\u00bfCu\u00e1les son las categor\u00edas de especializaci\u00f3n de los representantes listados en el informe y qu\u00e9 pa\u00edses est\u00e1n m\u00e1s representados en cada categor\u00eda?**\n   - Esta pregunta permite analizar la diversidad de especializaciones y la representaci\u00f3n geogr\u00e1fica en el \u00e1mbito de la salud, lo que puede ser \u00fatil para entender las fortalezas y debilidades en diferentes regiones.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las organizaciones de transporte, como IATA, en el contexto de la regulaci\u00f3n y distribuci\u00f3n de productos biol\u00f3gicos seg\u00fan el informe?**\n   - Esta pregunta se centra en el papel espec\u00edfico de las organizaciones de transporte en la cadena de suministro de productos biol\u00f3gicos, lo que puede no ser evidente en otros documentos relacionados con la salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y relevante que puede no estar disponible en otros contextos, aprovechando la informaci\u00f3n \u00fanica presentada en el documento.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 961\" presenta una lista de miembros de un grupo de trabajo compuesto por representantes de diversas organizaciones relacionadas con la salud y la regulaci\u00f3n. Los temas clave incluyen:\n\n- **Organizaciones Representadas**: \n  - Sensitech\n  - Topotarget\n  - PDA PCCIG\n  - FBA Health Systems\n  - TGA\n  - Johnson & Johnson\n  - Cemafroid\n  - EFPIA\n  - USP\n  - AstraZeneca\n  - BioFarma\n  - Berlinger\n  - Novartis Pharma\n  - Abbott\n\n- **Categor\u00edas de Participaci\u00f3n**:\n  - Monitoreo de temperatura\n  - Fabricante\n  - PDA (Pharmaceutical Development Association)\n  - Consultor\n  - Regulador\n  - IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)\n\n- **Pa\u00edses de Origen de los Miembros**:\n  - Estados Unidos de Am\u00e9rica\n  - Suiza\n  - Reino Unido\n  - Australia\n  - B\u00e9lgica\n  - Francia\n  - Indonesia\n\n- **Miembros de Organizaciones Reguladoras**:\n  - Richard Brown (TGA, Australia)\n  - Michael Eakins (USP, Estados Unidos de Am\u00e9rica)\n\nEste grupo de trabajo refleja una colaboraci\u00f3n internacional en el \u00e1mbito de la salud, con un enfoque en la regulaci\u00f3n y la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: WHO, Technical Report, regulation, biopharmaceuticals, international collaboration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a31f036-beec-4d53-938e-b11fbabb7b1d", "node_type": "4", "metadata": {"page_label": "383", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name                   | Organization                                      | Category               | Country                                           |\n|------------------------|---------------------------------------------------|------------------------|---------------------------------------------------|\n| Laila Jarrar           | Food & Drug Administration                        | Regulatory             | Jordan                                            |\n| Ryoko Krause           | IFPMA                                             | IFPMA                  | Switzerland                                       |\n| Santosh Kutty          | CDL Kasauli                                       | Regulatory             | India                                             |\n| Gilles Labranque       | Sofrigam                                          | IIR                    | France                                            |\n| Adrien Lehideux        | ColdPack                                          | Passive cooling        | France                                            |\n| Zhang Lei              | National Biotec Group (Chengdu Institute)         | DCVMN                  | China                                             |\n| Eric Lindquist         | Organization                                      | Category               | Passive cooling Country United States of America  |\n| K\u00e5re Lindroos          | Huure                                             | Active cooling         | Finland                                           |\n| Gianluca Minestrini    | Hoffmann-La Roche                                 | IFPMA                  | Switzerland                                       |\n| Ali Musa Muhaidat      | Vaccine & Sera Department                         | Ministry of Health     | Jordan                                            |\n| Fernand Muller         | Dometic                                           | Active cooling         | Luxembourg                                        |\n| Kevin O.Donnell        | IATA                                              | IATA                   | United States of America                          |\n| Girolamo Panozzo       | ITC/CNR                                           | IIR                    | Italy                                             |\n| Stefanie Pluschkell    | Pfizer                                            | IFPMA                  | United States of America                          |\n| Fabian De Paoli        | GSK Biologicals                                   | IFPMA                  | Belgium                                           |\n| Cristiane Frensch Pereira | Bio-Manguinhos                                 | DCVMN                  | Brazil                                            |\n| Thadeus Prusik         | TempTime                                          | Temperature monitoring | United States of America                          |\n| Eric Raemdonnck        | IATA                                              | IATA                   | Canada                                            |\n| Joanie Robertson       | PATH                                              | PATH                   | United States of America                          |\n| Isabel Rojas           | CIGB/ Cuba                                        | DCVMN                  | Cuba                                              |\n| Wolfram Schlimme       | Crucell                                           | IFPMA                  | Switzerland                                       |\n| Inder Jit Sharma       | Serum Institute of India Ltd                      | DCVMN                  | India                                             |\n| Sarah Skuce            | Health Canada                                     | Regulatory             | Canada                                            |\n| Engko Sosilaine        | National Agency of Drug and Food Control          | Regulatory             | Indonesia                                         |\n| John Taylor            | MHRA                                              | Regulatory             | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6d68c7707861ff5701074f8fa63e09fb7dd298d324ab6eb10362cfe8f1876599", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Name                   | Organization                                      | Category               | Country                                           |\n|------------------------|---------------------------------------------------|------------------------|---------------------------------------------------|\n| Laila Jarrar           | Food & Drug Administration                        | Regulatory             | Jordan                                            |\n| Ryoko Krause           | IFPMA                                             | IFPMA                  | Switzerland                                       |\n| Santosh Kutty          | CDL Kasauli                                       | Regulatory             | India                                             |\n| Gilles Labranque       | Sofrigam                                          | IIR                    | France                                            |\n| Adrien Lehideux        | ColdPack                                          | Passive cooling        | France                                            |\n| Zhang Lei              | National Biotec Group (Chengdu Institute)         | DCVMN                  | China                                             |\n| Eric Lindquist         | Organization                                      | Category               | Passive cooling Country United States of America  |\n| K\u00e5re Lindroos          | Huure                                             | Active cooling         | Finland                                           |\n| Gianluca Minestrini    | Hoffmann-La Roche                                 | IFPMA                  | Switzerland                                       |\n| Ali Musa Muhaidat      | Vaccine & Sera Department                         | Ministry of Health     | Jordan                                            |\n| Fernand Muller         | Dometic                                           | Active cooling         | Luxembourg                                        |\n| Kevin O.Donnell        | IATA                                              | IATA                   | United States of America                          |\n| Girolamo Panozzo       | ITC/CNR                                           | IIR                    | Italy                                             |\n| Stefanie Pluschkell    | Pfizer                                            | IFPMA                  | United States of America                          |\n| Fabian De Paoli        | GSK Biologicals                                   | IFPMA                  | Belgium                                           |\n| Cristiane Frensch Pereira | Bio-Manguinhos                                 | DCVMN                  | Brazil                                            |\n| Thadeus Prusik         | TempTime                                          | Temperature monitoring | United States of America                          |\n| Eric Raemdonnck        | IATA                                              | IATA                   | Canada                                            |\n| Joanie Robertson       | PATH                                              | PATH                   | United States of America                          |\n| Isabel Rojas           | CIGB/ Cuba                                        | DCVMN                  | Cuba                                              |\n| Wolfram Schlimme       | Crucell                                           | IFPMA                  | Switzerland                                       |\n| Inder Jit Sharma       | Serum Institute of India Ltd                      | DCVMN                  | India                                             |\n| Sarah Skuce            | Health Canada                                     | Regulatory             | Canada                                            |\n| Engko Sosilaine        | National Agency of Drug and Food Control          | Regulatory             | Indonesia                                         |\n| John Taylor            | MHRA                                              | Regulatory             | United Kingdom of Great Britain and Northern Ireland |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4215, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5dc38c12-b045-432b-a563-c88add55127e": {"__data__": {"id_": "5dc38c12-b045-432b-a563-c88add55127e", "embedding": null, "metadata": {"page_label": "384", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Mahbouba Vladakhani | Biological Dept Pharmaceutical & Narcotics | Regulatory | Iran (Islamic Republic of) |\n| Lisette Vromans | Merck | IFPMA | Netherlands (the) |\n\n\n### World Health Organization Performance, Quality and Safety Secretariat\n\n| | | | |\n| - | - | - | - |\n| Andrew Garnett | Author \u2014 Group leader | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| \u00dcmit Karto\\_lu | Family and Community Health/ Quality, Safety and Standards-Chair | WHO | Switzerland |\n| Denis Maire | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n\n\n### World Health Organization\n\n| | | | |\n| - | - | - | - |\n| Lahouari Belgharbi | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Ivana Knezevic | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Sabine Kopp | Health Systems and Services/ Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines | WHO | Switzerland |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". En \u00e9l se presentan diversas contribuciones de expertos y representantes de diferentes organizaciones y pa\u00edses en el \u00e1mbito de la salud, la calidad y la seguridad de los medicamentos. Se destacan los roles de varios individuos en la OMS y otras organizaciones, as\u00ed como su pa\u00eds de origen y su categor\u00eda profesional.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de Andrew Garnett en el contexto del informe de la OMS?**\n   - Respuesta: Andrew Garnett es el autor y l\u00edder del grupo consultor en el informe, lo que indica que tiene un papel clave en la direcci\u00f3n y contenido del documento.\n\n2. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas por los individuos mencionados en el informe y qu\u00e9 categor\u00edas profesionales tienen?**\n   - Respuesta: Las organizaciones representadas incluyen el Departamento Biol\u00f3gico de Productos Farmac\u00e9uticos y Narc\u00f3ticos de Ir\u00e1n, Merck, y la OMS. Las categor\u00edas profesionales incluyen regulador, IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones) y varios roles en calidad, seguridad y est\u00e1ndares de salud.\n\n3. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados por los expertos mencionados en el informe y qu\u00e9 \u00e1reas de salud abordan?**\n   - Respuesta: Los pa\u00edses representados son Ir\u00e1n, los Pa\u00edses Bajos y el Reino Unido, as\u00ed como Suiza (donde se encuentra la OMS). Las \u00e1reas de salud que abordan incluyen la calidad y seguridad de los medicamentos, as\u00ed como pol\u00edticas farmac\u00e9uticas esenciales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" presenta una lista de profesionales y representantes de diversas organizaciones involucradas en la regulaci\u00f3n y desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Regulaci\u00f3n de Productos Biol\u00f3gicos y Farmac\u00e9uticos**: La secci\u00f3n destaca la importancia de la regulaci\u00f3n en el \u00e1mbito de la salud global, con un enfoque en la colaboraci\u00f3n entre diferentes organizaciones y pa\u00edses.\n  \n2. **Diversidad de Organizaciones**: Se incluyen agencias regulatorias, empresas farmac\u00e9uticas, organizaciones de transporte y otras entidades que desempe\u00f1an un papel crucial en la cadena de suministro de productos biol\u00f3gicos.\n\n3. **Colaboraci\u00f3n Internacional**: La representaci\u00f3n de m\u00faltiples pa\u00edses y organizaciones sugiere un esfuerzo conjunto para abordar los desaf\u00edos en la regulaci\u00f3n y distribuci\u00f3n de productos de salud.\n\n#### Entidades Mencionadas:\n- **Organizaciones Regulatorias**:\n  - Food & Drug Administration (FDA) - Jordania\n  - Health Canada - Canad\u00e1\n  - MHRA - Reino Unido\n  - National Agency of Drug and Food Control - Indonesia\n\n- **Empresas Farmac\u00e9uticas**:\n  - Pfizer - Estados Unidos\n  - GSK Biologicals - B\u00e9lgica\n  - Hoffmann-La Roche - Suiza\n  - Bio-Manguinhos - Brasil\n\n- **Organizaciones de Transporte**:\n  - IATA - Estados Unidos y Canad\u00e1\n\n- **Instituciones de Investigaci\u00f3n y Desarrollo**:\n  - Serum Institute of India Ltd - India\n  - National Biotec Group (Chengdu Institute) - China\n\n- **Otras Entidades**:\n  - PATH - Estados Unidos\n  - Sofrigam - Francia\n  - TempTime - Estados Unidos\n\nEste resumen proporciona una visi\u00f3n general de los actores clave en el \u00e1mbito de la regulaci\u00f3n y desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos, as\u00ed como la diversidad geogr\u00e1fica y organizativa presente en el documento.", "excerpt_keywords": "Keywords: WHO, pharmaceutical regulation, quality assurance, international collaboration, health safety"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4efcbbe3-ace6-44bf-a9ef-07112f806ba6", "node_type": "4", "metadata": {"page_label": "384", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Mahbouba Vladakhani | Biological Dept Pharmaceutical & Narcotics | Regulatory | Iran (Islamic Republic of) |\n| Lisette Vromans | Merck | IFPMA | Netherlands (the) |\n\n\n### World Health Organization Performance, Quality and Safety Secretariat\n\n| | | | |\n| - | - | - | - |\n| Andrew Garnett | Author \u2014 Group leader | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| \u00dcmit Karto\\_lu | Family and Community Health/ Quality, Safety and Standards-Chair | WHO | Switzerland |\n| Denis Maire | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n\n\n### World Health Organization\n\n| | | | |\n| - | - | - | - |\n| Lahouari Belgharbi | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Ivana Knezevic | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Sabine Kopp | Health Systems and Services/ Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines | WHO | Switzerland |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "6a5ce6044d62a01d64fab34873e4c9d4fee5324cfe892759e27aff86dd1a8c1b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Name | Organization | Category | Country |\n| - | - | - | - |\n| Mahbouba Vladakhani | Biological Dept Pharmaceutical & Narcotics | Regulatory | Iran (Islamic Republic of) |\n| Lisette Vromans | Merck | IFPMA | Netherlands (the) |\n\n\n### World Health Organization Performance, Quality and Safety Secretariat\n\n| | | | |\n| - | - | - | - |\n| Andrew Garnett | Author \u2014 Group leader | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| \u00dcmit Karto\\_lu | Family and Community Health/ Quality, Safety and Standards-Chair | WHO | Switzerland |\n| Denis Maire | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n\n\n### World Health Organization\n\n| | | | |\n| - | - | - | - |\n| Lahouari Belgharbi | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Ivana Knezevic | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Sabine Kopp | Health Systems and Services/ Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines | WHO | Switzerland |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1069, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "29ea72a5-32cc-46cb-8385-5189e774f49e": {"__data__": {"id_": "29ea72a5-32cc-46cb-8385-5189e774f49e", "embedding": null, "metadata": {"page_label": "385", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 10\n\n## Procedure for prequalification of pharmaceutical products\n\n1. Introduction\n2. Glossary\n3. Purpose and principles\n4. Steps of the procedure\n5. Invitation for expressions of interest\n6. Data and information to be submitted\n7. Screening of dossiers submitted\n8. Dossier assessment\n9. Site inspection\n10. Reporting and communication of the results of the evaluation\n11. Outcome of the prequalification procedure\n12. Maintenance of prequalification status\n13. Cost recovery\n14. Confidentiality undertaking\n15. Conflict of interest\n\n### Appendix 1\nFlowchart of WHO prequalification of pharmaceutical products\n\n### Appendix 2\nCharacteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se siguen en el procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca detalles sobre el proceso, que incluye desde la invitaci\u00f3n para expresiones de inter\u00e9s hasta la comunicaci\u00f3n de los resultados de la evaluaci\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n y datos deben ser presentados por los solicitantes durante el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de documentaci\u00f3n y datos que los fabricantes deben proporcionar para que sus productos sean considerados para la precalificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se toman para mantener el estatus de precalificaci\u00f3n de un producto farmac\u00e9utico una vez que ha sido aprobado por la OMS?**\n   - Esta pregunta aborda el tema de la sostenibilidad y el mantenimiento del estatus de precalificaci\u00f3n, lo cual es crucial para asegurar que los productos contin\u00faen cumpliendo con los est\u00e1ndares establecidos.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS detalla el procedimiento para la precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye una serie de pasos desde la presentaci\u00f3n de solicitudes hasta la evaluaci\u00f3n y el mantenimiento del estatus de precalificaci\u00f3n. Tambi\u00e9n se menciona la importancia de la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en este proceso. Adem\u00e1s, se incluyen ap\u00e9ndices que ofrecen un flujo de trabajo visual y caracter\u00edsticas de los productos precalificados que estar\u00e1n disponibles p\u00fablicamente.", "prev_section_summary": "El contenido proporcionado es un extracto del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". Este informe incluye contribuciones de expertos y representantes de diversas organizaciones y pa\u00edses en el \u00e1mbito de la salud, la calidad y la seguridad de los medicamentos. \n\n### Temas Clave:\n1. **Contribuciones de Expertos**: Se destacan los roles de varios individuos en la OMS y otras organizaciones, enfatizando su experiencia en \u00e1reas relacionadas con la calidad y seguridad de los medicamentos.\n2. **Organizaciones Representadas**: Incluye el Departamento Biol\u00f3gico de Productos Farmac\u00e9uticos y Narc\u00f3ticos de Ir\u00e1n, Merck y la OMS.\n3. **Categor\u00edas Profesionales**: Los participantes tienen roles en regulaci\u00f3n, consultor\u00eda y est\u00e1ndares de calidad y seguridad en salud.\n4. **Pa\u00edses Representados**: Los expertos provienen de Ir\u00e1n, los Pa\u00edses Bajos, el Reino Unido y Suiza, lo que refleja una colaboraci\u00f3n internacional en temas de salud.\n\n### Entidades:\n- **Organizaciones**: \n  - Biological Dept Pharmaceutical & Narcotics (Ir\u00e1n)\n  - Merck (Pa\u00edses Bajos)\n  - Organizaci\u00f3n Mundial de la Salud (Suiza)\n  \n- **Expertos**:\n  - Mahbouba Vladakhani (Ir\u00e1n)\n  - Lisette Vromans (Pa\u00edses Bajos)\n  - Andrew Garnett (Reino Unido)\n  - \u00dcmit Karto\u011flu (Suiza)\n  - Denis Maire (Suiza)\n  - Lahouari Belgharbi (Suiza)\n  - Ivana Knezevic (Suiza)\n  - Sabine Kopp (Suiza)\n\nEste resumen destaca la colaboraci\u00f3n internacional y la diversidad de expertos involucrados en la mejora de la calidad y seguridad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, evaluation procedure, confidentiality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8cb7399f-8b8a-428b-80de-956778644a1a", "node_type": "4", "metadata": {"page_label": "385", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 10\n\n## Procedure for prequalification of pharmaceutical products\n\n1. Introduction\n2. Glossary\n3. Purpose and principles\n4. Steps of the procedure\n5. Invitation for expressions of interest\n6. Data and information to be submitted\n7. Screening of dossiers submitted\n8. Dossier assessment\n9. Site inspection\n10. Reporting and communication of the results of the evaluation\n11. Outcome of the prequalification procedure\n12. Maintenance of prequalification status\n13. Cost recovery\n14. Confidentiality undertaking\n15. Conflict of interest\n\n### Appendix 1\nFlowchart of WHO prequalification of pharmaceutical products\n\n### Appendix 2\nCharacteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "17b10a13766606e386792f2d1df15243cd86299d24f3de9977e95373bb71c6bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 10\n\n## Procedure for prequalification of pharmaceutical products\n\n1. Introduction\n2. Glossary\n3. Purpose and principles\n4. Steps of the procedure\n5. Invitation for expressions of interest\n6. Data and information to be submitted\n7. Screening of dossiers submitted\n8. Dossier assessment\n9. Site inspection\n10. Reporting and communication of the results of the evaluation\n11. Outcome of the prequalification procedure\n12. Maintenance of prequalification status\n13. Cost recovery\n14. Confidentiality undertaking\n15. Conflict of interest\n\n### Appendix 1\nFlowchart of WHO prequalification of pharmaceutical products\n\n### Appendix 2\nCharacteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 751, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "281ba61c-8e2c-453e-907a-f52be2ce464c": {"__data__": {"id_": "281ba61c-8e2c-453e-907a-f52be2ce464c", "embedding": null, "metadata": {"page_label": "386", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies with advice on the acceptability, in principle, of pharmaceutical products for procurement by such agencies.\n\nThis activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality. WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the manufacturers of such products or other applicants, and on an inspection of the corresponding manufacturing facilities and clinical sites. This is done through a standardized procedure which is based on WHO-recommended quality standards. The quality of pharmaceutical products is obviously crucial for the safety and efficacy of such products.\n\nThe pharmaceutical products found to meet the WHO-recommended quality standards are included in the list of medicines, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by United Nations agencies. The list of prequalified pharmaceutical products is principally intended for use by United Nations agencies \u2014 including the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children\u2019s Fund (UNICEF) and United Nations Population Fund (UNFPA) \u2014 to guide their procurement decisions. The growing list of pharmaceutical products that have been found to meet WHO-recommended standards may, however, also be of interest to other organizations and countries wishing to engage in the bulk procurement of pharmaceutical products.\n\nInclusion in the list does not imply any approval by WHO of the pharmaceutical products and manufacturing sites in question (which is the sole prerogative of national authorities). Moreover, inclusion in the list does not constitute an endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety and/or efficacy in the treatment of specific diseases.\n\n# 2. Glossary\n\nThe definitions given below apply to the terms used in this procedure. They may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nA substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos para su adquisici\u00f3n por agencias de las Naciones Unidas. La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de estos productos, bas\u00e1ndose en informaci\u00f3n de los fabricantes y en inspecciones de las instalaciones de fabricaci\u00f3n. Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS son incluidos en una lista destinada a guiar las decisiones de compra de agencias como UNAIDS, UNICEF y UNFPA. Sin embargo, la inclusi\u00f3n en esta lista no implica aprobaci\u00f3n o garant\u00eda de la OMS sobre la idoneidad de los productos para usos espec\u00edficos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el proceso que sigue la OMS para evaluar la calidad de los productos farmac\u00e9uticos antes de incluirlos en la lista de precalificaci\u00f3n?**\n   - La OMS lleva a cabo una evaluaci\u00f3n integral que incluye la revisi\u00f3n de la informaci\u00f3n proporcionada por los fabricantes y la inspecci\u00f3n de las instalaciones de fabricaci\u00f3n y sitios cl\u00ednicos, todo ello basado en procedimientos estandarizados y normas de calidad recomendadas por la OMS.\n\n2. **\u00bfQu\u00e9 implicaciones tiene la inclusi\u00f3n de un producto farmac\u00e9utico en la lista de precalificaci\u00f3n de la OMS para las agencias de la ONU?**\n   - La inclusi\u00f3n en la lista permite a las agencias de la ONU, como UNAIDS, UNICEF y UNFPA, tomar decisiones informadas sobre la adquisici\u00f3n de medicamentos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS, facilitando as\u00ed el acceso a medicamentos esenciales.\n\n3. **\u00bfQu\u00e9 limitaciones existen en cuanto a la interpretaci\u00f3n de la inclusi\u00f3n de productos en la lista de la OMS?**\n   - La inclusi\u00f3n en la lista no implica aprobaci\u00f3n por parte de la OMS de los productos o sitios de fabricaci\u00f3n, ya que esta es una prerrogativa exclusiva de las autoridades nacionales. Adem\u00e1s, no se considera un respaldo o garant\u00eda de la OMS sobre la idoneidad de los productos para un prop\u00f3sito espec\u00edfico, incluyendo su seguridad y eficacia en el tratamiento de enfermedades.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**Tema Principal:**\n- Procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan la OMS.\n\n**Estructura del Procedimiento:**\n1. **Introducci\u00f3n:** Contexto general del procedimiento.\n2. **Glosario:** Definiciones de t\u00e9rminos relevantes.\n3. **Prop\u00f3sito y principios:** Objetivos y fundamentos del procedimiento.\n4. **Pasos del procedimiento:** Descripci\u00f3n detallada de las etapas a seguir.\n5. **Invitaci\u00f3n para expresiones de inter\u00e9s:** Proceso para invitar a los fabricantes a participar.\n6. **Datos e informaci\u00f3n a presentar:** Requisitos de documentaci\u00f3n para los solicitantes.\n7. **Filtrado de expedientes:** Evaluaci\u00f3n inicial de las solicitudes recibidas.\n8. **Evaluaci\u00f3n del expediente:** An\u00e1lisis detallado de la documentaci\u00f3n presentada.\n9. **Inspecci\u00f3n del sitio:** Verificaci\u00f3n de las instalaciones del fabricante.\n10. **Informe y comunicaci\u00f3n de resultados:** Proceso de notificaci\u00f3n de los resultados de la evaluaci\u00f3n.\n11. **Resultado del procedimiento de precalificaci\u00f3n:** Determinaci\u00f3n final sobre la precalificaci\u00f3n.\n12. **Mantenimiento del estatus de precalificaci\u00f3n:** Requisitos para conservar la aprobaci\u00f3n.\n13. **Recuperaci\u00f3n de costos:** Aspectos financieros del procedimiento.\n14. **Compromiso de confidencialidad:** Protecci\u00f3n de la informaci\u00f3n sensible.\n15. **Conflicto de inter\u00e9s:** Gesti\u00f3n de posibles conflictos en el proceso.\n\n**Ap\u00e9ndices:**\n- **Ap\u00e9ndice 1:** Diagrama de flujo del procedimiento de precalificaci\u00f3n.\n- **Ap\u00e9ndice 2:** Caracter\u00edsticas de los productos farmac\u00e9uticos precalificados que se publicar\u00e1n en el sitio web de la OMS.\n\n**Entidades Clave:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad responsable del procedimiento de precalificaci\u00f3n.\n- **Productos farmac\u00e9uticos:** Objetos de evaluaci\u00f3n y precalificaci\u00f3n.\n- **Fabricantes:** Solicitantes del proceso de precalificaci\u00f3n.\n\nEste resumen destaca los componentes esenciales del procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las entidades involucradas y los requisitos establecidos por la OMS.", "excerpt_keywords": "Keywords: WHO, pharmaceutical products, prequalification, quality standards, United Nations agencies"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "38190395-f646-4c5b-aa0b-b3a65fbc2944", "node_type": "4", "metadata": {"page_label": "386", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies with advice on the acceptability, in principle, of pharmaceutical products for procurement by such agencies.\n\nThis activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality. WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the manufacturers of such products or other applicants, and on an inspection of the corresponding manufacturing facilities and clinical sites. This is done through a standardized procedure which is based on WHO-recommended quality standards. The quality of pharmaceutical products is obviously crucial for the safety and efficacy of such products.\n\nThe pharmaceutical products found to meet the WHO-recommended quality standards are included in the list of medicines, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by United Nations agencies. The list of prequalified pharmaceutical products is principally intended for use by United Nations agencies \u2014 including the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children\u2019s Fund (UNICEF) and United Nations Population Fund (UNFPA) \u2014 to guide their procurement decisions. The growing list of pharmaceutical products that have been found to meet WHO-recommended standards may, however, also be of interest to other organizations and countries wishing to engage in the bulk procurement of pharmaceutical products.\n\nInclusion in the list does not imply any approval by WHO of the pharmaceutical products and manufacturing sites in question (which is the sole prerogative of national authorities). Moreover, inclusion in the list does not constitute an endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety and/or efficacy in the treatment of specific diseases.\n\n# 2. Glossary\n\nThe definitions given below apply to the terms used in this procedure. They may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nA substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "31783266500ff430d7ccfe7ebc307c884844c519af77d372c50c92a918ba06f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies with advice on the acceptability, in principle, of pharmaceutical products for procurement by such agencies.\n\nThis activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality. WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the manufacturers of such products or other applicants, and on an inspection of the corresponding manufacturing facilities and clinical sites. This is done through a standardized procedure which is based on WHO-recommended quality standards. The quality of pharmaceutical products is obviously crucial for the safety and efficacy of such products.\n\nThe pharmaceutical products found to meet the WHO-recommended quality standards are included in the list of medicines, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by United Nations agencies. The list of prequalified pharmaceutical products is principally intended for use by United Nations agencies \u2014 including the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children\u2019s Fund (UNICEF) and United Nations Population Fund (UNFPA) \u2014 to guide their procurement decisions. The growing list of pharmaceutical products that have been found to meet WHO-recommended standards may, however, also be of interest to other organizations and countries wishing to engage in the bulk procurement of pharmaceutical products.\n\nInclusion in the list does not imply any approval by WHO of the pharmaceutical products and manufacturing sites in question (which is the sole prerogative of national authorities). Moreover, inclusion in the list does not constitute an endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety and/or efficacy in the treatment of specific diseases.\n\n# 2. Glossary\n\nThe definitions given below apply to the terms used in this procedure. They may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nA substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2432, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "12f4ae41-e427-4736-a7ab-aacf333d0e0c": {"__data__": {"id_": "12f4ae41-e427-4736-a7ab-aacf333d0e0c", "embedding": null, "metadata": {"page_label": "387", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "direct effect in restoring, correcting or modifying physiological functions in human beings.\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s).\n\n**contract research organization (CRO)**  \nAn organization (commercial, academic or other) to which an applicant may have transferred some of its tasks and obligations in relation to the conduct of clinical studies with the product submitted to WHO for assessment under the current procedure.\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling.\n\n**invitation for expressions of interest (EOIs) or invitation**  \nInvitation calling upon interested parties (e.g. manufacturers or other applicants) to submit an expression of interest (EOI) to WHO by a specified deadline for the purpose of participating in the WHO prequalification procedure in respect of the product(s) listed in the invitation. Such an EOI should be accompanied by the required documentation on the product(s) in question.\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products.\n\n**pharmaceutical product**  \nAny substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.\n\n**prequalification**  \nStandardized quality assessment procedure of WHO to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Agencies using information resulting from the prequalification procedure should perform additional steps of qualification prior to purchasing, such as ensuring financial stability and standing of the supplier, ability to supply the required quantities, security of the supply chain, preshipment quality control and other related aspects.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) describe procedimientos relacionados con la precalificaci\u00f3n de productos farmac\u00e9uticos. Define t\u00e9rminos clave como \"solicitante\", \"organizaci\u00f3n de investigaci\u00f3n por contrato (CRO)\", \"producto farmac\u00e9utico terminado (FPP)\", \"invitaci\u00f3n para expresiones de inter\u00e9s (EOIs)\", \"fabricante\", \"producto farmac\u00e9utico\" y \"precalificaci\u00f3n\". La precalificaci\u00f3n es un procedimiento estandarizado de evaluaci\u00f3n de calidad que permite a las agencias de las Naciones Unidas evaluar la aceptabilidad de productos farmac\u00e9uticos para su compra.\n\n### Preguntas\n1. **\u00bfQu\u00e9 documentaci\u00f3n debe presentar un solicitante junto con su expresi\u00f3n de inter\u00e9s (EOI) para participar en el procedimiento de precalificaci\u00f3n de la OMS?**\n   - Respuesta: El solicitante debe presentar la documentaci\u00f3n requerida sobre los productos listados en la invitaci\u00f3n junto con su expresi\u00f3n de inter\u00e9s (EOI).\n\n2. **\u00bfCu\u00e1l es el papel de una organizaci\u00f3n de investigaci\u00f3n por contrato (CRO) en el proceso de evaluaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS?**\n   - Respuesta: Una CRO es una organizaci\u00f3n a la que el solicitante puede haber transferido algunas de sus tareas y obligaciones relacionadas con la realizaci\u00f3n de estudios cl\u00ednicos del producto que se presenta a la OMS para su evaluaci\u00f3n.\n\n3. **\u00bfQu\u00e9 pasos adicionales deben realizar las agencias que utilizan la informaci\u00f3n de la precalificaci\u00f3n de la OMS antes de realizar una compra?**\n   - Respuesta: Las agencias deben llevar a cabo pasos adicionales de calificaci\u00f3n, como asegurar la estabilidad financiera y la reputaci\u00f3n del proveedor, la capacidad de suministrar las cantidades requeridas, la seguridad de la cadena de suministro, el control de calidad previo al env\u00edo y otros aspectos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS asesora a las agencias de las Naciones Unidas sobre la aceptabilidad de productos farmac\u00e9uticos para su adquisici\u00f3n.\n\n2. **Evaluaci\u00f3n de Calidad**: La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos, que incluye:\n   - Revisi\u00f3n de informaci\u00f3n proporcionada por los fabricantes.\n   - Inspecci\u00f3n de instalaciones de fabricaci\u00f3n y sitios cl\u00ednicos.\n   - Procedimientos estandarizados basados en normas de calidad recomendadas por la OMS.\n\n3. **Lista de Precalificaci\u00f3n**: Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS son incluidos en una lista destinada a guiar las decisiones de compra de agencias de la ONU, como:\n   - Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (UNAIDS).\n   - Fondo de las Naciones Unidas para la Infancia (UNICEF).\n   - Fondo de Poblaci\u00f3n de las Naciones Unidas (UNFPA).\n\n4. **Limitaciones de la Inclusi\u00f3n**: La inclusi\u00f3n en la lista no implica:\n   - Aprobaci\u00f3n de la OMS sobre los productos o sitios de fabricaci\u00f3n (esto es prerrogativa de las autoridades nacionales).\n   - Respaldo o garant\u00eda de la OMS sobre la idoneidad de los productos para usos espec\u00edficos, incluyendo su seguridad y eficacia en el tratamiento de enfermedades.\n\n5. **Ingrediente Farmac\u00e9utico Activo (API)**: Se define como una sustancia utilizada en un producto farmac\u00e9utico terminado que tiene actividad farmacol\u00f3gica o efecto directo en el diagn\u00f3stico, tratamiento o prevenci\u00f3n de enfermedades.\n\n### Entidades Clave\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **Agencias de la ONU**: Incluyen UNAIDS, UNICEF y UNFPA.\n- **Productos Farmac\u00e9uticos**: Medicamentos que cumplen con los est\u00e1ndares de calidad de la OMS.\n- **Autoridades Nacionales**: Entidades responsables de la aprobaci\u00f3n de productos farmac\u00e9uticos en sus respectivos pa\u00edses.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical product, expression of interest, contract research organization, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bc46a659-b482-46d9-92e2-51b58bc4d3b3", "node_type": "4", "metadata": {"page_label": "387", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "direct effect in restoring, correcting or modifying physiological functions in human beings.\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s).\n\n**contract research organization (CRO)**  \nAn organization (commercial, academic or other) to which an applicant may have transferred some of its tasks and obligations in relation to the conduct of clinical studies with the product submitted to WHO for assessment under the current procedure.\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling.\n\n**invitation for expressions of interest (EOIs) or invitation**  \nInvitation calling upon interested parties (e.g. manufacturers or other applicants) to submit an expression of interest (EOI) to WHO by a specified deadline for the purpose of participating in the WHO prequalification procedure in respect of the product(s) listed in the invitation. Such an EOI should be accompanied by the required documentation on the product(s) in question.\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products.\n\n**pharmaceutical product**  \nAny substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.\n\n**prequalification**  \nStandardized quality assessment procedure of WHO to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Agencies using information resulting from the prequalification procedure should perform additional steps of qualification prior to purchasing, such as ensuring financial stability and standing of the supplier, ability to supply the required quantities, security of the supply chain, preshipment quality control and other related aspects.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "60501fa124b34b06b639a8281dc9d0d8b1472fc38f9e70370198265576571f02", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "direct effect in restoring, correcting or modifying physiological functions in human beings.\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s).\n\n**contract research organization (CRO)**  \nAn organization (commercial, academic or other) to which an applicant may have transferred some of its tasks and obligations in relation to the conduct of clinical studies with the product submitted to WHO for assessment under the current procedure.\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling.\n\n**invitation for expressions of interest (EOIs) or invitation**  \nInvitation calling upon interested parties (e.g. manufacturers or other applicants) to submit an expression of interest (EOI) to WHO by a specified deadline for the purpose of participating in the WHO prequalification procedure in respect of the product(s) listed in the invitation. Such an EOI should be accompanied by the required documentation on the product(s) in question.\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products.\n\n**pharmaceutical product**  \nAny substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.\n\n**prequalification**  \nStandardized quality assessment procedure of WHO to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Agencies using information resulting from the prequalification procedure should perform additional steps of qualification prior to purchasing, such as ensuring financial stability and standing of the supplier, ability to supply the required quantities, security of the supply chain, preshipment quality control and other related aspects.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2258, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0d35f700-67ae-435e-8719-cd0947ff5ce0": {"__data__": {"id_": "0d35f700-67ae-435e-8719-cd0947ff5ce0", "embedding": null, "metadata": {"page_label": "388", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Stringent Regulatory Authority (SRA)\n\nFor the purpose of this procedure, a stringent regulatory authority (SRA) is:\n\n- The medicines regulatory authority in a country which is: \n  - (a) a member of the International Conference on Harmonisation (ICH) (European Union (EU) Japan and the United States of America); or \n  - (b) an ICH Observer, being the European Free Trade Association (EFTA) as represented by SwissMedic and Health Canada (as may be updated from time to time); or \n  - (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time); and\n- Only in relation to good manufacturing practices (GMP) inspections: a medicine regulatory authority that is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as specified at http://www.picscheme.org.\n\n## 3. Purpose and Principles\n\nThe purpose of this WHO procedure is to evaluate whether certain pharmaceutical products (considered by WHO to be vital for the prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, malaria and other diseases, or for reproductive health) meet the requirements recommended by WHO and are manufactured in compliance with current good manufacturing practices (hereinafter referred to as GMP).\n\nThis procedure established by WHO is based on the following principles:\n\n- The medicines eligible for prequalification are listed in invitations for EOI published on the WHO web site (http://who.int/prequal/info_applicants/info_for_applicants_EOIs.htm);\n- A general understanding of the production and quality control activities of the manufacturer;\n- Assessment of pharmaceutical product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results;\n- Inspection of finished pharmaceutical product (FPP) and active pharmaceutical ingredient (API) manufacturing site(s) for compliance with GMP;\n- Inspection of clinical testing units or contract research organizations (CROs) performing clinical trials for compliance with current good clinical practices (hereinafter referred to as GCP) and current good laboratory practices (hereinafter referred to as GLP);\n- Reliance on the information supplied by stringent national medicines regulatory authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece definiciones y procedimientos relacionados con las autoridades regulatorias estrictas (SRA) y su papel en la evaluaci\u00f3n de productos farmac\u00e9uticos. Se centra en la pre-calificaci\u00f3n de medicamentos esenciales para el tratamiento de enfermedades como el VIH/SIDA, tuberculosis y malaria, asegurando que cumplan con las buenas pr\u00e1cticas de manufactura (GMP). El procedimiento incluye la evaluaci\u00f3n de datos de seguridad, eficacia y calidad, as\u00ed como inspecciones de sitios de fabricaci\u00f3n y ensayos cl\u00ednicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios definen a una autoridad regulatoria estricta (SRA) seg\u00fan la OMS?**\n   - La OMS define una SRA como una autoridad regulatoria de medicamentos en un pa\u00eds que es miembro de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), un observador de la ICH, o una autoridad asociada a un miembro de la ICH mediante un acuerdo de reconocimiento mutuo. Adem\u00e1s, en relaci\u00f3n con las inspecciones de GMP, debe ser miembro del esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica (PIC/S).\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito principal del procedimiento establecido por la OMS en relaci\u00f3n con los productos farmac\u00e9uticos?**\n   - El prop\u00f3sito principal es evaluar si ciertos productos farmac\u00e9uticos, considerados vitales para la prevenci\u00f3n y tratamiento de enfermedades como el VIH/SIDA, tuberculosis y malaria, cumplen con los requisitos recomendados por la OMS y son fabricados de acuerdo con las buenas pr\u00e1cticas de manufactura (GMP).\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se eval\u00faa durante el proceso de pre-calificaci\u00f3n de medicamentos seg\u00fan la OMS?**\n   - Durante el proceso de pre-calificaci\u00f3n, se eval\u00faa la informaci\u00f3n sobre la producci\u00f3n y control de calidad del fabricante, as\u00ed como datos sobre la seguridad, eficacia y calidad del producto farmac\u00e9utico, incluyendo formulaciones, datos de fabricaci\u00f3n y resultados de pruebas. Tambi\u00e9n se realizan inspecciones de los sitios de fabricaci\u00f3n y de las unidades de ensayo cl\u00ednico para verificar el cumplimiento de las buenas pr\u00e1cticas cl\u00ednicas (GCP) y de laboratorio (GLP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, definiendo varios t\u00e9rminos y conceptos esenciales relacionados con este procedimiento. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Solicitante (Applicant)**: Persona o entidad que presenta una expresi\u00f3n de inter\u00e9s (EOI) para participar en el procedimiento de precalificaci\u00f3n, junto con la documentaci\u00f3n requerida sobre los productos.\n\n2. **Organizaci\u00f3n de Investigaci\u00f3n por Contrato (CRO)**: Entidad a la que el solicitante puede haber delegado algunas de sus tareas y obligaciones en la realizaci\u00f3n de estudios cl\u00ednicos del producto que se eval\u00faa.\n\n3. **Producto Farmac\u00e9utico Terminado (FPP)**: Forma de dosificaci\u00f3n final de un producto farmac\u00e9utico que ha completado todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado y etiquetado.\n\n4. **Invitaci\u00f3n para Expresiones de Inter\u00e9s (EOIs)**: Convocatoria a partes interesadas (como fabricantes) para que presenten una EOI a la OMS dentro de un plazo espec\u00edfico, acompa\u00f1ada de la documentaci\u00f3n requerida.\n\n5. **Fabricante (Manufacturer)**: Empresa responsable de la producci\u00f3n, empaquetado, reempaquetado, etiquetado y/o reetiquetado de productos farmac\u00e9uticos.\n\n6. **Producto Farmac\u00e9utico (Pharmaceutical Product)**: Sustancia o combinaci\u00f3n de sustancias comercializadas para tratar o prevenir enfermedades en humanos, realizar diagn\u00f3sticos m\u00e9dicos o modificar funciones fisiol\u00f3gicas.\n\n7. **Precalificaci\u00f3n (Prequalification)**: Procedimiento estandarizado de evaluaci\u00f3n de calidad de la OMS para determinar la aceptabilidad de productos farmac\u00e9uticos para la compra por agencias de las Naciones Unidas. Este proceso incluye pasos adicionales de calificaci\u00f3n antes de la compra.\n\n### Conclusi\u00f3n\nEl documento establece un marco claro para la participaci\u00f3n en el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, definiendo roles y responsabilidades de los solicitantes, fabricantes y organizaciones involucradas en la investigaci\u00f3n y evaluaci\u00f3n de estos productos.", "excerpt_keywords": "Keywords: regulatory authority, prequalification, good manufacturing practices, pharmaceutical products, WHO"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31786909-1a60-4d8a-b031-3fbeee0ddf5b", "node_type": "4", "metadata": {"page_label": "388", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Stringent Regulatory Authority (SRA)\n\nFor the purpose of this procedure, a stringent regulatory authority (SRA) is:\n\n- The medicines regulatory authority in a country which is: \n  - (a) a member of the International Conference on Harmonisation (ICH) (European Union (EU) Japan and the United States of America); or \n  - (b) an ICH Observer, being the European Free Trade Association (EFTA) as represented by SwissMedic and Health Canada (as may be updated from time to time); or \n  - (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time); and\n- Only in relation to good manufacturing practices (GMP) inspections: a medicine regulatory authority that is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as specified at http://www.picscheme.org.\n\n## 3. Purpose and Principles\n\nThe purpose of this WHO procedure is to evaluate whether certain pharmaceutical products (considered by WHO to be vital for the prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, malaria and other diseases, or for reproductive health) meet the requirements recommended by WHO and are manufactured in compliance with current good manufacturing practices (hereinafter referred to as GMP).\n\nThis procedure established by WHO is based on the following principles:\n\n- The medicines eligible for prequalification are listed in invitations for EOI published on the WHO web site (http://who.int/prequal/info_applicants/info_for_applicants_EOIs.htm);\n- A general understanding of the production and quality control activities of the manufacturer;\n- Assessment of pharmaceutical product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results;\n- Inspection of finished pharmaceutical product (FPP) and active pharmaceutical ingredient (API) manufacturing site(s) for compliance with GMP;\n- Inspection of clinical testing units or contract research organizations (CROs) performing clinical trials for compliance with current good clinical practices (hereinafter referred to as GCP) and current good laboratory practices (hereinafter referred to as GLP);\n- Reliance on the information supplied by stringent national medicines regulatory authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3745aabe8d7eed9a359198d97166795c76d27767e25c53c8f3c1bd15a38fb6cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Stringent Regulatory Authority (SRA)\n\nFor the purpose of this procedure, a stringent regulatory authority (SRA) is:\n\n- The medicines regulatory authority in a country which is: \n  - (a) a member of the International Conference on Harmonisation (ICH) (European Union (EU) Japan and the United States of America); or \n  - (b) an ICH Observer, being the European Free Trade Association (EFTA) as represented by SwissMedic and Health Canada (as may be updated from time to time); or \n  - (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time); and\n- Only in relation to good manufacturing practices (GMP) inspections: a medicine regulatory authority that is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as specified at http://www.picscheme.org.\n\n## 3. Purpose and Principles\n\nThe purpose of this WHO procedure is to evaluate whether certain pharmaceutical products (considered by WHO to be vital for the prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, malaria and other diseases, or for reproductive health) meet the requirements recommended by WHO and are manufactured in compliance with current good manufacturing practices (hereinafter referred to as GMP).\n\nThis procedure established by WHO is based on the following principles:\n\n- The medicines eligible for prequalification are listed in invitations for EOI published on the WHO web site (http://who.int/prequal/info_applicants/info_for_applicants_EOIs.htm);\n- A general understanding of the production and quality control activities of the manufacturer;\n- Assessment of pharmaceutical product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results;\n- Inspection of finished pharmaceutical product (FPP) and active pharmaceutical ingredient (API) manufacturing site(s) for compliance with GMP;\n- Inspection of clinical testing units or contract research organizations (CROs) performing clinical trials for compliance with current good clinical practices (hereinafter referred to as GCP) and current good laboratory practices (hereinafter referred to as GLP);\n- Reliance on the information supplied by stringent national medicines regulatory authorities.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2451, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bf89d188-c06e-402a-9c1f-7b3fe3b6a438": {"__data__": {"id_": "bf89d188-c06e-402a-9c1f-7b3fe3b6a438", "embedding": null, "metadata": {"page_label": "389", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the Procedure\n\nWHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the applicants, and inspection of the relevant manufacturing and clinical sites. (A flowchart showing the prequalification process is provided in Appendix 1.)\n\nAt regular intervals, and also taking into consideration pertinent input received from relevant United Nations agencies, WHO will publish an invitation to interested parties, requesting them to voluntarily participate in this procedure in respect of the products mentioned in the invitation.\n\nBy submitting an EOI, the applicant undertakes to share information with WHO on all relevant aspects of manufacture and control of the specified products along with changes made and/or planned. Interested applicants provide the necessary information to WHO by submitting a product dossier in the prescribed format, and other information as requested.\n\nThe procedure will normally include:\n\n- Assessment of product dossiers, which must include product data and information as specified in the guidelines for submission, available on the WHO website (http://apps.who.int/prequal/);\n- Inspection of manufacturing sites of FPPs and active pharmaceutical ingredients (APIs), to assess compliance with GMP;\n- Inspection of clinical sites (if applicable), to assess compliance with GCP and GLP as appropriate.\n\nIf the evaluation above demonstrates that a product and its corresponding manufacturing (and clinical) site(s) meet WHO-recommended standards, WHO may collaborate with national medicines regulatory authorities (NMRAs) regarding dossier assessments and inspections. Subject to the terms of section 4 below, the prequalification of a product may also be based on approval by a stringent regulatory authority (SRA).\n\nWHO recommends that applicants expressing interest in participation in the prequalification procedure inform the NMRAs in the country of manufacture of their intention and request them to collaborate with WHO in the quality assessment process. It is recommended that applicants provide the NMRAs with the necessary authorization to discuss the relevant product files with WHO representatives during dossier assessment and site inspections (subject to appropriate confidentiality provisions, if necessary).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nLa Organizaci\u00f3n Mundial de la Salud (OMS) lleva a cabo una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos a trav\u00e9s de la revisi\u00f3n de la informaci\u00f3n presentada por los solicitantes y la inspecci\u00f3n de los sitios de fabricaci\u00f3n y cl\u00ednicos relevantes. El proceso de precalificaci\u00f3n incluye la evaluaci\u00f3n de expedientes de productos, inspecciones de sitios de fabricaci\u00f3n y cl\u00ednicas, y la colaboraci\u00f3n con autoridades regulatorias nacionales. Se recomienda que los solicitantes informen a las autoridades regulatorias sobre su intenci\u00f3n de participar en el proceso de precalificaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluir un expediente de producto para ser evaluado por la OMS?**\n   - La OMS requiere que el expediente de producto incluya datos e informaci\u00f3n espec\u00edficos seg\u00fan las pautas de presentaci\u00f3n disponibles en su sitio web.\n\n2. **\u00bfCu\u00e1l es el papel de las autoridades regulatorias nacionales (NMRAs) en el proceso de precalificaci\u00f3n de la OMS?**\n   - Las NMRAs colaboran con la OMS en la evaluaci\u00f3n de expedientes y en las inspecciones de los sitios de fabricaci\u00f3n y cl\u00ednicos, y se recomienda que los solicitantes les informen sobre su intenci\u00f3n de participar en el proceso.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un producto sea precalificado por la OMS?**\n   - Un producto y sus sitios de fabricaci\u00f3n y cl\u00ednicos deben cumplir con los est\u00e1ndares recomendados por la OMS, y la precalificaci\u00f3n tambi\u00e9n puede basarse en la aprobaci\u00f3n por parte de una autoridad reguladora estricta (SRA).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Autoridad Regulatoria Estricta (SRA):**\n   - Definici\u00f3n de SRA como la autoridad regulatoria de medicamentos en pa\u00edses miembros de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), observadores de la ICH, o autoridades asociadas mediante acuerdos de reconocimiento mutuo.\n   - Inclusi\u00f3n de miembros del esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica (PIC/S) en relaci\u00f3n con las inspecciones de buenas pr\u00e1cticas de manufactura (GMP).\n\n2. **Prop\u00f3sito del Procedimiento de la OMS:**\n   - Evaluar productos farmac\u00e9uticos vitales para el tratamiento de enfermedades como VIH/SIDA, tuberculosis y malaria, asegurando que cumplan con los requisitos de la OMS y las GMP.\n\n3. **Principios del Procedimiento:**\n   - Inclusi\u00f3n de medicamentos elegibles en invitaciones publicadas en el sitio web de la OMS.\n   - Evaluaci\u00f3n de la producci\u00f3n y control de calidad del fabricante.\n   - Inspecciones de sitios de fabricaci\u00f3n y unidades de ensayo cl\u00ednico para verificar el cumplimiento de las GMP, buenas pr\u00e1cticas cl\u00ednicas (GCP) y buenas pr\u00e1cticas de laboratorio (GLP).\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Responsable de establecer el procedimiento y los criterios de evaluaci\u00f3n.\n- **Conferencia Internacional sobre Armonizaci\u00f3n (ICH):** Incluye a la Uni\u00f3n Europea, Jap\u00f3n y Estados Unidos.\n- **Asociaci\u00f3n Europea de Libre Comercio (EFTA):** Representada por SwissMedic y Health Canada.\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica (PIC/S):** Relacionado con las inspecciones de GMP.\n- **Productos Farmac\u00e9uticos:** Medicamentos considerados esenciales para la salud p\u00fablica y su evaluaci\u00f3n para la pre-calificaci\u00f3n. \n\nEste resumen destaca los elementos esenciales del procedimiento de la OMS en relaci\u00f3n con las autoridades regulatorias y la evaluaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, regulatory authorities, quality assessment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40f03c60-2c61-4687-ae54-fc20c1534fe7", "node_type": "4", "metadata": {"page_label": "389", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the Procedure\n\nWHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the applicants, and inspection of the relevant manufacturing and clinical sites. (A flowchart showing the prequalification process is provided in Appendix 1.)\n\nAt regular intervals, and also taking into consideration pertinent input received from relevant United Nations agencies, WHO will publish an invitation to interested parties, requesting them to voluntarily participate in this procedure in respect of the products mentioned in the invitation.\n\nBy submitting an EOI, the applicant undertakes to share information with WHO on all relevant aspects of manufacture and control of the specified products along with changes made and/or planned. Interested applicants provide the necessary information to WHO by submitting a product dossier in the prescribed format, and other information as requested.\n\nThe procedure will normally include:\n\n- Assessment of product dossiers, which must include product data and information as specified in the guidelines for submission, available on the WHO website (http://apps.who.int/prequal/);\n- Inspection of manufacturing sites of FPPs and active pharmaceutical ingredients (APIs), to assess compliance with GMP;\n- Inspection of clinical sites (if applicable), to assess compliance with GCP and GLP as appropriate.\n\nIf the evaluation above demonstrates that a product and its corresponding manufacturing (and clinical) site(s) meet WHO-recommended standards, WHO may collaborate with national medicines regulatory authorities (NMRAs) regarding dossier assessments and inspections. Subject to the terms of section 4 below, the prequalification of a product may also be based on approval by a stringent regulatory authority (SRA).\n\nWHO recommends that applicants expressing interest in participation in the prequalification procedure inform the NMRAs in the country of manufacture of their intention and request them to collaborate with WHO in the quality assessment process. It is recommended that applicants provide the NMRAs with the necessary authorization to discuss the relevant product files with WHO representatives during dossier assessment and site inspections (subject to appropriate confidentiality provisions, if necessary).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1f3a971c81fce95556ee8ceca4dbc6424d1509baa5d0127fd43c7e65be4e2316", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Steps of the Procedure\n\nWHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the applicants, and inspection of the relevant manufacturing and clinical sites. (A flowchart showing the prequalification process is provided in Appendix 1.)\n\nAt regular intervals, and also taking into consideration pertinent input received from relevant United Nations agencies, WHO will publish an invitation to interested parties, requesting them to voluntarily participate in this procedure in respect of the products mentioned in the invitation.\n\nBy submitting an EOI, the applicant undertakes to share information with WHO on all relevant aspects of manufacture and control of the specified products along with changes made and/or planned. Interested applicants provide the necessary information to WHO by submitting a product dossier in the prescribed format, and other information as requested.\n\nThe procedure will normally include:\n\n- Assessment of product dossiers, which must include product data and information as specified in the guidelines for submission, available on the WHO website (http://apps.who.int/prequal/);\n- Inspection of manufacturing sites of FPPs and active pharmaceutical ingredients (APIs), to assess compliance with GMP;\n- Inspection of clinical sites (if applicable), to assess compliance with GCP and GLP as appropriate.\n\nIf the evaluation above demonstrates that a product and its corresponding manufacturing (and clinical) site(s) meet WHO-recommended standards, WHO may collaborate with national medicines regulatory authorities (NMRAs) regarding dossier assessments and inspections. Subject to the terms of section 4 below, the prequalification of a product may also be based on approval by a stringent regulatory authority (SRA).\n\nWHO recommends that applicants expressing interest in participation in the prequalification procedure inform the NMRAs in the country of manufacture of their intention and request them to collaborate with WHO in the quality assessment process. It is recommended that applicants provide the NMRAs with the necessary authorization to discuss the relevant product files with WHO representatives during dossier assessment and site inspections (subject to appropriate confidentiality provisions, if necessary).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2321, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f6e1407b-1c99-440b-bead-f26c0c0cdaaa": {"__data__": {"id_": "f6e1407b-1c99-440b-bead-f26c0c0cdaaa", "embedding": null, "metadata": {"page_label": "390", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the product will be included in the list of pharmaceutical products that are considered to be acceptable, in principle, for procurement by United Nations agencies.\n\nWHO reserves the right to terminate the evaluation of a specific product if the applicant is not able to provide the required information, and/or is unable to implement any corrective actions which WHO may require within a specified time period, or when the information supplied is inadequate to complete this procedure.\n\nWHO recognizes the evaluation of relevant products by SRAs which apply standards for quality equivalent to those recommended by WHO. Provided that the NMRA is willing to share certain information with WHO on the products in question, WHO will consider such products for inclusion in the list of WHO-prequalified products. It will do so as and when information about such products becomes available to WHO and when the holders of the regulatory approval of such products express their interest in having these products prequalified by WHO. These products will be added to the list of products prequalified by WHO, on the basis of the scientific assessment and inspections conducted by the regulatory authority concerned, and the exchange of relevant information between the regulatory authority and WHO.\n\nAn inspection of a manufacturer or CRO may not be required if:\n\n1. There has been an inspection by an SRA; and\n2. The inspection was conducted within the last three years; and\n3. Information on the inspection (including inspection report and responses to any deficiencies) is available for review by WHO; and\n4. Based on this and other available information, it is determined that the site(s) in question meet(s) the applicable WHO-recommended standards.\n\nWith a view to coordinating inspection activities, avoiding duplication and promoting information sharing without prejudice to the protection of any confidential and or proprietary information of the applicants and manufacturers in accordance with the terms of this procedure, WHO may disclose inspection related information to regulatory authorities of WHO Member States as well as to regulatory authorities that are members of the PIC/S.\n\n## 5. Invitation for expressions of interest\n\nThe pharmaceutical products listed in an invitation for EOIs are considered by WHO to be vital for the effective treatment and prevention of the\n\n----\n\n1 Taking into account any known specific risk(s) associated with the product(s), the results of previous inspections conducted by WHO or an SRA, any complaints (if known), the scope and detail of the inspection report, the number and type of any GMP deficiencies reported, the comprehensiveness of the manufacturer\u2019s response and the timelines for implementation of corrective action(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece los procedimientos para la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos destinados a la adquisici\u00f3n por parte de agencias de las Naciones Unidas. Se menciona que la OMS puede terminar la evaluaci\u00f3n de un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa las acciones correctivas necesarias. Adem\u00e1s, se reconoce la evaluaci\u00f3n de productos por parte de Autoridades Reguladoras de Salud (SRA) que aplican est\u00e1ndares de calidad equivalentes a los de la OMS. Tambi\u00e9n se detalla que, bajo ciertas condiciones, no se requiere una inspecci\u00f3n de un fabricante si se ha realizado una inspecci\u00f3n reciente por una SRA. Finalmente, se invita a expresar inter\u00e9s en productos farmac\u00e9uticos considerados vitales para el tratamiento y prevenci\u00f3n de enfermedades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas bajo las cuales la OMS puede decidir no realizar una inspecci\u00f3n de un fabricante o CRO?**\n   - Esta pregunta busca detalles sobre los criterios que permiten a la OMS omitir una inspecci\u00f3n, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe compartir una Autoridad Nacional Reguladora de Medicamentos (NMRA) con la OMS para que sus productos sean considerados para la pre-calificaci\u00f3n?**\n   - Esta pregunta se centra en los requisitos de informaci\u00f3n que deben cumplirse para la inclusi\u00f3n en la lista de productos pre-calificados, un aspecto que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 factores se consideran al evaluar los riesgos espec\u00edficos asociados con un producto farmac\u00e9utico durante el proceso de pre-calificaci\u00f3n?**\n   - Esta pregunta busca profundizar en los criterios de evaluaci\u00f3n de riesgos que la OMS utiliza, lo cual puede no estar disponible en otras fuentes de informaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona un marco para la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la calidad y la transparencia en el proceso. Se enfatiza la colaboraci\u00f3n entre la OMS y las autoridades reguladoras nacionales, as\u00ed como la necesidad de compartir informaci\u00f3n relevante para garantizar que los productos cumplan con los est\u00e1ndares internacionales. Adem\u00e1s, se menciona la importancia de las inspecciones y la evaluaci\u00f3n de riesgos en la toma de decisiones sobre la inclusi\u00f3n de productos en la lista de pre-calificaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Calidad**: La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos, que incluye la revisi\u00f3n de informaci\u00f3n presentada por los solicitantes y la inspecci\u00f3n de sitios de fabricaci\u00f3n y cl\u00ednicos.\n\n2. **Proceso de Precalificaci\u00f3n**: El proceso incluye la evaluaci\u00f3n de expedientes de productos, inspecciones de sitios de fabricaci\u00f3n y cl\u00ednicas, y la colaboraci\u00f3n con autoridades regulatorias nacionales.\n\n3. **Documentaci\u00f3n Requerida**: Los solicitantes deben presentar un expediente de producto que contenga datos e informaci\u00f3n espec\u00edficos seg\u00fan las pautas de la OMS.\n\n4. **Colaboraci\u00f3n con NMRAs**: Se recomienda que los solicitantes informen a las autoridades regulatorias nacionales (NMRAs) sobre su intenci\u00f3n de participar en el proceso de precalificaci\u00f3n y que busquen su colaboraci\u00f3n.\n\n5. **Cumplimiento de Normas**: Para que un producto sea precalificado, debe cumplir con los est\u00e1ndares recomendados por la OMS, y la precalificaci\u00f3n tambi\u00e9n puede depender de la aprobaci\u00f3n por parte de una autoridad reguladora estricta (SRA).\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades Regulatorias Nacionales (NMRAs)**: Organismos que colaboran con la OMS en la evaluaci\u00f3n de la calidad de los productos.\n- **Autoridades Reguladoras Estrictas (SRA)**: Entidades que pueden influir en la precalificaci\u00f3n de un producto basado en su aprobaci\u00f3n.\n\nEste resumen destaca los aspectos fundamentales del proceso de precalificaci\u00f3n de la OMS y las entidades involucradas en la evaluaci\u00f3n de la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, regulatory authorities, inspection standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f3d83edb-b907-4083-baf1-c23cefa36fb7", "node_type": "4", "metadata": {"page_label": "390", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the product will be included in the list of pharmaceutical products that are considered to be acceptable, in principle, for procurement by United Nations agencies.\n\nWHO reserves the right to terminate the evaluation of a specific product if the applicant is not able to provide the required information, and/or is unable to implement any corrective actions which WHO may require within a specified time period, or when the information supplied is inadequate to complete this procedure.\n\nWHO recognizes the evaluation of relevant products by SRAs which apply standards for quality equivalent to those recommended by WHO. Provided that the NMRA is willing to share certain information with WHO on the products in question, WHO will consider such products for inclusion in the list of WHO-prequalified products. It will do so as and when information about such products becomes available to WHO and when the holders of the regulatory approval of such products express their interest in having these products prequalified by WHO. These products will be added to the list of products prequalified by WHO, on the basis of the scientific assessment and inspections conducted by the regulatory authority concerned, and the exchange of relevant information between the regulatory authority and WHO.\n\nAn inspection of a manufacturer or CRO may not be required if:\n\n1. There has been an inspection by an SRA; and\n2. The inspection was conducted within the last three years; and\n3. Information on the inspection (including inspection report and responses to any deficiencies) is available for review by WHO; and\n4. Based on this and other available information, it is determined that the site(s) in question meet(s) the applicable WHO-recommended standards.\n\nWith a view to coordinating inspection activities, avoiding duplication and promoting information sharing without prejudice to the protection of any confidential and or proprietary information of the applicants and manufacturers in accordance with the terms of this procedure, WHO may disclose inspection related information to regulatory authorities of WHO Member States as well as to regulatory authorities that are members of the PIC/S.\n\n## 5. Invitation for expressions of interest\n\nThe pharmaceutical products listed in an invitation for EOIs are considered by WHO to be vital for the effective treatment and prevention of the\n\n----\n\n1 Taking into account any known specific risk(s) associated with the product(s), the results of previous inspections conducted by WHO or an SRA, any complaints (if known), the scope and detail of the inspection report, the number and type of any GMP deficiencies reported, the comprehensiveness of the manufacturer\u2019s response and the timelines for implementation of corrective action(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "aeb6a0cb0c310c18de2fb1f36e1381b2947c790439f643615e290f0aad4a2f4c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the product will be included in the list of pharmaceutical products that are considered to be acceptable, in principle, for procurement by United Nations agencies.\n\nWHO reserves the right to terminate the evaluation of a specific product if the applicant is not able to provide the required information, and/or is unable to implement any corrective actions which WHO may require within a specified time period, or when the information supplied is inadequate to complete this procedure.\n\nWHO recognizes the evaluation of relevant products by SRAs which apply standards for quality equivalent to those recommended by WHO. Provided that the NMRA is willing to share certain information with WHO on the products in question, WHO will consider such products for inclusion in the list of WHO-prequalified products. It will do so as and when information about such products becomes available to WHO and when the holders of the regulatory approval of such products express their interest in having these products prequalified by WHO. These products will be added to the list of products prequalified by WHO, on the basis of the scientific assessment and inspections conducted by the regulatory authority concerned, and the exchange of relevant information between the regulatory authority and WHO.\n\nAn inspection of a manufacturer or CRO may not be required if:\n\n1. There has been an inspection by an SRA; and\n2. The inspection was conducted within the last three years; and\n3. Information on the inspection (including inspection report and responses to any deficiencies) is available for review by WHO; and\n4. Based on this and other available information, it is determined that the site(s) in question meet(s) the applicable WHO-recommended standards.\n\nWith a view to coordinating inspection activities, avoiding duplication and promoting information sharing without prejudice to the protection of any confidential and or proprietary information of the applicants and manufacturers in accordance with the terms of this procedure, WHO may disclose inspection related information to regulatory authorities of WHO Member States as well as to regulatory authorities that are members of the PIC/S.\n\n## 5. Invitation for expressions of interest\n\nThe pharmaceutical products listed in an invitation for EOIs are considered by WHO to be vital for the effective treatment and prevention of the\n\n----\n\n1 Taking into account any known specific risk(s) associated with the product(s), the results of previous inspections conducted by WHO or an SRA, any complaints (if known), the scope and detail of the inspection report, the number and type of any GMP deficiencies reported, the comprehensiveness of the manufacturer\u2019s response and the timelines for implementation of corrective action(s).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2773, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1fc5e80d-8172-46a6-9692-691b69114ea4": {"__data__": {"id_": "1fc5e80d-8172-46a6-9692-691b69114ea4", "embedding": null, "metadata": {"page_label": "391", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "specified diseases (including HIV/AIDS, malaria and tuberculosis) or for reproductive health. These products are normally included in either the WHO Model List of Essential Medicines or the relevant WHO treatment guidelines and recommendations (or both).\n\nThe products included in the WHO Model List of Essential Medicines are those that satisfy the priority health-care needs of a population. They are selected, among other criteria, on the basis of disease prevalence, evidence on efficacy and safety, and analysis of comparative cost-effectiveness. Products included in WHO treatment guidelines are selected on the basis of an assessment of the evidence for benefits, risks, costs and appropriateness for use in a variety of situations, taking into account the needs of special populations and the values and preferences of the groups (professional and patient) using them.\n\nEach invitation will be open and transparent, inviting all relevant parties to submit an EOI for the pharmaceutical products listed. Such an invitation will normally be published on the WHO web site and possibly also through other media, such as the international press.\n\nIn situations of high public health concern as determined by WHO, the Organization may also directly invite relevant parties to submit specified product dossiers for evaluation by WHO under this procedure without publication of an invitation for EOI.\n\n## 6. Data and information to be submitted\n\nInterested parties are expected to submit documentation on the pharmaceutical products as called for in the invitation for EOIs. Applicants should submit their product dossiers with the required information to the WHO focal point, before the deadline specified in the invitation. Guidance and instructions developed for the submission of the dossiers are made available on the WHO web site.\n\nNormally the applicants who participate in the WHO prequalification scheme for pharmaceutical products are the manufacturers of the FPPs, as specified in the invitations for EOIs. In the case that an applicant is not the manufacturer of the FPP, all relevant documentation, including (but not limited to) contract manufacturing documentation, should be submitted, demonstrating that the applicant is in full control of the manufacturing process for, and quality assurance of, the products submitted for prequalification.\n\nIn submitting an EOI for product evaluation, the applicant should send the following to the WHO focal point:\n\n- a covering letter, expressing interest in participating in the WHO prequalification procedure and confirming that the information submitted in the product dossier is complete and correct;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye la invitaci\u00f3n a partes interesadas a presentar expresiones de inter\u00e9s (EOI) para productos que satisfacen necesidades de salud prioritarias, como el VIH/SIDA, la malaria y la tuberculosis. Los productos se seleccionan en funci\u00f3n de criterios como la prevalencia de enfermedades, la eficacia, la seguridad y el costo-efectividad. Se requiere que los solicitantes presenten documentaci\u00f3n completa y precisa, y se especifican los requisitos para aquellos que no son fabricantes directos de los productos.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que utiliza la OMS para seleccionar los productos que se incluir\u00e1n en la Lista Modelo de Medicamentos Esenciales?**\n   - Esta pregunta busca detalles sobre los criterios de selecci\u00f3n que no se mencionan expl\u00edcitamente en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere de los solicitantes que no son fabricantes directos de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos para los solicitantes que act\u00faan como intermediarios, lo cual puede no estar claramente definido en otros contextos.\n\n3. **\u00bfC\u00f3mo se determina si una situaci\u00f3n de salud p\u00fablica es de alta preocupaci\u00f3n y qu\u00e9 implica esto para el proceso de evaluaci\u00f3n de productos?**\n   - Esta pregunta indaga sobre el proceso de evaluaci\u00f3n y las decisiones de la OMS en situaciones cr\u00edticas, lo que puede no estar ampliamente discutido en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n y Pre-calificaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La OMS establece procedimientos para la evaluaci\u00f3n de productos farmac\u00e9uticos que pueden ser adquiridos por agencias de la ONU.\n   - Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS pueden ser considerados para la lista de productos pre-calificados.\n\n2. **Derecho de la OMS**:\n   - La OMS se reserva el derecho de terminar la evaluaci\u00f3n de un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa acciones correctivas en el tiempo especificado.\n\n3. **Colaboraci\u00f3n con Autoridades Reguladoras**:\n   - La OMS reconoce la evaluaci\u00f3n de productos por parte de Autoridades Reguladoras de Salud (SRA) que aplican est\u00e1ndares equivalentes a los de la OMS.\n   - Se requiere que las Autoridades Nacionales Reguladoras de Medicamentos (NMRA) compartan informaci\u00f3n relevante para que sus productos sean considerados para la pre-calificaci\u00f3n.\n\n4. **Condiciones para Omitir Inspecciones**:\n   - No se requiere una inspecci\u00f3n de un fabricante o CRO si se cumplen ciertas condiciones, como la realizaci\u00f3n de una inspecci\u00f3n reciente por una SRA y la disponibilidad de informaci\u00f3n sobre dicha inspecci\u00f3n.\n\n5. **Transparencia y Compartici\u00f3n de Informaci\u00f3n**:\n   - La OMS puede compartir informaci\u00f3n relacionada con inspecciones con autoridades reguladoras de Estados Miembros de la OMS y miembros de PIC/S, respetando la confidencialidad de la informaci\u00f3n de los solicitantes y fabricantes.\n\n6. **Invitaci\u00f3n para Expresiones de Inter\u00e9s (EOIs)**:\n   - Se invita a expresar inter\u00e9s en productos farmac\u00e9uticos considerados vitales para el tratamiento y prevenci\u00f3n de enfermedades.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos.\n- **SRA (Autoridades Reguladoras de Salud)**: Entidades que eval\u00faan productos farmac\u00e9uticos y cuyos est\u00e1ndares son reconocidos por la OMS.\n- **NMRA (Autoridad Nacional Reguladora de Medicamentos)**: Entidad que debe compartir informaci\u00f3n con la OMS para la pre-calificaci\u00f3n de productos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n que promueve la cooperaci\u00f3n en inspecciones de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la calidad, la transparencia y la colaboraci\u00f3n en el proceso de evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS.", "excerpt_keywords": "Keywords: prequalification, essential medicines, WHO, pharmaceutical products, public health"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e7f686d-acd8-4588-962f-aa1a84b537ef", "node_type": "4", "metadata": {"page_label": "391", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "specified diseases (including HIV/AIDS, malaria and tuberculosis) or for reproductive health. These products are normally included in either the WHO Model List of Essential Medicines or the relevant WHO treatment guidelines and recommendations (or both).\n\nThe products included in the WHO Model List of Essential Medicines are those that satisfy the priority health-care needs of a population. They are selected, among other criteria, on the basis of disease prevalence, evidence on efficacy and safety, and analysis of comparative cost-effectiveness. Products included in WHO treatment guidelines are selected on the basis of an assessment of the evidence for benefits, risks, costs and appropriateness for use in a variety of situations, taking into account the needs of special populations and the values and preferences of the groups (professional and patient) using them.\n\nEach invitation will be open and transparent, inviting all relevant parties to submit an EOI for the pharmaceutical products listed. Such an invitation will normally be published on the WHO web site and possibly also through other media, such as the international press.\n\nIn situations of high public health concern as determined by WHO, the Organization may also directly invite relevant parties to submit specified product dossiers for evaluation by WHO under this procedure without publication of an invitation for EOI.\n\n## 6. Data and information to be submitted\n\nInterested parties are expected to submit documentation on the pharmaceutical products as called for in the invitation for EOIs. Applicants should submit their product dossiers with the required information to the WHO focal point, before the deadline specified in the invitation. Guidance and instructions developed for the submission of the dossiers are made available on the WHO web site.\n\nNormally the applicants who participate in the WHO prequalification scheme for pharmaceutical products are the manufacturers of the FPPs, as specified in the invitations for EOIs. In the case that an applicant is not the manufacturer of the FPP, all relevant documentation, including (but not limited to) contract manufacturing documentation, should be submitted, demonstrating that the applicant is in full control of the manufacturing process for, and quality assurance of, the products submitted for prequalification.\n\nIn submitting an EOI for product evaluation, the applicant should send the following to the WHO focal point:\n\n- a covering letter, expressing interest in participating in the WHO prequalification procedure and confirming that the information submitted in the product dossier is complete and correct;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cf2e3f93fb449aff61d160ca0eeadf946f96c48d08509749aa83854434bbb19a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "specified diseases (including HIV/AIDS, malaria and tuberculosis) or for reproductive health. These products are normally included in either the WHO Model List of Essential Medicines or the relevant WHO treatment guidelines and recommendations (or both).\n\nThe products included in the WHO Model List of Essential Medicines are those that satisfy the priority health-care needs of a population. They are selected, among other criteria, on the basis of disease prevalence, evidence on efficacy and safety, and analysis of comparative cost-effectiveness. Products included in WHO treatment guidelines are selected on the basis of an assessment of the evidence for benefits, risks, costs and appropriateness for use in a variety of situations, taking into account the needs of special populations and the values and preferences of the groups (professional and patient) using them.\n\nEach invitation will be open and transparent, inviting all relevant parties to submit an EOI for the pharmaceutical products listed. Such an invitation will normally be published on the WHO web site and possibly also through other media, such as the international press.\n\nIn situations of high public health concern as determined by WHO, the Organization may also directly invite relevant parties to submit specified product dossiers for evaluation by WHO under this procedure without publication of an invitation for EOI.\n\n## 6. Data and information to be submitted\n\nInterested parties are expected to submit documentation on the pharmaceutical products as called for in the invitation for EOIs. Applicants should submit their product dossiers with the required information to the WHO focal point, before the deadline specified in the invitation. Guidance and instructions developed for the submission of the dossiers are made available on the WHO web site.\n\nNormally the applicants who participate in the WHO prequalification scheme for pharmaceutical products are the manufacturers of the FPPs, as specified in the invitations for EOIs. In the case that an applicant is not the manufacturer of the FPP, all relevant documentation, including (but not limited to) contract manufacturing documentation, should be submitted, demonstrating that the applicant is in full control of the manufacturing process for, and quality assurance of, the products submitted for prequalification.\n\nIn submitting an EOI for product evaluation, the applicant should send the following to the WHO focal point:\n\n- a covering letter, expressing interest in participating in the WHO prequalification procedure and confirming that the information submitted in the product dossier is complete and correct;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2659, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9bed7da8-4e7a-464a-9445-feeb81bdd9df": {"__data__": {"id_": "9bed7da8-4e7a-464a-9445-feeb81bdd9df", "embedding": null, "metadata": {"page_label": "392", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a product dossier, in the format specified in the WHO guidance documents on submitting product data and information;\n- product samples, to enable visual examination and chemical and pharmaceutical analysis;\n- a site master file (SMF) for each manufacturing site listed in the product dossier, in the format specified in the WHO guidance documents for submitting an SMF; and\n- a contract research organization master file (CROMF) for each clinical site listed in the dossier, in the format specified in the WHO guidance documents for submitting a CROMF.\n\nAll documentation should be submitted in English.\n\nFor the purposes of this procedure, different requirements for documentation to be submitted apply to the following categories of products:\n\n- multisource (generic) FPPs to be assessed by WHO;\n- innovator FPPs approved by SRAs; and\n- multisource (generic) FPPs approved by SRAs.\n\nThe documentation requirements for each of the above categories can be found on the WHO web site at: http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nMultisource generic products must be shown, either directly or indirectly, to be therapeutically equivalent to the comparator product if they are to be considered interchangeable. WHO will maintain and make public the list of comparator products for this purpose. The WHO web site provides guidance on the evidence needed for a product to be considered equivalent without the need for in vivo equivalence studies (i.e. application of biowaiver).\n\nIf considered necessary or desirable by either party, and before the actual evaluation process starts, a discussion may be held between the manufacturer and WHO. This meeting should be scheduled as early as possible with a predefined agenda to address questions sent in advance to WHO by the manufacturer.\n\n## 7. Screening of dossiers submitted\n\nEach product dossier submitted by an applicant will be screened for completeness before being evaluated. Dossiers submitted for products which are not listed in an invitation for EOIs or have not otherwise been invited by WHO will not be accepted for assessment.\n\nSimilarly WHO will not consider dossiers that are incomplete. The applicant will be informed that an incomplete dossier has been received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece los requisitos para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, incluyendo la necesidad de un dossier de producto, muestras del producto, un archivo maestro del sitio de fabricaci\u00f3n (SMF) y un archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF). Se especifican diferentes requisitos de documentaci\u00f3n seg\u00fan el tipo de producto (multisource, innovador, etc.) y se menciona la importancia de demostrar la equivalencia terap\u00e9utica para los productos gen\u00e9ricos. Adem\u00e1s, se indica que los dossiers ser\u00e1n revisados por su integridad antes de la evaluaci\u00f3n y que no se aceptar\u00e1n aquellos que no cumplan con los criterios establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere espec\u00edficamente para los productos multisource (gen\u00e9ricos) que se eval\u00faan por la OMS?**\n   - La OMS requiere un dossier de producto, muestras del producto, un archivo maestro del sitio de fabricaci\u00f3n (SMF) y un archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF) para los productos multisource.\n\n2. **\u00bfC\u00f3mo puede un producto gen\u00e9rico ser considerado intercambiable con un producto de referencia seg\u00fan la OMS?**\n   - Un producto gen\u00e9rico debe demostrar, directa o indirectamente, que es terap\u00e9uticamente equivalente al producto de referencia para ser considerado intercambiable. La OMS mantiene una lista p\u00fablica de productos de referencia para este prop\u00f3sito.\n\n3. **\u00bfQu\u00e9 sucede si un dossier presentado a la OMS est\u00e1 incompleto?**\n   - Si un dossier est\u00e1 incompleto, la OMS no lo considerar\u00e1 para evaluaci\u00f3n y el solicitante ser\u00e1 informado de que se ha recibido un dossier incompleto.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la presentaci\u00f3n de documentaci\u00f3n para la evaluaci\u00f3n de productos farmac\u00e9uticos, diferenciando entre productos gen\u00e9ricos e innovadores. Se enfatiza la necesidad de cumplir con requisitos espec\u00edficos y de demostrar equivalencia terap\u00e9utica para los productos gen\u00e9ricos. Adem\u00e1s, se establece un proceso de revisi\u00f3n de la integridad de los dossiers antes de su evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Proceso de Precalificaci\u00f3n de Productos Farmac\u00e9uticos**: El documento describe el procedimiento de la OMS para la precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye la invitaci\u00f3n a partes interesadas a presentar expresiones de inter\u00e9s (EOI) para productos que abordan necesidades de salud prioritarias.\n\n2. **Enfermedades Espec\u00edficas**: Se mencionan enfermedades como el VIH/SIDA, malaria y tuberculosis, as\u00ed como la salud reproductiva, como \u00e1reas de enfoque para la inclusi\u00f3n de productos en la Lista Modelo de Medicamentos Esenciales de la OMS.\n\n3. **Criterios de Selecci\u00f3n**: Los productos se seleccionan bas\u00e1ndose en la prevalencia de enfermedades, la evidencia de eficacia y seguridad, y el an\u00e1lisis de costo-efectividad. Tambi\u00e9n se consideran las necesidades de poblaciones especiales y las preferencias de los grupos involucrados.\n\n4. **Transparencia en el Proceso**: Las invitaciones para presentar EOIs son abiertas y transparentes, public\u00e1ndose en el sitio web de la OMS y, potencialmente, en otros medios.\n\n5. **Situaciones de Alta Preocupaci\u00f3n de Salud P\u00fablica**: La OMS puede invitar directamente a partes relevantes a presentar dossiers de productos para evaluaci\u00f3n sin necesidad de una invitaci\u00f3n p\u00fablica en situaciones de alta preocupaci\u00f3n.\n\n6. **Documentaci\u00f3n Requerida**: Los solicitantes deben presentar documentaci\u00f3n completa y precisa, incluyendo cartas de presentaci\u00f3n que confirmen la veracidad de la informaci\u00f3n en el dossier del producto.\n\n7. **Fabricantes y Control de Calidad**: Normalmente, los solicitantes son los fabricantes de los productos farmac\u00e9uticos. Si un solicitante no es el fabricante, debe proporcionar documentaci\u00f3n que demuestre el control total sobre el proceso de fabricaci\u00f3n y la garant\u00eda de calidad.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable del proceso de precalificaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos para enfermedades espec\u00edficas y salud reproductiva.\n- **Solicitantes**: Pueden ser fabricantes o intermediarios que deben cumplir con requisitos espec\u00edficos de documentaci\u00f3n.\n- **Lista Modelo de Medicamentos Esenciales**: Un listado de productos que satisfacen las necesidades de salud prioritarias de la poblaci\u00f3n.", "excerpt_keywords": "Keywords: product dossier, WHO guidelines, therapeutic equivalence, multisource generic products, documentation requirements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ffe3a2c0-0d0d-4e6d-bd8f-e8cdf3a34a93", "node_type": "4", "metadata": {"page_label": "392", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a product dossier, in the format specified in the WHO guidance documents on submitting product data and information;\n- product samples, to enable visual examination and chemical and pharmaceutical analysis;\n- a site master file (SMF) for each manufacturing site listed in the product dossier, in the format specified in the WHO guidance documents for submitting an SMF; and\n- a contract research organization master file (CROMF) for each clinical site listed in the dossier, in the format specified in the WHO guidance documents for submitting a CROMF.\n\nAll documentation should be submitted in English.\n\nFor the purposes of this procedure, different requirements for documentation to be submitted apply to the following categories of products:\n\n- multisource (generic) FPPs to be assessed by WHO;\n- innovator FPPs approved by SRAs; and\n- multisource (generic) FPPs approved by SRAs.\n\nThe documentation requirements for each of the above categories can be found on the WHO web site at: http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nMultisource generic products must be shown, either directly or indirectly, to be therapeutically equivalent to the comparator product if they are to be considered interchangeable. WHO will maintain and make public the list of comparator products for this purpose. The WHO web site provides guidance on the evidence needed for a product to be considered equivalent without the need for in vivo equivalence studies (i.e. application of biowaiver).\n\nIf considered necessary or desirable by either party, and before the actual evaluation process starts, a discussion may be held between the manufacturer and WHO. This meeting should be scheduled as early as possible with a predefined agenda to address questions sent in advance to WHO by the manufacturer.\n\n## 7. Screening of dossiers submitted\n\nEach product dossier submitted by an applicant will be screened for completeness before being evaluated. Dossiers submitted for products which are not listed in an invitation for EOIs or have not otherwise been invited by WHO will not be accepted for assessment.\n\nSimilarly WHO will not consider dossiers that are incomplete. The applicant will be informed that an incomplete dossier has been received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "21b5520565d42b817894ac84df1f579ca3c619bba61eff0843c281143aa4f23b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- a product dossier, in the format specified in the WHO guidance documents on submitting product data and information;\n- product samples, to enable visual examination and chemical and pharmaceutical analysis;\n- a site master file (SMF) for each manufacturing site listed in the product dossier, in the format specified in the WHO guidance documents for submitting an SMF; and\n- a contract research organization master file (CROMF) for each clinical site listed in the dossier, in the format specified in the WHO guidance documents for submitting a CROMF.\n\nAll documentation should be submitted in English.\n\nFor the purposes of this procedure, different requirements for documentation to be submitted apply to the following categories of products:\n\n- multisource (generic) FPPs to be assessed by WHO;\n- innovator FPPs approved by SRAs; and\n- multisource (generic) FPPs approved by SRAs.\n\nThe documentation requirements for each of the above categories can be found on the WHO web site at: http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nMultisource generic products must be shown, either directly or indirectly, to be therapeutically equivalent to the comparator product if they are to be considered interchangeable. WHO will maintain and make public the list of comparator products for this purpose. The WHO web site provides guidance on the evidence needed for a product to be considered equivalent without the need for in vivo equivalence studies (i.e. application of biowaiver).\n\nIf considered necessary or desirable by either party, and before the actual evaluation process starts, a discussion may be held between the manufacturer and WHO. This meeting should be scheduled as early as possible with a predefined agenda to address questions sent in advance to WHO by the manufacturer.\n\n## 7. Screening of dossiers submitted\n\nEach product dossier submitted by an applicant will be screened for completeness before being evaluated. Dossiers submitted for products which are not listed in an invitation for EOIs or have not otherwise been invited by WHO will not be accepted for assessment.\n\nSimilarly WHO will not consider dossiers that are incomplete. The applicant will be informed that an incomplete dossier has been received.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2312, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "92180ee0-466e-4b38-8b20-74cc275fdbf3": {"__data__": {"id_": "92180ee0-466e-4b38-8b20-74cc275fdbf3", "embedding": null, "metadata": {"page_label": "393", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and will be requested to complete the dossier within a specified time period. In the event of non-compliance, the dossier may be rejected on grounds of incompleteness and returned to the applicant. Dossiers that are considered complete as the result of the screening will be retained by WHO for assessment.\n\nAfter screening, if the dossier is accepted for assessment the applicant will be informed of this, including the dossier reference number, by letter. This letter will serve as an agreement between WHO and the applicant for the participation in prequalification and a commitment to comply with the provisions of the prequalification procedure.\n\n## 8. Dossier assessment\n\nThe product information submitted in the dossiers will be assessed by teams of experts (assessors) appointed by WHO. The assessors involved in dossier assessment must have the relevant qualifications and experience in the fields of pharmaceutical development, quality assessment of pharmaceutical products, quality assurance, biopharmaceutics and other relevant fields. The assessors will be appointed in accordance with a standard operating procedure (SOP) established by WHO. The assessors should preferably be from NMRAs and they will act as temporary advisers to WHO. The assessors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure.\n\nThe assessment of product dossiers will be done in accordance with SOPs established by WHO for that purpose so as to ensure uniformity in evaluation and timeliness of assessment activities. If needed, WHO may provide training to these experts.\n\nFollowing the assessment of each part of the dossier, a report will be provided to the applicant. Applicants are expected to submit responses to comments and any additional information that may be requested as soon as possible. Within one month, the applicant should inform WHO of the estimated time frame required to address and respond to all queries. The procedure is usually suspended (i.e. WHO will not undertake any further action) until all required responses and any additional information is received by WHO.\n\nEach applicant may request a hearing or meeting with the WHO experts involved in the assessment of this applicant\u2019s dossier to clarify issues identified by the WHO experts. WHO may provide technical assistance to applicants regarding appropriate product information to be submitted as well as production and control requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento describe el proceso de evaluaci\u00f3n de dossiers para la precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla el procedimiento que deben seguir los solicitantes, incluyendo la presentaci\u00f3n de informaci\u00f3n del producto, la evaluaci\u00f3n por expertos designados por la OMS, y la comunicaci\u00f3n de resultados y requerimientos adicionales. Tambi\u00e9n se menciona la posibilidad de que los solicitantes soliciten reuniones con los expertos de la OMS para aclarar dudas y recibir asistencia t\u00e9cnica.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si un solicitante no cumple con el plazo para completar su dossier?**\n   - En caso de no cumplimiento, el dossier puede ser rechazado por incompleto y devuelto al solicitante.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n pueden recibir los evaluadores designados por la OMS?**\n   - La OMS puede proporcionar formaci\u00f3n a los expertos evaluadores si es necesario, para asegurar que est\u00e9n adecuadamente preparados para la evaluaci\u00f3n de los dossiers.\n\n3. **\u00bfCu\u00e1l es el procedimiento que debe seguir un solicitante si desea aclarar dudas sobre su dossier?**\n   - El solicitante puede solicitar una audiencia o reuni\u00f3n con los expertos de la OMS involucrados en la evaluaci\u00f3n de su dossier para aclarar los problemas identificados.\n\n### Resumen de nivel superior\n\nEl proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS implica la presentaci\u00f3n de un dossier por parte del solicitante, que ser\u00e1 evaluado por expertos en diversas \u00e1reas relacionadas con el desarrollo y la calidad de productos farmac\u00e9uticos. La OMS establece procedimientos operativos est\u00e1ndar para garantizar la uniformidad y la eficiencia en la evaluaci\u00f3n. Los solicitantes deben responder a los comentarios y solicitudes de informaci\u00f3n adicional en un plazo determinado, y tienen la opci\u00f3n de solicitar reuniones para discutir su dossier.", "prev_section_summary": "### Temas Clave\n\n1. **Requisitos de Documentaci\u00f3n**: Se especifican los documentos necesarios para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, que incluyen:\n   - Dossier de producto.\n   - Muestras del producto.\n   - Archivo maestro del sitio de fabricaci\u00f3n (SMF).\n   - Archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF).\n\n2. **Categor\u00edas de Productos**: Se diferencian los requisitos de documentaci\u00f3n seg\u00fan el tipo de producto:\n   - Productos multisource (gen\u00e9ricos) a ser evaluados por la OMS.\n   - Productos innovadores aprobados por Autoridades Reguladoras de Salud (SRA).\n   - Productos multisource aprobados por SRA.\n\n3. **Equivalencia Terap\u00e9utica**: Para que un producto gen\u00e9rico sea considerado intercambiable con un producto de referencia, debe demostrar equivalencia terap\u00e9utica, ya sea de forma directa o indirecta.\n\n4. **Proceso de Evaluaci\u00f3n**: Los dossiers ser\u00e1n revisados por su integridad antes de la evaluaci\u00f3n. No se aceptar\u00e1n dossiers incompletos ni aquellos que no est\u00e9n en la lista de invitaciones de la OMS.\n\n5. **Comunicaci\u00f3n Previa**: Se sugiere que, si es necesario, se realice una discusi\u00f3n entre el fabricante y la OMS antes del inicio del proceso de evaluaci\u00f3n.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n y aprobaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Formulaci\u00f3n Farmac\u00e9utica de Producto)**: T\u00e9rmino utilizado para referirse a los productos farmac\u00e9uticos en evaluaci\u00f3n.\n- **SRA (Autoridades Reguladoras de Salud)**: Organismos que aprueban productos innovadores y multisource.\n- **Dossier de Producto**: Documento que contiene informaci\u00f3n sobre el producto farmac\u00e9utico.\n- **SMF (Site Master File)**: Archivo que proporciona informaci\u00f3n sobre el sitio de fabricaci\u00f3n.\n- **CROMF (Contract Research Organization Master File)**: Archivo que contiene informaci\u00f3n sobre los sitios cl\u00ednicos de investigaci\u00f3n.\n\nEste resumen abarca los aspectos esenciales y las entidades mencionadas en la secci\u00f3n del documento de la OMS.", "excerpt_keywords": "Keywords: dossier assessment, WHO prequalification, pharmaceutical products, expert evaluators, compliance requirements"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "41c1b8e8-39ba-44b4-a432-d95966915e77", "node_type": "4", "metadata": {"page_label": "393", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and will be requested to complete the dossier within a specified time period. In the event of non-compliance, the dossier may be rejected on grounds of incompleteness and returned to the applicant. Dossiers that are considered complete as the result of the screening will be retained by WHO for assessment.\n\nAfter screening, if the dossier is accepted for assessment the applicant will be informed of this, including the dossier reference number, by letter. This letter will serve as an agreement between WHO and the applicant for the participation in prequalification and a commitment to comply with the provisions of the prequalification procedure.\n\n## 8. Dossier assessment\n\nThe product information submitted in the dossiers will be assessed by teams of experts (assessors) appointed by WHO. The assessors involved in dossier assessment must have the relevant qualifications and experience in the fields of pharmaceutical development, quality assessment of pharmaceutical products, quality assurance, biopharmaceutics and other relevant fields. The assessors will be appointed in accordance with a standard operating procedure (SOP) established by WHO. The assessors should preferably be from NMRAs and they will act as temporary advisers to WHO. The assessors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure.\n\nThe assessment of product dossiers will be done in accordance with SOPs established by WHO for that purpose so as to ensure uniformity in evaluation and timeliness of assessment activities. If needed, WHO may provide training to these experts.\n\nFollowing the assessment of each part of the dossier, a report will be provided to the applicant. Applicants are expected to submit responses to comments and any additional information that may be requested as soon as possible. Within one month, the applicant should inform WHO of the estimated time frame required to address and respond to all queries. The procedure is usually suspended (i.e. WHO will not undertake any further action) until all required responses and any additional information is received by WHO.\n\nEach applicant may request a hearing or meeting with the WHO experts involved in the assessment of this applicant\u2019s dossier to clarify issues identified by the WHO experts. WHO may provide technical assistance to applicants regarding appropriate product information to be submitted as well as production and control requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "850b9438c85b8e70bd00875dcbc3e36b62d1208f44075f17a658083c7df446e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "and will be requested to complete the dossier within a specified time period. In the event of non-compliance, the dossier may be rejected on grounds of incompleteness and returned to the applicant. Dossiers that are considered complete as the result of the screening will be retained by WHO for assessment.\n\nAfter screening, if the dossier is accepted for assessment the applicant will be informed of this, including the dossier reference number, by letter. This letter will serve as an agreement between WHO and the applicant for the participation in prequalification and a commitment to comply with the provisions of the prequalification procedure.\n\n## 8. Dossier assessment\n\nThe product information submitted in the dossiers will be assessed by teams of experts (assessors) appointed by WHO. The assessors involved in dossier assessment must have the relevant qualifications and experience in the fields of pharmaceutical development, quality assessment of pharmaceutical products, quality assurance, biopharmaceutics and other relevant fields. The assessors will be appointed in accordance with a standard operating procedure (SOP) established by WHO. The assessors should preferably be from NMRAs and they will act as temporary advisers to WHO. The assessors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure.\n\nThe assessment of product dossiers will be done in accordance with SOPs established by WHO for that purpose so as to ensure uniformity in evaluation and timeliness of assessment activities. If needed, WHO may provide training to these experts.\n\nFollowing the assessment of each part of the dossier, a report will be provided to the applicant. Applicants are expected to submit responses to comments and any additional information that may be requested as soon as possible. Within one month, the applicant should inform WHO of the estimated time frame required to address and respond to all queries. The procedure is usually suspended (i.e. WHO will not undertake any further action) until all required responses and any additional information is received by WHO.\n\nEach applicant may request a hearing or meeting with the WHO experts involved in the assessment of this applicant\u2019s dossier to clarify issues identified by the WHO experts. WHO may provide technical assistance to applicants regarding appropriate product information to be submitted as well as production and control requirements.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2491, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf7ab8f-2fcf-4c74-a7fc-fbff69205b04": {"__data__": {"id_": "7bf7ab8f-2fcf-4c74-a7fc-fbff69205b04", "embedding": null, "metadata": {"page_label": "394", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Site inspection\n\nWHO will plan and coordinate, in accordance with SOPs established by WHO and based on quality risk management (QRM) principles, the performance of inspections of the site(s) of manufacture of the API(s) and the FPP, and of the clinical testing units or CROs.\n\nThe following factors will be taken into account when planning inspections:\n\n- the results of previous inspection(s) by WHO or an SRA, and history of compliance of the company or facility with GMP, GCP and or GLP as appropriate;\n- the outcome of the assessment of data submitted to WHO;\n- complexity of the site, processes and product;\n- number and significance of known quality defects (e.g. complaints, recalls);\n- major changes to, e.g. buildings, equipment, processes, key personnel;\n- site experience with manufacturing and testing of a product; and\n- test results of official control laboratories.\n\nThe inspections of the manufacturing site(s) are conducted to assess compliance with GMP as recommended by WHO and include data verification. SMFs submitted by the applicant will be reviewed before an inspection is performed.\n\nThe inspections of clinical testing units or CROs are carried out to assess compliance with GCP and GLP, and to perform data verification.\n\nThe WHO norms and standards applicable to inspections of APIs and FPPs, and of clinical testing units or CROs, can be found on the WHO web site at http://who.int/prequal/assessment_inspect/info_inspection.htm#2. These requirements may be revised from time to time.\n\nThe inspections will be performed by a team of inspectors usually including experts appointed by WHO, preferably from NMRA inspectorates, who will act as temporary advisers to WHO. The inspectors must have the relevant qualifications and experience to perform such inspections, be competent in areas such as production and quality control of pharmaceuticals, and have appropriate experience in GMP and GCP or GLP. The inspectors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure. If needed, WHO may provide training to these experts.\n\nA WHO staff member will coordinate the team and will normally lead the inspection team. Each team will perform the inspections and report its findings to WHO in accordance with SOPs established by WHO for that purpose so as to ensure a standard harmonized approach. A representative", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Objetivo de las Inspecciones**: La Organizaci\u00f3n Mundial de la Salud (OMS) coordina inspecciones de sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos terminados (FPP), as\u00ed como de unidades de pruebas cl\u00ednicas o CROs, para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP).\n\n2. **Factores Considerados para la Inspecci\u00f3n**: Al planificar las inspecciones, la OMS toma en cuenta varios factores, incluyendo el historial de cumplimiento de la instalaci\u00f3n, la complejidad del sitio y los procesos, y los resultados de pruebas de laboratorios de control oficial.\n\n3. **Equipo de Inspecci\u00f3n**: Las inspecciones son realizadas por un equipo de inspectores con experiencia y calificaciones relevantes, coordinados por un miembro del personal de la OMS. Se espera que los inspectores cumplan con normas de confidencialidad y conflicto de intereses.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n puede recibir el personal de inspecci\u00f3n designado por la OMS?**\n   - La OMS puede proporcionar formaci\u00f3n a los expertos que act\u00faan como inspectores temporales, asegurando que tengan las competencias necesarias para llevar a cabo las inspecciones de acuerdo con los est\u00e1ndares establecidos.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia y el enfoque de las inspecciones de un sitio espec\u00edfico?**\n   - La frecuencia y el enfoque de las inspecciones se determinan en funci\u00f3n de varios factores, como los resultados de inspecciones anteriores, el historial de cumplimiento de la instalaci\u00f3n, la complejidad del sitio y los procesos, as\u00ed como la cantidad y significancia de defectos de calidad conocidos.\n\n3. **\u00bfQu\u00e9 medidas se toman si se encuentran defectos de calidad durante una inspecci\u00f3n?**\n   - Aunque el texto no detalla espec\u00edficamente las medidas a tomar, se infiere que los defectos de calidad significativos podr\u00edan influir en la evaluaci\u00f3n de cumplimiento de GMP, GCP o GLP, y podr\u00edan llevar a acciones correctivas o a una revisi\u00f3n m\u00e1s exhaustiva de las pr\u00e1cticas de la instalaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Proceso de Dossier**: Los solicitantes deben completar un dossier dentro de un plazo espec\u00edfico. Si no cumplen, el dossier puede ser rechazado por incompleto.\n\n2. **Aceptaci\u00f3n y Comunicaci\u00f3n**: Si el dossier es aceptado tras la revisi\u00f3n inicial, el solicitante recibe una carta que confirma la aceptaci\u00f3n y establece un acuerdo con la OMS.\n\n3. **Evaluaci\u00f3n del Dossier**: Equipos de expertos designados por la OMS eval\u00faan la informaci\u00f3n del producto presentada en los dossiers. Los evaluadores deben tener experiencia en desarrollo farmac\u00e9utico, evaluaci\u00f3n de calidad y otros campos relevantes.\n\n4. **Procedimientos Operativos Est\u00e1ndar (SOP)**: La evaluaci\u00f3n se realiza de acuerdo con SOP establecidos por la OMS para asegurar uniformidad y eficiencia.\n\n5. **Informe y Respuestas**: Despu\u00e9s de la evaluaci\u00f3n, se proporciona un informe al solicitante, quien debe responder a los comentarios y solicitudes de informaci\u00f3n adicional en un plazo determinado.\n\n6. **Suspensi\u00f3n del Proceso**: El proceso se suspende hasta que la OMS reciba todas las respuestas y la informaci\u00f3n adicional requerida.\n\n7. **Reuniones y Asistencia T\u00e9cnica**: Los solicitantes pueden solicitar reuniones con los expertos de la OMS para aclarar dudas y recibir asistencia t\u00e9cnica sobre la informaci\u00f3n del producto y requisitos de producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Solicitantes**: Empresas o individuos que presentan dossiers para la precalificaci\u00f3n.\n- **Expertos Evaluadores**: Profesionales designados por la OMS con experiencia en \u00e1reas relevantes para la evaluaci\u00f3n de productos farmac\u00e9uticos.\n- **Dossier**: Documento que contiene la informaci\u00f3n del producto que se eval\u00faa para la precalificaci\u00f3n.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades nacionales de regulaci\u00f3n de medicamentos que pueden participar como evaluadores.", "excerpt_keywords": "Keywords: inspections, WHO, GMP, GCP, quality risk management"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "104dc4d6-b559-40e9-b95e-adf0d6bec6ab", "node_type": "4", "metadata": {"page_label": "394", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Site inspection\n\nWHO will plan and coordinate, in accordance with SOPs established by WHO and based on quality risk management (QRM) principles, the performance of inspections of the site(s) of manufacture of the API(s) and the FPP, and of the clinical testing units or CROs.\n\nThe following factors will be taken into account when planning inspections:\n\n- the results of previous inspection(s) by WHO or an SRA, and history of compliance of the company or facility with GMP, GCP and or GLP as appropriate;\n- the outcome of the assessment of data submitted to WHO;\n- complexity of the site, processes and product;\n- number and significance of known quality defects (e.g. complaints, recalls);\n- major changes to, e.g. buildings, equipment, processes, key personnel;\n- site experience with manufacturing and testing of a product; and\n- test results of official control laboratories.\n\nThe inspections of the manufacturing site(s) are conducted to assess compliance with GMP as recommended by WHO and include data verification. SMFs submitted by the applicant will be reviewed before an inspection is performed.\n\nThe inspections of clinical testing units or CROs are carried out to assess compliance with GCP and GLP, and to perform data verification.\n\nThe WHO norms and standards applicable to inspections of APIs and FPPs, and of clinical testing units or CROs, can be found on the WHO web site at http://who.int/prequal/assessment_inspect/info_inspection.htm#2. These requirements may be revised from time to time.\n\nThe inspections will be performed by a team of inspectors usually including experts appointed by WHO, preferably from NMRA inspectorates, who will act as temporary advisers to WHO. The inspectors must have the relevant qualifications and experience to perform such inspections, be competent in areas such as production and quality control of pharmaceuticals, and have appropriate experience in GMP and GCP or GLP. The inspectors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure. If needed, WHO may provide training to these experts.\n\nA WHO staff member will coordinate the team and will normally lead the inspection team. Each team will perform the inspections and report its findings to WHO in accordance with SOPs established by WHO for that purpose so as to ensure a standard harmonized approach. A representative", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f81f7b2e0ef94a4f5b9213056e4e1e40cb6e4f2c353196c7f2dffb2c685e661f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9. Site inspection\n\nWHO will plan and coordinate, in accordance with SOPs established by WHO and based on quality risk management (QRM) principles, the performance of inspections of the site(s) of manufacture of the API(s) and the FPP, and of the clinical testing units or CROs.\n\nThe following factors will be taken into account when planning inspections:\n\n- the results of previous inspection(s) by WHO or an SRA, and history of compliance of the company or facility with GMP, GCP and or GLP as appropriate;\n- the outcome of the assessment of data submitted to WHO;\n- complexity of the site, processes and product;\n- number and significance of known quality defects (e.g. complaints, recalls);\n- major changes to, e.g. buildings, equipment, processes, key personnel;\n- site experience with manufacturing and testing of a product; and\n- test results of official control laboratories.\n\nThe inspections of the manufacturing site(s) are conducted to assess compliance with GMP as recommended by WHO and include data verification. SMFs submitted by the applicant will be reviewed before an inspection is performed.\n\nThe inspections of clinical testing units or CROs are carried out to assess compliance with GCP and GLP, and to perform data verification.\n\nThe WHO norms and standards applicable to inspections of APIs and FPPs, and of clinical testing units or CROs, can be found on the WHO web site at http://who.int/prequal/assessment_inspect/info_inspection.htm#2. These requirements may be revised from time to time.\n\nThe inspections will be performed by a team of inspectors usually including experts appointed by WHO, preferably from NMRA inspectorates, who will act as temporary advisers to WHO. The inspectors must have the relevant qualifications and experience to perform such inspections, be competent in areas such as production and quality control of pharmaceuticals, and have appropriate experience in GMP and GCP or GLP. The inspectors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure. If needed, WHO may provide training to these experts.\n\nA WHO staff member will coordinate the team and will normally lead the inspection team. Each team will perform the inspections and report its findings to WHO in accordance with SOPs established by WHO for that purpose so as to ensure a standard harmonized approach. A representative", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2419, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aee75c72-6eea-48bf-bd03-f117fafdcbf7": {"__data__": {"id_": "aee75c72-6eea-48bf-bd03-f117fafdcbf7", "embedding": null, "metadata": {"page_label": "395", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Reporting and Communication of the Results of the Evaluation\n\nEach assessment and inspection team will finalize its reports according to the established WHO SOP and format, describing the findings and including recommendations to the applicant, manufacturer(s) and/or CROs where relevant.\n\nThe findings from the dossier assessment including, but not limited to, deficiencies of the documentation and data submitted, shall be communicated in writing to the applicant requesting submission of the missing data and information, as appropriate.\n\nThe inspection report will be communicated to the manufacturer or CRO as applicable. With the written agreement of the manufacturer or CRO, a copy of the inspection report may also be provided to the applicant (if other than the manufacturer or CRO). If any additional information is required, or corrective action has to be taken by the manufacturer or CRO, WHO will postpone its decision on the acceptability of the site(s) concerned until such information has been evaluated or the corrective action has been taken and found satisfactory in light of the specified standards.\n\nWHO reserves the right to terminate this procedure for a specific product if the applicant is not able to provide the required information or implement the corrective actions within a specified time period, or if the information supplied is inadequate to complete this procedure.\n\nIn the event of any disagreement between an applicant and WHO, an SOP established by WHO for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the prequalification procedure, the ownership of the reports lies with WHO. Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any commercially", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe el proceso de evaluaci\u00f3n y comunicaci\u00f3n de resultados por parte de la OMS en relaci\u00f3n con la precalificaci\u00f3n de productos. Se detalla c\u00f3mo los equipos de evaluaci\u00f3n e inspecci\u00f3n finalizan sus informes, la comunicaci\u00f3n de hallazgos y deficiencias a los solicitantes, y el manejo de la informaci\u00f3n adicional o acciones correctivas necesarias. Tambi\u00e9n se menciona el derecho de la OMS a terminar el procedimiento si no se cumplen los requisitos y c\u00f3mo se manejan los desacuerdos entre los solicitantes y la OMS.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si un solicitante no puede proporcionar la informaci\u00f3n requerida dentro del plazo especificado?**\n   - La OMS se reserva el derecho de terminar el procedimiento para un producto espec\u00edfico si el solicitante no puede proporcionar la informaci\u00f3n requerida o implementar las acciones correctivas dentro del tiempo especificado.\n\n2. **\u00bfC\u00f3mo se maneja la comunicaci\u00f3n de los hallazgos de la evaluaci\u00f3n a los solicitantes?**\n   - Los hallazgos de la evaluaci\u00f3n del expediente, incluyendo deficiencias en la documentaci\u00f3n y datos presentados, se comunican por escrito al solicitante, solicitando la presentaci\u00f3n de los datos e informaci\u00f3n faltantes seg\u00fan sea apropiado.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS sobre los informes generados durante el proceso de evaluaci\u00f3n?**\n   - La OMS es responsable del procedimiento de precalificaci\u00f3n y, por lo tanto, posee los informes generados. Tiene el derecho de usar y publicar dichos informes, siempre que se protejan los intereses comerciales involucrados.", "prev_section_summary": "### Temas Clave\n\n1. **Objetivo de las Inspecciones**: La OMS coordina inspecciones para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP) en sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos terminados (FPP), as\u00ed como en unidades de pruebas cl\u00ednicas o CROs.\n\n2. **Factores para la Planificaci\u00f3n de Inspecciones**: Se consideran varios factores al planificar las inspecciones, incluyendo:\n   - Resultados de inspecciones anteriores.\n   - Historial de cumplimiento de la instalaci\u00f3n.\n   - Complejidad del sitio y procesos.\n   - N\u00famero y significancia de defectos de calidad conocidos.\n   - Cambios importantes en la instalaci\u00f3n.\n   - Experiencia del sitio en la fabricaci\u00f3n y pruebas de productos.\n   - Resultados de laboratorios de control oficial.\n\n3. **Equipo de Inspecci\u00f3n**: Las inspecciones son realizadas por un equipo de inspectores con experiencia y calificaciones relevantes, coordinados por un miembro del personal de la OMS. Se espera que los inspectores cumplan con normas de confidencialidad y conflicto de intereses.\n\n4. **Normas y Est\u00e1ndares**: Las normas y est\u00e1ndares aplicables a las inspecciones est\u00e1n disponibles en el sitio web de la OMS y pueden ser revisadas peri\u00f3dicamente.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de coordinar las inspecciones.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Productos Farmac\u00e9uticos Terminados)**: Productos que est\u00e1n listos para ser distribuidos y utilizados.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidades que realizan pruebas cl\u00ednicas.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran que los productos se fabriquen de manera consistente y controlada.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)**: Normas que aseguran la calidad y la \u00e9tica en la investigaci\u00f3n cl\u00ednica.\n- **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normas que aseguran la calidad y la integridad de los datos de laboratorio.", "excerpt_keywords": "Keywords: WHO, evaluation, inspection report, prequalification, communication"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "136170ca-c500-487e-b337-22d8b495d2aa", "node_type": "4", "metadata": {"page_label": "395", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Reporting and Communication of the Results of the Evaluation\n\nEach assessment and inspection team will finalize its reports according to the established WHO SOP and format, describing the findings and including recommendations to the applicant, manufacturer(s) and/or CROs where relevant.\n\nThe findings from the dossier assessment including, but not limited to, deficiencies of the documentation and data submitted, shall be communicated in writing to the applicant requesting submission of the missing data and information, as appropriate.\n\nThe inspection report will be communicated to the manufacturer or CRO as applicable. With the written agreement of the manufacturer or CRO, a copy of the inspection report may also be provided to the applicant (if other than the manufacturer or CRO). If any additional information is required, or corrective action has to be taken by the manufacturer or CRO, WHO will postpone its decision on the acceptability of the site(s) concerned until such information has been evaluated or the corrective action has been taken and found satisfactory in light of the specified standards.\n\nWHO reserves the right to terminate this procedure for a specific product if the applicant is not able to provide the required information or implement the corrective actions within a specified time period, or if the information supplied is inadequate to complete this procedure.\n\nIn the event of any disagreement between an applicant and WHO, an SOP established by WHO for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the prequalification procedure, the ownership of the reports lies with WHO. Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any commercially", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3afc37ef598e112e393f85d30b4a4cc9d3a21f3a65bd2f919f1fd51fda09237a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Reporting and Communication of the Results of the Evaluation\n\nEach assessment and inspection team will finalize its reports according to the established WHO SOP and format, describing the findings and including recommendations to the applicant, manufacturer(s) and/or CROs where relevant.\n\nThe findings from the dossier assessment including, but not limited to, deficiencies of the documentation and data submitted, shall be communicated in writing to the applicant requesting submission of the missing data and information, as appropriate.\n\nThe inspection report will be communicated to the manufacturer or CRO as applicable. With the written agreement of the manufacturer or CRO, a copy of the inspection report may also be provided to the applicant (if other than the manufacturer or CRO). If any additional information is required, or corrective action has to be taken by the manufacturer or CRO, WHO will postpone its decision on the acceptability of the site(s) concerned until such information has been evaluated or the corrective action has been taken and found satisfactory in light of the specified standards.\n\nWHO reserves the right to terminate this procedure for a specific product if the applicant is not able to provide the required information or implement the corrective actions within a specified time period, or if the information supplied is inadequate to complete this procedure.\n\nIn the event of any disagreement between an applicant and WHO, an SOP established by WHO for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the prequalification procedure, the ownership of the reports lies with WHO. Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any commercially", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1808, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0e73e4-2f49-434c-a4e2-8f447b024200": {"__data__": {"id_": "7c0e73e4-2f49-434c-a4e2-8f447b024200", "embedding": null, "metadata": {"page_label": "396", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nsensitive confidential information of the applicant, manufacturer(s) and/or testing organization(s). \"Confidential information\" in this context means:\n\n- confidential intellectual property, know-how and trade secrets (including, e.g. formulas, processes or information contained or embodied in a product, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans of a company).\n\nProvisions of confidentiality will be contained in the exchange of letters, to be concluded before the assessment of the product dossier or inspection of the manufacturing and clinical sites, between WHO and each applicant, manufacturer or CRO.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full assessment and inspection reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n## 11. Outcome of the prequalification procedure\n\nOnce WHO is satisfied that this procedure is complete for the relevant product, and that the WHO-recommended standards are met, the product, as manufactured at the specified manufacturing site(s), will be included in the list of prequalified pharmaceutical products. The list of prequalified pharmaceutical products will be compiled in accordance with an SOP established by WHO for final decision-making on inclusion in the list. The list will be published on the WHO web site and will specify the characteristics of the prequalified pharmaceutical products, as described in Appendix 2 to this procedure.\n\nEach applicant will receive a letter of prequalification from WHO informing it of the outcome of the quality assessment process in regard of the submitted product(s). Once the product(s) are included in the list of prequalified pharmaceutical products, the applicant shall be responsible for keeping WHO continuously updated on all relevant aspects of the manufacture and control of such product(s) and to meet any requirements, as agreed with WHO.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any commercially sensitive confidential information \u2014 publish WHO Public Assessment Reports (WHOPAR(s)) on the product dossier assessments and WHO Public Inspection Reports (WHOPIR(s)) on the manufacturers and CROs, that were found to be in compliance with WHO-recommended guidelines and standards. These reports will be published on the WHO web site. Subject always to the protection of commercially sensitive confidential\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla el procedimiento de precalificaci\u00f3n para productos farmac\u00e9uticos. Se enfatiza la importancia de la confidencialidad de la informaci\u00f3n sensible relacionada con los solicitantes, fabricantes y organizaciones de pruebas. La OMS se compromete a proteger la propiedad intelectual y los secretos comerciales, pero tambi\u00e9n se reserva el derecho de compartir informes de evaluaci\u00f3n con autoridades pertinentes. Una vez que un producto cumple con los est\u00e1ndares recomendados por la OMS, se incluir\u00e1 en una lista de productos farmac\u00e9uticos precalificados, y los solicitantes recibir\u00e1n una carta informativa sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se considera \"confidencial\" seg\u00fan el documento de la OMS y c\u00f3mo se protege durante el proceso de precalificaci\u00f3n?**\n   - Esta pregunta busca detalles sobre la definici\u00f3n de informaci\u00f3n confidencial y las medidas espec\u00edficas que se toman para protegerla durante el proceso de evaluaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el proceso que sigue la OMS para decidir la inclusi\u00f3n de un producto en la lista de productos farmac\u00e9uticos precalificados?**\n   - Esta pregunta se centra en el procedimiento espec\u00edfico que la OMS utiliza para evaluar y decidir sobre la precalificaci\u00f3n de un producto, incluyendo los criterios y pasos involucrados.\n\n3. **\u00bfQu\u00e9 obligaciones tienen los solicitantes una vez que su producto ha sido precalificado por la OMS?**\n   - Esta pregunta busca informaci\u00f3n sobre las responsabilidades continuas de los solicitantes despu\u00e9s de que su producto ha sido incluido en la lista de productos precalificados, as\u00ed como cualquier requisito adicional que deban cumplir.", "prev_section_summary": "### Temas Clave\n\n1. **Finalizaci\u00f3n de Informes**: Los equipos de evaluaci\u00f3n e inspecci\u00f3n de la OMS finalizan sus informes siguiendo procedimientos operativos est\u00e1ndar (SOP) establecidos, que incluyen hallazgos y recomendaciones.\n\n2. **Comunicaci\u00f3n de Hallazgos**: Los hallazgos de la evaluaci\u00f3n, incluidas las deficiencias en la documentaci\u00f3n, se comunican por escrito al solicitante, quien debe proporcionar la informaci\u00f3n faltante.\n\n3. **Informes de Inspecci\u00f3n**: Los informes de inspecci\u00f3n se env\u00edan al fabricante o CRO correspondiente, y pueden ser compartidos con el solicitante con el consentimiento por escrito del fabricante o CRO.\n\n4. **Acciones Correctivas y Evaluaci\u00f3n**: Si se requieren acciones correctivas o informaci\u00f3n adicional, la OMS pospone su decisi\u00f3n sobre la aceptabilidad del sitio hasta que se eval\u00fae la nueva informaci\u00f3n o se implementen las acciones correctivas.\n\n5. **Terminaci\u00f3n del Procedimiento**: La OMS puede terminar el procedimiento para un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa las acciones correctivas en el tiempo especificado.\n\n6. **Manejo de Desacuerdos**: En caso de desacuerdos entre un solicitante y la OMS, se seguir\u00e1 un SOP establecido para resolver el problema.\n\n7. **Propiedad de los Informes**: La OMS es propietaria de los informes generados durante el proceso de precalificaci\u00f3n y tiene derecho a usarlos y publicarlos, protegiendo los intereses comerciales involucrados.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable del procedimiento de precalificaci\u00f3n y de la evaluaci\u00f3n de productos.\n- **Solicitante**: Parte que presenta la documentaci\u00f3n y datos para la evaluaci\u00f3n.\n- **Fabricante**: Entidad que produce el producto evaluado.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad que puede estar involucrada en el proceso de evaluaci\u00f3n y fabricaci\u00f3n.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Normas establecidas por la OMS para la evaluaci\u00f3n y manejo de informes y desacuerdos.", "excerpt_keywords": "Keywords: prequalification, confidentiality, WHO, pharmaceutical products, assessment reports"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "663771ba-3789-4434-93c1-4aca524c9bb9", "node_type": "4", "metadata": {"page_label": "396", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nsensitive confidential information of the applicant, manufacturer(s) and/or testing organization(s). \"Confidential information\" in this context means:\n\n- confidential intellectual property, know-how and trade secrets (including, e.g. formulas, processes or information contained or embodied in a product, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans of a company).\n\nProvisions of confidentiality will be contained in the exchange of letters, to be concluded before the assessment of the product dossier or inspection of the manufacturing and clinical sites, between WHO and each applicant, manufacturer or CRO.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full assessment and inspection reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n## 11. Outcome of the prequalification procedure\n\nOnce WHO is satisfied that this procedure is complete for the relevant product, and that the WHO-recommended standards are met, the product, as manufactured at the specified manufacturing site(s), will be included in the list of prequalified pharmaceutical products. The list of prequalified pharmaceutical products will be compiled in accordance with an SOP established by WHO for final decision-making on inclusion in the list. The list will be published on the WHO web site and will specify the characteristics of the prequalified pharmaceutical products, as described in Appendix 2 to this procedure.\n\nEach applicant will receive a letter of prequalification from WHO informing it of the outcome of the quality assessment process in regard of the submitted product(s). Once the product(s) are included in the list of prequalified pharmaceutical products, the applicant shall be responsible for keeping WHO continuously updated on all relevant aspects of the manufacture and control of such product(s) and to meet any requirements, as agreed with WHO.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any commercially sensitive confidential information \u2014 publish WHO Public Assessment Reports (WHOPAR(s)) on the product dossier assessments and WHO Public Inspection Reports (WHOPIR(s)) on the manufacturers and CROs, that were found to be in compliance with WHO-recommended guidelines and standards. These reports will be published on the WHO web site. Subject always to the protection of commercially sensitive confidential\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5da42518b79819ff7d31be27932b375f417426afc90d9ac5658a613cd6a3d5d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "sensitive confidential information of the applicant, manufacturer(s) and/or testing organization(s). \"Confidential information\" in this context means:\n\n- confidential intellectual property, know-how and trade secrets (including, e.g. formulas, processes or information contained or embodied in a product, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans of a company).\n\nProvisions of confidentiality will be contained in the exchange of letters, to be concluded before the assessment of the product dossier or inspection of the manufacturing and clinical sites, between WHO and each applicant, manufacturer or CRO.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full assessment and inspection reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n## 11. Outcome of the prequalification procedure\n\nOnce WHO is satisfied that this procedure is complete for the relevant product, and that the WHO-recommended standards are met, the product, as manufactured at the specified manufacturing site(s), will be included in the list of prequalified pharmaceutical products. The list of prequalified pharmaceutical products will be compiled in accordance with an SOP established by WHO for final decision-making on inclusion in the list. The list will be published on the WHO web site and will specify the characteristics of the prequalified pharmaceutical products, as described in Appendix 2 to this procedure.\n\nEach applicant will receive a letter of prequalification from WHO informing it of the outcome of the quality assessment process in regard of the submitted product(s). Once the product(s) are included in the list of prequalified pharmaceutical products, the applicant shall be responsible for keeping WHO continuously updated on all relevant aspects of the manufacture and control of such product(s) and to meet any requirements, as agreed with WHO.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any commercially sensitive confidential information \u2014 publish WHO Public Assessment Reports (WHOPAR(s)) on the product dossier assessments and WHO Public Inspection Reports (WHOPIR(s)) on the manufacturers and CROs, that were found to be in compliance with WHO-recommended guidelines and standards. These reports will be published on the WHO web site. Subject always to the protection of commercially sensitive confidential", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2562, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "c73c7897-f0c0-48f9-8398-7aaaa55cf5fc": {"__data__": {"id_": "c73c7897-f0c0-48f9-8398-7aaaa55cf5fc", "embedding": null, "metadata": {"page_label": "397", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The decision to list a pharmaceutical product is made based upon information available to WHO at that time, i.e. information in the submitted dossier and on the status of GMP, GLP and GCP at the facilities used in the manufacture and testing of the product at the time of the site inspection(s) conducted by WHO or at the time of the site inspection(s) conducted by an SRA, the outcome of which has been determined by WHO to meet the applicable WHO-recommended standards, in accordance with the terms of this procedure. This decision is subject to change on the basis of new information that may become available to WHO. If serious safety and/or quality concerns arise in relation to a prequalified product, WHO may delist the product after evaluation of the new evidence and a risk\u2013benefit assessment, or may suspend the product until results of further investigations become available and are evaluated by WHO.\n\n## 12. Maintenance of prequalification status\n\nApplicants are required to communicate details to WHO of any changes (variations) in manufacture and control that may have an impact on the safety, efficacy and quality of the product.\n\nGuidance on variations to prequalified dossiers as can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nIt is the applicant\u2019s responsibility to provide WHO with the appropriate documentation (referring to relevant parts of the dossier) to prove that any intended or implemented variation will not have a negative impact on the quality of the product that has been prequalified. WHO will undertake an evaluation of variations according to the established WHO guidelines and SOPs and communicate the outcome to the applicant within the prescribed time lines. Adherence to the reporting requirements will be verified during the inspections carried out by WHO.\n\nRandom samples of prequalified products supplied by listed manufacturers or applicants will be taken for independent testing of final product characteristics. Certificates of analysis of final products released by the manufacturer and specifications for test methods should be provided by the manufacturer or applicant to WHO for review upon request. In the event of failure to meet the established criteria for testing, WHO will investigate the problem and communicate the outcome of this investigation to the manufacturer and applicant, if other than the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece el proceso y los criterios para la inclusi\u00f3n y el mantenimiento del estado de precalificaci\u00f3n de productos farmac\u00e9uticos. La decisi\u00f3n de listar un producto se basa en la informaci\u00f3n disponible en el momento de la evaluaci\u00f3n, incluyendo el estado de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Laboratorio (GLP) y Buenas Pr\u00e1cticas Cl\u00ednicas (GCP). La OMS puede cambiar su decisi\u00f3n si surgen nuevas evidencias sobre la seguridad o calidad del producto. Adem\u00e1s, los solicitantes deben informar sobre cualquier cambio en la fabricaci\u00f3n que pueda afectar la calidad del producto y proporcionar la documentaci\u00f3n necesaria para demostrar que dichos cambios no impactar\u00e1n negativamente en la calidad. La OMS tambi\u00e9n realiza pruebas independientes de muestras de productos precalificados y puede investigar problemas si los productos no cumplen con los criterios establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n debe proporcionar un solicitante a la OMS para demostrar que una variaci\u00f3n en la fabricaci\u00f3n no afectar\u00e1 negativamente la calidad del producto?**\n   - La documentaci\u00f3n debe referirse a las partes relevantes del dossier y demostrar que la variaci\u00f3n no tendr\u00e1 un impacto negativo en la calidad del producto precalificado.\n\n2. **\u00bfQu\u00e9 acciones puede tomar la OMS si surgen preocupaciones serias sobre la seguridad o calidad de un producto precalificado?**\n   - La OMS puede delistar el producto tras una evaluaci\u00f3n de nuevas evidencias y un an\u00e1lisis de riesgo-beneficio, o puede suspender el producto hasta que se completen investigaciones adicionales.\n\n3. **\u00bfC\u00f3mo verifica la OMS el cumplimiento de los requisitos de reporte por parte de los solicitantes?**\n   - La OMS verifica el cumplimiento de los requisitos de reporte durante las inspecciones realizadas en las instalaciones de fabricaci\u00f3n y control de los productos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o fuentes, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Confidencialidad de la Informaci\u00f3n**:\n   - Se define la \"informaci\u00f3n confidencial\" como propiedad intelectual, secretos comerciales y confidencias comerciales.\n   - La OMS establece medidas para proteger esta informaci\u00f3n durante el proceso de precalificaci\u00f3n, incluyendo el intercambio de cartas de confidencialidad con solicitantes, fabricantes y organizaciones de pruebas.\n\n2. **Proceso de Precalificaci\u00f3n**:\n   - La OMS eval\u00faa productos farmac\u00e9uticos para determinar si cumplen con los est\u00e1ndares recomendados.\n   - Una vez completada la evaluaci\u00f3n y verificaci\u00f3n de cumplimiento, el producto se incluye en una lista de productos farmac\u00e9uticos precalificados.\n   - La lista se publica en el sitio web de la OMS y detalla las caracter\u00edsticas de los productos precalificados.\n\n3. **Obligaciones de los Solicitantes**:\n   - Los solicitantes reciben una carta de precalificaci\u00f3n que informa sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n   - Tienen la responsabilidad de mantener a la OMS actualizada sobre todos los aspectos relevantes de la fabricaci\u00f3n y control de los productos precalificados.\n\n4. **Publicaci\u00f3n de Informes**:\n   - La OMS publicar\u00e1 informes de evaluaci\u00f3n p\u00fablica (WHOPAR) y de inspecci\u00f3n p\u00fablica (WHOPIR) sobre los productos y fabricantes que cumplan con las directrices y est\u00e1ndares recomendados, protegiendo la informaci\u00f3n confidencial sensible.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del procedimiento de precalificaci\u00f3n.\n- **Solicitantes**: Empresas o individuos que presentan productos para la precalificaci\u00f3n.\n- **Fabricantes**: Entidades que producen los productos farmac\u00e9uticos.\n- **Organizaciones de Pruebas (CROs)**: Organizaciones que realizan pruebas y evaluaciones de productos. \n\nEste resumen destaca los aspectos clave del procedimiento de precalificaci\u00f3n de la OMS, as\u00ed como las responsabilidades y derechos de las partes involucradas.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO guidelines, safety and quality, manufacturing variations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7ab705b2-4cc3-4f1a-bb68-e26733afbf78", "node_type": "4", "metadata": {"page_label": "397", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The decision to list a pharmaceutical product is made based upon information available to WHO at that time, i.e. information in the submitted dossier and on the status of GMP, GLP and GCP at the facilities used in the manufacture and testing of the product at the time of the site inspection(s) conducted by WHO or at the time of the site inspection(s) conducted by an SRA, the outcome of which has been determined by WHO to meet the applicable WHO-recommended standards, in accordance with the terms of this procedure. This decision is subject to change on the basis of new information that may become available to WHO. If serious safety and/or quality concerns arise in relation to a prequalified product, WHO may delist the product after evaluation of the new evidence and a risk\u2013benefit assessment, or may suspend the product until results of further investigations become available and are evaluated by WHO.\n\n## 12. Maintenance of prequalification status\n\nApplicants are required to communicate details to WHO of any changes (variations) in manufacture and control that may have an impact on the safety, efficacy and quality of the product.\n\nGuidance on variations to prequalified dossiers as can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nIt is the applicant\u2019s responsibility to provide WHO with the appropriate documentation (referring to relevant parts of the dossier) to prove that any intended or implemented variation will not have a negative impact on the quality of the product that has been prequalified. WHO will undertake an evaluation of variations according to the established WHO guidelines and SOPs and communicate the outcome to the applicant within the prescribed time lines. Adherence to the reporting requirements will be verified during the inspections carried out by WHO.\n\nRandom samples of prequalified products supplied by listed manufacturers or applicants will be taken for independent testing of final product characteristics. Certificates of analysis of final products released by the manufacturer and specifications for test methods should be provided by the manufacturer or applicant to WHO for review upon request. In the event of failure to meet the established criteria for testing, WHO will investigate the problem and communicate the outcome of this investigation to the manufacturer and applicant, if other than the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "5c39b299ce971bc8831b516f9d69003a10b4ce0b2b70b0269e174024b3b78156", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The decision to list a pharmaceutical product is made based upon information available to WHO at that time, i.e. information in the submitted dossier and on the status of GMP, GLP and GCP at the facilities used in the manufacture and testing of the product at the time of the site inspection(s) conducted by WHO or at the time of the site inspection(s) conducted by an SRA, the outcome of which has been determined by WHO to meet the applicable WHO-recommended standards, in accordance with the terms of this procedure. This decision is subject to change on the basis of new information that may become available to WHO. If serious safety and/or quality concerns arise in relation to a prequalified product, WHO may delist the product after evaluation of the new evidence and a risk\u2013benefit assessment, or may suspend the product until results of further investigations become available and are evaluated by WHO.\n\n## 12. Maintenance of prequalification status\n\nApplicants are required to communicate details to WHO of any changes (variations) in manufacture and control that may have an impact on the safety, efficacy and quality of the product.\n\nGuidance on variations to prequalified dossiers as can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nIt is the applicant\u2019s responsibility to provide WHO with the appropriate documentation (referring to relevant parts of the dossier) to prove that any intended or implemented variation will not have a negative impact on the quality of the product that has been prequalified. WHO will undertake an evaluation of variations according to the established WHO guidelines and SOPs and communicate the outcome to the applicant within the prescribed time lines. Adherence to the reporting requirements will be verified during the inspections carried out by WHO.\n\nRandom samples of prequalified products supplied by listed manufacturers or applicants will be taken for independent testing of final product characteristics. Certificates of analysis of final products released by the manufacturer and specifications for test methods should be provided by the manufacturer or applicant to WHO for review upon request. In the event of failure to meet the established criteria for testing, WHO will investigate the problem and communicate the outcome of this investigation to the manufacturer and applicant, if other than the manufacturer.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2487, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fe238e7f-95cd-4532-8c7f-c2dd097a1ae5": {"__data__": {"id_": "fe238e7f-95cd-4532-8c7f-c2dd097a1ae5", "embedding": null, "metadata": {"page_label": "398", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Complaints concerning prequalified pharmaceutical products communicated to WHO will be investigated in accordance with an SOP established by WHO for that purpose. After investigation, WHO will provide a written report of the problem and include recommendations for action where relevant. WHO will make the report available to the applicant/manufacturer, and to the NMRA of the country where the manufacturing site is located. Subject always to the protection of commercially sensitive information as referred to above, WHO shall be entitled to make such reports public. In addition, WHO reserves the right to share the full report with the relevant authorities of interested Member States of the Organization and interested United Nations agencies.\n\nManufacturers of prequalified pharmaceutical products and associated API manufacturers will be re-inspected at regular intervals as determined by WHO, but normally at least once every three years. Re-inspections are conducted to verify compliance with GMP as recommended by WHO and include data verification.\n\nFurthermore, in order to maintain their prequalification status, WHO will arrange for prequalified pharmaceutical products to be requalified at regular intervals.\n\nEvery five years from the date of prequalification, or when requested to do so by the WHO Prequalification of Medicines Programme, the holder of a prequalified product is required to submit data and information in relation to the product to WHO for assessment. The purpose of this assessment is to verify that the product conforms to information and data submitted in relation to prequalification, conforms to current norms and standards, and to verify the consistency of the quality of the product and its manufacturing process(es) over the identified period.\n\nThe procedure and guidelines on the requalification of prequalified products can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time. Re-inspection and/or requalification may also be performed:\n\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, become evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIf, as a result of re-inspection or requalification, it is found that a product and/or specified manufacturing site no longer complies with the WHO-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS establece procedimientos para investigar quejas sobre productos farmac\u00e9uticos prequalificados. La OMS realiza inspecciones regulares a los fabricantes para verificar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) y la calidad de los productos. Cada cinco a\u00f1os, los titulares de productos prequalificados deben presentar datos para su evaluaci\u00f3n. La OMS tambi\u00e9n tiene el derecho de hacer p\u00fablicos los informes de las investigaciones, siempre que se proteja la informaci\u00f3n comercial sensible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si se encuentra que un producto farmac\u00e9utico precalificado ya no cumple con las normas de la OMS durante una re-inspecci\u00f3n?**\n   - Si se determina que un producto o un sitio de fabricaci\u00f3n ya no cumple con las normas de la OMS, se pueden tomar medidas correctivas, que pueden incluir la suspensi\u00f3n de la precalificaci\u00f3n del producto y la notificaci\u00f3n a las autoridades pertinentes.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizan las re-inspecciones de los fabricantes de productos farmac\u00e9uticos prequalificados?**\n   - Las re-inspecciones se realizan normalmente al menos una vez cada tres a\u00f1os, aunque la OMS puede determinar intervalos diferentes seg\u00fan sea necesario.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n deben presentar los titulares de productos prequalificados a la OMS cada cinco a\u00f1os?**\n   - Los titulares deben presentar datos e informaci\u00f3n que verifiquen que el producto sigue cumpliendo con la informaci\u00f3n y datos presentados durante la precalificaci\u00f3n, as\u00ed como con las normas y est\u00e1ndares actuales, y que la calidad del producto y su proceso de fabricaci\u00f3n se mantienen consistentes durante el per\u00edodo identificado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Decisi\u00f3n de Listado de Productos Farmac\u00e9uticos**:\n   - La inclusi\u00f3n de un producto farmac\u00e9utico en la lista de la OMS se basa en la informaci\u00f3n disponible en el momento de la evaluaci\u00f3n, que incluye el dossier presentado y el estado de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Laboratorio (GLP) y Buenas Pr\u00e1cticas Cl\u00ednicas (GCP).\n   - La decisi\u00f3n puede cambiar si surgen nuevas evidencias sobre la seguridad o calidad del producto.\n\n2. **Mantenimiento del Estado de Precalificaci\u00f3n**:\n   - Los solicitantes deben informar a la OMS sobre cualquier cambio en la fabricaci\u00f3n que pueda afectar la seguridad, eficacia y calidad del producto.\n   - Es responsabilidad del solicitante proporcionar la documentaci\u00f3n adecuada que demuestre que las variaciones no impactar\u00e1n negativamente en la calidad del producto precalificado.\n\n3. **Evaluaci\u00f3n de Variaciones**:\n   - La OMS evaluar\u00e1 las variaciones seg\u00fan sus directrices y procedimientos operativos est\u00e1ndar (SOPs) y comunicar\u00e1 los resultados al solicitante dentro de los plazos establecidos.\n\n4. **Pruebas Independientes**:\n   - Se tomar\u00e1n muestras aleatorias de productos precalificados para pruebas independientes de sus caracter\u00edsticas finales.\n   - Los fabricantes deben proporcionar certificados de an\u00e1lisis y especificaciones de m\u00e9todos de prueba a la OMS cuando se solicite.\n\n5. **Investigaci\u00f3n de Problemas**:\n   - Si un producto no cumple con los criterios establecidos, la OMS investigar\u00e1 el problema y comunicar\u00e1 los resultados a los fabricantes y solicitantes.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran que los productos se fabriquen de manera consistente y controlada.\n- **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normas que garantizan la calidad y la integridad de los datos generados en laboratorios.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)**: Normas \u00e9ticas y cient\u00edficas para el dise\u00f1o, realizaci\u00f3n, registro y reporte de ensayos cl\u00ednicos que involucran la participaci\u00f3n de sujetos humanos.\n- **Solicitantes**: Empresas o entidades que presentan productos para su precalificaci\u00f3n ante la OMS.", "excerpt_keywords": "Keywords: prequalified pharmaceutical products, WHO, re-inspection, GMP compliance, requalification"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a5e0369-cc47-4cd1-a0a3-f90ca71347c7", "node_type": "4", "metadata": {"page_label": "398", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Complaints concerning prequalified pharmaceutical products communicated to WHO will be investigated in accordance with an SOP established by WHO for that purpose. After investigation, WHO will provide a written report of the problem and include recommendations for action where relevant. WHO will make the report available to the applicant/manufacturer, and to the NMRA of the country where the manufacturing site is located. Subject always to the protection of commercially sensitive information as referred to above, WHO shall be entitled to make such reports public. In addition, WHO reserves the right to share the full report with the relevant authorities of interested Member States of the Organization and interested United Nations agencies.\n\nManufacturers of prequalified pharmaceutical products and associated API manufacturers will be re-inspected at regular intervals as determined by WHO, but normally at least once every three years. Re-inspections are conducted to verify compliance with GMP as recommended by WHO and include data verification.\n\nFurthermore, in order to maintain their prequalification status, WHO will arrange for prequalified pharmaceutical products to be requalified at regular intervals.\n\nEvery five years from the date of prequalification, or when requested to do so by the WHO Prequalification of Medicines Programme, the holder of a prequalified product is required to submit data and information in relation to the product to WHO for assessment. The purpose of this assessment is to verify that the product conforms to information and data submitted in relation to prequalification, conforms to current norms and standards, and to verify the consistency of the quality of the product and its manufacturing process(es) over the identified period.\n\nThe procedure and guidelines on the requalification of prequalified products can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time. Re-inspection and/or requalification may also be performed:\n\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, become evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIf, as a result of re-inspection or requalification, it is found that a product and/or specified manufacturing site no longer complies with the WHO-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "89b7de6aaf803399886e287eaf2ee635ad12ec732dadd3187e608565cb9adbc6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Complaints concerning prequalified pharmaceutical products communicated to WHO will be investigated in accordance with an SOP established by WHO for that purpose. After investigation, WHO will provide a written report of the problem and include recommendations for action where relevant. WHO will make the report available to the applicant/manufacturer, and to the NMRA of the country where the manufacturing site is located. Subject always to the protection of commercially sensitive information as referred to above, WHO shall be entitled to make such reports public. In addition, WHO reserves the right to share the full report with the relevant authorities of interested Member States of the Organization and interested United Nations agencies.\n\nManufacturers of prequalified pharmaceutical products and associated API manufacturers will be re-inspected at regular intervals as determined by WHO, but normally at least once every three years. Re-inspections are conducted to verify compliance with GMP as recommended by WHO and include data verification.\n\nFurthermore, in order to maintain their prequalification status, WHO will arrange for prequalified pharmaceutical products to be requalified at regular intervals.\n\nEvery five years from the date of prequalification, or when requested to do so by the WHO Prequalification of Medicines Programme, the holder of a prequalified product is required to submit data and information in relation to the product to WHO for assessment. The purpose of this assessment is to verify that the product conforms to information and data submitted in relation to prequalification, conforms to current norms and standards, and to verify the consistency of the quality of the product and its manufacturing process(es) over the identified period.\n\nThe procedure and guidelines on the requalification of prequalified products can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time. Re-inspection and/or requalification may also be performed:\n\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, become evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIf, as a result of re-inspection or requalification, it is found that a product and/or specified manufacturing site no longer complies with the WHO-", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2641, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "3a5813ae-b462-4e22-9733-aa5c33b3f7b8": {"__data__": {"id_": "3a5813ae-b462-4e22-9733-aa5c33b3f7b8", "embedding": null, "metadata": {"page_label": "399", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13. Cost recovery\n\nWHO reserves the right to charge for this procedure on a cost-recovery basis.\n\n# 14. Confidentiality undertaking\n\nThe assessors and inspectors will treat all information to which they will gain access during the assessments and inspections, or otherwise in connection with the discharge of their responsibilities in regard to the above-mentioned project, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set forth below.\n\nAssessors and inspectors will take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the assessment/inspection activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nAssessors and inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by manufacturers); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by manufacturers); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n# 15. Conflict of interest\n\nBefore undertaking the work, each assessor and inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is no risk of a real or perceived conflict of interest (or it is", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos relacionados con la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en el contexto de evaluaciones e inspecciones. Se establece que la OMS tiene el derecho de cobrar por estos procedimientos en base a la recuperaci\u00f3n de costos. Adem\u00e1s, se enfatiza la importancia de mantener la confidencialidad de la informaci\u00f3n a la que los evaluadores e inspectores tienen acceso, as\u00ed como la necesidad de firmar una declaraci\u00f3n de intereses para evitar conflictos de inter\u00e9s.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomar los evaluadores e inspectores para garantizar la confidencialidad de la informaci\u00f3n a la que tienen acceso?**\n   - Los evaluadores e inspectores deben asegurarse de que la informaci\u00f3n confidencial no se utilice para ning\u00fan prop\u00f3sito que no sea las actividades de evaluaci\u00f3n o inspecci\u00f3n descritas en el documento y que no se divulgue a personas no vinculadas por obligaciones similares de confidencialidad.\n\n2. **\u00bfBajo qu\u00e9 circunstancias los evaluadores e inspectores no estar\u00e1n obligados por las obligaciones de confidencialidad y no uso?**\n   - No estar\u00e1n obligados si pueden demostrar que la informaci\u00f3n confidencial ya era conocida por ellos antes de la divulgaci\u00f3n, estaba en el dominio p\u00fablico en el momento de la divulgaci\u00f3n, se ha convertido en parte del dominio p\u00fablico sin culpa de su parte, o ha sido obtenida de un tercero que no est\u00e1 en violaci\u00f3n de obligaciones legales de confidencialidad.\n\n3. **\u00bfQu\u00e9 procedimiento deben seguir los evaluadores e inspectores antes de comenzar su trabajo en relaci\u00f3n con los conflictos de inter\u00e9s?**\n   - Antes de comenzar su trabajo, cada evaluador e inspector debe firmar una declaraci\u00f3n de inter\u00e9s para asegurar que no existe un riesgo de conflicto de inter\u00e9s real o percibido.", "prev_section_summary": "### Temas Clave\n\n1. **Investigaci\u00f3n de Quejas**: La OMS investiga quejas sobre productos farmac\u00e9uticos prequalificados siguiendo un procedimiento operativo est\u00e1ndar (SOP). Se emite un informe escrito con recomendaciones y se comparte con el fabricante y la autoridad reguladora nacional (NMRA) del pa\u00eds donde se encuentra el sitio de fabricaci\u00f3n.\n\n2. **Re-inspecciones**: Los fabricantes de productos farmac\u00e9uticos prequalificados son re-inspeccionados al menos cada tres a\u00f1os para verificar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) y la calidad del producto.\n\n3. **Recalificaci\u00f3n**: Cada cinco a\u00f1os, los titulares de productos prequalificados deben presentar datos a la OMS para evaluar la conformidad del producto con las normas actuales y la consistencia de su calidad y procesos de fabricaci\u00f3n.\n\n4. **Publicaci\u00f3n de Informes**: La OMS tiene el derecho de hacer p\u00fablicos los informes de las investigaciones, protegiendo la informaci\u00f3n comercial sensible.\n\n5. **Condiciones para Re-inspecci\u00f3n/Recalificaci\u00f3n**: Se pueden realizar re-inspecciones o recalificaciones si se detectan fraudes, omisiones o si se considera que un lote de productos no cumple con las especificaciones.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la investigaci\u00f3n de quejas y la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos prequalificados.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que recibe informes sobre quejas y problemas relacionados con productos farmac\u00e9uticos en su pa\u00eds.\n- **Fabricantes de Productos Farmac\u00e9uticos Prequalificados**: Empresas que producen medicamentos que han sido evaluados y aprobados por la OMS.\n- **CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que pueden estar involucradas en el proceso de evaluaci\u00f3n inicial y seguimiento de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: cost recovery, confidentiality, conflict of interest, assessors, inspections"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5caf1014-b62a-419f-a5d7-8c46a665f51e", "node_type": "4", "metadata": {"page_label": "399", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13. Cost recovery\n\nWHO reserves the right to charge for this procedure on a cost-recovery basis.\n\n# 14. Confidentiality undertaking\n\nThe assessors and inspectors will treat all information to which they will gain access during the assessments and inspections, or otherwise in connection with the discharge of their responsibilities in regard to the above-mentioned project, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set forth below.\n\nAssessors and inspectors will take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the assessment/inspection activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nAssessors and inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by manufacturers); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by manufacturers); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n# 15. Conflict of interest\n\nBefore undertaking the work, each assessor and inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is no risk of a real or perceived conflict of interest (or it is", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f7290398c0495113dd5fd4274238a546785c451eae086a0b58a12c456707d9f6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 13. Cost recovery\n\nWHO reserves the right to charge for this procedure on a cost-recovery basis.\n\n# 14. Confidentiality undertaking\n\nThe assessors and inspectors will treat all information to which they will gain access during the assessments and inspections, or otherwise in connection with the discharge of their responsibilities in regard to the above-mentioned project, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set forth below.\n\nAssessors and inspectors will take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the assessment/inspection activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nAssessors and inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by manufacturers); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by manufacturers); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n# 15. Conflict of interest\n\nBefore undertaking the work, each assessor and inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is no risk of a real or perceived conflict of interest (or it is", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1853, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "270cf6ee-a4c3-49d2-bac1-1fb268ac46f9": {"__data__": {"id_": "270cf6ee-a4c3-49d2-bac1-1fb268ac46f9", "embedding": null, "metadata": {"page_label": "400", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "felt that there is only an insignificant and/or irrelevant conflict of interest), and it is thus deemed appropriate for the assessor or inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each assessor and inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll inspectors furthermore agree that, at the manufacturer\u2019s or CRO\u2019s request, WHO will advise the manufacturer or CRO, in advance, of the identity of each inspector and the composition of the team performing the site inspection, and provide curricula vitae of the inspectors. The manufacturer or CRO then has the opportunity to express possible concerns regarding any of the inspectors to WHO before the visit. If such concerns cannot be resolved in consultation with WHO, the manufacturer or CRO may object to a team member\u2019s participation in the site visit. Such an objection must be made known to WHO by the manufacturer or CRO within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel all or part of its agreement with, and the activities to be undertaken by, that inspector.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de conflictos de inter\u00e9s para los inspectores y evaluadores que trabajan en nombre de la organizaci\u00f3n. Se requiere que estos profesionales declaren cualquier conflicto de inter\u00e9s y notifiquen a la OMS sobre cualquier cambio en su situaci\u00f3n. Adem\u00e1s, se detalla el proceso mediante el cual los fabricantes o CROs pueden expresar preocupaciones sobre los inspectores asignados a las inspecciones de sitios, as\u00ed como el derecho de la OMS a cancelar la participaci\u00f3n de un inspector si surgen objeciones.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 procedimientos deben seguir los inspectores para declarar conflictos de inter\u00e9s y c\u00f3mo deben notificar a la OMS sobre cambios en su situaci\u00f3n?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de declaraci\u00f3n de conflictos de inter\u00e9s y el proceso de notificaci\u00f3n a la OMS.\n\n2. **\u00bfCu\u00e1l es el plazo que tienen los fabricantes o CROs para expresar objeciones sobre los inspectores asignados antes de una visita de inspecci\u00f3n?**\n   - Esta pregunta aborda el tiempo l\u00edmite que tienen los fabricantes o CROs para comunicar sus preocupaciones sobre los inspectores.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS en caso de que un fabricante o CRO exprese una objeci\u00f3n sobre un inspector asignado?**\n   - Esta pregunta explora las acciones que puede tomar la OMS si se presenta una objeci\u00f3n por parte de un fabricante o CRO respecto a un inspector.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recuperaci\u00f3n de Costos**:\n   - La OMS se reserva el derecho de cobrar por los procedimientos de evaluaci\u00f3n e inspecci\u00f3n en base a la recuperaci\u00f3n de costos.\n\n2. **Confidencialidad**:\n   - Los evaluadores e inspectores deben tratar toda la informaci\u00f3n a la que acceden como confidencial y propietaria de la OMS o de sus colaboradores.\n   - Se establecen medidas para asegurar que la informaci\u00f3n confidencial no se utilice para otros prop\u00f3sitos ni se divulgue a personas no autorizadas.\n   - Existen excepciones a las obligaciones de confidencialidad si la informaci\u00f3n ya era conocida, estaba en el dominio p\u00fablico, se volvi\u00f3 p\u00fablica sin culpa de los evaluadores, o fue obtenida de un tercero sin violar obligaciones de confidencialidad.\n\n3. **Conflicto de Inter\u00e9s**:\n   - Antes de comenzar su trabajo, cada evaluador e inspector debe firmar una declaraci\u00f3n de intereses para asegurar que no existe un riesgo de conflicto de inter\u00e9s real o percibido.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de establecer las pol\u00edticas de confidencialidad y recuperaci\u00f3n de costos.\n- **Evaluadores e Inspectores**: Profesionales encargados de llevar a cabo las evaluaciones e inspecciones bajo las directrices de la OMS. \n\nEste resumen destaca la importancia de la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en el contexto de las evaluaciones realizadas por la OMS.", "excerpt_keywords": "Keywords: conflictos de inter\u00e9s, inspectores, OMS, evaluaci\u00f3n, fabricantes"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "42dfc961-226b-487c-bbeb-86d81c61c7f8", "node_type": "4", "metadata": {"page_label": "400", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "felt that there is only an insignificant and/or irrelevant conflict of interest), and it is thus deemed appropriate for the assessor or inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each assessor and inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll inspectors furthermore agree that, at the manufacturer\u2019s or CRO\u2019s request, WHO will advise the manufacturer or CRO, in advance, of the identity of each inspector and the composition of the team performing the site inspection, and provide curricula vitae of the inspectors. The manufacturer or CRO then has the opportunity to express possible concerns regarding any of the inspectors to WHO before the visit. If such concerns cannot be resolved in consultation with WHO, the manufacturer or CRO may object to a team member\u2019s participation in the site visit. Such an objection must be made known to WHO by the manufacturer or CRO within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel all or part of its agreement with, and the activities to be undertaken by, that inspector.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "fe8dd580309c5405c23b80da28e4d4ec0c856a001072d9b596529b2959d6dc02", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "felt that there is only an insignificant and/or irrelevant conflict of interest), and it is thus deemed appropriate for the assessor or inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each assessor and inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll inspectors furthermore agree that, at the manufacturer\u2019s or CRO\u2019s request, WHO will advise the manufacturer or CRO, in advance, of the identity of each inspector and the composition of the team performing the site inspection, and provide curricula vitae of the inspectors. The manufacturer or CRO then has the opportunity to express possible concerns regarding any of the inspectors to WHO before the visit. If such concerns cannot be resolved in consultation with WHO, the manufacturer or CRO may object to a team member\u2019s participation in the site visit. Such an objection must be made known to WHO by the manufacturer or CRO within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel all or part of its agreement with, and the activities to be undertaken by, that inspector.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1352, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "872752dd-d2bf-40c9-ba56-5ffe35407718": {"__data__": {"id_": "872752dd-d2bf-40c9-ba56-5ffe35407718", "embedding": null, "metadata": {"page_label": "401", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Flowchart of WHO prequalification of pharmaceutical products\n\n1. **EOI** by applicant to participate in WHO Prequalification of Medicines Programme\n\n2. **Receipt and processing of EOIs** and accompanying documentation by WHO Prequalification of Medicines Programme\n\n### 3A. Assessment of dossiers\nby WHO in two parallel tracks:\n- quality part\n- clinical part\n\n**Communication with the applicant**  \nResults from dossier assessment (including deficiencies found) are communicated to the applicant. If corrective actions are required, WHO will postpone its decision on the acceptability of data and information presented.\n\n### 3B. Inspection\nin three parallel tracks:\n- manufacturing site of FPPs\n- manufacturing site of APIs\n- clinical research sites\n\n**Communication with the applicant, manufacturer and CRO**  \nResults from inspections are communicated to the manufacturer or CRO, as applicable. If corrective actions are required, WHO will postpone its decision on the acceptability of the respective sites.\n\n4. **Final decision on prequalification**  \nIn the case that the product dossier and inspected manufacturing and clinical sites are found to be acceptable (i.e. to be in compliance with WHO-recommended standards).\n\n5. **Listing of prequalified product**  \nand manufacturing site(s) on the WHO web site  \nPublication of WHOPIRS and WHOPARs.\n\n6. **Maintenance of list of prequalified products**  \nSampling and testing, handling of variations and complaints, re-inspection, requalification, etc. WHO may suspend or remove products from the list.\n\n----\n\n**EOI**: expression of interest;  \n**FPP**: finished pharmaceutical product;  \n**API**: active pharmaceutical ingredient;  \n**CRO**: contract research organization;  \n**WHOPIR**: public inspection report;  \n**WHOPAR**: public assessment report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe el flujo del proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Este proceso incluye la presentaci\u00f3n de una expresi\u00f3n de inter\u00e9s (EOI) por parte del solicitante, la evaluaci\u00f3n de los expedientes en dos partes (calidad y cl\u00ednica), inspecciones de los sitios de fabricaci\u00f3n y de investigaci\u00f3n cl\u00ednica, y la decisi\u00f3n final sobre la precalificaci\u00f3n. Si se cumplen los est\u00e1ndares recomendados por la OMS, el producto se lista en el sitio web de la OMS y se mantiene un seguimiento continuo de los productos precalificados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si se encuentran deficiencias durante la evaluaci\u00f3n del expediente por parte de la OMS?**\n   - Respuesta: Si se encuentran deficiencias durante la evaluaci\u00f3n del expediente, la OMS comunica los resultados al solicitante y, si se requieren acciones correctivas, pospone su decisi\u00f3n sobre la aceptabilidad de los datos e informaci\u00f3n presentados.\n\n2. **\u00bfCu\u00e1les son los tres tipos de inspecciones que realiza la OMS durante el proceso de precalificaci\u00f3n?**\n   - Respuesta: La OMS realiza inspecciones en tres tipos de sitios: el sitio de fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs), el sitio de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y los sitios de investigaci\u00f3n cl\u00ednica.\n\n3. **\u00bfQu\u00e9 implica la \"mantenimiento de la lista de productos precalificados\" por parte de la OMS?**\n   - Respuesta: El mantenimiento de la lista de productos precalificados implica actividades como muestreo y pruebas, manejo de variaciones y quejas, re-inspecciones y re-calificaciones. La OMS tambi\u00e9n puede suspender o eliminar productos de la lista si es necesario.", "prev_section_summary": "### Temas Clave:\n1. **Conflictos de Inter\u00e9s**: Se establece la obligaci\u00f3n de los inspectores y evaluadores de declarar cualquier conflicto de inter\u00e9s y notificar a la OMS sobre cambios en su situaci\u00f3n.\n2. **Proceso de Inspecci\u00f3n**: Se detalla el procedimiento que deben seguir los fabricantes o CROs para expresar preocupaciones sobre los inspectores asignados a las inspecciones de sitios.\n3. **Derechos de la OMS**: La OMS tiene la autoridad para cancelar la participaci\u00f3n de un inspector si se presentan objeciones por parte de un fabricante o CRO.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de supervisar y regular los conflictos de inter\u00e9s y las inspecciones.\n- **Inspectores y Evaluadores**: Profesionales que realizan funciones de asesor\u00eda y evaluaci\u00f3n en nombre de la OMS.\n- **Fabricantes y CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que pueden expresar preocupaciones sobre los inspectores asignados a sus inspecciones.\n\n### Resumen:\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de conflictos de inter\u00e9s para inspectores y evaluadores, quienes deben declarar y notificar cualquier cambio en su situaci\u00f3n. Adem\u00e1s, se describe el proceso mediante el cual los fabricantes o CROs pueden expresar preocupaciones sobre los inspectores antes de una visita de inspecci\u00f3n, as\u00ed como el derecho de la OMS a cancelar la participaci\u00f3n de un inspector si surgen objeciones.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, inspection, assessment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd25c970-03cd-4d06-a610-617279aec832", "node_type": "4", "metadata": {"page_label": "401", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Flowchart of WHO prequalification of pharmaceutical products\n\n1. **EOI** by applicant to participate in WHO Prequalification of Medicines Programme\n\n2. **Receipt and processing of EOIs** and accompanying documentation by WHO Prequalification of Medicines Programme\n\n### 3A. Assessment of dossiers\nby WHO in two parallel tracks:\n- quality part\n- clinical part\n\n**Communication with the applicant**  \nResults from dossier assessment (including deficiencies found) are communicated to the applicant. If corrective actions are required, WHO will postpone its decision on the acceptability of data and information presented.\n\n### 3B. Inspection\nin three parallel tracks:\n- manufacturing site of FPPs\n- manufacturing site of APIs\n- clinical research sites\n\n**Communication with the applicant, manufacturer and CRO**  \nResults from inspections are communicated to the manufacturer or CRO, as applicable. If corrective actions are required, WHO will postpone its decision on the acceptability of the respective sites.\n\n4. **Final decision on prequalification**  \nIn the case that the product dossier and inspected manufacturing and clinical sites are found to be acceptable (i.e. to be in compliance with WHO-recommended standards).\n\n5. **Listing of prequalified product**  \nand manufacturing site(s) on the WHO web site  \nPublication of WHOPIRS and WHOPARs.\n\n6. **Maintenance of list of prequalified products**  \nSampling and testing, handling of variations and complaints, re-inspection, requalification, etc. WHO may suspend or remove products from the list.\n\n----\n\n**EOI**: expression of interest;  \n**FPP**: finished pharmaceutical product;  \n**API**: active pharmaceutical ingredient;  \n**CRO**: contract research organization;  \n**WHOPIR**: public inspection report;  \n**WHOPAR**: public assessment report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d5984a9a895d917c7ae984f76eebdd240bf2a1e34a593a7ac65977a2543fd1f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 1\n\n## Flowchart of WHO prequalification of pharmaceutical products\n\n1. **EOI** by applicant to participate in WHO Prequalification of Medicines Programme\n\n2. **Receipt and processing of EOIs** and accompanying documentation by WHO Prequalification of Medicines Programme\n\n### 3A. Assessment of dossiers\nby WHO in two parallel tracks:\n- quality part\n- clinical part\n\n**Communication with the applicant**  \nResults from dossier assessment (including deficiencies found) are communicated to the applicant. If corrective actions are required, WHO will postpone its decision on the acceptability of data and information presented.\n\n### 3B. Inspection\nin three parallel tracks:\n- manufacturing site of FPPs\n- manufacturing site of APIs\n- clinical research sites\n\n**Communication with the applicant, manufacturer and CRO**  \nResults from inspections are communicated to the manufacturer or CRO, as applicable. If corrective actions are required, WHO will postpone its decision on the acceptability of the respective sites.\n\n4. **Final decision on prequalification**  \nIn the case that the product dossier and inspected manufacturing and clinical sites are found to be acceptable (i.e. to be in compliance with WHO-recommended standards).\n\n5. **Listing of prequalified product**  \nand manufacturing site(s) on the WHO web site  \nPublication of WHOPIRS and WHOPARs.\n\n6. **Maintenance of list of prequalified products**  \nSampling and testing, handling of variations and complaints, re-inspection, requalification, etc. WHO may suspend or remove products from the list.\n\n----\n\n**EOI**: expression of interest;  \n**FPP**: finished pharmaceutical product;  \n**API**: active pharmaceutical ingredient;  \n**CRO**: contract research organization;  \n**WHOPIR**: public inspection report;  \n**WHOPAR**: public assessment report.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1822, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "43100b44-fcba-4fff-832a-aa6fd9f3b74d": {"__data__": {"id_": "43100b44-fcba-4fff-832a-aa6fd9f3b74d", "embedding": null, "metadata": {"page_label": "402", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n**Characteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site**\n\n- WHO product reference number\n- International Nonproprietary Name (INN) of active pharmaceutical ingredient(s) (API(s))\n- Dosage form and strength\n- Trade name(s) of the product (if applicable)\n- Name of applicant and official address\n- Name of manufacturer of finished pharmaceutical product (FPP)\n- Physical address of manufacturing site(s) (and unit, if applicable)\n- Name of API manufacturer, physical address of manufacturing site(s) (and unit, if applicable)\n- Product description (as in FPP specifications, i.e. coated, scored, etc.)\n- Pack size(s), primary and secondary packaging material(s)\n- Storage conditions\n- Shelf-life (provisional, if applicable)\n- Summary of product characteristics\n- Package leaflet\n- Labelling", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye un ap\u00e9ndice que detalla las caracter\u00edsticas de los productos farmac\u00e9uticos precalificados que se har\u00e1n disponibles para el acceso p\u00fablico en el sitio web de la OMS. Este ap\u00e9ndice enumera informaci\u00f3n clave que debe ser proporcionada para cada producto, incluyendo el nombre del fabricante, la forma de dosificaci\u00f3n, las condiciones de almacenamiento y otros detalles relevantes.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica se requiere sobre el fabricante del producto farmac\u00e9utico precalificado?**\n   - Esta pregunta busca detalles sobre los requisitos de informaci\u00f3n relacionados con el fabricante, como el nombre y la direcci\u00f3n f\u00edsica del sitio de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento y la vida \u00fatil que deben ser reportadas para un producto farmac\u00e9utico precalificado?**\n   - Esta pregunta se centra en los aspectos log\u00edsticos y de conservaci\u00f3n del producto, que son cruciales para su manejo y distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n adicional se debe incluir junto con la descripci\u00f3n del producto farmac\u00e9utico en el sitio web de la OMS?**\n   - Esta pregunta indaga sobre los documentos complementarios que deben acompa\u00f1ar la informaci\u00f3n del producto, como el prospecto y el etiquetado, que son esenciales para el usuario final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento presenta un flujo de trabajo detallado sobre el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Los temas clave incluyen:\n\n1. **Expresi\u00f3n de Inter\u00e9s (EOI)**: El proceso comienza con la presentaci\u00f3n de una EOI por parte del solicitante para participar en el programa de precalificaci\u00f3n de medicamentos de la OMS.\n\n2. **Recepci\u00f3n y Procesamiento de EOIs**: La OMS recibe y procesa las EOIs y la documentaci\u00f3n correspondiente.\n\n3. **Evaluaci\u00f3n de Dossiers**: La evaluaci\u00f3n se realiza en dos partes paralelas:\n   - Parte de calidad\n   - Parte cl\u00ednica  \n   Si se encuentran deficiencias, la OMS comunica los resultados al solicitante y puede posponer su decisi\u00f3n.\n\n4. **Inspecciones**: Se llevan a cabo inspecciones en tres tipos de sitios:\n   - Sitios de fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs)\n   - Sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs)\n   - Sitios de investigaci\u00f3n cl\u00ednica  \n   Los resultados de las inspecciones tambi\u00e9n se comunican a los involucrados, y se pueden requerir acciones correctivas.\n\n5. **Decisi\u00f3n Final sobre Precalificaci\u00f3n**: Se toma una decisi\u00f3n final si el expediente del producto y los sitios inspeccionados cumplen con los est\u00e1ndares recomendados por la OMS.\n\n6. **Listado de Productos Precalificados**: Los productos que cumplen son listados en el sitio web de la OMS, junto con la publicaci\u00f3n de informes de inspecci\u00f3n y evaluaci\u00f3n.\n\n7. **Mantenimiento de la Lista de Productos Precalificados**: Incluye actividades como muestreo, pruebas, manejo de quejas, re-inspecciones y re-calificaciones. La OMS tiene la autoridad para suspender o eliminar productos de la lista.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable del proceso de precalificaci\u00f3n.\n- **EOI (Expresi\u00f3n de Inter\u00e9s)**: Solicitud inicial para participar en el programa.\n- **FPP (Producto Farmac\u00e9utico Terminado)**: Producto final que se eval\u00faa.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Componente activo de los productos farmac\u00e9uticos.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad que puede estar involucrada en la investigaci\u00f3n cl\u00ednica.\n- **WHOPIR (Informe P\u00fablico de Inspecci\u00f3n)**: Informe sobre la inspecci\u00f3n de productos.\n- **WHOPAR (Informe P\u00fablico de Evaluaci\u00f3n)**: Informe sobre la evaluaci\u00f3n de productos. \n\nEste resumen proporciona una visi\u00f3n general del proceso de precalificaci\u00f3n de la OMS y las entidades involucradas en \u00e9l.", "excerpt_keywords": "Keywords: prequalified pharmaceuticals, WHO, product characteristics, manufacturing information, storage conditions"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd3f3f91-808e-4877-92ff-e233f4f7c290", "node_type": "4", "metadata": {"page_label": "402", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n**Characteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site**\n\n- WHO product reference number\n- International Nonproprietary Name (INN) of active pharmaceutical ingredient(s) (API(s))\n- Dosage form and strength\n- Trade name(s) of the product (if applicable)\n- Name of applicant and official address\n- Name of manufacturer of finished pharmaceutical product (FPP)\n- Physical address of manufacturing site(s) (and unit, if applicable)\n- Name of API manufacturer, physical address of manufacturing site(s) (and unit, if applicable)\n- Product description (as in FPP specifications, i.e. coated, scored, etc.)\n- Pack size(s), primary and secondary packaging material(s)\n- Storage conditions\n- Shelf-life (provisional, if applicable)\n- Summary of product characteristics\n- Package leaflet\n- Labelling", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0b6f97bf3bc8a13ec87c6af1243573473005c56287ab15a2fb082337a008d2dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 2\n\n**Characteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site**\n\n- WHO product reference number\n- International Nonproprietary Name (INN) of active pharmaceutical ingredient(s) (API(s))\n- Dosage form and strength\n- Trade name(s) of the product (if applicable)\n- Name of applicant and official address\n- Name of manufacturer of finished pharmaceutical product (FPP)\n- Physical address of manufacturing site(s) (and unit, if applicable)\n- Name of API manufacturer, physical address of manufacturing site(s) (and unit, if applicable)\n- Product description (as in FPP specifications, i.e. coated, scored, etc.)\n- Pack size(s), primary and secondary packaging material(s)\n- Storage conditions\n- Shelf-life (provisional, if applicable)\n- Summary of product characteristics\n- Package leaflet\n- Labelling", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 868, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b21ec205-87d0-4fc2-ab7c-fdcc4c97179b": {"__data__": {"id_": "b21ec205-87d0-4fc2-ab7c-fdcc4c97179b", "embedding": null, "metadata": {"page_label": "403", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 11\n\n## Guidelines on submission of documentation for prequalification of innovator<sup>1</sup> finished pharmaceutical products approved by stringent regulatory authorities<sup>2</sup>\n\nThe World Health Organization (WHO) recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. Where an applicant and a stringent regulatory authority (SRA) can agree to share the following information on an innovator FPP with WHO, WHO will consider such an FPP for inclusion in the list of WHO prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe following should be submitted:\n\n1. **A covering letter, which should include:**\n   - A statement indicating that the information submitted is true and correct;\n   - A statement confirming that, for WHO prequalification, the product, including composition, formulation, strength, specifications, packaging will at the time of submission be the same in all respects as the product registered with the relevant SRA; and\n   - The name of the person responsible for communication with WHO on any issues related to the product.\n\n2. **An original or certified copy of the current WHO-type Certificate of a Pharmaceutical Product issued and fully completed, including answers to each question, by the relevant SRA, together with the latest approved summary of product characteristics (SmPC), or an equivalent thereof, as well as the patient information leaflet (PIL) and the labelling.**\n\n----\n\n<sup>1</sup> Generally, the innovator pharmaceutical product is that which was first authorized for marketing, on the basis of documentation of quality, safety and efficacy (WHO Technical Report Series, No. 937, Annex 7, 2006).\n\n<sup>2</sup> Stringent regulatory authority (SRA): a regulatory authority which is: (a) a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or (b) an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) establece directrices para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores que han sido aprobados por autoridades regulatorias estrictas. Se reconoce la evaluaci\u00f3n cient\u00edfica de estos productos y se detalla la informaci\u00f3n que debe ser presentada para su consideraci\u00f3n en la lista de productos precalificados por la OMS.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la carta de presentaci\u00f3n para la precalificaci\u00f3n de un producto farmac\u00e9utico innovador?**\n   - La carta debe incluir una declaraci\u00f3n de veracidad de la informaci\u00f3n, una confirmaci\u00f3n de que el producto es id\u00e9ntico al registrado con la autoridad regulatoria, y el nombre de la persona responsable de la comunicaci\u00f3n con la OMS.\n\n2. **\u00bfQu\u00e9 documentos espec\u00edficos se requieren para la presentaci\u00f3n de un producto farmac\u00e9utico innovador a la OMS?**\n   - Se requiere un original o copia certificada del Certificado de Producto Farmac\u00e9utico tipo OMS, junto con el resumen de caracter\u00edsticas del producto (SmPC), el folleto de informaci\u00f3n para el paciente (PIL) y el etiquetado.\n\n3. **\u00bfC\u00f3mo se define una autoridad regulatoria estricta (SRA) seg\u00fan el documento de la OMS?**\n   - Una SRA es una autoridad que es miembro de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), un observador de la ICH, o una autoridad asociada a un miembro de la ICH mediante un acuerdo de reconocimiento mutuo legalmente vinculante.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n del ap\u00e9ndice del documento \"WHO - Technical Report Series 961\" se centra en las caracter\u00edsticas que deben ser proporcionadas para los productos farmac\u00e9uticos precalificados que estar\u00e1n disponibles en el sitio web de la OMS. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Informaci\u00f3n del Producto**:\n   - N\u00famero de referencia del producto de la OMS.\n   - Nombre no propietario internacional (INN) de los ingredientes activos (API).\n   - Forma de dosificaci\u00f3n y concentraci\u00f3n.\n\n2. **Informaci\u00f3n del Fabricante**:\n   - Nombre y direcci\u00f3n oficial del solicitante.\n   - Nombre y direcci\u00f3n f\u00edsica del fabricante del producto farmac\u00e9utico terminado (FPP).\n   - Informaci\u00f3n sobre el fabricante del API, incluyendo direcci\u00f3n f\u00edsica.\n\n3. **Detalles del Producto**:\n   - Descripci\u00f3n del producto seg\u00fan las especificaciones del FPP (ej. recubierto, ranurado).\n   - Tama\u00f1os de empaque y materiales de empaque primario y secundario.\n\n4. **Condiciones de Almacenamiento y Vida \u00datil**:\n   - Condiciones de almacenamiento requeridas.\n   - Vida \u00fatil del producto (provisional si es aplicable).\n\n5. **Documentaci\u00f3n Adicional**:\n   - Resumen de las caracter\u00edsticas del producto.\n   - Prospecto del producto.\n   - Etiquetado del producto.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n y regulaci\u00f3n de los productos farmac\u00e9uticos.\n- **Ingredientes Activos (API)**: Componentes farmac\u00e9uticos que tienen un efecto terap\u00e9utico.\n- **Producto Farmac\u00e9utico Terminado (FPP)**: Producto final que se ofrece al consumidor.\n- **Solicitante**: Entidad o persona que presenta la solicitud para la precalificaci\u00f3n del producto.\n\nEste resumen destaca la importancia de la transparencia y la regulaci\u00f3n en la disponibilidad de productos farmac\u00e9uticos, asegurando que la informaci\u00f3n relevante est\u00e9 accesible para el p\u00fablico y los profesionales de la salud.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, regulatory authorities, documentation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "04dc2aec-2f84-4178-97cb-b2e9cb25d29a", "node_type": "4", "metadata": {"page_label": "403", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 11\n\n## Guidelines on submission of documentation for prequalification of innovator<sup>1</sup> finished pharmaceutical products approved by stringent regulatory authorities<sup>2</sup>\n\nThe World Health Organization (WHO) recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. Where an applicant and a stringent regulatory authority (SRA) can agree to share the following information on an innovator FPP with WHO, WHO will consider such an FPP for inclusion in the list of WHO prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe following should be submitted:\n\n1. **A covering letter, which should include:**\n   - A statement indicating that the information submitted is true and correct;\n   - A statement confirming that, for WHO prequalification, the product, including composition, formulation, strength, specifications, packaging will at the time of submission be the same in all respects as the product registered with the relevant SRA; and\n   - The name of the person responsible for communication with WHO on any issues related to the product.\n\n2. **An original or certified copy of the current WHO-type Certificate of a Pharmaceutical Product issued and fully completed, including answers to each question, by the relevant SRA, together with the latest approved summary of product characteristics (SmPC), or an equivalent thereof, as well as the patient information leaflet (PIL) and the labelling.**\n\n----\n\n<sup>1</sup> Generally, the innovator pharmaceutical product is that which was first authorized for marketing, on the basis of documentation of quality, safety and efficacy (WHO Technical Report Series, No. 937, Annex 7, 2006).\n\n<sup>2</sup> Stringent regulatory authority (SRA): a regulatory authority which is: (a) a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or (b) an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "a8470f1b0994b08dce96f988ade7f099c0439b33fef47046d6e334c87cc9a85d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 11\n\n## Guidelines on submission of documentation for prequalification of innovator<sup>1</sup> finished pharmaceutical products approved by stringent regulatory authorities<sup>2</sup>\n\nThe World Health Organization (WHO) recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. Where an applicant and a stringent regulatory authority (SRA) can agree to share the following information on an innovator FPP with WHO, WHO will consider such an FPP for inclusion in the list of WHO prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe following should be submitted:\n\n1. **A covering letter, which should include:**\n   - A statement indicating that the information submitted is true and correct;\n   - A statement confirming that, for WHO prequalification, the product, including composition, formulation, strength, specifications, packaging will at the time of submission be the same in all respects as the product registered with the relevant SRA; and\n   - The name of the person responsible for communication with WHO on any issues related to the product.\n\n2. **An original or certified copy of the current WHO-type Certificate of a Pharmaceutical Product issued and fully completed, including answers to each question, by the relevant SRA, together with the latest approved summary of product characteristics (SmPC), or an equivalent thereof, as well as the patient information leaflet (PIL) and the labelling.**\n\n----\n\n<sup>1</sup> Generally, the innovator pharmaceutical product is that which was first authorized for marketing, on the basis of documentation of quality, safety and efficacy (WHO Technical Report Series, No. 937, Annex 7, 2006).\n\n<sup>2</sup> Stringent regulatory authority (SRA): a regulatory authority which is: (a) a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or (b) an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2524, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "0560e4e4-098f-480e-afe7-48e96c02ee58": {"__data__": {"id_": "0560e4e4-098f-480e-afe7-48e96c02ee58", "embedding": null, "metadata": {"page_label": "404", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Requirements\n\n3. An assessment report issued by the relevant SRA: a publicly available scientific assessment report, such as the Scientific Discussion of the European Public Assessment Report (EPAR), issued by the relevant SRA is also acceptable.\n\n4. A certified copy of the marketing authorization issued by the relevant SRA. If applicable a certified copy of the latest renewal of the marketing authorization should also be provided.\n\n5. A list of the SRA-approved manufacturer(s) of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n6. A list of the SRA-approved manufacturer(s) of the active pharmaceutical ingredient(s) (API(s)) used in the manufacture of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n7. A sample(s) of the product in market packaging(s) should be provided with the submission to enable a visual inspection to be made. The respective certificate of analysis should be attached.\n\nPlease note that the submission must be in English, which includes certified English translations of the SmPC and other documents. These documents should be made available both as hard copies and electronically. The SmPC and PIL should be submitted as Word files.\n\nVariations to and renewal of the marketing authorization of a product that has been prequalified by WHO based on the approval by an SRA, remain the responsibility of the relevant SRA.\n\nOnce the product has been prequalified, WHO should be provided with a copy of the regulatory acceptance letter of any changes to the main characteristics of the product \u2014 such as the labelling for storage, the nature and contents of the container, the shelf-life, manufacturing site(s) of the FPP or API, or any other relevant change to the product information \u2014 immediately after the variation has been approved by the relevant SRA. The main characteristics of the product will be listed in the Letter of Prequalification.\n\nThe preferred storage condition for WHO prequalified products is \u201cdo not store above 30 \u00b0C\u201d. If this is not indicated on the SmPC, PIL and labels of the innovator product, applicants are encouraged to apply for a variation in this respect with the relevant SRA. This could also be done after prequalification of the product.\n\nProducts that received tentative approval from the United States Food and Drug Administration (FDA) or positive opinions under Article 58 of European Union Regulation (EC) No. 726/2004 or the Canada S.C. 2004, c. 23 (Bill C-9) procedure are not within the scope of this guideline. Such products can be co-listed on the WHO List of Prequalified Products in accordance with mutual agreements between WHO and these regulatory authorities. \n\n----\n\n3 Information and the full text of the relevant WHO documents can be found on the web site http://apps.who.int/prequal/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la presentaci\u00f3n de productos farmac\u00e9uticos que buscan la precalificaci\u00f3n. Incluye la necesidad de informes de evaluaci\u00f3n de la autoridad reguladora correspondiente (SRA), copias certificadas de autorizaciones de comercializaci\u00f3n, listas de fabricantes aprobados y muestras del producto. Adem\u00e1s, se enfatiza que toda la documentaci\u00f3n debe estar en ingl\u00e9s y que las variaciones en la autorizaci\u00f3n de comercializaci\u00f3n son responsabilidad de la SRA. Tambi\u00e9n se menciona que los productos con aprobaci\u00f3n tentativa de la FDA o bajo ciertas regulaciones de la UE y Canad\u00e1 no est\u00e1n dentro del alcance de estas pautas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informe de evaluaci\u00f3n es aceptable para la presentaci\u00f3n de un producto farmac\u00e9utico a la OMS?**\n   - Se acepta un informe de evaluaci\u00f3n emitido por la SRA relevante, como el Informe de Discusi\u00f3n Cient\u00edfica del Informe de Evaluaci\u00f3n P\u00fablica Europea (EPAR).\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento preferidas para los productos precalificados por la OMS?**\n   - La condici\u00f3n de almacenamiento preferida es \"no almacenar por encima de 30 \u00b0C\". Si esto no est\u00e1 indicado en el SmPC, PIL y etiquetas del producto innovador, se alienta a los solicitantes a solicitar una variaci\u00f3n.\n\n3. **\u00bfQu\u00e9 documentos deben presentarse en ingl\u00e9s y en qu\u00e9 formato deben estar disponibles?**\n   - Todos los documentos, incluidas las traducciones certificadas del SmPC y otros documentos, deben estar en ingl\u00e9s y disponibles tanto en copias f\u00edsicas como electr\u00f3nicas. El SmPC y el PIL deben presentarse en archivos de Word.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **Precalificaci\u00f3n de productos farmac\u00e9uticos innovadores:** Directrices de la OMS para la presentaci\u00f3n de documentaci\u00f3n necesaria para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados que han sido aprobados por autoridades regulatorias estrictas.\n2. **Evaluaci\u00f3n cient\u00edfica:** Reconocimiento de la evaluaci\u00f3n realizada por autoridades regulatorias que cumplen con est\u00e1ndares rigurosos de calidad, seguridad y eficacia.\n3. **Documentaci\u00f3n requerida:** Detalles sobre la informaci\u00f3n y documentos que deben ser presentados, incluyendo una carta de presentaci\u00f3n y un Certificado de Producto Farmac\u00e9utico tipo OMS.\n4. **Definici\u00f3n de autoridad regulatoria estricta (SRA):** Criterios que determinan qu\u00e9 entidades se consideran SRA, incluyendo membres\u00eda en la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y acuerdos de reconocimiento mutuo.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad que establece las directrices para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades regulatorias estrictas (SRA):** Incluyen miembros de la ICH, observadores de la ICH y autoridades asociadas mediante acuerdos de reconocimiento mutuo.\n- **Productos farmac\u00e9uticos terminados innovadores (FPPs):** Productos que han sido autorizados para comercializaci\u00f3n bas\u00e1ndose en documentaci\u00f3n de calidad, seguridad y eficacia. \n\nEste resumen abarca los aspectos esenciales de la secci\u00f3n, destacando la importancia de la documentaci\u00f3n y la evaluaci\u00f3n regulatoria en el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: precalification, regulatory authority, marketing authorization, pharmaceutical products, WHO guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5536d671-c208-43c8-b192-afe434b0b1c9", "node_type": "4", "metadata": {"page_label": "404", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Requirements\n\n3. An assessment report issued by the relevant SRA: a publicly available scientific assessment report, such as the Scientific Discussion of the European Public Assessment Report (EPAR), issued by the relevant SRA is also acceptable.\n\n4. A certified copy of the marketing authorization issued by the relevant SRA. If applicable a certified copy of the latest renewal of the marketing authorization should also be provided.\n\n5. A list of the SRA-approved manufacturer(s) of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n6. A list of the SRA-approved manufacturer(s) of the active pharmaceutical ingredient(s) (API(s)) used in the manufacture of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n7. A sample(s) of the product in market packaging(s) should be provided with the submission to enable a visual inspection to be made. The respective certificate of analysis should be attached.\n\nPlease note that the submission must be in English, which includes certified English translations of the SmPC and other documents. These documents should be made available both as hard copies and electronically. The SmPC and PIL should be submitted as Word files.\n\nVariations to and renewal of the marketing authorization of a product that has been prequalified by WHO based on the approval by an SRA, remain the responsibility of the relevant SRA.\n\nOnce the product has been prequalified, WHO should be provided with a copy of the regulatory acceptance letter of any changes to the main characteristics of the product \u2014 such as the labelling for storage, the nature and contents of the container, the shelf-life, manufacturing site(s) of the FPP or API, or any other relevant change to the product information \u2014 immediately after the variation has been approved by the relevant SRA. The main characteristics of the product will be listed in the Letter of Prequalification.\n\nThe preferred storage condition for WHO prequalified products is \u201cdo not store above 30 \u00b0C\u201d. If this is not indicated on the SmPC, PIL and labels of the innovator product, applicants are encouraged to apply for a variation in this respect with the relevant SRA. This could also be done after prequalification of the product.\n\nProducts that received tentative approval from the United States Food and Drug Administration (FDA) or positive opinions under Article 58 of European Union Regulation (EC) No. 726/2004 or the Canada S.C. 2004, c. 23 (Bill C-9) procedure are not within the scope of this guideline. Such products can be co-listed on the WHO List of Prequalified Products in accordance with mutual agreements between WHO and these regulatory authorities. \n\n----\n\n3 Information and the full text of the relevant WHO documents can be found on the web site http://apps.who.int/prequal/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "c740c9c3e88f7c6180d7691f18a1d7dfdca7e7ffe8a6e4885c084c3e2a4b7e10", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Document Requirements\n\n3. An assessment report issued by the relevant SRA: a publicly available scientific assessment report, such as the Scientific Discussion of the European Public Assessment Report (EPAR), issued by the relevant SRA is also acceptable.\n\n4. A certified copy of the marketing authorization issued by the relevant SRA. If applicable a certified copy of the latest renewal of the marketing authorization should also be provided.\n\n5. A list of the SRA-approved manufacturer(s) of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n6. A list of the SRA-approved manufacturer(s) of the active pharmaceutical ingredient(s) (API(s)) used in the manufacture of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n7. A sample(s) of the product in market packaging(s) should be provided with the submission to enable a visual inspection to be made. The respective certificate of analysis should be attached.\n\nPlease note that the submission must be in English, which includes certified English translations of the SmPC and other documents. These documents should be made available both as hard copies and electronically. The SmPC and PIL should be submitted as Word files.\n\nVariations to and renewal of the marketing authorization of a product that has been prequalified by WHO based on the approval by an SRA, remain the responsibility of the relevant SRA.\n\nOnce the product has been prequalified, WHO should be provided with a copy of the regulatory acceptance letter of any changes to the main characteristics of the product \u2014 such as the labelling for storage, the nature and contents of the container, the shelf-life, manufacturing site(s) of the FPP or API, or any other relevant change to the product information \u2014 immediately after the variation has been approved by the relevant SRA. The main characteristics of the product will be listed in the Letter of Prequalification.\n\nThe preferred storage condition for WHO prequalified products is \u201cdo not store above 30 \u00b0C\u201d. If this is not indicated on the SmPC, PIL and labels of the innovator product, applicants are encouraged to apply for a variation in this respect with the relevant SRA. This could also be done after prequalification of the product.\n\nProducts that received tentative approval from the United States Food and Drug Administration (FDA) or positive opinions under Article 58 of European Union Regulation (EC) No. 726/2004 or the Canada S.C. 2004, c. 23 (Bill C-9) procedure are not within the scope of this guideline. Such products can be co-listed on the WHO List of Prequalified Products in accordance with mutual agreements between WHO and these regulatory authorities. \n\n----\n\n3 Information and the full text of the relevant WHO documents can be found on the web site http://apps.who.int/prequal/.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2863, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "07259642-448f-457e-9bb1-cd4b758a4a54": {"__data__": {"id_": "07259642-448f-457e-9bb1-cd4b758a4a54", "embedding": null, "metadata": {"page_label": "405", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 12\n\n**Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies**\n\n## Introduction\n\n1. **Steps of the procedure**\n   1.1 Publication of invitation for Expressions of Interest  \n   1.2 Submission of Expressions of Interest and laboratory information  \n   1.3 Screening of submitted laboratory information  \n   1.4 Evaluation of the laboratory information  \n   1.5 Site inspection  \n   1.6 Report and outcome of inspection  \n   1.7 Results of assessment  \n   1.8 Monitoring of prequalified quality control laboratories  \n   1.9 Monitoring of complaint(s)  \n   1.10 Cost recovery  \n   1.11 Confidentiality undertaking  \n   1.12 Conflict of interest  \n\n## References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un anexo del Informe T\u00e9cnico de la OMS que detalla el procedimiento para la precalificaci\u00f3n de laboratorios de control de calidad que ser\u00e1n utilizados por agencias de las Naciones Unidas. Se describen los pasos del proceso, que incluyen la publicaci\u00f3n de invitaciones, la evaluaci\u00f3n de la informaci\u00f3n del laboratorio, inspecciones en el sitio y el monitoreo de los laboratorios precalificados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos involucrados en el proceso de precalificaci\u00f3n de laboratorios de control de calidad seg\u00fan el documento?**\n   - Respuesta: Los pasos incluyen la publicaci\u00f3n de invitaciones para expresiones de inter\u00e9s, la presentaci\u00f3n de informaci\u00f3n del laboratorio, la evaluaci\u00f3n y el monitoreo de los laboratorios, entre otros.\n\n2. **\u00bfQu\u00e9 medidas se toman para asegurar la confidencialidad y evitar conflictos de inter\u00e9s durante el proceso de evaluaci\u00f3n de laboratorios?**\n   - Respuesta: El documento menciona la existencia de un compromiso de confidencialidad y la necesidad de abordar posibles conflictos de inter\u00e9s como parte del procedimiento.\n\n3. **\u00bfC\u00f3mo se lleva a cabo el monitoreo de los laboratorios de control de calidad que han sido precalificados?**\n   - Respuesta: El monitoreo incluye la supervisi\u00f3n continua de los laboratorios precalificados y la gesti\u00f3n de quejas que puedan surgir, asegurando as\u00ed que mantengan los est\u00e1ndares requeridos.", "prev_section_summary": "### Temas Clave\n\n1. **Requisitos de Documentaci\u00f3n**: Se detallan los documentos necesarios para la presentaci\u00f3n de productos farmac\u00e9uticos que buscan la precalificaci\u00f3n por parte de la OMS, incluyendo informes de evaluaci\u00f3n, copias certificadas de autorizaciones de comercializaci\u00f3n, listas de fabricantes aprobados y muestras del producto.\n\n2. **Idioma y Formato de Presentaci\u00f3n**: Todos los documentos deben estar en ingl\u00e9s, incluyendo traducciones certificadas, y deben presentarse tanto en formato f\u00edsico como electr\u00f3nico. El SmPC y el PIL deben ser enviados en archivos de Word.\n\n3. **Variaciones y Renovaciones**: Las variaciones y renovaciones de la autorizaci\u00f3n de comercializaci\u00f3n son responsabilidad de la SRA correspondiente. Se requiere notificaci\u00f3n a la OMS sobre cualquier cambio en las caracter\u00edsticas principales del producto tras la aprobaci\u00f3n de la SRA.\n\n4. **Condiciones de Almacenamiento**: La condici\u00f3n de almacenamiento preferida para los productos precalificados es \"no almacenar por encima de 30 \u00b0C\". Se alienta a los solicitantes a solicitar variaciones si esta informaci\u00f3n no est\u00e1 indicada en la documentaci\u00f3n del producto.\n\n5. **Exclusiones**: Productos con aprobaci\u00f3n tentativa de la FDA o bajo ciertas regulaciones de la UE y Canad\u00e1 no est\u00e1n dentro del alcance de estas pautas, aunque pueden ser co-listados en la lista de productos precalificados de la OMS bajo acuerdos mutuos.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad que establece los requisitos de precalificaci\u00f3n.\n- **SRA (Autoridad Reguladora Correspondiente)**: La autoridad que emite la autorizaci\u00f3n de comercializaci\u00f3n y eval\u00faa los productos.\n- **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Mencionada en el contexto de productos con aprobaci\u00f3n tentativa.\n- **Regulaci\u00f3n de la UE (Reglamento (CE) No. 726/2004)**: Referenciada en relaci\u00f3n con productos aprobados bajo ciertas condiciones.\n- **Canad\u00e1 (S.C. 2004, c. 23)**: Mencionada en el contexto de procedimientos de aprobaci\u00f3n de productos.\n\nEste resumen proporciona una visi\u00f3n general de los requisitos y procedimientos establecidos por la OMS para la precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: prequalification, quality control laboratories, United Nations, assessment procedure, confidentiality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "256f0a30-1a17-47f8-89bb-e2dcb5e12ee2", "node_type": "4", "metadata": {"page_label": "405", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 12\n\n**Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies**\n\n## Introduction\n\n1. **Steps of the procedure**\n   1.1 Publication of invitation for Expressions of Interest  \n   1.2 Submission of Expressions of Interest and laboratory information  \n   1.3 Screening of submitted laboratory information  \n   1.4 Evaluation of the laboratory information  \n   1.5 Site inspection  \n   1.6 Report and outcome of inspection  \n   1.7 Results of assessment  \n   1.8 Monitoring of prequalified quality control laboratories  \n   1.9 Monitoring of complaint(s)  \n   1.10 Cost recovery  \n   1.11 Confidentiality undertaking  \n   1.12 Conflict of interest  \n\n## References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0e32b1d07e1a79720498658cecd445ac028c3919add5695605ef4b6d84a811cf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 12\n\n**Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies**\n\n## Introduction\n\n1. **Steps of the procedure**\n   1.1 Publication of invitation for Expressions of Interest  \n   1.2 Submission of Expressions of Interest and laboratory information  \n   1.3 Screening of submitted laboratory information  \n   1.4 Evaluation of the laboratory information  \n   1.5 Site inspection  \n   1.6 Report and outcome of inspection  \n   1.7 Results of assessment  \n   1.8 Monitoring of prequalified quality control laboratories  \n   1.9 Monitoring of complaint(s)  \n   1.10 Cost recovery  \n   1.11 Confidentiality undertaking  \n   1.12 Conflict of interest  \n\n## References", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 786, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "104f2637-a7e8-4633-af7e-6744ff1ed9a7": {"__data__": {"id_": "104f2637-a7e8-4633-af7e-6744ff1ed9a7", "embedding": null, "metadata": {"page_label": "406", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies, on request, with advice on the acceptability, in principle, of quality control laboratories that are found to meet WHO recommended quality standards for such laboratories, i.e. *Good practices for pharmaceutical quality control laboratories* (GPCL) (1) and the relevant parts of good manufacturing practices (GMP) (2). This is done through a standardized quality assessment procedure. The purpose of the quality assessment procedure is to evaluate whether the quality control laboratories to be used for the quality control of pharmaceutical products meet the requirements recommended by WHO for such laboratories.\n\nParticipation in the prequalification procedure is voluntary and any pharmaceutical quality control laboratory (governmental or private) could participate. Certification such as ISO (in terms of ISO/IEC17025) is encouraged and will also be considered in the prequalification procedure. It is recommended that laboratories should work towards obtaining certification.\n\nThe quality assessment procedure established by WHO is based on the following principles:\n\n- Commitment of the laboratory to providing services of testing of pharmaceutical products to United Nations agencies;\n- A general understanding of the quality assurance management and quality control testing activities of the laboratory;\n- Evaluation of information submitted by the laboratory;\n- Assessment of compliance with WHO recommended quality standards for quality control laboratories, i.e. GPCL (1) and the relevant parts of GMP (2); and\n- Monitoring of performance of prequalified laboratories.\n\nWHO invites the national medicines regulatory authority (NMRA) having regulatory oversight over a laboratory participating in the prequalification procedure, to join as an observer in the inspection of the laboratory\u2019s compliance with WHO recommended standards for quality control laboratories. WHO recommends that laboratories expressing an interest in participating in the prequalification procedure, inform the regulatory authority of the country in which they are established as well as relevant networks (e.g. the Official Medicines Control Laboratories (OMCL) network) of their submission for prequalification.\n\nThis procedure is to be followed for prequalification of quality control laboratories for use by the United Nations agencies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) describe el procedimiento de evaluaci\u00f3n de calidad para laboratorios de control de calidad farmac\u00e9utica que desean participar en el proceso de precalificaci\u00f3n para su uso por agencias de las Naciones Unidas. Este procedimiento es voluntario y se basa en principios que incluyen el compromiso del laboratorio, la comprensi\u00f3n de la gesti\u00f3n de calidad, la evaluaci\u00f3n de la informaci\u00f3n presentada, el cumplimiento de est\u00e1ndares recomendados y el monitoreo del desempe\u00f1o. Adem\u00e1s, se invita a las autoridades reguladoras nacionales a participar como observadores en las inspecciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los est\u00e1ndares espec\u00edficos que deben cumplir los laboratorios para ser considerados en el procedimiento de precalificaci\u00f3n de la OMS?**\n   - Respuesta: Los laboratorios deben cumplir con las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* (GPCL) y las partes relevantes de las *buenas pr\u00e1cticas de manufactura* (GMP) recomendadas por la OMS.\n\n2. **\u00bfQu\u00e9 papel juegan las autoridades reguladoras nacionales en el proceso de precalificaci\u00f3n de laboratorios seg\u00fan la OMS?**\n   - Respuesta: Las autoridades reguladoras nacionales (NMRA) son invitadas a participar como observadores en la inspecci\u00f3n de los laboratorios que buscan la precalificaci\u00f3n, asegurando que se cumplan los est\u00e1ndares recomendados por la OMS.\n\n3. **\u00bfQu\u00e9 tipo de certificaci\u00f3n se recomienda a los laboratorios que desean participar en el procedimiento de precalificaci\u00f3n?**\n   - Respuesta: Se recomienda que los laboratorios trabajen hacia la obtenci\u00f3n de certificaciones como la ISO, espec\u00edficamente en t\u00e9rminos de ISO/IEC 17025, que ser\u00e1 considerada en el procedimiento de precalificaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n**Tema Principal:**\n- Precalificaci\u00f3n de laboratorios de control de calidad para su uso por agencias de las Naciones Unidas.\n\n**Pasos del Procedimiento:**\n1. **Publicaci\u00f3n de invitaciones**: Se invita a laboratorios a presentar expresiones de inter\u00e9s.\n2. **Presentaci\u00f3n de informaci\u00f3n**: Los laboratorios env\u00edan su informaci\u00f3n relevante.\n3. **Filtrado de informaci\u00f3n**: Se revisa la informaci\u00f3n presentada para determinar su adecuaci\u00f3n.\n4. **Evaluaci\u00f3n**: Se eval\u00faa la informaci\u00f3n del laboratorio para verificar su calidad.\n5. **Inspecci\u00f3n en el sitio**: Se realizan visitas a los laboratorios para inspeccionar sus instalaciones y procesos.\n6. **Informe y resultados**: Se elabora un informe sobre la inspecci\u00f3n y se comunican los resultados.\n7. **Monitoreo**: Se lleva a cabo un seguimiento continuo de los laboratorios precalificados.\n8. **Gesti\u00f3n de quejas**: Se monitorean y gestionan las quejas que puedan surgir.\n9. **Recuperaci\u00f3n de costos**: Se establecen mecanismos para la recuperaci\u00f3n de costos asociados al proceso.\n10. **Compromiso de confidencialidad**: Se asegura la confidencialidad de la informaci\u00f3n durante el proceso.\n11. **Conflictos de inter\u00e9s**: Se abordan y gestionan posibles conflictos de inter\u00e9s.\n\n**Entidades Clave:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del documento.\n- **Agencias de las Naciones Unidas**: Usuarios finales de los laboratorios precalificados.\n- **Laboratorios de control de calidad**: Sujetos del proceso de precalificaci\u00f3n.\n\nEste resumen destaca los pasos del procedimiento y las entidades involucradas en el proceso de precalificaci\u00f3n de laboratorios, as\u00ed como las medidas para asegurar la calidad y la integridad del proceso.", "excerpt_keywords": "Keywords: WHO, quality control laboratories, prequalification, GMP, pharmaceutical standards"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15b3f0de-dbb5-484b-b0ac-458ba3699965", "node_type": "4", "metadata": {"page_label": "406", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies, on request, with advice on the acceptability, in principle, of quality control laboratories that are found to meet WHO recommended quality standards for such laboratories, i.e. *Good practices for pharmaceutical quality control laboratories* (GPCL) (1) and the relevant parts of good manufacturing practices (GMP) (2). This is done through a standardized quality assessment procedure. The purpose of the quality assessment procedure is to evaluate whether the quality control laboratories to be used for the quality control of pharmaceutical products meet the requirements recommended by WHO for such laboratories.\n\nParticipation in the prequalification procedure is voluntary and any pharmaceutical quality control laboratory (governmental or private) could participate. Certification such as ISO (in terms of ISO/IEC17025) is encouraged and will also be considered in the prequalification procedure. It is recommended that laboratories should work towards obtaining certification.\n\nThe quality assessment procedure established by WHO is based on the following principles:\n\n- Commitment of the laboratory to providing services of testing of pharmaceutical products to United Nations agencies;\n- A general understanding of the quality assurance management and quality control testing activities of the laboratory;\n- Evaluation of information submitted by the laboratory;\n- Assessment of compliance with WHO recommended quality standards for quality control laboratories, i.e. GPCL (1) and the relevant parts of GMP (2); and\n- Monitoring of performance of prequalified laboratories.\n\nWHO invites the national medicines regulatory authority (NMRA) having regulatory oversight over a laboratory participating in the prequalification procedure, to join as an observer in the inspection of the laboratory\u2019s compliance with WHO recommended standards for quality control laboratories. WHO recommends that laboratories expressing an interest in participating in the prequalification procedure, inform the regulatory authority of the country in which they are established as well as relevant networks (e.g. the Official Medicines Control Laboratories (OMCL) network) of their submission for prequalification.\n\nThis procedure is to be followed for prequalification of quality control laboratories for use by the United Nations agencies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ea50915fea66cfe3dab5b91fe97f4fd25d4ab16a7e8e1fd71e303a0acfa17c72", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies, on request, with advice on the acceptability, in principle, of quality control laboratories that are found to meet WHO recommended quality standards for such laboratories, i.e. *Good practices for pharmaceutical quality control laboratories* (GPCL) (1) and the relevant parts of good manufacturing practices (GMP) (2). This is done through a standardized quality assessment procedure. The purpose of the quality assessment procedure is to evaluate whether the quality control laboratories to be used for the quality control of pharmaceutical products meet the requirements recommended by WHO for such laboratories.\n\nParticipation in the prequalification procedure is voluntary and any pharmaceutical quality control laboratory (governmental or private) could participate. Certification such as ISO (in terms of ISO/IEC17025) is encouraged and will also be considered in the prequalification procedure. It is recommended that laboratories should work towards obtaining certification.\n\nThe quality assessment procedure established by WHO is based on the following principles:\n\n- Commitment of the laboratory to providing services of testing of pharmaceutical products to United Nations agencies;\n- A general understanding of the quality assurance management and quality control testing activities of the laboratory;\n- Evaluation of information submitted by the laboratory;\n- Assessment of compliance with WHO recommended quality standards for quality control laboratories, i.e. GPCL (1) and the relevant parts of GMP (2); and\n- Monitoring of performance of prequalified laboratories.\n\nWHO invites the national medicines regulatory authority (NMRA) having regulatory oversight over a laboratory participating in the prequalification procedure, to join as an observer in the inspection of the laboratory\u2019s compliance with WHO recommended standards for quality control laboratories. WHO recommends that laboratories expressing an interest in participating in the prequalification procedure, inform the regulatory authority of the country in which they are established as well as relevant networks (e.g. the Official Medicines Control Laboratories (OMCL) network) of their submission for prequalification.\n\nThis procedure is to be followed for prequalification of quality control laboratories for use by the United Nations agencies.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ce315e9f-dd54-4731-830f-40d2e91b484e": {"__data__": {"id_": "ce315e9f-dd54-4731-830f-40d2e91b484e", "embedding": null, "metadata": {"page_label": "407", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the procedure\n\nWHO requires information related to the activities of, and quality control of pharmaceutical products in, laboratories interested in being assessed under this procedure. Interested quality control laboratories should submit the information about their activities as requested by WHO (see point 1.2 below). In addition to the evaluation of the information submitted, a site inspection (or inspections) may be performed.\n\nIf, due to insufficient resources and time constraints, WHO has to set priorities in the assessment of interested laboratories, then priority will be given to quality control laboratories in areas where United Nations agencies identify the need for testing of the quality of pharmaceutical products, and to national quality control laboratories and laboratories providing testing services to governments.\n\nWHO reserves the right to terminate the quality assessment of a laboratory when the laboratory is not able to provide, or fails to provide, the required information, when the information supplied is inadequate to complete the quality assessment effectively, the laboratory fails to collaborate in inspections required by WHO and/or is unable to implement corrective actions which WHO may require within a specified time period.\n\n## 1.1 Publication of invitation for Expressions of Interest\n\nWHO will publish an invitation to quality control laboratories to submit an Expression of Interest (EOI) to participate in the prequalification procedure. Such an invitation will specify the scope of quality control testing which is subject to prequalification and will be published widely, i.e. on the WHO web site and possibly also through other media, such as the international press. The invitation will be open and transparent, inviting all interested quality control laboratories to submit the EOI for prequalification.\n\n## 1.2 Submission of Expressions of Interest and laboratory information\n\nEach interested laboratory should provide the WHO focal point indicated in the invitation for EOIs with:\n\n- a letter expressing interest in participating in the prequalification procedure; and\n- the relevant laboratory information.\n\nWHO will record the receipt of the EOI from each laboratory in a register.\n\nGuidelines for the submission of EOIs and for the preparation and submission of the relevant information are available on the WHO web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS describe el procedimiento para la evaluaci\u00f3n y precalificaci\u00f3n de laboratorios de control de calidad de productos farmac\u00e9uticos. Se requiere que los laboratorios interesados env\u00eden informaci\u00f3n sobre sus actividades y colaboren en inspecciones. La OMS prioriza la evaluaci\u00f3n de laboratorios en \u00e1reas donde hay una necesidad identificada por agencias de la ONU. Adem\u00e1s, se establece un proceso para la publicaci\u00f3n de invitaciones a laboratorios para presentar su inter\u00e9s y la informaci\u00f3n relevante.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios utiliza la OMS para priorizar la evaluaci\u00f3n de laboratorios de control de calidad?**\n   - La OMS prioriza laboratorios en \u00e1reas donde las agencias de la ONU identifican la necesidad de pruebas de calidad de productos farmac\u00e9uticos, as\u00ed como laboratorios nacionales y aquellos que brindan servicios de prueba a gobiernos.\n\n2. **\u00bfQu\u00e9 sucede si un laboratorio no puede proporcionar la informaci\u00f3n requerida durante el proceso de evaluaci\u00f3n?**\n   - La OMS se reserva el derecho de terminar la evaluaci\u00f3n de calidad de un laboratorio si este no puede proporcionar la informaci\u00f3n requerida, si la informaci\u00f3n es inadecuada, si no colabora en las inspecciones o si no implementa las acciones correctivas solicitadas en un plazo especificado.\n\n3. **\u00bfD\u00f3nde se publicar\u00e1 la invitaci\u00f3n para que los laboratorios presenten su Expresi\u00f3n de Inter\u00e9s (EOI)?**\n   - La invitaci\u00f3n se publicar\u00e1 ampliamente, incluyendo el sitio web de la OMS y posiblemente otros medios, como la prensa internacional, para asegurar que todos los laboratorios interesados tengan la oportunidad de participar.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Calidad de Laboratorios**: La OMS establece un procedimiento de evaluaci\u00f3n de calidad para laboratorios de control de calidad farmac\u00e9utica que desean participar en el proceso de precalificaci\u00f3n para su uso por agencias de las Naciones Unidas.\n\n2. **Participaci\u00f3n Voluntaria**: La participaci\u00f3n en el procedimiento de precalificaci\u00f3n es voluntaria y est\u00e1 abierta a laboratorios gubernamentales y privados.\n\n3. **Est\u00e1ndares Recomendados**: Los laboratorios deben cumplir con las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* (GPCL) y las partes relevantes de las *buenas pr\u00e1cticas de manufactura* (GMP).\n\n4. **Certificaci\u00f3n**: Se recomienda que los laboratorios busquen certificaciones como la ISO/IEC 17025, que ser\u00e1 considerada en el procedimiento de precalificaci\u00f3n.\n\n5. **Principios de Evaluaci\u00f3n**: La evaluaci\u00f3n se basa en el compromiso del laboratorio, la comprensi\u00f3n de la gesti\u00f3n de calidad, la evaluaci\u00f3n de la informaci\u00f3n presentada, el cumplimiento de est\u00e1ndares recomendados y el monitoreo del desempe\u00f1o.\n\n6. **Rol de las Autoridades Reguladoras**: Las autoridades reguladoras nacionales (NMRA) son invitadas a participar como observadores en las inspecciones de los laboratorios que buscan la precalificaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer los est\u00e1ndares y procedimientos de evaluaci\u00f3n.\n- **Agencias de las Naciones Unidas**: Entidades que utilizan los laboratorios precalificados.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades que buscan participar en el procedimiento de precalificaci\u00f3n.\n- **Autoridades Reguladoras Nacionales (NMRA)**: Entidades que supervisan la regulaci\u00f3n de los laboratorios en sus respectivos pa\u00edses.\n- **Red de Laboratorios de Control de Medicamentos Oficiales (OMCL)**: Redes relevantes que pueden ser informadas sobre la participaci\u00f3n en el procedimiento de precalificaci\u00f3n.", "excerpt_keywords": "Keywords: WHO, quality control laboratories, prequalification procedure, Expressions of Interest, pharmaceutical products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fda169f1-d6e6-4c31-a68f-7a48980c3267", "node_type": "4", "metadata": {"page_label": "407", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the procedure\n\nWHO requires information related to the activities of, and quality control of pharmaceutical products in, laboratories interested in being assessed under this procedure. Interested quality control laboratories should submit the information about their activities as requested by WHO (see point 1.2 below). In addition to the evaluation of the information submitted, a site inspection (or inspections) may be performed.\n\nIf, due to insufficient resources and time constraints, WHO has to set priorities in the assessment of interested laboratories, then priority will be given to quality control laboratories in areas where United Nations agencies identify the need for testing of the quality of pharmaceutical products, and to national quality control laboratories and laboratories providing testing services to governments.\n\nWHO reserves the right to terminate the quality assessment of a laboratory when the laboratory is not able to provide, or fails to provide, the required information, when the information supplied is inadequate to complete the quality assessment effectively, the laboratory fails to collaborate in inspections required by WHO and/or is unable to implement corrective actions which WHO may require within a specified time period.\n\n## 1.1 Publication of invitation for Expressions of Interest\n\nWHO will publish an invitation to quality control laboratories to submit an Expression of Interest (EOI) to participate in the prequalification procedure. Such an invitation will specify the scope of quality control testing which is subject to prequalification and will be published widely, i.e. on the WHO web site and possibly also through other media, such as the international press. The invitation will be open and transparent, inviting all interested quality control laboratories to submit the EOI for prequalification.\n\n## 1.2 Submission of Expressions of Interest and laboratory information\n\nEach interested laboratory should provide the WHO focal point indicated in the invitation for EOIs with:\n\n- a letter expressing interest in participating in the prequalification procedure; and\n- the relevant laboratory information.\n\nWHO will record the receipt of the EOI from each laboratory in a register.\n\nGuidelines for the submission of EOIs and for the preparation and submission of the relevant information are available on the WHO web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "1740e0cf87451080e261aa1fcec1e37c4bfb550858bc981f6c33483c6310f3f4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Steps of the procedure\n\nWHO requires information related to the activities of, and quality control of pharmaceutical products in, laboratories interested in being assessed under this procedure. Interested quality control laboratories should submit the information about their activities as requested by WHO (see point 1.2 below). In addition to the evaluation of the information submitted, a site inspection (or inspections) may be performed.\n\nIf, due to insufficient resources and time constraints, WHO has to set priorities in the assessment of interested laboratories, then priority will be given to quality control laboratories in areas where United Nations agencies identify the need for testing of the quality of pharmaceutical products, and to national quality control laboratories and laboratories providing testing services to governments.\n\nWHO reserves the right to terminate the quality assessment of a laboratory when the laboratory is not able to provide, or fails to provide, the required information, when the information supplied is inadequate to complete the quality assessment effectively, the laboratory fails to collaborate in inspections required by WHO and/or is unable to implement corrective actions which WHO may require within a specified time period.\n\n## 1.1 Publication of invitation for Expressions of Interest\n\nWHO will publish an invitation to quality control laboratories to submit an Expression of Interest (EOI) to participate in the prequalification procedure. Such an invitation will specify the scope of quality control testing which is subject to prequalification and will be published widely, i.e. on the WHO web site and possibly also through other media, such as the international press. The invitation will be open and transparent, inviting all interested quality control laboratories to submit the EOI for prequalification.\n\n## 1.2 Submission of Expressions of Interest and laboratory information\n\nEach interested laboratory should provide the WHO focal point indicated in the invitation for EOIs with:\n\n- a letter expressing interest in participating in the prequalification procedure; and\n- the relevant laboratory information.\n\nWHO will record the receipt of the EOI from each laboratory in a register.\n\nGuidelines for the submission of EOIs and for the preparation and submission of the relevant information are available on the WHO web site.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2391, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b2cb0e6d-1cd3-4336-92ac-841d45e3bb86": {"__data__": {"id_": "b2cb0e6d-1cd3-4336-92ac-841d45e3bb86", "embedding": null, "metadata": {"page_label": "408", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "at http://apps.who.int/prequal/ and will be sent to interested laboratories upon request.\n\nIf the laboratory has documented its quality system as a quality manual, this can be submitted, provided that it is supplemented with the information required for the laboratory information file (LIF, see below) that is not provided in the quality manual.\n\nIf there is no quality manual, the information should be submitted as described in the document *Guidelines for preparing a laboratory information file* (3) and contain information on the areas listed below:\n\n- General information on the laboratory, including activities proposed for prequalification;\n- Quality management system implemented, and inspections and external audits performed in the laboratory;\n- Participation in proficiency testing schemes and/or collaborative trials;\n- Internal audits;\n- Control of documentation and records;\n- Personnel;\n- Premises;\n- Equipment;\n- Reagents, reference substances and reference materials;\n- Subcontracting of testing (where applicable);\n- Handling of samples;\n- Validation of analytical procedures;\n- Investigation of out-of-specification (OOS) results;\n- Stability testing (where applicable); and\n- Microbiological testing (where applicable).\n\n### 1.3 Screening of submitted laboratory information\n\nThe information submitted by the laboratory will be screened for completeness against the *Guidelines for preparing a laboratory information file* (3). Incomplete information will not be considered for evaluation. The laboratory will be informed that incomplete information has been received, and be requested to complete it within a specified time period. In the event of noncompliance with this request, the laboratory information will in principle be rejected on grounds of incompleteness and returned to the laboratory.\n\n### 1.4 Evaluation of the laboratory information\n\nLaboratory information that complies with the requirements set out in section 1.2 above will be evaluated in accordance with a standard operating", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio (LIF) que debe ser presentado por los laboratorios que buscan la precalificaci\u00f3n. Se detalla la informaci\u00f3n necesaria que debe incluirse, ya sea en un manual de calidad o en un formato alternativo si no se dispone de dicho manual. Adem\u00e1s, se describe el proceso de revisi\u00f3n de la informaci\u00f3n presentada, enfatizando la importancia de la completitud y la conformidad con las directrices establecidas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n adicional se requiere si un laboratorio presenta un manual de calidad?**\n   - Se requiere que el manual de calidad sea complementado con la informaci\u00f3n que no se proporciona en \u00e9l, seg\u00fan lo estipulado en las directrices para preparar un archivo de informaci\u00f3n de laboratorio (LIF).\n\n2. **\u00bfQu\u00e9 sucede si un laboratorio presenta informaci\u00f3n incompleta?**\n   - Si la informaci\u00f3n presentada es incompleta, el laboratorio ser\u00e1 informado y se le solicitar\u00e1 que complete la informaci\u00f3n dentro de un per\u00edodo de tiempo especificado. Si no cumple con esta solicitud, la informaci\u00f3n ser\u00e1 rechazada por incompletitud y devuelta al laboratorio.\n\n3. **\u00bfCu\u00e1les son algunos de los aspectos que deben incluirse en el archivo de informaci\u00f3n del laboratorio?**\n   - El archivo debe incluir informaci\u00f3n sobre la gesti\u00f3n de calidad implementada, auditor\u00edas internas, control de documentaci\u00f3n, personal, instalaciones, equipos, manejo de muestras, validaci\u00f3n de procedimientos anal\u00edticos, entre otros aspectos relevantes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Evaluaci\u00f3n y precalificaci\u00f3n de laboratorios**: La OMS establece un procedimiento para evaluar y precalificar laboratorios de control de calidad de productos farmac\u00e9uticos, requiriendo informaci\u00f3n sobre sus actividades.\n\n2. **Prioridades en la evaluaci\u00f3n**: La OMS prioriza la evaluaci\u00f3n de laboratorios en \u00e1reas donde las agencias de la ONU identifican la necesidad de pruebas de calidad, as\u00ed como laboratorios nacionales y aquellos que ofrecen servicios de prueba a gobiernos.\n\n3. **Requisitos de informaci\u00f3n**: Los laboratorios interesados deben enviar informaci\u00f3n espec\u00edfica y colaborar en inspecciones. La OMS puede terminar la evaluaci\u00f3n si la informaci\u00f3n es insuficiente o si el laboratorio no colabora.\n\n4. **Publicaci\u00f3n de invitaciones**: La OMS publicar\u00e1 invitaciones para que los laboratorios presenten su Expresi\u00f3n de Inter\u00e9s (EOI), especificando el alcance de las pruebas de control de calidad.\n\n5. **Proceso de presentaci\u00f3n de EOIs**: Los laboratorios deben enviar una carta de inter\u00e9s y la informaci\u00f3n relevante a un punto focal de la OMS, que registrar\u00e1 la recepci\u00f3n de la EOI.\n\n**Entidades:**\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de laboratorios.\n- **Laboratorios de control de calidad**: Entidades que realizan pruebas de calidad de productos farmac\u00e9uticos y que est\u00e1n interesadas en participar en el procedimiento de precalificaci\u00f3n.\n- **Agencias de la ONU**: Organismos que identifican necesidades de pruebas de calidad en diferentes \u00e1reas.", "excerpt_keywords": "Keywords: laboratory information file, quality management system, prequalification, WHO guidelines, evaluation process"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b9ac2e99-1c90-4d1f-8bf4-8bdf00425dae", "node_type": "4", "metadata": {"page_label": "408", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "at http://apps.who.int/prequal/ and will be sent to interested laboratories upon request.\n\nIf the laboratory has documented its quality system as a quality manual, this can be submitted, provided that it is supplemented with the information required for the laboratory information file (LIF, see below) that is not provided in the quality manual.\n\nIf there is no quality manual, the information should be submitted as described in the document *Guidelines for preparing a laboratory information file* (3) and contain information on the areas listed below:\n\n- General information on the laboratory, including activities proposed for prequalification;\n- Quality management system implemented, and inspections and external audits performed in the laboratory;\n- Participation in proficiency testing schemes and/or collaborative trials;\n- Internal audits;\n- Control of documentation and records;\n- Personnel;\n- Premises;\n- Equipment;\n- Reagents, reference substances and reference materials;\n- Subcontracting of testing (where applicable);\n- Handling of samples;\n- Validation of analytical procedures;\n- Investigation of out-of-specification (OOS) results;\n- Stability testing (where applicable); and\n- Microbiological testing (where applicable).\n\n### 1.3 Screening of submitted laboratory information\n\nThe information submitted by the laboratory will be screened for completeness against the *Guidelines for preparing a laboratory information file* (3). Incomplete information will not be considered for evaluation. The laboratory will be informed that incomplete information has been received, and be requested to complete it within a specified time period. In the event of noncompliance with this request, the laboratory information will in principle be rejected on grounds of incompleteness and returned to the laboratory.\n\n### 1.4 Evaluation of the laboratory information\n\nLaboratory information that complies with the requirements set out in section 1.2 above will be evaluated in accordance with a standard operating", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b2a7a60fe4049e49ae25b64cca05b0babd5d940d8219baab49fac8fa5b3c2b9b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "at http://apps.who.int/prequal/ and will be sent to interested laboratories upon request.\n\nIf the laboratory has documented its quality system as a quality manual, this can be submitted, provided that it is supplemented with the information required for the laboratory information file (LIF, see below) that is not provided in the quality manual.\n\nIf there is no quality manual, the information should be submitted as described in the document *Guidelines for preparing a laboratory information file* (3) and contain information on the areas listed below:\n\n- General information on the laboratory, including activities proposed for prequalification;\n- Quality management system implemented, and inspections and external audits performed in the laboratory;\n- Participation in proficiency testing schemes and/or collaborative trials;\n- Internal audits;\n- Control of documentation and records;\n- Personnel;\n- Premises;\n- Equipment;\n- Reagents, reference substances and reference materials;\n- Subcontracting of testing (where applicable);\n- Handling of samples;\n- Validation of analytical procedures;\n- Investigation of out-of-specification (OOS) results;\n- Stability testing (where applicable); and\n- Microbiological testing (where applicable).\n\n### 1.3 Screening of submitted laboratory information\n\nThe information submitted by the laboratory will be screened for completeness against the *Guidelines for preparing a laboratory information file* (3). Incomplete information will not be considered for evaluation. The laboratory will be informed that incomplete information has been received, and be requested to complete it within a specified time period. In the event of noncompliance with this request, the laboratory information will in principle be rejected on grounds of incompleteness and returned to the laboratory.\n\n### 1.4 Evaluation of the laboratory information\n\nLaboratory information that complies with the requirements set out in section 1.2 above will be evaluated in accordance with a standard operating", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2018, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1a9ed0d6-542f-4367-ba5b-14d0c70bf078": {"__data__": {"id_": "1a9ed0d6-542f-4367-ba5b-14d0c70bf078", "embedding": null, "metadata": {"page_label": "409", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 961\", aqu\u00ed tienes tres preguntas que podr\u00edan tener respuestas espec\u00edficas en este informe:\n\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe T\u00e9cnico 961 sobre la salud p\u00fablica y la seguridad sanitaria?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS ha emitido en este informe, que pueden no estar disponibles en otros documentos.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se describen en el Informe T\u00e9cnico 961 para la evaluaci\u00f3n de riesgos en la salud p\u00fablica?**\n   - Esta pregunta se centra en las t\u00e9cnicas o enfoques espec\u00edficos que la OMS propone para evaluar riesgos, lo cual puede ser un aspecto \u00fanico del informe.\n\n3. **\u00bfQu\u00e9 datos o estad\u00edsticas relevantes se presentan en el Informe T\u00e9cnico 961 sobre enfermedades infecciosas y su impacto global?**\n   - Esta pregunta busca informaci\u00f3n cuantitativa o cualitativa que el informe pueda contener sobre la prevalencia o el impacto de enfermedades infecciosas, que podr\u00eda no estar disponible en otras fuentes.\n\n### Resumen de nivel superior del contexto circundante:\nEl \"WHO - Technical Report Series 961\" es un documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Este tipo de informes suelen incluir recomendaciones, metodolog\u00edas de evaluaci\u00f3n, y datos estad\u00edsticos sobre diversas cuestiones de salud global, lo que los convierte en recursos valiosos para investigadores, profesionales de la salud y responsables de pol\u00edticas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Objetivo del Documento**: Establecer directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio (LIF) que los laboratorios deben presentar para la precalificaci\u00f3n.\n\n2. **Calidad del Laboratorio**:\n   - Se permite la presentaci\u00f3n de un manual de calidad, pero debe complementarse con informaci\u00f3n adicional requerida.\n   - Si no hay un manual de calidad, se debe seguir el formato descrito en las *Directrices para preparar un archivo de informaci\u00f3n de laboratorio*.\n\n3. **Informaci\u00f3n Requerida**: \n   - Informaci\u00f3n general sobre el laboratorio y actividades propuestas.\n   - Sistema de gesti\u00f3n de calidad y auditor\u00edas realizadas.\n   - Participaci\u00f3n en pruebas de competencia y ensayos colaborativos.\n   - Auditor\u00edas internas y control de documentaci\u00f3n.\n   - Detalles sobre personal, instalaciones, equipos, reactivos y materiales de referencia.\n   - Procedimientos de validaci\u00f3n anal\u00edtica y manejo de muestras.\n   - Investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS) y pruebas de estabilidad.\n\n4. **Proceso de Revisi\u00f3n**:\n   - La informaci\u00f3n presentada ser\u00e1 revisada por su completitud.\n   - Si la informaci\u00f3n es incompleta, el laboratorio ser\u00e1 notificado y deber\u00e1 completarla en un plazo determinado.\n   - La falta de cumplimiento resultar\u00e1 en el rechazo de la informaci\u00f3n.\n\n5. **Evaluaci\u00f3n**: La informaci\u00f3n que cumpla con los requisitos ser\u00e1 evaluada seg\u00fan un procedimiento operativo est\u00e1ndar.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que buscan la precalificaci\u00f3n y deben presentar el LIF.\n- **Archivo de Informaci\u00f3n de Laboratorio (LIF)**: Documento que debe ser preparado y presentado por los laboratorios.\n- **Sistema de Gesti\u00f3n de Calidad**: Estructura que los laboratorios deben tener documentada.\n- **Auditor\u00edas**: Inspecciones internas y externas que los laboratorios deben realizar. \n\nEste resumen destaca los aspectos esenciales y las entidades involucradas en el proceso de precalificaci\u00f3n de laboratorios seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, precalificaci\u00f3n, laboratorio, evaluaci\u00f3n de riesgos"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "628dd9b3-21da-4ea8-9141-e2dc6f642e5f", "node_type": "4", "metadata": {"page_label": "409", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6b8f8fa9-7c21-45af-8fde-88740d8d6fff": {"__data__": {"id_": "6b8f8fa9-7c21-45af-8fde-88740d8d6fff", "embedding": null, "metadata": {"page_label": "410", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Report and outcome of inspection\n\nThe inspector or inspection team will finalize a report describing the findings according to the established WHO SOP and format. The report will be communicated by WHO to the laboratory and a copy will be sent to the NMRA having regulatory oversight over the laboratory.\n\nIf any additional information is required, or if a corrective action has to be taken by the laboratory, WHO will postpone its decision on the acceptability of the laboratory concerned until the additional information has been evaluated, or the corrective action has been taken, and found satisfactory. If the decision cannot be made based on the information received, a follow-up inspection will be performed.\n\nIn the event of any disagreement between a laboratory and WHO, an SOP for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the quality assessment procedure, the ownership of the reports lies with WHO (without prejudice, however, to any confidential and proprietary information of the laboratory contained in this report). Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any confidential and proprietary information of the laboratory. \u201cConfidential information\u201d in this context means:\n\n- confidential intellectual property, \u201cknow-how\u201d and trade secrets (including, e.g. programs, processes or methods, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans).\n\nProvisions of confidentiality will be contained in the letters exchanged between WHO and the laboratory, to be agreed upon before the evaluation of the information and site inspection.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n# 1.7 Results of assessment\n\nOnce WHO is satisfied that the quality assessment process for the laboratory is complete, and that the laboratory is acceptable in principle for use by United Nations agencies (i.e. it has been found to meet the WHO recommended quality standards for quality control laboratories), the laboratory at the specified site will be included in a list referred to as \u201cList of prequalified quality control laboratories\u201d.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento describe el proceso de inspecci\u00f3n y evaluaci\u00f3n de laboratorios por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla c\u00f3mo se elabora un informe tras la inspecci\u00f3n, el manejo de la informaci\u00f3n confidencial, y el procedimiento a seguir en caso de desacuerdos entre un laboratorio y la OMS. Adem\u00e1s, se menciona que una vez que un laboratorio cumple con los est\u00e1ndares de calidad recomendados por la OMS, se incluir\u00e1 en una lista de laboratorios de control de calidad precalificados para su uso por agencias de las Naciones Unidas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 sucede si un laboratorio necesita realizar acciones correctivas despu\u00e9s de una inspecci\u00f3n de la OMS?**\n   - La OMS pospondr\u00e1 su decisi\u00f3n sobre la aceptabilidad del laboratorio hasta que se eval\u00fae la informaci\u00f3n adicional o se tomen las acciones correctivas necesarias y se consideren satisfactorias.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n se considera \"confidencial\" seg\u00fan el contexto del informe de la OMS?**\n   - La informaci\u00f3n confidencial incluye propiedad intelectual, \"know-how\", secretos comerciales, y confidencias comerciales, como estructuras y planes de desarrollo.\n\n3. **\u00bfCu\u00e1l es el proceso que sigue la OMS en caso de desacuerdo con un laboratorio?**\n   - Se seguir\u00e1 un procedimiento operativo est\u00e1ndar (SOP) para manejar y resolver el desacuerdo entre el laboratorio y la OMS.", "prev_section_summary": "El contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Recomendaciones de la OMS**: El informe incluye directrices y recomendaciones sobre salud p\u00fablica y seguridad sanitaria.\n2. **Metodolog\u00edas de Evaluaci\u00f3n de Riesgos**: Se describen t\u00e9cnicas y enfoques espec\u00edficos para la evaluaci\u00f3n de riesgos en la salud p\u00fablica.\n3. **Datos y Estad\u00edsticas sobre Enfermedades Infecciosas**: Se presentan datos relevantes sobre la prevalencia y el impacto global de enfermedades infecciosas.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico 961**: El documento espec\u00edfico que se analiza, que forma parte de la serie de informes t\u00e9cnicos de la OMS.\n\nEste informe es un recurso valioso para investigadores, profesionales de la salud y responsables de pol\u00edticas, ya que proporciona informaci\u00f3n crucial sobre la salud global.", "excerpt_keywords": "Keywords: inspection, quality assessment, confidentiality, corrective actions, prequalified laboratories"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "612f8d6e-7bef-4f3a-81a4-6cdcc610ad3c", "node_type": "4", "metadata": {"page_label": "410", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Report and outcome of inspection\n\nThe inspector or inspection team will finalize a report describing the findings according to the established WHO SOP and format. The report will be communicated by WHO to the laboratory and a copy will be sent to the NMRA having regulatory oversight over the laboratory.\n\nIf any additional information is required, or if a corrective action has to be taken by the laboratory, WHO will postpone its decision on the acceptability of the laboratory concerned until the additional information has been evaluated, or the corrective action has been taken, and found satisfactory. If the decision cannot be made based on the information received, a follow-up inspection will be performed.\n\nIn the event of any disagreement between a laboratory and WHO, an SOP for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the quality assessment procedure, the ownership of the reports lies with WHO (without prejudice, however, to any confidential and proprietary information of the laboratory contained in this report). Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any confidential and proprietary information of the laboratory. \u201cConfidential information\u201d in this context means:\n\n- confidential intellectual property, \u201cknow-how\u201d and trade secrets (including, e.g. programs, processes or methods, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans).\n\nProvisions of confidentiality will be contained in the letters exchanged between WHO and the laboratory, to be agreed upon before the evaluation of the information and site inspection.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n# 1.7 Results of assessment\n\nOnce WHO is satisfied that the quality assessment process for the laboratory is complete, and that the laboratory is acceptable in principle for use by United Nations agencies (i.e. it has been found to meet the WHO recommended quality standards for quality control laboratories), the laboratory at the specified site will be included in a list referred to as \u201cList of prequalified quality control laboratories\u201d.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "d737c04a8a7606cd89c828afad518067532299f6a68d07e054ba0f08b68f134b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1.6 Report and outcome of inspection\n\nThe inspector or inspection team will finalize a report describing the findings according to the established WHO SOP and format. The report will be communicated by WHO to the laboratory and a copy will be sent to the NMRA having regulatory oversight over the laboratory.\n\nIf any additional information is required, or if a corrective action has to be taken by the laboratory, WHO will postpone its decision on the acceptability of the laboratory concerned until the additional information has been evaluated, or the corrective action has been taken, and found satisfactory. If the decision cannot be made based on the information received, a follow-up inspection will be performed.\n\nIn the event of any disagreement between a laboratory and WHO, an SOP for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the quality assessment procedure, the ownership of the reports lies with WHO (without prejudice, however, to any confidential and proprietary information of the laboratory contained in this report). Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any confidential and proprietary information of the laboratory. \u201cConfidential information\u201d in this context means:\n\n- confidential intellectual property, \u201cknow-how\u201d and trade secrets (including, e.g. programs, processes or methods, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans).\n\nProvisions of confidentiality will be contained in the letters exchanged between WHO and the laboratory, to be agreed upon before the evaluation of the information and site inspection.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n# 1.7 Results of assessment\n\nOnce WHO is satisfied that the quality assessment process for the laboratory is complete, and that the laboratory is acceptable in principle for use by United Nations agencies (i.e. it has been found to meet the WHO recommended quality standards for quality control laboratories), the laboratory at the specified site will be included in a list referred to as \u201cList of prequalified quality control laboratories\u201d.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2398, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bfaaf6ba-66cd-4bfc-b3e7-d4c3bd250570": {"__data__": {"id_": "bfaaf6ba-66cd-4bfc-b3e7-d4c3bd250570", "embedding": null, "metadata": {"page_label": "411", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Laboratories on the list will be considered to be able to test products in compliance with WHO recommended quality standards for quality control laboratories. Inclusion in the list does not, however, imply any approval by WHO of the laboratories (which is the sole prerogative of national authorities).\n\nEach laboratory will receive a letter from WHO informing it of the outcome of the quality assessment process for that particular laboratory.\n\nA copy of this letter will be sent to the NMRA of the country where the laboratory is located. The list of prequalified laboratories will be published on the WHO web site and will specify the areas of expertise assessed and considered prequalified. The list will be updated whenever new relevant information is obtained.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any confidential and proprietary information \u2014 publish WHO Public Inspection Reports (WHOPIR(s)) on the laboratories considered to meet WHO recommended quality standards for quality control laboratories. These reports will be published on the WHO web site.\n\n### 1.8 Monitoring of prequalified quality control laboratories\n\nOnce the laboratory is included in the list of prequalified quality control laboratories, it should inform WHO without delay about any implemented changes which may have an impact on the prequalification of the laboratory (such as changes to facility, equipment or key personnel) and should submit an updated LIF.\n\nEach prequalified quality control laboratory will be re-evaluated on a routine basis at regular intervals (annually) or earlier, when information requiring re-evaluation is obtained by WHO.\n\nTo enable WHO to carry out re-evaluation, all prequalified laboratories are requested to submit a brief annual report on their activities. The report should cover all activities related to quality control of medicines within the preceding calendar year and should be submitted by the end of March of the subsequent year. The following items should be included in the report:\n\n- a summary of services provided to United Nations agencies, other public health organizations procuring medicines and other customers;\n- a summary of number of samples analysed, differentiating between compliant and non-compliant samples;\n- a list of analytical methods used;\n- a summary of complaints concerning results of analyses performed by the laboratory received from customers;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece un proceso para la inclusi\u00f3n de laboratorios en una lista de laboratorios de control de calidad precalificados, que cumplen con los est\u00e1ndares de calidad recomendados por la OMS. La inclusi\u00f3n en esta lista no implica aprobaci\u00f3n por parte de la OMS, ya que esta es prerrogativa de las autoridades nacionales. Los laboratorios deben informar a la OMS sobre cualquier cambio que pueda afectar su precalificaci\u00f3n y presentar informes anuales sobre sus actividades relacionadas con el control de calidad de medicamentos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de cambios deben informar los laboratorios a la OMS para mantener su estatus de precalificaci\u00f3n?**\n   - Los laboratorios deben informar a la OMS sin demora sobre cualquier cambio que pueda impactar su precalificaci\u00f3n, como modificaciones en las instalaciones, equipos o personal clave.\n\n2. **\u00bfCon qu\u00e9 frecuencia se re-evaluar\u00e1n los laboratorios precalificados y qu\u00e9 informaci\u00f3n deben proporcionar para esta re-evaluaci\u00f3n?**\n   - Los laboratorios precalificados ser\u00e1n re-evaluados de manera rutinaria a intervalos regulares (anualmente) o antes si se obtiene informaci\u00f3n que requiera una re-evaluaci\u00f3n. Deben presentar un informe anual que incluya un resumen de servicios, n\u00famero de muestras analizadas, m\u00e9todos anal\u00edticos utilizados y quejas recibidas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se publicar\u00e1 en los informes de inspecci\u00f3n p\u00fablica de la OMS (WHOPIR) sobre los laboratorios precalificados?**\n   - Los WHOPIR publicar\u00e1n informaci\u00f3n sobre los laboratorios que cumplen con los est\u00e1ndares de calidad recomendados por la OMS, especificando las \u00e1reas de experiencia evaluadas y consideradas precalificadas, siempre que se protejan la informaci\u00f3n confidencial y propietaria.", "prev_section_summary": "### Temas Clave:\n\n1. **Proceso de Inspecci\u00f3n y Reporte**: La OMS lleva a cabo inspecciones de laboratorios y elabora un informe que describe los hallazgos, el cual se comunica al laboratorio y a la autoridad reguladora correspondiente.\n\n2. **Acciones Correctivas**: Si un laboratorio necesita realizar acciones correctivas, la OMS pospone su decisi\u00f3n sobre la aceptabilidad del laboratorio hasta que se eval\u00faen las acciones correctivas o se reciba informaci\u00f3n adicional.\n\n3. **Manejo de Desacuerdos**: En caso de desacuerdo entre un laboratorio y la OMS, se seguir\u00e1 un procedimiento operativo est\u00e1ndar (SOP) para resolver el conflicto.\n\n4. **Confidencialidad**: La OMS es responsable de la propiedad de los informes, pero debe proteger la informaci\u00f3n confidencial y propietaria del laboratorio, que incluye propiedad intelectual y secretos comerciales.\n\n5. **Resultados de la Evaluaci\u00f3n**: Una vez que un laboratorio cumple con los est\u00e1ndares de calidad recomendados por la OMS, se incluye en una lista de laboratorios de control de calidad precalificados para su uso por agencias de las Naciones Unidas.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n de calidad de laboratorios.\n- **Laboratorios**: Entidades que son objeto de inspecci\u00f3n y evaluaci\u00f3n por parte de la OMS.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que tiene supervisi\u00f3n regulatoria sobre los laboratorios.\n- **Agencias de las Naciones Unidas**: Organismos que pueden utilizar los laboratorios precalificados.\n- **Informaci\u00f3n Confidencial**: Incluye propiedad intelectual, \"know-how\", secretos comerciales y confidencias comerciales. \n\nEste resumen abarca los aspectos esenciales del proceso de inspecci\u00f3n y evaluaci\u00f3n de laboratorios por parte de la OMS, as\u00ed como las implicaciones de confidencialidad y resoluci\u00f3n de desacuerdos.", "excerpt_keywords": "Keywords: prequalified laboratories, WHO standards, quality control, annual report, inspection reports"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6dcfe2a2-125c-49ac-9f0c-429d64377f5d", "node_type": "4", "metadata": {"page_label": "411", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Laboratories on the list will be considered to be able to test products in compliance with WHO recommended quality standards for quality control laboratories. Inclusion in the list does not, however, imply any approval by WHO of the laboratories (which is the sole prerogative of national authorities).\n\nEach laboratory will receive a letter from WHO informing it of the outcome of the quality assessment process for that particular laboratory.\n\nA copy of this letter will be sent to the NMRA of the country where the laboratory is located. The list of prequalified laboratories will be published on the WHO web site and will specify the areas of expertise assessed and considered prequalified. The list will be updated whenever new relevant information is obtained.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any confidential and proprietary information \u2014 publish WHO Public Inspection Reports (WHOPIR(s)) on the laboratories considered to meet WHO recommended quality standards for quality control laboratories. These reports will be published on the WHO web site.\n\n### 1.8 Monitoring of prequalified quality control laboratories\n\nOnce the laboratory is included in the list of prequalified quality control laboratories, it should inform WHO without delay about any implemented changes which may have an impact on the prequalification of the laboratory (such as changes to facility, equipment or key personnel) and should submit an updated LIF.\n\nEach prequalified quality control laboratory will be re-evaluated on a routine basis at regular intervals (annually) or earlier, when information requiring re-evaluation is obtained by WHO.\n\nTo enable WHO to carry out re-evaluation, all prequalified laboratories are requested to submit a brief annual report on their activities. The report should cover all activities related to quality control of medicines within the preceding calendar year and should be submitted by the end of March of the subsequent year. The following items should be included in the report:\n\n- a summary of services provided to United Nations agencies, other public health organizations procuring medicines and other customers;\n- a summary of number of samples analysed, differentiating between compliant and non-compliant samples;\n- a list of analytical methods used;\n- a summary of complaints concerning results of analyses performed by the laboratory received from customers;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "61e045b9839266e902cb7c3a118619d3f64ceadb4cfc6ec92256e76d65bcc4f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Laboratories on the list will be considered to be able to test products in compliance with WHO recommended quality standards for quality control laboratories. Inclusion in the list does not, however, imply any approval by WHO of the laboratories (which is the sole prerogative of national authorities).\n\nEach laboratory will receive a letter from WHO informing it of the outcome of the quality assessment process for that particular laboratory.\n\nA copy of this letter will be sent to the NMRA of the country where the laboratory is located. The list of prequalified laboratories will be published on the WHO web site and will specify the areas of expertise assessed and considered prequalified. The list will be updated whenever new relevant information is obtained.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any confidential and proprietary information \u2014 publish WHO Public Inspection Reports (WHOPIR(s)) on the laboratories considered to meet WHO recommended quality standards for quality control laboratories. These reports will be published on the WHO web site.\n\n### 1.8 Monitoring of prequalified quality control laboratories\n\nOnce the laboratory is included in the list of prequalified quality control laboratories, it should inform WHO without delay about any implemented changes which may have an impact on the prequalification of the laboratory (such as changes to facility, equipment or key personnel) and should submit an updated LIF.\n\nEach prequalified quality control laboratory will be re-evaluated on a routine basis at regular intervals (annually) or earlier, when information requiring re-evaluation is obtained by WHO.\n\nTo enable WHO to carry out re-evaluation, all prequalified laboratories are requested to submit a brief annual report on their activities. The report should cover all activities related to quality control of medicines within the preceding calendar year and should be submitted by the end of March of the subsequent year. The following items should be included in the report:\n\n- a summary of services provided to United Nations agencies, other public health organizations procuring medicines and other customers;\n- a summary of number of samples analysed, differentiating between compliant and non-compliant samples;\n- a list of analytical methods used;\n- a summary of complaints concerning results of analyses performed by the laboratory received from customers;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2476, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "2a5bde92-8d17-46b4-925e-67cf5acd90c1": {"__data__": {"id_": "2a5bde92-8d17-46b4-925e-67cf5acd90c1", "embedding": null, "metadata": {"page_label": "412", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 412 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe de la OMS en la p\u00e1gina 412 del \"Technical Report Series 961\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina del informe.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el \"Technical Report Series 961\" y c\u00f3mo se relacionan con las pol\u00edticas de salud global?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el \"Technical Report Series 961\" para evaluar la efectividad de las intervenciones de salud recomendadas?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos que la OMS podr\u00eda haber utilizado en el informe para respaldar sus recomendaciones.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre en otras fuentes, dado que se centran en el contenido particular del informe de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Precalificaci\u00f3n de Laboratorios:** Los laboratorios que cumplen con los est\u00e1ndares de calidad recomendados por la OMS pueden ser incluidos en una lista de laboratorios precalificados, lo que les permite realizar pruebas de productos.\n2. **Proceso de Inclusi\u00f3n:** La inclusi\u00f3n en la lista no implica aprobaci\u00f3n por parte de la OMS, ya que esta es prerrogativa de las autoridades nacionales.\n3. **Comunicaci\u00f3n de Resultados:** Cada laboratorio recibe una carta de la OMS informando sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n4. **Informes de Inspecci\u00f3n P\u00fablica (WHOPIR):** La OMS publicar\u00e1 informes sobre laboratorios que cumplen con los est\u00e1ndares, protegiendo la informaci\u00f3n confidencial.\n5. **Monitoreo y Re-evaluaci\u00f3n:** Los laboratorios precalificados deben informar sobre cambios que afecten su estatus y presentar informes anuales sobre sus actividades relacionadas con el control de calidad de medicamentos.\n6. **Contenido del Informe Anual:** Los informes deben incluir un resumen de servicios, n\u00famero de muestras analizadas, m\u00e9todos anal\u00edticos utilizados y quejas recibidas.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Organismo responsable de establecer est\u00e1ndares y evaluar laboratorios.\n- **NMRA (Autoridad Nacional Reguladora de Medicamentos):** Entidad que recibe copias de las cartas enviadas a los laboratorios.\n- **Laboratorios de Control de Calidad:** Entidades que realizan pruebas de calidad de medicamentos y deben cumplir con los est\u00e1ndares de la OMS.\n\nEste resumen destaca los aspectos fundamentales del proceso de precalificaci\u00f3n de laboratorios y la importancia de la comunicaci\u00f3n y el monitoreo continuo para garantizar el cumplimiento de los est\u00e1ndares de calidad.", "excerpt_keywords": "Keywords: OMS, precalificaci\u00f3n, laboratorios, control de calidad, salud p\u00fablica"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "02d8ebd5-3a6b-4df0-bd03-1384a053601d", "node_type": "4", "metadata": {"page_label": "412", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b89bc79e0508e0556a7c28e77a86574d9321a6c33834d13da4ff08b9e568a85c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "aa594a97-4c8e-460e-9857-cfcbc702f189": {"__data__": {"id_": "aa594a97-4c8e-460e-9857-cfcbc702f189", "embedding": null, "metadata": {"page_label": "413", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "After conducting its investigation, WHO will provide a written report of the problem, which may, where appropriate, include recommendations for action to the laboratory under investigation and to the NMRA having the regulatory oversight over the laboratory.\n\n### 1.10 Cost recovery\n\nWHO reserves the right to charge for the quality assessment procedure on a cost-recovery basis.\n\n### 1.11 Confidentiality undertaking\n\nWHO will require any external inspectors (acting as temporary advisers to WHO) to treat all information to which they gain access during the inspections of the laboratory, or otherwise in connection with the discharge of their responsibilities in regard to the prequalification procedure, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set out below.\n\nSuch inspectors will be required to take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nExternal inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by laboratories); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by laboratories); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n### 1.12 Conflict of interest\n\nBefore undertaking the work, each external inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is only an insignificant and/or irrelevant conflict of interest), and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece procedimientos y directrices para la evaluaci\u00f3n de calidad de laboratorios, incluyendo la confidencialidad de la informaci\u00f3n, la recuperaci\u00f3n de costos y la gesti\u00f3n de conflictos de inter\u00e9s. Se menciona que la OMS proporcionar\u00e1 un informe escrito tras una investigaci\u00f3n, que puede incluir recomendaciones para el laboratorio y la autoridad reguladora correspondiente. Adem\u00e1s, se requiere que los inspectores externos firmen un compromiso de confidencialidad y una declaraci\u00f3n de intereses antes de realizar su trabajo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas debe tomar un inspector externo para garantizar la confidencialidad de la informaci\u00f3n durante la evaluaci\u00f3n de calidad?**\n   - La OMS exige que los inspectores externos tomen todas las medidas razonables para asegurar que la informaci\u00f3n confidencial no se utilice para ning\u00fan prop\u00f3sito distinto a las actividades descritas en el documento y que no se divulgue a personas no vinculadas por obligaciones similares de confidencialidad.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales un inspector externo puede no estar obligado por las obligaciones de confidencialidad?**\n   - Un inspector externo no estar\u00e1 obligado por las obligaciones de confidencialidad si puede demostrar que la informaci\u00f3n confidencial ya era conocida por ellos antes de la divulgaci\u00f3n, estaba en el dominio p\u00fablico en el momento de la divulgaci\u00f3n, ha pasado al dominio p\u00fablico sin culpa de su parte, o ha sido obtenida de un tercero que no est\u00e1 en violaci\u00f3n de obligaciones legales de confidencialidad.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para evaluar si existe un conflicto de inter\u00e9s significativo para un inspector externo?**\n   - Antes de comenzar su trabajo, cada inspector externo debe firmar una declaraci\u00f3n de inter\u00e9s. Si, tras revisar esta declaraci\u00f3n, se determina que no hay riesgo de un conflicto de inter\u00e9s real o percibido, o que el conflicto es insignificante o irrelevante, el inspector puede proceder con su evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se presenta informaci\u00f3n espec\u00edfica de la p\u00e1gina 412, se pueden identificar algunos temas y entidades clave relacionados con el documento:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y las recomendaciones para mejorar las pr\u00e1cticas de salud a nivel global.\n\n2. **Informe T\u00e9cnico**: Parte de una serie de informes que abordan diversos temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Tema central del informe, que incluye hallazgos y recomendaciones relevantes para la salud global.\n\n4. **Metodolog\u00edas de Evaluaci\u00f3n**: Posibles enfoques utilizados en el informe para evaluar la efectividad de las intervenciones de salud.\n\n5. **Pol\u00edticas de Salud Global**: Relaci\u00f3n entre los hallazgos del informe y su impacto en las pol\u00edticas de salud a nivel internacional.\n\n### Resumen:\nEl \"WHO - Technical Report Series 961\" es un informe de la OMS que aborda temas de salud p\u00fablica y recomendaciones para mejorar las pr\u00e1cticas de salud. Aunque no se dispone de contenido espec\u00edfico de la p\u00e1gina 412, se destacan la importancia de la OMS, la relevancia de la salud p\u00fablica, y la posible utilizaci\u00f3n de metodolog\u00edas para evaluar intervenciones de salud.", "excerpt_keywords": "Keywords: WHO, quality assessment, confidentiality, conflict of interest, cost recovery"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c699624b-62e6-4b9d-9cd5-23b7f3889c73", "node_type": "4", "metadata": {"page_label": "413", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "After conducting its investigation, WHO will provide a written report of the problem, which may, where appropriate, include recommendations for action to the laboratory under investigation and to the NMRA having the regulatory oversight over the laboratory.\n\n### 1.10 Cost recovery\n\nWHO reserves the right to charge for the quality assessment procedure on a cost-recovery basis.\n\n### 1.11 Confidentiality undertaking\n\nWHO will require any external inspectors (acting as temporary advisers to WHO) to treat all information to which they gain access during the inspections of the laboratory, or otherwise in connection with the discharge of their responsibilities in regard to the prequalification procedure, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set out below.\n\nSuch inspectors will be required to take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nExternal inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by laboratories); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by laboratories); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n### 1.12 Conflict of interest\n\nBefore undertaking the work, each external inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is only an insignificant and/or irrelevant conflict of interest), and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cbe053b1e0010a398889756eccad7ecba553f005d4662ef3c5840c5feb634493", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "After conducting its investigation, WHO will provide a written report of the problem, which may, where appropriate, include recommendations for action to the laboratory under investigation and to the NMRA having the regulatory oversight over the laboratory.\n\n### 1.10 Cost recovery\n\nWHO reserves the right to charge for the quality assessment procedure on a cost-recovery basis.\n\n### 1.11 Confidentiality undertaking\n\nWHO will require any external inspectors (acting as temporary advisers to WHO) to treat all information to which they gain access during the inspections of the laboratory, or otherwise in connection with the discharge of their responsibilities in regard to the prequalification procedure, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set out below.\n\nSuch inspectors will be required to take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nExternal inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by laboratories); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by laboratories); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n### 1.12 Conflict of interest\n\nBefore undertaking the work, each external inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is only an insignificant and/or irrelevant conflict of interest), and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2163, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "382acb42-391c-4002-bc97-7c613ebd858b": {"__data__": {"id_": "382acb42-391c-4002-bc97-7c613ebd858b", "embedding": null, "metadata": {"page_label": "414", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "it is thus deemed appropriate for the inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll external inspectors furthermore agree that, at the laboratory\u2019s request, WHO will advise the laboratory in advance of the identity of each such inspector and the composition of the team performing the site inspection and provide curricula vitae of the external inspectors. The laboratory then has the opportunity to express possible concerns regarding any of the external inspectors to WHO prior to the visit. If such concerns cannot be resolved in consultation with WHO, the laboratory may object to an external inspector\u2019s participation in the site visit. Such an objection must be made known to WHO by the laboratory within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel its agreement with the inspector in question and the activities to be undertaken by that inspector, in whole or in part.\n\n# References\n\n1. Good practices for pharmaceutical quality control laboratories. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 1.\n\n2. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, Second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n3. WHO guidelines for preparing a laboratory information file. Revision. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se refiere a las responsabilidades y procedimientos que deben seguir los inspectores externos que trabajan con la Organizaci\u00f3n Mundial de la Salud (OMS) en el contexto de las inspecciones de laboratorios farmac\u00e9uticos. Se establece que los inspectores deben confirmar la veracidad de su declaraci\u00f3n de intereses y notificar cualquier cambio a la OMS. Adem\u00e1s, se menciona que los laboratorios tienen la oportunidad de expresar preocupaciones sobre los inspectores propuestos y pueden objetar su participaci\u00f3n si no se resuelven dichas preocupaciones. La OMS se reserva el derecho de cancelar el acuerdo con el inspector en caso de objeciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos debe seguir un inspector externo si hay un cambio en su declaraci\u00f3n de intereses?**\n   - Respuesta: El inspector debe notificar inmediatamente a la OMS sobre cualquier cambio en la informaci\u00f3n divulgada en su declaraci\u00f3n de intereses.\n\n2. **\u00bfCu\u00e1l es el plazo que tiene un laboratorio para expresar preocupaciones sobre un inspector externo propuesto?**\n   - Respuesta: El laboratorio tiene un plazo de 10 d\u00edas desde la recepci\u00f3n de la composici\u00f3n del equipo propuesto para hacer conocer sus preocupaciones a la OMS.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS en caso de que un laboratorio objete la participaci\u00f3n de un inspector externo?**\n   - Respuesta: La OMS se reserva el derecho de cancelar su acuerdo con el inspector en cuesti\u00f3n y las actividades que este debe realizar, total o parcialmente, si no se pueden resolver las objeciones planteadas por el laboratorio. \n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para proporcionar informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o contextos, centr\u00e1ndose en los procedimientos y derechos relacionados con la inspecci\u00f3n de laboratorios farmac\u00e9uticos por parte de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Informe de Investigaci\u00f3n**: La OMS proporcionar\u00e1 un informe escrito tras la investigaci\u00f3n de un laboratorio, que puede incluir recomendaciones para el laboratorio y la autoridad reguladora correspondiente (NMRA).\n\n2. **Recuperaci\u00f3n de Costos**: La OMS se reserva el derecho de cobrar por el procedimiento de evaluaci\u00f3n de calidad en base a la recuperaci\u00f3n de costos.\n\n3. **Compromiso de Confidencialidad**:\n   - Los inspectores externos deben tratar toda la informaci\u00f3n a la que accedan como confidencial y propietaria de la OMS.\n   - Se les exige tomar medidas razonables para asegurar que la informaci\u00f3n confidencial no se utilice para otros prop\u00f3sitos ni se divulgue a personas no autorizadas.\n   - Excepciones a la confidencialidad: informaci\u00f3n conocida previamente, en dominio p\u00fablico, o recibida de un tercero sin violaci\u00f3n de obligaciones de confidencialidad.\n\n4. **Conflicto de Inter\u00e9s**:\n   - Los inspectores externos deben firmar una declaraci\u00f3n de inter\u00e9s antes de comenzar su trabajo.\n   - Se evaluar\u00e1 si existe un riesgo de conflicto de inter\u00e9s real o percibido, permitiendo que el inspector proceda si se considera que el conflicto es insignificante o irrelevante.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n de calidad y la regulaci\u00f3n de laboratorios.\n- **NMRA (Autoridad Nacional de Regulaci\u00f3n de Medicamentos)**: Entidad que tiene la supervisi\u00f3n regulatoria sobre los laboratorios investigados.\n- **Inspectores Externos**: Asesores temporales de la OMS encargados de realizar las evaluaciones de calidad.", "excerpt_keywords": "Keywords: WHO, external inspectors, laboratory inspections, declaration of interest, quality assurance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "109584fe-8657-4c8e-8680-8bf6d55c267b", "node_type": "4", "metadata": {"page_label": "414", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "it is thus deemed appropriate for the inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll external inspectors furthermore agree that, at the laboratory\u2019s request, WHO will advise the laboratory in advance of the identity of each such inspector and the composition of the team performing the site inspection and provide curricula vitae of the external inspectors. The laboratory then has the opportunity to express possible concerns regarding any of the external inspectors to WHO prior to the visit. If such concerns cannot be resolved in consultation with WHO, the laboratory may object to an external inspector\u2019s participation in the site visit. Such an objection must be made known to WHO by the laboratory within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel its agreement with the inspector in question and the activities to be undertaken by that inspector, in whole or in part.\n\n# References\n\n1. Good practices for pharmaceutical quality control laboratories. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 1.\n\n2. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, Second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n3. WHO guidelines for preparing a laboratory information file. Revision. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7cbc08d1ecdb6ae67f2f17138ed4081d99fa405dc0e0d78eb924e2fca8943c95", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "it is thus deemed appropriate for the inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll external inspectors furthermore agree that, at the laboratory\u2019s request, WHO will advise the laboratory in advance of the identity of each such inspector and the composition of the team performing the site inspection and provide curricula vitae of the external inspectors. The laboratory then has the opportunity to express possible concerns regarding any of the external inspectors to WHO prior to the visit. If such concerns cannot be resolved in consultation with WHO, the laboratory may object to an external inspector\u2019s participation in the site visit. Such an objection must be made known to WHO by the laboratory within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel its agreement with the inspector in question and the activities to be undertaken by that inspector, in whole or in part.\n\n# References\n\n1. Good practices for pharmaceutical quality control laboratories. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 1.\n\n2. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, Second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n3. WHO guidelines for preparing a laboratory information file. Revision. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2174, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "bf647959-772e-40b2-bbd3-1de908615478": {"__data__": {"id_": "bf647959-772e-40b2-bbd3-1de908615478", "embedding": null, "metadata": {"page_label": "415", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 13\n\n## WHO guidelines for preparing a laboratory information file\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have recently been revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both sets of guidelines at its forty-third meeting in 2008 and recommended that if the *Guidelines for good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above and following the usual consultation process, the following text will replace the previously published guidelines.\n\n1. General information on the laboratory\n2. Quality management system\n3. Control of documentation and records\n4. Personnel\n5. Premises\n6. Equipment\n7. Materials\n8. Subcontracting of testing\n9. Handling of samples\n10. Validation of analytical procedures\n11. Investigation of out-of-specification results\n12. Stability testing (where applicable)\n13. Microbiological testing (where applicable)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un anexo de las directrices de la OMS para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio, adoptadas en 2003 y revisadas en 2009. Estas directrices est\u00e1n relacionadas con las buenas pr\u00e1cticas en laboratorios de control de calidad farmac\u00e9utica y abordan aspectos clave como la gesti\u00f3n de calidad, el control de documentaci\u00f3n, el personal, las instalaciones, el equipo, los materiales, y otros procedimientos anal\u00edticos y de muestreo.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un archivo de informaci\u00f3n de laboratorio seg\u00fan las directrices de la OMS?**\n   - Respuesta: Los elementos clave incluyen informaci\u00f3n general sobre el laboratorio, sistema de gesti\u00f3n de calidad, control de documentaci\u00f3n y registros, personal, instalaciones, equipo, materiales, subcontrataci\u00f3n de pruebas, manejo de muestras, validaci\u00f3n de procedimientos anal\u00edticos, investigaci\u00f3n de resultados fuera de especificaci\u00f3n, pruebas de estabilidad y pruebas microbiol\u00f3gicas (cuando sea aplicable).\n\n2. **\u00bfQu\u00e9 relaci\u00f3n existe entre las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio y las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica?**\n   - Respuesta: El contenido de las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio est\u00e1 estrechamente relacionado con las directrices sobre buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, que han sido recientemente revisadas. Ambas gu\u00edas buscan asegurar la calidad y la conformidad en los laboratorios farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos de la OMS en su reuni\u00f3n de 2008 respecto a las directrices de laboratorio?**\n   - Respuesta: En su reuni\u00f3n de 2008, el Comit\u00e9 de Expertos discuti\u00f3 la necesidad de revisar ambas directrices y recomend\u00f3 que si se revisaban las *Directrices para buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional*, las *Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio* tambi\u00e9n deber\u00edan ser revisadas en consecuencia.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidades de los Inspectores Externos**: Los inspectores deben actuar como asesores de la OMS y confirmar la veracidad de su declaraci\u00f3n de intereses.\n  \n2. **Notificaci\u00f3n de Cambios**: Los inspectores est\u00e1n obligados a notificar a la OMS cualquier cambio en su declaraci\u00f3n de intereses de manera inmediata.\n\n3. **Derechos de los Laboratorios**: Los laboratorios tienen el derecho de conocer la identidad de los inspectores y expresar preocupaciones sobre ellos antes de la visita.\n\n4. **Proceso de Objeci\u00f3n**: Si un laboratorio tiene preocupaciones que no se resuelven, puede objetar la participaci\u00f3n de un inspector, con un plazo de 10 d\u00edas para hacerlo.\n\n5. **Derechos de la OMS**: La OMS puede cancelar su acuerdo con un inspector si hay objeciones no resueltas por parte del laboratorio.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la regulaci\u00f3n y supervisi\u00f3n de las inspecciones de laboratorios.\n- **Inspectores Externos**: Profesionales que realizan las inspecciones en laboratorios farmac\u00e9uticos.\n- **Laboratorios Farmac\u00e9uticos**: Entidades que son objeto de las inspecciones y que pueden expresar preocupaciones sobre los inspectores.\n- **Declaraci\u00f3n de Intereses**: Documento que los inspectores deben completar y mantener actualizado.\n\nEste resumen destaca los procedimientos y derechos relacionados con la inspecci\u00f3n de laboratorios farmac\u00e9uticos por parte de la OMS, as\u00ed como las responsabilidades de los inspectores y los derechos de los laboratorios.", "excerpt_keywords": "Keywords: WHO, laboratory information file, quality management, pharmaceutical preparations, good practices"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a222ab60-a84f-43ff-bb26-720100fea95d", "node_type": "4", "metadata": {"page_label": "415", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 13\n\n## WHO guidelines for preparing a laboratory information file\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have recently been revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both sets of guidelines at its forty-third meeting in 2008 and recommended that if the *Guidelines for good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above and following the usual consultation process, the following text will replace the previously published guidelines.\n\n1. General information on the laboratory\n2. Quality management system\n3. Control of documentation and records\n4. Personnel\n5. Premises\n6. Equipment\n7. Materials\n8. Subcontracting of testing\n9. Handling of samples\n10. Validation of analytical procedures\n11. Investigation of out-of-specification results\n12. Stability testing (where applicable)\n13. Microbiological testing (where applicable)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "e85e179425a8009d13f763dfe3e91f680513ce8bfc7d1ce9b8b19580b49dac2b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 13\n\n## WHO guidelines for preparing a laboratory information file\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have recently been revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both sets of guidelines at its forty-third meeting in 2008 and recommended that if the *Guidelines for good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above and following the usual consultation process, the following text will replace the previously published guidelines.\n\n1. General information on the laboratory\n2. Quality management system\n3. Control of documentation and records\n4. Personnel\n5. Premises\n6. Equipment\n7. Materials\n8. Subcontracting of testing\n9. Handling of samples\n10. Validation of analytical procedures\n11. Investigation of out-of-specification results\n12. Stability testing (where applicable)\n13. Microbiological testing (where applicable)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1517, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "d405ea25-1bdf-4254-81ce-0f8c9cbff216": {"__data__": {"id_": "d405ea25-1bdf-4254-81ce-0f8c9cbff216", "embedding": null, "metadata": {"page_label": "416", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A laboratory information file (LIF) is a document prepared by the laboratory. It contains specific and factual information about the operations carried out at the named site and any closely integrated operations of the laboratory. If only some of the operations are carried out on the site, the LIF needs to describe only those operations, e.g. sampling, chemical analysis or stability testing.\n\nAn LIF should be written in English, succinct and, if possible, should not exceed 30 A4 pages, excluding appendices.\n\nThe laboratory should give a short description of its activities under each of the following headings. Policy or essential steps for each activity should be described and reference to a standard operating procedure (SOP) or other supporting documents should be given, where applicable. Where appropriate, supportive documentation should be appended.\n\n1. **General information on the laboratory**\n\n   1.1 Brief information on the laboratory (including name, physical (location) and mailing address, contact details and brief history). If the laboratory is part of an organization or company, provide details of its position within the organization or company, including reporting lines (e.g. organizational chart).\n\n   1.2 Summary of all laboratory activities, including objectives of the laboratory, categories of customers, types of sample tested. In addition, state the relation (if any) to a manufacturing site.\n\n   1.3 Areas of expertise proposed for prequalification (list methods and tests, for examples see the List of Prequalified Quality Control Laboratories).[^1]\n\n   | Type of analysis | Finished products | Active pharmaceutical ingredients |\n| - | - | - |\n| Physical/chemical analysis | | |\n| Identification | | |\n| Assay, impurities and related substances | | |\n| Microbiological tests | | |\n| Bacterial endotoxin testing (BET) | | |\n| Stability testing | | |\n\n\n   1.4 Brief description of a policy for participation in proficiency testing schemes and collaborative trials and for the evaluation of the performance. Attach the list of tests in which the laboratory has participated in the last three years, including the organizer and results.\n\n[^1]: http://www.who.int/prequal/lists/PQ_QCLabsList.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en la secci\u00f3n de \"Informaci\u00f3n general sobre el laboratorio\" en un archivo de informaci\u00f3n del laboratorio (LIF)?**\n   - Esta pregunta se centra en los detalles espec\u00edficos que se requieren para describir adecuadamente un laboratorio, como su nombre, direcci\u00f3n, actividades y relaci\u00f3n con otros sitios.\n\n2. **\u00bfQu\u00e9 tipo de an\u00e1lisis y pruebas se consideran para la precalificaci\u00f3n en un laboratorio, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre las \u00e1reas de especializaci\u00f3n que un laboratorio puede proponer para la precalificaci\u00f3n, lo que incluye los tipos de an\u00e1lisis y pruebas que se realizan.\n\n3. **\u00bfQu\u00e9 pol\u00edtica debe seguir un laboratorio en relaci\u00f3n con la participaci\u00f3n en esquemas de pruebas de competencia y ensayos colaborativos?**\n   - Esta pregunta se enfoca en la pol\u00edtica que un laboratorio debe tener respecto a la evaluaci\u00f3n de su desempe\u00f1o en pruebas de competencia, as\u00ed como la documentaci\u00f3n que debe adjuntarse.\n\n### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Descripci\u00f3n del Archivo de Informaci\u00f3n del Laboratorio (LIF):** \n   El LIF es un documento que proporciona informaci\u00f3n detallada sobre las operaciones de un laboratorio, incluyendo su ubicaci\u00f3n, actividades, y procedimientos operativos est\u00e1ndar. Debe ser conciso y no exceder las 30 p\u00e1ginas, excluyendo ap\u00e9ndices.\n\n2. **Estructura de la Informaci\u00f3n en el LIF:**\n   El LIF debe incluir secciones que describan la informaci\u00f3n general del laboratorio, un resumen de sus actividades, \u00e1reas de especializaci\u00f3n para la precalificaci\u00f3n y pol\u00edticas sobre pruebas de competencia. Cada secci\u00f3n debe ser respaldada por documentos de apoyo cuando sea necesario.\n\n3. **Importancia de la Precalificaci\u00f3n y Pruebas de Competencia:**\n   La precalificaci\u00f3n y la participaci\u00f3n en pruebas de competencia son esenciales para asegurar la calidad y la fiabilidad de los an\u00e1lisis realizados por el laboratorio. Esto incluye la necesidad de documentar la participaci\u00f3n en ensayos colaborativos y los resultados obtenidos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Directrices de la OMS**: Se presentan las *Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio*, adoptadas en 2003 y revisadas en 2009, que forman parte de la *Serie de Informes T\u00e9cnicos de la OMS*.\n\n2. **Relaci\u00f3n con otras directrices**: Estas directrices est\u00e1n estrechamente relacionadas con las *Directrices sobre buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica*, que tambi\u00e9n han sido revisadas.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: En 2008, el Comit\u00e9 de Expertos discuti\u00f3 la necesidad de revisar ambas directrices y recomend\u00f3 que cualquier revisi\u00f3n de las directrices de buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional deber\u00eda incluir una revisi\u00f3n de las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio.\n\n4. **Elementos clave del archivo de informaci\u00f3n de laboratorio**:\n   - Informaci\u00f3n general sobre el laboratorio\n   - Sistema de gesti\u00f3n de calidad\n   - Control de documentaci\u00f3n y registros\n   - Personal\n   - Instalaciones\n   - Equipos\n   - Materiales\n   - Subcontrataci\u00f3n de pruebas\n   - Manejo de muestras\n   - Validaci\u00f3n de procedimientos anal\u00edticos\n   - Investigaci\u00f3n de resultados fuera de especificaci\u00f3n\n   - Pruebas de estabilidad (cuando sea aplicable)\n   - Pruebas microbiol\u00f3gicas (cuando sea aplicable)\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable de la adopci\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que revisa y adopta las directrices.\n- **Laboratorios de control de calidad farmac\u00e9utica**: Entidades que deben seguir estas directrices para asegurar la calidad y conformidad en sus operaciones.", "excerpt_keywords": "Keywords: laboratory information file, prequalification, proficiency testing, quality control, standard operating procedures"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ac9950a3-7acb-48c2-be65-b9d6be556fe7", "node_type": "4", "metadata": {"page_label": "416", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A laboratory information file (LIF) is a document prepared by the laboratory. It contains specific and factual information about the operations carried out at the named site and any closely integrated operations of the laboratory. If only some of the operations are carried out on the site, the LIF needs to describe only those operations, e.g. sampling, chemical analysis or stability testing.\n\nAn LIF should be written in English, succinct and, if possible, should not exceed 30 A4 pages, excluding appendices.\n\nThe laboratory should give a short description of its activities under each of the following headings. Policy or essential steps for each activity should be described and reference to a standard operating procedure (SOP) or other supporting documents should be given, where applicable. Where appropriate, supportive documentation should be appended.\n\n1. **General information on the laboratory**\n\n   1.1 Brief information on the laboratory (including name, physical (location) and mailing address, contact details and brief history). If the laboratory is part of an organization or company, provide details of its position within the organization or company, including reporting lines (e.g. organizational chart).\n\n   1.2 Summary of all laboratory activities, including objectives of the laboratory, categories of customers, types of sample tested. In addition, state the relation (if any) to a manufacturing site.\n\n   1.3 Areas of expertise proposed for prequalification (list methods and tests, for examples see the List of Prequalified Quality Control Laboratories).[^1]\n\n   | Type of analysis | Finished products | Active pharmaceutical ingredients |\n| - | - | - |\n| Physical/chemical analysis | | |\n| Identification | | |\n| Assay, impurities and related substances | | |\n| Microbiological tests | | |\n| Bacterial endotoxin testing (BET) | | |\n| Stability testing | | |\n\n\n   1.4 Brief description of a policy for participation in proficiency testing schemes and collaborative trials and for the evaluation of the performance. Attach the list of tests in which the laboratory has participated in the last three years, including the organizer and results.\n\n[^1]: http://www.who.int/prequal/lists/PQ_QCLabsList.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "841ea30d0a8106d1f3953f84adc1d85b0e7ef6f1b4949cfb0cb5cfea8921534c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A laboratory information file (LIF) is a document prepared by the laboratory. It contains specific and factual information about the operations carried out at the named site and any closely integrated operations of the laboratory. If only some of the operations are carried out on the site, the LIF needs to describe only those operations, e.g. sampling, chemical analysis or stability testing.\n\nAn LIF should be written in English, succinct and, if possible, should not exceed 30 A4 pages, excluding appendices.\n\nThe laboratory should give a short description of its activities under each of the following headings. Policy or essential steps for each activity should be described and reference to a standard operating procedure (SOP) or other supporting documents should be given, where applicable. Where appropriate, supportive documentation should be appended.\n\n1. **General information on the laboratory**\n\n   1.1 Brief information on the laboratory (including name, physical (location) and mailing address, contact details and brief history). If the laboratory is part of an organization or company, provide details of its position within the organization or company, including reporting lines (e.g. organizational chart).\n\n   1.2 Summary of all laboratory activities, including objectives of the laboratory, categories of customers, types of sample tested. In addition, state the relation (if any) to a manufacturing site.\n\n   1.3 Areas of expertise proposed for prequalification (list methods and tests, for examples see the List of Prequalified Quality Control Laboratories).[^1]\n\n   | Type of analysis | Finished products | Active pharmaceutical ingredients |\n| - | - | - |\n| Physical/chemical analysis | | |\n| Identification | | |\n| Assay, impurities and related substances | | |\n| Microbiological tests | | |\n| Bacterial endotoxin testing (BET) | | |\n| Stability testing | | |\n\n\n   1.4 Brief description of a policy for participation in proficiency testing schemes and collaborative trials and for the evaluation of the performance. Attach the list of tests in which the laboratory has participated in the last three years, including the organizer and results.\n\n[^1]: http://www.who.int/prequal/lists/PQ_QCLabsList.pdf.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2230, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "15ada0bf-f678-4c82-89f3-ee03f5510e5a": {"__data__": {"id_": "15ada0bf-f678-4c82-89f3-ee03f5510e5a", "embedding": null, "metadata": {"page_label": "417", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management system\n\n2.1 Short description of the quality management system implemented in the laboratory, including reference to the standard used (such as WHO good practices for pharmaceutical quality control laboratories, ISO 17025, good manufacturing practices) and existence of a quality manual.\n\n2.2 Information on inspections carried out by national or regional authorities and external audits performed in the laboratory in the last three years, including reference to valid accreditation, certificate, authorization or licence.\n\n2.3 Brief description of the procedures for internal audits, implementation of corrective and preventive actions and complaints.\n\n# 3. Control of documentation and records\n\n3.1 Brief description of the procedures for the control of and changes to documents that form a part of the quality documentation. Attach a list of valid SOPs.\n\n3.2 Brief description of the procedures for the preparation, revision and distribution of necessary documentation for specifications, standard test procedures, analyst workbooks or worksheets.\n\n3.3 Brief description of any other documentation related to product testing, including reports, records, arrangements for the handling of results (including laboratory information management systems (LIMS), where used).\n\n3.4 Brief description of the procedures for release of certificates and analytical reports.\n\n# 4. Personnel\n\n4.1 Number of employees engaged in the following activities:\n\n| Activity | Number |\n| - | - |\n| Supervisors | |\n| Chemical sector | |\n| \u00a0\u00a0\u00a0\u00a0analysts | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Microbiological sector | |\n| \u00a0\u00a0\u00a0\u00a0microbiologists | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Quality assurance staff | |\n| Staff trained for sampling | |\n| Other | |\n| Total number of employees in the laboratory: | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento se centra en la gesti\u00f3n de la calidad en laboratorios de control de calidad farmac\u00e9utica, describiendo los sistemas de gesti\u00f3n de calidad implementados, el control de la documentaci\u00f3n y los registros, y la estructura del personal involucrado en estas actividades. Se mencionan est\u00e1ndares relevantes como las buenas pr\u00e1cticas de la OMS, ISO 17025 y buenas pr\u00e1cticas de fabricaci\u00f3n. Tambi\u00e9n se abordan las auditor\u00edas internas, la gesti\u00f3n de quejas y la documentaci\u00f3n relacionada con las pruebas de productos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 est\u00e1ndares espec\u00edficos se mencionan en el contexto como referencia para el sistema de gesti\u00f3n de calidad del laboratorio, y c\u00f3mo se implementan en la pr\u00e1ctica?**\n   - Esta pregunta busca detalles sobre la aplicaci\u00f3n pr\u00e1ctica de los est\u00e1ndares mencionados, lo que puede no estar disponible en otras fuentes.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la realizaci\u00f3n de auditor\u00edas internas y la implementaci\u00f3n de acciones correctivas y preventivas en el laboratorio?**\n   - Esta pregunta se centra en los procedimientos internos del laboratorio, que pueden no estar documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la preparaci\u00f3n y distribuci\u00f3n de especificaciones y procedimientos de prueba est\u00e1ndar, y c\u00f3mo se controla su modificaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo espec\u00edfico de la documentaci\u00f3n, que puede ser \u00fanica para el laboratorio en cuesti\u00f3n y no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Archivo de Informaci\u00f3n del Laboratorio (LIF)**:\n   - Documento que proporciona informaci\u00f3n espec\u00edfica y factual sobre las operaciones de un laboratorio.\n   - Debe ser conciso, escrito en ingl\u00e9s y no exceder las 30 p\u00e1ginas (excluyendo ap\u00e9ndices).\n\n2. **Estructura del LIF**:\n   - **Informaci\u00f3n General sobre el Laboratorio**:\n     - Nombre, direcci\u00f3n f\u00edsica y de correo, detalles de contacto y breve historia.\n     - Posici\u00f3n dentro de una organizaci\u00f3n, incluyendo l\u00edneas de reporte.\n   - **Resumen de Actividades del Laboratorio**:\n     - Objetivos, categor\u00edas de clientes y tipos de muestras analizadas.\n     - Relaci\u00f3n con sitios de manufactura, si aplica.\n   - **\u00c1reas de Especializaci\u00f3n para Precalificaci\u00f3n**:\n     - M\u00e9todos y pruebas que el laboratorio propone para precalificaci\u00f3n, incluyendo an\u00e1lisis f\u00edsico/qu\u00edmico, identificaci\u00f3n, ensayos, pruebas microbiol\u00f3gicas, pruebas de endotoxinas bacterianas y pruebas de estabilidad.\n   - **Pol\u00edtica de Participaci\u00f3n en Pruebas de Competencia**:\n     - Descripci\u00f3n de la pol\u00edtica para participar en esquemas de pruebas de competencia y ensayos colaborativos.\n     - Inclusi\u00f3n de una lista de pruebas en las que el laboratorio ha participado en los \u00faltimos tres a\u00f1os, junto con los organizadores y resultados.\n\n3. **Importancia de la Precalificaci\u00f3n y Pruebas de Competencia**:\n   - Asegura la calidad y fiabilidad de los an\u00e1lisis realizados por el laboratorio.\n   - Requiere documentaci\u00f3n de la participaci\u00f3n en ensayos colaborativos y evaluaci\u00f3n del desempe\u00f1o.\n\n### Entidades Clave:\n- **Laboratorio**: Entidad que realiza an\u00e1lisis y pruebas.\n- **Organizaci\u00f3n/Compa\u00f1\u00eda**: Estructura a la que pertenece el laboratorio.\n- **Clientes**: Categor\u00edas de usuarios de los servicios del laboratorio.\n- **M\u00e9todos y Pruebas**: Tipos de an\u00e1lisis que el laboratorio puede realizar y proponer para precalificaci\u00f3n.\n- **Esquemas de Pruebas de Competencia**: Programas en los que el laboratorio participa para evaluar su desempe\u00f1o.", "excerpt_keywords": "Keywords: quality management system, pharmaceutical quality control, internal audits, documentation control, laboratory personnel"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c8bc243a-d811-4a07-8528-6d5f342a1d1d", "node_type": "4", "metadata": {"page_label": "417", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management system\n\n2.1 Short description of the quality management system implemented in the laboratory, including reference to the standard used (such as WHO good practices for pharmaceutical quality control laboratories, ISO 17025, good manufacturing practices) and existence of a quality manual.\n\n2.2 Information on inspections carried out by national or regional authorities and external audits performed in the laboratory in the last three years, including reference to valid accreditation, certificate, authorization or licence.\n\n2.3 Brief description of the procedures for internal audits, implementation of corrective and preventive actions and complaints.\n\n# 3. Control of documentation and records\n\n3.1 Brief description of the procedures for the control of and changes to documents that form a part of the quality documentation. Attach a list of valid SOPs.\n\n3.2 Brief description of the procedures for the preparation, revision and distribution of necessary documentation for specifications, standard test procedures, analyst workbooks or worksheets.\n\n3.3 Brief description of any other documentation related to product testing, including reports, records, arrangements for the handling of results (including laboratory information management systems (LIMS), where used).\n\n3.4 Brief description of the procedures for release of certificates and analytical reports.\n\n# 4. Personnel\n\n4.1 Number of employees engaged in the following activities:\n\n| Activity | Number |\n| - | - |\n| Supervisors | |\n| Chemical sector | |\n| \u00a0\u00a0\u00a0\u00a0analysts | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Microbiological sector | |\n| \u00a0\u00a0\u00a0\u00a0microbiologists | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Quality assurance staff | |\n| Staff trained for sampling | |\n| Other | |\n| Total number of employees in the laboratory: | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "47bde6f2bf8501317dbc696c44f5a8504db72efecbe9f12752a6a963988f7052", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2. Quality management system\n\n2.1 Short description of the quality management system implemented in the laboratory, including reference to the standard used (such as WHO good practices for pharmaceutical quality control laboratories, ISO 17025, good manufacturing practices) and existence of a quality manual.\n\n2.2 Information on inspections carried out by national or regional authorities and external audits performed in the laboratory in the last three years, including reference to valid accreditation, certificate, authorization or licence.\n\n2.3 Brief description of the procedures for internal audits, implementation of corrective and preventive actions and complaints.\n\n# 3. Control of documentation and records\n\n3.1 Brief description of the procedures for the control of and changes to documents that form a part of the quality documentation. Attach a list of valid SOPs.\n\n3.2 Brief description of the procedures for the preparation, revision and distribution of necessary documentation for specifications, standard test procedures, analyst workbooks or worksheets.\n\n3.3 Brief description of any other documentation related to product testing, including reports, records, arrangements for the handling of results (including laboratory information management systems (LIMS), where used).\n\n3.4 Brief description of the procedures for release of certificates and analytical reports.\n\n# 4. Personnel\n\n4.1 Number of employees engaged in the following activities:\n\n| Activity | Number |\n| - | - |\n| Supervisors | |\n| Chemical sector | |\n| \u00a0\u00a0\u00a0\u00a0analysts | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Microbiological sector | |\n| \u00a0\u00a0\u00a0\u00a0microbiologists | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Quality assurance staff | |\n| Staff trained for sampling | |\n| Other | |\n| Total number of employees in the laboratory: | |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1784, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7d9e119e-b302-41f7-b535-937cc39c8d13": {"__data__": {"id_": "7d9e119e-b302-41f7-b535-937cc39c8d13", "embedding": null, "metadata": {"page_label": "418", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Organization chart showing the arrangements, responsibilities and reporting lines in the laboratory.\n\n4.3 Qualifications, experience and responsibilities of key personnel.\n\n4.4 Outline of arrangements for initial and ongoing training and its recording.\n\n# 5. Premises\n\n5.1 Simple plan or description of the layout of the laboratory areas with an indication of scale (architectural or engineering drawings not required, but photographs may be submitted if available).\n\n5.2 Nature of construction and finishing.\n\n5.3 Brief description of ventilation systems including those for microbiological testing areas, storage areas, etc. (Include reference to air circulation and control of temperature and relative humidity.)\n\n5.4 Brief description of special areas for the handling and storage of hazardous materials such as highly toxic (including genotoxic), poisonous and flammable materials.\n\n5.5 Description of planned programmes for preventive maintenance of the premises and the system for recording maintenance activities.\n\n5.6 Brief description of the procedures for cleaning of areas and equipment.\n\n5.7 Short description of the storage areas (size, location) including arrangements for the storage of materials and retention samples.\n\n# 6. Equipment\n\n6.1 Brief description of the main equipment used in the laboratory. Attach a list of equipment in use, in tabular form, indicating the equipment and its brand model and date of installation.\n\n6.2 Brief description of the planned programme for the preventive maintenance of equipment and the system for recording the maintenance activities.\n\n6.3 Brief description of arrangements and status for qualification of equipment (installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ)) as well as calibration of measuring equipment, including the recording system.\n\n6.4 Brief description of computer system and its validation and data integrity management, including access to data and frequency of back-up.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos clave relacionados con la organizaci\u00f3n y operaci\u00f3n de laboratorios, incluyendo la estructura organizativa, las calificaciones y responsabilidades del personal, la formaci\u00f3n continua, las instalaciones del laboratorio, el equipo utilizado, y los procedimientos de mantenimiento y limpieza. Se detallan tambi\u00e9n las caracter\u00edsticas de las \u00e1reas de almacenamiento, la gesti\u00f3n de materiales peligrosos y la validaci\u00f3n de sistemas inform\u00e1ticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos de calificaci\u00f3n y experiencia para el personal clave en el laboratorio seg\u00fan el informe?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las calificaciones y experiencias necesarias que no se pueden encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de mantenimiento preventivo se recomienda para las instalaciones del laboratorio y c\u00f3mo se debe registrar?**\n   - Esta pregunta se centra en los programas de mantenimiento preventivo, que son cruciales para la operaci\u00f3n segura y eficiente del laboratorio, y que pueden no estar ampliamente documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 procedimientos se sugieren para la limpieza de \u00e1reas y equipos en el laboratorio, y c\u00f3mo se asegura su efectividad?**\n   - Esta pregunta busca detalles sobre los procedimientos espec\u00edficos de limpieza y su importancia en la prevenci\u00f3n de contaminaci\u00f3n, que pueden no estar disponibles en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Sistema de gesti\u00f3n de calidad**:\n   - Descripci\u00f3n del sistema de gesti\u00f3n de calidad implementado en el laboratorio.\n   - Referencia a est\u00e1ndares como las buenas pr\u00e1cticas de la OMS, ISO 17025 y buenas pr\u00e1cticas de fabricaci\u00f3n.\n   - Existencia de un manual de calidad.\n\n2. **Inspecciones y auditor\u00edas**:\n   - Informaci\u00f3n sobre inspecciones realizadas por autoridades nacionales o regionales.\n   - Detalles sobre auditor\u00edas externas en los \u00faltimos tres a\u00f1os.\n   - Referencia a acreditaciones, certificados, autorizaciones o licencias v\u00e1lidas.\n\n3. **Auditor\u00edas internas y acciones correctivas**:\n   - Procedimientos para auditor\u00edas internas.\n   - Implementaci\u00f3n de acciones correctivas y preventivas.\n   - Gesti\u00f3n de quejas.\n\n4. **Control de documentaci\u00f3n y registros**:\n   - Procedimientos para el control y cambios en la documentaci\u00f3n de calidad.\n   - Preparaci\u00f3n, revisi\u00f3n y distribuci\u00f3n de documentaci\u00f3n necesaria (especificaciones, procedimientos de prueba est\u00e1ndar, etc.).\n   - Documentaci\u00f3n relacionada con pruebas de productos, incluyendo informes y sistemas de gesti\u00f3n de informaci\u00f3n de laboratorio (LIMS).\n   - Procedimientos para la liberaci\u00f3n de certificados e informes anal\u00edticos.\n\n5. **Personal**:\n   - Desglose del n\u00famero de empleados en diversas actividades, incluyendo supervisores, analistas, t\u00e9cnicos, microbi\u00f3logos, personal de aseguramiento de calidad y personal capacitado para muestreo.\n   - Total de empleados en el laboratorio.\n\n### Entidades:\n- **Est\u00e1ndares**: OMS, ISO 17025, buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Tipos de personal**: Supervisores, analistas, t\u00e9cnicos, microbi\u00f3logos, personal de calidad.\n- **Documentaci\u00f3n**: Manual de calidad, SOPs (Procedimientos Operativos Est\u00e1ndar), informes anal\u00edticos, certificados. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos clave relacionados con la gesti\u00f3n de calidad en laboratorios de control de calidad farmac\u00e9utica, as\u00ed como la estructura del personal y los procedimientos documentales.", "excerpt_keywords": "Keywords: laboratory management, quality assurance, preventive maintenance, personnel qualifications, equipment validation"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e948d067-ee7c-4787-9c16-e934d3780167", "node_type": "4", "metadata": {"page_label": "418", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Organization chart showing the arrangements, responsibilities and reporting lines in the laboratory.\n\n4.3 Qualifications, experience and responsibilities of key personnel.\n\n4.4 Outline of arrangements for initial and ongoing training and its recording.\n\n# 5. Premises\n\n5.1 Simple plan or description of the layout of the laboratory areas with an indication of scale (architectural or engineering drawings not required, but photographs may be submitted if available).\n\n5.2 Nature of construction and finishing.\n\n5.3 Brief description of ventilation systems including those for microbiological testing areas, storage areas, etc. (Include reference to air circulation and control of temperature and relative humidity.)\n\n5.4 Brief description of special areas for the handling and storage of hazardous materials such as highly toxic (including genotoxic), poisonous and flammable materials.\n\n5.5 Description of planned programmes for preventive maintenance of the premises and the system for recording maintenance activities.\n\n5.6 Brief description of the procedures for cleaning of areas and equipment.\n\n5.7 Short description of the storage areas (size, location) including arrangements for the storage of materials and retention samples.\n\n# 6. Equipment\n\n6.1 Brief description of the main equipment used in the laboratory. Attach a list of equipment in use, in tabular form, indicating the equipment and its brand model and date of installation.\n\n6.2 Brief description of the planned programme for the preventive maintenance of equipment and the system for recording the maintenance activities.\n\n6.3 Brief description of arrangements and status for qualification of equipment (installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ)) as well as calibration of measuring equipment, including the recording system.\n\n6.4 Brief description of computer system and its validation and data integrity management, including access to data and frequency of back-up.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "02be1a592ed44bf3a9b3aac1da6604ff4141d363959ea513229d63239ebaa350", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.2 Organization chart showing the arrangements, responsibilities and reporting lines in the laboratory.\n\n4.3 Qualifications, experience and responsibilities of key personnel.\n\n4.4 Outline of arrangements for initial and ongoing training and its recording.\n\n# 5. Premises\n\n5.1 Simple plan or description of the layout of the laboratory areas with an indication of scale (architectural or engineering drawings not required, but photographs may be submitted if available).\n\n5.2 Nature of construction and finishing.\n\n5.3 Brief description of ventilation systems including those for microbiological testing areas, storage areas, etc. (Include reference to air circulation and control of temperature and relative humidity.)\n\n5.4 Brief description of special areas for the handling and storage of hazardous materials such as highly toxic (including genotoxic), poisonous and flammable materials.\n\n5.5 Description of planned programmes for preventive maintenance of the premises and the system for recording maintenance activities.\n\n5.6 Brief description of the procedures for cleaning of areas and equipment.\n\n5.7 Short description of the storage areas (size, location) including arrangements for the storage of materials and retention samples.\n\n# 6. Equipment\n\n6.1 Brief description of the main equipment used in the laboratory. Attach a list of equipment in use, in tabular form, indicating the equipment and its brand model and date of installation.\n\n6.2 Brief description of the planned programme for the preventive maintenance of equipment and the system for recording the maintenance activities.\n\n6.3 Brief description of arrangements and status for qualification of equipment (installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ)) as well as calibration of measuring equipment, including the recording system.\n\n6.4 Brief description of computer system and its validation and data integrity management, including access to data and frequency of back-up.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2002, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "92ae8602-c007-4512-8323-02717be0ff33": {"__data__": {"id_": "92ae8602-c007-4512-8323-02717be0ff33", "embedding": null, "metadata": {"page_label": "419", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7. Materials\n\n7.1 Brief description of general policy for purchasing and handling of materials (including chemicals and reagents and availability of safety data sheets) and for handling of waste. Brief description of the procedure for selection and evaluation of suppliers.\n\n7.2 Brief description of the water system in the laboratory, its qualification and arrangements for the sampling and testing of the water.\n\n7.3 Brief description of the system for purchasing, preparation, handling and storage of reference substances and reference materials.\n\n# 8. Subcontracting of testing\n\n8.1 List of activities contracted out to other laboratories, including names and addresses of subcontractors of subcontractors. Description of the way in which the compliance with standards for activities contracted out is assessed.\n\n# 9. Handling of samples\n\n9.1 Brief description of general policy for sampling. If the laboratory is responsible for sampling describe briefly the procedures used and standards applied.\n\n9.2 Brief description of the procedures for handling of samples from their receipt to storage after completion of testing. Where possible, flow charts describing important steps and work allocation in the laboratory should be supplied.\n\n# 10. Validation of analytical procedures\n\n10.1 Brief description of general policy for validation of analytical methods, including verification of pharmacopoeial methods or analytical procedures validated by manufacturers.\n\n# 11. Investigation of out-of-specification results\n\n11.1 Brief description of the procedure for recording and investigation of out-of-specification results.\n\n# 12. Stability testing (where applicable)\n\n12.1 Brief description of the stability testing procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda varios aspectos cr\u00edticos relacionados con la gesti\u00f3n de laboratorios, incluyendo pol\u00edticas para la compra y manejo de materiales, procedimientos de muestreo, validaci\u00f3n de m\u00e9todos anal\u00edticos, y manejo de resultados fuera de especificaci\u00f3n. Se detallan las pr\u00e1cticas para la selecci\u00f3n de proveedores, el manejo de muestras, y la realizaci\u00f3n de pruebas de estabilidad, as\u00ed como la subcontrataci\u00f3n de actividades de laboratorio.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la pol\u00edtica general para la compra y manejo de materiales en el laboratorio, y c\u00f3mo se asegura la disponibilidad de hojas de datos de seguridad?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las pol\u00edticas y procedimientos que el laboratorio sigue para la adquisici\u00f3n y manejo seguro de materiales, as\u00ed como la gesti\u00f3n de residuos.\n\n2. **\u00bfQu\u00e9 procedimientos se utilizan para la validaci\u00f3n de m\u00e9todos anal\u00edticos, y c\u00f3mo se verifica la conformidad con los m\u00e9todos farmacopoeiales?**\n   - Esta pregunta se centra en los procesos de validaci\u00f3n de m\u00e9todos anal\u00edticos, un aspecto crucial para garantizar la calidad y precisi\u00f3n de los resultados en un laboratorio.\n\n3. **\u00bfC\u00f3mo se lleva a cabo la investigaci\u00f3n de resultados fuera de especificaci\u00f3n y qu\u00e9 procedimientos se siguen para documentar estos casos?**\n   - Esta pregunta busca detalles sobre el manejo de resultados que no cumplen con los est\u00e1ndares establecidos, lo que es fundamental para la integridad de los procesos de laboratorio y la confianza en los resultados obtenidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n del Laboratorio**\n   - **Estructura Organizativa**: Se menciona un organigrama que detalla las responsabilidades y l\u00edneas de reporte del personal en el laboratorio.\n   - **Personal Clave**: Se requiere informaci\u00f3n sobre las calificaciones, experiencia y responsabilidades del personal esencial.\n\n2. **Formaci\u00f3n**\n   - **Capacitaci\u00f3n Inicial y Continua**: Se describe la organizaci\u00f3n de la formaci\u00f3n y su registro, asegurando que el personal est\u00e9 adecuadamente capacitado.\n\n3. **Instalaciones del Laboratorio**\n   - **Dise\u00f1o y Construcci\u00f3n**: Se solicita un plano simple o descripci\u00f3n del layout del laboratorio, as\u00ed como detalles sobre la construcci\u00f3n y acabados.\n   - **Sistemas de Ventilaci\u00f3n**: Se requiere una breve descripci\u00f3n de los sistemas de ventilaci\u00f3n, incluyendo control de temperatura y humedad.\n   - **Manejo de Materiales Peligrosos**: Se abordan \u00e1reas especiales para el manejo y almacenamiento de materiales altamente t\u00f3xicos y peligrosos.\n   - **Mantenimiento Preventivo**: Se describe un programa de mantenimiento preventivo para las instalaciones y un sistema para registrar las actividades de mantenimiento.\n   - **Procedimientos de Limpieza**: Se detallan los procedimientos para la limpieza de \u00e1reas y equipos, asegurando su efectividad.\n   - **\u00c1reas de Almacenamiento**: Se proporciona una descripci\u00f3n de las \u00e1reas de almacenamiento, incluyendo tama\u00f1o y ubicaci\u00f3n.\n\n4. **Equipamiento del Laboratorio**\n   - **Descripci\u00f3n del Equipamiento**: Se requiere una lista de los equipos principales utilizados en el laboratorio, incluyendo marca, modelo y fecha de instalaci\u00f3n.\n   - **Mantenimiento del Equipamiento**: Se describe un programa de mantenimiento preventivo para el equipo y un sistema de registro de actividades.\n   - **Calificaci\u00f3n del Equipamiento**: Se abordan los procesos de calificaci\u00f3n del equipo (IQ, OQ, PQ) y la calibraci\u00f3n de equipos de medici\u00f3n.\n   - **Sistema Inform\u00e1tico**: Se menciona la validaci\u00f3n del sistema inform\u00e1tico y la gesti\u00f3n de la integridad de los datos, incluyendo acceso y frecuencia de respaldo.\n\n### Entidades Clave\n- **Laboratorio**: Entidad principal donde se llevan a cabo las actividades descritas.\n- **Personal Clave**: Individuos con calificaciones y responsabilidades espec\u00edficas.\n- **Equipamiento**: Herramientas y m\u00e1quinas utilizadas en el laboratorio.\n- **Materiales Peligrosos**: Sustancias que requieren manejo especial debido a su toxicidad o peligrosidad.\n- **Sistemas de Ventilaci\u00f3n**: Infraestructura cr\u00edtica para el control ambiental del laboratorio. \n\nEste resumen abarca los aspectos fundamentales de la organizaci\u00f3n, mantenimiento y operaci\u00f3n de laboratorios seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: laboratory management, analytical procedures, sample handling, stability testing, subcontracting"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "03a3a8d3-4b8f-4df9-9303-a76d54e86ef2", "node_type": "4", "metadata": {"page_label": "419", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7. Materials\n\n7.1 Brief description of general policy for purchasing and handling of materials (including chemicals and reagents and availability of safety data sheets) and for handling of waste. Brief description of the procedure for selection and evaluation of suppliers.\n\n7.2 Brief description of the water system in the laboratory, its qualification and arrangements for the sampling and testing of the water.\n\n7.3 Brief description of the system for purchasing, preparation, handling and storage of reference substances and reference materials.\n\n# 8. Subcontracting of testing\n\n8.1 List of activities contracted out to other laboratories, including names and addresses of subcontractors of subcontractors. Description of the way in which the compliance with standards for activities contracted out is assessed.\n\n# 9. Handling of samples\n\n9.1 Brief description of general policy for sampling. If the laboratory is responsible for sampling describe briefly the procedures used and standards applied.\n\n9.2 Brief description of the procedures for handling of samples from their receipt to storage after completion of testing. Where possible, flow charts describing important steps and work allocation in the laboratory should be supplied.\n\n# 10. Validation of analytical procedures\n\n10.1 Brief description of general policy for validation of analytical methods, including verification of pharmacopoeial methods or analytical procedures validated by manufacturers.\n\n# 11. Investigation of out-of-specification results\n\n11.1 Brief description of the procedure for recording and investigation of out-of-specification results.\n\n# 12. Stability testing (where applicable)\n\n12.1 Brief description of the stability testing procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3de9fa53c70d7aa1efd489c182738d411eedfe62a89972c0a3ff56d98dfa9e5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 7. Materials\n\n7.1 Brief description of general policy for purchasing and handling of materials (including chemicals and reagents and availability of safety data sheets) and for handling of waste. Brief description of the procedure for selection and evaluation of suppliers.\n\n7.2 Brief description of the water system in the laboratory, its qualification and arrangements for the sampling and testing of the water.\n\n7.3 Brief description of the system for purchasing, preparation, handling and storage of reference substances and reference materials.\n\n# 8. Subcontracting of testing\n\n8.1 List of activities contracted out to other laboratories, including names and addresses of subcontractors of subcontractors. Description of the way in which the compliance with standards for activities contracted out is assessed.\n\n# 9. Handling of samples\n\n9.1 Brief description of general policy for sampling. If the laboratory is responsible for sampling describe briefly the procedures used and standards applied.\n\n9.2 Brief description of the procedures for handling of samples from their receipt to storage after completion of testing. Where possible, flow charts describing important steps and work allocation in the laboratory should be supplied.\n\n# 10. Validation of analytical procedures\n\n10.1 Brief description of general policy for validation of analytical methods, including verification of pharmacopoeial methods or analytical procedures validated by manufacturers.\n\n# 11. Investigation of out-of-specification results\n\n11.1 Brief description of the procedure for recording and investigation of out-of-specification results.\n\n# 12. Stability testing (where applicable)\n\n12.1 Brief description of the stability testing procedure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1729, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "8e520bfa-475b-450b-98c9-c8f4a20e3ce3": {"__data__": {"id_": "8e520bfa-475b-450b-98c9-c8f4a20e3ce3", "embedding": null, "metadata": {"page_label": "420", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.2 \nBrief description of the conditions under which samples are kept, the arrangements for monitoring and the equipment used.\n\n# 13. Microbiological testing (where applicable)\n\n13.1 Brief description of the activities for microbiological testing.\n\n13.2 Brief description of preparation and control of media and types of media used.\n\n13.3 Brief description of the procedure in place for positive and negative controls.\n\n13.4 Brief description of validation policy.\n\n13.5 Brief description of arrangements for waste disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos relacionados con la conservaci\u00f3n de muestras y las pruebas microbiol\u00f3gicas. Se detalla c\u00f3mo se mantienen las muestras, los equipos utilizados, las actividades de pruebas microbiol\u00f3gicas, la preparaci\u00f3n y control de medios, as\u00ed como los procedimientos de control positivo y negativo, la pol\u00edtica de validaci\u00f3n y la gesti\u00f3n de residuos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas bajo las cuales se deben almacenar las muestras y qu\u00e9 tipo de equipo se utiliza para monitorear estas condiciones?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las condiciones de almacenamiento y el equipo de monitoreo, que probablemente no se encuentre en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipos de medios se utilizan en las pruebas microbiol\u00f3gicas y c\u00f3mo se lleva a cabo su preparaci\u00f3n y control?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos de la preparaci\u00f3n de medios, que son cruciales para la validez de las pruebas microbiol\u00f3gicas.\n\n3. **\u00bfQu\u00e9 procedimientos se implementan para garantizar la efectividad de los controles positivos y negativos en las pruebas microbiol\u00f3gicas?**\n   - Esta pregunta indaga sobre los procedimientos espec\u00edficos que aseguran la fiabilidad de los resultados de las pruebas, un aspecto fundamental en la microbiolog\u00eda que puede no estar ampliamente documentado en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Pol\u00edtica de Materiales**:\n   - **Compra y Manejo**: Se describe la pol\u00edtica general para la adquisici\u00f3n y manejo de materiales, incluyendo productos qu\u00edmicos y reactivos, as\u00ed como la disponibilidad de hojas de datos de seguridad.\n   - **Manejo de Residuos**: Incluye procedimientos para la gesti\u00f3n de desechos generados en el laboratorio.\n   - **Selecci\u00f3n de Proveedores**: Proceso para la evaluaci\u00f3n y selecci\u00f3n de proveedores de materiales.\n\n2. **Sistema de Agua**:\n   - **Calificaci\u00f3n y Muestreo**: Descripci\u00f3n del sistema de agua en el laboratorio, incluyendo su calificaci\u00f3n y los arreglos para el muestreo y pruebas del agua.\n\n3. **Sustancias de Referencia**:\n   - **Compra y Almacenamiento**: Procedimientos para la compra, preparaci\u00f3n, manejo y almacenamiento de sustancias y materiales de referencia.\n\n4. **Subcontrataci\u00f3n**:\n   - **Actividades Contratadas**: Listado de actividades subcontratadas a otros laboratorios, incluyendo nombres y direcciones de los subcontratistas.\n   - **Cumplimiento de Normas**: Descripci\u00f3n de c\u00f3mo se eval\u00faa el cumplimiento de est\u00e1ndares en actividades subcontratadas.\n\n5. **Manejo de Muestras**:\n   - **Pol\u00edtica de Muestreo**: Procedimientos generales para el muestreo, incluyendo est\u00e1ndares aplicados.\n   - **Manejo de Muestras**: Procedimientos desde la recepci\u00f3n hasta el almacenamiento de muestras despu\u00e9s de las pruebas, con posibilidad de incluir diagramas de flujo.\n\n6. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**:\n   - **Pol\u00edtica de Validaci\u00f3n**: Descripci\u00f3n de la pol\u00edtica para la validaci\u00f3n de m\u00e9todos anal\u00edticos, incluyendo la verificaci\u00f3n de m\u00e9todos farmacopoeiales.\n\n7. **Resultados Fuera de Especificaci\u00f3n**:\n   - **Investigaci\u00f3n y Documentaci\u00f3n**: Procedimientos para registrar e investigar resultados que no cumplen con las especificaciones establecidas.\n\n8. **Pruebas de Estabilidad**:\n   - **Procedimiento de Estabilidad**: Descripci\u00f3n del procedimiento para realizar pruebas de estabilidad, cuando sea aplicable.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Laboratorio**: Entidad que implementa las pol\u00edticas y procedimientos descritos.\n- **Proveedores**: Entidades externas que suministran materiales y reactivos.\n- **Subcontratistas**: Laboratorios externos que realizan actividades contratadas.\n- **Sustancias de Referencia**: Materiales utilizados para calibraci\u00f3n y control de calidad en el laboratorio. \n\nEste resumen abarca los aspectos fundamentales de la gesti\u00f3n de laboratorios seg\u00fan el documento de la OMS, destacando las pol\u00edticas y procedimientos esenciales para asegurar la calidad y seguridad en las operaciones de laboratorio.", "excerpt_keywords": "Keywords: microbiological testing, sample storage, media preparation, validation policy, waste disposal"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "705df9e9-98a2-4d99-87d9-ced452bce29c", "node_type": "4", "metadata": {"page_label": "420", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.2 \nBrief description of the conditions under which samples are kept, the arrangements for monitoring and the equipment used.\n\n# 13. Microbiological testing (where applicable)\n\n13.1 Brief description of the activities for microbiological testing.\n\n13.2 Brief description of preparation and control of media and types of media used.\n\n13.3 Brief description of the procedure in place for positive and negative controls.\n\n13.4 Brief description of validation policy.\n\n13.5 Brief description of arrangements for waste disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "51d7f3c0ae5625f9a5a4cc5d580132d4823a2dc675573acfb1cd32a6af7e9c51", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 12.2 \nBrief description of the conditions under which samples are kept, the arrangements for monitoring and the equipment used.\n\n# 13. Microbiological testing (where applicable)\n\n13.1 Brief description of the activities for microbiological testing.\n\n13.2 Brief description of preparation and control of media and types of media used.\n\n13.3 Brief description of the procedure in place for positive and negative controls.\n\n13.4 Brief description of validation policy.\n\n13.5 Brief description of arrangements for waste disposal.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 527, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "7ef3aa49-8532-4e58-b2a7-006293d91d3c": {"__data__": {"id_": "7ef3aa49-8532-4e58-b2a7-006293d91d3c", "embedding": null, "metadata": {"page_label": "421", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 14\n\n## WHO guidelines for drafting a site master file\n\n1. Introduction\n2. Purpose\n3. Scope\n4. Content of site master file\n\n### Appendix\nContent of a site master file\n\n----\n\n\u00b9 Based on the *Explanatory notes for pharmaceutical manufacturers on the preparation of a site master file* of the Pharmaceutical Inspection Convention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una secci\u00f3n titulada \"Annex 14\", que proporciona directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) para la elaboraci\u00f3n de un archivo maestro del sitio (site master file). Este archivo es un documento esencial para los fabricantes farmac\u00e9uticos, ya que detalla la informaci\u00f3n relevante sobre las instalaciones y procesos de producci\u00f3n. La secci\u00f3n abarca la introducci\u00f3n, el prop\u00f3sito, el alcance y el contenido que debe incluirse en el archivo maestro del sitio, adem\u00e1s de un ap\u00e9ndice que detalla el contenido espec\u00edfico.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal de un archivo maestro del sitio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca una respuesta espec\u00edfica sobre la funci\u00f3n y la importancia del archivo maestro del sitio en el contexto de la fabricaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 se incluye en el contenido del archivo maestro del sitio seg\u00fan el documento mencionado?**\n   - Esta pregunta se centra en los elementos espec\u00edficos que deben ser parte del archivo maestro del sitio, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 se menciona en el ap\u00e9ndice del documento sobre el contenido del archivo maestro del sitio?**\n   - Esta pregunta busca detalles sobre la informaci\u00f3n adicional o espec\u00edfica que se proporciona en el ap\u00e9ndice, que podr\u00eda no estar disponible en otros documentos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\n1. **Condiciones de Almacenamiento de Muestras**:\n   - Descripci\u00f3n de las condiciones espec\u00edficas bajo las cuales se mantienen las muestras biol\u00f3gicas.\n   - Arreglos para el monitoreo de estas condiciones.\n   - Equipos utilizados para asegurar la integridad de las muestras.\n\n2. **Pruebas Microbiol\u00f3gicas**:\n   - Actividades relacionadas con la realizaci\u00f3n de pruebas microbiol\u00f3gicas.\n   - Preparaci\u00f3n y control de medios de cultivo, incluyendo los tipos de medios utilizados.\n   - Procedimientos para controles positivos y negativos, asegurando la validez de los resultados.\n   - Pol\u00edtica de validaci\u00f3n que respalda los m\u00e9todos de prueba.\n   - Disposici\u00f3n de residuos generados durante las pruebas microbiol\u00f3gicas.\n\n### Entidades Clave:\n- **Muestras**: Elementos biol\u00f3gicos que se almacenan y analizan.\n- **Equipos de Monitoreo**: Herramientas utilizadas para supervisar las condiciones de almacenamiento.\n- **Medios de Cultivo**: Sustancias utilizadas para el crecimiento de microorganismos en pruebas microbiol\u00f3gicas.\n- **Controles Positivos y Negativos**: Procedimientos que garantizan la fiabilidad de las pruebas.\n- **Pol\u00edtica de Validaci\u00f3n**: Normativas que aseguran la efectividad de los m\u00e9todos de prueba.\n- **Gesti\u00f3n de Residuos**: Proceso de disposici\u00f3n de desechos generados en el laboratorio.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos cr\u00edticos relacionados con la conservaci\u00f3n de muestras y las pruebas microbiol\u00f3gicas, as\u00ed como las entidades involucradas en estos procesos.", "excerpt_keywords": "Keywords: site master file, WHO guidelines, pharmaceutical manufacturing, document preparation, technical report"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e8ad89d-6cf5-4b15-b1a7-9e9d5a9f42b4", "node_type": "4", "metadata": {"page_label": "421", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 14\n\n## WHO guidelines for drafting a site master file\n\n1. Introduction\n2. Purpose\n3. Scope\n4. Content of site master file\n\n### Appendix\nContent of a site master file\n\n----\n\n\u00b9 Based on the *Explanatory notes for pharmaceutical manufacturers on the preparation of a site master file* of the Pharmaceutical Inspection Convention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "dfd531335fbda15a54f8b76a2cb5ad789f3644437ad26462eb43b6e092c59885", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 14\n\n## WHO guidelines for drafting a site master file\n\n1. Introduction\n2. Purpose\n3. Scope\n4. Content of site master file\n\n### Appendix\nContent of a site master file\n\n----\n\n\u00b9 Based on the *Explanatory notes for pharmaceutical manufacturers on the preparation of a site master file* of the Pharmaceutical Inspection Convention.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 334, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "81facdc1-e569-4803-af5e-049d8dc6a18d": {"__data__": {"id_": "81facdc1-e569-4803-af5e-049d8dc6a18d", "embedding": null, "metadata": {"page_label": "422", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 The site master file (SMF) is prepared by the pharmaceutical manufacturer and should contain specific information about the quality management policies and activities of the site, the production and/or quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, an SMF need only describe those operations, e.g. analysis, packaging, etc.\n\n1.2 When submitted to a regulatory authority, the SMF should provide clear information on the manufacturer\u2019s good manufacturing practices (GMP)-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.\n\n1.3 An SMF should contain adequate information but, as far as possible, not exceed 25\u201330 pages plus appendices. Simple plans, outline drawings or schematic layouts are preferred instead of narratives. The SMF, including appendices, should be readable when printed on A4 paper sheets.\n\n1.4 The SMF should be a part of documentation belonging to the quality management system of the manufacturer and kept updated accordingly. The SMF should have an edition number, the date it becomes effective and the date by which it has to be reviewed. It should be subject to regular review to ensure that it is up to date and representative of current activities. Each annex can have an individual effective date, allowing for independent updating.\n\n# 2. Purpose\n\nThe aim of these explanatory notes is to guide the manufacturer of medicinal products in the preparation of an SMF that is useful to the regulatory authority in planning and conducting GMP inspections.\n\n# 3. Scope\n\nThese explanatory notes apply to the preparation and content of the SMF. Manufacturers should refer to regional and or national regulatory requirements to establish whether it is mandatory for manufacturers of medicinal products to prepare an SMF.\n\nThese explanatory notes apply for all kinds of manufacturing operations such as production, packaging and labelling, testing, relabelling and repackaging of all types of medicinal products. The outlines of this guide could also be used in the preparation of an SMF or corresponding document by blood and tissue establishments and manufacturers of active pharmaceutical ingredients (APIs).\n\n# 4. Content of site master file\n\nRefer to the Appendix for the format to be used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento se centra en la elaboraci\u00f3n del archivo maestro del sitio (SMF) por parte de los fabricantes de productos farmac\u00e9uticos. El SMF debe contener informaci\u00f3n sobre las pol\u00edticas de gesti\u00f3n de calidad y las actividades del sitio, as\u00ed como detalles sobre las operaciones de fabricaci\u00f3n y control de calidad. Se establece que el SMF debe ser claro, conciso y estar actualizado, y se menciona su importancia para las inspecciones de buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) por parte de las autoridades regulatorias. Adem\u00e1s, se indica que el SMF debe seguir un formato espec\u00edfico y puede aplicarse a diversas operaciones de fabricaci\u00f3n.\n\n### Preguntas\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n espec\u00edfica debe incluirse en el archivo maestro del sitio (SMF) para cumplir con los requisitos de las autoridades regulatorias?**\n   - Esta pregunta busca detalles sobre los elementos espec\u00edficos que deben estar presentes en el SMF, m\u00e1s all\u00e1 de lo que se menciona en el resumen.\n\n2. **\u00bfCu\u00e1les son las implicaciones de no mantener actualizado el archivo maestro del sitio (SMF) seg\u00fan las directrices establecidas?**\n   - Esta pregunta se centra en las consecuencias de no cumplir con los requisitos de actualizaci\u00f3n del SMF, lo que podr\u00eda no estar expl\u00edcitamente mencionado en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias existen en la preparaci\u00f3n del SMF para diferentes tipos de operaciones de fabricaci\u00f3n, como la producci\u00f3n de medicamentos frente a la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs)?**\n   - Esta pregunta busca aclarar c\u00f3mo var\u00edan los requisitos del SMF seg\u00fan el tipo de operaci\u00f3n de fabricaci\u00f3n, lo que podr\u00eda no estar claramente delineado en otros contextos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n**Tema clave:**\n- **Archivo Maestro del Sitio (Site Master File):** Documento esencial para los fabricantes farmac\u00e9uticos que proporciona informaci\u00f3n detallada sobre las instalaciones y procesos de producci\u00f3n.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices para la elaboraci\u00f3n del archivo maestro del sitio.\n- **Pharmaceutical Inspection Convention:** Fuente de las notas explicativas que sirven de base para las directrices de la OMS.\n\n**Estructura del contenido:**\n1. **Introducci\u00f3n:** Presentaci\u00f3n del tema y su relevancia.\n2. **Prop\u00f3sito:** Objetivos del archivo maestro del sitio.\n3. **Alcance:** \u00c1reas y aspectos cubiertos por el documento.\n4. **Contenido del archivo maestro del sitio:** Detalles sobre la informaci\u00f3n que debe incluirse.\n5. **Ap\u00e9ndice:** Informaci\u00f3n adicional sobre el contenido espec\u00edfico del archivo maestro del sitio.\n\nEste resumen destaca la importancia del archivo maestro del sitio en la industria farmac\u00e9utica y la gu\u00eda proporcionada por la OMS para su elaboraci\u00f3n.", "excerpt_keywords": "Keywords: Site Master File, pharmaceutical manufacturing, good manufacturing practices, quality management system, regulatory authority"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "984cb7ef-d327-4df6-bc45-1c410e296bd6", "node_type": "4", "metadata": {"page_label": "422", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 The site master file (SMF) is prepared by the pharmaceutical manufacturer and should contain specific information about the quality management policies and activities of the site, the production and/or quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, an SMF need only describe those operations, e.g. analysis, packaging, etc.\n\n1.2 When submitted to a regulatory authority, the SMF should provide clear information on the manufacturer\u2019s good manufacturing practices (GMP)-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.\n\n1.3 An SMF should contain adequate information but, as far as possible, not exceed 25\u201330 pages plus appendices. Simple plans, outline drawings or schematic layouts are preferred instead of narratives. The SMF, including appendices, should be readable when printed on A4 paper sheets.\n\n1.4 The SMF should be a part of documentation belonging to the quality management system of the manufacturer and kept updated accordingly. The SMF should have an edition number, the date it becomes effective and the date by which it has to be reviewed. It should be subject to regular review to ensure that it is up to date and representative of current activities. Each annex can have an individual effective date, allowing for independent updating.\n\n# 2. Purpose\n\nThe aim of these explanatory notes is to guide the manufacturer of medicinal products in the preparation of an SMF that is useful to the regulatory authority in planning and conducting GMP inspections.\n\n# 3. Scope\n\nThese explanatory notes apply to the preparation and content of the SMF. Manufacturers should refer to regional and or national regulatory requirements to establish whether it is mandatory for manufacturers of medicinal products to prepare an SMF.\n\nThese explanatory notes apply for all kinds of manufacturing operations such as production, packaging and labelling, testing, relabelling and repackaging of all types of medicinal products. The outlines of this guide could also be used in the preparation of an SMF or corresponding document by blood and tissue establishments and manufacturers of active pharmaceutical ingredients (APIs).\n\n# 4. Content of site master file\n\nRefer to the Appendix for the format to be used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "4b00ee0eafbd87032adda33b1388b876d3e1f358d8a08caa36cafd58716fa6b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. Introduction\n\n1.1 The site master file (SMF) is prepared by the pharmaceutical manufacturer and should contain specific information about the quality management policies and activities of the site, the production and/or quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, an SMF need only describe those operations, e.g. analysis, packaging, etc.\n\n1.2 When submitted to a regulatory authority, the SMF should provide clear information on the manufacturer\u2019s good manufacturing practices (GMP)-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.\n\n1.3 An SMF should contain adequate information but, as far as possible, not exceed 25\u201330 pages plus appendices. Simple plans, outline drawings or schematic layouts are preferred instead of narratives. The SMF, including appendices, should be readable when printed on A4 paper sheets.\n\n1.4 The SMF should be a part of documentation belonging to the quality management system of the manufacturer and kept updated accordingly. The SMF should have an edition number, the date it becomes effective and the date by which it has to be reviewed. It should be subject to regular review to ensure that it is up to date and representative of current activities. Each annex can have an individual effective date, allowing for independent updating.\n\n# 2. Purpose\n\nThe aim of these explanatory notes is to guide the manufacturer of medicinal products in the preparation of an SMF that is useful to the regulatory authority in planning and conducting GMP inspections.\n\n# 3. Scope\n\nThese explanatory notes apply to the preparation and content of the SMF. Manufacturers should refer to regional and or national regulatory requirements to establish whether it is mandatory for manufacturers of medicinal products to prepare an SMF.\n\nThese explanatory notes apply for all kinds of manufacturing operations such as production, packaging and labelling, testing, relabelling and repackaging of all types of medicinal products. The outlines of this guide could also be used in the preparation of an SMF or corresponding document by blood and tissue establishments and manufacturers of active pharmaceutical ingredients (APIs).\n\n# 4. Content of site master file\n\nRefer to the Appendix for the format to be used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2492, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "4b1f93f6-8271-43b4-93f8-8d526d920a48": {"__data__": {"id_": "4b1f93f6-8271-43b4-93f8-8d526d920a48", "embedding": null, "metadata": {"page_label": "423", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Content of a site master file\n\n1. **General information on the manufacturer**\n\n   1.1 **Contact information on the manufacturer**\n   \n   - Name and official address of the manufacturer;\n   - Names and street addresses of the site, buildings and production units located on the site;\n   - Contact information of the manufacturer including 24-hour telephone number of the contact personnel in the case of product defects or recalls; and\n   - Identification number of the site as e.g. global positioning system (GPS) details, D-U-N-S (Data Universal Numbering System) number (a unique identification number provided by Dun & Bradstreet) of the site or any other geographical location system.\n\n   1.2 **Authorized pharmaceutical manufacturing activities of the site**\n   \n   - Copy of the valid manufacturing authorization issued by the relevant competent authority in Annex 1; or when applicable, reference to the EudraGMP database. If the competent authority does not issue manufacturing authorizations, this should be stated;\n   - Brief description of manufacture, import, export, distribution and other activities as authorized by the relevant competent authorities including foreign authorities with authorized dosage forms/activities, respectively; where not covered by the manufacturing authorization;\n   - Type of products currently manufactured on-site (list in Annex 2) where not covered by Annex 1 or the EudraGMP database; and\n   - List of GMP inspections of the site within the last five years; including dates and name/country of the competent authority having performed the inspection. A copy of the current GMP certificate (Annex 3) or reference to the EudraGMP database should be included, if available.\n\n   1.3 **Any other manufacturing activities carried out on the site**\n   \n   - Description of nonpharmaceutical activities on site, if any.\n\n2. **Quality management**\n\n   2.1 **The quality management system of the manufacturer**\n   \n   - Brief description of the quality management systems run by the company and reference to the standards used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (Serie 961) que detalla el contenido de un archivo maestro del sitio (site master file) para fabricantes de productos farmac\u00e9uticos. Se divide en secciones que abordan la informaci\u00f3n general sobre el fabricante, incluyendo datos de contacto, actividades de fabricaci\u00f3n autorizadas, y el sistema de gesti\u00f3n de calidad implementado por la empresa. Tambi\u00e9n se menciona la necesidad de documentaci\u00f3n espec\u00edfica, como autorizaciones de fabricaci\u00f3n y certificados de buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n de contacto debe incluirse en el archivo maestro del sitio seg\u00fan el documento?**\n   - El archivo debe incluir el nombre y direcci\u00f3n oficial del fabricante, direcciones de los edificios y unidades de producci\u00f3n, informaci\u00f3n de contacto con un n\u00famero telef\u00f3nico de 24 horas para casos de defectos o retiradas de productos, y un n\u00famero de identificaci\u00f3n del sitio, como detalles GPS o un n\u00famero D-U-N-S.\n\n2. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para las actividades de fabricaci\u00f3n autorizadas en el sitio?**\n   - Se requiere una copia de la autorizaci\u00f3n de fabricaci\u00f3n v\u00e1lida emitida por la autoridad competente, una descripci\u00f3n breve de las actividades autorizadas (fabricaci\u00f3n, importaci\u00f3n, exportaci\u00f3n, distribuci\u00f3n), un listado de los productos fabricados actualmente en el sitio, y un registro de las inspecciones GMP realizadas en los \u00faltimos cinco a\u00f1os.\n\n3. **\u00bfQu\u00e9 aspectos del sistema de gesti\u00f3n de calidad del fabricante se deben describir en el archivo maestro del sitio?**\n   - Se debe proporcionar una breve descripci\u00f3n de los sistemas de gesti\u00f3n de calidad que opera la empresa, as\u00ed como una referencia a los est\u00e1ndares utilizados en dichos sistemas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Archivo Maestro del Sitio (SMF)**:\n   - Definici\u00f3n: Documento preparado por el fabricante farmac\u00e9utico que contiene informaci\u00f3n sobre las pol\u00edticas de gesti\u00f3n de calidad y las actividades del sitio.\n   - Contenido: Debe incluir detalles sobre la producci\u00f3n y control de calidad, as\u00ed como operaciones integradas en edificios cercanos.\n\n2. **Importancia del SMF**:\n   - Utilidad: Proporciona informaci\u00f3n clara sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para facilitar la supervisi\u00f3n y planificaci\u00f3n de inspecciones por parte de autoridades regulatorias.\n   - Extensi\u00f3n: Debe ser conciso, no excediendo 25-30 p\u00e1ginas m\u00e1s ap\u00e9ndices, y preferiblemente incluir esquemas en lugar de narrativas.\n\n3. **Mantenimiento y Actualizaci\u00f3n**:\n   - Requisitos: El SMF debe ser parte del sistema de gesti\u00f3n de calidad del fabricante, actualizado regularmente y con un n\u00famero de edici\u00f3n y fechas de efectividad y revisi\u00f3n.\n\n4. **Prop\u00f3sito y Alcance**:\n   - Gu\u00eda: Las notas explicativas tienen como objetivo ayudar a los fabricantes en la preparaci\u00f3n del SMF para que sea \u00fatil en las inspecciones GMP.\n   - Aplicaci\u00f3n: Se aplica a diversas operaciones de fabricaci\u00f3n, incluyendo producci\u00f3n, envasado, etiquetado, y tambi\u00e9n puede ser utilizado por fabricantes de ingredientes farmac\u00e9uticos activos (APIs) y establecimientos de sangre y tejidos.\n\n5. **Formato**:\n   - Referencia: Se menciona que el formato espec\u00edfico para el SMF se encuentra en un ap\u00e9ndice del documento.\n\n### Entidades Clave\n- **Fabricante farmac\u00e9utico**: Entidad responsable de la preparaci\u00f3n del SMF.\n- **Autoridades regulatorias**: Entidades que supervisan y realizan inspecciones basadas en el SMF.\n- **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Normativas que gu\u00edan las operaciones de fabricaci\u00f3n y control de calidad.\n- **Medicamentos**: Productos cuya fabricaci\u00f3n y control son objeto del SMF.\n- **Ingredientes farmac\u00e9uticos activos (APIs)**: Tipo de producto que tambi\u00e9n puede requerir un SMF.", "excerpt_keywords": "Keywords: site master file, pharmaceutical manufacturing, quality management, GMP inspections, manufacturing authorization"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "197a0af0-4bad-4f48-b8cf-581a986f26a0", "node_type": "4", "metadata": {"page_label": "423", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Content of a site master file\n\n1. **General information on the manufacturer**\n\n   1.1 **Contact information on the manufacturer**\n   \n   - Name and official address of the manufacturer;\n   - Names and street addresses of the site, buildings and production units located on the site;\n   - Contact information of the manufacturer including 24-hour telephone number of the contact personnel in the case of product defects or recalls; and\n   - Identification number of the site as e.g. global positioning system (GPS) details, D-U-N-S (Data Universal Numbering System) number (a unique identification number provided by Dun & Bradstreet) of the site or any other geographical location system.\n\n   1.2 **Authorized pharmaceutical manufacturing activities of the site**\n   \n   - Copy of the valid manufacturing authorization issued by the relevant competent authority in Annex 1; or when applicable, reference to the EudraGMP database. If the competent authority does not issue manufacturing authorizations, this should be stated;\n   - Brief description of manufacture, import, export, distribution and other activities as authorized by the relevant competent authorities including foreign authorities with authorized dosage forms/activities, respectively; where not covered by the manufacturing authorization;\n   - Type of products currently manufactured on-site (list in Annex 2) where not covered by Annex 1 or the EudraGMP database; and\n   - List of GMP inspections of the site within the last five years; including dates and name/country of the competent authority having performed the inspection. A copy of the current GMP certificate (Annex 3) or reference to the EudraGMP database should be included, if available.\n\n   1.3 **Any other manufacturing activities carried out on the site**\n   \n   - Description of nonpharmaceutical activities on site, if any.\n\n2. **Quality management**\n\n   2.1 **The quality management system of the manufacturer**\n   \n   - Brief description of the quality management systems run by the company and reference to the standards used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3fd346b6eaa4501c029c646361388a8bce70a73e6d5f959f491890b6498c87a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix\n\n## Content of a site master file\n\n1. **General information on the manufacturer**\n\n   1.1 **Contact information on the manufacturer**\n   \n   - Name and official address of the manufacturer;\n   - Names and street addresses of the site, buildings and production units located on the site;\n   - Contact information of the manufacturer including 24-hour telephone number of the contact personnel in the case of product defects or recalls; and\n   - Identification number of the site as e.g. global positioning system (GPS) details, D-U-N-S (Data Universal Numbering System) number (a unique identification number provided by Dun & Bradstreet) of the site or any other geographical location system.\n\n   1.2 **Authorized pharmaceutical manufacturing activities of the site**\n   \n   - Copy of the valid manufacturing authorization issued by the relevant competent authority in Annex 1; or when applicable, reference to the EudraGMP database. If the competent authority does not issue manufacturing authorizations, this should be stated;\n   - Brief description of manufacture, import, export, distribution and other activities as authorized by the relevant competent authorities including foreign authorities with authorized dosage forms/activities, respectively; where not covered by the manufacturing authorization;\n   - Type of products currently manufactured on-site (list in Annex 2) where not covered by Annex 1 or the EudraGMP database; and\n   - List of GMP inspections of the site within the last five years; including dates and name/country of the competent authority having performed the inspection. A copy of the current GMP certificate (Annex 3) or reference to the EudraGMP database should be included, if available.\n\n   1.3 **Any other manufacturing activities carried out on the site**\n   \n   - Description of nonpharmaceutical activities on site, if any.\n\n2. **Quality management**\n\n   2.1 **The quality management system of the manufacturer**\n   \n   - Brief description of the quality management systems run by the company and reference to the standards used;", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2078, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "9316ad7c-8446-4a74-955e-7f6272f7996e": {"__data__": {"id_": "9316ad7c-8446-4a74-955e-7f6272f7996e", "embedding": null, "metadata": {"page_label": "424", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Release procedure of finished products\n\n\u2014 detailed description of qualification requirements (education and work experience) of the authorized person(s)/qualified person(s) responsible for batch certification and releasing procedures;  \n\u2014 general description of batch certification and releasing procedure;  \n\u2014 role of authorized person/qualified person in quarantine and release of finished products and in assessment of compliance with the marketing authorization;  \n\u2014 the arrangements between authorized persons/qualified persons when several authorized persons/qualified persons are involved; and  \n\u2014 statement on whether the control strategy employs process analytical technology (PAT) and/or real-time release or parametric release.  \n\n# 2.3 Management of suppliers and contractors\n\n\u2014 a brief summary of the establishment/knowledge of supply chain and the external audit programme;  \n\u2014 a brief description of the qualification system of contractors, manufacturers of APIs and other critical materials suppliers;  \n\u2014 measures taken to ensure that products manufactured are compliant with transmitting animal spongiform encephalopathy (TSE) guidance;[^1]  \n\u2014 measures adopted where substandard/spurious/falsely-labelled/falsified/counterfeit medical products, bulk products (i.e. unpacked tablets), APIs or excipients are suspected or identified;  \n\u2014 use of outside scientific, analytical or other technical assistance in relation to manufacture and analysis;  \n\u2014 list of contract manufacturers and laboratories including the addresses and contact information and flowcharts of supply chains for outsourced manufacturing and QC activities, e.g. sterilization of primary packaging material for aseptic processes, testing of starting raw materials, etc., should be presented in Annex 4; and  \n\u2014 brief overview of the responsibility sharing between the contract giver and acceptor with respect to compliance with the marketing authorization (where not included under 2.2).  \n\n[^1]: For further information please see: http://www.who.int/bloodproducts/tse.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos cr\u00edticos en la gesti\u00f3n de productos farmac\u00e9uticos terminados, centr\u00e1ndose en la certificaci\u00f3n de lotes y la liberaci\u00f3n de productos, as\u00ed como en la gesti\u00f3n de proveedores y contratistas. Se detallan los requisitos de calificaci\u00f3n para las personas autorizadas responsables de la certificaci\u00f3n de lotes, el proceso de liberaci\u00f3n, y las medidas para garantizar la conformidad con las normativas, incluyendo la gesti\u00f3n de la cadena de suministro y la auditor\u00eda externa.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los requisitos de calificaci\u00f3n espec\u00edficos para las personas autorizadas responsables de la certificaci\u00f3n y liberaci\u00f3n de lotes de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre la educaci\u00f3n y experiencia laboral necesarias para estas personas, que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas se implementan para asegurar que los productos fabricados cumplan con las directrices sobre la encefalopat\u00eda espongiforme transmisible (TSE)?**\n   - La respuesta a esta pregunta proporcionar\u00e1 informaci\u00f3n espec\u00edfica sobre las pr\u00e1cticas de fabricaci\u00f3n y control de calidad que se deben seguir para cumplir con estas directrices.\n\n3. **\u00bfC\u00f3mo se gestionan las responsabilidades entre el contratista y el contratante en relaci\u00f3n con el cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n?**\n   - Esta pregunta se centra en la divisi\u00f3n de responsabilidades en la relaci\u00f3n contractual, un aspecto que puede no estar claramente definido en otros documentos o normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto proporcionado, y que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Archivo Maestro del Sitio (Site Master File)**:\n   - Documento esencial para fabricantes de productos farmac\u00e9uticos que detalla la informaci\u00f3n relevante sobre el sitio de fabricaci\u00f3n.\n\n2. **Informaci\u00f3n General sobre el Fabricante**:\n   - **Datos de Contacto**: Incluye nombre, direcci\u00f3n oficial, direcciones de edificios y unidades de producci\u00f3n, informaci\u00f3n de contacto (n\u00famero telef\u00f3nico de 24 horas) y n\u00famero de identificaci\u00f3n del sitio (GPS, D-U-N-S).\n   - **Actividades de Fabricaci\u00f3n Autorizadas**: Requiere copia de la autorizaci\u00f3n de fabricaci\u00f3n, descripci\u00f3n de actividades autorizadas (fabricaci\u00f3n, importaci\u00f3n, exportaci\u00f3n, distribuci\u00f3n), lista de productos fabricados y registro de inspecciones GMP en los \u00faltimos cinco a\u00f1os.\n   - **Otras Actividades de Fabricaci\u00f3n**: Descripci\u00f3n de actividades no farmac\u00e9uticas realizadas en el sitio.\n\n3. **Gesti\u00f3n de Calidad**:\n   - **Sistema de Gesti\u00f3n de Calidad**: Breve descripci\u00f3n de los sistemas de gesti\u00f3n de calidad implementados por el fabricante y referencia a los est\u00e1ndares utilizados.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **D-U-N-S**: Sistema de numeraci\u00f3n \u00fanico proporcionado por Dun & Bradstreet.\n- **EudraGMP**: Base de datos de autorizaciones de fabricaci\u00f3n en Europa.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que regula la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca los elementos esenciales que deben incluirse en un archivo maestro del sitio, as\u00ed como la importancia de la documentaci\u00f3n y el cumplimiento de las normativas de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: batch certification, release procedure, qualified person, supply chain management, TSE compliance"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4c4408f7-71f8-4442-aca8-c48541ab3e6d", "node_type": "4", "metadata": {"page_label": "424", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Release procedure of finished products\n\n\u2014 detailed description of qualification requirements (education and work experience) of the authorized person(s)/qualified person(s) responsible for batch certification and releasing procedures;  \n\u2014 general description of batch certification and releasing procedure;  \n\u2014 role of authorized person/qualified person in quarantine and release of finished products and in assessment of compliance with the marketing authorization;  \n\u2014 the arrangements between authorized persons/qualified persons when several authorized persons/qualified persons are involved; and  \n\u2014 statement on whether the control strategy employs process analytical technology (PAT) and/or real-time release or parametric release.  \n\n# 2.3 Management of suppliers and contractors\n\n\u2014 a brief summary of the establishment/knowledge of supply chain and the external audit programme;  \n\u2014 a brief description of the qualification system of contractors, manufacturers of APIs and other critical materials suppliers;  \n\u2014 measures taken to ensure that products manufactured are compliant with transmitting animal spongiform encephalopathy (TSE) guidance;[^1]  \n\u2014 measures adopted where substandard/spurious/falsely-labelled/falsified/counterfeit medical products, bulk products (i.e. unpacked tablets), APIs or excipients are suspected or identified;  \n\u2014 use of outside scientific, analytical or other technical assistance in relation to manufacture and analysis;  \n\u2014 list of contract manufacturers and laboratories including the addresses and contact information and flowcharts of supply chains for outsourced manufacturing and QC activities, e.g. sterilization of primary packaging material for aseptic processes, testing of starting raw materials, etc., should be presented in Annex 4; and  \n\u2014 brief overview of the responsibility sharing between the contract giver and acceptor with respect to compliance with the marketing authorization (where not included under 2.2).  \n\n[^1]: For further information please see: http://www.who.int/bloodproducts/tse.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "30bc2cfa1b44be189d95b746f54be86558e87fa3da1c2f3923f1b9de97bde314", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.2 Release procedure of finished products\n\n\u2014 detailed description of qualification requirements (education and work experience) of the authorized person(s)/qualified person(s) responsible for batch certification and releasing procedures;  \n\u2014 general description of batch certification and releasing procedure;  \n\u2014 role of authorized person/qualified person in quarantine and release of finished products and in assessment of compliance with the marketing authorization;  \n\u2014 the arrangements between authorized persons/qualified persons when several authorized persons/qualified persons are involved; and  \n\u2014 statement on whether the control strategy employs process analytical technology (PAT) and/or real-time release or parametric release.  \n\n# 2.3 Management of suppliers and contractors\n\n\u2014 a brief summary of the establishment/knowledge of supply chain and the external audit programme;  \n\u2014 a brief description of the qualification system of contractors, manufacturers of APIs and other critical materials suppliers;  \n\u2014 measures taken to ensure that products manufactured are compliant with transmitting animal spongiform encephalopathy (TSE) guidance;[^1]  \n\u2014 measures adopted where substandard/spurious/falsely-labelled/falsified/counterfeit medical products, bulk products (i.e. unpacked tablets), APIs or excipients are suspected or identified;  \n\u2014 use of outside scientific, analytical or other technical assistance in relation to manufacture and analysis;  \n\u2014 list of contract manufacturers and laboratories including the addresses and contact information and flowcharts of supply chains for outsourced manufacturing and QC activities, e.g. sterilization of primary packaging material for aseptic processes, testing of starting raw materials, etc., should be presented in Annex 4; and  \n\u2014 brief overview of the responsibility sharing between the contract giver and acceptor with respect to compliance with the marketing authorization (where not included under 2.2).  \n\n[^1]: For further information please see: http://www.who.int/bloodproducts/tse.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2062, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e2b847a1-3c8c-4dc6-b816-c787d7048ab6": {"__data__": {"id_": "e2b847a1-3c8c-4dc6-b816-c787d7048ab6", "embedding": null, "metadata": {"page_label": "425", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4 Quality risk management\n\n- brief description of quality risk management (QRM) methodologies used by the manufacturer; and\n- scope and focus of QRM including brief description of any activities which are performed at corporate level, and those which are performed locally. Any application of the QRM system to assess continuity of supply should be mentioned.\n\n# 2.5 Product quality reviews\n\n- brief description of methodologies used.\n\n# 3. Personnel\n\n- organization chart showing the arrangements for quality management, production and quality control positions/titles in Annex 5, including senior management and authorized person(s)/qualified person(s); and\n- number of employees engaged in the quality management, production, quality control, storage and distribution, respectively.\n\n# 4. Premises and equipment\n\n## 4.1 Premises\n\n- short description of plant: size of the site and list of buildings. If the production for different markets, i.e. for local country or regional economic areas, takes place in different buildings on the site, the buildings should be listed with destined markets identified (if not identified under 1.1);\n- simple plan or description of manufacturing areas with indication of scale (architectural or engineering drawings are not required);\n- layouts and flowcharts of the production areas (in Annex 6) showing the room classification and pressure differentials between adjoining areas and indicating the production activities (i.e. compounding, filling, storage, packaging, etc.) in the rooms;\n- layouts of warehouses and storage areas, with special areas for the storage and handling of highly toxic, hazardous and sensitizing materials indicated, if applicable; and\n- brief description of specific storage conditions if applicable, but not indicated on the layouts.\n\n### 4.1.1 Brief description of heating, ventilation and air-conditioning (HVAC) systems\n\n- principles for defining the air supply, temperature, humidity, pressure differentials and air-change rates, policy of air recirculation (%).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son las metodolog\u00edas espec\u00edficas de gesti\u00f3n de riesgos de calidad (QRM) que utiliza el fabricante y c\u00f3mo se aplican a la continuidad del suministro?**\n   - Esta pregunta busca detalles sobre las metodolog\u00edas de QRM que no se mencionan expl\u00edcitamente en otros documentos y c\u00f3mo estas metodolog\u00edas impactan la capacidad del fabricante para mantener un suministro constante de productos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el organigrama de calidad y cu\u00e1ntos empleados est\u00e1n involucrados en cada \u00e1rea de gesti\u00f3n de calidad, producci\u00f3n y control de calidad?**\n   - Esta pregunta se centra en la estructura organizativa y la distribuci\u00f3n del personal, lo que puede no estar disponible en otros informes o documentos.\n\n3. **\u00bfCu\u00e1les son las condiciones espec\u00edficas de almacenamiento requeridas para materiales altamente t\u00f3xicos y c\u00f3mo se gestionan en las instalaciones?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las pr\u00e1cticas de almacenamiento y manejo de materiales peligrosos, que puede no estar ampliamente documentada en otras fuentes.\n\n### Resumen de nivel superior del contexto:\n\nEl documento proporciona directrices sobre la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, incluyendo la gesti\u00f3n de riesgos de calidad, revisiones de calidad del producto, organizaci\u00f3n del personal y descripciones de las instalaciones y equipos. Se enfatiza la importancia de un enfoque sistem\u00e1tico para asegurar la calidad en todas las etapas de producci\u00f3n, as\u00ed como la necesidad de un dise\u00f1o adecuado de las instalaciones para cumplir con los est\u00e1ndares de calidad y seguridad. Adem\u00e1s, se menciona la importancia de los sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en el mantenimiento de condiciones \u00f3ptimas para la producci\u00f3n y almacenamiento de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave\n\n1. **Procedimiento de Liberaci\u00f3n de Productos Terminados (Secci\u00f3n 2.2)**\n   - **Requisitos de Calificaci\u00f3n**: Se especifican las calificaciones necesarias (educaci\u00f3n y experiencia laboral) para las personas autorizadas o calificadas responsables de la certificaci\u00f3n y liberaci\u00f3n de lotes.\n   - **Descripci\u00f3n General del Procedimiento**: Se proporciona una visi\u00f3n general del proceso de certificaci\u00f3n y liberaci\u00f3n de lotes.\n   - **Rol de las Personas Autorizadas**: Se detalla el papel de estas personas en la cuarentena, liberaci\u00f3n de productos terminados y evaluaci\u00f3n de la conformidad con la autorizaci\u00f3n de comercializaci\u00f3n.\n   - **Colaboraci\u00f3n entre Personas Autorizadas**: Se abordan los arreglos entre varias personas autorizadas involucradas en el proceso.\n   - **Estrategia de Control**: Se menciona si se emplea tecnolog\u00eda anal\u00edtica de procesos (PAT) y/o liberaci\u00f3n en tiempo real o liberaci\u00f3n param\u00e9trica.\n\n2. **Gesti\u00f3n de Proveedores y Contratistas (Secci\u00f3n 2.3)**\n   - **Cadena de Suministro y Auditor\u00eda Externa**: Resumen sobre el conocimiento de la cadena de suministro y el programa de auditor\u00eda externa.\n   - **Sistema de Calificaci\u00f3n de Contratistas**: Descripci\u00f3n del sistema de calificaci\u00f3n para contratistas y fabricantes de ingredientes farmac\u00e9uticos activos (APIs).\n   - **Cumplimiento de Directrices TSE**: Medidas para asegurar que los productos fabricados cumplan con las directrices sobre encefalopat\u00eda espongiforme transmisible (TSE).\n   - **Manejo de Productos Subest\u00e1ndar**: Medidas adoptadas ante la sospecha o identificaci\u00f3n de productos m\u00e9dicos subest\u00e1ndar o falsificados.\n   - **Asistencia T\u00e9cnica Externa**: Uso de asistencia cient\u00edfica o t\u00e9cnica externa en la fabricaci\u00f3n y an\u00e1lisis.\n   - **Responsabilidad Compartida**: Resumen de la divisi\u00f3n de responsabilidades entre el contratista y el contratante respecto al cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n#### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **Personas Autorizadas/Calificadas**: Profesionales responsables de la certificaci\u00f3n y liberaci\u00f3n de productos.\n- **Contratistas y Proveedores**: Entidades involucradas en la fabricaci\u00f3n y suministro de productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Materiales cr\u00edticos en la producci\u00f3n de medicamentos.\n- **Directrices sobre TSE**: Normativas relacionadas con la encefalopat\u00eda espongiforme transmisible.\n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en el contexto de la gesti\u00f3n de productos farmac\u00e9uticos y la relaci\u00f3n con proveedores y contratistas.", "excerpt_keywords": "Keywords: Quality Risk Management, Product Quality Reviews, Personnel Organization, Premises and Equipment, HVAC Systems"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4b7b0220-8915-48d1-8928-546b959adca6", "node_type": "4", "metadata": {"page_label": "425", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4 Quality risk management\n\n- brief description of quality risk management (QRM) methodologies used by the manufacturer; and\n- scope and focus of QRM including brief description of any activities which are performed at corporate level, and those which are performed locally. Any application of the QRM system to assess continuity of supply should be mentioned.\n\n# 2.5 Product quality reviews\n\n- brief description of methodologies used.\n\n# 3. Personnel\n\n- organization chart showing the arrangements for quality management, production and quality control positions/titles in Annex 5, including senior management and authorized person(s)/qualified person(s); and\n- number of employees engaged in the quality management, production, quality control, storage and distribution, respectively.\n\n# 4. Premises and equipment\n\n## 4.1 Premises\n\n- short description of plant: size of the site and list of buildings. If the production for different markets, i.e. for local country or regional economic areas, takes place in different buildings on the site, the buildings should be listed with destined markets identified (if not identified under 1.1);\n- simple plan or description of manufacturing areas with indication of scale (architectural or engineering drawings are not required);\n- layouts and flowcharts of the production areas (in Annex 6) showing the room classification and pressure differentials between adjoining areas and indicating the production activities (i.e. compounding, filling, storage, packaging, etc.) in the rooms;\n- layouts of warehouses and storage areas, with special areas for the storage and handling of highly toxic, hazardous and sensitizing materials indicated, if applicable; and\n- brief description of specific storage conditions if applicable, but not indicated on the layouts.\n\n### 4.1.1 Brief description of heating, ventilation and air-conditioning (HVAC) systems\n\n- principles for defining the air supply, temperature, humidity, pressure differentials and air-change rates, policy of air recirculation (%).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "61d00aaa05963cf975a64c607509aa6b7f2f664cdbd7ab672133e114724d1f76", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 2.4 Quality risk management\n\n- brief description of quality risk management (QRM) methodologies used by the manufacturer; and\n- scope and focus of QRM including brief description of any activities which are performed at corporate level, and those which are performed locally. Any application of the QRM system to assess continuity of supply should be mentioned.\n\n# 2.5 Product quality reviews\n\n- brief description of methodologies used.\n\n# 3. Personnel\n\n- organization chart showing the arrangements for quality management, production and quality control positions/titles in Annex 5, including senior management and authorized person(s)/qualified person(s); and\n- number of employees engaged in the quality management, production, quality control, storage and distribution, respectively.\n\n# 4. Premises and equipment\n\n## 4.1 Premises\n\n- short description of plant: size of the site and list of buildings. If the production for different markets, i.e. for local country or regional economic areas, takes place in different buildings on the site, the buildings should be listed with destined markets identified (if not identified under 1.1);\n- simple plan or description of manufacturing areas with indication of scale (architectural or engineering drawings are not required);\n- layouts and flowcharts of the production areas (in Annex 6) showing the room classification and pressure differentials between adjoining areas and indicating the production activities (i.e. compounding, filling, storage, packaging, etc.) in the rooms;\n- layouts of warehouses and storage areas, with special areas for the storage and handling of highly toxic, hazardous and sensitizing materials indicated, if applicable; and\n- brief description of specific storage conditions if applicable, but not indicated on the layouts.\n\n### 4.1.1 Brief description of heating, ventilation and air-conditioning (HVAC) systems\n\n- principles for defining the air supply, temperature, humidity, pressure differentials and air-change rates, policy of air recirculation (%).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2037, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "fed06ec9-82d1-4fda-a83f-785b21621fba": {"__data__": {"id_": "fed06ec9-82d1-4fda-a83f-785b21621fba", "embedding": null, "metadata": {"page_label": "426", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.2 Brief description of water systems\n\n- quality references of water produced; and\n- schematic drawings of the systems in Annex 7.\n\n# 4.1.3 Brief description of other relevant utilities such as steam, compressed air, nitrogen, etc.\n\n# 4.2 Equipment\n\n4.2.1 Listing of major production and control laboratory equipment with critical pieces of equipment identified should be provided in Annex 8.\n\n## 4.2.2 Cleaning and sanitation\n\n- brief description of cleaning and sanitation methods of product contact surfaces (i.e. manual cleaning, automatic clean-in-place, etc.).\n\n## 4.2.3 Good manufacturing practices critical computerized systems\n\n- description of GMP critical computerized systems (excluding equipment-specific programmable logic controllers (PLCs)).\n\n# 5. Documentation\n\n- description of documentation system (i.e. electronic, manual); and\n- when documents and records are stored or archived off-site (including pharmacovigilance data, when applicable): list of types of documents/records; name and address of storage site; and an estimate of time required to retrieve documents from the off-site archive.\n\n# 6. Production\n\n## 1.1 Type of products\n\nReferences to Annex 1 or 2 can be made.\n\n- type of products manufactured including:\n  - list of dosage forms of both human and veterinary products which are manufactured on the site\n  - list of dosage forms of investigational medicinal products (IMP) manufactured for any clinical trials on the site, and when different from the commercial manufacturing, information on production areas and personnel;\n- toxic or hazardous substances handled (e.g. with high pharmacological activity and/or with sensitizing properties);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda aspectos clave de la producci\u00f3n y control de calidad en instalaciones farmac\u00e9uticas. Se enfoca en la descripci\u00f3n de sistemas de agua, equipos de producci\u00f3n, m\u00e9todos de limpieza y saneamiento, sistemas de documentaci\u00f3n, y tipos de productos fabricados, incluyendo tanto productos humanos como veterinarios. Tambi\u00e9n se menciona la gesti\u00f3n de sustancias t\u00f3xicas y peligrosas.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de m\u00e9todos de limpieza y saneamiento se describen para las superficies de contacto con el producto en las instalaciones?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las pr\u00e1cticas de limpieza y saneamiento que se implementan, que son cruciales para garantizar la calidad del producto.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se debe incluir en el listado de equipos de producci\u00f3n y control de laboratorio seg\u00fan el documento?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos para la documentaci\u00f3n de equipos, lo que puede ser vital para auditor\u00edas y cumplimiento normativo.\n\n3. **\u00bfCu\u00e1les son los tipos de productos que se fabrican en el sitio y c\u00f3mo se gestionan las sustancias t\u00f3xicas o peligrosas?**\n   - Esta pregunta busca informaci\u00f3n sobre la gama de productos fabricados y las medidas de seguridad relacionadas con el manejo de sustancias que pueden representar un riesgo, lo que es esencial para la seguridad en el entorno de producci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Gesti\u00f3n de Riesgos de Calidad (QRM)**:\n   - Descripci\u00f3n breve de las metodolog\u00edas de QRM utilizadas por el fabricante.\n   - Alcance y enfoque de QRM, incluyendo actividades a nivel corporativo y local.\n   - Aplicaci\u00f3n del sistema QRM para evaluar la continuidad del suministro.\n\n2. **Revisiones de Calidad del Producto**:\n   - Descripci\u00f3n breve de las metodolog\u00edas empleadas para las revisiones de calidad.\n\n3. **Personal**:\n   - Organigrama que muestra la disposici\u00f3n de los puestos/t\u00edtulos en gesti\u00f3n de calidad, producci\u00f3n y control de calidad.\n   - N\u00famero de empleados en las \u00e1reas de gesti\u00f3n de calidad, producci\u00f3n, control de calidad, almacenamiento y distribuci\u00f3n.\n\n4. **Instalaciones y Equipos**:\n   - Descripci\u00f3n breve de la planta, incluyendo tama\u00f1o y lista de edificios.\n   - Plan o descripci\u00f3n simple de las \u00e1reas de fabricaci\u00f3n y sus actividades (compounding, filling, almacenamiento, empaque, etc.).\n   - Layouts de \u00e1reas de almacenamiento, incluyendo zonas para materiales altamente t\u00f3xicos y peligrosos.\n   - Descripci\u00f3n de condiciones espec\u00edficas de almacenamiento, si es aplicable.\n\n5. **Sistemas de HVAC**:\n   - Principios para definir el suministro de aire, temperatura, humedad, diferenciales de presi\u00f3n y tasas de cambio de aire.\n   - Pol\u00edtica de recirculaci\u00f3n de aire.\n\n### Entidades Clave:\n- **Fabricante**: Entidad responsable de la producci\u00f3n y gesti\u00f3n de calidad.\n- **Personal**: Empleados involucrados en diversas \u00e1reas de gesti\u00f3n de calidad y producci\u00f3n.\n- **Instalaciones**: Plantas y edificios donde se lleva a cabo la producci\u00f3n.\n- **Materiales**: Incluye materiales altamente t\u00f3xicos y peligrosos que requieren manejo especial.\n- **Sistemas de HVAC**: Infraestructura cr\u00edtica para mantener condiciones \u00f3ptimas en la producci\u00f3n y almacenamiento. \n\nEste resumen destaca los aspectos fundamentales de la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, enfatizando la importancia de un enfoque sistem\u00e1tico y la infraestructura adecuada para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: water systems, cleaning and sanitation, production equipment, documentation system, hazardous substances"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a007a30e-a754-4c12-8119-7e843a152aae", "node_type": "4", "metadata": {"page_label": "426", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.2 Brief description of water systems\n\n- quality references of water produced; and\n- schematic drawings of the systems in Annex 7.\n\n# 4.1.3 Brief description of other relevant utilities such as steam, compressed air, nitrogen, etc.\n\n# 4.2 Equipment\n\n4.2.1 Listing of major production and control laboratory equipment with critical pieces of equipment identified should be provided in Annex 8.\n\n## 4.2.2 Cleaning and sanitation\n\n- brief description of cleaning and sanitation methods of product contact surfaces (i.e. manual cleaning, automatic clean-in-place, etc.).\n\n## 4.2.3 Good manufacturing practices critical computerized systems\n\n- description of GMP critical computerized systems (excluding equipment-specific programmable logic controllers (PLCs)).\n\n# 5. Documentation\n\n- description of documentation system (i.e. electronic, manual); and\n- when documents and records are stored or archived off-site (including pharmacovigilance data, when applicable): list of types of documents/records; name and address of storage site; and an estimate of time required to retrieve documents from the off-site archive.\n\n# 6. Production\n\n## 1.1 Type of products\n\nReferences to Annex 1 or 2 can be made.\n\n- type of products manufactured including:\n  - list of dosage forms of both human and veterinary products which are manufactured on the site\n  - list of dosage forms of investigational medicinal products (IMP) manufactured for any clinical trials on the site, and when different from the commercial manufacturing, information on production areas and personnel;\n- toxic or hazardous substances handled (e.g. with high pharmacological activity and/or with sensitizing properties);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "faff13230a0600d5b62cf9017d759cd992129e3fee9d6d869ae5d6d4f4193b8f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 4.1.2 Brief description of water systems\n\n- quality references of water produced; and\n- schematic drawings of the systems in Annex 7.\n\n# 4.1.3 Brief description of other relevant utilities such as steam, compressed air, nitrogen, etc.\n\n# 4.2 Equipment\n\n4.2.1 Listing of major production and control laboratory equipment with critical pieces of equipment identified should be provided in Annex 8.\n\n## 4.2.2 Cleaning and sanitation\n\n- brief description of cleaning and sanitation methods of product contact surfaces (i.e. manual cleaning, automatic clean-in-place, etc.).\n\n## 4.2.3 Good manufacturing practices critical computerized systems\n\n- description of GMP critical computerized systems (excluding equipment-specific programmable logic controllers (PLCs)).\n\n# 5. Documentation\n\n- description of documentation system (i.e. electronic, manual); and\n- when documents and records are stored or archived off-site (including pharmacovigilance data, when applicable): list of types of documents/records; name and address of storage site; and an estimate of time required to retrieve documents from the off-site archive.\n\n# 6. Production\n\n## 1.1 Type of products\n\nReferences to Annex 1 or 2 can be made.\n\n- type of products manufactured including:\n  - list of dosage forms of both human and veterinary products which are manufactured on the site\n  - list of dosage forms of investigational medicinal products (IMP) manufactured for any clinical trials on the site, and when different from the commercial manufacturing, information on production areas and personnel;\n- toxic or hazardous substances handled (e.g. with high pharmacological activity and/or with sensitizing properties);", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1681, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f0b0cc-57cb-406e-95fa-491304cf3b96": {"__data__": {"id_": "e7f0b0cc-57cb-406e-95fa-491304cf3b96", "embedding": null, "metadata": {"page_label": "427", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Process Validation\n\n- Brief description of general policy for process validation; and\n- Policy for reprocessing or reworking.\n\n## Material Management and Warehousing\n\n- Arrangements for the handling of starting materials, packaging materials, bulk and finished products including sampling, quarantine, release and storage; and\n- Arrangements for the handling of rejected materials and products.\n\n# Quality Control\n\n- Description of the QC activities carried out on the site in terms of physical, chemical and microbiological and biological testing.\n\n# Distribution, Complaints, Product Defects and Recalls\n\n## Distribution (to the part under the responsibility of the manufacturer)\n\n- Types (wholesale licence holders, manufacturing licence holders, etc.) and locations (countries or regional economic areas) of the companies to which the products are shipped from the site;\n- Description of the system used to verify that each customer/recipient is legally entitled to receive medicinal products from the manufacturer;\n- Brief description of the system to ensure appropriate environmental conditions during transit, e.g. temperature monitoring/control;\n- Arrangements for product distribution and methods by which product traceability is maintained; and\n- Measures taken to prevent manufacturers\u2019 products entering into the illegal supply chain.\n\n## Complaints, Product Defects and Recalls\n\n- Brief description of the system for handling complaints, product defects and recalls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de la validaci\u00f3n de procesos, la gesti\u00f3n de materiales, el control de calidad y la distribuci\u00f3n de productos farmac\u00e9uticos. Se detalla la pol\u00edtica de validaci\u00f3n de procesos, la gesti\u00f3n de materiales desde su recepci\u00f3n hasta su almacenamiento, las actividades de control de calidad realizadas en el sitio, y los procedimientos para la distribuci\u00f3n de productos, as\u00ed como la gesti\u00f3n de quejas, defectos de productos y retiradas del mercado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la pol\u00edtica general de validaci\u00f3n de procesos mencionada en el documento y c\u00f3mo se aborda el reprocesamiento o reworking?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las pol\u00edticas de validaci\u00f3n de procesos y las directrices para el reprocesamiento, que son fundamentales para garantizar la calidad y la seguridad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se describen para asegurar que las condiciones ambientales durante el transporte de productos farmac\u00e9uticos sean adecuadas?**\n   - Esta pregunta se centra en las pr\u00e1cticas de monitoreo y control de temperatura durante el transporte, lo cual es crucial para mantener la integridad de los productos.\n\n3. **\u00bfC\u00f3mo se gestiona el sistema de quejas y defectos de productos seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre el procedimiento espec\u00edfico para manejar quejas y defectos, lo que es esencial para la mejora continua y la seguridad del paciente. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada que puede no estar disponible en otras fuentes, centr\u00e1ndose en aspectos cr\u00edticos de la gesti\u00f3n de calidad y la seguridad en la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda varios aspectos fundamentales relacionados con la producci\u00f3n y el control de calidad en instalaciones farmac\u00e9uticas. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n\n1. **Sistemas de Agua**:\n   - Referencias de calidad del agua producida.\n   - Diagramas esquem\u00e1ticos de los sistemas (ver Anexo 7).\n\n2. **Utilidades Relevantes**:\n   - Descripci\u00f3n de otras utilidades como vapor, aire comprimido y nitr\u00f3geno.\n\n3. **Equipos**:\n   - Listado de equipos de producci\u00f3n y control de laboratorio, con identificaci\u00f3n de equipos cr\u00edticos (ver Anexo 8).\n\n4. **Limpieza y Saneamiento**:\n   - M\u00e9todos de limpieza y saneamiento para superficies de contacto con el producto (ej. limpieza manual, limpieza autom\u00e1tica en el lugar).\n\n5. **Sistemas Computarizados Cr\u00edticos de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Descripci\u00f3n de sistemas computarizados cr\u00edticos, excluyendo controladores l\u00f3gicos programables espec\u00edficos de equipos.\n\n6. **Documentaci\u00f3n**:\n   - Sistema de documentaci\u00f3n (electr\u00f3nico, manual).\n   - Almacenamiento y archivo de documentos y registros fuera del sitio, incluyendo datos de farmacovigilancia.\n\n7. **Producci\u00f3n**:\n   - Tipos de productos fabricados, incluyendo formas de dosificaci\u00f3n de productos humanos y veterinarios.\n   - Productos investigacionales fabricados para ensayos cl\u00ednicos.\n   - Manejo de sustancias t\u00f3xicas o peligrosas.\n\n#### Entidades:\n\n- **Anexos**: \n  - Anexo 7 (esquemas de sistemas de agua).\n  - Anexo 8 (listado de equipos).\n\n- **Tipos de Productos**:\n  - Productos humanos.\n  - Productos veterinarios.\n  - Productos medicinales investigacionales (IMP).\n\n- **Sustancias**:\n  - Sustancias t\u00f3xicas o peligrosas con alta actividad farmacol\u00f3gica o propiedades sensibilizantes.\n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales que se abordan en la secci\u00f3n, destacando la importancia de la calidad, la seguridad y la documentaci\u00f3n en el contexto de la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: process validation, quality control, material management, product distribution, complaints handling"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "34d0166b-75ba-435b-be75-60c48bf5be46", "node_type": "4", "metadata": {"page_label": "427", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Process Validation\n\n- Brief description of general policy for process validation; and\n- Policy for reprocessing or reworking.\n\n## Material Management and Warehousing\n\n- Arrangements for the handling of starting materials, packaging materials, bulk and finished products including sampling, quarantine, release and storage; and\n- Arrangements for the handling of rejected materials and products.\n\n# Quality Control\n\n- Description of the QC activities carried out on the site in terms of physical, chemical and microbiological and biological testing.\n\n# Distribution, Complaints, Product Defects and Recalls\n\n## Distribution (to the part under the responsibility of the manufacturer)\n\n- Types (wholesale licence holders, manufacturing licence holders, etc.) and locations (countries or regional economic areas) of the companies to which the products are shipped from the site;\n- Description of the system used to verify that each customer/recipient is legally entitled to receive medicinal products from the manufacturer;\n- Brief description of the system to ensure appropriate environmental conditions during transit, e.g. temperature monitoring/control;\n- Arrangements for product distribution and methods by which product traceability is maintained; and\n- Measures taken to prevent manufacturers\u2019 products entering into the illegal supply chain.\n\n## Complaints, Product Defects and Recalls\n\n- Brief description of the system for handling complaints, product defects and recalls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "9e314a3bfab89eefd3daa83772dd4a9294a445dd56d14cf198e6f572c4e667b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Process Validation\n\n- Brief description of general policy for process validation; and\n- Policy for reprocessing or reworking.\n\n## Material Management and Warehousing\n\n- Arrangements for the handling of starting materials, packaging materials, bulk and finished products including sampling, quarantine, release and storage; and\n- Arrangements for the handling of rejected materials and products.\n\n# Quality Control\n\n- Description of the QC activities carried out on the site in terms of physical, chemical and microbiological and biological testing.\n\n# Distribution, Complaints, Product Defects and Recalls\n\n## Distribution (to the part under the responsibility of the manufacturer)\n\n- Types (wholesale licence holders, manufacturing licence holders, etc.) and locations (countries or regional economic areas) of the companies to which the products are shipped from the site;\n- Description of the system used to verify that each customer/recipient is legally entitled to receive medicinal products from the manufacturer;\n- Brief description of the system to ensure appropriate environmental conditions during transit, e.g. temperature monitoring/control;\n- Arrangements for product distribution and methods by which product traceability is maintained; and\n- Measures taken to prevent manufacturers\u2019 products entering into the illegal supply chain.\n\n## Complaints, Product Defects and Recalls\n\n- Brief description of the system for handling complaints, product defects and recalls.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1481, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ec70265e-82f2-4863-bc39-9e7aa7cfb544": {"__data__": {"id_": "ec70265e-82f2-4863-bc39-9e7aa7cfb544", "embedding": null, "metadata": {"page_label": "428", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Self-inspections\n\n\u2014 short description of the self-inspection system with focus on criteria used for selection of the areas to be covered during planned inspections, practical arrangements and follow-up activities.\n\n## Annexes to a submission of a site master file\n\n- **Annex 1**: Copy of valid manufacturing authorization\n- **Annex 2**: List of dosage forms manufactured including the International Nonproprietary Names (INN) or common name (as available) of APIs used\n- **Annex 3**: Copy of valid GMP certificate\n- **Annex 4**: List of contract manufacturers and laboratories including the addresses and contact information, and flowcharts of the supply chains for these outsourced activities\n- **Annex 5**: Organizational charts\n- **Annex 6**: Layouts of production areas including material and personnel flows, general flowcharts of manufacturing processes of each product type (dosage form)\n- **Annex 7**: Schematic drawings of water systems\n- **Annex 8**: List of major production and laboratory equipment", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 961\" aborda el sistema de autoinspecci\u00f3n en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en los criterios utilizados para seleccionar las \u00e1reas a inspeccionar, as\u00ed como en los arreglos pr\u00e1cticos y las actividades de seguimiento. Adem\u00e1s, se enumeran los anexos que deben acompa\u00f1ar la presentaci\u00f3n de un archivo maestro del sitio, que incluyen autorizaciones de fabricaci\u00f3n, certificados de Buenas Pr\u00e1cticas de Manufactura (GMP), listas de formas de dosificaci\u00f3n, y esquemas de equipos y sistemas de agua.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos utilizados para seleccionar las \u00e1reas a ser cubiertas durante las autoinspecciones en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre los criterios de selecci\u00f3n que no se mencionan expl\u00edcitamente en el resumen.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n se requiere en el \"Anexo 4\" sobre los fabricantes y laboratorios contratados, y por qu\u00e9 es importante incluir esta informaci\u00f3n en la presentaci\u00f3n del archivo maestro del sitio?**\n   - Esta pregunta se centra en la importancia de la informaci\u00f3n sobre contratistas y su relevancia para la calidad y la seguridad en la fabricaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de flujos de materiales y personal se deben incluir en el \"Anexo 6\" y c\u00f3mo pueden afectar estos flujos a la eficiencia de la producci\u00f3n?**\n   - Esta pregunta busca profundizar en los detalles sobre la disposici\u00f3n de las \u00e1reas de producci\u00f3n y su impacto en la operaci\u00f3n general, lo cual no se detalla en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Procesos**:\n   - Pol\u00edticas generales para la validaci\u00f3n de procesos.\n   - Directrices para el reprocesamiento o reworking de productos.\n\n2. **Gesti\u00f3n de Materiales y Almacenamiento**:\n   - Procedimientos para el manejo de materiales iniciales, materiales de embalaje, productos a granel y productos terminados, incluyendo muestreo, cuarentena, liberaci\u00f3n y almacenamiento.\n   - Manejo de materiales y productos rechazados.\n\n3. **Control de Calidad (QC)**:\n   - Actividades de control de calidad realizadas en el sitio, abarcando pruebas f\u00edsicas, qu\u00edmicas, microbiol\u00f3gicas y biol\u00f3gicas.\n\n4. **Distribuci\u00f3n, Quejas, Defectos de Productos y Retiradas**:\n   - **Distribuci\u00f3n**:\n     - Tipos y ubicaciones de las empresas que reciben productos.\n     - Sistema para verificar la legalidad de los clientes/recipientes para recibir productos medicinales.\n     - Monitoreo y control de condiciones ambientales durante el transporte.\n     - M\u00e9todos para mantener la trazabilidad de los productos.\n     - Medidas para prevenir la entrada de productos en la cadena de suministro ilegal.\n   \n   - **Quejas, Defectos de Productos y Retiradas**:\n     - Sistema para manejar quejas, defectos de productos y retiradas del mercado.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos Farmac\u00e9uticos**: Enfocados en la calidad y seguridad.\n- **Materiales**: Incluyendo materiales iniciales, de embalaje y productos terminados.\n- **Clientes/Recipientes**: Empresas que reciben productos farmac\u00e9uticos.\n- **Sistema de Quejas**: Procedimientos para la gesti\u00f3n de quejas y defectos.\n\nEste resumen destaca los aspectos fundamentales de la gesti\u00f3n de calidad y la seguridad en la industria farmac\u00e9utica, seg\u00fan lo establecido en el documento de la OMS.", "excerpt_keywords": "Keywords: self-inspection, GMP certificate, manufacturing authorization, contract manufacturers, production layouts"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33f7c5b4-4150-435f-867f-37b1608f061a", "node_type": "4", "metadata": {"page_label": "428", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Self-inspections\n\n\u2014 short description of the self-inspection system with focus on criteria used for selection of the areas to be covered during planned inspections, practical arrangements and follow-up activities.\n\n## Annexes to a submission of a site master file\n\n- **Annex 1**: Copy of valid manufacturing authorization\n- **Annex 2**: List of dosage forms manufactured including the International Nonproprietary Names (INN) or common name (as available) of APIs used\n- **Annex 3**: Copy of valid GMP certificate\n- **Annex 4**: List of contract manufacturers and laboratories including the addresses and contact information, and flowcharts of the supply chains for these outsourced activities\n- **Annex 5**: Organizational charts\n- **Annex 6**: Layouts of production areas including material and personnel flows, general flowcharts of manufacturing processes of each product type (dosage form)\n- **Annex 7**: Schematic drawings of water systems\n- **Annex 8**: List of major production and laboratory equipment", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ccf48cbeb06e8a7089fc7d0032a0f02694d5392ac01f9353c10797946036c183", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9. Self-inspections\n\n\u2014 short description of the self-inspection system with focus on criteria used for selection of the areas to be covered during planned inspections, practical arrangements and follow-up activities.\n\n## Annexes to a submission of a site master file\n\n- **Annex 1**: Copy of valid manufacturing authorization\n- **Annex 2**: List of dosage forms manufactured including the International Nonproprietary Names (INN) or common name (as available) of APIs used\n- **Annex 3**: Copy of valid GMP certificate\n- **Annex 4**: List of contract manufacturers and laboratories including the addresses and contact information, and flowcharts of the supply chains for these outsourced activities\n- **Annex 5**: Organizational charts\n- **Annex 6**: Layouts of production areas including material and personnel flows, general flowcharts of manufacturing processes of each product type (dosage form)\n- **Annex 7**: Schematic drawings of water systems\n- **Annex 8**: List of major production and laboratory equipment", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1015, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "6e619cf2-52e5-438d-a504-94a7b23a85f4": {"__data__": {"id_": "6e619cf2-52e5-438d-a504-94a7b23a85f4", "embedding": null, "metadata": {"page_label": "429", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 15\n\n## Guidelines on submission of documentation for a multisource (generic) finished product. General format: preparation of product dossiers in common technical document format\n\n1. **Introduction**\n   1.1 Background  \n   1.2 Objectives  \n   1.3 Scope  \n   1.4 General principles  \n\n2. **Glossary**\n\n3. **Organization of a product dossier for a multisource pharmaceutical product in common technical document format**\n\n4. **Modules (including Module 1) of a product dossier for a multisource pharmaceutical product**\n\n5. **Module 3 \u2014 quality**\n\n6. **Module 5 of a product dossier for a multisource pharmaceutical product**\n\n7. **Guidance on format and presentation of a product dossier in common technical document format**\n   7.1 Guidance on format  \n   7.2 Guidance on presentation  \n\n8. **Variations**\n\n**References**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de las directrices en el Anexo 15 del informe de la OMS?**\n   - **Respuesta:** El objetivo principal de las directrices en el Anexo 15 es proporcionar un marco para la presentaci\u00f3n de la documentaci\u00f3n necesaria para productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan, asegurando que se sigan principios generales y se cumplan los requisitos de calidad.\n\n2. **\u00bfQu\u00e9 m\u00f3dulos se incluyen en el dossier de producto para un producto farmac\u00e9utico multisource seg\u00fan el Anexo 15?**\n   - **Respuesta:** El dossier de producto para un producto farmac\u00e9utico multisource incluye varios m\u00f3dulos, entre ellos el M\u00f3dulo 1, que abarca aspectos administrativos y de informaci\u00f3n general, el M\u00f3dulo 3, que se centra en la calidad del producto, y el M\u00f3dulo 5, que trata sobre la eficacia y seguridad del producto.\n\n3. **\u00bfQu\u00e9 tipo de orientaci\u00f3n se proporciona en la secci\u00f3n 7 del Anexo 15?**\n   - **Respuesta:** En la secci\u00f3n 7 del Anexo 15 se proporciona orientaci\u00f3n sobre el formato y la presentaci\u00f3n de un dossier de producto en el formato de documento t\u00e9cnico com\u00fan. Esto incluye directrices espec\u00edficas sobre c\u00f3mo estructurar la informaci\u00f3n y presentarla de manera clara y coherente.\n\n### Resumen de nivel superior del contexto:\nEl Anexo 15 del informe de la OMS establece directrices para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan. Incluye secciones sobre la organizaci\u00f3n del dossier, m\u00f3dulos espec\u00edficos que abordan calidad y eficacia, y proporciona orientaci\u00f3n sobre el formato y la presentaci\u00f3n de la documentaci\u00f3n. Tambi\u00e9n se menciona la importancia de las variaciones en el contexto de la presentaci\u00f3n de estos dossiers.", "prev_section_summary": "### Resumen de la Secci\u00f3n 9: Autoinspecciones\n\nLa secci\u00f3n aborda el sistema de autoinspecci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos, destacando los criterios para seleccionar las \u00e1reas a inspeccionar, as\u00ed como los arreglos pr\u00e1cticos y las actividades de seguimiento que deben llevarse a cabo. \n\n#### Anexos a la Presentaci\u00f3n del Archivo Maestro del Sitio\n\nSe enumeran los siguientes anexos que deben acompa\u00f1ar la presentaci\u00f3n del archivo maestro del sitio:\n\n1. **Anexo 1**: Copia de la autorizaci\u00f3n de fabricaci\u00f3n v\u00e1lida.\n2. **Anexo 2**: Lista de formas de dosificaci\u00f3n fabricadas, incluyendo los Nombres Comunes Internacionales (INN) o nombres comunes de los ingredientes activos (APIs) utilizados.\n3. **Anexo 3**: Copia del certificado de Buenas Pr\u00e1cticas de Manufactura (GMP) v\u00e1lido.\n4. **Anexo 4**: Lista de fabricantes y laboratorios contratados, incluyendo direcciones, informaci\u00f3n de contacto y diagramas de flujo de las cadenas de suministro para estas actividades externalizadas.\n5. **Anexo 5**: Organigramas de la empresa.\n6. **Anexo 6**: Disposici\u00f3n de las \u00e1reas de producci\u00f3n, incluyendo flujos de materiales y personal, as\u00ed como diagramas de flujo generales de los procesos de fabricaci\u00f3n de cada tipo de producto.\n7. **Anexo 7**: Dibujos esquem\u00e1ticos de los sistemas de agua.\n8. **Anexo 8**: Lista de equipos de producci\u00f3n y laboratorio principales.\n\n### Temas Clave\n\n- **Sistema de Autoinspecci\u00f3n**: Importancia de la autoevaluaci\u00f3n en la calidad de la fabricaci\u00f3n.\n- **Criterios de Selecci\u00f3n**: Necesidad de criterios espec\u00edficos para determinar las \u00e1reas a inspeccionar.\n- **Documentaci\u00f3n Requerida**: Importancia de la documentaci\u00f3n y los anexos para garantizar la conformidad y la calidad en la fabricaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Fabricantes y Laboratorios Contratados**: Entidades externas involucradas en la producci\u00f3n.\n- **Ingredientes Activos (APIs)**: Componentes esenciales en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativa que asegura la calidad en la producci\u00f3n.", "excerpt_keywords": "Keywords: guidelines, multisource, pharmaceutical, documentation, quality"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4760e4e7-5963-444f-9cb8-d6a5e2c7849e", "node_type": "4", "metadata": {"page_label": "429", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 15\n\n## Guidelines on submission of documentation for a multisource (generic) finished product. General format: preparation of product dossiers in common technical document format\n\n1. **Introduction**\n   1.1 Background  \n   1.2 Objectives  \n   1.3 Scope  \n   1.4 General principles  \n\n2. **Glossary**\n\n3. **Organization of a product dossier for a multisource pharmaceutical product in common technical document format**\n\n4. **Modules (including Module 1) of a product dossier for a multisource pharmaceutical product**\n\n5. **Module 3 \u2014 quality**\n\n6. **Module 5 of a product dossier for a multisource pharmaceutical product**\n\n7. **Guidance on format and presentation of a product dossier in common technical document format**\n   7.1 Guidance on format  \n   7.2 Guidance on presentation  \n\n8. **Variations**\n\n**References**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "182a684cd1fdd95ae5acac8fc401879ec93f62efbf0ebccf36e0589ad6c64bbc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Annex 15\n\n## Guidelines on submission of documentation for a multisource (generic) finished product. General format: preparation of product dossiers in common technical document format\n\n1. **Introduction**\n   1.1 Background  \n   1.2 Objectives  \n   1.3 Scope  \n   1.4 General principles  \n\n2. **Glossary**\n\n3. **Organization of a product dossier for a multisource pharmaceutical product in common technical document format**\n\n4. **Modules (including Module 1) of a product dossier for a multisource pharmaceutical product**\n\n5. **Module 3 \u2014 quality**\n\n6. **Module 5 of a product dossier for a multisource pharmaceutical product**\n\n7. **Guidance on format and presentation of a product dossier in common technical document format**\n   7.1 Guidance on format  \n   7.2 Guidance on presentation  \n\n8. **Variations**\n\n**References**", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 829, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "01234734-a600-4434-a226-79650cdb5e92": {"__data__": {"id_": "01234734-a600-4434-a226-79650cdb5e92", "embedding": null, "metadata": {"page_label": "430", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n## 1.1 Background\n\nIn its forty-fifth report, the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations published the *Procedure for prequalification of pharmaceutical products (1)* which outlines the procedure and considerations for the process undertaken by WHO in providing United Nations agencies with advice on the acceptability in principle of pharmaceutical products for procurement by such agencies. The above-mentioned report states:\n\n> \"This activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality\".\n\nAs mentioned in this report, when submitting an Expression of Interest (EOI) for product evaluation, the applicant should send to the WHO focal point (together with the other data requirements) a product dossier (PD), in the format specified in the WHO guidance documents on submitting product data and information.\n\nThrough the International Conference on Harmonisation (ICH) process, considerable harmonization has been achieved in the organization of the registration documents with the issuance of the common technical document (CTD) guideline (2-5). This recommended format in the CTD guideline for registration applications has become widely accepted by regulatory authorities both within and beyond the ICH Regions.\n\nThis document provides recommendations on the format and presentation for these types of PDs.\n\n## 1.2 Objectives\n\nThese guidelines are intended to:\n\n- Assist applicants in the preparation of PDs for multisource products by providing clear general guidance on the format of these dossiers;\n- Fully adopt the modular format of the CTD as developed by ICH; and\n- Provide guidance on the location of regional information (Module 1) and other general data requirements.\n\nThese measures are intended to promote effective and efficient processes for the development of these PDs and the subsequent assessment procedures.\n\n## 1.3 Scope\n\nThese guidelines apply to PDs for multisource pharmaceutical products containing existing active pharmaceutical ingredients (APIs) of synthetic origin.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el procedimiento para la precalificaci\u00f3n de productos farmac\u00e9uticos. Se centra en la preparaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource que contienen ingredientes activos existentes de origen sint\u00e9tico. El informe tambi\u00e9n menciona la importancia de seguir el formato del Documento T\u00e9cnico Com\u00fan (CTD) para facilitar la evaluaci\u00f3n y aprobaci\u00f3n de estos productos por parte de las agencias de la ONU.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal de la actividad de la OMS en relaci\u00f3n con la precalificaci\u00f3n de productos farmac\u00e9uticos?**\n   - La actividad de la OMS tiene como objetivo facilitar el acceso a medicamentos esenciales prioritarios que cumplan con las normas y est\u00e1ndares de calidad recomendados por la OMS.\n\n2. **\u00bfQu\u00e9 formato se recomienda para la presentaci\u00f3n de los Dossiers de Producto (PD) seg\u00fan el informe?**\n   - Se recomienda adoptar completamente el formato modular del Documento T\u00e9cnico Com\u00fan (CTD) desarrollado por la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) para la preparaci\u00f3n de los Dossiers de Producto.\n\n3. **\u00bfA qu\u00e9 tipo de productos farmac\u00e9uticos se aplican estas directrices?**\n   - Estas directrices se aplican a los Dossiers de Producto para productos farmac\u00e9uticos multisource que contienen ingredientes activos farmac\u00e9uticos (APIs) existentes de origen sint\u00e9tico.", "prev_section_summary": "El Anexo 15 del informe de la OMS se centra en las directrices para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan. Los temas clave incluyen:\n\n1. **Introducci\u00f3n**: Proporciona el contexto, objetivos, alcance y principios generales de las directrices.\n2. **Glosario**: Define t\u00e9rminos relevantes utilizados en el documento.\n3. **Organizaci\u00f3n del dossier de producto**: Describe c\u00f3mo debe estructurarse un dossier para un producto farmac\u00e9utico multisource.\n4. **M\u00f3dulos del dossier**: Incluye detalles sobre los m\u00f3dulos espec\u00edficos, como el M\u00f3dulo 1 (informaci\u00f3n administrativa), el M\u00f3dulo 3 (calidad) y el M\u00f3dulo 5 (eficacia y seguridad).\n5. **Orientaci\u00f3n sobre formato y presentaci\u00f3n**: Ofrece directrices sobre c\u00f3mo presentar la informaci\u00f3n de manera clara y coherente.\n6. **Variaciones**: Aborda la importancia de las variaciones en la presentaci\u00f3n de los dossiers.\n\nLas entidades clave incluyen \"productos farmac\u00e9uticos multisource\", \"dossier de producto\", \"M\u00f3dulo 1\", \"M\u00f3dulo 3\", \"M\u00f3dulo 5\", y \"documento t\u00e9cnico com\u00fan\". Estas directrices son fundamentales para asegurar la calidad y la conformidad en la presentaci\u00f3n de productos gen\u00e9ricos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, product dossier, CTD"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1a7e0389-5ef6-4163-b777-93f2a862a24a", "node_type": "4", "metadata": {"page_label": "430", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n## 1.1 Background\n\nIn its forty-fifth report, the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations published the *Procedure for prequalification of pharmaceutical products (1)* which outlines the procedure and considerations for the process undertaken by WHO in providing United Nations agencies with advice on the acceptability in principle of pharmaceutical products for procurement by such agencies. The above-mentioned report states:\n\n> \"This activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality\".\n\nAs mentioned in this report, when submitting an Expression of Interest (EOI) for product evaluation, the applicant should send to the WHO focal point (together with the other data requirements) a product dossier (PD), in the format specified in the WHO guidance documents on submitting product data and information.\n\nThrough the International Conference on Harmonisation (ICH) process, considerable harmonization has been achieved in the organization of the registration documents with the issuance of the common technical document (CTD) guideline (2-5). This recommended format in the CTD guideline for registration applications has become widely accepted by regulatory authorities both within and beyond the ICH Regions.\n\nThis document provides recommendations on the format and presentation for these types of PDs.\n\n## 1.2 Objectives\n\nThese guidelines are intended to:\n\n- Assist applicants in the preparation of PDs for multisource products by providing clear general guidance on the format of these dossiers;\n- Fully adopt the modular format of the CTD as developed by ICH; and\n- Provide guidance on the location of regional information (Module 1) and other general data requirements.\n\nThese measures are intended to promote effective and efficient processes for the development of these PDs and the subsequent assessment procedures.\n\n## 1.3 Scope\n\nThese guidelines apply to PDs for multisource pharmaceutical products containing existing active pharmaceutical ingredients (APIs) of synthetic origin.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "ff9351593afa0b686c492b2bfe63c593dfea3b55101900661cefd94e3fbad1fc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1. Introduction\n\n## 1.1 Background\n\nIn its forty-fifth report, the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations published the *Procedure for prequalification of pharmaceutical products (1)* which outlines the procedure and considerations for the process undertaken by WHO in providing United Nations agencies with advice on the acceptability in principle of pharmaceutical products for procurement by such agencies. The above-mentioned report states:\n\n> \"This activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality\".\n\nAs mentioned in this report, when submitting an Expression of Interest (EOI) for product evaluation, the applicant should send to the WHO focal point (together with the other data requirements) a product dossier (PD), in the format specified in the WHO guidance documents on submitting product data and information.\n\nThrough the International Conference on Harmonisation (ICH) process, considerable harmonization has been achieved in the organization of the registration documents with the issuance of the common technical document (CTD) guideline (2-5). This recommended format in the CTD guideline for registration applications has become widely accepted by regulatory authorities both within and beyond the ICH Regions.\n\nThis document provides recommendations on the format and presentation for these types of PDs.\n\n## 1.2 Objectives\n\nThese guidelines are intended to:\n\n- Assist applicants in the preparation of PDs for multisource products by providing clear general guidance on the format of these dossiers;\n- Fully adopt the modular format of the CTD as developed by ICH; and\n- Provide guidance on the location of regional information (Module 1) and other general data requirements.\n\nThese measures are intended to promote effective and efficient processes for the development of these PDs and the subsequent assessment procedures.\n\n## 1.3 Scope\n\nThese guidelines apply to PDs for multisource pharmaceutical products containing existing active pharmaceutical ingredients (APIs) of synthetic origin.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2165, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "ed5782ff-d0d5-4a36-a3e0-a7f0ab049f98": {"__data__": {"id_": "ed5782ff-d0d5-4a36-a3e0-a7f0ab049f98", "embedding": null, "metadata": {"page_label": "431", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "or semi-synthetic origin and their corresponding finished pharmaceutical products (FPPs). For the purposes of these guidelines, an existing API is one that has been previously authorized through a finished product by a stringent regulatory authority (SRA).<sup>1</sup> APIs from fermentation, biological, biotechnological or herbal origin are covered by other guidelines.\n\nThese guidelines primarily address the organization of the information to be presented in PDs for multisource products. They are not intended to indicate what studies are required. They merely indicate an appropriate format for the data that have been acquired. Applicants should not modify the overall organization of the CTD as outlined in the guidelines.\n\n### 1.4 General principles\n\nThese guidelines present the agreed-upon common format for the preparation of a well-structured CTD for PDs that will be submitted to WHO. A common format for the technical documentation will significantly reduce the time and resources needed to compile PDs for the prequalification of multisource pharmaceutical products and will ease the preparation of electronic submissions. Assessments and communication with the applicant will be facilitated by a standard document containing common elements. In addition, exchange of regulatory information between national medicine regulatory authorities (NMRAs) and with WHO will be simplified.\n\nUltimately, this is intended to support the objectives of the WHO-managed Prequalification of Medicines Programme in listing pharmaceutical products of acceptable safety, efficacy and quality in the interest of public health.\n\nThese general filing guidelines should be read in conjunction with other applicable WHO and ICH reference documents and guidelines that provide further guidance and recommendations on the topic-specific content requirements for multisource products, notably:\n\n- *Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability* (6);\n- *Bioequivalence trial information form (BTIF)* (7);\n- *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8);\n- *Quality overall summary \u2014 product dossier (QOS\u2013PD)* (9).\n\n----\n\n<sup>1</sup> Stringent regulatory authority (SRA): a regulatory authority which is:\n- a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n- an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic, Health Canada and World Health Organization (WHO), and may be updated from time to time); or\n- a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices para la preparaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource (gen\u00e9ricos). Se enfoca en la organizaci\u00f3n de la informaci\u00f3n y el formato del Dossier T\u00e9cnico Com\u00fan (CTD) que debe ser presentado a la OMS. Estas directrices buscan facilitar la precalificaci\u00f3n de productos farmac\u00e9uticos, asegurando que cumplan con est\u00e1ndares de seguridad, eficacia y calidad. Adem\u00e1s, se menciona la importancia de seguir otras gu\u00edas y documentos de referencia de la OMS y la Conferencia Internacional sobre Armonizaci\u00f3n (ICH).\n\n### Preguntas espec\u00edficas\n1. **\u00bfQu\u00e9 se entiende por un \"API existente\" seg\u00fan las directrices de la OMS y c\u00f3mo se relaciona con las autoridades regulatorias estrictas (SRA)?**\n   - Respuesta: Un \"API existente\" es aquel que ha sido previamente autorizado a trav\u00e9s de un producto terminado por una autoridad regulatoria estricta (SRA). Esto implica que el API ha pasado por un proceso de evaluaci\u00f3n riguroso que garantiza su calidad y seguridad.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito principal de las directrices sobre la presentaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource?**\n   - Respuesta: El prop\u00f3sito principal es establecer un formato com\u00fan para la preparaci\u00f3n de Dossiers de Producto que facilite la compilaci\u00f3n y presentaci\u00f3n de informaci\u00f3n t\u00e9cnica, reduciendo el tiempo y los recursos necesarios para la precalificaci\u00f3n de productos farmac\u00e9uticos y mejorando la comunicaci\u00f3n entre las autoridades regulatorias y la OMS.\n\n3. **\u00bfQu\u00e9 documentos y gu\u00edas adicionales deben considerarse junto con estas directrices al preparar un Dossier de Producto para productos farmac\u00e9uticos multisource?**\n   - Respuesta: Adem\u00e1s de estas directrices, se deben considerar otros documentos de la OMS y de la ICH, como las gu\u00edas sobre productos farmac\u00e9uticos multisource, formularios de informaci\u00f3n de ensayos de bioequivalencia, y la parte de calidad del Dossier de Producto para productos farmac\u00e9uticos gen\u00e9ricos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS es la entidad responsable de la publicaci\u00f3n del informe y de la precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Precalificaci\u00f3n de Productos Farmac\u00e9uticos**: El informe detalla el procedimiento que la OMS sigue para evaluar la aceptabilidad de productos farmac\u00e9uticos para su adquisici\u00f3n por agencias de la ONU, con el objetivo de facilitar el acceso a medicamentos esenciales de calidad.\n\n3. **Dossier de Producto (PD)**: Se menciona la importancia de enviar un Dossier de Producto al solicitar una Evaluaci\u00f3n de Inter\u00e9s (EOI), siguiendo las directrices de la OMS.\n\n4. **Documento T\u00e9cnico Com\u00fan (CTD)**: Se recomienda adoptar el formato modular del CTD, que ha sido ampliamente aceptado por las autoridades regulatorias, para la presentaci\u00f3n de los Dossiers de Producto.\n\n5. **Objetivos de las Directrices**: Las directrices tienen como objetivo ayudar a los solicitantes en la preparaci\u00f3n de Dossiers de Producto para productos multisource, promoviendo procesos eficientes para su desarrollo y evaluaci\u00f3n.\n\n6. **Alcance**: Las directrices se aplican a productos farmac\u00e9uticos multisource que contienen ingredientes activos existentes de origen sint\u00e9tico.\n\n### Entidades Clave\n- **World Health Organization (WHO)**: Organizaci\u00f3n responsable del informe.\n- **International Conference on Harmonisation (ICH)**: Entidad que desarroll\u00f3 el formato CTD.\n- **Agencias de la ONU**: Entidades que adquieren productos farmac\u00e9uticos precalificados.\n\nEste resumen destaca los aspectos fundamentales del informe, incluyendo su prop\u00f3sito, el formato recomendado para la presentaci\u00f3n de documentos y el tipo de productos a los que se aplican las directrices.", "excerpt_keywords": "Keywords: WHO, pharmaceutical products, guidelines, prequalification, CTD"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3a151fca-debd-4c53-a595-bc5635401999", "node_type": "4", "metadata": {"page_label": "431", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "or semi-synthetic origin and their corresponding finished pharmaceutical products (FPPs). For the purposes of these guidelines, an existing API is one that has been previously authorized through a finished product by a stringent regulatory authority (SRA).<sup>1</sup> APIs from fermentation, biological, biotechnological or herbal origin are covered by other guidelines.\n\nThese guidelines primarily address the organization of the information to be presented in PDs for multisource products. They are not intended to indicate what studies are required. They merely indicate an appropriate format for the data that have been acquired. Applicants should not modify the overall organization of the CTD as outlined in the guidelines.\n\n### 1.4 General principles\n\nThese guidelines present the agreed-upon common format for the preparation of a well-structured CTD for PDs that will be submitted to WHO. A common format for the technical documentation will significantly reduce the time and resources needed to compile PDs for the prequalification of multisource pharmaceutical products and will ease the preparation of electronic submissions. Assessments and communication with the applicant will be facilitated by a standard document containing common elements. In addition, exchange of regulatory information between national medicine regulatory authorities (NMRAs) and with WHO will be simplified.\n\nUltimately, this is intended to support the objectives of the WHO-managed Prequalification of Medicines Programme in listing pharmaceutical products of acceptable safety, efficacy and quality in the interest of public health.\n\nThese general filing guidelines should be read in conjunction with other applicable WHO and ICH reference documents and guidelines that provide further guidance and recommendations on the topic-specific content requirements for multisource products, notably:\n\n- *Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability* (6);\n- *Bioequivalence trial information form (BTIF)* (7);\n- *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8);\n- *Quality overall summary \u2014 product dossier (QOS\u2013PD)* (9).\n\n----\n\n<sup>1</sup> Stringent regulatory authority (SRA): a regulatory authority which is:\n- a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n- an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic, Health Canada and World Health Organization (WHO), and may be updated from time to time); or\n- a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "8e97f4a17fd0ec03b0fa6abcf476ac9ee52436bdde5515401b6071b7570641cd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "or semi-synthetic origin and their corresponding finished pharmaceutical products (FPPs). For the purposes of these guidelines, an existing API is one that has been previously authorized through a finished product by a stringent regulatory authority (SRA).<sup>1</sup> APIs from fermentation, biological, biotechnological or herbal origin are covered by other guidelines.\n\nThese guidelines primarily address the organization of the information to be presented in PDs for multisource products. They are not intended to indicate what studies are required. They merely indicate an appropriate format for the data that have been acquired. Applicants should not modify the overall organization of the CTD as outlined in the guidelines.\n\n### 1.4 General principles\n\nThese guidelines present the agreed-upon common format for the preparation of a well-structured CTD for PDs that will be submitted to WHO. A common format for the technical documentation will significantly reduce the time and resources needed to compile PDs for the prequalification of multisource pharmaceutical products and will ease the preparation of electronic submissions. Assessments and communication with the applicant will be facilitated by a standard document containing common elements. In addition, exchange of regulatory information between national medicine regulatory authorities (NMRAs) and with WHO will be simplified.\n\nUltimately, this is intended to support the objectives of the WHO-managed Prequalification of Medicines Programme in listing pharmaceutical products of acceptable safety, efficacy and quality in the interest of public health.\n\nThese general filing guidelines should be read in conjunction with other applicable WHO and ICH reference documents and guidelines that provide further guidance and recommendations on the topic-specific content requirements for multisource products, notably:\n\n- *Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability* (6);\n- *Bioequivalence trial information form (BTIF)* (7);\n- *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8);\n- *Quality overall summary \u2014 product dossier (QOS\u2013PD)* (9).\n\n----\n\n<sup>1</sup> Stringent regulatory authority (SRA): a regulatory authority which is:\n- a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n- an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic, Health Canada and World Health Organization (WHO), and may be updated from time to time); or\n- a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (may be updated from time to time).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2841, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "46a1d47c-105b-4cd4-a8e5-46ecf5b8bf9a": {"__data__": {"id_": "46a1d47c-105b-4cd4-a8e5-46ecf5b8bf9a", "embedding": null, "metadata": {"page_label": "432", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Together, these guidelines, templates and reference documents mentioned within them are intended to assist applicants and WHO by harmonizing with international approaches and facilitating the preparation and subsequent assessment procedures for PDs through the integration of the internationally accepted CTD format and, where possible, terminology.\n\nOnce implemented these guidelines will supersede the following guidelines and template which were in use previously:\n\n- *Guideline on submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*;\n  - Supplement 1 \u2014 Dissolution testing;\n  - Supplement 2 \u2014 Extension of the WHO List of Stable (not easily degradable ARV) APIs;\n- *Pharmaceutical Quality Information Form (PQIF)*.\n\n## 2. Glossary\n\n**active pharmaceutical ingredient (API)**  \nAny substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings (1).\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s) (1).\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling (1).\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products (1).\n\n**multisource (generic) pharmaceutical products**  \nPharmaceutically equivalent or pharmaceutically alternative products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta nuevas directrices, plantillas y documentos de referencia destinados a ayudar a los solicitantes y a la OMS en la armonizaci\u00f3n de enfoques internacionales para la preparaci\u00f3n y evaluaci\u00f3n de documentos de productos farmac\u00e9uticos. Estas nuevas directrices reemplazar\u00e1n las anteriores relacionadas con la precalificaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos utilizados en el tratamiento de enfermedades como el VIH/SIDA, la malaria y la tuberculosis. Adem\u00e1s, se incluye un glosario que define t\u00e9rminos clave como \"ingrediente farmac\u00e9utico activo\" (API), \"producto farmac\u00e9utico terminado\" (FPP) y \"productos farmac\u00e9uticos multisource\".\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 documentos y directrices anteriores ser\u00e1n reemplazados por las nuevas directrices de la OMS?**\n   - Las nuevas directrices reemplazar\u00e1n la \"Gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos)\" utilizados en el tratamiento de VIH/SIDA, malaria y tuberculosis, as\u00ed como el \"Formulario de Informaci\u00f3n de Calidad Farmac\u00e9utica (PQIF)\" y sus suplementos relacionados.\n\n2. **\u00bfCu\u00e1l es la definici\u00f3n de un \"producto farmac\u00e9utico terminado\" (FPP) seg\u00fan el documento?**\n   - Un \"producto farmac\u00e9utico terminado\" (FPP) se define como una forma de dosificaci\u00f3n final de un producto farmac\u00e9utico que ha pasado por todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado en su contenedor final y el etiquetado.\n\n3. **\u00bfQu\u00e9 se entiende por \"productos farmac\u00e9uticos multisource\" y c\u00f3mo se relacionan con la equivalencia terap\u00e9utica?**\n   - Los \"productos farmac\u00e9uticos multisource\" son productos que son farmac\u00e9uticamente equivalentes o alternativamente farmac\u00e9uticos, que pueden o no ser terap\u00e9uticamente equivalentes. Aquellos que son terap\u00e9uticamente equivalentes son intercambiables.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **API existente:** Se define como un ingrediente farmac\u00e9utico activo que ha sido autorizado previamente a trav\u00e9s de un producto terminado por una autoridad regulatoria estricta (SRA).\n2. **Directrices para Dossiers de Producto (PD):** Se centran en la organizaci\u00f3n y formato del Dossier T\u00e9cnico Com\u00fan (CTD) para productos farmac\u00e9uticos multisource (gen\u00e9ricos), sin especificar los estudios requeridos.\n3. **Objetivos de las directrices:** Facilitar la precalificaci\u00f3n de productos farmac\u00e9uticos, asegurando que cumplan con est\u00e1ndares de seguridad, eficacia y calidad, y mejorar la comunicaci\u00f3n entre las autoridades regulatorias y la OMS.\n4. **Documentaci\u00f3n adicional:** Se deben considerar otras gu\u00edas y documentos de referencia de la OMS y la ICH para el contenido espec\u00edfico de los productos multisource.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de establecer las directrices.\n- **Autoridades regulatorias estrictas (SRA):** Incluyen miembros de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y otras autoridades asociadas.\n- **Dossier T\u00e9cnico Com\u00fan (CTD):** Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n t\u00e9cnica.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la OMS:** Iniciativa para listar productos farmac\u00e9uticos que cumplen con los est\u00e1ndares de calidad y seguridad.\n\nEste resumen destaca la importancia de seguir un formato com\u00fan en la documentaci\u00f3n de productos farmac\u00e9uticos y la colaboraci\u00f3n entre diferentes entidades regulatorias para garantizar la salud p\u00fablica.", "excerpt_keywords": "Keywords: guidelines, pharmaceutical, prequalification, active pharmaceutical ingredient, multisource"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a905d89a-adfb-4fd1-9447-18d950119f11", "node_type": "4", "metadata": {"page_label": "432", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Together, these guidelines, templates and reference documents mentioned within them are intended to assist applicants and WHO by harmonizing with international approaches and facilitating the preparation and subsequent assessment procedures for PDs through the integration of the internationally accepted CTD format and, where possible, terminology.\n\nOnce implemented these guidelines will supersede the following guidelines and template which were in use previously:\n\n- *Guideline on submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*;\n  - Supplement 1 \u2014 Dissolution testing;\n  - Supplement 2 \u2014 Extension of the WHO List of Stable (not easily degradable ARV) APIs;\n- *Pharmaceutical Quality Information Form (PQIF)*.\n\n## 2. Glossary\n\n**active pharmaceutical ingredient (API)**  \nAny substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings (1).\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s) (1).\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling (1).\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products (1).\n\n**multisource (generic) pharmaceutical products**  \nPharmaceutically equivalent or pharmaceutically alternative products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "3e01e19ea723d1578852f2cf50341cbea7aa83fd6a6c52ba60960cfcbd9fdd37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Together, these guidelines, templates and reference documents mentioned within them are intended to assist applicants and WHO by harmonizing with international approaches and facilitating the preparation and subsequent assessment procedures for PDs through the integration of the internationally accepted CTD format and, where possible, terminology.\n\nOnce implemented these guidelines will supersede the following guidelines and template which were in use previously:\n\n- *Guideline on submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*;\n  - Supplement 1 \u2014 Dissolution testing;\n  - Supplement 2 \u2014 Extension of the WHO List of Stable (not easily degradable ARV) APIs;\n- *Pharmaceutical Quality Information Form (PQIF)*.\n\n## 2. Glossary\n\n**active pharmaceutical ingredient (API)**  \nAny substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings (1).\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s) (1).\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling (1).\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products (1).\n\n**multisource (generic) pharmaceutical products**  \nPharmaceutically equivalent or pharmaceutically alternative products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable (6).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2132, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5bacb323-f328-4ec5-b58a-152dc7408b1a": {"__data__": {"id_": "5bacb323-f328-4ec5-b58a-152dc7408b1a", "embedding": null, "metadata": {"page_label": "433", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization of a product dossier for a multisource product in common technical document format\n\nThe CTD is organized into five modules. Module 1 is region-specific. Modules 2, 3, 4 and 5 are intended to be common for all regions. Conformance with these guidelines should ensure that Modules 2, 3, 4 and 5 are provided in a format acceptable to WHO and to regulatory authorities.\n\nThis section provides an overview of module contents for a multisource product in greater detail.\n\n- **Module 1: Administrative information and prescribing information**\n  - This module should contain documents specific to WHO and each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by WHO and the relevant regulatory authorities.\n  - A summary of the bioequivalence/bioavailability information should be provided according to WHO\u2019s *Bioequivalence Trial Information Form (BTIF)* (7).\n  - Quality information summary (QIS): see WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* for instructions (8).\n\n- **Module 2: CTD summaries**\n  - This Module should begin with a general introduction to the pharmaceutical, including its pharmacological class, mode of action and proposed clinical use. In general, the Introduction should not exceed one page.\n  - A summary of the quality information should be provided according to WHO\u2019s *Quality overall summary \u2014 product dossier (QOS\u2013PD)* template (9).\n  - The organization of these summaries is described in Guidelines for ICH M4, M4Q and M4S (3-5).\n\n- **Module 3: Quality**\n  - Information on quality should be presented in the structured format described in ICH M4Q and WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8).\n\n- **Module 4: Nonclinical study reports**\n  - Generally not applicable for multisource products (some exceptions may apply).\n\n- **Module 5: Clinical study reports**\n  - The human study reports and related information should be presented in the order described in ICH M4E (3) and WHO\u2019s *Multisource (generic)*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe la organizaci\u00f3n de un dossier de producto para un producto multisource en formato de documento t\u00e9cnico com\u00fan (CTD). Se divide en cinco m\u00f3dulos, donde el M\u00f3dulo 1 es espec\u00edfico para cada regi\u00f3n y los M\u00f3dulos 2, 3, 4 y 5 son comunes para todas las regiones. Cada m\u00f3dulo tiene requisitos espec\u00edficos sobre la informaci\u00f3n que debe incluirse, como informaci\u00f3n administrativa, res\u00famenes de calidad, informes de estudios no cl\u00ednicos y cl\u00ednicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentos se deben incluir en el M\u00f3dulo 1 del dossier de producto para un producto multisource?**\n   - El M\u00f3dulo 1 debe contener documentos espec\u00edficos para la OMS y cada regi\u00f3n, como formularios de solicitud y la etiqueta propuesta para uso en la regi\u00f3n. Tambi\u00e9n debe incluir un resumen de la informaci\u00f3n de bioequivalencia/bioavailability seg\u00fan el Formulario de Informaci\u00f3n de Ensayo de Bioequivalencia (BTIF) de la OMS y un resumen de informaci\u00f3n de calidad (QIS).\n\n2. **\u00bfCu\u00e1l es la estructura recomendada para el resumen de calidad en el M\u00f3dulo 2?**\n   - El M\u00f3dulo 2 debe comenzar con una introducci\u00f3n general al producto farmac\u00e9utico, que incluya su clase farmacol\u00f3gica, modo de acci\u00f3n y uso cl\u00ednico propuesto. Adem\u00e1s, debe incluir un resumen de la informaci\u00f3n de calidad seg\u00fan la plantilla de Resumen General de Calidad \u2014 dossier de producto (QOS\u2013PD) de la OMS.\n\n3. **\u00bfQu\u00e9 se debe considerar en el M\u00f3dulo 4 respecto a los informes de estudios no cl\u00ednicos para productos multisource?**\n   - En general, el M\u00f3dulo 4 no es aplicable para productos multisource, aunque pueden existir algunas excepciones. Esto implica que, en la mayor\u00eda de los casos, no se requerir\u00e1n informes de estudios no cl\u00ednicos para estos productos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la implementaci\u00f3n de nuevas directrices y documentos de referencia que buscan facilitar la preparaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos. Estos son algunos de los temas y entidades clave:\n\n1. **Nuevas Directrices**: Se introducen directrices y plantillas que armonizan los enfoques internacionales para la evaluaci\u00f3n de productos farmac\u00e9uticos, integrando el formato CTD (Common Technical Document).\n\n2. **Documentos Reemplazados**: Las nuevas directrices reemplazar\u00e1n las anteriores, que inclu\u00edan:\n   - Gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos) para el tratamiento de VIH/SIDA, malaria y tuberculosis.\n   - Formulario de Informaci\u00f3n de Calidad Farmac\u00e9utica (PQIF) y sus suplementos.\n\n3. **Glosario de T\u00e9rminos Clave**:\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia que proporciona actividad farmacol\u00f3gica en un producto farmac\u00e9utico terminado (FPP).\n   - **Solicitante**: Persona o entidad que presenta una expresi\u00f3n de inter\u00e9s para participar en el procedimiento de precalificaci\u00f3n.\n   - **Producto Farmac\u00e9utico Terminado (FPP)**: Forma de dosificaci\u00f3n final que ha pasado por todas las etapas de fabricaci\u00f3n.\n   - **Fabricante**: Empresa que produce y etiqueta productos farmac\u00e9uticos.\n   - **Productos Farmac\u00e9uticos Multisource**: Productos que son farmac\u00e9uticamente equivalentes o alternativamente farmac\u00e9uticos, que pueden ser intercambiables si son terap\u00e9uticamente equivalentes.\n\n4. **Objetivo General**: Las nuevas directrices tienen como objetivo mejorar la calidad y la consistencia en la evaluaci\u00f3n de productos farmac\u00e9uticos, especialmente aquellos utilizados en el tratamiento de enfermedades cr\u00edticas como el VIH/SIDA, la malaria y la tuberculosis. \n\nEste resumen destaca la importancia de la armonizaci\u00f3n en la presentaci\u00f3n de documentaci\u00f3n y la definici\u00f3n clara de t\u00e9rminos clave en el contexto de la precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: product dossier, multisource product, common technical document, WHO guidelines, regulatory authorities"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6b763825-5d5a-47c3-b589-3188a396fda6", "node_type": "4", "metadata": {"page_label": "433", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization of a product dossier for a multisource product in common technical document format\n\nThe CTD is organized into five modules. Module 1 is region-specific. Modules 2, 3, 4 and 5 are intended to be common for all regions. Conformance with these guidelines should ensure that Modules 2, 3, 4 and 5 are provided in a format acceptable to WHO and to regulatory authorities.\n\nThis section provides an overview of module contents for a multisource product in greater detail.\n\n- **Module 1: Administrative information and prescribing information**\n  - This module should contain documents specific to WHO and each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by WHO and the relevant regulatory authorities.\n  - A summary of the bioequivalence/bioavailability information should be provided according to WHO\u2019s *Bioequivalence Trial Information Form (BTIF)* (7).\n  - Quality information summary (QIS): see WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* for instructions (8).\n\n- **Module 2: CTD summaries**\n  - This Module should begin with a general introduction to the pharmaceutical, including its pharmacological class, mode of action and proposed clinical use. In general, the Introduction should not exceed one page.\n  - A summary of the quality information should be provided according to WHO\u2019s *Quality overall summary \u2014 product dossier (QOS\u2013PD)* template (9).\n  - The organization of these summaries is described in Guidelines for ICH M4, M4Q and M4S (3-5).\n\n- **Module 3: Quality**\n  - Information on quality should be presented in the structured format described in ICH M4Q and WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8).\n\n- **Module 4: Nonclinical study reports**\n  - Generally not applicable for multisource products (some exceptions may apply).\n\n- **Module 5: Clinical study reports**\n  - The human study reports and related information should be presented in the order described in ICH M4E (3) and WHO\u2019s *Multisource (generic)*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "bc0fbac2acc4b3703d39b3890899bc94387d332d8b1648df8f5b0ac30da52cb9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Organization of a product dossier for a multisource product in common technical document format\n\nThe CTD is organized into five modules. Module 1 is region-specific. Modules 2, 3, 4 and 5 are intended to be common for all regions. Conformance with these guidelines should ensure that Modules 2, 3, 4 and 5 are provided in a format acceptable to WHO and to regulatory authorities.\n\nThis section provides an overview of module contents for a multisource product in greater detail.\n\n- **Module 1: Administrative information and prescribing information**\n  - This module should contain documents specific to WHO and each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by WHO and the relevant regulatory authorities.\n  - A summary of the bioequivalence/bioavailability information should be provided according to WHO\u2019s *Bioequivalence Trial Information Form (BTIF)* (7).\n  - Quality information summary (QIS): see WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* for instructions (8).\n\n- **Module 2: CTD summaries**\n  - This Module should begin with a general introduction to the pharmaceutical, including its pharmacological class, mode of action and proposed clinical use. In general, the Introduction should not exceed one page.\n  - A summary of the quality information should be provided according to WHO\u2019s *Quality overall summary \u2014 product dossier (QOS\u2013PD)* template (9).\n  - The organization of these summaries is described in Guidelines for ICH M4, M4Q and M4S (3-5).\n\n- **Module 3: Quality**\n  - Information on quality should be presented in the structured format described in ICH M4Q and WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8).\n\n- **Module 4: Nonclinical study reports**\n  - Generally not applicable for multisource products (some exceptions may apply).\n\n- **Module 5: Clinical study reports**\n  - The human study reports and related information should be presented in the order described in ICH M4E (3) and WHO\u2019s *Multisource (generic)*.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2211, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "f1ead976-e54a-44fe-80f4-df1d4fc1457c": {"__data__": {"id_": "f1ead976-e54a-44fe-80f4-df1d4fc1457c", "embedding": null, "metadata": {"page_label": "434", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical products: guidelines on registration requirements to establish interchangeability (6).\n\nThe overall organization of the CTD is presented in Figure 1.\n\n### Figure 1  \n**Organization of the CTD**\n\n```\n          Not part of the CTD\n              (Module 1)\n          ___________________\n         |                   |\n         | Module 1          |\n         | Regional          |\n         | Administrative    |\n         | Information       |\n         |___________________|\n         | CTD Table of      |\n         | Contents          |\n         | 2.1               |\n         |___________________|\n         | CTD Introduction  |\n         | 2.2               |\n         |___________________|\n         | Quality Overall   |\n         | Summary           |\n         | 2.3               |\n         |___________________|\n         | Nonclinical       |\n         | Overview          |\n         | 2.4               |\n         |___________________|\n         | Nonclinical       |\n         | Written and       |\n         | Tabulated         |\n         | Summaries         |\n         | 2.6               |\n         |___________________|\n         | Clinical Overview |\n         | 2.5               |\n         |___________________|\n         | Clinical Summary  |\n         | 2.7               |\n         |___________________|\n         | Module 3          |\n         | Quality           |\n         | 3.0               |\n         |___________________|\n         | Module 4          |\n         | Nonclinical       |\n         | Study Reports     |\n         | 4.0               |\n         |___________________|\n         | Module 5          |\n         | Clinical Study    |\n         | Reports           |\n         | 5.0               |\n         |___________________|\n```\n\nThis figure is reproduced with the kind permission of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).\n\nIn preparing PDs for multisource products, it is acknowledged that certain modules or sections of the CTD would generally **not be applicable** (e.g. Module 4 \u2014 nonclinical study reports, although some exceptions may apply) and should be marked as such.\n\n### 4. Modules (including Module 1) of a product dossier for a multisource pharmaceutical product\n\nThis section outlines filing considerations for PDs in the CTD format. Table 1 provides an overview of the presentation of the PD, including modular structure and main headings.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en las pautas de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre los requisitos de registro para establecer la intercambiabilidad de productos farmac\u00e9uticos. Se presenta la organizaci\u00f3n del Dossier de Producto (PD) en formato CTD (Common Technical Document), que incluye varios m\u00f3dulos, como informaci\u00f3n administrativa, res\u00famenes de calidad, y reportes de estudios cl\u00ednicos y no cl\u00ednicos. Se menciona que ciertos m\u00f3dulos pueden no ser aplicables para productos multisource, como el m\u00f3dulo 4, y se deben marcar como tales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los m\u00f3dulos que generalmente no son aplicables al preparar Dossiers de Producto para productos multisource, y por qu\u00e9?**\n   - Respuesta: Generalmente, el M\u00f3dulo 4 (reportes de estudios no cl\u00ednicos) no es aplicable al preparar Dossiers de Producto para productos multisource, aunque pueden existir excepciones. Esto se debe a que los productos multisource suelen basarse en estudios de bioequivalencia en lugar de estudios no cl\u00ednicos extensivos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el M\u00f3dulo 1 del Dossier de Producto seg\u00fan el formato CTD?**\n   - Respuesta: El M\u00f3dulo 1 incluye informaci\u00f3n administrativa regional, la tabla de contenidos del CTD, la introducci\u00f3n del CTD, y res\u00famenes de calidad, no cl\u00ednicos y cl\u00ednicos, entre otros.\n\n3. **\u00bfQu\u00e9 figura se presenta en el documento y qu\u00e9 informaci\u00f3n proporciona sobre la organizaci\u00f3n del CTD?**\n   - Respuesta: La figura presentada es la \"Organizaci\u00f3n del CTD\", que ilustra la estructura modular del Dossier de Producto, destacando los diferentes m\u00f3dulos y sus respectivas secciones, as\u00ed como la distinci\u00f3n de que el M\u00f3dulo 1 no forma parte del CTD en s\u00ed. \n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para proporcionar informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, centr\u00e1ndose en detalles sobre la estructura y requisitos del Dossier de Producto en el contexto de productos farmac\u00e9uticos multisource.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Estructura del Dossier de Producto:**\n   - El dossier se organiza en cinco m\u00f3dulos: M\u00f3dulo 1 (espec\u00edfico para la regi\u00f3n) y M\u00f3dulos 2, 3, 4 y 5 (comunes para todas las regiones).\n\n2. **Contenido de los M\u00f3dulos:**\n   - **M\u00f3dulo 1:** Informaci\u00f3n administrativa y de prescripci\u00f3n, incluyendo documentos espec\u00edficos para la OMS y cada regi\u00f3n, res\u00famenes de bioequivalencia/bioavailability y un resumen de informaci\u00f3n de calidad (QIS).\n   - **M\u00f3dulo 2:** Res\u00famenes CTD que incluyen una introducci\u00f3n general al producto y un resumen de la informaci\u00f3n de calidad (QOS\u2013PD).\n   - **M\u00f3dulo 3:** Informaci\u00f3n de calidad presentada en un formato estructurado.\n   - **M\u00f3dulo 4:** Informes de estudios no cl\u00ednicos, generalmente no aplicables para productos multisource.\n   - **M\u00f3dulo 5:** Informes de estudios cl\u00ednicos presentados en el orden especificado por ICH M4E.\n\n3. **Conformidad con Directrices:**\n   - Se enfatiza la necesidad de cumplir con las directrices de la OMS y las autoridades regulatorias para asegurar que los m\u00f3dulos sean aceptables.\n\n**Entidades:**\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Autoridad que establece las directrices para la presentaci\u00f3n de documentaci\u00f3n.\n- **CTD (Common Technical Document):** Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n sobre productos farmac\u00e9uticos.\n- **M\u00f3dulos:** Seis secciones del dossier (M\u00f3dulo 1 a M\u00f3dulo 5) que abordan diferentes aspectos de la informaci\u00f3n del producto.\n- **Bioequivalence Trial Information Form (BTIF):** Formulario de la OMS para resumir informaci\u00f3n de bioequivalencia/bioavailability.\n- **Quality overall summary (QOS\u2013PD):** Plantilla de la OMS para resumir la informaci\u00f3n de calidad del producto.\n- **ICH (International Council for Harmonisation):** Consejo que proporciona directrices sobre la organizaci\u00f3n de los res\u00famenes y la informaci\u00f3n de calidad.\n\nEste resumen destaca la organizaci\u00f3n y los requisitos espec\u00edficos para la presentaci\u00f3n de un dossier de producto multisource, as\u00ed como la importancia de seguir las directrices establecidas por la OMS y otras autoridades regulatorias.", "excerpt_keywords": "Keywords: pharmaceutical products, CTD, product dossier, interchangeability, regulatory guidelines"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f1cb2359-9cf6-49a8-bcfe-303468a1b5fc", "node_type": "4", "metadata": {"page_label": "434", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical products: guidelines on registration requirements to establish interchangeability (6).\n\nThe overall organization of the CTD is presented in Figure 1.\n\n### Figure 1  \n**Organization of the CTD**\n\n```\n          Not part of the CTD\n              (Module 1)\n          ___________________\n         |                   |\n         | Module 1          |\n         | Regional          |\n         | Administrative    |\n         | Information       |\n         |___________________|\n         | CTD Table of      |\n         | Contents          |\n         | 2.1               |\n         |___________________|\n         | CTD Introduction  |\n         | 2.2               |\n         |___________________|\n         | Quality Overall   |\n         | Summary           |\n         | 2.3               |\n         |___________________|\n         | Nonclinical       |\n         | Overview          |\n         | 2.4               |\n         |___________________|\n         | Nonclinical       |\n         | Written and       |\n         | Tabulated         |\n         | Summaries         |\n         | 2.6               |\n         |___________________|\n         | Clinical Overview |\n         | 2.5               |\n         |___________________|\n         | Clinical Summary  |\n         | 2.7               |\n         |___________________|\n         | Module 3          |\n         | Quality           |\n         | 3.0               |\n         |___________________|\n         | Module 4          |\n         | Nonclinical       |\n         | Study Reports     |\n         | 4.0               |\n         |___________________|\n         | Module 5          |\n         | Clinical Study    |\n         | Reports           |\n         | 5.0               |\n         |___________________|\n```\n\nThis figure is reproduced with the kind permission of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).\n\nIn preparing PDs for multisource products, it is acknowledged that certain modules or sections of the CTD would generally **not be applicable** (e.g. Module 4 \u2014 nonclinical study reports, although some exceptions may apply) and should be marked as such.\n\n### 4. Modules (including Module 1) of a product dossier for a multisource pharmaceutical product\n\nThis section outlines filing considerations for PDs in the CTD format. Table 1 provides an overview of the presentation of the PD, including modular structure and main headings.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "f38e0334c2ed283aa9bf6153b468e305c50d4a539f938dda204db31972cf6f34", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "pharmaceutical products: guidelines on registration requirements to establish interchangeability (6).\n\nThe overall organization of the CTD is presented in Figure 1.\n\n### Figure 1  \n**Organization of the CTD**\n\n```\n          Not part of the CTD\n              (Module 1)\n          ___________________\n         |                   |\n         | Module 1          |\n         | Regional          |\n         | Administrative    |\n         | Information       |\n         |___________________|\n         | CTD Table of      |\n         | Contents          |\n         | 2.1               |\n         |___________________|\n         | CTD Introduction  |\n         | 2.2               |\n         |___________________|\n         | Quality Overall   |\n         | Summary           |\n         | 2.3               |\n         |___________________|\n         | Nonclinical       |\n         | Overview          |\n         | 2.4               |\n         |___________________|\n         | Nonclinical       |\n         | Written and       |\n         | Tabulated         |\n         | Summaries         |\n         | 2.6               |\n         |___________________|\n         | Clinical Overview |\n         | 2.5               |\n         |___________________|\n         | Clinical Summary  |\n         | 2.7               |\n         |___________________|\n         | Module 3          |\n         | Quality           |\n         | 3.0               |\n         |___________________|\n         | Module 4          |\n         | Nonclinical       |\n         | Study Reports     |\n         | 4.0               |\n         |___________________|\n         | Module 5          |\n         | Clinical Study    |\n         | Reports           |\n         | 5.0               |\n         |___________________|\n```\n\nThis figure is reproduced with the kind permission of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).\n\nIn preparing PDs for multisource products, it is acknowledged that certain modules or sections of the CTD would generally **not be applicable** (e.g. Module 4 \u2014 nonclinical study reports, although some exceptions may apply) and should be marked as such.\n\n### 4. Modules (including Module 1) of a product dossier for a multisource pharmaceutical product\n\nThis section outlines filing considerations for PDs in the CTD format. Table 1 provides an overview of the presentation of the PD, including modular structure and main headings.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2430, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "1315c207-b295-420a-9879-f2f1f78fb554": {"__data__": {"id_": "1315c207-b295-420a-9879-f2f1f78fb554", "embedding": null, "metadata": {"page_label": "435", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Modular format of PDs for multisource products in CTD format\n\n| Module 1 \u2014 Administrative information and prescribing information |\n| - |\n| 1.0 Cover letter |\n| 1.1 Table of contents of the application including Module 1 (Modules 1\u20135) |\n| 1.2 Application information: |\n| 1.2.1 Copy of the expression of interest (EOI) |\n| 1.2.2 Manufacturing and marketing authorization(s)/international registration status and/or the WHO certificate of pharmaceutical product (CPP) |\n| 1.2.3 Copy of certificate(s) of suitability of the *European Pharmacopoeia* (CEP) (including any annexes) |\n| 1.2.4 Letters of access for active pharmaceutical ingredient master files (APIMFs) |\n| 1.2.5 Good manufacturing practices (GMP) information |\n| 1.2.6 Biowaiver requests in relation to conducting a comparative bioavailability study |\n| 1.3 Product information: |\n| 1.3.1 Summary of product characteristics (SmPC) |\n| 1.3.2 Labelling (outer and inner labels) |\n| 1.3.3 Package leaflet (also known as patient information leaflet or PIL) |\n| 1.4 Regional summaries: |\n| 1.4.1 Bioequivalence trial information form (BTIF) |\n| 1.4.2 Quality information summary (QIS) |\n| 1.5 Electronic review documents (e.g. product information, BTIF, QIS, QOS\u2013PD) |\n| 1.6 Samples (e.g. FPP, device(s), certificates of analysis) |\n\n\n| Module 2 \u2014 Common technical document (CTD) summaries |\n| - |\n| 2.1 CTD Table of contents (Modules 2\u20135) |\n| 2.2 CTD Introduction |\n| 2.3 Quality overall summary \u2014 product dossier (QOS\u2013PD) |\n| 2.4 Nonclinical overview \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.5 Clinical overview |\n| 2.6 Nonclinical written and tabulated summaries \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.7 Clinical summary |\n\n\n| Module 3 \u2014 Quality |\n| - |\n| 3.1 Table of contents of Module 3 |\n| 3.2 Body of data |\n| 3.3 Literature references |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se requiere en la secci\u00f3n 1.2.2 del M\u00f3dulo 1 del formato modular para productos multisource?**\n   - **Respuesta:** En la secci\u00f3n 1.2.2 se requiere informaci\u00f3n sobre las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n, el estado de registro internacional y/o el certificado de producto farmac\u00e9utico de la OMS (CPP).\n\n2. **\u00bfCu\u00e1l es la finalidad de la secci\u00f3n 2.4 en el M\u00f3dulo 2 del documento?**\n   - **Respuesta:** La secci\u00f3n 2.4, titulada \"Nonclinical overview\", generalmente no es aplicable para productos multisource, aunque pueden existir algunas excepciones. Su finalidad es proporcionar un resumen de los datos no cl\u00ednicos relevantes para la evaluaci\u00f3n del producto.\n\n3. **\u00bfQu\u00e9 tipo de documentos se incluyen en la secci\u00f3n 1.5 del M\u00f3dulo 1?**\n   - **Respuesta:** En la secci\u00f3n 1.5 se incluyen documentos de revisi\u00f3n electr\u00f3nica, tales como informaci\u00f3n del producto, el formulario de informaci\u00f3n del ensayo de bioequivalencia (BTIF), el resumen de informaci\u00f3n de calidad (QIS) y el resumen del dossier de calidad (QOS\u2013PD).\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 961\" presenta un formato modular para los documentos de producto (PDs) de productos multisource en formato de documento t\u00e9cnico com\u00fan (CTD). Se divide en varios m\u00f3dulos que incluyen informaci\u00f3n administrativa, res\u00famenes t\u00e9cnicos comunes, y datos de calidad. Cada m\u00f3dulo contiene secciones espec\u00edficas que detallan la informaci\u00f3n requerida para la evaluaci\u00f3n y autorizaci\u00f3n de productos farmac\u00e9uticos, incluyendo aspectos como la informaci\u00f3n de fabricaci\u00f3n, caracter\u00edsticas del producto, y res\u00famenes cl\u00ednicos y no cl\u00ednicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Tema Principal**: \n   - Pautas de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre los requisitos de registro para establecer la intercambiabilidad de productos farmac\u00e9uticos.\n\n2. **Estructura del Dossier de Producto (PD)**:\n   - Se presenta la organizaci\u00f3n del Dossier de Producto en formato CTD (Common Technical Document), que incluye varios m\u00f3dulos.\n\n3. **M\u00f3dulos del CTD**:\n   - **M\u00f3dulo 1**: Informaci\u00f3n administrativa regional, tabla de contenidos, introducci\u00f3n, res\u00famenes de calidad, no cl\u00ednicos y cl\u00ednicos.\n   - **M\u00f3dulo 3**: Calidad.\n   - **M\u00f3dulo 4**: Reportes de estudios no cl\u00ednicos (generalmente no aplicable para productos multisource).\n   - **M\u00f3dulo 5**: Reportes de estudios cl\u00ednicos.\n\n4. **Excepciones**:\n   - Se menciona que ciertos m\u00f3dulos, como el M\u00f3dulo 4, no son aplicables al preparar Dossiers de Producto para productos multisource, aunque pueden existir excepciones.\n\n5. **Figura 1**: \n   - Ilustra la organizaci\u00f3n del CTD, destacando la estructura modular y la distinci\u00f3n de que el M\u00f3dulo 1 no forma parte del CTD en s\u00ed.\n\n6. **Entidades**:\n   - **OMS**: Organizaci\u00f3n Mundial de la Salud.\n   - **CTD**: Common Technical Document.\n   - **IFPMA**: Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos.\n\nEste resumen destaca los aspectos clave relacionados con la organizaci\u00f3n y requisitos del Dossier de Producto en el contexto de productos farmac\u00e9uticos multisource, as\u00ed como las entidades relevantes involucradas en el proceso.", "excerpt_keywords": "Keywords: WHO, Technical Report, multisource products, CTD format, pharmaceutical registration"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "94bce007-7d32-4c48-8cdf-739101c4e263", "node_type": "4", "metadata": {"page_label": "435", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Modular format of PDs for multisource products in CTD format\n\n| Module 1 \u2014 Administrative information and prescribing information |\n| - |\n| 1.0 Cover letter |\n| 1.1 Table of contents of the application including Module 1 (Modules 1\u20135) |\n| 1.2 Application information: |\n| 1.2.1 Copy of the expression of interest (EOI) |\n| 1.2.2 Manufacturing and marketing authorization(s)/international registration status and/or the WHO certificate of pharmaceutical product (CPP) |\n| 1.2.3 Copy of certificate(s) of suitability of the *European Pharmacopoeia* (CEP) (including any annexes) |\n| 1.2.4 Letters of access for active pharmaceutical ingredient master files (APIMFs) |\n| 1.2.5 Good manufacturing practices (GMP) information |\n| 1.2.6 Biowaiver requests in relation to conducting a comparative bioavailability study |\n| 1.3 Product information: |\n| 1.3.1 Summary of product characteristics (SmPC) |\n| 1.3.2 Labelling (outer and inner labels) |\n| 1.3.3 Package leaflet (also known as patient information leaflet or PIL) |\n| 1.4 Regional summaries: |\n| 1.4.1 Bioequivalence trial information form (BTIF) |\n| 1.4.2 Quality information summary (QIS) |\n| 1.5 Electronic review documents (e.g. product information, BTIF, QIS, QOS\u2013PD) |\n| 1.6 Samples (e.g. FPP, device(s), certificates of analysis) |\n\n\n| Module 2 \u2014 Common technical document (CTD) summaries |\n| - |\n| 2.1 CTD Table of contents (Modules 2\u20135) |\n| 2.2 CTD Introduction |\n| 2.3 Quality overall summary \u2014 product dossier (QOS\u2013PD) |\n| 2.4 Nonclinical overview \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.5 Clinical overview |\n| 2.6 Nonclinical written and tabulated summaries \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.7 Clinical summary |\n\n\n| Module 3 \u2014 Quality |\n| - |\n| 3.1 Table of contents of Module 3 |\n| 3.2 Body of data |\n| 3.3 Literature references |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "b8e46383b32c5a0263d8d77cc8277cd1d696046b9496c9073df7cc7d198f7fb1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Modular format of PDs for multisource products in CTD format\n\n| Module 1 \u2014 Administrative information and prescribing information |\n| - |\n| 1.0 Cover letter |\n| 1.1 Table of contents of the application including Module 1 (Modules 1\u20135) |\n| 1.2 Application information: |\n| 1.2.1 Copy of the expression of interest (EOI) |\n| 1.2.2 Manufacturing and marketing authorization(s)/international registration status and/or the WHO certificate of pharmaceutical product (CPP) |\n| 1.2.3 Copy of certificate(s) of suitability of the *European Pharmacopoeia* (CEP) (including any annexes) |\n| 1.2.4 Letters of access for active pharmaceutical ingredient master files (APIMFs) |\n| 1.2.5 Good manufacturing practices (GMP) information |\n| 1.2.6 Biowaiver requests in relation to conducting a comparative bioavailability study |\n| 1.3 Product information: |\n| 1.3.1 Summary of product characteristics (SmPC) |\n| 1.3.2 Labelling (outer and inner labels) |\n| 1.3.3 Package leaflet (also known as patient information leaflet or PIL) |\n| 1.4 Regional summaries: |\n| 1.4.1 Bioequivalence trial information form (BTIF) |\n| 1.4.2 Quality information summary (QIS) |\n| 1.5 Electronic review documents (e.g. product information, BTIF, QIS, QOS\u2013PD) |\n| 1.6 Samples (e.g. FPP, device(s), certificates of analysis) |\n\n\n| Module 2 \u2014 Common technical document (CTD) summaries |\n| - |\n| 2.1 CTD Table of contents (Modules 2\u20135) |\n| 2.2 CTD Introduction |\n| 2.3 Quality overall summary \u2014 product dossier (QOS\u2013PD) |\n| 2.4 Nonclinical overview \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.5 Clinical overview |\n| 2.6 Nonclinical written and tabulated summaries \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.7 Clinical summary |\n\n\n| Module 3 \u2014 Quality |\n| - |\n| 3.1 Table of contents of Module 3 |\n| 3.2 Body of data |\n| 3.3 Literature references |", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1896, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "59f62c0c-d266-4a67-845d-142022f3f7a6": {"__data__": {"id_": "59f62c0c-d266-4a67-845d-142022f3f7a6", "embedding": null, "metadata": {"page_label": "436", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) | Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| - | - |\n| 4.1 | Table of contents of Module 4 |\n| 4.2 | Study reports |\n| 4.3 | Literature references |\n| Module 5 \u2014 Clinical study reports | |\n| 5.1 | Table of contents of Module 5 |\n| 5.2 | Tabular listing of all clinical studies |\n| 5.3 | Clinical study reports |\n| 5.3.1 | Reports of biopharmaceutical studies |\n| 5.3.7 | Case-report forms and individual patient listings |\n| 5.4 | Literature references |\n\n\nAdditional guidance for some of the sections to be included in Module 1 is provided below:\n\n### 1.0 Cover letter\n\nThe cover letter submitted with the PD should include a clear statement by the responsible person submitting the PD, indicating that the information submitted is true and correct.\n\n### 1.2.2 Manufacturing and marketing authorization(s)/international registration status\n\nList the countries in which:\n\n- the FPP (or set of FPPs) has been granted a marketing authorization;\n- the FPP (or one or more of the set of FPPs) has been withdrawn from the market; and\n- an application for the marketing of the FPP (or one or more of the set of FPPs) has been rejected, deferred or withdrawn.\n\nFor further guidance see section 3.2.P.3.1 of the *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)*.\n\n### 1.4 Regional summaries\n\nThe regional summaries should be prepared in accordance with the available WHO templates, which are available on the WHO Prequalification website.\n\n### 1.5 Electronic review documents\n\nElectronic submission of documentation (CD or DVD) should be submitted in Microsoft Word (required for templates/summaries, e.g. QOS\u2013PD, QIS, BTIF) or text-selectable PDF format (other documentation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en los m\u00f3dulos de informes no cl\u00ednicos y cl\u00ednicos para productos farmac\u00e9uticos multisource (gen\u00e9ricos). Se detallan las secciones que deben incluirse en la presentaci\u00f3n de documentaci\u00f3n para productos farmac\u00e9uticos terminados (FPP), as\u00ed como las pautas para la presentaci\u00f3n de documentos electr\u00f3nicos y res\u00famenes regionales. Se enfatiza la importancia de la veracidad de la informaci\u00f3n presentada y se proporcionan directrices sobre autorizaciones de comercializaci\u00f3n y el estado de registro internacional.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la carta de presentaci\u00f3n al enviar la documentaci\u00f3n para un producto farmac\u00e9utico terminado (FPP)?**\n   - La carta de presentaci\u00f3n debe incluir una declaraci\u00f3n clara por parte de la persona responsable que indique que la informaci\u00f3n presentada es verdadera y correcta.\n\n2. **\u00bfCu\u00e1les son los requisitos para listar el estado de autorizaci\u00f3n de comercializaci\u00f3n de un FPP en diferentes pa\u00edses?**\n   - Se debe listar los pa\u00edses donde el FPP ha recibido autorizaci\u00f3n de comercializaci\u00f3n, aquellos donde ha sido retirado del mercado, y aquellos donde la solicitud de comercializaci\u00f3n ha sido rechazada, diferida o retirada.\n\n3. **\u00bfQu\u00e9 formatos se requieren para la presentaci\u00f3n electr\u00f3nica de documentos relacionados con la evaluaci\u00f3n de productos farmac\u00e9uticos?**\n   - La presentaci\u00f3n electr\u00f3nica debe realizarse en formato Microsoft Word (para plantillas y res\u00famenes) o en formato PDF seleccionable por texto (para otra documentaci\u00f3n).", "prev_section_summary": "La secci\u00f3n del documento \"WHO - Technical Report Series 961\" se centra en el formato modular para los documentos de producto (PDs) de productos multisource en el contexto del formato de documento t\u00e9cnico com\u00fan (CTD). A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n### Temas Clave:\n1. **Formato Modular**: Se establece un formato estructurado para la presentaci\u00f3n de informaci\u00f3n sobre productos farmac\u00e9uticos multisource.\n2. **M\u00f3dulos Espec\u00edficos**: El documento se divide en varios m\u00f3dulos, cada uno con secciones que abordan diferentes aspectos de la evaluaci\u00f3n y autorizaci\u00f3n de productos.\n   - **M\u00f3dulo 1**: Informaci\u00f3n administrativa y de prescripci\u00f3n, que incluye detalles sobre autorizaciones, informaci\u00f3n del producto y documentos de revisi\u00f3n electr\u00f3nica.\n   - **M\u00f3dulo 2**: Res\u00famenes del documento t\u00e9cnico com\u00fan, que abordan la calidad, la no cl\u00ednica y la informaci\u00f3n cl\u00ednica.\n   - **M\u00f3dulo 3**: Datos de calidad, que incluyen el cuerpo de datos y referencias bibliogr\u00e1ficas.\n\n### Entidades:\n- **Secciones del M\u00f3dulo 1**:\n  - **1.2**: Informaci\u00f3n de la aplicaci\u00f3n, que incluye autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n, certificados de la OMS, y buenas pr\u00e1cticas de manufactura (GMP).\n  - **1.3**: Informaci\u00f3n del producto, que abarca caracter\u00edsticas del producto, etiquetado y folletos informativos.\n  - **1.5**: Documentos de revisi\u00f3n electr\u00f3nica, como el resumen de informaci\u00f3n de calidad (QIS) y el resumen del dossier de calidad (QOS\u2013PD).\n\n- **Secciones del M\u00f3dulo 2**:\n  - **2.4**: Resumen no cl\u00ednico, que generalmente no se aplica a productos multisource, pero puede tener excepciones.\n  - **2.5**: Resumen cl\u00ednico.\n\n- **Secciones del M\u00f3dulo 3**:\n  - **3.1**: Tabla de contenidos del m\u00f3dulo de calidad.\n  - **3.2**: Cuerpo de datos que respalda la calidad del producto.\n\n### Conclusi\u00f3n:\nEl documento proporciona una gu\u00eda detallada sobre la informaci\u00f3n necesaria para la evaluaci\u00f3n de productos farmac\u00e9uticos multisource, estructurada en un formato modular que facilita la revisi\u00f3n y autorizaci\u00f3n por parte de las autoridades competentes.", "excerpt_keywords": "Keywords: WHO, Technical Report, multisource products, clinical study reports, electronic submission"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1fa5f1ae-e269-43d7-9cf7-18c7a65d69e6", "node_type": "4", "metadata": {"page_label": "436", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) | Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| - | - |\n| 4.1 | Table of contents of Module 4 |\n| 4.2 | Study reports |\n| 4.3 | Literature references |\n| Module 5 \u2014 Clinical study reports | |\n| 5.1 | Table of contents of Module 5 |\n| 5.2 | Tabular listing of all clinical studies |\n| 5.3 | Clinical study reports |\n| 5.3.1 | Reports of biopharmaceutical studies |\n| 5.3.7 | Case-report forms and individual patient listings |\n| 5.4 | Literature references |\n\n\nAdditional guidance for some of the sections to be included in Module 1 is provided below:\n\n### 1.0 Cover letter\n\nThe cover letter submitted with the PD should include a clear statement by the responsible person submitting the PD, indicating that the information submitted is true and correct.\n\n### 1.2.2 Manufacturing and marketing authorization(s)/international registration status\n\nList the countries in which:\n\n- the FPP (or set of FPPs) has been granted a marketing authorization;\n- the FPP (or one or more of the set of FPPs) has been withdrawn from the market; and\n- an application for the marketing of the FPP (or one or more of the set of FPPs) has been rejected, deferred or withdrawn.\n\nFor further guidance see section 3.2.P.3.1 of the *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)*.\n\n### 1.4 Regional summaries\n\nThe regional summaries should be prepared in accordance with the available WHO templates, which are available on the WHO Prequalification website.\n\n### 1.5 Electronic review documents\n\nElectronic submission of documentation (CD or DVD) should be submitted in Microsoft Word (required for templates/summaries, e.g. QOS\u2013PD, QIS, BTIF) or text-selectable PDF format (other documentation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "87e54b3d7db9d4bec50fea67d8a569ef76b3fda9f2df174fdb32a9b108fade39", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) | Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| - | - |\n| 4.1 | Table of contents of Module 4 |\n| 4.2 | Study reports |\n| 4.3 | Literature references |\n| Module 5 \u2014 Clinical study reports | |\n| 5.1 | Table of contents of Module 5 |\n| 5.2 | Tabular listing of all clinical studies |\n| 5.3 | Clinical study reports |\n| 5.3.1 | Reports of biopharmaceutical studies |\n| 5.3.7 | Case-report forms and individual patient listings |\n| 5.4 | Literature references |\n\n\nAdditional guidance for some of the sections to be included in Module 1 is provided below:\n\n### 1.0 Cover letter\n\nThe cover letter submitted with the PD should include a clear statement by the responsible person submitting the PD, indicating that the information submitted is true and correct.\n\n### 1.2.2 Manufacturing and marketing authorization(s)/international registration status\n\nList the countries in which:\n\n- the FPP (or set of FPPs) has been granted a marketing authorization;\n- the FPP (or one or more of the set of FPPs) has been withdrawn from the market; and\n- an application for the marketing of the FPP (or one or more of the set of FPPs) has been rejected, deferred or withdrawn.\n\nFor further guidance see section 3.2.P.3.1 of the *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)*.\n\n### 1.4 Regional summaries\n\nThe regional summaries should be prepared in accordance with the available WHO templates, which are available on the WHO Prequalification website.\n\n### 1.5 Electronic review documents\n\nElectronic submission of documentation (CD or DVD) should be submitted in Microsoft Word (required for templates/summaries, e.g. QOS\u2013PD, QIS, BTIF) or text-selectable PDF format (other documentation).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1943, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "61d47c0d-a1be-4d36-ba8a-75078adddd2a": {"__data__": {"id_": "61d47c0d-a1be-4d36-ba8a-75078adddd2a", "embedding": null, "metadata": {"page_label": "437", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Samples (e.g. FPP, device(s))\n\nA sample and certificate of analysis of the FPP(s) and devices(s) should be provided to enable visual inspection of the pharmaceutical product, the packaging materials and the label as well as comparison of the data with those in the SmPC, labelling and the package leaflet.\n\nDraft labelling may be submitted at the time of dossier submission when labelling for marketing has not been finalized. For guidance regarding labelling, refer to the information on WHO public assessment reports (WHOPARs) available on the Prequalification web site under Information for Applicants (Prequalification Guidelines).\n\n## 5. Module 3 \u2014 quality\n\nFor Module 3.2.S Drug substance (or active pharmaceutical ingredient (API)), there are three options to satisfy the information requirements for APIs within the Prequalification Programme. In brief these are:\n\n- **Option 1**: certificate of suitability of the *European Pharmacopoeia* (CEP) procedure;\n- **Option 2**: active pharmaceutical ingredient master file (APIMF) procedure; or\n- **Option 3**: full details in the PD.\n\nAll options require the submission of information in CTD format (3.2.S), although the content may differ in places. The *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)* provides detailed guidance on this issue and on the preparation of the FPP information by the applicant.\n\n## 6. Module 5 of a product dossier for a multisource pharmaceutical product\n\nThe majority of PDs for multisource products are supported by one or more pivotal comparative bioavailability studies. When filing a PD in the CTD format, it is anticipated that only the following relevant sections of Module 5 will normally be required.\n\n**Module 5: Clinical study reports**\n\n- 5.1 Table of contents for Module 5\n- 5.2 Tabular listing of all clinical studies\n- 5.3 Clinical study reports\n  - 5.3.1 Reports of biopharmaceutical studies\n    - 5.3.1.2 Comparative bioavailability and bioequivalence study reports", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la presentaci\u00f3n de un dossier de productos farmac\u00e9uticos, espec\u00edficamente para productos farmac\u00e9uticos terminados (FPP) y dispositivos. Se enfatiza la importancia de proporcionar muestras y certificados de an\u00e1lisis para permitir la inspecci\u00f3n visual y la comparaci\u00f3n de datos. Adem\u00e1s, se describen las opciones para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas (API) y se mencionan los m\u00f3dulos relevantes para la presentaci\u00f3n de informes de estudios cl\u00ednicos, especialmente en el contexto de productos farmac\u00e9uticos multisource.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres m\u00e9todos aceptables para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas (API) en el Programa de Precalificaci\u00f3n de la OMS?**\n   - Respuesta: Los tres m\u00e9todos son: \n     - Opci\u00f3n 1: Certificado de idoneidad del procedimiento de la Farmacopea Europea (CEP).\n     - Opci\u00f3n 2: Procedimiento de archivo maestro de ingrediente farmac\u00e9utico activo (APIMF).\n     - Opci\u00f3n 3: Detalles completos en el dossier del producto (PD).\n\n2. **\u00bfQu\u00e9 se debe incluir en la presentaci\u00f3n de un dossier de producto (PD) para un producto farmac\u00e9utico multisource en relaci\u00f3n con los estudios de bioequivalencia?**\n   - Respuesta: Se debe incluir una tabla de contenido para el M\u00f3dulo 5, un listado tabular de todos los estudios cl\u00ednicos y los informes de estudios cl\u00ednicos, espec\u00edficamente los informes de estudios biofarmac\u00e9uticos y los informes de estudios de bioequivalencia y comparativa.\n\n3. **\u00bfQu\u00e9 se debe proporcionar junto con las muestras de productos farmac\u00e9uticos y dispositivos para facilitar la inspecci\u00f3n visual?**\n   - Respuesta: Se debe proporcionar un certificado de an\u00e1lisis de los FPP y dispositivos, que permita la inspecci\u00f3n visual del producto farmac\u00e9utico, los materiales de embalaje y la etiqueta, as\u00ed como la comparaci\u00f3n de los datos con los que se encuentran en el Resumen de las Caracter\u00edsticas del Producto (SmPC), el etiquetado y el prospecto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las pautas y requisitos para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en el contexto de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961). A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **M\u00f3dulos de Informes**:\n   - **M\u00f3dulo 4**: Informes de estudios no cl\u00ednicos, generalmente no aplicables para productos multisource, con algunas excepciones.\n   - **M\u00f3dulo 5**: Informes de estudios cl\u00ednicos, que incluye listados tabulares y reportes de estudios biopharmaceuticals.\n\n2. **Carta de Presentaci\u00f3n**:\n   - Debe incluir una declaraci\u00f3n de veracidad de la informaci\u00f3n presentada por la persona responsable.\n\n3. **Autorizaci\u00f3n de Comercializaci\u00f3n**:\n   - Requisitos para listar el estado de autorizaci\u00f3n de comercializaci\u00f3n en diferentes pa\u00edses, incluyendo autorizaciones, retiradas y solicitudes rechazadas.\n\n4. **Res\u00famenes Regionales**:\n   - Deben prepararse de acuerdo con las plantillas disponibles en el sitio web de Precalificaci\u00f3n de la OMS.\n\n5. **Documentos Electr\u00f3nicos**:\n   - La presentaci\u00f3n electr\u00f3nica debe realizarse en formatos espec\u00edficos: Microsoft Word para plantillas y res\u00famenes, y PDF seleccionable por texto para otra documentaci\u00f3n.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de las directrices y est\u00e1ndares mencionados.\n- **FPP (Producto Farmac\u00e9utico Terminado)**: Producto cuyo estado de autorizaci\u00f3n se debe detallar en la documentaci\u00f3n.\n- **M\u00f3dulos 4 y 5**: Secciones espec\u00edficas del documento que abordan estudios no cl\u00ednicos y cl\u00ednicos, respectivamente.\n\nEste resumen destaca la estructura y los requisitos esenciales para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos, enfatizando la importancia de la precisi\u00f3n y el cumplimiento de las normativas establecidas por la OMS.", "excerpt_keywords": "Keywords: pharmaceutical products, WHO guidelines, active pharmaceutical ingredient, bioequivalence studies, product dossier"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "633835fa-fe82-4309-a401-2fdb012acd53", "node_type": "4", "metadata": {"page_label": "437", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Samples (e.g. FPP, device(s))\n\nA sample and certificate of analysis of the FPP(s) and devices(s) should be provided to enable visual inspection of the pharmaceutical product, the packaging materials and the label as well as comparison of the data with those in the SmPC, labelling and the package leaflet.\n\nDraft labelling may be submitted at the time of dossier submission when labelling for marketing has not been finalized. For guidance regarding labelling, refer to the information on WHO public assessment reports (WHOPARs) available on the Prequalification web site under Information for Applicants (Prequalification Guidelines).\n\n## 5. Module 3 \u2014 quality\n\nFor Module 3.2.S Drug substance (or active pharmaceutical ingredient (API)), there are three options to satisfy the information requirements for APIs within the Prequalification Programme. In brief these are:\n\n- **Option 1**: certificate of suitability of the *European Pharmacopoeia* (CEP) procedure;\n- **Option 2**: active pharmaceutical ingredient master file (APIMF) procedure; or\n- **Option 3**: full details in the PD.\n\nAll options require the submission of information in CTD format (3.2.S), although the content may differ in places. The *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)* provides detailed guidance on this issue and on the preparation of the FPP information by the applicant.\n\n## 6. Module 5 of a product dossier for a multisource pharmaceutical product\n\nThe majority of PDs for multisource products are supported by one or more pivotal comparative bioavailability studies. When filing a PD in the CTD format, it is anticipated that only the following relevant sections of Module 5 will normally be required.\n\n**Module 5: Clinical study reports**\n\n- 5.1 Table of contents for Module 5\n- 5.2 Tabular listing of all clinical studies\n- 5.3 Clinical study reports\n  - 5.3.1 Reports of biopharmaceutical studies\n    - 5.3.1.2 Comparative bioavailability and bioequivalence study reports", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "cb22c31982e8568ee5f6b3ea0c52df7f759e62199d743a40e9b5bbc2490c3ebb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 1.6 Samples (e.g. FPP, device(s))\n\nA sample and certificate of analysis of the FPP(s) and devices(s) should be provided to enable visual inspection of the pharmaceutical product, the packaging materials and the label as well as comparison of the data with those in the SmPC, labelling and the package leaflet.\n\nDraft labelling may be submitted at the time of dossier submission when labelling for marketing has not been finalized. For guidance regarding labelling, refer to the information on WHO public assessment reports (WHOPARs) available on the Prequalification web site under Information for Applicants (Prequalification Guidelines).\n\n## 5. Module 3 \u2014 quality\n\nFor Module 3.2.S Drug substance (or active pharmaceutical ingredient (API)), there are three options to satisfy the information requirements for APIs within the Prequalification Programme. In brief these are:\n\n- **Option 1**: certificate of suitability of the *European Pharmacopoeia* (CEP) procedure;\n- **Option 2**: active pharmaceutical ingredient master file (APIMF) procedure; or\n- **Option 3**: full details in the PD.\n\nAll options require the submission of information in CTD format (3.2.S), although the content may differ in places. The *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)* provides detailed guidance on this issue and on the preparation of the FPP information by the applicant.\n\n## 6. Module 5 of a product dossier for a multisource pharmaceutical product\n\nThe majority of PDs for multisource products are supported by one or more pivotal comparative bioavailability studies. When filing a PD in the CTD format, it is anticipated that only the following relevant sections of Module 5 will normally be required.\n\n**Module 5: Clinical study reports**\n\n- 5.1 Table of contents for Module 5\n- 5.2 Tabular listing of all clinical studies\n- 5.3 Clinical study reports\n  - 5.3.1 Reports of biopharmaceutical studies\n    - 5.3.1.2 Comparative bioavailability and bioequivalence study reports", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2052, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f2ba95-4466-4310-8433-176fcae01627": {"__data__": {"id_": "b8f2ba95-4466-4310-8433-176fcae01627", "embedding": null, "metadata": {"page_label": "438", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.3.1.3 In vitro\u2013in vivo correlation study reports if available\n# 5.3.1.4 Reports of bioanalytical and analytical method for human studies<sup>2</sup>\n\n\u2014 5.3.7 Case-report forms (CRFs) and individual patient listings: only CRFs for subjects who experienced serious adverse events should be included. All CRFs should be available upon request.\n\n- 5.4 Literature references\n\nFor guidance regarding biowaivers, refer to the biowaiver implementation documents available on the Prequalification web site. For guidance regarding comparator products, refer to the information available under Guidance on bioequivalence studies on the Prequalification web site.\n\n## 7. Guidance on format and presentation of a product dossier in common technical document format\n\n### 7.1 Guidance on format\n\nThroughout the CTD, the information should be displayed in an unambiguous and transparent manner. Text and tables should be prepared using margins that allow the document to be printed on both A4-sized paper (European Union and Japan) and 8.5 \u00d7 11-inch paper (US). The left-hand margin should be sufficiently large that information is not obscured whatever the method of binding. Fonts for text and tables should be of a style and size large enough to be easily legible, even after photocopying. Times New Roman, 12-point font is recommended for narrative text.\n\nAcronyms and abbreviations should be defined the first time they are used in each module.\n\nReferences should be cited in accordance with the current edition of the *Uniform requirements for manuscripts submitted to biomedical journals*, International Committee of Medical Journal Editors (ICMJE).<sup>3</sup> Copies of relevant pages of references should be provided, with a copy of the full article in the case of a publication. English translations should be provided as necessary.\n\n### 7.2 Guidance on presentation\n\nThe paper copies of the application should be bound for easy access to information.\n\n----\n\n<sup>2</sup> Bioanalytical or analytical methods for BA/BE or in vitro dissolution studies should ordinarily be provided in the individual clinical study reports. However, where a method is used in multiple studies, the method and its validation should only be included once in section 5.3.1.4 and referenced in the appropriate individual clinical study reports.\n\n<sup>3</sup> The first edition of the *Uniform requirements for manuscripts submitted to biomedical journals* was conceived by the Vancouver Group and was published in 1979.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento proporciona directrices sobre la presentaci\u00f3n y formato de un dossier de producto en el formato del documento t\u00e9cnico com\u00fan (CTD). Incluye secciones espec\u00edficas sobre estudios de correlaci\u00f3n in vitro-in vivo, m\u00e9todos bioanal\u00edticos y anal\u00edticos, formularios de informes de casos (CRFs) y referencias literarias. Tambi\u00e9n se menciona la importancia de la claridad y legibilidad en la presentaci\u00f3n de la informaci\u00f3n, as\u00ed como la necesidad de cumplir con las normas de citaci\u00f3n establecidas por el Comit\u00e9 Internacional de Editores de Revistas M\u00e9dicas.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de formularios de informes de casos (CRFs) deben incluirse en el dossier de producto y cu\u00e1les son las condiciones para su inclusi\u00f3n?**\n   - Respuesta: Solo se deben incluir los CRFs de los sujetos que experimentaron eventos adversos graves, y todos los CRFs deben estar disponibles a solicitud.\n\n2. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre el formato y la presentaci\u00f3n de la informaci\u00f3n en el dossier del producto seg\u00fan el documento?**\n   - Respuesta: La informaci\u00f3n debe presentarse de manera clara y transparente, utilizando m\u00e1rgenes adecuados para la impresi\u00f3n en papel A4 y 8.5 \u00d7 11 pulgadas, con un tama\u00f1o de fuente de 12 puntos en Times New Roman para asegurar la legibilidad.\n\n3. **\u00bfC\u00f3mo deben citarse las referencias en el dossier del producto y qu\u00e9 se debe proporcionar junto con ellas?**\n   - Respuesta: Las referencias deben citarse de acuerdo con la edici\u00f3n actual de los *Uniform requirements for manuscripts submitted to biomedical journals* del ICMJE, y se deben proporcionar copias de las p\u00e1ginas relevantes de las referencias, as\u00ed como una copia del art\u00edculo completo en caso de publicaciones, junto con traducciones al ingl\u00e9s si es necesario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Muestras y Certificados de An\u00e1lisis**:\n   - Se requiere la presentaci\u00f3n de muestras y certificados de an\u00e1lisis de productos farmac\u00e9uticos terminados (FPP) y dispositivos para permitir la inspecci\u00f3n visual y la comparaci\u00f3n de datos con el Resumen de las Caracter\u00edsticas del Producto (SmPC), etiquetado y prospecto.\n\n2. **Opciones para Sustancias Activas (API)**:\n   - Existen tres m\u00e9todos aceptables para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas en el Programa de Precalificaci\u00f3n de la OMS:\n     - **Opci\u00f3n 1**: Certificado de idoneidad del procedimiento de la Farmacopea Europea (CEP).\n     - **Opci\u00f3n 2**: Procedimiento de archivo maestro de ingrediente farmac\u00e9utico activo (APIMF).\n     - **Opci\u00f3n 3**: Detalles completos en el dossier del producto (PD).\n\n3. **M\u00f3dulo 5 del Dossier de Producto**:\n   - Para productos farmac\u00e9uticos multisource, se requiere la presentaci\u00f3n de secciones espec\u00edficas del M\u00f3dulo 5, que incluye:\n     - Tabla de contenido para el M\u00f3dulo 5.\n     - Listado tabular de todos los estudios cl\u00ednicos.\n     - Informes de estudios cl\u00ednicos, incluyendo estudios biofarmac\u00e9uticos y de bioequivalencia.\n\n4. **Formato de Presentaci\u00f3n**:\n   - Todos los documentos deben ser presentados en formato CTD (Common Technical Document), aunque el contenido puede variar.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la regulaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Finished Pharmaceutical Product)**: Producto farmac\u00e9utico terminado que se eval\u00faa.\n- **API (Active Pharmaceutical Ingredient)**: Sustancia activa en un producto farmac\u00e9utico.\n- **CEP (Certificate of Suitability)**: Certificado que asegura que un producto cumple con los est\u00e1ndares de la Farmacopea Europea.\n- **APIMF (Active Pharmaceutical Ingredient Master File)**: Archivo maestro que contiene informaci\u00f3n sobre el ingrediente farmac\u00e9utico activo.\n- **CTD (Common Technical Document)**: Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n t\u00e9cnica sobre productos farmac\u00e9uticos. \n\nEste resumen destaca los requisitos y procedimientos clave para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, as\u00ed como las entidades y t\u00e9rminos relevantes en el contexto de la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: dossier, bioanalytical methods, case-report forms, CTD format, literature references"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c79f3868-0e6b-458a-a17e-354a38d4f9ae", "node_type": "4", "metadata": {"page_label": "438", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.3.1.3 In vitro\u2013in vivo correlation study reports if available\n# 5.3.1.4 Reports of bioanalytical and analytical method for human studies<sup>2</sup>\n\n\u2014 5.3.7 Case-report forms (CRFs) and individual patient listings: only CRFs for subjects who experienced serious adverse events should be included. All CRFs should be available upon request.\n\n- 5.4 Literature references\n\nFor guidance regarding biowaivers, refer to the biowaiver implementation documents available on the Prequalification web site. For guidance regarding comparator products, refer to the information available under Guidance on bioequivalence studies on the Prequalification web site.\n\n## 7. Guidance on format and presentation of a product dossier in common technical document format\n\n### 7.1 Guidance on format\n\nThroughout the CTD, the information should be displayed in an unambiguous and transparent manner. Text and tables should be prepared using margins that allow the document to be printed on both A4-sized paper (European Union and Japan) and 8.5 \u00d7 11-inch paper (US). The left-hand margin should be sufficiently large that information is not obscured whatever the method of binding. Fonts for text and tables should be of a style and size large enough to be easily legible, even after photocopying. Times New Roman, 12-point font is recommended for narrative text.\n\nAcronyms and abbreviations should be defined the first time they are used in each module.\n\nReferences should be cited in accordance with the current edition of the *Uniform requirements for manuscripts submitted to biomedical journals*, International Committee of Medical Journal Editors (ICMJE).<sup>3</sup> Copies of relevant pages of references should be provided, with a copy of the full article in the case of a publication. English translations should be provided as necessary.\n\n### 7.2 Guidance on presentation\n\nThe paper copies of the application should be bound for easy access to information.\n\n----\n\n<sup>2</sup> Bioanalytical or analytical methods for BA/BE or in vitro dissolution studies should ordinarily be provided in the individual clinical study reports. However, where a method is used in multiple studies, the method and its validation should only be included once in section 5.3.1.4 and referenced in the appropriate individual clinical study reports.\n\n<sup>3</sup> The first edition of the *Uniform requirements for manuscripts submitted to biomedical journals* was conceived by the Vancouver Group and was published in 1979.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0d9573e4aa7c58ae4766b42b5806d5cf4ace08d47f375f4d99cad72f0c0038c3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5.3.1.3 In vitro\u2013in vivo correlation study reports if available\n# 5.3.1.4 Reports of bioanalytical and analytical method for human studies<sup>2</sup>\n\n\u2014 5.3.7 Case-report forms (CRFs) and individual patient listings: only CRFs for subjects who experienced serious adverse events should be included. All CRFs should be available upon request.\n\n- 5.4 Literature references\n\nFor guidance regarding biowaivers, refer to the biowaiver implementation documents available on the Prequalification web site. For guidance regarding comparator products, refer to the information available under Guidance on bioequivalence studies on the Prequalification web site.\n\n## 7. Guidance on format and presentation of a product dossier in common technical document format\n\n### 7.1 Guidance on format\n\nThroughout the CTD, the information should be displayed in an unambiguous and transparent manner. Text and tables should be prepared using margins that allow the document to be printed on both A4-sized paper (European Union and Japan) and 8.5 \u00d7 11-inch paper (US). The left-hand margin should be sufficiently large that information is not obscured whatever the method of binding. Fonts for text and tables should be of a style and size large enough to be easily legible, even after photocopying. Times New Roman, 12-point font is recommended for narrative text.\n\nAcronyms and abbreviations should be defined the first time they are used in each module.\n\nReferences should be cited in accordance with the current edition of the *Uniform requirements for manuscripts submitted to biomedical journals*, International Committee of Medical Journal Editors (ICMJE).<sup>3</sup> Copies of relevant pages of references should be provided, with a copy of the full article in the case of a publication. English translations should be provided as necessary.\n\n### 7.2 Guidance on presentation\n\nThe paper copies of the application should be bound for easy access to information.\n\n----\n\n<sup>2</sup> Bioanalytical or analytical methods for BA/BE or in vitro dissolution studies should ordinarily be provided in the individual clinical study reports. However, where a method is used in multiple studies, the method and its validation should only be included once in section 5.3.1.4 and referenced in the appropriate individual clinical study reports.\n\n<sup>3</sup> The first edition of the *Uniform requirements for manuscripts submitted to biomedical journals* was conceived by the Vancouver Group and was published in 1979.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2495, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "54298ac0-53f7-4c73-9d3c-ef9514bc5b5f": {"__data__": {"id_": "54298ac0-53f7-4c73-9d3c-ef9514bc5b5f", "embedding": null, "metadata": {"page_label": "439", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Each binder should be labelled with the proprietary name (if applicable) and the non-proprietary name of the FPP (e.g. \u201cName ABC\u201d Abacavir (as sulfate) 300 mg tablets) and the company name of the applicant. For ease of reference, the following information could also be included on the label of each binder (space permitting): the volume number for that binder (out of the total number of volumes for that module), the section(s) contained within each volume and the date of the application (month and year), e.g.:\n\n```\nFPP \u201cName ABC\u201d\nNonproprietary name\nApplicant \u201cXYZ\u201d\nModule 3 \u2014 Quality\nVolume 1 of 3\nModule 3.1 \u2014 3.2.S.3\nMonth/year\n```\n\n8. **Variations**\n\nAll variation applications should be submitted using the CTD format, regardless of the original PD format.\n\nIn the case of the filing of a variation, applicants would normally provide only the relevant modules or sections affected by the change. For example, if the variation was for a change in the shelf-life of the FPP, only those sections affected by the change would need to be submitted (10).\n\nAn updated and annotated QIS should be provided with each variation application.\n\n# References\n\n1. Procedure for prequalification of pharmaceutical products. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 10.\n\n2. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Efficacy (ICH M4E) together with the complementary ICH Questions and Answers documents for the above mentioned guidelines.\n\n3. Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (ICH M4) (2003): Efficacy.\n\n4. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality (ICH M4Q) (2003): Quality.\n\n5. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety (ICH M4S) (2003): Safety.\n\n6. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability In: *WHO Expert Committee on*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre c\u00f3mo etiquetar los archivos de solicitudes de productos farmac\u00e9uticos, espec\u00edficamente en el contexto de la presentaci\u00f3n de variaciones en la documentaci\u00f3n regulatoria. Se enfatiza la importancia de incluir tanto el nombre comercial como el nombre no propietario del producto farmac\u00e9utico, as\u00ed como informaci\u00f3n adicional que facilite la identificaci\u00f3n del contenido del archivo. Adem\u00e1s, se establece que todas las solicitudes de variaciones deben seguir el formato del Documento T\u00e9cnico Com\u00fan (CTD) y que solo se deben presentar los m\u00f3dulos o secciones relevantes que se vean afectados por el cambio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n adicional se sugiere incluir en la etiqueta de cada carpeta, adem\u00e1s del nombre del FPP y el nombre del solicitante?**\n   - Se sugiere incluir el n\u00famero de volumen de la carpeta (de un total de vol\u00famenes para ese m\u00f3dulo), las secciones contenidas en cada volumen y la fecha de la solicitud (mes y a\u00f1o).\n\n2. **\u00bfQu\u00e9 se debe proporcionar junto con cada solicitud de variaci\u00f3n y por qu\u00e9 es importante?**\n   - Se debe proporcionar un QIS (Resumen de Informaci\u00f3n de Calidad) actualizado y anotado con cada solicitud de variaci\u00f3n. Esto es importante para asegurar que la informaci\u00f3n sobre la calidad del producto se mantenga actualizada y refleje los cambios realizados.\n\n3. **\u00bfCu\u00e1l es el procedimiento recomendado para la presentaci\u00f3n de solicitudes de variaciones en comparaci\u00f3n con la presentaci\u00f3n original?**\n   - Todas las solicitudes de variaciones deben ser presentadas utilizando el formato CTD, independientemente del formato original de la presentaci\u00f3n. Adem\u00e1s, solo se deben presentar los m\u00f3dulos o secciones que se vean afectados por el cambio, lo que simplifica el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estudios de Correlaci\u00f3n In Vitro-In Vivo**:\n   - Secci\u00f3n 5.3.1.3 menciona la inclusi\u00f3n de informes de estudios de correlaci\u00f3n in vitro-in vivo si est\u00e1n disponibles.\n\n2. **M\u00e9todos Bioanal\u00edticos y Anal\u00edticos**:\n   - Secci\u00f3n 5.3.1.4 se refiere a los informes de m\u00e9todos bioanal\u00edticos y anal\u00edticos para estudios en humanos.\n\n3. **Formularios de Informes de Casos (CRFs)**:\n   - Secci\u00f3n 5.3.7 establece que solo se deben incluir CRFs de sujetos que experimentaron eventos adversos graves, y que todos los CRFs deben estar disponibles a solicitud.\n\n4. **Referencias Literarias**:\n   - Secci\u00f3n 5.4 menciona la necesidad de incluir referencias literarias y proporciona orientaci\u00f3n sobre biowaivers y productos comparadores.\n\n5. **Formato y Presentaci\u00f3n del Dossier del Producto**:\n   - Secci\u00f3n 7 proporciona directrices sobre el formato y la presentaci\u00f3n del dossier en el formato del documento t\u00e9cnico com\u00fan (CTD).\n   - Se recomienda el uso de m\u00e1rgenes adecuados para impresi\u00f3n en papel A4 y 8.5 \u00d7 11 pulgadas, y el uso de la fuente Times New Roman en tama\u00f1o 12 puntos para asegurar la legibilidad.\n\n6. **Citaci\u00f3n de Referencias**:\n   - Las referencias deben citarse seg\u00fan los *Uniform requirements for manuscripts submitted to biomedical journals* del ICMJE, y se deben proporcionar copias de las p\u00e1ginas relevantes y traducciones al ingl\u00e9s si es necesario.\n\n7. **Accesibilidad de la Informaci\u00f3n**:\n   - Se sugiere que las copias en papel de la solicitud est\u00e9n encuadernadas para facilitar el acceso a la informaci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **CTD (Common Technical Document)**: Formato para la presentaci\u00f3n de informaci\u00f3n sobre productos.\n- **CRFs (Case-Report Forms)**: Formularios utilizados para documentar eventos adversos en estudios cl\u00ednicos.\n- **ICMJE (International Committee of Medical Journal Editors)**: Comit\u00e9 que establece normas para la citaci\u00f3n de referencias en publicaciones biom\u00e9dicas.\n- **Biowaivers**: Exenciones relacionadas con estudios de bioequivalencia.\n\nEste resumen destaca los aspectos m\u00e1s relevantes y las entidades mencionadas en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de su contenido y directrices.", "excerpt_keywords": "Keywords: pharmaceutical regulation, Common Technical Document, variation applications, quality information summary, product labeling"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b4a14a89-c3a5-4803-acc4-0b1094d5d162", "node_type": "4", "metadata": {"page_label": "439", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Each binder should be labelled with the proprietary name (if applicable) and the non-proprietary name of the FPP (e.g. \u201cName ABC\u201d Abacavir (as sulfate) 300 mg tablets) and the company name of the applicant. For ease of reference, the following information could also be included on the label of each binder (space permitting): the volume number for that binder (out of the total number of volumes for that module), the section(s) contained within each volume and the date of the application (month and year), e.g.:\n\n```\nFPP \u201cName ABC\u201d\nNonproprietary name\nApplicant \u201cXYZ\u201d\nModule 3 \u2014 Quality\nVolume 1 of 3\nModule 3.1 \u2014 3.2.S.3\nMonth/year\n```\n\n8. **Variations**\n\nAll variation applications should be submitted using the CTD format, regardless of the original PD format.\n\nIn the case of the filing of a variation, applicants would normally provide only the relevant modules or sections affected by the change. For example, if the variation was for a change in the shelf-life of the FPP, only those sections affected by the change would need to be submitted (10).\n\nAn updated and annotated QIS should be provided with each variation application.\n\n# References\n\n1. Procedure for prequalification of pharmaceutical products. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 10.\n\n2. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Efficacy (ICH M4E) together with the complementary ICH Questions and Answers documents for the above mentioned guidelines.\n\n3. Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (ICH M4) (2003): Efficacy.\n\n4. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality (ICH M4Q) (2003): Quality.\n\n5. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety (ICH M4S) (2003): Safety.\n\n6. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability In: *WHO Expert Committee on*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "0bbaadba403fdcfa5ee820c66b77dbb566059acd0165ce9753aeace94d834979", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Each binder should be labelled with the proprietary name (if applicable) and the non-proprietary name of the FPP (e.g. \u201cName ABC\u201d Abacavir (as sulfate) 300 mg tablets) and the company name of the applicant. For ease of reference, the following information could also be included on the label of each binder (space permitting): the volume number for that binder (out of the total number of volumes for that module), the section(s) contained within each volume and the date of the application (month and year), e.g.:\n\n```\nFPP \u201cName ABC\u201d\nNonproprietary name\nApplicant \u201cXYZ\u201d\nModule 3 \u2014 Quality\nVolume 1 of 3\nModule 3.1 \u2014 3.2.S.3\nMonth/year\n```\n\n8. **Variations**\n\nAll variation applications should be submitted using the CTD format, regardless of the original PD format.\n\nIn the case of the filing of a variation, applicants would normally provide only the relevant modules or sections affected by the change. For example, if the variation was for a change in the shelf-life of the FPP, only those sections affected by the change would need to be submitted (10).\n\nAn updated and annotated QIS should be provided with each variation application.\n\n# References\n\n1. Procedure for prequalification of pharmaceutical products. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 10.\n\n2. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Efficacy (ICH M4E) together with the complementary ICH Questions and Answers documents for the above mentioned guidelines.\n\n3. Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (ICH M4) (2003): Efficacy.\n\n4. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality (ICH M4Q) (2003): Quality.\n\n5. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety (ICH M4S) (2003): Safety.\n\n6. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability In: *WHO Expert Committee on*", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2145, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}, "5f237146-bcd6-4eb1-8099-40a0bdbb7324": {"__data__": {"id_": "5f237146-bcd6-4eb1-8099-40a0bdbb7324", "embedding": null, "metadata": {"page_label": "440", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 7.\n\n7. Bioequivalence trial information form (BTIF) on: http://apps.who.int/prequal/.\n\n8. Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part: on: http://apps.who.int/prequal/.\n\n9. Quality overall summary - product dossier (QOS-PD): on: http://apps.who.int/prequal/.\n\n10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009 (WHO Technical Report Series, No. 953), Annex 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito del formulario de informaci\u00f3n sobre ensayos de bioequivalencia (BTIF) mencionado en el documento?**\n   - El formulario de informaci\u00f3n sobre ensayos de bioequivalencia (BTIF) tiene como prop\u00f3sito recopilar y estandarizar la informaci\u00f3n necesaria para evaluar la bioequivalencia de productos farmac\u00e9uticos gen\u00e9ricos en comparaci\u00f3n con los productos de referencia. Esto es esencial para garantizar que los medicamentos gen\u00e9ricos sean equivalentes en t\u00e9rminos de eficacia y seguridad.\n\n2. **\u00bfD\u00f3nde se puede encontrar la gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos)?**\n   - La gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para un producto farmac\u00e9utico terminado multisource (gen\u00e9rico) se puede encontrar en el sitio web de la Organizaci\u00f3n Mundial de la Salud (OMS) en la siguiente direcci\u00f3n: http://apps.who.int/prequal/.\n\n3. **\u00bfQu\u00e9 informe de la OMS se menciona en relaci\u00f3n con las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados?**\n   - Se menciona el informe de la OMS titulado *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* publicado en 2009 (WHO Technical Report Series, No. 953), que incluye un anexo sobre las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados.\n\n### Resumen de nivel superior del contexto:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que proporciona especificaciones para preparaciones farmac\u00e9uticas, destacando la importancia de la bioequivalencia y la calidad en los productos farmac\u00e9uticos gen\u00e9ricos. Incluye referencias a formularios y gu\u00edas disponibles en el sitio web de la OMS, as\u00ed como a informes anteriores que abordan temas relacionados con la estabilidad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Carpetas**:\n   - Cada carpeta debe llevar la siguiente informaci\u00f3n:\n     - Nombre comercial (si aplica) y nombre no propietario del producto farmac\u00e9utico (FPP).\n     - Nombre de la empresa solicitante.\n     - N\u00famero de volumen de la carpeta (de un total de vol\u00famenes para ese m\u00f3dulo).\n     - Secciones contenidas en cada volumen.\n     - Fecha de la solicitud (mes y a\u00f1o).\n\n   **Ejemplo de Etiqueta**:\n   ```\n   FPP \u201cName ABC\u201d\n   Nonproprietary name\n   Applicant \u201cXYZ\u201d\n   Module 3 \u2014 Quality\n   Volume 1 of 3\n   Module 3.1 \u2014 3.2.S.3\n   Month/year\n   ```\n\n2. **Solicitudes de Variaciones**:\n   - Todas las solicitudes de variaciones deben presentarse utilizando el formato del Documento T\u00e9cnico Com\u00fan (CTD), sin importar el formato original.\n   - Solo se deben presentar los m\u00f3dulos o secciones relevantes que se vean afectados por el cambio (por ejemplo, cambios en la vida \u00fatil del FPP).\n   - Es necesario proporcionar un Resumen de Informaci\u00f3n de Calidad (QIS) actualizado y anotado con cada solicitud de variaci\u00f3n.\n\n3. **Importancia del QIS**:\n   - Mantiene la informaci\u00f3n sobre la calidad del producto actualizada y refleja los cambios realizados en la solicitud.\n\n### Entidades Clave\n- **FPP**: Producto Farmac\u00e9utico Final.\n- **CTD**: Documento T\u00e9cnico Com\u00fan.\n- **QIS**: Resumen de Informaci\u00f3n de Calidad.\n- **WHO**: Organizaci\u00f3n Mundial de la Salud.\n- **M\u00f3dulos**: Secciones espec\u00edficas dentro de la documentaci\u00f3n regulatoria. \n\nEste resumen destaca la importancia del etiquetado adecuado y el cumplimiento de los formatos establecidos para la presentaci\u00f3n de solicitudes de variaciones en productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: bioequivalence, pharmaceutical preparations, WHO guidelines, stability testing, generic products"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "69a9048c-3ef4-4ec1-8d12-bb6788c37667", "node_type": "4", "metadata": {"page_label": "440", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 7.\n\n7. Bioequivalence trial information form (BTIF) on: http://apps.who.int/prequal/.\n\n8. Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part: on: http://apps.who.int/prequal/.\n\n9. Quality overall summary - product dossier (QOS-PD): on: http://apps.who.int/prequal/.\n\n10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009 (WHO Technical Report Series, No. 953), Annex 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961"}, "hash": "7ab30e800bb1046f89f77f320f9341855de1ff849b4b660711fc0886a143b50b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 7.\n\n7. Bioequivalence trial information form (BTIF) on: http://apps.who.int/prequal/.\n\n8. Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part: on: http://apps.who.int/prequal/.\n\n9. Quality overall summary - product dossier (QOS-PD): on: http://apps.who.int/prequal/.\n\n10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009 (WHO Technical Report Series, No. 953), Annex 2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 770, "metadata_seperator": "\n", "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"a31587f5-80d9-4809-ba6c-865cc6d57693": {"doc_hash": "9eb295e8598f87ca5cfdbf16b2255985bc21399e74ece223b0e1a608a6a6e142", "ref_doc_id": "6a6ef094-cfc3-49bc-96bf-f3a9cf1b9eaa"}, "b8f2b78f-8b97-4eae-a1fd-f965eca10ede": {"doc_hash": "57e3ff6c08455d2350f1d2637c91bc2337da4b277049bf7e929b4bc0b5fc1497", "ref_doc_id": "e754d05f-506f-4b4f-a402-b86461b618aa"}, "1376bc00-53db-495a-8f54-b2bb554036fe": {"doc_hash": "8c9a067d39234073ea173b1289ccef3955ffb4baa1e566eb02958c54cadbe33c", "ref_doc_id": "c963115b-9aa0-4e23-a1e7-76d051e60ab3"}, "684152ea-734c-47e8-88be-4f84085af171": {"doc_hash": "2be26d30accf118679262ef79846eec5027ce766030f3ff032264aa02c70b196", "ref_doc_id": "a59ec511-ba1c-4bd0-817a-b3db692fc091"}, "ffa1bc67-b137-4238-be34-8e4fd01c28ea": {"doc_hash": "e48f870276e6a7a07943684ebaf281d0539e6d81da4b629f98e3d3142f907940", "ref_doc_id": "73edfbe1-7061-4358-a6f4-32dedc58c618"}, "a1ecab18-de64-436a-8798-0d489a43a096": {"doc_hash": "2515478723d7eed982fc0e9d441caf91e381823c2a51b688dd2fbafc1cbfeaa2", "ref_doc_id": "e852ec3e-5c14-408f-ad9a-ffc3506ebb54"}, "d8f8e63b-79a0-4780-bb54-004cf6cac52d": {"doc_hash": "137b09cd3ddb78d9c5149797e8ec2994509beaad783472a93f030da48bc009b0", "ref_doc_id": "1e995c61-7702-49bd-94e2-3ec7b9a869f2"}, "4ec10afe-30bc-42d0-962b-cf9155c2cfe8": {"doc_hash": "f2dc94a196b723036d9ff59843439bd7760f4ea560e155fa10edac7f4f4b7cc9", "ref_doc_id": "fd2485c8-6655-4995-aa39-2fdb789fd598"}, "f86065bd-66f5-40df-ae5e-68b8d956dda3": {"doc_hash": "bde0e9984376a4320febca202806c2f418d731e7db00f91595de106173b31368", "ref_doc_id": "5ed767ab-bedc-4e23-92fc-fca7dd7cbabb"}, "8d980cc6-49e5-4aea-bdfb-290f64850447": {"doc_hash": "883d4e99d6fd1713e40377b36a58520fb9ab204e3af2dd3680d5b13ce6780821", "ref_doc_id": "d8f891e8-8c19-415a-af50-d6c4dda34d92"}, "1c6b71ab-1bbe-498b-b331-3c0f4c1c4bf2": {"doc_hash": "2577ed68f3f911ffc8d8bbb190e504b223e6f53696401bfb4dd6bd7fd50728db", "ref_doc_id": "3dd9cfa2-f03d-4d4c-bd2c-67586ce1fb35"}, "a37ff2e6-b21b-487a-b9bf-b84829cea23b": {"doc_hash": "cf1973a8851ccbe87f95a677d3ebe53b21e3d0f714ecf099355bbea95e2e85bd", "ref_doc_id": "3e87e20c-d4a0-4c89-a29a-8a5d0760116e"}, "139e3cf3-b165-4a36-910a-0c528b03bb20": {"doc_hash": "1caa3790cee4e259d024e7ed080ea0d4346e5b37f6ab98aa69bab5a334595fe8", "ref_doc_id": "c8bfc126-4867-494f-8b13-5cf80484ad1d"}, "1c371707-9d18-45d3-b60a-882483ac3f24": {"doc_hash": "93eab879e9ca551029503682fb42fb797bc2de5ba97c4ed1722acd1c56a7b95b", "ref_doc_id": "1ec53c41-f4c8-4d4e-a0b3-80a38bdbc8fc"}, "706a44cc-c5f7-4c06-80ff-6dc663e5e3f7": {"doc_hash": "bb7fbd1407c0d41dcbf50d120cbd11630f2686186694018888a84b0680318c80", "ref_doc_id": "c2383af1-4acf-4bcd-a8dd-c2a52649cbb7"}, "244a31bc-dbb4-41c1-950a-dbd88695f224": {"doc_hash": "f1229532fe76b75ee639d1d08793ba5fc7dddc734d393564dea1f1cb45a0b86e", "ref_doc_id": "6500ca0c-105b-4a3f-baf7-7c711681d3c6"}, "56a41663-bc1a-47c1-8b8e-c417dbf9da4e": {"doc_hash": "e1b60f6cd6240c39b94eb983b9ad9f5138f42120827296f0db6c367f84ad3ead", "ref_doc_id": "67ef6095-1560-47a4-b7ae-15e54bb45a6b"}, "c7b70f42-c995-4d85-a9a9-4c3530365396": {"doc_hash": "d9a7d0ab05e91562355c7f9d4180dce254cddeb2efe5c62bd1e7a090dab2026c", "ref_doc_id": "93aa5da2-439c-4cda-b1a3-441ce01c6961"}, "6806560e-3e9c-4257-ac4e-0a84d41a1961": {"doc_hash": "c038c937d9aa3416fb1c60d23dc876715d6d3aabd08c36475c354d0776a45149", "ref_doc_id": "82cde47b-c7e3-4546-80f5-6c3ef0117d3c"}, "c2809b67-3469-4a57-8e29-ccf56d8e06cd": {"doc_hash": "141ea149374c10b521e924c4fbc9c772a2b7943d58054c20f69cc5285f10a55f", "ref_doc_id": "5c1196e0-1ef0-4d74-8944-72040e76d9ca"}, "e80a7397-6b1a-4efa-8a4b-500e045757f5": {"doc_hash": "1b77b0c97693fb166a97f3b407dd59b19d6cc32ee439ec2eb4a0062af8d21241", "ref_doc_id": "1934e0f7-e4ce-4eee-a7bc-722897bf7e30"}, "50477378-2887-453f-ac6c-7b6e79633095": {"doc_hash": "12f22b4d73b9c3e57d27872ddda10f8c79472e41bcc13d4d77f7de53952d8024", "ref_doc_id": "7028b56b-2994-46d1-82dc-9277c758f3e7"}, "40ac988c-786a-4169-9dd0-bb88047256ea": {"doc_hash": "f4aaf738f4bba089bff2d68ce2b277f5cdd79930aed4500cdb6ef8e6493872b4", "ref_doc_id": "28274d98-b7c5-4399-ba80-8aa8a181a954"}, "4e3c8add-2de2-4754-9221-cecf48510225": {"doc_hash": "85dd62adc4231009df21d93293b5fa18f5c5cab8aeca5b89b96c589ced027762", "ref_doc_id": "962f93e4-ba47-4cdf-83cf-de27676441ec"}, "f535be60-caa2-4dce-9c8e-357625b5ace9": {"doc_hash": "ba09b6045b6252f0db7899fab7798f3812b89ad643e6ac66186cf91ac1e8f966", "ref_doc_id": "890d8145-8a8c-441e-b648-5c670348eedd"}, "46bcff2e-e72f-4633-8c60-988b689058a0": {"doc_hash": "54a299c6726d2a4a33b6f33cc92c7cdda555ce13e92cd3050bd60273ff0054e3", "ref_doc_id": "ca2b0f9f-d597-4167-a55d-194ff807b120"}, "f30e4055-334a-429f-a3ec-019f8c0827d3": {"doc_hash": "3ec99db3495590eabeba744a5480522a4a0746da540a145cbc1843c0e1e970d8", "ref_doc_id": "858e9273-6024-4417-abc7-428e6d7556ca"}, "1e656917-84f3-4359-898a-18076fe0501c": {"doc_hash": "ca8e816b20c4c3ec7630a7a6f592fa848140941c8f3892ae09514cfbf10fd0e0", "ref_doc_id": "83944ce6-be92-4986-826b-98a11f37d929"}, "e5d4ef04-9a29-4c51-aee8-71564d5541ea": {"doc_hash": "e04875675c0e11ef6199f5077480af2fb87f36ae21c29f78437337d3c4af2663", "ref_doc_id": "7d2eb902-2a57-4609-8a86-8a8874e0a8b2"}, "244bacfa-f2ef-491c-a309-9bfccff41560": {"doc_hash": "5296d67ed2dcd8bc257acbef4937c9057819693b1bc170519495c253b7ab9e3d", "ref_doc_id": "a0931613-4d59-4955-9199-fcb35bd775bc"}, "c353204a-4539-4877-8d2f-920d257a9348": {"doc_hash": "f679b7911fe5951cd6609100f0abfeeb4081712f954c065bf0432e2b7dbfd74a", "ref_doc_id": "7e892882-30bc-4641-8370-d2bc7584b710"}, "b40c9031-0f19-4a9b-9733-dcfdc05b8b7a": {"doc_hash": "2224e07f64dfb34237e2b8e71013466900784c1edb798f4c1b0f35d64410678d", "ref_doc_id": "b2115570-1b4e-4bd4-a479-f6eb1fbcb4a4"}, "b1719e63-8e25-4dbe-9c52-34584f173a6b": {"doc_hash": "d456c8923b5b8ecb50e75bacbcaad68d9f90f9c5a7285e3259ed4b681f04c88f", "ref_doc_id": "11d257e1-c843-48e3-b272-d43c0ba75edb"}, "0a5b9ad6-787b-4d09-adf2-6dce80785c54": {"doc_hash": "123ca841a134e6fd94db9f13daed5c2570c8319610d8eec1848f6ec2a2cdf97a", "ref_doc_id": "b178ca83-ad45-4659-b54b-8ad877711275"}, "b712c83b-cf5d-4f8c-ac1a-b11f05f8d68f": {"doc_hash": "4f76cf30fc1099a1f222fd3a333f5f4b73e0a0e5442d7f6cbb5c233629fe328c", "ref_doc_id": "e288a05f-9d27-4894-9c72-312ce8b11337"}, "e1f728f6-2cba-45d2-a78b-54ffdf5a239f": {"doc_hash": "0b2904d1e4ac5ed44b6a92383efb693117e7da37ce05e97ddb32d68218cacfc6", "ref_doc_id": "8013bd4d-774e-43fc-a3a6-8e48d19fae17"}, "43036a63-3ff0-4a3b-98f0-7b847bdd7a6a": {"doc_hash": "6c34bee1212fee14f426071fe88faca20c32f94cb04001427354510c4a3ca968", "ref_doc_id": "9834bc1c-22b5-4a86-94e3-e1e43e85e974"}, "b94bef14-cf9e-4fc1-8980-b0f656f5e6e6": {"doc_hash": "17a5393957163860a26e428e4c387270b3c7840fb09bea8ea880617683afe949", "ref_doc_id": "7f8bf3f0-dc32-4b98-af10-0e9489068176"}, "1039ab9a-2418-408c-8868-416ed97f22ca": {"doc_hash": "e02998845372997e14692e010573dbf461b65b8f3068e310fea3582e79e74aad", "ref_doc_id": "a7c171f4-c774-4d8f-a95e-31ade53f23bd"}, "70301980-32b3-4bb6-99e5-59fd0e688887": {"doc_hash": "e9e207a875c4110cd635cabbb1fe6398dd675df5ca7414bae407bd8c69086c2d", "ref_doc_id": "1ea1f372-1c23-4a48-8f69-f34b0e1ea580"}, "2c61ee16-b87c-48e6-9186-51b71cec377e": {"doc_hash": "b9c0b18beb09bbff4295ad9af2b071621bdb393a23ecda7ba06ad84efed7074c", "ref_doc_id": "3521c9d5-63ab-4889-9c96-72cbcd59bb52"}, "29d1fae7-8d93-437f-b8d1-b9acb29548eb": {"doc_hash": "5dfcd379076527ecca761c98de1b3d2f43b9fa0f9f349e737329dd7070db9e2b", "ref_doc_id": "d6deb826-0abe-4faf-bc01-dc256f059da7"}, "df576e40-de5a-455a-97b7-1315332744a9": {"doc_hash": "f6e58ac694a87a57d3b7fee300a181195498b39f61980a04459157735c674090", "ref_doc_id": "e6aba167-edd1-4aeb-abca-e7bcb31731b9"}, "b72473e7-dcf5-462c-93c6-1a0c8d6fae57": {"doc_hash": "bf9d5ccaef1acdfe514ff62f905a9d3c39ceebb78b1d51fba08714f4e2da8de6", "ref_doc_id": "7c369f30-cee6-4cc7-9639-358aa3e1bad2"}, "981e7f2d-0535-45b5-a00c-509383e0840c": {"doc_hash": "80fb8835c0f1ea6bf57a2b11c41f68911e47ebc8b7546eea12d94cd54acdd372", "ref_doc_id": "f2709bb6-7851-466e-af5c-e6bf28107485"}, "95fa52ac-7261-4be6-a584-89687d11c5ba": {"doc_hash": "d7aa0a03db4d59a51b46170295f6d91724c027f57cd04ef8a8131c58dec88536", "ref_doc_id": "53db57f2-b686-4280-84e1-50c909e495fb"}, "87811e47-752d-4576-876c-c0d3d99665e6": {"doc_hash": "83e63bb7917db726afddf13918357af3a42b0ba1a042f4962d6ec8fab1ec970c", "ref_doc_id": "1046723d-2572-45db-9fa0-a3a684a20ec9"}, "3347c8eb-f557-4f31-af2b-37b7324fb09d": {"doc_hash": "3f3c29a2ef7f36d38eefc9094fdd7fa4c921c2f256a9459be634a61422db6329", "ref_doc_id": "36cff4f7-671f-4cad-acc9-7c1bc4e09f4b"}, "eb56b330-ba5c-4bc4-b603-2df536ebb47f": {"doc_hash": "e5fc4d02d1f8b44f06192326e398fe70a82dd5055210c497e68737c8f2ac243c", "ref_doc_id": "bc0ad7e0-8243-4837-84f8-497dab1b19ff"}, "1a2f9343-ce5b-427e-8697-d082ec8b5126": {"doc_hash": "5a1b19c76dd38ae99707e569903a4808dd6a30439e7c440b958ff82f949bd573", "ref_doc_id": "7bc6d502-8762-4cf9-8534-12cb7c55f9e3"}, "b9c1f33f-a21e-4a1e-9ba6-84f1d875f8c4": {"doc_hash": "148afbdbc876787652aaea08a78280a57343977d054cc143dbbe964683e0a805", "ref_doc_id": "19dccc4c-6b5e-4816-a660-c1de83206033"}, "32db387a-b2af-4e41-8049-63230d49b395": {"doc_hash": "c9408c81ef68899b3a66eeed6979a82bab07ff4f763066d871354334888f6307", "ref_doc_id": "b8b39cd2-537d-41bb-9b8e-db31a27218f0"}, "5fa44765-a1ed-461b-9a17-ff548e3dbbc8": {"doc_hash": "b0cc90b959c95f1099fc0defb2facf7fb060cf0a76ba543813bf7958145c3322", "ref_doc_id": "21c057ff-80f0-4c74-970b-85efb1b45776"}, "5be04e97-dd90-42e6-8f48-fed6c01cefe3": {"doc_hash": "c8a22b653a84e8c14849f389727f604329cf3da79e201184ec9ef261f18a753f", "ref_doc_id": "354bc02a-4e1c-47f3-a7f9-1a7434b7b944"}, "6cf14604-33db-4c89-82aa-9608279f1a21": {"doc_hash": "976f148971fe6890d92a6aac7378287486b6a6aa11d74351f209aaf30f15f656", "ref_doc_id": "029fdbe0-b0dc-48e2-9ad5-1d5882355445"}, "c3bb808f-8705-42da-b258-e8d8e8818aa4": {"doc_hash": "bff08baddf705ad060a805fd74ee85636a0d6fa63b033784acb58b2760c4bd0f", "ref_doc_id": "578a1f9a-5c3a-4f83-9bd3-cecea869edc2"}, "0d72cca8-2cfe-4d80-93d8-44b00852c8fe": {"doc_hash": "28589c293e799618ed72955b726afa0f6c66b734602dc15dfb2d082d2250933b", "ref_doc_id": "c688a84f-539f-41c4-944a-430f5b7f3294"}, "36d6631b-7702-4c7b-befd-8f39fce6a2c9": {"doc_hash": "8d05db18f5fa43e1c949ccbcde7e755cbd603fa9236ba691d970d450670265c5", "ref_doc_id": "558b4ae6-3fd2-46af-9672-bfcc3e76ea40"}, "ea0ffe74-7b38-48cc-a630-44d8541e9c77": {"doc_hash": "7b683a7cd1f1962271e64294f9be9ad08435dbce99d6136c895d3d8b6dbcdf7b", "ref_doc_id": "4d470028-b78e-436e-ba7d-6b59b593418c"}, "ac122610-e46f-4792-8cbd-3fc19d40f92d": {"doc_hash": "35e4271f45369df6c0faa4d57a311b67c7ed68c22796cd13f0afcf1702f55cec", "ref_doc_id": "cbd2c5d4-241d-4509-9841-cdb001ad0149"}, "16cd16d3-72f1-45d5-80b5-739d23fdf9f6": {"doc_hash": "c955e02f06d79c3dab85b5c8e206bcecb68e8e8678d8dfda9d7e4ccad1b594b6", "ref_doc_id": "a06d718b-4607-4c86-a9c3-dd5b6089e88d"}, "c2feba45-2e4d-4a22-b29d-813aa0654ee0": {"doc_hash": "a7b92d74ed8e36cf74d54d6f845cac5a8d2228f3549a67603c9280d5ad61ce9e", "ref_doc_id": "0403bbe6-f9ca-4ddf-b1b5-8fd54f73505d"}, "1242b20e-6ff8-491d-b960-ba331aacc7f8": {"doc_hash": "ef7b73078ed60fe9468d13dab2ead12ddbef7f65fb1669d1c324ab6abcbbf31b", "ref_doc_id": "2f850563-9241-4302-9568-eb85e14ede57"}, "b93eac3e-dc0c-42ec-80d8-0e50e65779f4": {"doc_hash": "cc50bf56f09342d4c08845d8d908cda51b027b6de19c0b644531dbaa2224e405", "ref_doc_id": "9d4aa148-243b-4dca-a061-e3a0480c1bd6"}, "f15c450b-21c3-4dc7-9621-eacd28689eab": {"doc_hash": "deb8cf6fcb6a5b9c485629c0ed0e867aa0388d945d1278cc914dd5bf2b4451f6", "ref_doc_id": "7385c5da-6f7c-466f-be7b-2f6fc8830d18"}, "44efd664-50a9-423b-9cf5-c94d7ceac684": {"doc_hash": "acb028e9fc159c777d0054c22bd90097c1e8fa1757154f73592cd669e7225e36", "ref_doc_id": "f359c971-0ddf-415b-9b3f-12ac4c54293b"}, "24d1aa3d-f3c4-44cf-8875-36ec3f4fe43a": {"doc_hash": "7f4d149f41fb08e7425240eab72938bcdea7347556222e76d071ca05e4cfe5d9", "ref_doc_id": "34b318e3-92af-428c-ab83-d12200205b1b"}, "99e4d7fc-0bb7-4fd7-a96a-a992d4440eb9": {"doc_hash": "a5e1d7bf17f3fc13b5614e770d882c240ecf5628b34d1c4288c0471b8ea68beb", "ref_doc_id": "972cc3cd-eb70-41c7-998d-08cfe2d94c14"}, "0ab2f86c-4e05-4827-9d78-31ed6db870ad": {"doc_hash": "7d737de7efacf334ab1711af24b8ae39592539781f8b0d2f4f123d12400a2224", "ref_doc_id": "e7792b55-ae8a-439c-be5f-0e7b6cde7d9c"}, "c4dc1831-7a7a-4ec0-842f-1a8e2c6407ab": {"doc_hash": "f68a7be31647b53d2651c353e1e490530696d28b6f17900ac0e0c2145038d9ef", "ref_doc_id": "ab770d45-947b-4b8c-be20-71b05a6e31a4"}, "3a40dc8f-f02e-4852-92b2-3e6e59f2f609": {"doc_hash": "73dad026464fea364001dd0c08ffb50761b05bfd4c42bfbc13abfbce59075847", "ref_doc_id": "35e7f3ca-b825-404c-91b1-53a00dddc5aa"}, "c34a58b8-6924-4a41-b918-433456f6e639": {"doc_hash": "a97e77c998efb5385b3362a5da96de8c8684456d514679430a200deb40e795ba", "ref_doc_id": "3259638f-4c0d-452a-93a1-bd2d1b0866e3"}, "abb4277d-ae9e-422d-ad20-de692a007b7b": {"doc_hash": "874bc9203a6b19d2cd82decb25ca4c6617dbf825a4fd82671ad727155bf49394", "ref_doc_id": "0047ba1a-3e68-47f8-b9eb-39feaf091cfb"}, "ed9819b5-1fd0-4ebd-9f5b-6a173b56f7ff": {"doc_hash": "2e981258d78be200244635e1935e1d8c306c593690a1ff0538f477345e828443", "ref_doc_id": "95f156ba-4603-449a-8285-4b92d1d80841"}, "7d3688c8-8707-4c44-aaf5-347975317eb2": {"doc_hash": "4c2f3e74acb21e9eaad22d2492e99d565128986d53a690d065ebf2bbda55419d", "ref_doc_id": "c89c5f9e-c1d8-4803-bb80-6221b8f6b131"}, "bcbbadd4-9664-4909-b472-e732179ab0cc": {"doc_hash": "f7b1c804b8ba700f7e00497aefaee77e5750462deef0b4ba113217da43549218", "ref_doc_id": "c7e2495b-99f0-48ff-9c4c-fa9978e99111"}, "6f1629b2-3e89-4256-86ef-7619a1761189": {"doc_hash": "cd10f57490b3ab3816ecab2ca672ff4c32de424313b88deb8c12ece4cca5b51d", "ref_doc_id": "94b1c634-0d86-46f1-951c-ef30ed9c2287"}, "3aaa60ec-9d5b-4f72-898e-c3996f001293": {"doc_hash": "90c31f6a9ee67287d45f8ad8ef08266270a7dc008327d373bbfc02d7f5e743d4", "ref_doc_id": "d15597a0-776e-4dca-ac6e-593a55ebc256"}, "1bea7730-0992-49d1-8bff-f10e485183f8": {"doc_hash": "88252cfb1a447b5a1dc9b45edd2955bc02c240a4a31bbbf3e9dfde5949b5d733", "ref_doc_id": "7ea24d60-7933-46f2-b85b-0b641832d927"}, "79a8960d-8976-42bc-b47c-593b0438894a": {"doc_hash": "bf3ce0ee8734502191d14e99a24661f165cc8fbef88fbd7f2bbcf45ba26b170e", "ref_doc_id": "2adec23b-e344-4ffa-8a54-c9c1ee8fb8e4"}, "5041f021-5224-4701-aaa4-81917fbcfca6": {"doc_hash": "d8449b0f65cb5795c282816b66635fd95af37495d7ca8cd93e13eaba36002cdb", "ref_doc_id": "5b27cfd1-6645-4e47-84e6-8ce6dfb2f491"}, "d5838c7f-b2dd-4006-b2ce-f76927c2db2f": {"doc_hash": "ae718738c0729fc415e9382fa2a499eb356018dbd917285b2ae6befd4a43b5fe", "ref_doc_id": "1d1cbdab-74ac-4489-8c0d-72223073dd35"}, "ce200727-3ba2-4149-b1d1-a4d8127a4db5": {"doc_hash": "76012e5704a85c26b005fbcc8da8fd79210f33b09e10749207534eefae20a3f9", "ref_doc_id": "f57177f4-3da1-400a-b3af-0aaa415f6838"}, "04376628-07b7-4fed-8993-c968dcdccd13": {"doc_hash": "fd0bbbb29a7e6dd8bcb147032516756b3e43d40b70eb78250209ab299fb1015b", "ref_doc_id": "858eb68a-5a72-4859-b4e7-12449b9c3c2a"}, "b1c80ef4-9fa6-4379-a50e-34e12f717087": {"doc_hash": "3cb21b8222cca7c9a36ff134dfb046d739a92ec26ada77bff9310cc43059433d", "ref_doc_id": "1b9dedcb-fe53-4715-8668-6ffb821bef57"}, "40b7fea4-8170-438d-bd3c-8711682ebec1": {"doc_hash": "162926623f1d361597f5ca3597d640946443fd0359a9c673b4d745a5c1bea823", "ref_doc_id": "54de6d59-2eed-4668-bc36-4b405330cba9"}, "2baaeac0-3da2-4794-a8cc-46dc65e9818a": {"doc_hash": "f2969a4d306dd87031bda98d1f6302103bf93c0c35f853248016fb08d63768f9", "ref_doc_id": "7a0374cf-db31-4df6-b1c5-e88e80c8755e"}, "c6d212b6-51f0-4c9d-ac3d-da282f274808": {"doc_hash": "c796898e3f02661b1fa5e5decf27d457bd71827f386d0135a1cea25851be190a", "ref_doc_id": "ba02e8f9-bd26-48a1-860f-feaa710fa1c0"}, "a284f471-df50-4b7e-8d42-b5e73a18156b": {"doc_hash": "2ff9ac748deb5067a99ce5a273c147db255a96b02926ebcfd2bc7cbc58e28fb0", "ref_doc_id": "2c00ab3a-349c-46fc-be03-e412490148dd"}, "76177e2f-e484-4f14-bb76-32c9f801fdf8": {"doc_hash": "ca2957afba5f2bd03de179e20cd750a65a4f29a1d4b09a3b14ffcd8302de458f", "ref_doc_id": "243e3a78-bb63-495d-a81e-2e09fdb2d3f5"}, "4ff3464c-65b3-4c83-b133-8f350c209acf": {"doc_hash": "a34381202b771ac9c7d9d711aeddeb722c89225d8bd776a0b4b1cd0960d5922d", "ref_doc_id": "06f98a8f-f3be-4136-8c86-56975dbc825c"}, "4946f072-18e1-4f55-9234-292e759fb79e": {"doc_hash": "eae6f08c9d0282633ed4f75dfcbe9a280640625cf35aea25e045625729850b13", "ref_doc_id": "a3a8efb1-dd28-4771-86f1-ecc02e4af675"}, "53ab478d-6501-4582-bb74-1256e4d15850": {"doc_hash": "ab01ca5439eda201ab64aa99bec38f4c335dc45b8c6ea32ff5fa8a226c081141", "ref_doc_id": "195520c2-8974-4a5b-80ab-424f6d7aa24f"}, "63885521-a2be-4269-9aac-2e1bcc1dfebe": {"doc_hash": "922cf438ab4ac4017ac4ca70b56e195bd24ff8831f3388392e9794e99d99feb5", "ref_doc_id": "83aad718-a0a9-4e33-9e0d-b5e62433e42c"}, "6bcb0688-ea6c-4e2a-9cf0-8918d51c2152": {"doc_hash": "cf54f88ee71a2b704f16960b75781275210e800a6eb80dc00e3868326c70b77f", "ref_doc_id": "a653341d-c746-4c05-b737-30dcda557729"}, "de8c1d12-f15c-4006-98b1-bf2e62e7b5ca": {"doc_hash": "27c9f5e5ed03bd494a95787db93d6cd8b08b88cd48147eb5f78d377805428085", "ref_doc_id": "8fcfdf11-b583-4247-b20c-27787e337598"}, "c68d64ae-6777-4bbe-912b-a56b98454000": {"doc_hash": "246e8fc09fdfb6d49d591732e5f0e1fcb1be3e008c366aeea737193f71bf5f4d", "ref_doc_id": "16898a0e-9a65-4267-9ff2-a09f28762b19"}, "128ac73b-dac6-4511-a87e-e3f9c8b839cb": {"doc_hash": "38c00c8297e32d3fa86ba9a71de60b55ceaf68bae547e9f3a39f2aca0ab4ba28", "ref_doc_id": "0888c69c-878b-4e1d-87a3-bf11351f4411"}, "ebbbcf7a-42f2-458b-b933-93aa7944914e": {"doc_hash": "4656fd65f72a750bee32817e8d566f1146d3b967e8116b4475df7c0f45eb4746", "ref_doc_id": "0ad953cb-de46-4ef8-972c-06d1b64601d3"}, "0f3680c6-556c-490d-a69b-ebbcbbb722d1": {"doc_hash": "9d142554d910239b1a99fb7159690f9e9b485bb0f4568e7d4d7bd1738f10ef7d", "ref_doc_id": "788bc9cc-9680-4e71-ab52-953614b5a72c"}, "c5488713-7813-4cf0-bf40-be4dc52c5c5c": {"doc_hash": "b13e6887d31ad523dba604684714ad733f7df316a88d22cadebc0e0e16a36cf2", "ref_doc_id": "24c480c9-75f4-44b8-8cc8-f800d35474d7"}, "30b9505c-7f22-4880-a817-b50f40b84fb9": {"doc_hash": "4dec59bccf90c9a78b27c43dce45baad76c7916b2c0ad09dfb6b4fb81246d408", "ref_doc_id": "597feba6-d4a7-46a7-9b4d-a18e03a5f246"}, "2060f4b8-afae-44bc-9689-b6a18dbcf4c3": {"doc_hash": "c92df31de4b33c2adfb3e5cfb474f082f0d0a52f510d7676ca2a5eff97365f1d", "ref_doc_id": "106b2a9b-27cb-4721-8947-b22239a78b2a"}, "e44102cb-7058-4c2f-a6f2-ac483141a9d4": {"doc_hash": "40a396dd7417c44dee617d6343be5b6af3a22a01eadd3290368b529ec8b13c79", "ref_doc_id": "4f428e5b-084c-401f-baf0-720797e09aa0"}, "ca9d46c7-4dc9-4cb3-a735-f3904eb54ff8": {"doc_hash": "588a195e9e86e7a64b8339f3e3ae4f9e929b1698dfa7b6d6625529a2308be095", "ref_doc_id": "93e0de66-568c-4ce4-9ab2-2f1a6dd9cf32"}, "cf80f5b0-1fb0-46d9-b684-56d263cefe9b": {"doc_hash": "7af0d440f0c5c1158717965c38618fb1c2456a66d2805e1f8289812c77a4d2c0", "ref_doc_id": "86e35b7d-b110-4385-bfdf-79f0a9610f8b"}, "954a9543-aa64-45f4-af7c-cede1097d9d8": {"doc_hash": "21a0708a0422495db0832b37e02520d463416eb428ac80b52beeec2bb7a037cc", "ref_doc_id": "3906fb76-3e23-42f2-b88f-eda7f26bd97d"}, "a0b58538-14ad-498f-ac60-127c6269436e": {"doc_hash": "34edd473b13cb5d6e6ef4716ad1e52fe830475d295c9692282c10cd294fcd8c4", "ref_doc_id": "9735e006-04ff-45e5-8e8e-a94f50298bce"}, "5dac3e96-a633-49d9-8788-9ccfef29d9bd": {"doc_hash": "3656383edfc982cd953e035558aa1ff3c86dab6d1d1fdc0fcdb20c4f231a1cbc", "ref_doc_id": "c27229c8-5df7-476b-98a2-0adc504ed4c2"}, "d6d39414-e870-4385-ba92-02d492357943": {"doc_hash": "b5a12aa83ff2a7acb029c0c4550bff9c650ebb8b786810cd9231f1f5c44f3402", "ref_doc_id": "f93398a3-9fb1-40c4-83fe-4ce3a7d251fe"}, "65e270d1-6244-4912-94c5-b437946a0b3a": {"doc_hash": "2aeb19da6743a86d7a0d654c8045323c9b8b67d500aacc16f220b82de2f3fa7a", "ref_doc_id": "98c91bf7-a815-4f49-9ee7-f0a206532709"}, "dd90313b-6e2a-484c-83ac-371dd5bcb57e": {"doc_hash": "74ce09c0a7b3729e1943c7a6d827c639996fee5a983854180aed6a7657407e8a", "ref_doc_id": "27116857-0b72-4473-9308-685cab6e04f3"}, "45d0c3fd-66f4-4b83-905c-818d550d556e": {"doc_hash": "c298ad3eb51e95081799dd624d36ca39160756ccd6d8d12f45b361a4384fc1d0", "ref_doc_id": "81be738d-dbc4-4bcc-827c-4686cd9c6e93"}, "2b2418f3-34a4-4344-8404-a249f12e4f19": {"doc_hash": "71b29f65b9f20c2212fff1b72237185a646d4cb70d5604f904c571fa9132ffb5", "ref_doc_id": "3833504c-700e-4bc5-9bad-a5ab10b8e627"}, "2c8cd534-3ffc-44c8-9b97-db383f6fc67c": {"doc_hash": "64b9db44ba86baedbbf24de91dc14102cfbe0d2996770bc451f49c18838dade2", "ref_doc_id": "6132a061-25a2-46a9-bf20-bc4885c781f0"}, "1f19a8f7-2bec-4fc8-a888-386a761cbdfc": {"doc_hash": "cae0cef7b9800f92eb774b49517e4bd224356be1822417d821ce1b886b69e366", "ref_doc_id": "caaa73ce-3153-4f64-a933-2c91e37e375c"}, "4cb3e331-167f-4e0a-90c5-8672d3f672f5": {"doc_hash": "9cb76c1a54f76ed2bd13cadf74743db166fd49e5d688bde111d9f4bf50216aa0", "ref_doc_id": "ebd17cfd-fd16-4463-ba49-164922c6b3b3"}, "f960de94-9ee4-4f3e-b8ba-d1d2b952d849": {"doc_hash": "695f55247cdd95ea0c9bb92a9f3a0f4ac80cd35a872d9b58ebf10aeccca42c46", "ref_doc_id": "50bd8d52-ded6-4de9-b1e7-851cc6c8eea8"}, "b6278983-f599-49b1-b2b0-ccc27a83e987": {"doc_hash": "d381dbbff169631806a6db9cf1c4723c4293466107035f06807cb56d6592c7b6", "ref_doc_id": "d8706bb8-96e5-4e4f-9c46-6e8a67a86b2b"}, "ed623c95-7706-443e-958d-168637c15095": {"doc_hash": "5c5317b6ac9b1361866a728fcd6baa5f550532115368a253ab4dcca92ec72016", "ref_doc_id": "3da5286d-4d06-4b84-bbfd-fac1da6895bf"}, "f8bad3e5-3294-4daa-a4f8-5518307f7cc3": {"doc_hash": "580ac88999b1532360b93658171df6c8f95bbf9264ca98a20e7ad7322a537abd", "ref_doc_id": "8261ec14-fd23-41a9-9d24-b5920d1f94f5"}, "1ca778f3-c1d6-4d68-b989-f5a1df68de59": {"doc_hash": "e2b89d6f97816485392d6d4f56c5c771d5d36ee0b5aa26d571d892ba80c714a8", "ref_doc_id": "ea434e57-1b3a-42fc-93db-d91f93cad7e9"}, "3f276451-e722-4213-b843-2b740cffc9de": {"doc_hash": "1168688068b6dbffa4bbf28786725e7f36907ce719940f08226a7feb87a46c88", "ref_doc_id": "c9790b68-a89f-4505-af93-725cd407b856"}, "8c1a6659-7e9a-4c51-9328-9be86746bbd6": {"doc_hash": "1723541b58499f67508e2ae0f0c26de1da3918661c1ec45779923b52fdc5c2cb", "ref_doc_id": "b86d61f6-6b7d-4796-93f0-2ce2de15733e"}, "d754f115-f7b2-491d-a714-71726f52b7da": {"doc_hash": "c13543240122e8d6349000b2dea06e7bff718732d001d32b07f8b8a7ba82c7ed", "ref_doc_id": "13a6e3e6-0034-40c1-8998-7fcfb9309841"}, "7b210a65-917f-40ad-a97d-fd462a804b0c": {"doc_hash": "8e9d86247f2b6fbede68ab1a769beba72e4e7d3deb3d53ea6023f2316a92b093", "ref_doc_id": "b4291a05-af7e-45ad-8c11-9b68b322ba11"}, "10555d1a-0ee7-4970-8519-36296c2b12ac": {"doc_hash": "5d97ccfa111443033317b99d9481a7260a36548123c30942b5a61e87905b185e", "ref_doc_id": "660b518a-62ff-46c2-be27-0a10f9fc2a1a"}, "a2550d3e-d860-4512-9bc4-90ecbfb3b335": {"doc_hash": "c24111d7a2913eb8d373ae0e375778af6a8949f45c2c66d0d530befeab566f0c", "ref_doc_id": "901ff636-16c5-4fdf-9703-58f14701d39f"}, "3f5de2c0-ba1f-47f8-879d-398ca06db321": {"doc_hash": "81d8af28228d70be24a79a62f066ac5a39c43eb83e38f49be828e50408843e9a", "ref_doc_id": "0373e499-7b6e-4575-ad0a-7ce3de8e4edb"}, "a36199ad-3c03-4429-8b5c-e57d5e634193": {"doc_hash": "2cf6874203fd2cda39ad71dd6e5c1d1eb14e69cb6e4a41e13c4a304b02711513", "ref_doc_id": "4e20a861-0f16-4c1b-a5bd-9c1f9cef05a7"}, "b9ebb719-8515-48a2-808f-4f63d1040161": {"doc_hash": "8c5d837192cf8c67b85d2b8c87ef295cbb0cef486e11eb578949c7980ba99f48", "ref_doc_id": "0c47e034-ffd0-4a59-bf70-381392ec61d6"}, "ababaf3e-21ef-41b3-bc8d-1d130753de1a": {"doc_hash": "d36bc255b4fb360b439a77b0e0f4250c38f9393205d254d3c82f164edb115315", "ref_doc_id": "a3fd74cf-835f-47c4-816f-b55a5fa1ccd8"}, "3c7a9c42-5b07-46e1-9554-7645f1e1ff00": {"doc_hash": "b851bec0c09507cb148df80881aaa17315dcd2be70be1d0659e90732bd11cb0f", "ref_doc_id": "9fc19df6-6a3d-4de8-9b9f-eae38f213ab5"}, "60c21ef0-940d-4830-8ea2-f055c159f5f8": {"doc_hash": "64ce8253f0e014196fd952a8950e145cd89efc6dcadc88acbb0e0bf5bac70bfc", "ref_doc_id": "bd5fc366-13d1-420e-b455-db4bb5498200"}, "9466d7a9-7c50-48c4-ad40-e2874e28b3da": {"doc_hash": "6e55b71e2154cea23b841a1fc8bc377188eb4c5fe016165e1379f13114670a86", "ref_doc_id": "15c08a2c-fae2-4c62-b775-40e72f27298b"}, "613bca58-f01c-479a-adc4-9a562a3e8cd7": {"doc_hash": "39bb20bb2e7182f67e7a3b8a85e37454013a466f01ce358e5e2690f7fa41bc89", "ref_doc_id": "423eeb76-d73e-4c97-beb6-5990d14068f8"}, "fd3560fc-e6ef-4fef-b07d-4871ba2e9a1f": {"doc_hash": "aae2fb9e6d494d1ab1ee41f483a69680e06a1fd162d0e2dea940dce86e2b16d4", "ref_doc_id": "9bc7d670-f000-4e31-9722-50542d0f6f50"}, "e5ab1182-3a60-4e25-bdfa-111e3c4b58c7": {"doc_hash": "b164944910d8815089c1ff57426049f4e6ab869346ae09f85bad38fccdd02545", "ref_doc_id": "750969e6-90ce-4315-b235-66f93f22186e"}, "219e52ee-f8c8-44d6-b8b0-8cd189cf367e": {"doc_hash": "d0836ed019dc12870ac91938c7e0cfd643302e9af246804dfe28493ad11de920", "ref_doc_id": "5acc770d-4fbf-4092-b743-e63da6b8dbb7"}, "dc795fc0-17d2-47bf-ae5c-1c6ff48c6963": {"doc_hash": "bd618c7923c43637fb85abb405db16bc32d1f23f77221e4be7136259f79b5098", "ref_doc_id": "a2d829f2-8188-4b0c-8a61-d916556c8a2e"}, "63956f82-650d-45d4-8c49-2a474d1aa82c": {"doc_hash": "68a9ab6b30aec19d1cab6050e139a8af263992bcb5dd6c958d6a9c7955bb34c9", "ref_doc_id": "fbe8be77-2b56-4196-8191-929433d9773e"}, "398848c8-ac16-4cb6-9a9f-55051b4791e5": {"doc_hash": "2267ba66f9bb0d006acb7f653b45e83aed0e9358f1ca237686e10931c024677b", "ref_doc_id": "39661e39-ffb1-4b39-93dd-9ab9ccb2448b"}, "64f99230-4c11-4200-83a5-57ec1aa8b6b5": {"doc_hash": "59029e6cbb160792a478c9949c137d931469f93f89bf08f7e6865ecdeb2fbe04", "ref_doc_id": "2209a194-ed92-47a6-acac-2f1b58e3757b"}, "a13168f9-79d8-4a7c-8eae-70ab564d4a2b": {"doc_hash": "587c201018d9fd62b4fd714b29cca835cbdb84410d593ff4283ec73efaa5cccf", "ref_doc_id": "19830688-c984-47d5-9222-4f1acc29a4d0"}, "0ffffb41-24dd-474a-bd4e-75371b2690fb": {"doc_hash": "44621630a8630520bfbf083cd706a677178273650580e0f7ae7b223a2e300357", "ref_doc_id": "7ee095bb-b29a-4577-9a56-522eade188df"}, "c2a01450-5853-4f1d-bf27-6ced91adb5a9": {"doc_hash": "e6e974af11748f0fea18edd0268de478ff861ed7b29543a3e24076e8f1dba374", "ref_doc_id": "2fc10379-e88d-4215-aa3b-b2cb0870dc2a"}, "144d48d2-1dcf-4e8f-895c-68db421f2c56": {"doc_hash": "b0fcf9c7a4271f7d9088e9042ce22eec8a5631ca80117e3529e907a15716b21c", "ref_doc_id": "7650e8ea-75db-4b65-b8b2-c0840e94899f"}, "f1fe2044-1745-4137-8d35-a67cf31d4db1": {"doc_hash": "7c8a601565fba72917ccc2bd9f9e123191e8416b20af7b924c511d1e2968d3e9", "ref_doc_id": "25989f5e-bdc0-44fc-8ef1-e5782fd460a7"}, "8693c261-81af-4e3b-b385-b3bedfb45311": {"doc_hash": "1eb3e38e9328685b517cd1f3f8a5eeebf2e1dd8c56d39f62514d62b70f629df2", "ref_doc_id": "c0d94ae8-2c67-4d75-959a-e2c2734d3803"}, "45518f1b-86bf-4879-a76f-2140fc7fe659": {"doc_hash": "b6434baa401eecf092e5b40628fd36cb2a2d9d8bc3eb24e8b1180ffb9187fd50", "ref_doc_id": "475ae1cb-457f-43ee-b265-e372ef46493a"}, "924e713f-3586-44ad-8ee0-c6a52e34579a": {"doc_hash": "fbe3caa670131b47d484e2b814bdf38b4fd7afbda059f8e1936c3239496b23af", "ref_doc_id": "cbd116d1-16ee-46f7-a1c4-9d4e3a6d51bd"}, "c136df7d-8c91-489a-ad09-0ca70ef663ad": {"doc_hash": "a3ea8bb0144203ebdb55bfcc97bc88fb9cc56fffea86cef634411089b2cc559c", "ref_doc_id": "66bda493-22aa-4818-b6ba-93abfbb77e68"}, "10a304a3-12bb-4a33-ba8a-79c7c3f845df": {"doc_hash": "f5e6595c3755e8532e0d60afa7cc32c4df13976be05e62999957ceb2915c763c", "ref_doc_id": "c2578a11-a3ce-43df-bc2d-3ea5195cae6c"}, "84e6010c-73b2-46f1-a102-bdc36f325fb8": {"doc_hash": "70a88519906681cce489fdd4d0eb6a3e600afee7061ce49cfe286ccaa24ed7c5", "ref_doc_id": "9baf9cfe-003e-4e10-a38b-b2b997f6c97b"}, "6bc684c3-945a-494c-bbec-71e427f6b3a7": {"doc_hash": "0585a8e48fe2f0737bee07b8089a6c19a5aba2733eff330a2163a5290f979b07", "ref_doc_id": "188da637-1a00-4772-9d35-a7137bc7eb22"}, "d8f70c88-8dfa-4c2f-b442-3875c39f0a69": {"doc_hash": "b01a9d1f3e8ebdabbf71c58beabf6cf197f2e71873e3b73275b7235bff53c6bb", "ref_doc_id": "873ddd4a-bb00-402e-bb3f-cb0925e89263"}, "198e0c74-b97d-4d8e-8962-94cf7b764c26": {"doc_hash": "bb408e99b53ceb7ce4b7a8916b3c5eb35d6349ad0acb8e9efdb4a9ff459522ee", "ref_doc_id": "92024896-d8dc-40ec-8113-cfbf90b70e0f"}, "007d50e8-a64a-459e-bd3f-aed6f0dece60": {"doc_hash": "41321334341cbe856398d6e09ea2cffd914160aa8c8fb712d9c4ba41cb32eb09", "ref_doc_id": "776d97f0-360c-427d-9a08-f443ae2a5d02"}, "e4a2c318-254b-4764-8456-bfab5a5ec9ad": {"doc_hash": "9f49f7143a417bb133a450d2ab616e0e77e3a5d6135a6abe32aeec7cef8602e6", "ref_doc_id": "495b6b00-0501-45ac-bb1c-45fb284f11b2"}, "c31cf40e-8729-42f2-a82f-085214cb03f8": {"doc_hash": "62c1cc4597f45bf64a285e4cef187a5ac221ca3a384ade15944279b39b2a2c46", "ref_doc_id": "6c79e4ea-1009-489d-aa64-4f60c40339bd"}, "4b0dcfcc-3205-4f86-bf26-7b4efb411e9c": {"doc_hash": "4afebd7facf73d77376ce81ffefb79dcf620c6d511d6528ee9c3259194f0537b", "ref_doc_id": "3d2ffa7a-377d-43f4-8ed3-e56c2499ea1e"}, "ea249425-34f3-41dc-b8e5-41e7ae7c7c8a": {"doc_hash": "51c20974e39d20ba87af226b81f73cdddcd8beadbe03bde84a4f95e592586a2f", "ref_doc_id": "5f0229e8-424c-48ed-8c2f-e256249407fb"}, "7315bb40-2807-462f-914e-2ac95901dec4": {"doc_hash": "05d53f58dc9d31cf23d877f1b1edab51e663cab058881fc118112e3e8f6d78b1", "ref_doc_id": "0598e74c-934b-4034-9876-cf51a2e35cc2"}, "8d9b221d-13f3-4e45-96ff-207125d31a7f": {"doc_hash": "607fc538c7a07fc4c5e6cca92a1a9787f687705d5d51a9319144d95935667fb5", "ref_doc_id": "324df83e-586e-489a-b9d3-0030ca3f5322"}, "56c8b348-48d2-473a-8b98-a6f4850d09da": {"doc_hash": "3b6fd5715383dcbb82ad205d699a00a8f6a075a925b50882524e8ba88aef71a3", "ref_doc_id": "5d0756e1-9162-41fb-8455-9a451eae6330"}, "85c96ee5-597a-4573-9499-d05aca352d72": {"doc_hash": "6963f7ef2576053ac78b1ea7a8fa0b53a2d2efd952fd42e887fc321a48007926", "ref_doc_id": "59dabd56-7c3f-41fa-859b-b3d7dc7a021f"}, "fc389e87-1d90-4dbf-a300-bdd54ba928ff": {"doc_hash": "393388c870e3ee525669e3166ffa531836406a2764a85712820877a53a66e1d6", "ref_doc_id": "3b3a2734-eb46-4005-ab47-4f286ff513ed"}, "4205fdaf-3bb3-403a-8462-aa5a645ed67e": {"doc_hash": "a858cb39346f47e70829c0e0487ff0c9ccd1b8d08a0e5d7b6b7bc9a87abf4403", "ref_doc_id": "ecae8993-3ae8-4217-b48d-d6bb1114a11b"}, "4628ed41-9fc9-4b62-9ffe-98ad1080ba36": {"doc_hash": "7e5ed93e2cf9a88ad95db2649aa04182bb4bd86d036247b5129d18f5d2621c8b", "ref_doc_id": "5c7146bf-73e2-42d7-befc-549a2c20a406"}, "87d15081-3f3a-45ff-a397-0fa275df7566": {"doc_hash": "154110a388758938a650c396d56bebd7e32062f5739bc8459aaf057f9031b368", "ref_doc_id": "2fb7de1d-6242-4a98-bf57-066880b58888"}, "d6e72dbe-6273-4322-8d55-a12a4a4c58ba": {"doc_hash": "cc93f5516dab9bcaf3a5f8dd55d9e53d71bc77622ad8002f134e25ef4c4a15eb", "ref_doc_id": "9c4adfa4-2229-436c-913c-0cf7a3a24501"}, "4d7f8905-5915-4e87-9736-9c99ae8bbef4": {"doc_hash": "fc3cc743fafce1abd145531dc32dd60576ea48d13805aa31f3cb300a0baace9f", "ref_doc_id": "3cd32915-ddf5-48bc-95d3-5c5d5c7acd92"}, "7303c467-b822-496f-b8aa-1185312b39da": {"doc_hash": "bedf99d0c6b362b80c2531295a65e8bf9561aa4f9c7c83c363ca6e3fd584672b", "ref_doc_id": "6be07ce3-4a5f-49c6-bf1d-49da587b6c1a"}, "35577413-a7da-4ece-b177-f597aec8c67d": {"doc_hash": "98fa80e931e7d4e53782d62634bda6d77ae4c122f6ba2aa056029afcfac1a6f5", "ref_doc_id": "f90085d3-510a-414c-9298-e6ed720bdb91"}, "02486149-6e2f-4aa5-9cf9-1684e888f0d3": {"doc_hash": "3089917b9fd234e42426162c784d71782104be31901acc02da53c0e36b77fec2", "ref_doc_id": "a2a9afb3-0e0a-46ec-8bf7-821cfbe7c1a8"}, "419afb36-9875-4d41-a40b-27c62ae952ae": {"doc_hash": "161e136fd5226e6a8f861bce5e3e393f18da080e57a143d8e167db29b9c0ff9b", "ref_doc_id": "d8811a34-1223-436e-b383-97a8e5afb083"}, "69777f40-adaa-4a72-a751-1f1d2f3c633e": {"doc_hash": "e118120040c1dcb3ad50dd931f420dfd2033819f7855a621aea04f400ae15419", "ref_doc_id": "656f6374-5534-4ee9-8da9-328cddd6b575"}, "cf33c91c-93b4-4f85-aa36-9e3482c93466": {"doc_hash": "d864313ee8d97687974283181d4f61f8239014fa7a1378b1ae7974e4579f6f88", "ref_doc_id": "e5c7cb16-708c-44f1-8d1a-8d1a66077c24"}, "a26a1888-c7e3-42d2-aa26-cc4ddc89315b": {"doc_hash": "8b3de508c2603c31816412f15460395d48148dd5b2548895be09fc110571cba9", "ref_doc_id": "b094b263-565b-4f08-8136-97227814a88e"}, "dc98f17c-9017-4569-84f5-3a09f7c59549": {"doc_hash": "4cf4859640fbc6f91cb4ee2def42860c6f3707e36587ef7358c4c345f91dbc7e", "ref_doc_id": "879717b8-6191-4454-a0ee-01d5fdee4f0b"}, "9fd0b9ec-01f2-401d-8473-3b76d182180f": {"doc_hash": "d042f0b72614b51e710d712f8deb811c94f786689b13bac141a29b79769eed51", "ref_doc_id": "a9a643c2-a51c-479c-9c93-18c16195f0fe"}, "ccf8a8df-5e70-428d-85e2-f6a9bdf869b5": {"doc_hash": "8110d33f00df9564e83106ac58a16cfcd241e99d19626e3f6bea9443fbe37732", "ref_doc_id": "9ae82005-3760-4cad-8c67-37178410eff0"}, "89166a3f-0249-48e4-a48c-7db3bcf22dba": {"doc_hash": "04255c11b9d272c2fc336c78f7a868d8efd0ccb164ed190061b769a1f72f5dc2", "ref_doc_id": "8af85296-e848-4a28-bb9d-b14a938c6300"}, "36c1df59-776b-4ef7-9ccc-cacf13ccaf9d": {"doc_hash": "5d6d626b46a68e3aadddd6763c9f6ea97eef87fd0a001427e7c7b5adf06ad0ea", "ref_doc_id": "d9f9fbc9-784f-4996-932d-83f1e2a78153"}, "3e5eeb5a-4909-44e1-8d87-57358e86f236": {"doc_hash": "b46fe0401d6110982bc13e038de4ceabf09e34c92cb6492c03d344b67e9b384c", "ref_doc_id": "164c8882-b418-46dc-b721-92cbd3efb461"}, "a09e834a-3f48-42bb-a8b4-20b0fc211d65": {"doc_hash": "3012e3dcc806f5d97ae7ba45ba2a412cff510cb6cfa07547fda13770db2f30fa", "ref_doc_id": "3e41021e-cd49-4fed-840e-5589c34d2645"}, "1878db4f-8044-44a1-94df-fc895e491433": {"doc_hash": "fadaf213836c0d7f61cf7b9e97860da266d578903221840381b06bffdd4bfe20", "ref_doc_id": "0d5133d2-49e4-46d9-8302-26ecc58bb2a4"}, "f5d1f4cc-f430-468b-9eb2-e7ed7be228f1": {"doc_hash": "9615b847eb1063a739390f32d5e9d4883bb5e620c3069de3f93e17396158cda4", "ref_doc_id": "6e339d98-3710-45ca-b1f2-297c69024dd0"}, "7be22bce-e32c-4142-80bd-d05291c6fa24": {"doc_hash": "91d574a673ef63c80a4a8700e0b40a7fbab617630334e92180257e5b95202e8d", "ref_doc_id": "caf6c1ed-369a-41e1-83b9-f67d1d0dcf44"}, "6a2b970e-3b22-487f-acd6-6c52437eb955": {"doc_hash": "3ea6e6f35eb3a195b2cc5639092eb3fcbb48151277855be2176831dbcf534385", "ref_doc_id": "b57526c7-0e92-41bc-95e7-360a47327ef1"}, "c2e0ac89-856f-4809-8cb9-0087f2dc5bf1": {"doc_hash": "8af671d5bff7dc3162420a6f98cffabffae41dfe0c19444ab239f37ddc66eb13", "ref_doc_id": "9cca0e5b-d88c-4b61-8dba-1597582a0be4"}, "cb12c49e-d315-4601-9d48-67b515892934": {"doc_hash": "f6da058cff5fc6f200a21d8d045d255694de0df7b48bf658925fab873cd44894", "ref_doc_id": "777726ca-6a5a-4a02-992a-df367979d933"}, "8567b9ff-c95c-47bc-8b2c-d19c8b3dd008": {"doc_hash": "20438b9888e36b616b746640e14413079327970cf8969c63167ee2e70d9631a2", "ref_doc_id": "f682a4b3-8dbe-435b-9e4a-273d2e5f89b9"}, "9ab04849-237e-4c56-9fbd-f47b7c187ac2": {"doc_hash": "dbabeeebfb1dbcaf49e11b8a6c129131de7740edbfb81ff0fa6458f7dec122c2", "ref_doc_id": "25eae283-4f8c-4ea5-8de2-f69a343d349c"}, "f1cefe0e-d02f-4cae-811d-c1e30ff9e37c": {"doc_hash": "49aabc08ba06284f99e3177bb0400a4cce1c7550a5ab8cbdd2ea67bfb290faa3", "ref_doc_id": "d4026735-ef8b-4edc-81f6-fd111a0096cf"}, "22010588-d73b-4a1a-ace3-35d2eebcf8ac": {"doc_hash": "2acad90f0490cd2a43b71739856d9b2e7b52c313426f8a69b5020a98d22d3150", "ref_doc_id": "3aa21772-8d1d-4dd9-8633-83e24e17c5f8"}, "5a5b60d0-47ec-4386-b8de-637bda2b9d68": {"doc_hash": "f61966a646067f8aa19270ce9730739164fabee6aee00996204c46d025b54ee4", "ref_doc_id": "d0dea423-358c-4495-89b6-a7bf51ba2238"}, "43b396f1-92cf-45eb-bd41-7eab82f240e5": {"doc_hash": "46f0d15f070128acf682c83c9f9e2ae99ef9912fa1536c677211f8b56f708db1", "ref_doc_id": "53007525-d566-4d96-81d6-63792e658921"}, "ccb511ca-6a2f-4f69-b5f0-44e274e6939b": {"doc_hash": "b689b4082ca2a5ddb0af1f34c866df5e823375701c10d699a13cd46fa175f07a", "ref_doc_id": "fa59ff74-9d9b-41eb-a800-38a1acc6da7e"}, "c408557f-560e-4ba0-b6e0-9e5a598239f8": {"doc_hash": "c9d9d901db230d380e47537415943557685a55a08eac84ea28ad098894cd8ef5", "ref_doc_id": "6daaa8ba-0694-46df-8e8e-9c83d1dafb58"}, "86c6eab2-3614-491d-8f28-0ed9e1838b74": {"doc_hash": "a30b50fa6d4322a8e5918bd93888001b668872adf5d98265abfdd7594ec1e756", "ref_doc_id": "8bea4c23-f9ac-4054-8055-99ad20e43e45"}, "7b7f59f6-8193-4713-afbf-405a61ae80c5": {"doc_hash": "2151ffa3e43cc54e4942dc3780d8146fbdf44f440b823134a601d1d63e8e2383", "ref_doc_id": "a8b33015-a1b5-4982-ac37-de56aef322c0"}, "2b122bea-1e58-43e5-b16f-9938592c96b7": {"doc_hash": "4488707f2eeccad03d82be9b8bb1d648c4de331f078ec061fd20e2f06908ae29", "ref_doc_id": "2ccdb7fb-bb57-41f1-a382-e304154d9101"}, "45e76eda-b3e6-43e0-97dd-61603016641f": {"doc_hash": "f0e6ace5ab46287a8450d807d7c81282e287661f98fec4b4a73feabb327f4e45", "ref_doc_id": "7af0b18f-1a4a-4e40-bf5d-2b96f2154d60"}, "1897280d-5a38-4ad4-a92d-cb19c33e0e9d": {"doc_hash": "17f4fc6faa564029c586d3f9074f2cb0afd4337084d509bcdc3ef69769042bf4", "ref_doc_id": "6343f713-47ff-4663-a284-830d9acfc825"}, "e88a6390-e6e0-4ec3-b001-c20c4c55427c": {"doc_hash": "25e6f382e622ea6798b4d51d3b8b9a8db5226e38ba41395a4c9eba680535add6", "ref_doc_id": "dd3d20e7-5d8a-4247-b8bc-ea74dec650bf"}, "738cd72e-7cae-4408-adeb-cc1f16412a00": {"doc_hash": "751e90d0fe0ba462880acaf55edaf8e7215f97254964adf2a50a8047e7cf71eb", "ref_doc_id": "e5c0a73a-0587-47f6-b40b-ee276295ae61"}, "c94d4fdd-433b-4588-92b8-2a8fc14e23a4": {"doc_hash": "1bc5d59513e4ede0b3b3eda9153511ee8c9014f533271b666e7645ce8ee98e92", "ref_doc_id": "a7ab810a-10ff-42a5-86f8-a8cde489b2be"}, "87e3ed6f-2352-4f9f-8e58-2cd116a10a4d": {"doc_hash": "5ac838d731402f4266b5a8ea77b88b650310c9372fbfae82a6331f32acfd6e19", "ref_doc_id": "513e3499-a3d9-41c2-8dea-ada5884b6527"}, "4c254fd3-695b-4356-b554-349e1610809e": {"doc_hash": "140f9b5d65a239d6617e67bff79a13dc83b8968611548c6cd9042bd466666257", "ref_doc_id": "e34f0a79-d386-4433-807d-460c1883d25b"}, "05b078ba-9f7d-475e-b691-6d5abcb01b4a": {"doc_hash": "f5ddce4b47090e3a4eacd880a276545ef4a7777a0ed623ebac4bd1de2f3b2495", "ref_doc_id": "50124653-f4a5-4093-b81d-ece57fe9d2e3"}, "f62791f0-9b6c-4155-adce-c20748b7a87f": {"doc_hash": "31a322ffb28f021c72cc441a387bfc504e66cdcf100338ac481c3add94edc596", "ref_doc_id": "d4916332-91ac-4d2b-99e2-19e058b2269d"}, "a8f1f58a-9fdc-4d8e-9e95-13836736081a": {"doc_hash": "c975d47d4103e06f8c9c88ddd3d8df4c289db98b55e76b518f6fe81c1113666a", "ref_doc_id": "f9043b08-a6e0-45b1-a69d-a1ce6103efa5"}, "3c016e80-aa13-450c-9350-6551c27afd58": {"doc_hash": "f32e960d6422413ee4a59c7d1b0b5262d84706bbb4958b3e07bdb4149e0d8b89", "ref_doc_id": "daa84405-4dc6-4745-a741-5e208e91c2da"}, "33bf4b0d-90b1-495d-9608-9988250a6d4c": {"doc_hash": "3174621619713a913fa95251bc5f8e45ef0c8a12816137c54a2247bd8f388a40", "ref_doc_id": "de4346e7-75de-4411-9bc6-d73ebf038597"}, "f2629072-ea90-41ff-8292-188a93735ac8": {"doc_hash": "c30a647e61195bc52915bf042a9fbf23347597446a026cec262d5f41040a9e10", "ref_doc_id": "ac32a1bb-976b-42c1-8fae-c0b9068b583d"}, "9286d6c9-2277-42d0-9cb6-5e1c5c691985": {"doc_hash": "de165e3051cad0120c7917a9047fd78c91a66b88420bb763724fa862c6cff8b5", "ref_doc_id": "7d289599-0bdd-4cf7-b527-905dce8edd64"}, "f30cfd36-b3fa-431e-9881-e1524fc927e8": {"doc_hash": "3b441dfca88ec30580041e60abfc7290300eb41eb222340f7b97aed50ec5e487", "ref_doc_id": "37d81d42-e015-4bbe-ad11-d621aabb7b70"}, "ce1fa88e-0f1c-4b3f-9b8b-10cb852626b3": {"doc_hash": "a17e0242a184b18ca61afd587160cd276fe264f23e21b0e30377ec38f0b9d5ca", "ref_doc_id": "a441866f-17cf-4d44-b960-f40be2e47565"}, "69798271-cc9b-4c52-94dd-48153ebee1e0": {"doc_hash": "21dd2913bb58bbe59abaa25a779eaa609c21660f1f927463efff9b379a4e6208", "ref_doc_id": "da9e8f1c-ba83-4ead-b0e0-1dc12ba39f04"}, "01e6b08d-df45-44ba-a332-79b1f1966828": {"doc_hash": "80512aa18c19893d19fb4a04e722c88674c092130fea68884e97a37f597dde4a", "ref_doc_id": "6d3b0664-6556-42df-bb07-ec3b69427855"}, "84d8155e-b19f-4da9-a9e5-bc5a7ef54060": {"doc_hash": "946c29c9de975ea5570cf7428d2984c7a05195575e01653e0a23958c59cd81bd", "ref_doc_id": "e58dd580-7d8c-4044-ac40-0fa6307d8153"}, "b94f7827-9774-406a-9696-e254171e331a": {"doc_hash": "a4b9e168ad032daae82289ccf690d56e9be83410d9b3ef08aae3155de6be6af8", "ref_doc_id": "ac23648e-ee1f-455b-ab7f-0b11da796559"}, "926dbb25-fc22-4d50-b08e-1901893ad282": {"doc_hash": "5f9df3f242e059448afeb54ce796b3c724f535b0b3e13340f87095989795a076", "ref_doc_id": "30494564-ff06-4f01-b4e5-c24c15f32ca0"}, "38011d52-b428-4bb5-b796-e75a35c75644": {"doc_hash": "791ce22fd40c9630746e6a3c35557be7832c3a7d9083ab17887880fd4e445d4e", "ref_doc_id": "3b9866aa-ad9a-4d06-9886-38c436f576ea"}, "1f61e206-b0c6-4ff2-9336-24e054f0af4d": {"doc_hash": "0240fe9867364f104c81e2cf3526ed9bd772a9508fdb46c8a0cdfb5887eb2313", "ref_doc_id": "5a3c4e9f-e84d-4080-98cc-3367f01251d0"}, "0ff45878-fc55-44db-afaa-8e475332184b": {"doc_hash": "190b096e0c45086f0fce279d29cdbb4921b17fd14567f1633a7c0dc4dfa02236", "ref_doc_id": "4853fcfb-31f6-41e7-93c2-ceadefae913c"}, "9fa36202-33d7-4cc3-97c7-e163966777e4": {"doc_hash": "1ed3f87036f3cecfc4c3e4e0e87df7a5413850bbc204cfd57da3ce7a6220bc23", "ref_doc_id": "294fb64f-8272-4854-ac81-abbbd16833d8"}, "f29dcee4-839a-44ec-93ca-5bcbd487fc9f": {"doc_hash": "be3464d6edb674af09f6b43f498f8ba756b0c316d3cdacc09420f8d8dee974e1", "ref_doc_id": "812b1ab3-5fb3-46ff-8154-033bfa006c7c"}, "e538b7b3-9b0e-4908-99a0-d351cc532480": {"doc_hash": "099a61b9e6f16b7366807c75cb15576e3646c3e37c974b52b24644baf5f0323b", "ref_doc_id": "d2dc39a2-a25d-4cc2-9ee3-cfb11aa4bd07"}, "e5fa9463-f759-4cd6-ba07-7e94f10afb71": {"doc_hash": "73ad957362a075918b91984a78c43a47895caab0c127fd724627cd856607ec42", "ref_doc_id": "5ac418bc-2647-4ea9-b129-59e534642a12"}, "1fbe2aec-c438-435c-bcfd-0118e979ddc8": {"doc_hash": "1101db1127a89c11257b5dfed9e4915bf3ce0ce858231fb3171a1c45273aa5b3", "ref_doc_id": "890be5fc-cea5-495f-b880-ffc6f70b7083"}, "8da5f3cb-3b8b-473b-a41c-e4aec900272d": {"doc_hash": "5a5c48ac5af5d26e437602466edfbe31a9215b94b88d05cea6b4d6723bdf09c3", "ref_doc_id": "101cd49b-3261-46e2-9745-4a3639211afd"}, "aeba0ab0-52a8-4d5e-b7cf-3fd799f35fd7": {"doc_hash": "e268bd9263a768325b5b37c89c67f7601a7be6456506c8fdff3b6230921d38c5", "ref_doc_id": "e8de84f5-c3e2-4d92-b11a-28d545eb5a61"}, "e356085d-3770-45ab-bfea-b8e38625f372": {"doc_hash": "7b46dc33228945bfa0306a5a22184419ff64b21795b2f02817ef6ed998118f28", "ref_doc_id": "e10cb40c-d0a9-41a3-bdb7-15575210f16c"}, "9ef35ea5-48d4-4dfa-a5a4-afe5a77f4fa5": {"doc_hash": "b1b2f22f336ce388d0343c34159fd586e10aea040ac14c87c85db2a117867cad", "ref_doc_id": "97818a69-4b47-421d-9ec2-c6d036cccab0"}, "e8b9607b-e8f2-4a10-a672-3eee7306b2b7": {"doc_hash": "f2e5391f017d957607f1d5e63319361384a299e49d90adc5d2249a84dfc41c7b", "ref_doc_id": "3531999e-5301-4cbf-b355-cc73b510a9e8"}, "88f68d68-1985-4b74-8e80-1e661785585a": {"doc_hash": "9aa2d528dffec047d599f855c4f19539a48b8d892eb28c79ad3ea1f5e47cef97", "ref_doc_id": "60ff69b6-debd-4d10-aa26-99b08eb55620"}, "730fa726-ef69-4ccc-9fa5-d7d92963bb90": {"doc_hash": "10bb164ce1f37d25fb90eb628b77e3f9e268888378a0cd154f6f56f85d3bd305", "ref_doc_id": "d49a497d-093b-46dc-ac75-15f52dc73552"}, "ca4c1f6f-ef3f-4e3f-8460-deb7a3a0ac9f": {"doc_hash": "0cc4ebf098899400e9a19c4737300ca5c8516d27becb7eb77d9a471020421f4b", "ref_doc_id": "fcdb506d-6edd-4cf9-bfb3-5f1fba46da33"}, "98974cca-b28a-425c-af36-34c528d645d8": {"doc_hash": "8854e0e9b65d4fd4c74b985202485050b3dbd133fcf8a4b016ad4dc7ffacffe8", "ref_doc_id": "3690a798-f7c6-4544-a17c-60ba973af53d"}, "2589ffd6-17cd-432c-a386-a829e451fbe9": {"doc_hash": "11e83c4c4d0ac416316cbe77d39080446c4b83c93c2a66368e6a3c95ca364309", "ref_doc_id": "25268c96-b926-4075-9bf7-ee6789f0b550"}, "15a3d6df-c9ab-4f17-acdd-abe6cb4ba82c": {"doc_hash": "1dd29493bec68e6ae6d305bb83c9b0125ca6cbd127a4a12dcf0135d75a3de45a", "ref_doc_id": "c7314169-b847-4aed-910b-2dda789ef23f"}, "03f46bcd-d627-475f-b6f8-f2e3ebc1474d": {"doc_hash": "fdc105b2ad56a464dba3283ecf7fc480b7a6e4e06676b8f527ebca0941dbc371", "ref_doc_id": "ddf7c2ce-f6c9-4029-ada0-553705c31d5f"}, "7c4592f1-0f56-411a-b101-eca8b0240535": {"doc_hash": "f17db1025bebdf919a156b8125786acab1ecb92107262090e81446e9c95ce28a", "ref_doc_id": "8b60474a-b1d1-4057-b813-f615d6b16c79"}, "cec580f3-b046-4bd5-81ef-4fc658deda1c": {"doc_hash": "0266deead26c992cb7e493d0a1f1658441c6a05128441d891319d7f6b744a60a", "ref_doc_id": "25b0c416-f3fe-4e67-82b3-934db0e96d2b"}, "3536364c-71c6-4b1e-813a-b43f99fa7a1b": {"doc_hash": "2ffe9ab78649f1f0424ca128aa64387fce00e4ac42030f56571de9a1a5bcb2c8", "ref_doc_id": "d05d909d-1d1b-4f1b-8e50-4dd9b8e4ec67"}, "e093f4b6-8e36-4d62-b775-40e9795a8306": {"doc_hash": "6b0ca1a2b8b973402c3697522b37800e25a30470cf81cb391beb26481ebfc292", "ref_doc_id": "8edf9028-6288-416a-a610-605caa51533f"}, "d56d77a8-6a4f-4297-87e9-6325aea8d4a6": {"doc_hash": "3d37b3cb873ec038247b8ad752560c955677e199dc1772095595a9bee5b9c6e9", "ref_doc_id": "edd88bd1-d9fc-47e4-bdb2-d1802eb17148"}, "249f01ba-f67d-480b-a9f2-3f53f29135b8": {"doc_hash": "b1d522187aade4cf40b6c2b959328b6922c21d83deefe85b27f406164c7da174", "ref_doc_id": "efd474a7-c291-496f-a23d-04d0747f29b7"}, "624a286a-20fa-4c59-a601-11b20f05b9f2": {"doc_hash": "f7b0d44b99fec4d527bf8dda3455bf78450e72c45c5108dcd783882366dfa2cc", "ref_doc_id": "b3c157e6-e0ae-486c-a4c6-d05a707563ec"}, "0281fcd1-728d-4d6c-8bf5-83ce8adffdf0": {"doc_hash": "99d6aee88101740e3cf557d3d3c4b8db815f1adc0445bde3cb8209ed3f8e71a2", "ref_doc_id": "6deff116-2930-4a27-83e7-9a596b4e2365"}, "1c7048a8-cf00-45b8-99f3-10ec1efcd1b5": {"doc_hash": "375c164aa875458db7b25d601bff65fd8ba61d6ec45277d465d5a6ee75111e22", "ref_doc_id": "a2144fde-ac86-4cde-8816-217f34d49dd2"}, "0c6dc04a-f7bf-4a9d-8df8-aeb08491250d": {"doc_hash": "c24708871e8778b2e35344c1a1d8453ffc86128d61d8131a86aca4da29f41e27", "ref_doc_id": "4d7c517a-dee7-4fc3-a7f9-a3d1f8552ee7"}, "22282cf5-bb37-4382-bddb-de17e1509c45": {"doc_hash": "b931975db6a7d95bbeb5113a86bcb377da9d80ba5aecbcc7b1d6d3e6257a158a", "ref_doc_id": "e79ad889-4c4a-41b4-8cd0-589cc62d579b"}, "e650108a-0745-4f56-bd8f-2db170cda741": {"doc_hash": "a296b6335dfc189d0d92e9ff3d91fcd357d45ef1b23369b78d1724ee073cdfb9", "ref_doc_id": "796f4878-e7f9-4ad3-8df4-f3c0e0266af8"}, "d21c7f4b-1b77-4276-98e1-bec3a161e481": {"doc_hash": "ed9aea3cfd21d2b6b8ce6db8c94a2d2d7a314eea6673a185775625af1868d89f", "ref_doc_id": "95b79d7b-cf4c-45fb-94ab-de9e28d1934c"}, "039ac4c7-d9f9-4d71-8167-5a63d8718e84": {"doc_hash": "1579b052a90f568151ce8f3bf33b57eff799ca7d32c97f28533d00a38e49577e", "ref_doc_id": "3372f70f-eb5e-481d-b4d1-dce9e6b9a5ad"}, "93184b82-c88f-4f1c-b385-9f845ee3fe56": {"doc_hash": "f2a64a245e93dccd7e163b1d208317a96c8b7a592139cafcf114eaeaf948c1d0", "ref_doc_id": "b5b2caf2-2fc0-485c-95ca-88723c4fcb25"}, "b3f8d196-fd27-446c-9a39-e53533711163": {"doc_hash": "c1e2e0e1c1005b45ec4143eb8b529f068b864c3bf265abc26a493413ef39758f", "ref_doc_id": "4c6cbcaf-3e8f-4366-a260-5e9e56052bf2"}, "25acc001-0e15-45bb-8675-a065758397b9": {"doc_hash": "474405ee75a6d02cbd80ea8abb73b89ac65d5e9f17a41bed7a5f8209ae3901a8", "ref_doc_id": "674d7cdc-814c-455c-b346-9e9a6b6a629e"}, "901a3fcd-606f-4d27-b4de-a098db0a466f": {"doc_hash": "5ea9154fc45f083c2d81410674a9984b6e927b6bda40a4a5df818033e2158ef8", "ref_doc_id": "90915b08-a8b6-40ee-9cf1-4819db141d87"}, "ca3468fa-2780-43d2-a01d-02f37cba594e": {"doc_hash": "6123fb134f638ef953b5bd2ec4319380c0993a07663c097c828391109654a430", "ref_doc_id": "202361ba-37f0-4f28-83e7-e884864bda45"}, "c622ac40-029f-4e66-9d85-0a7f4fce6ffd": {"doc_hash": "812fd7fb3b5a70e769a61512dbd954ad4ca00ebaff5c4c203eafcb63a8b5591d", "ref_doc_id": "ffa23a9f-2520-401b-809a-a417c0db493c"}, "0199facb-18cd-4c05-b6ba-38f7a0805a82": {"doc_hash": "bb410fd7b790d164164f7b67a1e8b0458d3df17c1789dc83627154232f37af3b", "ref_doc_id": "fc6e2cd0-c24f-48b0-b795-4eda9ec3d3f7"}, "cf3a5a2e-a4ae-4fcd-bbb9-704f652c5467": {"doc_hash": "c560440a310b48a16940dda56ebce58d0d29e4efb6a1e8f060245d836f849777", "ref_doc_id": "93632837-eab3-4f7b-ba24-094995b3ef23"}, "ff4a8ef2-a926-4e12-a790-8ad10385dc56": {"doc_hash": "799ffda0c137e18c6ee3bb12264c637aead7d2a3d700e0b3ebe2f8531a10aeb1", "ref_doc_id": "eac5488b-22bd-489e-afe9-13e7b32affd0"}, "72118518-036f-4ec6-b989-148216b470d0": {"doc_hash": "cdfc548679fc226ff7f741b9c7529388b27ca3e006d45d8e9f82de54d153b14a", "ref_doc_id": "8fd1404a-701d-472d-9e7c-eb5736cf0acf"}, "6dcb2e44-3e00-4ade-867e-0512f5ca66fe": {"doc_hash": "4ce005d4ca2d4c460ad7b48d9a7e8a230a61a6b2b9e90f1fd6f0034af9e790a1", "ref_doc_id": "23622f76-3be0-4fd5-8470-679ecccdd3c0"}, "8fd7f768-396a-4481-a9fa-090cc77be9cc": {"doc_hash": "593b1475ec1dfdd58416a26045cf9cf78efae3350619e91ea6c9076dd6fe371d", "ref_doc_id": "0081e52b-fd04-49c6-bc7a-cb0937059387"}, "fe8ee19e-04be-4e37-a6c7-f6f49b741e6b": {"doc_hash": "a6df5acfa21fc73996de137ee8ab6f555dc4d96dc326c398bfbaa7563b74bbfb", "ref_doc_id": "92028b1f-4c79-4e65-a705-d7d49f988666"}, "ae20f725-7154-4e5a-9603-0e539c19534e": {"doc_hash": "74501b78118dbad52500147d40a9ca29593fecc0e63b9db6c51e5132b493b80b", "ref_doc_id": "66c9f6dc-5f35-4beb-81c5-617a16d8b683"}, "ada3baa9-2052-413b-8ca1-88a636fe891d": {"doc_hash": "a1e97997a23ecf84153b844e128641da6fdd35307a11071282c5608ac8e97958", "ref_doc_id": "7bc36d2a-ab8c-4d8b-99d1-a4d32daef57c"}, "e2acf45d-b1a6-4000-bc5e-6b7104991009": {"doc_hash": "671caee315cca710bead398da8ec5129c15e1ae4beee949d687a291872b7b80c", "ref_doc_id": "5e431ff8-1ca7-4e34-8aff-e1a70d84643c"}, "7fde23c2-5965-4646-a4dd-be0439b874ef": {"doc_hash": "47483d439bfcb451960281763de64e5e9b78e01f6deeb7b834ee27cc14bd7aa6", "ref_doc_id": "48b051a2-6413-46c9-a232-bd916188f036"}, "ff43af36-43ed-4497-85b2-c0c5bcba89c3": {"doc_hash": "0c784a3a21158f9668fbf8fa9a1a21708abd7abc2920772d228c36b82b59c852", "ref_doc_id": "6d0d0a6f-50b6-4c62-83f6-434fff41b09d"}, "ee393476-b032-4a7f-b1b4-3e028c246730": {"doc_hash": "47431248dcd695ca275538a79e8ca31f1192be9cf80dfcdfe0738f84f8f166f4", "ref_doc_id": "5b3130d4-c8aa-482d-b53e-837029e266d0"}, "c9de14c5-51f9-446d-9095-0e214338c624": {"doc_hash": "be6ad21e521b984c8e67dc0a5e3dad4a096762b3fb1e0d4c4059a3dbf2a2ee9b", "ref_doc_id": "f9ab6a15-e7dd-46f1-9454-ec9047e93082"}, "e56d3bc0-bc8d-4073-8193-c4b5a007a624": {"doc_hash": "6412f72e8c84df7cf5b97820dab2dc29f24d4d6c351e452ef4105143ad20c63a", "ref_doc_id": "49aff1be-42d8-41ca-8f5e-43dfc0e26c21"}, "d9274fd1-9dd6-4fcf-a291-b0050ff44d98": {"doc_hash": "11c788ea4a45692adf246b4980cd979045cfc9416ad755845654043944dfd327", "ref_doc_id": "762b4ae6-6973-4571-b9c7-5d6d99d0dd68"}, "26adbbef-2876-4276-9a93-276724b3ad01": {"doc_hash": "9f10b9feef02211714c281ae69f5b435830c17bcda99ba0f5e39a35b24c89955", "ref_doc_id": "4900ee81-1cd4-4618-a0d2-7711a6325a19"}, "128aabad-5c09-487c-8166-3b44de5fcbd4": {"doc_hash": "5a65cb0ec3467887974334f6c46bebf43ebdb1af455a012b3fa782757a31c5c2", "ref_doc_id": "f4ffe037-f0db-43c1-9870-d281aa2bd9da"}, "0e2ebebb-ea02-44ff-a686-c5d28a50e172": {"doc_hash": "c38062c50da605821dc4f46cb5f8b6988c905c116c49333affb21842f1b94573", "ref_doc_id": "4eed555b-950c-47f1-aba7-ac927a452ddb"}, "01d12d1a-36b1-4d6c-bb76-c8ee2ff6015b": {"doc_hash": "1c3073de700f2ce3304046dbbf80fbdce4961df1809d1181ba14df7e8f0db9d0", "ref_doc_id": "01e722a5-b8de-4775-b4f2-b325f1be6565"}, "db5a0b0c-34fd-4e26-aadb-22d1cd057f66": {"doc_hash": "53070dbabdefa619798dde8f3e7ecb926b01ae9869477f8129dda6a837fa4719", "ref_doc_id": "b371a2ed-a0ea-4ef3-9a4d-e2aaa9fba7d3"}, "c3327aef-df58-4257-8a21-8190ebd5de14": {"doc_hash": "04bd0cf9c4e0800a8d064995df23ce3ced3018e0205d62ab5304fc7460f94da6", "ref_doc_id": "833de9f9-151d-4b36-83ee-8fae5c6ceed7"}, "12897d53-0be0-4c16-9174-ccc133af46b7": {"doc_hash": "40b5b41b306b8f53a9cc49e736d498a0a1456f66922db1b4ec75179c10e735ad", "ref_doc_id": "a720a272-803d-46e1-bfb3-8446e3cf24fe"}, "5872b667-0fbf-46a9-87bd-ea6dbe0253e2": {"doc_hash": "85f0cc505e3c3d17c57d1ab1ecc8a245ef8773b5b92c10218164cf4bc7f5d0a2", "ref_doc_id": "82b87288-e773-4512-9416-9b1c7bcde0de"}, "f315fa59-f714-4257-9e26-5cee763bcdf6": {"doc_hash": "0a0ec59538e2418fc8dba34acb03bc43750f2b341244aeef638a0665ae72e563", "ref_doc_id": "b509ef7d-c8d7-4ee5-a41d-aabd5f2a9290"}, "20c2267b-66d4-4c39-80df-bc61724d8140": {"doc_hash": "c55e4e213f75379de4e03ad489e305b09fe0822ae1e13da5f4a27c9c44cb0375", "ref_doc_id": "04f62060-dd08-4c9d-8476-60cc3659d39f"}, "918c61e7-8776-4bf3-a483-6501a1fe6385": {"doc_hash": "117a6c3acd461267c7d82de6e30fb309e9c40431c98e0f1247c1d2bdfba48b8d", "ref_doc_id": "21c4b7c1-2ca2-41f1-839d-a13aa2dea394"}, "3c394d04-c360-45b5-afe0-d72f9d779f02": {"doc_hash": "960fea1d6027d6ac234552ffee5b3cc5df5c01fa73f412b9c26992a93f4f2e5a", "ref_doc_id": "e6c1e64b-255c-48f4-85a7-5cc6b741bd50"}, "66a5c9f3-e91f-478c-9d3f-ffa2a9f7c42a": {"doc_hash": "2ef470c2b4cb6c1225c8108b0aa6c65b356610035b61a3f7189a8cc8b42d9836", "ref_doc_id": "6646fe25-720d-4a5a-9b1d-df14f4ab3d56"}, "e4d08e75-a422-44df-956e-93d1cb614c66": {"doc_hash": "042fd07895e061060dd270d2f9ab3080007349911a5d212e293281948b61ec61", "ref_doc_id": "f87a4bd3-a097-4637-b479-b625edca762c"}, "05e2c9db-6f03-4415-944c-dea324052c8b": {"doc_hash": "7a99da95f4e559dfbec6a93c3b6bfd80a7791a6698fe8ba76bcebbef7c684fe1", "ref_doc_id": "24880c04-83f7-4990-93d7-fc302649b66d"}, "2a1d7c0f-814b-45bb-8c31-cff45bc41183": {"doc_hash": "d4a01a7262ba76ca8ce8dc2e93a5694f44a761abd69e1d081d3f3e676891c5f6", "ref_doc_id": "8f43f4f3-fca5-4d79-8bef-c24ebfe0bf33"}, "39383a4f-621f-4401-9797-1eb11f33ffa7": {"doc_hash": "dbe2129fa88f82cc6bb36d1cf0008501160f660a492ddf559bf65d9b6d902380", "ref_doc_id": "9b94f19d-ceac-4f40-a2ad-ff8e943a4d6a"}, "ec11e5b2-352a-4546-9394-ef3460de2b5f": {"doc_hash": "af8c15692167fd64417301a470a86e451a5e5bf9fcf1d47d9941bd2e8812b3b7", "ref_doc_id": "c2c147a2-7f1b-43d0-bdf1-3461e9891d82"}, "19da3a1e-32ce-43f2-b13b-152455619c80": {"doc_hash": "28ed774781895c6b8d0e1aa406d42b746295f61ac774d60957529c2c436c1bad", "ref_doc_id": "13a03394-23fc-4f92-92cb-7c5e59177645"}, "6fa5a13f-550d-45fb-ac55-41488b9658a1": {"doc_hash": "9e5b98b4f084033400a8a81309f3757c78aa2ab0e2aab4178b71c716d825beb6", "ref_doc_id": "5f437563-b9a1-46e1-ac72-0ba3e714c271"}, "4cb66485-3dc5-41f7-9e3a-83cc7625652b": {"doc_hash": "c89e5fca6b0b9983604830b3eae60f6935dd24c2f5cca84012dc320303d10e65", "ref_doc_id": "18991383-76df-4d26-a806-fb84871e3e00"}, "e751b12b-9e56-4949-8fcc-38f76ebb8e2e": {"doc_hash": "aade9b8230ed65338cfae65a5f1c0237f7b7f67f2ac84b32df481076c7820082", "ref_doc_id": "9f44f7d2-2903-45e8-b515-21b13212f5dd"}, "1d3f3251-8fe7-46d6-ae19-9472374cd5c8": {"doc_hash": "731e5a66a465ce11bebc6957aa035f12b73077659a41808e5e8337ce78ce1f65", "ref_doc_id": "4f41deae-a3cf-42c5-88b8-36d8ec03ea42"}, "79cb584d-d8d1-49b1-b957-7881620b4364": {"doc_hash": "c4d3315c6f8a4749fdef7a6a8996941be521e0ed353e23caf1e9fe0481a8062c", "ref_doc_id": "ea35f195-1c39-4c57-b1af-4c75a97b49a9"}, "bd04b1ce-7586-4fbc-a0a1-1a37e199e179": {"doc_hash": "1882f90420b8957df29a654b767dd18a64c6e1d8785d1cd40d808070e441a9fe", "ref_doc_id": "73a5b4c6-baf3-4703-bb6c-8d2ef7e9dbb9"}, "01b990a6-d92c-4b39-8952-b1eaf3d060bc": {"doc_hash": "7e1a4816fd05097203e3f5ea4fcdec37741d298b187e193f5b1688039e3ac7b8", "ref_doc_id": "46afcb6d-2b39-47c6-86d1-b0de08358a85"}, "c993cbcf-4237-474e-b5a6-32eeedb0530a": {"doc_hash": "b3d689ce0118418e09eb2b639e2bdaae4ff45095e382a4adb0751f57ccec913d", "ref_doc_id": "fc0302f0-c2a1-43ee-aabd-75b7a3be177a"}, "71137471-68c8-4efe-8f9b-494a73bfe6d2": {"doc_hash": "4f5b4795b6b9f1771f747a52456dd3d9938c46ee5dab0dcbf6016a1fd02eed6d", "ref_doc_id": "74cac053-556d-4880-bdc8-de6bf3a3470e"}, "7be3f6de-8651-4d41-99ca-1ef9ffcfa64e": {"doc_hash": "6c8945935be911341d8637b69495dac34ec6abb981e5f79e7fe4800e652d637a", "ref_doc_id": "7d8ffe89-0950-4099-b3c0-0c30069f1d6b"}, "04c53214-34d1-49f9-9386-547d1ff551a9": {"doc_hash": "b522bce2e708e8c2b3105de945d22290873376eac293dcce64a074ec20056e98", "ref_doc_id": "3b0c0b44-13af-459b-ba25-c1729e3166a2"}, "443d8d01-ba6f-4610-be4d-385e3285b4bc": {"doc_hash": "f2d044a1e35cd4835bfa95fd3f489778370b3048482b4f6ae5984cf2f8064ee7", "ref_doc_id": "b811555b-b31d-4c84-bfa7-fbbc64503be5"}, "4c9186f0-4779-4b7e-9b4f-57001dc50d39": {"doc_hash": "73eb8560774770dcbb130fa4cc6f2093a8005656e69cb35bbceb7aa36ef1f384", "ref_doc_id": "5084db76-55e4-47a8-a2f9-cb19cb8555d2"}, "8144d89d-0238-4e91-8f37-ef948a021a9e": {"doc_hash": "fe6b5f7a03220963b3fa03cfb9a067557695c8fec2eb31e8bec7ca26781cea28", "ref_doc_id": "9e3955db-8469-4935-8728-4610f5ade1e5"}, "92171587-7adb-4a2a-bbe5-5bd7f82917cc": {"doc_hash": "21dbcaabd3a5f0882e534c0ca00ccca3f334c8634db9e70ecef66a178b59c19b", "ref_doc_id": "dd987a76-4793-4a4f-9fa8-3eb89c396a3f"}, "c0a7d32a-1aa9-45db-8889-332f4b4020e0": {"doc_hash": "7a9a40bb8093ebc75b1fb330ad27fbc109d125d97eb908633281142f1db08819", "ref_doc_id": "c8161264-b91f-4406-a437-5a82f63d0b4e"}, "f54b5582-c94f-492d-8425-3644a2456280": {"doc_hash": "0d87a5a7cf79863639b259cc185771df9b76d0432e779920b5b1641bd6f5918e", "ref_doc_id": "05ccd945-9223-4c79-b45c-02c20166a010"}, "67905ef3-4462-48b2-851d-ddeb37cc2a6a": {"doc_hash": "b51732d180b392fb36d3e057e0636d8d23b6e99a810b2022ebe00fe8a23ee94c", "ref_doc_id": "0e1e6011-65d7-4925-ac6b-7f5d37bffcb6"}, "02e54b8b-aa10-40f5-8cba-ccf7249561b2": {"doc_hash": "27210236ce4680889fb0bb816f345e24359ff9a206d1c7394749c8b321b42e37", "ref_doc_id": "7617f773-ade7-4cc4-8bc3-f191c64faf7a"}, "d4530800-75bd-4c1b-9588-0837c4d290c7": {"doc_hash": "4f05f149f16c1c33dd68247a3f2ceb3d1bdd68b95b5aa7de4e2a83deb1923d24", "ref_doc_id": "8aa848ba-e5fb-483d-a766-308e55eb1394"}, "35066ccf-6258-40de-b778-08dbb233a492": {"doc_hash": "c47b2d6f71943f354a0cdc394c47c7d2b9d5f4410fd8dbc5b9d6f68f5577170b", "ref_doc_id": "8032ae35-979a-40bf-97a6-8c412d97d675"}, "8a91e37a-4440-49fd-833a-96078a718fda": {"doc_hash": "7e641658649be8b29335c08952d1b1824c0670138ba594df8a67867cb736ade2", "ref_doc_id": "fbabd06b-d065-4db2-be9d-76f63ff6ee24"}, "b3ccef19-6656-46ab-92b1-ebb984cf7a12": {"doc_hash": "d7ddae36ce1ad6877ebb209c14518644f584ab908575121218d572ecf760419a", "ref_doc_id": "3a20e2c8-d6dc-4b6c-a08f-3e5bf7c525a2"}, "fcf69961-d6b9-4cdb-8477-35c00c2d223d": {"doc_hash": "4da91cddc88d3aacb59eee3f28e019c93ee95dbb63788b1ba209e673ae204814", "ref_doc_id": "4dc16ac7-5306-4f5f-a055-f7ac2e16621b"}, "c8b20f1a-f70a-4bb1-bf4b-4f24c238dddd": {"doc_hash": "ff4a25ee8dc48c13b28b927d8a4a8ac41204ade0ece08ddf1147544dad2e7d15", "ref_doc_id": "e93e1446-0faa-4853-96e4-69abba33e17a"}, "ee14ac38-b760-41b0-854c-8519d2bcf1f0": {"doc_hash": "c591abf62105b37691bb0b591ede5cb0a27e5199ef1b238aaff890daa831ad34", "ref_doc_id": "65332d51-d814-4342-a93d-7086fec28e32"}, "7eff5369-7e46-48a3-8625-1f43a3e01375": {"doc_hash": "edec0c8bdd8b4ab6b8826ac4de0b36a41b0de5a28ddb17340f3ef7ec9d8c6c7f", "ref_doc_id": "ea34979e-ddff-4647-bf0c-4b09bdfaf008"}, "c1903f8b-156d-4812-8c41-dc28cbc6de33": {"doc_hash": "9f700f88946e9c2c454b0a3be75ffb334062c4bc59d33695de51d66f82233029", "ref_doc_id": "4ccb1c6d-a09f-4ea9-a187-4ef31116cc22"}, "79ae37b1-921b-456a-ae45-2bb13d5e7cc4": {"doc_hash": "6020e0a0413c42227d8408ca67ea662dcf4f9869fbf584906ea5ff57bf96caa5", "ref_doc_id": "c5e75454-5341-48d9-bd7f-78661e3ef08e"}, "5c729dc2-f44e-40c0-b443-83348b6c93b6": {"doc_hash": "aad0547b5ab1fe19235cbe8e2655bbb793f7c1d9d9ff3c77aecb9b3ec366c7bd", "ref_doc_id": "ef8b9609-f356-4b98-a91f-201b2a1025c0"}, "f52e2a4c-c188-4ac8-b34b-796a2d2304ff": {"doc_hash": "a3cce61540c899cb18444d3e31c330337513534fd9bd8a69cbc0d12a0ad5f91e", "ref_doc_id": "aa26da2e-2915-420e-9f94-8b22bfc5767a"}, "68374f1d-8116-4e7c-bb16-2893dabb99ce": {"doc_hash": "adb536b062f9fcc762ed7ffa696b125a299c0bbd24c0ff241167eeace28a3acb", "ref_doc_id": "9724ea0b-82de-4a4d-a81a-bcf136655a29"}, "804272a5-1dd2-4cc7-94f7-c7f69f05420b": {"doc_hash": "e1308e6facbd54c64e636a640135baf63ad56b496d765a99fb9c5da62ba10dc9", "ref_doc_id": "53a19ddc-c125-4f93-a410-f84c9aca8637"}, "3bb7142d-1463-4a32-af87-88cbcf8bb6dc": {"doc_hash": "b091c3edadfe8d599814ce0a9736806001910b5f86c85b3f3a30a77226955fb4", "ref_doc_id": "ee4a1e10-76fb-406c-a24e-3f3bdd66d064"}, "7eb0bec4-3af4-4ba1-8069-eebeccc5609e": {"doc_hash": "5677d0742a017442430d53753c14b0dae1b85c0701137c7f314bd40ebdfface8", "ref_doc_id": "7975bd48-7abc-4e9a-801e-3624e4da99ca"}, "b8c4581a-0858-4299-8e48-71f9c05b4f37": {"doc_hash": "5f58d2de3d4388be999975b7ad321bc997639d9e0abcb17ef6f5c3471b80a659", "ref_doc_id": "4896154a-41cf-46f3-ba30-c4219d760818"}, "ebdbacc2-1670-4315-8666-1da19fc441ba": {"doc_hash": "f327edc783d210076b1d30faa48815424fac94e8be67f0cc0f49a5c0f6efa504", "ref_doc_id": "d8dd7fbe-8bac-4591-9ace-be8504f6f024"}, "47c1a897-28bf-4b7c-9c95-0fae78c38f66": {"doc_hash": "3854373c5ff3d62c8472e3d0d943767755a31a5bea5816aae705cffb39496333", "ref_doc_id": "a837d3a5-79e3-4cc2-9b51-17ab687b2bd1"}, "81e475a8-8919-4748-9b00-41fcebfc9d1d": {"doc_hash": "b6edaf2af793970eb54c14508d37769aa8bedaa3b80d397aba1cc61d596afe6f", "ref_doc_id": "dc722788-7530-4bcf-999e-db8ae7c6a668"}, "48c37ecc-1564-4833-ac64-47499fe8b50c": {"doc_hash": "cdd2a995b554f924e34a48e84eda6f4d86ad1cb43de47b0368ddd81870b15f93", "ref_doc_id": "b41dd8a2-cec6-4dee-b6bf-5e7666b7404b"}, "dadbf5a0-7a85-40bc-831f-34ebe40a71c2": {"doc_hash": "0a0c19a88aa1cf957baabc577a6659ab036ef259235ca4ffe2715c068bb753f4", "ref_doc_id": "e7dec974-a9c1-46e0-9321-c694daf0faf3"}, "7ce447c5-e03d-458c-96e5-4fce75c00442": {"doc_hash": "9f3a07e2db784284d311e3e03d9a606db97be707f0b0bcf1b9e5e65b5a6854a9", "ref_doc_id": "681e3c2f-a98e-499d-b892-683be2ab6287"}, "22ff7347-4f6d-4bb4-b176-20e7c2a8ee3a": {"doc_hash": "54b51887f2efbfff546f2cbf8cada1ff75582f1037d894b71067fc15f251fc9c", "ref_doc_id": "f7a0ac2e-2396-47b1-a62e-a4aca54ce7aa"}, "25f2ef48-c9bb-4654-997c-9af8fad4f475": {"doc_hash": "8c04bd90f6349370b01ffb659020c3b72724adff6ec42a900be0d977b1b4bffe", "ref_doc_id": "3b78f7af-17e8-4728-9416-fd528200309f"}, "cab84831-2f53-4e2d-a046-e36e389b3368": {"doc_hash": "402a1da9c36643a69aa80b1335356a71ddd176f5ecd7ca12620ac454d96435f7", "ref_doc_id": "fa014ee9-f1e6-4f71-a158-0a13c7e7aadb"}, "8f4a2c9a-fc33-4b23-8292-dfa8efe897de": {"doc_hash": "b2ff0c4f5648ac3f3a5132e12c36fbaae3f59229a3753701c50fefd9066e763a", "ref_doc_id": "6fa8416a-de44-43ef-8df7-a215ce99f304"}, "3422c813-05f3-478a-8f71-f4dd4e756060": {"doc_hash": "a1b92cc193af89e7acc67f79e76f7f0249ceca16e76b29843f1ea5a56230f290", "ref_doc_id": "767d9fd5-1d5e-4816-98f2-a5c9b9afe358"}, "e6d91171-4386-46fa-8960-0d5a201ddfeb": {"doc_hash": "cedb702eaafd8753d459115ffea80d93d8134e4afed854cbc0773843ceb5d94f", "ref_doc_id": "161142ff-566d-41c8-8691-6d537c8d48a5"}, "d1b3e2da-7bd2-4018-a237-b2d147d2100b": {"doc_hash": "b4bea17de6379a1df85e74324c9871da74a40300d9fdb58107363bc1a9a37cbd", "ref_doc_id": "b6371738-eb6f-4bcd-9ecb-cf45a2d10bb3"}, "6f0afbee-f0fb-481b-8792-a90b13c62316": {"doc_hash": "5ba0e333ef1e713df081bda27ffa72782bf3f335577bb52f9f33871fce7d27b0", "ref_doc_id": "eeeb5a3b-b6b5-41b4-ab03-e092921dd207"}, "9e89cac9-3bb3-4aa4-9ea1-6e82ad1b406f": {"doc_hash": "2a6abd58da2c72158f30f85a1b1d811b2a579d65bd7fbb304600d83356ecd8c0", "ref_doc_id": "f41c4458-6c59-4417-a034-b6ff4c8334ed"}, "e270facf-1c08-44b6-90dc-0039cdebdfb7": {"doc_hash": "310eb9444d66863ca565137572eca48e64950fe391f02de9ff03cd60943fd2e4", "ref_doc_id": "58ccd3d8-9628-4fef-962d-04433a0035dc"}, "9866f1b2-f068-4e7b-ad4b-05b9e059e49e": {"doc_hash": "f4d3177a36cbfc026d110848d677239a86c2ab997c1d8660e4f5486320102aa7", "ref_doc_id": "30587ff2-ef25-48c4-a1d9-04bb06793b35"}, "110fcc70-98f0-4267-bdd6-dd184fcc2f74": {"doc_hash": "1458fd1542af2bac384192b2c67ae0eb7aa4f9e46138270639834e62739aadb1", "ref_doc_id": "e3baed74-35a3-4267-98d9-b0129c46da3f"}, "ef1c1ddc-b372-421d-9596-6d5c9bd64211": {"doc_hash": "5a6a8d7f12ce403a7c971b76efbfde2e5e0404e6e2fa6580a44f581d65dc60bc", "ref_doc_id": "f7bc63ee-6b2c-422d-8a81-aa20f18dff20"}, "7684478d-1fb9-4f82-8c13-10e3d257660c": {"doc_hash": "a0d2ee98f19844bd57b10127379a6ba4abab067e2c9e78cba954c5fa9c31370e", "ref_doc_id": "29c12703-2440-47ac-93ff-d413c8b07ed5"}, "d35e192b-d33a-4aaf-8e5f-2d6e4b0117f1": {"doc_hash": "a8b1afac3127fd8af3f37fe72da7f28f83bdb290f97c0d250f74baf43de06e36", "ref_doc_id": "1abcd144-b47a-4196-a137-4f6905fdbcba"}, "9f77e6d9-e8ca-4ab9-8714-cbb068e314ef": {"doc_hash": "8bd6ff2cc5d92b906be95286b23ddd331cddf5f5063fe017ec0f412134090551", "ref_doc_id": "f6d4527f-9ca5-40f7-bacd-c2fb6f4b955f"}, "6257a5f0-a145-452e-99b4-ef5978999f7a": {"doc_hash": "212ea906fb9ee8a864c88f0a7472ab9842afba85e50db672f66e726f898536c3", "ref_doc_id": "4407880f-81c8-44ad-b4f5-4d725cbbb5ca"}, "4a87a2e1-9e07-4e33-a630-d5ab40fe196e": {"doc_hash": "8d6ac7087b3f7f0a5b9850b891def770196c4d34d522389456713f2b1ad54156", "ref_doc_id": "4ce659d3-381d-4df8-aa5f-a829932d760e"}, "e237ac85-56f2-43d1-89d4-18a7ffaa893c": {"doc_hash": "a9c4b444a6744fa997b4526f9d8f25a2cd76480a10234e6c312e1ff0497c066f", "ref_doc_id": "f1482fd4-de70-4fdb-90be-5cbac8082963"}, "b5e365a0-7a8c-4505-83fb-df4d965cb6c3": {"doc_hash": "2ef52aa045c211987bb74a072189314cdc7dde1ee1a22ff49be186a0c9debbf7", "ref_doc_id": "db3bf11d-3918-4f14-a8f6-93e14ff03324"}, "8c7c56d5-e107-45c6-9e62-83b65a4dcf4c": {"doc_hash": "a4acdc0f60554555762ae922c20eb6a401880839591f55378afb8b3817ea4fe4", "ref_doc_id": "8f3b27ee-2718-4801-a25a-a0ce32d59729"}, "864e23a5-35f8-4088-b8ea-cd1147bdbc2e": {"doc_hash": "a5e1c331b6b0be4b429d7a1a53cf2de5c79138ca4356be9e5b645836dd2d7296", "ref_doc_id": "c0ba0514-3b1d-4937-b612-8adbf59142e5"}, "c5f408ff-3f6f-4247-a250-688732341413": {"doc_hash": "b96338d184fcdd1b16a2114a52a379aadd04b1141240a809099a2fe6c8de7b40", "ref_doc_id": "04b5bf76-2147-49a9-9637-744810d0cdc2"}, "5d0c05b6-e7bd-4a6d-be3c-fbb8693d6cf5": {"doc_hash": "6ae0dbd0013ca737c33725072e5dc860b3e503171d30fdd10df44090870a1846", "ref_doc_id": "3cf6a336-ea6b-454a-8c69-64330f430667"}, "a1904806-ba76-4daf-8166-3e64d8f9c5e7": {"doc_hash": "83571e32afacc37da7302e9c4d908ab24f5f7b8856c31ed434d2ea543f6c343a", "ref_doc_id": "199872c4-c733-4e4a-85ee-01cf906c2615"}, "5db4884c-878d-4a8a-8075-1e05e17f046d": {"doc_hash": "f795e3e57f9422f373247ba51ad6da44022786571fd9d3d44acef61f91cd59b2", "ref_doc_id": "3cecdb73-bdbc-4f7b-b82d-4380b3c903ba"}, "256d9946-a0b5-4105-8909-8cf623f31d06": {"doc_hash": "e124def095b9ffdb17fee57ece9f2c0233e3b8a3c2b79f79962e90d5f0711919", "ref_doc_id": "ff7d50f3-e153-44d6-82d6-25997e2a22b4"}, "b292d080-4542-432a-8a36-f101b395aa25": {"doc_hash": "5e968f9dad8f40263ce8998a0a7b876c478cb95b7e19fadb946469de884cf2fc", "ref_doc_id": "da6b2abe-804d-4b37-8bc8-6806c5b54a28"}, "6a813e00-31d7-414f-812f-98ba8d15a54e": {"doc_hash": "e347c9aa37fdde8b45b32deff103176ee285050af2ef13f6f396d078a768a377", "ref_doc_id": "71390f54-4539-420e-9c33-20727114f280"}, "4d6aef1d-f58f-49d0-a42e-db2d140b93b0": {"doc_hash": "016e138ee73c0ed0a660ae037225c11450b952e08952b98b9e44594aa83106ac", "ref_doc_id": "6af8dcfd-c0d8-4fbd-8883-f09d41d4aed7"}, "21544908-0f1c-4360-b228-12b610aebc39": {"doc_hash": "24b6e081365ff6c2ad44b3ac890cf3f447e742a9b781cf010e92485dc1eacaca", "ref_doc_id": "c92f3df4-199d-4d6b-838c-42881f5e3608"}, "8909c322-fe28-46c3-8315-959451b24de1": {"doc_hash": "22e67029d780eea37ba16140127d3a2e42d634cea4f30a68c9693775d2573c1a", "ref_doc_id": "734e37d3-a592-4ffc-875a-ce92d938e6a1"}, "0e170f1e-debe-4b09-b766-725b6a3104ba": {"doc_hash": "78f6c52351c58bc24a903019eb707cfa05ef53e19a0dd785e1dc818b0079fa2f", "ref_doc_id": "777245b2-8aad-40f0-bae7-38559b41654f"}, "671c90b1-1f49-49aa-82be-adb24fe18b2b": {"doc_hash": "63824b23b9af392795400d912dc9e3deea075747815a028a82bc673464d19a79", "ref_doc_id": "7397c490-5cea-4483-81e9-e9c467c85cd7"}, "179cac5f-1988-4b79-aba6-3e78642c9eda": {"doc_hash": "5509033d6adc71b39eb638eb872fc60f4c96831d4f2283d18ab24c36fe29ab0b", "ref_doc_id": "c298ebf1-9fc9-48be-9903-9dd238946b52"}, "014cbe89-7a69-46cb-8dba-bd96b8f77cd1": {"doc_hash": "dc694a5d0b759d4efe69993c7cf28e63c8d618652548cc5ce43424b8386eb7ef", "ref_doc_id": "cb003069-afee-409f-80dc-4563de93186d"}, "ba5cbc2e-68a1-4fd6-a7cd-be1ba1d89326": {"doc_hash": "72a751f67bdcb197dc94aeea74b6b04e9f850f86eee9ad5b916812fdd7aba26b", "ref_doc_id": "40e85c16-40a2-448a-a4c3-423625087924"}, "43457019-1d65-49b8-9461-ccfd9a35f78f": {"doc_hash": "652aca45f4ac4700e5a489bca7b38b1dfd5e6d70fa4e4d7a55bfa1ff6e79bd99", "ref_doc_id": "227de9f2-0ea6-41fc-950a-ccd00fd2c345"}, "bef04473-0a6c-45c3-adb2-541a859d9df2": {"doc_hash": "6c97df8a3974cad8646a3c2c46f046463b5c73d50158dc76889ec7c622a19c3b", "ref_doc_id": "0b47360d-b606-4a29-9119-c74d91a5b743"}, "85406487-299c-4930-9155-949b1e88e664": {"doc_hash": "7a3e6d5c8256df8c1bf7a8946d589dc023aad42bbd04629deb3c88396872944e", "ref_doc_id": "cd18a2a6-89a0-43c3-9ba2-f6413dd56639"}, "97ca69d7-af96-4826-8b0b-65ca5ae9c3ac": {"doc_hash": "f2084a6e2e2d8ecee24df634ae779cc39df39a79026f65d52a000287e4bf961d", "ref_doc_id": "98716d2f-5b54-4de9-b2df-031fda86dc8f"}, "d73aa760-852c-419e-8925-5abc34efd4c9": {"doc_hash": "5d83fae02a26be2f166a57104cd24d6273f4ab79b65e15c9d55fd73f74ada496", "ref_doc_id": "6a31f036-beec-4d53-938e-b11fbabb7b1d"}, "5dc38c12-b045-432b-a563-c88add55127e": {"doc_hash": "fcdd28785cd2e87b60a1c44c5c3b9d70a64d8103414feabade316d1676f16cf3", "ref_doc_id": "4efcbbe3-ace6-44bf-a9ef-07112f806ba6"}, "29ea72a5-32cc-46cb-8385-5189e774f49e": {"doc_hash": "c7baa57fc45a08bd31ab7a7dee3608efb79c4cd330efd1429faf28f42204f4e1", "ref_doc_id": "8cb7399f-8b8a-428b-80de-956778644a1a"}, "281ba61c-8e2c-453e-907a-f52be2ce464c": {"doc_hash": "655a14975672e33d36f62d4d935ab3a49f2e86bc58f357c00042792147ff1058", "ref_doc_id": "38190395-f646-4c5b-aa0b-b3a65fbc2944"}, "12f4ae41-e427-4736-a7ab-aacf333d0e0c": {"doc_hash": "e7d2aafa585518f193bf21ad57419c3e7d19ebfd1805b613d588ce905dab3988", "ref_doc_id": "bc46a659-b482-46d9-92e2-51b58bc4d3b3"}, "0d35f700-67ae-435e-8719-cd0947ff5ce0": {"doc_hash": "527ea1b91482bf5c61ce821227af310f338c912252d5495ccf791d891af3fef1", "ref_doc_id": "31786909-1a60-4d8a-b031-3fbeee0ddf5b"}, "bf89d188-c06e-402a-9c1f-7b3fe3b6a438": {"doc_hash": "be4404e579db8ba9d34c9b96b18700cbd059d781dcc1d57438f050574432d39f", "ref_doc_id": "40f03c60-2c61-4687-ae54-fc20c1534fe7"}, "f6e1407b-1c99-440b-bead-f26c0c0cdaaa": {"doc_hash": "e4047f325fb7b99e0bb433a73689db2d10d0f087ef73f8ea242872fc43b4a6ca", "ref_doc_id": "f3d83edb-b907-4083-baf1-c23cefa36fb7"}, "1fc5e80d-8172-46a6-9692-691b69114ea4": {"doc_hash": "3d4ca2ea17a7c7925db4b8787a7ff1bdbe3961cc5f7e310b9c77a12fe009b8b5", "ref_doc_id": "4e7f686d-acd8-4588-962f-aa1a84b537ef"}, "9bed7da8-4e7a-464a-9445-feeb81bdd9df": {"doc_hash": "cbbabd1e9cc5f5a39a3ec1c2c1830f278006237adec1291fa6dbc3291f43e509", "ref_doc_id": "ffe3a2c0-0d0d-4e6d-bd8f-e8cdf3a34a93"}, "92180ee0-466e-4b38-8b20-74cc275fdbf3": {"doc_hash": "e99a67b213bb4d28f5dd3b3044a43b08ea6a841234680d82ab752c8d4aee8292", "ref_doc_id": "41c1b8e8-39ba-44b4-a432-d95966915e77"}, "7bf7ab8f-2fcf-4c74-a7fc-fbff69205b04": {"doc_hash": "fceda5b1cd336c63d064e0b4193df3cfc086952b8fd9957294117c08de5ba3e9", "ref_doc_id": "104dc4d6-b559-40e9-b95e-adf0d6bec6ab"}, "aee75c72-6eea-48bf-bd03-f117fafdcbf7": {"doc_hash": "38b09e86793b20dd73ad5863cd78234a856e0175afa128bb1ed2bd781ebac0d2", "ref_doc_id": "136170ca-c500-487e-b337-22d8b495d2aa"}, "7c0e73e4-2f49-434c-a4e2-8f447b024200": {"doc_hash": "f359a90edba842a481292bfa533647b9cf76b35d6023a77b10f94a57cfad3985", "ref_doc_id": "663771ba-3789-4434-93c1-4aca524c9bb9"}, "c73c7897-f0c0-48f9-8398-7aaaa55cf5fc": {"doc_hash": "00312c8a5383d115de292446b85ddc229bef0428579b4865fc3613690db99ba0", "ref_doc_id": "7ab705b2-4cc3-4f1a-bb68-e26733afbf78"}, "fe238e7f-95cd-4532-8c7f-c2dd097a1ae5": {"doc_hash": "9893faeee75c5be455c016b904ec30e6010141763b516bba65946b5f7845bd07", "ref_doc_id": "9a5e0369-cc47-4cd1-a0a3-f90ca71347c7"}, "3a5813ae-b462-4e22-9733-aa5c33b3f7b8": {"doc_hash": "9bc972b25d84f5c6f02d84544357802f979f717595feb9e9bdbffb6f24dfe97c", "ref_doc_id": "5caf1014-b62a-419f-a5d7-8c46a665f51e"}, "270cf6ee-a4c3-49d2-bac1-1fb268ac46f9": {"doc_hash": "5b191f0faf4742b88e068e8714da99fc651b47f611686ff5b77ee64d3a375044", "ref_doc_id": "42dfc961-226b-487c-bbeb-86d81c61c7f8"}, "872752dd-d2bf-40c9-ba56-5ffe35407718": {"doc_hash": "da78cc1adc027788c8e4be12cf5bbb308922ab07ed97bcdf6613f28f82211b1d", "ref_doc_id": "cd25c970-03cd-4d06-a610-617279aec832"}, "43100b44-fcba-4fff-832a-aa6fd9f3b74d": {"doc_hash": "a8f2e76bbf22de42357ac844b859e9f72d4fafcb99e7b8875fbb4e37d43cbd6f", "ref_doc_id": "cd3f3f91-808e-4877-92ff-e233f4f7c290"}, "b21ec205-87d0-4fc2-ab7c-fdcc4c97179b": {"doc_hash": "e6865864b5eb627a140837d09d6117f3e4f60842c4593d2fdbf233f58d43181f", "ref_doc_id": "04dc2aec-2f84-4178-97cb-b2e9cb25d29a"}, "0560e4e4-098f-480e-afe7-48e96c02ee58": {"doc_hash": "242996be408d21b31f0a3f8962df38a80953fcc36f4e3540f5a48992c3baaf87", "ref_doc_id": "5536d671-c208-43c8-b192-afe434b0b1c9"}, "07259642-448f-457e-9bb1-cd4b758a4a54": {"doc_hash": "1788c245a97e62cd32dc9a30bc957bec0e76e3789662f4d3bb9559af6cd2b30d", "ref_doc_id": "256f0a30-1a17-47f8-89bb-e2dcb5e12ee2"}, "104f2637-a7e8-4633-af7e-6744ff1ed9a7": {"doc_hash": "195068c5021ebb2d7276530a8cb718c47a3668a3c30d0a884a2019aab2764332", "ref_doc_id": "15b3f0de-dbb5-484b-b0ac-458ba3699965"}, "ce315e9f-dd54-4731-830f-40d2e91b484e": {"doc_hash": "6c7ecf76aeb71e39e3e68d5f7279b40f6d3bcf34cb521d2bb9d87419d1f8c2ac", "ref_doc_id": "fda169f1-d6e6-4c31-a68f-7a48980c3267"}, "b2cb0e6d-1cd3-4336-92ac-841d45e3bb86": {"doc_hash": "4953d17e4aa0839ab2d900262605cb05e1d3b56daccac5d6bf5d0d39d2cd2730", "ref_doc_id": "b9ac2e99-1c90-4d1f-8bf4-8bdf00425dae"}, "1a9ed0d6-542f-4367-ba5b-14d0c70bf078": {"doc_hash": "ae215af596d60c022501d5c1dcb7519b23c039db6e8b7693214b65a97f9fcb03", "ref_doc_id": "628dd9b3-21da-4ea8-9141-e2dc6f642e5f"}, "6b8f8fa9-7c21-45af-8fde-88740d8d6fff": {"doc_hash": "96f619f86eff2d61048735bc6f9765202a6cb270fbf03539bed65433f9fe72ef", "ref_doc_id": "612f8d6e-7bef-4f3a-81a4-6cdcc610ad3c"}, "bfaaf6ba-66cd-4bfc-b3e7-d4c3bd250570": {"doc_hash": "79f0147967b4a63a4c5acee6fb0770e9654df69aa6ec0fbc24c85b47ef58f397", "ref_doc_id": "6dcfe2a2-125c-49ac-9f0c-429d64377f5d"}, "2a5bde92-8d17-46b4-925e-67cf5acd90c1": {"doc_hash": "2e05934798a0a7760ba682e554d83f5aa5b82112de6d7c771bfdb63da8b2d0c9", "ref_doc_id": "02d8ebd5-3a6b-4df0-bd03-1384a053601d"}, "aa594a97-4c8e-460e-9857-cfcbc702f189": {"doc_hash": "322670d8684f78dcefc2cfc18d5cda40be3bf4235e8c25104ce8c097a9abbb21", "ref_doc_id": "c699624b-62e6-4b9d-9cd5-23b7f3889c73"}, "382acb42-391c-4002-bc97-7c613ebd858b": {"doc_hash": "bc6708602e9a9f5a128282174b4004add180a55a1c488586da789c264076b861", "ref_doc_id": "109584fe-8657-4c8e-8680-8bf6d55c267b"}, "bf647959-772e-40b2-bbd3-1de908615478": {"doc_hash": "3a2fa6660054dbe5ab7855fc84833ca8977716580a38528dc45c96e9ed3a142d", "ref_doc_id": "a222ab60-a84f-43ff-bb26-720100fea95d"}, "d405ea25-1bdf-4254-81ce-0f8c9cbff216": {"doc_hash": "d9f2cc4f28560f3283874a6ac4eb16086ee7760fc0b904ae769e99935ec1d6e3", "ref_doc_id": "ac9950a3-7acb-48c2-be65-b9d6be556fe7"}, "15ada0bf-f678-4c82-89f3-ee03f5510e5a": {"doc_hash": "245ef3e22ee8e0c10d84b9a44a0bb62fa150787096e52b988ba945be45fec323", "ref_doc_id": "c8bc243a-d811-4a07-8528-6d5f342a1d1d"}, "7d9e119e-b302-41f7-b535-937cc39c8d13": {"doc_hash": "9b3c0fe65ad9115018ab477b3da351811537ac20edb3919b1927939701e91492", "ref_doc_id": "e948d067-ee7c-4787-9c16-e934d3780167"}, "92ae8602-c007-4512-8323-02717be0ff33": {"doc_hash": "4d1cced7bc8fa5db5de6d08e75c0e8c26e8c52dd0f528adc4b99c1b52dfafb68", "ref_doc_id": "03a3a8d3-4b8f-4df9-9303-a76d54e86ef2"}, "8e520bfa-475b-450b-98c9-c8f4a20e3ce3": {"doc_hash": "c28035a358a3587d46571d3446948ebc6c331ef3042686ab5f1b313542bb1e73", "ref_doc_id": "705df9e9-98a2-4d99-87d9-ced452bce29c"}, "7ef3aa49-8532-4e58-b2a7-006293d91d3c": {"doc_hash": "3ae2b564e66ebb43b27b02619bf1242e898b6392f56c6ed3aee63c0f588a3223", "ref_doc_id": "8e8ad89d-6cf5-4b15-b1a7-9e9d5a9f42b4"}, "81facdc1-e569-4803-af5e-049d8dc6a18d": {"doc_hash": "d1cbced69e95783b35f9aa4ddf187f471f3e65d63e69149e76535bd70189e259", "ref_doc_id": "984cb7ef-d327-4df6-bc45-1c410e296bd6"}, "4b1f93f6-8271-43b4-93f8-8d526d920a48": {"doc_hash": "ef206747cdb696a8778816e15cf985106f07d5a6e1207db111b7b7186273b588", "ref_doc_id": "197a0af0-4bad-4f48-b8cf-581a986f26a0"}, "9316ad7c-8446-4a74-955e-7f6272f7996e": {"doc_hash": "d47b66e4360c6649f568961f2d2f6c0225a41140a7decb60e764358c153f2dc4", "ref_doc_id": "4c4408f7-71f8-4442-aca8-c48541ab3e6d"}, "e2b847a1-3c8c-4dc6-b816-c787d7048ab6": {"doc_hash": "2244e615953a008a38cb5c4f5f2a085b83c3a7bdfcb6c93a5bba4015e27fe94b", "ref_doc_id": "4b7b0220-8915-48d1-8928-546b959adca6"}, "fed06ec9-82d1-4fda-a83f-785b21621fba": {"doc_hash": "1ba6a61bf1e5f53806fb81101a184b6e27bc11b052114d41202f863114ac59d1", "ref_doc_id": "a007a30e-a754-4c12-8119-7e843a152aae"}, "e7f0b0cc-57cb-406e-95fa-491304cf3b96": {"doc_hash": "867081a1aa20111388ecdbe58eeaa8c6ccd6ccf925cb403b21e9eae7bb3401a2", "ref_doc_id": "34d0166b-75ba-435b-be75-60c48bf5be46"}, "ec70265e-82f2-4863-bc39-9e7aa7cfb544": {"doc_hash": "db104c201db58b329266be53754eb53713593c1f61538c29793e84db6ecd6367", "ref_doc_id": "33f7c5b4-4150-435f-867f-37b1608f061a"}, "6e619cf2-52e5-438d-a504-94a7b23a85f4": {"doc_hash": "b1aaf6a65645f8835297b8c822f217df61ef4645a14e4fb4a23c6c3b9f188cae", "ref_doc_id": "4760e4e7-5963-444f-9cb8-d6a5e2c7849e"}, "01234734-a600-4434-a226-79650cdb5e92": {"doc_hash": "9c07fda77e5c7ac32f34f2a067babee3c20c5887991b1a37259e6995bd792cd5", "ref_doc_id": "1a7e0389-5ef6-4163-b777-93f2a862a24a"}, "ed5782ff-d0d5-4a36-a3e0-a7f0ab049f98": {"doc_hash": "3fbae9a0a4b3b44202a0590dde037c01ad14c08fe875568917900077ae4ee182", "ref_doc_id": "3a151fca-debd-4c53-a595-bc5635401999"}, "46a1d47c-105b-4cd4-a8e5-46ecf5b8bf9a": {"doc_hash": "b9301797b984a91a5c9658abb9d6d37c04a710f6e6dcf99062371e57b21902c1", "ref_doc_id": "a905d89a-adfb-4fd1-9447-18d950119f11"}, "5bacb323-f328-4ec5-b58a-152dc7408b1a": {"doc_hash": "ab6a0a49c418e4f7b9341599a87a19e9e42ce0c567feeb90e7ebb0c445456b6b", "ref_doc_id": "6b763825-5d5a-47c3-b589-3188a396fda6"}, "f1ead976-e54a-44fe-80f4-df1d4fc1457c": {"doc_hash": "ea80956a6dd09a0db0358467796890a7c0f4afcdbad965a21ed3459a7c148393", "ref_doc_id": "f1cb2359-9cf6-49a8-bcfe-303468a1b5fc"}, "1315c207-b295-420a-9879-f2f1f78fb554": {"doc_hash": "917386dc8f175f98e44c0d899f48e62a2a8b5cdc7c3ede4d3479860e854e6671", "ref_doc_id": "94bce007-7d32-4c48-8cdf-739101c4e263"}, "59f62c0c-d266-4a67-845d-142022f3f7a6": {"doc_hash": "b5b0eec98d2280cfc6eb38b33e5f8b6b712c293fa7d1ecc0abc7ef9f021926e9", "ref_doc_id": "1fa5f1ae-e269-43d7-9cf7-18c7a65d69e6"}, "61d47c0d-a1be-4d36-ba8a-75078adddd2a": {"doc_hash": "6d7a27cb8785c7d7508e4742f154fc40708285d1a92eb8fea37c68ff53bbcfb7", "ref_doc_id": "633835fa-fe82-4309-a401-2fdb012acd53"}, "b8f2ba95-4466-4310-8433-176fcae01627": {"doc_hash": "32e1e8af83cf17b1d198e688b6499004f14832fa77af05c04d0e2e6cdf51c4e8", "ref_doc_id": "c79f3868-0e6b-458a-a17e-354a38d4f9ae"}, "54298ac0-53f7-4c73-9d3c-ef9514bc5b5f": {"doc_hash": "bbb803e511c5afe45cffc53fa966124cc3f43a48a3cf69d411195b1b0a832b1a", "ref_doc_id": "b4a14a89-c3a5-4803-acc4-0b1094d5d162"}, "5f237146-bcd6-4eb1-8099-40a0bdbb7324": {"doc_hash": "08be19fa9d03ba037e041185cebcdda15a79015501b7c84034e1191cd83807aa", "ref_doc_id": "69a9048c-3ef4-4ec1-8d12-bb6788c37667"}}, "docstore/ref_doc_info": {"6a6ef094-cfc3-49bc-96bf-f3a9cf1b9eaa": {"node_ids": ["a31587f5-80d9-4809-ba6c-865cc6d57693"], "metadata": {"page_label": "1", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar presente en el documento:\n\n### Resumen del Contexto\nEl documento titulado \"WHO - Technical Report Series 961\" es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se proporciona contenido espec\u00edfico en el texto, los informes de esta serie suelen abordar temas relacionados con la salud p\u00fablica, investigaciones cient\u00edficas, recomendaciones sobre pr\u00e1cticas de salud y pol\u00edticas sanitarias.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS presentadas en el informe t\u00e9cnico 961?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS ha emitido en este informe, que podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el informe WHO TRS 961 y c\u00f3mo se relacionan con las tendencias actuales en salud global?**\n   - Esta pregunta se enfoca en identificar los temas tratados en el informe y su relevancia en el contexto de los desaf\u00edos actuales en salud p\u00fablica a nivel mundial.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas de investigaci\u00f3n se utilizaron para recopilar los datos presentados en el informe WHO TRS 961?**\n   - Esta pregunta busca detalles sobre las t\u00e9cnicas y enfoques de investigaci\u00f3n que respaldan las conclusiones del informe, lo que podr\u00eda ser \u00fatil para investigadores y acad\u00e9micos interesados en la validez de los datos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otras fuentes, dado que se centran en el contenido particular del informe de la OMS.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, recomendaciones, investigaci\u00f3n, pol\u00edticas sanitarias"}}, "e754d05f-506f-4b4f-a402-b86461b618aa": {"node_ids": ["b8f2b78f-8b97-4eae-a1fd-f965eca10ede"], "metadata": {"page_label": "2", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Library Cataloguing-in-Publication Data\n\nForty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations.\n\n(WHO technical report series ; no. 961)\n\n1. Pharmaceutical preparations \u2014 standards. 2. Technology, Pharmaceutical \u2014 standards. 3. Drug industry \u2014 legislation. 4. Quality control. I. World Health Organization. II. Series.\n\nISBN 978 92 4 120961 8  \nISSN 0512-3054  \n(NLM classification: QV 771)\n\n----\n\n\u00a9 World Health Organization 2011\n\nAll rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications \u2014 whether for sale or for noncommercial distribution \u2014 should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).\n\nThe designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.\n\nThe mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.\n\nAll reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.\n\nThis publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.\n\n*Typeset in Switzerland*  \n*Printed in Switzerland*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es el \"Cuarenta y quinto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas\", publicado en la Serie de Informes T\u00e9cnicos de la OMS (n\u00famero 961). Este informe aborda est\u00e1ndares para preparaciones farmac\u00e9uticas, tecnolog\u00eda farmac\u00e9utica, legislaci\u00f3n de la industria farmac\u00e9utica y control de calidad. Tambi\u00e9n incluye informaci\u00f3n sobre la obtenci\u00f3n de publicaciones de la OMS, as\u00ed como una declaraci\u00f3n de responsabilidad sobre la interpretaci\u00f3n y uso del material presentado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales est\u00e1ndares discutidos en el informe sobre preparaciones farmac\u00e9uticas y c\u00f3mo se relacionan con la calidad del producto final?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los est\u00e1ndares mencionados en el informe y su impacto en la calidad de las preparaciones farmac\u00e9uticas.\n\n2. **\u00bfQu\u00e9 recomendaciones hace la OMS en relaci\u00f3n con la legislaci\u00f3n de la industria farmac\u00e9utica en el contexto de este informe?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que la OMS proporciona sobre la legislaci\u00f3n en la industria farmac\u00e9utica, que pueden no estar disponibles en otras fuentes.\n\n3. **\u00bfC\u00f3mo se asegura la OMS de la veracidad de la informaci\u00f3n presentada en este informe y cu\u00e1les son las limitaciones de esta verificaci\u00f3n?**\n   - Esta pregunta indaga sobre los m\u00e9todos de verificaci\u00f3n utilizados por la OMS y las limitaciones que pueden existir en la informaci\u00f3n presentada, lo que puede no ser evidente en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" de la Organizaci\u00f3n Mundial de la Salud (OMS) se centra en temas relevantes de salud p\u00fablica y proporciona recomendaciones y directrices basadas en investigaciones cient\u00edficas. Aunque no se presenta contenido espec\u00edfico en el texto, se pueden inferir los siguientes temas clave y entidades:\n\n#### Temas Clave:\n1. **Recomendaciones de Salud P\u00fablica**: Directrices emitidas por la OMS para mejorar las pr\u00e1cticas de salud y pol\u00edticas sanitarias.\n2. **Investigaci\u00f3n Cient\u00edfica**: An\u00e1lisis y estudios que respaldan las conclusiones y recomendaciones del informe.\n3. **Tendencias en Salud Global**: Relaci\u00f3n de los temas tratados en el informe con los desaf\u00edos actuales en el \u00e1mbito de la salud a nivel mundial.\n4. **Metodolog\u00edas de Investigaci\u00f3n**: T\u00e9cnicas y enfoques utilizados para recopilar y analizar datos en el contexto del informe.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la elaboraci\u00f3n del informe y de la promoci\u00f3n de la salud p\u00fablica a nivel global.\n- **Informe T\u00e9cnico**: Tipo de documento que presenta hallazgos y recomendaciones sobre temas espec\u00edficos de salud.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos que podr\u00edan ser relevantes en el informe, aunque no se disponga de contenido espec\u00edfico en el texto proporcionado.", "excerpt_keywords": "Keywords: pharmaceutical standards, quality control, WHO report, drug legislation, health technology"}}, "c963115b-9aa0-4e23-a1e7-76d051e60ab3": {"node_ids": ["1376bc00-53db-495a-8f54-b2bb554036fe"], "metadata": {"page_label": "3", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Contents\n\n1. **Introduction**  \n   1\n\n2. **General policy**  \n   6  \n   2.1 International collaboration  \n   6  \n   2.1.1 Collaboration with international organizations and agencies  \n   6  \n   European Directorate for the Quality of Medicines and HealthCare (Council of Europe)  \n   6  \n   The Global Fund to Fight AIDS, Tuberculosis and Malaria  \n   6  \n   United Nations Children's Fund  \n   7  \n   2.1.2 Pharmacopoeial Discussion Group  \n   8  \n   2.1.3 International Conference on Harmonisation  \n   9  \n   2.1.4 International Conference of Drug Regulatory Authorities  \n   9  \n   2.2 Cross-cutting issues in pharmaceuticals \u2013 quality assurance issues  \n   10  \n   2.2.1 Essential medicines  \n   10  \n   2.2.2 Herbal and complementary medicines  \n   11  \n   2.2.3 Regulatory support  \n   12\n\n3. **Joint session with the Expert Committee on Biological Standardization**  \n   13\n\n4. **Quality control \u2013 specifications and tests**  \n   14  \n   4.1 *The International Pharmacopoeia*  \n   14  \n   4.2 Current work plan and future work programme  \n   15  \n   4.3 Specifications for medicines, including children's medicines  \n   16  \n   4.3.1 Medicines for HIV and related conditions  \n   16  \n   4.3.2 Antimalarial medicines  \n   16  \n   4.3.3 Antituberculosis medicines  \n   17  \n   4.3.4 Anti-infectives  \n   18  \n   4.3.5 Other medicines  \n   19  \n   4.4 Revision of texts of *The International Pharmacopoeia*  \n   19  \n   4.4.1 Antimalarials: artemisinin derivatives  \n   19  \n   4.4.2 Other medicines  \n   20  \n   4.5 Review of published general monographs for dosage forms and associated method texts  \n   21  \n   4.5.1 Pharmacopoeial Discussion Group: harmonized general texts  \n   21  \n   4.5.2 Uniformity of content for single-dose preparations  \n   23  \n   4.6 General policy topics and general revision issues for *The International Pharmacopoeia*  \n   24  \n   4.6.1 Update on dissolution tests  \n   24  \n   4.6.2 Dry powders  \n   25\n\n5. **Quality control \u2013 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)**  \n   28  \n   5.1 Update on transfer of International Chemical Reference Substances  \n   28  \n   5.2 Proposal for an accelerated release of International Chemical Reference Standards  \n   29  \n   5.3 Proposed first International Standard for biosynthetic human insulin  \n   30", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda temas relacionados con la pol\u00edtica general de colaboraci\u00f3n internacional en el \u00e1mbito de la calidad de los medicamentos. Se discuten las colaboraciones con diversas organizaciones internacionales, as\u00ed como cuestiones transversales en farmac\u00e9uticos, incluyendo la calidad y la regulaci\u00f3n de medicamentos esenciales, herbales y complementarios. Tambi\u00e9n se detalla el control de calidad, especificaciones y pruebas, incluyendo la revisi\u00f3n de textos de la Farmacopea Internacional y la propuesta de est\u00e1ndares internacionales para sustancias qu\u00edmicas y espectros infrarrojos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 organizaciones internacionales se mencionan en el documento como colaboradoras en la mejora de la calidad de los medicamentos y cu\u00e1les son sus roles espec\u00edficos?**\n   - Esta pregunta busca respuestas sobre la naturaleza de la colaboraci\u00f3n y el impacto de cada organizaci\u00f3n en la calidad de los medicamentos.\n\n2. **\u00bfCu\u00e1les son las especificaciones y pruebas propuestas para los medicamentos dirigidos a condiciones espec\u00edficas como el VIH, la malaria y la tuberculosis?**\n   - Esta pregunta se centra en los detalles t\u00e9cnicos y las normativas espec\u00edficas que se aplican a medicamentos para estas condiciones, que pueden no estar disponibles en otras fuentes.\n\n3. **\u00bfQu\u00e9 actualizaciones se han propuesto en relaci\u00f3n con los est\u00e1ndares internacionales para las sustancias qu\u00edmicas de referencia y c\u00f3mo se espera que impacten en la calidad de los medicamentos?**\n   - Esta pregunta busca informaci\u00f3n sobre las propuestas recientes y su relevancia en el contexto de la regulaci\u00f3n y control de calidad de los medicamentos a nivel internacional. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **T\u00edtulo del Documento**: Cuarenta y quinto informe del Comit\u00e9 de Expertos de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas (WHO Technical Report Series, no. 961).\n\n2. **Temas Principales**:\n   - **Est\u00e1ndares para Preparaciones Farmac\u00e9uticas**: Discusi\u00f3n sobre los est\u00e1ndares que deben cumplir las preparaciones farmac\u00e9uticas.\n   - **Tecnolog\u00eda Farmac\u00e9utica**: Normativas y est\u00e1ndares relacionados con la tecnolog\u00eda utilizada en la industria farmac\u00e9utica.\n   - **Legislaci\u00f3n de la Industria Farmac\u00e9utica**: Recomendaciones y regulaciones que afectan a la industria farmac\u00e9utica.\n   - **Control de Calidad**: M\u00e9todos y pr\u00e1cticas para asegurar la calidad de los productos farmac\u00e9uticos.\n\n3. **Entidades**:\n   - **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad responsable de la publicaci\u00f3n y contenido del informe.\n   - **WHO Press**: Entidad encargada de la distribuci\u00f3n de las publicaciones de la OMS.\n\n4. **Informaci\u00f3n Adicional**:\n   - **ISBN y ISSN**: Identificadores del documento (ISBN 978 92 4 120961 8, ISSN 0512-3054).\n   - **Declaraci\u00f3n de Responsabilidad**: Aclaraciones sobre la veracidad de la informaci\u00f3n y la responsabilidad del lector en la interpretaci\u00f3n del material.\n   - **Ubicaci\u00f3n de la OMS**: Direcci\u00f3n de la sede de la OMS en Ginebra, Suiza.\n\nEste resumen destaca los aspectos fundamentales del informe, as\u00ed como las entidades involucradas en su creaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceuticals, quality assurance, international collaboration, pharmacopoeia, drug regulation"}}, "a59ec511-ba1c-4bd0-817a-b3db692fc091": {"node_ids": ["684152ea-734c-47e8-88be-4f84085af171"], "metadata": {"page_label": "4", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6. Quality control \u2013 national laboratories  \n   6.1 External Quality Assurance Assessment Scheme 31  \n   6.2 WHO good practices for pharmaceutical microbiology laboratories 32  \n\n7. Quality assurance \u2013 good manufacturing practices  \n   7.1 Update of WHO good manufacturing practices: main principles for pharmaceutical products 33  \n   7.2 WHO good manufacturing practices for blood establishments 33  \n   7.3 Update of WHO good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 34  \n   7.4 Update of WHO good manufacturing practices: Water for pharmaceutical use 34  \n   7.5 Revision of WHO good manufacturing practices: Sterile pharmaceutical products 35  \n\n8. Quality Assurance \u2013 new approaches  \n   8.1 WHO guidelines on quality risk management 35  \n   8.2 WHO guidelines on technology transfer 36  \n\n9. Quality assurance \u2013 distribution and trade of pharmaceuticals  \n   9.1 Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services 36  \n   9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products 38  \n   9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce 38  \n      9.3.1 Update on current activities 38  \n      9.3.2 Questions and answers 39  \n\n10. Prequalification of priority essential medicines  \n    10.1 Update on the WHO Prequalification of Medicines Programme 39  \n    10.2 Procedure for prequalification of pharmaceutical products 41  \n    10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities 41  \n\n11. Prequalification of quality control laboratories  \n    11.1 Update of activities 41  \n    11.2 Procedure for prequalifying laboratories 42  \n    11.3 Update on the WHO guidelines for preparing a laboratory information file 43  \n\n12. Prequalification of active pharmaceutical ingredients 44  \n\n13. Regulatory guidance  \n    13.1 WHO guidelines for preparing a site master file 44  \n    13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format 45  \n    13.3 Guidelines on submission of documentation for a multisource (generic) finished product: quality part 45  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos de la calidad y regulaci\u00f3n en la industria farmac\u00e9utica. Se centra en la calidad del control en laboratorios nacionales, las buenas pr\u00e1cticas de fabricaci\u00f3n, la precalificaci\u00f3n de medicamentos esenciales y laboratorios de control de calidad, as\u00ed como la orientaci\u00f3n regulatoria para productos farmac\u00e9uticos. Se incluyen actualizaciones sobre esquemas de aseguramiento de calidad, directrices sobre gesti\u00f3n de riesgos y pr\u00e1cticas de farmacia, as\u00ed como procedimientos para la prequalificaci\u00f3n de productos y laboratorios.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las actualizaciones m\u00e1s recientes sobre las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan el documento?**\n   - Esta pregunta se puede responder al revisar las secciones que abordan las actualizaciones de las buenas pr\u00e1cticas de fabricaci\u00f3n, incluyendo principios para productos farmac\u00e9uticos, pr\u00e1cticas para establecimientos de sangre y sistemas de ventilaci\u00f3n.\n\n2. **\u00bfQu\u00e9 procedimientos se describen para la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad?**\n   - El contexto proporciona detalles sobre los procedimientos espec\u00edficos para la precalificaci\u00f3n de medicamentos esenciales y laboratorios, as\u00ed como la gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n necesaria.\n\n3. **\u00bfQu\u00e9 directrices ofrece la OMS sobre la gesti\u00f3n de riesgos en la calidad de los productos farmac\u00e9uticos?**\n   - La secci\u00f3n sobre nuevas aproximaciones incluye directrices espec\u00edficas sobre la gesti\u00f3n de riesgos, lo que permite entender c\u00f3mo la OMS aborda este aspecto cr\u00edtico en la calidad farmac\u00e9utica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que se encuentra en el contexto y que puede no estar disponible en otras fuentes.", "prev_section_summary": "El documento \"WHO - Technical Report Series 961\" aborda varios temas clave relacionados con la calidad de los medicamentos y la colaboraci\u00f3n internacional en este \u00e1mbito. A continuaci\u00f3n se presenta un resumen de los temas y entidades m\u00e1s relevantes:\n\n### Temas Clave\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de la calidad de los medicamentos a nivel global.\n\n2. **Pol\u00edtica General**:\n   - **Colaboraci\u00f3n Internacional**: Se discuten las colaboraciones con diversas organizaciones y agencias internacionales que trabajan en la mejora de la calidad de los medicamentos.\n   - **Cuestiones Transversales en Farmac\u00e9uticos**: Se abordan temas de aseguramiento de calidad, incluyendo medicamentos esenciales y productos herbales y complementarios.\n\n3. **Control de Calidad**:\n   - **Especificaciones y Pruebas**: Se detallan las especificaciones para diferentes tipos de medicamentos, incluyendo aquellos dirigidos a condiciones espec\u00edficas como VIH, malaria y tuberculosis.\n   - **Revisi\u00f3n de la Farmacopea Internacional**: Se menciona la revisi\u00f3n de textos y monograf\u00edas relacionadas con la calidad de los medicamentos.\n\n4. **Materiales de Referencia Internacional**: Se discuten los est\u00e1ndares internacionales para sustancias qu\u00edmicas de referencia y espectros infrarrojos, as\u00ed como propuestas para su actualizaci\u00f3n y aceleraci\u00f3n en la liberaci\u00f3n.\n\n### Entidades Mencionadas\n\n- **European Directorate for the Quality of Medicines and HealthCare**: Colabora en la regulaci\u00f3n y calidad de los medicamentos en Europa.\n- **The Global Fund to Fight AIDS, Tuberculosis and Malaria**: Trabaja en la lucha contra estas enfermedades a trav\u00e9s de la mejora de la calidad de los medicamentos.\n- **United Nations Children's Fund (UNICEF)**: Se involucra en la provisi\u00f3n de medicamentos esenciales para la salud infantil.\n- **Pharmacopoeial Discussion Group**: Grupo que trabaja en la armonizaci\u00f3n de textos farmacop\u00e9icos.\n- **International Conference on Harmonisation**: Se enfoca en la armonizaci\u00f3n de regulaciones y est\u00e1ndares en la industria farmac\u00e9utica.\n- **International Conference of Drug Regulatory Authorities**: Re\u00fane a autoridades reguladoras para discutir y mejorar la regulaci\u00f3n de medicamentos.\n\nEste resumen destaca la importancia de la colaboraci\u00f3n internacional y el control de calidad en el \u00e1mbito farmac\u00e9utico, as\u00ed como las entidades clave que participan en estos esfuerzos.", "excerpt_keywords": "Keywords: quality control, good manufacturing practices, prequalification, pharmaceutical regulations, risk management"}}, "73edfbe1-7061-4358-a6f4-32dedc58c618": {"node_ids": ["ffa1bc67-b137-4238-be34-8e4fd01c28ea"], "metadata": {"page_label": "5", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n13.4 Pharmaceutical development for multisource (generic) pharmaceutical products 46\n\n13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System 46\n\n13.6 Development of paediatric medicines: pharmaceutical development 47\n\n13.7 Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients 47\n\n14. Nomenclature, terminology and databases 48\n   14.1 New definition for \u201csubstandard medicines\u201d 48\n   14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d 49\n   14.3 International Nonproprietary Names (INN) for pharmaceutical substances 51\n\n15. Summary and recommendations 51\n\nAcknowledgements 58\n\nAnnex 1\nRelease procedure of International Chemical Reference Substances 67\n\nAnnex 2\nWHO good practices for pharmaceutical microbiology laboratories 69\n\nAnnex 3\nWHO good manufacturing practices: main principles for pharmaceutical products 94\n\nAnnex 4\nWHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) 148\n\nAnnex 5\nWHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms 215\n\nAnnex 6\nWHO good manufacturing practices for sterile pharmaceutical products 261\n\nAnnex 7\nWHO guidelines on transfer of technology in pharmaceutical manufacturing 285\n\nAnnex 8\nGood pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) 310\n\nAnnex 9\nModel guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) 324\n\nAnnex 10\nProcedure for prequalification of pharmaceutical products 373\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con el desarrollo y la regulaci\u00f3n de productos farmac\u00e9uticos. Incluye secciones sobre el desarrollo de medicamentos gen\u00e9ricos, la clasificaci\u00f3n de medicamentos esenciales, la calidad de ingredientes activos, y la nomenclatura de medicamentos. Adem\u00e1s, se presentan buenas pr\u00e1cticas de fabricaci\u00f3n y directrices para el manejo de productos farmac\u00e9uticos sensibles a la temperatura, as\u00ed como procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos?**\n   - Esta pregunta se centra en la secci\u00f3n 13.7 del documento, que aborda espec\u00edficamente los est\u00e1ndares de calidad necesarios para la artemisinina.\n\n2. **\u00bfQu\u00e9 define la OMS como \"medicamentos subest\u00e1ndar\" y c\u00f3mo se diferencia de los \"medicamentos falsificados\"?**\n   - Esta pregunta se relaciona con la secci\u00f3n 14.1 y 14.2, donde se presentan nuevas definiciones y clasificaciones de medicamentos, lo que permite entender las diferencias clave entre estos t\u00e9rminos.\n\n3. **\u00bfCu\u00e1les son las principales directrices de la OMS para las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta se refiere a la secci\u00f3n 14.6, que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n espec\u00edficas para productos farmac\u00e9uticos est\u00e9riles, proporcionando informaci\u00f3n sobre los est\u00e1ndares que deben seguirse en su producci\u00f3n. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que probablemente no se encuentre f\u00e1cilmente en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda varios temas fundamentales relacionados con la calidad y regulaci\u00f3n en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave\n\n1. **Control de Calidad en Laboratorios Nacionales**\n   - Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa.\n   - Buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica.\n\n2. **Aseguramiento de Calidad y Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**\n   - Actualizaciones sobre principios de BPF para productos farmac\u00e9uticos.\n   - Buenas pr\u00e1cticas para establecimientos de sangre.\n   - BPF para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en formas farmac\u00e9uticas no est\u00e9riles.\n   - BPF para agua de uso farmac\u00e9utico.\n   - Revisi\u00f3n de BPF para productos farmac\u00e9uticos est\u00e9riles.\n\n3. **Nuevas Aproximaciones en Aseguramiento de Calidad**\n   - Directrices sobre gesti\u00f3n de riesgos de calidad.\n   - Directrices sobre transferencia de tecnolog\u00eda.\n\n4. **Distribuci\u00f3n y Comercio de Productos Farmac\u00e9uticos**\n   - Directrices conjuntas FIP/OMS sobre buenas pr\u00e1cticas de farmacia.\n   - Orientaci\u00f3n para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y temperatura.\n   - Esquema de Certificaci\u00f3n de la OMS sobre la calidad de productos farmac\u00e9uticos en comercio internacional.\n\n5. **Precalificaci\u00f3n de Medicamentos Esenciales**\n   - Actualizaci\u00f3n del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n   - Procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n   - Gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos innovadores.\n\n6. **Precalificaci\u00f3n de Laboratorios de Control de Calidad**\n   - Actualizaci\u00f3n de actividades relacionadas.\n   - Procedimientos para la precalificaci\u00f3n de laboratorios.\n   - Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio.\n\n7. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos**\n\n8. **Orientaci\u00f3n Regulatoria**\n   - Directrices para la preparaci\u00f3n de un archivo maestro del sitio.\n   - Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para productos terminados multisource (gen\u00e9ricos).\n\n#### Entidades Mencionadas\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de establecer directrices y est\u00e1ndares en la industria farmac\u00e9utica.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Colaboraci\u00f3n con la OMS en la elaboraci\u00f3n de directrices sobre buenas pr\u00e1cticas de farmacia.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad y regulaci\u00f3n en la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: pharmaceutical development, quality requirements, essential medicines, good manufacturing practices, prequalification"}}, "e852ec3e-5c14-408f-ad9a-ffc3506ebb54": {"node_ids": ["a1ecab18-de64-436a-8798-0d489a43a096"], "metadata": {"page_label": "6", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\nAnnex 11  \nGuidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities  391\n\nAnnex 12  \nPrequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies  393\n\nAnnex 13  \nWHO guidelines for preparing a laboratory information file  403\n\nAnnex 14  \nWHO guidelines for drafting a site master file  409\n\nAnnex 15  \nGuidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format  417\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 se aborda en el Anexo 11 del documento?**\n   - El Anexo 11 del documento trata sobre las \"Gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas\". Este anexo proporciona directrices sobre c\u00f3mo presentar la documentaci\u00f3n necesaria para que un producto farmac\u00e9utico innovador sea considerado para la precalificaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito del Anexo 12 en el informe?**\n   - El Anexo 12 se centra en la \"Precalificaci\u00f3n de laboratorios de control de calidad\". Su prop\u00f3sito es establecer un procedimiento para evaluar la aceptabilidad, en principio, de los laboratorios de control de calidad que ser\u00e1n utilizados por las agencias de las Naciones Unidas, asegurando que cumplan con los est\u00e1ndares necesarios.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se espera en un archivo de informaci\u00f3n de laboratorio seg\u00fan el Anexo 13?**\n   - El Anexo 13 proporciona las \"Gu\u00edas de la OMS para preparar un archivo de informaci\u00f3n de laboratorio\". Este anexo detalla la informaci\u00f3n que debe incluirse en dicho archivo, que es esencial para la evaluaci\u00f3n de la calidad y la seguridad de los productos farmac\u00e9uticos, as\u00ed como para facilitar la comunicaci\u00f3n entre los laboratorios y las autoridades reguladoras.\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 961\" incluye varios anexos que ofrecen directrices y procedimientos relacionados con la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad. Estos anexos son cruciales para asegurar que los productos y laboratorios cumplan con los est\u00e1ndares internacionales establecidos por la OMS y otras autoridades regulatorias.\n\n### Preguntas adicionales basadas en el resumen:\n1. **\u00bfQu\u00e9 importancia tienen los anexos en el contexto de la precalificaci\u00f3n de productos farmac\u00e9uticos?**\n2. **\u00bfC\u00f3mo contribuyen las gu\u00edas de la OMS a la estandarizaci\u00f3n de los procesos de evaluaci\u00f3n de laboratorios de control de calidad?**\n3. **\u00bfQu\u00e9 se entiende por \"dossier de producto\" en el contexto del Anexo 15 y por qu\u00e9 es relevante?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda una variedad de temas relacionados con el desarrollo, regulaci\u00f3n y buenas pr\u00e1cticas en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n1. **Desarrollo Farmac\u00e9utico**:\n   - **Medicamentos Multifuente (Gen\u00e9ricos)**: Secci\u00f3n 13.4 que trata sobre el desarrollo de productos farmac\u00e9uticos gen\u00e9ricos.\n   - **Medicamentos Pedi\u00e1tricos**: Secci\u00f3n 13.6 que se enfoca en el desarrollo de medicamentos para ni\u00f1os.\n\n2. **Clasificaci\u00f3n de Medicamentos**:\n   - **Medicamentos Esenciales**: Secci\u00f3n 13.5 que clasifica los medicamentos administrados por v\u00eda oral seg\u00fan el Sistema de Clasificaci\u00f3n Biofarmac\u00e9utica.\n\n3. **Calidad de Ingredientes Activos**:\n   - **Artemisinina**: Secci\u00f3n 13.7 que establece los requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos.\n\n4. **Nomenclatura y Terminolog\u00eda**:\n   - **Medicamentos Subest\u00e1ndar**: Nueva definici\u00f3n presentada en la secci\u00f3n 14.1.\n   - **Medicamentos Falsificados**: Definiciones y diferencias en la secci\u00f3n 14.2.\n   - **Nombres No Propietarios Internacionales (INN)**: Secci\u00f3n 14.3 que aborda la nomenclatura de sustancias farmac\u00e9uticas.\n\n5. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n**:\n   - Directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos, incluyendo secciones espec\u00edficas para productos est\u00e9riles y no est\u00e9riles, as\u00ed como para laboratorios de microbiolog\u00eda.\n\n6. **Anexos**:\n   - Procedimientos y gu\u00edas adicionales sobre la liberaci\u00f3n de sustancias qu\u00edmicas de referencia, almacenamiento y transporte de productos farmac\u00e9uticos sensibles a la temperatura, y procedimientos de precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de las directrices y recomendaciones presentadas en el documento.\n- **Artemisinina**: Ingrediente activo clave en el tratamiento de la malaria.\n- **Medicamentos Esenciales**: Categor\u00eda de medicamentos que son fundamentales para satisfacer las necesidades de salud de la poblaci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de la calidad, la regulaci\u00f3n y las buenas pr\u00e1cticas en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, quality control laboratories, WHO guidelines, product dossiers"}}, "1e995c61-7702-49bd-94e2-3ec7b9a869f2": {"node_ids": ["d8f8e63b-79a0-4780-bb54-004cf6cac52d"], "metadata": {"page_label": "7", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# WHO Expert Committee on Specifications for Pharmaceutical Preparations\n\nGeneva, 18\u201322 October 2010\n\n## Members\n\n- **Professor Ivan Addae-Mensah**, Professor of Chemistry, University of Ghana, Legon, Ghana *(Chairperson)*\n\n- **Professor Saleh A. Bawazir**, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia *(Co-Chairperson)*\n\n- **Mr Eshetu Wondemagegnehu Biwota**, Addis Ababa, Ethiopia *(Co-Rapporteur)*\n\n- **Mr Jean-Michel Caudron**, Braine-le-Ch\u00e2teau, Belgium\n\n- **Professor Theo G. Dekker**, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa\n\n- **Ms Nilka M. Guerrero Rivas**, Head of Quality Assurance, Instituto Especializado de An\u00e1lisis, Ciudad Universitaria Octavio M\u00e9ndez Pereira, Panam\u00e1, Republic of Panama\n\n- **Professor Jos Hoogmartens**, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium\n\n- **Professor Jin Shaohong**, Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People\u2019s Republic of China\u00b9\n\n- **Dr Toru Kawanishi**, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan\n\n- **Dr Justina A. Molzon**, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA *(Co-Rapporteur)*\n\n- **Professor Tam\u00e1s L. Pa\u00e1l**, President, Scientific Board, National Institute of Pharmacy, and Professor, University of Szeged, Budapest, Hungary\n\n## Temporary Advisers\n\n- **Dr Lucette Cargill**, Director, Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica\n\n- **Mr Antonio Carlos da Costa Bezerra**, Senior Pharmacist, Brazilian Health Surveillance Agency, Brasilia, Brazil\n\n- **Professor Konstantin Keller**, Director and Professor, Federal Ministry of Health, Bonn, Germany\n\n- **Professor Henning G. Kristensen**, Vedbaek, Denmark\n\n- **Ms Gugu N. Mahlangu**, Acting Director for Laboratory Services, Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe\n\n----\n\n\u00b9 Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe de la **Comisi\u00f3n de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**, que tuvo lugar en Ginebra del 18 al 22 de octubre de 2010. La reuni\u00f3n reuni\u00f3 a expertos de diversas partes del mundo, incluyendo acad\u00e9micos y funcionarios de agencias de salud, para discutir y establecer est\u00e1ndares en la preparaci\u00f3n de productos farmac\u00e9uticos. Se mencionan los miembros y asesores temporales que participaron en la reuni\u00f3n, destacando sus roles y afiliaciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes fueron los co-rapporteurs de la reuni\u00f3n y cu\u00e1l es su afiliaci\u00f3n?**\n   - Respuesta: Los co-rapporteurs fueron **Mr Eshetu Wondemagegnehu Biwota** de Addis Ababa, Etiop\u00eda, y **Dr Justina A. Molzon**, Associate Director for International Programs en el Center for Drug Evaluation and Research de la US Food and Drug Administration, Silver Spring, MD, USA.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1\u00f3 el Profesor Ivan Addae-Mensah en la reuni\u00f3n?**\n   - Respuesta: El Profesor Ivan Addae-Mensah fue el **Chairperson** (presidente) de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre la participaci\u00f3n del Profesor Jin Shaohong en la reuni\u00f3n?**\n   - Respuesta: El Profesor Jin Shaohong, Executive Deputy Director del National Institute for the Control of Pharmaceutical and Biological Products en el Ministerio de Salud P\u00fablica de Beijing, Rep\u00fablica Popular de China, **no pudo asistir** a la reuni\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Documentaci\u00f3n para Precalificaci\u00f3n**:\n   - **Anexo 11**: Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos innovadores aprobados por autoridades regulatorias estrictas.\n\n2. **Laboratorios de Control de Calidad**:\n   - **Anexo 12**: Procedimiento para la precalificaci\u00f3n de laboratorios de control de calidad, enfocado en su aceptabilidad para uso por agencias de las Naciones Unidas.\n\n3. **Informaci\u00f3n de Laboratorio**:\n   - **Anexo 13**: Gu\u00edas de la OMS para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio, que incluye informaci\u00f3n esencial para la evaluaci\u00f3n de calidad y seguridad.\n\n4. **Archivo Maestro del Sitio**:\n   - **Anexo 14**: Directrices de la OMS para la redacci\u00f3n de un archivo maestro del sitio, que detalla la informaci\u00f3n sobre las instalaciones y procesos de un laboratorio o fabricante.\n\n5. **Dossier de Producto**:\n   - **Anexo 15**: Directrices sobre la presentaci\u00f3n de documentaci\u00f3n para productos terminados multisource (gen\u00e9ricos), incluyendo el formato general para la preparaci\u00f3n de dossiers de productos en formato de documento t\u00e9cnico com\u00fan.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona las directrices y procedimientos mencionados en los anexos.\n- **Agencias de las Naciones Unidas**: Entidades que utilizar\u00e1n los laboratorios de control de calidad precalificados.\n- **Productos farmac\u00e9uticos**: Incluye tanto productos innovadores como gen\u00e9ricos que deben cumplir con est\u00e1ndares de calidad y seguridad.\n\n### Importancia:\nEstos anexos son fundamentales para asegurar que los productos farmac\u00e9uticos y los laboratorios de control de calidad cumplan con los est\u00e1ndares internacionales, promoviendo la seguridad y eficacia de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, expert committee, quality assurance, global health"}}, "fd2485c8-6655-4995-aa39-2fdb789fd598": {"node_ids": ["4ec10afe-30bc-42d0-962b-cf9155c2cfe8"], "metadata": {"page_label": "8", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ms Lynda Paleshnuik, Senior Quality Assessor, Val-des-Mont, QC, Canada\n\nMs Eija Pelkonen,\u00b2 Head of Inspectorate, National Agency for Medicines, Helsinki, Finland\n\nMs Marie-Louise Rabouhans, Chiswick, London, England\n\nDr Jean-Louis Robert, Head, Official Medicines Control Laboratory, Service du Contr\u00f4le des M\u00e9dicaments, Laboratoire National de Sant\u00e9, Luxembourg\n\nDr Saranjit Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India\n\nMr Deryck Smith, Principal Specialist, SSI, Cleanrooms Division, Gauteng, South Africa\n\nDr Angelika Spreitzhofer,\u00b2 AGES PharmMed GmbH, Vienna, Austria\n\n# Representation from United Nations offices\u00b3\n\n**United Nations Children\u2019s Fund (UNICEF)**  \nDr Peter Svarrer Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark\n\n# Representation from specialized agencies and related organizations\u2074\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**  \nMs Joelle Daviaud, Senior QA Technical Officer, Pharmaceutical Management Unit  \nand Mr Raghu Kumar Krishna Swamy, Geneva, Switzerland\n\n**World Intellectual Property Organization (WIPO)**  \nMs Konji Sebati, Consultant, Department for Traditional Knowledge and Global Challenges  \nand Ms Maria Soledad Iglesias-Vega, Program Officer, Department of External Relations, Geneva, Switzerland\n\n**The World Bank**  \nDr Andreas Seiter, Senior Health Specialist \u2014 Pharmaceuticals, Health, Nutrition and Population, Washington, DC, USA\n\n**World Customs Organization (WCO)**  \nMr Alvaro Fernandez Acebes, Technical Officer, Tariff and Trade Affairs Directorate, Brussels, Belgium\n\n**World Trade Organization (WTO)**  \nMr Roger Kampf, Counsellor, Intellectual Property Division, Geneva, Switzerland\n\n# Representation from intergovernmental organizations\u2075\n\n**European Union (EU)**  \nMs Jinna Lee, Permanent Delegation of the European Union, Geneva, Switzerland\n\n----\n\n\u00b2 Unable to attend.  \n\u00b3 Unable to attend: United Nations Development Programme (UNDP), New York, NY, USA.  \n\u2074 Unable to attend: International Atomic Energy Agency (IAEA), Vienna, Austria; United Nations Industrial Development Organization (UNIDO), Vienna, Austria.  \n\u2075 Unable to attend: European Medicines Agency (EMA), London, England.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y presenta una lista de participantes en una reuni\u00f3n, incluyendo representantes de diversas organizaciones, agencias de la ONU y organismos intergubernamentales. Se mencionan nombres, cargos y ubicaciones de los asistentes, as\u00ed como aquellos que no pudieron asistir. La reuni\u00f3n parece centrarse en temas relacionados con la calidad y regulaci\u00f3n de medicamentos, con la participaci\u00f3n de expertos de diferentes pa\u00edses y organizaciones internacionales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 roles desempe\u00f1an los representantes de las organizaciones mencionadas en el contexto de la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta busca profundizar en las funciones espec\u00edficas de cada representante y c\u00f3mo contribuyen a la regulaci\u00f3n y control de medicamentos a nivel internacional.\n\n2. **\u00bfCu\u00e1les son las implicaciones de la ausencia de representantes de organizaciones clave como el PNUD y la EMA en esta reuni\u00f3n?**\n   - Esta pregunta permite explorar c\u00f3mo la falta de participaci\u00f3n de estas organizaciones podr\u00eda afectar las decisiones y recomendaciones que surjan de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos podr\u00edan haber sido discutidos en la reuni\u00f3n, considerando la diversidad de expertos presentes?**\n   - Esta pregunta invita a especular sobre los posibles temas de discusi\u00f3n basados en la experiencia y los roles de los participantes, lo que podr\u00eda incluir la calidad de los medicamentos, la propiedad intelectual y la cooperaci\u00f3n internacional en salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un informe de la **Comisi\u00f3n de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**, que se llev\u00f3 a cabo en Ginebra del 18 al 22 de octubre de 2010. La reuni\u00f3n reuni\u00f3 a un grupo diverso de expertos en farmacolog\u00eda y regulaci\u00f3n de medicamentos de diferentes pa\u00edses, con el objetivo de discutir y establecer est\u00e1ndares para la preparaci\u00f3n de productos farmac\u00e9uticos.\n\n#### Temas Clave:\n- **Establecimiento de est\u00e1ndares**: La reuni\u00f3n se centr\u00f3 en la creaci\u00f3n de especificaciones para la preparaci\u00f3n de productos farmac\u00e9uticos.\n- **Colaboraci\u00f3n internacional**: Participaci\u00f3n de expertos de diversas naciones, reflejando un enfoque global en la regulaci\u00f3n de medicamentos.\n- **Roles y responsabilidades**: Se detallan los roles de los miembros y asesores temporales, destacando sus afiliaciones y contribuciones.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Organismo que convoc\u00f3 la reuni\u00f3n.\n- **Miembros de la Comisi\u00f3n**:\n  - **Profesor Ivan Addae-Mensah** (Ghana) - Chairperson\n  - **Profesor Saleh A. Bawazir** (Arabia Saudita) - Co-Chairperson\n  - **Mr Eshetu Wondemagegnehu Biwota** (Etiop\u00eda) - Co-Rapporteur\n  - **Dr Justina A. Molzon** (EE. UU.) - Co-Rapporteur\n  - Otros miembros de B\u00e9lgica, Sud\u00e1frica, Panam\u00e1, China, Jap\u00f3n, y Hungr\u00eda.\n- **Asesores Temporales**: Expertos de Jamaica, Brasil, Alemania, Dinamarca y Zimbabue.\n\nEste informe destaca la importancia de la cooperaci\u00f3n internacional en la regulaci\u00f3n de productos farmac\u00e9uticos y el establecimiento de est\u00e1ndares de calidad.", "excerpt_keywords": "Keywords: WHO, pharmaceutical regulation, international cooperation, quality assurance, expert meeting"}}, "5ed767ab-bedc-4e23-92fc-fca7dd7cbabb": {"node_ids": ["f86065bd-66f5-40df-ae5e-68b8d956dda3"], "metadata": {"page_label": "9", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Representation from Nongovernmental Organizations\n\n**Commonwealth Pharmacists Association (CPA)**  \nProfessor Douglas Oliver, Chairman, South Africa Pharmacology Society, North-West University, South Africa\n\n**European Chemical Industry Council (CEFIC)/APIC**  \nDr Boris Pimentel, Board Member, APIC, and Global Regulatory Affairs Manager, DSM Nutritional Products AG, Basel, Switzerland\n\n**International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**  \nDr Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, Abbott Park, IL, USA  \nand Dr Rodney Horder, Consultant, Abbott Quality & Regulatory, Torquay, United Kingdom\n\n**International Generic Pharmaceutical Alliance (IGPA)**  \nDr Nicholas Cappuccino, General Partner, Pharmaceutical Intellectual Resource Services LLC, Lambertville, NJ, USA\n\n**International Pharmaceutical Excipients Council (IPEC)**  \nMrs Beam Suffolk, Vice Chair, IPEC Europe, Brussels, Belgium\n\n**International Pharmaceutical Federation (FIP)**  \nMr A.J.M. Hoek, General Secretary and CEO  \nand Mr Xuan Hao Chan, Manager, Professional and Scientific Affairs, The Hague, The Netherlands\n\n**World Self-Medication Industry (WSMI)**  \nDr David Webber, Director General, Ferney-Voltaire, France\n\n# Observers\n\n**Brazilian Health Surveillance Agency (ANVISA)**  \nMr Mateus R. Cerqueira, Specialist in Regulation and Health Surveillance, International Affairs Office, Brasilia, DF, Brazil\n\n**Pharmaceutical Inspection Co-operation Scheme (PIC/S)**  \nMs Helena Bai\u00e3o, First Deputy Chairperson, PIC/S, Inspection and Licensing Directorate, Inspection Department, National Authority of Medicines and Health Products, I.P., Lisbon, Portugal\n\n# Pharmacopoeias\n\n**British Pharmacopoeia Commission**  \nMr Richard Turner, Secretariat, London, England\n\n----\n\n6 Unable to attend: International Society for Pharmaceutical Engineering (ISPE), Tampa, Florida, USA.  \n7 Unable to attend: Farmacopea Argentina, Buenos Aires, Argentina; Farmacope\u00eda Brasileira, Santa Maria, RS, Brazil; Pharmacopoeia of the People's Republic of China, Beijing, People's Republic of China; Indian Pharmacopoeia, New Delhi, India; Japanese Pharmacopoeia, Tokyo, Japan; Pharmacopoeia of the Republic of Korea, Seoul, Republic of Korea; State Pharmacopoeia of the Russian Federation, Moscow, Russian Federation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y presenta una representaci\u00f3n de diversas organizaciones no gubernamentales (ONG) relacionadas con la farmacolog\u00eda y la industria farmac\u00e9utica. Se mencionan representantes de varias organizaciones, como la Commonwealth Pharmacists Association, la International Federation of Pharmaceutical Manufacturers and Associations, y la World Self-Medication Industry, entre otras. Tambi\u00e9n se incluyen observadores de agencias reguladoras como ANVISA y PIC/S, as\u00ed como representantes de diversas farmacopeas. Adem\u00e1s, se se\u00f1ala que algunas organizaciones no pudieron asistir a la reuni\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQui\u00e9nes son los representantes de la International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) y cu\u00e1les son sus roles espec\u00edficos?**\n   - Respuesta: Los representantes de la IFPMA son el Dr. Michael G. Beatrice, Vice President, Corporate Regulatory & Quality Science, Abbott, y el Dr. Rodney Horder, Consultant, Abbott Quality & Regulatory.\n\n2. **\u00bfQu\u00e9 organizaciones no gubernamentales est\u00e1n representadas en el documento y qu\u00e9 pa\u00edses representan sus miembros?**\n   - Respuesta: Las organizaciones no gubernamentales representadas incluyen la Commonwealth Pharmacists Association (Sud\u00e1frica), el European Chemical Industry Council (Suiza), la International Generic Pharmaceutical Alliance (EE. UU.), la International Pharmaceutical Excipients Council (B\u00e9lgica), la International Pharmaceutical Federation (Pa\u00edses Bajos), y la World Self-Medication Industry (Francia).\n\n3. **\u00bfQu\u00e9 farmacopeas y organizaciones no pudieron asistir a la reuni\u00f3n mencionada en el documento?**\n   - Respuesta: Las organizaciones que no pudieron asistir incluyen la International Society for Pharmaceutical Engineering (ISPE) de EE. UU., as\u00ed como varias farmacopeas como la Farmacopea Argentina, la Farmacope\u00eda Brasileira, la Pharmacopoeia of the People's Republic of China, la Indian Pharmacopoeia, la Japanese Pharmacopoeia, la Pharmacopoeia of the Republic of Korea, y la State Pharmacopoeia of the Russian Federation.\n\n### Resumen de Nivel Superior\n\nEl documento proporciona una visi\u00f3n general de la participaci\u00f3n de diversas organizaciones no gubernamentales y agencias reguladoras en el \u00e1mbito farmac\u00e9utico, destacando sus representantes y roles. Tambi\u00e9n menciona la ausencia de ciertas organizaciones y farmacopeas, lo que puede indicar la diversidad y la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y la calidad de los productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de participantes en una reuni\u00f3n relacionada con la calidad y regulaci\u00f3n de medicamentos, en el marco de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961). Los asistentes incluyen representantes de diversas organizaciones, agencias de la ONU y organismos intergubernamentales, destacando sus nombres, cargos y ubicaciones.\n\n### Temas Clave:\n1. **Calidad y Regulaci\u00f3n de Medicamentos**: La reuni\u00f3n se centra en la discusi\u00f3n de temas relacionados con la calidad de los medicamentos y su regulaci\u00f3n a nivel internacional.\n2. **Colaboraci\u00f3n Internacional**: Se evidencia la participaci\u00f3n de expertos de diferentes pa\u00edses y organizaciones, lo que sugiere un enfoque en la cooperaci\u00f3n internacional en salud p\u00fablica.\n\n### Entidades Representadas:\n- **Organizaciones de la ONU**: \n  - UNICEF (Dr. Peter Svarrer Jakobsen)\n  \n- **Agencias Especializadas y Organizaciones Relacionadas**:\n  - The Global Fund to Fight AIDS, Tuberculosis and Malaria (Ms. Joelle Daviaud y Mr. Raghu Kumar Krishna Swamy)\n  - World Intellectual Property Organization (WIPO) (Ms. Konji Sebati y Ms. Maria Soledad Iglesias-Vega)\n  - The World Bank (Dr. Andreas Seiter)\n  - World Customs Organization (WCO) (Mr. Alvaro Fernandez Acebes)\n  - World Trade Organization (WTO) (Mr. Roger Kampf)\n\n- **Organizaciones Intergubernamentales**:\n  - Uni\u00f3n Europea (EU) (Ms. Jinna Lee)\n\n### Ausencias Notables:\nSe menciona que no pudieron asistir representantes de organizaciones clave como el Programa de las Naciones Unidas para el Desarrollo (PNUD) y la Agencia Europea de Medicamentos (EMA), lo que podr\u00eda tener implicaciones en las decisiones y recomendaciones de la reuni\u00f3n. \n\nEn resumen, la secci\u00f3n destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la diversidad de expertos presentes, as\u00ed como las ausencias que podr\u00edan afectar el desarrollo de las discusiones.", "excerpt_keywords": "Keywords: pharmaceutical regulation, nongovernmental organizations, international collaboration, pharmacopoeias, quality assurance"}}, "d8f891e8-8c19-415a-af50-d6c4dda34d92": {"node_ids": ["8d980cc6-49e5-4aea-bdfb-290f64850447"], "metadata": {"page_label": "10", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# European Pharmacopoeia<sup>8</sup>\nCouncil of Europe, Strasbourg, France\n\n# United States Pharmacopeia\nDr Karen A. Russo, Vice President, Small Molecules, Documentary Standards Division, Rockville, MD, USA\n\n## Representation from WHO regional offices\n- Regional Office for Africa, Brazzaville, Republic of Congo\n- Regional Office for the Americas, Pan American Health Organization, Washington, DC, United States of America\n- Regional Office for the Eastern Mediterranean, Cairo, Egypt\n- Regional Office for Europe, Copenhagen, Denmark\n- Regional Office for South-East Asia, New Delhi, India\n- Regional Office for the Western Pacific, Manila, Philippines\n\n## WHO Secretariat\n- Dr C.F. Etienne, Assistant Director-General, Health Systems and Services,<sup>9</sup> WHO, Geneva, Switzerland\n- Dr H.V. Hogerzeil, Director, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland\n- Dr L. R\u00e4go, Coordinator, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland *(Secretary)*\n- Ms C. Mendy, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr H. Schmidt, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr R. Balocco, Manager, International Nonproprietary Names Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Chemwolo, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Ms S.C. Croft, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Dr A. Fake, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr A. Gould, Manager, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n- Mr J.R. Kuwana, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\n----\n\n<sup>8</sup> See Council of Europe.  \n<sup>9</sup> Unable to attend.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye la representaci\u00f3n de diversas oficinas regionales de la OMS y miembros del secretariado. Se menciona la participaci\u00f3n de la Farmacopea Europea y la Farmacopea de los Estados Unidos, as\u00ed como los nombres y cargos de varios funcionarios de la OMS que est\u00e1n involucrados en programas relacionados con la calidad y seguridad de los medicamentos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQui\u00e9nes son los representantes de las oficinas regionales de la OMS mencionados en el informe y cu\u00e1les son sus ubicaciones?**\n   - Respuesta: Los representantes de las oficinas regionales de la OMS son: \n     - Oficina Regional para \u00c1frica, Brazzaville, Rep\u00fablica del Congo\n     - Oficina Regional para las Am\u00e9ricas, Washington, DC, Estados Unidos\n     - Oficina Regional para el Mediterr\u00e1neo Oriental, El Cairo, Egipto\n     - Oficina Regional para Europa, Copenhague, Dinamarca\n     - Oficina Regional para el Sudeste Asi\u00e1tico, Nueva Delhi, India\n     - Oficina Regional para el Pac\u00edfico Occidental, Manila, Filipinas.\n\n2. **\u00bfQu\u00e9 roles desempe\u00f1an los miembros del secretariado de la OMS mencionados en el documento?**\n   - Respuesta: Los roles incluyen:\n     - Dr. C.F. Etienne: Asistente del Director General, Sistemas de Salud y Servicios.\n     - Dr. H.V. Hogerzeil: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n     - Dr. L. R\u00e4go: Coordinador de Aseguramiento de Calidad y Seguridad: Medicamentos.\n     - Dr. S. Kopp: Gerente del Programa de Aseguramiento de Calidad de Medicamentos (Secretario).\n     - Otros miembros est\u00e1n involucrados en programas de calidad y precalificaci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se proporciona sobre la Farmacopea Europea y la Farmacopea de los Estados Unidos en el contexto del informe?**\n   - Respuesta: Se menciona que la Farmacopea Europea es publicada por el Consejo de Europa en Estrasburgo, Francia, y que la Farmacopea de los Estados Unidos est\u00e1 representada por la Dra. Karen A. Russo, Vicepresidenta de la Divisi\u00f3n de Normas Documentarias de Peque\u00f1as Mol\u00e9culas en Rockville, MD, EE. UU.", "prev_section_summary": "La secci\u00f3n proporciona una representaci\u00f3n de diversas organizaciones no gubernamentales (ONG) y agencias reguladoras en el \u00e1mbito farmac\u00e9utico, destacando sus representantes y roles. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Participaci\u00f3n de ONG**: Se presentan representantes de varias ONG relacionadas con la farmacolog\u00eda y la industria farmac\u00e9utica.\n2. **Observadores de Agencias Reguladoras**: Se mencionan representantes de agencias reguladoras que observan las actividades de las ONG.\n3. **Farmacopeas**: Se incluye informaci\u00f3n sobre farmacopeas y la ausencia de ciertas organizaciones en la reuni\u00f3n.\n\n### Entidades Mencionadas:\n- **ONG Representadas**:\n  - **Commonwealth Pharmacists Association (CPA)**: Representada por el Profesor Douglas Oliver (Sud\u00e1frica).\n  - **European Chemical Industry Council (CEFIC)/APIC**: Representado por el Dr. Boris Pimentel (Suiza).\n  - **International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)**: Representada por el Dr. Michael G. Beatrice y el Dr. Rodney Horder (EE. UU. y Reino Unido).\n  - **International Generic Pharmaceutical Alliance (IGPA)**: Representado por el Dr. Nicholas Cappuccino (EE. UU.).\n  - **International Pharmaceutical Excipients Council (IPEC)**: Representada por la Sra. Beam Suffolk (B\u00e9lgica).\n  - **International Pharmaceutical Federation (FIP)**: Representada por el Sr. A.J.M. Hoek y el Sr. Xuan Hao Chan (Pa\u00edses Bajos).\n  - **World Self-Medication Industry (WSMI)**: Representado por el Dr. David Webber (Francia).\n\n- **Observadores**:\n  - **Brazilian Health Surveillance Agency (ANVISA)**: Representado por el Sr. Mateus R. Cerqueira (Brasil).\n  - **Pharmaceutical Inspection Co-operation Scheme (PIC/S)**: Representada por la Sra. Helena Bai\u00e3o (Portugal).\n\n- **Farmacopeas que no asistieron**:\n  - International Society for Pharmaceutical Engineering (ISPE) (EE. UU.).\n  - Farmacopea Argentina (Argentina).\n  - Farmacope\u00eda Brasileira (Brasil).\n  - Pharmacopoeia of the People's Republic of China (China).\n  - Indian Pharmacopoeia (India).\n  - Japanese Pharmacopoeia (Jap\u00f3n).\n  - Pharmacopoeia of the Republic of Korea (Corea del Sur).\n  - State Pharmacopoeia of the Russian Federation (Rusia).\n\nEste resumen destaca la diversidad de la participaci\u00f3n internacional en la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos, as\u00ed como la importancia de la colaboraci\u00f3n entre diferentes entidades.", "excerpt_keywords": "Keywords: WHO, Pharmacopoeia, Medicines Quality Assurance, Regional Offices, Health Systems"}}, "3dd9cfa2-f03d-4d4c-bd2c-67586ce1fb35": {"node_ids": ["1c6b71ab-1bbe-498b-b331-3c0f4c1c4bf2"], "metadata": {"page_label": "11", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Mr D. Mubangizi, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr J. Sabartova, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Smid, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr M. Stahl, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs I. Streipa, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr A.J. van Zyl, Head, Inspections, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMr W.Z. Worku, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nMrs Hua Yin, Prequalification of Medicines Programme, Quality Assurance and Safety: Medicines, WHO, Geneva, Switzerland\n\nDr S. Azatyan, Manager, Medicines Regulatory Support Programme, WHO, Geneva, Switzerland\n\nDr G.B. Forte, Coordinator, Medicines Programme Coordination, WHO, Geneva, Switzerland\n\nDr S. Hill, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr R.O. Laing, Medicines Information and Evidence, WHO, Geneva, Switzerland\n\nMs Y. Maruyama, Traditional Medicine, WHO, Geneva, Switzerland\n\nDr C. Ondari, Coordinator, Medicines Access and Rational Use, WHO, Geneva, Switzerland\n\nDr K. Weerasuriya, Medicines Access and Rational Use, WHO, Geneva, Switzerland", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". En \u00e9l se mencionan varios profesionales que trabajan en el Programa de Precalificaci\u00f3n de Medicamentos y otros programas relacionados con la calidad, seguridad y acceso a los medicamentos. Estos individuos desempe\u00f1an roles clave en la regulaci\u00f3n y evaluaci\u00f3n de medicamentos a nivel internacional.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de Dr. A.J. van Zyl dentro del Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Respuesta: Dr. A.J. van Zyl es el Jefe de Inspecciones en el Programa de Precalificaci\u00f3n de Medicamentos, lo que implica que supervisa las inspecciones relacionadas con la calidad y seguridad de los medicamentos.\n\n2. **\u00bfQu\u00e9 programas adicionales, adem\u00e1s del Programa de Precalificaci\u00f3n de Medicamentos, est\u00e1n representados por los profesionales mencionados en el documento?**\n   - Respuesta: Adem\u00e1s del Programa de Precalificaci\u00f3n de Medicamentos, se mencionan el Programa de Soporte Regulatorio de Medicamentos, el Programa de Coordinaci\u00f3n de Medicamentos, y el \u00e1rea de Acceso y Uso Racional de Medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de experiencia o enfoque tiene la Sra. Hua Yin en el contexto de la OMS?**\n   - Respuesta: La Sra. Hua Yin trabaja en el Programa de Precalificaci\u00f3n de Medicamentos, lo que sugiere que su enfoque est\u00e1 relacionado con la evaluaci\u00f3n y aseguramiento de la calidad y seguridad de los medicamentos a nivel internacional, aunque el documento no especifica su rol exacto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que destaca la colaboraci\u00f3n y representaci\u00f3n de diversas entidades en el \u00e1mbito de la calidad y seguridad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Farmacopeas**:\n   - **Farmacopea Europea**: Publicada por el Consejo de Europa, ubicada en Estrasburgo, Francia.\n   - **Farmacopea de los Estados Unidos**: Representada por la Dra. Karen A. Russo, Vicepresidenta de la Divisi\u00f3n de Normas Documentarias de Peque\u00f1as Mol\u00e9culas, Rockville, MD, EE. UU.\n\n2. **Representaci\u00f3n de Oficinas Regionales de la OMS**:\n   - **Oficina Regional para \u00c1frica**: Brazzaville, Rep\u00fablica del Congo.\n   - **Oficina Regional para las Am\u00e9ricas**: Washington, DC, Estados Unidos.\n   - **Oficina Regional para el Mediterr\u00e1neo Oriental**: El Cairo, Egipto.\n   - **Oficina Regional para Europa**: Copenhague, Dinamarca.\n   - **Oficina Regional para el Sudeste Asi\u00e1tico**: Nueva Delhi, India.\n   - **Oficina Regional para el Pac\u00edfico Occidental**: Manila, Filipinas.\n\n3. **Secretariado de la OMS**:\n   - **Dr. C.F. Etienne**: Asistente del Director General, Sistemas de Salud y Servicios.\n   - **Dr. H.V. Hogerzeil**: Director de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas.\n   - **Dr. L. R\u00e4go**: Coordinador de Aseguramiento de Calidad y Seguridad: Medicamentos.\n   - **Dr. S. Kopp**: Gerente del Programa de Aseguramiento de Calidad de Medicamentos (Secretario).\n   - Otros miembros involucrados en programas de calidad y precalificaci\u00f3n de medicamentos.\n\nEste informe resalta la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, as\u00ed como la participaci\u00f3n activa de diversas oficinas y expertos en el campo.", "excerpt_keywords": "Keywords: WHO, Prequalification, Medicines, Quality Assurance, Safety"}}, "3e87e20c-d4a0-4c89-a29a-8a5d0760116e": {"node_ids": ["a37ff2e6-b21b-487a-b9bf-b84829cea23b"], "metadata": {"page_label": "12", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Declarations of interest\n\nMembers and temporary advisers of the WHO Expert Committee on Specifications for Pharmaceutical Preparations reported the following:\n\n**Dr Nilka Guerrero Rivas:** Her Institute at the University Octavio M\u00e9ndez Pereira in Panama performs, as part of its public health mandate, as reference laboratory for quality control of pharmaceutical products, fixed-fee quality control services for local manufacturers, including Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 and Laboratorios Rigar/Panam\u00e1.\n\n**Professor Henning Kristensen:** His wife is a former employee of Novo Nordisk and holds approximately US$ 20,000 in stocks in this company. The WHO Expert Committee on Specifications for Pharmaceutical Preparations does not consider any of the products manufactured by Novo Nordisk.\n\nProfessor I. Addae-Mensah, Professor S. Bawazir, Mr E. Wondemagegnehu Biwota, Dr L. Cargill, Mr J.-M. Caudron, Mr A.C. da Costa Bezerra, Professor T.G. Dekker, Professor J. Hoogmartens, Dr T. Kawanishi, Dr K. Keller, Dr G.N. Mahlangu, Dr J.A. Molzon, Professor T.L. Pa\u00e1l, Dr L. Paleshnuik, Ms M.-L. Rabouhans, Dr J.-L. Robert, Dr S. Singh and Mr D. Smith reported no conflict of interest.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las declaraciones de inter\u00e9s de los miembros y asesores temporales del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas. Se mencionan dos casos espec\u00edficos de conflictos de inter\u00e9s: uno relacionado con la Dra. Nilka Guerrero Rivas, quien trabaja en un laboratorio de control de calidad en Panam\u00e1, y otro con el Profesor Henning Kristensen, cuya esposa tiene acciones en Novo Nordisk. Adem\u00e1s, se indica que otros miembros del comit\u00e9 no reportaron conflictos de inter\u00e9s.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de servicios ofrece el Instituto de la Dra. Nilka Guerrero Rivas y a qui\u00e9nes est\u00e1n dirigidos?**\n   - Respuesta: El Instituto de la Dra. Nilka Guerrero Rivas ofrece servicios de control de calidad de productos farmac\u00e9uticos y servicios de control de calidad a tarifa fija para fabricantes locales, incluyendo Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 y Laboratorios Rigar/Panam\u00e1.\n\n2. **\u00bfCu\u00e1l es la relaci\u00f3n del Profesor Henning Kristensen con Novo Nordisk y c\u00f3mo afecta esto a su participaci\u00f3n en el comit\u00e9?**\n   - Respuesta: La esposa del Profesor Henning Kristensen es una ex-empleada de Novo Nordisk y posee aproximadamente US$ 20,000 en acciones de la compa\u00f1\u00eda. Sin embargo, el Comit\u00e9 de Expertos de la OMS no considera ning\u00fan producto fabricado por Novo Nordisk, lo que mitiga el posible conflicto de inter\u00e9s.\n\n3. **\u00bfQu\u00e9 medidas se toman en el Comit\u00e9 de Expertos de la OMS para asegurar la transparencia en cuanto a los conflictos de inter\u00e9s?**\n   - Respuesta: Los miembros y asesores del Comit\u00e9 de Expertos deben declarar cualquier conflicto de inter\u00e9s, como se evidencia en las declaraciones presentadas por la Dra. Nilka Guerrero Rivas y el Profesor Henning Kristensen, as\u00ed como la confirmaci\u00f3n de que otros miembros no tienen conflictos de inter\u00e9s. Esto ayuda a mantener la transparencia y la integridad del proceso.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado se centra en el informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Precalificaci\u00f3n de Medicamentos**: El documento destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos, que se enfoca en asegurar la calidad y seguridad de los medicamentos a nivel internacional.\n2. **Calidad y Seguridad de Medicamentos**: Se enfatiza la necesidad de garantizar que los medicamentos cumplan con est\u00e1ndares internacionales de calidad y seguridad.\n3. **Acceso y Uso Racional de Medicamentos**: Se menciona la importancia de facilitar el acceso a medicamentos y promover su uso racional en la poblaci\u00f3n.\n\n#### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n responsable de la salud p\u00fablica internacional.\n- **Profesionales del Programa de Precalificaci\u00f3n de Medicamentos**:\n  - Mr. D. Mubangizi\n  - Dr. J. Sabartova\n  - Dr. M. Smid\n  - Dr. M. Stahl\n  - Mrs. I. Streipa\n  - Dr. A.J. van Zyl (Jefe de Inspecciones)\n  - Mr. W.Z. Worku\n  - Mrs. Hua Yin\n- **Otros Programas y Coordinadores**:\n  - Dr. S. Azatyan (Programa de Soporte Regulatorio de Medicamentos)\n  - Dr. G.B. Forte (Coordinador, Programa de Coordinaci\u00f3n de Medicamentos)\n  - Dr. S. Hill, Dr. C. Ondari, Dr. K. Weerasuriya (Acceso y Uso Racional de Medicamentos)\n  - Dr. R.O. Laing (Informaci\u00f3n y Evidencia sobre Medicamentos)\n  - Ms. Y. Maruyama (Medicina Tradicional)\n\nEste resumen destaca la estructura del documento y los roles de los profesionales involucrados en la regulaci\u00f3n y evaluaci\u00f3n de medicamentos, as\u00ed como la misi\u00f3n de la OMS en la promoci\u00f3n de la salud global.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, conflict of interest, quality control, expert committee"}}, "c8bfc126-4867-494f-8b13-5cf80484ad1d": {"node_ids": ["139e3cf3-b165-4a36-910a-0c528b03bb20"], "metadata": {"page_label": "13", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations met in Geneva from 18 to 22 October 2010. Dr Hans V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies, opened the meeting, and on behalf of the Director-General of the World Health Organization, welcomed all the participants to the forty-fifth meeting of the Expert Committee. He expressed his appreciation of the Expert Committee for its knowledge of and expertise in the work of WHO in the area of quality assurance of medicines and for its major contributions with technical expertise as well as with practical laboratory studies.\n\nDr Hogerzeil welcomed the members of the Committee and temporary advisers; representatives of the United Nations Children\u2019s Fund, the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Industrial Development Organization, World Intellectual Property Organization, the World Bank, World Customs Organization, World Trade Organization, European Union, Council of Europe/European Directorate for the Quality of Medicines and HealthCare, Commonwealth Pharmacists Association, European Chemical Industry Council/APIC, International Federation of Pharmaceutical Manufacturers Association, International Generic Pharmaceutical Alliance, International Pharmaceutical Federation and the World Self-Medication Industry; representatives of the Pharmacopoeias of Great Britain and of the United States of America; representatives from WHO Collaborating Centres in Hungary and South Africa; and observers from the Brazilian Health Surveillance Agency and from the Pharmaceutical Inspection Co-operation Scheme (PIC/S).\n\nDr C.F. Etienne, Assistant Director-General for the Health Systems and Services Cluster, who was unable to attend the meeting, welcomed the Expert Committee with a written speech and acknowledged the elected Chairs, i.e. Professors I. Addae-Mensah (Chairperson) and S. Bawazir (Co-Chairperson), and the Co-Rapporteurs, Dr J.A. Molzon and Mr E. Wondemagegnehu Biwota.\n\nShe stated that the open session of the forty-fifth WHO Expert Committee on Specifications for Pharmaceutical Preparations had been organized in order to respond to the interest raised by Member States during the World Health Assembly held in May 2010 on the quality of medicines. The aim was to provide more information on this Expert Committee in an open and transparent manner. All the materials relating to the Expert Committee, both concerning the past and ongoing work, were to be found on their web sites. The Expert Committee members and the WHO Secretariat were here to explain the work related to the Committee and to respond to any questions.\n\nPoor quality of medicines and \u201cspurious/falsely-labelled/falsified/counterfeit medicines\u201d are unfortunately a major threat to public health.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas se reuni\u00f3 en Ginebra del 18 al 22 de octubre de 2010. Durante la reuni\u00f3n, se discuti\u00f3 la calidad de los medicamentos, un tema de gran preocupaci\u00f3n para los Estados Miembros, especialmente tras la Asamblea Mundial de la Salud de mayo de 2010. Se destac\u00f3 la importancia de la experiencia del Comit\u00e9 en el aseguramiento de la calidad de los medicamentos y se mencionaron diversas organizaciones y representantes que participaron en la reuni\u00f3n. La calidad deficiente de los medicamentos y la presencia de medicamentos falsificados son amenazas significativas para la salud p\u00fablica.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales objetivos de la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en octubre de 2010?**\n   - La reuni\u00f3n se organiz\u00f3 para abordar el inter\u00e9s de los Estados Miembros sobre la calidad de los medicamentos, proporcionando informaci\u00f3n sobre el trabajo del Comit\u00e9 de manera abierta y transparente.\n\n2. **\u00bfQu\u00e9 organizaciones y representantes estuvieron presentes en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Estuvieron presentes representantes de UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, la Organizaci\u00f3n Mundial de la Propiedad Intelectual, el Banco Mundial, la Organizaci\u00f3n Mundial del Comercio, entre otros.\n\n3. **\u00bfQu\u00e9 amenazas a la salud p\u00fablica se mencionaron en el contexto de la calidad de los medicamentos?**\n   - Se mencion\u00f3 que la calidad deficiente de los medicamentos y la existencia de \"medicamentos espurios/falsamente etiquetados/falsificados/contrabandeados\" son amenazas importantes para la salud p\u00fablica.\n\n### Resumen de Nivel Superior\n\nLa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2010 se centr\u00f3 en la calidad de los medicamentos, un tema cr\u00edtico para la salud p\u00fablica. Se destac\u00f3 la participaci\u00f3n de diversas organizaciones internacionales y se abordaron las preocupaciones sobre los medicamentos falsificados y de baja calidad. La reuni\u00f3n busc\u00f3 proporcionar claridad y transparencia sobre el trabajo del Comit\u00e9 y su relevancia en el contexto global de la salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Declaraciones de Inter\u00e9s**: La secci\u00f3n se centra en las declaraciones de inter\u00e9s de los miembros y asesores temporales del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **Dr. Nilka Guerrero Rivas**:\n   - **Instituci\u00f3n**: Universidad Octavio M\u00e9ndez Pereira, Panam\u00e1.\n   - **Servicios**: Control de calidad de productos farmac\u00e9uticos y servicios de control de calidad a tarifa fija para fabricantes locales.\n   - **Clientes**: Laboratorios Prieto, S.A./Panam\u00e1, LAFSA/Panam\u00e1, Medip\u00e1n/Panam\u00e1 y Laboratorios Rigar/Panam\u00e1.\n\n3. **Profesor Henning Kristensen**:\n   - **Relaci\u00f3n con Novo Nordisk**: Su esposa es ex-empleada de la compa\u00f1\u00eda y posee acciones valoradas en aproximadamente US$ 20,000.\n   - **Impacto en el Comit\u00e9**: El Comit\u00e9 no considera productos de Novo Nordisk, lo que reduce el riesgo de conflicto de inter\u00e9s.\n\n4. **Otros Miembros**: Un grupo de miembros del comit\u00e9, incluyendo a profesores y otros profesionales, no reportaron conflictos de inter\u00e9s.\n\n5. **Transparencia**: Se enfatiza la importancia de declarar conflictos de inter\u00e9s para mantener la integridad y transparencia en el proceso del comit\u00e9.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality assurance, counterfeit medicines, public health"}}, "1ec53c41-f4c8-4d4e-a0b3-80a38bdbc8fc": {"node_ids": ["1c371707-9d18-45d3-b60a-882483ac3f24"], "metadata": {"page_label": "14", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "putting the health of numerous patients at risk and the trust of the patients in their health systems at stake; thus this was of critical importance for WHO.\n\nWHO has been involved in medicines quality assurance and quality control since 1948. This Committee was created in the very first World Health Assembly. Its work had already begun in 1947, during the transition of health matters previously dealt with under the League of Nations. Thus it is one of WHO\u2019s oldest programmes.\n\nStrong links exist with other WHO activities, such as support of national medicines regulatory authorities (NMRAs), the Prequalification of Medicines Programme, the Expert Committee on Biological Standardization, the Expert Committee on Selection and Use of Essential Medicines, Traditional Medicine and specific disease programmes.\n\nThe normative activities covered by this Expert Committee not only directly serve WHO Member States, but also, through implementation by programmes within WHO, international organizations as well, such as, UNICEF and The Global Fund to Fight AIDS, Tuberculosis and Malaria.\n\nMost of these activities have in the past been funded from WHO\u2019s regular budget. Nowadays more than 80% of the finance is secured through extrabudgetary funding by donors, such as the European Union, UNITAID, and the Bill & Melinda Gates Foundation.\n\nDr Hogerzeil stated that the work of the Expert Committee within the Quality Assurance and Safety: Medicines team was becoming a focus of interest. The meetings of the Expert Committee used to be held every two years but had been held annually for the past four years in response to the increased need for normative work. The work of the Expert Committee is of the highest level of normative work existing at WHO and the outcome of each meeting is published in the WHO Technical Report Series, which is then presented to the WHO governing bodies at the Executive Board meeting, usually in May.\n\nMembers of the Expert Committee are invited in a personal capacity and do not represent their respective governments.\n\nThe work of *The International Pharmacopoeia* and the WHO Prequalification of Medicines Programme is based entirely on the work of the Expert Committee on Specifications for Pharmaceutical Preparations; all guidance documents are sent out worldwide for comments, revised and finally adopted by the Expert Committee.\n\nWhile the normative work is unique, norms and standards is one of the key activities of the United Nations system. Dr Hogerzeil stated that WHO was supporting medicines related activities in nearly 100 countries.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Historia y Evoluci\u00f3n de la OMS en Aseguramiento de Calidad de Medicamentos**: La Organizaci\u00f3n Mundial de la Salud (OMS) ha estado involucrada en la garant\u00eda de calidad de los medicamentos desde 1948, con un enfoque en la creaci\u00f3n de normas y est\u00e1ndares que beneficien a los Estados miembros y organizaciones internacionales.\n\n2. **Financiamiento y Actividades Normativas**: Aunque hist\u00f3ricamente la OMS ha financiado sus actividades a trav\u00e9s de su presupuesto regular, actualmente m\u00e1s del 80% de los fondos provienen de donantes externos, lo que refleja un cambio en la forma en que se asegura la calidad de los medicamentos a nivel global.\n\n3. **Importancia del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos de la OMS en Especificaciones para Preparaciones Farmac\u00e9uticas juega un papel crucial en la creaci\u00f3n de normas y gu\u00edas que son adoptadas a nivel mundial, y su trabajo ha aumentado en frecuencia debido a la creciente necesidad de regulaci\u00f3n en el sector de la salud.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1les son las principales fuentes de financiamiento para las actividades de la OMS relacionadas con la calidad de los medicamentos en la actualidad?**\n   - Respuesta: M\u00e1s del 80% de la financiaci\u00f3n proviene de donantes externos, como la Uni\u00f3n Europea, UNITAID y la Fundaci\u00f3n Bill y Melinda Gates.\n\n2. **\u00bfQu\u00e9 cambios se han realizado en la frecuencia de las reuniones del Comit\u00e9 de Expertos de la OMS y por qu\u00e9?**\n   - Respuesta: Las reuniones del Comit\u00e9 de Expertos sol\u00edan celebrarse cada dos a\u00f1os, pero han pasado a ser anuales en los \u00faltimos cuatro a\u00f1os debido a la creciente necesidad de trabajo normativo.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1a el Comit\u00e9 de Expertos en la creaci\u00f3n de documentos de orientaci\u00f3n para la calidad de los medicamentos?**\n   - Respuesta: El trabajo del Comit\u00e9 de Expertos es fundamental para la elaboraci\u00f3n de *La Farmacopea Internacional* y el Programa de Precalificaci\u00f3n de Medicamentos de la OMS, donde todos los documentos de orientaci\u00f3n son enviados a nivel mundial para comentarios, revisados y finalmente adoptados por el Comit\u00e9.", "prev_section_summary": "### Temas Clave\n\n1. **Reuni\u00f3n del Comit\u00e9 de Expertos de la OMS**: El Comit\u00e9 se reuni\u00f3 en Ginebra del 18 al 22 de octubre de 2010 para discutir la calidad de los medicamentos, un tema de gran preocupaci\u00f3n para los Estados Miembros.\n\n2. **Agradecimientos y Bienvenida**: Dr. Hans V. Hogerzeil, Director del Departamento de Medicamentos Esenciales y Pol\u00edticas Farmac\u00e9uticas, abri\u00f3 la reuni\u00f3n y agradeci\u00f3 al Comit\u00e9 por su experiencia en el aseguramiento de la calidad de los medicamentos.\n\n3. **Participaci\u00f3n de Organizaciones Internacionales**: Se destac\u00f3 la presencia de representantes de diversas organizaciones, incluyendo UNICEF, el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, y la Organizaci\u00f3n Mundial de la Propiedad Intelectual, entre otros.\n\n4. **Objetivos de la Reuni\u00f3n**: La sesi\u00f3n abierta se organiz\u00f3 para abordar el inter\u00e9s de los Estados Miembros sobre la calidad de los medicamentos, proporcionando informaci\u00f3n de manera transparente.\n\n5. **Amenazas a la Salud P\u00fablica**: Se mencion\u00f3 que la calidad deficiente de los medicamentos y la existencia de medicamentos falsificados son amenazas significativas para la salud p\u00fablica.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **UNICEF (Fondo de las Naciones Unidas para la Infancia)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Organizaci\u00f3n Mundial de la Propiedad Intelectual (OMPI)**\n- **Banco Mundial**\n- **Organizaci\u00f3n Mundial del Comercio (OMC)**\n- **Uni\u00f3n Europea**\n- **Consejo de Europa/Directorio Europeo para la Calidad de Medicamentos y Atenci\u00f3n Sanitaria**\n- **Asociaci\u00f3n de Farmac\u00e9uticos de la Commonwealth**\n- **Consejo de la Industria Qu\u00edmica Europea/APIC**\n- **Federaci\u00f3n Internacional de Asociaciones de Fabricantes Farmac\u00e9uticos**\n- **Alianza Internacional de Medicamentos Gen\u00e9ricos**\n- **Federaci\u00f3n Internacional Farmac\u00e9utica**\n- **Industria Mundial de la Automedicaci\u00f3n**\n- **Agencia de Vigilancia Sanitaria de Brasil**\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica (PIC/S)**\n\nEste resumen destaca los puntos clave y las entidades involucradas en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS, enfoc\u00e1ndose en la calidad de los medicamentos y su impacto en la salud p\u00fablica.", "excerpt_keywords": "Keywords: WHO, medicines quality assurance, Expert Committee, funding, international collaboration"}}, "c2383af1-4acf-4bcd-a8dd-c2a52649cbb7": {"node_ids": ["706a44cc-c5f7-4c06-80ff-6dc663e5e3f7"], "metadata": {"page_label": "15", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In the medicines area, standard-setting work continues to be a pillar of WHO\u2019s activities and priorities.\n\nOverall the Expert Committee structure has been and will continue to be the \u201cbackbone\u201d of the Organization\u2019s standard-setting process.\n\nThe work of this Expert Committee is important for WHO Member States, United Nations agencies and international organizations, and in-house for all medicines-related programmes.\n\nWork of this Expert Committee is closely linked to other organizations, for example, the European Medicines Agency (EMA), the European Directorate for the Quality of Medicines and HealthCare (EDQM), the Global Fund to Fight AIDS, Tuberculosis and Malaria, United Nations Children\u2019s Fund (UNICEF), World Intellectual Property Organization (WIPO), the World Bank, International Pharmaceutical Federation (FIP), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), International Generic Pharmaceutical Alliance (IGPA), World Self-Medication Industry (WSMI), national and regional pharmacopoeias, and other clusters, institutions, bodies, authorities and other WHO Expert Committees.\n\nExperts and WHO staff are committed to this important work, which enables quality medicines to reach the patients.\n\nQuality for some essential medicines with a major health impact, e.g. for the treatment of tuberculosis and malaria, is still a problem worldwide. This is especially notable when looking at submission for prequalification dossiers and also in recent articles published by colleagues from M\u00e9decins sans Fronti\u00e8res (MSF) and related nongovernmental organizations. However, the international (donor) community is becoming increasingly aware about the problem of poor quality drugs, and countries with the above problem are more open to recognizing it. Nevertheless, there is still a long way to go before poor people will also gain access to good quality medicines.\n\n*Open session*\n\nThe open session, held on Monday, 18 October 2010, was opened by Dr H.V. Hogerzeil, Director, Department of Essential Medicines and Pharmaceutical Policies on behalf of Dr C.F. Etienne, Assistant Director-General, Health Systems and Services. Dr Hogerzeil welcomed representation from a number of Permanent Representatives to the United Nations Offices, International Organizations based in Geneva, and Specialized Agencies in Switzerland; representatives from the WHO Regional Offices for Africa, the Americas (Pan American Health", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS destaca la importancia del trabajo de los Comit\u00e9s de Expertos en el establecimiento de est\u00e1ndares para medicamentos, que es fundamental para las actividades y prioridades de la organizaci\u00f3n. Este trabajo est\u00e1 vinculado a diversas organizaciones internacionales y es crucial para garantizar que los medicamentos de calidad lleguen a los pacientes. A pesar de los esfuerzos, la calidad de algunos medicamentos esenciales, especialmente para el tratamiento de enfermedades como la tuberculosis y la malaria, sigue siendo un problema a nivel mundial. La comunidad internacional est\u00e1 cada vez m\u00e1s consciente de este problema, pero a\u00fan queda un largo camino por recorrer para asegurar que las personas con menos recursos tengan acceso a medicamentos de buena calidad.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 papel desempe\u00f1an los Comit\u00e9s de Expertos en el proceso de establecimiento de est\u00e1ndares de la OMS?**\n   - Los Comit\u00e9s de Expertos son considerados la \"columna vertebral\" del proceso de establecimiento de est\u00e1ndares de la OMS, siendo fundamentales para las actividades relacionadas con medicamentos y para asegurar que estos cumplan con los requisitos de calidad.\n\n2. **\u00bfCu\u00e1les son algunos de los desaf\u00edos actuales en la calidad de los medicamentos esenciales mencionados en el documento?**\n   - Se menciona que la calidad de medicamentos esenciales para el tratamiento de enfermedades como la tuberculosis y la malaria sigue siendo un problema a nivel mundial, especialmente en lo que respecta a la presentaci\u00f3n de expedientes de precalificaci\u00f3n y en informes de organizaciones como M\u00e9dicos Sin Fronteras.\n\n3. **\u00bfQu\u00e9 acciones se est\u00e1n tomando para abordar el problema de los medicamentos de mala calidad a nivel internacional?**\n   - La comunidad internacional, incluidos donantes y pa\u00edses afectados, est\u00e1 comenzando a reconocer el problema de los medicamentos de mala calidad, lo que indica un aumento en la conciencia y la disposici\u00f3n para abordar esta cuesti\u00f3n, aunque a\u00fan queda mucho por hacer para garantizar el acceso a medicamentos de calidad para las poblaciones m\u00e1s vulnerables.\n\n### Resumen de Nivel Superior\nEl documento de la OMS subraya la importancia de los Comit\u00e9s de Expertos en el establecimiento de est\u00e1ndares para medicamentos, destacando su papel en la mejora de la calidad de los medicamentos a nivel global. A pesar de los esfuerzos realizados, persisten desaf\u00edos significativos en la calidad de medicamentos esenciales, especialmente en el contexto de enfermedades cr\u00edticas. La creciente conciencia de la comunidad internacional sobre estos problemas es un paso positivo, pero se requiere un esfuerzo continuo para garantizar que todos, especialmente los m\u00e1s desfavorecidos, tengan acceso a medicamentos de calidad.", "prev_section_summary": "### Temas Clave:\n\n1. **Historia de la OMS en Aseguramiento de Calidad de Medicamentos**: La OMS ha estado involucrada en la garant\u00eda de calidad de los medicamentos desde 1948, siendo uno de sus programas m\u00e1s antiguos, con un enfoque en la creaci\u00f3n de normas y est\u00e1ndares.\n\n2. **Financiamiento**: M\u00e1s del 80% de las actividades relacionadas con la calidad de los medicamentos son financiadas actualmente a trav\u00e9s de donantes externos, en lugar del presupuesto regular de la OMS.\n\n3. **Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas es fundamental para la creaci\u00f3n de normas y gu\u00edas, y ha aumentado la frecuencia de sus reuniones a anuales debido a la creciente necesidad de trabajo normativo.\n\n4. **Colaboraci\u00f3n Internacional**: Las actividades normativas de la OMS no solo benefician a los Estados miembros, sino tambi\u00e9n a organizaciones internacionales como UNICEF y el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria.\n\n5. **Publicaciones y Normas**: Los resultados de las reuniones del Comit\u00e9 de Expertos se publican en la Serie de Informes T\u00e9cnicos de la OMS y son presentados a los cuerpos de gobierno de la OMS.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Agencia de la ONU responsable de la salud p\u00fablica internacional.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que establece normas y gu\u00edas para la calidad de los medicamentos.\n- **Uni\u00f3n Europea**: Donante externo que financia actividades de la OMS.\n- **UNITAID**: Organizaci\u00f3n que apoya la financiaci\u00f3n de medicamentos y tratamientos.\n- **Fundaci\u00f3n Bill y Melinda Gates**: Donante que contribuye a las actividades de la OMS.\n- **UNICEF**: Organizaci\u00f3n de la ONU que trabaja en la salud y bienestar de los ni\u00f1os.\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: Organizaci\u00f3n que colabora con la OMS en actividades relacionadas con la salud.", "excerpt_keywords": "Keywords: WHO, standard-setting, quality medicines, Expert Committee, essential medicines"}}, "6500ca0c-105b-4a3f-baf7-7c711681d3c6": {"node_ids": ["244a31bc-dbb4-41c1-950a-dbd88695f224"], "metadata": {"page_label": "16", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Overview of WHO Expert Committee Presentation\n\nThe Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations provided an overview of the processes involved and the key areas covered. Time was allowed for questions, comments, and suggestions following the Secretary\u2019s presentation.\n\n## Recommendation\n\nIt was recommended that the key points of the Secretary\u2019s presentation be developed into a short article for wider dissemination to highlight the importance of the Expert Committee\u2019s work over the years and the need for normative standards and maintenance of quality guidelines.\n\nThe presentation would also be sent to interested parties and posted on the Medicines website.\n\n## Questions and Responses\n\nQuestions were asked regarding WHO guidelines, particularly concerning implementation, use of standards for procurement, and financing.\n\nThe Coordinator of the Quality Assurance and Safety: Medicines team replied that the guidelines were developed for use and implementation by Member States, and within WHO they were used within the Prequalification of Medicines Programme. Many partners and international organizations, such as the Global Fund, also use the guidance developed by this Expert Committee.\n\nA question was posed about specifications for neglected diseases, such as Chagas\u2019 disease and leishmania, which seemed to be missing from the work plan. The Secretary replied that the Quality Assurance and Safety: Medicines team would investigate this further when reviewing the Expert Committee\u2019s work plan.\n\n## Support and Contributions\n\nThe Secretary noted that significant support was received from national authorities and quality control laboratories, and that experts contribute significantly without necessarily being paid by WHO.\n\n## Co-Chairperson's Statement\n\nThe Co-Chairperson stated his 25 years of experience in implementing guidelines from WHO to raise the quality of NMRAs. He emphasized that without WHO\u2019s involvement, research for guidelines would largely be conducted by developed countries. WHO good manufacturing practices (GMP) as adopted by the Expert Committee on Specifications for Pharmaceutical Preparations are used by many countries.\n\n## Concerns Raised\n\nThe focus of comments by the Expert Committee members was on the impact of funding cuts, which were undermining normative functions supporting prequalification and assisting Member States\u2019 responsibilities and expectations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento presenta un resumen de la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas. Se discuten los procesos y \u00e1reas clave abordadas por el Secretario del Comit\u00e9, as\u00ed como la importancia de las normas y directrices de calidad en la farmac\u00e9utica. Se plantean preguntas sobre la implementaci\u00f3n de las directrices de la OMS, el uso de est\u00e1ndares para la adquisici\u00f3n de medicamentos y la financiaci\u00f3n. Tambi\u00e9n se menciona la falta de atenci\u00f3n a enfermedades desatendidas en el plan de trabajo del Comit\u00e9. Adem\u00e1s, se destaca el apoyo recibido de autoridades nacionales y laboratorios de control de calidad, as\u00ed como las preocupaciones sobre los recortes de financiaci\u00f3n que afectan las funciones normativas del Comit\u00e9.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se est\u00e1n tomando para abordar la falta de especificaciones para enfermedades desatendidas como la enfermedad de Chagas y la leishmaniasis en el plan de trabajo del Comit\u00e9?**\n   - Esta pregunta busca informaci\u00f3n sobre las acciones espec\u00edficas que se est\u00e1n considerando para incluir estas enfermedades en las directrices de la OMS, lo cual no se detalla en el documento.\n\n2. **\u00bfC\u00f3mo se est\u00e1n utilizando las directrices de la OMS en el Programa de Precalificaci\u00f3n de Medicamentos y qu\u00e9 impacto tienen en los pa\u00edses en desarrollo?**\n   - Esta pregunta se centra en el uso pr\u00e1ctico de las directrices de la OMS y su efecto en la calidad de los medicamentos en pa\u00edses que enfrentan desaf\u00edos en la regulaci\u00f3n y adquisici\u00f3n de productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 estrategias se est\u00e1n considerando para mitigar el impacto de los recortes de financiaci\u00f3n en las funciones normativas del Comit\u00e9 y en el apoyo a los Estados Miembros?**\n   - Esta pregunta busca entender las posibles soluciones o planes que el Comit\u00e9 podr\u00eda estar considerando para enfrentar los desaf\u00edos financieros que afectan su capacidad de operaci\u00f3n y apoyo a los pa\u00edses.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia del Establecimiento de Est\u00e1ndares**: El trabajo de establecimiento de est\u00e1ndares en el \u00e1rea de medicamentos es fundamental para las actividades y prioridades de la OMS.\n\n2. **Estructura de los Comit\u00e9s de Expertos**: Los Comit\u00e9s de Expertos son considerados la \"columna vertebral\" del proceso de establecimiento de est\u00e1ndares de la OMS, desempe\u00f1ando un papel crucial en la garant\u00eda de calidad de los medicamentos.\n\n3. **Colaboraci\u00f3n Internacional**: El trabajo de los Comit\u00e9s de Expertos est\u00e1 estrechamente vinculado a diversas organizaciones internacionales, lo que resalta la importancia de la colaboraci\u00f3n en la mejora de la calidad de los medicamentos.\n\n4. **Desaf\u00edos en la Calidad de Medicamentos**: A pesar de los esfuerzos, la calidad de algunos medicamentos esenciales, especialmente para el tratamiento de enfermedades como la tuberculosis y la malaria, sigue siendo un problema a nivel mundial.\n\n5. **Conciencia Internacional**: La comunidad internacional, incluidos donantes y pa\u00edses afectados, est\u00e1 cada vez m\u00e1s consciente del problema de los medicamentos de mala calidad, aunque a\u00fan queda mucho por hacer para garantizar el acceso a medicamentos de calidad para las poblaciones vulnerables.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Agencia Europea de Medicamentos (EMA)**\n- **Direcci\u00f3n Europea para la Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Fondo de las Naciones Unidas para la Infancia (UNICEF)**\n- **Organizaci\u00f3n Mundial de la Propiedad Intelectual (WIPO)**\n- **Banco Mundial**\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**\n- **Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos (IFPMA)**\n- **Alianza Internacional de Productos Farmac\u00e9uticos Gen\u00e9ricos (IGPA)**\n- **Industria Mundial de la Autocuidado (WSMI)**\n- **M\u00e9dicos Sin Fronteras (MSF)**\n\nEste resumen destaca la relevancia del trabajo de la OMS y sus Comit\u00e9s de Expertos en la mejora de la calidad de los medicamentos a nivel global, as\u00ed como los desaf\u00edos persistentes que enfrentan en este \u00e1mbito.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, quality assurance, neglected diseases, funding cuts"}}, "67ef6095-1560-47a4-b7ae-15e54bb45a6b": {"node_ids": ["56a41663-bc1a-47c1-8b8e-c417dbf9da4e"], "metadata": {"page_label": "17", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee members were concerned about the serious problems regarding the funding of WHO\u2019s normative work in the area of quality assurance.\n\n**Update on spurious/falsely-labelled/falsified/counterfeit medicines**\n\nDiscussion took place during the World Health Assembly in May 2010 regarding the *International Medical Products Anti-Counterfeiting Taskforce* (IMPACT) and issues regarding spurious/falsely-labelled/falsified/counterfeit medicines in general. The organization of an intergovernmental working group for Member States was currently ongoing based on a World Health Assembly decision. Concerns had been raised regarding WHO\u2019s role in this area. Two background papers had been prepared by the WHO Secretariat and submitted to the World Health Assembly. Several background papers were provided in the Expert Committee file regarding nomenclature and legal issues relating to substandard/spurious/falsely-labelled/falsified/counterfeit medicines. WHO has currently put on hold activities related to serving the Secretariat for IMPACT. The Director-General of WHO reconfirmed that spurious/falsely-labelled/falsified/counterfeit medicines are an important issue for the Organization.\n\nThe WHO Anti-Counterfeiting Programme is part of the Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines work plan and team.\n\n**Major publications since October 2009**\n\n- The forty-fourth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 957) was ready for its presentation to the WHO Executive Board meeting held in May 2010. It is now available in printed and electronic form and published copies were distributed to the participants at the forty-fifth meeting of the Expert Committee.\n\n**In the pipeline**\n\n- The Second supplement to the fourth edition of *The International Pharmacopoeia* would soon be available on CD-ROM and online.\n- A CD-ROM including all 60 current WHO quality assurance guidelines adopted by the Expert Committee on Specifications for Pharmaceutical Preparations would be available in a comprehensive and structured form by the end of 2010.\n\n**Expert Committee meeting topics**\n\nA variety of aspects relating to quality assurance were discussed, which involved more than 80 documents (including 30 quality assurance-related...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las preocupaciones del Comit\u00e9 de Expertos de la OMS sobre la financiaci\u00f3n de su trabajo normativo en el \u00e1rea de aseguramiento de la calidad. Se discuten los problemas relacionados con medicamentos falsificados y la creaci\u00f3n de un grupo de trabajo intergubernamental. Tambi\u00e9n se mencionan publicaciones recientes y futuras en el \u00e1mbito de la calidad de los medicamentos, as\u00ed como la organizaci\u00f3n de documentos relevantes para la reuni\u00f3n del Comit\u00e9 de Expertos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales preocupaciones del Comit\u00e9 de Expertos de la OMS respecto a la financiaci\u00f3n de su trabajo en calidad?**\n   - El Comit\u00e9 de Expertos est\u00e1 preocupado por los problemas serios relacionados con la financiaci\u00f3n de las actividades normativas de la OMS en el \u00e1rea de aseguramiento de la calidad.\n\n2. **\u00bfQu\u00e9 acciones se est\u00e1n tomando en relaci\u00f3n con el Taskforce Internacional de Productos M\u00e9dicos Anti-Falsificaci\u00f3n (IMPACT)?**\n   - Actualmente, la OMS ha puesto en espera las actividades relacionadas con el servicio de la Secretar\u00eda para IMPACT, aunque se est\u00e1n organizando trabajos intergubernamentales basados en decisiones de la Asamblea Mundial de la Salud.\n\n3. **\u00bfQu\u00e9 publicaciones importantes se han producido desde octubre de 2009 y cu\u00e1les son las futuras disponibilidades en el \u00e1mbito de la calidad de los medicamentos?**\n   - Desde octubre de 2009, se ha presentado el informe n\u00famero 44 del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas. En el futuro, se espera que el segundo suplemento de la cuarta edici\u00f3n de *The International Pharmacopoeia* est\u00e9 disponible en CD-ROM y en l\u00ednea, as\u00ed como un CD-ROM que contenga todas las directrices de aseguramiento de calidad de la OMS adoptadas por el Comit\u00e9 de Expertos.\n\n### Resumen de Nivel Superior\n\nEl documento aborda la situaci\u00f3n actual de la OMS en relaci\u00f3n con la calidad de los medicamentos, destacando la preocupaci\u00f3n por la financiaci\u00f3n y el impacto de los medicamentos falsificados. Se mencionan esfuerzos para abordar estos problemas a trav\u00e9s de la creaci\u00f3n de grupos de trabajo y la publicaci\u00f3n de informes y directrices relevantes. La OMS contin\u00faa trabajando en la mejora de sus pol\u00edticas y pr\u00e1cticas en el \u00e1mbito de la calidad de los medicamentos.", "prev_section_summary": "### Temas Clave\n\n1. **Presentaci\u00f3n del Comit\u00e9 de Expertos de la OMS**: Se proporcion\u00f3 un resumen de los procesos y \u00e1reas clave abordadas por el Secretario del Comit\u00e9 sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **Recomendaciones**: Se sugiri\u00f3 desarrollar un art\u00edculo corto para difundir la importancia del trabajo del Comit\u00e9 y la necesidad de normas y directrices de calidad.\n\n3. **Preguntas y Respuestas**: Se discutieron temas sobre la implementaci\u00f3n de las directrices de la OMS, el uso de est\u00e1ndares para la adquisici\u00f3n de medicamentos y cuestiones de financiaci\u00f3n.\n\n4. **Enfermedades Desatendidas**: Se plante\u00f3 la falta de especificaciones para enfermedades como la enfermedad de Chagas y la leishmaniasis en el plan de trabajo del Comit\u00e9.\n\n5. **Apoyo y Contribuciones**: Se destac\u00f3 el apoyo recibido de autoridades nacionales y laboratorios de control de calidad, as\u00ed como la contribuci\u00f3n de expertos no remunerados por la OMS.\n\n6. **Declaraci\u00f3n del Co-Presidente**: Se enfatiz\u00f3 la importancia de la participaci\u00f3n de la OMS en la investigaci\u00f3n y desarrollo de directrices, especialmente en pa\u00edses en desarrollo.\n\n7. **Preocupaciones sobre Financiaci\u00f3n**: Se expresaron inquietudes sobre el impacto de los recortes de financiaci\u00f3n en las funciones normativas del Comit\u00e9 y en el apoyo a los Estados Miembros.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n de directrices y normas en el \u00e1mbito farmac\u00e9utico.\n- **Comit\u00e9 de Expertos de la OMS sobre Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo encargado de desarrollar y revisar normas y directrices.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**: Iniciativa que utiliza las directrices del Comit\u00e9 para asegurar la calidad de los medicamentos.\n- **Global Fund**: Organizaci\u00f3n internacional que utiliza las directrices desarrolladas por el Comit\u00e9.\n- **Autoridades Nacionales y Laboratorios de Control de Calidad**: Entidades que brindan apoyo significativo al trabajo del Comit\u00e9.", "excerpt_keywords": "Keywords: WHO, quality assurance, counterfeit medicines, IMPACT, pharmaceutical preparations"}}, "93aa5da2-439c-4cda-b1a3-441ce01c6961": {"node_ids": ["c7b70f42-c995-4d85-a9a9-4c3530365396"], "metadata": {"page_label": "18", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General Policy\n\n## 2. International Collaboration\n\n### 2.1 International Collaboration\n\n#### 2.1.1 Collaboration with International Organizations and Agencies\n\n**European Directorate for the Quality of Medicines and HealthCare (Council of Europe)**\n\nA short update on the collaboration between the European Directorate for the Quality of Medicines and HealthCare (EDQM) and the WHO activities under this Expert Committee was given.\n\n**The Global Fund to Fight AIDS, Tuberculosis and Malaria**\n\nThe Global Fund to Fight AIDS, Tuberculosis and Malaria works in partnership with governments, civil society, the private sector and affected communities.\n\nOf the approved Global Fund budget, 37% is used for medicines and health products. For instance, of US$ 19.4 billion approved by the Board, 62% was used for HIV/AIDS, 22% for malaria and 16% for tuberculosis. By region this amounts to: sub-Saharan Africa, 57%; East Asia and Pacific, 14%; Eastern Europe and Central Asia, 7%; South Asia, 9%; Middle East and North Africa, 6%. Overall the Global Fund has 600 active grants in 144 countries.\n\nThe Global Fund's quality policy for pharmaceuticals has been revised following advice from this Expert Committee and since 2009 the policy has been based on three criteria:\n\n- **Clinical criteria** \u2014 medicines listed in WHO, national or institutional standard treatment guidelines (if not listed in one of the standard treatment guidelines, medicines require justification for selection from applicants or recipients).\n\n- **Quality criteria** \u2014 authorization of a product in the recipient country is necessary for all products. In the case of antiretrovirals (ARVs) and medicines for treating TB and malaria, WHO prequalification or authorization by stringent regulatory authorities (SRAs) or recommendation by the Expert Review Panel (ERP) is applied.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n Internacional en Salud**: El documento aborda la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y diversas organizaciones internacionales, destacando la importancia de trabajar en conjunto para mejorar la calidad de los medicamentos y productos de salud a nivel global.\n\n2. **El Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: Se presenta informaci\u00f3n sobre el presupuesto del Fondo Global, que destina una parte significativa a medicamentos y productos de salud, y se detalla c\u00f3mo se distribuyen estos fondos por regi\u00f3n y enfermedad.\n\n3. **Pol\u00edtica de Calidad de Productos Farmac\u00e9uticos**: Se describe la pol\u00edtica de calidad del Fondo Global para los productos farmac\u00e9uticos, que se basa en criterios cl\u00ednicos y de calidad, incluyendo la necesidad de autorizaci\u00f3n en el pa\u00eds receptor y la pre-calificaci\u00f3n por parte de la OMS o autoridades regulatorias estrictas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios cl\u00ednicos que deben cumplir los medicamentos para ser aprobados por el Fondo Global?**\n   - Respuesta: Los medicamentos deben estar listados en las gu\u00edas de tratamiento est\u00e1ndar de la OMS, nacionales o institucionales. Si no est\u00e1n listados, se requiere justificaci\u00f3n para su selecci\u00f3n por parte de los solicitantes o beneficiarios.\n\n2. **\u00bfQu\u00e9 porcentaje del presupuesto aprobado por el Fondo Global se destina a la lucha contra el VIH/SIDA, la malaria y la tuberculosis?**\n   - Respuesta: Del presupuesto aprobado de US$ 19.4 mil millones, el 62% se destina al VIH/SIDA, el 22% a la malaria y el 16% a la tuberculosis.\n\n3. **\u00bfQu\u00e9 requisitos de autorizaci\u00f3n se aplican a los productos farmac\u00e9uticos en el contexto del Fondo Global?**\n   - Respuesta: Es necesaria la autorizaci\u00f3n de un producto en el pa\u00eds receptor para todos los productos. En el caso de antirretrovirales y medicamentos para tratar la tuberculosis y la malaria, se aplica la pre-calificaci\u00f3n de la OMS o la autorizaci\u00f3n por parte de autoridades regulatorias estrictas (SRA) o la recomendaci\u00f3n del Panel de Revisi\u00f3n de Expertos (ERP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Preocupaciones sobre Financiaci\u00f3n**: \n   - El Comit\u00e9 de Expertos de la OMS expresa su preocupaci\u00f3n por los problemas serios relacionados con la financiaci\u00f3n de su trabajo normativo en el \u00e1rea de aseguramiento de la calidad.\n\n2. **Medicamentos Falsificados**:\n   - Se discutieron temas sobre medicamentos espurios, falsamente etiquetados, falsificados y de contrabando durante la Asamblea Mundial de la Salud en mayo de 2010.\n   - Se est\u00e1 organizando un grupo de trabajo intergubernamental para abordar estos problemas, aunque las actividades de la OMS relacionadas con el Taskforce Internacional de Productos M\u00e9dicos Anti-Falsificaci\u00f3n (IMPACT) est\u00e1n actualmente en espera.\n\n3. **Publicaciones Importantes**:\n   - Se menciona la disponibilidad del informe n\u00famero 44 del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas (WHO Technical Report Series, No. 957), que fue presentado en mayo de 2010.\n\n4. **Futuras Disponibilidades**:\n   - Se anticipa la publicaci\u00f3n del segundo suplemento de la cuarta edici\u00f3n de *The International Pharmacopoeia* en CD-ROM y en l\u00ednea.\n   - Un CD-ROM que incluir\u00e1 todas las directrices actuales de aseguramiento de calidad de la OMS adoptadas por el Comit\u00e9 de Expertos estar\u00e1 disponible a finales de 2010.\n\n5. **Temas de Reuni\u00f3n del Comit\u00e9 de Expertos**:\n   - Se discutieron diversos aspectos relacionados con el aseguramiento de la calidad, abarcando m\u00e1s de 80 documentos, incluidos 30 relacionados con la calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable de la salud p\u00fablica a nivel global.\n- **IMPACT (International Medical Products Anti-Counterfeiting Taskforce)**: Grupo de trabajo enfocado en combatir la falsificaci\u00f3n de productos m\u00e9dicos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que asesora a la OMS sobre especificaciones y calidad de los medicamentos.\n- **Asamblea Mundial de la Salud**: \u00d3rgano decisorio de la OMS donde se discuten temas de salud global. \n\nEste resumen destaca las preocupaciones sobre la financiaci\u00f3n y la calidad de los medicamentos, as\u00ed como las iniciativas y publicaciones recientes de la OMS en este \u00e1mbito.", "excerpt_keywords": "Keywords: International Collaboration, Global Fund, Pharmaceuticals Quality, HIV/AIDS, Health Products"}}, "82cde47b-c7e3-4546-80f5-6c3ef0117d3c": {"node_ids": ["6806560e-3e9c-4257-ac4e-0a84d41a1961"], "metadata": {"page_label": "19", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- *Quality monitoring* \u2014 quality of products is monitored all along the supply chain recipients and the results are reported to The Global Fund.\n\nThe ERP hosted by WHO lessens potential use or benefits associated with the use of finished pharmaceutical products (FPPs) that are not WHO-prequalified or SRA-authorized. Eligibility criteria for dossier submission include products being manufactured at a GMP site and having already submitted a dossier to WHO for prequalification or SRA review. Recommendations by ERP are valid for 12 months.\n\nSince 2009 the number of products permitted for use based on different approaches are 51 based on ERP advice, 18 prequalified by WHO and 7 approved by SRAs.\n\nChallenges for The Global Fund include: an increased demand for malaria, tuberculosis and opportunistic infections (OI) medicines of assured quality; finding quality control laboratories with Global Fund requirements; and strengthening national regulatory capacity and regulatory networks for harmonization.\n\n### United Nations Children's Fund\n\nThe Expert Committee was briefed on the role of the Supply Division of the United Nations Children's Fund (UNICEF) which was established in 1946.\n\nOne of the main activities is the timely supply of quality medicines to countries and communities in need. The role of the Supply Division is to:\n\n- oversee UNICEF's global procurement and logistic operations;\n- procure supplies on behalf of UNICEF and procurement services partners; and\n- ensure that high quality, good value supplies reach children and their families quickly.\n\nProcurement of pharmaceuticals by UNICEF involves prequalification of supplies, which is based on assessment of suppliers by undertaking:\n\n- a review of the documentation submitted and/or GMP inspection to ensure compliance with WHO GMP requirements; and\n- assessment of products using the WHO Product Questionnaire in WHO Technical Report Series, No. 937.\n\nLocal authorities are invited to participate in GMP decisions based on:\n\n- the regulatory environment in the country of origin and prior experience of UNICEF; and\n- GMP inspection by UNICEF or a representative selected by UNICEF.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro, destacando el papel de la Organizaci\u00f3n Mundial de la Salud (OMS) y el Fondo de las Naciones Unidas para la Infancia (UNICEF). La OMS, a trav\u00e9s de su Programa de Evaluaci\u00f3n de Productos (ERP), establece criterios de elegibilidad para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, asegurando que solo aquellos fabricados en sitios que cumplen con las Buenas Pr\u00e1cticas de Manufactura (GMP) sean considerados. Desde 2009, se han permitido varios productos para su uso, y se identifican desaf\u00edos en la demanda de medicamentos de calidad para enfermedades como la malaria y la tuberculosis. Por su parte, UNICEF se encarga de la adquisici\u00f3n y log\u00edstica de medicamentos, asegurando que lleguen a las comunidades necesitadas, y tambi\u00e9n realiza evaluaciones de proveedores para garantizar el cumplimiento de los est\u00e1ndares de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplir los productos farmac\u00e9uticos para ser elegibles para la presentaci\u00f3n de dossiers ante la OMS?**\n   - Respuesta: Los productos deben ser fabricados en un sitio que cumpla con las Buenas Pr\u00e1cticas de Manufactura (GMP) y haber presentado previamente un dossier a la OMS para su precalificaci\u00f3n o revisi\u00f3n por una Autoridad Reguladora de Salud (SRA).\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el ERP de la OMS en la autorizaci\u00f3n de productos farmac\u00e9uticos y cu\u00e1l es la duraci\u00f3n de sus recomendaciones?**\n   - Respuesta: El ERP de la OMS eval\u00faa y reduce el uso de productos farmac\u00e9uticos terminados que no est\u00e1n precalificados por la OMS o autorizados por una SRA. Las recomendaciones del ERP son v\u00e1lidas por un per\u00edodo de 12 meses.\n\n3. **\u00bfC\u00f3mo se involucran las autoridades locales en las decisiones sobre las Buenas Pr\u00e1cticas de Manufactura (GMP) en el proceso de adquisici\u00f3n de medicamentos por parte de UNICEF?**\n   - Respuesta: Las autoridades locales son invitadas a participar en las decisiones sobre GMP bas\u00e1ndose en el entorno regulatorio del pa\u00eds de origen y la experiencia previa de UNICEF, as\u00ed como en las inspecciones GMP realizadas por UNICEF o un representante designado por UNICEF.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n Internacional en Salud**: Se destaca la importancia de la colaboraci\u00f3n entre la Organizaci\u00f3n Mundial de la Salud (OMS) y diversas organizaciones internacionales para mejorar la calidad de los medicamentos y productos de salud a nivel global.\n\n2. **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**: \n   - **Asociaciones**: Trabaja en conjunto con gobiernos, sociedad civil, sector privado y comunidades afectadas.\n   - **Presupuesto**: De un total de US$ 19.4 mil millones, se destina el 37% a medicamentos y productos de salud, con un desglose del 62% para VIH/SIDA, 22% para malaria y 16% para tuberculosis.\n   - **Distribuci\u00f3n Regional**: Los fondos se distribuyen principalmente en sub-Sahara (57%), Asia Oriental y Pac\u00edfico (14%), Europa del Este y Asia Central (7%), Asia del Sur (9%) y Medio Oriente y \u00c1frica del Norte (6%).\n\n3. **Pol\u00edtica de Calidad de Productos Farmac\u00e9uticos del Fondo Global**:\n   - **Criterios Cl\u00ednicos**: Los medicamentos deben estar listados en las gu\u00edas de tratamiento est\u00e1ndar de la OMS o requerir justificaci\u00f3n si no est\u00e1n incluidos.\n   - **Criterios de Calidad**: Se requiere autorizaci\u00f3n del producto en el pa\u00eds receptor. Para antirretrovirales y medicamentos para tuberculosis y malaria, se aplica la pre-calificaci\u00f3n de la OMS o autorizaci\u00f3n por autoridades regulatorias estrictas (SRA) o recomendaci\u00f3n del Panel de Revisi\u00f3n de Expertos (ERP).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria**\n- **Direcci\u00f3n Europea para la Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (Consejo de Europa)**", "excerpt_keywords": "Keywords: quality monitoring, pharmaceutical products, WHO prequalification, UNICEF procurement, regulatory capacity"}}, "5c1196e0-1ef0-4d74-8944-72040e76d9ca": {"node_ids": ["c2809b67-3469-4a57-8e29-ccf56d8e06cd"], "metadata": {"page_label": "20", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Contract manufacture is only accepted if the subcontractor is also approved by UNICEF.\n\nInspections are carried out primarily by UNICEF staff who check compliance with WHO GMP guidelines.\n\nDuring 2006\u20132009, 89 GMP inspections were carried out and 27 companies failed (30%). In the case of GMP noncompliance (failure), a detailed GMP inspection report is forwarded to the company with a request to respond within one month.\n\nUNICEF does GMP in collaboration with local authorities and also carries out joint inspection with WHO, ICRC and MSF. It is also a partner to PIC/S.\n\nIn the case of prequalification of vaccines, HIV/AIDS, malaria and tuberculosis products:\n\n- products must be prequalified by WHO and listed on the WHO web site;\n- the supplier has to confirm to UNICEF that its products are identical to those assessed by WHO; and\n- UNICEF's purchase is \u201ctraced\u201d in WHO/UNICEF GMP inspection.\n\n## 2.1.2 Pharmacopoeial Discussion Group\n\nA brief update was given by the representative from the Japanese Pharmacopoeia on the current activities of the Pharmacopoeial Discussion Group (PDG) which consists of the European Pharmacopoeia (PhEur), Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP). At present, 27 of the 34 general chapters and 40 of the 63 excipient monographs of the current PDG work programme have been harmonized by these three pharmacopoeias. During the latest PDG meeting, a revision of the general chapter for Dissolution and corrections to Capillary electrophoresis were signed off. The sign-offs for excipients included revisions to previously harmonized excipient monographs. This exercise is aimed at achieving a higher level of harmonization of previously signed-off monographs. Harmonization has been achieved on nine of the 10 general chapters identified by the ICH Q6A Guideline. PDG\u2019s submission of Bulk and tapped density and bacterial endotoxins enabled the ICH Q4B to sign off the two texts at step 2. PDG re-emphasized the importance of consistent regulatory positions on harmonized text. At their joint meeting, PDG and ICH Q4B reflected on additional ways in which to accelerate declaration of regulatory interchangeability of pharmacopoeial texts.\n\nThe PDG parties agreed to provide their harmonized texts for the general methods in order to further enhance harmonization and to enable WHO to revise its text currently included in *The International Pharmacopoeia*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Inspecciones de GMP y Colaboraci\u00f3n de UNICEF**: Durante el per\u00edodo de 2006 a 2009, UNICEF llev\u00f3 a cabo 89 inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP), de las cuales el 30% resultaron en fallos. UNICEF colabora con autoridades locales y realiza inspecciones conjuntas con organizaciones como la OMS, ICRC y MSF. Adem\u00e1s, para la precalificaci\u00f3n de productos relacionados con enfermedades como el VIH/SIDA, malaria y tuberculosis, es esencial que los productos est\u00e9n prequalificados por la OMS.\n\n2. **Grupo de Discusi\u00f3n Farmacopeica (PDG)**: El PDG, que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos, ha logrado armonizar una parte significativa de sus cap\u00edtulos generales y monograf\u00edas de excipientes. En su \u00faltima reuni\u00f3n, se firmaron revisiones importantes y se discutieron formas de acelerar la declaraci\u00f3n de intercambiabilidad regulatoria de los textos farmacopeicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones toma UNICEF en caso de incumplimiento de GMP por parte de una empresa?**\n   - En caso de incumplimiento de GMP, UNICEF env\u00eda un informe detallado de la inspecci\u00f3n a la empresa con una solicitud para que respondan dentro de un mes.\n\n2. **\u00bfCu\u00e1ntas de las monograf\u00edas de excipientes del programa de trabajo actual del PDG han sido armonizadas hasta la fecha?**\n   - Hasta el momento, 40 de las 63 monograf\u00edas de excipientes del programa de trabajo actual del PDG han sido armonizadas.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplir los productos para ser precalificados por UNICEF en relaci\u00f3n con las vacunas y tratamientos para enfermedades espec\u00edficas?**\n   - Los productos deben estar precalificados por la OMS, el proveedor debe confirmar que sus productos son id\u00e9nticos a los evaluados por la OMS, y la compra de UNICEF debe ser \"rastreada\" en la inspecci\u00f3n GMP de la OMS/UNICEF.", "prev_section_summary": "La secci\u00f3n aborda la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos a lo largo de la cadena de suministro, destacando el papel de dos entidades clave: la Organizaci\u00f3n Mundial de la Salud (OMS) y el Fondo de las Naciones Unidas para la Infancia (UNICEF).\n\n### Temas Clave:\n\n1. **Monitoreo de Calidad**: Se enfatiza la importancia de monitorear la calidad de los productos farmac\u00e9uticos en toda la cadena de suministro, con informes de resultados al Fondo Global.\n\n2. **Programa de Evaluaci\u00f3n de Productos (ERP)**: La OMS, a trav\u00e9s del ERP, establece criterios de elegibilidad para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, asegurando que solo se consideren aquellos fabricados en sitios que cumplen con las Buenas Pr\u00e1cticas de Manufactura (GMP). Las recomendaciones del ERP son v\u00e1lidas por 12 meses.\n\n3. **Desaf\u00edos para el Fondo Global**: Se identifican retos como el aumento de la demanda de medicamentos de calidad para enfermedades como malaria y tuberculosis, la necesidad de laboratorios de control de calidad que cumplan con los requisitos del Fondo Global, y el fortalecimiento de la capacidad regulatoria nacional.\n\n4. **Rol de UNICEF**: La Divisi\u00f3n de Suministros de UNICEF se encarga de la adquisici\u00f3n y log\u00edstica de medicamentos, asegurando que lleguen a las comunidades necesitadas. Esto incluye la pre-calificaci\u00f3n de suministros mediante la evaluaci\u00f3n de proveedores y el cumplimiento de los est\u00e1ndares de calidad de la OMS.\n\n5. **Participaci\u00f3n de Autoridades Locales**: Las autoridades locales son invitadas a participar en decisiones sobre GMP, considerando el entorno regulatorio del pa\u00eds de origen y la experiencia previa de UNICEF.\n\n### Entidades Clave:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Responsable de establecer est\u00e1ndares y monitorear la calidad de los productos farmac\u00e9uticos.\n- **Fondo de las Naciones Unidas para la Infancia (UNICEF)**: Encargado de la adquisici\u00f3n y distribuci\u00f3n de medicamentos de calidad a comunidades necesitadas. \n- **Fondo Global**: Entidad que recibe informes sobre la calidad de los productos y enfrenta desaf\u00edos en la provisi\u00f3n de medicamentos de calidad. \n\nEste resumen destaca la colaboraci\u00f3n entre estas entidades para garantizar el acceso a medicamentos de calidad y la importancia de la regulaci\u00f3n y el monitoreo en la cadena de suministro farmac\u00e9utica.", "excerpt_keywords": "Keywords: UNICEF, GMP inspections, pharmacopoeial harmonization, WHO prequalification, pharmaceutical quality"}}, "1934e0f7-e4ce-4eee-a7bc-722897bf7e30": {"node_ids": ["e80a7397-6b1a-4efa-8a4b-500e045757f5"], "metadata": {"page_label": "21", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.1.3 International Conference on Harmonisation\n\nThe Expert Committee was informed about the International Conference on Harmonisation (ICH) meeting held in Tallinn, Estonia from 5 to 10 June 2010, with a focus on the area of quality of pharmaceuticals. It was reported that the highlight of this meeting was the progress made in the global implementation of ICH.\n\nGuidelines Q8 (*Pharmaceutical development*), Q9 (*Quality risk management*) and Q10 (*Pharmaceutical quality system*) reflect the new paradigm in pharmaceutical quality towards more process\u2013product understanding and process control rather than end-product testing. The ICH Quality Implementation Working Group (IWG) had held its first training workshop in Tallinn. The training consisted of a case-study representing the different phases of the life-cycle of a pharmaceutical product. The training was subsequently held in Washington, DC (USA) and in Tokyo (Japan).\n\nFurther progress was made on the harmonization of pharmacopoeial texts in the three ICH regions, with the aim of reducing testing requirements. Two annexes for the Q4B Guideline *Evaluation and recommendation of pharmacopoeial text for use in the ICH regions* (Annex 11 on *Capillary electrophoresis* and Annex 12 on *Analytical sieving*) reached Step 4, and another two annexes (Annex 13 on *Bulk and tapped density* and Annex 14 on *Bacterial endotoxin*) reached Step 2. These texts will also be considered for further harmonization within the context of *The International Pharmacopoeia*.\n\nThe Q3D Expert Working Group (EWG) began work on guidelines that will provide limits for *Metal impurities* in medicines, products and ingredients both qualitatively and quantitatively.\n\nThe ICH Steering Committee approved the establishment of an EWG for a new multidisciplinary topic (M7) on *Genotoxic impurities*. The guidelines will describe the evaluation, qualification and control of these impurities in medicines during development and after licensing.\n\n## 2.1.4 International Conference of Drug Regulatory Authorities\n\nThe Committee was provided with an update on the 14th International Conference of Drug Regulatory Authorities (ICDRA) hosted by the Health Sciences Authority of Singapore (HSA) together with WHO from 30 November to 3 December 2010 in Singapore. In conjunction with the 14th ICDRA, a pre-conference, entitled \u201cEffective collaboration: the future for medicines regulation,\u201d was to be held at the same location from 28 to 29 November 2010.\n\nGlobalization and rapid advances in information technology have brought about countless benefits and have improved living standards, but they...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto se centra en dos eventos importantes relacionados con la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos: la reuni\u00f3n de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) en Tallin, Estonia, y la 14\u00aa Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA) en Singapur. Durante la reuni\u00f3n del ICH, se discutieron avances en la implementaci\u00f3n de directrices que promueven un enfoque m\u00e1s comprensivo hacia la calidad farmac\u00e9utica, as\u00ed como la armonizaci\u00f3n de textos farmacop\u00e9icos. Tambi\u00e9n se mencionaron nuevas directrices sobre impurezas met\u00e1licas y genot\u00f3xicas en medicamentos. La ICDRA se centr\u00f3 en la colaboraci\u00f3n efectiva en la regulaci\u00f3n de medicamentos en un contexto de globalizaci\u00f3n y avances tecnol\u00f3gicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales directrices discutidas en la reuni\u00f3n del ICH y c\u00f3mo reflejan el nuevo paradigma en la calidad farmac\u00e9utica?**\n   - Respuesta: Las principales directrices discutidas son Q8 (*Desarrollo farmac\u00e9utico*), Q9 (*Gesti\u00f3n de riesgos de calidad*) y Q10 (*Sistema de calidad farmac\u00e9utica*), que enfatizan la comprensi\u00f3n del proceso y el control del mismo en lugar de solo la prueba del producto final.\n\n2. **\u00bfQu\u00e9 avances se lograron en la armonizaci\u00f3n de textos farmacop\u00e9icos durante la reuni\u00f3n del ICH y cu\u00e1les son los anexos que alcanzaron diferentes etapas?**\n   - Respuesta: Se lograron avances en la armonizaci\u00f3n de textos farmacop\u00e9icos, con dos anexos (Anexo 11 sobre *Electroforesis capilar* y Anexo 12 sobre *Tamizado anal\u00edtico*) alcanzando el Paso 4, y otros dos anexos (Anexo 13 sobre *Densidad a granel y apilada* y Anexo 14 sobre *Endotoxinas bacterianas*) alcanzando el Paso 2.\n\n3. **\u00bfQu\u00e9 temas se abordaron en la 14\u00aa ICDRA y cu\u00e1l fue el enfoque principal de la pre-conferencia?**\n   - Respuesta: En la 14\u00aa ICDRA se abordaron temas relacionados con la regulaci\u00f3n de medicamentos en un contexto global. El enfoque principal de la pre-conferencia fue \"Colaboraci\u00f3n efectiva: el futuro de la regulaci\u00f3n de medicamentos\".\n\n### Resumen de Nivel Superior\n\nLa reuni\u00f3n del ICH en Tallin se centr\u00f3 en la calidad de los productos farmac\u00e9uticos, destacando la importancia de un enfoque m\u00e1s integral hacia la calidad y la reducci\u00f3n de requisitos de prueba a trav\u00e9s de la armonizaci\u00f3n de textos. La 14\u00aa ICDRA en Singapur se enfoc\u00f3 en la colaboraci\u00f3n en la regulaci\u00f3n de medicamentos, reconociendo los desaf\u00edos y oportunidades presentados por la globalizaci\u00f3n y la tecnolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - UNICEF realiza inspecciones de GMP para asegurar el cumplimiento de las directrices de la OMS.\n   - Entre 2006 y 2009, se llevaron a cabo 89 inspecciones, de las cuales 27 empresas (30%) no cumplieron con los est\u00e1ndares.\n   - En caso de incumplimiento, se env\u00eda un informe detallado a la empresa con un plazo de respuesta de un mes.\n   - UNICEF colabora con autoridades locales y realiza inspecciones conjuntas con la OMS, el Comit\u00e9 Internacional de la Cruz Roja (ICRC) y M\u00e9dicos Sin Fronteras (MSF).\n\n2. **Precalificaci\u00f3n de Productos**:\n   - Para productos relacionados con VIH/SIDA, malaria y tuberculosis, deben estar precalificados por la OMS y confirmados por el proveedor como id\u00e9nticos a los evaluados por la OMS.\n   - Las compras de UNICEF deben ser rastreadas en las inspecciones GMP de la OMS/UNICEF.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica (PDG)**:\n   - Compuesto por la Farmacopea Europea (PhEur), la Farmacopea Japonesa (JP) y la Farmacopea de los Estados Unidos (USP).\n   - Se han armonizado 27 de los 34 cap\u00edtulos generales y 40 de las 63 monograf\u00edas de excipientes en el programa de trabajo actual.\n   - Se firmaron revisiones importantes en la \u00faltima reuni\u00f3n, incluyendo la disoluci\u00f3n y la electroforesis capilar.\n   - Se enfatiza la importancia de posiciones regulatorias consistentes sobre textos armonizados.\n\n4. **Harmonizaci\u00f3n y Regulaci\u00f3n**:\n   - Se ha logrado armonizaci\u00f3n en nueve de los diez cap\u00edtulos generales identificados por la Gu\u00eda ICH Q6A.\n   - Se discuten formas de acelerar la declaraci\u00f3n de intercambiabilidad regulatoria de los textos farmacopeicos.\n\n### Entidades Clave:\n- **UNICEF**: Organizaci\u00f3n que realiza inspecciones de GMP y colabora en la precalificaci\u00f3n de productos.\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Establece directrices de GMP y precalificaci\u00f3n de productos.\n- **ICRC (Comit\u00e9 Internacional de la Cruz Roja)** y **MSF (M\u00e9dicos Sin Fronteras)**: Organizaciones con las que UNICEF colabora en inspecciones.\n- **PDG (Pharmacopoeial Discussion Group)**: Grupo que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos, trabajando en la armonizaci\u00f3n de textos farmacopeicos.", "excerpt_keywords": "Keywords: International Conference on Harmonisation, pharmaceutical quality, guidelines, harmonization, genotoxic impurities"}}, "7028b56b-2994-46d1-82dc-9277c758f3e7": {"node_ids": ["50477378-2887-453f-ac6c-7b6e79633095"], "metadata": {"page_label": "22", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have also raised new challenges for public health and NMRAs. Increasing sophistication of health products, the development of cutting-edge technologies and extensive use of the Internet pose many challenges to the regulatory authorities of both developing and developed countries. ICDRA is a unique platform for NMRAs of WHO Member States to meet and discuss ways to strengthen collaboration and address issues of common concern. The organizing committee elaborated a programme that will provide opportunities for medicines regulators and interested stakeholders to share and discuss current and topical issues of global concern, for example, the H1N1 influenza situation, and access to high-quality medicines.\n\nThe pre-meeting would be open to other parties upon registration and would discuss collaboration and cooperation between NMRAs focusing on assessment and inspection.\n\n## 2.2 Cross-cutting issues in pharmaceuticals \u2014 quality assurance issues\n\n### 2.2.1 Essential medicines\n\nAn update on the activities of the Expert Committee on Selection and Use of Essential Medicines was given by its Secretary. Currently, the WHO Model List of Essential Medicines (EML) lists all medicines that are recommended for adults and children, including formulations. The 2nd WHO Model List of Essential Medicines for children (EMLc) includes children's medicines, together with age restrictions and medicines for neonates. However, at the moment there are certain discrepancies and difficulties between the two lists. For example, section 8.4 for palliative care does not list any medicines listed for adults and has a long list for children. It was explained that certain national contexts may not be evidence-based and made little use of the WHO Model List.\n\nThe Expert Committee was briefed on the project Better Medicines for Children, which provides intensive support to Ghana, two states in India and to the United Republic of Tanzania. Work is commencing with francophone African countries and there is ongoing support to other regions in aspects of implementation.\n\nThe eighteenth meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines will be held in Accra, Ghana from 21 to 25 March 2011. The agenda includes discussion on dosage forms, fixed-dose combinations, extemporaneous preparations, and ongoing application reviews.\n\nThe Committee recommended that the Expert Committee on Selection and Use of Essential Medicines consult with it on all issues relating to quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en los desaf\u00edos actuales que enfrentan las autoridades reguladoras de medicamentos (NMRAs) en el contexto de la creciente sofisticaci\u00f3n de los productos de salud y el uso de tecnolog\u00edas avanzadas. Se menciona la importancia de la colaboraci\u00f3n entre NMRAs a trav\u00e9s de la ICDRA y se discuten temas relacionados con la selecci\u00f3n y uso de medicamentos esenciales, incluyendo las discrepancias entre las listas de medicamentos esenciales para adultos y ni\u00f1os. Tambi\u00e9n se destaca el proyecto \"Better Medicines for Children\" y se anuncia la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos de la OMS sobre la selecci\u00f3n y uso de medicamentos esenciales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales discrepancias entre la Lista Modelo de Medicamentos Esenciales de la OMS para adultos y la de ni\u00f1os, y c\u00f3mo afectan estas diferencias a la atenci\u00f3n m\u00e9dica en diferentes contextos nacionales?**\n   - Esta pregunta busca profundizar en las implicaciones pr\u00e1cticas de las discrepancias mencionadas en el documento, que no se abordan en otros lugares.\n\n2. **\u00bfQu\u00e9 tipo de apoyo se est\u00e1 brindando a los pa\u00edses involucrados en el proyecto \"Better Medicines for Children\" y cu\u00e1les son los objetivos espec\u00edficos de este proyecto?**\n   - Esta pregunta se centra en los detalles del proyecto y su impacto en la mejora de la calidad de los medicamentos para ni\u00f1os, informaci\u00f3n que puede no estar disponible en otras fuentes.\n\n3. **\u00bfQu\u00e9 temas espec\u00edficos se discutir\u00e1n en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos sobre la selecci\u00f3n y uso de medicamentos esenciales en Accra, Ghana, y por qu\u00e9 son relevantes para la calidad de los medicamentos?**\n   - Esta pregunta busca obtener informaci\u00f3n sobre la agenda de la reuni\u00f3n y su relevancia, lo que puede no estar ampliamente documentado en otros contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. **Conferencia Internacional sobre Armonizaci\u00f3n (ICH)**\n   - **Evento**: Reuni\u00f3n en Tallin, Estonia (5-10 de junio de 2010).\n   - **Enfoque**: Calidad de los productos farmac\u00e9uticos.\n   - **Directrices Principales**:\n     - **Q8**: Desarrollo farmac\u00e9utico.\n     - **Q9**: Gesti\u00f3n de riesgos de calidad.\n     - **Q10**: Sistema de calidad farmac\u00e9utica.\n   - **Nuevo Paradigma**: Enfoque en la comprensi\u00f3n del proceso y control en lugar de solo pruebas del producto final.\n   - **Avances en Armonizaci\u00f3n**:\n     - Anexos alcanzados:\n       - **Paso 4**: Anexo 11 (*Electroforesis capilar*), Anexo 12 (*Tamizado anal\u00edtico*).\n       - **Paso 2**: Anexo 13 (*Densidad a granel y apilada*), Anexo 14 (*Endotoxinas bacterianas*).\n   - **Nuevas Iniciativas**:\n     - **Q3D EWG**: L\u00edmites para impurezas met\u00e1licas en medicamentos.\n     - **M7 EWG**: Directrices sobre impurezas genot\u00f3xicas.\n\n#### 2. **Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA)**\n   - **Evento**: 14\u00aa ICDRA en Singapur (30 de noviembre - 3 de diciembre de 2010).\n   - **Colaboraci\u00f3n**: Organizada por la Autoridad de Ciencias de la Salud de Singapur y la OMS.\n   - **Pre-conferencia**: \"Colaboraci\u00f3n efectiva: el futuro de la regulaci\u00f3n de medicamentos\" (28-29 de noviembre de 2010).\n   - **Contexto**: Enfoque en la regulaci\u00f3n de medicamentos en un entorno de globalizaci\u00f3n y avances tecnol\u00f3gicos.\n\n### Entidades Clave\n- **ICH**: Conferencia Internacional sobre Armonizaci\u00f3n.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **HSA**: Autoridad de Ciencias de la Salud de Singapur.\n- **Q3D EWG**: Grupo de trabajo sobre impurezas met\u00e1licas.\n- **M7 EWG**: Grupo de trabajo sobre impurezas genot\u00f3xicas. \n\nEste resumen destaca los eventos, directrices y enfoques discutidos en las reuniones, as\u00ed como las entidades involucradas en la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: NMRAs, essential medicines, quality assurance, ICDRA, Better Medicines for Children"}}, "28274d98-b7c5-4399-ba80-8aa8a181a954": {"node_ids": ["40ac988c-786a-4169-9dd0-bb88047256ea"], "metadata": {"page_label": "23", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2.2 Herbal and complementary medicines\n\nThe Traditional Medicine team, which used to be part of the Department of Essential Medicines and Pharmaceutical Policies is now under the Department of Health Policy, Development and Services. The resolution on traditional medicine adopted at the 62nd World Health Assembly in 2010 serves as the basis for its activities. The resolution requests WHO to strengthen cooperation with collaborating centres, research institutions and nongovernmental organizations in order to share evidence-based information and to support training programmes for national capacity building in the field of traditional medicines. It also requested WHO to continue providing technical guidance to support countries in ensuring the safety, efficacy and quality of traditional medicine, provide policy guidance to countries on how to integrate traditional medicine into health systems, and update the WHO traditional medicine strategy based on countries\u2019 progress and new challenges.\n\nStrategic objectives and priority areas of the Programme include:\n\n- Capitalization on the potential contribution of traditional medicines to self-care and to people-centred primary care;\n- Modality of integration of traditional medicines into health systems;\n- Promoting agreement and consensus on criteria for endorsement, integration and evaluation of traditional medicine as a subsystem of national health systems; and\n- Strengthening research to promote the quality, safety and efficacy of traditional medicines and products.\n\nAn update on the activities undertaken in 2010 in the area of quality and safety of herbal medicines included the following:\n\n- *Quality control methods for medicinal plant materials* \u2014 updated edition (currently in preparation for printing)\n- *Key technical issues of quality impacting on the safety of homeopathic medicines* (printed in 2010)\n- *Guidelines for selecting substances for quality control of herbal medicines* (in preparation)\n- *Good processing practices for herbal materials* (in preparation)\n- *Guidelines on safety management of toxic medicinal plants and monographs on selected commonly used toxic medicinal plants* (in preparation)\n\nImportant WHO documents on medicinal plants developed by the Programme include:\n\n*WHO monographs on selected medicinal plants* \u2014 Volumes 1, 2, 3 and 4. These monographs provide scientific information on safety, efficacy and quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl equipo de Medicina Tradicional de la OMS, ahora bajo el Departamento de Pol\u00edticas de Salud, se basa en una resoluci\u00f3n adoptada en 2010 para fortalecer la cooperaci\u00f3n en el \u00e1mbito de las medicinas tradicionales. Esta resoluci\u00f3n busca asegurar la seguridad, eficacia y calidad de las medicinas tradicionales, as\u00ed como su integraci\u00f3n en los sistemas de salud. Se destacan objetivos estrat\u00e9gicos como la promoci\u00f3n de la auto-cuidado y la investigaci\u00f3n sobre la calidad y seguridad de las medicinas herbales. Adem\u00e1s, se mencionan varias actividades y documentos importantes relacionados con el control de calidad y la gesti\u00f3n de plantas medicinales t\u00f3xicas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los objetivos estrat\u00e9gicos del Programa de Medicina Tradicional de la OMS seg\u00fan la resoluci\u00f3n de 2010?**\n   - Esta pregunta busca respuestas sobre los objetivos espec\u00edficos que gu\u00edan las actividades del programa, que no se encuentran f\u00e1cilmente en otros documentos.\n\n2. **\u00bfQu\u00e9 documentos importantes ha desarrollado la OMS en relaci\u00f3n con las plantas medicinales y cu\u00e1les son sus enfoques principales?**\n   - Esta pregunta se centra en los documentos espec\u00edficos mencionados en el contexto, proporcionando informaci\u00f3n sobre su contenido y prop\u00f3sito.\n\n3. **\u00bfQu\u00e9 actividades se llevaron a cabo en 2010 para mejorar la calidad y seguridad de las medicinas herbales?**\n   - Esta pregunta busca detalles sobre las iniciativas espec\u00edficas que se implementaron en ese a\u00f1o, lo que puede no estar documentado en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desaf\u00edos para la Salud P\u00fablica y NMRAs**:\n   - La creciente sofisticaci\u00f3n de los productos de salud, el desarrollo de tecnolog\u00edas avanzadas y el uso extensivo de Internet presentan nuevos retos para las autoridades reguladoras de medicamentos (NMRAs) en pa\u00edses en desarrollo y desarrollados.\n\n2. **ICDRA**:\n   - La ICDRA (International Conference of Drug Regulatory Authorities) es una plataforma \u00fanica para que las NMRAs de los Estados Miembros de la OMS se re\u00fanan y discutan formas de fortalecer la colaboraci\u00f3n y abordar problemas de inter\u00e9s com\u00fan, como la situaci\u00f3n de la influenza H1N1 y el acceso a medicamentos de alta calidad.\n\n3. **Medicamentos Esenciales**:\n   - Se actualiz\u00f3 sobre las actividades del Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales. La Lista Modelo de Medicamentos Esenciales de la OMS (EML) incluye medicamentos recomendados para adultos y ni\u00f1os, pero existen discrepancias entre la EML y la Lista Modelo de Medicamentos Esenciales para Ni\u00f1os (EMLc), especialmente en el \u00e1rea de cuidados paliativos.\n\n4. **Proyecto \"Better Medicines for Children\"**:\n   - Este proyecto brinda apoyo intensivo a Ghana, dos estados en India y la Rep\u00fablica Unida de Tanzania, y est\u00e1 comenzando a trabajar con pa\u00edses franc\u00f3fonos de \u00c1frica. Su objetivo es mejorar la calidad de los medicamentos para ni\u00f1os.\n\n5. **Pr\u00f3xima Reuni\u00f3n del Comit\u00e9 de Expertos**:\n   - La d\u00e9cimo octava reuni\u00f3n del Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales se llevar\u00e1 a cabo en Accra, Ghana, del 21 al 25 de marzo de 2011. La agenda incluir\u00e1 discusiones sobre formas de dosificaci\u00f3n, combinaciones de dosis fijas, preparaciones extempor\u00e1neas y revisiones de aplicaciones en curso.\n\n6. **Recomendaciones del Comit\u00e9**:\n   - Se recomend\u00f3 que el Comit\u00e9 de Expertos sobre la Selecci\u00f3n y Uso de Medicamentos Esenciales consulte sobre todos los temas relacionados con la garant\u00eda de calidad de los medicamentos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que coordina las actividades de salud p\u00fablica y regula medicamentos esenciales.\n- **NMRAs (Autoridades Reguladoras de Medicamentos)**: Entidades responsables de la regulaci\u00f3n de medicamentos en diferentes pa\u00edses.\n- **ICDRA**: Conferencia Internacional de Autoridades Reguladoras de Medicamentos.\n- **Ghana, India, Rep\u00fablica Unida de Tanzania**: Pa\u00edses que reciben apoyo del proyecto \"Better Medicines for Children\".", "excerpt_keywords": "Keywords: traditional medicine, herbal medicines, WHO, quality control, safety management"}}, "962f93e4-ba47-4cdf-83cf-de27676441ec": {"node_ids": ["4e3c8add-2de2-4754-9221-cecf48510225"], "metadata": {"page_label": "24", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality control of widely used medicinal plants as well as providing models to assist countries in developing their own monographs or formularies.\n\n*WHO monographs on selected medicinal plants used in the Newly Independent States* (2010). The publication is available in English and in Russian and includes monographs adopted from existing WHO monographs, and of which 14 are new.\n\nWork is also being done to expand the evidence base on the quality, safety and efficacy of herbal medicines, including review and analysis of reports of clinical studies; technical documents on the safety of herbal medicines with reference to interaction with other medicines; and key technical issues of research methodologies.\n\nAnother ongoing activity is the 2nd WHO Global Survey on Material Policy and Regulation of Traditional Medicine. The objective of the survey is to assess the impact of implementation of the WHO Traditional Medicine Strategy: 2002\u20132005 and 2004\u20132007. The survey attempts to collect updated and more comprehensive information relating to practices and qualifications and to monitor progress in Member States. It also aims to identify new needs of each Member State and to update the WHO Traditional Medicine Strategy.\n\nBasic training guidelines, benchmarks and manuals developed in 2010 include: osteopathy; Tuina; Nua Thai; therapies using herbal medicines \u2014 Chinese traditional medicines; ayurvedic medicine; Unani medicine; naturopathic medicine; and naturopathy.\n\n### 2.2.3 Regulatory support\n\nAll WHO\u2019s normative work in the area of quality, safety and efficacy is intended to support NMRAs and is developed with them through the global consultative processes referred to above. The core functions of WHO\u2019s Medicines Regulatory Support Programme include the provision of direct support to countries and regions for strengthening medicines regulation; developing and continuously improving tools to assist regulatory work; facilitating communication; and promoting harmonization among NMRAs. Country support involves assessing medicines regulatory systems to identify needs, preparing institutional plans and providing technical support and capacity building, based on WHO\u2019s data collection tools and methodology.\n\nThe Programme Manager of the Medicines Regulatory Support Programme briefed the Expert Committee members on the current activities of this programme. To date 51 assessments have been made of 47 regulatory systems, with the involvement of regional offices, and in close collaboration with the capacity-building teams from the WHO Secretariat. Technical", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monograf\u00edas de plantas medicinales**: La OMS ha desarrollado monograf\u00edas sobre plantas medicinales utilizadas en los Estados Independientes Nuevos, incluyendo 14 nuevas monograf\u00edas, con el objetivo de proporcionar modelos para que los pa\u00edses desarrollen sus propios formularios y monograf\u00edas.\n\n2. **Evidencia sobre medicamentos herbales**: Se est\u00e1 trabajando para expandir la base de evidencia sobre la calidad, seguridad y eficacia de los medicamentos herbales, lo que incluye la revisi\u00f3n de estudios cl\u00ednicos y documentos t\u00e9cnicos sobre la seguridad de estos medicamentos.\n\n3. **Encuesta global sobre medicina tradicional**: La OMS est\u00e1 llevando a cabo la 2\u00aa Encuesta Global sobre Pol\u00edtica y Regulaci\u00f3n de la Medicina Tradicional para evaluar el impacto de la Estrategia de Medicina Tradicional de la OMS y recopilar informaci\u00f3n actualizada sobre pr\u00e1cticas y necesidades en los Estados Miembros.\n\n4. **Apoyo regulatorio**: El Programa de Apoyo Regulatorio de Medicamentos de la OMS se centra en fortalecer la regulaci\u00f3n de medicamentos en los pa\u00edses, proporcionando apoyo t\u00e9cnico y herramientas para mejorar los sistemas regulatorios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los objetivos espec\u00edficos de la 2\u00aa Encuesta Global sobre Pol\u00edtica y Regulaci\u00f3n de la Medicina Tradicional de la OMS?**\n   - Esta pregunta busca detalles sobre los objetivos y el enfoque de la encuesta, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipos de terapias y medicinas se incluyen en las pautas de formaci\u00f3n b\u00e1sica desarrolladas por la OMS en 2010?**\n   - Esta pregunta se centra en las terapias espec\u00edficas mencionadas en el contexto, proporcionando informaci\u00f3n que podr\u00eda no estar ampliamente disponible.\n\n3. **\u00bfCu\u00e1ntas evaluaciones de sistemas regulatorios se han realizado hasta la fecha y qu\u00e9 implicaciones tienen para el fortalecimiento de la regulaci\u00f3n de medicamentos en los pa\u00edses?**\n   - Esta pregunta busca informaci\u00f3n cuantitativa y cualitativa sobre el impacto de las evaluaciones realizadas por la OMS en la regulaci\u00f3n de medicamentos, que puede no estar documentada en otros lugares.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Equipo de Medicina Tradicional de la OMS**:\n   - Ahora forma parte del Departamento de Pol\u00edticas de Salud, Desarrollo y Servicios.\n   - Basado en la resoluci\u00f3n adoptada en la 62\u00aa Asamblea Mundial de la Salud en 2010.\n\n2. **Resoluci\u00f3n de 2010**:\n   - Busca fortalecer la cooperaci\u00f3n con centros colaboradores, instituciones de investigaci\u00f3n y organizaciones no gubernamentales.\n   - Enfocada en compartir informaci\u00f3n basada en evidencia y apoyar programas de capacitaci\u00f3n para el desarrollo de capacidades nacionales en medicina tradicional.\n   - Proporcionar orientaci\u00f3n t\u00e9cnica para asegurar la seguridad, eficacia y calidad de la medicina tradicional.\n   - Integrar la medicina tradicional en los sistemas de salud y actualizar la estrategia de medicina tradicional de la OMS.\n\n3. **Objetivos estrat\u00e9gicos del Programa**:\n   - Contribuci\u00f3n de las medicinas tradicionales al autocuidado y atenci\u00f3n primaria centrada en las personas.\n   - Modalidades de integraci\u00f3n de las medicinas tradicionales en los sistemas de salud.\n   - Promoci\u00f3n de criterios para la evaluaci\u00f3n y la integraci\u00f3n de la medicina tradicional en los sistemas de salud nacionales.\n   - Fortalecimiento de la investigaci\u00f3n sobre la calidad, seguridad y eficacia de las medicinas y productos tradicionales.\n\n4. **Actividades de 2010**:\n   - Actualizaci\u00f3n de m\u00e9todos de control de calidad para materiales de plantas medicinales.\n   - Publicaci\u00f3n de cuestiones t\u00e9cnicas clave sobre la calidad y seguridad de los medicamentos homeop\u00e1ticos.\n   - Desarrollo de directrices para la selecci\u00f3n de sustancias para el control de calidad de las medicinas herbales.\n   - Buenas pr\u00e1cticas de procesamiento para materiales herbales.\n   - Directrices sobre la gesti\u00f3n de la seguridad de plantas medicinales t\u00f3xicas y monograf\u00edas sobre plantas t\u00f3xicas com\u00fanmente utilizadas.\n\n5. **Documentos importantes de la OMS**:\n   - Monograf\u00edas de la OMS sobre plantas medicinales seleccionadas (Vol\u00famenes 1, 2, 3 y 4), que proporcionan informaci\u00f3n cient\u00edfica sobre seguridad, eficacia y calidad.\n\n### Entidades clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica global.\n- **Medicinas tradicionales**: Incluye pr\u00e1cticas y productos que se basan en tradiciones culturales y conocimientos ancestrales.\n- **Centros colaboradores, instituciones de investigaci\u00f3n y ONG**: Entidades con las que la OMS busca colaborar para fortalecer la medicina tradicional.", "excerpt_keywords": "Keywords: medicinal plants, herbal medicines, WHO Traditional Medicine Strategy, regulatory support, quality control"}}, "890d8145-8a8c-441e-b648-5c670348eedd": {"node_ids": ["f535be60-caa2-4dce-9c8e-357625b5ace9"], "metadata": {"page_label": "25", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Joint Session with the Expert Committee on Biological Standardization\n\nAssistance has also been given to regional harmonization initiatives and for supporting the participation of bodies such as the Southern African Development Community, the East African Community and the Caribbean Community.\n\nIn response to the need for continuous learning by the staff of NMRAs, WHO has delivered training courses on the assessment of quality, safety and efficacy in the marketing authorization process in all WHO regions, involving participants from more than 50 Member States. To support the work and decision-making processes of NMRAs, a model for medicines regulation \u2014 the WHO Medicines Regulatory Package \u2014 has been developed, field-tested and implemented in seven African countries as a tool for exchange of regulatory information and for building regulatory capacity.\n\nThe African Medicines Registration Harmonization Initiative has been established in response to the increased responsibilities placed on national regulatory systems. WHO is working with the Department for International Development of the United Kingdom of Great Britain and Northern Ireland, the World Bank, the Bill & Melinda Gates Foundation, the William J. Clinton Foundation and the New Partnership for Africa Development (NEPAD) to improve health in Africa by increasing the availability of medical products that meet standards for safety, efficacy and quality through regional regulatory harmonization. The issue was discussed at the Second African Medicines Regulatory Authorities Conference (held in Maputo, 16\u201318 November 2009) which brought together 54 heads and staff of NMRAs from 40 countries. A World Bank Trust Fund has been established to pool donors\u2019 contributions to the initiative.\n\nWHO has continued to work closely with the NMRAs of Member States from all WHO regions in facilitating information exchange and knowledge transfer. Cooperation with regional networks \u2014 such as DRUGNET, which concerns the Newly Independent States \u2014 has enabled regulatory support to be provided to a large number of countries. Training has been offered to inspectors in conducting inspections of GMP, while quality control laboratories have received training in good practices for managing pharmaceutical laboratories in order to achieve a good level of quality assurance. Numerous capacity-building workshops have been organized with regulators, including workshops on new pharmaceutical legislation and on regulating medicines promotion.\n\n## 3. Joint Session with the Expert Committee on Biological Standardization\n\nThe joint session raised the following three topics that were of common interest:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento aborda las iniciativas de la Organizaci\u00f3n Mundial de la Salud (OMS) para mejorar la regulaci\u00f3n de medicamentos en \u00c1frica y otras regiones. Se menciona la capacitaci\u00f3n de personal de Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) en la evaluaci\u00f3n de calidad, seguridad y eficacia de productos m\u00e9dicos. Adem\u00e1s, se destaca la creaci\u00f3n de la Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos Africanos y la colaboraci\u00f3n con diversas organizaciones para aumentar la disponibilidad de productos m\u00e9dicos que cumplan con est\u00e1ndares de calidad. Tambi\u00e9n se discuten esfuerzos de intercambio de informaci\u00f3n y capacitaci\u00f3n en buenas pr\u00e1cticas de manufactura y gesti\u00f3n de laboratorios farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 modelo ha desarrollado la OMS para apoyar la regulaci\u00f3n de medicamentos y en cu\u00e1ntos pa\u00edses africanos se ha implementado?**\n   - Respuesta: La OMS ha desarrollado el \"WHO Medicines Regulatory Package\", que ha sido implementado en siete pa\u00edses africanos como herramienta para el intercambio de informaci\u00f3n regulatoria y para construir capacidad regulatoria.\n\n2. **\u00bfCu\u00e1les son las organizaciones con las que la OMS colabora para mejorar la salud en \u00c1frica a trav\u00e9s de la armonizaci\u00f3n regulatoria?**\n   - Respuesta: La OMS colabora con el Departamento para el Desarrollo Internacional del Reino Unido, el Banco Mundial, la Fundaci\u00f3n Bill y Melinda Gates, la Fundaci\u00f3n William J. Clinton y la Nueva Alianza para el Desarrollo de \u00c1frica (NEPAD).\n\n3. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se ha ofrecido a los inspectores y laboratorios de control de calidad en el contexto de la regulaci\u00f3n de medicamentos?**\n   - Respuesta: Se ha ofrecido capacitaci\u00f3n a inspectores en la realizaci\u00f3n de inspecciones de Buenas Pr\u00e1cticas de Manufactura (GMP) y a laboratorios de control de calidad en buenas pr\u00e1cticas para la gesti\u00f3n de laboratorios farmac\u00e9uticos, con el fin de lograr un buen nivel de aseguramiento de la calidad.\n\n### Resumen de Nivel Superior\n\nEl documento destaca los esfuerzos de la OMS para fortalecer la regulaci\u00f3n de medicamentos a trav\u00e9s de la capacitaci\u00f3n de personal, el desarrollo de modelos regulatorios y la colaboraci\u00f3n con diversas organizaciones. Se enfatiza la importancia de la armonizaci\u00f3n regional y el intercambio de informaci\u00f3n para mejorar la calidad y disponibilidad de productos m\u00e9dicos en \u00c1frica y otras regiones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00edas de Plantas Medicinales**:\n   - La OMS ha desarrollado monograf\u00edas sobre plantas medicinales utilizadas en los Estados Independientes Nuevos, incluyendo 14 nuevas monograf\u00edas. Estas monograf\u00edas sirven como modelos para que los pa\u00edses creen sus propios formularios y monograf\u00edas.\n\n2. **Evidencia sobre Medicamentos Herbales**:\n   - Se est\u00e1 trabajando en expandir la base de evidencia sobre la calidad, seguridad y eficacia de los medicamentos herbales. Esto incluye la revisi\u00f3n de estudios cl\u00ednicos y la elaboraci\u00f3n de documentos t\u00e9cnicos sobre la seguridad de estos medicamentos, as\u00ed como su interacci\u00f3n con otros f\u00e1rmacos.\n\n3. **2\u00aa Encuesta Global sobre Medicina Tradicional**:\n   - La OMS est\u00e1 llevando a cabo esta encuesta para evaluar el impacto de la Estrategia de Medicina Tradicional de la OMS y recopilar informaci\u00f3n actualizada sobre pr\u00e1cticas y necesidades en los Estados Miembros. La encuesta busca identificar nuevas necesidades y actualizar la estrategia.\n\n4. **Apoyo Regulatorio**:\n   - El Programa de Apoyo Regulatorio de Medicamentos de la OMS se centra en fortalecer la regulaci\u00f3n de medicamentos en los pa\u00edses. Esto incluye la provisi\u00f3n de apoyo t\u00e9cnico, herramientas para mejorar los sistemas regulatorios y la promoci\u00f3n de la armonizaci\u00f3n entre las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs).\n\n5. **Pautas de Formaci\u00f3n B\u00e1sica**:\n   - En 2010, se desarrollaron pautas de formaci\u00f3n que abarcan diversas terapias, incluyendo osteopat\u00eda, Tuina, Nua Thai, medicinas tradicionales chinas, medicina ayurv\u00e9dica, medicina Unani, medicina naturop\u00e1tica y naturopat\u00eda.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Principal entidad responsable de la regulaci\u00f3n y apoyo en el \u00e1mbito de la medicina tradicional y los medicamentos herbales.\n- **NMRAs (Autoridades Nacionales de Regulaci\u00f3n de Medicamentos)**: Entidades que se benefician del apoyo regulatorio y de las evaluaciones realizadas por la OMS.\n- **Estados Independientes Nuevos**: Regiones espec\u00edficas donde se han desarrollado las monograf\u00edas de plantas medicinales. \n\nEste resumen destaca los esfuerzos de la OMS en la regulaci\u00f3n y promoci\u00f3n de la medicina tradicional y los medicamentos herbales, as\u00ed como su compromiso con la capacitaci\u00f3n y el fortalecimiento de los sistemas regulatorios en los pa\u00edses miembros.", "excerpt_keywords": "Keywords: WHO, medicines regulation, training, Africa, harmonization"}}, "ca2b0f9f-d597-4167-a55d-194ff807b120": {"node_ids": ["46bcff2e-e72f-4633-8c60-988b689058a0"], "metadata": {"page_label": "26", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products;\n\u2014 Proposal to initiate a project to evaluate a candidate International Standard for Human Recombinant Insulin; and\n\u2014 WHO GMP for blood establishments.\n\nEach of these topics was discussed jointly and again in each Committee's sessions; each Committee has taken appropriate action in a coordinated manner. Further details and recommendations are included under the specific sections of this report.\n\nThe Expert Committee appreciated the opportunity for joint discussion between the two Expert Committees of issues of mutual interest.\n\nThe conclusion and recommendation was that work should progress and the Expert Committees on Specifications for Pharmaceutical Preparations and on Biological Standardization should continue to collaborate on topics of common interest.\n\n## 4. Quality control \u2014 specifications and tests\n\n### 4.1 The International Pharmacopoeia\n\n**Second supplement**\n\nAn update was presented on *The International Pharmacopoeia* (Ph.Int.) activities and work plan. The Expert Committee noted that the work on the compilation of the Second supplement to the fourth edition was progressing and that it would be published as a replacement CD-ROM and an online version.\n\nThis publication would comprise new and revised texts adopted by the Expert Committee since 2007.\n\nAs per the work process, the final version of the monographs adopted during the present meeting would be made available on the WHO Medicines web site once completed and would subsequently be compiled into a publication.\n\n**Collaboration with other pharmacopoeias**\n\nThe Secretariat reported to the Expert Committee that an enhanced collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia* had commenced.\n\nThis collaboration between The Medicines and Healthcare products Regulatory Agency of the United Kingdom of Great Britain and Northern Ireland (MHRA), which hosts *The British Pharmacopoeia* and WHO, which hosts *The International Pharmacopoeia*, was aimed at developing.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Colaboraci\u00f3n entre Comit\u00e9s de Expertos**: Se llev\u00f3 a cabo una discusi\u00f3n conjunta entre dos Comit\u00e9s de Expertos de la OMS sobre temas de inter\u00e9s mutuo, incluyendo la gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura, la evaluaci\u00f3n de un est\u00e1ndar internacional para la insulina humana recombinante y las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre. Se recomend\u00f3 que ambos Comit\u00e9s contin\u00faen colaborando en estos temas.\n\n2. **Actualizaci\u00f3n sobre la Farmacopea Internacional**: Se present\u00f3 un informe sobre el progreso de la compilaci\u00f3n del Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional*. Este suplemento incluir\u00e1 textos nuevos y revisados adoptados desde 2007 y se publicar\u00e1 en formato CD-ROM y en l\u00ednea. Adem\u00e1s, se destac\u00f3 la colaboraci\u00f3n mejorada entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los temas espec\u00edficos discutidos en la reuni\u00f3n conjunta de los Comit\u00e9s de Expertos de la OMS?**\n   - Los temas discutidos incluyen la gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura, la propuesta para evaluar un est\u00e1ndar internacional para la insulina humana recombinante y las Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n\n2. **\u00bfQu\u00e9 novedades se esperan en la publicaci\u00f3n del Segundo suplemento de *La Farmacopea Internacional*?**\n   - Se espera que el Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional* incluya nuevos y revisados textos adoptados desde 2007, y se publicar\u00e1 tanto en formato CD-ROM como en l\u00ednea.\n\n3. **\u00bfQu\u00e9 objetivos tiene la colaboraci\u00f3n entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*?**\n   - La colaboraci\u00f3n tiene como objetivo desarrollar y mejorar la armonizaci\u00f3n de los est\u00e1ndares farmac\u00e9uticos entre ambas farmacopeas, facilitando as\u00ed un mejor control de calidad y especificaciones en la producci\u00f3n de productos farmac\u00e9uticos.", "prev_section_summary": "La secci\u00f3n aborda los esfuerzos de la Organizaci\u00f3n Mundial de la Salud (OMS) para mejorar la regulaci\u00f3n de medicamentos, especialmente en \u00c1frica, a trav\u00e9s de diversas iniciativas y colaboraciones. Los temas clave incluyen:\n\n1. **Capacitaci\u00f3n de Personal**: La OMS ha proporcionado cursos de formaci\u00f3n a los empleados de las Autoridades Nacionales de Regulaci\u00f3n de Medicamentos (NMRAs) sobre la evaluaci\u00f3n de calidad, seguridad y eficacia en el proceso de autorizaci\u00f3n de comercializaci\u00f3n, involucrando a m\u00e1s de 50 Estados Miembros.\n\n2. **Modelo Regulatorio**: Se ha desarrollado y implementado el \"WHO Medicines Regulatory Package\" en siete pa\u00edses africanos, como herramienta para el intercambio de informaci\u00f3n regulatoria y para fortalecer la capacidad regulatoria.\n\n3. **Iniciativa de Armonizaci\u00f3n de Registro de Medicamentos Africanos**: Esta iniciativa se ha establecido para abordar las crecientes responsabilidades de los sistemas regulatorios nacionales, con el objetivo de aumentar la disponibilidad de productos m\u00e9dicos que cumplan con est\u00e1ndares de calidad.\n\n4. **Colaboraciones**: La OMS trabaja con varias organizaciones, incluyendo el Departamento para el Desarrollo Internacional del Reino Unido, el Banco Mundial, la Fundaci\u00f3n Bill y Melinda Gates, la Fundaci\u00f3n William J. Clinton y la Nueva Alianza para el Desarrollo de \u00c1frica (NEPAD), para mejorar la salud en \u00c1frica mediante la armonizaci\u00f3n regulatoria.\n\n5. **Intercambio de Informaci\u00f3n y Capacitaci\u00f3n**: Se han facilitado intercambios de informaci\u00f3n y transferencia de conocimientos entre NMRAs de diferentes regiones, as\u00ed como capacitaci\u00f3n a inspectores en Buenas Pr\u00e1cticas de Manufactura (GMP) y a laboratorios de control de calidad en buenas pr\u00e1cticas de gesti\u00f3n.\n\nEn resumen, la OMS est\u00e1 trabajando activamente para fortalecer la regulaci\u00f3n de medicamentos a trav\u00e9s de la capacitaci\u00f3n, el desarrollo de modelos regulatorios y la colaboraci\u00f3n con diversas entidades, enfatizando la importancia de la armonizaci\u00f3n regional y el intercambio de informaci\u00f3n.", "excerpt_keywords": "Keywords: pharmaceutical products, International Pharmacopoeia, quality control, collaboration, WHO GMP"}}, "858e9273-6024-4417-abc7-428e6d7556ca": {"node_ids": ["f30e4055-334a-429f-a3ec-019f8c0827d3"], "metadata": {"page_label": "27", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "a closer cooperation and exchange in the field of quality specifications for medicines, which would be based on common priorities as identified by both pharmacopoeias in their respective work plans.\n\nIt was foreseen that by sharing their experience in the development of specifications for formulated products, this collaboration would be of mutual benefit for these pharmacopoeias, notably in making more specifications available to users.\n\nThe Secretariat informed the Expert Committee that, in the context of this cooperation, work had been rapidly initiated with a pilot phase comprising three monographs for anti-infectives (amoxicillin oral suspension, metronidazole oral suspension, sulfamethoxazole and trimethoprim tablets) that could be developed and discussed at the meeting of the Expert Committee.\n\nNoting that this collaboration was to be formalized by an agreement between the two organizations hosting the pharmacopoeias, the Expert Committee welcomed this initiative and the outcome of this pilot phase in adopting the presented texts (see section 4.3.4 of this report on specifications for anti-infectives).\n\n### 4.2 Current work plan and future work programme\n\nBased on the 2010 work plan, the Expert Committee discussed and reviewed:\n\n\u2014 the current development status of the monographs; and  \n\u2014 new proposals for developing specifications for active substances and dosage forms, including those for paediatric use.\n\nNew proposals were made, taking into account:\n\n- substances remaining in the current work plan;\n- substances initially listed in the previously adopted work programmes that were then prioritized, based on the importance of the products for the treatment of WHO priority diseases (including HIV/AIDS, tuberculosis, malaria, programmes and diseases with high prevalence in developing countries);\n- new additions from the updated sixteenth WHO Model List of Essential Medicines (March 2010) and the updated second WHO Model List of Essential Medicines for Children (March 2010);\n- new additions from the expressions of interest within the WHO Prequalification of Medicines Programme; and\n- requests for medicines recommended in WHO\u2019s specific disease programmes.\n\nCategories covered in the work programme included medicines used in the treatment of HIV/AIDS, malaria, tuberculosis, as well as anti-infectives (anthelmintics, antibacterial, antiprotozoal, antifungal, antiviral).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla la cooperaci\u00f3n entre dos organizaciones que albergan farmacopoeias, enfoc\u00e1ndose en el desarrollo de especificaciones de calidad para medicamentos. Se menciona una fase piloto que incluye tres monograf\u00edas para anti-infectivos, y se discuten propuestas para el desarrollo de especificaciones de sustancias activas y formas de dosificaci\u00f3n, con un \u00e9nfasis particular en medicamentos para el tratamiento de enfermedades prioritarias de la OMS, como el VIH/SIDA, la tuberculosis y la malaria. Adem\u00e1s, se abordan las prioridades basadas en la lista de medicamentos esenciales de la OMS y las solicitudes de medicamentos recomendados en programas espec\u00edficos de enfermedades.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres anti-infectivos que se incluyeron en la fase piloto de colaboraci\u00f3n entre las farmacopoeias?**\n   - Respuesta: Los tres anti-infectivos son amoxicilina en suspensi\u00f3n oral, metronidazol en suspensi\u00f3n oral y tabletas de sulfametoxazol y trimetoprima.\n\n2. **\u00bfQu\u00e9 criterios se utilizaron para priorizar las sustancias en el plan de trabajo actual de la OMS?**\n   - Respuesta: Las sustancias se priorizaron en funci\u00f3n de su importancia para el tratamiento de enfermedades prioritarias de la OMS, as\u00ed como de su inclusi\u00f3n en la lista actualizada de medicamentos esenciales y las expresiones de inter\u00e9s dentro del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n\n3. **\u00bfQu\u00e9 categor\u00edas de medicamentos se abordan en el programa de trabajo mencionado en el documento?**\n   - Respuesta: Las categor\u00edas de medicamentos incluyen aquellos utilizados en el tratamiento del VIH/SIDA, malaria, tuberculosis, as\u00ed como anti-infectivos (anthelminticos, antibacterianos, antiprotozoarios, antif\u00fangicos y antivirales).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Colaboraci\u00f3n entre Comit\u00e9s de Expertos de la OMS**:\n   - Se discutieron temas de inter\u00e9s mutuo, incluyendo:\n     - Gu\u00eda para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n     - Evaluaci\u00f3n de un est\u00e1ndar internacional para la insulina humana recombinante.\n     - Buenas Pr\u00e1cticas de Manufactura (GMP) para establecimientos de sangre.\n   - Se recomend\u00f3 que los Comit\u00e9s contin\u00faen colaborando en estos temas.\n\n2. **Actualizaci\u00f3n sobre *La Farmacopea Internacional***:\n   - Se present\u00f3 un informe sobre el progreso del Segundo suplemento de la cuarta edici\u00f3n de *La Farmacopea Internacional* (Ph.Int.).\n   - Este suplemento incluir\u00e1 nuevos y revisados textos adoptados desde 2007 y se publicar\u00e1 en formato CD-ROM y en l\u00ednea.\n   - La versi\u00f3n final de los monograf\u00edas adoptadas se publicar\u00e1 en el sitio web de Medicamentos de la OMS.\n\n3. **Colaboraci\u00f3n con otras farmacopeas**:\n   - Se inici\u00f3 una colaboraci\u00f3n mejorada entre *La Farmacopea Internacional* y *La Farmacopea Brit\u00e1nica*.\n   - Esta colaboraci\u00f3n involucra a la Agencia de Medicamentos y Productos de Salud del Reino Unido (MHRA) y la OMS, con el objetivo de desarrollar y armonizar est\u00e1ndares farmac\u00e9uticos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Coordinadora de las discusiones y publicaciones.\n- **Comit\u00e9s de Expertos**: Dos comit\u00e9s involucrados en la discusi\u00f3n de temas farmac\u00e9uticos y biol\u00f3gicos.\n- **La Farmacopea Internacional**: Publicaci\u00f3n que est\u00e1 en proceso de actualizaci\u00f3n.\n- **La Farmacopea Brit\u00e1nica**: Colaboradora en el desarrollo de est\u00e1ndares farmac\u00e9uticos.\n- **MHRA**: Agencia reguladora del Reino Unido que participa en la colaboraci\u00f3n con la OMS.", "excerpt_keywords": "Keywords: pharmacopoeias, quality specifications, anti-infectives, WHO Model List, collaboration"}}, "83944ce6-be92-4986-826b-98a11f37d929": {"node_ids": ["1e656917-84f3-4359-898a-18076fe0501c"], "metadata": {"page_label": "28", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Medicines, Including Children's Medicines\n\n## 4.3.1 Medicines for HIV and Related Conditions\n\nNew monographs for the following ARVs were presented to the Expert Committee for discussion:\n\n**Dosage Forms:**\n\n- didanosine capsules\n- efavirenz tablets\n- emtricitabine capsules\n- emtricitabine and tenofovir tablets\n- emtricitabine, tenofovir and efavirenz tablets.\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.2 Antimalarial Medicines\n\nNew monographs for the following antimalarials were presented to the Expert Committee for discussion:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las especificaciones de medicamentos, incluyendo aquellos para ni\u00f1os. En la secci\u00f3n 4.3.1, se discuten nuevos monogr\u00e1ficos para medicamentos antirretrovirales (ARVs) utilizados en el tratamiento del VIH y condiciones relacionadas. Se presentan varias formas de dosificaci\u00f3n, como c\u00e1psulas de didanosina y tabletas de efavirenz, que fueron adoptadas con cambios acordados tras un proceso consultivo. La secci\u00f3n 4.3.2 menciona que tambi\u00e9n se presentaron nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las formas de dosificaci\u00f3n espec\u00edficas de los medicamentos antirretrovirales (ARVs) que fueron discutidas y adoptadas por el Comit\u00e9 de Expertos?**\n   - Respuesta: Las formas de dosificaci\u00f3n discutidas y adoptadas incluyen c\u00e1psulas de didanosina, tabletas de efavirenz, c\u00e1psulas de emtricitabina, tabletas de emtricitabina y tenofovir, y tabletas de emtricitabina, tenofovir y efavirenz.\n\n2. **\u00bfQu\u00e9 proceso se sigui\u00f3 para la adopci\u00f3n de los monogr\u00e1ficos de los medicamentos antirretrovirales?**\n   - Respuesta: Los monogr\u00e1ficos fueron adoptados tras la inclusi\u00f3n de cambios acordados, basados en comentarios recibidos durante el proceso consultivo normal y en las discusiones mantenidas.\n\n3. **\u00bfQu\u00e9 se menciona sobre los nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos en el documento?**\n   - Respuesta: Se indica que nuevos monogr\u00e1ficos para antimalariales fueron presentados al Comit\u00e9 de Expertos para discusi\u00f3n, aunque no se detallan los medicamentos espec\u00edficos en el texto proporcionado.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otros documentos o contextos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Cooperaci\u00f3n entre Organizaciones**: Se establece una colaboraci\u00f3n entre dos organizaciones que albergan farmacopoeias, enfoc\u00e1ndose en el desarrollo de especificaciones de calidad para medicamentos.\n\n2. **Fase Piloto**: Se inici\u00f3 una fase piloto que incluye tres monograf\u00edas para anti-infectivos:\n   - Amoxicilina en suspensi\u00f3n oral\n   - Metronidazol en suspensi\u00f3n oral\n   - Tabletas de sulfametoxazol y trimetoprima\n\n3. **Beneficios de la Colaboraci\u00f3n**: La cooperaci\u00f3n busca compartir experiencias en el desarrollo de especificaciones, lo que beneficiar\u00e1 a ambas farmacopoeias al aumentar la disponibilidad de especificaciones para los usuarios.\n\n4. **Plan de Trabajo Actual y Futuro**: Se revisaron el estado de desarrollo de las monograf\u00edas y se discutieron nuevas propuestas para especificaciones de sustancias activas y formas de dosificaci\u00f3n, con un enfoque en el uso pedi\u00e1trico.\n\n5. **Criterios de Priorizaci\u00f3n**: Las sustancias se priorizan seg\u00fan su importancia para el tratamiento de enfermedades prioritarias de la OMS, incluyendo VIH/SIDA, tuberculosis y malaria, as\u00ed como su inclusi\u00f3n en la lista de medicamentos esenciales de la OMS.\n\n6. **Categor\u00edas de Medicamentos**: El programa de trabajo abarca medicamentos para:\n   - VIH/SIDA\n   - Malaria\n   - Tuberculosis\n   - Anti-infectivos (anthelminticos, antibacterianos, antiprotozoarios, antif\u00fangicos, antivirales)\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Expert Committee** (Comit\u00e9 de Expertos)\n- **Farmacopeas** (organizaciones que desarrollan especificaciones de calidad para medicamentos)\n- **Medicamentos Esenciales de la OMS** (listas de medicamentos priorizados para el tratamiento de enfermedades)", "excerpt_keywords": "Keywords: medicines, HIV, antimalarials, specifications, WHO"}}, "7d2eb902-2a57-4609-8a86-8a8874e0a8b2": {"node_ids": ["e5d4ef04-9a29-4c51-aee8-71564d5541ea"], "metadata": {"page_label": "29", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage forms\n- mefloquine tablets\n- sulfadoxine and pyrimethamine tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nWhile carrying out the work for the general revision on the artemisinin derivatives monographs (artemether, artemisinin, artemotil, artenimol, artesunate and their associated dosage forms), the opportunity was taken to develop in parallel a new specification for the parenteral preparation of artesunate, which is particularly recommended in the treatment of severe malaria.\n\nThe following monograph could, therefore, be presented to the Expert Committee for discussion:\n\n**dosage form**\n- artesunate for injection.\n\nThe monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.3.3 Antituberculosis medicines\n\nNew monographs for the following antituberculosis active substances and dosage forms were presented to the Expert Committee for discussion:\n\n**active pharmaceutical ingredients (APIs)**\n- capreomycin sulfate\n- ofloxacin\n- levofloxacin\n\n**dosage forms**\n- capreomycin injection\n- ofloxacin tablets\n- levofloxacin tablets\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\nThe following monograph was presented to the Expert Committee in October 2009 for addition to *The International Pharmacopoeia*:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla la adopci\u00f3n de nuevas monograf\u00edas para diversas formas de dosificaci\u00f3n de medicamentos, incluyendo antimal\u00e1ricos y antituberculosos. Se menciona la revisi\u00f3n de monograf\u00edas de derivados de artemisinina y la introducci\u00f3n de una nueva especificaci\u00f3n para la preparaci\u00f3n parenteral de artesunato, recomendada para el tratamiento de la malaria severa. Tambi\u00e9n se presentan nuevas monograf\u00edas para ingredientes farmac\u00e9uticos activos (APIs) y sus formas de dosificaci\u00f3n asociadas en el contexto de medicamentos antituberculosos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 cambios se acordaron para las monograf\u00edas de los medicamentos mencionados en el informe y c\u00f3mo se incorporaron en el proceso de revisi\u00f3n?**\n   - Esta pregunta busca detalles sobre los cambios espec\u00edficos que se discutieron y acordaron durante el proceso consultivo, que no se detallan expl\u00edcitamente en el texto.\n\n2. **\u00bfCu\u00e1l es la importancia del artesunato para inyecci\u00f3n en el tratamiento de la malaria severa y c\u00f3mo se compara con otras formas de dosificaci\u00f3n de artemisinina?**\n   - Esta pregunta se centra en la relevancia cl\u00ednica del artesunato para inyecci\u00f3n y su papel en comparaci\u00f3n con otros tratamientos, lo que podr\u00eda no estar claramente indicado en el documento.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para la adopci\u00f3n de nuevas monograf\u00edas en la OMS y c\u00f3mo se asegura la calidad de los medicamentos a trav\u00e9s de este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre los criterios y procedimientos espec\u00edficos que la OMS sigue para garantizar que las nuevas monograf\u00edas cumplan con los est\u00e1ndares de calidad y eficacia, lo cual no se aborda directamente en el texto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Principal: Especificaciones de Medicamentos, Incluyendo Medicamentos para Ni\u00f1os**\n\n1. **Medicamentos Antirretrovirales (ARVs) para VIH y Condiciones Relacionadas:**\n   - Se presentaron nuevos monogr\u00e1ficos para discusi\u00f3n por parte del Comit\u00e9 de Expertos.\n   - **Formas de Dosificaci\u00f3n Presentadas:**\n     - C\u00e1psulas de didanosina\n     - Tabletas de efavirenz\n     - C\u00e1psulas de emtricitabina\n     - Tabletas de emtricitabina y tenofovir\n     - Tabletas de emtricitabina, tenofovir y efavirenz\n   - Los monogr\u00e1ficos fueron adoptados con cambios acordados, tras un proceso consultivo normal.\n\n2. **Medicamentos Antimal\u00e1ricos:**\n   - Nuevos monogr\u00e1ficos para medicamentos antimal\u00e1ricos tambi\u00e9n fueron presentados al Comit\u00e9 de Expertos para discusi\u00f3n, aunque no se especifican los medicamentos en el texto proporcionado.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Comit\u00e9 de Expertos**\n- **Medicamentos Antirretrovirales (ARVs)**\n- **Medicamentos Antimal\u00e1ricos**\n- **Formas de Dosificaci\u00f3n:**\n  - Didanosina\n  - Efavirenz\n  - Emtricitabina\n  - Tenofovir\n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo los tipos de medicamentos discutidos y el proceso de adopci\u00f3n de los monogr\u00e1ficos.", "excerpt_keywords": "dosage forms, artesunate, antituberculosis, monographs, WHO"}}, "a0931613-4d59-4955-9199-fcb35bd775bc": {"node_ids": ["244bacfa-f2ef-491c-a309-9bfccff41560"], "metadata": {"page_label": "30", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dosage form\n\n- kanamycin injection\n\nAlthough the monograph was adopted, recirculation was recommended by the Expert Committee requesting comments on the shifting of the determination of the conversion factor from international units (IU) to micrograms.\n\nTo avoid the use of an arbitrary conversion factor, a revised version of the text was proposed for discussion during the consultation on specifications for medicines and quality control issues held in May 2010, where it was agreed that the replacement of the current microbiological assay by a high-performance liquid chromatography (HPLC) method would be preferable as this would allow direct expression of the quantities of kanamycin in terms of mass.\n\nIt was recognized, however, that the application of HPLC to this substance would be subject to detection difficulties owing to the poor absorbance properties of kanamycin in ultraviolet (UV). Possible HPLC methods and their suitability for inclusion in Ph.Int. were thus discussed and it was finally recommended that a UV detection method using derivatization be developed, rather than a method using more sophisticated detectors such as electrochemical ones that may not be widely available. While this HPLC method was still under investigation, it was agreed that, once ready, the revised monograph would be circulated for comment.\n\nMeanwhile, and in order to make the monograph available to users, it was agreed that the text adopted in October 2009 be posted on the WHO Medicines web site with an appropriate *Note from the Secretariat* indicating that a forthcoming revision was envisaged for the assay.\n\nThe Expert Committee endorsed the recommendations made by the participants at the consultation.\n\n## 4.3.4 Anti-infectives\n\nNew monographs for the active dosage forms of the following anti-infectives were presented to the Expert Committee for discussion:\n\n- amoxicillin oral suspension<sup>10</sup>\n- levamisole tablets\n- metronidazole oral suspension<sup>10</sup>\n- sulfamethoxazole and trimethoprim tablets<sup>10</sup>\n\n----\n\n<sup>10</sup> These monographs were developed in the context of collaboration between *The International Pharmacopoeia* and *The British Pharmacopoeia*, on which these texts are based.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monograf\u00eda de Kanamicina**: La monograf\u00eda de kanamicina fue adoptada, pero se recomend\u00f3 su recirculaci\u00f3n para discutir el cambio en el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos. Se propuso reemplazar el ensayo microbiol\u00f3gico actual por un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para expresar las cantidades de kanamicina en t\u00e9rminos de masa, aunque se reconocieron dificultades en la detecci\u00f3n debido a las propiedades de absorbancia del compuesto.\n\n2. **Desarrollo de Nuevas Monograf\u00edas**: Se presentaron nuevas monograf\u00edas para varios anti-infectivos, incluyendo amoxicilina, levamisol, metronidazol y sulfametoxazol con trimetoprima, en el contexto de una colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos respald\u00f3 las recomendaciones de los participantes en la consulta sobre especificaciones para medicamentos y cuestiones de control de calidad, y se acord\u00f3 que la versi\u00f3n adoptada en octubre de 2009 se publicara en el sitio web de la OMS con una nota indicando que se prev\u00e9 una revisi\u00f3n futura.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las dificultades espec\u00edficas que se anticipan al aplicar el m\u00e9todo HPLC para la kanamicina, y qu\u00e9 soluciones se proponen para superarlas?**\n   - La aplicaci\u00f3n de HPLC a la kanamicina enfrenta dificultades de detecci\u00f3n debido a sus pobres propiedades de absorbancia en UV. Se propone desarrollar un m\u00e9todo de detecci\u00f3n UV utilizando derivatizaci\u00f3n como soluci\u00f3n.\n\n2. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en la conversi\u00f3n de unidades para la kanamicina y por qu\u00e9 se considera necesario evitar un factor de conversi\u00f3n arbitrario?**\n   - Se est\u00e1 considerando cambiar la determinaci\u00f3n del factor de conversi\u00f3n de IU a microgramos para evitar el uso de un factor de conversi\u00f3n arbitrario, lo que podr\u00eda llevar a inconsistencias en la dosificaci\u00f3n y efectividad del medicamento.\n\n3. **\u00bfQu\u00e9 colaboraci\u00f3n se menciona en el desarrollo de las nuevas monograf\u00edas de anti-infectivos y cu\u00e1l es su relevancia?**\n   - Las nuevas monograf\u00edas para anti-infectivos fueron desarrolladas en colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*, lo que es relevante porque asegura que las monograf\u00edas est\u00e9n basadas en est\u00e1ndares internacionales y mejores pr\u00e1cticas en farmacolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00edas de Medicamentos**:\n   - Se adoptaron nuevas monograf\u00edas para diversas formas de dosificaci\u00f3n de medicamentos, incluyendo:\n     - **Antimal\u00e1ricos**:\n       - Tabletas de mefloquina.\n       - Tabletas de sulfadoxina y pirimetamina.\n       - Artesunato para inyecci\u00f3n (nueva especificaci\u00f3n para la preparaci\u00f3n parenteral, recomendada para el tratamiento de malaria severa).\n     - **Antituberculosos**:\n       - Ingredientes farmac\u00e9uticos activos (APIs):\n         - Sulfato de capreomicina.\n         - Ofloxacino.\n         - Levofloxacino.\n       - Formas de dosificaci\u00f3n:\n         - Inyecci\u00f3n de capreomicina.\n         - Tabletas de ofloxacino.\n         - Tabletas de levofloxacino.\n\n2. **Proceso de Adopci\u00f3n**:\n   - Las monograf\u00edas fueron adoptadas con la inclusi\u00f3n de cambios acordados, basados en comentarios recibidos durante el proceso consultivo normal, siguiendo los pasos establecidos para el desarrollo de nuevas monograf\u00edas.\n\n3. **Importancia del Artesunato**:\n   - Se destaca la relevancia del artesunato para inyecci\u00f3n en el tratamiento de la malaria severa, en comparaci\u00f3n con otras formas de dosificaci\u00f3n de artemisinina.\n\n4. **Criterios de Calidad**:\n   - Se menciona que la adopci\u00f3n de nuevas monograf\u00edas se basa en un proceso consultivo que asegura la calidad y eficacia de los medicamentos, aunque no se detallan los criterios espec\u00edficos en el texto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medicamentos**:\n  - Mefloquina\n  - Sulfadoxina\n  - Pirimetamina\n  - Artesunato\n  - Capreomicina\n  - Ofloxacino\n  - Levofloxacino\n- **Formas de Dosificaci\u00f3n**:\n  - Tabletas\n  - Inyecci\u00f3n\n\nEste resumen abarca los aspectos m\u00e1s relevantes del contenido, destacando las nuevas monograf\u00edas adoptadas y el proceso que las respalda.", "excerpt_keywords": "Keywords: kanamycin, HPLC, anti-infectives, monographs, WHO"}}, "7e892882-30bc-4641-8370-d2bc7584b710": {"node_ids": ["c353204a-4539-4877-8d2f-920d257a9348"], "metadata": {"page_label": "31", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n### 4.3.5 Other medicines\n\nNew monographs for the following dosage forms were presented to the Expert Committee for discussion:\n\n- levonorgestrel tablets\n- oseltamivir capsules\n- sodium bicarbonate intravenous injection\n\nThe monographs were adopted, subject to inclusion of the agreed changes, based on the comments received during the normal consultative process, i.e. in line with the steps followed in the development of new monographs, and based on comments made during discussion.\n\n## 4.4 Revision of texts of The International Pharmacopoeia\n\n### 4.4.1 Antimalarials: artemisinin derivatives\n\nSince 2008, extensive revision work had been initiated for the general revision of the artemisinin derivatives monographs of *The International Pharmacopoeia*.\n\nParticular aspects that required revision were the method used for the Related substances test and the Assay; and the addition of potential impurities shown to be controlled by the requirements of the monographs.\n\n**Artesunate**\n\nSubsequent to the development of a new monograph for artesunate for injection, the monograph for artesunate, revised in 2009, needed further modification to add specific requirements for the API intended to be used for parenteral preparations. A newly revised text was thus presented to the Expert Committee for discussion. The monograph was adopted, subject to inclusion of the agreed changes, based on the comments received during the public inquiry and those made during the discussion.\n\n**Other artemisinin derivatives**\n\nThis general revision of artemisinin derivatives involved about 15 texts. Monographs for artesunate and artesunate tablets had already been adopted in October 2009. Prioritization for revision had been proposed for the rest of this series in order to make the most useful monographs available to users in a timely manner.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas monograf\u00edas**: Se presentaron nuevas monograf\u00edas para varios medicamentos, incluyendo tabletas de levonorgestrel, c\u00e1psulas de oseltamivir e inyecci\u00f3n intravenosa de bicarbonato de sodio. Estas monograf\u00edas fueron adoptadas tras la inclusi\u00f3n de cambios acordados y comentarios recibidos durante el proceso consultivo.\n\n2. **Revisi\u00f3n de monograf\u00edas de derivados de artemisinina**: Desde 2008, se ha llevado a cabo una revisi\u00f3n extensa de las monograf\u00edas de los derivados de artemisinina en *The International Pharmacopoeia*. Se han realizado modificaciones espec\u00edficas en la monograf\u00eda de artesunato, especialmente para su uso en preparaciones parenterales, y se ha priorizado la revisi\u00f3n de otros derivados.\n\n3. **Proceso de consulta y modificaci\u00f3n**: Las monograf\u00edas adoptadas y revisadas se basan en un proceso de consulta p\u00fablica y discusi\u00f3n, asegurando que se incorporen los comentarios y se realicen las modificaciones necesarias para cumplir con los est\u00e1ndares requeridos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios espec\u00edficos se realizaron en la monograf\u00eda de artesunato para inyecci\u00f3n en comparaci\u00f3n con la versi\u00f3n revisada en 2009?**\n   - La monograf\u00eda de artesunato para inyecci\u00f3n fue modificada para incluir requisitos espec\u00edficos para el principio activo (API) destinado a preparaciones parenterales, lo que no estaba presente en la versi\u00f3n anterior.\n\n2. **\u00bfCu\u00e1ntos textos en total se est\u00e1n revisando en la serie de derivados de artemisinina y cu\u00e1les ya han sido adoptados?**\n   - Aproximadamente 15 textos est\u00e1n siendo revisados en la serie de derivados de artemisinina. Las monograf\u00edas para artesunato y tabletas de artesunato ya fueron adoptadas en octubre de 2009.\n\n3. **\u00bfCu\u00e1l es el proceso seguido para la adopci\u00f3n de nuevas monograf\u00edas seg\u00fan el contexto proporcionado?**\n   - El proceso para la adopci\u00f3n de nuevas monograf\u00edas incluye la presentaci\u00f3n de los textos a un Comit\u00e9 de Expertos, la discusi\u00f3n de los mismos, la inclusi\u00f3n de cambios acordados y la consideraci\u00f3n de comentarios recibidos durante el proceso consultivo normal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monograf\u00eda de Kanamicina**:\n   - **Forma de Dosificaci\u00f3n**: Inyecci\u00f3n de kanamicina.\n   - **Recomendaciones del Comit\u00e9 de Expertos**: Se adopt\u00f3 la monograf\u00eda, pero se recomend\u00f3 su recirculaci\u00f3n para discutir el cambio en el factor de conversi\u00f3n de unidades internacionales (IU) a microgramos.\n   - **M\u00e9todo Propuesto**: Se sugiere reemplazar el ensayo microbiol\u00f3gico actual por un m\u00e9todo de cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n (HPLC) para expresar las cantidades de kanamicina en t\u00e9rminos de masa.\n   - **Desaf\u00edos**: Dificultades de detecci\u00f3n debido a las pobres propiedades de absorbancia de kanamicina en UV.\n   - **Soluci\u00f3n Propuesta**: Desarrollo de un m\u00e9todo de detecci\u00f3n UV utilizando derivatizaci\u00f3n.\n\n2. **Desarrollo de Nuevas Monograf\u00edas de Anti-infectivos**:\n   - **Anti-infectivos Presentados**:\n     - Amoxicilina (suspensi\u00f3n oral)\n     - Levamisol (tabletas)\n     - Metronidazol (suspensi\u00f3n oral)\n     - Sulfametoxazol y trimetoprima (tabletas)\n   - **Colaboraci\u00f3n**: Estas monograf\u00edas fueron desarrolladas en colaboraci\u00f3n entre *The International Pharmacopoeia* y *The British Pharmacopoeia*.\n\n3. **Publicaci\u00f3n y Revisi\u00f3n**:\n   - Se acord\u00f3 que la versi\u00f3n adoptada en octubre de 2009 se publicara en el sitio web de la OMS con una nota indicando que se prev\u00e9 una revisi\u00f3n futura.\n\n4. **Endoso del Comit\u00e9 de Expertos**: El Comit\u00e9 respald\u00f3 las recomendaciones de los participantes en la consulta sobre especificaciones para medicamentos y control de calidad.\n\n### Entidades Clave\n- **Kanamicina**: Antibi\u00f3tico en forma de inyecci\u00f3n.\n- **HPLC**: Cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **The International Pharmacopoeia**: Referencia internacional para est\u00e1ndares de medicamentos.\n- **The British Pharmacopoeia**: Referencia nacional para est\u00e1ndares de medicamentos en el Reino Unido.", "excerpt_keywords": "Keywords: monographs, artemisinin, WHO, pharmacopoeia, levonorgestrel"}}, "b2115570-1b4e-4bd4-a479-f6eb1fbcb4a4": {"node_ids": ["b40c9031-0f19-4a9b-9733-dcfdc05b8b7a"], "metadata": {"page_label": "32", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "In line with the WHO treatment guidelines for malaria, where the use of these antimalarials as a monotherapy was no longer prescribed, the Expert Committee agreed that while revising the monographs for the corresponding monocomponent dosage forms, priority would be assigned to the products that could be co-packaged.\n\nThe Expert Committee was pleased to note that work had progressed, notably for the API monographs on artenimol (dihydroartemisinin) and artemether. Further, it was acknowledged that the development of other specifications had been initiated for fixed-dose combination medicines used in the combination therapy, such as that for artesunate and amodiaquine tablets or artenimol and piperaquine phosphate tablets.\n\n### 4.4.2 Other medicines\n\n**Oseltamivir phosphate**\n\nThe monograph for oseltamivir phosphate was initially adopted in October 2008. A revision of this text was presented in October 2009 after receipt of several comments on the tests for Sulfated ash and Related substances, leading to the adoption of a revised text where only the correction proposed for the Related substances test was retained. To respond to the continuing difficulties encountered by users when carrying out the test for sulfated ash, a revised version of this monograph was considered.\n\nThe Expert Committee adopted the newly revised text, which now harmonized the Ph.Int. text to the specifications for oseltamivir phosphate, also available in other pharmacopoeias (Ph.Eur and USP).\n\n**Heparins**\n\nA brief update was presented on the revision of the Heparins monographs decided upon in 2009, in order to include an electrophoresis method capable of detecting potential glycosaminoglycan impurities of heparin (dermatan sulfate, chondroitin sulfate and oversulfated chondroitin sulfate). The Expert Committee noted that the revision work had been initiated.\n\n**Retinol**\n\nVitamin A supplementation therapy was supported by several initiatives of WHO and partner organizations. UNICEF had expressed interest in pharmacopoeial specifications for oral dosage forms containing retinol concentrate, oily form, to fight vitamin A deficiency, xerophthalmia and nutritional blindness.\n\nTo satisfy these needs, draft versions of the monographs:\n\n- retinol concentrate, oily form\n- paediatric retinol capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices de tratamiento para la malaria, destacando la importancia de no usar antimal\u00e1ricos como monoterapia. Se menciona el progreso en la revisi\u00f3n de monograf\u00edas para medicamentos antimal\u00e1ricos, as\u00ed como la adopci\u00f3n de nuevas especificaciones para otros medicamentos, como oseltamivir, heparinas y retinol. Se enfatiza la necesidad de co-empaquetar productos y la armonizaci\u00f3n de especificaciones con otras farmacopeas. Adem\u00e1s, se discuten iniciativas para combatir la deficiencia de vitamina A.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se consideraron para priorizar los productos en la revisi\u00f3n de monograf\u00edas de antimal\u00e1ricos?**\n   - La Expert Committee acord\u00f3 que se asignar\u00eda prioridad a los productos que pudieran ser co-empaquetados, en l\u00ednea con las directrices de tratamiento de la OMS para la malaria.\n\n2. **\u00bfCu\u00e1les fueron las principales modificaciones realizadas en la monograf\u00eda de oseltamivir fosfato desde su adopci\u00f3n inicial?**\n   - La monograf\u00eda fue revisada para abordar comentarios sobre las pruebas de cenizas sulfatadas y sustancias relacionadas, resultando en una versi\u00f3n revisada que armoniza el texto con las especificaciones de otras farmacopeas, como Ph.Eur y USP.\n\n3. **\u00bfQu\u00e9 iniciativas apoyan la terapia de suplementaci\u00f3n de vitamina A y qu\u00e9 especificaciones farmacop\u00e9uticas se est\u00e1n desarrollando?**\n   - La OMS y organizaciones asociadas, como UNICEF, apoyan la terapia de suplementaci\u00f3n de vitamina A, y se est\u00e1n desarrollando especificaciones farmacop\u00e9uticas para formas orales que contienen concentrado de retinol en forma oleosa y c\u00e1psulas pedi\u00e1tricas de retinol.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Adopci\u00f3n de Nuevas Monograf\u00edas**:\n   - Se presentaron nuevas monograf\u00edas para:\n     - **Levonorgestrel** (tabletas)\n     - **Oseltamivir** (c\u00e1psulas)\n     - **Bicarbonato de sodio** (inyecci\u00f3n intravenosa)\n   - Las monograf\u00edas fueron adoptadas tras la inclusi\u00f3n de cambios acordados y comentarios del proceso consultivo.\n\n2. **Revisi\u00f3n de Monograf\u00edas de Derivados de Artemisinina**:\n   - Desde 2008, se ha llevado a cabo una revisi\u00f3n extensa de las monograf\u00edas de derivados de artemisinina en *The International Pharmacopoeia*.\n   - Se revisaron aspectos como el m\u00e9todo para la prueba de sustancias relacionadas y el ensayo, as\u00ed como la inclusi\u00f3n de impurezas potenciales.\n\n3. **Modificaci\u00f3n de la Monograf\u00eda de Artesunato**:\n   - La monograf\u00eda de **Artesunato** para inyecci\u00f3n fue revisada para incluir requisitos espec\u00edficos para el principio activo (API) destinado a preparaciones parenterales.\n   - Se adopt\u00f3 un texto revisado basado en comentarios de la consulta p\u00fablica y discusiones.\n\n4. **Revisi\u00f3n General de Derivados de Artemisinina**:\n   - Aproximadamente **15 textos** est\u00e1n siendo revisados en esta serie.\n   - Las monograf\u00edas para **Artesunato** y **tabletas de Artesunato** ya fueron adoptadas en octubre de 2009.\n   - Se propuso priorizar la revisi\u00f3n de los restantes textos para su disponibilidad oportuna.\n\n### Entidades Clave\n- **Medicamentos**: Levonorgestrel, Oseltamivir, Bicarbonato de sodio, Artesunato.\n- **Documentos**: *The International Pharmacopoeia*.\n- **Comit\u00e9**: Comit\u00e9 de Expertos.\n- **Proceso**: Proceso consultivo, adopci\u00f3n de monograf\u00edas, revisi\u00f3n de textos.", "excerpt_keywords": "Keywords: malaria treatment, oseltamivir phosphate, heparins, vitamin A supplementation, pharmacopoeial specifications"}}, "11d257e1-c843-48e3-b272-d43c0ba75edb": {"node_ids": ["b1719e63-8e25-4dbe-9c52-34584f173a6b"], "metadata": {"page_label": "33", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Paediatric Retinol Oral Solution\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monograph on retinol concentrate, oily form, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\nPaediatric vitamin A soft-gel capsules have a unique mode of delivery. They are furnished with a small nipple which can be cut off so that the liquid content can be easily squeezed into the mouth of a child. The Committee decided to subsume this dosage form under the monograph on vitamin A oral solution, considering the soft gelatin shell as a single-unit container and the liquid content as the actual dosage form. The Expert Committee recommended that the monograph on paediatric retinol oral solution be modified so that its specifications can also be applied to these single-dose units. The capsule monograph was then to be withdrawn.\n\n# Paracetamol\n\nDraft versions of the monographs:\n\n- Paracetamol oral solution\n- Paracetamol oral suspension\n\n- Prepared and preliminarily discussed during a tele-/videoconference on specifications for medicines and quality control laboratory issues in August 2010.\n- Draft monographs were circulated and comments were collated.\n- Revised monographs were presented at the 45th meeting of the Expert Committee.\n\nThe Committee adopted the monographs, subject to inclusion of the agreed changes, based on the comments received and those made during the discussion.\n\n## 4.5 Review of Published General Monographs for Dosage Forms and Associated Method Texts\n\n### 4.5.1 Pharmacopoeial Discussion Group: Harmonized General Texts\n\nThe Expert Committee members were updated on the discussions and recommendations of the informal consultation held in May 2010. Ph.Int. general methods, as discussed during previous Expert Committee meetings, are suggested for revision, taking into account the texts harmonized by the PDG (*European Pharmacopoeia, Japanese Pharmacopoeia and United States Pharmacopeia*).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Monograf\u00eda sobre la Soluci\u00f3n Oral de Retinol Pedi\u00e1trico**: En agosto de 2010, se discutieron y revisaron las especificaciones para la soluci\u00f3n oral de retinol pedi\u00e1trico, que incluye un nuevo formato de c\u00e1psulas de gel blando. La monograf\u00eda fue adoptada por el Comit\u00e9 de Expertos, que decidi\u00f3 incluir las c\u00e1psulas como una forma de dosificaci\u00f3n bajo la misma monograf\u00eda.\n\n2. **Monograf\u00edas de Paracetamol**: Se prepararon y discutieron borradores de monograf\u00edas para soluciones y suspensiones orales de paracetamol. Estas monograf\u00edas fueron adoptadas por el Comit\u00e9 de Expertos, con cambios acordados basados en comentarios recibidos.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica**: Se actualiz\u00f3 a los miembros del Comit\u00e9 de Expertos sobre las recomendaciones de una consulta informal en mayo de 2010, sugiriendo revisiones a los m\u00e9todos generales de la Ph.Int. en armon\u00eda con textos de farmacopeas europeas, japonesas y estadounidenses.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas \u00fanicas tienen las c\u00e1psulas de gel blando de vitamina A pedi\u00e1trica y c\u00f3mo se integran en la monograf\u00eda de la soluci\u00f3n oral de retinol?**\n   - Las c\u00e1psulas de gel blando tienen un peque\u00f1o pez\u00f3n que se puede cortar para facilitar la administraci\u00f3n del contenido l\u00edquido a un ni\u00f1o. El Comit\u00e9 decidi\u00f3 incluir este formato bajo la monograf\u00eda de la soluci\u00f3n oral de vitamina A, considerando la c\u00e1psula como un contenedor de unidad \u00fanica.\n\n2. **\u00bfCu\u00e1les fueron los pasos seguidos para la adopci\u00f3n de las monograf\u00edas de paracetamol y qu\u00e9 cambios se acordaron?**\n   - Las monograf\u00edas de paracetamol fueron preparadas y discutidas en una teleconferencia en agosto de 2010, se circularon borradores y se recopilaron comentarios. Las versiones revisadas fueron presentadas en la 45\u00aa reuni\u00f3n del Comit\u00e9 de Expertos, donde se adoptaron con la inclusi\u00f3n de cambios acordados basados en los comentarios recibidos.\n\n3. **\u00bfQu\u00e9 recomendaciones surgieron de la consulta informal de mayo de 2010 respecto a los m\u00e9todos generales de la Ph.Int.?**\n   - Se sugiri\u00f3 que los m\u00e9todos generales de la Ph.Int. sean revisados, teniendo en cuenta los textos armonizados por el Grupo de Discusi\u00f3n Farmacopeica (PDG), que incluye la Farmacopea Europea, la Farmacopea Japonesa y la Farmacopea de los Estados Unidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Directrices de Tratamiento para la Malaria**:\n   - La OMS ha dejado de prescribir antimal\u00e1ricos como monoterapia.\n   - Se prioriza la revisi\u00f3n de monograf\u00edas para productos que puedan ser co-empaquetados.\n\n2. **Progreso en Monograf\u00edas de Antimal\u00e1ricos**:\n   - Se ha avanzado en las monograf\u00edas de artenimol (dihidroartemisina) y artem\u00e9ter.\n   - Se han iniciado especificaciones para medicamentos de combinaci\u00f3n de dosis fijas, como artesunato y amodiaquina, y artenimol y fosfato de piperaquina.\n\n3. **Oseltamivir Fosfato**:\n   - La monograf\u00eda fue adoptada inicialmente en octubre de 2008 y revisada en 2009.\n   - Se realizaron correcciones en las pruebas de cenizas sulfatadas y sustancias relacionadas, armonizando el texto con otras farmacopeas (Ph.Eur y USP).\n\n4. **Heparinas**:\n   - Se est\u00e1 revisando la monograf\u00eda de heparinas para incluir un m\u00e9todo de electroforesis que detecte impurezas potenciales de glicosaminoglicanos.\n\n5. **Retinol (Vitamina A)**:\n   - La OMS y UNICEF apoyan la terapia de suplementaci\u00f3n de vitamina A.\n   - Se est\u00e1n desarrollando especificaciones farmacop\u00e9uticas para formas orales que contienen concentrado de retinol en forma oleosa y c\u00e1psulas pedi\u00e1tricas de retinol.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **UNICEF**\n- **Artenimol (dihidroartemisina)**\n- **Artem\u00e9ter**\n- **Oseltamivir Fosfato**\n- **Heparinas**\n- **Retinol (Vitamina A)**\n\nEste resumen destaca los avances en la regulaci\u00f3n y especificaciones de medicamentos, as\u00ed como las iniciativas para abordar problemas de salud p\u00fablica como la malaria y la deficiencia de vitamina A.", "excerpt_keywords": "Keywords: Retinol, Paracetamol, Pediatric, Monographs, Pharmacopoeia"}}, "b178ca83-ad45-4659-b54b-8ad877711275": {"node_ids": ["0a5b9ad6-787b-4d09-adf2-6dce80785c54"], "metadata": {"page_label": "34", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "During their 42nd and 44th meetings, the Expert Committee endorsed the suggestion that \u201cthe relevant method texts of *The International Pharmacopoeia* should be reviewed alongside the finalized, harmonized PDG texts in order to identify any differences and to ascertain to what extent it might be appropriate to revise the texts of *The International Pharmacopoeia*. Any proposed changes would then be circulated in accordance with the usual WHO consultation process. Once the suggested actions had been identified and agreed by the Expert Committee, the WHO Secretariat would contact the PDG, as appropriate, with regard to its decisions on the use of PDG harmonized texts\u201d.\n\nFollowing this recommendation, a formal request was formulated by the WHO Secretariat to the PDG, which resulted in authorization being given by all three pharmacopoeias of the PDG to use the sign-off text as a basis for publication in *The International Pharmacopoeia* and agreeing that the text needed to be converted into the style of *The International Pharmacopoeia*.\n\nThe Expert Committee agreed that individual PDG method texts might be included in the Ph.Int. as follows, either as:\n\n- **methods supporting the text requirements of the Ph.Int. monographs**: included within the Methods of analysis section either in place of an existing method or as a new method.  \n  In the case of a method intended to replace an existing method, it might be possible to publish both for an interim period so that the \u201cold\u201d method can be used until the relevant monographs are revised; or\n- **methods provided as guidance** with a specific reference made in the Ph.Int. monographs: included within the Supplementary information section; or\n- **as general information** to which no reference is made within the Ph.Int. monographs: included within the Supplementary information section.\n\nRevisions to existing Ph.Int. texts would be circulated in accordance with the usual WHO consultation process.\n\nIn the case of a new text to be included in the Method of analysis section of the Ph.Int., it was recommended to indicate the monographs (published and under elaboration) to which it was intended that the new texts should apply.\n\nThe PDG harmonized general methods reviewed and covered by this approach were the following:\n\n- Residue on ignition/sulfated ash\n- Test for extractable volume of parenteral preparations\n- Test for particulate contamination: subvisible particles\n- Microbial examination of non-sterile products: microbial enumeration tests\n- Microbial examination of non-sterile products: tests for specified microorganisms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento detalla las recomendaciones del Comit\u00e9 de Expertos de la OMS sobre la revisi\u00f3n de los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG (Pharmacopoeial Discussion Group). Se sugiere que se identifiquen las diferencias entre los textos y se eval\u00fae la necesidad de revisarlos. Se establece un proceso para incluir m\u00e9todos del PDG en *The International Pharmacopoeia*, ya sea como m\u00e9todos que apoyan los requisitos de los monograf\u00edas, como m\u00e9todos de orientaci\u00f3n, o como informaci\u00f3n general. Adem\u00e1s, se mencionan m\u00e9todos espec\u00edficos que han sido armonizados y revisados bajo este enfoque.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se utilizar\u00e1n para determinar si un m\u00e9todo del PDG debe reemplazar un m\u00e9todo existente en *The International Pharmacopoeia*?**\n   - Esta pregunta busca entender el proceso de evaluaci\u00f3n y decisi\u00f3n que se seguir\u00e1 para la inclusi\u00f3n o sustituci\u00f3n de m\u00e9todos.\n\n2. **\u00bfC\u00f3mo se llevar\u00e1 a cabo el proceso de consulta de la OMS para las revisiones de los textos existentes de *The International Pharmacopoeia*?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se implementar\u00e1n para asegurar que las revisiones sean adecuadamente discutidas y aprobadas.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la inclusi\u00f3n de m\u00e9todos como \"informaci\u00f3n general\" en comparaci\u00f3n con aquellos que son \"m\u00e9todos de orientaci\u00f3n\" en el contexto de las monograf\u00edas de *The International Pharmacopoeia*?**\n   - Esta pregunta busca aclarar las diferencias en el uso y la aplicaci\u00f3n de los m\u00e9todos seg\u00fan su clasificaci\u00f3n en el documento.\n\n### Resumen de Nivel Superior\n\nEl Comit\u00e9 de Expertos de la OMS ha recomendado revisar los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG. Se han establecido criterios para la inclusi\u00f3n de m\u00e9todos, que pueden ser utilizados como soporte para monograf\u00edas, como orientaci\u00f3n, o como informaci\u00f3n general. Se enfatiza la importancia de un proceso de consulta para las revisiones y se identifican m\u00e9todos espec\u00edficos que han sido armonizados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Soluci\u00f3n Oral de Retinol Pedi\u00e1trico**:\n   - Se discutieron y revisaron especificaciones en agosto de 2010.\n   - Se adopt\u00f3 una monograf\u00eda sobre el concentrado de retinol en forma oleosa, con cambios acordados.\n   - Las c\u00e1psulas de gel blando de vitamina A pedi\u00e1trica se integraron en la monograf\u00eda de soluci\u00f3n oral, consider\u00e1ndose como un contenedor de unidad \u00fanica.\n\n2. **Monograf\u00edas de Paracetamol**:\n   - Se prepararon borradores para soluciones y suspensiones orales de paracetamol.\n   - Las monograf\u00edas fueron adoptadas por el Comit\u00e9 de Expertos, con inclusi\u00f3n de cambios basados en comentarios recibidos.\n\n3. **Grupo de Discusi\u00f3n Farmacopeica**:\n   - Se actualiz\u00f3 a los miembros del Comit\u00e9 sobre recomendaciones de una consulta informal en mayo de 2010.\n   - Se sugiri\u00f3 la revisi\u00f3n de m\u00e9todos generales de la Ph.Int. en armon\u00eda con textos de farmacopeas europeas, japonesas y estadounidenses.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo responsable de la adopci\u00f3n de monograf\u00edas.\n- **Retinol**: Compuesto discutido en la monograf\u00eda pedi\u00e1trica.\n- **Paracetamol**: Medicamento para el cual se desarrollaron monograf\u00edas.\n- **Pharmacopoeial Discussion Group (PDG)**: Grupo que armoniza textos de farmacopeas.\n- **Farmacopeas**: Documentos de referencia como la Farmacopea Europea, Japonesa y de los Estados Unidos.", "excerpt_keywords": "Keywords: International Pharmacopoeia, Expert Committee, PDG harmonization, method texts, WHO consultation"}}, "e288a05f-9d27-4894-9c72-312ce8b11337": {"node_ids": ["b712c83b-cf5d-4f8c-ac1a-b11f05f8d68f"], "metadata": {"page_label": "35", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\nHarmonization of the tests was still under discussion at the PDG and would be considered at a later date.\n\nThe Expert Committee endorsed the proposals presented and the general approach outlined in the background paper. It advised that clear indications be added to the proposed revised texts when circulating them for comment to explain the approach followed for each harmonized method (e.g. revision, addition or for supplementary information).\n\nThe Expert Committee also recommended that once a harmonized PDG method was included in the Ph.Int. a mechanism would be needed to ensure that any further change implemented in the PDG texts be captured in the corresponding text published in Ph.Int.\n\n### 4.5.2 Uniformity of content for single-dose preparations\n\nThe Expert Committee discussed the application of the test for uniformity of content as described in Method 5.1 of the Ph.Int. for fixed-dose combinations (FDCs) in view of the increasing importance of these products.\n\nThe Expert Committee recommended that, in deciding whether a requirement should be included in monographs for FDC tablets or capsules, where none of the APIs are present in less than 5 mg, each case would be judged on its merits. During development of the monograph, account would be taken of the WHO FDC guidelines. A test for uniformity of content of one or more of the active ingredients would be specified for application to the relevant tablet/capsule strength(s). Meanwhile, in accordance with the new approach adopted on the implementation of PDG harmonized texts in the Ph.Int., the general method text 5.1 would not be modified. It was noted that, in the absence of a requirement for uniformity of content in a specific, individual tablet/capsule monograph, compliance with the test for uniformity of mass (5.2) was usually required by means of the relevant general monograph.\n\nThe Expert Committee recommended that, when a requirement for uniformity was specified in a monograph:\n\n\u2014 wherever possible, the analytical method would be described in the individual monograph; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Harmonizaci\u00f3n de M\u00e9todos de Prueba**: El Comit\u00e9 de Expertos est\u00e1 trabajando en la armonizaci\u00f3n de m\u00e9todos de prueba para productos farmac\u00e9uticos, incluyendo criterios de aceptaci\u00f3n para productos no est\u00e9riles y pruebas espec\u00edficas como la disoluci\u00f3n y la uniformidad de contenido. Se discute la necesidad de un mecanismo para actualizar los textos armonizados en la Farmacopea Internacional (Ph.Int).\n\n2. **Uniformidad de Contenido en Preparaciones de Dosis \u00danica**: Se aborda la aplicaci\u00f3n de pruebas de uniformidad de contenido para combinaciones de dosis fijas (FDCs), destacando que cada caso se evaluar\u00e1 individualmente y se tendr\u00e1n en cuenta las directrices de la OMS. Se recomienda que, cuando se especifique un requisito de uniformidad en un monogr\u00e1fico, se describa el m\u00e9todo anal\u00edtico correspondiente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al decidir si incluir un requisito de uniformidad de contenido en los monogr\u00e1ficos de tabletas o c\u00e1psulas de combinaciones de dosis fijas (FDCs)?**\n   - Se deben considerar los m\u00e9ritos de cada caso, especialmente si ninguno de los ingredientes activos (APIs) est\u00e1 presente en menos de 5 mg, y se tendr\u00e1n en cuenta las directrices de la OMS para FDC.\n\n2. **\u00bfQu\u00e9 se recomienda hacer cuando se especifica un requisito de uniformidad en un monogr\u00e1fico?**\n   - Se recomienda que, siempre que sea posible, el m\u00e9todo anal\u00edtico se describa en el monogr\u00e1fico individual correspondiente.\n\n3. **\u00bfCu\u00e1l es la relaci\u00f3n entre la prueba de uniformidad de contenido y la prueba de uniformidad de masa en el contexto de los monogr\u00e1ficos de tabletas/c\u00e1psulas?**\n   - En ausencia de un requisito espec\u00edfico para la uniformidad de contenido en un monogr\u00e1fico individual, generalmente se requiere el cumplimiento de la prueba de uniformidad de masa (5.2) a trav\u00e9s del monogr\u00e1fico general relevante.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de M\u00e9todos**: Se recomienda revisar los textos de m\u00e9todos de *The International Pharmacopoeia* en relaci\u00f3n con los textos armonizados del PDG para identificar diferencias y evaluar la necesidad de revisiones.\n\n2. **Proceso de Inclusi\u00f3n**: Se establecen criterios para la inclusi\u00f3n de m\u00e9todos del PDG en *The International Pharmacopoeia*, que pueden ser:\n   - M\u00e9todos que apoyan los requisitos de las monograf\u00edas.\n   - M\u00e9todos de orientaci\u00f3n.\n   - Informaci\u00f3n general sin referencia espec\u00edfica en las monograf\u00edas.\n\n3. **Consulta de la OMS**: Las revisiones de los textos existentes se llevar\u00e1n a cabo siguiendo el proceso de consulta habitual de la OMS.\n\n4. **M\u00e9todos Espec\u00edficos**: Se mencionan m\u00e9todos espec\u00edficos que han sido armonizados y revisados, incluyendo pruebas para residuos, volumen extra\u00edble, contaminaci\u00f3n particulada y ex\u00e1menes microbianos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n y consulta de los textos.\n- **Pharmacopoeial Discussion Group (PDG)**: Grupo que proporciona textos armonizados que se est\u00e1n considerando para su inclusi\u00f3n.\n- **The International Pharmacopoeia**: Documento que contiene los m\u00e9todos y monograf\u00edas que se est\u00e1n revisando y actualizando.\n- **M\u00e9todos Espec\u00edficos**:\n  - Residuo en ignici\u00f3n/ash sulfatado.\n  - Volumen extra\u00edble de preparaciones parenterales.\n  - Contaminaci\u00f3n particulada: part\u00edculas subvisibles.\n  - Examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana.\n  - Examen microbiano de productos no est\u00e9riles: pruebas para microorganismos espec\u00edficos. \n\nEste resumen destaca los aspectos fundamentales de la secci\u00f3n, incluyendo el proceso de revisi\u00f3n y los m\u00e9todos espec\u00edficos que se est\u00e1n considerando para su inclusi\u00f3n en *The International Pharmacopoeia*.", "excerpt_keywords": "Harmonization, Pharmaceutical, Uniformity, Fixed-dose combinations, Analytical methods"}}, "8013bd4d-774e-43fc-a3a6-8e48d19fae17": {"node_ids": ["e1f728f6-2cba-45d2-a78b-54ffdf5a239f"], "metadata": {"page_label": "36", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 General policy topics and general revision issues for The International Pharmacopoeia\n\n## 4.6.1 Update on dissolution tests\n\nFollowing the discussions held at several Expert Committee meetings and during consultations on the issue of the addition of dissolution tests in specific monographs, a document summarizing the previous discussions and recommendations was presented to the Expert Committee.\n\nThe main recommendations and priorities endorsed by the Expert Committee during previous discussions were as follows:\n\n- A standardized dissolution test would be applied to tablets and capsules containing highly soluble APIs:\n  - As an alternative to disintegration (using a defined format, that applied, for example, to the monograph of isoniazid and ethambutol hydrochloride tablets),\n  - Subject to amendment of the criteria; and\n- The development of additional dissolution tests would be further reviewed.\n\nIn line with these recommendations, a dissolution test had recently been developed for a certain number of new or published monographs for products with highly soluble APIs (for example, during the process of the general revision on artemisinin derivatives). However, work still needed to be done on those monographs where a cross-reference to the general method was made.\n\nIn view of the amount of work that these revisions would require, it was proposed that priority for revision be given to those monographs where a statement clearly indicated that the test was under development or where a reference to the general method without requirements was made and to those monographs that were already assigned priority due to bioavailability or poor solubility problems (as identified in the 31st report of the Expert Committee and indicated with an asterisk* within the list below).\n\nThis represented 16 monographs, extracted from the list of preparations presented in Annex 1 of document QSM/EC/07.21, amended to include affected monographs published since 2007:\n\n- ampicillin capsules\n- artemether capsules\n- artemether tablets", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento aborda las actualizaciones sobre las pruebas de disoluci\u00f3n en la Farmacopea Internacional, destacando las recomendaciones del Comit\u00e9 de Expertos sobre la aplicaci\u00f3n de pruebas estandarizadas para tabletas y c\u00e1psulas que contienen principios activos altamente solubles. Se menciona la necesidad de desarrollar pruebas adicionales y se priorizan ciertas monograf\u00edas para revisi\u00f3n, especialmente aquellas con problemas de bioavailability o solubilidad. Se enumeran ejemplos de monograf\u00edas afectadas, como las c\u00e1psulas de ampicilina y artemeter.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que se deben considerar para la enmienda de las pruebas de disoluci\u00f3n en las monograf\u00edas de la Farmacopea Internacional?**\n   - Esta pregunta busca detalles sobre los criterios que el Comit\u00e9 de Expertos considera al modificar las pruebas de disoluci\u00f3n, que no se especifican en el resumen.\n\n2. **\u00bfQu\u00e9 monograf\u00edas se consideran prioritarias para la revisi\u00f3n debido a problemas de bioavailability o solubilidad, y cu\u00e1les son los criterios para su selecci\u00f3n?**\n   - Esta pregunta se centra en entender c\u00f3mo se determina la prioridad de revisi\u00f3n de las monograf\u00edas y qu\u00e9 caracter\u00edsticas espec\u00edficas las hacen elegibles.\n\n3. **\u00bfQu\u00e9 avances se han realizado en el desarrollo de pruebas de disoluci\u00f3n para los derivados de artemisinina y qu\u00e9 desaf\u00edos persisten en este proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre el progreso espec\u00edfico en las pruebas de disoluci\u00f3n para un grupo particular de medicamentos y los obst\u00e1culos que a\u00fan deben superarse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Harmonizaci\u00f3n de M\u00e9todos de Prueba**:\n   - Se est\u00e1 trabajando en la armonizaci\u00f3n de m\u00e9todos de prueba para productos farmac\u00e9uticos no est\u00e9riles.\n   - Se discuten criterios de aceptaci\u00f3n y pruebas espec\u00edficas como la disoluci\u00f3n, la uniformidad de contenido, y la friabilidad de tabletas.\n   - Se recomienda establecer un mecanismo para actualizar los textos armonizados en la Farmacopea Internacional (Ph.Int) conforme se realicen cambios en los textos del PDG.\n\n2. **Uniformidad de Contenido en Preparaciones de Dosis \u00danica**:\n   - Se analiza la aplicaci\u00f3n de la prueba de uniformidad de contenido para combinaciones de dosis fijas (FDCs).\n   - Cada caso se evaluar\u00e1 individualmente, considerando las directrices de la OMS, especialmente si los ingredientes activos (APIs) est\u00e1n presentes en cantidades superiores a 5 mg.\n   - Se sugiere que, cuando se especifique un requisito de uniformidad en un monogr\u00e1fico, se incluya la descripci\u00f3n del m\u00e9todo anal\u00edtico correspondiente.\n\n3. **Relaci\u00f3n entre Pruebas**:\n   - En ausencia de un requisito espec\u00edfico para la uniformidad de contenido en un monogr\u00e1fico individual, se requiere el cumplimiento de la prueba de uniformidad de masa (5.2) a trav\u00e9s del monogr\u00e1fico general relevante.\n\n### Entidades Clave\n- **Comit\u00e9 de Expertos**: Grupo que discute y recomienda sobre m\u00e9todos de prueba y criterios de aceptaci\u00f3n.\n- **Farmacopea Internacional (Ph.Int)**: Documento que contiene est\u00e1ndares para productos farmac\u00e9uticos.\n- **Combinaciones de Dosis Fijas (FDCs)**: Preparaciones que contienen dos o m\u00e1s ingredientes activos en una sola forma de dosificaci\u00f3n.\n- **M\u00e9todos de Prueba**: Incluyen pruebas de disoluci\u00f3n, uniformidad de contenido, y pruebas de esterilidad, entre otros.", "excerpt_keywords": "Keywords: dissolution tests, International Pharmacopoeia, Expert Committee, bioavailability, artemisinin derivatives"}}, "9834bc1c-22b5-4a86-94e3-e1e43e85e974": {"node_ids": ["43036a63-3ff0-4a3b-98f0-7b847bdd7a6a"], "metadata": {"page_label": "37", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- artemisinin capsules\n- artemisinin tablets\n- artenimol tablets\n- carbamazepine tablets\n- erythromycin ethylsuccinate tablets*\n- erythromycin stearate tablets*\n- griseofulvin tablets*\n- ibuprofen tablets\n- indometacin tablets\n- phenytoin sodium tablets*\n- rifampicin, isoniazid and ethambutol tablets\n- rifampicin and isoniazid dispersible tablets\n- rifampicin, isoniazid and pyrazinamide dispersible tablets\n\nThis priority list was discussed during the consultation held in May 2010, where it was recommended that priority should indeed be assigned to those monographs listed, with the exception, however, of the following monographs on artemisinin derivatives, the products of which were no longer marketed and, therefore, a revision was not required:\n\n- artemether capsules\n- artemether tablets\n- artemisinin capsules\n- artemisinin tablets\n\nIn order to be able to rapidly develop and include a dissolution test in the monographs that have been identified, the Expert Committee endorsed the recommendation that a pragmatic approach be followed, based on methods that are publicly available.\n\nThe Expert Committee further recommended that general guidance be developed for the dissolution test so that a clear general policy could be established on when to include this test in new monographs, preferably, if at all possible, at the early stages of their development.\n\n### 4.6.2 Dry powders\n\nWith the development of the monograph on amoxicillin oral suspension in collaboration with The British Pharmacopoeia (BP), the issue of how to deal in The International Pharmacopoeia with formulations that are intended to be modified by the patient before use was raised. It was noted that the two pharmacopoeias had different approaches for these formulations:\n\n- BP was considering the final product (i.e. the reconstituted solution, suspension or injection) and reflecting this in the monograph titles (in this case Amoxicillin oral suspension); and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Prioridad en Monograf\u00edas de Medicamentos**: Durante una consulta en mayo de 2010, se discuti\u00f3 una lista de monograf\u00edas prioritarias para el desarrollo, excluyendo ciertos derivados de artemisinina que ya no estaban en el mercado. Se enfatiz\u00f3 la necesidad de un enfoque pragm\u00e1tico para el desarrollo de pruebas de disoluci\u00f3n en estas monograf\u00edas.\n\n2. **Enfoque sobre Formulaciones Modificadas**: Se abord\u00f3 la cuesti\u00f3n de c\u00f3mo manejar las formulaciones que los pacientes deben modificar antes de su uso, destacando las diferencias entre la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en cuanto a la consideraci\u00f3n del producto final en sus monograf\u00edas.\n\n3. **Desarrollo de Pruebas de Disoluci\u00f3n**: Se recomend\u00f3 que se desarrollara una gu\u00eda general para las pruebas de disoluci\u00f3n, estableciendo una pol\u00edtica clara sobre cu\u00e1ndo incluir estas pruebas en nuevas monograf\u00edas, preferiblemente desde las etapas iniciales de desarrollo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los medicamentos que fueron excluidos de la revisi\u00f3n de monograf\u00edas debido a que ya no estaban en el mercado?**\n   - Los medicamentos excluidos son: artemether c\u00e1psulas, artemether tabletas, artemisinin c\u00e1psulas y artemisinin tabletas.\n\n2. **\u00bfQu\u00e9 enfoque se recomienda para el desarrollo de pruebas de disoluci\u00f3n en las monograf\u00edas identificadas?**\n   - Se recomienda un enfoque pragm\u00e1tico basado en m\u00e9todos que son p\u00fablicamente disponibles, junto con el desarrollo de una gu\u00eda general para establecer una pol\u00edtica clara sobre la inclusi\u00f3n de pruebas de disoluci\u00f3n en nuevas monograf\u00edas.\n\n3. **\u00bfC\u00f3mo difieren la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en su tratamiento de formulaciones que deben ser modificadas por el paciente?**\n   - La Farmacopea Brit\u00e1nica considera el producto final (como la soluci\u00f3n reconstituida, suspensi\u00f3n o inyecci\u00f3n) y refleja esto en los t\u00edtulos de las monograf\u00edas, mientras que la Farmacopea Internacional aborda estas formulaciones de manera diferente, aunque el texto no especifica c\u00f3mo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Actualizaci\u00f3n sobre Pruebas de Disoluci\u00f3n**: Se discuten las recomendaciones del Comit\u00e9 de Expertos sobre la implementaci\u00f3n de pruebas de disoluci\u00f3n estandarizadas para tabletas y c\u00e1psulas que contienen principios activos altamente solubles.\n  \n2. **Pruebas Estandarizadas**: Se propone que estas pruebas se utilicen como alternativa a las pruebas de desintegraci\u00f3n, con la posibilidad de enmendar los criterios existentes.\n\n3. **Desarrollo de Nuevas Pruebas**: Se menciona la necesidad de revisar el desarrollo de pruebas adicionales de disoluci\u00f3n.\n\n4. **Prioridades de Revisi\u00f3n**: Se establece que la revisi\u00f3n debe centrarse en monograf\u00edas donde se indique que la prueba est\u00e1 en desarrollo o donde se haga referencia a un m\u00e9todo general sin requisitos espec\u00edficos, as\u00ed como en aquellas con problemas de bioavailability o solubilidad.\n\n5. **Monograf\u00edas Afectadas**: Se identifican 16 monograf\u00edas prioritarias para revisi\u00f3n, incluyendo ejemplos espec\u00edficos como las c\u00e1psulas de ampicilina y artemeter.\n\n#### Entidades:\n- **Comit\u00e9 de Expertos**: Grupo responsable de discutir y recomendar cambios en las pruebas de disoluci\u00f3n.\n- **Farmacopea Internacional**: Documento regulador que incluye monograf\u00edas de medicamentos.\n- **Principios Activos Altamente Solubles (APIs)**: Sustancias que se consideran para la aplicaci\u00f3n de pruebas de disoluci\u00f3n estandarizadas.\n- **Monograf\u00edas**: Documentos espec\u00edficos que describen los est\u00e1ndares para productos farmac\u00e9uticos, como:\n  - C\u00e1psulas de ampicilina\n  - C\u00e1psulas de artemeter\n  - Tabletas de artemeter\n\nEste resumen destaca la importancia de las pruebas de disoluci\u00f3n en la regulaci\u00f3n de medicamentos y la necesidad de priorizar ciertas monograf\u00edas para asegurar la calidad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: artemisinin, dissolution test, pharmacopoeia, monographs, drug formulation"}}, "7f8bf3f0-dc32-4b98-af10-0e9489068176": {"node_ids": ["b94bef14-cf9e-4fc1-8980-b0f656f5e6e6"], "metadata": {"page_label": "38", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 Ph.Int. had so far been taking into consideration the product before reconstitution (i.e. the powders \u2014 several examples of powders for injections or oral powders can be found in the fourth edition).\n\nWhen discussing the draft monograph on amoxicillin oral suspension during the consultation held in May 2010, it was recommended that a standardized policy be followed in *The International Pharmacopoeia* for monographs on oral solutions or suspensions that need to be reconstituted from powders.\n\nIt was recognized during the consultation that the particular case of powders for injections which are also formulations that should be reconstituted before use, was not affected by the policy to be defined for powders for oral use, because these reconstituted formulations were to be used immediately after reconstitution and, therefore, were not intended to be kept and eventually stored for analysis purposes, for reasons concerning stability and sterility.\n\nThe Expert Committee recommended distinguishing from now on in the titles of the Ph.Int. monographs between the injections that are manufactured as liquid preparations and those intended to be reconstituted before use from a powder, by adding the preposition \u201cfor\u201d in the title of the monographs on reconstituted injections.\n\nThe titles of the following draft monographs presented to the Expert Committee illustrate this approach:\n\n\u2014 Capreomycin *powder for injections* revised to Capreomycin *for injection*  \n\u2014 Artesunate *powder for injections* revised to Artesunate *for injection*\n\nThis revision has also been applied to the following texts, adopted in October 2009 and available on the WHO Medicines web site:\n\n\u2014 Amikacin *powder for injections* revised to Amikacin *for injection*  \n\u2014 Kanamycin *powder for injections* revised to Kanamycin *for injection*\n\nFor the published monographs (listed below) on powders for injection, which now require revision, it was recommended that the same approach be followed. Any revision of the current titles could be made when the opportunity arose, either when the monographs in question were revised for technical reasons or on publication of a new edition:\n\n\u2014 amphotericin B powder for injections  \n\u2014 ampicillin sodium powder for injections  \n\u2014 benzylpenicillin potassium powder for injections  \n\u2014 cloxacillin sodium powder for injections  \n\u2014 pentamidine isetionate powder for injections  \n\u2014 prednisolone sodium succinate powder for injections  \n\u2014 procaine benzylpenicillin powder for injections  \n\u2014 streptomycin sulfate powder for injections", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior\n\nEl documento de la OMS discute la necesidad de estandarizar las pol\u00edticas en la *Farmacopea Internacional* (Ph.Int.) para las monograf\u00edas de soluciones orales o suspensiones que deben ser reconstituidas a partir de polvos. Durante una consulta en mayo de 2010, se recomend\u00f3 distinguir entre inyecciones que se fabrican como preparaciones l\u00edquidas y aquellas que deben ser reconstituidas antes de su uso. Se propuso modificar los t\u00edtulos de las monograf\u00edas para reflejar esta distinci\u00f3n, a\u00f1adiendo la preposici\u00f3n \"para\" en los t\u00edtulos de las inyecciones reconstituidas. Se presentan ejemplos de monograf\u00edas que han sido revisadas y se sugiere que las monograf\u00edas publicadas que a\u00fan no han sido actualizadas sigan este mismo enfoque.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la raz\u00f3n por la que las formulaciones reconstituidas de polvos para inyecci\u00f3n no se ven afectadas por la pol\u00edtica que se define para los polvos de uso oral?**\n   - Las formulaciones reconstituidas de polvos para inyecci\u00f3n deben ser utilizadas inmediatamente despu\u00e9s de la reconstituci\u00f3n y no est\u00e1n destinadas a ser almacenadas para an\u00e1lisis, debido a preocupaciones sobre la estabilidad y la esterilidad.\n\n2. **\u00bfQu\u00e9 cambios se proponen en los t\u00edtulos de las monograf\u00edas de la Ph.Int. para las inyecciones reconstituidas y por qu\u00e9?**\n   - Se propone a\u00f1adir la preposici\u00f3n \"para\" en los t\u00edtulos de las monograf\u00edas de inyecciones reconstituidas para distinguirlas de las inyecciones que se fabrican como preparaciones l\u00edquidas, facilitando as\u00ed la identificaci\u00f3n de su forma de preparaci\u00f3n.\n\n3. **\u00bfCu\u00e1les son algunos ejemplos de monograf\u00edas que han sido revisadas y c\u00f3mo se han modificado sus t\u00edtulos?**\n   - Ejemplos de monograf\u00edas que han sido revisadas incluyen: \n     - Capreomycin *powder for injections* se revis\u00f3 a Capreomycin *for injection*.\n     - Artesunate *powder for injections* se revis\u00f3 a Artesunate *for injection*.\n     - Adem\u00e1s, se menciona que otras monograf\u00edas publicadas, como la de ampicilina y la de estreptomicina, tambi\u00e9n requieren revisi\u00f3n siguiendo este enfoque.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prioridad en Monograf\u00edas de Medicamentos**:\n   - Se discuti\u00f3 una lista de monograf\u00edas prioritarias durante una consulta en mayo de 2010.\n   - Se excluyeron ciertos derivados de artemisinina (artemether y artemisinin) de la revisi\u00f3n debido a que ya no estaban en el mercado.\n\n2. **Medicamentos Listados**:\n   - Medicamentos en la lista de prioridad incluyen:\n     - Artemisinin c\u00e1psulas y tabletas\n     - Artenimol tabletas\n     - Carbamazepina tabletas\n     - Erythromycin ethylsuccinate tabletas\n     - Erythromycin stearate tabletas\n     - Griseofulvin tabletas\n     - Ibuprofeno tabletas\n     - Indometacina tabletas\n     - Phenytoin sodium tabletas\n     - Rifampicina, isoniazida y etambutol tabletas\n     - Rifampicina e isoniazida tabletas dispersables\n     - Rifampicina, isoniazida y pirazinamida tabletas dispersables\n\n3. **Desarrollo de Pruebas de Disoluci\u00f3n**:\n   - Se recomend\u00f3 un enfoque pragm\u00e1tico para el desarrollo de pruebas de disoluci\u00f3n en las monograf\u00edas identificadas, utilizando m\u00e9todos disponibles p\u00fablicamente.\n   - Se sugiri\u00f3 la creaci\u00f3n de una gu\u00eda general para establecer pol\u00edticas claras sobre la inclusi\u00f3n de pruebas de disoluci\u00f3n en nuevas monograf\u00edas, preferiblemente desde las etapas iniciales de desarrollo.\n\n4. **Formulaciones Modificadas por el Paciente**:\n   - Se abord\u00f3 la diferencia entre la Farmacopea Brit\u00e1nica y la Farmacopea Internacional en el tratamiento de formulaciones que deben ser modificadas por el paciente.\n   - La Farmacopea Brit\u00e1nica considera el producto final (soluci\u00f3n reconstituida, suspensi\u00f3n o inyecci\u00f3n) en sus monograf\u00edas, mientras que la Farmacopea Internacional tiene un enfoque diferente.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Medicamentos**: Artemisinin, Carbamazepina, Erythromycin, Griseofulvin, Ibuprofeno, Indometacina, Phenytoin, Rifampicina, Isoniazida, Etambutol, Pirazinamida.\n- **Consultas**: Consulta de mayo de 2010.\n- **Farmacopeas**: Farmacopea Brit\u00e1nica (BP), Farmacopea Internacional.", "excerpt_keywords": "Pharmacopoeia, reconstitution, injections, monographs, WHO"}}, "a7c171f4-c774-4d8f-a95e-31ade53f23bd": {"node_ids": ["1039ab9a-2418-408c-8868-416ed97f22ca"], "metadata": {"page_label": "39", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "As regards oral suspensions or solutions reconstituted from powders it was recommended to consider the final preparation throughout the monograph. This approach was reflected in the text for amoxicillin oral suspension presented for discussion and adopted at the present meeting, when considering the aspects of the monograph, as described hereafter.\n\nBased on the above, the Expert Committee adopted the following new policy for such monographs.\n\n**Title of the monograph.** Title and requirements of the monograph would correspond to the final preparation rather than the powder.\n\n**Definition.** Any distinction, as to whether the oral suspension or solution needed to be reconstituted or was directly manufactured as a liquid, would be mentioned under Definition. Any necessary indication on the reconstitution of the final preparation would be given in this section as well.\n\n**Reference to general monographs.** Compliance of the final product with the general monograph for \u201cLiquid preparations for oral use\u201d and that of the powder with the section of the monograph entitled \u201cPowders for oral solutions, oral suspensions and oral drops\u201d would be maintained, as it is currently mentioned in published monographs on powders for oral use.\n\n**Manufacture.** When specific requirements referring to the powder needed to be included in the monograph, they would be mentioned by means of a statement or a test with or without specific limits, under this section (e.g. Test for water content).\n\nIt was also recognized that the quality of the reconstituted product during the in-use period as stated on the label should be considered. It was, therefore, proposed to cover this aspect by introducing, under the Manufacture section, a requirement with a minimum limit to be met at the end of the defined in-use period for content, with a statement as follows:\n\n\u201cThe product is formulated in such a way that when the suspension is constituted following manufacturer\u2019s instructions, stored at the temperature for the in-use period stated on the label and assayed using the method described below under Assay, it contains not less than 80.0% of the amount of amoxicillin (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S) stated on the label.\u201d\n\n**Tests.** Amounts to be taken for testing would be expressed in terms of quantities of the reconstituted solution or suspension and not the powder.\n\nFor example, \u201cdilute an accurately weighed *quantity of the oral suspension containing the equivalent of 60 mg of amoxicillin*.\u201d\n\nThe published monographs on oral powders should be revised in accordance with this new policy. It was recommended to follow the same approach as above for the future revisions of monographs for powders for injections.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento discute una nueva pol\u00edtica adoptada por el Comit\u00e9 de Expertos de la OMS para las monograf\u00edas de suspensiones orales o soluciones reconstituidas a partir de polvos. Se enfatiza que el t\u00edtulo y los requisitos de la monograf\u00eda deben corresponder a la preparaci\u00f3n final, no al polvo. Se establecen definiciones claras, referencias a monograf\u00edas generales, requisitos de fabricaci\u00f3n y pruebas espec\u00edficas para asegurar la calidad del producto reconstituido durante su per\u00edodo de uso. Se menciona la importancia de que el producto contenga al menos el 80% de la cantidad de amoxicilina indicada en la etiqueta al final del per\u00edodo de uso.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 porcentaje m\u00ednimo de amoxicilina debe contener el producto reconstituido al final del per\u00edodo de uso seg\u00fan la nueva pol\u00edtica adoptada?**\n   - Respuesta: El producto debe contener no menos del 80.0% de la cantidad de amoxicilina indicada en la etiqueta al final del per\u00edodo de uso.\n\n2. **\u00bfC\u00f3mo se debe expresar la cantidad para las pruebas en las monograf\u00edas de suspensiones orales seg\u00fan la nueva pol\u00edtica?**\n   - Respuesta: Las cantidades para las pruebas deben expresarse en t\u00e9rminos de cantidades de la soluci\u00f3n o suspensi\u00f3n reconstituida y no del polvo.\n\n3. **\u00bfQu\u00e9 cambios se proponen para las monograf\u00edas publicadas sobre polvos orales en relaci\u00f3n con la nueva pol\u00edtica?**\n   - Respuesta: Se recomienda que las monograf\u00edas publicadas sobre polvos orales sean revisadas de acuerdo con la nueva pol\u00edtica adoptada, siguiendo el mismo enfoque para futuras revisiones de monograf\u00edas de polvos para inyecciones.", "prev_section_summary": "### Temas Clave\n\n1. **Estandarizaci\u00f3n de Monograf\u00edas**: Se discute la necesidad de establecer una pol\u00edtica estandarizada en la *Farmacopea Internacional* (Ph.Int.) para las monograf\u00edas de soluciones orales o suspensiones que deben ser reconstituidas a partir de polvos.\n\n2. **Distinci\u00f3n entre Formulaciones**: Se recomienda distinguir entre inyecciones que se fabrican como preparaciones l\u00edquidas y aquellas que deben ser reconstituidas antes de su uso. \n\n3. **Modificaci\u00f3n de T\u00edtulos**: Se propone a\u00f1adir la preposici\u00f3n \"para\" en los t\u00edtulos de las monograf\u00edas de inyecciones reconstituidas para facilitar su identificaci\u00f3n.\n\n4. **Ejemplos de Revisiones**: Se presentan ejemplos de monograf\u00edas que han sido revisadas y c\u00f3mo se han modificado sus t\u00edtulos, as\u00ed como la recomendaci\u00f3n de revisar otras monograf\u00edas publicadas.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: *WHO - Technical Report Series 961*\n- **Consultas**: Consulta de mayo de 2010\n- **Formulaciones**: \n  - Capreomycin\n  - Artesunate\n  - Amikacin\n  - Kanamycin\n  - Amfotericina B\n  - Ampicilina s\u00f3dica\n  - Benzilpenicilina pot\u00e1sica\n  - Cloxacilina s\u00f3dica\n  - Pentamidina isetionato\n  - Prednisolona s\u00f3dica succinato\n  - Benzilpenicilina proca\u00edna\n  - Estreptomicina sulfato\n\n### Conclusi\u00f3n\n\nEl documento enfatiza la importancia de una nomenclatura clara y estandarizada en la farmacolog\u00eda para asegurar la correcta identificaci\u00f3n y uso de las formulaciones inyectables, especialmente aquellas que requieren reconstituci\u00f3n.", "excerpt_keywords": "Keywords: oral suspensions, amoxicillin, reconstitution, monographs, quality standards"}}, "1ea1f372-1c23-4a48-8f69-f34b0e1ea580": {"node_ids": ["70301980-32b3-4bb6-99e5-59fd0e688887"], "metadata": {"page_label": "40", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5. Quality control \u2014 international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)\n\n## 5.1 Update on transfer of International Chemical Reference Substances\n\nIn April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe took over the responsibility for the establishment, preparation, storage and distribution of WHO International Chemical Reference Standards (ICRS) from Apoteket AB, the previous WHO Collaborating Centre for Chemical Reference Substances. Reference material that was held and distributed by Apoteket AB will from now on be distributed by EDQM.\n\nStart-up meetings were held in June and September 2010 in Strasbourg, France. Essential agreements were made as follows:\n\n1. For the analytical characterization of the reference substances, EDQM will follow the general *WHO Guidelines for the establishment, maintenance and distribution of chemical reference substances*, last revised and adopted during the 41st meeting of the Expert Committee on Specifications for Pharmaceutical Preparations.\n2. In the first campaign EDQM will establish as a priority the following 10 ICRS (Table 1).\n\n**Table 1**  \nPriority International Chemical Reference Substances for establishment by EDQM\n\n| No. | Substance |\n| - | - |\n| 1 | artemisinin |\n| 2 | lumefantrine for system suitability |\n| 3 | artenimol |\n| 4 | artesunate |\n| 5 | artemether |\n| 6 | efavirenz impurity B |\n| 7 | lopinavir |\n| 8 | emtricitabine |\n| 9 | tenofovir disoproxil fumarate |\n| 10 | alpha-artemether |\n\n\nThe Expert Committee members expressed their appreciation for these new developments in light of the technical expertise and experience of EDQM in establishing primary reference standards. This new collaboration was considered to enhance the availability of ICRS and thus foster the use of...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en la transferencia de la responsabilidad de los Est\u00e1ndares Internacionales de Referencia Qu\u00edmica (ICRS) de la Organizaci\u00f3n Mundial de la Salud (OMS) al Directorado Europeo para la Calidad de los Medicamentos y la Atenci\u00f3n Sanitaria (EDQM) en 2010. Se menciona que EDQM asumi\u00f3 esta responsabilidad de Apoteket AB y que se llevaron a cabo reuniones para establecer acuerdos sobre la caracterizaci\u00f3n anal\u00edtica de las sustancias de referencia. Se presenta una lista de diez sustancias qu\u00edmicas prioritarias que EDQM se comprometi\u00f3 a establecer en su primera campa\u00f1a.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios que EDQM seguir\u00e1 para la caracterizaci\u00f3n anal\u00edtica de los ICRS?**\n   - EDQM seguir\u00e1 las *Directrices de la OMS para el establecimiento, mantenimiento y distribuci\u00f3n de sustancias de referencia qu\u00edmica*, que fueron revisadas y adoptadas en la 41\u00aa reuni\u00f3n del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n2. **\u00bfQu\u00e9 importancia tiene la colaboraci\u00f3n entre la OMS y el EDQM en el contexto de los ICRS?**\n   - La colaboraci\u00f3n se considera importante porque se espera que mejore la disponibilidad de los ICRS, lo que a su vez fomentar\u00e1 su uso en la industria farmac\u00e9utica y en la investigaci\u00f3n.\n\n3. **\u00bfCu\u00e1les son las diez sustancias qu\u00edmicas que EDQM ha priorizado para su establecimiento como ICRS?**\n   - Las diez sustancias prioritarias son: artemisinin, lumefantrine para la idoneidad del sistema, artenimol, artesunate, artemether, impureza B de efavirenz, lopinavir, emtricitabina, tenofovir disoproxil fumarato y alpha-artemether.", "prev_section_summary": "### Temas Clave:\n1. **Nueva Pol\u00edtica para Monograf\u00edas**: Se adopta una nueva pol\u00edtica para las monograf\u00edas de suspensiones orales o soluciones reconstituidas a partir de polvos, enfoc\u00e1ndose en la preparaci\u00f3n final en lugar del polvo.\n   \n2. **T\u00edtulo y Definici\u00f3n**: El t\u00edtulo y los requisitos de la monograf\u00eda deben corresponder a la preparaci\u00f3n final. Se definen claramente las distinciones entre suspensiones reconstituidas y soluciones fabricadas directamente.\n\n3. **Cumplimiento de Monograf\u00edas Generales**: Se mantiene la conformidad del producto final con las monograf\u00edas generales para \"Preparaciones l\u00edquidas para uso oral\" y con la secci\u00f3n correspondiente a \"Polvos para soluciones orales, suspensiones orales y gotas orales\".\n\n4. **Requisitos de Fabricaci\u00f3n**: Se introducen requisitos espec\u00edficos para asegurar la calidad del producto reconstituido, incluyendo un l\u00edmite m\u00ednimo de contenido de amoxicilina.\n\n5. **Pruebas**: Las cantidades para las pruebas deben expresarse en t\u00e9rminos de la soluci\u00f3n o suspensi\u00f3n reconstituida, no del polvo.\n\n6. **Revisi\u00f3n de Monograf\u00edas Publicadas**: Se recomienda revisar las monograf\u00edas publicadas sobre polvos orales y seguir el mismo enfoque para futuras revisiones de monograf\u00edas de polvos para inyecciones.\n\n### Entidades:\n- **Comit\u00e9 de Expertos de la OMS**: Organismo que adopta la nueva pol\u00edtica.\n- **Amoxicilina (C\u2081\u2086H\u2081\u2089N\u2083O\u2085S)**: Compuesto cuya cantidad debe ser verificada en el producto reconstituido.\n- **Monograf\u00edas**: Documentos que establecen los requisitos y est\u00e1ndares para las preparaciones farmac\u00e9uticas.\n- **Preparaciones l\u00edquidas para uso oral**: Categor\u00eda general bajo la cual se clasifica el producto final.\n- **Polvos para soluciones orales, suspensiones orales y gotas orales**: Secci\u00f3n de la monograf\u00eda que se relaciona con los polvos utilizados para la reconstituci\u00f3n.\n\n### Resumen:\nEl documento establece una nueva pol\u00edtica para las monograf\u00edas de suspensiones orales y soluciones reconstituidas, enfatizando que los t\u00edtulos y requisitos deben referirse a la preparaci\u00f3n final. Se definen claramente las distinciones entre diferentes tipos de preparaciones, se mantienen los est\u00e1ndares de calidad y se introducen requisitos espec\u00edficos para asegurar que el producto reconstituido contenga al menos el 80% de amoxicilina al final del per\u00edodo de uso. Adem\u00e1s, se recomienda revisar las monograf\u00edas existentes para alinearlas con esta nueva pol\u00edtica.", "excerpt_keywords": "Keywords: International Chemical Reference Substances, EDQM, WHO Guidelines, pharmaceutical standards, reference materials"}}, "3521c9d5-63ab-4889-9c96-72cbcd59bb52": {"node_ids": ["2c61ee16-b87c-48e6-9186-51b71cec377e"], "metadata": {"page_label": "41", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The International Pharmacopoeia as a reference for specifications and analytical methods for medicines of major public health impact.\n\nThe Expert Committee took note of the report and endorsed the agreements made.\n\n### 5.2 Proposal for an accelerated release of International Chemical References Standards\n\nICRS were in the past first provisionally adopted by the Expert Panel and then finally adopted by the Expert Committee during its annual meeting. The following process was followed:\n\n> \"Newly established International Chemical Reference Substances, proposed by the WHO Collaborating Centre for Chemical Reference Substances on the basis of adequate testing and characterization, are included in the Centre's annual report. The report is circulated, inter alia, to members of the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, who are requested to consider the proposals carefully together with the attached analytical documentation, and to notify the Centre of any reservations or adverse comment within three months of the date of mailing. In these cases the Centre will proceed with any consultations or additional analyses necessary for the validation.\n>\n> If no adverse comments are received within the three-month period, the proposed new International Chemical Reference Substance may be considered provisionally adopted. It will be considered for final adoption during the subsequent meeting of the Expert Committee.\"[^11]\n\nEDQM will issue an individual analytical report after the establishment of a new reference substance, after the analysis of candidate material for stock replenishment and after monitoring the stability of material in stock.\n\nThe Secretariat made the proposal that these analytical case-reports be reviewed a priori by the Secretariat with assistance from the collaborating laboratory. If the testing is performed according to the above-mentioned adopted guidelines and if the candidate material is considered to be suitable to serve as a reference material the ICRS will be released provisionally. The Secretariat will contact the collaborating laboratory for assistance in the case that the analytical testing reveals information that requires further consideration. The distribution of the ICRS could start after the provisional release.\n\n[^11]: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790, p. 15).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en el proceso de adopci\u00f3n de Sustancias de Referencia Qu\u00edmica Internacional (ICRS) por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se describe c\u00f3mo estas sustancias son propuestas, revisadas y adoptadas provisionalmente antes de su adopci\u00f3n final. El proceso incluye la evaluaci\u00f3n de informes anal\u00edticos y la consideraci\u00f3n de comentarios de expertos. Adem\u00e1s, se menciona la colaboraci\u00f3n con laboratorios para asegurar que las pruebas se realicen de acuerdo con las pautas establecidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el proceso que sigue una Sustancia de Referencia Qu\u00edmica Internacional (ICRS) desde su propuesta hasta su adopci\u00f3n provisional?**\n   - El proceso incluye la propuesta por el Centro de Referencia Qu\u00edmica de la OMS, la circulaci\u00f3n del informe a los miembros del Panel Asesor, la consideraci\u00f3n de comentarios durante un per\u00edodo de tres meses, y la adopci\u00f3n provisional si no se reciben objeciones.\n\n2. **\u00bfQu\u00e9 papel juega el EDQM en la creaci\u00f3n de nuevas Sustancias de Referencia Qu\u00edmica Internacional (ICRS)?**\n   - El EDQM emite un informe anal\u00edtico individual despu\u00e9s de establecer una nueva sustancia de referencia, analizando el material candidato y monitoreando la estabilidad del material en stock.\n\n3. **\u00bfQu\u00e9 sucede si se reciben comentarios adversos sobre una propuesta de ICRS durante el per\u00edodo de revisi\u00f3n de tres meses?**\n   - Si se reciben comentarios adversos, el Centro proceder\u00e1 con consultas o an\u00e1lisis adicionales necesarios para la validaci\u00f3n de la sustancia propuesta antes de su adopci\u00f3n provisional.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Transferencia de Responsabilidad**: En abril de 2010, el Directorado Europeo para la Calidad de los Medicamentos y la Atenci\u00f3n Sanitaria (EDQM) asumi\u00f3 la responsabilidad de los Est\u00e1ndares Internacionales de Referencia Qu\u00edmica (ICRS) de la OMS, anteriormente gestionados por Apoteket AB.\n\n2. **Reuniones de Inicio**: Se llevaron a cabo reuniones en junio y septiembre de 2010 en Estrasburgo, Francia, donde se establecieron acuerdos esenciales sobre la caracterizaci\u00f3n anal\u00edtica de las sustancias de referencia.\n\n3. **Directrices de la OMS**: EDQM seguir\u00e1 las *Directrices de la OMS para el establecimiento, mantenimiento y distribuci\u00f3n de sustancias de referencia qu\u00edmica*, revisadas en la 41\u00aa reuni\u00f3n del Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n4. **Sustancias Qu\u00edmicas Prioritarias**: EDQM se comprometi\u00f3 a establecer diez ICRS prioritarios en su primera campa\u00f1a, que son:\n   - Artemisinin\n   - Lumefantrine para la idoneidad del sistema\n   - Artenimol\n   - Artesunate\n   - Artemether\n   - Impureza B de efavirenz\n   - Lopinavir\n   - Emtricitabina\n   - Tenofovir disoproxil fumarato\n   - Alpha-artemether\n\n5. **Colaboraci\u00f3n OMS-EDQM**: La colaboraci\u00f3n entre la OMS y el EDQM se considera crucial para mejorar la disponibilidad de los ICRS, lo que fomentar\u00e1 su uso en la industria farmac\u00e9utica y en la investigaci\u00f3n. \n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Directorate for the Quality of Medicines & HealthCare (EDQM)**\n- **Apoteket AB**\n- **Comit\u00e9 de Expertos sobre Especificaciones para Preparaciones Farmac\u00e9uticas**", "excerpt_keywords": "Keywords: International Chemical Reference Standards, WHO, pharmacopoeia, analytical methods, public health"}}, "d6deb826-0abe-4faf-bc01-dc256f059da7": {"node_ids": ["29d1fae7-8d93-437f-b8d1-b9acb29548eb"], "metadata": {"page_label": "42", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The analytical case-reports, together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS, are then distributed first to the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations for comment, then again to the Expert Panel for adoption. The analytical case-reports are appended to the annual report as annexes.\n\nThe proposed simplification of the process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.\n\nSupport for the accelerated release procedure to speed up the availability of ICRS was given by the Committee.\n\nThe Expert Committee members approved this new procedure (Annex 1).\n\n### 5.3 Proposed first International Standard for biosynthetic human insulin\n\nIn a joint session with the Expert Committee on Biological Standardization, the Committee discussed an initiative to evaluate a candidate International Standard for Human Recombinant Insulin.\n\nThe WHO Expert Committee on Biological Standardization establishes International Biological Reference preparations of complex composition that require the use of biological or immunological assays for appropriate characterization.\n\nReference standards (ICRS) for physicochemical assays are described in the *International Pharmacopoeia*. These are endorsed by the Expert Committee on Specifications for Pharmaceutical Preparations.\n\nThe Expert Committee on Biological Standardization agreed with a proposal to develop a reference preparation so that it continues to be possible to define the IU and also to investigate potential use of the reference preparations in the diagnostic area. The Expert Committee on Specifications for Pharmaceutical Preparations noted that diagnostics was outside its mandate. Both Expert Committees considered that further work was needed to make a decision on whether the proposed reference material would be of potential use in the therapeutic area. Both Committees requested WHO to publish a statement on the conversion factor between activity and mass units.\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations recommended developing International Chemical Reference Standards on Insulin to be used as primary standards in physical and physicochemical assays.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Establecimiento de ICRS**: El proceso de establecimiento de Sustancias de Referencia Internacionales (ICRS) se ha simplificado para permitir una respuesta m\u00e1s r\u00e1pida de la OMS a la demanda urgente de estas sustancias. Los informes anal\u00edticos y el informe anual consolidado del EDQM se distribuyen a los paneles de expertos para su revisi\u00f3n y adopci\u00f3n.\n\n2. **Propuesta de Est\u00e1ndar Internacional para Insulina**: Se discuti\u00f3 la evaluaci\u00f3n de un candidato para un Est\u00e1ndar Internacional de Insulina Recombinante Humana en una sesi\u00f3n conjunta con el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica. Se acord\u00f3 desarrollar preparaciones de referencia para definir unidades internacionales (IU) y explorar su uso potencial en el \u00e1rea diagn\u00f3stica.\n\n3. **Recomendaciones de los Comit\u00e9s de Expertos**: Los Comit\u00e9s de Expertos recomendaron el desarrollo de Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina, que se utilizar\u00e1n como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito de simplificar el proceso de establecimiento de ICRS seg\u00fan el contexto?**\n   - La simplificaci\u00f3n del proceso tiene como objetivo acelerar el establecimiento de nuevas sustancias de referencia y permitir que la OMS responda m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS.\n\n2. **\u00bfQu\u00e9 se acord\u00f3 en la sesi\u00f3n conjunta sobre el Est\u00e1ndar Internacional de Insulina Recombinante Humana?**\n   - Se acord\u00f3 desarrollar una preparaci\u00f3n de referencia para seguir definiendo la unidad internacional (IU) y explorar su posible uso en el \u00e1rea diagn\u00f3stica, aunque se reconoci\u00f3 que el diagn\u00f3stico est\u00e1 fuera del mandato del Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas.\n\n3. **\u00bfQu\u00e9 recomendaci\u00f3n se hizo respecto a los Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina?**\n   - Se recomend\u00f3 desarrollar Est\u00e1ndares de Referencia Qu\u00edmica Internacionales sobre insulina para ser utilizados como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Sustancias de Referencia Qu\u00edmica Internacional (ICRS):** \n   - Proceso de adopci\u00f3n que incluye propuestas, revisi\u00f3n y adopci\u00f3n provisional por parte de la OMS.\n   - Importancia de la evaluaci\u00f3n de informes anal\u00edticos y la consideraci\u00f3n de comentarios de expertos.\n\n2. **Proceso de Adopci\u00f3n:**\n   - Propuestas realizadas por el Centro de Referencia Qu\u00edmica de la OMS.\n   - Circulaci\u00f3n de informes a miembros del Panel Asesor de la OMS.\n   - Per\u00edodo de revisi\u00f3n de tres meses para recibir comentarios adversos.\n   - Adopci\u00f3n provisional si no hay objeciones, seguida de una consideraci\u00f3n final en la reuni\u00f3n anual del Comit\u00e9 de Expertos.\n\n3. **Rol del EDQM:**\n   - Emisi\u00f3n de informes anal\u00edticos individuales tras el establecimiento de nuevas sustancias de referencia.\n   - An\u00e1lisis de material candidato y monitoreo de la estabilidad del material en stock.\n\n4. **Revisi\u00f3n de Informes Anal\u00edticos:**\n   - Propuesta de revisi\u00f3n a priori de informes anal\u00edticos por parte de la Secretar\u00eda con ayuda de laboratorios colaboradores.\n   - Provisionalidad en la liberaci\u00f3n de ICRS basada en pruebas adecuadas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la propuesta y adopci\u00f3n de ICRS.\n- **Centro de Referencia Qu\u00edmica de la OMS:** Proponente de nuevas sustancias de referencia.\n- **Panel Asesor de la OMS sobre la Farmacopea Internacional y Preparaciones Farmac\u00e9uticas:** Receptor de informes para revisi\u00f3n.\n- **EDQM (European Directorate for the Quality of Medicines):** Encargado de emitir informes anal\u00edticos y monitorear la estabilidad de las sustancias de referencia.\n\nEste resumen destaca los procesos y entidades involucradas en la adopci\u00f3n de ICRS, as\u00ed como la importancia de la colaboraci\u00f3n y la revisi\u00f3n anal\u00edtica en el contexto de la salud p\u00fablica.", "excerpt_keywords": "Keywords: ICRS, WHO, International Standard, Insulin, Reference Standards"}}, "e6aba167-edd1-4aeb-abca-e7bcb31731b9": {"node_ids": ["df576e40-de5a-455a-97b7-1315332744a9"], "metadata": {"page_label": "43", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control \u2014 National Laboratories\n\n## 6.1 External Quality Assurance Assessment Scheme\n\nThe External Quality Assurance Assessment Scheme (EQAAS) aims to give each participating laboratory the opportunity to measure its performance through a confidential system of testing of blind samples and to determine its ability to perform a given analytical procedure within a network of governmental control laboratories. The system should reinforce mutual confidence within the network.\n\nCurrently, WHO has been able to maintain this service and provides samples and testing protocols for Phase 5 of the EQAAS programme. Some 60 quality control laboratories from all six WHO regions have been invited to participate in this Scheme.\n\n### Phase 5 \u2014 Procedure 1: Assay by Water-Free Titration\n\nParticipants were requested to determine the content of metronidazole in a common sample according to a method described in the monograph on metronidazole published in the fourth edition of *The International Pharmacopoeia*. Fifty-two participants submitted their results.\n\nTwelve laboratories (23% of the participants) reported results that were either questionable or unsatisfactory. These laboratories were invited to share their investigations with WHO into the cause of the failure and their corrective and preventive actions. The laboratories concerned were informed by the Secretariat about the main approaches to dealing with questionable or unsatisfactory results.\n\n### Phase 5 \u2014 Procedure 2: Semi-Microdetermination of Water by Karl-Fischer\n\nThe study is currently taking place. The Committee was informed about the time lines.\n\n### Overview of Planned Proficiency Tests in Phase 5\n\nThe planned proficiency tests were presented to the Committee and are listed in Table 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en el Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS) de la OMS, que permite a los laboratorios participantes medir su rendimiento mediante pruebas de muestras ciegas. Se menciona que actualmente hay 60 laboratorios de control de calidad de las seis regiones de la OMS participando en la Fase 5 del programa. Se describen dos procedimientos espec\u00edficos: el primero, relacionado con la determinaci\u00f3n del contenido de metronidazol, donde el 23% de los laboratorios reportaron resultados cuestionables o insatisfactorios; y el segundo, que se centra en la determinaci\u00f3n de agua mediante el m\u00e9todo de Karl-Fischer, que est\u00e1 en curso. Tambi\u00e9n se menciona que se presentaron pruebas de competencia planificadas para la Fase 5.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 porcentaje de laboratorios participantes en la Fase 5 del EQAAS reportaron resultados cuestionables o insatisfactorios en el an\u00e1lisis de metronidazol?**\n   - Respuesta: El 23% de los laboratorios participantes reportaron resultados cuestionables o insatisfactorios.\n\n2. **\u00bfQu\u00e9 acciones se les solicit\u00f3 a los laboratorios que reportaron resultados insatisfactorios en la Fase 5, Procedimiento 1?**\n   - Respuesta: Se les invit\u00f3 a compartir sus investigaciones sobre la causa del fallo y las acciones correctivas y preventivas que implementaron.\n\n3. **\u00bfCu\u00e1l es el objetivo principal del Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS) seg\u00fan el texto?**\n   - Respuesta: El objetivo principal es permitir que cada laboratorio participante mida su rendimiento a trav\u00e9s de un sistema confidencial de pruebas de muestras ciegas y determine su capacidad para realizar un procedimiento anal\u00edtico espec\u00edfico dentro de una red de laboratorios de control gubernamental, reforzando as\u00ed la confianza mutua en la red.", "prev_section_summary": "### Temas Clave:\n\n1. **Establecimiento de ICRS**:\n   - Se ha simplificado el proceso para la creaci\u00f3n de Sustancias de Referencia Internacionales (ICRS) con el fin de responder m\u00e1s r\u00e1pidamente a la demanda urgente de estas sustancias.\n   - Los informes anal\u00edticos y el informe anual del EDQM se distribuyen a los paneles de expertos para su revisi\u00f3n y adopci\u00f3n.\n\n2. **Propuesta de Est\u00e1ndar Internacional para Insulina Recombinante Humana**:\n   - Se discuti\u00f3 la evaluaci\u00f3n de un candidato para un Est\u00e1ndar Internacional de Insulina Recombinante Humana en una sesi\u00f3n conjunta con el Comit\u00e9 de Estandarizaci\u00f3n Biol\u00f3gica.\n   - Se acord\u00f3 desarrollar preparaciones de referencia para definir unidades internacionales (IU) y explorar su uso en el \u00e1rea diagn\u00f3stica.\n\n3. **Recomendaciones de los Comit\u00e9s de Expertos**:\n   - Se recomend\u00f3 el desarrollo de Est\u00e1ndares de Referencia Qu\u00edmica Internacionales para la insulina, que se utilizar\u00e1n como est\u00e1ndares primarios en ensayos f\u00edsicos y fisicoqu\u00edmicos.\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que supervisa el establecimiento de ICRS.\n- **EDQM (European Directorate for the Quality of Medicines & HealthCare)**: Entidad que elabora informes anuales sobre actividades relacionadas con ICRS.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que establece preparaciones de referencia biol\u00f3gica y discute est\u00e1ndares internacionales.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Panel que respalda los est\u00e1ndares de referencia para ensayos fisicoqu\u00edmicos.\n- **Insulina Recombinante Humana**: Sustancia objeto de evaluaci\u00f3n para establecer un est\u00e1ndar internacional. \n\nEste resumen destaca los aspectos fundamentales y las entidades involucradas en el proceso de establecimiento de ICRS y la propuesta de un est\u00e1ndar internacional para la insulina.", "excerpt_keywords": "Quality Assurance, EQAAS, Metronidazole, Proficiency Tests, WHO"}}, "7c369f30-cee6-4cc7-9639-358aa3e1bad2": {"node_ids": ["b72473e7-dcf5-462c-93c6-1a0c8d6fae57"], "metadata": {"page_label": "44", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Number | Test | Sample | Return of results by |\n| - | - | - | - |\n| 5.3 | Dissolution test | Artemether and lumefantrine tablets | 1 April 2011 |\n| 5.4 | Density and pH measurement | Abacavir oral solution | 15 September 2011 |\n| 5.5 | Assay by high-performance liquid chromatography | Amodiaquine and artesunate tablets | 15 March 2012 |\n| 5.6 | Dissolution test | Rifampicin capsules | 15 August 2012 |\n| 5.7 | Related substances by thin-layer chromatography | Artemether and lumefantrine oral suspension | 15 December 2012 |\n\n\nA discussion was held and questions were posed about the performance of laboratories and whether a change in personnel, e.g. laboratory staff, had an influence on performance. It was suggested that cross-checks be made to see whether in laboratories that had failures, these had been triggered by changes in personnel.\n\nThe Committee took note of the latest activities in this programme and fully supported the work carried out to assist quality control laboratories in their capacity-building efforts.\n\n### 6.2 WHO good practices for pharmaceutical microbiology laboratories\n\nFurther to the revision of the WHO good practices for pharmaceutical control laboratories, during the inspections carried out when prequalifying laboratories, the inspectors had noticed that these guidelines might benefit from complementation with a specific text for pharmaceutical microbiology laboratories.\n\nA draft document was presented to the WHO Expert Committee on Specifications for Pharmaceutical Preparations at its 44th meeting and circulated for comments in accordance with the usual procedure. A revised draft was discussed during the informal consultation on quality assurance systems, medicines and risk analysis in May 2010 and mailed out for comments. These responses were currently under evaluation.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evaluaci\u00f3n del rendimiento de laboratorios**: Se llev\u00f3 a cabo una discusi\u00f3n sobre el rendimiento de los laboratorios de control de calidad, centr\u00e1ndose en c\u00f3mo los cambios en el personal podr\u00edan afectar los resultados. Se sugiri\u00f3 realizar verificaciones cruzadas para identificar si las fallas en los laboratorios estaban relacionadas con cambios en el personal.\n\n2. **Revisi\u00f3n de buenas pr\u00e1cticas de microbiolog\u00eda farmac\u00e9utica**: Se present\u00f3 un borrador de directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica a la Comisi\u00f3n de Expertos de la OMS. Estas directrices se desarrollaron a partir de la revisi\u00f3n de las buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y est\u00e1n en proceso de evaluaci\u00f3n tras recibir comentarios de especialistas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas se realizaron en los laboratorios y cu\u00e1les fueron las fechas de retorno de resultados?**\n   - Las pruebas incluyeron un test de disoluci\u00f3n para tabletas de artemeter y lumefantrina, medici\u00f3n de densidad y pH para soluci\u00f3n oral de abacavir, y un ensayo por cromatograf\u00eda l\u00edquida de alta eficacia para tabletas de amodiaquina y artesunato, entre otros. Las fechas de retorno de resultados var\u00edan desde el 1 de abril de 2011 hasta el 15 de diciembre de 2012.\n\n2. **\u00bfQu\u00e9 acciones se sugirieron para abordar las fallas en el rendimiento de los laboratorios?**\n   - Se sugiri\u00f3 realizar verificaciones cruzadas para determinar si las fallas en los laboratorios estaban relacionadas con cambios en el personal, lo que podr\u00eda ayudar a identificar \u00e1reas de mejora en la gesti\u00f3n del personal y el rendimiento del laboratorio.\n\n3. **\u00bfCu\u00e1l es el estado actual de las directrices de buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica?**\n   - Las directrices fueron adoptadas, pero est\u00e1n sujetas a revisi\u00f3n por un grupo de especialistas seleccionados, quienes evaluar\u00e1n los comentarios recibidos. Actualmente, las respuestas a la consulta est\u00e1n en proceso de evaluaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Esquema de Evaluaci\u00f3n Externa de Aseguramiento de la Calidad (EQAAS)**:\n   - Objetivo: Permitir a los laboratorios medir su rendimiento mediante pruebas de muestras ciegas y evaluar su capacidad para realizar procedimientos anal\u00edticos espec\u00edficos.\n   - Importancia: Refuerza la confianza mutua dentro de la red de laboratorios de control gubernamental.\n\n2. **Participaci\u00f3n**:\n   - N\u00famero de laboratorios: 60 laboratorios de control de calidad de las seis regiones de la OMS est\u00e1n participando en la Fase 5 del programa.\n\n3. **Fase 5 \u2014 Procedimientos**:\n   - **Procedimiento 1: Determinaci\u00f3n de metronidazol**:\n     - M\u00e9todo: Titraci\u00f3n sin agua, seg\u00fan la monograf\u00eda en *The International Pharmacopoeia*.\n     - Resultados: 52 participantes; 12 laboratorios (23%) reportaron resultados cuestionables o insatisfactorios.\n     - Acciones: Se solicit\u00f3 a los laboratorios que compartieran sus investigaciones sobre las causas de los fallos y las acciones correctivas implementadas.\n   \n   - **Procedimiento 2: Determinaci\u00f3n de agua por Karl-Fischer**:\n     - Estado: Actualmente en curso, con informaci\u00f3n sobre los plazos proporcionada al Comit\u00e9.\n\n4. **Pruebas de Competencia Planificadas**:\n   - Se presentaron pruebas de competencia planificadas para la Fase 5, que est\u00e1n listadas en una tabla (Tabla 2).\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable del EQAAS.\n- **Metronidazol**: Sustancia analizada en el Procedimiento 1.\n- **Karl-Fischer**: M\u00e9todo utilizado en el Procedimiento 2 para la determinaci\u00f3n de agua.", "excerpt_keywords": "Keywords: laboratory performance, quality control, WHO guidelines, pharmaceutical microbiology, capacity-building"}}, "f2709bb6-7851-466e-af5c-e6bf28107485": {"node_ids": ["981e7f2d-0535-45b5-a00c-509383e0840c"], "metadata": {"page_label": "45", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Assurance \u2014 Good Manufacturing Practices\n\n## 7.1 Update of WHO GMP Main Principles for Pharmaceutical Products\n\nProposals for updating the WHO GMP main principles were discussed at various informal consultations and received as feedback to the increased implementation of this text. Discussion during the consultation on WHO guidelines for medicines quality assurance, quality control laboratories and transfer of technology on 27\u201331 July 2009, revealed the need to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d in the *WHO good manufacturing practices (GMP): main principles for pharmaceutical products*.\n\nIn addition, several updates have been suggested to further enhance and include the concept of risk management (in paragraphs 1.2 and 1.4 and 1.5 (new) of the text), replacement of \u201cdrugs\u201d by \u201cmedicines\u201d and inclusion of the concept of a \u201cquality unit\u201d in the section on key personnel and related paragraphs in other parts of the text.\n\nThe Expert Committee agreed to update the guidelines accordingly and recommended publication of the entire guidelines as an Annex to its report in order to replace the one previously published as Annex 4, WHO Technical Report Series, No. 908 in 2003 (Annex 3).\n\n## 7.2 WHO GMP for Blood Establishments\n\nBased on recent discussions worldwide, including during the 63rd World Health Assembly, quality assurance for blood products has received increased attention. New concepts for blood establishments and blood collection are being discussed internationally as, currently, large amounts of blood samples have to be discarded. The World Health Assembly resolution was passed with the intention of strengthening the regulatory oversight for blood products. In response to these efforts, and in order to serve Member States, new good practices for blood establishments were drafted.\n\nRelying on the expertise of the specialists in the Expert Committee on Biological Standardization \u2014 blood products track, the Expert Committee on Specifications for Pharmaceutical Preparations agreed to consider this new GMP text in order to provide Member States with the full set of WHO GMP texts in a comprehensive manner. The new GMP text describes the full series of steps to be covered by blood establishments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la actualizaci\u00f3n de los principios de Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos y establece nuevas directrices para los establecimientos de sangre. Se discuten propuestas para mejorar la calidad y la gesti\u00f3n de riesgos en la producci\u00f3n de medicamentos, as\u00ed como la necesidad de un enfoque m\u00e1s riguroso en la regulaci\u00f3n de productos sangu\u00edneos. Se menciona la incorporaci\u00f3n de un nuevo apartado sobre la revisi\u00f3n de la calidad del producto y la inclusi\u00f3n de un \"unidad de calidad\" en el personal clave.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 cambios espec\u00edficos se han propuesto en la secci\u00f3n sobre \"Product quality review\" en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos?**\n   - Respuesta: Se ha propuesto la incorporaci\u00f3n de una nueva secci\u00f3n (1.6) sobre \"Product quality review\" en el Cap\u00edtulo 1: \"Quality assurance\", as\u00ed como la inclusi\u00f3n del concepto de gesti\u00f3n de riesgos en varios p\u00e1rrafos del texto.\n\n2. **\u00bfCu\u00e1l es el objetivo de la resoluci\u00f3n de la Asamblea Mundial de la Salud en relaci\u00f3n con los productos sangu\u00edneos y qu\u00e9 nuevas pr\u00e1cticas se han desarrollado como respuesta?**\n   - Respuesta: La resoluci\u00f3n tiene como objetivo fortalecer la supervisi\u00f3n regulatoria de los productos sangu\u00edneos, y se han redactado nuevas Buenas Pr\u00e1cticas para los establecimientos de sangre para abordar la alta tasa de descarte de muestras de sangre.\n\n3. **\u00bfC\u00f3mo se planea integrar el nuevo texto de GMP para los establecimientos de sangre con los textos existentes de la OMS?**\n   - Respuesta: El nuevo texto de GMP para los establecimientos de sangre se integrar\u00e1 en un conjunto completo de textos de GMP de la OMS, asegurando que los Estados Miembros tengan acceso a una gu\u00eda integral sobre las pr\u00e1cticas de calidad en la producci\u00f3n de productos sangu\u00edneos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n del Rendimiento de Laboratorios**:\n   - Se discuti\u00f3 el rendimiento de los laboratorios de control de calidad, con \u00e9nfasis en c\u00f3mo los cambios en el personal pueden afectar los resultados. \n   - Se propuso realizar verificaciones cruzadas para identificar si las fallas en los laboratorios estaban relacionadas con cambios en el personal.\n\n2. **Pruebas Realizadas**:\n   - Se presentaron diversas pruebas realizadas en laboratorios, incluyendo:\n     - **Test de disoluci\u00f3n** para tabletas de artemeter y lumefantrina (resultado el 1 de abril de 2011).\n     - **Medici\u00f3n de densidad y pH** para soluci\u00f3n oral de abacavir (resultado el 15 de septiembre de 2011).\n     - **Ensayo por cromatograf\u00eda l\u00edquida de alta eficacia** para tabletas de amodiaquina y artesunato (resultado el 15 de marzo de 2012).\n     - **Test de disoluci\u00f3n** para c\u00e1psulas de rifampicina (resultado el 15 de agosto de 2012).\n     - **Sustancias relacionadas por cromatograf\u00eda en capa fina** para suspensi\u00f3n oral de artemeter y lumefantrina (resultado el 15 de diciembre de 2012).\n\n3. **Buenas Pr\u00e1cticas de Microbiolog\u00eda Farmac\u00e9utica**:\n   - Se present\u00f3 un borrador de directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica a la Comisi\u00f3n de Expertos de la OMS.\n   - Estas directrices se desarrollaron a partir de la revisi\u00f3n de buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y est\u00e1n en proceso de evaluaci\u00f3n tras recibir comentarios de especialistas.\n   - Las directrices fueron adoptadas, pero est\u00e1n sujetas a revisi\u00f3n por un grupo de especialistas seleccionados.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la revisi\u00f3n y adopci\u00f3n de buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que eval\u00faa y discute las directrices y pr\u00e1cticas en laboratorios.\n- **Laboratorios de Control de Calidad**: Entidades que realizan pruebas y an\u00e1lisis de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, quality assurance, pharmaceutical products, blood establishments, risk management"}}, "53db57f2-b686-4280-84e1-50c909e495fb": {"node_ids": ["95fa52ac-7261-4be6-a584-89687d11c5ba"], "metadata": {"page_label": "46", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\na special taskforce, widely reviewed in-house and by WHO Regions, as well as by the blood regulatory network. Moreover, it was posted on the web for public comments.\n\nThe Expert Committee members considered this text to be more comprehensive than the texts for the rest of the pharmaceutical products. However, due to the special environment in which the new guidance will be used, it was found to be acceptable in this format to make it more user-friendly, as the users of this text are traditionally not used to working with the overall applied GMP principles.\n\nThe new good practices were adopted as amended by the specialists in the Expert Committee on Biological Standardization blood products track (Annex 4). It was recommended to add an explanatory note as to why it is more comprehensive than the guidelines for other pharmaceutical products.\n\n### 7.3 Update of WHO GMP for heating, ventilation and air-conditioning for non-sterile pharmaceutical dosage forms\n\nThe supplementary guidelines on GMP for heating, ventilation and air-conditioning (HVAC) for non-sterile pharmaceutical dosage forms were published in 2006. This text was considered to be rather unique in the NMRA-related environment.\n\nFeedback was received from inspectors and users suggesting that this text would benefit from an update in order to allow for inclusion of new trends in this area and to harmonize with other related new documents published, e.g. by the International Organization for Standardization (ISO). Comments received when circulating the proposal were discussed in an informal consultation on quality assurance systems, medicines and risk analysis on 4\u20136 May 2010. The Expert Committee members reviewed the proposed text and requested technical assistance from specialists in this area. A small subgroup was created which looked at the additional comments received prior to and during the Expert Committee meeting.\n\nThe guidelines were adopted subject to review by a group of selected specialists (constituted during the meeting) in light of the comments received. The Expert Committee members would receive the outcome of this review for their final adoption of the guidelines (Annex 5). The Committee further recommended publication of the entire guidelines as an annex to the report.\n\n### 7.4 Update of WHO GMP: Water for pharmaceutical use\n\nThe *WHO good manufacturing practices: water for pharmaceutical use* was adopted by the Expert Committee on Specifications for Pharmaceutical Preparations in 2005 and published in its thirty-ninth report, WHO Technical\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas buenas pr\u00e1cticas**: Se menciona que un grupo de expertos revis\u00f3 y adopt\u00f3 nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos, destacando la necesidad de hacer el texto m\u00e1s accesible para los usuarios que no est\u00e1n familiarizados con los principios generales de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **Actualizaci\u00f3n de directrices sobre HVAC**: Se discute la necesidad de actualizar las directrices sobre calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para formas farmac\u00e9uticas no est\u00e9riles, en respuesta a comentarios de inspectores y usuarios, as\u00ed como para alinearse con nuevas normativas internacionales.\n\n3. **Revisi\u00f3n de las pr\u00e1cticas de agua para uso farmac\u00e9utico**: Se menciona que las buenas pr\u00e1cticas de manufactura relacionadas con el agua para uso farmac\u00e9utico fueron adoptadas en 2005 y que se est\u00e1 considerando su revisi\u00f3n para asegurar que se mantengan actualizadas y relevantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfPor qu\u00e9 se consider\u00f3 necesario hacer el texto de las nuevas buenas pr\u00e1cticas m\u00e1s accesible para los usuarios?**\n   - La necesidad de hacer el texto m\u00e1s accesible se debe a que los usuarios de este texto tradicionalmente no est\u00e1n familiarizados con los principios generales de las Buenas Pr\u00e1cticas de Manufactura (GMP), lo que podr\u00eda dificultar su comprensi\u00f3n y aplicaci\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de comentarios se recibieron sobre las directrices de HVAC y c\u00f3mo se abordaron?**\n   - Se recibieron comentarios de inspectores y usuarios que suger\u00edan que las directrices sobre HVAC se beneficiar\u00edan de una actualizaci\u00f3n para incluir nuevas tendencias y armonizar con documentos recientes de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO). Estos comentarios fueron discutidos en una consulta informal y se form\u00f3 un subgrupo para revisar las observaciones adicionales antes de la adopci\u00f3n final.\n\n3. **\u00bfCu\u00e1l fue el proceso seguido para la adopci\u00f3n de las nuevas buenas pr\u00e1cticas en productos biol\u00f3gicos?**\n   - Las nuevas buenas pr\u00e1cticas fueron revisadas por un grupo de expertos, quienes consideraron el texto m\u00e1s completo que otros relacionados con productos farmac\u00e9uticos. Se adoptaron en su formato actual, con la recomendaci\u00f3n de incluir una nota explicativa sobre su mayor amplitud en comparaci\u00f3n con otras gu\u00edas, y se realizaron enmiendas basadas en las sugerencias de los especialistas en la materia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Actualizaci\u00f3n de los Principios de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se discutieron propuestas para actualizar los principios de GMP de la OMS para productos farmac\u00e9uticos.\n   - Se incorporar\u00e1 una nueva secci\u00f3n (1.6) sobre \"Revisi\u00f3n de la calidad del producto\" en el Cap\u00edtulo 1: \"Aseguramiento de la calidad\".\n   - Se sugiere incluir el concepto de gesti\u00f3n de riesgos y reemplazar \"drugs\" por \"medicines\".\n   - Se introduce el concepto de \"unidad de calidad\" en el personal clave.\n\n2. **Buenas Pr\u00e1cticas de Manufactura para Establecimientos de Sangre**:\n   - La calidad de los productos sangu\u00edneos ha recibido mayor atenci\u00f3n a nivel mundial, especialmente tras la 63\u00aa Asamblea Mundial de la Salud.\n   - Se discuten nuevos conceptos para los establecimientos de sangre debido al alto descarte de muestras.\n   - La resoluci\u00f3n de la Asamblea busca fortalecer la supervisi\u00f3n regulatoria de los productos sangu\u00edneos.\n   - Se han redactado nuevas Buenas Pr\u00e1cticas para los establecimientos de sangre, integr\u00e1ndose en un conjunto completo de textos de GMP de la OMS.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la regulaci\u00f3n y directrices sobre la calidad de productos farmac\u00e9uticos y sangu\u00edneos.\n- **Asamblea Mundial de la Salud**: Foro donde se discuten y aprueban resoluciones relacionadas con la salud global.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y actualiza las directrices de GMP y asegura la implementaci\u00f3n de buenas pr\u00e1cticas en la producci\u00f3n de medicamentos y productos sangu\u00edneos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, Biological Standardization, HVAC guidelines, Pharmaceutical use"}}, "1046723d-2572-45db-9fa0-a3a684a20ec9": {"node_ids": ["87811e47-752d-4576-876c-c0d3d99665e6"], "metadata": {"page_label": "47", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Revision of WHO GMP: Sterile pharmaceutical products\n\nDuring the 44th WHO Expert Committee on Specifications for Pharmaceutical Preparations in 2009, **GMP on sterile pharmaceutical products** were adopted in a revised version as Annex 4 to the Expert Committee report and published in the WHO Technical Report Series, No. 957, 2010. Since then a proposal for a maintenance process had been received and submitted to the Expert Committee members.\n\nThe Expert Committee reviewed all proposed changes in detail and found them to be of good editorial nature involving no change to the technical requirements. The Expert Committee members agreed to all modifications and recommended, in order to make the updated text easily available and to avoid confusion and misinterpretation, to republish the text in its entirety as Annex 6.\n\nThe Expert Committee members took this opportunity to recommend that the Secretariat should develop a general policy with regard to future maintenance processes and present it to the Expert Committee at its forty-sixth meeting.\n\n# Quality Assurance \u2014 new approaches\n\n## WHO guidelines on quality risk management\n\nIn response to the recommendations of the 44th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, the Secretariat had initiated the drafting of the **WHO guidelines on quality risk management**. The initial draft structure was reviewed at the informal consultation on quality assurance systems, medicines and risk analysis held in May 2010 and further elaborated thereafter. Upon circulation, numerous comments were received.\n\nThe Expert Committee members expressed their general support for this document which included more detail than other international guidance, e.g. the ICH Q9. It was recommended that a group of experts should continue to work on the document to bring it to a more mature level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento se centra en la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos est\u00e9riles, adoptadas por el Comit\u00e9 de Expertos de la OMS en 2009. Se menciona la revisi\u00f3n de cambios editoriales sin alteraciones t\u00e9cnicas significativas y la recomendaci\u00f3n de republicar el texto actualizado. Adem\u00e1s, se aborda el desarrollo de directrices sobre gesti\u00f3n de riesgos de calidad, en respuesta a las recomendaciones del mismo comit\u00e9, destacando la necesidad de un enfoque m\u00e1s detallado que otras gu\u00edas internacionales.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 modificaciones se realizaron en las GMP de productos farmac\u00e9uticos est\u00e9riles durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Las modificaciones fueron de naturaleza editorial y no implicaron cambios en los requisitos t\u00e9cnicos. Se acord\u00f3 repubicar el texto en su totalidad como Anexo 6 para evitar confusiones.\n\n2. **\u00bfCu\u00e1l fue la recomendaci\u00f3n del Comit\u00e9 de Expertos respecto al proceso de mantenimiento de las GMP en el futuro?**\n   - Se recomend\u00f3 que la Secretar\u00eda desarrolle una pol\u00edtica general sobre los procesos de mantenimiento y que se presente en la 46\u00aa reuni\u00f3n del Comit\u00e9 de Expertos.\n\n3. **\u00bfQu\u00e9 aspectos se consideraron en la elaboraci\u00f3n de las directrices de la OMS sobre gesti\u00f3n de riesgos de calidad?**\n   - Se revis\u00f3 una estructura inicial del documento en una consulta informal y se recibieron numerosos comentarios. Los miembros del Comit\u00e9 expresaron su apoyo general, destacando que el documento inclu\u00eda m\u00e1s detalles que otras gu\u00edas internacionales, como el ICH Q9. Se recomend\u00f3 que un grupo de expertos contin\u00fae trabajando en el documento para mejorarlo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Nuevas Buenas Pr\u00e1cticas para Productos Biol\u00f3gicos**:\n   - Se adoptaron nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos, revisadas por un grupo de expertos y la red reguladora de sangre de la OMS.\n   - Se enfatiz\u00f3 la necesidad de hacer el texto m\u00e1s accesible para usuarios que no est\u00e1n familiarizados con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Se recomend\u00f3 incluir una nota explicativa sobre la amplitud del texto en comparaci\u00f3n con otras gu\u00edas farmac\u00e9uticas.\n\n2. **Actualizaci\u00f3n de Directrices sobre HVAC**:\n   - Las directrices sobre calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) para formas farmac\u00e9uticas no est\u00e9riles, publicadas en 2006, necesitan actualizaci\u00f3n.\n   - Se recibieron comentarios de inspectores y usuarios que sugirieron incluir nuevas tendencias y armonizar con documentos de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO).\n   - Se realiz\u00f3 una consulta informal y se form\u00f3 un subgrupo para revisar los comentarios antes de la adopci\u00f3n final de las directrices.\n\n3. **Revisi\u00f3n de Buenas Pr\u00e1cticas de Agua para Uso Farmac\u00e9utico**:\n   - Las buenas pr\u00e1cticas de manufactura relacionadas con el agua para uso farmac\u00e9utico fueron adoptadas en 2005.\n   - Se est\u00e1 considerando su revisi\u00f3n para asegurar que se mantengan actualizadas y relevantes.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la adopci\u00f3n y revisi\u00f3n de las buenas pr\u00e1cticas.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Grupo que revis\u00f3 y adopt\u00f3 las nuevas buenas pr\u00e1cticas para productos biol\u00f3gicos.\n- **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Entidad con la que se busca armonizar las directrices de HVAC.\n- **NMRA (Autoridad Nacional de Regulaci\u00f3n de Medicamentos)**: Contexto en el que se consideran las directrices de HVAC.", "excerpt_keywords": "Keywords: GMP, sterile pharmaceutical products, quality risk management, WHO guidelines, Expert Committee"}}, "36cff4f7-671f-4cad-acc9-7c1bc4e09f4b": {"node_ids": ["3347c8eb-f557-4f31-af2b-37b7324fb09d"], "metadata": {"page_label": "48", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.2 WHO guidelines on technology transfer\n\nThe Expert Committee members reviewed the feedback on the newly proposed *WHO guiding principles on transfer of technology in pharmaceutical manufacturing*. It was noted that a large number of comments were received. A small group was then constituted to discuss the feedback obtained both in the meeting and following circulation.\n\nThe Expert Committee subsequently reviewed the outcome of these discussions and adopted the revised text as Annex 7.\n\n# 9. Quality assurance \u2014 distribution and trade of pharmaceuticals\n\n## 9.1 Good pharmacy practice: standards for quality of pharmacy services\n\nThe Expert Committee members were briefed in detail about the steps undertaken towards a revision of the joint WHO/FIP good pharmacy practice (GPP) in order to accommodate new trends and developments.\n\nThe first text on good pharmacy practice had been submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on GPP was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO Guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out a strong commitment towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines Strategy), WHA54.13 (Strengthening health systems in developing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda dos temas principales: las directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica y la garant\u00eda de calidad en la distribuci\u00f3n y comercio de productos farmac\u00e9uticos. Se menciona la revisi\u00f3n de los principios de la OMS sobre la transferencia de tecnolog\u00eda, as\u00ed como la evoluci\u00f3n de las buenas pr\u00e1cticas de farmacia (GPP) desde su primera publicaci\u00f3n en 1999. Adem\u00e1s, se destaca la colaboraci\u00f3n de la FIP con varios pa\u00edses para desarrollar est\u00e1ndares nacionales de GPP y la adopci\u00f3n de la Declaraci\u00f3n de Bangkok en 2007, que reafirma el compromiso de elevar los est\u00e1ndares de los servicios farmac\u00e9uticos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron los principales cambios en las buenas pr\u00e1cticas de farmacia (GPP) desde su primera publicaci\u00f3n en 1999 hasta la revisi\u00f3n actual mencionada en el documento?**\n   - Esta pregunta busca detalles sobre las actualizaciones y cambios espec\u00edficos en las GPP que se han implementado a lo largo de los a\u00f1os.\n\n2. **\u00bfQu\u00e9 pa\u00edses participaron en el estudio piloto para desarrollar est\u00e1ndares nacionales de GPP entre 2005 y 2007, y cu\u00e1l fue el objetivo de este estudio?**\n   - Esta pregunta se centra en la colaboraci\u00f3n internacional y los objetivos espec\u00edficos del estudio piloto mencionado en el contexto.\n\n3. **\u00bfQu\u00e9 resoluciones de la Asamblea Mundial de la Salud son relevantes para las pr\u00e1cticas farmac\u00e9uticas y c\u00f3mo han influido en la evoluci\u00f3n de las GPP?**\n   - Esta pregunta busca informaci\u00f3n sobre la relaci\u00f3n entre las resoluciones de la OMS y su impacto en las pr\u00e1cticas farmac\u00e9uticas, lo que puede no estar ampliamente documentado en otros lugares.", "prev_section_summary": "### Temas Clave:\n1. **Revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se adoptaron modificaciones editoriales a las GMP para productos farmac\u00e9uticos est\u00e9riles durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2009, con el objetivo de repubicar el texto actualizado como Anexo 6.\n\n2. **Proceso de Mantenimiento**: Se recomend\u00f3 que la Secretar\u00eda de la OMS desarrolle una pol\u00edtica general sobre los procesos de mantenimiento de las GMP y que esta se presente en la 46\u00aa reuni\u00f3n del Comit\u00e9.\n\n3. **Gesti\u00f3n de Riesgos de Calidad**: Se inici\u00f3 la redacci\u00f3n de las directrices de la OMS sobre gesti\u00f3n de riesgos de calidad, con un enfoque m\u00e1s detallado que otras gu\u00edas internacionales, como el ICH Q9. Se recibi\u00f3 apoyo general del Comit\u00e9 para continuar el desarrollo del documento.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la adopci\u00f3n y revisi\u00f3n de las GMP y de la elaboraci\u00f3n de directrices sobre gesti\u00f3n de riesgos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y aprueba las modificaciones a las GMP y otras directrices relacionadas con la calidad de los productos farmac\u00e9uticos.\n- **ICH (International Council for Harmonisation)**: Organizaci\u00f3n que proporciona gu\u00edas internacionales, mencionada en comparaci\u00f3n con las nuevas directrices de la OMS. \n\nEste resumen destaca los aspectos m\u00e1s relevantes de la secci\u00f3n, incluyendo las acciones tomadas y las recomendaciones formuladas por el Comit\u00e9 de Expertos de la OMS.", "excerpt_keywords": "Keywords: technology transfer, good pharmacy practice, WHO guidelines, pharmaceutical manufacturing, quality assurance"}}, "bc0ad7e0-8243-4837-84f8-497dab1b19ff": {"node_ids": ["eb56b330-ba5c-4bc4-b603-2df536ebb47f"], "metadata": {"page_label": "49", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Content\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 124 national Member Organizations, relevant experts and WHO. A proposal for this initiative was presented to the Committee on Specifications for Pharmaceutical Preparations at its forty-third meeting in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.\n\nThe revised GPP proposal was widely circulated for comments within the FIP and WHO consultation process. The outcome was presented to the FIP Member Organizations at their annual meeting in September 2010 and subsequent to additional discussions, it was adopted in principle with a view to presenting it to this Expert Committee.\n\nThis newly revised guidance is intended to serve as a standard forming a baseline to be adjusted to the needs in a specific country. The document is directed at civil society and Member States.\n\nThe Expert Committee members acknowledged the role of pharmacists in the supply chain. It was considered that it is up to each country itself to determine what can be done according to its regulatory framework. The Expert Committee also noted the shortage of pharmacists in numerous developing countries.\n\nThe Expert Committee welcomed the updated GPP, discussed several modifications to the text and adopted it in its revised form as new standards for quality of pharmacy services (Annex 8).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto describe el proceso de actualizaci\u00f3n de las directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP) liderado por la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) desde 2007. Se menciona la creaci\u00f3n de un grupo de trabajo, consultas con expertos y la revisi\u00f3n de est\u00e1ndares nacionales en al menos 37 pa\u00edses. El resultado de este proceso fue la adopci\u00f3n de nuevas normas para la calidad de los servicios farmac\u00e9uticos, que se presentaron a la Comisi\u00f3n de Expertos de la OMS. Tambi\u00e9n se destaca la importancia del papel de los farmac\u00e9uticos en la cadena de suministro y la escasez de estos profesionales en muchos pa\u00edses en desarrollo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales objetivos identificados por el grupo de trabajo de la FIP en su primera reuni\u00f3n en 2007?**\n   - Respuesta: El grupo de trabajo se reuni\u00f3 para identificar los problemas clave que necesitaban ser considerados en la revisi\u00f3n de las directrices sobre GPP.\n\n2. **\u00bfQu\u00e9 pa\u00edses estuvieron representados en la consulta de expertos organizada por la FIP en 2008 y qu\u00e9 roles desempe\u00f1aron sus representantes?**\n   - Respuesta: En la consulta de expertos en 2008, participaron representantes de Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania, as\u00ed como miembros de la FIP y expertos invitados, quienes aportaron sus conocimientos y experiencias en el \u00e1mbito farmac\u00e9utico.\n\n3. **\u00bfQu\u00e9 se discuti\u00f3 en la reuni\u00f3n de la Comisi\u00f3n de Expertos en relaci\u00f3n con la escasez de farmac\u00e9uticos en pa\u00edses en desarrollo?**\n   - Respuesta: La Comisi\u00f3n de Expertos reconoci\u00f3 la escasez de farmac\u00e9uticos en numerosos pa\u00edses en desarrollo y consider\u00f3 que cada pa\u00eds debe determinar lo que puede hacerse seg\u00fan su marco regulatorio.\n\n### Resumen de Nivel Superior\n\nEl proceso de actualizaci\u00f3n de las directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP) por parte de la FIP y la OMS se inici\u00f3 en 2007 y culmin\u00f3 con la adopci\u00f3n de nuevas normas en 2010. Este proceso incluy\u00f3 consultas con expertos y una revisi\u00f3n exhaustiva de est\u00e1ndares en varios pa\u00edses. Se enfatiz\u00f3 la importancia del papel de los farmac\u00e9uticos y se abord\u00f3 la problem\u00e1tica de su escasez en pa\u00edses en desarrollo, dejando a cada naci\u00f3n la responsabilidad de adaptar las directrices a su contexto regulatorio.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Transferencia de Tecnolog\u00eda**:\n   - Se revisaron los principios de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica.\n   - Se constituy\u00f3 un grupo peque\u00f1o para discutir el feedback recibido y se adopt\u00f3 un texto revisado como Anexo 7.\n\n2. **Buenas Pr\u00e1cticas de Farmacia (GPP)**:\n   - Se abord\u00f3 la revisi\u00f3n de las GPP en colaboraci\u00f3n con la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) para adaptarse a nuevas tendencias y desarrollos.\n   - La primera versi\u00f3n de las GPP fue presentada en 1994 y se public\u00f3 oficialmente en 1999.\n\n3. **Colaboraci\u00f3n Internacional**:\n   - Se realiz\u00f3 un estudio piloto entre 2005 y 2007 en varios pa\u00edses (Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam) para desarrollar est\u00e1ndares nacionales de GPP.\n   - En 2007, se adopt\u00f3 la \"Declaraci\u00f3n de Bangkok sobre buenas pr\u00e1cticas de farmacia en entornos comunitarios\" en la Regi\u00f3n del Sudeste Asi\u00e1tico.\n\n4. **Impacto de Resoluciones de la OMS**:\n   - Se mencionan resoluciones recientes de la Asamblea Mundial de la Salud (WHA54.11 y WHA54.13) que son relevantes para la evoluci\u00f3n de las GPP y la mejora de los sistemas de salud.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece directrices y est\u00e1ndares en salud p\u00fablica.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Colabora con la OMS en el desarrollo de buenas pr\u00e1cticas de farmacia.\n- **Expert Committee**: Grupo de expertos que revisa y adopta directrices y principios en el \u00e1mbito farmac\u00e9utico.\n- **Pa\u00edses Participantes**: Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Farmacia, FIP, OMS, est\u00e1ndares farmac\u00e9uticos, escasez de farmac\u00e9uticos"}}, "7bc6d502-8762-4cf9-8534-12cb7c55f9e3": {"node_ids": ["1a2f9343-ce5b-427e-8697-d082ec8b5126"], "metadata": {"page_label": "50", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products\n\nThe Expert Committee was briefed about the history and steps involved in the development of this new guidance in the joint session with the Expert Committee on Biological Standardization. After making suitable amendments, the Expert Committee on Biological Standardization and the Expert Committee on Specifications for Pharmaceutical Preparations recommended that the Guidelines be adopted and appended to their respective reports. In addition, the Expert Committee on Biological Standardization recommended:\n\n- that an addendum to the document be developed for labile blood products; and\n- that WHO consider providing guidance to national regulatory authorities on how to define transport requirements for time- and temperature-sensitive pharmaceutical products (TTSPS).\n\nDuring the joint session with the Expert Committee on Biological Standardization it was recommended to refer to \u201csuspect\u201d products in section 8.5 to allow for dealing with problems related to the quality of the product not covered in other sections of the document.\n\nThe Expert Committee adopted the text with the changes proposed (Annex 9).\n\n## 9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n### 9.3.1 Update on current activities\n\nThe Expert Committee was updated on the WHO Certification Scheme. The Committee was informed that a Circular Letter had been sent to Member States on 15 January 2010 asking them to comment on the report of the Expert Committee on Specifications for Pharmaceutical Preparations and to provide updated contact addresses of the respective competent authorities of Member States participating in the WHO Certification Scheme. The response received so far had been extremely low and comments received on the suggestions and recommendations made in previous Expert Committee meetings lacked uniformity. Countries made a number of requests to be covered by the Certification Scheme such as attachment of summary product characteristics (SPC), access to the WHO assessment report, creation of low-risk products, a separate certificate for low-risk products, and inclusion of a date of validity of the issued certificate, among others.\n\nThe Committee was also informed that Poland had joined the WHO pharmaceutical starting materials certification scheme (SMACS).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Gu\u00eda sobre almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y temperatura**: Se discute el desarrollo de nuevas directrices para el manejo de productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento y transporte, con \u00e9nfasis en la necesidad de abordar productos labiles como los productos sangu\u00edneos.\n\n2. **Actualizaci\u00f3n sobre el esquema de certificaci\u00f3n de la OMS**: Se proporciona informaci\u00f3n sobre el estado actual del esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional, destacando la baja respuesta de los Estados Miembros y las solicitudes espec\u00edficas de los pa\u00edses para mejorar el esquema.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se hicieron para el manejo de productos sangu\u00edneos labiles en la nueva gu\u00eda de la OMS?**\n   - La Expert Committee recomend\u00f3 que se desarrollara un adendum a la gu\u00eda para abordar espec\u00edficamente los productos sangu\u00edneos labiles.\n\n2. **\u00bfCu\u00e1les fueron algunas de las solicitudes realizadas por los pa\u00edses en relaci\u00f3n con el esquema de certificaci\u00f3n de la OMS?**\n   - Los pa\u00edses solicitaron la inclusi\u00f3n de caracter\u00edsticas del producto resumidas (SPC), acceso al informe de evaluaci\u00f3n de la OMS, la creaci\u00f3n de productos de bajo riesgo, un certificado separado para estos productos y la inclusi\u00f3n de una fecha de validez en el certificado emitido.\n\n3. **\u00bfQu\u00e9 desaf\u00edos se identificaron en la respuesta de los Estados Miembros al informe de la Expert Committee sobre las Preparaciones Farmac\u00e9uticas?**\n   - Se observ\u00f3 una respuesta extremadamente baja de los Estados Miembros y una falta de uniformidad en los comentarios sobre las sugerencias y recomendaciones de reuniones anteriores del Comit\u00e9.", "prev_section_summary": "### Temas Clave\n\n1. **Actualizaci\u00f3n de Directrices sobre Buenas Pr\u00e1cticas de Farmacia (GPP)**: La Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 en 2007 un proceso para actualizar las directrices de GPP para alinearlas con los est\u00e1ndares contempor\u00e1neos de pr\u00e1ctica.\n\n2. **Consulta de Expertos**: En 2008, se llev\u00f3 a cabo una consulta de expertos en Basilea, Suiza, donde participaron representantes de diversas organizaciones y pa\u00edses, incluyendo Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania.\n\n3. **Revisi\u00f3n de Est\u00e1ndares Nacionales**: El grupo de trabajo de la FIP revis\u00f3 los est\u00e1ndares nacionales de GPP en al menos 37 pa\u00edses y estableci\u00f3 un marco temporal para consultar a las 124 organizaciones nacionales miembros de la FIP y a expertos relevantes.\n\n4. **Adopci\u00f3n de Nuevas Normas**: Las nuevas directrices fueron presentadas y adoptadas en principio por las organizaciones miembros de la FIP en 2010, con el objetivo de servir como un est\u00e1ndar adaptable a las necesidades espec\u00edficas de cada pa\u00eds.\n\n5. **Rol de los Farmac\u00e9uticos**: Se reconoci\u00f3 la importancia del papel de los farmac\u00e9uticos en la cadena de suministro y se destac\u00f3 la escasez de estos profesionales en muchos pa\u00edses en desarrollo.\n\n### Entidades Involucradas\n\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organismo que lidera la actualizaci\u00f3n de las directrices de GPP.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Colaboradora en el proceso de consulta y revisi\u00f3n.\n- **Representantes de Pa\u00edses**: Incluyendo asesores de medicamentos de Ghana, Nigeria y la Rep\u00fablica Unida de Tanzania.\n- **Comit\u00e9 de Especificaciones para Preparaciones Farmac\u00e9uticas**: Entidad que recibi\u00f3 propuestas y reportes sobre la actualizaci\u00f3n de GPP.\n- **Organizaciones Miembros de la FIP**: Participantes en el proceso de consulta y adopci\u00f3n de las nuevas normas. \n\nEste resumen destaca los aspectos fundamentales del proceso de actualizaci\u00f3n de las directrices de GPP y las entidades clave involucradas en este esfuerzo.", "excerpt_keywords": "Keywords: pharmaceutical products, storage and transport, WHO Certification Scheme, temperature-sensitive, labile blood products"}}, "19dccc4c-6b5e-4816-a660-c1de83206033": {"node_ids": ["b9c1f33f-a21e-4a1e-9ba6-84f1d875f8c4"], "metadata": {"page_label": "51", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted the update and recommended further encouragement to Member States to respond to the Circular Letter, e.g. during the forthcoming ICDRA meeting.\n\n### 9.3.2 Questions and answers\n\nBased on the Committee\u2019s recommendations, a question and answer paper was prepared on the function of the Scheme for posting on the WHO web site and for publication in *WHO Drug Information*, with the possibility for receiving comments and reviewing any question(s) and answers.\n\nThe Expert Committee noted the updated report from the Secretariat.\n\n## 10. Prequalification of priority essential medicines\n\n### 10.1 Update on the WHO Prequalification of Medicines Programme\n\nThe Manager of the WHO Prequalification of Medicines Programme briefed the Expert Committee on the existing procedure for prequalification of pharmaceutical products and activities undertaken so far. He said that the Programme provided services to United Nations and international agencies that procure and purchase medicines with donated funds. The work of the Programme includes dossier assessment and inspection of manufacturers, clinical trial sites and laboratories to ensure compliance with good practices. So far the Programme has prequalified 39 medicines of which three are manufactured in Africa (one in South Africa, one in Uganda and one in Zimbabwe). The Programme also has prequalified laboratories; for details see section 11.1.\n\nAnother activity of the Prequalification of Medicines Programme is to build NMRA capacity by conducting training seminars and providing technical assistance.\n\nThe Committee was informed that the Programme had also been active in quality surveys of antimalarials (QAMSA) in six African countries in 2008\u20132009. The activity involves collection of sample antimalarial drugs, using a standard protocol, from different levels of the supply chain, public and private as well as formal and informal outlets. The survey was conducted through WHO cooperation with the NMRAs from participating countries. Trained survey teams in each country were responsible for collecting samples according to national sampling plans from different distribution levels, including the informal market in at least three geographical regions of high malaria prevalence. In total 935 samples were collected from April to June 2008 and screened. Based on predefined criteria, 306 samples (from 64 manufacturers and 218 sampling sites) were selected for full quality control testing in the WHO-prequalified laboratory in South Africa and in the United States Pharmacopeia (USP) laboratory in the USA.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Actualizaci\u00f3n sobre el Programa de Precalificaci\u00f3n de Medicamentos de la OMS**: El Programa de Precalificaci\u00f3n de Medicamentos de la OMS se encarga de evaluar y certificar la calidad de los productos farmac\u00e9uticos para su uso en programas de salud p\u00fablica. Hasta la fecha, ha precalificado 39 medicamentos, de los cuales tres son fabricados en \u00c1frica. Adem\u00e1s, el programa realiza capacitaciones y asistencia t\u00e9cnica a las Autoridades Reguladoras Nacionales de Medicamentos (NMRA) y ha llevado a cabo encuestas de calidad de antimal\u00e1ricos en varios pa\u00edses africanos.\n\n2. **Actividades de Capacitaci\u00f3n y Asistencia T\u00e9cnica**: El Programa no solo se enfoca en la precalificaci\u00f3n de medicamentos, sino que tambi\u00e9n trabaja en el fortalecimiento de las capacidades de las NMRA mediante seminarios de capacitaci\u00f3n y asistencia t\u00e9cnica, lo que es crucial para mejorar la regulaci\u00f3n y la calidad de los medicamentos en los pa\u00edses en desarrollo.\n\n3. **Encuestas de Calidad de Antimal\u00e1ricos**: En 2008-2009, el Programa realiz\u00f3 encuestas de calidad de antimal\u00e1ricos en seis pa\u00edses africanos, recolectando y analizando muestras de medicamentos para asegurar su calidad y eficacia. Este esfuerzo es parte de un enfoque m\u00e1s amplio para combatir la malaria y mejorar la disponibilidad de medicamentos de calidad en el continente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios utilizados para seleccionar las muestras de medicamentos antimal\u00e1ricos en las encuestas de calidad realizadas por la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los criterios de selecci\u00f3n que no se detalla en el contexto, pero que son cruciales para entender la metodolog\u00eda de las encuestas.\n\n2. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se ofrece a las NMRA a trav\u00e9s del Programa de Precalificaci\u00f3n de Medicamentos de la OMS?**\n   - Esta pregunta se centra en los detalles de las capacitaciones y el tipo de asistencia t\u00e9cnica que se proporciona, lo cual no se menciona expl\u00edcitamente en el texto.\n\n3. **\u00bfQu\u00e9 pasos se siguen despu\u00e9s de que un medicamento es precalificado por la OMS?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso posterior a la precalificaci\u00f3n, incluyendo c\u00f3mo se monitorea la calidad de los medicamentos precalificados y qu\u00e9 acciones se toman si se detectan problemas, lo cual no se aborda en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gu\u00eda sobre Almacenamiento y Transporte de Productos Farmac\u00e9uticos Sensibles al Tiempo y Temperatura**:\n   - Se desarrollaron nuevas directrices para el manejo de productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento y transporte.\n   - Se recomend\u00f3 la creaci\u00f3n de un adendum para abordar espec\u00edficamente los productos sangu\u00edneos labiles.\n   - Se sugiri\u00f3 que la OMS proporcione orientaci\u00f3n a las autoridades regulatorias nacionales sobre los requisitos de transporte para productos farmac\u00e9uticos sensibles al tiempo y temperatura (TTSPS).\n\n2. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Se present\u00f3 una actualizaci\u00f3n sobre el esquema de certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional.\n   - Se destac\u00f3 la baja respuesta de los Estados Miembros a la solicitud de comentarios sobre el informe del Comit\u00e9 de Expertos sobre Preparaciones Farmac\u00e9uticas.\n   - Se mencionaron solicitudes espec\u00edficas de los pa\u00edses, como la inclusi\u00f3n de caracter\u00edsticas del producto resumidas (SPC), acceso a informes de evaluaci\u00f3n de la OMS, creaci\u00f3n de productos de bajo riesgo, un certificado separado para estos productos y la inclusi\u00f3n de una fecha de validez en los certificados emitidos.\n\n3. **Entidades Involucradas**:\n   - **Comit\u00e9 de Expertos de la OMS**: Incluye el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica y el Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas.\n   - **Estados Miembros de la OMS**: Participan en el esquema de certificaci\u00f3n y proporcionan comentarios sobre las directrices.\n   - **Polonia**: Se uni\u00f3 al esquema de certificaci\u00f3n de materiales de partida farmac\u00e9uticos de la OMS (SMACS). \n\nEste resumen destaca los principales temas tratados en la secci\u00f3n, as\u00ed como las entidades clave involucradas en el desarrollo y la implementaci\u00f3n de las directrices y el esquema de certificaci\u00f3n.", "excerpt_keywords": "Keywords: WHO, Prequalification, Medicines, Antimalarials, NMRA"}}, "b8b39cd2-537d-41bb-9b8e-db31a27218f0": {"node_ids": ["32db387a-b2af-4e41-8049-63230d49b395"], "metadata": {"page_label": "52", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Testing was coordinated by WHO and specifications of *The International Pharmacopoeia* or USP were used.\n\nDuring the survey, data were collected that made it possible to relate the results of quality testing to distribution levels, geographical regions, domestic production or import, registration status and prequalification status.\n\nOf 306 samples selected for laboratory testing, 267 were fully tested and 28.5% of them failed to comply with specifications. Although noncompliance with pre-established criteria cannot be directly related to a risk for patients' health, such a high failure rate indicates a substantial problem with the quality of antimalarials present in distribution channels.\n\nComparison of results obtained during laboratory testing with the screening method indicated a substantially lower sensitivity of the latter to detect noncompliance in dissolution and in assay/related substances test (15% and 42% detected, respectively).\n\nThe difference between WHO-prequalified and non-WHO-prequalified products was striking. The failure rate of samples of non-prequalified co-packed samples was more than 10 times higher than that of samples of WHO-prequalified co-packed samples. In total three failures were identified. Two were not critical for patients\u2019 health and the third had a content of one API that was 8% below the acceptance limit. This demonstrates that medicines for which quality was confirmed by WHO prequalification have a much lower quality risk than do non-prequalified products.\n\nAnother quality survey of antituberculosis medicines was also carried out in 2009 in East European countries and Newly Independent States (NIS); 291 samples were collected and tested by independent laboratories. Among the samples collected and tested, a small percentage of samples (isoniazid, ofloxacin and rifampicin) failed to pass the test. None of the WHO-prequalified products failed to comply with specifications.\n\nThe Expert Committee reconfirmed that results obtained with screening tests should always be treated with caution and only be used for qualitative and semiquantitative testing. The results of this survey have again demonstrated that in situations requiring regulatory or forensic decisions, laboratory quality control testing should always be applied.\n\nThe Expert Committee acknowledged with satisfaction the work done by the Prequalification of Medicines Programme, in particular the WHO quality monitoring project, and advised the Programme to publish the results of the survey and use the publication to promote awareness among countries. It was noted that when the report was ready the Expert Committee members would be provided with copies. The Committee was pleased to note that", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Calidad de Medicamentos Antimal\u00e1ricos**: Se realiz\u00f3 una encuesta sobre la calidad de antimal\u00e1ricos, donde se analizaron 306 muestras, de las cuales el 28.5% no cumpli\u00f3 con las especificaciones. Se observ\u00f3 una diferencia significativa en la tasa de fallos entre productos precalificados por la OMS y aquellos que no lo estaban.\n\n2. **Comparaci\u00f3n de M\u00e9todos de Prueba**: Se compararon los resultados de pruebas de laboratorio con m\u00e9todos de cribado, encontrando que el m\u00e9todo de cribado ten\u00eda una sensibilidad considerablemente menor para detectar incumplimientos en las pruebas de disoluci\u00f3n y en el an\u00e1lisis de sustancias relacionadas.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos reafirm\u00f3 la importancia de utilizar pruebas de control de calidad de laboratorio en situaciones que requieren decisiones regulatorias o forenses, y recomend\u00f3 la publicaci\u00f3n de los resultados de la encuesta para aumentar la conciencia sobre la calidad de los medicamentos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1l fue la tasa de incumplimiento de las muestras de antimal\u00e1ricos en la encuesta realizada por la OMS y qu\u00e9 implicaciones tiene esto para la salud p\u00fablica?**\n   - La tasa de incumplimiento fue del 28.5%, lo que indica un problema significativo con la calidad de los antimal\u00e1ricos en los canales de distribuci\u00f3n, aunque no se puede relacionar directamente con un riesgo para la salud de los pacientes.\n\n2. **\u00bfQu\u00e9 diferencias se encontraron entre los productos prequalificados por la OMS y los no prequalificados en t\u00e9rminos de calidad?**\n   - Los productos no prequalificados tuvieron una tasa de fallos m\u00e1s de 10 veces mayor que los productos prequalificados por la OMS, lo que demuestra que la precalificaci\u00f3n est\u00e1 asociada con un menor riesgo de calidad.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a los m\u00e9todos de prueba y la publicaci\u00f3n de resultados?**\n   - El Comit\u00e9 recomend\u00f3 tratar los resultados de las pruebas de cribado con cautela y utilizar pruebas de control de calidad de laboratorio para decisiones regulatorias. Tambi\u00e9n aconsej\u00f3 publicar los resultados de la encuesta para aumentar la conciencia en los pa\u00edses sobre la calidad de los medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**:\n   - **Objetivo**: Evaluar y certificar la calidad de productos farmac\u00e9uticos para su uso en programas de salud p\u00fablica.\n   - **Resultados**: Hasta la fecha, se han precalificado 39 medicamentos, de los cuales tres son fabricados en \u00c1frica (Sud\u00e1frica, Uganda y Zimbabue).\n   - **Actividades**: Incluye evaluaci\u00f3n de expedientes, inspecci\u00f3n de fabricantes, sitios de ensayos cl\u00ednicos y laboratorios para asegurar el cumplimiento de buenas pr\u00e1cticas.\n\n2. **Capacitaci\u00f3n y Asistencia T\u00e9cnica**:\n   - **Enfoque**: Fortalecimiento de las capacidades de las Autoridades Reguladoras Nacionales de Medicamentos (NMRA) mediante seminarios de capacitaci\u00f3n y asistencia t\u00e9cnica.\n\n3. **Encuestas de Calidad de Antimal\u00e1ricos (QAMSA)**:\n   - **Contexto**: Realizadas en seis pa\u00edses africanos entre 2008 y 2009.\n   - **Metodolog\u00eda**: Recolecci\u00f3n de muestras de medicamentos antimal\u00e1ricos de diferentes niveles de la cadena de suministro, tanto del sector p\u00fablico como privado, as\u00ed como del mercado informal.\n   - **Resultados**: Se recolectaron 935 muestras, de las cuales 306 fueron seleccionadas para pruebas de control de calidad en laboratorios precalificados por la OMS y en el laboratorio de la Farmacopea de los Estados Unidos (USP).\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable del Programa de Precalificaci\u00f3n de Medicamentos.\n- **NMRA (Autoridades Reguladoras Nacionales de Medicamentos)**: Entidades que se benefician de la capacitaci\u00f3n y asistencia t\u00e9cnica del programa.\n- **Laboratorios Precalificados**: Laboratorios que cumplen con los est\u00e1ndares de calidad establecidos por la OMS para realizar pruebas de control de calidad.\n\nEste resumen destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos de la OMS en la mejora de la calidad de los medicamentos, as\u00ed como sus esfuerzos en la capacitaci\u00f3n de las autoridades reguladoras y la realizaci\u00f3n de encuestas de calidad en el contexto de la lucha contra la malaria.", "excerpt_keywords": "Keywords: antimalarials, quality testing, WHO prequalification, noncompliance, pharmaceutical standards"}}, "21c057ff-80f0-4c74-970b-85efb1b45776": {"node_ids": ["5fa44765-a1ed-461b-9a17-ff548e3dbbc8"], "metadata": {"page_label": "53", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the detailed conclusions of the report would be published and put on the Prequalification of Medicines Programme web site. The Committee took note that the failure of prequalified products, in the above-reported studies on the antimalarial and tuberculosis medicines, was much less than for non-prequalified products, which is an important indicator for the work of the Prequalification of Medicines Programme.\n\n### 10.2 Procedure for prequalification of pharmaceutical products\n\nFollowing the update, the Manager of the Prequalification of Medicines Programme briefed the Expert Committee on the proposed modifications to the existing procedure for prequalification. Following discussion, the Committee adopted the document as recommended (Annex 10), provided no major comments were received during the remaining consultation period and with the understanding that WHO\u2019s Legal Counsel would be consulted during this update process.\n\n### 10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities\n\nWHO recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. A proposal was, therefore, presented to facilitate the submission of documentation to the Prequalification of Medicines Programme for those products approved by such authorities. This proposal would be applicable where an applicant and a stringent regulatory authority (SRA) can agree to share information on an innovator FPP with WHO. WHO will then consider such an FPP for inclusion in the list of WHO-prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe guide summarizing this proposal was discussed. A definition of SRAs and stability conditions prevailing in hot and humid countries are specially included in this document. A comment was made regarding the possible expansion of NMRAs beyond SRA, i.e. ICH and associated members.\n\nThe Expert Committee adopted the guide as amended (Annex 11).\n\n## 11. Prequalification of quality control laboratories\n\n### 11.1 Update of activities\n\nThe Prequalification of Quality Control Laboratories Programme was established in 2004 for quality control laboratories in Africa. It is a voluntary", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Precalificaci\u00f3n de Medicamentos**: El informe destaca la importancia del Programa de Precalificaci\u00f3n de Medicamentos de la OMS, se\u00f1alando que los productos precalificados tienen una tasa de fallos significativamente menor en estudios sobre medicamentos antipal\u00fadicos y antituberculosos en comparaci\u00f3n con los productos no precalificados.\n\n2. **Modificaciones al Procedimiento de Precalificaci\u00f3n**: Se discuten modificaciones propuestas al procedimiento existente para la precalificaci\u00f3n de productos farmac\u00e9uticos, que fueron adoptadas por el Comit\u00e9, sujeto a la consulta con el Asesor Legal de la OMS.\n\n3. **Gu\u00eda para la Documentaci\u00f3n de Productos Innovadores**: Se presenta una gu\u00eda para facilitar la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas, con el objetivo de incluir estos productos en la lista de productos precalificados por la OMS.\n\n4. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad**: Se menciona la creaci\u00f3n del Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad en 2004, destinado a laboratorios en \u00c1frica, como un esfuerzo voluntario para asegurar la calidad en el control de medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los indicadores clave que demuestran la efectividad del Programa de Precalificaci\u00f3n de Medicamentos de la OMS en comparaci\u00f3n con productos no precalificados?**\n   - Respuesta: La tasa de fallos de los productos precalificados en estudios sobre medicamentos antipal\u00fadicos y antituberculosos es significativamente menor que la de los productos no precalificados, lo que indica una mayor efectividad y confiabilidad de los productos precalificados.\n\n2. **\u00bfQu\u00e9 modificaciones espec\u00edficas se propusieron al procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos y cu\u00e1l es el proceso para su adopci\u00f3n final?**\n   - Respuesta: Se propusieron modificaciones al procedimiento existente, que fueron adoptadas por el Comit\u00e9, siempre que no se recibieran comentarios importantes durante el per\u00edodo de consulta restante y con la condici\u00f3n de que se consultara a la Asesor\u00eda Legal de la OMS durante el proceso de actualizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 criterios se establecen en la gu\u00eda para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos innovadores aprobados por autoridades regulatorias estrictas?**\n   - Respuesta: La gu\u00eda establece que se facilitar\u00e1 la presentaci\u00f3n de documentaci\u00f3n para productos aprobados por autoridades regulatorias estrictas, siempre que el solicitante y la autoridad puedan acordar compartir informaci\u00f3n con la OMS, y se incluyen definiciones de autoridades regulatorias estrictas (SRA) y condiciones de estabilidad en pa\u00edses c\u00e1lidos y h\u00famedos.", "prev_section_summary": "### Temas Clave:\n\n1. **Calidad de Medicamentos Antimal\u00e1ricos**: Se realiz\u00f3 una encuesta sobre la calidad de antimal\u00e1ricos, donde se analizaron 306 muestras. De estas, el 28.5% no cumpli\u00f3 con las especificaciones, lo que indica un problema significativo en la calidad de los medicamentos en los canales de distribuci\u00f3n.\n\n2. **Comparaci\u00f3n de M\u00e9todos de Prueba**: Se observ\u00f3 que los m\u00e9todos de cribado tienen una sensibilidad considerablemente menor para detectar incumplimientos en pruebas de disoluci\u00f3n y an\u00e1lisis de sustancias relacionadas, con tasas de detecci\u00f3n del 15% y 42%, respectivamente.\n\n3. **Diferencias entre Productos Precalificados y No Precalificados**: Los productos no precalificados por la OMS presentaron una tasa de fallos m\u00e1s de 10 veces mayor que los productos precalificados, lo que resalta la importancia de la precalificaci\u00f3n en la reducci\u00f3n del riesgo de calidad.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 enfatiz\u00f3 la necesidad de utilizar pruebas de control de calidad de laboratorio en decisiones regulatorias y forenses, y recomend\u00f3 la publicaci\u00f3n de los resultados de la encuesta para aumentar la conciencia sobre la calidad de los medicamentos.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Coordin\u00f3 las pruebas y supervis\u00f3 la calidad de los medicamentos.\n- **The International Pharmacopoeia**: Se utilizaron sus especificaciones para las pruebas de calidad.\n- **Medicamentos Antimal\u00e1ricos**: El foco principal de la encuesta.\n- **Medicamentos Antituberculosis**: Se mencion\u00f3 una encuesta adicional realizada en 2009 en Europa del Este y Estados Independientes Nuevos (NIS).\n- **Comit\u00e9 de Expertos**: Grupo que revis\u00f3 y recomend\u00f3 acciones basadas en los resultados de la encuesta.\n\nEste resumen destaca los problemas de calidad en los medicamentos antimal\u00e1ricos, la efectividad de los m\u00e9todos de prueba, la importancia de la precalificaci\u00f3n y las recomendaciones para mejorar la regulaci\u00f3n y la conciencia sobre la calidad de los medicamentos.", "excerpt_keywords": "Keywords: Prequalification, Pharmaceuticals, Quality Control, Regulatory Authorities, WHO"}}, "354bc02a-4e1c-47f3-a7f9-1a7434b7b944": {"node_ids": ["5be04e97-dd90-42e6-8f48-fed6c01cefe3"], "metadata": {"page_label": "54", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda rodear el documento:\n\n### Resumen del Contexto\nEl documento mencionado es parte de la Serie de Informes T\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el Informe 961. Esta serie se centra en la investigaci\u00f3n y las recomendaciones sobre temas de salud p\u00fablica, pol\u00edticas de salud, y pr\u00e1cticas m\u00e9dicas. Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, es probable que aborde temas relevantes para la salud global, la prevenci\u00f3n de enfermedades, y el desarrollo de pol\u00edticas sanitarias.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe 961 sobre la prevenci\u00f3n de enfermedades infecciosas?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS podr\u00eda haber emitido en este informe en particular.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas de investigaci\u00f3n se discuten en el Informe 961 para evaluar la efectividad de las intervenciones de salud p\u00fablica?**\n   - Esta pregunta se centra en las t\u00e9cnicas o enfoques que la OMS podr\u00eda haber utilizado o recomendado para medir el impacto de las pol\u00edticas de salud.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 961 con otros informes anteriores de la OMS en t\u00e9rminos de evoluci\u00f3n de las pol\u00edticas de salud global?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda proporcionar una visi\u00f3n sobre c\u00f3mo han cambiado las recomendaciones y enfoques a lo largo del tiempo.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, y que son relevantes para el contexto de salud p\u00fablica abordado por la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Programa de Precalificaci\u00f3n de Medicamentos de la OMS**:\n   - Importancia del programa en la reducci\u00f3n de la tasa de fallos de productos precalificados en comparaci\u00f3n con productos no precalificados, especialmente en medicamentos antipal\u00fadicos y antituberculosos.\n\n2. **Modificaciones al Procedimiento de Precalificaci\u00f3n**:\n   - Se discutieron y adoptaron modificaciones al procedimiento existente para la precalificaci\u00f3n de productos farmac\u00e9uticos, con la condici\u00f3n de que no se recibieran comentarios significativos durante el per\u00edodo de consulta y que se consultara a la Asesor\u00eda Legal de la OMS.\n\n3. **Gu\u00eda para la Documentaci\u00f3n de Productos Innovadores**:\n   - Se present\u00f3 una gu\u00eda para facilitar la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas (SRA). Esta gu\u00eda incluye definiciones de SRA y condiciones de estabilidad en climas c\u00e1lidos y h\u00famedos.\n\n4. **Programa de Precalificaci\u00f3n de Laboratorios de Control de Calidad**:\n   - Establecido en 2004, este programa se centra en laboratorios de control de calidad en \u00c1frica y es un esfuerzo voluntario para asegurar la calidad en el control de medicamentos.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Responsable de la implementaci\u00f3n y supervisi\u00f3n del Programa de Precalificaci\u00f3n de Medicamentos y de la gu\u00eda para la documentaci\u00f3n de productos innovadores.\n- **Comit\u00e9 de Expertos**: Grupo que revisa y adopta modificaciones y gu\u00edas relacionadas con la precalificaci\u00f3n de medicamentos.\n- **Autoridades Regulatorias Estrictas (SRA)**: Entidades que eval\u00faan productos farmac\u00e9uticos bajo est\u00e1ndares rigurosos de calidad, seguridad y eficacia.\n- **Laboratorios de Control de Calidad**: Instituciones que participan en el Programa de Precalificaci\u00f3n para asegurar la calidad de los medicamentos en \u00c1frica.", "excerpt_keywords": "Keywords: OMS, precalificaci\u00f3n, medicamentos, salud p\u00fablica, pol\u00edticas sanitarias"}}, "029fdbe0-b0dc-48e2-9ad5-1d5882355445": {"node_ids": ["6cf14604-33db-4c89-82aa-9608279f1a21"], "metadata": {"page_label": "55", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Update on WHO Guidelines\n\npharmaceutical products also led to the need for some amendments of the procedure for prequalification of quality control laboratories.\n\nThe first draft revision of the procedure was mailed out for comments in March 2010 and discussed during the informal consultation held on 10\u201312 May 2010. Based on this discussion the second draft was prepared and submitted to the WHO Legal Counsel for comments. The comments of the WHO Legal Counsel were implemented in this third draft revision.\n\nOn the basis of the above, the revised text is proposed to replace the previously published procedure.\n\nThe discussion focused on the cooperation with other authorities doing audits. The proposal includes rules for prioritization of laboratories applying for prequalification and rules for monitoring of laboratories after prequalification.\n\nIt was suggested to include United Nations agencies in the appropriate paragraphs of the revised procedure.\n\nThe new procedure was adopted including the changes proposed and discussed (Annex 12).\n\n## 11.3 Update on the WHO guidelines for preparing a laboratory information file\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to the *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have been recently revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both guidelines at its forty-third meeting in 2008 and recommended that if the WHO guidelines on *Good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above the revised text is proposed to replace the previously published guidelines. It was presented in track-change mode in order to show the changes that had been made.\n\nThe Expert Committee adopted the revised guidelines as proposed (Annex 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona una actualizaci\u00f3n sobre las directrices de la OMS relacionadas con la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se menciona la revisi\u00f3n de procedimientos y directrices, incluyendo la cooperaci\u00f3n con otras autoridades y la inclusi\u00f3n de agencias de las Naciones Unidas. Tambi\u00e9n se discute la necesidad de revisar las directrices sobre buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico y c\u00f3mo estas revisiones est\u00e1n interrelacionadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales modificaciones propuestas en el procedimiento de precalificaci\u00f3n de laboratorios de control de calidad seg\u00fan la discusi\u00f3n de mayo de 2010?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las modificaciones discutidas y adoptadas en el nuevo procedimiento.\n\n2. **\u00bfQu\u00e9 relaci\u00f3n existe entre las *Guidelines for preparing a laboratory information file* y las *WHO guidelines on good practices for pharmaceutical quality control laboratories*?**\n   - Esta pregunta se centra en la conexi\u00f3n entre las dos directrices y c\u00f3mo se influencian mutuamente.\n\n3. **\u00bfQu\u00e9 recomendaciones se hicieron en la reuni\u00f3n del Comit\u00e9 de Expertos de la OMS en 2008 respecto a la revisi\u00f3n de las directrices de preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio?**\n   - Esta pregunta busca informaci\u00f3n sobre las recomendaciones espec\u00edficas que llevaron a la revisi\u00f3n de las directrices.\n\n### Resumen de Nivel Superior\n\nEl documento detalla las actualizaciones en las directrices de la OMS para la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se discuten las revisiones necesarias y la cooperaci\u00f3n con otras autoridades, as\u00ed como la adopci\u00f3n de nuevas directrices que reflejan cambios en el enfoque de la OMS hacia la calidad en el control farmac\u00e9utico.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Documento:** WHO - Technical Report Series 961  \n**Tipo de Documento:** Informe T\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS)  \n**Contenido General:** Aunque el contenido espec\u00edfico no est\u00e1 disponible, se infiere que el informe aborda temas relacionados con la salud p\u00fablica, pol\u00edticas de salud y pr\u00e1cticas m\u00e9dicas. \n\n#### Temas Clave:\n1. **Prevenci\u00f3n de Enfermedades:** Posibles recomendaciones y directrices de la OMS sobre c\u00f3mo prevenir enfermedades infecciosas.\n2. **Investigaci\u00f3n en Salud P\u00fablica:** Metodolog\u00edas para evaluar la efectividad de intervenciones en salud p\u00fablica.\n3. **Evoluci\u00f3n de Pol\u00edticas de Salud:** Comparaci\u00f3n y conexi\u00f3n con informes anteriores de la OMS, analizando c\u00f3mo han cambiado las recomendaciones a lo largo del tiempo.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico (Informe 961):** Parte de la serie de informes que aborda temas de salud global.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en el contexto del Informe 961 de la OMS, destacando su enfoque en la salud p\u00fablica y la prevenci\u00f3n de enfermedades.", "excerpt_keywords": "Keywords: WHO guidelines, laboratory prequalification, quality control, pharmaceutical preparations, good practices"}}, "578a1f9a-5c3a-4f83-9bd3-cecea869edc2": {"node_ids": ["c3bb808f-8705-42da-b258-e8d8e8818aa4"], "metadata": {"page_label": "56", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Prequalification of active pharmaceutical ingredients\n\nThe Manager of the WHO Prequalification of Medicines Programme provided an update on the Programme and the prequalification of active pharmaceutical ingredients (APIs).\n\nThe Programme facilitates access to quality medicines through assessment of products and inspection of manufacturing sites. Since good-quality APIs are vital to the production of good-quality medicines, and in response to requests from Member States, the Programme has started a pilot project to prequalify APIs. Details of the pilot project are posted on the Prequalification of Medicines Programme web site.\n\nThe API prequalification procedure, which will guide this process, was adopted by the Expert Committee in 2008 and is published as Annex 4 in the WHO Technical Report Series, No. 953, Annex 4.\n\nPrequalification of APIs consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements. Prequalification of an API is done with specific reference to the manufacturing details and quality controls described in the APIMF submitted for assessment.\n\nWHO-prequalified APIs are listed on the WHO List of prequalified active pharmaceutical ingredients. The list provides United Nations agencies, NMRAs and others with information on APIs that have been found to meet WHO-recommended quality standards. It is believed that identification of sources of good-quality APIs will facilitate the manufacture of good-quality FPPs needed for procurement by United Nations agencies and disease treatment programmes.\n\nThe Expert Committee noted with appreciation these new developments.\n\n# 13. Regulatory guidance\n\n## 13.1 WHO guidelines for preparing a site master file\n\nThe Committee was informed about the current style used in the WHO Prequalification of Medicines Programme for the submission of a site master file (SMF) and its intent to review it through the Expert Committee and the related consultation process. The SMF has been in place for a number of years within the context of the inspections carried out in the Prequalification of Medicines Programme. When the document including the SMF was circulated globally, numerous comments were received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs)**: La OMS ha iniciado un proyecto piloto para la precalificaci\u00f3n de APIs, que es esencial para garantizar la calidad de los medicamentos. Este proceso incluye la evaluaci\u00f3n de archivos maestros de APIs y la inspecci\u00f3n de los sitios de fabricaci\u00f3n para asegurar el cumplimiento de las normas y est\u00e1ndares de la OMS.\n\n2. **Gu\u00edas Regulatorias de la OMS**: La OMS est\u00e1 revisando las directrices para la preparaci\u00f3n de un archivo maestro del sitio (SMF) en el contexto de su Programa de Precalificaci\u00f3n de Medicamentos. Este documento ha sido utilizado durante varios a\u00f1os y ha recibido comentarios globales para su mejora.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los dos componentes principales del procedimiento de precalificaci\u00f3n de APIs seg\u00fan la OMS?**\n   - Respuesta: Los dos componentes principales son la evaluaci\u00f3n del archivo maestro de API (APIMF) para verificar el cumplimiento con las normas y est\u00e1ndares de la OMS, y la evaluaci\u00f3n de los sitios de fabricaci\u00f3n de API para verificar el cumplimiento con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) de la OMS.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n proporciona la lista de APIs precalificadas por la OMS a las agencias de la ONU y a las Autoridades Nacionales Reguladoras de Medicamentos (NMRAs)?**\n   - Respuesta: La lista proporciona informaci\u00f3n sobre los APIs que han sido encontrados en cumplimiento con los est\u00e1ndares de calidad recomendados por la OMS, facilitando as\u00ed la identificaci\u00f3n de fuentes de APIs de buena calidad para la fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs).\n\n3. **\u00bfQu\u00e9 cambios se est\u00e1n considerando en el archivo maestro del sitio (SMF) y por qu\u00e9?**\n   - Respuesta: Se est\u00e1 considerando una revisi\u00f3n del estilo actual del SMF utilizado en el Programa de Precalificaci\u00f3n de Medicamentos de la OMS, debido a los numerosos comentarios recibidos globalmente tras la circulaci\u00f3n del documento. Esto busca mejorar la claridad y efectividad del SMF en el contexto de las inspecciones.", "prev_section_summary": "### Temas Clave\n\n1. **Revisi\u00f3n de Procedimientos de Precalificaci\u00f3n**: Se discuten enmiendas al procedimiento de precalificaci\u00f3n de laboratorios de control de calidad, incluyendo la priorizaci\u00f3n de solicitudes y el monitoreo post-precalificaci\u00f3n.\n\n2. **Cooperaci\u00f3n con Otras Autoridades**: Se enfatiza la importancia de colaborar con otras autoridades que realizan auditor\u00edas, as\u00ed como la inclusi\u00f3n de agencias de las Naciones Unidas en el procedimiento revisado.\n\n3. **Actualizaci\u00f3n de Directrices**: Se presenta una actualizaci\u00f3n sobre las *Guidelines for preparing a laboratory information file* y su relaci\u00f3n con las *WHO guidelines on good practices for pharmaceutical quality control laboratories*.\n\n4. **Recomendaciones del Comit\u00e9 de Expertos**: En 2008, se recomend\u00f3 la revisi\u00f3n de las directrices de preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio en funci\u00f3n de las revisiones de las directrices sobre buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de la elaboraci\u00f3n y revisi\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopta y revisa las directrices relacionadas con la calidad farmac\u00e9utica.\n- **Agencias de las Naciones Unidas**: Se sugiere su inclusi\u00f3n en el procedimiento revisado para mejorar la cooperaci\u00f3n.\n\n### Resumen General\n\nEl documento aborda las actualizaciones en las directrices de la OMS sobre la precalificaci\u00f3n de laboratorios de control de calidad y la preparaci\u00f3n de archivos de informaci\u00f3n de laboratorio. Se destacan las revisiones necesarias, la cooperaci\u00f3n con otras autoridades y la adopci\u00f3n de nuevas directrices que reflejan un enfoque renovado hacia la calidad en el control farmac\u00e9utico.", "excerpt_keywords": "Keywords: prequalification, active pharmaceutical ingredients, WHO guidelines, site master file, quality standards"}}, "c688a84f-539f-41c4-944a-430f5b7f3294": {"node_ids": ["0d72cca8-2cfe-4d80-93d8-44b00852c8fe"], "metadata": {"page_label": "57", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Based on the new developments and the comments received, the proposal was made to align the current WHO format with the new PIC/S format which was being finalized. This would address the majority of the comments received and be in line with the intent to harmonize internationally.\n\nThe Expert Committee recommended that the current WHO format used in prequalification be harmonized with the new PIC/S format and adopted the site master file (Annex 14).\n\n### 13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format\n\nThe document was presented to the Expert Committee together with the guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part. It was proposed to create a short document explaining how the two documents fitted together to assist NMRAs and companies in implementing the documents.\n\nThe Expert Committee adopted these guidelines with a view to enhancing exchange of information between NMRAs and also the Prequalification of Medicines Programme (Annex 15).\n\n### 13.3 Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product: quality part\n\nThe newly proposed *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* was adapted from the one used in the WHO Prequalification of Medicines Programme with the intent to serve NMRAs wishing to update their generic medicine registration process. It was meant to be used together with the *Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): preparation of product dossiers (PDS) in common technical document (CTD) format* (see section 13.2).\n\nThe guidelines were developed with the intent to update and not to increase the requirements. It was considered to be helpful to developing countries wishing to update requirements for generics and would also assist in switching to a CTD format.\n\nNumerous comments were received, reviewed and discussed at the meeting. The ICH Q11 Manufacturing development of drug substances: treatment of starting materials, is expected to reach the deadline for public comment in the near future and should also be considered when further developing this document.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Harmonizaci\u00f3n de formatos**: Se propone alinear el formato actual de la OMS con el nuevo formato de PIC/S para abordar comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **Gu\u00edas para productos farmac\u00e9uticos multisource**: Se presentan nuevas gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos, con el objetivo de facilitar la actualizaci\u00f3n de los procesos de registro en las Autoridades Reguladoras Nacionales (NMRAs) y mejorar el intercambio de informaci\u00f3n.\n\n3. **Desarrollo de directrices**: Las nuevas directrices est\u00e1n dise\u00f1adas para actualizar los requisitos sin aumentarlos, ayudando especialmente a los pa\u00edses en desarrollo a adoptar un formato t\u00e9cnico com\u00fan (CTD) para la documentaci\u00f3n de productos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de la propuesta de alineaci\u00f3n entre el formato de la OMS y el formato de PIC/S?**\n   - El objetivo principal es abordar la mayor\u00eda de los comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **\u00bfC\u00f3mo se espera que las nuevas gu\u00edas sobre la presentaci\u00f3n de documentaci\u00f3n beneficien a las NMRAs y a las empresas?**\n   - Se espera que las nuevas gu\u00edas faciliten la actualizaci\u00f3n de los procesos de registro de medicamentos gen\u00e9ricos en las NMRAs y mejoren el intercambio de informaci\u00f3n entre estas autoridades y el Programa de Precalificaci\u00f3n de Medicamentos.\n\n3. **\u00bfQu\u00e9 se considera al desarrollar las nuevas directrices para productos farmac\u00e9uticos gen\u00e9ricos?**\n   - Se considera que las directrices est\u00e1n dise\u00f1adas para actualizar los requisitos existentes sin aumentarlos, lo que es especialmente \u00fatil para los pa\u00edses en desarrollo que buscan modernizar sus requisitos para medicamentos gen\u00e9ricos y facilitar la transici\u00f3n a un formato de documento t\u00e9cnico com\u00fan (CTD).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Precalificaci\u00f3n de Ingredientes Farmac\u00e9uticos Activos (APIs)**:\n   - La OMS ha iniciado un **proyecto piloto** para la precalificaci\u00f3n de APIs, esencial para asegurar la calidad de los medicamentos.\n   - El proceso incluye la **evaluaci\u00f3n del archivo maestro de API (APIMF)** y la **inspecci\u00f3n de los sitios de fabricaci\u00f3n** para verificar el cumplimiento de las normas y est\u00e1ndares de la OMS.\n   - La **lista de APIs precalificadas** por la OMS proporciona informaci\u00f3n a agencias de la ONU y Autoridades Nacionales Reguladoras de Medicamentos (NMRAs) sobre APIs que cumplen con los est\u00e1ndares de calidad recomendados.\n\n2. **Gu\u00edas Regulatorias de la OMS**:\n   - Se est\u00e1 revisando el **archivo maestro del sitio (SMF)** utilizado en el Programa de Precalificaci\u00f3n de Medicamentos, con el objetivo de mejorar su claridad y efectividad tras recibir numerosos comentarios globales.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la precalificaci\u00f3n de medicamentos y APIs.\n- **APIs (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que son esenciales para la producci\u00f3n de medicamentos de calidad.\n- **NMRAs (Autoridades Nacionales Reguladoras de Medicamentos)**: Entidades que regulan y supervisan la calidad de los medicamentos en sus respectivos pa\u00edses.\n- **FPPs (Productos Farmac\u00e9uticos Terminados)**: Medicamentos que se producen a partir de APIs precalificados.\n\nEste resumen destaca la importancia de la precalificaci\u00f3n de APIs y las gu\u00edas regulatorias de la OMS para garantizar el acceso a medicamentos de calidad a nivel global.", "excerpt_keywords": "Keywords: WHO, PIC/S, guidelines, multisource, harmonization"}}, "558b4ae6-3fd2-46af-9672-bfcc3e76ea40": {"node_ids": ["36d6631b-7702-4c7b-befd-8f39fce6a2c9"], "metadata": {"page_label": "58", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Committee noted that the guidelines were more advanced than the present ones used by a number of Member States.\n\nThe Expert Committee recommended that the document be provisionally adopted and that it should be issued in a pilot phase after consolidation of comments within the Prequalification of Medicines Programme.\n\n### 13.4 Pharmaceutical development for multisource (generic) pharmaceutical products\n\nThe Expert Committee was briefed on the progress regarding the new guidance on pharmaceutical development for multisource (generic) pharmaceutical products. The draft guidance was widely circulated for comments and underwent a major revision during the informal consultation in April 2010; thereafter numerous comments were received. The Expert Committee reviewed the feedback and considered that the comments received would need to be revisited by a group of experts. It was also suggested that the document be reorganized to follow the CTD format in order to bring it in line with the other approaches recommended by the Committee during the present meeting.\n\nThe Expert Committee recommended following the normal procedure, organizing an informal consultation and providing feedback to the next Expert Committee meeting.\n\n### 13.5 Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System\n\nThe WHO Collaborating Centre for Research on Bioequivalence Testing of Medicines in Frankfurt, Germany, provided a report with a proposal to update the *Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms* published in 2006, with a view to including the new medicines selected for inclusion in the Model list of Essential Medicines (EML) since 2006.\n\nThe Expert Committee members:\n\n- endorsed the follow-up and continuation of this update;\n- endorsed the efforts to update the list by adding the new EML entries through publication of those that are unambiguously classified in the report;\n- advised that WHO collaborating centres should be contacted and that laboratories collaborating in the development of new monographs for *The International Pharmacopoeia* should collaborate by possibly either undertaking the solubility studies or by providing APIs to the WHO Collaborating Centre in Frankfurt;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Adopci\u00f3n de nuevas directrices**: El Comit\u00e9 de Expertos recomend\u00f3 la adopci\u00f3n provisional de nuevas directrices que son m\u00e1s avanzadas que las actualmente utilizadas por varios Estados Miembros, sugiriendo que se emita en una fase piloto tras la consolidaci\u00f3n de comentarios.\n\n2. **Desarrollo farmac\u00e9utico para productos farmac\u00e9uticos multisource**: Se discuti\u00f3 el progreso de nuevas orientaciones sobre el desarrollo farmac\u00e9utico de productos gen\u00e9ricos, con la necesidad de revisar los comentarios recibidos y reorganizar el documento seg\u00fan el formato CTD.\n\n3. **Clasificaci\u00f3n de medicamentos en la Lista Modelo de Medicamentos Esenciales de la OMS**: Se present\u00f3 una propuesta para actualizar los requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata, con el objetivo de incluir nuevos medicamentos en la lista desde 2006, y se recomend\u00f3 la colaboraci\u00f3n entre centros y laboratorios para estudios de solubilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 se recomend\u00f3 respecto a la adopci\u00f3n de las nuevas directrices y cu\u00e1l es el siguiente paso propuesto?**\n   - Se recomend\u00f3 que el documento sea adoptado provisionalmente y que se emita en una fase piloto despu\u00e9s de consolidar los comentarios dentro del Programa de Precalificaci\u00f3n de Medicamentos.\n\n2. **\u00bfQu\u00e9 cambios se sugirieron para el documento sobre el desarrollo farmac\u00e9utico de productos multisource y por qu\u00e9?**\n   - Se sugiri\u00f3 reorganizar el documento para seguir el formato CTD, con el fin de alinearlo con otros enfoques recomendados por el Comit\u00e9, tras recibir numerosos comentarios durante la consulta informal.\n\n3. **\u00bfCu\u00e1l fue la propuesta presentada por el Centro Colaborador de la OMS en Frankfurt respecto a la bioequivalencia y qu\u00e9 acciones se recomendaron?**\n   - Se propuso actualizar el documento sobre la exenci\u00f3n de requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales, y se recomend\u00f3 contactar a centros colaboradores y laboratorios para realizar estudios de solubilidad o proporcionar APIs.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Harmonizaci\u00f3n de formatos**:\n   - Se propone alinear el formato actual de la OMS con el nuevo formato de PIC/S, con el objetivo de abordar comentarios recibidos y promover la armonizaci\u00f3n internacional en la precalificaci\u00f3n de medicamentos.\n\n2. **Gu\u00edas para productos farmac\u00e9uticos multisource**:\n   - Se presentan nuevas gu\u00edas para la presentaci\u00f3n de documentaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos (FPP), que buscan facilitar la actualizaci\u00f3n de los procesos de registro en las Autoridades Reguladoras Nacionales (NMRAs) y mejorar el intercambio de informaci\u00f3n entre estas y el Programa de Precalificaci\u00f3n de Medicamentos.\n\n3. **Desarrollo de directrices**:\n   - Las nuevas directrices est\u00e1n dise\u00f1adas para actualizar los requisitos existentes sin aumentarlos, lo que es especialmente \u00fatil para los pa\u00edses en desarrollo que buscan modernizar sus requisitos para medicamentos gen\u00e9ricos y facilitar la transici\u00f3n a un formato de documento t\u00e9cnico com\u00fan (CTD).\n\n### Entidades mencionadas:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n que propone la alineaci\u00f3n de formatos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n cuyo formato se busca adoptar.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades que se beneficiar\u00e1n de las nuevas gu\u00edas.\n- **ICH (International Council for Harmonisation)**: Consejo que est\u00e1 desarrollando directrices relacionadas con la fabricaci\u00f3n de sustancias farmac\u00e9uticas. \n\n### Conclusi\u00f3n:\nLa secci\u00f3n aborda la necesidad de armonizar los formatos de documentaci\u00f3n para la precalificaci\u00f3n de medicamentos, presentando nuevas gu\u00edas que faciliten la actualizaci\u00f3n de procesos en las NMRAs y apoyen a los pa\u00edses en desarrollo en la adopci\u00f3n de est\u00e1ndares internacionales.", "excerpt_keywords": "Keywords: guidelines, pharmaceutical development, bioequivalence, essential medicines, WHO"}}, "4d470028-b78e-436e-ba7d-6b59b593418c": {"node_ids": ["ea0ffe74-7b38-48cc-a630-44d8541e9c77"], "metadata": {"page_label": "59", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Development of paediatric medicines: pharmaceutical development\n\nThe document summarizing the *Points to consider in the development of paediatric medicines: pharmaceutical development* was discussed at the informal WHO consultation on pharmaceutical development of paediatric medicines and pharmaceutical development for multisource (generic) pharmaceutical products, which was held in Geneva on 29\u201330 April 2010.\n\nThe Expert Committee was provided with a short history of the document, including previous comments and proposed further revision. It reviewed the main comments in detail.\n\nThe Expert Committee recommended that taste-masking and palatability should be addressed in more detail in the text provided, with special reference to other WHO documents, including, e.g. the one on zinc tablets.\n\nThe Expert Committee recommended that the revised version of this document should again be circulated widely for comments, including to the paediatric regulatory network. Progress would be reported to the next Expert Committee meeting.\n\nThe Committee noted that the guidelines currently under development did not include any details on extemporaneous preparations. The Expert Committee recommended that the paediatric regulatory network, and especially the group dealing with extemporaneous preparations, take advantage of the expertise provided by this Expert Committee.\n\n# Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients\n\nThe Secretariat briefed the Expert Committee on the history and purpose of the document which was prepared in response to the need expressed by major donor organizations.\n\nIt was discussed that on various occasions the quality control specifications applicable to active substances are used not only per se but also as starting materials for the production of other active substances. An illustrative example was provided.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento discutido en la consulta informal de la OMS sobre el desarrollo de medicamentos pedi\u00e1tricos aborda aspectos clave en la formulaci\u00f3n y desarrollo de medicamentos para ni\u00f1os, incluyendo la importancia de la palatabilidad y el enmascaramiento del sabor. Se recomienda que el documento revisado se comparta ampliamente para recibir comentarios, especialmente del grupo regulador pedi\u00e1trico. Adem\u00e1s, se menciona la necesidad de establecer requisitos de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos activos antimal\u00e1ricos, en respuesta a las necesidades de organizaciones donantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos sobre el enmascaramiento del sabor y la palatabilidad se sugiri\u00f3 que se incluyeran en el documento revisado sobre medicamentos pedi\u00e1tricos?**\n   - La Expert Committee recomend\u00f3 que se abordara el enmascaramiento del sabor y la palatabilidad en m\u00e1s detalle, haciendo referencia a otros documentos de la OMS, como el que trata sobre tabletas de zinc.\n\n2. **\u00bfCu\u00e1l es la importancia de la red reguladora pedi\u00e1trica en el contexto del desarrollo de medicamentos pedi\u00e1tricos seg\u00fan el documento?**\n   - La red reguladora pedi\u00e1trica es crucial para proporcionar comentarios sobre el documento revisado y se sugiere que aproveche la experiencia del Comit\u00e9 de Expertos, especialmente en lo que respecta a las preparaciones extempor\u00e1neas.\n\n3. **\u00bfQu\u00e9 se discuti\u00f3 sobre las especificaciones de control de calidad aplicables a las sustancias activas en el contexto de la producci\u00f3n de ingredientes farmac\u00e9uticos antimal\u00e1ricos?**\n   - Se discuti\u00f3 que las especificaciones de control de calidad para las sustancias activas no solo se utilizan por s\u00ed mismas, sino tambi\u00e9n como materias primas para la producci\u00f3n de otras sustancias activas, lo que subraya la importancia de establecer requisitos de calidad adecuados.", "prev_section_summary": "### Temas Clave\n\n1. **Adopci\u00f3n de Nuevas Directrices**: Se recomienda la adopci\u00f3n provisional de nuevas directrices m\u00e1s avanzadas que las actualmente utilizadas por varios Estados Miembros, con la intenci\u00f3n de emitirlas en una fase piloto tras la consolidaci\u00f3n de comentarios.\n\n2. **Desarrollo Farmac\u00e9utico para Productos Gen\u00e9ricos**: Se discute el progreso en la elaboraci\u00f3n de nuevas orientaciones sobre el desarrollo farmac\u00e9utico de productos multisource (gen\u00e9ricos). Se sugiere reorganizar el documento seg\u00fan el formato CTD y realizar una consulta informal para revisar los comentarios recibidos.\n\n3. **Clasificaci\u00f3n de Medicamentos en la Lista Modelo de Medicamentos Esenciales**: Se presenta una propuesta para actualizar los requisitos de bioequivalencia in vivo para medicamentos de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales, con el objetivo de incluir nuevos medicamentos desde 2006. Se recomienda la colaboraci\u00f3n entre centros y laboratorios para realizar estudios de solubilidad.\n\n### Entidades\n\n- **Comit\u00e9 de Expertos**: Grupo que revisa y recomienda acciones sobre directrices y documentos relacionados con medicamentos.\n- **Programa de Precalificaci\u00f3n de Medicamentos**: Iniciativa de la OMS para asegurar la calidad de los medicamentos.\n- **Centro Colaborador de la OMS en Frankfurt**: Entidad que proporciona informes y propuestas sobre bioequivalencia.\n- **Lista Modelo de Medicamentos Esenciales (EML)**: Lista de medicamentos considerados esenciales por la OMS.\n- **CTD (Common Technical Document)**: Formato recomendado para la presentaci\u00f3n de informaci\u00f3n sobre medicamentos.\n\nEste resumen destaca los puntos clave y las entidades involucradas en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: paediatric medicines, taste-masking, quality control, artemisinin, pharmaceutical development"}}, "cbd2c5d4-241d-4509-9841-cdb001ad0149": {"node_ids": ["ac122610-e46f-4792-8cbd-3fc19d40f92d"], "metadata": {"page_label": "60", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "example is artemisinin which is an important API itself and also serves as a starting material for the production of artemisinin-derived antimalarials.\n\nThe main challenge identified is that some national authorities require the same quality standard for an API and for a starting material. However, it was considered sufficient that a starting material has a quality that guarantees that the final product meets a relevant pharmacopoeial standard. Demanding a quality for a starting material that is too exacting will increase the price and in consequence reduce the availability of the API.\n\nWorking document QAS/10.349/Rev.1 has been prepared to clarify the need for different quality levels. It includes a specification for artemisinin used as a starting material for the synthesis of artemisinin derivatives.\n\nThe original paper was circulated for comments in March\u2013April 2010. Comments were consolidated and the revised draft, based on an additional review by a subgroup of experts in August 2010, was presented to the Expert Committee.\n\nThe assignment of possible impurities to signals in the chromatographic assay for related substances is based on literature data and regarded as tentative until further experimental validation has been obtained.\n\nFinalization of the impurity profile was required and would determine when the document could be discussed. The manufacturer was contacted to submit the starting material needed to carry out the analyses at the laboratory level.\n\nIt was noted that a WHO botanical \u201cmonograph\u201d was available which detailed the cultivation and collection of the starting material.\n\nThe Expert Committee recognized the need to finalize the impurity profile before the document could be completed. It further recommended that the document be revised by a subgroup of experts in light of the comments received.\n\n## 14. Nomenclature, terminology and databases\n\n### 14.1 New definition for \u201csubstandard medicines\u201d\n\nIn connection with the discussions during the meetings of the WHO governing bodies, the terminology for \u201csubstandard medicines\u201d was raised during the forty-fourth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\nWithin the context of the work of this Expert Committee no officially adopted definition currently existed for \u201csubstandard medicines\u201d. As this question was frequently raised a \u201cQuestion and Answer\u201d section had been introduced on the WHO web site. On the basis of this the Expert Committee proposed during its 44th meeting to circulate a slightly modified proposal for the elaboration of a new definition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Desaf\u00edos en la regulaci\u00f3n de materias primas farmac\u00e9uticas**: El texto discute la problem\u00e1tica que enfrentan las autoridades nacionales al exigir est\u00e1ndares de calidad id\u00e9nticos para los ingredientes farmac\u00e9uticos activos (API) y los materiales de partida. Se argumenta que un est\u00e1ndar de calidad adecuado para los materiales de partida es suficiente si garantiza que el producto final cumpla con los est\u00e1ndares farmacop\u00e9icos relevantes.\n\n2. **Desarrollo de documentos de especificaci\u00f3n**: Se menciona el trabajo realizado en el documento QAS/10.349/Rev.1, que busca aclarar la necesidad de diferentes niveles de calidad para los materiales de partida, espec\u00edficamente para la artemisinina, un API importante. Este documento ha pasado por varias revisiones y se requiere la finalizaci\u00f3n del perfil de impurezas antes de su discusi\u00f3n final.\n\n3. **Terminolog\u00eda sobre medicamentos subest\u00e1ndar**: Se aborda la falta de una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\" en el contexto de las discusiones de la OMS. Se propone la elaboraci\u00f3n de una nueva definici\u00f3n, destacando la importancia de establecer un marco terminol\u00f3gico claro en el \u00e1mbito farmac\u00e9utico.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfPor qu\u00e9 se considera suficiente que un material de partida tenga un est\u00e1ndar de calidad que garantice que el producto final cumpla con un est\u00e1ndar farmacop\u00e9ico relevante?**\n   - Esta pregunta busca profundizar en la l\u00f3gica detr\u00e1s de la regulaci\u00f3n de calidad y c\u00f3mo se relaciona con la disponibilidad y el costo de los APIs.\n\n2. **\u00bfQu\u00e9 pasos se han tomado para finalizar el perfil de impurezas de la artemisinina y por qu\u00e9 es crucial para la discusi\u00f3n del documento QAS/10.349/Rev.1?**\n   - Esta pregunta se centra en el proceso de validaci\u00f3n y la importancia de los perfiles de impurezas en la regulaci\u00f3n de los materiales de partida.\n\n3. **\u00bfQu\u00e9 modificaciones se propusieron en la definici\u00f3n de \"medicamentos subest\u00e1ndar\" durante la 44\u00aa reuni\u00f3n del Comit\u00e9 de Expertos de la OMS?**\n   - Esta pregunta busca obtener detalles sobre las discusiones y propuestas espec\u00edficas que se hicieron en relaci\u00f3n con la terminolog\u00eda de medicamentos subest\u00e1ndar, lo que podr\u00eda no estar ampliamente documentado en otras fuentes.", "prev_section_summary": "### Temas Clave\n\n1. **Desarrollo de Medicamentos Pedi\u00e1tricos**:\n   - Se discutieron los *Puntos a considerar en el desarrollo de medicamentos pedi\u00e1tricos* en una consulta informal de la OMS.\n   - Se enfatiz\u00f3 la importancia del enmascaramiento del sabor y la palatabilidad en la formulaci\u00f3n de medicamentos para ni\u00f1os.\n   - Se recomend\u00f3 que el documento revisado se compartiera ampliamente para recibir comentarios, especialmente de la red reguladora pedi\u00e1trica.\n\n2. **Requisitos de Calidad para la Artemisinina**:\n   - Se abordaron las especificaciones de control de calidad para la artemisinina como materia prima en la producci\u00f3n de ingredientes farmac\u00e9uticos activos antimal\u00e1ricos.\n   - Se destac\u00f3 que estas especificaciones no solo se aplican a las sustancias activas en s\u00ed, sino tambi\u00e9n como materias primas para la producci\u00f3n de otras sustancias activas.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que facilit\u00f3 la consulta y discusi\u00f3n sobre el desarrollo de medicamentos pedi\u00e1tricos.\n- **Comit\u00e9 de Expertos**: Grupo que revis\u00f3 el documento y proporcion\u00f3 recomendaciones sobre el desarrollo de medicamentos pedi\u00e1tricos y la calidad de la artemisinina.\n- **Red Reguladora Pedi\u00e1trica**: Entidad recomendada para proporcionar comentarios sobre el documento revisado y aprovechar la experiencia del Comit\u00e9 de Expertos.\n- **Organizaciones Donantes**: Entidades que expresaron la necesidad de establecer requisitos de calidad para la artemisinina.", "excerpt_keywords": "Keywords: artemisinin, quality standards, pharmaceutical preparations, impurity profile, substandard medicines"}}, "a06d718b-4607-4c86-a9c3-dd5b6089e88d": {"node_ids": ["16cd16d3-72f1-45d5-80b5-739d23fdf9f6"], "metadata": {"page_label": "61", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The comments received upon circulation were reviewed during the following two WHO consultations which took place in Geneva: Quality assurance systems, medicines and risk analysis (4\u20136 May 2010); and Specifications for medicines and quality control laboratory issues (10\u201312 May 2010). An extensive discussion took place on the feedback received and additional input was provided by all experts who participated in the consultations. On the basis of this outcome a new revised definition was suggested and reviewed by the Expert Committee.\n\nThe Chair noted that it was not feasible to write a definition for every country in the world, but there was a need to provide sufficient background so that countries could interpret the underlying concepts. The Expert Committee recommended that the definition be reviewed by a legal expert to ensure that the text covers both standards and specifications in an appropriate manner.\n\nThe following new proposal was discussed based on the comments received and adopted by the Expert Committee:\n\n\u201cSubstandard medicines are pharmaceutical products that fail to meet either their quality standards or their specifications, or both.12\n\nEach pharmaceutical product that a manufacturer produces has to comply with quality assurance standards and specifications, at release and throughout its shelf-life, according to the requirements of the territory of use. Normally, these standards and specifications are reviewed, assessed and approved by the applicable national or regional medicines regulatory authority before the product is authorized for marketing.\u201d\n\n## 14.2 \u201cSpurious/falsely-labelled/falsified/counterfeit medicines\u201d\n\nIn connection with the discussions during the WHO governing bodies\u2019 meetings, the terminology for \u201ccounterfeit medicines\u201d has been raised since 2008. During the 63rd World Health Assembly the proposal was made that, until consensus could be reached, the following term should be used: \u201csubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d.\n\nWithin the context of the work of this Expert Committee, definitions for \u201ccounterfeit medicines\u201d were included in the glossary of the various WHO guidelines, e.g. in the WHO Good distribution practices for pharmaceutical products (40th report, 2006), the WHO Guidelines for inspection of drug distribution channels (35th report, 1999); and the WHO Guidelines on import procedures for pharmaceutical products (34th report, 1996).13\n\n----\n\n12 Modified after review by the WHO Legal Counsel.  \n13 WHO Database on Quality Assurance (http://www.who.int/medicines/services/expertcommittees/pharmprep/TermListcategory.pdf).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se centra en las discusiones y definiciones relacionadas con los medicamentos subest\u00e1ndar y falsificados, abordadas en consultas de la OMS en 2010. Se destaca la necesidad de establecer definiciones claras que puedan ser interpretadas por diferentes pa\u00edses, as\u00ed como la importancia de que los productos farmac\u00e9uticos cumplan con est\u00e1ndares de calidad y especificaciones aprobadas por las autoridades reguladoras. Adem\u00e1s, se menciona la evoluci\u00f3n del t\u00e9rmino \"medicamentos falsificados\" y la propuesta de un t\u00e9rmino m\u00e1s inclusivo que abarque varias categor\u00edas de productos m\u00e9dicos problem\u00e1ticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la definici\u00f3n adoptada por el Comit\u00e9 de Expertos de la OMS para los medicamentos subest\u00e1ndar y qu\u00e9 criterios deben cumplir los productos farmac\u00e9uticos?**\n   - Respuesta: Los medicamentos subest\u00e1ndar son aquellos productos farmac\u00e9uticos que no cumplen con sus est\u00e1ndares de calidad o especificaciones, o ambos. Cada producto debe cumplir con los est\u00e1ndares de calidad y especificaciones desde su liberaci\u00f3n y a lo largo de su vida \u00fatil, seg\u00fan los requisitos del territorio de uso.\n\n2. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos respecto a la revisi\u00f3n de la definici\u00f3n de medicamentos subest\u00e1ndar y qui\u00e9n deber\u00eda realizar esta revisi\u00f3n?**\n   - Respuesta: El Comit\u00e9 de Expertos recomend\u00f3 que la definici\u00f3n fuera revisada por un experto legal para asegurar que el texto cubriera adecuadamente tanto los est\u00e1ndares como las especificaciones.\n\n3. **\u00bfQu\u00e9 t\u00e9rmino se propuso utilizar en la 63\u00aa Asamblea Mundial de la Salud para referirse a los medicamentos falsificados y cu\u00e1l es su significado?**\n   - Respuesta: Se propuso utilizar el t\u00e9rmino \"substandard/spurious/falsely-labelled/falsified/counterfeit medical products\" hasta que se alcanzara un consenso. Este t\u00e9rmino abarca una variedad de productos m\u00e9dicos que pueden ser problem\u00e1ticos, incluyendo aquellos que son subest\u00e1ndar, falsamente etiquetados o falsificados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Desaf\u00edos en la Regulaci\u00f3n de Materias Primas Farmac\u00e9uticas**:\n   - Se discute la problem\u00e1tica de que algunas autoridades nacionales exigen los mismos est\u00e1ndares de calidad para los ingredientes farmac\u00e9uticos activos (API) y los materiales de partida. \n   - Se argumenta que un est\u00e1ndar de calidad adecuado para los materiales de partida es suficiente si asegura que el producto final cumpla con los est\u00e1ndares farmacop\u00e9icos relevantes.\n\n2. **Especificaci\u00f3n de Artemisinina**:\n   - Se menciona el documento de trabajo QAS/10.349/Rev.1, que busca aclarar la necesidad de diferentes niveles de calidad, espec\u00edficamente para la artemisinina, que es un API importante y material de partida para antimal\u00e1ricos derivados.\n   - El documento ha pasado por varias revisiones y se requiere la finalizaci\u00f3n del perfil de impurezas antes de su discusi\u00f3n final.\n\n3. **Terminolog\u00eda sobre Medicamentos Subest\u00e1ndar**:\n   - Se aborda la falta de una definici\u00f3n oficialmente adoptada para \"medicamentos subest\u00e1ndar\" en el contexto de las discusiones de la OMS.\n   - Se propone la elaboraci\u00f3n de una nueva definici\u00f3n, destacando la importancia de establecer un marco terminol\u00f3gico claro en el \u00e1mbito farmac\u00e9utico.\n\n### Entidades Clave\n- **Artemisinina**: Ingrediente farmac\u00e9utico activo y material de partida para la producci\u00f3n de antimal\u00e1ricos.\n- **Documento QAS/10.349/Rev.1**: Documento de trabajo que especifica los niveles de calidad para la artemisinina.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que discute y propone definiciones y est\u00e1ndares en el \u00e1mbito farmac\u00e9utico.\n- **Medicamentos Subest\u00e1ndar**: T\u00e9rmino que carece de una definici\u00f3n oficial en el contexto de la OMS, pero que se est\u00e1 trabajando para clarificar.\n\nEste resumen destaca los principales desaf\u00edos en la regulaci\u00f3n de materias primas farmac\u00e9uticas, el desarrollo de especificaciones para la artemisinina y la necesidad de una terminolog\u00eda clara sobre medicamentos subest\u00e1ndar.", "excerpt_keywords": "Keywords: substandard medicines, counterfeit medicines, quality assurance, WHO consultations, pharmaceutical standards"}}, "0403bbe6-f9ca-4ddf-b1b5-8fd54f73505d": {"node_ids": ["c2feba45-2e4d-4a22-b29d-813aa0654ee0"], "metadata": {"page_label": "62", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Within the context of the work of the IMPACT Annual Meeting held in December 2008 (Hammamet, Tunisia) and based on the work carried out in the IMPACT Working Group on Legislative and Regulatory Infrastructure, a new definition was developed. This definition is included in the document entitled *Draft principles and elements for national legislation against counterfeit medical products* which was sent out for comments.\n\nTriggered by the governing bodies' discussion, a Circular Letter was mailed inviting Member States to share the terms and details of what national legislations regarded as \u201ccounterfeit medicines\u201d. The feedback was summarized by specialists and posted as a preliminary report on the WHO website to allow for additional feedback. The responses of Member States to the Circular Letter of the Director-General of WHO were presented to the Expert Committee. They related to:\n\n- definitions of \u201ccounterfeit medicines\u201d in the Member States;\n- Member States\u2019 national legislation; and\n- definition included in the above-cited IMPACT document.\n\nIt was explained that different types of legislation address the problem in the various Member States, which led to the diversity of responses. Also, English is not necessarily the language used in the national or regional legislations, which adds to the complexity. Many Member States are, however, in line with the current WHO definition. The Expert Committee took note that, although the majority of Member States supported the IMPACT definition and document, a considerable number of Member States did not, for various reasons.\n\nThe Expert Committee members fully recognized that spurious/falsely-labelled/falsified/counterfeit medical products presented a major public health problem. Several political and technical issues were raised. There was discussion whether or not APIs and excipients should be included in the definition and whether it was better to address \u201cmedicines\u201d only rather than the broader category of \u201cmedical products\u201d.\n\nThe Expert Committee took note that there was neither agreement among the Member States\u2019 definitions nor the terms used in the various legal contexts. However, several participants indicated that whatever the decision was on the future terminology within the WHO context, the word \u201ccounterfeit\u201d was already widely used by the public.\n\nDuring the 63rd World Health Assembly all Member States adopted by consensus the decision to have a working group on \u201cSubstandard/spurious/falsely-labelled/falsified/counterfeit medical products\u201d and had requested\n\n----\n\n[^14]: http://www.who.int/impact/resources/IMPACTthirdgeneralmeeting_%20report.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl contexto se centra en la reuni\u00f3n anual de IMPACT celebrada en diciembre de 2008 en Hammamet, T\u00fanez, donde se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\". Se solicit\u00f3 a los Estados Miembros que compartieran sus legislaciones nacionales sobre este tema, lo que result\u00f3 en una diversidad de respuestas debido a diferencias en los marcos legales y el uso de distintos idiomas. Aunque muchos Estados Miembros apoyaron la definici\u00f3n de la OMS, otros no lo hicieron por diversas razones. Se discutieron cuestiones pol\u00edticas y t\u00e9cnicas, incluyendo la inclusi\u00f3n de ingredientes activos y excipientes en la definici\u00f3n. Durante la 63\u00aa Asamblea Mundial de la Salud, se decidi\u00f3 establecer un grupo de trabajo sobre productos m\u00e9dicos subest\u00e1ndar y falsificados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les fueron las principales razones por las que algunos Estados Miembros no apoyaron la definici\u00f3n de \"medicamentos falsificados\" propuesta por la OMS?**\n   - Esta pregunta busca explorar las razones espec\u00edficas detr\u00e1s de la falta de consenso entre los Estados Miembros, que no se detallan en el contexto.\n\n2. **\u00bfQu\u00e9 tipo de legislaciones nacionales se identificaron en las respuestas de los Estados Miembros sobre los \"medicamentos falsificados\"?**\n   - Esta pregunta se centra en los diferentes enfoques legislativos que adoptan los Estados Miembros, lo que podr\u00eda proporcionar ejemplos concretos de c\u00f3mo se aborda el problema en distintas jurisdicciones.\n\n3. **\u00bfQu\u00e9 implicaciones pol\u00edticas y t\u00e9cnicas se discutieron en relaci\u00f3n con la inclusi\u00f3n de APIs y excipientes en la definici\u00f3n de \"medicamentos falsificados\"?**\n   - Esta pregunta busca profundizar en las discusiones espec\u00edficas que tuvieron lugar sobre la definici\u00f3n y c\u00f3mo estas implicaciones podr\u00edan afectar la regulaci\u00f3n y el control de productos m\u00e9dicos.", "prev_section_summary": "### Temas Clave\n\n1. **Definici\u00f3n de Medicamentos Subest\u00e1ndar**: Se establece que los medicamentos subest\u00e1ndar son aquellos que no cumplen con sus est\u00e1ndares de calidad o especificaciones, o ambos. Se enfatiza la necesidad de que cada producto farmac\u00e9utico cumpla con estos criterios desde su liberaci\u00f3n y a lo largo de su vida \u00fatil, conforme a los requisitos del territorio de uso.\n\n2. **Revisi\u00f3n de Definiciones**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 que la definici\u00f3n de medicamentos subest\u00e1ndar sea revisada por un experto legal para asegurar que aborde adecuadamente tanto los est\u00e1ndares como las especificaciones.\n\n3. **Terminolog\u00eda de Medicamentos Falsificados**: Se discute la evoluci\u00f3n del t\u00e9rmino \"medicamentos falsificados\" y se propone un t\u00e9rmino m\u00e1s inclusivo: \"substandard/spurious/falsely-labelled/falsified/counterfeit medical products\", que abarca diversas categor\u00edas de productos m\u00e9dicos problem\u00e1ticos.\n\n4. **Consultas de la OMS**: Se mencionan dos consultas de la OMS realizadas en Ginebra en 2010, donde se revisaron los comentarios recibidos y se discutieron las definiciones y est\u00e1ndares relacionados con la calidad de los medicamentos.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional que lidera las discusiones sobre est\u00e1ndares y definiciones de medicamentos.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que revisa y propone definiciones y est\u00e1ndares relacionados con los medicamentos.\n- **Asamblea Mundial de la Salud**: Evento donde se discuten temas de salud global, incluyendo la terminolog\u00eda de medicamentos falsificados.\n- **Autoridades Reguladoras Nacionales o Regionales**: Entidades que revisan, eval\u00faan y aprueban los est\u00e1ndares y especificaciones de los productos farmac\u00e9uticos antes de su comercializaci\u00f3n.", "excerpt_keywords": "Keywords: counterfeit medicines, WHO, IMPACT, public health, legislation"}}, "2f850563-9241-4302-9568-eb85e14ede57": {"node_ids": ["1242b20e-6ff8-491d-b960-ba331aacc7f8"], "metadata": {"page_label": "63", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the Director-General of WHO to convene a meeting to discuss this issue. It was, therefore, agreed that in light of the Member States\u2019 decision, a specially constituted working group would be the most appropriate forum to discuss this issue and that the Expert Committee on Specifications for Pharmaceutical Preparations should, therefore, not take the discussion further for the time being.\n\nIn summary, further to the discussions, the Expert Committee recommended that:\n\n- the working group of the Member States considers the WHO and the IMPACT definitions in order to develop an appropriate definition and include an explanation that will avoid confusion;\n- in so doing WHO should address the issue and its public health consequences instead of concentrating on the terminologies; and\n- as the first step, the work of this Committee should concentrate on medicines.\n\n### 14.3 International Nonproprietary Names (INN) for pharmaceutical substances\n\nVarious background materials including the cumulative list of International Nonproprietary Names (INN) were presented by the Manager of the INN Programme, including the use of stems and radicals in the selection of INN for pharmaceutical substances.\n\nINN online application architecture was described. It was scheduled for implementation with the USA being used as beta tester. A training programme for industry would be held in January\u2013February 2011. An instruction manual was available and two systems would be used at the beginning: online and also paper submissions.\n\nDuring 2009\u20132010, WHO published 299 Proposed INNs and 252 Recommended INNs in lists 101-104 of proposed and lists 61-64 of recommended INNs, respectively. Discussion was based around the number of new INNs, objections to proposed INNs and a recent request for substitution of a recommended INN due to possible confusion between two INNs.\n\nThe Expert Committee noted the report.\n\n### 15. Summary and recommendations\n\nThe Expert Committee on Specifications for Pharmaceutical Preparations provides recommendations and tools to assure the quality of medicines from their development phase to their final distribution to the patients. It advises the Director-General of WHO in the area of quality assurance of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones del Comit\u00e9 de Expertos**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas recomend\u00f3 la creaci\u00f3n de un grupo de trabajo de los Estados Miembros para desarrollar definiciones adecuadas y abordar las consecuencias de salud p\u00fablica relacionadas con la terminolog\u00eda, enfoc\u00e1ndose inicialmente en los medicamentos.\n\n2. **Nombres No Propietarios Internacionales (INN)**: Se present\u00f3 informaci\u00f3n sobre el uso de nombres no propietarios internacionales (INN) para sustancias farmac\u00e9uticas, incluyendo la arquitectura de la aplicaci\u00f3n en l\u00ednea para la gesti\u00f3n de INN, que se implementar\u00e1 con Estados Unidos como beta tester. Durante el per\u00edodo 2009-2010, se publicaron 299 INN propuestos y 252 INN recomendados.\n\n3. **Funci\u00f3n del Comit\u00e9 de Expertos**: El Comit\u00e9 proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final, asesorando al Director General de la OMS en temas de aseguramiento de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 se acord\u00f3 respecto a la discusi\u00f3n de las definiciones de la OMS y de IMPACT?**\n   - Se acord\u00f3 que un grupo de trabajo especialmente constituido ser\u00eda el foro m\u00e1s apropiado para discutir las definiciones de la OMS y de IMPACT, y que el Comit\u00e9 de Expertos no continuar\u00eda con la discusi\u00f3n por el momento.\n\n2. **\u00bfCu\u00e1ntos INN propuestos y recomendados public\u00f3 la OMS durante el per\u00edodo 2009-2010?**\n   - Durante el per\u00edodo 2009-2010, la OMS public\u00f3 299 INN propuestos y 252 INN recomendados.\n\n3. **\u00bfCu\u00e1l es el enfoque inicial del trabajo del Comit\u00e9 de Expertos en relaci\u00f3n con los medicamentos?**\n   - El enfoque inicial del trabajo del Comit\u00e9 de Expertos debe concentrarse en los medicamentos, abordando las definiciones y sus consecuencias en la salud p\u00fablica en lugar de centrarse \u00fanicamente en la terminolog\u00eda.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Definici\u00f3n de Medicamentos Falsificados:** Se desarroll\u00f3 una nueva definici\u00f3n de \"medicamentos falsificados\" durante la reuni\u00f3n anual de IMPACT en diciembre de 2008, que se incluy\u00f3 en un documento para comentarios.\n2. **Diversidad Legislativa:** Las respuestas de los Estados Miembros revelaron una diversidad en las definiciones y legislaciones nacionales sobre medicamentos falsificados, influenciada por diferencias en los marcos legales y el uso de distintos idiomas.\n3. **Apoyo y Oposici\u00f3n a la Definici\u00f3n de la OMS:** Aunque la mayor\u00eda de los Estados Miembros apoyaron la definici\u00f3n de la OMS, un n\u00famero considerable no lo hizo, lo que gener\u00f3 discusiones sobre las razones detr\u00e1s de esta falta de consenso.\n4. **Cuestiones Pol\u00edticas y T\u00e9cnicas:** Se discutieron implicaciones sobre si incluir ingredientes activos (APIs) y excipientes en la definici\u00f3n, as\u00ed como la preferencia por abordar solo \"medicamentos\" en lugar de \"productos m\u00e9dicos\" en general.\n5. **Creaci\u00f3n de un Grupo de Trabajo:** Durante la 63\u00aa Asamblea Mundial de la Salud, se decidi\u00f3 establecer un grupo de trabajo sobre productos m\u00e9dicos subest\u00e1ndar y falsificados.\n\n**Entidades:**\n- **IMPACT:** Grupo de trabajo que se centra en la infraestructura legislativa y regulatoria relacionada con los medicamentos falsificados.\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad que lidera la discusi\u00f3n y desarrollo de definiciones y principios sobre medicamentos falsificados.\n- **Estados Miembros:** Pa\u00edses que participan en la OMS y que proporcionan retroalimentaci\u00f3n sobre sus legislaciones nacionales.\n- **Comit\u00e9 de Expertos:** Grupo que revisa las respuestas de los Estados Miembros y discute las definiciones y t\u00e9rminos relacionados con los medicamentos falsificados. \n\nEste resumen destaca la importancia de la colaboraci\u00f3n internacional en la lucha contra los medicamentos falsificados y las complejidades que surgen de las diferencias legislativas y ling\u00fc\u00edsticas entre los Estados Miembros.", "excerpt_keywords": "Keywords: WHO, pharmaceutical preparations, International Nonproprietary Names, quality assurance, working group"}}, "9d4aa148-243b-4dca-a061-e3a0480c1bd6": {"node_ids": ["b93eac3e-dc0c-42ec-80d8-0e50e65779f4"], "metadata": {"page_label": "64", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The Expert Committee on Specifications for Pharmaceutical Preparations is looking back on a history of more than 60 years! The first meeting of the Expert Committee, named \u201cUnification on Pharmacopoeias\u201d at that time, was held in 1947. Since the inception of this WHO Expert Committee, its members have worked towards making available clear, independent and practical recommendations, written and physical standards, as well as international guidelines for quality medicines. Standards in the area of quality assurance for medicines are developed by the Committee through a wide international consensus building process. Detailed recommendations can be found under each relevant section in the report.\n\nThe activities discussed during this Expert Committee meeting have broad inter- and intrastructural relationships and links. There are joint activities, specifically with the WHO Expert Committees on Biological Standardization, and on the Selection and Use of Essential Medicines and its Subcommittee on Medicines for Children. In addition, the Committee serves to develop specific additional guidance and specifications as needed for the various medicines recommended by WHO Programmes.\n\nThis Committee also serves the United Nations Prequalification of Medicines Programme managed and operated by WHO, as the Programme could not function without the guidelines, standards and specifications adopted by this Committee after passage through its rigorous, international and wide consultative process. The advantage for the Committee is that, as a result of implementing these guidelines and specifications, practical suggestions for potential revision or on the need for additional guidance are communicated in return to the Expert Committee.\n\nRegarding implementation from a wider perspective the international guidelines, specifications and nomenclature developed under the aegis of this Committee serve all Member States, international organizations, United Nations agencies, regional and interregional harmonization efforts, and underpin important initiatives, including the prequalification of medicines, the Roll Back Malaria Programme, Stop TB, essential medicines and medicines for children. The advice and recommendations provided by this Expert Committee are intended to help national and regional authorities and procurement agencies, as well as major international bodies and institutions, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and international organizations such as UNICEF to combat circulation of substandard medicines and to work towards access to good-quality medicines.\n\nIn conclusion, the Expert Committee on Specifications for Pharmaceutical Preparations gives recommendations and provides independent international standards and guidelines in the area of quality assurance for implementation by WHO Member States, international organizations, United Nations", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son las principales funciones del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS y c\u00f3mo se relacionan con otros comit\u00e9s de la OMS?**\n   - Esta pregunta busca detallar las funciones espec\u00edficas del Comit\u00e9 y su interacci\u00f3n con otros comit\u00e9s de la OMS, lo que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfC\u00f3mo contribuye el Comit\u00e9 a la implementaci\u00f3n de programas internacionales como el Programa de Precalificaci\u00f3n de Medicamentos y la Iniciativa Roll Back Malaria?**\n   - Esta pregunta se centra en el impacto pr\u00e1ctico de las recomendaciones del Comit\u00e9 en programas espec\u00edficos, lo que puede no estar documentado en otros lugares.\n\n3. **\u00bfQu\u00e9 procesos se siguen para desarrollar las normas y directrices internacionales en el \u00e1mbito de la calidad de los medicamentos, seg\u00fan el Comit\u00e9?**\n   - Esta pregunta busca entender el proceso de consenso internacional que se utiliza para establecer las normas, un aspecto que puede no ser ampliamente discutido en otras fuentes.\n\n### Resumen de nivel superior del contexto:\n\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS tiene m\u00e1s de 60 a\u00f1os de historia y se ha dedicado a proporcionar recomendaciones claras y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos. Sus actividades est\u00e1n interconectadas con otros comit\u00e9s de la OMS y son fundamentales para el funcionamiento de programas internacionales, como el de Precalificaci\u00f3n de Medicamentos. Las directrices y normas que desarrolla el Comit\u00e9 son utilizadas por Estados Miembros y organizaciones internacionales para combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de buena calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Grupo de Trabajo de Estados Miembros**: Se acord\u00f3 la creaci\u00f3n de un grupo de trabajo constituido especialmente para discutir las definiciones de la OMS y de IMPACT, evitando que el Comit\u00e9 de Expertos contin\u00fae con la discusi\u00f3n por el momento.\n\n2. **Recomendaciones del Comit\u00e9 de Expertos**:\n   - Desarrollar definiciones adecuadas que eviten confusiones.\n   - Abordar las consecuencias de salud p\u00fablica en lugar de centrarse solo en la terminolog\u00eda.\n   - Enfocar el trabajo inicial en los medicamentos.\n\n3. **Nombres No Propietarios Internacionales (INN)**:\n   - Se presentaron materiales sobre INN, incluyendo una lista acumulativa y el uso de ra\u00edces en la selecci\u00f3n de nombres.\n   - Se describi\u00f3 la arquitectura de la aplicaci\u00f3n en l\u00ednea para la gesti\u00f3n de INN, con Estados Unidos como beta tester.\n   - Durante 2009-2010, se publicaron 299 INN propuestos y 252 INN recomendados.\n\n4. **Funci\u00f3n del Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**:\n   - Proporciona recomendaciones y herramientas para asegurar la calidad de los medicamentos desde su desarrollo hasta su distribuci\u00f3n final.\n   - Asesora al Director General de la OMS en temas de aseguramiento de calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica a nivel internacional.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que asesora sobre la calidad de los medicamentos.\n- **INN (Nombres No Propietarios Internacionales)**: Sistema de nomenclatura para sustancias farmac\u00e9uticas.", "excerpt_keywords": "Keywords: Expert Committee, Pharmaceutical Preparations, quality assurance, international guidelines, WHO Member States"}}, "7385c5da-6f7c-466f-be7b-2f6fc8830d18": {"node_ids": ["f15c450b-21c3-4dc7-9621-eacd28689eab"], "metadata": {"page_label": "65", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The following new guidelines were adopted and recommended for use:\n\n- Release procedure of International Chemical Reference Substances (Annex 1)\n- WHO good practices for pharmaceutical microbiology laboratories (Annex 2)\n- WHO good manufacturing practices: main principles for pharmaceutical products (Annex 3)\n- WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization) (Annex 4)\n- WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms (Annex 5)\n- WHO good manufacturing practices for sterile pharmaceutical products (Annex 6)\n- WHO guidelines on transfer of technology in pharmaceutical manufacturing (Annex 7)\n- Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO) (Annex 8)\n- Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization) (Annex 9)\n- Procedure for prequalification of pharmaceutical products (Annex 10)\n- Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities (Annex 11)\n- Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies (Annex 12)\n- WHO guidelines for preparing a laboratory information file (Annex 13)\n- WHO guidelines for drafting a site master file (Annex 14)\n- Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format (Annex 15)\n\nFor inclusion in *The International Pharmacopoeia*\n\nThe following monographs were adopted:\n\n- *For antiretroviral medicines*\n  - efavirenz tablets\n  - didanosine capsules", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta nuevas directrices adoptadas para el uso en la industria farmac\u00e9utica, que incluyen procedimientos de liberaci\u00f3n de sustancias qu\u00edmicas de referencia internacional, buenas pr\u00e1cticas de fabricaci\u00f3n y microbiolog\u00eda, as\u00ed como gu\u00edas para la precalificaci\u00f3n de productos farmac\u00e9uticos. Adem\u00e1s, se han adoptado monograf\u00edas para medicamentos antirretrovirales, espec\u00edficamente efavirenz y didanosina.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales directrices adoptadas por la OMS para las buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las principales directrices incluyen: \n     - Buenas pr\u00e1cticas de fabricaci\u00f3n: principios principales para productos farmac\u00e9uticos (Anexo 3).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles (Anexo 6).\n     - Buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre (Anexo 4).\n\n2. **\u00bfQu\u00e9 monograf\u00edas espec\u00edficas se han adoptado para los medicamentos antirretrovirales en *The International Pharmacopoeia*?**\n   - Respuesta: Se han adoptado las siguientes monograf\u00edas para medicamentos antirretrovirales:\n     - Efavirenz en tabletas.\n     - Didanosina en c\u00e1psulas.\n\n3. **\u00bfQu\u00e9 procedimiento se recomienda para la precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan las nuevas directrices de la OMS?**\n   - Respuesta: Se recomienda un procedimiento espec\u00edfico para la precalificaci\u00f3n de productos farmac\u00e9uticos (Anexo 10), que incluye una gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores aprobados por autoridades regulatorias estrictas (Anexo 11).", "prev_section_summary": "### Temas Clave:\n\n1. **Historia y Funci\u00f3n del Comit\u00e9**: El Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS tiene m\u00e1s de 60 a\u00f1os de historia, habiendo sido fundado en 1947. Su principal funci\u00f3n es proporcionar recomendaciones claras y est\u00e1ndares internacionales para asegurar la calidad de los medicamentos.\n\n2. **Desarrollo de Normas y Directrices**: Las normas en el \u00e1mbito de la calidad de los medicamentos son desarrolladas a trav\u00e9s de un proceso de consenso internacional, lo que garantiza que las recomendaciones sean pr\u00e1cticas y aplicables a nivel global.\n\n3. **Interconexi\u00f3n con Otros Comit\u00e9s**: El Comit\u00e9 colabora con otros comit\u00e9s de la OMS, como el de Estandarizaci\u00f3n Biol\u00f3gica y el de Selecci\u00f3n y Uso de Medicamentos Esenciales, as\u00ed como su Subcomit\u00e9 sobre Medicamentos para Ni\u00f1os.\n\n4. **Contribuci\u00f3n a Programas Internacionales**: El Comit\u00e9 apoya el Programa de Precalificaci\u00f3n de Medicamentos de la ONU y otras iniciativas importantes como el Programa Roll Back Malaria y Stop TB, proporcionando las directrices necesarias para su funcionamiento.\n\n5. **Impacto en la Salud Global**: Las recomendaciones del Comit\u00e9 est\u00e1n dise\u00f1adas para ayudar a los Estados Miembros, organizaciones internacionales y agencias de la ONU a combatir la circulaci\u00f3n de medicamentos de calidad inferior y mejorar el acceso a medicamentos de buena calidad.\n\n### Entidades Clave:\n\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS**: Organismo responsable de establecer normas y directrices para la calidad de los medicamentos.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que gestiona el Comit\u00e9 y sus actividades.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la ONU**: Iniciativa que se beneficia de las directrices del Comit\u00e9.\n- **Global Fund to Fight AIDS, Tuberculosis and Malaria**: Organizaci\u00f3n que utiliza las recomendaciones del Comit\u00e9 para mejorar la calidad de los medicamentos.\n- **UNICEF**: Organizaci\u00f3n que tambi\u00e9n se apoya en las directrices del Comit\u00e9 para asegurar el acceso a medicamentos de calidad, especialmente para ni\u00f1os. \n\n### Conclusi\u00f3n:\nEl Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas de la OMS desempe\u00f1a un papel crucial en la garant\u00eda de la calidad de los medicamentos a nivel internacional, colaborando con diversas entidades y programas para mejorar la salud global.", "excerpt_keywords": "Keywords: WHO guidelines, pharmaceutical microbiology, good manufacturing practices, antiretroviral medicines, prequalification procedures"}}, "f359c971-0ddf-415b-9b3f-12ac4c54293b": {"node_ids": ["44efd664-50a9-423b-9cf5-c94d7ceac684"], "metadata": {"page_label": "66", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "emtricitabine capsules  \nemtricitabine and tenofovir tablets  \nefavirenz, emtricitabine and tenofovir tablets  \n\n- *For antimalarial medicines*  \n  artesunate  \n  artesunate for injection  \n  mefloquine tablets  \n  sulfadoxine and pyrimethamine tablets  \n\n- *For antituberculosis medicines*  \n  capreomycin sulfate  \n  capreomycin for injection  \n  ofloxacin  \n  ofloxacin tablets  \n  levofloxacin  \n  levofloxacin tablets  \n\n- *For anti-infectives*  \n  amoxicillin oral suspension  \n  levamisole tablets  \n  metronidazole oral suspension  \n  sulfamethoxazole and trimethoprim tablets  \n\n- *For other medicines*  \n  oseltamivir phosphate  \n  oseltamivir capsules  \n  sodium bicarbonate intravenous infusion  \n  paracetamol oral solution  \n  paracetamol oral suspension  \n  levonorgestrel tablets  \n  retinol concentrate  \n\n**General policy topics and general revision issues for:**  \n- uniformity of content for single-dose preparations  \n- oral suspension/solutions reconstituted from powder  \n- dissolution testing  \n\n**Harmonization with PDG general texts for the following:**  \n- Residue on ignition/sulfated ash  \n- Test for extractable volume of parenteral preparations  \n- Test for particulate contamination: subvisible particles  \n- Microbial examination of non-sterile products: microbial enumeration tests  \n- Microbial examination of non-sterile products: tests for specified microorganisms  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Medicamentos listados**: El documento proporciona una lista de medicamentos clasificados en varias categor\u00edas, incluyendo antirretrovirales, antimal\u00e1ricos, antituberculosos, antiinfecciosos y otros medicamentos. Cada categor\u00eda incluye nombres espec\u00edficos de medicamentos y sus formas de presentaci\u00f3n.\n\n2. **Temas de pol\u00edtica general y cuestiones de revisi\u00f3n**: Se mencionan temas de pol\u00edtica general relacionados con la uniformidad de contenido en preparaciones de dosis \u00fanica, as\u00ed como cuestiones sobre la reconstituci\u00f3n de soluciones orales y pruebas de disoluci\u00f3n.\n\n3. **Harmonizaci\u00f3n con textos generales de PDG**: El documento tambi\u00e9n aborda la necesidad de armonizaci\u00f3n con textos generales de la Farmacopea de la OMS (PDG) en relaci\u00f3n con pruebas espec\u00edficas, como residuos de ignici\u00f3n, volumen extra\u00edble de preparaciones parenterales, y ex\u00e1menes microbianos de productos no est\u00e9riles.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los medicamentos antituberculosos mencionados en el documento y qu\u00e9 formas de presentaci\u00f3n tienen?**\n   - Respuesta: Los medicamentos antituberculosos mencionados son capreomycin sulfate (sulfato de capreomicina), capreomycin for injection (capreomicina para inyecci\u00f3n), ofloxacin (ofloxacino), ofloxacin tablets (tabletas de ofloxacino), levofloxacin (levofloxacino) y levofloxacin tablets (tabletas de levofloxacino).\n\n2. **\u00bfQu\u00e9 temas de pol\u00edtica general se abordan en relaci\u00f3n con las preparaciones de dosis \u00fanica y las soluciones orales?**\n   - Respuesta: Se abordan temas de uniformidad de contenido para preparaciones de dosis \u00fanica, la reconstituci\u00f3n de soluciones orales a partir de polvo y las pruebas de disoluci\u00f3n.\n\n3. **\u00bfQu\u00e9 pruebas espec\u00edficas se mencionan para la armonizaci\u00f3n con los textos generales de PDG?**\n   - Respuesta: Las pruebas espec\u00edficas mencionadas para la armonizaci\u00f3n incluyen: Residue on ignition/sulfated ash (residuos de ignici\u00f3n/ash sulfatada), Test for extractable volume of parenteral preparations (prueba para el volumen extra\u00edble de preparaciones parenterales), Test for particulate contamination: subvisible particles (prueba para contaminaci\u00f3n particulada: part\u00edculas subvisibles), y Microbial examination of non-sterile products: microbial enumeration tests (examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta una serie de nuevas directrices y monograf\u00edas adoptadas para mejorar las pr\u00e1cticas en la industria farmac\u00e9utica. Los temas clave incluyen:\n\n1. **Directrices Adoptadas**:\n   - Procedimientos para la liberaci\u00f3n de sustancias qu\u00edmicas de referencia internacional.\n   - Buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, incluyendo:\n     - Principios generales de BPF.\n     - BPF para productos farmac\u00e9uticos est\u00e9riles.\n     - BPF para establecimientos de sangre.\n   - Buenas pr\u00e1cticas de microbiolog\u00eda farmac\u00e9utica.\n   - Directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica.\n   - Normas de pr\u00e1ctica farmac\u00e9utica y almacenamiento de productos farmac\u00e9uticos sensibles al tiempo y temperatura.\n   - Procedimientos para la precalificaci\u00f3n de productos farmac\u00e9uticos y laboratorios de control de calidad.\n\n2. **Monograf\u00edas Adoptadas para Medicamentos Antirretrovirales**:\n   - Efavirenz en tabletas.\n   - Didanosina en c\u00e1psulas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices y recomendaciones.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos antirretrovirales como efavirenz y didanosina.\n- **Anexos**: Documentos que detallan cada una de las directrices y procedimientos adoptados.\n\nEste resumen destaca la importancia de las nuevas directrices para asegurar la calidad y seguridad en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos, as\u00ed como la inclusi\u00f3n de monograf\u00edas espec\u00edficas en *The International Pharmacopoeia*.", "excerpt_keywords": "Keywords: emtricitabine, antimalarial, antituberculosis, harmonization, pharmaceutical guidelines"}}, "34b318e3-92af-428c-ab83-d12200205b1b": {"node_ids": ["24d1aa3d-f3c4-44cf-8875-36ec3f4fe43a"], "metadata": {"page_label": "67", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Microbial examination of non-sterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use\n- Disintegration test\n- Uniformity of dosage units\n- Dissolution test\n- Sterility test\n- Tablet friability\n\n**International reference standards:**\n- New procedure for the release of International Chemical Reference Substances (see also Annex 1)\n- General policy regarding international standards for human recombinant insulin\n\nThe following recommendations were made in the various quality assurance-related areas. Progress on the suggested actions should be reported to the Expert Committee at its next meeting.\n\nThe underlying principle is that the development of specifications and guidelines will be carried out using the established international consultative process.\n\n**Overall policy**\n- To prepare overviews on the key activities and on the history and working process of this Expert Committee for wide dissemination and information.\n- To prepare a general policy paper for future maintenance, revision and update of WHO guidelines adopted by this Expert Committee.\n\n**The International Pharmacopoeia**\n- Continue development of specifications for medicines, general methods and texts and general supplementary information in accordance with the work plan and as decided at this meeting.\n- Continue the efforts of international collaboration in relation to the revision and inclusion of general methods.\n- Continue the preparatory work on the Second supplement to *The International Pharmacopoeia*, fourth edition and towards the fifth edition, especially in electronic form (CD-ROM and online).\n\n**International Chemical Reference Substances (ICRS)**\n- Continue promoting the use of ICRS through various activities, including a promotional offer to national authorities and improvements to the ICRS web site.\n- Continue the efforts to further enhance the development of new ICRS.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos relacionados con la calidad y los est\u00e1ndares de los productos farmac\u00e9uticos. Se discuten criterios de aceptaci\u00f3n para la evaluaci\u00f3n microbiana de productos no est\u00e9riles, as\u00ed como pruebas de disoluci\u00f3n, desintegraci\u00f3n y esterilidad. Tambi\u00e9n se menciona la importancia de las sustancias qu\u00edmicas de referencia internacional y se establecen recomendaciones para el desarrollo de especificaciones y directrices. Se enfatiza la colaboraci\u00f3n internacional y la necesidad de mantener y actualizar las gu\u00edas de la OMS.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la evaluaci\u00f3n microbiana de productos no est\u00e9riles seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los criterios establecidos para la evaluaci\u00f3n de productos farmac\u00e9uticos no est\u00e9riles, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 acciones se sugieren para la promoci\u00f3n y desarrollo de las Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)?**\n   - Esta pregunta se centra en las iniciativas espec\u00edficas mencionadas en el documento para mejorar el uso y desarrollo de las ICRS, proporcionando informaci\u00f3n que puede no estar disponible en otros lugares.\n\n3. **\u00bfQu\u00e9 pasos se est\u00e1n tomando para la actualizaci\u00f3n y mantenimiento de las gu\u00edas de la OMS adoptadas por el Comit\u00e9 de Expertos?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso y las pol\u00edticas que se est\u00e1n implementando para asegurar que las gu\u00edas de la OMS se mantengan actualizadas y relevantes, un aspecto que puede no ser ampliamente discutido en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Medicamentos Listados**:\n   - **Antirretrovirales**:\n     - Emtricitabina (c\u00e1psulas)\n     - Emtricitabina y tenofovir (tabletas)\n     - Efavirenz, emtricitabina y tenofovir (tabletas)\n   - **Antimal\u00e1ricos**:\n     - Artesunato\n     - Artesunato para inyecci\u00f3n\n     - Mefloquina (tabletas)\n     - Sulfadoxina y pirimetamina (tabletas)\n   - **Antituberculosos**:\n     - Sulfato de capreomicina\n     - Capreomicina para inyecci\u00f3n\n     - Ofloxacino\n     - Ofloxacino (tabletas)\n     - Levofloxacino\n     - Levofloxacino (tabletas)\n   - **Anti-infectivos**:\n     - Amoxicilina (suspensi\u00f3n oral)\n     - Levamisole (tabletas)\n     - Metronidazol (suspensi\u00f3n oral)\n     - Sulfametoxazol y trimetoprim (tabletas)\n   - **Otros Medicamentos**:\n     - Fosfato de oseltamivir\n     - Oseltamivir (c\u00e1psulas)\n     - Bicarbonato de sodio (infusi\u00f3n intravenosa)\n     - Paracetamol (soluci\u00f3n oral y suspensi\u00f3n oral)\n     - Tabletas de levonorgestrel\n     - Concentrado de retinol\n\n2. **Temas de Pol\u00edtica General y Cuestiones de Revisi\u00f3n**:\n   - Uniformidad de contenido para preparaciones de dosis \u00fanica.\n   - Reconstituci\u00f3n de soluciones orales a partir de polvo.\n   - Pruebas de disoluci\u00f3n.\n\n3. **Harmonizaci\u00f3n con Textos Generales de PDG**:\n   - Residuo de ignici\u00f3n/ash sulfatada.\n   - Prueba para el volumen extra\u00edble de preparaciones parenterales.\n   - Prueba para contaminaci\u00f3n particulada: part\u00edculas subvisibles.\n   - Examen microbiano de productos no est\u00e9riles: pruebas de enumeraci\u00f3n microbiana.\n   - Examen microbiano de productos no est\u00e9riles: pruebas para microorganismos espec\u00edficos.\n\nEste resumen destaca los medicamentos clasificados en diferentes categor\u00edas, los temas de pol\u00edtica general relacionados con la uniformidad y las pruebas, as\u00ed como la necesidad de armonizaci\u00f3n con los est\u00e1ndares de la Farmacopea de la OMS.", "excerpt_keywords": "Keywords: microbial examination, pharmaceutical standards, International Pharmacopoeia, quality assurance, chemical reference substances"}}, "972cc3cd-eb70-41c7-998d-08cfe2d94c14": {"node_ids": ["99e4d7fc-0bb7-4fd7-a96a-a992d4440eb9"], "metadata": {"page_label": "68", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# External Quality Assurance Assessment Scheme (EQAAS)\n\n- Continue the External Quality Assurance Assessment Scheme (EQAAS) for pharmaceutical quality control laboratories, Phase 5, test series 3 onwards.\n\n# Good manufacturing practices (GMP) and manufacture\n\n- Follow up on the revision process for GMP for biologicals undertaken under the aegis of the Expert Committee on Biological Standardization.\n- Continue the consultation process with regard to a revision of GMP: water for pharmaceutical use.\n- Continue the consultation process on Quality risk management principles with a view to updating the WHO guidelines on hazard analysis and critical control points (HACCP) to cover new trends.\n- Finalize the special guidance for artemisinin as a starting material for production of antimalarials based on the confirmation of the impurity profile through additional laboratory analysis.\n\n# WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce\n\n- Continue the steps to be taken regarding the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce in consultation with WHO Member States and the WHO Legal Counsel.\n\n# Regulatory guidance\n\n- Continue the consultation process and advancement of the Development of paediatric medicines: pharmaceutical development. Points to consider.\n- Continue the development of the Pharmaceutical development for multisource (generic) pharmaceutical products.\n- Continue the update of the Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms published in 2006, with a view to including the new medicines selected for the WHO Model List of Essential Medicines (EML).\n- Report back to the next Expert Committee meeting on the pilot project undertaken by the Prequalification of Medicines Programme regarding the implementation of the provisionally adopted Guidelines on submission of documentation for multisource (generic) finished pharmaceutical product: quality part.\n\n# Quality assurance terminology\n\n- Make the updated database on quality assurance terminology widely available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas iniciativas y procesos relacionados con la calidad de los productos farmac\u00e9uticos. Se enfoca en la continuaci\u00f3n del Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS) para laboratorios de control de calidad, la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP), la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional, y la gu\u00eda regulatoria para el desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource. Tambi\u00e9n se menciona la importancia de actualizar la terminolog\u00eda de aseguramiento de calidad.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se est\u00e1n tomando para la revisi\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos biol\u00f3gicos?**\n   - Esta pregunta busca detalles sobre el proceso de revisi\u00f3n de GMP, que se menciona en el contexto, y c\u00f3mo se est\u00e1 llevando a cabo bajo la direcci\u00f3n del Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica.\n\n2. **\u00bfQu\u00e9 medidas se est\u00e1n implementando para actualizar las directrices de la OMS sobre el an\u00e1lisis de riesgos y los puntos cr\u00edticos de control (HACCP)?**\n   - Esta pregunta se centra en el proceso de consulta mencionado en el contexto sobre la actualizaci\u00f3n de las directrices de HACCP, buscando informaci\u00f3n sobre las nuevas tendencias que se est\u00e1n considerando.\n\n3. **\u00bfC\u00f3mo se est\u00e1 llevando a cabo la consulta con los Estados Miembros de la OMS respecto al Esquema de Certificaci\u00f3n de la OMS para productos farmac\u00e9uticos en comercio internacional?**\n   - Esta pregunta indaga sobre el proceso de consulta y colaboraci\u00f3n con los Estados Miembros en relaci\u00f3n con la certificaci\u00f3n de productos farmac\u00e9uticos, buscando detalles sobre la interacci\u00f3n y los pasos espec\u00edficos que se est\u00e1n tomando.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos fundamentales relacionados con la calidad y los est\u00e1ndares de los productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Evaluaci\u00f3n Microbiana**:\n   - Criterios de aceptaci\u00f3n para productos farmac\u00e9uticos no est\u00e9riles.\n   - M\u00e9todos de prueba como la prueba de disoluci\u00f3n, desintegraci\u00f3n, esterilidad y friabilidad de tabletas.\n\n2. **Est\u00e1ndares Internacionales**:\n   - Procedimientos para la liberaci\u00f3n de Sustancias Qu\u00edmicas de Referencia Internacional (ICRS).\n   - Pol\u00edticas generales sobre est\u00e1ndares internacionales para insulina recombinante humana.\n\n3. **Recomendaciones de Calidad**:\n   - Desarrollo de especificaciones y directrices mediante un proceso consultivo internacional.\n   - Necesidad de informar sobre el progreso de las acciones sugeridas al Comit\u00e9 de Expertos en su pr\u00f3xima reuni\u00f3n.\n\n4. **Pol\u00edtica General**:\n   - Preparaci\u00f3n de res\u00famenes sobre actividades clave y el proceso de trabajo del Comit\u00e9 de Expertos.\n   - Elaboraci\u00f3n de un documento de pol\u00edtica general para el mantenimiento y actualizaci\u00f3n de las gu\u00edas de la OMS.\n\n5. **Farmacopea Internacional**:\n   - Continuaci\u00f3n del desarrollo de especificaciones para medicamentos y m\u00e9todos generales.\n   - Colaboraci\u00f3n internacional para la revisi\u00f3n e inclusi\u00f3n de m\u00e9todos generales.\n   - Trabajo preparatorio para suplementos de la Farmacopea Internacional.\n\n6. **Promoci\u00f3n de ICRS**:\n   - Actividades para promover el uso de ICRS, incluyendo ofertas promocionales a autoridades nacionales.\n   - Desarrollo de nuevas ICRS.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer est\u00e1ndares y gu\u00edas en el \u00e1mbito de la salud p\u00fablica y farmac\u00e9utica.\n- **Comit\u00e9 de Expertos**: Grupo encargado de revisar y recomendar acciones relacionadas con la calidad de los productos farmac\u00e9uticos.\n- **Sustancias Qu\u00edmicas de Referencia Internacional (ICRS)**: Sustancias utilizadas como referencia en la evaluaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la calidad y los est\u00e1ndares en la producci\u00f3n farmac\u00e9utica, as\u00ed como el enfoque colaborativo y consultivo adoptado por la OMS para el desarrollo de gu\u00edas y pol\u00edticas.", "excerpt_keywords": "Keywords: EQAAS, GMP, pharmaceutical quality, WHO Certification Scheme, regulatory guidance"}}, "e7792b55-ae8a-439c-be5f-0e7b6cde7d9c": {"node_ids": ["0ab2f86c-4e05-4827-9d78-31ed6db870ad"], "metadata": {"page_label": "69", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Provide feedback from the Working Group of Member States regarding the terminology for \"spurious/falsely-labelled/falsified/counterfeit medical products\", with a view to further discussion of the outcome during the next meeting of the Expert Committee.\n\n**Pharmacopoeia references**\n\n- Post an update of the references and contact details for national, regional and international pharmacopoeias on the Medicines Quality Assurance web site.\n\n**WHO databases**\n\n- Maintain the consolidated database on nomenclature used in WHO quality assurance.\n- Maintain the INN database and continue to make it available on the web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la terminolog\u00eda relacionada con productos m\u00e9dicos falsificados y la necesidad de retroalimentaci\u00f3n de los Estados Miembros. Tambi\u00e9n se menciona la actualizaci\u00f3n de referencias de farmacopeas y la importancia de mantener bases de datos sobre nomenclatura y nombres no comerciales (INN) en el sitio web de Aseguramiento de la Calidad de Medicamentos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el objetivo principal de la retroalimentaci\u00f3n solicitada a los Estados Miembros sobre la terminolog\u00eda de productos m\u00e9dicos falsificados?**\n   - La retroalimentaci\u00f3n busca facilitar una discusi\u00f3n m\u00e1s profunda sobre la terminolog\u00eda utilizada para describir productos m\u00e9dicos que son \"espurios\", \"falsamente etiquetados\", \"falsificados\" o \"de contrabando\", con el fin de llegar a un consenso en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **\u00bfQu\u00e9 tipo de actualizaciones se planean realizar en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS?**\n   - Se planea publicar una actualizaci\u00f3n de las referencias y detalles de contacto para las farmacopeas nacionales, regionales e internacionales, asegurando que la informaci\u00f3n est\u00e9 actualizada y accesible.\n\n3. **\u00bfQu\u00e9 bases de datos espec\u00edficas se mencionan que la OMS se compromete a mantener y actualizar?**\n   - La OMS se compromete a mantener la base de datos consolidada sobre nomenclatura utilizada en el aseguramiento de la calidad, as\u00ed como la base de datos de Nombres Comunes Internacionales (INN), asegurando su disponibilidad en el sitio web.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Esquema de Evaluaci\u00f3n de Aseguramiento de Calidad Externa (EQAAS)**:\n   - Continuaci\u00f3n del EQAAS para laboratorios de control de calidad farmac\u00e9utica, espec\u00edficamente en la Fase 5, serie de pruebas 3 en adelante.\n\n2. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Revisi\u00f3n de GMP para productos biol\u00f3gicos bajo el Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica.\n   - Consulta sobre la revisi\u00f3n de GMP relacionada con el agua para uso farmac\u00e9utico.\n   - Actualizaci\u00f3n de las directrices de gesti\u00f3n de riesgos de calidad, incluyendo HACCP, para adaptarse a nuevas tendencias.\n   - Finalizaci\u00f3n de la gu\u00eda especial para la artemisinina como materia prima en la producci\u00f3n de antimal\u00e1ricos.\n\n3. **Esquema de Certificaci\u00f3n de la OMS**:\n   - Proceso de consulta con Estados Miembros sobre la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional.\n\n4. **Orientaci\u00f3n regulatoria**:\n   - Desarrollo de medicamentos pedi\u00e1tricos y productos farmac\u00e9uticos multisource (gen\u00e9ricos).\n   - Actualizaci\u00f3n de la propuesta para eximir requisitos de bioequivalencia in vivo para formas de dosificaci\u00f3n oral s\u00f3lida de liberaci\u00f3n inmediata en la Lista Modelo de Medicamentos Esenciales de la OMS.\n   - Informe sobre un proyecto piloto del Programa de Precalificaci\u00f3n de Medicamentos relacionado con la documentaci\u00f3n de productos farmac\u00e9uticos multisource.\n\n5. **Terminolog\u00eda de aseguramiento de calidad**:\n   - Disponibilidad amplia de una base de datos actualizada sobre terminolog\u00eda de aseguramiento de calidad.\n\n### Entidades involucradas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Principal entidad responsable de las iniciativas mencionadas.\n- **Comit\u00e9 de Expertos en Estandarizaci\u00f3n Biol\u00f3gica**: Encargado de la revisi\u00f3n de GMP para productos biol\u00f3gicos.\n- **Estados Miembros de la OMS**: Participantes en el proceso de consulta sobre la certificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: terminology, spurious medical products, pharmacopoeia, WHO databases, quality assurance"}}, "ab770d45-947b-4b8c-be20-71b05a6e31a4": {"node_ids": ["c4dc1831-7a7a-4ec0-842f-1a8e2c6407ab"], "metadata": {"page_label": "70", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Acknowledgements\n\nSpecial acknowledgement was made by the Committee to Mrs W. Bonny, Ms M. Gaspard, Dr S. Kopp, Ms C. Mendy, Dr H. Schmidt and to Dr L. R\u00e4go, Quality Assurance and Safety: Medicines, Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, who were instrumental in the preparation and proceedings of the meeting.\n\nTechnical guidance included in this report has been produced with the financial assistance of the European Union, the Bill & Melinda Gates Foundation and UNITAID.\n\nThe Committee also acknowledged with thanks the valuable contributions made to its work by the following agencies, institutions, organizations, WHO Collaborating Centres, WHO programmes and persons:\n\nActive Pharmaceutical Ingredients Committee, European Chemical Industry Council, Brussels, Belgium; Danish Medicines Agency, Copenhagen, Denmark; European Association of Pharmaceutical Full-line Wholesalers, Groupement International de la R\u00e9partition Pharmaceutique, Brussels, Belgium; European Commission, Brussels, Belgium; European Directorate for the Quality of Medicines and HealthCare, Council of Europe, Strasbourg, France; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; European Medicines Agency, London, England; Global Fund to Fight AIDS, Tuberculosis and Malaria, Vernier, Switzerland; Healthcare Distribution Management Association, Arlington, VA, USA; International Atomic Energy Agency, Vienna, Austria; Indian Drug Manufacturers' Association, Mumbai, India; International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland; International Generic Pharmaceutical Alliance, Brussels, Belgium; International Pharmaceutical Excipients Council, Strasbourg, France; International Pharmaceutical Federation, The Hague, Netherlands; International Society for Pharmaceutical Engineering, Tampa, Florida, USA; Pharmaceutical Research and Manufacturers of America, Washington, DC, USA; Swissmedic, Swiss Agency for Therapeutic Products, Berne, Switzerland; Therapeutic Goods Administration, Woden, ACT, Australia; United Nations Children's Fund, New York, USA; Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; United Nations Development Programme, New York, USA; World Bank, Washington, DC, USA; World Intellectual Property Organization, Geneva, Switzerland; World Self-Medication Industry, Ferney-Voltaire, France.\n\nLaboratoire National de Contr\u00f4le des Produits Pharmaceutiques, Ch\u00e9raga, Algeria; Instituto Nacional de Medicamentos, Buenos Aires, Argentina; Expert Analytic Laboratory, Centre of Drug and Medical Technology Expertise, Yerevan, Armenia; Institute for Quality Control of Medicines, Sarajevo, Bosnia and Herzegovina; Instituto Nacional de Controle de Qualidade em Sa\u00fade, Rio de Janeiro, Brazil; Laboratoire National de Sant\u00e9 Publique, Ouagadougou, Burkina Faso; National Laboratory for Drug Quality Control, Ministry of Health, Phnom Penh, Cambodia; Departamento de Control Nacional, Unidad de control de calidad de productos farmac\u00e9uticos del mercado nacional (Control de Estanter\u00eda), Instituto de Salud P\u00fablica, Santiago de Chile, Chile; Medicamentos y Productos Biol\u00f3gicos del INVIMA, Bogot\u00e1, Colombia; Laboratorio de An\u00e1lisis y Asesor\u00eda Farmac\u00e9utica, Facultad de Farmacia, Universidad.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Reconocimiento de Contribuciones**: El documento destaca el agradecimiento del Comit\u00e9 a varias personas y organizaciones que jugaron un papel crucial en la preparaci\u00f3n y desarrollo de la reuni\u00f3n, as\u00ed como en la elaboraci\u00f3n de la gu\u00eda t\u00e9cnica presentada en el informe.\n\n2. **Financiamiento del Informe**: Se menciona que la gu\u00eda t\u00e9cnica incluida en el informe fue producida con el apoyo financiero de entidades como la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Colaboraciones Internacionales**: El informe reconoce las contribuciones de una amplia gama de agencias, instituciones y organizaciones de diferentes pa\u00edses que colaboraron en el trabajo del Comit\u00e9, lo que refleja un esfuerzo global en el \u00e1mbito de la calidad y seguridad de los medicamentos.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQu\u00e9 entidades financiaron la gu\u00eda t\u00e9cnica incluida en el informe?**\n   - El informe menciona que la gu\u00eda t\u00e9cnica fue producida con la asistencia financiera de la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n2. **\u00bfQui\u00e9nes fueron las personas clave reconocidas por el Comit\u00e9 en la preparaci\u00f3n del informe?**\n   - El Comit\u00e9 agradeci\u00f3 especialmente a Mrs. W. Bonny, Ms. M. Gaspard, Dr. S. Kopp, Ms. C. Mendy, Dr. H. Schmidt y Dr. L. R\u00e4go por su papel instrumental en la preparaci\u00f3n y desarrollo de la reuni\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de organizaciones y agencias fueron reconocidas por sus contribuciones al trabajo del Comit\u00e9?**\n   - El informe reconoce una variedad de organizaciones, incluyendo agencias gubernamentales, asociaciones de la industria farmac\u00e9utica, y centros de colaboraci\u00f3n de la OMS, provenientes de diferentes pa\u00edses, como la Agencia Danesa de Medicamentos, la Agencia Europea de Medicamentos, y el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, entre otros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Retroalimentaci\u00f3n de Estados Miembros**: Se solicita a los Estados Miembros que proporcionen comentarios sobre la terminolog\u00eda relacionada con productos m\u00e9dicos falsificados, con el objetivo de discutir los resultados en la pr\u00f3xima reuni\u00f3n del Comit\u00e9 de Expertos.\n\n2. **Actualizaci\u00f3n de Farmacopeas**: Se planea actualizar las referencias y los detalles de contacto de las farmacopeas nacionales, regionales e internacionales en el sitio web de Aseguramiento de la Calidad de Medicamentos de la OMS.\n\n3. **Mantenimiento de Bases de Datos**:\n   - **Base de Datos de Nomenclatura**: La OMS se compromete a mantener la base de datos consolidada sobre nomenclatura utilizada en el aseguramiento de la calidad.\n   - **Base de Datos de Nombres Comunes Internacionales (INN)**: La OMS tambi\u00e9n mantendr\u00e1 la base de datos de INN y asegurar\u00e1 su disponibilidad en el sitio web.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la regulaci\u00f3n y aseguramiento de la calidad de medicamentos.\n- **Estados Miembros**: Pa\u00edses que forman parte de la OMS y que est\u00e1n involucrados en la retroalimentaci\u00f3n sobre la terminolog\u00eda.\n- **Comit\u00e9 de Expertos**: Grupo que discutir\u00e1 la retroalimentaci\u00f3n y los resultados relacionados con la terminolog\u00eda de productos m\u00e9dicos falsificados.", "excerpt_keywords": "Keywords: acknowledgements, WHO, pharmaceutical policies, technical guidance, international collaboration"}}, "35e7f3ca-b825-404c-91b1-53a00dddc5aa": {"node_ids": ["3a40dc8f-f02e-4852-92b2-3e6e59f2f609"], "metadata": {"page_label": "71", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto del documento mencionado:\n\n1. **\u00bfCu\u00e1l es el objetivo principal del Informe T\u00e9cnico de la OMS en la Serie 961?**\n   - Esta pregunta busca entender el prop\u00f3sito y los objetivos espec\u00edficos del informe, que pueden no estar claramente delineados en otros documentos o res\u00famenes.\n\n2. **\u00bfQu\u00e9 recomendaciones clave se presentan en el Informe T\u00e9cnico de la OMS 961 para mejorar la salud p\u00fablica?**\n   - Esta pregunta se centra en las recomendaciones pr\u00e1cticas que el informe puede ofrecer, las cuales podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en el desarrollo del Informe T\u00e9cnico de la OMS 961 para recopilar y analizar datos?**\n   - Esta pregunta indaga sobre los m\u00e9todos espec\u00edficos empleados en la investigaci\u00f3n y an\u00e1lisis que sustentan las conclusiones del informe, lo que puede ser crucial para evaluar la validez de los resultados.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas relevantes en el \u00e1mbito de la salud p\u00fablica, proporcionando an\u00e1lisis, recomendaciones y directrices basadas en la evidencia. Aunque el contenido espec\u00edfico del informe no est\u00e1 disponible en el contexto proporcionado, es probable que incluya informaci\u00f3n sobre pol\u00edticas de salud, pr\u00e1cticas recomendadas y metodolog\u00edas de investigaci\u00f3n.", "prev_section_summary": "La secci\u00f3n de \"Agradecimientos\" del informe de la OMS destaca varios temas clave y entidades que contribuyeron a la preparaci\u00f3n y desarrollo del documento:\n\n1. **Reconocimiento a Individuos Clave**: Se agradece especialmente a varias personas, incluyendo a Mrs. W. Bonny, Ms. M. Gaspard, Dr. S. Kopp, Ms. C. Mendy, Dr. H. Schmidt y Dr. L. R\u00e4go, por su papel fundamental en la organizaci\u00f3n de la reuni\u00f3n.\n\n2. **Financiamiento del Informe**: La gu\u00eda t\u00e9cnica presentada en el informe fue elaborada con el apoyo financiero de la Uni\u00f3n Europea, la Fundaci\u00f3n Bill & Melinda Gates y UNITAID.\n\n3. **Colaboraciones Internacionales**: Se reconoce la valiosa contribuci\u00f3n de diversas agencias, instituciones y organizaciones de todo el mundo, que incluyen:\n   - **Agencias Gubernamentales**: Como la Agencia Danesa de Medicamentos y la Agencia Europea de Medicamentos.\n   - **Organizaciones Internacionales**: Incluyendo el Fondo Global para la Lucha contra el SIDA, la Tuberculosis y la Malaria, UNICEF y el Programa de las Naciones Unidas para el Desarrollo.\n   - **Asociaciones de la Industria**: Como la Federaci\u00f3n Internacional de Fabricantes y Asociaciones Farmac\u00e9uticas y la Asociaci\u00f3n Internacional de Gen\u00e9ricos.\n   - **Centros de Control de Calidad**: De varios pa\u00edses, como el Laboratorio Nacional de Control de Productos Farmac\u00e9uticos en Argelia y el Instituto Nacional de Medicamentos en Argentina.\n\nEste reconocimiento refleja un esfuerzo global y colaborativo en el \u00e1mbito de la calidad y seguridad de los medicamentos.", "excerpt_keywords": "Keywords: OMS, Informe T\u00e9cnico, salud p\u00fablica, recomendaciones, colaboraci\u00f3n internacional"}}, "3259638f-4c0d-452a-93a1-bd2d1b0866e3": {"node_ids": ["c34a58b8-6924-4a41-b918-433456f6e639"], "metadata": {"page_label": "72", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Pharmaceutical Control Bureau, Jalan University, Ministry of Health, Petaling Jaya, Malaysia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China; WHO Collaborating Centre for Drug Quality Assurance, Pharmaceutical Laboratory, Centre for Analytical Science, Health Sciences Authority, Singapore; WHO Collaborating Centre for Quality Assurance of Drugs, North-West University, Potchefstroom, South Africa; WHO Collaborating Centre for International Infrared Reference Spectra, Institute for Pharmaceutical Sciences, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Bureau of Drug and Narcotics, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.\n\nAnti-Counterfeiting Medicines Programme, WHO, Geneva, Switzerland; Blood Products and Related Biologicals Programme, WHO, Geneva, Switzerland; Global Malaria Programme, WHO, Geneva, Switzerland; HIV/AIDS Programme, WHO, Geneva, Switzerland; International Medical Products Anti-Counterfeiting Taskforce (IMPACT), WHO, Geneva, Switzerland; Medicine Access and Rational Use Team, WHO, Geneva, Switzerland; Medicines Regulatory Support Programme, WHO, Geneva, Switzerland; Prequalification of Medicines Programme, WHO, Geneva, Switzerland; Quality and Safety: Medicines Team, WHO, Geneva, Switzerland; Quality, Safety and Standards Team, WHO, Geneva, Switzerland; Traditional Medicine Team, WHO, Geneva, Switzerland; WHO Regional Office for Africa, Brazzaville, Congo; WHO Regional Office for the Americas/Pan American Health Organization, Washington, DC, USA; WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt; WHO Regional Office for Europe, Copenhagen, Denmark; WHO Regional Office for South-East Asia, New Delhi, India; WHO Regional Office for the Western Pacific, Manila, Philippines.\n\nMrs T. Abdul Sattar, Acting Director General, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Dr F. Abiodun, Benin City, Nigeria; Dr E. Adams, Laboratorium voor Farmaceutische Chemie en Analyse van Geneesmiddelen, Leuven, Belgium; Dr M. Adarkwah-Yiadom, Standard Officer, Ghana Standards Board, Drugs, Cosmetics and Forensic Laboratory Testing Division, Accra, Ghana; Professor I. Addae-Mensah, University of Ghana, Legon, Ghana; Ms R. Ahmad, Centre for Product Registration, National Pharmaceutical Control Bureau, Ministry of Health, Petaling Jaya, Malaysia; Mrs S. Ahmed Jaffar, Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Muscat, Oman; Professor J.-M. Aiaiche, Clermont-Ferrand, France; Dr A. Akkermans, the Netherlands; Dr R. Andrews, Medicines and Healthcare products Regulatory Agency, London, England; Dr C. Anquez Traxler, European Self-Medication Industry, Brussels, Belgium; Dr H. Arentsen, Regulatory Intelligence and Policy Specialist, Regulatory Development Strategy, H. Lundbeck A/S, Copenhagen-Valby, Denmark; Dr C. Athlan, Quality Reviewer, Swissmedic, Berne, Switzerland; Dr A. Ba, Directeur, Qualit\u00e9 et D\u00e9veloppement, Centrale Humanitaire Medico-Pharmaceutique, Clermont-Ferrand, France; Dr H. Batista, US Food and Drug Administration, Silver Spring, MD, USA; Mr B. Baudrand, OTECI, Paris, France; Dr O.P. Baula, Deputy Director, State Pharmacological Center, Ministry of Health, Kiev, Ukraine; Professor S.A. Bawazir, Vice-President, Saudi Food and Drug Authority, and Head of Drug Sector, Riyadh, Saudi Arabia; Dr M.G.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla diversas colaboraciones y programas relacionados con la calidad y regulaci\u00f3n de medicamentos a nivel internacional. Se mencionan m\u00faltiples centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses, as\u00ed como programas espec\u00edficos que abordan temas como la lucha contra medicamentos falsificados, productos biol\u00f3gicos, malaria, VIH/SIDA, y el acceso y uso racional de medicamentos. Tambi\u00e9n se enumeran varios expertos y representantes de diferentes instituciones y pa\u00edses que participan en estas iniciativas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales programas de la OMS mencionados en el informe que se enfocan en la calidad y seguridad de los medicamentos?**\n   - Esta pregunta busca identificar los programas espec\u00edficos de la OMS que se centran en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 instituciones y pa\u00edses est\u00e1n involucrados en la colaboraci\u00f3n con la OMS para la garant\u00eda de calidad de los medicamentos?**\n   - Esta pregunta se enfoca en las instituciones y pa\u00edses espec\u00edficos que colaboran con la OMS, proporcionando una visi\u00f3n m\u00e1s clara de la red internacional de apoyo en la regulaci\u00f3n de medicamentos.\n\n3. **\u00bfQui\u00e9nes son algunos de los expertos y representantes clave mencionados en el informe que contribuyen a los programas de la OMS?**\n   - Esta pregunta busca resaltar a individuos espec\u00edficos que tienen un papel importante en los esfuerzos de la OMS, lo que puede no estar disponible en otras fuentes.\n\n### Resumen de Nivel Superior\nEl informe de la OMS destaca la importancia de la colaboraci\u00f3n internacional en la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos. Se enumeran varios programas y centros de colaboraci\u00f3n que trabajan en \u00e1reas cr\u00edticas como la lucha contra medicamentos falsificados y la mejora del acceso a medicamentos esenciales. Adem\u00e1s, se menciona una lista de expertos y representantes de diversas instituciones que contribuyen a estos esfuerzos, reflejando un enfoque global en la salud p\u00fablica y la seguridad de los medicamentos.", "prev_section_summary": "El documento \"WHO - Technical Report Series 961\" es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Aunque no se proporciona contenido espec\u00edfico en el extracto, se pueden identificar algunos temas clave y entidades relacionadas:\n\n### Temas Clave:\n1. **Objetivo del Informe**: El informe tiene como prop\u00f3sito principal abordar y analizar cuestiones relevantes para la salud p\u00fablica.\n2. **Recomendaciones**: Se espera que el informe presente recomendaciones pr\u00e1cticas para mejorar la salud p\u00fablica, dirigidas a profesionales de la salud y responsables de pol\u00edticas.\n3. **Metodolog\u00edas de Investigaci\u00f3n**: El informe probablemente detalla las metodolog\u00edas utilizadas para recopilar y analizar datos, lo que es crucial para validar las conclusiones presentadas.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe y de la promoci\u00f3n de la salud a nivel global.\n- **Salud P\u00fablica**: \u00c1rea de enfoque del informe, que incluye pol\u00edticas, pr\u00e1cticas y recomendaciones para mejorar la salud de las poblaciones.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y su potencial impacto en la formulaci\u00f3n de pol\u00edticas y pr\u00e1cticas de salud.", "excerpt_keywords": "Keywords: WHO, drug quality assurance, pharmaceutical regulation, anti-counterfeiting, international collaboration"}}, "0047ba1a-3e68-47f8-b9eb-39feaf091cfb": {"node_ids": ["abb4277d-ae9e-422d-ad20-de692a007b7b"], "metadata": {"page_label": "73", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Beatrice, Vice President, Corporate Regulatory and Quality Science, Abbott, Abbott Park, IL, USA; Dr T.L. Bedane, Drug Administration and Control, Addis Ababa, Ethiopia; Ms T.J. Bell, WHO Focal Point, US Food and Drug Administration, Silver Spring, MD, USA; Dr I.B.G. Bernstein, Director, Pharmacy Affairs, Office of the Commissioner/Office of Policy, US Food and Drug Administration, Silver Spring, MD, USA; Dr R.P. Best, President and CEO, International Society for Pharmaceutical Engineering, Tampa, FL, USA; Dr A. Bevilacqua, US Pharmacopeia, Bedford, MA, USA; Dr L. Bigger, Regulatory and Scientific Affairs, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland; Dr J. Bishop III, Review Management Staff, Office of the Director, Center for Biologics Evaluation and Research/FDA, Rockville, MD, USA; Dr L. Bonthuys, Pretoria, South Africa; Professor R. Boudet-Dalbin, Facult\u00e9 de Pharmacie, Laboratoire de Chimie Th\u00e9rapeutique, Paris, France; Dr S.K. Branch, Acting Group Manager, Special Populations Group, Medicines and Healthcare Products Regulatory Agency, London, England; Dr E. Brendel, Bayer HealthCare AG, Elberfeld, Germany; Mr C. Brown, Inspections Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, England; Dr W. Bukachi, Project Coordinator, International Affairs, US Pharmacopeia, Rockville, MD, USA; Ms A. Bukirwa, National (Food and) Drug Authority, Kampala, Uganda; Dr F. Burnett, Managing Director, Pharmaceutical Procurement Service, Organization of Eastern Caribbean States, Casties, St Lucia; Dr. D. Calam, Wiltshire, England; Dr N. Cappuccino, Lambertville, NJ, USA; Dr A. Castro, Regulatory Affairs Director and Senior Pharmacist, Roche Servicios SA, Heredia, Costa Rica; Dr D. Catsoulacos, Scientific Administrator, Manufacturing and Quality Compliance, Compliance and Inspection, European Medicines Agency, London, England; Mr Paulo Cenizo, Southern African Pharmaceutical Regulatory Affairs Association (SAPRAA), Randburg, South Africa; Mr Xuanhao Chan, Project Manager, International Pharmaceutical Federation, The Hague, Netherlands; Dr B. Chapart, Pharma Review Manager, Global Analytical Development, Sanofi-Aventis Pharma, Anthony, France; Ms Cheah Nuan Ping, Director, Cosmetics & Cigarette Testing Laboratory, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr Xu Chen, Director, Division of Drug Distribution Supervision, State Food and Drug Administration, Beijing, People\u2019s Republic of China; Professor Y. Cherrah, Facult\u00e9 de M\u00e9decine et Pharmacie, Rabat, Morocco; Ms I. Clamou, Assistant Manager, Scientific, Technical and Regulatory Affairs, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium; Dr M. Cooke, Senior Manager, Global Quality, Operations, AstraZeneca, Macclesfield, Cheshire, England; Dr C. Craft, Member, United States Pharmacopeia International Health Expert Committee, Rockville, MD, USA; Dr R.L. Dana, Senior Vice President, Regulatory Affairs and Parenteral Drug Association Training and Research Institute, Parenteral Drug Association, Bethesda, MD, USA; Mr M.M. Das, Kolkata, India; Dr V. Davoust, Quality & Regulatory Policy, Global CMC, WW Pharmaceutical Sciences, Pfizer Global Research & Development, Paris, France; Professor T. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa; Dr Laurent De-Moor, GlaxoSmithKline, Belgium; Dr M. Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers, Brussels, Belgium; Dr V. Divecha, Cipla, India; Professor J.B. Dressman, Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que incluye una lista de participantes de diversas organizaciones y pa\u00edses en el \u00e1mbito de la regulaci\u00f3n y la calidad de productos farmac\u00e9uticos. Los participantes provienen de instituciones como la FDA de EE. UU., la Agencia Europea de Medicamentos, y varias universidades y asociaciones farmac\u00e9uticas. Este contexto destaca la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos y la importancia de la calidad en la industria farmac\u00e9utica.\n\n### Preguntas Generadas\n\n1. **\u00bfCu\u00e1les son las principales organizaciones representadas por los participantes mencionados en el informe y qu\u00e9 roles desempe\u00f1an en la regulaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta busca identificar las organizaciones clave y sus funciones espec\u00edficas en el contexto de la regulaci\u00f3n y calidad de los productos farmac\u00e9uticos, lo que puede no estar claramente documentado en otros lugares.\n\n2. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados en la lista de participantes y c\u00f3mo refleja esto la colaboraci\u00f3n internacional en la regulaci\u00f3n de medicamentos?**\n   - Esta pregunta se centra en la diversidad geogr\u00e1fica de los participantes y c\u00f3mo su inclusi\u00f3n en el informe indica un esfuerzo global para abordar los desaf\u00edos en la regulaci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 tipo de experiencia y especializaci\u00f3n aportan los individuos mencionados en el informe a la discusi\u00f3n sobre la calidad y regulaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca profundizar en las credenciales y \u00e1reas de especializaci\u00f3n de los participantes, lo que puede proporcionar una visi\u00f3n m\u00e1s clara de la experiencia colectiva que se re\u00fane para abordar temas cr\u00edticos en la industria farmac\u00e9utica.", "prev_section_summary": "El contenido de la secci\u00f3n del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) se centra en la colaboraci\u00f3n internacional para la regulaci\u00f3n y aseguramiento de la calidad de los medicamentos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n### Temas Clave:\n1. **Colaboraci\u00f3n Internacional**: Se destaca la importancia de la cooperaci\u00f3n entre diferentes pa\u00edses y organizaciones para garantizar la calidad y seguridad de los medicamentos.\n2. **Programas de la OMS**: Se enumeran varios programas espec\u00edficos que abordan temas cr\u00edticos como la lucha contra medicamentos falsificados, productos biol\u00f3gicos, malaria, VIH/SIDA, y el acceso y uso racional de medicamentos.\n3. **Centros de Colaboraci\u00f3n**: Se mencionan m\u00faltiples centros de colaboraci\u00f3n de la OMS en diferentes pa\u00edses que trabajan en la garant\u00eda de calidad de los medicamentos.\n4. **Expertos y Representantes**: Se identifican a varios expertos y representantes de diversas instituciones que contribuyen a los esfuerzos de la OMS en la regulaci\u00f3n de medicamentos.\n\n### Entidades Mencionadas:\n- **Centros de Colaboraci\u00f3n de la OMS**:\n  - Pharmaceutical Control Bureau, Malasia\n  - National Institute for the Control of Pharmaceutical and Biological Products, China\n  - Health Sciences Authority, Singapur\n  - North-West University, Sud\u00e1frica\n  - Institute for Pharmaceutical Sciences, Suiza\n  - Bureau of Drug and Narcotics, Tailandia\n\n- **Programas de la OMS**:\n  - Anti-Counterfeiting Medicines Programme\n  - Blood Products and Related Biologicals Programme\n  - Global Malaria Programme\n  - HIV/AIDS Programme\n  - International Medical Products Anti-Counterfeiting Taskforce (IMPACT)\n  - Medicines Regulatory Support Programme\n  - Prequalification of Medicines Programme\n  - Quality and Safety: Medicines Team\n  - Traditional Medicine Team\n\n- **Oficinas Regionales de la OMS**:\n  - Oficina Regional para \u00c1frica\n  - Oficina Regional para las Am\u00e9ricas\n  - Oficina Regional para el Mediterr\u00e1neo Oriental\n  - Oficina Regional para Europa\n  - Oficina Regional para el Sudeste Asi\u00e1tico\n  - Oficina Regional para el Pac\u00edfico Occidental\n\n- **Expertos y Representantes**:\n  - Mrs T. Abdul Sattar, Om\u00e1n\n  - Dr. E. Adams, B\u00e9lgica\n  - Dr. M. Adarkwah-Yiadom, Ghana\n  - Professor I. Addae-Mensah, Ghana\n  - Dr. R. Andrews, Inglaterra\n  - Dr. H. Batista, EE. UU.\n  - Professor S.A. Bawazir, Arabia Saudita\n\nEste resumen refleja el enfoque global de la OMS en la salud p\u00fablica y la seguridad de los medicamentos, destacando la colaboraci\u00f3n entre diversas entidades y expertos en el campo.", "excerpt_keywords": "Keywords: pharmaceutical regulation, international collaboration, quality assurance, WHO participants, drug safety"}}, "95f156ba-4603-449a-8285-4b92d1d80841": {"node_ids": ["ed9819b5-1fd0-4ebd-9f5b-6a173b56f7ff"], "metadata": {"page_label": "74", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que probablemente contiene informaci\u00f3n t\u00e9cnica y recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre un tema espec\u00edfico relacionado con la salud p\u00fablica. Sin embargo, el contenido espec\u00edfico no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el informe t\u00e9cnico 961 sobre el tema tratado?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las recomendaciones que la OMS ha hecho en este informe, que podr\u00eda ser crucial para profesionales de la salud o investigadores.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron para recopilar datos en el informe t\u00e9cnico de la OMS 961?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques que la OMS pudo haber utilizado para obtener y analizar datos, lo que es fundamental para entender la validez y aplicabilidad de los hallazgos.\n\n3. **\u00bfQu\u00e9 impacto ha tenido el informe t\u00e9cnico 961 en las pol\u00edticas de salud p\u00fablica desde su publicaci\u00f3n?**\n   - Esta pregunta busca explorar las repercusiones y cambios en las pol\u00edticas de salud p\u00fablica que podr\u00edan haber resultado de las conclusiones y recomendaciones del informe, lo que es relevante para evaluar su influencia en la pr\u00e1ctica de la salud global.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar f\u00e1cilmente disponible en otros documentos o fuentes.", "prev_section_summary": "La secci\u00f3n del documento presenta una lista de participantes de diversas organizaciones y pa\u00edses que est\u00e1n involucrados en la regulaci\u00f3n y calidad de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se destaca la participaci\u00f3n de representantes de m\u00faltiples pa\u00edses y organizaciones, lo que refleja un esfuerzo global en la regulaci\u00f3n de medicamentos.\n\n2. **Diversidad de Organizaciones**: Las entidades representadas incluyen la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. (FDA), la Agencia Europea de Medicamentos, la Organizaci\u00f3n Mundial de la Salud (OMS), as\u00ed como diversas universidades y asociaciones farmac\u00e9uticas.\n\n3. **Expertise y Roles**: Los participantes tienen roles variados, desde directores y gerentes en agencias regulatorias hasta acad\u00e9micos y profesionales de la industria farmac\u00e9utica, lo que aporta una amplia gama de experiencia y especializaci\u00f3n en el \u00e1mbito de la calidad y regulaci\u00f3n de productos farmac\u00e9uticos.\n\n4. **Importancia de la Calidad**: La inclusi\u00f3n de expertos en calidad y regulaci\u00f3n subraya la relevancia de mantener altos est\u00e1ndares en la industria farmac\u00e9utica para garantizar la seguridad y eficacia de los medicamentos.\n\nEn resumen, la secci\u00f3n resalta la importancia de la colaboraci\u00f3n internacional y la diversidad de experiencia en la regulaci\u00f3n y calidad de productos farmac\u00e9uticos, con un enfoque en la participaci\u00f3n de entidades clave en el \u00e1mbito.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n, productos farmac\u00e9uticos, colaboraci\u00f3n internacional, calidad"}}, "c89c5f9e-c1d8-4803-bb80-6221b8f6b131": {"node_ids": ["7d3688c8-8707-4c44-aaf5-347975317eb2"], "metadata": {"page_label": "75", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Petaling Jaya, Indonesia; Dr R. J\u00e4hnke, Global Pharma Health Fund e.V., Frankfurt, Germany; Dr M. James, GlaxoSmithKline, Brentford, Middlesex, England; Professor Jin Shaohong, Executive Director-General, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People\u2019s Republic of China; Dr P. Jones, Director, Analytical Control, Pharmaceutical Sciences, Pfizer Global R&D, Sandwich, England; Dr Y. Juillet, France; Ms A. Junttonen, Senior Pharmaceutical Inspector, National Agency for Medicines, Helsinki, Finland; Mr D. J\u00fcnemann, Teaching Assistant; Institut f\u00fcr Pharmazeutische Technologie, Biozentrum, Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt/Main, Germany; Dr M. Kaplan, Director, Institute for Standardization and Control of Pharmaceuticals, Jerusalem, Israel; Dr A.M. Kaukonen, National Agency for Medicines, Helsinki, Finland; Dr T. Kawanishi, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan; Ms H. Kavale, Cipla, Mumbai, India; Dr S. Keitel, Director, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Dr K. Keller, Director and Professor, Federal Ministry of Health, Bonn, Germany; Dr M. Keller, Division of Certificates & Licences, Licensing Sector, Berne, Switzerland; Dr L. Kerr, Scientific Operations Adviser, Office of Laboratories and Scientific Services, Therapeutic Goods Administration, Woden, ACT, Australia; Professor Kazuko Kimura, Institute of Medicine, Pharmacy and Health Sciences, Kanazawa University, Kanazawa-city, Japan; Dr H. K\u00f6szegi-Szalai, Head, Department for Quality Assessment and Control, National Institute of Pharmacy, Budapest, Hungary; Dr A. Kovacs, Secretariat, Pharmaceutical Inspection Co-operation Scheme, Geneva, Switzerland; Ms S. Kox, Senior Director Scientific Affairs, European Generic Medicines Association, Brussels, Belgium; Dr A. Krauss, Principal Scientist, Chemist Laboratory, Therapeutic Goods Administration Laboratories, Woden, ACT, Australia; Professor H.G. Kristensen, Vedbaek, Denmark; Mr A. Kupferman, Industry Pharmacist, Strasbourg, France; Professor S. L\u00e4er, Institut f\u00fcr Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universit\u00e4t, D\u00fcsseldorf, Germany; Dr J.-M. Legrand, GlaxoSmithKline Biologicals, Wavre, Belgium; Dr A. Lodi, European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France; Mr M. Lok, Head of Office, Office of Manufacturing Quality, Therapeutic Goods Administration, Woden, ACT, Australia; Ms Low Min Yong, Director, Pharmaceutical Division, Applied Sciences Group, Health Sciences Authority, Singapore; Dr R. Luigetti, Emea, Europe; Dr J.C. Lyda, Senior Director, Regulatory Affairs, Parenteral Drug Association Europe, Glienicke/ Berlin, Germany; Mr D. Mader, Compliance Auditor, GlaxoSmithKline, Cape Town, South Africa; Dr F. Malik, Pakistan; Mr J-D. Mallet, OTECI, Paris, France; Reverend J.Y. Martey, Head, Laboratory Services, Quality Control Laboratory, Food and Drugs Board, Accra, Ghana; Dr T. Massa, Vice President, Global Regulatory Sciences \u2014 Chemistry, Manufacturing and Control, Bristol-Myers Squibb, USA; Dr B. Matthews, Alcon, Hemel Hempstead, Herts, England; Dr Y. Matthews, Regulatory Operations Executive, GE Healthcare, Amersham, Bucks, England; Dr J.-L. Mazert, Rueil, France; Dr G. McGurk, Executive Inspector, Irish Medicines Board, Dublin, Ireland; Dr A. Mechkovski, Moscow, Russian Federation; Dr M. Mehmandoost, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9, Saint-Denis, France; Dr D. Mehta, Vigilance and Risk Management of Medicines, Medicines and Healthcare Products Regulatory Agency, London, England; Dr J.H.McB. Miller, Strasbourg, France; Dr O. Milling, Medicines Inspector, Medicines Control Division, Danish", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proviene del \"WHO - Technical Report Series 961\" y menciona una lista de profesionales y sus respectivas instituciones en el \u00e1mbito de la salud y la farmacolog\u00eda. Los participantes provienen de diversas partes del mundo, incluyendo Europa, Asia, \u00c1frica y Am\u00e9rica, y representan una variedad de roles, desde inspectores farmac\u00e9uticos hasta directores de investigaci\u00f3n y desarrollo en grandes empresas farmac\u00e9uticas. Este informe parece estar relacionado con la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1l es el papel de Dr. R. J\u00e4hnke en el contexto del informe y qu\u00e9 organizaci\u00f3n representa?**\n   - Respuesta: Dr. R. J\u00e4hnke es parte del Global Pharma Health Fund e.V. y su papel podr\u00eda estar relacionado con la promoci\u00f3n de la salud global y la regulaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 tipo de instituciones est\u00e1n representadas por los profesionales mencionados en el informe?**\n   - Respuesta: Las instituciones incluyen agencias nacionales de medicamentos, universidades, empresas farmac\u00e9uticas, y organizaciones internacionales, lo que indica una colaboraci\u00f3n global en la regulaci\u00f3n y control de productos farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 importancia tiene la diversidad geogr\u00e1fica de los participantes en la regulaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el informe?**\n   - Respuesta: La diversidad geogr\u00e1fica sugiere un enfoque global en la regulaci\u00f3n de productos farmac\u00e9uticos, lo que puede contribuir a la armonizaci\u00f3n de est\u00e1ndares y pr\u00e1cticas en diferentes pa\u00edses, mejorando as\u00ed la seguridad y eficacia de los medicamentos a nivel mundial.\n\n### Resumen de Nivel Superior\nEl informe de la OMS destaca la colaboraci\u00f3n internacional en el \u00e1mbito de la regulaci\u00f3n farmac\u00e9utica, con la participaci\u00f3n de expertos de diversas instituciones y pa\u00edses. Esto refleja un esfuerzo conjunto para abordar los desaf\u00edos en la calidad y control de productos farmac\u00e9uticos y biol\u00f3gicos, promoviendo la salud p\u00fablica a nivel global.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda temas t\u00e9cnicos y recomendaciones relacionadas con la salud p\u00fablica. Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n#### Temas Clave\n1. **Recomendaciones de Salud P\u00fablica**: El informe probablemente incluye directrices y sugerencias para mejorar la salud p\u00fablica a nivel global.\n2. **Metodolog\u00eda de Investigaci\u00f3n**: Es probable que se discutan las metodolog\u00edas utilizadas para la recopilaci\u00f3n y an\u00e1lisis de datos, lo que es esencial para la credibilidad de los hallazgos.\n3. **Impacto en Pol\u00edticas de Salud**: El informe podr\u00eda analizar c\u00f3mo sus recomendaciones han influido en las pol\u00edticas de salud p\u00fablica desde su publicaci\u00f3n.\n\n#### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe, que se centra en mejorar la salud a nivel mundial.\n- **Salud P\u00fablica**: El \u00e1mbito general al que se dirigen las recomendaciones y hallazgos del informe.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: pharmaceutical regulation, global health, quality control, international collaboration, health sciences"}}, "c7e2495b-99f0-48ff-9c4c-fa9978e99111": {"node_ids": ["bcbbadd4-9664-4909-b472-e732179ab0cc"], "metadata": {"page_label": "76", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para la pr\u00e1ctica cl\u00ednica y la pol\u00edtica de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 76 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe de la OMS en la p\u00e1gina 76 del Technical Report Series 961?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina del informe.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el Technical Report Series 961 y c\u00f3mo se relacionan con las pol\u00edticas de salud actuales?**\n   - Esta pregunta se centra en el contexto m\u00e1s amplio del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe para evaluar los problemas de salud discutidos en el Technical Report Series 961?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos que la OMS emplea en sus informes t\u00e9cnicos, lo cual puede ser crucial para entender la validez de las recomendaciones presentadas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, dado que se centran en el contenido particular del informe y su contexto.", "prev_section_summary": "La secci\u00f3n del documento \"WHO - Technical Report Series 961\" destaca la participaci\u00f3n de una amplia variedad de profesionales en el \u00e1mbito de la salud y la farmacolog\u00eda, provenientes de diferentes partes del mundo. Los temas clave incluyen:\n\n1. **Colaboraci\u00f3n Internacional**: Se enfatiza la importancia de la cooperaci\u00f3n global en la regulaci\u00f3n y control de productos farmac\u00e9uticos y biol\u00f3gicos, con la participaci\u00f3n de expertos de diversas instituciones.\n\n2. **Diversidad de Instituciones**: Los participantes representan una mezcla de agencias nacionales de medicamentos, universidades, empresas farmac\u00e9uticas y organizaciones internacionales, lo que refleja un enfoque multidisciplinario en la regulaci\u00f3n farmac\u00e9utica.\n\n3. **Roles de los Participantes**: Los profesionales mencionados ocupan diversos roles, desde inspectores farmac\u00e9uticos hasta directores de investigaci\u00f3n y desarrollo, lo que sugiere un esfuerzo conjunto para abordar los desaf\u00edos en la calidad y control de medicamentos.\n\n4. **Importancia de la Diversidad Geogr\u00e1fica**: La variedad geogr\u00e1fica de los participantes indica un enfoque global que puede contribuir a la armonizaci\u00f3n de est\u00e1ndares y pr\u00e1cticas en la regulaci\u00f3n de productos farmac\u00e9uticos, mejorando as\u00ed la seguridad y eficacia de los medicamentos a nivel mundial.\n\nEntidades clave mencionadas incluyen:\n- **Organizaciones**: Global Pharma Health Fund e.V., GlaxoSmithKline, Pfizer Global R&D, European Directorate for the Quality of Medicines and Healthcare, Therapeutic Goods Administration, entre otras.\n- **Profesionales**: Dr. R. J\u00e4hnke, Dr. M. James, Professor Jin Shaohong, Dr. P. Jones, entre otros, que representan diversas instituciones de diferentes pa\u00edses, incluyendo Alemania, Jap\u00f3n, Francia, India, y m\u00e1s.\n\nEn resumen, el informe resalta la importancia de la colaboraci\u00f3n internacional y la diversidad en la regulaci\u00f3n farmac\u00e9utica, con el objetivo de promover la salud p\u00fablica a nivel global.", "excerpt_keywords": "Keywords: OMS, regulaci\u00f3n farmac\u00e9utica, colaboraci\u00f3n internacional, salud p\u00fablica, diversidad geogr\u00e1fica"}}, "94b1c634-0d86-46f1-951c-ef30ed9c2287": {"node_ids": ["6f1629b2-3e89-4256-86ef-7619a1761189"], "metadata": {"page_label": "77", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 77 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en la p\u00e1gina 77 del informe \"WHO - Technical Report Series 961\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina, relacionada con la salud p\u00fablica o recomendaciones de la OMS.\n\n2. **\u00bfQu\u00e9 temas generales se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 961 con esos temas?**\n   - Esta pregunta permite explorar el contexto m\u00e1s amplio de la serie de informes y c\u00f3mo el informe espec\u00edfico se integra en la discusi\u00f3n general sobre salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas o enfoques se utilizan en el informe \"WHO - Technical Report Series 961\" para abordar los problemas de salud discutidos?**\n   - Esta pregunta se centra en las t\u00e9cnicas o m\u00e9todos que la OMS podr\u00eda haber utilizado en el informe, lo que podr\u00eda ser relevante para investigadores o profesionales de la salud interesados en la implementaci\u00f3n de pol\u00edticas basadas en evidencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento mencionado, \"WHO - Technical Report Series 961\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico de la p\u00e1gina 76 no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.\n\n2. **Informes T\u00e9cnicos**: La serie aborda temas relacionados con la salud p\u00fablica, recomendaciones para la pr\u00e1ctica cl\u00ednica y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Un tema central del informe, que puede incluir hallazgos sobre enfermedades, intervenciones de salud y estrategias de prevenci\u00f3n.\n\n4. **Metodolog\u00edas de Evaluaci\u00f3n**: Aunque no se detalla en el contenido proporcionado, es probable que el informe utilice diversas metodolog\u00edas para evaluar problemas de salud y formular recomendaciones.\n\n5. **Pol\u00edticas de Salud**: El informe puede relacionar sus hallazgos con las pol\u00edticas de salud actuales, sugiriendo c\u00f3mo se pueden aplicar las recomendaciones en la pr\u00e1ctica.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y su potencial impacto en las pol\u00edticas y pr\u00e1cticas de salud.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, informes t\u00e9cnicos, pol\u00edticas de salud, metodolog\u00edas de evaluaci\u00f3n"}}, "d15597a0-776e-4dca-ac6e-593a55ebc256": {"node_ids": ["3aaa60ec-9d5b-4f72-898e-c3996f001293"], "metadata": {"page_label": "78", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del Contexto\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones sobre pr\u00e1cticas y pol\u00edticas en el \u00e1mbito de la salud. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 78 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el informe t\u00e9cnico 961 sobre la salud p\u00fablica?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las recomendaciones que podr\u00edan estar incluidas en el informe, que son relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en la p\u00e1gina 78 del informe WHO TRS 961?**\n   - Aunque el contenido no est\u00e1 disponible, esta pregunta se centra en el contenido espec\u00edfico de esa p\u00e1gina, que podr\u00eda contener informaci\u00f3n crucial sobre un tema particular.\n\n3. **\u00bfC\u00f3mo se relaciona el informe WHO TRS 961 con otros informes t\u00e9cnicos anteriores de la OMS?**\n   - Esta pregunta busca establecer conexiones entre este informe y otros documentos de la OMS, lo que podr\u00eda ayudar a entender la evoluci\u00f3n de las recomendaciones y pol\u00edticas de salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros lugares, dado que se centran en el contenido espec\u00edfico del informe y su contexto en la serie de informes de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS) que se enfoca en temas de salud p\u00fablica y recomendaciones para pol\u00edticas de salud. Aunque el contenido espec\u00edfico de la p\u00e1gina 77 no est\u00e1 disponible, se puede inferir que el informe aborda hallazgos relevantes y metodolog\u00edas en el \u00e1mbito de la salud.\n\n#### Temas Clave:\n- **Salud P\u00fablica:** El informe probablemente discute cuestiones cr\u00edticas relacionadas con la salud de la poblaci\u00f3n.\n- **Investigaci\u00f3n M\u00e9dica:** Es posible que se presenten hallazgos de investigaciones recientes en el campo de la medicina.\n- **Pol\u00edticas de Salud:** Se espera que el informe ofrezca recomendaciones para la formulaci\u00f3n de pol\u00edticas basadas en evidencia.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de la publicaci\u00f3n del informe.\n- **Informe T\u00e9cnico:** Parte de la serie de informes t\u00e9cnicos que la OMS publica regularmente.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en el contexto del informe, aunque no se dispone de detalles espec\u00edficos del contenido de la p\u00e1gina 77.", "excerpt_keywords": "Keywords: salud p\u00fablica, OMS, informe t\u00e9cnico, pol\u00edticas de salud, investigaci\u00f3n m\u00e9dica"}}, "7ea24d60-7933-46f2-b85b-0b641832d927": {"node_ids": ["1bea7730-0992-49d1-8bff-f10e485183f8"], "metadata": {"page_label": "79", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 1\n\n## Release procedure of International Chemical Reference Substances\n\nInternational Chemical Reference Substances (ICRS) were in the past first provisionally adopted by the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations and then finally adopted by the Expert Committee on Specifications for Pharmaceutical Preparations during its annual meeting.\n\nSince April 2010 the European Directorate for the Quality of Medicines & HealthCare (EDQM) has been responsible for the establishment, preparation, storage and distribution of WHO ICRS. For the analytical characterization of ICRS, EDQM follows the *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n\nEDQM will issue an individual analytical report after:\n\n- the establishment of a new reference substance;\n- analysis of candidate material for stock replenishment; and\n- monitoring the stability of material in stock.\n\nThe Expert Committee members newly adopted the following procedure:\n\nAnalytical case-reports to be reviewed *a priori* by the Secretariat with assistance from the collaborating laboratories. If the testing has been performed according to the above-mentioned adopted guidelines (1) and the candidate material has been proven to be suitable, the Secretariat with assistance from the collaborating laboratories, will then in future provisionally release the ICRS. The distribution of the ICRS will start after the provisional release.\n\nThe analytical case-reports together with a consolidated EDQM annual report describing all activities related to the establishment of ICRS will then be distributed to the WHO Expert Committee on Specifications for Pharmaceutical Preparations for adoption. The analytical case-reports will be appended to the annual report as annexes.\n\nThe new process will expedite the establishment of new reference substances and will enable WHO to react faster to the urgent demand for ICRS. The new procedure is illustrated in Figure 1.\n\nIf additional explicit provisions for the release of reference substances are needed, they will also be presented to the Expert Committee for approval.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento describe el procedimiento de liberaci\u00f3n de las Sustancias de Referencia Qu\u00edmica Internacional (ICRS) por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Desde abril de 2010, la Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) es responsable de la creaci\u00f3n, preparaci\u00f3n, almacenamiento y distribuci\u00f3n de las ICRS. Se establece un proceso para la revisi\u00f3n de informes anal\u00edticos que permite la liberaci\u00f3n provisional de las ICRS, facilitando as\u00ed una respuesta m\u00e1s r\u00e1pida a la demanda urgente de estas sustancias. Los informes anal\u00edticos se revisan antes de la liberaci\u00f3n y se distribuyen al Comit\u00e9 de Expertos de la OMS para su adopci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 organismo es responsable de la preparaci\u00f3n y distribuci\u00f3n de las ICRS desde abril de 2010 y cu\u00e1les son sus funciones espec\u00edficas en este proceso?**\n   - Respuesta: La Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) es responsable de la creaci\u00f3n, preparaci\u00f3n, almacenamiento y distribuci\u00f3n de las ICRS. Sus funciones incluyen la emisi\u00f3n de informes anal\u00edticos individuales tras el establecimiento de nuevas sustancias de referencia, el an\u00e1lisis de materiales candidatos para reabastecimiento y el monitoreo de la estabilidad del material en stock.\n\n2. **\u00bfCu\u00e1l es el procedimiento adoptado por el Comit\u00e9 de Expertos para la revisi\u00f3n de los informes anal\u00edticos antes de la liberaci\u00f3n de las ICRS?**\n   - Respuesta: Los informes anal\u00edticos son revisados *a priori* por la Secretar\u00eda con la asistencia de laboratorios colaboradores. Si las pruebas se han realizado de acuerdo con las directrices adoptadas y el material candidato ha demostrado ser adecuado, la Secretar\u00eda proceder\u00e1 a liberar provisionalmente la ICRS.\n\n3. **\u00bfQu\u00e9 cambios se implementaron en el proceso de establecimiento de nuevas sustancias de referencia para mejorar la respuesta a la demanda urgente de ICRS?**\n   - Respuesta: Se implement\u00f3 un nuevo proceso que acelera el establecimiento de nuevas sustancias de referencia, permitiendo a la OMS reaccionar m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS. Esto incluye la revisi\u00f3n anticipada de informes anal\u00edticos y la distribuci\u00f3n de estos informes junto con un informe anual consolidado al Comit\u00e9 de Expertos para su adopci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Documento:** WHO - Technical Report Series 961  \n**Entidad:** Organizaci\u00f3n Mundial de la Salud (OMS)  \n**Tipo de Documento:** Informe t\u00e9cnico sobre salud p\u00fablica  \n\n#### Temas Clave:\n1. **Salud P\u00fablica:** El informe aborda temas relevantes para la salud p\u00fablica, incluyendo recomendaciones y pol\u00edticas.\n2. **Investigaci\u00f3n M\u00e9dica:** Se espera que el documento incluya hallazgos de investigaciones que impactan la salud global.\n3. **Pr\u00e1cticas y Pol\u00edticas de Salud:** El informe probablemente proporciona directrices sobre pr\u00e1cticas recomendadas en el \u00e1mbito de la salud.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad responsable de la publicaci\u00f3n del informe y de la formulaci\u00f3n de pol\u00edticas de salud a nivel global.\n- **Informe T\u00e9cnico:** Parte de una serie que busca informar y guiar a profesionales de la salud y responsables de pol\u00edticas.\n\n### Conclusi\u00f3n\nEl informe WHO TRS 961 es un documento t\u00e9cnico que se centra en la salud p\u00fablica y las recomendaciones de la OMS, aunque el contenido espec\u00edfico de la p\u00e1gina 78 no est\u00e1 disponible en el contexto proporcionado. Las preguntas formuladas buscan profundizar en el contenido y la relevancia del informe en el \u00e1mbito de la salud.", "excerpt_keywords": "Keywords: International Chemical Reference Substances, EDQM, WHO, analytical reports, release procedure"}}, "2adec23b-e344-4ffa-8a54-c9c1ee8fb8e4": {"node_ids": ["79a8960d-8976-42bc-b47c-593b0438894a"], "metadata": {"page_label": "80", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# New procedure\n\n1. **EDQM characterizes candidate material and issues analytical report**\n\n2. **WHO Secretariat, with assistance from the collaborating laboratories, reviews documentation and releases ICRS provisionally**\n\n3. **EDQM starts distribution of ICRS**\n\n4. **WHO Secretariat submits case-reports together with annual report to the Expert Committee**\n\n5. **Final release of ICRS by Expert Committee**\n\n- **Feedback to EDQM**\n\n----\n\n*EDQM, European Directorate for the Quality of Medicines & HealthCare; ICRS, International Chemical Reference Substances.*\n\n# Reference\n\n1. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No 790), p. 15.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en un nuevo procedimiento relacionado con la caracterizaci\u00f3n y distribuci\u00f3n de sustancias qu\u00edmicas de referencia internacional (ICRS) por parte de la Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM) y la Secretar\u00eda de la OMS. Se describen los pasos que incluyen la caracterizaci\u00f3n del material candidato, la revisi\u00f3n de la documentaci\u00f3n, la distribuci\u00f3n provisional de ICRS, la presentaci\u00f3n de informes al Comit\u00e9 de Expertos y la liberaci\u00f3n final de ICRS. Tambi\u00e9n se menciona la importancia del feedback a EDQM.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de la EDQM en el proceso de caracterizaci\u00f3n y distribuci\u00f3n de ICRS?**\n   - Respuesta: La EDQM se encarga de caracterizar el material candidato y emitir un informe anal\u00edtico, as\u00ed como iniciar la distribuci\u00f3n de las ICRS.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n revisa la Secretar\u00eda de la OMS antes de liberar provisionalmente las ICRS?**\n   - Respuesta: La Secretar\u00eda de la OMS, con la ayuda de laboratorios colaboradores, revisa la documentaci\u00f3n relacionada con el material candidato antes de liberar las ICRS de manera provisional.\n\n3. **\u00bfQu\u00e9 sucede despu\u00e9s de que la Secretar\u00eda de la OMS presenta los informes de casos y el informe anual al Comit\u00e9 de Expertos?**\n   - Respuesta: Despu\u00e9s de la presentaci\u00f3n, el Comit\u00e9 de Expertos realiza la liberaci\u00f3n final de las ICRS y proporciona retroalimentaci\u00f3n a la EDQM.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sustancias de Referencia Qu\u00edmica Internacional (ICRS)**:\n   - Definici\u00f3n: Sustancias utilizadas como est\u00e1ndares en an\u00e1lisis qu\u00edmicos y farmac\u00e9uticos.\n\n2. **Responsabilidad de la EDQM**:\n   - Desde abril de 2010, la **Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria (EDQM)** es responsable de:\n     - Establecimiento\n     - Preparaci\u00f3n\n     - Almacenamiento\n     - Distribuci\u00f3n de las ICRS.\n   - Emisi\u00f3n de informes anal\u00edticos individuales tras:\n     - Establecimiento de nuevas sustancias de referencia.\n     - An\u00e1lisis de materiales candidatos para reabastecimiento.\n     - Monitoreo de la estabilidad del material en stock.\n\n3. **Procedimiento de Revisi\u00f3n y Liberaci\u00f3n**:\n   - Los informes anal\u00edticos son revisados *a priori* por la Secretar\u00eda con ayuda de laboratorios colaboradores.\n   - Si el material candidato es adecuado, se procede a la liberaci\u00f3n provisional de las ICRS.\n   - La distribuci\u00f3n de las ICRS comienza tras esta liberaci\u00f3n provisional.\n\n4. **Informes y Adopci\u00f3n**:\n   - Los informes anal\u00edticos se distribuyen junto con un informe anual consolidado al **Comit\u00e9 de Expertos de la OMS** para su adopci\u00f3n.\n   - Los informes anal\u00edticos se anexan al informe anual.\n\n5. **Objetivo del Nuevo Proceso**:\n   - Acelerar el establecimiento de nuevas sustancias de referencia.\n   - Permitir a la OMS reaccionar m\u00e1s r\u00e1pidamente a la demanda urgente de ICRS.\n\n6. **Provisiones Adicionales**:\n   - Si se requieren disposiciones expl\u00edcitas adicionales para la liberaci\u00f3n de sustancias de referencia, se presentar\u00e1n al Comit\u00e9 de Expertos para su aprobaci\u00f3n. \n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la salud p\u00fablica internacional.\n- **EDQM (Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria)**: Entidad encargada de la calidad de medicamentos en Europa y responsable de las ICRS desde 2010.\n- **Comit\u00e9 de Expertos de la OMS**: Grupo que adopta las ICRS y revisa los informes anal\u00edticos.", "excerpt_keywords": "Keywords: EDQM, ICRS, WHO Secretariat, analytical report, Expert Committee"}}, "5b27cfd1-6645-4e47-84e6-8ce6dfb2f491": {"node_ids": ["5041f021-5224-4701-aaa4-81917fbcfca6"], "metadata": {"page_label": "81", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 2\n\n## WHO good practices for pharmaceutical microbiology laboratories\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in 2009 a revised version of the *Good practices for pharmaceutical quality control laboratories* (1).\n\nDuring the inspections carried out when prequalifying laboratories, the inspectors had noticed that some of the texts of these guidelines might benefit from additional guidance, with a special focus on microbiology.\n\nIn light of the above, the Expert Committee recommended that the WHO Secretariat initiate the process of developing a new text on good practices for pharmaceutical microbiology laboratories.\n\nThe following text is proposed to cover this specific type of laboratory.\n\n### Introduction and scope of document\n\n### Glossary\n\n1. **Personnel**\n\n2. **Environment**\n   - 2.1 Premises\n   - 2.2 Environmental monitoring in the laboratory\n   - 2.3 Cleaning, disinfection and hygiene\n   - 2.4 Sterility test facilities\n\n3. **Validation of test methods**\n\n4. **Equipment**\n   - 4.1 Maintenance of equipment\n   - 4.2 Qualification\n   - 4.3 Calibration, performance verification and monitoring of use\n\n5. **Reagents and culture media**\n   - 5.1 Reagents\n   - 5.2 Media\n   - 5.3 Labelling\n   - 5.4 Organism resuscitation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento es un anexo del *Technical Report Series 961* de la OMS, que se centra en las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica. Se menciona que, tras las inspecciones de laboratorios, se identific\u00f3 la necesidad de proporcionar orientaci\u00f3n adicional en microbiolog\u00eda. El texto propuesto abarca aspectos como el personal, el entorno, la validaci\u00f3n de m\u00e9todos de prueba, el equipo y los reactivos y medios de cultivo.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 aspectos espec\u00edficos del entorno del laboratorio se abordan en las buenas pr\u00e1cticas propuestas por la OMS?**\n   - Respuesta: El documento menciona varios aspectos del entorno del laboratorio, incluyendo las instalaciones (premises), el monitoreo ambiental, la limpieza, desinfecci\u00f3n e higiene, y las instalaciones para pruebas de esterilidad.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave para la validaci\u00f3n de m\u00e9todos de prueba en laboratorios de microbiolog\u00eda farmac\u00e9utica seg\u00fan la OMS?**\n   - Respuesta: Aunque el texto no proporciona detalles espec\u00edficos en el fragmento, se menciona que la validaci\u00f3n de m\u00e9todos de prueba es un tema importante que se aborda en el documento, sugiriendo que se deben seguir protocolos rigurosos para asegurar la fiabilidad y precisi\u00f3n de los m\u00e9todos utilizados.\n\n3. **\u00bfQu\u00e9 se incluye en la secci\u00f3n sobre reactivos y medios de cultivo en las buenas pr\u00e1cticas de la OMS?**\n   - Respuesta: La secci\u00f3n sobre reactivos y medios de cultivo incluye consideraciones sobre los reactivos en general, los medios de cultivo, el etiquetado de estos, y la resucitaci\u00f3n de organismos, lo que es crucial para asegurar la calidad y efectividad de los cultivos microbiol\u00f3gicos en el laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Procedimiento Nuevo**: Se describe un nuevo procedimiento para la caracterizaci\u00f3n y distribuci\u00f3n de sustancias qu\u00edmicas de referencia internacional (ICRS).\n2. **Caracterizaci\u00f3n y An\u00e1lisis**: La EDQM se encarga de caracterizar el material candidato y emitir un informe anal\u00edtico.\n3. **Revisi\u00f3n de Documentaci\u00f3n**: La Secretar\u00eda de la OMS, con la ayuda de laboratorios colaboradores, revisa la documentaci\u00f3n antes de liberar provisionalmente las ICRS.\n4. **Distribuci\u00f3n de ICRS**: La EDQM inicia la distribuci\u00f3n de las ICRS tras su caracterizaci\u00f3n.\n5. **Informes al Comit\u00e9 de Expertos**: La Secretar\u00eda de la OMS presenta informes de casos y un informe anual al Comit\u00e9 de Expertos.\n6. **Liberaci\u00f3n Final**: El Comit\u00e9 de Expertos realiza la liberaci\u00f3n final de las ICRS y proporciona retroalimentaci\u00f3n a la EDQM.\n\n**Entidades:**\n- **EDQM**: Direcci\u00f3n Europea de Calidad de los Medicamentos y Atenci\u00f3n Sanitaria.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **ICRS**: Sustancias Qu\u00edmicas de Referencia Internacional.\n- **Comit\u00e9 de Expertos**: Grupo encargado de la revisi\u00f3n y liberaci\u00f3n final de las ICRS. \n\nEste resumen destaca los pasos del nuevo procedimiento y las entidades involucradas en el proceso de caracterizaci\u00f3n y distribuci\u00f3n de ICRS.", "excerpt_keywords": "Keywords: WHO, pharmaceutical microbiology, good practices, laboratory guidelines, validation methods"}}, "1d1cbdab-74ac-4489-8c0d-72223073dd35": {"node_ids": ["d5838c7f-b2dd-4006-b2ce-f76927c2db2f"], "metadata": {"page_label": "82", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n6.1 International standards and pharmacopoeial reference substances  \n6.2 Reference cultures\n\n7. Sampling\n\n8. Sample handling and identification\n\n9. Disposal of contaminated waste\n\n10. Quality assurance of results and quality control of performance  \n10.1 Internal quality control\n\n11. Testing procedures\n\n12. Test reports\n\nReferences\n\nFurther reading\n\n## Appendix 1\nExamples of zones in which operations could be carried out\n\n## Appendix 2\nExamples of maintenance of equipment\n\n## Appendix 3\nExamples of calibration checks and intervals for different laboratory equipment\n\n## Appendix 4\nExamples of equipment qualification and monitoring\n\n## Appendix 5\nGeneral use of reference cultures", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la calidad y el control en laboratorios, incluyendo materiales de referencia, procedimientos de muestreo, manejo de muestras, eliminaci\u00f3n de desechos contaminados, aseguramiento de la calidad, y procedimientos de prueba. Adem\u00e1s, incluye ap\u00e9ndices que ofrecen ejemplos pr\u00e1cticos sobre operaciones, mantenimiento de equipos, calibraci\u00f3n y uso de cultivos de referencia.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los ejemplos de mantenimiento de equipos que se mencionan en el Ap\u00e9ndice 2 del informe?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las pr\u00e1cticas de mantenimiento recomendadas para asegurar el funcionamiento adecuado de los equipos de laboratorio.\n\n2. **\u00bfQu\u00e9 tipos de controles de calidad interna se sugieren en la secci\u00f3n 10.1 del documento?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos de control de calidad interna que se deben implementar para garantizar la fiabilidad de los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 se entiende por \"cultivos de referencia\" y cu\u00e1l es su uso general seg\u00fan el Ap\u00e9ndice 5?**\n   - Esta pregunta busca una definici\u00f3n y explicaci\u00f3n del prop\u00f3sito de los cultivos de referencia en el contexto de las pruebas de laboratorio, as\u00ed como ejemplos de su aplicaci\u00f3n pr\u00e1ctica.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nEl anexo 2 del *Technical Report Series 961* de la OMS se centra en las buenas pr\u00e1cticas para laboratorios de microbiolog\u00eda farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionados en la secci\u00f3n:\n\n1. **Contexto y Justificaci\u00f3n**:\n   - La OMS revis\u00f3 las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* en 2009.\n   - Se identific\u00f3 la necesidad de proporcionar orientaci\u00f3n adicional en microbiolog\u00eda durante las inspecciones de laboratorios.\n\n2. **Estructura del Documento**:\n   - **Introducci\u00f3n y alcance**: Define el prop\u00f3sito del documento.\n   - **Glosario**: Incluye t\u00e9rminos clave utilizados en el documento.\n\n3. **Temas Principales**:\n   - **Personal**: Consideraciones sobre la capacitaci\u00f3n y competencias del personal en el laboratorio.\n   - **Entorno**: \n     - **Instalaciones (Premises)**: Dise\u00f1o y mantenimiento de las instalaciones del laboratorio.\n     - **Monitoreo ambiental**: Estrategias para asegurar un ambiente controlado.\n     - **Limpieza, desinfecci\u00f3n e higiene**: Protocolos para mantener la limpieza y la seguridad.\n     - **Instalaciones para pruebas de esterilidad**: Espacios espec\u00edficos para realizar pruebas de esterilidad.\n   - **Validaci\u00f3n de m\u00e9todos de prueba**: Importancia de validar los m\u00e9todos utilizados en el laboratorio.\n   - **Equipo**: \n     - **Mantenimiento**: Procedimientos para el mantenimiento adecuado del equipo.\n     - **Calificaci\u00f3n**: Aseguramiento de que el equipo cumple con los est\u00e1ndares requeridos.\n     - **Calibraci\u00f3n y verificaci\u00f3n de rendimiento**: Monitoreo continuo del uso y precisi\u00f3n del equipo.\n   - **Reactivos y medios de cultivo**: \n     - **Reactivos**: Consideraciones sobre la calidad y manejo de reactivos.\n     - **Medios de cultivo**: Importancia de los medios utilizados para el crecimiento microbiol\u00f3gico.\n     - **Etiquetado**: Normas para el etiquetado adecuado de reactivos y medios.\n     - **Resucitaci\u00f3n de organismos**: M\u00e9todos para la recuperaci\u00f3n y mantenimiento de cultivos microbiol\u00f3gicos.\n\nEste resumen destaca la importancia de seguir buenas pr\u00e1cticas en laboratorios de microbiolog\u00eda farmac\u00e9utica para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: reference materials, quality assurance, laboratory procedures, microbiology, equipment maintenance"}}, "f57177f4-3da1-400a-b3af-0aaa415f6838": {"node_ids": ["ce200727-3ba2-4149-b1d1-a4d8127a4db5"], "metadata": {"page_label": "83", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction and scope of document\n\nPharmaceutical microbiology laboratories may be involved in:\n\n- sterility testing;\n- detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and moulds) and testing for bacterial endotoxins in different materials (e.g. starting materials, water), products, surfaces, garments and the environment; and\n- assay using microorganisms as part of the test system.\n\nThese guidelines relate to all microbiology laboratories involved in the above-mentioned testing activities, whether they are independent or a department or unit of a pharmaceutical manufacturing facility.\n\nThese guidelines are based on and supplement the requirements described in *Good practices for pharmaceutical quality control laboratories* (1); *General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision* (2); *The International Pharmacopoeia, Fourth Edition* (3); *First Supplement to The International Pharmacopoeia, Fourth Edition* (4); and *ISO/IEC 17025* (5).\n\n# Glossary\n\n**calibration**  \nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n**certified reference material**  \nReference material, characterized by a metrologically valid procedure for one or more specified properties, accompanied by a certificate that provides the value of the specified property, its associated uncertainty and a statement of metrological traceability.\n\n**limit of detection**  \nThe lowest number of microorganisms that can be detected, but in numbers that cannot be estimated accurately.\n\n**precision**  \nThe degree of agreement among individual results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, *Technical Report Series 961*, establece directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica que realizan pruebas de esterilidad, detecci\u00f3n e identificaci\u00f3n de microorganismos, y ensayos utilizando microorganismos. Estas directrices son aplicables a laboratorios independientes y a departamentos dentro de instalaciones de fabricaci\u00f3n farmac\u00e9utica. Adem\u00e1s, se incluyen definiciones clave relacionadas con la calibraci\u00f3n, materiales de referencia certificados, l\u00edmites de detecci\u00f3n y precisi\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipos de pruebas microbiol\u00f3gicas est\u00e1n cubiertas por las directrices de la OMS en el documento?**\n   - Las directrices cubren pruebas de esterilidad, detecci\u00f3n, aislamiento, enumeraci\u00f3n e identificaci\u00f3n de microorganismos (bacterias, levaduras y mohos), as\u00ed como pruebas de endotoxinas bacterianas en diversos materiales, productos, superficies, prendas y el entorno.\n\n2. **\u00bfCu\u00e1les son las bases sobre las que se fundamentan estas directrices?**\n   - Estas directrices se basan en y complementan los requisitos descritos en documentos como *Good practices for pharmaceutical quality control laboratories*, *The International Pharmacopoeia*, y normas como *ISO/IEC 17025*.\n\n3. **\u00bfQu\u00e9 se entiende por \"material de referencia certificado\" seg\u00fan el documento?**\n   - Un material de referencia certificado es aquel que ha sido caracterizado mediante un procedimiento metrol\u00f3gicamente v\u00e1lido para una o m\u00e1s propiedades especificadas, y que viene acompa\u00f1ado de un certificado que proporciona el valor de la propiedad especificada, su incertidumbre asociada y una declaraci\u00f3n de trazabilidad metrol\u00f3gica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Materiales de referencia y cultivos de referencia**:\n   - Secci\u00f3n 6 aborda la importancia de los est\u00e1ndares internacionales y las sustancias de referencia farmacop\u00e9utica, as\u00ed como el uso de cultivos de referencia en laboratorios.\n\n2. **Muestreo**:\n   - Secci\u00f3n 7 se centra en los procedimientos de muestreo, que son fundamentales para la obtenci\u00f3n de muestras representativas.\n\n3. **Manejo e identificaci\u00f3n de muestras**:\n   - Secci\u00f3n 8 trata sobre c\u00f3mo manejar e identificar adecuadamente las muestras para evitar contaminaciones y asegurar la integridad de los resultados.\n\n4. **Eliminaci\u00f3n de desechos contaminados**:\n   - Secci\u00f3n 9 discute las pr\u00e1cticas adecuadas para la disposici\u00f3n de residuos contaminados, un aspecto cr\u00edtico para la seguridad en el laboratorio.\n\n5. **Aseguramiento de la calidad y control de calidad**:\n   - Secci\u00f3n 10 se enfoca en la garant\u00eda de resultados de calidad y el control de rendimiento, incluyendo controles de calidad internos en la subsecci\u00f3n 10.1.\n\n6. **Procedimientos de prueba**:\n   - Secci\u00f3n 11 describe los m\u00e9todos y procedimientos utilizados para realizar pruebas en el laboratorio.\n\n7. **Informes de prueba**:\n   - Secci\u00f3n 12 se refiere a la elaboraci\u00f3n y presentaci\u00f3n de informes de prueba, que son esenciales para la comunicaci\u00f3n de resultados.\n\n8. **Ap\u00e9ndices**:\n   - **Ap\u00e9ndice 1**: Ejemplos de zonas para operaciones de laboratorio.\n   - **Ap\u00e9ndice 2**: Ejemplos de mantenimiento de equipos.\n   - **Ap\u00e9ndice 3**: Ejemplos de verificaciones de calibraci\u00f3n y sus intervalos.\n   - **Ap\u00e9ndice 4**: Ejemplos de calificaci\u00f3n y monitoreo de equipos.\n   - **Ap\u00e9ndice 5**: Uso general de cultivos de referencia.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el informe.\n- **Laboratorios**: Contexto en el que se aplican los procedimientos y est\u00e1ndares mencionados.\n- **Cultivos de referencia**: Elementos esenciales para la validaci\u00f3n de pruebas en laboratorios.\n- **Contaminaci\u00f3n**: Riesgo que se aborda en la eliminaci\u00f3n de desechos y manejo de muestras.\n- **Calidad**: Concepto central en el aseguramiento de resultados y control de rendimiento. \n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando la importancia de los est\u00e1ndares y procedimientos en el contexto de la calidad en laboratorios.", "excerpt_keywords": "Keywords: pharmaceutical microbiology, sterility testing, certified reference material, limit of detection, quality control"}}, "858eb68a-5a72-4859-b4e7-12449b9c3c2a": {"node_ids": ["04376628-07b7-4fed-8993-c968dcdccd13"], "metadata": {"page_label": "84", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# quantitation limit (limit of quantitation)\n\nApplied to quantitative microbiological tests. The lowest number of microorganisms within a defined variability that may be counted under the experimental conditions of the method under evaluation.\n\n# reference cultures\n\nCollective term for reference strain and reference stocks.\n\n# reference material\n\nMaterial sufficiently homogeneous and stable with respect to one or more specified properties, which has been established to be fit for its intended use in a measurement process.\n\n# reference method\n\nA method which has been validated as being fit for purpose, with which an alternative method may be compared.\n\n# reference stocks\n\nA set of separate identical cultures obtained by a single subculture from the reference strain (6).\n\n# reference strains\n\nMicroorganisms defined at least to the genus and species level, catalogued and described according to its characteristics and preferably stating its origin (6). Normally obtained from a recognized national or international collection.\n\n# repeatability\n\nCloseness of the agreement between the results of successive measurements of the same measure and under the same conditions of measurement (adapted from ISO).\n\n# reproducibility\n\nReproducibility expresses precision between laboratories.\n\n# robustness (or ruggedness)\n\nThe ability of the procedure to provide analytical results of acceptable accuracy and precision under a variety of conditions.\n\n# sensitivity\n\nThe fraction of the total number of positive cultures or colonies correctly assigned in the presumptive inspection (7).\n\n# specificity (selectivity)\n\nThe ability of the method to detect the required range of microorganisms that might be present in the test sample.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) titulado \"Technical Report Series 961\" aborda conceptos clave relacionados con pruebas microbiol\u00f3gicas cuantitativas. Se definen t\u00e9rminos como l\u00edmite de cuantificaci\u00f3n, cultivos de referencia, m\u00e9todos de referencia, y se discuten aspectos de precisi\u00f3n y exactitud en mediciones microbiol\u00f3gicas, incluyendo repetibilidad, reproducibilidad, robustez, sensibilidad y especificidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la importancia del l\u00edmite de cuantificaci\u00f3n en las pruebas microbiol\u00f3gicas y c\u00f3mo se determina?**\n   - Esta pregunta busca profundizar en el concepto de l\u00edmite de cuantificaci\u00f3n, que se menciona en el contexto, y su relevancia en la pr\u00e1ctica de pruebas microbiol\u00f3gicas.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para validar un m\u00e9todo de referencia y c\u00f3mo se compara con m\u00e9todos alternativos?**\n   - Esta pregunta se centra en el proceso de validaci\u00f3n de m\u00e9todos de referencia, un aspecto clave mencionado en el texto, y busca entender los criterios espec\u00edficos que se aplican.\n\n3. **\u00bfC\u00f3mo se define y mide la robustez de un procedimiento anal\u00edtico en microbiolog\u00eda?**\n   - Esta pregunta explora el concepto de robustez, que se describe en el contexto, y busca detalles sobre c\u00f3mo se eval\u00faa en la pr\u00e1ctica.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona definiciones y explicaciones sobre t\u00e9rminos y conceptos fundamentales en la microbiolog\u00eda cuantitativa, enfatizando la importancia de la precisi\u00f3n y la exactitud en las mediciones. Se abordan aspectos como la validaci\u00f3n de m\u00e9todos, la homogeneidad de los materiales de referencia y la capacidad de los m\u00e9todos para detectar microorganismos espec\u00edficos. Estos conceptos son esenciales para garantizar la fiabilidad de los resultados en pruebas microbiol\u00f3gicas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, *Technical Report Series 961*, aborda las directrices para laboratorios de microbiolog\u00eda farmac\u00e9utica, centr\u00e1ndose en las siguientes \u00e1reas clave:\n\n1. **Actividades de Laboratorio**:\n   - Pruebas de esterilidad.\n   - Detecci\u00f3n, aislamiento, enumeraci\u00f3n e identificaci\u00f3n de microorganismos (bacterias, levaduras y mohos).\n   - Pruebas de endotoxinas bacterianas en diversos materiales, productos, superficies, prendas y el entorno.\n   - Ensayos que utilizan microorganismos como parte del sistema de prueba.\n\n2. **Aplicabilidad**:\n   - Las directrices son relevantes para todos los laboratorios de microbiolog\u00eda, ya sean independientes o parte de una instalaci\u00f3n de fabricaci\u00f3n farmac\u00e9utica.\n\n3. **Fundamentaci\u00f3n**:\n   - Las directrices complementan requisitos establecidos en documentos como:\n     - *Good practices for pharmaceutical quality control laboratories*.\n     - *General guidelines for the establishment, maintenance and distribution of chemical reference substances*.\n     - *The International Pharmacopoeia* (Cuarta Edici\u00f3n y su Primer Suplemento).\n     - Normas como *ISO/IEC 17025*.\n\n4. **Glosario de T\u00e9rminos Clave**:\n   - **Calibraci\u00f3n**: Proceso para establecer la relaci\u00f3n entre los valores indicados por un instrumento y los valores conocidos de un est\u00e1ndar de referencia.\n   - **Material de referencia certificado**: Material caracterizado por un procedimiento metrol\u00f3gicamente v\u00e1lido, acompa\u00f1ado de un certificado que proporciona el valor de una propiedad especificada y su incertidumbre.\n   - **L\u00edmite de detecci\u00f3n**: La menor cantidad de microorganismos que puede ser detectada, aunque no se pueda estimar con precisi\u00f3n.\n   - **Precisi\u00f3n**: Grado de acuerdo entre resultados individuales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorios de Microbiolog\u00eda Farmac\u00e9utica**: Entidades que realizan las pruebas mencionadas.\n- **Documentos de Referencia**: Incluyen pr\u00e1cticas de control de calidad, farmacopoeias y normas ISO.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades relevantes en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: microbiology, quantitation limit, reference method, sensitivity, reproducibility"}}, "1b9dedcb-fe53-4715-8668-6ffb821bef57": {"node_ids": ["b1c80ef4-9fa6-4379-a50e-34e12f717087"], "metadata": {"page_label": "85", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n1. **Validation**\n\n   Action of proving, in accordance with the principles of good practice quality guidelines and regulations (GxP), that any procedure, process, equipment (including the software or hardware used), material, activity or system actually and consistently leads to the expected results.\n\n2. **Verification**\n\n   The application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine compliance with GxP principles.\n\n3. **Working Culture**\n\n   A primary subculture from a reference stock (6).\n\n## 1. Personnel\n\n1.1 Microbiological testing should be performed and supervised by an experienced person, qualified in microbiology or equivalent. Staff should have basic training in microbiology and relevant practical experience before being allowed to perform work covered by the scope of testing.\n\n1.2 Current job descriptions for all personnel involved in tests and/or calibrations, validations and verifications should be maintained. The laboratory should also maintain records of all technical personnel, describing their qualifications, training and experience.\n\n1.3 If the laboratory includes opinions and interpretations of test results in reports, this should be done by authorized personnel with suitable experience and relevant knowledge of the specific application including, for example, regulatory and technological requirements and acceptability criteria.\n\n1.4 The laboratory management should ensure that all personnel have received adequate training for the competent performance of tests and operation of equipment. This should include training in basic techniques, e.g. plate pouring, counting of colonies, aseptic technique, media preparation, serial dilutions, and basic techniques in identification, with acceptability determined using objective criteria where relevant. Personnel may only perform tests on samples if they are either recognized as competent to do so, or if they do so under adequate supervision. Competence should be monitored continuously with provision for retraining where necessary. Where a method or technique is not in regular use, the competency of the personnel to perform the test should be verified before testing is undertaken. In some cases it is acceptable to relate competence to a general technique or instrument being used rather than to particular methods.\n\n1.5 Personnel should be trained in necessary procedures for containment of microorganisms within the laboratory facility.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Validaci\u00f3n y Verificaci\u00f3n**: El documento establece definiciones claras de validaci\u00f3n y verificaci\u00f3n en el contexto de las buenas pr\u00e1cticas de calidad (GxP), enfatizando la importancia de demostrar que los procedimientos y sistemas cumplen consistentemente con los resultados esperados.\n\n2. **Requisitos de Personal**: Se detallan las calificaciones y la formaci\u00f3n necesarias para el personal que realiza pruebas microbiol\u00f3gicas, as\u00ed como la importancia de mantener registros actualizados de las competencias y experiencias del personal t\u00e9cnico.\n\n3. **Capacitaci\u00f3n y Competencia**: Se subraya la necesidad de que el personal reciba capacitaci\u00f3n adecuada en t\u00e9cnicas microbiol\u00f3gicas y en procedimientos de contenci\u00f3n de microorganismos, asegurando que solo personal competente realice pruebas y que se lleve a cabo un monitoreo continuo de la competencia.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n se requiere para el personal que realiza pruebas microbiol\u00f3gicas seg\u00fan el documento?**\n   - El personal debe tener formaci\u00f3n b\u00e1sica en microbiolog\u00eda y experiencia pr\u00e1ctica relevante antes de realizar trabajos cubiertos por el alcance de las pruebas. Adem\u00e1s, deben recibir capacitaci\u00f3n en t\u00e9cnicas espec\u00edficas como el vertido de placas, conteo de colonias, t\u00e9cnica as\u00e9ptica, preparaci\u00f3n de medios y diluciones seriadas.\n\n2. **\u00bfC\u00f3mo se asegura la competencia del personal en el laboratorio?**\n   - La competencia del personal debe ser monitoreada continuamente, y se debe proporcionar reentrenamiento cuando sea necesario. Si un m\u00e9todo o t\u00e9cnica no se utiliza regularmente, la competencia del personal para realizar la prueba debe ser verificada antes de que se lleve a cabo la prueba.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar al incluir opiniones e interpretaciones de resultados de pruebas en los informes del laboratorio?**\n   - Las opiniones e interpretaciones de los resultados de las pruebas deben ser realizadas por personal autorizado que tenga experiencia adecuada y conocimiento relevante de la aplicaci\u00f3n espec\u00edfica, incluyendo requisitos regulatorios y tecnol\u00f3gicos, as\u00ed como criterios de aceptabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **L\u00edmite de Cuantificaci\u00f3n (Quantitation Limit)**: Se refiere al n\u00famero m\u00e1s bajo de microorganismos que puede contarse en condiciones experimentales definidas durante pruebas microbiol\u00f3gicas cuantitativas.\n\n2. **Cultivos de Referencia**: T\u00e9rmino colectivo que incluye cepas de referencia y stocks de referencia, utilizados para asegurar la consistencia en las pruebas.\n\n3. **Material de Referencia**: Material que es homog\u00e9neo y estable en propiedades espec\u00edficas, validado para su uso en procesos de medici\u00f3n.\n\n4. **M\u00e9todo de Referencia**: M\u00e9todo validado que sirve como est\u00e1ndar para comparar otros m\u00e9todos alternativos.\n\n5. **Stocks de Referencia**: Culturas id\u00e9nticas obtenidas a partir de una \u00fanica subcultivo de una cepa de referencia.\n\n6. **Cepas de Referencia**: Microorganismos catalogados y descritos al menos a nivel de g\u00e9nero y especie, normalmente obtenidos de colecciones reconocidas.\n\n7. **Repetibilidad**: Grado de concordancia entre resultados de mediciones sucesivas bajo las mismas condiciones.\n\n8. **Reproducibilidad**: Precisi\u00f3n de los resultados entre diferentes laboratorios.\n\n9. **Robustez (o Rugosidad)**: Capacidad de un procedimiento para proporcionar resultados anal\u00edticos precisos y exactos bajo diversas condiciones.\n\n10. **Sensibilidad**: Proporci\u00f3n de cultivos o colonias positivas correctamente identificadas en una inspecci\u00f3n presuntiva.\n\n11. **Especificidad (Selectividad)**: Capacidad del m\u00e9todo para detectar un rango espec\u00edfico de microorganismos en una muestra de prueba.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el documento.\n- **ISO**: Organizaci\u00f3n que proporciona est\u00e1ndares para la medici\u00f3n y evaluaci\u00f3n en microbiolog\u00eda.\n\nEste resumen destaca los conceptos fundamentales y las definiciones esenciales que son cruciales para la pr\u00e1ctica de pruebas microbiol\u00f3gicas cuantitativas, enfatizando la importancia de la precisi\u00f3n y la validaci\u00f3n de m\u00e9todos.", "excerpt_keywords": "Keywords: validation, verification, microbiological testing, personnel training, good practice quality guidelines"}}, "54de6d59-2eed-4668-bc36-4b405330cba9": {"node_ids": ["40b7fea4-8170-438d-bd3c-8711682ebec1"], "metadata": {"page_label": "86", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Environment\n\n## 2.1 Premises\n\n2.1.1 Microbiology laboratories and certain support equipment (e.g. autoclaves and glassware) should be dedicated and separated from other areas, especially from production areas.\n\n2.1.2 Microbiology laboratories should be designed to suit the operations to be carried out in them. There should be sufficient space for all activities to avoid mix ups, contamination and cross-contamination. There should be adequate suitable space for samples, reference organisms, media (if necessary, with cooling), testing and records. Due to the nature of some materials (e.g. sterile media versus reference organisms or incubated cultures), separate storage locations may be necessary.\n\n2.1.3 Laboratories should be appropriately designed and should take into account the suitability of construction materials to enable appropriate cleaning, disinfection and minimize the risks of contamination.\n\n2.1.4 There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions, including temperature and humidity controls where required, should be in place for microbiological laboratories. The air supplied to the laboratory should be of appropriate quality and should not be a source of contamination.\n\n2.1.5 Access to the microbiological laboratory should be restricted to authorized personnel. Personnel should be made aware of:\n\n- the appropriate entry and exit procedures including gowning;\n- the intended use of a particular area;\n- the restrictions imposed on working within such areas;\n- the reasons for imposing such restrictions; and\n- the appropriate containment levels.\n\n2.1.6 Laboratory activities, such as sample preparation, media and equipment preparation and enumeration of microorganisms, should be segregated by space or at least in time, so as to minimize risks of cross-contamination, false-positive results and false-negative results. Where non-dedicated areas are used, risk management principles should be applied. Sterility testing should always be performed in a dedicated area.\n\n2.1.7 Consideration should be given to designing appropriate classified areas for the operations to be performed within the microbiology laboratory. The classification should be based on the criticality of the product and the operations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Dise\u00f1o y separaci\u00f3n de laboratorios**: Los laboratorios de microbiolog\u00eda deben estar dise\u00f1ados espec\u00edficamente para sus operaciones, con suficiente espacio para evitar la contaminaci\u00f3n y el cruce de muestras. Adem\u00e1s, deben estar separados de otras \u00e1reas, especialmente de las de producci\u00f3n.\n\n2. **Control de acceso y procedimientos**: El acceso a los laboratorios microbiol\u00f3gicos debe ser restringido a personal autorizado, que debe estar informado sobre los procedimientos de entrada y salida, el uso de las \u00e1reas y las restricciones pertinentes.\n\n3. **Manejo de actividades y clasificaci\u00f3n de \u00e1reas**: Las actividades dentro del laboratorio deben estar segregadas para minimizar riesgos de contaminaci\u00f3n. Adem\u00e1s, se debe considerar la clasificaci\u00f3n de \u00e1reas seg\u00fan la criticidad del producto y las operaciones realizadas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar un laboratorio de microbiolog\u00eda para evitar la contaminaci\u00f3n?**\n   - Esta pregunta se centra en los aspectos espec\u00edficos del dise\u00f1o del laboratorio, como el espacio, los materiales de construcci\u00f3n y la segregaci\u00f3n de actividades.\n\n2. **\u00bfCu\u00e1les son los procedimientos que el personal debe seguir al acceder a un laboratorio microbiol\u00f3gico?**\n   - Esta pregunta busca detalles sobre los procedimientos de entrada y salida, as\u00ed como las restricciones que deben conocer los empleados.\n\n3. **\u00bfC\u00f3mo se deben clasificar las \u00e1reas dentro de un laboratorio de microbiolog\u00eda y qu\u00e9 factores influyen en esta clasificaci\u00f3n?**\n   - Esta pregunta se enfoca en la clasificaci\u00f3n de \u00e1reas dentro del laboratorio y los criterios que determinan dicha clasificaci\u00f3n, como la criticidad del producto y las operaciones realizadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n y Verificaci\u00f3n**:\n   - **Validaci\u00f3n**: Proceso de demostrar que procedimientos, procesos, equipos y sistemas cumplen consistentemente con los resultados esperados, de acuerdo con las buenas pr\u00e1cticas de calidad (GxP).\n   - **Verificaci\u00f3n**: Aplicaci\u00f3n de m\u00e9todos y evaluaciones para determinar el cumplimiento de los principios GxP.\n\n2. **Requisitos de Personal**:\n   - **Calificaciones**: El personal que realiza pruebas microbiol\u00f3gicas debe ser experimentado y calificado en microbiolog\u00eda o equivalente.\n   - **Formaci\u00f3n**: Se requiere formaci\u00f3n b\u00e1sica en microbiolog\u00eda y experiencia pr\u00e1ctica relevante antes de realizar pruebas.\n\n3. **Registros de Personal**:\n   - Mantener descripciones de trabajo actualizadas y registros de calificaciones, formaci\u00f3n y experiencia de todo el personal t\u00e9cnico involucrado en pruebas, calibraciones, validaciones y verificaciones.\n\n4. **Opiniones e Interpretaciones**:\n   - Solo personal autorizado con experiencia y conocimiento relevante debe incluir opiniones e interpretaciones de resultados en los informes del laboratorio.\n\n5. **Capacitaci\u00f3n y Competencia**:\n   - El personal debe recibir capacitaci\u00f3n adecuada en t\u00e9cnicas microbiol\u00f3gicas y operaci\u00f3n de equipos, incluyendo t\u00e9cnicas como vertido de placas, conteo de colonias, t\u00e9cnica as\u00e9ptica, preparaci\u00f3n de medios y diluciones seriadas.\n   - La competencia del personal debe ser monitoreada continuamente, con provisiones para reentrenamiento cuando sea necesario.\n\n6. **Contenci\u00f3n de Microorganismos**:\n   - El personal debe estar capacitado en procedimientos necesarios para la contenci\u00f3n de microorganismos dentro de las instalaciones del laboratorio.\n\n### Entidades Clave\n- **GxP**: Buenas pr\u00e1cticas de calidad.\n- **Microbiolog\u00eda**: Campo de estudio relevante para el personal.\n- **Laboratorio**: Entidad donde se realizan las pruebas microbiol\u00f3gicas.\n- **Personal Autorizado**: Individuos con la experiencia y conocimiento necesarios para interpretar resultados.", "excerpt_keywords": "Keywords: microbiology laboratories, contamination control, access procedures, laboratory design, classified areas"}}, "7a0374cf-db31-4df6-b1c5-e88e80c8755e": {"node_ids": ["2baaeac0-3da2-4794-a8cc-46dc65e9818a"], "metadata": {"page_label": "87", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Environmental monitoring in the laboratory\n\n2.2.1 Where necessary and appropriate (e.g. in areas for sterility testing) an environmental monitoring programme should be in place which covers, for example, use of active air monitoring, air settling or contact plates, temperature and pressure differentials. Alert and action limits should be defined. Trending of environmental monitoring results should be carried out.\n\n# 2.3 Cleaning, disinfection and hygiene\n\n2.3.1 There should be a documented cleaning and disinfection programme. Results of environmental monitoring should be considered where relevant.\n\n2.3.2 There should be a procedure for dealing with spillages.\n\n2.3.3 Adequate hand-washing and hand-disinfection facilities should be available.\n\n# 2.4 Sterility test facilities\n\n2.4.1 Sterility test facilities have specific environmental requirements to ensure the integrity of tests carried out. *WHO good manufacturing practices (GMP) for sterile pharmaceutical products* (8) requires that sterility testing should be carried out and specifies requirements for sterility testing. This section details the clean-room requirements for a sterility test facility.\n\n2.4.2 Sterility testing should be performed under aseptic conditions, which should be equivalent to air quality standards required for the aseptic manufacture of pharmaceutical products. The premises, services and equipment should be subject to the appropriate qualification process.\n\n2.4.3 The sterility testing should be carried out within a Grade A unidirectional airflow protected zone or a biosafety cabinet (if warranted), which should be located within a clean room with a Grade B background. Alternatively, the testing can be carried out within a barrier isolator. Care should be taken with the design of the facility layout and room airflow patterns, to ensure that the unidirectional airflow patterns are not disrupted.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles, enfoc\u00e1ndose en la importancia del monitoreo ambiental, la limpieza y desinfecci\u00f3n, as\u00ed como los requisitos espec\u00edficos para las instalaciones de pruebas de esterilidad. Se enfatiza la necesidad de mantener condiciones ambientales controladas y procedimientos adecuados para garantizar la integridad de las pruebas de esterilidad.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en un programa de monitoreo ambiental en \u00e1reas de pruebas de esterilidad?**\n   - Respuesta: Un programa de monitoreo ambiental debe incluir el uso de monitoreo activo del aire, placas de contacto, monitoreo de asentamiento de aire, as\u00ed como el control de diferenciales de temperatura y presi\u00f3n. Tambi\u00e9n se deben definir l\u00edmites de alerta y acci\u00f3n, y realizar un seguimiento de los resultados del monitoreo ambiental.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para llevar a cabo pruebas de esterilidad seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n de la OMS?**\n   - Respuesta: Las pruebas de esterilidad deben realizarse bajo condiciones as\u00e9pticas equivalentes a los est\u00e1ndares de calidad del aire requeridos para la fabricaci\u00f3n as\u00e9ptica de productos farmac\u00e9uticos. Esto incluye realizar las pruebas en una zona de flujo de aire unidireccional de Grado A o en una cabina de bioseguridad, dentro de una sala limpia con un fondo de Grado B.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para garantizar la higiene y la limpieza en las instalaciones de pruebas de esterilidad?**\n   - Respuesta: Debe existir un programa documentado de limpieza y desinfecci\u00f3n, procedimientos para manejar derrames, y se deben proporcionar instalaciones adecuadas para el lavado y desinfecci\u00f3n de manos. Adem\u00e1s, los resultados del monitoreo ambiental deben ser considerados donde sea relevante.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de Laboratorios de Microbiolog\u00eda**:\n   - Los laboratorios deben ser dedicados y separados de otras \u00e1reas, especialmente de las de producci\u00f3n.\n   - Deben estar dise\u00f1ados para las operaciones espec\u00edficas, con suficiente espacio para evitar contaminaci\u00f3n y confusiones.\n   - Es necesario considerar los materiales de construcci\u00f3n para facilitar la limpieza y desinfecci\u00f3n.\n\n2. **Control de Aire**:\n   - Se requiere un suministro de aire separado para los laboratorios y las \u00e1reas de producci\u00f3n, con unidades de manejo de aire y controles de temperatura y humedad.\n\n3. **Acceso Restringido**:\n   - El acceso a los laboratorios debe ser limitado a personal autorizado, que debe estar informado sobre procedimientos de entrada y salida, uso de \u00e1reas y restricciones.\n\n4. **Segregaci\u00f3n de Actividades**:\n   - Las actividades dentro del laboratorio deben estar segregadas por espacio o tiempo para minimizar riesgos de contaminaci\u00f3n y errores en los resultados.\n   - Las pruebas de esterilidad deben realizarse en \u00e1reas dedicadas.\n\n5. **Clasificaci\u00f3n de \u00c1reas**:\n   - Se debe considerar la clasificaci\u00f3n de \u00e1reas dentro del laboratorio seg\u00fan la criticidad del producto y las operaciones realizadas.\n\n### Entidades Clave\n- **Laboratorios de Microbiolog\u00eda**: Espacios dedicados para la realizaci\u00f3n de pruebas microbiol\u00f3gicas.\n- **Equipos de Soporte**: Incluyen autoclaves y material de vidrio.\n- **Personal Autorizado**: Empleados que tienen acceso a las \u00e1reas restringidas del laboratorio.\n- **Contaminaci\u00f3n**: Riesgo que se busca minimizar mediante el dise\u00f1o y las pr\u00e1cticas de laboratorio.\n- **Pruebas de Esterilidad**: Actividades cr\u00edticas que deben realizarse en \u00e1reas espec\u00edficas para asegurar resultados confiables.", "excerpt_keywords": "Keywords: environmental monitoring, sterility testing, good manufacturing practices, cleaning and disinfection, aseptic conditions"}}, "ba02e8f9-bd26-48a1-860f-feaa710fa1c0": {"node_ids": ["c6d212b6-51f0-4c9d-ac3d-da282f274808"], "metadata": {"page_label": "88", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4.4 \nThe clean-room classification and air-handling equipment of the sterility test facilities should be requalified at least annually by a competent person or contractor. The environment should comply with the non-viable and viable limits, and verification of high efficiency particulate air (HEPA) filter integrity and room airflows should be performed. However, an alternative frequency of the monitoring may be justified based on quality risk management (QRM). Mapping locations for sample points for routine monitoring should be documented, as well as exposure duration, and frequency of all types of microbiological environmental monitoring should be specified in written procedures.\n\n## 2.4.5 \nAir supplied to Grade A and B zones should be via terminal HEPA filters.\n\n## 2.4.6 \nAppropriate airflow alarms and pressure differentials and indication instruments should be provided (*GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms* (8); and *GMP for sterile pharmaceutical products* (8)).\n\n## 2.4.7 \nRoom pressure readings should be taken and recorded from externally mounted gauges unless a validated continuous monitoring system is installed. As a minimum, readings should be taken prior to entry of the operator to the test suite. Pressure gauges should be labelled to indicate the area served and the acceptable specification.\n\n## 2.4.8 \nEntry to the clean room should be via a system of airlocks and a change room where operators are required to don suitable clean-room garments. The final change room should be under \u201cat rest\u201d conditions of the same grade as the room it serves. Change rooms should be of adequate size for ease of changing. There should be clear demarcation of the different zones.\n\n## 2.4.9 \nGarments for the sterility test operator should comply with the principles of section 10 of *WHO GMP for sterile pharmaceutical products* (8). Operators should be trained and certified in gowning procedures with training records maintained.\n\n## 2.4.10 \nThe fittings and finishes of the premises should comply with section 11 of *WHO GMP for sterile pharmaceutical products* (8).\n\n## 2.4.11 \nEnvironmental microbiological monitoring should reflect the facility used (room or isolator) and include a combination of air and surface sampling methods appropriate to the facility, such as:\n\n- active air sampling;\n- settle (exposure) plates;\n- surface contact \u2014 replicate organism detection and counting (RODAC) plates, swabs or flexible films;\n- operators\u2019 glove prints.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda las normativas y procedimientos necesarios para garantizar la esterilidad en las instalaciones de pruebas de esterilidad. Se enfatiza la importancia de la clasificaci\u00f3n de salas limpias, el manejo del aire, la capacitaci\u00f3n de los operadores y el monitoreo microbiol\u00f3gico ambiental. Se establecen requisitos espec\u00edficos para la revalidaci\u00f3n de equipos, el uso de filtros HEPA, la toma de lecturas de presi\u00f3n, y la vestimenta adecuada para los operadores, as\u00ed como la documentaci\u00f3n de los procedimientos de monitoreo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la frecuencia m\u00ednima recomendada para la revalidaci\u00f3n de la clasificaci\u00f3n de salas limpias y el equipo de manejo de aire en las instalaciones de pruebas de esterilidad?**\n   - La revalidaci\u00f3n debe realizarse al menos anualmente por una persona o contratista competente.\n\n2. **\u00bfQu\u00e9 tipo de m\u00e9todos de muestreo microbiol\u00f3gico ambiental se deben utilizar en las instalaciones de pruebas de esterilidad?**\n   - Se deben utilizar m\u00e9todos como muestreo de aire activo, placas de asentamiento, placas RODAC, hisopos o pel\u00edculas flexibles, y huellas de guantes de los operadores.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplirse para la vestimenta de los operadores en las instalaciones de pruebas de esterilidad?**\n   - Los operadores deben usar prendas que cumplan con los principios establecidos en la secci\u00f3n 10 de las *GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles* y deben estar capacitados y certificados en los procedimientos de vestimenta, manteniendo registros de capacitaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo Ambiental**: Se establece la necesidad de un programa de monitoreo ambiental en \u00e1reas de pruebas de esterilidad, que incluya t\u00e9cnicas como el monitoreo activo del aire, el uso de placas de contacto y el control de temperatura y presi\u00f3n. Se deben definir l\u00edmites de alerta y acci\u00f3n, y realizar un seguimiento de los resultados.\n\n2. **Limpieza y Desinfecci\u00f3n**: Es fundamental contar con un programa documentado de limpieza y desinfecci\u00f3n, as\u00ed como procedimientos para manejar derrames. Tambi\u00e9n se requiere la disponibilidad de instalaciones adecuadas para el lavado y desinfecci\u00f3n de manos.\n\n3. **Instalaciones de Pruebas de Esterilidad**: Las instalaciones deben cumplir con requisitos ambientales espec\u00edficos para garantizar la integridad de las pruebas. Las pruebas de esterilidad deben realizarse bajo condiciones as\u00e9pticas en zonas de flujo de aire unidireccional de Grado A o en cabinas de bioseguridad, dentro de un entorno de sala limpia de Grado B.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles.\n- **Grado A y Grado B**: Clasificaciones de calidad del aire en salas limpias que son cr\u00edticas para la realizaci\u00f3n de pruebas de esterilidad.\n- **Asepsia**: Condiciones necesarias para llevar a cabo pruebas de esterilidad, asegurando que no haya contaminaci\u00f3n.\n- **Monitoreo Ambiental**: Proceso de supervisi\u00f3n de las condiciones ambientales en laboratorios, especialmente en \u00e1reas cr\u00edticas como las de pruebas de esterilidad.\n\n### Resumen General:\nEl documento de la OMS enfatiza la importancia del monitoreo ambiental, la limpieza y desinfecci\u00f3n, y los requisitos espec\u00edficos para las instalaciones de pruebas de esterilidad, con el objetivo de garantizar la integridad y la calidad de los productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: clean-room classification, sterility testing, HEPA filters, microbiological monitoring, gowning procedures"}}, "2c00ab3a-349c-46fc-be03-e412490148dd": {"node_ids": ["a284f471-df50-4b7e-8d42-b5e73a18156b"], "metadata": {"page_label": "89", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Microbial environmental monitoring of the sterility test zone should be performed during every work session under operational (dynamic) conditions.\n\nThere should be written specifications, including appropriate alert and action limits for microbial contamination. Limits for microbiological environmental monitoring are given in the *WHO GMP for sterile pharmaceutical products* (8).\n\n## 3. Validation of test methods\n\n3.1 Standard (pharmacopoeial) test methods are considered to be validated. However, the specific test method to be used by a specific laboratory for testing of a specific product needs to be shown to be suitable for use in recovering bacteria, yeast and mould in the presence of the specific product. The laboratory should demonstrate that the performance criteria of the standard test method can be met by the laboratory before introducing the test for routine purposes (method verification) and that the specific test method for the specific product is suitable (test method suitability including positive and negative controls).\n\n3.2 Test methods not based on compendial or other recognized references should be validated before use. The validation should comprise, where appropriate, determining accuracy, precision, specificity, limit of detection, limit of quantitation, linearity and robustness. Potentially inhibitory effects from the sample should be taken into account when testing different types of sample. The results should be evaluated with appropriate statistical methods, e.g. as described in the national, regional or international pharmacopoeias.\n\n## 4. Equipment\n\nEach item of equipment, instrument or other device used for testing, verification and calibration should be uniquely identified.\n\nAs part of its quality system, a laboratory should have a documented programme for the qualification, calibration, performance verification, maintenance and a system for monitoring the use of its equipment.\n\n### 4.1 Maintenance of equipment\n\n4.1.1 Maintenance of essential equipment should be carried out at predetermined intervals in accordance with a documented procedure. Detailed records should be kept. (For examples of maintenance of equipment and intervals see Appendix 2.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia del monitoreo ambiental microbiano en zonas de pruebas de esterilidad, la validaci\u00f3n de m\u00e9todos de prueba y el mantenimiento de equipos en laboratorios. Se enfatiza que los m\u00e9todos de prueba deben ser adecuados para el producto espec\u00edfico y que el equipo utilizado debe ser identificado y mantenido de acuerdo con procedimientos documentados.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios de rendimiento que un laboratorio debe demostrar para validar un m\u00e9todo de prueba est\u00e1ndar antes de su uso rutinario?**\n   - El laboratorio debe demostrar que puede cumplir con los criterios de rendimiento del m\u00e9todo de prueba est\u00e1ndar, lo que incluye la verificaci\u00f3n del m\u00e9todo y la adecuaci\u00f3n del m\u00e9todo espec\u00edfico para el producto, incluyendo controles positivos y negativos.\n\n2. **\u00bfQu\u00e9 aspectos deben considerarse al validar m\u00e9todos de prueba que no se basan en referencias reconocidas?**\n   - La validaci\u00f3n debe incluir la determinaci\u00f3n de la precisi\u00f3n, exactitud, especificidad, l\u00edmite de detecci\u00f3n, l\u00edmite de cuantificaci\u00f3n, linealidad y robustez. Adem\u00e1s, se deben tener en cuenta los efectos inhibitorios potenciales del muestreo.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para el mantenimiento del equipo esencial en un laboratorio?**\n   - El mantenimiento del equipo esencial debe realizarse a intervalos predeterminados de acuerdo con un procedimiento documentado, y se deben mantener registros detallados de dicho mantenimiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revalidaci\u00f3n de Instalaciones**:\n   - La clasificaci\u00f3n de salas limpias y el equipo de manejo de aire en las instalaciones de pruebas de esterilidad deben revalidarse al menos anualmente por personal competente.\n\n2. **Control del Aire**:\n   - El aire en las zonas de Grado A y B debe suministrarse a trav\u00e9s de filtros HEPA terminales.\n   - Se deben proporcionar alarmas de flujo de aire y instrumentos de indicaci\u00f3n de diferencias de presi\u00f3n.\n\n3. **Monitoreo de Presi\u00f3n**:\n   - Las lecturas de presi\u00f3n deben tomarse de man\u00f3metros montados externamente, registr\u00e1ndose antes de la entrada del operador a la sala de pruebas.\n\n4. **Acceso a la Sala Limpia**:\n   - El acceso debe realizarse a trav\u00e9s de un sistema de airelocks y una sala de cambio donde los operadores deben usar prendas adecuadas.\n\n5. **Vestimenta de los Operadores**:\n   - Las prendas deben cumplir con los principios de las *GMP de la OMS para productos farmac\u00e9uticos est\u00e9riles* y los operadores deben estar capacitados y certificados en los procedimientos de vestimenta.\n\n6. **Monitoreo Microbiol\u00f3gico Ambiental**:\n   - Debe incluir m\u00e9todos de muestreo de aire y superficie, como muestreo de aire activo, placas de asentamiento, placas RODAC, hisopos y huellas de guantes.\n\n7. **Documentaci\u00f3n y Procedimientos**:\n   - Se debe documentar la ubicaci\u00f3n de los puntos de muestreo y especificar la duraci\u00f3n de la exposici\u00f3n y la frecuencia de monitoreo microbiol\u00f3gico en procedimientos escritos.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que regulan la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n- **HEPA (Filtros de Aire de Alta Eficiencia)**: Tecnolog\u00eda utilizada para el manejo del aire en salas limpias.\n- **RODAC (Replicate Organism Detection and Counting)**: M\u00e9todo de muestreo para monitoreo microbiol\u00f3gico.\n\nEste resumen destaca los aspectos esenciales relacionados con la esterilidad en las instalaciones de pruebas, enfatizando la importancia de la revalidaci\u00f3n, el control ambiental y la capacitaci\u00f3n del personal.", "excerpt_keywords": "Keywords: microbial monitoring, sterility testing, method validation, equipment maintenance, WHO GMP"}}, "243e3a78-bb63-495d-a81e-2e09fdb2d3f5": {"node_ids": ["76177e2f-e484-4f14-bb76-32c9f801fdf8"], "metadata": {"page_label": "90", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Qualification\n\n4.2.1 For qualification of equipment see sections 8 and 12 in *Good practices for pharmaceutical quality control laboratories* (1).\n\n# 4.3 Calibration, performance verification and monitoring of use\n\n4.3.1 The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n4.3.2 The frequency of calibration and performance verification will be determined by documented experience and will be based on need, type and previous performance of the equipment. Intervals between calibration and verification should be shorter than the time the equipment has been found to take to drift outside acceptable limits. (For examples of calibration checks and intervals for different laboratory equipment, see Appendix 3; and for equipment qualification and monitoring, see Appendix 4.) The performance of the equipment should conform to predefined acceptance criteria.\n\n## 4.3.3 Temperature measurement devices\n\n4.3.3.1 Where temperature has a direct effect on the result of an analysis or is critical for the correct performance of equipment, temperature measuring devices should be of appropriate quality to achieve the accuracy required (e.g. liquid-in-glass thermometers, thermocouples and platinum resistance thermometers (PRTs) used in incubators and autoclaves).\n\n4.3.3.2 Calibration of devices should be traceable to national or international standards for temperature.\n\n## 4.3.4 Incubators, water-baths and ovens\n\nThe stability of temperature, uniformity of temperature distribution and time required to achieve equilibrium conditions in incubators, water-baths, ovens and temperature-controlled rooms should be established initially and documented, in particular with respect to typical uses (for example, position, space between, and height of, stacks of Petri dishes). The constancy of the characteristics recorded during initial validation of the equipment should be checked and recorded after each significant repair or modification. The operating temperature of this type of equipment should be monitored and records retained. The use of the equipment should be considered when determining what temperature controls are required.\n\n## 4.3.5 Autoclaves, including media preparators\n\n4.3.5.1 Autoclaves should be capable of meeting specified time and temperature tolerances; monitoring pressure alone is not acceptable. Sensors", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento proporciona directrices sobre la calificaci\u00f3n, calibraci\u00f3n y verificaci\u00f3n del rendimiento de equipos en laboratorios de control de calidad farmac\u00e9utica. Se enfatiza la importancia de mantener registros claros sobre la calibraci\u00f3n y el servicio de los instrumentos, as\u00ed como la necesidad de que los dispositivos de medici\u00f3n de temperatura sean de calidad adecuada y calibrados de acuerdo con est\u00e1ndares nacionales o internacionales. Tambi\u00e9n se abordan aspectos espec\u00edficos sobre incubadoras, ba\u00f1os de agua, hornos y autoclaves, destacando la necesidad de documentar la estabilidad y uniformidad de la temperatura, as\u00ed como los requisitos de monitoreo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que los dispositivos de medici\u00f3n de temperatura sean considerados de calidad adecuada en un laboratorio?**\n   - Respuesta: Los dispositivos de medici\u00f3n de temperatura deben ser de calidad apropiada para lograr la precisi\u00f3n requerida, como term\u00f3metros de l\u00edquido en vidrio, termopares y term\u00f3metros de resistencia de platino (PRTs) utilizados en incubadoras y autoclaves.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia de calibraci\u00f3n y verificaci\u00f3n del rendimiento de los equipos en un laboratorio?**\n   - Respuesta: La frecuencia de calibraci\u00f3n y verificaci\u00f3n se determina mediante experiencia documentada y se basa en la necesidad, el tipo y el rendimiento previo del equipo. Los intervalos deben ser m\u00e1s cortos que el tiempo que el equipo ha demostrado tardar en desviarse de los l\u00edmites aceptables.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse despu\u00e9s de una reparaci\u00f3n o modificaci\u00f3n significativa de un equipo de laboratorio?**\n   - Respuesta: Despu\u00e9s de una reparaci\u00f3n o modificaci\u00f3n significativa, se debe verificar y registrar la constancia de las caracter\u00edsticas que se documentaron durante la validaci\u00f3n inicial del equipo. Adem\u00e1s, se debe monitorear la temperatura de operaci\u00f3n y conservar los registros correspondientes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Monitoreo Ambiental Microbiano**:\n   - Se debe realizar un monitoreo ambiental microbiano en la zona de pruebas de esterilidad durante cada sesi\u00f3n de trabajo bajo condiciones operativas (din\u00e1micas).\n   - Es necesario establecer especificaciones escritas que incluyan l\u00edmites de alerta y acci\u00f3n para la contaminaci\u00f3n microbiana, conforme a las directrices de la *OMS GMP para productos farmac\u00e9uticos est\u00e9riles*.\n\n2. **Validaci\u00f3n de M\u00e9todos de Prueba**:\n   - Los m\u00e9todos de prueba est\u00e1ndar (farmacopeicos) se consideran validados, pero cada laboratorio debe demostrar que el m\u00e9todo espec\u00edfico es adecuado para recuperar microorganismos en presencia del producto espec\u00edfico.\n   - Para m\u00e9todos no basados en referencias reconocidas, se debe validar su precisi\u00f3n, exactitud, especificidad, l\u00edmites de detecci\u00f3n y cuantificaci\u00f3n, linealidad y robustez, considerando efectos inhibitorios potenciales del muestreo.\n\n3. **Equipos de Laboratorio**:\n   - Cada equipo, instrumento o dispositivo utilizado para pruebas debe ser identificado de manera \u00fanica.\n   - Los laboratorios deben tener un programa documentado para la calificaci\u00f3n, calibraci\u00f3n, verificaci\u00f3n de rendimiento y mantenimiento del equipo, as\u00ed como un sistema para monitorear su uso.\n\n4. **Mantenimiento de Equipos**:\n   - El mantenimiento del equipo esencial debe realizarse a intervalos predeterminados seg\u00fan un procedimiento documentado, y se deben mantener registros detallados de dicho mantenimiento.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece directrices sobre buenas pr\u00e1cticas de manufactura (GMP).\n- **M\u00e9todos de Prueba**: Incluyen m\u00e9todos est\u00e1ndar y no est\u00e1ndar que requieren validaci\u00f3n.\n- **Contaminaci\u00f3n Microbiana**: Aspecto cr\u00edtico a monitorear en laboratorios de pruebas de esterilidad.\n- **Equipos de Laboratorio**: Elementos esenciales que deben ser mantenidos y verificados regularmente.", "excerpt_keywords": "Keywords: qualification, calibration, temperature measurement, pharmaceutical quality control, equipment performance"}}, "06f98a8f-f3be-4136-8c86-56975dbc825c": {"node_ids": ["4ff3464c-65b3-4c83-b133-8f350c209acf"], "metadata": {"page_label": "91", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "used for controlling or monitoring operating cycles require calibration and the performance of timers should be verified.\n\n4.3.5.2 Initial validation should include performance studies (spatial temperature distribution surveys) for each operating cycle and each load configuration used in practice. This process must be repeated after any significant repair or modification (e.g. replacement of thermoregulator probe or programmer, change to loading arrangements or operating cycle) or where indicated by the results of quality control checks on media or risk assessment. Sufficient temperature sensors should be positioned within the load (e.g. in containers filled with liquid/medium) to enable location differences to be demonstrated. In the case of media preparators, where uniform heating cannot be demonstrated by other means, the use of two sensors, one adjacent to the control probe and one remote from it, would generally be considered appropriate. Validation and revalidation should consider the suitability of come-up and come-down times as well as time at sterilization temperature.\n\n4.3.5.3 Clear operating instructions should be provided based on the heating profiles determined for typical uses during validation/revalidation. Acceptance/rejection criteria should be established and records of autoclave operations, including temperature and time, maintained for every cycle.\n\n4.3.5.4 Monitoring may be achieved by one of the following:\n\n- using a thermocouple and recorder to produce a chart or printout;\n- direct observation and recording of maximum temperature achieved and time at that temperature.\n\nIn addition to directly monitoring the temperature of an autoclave, the effectiveness of its operation during each cycle may be checked by the use of chemical or biological indicators for sterilization or decontamination purposes. Autoclave tape or indicator strips should be used only to show that a load has been processed, not to demonstrate completion of an acceptable cycle.\n\nLaboratories should have a separate autoclave for decontamination. However, in exceptional cases one autoclave may be acceptable provided that extensive precautions are taken to separate decontamination and sterilization loads, and a documented cleaning programme is in place to address both the internal and external environment of the autoclave.\n\n### 4.3.6 Weights and balances\n\nWeights and balances shall be calibrated traceably at regular intervals (according to their intended use) using appropriate standard weights traceable to certified standard weights.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Validaci\u00f3n y monitoreo de autoclaves**: El documento establece la importancia de la validaci\u00f3n inicial y la revalidaci\u00f3n de autoclaves, incluyendo la realizaci\u00f3n de estudios de rendimiento y la colocaci\u00f3n adecuada de sensores de temperatura. Se enfatiza la necesidad de seguir procedimientos claros y mantener registros detallados de cada ciclo de operaci\u00f3n.\n\n2. **Calibraci\u00f3n de equipos de pesaje**: Se menciona que los pesos y balances deben ser calibrados de manera trazable y regular, utilizando pesos est\u00e1ndar apropiados que est\u00e9n certificados, lo cual es crucial para asegurar la precisi\u00f3n en las mediciones.\n\n3. **Separaci\u00f3n de cargas de esterilizaci\u00f3n y descontaminaci\u00f3n**: Se discute la necesidad de tener autoclaves separados para descontaminaci\u00f3n y esterilizaci\u00f3n, aunque se permiten excepciones bajo estrictas condiciones de limpieza y separaci\u00f3n de cargas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la revalidaci\u00f3n de un autoclave despu\u00e9s de una modificaci\u00f3n significativa?**\n   - La revalidaci\u00f3n debe incluir la repetici\u00f3n de estudios de rendimiento, como encuestas de distribuci\u00f3n de temperatura, y la colocaci\u00f3n de sensores de temperatura en el interior de la carga para demostrar diferencias de ubicaci\u00f3n. Adem\u00e1s, se deben considerar los tiempos de calentamiento y enfriamiento, as\u00ed como el tiempo a la temperatura de esterilizaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n y rechazo que deben establecerse para las operaciones de autoclave?**\n   - Los criterios de aceptaci\u00f3n y rechazo deben basarse en las instrucciones operativas claras derivadas de los perfiles de calentamiento determinados durante la validaci\u00f3n/revalidaci\u00f3n. Adem\u00e1s, se deben mantener registros de las operaciones del autoclave, incluyendo temperatura y tiempo, para cada ciclo.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse si se utiliza un solo autoclave para descontaminaci\u00f3n y esterilizaci\u00f3n?**\n   - En casos excepcionales donde se utilice un solo autoclave, se deben tomar precauciones extensas para separar las cargas de descontaminaci\u00f3n y esterilizaci\u00f3n. Tambi\u00e9n es necesario implementar un programa de limpieza documentado que aborde tanto el entorno interno como externo del autoclave.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n de Equipos**:\n   - Se refiere a la validaci\u00f3n de equipos en laboratorios de control de calidad farmac\u00e9utica, con referencia a secciones espec\u00edficas de buenas pr\u00e1cticas.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n del Rendimiento**:\n   - Importancia de documentar la fecha de calibraci\u00f3n y el servicio de los instrumentos.\n   - La frecuencia de calibraci\u00f3n se basa en la experiencia documentada, el tipo de equipo y su rendimiento previo.\n   - Se deben establecer intervalos de calibraci\u00f3n m\u00e1s cortos que el tiempo que el equipo tarda en desviarse de los l\u00edmites aceptables.\n\n3. **Dispositivos de Medici\u00f3n de Temperatura**:\n   - Los dispositivos deben ser de calidad adecuada para lograr la precisi\u00f3n necesaria (ej. term\u00f3metros de l\u00edquido en vidrio, termopares, term\u00f3metros de resistencia de platino).\n   - La calibraci\u00f3n debe ser trazable a est\u00e1ndares nacionales o internacionales.\n\n4. **Incubadoras, Ba\u00f1os de Agua y Hornos**:\n   - Necesidad de establecer y documentar la estabilidad y uniformidad de la temperatura.\n   - Monitoreo de la temperatura de operaci\u00f3n y conservaci\u00f3n de registros despu\u00e9s de reparaciones o modificaciones significativas.\n\n5. **Autoclaves**:\n   - Deben cumplir con tolerancias espec\u00edficas de tiempo y temperatura; el monitoreo de presi\u00f3n no es suficiente.\n\n### Entidades Clave\n- **Equipos de Laboratorio**: Incluyen incubadoras, autoclaves, term\u00f3metros, etc.\n- **Est\u00e1ndares de Calibraci\u00f3n**: Nacionales e internacionales.\n- **Documentaci\u00f3n**: Registros de calibraci\u00f3n, verificaci\u00f3n y mantenimiento de equipos.\n- **Condiciones de Operaci\u00f3n**: Estabilidad y uniformidad de la temperatura en equipos de laboratorio. \n\nEste resumen destaca la importancia de la calificaci\u00f3n, calibraci\u00f3n y monitoreo de equipos en laboratorios farmac\u00e9uticos, as\u00ed como los est\u00e1ndares de calidad necesarios para asegurar resultados precisos y confiables.", "excerpt_keywords": "Keywords: autoclave validation, temperature monitoring, calibration, sterilization procedures, laboratory equipment"}}, "a3a8efb1-dd28-4771-86f1-ecc02e4af675": {"node_ids": ["4946f072-18e1-4f55-9234-292e759fb79e"], "metadata": {"page_label": "92", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.7 Volumetric equipment\n\n4.3.7.1 Microbiology laboratories should carry out initial verification of volumetric equipment (automatic dispensers, dispenser/diluters, mechanical hand pipettes and disposable pipettes) and then make regular checks, as appropriate, to ensure that the equipment is performing within the required specification. Initial verification should not be necessary for glassware which has been certified to a specific tolerance. Equipment should be checked for the accuracy of the delivered volume against the set volume (for several different settings in the case of variable volume instruments) and the precision of the repeat deliveries should be measured.\n\n4.3.7.2 For \u201csingle-use\u201d disposable volumetric equipment, laboratories should obtain supplies from companies with a recognized and relevant quality system. After initial validation of the suitability of the equipment, it is recommended that random checks on accuracy are carried out. If the supplier does not have a recognized quality system, laboratories should check each batch of equipment for suitability.\n\n# 4.3.8 Other equipment\n\nConductivity meters, oxygen meters, pH meters and other similar instruments should be verified regularly or before each use. The buffers used for verification purposes should be stored in appropriate conditions and should be marked with an expiry date.\n\nWhere humidity is important to the outcome of the test, hygrometers should be calibrated, the calibration being traceable to national or international standards.\n\nTimers, including the autoclave timer, should be verified using a calibrated timer or national time signal.\n\nWhen centrifuges are used in test procedures, an assessment of the rotations per minute (RPM) should be made. Where it is critical, the centrifuge should be calibrated.\n\n# 5. Reagents and culture media\n\nLaboratories should ensure that the quality of reagents and media used is appropriate for the test concerned.\n\n## 5.1 Reagents\n\n5.1.1 Laboratories should verify the suitability of each batch of reagents critical for the test, initially and during its shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) proporciona directrices sobre la verificaci\u00f3n y el mantenimiento de equipos volum\u00e9tricos y otros instrumentos utilizados en laboratorios de microbiolog\u00eda. Se enfatiza la importancia de realizar verificaciones iniciales y controles regulares para asegurar que el equipo funcione dentro de las especificaciones requeridas. Tambi\u00e9n se menciona la necesidad de obtener suministros de equipos desechables de empresas con sistemas de calidad reconocidos y de realizar verificaciones aleatorias de precisi\u00f3n. Adem\u00e1s, se abordan otros equipos como medidores de pH, conductividad y centrifugadoras, destacando la importancia de la calibraci\u00f3n y verificaci\u00f3n regular. Por \u00faltimo, se subraya la necesidad de garantizar la calidad de los reactivos y medios de cultivo utilizados en las pruebas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de verificaci\u00f3n inicial se recomienda para los equipos volum\u00e9tricos en laboratorios de microbiolog\u00eda?**\n   - Se recomienda que los laboratorios realicen una verificaci\u00f3n inicial de los equipos volum\u00e9tricos, como dispensadores autom\u00e1ticos y pipetas, y luego realicen controles regulares para asegurar que el equipo est\u00e9 funcionando dentro de las especificaciones requeridas.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los laboratorios al adquirir equipos volum\u00e9tricos desechables de proveedores sin un sistema de calidad reconocido?**\n   - Si el proveedor no tiene un sistema de calidad reconocido, los laboratorios deben verificar cada lote de equipo desechable para asegurar su idoneidad.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la verificaci\u00f3n de instrumentos como medidores de pH y conductividad?**\n   - Los medidores de pH, conductividad y otros instrumentos similares deben ser verificados regularmente o antes de cada uso, y los buffers utilizados para la verificaci\u00f3n deben ser almacenados adecuadamente y marcados con una fecha de caducidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n y Monitoreo de Autoclaves**:\n   - **Importancia de la Validaci\u00f3n**: Se requiere realizar estudios de rendimiento y encuestas de distribuci\u00f3n de temperatura para cada ciclo operativo y configuraci\u00f3n de carga.\n   - **Revalidaci\u00f3n**: Debe llevarse a cabo despu\u00e9s de reparaciones significativas o modificaciones, y se deben utilizar sensores de temperatura para demostrar diferencias de ubicaci\u00f3n dentro de la carga.\n   - **Instrucciones Operativas**: Se deben proporcionar instrucciones claras basadas en los perfiles de calentamiento determinados durante la validaci\u00f3n.\n   - **Registros de Operaci\u00f3n**: Es esencial mantener registros detallados de cada ciclo, incluyendo temperatura y tiempo.\n\n2. **Monitoreo de Temperatura**:\n   - **M\u00e9todos de Monitoreo**: Se pueden utilizar termopares y grabadores, as\u00ed como la observaci\u00f3n directa de la temperatura m\u00e1xima alcanzada.\n   - **Indicadores de Esterilizaci\u00f3n**: Se sugiere el uso de indicadores qu\u00edmicos o biol\u00f3gicos para verificar la efectividad del ciclo de esterilizaci\u00f3n.\n\n3. **Separaci\u00f3n de Cargas**:\n   - **Autoclaves para Descontaminaci\u00f3n y Esterilizaci\u00f3n**: Se recomienda tener autoclaves separados para cada prop\u00f3sito, aunque se permiten excepciones bajo estrictas condiciones de limpieza y separaci\u00f3n de cargas.\n\n4. **Calibraci\u00f3n de Equipos de Pesaje**:\n   - **Pesos y Balances**: Deben ser calibrados de manera trazable y regular, utilizando pesos est\u00e1ndar certificados para asegurar la precisi\u00f3n en las mediciones.\n\n### Entidades Clave\n- **Autoclaves**: Equipos utilizados para la esterilizaci\u00f3n y descontaminaci\u00f3n.\n- **Sensores de Temperatura**: Dispositivos utilizados para medir la temperatura dentro de las cargas.\n- **Termopares**: Herramientas para el monitoreo de temperatura.\n- **Indicadores Qu\u00edmicos/Biol\u00f3gicos**: M\u00e9todos para verificar la efectividad de la esterilizaci\u00f3n.\n- **Pesos y Balances**: Equipos de medici\u00f3n que requieren calibraci\u00f3n regular. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el monitoreo y la calibraci\u00f3n en los procesos de esterilizaci\u00f3n y medici\u00f3n en laboratorios.", "excerpt_keywords": "Keywords: volumetric equipment, microbiology laboratories, verification, reagents, calibration"}}, "195520c2-8974-4a5b-80ab-424f6d7aa24f": {"node_ids": ["53ab478d-6501-4582-bb74-1256e4d15850"], "metadata": {"page_label": "93", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.2 Media\n\n5.2.1 Media may be prepared in-house or purchased either partially or fully prepared. Vendors of purchased media should be approved and qualified. The qualified vendor may certify some of the quality parameters listed subsequently. Growth promotion and, if appropriate, other suitable performance tests (see section 5.2.2) should be done on all media on every batch and on every shipment. Where the supplier of fully prepared media is qualified and provides growth promotion certification per batch of media and transportation conditions have been qualified, the user may rely on the manufacturer\u2019s certificate with periodic verification of his or her results.\n\n5.2.2 The suitable performance of culture media, diluents and other suspension fluids should be checked, where relevant, with regard to:\n\n- recovery or survival maintenance of target organisms. Recovery of 50\u2013200% (after inoculation of not more than 100 colony-forming units (CFU or cfu) should be demonstrated;\n- inhibition or suppression of non-target organisms;\n- biochemical (differential and diagnostic) properties; and\n- other appropriate properties (e.g. pH, volume and sterility).\n\nQuantitative procedures for evaluation of recovery or survival are preferred.\n\n5.2.3 Raw materials (both commercial dehydrated formulations and individual constituents) and media should be stored under appropriate conditions recommended by the manufacturer, e.g. cool, dry and dark. All containers, especially those for dehydrated media, should be sealed tightly. Dehydrated media that are caked or cracked or show a colour change should not be used.\n\n5.2.4 Water of a suitable microbiological quality and which is free from bactericidal, inhibitory or interfering substances, should be used for preparation unless the test method specifies otherwise.\n\n5.2.5 Media containing antimetabolites or inhibitors should be prepared using dedicated glassware, as carry-over of these agents into other media could inhibit the growth and detection of microorganisms present in the sample under test. If dedicated glassware is not used, washing procedures for glassware should be validated.\n\n5.2.6 Repartition of media after sterilization should be performed under unidirectional airflow (UDAF) to minimize potential for environmental contamination. This should be considered a minimum requirement for media to be used in relation to sterile product testing. This includes the cooling of media, as container lids will need to be removed during cooling to prevent build-up of condensation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Preparaci\u00f3n y Certificaci\u00f3n de Medios**: Los medios de cultivo pueden ser preparados internamente o adquiridos de proveedores calificados. Es esencial que se realicen pruebas de promoci\u00f3n de crecimiento y otros tests de rendimiento en cada lote y env\u00edo de medios, garantizando as\u00ed su calidad y eficacia.\n\n2. **Evaluaci\u00f3n del Rendimiento de Medios**: Se deben verificar varios par\u00e1metros de rendimiento de los medios, incluyendo la recuperaci\u00f3n de organismos objetivo, la inhibici\u00f3n de organismos no deseados, y propiedades bioqu\u00edmicas y f\u00edsicas como pH y esterilidad.\n\n3. **Almacenamiento y Manejo de Medios**: Los medios y sus componentes deben almacenarse en condiciones adecuadas para mantener su calidad. Adem\u00e1s, se deben seguir procedimientos espec\u00edficos para la preparaci\u00f3n y manipulaci\u00f3n de medios que contengan antimetabolitos o inhibidores, as\u00ed como para la repartici\u00f3n despu\u00e9s de la esterilizaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplir los proveedores de medios de cultivo para ser considerados calificados?**\n   - Los proveedores deben ser aprobados y calificados, y pueden certificar algunos de los par\u00e1metros de calidad de los medios que ofrecen.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros espec\u00edficos que se deben evaluar para asegurar el rendimiento adecuado de los medios de cultivo?**\n   - Se deben evaluar la recuperaci\u00f3n o mantenimiento de supervivencia de organismos objetivo (50-200%), la inhibici\u00f3n de organismos no deseados, propiedades bioqu\u00edmicas, y otras propiedades relevantes como pH, volumen y esterilidad.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar la contaminaci\u00f3n ambiental durante la repartici\u00f3n de medios despu\u00e9s de la esterilizaci\u00f3n?**\n   - La repartici\u00f3n debe realizarse bajo flujo de aire unidireccional (UDAF) y se deben retirar las tapas de los contenedores durante el enfriamiento para prevenir la acumulaci\u00f3n de condensaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Equipos Volum\u00e9tricos**:\n   - **Verificaci\u00f3n Inicial**: Los laboratorios de microbiolog\u00eda deben realizar una verificaci\u00f3n inicial de equipos volum\u00e9tricos (dispensadores autom\u00e1ticos, pipetas mec\u00e1nicas y desechables) y controles regulares para asegurar su correcto funcionamiento.\n   - **Tolerancia de Cristaler\u00eda**: No se requiere verificaci\u00f3n inicial para cristaler\u00eda certificada con tolerancias espec\u00edficas.\n   - **Precisi\u00f3n y Exactitud**: Se debe comprobar la precisi\u00f3n del volumen entregado en comparaci\u00f3n con el volumen establecido y medir la precisi\u00f3n de las entregas repetidas.\n\n2. **Equipos Desechables**:\n   - **Proveedores**: Los laboratorios deben adquirir equipos volum\u00e9tricos desechables de empresas con sistemas de calidad reconocidos.\n   - **Controles Aleatorios**: Se recomienda realizar verificaciones aleatorias de precisi\u00f3n tras la validaci\u00f3n inicial. Si el proveedor carece de un sistema de calidad reconocido, se debe verificar cada lote.\n\n3. **Otros Equipos**:\n   - **Instrumentos de Medici\u00f3n**: Medidores de pH, conductividad y ox\u00edgeno deben ser verificados regularmente o antes de cada uso, con buffers almacenados adecuadamente y con fecha de caducidad.\n   - **Higr\u00f3metros y Centrifugadoras**: Los higr\u00f3metros deben calibrarse y la calibraci\u00f3n debe ser trazable a est\u00e1ndares nacionales o internacionales. Las centrifugadoras deben ser evaluadas en RPM y calibradas si es cr\u00edtico.\n\n4. **Reactivos y Medios de Cultivo**:\n   - **Calidad de Reactivos**: Los laboratorios deben asegurar que la calidad de los reactivos y medios de cultivo sea adecuada para las pruebas realizadas.\n   - **Verificaci\u00f3n de Reactivos**: Se debe verificar la idoneidad de cada lote de reactivos cr\u00edticos inicialmente y durante su vida \u00fatil.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Laboratorios de Microbiolog\u00eda**: Entidad responsable de la verificaci\u00f3n y mantenimiento de equipos.\n- **Equipos Volum\u00e9tricos**: Incluyen dispensadores autom\u00e1ticos, pipetas mec\u00e1nicas y desechables.\n- **Instrumentos de Medici\u00f3n**: Medidores de pH, conductividad, ox\u00edgeno, higr\u00f3metros y centrifugadoras.\n- **Reactivos y Medios de Cultivo**: Elementos cr\u00edticos para la realizaci\u00f3n de pruebas en laboratorios.", "excerpt_keywords": "Keywords: media preparation, quality certification, microbial testing, storage conditions, contamination prevention"}}, "83aad718-a0a9-4e33-9e0d-b5e62433e42c": {"node_ids": ["63885521-a2be-4269-9aac-2e1bcc1dfebe"], "metadata": {"page_label": "94", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2.7\n\nPlated media which is to be irradiated may require the addition of an antioxidant and free radical scavenger to provide protection from the effects of the irradiation process. The irradiated media should be validated by performing quantitative growth promotion testing on both irradiated and non-irradiated media.\n\n## 5.2.8\n\nShelf-life of prepared media under defined storage conditions shall be determined and verified.\n\n## 5.2.9\n\nBatches of media should be identifiable and their conformance with quality specifications documented. For purchased media the user laboratory should ensure that it will be notified by the manufacturer of any changes to the quality specification.\n\n## 5.2.10\n\nMedia should be prepared in accordance with any manufacturer\u2019s instructions, taking into careful account specifications such as time and temperature for sterilization.\n\n## 5.2.11\n\nMicrowave devices should not be used for the melting of media due to the inconsistent distribution of the heating process.\n\n## 5.3 Labelling\n\n5.3.1 Laboratories should ensure that all reagents (including stock solutions), media, diluents and other suspending fluids are adequately labelled to indicate, as appropriate, identity, concentration, storage conditions, preparation date, validated expiry date and/or recommended storage periods. The person responsible for preparation should be identifiable from records.\n\n## 5.4 Organism resuscitation\n\n5.4.1 Organism resuscitation is required where test methodologies may produce sublethally injured cells. For example, exposure to:\n\n- injurious effects of processing, e.g. heat;\n- antimicrobial agents;\n- preservatives;\n- extremes of osmotic pressure; and\n- extremes of pH.\n\n5.4.2 Organism resuscitation may be achieved by:\n\n- exposure to a liquid media like a simple salt solution at room temperature for 2 hours;\n- exposure to a solid repair medium for 4\u20136 hours.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda directrices sobre la preparaci\u00f3n y manejo de medios de cultivo en laboratorios. Se enfatiza la importancia de la irradiaci\u00f3n de medios, la identificaci\u00f3n y documentaci\u00f3n de lotes, el etiquetado adecuado de reactivos y la resucitaci\u00f3n de organismos que pueden haber sufrido da\u00f1os subletales. Se mencionan pr\u00e1cticas espec\u00edficas para garantizar la calidad y la eficacia de los medios de cultivo, as\u00ed como la necesidad de seguir las instrucciones del fabricante y evitar el uso de microondas para la fusi\u00f3n de medios.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de aditivos se recomienda agregar a los medios de cultivo que ser\u00e1n irradiados y por qu\u00e9?**\n   - Respuesta: Se recomienda la adici\u00f3n de un antioxidante y un captador de radicales libres para proteger los medios de cultivo de los efectos del proceso de irradiaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para la resucitaci\u00f3n de organismos que han sido expuestos a condiciones que podr\u00edan da\u00f1arlos?**\n   - Respuesta: La resucitaci\u00f3n de organismos puede lograrse mediante la exposici\u00f3n a un medio l\u00edquido, como una soluci\u00f3n salina simple a temperatura ambiente durante 2 horas, o mediante la exposici\u00f3n a un medio s\u00f3lido de reparaci\u00f3n durante 4 a 6 horas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los reactivos y medios de cultivo en el laboratorio?**\n   - Respuesta: Las etiquetas deben indicar, seg\u00fan corresponda, la identidad, concentraci\u00f3n, condiciones de almacenamiento, fecha de preparaci\u00f3n, fecha de caducidad validada y/o per\u00edodos de almacenamiento recomendados. Adem\u00e1s, debe ser identificable la persona responsable de la preparaci\u00f3n a partir de los registros.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n 5.2 - Medios\n\n1. **Preparaci\u00f3n de Medios**:\n   - Los medios de cultivo pueden ser preparados internamente o adquiridos de proveedores calificados.\n   - Es fundamental que los proveedores certifiquen algunos par\u00e1metros de calidad y que se realicen pruebas de promoci\u00f3n de crecimiento en cada lote y env\u00edo.\n\n2. **Evaluaci\u00f3n del Rendimiento**:\n   - Se deben verificar varios par\u00e1metros de rendimiento de los medios, incluyendo:\n     - Recuperaci\u00f3n o mantenimiento de supervivencia de organismos objetivo (50-200%).\n     - Inhibici\u00f3n de organismos no deseados.\n     - Propiedades bioqu\u00edmicas (diferenciales y diagn\u00f3sticas).\n     - Otras propiedades relevantes como pH, volumen y esterilidad.\n   - Se prefieren procedimientos cuantitativos para la evaluaci\u00f3n de recuperaci\u00f3n o supervivencia.\n\n3. **Almacenamiento y Manejo**:\n   - Los medios y sus componentes deben almacenarse en condiciones adecuadas (frescos, secos y oscuros).\n   - Los contenedores deben estar sellados y los medios deshidratados que presenten cambios (caked, agrietados o de color alterado) no deben usarse.\n\n4. **Calidad del Agua**:\n   - Se debe utilizar agua de calidad microbiol\u00f3gica adecuada, libre de sustancias bactericidas, inhibidoras o interferentes, a menos que el m\u00e9todo de prueba indique lo contrario.\n\n5. **Manipulaci\u00f3n de Medios con Antimetabolitos**:\n   - Los medios que contienen antimetabolitos o inhibidores deben prepararse con vidrio dedicado para evitar la contaminaci\u00f3n cruzada.\n   - Si no se utiliza vidrio dedicado, se deben validar los procedimientos de lavado.\n\n6. **Repartici\u00f3n de Medios**:\n   - La repartici\u00f3n de medios despu\u00e9s de la esterilizaci\u00f3n debe realizarse bajo flujo de aire unidireccional (UDAF) para minimizar la contaminaci\u00f3n ambiental.\n   - Durante el enfriamiento, las tapas de los contenedores deben retirarse para evitar la acumulaci\u00f3n de condensaci\u00f3n.\n\n### Entidades Clave:\n- **Medios de Cultivo**: Preparaci\u00f3n, evaluaci\u00f3n y almacenamiento.\n- **Proveedores Calificados**: Certificaci\u00f3n de calidad y pruebas de rendimiento.\n- **Par\u00e1metros de Rendimiento**: Recuperaci\u00f3n, inhibici\u00f3n, propiedades bioqu\u00edmicas y f\u00edsicas.\n- **Condiciones de Almacenamiento**: Fresco, seco, oscuro.\n- **Agua Microbiol\u00f3gicamente Adecuada**: Libre de contaminantes.\n- **Flujo de Aire Unidireccional (UDAF)**: Para la repartici\u00f3n y enfriamiento de medios.", "excerpt_keywords": "Keywords: media preparation, irradiation, organism resuscitation, quality specifications, laboratory practices"}}, "a653341d-c746-4c05-b737-30dcda557729": {"node_ids": ["6bcb0688-ea6c-4e2a-9cf0-8918d51c2152"], "metadata": {"page_label": "95", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Reference materials and reference cultures\n\n## 6.1 International standards and pharmacopoeial reference substances\n\n6.1.1 Reference materials and certified reference materials are generally used in a microbiological laboratory to qualify, verify and calibrate equipment.\n\nWhenever possible these reference materials should be used in appropriate matrices.\n\nInternational standards and pharmacopoeial reference substances are employed, for example, to:\n\n- determine potency or content;\n- validate methods;\n- enable comparison of methods;\n- perform positive controls; and\n- perform growth promotion tests.\n\nIf possible reference materials should be used in appropriate matrices.\n\n## 6.2 Reference cultures\n\n6.2.1 Reference cultures are required for establishing acceptable performance of media (including test kits), for validating methods, for verifying the suitability of test methods and for assessing or evaluating ongoing performance. Traceability is necessary, for example, when establishing media performance for test kit and method validations. To demonstrate traceability, laboratories must use reference strains of microorganisms obtained directly from a recognized national or international collection, where these exist. Alternatively, commercial derivatives for which all relevant properties have been shown by the laboratory to be equivalent at the point of use may be used.\n\n6.2.2 Reference strains may be subcultured once to provide reference stocks. Purity and biochemical checks should be made in parallel as appropriate. It is recommended to store reference stocks in aliquots either deep-frozen or lyophilized. Working cultures for routine use should be primary subcultures from the reference stock (see Appendix 5 on general use of reference cultures). If reference stocks have been thawed, they must not be refrozen and reused.\n\n6.2.3 Working stocks should not normally be subcultured. Usually not more than five generations (or passages) from the original reference strain can be subcultured if defined by a standard method or laboratories can", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de los materiales de referencia y las culturas de referencia en laboratorios microbiol\u00f3gicos. Se destacan dos secciones principales: \n\n1. **Materiales de referencia y sustancias de referencia farmacop\u00e9uticas**: Se utilizan para calificar, verificar y calibrar equipos, as\u00ed como para determinar la potencia, validar m\u00e9todos y realizar controles positivos.\n\n2. **Culturas de referencia**: Son esenciales para establecer el rendimiento aceptable de medios y kits de prueba, validar m\u00e9todos y evaluar el rendimiento continuo. Se enfatiza la necesidad de trazabilidad mediante el uso de cepas de microorganismos de colecciones reconocidas y se dan recomendaciones sobre el manejo y almacenamiento de estas cepas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el almacenamiento de las cepas de referencia y por qu\u00e9 es importante seguir estas recomendaciones?**\n   - Las cepas de referencia deben almacenarse en al\u00edcuotas, ya sea congeladas en profundidad o liofilizadas. Esto es importante para mantener la viabilidad y pureza de las cepas, evitando la contaminaci\u00f3n y asegurando que las cepas utilizadas en experimentos sean representativas de la cepa original.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse para que un laboratorio utilice derivados comerciales de cepas de referencia?**\n   - Los derivados comerciales deben haber demostrado que todas sus propiedades relevantes son equivalentes a las de la cepa de referencia original en el punto de uso, asegurando as\u00ed la validez de los resultados obtenidos con estos derivados.\n\n3. **\u00bfQu\u00e9 limitaciones existen en el subcultivo de las cepas de referencia y cu\u00e1l es la raz\u00f3n detr\u00e1s de estas limitaciones?**\n   - Normalmente, las cepas de trabajo no deben subcultivarse m\u00e1s de cinco generaciones (o pasajes) a partir de la cepa de referencia original. Esto se debe a que el subcultivo excesivo puede llevar a cambios gen\u00e9ticos o fenot\u00edpicos que comprometan la validez de los resultados experimentales y la comparabilidad con los est\u00e1ndares establecidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Irradiaci\u00f3n de Medios de Cultivo**:\n   - Se sugiere la adici\u00f3n de un **antioxidante** y un **captador de radicales libres** para proteger los medios de cultivo de los efectos de la irradiaci\u00f3n.\n   - Es necesario validar los medios irradiados mediante pruebas cuantitativas de promoci\u00f3n del crecimiento.\n\n2. **Vida \u00datil de los Medios**:\n   - Se debe determinar y verificar la vida \u00fatil de los medios preparados bajo condiciones de almacenamiento definidas.\n\n3. **Identificaci\u00f3n y Documentaci\u00f3n de Lotes**:\n   - Los lotes de medios deben ser identificables y su conformidad con las especificaciones de calidad debe estar documentada.\n   - Los laboratorios deben ser notificados por los fabricantes sobre cualquier cambio en las especificaciones de calidad de los medios comprados.\n\n4. **Instrucciones del Fabricante**:\n   - Los medios deben prepararse de acuerdo con las instrucciones del fabricante, considerando cuidadosamente el tiempo y la temperatura para la esterilizaci\u00f3n.\n\n5. **Uso de Microondas**:\n   - No se deben utilizar dispositivos de microondas para la fusi\u00f3n de medios debido a la distribuci\u00f3n inconsistente del calor.\n\n6. **Etiquetado**:\n   - Todos los reactivos, medios, diluyentes y otros fluidos deben estar adecuadamente etiquetados, indicando identidad, concentraci\u00f3n, condiciones de almacenamiento, fecha de preparaci\u00f3n, fecha de caducidad validada y/o per\u00edodos de almacenamiento recomendados.\n   - La persona responsable de la preparaci\u00f3n debe ser identificable a partir de los registros.\n\n7. **Resucitaci\u00f3n de Organismos**:\n   - La resucitaci\u00f3n es necesaria para c\u00e9lulas que pueden haber sufrido da\u00f1os subletales debido a factores como calor, agentes antimicrobianos, conservantes, presi\u00f3n osm\u00f3tica extrema y pH extremo.\n   - M\u00e9todos de resucitaci\u00f3n incluyen:\n     - Exposici\u00f3n a un medio l\u00edquido (soluci\u00f3n salina simple) a temperatura ambiente durante 2 horas.\n     - Exposici\u00f3n a un medio s\u00f3lido de reparaci\u00f3n durante 4 a 6 horas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medios de Cultivo**\n- **Antioxidantes**\n- **Captadores de Radicales Libres**\n- **Vida \u00datil**\n- **Etiquetado**\n- **Resucitaci\u00f3n de Organismos**\n- **Condiciones de Almacenamiento**", "excerpt_keywords": "Keywords: reference materials, microbiological laboratory, traceability, reference cultures, international standards"}}, "8fcfdf11-b583-4247-b20c-27787e337598": {"node_ids": ["de8c1d12-f15c-4006-98b1-bf2e62e7b5ca"], "metadata": {"page_label": "96", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sampling\n\nFor general principles reference is made to *Good practices for pharmaceutical quality control laboratories (1)*.\n\n7.1 Where testing laboratories are responsible for primary sampling to obtain test items, it is strongly recommended that this sampling be covered by a quality assurance system and it should be subject to regular audits.\n\n7.2 Any disinfection processes used in obtaining the sample (e.g. disinfection of sample points) should not compromise the microbial level within the sample.\n\n7.3 Transport and storage of samples should be under conditions that maintain the integrity of the sample (e.g. chilled or frozen where appropriate). Testing of the samples should be performed as soon as possible after sampling. For samples where a growth in the microbial population during transport and storage is possible it should be demonstrated that the storage conditions, time and temperature, will not affect the accuracy of the testing result. The storage conditions should be monitored and records kept. The responsibility for transport, storage between sampling and arrival at the testing laboratory should be clearly documented.\n\n7.4 Sampling should only be performed by trained personnel. It should be carried out aseptically using sterile equipment. Appropriate precautions should be taken to ensure that sample integrity is maintained through the use of sterile sealed containers for the collection of samples where appropriate. It may be necessary to monitor environmental conditions, for example, air contamination and temperature, at the sampling site. Time of sampling should be recorded, if appropriate.\n\n# Sample handling and identification\n\n8.1 The laboratory should have procedures that cover the delivery and receipt of samples and sample identification. If there is insufficient sample or the sample is in poor condition due to physical deterioration, incorrect temperature, torn packaging or deficient labelling, the laboratory should consult with the client before deciding whether to test or refuse the sample.\n\n8.2 The laboratory should record all relevant information, e.g.\n\n- date and, where relevant, the time of receipt;\n- condition of the sample on receipt and, when necessary, temperature; and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para los laboratorios de control de calidad farmac\u00e9utica, centr\u00e1ndose en los procedimientos de muestreo y manejo de muestras. Se enfatiza la importancia de un sistema de aseguramiento de la calidad en el muestreo, la necesidad de mantener la integridad de las muestras durante el transporte y almacenamiento, y la capacitaci\u00f3n del personal encargado de realizar el muestreo. Tambi\u00e9n se mencionan procedimientos para la identificaci\u00f3n y manejo de muestras en el laboratorio, as\u00ed como la documentaci\u00f3n necesaria para garantizar la trazabilidad y la calidad de los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que los procesos de desinfecci\u00f3n no afecten el nivel microbiano de la muestra?**\n   - El documento menciona que cualquier proceso de desinfecci\u00f3n utilizado en la obtenci\u00f3n de la muestra no debe comprometer el nivel microbiano dentro de la misma. Esto implica que se deben seleccionar m\u00e9todos de desinfecci\u00f3n que sean efectivos pero que no alteren la composici\u00f3n microbiana de la muestra.\n\n2. **\u00bfCu\u00e1les son las responsabilidades documentadas en el transporte y almacenamiento de muestras entre el muestreo y la llegada al laboratorio de pruebas?**\n   - La responsabilidad del transporte y almacenamiento debe estar claramente documentada, incluyendo las condiciones de almacenamiento, el tiempo y la temperatura, para asegurar que la integridad de la muestra se mantenga y que no se afecten los resultados de las pruebas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n relevante debe registrar el laboratorio al recibir una muestra?**\n   - El laboratorio debe registrar informaci\u00f3n como la fecha y, cuando sea relevante, la hora de recepci\u00f3n; la condici\u00f3n de la muestra al recibirla; y, cuando sea necesario, la temperatura de la muestra. Esto es crucial para evaluar la calidad y la idoneidad de la muestra para su an\u00e1lisis.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n\n1. **Materiales de Referencia**:\n   - Utilizados en laboratorios microbiol\u00f3gicos para calificar, verificar y calibrar equipos.\n   - Aplicaciones incluyen la determinaci\u00f3n de potencia, validaci\u00f3n de m\u00e9todos, comparaci\u00f3n de m\u00e9todos, controles positivos y pruebas de promoci\u00f3n de crecimiento.\n\n2. **Culturas de Referencia**:\n   - Esenciales para establecer el rendimiento aceptable de medios y kits de prueba, validar m\u00e9todos y evaluar el rendimiento continuo.\n   - La trazabilidad es crucial, requiriendo el uso de cepas de microorganismos de colecciones reconocidas o derivados comerciales equivalentes.\n\n3. **Almacenamiento y Manejo**:\n   - Las cepas de referencia deben almacenarse en al\u00edcuotas, ya sea congeladas en profundidad o liofilizadas, para mantener su viabilidad y pureza.\n   - Se recomienda que las cepas de trabajo sean subcultivos primarios de las cepas de referencia.\n\n4. **Limitaciones en el Subcultivo**:\n   - No se deben subcultivar las cepas de trabajo m\u00e1s de cinco generaciones a partir de la cepa de referencia original para evitar cambios que comprometan la validez de los resultados.\n\n#### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Materiales de Referencia**: Incluyen est\u00e1ndares internacionales y sustancias de referencia farmacop\u00e9uticas.\n- **Culturas de Referencia**: Cepas de microorganismos utilizadas para asegurar la calidad y validez en pruebas microbiol\u00f3gicas.\n- **Colecciones Nacionales o Internacionales**: Fuentes reconocidas de cepas de referencia.\n- **Derivados Comerciales**: Cepas que han demostrado equivalencia con las cepas de referencia originales.\n\nEste resumen destaca la importancia de los materiales y culturas de referencia en la microbiolog\u00eda, as\u00ed como las mejores pr\u00e1cticas para su manejo y uso en laboratorios.", "excerpt_keywords": "Keywords: sampling, quality assurance, microbial integrity, sample handling, laboratory procedures"}}, "16898a0e-9a65-4267-9ff2-a09f28762b19": {"node_ids": ["c68d64ae-6777-4bbe-912b-a56b98454000"], "metadata": {"page_label": "97", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8.3\n\nSamples awaiting testing should be stored under suitable conditions to minimize changes to any microbial population present. Storage conditions should be validated, defined and recorded.\n\n# 8.4\n\nThe packaging and labels of samples may be highly contaminated and should be handled and stored with care so as to avoid any spread of contamination. Disinfection processes applied to the outer container should not affect the integrity of the sample. It should be noted that alcohol is not sporicidal.\n\n# 8.5\n\nSubsampling by the laboratory immediately prior to testing may be required as part of the test method. It may be appropriate that it is performed according to national or international standards, where they exist, or by validated in-house methods. Subsampling procedures should be designed to collect a representative sample.\n\n# 8.6\n\nThere should be a written procedure for the retention and disposal of samples. If sample integrity can be maintained it may be appropriate that samples are stored until the test results are obtained, or longer if required. Laboratory sample portions that are known to be contaminated should be decontaminated prior to being discarded (see section 11.1).\n\n# 9. Disposal of contaminated waste\n\n9.1 The procedures for the disposal of contaminated materials should be designed to minimize the possibility of contaminating the test environment or materials. It is a matter of good laboratory management and should conform to national/international environmental or health and safety regulations.\n\n# 10. Quality assurance of results and quality control of performance\n\n## 10.1 Internal quality control\n\n10.1.1 The laboratory should have a system of internal quality assurance or quality control (e.g. handling deviations, use of spiked samples, replicate testing and participation in proficiency testing, where appropriate) to ensure the consistency of results from day to day and their conformity with defined criteria.\n\n# 11. Testing procedures\n\n11.1 Testing should normally be performed according to procedures described in the national, regional and international pharmacopoeias.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y directrices para el manejo de muestras en laboratorios, incluyendo el almacenamiento, la manipulaci\u00f3n, el muestreo, la disposici\u00f3n de desechos contaminados y el aseguramiento de la calidad de los resultados. Se enfatiza la importancia de mantener la integridad de las muestras, seguir procedimientos estandarizados y cumplir con regulaciones ambientales y de salud. Tambi\u00e9n se menciona la necesidad de un control de calidad interno para asegurar la consistencia de los resultados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones adecuadas para el almacenamiento de muestras que est\u00e1n a la espera de pruebas, y por qu\u00e9 es importante validar estas condiciones?**\n   - Respuesta: Las muestras deben ser almacenadas bajo condiciones adecuadas que minimicen los cambios en la poblaci\u00f3n microbiana presente. Es importante validar estas condiciones para asegurar que las muestras mantengan su integridad y que los resultados de las pruebas sean confiables.\n\n2. **\u00bfQu\u00e9 precauciones deben tomarse al manejar el embalaje y las etiquetas de las muestras, y por qu\u00e9 el alcohol no es adecuado para la desinfecci\u00f3n de contenedores externos?**\n   - Respuesta: El embalaje y las etiquetas pueden estar altamente contaminados y deben ser manejados con cuidado para evitar la propagaci\u00f3n de la contaminaci\u00f3n. El alcohol no es adecuado para la desinfecci\u00f3n de contenedores externos porque no es esporicida, lo que significa que no puede eliminar esporas de microorganismos que podr\u00edan comprometer la muestra.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la retenci\u00f3n y disposici\u00f3n de muestras contaminadas, y qu\u00e9 se debe hacer antes de desechar porciones de muestras contaminadas?**\n   - Respuesta: Debe existir un procedimiento escrito para la retenci\u00f3n y disposici\u00f3n de muestras. Las muestras contaminadas deben ser decontaminadas antes de ser descartadas para evitar riesgos de contaminaci\u00f3n en el entorno de prueba.", "prev_section_summary": "### Temas Clave\n\n1. **Principios Generales de Muestreo**: Se hace referencia a las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, enfatizando la importancia de un sistema de aseguramiento de la calidad en el muestreo.\n\n2. **Calidad y Auditor\u00eda**: Se recomienda que el muestreo est\u00e9 cubierto por un sistema de calidad y sea objeto de auditor\u00edas regulares.\n\n3. **Desinfecci\u00f3n**: Los procesos de desinfecci\u00f3n no deben comprometer el nivel microbiano de la muestra.\n\n4. **Transporte y Almacenamiento**: Las muestras deben transportarse y almacenarse en condiciones que mantengan su integridad, y se deben documentar las responsabilidades y condiciones de almacenamiento.\n\n5. **Capacitaci\u00f3n del Personal**: El muestreo debe ser realizado por personal capacitado y utilizando equipos est\u00e9riles.\n\n6. **Manejo e Identificaci\u00f3n de Muestras**: Se deben establecer procedimientos para la entrega, recepci\u00f3n e identificaci\u00f3n de muestras, as\u00ed como registrar informaci\u00f3n relevante sobre su estado.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades responsables del muestreo y an\u00e1lisis de muestras.\n- **Personal Capacitado**: Individuos que realizan el muestreo y manejo de muestras.\n- **Condiciones de Almacenamiento**: Factores como temperatura y tiempo que afectan la integridad de las muestras.\n- **Sistemas de Aseguramiento de la Calidad**: Protocolos que garantizan la calidad en el proceso de muestreo y an\u00e1lisis. \n\nEste resumen destaca la importancia de seguir procedimientos estandarizados y documentados para asegurar la calidad y la integridad de las muestras en el contexto de laboratorios farmac\u00e9uticos.", "excerpt_keywords": "Keywords: samples, contamination, quality assurance, disposal, testing procedures"}}, "0888c69c-878b-4e1d-87a3-bf11351f4411": {"node_ids": ["128ac73b-dac6-4511-a87e-e3f9c8b839cb"], "metadata": {"page_label": "98", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Test reports\n\n12.1 If the result of the enumeration is negative, it should be reported as \u201cnot detected for a defined unit\u201d or \u201cless than the detection limit for a defined unit\u201d. The result should not be given as \u201czero for a defined unit\u201d unless it is a regulatory requirement. Qualitative test results should be reported as \u201cdetected/not detected in a defined quantity or volume\u201d. They may also be expressed as \u201cless than a specified number of organisms for a defined unit\u201d where the specified number of organisms exceeds the detection limit of the method and this has been agreed with the client. In the raw data the result should not be given as zero for a defined unit unless it is a regulatory requirement. A reported value of \u201c0\u201d may be used for data entry and calculations or trend analysis in electronic databases.\n\n12.2 Where an estimate of the uncertainty of the test result is expressed on the test report, any limitations (particularly if the estimate does not include the component contributed by the distribution of microorganisms within the sample) have to be made clear to the client.\n\n# References\n\n1. Good Practices for pharmaceutical quality control laboratories. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 957, 2010, Annex 1.\n\n2. General guidelines for the establishment, maintenance and distribution of chemical reference substances. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report.* Geneva, World Health Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.\n\n3. *The International Pharmacopoeia,* Fourth Edition. Geneva, World Health Organization, 2006. Also available on CD-ROM.\n\n4. *The International Pharmacopoeia,* Fourth Edition, First Supplement. Geneva, World Health Organization, 2008. Also available on CD-ROM.\n\n5. ISO/IEC 17025 (2005) *General requirements for the competence of testing and calibration laboratories.*\n\n6. ISO 11133-1 (2000) *Microbiology of food and animal feeding stuffs \u2014 Guidelines on preparation and production of culture media \u2014 Part 1: General guidelines on quality assurance for the preparation of culture media in the laboratory.*\n\n7. ISO 13843 (2000) *Water quality \u2014 Guidance on validation of microbiological methods.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para la elaboraci\u00f3n de informes de pruebas microbiol\u00f3gicas. Se especifica c\u00f3mo deben reportarse los resultados negativos, enfatizando que no deben ser presentados como \"cero\" a menos que sea un requisito regulatorio. Tambi\u00e9n se menciona la importancia de comunicar cualquier limitaci\u00f3n en la estimaci\u00f3n de la incertidumbre de los resultados. Adem\u00e1s, se citan referencias relevantes que respaldan estas pr\u00e1cticas, incluyendo normas ISO y documentos de la OMS.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de reportar un resultado negativo como \"cero\" en un informe de pruebas microbiol\u00f3gicas, y en qu\u00e9 situaciones esto es aceptable?**\n   - Esta pregunta busca profundizar en las consecuencias de un mal reporte y las excepciones a la regla.\n\n2. **\u00bfQu\u00e9 consideraciones deben tener en cuenta los laboratorios al estimar la incertidumbre de los resultados de las pruebas microbiol\u00f3gicas?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos y las limitaciones que deben ser comunicadas al cliente.\n\n3. **\u00bfC\u00f3mo se deben manejar los datos de entrada y an\u00e1lisis de tendencias en bases de datos electr\u00f3nicas cuando se reportan resultados de pruebas microbiol\u00f3gicas?**\n   - Esta pregunta explora el uso de valores reportados y su impacto en el an\u00e1lisis de datos, lo cual no se detalla ampliamente en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que puede no estar disponible en otros documentos o contextos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento de Muestras**:\n   - Las muestras deben ser almacenadas en condiciones adecuadas para minimizar cambios en la poblaci\u00f3n microbiana.\n   - Es crucial validar y registrar estas condiciones para mantener la integridad de las muestras.\n\n2. **Manejo de Embalajes y Etiquetas**:\n   - Los embalajes y etiquetas pueden estar contaminados y deben ser manipulados con cuidado para evitar la propagaci\u00f3n de la contaminaci\u00f3n.\n   - Se destaca que el alcohol no es esporicida, lo que limita su efectividad en la desinfecci\u00f3n de contenedores externos.\n\n3. **Submuestreo**:\n   - Puede ser necesario realizar submuestreo antes de las pruebas, siguiendo est\u00e1ndares nacionales o internacionales o m\u00e9todos internos validados.\n   - Los procedimientos de submuestreo deben asegurar la recolecci\u00f3n de muestras representativas.\n\n4. **Retenci\u00f3n y Disposici\u00f3n de Muestras**:\n   - Debe existir un procedimiento escrito para la retenci\u00f3n y disposici\u00f3n de muestras.\n   - Las muestras contaminadas deben ser decontaminadas antes de ser desechadas.\n\n5. **Disposici\u00f3n de Desechos Contaminados**:\n   - Los procedimientos de disposici\u00f3n deben minimizar la contaminaci\u00f3n del entorno de prueba y cumplir con regulaciones ambientales y de salud.\n\n6. **Aseguramiento de Calidad**:\n   - Se requiere un sistema de control de calidad interno en el laboratorio para asegurar la consistencia de los resultados y su conformidad con criterios definidos.\n\n7. **Procedimientos de Prueba**:\n   - Las pruebas deben realizarse de acuerdo con procedimientos establecidos en farmacopoeias nacionales, regionales e internacionales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Laboratorio**: Entidad responsable de realizar pruebas y manejar muestras.\n- **Muestras**: Elementos que se est\u00e1n probando y que requieren manejo cuidadoso.\n- **Contaminaci\u00f3n**: Riesgo asociado al manejo de muestras y embalajes.\n- **Regulaciones Ambientales y de Salud**: Normativas que deben seguirse en la disposici\u00f3n de desechos contaminados.", "excerpt_keywords": "Keywords: microbiological testing, reporting standards, uncertainty estimation, WHO guidelines, quality assurance"}}, "0ad953cb-de46-4ef8-972c-06d1b64601d3": {"node_ids": ["ebbbcf7a-42f2-458b-b933-93aa7944914e"], "metadata": {"page_label": "99", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8. WHO good manufacturing practices: main principles for pharmaceutical products. In: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, 2nd updated edition. Good manufacturing practices (GMP) and inspection.* Geneva, World Health Organization, 2007, and subsequent updates, including WHO GMP for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, Annex 6, 2011; and GMP: Heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization. WHO Technical Report Series, No. 961, 2011, Annex 5.\n\n# Further reading\n\n- ISO 7218 (2007) *Microbiology of food and animal feeding stuffs \u2014 General requirements and guidance for microbiological examinations.*\n\n- ISO 6887-1 (1999) *Microbiology of food and animal feeding stuffs \u2014 Preparation of test samples, initial suspension and decimal dilutions for microbiological examination \u2014 Part 1: General rules for the preparation of the initial suspension and decimal dilutions.*\n\n- ISO Guide 30 (1992) *Terms and definitions used in connection with reference materials.*\n\n- ISO 9000 (2008) *Quality management systems \u2014 fundamentals and vocabulary.*\n\n- ISO Guide 99 (1993) *International vocabulary of basic and general terms in metrology (VIM).*\n\n- ISO (CIPM):1995. *Guide to the expression of uncertainty in measurements.*\n\n- Draft ISO/DIS 16140. (1999) *Food microbiology. Protocol for the validation of alternative methods.*\n\n- Draft ISO/FDIS (2003) 11133-2. *Microbiology of food and animal feeding stuffs. Guidelines on preparation and production of culture media. Part 2 \u2014 Practical guidelines on performance testing on culture media.*\n\n- EN 12741 (1999). *Biotechnology \u2014 Laboratories for research, development and analysis \u2014 Guidance for biotechnology laboratory operations.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las Buenas Pr\u00e1cticas de Manufactura (BPM) seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS), destacando los principios fundamentales para la producci\u00f3n de productos farmac\u00e9uticos. Se menciona la importancia de la calidad en la fabricaci\u00f3n y se hace referencia a varias normas ISO relacionadas con la microbiolog\u00eda y la gesti\u00f3n de calidad. Adem\u00e1s, se incluyen gu\u00edas sobre la preparaci\u00f3n de medios de cultivo y la validaci\u00f3n de m\u00e9todos alternativos en microbiolog\u00eda.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales principios de las Buenas Pr\u00e1cticas de Manufactura (BPM) seg\u00fan la OMS, y c\u00f3mo se aplican a los productos farmac\u00e9uticos est\u00e9riles y no est\u00e9riles?**\n   - Esta pregunta busca una respuesta detallada sobre los principios espec\u00edficos de BPM y su aplicaci\u00f3n en diferentes tipos de productos farmac\u00e9uticos, que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 actualizaciones se han realizado en las gu\u00edas de BPM desde la publicaci\u00f3n de la segunda edici\u00f3n de \"Quality assurance of pharmaceuticals\" en 2007?**\n   - Esta pregunta se enfoca en las modificaciones y mejoras en las gu\u00edas de BPM desde 2007, lo que puede no estar documentado en otras publicaciones.\n\n3. **\u00bfC\u00f3mo se relacionan las normas ISO mencionadas en el documento con la implementaci\u00f3n de Buenas Pr\u00e1cticas de Manufactura en la industria farmac\u00e9utica?**\n   - Esta pregunta busca una conexi\u00f3n espec\u00edfica entre las normas ISO y las BPM, proporcionando un an\u00e1lisis que puede no estar disponible en otras fuentes.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre las Buenas Pr\u00e1cticas de Manufactura (BPM) para productos farmac\u00e9uticos, enfatizando la importancia de la calidad y la seguridad en la producci\u00f3n. Se mencionan varias normas ISO que complementan estas pr\u00e1cticas, abordando aspectos de microbiolog\u00eda y gesti\u00f3n de calidad. Las actualizaciones y anexos espec\u00edficos de las gu\u00edas de BPM son cruciales para asegurar que los est\u00e1ndares se mantengan al d\u00eda con los avances en la industria.", "prev_section_summary": "### Temas Clave\n\n1. **Reportes de Resultados Negativos**: Los resultados negativos en pruebas microbiol\u00f3gicas deben ser reportados como \"no detectado para una unidad definida\" o \"menos que el l\u00edmite de detecci\u00f3n para una unidad definida\". No se debe utilizar \"cero\" a menos que sea un requisito regulatorio.\n\n2. **Resultados Cualitativos**: Deben ser reportados como \"detectado/no detectado en una cantidad o volumen definido\". Tambi\u00e9n pueden expresarse como \"menos de un n\u00famero espec\u00edfico de organismos para una unidad definida\", siempre que este n\u00famero supere el l\u00edmite de detecci\u00f3n y haya sido acordado con el cliente.\n\n3. **Manejo de Datos en Bases Electr\u00f3nicas**: Un valor reportado de \"0\" puede ser utilizado para la entrada de datos y c\u00e1lculos o an\u00e1lisis de tendencias en bases de datos electr\u00f3nicas, pero no debe ser utilizado en el informe a menos que sea un requisito regulatorio.\n\n4. **Estimaci\u00f3n de Incertidumbre**: Si se expresa una estimaci\u00f3n de la incertidumbre del resultado de la prueba, se deben aclarar las limitaciones, especialmente si la estimaci\u00f3n no incluye la variabilidad de los microorganismos en la muestra.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **ISO/IEC 17025**: Norma que establece requisitos para la competencia de laboratorios de ensayo y calibraci\u00f3n.\n- **ISO 11133-1**: Norma que proporciona directrices sobre la preparaci\u00f3n y producci\u00f3n de medios de cultivo en microbiolog\u00eda.\n- **ISO 13843**: Norma que ofrece orientaci\u00f3n sobre la validaci\u00f3n de m\u00e9todos microbiol\u00f3gicos en calidad del agua.\n\n### Referencias\n\nSe citan varias referencias relevantes que respaldan las pr\u00e1cticas recomendadas, incluyendo informes de la OMS y normas ISO.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Manufactura, farmac\u00e9uticos, OMS, normas ISO, calidad"}}, "788bc9cc-9680-4e71-ab52-953614b5a72c": {"node_ids": ["0f3680c6-556c-490d-a69b-ebbcbbb722d1"], "metadata": {"page_label": "100", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Examples of zones in which operations could be carried out\n\nThe zones are designed as the following grades, during the installation and monitoring can be carried out, e.g. through appropriate air supply.\n\n| Zone | Installation grade | Proposed |\n| - | - | - |\n| Sample receipt | Unclassified | Unclassified |\n| Media preparation | Unclassified | Unclassified |\n| Autoclave loading | Unclassified | Unclassified |\n| Autoclave unloading, inside the sterility testing area | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 UDAF | Grade A | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to UDAF | Grade B | ISO 5 (turbulent) and <10 cfu/m\u00b3 |\n| Sterility testing \u2014 isolator | Grade A (NVP and microbiology only) | ISO 5 (UDAF) and <1 cfu/m\u00b3 |\n| Sterility testing \u2014 background to isolator | Unclassified | Unclassified |\n| Incubator | Unclassified | Unclassified |\n| Enumeration | Unclassifieda | Unclassifieda |\n| Decontamination | Unclassified | Unclassified |\n\n\ncfu, colony-forming unit.  \n<sup>a</sup> Critical steps should be done under laminar flow.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta ejemplos de zonas en las que se pueden llevar a cabo operaciones relacionadas con pruebas de esterilidad. Estas zonas est\u00e1n clasificadas seg\u00fan diferentes grados de instalaci\u00f3n y proponen est\u00e1ndares de calidad del aire, medidos en unidades de formaci\u00f3n de colonias (cfu). Las zonas incluyen desde la recepci\u00f3n de muestras hasta la preparaci\u00f3n de medios y la carga y descarga de autoclaves, con un enfoque particular en las \u00e1reas de pruebas de esterilidad.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 grado de instalaci\u00f3n se requiere para la descarga del autoclave dentro del \u00e1rea de pruebas de esterilidad?**\n   - Respuesta: La descarga del autoclave dentro del \u00e1rea de pruebas de esterilidad requiere un grado B, con un est\u00e1ndar de calidad del aire de ISO 5 (turbulento) y menos de 10 cfu/m\u00b3.\n\n2. **\u00bfCu\u00e1les son las especificaciones de calidad del aire para las pruebas de esterilidad en un aislador?**\n   - Respuesta: Las pruebas de esterilidad en un aislador requieren un grado A (solo para NVP y microbiolog\u00eda), con un est\u00e1ndar de calidad del aire de ISO 5 (UDAF) y menos de 1 cfu/m\u00b3.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar durante los pasos cr\u00edticos en la enumeraci\u00f3n?**\n   - Respuesta: Durante los pasos cr\u00edticos en la enumeraci\u00f3n, se deben realizar bajo flujo laminar, ya que se indica que son pasos cr\u00edticos que requieren un ambiente controlado.", "prev_section_summary": "### Temas Clave\n\n1. **Buenas Pr\u00e1cticas de Manufactura (BPM)**: Se destacan los principios fundamentales de las BPM seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS) para la producci\u00f3n de productos farmac\u00e9uticos, tanto est\u00e9riles como no est\u00e9riles.\n\n2. **Calidad en la Fabricaci\u00f3n**: Se enfatiza la importancia de mantener altos est\u00e1ndares de calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n\n3. **Normas ISO**: Se mencionan varias normas ISO relevantes que complementan las BPM, abarcando aspectos de microbiolog\u00eda, gesti\u00f3n de calidad y metrolog\u00eda.\n\n4. **Actualizaciones de Gu\u00edas**: Se hace referencia a las actualizaciones de las gu\u00edas de BPM desde 2007, incluyendo anexos espec\u00edficos que abordan temas como sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado para productos farmac\u00e9uticos no est\u00e9riles.\n\n5. **Microbiolog\u00eda y Validaci\u00f3n**: Se incluyen gu\u00edas sobre la preparaci\u00f3n de medios de cultivo y la validaci\u00f3n de m\u00e9todos alternativos en microbiolog\u00eda, lo que es crucial para asegurar la calidad en la producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las BPM y las gu\u00edas relacionadas.\n- **ISO (Organizaci\u00f3n Internacional de Normalizaci\u00f3n)**: Cuerpo que establece normas internacionales, mencionadas en el documento, que son relevantes para la BPM.\n- **Documentos y Normas ISO**: Incluyen ISO 7218, ISO 6887-1, ISO 9000, entre otros, que proporcionan directrices sobre microbiolog\u00eda y gesti\u00f3n de calidad.\n- **WHO Technical Report Series**: Serie de informes t\u00e9cnicos de la OMS que incluye las gu\u00edas de BPM y sus actualizaciones.\n\n### Resumen General\n\nEl documento de la OMS aborda las Buenas Pr\u00e1cticas de Manufactura (BPM) para productos farmac\u00e9uticos, subrayando la importancia de la calidad y la seguridad en la producci\u00f3n. Se mencionan diversas normas ISO que respaldan estas pr\u00e1cticas, as\u00ed como actualizaciones en las gu\u00edas de BPM desde 2007. Adem\u00e1s, se incluyen directrices sobre microbiolog\u00eda y validaci\u00f3n de m\u00e9todos, esenciales para mantener est\u00e1ndares de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: sterility testing, installation grade, air quality standards, Good Manufacturing Practices, ISO standards"}}, "24c480c9-75f4-44b8-8cc8-f800d35474d7": {"node_ids": ["c5488713-7813-4cf0-bf40-be4dc52c5c5c"], "metadata": {"page_label": "101", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n## Examples of maintenance of equipment\n\nThis information is provided as an example and the frequency will be based on the need, type and previous performance of the equipment and on the recommendations in suppliers\u2019 manuals.\n\n| Type of equipment | Requirement | Suggested frequency | |\n| - | - | - | - |\n| \u2014 Incubators \u2014 Fridges \u2014 Freezers, ovens | Clean and disinfect internal surfaces | \u2014 Monthly \u2014 When required (e.g. every 3 months) \u2014 When required (e.g. annually) | |\n| | Water-baths | Empty, clean, disinfect and refill | \u2014 Monthly, or every 6 months if biocide used |\n| | Centrifuges | \u2014 Service | \u2014 Annually |\n| \u2014 Clean and disinfect | | \u2014 Each use | |\n| Autoclaves | \u2014 Make visual checks of gasket, clean/drain chamber | \u2014 Regularly, as recommended by manufacturer | |\n| | \u2014 Full service | \u2014 Annually or as recommended by manufacturer | |\n| | \u2014 Safety check of pressure vessel | \u2014 Annually | |\n| Safety cabinets unidirectional cabinets | Full service and mechanical check | Annually or as recommended by manufacturer | |\n| Microscopes | Full maintenance service | Annually | |\n| pH meters | Clean electrode | Each use | |\n| Balances, gravimetric diluters | \u2014 Clean | \u2014 Each use | |\n| | \u2014 Service | \u2014 Annually | |\n| Stills | Clean and descale | As required (e.g. every 3 months) | |\n| De-ionizers, reverse osmosis units | Replace cartridge/membrane | As recommended by manufacturer | |\n| Anaerobic jars | Clean/disinfect | After each use | |\n| Media dispensers, volumetric equipment, pipettes and general service equipment | Decontaminate, clean and sterilize as appropriate | Each use | |\n| Spiral platers | \u2014 Service | \u2014 Annually | |\n| | \u2014 Decontaminate, clean and sterilize | \u2014 Each use | |\n| Laboratory | \u2014 Clean and disinfect working surfaces | \u2014 Daily and during use | |\n| | \u2014 Clean floors, disinfect sinks and basins | \u2014 Daily | |\n| | \u2014 Clean and disinfect other surfaces | \u2014 Every 3 months | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 961) que proporciona ejemplos de mantenimiento de equipos en laboratorios. Se detalla la frecuencia y los requisitos de mantenimiento para diversos tipos de equipos, como incubadoras, autoclaves, microscopios, y otros. La informaci\u00f3n se basa en la necesidad, el tipo de equipo, su rendimiento previo y las recomendaciones de los manuales de los proveedores.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la frecuencia recomendada para limpiar y desinfectar las superficies internas de incubadoras, refrigeradores y congeladores?**\n   - Respuesta: Se recomienda limpiar y desinfectar las superficies internas de estos equipos mensualmente, cuando sea necesario (por ejemplo, cada 3 meses) o anualmente.\n\n2. **\u00bfQu\u00e9 procedimiento se sugiere para el mantenimiento de los autoclaves y con qu\u00e9 frecuencia debe realizarse?**\n   - Respuesta: Para los autoclaves, se sugiere hacer revisiones visuales del sello, limpiar y drenar la c\u00e1mara regularmente seg\u00fan lo recomendado por el fabricante, realizar un servicio completo anualmente o seg\u00fan lo indicado por el fabricante, y realizar una verificaci\u00f3n de seguridad del recipiente a presi\u00f3n anualmente.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse con los frascos anaer\u00f3bicos despu\u00e9s de cada uso?**\n   - Respuesta: Los frascos anaer\u00f3bicos deben limpiarse y desinfectarse despu\u00e9s de cada uso.\n\n### Resumen de Nivel Superior\n\nEl ap\u00e9ndice proporciona directrices sobre el mantenimiento de equipos de laboratorio, enfatizando la importancia de seguir las recomendaciones de los fabricantes y ajustar la frecuencia de mantenimiento seg\u00fan el uso y el rendimiento del equipo. Se abordan diversos tipos de equipos y se especifican las acciones de limpieza, desinfecci\u00f3n y servicio necesarias para garantizar su correcto funcionamiento y seguridad.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Zonas de operaci\u00f3n**: El documento describe diferentes zonas donde se pueden realizar operaciones relacionadas con pruebas de esterilidad, cada una con un grado de instalaci\u00f3n espec\u00edfico.\n\n2. **Clasificaci\u00f3n de zonas**:\n   - **Unclassified**: Zonas como recepci\u00f3n de muestras, preparaci\u00f3n de medios, carga y descarga de autoclaves, incubadoras, enumeraci\u00f3n y decontaminaci\u00f3n no tienen una clasificaci\u00f3n espec\u00edfica.\n   - **Grade A**: Se requiere para pruebas de esterilidad en un aislador y UDAF, con est\u00e1ndares de calidad del aire muy estrictos.\n   - **Grade B**: Aplicable a la descarga del autoclave y pruebas de esterilidad en el fondo de UDAF, con est\u00e1ndares de calidad del aire menos estrictos que Grade A.\n\n3. **Est\u00e1ndares de calidad del aire**: Se especifican los est\u00e1ndares de calidad del aire en t\u00e9rminos de unidades de formaci\u00f3n de colonias (cfu), que son cr\u00edticos para garantizar la esterilidad en las operaciones.\n\n4. **Precauciones en pasos cr\u00edticos**: Se menciona que los pasos cr\u00edticos en la enumeraci\u00f3n deben realizarse bajo flujo laminar para mantener un ambiente controlado.\n\n5. **Entidades**:\n   - **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n   - **cfu (unidad formadora de colonias)**: Medida utilizada para evaluar la calidad del aire en las zonas de operaci\u00f3n.\n\nEste resumen destaca la importancia de la clasificaci\u00f3n de las zonas y los est\u00e1ndares de calidad del aire en las operaciones de pruebas de esterilidad, as\u00ed como las precauciones necesarias para mantener la integridad del proceso.", "excerpt_keywords": "Keywords: maintenance, laboratory equipment, cleaning, disinfection, frequency"}}, "597feba6-d4a7-46a7-9b4d-a18e03a5f246": {"node_ids": ["30b9505c-7f22-4880-a817-b50f40b84fb9"], "metadata": {"page_label": "102", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 3\n\n## Examples of calibration checks and intervals for different laboratory equipment\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Reference thermometers (liquid-in-glass) | Full traceable recalibration Single point (e.g. ice-point check) | Every 3 years Annually |\n| Reference thermocouples | Full traceable recalibration Check against reference thermometer | Every 3 years Annually |\n| Working thermometers and working thermocouples | Check against reference thermometer at ice-point and/or working temperature range | Annually |\n| Balances | Full traceable calibration | Annually |\n| Calibration weights | Full traceable calibration | Annually |\n| Check weight(s) | Check against calibrated weight or check on balance immediately following traceable calibration | Annually |\n| Volumetric glassware | Gravimetric calibration to required tolerance | Annually |\n| Microscopes | Traceable calibration of stage micrometer (where appropriate) | Initially |\n| Hygrometers | Traceable calibration | Annually |\n| Centrifuges | Traceable calibration or check against an independent tachometer, as appropriate | Annually |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (Serie 961) que presenta ejemplos de controles de calibraci\u00f3n y sus intervalos para diferentes equipos de laboratorio. Se destaca que la frecuencia de calibraci\u00f3n debe basarse en la necesidad, el tipo de equipo, su rendimiento previo y su criticidad. Se proporciona una tabla que detalla el tipo de equipo, los requisitos de calibraci\u00f3n y la frecuencia sugerida para cada uno.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 factores deben considerarse al determinar la frecuencia de calibraci\u00f3n de los equipos de laboratorio seg\u00fan el documento?**\n   - Respuesta: La frecuencia de calibraci\u00f3n debe basarse en la necesidad, el tipo de equipo, el rendimiento previo y la criticidad del equipo.\n\n2. **\u00bfCu\u00e1l es la diferencia en la frecuencia de calibraci\u00f3n entre term\u00f3metros de referencia y term\u00f3metros de trabajo seg\u00fan el ap\u00e9ndice?**\n   - Respuesta: Los term\u00f3metros de referencia requieren recalibraci\u00f3n completa y trazable cada 3 a\u00f1os, mientras que los term\u00f3metros de trabajo deben ser verificados anualmente contra un term\u00f3metro de referencia.\n\n3. **\u00bfQu\u00e9 tipo de calibraci\u00f3n se sugiere para los microscopios y en qu\u00e9 momento debe realizarse?**\n   - Respuesta: Se sugiere una calibraci\u00f3n trazable del micr\u00f3metro de etapa (donde sea apropiado) y debe realizarse inicialmente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Secci\u00f3n:** Ap\u00e9ndice 2 - Ejemplos de mantenimiento de equipos\n\n**Temas Clave:**\n1. **Mantenimiento de Equipos de Laboratorio:** Se proporciona una gu\u00eda sobre la frecuencia y los requisitos de mantenimiento para diversos equipos de laboratorio.\n2. **Frecuencia de Mantenimiento:** La frecuencia de mantenimiento se basa en la necesidad, el tipo de equipo, su rendimiento previo y las recomendaciones de los manuales de los proveedores.\n3. **Tipos de Equipos y Requisitos:**\n   - **Incubadoras, Refrigeradores, Congeladores y Hornos:** Limpieza y desinfecci\u00f3n mensual, trimestral o anual.\n   - **Ba\u00f1os de Agua:** Vaciar, limpiar, desinfectar y rellenar mensualmente o cada seis meses si se utiliza biocida.\n   - **Centr\u00edfugas:** Servicio anual.\n   - **Autoclaves:** Revisiones visuales, limpieza y drenaje regular, servicio completo anual y verificaci\u00f3n de seguridad anual.\n   - **Cabinetes de Seguridad y Microscopios:** Servicio completo y chequeo mec\u00e1nico anual.\n   - **Electrodos de pH y Balanzas:** Limpieza y servicio anuales.\n   - **Frascos Anaer\u00f3bicos:** Limpieza y desinfecci\u00f3n despu\u00e9s de cada uso.\n   - **Laboratorio:** Limpieza y desinfecci\u00f3n diaria de superficies de trabajo, suelos y otros espacios cada tres meses.\n\n**Entidades:**\n- **Equipos de Laboratorio:** Incubadoras, refrigeradores, congeladores, autoclaves, microscopios, pH metros, balanzas, frascos anaer\u00f3bicos, etc.\n- **Requisitos de Mantenimiento:** Limpieza, desinfecci\u00f3n, servicio, chequeo mec\u00e1nico, reemplazo de cartuchos/membranas.\n- **Frecuencia Recomendada:** Mensual, trimestral, anual, seg\u00fan el uso y las recomendaciones del fabricante.\n\n**Importancia:** Este ap\u00e9ndice enfatiza la necesidad de seguir las recomendaciones de los fabricantes y ajustar la frecuencia de mantenimiento seg\u00fan el uso y el rendimiento del equipo para garantizar su correcto funcionamiento y seguridad.", "excerpt_keywords": "Keywords: calibration, laboratory equipment, traceable, maintenance frequency, technical report"}}, "106b2a9b-27cb-4721-8947-b22239a78b2a": {"node_ids": ["2060f4b8-afae-44bc-9689-b6a18dbcf4c3"], "metadata": {"page_label": "103", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n\n## Examples of equipment qualification and monitoring\n\nThis information is provided as an example and the frequency will be based on the need, type, previous performance and criticality of the equipment.\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Temperature-controlled equipment (incubators, baths, fridges, freezers) | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Daily/each use |\n| Sterilizing ovens | \u2014 Establish stability and uniformity of temperature \u2014 Monitor temperature | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Autoclaves | \u2014 Establish characteristics for loads/cycles \u2014 Monitor temperature/pressure/time | \u2014 Initially, every 2 years and after repair/modification \u2014 Each use |\n| Grade A areas used for sterility testing: \u2022 safety unidirectional cabinets \u2022 isolators | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, every year and after repair/modification \u2014 Each use \u2014 6-monthly \u2014 6-monthly |\n| Unidirectional cabinets | \u2014 Establish performance \u2014 Microbiological monitoring \u2014 Airflow monitoring \u2014 Test for integrity of HEPA filters | \u2014 Initially, and after repair/modification \u2014 Weekly \u2014 6-monthly \u2014 6-monthly |\n| Timers | Check against national time signal | Annually |\n| Microscopes | Check alignment | Daily/each use |\n| pH meters | Adjust using at least two buffers of suitable quality | Daily/each use |\n| Balances | Check zero, and reading against check weight | Daily/each use |\n| De-ionizers and reverse osmosis units | \u2014 Check conductivity \u2014 Check for microbial contamination | \u2014 Weekly \u2014 Monthly |\n| Gravimetric diluters | \u2014 Check weight of volume dispensed \u2014 Check dilution ratio | \u2014 Daily \u2014 Daily |\n| Media dispensers | Check volume dispensed | Each adjustment or replacement |\n| Pipettors/pipettes | Check accuracy and precision of volume dispensed | Regularly (to be defined by taking account of the frequency and nature of use) |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta ejemplos de calificaci\u00f3n y monitoreo de equipos utilizados en laboratorios y entornos de investigaci\u00f3n. Se detalla el tipo de equipo, los requisitos necesarios para su funcionamiento adecuado y la frecuencia sugerida para las verificaciones y mantenimientos. La informaci\u00f3n est\u00e1 dise\u00f1ada para asegurar la estabilidad, uniformidad y precisi\u00f3n de los equipos cr\u00edticos, lo que es esencial para garantizar la calidad y la seguridad en los procesos de investigaci\u00f3n y pruebas.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de monitoreo se recomienda para los equipos de temperatura controlada, y con qu\u00e9 frecuencia se debe realizar?**\n   - Respuesta: Se recomienda establecer la estabilidad y uniformidad de la temperatura y monitorear la temperatura. La frecuencia sugerida es inicialmente cada 2 a\u00f1os y despu\u00e9s de reparaciones o modificaciones, y diariamente o en cada uso.\n\n2. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para los gabinetes unidireccionales y qu\u00e9 frecuencia de monitoreo se sugiere?**\n   - Respuesta: Los requisitos incluyen establecer el rendimiento, monitoreo microbiol\u00f3gico, monitoreo del flujo de aire y pruebas de integridad de los filtros HEPA. La frecuencia sugerida es inicialmente y despu\u00e9s de reparaciones o modificaciones, semanalmente, cada 6 meses y cada 6 meses, respectivamente.\n\n3. **\u00bfQu\u00e9 procedimientos se deben seguir para verificar la precisi\u00f3n de los pipetores/pipetas y con qu\u00e9 frecuencia se debe realizar esta verificaci\u00f3n?**\n   - Respuesta: Se debe verificar la precisi\u00f3n y exactitud del volumen dispensado. La frecuencia de esta verificaci\u00f3n debe definirse regularmente, teniendo en cuenta la frecuencia y la naturaleza del uso.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl ap\u00e9ndice 3 del Informe T\u00e9cnico de la OMS (Serie 961) se centra en los controles de calibraci\u00f3n y los intervalos recomendados para diversos equipos de laboratorio. Los temas clave incluyen:\n\n1. **Frecuencia de Calibraci\u00f3n**: La frecuencia de calibraci\u00f3n debe determinarse en funci\u00f3n de la necesidad, el tipo de equipo, el rendimiento previo y la criticidad del mismo.\n\n2. **Tipos de Equipos y Requisitos**: Se presenta una tabla que clasifica diferentes tipos de equipos de laboratorio, sus requisitos de calibraci\u00f3n y la frecuencia sugerida para cada uno. Los equipos mencionados incluyen:\n   - Term\u00f3metros de referencia\n   - Termocuplas de referencia\n   - Term\u00f3metros y termocuplas de trabajo\n   - Balanzas\n   - Pesas de calibraci\u00f3n\n   - Vidrio volum\u00e9trico\n   - Microsc\u00f3pios\n   - Higr\u00f3metros\n   - Centr\u00edfugas\n\n3. **Intervalos de Calibraci\u00f3n**: La tabla sugiere diferentes intervalos de calibraci\u00f3n, que var\u00edan desde anualmente hasta cada tres a\u00f1os, dependiendo del tipo de equipo.\n\n4. **Calibraci\u00f3n Trazable**: Se enfatiza la importancia de la calibraci\u00f3n trazable para asegurar la precisi\u00f3n y confiabilidad de los equipos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Informe T\u00e9cnico (Serie 961)**\n- **Equipos de laboratorio**: term\u00f3metros, termocuplas, balanzas, pesas, vidrio volum\u00e9trico, microscopios, higr\u00f3metros, centr\u00edfugas.\n- **Frecuencia de calibraci\u00f3n**: anualmente, cada 3 a\u00f1os, inicialmente.\n\nEste resumen destaca la importancia de la calibraci\u00f3n adecuada en los laboratorios para garantizar resultados precisos y confiables.", "excerpt_keywords": "Keywords: equipment qualification, monitoring frequency, laboratory standards, temperature control, microbiological testing"}}, "4f428e5b-084c-401f-baf0-720797e09aa0": {"node_ids": ["e44102cb-7058-4c2f-a6f2-ac483141a9d4"], "metadata": {"page_label": "104", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 4\n## Examples of equipment qualification and monitoring (continued)\n\n| Type of equipment | Requirement | Suggested frequency |\n| - | - | - |\n| Spiral platers | \u2014 Establish performance against conventional method \u2014 Check stylus condition and the art start and end-points \u2014 Check volume dispensed | \u2014 Initially and annually \u2014 Daily/each use \u2014 Monthly |\n| Colony counters | Check against number counted manually | Annually |\n| Centrifuges | Check speed against a calibrated and independent tachometer | Annually |\n| Anaerobic jars/incubators | Check with anaerobic indicator | Each use |\n| Laboratory environment | Monitor for airborne and surface microbial contamination using, e.g. air samplers, settle plates, contact plates or swabs | Based on risk assessment, an appropriate environmental monitoring programme should be established |\n\n\nHEPA, high-efficiency particulate air.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, \"Technical Report Series 961\", incluye un ap\u00e9ndice que detalla ejemplos de calificaci\u00f3n y monitoreo de equipos en laboratorios. Se presentan diferentes tipos de equipos, los requisitos para su funcionamiento y la frecuencia sugerida para las verificaciones necesarias. Esto es crucial para asegurar la calidad y la precisi\u00f3n en los resultados de los laboratorios.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de verificaci\u00f3n se sugiere realizar inicialmente y anualmente para los platers espirales?**\n   - Respuesta: Se sugiere establecer el rendimiento contra el m\u00e9todo convencional, verificar la condici\u00f3n del estilete y los puntos de inicio y final, as\u00ed como comprobar el volumen dispensado.\n\n2. **\u00bfCon qu\u00e9 frecuencia se debe verificar la velocidad de las centr\u00edfugas y qu\u00e9 herramienta se recomienda para esta verificaci\u00f3n?**\n   - Respuesta: La velocidad de las centr\u00edfugas debe verificarse anualmente utilizando un tac\u00f3metro calibrado e independiente.\n\n3. **\u00bfQu\u00e9 tipo de monitoreo ambiental se recomienda para los laboratorios y c\u00f3mo se debe establecer la frecuencia de este monitoreo?**\n   - Respuesta: Se recomienda monitorear la contaminaci\u00f3n microbiana en el aire y en superficies utilizando muestreadores de aire, placas de asentamiento, placas de contacto o hisopos. La frecuencia de este monitoreo debe basarse en una evaluaci\u00f3n de riesgos, estableciendo un programa de monitoreo ambiental apropiado.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **Calificaci\u00f3n y monitoreo de equipos:** El documento proporciona ejemplos de c\u00f3mo calificar y monitorear diversos equipos utilizados en laboratorios y entornos de investigaci\u00f3n.\n2. **Requisitos de funcionamiento:** Se detallan los requisitos espec\u00edficos que cada tipo de equipo debe cumplir para asegurar su correcto funcionamiento.\n3. **Frecuencia de verificaci\u00f3n:** Se sugiere una frecuencia de verificaci\u00f3n y mantenimiento basada en la necesidad, tipo de equipo, rendimiento previo y criticidad del mismo.\n\n**Entidades:**\n- **Equipos mencionados:**\n  - Equipos controlados por temperatura (incubadoras, ba\u00f1os, refrigeradores, congeladores)\n  - Hornos de esterilizaci\u00f3n\n  - Autoclaves\n  - Gabinetes unidireccionales de seguridad\n  - Aisladores\n  - Temporizadores\n  - Microscopios\n  - Medidores de pH\n  - Balanzas\n  - Desionizadores y unidades de \u00f3smosis inversa\n  - Dilutores gravim\u00e9tricos\n  - Dispensadores de medios\n  - Pipetores/pipetas\n\n- **Requisitos de monitoreo:**\n  - Estabilidad y uniformidad de temperatura\n  - Monitoreo microbiol\u00f3gico\n  - Monitoreo del flujo de aire\n  - Pruebas de integridad de filtros HEPA\n  - Verificaci\u00f3n de precisi\u00f3n y exactitud\n\n- **Frecuencias sugeridas:**\n  - Inicialmente cada 2 a\u00f1os, anualmente, semanalmente, diariamente, y en cada uso, dependiendo del equipo y su funci\u00f3n.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y el monitoreo de equipos en el contexto de la investigaci\u00f3n y la calidad en laboratorios, asegurando que se mantengan est\u00e1ndares adecuados para la seguridad y eficacia de los procesos.", "excerpt_keywords": "Keywords: equipment qualification, laboratory monitoring, microbial contamination, frequency of checks, WHO Technical Report"}}, "93e0de66-568c-4ce4-9ab2-2f1a6dd9cf32": {"node_ids": ["ca9d46c7-4dc9-4cb3-a735-f3904eb54ff8"], "metadata": {"page_label": "105", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 5\n\n## General use of reference cultures\n\n**Reference strain**  \nfrom source recognized by accreditation body\n\n**Reference stock G1**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G2**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G3**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\n**Reference stock G4**  \nFreeze-dried, liquid nitrogen storage, deep frozen, etc.  \nSpecified conditions and recommended storage times\n\n**Working culture**  \nSpecified conditions and recommended storage times  \nRoutine use\n\nAll parts of the process should be fully documented and detailed records of all stages must be maintained. Purity checks and biochemical tests should be made as appropriate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) incluye un ap\u00e9ndice que detalla el uso general de cultivos de referencia en laboratorios. Se describen diferentes tipos de cultivos de referencia (G1, G2, G3, G4), sus condiciones de almacenamiento y uso, as\u00ed como la importancia de mantener registros detallados y realizar pruebas de pureza y bioqu\u00edmicas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los cultivos de referencia G1, G2, G3 y G4?**\n   - Respuesta: Todos los cultivos de referencia deben ser almacenados en condiciones como liofilizaci\u00f3n, almacenamiento en nitr\u00f3geno l\u00edquido o congelaci\u00f3n profunda, aunque el texto no especifica las condiciones exactas para cada uno.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el manejo de cultivos de referencia seg\u00fan el ap\u00e9ndice?**\n   - Respuesta: Se requiere que todas las partes del proceso est\u00e9n completamente documentadas y que se mantengan registros detallados de todas las etapas.\n\n3. **\u00bfQu\u00e9 tipo de pruebas se deben realizar en los cultivos de referencia y por qu\u00e9 son importantes?**\n   - Respuesta: Se deben realizar pruebas de pureza y pruebas bioqu\u00edmicas, ya que son importantes para asegurar la calidad y la validez de los cultivos utilizados en los experimentos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Calificaci\u00f3n y Monitoreo de Equipos**: La secci\u00f3n proporciona ejemplos de c\u00f3mo calificar y monitorear diferentes tipos de equipos utilizados en laboratorios, lo cual es esencial para garantizar la calidad y precisi\u00f3n de los resultados.\n\n2. **Tipos de Equipos**:\n   - **Platers Espirales**: Se requiere establecer el rendimiento en comparaci\u00f3n con m\u00e9todos convencionales, verificar la condici\u00f3n del estilete y comprobar el volumen dispensado.\n   - **Contadores de Colonias**: Se debe verificar el conteo manualmente, con una frecuencia anual.\n   - **Centr\u00edfugas**: La velocidad debe ser verificada anualmente utilizando un tac\u00f3metro calibrado.\n   - **Frascos/Incubadoras Anaerobias**: Se debe verificar el indicador anaerobio en cada uso.\n   - **Entorno de Laboratorio**: Se recomienda monitorear la contaminaci\u00f3n microbiana en el aire y superficies, estableciendo un programa de monitoreo ambiental basado en una evaluaci\u00f3n de riesgos.\n\n3. **Frecuencia de Verificaci\u00f3n**: Se especifica la frecuencia sugerida para cada tipo de equipo, que var\u00eda desde verificaciones diarias hasta anuales, dependiendo del equipo y su uso.\n\n4. **Monitoreo Ambiental**: Se enfatiza la importancia de establecer un programa de monitoreo ambiental adecuado para asegurar un entorno de laboratorio seguro y controlado.\n\n5. **Terminolog\u00eda**: Se menciona el t\u00e9rmino HEPA (filtro de aire de alta eficiencia), que es relevante para la filtraci\u00f3n de aire en entornos de laboratorio.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y el monitoreo sistem\u00e1tico de equipos en laboratorios para mantener est\u00e1ndares de calidad y seguridad.", "excerpt_keywords": "Keywords: reference cultures, storage conditions, purity checks, biochemical tests, laboratory documentation"}}, "86e35b7d-b110-4385-bfdf-79f0a9610f8b": {"node_ids": ["cf80f5b0-1fb0-46d9-b684-56d263cefe9b"], "metadata": {"page_label": "106", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 3\n\n## WHO good manufacturing practices for pharmaceutical products: main principles\n\n### Introduction\n\n### General considerations\n\n### Glossary\n\n### Quality management in the medicines industry: philosophy and essential elements\n\n1. **Quality assurance**  \n   Product quality review\n\n2. **Good manufacturing practices for pharmaceutical products**\n\n3. **Sanitation and hygiene**\n\n4. **Qualification and validation**\n\n5. **Complaints**\n\n6. **Product recalls**\n\n7. **Contract production and analysis**  \n   General  \n   The contract giver  \n   The contract accepter  \n   The contract\n\n8. **Self-inspection, quality audits and supplier\u2019s audits and approval**  \n   Items for self-inspection  \n   Self-inspection team  \n   Frequency of self-inspection  \n   Self-inspection report  \n   Follow-up action  \n   Quality audit  \n   Suppliers\u2019 audits and approval\n\n9. **Personnel**  \n   General  \n   Key personnel\n\n10. **Training**\n\n11. **Personal hygiene**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye un anexo que detalla las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos, destacando principios clave como la gesti\u00f3n de calidad, la higiene, la capacitaci\u00f3n del personal y la auditor\u00eda de calidad. Se abordan aspectos esenciales como la garant\u00eda de calidad, la validaci\u00f3n, la gesti\u00f3n de quejas y los procedimientos de retiro de productos. Tambi\u00e9n se discuten las responsabilidades en la producci\u00f3n y an\u00e1lisis por contrato, as\u00ed como la importancia de la autoinspecci\u00f3n y la auditor\u00eda de proveedores.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los elementos esenciales de la gesti\u00f3n de calidad en la industria farmac\u00e9utica seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre la filosof\u00eda y los elementos que constituyen la gesti\u00f3n de calidad, que son fundamentales para asegurar la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir en caso de quejas y retiradas de productos seg\u00fan las buenas pr\u00e1cticas de fabricaci\u00f3n?**\n   - Esta pregunta se centra en los protocolos establecidos para manejar quejas y retiradas, lo que es crucial para la seguridad del paciente y la integridad del producto.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la autoinspecci\u00f3n y auditor\u00eda de proveedores seg\u00fan el documento?**\n   - Esta pregunta indaga sobre los criterios y procedimientos espec\u00edficos que se deben seguir durante la autoinspecci\u00f3n y la auditor\u00eda de proveedores, lo que es vital para mantener est\u00e1ndares de calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Cultivos de referencia**: Se mencionan diferentes tipos de cultivos de referencia (G1, G2, G3, G4) que son esenciales para la investigaci\u00f3n y el control de calidad en laboratorios.\n\n2. **Condiciones de almacenamiento**: Todos los cultivos de referencia deben ser almacenados en condiciones espec\u00edficas, como liofilizaci\u00f3n, almacenamiento en nitr\u00f3geno l\u00edquido o congelaci\u00f3n profunda, aunque no se detallan las condiciones exactas para cada tipo.\n\n3. **Cultivos de trabajo**: Se hace referencia a las condiciones y tiempos de almacenamiento recomendados para los cultivos de trabajo, que son utilizados de manera rutinaria.\n\n4. **Documentaci\u00f3n y registros**: Se enfatiza la importancia de mantener una documentaci\u00f3n completa y registros detallados de todas las etapas del manejo de cultivos de referencia.\n\n5. **Pruebas de calidad**: Se requiere realizar pruebas de pureza y bioqu\u00edmicas para asegurar la calidad y validez de los cultivos utilizados en experimentos.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que publica el informe t\u00e9cnico.\n- **Cultivos de referencia**: G1, G2, G3, G4.\n- **Condiciones de almacenamiento**: Liofilizaci\u00f3n, nitr\u00f3geno l\u00edquido, congelaci\u00f3n profunda.\n- **Documentaci\u00f3n**: Registros detallados de procesos y pruebas de calidad.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, gesti\u00f3n de calidad, auditor\u00eda, higiene, formaci\u00f3n del personal"}}, "3906fb76-3e23-42f2-b88f-eda7f26bd97d": {"node_ids": ["954a9543-aa64-45f4-af7c-cede1097d9d8"], "metadata": {"page_label": "107", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n12. Premises  \n   General  \n   Ancillary areas  \n   Storage areas  \n   Weighing areas  \n   Production areas  \n   Quality control areas  \n\n13. Equipment  \n\n14. Materials  \n   General  \n   Starting materials  \n   Packaging materials  \n   Intermediate and bulk products  \n   Finished products  \n   Rejected, recovered, reprocessed and reworked materials  \n   Recalled products  \n   Returned goods  \n   Reagents and culture media  \n   Reference standards  \n   Waste materials  \n   Miscellaneous  \n\n15. Documentation  \n   General  \n   Documents required  \n\n16. Good practices in production  \n   General  \n   Prevention of cross-contamination and bacterial contamination during production  \n   Processing operations  \n   Packaging operations  \n\n17. Good practices in quality control  \n   Control of starting materials and intermediate, bulk and finished products  \n   Test requirements  \n   Batch record review  \n   Stability studies  \n\nReferences\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la producci\u00f3n y control de calidad en la industria farmac\u00e9utica. Se detallan las instalaciones necesarias, el equipo, los materiales, la documentaci\u00f3n requerida y las buenas pr\u00e1cticas tanto en producci\u00f3n como en control de calidad. Se enfatiza la importancia de prevenir la contaminaci\u00f3n cruzada y se establecen requisitos para el control de materiales y productos en diferentes etapas del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas que se deben considerar al evaluar las instalaciones de producci\u00f3n seg\u00fan el informe?**\n   - El informe menciona varias \u00e1reas que deben ser evaluadas, incluyendo \u00e1reas generales, \u00e1reas auxiliares, \u00e1reas de almacenamiento, \u00e1reas de pesaje, \u00e1reas de producci\u00f3n y \u00e1reas de control de calidad.\n\n2. **\u00bfQu\u00e9 tipos de materiales se clasifican en el informe y cu\u00e1les son sus categor\u00edas espec\u00edficas?**\n   - Los materiales se clasifican en varias categor\u00edas, que incluyen materiales de partida, materiales de embalaje, productos intermedios y a granel, productos terminados, materiales rechazados, recuperados, reprocesados y re-trabajados, productos retirados, bienes devueltos, reactivos y medios de cultivo, est\u00e1ndares de referencia, materiales de desecho y otros materiales diversos.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas se recomiendan para prevenir la contaminaci\u00f3n durante el proceso de producci\u00f3n?**\n   - Se recomienda implementar buenas pr\u00e1cticas en la producci\u00f3n, que incluyen la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la contaminaci\u00f3n bacteriana, as\u00ed como la correcta ejecuci\u00f3n de operaciones de procesamiento y embalaje.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl anexo 3 del documento \"WHO - Technical Report Series 961\" aborda las **buenas pr\u00e1cticas de fabricaci\u00f3n (BPF)** para productos farmac\u00e9uticos, destacando los siguientes temas clave:\n\n1. **Gesti\u00f3n de Calidad**: Se enfatiza la importancia de la **garant\u00eda de calidad** y la revisi\u00f3n de la calidad del producto como elementos fundamentales en la industria farmac\u00e9utica.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n**: Se describen los principios y procedimientos que deben seguirse para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n3. **Sanitaci\u00f3n e Higiene**: Se subraya la necesidad de mantener altos est\u00e1ndares de higiene en el proceso de fabricaci\u00f3n.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n**: Se discuten los procesos necesarios para validar equipos y procedimientos en la producci\u00f3n.\n\n5. **Gesti\u00f3n de Quejas**: Se establecen protocolos para manejar quejas de los consumidores y asegurar la respuesta adecuada.\n\n6. **Retiradas de Productos**: Se detallan los procedimientos a seguir en caso de que sea necesario retirar productos del mercado.\n\n7. **Producci\u00f3n y An\u00e1lisis por Contrato**: Se abordan las responsabilidades de las partes involucradas en la producci\u00f3n y an\u00e1lisis de productos farmac\u00e9uticos bajo contrato.\n\n8. **Autoinspecci\u00f3n y Auditor\u00edas**: Se describen los elementos y procedimientos para llevar a cabo autoinspecciones y auditor\u00edas de calidad, as\u00ed como la aprobaci\u00f3n de proveedores.\n\n9. **Personal**: Se menciona la importancia del personal clave y su capacitaci\u00f3n en el cumplimiento de las BPF.\n\n10. **Capacitaci\u00f3n**: Se destaca la necesidad de formaci\u00f3n continua del personal para mantener est\u00e1ndares de calidad.\n\n11. **Higiene Personal**: Se enfatiza la importancia de la higiene personal de los empleados en el entorno de fabricaci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **BPF (Buenas Pr\u00e1cticas de Fabricaci\u00f3n)**: Conjunto de principios y procedimientos para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.\n- **Calidad**: Concepto central en la gesti\u00f3n de productos farmac\u00e9uticos.\n- **Personal Clave**: Empleados responsables de mantener los est\u00e1ndares de calidad.\n- **Auditor\u00edas**: Proceso de revisi\u00f3n y evaluaci\u00f3n de pr\u00e1cticas de calidad.\n\nEste resumen proporciona una visi\u00f3n general de los principios y pr\u00e1cticas esenciales que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: producci\u00f3n farmac\u00e9utica, buenas pr\u00e1cticas, control de calidad, materiales, instalaciones"}}, "9735e006-04ff-45e5-8e8e-a94f50298bce": {"node_ids": ["a0b58538-14ad-498f-ac60-127c6269436e"], "metadata": {"page_label": "108", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe first WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth World Health Assembly (resolution WHA20.34). It was subsequently submitted to the Twenty-first World Health Assembly under the title \u201cDraft requirements for good manufacturing practice in the manufacture and quality control of medicines and pharmaceutical specialities\u201d and was accepted.\n\nThe revised text was discussed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its twenty-second report. The text was then reproduced (with some revisions) in 1971 in the Supplement to the second edition of *The International Pharmacopoeia*.\n\nIn 1969, when the World Health Assembly recommended the first version of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce in resolution WHA22.50, it accepted at the same time the GMP text as an integral part of the Scheme. Revised versions of both the Certification Scheme and the GMP text were adopted in 1975 by resolution WHA28.65. Since then, the Certification Scheme has been extended to include the certification of:\n\n- veterinary products administered to food-producing animals;\n- starting materials for use in dosage forms, when they are subject to control by legislation in both the exporting Member State and the importing Member State;\n- information on safety and efficacy (resolution WHA41.18, 1988).\n\nIn 1992, the revised draft requirements for GMP were presented in three parts, of which only Parts One and Two are reproduced in this document (1).\n\n\u201cQuality management in the medicines industry: philosophy and essential elements\u201d, outlines the general concepts of quality assurance (QA) as well as the principal components or subsystems of GMP, which are joint responsibilities of top management and of production and quality control management. These include hygiene, validation, self-inspection, personnel, premises, equipment, materials and documentation.\n\n\u201cGood practices in production and quality control\u201d, provides guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of QA.\n\nThese two parts were subsequently supplemented by further guidelines which are integral parts of these GMP for pharmaceutical products. All these texts are available on the Medicines web page (http.www.who.int/).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona una visi\u00f3n general de la evoluci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan la Organizaci\u00f3n Mundial de la Salud (OMS). Se menciona que el primer borrador de GMP fue preparado en 1967 y aceptado por la Asamblea Mundial de la Salud. A lo largo de los a\u00f1os, se han revisado y ampliado tanto el texto de GMP como el esquema de certificaci\u00f3n de productos farmac\u00e9uticos. En 1992, se presentaron requisitos revisados para GMP en tres partes, de las cuales solo se incluyen dos en el documento. Se destacan los conceptos de gesti\u00f3n de calidad y las responsabilidades compartidas entre la alta direcci\u00f3n y la gesti\u00f3n de producci\u00f3n y control de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes principales de las Buenas Pr\u00e1cticas de Manufactura (GMP) seg\u00fan el documento de la OMS?**\n   - Respuesta: Los componentes principales de GMP incluyen higiene, validaci\u00f3n, autoinspecci\u00f3n, personal, instalaciones, equipos, materiales y documentaci\u00f3n.\n\n2. **\u00bfQu\u00e9 cambios se realizaron en el esquema de certificaci\u00f3n de productos farmac\u00e9uticos desde su adopci\u00f3n inicial en 1969?**\n   - Respuesta: Desde su adopci\u00f3n inicial, el esquema de certificaci\u00f3n se ha ampliado para incluir la certificaci\u00f3n de productos veterinarios administrados a animales de producci\u00f3n, materiales iniciales para formas de dosificaci\u00f3n bajo control legislativo y la informaci\u00f3n sobre seguridad y eficacia.\n\n3. **\u00bfQu\u00e9 partes del documento de requisitos revisados para GMP se incluyen en el informe de la OMS de 1992?**\n   - Respuesta: En el informe de 1992, se incluyen las Partes Uno y Dos de los requisitos revisados para GMP, que abordan la gesti\u00f3n de calidad en la industria de medicamentos y las buenas pr\u00e1cticas en producci\u00f3n y control de calidad.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS detalla la historia y evoluci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP) desde su creaci\u00f3n en 1967, resaltando su importancia en la calidad de los productos farmac\u00e9uticos. Se discuten los principios de gesti\u00f3n de calidad y las responsabilidades compartidas entre diferentes niveles de gesti\u00f3n en la industria farmac\u00e9utica. Adem\u00e1s, se menciona la evoluci\u00f3n del esquema de certificaci\u00f3n de productos farmac\u00e9uticos, que ha sido ampliado para incluir m\u00e1s categor\u00edas de productos y requisitos.\n\n### Preguntas Adicionales\n\n1. **\u00bfQu\u00e9 resoluci\u00f3n de la Asamblea Mundial de la Salud acept\u00f3 el texto de GMP como parte del esquema de certificaci\u00f3n en 1969?**\n   - Respuesta: La resoluci\u00f3n WHA22.50.\n\n2. **\u00bfQu\u00e9 documento de la OMS se menciona como una fuente de informaci\u00f3n sobre las pr\u00e1cticas de calidad en la industria de medicamentos?**\n   - Respuesta: El documento titulado \u201cQuality management in the medicines industry: philosophy and essential elements\u201d.\n\n3. **\u00bfQu\u00e9 a\u00f1o se menciona como el de la adopci\u00f3n de versiones revisadas del esquema de certificaci\u00f3n y el texto de GMP?**\n   - Respuesta: 1975, bajo la resoluci\u00f3n WHA28.65.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos fundamentales en la producci\u00f3n y control de calidad en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Instalaciones (Premises)**:\n   - **\u00c1reas Generales**: Espacios comunes y de acceso.\n   - **\u00c1reas Auxiliares**: Espacios que apoyan la producci\u00f3n.\n   - **\u00c1reas de Almacenamiento**: Espacios para guardar materiales y productos.\n   - **\u00c1reas de Pesaje**: Espacios designados para la medici\u00f3n de ingredientes.\n   - **\u00c1reas de Producci\u00f3n**: Espacios donde se lleva a cabo la fabricaci\u00f3n.\n   - **\u00c1reas de Control de Calidad**: Espacios dedicados a la verificaci\u00f3n de calidad.\n\n2. **Equipamiento (Equipment)**:\n   - Se menciona la importancia de contar con el equipo adecuado para la producci\u00f3n y control de calidad.\n\n3. **Materiales (Materials)**:\n   - **Materiales de Partida**: Ingredientes iniciales para la producci\u00f3n.\n   - **Materiales de Embalaje**: Materiales utilizados para el empaquetado de productos.\n   - **Productos Intermedios y a Granel**: Productos en diferentes etapas de producci\u00f3n.\n   - **Productos Terminados**: Productos listos para la distribuci\u00f3n.\n   - **Materiales Rechazados, Recuperados, Reprocesados y Re-trabajados**: Materiales que no cumplen con los est\u00e1ndares y su manejo.\n   - **Productos Retirados y Bienes Devueltos**: Productos que han sido retirados del mercado o devueltos por clientes.\n   - **Reactivos y Medios de Cultivo**: Sustancias utilizadas en pruebas y cultivos.\n   - **Est\u00e1ndares de Referencia**: Materiales utilizados para calibraci\u00f3n y control.\n   - **Materiales de Desecho**: Residuos generados durante el proceso.\n   - **Materiales Diversos**: Otros materiales no clasificados en las categor\u00edas anteriores.\n\n4. **Documentaci\u00f3n (Documentation)**:\n   - Importancia de la documentaci\u00f3n general y de los documentos requeridos para asegurar la trazabilidad y cumplimiento de normativas.\n\n5. **Buenas Pr\u00e1cticas en Producci\u00f3n (Good Practices in Production)**:\n   - Prevenci\u00f3n de contaminaci\u00f3n cruzada y bacteriana.\n   - Ejecuci\u00f3n adecuada de operaciones de procesamiento y embalaje.\n\n6. **Buenas Pr\u00e1cticas en Control de Calidad (Good Practices in Quality Control)**:\n   - Control de materiales y productos en diferentes etapas.\n   - Requisitos de pruebas y revisi\u00f3n de registros de lotes.\n   - Estudios de estabilidad para asegurar la calidad a lo largo del tiempo.\n\n### Conclusi\u00f3n\nEl informe enfatiza la importancia de mantener est\u00e1ndares rigurosos en las instalaciones, el uso de materiales adecuados, la documentaci\u00f3n precisa y la implementaci\u00f3n de buenas pr\u00e1cticas para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, WHO, pharmaceutical quality, certification scheme, quality assurance"}}, "c27229c8-5df7-476b-98a2-0adc504ed4c2": {"node_ids": ["5dac3e96-a633-49d9-8788-9ccfef29d9bd"], "metadata": {"page_label": "109", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medicines/organization/qsm/activities/qualityassurance/gmp/gmpcover.html).\n\nConsiderable developments in GMP have taken place in the intervening years, and important national and international documents, including new revisions, have appeared (2,3,4,5). Thus the necessity to revise the main principles and incorporate the concept of validation.\n\nAmong other feedback which was discussed during the consultation on WHO guidelines for medicines quality assurance, quality control (QC) laboratories and transfer of technology on 27\u201331 July 2009, the need was identified to incorporate a new section (1.6) on \u201cProduct quality review\u201d under Chapter 1: \u201cQuality assurance\u201d.\n\nIn addition, several updates were suggested to further enhance the guidelines and include the concept of risk management, replacing \u201cdrugs\u201d by the term \u201cmedicines\u201d and newly introduce the concept of a \u201cquality unit\u201d.\n\n# General considerations\n\nLicensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status, which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry.\n\nThe guide is applicable to operations for the manufacture of medicines in their finished dosage forms, including large-scale processes in hospitals and the preparation of supplies for use in clinical trials.\n\nThe good practices outlined below are to be considered general guides[^1], and they may be adapted to meet individual needs. The equivalence of alternative approaches to QA, however, should be validated. The guide as a whole does not cover safety aspects for the personnel engaged in manufacture or environmental protection: these are normally governed by national legislation. A new concept of hazard analysis related to the risks in production and personnel safety is also newly recommended (Annex 7). The manufacturer should assure the safety of workers and take the necessary measures to prevent pollution of the external environment.\n\n[^1]: The word \u201cshould\u201d in the text means a strong recommendation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 961\", aborda los desarrollos recientes en las Buenas Pr\u00e1cticas de Manufactura (GMP) y la necesidad de actualizar las directrices para asegurar la calidad de los medicamentos. Se enfatiza la importancia de la validaci\u00f3n, la gesti\u00f3n de riesgos y la introducci\u00f3n de un \"unidad de calidad\". Adem\u00e1s, se establece que los productos farmac\u00e9uticos deben ser fabricados por fabricantes autorizados y que las pr\u00e1cticas recomendadas pueden adaptarse a las necesidades individuales, siempre que se valide la equivalencia de los enfoques alternativos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 cambios se han propuesto en las directrices de GMP en relaci\u00f3n con la terminolog\u00eda utilizada para referirse a los medicamentos?**\n   - Respuesta: Se ha propuesto reemplazar el t\u00e9rmino \"drugs\" por \"medicines\" en las directrices de GMP.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito del nuevo concepto de \"an\u00e1lisis de peligros\" mencionado en el documento?**\n   - Respuesta: El nuevo concepto de an\u00e1lisis de peligros se recomienda para abordar los riesgos en la producci\u00f3n y la seguridad del personal, asegurando que los fabricantes tomen medidas para proteger a los trabajadores y prevenir la contaminaci\u00f3n del medio ambiente.\n\n3. **\u00bfC\u00f3mo se utilizar\u00e1 la gu\u00eda de GMP en el contexto de la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional?**\n   - Respuesta: La gu\u00eda de GMP se utilizar\u00e1 como est\u00e1ndar para justificar el estado de GMP, lo que es un elemento del esquema de certificaci\u00f3n de la OMS sobre la calidad de los productos farmac\u00e9uticos que se mueven en el comercio internacional, a trav\u00e9s de la evaluaci\u00f3n de solicitudes de autorizaciones de fabricaci\u00f3n y como base para la inspecci\u00f3n de instalaciones de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Historia de las Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - El primer borrador de GMP fue preparado en 1967 por consultores a solicitud de la Asamblea Mundial de la Salud.\n   - Aceptaci\u00f3n del texto en la vig\u00e9sima primera Asamblea Mundial de la Salud.\n\n2. **Evoluci\u00f3n y Revisi\u00f3n**:\n   - El texto fue discutido por el Comit\u00e9 de Expertos de la OMS en 1968 y publicado en 1971 en *The International Pharmacopoeia*.\n   - En 1969, la Asamblea Mundial de la Salud acept\u00f3 el texto de GMP como parte del esquema de certificaci\u00f3n de productos farmac\u00e9uticos (resoluci\u00f3n WHA22.50).\n   - En 1975, se adoptaron versiones revisadas del esquema de certificaci\u00f3n y del texto de GMP (resoluci\u00f3n WHA28.65).\n\n3. **Ampliaci\u00f3n del Esquema de Certificaci\u00f3n**:\n   - Inclusi\u00f3n de productos veterinarios, materiales iniciales para formas de dosificaci\u00f3n y requisitos de informaci\u00f3n sobre seguridad y eficacia.\n\n4. **Requisitos Revisados de GMP (1992)**:\n   - Presentaci\u00f3n de requisitos en tres partes, de las cuales se incluyen las Partes Uno y Dos en el documento.\n   - Parte Uno: \"Quality management in the medicines industry: philosophy and essential elements\", que aborda conceptos de aseguramiento de calidad y componentes de GMP.\n   - Parte Dos: \"Good practices in production and quality control\", que proporciona orientaci\u00f3n sobre acciones para producci\u00f3n y control de calidad.\n\n5. **Componentes Principales de GMP**:\n   - Higiene, validaci\u00f3n, autoinspecci\u00f3n, personal, instalaciones, equipos, materiales y documentaci\u00f3n.\n\n6. **Acceso a Documentos**:\n   - Todos los textos relacionados est\u00e1n disponibles en la p\u00e1gina web de Medicamentos de la OMS.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la creaci\u00f3n y revisi\u00f3n de las GMP.\n- **Asamblea Mundial de la Salud**: Cuerpo que aprob\u00f3 el texto de GMP y el esquema de certificaci\u00f3n.\n- **Resoluciones**: WHA20.34, WHA22.50, WHA28.65, WHA41.18.\n- **Documentos**: *The International Pharmacopoeia*, \"Quality management in the medicines industry\", \"Good practices in production and quality control\". \n\nEste resumen destaca la evoluci\u00f3n de las GMP, su importancia en la industria farmac\u00e9utica y los componentes esenciales que garantizan la calidad de los productos.", "excerpt_keywords": "Keywords: GMP, quality assurance, medicines, risk management, validation"}}, "f93398a3-9fb1-40c4-83fe-4ce3a7d251fe": {"node_ids": ["d6d39414-e870-4385-ba92-02d492357943"], "metadata": {"page_label": "110", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "International Nonproprietary Names (INN) for pharmaceutical substances designated by WHO should be used when available, together with other designated names.\n\n# Glossary\n\nThe definitions given below apply to the terms used in this guide.\n\nThey may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for use either by people or for goods and/or equipment.\n\n**authorized person**  \nThe person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n\n**batch (or lot)**  \nA defined quantity of starting material, packaging material, or product processed in a single process or series of processes so that it is expected to be homogeneous. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch. In the case of terminal sterilization, the batch size is determined by the capacity of the autoclave. In continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. The batch size can be defined either as a fixed quantity or as the amount produced in a fixed time interval.\n\n**batch number (or lot number)**  \nA distinctive combination of numbers and/or letters which uniquely identifies a batch on the labels, its batch records and corresponding certificates of analysis, etc.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" proporciona definiciones clave relacionadas con la fabricaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos. Incluye t\u00e9rminos como \"ingrediente farmac\u00e9utico activo\" (API), \"airlock\", \"persona autorizada\", \"lote\" y \"n\u00famero de lote\". Estas definiciones son esenciales para entender los procesos de producci\u00f3n y control de calidad en la industria farmac\u00e9utica, as\u00ed como la importancia de utilizar nombres no propietarios internacionales (INN) para las sustancias farmac\u00e9uticas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de un \"airlock\" en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un \"airlock\" es un espacio cerrado con dos o m\u00e1s puertas que se utiliza para controlar el flujo de aire entre habitaciones de diferentes clases de limpieza, permitiendo el acceso a personas o bienes y/o equipos sin comprometer la limpieza del entorno.\n\n2. **\u00bfQu\u00e9 criterios debe cumplir una \"persona autorizada\" seg\u00fan el contexto del documento?**\n   - Respuesta: La \"persona autorizada\" es reconocida por la autoridad reguladora nacional y tiene la responsabilidad de asegurar que cada lote de producto terminado haya sido fabricado, probado y aprobado para su liberaci\u00f3n de acuerdo con las leyes y regulaciones vigentes en el pa\u00eds.\n\n3. **\u00bfC\u00f3mo se define un \"lote\" en el contexto de la producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un \"lote\" se define como una cantidad determinada de material inicial, material de embalaje o producto procesado en un solo proceso o serie de procesos, con la expectativa de que sea homog\u00e9neo. Puede dividirse en sub-lotes que luego se combinan para formar un lote final homog\u00e9neo.", "prev_section_summary": "### Temas Clave\n1. **Desarrollo de Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se han realizado importantes avances en las GMP, lo que ha llevado a la necesidad de revisar y actualizar las directrices existentes.\n   \n2. **Incorporaci\u00f3n de Nuevos Conceptos**: Se sugiere la inclusi\u00f3n de un nuevo apartado sobre \"Revisi\u00f3n de la calidad del producto\" y la introducci\u00f3n del concepto de \"unidad de calidad\".\n\n3. **Terminolog\u00eda Actualizada**: Se propone reemplazar el t\u00e9rmino \"drugs\" por \"medicines\" en las directrices.\n\n4. **Gesti\u00f3n de Riesgos**: Se enfatiza la importancia de incorporar la gesti\u00f3n de riesgos en las pr\u00e1cticas de calidad.\n\n5. **Fabricaci\u00f3n Autorizada**: Los productos farmac\u00e9uticos deben ser fabricados \u00fanicamente por fabricantes autorizados, cuyas actividades son inspeccionadas regularmente por autoridades competentes.\n\n6. **Gu\u00eda de GMP como Est\u00e1ndar**: La gu\u00eda de GMP se utilizar\u00e1 como est\u00e1ndar para justificar el estado de GMP y como base para la certificaci\u00f3n de productos farmac\u00e9uticos en el comercio internacional.\n\n7. **An\u00e1lisis de Peligros**: Se recomienda un nuevo concepto de an\u00e1lisis de peligros para abordar los riesgos en la producci\u00f3n y la seguridad del personal.\n\n### Entidades\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices y est\u00e1ndares para la calidad de los medicamentos.\n- **Fabricantes Autorizados**: Entidades que poseen la autorizaci\u00f3n para fabricar productos farmac\u00e9uticos.\n- **Autoridades Nacionales Competentes**: Organismos responsables de la inspecci\u00f3n y regulaci\u00f3n de las pr\u00e1cticas de fabricaci\u00f3n de medicamentos.\n- **Laboratorios de Control de Calidad (QC)**: Entidades que aseguran la calidad de los productos farmac\u00e9uticos a trav\u00e9s de pruebas y an\u00e1lisis.\n\n### Resumen\nEl documento de la OMS, \"Technical Report Series 961\", aborda la necesidad de actualizar las Buenas Pr\u00e1cticas de Manufactura (GMP) para asegurar la calidad de los medicamentos. Se proponen cambios en la terminolog\u00eda, la incorporaci\u00f3n de nuevos conceptos como la gesti\u00f3n de riesgos y la revisi\u00f3n de la calidad del producto, y se establece que solo los fabricantes autorizados pueden producir medicamentos. La gu\u00eda de GMP servir\u00e1 como est\u00e1ndar para la certificaci\u00f3n de productos en el comercio internacional y se recomienda un an\u00e1lisis de peligros para garantizar la seguridad del personal y del medio ambiente.", "excerpt_keywords": "Keywords: pharmaceutical, active ingredient, airlock, batch number, regulatory authority"}}, "98c91bf7-a815-4f49-9ee7-f0a206532709": {"node_ids": ["65e270d1-6244-4912-94c5-b437946a0b3a"], "metadata": {"page_label": "111", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# batch records\n\nAll documents associated with the manufacture of a batch of bulk product or finished product. They provide a history of each batch of product and of all circumstances pertinent to the quality of the final product.\n\n# bulk product\n\nAny product that has completed all processing stages up to, but not including, final packaging.\n\n# calibration\n\nThe set of operations that establish, under specified conditions, the relationship between values indicated by an instrument or system for measuring (especially weighing), recording, and controlling, or the values represented by a material measure, and the corresponding known values of a reference standard. Limits for acceptance of the results of measuring should be established.\n\n# clean area\n\nAn area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation, and retention of contaminants within the area.\n\n# consignment (or delivery)\n\nThe quantity of a pharmaceutical(s), made by one manufacturer and supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include material belonging to more than one batch.\n\n# contamination\n\nThe undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or on to a starting material or intermediate during production, sampling, packaging or repackaging, storage or transport.\n\n# critical operation\n\nAn operation in the manufacturing process that may cause variation in the quality of the pharmaceutical product.\n\n# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# finished product\n\nA finished dosage form that has undergone all stages of manufacture, including packaging in its final container and labelling.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar preguntas m\u00e1s espec\u00edficas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones y procedimientos cr\u00edticos para asegurar la calidad y seguridad de los productos. Se discuten t\u00e9rminos como \"registros de lote\", \"producto a granel\", \"calibraci\u00f3n\", \"\u00e1rea limpia\", \"contaminaci\u00f3n\", \"operaci\u00f3n cr\u00edtica\", \"contaminaci\u00f3n cruzada\" y \"producto terminado\".\n\n### Preguntas:\n1. **\u00bfQu\u00e9 documentos son necesarios para garantizar la calidad de un lote de producto farmac\u00e9utico y qu\u00e9 informaci\u00f3n espec\u00edfica deben contener?**\n   - Esta pregunta se centra en los \"registros de lote\" y su importancia en el proceso de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las medidas que se deben tomar para evitar la contaminaci\u00f3n cruzada durante la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta aborda el concepto de \"contaminaci\u00f3n cruzada\" y las pr\u00e1cticas necesarias para prevenirla, lo que es crucial para la seguridad del producto.\n\n3. **\u00bfQu\u00e9 criterios se deben establecer para la calibraci\u00f3n de instrumentos de medici\u00f3n en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se enfoca en el proceso de \"calibraci\u00f3n\" y los l\u00edmites de aceptaci\u00f3n que son esenciales para asegurar la precisi\u00f3n en la medici\u00f3n durante la producci\u00f3n.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar f\u00e1cilmente disponible en otras fuentes, centr\u00e1ndose en los procedimientos y definiciones clave del contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda conceptos fundamentales en la fabricaci\u00f3n y regulaci\u00f3n de productos farmac\u00e9uticos, proporcionando definiciones esenciales que son cruciales para la comprensi\u00f3n de los procesos de producci\u00f3n y control de calidad en la industria. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Nombres No Propietarios Internacionales (INN)**: Se enfatiza la importancia de utilizar los INN designados por la OMS para las sustancias farmac\u00e9uticas, junto con otros nombres designados.\n\n2. **Definiciones Clave**:\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia o mezcla utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efectos directos en el tratamiento de enfermedades.\n   - **Airlock**: Espacio cerrado con m\u00faltiples puertas que controla el flujo de aire entre habitaciones de diferentes niveles de limpieza, utilizado para el acceso seguro de personas y equipos.\n   - **Persona Autorizada**: Individuo reconocido por la autoridad reguladora nacional, responsable de asegurar que cada lote de producto terminado cumpla con las regulaciones y leyes vigentes.\n   - **Lote (Batch)**: Cantidad definida de material procesado en un solo proceso, esperado ser homog\u00e9neo, que puede dividirse en sub-lotes.\n   - **N\u00famero de Lote (Batch Number)**: Combinaci\u00f3n distintiva de n\u00fameros y/o letras que identifica de manera \u00fanica un lote en etiquetas y registros.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que designa los INN para sustancias farmac\u00e9uticas.\n- **Autoridad Reguladora Nacional**: Organismo que reconoce a la persona autorizada y establece las normativas para la fabricaci\u00f3n y liberaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los t\u00e9rminos y conceptos esenciales que son fundamentales para la regulaci\u00f3n y producci\u00f3n en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: batch records, bulk product, calibration, contamination, finished product"}}, "27116857-0b72-4473-9308-685cab6e04f3": {"node_ids": ["dd90313b-6e2a-484c-83ac-371dd5bcb57e"], "metadata": {"page_label": "112", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# In-Process Control\n\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# Intermediate Product\n\nPartly processed product that must undergo further manufacturing steps before it becomes a bulk product.\n\n# Large-Volume Parenterals\n\nSterile solutions intended for parenteral application with a volume of 100 ml or more in one container of the finished dosage form.\n\n# Manufacture\n\nAll operations of purchase of materials and products, production, quality control (QC), release, storage and distribution of pharmaceutical products, and the related controls.\n\n# Manufacturer\n\nA company that carries out operations such as production, packaging, repackaging, labelling and relabelling of pharmaceuticals.\n\n# Marketing Authorization (Product Licence, Registration Certificate)\n\nA legal document issued by the competent medicines regulatory authority that establishes the detailed composition and formulation of the product and the pharmacopoeial or other recognized specifications of its ingredients and of the final product itself, and includes details of packaging, labelling and shelf-life.\n\n# Master Formula\n\nA document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls.\n\n# Master Record\n\nA document or set of documents that serve as a basis for the batch documentation (blank batch record).\n\n# Packaging\n\nAll operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 961 aborda varios conceptos clave relacionados con la producci\u00f3n y control de productos farmac\u00e9uticos. Se definen t\u00e9rminos como \"control en proceso\", \"producto intermedio\", \"parenterales de gran volumen\", \"fabricaci\u00f3n\", \"fabricante\", \"autorizaci\u00f3n de comercializaci\u00f3n\", \"f\u00f3rmula maestra\", \"registro maestro\" y \"empaquetado\". Cada uno de estos t\u00e9rminos se relaciona con las operaciones y regulaciones necesarias para garantizar que los productos farmac\u00e9uticos cumplan con las especificaciones y est\u00e1ndares de calidad.\n\n### Preguntas\n1. **\u00bfQu\u00e9 incluye el control en proceso durante la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: El control en proceso incluye las verificaciones realizadas durante la producci\u00f3n para monitorear y, si es necesario, ajustar el proceso para asegurar que el producto cumpla con sus especificaciones. Tambi\u00e9n puede incluir el control del entorno o del equipo.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto intermedio y un producto terminado en el contexto de la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Un producto intermedio es un producto que ha sido parcialmente procesado y que debe someterse a pasos adicionales de fabricaci\u00f3n antes de convertirse en un producto a granel, mientras que un producto terminado es aquel que ha completado todos los procesos de fabricaci\u00f3n y est\u00e1 listo para su distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se incluye en una autorizaci\u00f3n de comercializaci\u00f3n para un producto farmac\u00e9utico?**\n   - Respuesta: Una autorizaci\u00f3n de comercializaci\u00f3n incluye un documento legal emitido por la autoridad reguladora competente que establece la composici\u00f3n detallada y la formulaci\u00f3n del producto, las especificaciones reconocidas de sus ingredientes y del producto final, as\u00ed como detalles sobre el empaquetado, etiquetado y vida \u00fatil del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Registros de Lote**: Documentos que registran la fabricaci\u00f3n de un lote de producto farmac\u00e9utico, proporcionando un historial y detalles relevantes para asegurar la calidad del producto final.\n\n2. **Producto a Granel**: Se refiere a productos que han completado todas las etapas de procesamiento, excepto el empaquetado final.\n\n3. **Calibraci\u00f3n**: Proceso que establece la relaci\u00f3n entre los valores medidos por un instrumento y los valores de un est\u00e1ndar de referencia, incluyendo la necesidad de establecer l\u00edmites de aceptaci\u00f3n para los resultados.\n\n4. **\u00c1rea Limpia**: Espacio controlado ambientalmente para minimizar la contaminaci\u00f3n particulada y microbiana, dise\u00f1ado para reducir la introducci\u00f3n y retenci\u00f3n de contaminantes.\n\n5. **Consignaci\u00f3n (o Entrega)**: Cantidad de productos farmac\u00e9uticos suministrados por un fabricante en respuesta a un pedido, que puede incluir m\u00faltiples paquetes o contenedores.\n\n6. **Contaminaci\u00f3n**: Introducci\u00f3n no deseada de impurezas qu\u00edmicas o microbiol\u00f3gicas en materiales durante diversas etapas de producci\u00f3n y transporte.\n\n7. **Operaci\u00f3n Cr\u00edtica**: Etapa en el proceso de fabricaci\u00f3n que puede afectar la calidad del producto farmac\u00e9utico.\n\n8. **Contaminaci\u00f3n Cruzada**: Contaminaci\u00f3n de un material o producto con otro durante el proceso de producci\u00f3n.\n\n9. **Producto Terminado**: Forma de dosificaci\u00f3n que ha completado todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado y etiquetado final.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos**: Bienes que requieren un control riguroso en su fabricaci\u00f3n para garantizar su calidad y seguridad.\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de los procedimientos y controles para asegurar la calidad del producto final.", "excerpt_keywords": "Keywords: In-Process Control, Intermediate Product, Marketing Authorization, Master Formula, Large-Volume Parenterals"}}, "81be738d-dbc4-4bcc-827c-4686cd9c6e93": {"node_ids": ["45d0c3fd-66f4-4b83-905c-818d550d556e"], "metadata": {"page_label": "113", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# packaging material\n\nAny material, including printed material, employed in the packaging of a pharmaceutical, but excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product.\n\n# pharmaceutical product\n\nAny material or product intended for human or veterinary use presented in its finished dosage form or as a starting material for use in such a dosage form, that is subject to control by pharmaceutical legislation in the exporting state and/or the importing state.\n\n# production\n\nAll operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product.\n\n# qualification\n\nAction of proving that any premises, systems and items of equipment work correctly and actually lead to the expected results. The meaning of the word \u201cvalidation\u201d is sometimes extended to incorporate the concept of qualification.\n\n# quality assurance\n\nSee Part One (6).\n\n# quality control\n\nSee Part One (6).\n\n# quality unit(s)\n\nAn organizational unit independent of production which fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.\n\n# quarantine\n\nThe status of starting or packaging materials, intermediates, or bulk or finished products isolated physically or by other effective means while a decision is awaited on their release, rejection or reprocessing.\n\n# reconciliation\n\nA comparison between the theoretical quantity and the actual quantity.\n\n# recovery\n\nThe introduction of all or part of previous batches (or of redistilled solvents and similar products) of the required quality into another batch at a defined stage.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Definici\u00f3n de Materiales de Empaque**: El documento define qu\u00e9 se entiende por materiales de empaque en el contexto farmac\u00e9utico, diferenciando entre materiales primarios y secundarios, y excluyendo el empaque exterior utilizado para transporte.\n\n2. **Concepto de Producto Farmac\u00e9utico**: Se establece que un producto farmac\u00e9utico puede ser cualquier material destinado al uso humano o veterinario, que est\u00e9 sujeto a la legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador o importador.\n\n3. **Proceso de Producci\u00f3n**: Se describe el proceso completo de producci\u00f3n de un producto farmac\u00e9utico, desde la recepci\u00f3n de materiales hasta la finalizaci\u00f3n del producto, incluyendo etapas como el etiquetado y el envasado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre los materiales de empaque primarios y secundarios en la industria farmac\u00e9utica?**\n   - Esta pregunta busca una aclaraci\u00f3n sobre la clasificaci\u00f3n de los materiales de empaque, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 implica el proceso de calificaci\u00f3n en la producci\u00f3n farmac\u00e9utica y c\u00f3mo se relaciona con la validaci\u00f3n?**\n   - Esta pregunta se centra en el concepto de calificaci\u00f3n y su relaci\u00f3n con la validaci\u00f3n, proporcionando una comprensi\u00f3n m\u00e1s profunda de estos t\u00e9rminos t\u00e9cnicos.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las unidades de calidad en la organizaci\u00f3n de producci\u00f3n farmac\u00e9utica y c\u00f3mo se estructuran?**\n   - Esta pregunta busca informaci\u00f3n sobre la estructura y funciones de las unidades de calidad, que es un aspecto crucial en la garant\u00eda de la calidad en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS en la Serie de Informes T\u00e9cnicos 961 aborda varios conceptos fundamentales relacionados con la producci\u00f3n y control de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Control en Proceso**: Se refiere a las verificaciones realizadas durante la producci\u00f3n para asegurar que el producto cumpla con sus especificaciones, incluyendo el control del entorno y del equipo.\n\n2. **Producto Intermedio**: Es un producto que ha sido parcialmente procesado y que requiere pasos adicionales de fabricaci\u00f3n antes de convertirse en un producto a granel.\n\n3. **Parenterales de Gran Volumen**: Soluciones est\u00e9riles destinadas a la aplicaci\u00f3n parenteral con un volumen de 100 ml o m\u00e1s en un solo contenedor.\n\n4. **Fabricaci\u00f3n**: Engloba todas las operaciones relacionadas con la compra de materiales, producci\u00f3n, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos.\n\n5. **Fabricante**: Una empresa que realiza operaciones como producci\u00f3n, empaquetado, reempaquetado, etiquetado y reetiquetado de productos farmac\u00e9uticos.\n\n6. **Autorizaci\u00f3n de Comercializaci\u00f3n**: Documento legal emitido por la autoridad reguladora que establece la composici\u00f3n, formulaci\u00f3n, especificaciones y detalles de empaquetado y etiquetado del producto.\n\n7. **F\u00f3rmula Maestra**: Documento que especifica los materiales iniciales, sus cantidades, materiales de empaquetado y procedimientos necesarios para producir una cantidad espec\u00edfica de un producto terminado.\n\n8. **Registro Maestro**: Documento que sirve como base para la documentaci\u00f3n de lotes.\n\n9. **Embalaje**: Todas las operaciones, incluyendo el llenado y etiquetado, que un producto a granel debe pasar para convertirse en un producto terminado.\n\n### Conclusi\u00f3n\nEstos t\u00e9rminos y conceptos son esenciales para entender el proceso de fabricaci\u00f3n y control de calidad en la industria farmac\u00e9utica, asegurando que los productos cumplan con los est\u00e1ndares requeridos para su seguridad y eficacia.", "excerpt_keywords": "Keywords: packaging material, pharmaceutical product, production, quality assurance, qualification"}}, "3833504c-700e-4bc5-9bad-a5ab10b8e627": {"node_ids": ["2b2418f3-34a4-4344-8404-a249f12e4f19"], "metadata": {"page_label": "114", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "stage of manufacture. It includes the removal of impurities from waste to obtain a pure substance or the recovery of used materials for a separate use.\n\n**reprocessing**  \nSubjecting all or part of a batch or lot of an in-process medicine, bulk process intermediate (final biological bulk intermediate) or bulk product of a single batch/lot to a previous step in the validated manufacturing process due to failure to meet predetermined specifications. Reprocessing procedures are foreseen as occasionally necessary for biological medicines and, in such cases, are validated and pre-approved as part of the marketing authorization.\n\n**reworking**  \nSubjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre-approved as part of the marketing authorization.\n\n**self-contained area**  \nPremises which provide complete and total separation of all aspects of an operation, including personnel and equipment movement, with well established procedures, controls and monitoring. This includes physical barriers as well as separate air-handling systems, but does not necessarily imply two distinct and separate buildings.\n\n**specification**  \nA list of detailed requirements with which the products or materials used or obtained during manufacture have to conform. They serve as a basis for quality evaluation.\n\n**standard operating procedure (SOP)**  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning; validation; cleaning of premises and environmental control; sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n**starting material**  \nAny substance of a defined quality used in the production of a pharmaceutical product, but excluding packaging materials.\n\n**validation**  \nAction of proving, in accordance with the principles of GMP, that any procedure, process, equipment, material, activity or system actually leads to the expected results (see also qualification).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo definiciones y procedimientos relacionados con la reprocesamiento y reworking de medicamentos, la importancia de \u00e1reas auto contenidas, especificaciones de calidad, procedimientos operativos est\u00e1ndar (SOP), materiales de inicio y el proceso de validaci\u00f3n. Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares de calidad y seguridad establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre reprocessing y reworking en el contexto de la fabricaci\u00f3n de medicamentos?**\n   - Respuesta: El reprocessing implica someter una parte de un lote de un medicamento en proceso a un paso anterior en el proceso de fabricaci\u00f3n validado debido a que no cumple con especificaciones predeterminadas, y est\u00e1 preaprobado como parte de la autorizaci\u00f3n de comercializaci\u00f3n. En cambio, el reworking se refiere a someter un producto final o intermedio a un proceso alternativo debido a un fallo en las especificaciones, y no est\u00e1 preaprobado.\n\n2. **\u00bfQu\u00e9 se entiende por un \u00e1rea auto contenida y por qu\u00e9 es importante en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Un \u00e1rea auto contenida es un espacio que proporciona separaci\u00f3n total de todos los aspectos de una operaci\u00f3n, incluyendo el movimiento de personal y equipos, con procedimientos y controles bien establecidos. Es importante porque ayuda a prevenir la contaminaci\u00f3n cruzada y asegura que se mantengan las condiciones de calidad necesarias durante la fabricaci\u00f3n.\n\n3. **\u00bfQu\u00e9 papel juegan las especificaciones en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las especificaciones son una lista de requisitos detallados que los productos o materiales utilizados en la fabricaci\u00f3n deben cumplir. Sirven como base para la evaluaci\u00f3n de calidad, asegurando que los productos finales sean seguros y efectivos para su uso.", "prev_section_summary": "### Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Materiales de Empaque**:\n   - Definici\u00f3n: Materiales utilizados en el empaque de productos farmac\u00e9uticos, excluyendo el empaque exterior para transporte.\n   - Clasificaci\u00f3n: Primarios (en contacto directo con el producto) y secundarios (sin contacto directo).\n\n2. **Producto Farmac\u00e9utico**:\n   - Definici\u00f3n: Material o producto destinado al uso humano o veterinario, presentado en forma de dosis terminada o como materia prima, sujeto a legislaci\u00f3n farmac\u00e9utica.\n\n3. **Producci\u00f3n**:\n   - Proceso: Incluye todas las operaciones desde la recepci\u00f3n de materiales hasta la finalizaci\u00f3n del producto, abarcando procesamiento, empaque, etiquetado y reetiquetado.\n\n4. **Calificaci\u00f3n**:\n   - Definici\u00f3n: Proceso de demostrar que instalaciones, sistemas y equipos funcionan correctamente y producen los resultados esperados. Relaci\u00f3n con la validaci\u00f3n.\n\n5. **Unidades de Calidad**:\n   - Estructura: Unidad organizativa independiente de producci\u00f3n que cumple funciones de aseguramiento y control de calidad, que puede ser una unidad separada o un grupo \u00fanico.\n\n6. **Otros T\u00e9rminos Clave**:\n   - **Cuarentena**: Estado de materiales aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n   - **Reconciliaci\u00f3n**: Comparaci\u00f3n entre la cantidad te\u00f3rica y la cantidad real.\n   - **Recuperaci\u00f3n**: Introducci\u00f3n de lotes anteriores de calidad requerida en un nuevo lote en una etapa definida.\n\n### Entidades:\n- **Organizaci\u00f3n**: Unidades de calidad (QA y QC).\n- **Legislaci\u00f3n**: Legislaci\u00f3n farmac\u00e9utica del pa\u00eds exportador e importador.\n- **Productos**: Productos farmac\u00e9uticos, materiales de empaque, materias primas.", "excerpt_keywords": "Keywords: reprocessing, reworking, self-contained area, specifications, validation"}}, "6132a061-25a2-46a9-bf20-bc4885c781f0": {"node_ids": ["2c8cd534-3ffc-44c8-9b97-db383f6fc67c"], "metadata": {"page_label": "115", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality management in the medicines industry: philosophy and essential elements\n\nIn the medicines industry at large, quality management is usually defined as the aspect of management function that determines and implements the \u201cquality policy\u201d, i.e. the overall intention and direction of an organization regarding quality, as formally expressed and authorized by top management.\n\nThe basic elements of quality management are:\n\n\u2014 an appropriate infrastructure or \u201cquality system\u201d, encompassing the organizational structure, procedures, processes and resources; and  \n\u2014 systematic actions necessary to ensure adequate confidence that a product (or service) will satisfy given requirements for quality.\n\nThe totality of these actions is termed \u201cquality assurance\u201d (QA). Within an organization, QA serves as a management tool. In contractual situations, QA also serves to generate confidence in the supplier.\n\nThe concepts of QA, GMP, QC and quality risk management (QRM) are interrelated aspects of quality management and should be the responsibility of all personnel. They are described here in order to emphasize their relationship and their fundamental importance to the production and control of pharmaceutical products.\n\n## 1. Quality assurance\n\n### 1.1 Principle\n\nQA is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use. QA, therefore, incorporates GMP and other factors, including those outside the scope of this guide such as product design and development.\n\n### 1.2 The system of QA appropriate to the manufacture of pharmaceutical products should ensure that:\n\n(a) pharmaceutical products are designed and developed in a way that takes account of the requirements of GMP and other associated codes such\n\n----\n\n<sup>6</sup> Good manufacturing practices for pharmaceutical products, Part One. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Definici\u00f3n de gesti\u00f3n de calidad en la industria farmac\u00e9utica**: La gesti\u00f3n de calidad se refiere a la funci\u00f3n de gesti\u00f3n que establece y aplica la pol\u00edtica de calidad de una organizaci\u00f3n, asegurando que los productos farmac\u00e9uticos cumplan con los requisitos de calidad necesarios para su uso previsto.\n\n2. **Elementos b\u00e1sicos de la gesti\u00f3n de calidad**: Incluyen un sistema de calidad adecuado que abarca la estructura organizativa, procedimientos, procesos y recursos, as\u00ed como acciones sistem\u00e1ticas para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n3. **Relaci\u00f3n entre QA, GMP, QC y QRM**: Estos conceptos son aspectos interrelacionados de la gesti\u00f3n de calidad que deben ser responsabilidad de todo el personal involucrado en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de la gesti\u00f3n de calidad para el dise\u00f1o y desarrollo de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en c\u00f3mo la gesti\u00f3n de calidad influye en las etapas iniciales de creaci\u00f3n de un producto, lo que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 papel juega la garant\u00eda de calidad (QA) como herramienta de gesti\u00f3n dentro de una organizaci\u00f3n farmac\u00e9utica?**\n   - Aqu\u00ed se busca entender el uso pr\u00e1ctico de QA como un mecanismo de control y confianza, un aspecto que puede no ser ampliamente discutido en otros contextos.\n\n3. **\u00bfC\u00f3mo se relacionan los conceptos de QA, GMP, QC y QRM en la pr\u00e1ctica diaria de la industria farmac\u00e9utica?**\n   - Esta pregunta explora la interconexi\u00f3n de estos conceptos en la operaci\u00f3n diaria, lo que puede no ser evidente en otros textos que abordan cada uno de estos temas de manera aislada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reprocessing**: Proceso que implica someter un lote de medicamento en proceso a un paso anterior en la fabricaci\u00f3n debido a que no cumple con especificaciones predeterminadas. Este procedimiento es validado y preaprobado como parte de la autorizaci\u00f3n de comercializaci\u00f3n, especialmente en medicamentos biol\u00f3gicos.\n\n2. **Reworking**: Proceso que consiste en someter un producto final o intermedio a un proceso alternativo debido a un fallo en las especificaciones. A diferencia del reprocessing, el reworking es un evento inesperado y no est\u00e1 preaprobado.\n\n3. **\u00c1rea Auto Contenida**: Espacio que proporciona separaci\u00f3n total de todos los aspectos de una operaci\u00f3n, incluyendo el movimiento de personal y equipos, con procedimientos y controles bien establecidos. Es crucial para prevenir la contaminaci\u00f3n cruzada y mantener la calidad.\n\n4. **Especificaciones**: Lista de requisitos detallados que los productos o materiales deben cumplir durante la fabricaci\u00f3n. Son fundamentales para la evaluaci\u00f3n de calidad.\n\n5. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones que no son espec\u00edficas de un producto o material en particular. Incluye aspectos como operaci\u00f3n de equipos, mantenimiento, limpieza y control ambiental.\n\n6. **Material de Inicio**: Sustancia de calidad definida utilizada en la producci\u00f3n de un producto farmac\u00e9utico, excluyendo materiales de embalaje.\n\n7. **Validaci\u00f3n**: Proceso de demostrar que cualquier procedimiento, proceso, equipo, material, actividad o sistema cumple con los resultados esperados, de acuerdo con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Medicamentos Biol\u00f3gicos**\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**\n- **Productos Farmac\u00e9uticos**\n- **Autorizaci\u00f3n de Comercializaci\u00f3n** \n\nEste resumen abarca los conceptos fundamentales y las entidades relevantes en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: quality management, quality assurance, pharmaceutical products, good manufacturing practices, quality risk management"}}, "caaa73ce-3153-4f64-a933-2c91e37e375c": {"node_ids": ["1f19a8f7-2bec-4fc8-a888-386a761cbdfc"], "metadata": {"page_label": "116", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nas those of good laboratory practice (GLP)<sup>7</sup> and good clinical practice (GCP);\n\n(b) production and control operations are clearly specified in a written form and GMP requirements are adopted;\n\n(c) managerial responsibilities are clearly specified in job descriptions;\n\n(d) arrangements are made for the manufacture, supply and use of the correct starting and packaging materials;\n\n(e) all necessary controls on starting materials, intermediate products, and bulk products and other in-process controls, calibrations, and validations are carried out;\n\n(f) the finished product is correctly processed and checked, according to the defined procedures;\n\n(g) pharmaceutical products are not sold or supplied before the authorized persons (see also sections 9.11 & 9.12) have certified that each production batch has been produced and controlled in accordance with the requirements of the marketing authorization and any other regulations relevant to the production, control and release of pharmaceutical products;\n\n(h) satisfactory arrangements exist to ensure, as far as possible, that the pharmaceutical products are stored by the manufacturer, distributed, and subsequently handled so that quality is maintained throughout their shelf-life;\n\n(i) there is a procedure for self-inspection and/or quality audit that regularly appraises the effectiveness and applicability of the QA system;\n\n(j) deviations are reported, investigated and recorded;\n\n(k) there is a system for approving changes that may have an impact on product quality;\n\n(l) regular evaluations of the quality of pharmaceutical products should be conducted with the objective of verifying the consistency of the process and ensuring its continuous improvement; and\n\n(m) there is a system for QRM.\n\n1.3 The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the marketing authorization and do not place patients at risk due to inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment of staff in many different departments and at all levels within the company, the company\u2019s\n\n----\n\n<sup>7</sup> This is a code governing the testing of chemicals to obtain data on their properties and ensuring safety with respect to human health and the environment. It is different from that described in \"Good laboratory practices in governmental drug control laboratories\" in the Thirtieth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 748, 1987, Annex 1).\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Responsabilidad del Fabricante**: El fabricante de productos farmac\u00e9uticos debe asumir la responsabilidad de garantizar que los productos sean aptos para su uso previsto, cumplan con los requisitos de autorizaci\u00f3n de comercializaci\u00f3n y no representen un riesgo para los pacientes debido a deficiencias en seguridad, calidad o eficacia. Esta responsabilidad recae en la alta direcci\u00f3n y requiere la participaci\u00f3n de todo el personal en diferentes departamentos.\n\n2. **Pr\u00e1cticas de Calidad**: Se establecen varios requisitos y procedimientos para asegurar la calidad de los productos farmac\u00e9uticos, incluyendo la especificaci\u00f3n de operaciones de producci\u00f3n y control, la gesti\u00f3n de materiales, la realizaci\u00f3n de controles necesarios, y la implementaci\u00f3n de auditor\u00edas de calidad. Adem\u00e1s, se requiere un sistema para la gesti\u00f3n de riesgos de calidad (QRM).\n\n3. **Evaluaci\u00f3n y Mejora Continua**: Es fundamental realizar evaluaciones regulares de la calidad de los productos farmac\u00e9uticos para verificar la consistencia del proceso y asegurar la mejora continua. Esto incluye la gesti\u00f3n de desviaciones y la aprobaci\u00f3n de cambios que puedan afectar la calidad del producto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar que los productos farmac\u00e9uticos no se vendan o suministren antes de recibir la certificaci\u00f3n de las personas autorizadas?**\n   - Esta pregunta se centra en el proceso de certificaci\u00f3n y control de calidad antes de la comercializaci\u00f3n de los productos.\n\n2. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas que deben estar claramente definidas en las descripciones de trabajo dentro de una empresa farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre la asignaci\u00f3n de responsabilidades en la gesti\u00f3n de calidad y producci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de controles y auditor\u00edas se deben implementar para evaluar la efectividad del sistema de aseguramiento de calidad (QA) en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se enfoca en los mecanismos de evaluaci\u00f3n y auditor\u00eda que aseguran la calidad y la mejora continua en el proceso de producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Tema principal: Gesti\u00f3n de calidad en la industria farmac\u00e9utica**\n- **Definici\u00f3n**: La gesti\u00f3n de calidad se refiere a la funci\u00f3n de gesti\u00f3n que establece y aplica la pol\u00edtica de calidad de una organizaci\u00f3n, asegurando que los productos farmac\u00e9uticos cumplan con los requisitos de calidad necesarios para su uso previsto.\n\n**Elementos b\u00e1sicos de la gesti\u00f3n de calidad**:\n1. **Sistema de calidad**: Infraestructura que incluye la estructura organizativa, procedimientos, procesos y recursos.\n2. **Acciones sistem\u00e1ticas**: Acciones necesarias para garantizar que un producto o servicio satisfaga los requisitos de calidad.\n\n**Conceptos interrelacionados**:\n- **Garant\u00eda de calidad (QA)**: Herramienta de gesti\u00f3n que asegura que los productos farmac\u00e9uticos cumplen con los est\u00e1ndares de calidad requeridos.\n- **Buenas pr\u00e1cticas de manufactura (GMP)**: Normativas que deben seguirse en la producci\u00f3n de productos farmac\u00e9uticos.\n- **Control de calidad (QC)**: Proceso de asegurar que los productos cumplen con los est\u00e1ndares de calidad.\n- **Gesti\u00f3n de riesgos de calidad (QRM)**: Enfoque para identificar y gestionar riesgos que pueden afectar la calidad del producto.\n\n**Responsabilidad**: La gesti\u00f3n de calidad es responsabilidad de todo el personal involucrado en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n**Implicaciones para el dise\u00f1o y desarrollo de productos**: La gesti\u00f3n de calidad influye en las etapas iniciales de creaci\u00f3n de un producto, asegurando que se consideren los requisitos de GMP y otros c\u00f3digos asociados.\n\n**Papel de QA**: Act\u00faa como un mecanismo de control y confianza dentro de la organizaci\u00f3n y en situaciones contractuales.\n\n### Entidades clave:\n- **Organizaci\u00f3n**: Entidad que implementa la pol\u00edtica de calidad.\n- **Productos farmac\u00e9uticos**: Objetos de la gesti\u00f3n de calidad.\n- **Normativas**: GMP, QC, QRM que gu\u00edan la gesti\u00f3n de calidad en la industria.", "excerpt_keywords": "Keywords: calidad farmac\u00e9utica, buenas pr\u00e1cticas de manufactura, gesti\u00f3n de riesgos, auditor\u00eda de calidad, responsabilidad del fabricante"}}, "ebd17cfd-fd16-4463-ba49-164922c6b3b3": {"node_ids": ["4cb3e331-167f-4e0a-90c5-8672d3f672f5"], "metadata": {"page_label": "117", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Product Quality Review\n\nsuppliers, and the distributors. To achieve the quality objective reliably there must be a comprehensively designed and correctly implemented system of QA incorporating GMP and QC. It should be fully documented and its effectiveness monitored. All parts of the QA system should be adequately staffed with competent personnel, and should have suitable and sufficient premises, equipment and facilities.\n\n1.4 QRM is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively.\n\n1.5 QRM should ensure that:\n\n- the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient; and\n- the level of effort, formality and documentation of the QRM process is commensurate with the level of risk.\n\n## Product Quality Review\n\n1.6 Regular, periodic or rolling quality reviews of all medicinal products, including export-only products, should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product to highlight any trends and to identify product and process improvements. Such reviews should normally be conducted and documented annually, taking into account previous reviews, and should include at least:\n\n(i) a review of starting materials and packaging materials used for the product, especially those from new sources;\n\n(ii) a review of critical in-process controls and finished product results;\n\n(iii) a review of all batches that failed to meet established specification(s) and their investigation;\n\n(iv) a review of all significant deviations or non-conformances, the related investigations and the effectiveness of resultant corrective and preventive actions taken;\n\n(v) a review of all changes made to the processes or analytical methods;\n\n(vi) a review of dossier variations submitted, granted or refused;\n\n(vii) a review of the results of the stability monitoring programme and any adverse trends;\n\n(viii) a review of all quality-related returns, complaints and recalls and the investigations performed at the time;\n\n(ix) a review of adequacy of any other previous corrective actions on product process or equipment;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de un sistema de aseguramiento de calidad (QA) en la producci\u00f3n de productos medicinales. Este sistema debe incluir buenas pr\u00e1cticas de manufactura (GMP) y control de calidad (QC), y debe ser dise\u00f1ado e implementado de manera integral. Se introduce el concepto de gesti\u00f3n de riesgos de calidad (QRM), que es un proceso sistem\u00e1tico para evaluar y controlar los riesgos que pueden afectar la calidad del producto. Adem\u00e1s, se enfatiza la necesidad de realizar revisiones peri\u00f3dicas de calidad de los productos medicinales para asegurar la consistencia del proceso y la adecuaci\u00f3n de las especificaciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en un sistema de aseguramiento de calidad (QA) para productos medicinales?**\n   - Respuesta: Un sistema de QA debe incluir un dise\u00f1o integral, implementaci\u00f3n correcta, documentaci\u00f3n completa, monitoreo de efectividad, personal competente, y contar con instalaciones, equipos y recursos adecuados.\n\n2. **\u00bfQu\u00e9 aspectos se deben revisar durante una revisi\u00f3n de calidad peri\u00f3dica de productos medicinales?**\n   - Respuesta: Las revisiones deben incluir la evaluaci\u00f3n de materiales de inicio y empaque, controles cr\u00edticos en proceso, resultados de productos terminados, lotes que no cumplieron especificaciones, desviaciones significativas, cambios en procesos o m\u00e9todos anal\u00edticos, variaciones en dossiers, resultados de programas de monitoreo de estabilidad, quejas y devoluciones relacionadas con la calidad, y la efectividad de acciones correctivas previas.\n\n3. **\u00bfC\u00f3mo se debe abordar la gesti\u00f3n de riesgos de calidad (QRM) en relaci\u00f3n con la protecci\u00f3n del paciente?**\n   - Respuesta: La QRM debe basarse en conocimientos cient\u00edficos y experiencias del proceso, asegurando que la evaluaci\u00f3n del riesgo est\u00e9 vinculada a la protecci\u00f3n del paciente. Adem\u00e1s, el nivel de formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo identificado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Responsabilidad del Fabricante**: \n   - El fabricante de productos farmac\u00e9uticos debe garantizar que los productos sean seguros, eficaces y de calidad, cumpliendo con los requisitos de autorizaci\u00f3n de comercializaci\u00f3n. Esta responsabilidad es asumida por la alta direcci\u00f3n y requiere la colaboraci\u00f3n de todo el personal.\n\n2. **Pr\u00e1cticas de Calidad**: \n   - Se establecen procedimientos claros para la producci\u00f3n y control de productos farmac\u00e9uticos, incluyendo:\n     - Especificaci\u00f3n de operaciones de producci\u00f3n y control.\n     - Gesti\u00f3n adecuada de materiales de inicio y empaque.\n     - Realizaci\u00f3n de controles y auditor\u00edas de calidad.\n     - Implementaci\u00f3n de un sistema de gesti\u00f3n de riesgos de calidad (QRM).\n\n3. **Evaluaci\u00f3n y Mejora Continua**: \n   - Es esencial llevar a cabo evaluaciones regulares de la calidad para asegurar la consistencia del proceso y fomentar la mejora continua. Esto incluye la gesti\u00f3n de desviaciones y la aprobaci\u00f3n de cambios que puedan afectar la calidad del producto.\n\n### Entidades Clave\n\n- **GLP (Good Laboratory Practice)**: Buenas pr\u00e1cticas de laboratorio.\n- **GCP (Good Clinical Practice)**: Buenas pr\u00e1cticas cl\u00ednicas.\n- **GMP (Good Manufacturing Practice)**: Buenas pr\u00e1cticas de manufactura.\n- **QA (Quality Assurance)**: Aseguramiento de la calidad.\n- **QRM (Quality Risk Management)**: Gesti\u00f3n de riesgos de calidad.\n- **Autorizaci\u00f3n de Comercializaci\u00f3n**: Requisitos regulatorios para la venta de productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la responsabilidad del fabricante en la calidad de los productos farmac\u00e9uticos y los procedimientos necesarios para garantizar su seguridad y eficacia.", "excerpt_keywords": "Keywords: Quality Assurance, Quality Risk Management, Good Manufacturing Practice, Product Quality Review, Pharmaceutical Compliance"}}, "50bd8d52-ded6-4de9-b1e7-851cc6c8eea8": {"node_ids": ["f960de94-9ee4-4f3e-b8ba-d1d2b952d849"], "metadata": {"page_label": "118", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(x) for new dossiers and variations to the dossiers, a review of post-marketing commitments;\n\n(xi) the qualification status of relevant equipment and utilities, e.g. heating, ventilation and air-conditioning (HVAC), water, or compressed gases; and\n\n(xii) a review of technical agreements to ensure that they are up to date.\n\nThe manufacturer and marketing authorization holder, where different, should evaluate the results of this review and an assessment should be made whether corrective and preventive action or any revalidation should be undertaken. Reasons for such corrective actions should be documented. Agreed corrective and preventive actions should be completed in a timely and effective manner. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures should be verified during self-inspection.\n\nQuality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, or sterile products, where scientifically justified.\n\nWhere the marketing authorization holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the quality review. The authorized person responsible for final batch certification, together with the marketing authorization holder, should ensure that the quality review is performed in a timely manner and is accurate.\n\n## 2. Good manufacturing practices for pharmaceutical products\n\n2.1 GMP is that part of QA which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization. GMP are aimed primarily at diminishing the risks inherent in any pharmaceutical production.\n\nSuch risks are essentially of two types: cross-contamination (in particular of unexpected contaminants) and mix ups (confusion) caused by, for example, false labels being put on containers. Under GMP:\n\n(a) all manufacturing processes are clearly defined, systematically reviewed in the light of experience, and shown to be capable of consistently manufacturing pharmaceutical products of the required quality that comply with their specifications;\n\n(b) qualification and validation are performed;\n\n(c) all necessary resources are provided, including:\n   (i) appropriately qualified and trained personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla los procedimientos y pr\u00e1cticas de calidad que deben seguirse en la revisi\u00f3n de productos farmac\u00e9uticos, incluyendo la evaluaci\u00f3n de compromisos post-comercializaci\u00f3n, la calificaci\u00f3n de equipos y utilidades, y la revisi\u00f3n de acuerdos t\u00e9cnicos. Se enfatiza la importancia de las Buenas Pr\u00e1cticas de Manufactura (GMP) para garantizar que los productos se produzcan de manera consistente y cumplan con los est\u00e1ndares de calidad requeridos. Tambi\u00e9n se menciona la necesidad de documentaci\u00f3n y gesti\u00f3n de acciones correctivas y preventivas, as\u00ed como la importancia de la capacitaci\u00f3n del personal.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para asegurar que las acciones correctivas y preventivas se implementen de manera efectiva en la revisi\u00f3n de calidad de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en el proceso de gesti\u00f3n de acciones correctivas y preventivas, que incluye la documentaci\u00f3n de razones, la finalizaci\u00f3n oportuna de las acciones acordadas y la verificaci\u00f3n de la efectividad durante la autoinspecci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los tipos de riesgos que las Buenas Pr\u00e1cticas de Manufactura (GMP) buscan minimizar en la producci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta aborda los riesgos espec\u00edficos mencionados en el documento, como la contaminaci\u00f3n cruzada y los errores de etiquetado, y c\u00f3mo las GMP est\u00e1n dise\u00f1adas para mitigarlos.\n\n3. **\u00bfQu\u00e9 requisitos deben cumplirse en un acuerdo t\u00e9cnico entre el titular de la autorizaci\u00f3n de comercializaci\u00f3n y el fabricante cuando son entidades diferentes?**\n   - Esta pregunta se enfoca en la necesidad de un acuerdo t\u00e9cnico que defina las responsabilidades de cada parte en la producci\u00f3n de la revisi\u00f3n de calidad, asegurando que se realice de manera precisa y oportuna.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Aseguramiento de Calidad (QA):** \n   - Importancia de un sistema de QA bien dise\u00f1ado e implementado que incluya Buenas Pr\u00e1cticas de Manufactura (GMP) y Control de Calidad (QC).\n   - Necesidad de documentaci\u00f3n completa y monitoreo de la efectividad del sistema.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM):**\n   - Proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar riesgos que afectan la calidad del producto medicinal.\n   - Evaluaci\u00f3n basada en conocimientos cient\u00edficos y experiencia, vinculada a la protecci\u00f3n del paciente.\n   - Proporcionalidad entre el nivel de riesgo y el esfuerzo/documentaci\u00f3n del proceso de QRM.\n\n3. **Revisiones de Calidad de Productos Medicinales:**\n   - Realizaci\u00f3n de revisiones peri\u00f3dicas para verificar la consistencia del proceso y la adecuaci\u00f3n de especificaciones.\n   - Elementos a revisar incluyen materiales de inicio, controles en proceso, resultados de productos terminados, lotes no conformes, desviaciones significativas, cambios en procesos, variaciones de dossiers, resultados de programas de estabilidad, quejas y devoluciones, y efectividad de acciones correctivas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre la calidad de productos medicinales.\n- **Medicamentos:** Productos cuya calidad debe ser asegurada a trav\u00e9s de un sistema de QA y revisiones peri\u00f3dicas.\n- **Proveedores y Distribuidores:** Entidades involucradas en la cadena de suministro de productos medicinales.\n- **Personal Competente:** Recurso humano necesario para implementar y mantener el sistema de QA.\n- **Materiales de Inicio y Empaque:** Componentes cr\u00edticos que deben ser revisados en el proceso de aseguramiento de calidad.\n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para garantizar la calidad de los productos medicinales, as\u00ed como la necesidad de una gesti\u00f3n de riesgos adecuada para proteger la salud del paciente.", "excerpt_keywords": "Keywords: quality assurance, good manufacturing practices, pharmaceutical production, corrective actions, technical agreements"}}, "d8706bb8-96e5-4e4f-9c46-6e8a67a86b2b": {"node_ids": ["b6278983-f599-49b1-b2b0-ccc27a83e987"], "metadata": {"page_label": "119", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n(ii)   adequate premises and space;\n(iii)  suitable equipment and services;\n(iv)   appropriate materials, containers and labels;\n(v)    approved procedures and instructions;\n(vi)   suitable storage and transport;\n(vii)  adequate personnel, laboratories and equipment for in-process\n       controls;\n(d)    instructions and procedures are written in clear and unambiguous\n       language, specifically applicable to the facilities provided;\n(e)    operators are trained to carry out procedures correctly;\n(f)    records are made (manually and/or by recording instruments) during\n       manufacture to show that all the steps required by the defined procedures\n       and instructions have in fact been taken and that the quantity and\n       quality of the product are as expected; any significant deviations are\n       fully recorded and investigated;\n(g)    records covering manufacture and distribution, which enable the\n       complete history of a batch to be traced, are retained in a comprehensible\n       and accessible form;\n(h)    the proper storage and distribution of the products minimizes any risk\n       to their quality;\n(i)    a system is available to recall any batch of product from sale or supply;\n(j)    complaints about marketed products are examined, the causes of\n       quality defects investigated, and appropriate measures taken in respect\n       of the defective products to prevent recurrence.\n\n3. **Sanitation and hygiene**\n\n3.1  A high level of sanitation and hygiene should be practised in every\n     aspect of the manufacture of medicines products. The scope of sanitation and\n     hygiene covers personnel, premises, equipment and apparatus, production\n     materials and containers, products for cleaning and disinfection, and anything\n     that could become a source of contamination to the product. Potential sources\n     of contamination should be eliminated through an integrated comprehensive\n     programme of sanitation and hygiene. (For *Personal hygiene* see section 11,\n     and for *sanitation* see section 12, \u201cPremises\u201d.)\n\n4. **Qualification and validation**\n\n4.1  In accordance with GMP, each pharmaceutical company should\n     identify what qualification and validation work is required to prove that the\n     critical aspects of their particular operation are controlled.\n\n4.2  The key elements of a qualification and validation programme of a\n     company should be clearly defined and documented in a validation master plan.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la Serie de Informes T\u00e9cnicos 961 aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener instalaciones adecuadas, equipos apropiados, procedimientos claros, y un alto nivel de sanidad e higiene en todas las etapas de la fabricaci\u00f3n. Adem\u00e1s, se menciona la necesidad de un sistema de calificaci\u00f3n y validaci\u00f3n para asegurar que los procesos cr\u00edticos est\u00e9n controlados y documentados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben estar documentados en un plan maestro de validaci\u00f3n seg\u00fan las Buenas Pr\u00e1cticas de Manufactura (GMP)?**\n   - Respuesta: Los elementos clave de un programa de calificaci\u00f3n y validaci\u00f3n deben estar claramente definidos y documentados en un plan maestro de validaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en caso de que se identifiquen desviaciones significativas durante el proceso de fabricaci\u00f3n?**\n   - Respuesta: Cualquier desviaci\u00f3n significativa debe ser completamente registrada e investigada para determinar su causa y tomar las medidas apropiadas para prevenir su recurrencia.\n\n3. **\u00bfQu\u00e9 aspectos de la sanidad y la higiene se deben considerar en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Se debe practicar un alto nivel de sanidad y higiene en todos los aspectos de la fabricaci\u00f3n, incluyendo el personal, las instalaciones, el equipo, los materiales de producci\u00f3n, los productos de limpieza y desinfecci\u00f3n, y cualquier cosa que pueda convertirse en una fuente de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Revisi\u00f3n de Calidad de Productos Farmac\u00e9uticos**:\n   - Importancia de realizar revisiones de calidad que incluyan compromisos post-comercializaci\u00f3n, estado de calificaci\u00f3n de equipos y utilidades, y revisi\u00f3n de acuerdos t\u00e9cnicos.\n   - Evaluaci\u00f3n de resultados y necesidad de acciones correctivas y preventivas documentadas.\n\n2. **Acciones Correctivas y Preventivas**:\n   - Procedimientos de gesti\u00f3n para asegurar que las acciones acordadas se implementen de manera oportuna y efectiva.\n   - Verificaci\u00f3n de la efectividad de estas acciones durante autoinspecciones.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Definici\u00f3n de GMP como parte del aseguramiento de calidad (QA) que garantiza la producci\u00f3n consistente de productos farmac\u00e9uticos de acuerdo con est\u00e1ndares de calidad.\n   - Enfoque en la reducci\u00f3n de riesgos como la contaminaci\u00f3n cruzada y confusiones por etiquetado incorrecto.\n\n4. **Requisitos de Acuerdos T\u00e9cnicos**:\n   - Necesidad de un acuerdo t\u00e9cnico entre el titular de la autorizaci\u00f3n de comercializaci\u00f3n y el fabricante cuando son entidades diferentes, definiendo responsabilidades en la producci\u00f3n de la revisi\u00f3n de calidad.\n\n5. **Recursos Necesarios**:\n   - Importancia de contar con personal calificado y capacitado para llevar a cabo los procesos de manufactura y asegurar la calidad del producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre pr\u00e1cticas de calidad en la producci\u00f3n farmac\u00e9utica.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad responsable de la revisi\u00f3n de calidad y cumplimiento de est\u00e1ndares.\n- **Fabricante**: Entidad que produce los productos farmac\u00e9uticos y debe cumplir con las GMP.\n- **Personal Calificado**: Recursos humanos necesarios para garantizar la calidad en la producci\u00f3n. \n\nEste resumen destaca los aspectos fundamentales relacionados con la calidad y la producci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las entidades involucradas en estos procesos.", "excerpt_keywords": "Keywords: Buenas Pr\u00e1cticas de Manufactura, sanidad, higiene, calificaci\u00f3n, validaci\u00f3n"}}, "3da5286d-4d06-4b84-bbfd-fac1da6895bf": {"node_ids": ["ed623c95-7706-443e-958d-168637c15095"], "metadata": {"page_label": "120", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3 Qualification and validation should establish and provide documentary evidence that:\n\n(a) the premises, supporting utilities, equipment and processes have been designed in accordance with the requirements for GMP (design qualification or DQ);\n\n(b) the premises, supporting utilities and equipment have been built and installed in compliance with their design specifications (installation qualification or IQ);\n\n(c) the premises, supporting utilities and equipment operate in accordance with their design specifications (operational qualification or OQ);\n\n(d) a specific process will consistently produce a product meeting its predetermined specifications and quality attributes (process validation or PV, also called performance qualification or PQ).\n\n4.4 Any aspect of operation, including significant changes to the premises, facilities, equipment or processes, which may affect the quality of the product, directly or indirectly, should be qualified and validated.\n\n4.5 Qualification and validation should not be considered as one-off exercises. An ongoing programme should follow their first implementation and should be based on an annual review.\n\n4.6 The commitment to maintain continued validation status should be stated in the relevant company documentation, such as the quality manual or validation master plan.\n\n4.7 The responsibility of performing validation should be clearly defined.\n\n4.8 Validation studies are an essential part of GMP and should be conducted in accordance with predefined and approved protocols.\n\n4.9 A written report summarizing the results recorded and the conclusions reached should be prepared and stored.\n\n4.10 Processes and procedures should be established on the basis of the results of the validation performed.\n\n4.11 Particular attention should be paid to the validation of analytical test methods, automated systems and cleaning procedures.\n\n# 5. Complaints\n\n## 5.1 Principle\n\nAll complaints and other information concerning potentially defective products should be carefully reviewed according to written procedures and the corrective action should be taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP). Se detallan los diferentes tipos de calificaci\u00f3n (DQ, IQ, OQ, PV/PQ) y se enfatiza que la calificaci\u00f3n y validaci\u00f3n no son ejercicios \u00fanicos, sino que deben ser parte de un programa continuo. Adem\u00e1s, se menciona la necesidad de revisar y actuar sobre las quejas relacionadas con productos potencialmente defectuosos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los cuatro tipos de calificaci\u00f3n mencionados en el documento y qu\u00e9 aspectos espec\u00edficos eval\u00faan?**\n   - Respuesta: Los cuatro tipos de calificaci\u00f3n son: \n     - **Design Qualification (DQ)**: Eval\u00faa si las instalaciones, utilidades, equipos y procesos est\u00e1n dise\u00f1ados de acuerdo con los requisitos de GMP.\n     - **Installation Qualification (IQ)**: Verifica que las instalaciones, utilidades y equipos se hayan construido e instalado conforme a las especificaciones de dise\u00f1o.\n     - **Operational Qualification (OQ)**: Asegura que las instalaciones, utilidades y equipos operen de acuerdo con sus especificaciones de dise\u00f1o.\n     - **Process Validation (PV) o Performance Qualification (PQ)**: Confirma que un proceso espec\u00edfico producir\u00e1 consistentemente un producto que cumpla con las especificaciones y atributos de calidad predeterminados.\n\n2. **\u00bfPor qu\u00e9 es importante que la calificaci\u00f3n y validaci\u00f3n se consideren como un programa continuo y no como ejercicios \u00fanicos?**\n   - Respuesta: Es importante porque cualquier aspecto de la operaci\u00f3n, incluidos cambios significativos en las instalaciones, equipos o procesos, puede afectar la calidad del producto. Un programa continuo permite realizar revisiones anuales y mantener la validez de los procesos, asegurando que se cumplan los est\u00e1ndares de calidad de manera constante.\n\n3. **\u00bfQu\u00e9 se debe hacer con las quejas relacionadas con productos potencialmente defectuosos seg\u00fan el documento?**\n   - Respuesta: Todas las quejas y la informaci\u00f3n relacionada con productos potencialmente defectuosos deben ser revisadas cuidadosamente de acuerdo con procedimientos escritos, y se deben tomar acciones correctivas basadas en esa revisi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Se enfatiza la importancia de mantener est\u00e1ndares adecuados en la producci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Elementos esenciales para la manufactura**:\n   - **Instalaciones y espacio adecuados**: Se requiere un entorno f\u00edsico que cumpla con los est\u00e1ndares necesarios.\n   - **Equipos y servicios apropiados**: Deben estar disponibles para asegurar la calidad del proceso.\n   - **Materiales, contenedores y etiquetas**: Deben ser adecuados y aprobados para su uso.\n   - **Procedimientos e instrucciones aprobadas**: Deben estar documentados y ser claros.\n   - **Almacenamiento y transporte adecuados**: Para minimizar riesgos a la calidad del producto.\n   - **Personal capacitado**: Los operadores deben estar entrenados para seguir los procedimientos correctamente.\n\n3. **Documentaci\u00f3n y registros**:\n   - Se deben mantener registros durante la fabricaci\u00f3n para demostrar que se han seguido todos los pasos requeridos.\n   - Los registros deben permitir rastrear la historia completa de un lote y ser accesibles.\n\n4. **Sistema de gesti\u00f3n de quejas**:\n   - Las quejas sobre productos comercializados deben ser investigadas y se deben tomar medidas para prevenir recurrencias.\n\n5. **Sanidad e higiene**:\n   - Se debe mantener un alto nivel de sanidad e higiene en todos los aspectos de la fabricaci\u00f3n, abarcando personal, instalaciones, equipos, materiales de producci\u00f3n y limpieza.\n\n6. **Calificaci\u00f3n y validaci\u00f3n**:\n   - Cada empresa farmac\u00e9utica debe identificar y documentar el trabajo de calificaci\u00f3n y validaci\u00f3n necesario para controlar los aspectos cr\u00edticos de sus operaciones.\n   - Los elementos clave de este programa deben estar claramente definidos en un plan maestro de validaci\u00f3n.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos farmac\u00e9uticos**: El foco del documento.\n- **Personal**: Operadores y personal involucrado en la manufactura.\n- **Equipos y materiales**: Elementos necesarios para la producci\u00f3n.\n- **Registros**: Documentaci\u00f3n necesaria para asegurar la trazabilidad y el cumplimiento de los procedimientos.", "excerpt_keywords": "Keywords: calificaci\u00f3n, validaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura, quejas, documentaci\u00f3n"}}, "8261ec14-fd23-41a9-9d24-b5920d1f94f5": {"node_ids": ["f8bad3e5-3294-4daa-a4f8-5518307f7cc3"], "metadata": {"page_label": "121", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.2\n\nA person responsible for handling the complaints and deciding the measures to be taken should be designated, together with sufficient supporting staff to assist him or her. If this person is different from the authorized person, the latter should be made aware of any complaint, investigation or recall.\n\n## 5.3\n\nThere should be written procedures describing the action to be taken, including the need to consider a recall, in the case of a complaint concerning a possible product defect.\n\n## 5.4\n\nSpecial attention should be given to establishing whether a complaint was caused because of a suspect product.\n\n## 5.5\n\nAny complaint concerning a product defect should be recorded with all the original details and thoroughly investigated. The person responsible for QC should normally be involved in the review of such investigations.\n\n## 5.6\n\nIf a product defect is discovered or suspected in a batch, consideration should be given to whether other batches should be checked in order to determine whether they are also affected. In particular, other batches that may contain reprocessed product from the defective batch should be investigated.\n\n## 5.7\n\nWhere necessary, appropriate follow-up action, possibly including product recall, should be taken after investigation and evaluation of the complaint.\n\n## 5.8\n\nAll decisions made and measures taken as a result of a complaint should be recorded and referenced to the corresponding batch records.\n\n## 5.9\n\nComplaints records should be regularly reviewed for any indication of specific or recurring problems that require attention and might justify the recall of marketed products.\n\n## 5.10\n\nThe competent authorities should be informed if a manufacturer is considering action following possibly faulty manufacture, product deterioration, a suspect product or any other serious quality problems with a product.\n\n## 6. Product recalls\n\n### 6.1 Principle\n\nThere should be a system to recall from the market, promptly and effectively, products known or suspected to be defective.\n\n### 6.2\n\nThe authorized person should be responsible for the execution and coordination of recalls. He/she should have sufficient staff to handle all aspects of the recalls with the appropriate degree of urgency.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos y responsabilidades relacionados con la gesti\u00f3n de quejas y la retirada de productos del mercado en caso de defectos. Se establece la necesidad de designar a una persona responsable de manejar quejas, investigar defectos y coordinar retiradas de productos. Se enfatiza la importancia de tener procedimientos escritos, registrar quejas y decisiones, y mantener informadas a las autoridades competentes sobre problemas de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para investigar una queja sobre un posible defecto de producto y qui\u00e9n debe estar involucrado en este proceso?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que deben seguirse y en la participaci\u00f3n del personal de control de calidad (QC) en la investigaci\u00f3n de quejas.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al decidir si se debe realizar un retiro de producto tras recibir una queja?**\n   - Esta pregunta busca detalles sobre los factores que influyen en la decisi\u00f3n de llevar a cabo un retiro de producto, incluyendo la evaluaci\u00f3n de la queja y la posible afectaci\u00f3n de otros lotes.\n\n3. **\u00bfC\u00f3mo se deben documentar y revisar las quejas para identificar problemas recurrentes que puedan justificar un retiro de productos comercializados?**\n   - Esta pregunta se enfoca en la importancia de la documentaci\u00f3n y el an\u00e1lisis de las quejas para detectar patrones que requieran atenci\u00f3n y posibles acciones correctivas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se encuentra f\u00e1cilmente en otros documentos o contextos, bas\u00e1ndose en los procedimientos y responsabilidades descritos en el texto.", "prev_section_summary": "### Temas Clave:\n\n1. **Calificaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de establecer y proporcionar evidencia documental de que las instalaciones, utilidades, equipos y procesos cumplen con los requisitos de las Buenas Pr\u00e1cticas de Manufactura (GMP) a trav\u00e9s de diferentes tipos de calificaci\u00f3n:\n   - **Design Qualification (DQ)**: Dise\u00f1o conforme a GMP.\n   - **Installation Qualification (IQ)**: Construcci\u00f3n e instalaci\u00f3n seg\u00fan especificaciones.\n   - **Operational Qualification (OQ)**: Operaci\u00f3n conforme a especificaciones.\n   - **Process Validation (PV) o Performance Qualification (PQ)**: Producci\u00f3n consistente de productos que cumplen con especificaciones.\n\n2. **Programa Continuo**: La calificaci\u00f3n y validaci\u00f3n deben ser parte de un programa continuo, no ejercicios \u00fanicos, con revisiones anuales para asegurar la calidad del producto.\n\n3. **Documentaci\u00f3n y Responsabilidad**: Se requiere que la documentaci\u00f3n relevante, como el manual de calidad o el plan maestro de validaci\u00f3n, indique el compromiso de mantener el estado de validaci\u00f3n. Adem\u00e1s, la responsabilidad de realizar la validaci\u00f3n debe estar claramente definida.\n\n4. **Estudios de Validaci\u00f3n**: Deben realizarse de acuerdo con protocolos predefinidos y aprobados, y se debe preparar un informe escrito que resuma los resultados y conclusiones.\n\n5. **Quejas de Productos**: Todas las quejas sobre productos potencialmente defectuosos deben ser revisadas cuidadosamente y se deben tomar acciones correctivas seg\u00fan procedimientos escritos.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativa que gu\u00eda la calificaci\u00f3n y validaci\u00f3n.\n- **Tipos de Calificaci\u00f3n**: DQ, IQ, OQ, PV/PQ.\n- **Documentaci\u00f3n**: Manual de calidad, plan maestro de validaci\u00f3n.\n- **Quejas**: Informaci\u00f3n sobre productos defectuosos que requiere revisi\u00f3n y acci\u00f3n correctiva. \n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en la manufactura de productos, as\u00ed como la necesidad de un enfoque sistem\u00e1tico y continuo para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: complaints management, product recall, quality control, defect investigation, regulatory compliance"}}, "ea434e57-1b3a-42fc-93db-d91f93cad7e9": {"node_ids": ["1ca778f3-c1d6-4d68-b989-f5a1df68de59"], "metadata": {"page_label": "122", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.3 \nThere should be established written procedures, which are regularly reviewed and updated, for the organization of any recall activity. Recall operations should be capable of being initiated promptly down to the required level in the distribution chain.\n\n6.4 \nAn instruction should be included in the written procedures to store recalled products in a secure segregated area while their fate is decided.\n\n6.5 \nAll competent authorities of all countries to which a given product has been distributed should be promptly informed of any intention to recall the product because it is, or is suspected of being, defective.\n\n6.6 \nThe distribution records should be readily available to the authorized person, and they should contain sufficient information on wholesalers and directly supplied customers (including, for exported products, those who have received samples for clinical tests and medical samples) to permit an effective recall.\n\n6.7 \nThe progress of the recall process should be monitored and recorded. Records should include the disposition of the product. A final report should be issued, including a reconciliation between the delivered and recovered quantities of the products.\n\n6.8 \nThe effectiveness of the arrangements for recalls should be tested and evaluated from time to time.\n\n# 7. Contract production and analysis\n\n7.1 Principle. \nContract production and analysis must be correctly defined, agreed and controlled in order to avoid misunderstandings that could result in a product or work or analysis of unsatisfactory quality.\n\n## General\n\n7.2 \nAll arrangements for contract production and analysis, including any proposed changes in technical or other arrangements, should be in accordance with the marketing authorization for the product concerned.\n\n7.3 \nThe contract should permit the contract giver to audit the facilities of the contract acceptor.\n\n7.4 \nIn the case of contract analysis, the final approval for release must be given by the authorized person.\n\n## The contract giver\n\n7.5 \nThe contract giver is responsible for assessing the competence of the contract acceptor in successfully carrying out the work or tests required, for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl contexto se centra en las directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la gesti\u00f3n de retiros de productos y la producci\u00f3n y an\u00e1lisis por contrato. Se enfatiza la importancia de tener procedimientos escritos para las actividades de retiro, la comunicaci\u00f3n con las autoridades competentes, el mantenimiento de registros de distribuci\u00f3n, y la evaluaci\u00f3n de la efectividad de los procesos de retiro. Adem\u00e1s, se aborda la necesidad de definir y controlar adecuadamente los acuerdos de producci\u00f3n y an\u00e1lisis por contrato, asegurando que se cumplan los requisitos de autorizaci\u00f3n de comercializaci\u00f3n y que el contratante tenga la capacidad de auditar al contratista.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben establecerse para garantizar que las operaciones de retiro de productos se inicien de manera oportuna en la cadena de distribuci\u00f3n?**\n   - Respuesta: Se deben establecer procedimientos escritos que sean revisados y actualizados regularmente, permitiendo que las operaciones de retiro se inicien de manera r\u00e1pida y efectiva en todos los niveles de la cadena de distribuci\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener los registros de distribuci\u00f3n para facilitar un retiro efectivo de productos?**\n   - Respuesta: Los registros de distribuci\u00f3n deben contener informaci\u00f3n suficiente sobre los mayoristas y los clientes directamente suministrados, incluyendo aquellos que han recibido muestras para pruebas cl\u00ednicas y muestras m\u00e9dicas, para permitir un retiro efectivo.\n\n3. **\u00bfCu\u00e1l es la responsabilidad del contratante en relaci\u00f3n con la competencia del contratista en el contexto de la producci\u00f3n y an\u00e1lisis por contrato?**\n   - Respuesta: El contratante es responsable de evaluar la competencia del contratista para llevar a cabo con \u00e9xito el trabajo o las pruebas requeridas, asegurando que se cumplan los est\u00e1ndares de calidad necesarios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Responsabilidad en la Gesti\u00f3n de Quejas:**\n   - Designaci\u00f3n de una persona responsable para manejar quejas y tomar decisiones sobre medidas a seguir.\n   - Importancia de contar con personal de apoyo adecuado.\n\n2. **Procedimientos Escritos:**\n   - Necesidad de tener procedimientos documentados para abordar quejas y considerar retiradas de productos en caso de defectos.\n\n3. **Investigaci\u00f3n de Quejas:**\n   - Registro detallado de quejas sobre defectos de productos y la implicaci\u00f3n del personal de control de calidad (QC) en las investigaciones.\n\n4. **Evaluaci\u00f3n de Lotes:**\n   - Consideraci\u00f3n de la revisi\u00f3n de otros lotes si se descubre o sospecha un defecto en un lote espec\u00edfico.\n\n5. **Acciones de Seguimiento:**\n   - Implementaci\u00f3n de acciones adecuadas, incluyendo retiradas de productos, tras la evaluaci\u00f3n de quejas.\n\n6. **Documentaci\u00f3n y Revisi\u00f3n:**\n   - Registro de decisiones y medidas tomadas en respuesta a quejas, as\u00ed como revisi\u00f3n regular de registros de quejas para identificar problemas recurrentes.\n\n7. **Comunicaci\u00f3n con Autoridades:**\n   - Obligaci\u00f3n de informar a las autoridades competentes sobre acciones relacionadas con fabricaci\u00f3n defectuosa o problemas graves de calidad.\n\n8. **Sistema de Retiro de Productos:**\n   - Establecimiento de un sistema efectivo para retirar del mercado productos defectuosos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre la gesti\u00f3n de quejas y retiradas de productos.\n- **Persona Responsable:** Individuo designado para manejar quejas y coordinar acciones.\n- **Personal de Control de Calidad (QC):** Equipo involucrado en la investigaci\u00f3n de quejas sobre defectos de productos.\n- **Autoridades Competentes:** Entidades reguladoras que deben ser informadas sobre problemas de calidad y acciones a tomar.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de quejas y retiradas de productos, as\u00ed como la necesidad de procedimientos claros y comunicaci\u00f3n efectiva con las autoridades.", "excerpt_keywords": "Keywords: recall procedures, contract production, quality assurance, distribution records, regulatory compliance"}}, "c9790b68-a89f-4505-af93-725cd407b856": {"node_ids": ["3f276451-e722-4213-b843-2b740cffc9de"], "metadata": {"page_label": "123", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# The Contract\n\n7.6 The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations correctly in accordance with the marketing authorization and any other legal requirements. The contract giver should ensure that the contract acceptor is fully aware of any problems associated with the product, work or tests that might pose a hazard to premises, equipment, personnel, other materials or other products.\n\n7.7 The contract giver should ensure that all processed products and materials delivered by the contract acceptor comply with their specifications or that the product has been released by the authorized person.\n\n## The Contract Acceptor\n\n7.8 The contract acceptor must have adequate premises, equipment, knowledge, and experience and competent personnel to carry out satisfactorily the work ordered by the contract giver. Contract manufacture may be undertaken only by a manufacturer who holds a manufacturing authorization.\n\n7.9 The contract acceptor should not pass to a third party any of the work entrusted to him or her under the contract without the contract giver\u2019s prior evaluation and approval of the arrangements. Arrangements made between the contract acceptor and any third party should ensure that the manufacturing and analytical information is made available in the same way as between the original contract giver and contract acceptor.\n\n7.10 The contract acceptor should refrain from any activity that may adversely affect the quality of the product manufactured and/or analysed for the contract giver.\n\n## The Contract\n\n7.11 There must be a written contract between the contract giver and the contract acceptor which clearly establishes the responsibilities of each party.\n\n7.12 The contract must clearly state the way in which the authorized person, in releasing each batch of product for sale or issuing the certificate of analysis, exercises his or her full responsibility and ensures that each batch has been manufactured in, and checked for, compliance with the requirements of the marketing authorization.\n\n7.13 Technical aspects of the contract should be drawn up by competent persons suitably knowledgeable in pharmaceutical technology, analysis and GMP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento se centra en las responsabilidades y requisitos de las partes involucradas en un contrato de fabricaci\u00f3n en el \u00e1mbito farmac\u00e9utico. Se detalla la obligaci\u00f3n del \"contract giver\" (quien otorga el contrato) de proporcionar informaci\u00f3n necesaria y asegurar que el \"contract acceptor\" (quien acepta el contrato) cumpla con las especificaciones y normativas. Tambi\u00e9n se enfatiza la necesidad de que el \"contract acceptor\" tenga las instalaciones, el equipo y el personal competente para llevar a cabo el trabajo. Adem\u00e1s, se establece que debe existir un contrato escrito que defina claramente las responsabilidades de ambas partes y que los aspectos t\u00e9cnicos del contrato deben ser elaborados por personas competentes en tecnolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe proporcionar el contract giver al contract acceptor para asegurar el cumplimiento de las operaciones contratadas?**\n   - El contract giver debe proporcionar toda la informaci\u00f3n necesaria para llevar a cabo las operaciones de acuerdo con la autorizaci\u00f3n de comercializaci\u00f3n y otros requisitos legales, as\u00ed como informar sobre cualquier problema que pueda representar un riesgo.\n\n2. **\u00bfCu\u00e1les son las condiciones que debe cumplir el contract acceptor para llevar a cabo el trabajo solicitado?**\n   - El contract acceptor debe contar con instalaciones adecuadas, equipo, conocimiento, experiencia y personal competente para realizar satisfactoriamente el trabajo ordenado por el contract giver.\n\n3. **\u00bfQu\u00e9 debe incluir el contrato escrito entre el contract giver y el contract acceptor?**\n   - El contrato debe establecer claramente las responsabilidades de cada parte y detallar c\u00f3mo el personal autorizado ejerce su responsabilidad al liberar cada lote de producto para la venta o emitir el certificado de an\u00e1lisis, asegurando que cada lote cumple con los requisitos de la autorizaci\u00f3n de comercializaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos de Retiro de Productos**:\n   - Importancia de establecer procedimientos escritos para la organizaci\u00f3n de actividades de retiro.\n   - Necesidad de iniciar operaciones de retiro de manera r\u00e1pida en la cadena de distribuci\u00f3n.\n   - Almacenamiento seguro de productos retirados mientras se decide su destino.\n\n2. **Comunicaci\u00f3n con Autoridades Competentes**:\n   - Obligatoriedad de informar a las autoridades de todos los pa\u00edses donde se distribuy\u00f3 el producto sobre cualquier intenci\u00f3n de retiro debido a defectos.\n\n3. **Registros de Distribuci\u00f3n**:\n   - Los registros deben ser accesibles y contener informaci\u00f3n suficiente sobre mayoristas y clientes para facilitar un retiro efectivo.\n\n4. **Monitoreo y Evaluaci\u00f3n del Proceso de Retiro**:\n   - Registro del progreso del proceso de retiro y disposici\u00f3n del producto.\n   - Emisi\u00f3n de un informe final que incluya la reconciliaci\u00f3n de cantidades entregadas y recuperadas.\n   - Evaluaci\u00f3n peri\u00f3dica de la efectividad de los procedimientos de retiro.\n\n5. **Producci\u00f3n y An\u00e1lisis por Contrato**:\n   - Definici\u00f3n y control adecuados de los acuerdos de producci\u00f3n y an\u00e1lisis para evitar malentendidos.\n   - Cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n en todos los arreglos.\n   - Derecho del contratante a auditar las instalaciones del contratista.\n   - Aprobaci\u00f3n final de an\u00e1lisis por parte de una persona autorizada.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que proporciona las directrices.\n- **Autoridades Competentes**: Organismos responsables en cada pa\u00eds que deben ser informados sobre retiros.\n- **Contratante y Contratista**: Partes involucradas en la producci\u00f3n y an\u00e1lisis por contrato, donde el contratante eval\u00faa la competencia del contratista. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de retiros de productos y la producci\u00f3n por contrato, asegurando la calidad y la seguridad en el proceso.", "excerpt_keywords": "Keywords: contract giver, contract acceptor, pharmaceutical manufacturing, marketing authorization, good manufacturing practices"}}, "b86d61f6-6b7d-4796-93f0-2ce2de15733e": {"node_ids": ["8c1a6659-7e9a-4c51-9328-9be86746bbd6"], "metadata": {"page_label": "124", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.14 \nAll arrangements for production and analysis must be in accordance with the marketing authorization and agreed by both parties.\n\n7.15 \nThe contract should describe clearly who is responsible for purchasing, testing and releasing materials and for undertaking production and QC, including in-process controls, and who has responsibility for sampling and analysis. In the case of contract analysis, the contract should state whether or not the contract acceptor should take samples at the premises of the manufacturer.\n\n7.16 \nManufacturing, analytical, distribution records and reference samples should be kept by, or be available to, the contract giver. Any records relevant to assessing the quality of a product in the event of complaints or a suspected defect must be accessible and specified in the defect/recall procedures of the contract giver.\n\n7.17 \nThe contract should describe the handling of starting materials, intermediate and bulk products and finished products if they are rejected. It should also describe the procedure to be followed if the contract analysis shows that the tested product must be rejected.\n\n# 8. Self-inspection, quality audits and supplier\u2019s audits and approval\n\n8.1 **Principle.** \nThe purpose of self-inspection is to evaluate the manufacturer\u2019s compliance with GMP in all aspects of production and QC. The self-inspection programme should be designed to detect any shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections should be performed routinely, and may be, in addition, performed on special occasions, e.g. in the case of product recalls or repeated rejections, or when an inspection by the health authorities is announced. The team responsible for self-inspection should consist of personnel who can evaluate the implementation of GMP objectively. All recommendations for corrective action should be implemented. The procedure for self-inspection should be documented, and there should be an effective follow-up programme.\n\n## Items for self-inspection\n\n8.2 \nWritten instructions for self-inspection should be established to provide a minimum and uniform standard of requirements. These may include questionnaires on GMP requirements covering at least the following items:\n\n(a) personnel;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Producci\u00f3n y An\u00e1lisis**: El documento establece que todos los arreglos para la producci\u00f3n y an\u00e1lisis de productos deben estar en conformidad con la autorizaci\u00f3n de comercializaci\u00f3n y ser acordados por ambas partes involucradas en el contrato. Se enfatiza la importancia de definir claramente las responsabilidades de cada parte en el proceso de producci\u00f3n y control de calidad (QC).\n\n2. **Autocontrol y Auditor\u00edas**: Se detalla la importancia de la autoinspecci\u00f3n como un medio para evaluar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los aspectos de la producci\u00f3n y el control de calidad. Se sugiere que estas autoinspecciones se realicen de manera rutinaria y en ocasiones especiales, y que se documenten adecuadamente.\n\n3. **Manejo de Productos Rechazados**: El documento tambi\u00e9n aborda c\u00f3mo manejar los materiales y productos que son rechazados, as\u00ed como los procedimientos a seguir en caso de que un an\u00e1lisis de contrato indique que un producto debe ser rechazado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos deben ser considerados en el contrato para la gesti\u00f3n de materiales rechazados?**\n   - El contrato debe describir claramente el manejo de los materiales iniciales, intermedios, productos a granel y productos terminados que sean rechazados. Tambi\u00e9n debe incluir el procedimiento a seguir si el an\u00e1lisis de contrato determina que un producto debe ser rechazado.\n\n2. **\u00bfCu\u00e1l es el objetivo principal de la autoinspecci\u00f3n seg\u00fan el documento?**\n   - El objetivo principal de la autoinspecci\u00f3n es evaluar el cumplimiento del fabricante con las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los aspectos de producci\u00f3n y control de calidad, as\u00ed como detectar cualquier deficiencia en la implementaci\u00f3n de GMP y recomendar acciones correctivas necesarias.\n\n3. **\u00bfQu\u00e9 tipo de personal debe formar parte del equipo responsable de la autoinspecci\u00f3n?**\n   - El equipo responsable de la autoinspecci\u00f3n debe estar compuesto por personal que pueda evaluar objetivamente la implementaci\u00f3n de las Buenas Pr\u00e1cticas de Manufactura (GMP). Esto asegura que las evaluaciones sean imparciales y efectivas.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidades del Contract Giver**:\n   - Proporcionar informaci\u00f3n necesaria para las operaciones contratadas.\n   - Asegurar que el contract acceptor est\u00e9 informado sobre problemas que puedan representar riesgos.\n   - Verificar que los productos y materiales procesados cumplan con las especificaciones.\n\n2. **Requisitos para el Contract Acceptor**:\n   - Contar con instalaciones, equipo, conocimiento y personal competente.\n   - No subcontratar el trabajo sin la aprobaci\u00f3n del contract giver.\n   - Evitar actividades que puedan afectar la calidad del producto.\n\n3. **Contrato Escrito**:\n   - Debe establecer claramente las responsabilidades de ambas partes.\n   - Incluir detalles sobre la responsabilidad del personal autorizado en la liberaci\u00f3n de lotes y emisi\u00f3n de certificados de an\u00e1lisis.\n   - Los aspectos t\u00e9cnicos deben ser elaborados por expertos en tecnolog\u00eda farmac\u00e9utica y buenas pr\u00e1cticas de manufactura (GMP).\n\n### Entidades\n\n- **Contract Giver**: Parte que otorga el contrato y tiene la responsabilidad de proporcionar informaci\u00f3n y asegurar el cumplimiento de especificaciones.\n- **Contract Acceptor**: Parte que acepta el contrato y debe cumplir con requisitos espec\u00edficos para realizar el trabajo.\n- **Autorizaci\u00f3n de Fabricaci\u00f3n**: Licencia necesaria para que el contract acceptor realice la fabricaci\u00f3n.\n- **Personal Autorizado**: Individuo responsable de liberar lotes de productos y emitir certificados de an\u00e1lisis.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que deben seguirse para asegurar la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: production, quality control, self-inspection, contract management, Good Manufacturing Practices"}}, "13a6e3e6-0034-40c1-8998-7fcfb9309841": {"node_ids": ["d754f115-f7b2-491d-a714-71726f52b7da"], "metadata": {"page_label": "125", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(b) premises including personnel facilities;  \n(c) maintenance of buildings and equipment;  \n(d) storage of starting materials and finished products;  \n(e) equipment;  \n(f) production and in-process controls;  \n(g) QC;  \n(h) documentation;  \n(i) sanitation and hygiene;  \n(j) validation and revalidation programmes;  \n(k) calibration of instruments or measurement systems;  \n(l) recall procedures;  \n(m) complaints management;  \n(n) labels control;  \n(o) results of previous self-inspections and any corrective steps taken.  \n\n# Self-inspection team\n\n8.3 Management should appoint a self-inspection team consisting of experts in their respective fields and familiar with GMP. The members of the team may be appointed from inside or outside the company.\n\n# Frequency of self-inspection\n\n8.4 The frequency at which self-inspections are conducted may depend on company requirements but should preferably be at least once a year. The frequency should be stated in the procedure.\n\n# Self-inspection report\n\n8.5 A report should be made at the completion of a self-inspection. The report should include:\n\n(a) self-inspection results;  \n(b) evaluation and conclusions; and  \n(c) recommended corrective actions.\n\n# Follow-up action\n\n8.6 There should be an effective follow-up programme. The company management should evaluate both the self-inspection report and the corrective actions as necessary.\n\n# Quality audit\n\n8.7 It may be useful to supplement self-inspections with a quality audit. A quality audit consists of an examination and assessment of all or part of the quality system with the specific purpose of improving the system.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Importancia de la autoinspecci\u00f3n en GMP**: La autoinspecci\u00f3n es un proceso cr\u00edtico en la gesti\u00f3n de la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en evaluar diversos aspectos de las instalaciones, el equipo, los controles de producci\u00f3n y otros elementos clave para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **Estructura y frecuencia de la autoinspecci\u00f3n**: La autoinspecci\u00f3n debe ser realizada por un equipo designado por la direcci\u00f3n, compuesto por expertos en sus respectivos campos. Se recomienda que estas autoinspecciones se realicen al menos una vez al a\u00f1o, y los resultados deben ser documentados en un informe que incluya hallazgos, evaluaciones y acciones correctivas recomendadas.\n\n3. **Seguimiento y auditor\u00eda de calidad**: Despu\u00e9s de la autoinspecci\u00f3n, es esencial implementar un programa de seguimiento efectivo para evaluar los informes y las acciones correctivas. Adem\u00e1s, se sugiere complementar las autoinspecciones con auditor\u00edas de calidad para mejorar el sistema de gesti\u00f3n de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar a los miembros del equipo de autoinspecci\u00f3n?**\n   - La selecci\u00f3n debe basarse en la experiencia y el conocimiento de los miembros en sus respectivos campos, as\u00ed como su familiaridad con las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n2. **\u00bfQu\u00e9 elementos espec\u00edficos deben incluirse en el informe de autoinspecci\u00f3n?**\n   - El informe debe incluir los resultados de la autoinspecci\u00f3n, una evaluaci\u00f3n y conclusiones, as\u00ed como las acciones correctivas recomendadas.\n\n3. **\u00bfCu\u00e1l es la relaci\u00f3n entre la autoinspecci\u00f3n y la auditor\u00eda de calidad en el contexto de GMP?**\n   - La auditor\u00eda de calidad complementa la autoinspecci\u00f3n al proporcionar una evaluaci\u00f3n m\u00e1s amplia y detallada del sistema de calidad, con el objetivo de identificar \u00e1reas de mejora y asegurar el cumplimiento de los est\u00e1ndares de calidad.", "prev_section_summary": "### Temas Clave\n\n1. **Producci\u00f3n y An\u00e1lisis**: Se establece que todos los arreglos para la producci\u00f3n y an\u00e1lisis deben cumplir con la autorizaci\u00f3n de comercializaci\u00f3n y ser acordados por ambas partes. Es crucial definir las responsabilidades de cada parte en el proceso de producci\u00f3n y control de calidad (QC).\n\n2. **Responsabilidades Contractuales**: El contrato debe especificar qui\u00e9n es responsable de la compra, prueba y liberaci\u00f3n de materiales, as\u00ed como de la producci\u00f3n y el control de calidad, incluyendo controles en proceso y an\u00e1lisis de muestras.\n\n3. **Manejo de Productos Rechazados**: Se debe detallar en el contrato c\u00f3mo se manejar\u00e1n los materiales y productos rechazados, as\u00ed como el procedimiento a seguir si un an\u00e1lisis indica que un producto debe ser rechazado.\n\n4. **Autoinspecci\u00f3n y Auditor\u00edas**: La autoinspecci\u00f3n es fundamental para evaluar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP). Debe realizarse de manera rutinaria y documentarse adecuadamente, con un equipo que eval\u00fae objetivamente la implementaci\u00f3n de GMP.\n\n5. **Documentaci\u00f3n y Registros**: Los registros de fabricaci\u00f3n, an\u00e1lisis y distribuci\u00f3n deben estar disponibles para el contratante, y cualquier registro relevante para evaluar la calidad del producto debe ser accesible en caso de quejas o defectos.\n\n### Entidades\n\n- **Partes Contratantes**: Contratante (contract giver) y contratista (contract acceptor).\n- **Productos**: Materiales iniciales, intermedios, productos a granel y productos terminados.\n- **Normativas**: Buenas Pr\u00e1cticas de Manufactura (GMP).\n- **Documentaci\u00f3n**: Contratos, registros de producci\u00f3n y an\u00e1lisis, procedimientos de defectos/recalls.\n- **Equipo de Autoinspecci\u00f3n**: Personal capacitado para evaluar la implementaci\u00f3n de GMP.\n\nEste resumen destaca la importancia de la claridad en los contratos, la responsabilidad en la producci\u00f3n y el an\u00e1lisis, y la necesidad de un sistema robusto de autoinspecci\u00f3n para garantizar la calidad y el cumplimiento normativo.", "excerpt_keywords": "Keywords: self-inspection, GMP, quality audit, corrective actions, documentation"}}, "b4291a05-af7e-45ad-8c11-9b68b322ba11": {"node_ids": ["7b210a65-917f-40ad-a97d-fd462a804b0c"], "metadata": {"page_label": "126", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of a quality system with the specific purpose of improving it. A quality audit is usually conducted by outside or independent specialists or a team designated by the management for this purpose. Such audits may also be extended to suppliers and contractors (see section 7, \u201cContract production and analysis\u201d).\n\n### Suppliers\u2019 audits and approval\n\n8.8 The person responsible for QC should have responsibility together with other relevant departments for approving suppliers who can reliably supply starting and packaging materials that meet established specifications.\n\n8.9 Before suppliers are approved and included in the approved supplier\u2019s list or specifications, they should be evaluated. The evaluation should take into account a supplier\u2019s history and the nature of the materials to be supplied. If an audit is required, it should determine the supplier\u2019s ability to conform with GMP standards.\n\n## 9. Personnel\n\n### 9.1 Principle\n\nThe establishment and maintenance of a satisfactory system of QA and the correct manufacture and control of pharmaceutical products and active ingredients rely upon people. For this reason there must be sufficient qualified personnel to carry out all the tasks for which the manufacturer is responsible. Individual responsibilities should be clearly defined and understood by the persons concerned and recorded as written descriptions.\n\n### General\n\n9.2 The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. The responsibilities placed on any one individual should not be so extensive so as to present any risk to quality.\n\n9.3 Responsible staff should have its specific duties recorded in written descriptions and adequate authority to carry out its responsibilities.\n\nIts duties may be delegated to designated deputies of a satisfactory qualification level. There should be no gaps or unexplained overlaps in the responsibilities of personnel concerned with the application of GMP. The manufacturer should have an organization chart.\n\n9.4 All personnel should be aware of the principles of GMP that affect them and receive initial and continuing training, including hygiene instructions, relevant to their needs. All personnel should be motivated to support the establishment and maintenance of high quality standards.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la importancia de los sistemas de calidad (QA) y de control de calidad (QC) en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se menciona la necesidad de realizar auditor\u00edas de calidad, tanto internas como externas, y la evaluaci\u00f3n de proveedores para asegurar que cumplan con las especificaciones establecidas. Adem\u00e1s, se destaca la importancia del personal calificado en la implementaci\u00f3n de buenas pr\u00e1cticas de manufactura (GMP), as\u00ed como la necesidad de definir claramente las responsabilidades y proporcionar formaci\u00f3n continua al personal.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben considerarse al evaluar a un proveedor antes de su aprobaci\u00f3n en la lista de proveedores?**\n   - El texto menciona que la evaluaci\u00f3n debe tener en cuenta la historia del proveedor y la naturaleza de los materiales que se suministrar\u00e1n, as\u00ed como la capacidad del proveedor para cumplir con los est\u00e1ndares de GMP.\n\n2. **\u00bfCu\u00e1l es la importancia de la formaci\u00f3n continua del personal en el contexto de las buenas pr\u00e1cticas de manufactura (GMP)?**\n   - La formaci\u00f3n continua es crucial para que todo el personal est\u00e9 al tanto de los principios de GMP que les afectan, lo que contribuye a mantener altos est\u00e1ndares de calidad en la producci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfC\u00f3mo se debe estructurar la organizaci\u00f3n del personal para evitar solapamientos o vac\u00edos en las responsabilidades relacionadas con GMP?**\n   - La organizaci\u00f3n del personal debe estar claramente definida mediante un organigrama, y las responsabilidades deben estar registradas en descripciones escritas, asegurando que no haya solapamientos o vac\u00edos en las funciones de quienes aplican las GMP.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia de la Autoinspecci\u00f3n**: La autoinspecci\u00f3n es fundamental para garantizar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) en la industria farmac\u00e9utica, evaluando aspectos cr\u00edticos como instalaciones, equipos y controles de producci\u00f3n.\n\n2. **Composici\u00f3n del Equipo de Autoinspecci\u00f3n**: La direcci\u00f3n debe designar un equipo de autoinspecci\u00f3n compuesto por expertos en sus respectivos campos, que est\u00e9n familiarizados con las GMP. Los miembros pueden ser internos o externos a la empresa.\n\n3. **Frecuencia de Autoinspecci\u00f3n**: Se recomienda que las autoinspecciones se realicen al menos una vez al a\u00f1o, y esta frecuencia debe estar claramente definida en los procedimientos de la empresa.\n\n4. **Informe de Autoinspecci\u00f3n**: Al finalizar una autoinspecci\u00f3n, se debe elaborar un informe que incluya los resultados, evaluaciones, conclusiones y acciones correctivas recomendadas.\n\n5. **Programa de Seguimiento**: Es esencial implementar un programa de seguimiento efectivo para evaluar los informes de autoinspecci\u00f3n y las acciones correctivas.\n\n6. **Auditor\u00eda de Calidad**: Se sugiere complementar las autoinspecciones con auditor\u00edas de calidad, que proporcionan una evaluaci\u00f3n m\u00e1s exhaustiva del sistema de calidad con el objetivo de identificar \u00e1reas de mejora.\n\n### Entidades\n\n- **Autoinspecci\u00f3n**: Proceso de evaluaci\u00f3n interna para asegurar el cumplimiento de GMP.\n- **Equipo de Autoinspecci\u00f3n**: Grupo designado por la direcci\u00f3n, compuesto por expertos en GMP.\n- **Frecuencia**: Al menos una vez al a\u00f1o.\n- **Informe de Autoinspecci\u00f3n**: Documento que resume los hallazgos y recomendaciones tras la autoinspecci\u00f3n.\n- **Programa de Seguimiento**: Proceso para evaluar la implementaci\u00f3n de acciones correctivas.\n- **Auditor\u00eda de Calidad**: Evaluaci\u00f3n adicional del sistema de calidad para mejorar su eficacia.", "excerpt_keywords": "Keywords: quality audit, suppliers' approval, GMP standards, qualified personnel, training"}}, "660b518a-62ff-46c2-be27-0a10f9fc2a1a": {"node_ids": ["10555d1a-0ee7-4970-8519-36296c2b12ac"], "metadata": {"page_label": "127", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key Personnel\n\n9.5 Steps should be taken to prevent unauthorized people from entering production, storage and QC areas. Personnel who do not work in these areas should not use them as a passageway.\n\n## Key Personnel\n\n9.6 Key personnel include the heads of production, the head(s) of quality unit(s) and the authorized person. The quality unit(s) typically comprise the quality assurance and quality control functions. In some cases, these could be combined in one department. The authorized person may also be responsible for one or more of these quality unit(s). Normally, key posts should be occupied by full-time personnel. The heads of production and quality unit(s) should be independent of each other. In large organizations, it may be necessary to delegate some of the functions; however, the responsibility cannot be delegated.\n\n9.7 Key personnel responsible for supervising the production and quality unit(s) for pharmaceutical products should possess the qualifications of a scientific education and practical experience required by national legislation. Their education should include the study of an appropriate combination of:\n\n- (a) chemistry (analytical or organic) or biochemistry;\n- (b) chemical engineering;\n- (c) microbiology;\n- (d) pharmaceutical sciences and technology;\n- (e) pharmacology and toxicology;\n- (f) physiology; and\n- (g) other related sciences.\n\nThey should also have adequate practical experience in the manufacture and QA of pharmaceutical products. In order to gain such experience, a preparatory period may be required, during which they should exercise their duties under professional guidance. The scientific education and practical experience of experts should be such as to enable them to exercise independent professional judgement, based on the application of scientific principles and understanding to the practical problems encountered in the manufacture and QC of pharmaceutical products.\n\n9.8 The heads of the production and the quality unit(s) generally have some shared, or jointly exercised, responsibilities relating to quality.\n\nThese may include, depending on national regulations:\n\n- (a) authorization of written procedures and other documents, including amendments;\n- (b) monitoring and control of the manufacturing environment;\n- (c) plant hygiene;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la gesti\u00f3n de personal clave en la producci\u00f3n y control de calidad de productos farmac\u00e9uticos. Se enfatiza la importancia de prevenir el acceso no autorizado a \u00e1reas cr\u00edticas, la independencia de los jefes de producci\u00f3n y calidad, y la necesidad de que el personal clave posea una educaci\u00f3n cient\u00edfica adecuada y experiencia pr\u00e1ctica. Adem\u00e1s, se mencionan las responsabilidades compartidas entre los jefes de producci\u00f3n y calidad en relaci\u00f3n con la calidad del producto.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las calificaciones educativas y la experiencia pr\u00e1ctica requeridas para el personal clave en la producci\u00f3n y control de calidad de productos farmac\u00e9uticos?**\n   - El contexto detalla que el personal clave debe tener una educaci\u00f3n cient\u00edfica que incluya qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda, fisiolog\u00eda y otras ciencias relacionadas, as\u00ed como experiencia pr\u00e1ctica en la fabricaci\u00f3n y aseguramiento de calidad de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Se menciona que se deben tomar pasos para prevenir que personas no autorizadas ingresen a las \u00e1reas de producci\u00f3n, almacenamiento y control de calidad, y que el personal que no trabaja en estas \u00e1reas no debe usarlas como pasadizos.\n\n3. **\u00bfQu\u00e9 responsabilidades comparten los jefes de producci\u00f3n y de las unidades de calidad en el contexto de la calidad del producto?**\n   - Seg\u00fan el documento, los jefes de producci\u00f3n y de las unidades de calidad generalmente comparten responsabilidades relacionadas con la calidad, que pueden incluir la autorizaci\u00f3n de procedimientos escritos, el monitoreo y control del entorno de fabricaci\u00f3n, y la higiene de la planta, dependiendo de las regulaciones nacionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Calidad (QA) y Control de Calidad (QC)**:\n   - Importancia de las auditor\u00edas de calidad, tanto internas como externas, para mejorar los sistemas de calidad.\n   - Las auditor\u00edas pueden ser realizadas por especialistas externos o equipos designados por la direcci\u00f3n.\n\n2. **Auditor\u00edas y Aprobaci\u00f3n de Proveedores**:\n   - El responsable de QC debe colaborar con otros departamentos para aprobar proveedores que suministren materiales que cumplan con las especificaciones.\n   - La evaluaci\u00f3n de proveedores debe considerar su historial, la naturaleza de los materiales y su capacidad para cumplir con los est\u00e1ndares de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n3. **Personal Calificado**:\n   - La correcta fabricaci\u00f3n y control de productos farmac\u00e9uticos dependen de contar con personal calificado.\n   - Es esencial definir claramente las responsabilidades del personal y documentarlas por escrito.\n   - La organizaci\u00f3n del personal debe estar estructurada para evitar solapamientos o vac\u00edos en las responsabilidades relacionadas con GMP.\n\n4. **Formaci\u00f3n Continua**:\n   - Todo el personal debe recibir formaci\u00f3n inicial y continua sobre los principios de GMP y otros aspectos relevantes, incluyendo instrucciones de higiene.\n   - La motivaci\u00f3n del personal es clave para mantener altos est\u00e1ndares de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Fabricante de productos farmac\u00e9uticos.\n- **Roles**: Responsable de QC, personal calificado, personal de apoyo.\n- **Documentaci\u00f3n**: Descripciones escritas de responsabilidades, organigrama.\n- **Normativas**: Buenas Pr\u00e1cticas de Manufactura (GMP). \n\nEste resumen destaca la importancia de un sistema de calidad robusto, la evaluaci\u00f3n de proveedores, la capacitaci\u00f3n del personal y la claridad en las responsabilidades para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmaceutical production, quality assurance, key personnel, regulatory compliance, scientific education"}}, "901ff636-16c5-4fdf-9703-58f14701d39f": {"node_ids": ["a2550d3e-d860-4512-9bc4-90ecbfb3b335"], "metadata": {"page_label": "128", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) process validation and calibration of analytical apparatus;  \n(e) training, including the application and principles of QA;  \n(f) approval and monitoring of suppliers of materials;  \n(g) approval and monitoring of contract manufacturers;  \n(h) designation and monitoring of storage conditions for materials and products;  \n(i) performance and evaluation of in-process controls;  \n(j) retention of records;  \n(k) monitoring of compliance with GMP requirements; and  \n(l) inspection, investigation and taking of samples in order to monitor factors that may affect product quality.  \n\n9.9 The head of the production generally has the following responsibilities:\n\n(a) to ensure that products are produced and stored according to the appropriate documentation in order to obtain the required quality;  \n(b) to approve the instructions relating to production operations, including the in-process controls, and to ensure their strict implementation;  \n(c) to ensure that the production records are evaluated and signed by a designated person;  \n(d) to check the maintenance of the department, premises and equipment;  \n(e) to ensure that the appropriate process validations and calibrations of control equipment are performed and recorded and the reports made available;  \n(f) to ensure that the required initial and continuing training of production personnel is carried out and adapted according to need.  \n\n9.10 The head(s) of the quality unit(s) generally have the following responsibilities:\n\n(a) to approve or reject starting materials, packaging materials, and intermediate, bulk and finished products in relation with their specifications;  \n(b) to evaluate batch records;  \n(c) to ensure that all necessary testing is carried out;  \n(d) to approve sampling instructions, specifications, test methods and other QC procedures;  \n(e) to approve and monitor analyses carried out under contract;  \n(f) to check the maintenance of the department, premises and equipment;  \n(g) to ensure that the appropriate validations, including those of analytical procedures, and calibrations of control equipment are carried out;  \n(h) to ensure that the required initial and continuing training of quality unit personnel is carried out and adapted according to need.  \n(i) establishment, implementation and maintenance of the quality system;  \n(j) supervision of the regular internal audits or self-inspections;  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades de los l\u00edderes en producci\u00f3n y calidad dentro de un sistema de gesti\u00f3n de calidad (QA) en la industria farmac\u00e9utica. Se enfatiza la importancia de la validaci\u00f3n de procesos, la capacitaci\u00f3n del personal, la aprobaci\u00f3n y monitoreo de materiales y proveedores, as\u00ed como el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP). Las responsabilidades est\u00e1n divididas entre el jefe de producci\u00f3n y el jefe de la unidad de calidad, cada uno con tareas espec\u00edficas que aseguran la calidad y la conformidad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos que debe seguir el jefe de producci\u00f3n para garantizar que los productos se produzcan y almacenen de acuerdo con la documentaci\u00f3n adecuada?**\n   - Esta pregunta se centra en el proceso espec\u00edfico que el jefe de producci\u00f3n debe seguir, lo que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n inicial y continua se requiere para el personal de producci\u00f3n y c\u00f3mo se adapta seg\u00fan las necesidades?**\n   - Esta pregunta busca informaci\u00f3n sobre el contenido y la adaptaci\u00f3n de la formaci\u00f3n, que no se menciona en detalle en el contexto.\n\n3. **\u00bfC\u00f3mo se lleva a cabo la supervisi\u00f3n de las auditor\u00edas internas o autoinspecciones en la unidad de calidad?**\n   - Esta pregunta se enfoca en el proceso de supervisi\u00f3n de auditor\u00edas, que no se aborda en profundidad en el texto proporcionado.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS establece un marco para la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, destacando la importancia de la validaci\u00f3n de procesos, la capacitaci\u00f3n del personal y el cumplimiento de las regulaciones. Los l\u00edderes en producci\u00f3n y calidad tienen responsabilidades espec\u00edficas que aseguran que los productos cumplan con los est\u00e1ndares requeridos, desde la aprobaci\u00f3n de materiales hasta la supervisi\u00f3n de auditor\u00edas internas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prevenci\u00f3n de Acceso No Autorizado**:\n   - Se deben implementar medidas para evitar que personas no autorizadas ingresen a las \u00e1reas de producci\u00f3n, almacenamiento y control de calidad (QC).\n\n2. **Personal Clave**:\n   - Incluye a los jefes de producci\u00f3n, jefes de unidades de calidad y personas autorizadas.\n   - Las unidades de calidad abarcan funciones de aseguramiento y control de calidad, que pueden estar combinadas en un solo departamento.\n\n3. **Independencia de Funciones**:\n   - Los jefes de producci\u00f3n y de las unidades de calidad deben ser independientes entre s\u00ed, aunque en organizaciones grandes puede ser necesario delegar algunas funciones, manteniendo la responsabilidad.\n\n4. **Calificaciones Requeridas**:\n   - El personal clave debe tener educaci\u00f3n cient\u00edfica y experiencia pr\u00e1ctica, que incluya disciplinas como qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda y fisiolog\u00eda.\n\n5. **Experiencia Pr\u00e1ctica**:\n   - Se requiere experiencia adecuada en la fabricaci\u00f3n y aseguramiento de calidad de productos farmac\u00e9uticos, con un per\u00edodo preparatorio bajo supervisi\u00f3n profesional.\n\n6. **Responsabilidades Compartidas**:\n   - Los jefes de producci\u00f3n y de las unidades de calidad comparten responsabilidades relacionadas con la calidad, que pueden incluir la autorizaci\u00f3n de procedimientos, monitoreo del entorno de fabricaci\u00f3n y mantenimiento de la higiene de la planta.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Personal Clave**: Jefes de producci\u00f3n, jefes de unidades de calidad, persona autorizada.\n- **\u00c1reas Cr\u00edticas**: Producci\u00f3n, almacenamiento, control de calidad (QC).\n- **Disciplinas Cient\u00edficas**: Qu\u00edmica, ingenier\u00eda qu\u00edmica, microbiolog\u00eda, ciencias farmac\u00e9uticas, farmacolog\u00eda, toxicolog\u00eda, fisiolog\u00eda. \n\nEste resumen destaca la importancia de la educaci\u00f3n, experiencia y organizaci\u00f3n del personal clave en la industria farmac\u00e9utica, as\u00ed como las medidas de seguridad necesarias para mantener la integridad de las \u00e1reas de producci\u00f3n y control de calidad.", "excerpt_keywords": "Keywords: calidad, producci\u00f3n, validaci\u00f3n de procesos, capacitaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura"}}, "0373e499-7b6e-4575-ad0a-7ce3de8e4edb": {"node_ids": ["3f5de2c0-ba1f-47f8-879d-398ca06db321"], "metadata": {"page_label": "129", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(k) participation in external audit (vendor audit);  \n(l) participation in validation programmes.\n\nOther duties of QC are summarized in sections 17.3 and 17.4.\n\n9.11 The authorized person is responsible for compliance with technical or regulatory requirements related to the quality of finished products and the approval of the release of the finished product for sale or supply.\n\n9.12 Assessment of finished products should embrace all relevant factors, including the production conditions, the results of in-process testing, the manufacturing (including packaging) documentation, compliance with the specification for the finished product, and an examination of the finished pack.\n\n9.13 No batch of product is to be released for sale or supply prior to certification by the authorized person(s). In certain countries, by law, the batch release is a task of the authorized person from production together with the authorized person from QC.\n\n9.14 The authorized person responsible for approving a batch for release should always ensure that the following requirements have been met:\n\n(a) the marketing authorization and the manufacturing authorization requirements for the product have been met for the batch concerned;  \n(b) the principles and guidelines of GMP, as laid down in the guidelines published by WHO, have been followed;  \n(c) the principal manufacturing and testing processes have been validated, if different;  \n(d) all the necessary checks and tests have been performed and account taken of the production conditions and manufacturing records;  \n(e) any planned changes or deviations in manufacturing or quality control have been notified in accordance with a well-defined reporting system before any product is released. Such changes may need notification to, and approval by, the medicines regulatory authority;  \n(f) any additional sampling, inspection, tests and checks have been carried out or initiated, as appropriate, to cover planned changes and deviations;  \n(g) all necessary production and QC documentation has been completed and endorsed by supervisors trained in appropriate disciplines;  \n(h) appropriate audits, self-inspections and spot-checks are carried out by experienced and trained staff;  \n(i) approval has been given by the head of QC; and  \n(j) all relevant factors have been considered, including any not specifically associated with the output batch directly under review (e.g. subdivision of output batches from a common input, factors associated with continuous production runs).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las responsabilidades y requisitos relacionados con la calidad de los productos terminados en el \u00e1mbito de la fabricaci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de la certificaci\u00f3n por parte de una persona autorizada antes de que un lote de producto sea liberado para la venta o suministro. Se enumeran los criterios que deben cumplirse para la aprobaci\u00f3n de un lote, incluyendo el cumplimiento de las autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n, la validaci\u00f3n de procesos, la realizaci\u00f3n de pruebas y controles necesarios, y la consideraci\u00f3n de cualquier cambio o desviaci\u00f3n en la producci\u00f3n o control de calidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones legales de la liberaci\u00f3n de un lote de producto en pa\u00edses donde se requiere la certificaci\u00f3n conjunta de la persona autorizada de producci\u00f3n y la de control de calidad?**\n   - Esta pregunta aborda la responsabilidad legal y las consecuencias de no cumplir con los requisitos de liberaci\u00f3n de lotes en diferentes jurisdicciones.\n\n2. **\u00bfQu\u00e9 tipo de auditor\u00edas y autoinspecciones se consideran apropiadas seg\u00fan el contexto del documento, y qui\u00e9n debe llevarlas a cabo?**\n   - Esta pregunta se centra en los procedimientos de auditor\u00eda y autoinspecci\u00f3n, as\u00ed como en la capacitaci\u00f3n y experiencia del personal encargado de realizarlas.\n\n3. **\u00bfQu\u00e9 factores adicionales deben ser considerados por la persona autorizada al evaluar un lote, m\u00e1s all\u00e1 de los criterios espec\u00edficos mencionados en el documento?**\n   - Esta pregunta busca explorar los factores no espec\u00edficos que pueden influir en la decisi\u00f3n de liberar un lote, lo que podr\u00eda incluir aspectos de producci\u00f3n continua o subdivisiones de lotes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Responsabilidades en la Producci\u00f3n:**\n   - Validaci\u00f3n de procesos y calibraci\u00f3n de equipos anal\u00edticos.\n   - Capacitaci\u00f3n del personal en principios de gesti\u00f3n de calidad (QA).\n   - Aprobaci\u00f3n y monitoreo de proveedores y fabricantes contratados.\n   - Monitoreo de condiciones de almacenamiento y cumplimiento de Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - Evaluaci\u00f3n de controles en proceso y retenci\u00f3n de registros.\n\n2. **Responsabilidades en la Unidad de Calidad:**\n   - Aprobaci\u00f3n o rechazo de materiales y productos seg\u00fan especificaciones.\n   - Evaluaci\u00f3n de registros de lotes y aseguramiento de pruebas necesarias.\n   - Aprobaci\u00f3n de instrucciones de muestreo y procedimientos de control de calidad (QC).\n   - Supervisi\u00f3n de auditor\u00edas internas y mantenimiento del sistema de calidad.\n\n3. **Capacitaci\u00f3n y Formaci\u00f3n:**\n   - Importancia de la formaci\u00f3n inicial y continua del personal de producci\u00f3n y calidad, adapt\u00e1ndose a las necesidades.\n\n4. **Cumplimiento Normativo:**\n   - Monitoreo de la conformidad con los requisitos de GMP y la implementaci\u00f3n de auditor\u00edas internas.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que proporciona directrices sobre gesti\u00f3n de calidad en la industria farmac\u00e9utica.\n- **Jefe de Producci\u00f3n:** Responsable de asegurar la calidad en la producci\u00f3n y almacenamiento de productos.\n- **Jefe de la Unidad de Calidad:** Encargado de la aprobaci\u00f3n de materiales y productos, as\u00ed como de la supervisi\u00f3n de la calidad.\n- **Personal de Producci\u00f3n y Calidad:** Requiere formaci\u00f3n y capacitaci\u00f3n continua para cumplir con los est\u00e1ndares de calidad.\n\nEste resumen destaca la estructura de responsabilidades y la importancia de la calidad en la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de formaci\u00f3n y cumplimiento normativo.", "excerpt_keywords": "Keywords: calidad, autorizaci\u00f3n, liberaci\u00f3n de lotes, Buenas Pr\u00e1cticas de Manufactura, auditor\u00edas"}}, "4e20a861-0f16-4c1b-a5bd-9c1f9cef05a7": {"node_ids": ["a36199ad-3c03-4429-8b5c-e57d5e634193"], "metadata": {"page_label": "130", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10. Training\n\n10.1 The manufacturer should provide training in accordance with a written programme for all personnel whose duties take them into manufacturing areas or into control laboratories (including the technical, maintenance and cleaning personnel) and for other personnel as required.\n\n10.2 Besides basic training on the theory and practice of GMP, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness periodically assessed. Approved training programmes should be available. Training records should be kept.\n\n10.3 Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitizing materials are handled, should be given specific training.\n\n10.4 The concept of QA and all the measures which aid its understanding and implementation should be fully discussed during the training sessions.\n\n10.5 Visitors or untrained personnel should preferably not be taken into the production and QC areas. If this is unavoidable, they should be given relevant information in advance (particularly about personal hygiene) and the prescribed protective clothing. They should be closely supervised.\n\n10.6 Consultant and contract staff should be qualified for the services they provide. Evidence of this should be included in the training records.\n\n# 11. Personal hygiene\n\n11.1 All personnel, prior to and during employment, as appropriate, should undergo health examinations. Personnel conducting visual inspections should also undergo periodic eye examinations.\n\n11.2 All personnel should be trained in the practices of personal hygiene. A high level of personal hygiene should be observed by all those concerned with manufacturing processes. In particular, personnel should be instructed to wash their hands before entering production areas. Signs to this effect should be posted and instructions observed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos cruciales de la formaci\u00f3n y la higiene personal en el \u00e1mbito de la fabricaci\u00f3n y el control de calidad (QC) de productos. Se enfatiza la importancia de proporcionar capacitaci\u00f3n adecuada a todo el personal involucrado en estas \u00e1reas, as\u00ed como la necesidad de mantener altos est\u00e1ndares de higiene personal. Se detallan las responsabilidades del fabricante en cuanto a la formaci\u00f3n, la supervisi\u00f3n de visitantes y la calificaci\u00f3n del personal contratado. Adem\u00e1s, se menciona la importancia de realizar ex\u00e1menes de salud y de instruir al personal sobre pr\u00e1cticas de higiene.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n espec\u00edfica se debe proporcionar al personal que trabaja en \u00e1reas donde hay un riesgo de contaminaci\u00f3n?**\n   - El personal que trabaja en \u00e1reas donde la contaminaci\u00f3n es un riesgo, como \u00e1reas limpias o donde se manejan materiales altamente activos, t\u00f3xicos, infecciosos o sensibilizantes, debe recibir una formaci\u00f3n espec\u00edfica relacionada con esos riesgos.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para garantizar que los visitantes o el personal no capacitado no interfieran en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Se recomienda que los visitantes o el personal no capacitado no sean llevados a las \u00e1reas de producci\u00f3n y QC. Si esto es inevitable, deben recibir informaci\u00f3n relevante sobre higiene personal y usar la vestimenta protectora prescrita, adem\u00e1s de ser supervisados de cerca.\n\n3. **\u00bfQu\u00e9 registros deben mantenerse en relaci\u00f3n con la formaci\u00f3n del personal y por qu\u00e9 son importantes?**\n   - Se deben mantener registros de formaci\u00f3n que incluyan evidencia de la calificaci\u00f3n del personal, especialmente para consultores y personal contratado. Estos registros son importantes para demostrar que el personal est\u00e1 adecuadamente capacitado para realizar los servicios que proporcionan, lo que contribuye a la calidad y seguridad en los procesos de fabricaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad de la Persona Autorizada**: La persona autorizada es responsable de garantizar el cumplimiento de los requisitos t\u00e9cnicos y regulatorios relacionados con la calidad de los productos terminados y de aprobar la liberaci\u00f3n de estos para la venta o suministro.\n\n2. **Evaluaci\u00f3n de Productos Terminados**: La evaluaci\u00f3n debe considerar factores relevantes como las condiciones de producci\u00f3n, resultados de pruebas en proceso, documentaci\u00f3n de fabricaci\u00f3n y cumplimiento de especificaciones.\n\n3. **Certificaci\u00f3n de Lotes**: Ning\u00fan lote puede ser liberado para venta o suministro sin la certificaci\u00f3n de la persona autorizada. En algunos pa\u00edses, esto requiere la certificaci\u00f3n conjunta de la persona autorizada de producci\u00f3n y la de control de calidad.\n\n4. **Requisitos para la Liberaci\u00f3n de Lotes**: Se enumeran varios requisitos que deben cumplirse antes de la liberaci\u00f3n de un lote, incluyendo autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n, cumplimiento de Buenas Pr\u00e1cticas de Manufactura (GMP), validaci\u00f3n de procesos, y realizaci\u00f3n de controles y pruebas necesarias.\n\n5. **Auditor\u00edas y Autoinspecciones**: Se requiere que se realicen auditor\u00edas, autoinspecciones y controles por parte de personal experimentado y capacitado.\n\n6. **Consideraci\u00f3n de Factores Adicionales**: La persona autorizada debe considerar factores adicionales que puedan influir en la decisi\u00f3n de liberar un lote, m\u00e1s all\u00e1 de los criterios espec\u00edficos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que publica las directrices y normas relacionadas con la calidad en la fabricaci\u00f3n farmac\u00e9utica.\n- **Persona Autorizada**: Profesional responsable de la certificaci\u00f3n y liberaci\u00f3n de productos terminados.\n- **Reguladores de Medicamentos**: Autoridades que pueden requerir notificaci\u00f3n y aprobaci\u00f3n de cambios en la producci\u00f3n o control de calidad.\n- **Documentaci\u00f3n de Producci\u00f3n y Control de Calidad (QC)**: Registros necesarios para la evaluaci\u00f3n y liberaci\u00f3n de lotes.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Principios y directrices que deben seguirse en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: training, personal hygiene, GMP, contamination, quality assurance"}}, "0c47e034-ffd0-4a59-bf70-381392ec61d6": {"node_ids": ["b9ebb719-8515-48a2-808f-4f63d1040161"], "metadata": {"page_label": "131", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3\nAny person shown at any time to have an apparent illness or open lesions that may adversely affect the quality of products should not be allowed to handle starting materials, packaging materials, in-process materials or medicines products until the condition is no longer judged to be a risk.\n\n11.4 All employees should be instructed and encouraged to report to their immediate supervisor any conditions (relating to plant, equipment or personnel) that they consider may adversely affect the products.\n\n11.5 Direct contact should be avoided between the operator\u2019s hands and starting materials, primary packaging materials and intermediate or bulk product.\n\n11.6 To ensure protection of the product from contamination, personnel should wear clean body coverings appropriate to the duties they perform, including appropriate hair covering. Used clothes, if reusable, should be stored in separate closed containers until properly laundered and, if necessary, disinfected or sterilized.\n\n11.7 Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and personal medicines should not be permitted in production, laboratory and storage areas, or in any other areas where they might adversely influence product quality.\n\n11.8 Personal hygiene procedures including the use of protective clothing should apply to all persons entering production areas, whether they are temporary or full-time employees or nonemployees, e.g. contractors\u2019 employees, visitors, senior managers and inspectors.\n\n# 12. Premises\n\n12.1 **Principle.** Premises must be located, designed, constructed, adapted and maintained to suit the operations to be carried out.\n\n## General\n\n12.2 The layout and design of premises must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and in general, any adverse effect on the quality of products.\n\n12.3 Where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of powder), measures should be taken to avoid cross-contamination and facilitate cleaning.\n\n12.4 Premises should be situated in an environment that, when considered together with measures to protect the manufacturing process, presents minimum risk of causing any contamination of materials or products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la higiene y el dise\u00f1o de las instalaciones en la producci\u00f3n de medicamentos. Se enfatiza la importancia de la salud del personal, la limpieza de las instalaciones y la prevenci\u00f3n de la contaminaci\u00f3n para asegurar la calidad de los productos. Se proh\u00edben actividades que puedan comprometer la higiene en \u00e1reas de producci\u00f3n y se requiere que todos los individuos que ingresen a estas \u00e1reas sigan procedimientos de higiene estrictos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si un empleado presenta una enfermedad aparente o lesiones abiertas?**\n   - Cualquier persona que presente una enfermedad aparente o lesiones abiertas que puedan afectar la calidad de los productos no debe manejar materiales hasta que su condici\u00f3n ya no se considere un riesgo.\n\n2. **\u00bfQu\u00e9 tipo de ropa y medidas de higiene se requieren para el personal en \u00e1reas de producci\u00f3n?**\n   - El personal debe usar ropa limpia adecuada a sus funciones, incluyendo cubiertas para el cabello. La ropa usada, si es reutilizable, debe almacenarse en contenedores cerrados hasta su lavado y, si es necesario, desinfecci\u00f3n o esterilizaci\u00f3n.\n\n3. **\u00bfC\u00f3mo debe estar dise\u00f1ada la disposici\u00f3n de las instalaciones para minimizar riesgos en la producci\u00f3n?**\n   - La disposici\u00f3n y dise\u00f1o de las instalaciones deben minimizar el riesgo de errores y permitir una limpieza y mantenimiento efectivos para evitar la contaminaci\u00f3n cruzada y la acumulaci\u00f3n de polvo o suciedad, asegurando as\u00ed la calidad de los productos.", "prev_section_summary": "### Temas Clave\n\n1. **Formaci\u00f3n del Personal**:\n   - Importancia de proporcionar capacitaci\u00f3n adecuada a todo el personal que trabaja en \u00e1reas de fabricaci\u00f3n y laboratorios de control.\n   - Necesidad de formaci\u00f3n espec\u00edfica para personal en \u00e1reas de riesgo de contaminaci\u00f3n.\n   - Requisitos de formaci\u00f3n continua y evaluaci\u00f3n de su efectividad.\n   - Mantenimiento de registros de formaci\u00f3n.\n\n2. **Higiene Personal**:\n   - Ex\u00e1menes de salud para todo el personal antes y durante el empleo.\n   - Capacitaci\u00f3n en pr\u00e1cticas de higiene personal.\n   - Instrucciones espec\u00edficas sobre el lavado de manos antes de ingresar a \u00e1reas de producci\u00f3n.\n\n3. **Supervisi\u00f3n de Visitantes**:\n   - Restricciones sobre la entrada de visitantes o personal no capacitado en \u00e1reas de producci\u00f3n y control de calidad.\n   - Provisi\u00f3n de informaci\u00f3n relevante y equipo de protecci\u00f3n para visitantes, junto con supervisi\u00f3n cercana.\n\n4. **Calificaci\u00f3n del Personal Contratado**:\n   - Requisitos de calificaci\u00f3n para consultores y personal contratado, con evidencia documentada en los registros de formaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Personal**: Incluye t\u00e9cnicos, mantenimiento, limpieza y otros involucrados en la fabricaci\u00f3n y control de calidad.\n- **\u00c1reas de Riesgo**: Espacios donde se manejan materiales peligrosos o donde la contaminaci\u00f3n es un riesgo.\n- **Registros de Formaci\u00f3n**: Documentaci\u00f3n que evidencia la capacitaci\u00f3n recibida por el personal.\n- **Pr\u00e1cticas de Higiene**: Normas y procedimientos que deben seguirse para mantener altos est\u00e1ndares de higiene personal.", "excerpt_keywords": "Keywords: hygiene, contamination, production, premises, personal protective equipment"}}, "a3fd74cf-835f-47c4-816f-b55a5fa1ccd8": {"node_ids": ["ababaf3e-21ef-41b3-bc8d-1d130753de1a"], "metadata": {"page_label": "132", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.5 \nPremises used for the manufacture of finished products should be suitably designed and constructed to facilitate good sanitation.\n\n12.6 \nPremises should be carefully maintained, and it should be ensured that repair and maintenance operations do not present any hazard to the quality of products.\n\n12.7 \nPremises should be cleaned and, where applicable, disinfected according to detailed written procedures. Records should be maintained.\n\n12.8 \nElectrical supply, lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\n12.9 \nPremises should be designed and equipped so as to afford maximum protection against the entry of insects, birds or other animals. There should be a procedure for rodent and pest control.\n\n12.10 \nPremises should be designed to ensure the logical flow of materials and personnel.\n\n## Ancillary areas\n\n12.11 \nRest and refreshment rooms should be separate from manufacturing and control areas.\n\n12.12 \nFacilities for changing and storing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not communicate directly with production or storage areas.\n\n12.13 \nMaintenance workshops should if possible be separated from production areas. Whenever parts and tools are stored in the production area, they should be kept in rooms or lockers reserved for that use.\n\n12.14 \nAnimal houses should be well isolated from other areas, with separate entrance (animal access) and air-handling facilities.\n\n## Storage areas\n\n12.15 \nStorage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products with proper separation and segregation: starting and packaging materials, intermediates, bulk and finished products, products in quarantine, and released, rejected, returned or recalled products.\n\n12.16 \nStorage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean, dry, sufficiently lit and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre el dise\u00f1o y mantenimiento de las instalaciones utilizadas para la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la sanidad, el mantenimiento adecuado, la limpieza, el control de plagas, y la separaci\u00f3n de \u00e1reas espec\u00edficas para garantizar la calidad y seguridad de los productos. Tambi\u00e9n se abordan las condiciones de almacenamiento y la organizaci\u00f3n de las \u00e1reas auxiliares, como los vestuarios y los talleres de mantenimiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para garantizar la limpieza y desinfecci\u00f3n de las instalaciones de fabricaci\u00f3n?**\n   - El contexto menciona que las instalaciones deben ser limpiadas y desinfectadas de acuerdo con procedimientos escritos detallados, y que se deben mantener registros de estas actividades.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar \u00e1reas de almacenamiento para productos farmac\u00e9uticos?**\n   - Las \u00e1reas de almacenamiento deben tener suficiente capacidad para permitir un almacenamiento ordenado de diferentes categor\u00edas de materiales y productos, asegurando la separaci\u00f3n y segregaci\u00f3n adecuadas.\n\n3. **\u00bfQu\u00e9 tipo de instalaciones auxiliares se requieren para el personal que trabaja en las \u00e1reas de producci\u00f3n?**\n   - Se requiere que las instalaciones para cambiar y almacenar ropa, as\u00ed como las de lavado y aseo, sean f\u00e1cilmente accesibles y adecuadas para el n\u00famero de usuarios, y que los ba\u00f1os no se comuniquen directamente con las \u00e1reas de producci\u00f3n o almacenamiento.", "prev_section_summary": "### Temas Clave\n\n1. **Salud del Personal**: Se establece que cualquier persona con enfermedades aparentes o lesiones abiertas no debe manejar materiales hasta que su condici\u00f3n no represente un riesgo para la calidad del producto.\n\n2. **Reportes de Condiciones Adversas**: Se alienta a los empleados a informar sobre cualquier condici\u00f3n que pueda afectar negativamente la calidad de los productos.\n\n3. **Prevenci\u00f3n de Contaminaci\u00f3n**: Se deben evitar el contacto directo entre las manos del operador y los materiales, y se requiere el uso de ropa limpia y adecuada, as\u00ed como cubiertas para el cabello.\n\n4. **Prohibiciones en \u00c1reas de Producci\u00f3n**: Se proh\u00edben actividades como fumar, comer o beber en \u00e1reas de producci\u00f3n y almacenamiento para mantener la calidad del producto.\n\n5. **Higiene Personal**: Todos los individuos que ingresen a las \u00e1reas de producci\u00f3n deben seguir estrictos procedimientos de higiene.\n\n6. **Dise\u00f1o y Mantenimiento de Instalaciones**: Las instalaciones deben estar dise\u00f1adas y mantenidas para minimizar errores y evitar la contaminaci\u00f3n cruzada, as\u00ed como facilitar la limpieza.\n\n7. **Control de Polvo**: Se deben implementar medidas para evitar la generaci\u00f3n de polvo y facilitar la limpieza en \u00e1reas donde se manipulan materiales en polvo.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Empleados**: Personal que debe seguir las normas de higiene y reportar condiciones adversas.\n- **Materiales**: Incluyen materiales de inicio, empaques y productos en proceso.\n- **Instalaciones**: Deben estar dise\u00f1adas y mantenidas adecuadamente para la producci\u00f3n de medicamentos.\n- **Contaminaci\u00f3n**: Riesgo que se busca minimizar a trav\u00e9s de pr\u00e1cticas de higiene y dise\u00f1o de instalaciones.\n\nEste resumen destaca la importancia de la salud del personal y el dise\u00f1o adecuado de las instalaciones para asegurar la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: sanitation, pharmaceutical manufacturing, storage conditions, pest control, facility design"}}, "9fc19df6-6a3d-4de8-9b9f-eae38f213ab5": {"node_ids": ["3c7a9c42-5b07-46e1-9554-7645f1e1ff00"], "metadata": {"page_label": "133", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Storage and Handling Guidelines\n\nMaintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, controlled, monitored and recorded where appropriate.\n\n## Receiving and Dispatch\n\n12.17 Receiving and dispatch bays should be separated and protect materials and products from the weather. Receiving areas should be designed and equipped to allow containers of incoming materials to be cleaned if necessary before storage.\n\n12.18 Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authorized personnel. Any system replacing the physical quarantine should give equivalent security.\n\n12.19 Segregation should be provided for the storage of rejected, recalled, or returned materials or products.\n\n12.20 Highly active and radioactive materials, narcotics, other dangerous medicines, and substances presenting special risks of abuse, fire or explosion should be stored in safe and secure areas.\n\n12.21 Printed packaging materials are considered critical to the conformity of the pharmaceutical product to its labelling and special attention should be paid to sampling and the safe and secure storage of these materials.\n\n12.22 There should normally be a separate sampling area for starting materials. (If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination.)\n\n## Weighing Areas\n\n12.23 The weighing of starting materials and the estimation of yield by weighing should be carried out in separate weighing areas designed for that use, for example, with provisions for dust control. Such areas may be part of either storage or production areas.\n\n## Production Areas\n\n12.24 In order to minimize the risk of a serious medical hazard due to cross-contamination, dedicated and self-contained facilities must be available for the production of particular pharmaceutical products, such as highly sensitizing materials (e.g. penicillins) or biological preparations (e.g. live microorganisms). The production of certain other highly active products, such as some antibiotics, hormones, cytotoxic substances and certain non-pharmaceutical products, should not be conducted in the same facilities. In exceptional cases, the principle of campaign working in the same facilities can be accepted provided that specific precautions are taken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre el almacenamiento y manejo de materiales farmac\u00e9uticos, enfatizando la importancia de mantener condiciones adecuadas de temperatura y humedad. Se detallan procedimientos para la recepci\u00f3n y despacho de materiales, la segregaci\u00f3n de productos rechazados o en cuarentena, y el almacenamiento seguro de sustancias peligrosas. Tambi\u00e9n se abordan \u00e1reas espec\u00edficas para el pesaje de materiales y la producci\u00f3n de productos farmac\u00e9uticos, destacando la necesidad de instalaciones dedicadas para evitar la contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para garantizar la seguridad en el almacenamiento de materiales altamente activos y peligrosos?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de seguridad que no se mencionan expl\u00edcitamente en otras fuentes, como el tipo de controles de acceso o las caracter\u00edsticas de las \u00e1reas de almacenamiento.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al dise\u00f1ar un \u00e1rea de muestreo para materiales de inicio, y c\u00f3mo se debe prevenir la contaminaci\u00f3n durante el muestreo?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos y operativos del muestreo, que pueden no estar ampliamente cubiertos en otras directrices.\n\n3. **\u00bfQu\u00e9 precauciones espec\u00edficas se deben tomar al realizar trabajos de campa\u00f1a en instalaciones que producen productos farmac\u00e9uticos altamente activos?**\n   - Esta pregunta busca informaci\u00f3n sobre las medidas de seguridad y protocolos que deben implementarse en situaciones excepcionales, lo cual puede no estar claramente definido en otras normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Las instalaciones para la fabricaci\u00f3n de productos farmac\u00e9uticos deben estar dise\u00f1adas y construidas para facilitar una buena sanidad.\n\n2. **Mantenimiento y Limpieza**:\n   - Es esencial que las instalaciones se mantengan adecuadamente y que las operaciones de reparaci\u00f3n no comprometan la calidad de los productos.\n   - Se deben seguir procedimientos escritos detallados para la limpieza y desinfecci\u00f3n, manteniendo registros de estas actividades.\n\n3. **Condiciones Ambientales**:\n   - La electricidad, iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n deben ser adecuadas para no afectar negativamente los productos farmac\u00e9uticos ni el funcionamiento del equipo.\n\n4. **Control de Plagas**:\n   - Las instalaciones deben protegerse contra la entrada de insectos, aves y otros animales, implementando procedimientos de control de roedores y plagas.\n\n5. **Flujo L\u00f3gico de Materiales y Personal**:\n   - El dise\u00f1o de las instalaciones debe asegurar un flujo l\u00f3gico de materiales y personal.\n\n6. **\u00c1reas Auxiliares**:\n   - Las salas de descanso y refrigerio deben estar separadas de las \u00e1reas de fabricaci\u00f3n y control.\n   - Las instalaciones para cambiar y almacenar ropa, as\u00ed como para el lavado y aseo, deben ser accesibles y adecuadas para el n\u00famero de usuarios, evitando la comunicaci\u00f3n directa de los ba\u00f1os con las \u00e1reas de producci\u00f3n.\n\n7. **Talleres de Mantenimiento**:\n   - Los talleres de mantenimiento deben estar separados de las \u00e1reas de producci\u00f3n siempre que sea posible.\n\n8. **Almacenamiento**:\n   - Las \u00e1reas de almacenamiento deben tener suficiente capacidad para un almacenamiento ordenado y adecuado de diferentes categor\u00edas de materiales y productos, asegurando la separaci\u00f3n y segregaci\u00f3n necesarias.\n   - Deben garantizarse buenas condiciones de almacenamiento, siendo limpias, secas y bien iluminadas.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **Productos Farmac\u00e9uticos**: Objetivo principal de las instalaciones descritas.\n- **Instalaciones de Fabricaci\u00f3n**: Espacios donde se producen los productos farmac\u00e9uticos.\n- **\u00c1reas Auxiliares**: Espacios como vestuarios y talleres que apoyan la producci\u00f3n.\n- **Condiciones de Almacenamiento**: Requisitos para el almacenamiento seguro de productos.", "excerpt_keywords": "Keywords: storage guidelines, pharmaceutical safety, contamination prevention, handling procedures, production facilities"}}, "bd5fc366-13d1-420e-b455-db4bb5498200": {"node_ids": ["60c21ef0-940d-4830-8ea2-f055c159f5f8"], "metadata": {"page_label": "134", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and the necessary validations (including cleaning validation) are made. The manufacture of technical poisons, such as pesticides and herbicides, should not be allowed in premises used for the manufacture of pharmaceutical products.\n\n12.25 Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresponding to the sequence of the operations and to the requisite cleanliness levels.\n\n12.26 The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as to minimize the risk of confusion between different pharmaceutical products or their components, to avoid cross-contamination, and to minimize the risk of omission or wrong application of any of the manufacturing or control steps.\n\n12.27 Where starting and primary packaging materials and intermediate or bulk products are exposed to the environment, interior surfaces (walls, floors and ceilings) should be smooth and free from cracks and open joints, should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.\n\n12.28 Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses that are difficult to clean. As far as possible, for maintenance purposes, they should be accessible from outside the manufacturing areas.\n\n12.29 Drains should be of adequate size and designed and equipped to prevent back-flow. Open channels should be avoided where possible, but if they are necessary they should be shallow to facilitate cleaning and disinfection.\n\n12.30 Production areas should be effectively ventilated, with air-control facilities (including filtration of air to a sufficient level to prevent contamination and cross-contamination, as well as control of temperature and, where necessary, humidity) appropriate to the products handled, to the operations undertaken and to the external environment. These areas should be regularly monitored during both production and non-production periods to ensure compliance with their design specifications.\n\n12.31 Premises for the packaging of pharmaceutical products should be specifically designed and laid out so as to avoid mix-ups, contamination or cross-contamination.\n\n12.32 Production areas should be well lit, particularly where visual online controls are carried out.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto extra\u00eddo del documento de la OMS (Informe T\u00e9cnico 961) aborda las directrices para el dise\u00f1o y la disposici\u00f3n de las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de las \u00e1reas de producci\u00f3n, la prevenci\u00f3n de la contaminaci\u00f3n cruzada, y la adecuada ventilaci\u00f3n y mantenimiento de las instalaciones. Tambi\u00e9n se menciona la necesidad de que los materiales y productos est\u00e9n protegidos del ambiente y que las \u00e1reas de producci\u00f3n est\u00e9n bien iluminadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las superficies interiores de las instalaciones donde se manejan materiales farmac\u00e9uticos expuestos al ambiente?**\n   - Respuesta: Las superficies interiores (paredes, pisos y techos) deben ser lisas, estar libres de grietas y juntas abiertas, no desprender part\u00edculas, y permitir una limpieza y desinfecci\u00f3n efectivas.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar el sistema de drenaje en las \u00e1reas de producci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los desag\u00fces deben ser de tama\u00f1o adecuado y dise\u00f1ados para prevenir el retroceso de agua. Se deben evitar canales abiertos siempre que sea posible, y si son necesarios, deben ser poco profundos para facilitar la limpieza y desinfecci\u00f3n.\n\n3. **\u00bfC\u00f3mo se debe garantizar la ventilaci\u00f3n adecuada en las \u00e1reas de producci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Las \u00e1reas de producci\u00f3n deben estar efectivamente ventiladas, con instalaciones de control de aire que incluyan filtraci\u00f3n para prevenir la contaminaci\u00f3n y control de temperatura y humedad, seg\u00fan sea necesario. Estas \u00e1reas deben ser monitoreadas regularmente para asegurar el cumplimiento de las especificaciones de dise\u00f1o.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre el dise\u00f1o y la operaci\u00f3n de instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de los espacios, la prevenci\u00f3n de la contaminaci\u00f3n y la ventilaci\u00f3n adecuada. Estas medidas son esenciales para asegurar la calidad y seguridad de los productos farmac\u00e9uticos fabricados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Almacenamiento y Manejo:**\n   - Importancia de mantener condiciones adecuadas de temperatura y humedad.\n   - Necesidad de controlar, monitorear y registrar condiciones especiales de almacenamiento.\n\n2. **Recepci\u00f3n y Despacho:**\n   - Separaci\u00f3n de \u00e1reas de recepci\u00f3n y despacho para proteger materiales de las inclemencias del tiempo.\n   - Limpieza de contenedores de materiales entrantes antes del almacenamiento.\n   - \u00c1reas de cuarentena claramente marcadas y restringidas a personal autorizado.\n\n3. **Segregaci\u00f3n de Materiales:**\n   - Almacenamiento separado para materiales rechazados, retirados o devueltos.\n   - Almacenamiento seguro de materiales altamente activos, radiactivos, narc\u00f3ticos y sustancias peligrosas.\n\n4. **Muestreo:**\n   - Importancia de un \u00e1rea de muestreo separada para materiales de inicio.\n   - Prevenci\u00f3n de contaminaci\u00f3n durante el muestreo.\n\n5. **\u00c1reas de Pesaje:**\n   - Pesaje de materiales de inicio en \u00e1reas dise\u00f1adas espec\u00edficamente para ese prop\u00f3sito, con control de polvo.\n\n6. **\u00c1reas de Producci\u00f3n:**\n   - Instalaciones dedicadas y auto-contenidas para la producci\u00f3n de productos farmac\u00e9uticos sensibles.\n   - Prohibici\u00f3n de producci\u00f3n de ciertos productos altamente activos en las mismas instalaciones, salvo en casos excepcionales con precauciones espec\u00edficas.\n\n**Entidades:**\n\n- **Materiales Farmac\u00e9uticos:** Incluyen sustancias altamente activas, radiactivas, narc\u00f3ticos y otros medicamentos peligrosos.\n- **\u00c1reas de Almacenamiento:** Espacios designados para el almacenamiento seguro de materiales y productos.\n- **Personal Autorizado:** Individuos con permiso para acceder a \u00e1reas restringidas, especialmente en zonas de cuarentena.\n- **Instalaciones de Producci\u00f3n:** Espacios dedicados a la fabricaci\u00f3n de productos farmac\u00e9uticos, que deben cumplir con est\u00e1ndares de seguridad para evitar la contaminaci\u00f3n cruzada.\n\nEste resumen destaca la importancia de las pr\u00e1cticas de almacenamiento y manejo en la industria farmac\u00e9utica, as\u00ed como las medidas de seguridad necesarias para proteger tanto los productos como a las personas involucradas en su manejo.", "excerpt_keywords": "Keywords: pharmaceutical manufacturing, contamination prevention, facility design, ventilation standards, cleanliness requirements"}}, "15c08a2c-fae2-4c62-b775-40e72f27298b": {"node_ids": ["9466d7a9-7c50-48c4-ad40-e2874e28b3da"], "metadata": {"page_label": "135", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality control areas\n\n12.33 QC laboratories should be separated from production areas. Areas where biological, microbiological or radioisotope test methods are employed should be separated from each other.\n\n12.34 QC laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix ups and cross-contamination. There should be adequate suitable storage space for samples, reference standards (if necessary, with cooling), solvents, reagents and records.\n\n12.35 The design of the laboratories should take into account the suitability of construction materials, prevention of fumes and ventilation. There should be separate air supply to laboratories and production areas. Separate air-handling units and other provisions are needed for biological, microbiological and radioisotope laboratories.\n\n12.36 A separate room may be needed for instruments to protect them against electrical interference, vibration, contact with excessive moisture and other external factors, or where it is necessary to isolate the instruments.\n\n# Equipment\n\n13.1 Equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. The layout and design of equipment must aim to minimize the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt, and, in general, any adverse effect on the quality of products.\n\n13.2 Equipment should be installed in such a way as to minimize any risk of error or of contamination.\n\n13.3 Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.\n\n13.4 All service pipings and devices should be adequately marked and special attention paid to the provision of non-interchangeable connections or adaptors for dangerous gases and liquids.\n\n13.5 Balances and other measuring equipment of an appropriate range and precision should be available for production and control operations and should be calibrated on a scheduled basis.\n\n13.6 Production equipment should be thoroughly cleaned on a scheduled basis.\n\n13.7 Laboratory equipment and instruments should be suited to the testing procedures undertaken.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las \u00e1reas de control de calidad (QC) y el equipamiento necesario en laboratorios. Se enfatiza la importancia de separar los laboratorios de QC de las \u00e1reas de producci\u00f3n, as\u00ed como la necesidad de un dise\u00f1o adecuado para evitar la contaminaci\u00f3n cruzada y asegurar un ambiente de trabajo seguro y eficiente. Se detallan requisitos espec\u00edficos para el dise\u00f1o de laboratorios, la instalaci\u00f3n de equipos y la limpieza programada, as\u00ed como la importancia de etiquetar adecuadamente las tuber\u00edas y conexiones.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de laboratorios de control de calidad seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca respuestas sobre los aspectos espec\u00edficos del dise\u00f1o de laboratorios que se mencionan en el texto, como la separaci\u00f3n de \u00e1reas, el espacio adecuado y la ventilaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para minimizar el riesgo de contaminaci\u00f3n en el equipamiento de producci\u00f3n y control?**\n   - Aqu\u00ed se busca informaci\u00f3n sobre las pr\u00e1cticas recomendadas para la instalaci\u00f3n y mantenimiento del equipamiento, as\u00ed como la limpieza programada.\n\n3. **\u00bfQu\u00e9 tipo de etiquetado y marcado es necesario para las tuber\u00edas y dispositivos de servicio en un laboratorio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de etiquetado y marcado para garantizar la seguridad y la correcta identificaci\u00f3n de los contenidos en las instalaciones de laboratorio.", "prev_section_summary": "### Temas Clave\n\n1. **Dise\u00f1o de Instalaciones**: La disposici\u00f3n de las instalaciones debe seguir un orden l\u00f3gico que facilite la producci\u00f3n y cumpla con los niveles de limpieza requeridos.\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n**: Se deben tomar medidas para minimizar el riesgo de confusi\u00f3n entre productos farmac\u00e9uticos, evitar la contaminaci\u00f3n cruzada y asegurar la correcta aplicaci\u00f3n de los pasos de fabricaci\u00f3n y control.\n\n3. **Superficies Interiores**: Las superficies donde se manejan materiales expuestos al ambiente deben ser lisas, sin grietas, no desprender part\u00edculas y permitir una limpieza y desinfecci\u00f3n efectivas.\n\n4. **Sistema de Drenaje**: Los desag\u00fces deben ser adecuados para prevenir el retroceso de agua y facilitar la limpieza, evitando canales abiertos siempre que sea posible.\n\n5. **Ventilaci\u00f3n**: Las \u00e1reas de producci\u00f3n deben estar bien ventiladas, con sistemas de control de aire que incluyan filtraci\u00f3n y control de temperatura y humedad, y deben ser monitoreadas regularmente.\n\n6. **Iluminaci\u00f3n**: Las \u00e1reas de producci\u00f3n deben estar bien iluminadas, especialmente donde se realizan controles visuales.\n\n7. **Dise\u00f1o de \u00c1reas de Empaque**: Las instalaciones para el empaque de productos farmac\u00e9uticos deben estar dise\u00f1adas para evitar confusiones y contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Productos cuya fabricaci\u00f3n se regula en el documento.\n- **Materiales de Empaque**: Incluyen materiales de inicio y empaque primario.\n- **Contaminaci\u00f3n Cruzada**: Riesgo que se busca prevenir en las instalaciones.\n- **Instalaciones de Producci\u00f3n**: Espacios donde se lleva a cabo la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Sistemas de Ventilaci\u00f3n y Drenaje**: Elementos cr\u00edticos en el dise\u00f1o de las instalaciones.\n\n### Resumen General\nEl documento de la OMS establece directrices para el dise\u00f1o y operaci\u00f3n de instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la limpieza, la organizaci\u00f3n l\u00f3gica de los espacios, la prevenci\u00f3n de la contaminaci\u00f3n y la adecuada ventilaci\u00f3n. Estas medidas son esenciales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: quality control, laboratory design, contamination prevention, equipment maintenance, air supply"}}, "423eeb76-d73e-4c97-beb6-5990d14068f8": {"node_ids": ["613bca58-f01c-479a-adc4-9a562a3e8cd7"], "metadata": {"page_label": "136", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13.8\n\nWashing, cleaning and drying equipment should be chosen and used so as not to be a source of contamination.\n\n# 13.9\n\nProduction equipment should not present any hazard to the products. The parts of the production equipment that come into contact with the product must not be reactive, additive, or absorptive to an extent that would affect the quality of the product.\n\n# 13.10\n\nDefective equipment should be removed from production and QC areas. If this is not possible, it should be clearly labelled as defective to prevent use.\n\n# 13.11\n\nClosed equipment should be used whenever appropriate. Where open equipment is used or equipment is opened, precautions should be taken to minimize contamination.\n\n# 13.12\n\nNon-dedicated equipment should be cleaned according to validated cleaning procedures between production of different pharmaceutical products to prevent cross-contamination.\n\n# 13.13\n\nCurrent drawings of critical equipment and support systems should be maintained.\n\n# 14. Materials\n\n## 14.1 Principle\n\nThe main objective of a pharmaceutical plant is to produce finished products for patients\u2019 use from a combination of materials (starting and packaging).\n\n## 14.2\n\nMaterials include starting materials, packaging materials, gases, solvents, process aids, reagents and labelling materials.\n\n### General\n\n## 14.3\n\nNo materials used for operations such as cleaning, lubrication of equipment and pest control, should come into direct contact with the product. Where possible, such materials should be of a suitable grade (e.g. food grade) to minimize health risks.\n\n## 14.4\n\nAll incoming materials and finished products should be quarantined immediately after receipt or processing, until they are released for use or distribution.\n\n## 14.5\n\nAll materials and products should be stored under the appropriate conditions established by the manufacturer and in an orderly fashion to permit batch segregation and stock rotation by a first-expire, first-out rule.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece directrices sobre el uso y mantenimiento de equipos en plantas farmac\u00e9uticas, as\u00ed como sobre la gesti\u00f3n de materiales. Se enfatiza la importancia de evitar la contaminaci\u00f3n, asegurar que el equipo no represente un peligro para los productos, y mantener un manejo adecuado de los materiales para garantizar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse con respecto al equipo defectuoso en las \u00e1reas de producci\u00f3n y control de calidad?**\n   - Respuesta: El equipo defectuoso debe ser retirado de las \u00e1reas de producci\u00f3n y control de calidad. Si no es posible retirarlo, debe ser claramente etiquetado como defectuoso para prevenir su uso.\n\n2. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para el almacenamiento de materiales y productos en una planta farmac\u00e9utica?**\n   - Respuesta: Todos los materiales y productos deben ser almacenados bajo las condiciones apropiadas establecidas por el fabricante y de manera ordenada para permitir la segregaci\u00f3n de lotes y la rotaci\u00f3n de stock seg\u00fan la regla de primero en caducar, primero en salir.\n\n3. **\u00bfQu\u00e9 tipo de materiales se deben evitar en contacto directo con los productos farmac\u00e9uticos y por qu\u00e9?**\n   - Respuesta: No se deben utilizar materiales para operaciones como limpieza, lubricaci\u00f3n de equipos y control de plagas que entren en contacto directo con el producto. Estos materiales deben ser de un grado adecuado (por ejemplo, grado alimenticio) para minimizar los riesgos para la salud.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Separaci\u00f3n de Laboratorios de Control de Calidad (QC):**\n   - Los laboratorios de QC deben estar separados de las \u00e1reas de producci\u00f3n.\n   - Se requiere separaci\u00f3n entre \u00e1reas que emplean m\u00e9todos de prueba biol\u00f3gicos, microbiol\u00f3gicos o de radiois\u00f3topos.\n\n2. **Dise\u00f1o de Laboratorios:**\n   - Los laboratorios deben ser dise\u00f1ados para las operaciones espec\u00edficas que se llevar\u00e1n a cabo.\n   - Es necesario proporcionar suficiente espacio para evitar confusiones y contaminaci\u00f3n cruzada.\n   - Debe haber almacenamiento adecuado para muestras, est\u00e1ndares de referencia, solventes, reactivos y registros.\n\n3. **Materiales y Ventilaci\u00f3n:**\n   - Se debe considerar la idoneidad de los materiales de construcci\u00f3n y la prevenci\u00f3n de humos.\n   - Se requiere un suministro de aire separado para laboratorios y \u00e1reas de producci\u00f3n, as\u00ed como unidades de manejo de aire espec\u00edficas para laboratorios biol\u00f3gicos, microbiol\u00f3gicos y de radiois\u00f3topos.\n\n4. **Protecci\u00f3n de Equipos:**\n   - Puede ser necesario un cuarto separado para instrumentos para protegerlos de interferencias el\u00e9ctricas, vibraciones y humedad excesiva.\n\n5. **Equipamiento:**\n   - El equipamiento debe estar ubicado, dise\u00f1ado y mantenido para minimizar errores y permitir una limpieza efectiva.\n   - Las tuber\u00edas fijas deben estar claramente etiquetadas para indicar su contenido y direcci\u00f3n de flujo.\n   - Se deben proporcionar conexiones no intercambiables para gases y l\u00edquidos peligrosos.\n\n6. **Calibraci\u00f3n y Limpieza:**\n   - Se requiere que los equipos de medici\u00f3n est\u00e9n disponibles y calibrados regularmente.\n   - El equipo de producci\u00f3n debe limpiarse de manera programada.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**\n- **Laboratorios de Control de Calidad (QC)**\n- **Equipos de medici\u00f3n (balanzas, instrumentos de laboratorio)**\n- **Materiales de construcci\u00f3n**\n- **Sistemas de ventilaci\u00f3n y manejo de aire**\n- **Sustancias peligrosas (gases y l\u00edquidos)**\n\nEste resumen destaca la importancia de la separaci\u00f3n, el dise\u00f1o adecuado, la limpieza y el etiquetado en los laboratorios de control de calidad, as\u00ed como las pr\u00e1cticas recomendadas para el equipamiento y su mantenimiento.", "excerpt_keywords": "Keywords: contamination, pharmaceutical equipment, materials management, quality control, storage conditions"}}, "9bc7d670-f000-4e31-9722-50542d0f6f50": {"node_ids": ["fd3560fc-e6ef-4fef-b07d-4871ba2e9a1f"], "metadata": {"page_label": "137", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Starting materials\n\n14.6 Water used in the manufacture of pharmaceutical products should be suitable for its intended use.\n\n## Starting materials\n\n14.7 The purchase of starting materials is an important operation that should involve staff who have a particular and thorough knowledge of the products and suppliers.\n\n14.8 Starting materials should be purchased only from approved suppliers and, where possible, directly from the producer. It is also recommended that the specifications established by the manufacturer for the starting materials be discussed with the suppliers. It is of benefit that all critical aspects of the production and control of the starting material in question, including handling, labelling and packaging requirements as well as complaints and rejection procedures, are contractually agreed between the manufacturer and the supplier.\n\n14.9 For each consignment, the containers should be checked for at least integrity of package and seal and for correspondence between the order, the delivery note, and the supplier\u2019s labels.\n\n14.10 All incoming materials should be checked to ensure that the consignment corresponds to the order. Containers should be cleaned where necessary and labelled, if required, with the prescribed information. Where additional labels are attached to containers, the original information should not be lost.\n\n14.11 Damage to containers and any other problem that might adversely affect the quality of a material should be recorded and reported to the QC department and investigated.\n\n14.12 If one delivery of material is made up of different batches, each batch must be considered as separate for sampling, testing and release.\n\n14.13 Starting materials in the storage area should be appropriately labelled. Labels should bear at least the following information:\n\n- (a) the designated name of the product and the internal code reference where applicable;\n- (b) the batch number given by the supplier and, on receipt, the control or batch number given by the manufacturer, if any, documented so as to ensure traceability;\n- (c) the status of the contents (e.g. on quarantine, on test, released, rejected, returned, recalled);\n- (d) where appropriate, an expiry date or a date beyond which retesting is necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la gesti\u00f3n de materiales de partida en la fabricaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la compra, el control de calidad y el etiquetado adecuado. Se enfatiza que el agua utilizada debe ser adecuada para su prop\u00f3sito, que los materiales deben ser adquiridos de proveedores aprobados, y que se deben seguir procedimientos rigurosos para asegurar la integridad y trazabilidad de los materiales. Adem\u00e1s, se menciona la necesidad de registrar cualquier da\u00f1o a los contenedores y de etiquetar adecuadamente los materiales en el \u00e1rea de almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluir una etiqueta en los materiales de partida almacenados?**\n   - Las etiquetas deben incluir el nombre designado del producto, el n\u00famero de lote proporcionado por el proveedor, el n\u00famero de control o lote del fabricante, el estado del contenido y, si es pertinente, una fecha de caducidad o una fecha para rean\u00e1lisis.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si se recibe un lote de material que contiene diferentes lotes?**\n   - Cada lote debe ser considerado como separado para los procesos de muestreo, pruebas y liberaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta da\u00f1o en los contenedores de materiales de partida?**\n   - Cualquier da\u00f1o a los contenedores o problemas que puedan afectar la calidad del material deben ser registrados, reportados al departamento de control de calidad (QC) e investigados.", "prev_section_summary": "### Temas Clave\n\n1. **Equipos de Producci\u00f3n**:\n   - Importancia de elegir y utilizar equipos de lavado, limpieza y secado que no sean fuentes de contaminaci\u00f3n.\n   - Los equipos de producci\u00f3n no deben representar peligros para los productos; las partes en contacto con el producto no deben ser reactivas, aditivas o absorbentes.\n   - El equipo defectuoso debe ser retirado o etiquetado claramente para prevenir su uso.\n   - Se debe utilizar equipo cerrado siempre que sea posible y tomar precauciones con el equipo abierto para minimizar la contaminaci\u00f3n.\n   - El equipo no dedicado debe limpiarse seg\u00fan procedimientos validados para evitar la contaminaci\u00f3n cruzada.\n   - Mantener dibujos actuales de equipos cr\u00edticos y sistemas de soporte.\n\n2. **Gesti\u00f3n de Materiales**:\n   - El objetivo principal de una planta farmac\u00e9utica es producir productos terminados a partir de una combinaci\u00f3n de materiales.\n   - Los materiales incluyen materias primas, materiales de embalaje, gases, solventes, ayudas de proceso, reactivos y materiales de etiquetado.\n   - Los materiales utilizados para limpieza, lubricaci\u00f3n y control de plagas no deben entrar en contacto directo con los productos y deben ser de un grado adecuado para minimizar riesgos de salud.\n   - Todos los materiales y productos deben ser puestos en cuarentena inmediatamente despu\u00e9s de su recepci\u00f3n o procesamiento.\n   - Almacenamiento de materiales y productos debe realizarse bajo condiciones apropiadas y de manera ordenada, siguiendo la regla de primero en caducar, primero en salir.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: WHO - Technical Report Series 961\n- **Secciones**: \n  - Equipos de producci\u00f3n (Secci\u00f3n 13)\n  - Gesti\u00f3n de materiales (Secci\u00f3n 14)\n- **Tipos de Materiales**: \n  - Materiales de inicio\n  - Materiales de embalaje\n  - Gases\n  - Solventes\n  - Ayudas de proceso\n  - Reactivos\n  - Materiales de etiquetado\n\nEste resumen destaca la importancia de la calidad y seguridad en la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de un manejo adecuado de equipos y materiales.", "excerpt_keywords": "Keywords: starting materials, pharmaceutical manufacturing, quality control, supplier approval, labeling requirements"}}, "750969e6-90ce-4315-b235-66f93f22186e": {"node_ids": ["e5ab1182-3a60-4e25-bdfa-111e3c4b58c7"], "metadata": {"page_label": "138", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When fully validated computerized storage systems are used, not all of the above information need be in a legible form on the label.\n\n14.14 There should be appropriate procedures or measures to ensure the identity of the contents of each container of starting material.\n\nBulk containers from which samples have been drawn should be identified.\n\n14.15 Only starting materials released by the QC department and within their shelf-life should be used.\n\n14.16 Starting materials should be dispensed only by designated persons, following a written procedure, to ensure that the correct materials are accurately weighed or measured into clean and properly labelled containers.\n\n14.17 Each dispensed material and its weight or volume should be independently checked and the check recorded.\n\n14.18 Materials dispensed for each batch of the final product should be kept together and conspicuously labelled as such.\n\n# Packaging materials\n\n14.19 The purchase, handling and control of primary and printed packaging materials should be as for starting materials.\n\n14.20 Particular attention should be paid to printed packaging materials. They should be stored in secure conditions so as to exclude the possibility of unauthorized access. Roll feed labels should be used wherever possible. Cut labels and other loose printed materials should be stored and transported in separate closed containers so as to avoid mix-ups. Packaging materials should be issued for use only by designated personnel following an approved and documented procedure.\n\n14.21 Each delivery or batch of printed or primary packaging material should be given a specific reference number or identification mark.\n\n14.22 Outdated or obsolete primary packaging material or printed packaging material should be destroyed and its disposal recorded.\n\n14.23 All products and packaging materials to be used should be checked on delivery to the packaging department for quantity, identity and conformity with the packaging instructions.\n\n# Intermediate and bulk products\n\n14.24 Intermediate and bulk products should be kept under appropriate conditions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el manejo y control de materiales de inicio, materiales de embalaje y productos intermedios y a granel en un entorno de producci\u00f3n. Se enfatiza la importancia de la identificaci\u00f3n, el almacenamiento seguro, la dispensaci\u00f3n controlada y la verificaci\u00f3n de los materiales utilizados en la fabricaci\u00f3n de productos. Se menciona la necesidad de procedimientos escritos y la designaci\u00f3n de personal responsable para garantizar la calidad y la conformidad de los materiales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar la identidad de los contenidos de los contenedores de materiales de inicio?**\n   - Respuesta: Deben implementarse procedimientos o medidas apropiadas para garantizar la identidad de los contenidos de cada contenedor de materiales de inicio, y los contenedores a granel de los cuales se han extra\u00eddo muestras deben estar identificados.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar con respecto a los materiales de embalaje impresos para evitar accesos no autorizados?**\n   - Respuesta: Los materiales de embalaje impresos deben almacenarse en condiciones seguras para excluir la posibilidad de acceso no autorizado. Adem\u00e1s, se deben utilizar etiquetas de alimentaci\u00f3n en rollo siempre que sea posible, y las etiquetas cortadas y otros materiales impresos sueltos deben almacenarse y transportarse en contenedores cerrados separados para evitar confusiones.\n\n3. **\u00bfC\u00f3mo se debe manejar el material de embalaje obsoleto o caducado?**\n   - Respuesta: El material de embalaje primario o impreso que est\u00e9 obsoleto o caducado debe ser destruido, y su disposici\u00f3n debe ser registrada adecuadamente.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otros documentos o contextos, centr\u00e1ndose en los procedimientos y medidas de control mencionados en el texto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Agua en la Fabricaci\u00f3n**: El agua utilizada en la producci\u00f3n de productos farmac\u00e9uticos debe ser adecuada para su uso previsto.\n\n2. **Compra de Materiales de Partida**: \n   - La adquisici\u00f3n de materiales de partida es crucial y debe ser realizada por personal con conocimiento espec\u00edfico de los productos y proveedores.\n   - Los materiales deben ser comprados solo de proveedores aprobados y, preferiblemente, directamente del productor.\n\n3. **Especificaciones y Acuerdos**: \n   - Se recomienda discutir las especificaciones de los materiales con los proveedores y formalizar contractualmente aspectos cr\u00edticos como manejo, etiquetado, requisitos de empaque, y procedimientos de quejas y rechazos.\n\n4. **Control de Calidad en Recepci\u00f3n**: \n   - Se deben verificar los contenedores para asegurar la integridad del paquete y la correspondencia entre el pedido, la nota de entrega y las etiquetas del proveedor.\n   - Todos los materiales entrantes deben ser revisados para confirmar que coinciden con el pedido.\n\n5. **Manejo de Contenedores Da\u00f1ados**: \n   - Cualquier da\u00f1o a los contenedores debe ser registrado, reportado al departamento de control de calidad (QC) e investigado.\n\n6. **Lotes Diferentes**: \n   - Si un env\u00edo incluye diferentes lotes, cada lote debe ser tratado como separado para muestreo, pruebas y liberaci\u00f3n.\n\n7. **Etiquetado de Materiales**: \n   - Los materiales en el \u00e1rea de almacenamiento deben estar etiquetados adecuadamente, incluyendo informaci\u00f3n como el nombre del producto, n\u00famero de lote, estado del contenido y, si es pertinente, fechas de caducidad o rean\u00e1lisis.\n\n### Entidades Clave\n- **Materiales de Partida**: Ingredientes utilizados en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Proveedores**: Entidades que suministran los materiales de partida.\n- **Departamento de Control de Calidad (QC)**: Unidad responsable de la supervisi\u00f3n de la calidad de los materiales y productos.\n- **Lotes**: Grupos de materiales que se manejan y controlan de manera individual en el proceso de producci\u00f3n.", "excerpt_keywords": "Keywords: starting materials, packaging materials, quality control, labeling procedures, inventory management"}}, "5acc770d-4fbf-4092-b743-e63da6b8dbb7": {"node_ids": ["219e52ee-f8c8-44d6-b8b0-8cd189cf367e"], "metadata": {"page_label": "139", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n14.25 Intermediate and bulk products purchased as such should be handled on receipt as though they were starting materials.\n\n## Finished Products\n\n14.26 Finished products should be held in quarantine until their final release, after which they should be stored as usable stock under conditions established by the manufacturer.\n\n14.27 The evaluation of finished products and the documentation necessary for release of a product for sale are described in section 17, \"Good practices in quality control\".\n\n## Rejected, Recovered, Reprocessed and Reworked Materials\n\n14.28 Rejected materials and products should be clearly marked as such and stored separately in restricted areas. They should either be returned to the suppliers or, where appropriate, reprocessed or destroyed in a timely manner. Whatever action is taken should be approved by authorized personnel and recorded.\n\n14.29 The reworking or recovery of rejected products should be exceptional. It is permitted only if the quality of the final product is not affected, if the specifications are met, and if it is done in accordance with a defined and authorized procedure after evaluation of the risks involved. A record should be kept of the reworking or recovery. A reworked batch should be given a new batch number.\n\n14.30 The introduction of all or part of earlier batches, conforming to the required quality, into a batch of the same product at a defined stage of manufacture should be authorized beforehand. This recovery should be carried out in accordance with a defined procedure after evaluation of the risks involved, including any possible effect on shelf-life. The recovery should be recorded.\n\n14.31 The need for additional testing of any finished product that has been reprocessed, reworked or into which a recovered product has been incorporated, should be considered by the QC department.\n\n## Recalled Products\n\n14.32 Recalled products should be identified and stored separately in a secure area until a decision is taken on their fate. The decision should be made as soon as possible.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Manejo de Productos Terminados**: Los productos terminados deben ser mantenidos en cuarentena hasta su liberaci\u00f3n final y almacenados bajo condiciones espec\u00edficas establecidas por el fabricante. La evaluaci\u00f3n y documentaci\u00f3n necesarias para su liberaci\u00f3n se detallan en una secci\u00f3n dedicada a las buenas pr\u00e1cticas en control de calidad.\n\n2. **Gesti\u00f3n de Materiales Rechazados y Recuperados**: Los materiales y productos rechazados deben ser claramente marcados y almacenados en \u00e1reas restringidas. Su reprocesamiento o destrucci\u00f3n debe ser aprobado por personal autorizado. La recuperaci\u00f3n de productos rechazados es excepcional y debe cumplir con criterios espec\u00edficos para asegurar que la calidad del producto final no se vea afectada.\n\n3. **Productos Retirados**: Los productos que han sido retirados del mercado deben ser identificados y almacenados de manera segura hasta que se tome una decisi\u00f3n sobre su destino, la cual debe ser realizada lo m\u00e1s pronto posible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la reintroducci\u00f3n de lotes anteriores en un nuevo lote de producto?**\n   - La introducci\u00f3n de lotes anteriores en un nuevo lote debe ser autorizada previamente y realizada de acuerdo con un procedimiento definido, tras una evaluaci\u00f3n de riesgos que considere el impacto en la vida \u00fatil del producto.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse para que un producto rechazado pueda ser reprocesado o recuperado?**\n   - El reprocesamiento o recuperaci\u00f3n de productos rechazados solo es permitido si la calidad del producto final no se ve afectada, se cumplen las especificaciones y se realiza conforme a un procedimiento autorizado tras una evaluaci\u00f3n de riesgos.\n\n3. **\u00bfCu\u00e1l es el protocolo para el almacenamiento de productos retirados del mercado?**\n   - Los productos retirados deben ser identificados y almacenados en un \u00e1rea segura hasta que se tome una decisi\u00f3n sobre su destino, y esta decisi\u00f3n debe ser realizada lo m\u00e1s pronto posible.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Identificaci\u00f3n de Materiales de Inicio**:\n   - Se deben implementar procedimientos para asegurar la identidad de los contenidos de cada contenedor de materiales de inicio.\n   - Los contenedores a granel de los cuales se han extra\u00eddo muestras deben estar identificados.\n\n2. **Control de Calidad**:\n   - Solo se deben utilizar materiales de inicio que hayan sido liberados por el departamento de Control de Calidad (QC) y que est\u00e9n dentro de su vida \u00fatil.\n\n3. **Dispensaci\u00f3n de Materiales**:\n   - La dispensaci\u00f3n de materiales debe ser realizada \u00fanicamente por personal designado, siguiendo procedimientos escritos para asegurar la precisi\u00f3n en el pesaje o medici\u00f3n en contenedores limpios y debidamente etiquetados.\n   - Cada material dispensado y su peso o volumen deben ser verificados de manera independiente y registrados.\n\n4. **Manejo de Materiales de Embalaje**:\n   - La compra, manejo y control de materiales de embalaje primarios e impresos deben seguir procedimientos similares a los de los materiales de inicio.\n   - Los materiales de embalaje impresos deben ser almacenados en condiciones seguras para prevenir accesos no autorizados, utilizando etiquetas de alimentaci\u00f3n en rollo siempre que sea posible.\n\n5. **Control de Materiales Obsoletos**:\n   - Los materiales de embalaje primario o impreso que est\u00e9n obsoletos o caducados deben ser destruidos y su disposici\u00f3n registrada.\n\n6. **Verificaci\u00f3n de Productos y Materiales**:\n   - Todos los productos y materiales de embalaje deben ser verificados al momento de la entrega al departamento de embalaje para asegurar cantidad, identidad y conformidad con las instrucciones de embalaje.\n\n7. **Condiciones de Almacenamiento**:\n   - Los productos intermedios y a granel deben ser mantenidos bajo condiciones apropiadas.\n\n### Entidades Clave\n- **Materiales de Inicio**: Materias primas utilizadas en la producci\u00f3n.\n- **Control de Calidad (QC)**: Departamento responsable de la verificaci\u00f3n de la calidad de los materiales.\n- **Materiales de Embalaje**: Incluye materiales primarios e impresos utilizados para el empaquetado de productos.\n- **Personal Designado**: Empleados autorizados para manejar y dispensar materiales.\n- **Procedimientos Escritos**: Documentaci\u00f3n que gu\u00eda las pr\u00e1cticas de manejo y control de materiales. \n\nEste resumen destaca la importancia de los procedimientos de control y la seguridad en el manejo de materiales en un entorno de producci\u00f3n, asegurando la calidad y la conformidad de los productos finales.", "excerpt_keywords": "Keywords: Finished Products, Quality Control, Rejected Materials, Reprocessing, Recalled Products"}}, "a2d829f2-8188-4b0c-8a61-d916556c8a2e": {"node_ids": ["dc795fc0-17d2-47bf-ae5c-1c6ff48c6963"], "metadata": {"page_label": "140", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Returned goods\n\n14.33 Products returned from the market should be destroyed unless it is certain that their quality is satisfactory; in such cases they may be considered for resale or relabelling, or alternative action taken only after they have been critically assessed by the QC function in accordance with a written procedure. The nature of the product, any special storage conditions it requires, its condition and history, and the time elapsed since it was issued should all be taken into account in this assessment. Where any doubt arises over the quality of the product, it should not be considered suitable for reissue or reuse.\n\nAny action taken should be appropriately recorded.\n\n# Reagents and culture media\n\n14.34 There should be records for the receipt and preparation of reagents and culture media.\n\n14.35 Reagents made up in the laboratory should be prepared according to written procedures and appropriately labelled. The label should indicate the concentration, standardization factor, shelf-life, the date when restandardization is due, and the storage conditions. The label should be signed and dated by the person preparing the reagent.\n\n14.36 Both positive and negative controls should be applied to verify the suitability of culture media each time they are prepared and used. The size of the inoculum used in positive controls should be appropriate to the sensitivity required.\n\n# Reference standards\n\n14.37 Whenever official reference standards exist, these should preferably be used.\n\n14.38 Official reference standards should be used only for the purpose described in the appropriate monograph.\n\n14.39 Reference standards prepared by the producer should be tested, released and stored in the same way as official standards. They should be kept under the responsibility of a designated person in a secure area.\n\n14.40 Secondary or working standards may be established by the application of appropriate tests and checks at regular intervals to ensure standardization.\n\n14.41 Reference standards should be properly labelled with at least the following information:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda procedimientos relacionados con la gesti\u00f3n de productos devueltos, reactivos y medios de cultivo, as\u00ed como est\u00e1ndares de referencia. Se establece que los productos devueltos deben ser destruidos a menos que se confirme su calidad, y se deben seguir procedimientos escritos para su evaluaci\u00f3n. Adem\u00e1s, se requiere un registro detallado de la recepci\u00f3n y preparaci\u00f3n de reactivos, que deben estar etiquetados adecuadamente. Se enfatiza la importancia de utilizar est\u00e1ndares de referencia oficiales y de mantener un control riguroso sobre los est\u00e1ndares preparados por el productor.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar al evaluar la calidad de un producto devuelto antes de decidir su reventa o reutilizaci\u00f3n?**\n   - La evaluaci\u00f3n debe considerar la naturaleza del producto, las condiciones especiales de almacenamiento requeridas, su estado y historial, y el tiempo transcurrido desde su emisi\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluir la etiqueta de un reactivo preparado en el laboratorio?**\n   - La etiqueta debe indicar la concentraci\u00f3n, el factor de estandarizaci\u00f3n, la vida \u00fatil, la fecha en que se debe reestandarizar y las condiciones de almacenamiento, adem\u00e1s de estar firmada y fechada por la persona que lo prepar\u00f3.\n\n3. **\u00bfC\u00f3mo se deben manejar los est\u00e1ndares de referencia preparados por el productor en comparaci\u00f3n con los est\u00e1ndares oficiales?**\n   - Los est\u00e1ndares de referencia preparados por el productor deben ser probados, liberados y almacenados de la misma manera que los est\u00e1ndares oficiales, y deben estar bajo la responsabilidad de una persona designada en un \u00e1rea segura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Terminados**:\n   - Los productos terminados deben ser mantenidos en cuarentena hasta su liberaci\u00f3n final.\n   - Deben ser almacenados bajo condiciones espec\u00edficas establecidas por el fabricante.\n   - La evaluaci\u00f3n y documentaci\u00f3n para la liberaci\u00f3n se detalla en la secci\u00f3n sobre buenas pr\u00e1cticas en control de calidad.\n\n2. **Gesti\u00f3n de Materiales Rechazados**:\n   - Los materiales y productos rechazados deben ser claramente marcados y almacenados en \u00e1reas restringidas.\n   - Deben ser devueltos a los proveedores o reprocesados/destruidos de manera oportuna, con aprobaci\u00f3n y registro por parte de personal autorizado.\n   - La recuperaci\u00f3n de productos rechazados es excepcional y debe cumplir con criterios espec\u00edficos para asegurar la calidad del producto final.\n\n3. **Reintroducci\u00f3n de Lotes Anteriores**:\n   - La introducci\u00f3n de lotes anteriores en un nuevo lote debe ser autorizada y realizada conforme a un procedimiento definido, tras una evaluaci\u00f3n de riesgos.\n\n4. **Productos Retirados**:\n   - Los productos retirados del mercado deben ser identificados y almacenados en un \u00e1rea segura hasta que se tome una decisi\u00f3n sobre su destino, la cual debe ser realizada lo m\u00e1s pronto posible.\n\n### Entidades Clave\n- **Productos Terminados**: Productos que han completado su proceso de fabricaci\u00f3n.\n- **Materiales Rechazados**: Productos o materiales que no cumplen con los est\u00e1ndares de calidad.\n- **Reprocesamiento**: Proceso de volver a trabajar productos rechazados.\n- **Productos Retirados**: Productos que han sido retirados del mercado por razones de seguridad o calidad.\n- **Personal Autorizado**: Individuos con la autoridad para aprobar acciones relacionadas con la gesti\u00f3n de productos y materiales. \n\nEste resumen abarca los procedimientos y regulaciones clave para el manejo de productos terminados, materiales rechazados y productos retirados, enfatizando la importancia de la calidad y la documentaci\u00f3n en el proceso.", "excerpt_keywords": "Keywords: returned goods, quality assessment, reagents, reference standards, laboratory procedures"}}, "fbe8be77-2b56-4196-8191-929433d9773e": {"node_ids": ["63956f82-650d-45d4-8c49-2a474d1aa82c"], "metadata": {"page_label": "141", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) name of the material;  \n(b) batch or lot number and control number;  \n(c) date of preparation;  \n(d) shelf-life;  \n(e) potency;  \n(f) storage conditions.\n\n14.42 All in-house reference standards should be standardized against an official reference standard, when available, initially and at regular intervals thereafter.\n\n14.43 All reference standards should be stored and used in a manner that will not adversely affect their quality.\n\n### Waste materials\n\n14.44 Provision should be made for the proper and safe storage of waste materials awaiting disposal. Toxic substances and flammable materials should be stored in suitably designed, separate, enclosed cupboards, as required by national legislation.\n\n14.45 Waste material should not be allowed to accumulate. It should be collected in suitable receptacles for removal to collection points outside the buildings and disposed of safely and in a sanitary manner at regular and frequent intervals.\n\n### Miscellaneous\n\n14.46 Rodenticides, insecticides, fumigating agents and sanitizing materials should not be permitted to contaminate equipment, starting materials, packaging materials, in-process materials or finished products.\n\n## 15. Documentation\n\n15.1 **Principle.** Good documentation is an essential part of the quality assurance system and, as such, should exist for all aspects of GMP. Its aims are to define the specifications and procedures for all materials and methods of manufacture and control; to ensure that all personnel concerned with manufacture know what to do and when to do it; to ensure that authorized persons have all the information necessary to decide whether or not to release a batch of a medicine for sale, to ensure the existence of documented evidence, traceability, and to provide records and an audit trail that will permit investigation. It ensures the availability of the data needed for validation, review and statistical analysis. The design and use of documents depend upon the manufacturer. In some cases some or all of the documents described below may be brought together, but they will usually be separate.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre la gesti\u00f3n de est\u00e1ndares de referencia, el manejo de materiales de desecho y la importancia de la documentaci\u00f3n en el contexto de las Buenas Pr\u00e1cticas de Manufactura (GMP). Se enfatiza la necesidad de estandarizar los est\u00e1ndares de referencia, almacenar adecuadamente los materiales de desecho y mantener una documentaci\u00f3n rigurosa para asegurar la calidad y la trazabilidad en la producci\u00f3n de medicamentos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para el almacenamiento de est\u00e1ndares de referencia in-house seg\u00fan las directrices de la OMS?**\n   - Respuesta: Todos los est\u00e1ndares de referencia in-house deben ser estandarizados contra un est\u00e1ndar de referencia oficial, cuando est\u00e9 disponible, inicialmente y a intervalos regulares. Adem\u00e1s, deben ser almacenados y utilizados de manera que no afecten negativamente su calidad.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para el manejo de materiales de desecho que contienen sustancias t\u00f3xicas o inflamables?**\n   - Respuesta: Se debe proporcionar un almacenamiento adecuado y seguro para los materiales de desecho, asegurando que las sustancias t\u00f3xicas y los materiales inflamables se guarden en armarios separados y dise\u00f1ados espec\u00edficamente, de acuerdo con la legislaci\u00f3n nacional.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito principal de la documentaci\u00f3n en el sistema de aseguramiento de calidad seg\u00fan las directrices de la OMS?**\n   - Respuesta: El prop\u00f3sito principal de la documentaci\u00f3n es definir las especificaciones y procedimientos para todos los materiales y m\u00e9todos de fabricaci\u00f3n y control, asegurando que el personal sepa qu\u00e9 hacer y cu\u00e1ndo, y proporcionando la informaci\u00f3n necesaria para decidir sobre la liberaci\u00f3n de lotes de medicamentos, as\u00ed como para garantizar la existencia de evidencia documentada y trazabilidad.", "prev_section_summary": "### Temas Clave\n\n1. **Productos Devueltos**:\n   - Los productos devueltos deben ser destruidos a menos que se confirme su calidad.\n   - La evaluaci\u00f3n de la calidad debe considerar la naturaleza del producto, condiciones de almacenamiento, estado, historial y tiempo desde su emisi\u00f3n.\n   - Cualquier acci\u00f3n tomada debe ser registrada adecuadamente.\n\n2. **Reactivos y Medios de Cultivo**:\n   - Se deben mantener registros de recepci\u00f3n y preparaci\u00f3n de reactivos y medios de cultivo.\n   - Los reactivos deben ser preparados seg\u00fan procedimientos escritos y etiquetados con informaci\u00f3n espec\u00edfica (concentraci\u00f3n, factor de estandarizaci\u00f3n, vida \u00fatil, fecha de reestandarizaci\u00f3n y condiciones de almacenamiento).\n   - Se deben aplicar controles positivos y negativos para verificar la idoneidad de los medios de cultivo.\n\n3. **Est\u00e1ndares de Referencia**:\n   - Se deben utilizar est\u00e1ndares de referencia oficiales siempre que existan.\n   - Los est\u00e1ndares de referencia preparados por el productor deben ser probados y almacenados de manera similar a los est\u00e1ndares oficiales, bajo la responsabilidad de una persona designada.\n   - Se pueden establecer est\u00e1ndares secundarios o de trabajo mediante pruebas y controles regulares.\n   - Los est\u00e1ndares de referencia deben estar etiquetados con informaci\u00f3n relevante.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos**: Elementos devueltos del mercado que requieren evaluaci\u00f3n de calidad.\n- **Reactivos**: Sustancias qu\u00edmicas preparadas en el laboratorio que deben ser etiquetadas y registradas.\n- **Medios de Cultivo**: Sustancias utilizadas para cultivar microorganismos, que requieren controles de calidad.\n- **Est\u00e1ndares de Referencia**: Normas oficiales y preparadas por el productor que garantizan la calidad y consistencia de los productos.", "excerpt_keywords": "Keywords: est\u00e1ndares de referencia, gesti\u00f3n de desechos, documentaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura, calidad y trazabilidad"}}, "39661e39-ffb1-4b39-93dd-9ab9ccb2448b": {"node_ids": ["398848c8-ac16-4cb6-9a9f-55051b4791e5"], "metadata": {"page_label": "142", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# General\n\n15.2 Documents should be designed, prepared, reviewed and distributed with care. They should comply with the relevant parts of the manufacturing and marketing authorizations.\n\n15.3 Documents should be approved, signed and dated by the appropriate responsible persons. No document should be changed without authorization and approval.\n\n15.4 Documents should have unambiguous contents: the title, nature and purpose should be clearly stated. They should be laid out in an orderly fashion and be easy to check. Reproduced documents should be clear and legible. The reproduction of working documents from master documents must not allow any error to be introduced through the reproduction process.\n\n15.5 Documents should be regularly reviewed and kept up to date. When a document has been revised, a system should exist to prevent inadvertent use of the superseded version. Superseded documents should be retained for a specific period of time.\n\n15.6 Where documents require the entry of data, these entries should be clear, legible and indelible. Sufficient space should be provided for such entries.\n\n15.7 Any alteration made to a document should be signed and dated; the alteration should permit the reading of the original information. Where appropriate, the reason for the alteration should be recorded.\n\n15.8 Records should be made or completed when any action is taken and in such a way that all significant activities concerning the manufacture of pharmaceutical products are traceable. Records should be retained for at least one year after the expiry date of the finished product.\n\n15.9 Data (and records for storage) may be recorded by electronic data-processing systems or by photographic or other reliable means. Master formulae and detailed standard operating procedures (SOPs) relating to the system in use should be available and the accuracy of the records should be checked. If documentation is handled by electronic data-processing methods, only authorized persons should be able to enter or modify data in the computer, and there should be a record of changes and deletions; access should be restricted by passwords or other means and the entry of critical data should be independently checked. Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper print-outs or other means. It is particularly important that, during the period of retention, the data are readily available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre la gesti\u00f3n de documentos en el \u00e1mbito de la fabricaci\u00f3n y comercializaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de dise\u00f1ar, revisar y distribuir documentos con cuidado, asegurando que sean claros, legibles y actualizados. Tambi\u00e9n se establece la necesidad de que los documentos sean aprobados por personas responsables y que cualquier alteraci\u00f3n sea debidamente registrada. Adem\u00e1s, se menciona la importancia de mantener registros precisos y accesibles, ya sea en formato f\u00edsico o electr\u00f3nico, y de garantizar la trazabilidad de las actividades significativas relacionadas con la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los documentos no sean utilizados inadvertidamente despu\u00e9s de ser revisados?**\n   - El contexto menciona que debe existir un sistema para prevenir el uso inadvertido de versiones supersedidas de documentos, y que estos deben ser retenidos por un per\u00edodo espec\u00edfico.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la integridad de los datos registrados electr\u00f3nicamente?**\n   - Se indica que solo personas autorizadas deben poder ingresar o modificar datos en sistemas electr\u00f3nicos, y que debe haber un registro de cambios y eliminaciones. Adem\u00e1s, el acceso debe estar restringido por contrase\u00f1as y la entrada de datos cr\u00edticos debe ser verificada de manera independiente.\n\n3. **\u00bfCu\u00e1l es el tiempo m\u00ednimo que se deben conservar los registros relacionados con la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Los registros deben ser retenidos por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto terminado, asegurando as\u00ed la trazabilidad de las actividades significativas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Est\u00e1ndares de Referencia:**\n   - **Estandarizaci\u00f3n:** Los est\u00e1ndares de referencia in-house deben ser estandarizados contra un est\u00e1ndar oficial disponible, tanto al inicio como en intervalos regulares.\n   - **Almacenamiento:** Deben ser almacenados y utilizados de manera que no se comprometa su calidad.\n\n2. **Manejo de Materiales de Desecho:**\n   - **Almacenamiento Seguro:** Se debe garantizar un almacenamiento adecuado y seguro para los materiales de desecho, especialmente aquellos que contienen sustancias t\u00f3xicas o inflamables, en armarios dise\u00f1ados espec\u00edficamente.\n   - **Eliminaci\u00f3n:** Los materiales de desecho no deben acumularse y deben ser recolectados y eliminados de manera segura y sanitaria de forma regular.\n\n3. **Contaminaci\u00f3n:**\n   - **Prohibici\u00f3n de Contaminantes:** Se proh\u00edbe que rodenticidas, insecticidas, agentes de fumigaci\u00f3n y materiales de saneamiento contaminen equipos, materiales de inicio, materiales de envasado, materiales en proceso o productos terminados.\n\n4. **Documentaci\u00f3n:**\n   - **Importancia:** La documentaci\u00f3n es esencial para el sistema de aseguramiento de calidad y debe existir para todos los aspectos de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n   - **Objetivos:** Definir especificaciones y procedimientos, asegurar que el personal sepa qu\u00e9 hacer y cu\u00e1ndo, proporcionar informaci\u00f3n para la liberaci\u00f3n de lotes de medicamentos, y garantizar la existencia de evidencia documentada y trazabilidad.\n   - **Dise\u00f1o y Uso:** La forma y uso de los documentos dependen del fabricante, y aunque algunos documentos pueden combinarse, generalmente son separados.\n\n### Entidades Clave:\n- **Materiales:** Est\u00e1ndares de referencia, materiales de desecho.\n- **Sustancias:** T\u00f3xicas, inflamables, rodenticidas, insecticidas, agentes de fumigaci\u00f3n.\n- **Documentaci\u00f3n:** Especificaciones, procedimientos, registros, auditor\u00edas.\n- **Normativas:** Buenas Pr\u00e1cticas de Manufactura (GMP), legislaci\u00f3n nacional.", "excerpt_keywords": "Keywords: documentos, fabricaci\u00f3n, registros, autorizaci\u00f3n, trazabilidad"}}, "2209a194-ed92-47a6-acac-2f1b58e3757b": {"node_ids": ["64f99230-4c11-4200-83a5-57ec1aa8b6b5"], "metadata": {"page_label": "143", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documents required\n\n## Labels\n\n15.10 Labels applied to containers, equipment or premises should be clear, unambiguous and in the company\u2019s agreed format. It is often helpful in addition to the wording on the labels to use colours to indicate status (e.g. quarantined, accepted, rejected, clean).\n\n15.11 All finished medicines products should be identified by labelling, as required by the national legislation, bearing at least the following information:\n\n- (a) the name of the medicines product;\n- (b) a list of the active ingredients (if applicable, with the INNs), showing the amount of each present and a statement of the net contents (e.g. number of dosage units, weight, volume);\n- (c) the batch number assigned by the manufacturer;\n- (d) the expiry date in an uncoded form;\n- (e) any special storage conditions or handling precautions that may be necessary;\n- (f) directions for use, and warnings and precautions that may be necessary;\n- (g) the name and address of the manufacturer or the company or the person responsible for placing the product on the market.\n\n15.12 For reference standards, the label and/or accompanying document should indicate potency or concentration, date of manufacture, expiry date, date the closure is first opened, storage conditions and control number, as appropriate.\n\n## Specifications and testing procedures\n\n15.13 Testing procedures described in documents should be validated in the context of available facilities and equipment before they are adopted for routine testing.\n\n15.14 There should be appropriately authorized and dated specifications, including tests on identity, content, purity and quality, for starting and packaging materials and for finished products; where appropriate, they should also be available for intermediate or bulk products. Specifications for water, solvents and reagents (e.g. acids and bases) used in production should be included.\n\n15.15 Each specification should be approved, signed and dated, and maintained by the QC, QA units or documentation centre. Specifications for starting materials, intermediates, and bulk, finished products and packaging materials are referred to in sections 15.18\u201315.21.\n\n15.16 Periodic revisions of the specifications may be necessary to comply with new editions of the national pharmacopoeia or other official compendia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para el etiquetado de productos farmac\u00e9uticos y las especificaciones y procedimientos de prueba necesarios para garantizar la calidad y seguridad de los medicamentos. Se enfatiza la importancia de que las etiquetas sean claras y contengan informaci\u00f3n esencial como el nombre del producto, ingredientes activos, n\u00famero de lote, fecha de caducidad, condiciones de almacenamiento, y m\u00e1s. Adem\u00e1s, se menciona que los procedimientos de prueba deben ser validados y que las especificaciones deben ser autorizadas y mantenidas adecuadamente.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluirse en la etiqueta de un producto farmac\u00e9utico seg\u00fan la legislaci\u00f3n nacional?**\n   - La etiqueta debe incluir el nombre del producto, una lista de ingredientes activos, el n\u00famero de lote, la fecha de caducidad, condiciones de almacenamiento, instrucciones de uso, y la informaci\u00f3n del fabricante.\n\n2. **\u00bfQu\u00e9 se debe indicar en la etiqueta de los est\u00e1ndares de referencia?**\n   - La etiqueta debe indicar la potencia o concentraci\u00f3n, la fecha de fabricaci\u00f3n, la fecha de caducidad, la fecha en que se abri\u00f3 por primera vez, las condiciones de almacenamiento y el n\u00famero de control, seg\u00fan sea apropiado.\n\n3. **\u00bfCu\u00e1l es el proceso para la aprobaci\u00f3n y mantenimiento de las especificaciones de los productos farmac\u00e9uticos?**\n   - Cada especificaci\u00f3n debe ser aprobada, firmada y fechada, y mantenida por las unidades de Control de Calidad (QC), Aseguramiento de Calidad (QA) o el centro de documentaci\u00f3n. Adem\u00e1s, las especificaciones deben ser revisadas peri\u00f3dicamente para cumplir con las nuevas ediciones de la farmacopea nacional u otros compendios oficiales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Documentos**:\n   - Importancia de dise\u00f1ar, preparar, revisar y distribuir documentos con cuidado.\n   - Cumplimiento de las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n.\n\n2. **Aprobaci\u00f3n y Autorizaci\u00f3n**:\n   - Documentos deben ser aprobados, firmados y fechados por personas responsables.\n   - Cambios en documentos requieren autorizaci\u00f3n y aprobaci\u00f3n.\n\n3. **Claridad y Legibilidad**:\n   - Contenido de documentos debe ser claro y sin ambig\u00fcedades.\n   - Documentos reproducidos deben ser legibles y sin errores de reproducci\u00f3n.\n\n4. **Revisi\u00f3n y Actualizaci\u00f3n**:\n   - Documentos deben ser revisados regularmente y mantenerse actualizados.\n   - Sistema para prevenir el uso inadvertido de versiones supersedidas.\n\n5. **Registro de Datos**:\n   - Entradas de datos deben ser claras, legibles e indelebles.\n   - Espacio suficiente debe ser proporcionado para las entradas.\n\n6. **Alteraciones de Documentos**:\n   - Cualquier alteraci\u00f3n debe ser firmada y fechada, permitiendo la lectura de la informaci\u00f3n original.\n   - Registro de la raz\u00f3n de la alteraci\u00f3n cuando sea apropiado.\n\n7. **Trazabilidad de Registros**:\n   - Registros deben ser completados para todas las acciones significativas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n   - Retenci\u00f3n de registros por al menos un a\u00f1o despu\u00e9s de la fecha de caducidad del producto.\n\n8. **Manejo Electr\u00f3nico de Datos**:\n   - Uso de sistemas electr\u00f3nicos para registrar datos, con acceso restringido a personas autorizadas.\n   - Registro de cambios y eliminaciones, con verificaci\u00f3n independiente de datos cr\u00edticos.\n   - Protecci\u00f3n de registros electr\u00f3nicos mediante copias de seguridad.\n\n### Entidades Clave\n- **Documentos**: Incluyen formularios, registros y procedimientos operativos est\u00e1ndar (SOPs).\n- **Personas Responsables**: Aquellos que aprueban y firman documentos.\n- **Datos**: Informaci\u00f3n registrada en documentos, ya sea en formato f\u00edsico o electr\u00f3nico.\n- **Registros**: Documentaci\u00f3n de actividades significativas en la fabricaci\u00f3n de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de documentos y registros en el contexto de la fabricaci\u00f3n y comercializaci\u00f3n de productos farmac\u00e9uticos, enfatizando la claridad, la trazabilidad y la seguridad de los datos.", "excerpt_keywords": "Keywords: labeling, specifications, quality control, pharmaceuticals, testing procedures"}}, "19830688-c984-47d5-9222-4f1acc29a4d0": {"node_ids": ["a13168f9-79d8-4a7c-8eae-70ab564d4a2b"], "metadata": {"page_label": "144", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Specifications for Starting and Packaging Materials\n\n15.17 Pharmacopoeias, reference standards, reference spectra and other reference materials should be available in the QC laboratory.\n\n## Specifications for Starting and Packaging Materials\n\n15.18 Specifications for starting, primary and printed packaging materials should provide, if applicable, a description of the materials, including:\n\n- (a) the designated name (if applicable, the INN) and internal code reference;\n- (b) the reference, if any, to a pharmacopoeial monograph;\n- (c) qualitative and quantitative requirements with acceptance limits.\n\nDepending on the company\u2019s practice other data may be added to the specification, such as:\n\n- (a) the supplier and the original producer of the materials;\n- (b) a specimen of printed materials;\n- (c) directions for sampling and testing, or a reference to procedures;\n- (d) storage conditions and precautions;\n- (e) the maximum period of storage before re-examination.\n\nPackaging material should conform to specifications, and should be compatible with the material and/or with the medicines product it contains.\n\nThe material should be examined for compliance with the specification, and for defects as well as for the correctness of identity markings.\n\n15.19 Documents describing testing procedures should state the required frequency for re-assaying each starting material, as determined by its stability.\n\n## Specifications for Intermediate and Bulk Products\n\n15.20 Specifications for intermediate and bulk products should be available. The specifications should be similar to specifications for starting materials or for finished products, as appropriate.\n\n## Specifications for Finished Products\n\n15.21 Specifications for finished products should include:\n\n- (a) the designated name of the product and the code reference, where applicable;\n- (b) the designated name(s) of the active ingredient(s) (if applicable, with the INN(s));\n- (c) the formula or a reference to the formula;\n- (d) a description of the dosage form and package details;\n- (e) directions for sampling and testing or a reference to procedures;\n- (f) the qualitative and quantitative requirements, with acceptance limits;\n- (g) the storage conditions and precautions, where applicable;\n- (h) the shelf-life.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de materiales de referencia deben estar disponibles en el laboratorio de control de calidad (QC)?**\n   - En el laboratorio de control de calidad (QC) deben estar disponibles farmacopoeias, est\u00e1ndares de referencia, espectros de referencia y otros materiales de referencia.\n\n2. **\u00bfCu\u00e1les son algunos de los datos adicionales que pueden incluirse en las especificaciones de los materiales de embalaje, seg\u00fan las pr\u00e1cticas de la empresa?**\n   - Adem\u00e1s de la descripci\u00f3n de los materiales, las especificaciones pueden incluir: (a) el proveedor y el productor original de los materiales; (b) una muestra de los materiales impresos; (c) direcciones para el muestreo y pruebas, o una referencia a los procedimientos; (d) condiciones de almacenamiento y precauciones; y (e) el per\u00edodo m\u00e1ximo de almacenamiento antes de la re-examinaci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las especificaciones de los productos terminados?**\n   - Las especificaciones de los productos terminados deben incluir: (a) el nombre designado del producto y la referencia del c\u00f3digo, si corresponde; (b) el nombre(s) de los ingredientes activos (si corresponde, con el INN(s)); (c) la f\u00f3rmula o una referencia a la f\u00f3rmula; (d) una descripci\u00f3n de la forma de dosificaci\u00f3n y detalles del paquete; (e) direcciones para el muestreo y pruebas o una referencia a los procedimientos; (f) los requisitos cualitativos y cuantitativos, con l\u00edmites de aceptaci\u00f3n; (g) las condiciones de almacenamiento y precauciones, si corresponde; y (h) la vida \u00fatil.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona especificaciones detalladas para los materiales de inicio, intermedios, a granel y productos terminados en el contexto de la fabricaci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de tener materiales de referencia en el laboratorio de control de calidad y se describen los requisitos que deben cumplirse para asegurar la calidad y la conformidad de los materiales y productos. Las especificaciones incluyen detalles sobre la identificaci\u00f3n, pruebas, almacenamiento y vida \u00fatil de los productos, as\u00ed como la documentaci\u00f3n necesaria para los procedimientos de prueba.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n#### Temas clave:\n1. **Etiquetado de productos farmac\u00e9uticos**:\n   - Importancia de etiquetas claras y sin ambig\u00fcedades.\n   - Uso de colores para indicar el estado de los productos (cuarentena, aceptado, rechazado, limpio).\n   - Informaci\u00f3n m\u00ednima requerida en las etiquetas seg\u00fan la legislaci\u00f3n nacional, que incluye:\n     - Nombre del producto.\n     - Lista de ingredientes activos y cantidades.\n     - N\u00famero de lote.\n     - Fecha de caducidad.\n     - Condiciones de almacenamiento y precauciones.\n     - Instrucciones de uso y advertencias.\n     - Informaci\u00f3n del fabricante.\n\n2. **Est\u00e1ndares de referencia**:\n   - Etiquetas deben incluir potencia o concentraci\u00f3n, fechas relevantes (fabricaci\u00f3n, caducidad, apertura), condiciones de almacenamiento y n\u00famero de control.\n\n3. **Especificaciones y procedimientos de prueba**:\n   - Validaci\u00f3n de procedimientos de prueba antes de su adopci\u00f3n.\n   - Especificaciones autorizadas y fechadas para materiales de inicio, intermedios, productos terminados y materiales de embalaje.\n   - Mantenimiento y revisi\u00f3n peri\u00f3dica de especificaciones para cumplir con actualizaciones de farmacopeas nacionales u otros compendios oficiales.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Control de Calidad (QC)**: Unidad responsable de la aprobaci\u00f3n y mantenimiento de especificaciones.\n- **Aseguramiento de Calidad (QA)**: Unidad que tambi\u00e9n participa en la gesti\u00f3n de especificaciones.\n- **Productos farmac\u00e9uticos**: Objetos de las regulaciones y requisitos de etiquetado y especificaciones.\n- **Legislaci\u00f3n nacional**: Marco legal que establece los requisitos de etiquetado y especificaciones.", "excerpt_keywords": "Keywords: specifications, quality control, pharmacopoeias, packaging materials, finished products"}}, "7ee095bb-b29a-4577-9a56-522eade188df": {"node_ids": ["0ffffb41-24dd-474a-bd4e-75371b2690fb"], "metadata": {"page_label": "145", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Master formulae\n\n15.22 A formally authorized master formula should exist for each product and batch size to be manufactured.\n\n15.23 The master formula should include:\n\n(a) the name of the product, with a product reference code relating to its specification;\n\n(b) a description of the dosage form, strength of the product and batch size;\n\n(c) a list of all starting materials to be used (if applicable, with the INNs), with the amount of each, described using the designated name and a reference that is unique to that material (mention should be made of any substance that may disappear in the course of processing);\n\n(d) a statement of the expected final yield with the acceptable limits, and of relevant intermediate yields, where applicable;\n\n(e) a statement of the processing location and the principal equipment to be used;\n\n(f) the methods, or reference to the methods, to be used for preparing and operating the critical equipment, e.g. cleaning (especially after a change in product), assembling, calibrating, sterilizing, use;\n\n(g) detailed step-wise processing instructions (e.g. checks on materials, pretreatments, sequence for adding materials, mixing times, temperatures);\n\n(h) the instructions for any in-process controls with their limits;\n\n(i) where necessary, the requirements for storage of the products, including the container, the labelling, and any special storage conditions;\n\n(j) any special precautions to be observed.\n\n# Packaging instructions\n\n15.24 Formally authorized packaging instructions should exist for each product, pack size and type. These should normally include, or make reference to:\n\n(a) the name of the product;\n\n(b) a description of its pharmaceutical form, strength and, where applicable, method of application;\n\n(c) the pack size expressed in terms of the number, weight or volume of the product in the final container;\n\n(d) a complete list of all the packaging materials required for a standard batch size, including quantities, sizes and types, with the code or reference number relating to the specifications for each packaging material;\n\n(e) where appropriate, an example or reproduction of the relevant printed packaging materials and specimens, indicating where the batch number and expiry date of the product have been marked;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con res\u00famenes de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre la elaboraci\u00f3n de f\u00f3rmulas maestras y las instrucciones de empaque para productos farmac\u00e9uticos. Se enfatiza la importancia de tener una f\u00f3rmula maestra autorizada para cada producto y tama\u00f1o de lote, que incluya detalles sobre los ingredientes, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento. Asimismo, se requiere que existan instrucciones de empaque formalmente autorizadas que detallen los materiales y el etiquetado necesarios.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la f\u00f3rmula maestra de un producto farmac\u00e9utico seg\u00fan las directrices de la OMS?**\n   - La f\u00f3rmula maestra debe incluir el nombre del producto, una descripci\u00f3n de la forma de dosificaci\u00f3n, la lista de materiales iniciales, el rendimiento final esperado, la ubicaci\u00f3n del procesamiento, los m\u00e9todos de operaci\u00f3n del equipo cr\u00edtico, instrucciones de procesamiento detalladas, controles en proceso, requisitos de almacenamiento y precauciones especiales.\n\n2. **\u00bfCu\u00e1les son los elementos esenciales que deben estar presentes en las instrucciones de empaque para un producto farmac\u00e9utico?**\n   - Las instrucciones de empaque deben incluir el nombre del producto, una descripci\u00f3n de su forma farmac\u00e9utica y m\u00e9todo de aplicaci\u00f3n, el tama\u00f1o del paquete, una lista completa de los materiales de empaque requeridos y, si es necesario, ejemplos de los materiales impresos que indiquen el n\u00famero de lote y la fecha de caducidad.\n\n3. **\u00bfPor qu\u00e9 es importante mencionar cualquier sustancia que pueda desaparecer durante el procesamiento en la f\u00f3rmula maestra?**\n   - Es crucial mencionar estas sustancias para asegurar que se tenga en cuenta su posible p\u00e9rdida durante el proceso de fabricaci\u00f3n, lo que puede afectar el rendimiento final del producto y su conformidad con las especificaciones establecidas. Esto ayuda a garantizar la calidad y la eficacia del producto farmac\u00e9utico final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Materiales de Referencia en el Laboratorio de Control de Calidad (QC)**:\n   - Importancia de tener farmacopoeias, est\u00e1ndares de referencia, espectros de referencia y otros materiales de referencia disponibles.\n\n2. **Especificaciones para Materiales de Inicio y Embalaje**:\n   - Descripci\u00f3n de materiales, incluyendo nombre designado, referencia a monograf\u00edas farmacopoeiales, y requisitos cualitativos y cuantitativos.\n   - Datos adicionales que pueden incluirse: proveedor, productor original, muestra de materiales impresos, direcciones para muestreo y pruebas, condiciones de almacenamiento, y per\u00edodo m\u00e1ximo de almacenamiento antes de re-examinaci\u00f3n.\n\n3. **Cumplimiento y Compatibilidad**:\n   - Los materiales de embalaje deben cumplir con las especificaciones y ser compatibles con el producto medicinal que contienen.\n   - Examen de los materiales para verificar conformidad, defectos y marcas de identidad.\n\n4. **Frecuencia de Rean\u00e1lisis**:\n   - Documentos de procedimientos de prueba deben indicar la frecuencia requerida para el rean\u00e1lisis de cada material de inicio, basado en su estabilidad.\n\n5. **Especificaciones para Productos Intermedios y a Granel**:\n   - Disponibilidad de especificaciones que sean similares a las de los materiales de inicio o productos terminados, seg\u00fan corresponda.\n\n6. **Especificaciones para Productos Terminados**:\n   - Informaci\u00f3n que debe incluirse: nombre designado del producto, nombre(s) de ingredientes activos, f\u00f3rmula, descripci\u00f3n de la forma de dosificaci\u00f3n y detalles del paquete, direcciones para muestreo y pruebas, requisitos cualitativos y cuantitativos, condiciones de almacenamiento, y vida \u00fatil.\n\n### Entidades Clave:\n- **Laboratorio de Control de Calidad (QC)**\n- **Materiales de Inicio**\n- **Materiales de Embalaje**\n- **Productos Intermedios**\n- **Productos a Granel**\n- **Productos Terminados**\n- **Farmacopoeias**\n- **Est\u00e1ndares de Referencia**\n- **Espectros de Referencia**\n- **Ingredientes Activos**\n- **INN (Nombre Com\u00fan Internacional)**\n\nEste resumen destaca la importancia de las especificaciones y el cumplimiento en la fabricaci\u00f3n farmac\u00e9utica, asegurando la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: master formula, packaging instructions, pharmaceutical products, quality control, manufacturing specifications"}}, "2fc10379-e88d-4215-aa3b-b2cb0870dc2a": {"node_ids": ["c2a01450-5853-4f1d-bf27-6ced91adb5a9"], "metadata": {"page_label": "146", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(f) special precautions to be observed, including a careful examination of the packaging area and equipment in order to ascertain the line clearance before and after packaging operations;\n\n(g) a description of the packaging operation, including any significant subsidiary operations, and equipment to be used;\n\n(h) details of in-process controls with instructions for sampling and acceptance limits.\n\n## Batch processing records\n\n15.25 A batch processing record should be kept for each batch processed. It should be based on the relevant parts of the currently approved specifications on the record. The method of preparation of such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.26 Before any processing begins, a check should be made that the equipment and work station are clear of previous products, documents, or materials not required for the planned process, and that the equipment is clean and suitable for use. This check should be recorded.\n\n15.27 During processing, the following information should be recorded at the time each action is taken, and after completion the record should be dated and signed by the person responsible for the processing operations:\n\n(a) the name of the product;\n\n(b) the number of the batch being manufactured;\n\n(c) dates and times of commencement, of significant intermediate stages, and of completion of production;\n\n(d) the name of the person responsible for each stage of production;\n\n(e) the initials of the operator(s) of different significant steps of production and, where appropriate, of the person(s) who checked each of these operations (e.g. weighing);\n\n(f) the batch number and/or analytical control number and the quantity of each starting material actually weighed (including the batch number and amount of any recovered or reprocessed material added);\n\n(g) any relevant processing operation or event and the major equipment used;\n\n(h) the in-process controls performed, the initials of the person(s) carrying them out, and the results obtained;\n\n(i) the amount of product obtained at different and pertinent stages of manufacture (yield), together with comments or explanations for significant deviations from the expected yield;\n\n(j) notes on special problems including details, with signed authorization for any deviation from the master formula.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proviene del \"WHO - Technical Report Series 961\" y se centra en los procedimientos de registro y control durante el procesamiento de lotes en la producci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de mantener registros precisos y detallados para cada lote, asegurando que se sigan las especificaciones aprobadas y que se realicen controles en proceso. Se describen las precauciones especiales que deben observarse antes y despu\u00e9s de las operaciones de envasado, as\u00ed como la informaci\u00f3n que debe registrarse durante el procesamiento, incluyendo detalles sobre el producto, el lote, los operadores, y cualquier desviaci\u00f3n de los procedimientos est\u00e1ndar.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe registrarse antes de comenzar el procesamiento de un lote y por qu\u00e9 es importante este registro?**\n   - Respuesta: Antes de comenzar el procesamiento, se debe registrar que el equipo y el \u00e1rea de trabajo est\u00e1n libres de productos, documentos o materiales no requeridos, y que el equipo est\u00e1 limpio y adecuado para su uso. Este registro es importante para garantizar que no haya contaminaci\u00f3n cruzada y que el proceso se realice en condiciones \u00f3ptimas.\n\n2. **\u00bfCu\u00e1les son las consecuencias de no seguir las recomendaciones sobre la preparaci\u00f3n de registros de procesamiento de lotes?**\n   - Respuesta: No seguir las recomendaciones puede llevar a errores en la documentaci\u00f3n, lo que podr\u00eda resultar en problemas de calidad del producto, incumplimiento de regulaciones, y potencialmente en la retirada de productos del mercado. Adem\u00e1s, podr\u00eda dificultar la trazabilidad y la identificaci\u00f3n de problemas en el proceso de producci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de autorizaciones son necesarias en caso de desviaciones del procedimiento est\u00e1ndar durante el procesamiento de un lote?**\n   - Respuesta: En caso de desviaciones del procedimiento est\u00e1ndar, se deben incluir notas sobre problemas especiales, junto con detalles y la autorizaci\u00f3n firmada para cualquier desviaci\u00f3n de la f\u00f3rmula maestra. Esto asegura que cualquier cambio est\u00e9 documentado y aprobado por la persona responsable, manteniendo la integridad del proceso de producci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices para el registro y control de procesos en la producci\u00f3n farmac\u00e9utica, subrayando la importancia de la documentaci\u00f3n precisa y la limpieza del equipo. Se detallan los requisitos para los registros de procesamiento de lotes, incluyendo la informaci\u00f3n que debe ser recopilada y las precauciones que deben tomarse para asegurar la calidad y la conformidad del producto final.", "prev_section_summary": "### Temas Clave:\n\n1. **F\u00f3rmula Maestra**: La secci\u00f3n establece la necesidad de una f\u00f3rmula maestra formalmente autorizada para cada producto y tama\u00f1o de lote. Esta f\u00f3rmula debe contener informaci\u00f3n detallada sobre el producto, los materiales iniciales, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento.\n\n2. **Instrucciones de Empaque**: Se requiere que existan instrucciones de empaque autorizadas que especifiquen los materiales de empaque, el etiquetado y otros detalles relevantes para cada producto.\n\n3. **Control de Calidad**: Se enfatiza la importancia de los controles en proceso y las precauciones especiales para garantizar la calidad y la eficacia del producto final.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **F\u00f3rmula Maestra**: Documento que detalla la fabricaci\u00f3n de un producto farmac\u00e9utico.\n- **Materiales Iniciales**: Ingredientes utilizados en la producci\u00f3n del producto.\n- **Instrucciones de Empaque**: Directrices sobre c\u00f3mo empaquetar el producto farmac\u00e9utico.\n- **Producto Farmac\u00e9utico**: El resultado final que se fabrica y empaqueta.\n- **Lote**: Cantidad espec\u00edfica de producto fabricado en un proceso de producci\u00f3n.\n\n### Resumen:\n\nEl documento de la OMS establece directrices sobre la creaci\u00f3n de f\u00f3rmulas maestras y las instrucciones de empaque para productos farmac\u00e9uticos. Se requiere que cada producto tenga una f\u00f3rmula maestra autorizada que incluya detalles sobre el nombre del producto, la forma de dosificaci\u00f3n, los materiales iniciales, el rendimiento esperado, el proceso de fabricaci\u00f3n y las condiciones de almacenamiento. Adem\u00e1s, las instrucciones de empaque deben detallar el nombre del producto, su forma farmac\u00e9utica, el tama\u00f1o del paquete y los materiales de empaque necesarios. Estas directrices son fundamentales para asegurar la calidad y la conformidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: batch processing, quality control, pharmaceutical production, documentation, in-process controls"}}, "7650e8ea-75db-4b65-b8b2-c0840e94899f": {"node_ids": ["144d48d2-1dcf-4e8f-895c-68db421f2c56"], "metadata": {"page_label": "147", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Batch Packaging Records\n\n15.28 A batch packaging record should be kept for each batch or part batch processed. It should be based on the relevant parts of the approved packaging instructions, and the method of preparing such records should be designed to avoid errors. (Copying or validated computer programmes are recommended. Transcribing from approved documents should be avoided.)\n\n15.29 Before any packaging operation begins, checks should be made that the equipment and work station are clear of previous products, documents or materials not required for the planned packaging operations, and that equipment is clean and suitable for use. These checks should be recorded.\n\n15.30 The following information should be recorded at the time each action is taken, and the date and the person responsible should be clearly identified by signature or electronic password:\n\n(a) the name of the product, the batch number and the quantity of bulk product to be packed, as well as the batch number and the planned quantity of finished product that will be obtained, the quantity actually obtained and the reconciliation;\n\n(b) the date(s) and time(s) of the packaging operations;\n\n(c) the name of the responsible person carrying out the packaging operation;\n\n(d) the initials of the operators of the different significant steps;\n\n(e) the checks made for identity and conformity with the packaging instructions, including the results of in-process controls;\n\n(f) details of the packaging operations carried out, including references to equipment and the packaging lines used, and, when necessary, the instructions for keeping the product unpacked or a record of returning product that has not been packaged to the storage area;\n\n(g) whenever possible, samples of the printed packaging materials used, including specimens bearing the approval for the printing of and regular check (where appropriate) of the batch number, expiry date, and any additional overprinting;\n\n(h) notes on any special problems, including details of any deviation from the packaging instructions, with written authorization by an appropriate person;\n\n(i) the quantities and reference number or identification of all printed packaging materials and bulk product issued, used, destroyed or returned to stock and the quantities of product obtained to permit an adequate reconciliation.\n\n# Standard Operating Procedures and Records\n\n15.31 SOPs and associated records of actions taken or, where appropriate, conclusions reached should be available for:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre la creaci\u00f3n y mantenimiento de registros de empaquetado de lotes en el contexto de la producci\u00f3n farmac\u00e9utica. Se enfatiza la importancia de seguir las instrucciones de empaquetado aprobadas y de registrar informaci\u00f3n cr\u00edtica durante el proceso de empaquetado para garantizar la trazabilidad y la conformidad. Se detallan los elementos espec\u00edficos que deben ser documentados, como el nombre del producto, el n\u00famero de lote, las cantidades, las fechas y los responsables, as\u00ed como cualquier problema especial que surja durante el proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluirse en un registro de empaquetado de lotes y por qu\u00e9 es importante cada uno de estos elementos?**\n   - Esta pregunta busca una explicaci\u00f3n detallada de cada elemento requerido en el registro y su relevancia para la calidad y la trazabilidad del producto.\n\n2. **\u00bfCu\u00e1les son las consecuencias de no seguir las directrices establecidas para la creaci\u00f3n de registros de empaquetado de lotes?**\n   - Esta pregunta se centra en las implicaciones legales, de calidad y de seguridad que pueden surgir si no se cumplen las normativas descritas.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse si se identifica una desviaci\u00f3n de las instrucciones de empaquetado durante el proceso?**\n   - Esta pregunta busca informaci\u00f3n sobre los pasos espec\u00edficos que deben tomarse en caso de desviaciones, incluyendo la documentaci\u00f3n y la autorizaci\u00f3n necesaria.\n\n### Resumen de Nivel Superior\n\nEl documento establece normas claras para la documentaci\u00f3n y el control de los procesos de empaquetado en la industria farmac\u00e9utica, subrayando la importancia de la precisi\u00f3n y la conformidad con las instrucciones aprobadas. Se requiere que se mantengan registros detallados para cada lote, lo que ayuda a garantizar la calidad del producto y la seguridad del consumidor. Adem\u00e1s, se enfatiza la necesidad de procedimientos operativos est\u00e1ndar (SOP) y registros asociados para asegurar que todas las acciones y decisiones sean trazables y verificables.", "prev_section_summary": "### Temas Clave\n\n1. **Precauciones Especiales en el Envasado**: Se enfatiza la necesidad de examinar cuidadosamente el \u00e1rea de envasado y el equipo para asegurar la limpieza de la l\u00ednea antes y despu\u00e9s de las operaciones de envasado.\n\n2. **Registros de Procesamiento de Lotes**: Se requiere mantener un registro detallado para cada lote procesado, basado en especificaciones aprobadas, con un enfoque en evitar errores en la documentaci\u00f3n.\n\n3. **Verificaci\u00f3n Previa al Procesamiento**: Antes de iniciar el procesamiento, es crucial verificar que el equipo y el \u00e1rea de trabajo est\u00e9n libres de materiales no requeridos y que el equipo est\u00e9 limpio y adecuado para su uso.\n\n4. **Documentaci\u00f3n Durante el Procesamiento**: Se debe registrar informaci\u00f3n clave durante el procesamiento, incluyendo el nombre del producto, n\u00famero de lote, fechas y horas de producci\u00f3n, responsables de cada etapa, y resultados de controles en proceso.\n\n5. **Autorizaciones para Desviaciones**: Cualquier desviaci\u00f3n del procedimiento est\u00e1ndar debe ser documentada y autorizada, asegurando que se mantenga la integridad del proceso de producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documento**: WHO - Technical Report Series 961\n- **Secci\u00f3n**: Registros de procesamiento de lotes\n- **Elementos de Registro**: Nombre del producto, n\u00famero de lote, fechas y horas, responsables, iniciales de operadores, n\u00famero de control anal\u00edtico, cantidad de materiales, operaciones relevantes, controles en proceso, rendimiento del producto, notas sobre problemas especiales.\n- **Recomendaciones**: Uso de programas inform\u00e1ticos validados para la preparaci\u00f3n de registros, evitar la transcripci\u00f3n de documentos aprobados. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y la conformidad del producto final.", "excerpt_keywords": "Keywords: batch packaging records, pharmaceutical production, documentation, standard operating procedures, quality control"}}, "25989f5e-bdc0-44fc-8ef1-e5782fd460a7": {"node_ids": ["f1fe2044-1745-4137-8d35-a67cf31d4db1"], "metadata": {"page_label": "148", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(a) equipment assembly and validation;  \n(b) analytical apparatus and calibration;  \n(c) maintenance, cleaning and sanitization;  \n(d) personnel matters including qualification, training, clothing and hygiene;  \n(e) environmental monitoring;  \n(f) pest control;  \n(g) complaints;  \n(h) recalls;  \n(i) returns.  \n\n15.32 There should be SOPs and records for the receipt of each delivery of starting material and primary and printed packaging material.\n\n15.33 The records of the receipts should include:\n\n(a) the name of the material on the delivery note and the containers;  \n(b) the \u201cin-house\u201d name and/or code of material if different from (a);  \n(c) the date of receipt;  \n(d) the supplier\u2019s name and, if possible, manufacturer\u2019s name;  \n(e) the manufacturer\u2019s batch or reference number;  \n(f) the total quantity, and number of containers received;  \n(g) the batch number assigned after receipt;  \n(h) any relevant comment (e.g. state of the containers).\n\n15.34 There should be SOPs for the internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate.\n\n15.35 SOPs should be available for each instrument and piece of equipment (e.g. use, calibration, cleaning, maintenance) and placed in close proximity to the equipment.\n\n15.36 There should be SOPs for sampling, which specify the person(s) authorized to take samples.\n\n15.37 The sampling instructions should include:\n\n(a) the method of sampling and the sampling plan;  \n(b) the equipment to be used;  \n(c) any precautions to be observed to avoid contamination of the material or any deterioration in its quality;  \n(d) the amount(s) of sample(s) to be taken;  \n(e) instructions for any required subdivision of the sample;  \n(f) the type of sample container(s) to be used, and whether they are for aseptic sampling or for normal sampling, and labelling;  \n(g) any specific precautions to be observed, especially in regard to the sampling of sterile or noxious material.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOPs)**: El documento enfatiza la importancia de contar con SOPs para diversas actividades relacionadas con la recepci\u00f3n, almacenamiento, muestreo y manejo de materiales en un entorno regulado. Esto incluye la validaci\u00f3n de equipos, calibraci\u00f3n de aparatos anal\u00edticos, mantenimiento y limpieza, as\u00ed como la formaci\u00f3n y calificaci\u00f3n del personal.\n\n2. **Registros de Recepci\u00f3n**: Se detalla la necesidad de mantener registros precisos de la recepci\u00f3n de materiales, que deben incluir informaci\u00f3n espec\u00edfica sobre el proveedor, el material recibido y su estado. Esto es crucial para asegurar la trazabilidad y la calidad de los materiales utilizados en la producci\u00f3n.\n\n3. **Muestreo y Precauciones**: Se subraya la importancia de tener instrucciones claras para el muestreo, incluyendo m\u00e9todos, equipos y precauciones necesarias para evitar la contaminaci\u00f3n y asegurar la calidad del material muestreado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en los registros de recepci\u00f3n de materiales seg\u00fan el documento?**\n   - Respuesta: Los registros de recepci\u00f3n deben incluir el nombre del material, el nombre \"in-house\" o c\u00f3digo, la fecha de recepci\u00f3n, el nombre del proveedor y, si es posible, del fabricante, el n\u00famero de lote o referencia del fabricante, la cantidad total y el n\u00famero de contenedores recibidos, el n\u00famero de lote asignado despu\u00e9s de la recepci\u00f3n y cualquier comentario relevante sobre el estado de los contenedores.\n\n2. **\u00bfCu\u00e1les son las precauciones que deben observarse durante el muestreo de materiales, especialmente en el caso de materiales est\u00e9riles o nocivos?**\n   - Respuesta: Las instrucciones de muestreo deben incluir precauciones para evitar la contaminaci\u00f3n del material y cualquier deterioro en su calidad, as\u00ed como especificaciones sobre el tipo de contenedor de muestra a utilizar y las precauciones espec\u00edficas a observar en el muestreo de materiales est\u00e9riles o nocivos.\n\n3. **\u00bfPor qu\u00e9 es importante que los SOPs est\u00e9n disponibles y ubicados cerca de cada instrumento y equipo?**\n   - Respuesta: Es importante que los SOPs est\u00e9n disponibles y ubicados cerca de cada instrumento y equipo para garantizar que el personal tenga acceso inmediato a las instrucciones necesarias para el uso, calibraci\u00f3n, limpieza y mantenimiento, lo que ayuda a asegurar la correcta operaci\u00f3n y la calidad de los procesos.", "prev_section_summary": "### Temas Clave\n\n1. **Registros de Empaquetado de Lotes**: Se requiere mantener un registro para cada lote o parte de lote procesado, basado en instrucciones de empaquetado aprobadas.\n\n2. **Prevenci\u00f3n de Errores**: La preparaci\u00f3n de registros debe dise\u00f1arse para evitar errores, recomend\u00e1ndose el uso de programas inform\u00e1ticos validados en lugar de la transcripci\u00f3n manual.\n\n3. **Verificaci\u00f3n Previa al Empaque**: Antes de iniciar las operaciones de empaquetado, se deben realizar verificaciones para asegurar que el equipo y el \u00e1rea de trabajo est\u00e9n limpios y libres de materiales no necesarios.\n\n4. **Informaci\u00f3n a Registrar**: Se debe documentar informaci\u00f3n cr\u00edtica durante el proceso de empaquetado, incluyendo:\n   - Nombre del producto y n\u00famero de lote.\n   - Cantidades de producto a empaquetar y obtenidas.\n   - Fechas y horas de las operaciones.\n   - Identificaci\u00f3n de la persona responsable y operadores.\n   - Resultados de controles en proceso.\n   - Detalles de las operaciones de empaquetado.\n   - Muestras de materiales de empaquetado impresos.\n   - Notas sobre problemas especiales y desviaciones.\n   - Cantidades y referencias de materiales impresos utilizados.\n\n5. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Se enfatiza la importancia de tener SOPs y registros asociados para asegurar la trazabilidad y la verificaci\u00f3n de acciones y decisiones.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS).\n- **Documentos**: Instrucciones de empaquetado aprobadas, registros de empaquetado de lotes, SOPs.\n- **Elementos de Registro**: Nombre del producto, n\u00famero de lote, cantidades, fechas, responsables, resultados de controles, materiales de empaquetado.\n- **Acciones**: Verificaciones, documentaci\u00f3n de problemas, autorizaci\u00f3n de desviaciones.\n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control en el proceso de empaquetado en la industria farmac\u00e9utica, asegurando la calidad y la seguridad del producto.", "excerpt_keywords": "Keywords: SOPs, material receipt, sampling instructions, quality control, pharmaceutical standards"}}, "c0d94ae8-2c67-4d75-959a-e2c2734d3803": {"node_ids": ["8693c261-81af-4e3b-b385-b3bedfb45311"], "metadata": {"page_label": "149", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 15.38 \nThere should be an SOP describing the details of the batch (lot) numbering system, with the objective of ensuring that each batch of intermediate, bulk or finished product is identified with a specific batch number.\n\n# 15.39 \nThe SOPs for batch numbering that are applied to the processing stage and to the respective packaging stage should be related to each other.\n\n# 15.40 \nThe SOP for batch numbering should ensure that the same batch numbers will not be used repeatedly; this applies also to reprocessing.\n\n# 15.41 \nBatch-number allocation should be immediately recorded, e.g. in a logbook. The record should include at least the date of allocation, product identity and size of batch.\n\n# 15.42 \nThere should be written procedures for testing materials and products at different stages of manufacture, describing the methods and equipment to be used. The tests performed should be recorded.\n\n# 15.43 \nAnalysis records should include at least the following data:\n\n(a) the name of the material or product and, where applicable, dosage form;  \n(b) the batch number and, where appropriate, the manufacturer and/or supplier;  \n(c) references to the relevant specifications and testing procedures;  \n(d) test results, including observations and calculations, and reference to any specifications (limits);  \n(e) date(s) and reference number(s) of testing;  \n(f) the initials of the persons who performed the testing;  \n(g) the date and initials of the persons who verified the testing and the calculations, where appropriate;  \n(h) a clear statement of release or rejection (or other status decision) and the dated signature of the designated responsible person.\n\n# 15.44 \nWritten release and rejection procedures should be available for materials and products, and in particular for the release for sale of the finished product by an authorized person.\n\n# 15.45 \nRecords should be maintained of the distribution of each batch of a product in order, e.g. to facilitate the recall of the batch if necessary.\n\n# 15.46 \nRecords should be kept for major and critical equipment, as appropriate, of any validations, calibrations, maintenance, cleaning, or repair operations, including dates and the identity of the people who carried these operations out.\n\n# 15.47 \nThe use of major and critical equipment and the areas where products have been processed should be appropriately recorded in chronological order.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl contexto se centra en la importancia de establecer procedimientos operativos est\u00e1ndar (SOP) para el sistema de numeraci\u00f3n de lotes en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la necesidad de un registro adecuado de la asignaci\u00f3n de n\u00fameros de lote, la realizaci\u00f3n de pruebas en diferentes etapas de producci\u00f3n, y el mantenimiento de registros de an\u00e1lisis, liberaci\u00f3n y distribuci\u00f3n de productos. Tambi\u00e9n se menciona la importancia de documentar el uso y mantenimiento de equipos cr\u00edticos.\n\n### Preguntas espec\u00edficas\n1. **\u00bfQu\u00e9 informaci\u00f3n m\u00ednima debe incluirse en el registro de asignaci\u00f3n de n\u00fameros de lote seg\u00fan el SOP?**\n   - Respuesta: El registro debe incluir al menos la fecha de asignaci\u00f3n, la identidad del producto y el tama\u00f1o del lote.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben estar presentes en los registros de an\u00e1lisis de materiales y productos?**\n   - Respuesta: Los registros de an\u00e1lisis deben incluir el nombre del material o producto, el n\u00famero de lote, referencias a especificaciones y procedimientos de prueba, resultados de pruebas, fechas y n\u00fameros de referencia de las pruebas, iniciales de los responsables de las pruebas, y una declaraci\u00f3n clara de liberaci\u00f3n o rechazo con la firma del responsable designado.\n\n3. **\u00bfQu\u00e9 procedimientos deben estar disponibles para la liberaci\u00f3n y rechazo de productos terminados?**\n   - Respuesta: Deben existir procedimientos escritos para la liberaci\u00f3n y rechazo de materiales y productos, especialmente para la liberaci\u00f3n para la venta del producto terminado por una persona autorizada.\n\n### Resumen de nivel superior\nEl documento establece directrices para asegurar la trazabilidad y la calidad en la producci\u00f3n de productos farmac\u00e9uticos mediante la implementaci\u00f3n de SOPs para la numeraci\u00f3n de lotes, pruebas de calidad y mantenimiento de registros. Se destaca la importancia de la documentaci\u00f3n en cada etapa del proceso de fabricaci\u00f3n, desde la asignaci\u00f3n de n\u00fameros de lote hasta la liberaci\u00f3n de productos, para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOPs)**:\n   - Importancia de contar con SOPs para diversas actividades en entornos regulados, incluyendo:\n     - Ensamblaje y validaci\u00f3n de equipos.\n     - Calibraci\u00f3n de aparatos anal\u00edticos.\n     - Mantenimiento, limpieza y sanitizaci\u00f3n.\n     - Formaci\u00f3n y calificaci\u00f3n del personal.\n     - Monitoreo ambiental y control de plagas.\n     - Manejo de quejas, retiradas y devoluciones.\n\n2. **Registros de Recepci\u00f3n**:\n   - Necesidad de mantener registros detallados para cada entrega de materiales iniciales y empaques.\n   - Informaci\u00f3n que debe incluirse en los registros:\n     - Nombre del material.\n     - Nombre \"in-house\" o c\u00f3digo.\n     - Fecha de recepci\u00f3n.\n     - Nombre del proveedor y, si es posible, del fabricante.\n     - N\u00famero de lote o referencia del fabricante.\n     - Cantidad total y n\u00famero de contenedores recibidos.\n     - N\u00famero de lote asignado despu\u00e9s de la recepci\u00f3n.\n     - Comentarios relevantes sobre el estado de los contenedores.\n\n3. **Muestreo y Precauciones**:\n   - Importancia de tener SOPs para el muestreo, especificando:\n     - M\u00e9todo de muestreo y plan de muestreo.\n     - Equipos a utilizar.\n     - Precauciones para evitar contaminaci\u00f3n y deterioro de la calidad del material.\n     - Cantidades de muestra a tomar y subdivisi\u00f3n de muestras.\n     - Tipo de contenedor de muestra y etiquetado.\n     - Precauciones espec\u00edficas para materiales est\u00e9riles o nocivos.\n\n4. **Accesibilidad de SOPs**:\n   - Los SOPs deben estar disponibles y ubicados cerca de cada instrumento y equipo para asegurar que el personal tenga acceso inmediato a las instrucciones necesarias para su correcto uso y mantenimiento.\n\n### Entidades Clave\n- **Materiales**: Materiales iniciales, empaques primarios y secundarios.\n- **Proveedores**: Nombres de proveedores y fabricantes.\n- **Equipos**: Instrumentos y equipos utilizados en el proceso.\n- **Personal**: Personal autorizado para el muestreo y manejo de materiales.\n- **Documentaci\u00f3n**: Registros de recepci\u00f3n y SOPs.", "excerpt_keywords": "Keywords: SOP, batch numbering, quality control, product release, traceability"}}, "475ae1cb-457f-43ee-b265-e372ef46493a": {"node_ids": ["45518f1b-86bf-4879-a76f-2140fc7fe659"], "metadata": {"page_label": "150", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Good Practices in Production\n\n## 16.1 Principle\n\nProduction operations must follow clearly defined procedures in accordance with manufacturing and marketing authorizations, with the objective of obtaining products of the requisite quality.\n\n### General\n\n16.2 All handling of materials and products, such as receipt and cleaning, quarantine, sampling, storage, labelling, dispensing, processing, packaging, and distribution should be done in accordance with written procedures or instructions and, where necessary, recorded.\n\n16.3 Any deviation from instructions or procedures should be avoided as far as possible. If deviations occur, they should be done in accordance with an approved procedure. The authorization of the deviation should be approved in writing by a designated person, with the involvement of the QC department, when appropriate.\n\n16.4 Checks on yields and reconciliation of quantities should be carried out as necessary to ensure that there are no discrepancies outside acceptable limits.\n\n16.5 Operations on different products should not be carried out simultaneously or consecutively in the same room or area unless there is no risk of mix-up or cross-contamination.\n\n16.6 At all times during processing, all materials, bulk containers, major items of equipment, and where appropriate, the rooms and packaging lines being used should be labelled or otherwise identified with an indication of the product or material being processed, its strength (where applicable) and the batch number. Where applicable, this indication should also mention the stage of production. In some cases, it may be useful to also record the name of the previous product that has been processed.\n\n16.7 Access to production premises should be restricted to authorized personnel.\n\n16.8 Normally, non-medicinal products should not be produced in areas or with equipment destined for the production of pharmaceutical products.\n\n16.9 In-process controls are usually performed within the production area. The performance of such in-process controls should not have any", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" establece buenas pr\u00e1cticas en la producci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de seguir procedimientos claramente definidos para garantizar la calidad del producto. Se abordan aspectos como el manejo de materiales, la gesti\u00f3n de desviaciones, el control de procesos y la restricci\u00f3n de acceso a las \u00e1reas de producci\u00f3n. Tambi\u00e9n se menciona la necesidad de etiquetar adecuadamente todos los materiales y equipos utilizados en el proceso de producci\u00f3n.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para manejar materiales y productos en la producci\u00f3n farmac\u00e9utica?**\n   - El manejo de materiales y productos debe realizarse de acuerdo con procedimientos escritos que incluyan recepci\u00f3n, limpieza, cuarentena, muestreo, almacenamiento, etiquetado, dispensaci\u00f3n, procesamiento, envasado y distribuci\u00f3n.\n\n2. **\u00bfQu\u00e9 debe hacerse en caso de que se produzcan desviaciones de los procedimientos establecidos?**\n   - Las desviaciones deben evitarse en la medida de lo posible. Si ocurren, deben seguir un procedimiento aprobado y ser autorizadas por una persona designada, con la participaci\u00f3n del departamento de control de calidad (QC) cuando sea apropiado.\n\n3. **\u00bfPor qu\u00e9 es importante etiquetar adecuadamente los materiales y equipos durante el procesamiento?**\n   - Es crucial etiquetar todos los materiales, contenedores a granel, equipos y \u00e1reas de producci\u00f3n para identificar claramente el producto o material que se est\u00e1 procesando, su fuerza y el n\u00famero de lote, lo que ayuda a prevenir confusiones y contaminaci\u00f3n cruzada.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos Operativos Est\u00e1ndar (SOP)**: Se enfatiza la necesidad de establecer SOPs para el sistema de numeraci\u00f3n de lotes en la fabricaci\u00f3n de productos farmac\u00e9uticos, asegurando que cada lote est\u00e9 identificado de manera \u00fanica.\n\n2. **Registro de N\u00fameros de Lote**: La asignaci\u00f3n de n\u00fameros de lote debe ser registrada de inmediato, incluyendo informaci\u00f3n como la fecha de asignaci\u00f3n, la identidad del producto y el tama\u00f1o del lote.\n\n3. **Pruebas y An\u00e1lisis**: Se requieren procedimientos escritos para la realizaci\u00f3n de pruebas en diferentes etapas de fabricaci\u00f3n, as\u00ed como registros detallados de los an\u00e1lisis realizados, que incluyan resultados, especificaciones y responsables.\n\n4. **Liberaci\u00f3n y Rechazo de Productos**: Deben existir procedimientos documentados para la liberaci\u00f3n y rechazo de materiales y productos, especialmente para la autorizaci\u00f3n de la venta de productos terminados.\n\n5. **Mantenimiento de Registros**: Es crucial mantener registros de la distribuci\u00f3n de cada lote, as\u00ed como de las operaciones de validaci\u00f3n, calibraci\u00f3n, mantenimiento y limpieza de equipos cr\u00edticos.\n\n6. **Trazabilidad**: La documentaci\u00f3n adecuada en cada etapa del proceso de fabricaci\u00f3n es esencial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.\n\n### Entidades\n\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen los procedimientos para la numeraci\u00f3n de lotes y pruebas.\n- **Lotes**: Grupos de productos intermedios, a granel o terminados identificados por un n\u00famero espec\u00edfico.\n- **Registros de An\u00e1lisis**: Documentos que contienen datos sobre pruebas realizadas, incluyendo resultados y responsables.\n- **Productos**: Materiales farmac\u00e9uticos que son objeto de pruebas y liberaci\u00f3n.\n- **Equipos Cr\u00edticos**: Equipos importantes en el proceso de fabricaci\u00f3n que requieren mantenimiento y validaci\u00f3n.\n- **Autorizados**: Personas responsables de la liberaci\u00f3n de productos terminados para la venta. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y los procedimientos estandarizados en la producci\u00f3n farmac\u00e9utica para asegurar la calidad y la trazabilidad de los productos.", "excerpt_keywords": "Keywords: production practices, pharmaceutical quality, standard procedures, deviation management, in-process controls"}}, "cbd116d1-16ee-46f7-a1c4-9d4e3a6d51bd": {"node_ids": ["924e713f-3586-44ad-8ee0-c6a52e34579a"], "metadata": {"page_label": "151", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Prevention of Cross-Contamination and Bacterial Contamination During Production\n\n16.10 When dry materials and products are used in production, special precautions should be taken to prevent the generation and dissemination of dust. Provision should be made for proper air control (e.g. supply and extraction of air of suitable quality).\n\n16.11 Contamination of a starting material or of a product by another material or product must be avoided. This risk of accidental cross-contamination arises from the uncontrolled release of dust, gases, particles, vapours, sprays or organisms from materials and products in process, from residues on equipment, from intruding insects, and from operators\u2019 clothing, skin, etc. The significance of this risk varies with the type of contaminant and of the product being contaminated.\n\nAmong the most hazardous contaminants are highly sensitizing materials, biological preparations such as living organisms, certain hormones, cytotoxic substances, and other highly active materials.\n\nProducts in which contamination is likely to be most significant are those administered by injection or applied to open wounds and those given in large doses and/or over a long time.\n\n16.12 Cross-contamination should be avoided by taking appropriate technical or organizational measures, for example:\n\n(a) carrying out production in dedicated and self-contained areas (which may be required for products such as penicillins, live vaccines, live bacterial preparations and certain other biologicals);\n\n(b) conducting campaign production (separation in time) followed by appropriate cleaning in accordance with a validated cleaning procedure;\n\n(c) providing appropriately designed airlocks, pressure differentials, and air supply and extraction systems;\n\n(d) minimizing the risk of contamination caused by recirculation or re-entry of untreated or insufficiently treated air;\n\n(e) wearing protective clothing where products or materials are handled;\n\n(f) using cleaning and decontamination procedures of known effectiveness;\n\n(g) using a \u201cclosed system\u201d in production;\n\n(h) testing for residues;\n\n(i) using cleanliness status labels on equipment.\n\n16.13 Measures to prevent cross-contamination and their effectiveness should be checked periodically according to SOPs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS aborda la prevenci\u00f3n de la contaminaci\u00f3n cruzada y la contaminaci\u00f3n bacteriana durante la producci\u00f3n de materiales y productos. Se enfatiza la importancia de tomar precauciones especiales al manejar materiales secos para evitar la generaci\u00f3n de polvo y la contaminaci\u00f3n accidental. Se describen diversas medidas t\u00e9cnicas y organizativas que deben implementarse para minimizar el riesgo de contaminaci\u00f3n, especialmente en productos que se administran por inyecci\u00f3n o se aplican a heridas abiertas. Adem\u00e1s, se menciona la necesidad de verificar peri\u00f3dicamente la efectividad de estas medidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tipos de contaminantes que se consideran m\u00e1s peligrosos en el contexto de la producci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Entre los contaminantes m\u00e1s peligrosos se encuentran materiales altamente sensibilizantes, preparaciones biol\u00f3gicas como organismos vivos, ciertas hormonas, sustancias citot\u00f3xicas y otros materiales altamente activos.\n\n2. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la contaminaci\u00f3n cruzada en la producci\u00f3n de productos como penicilinas y vacunas vivas?**\n   - Respuesta: Se deben llevar a cabo la producci\u00f3n en \u00e1reas dedicadas y autoconfinadas, realizar producci\u00f3n por campa\u00f1as seguida de limpieza adecuada, y proporcionar sistemas de aire dise\u00f1ados apropiadamente, entre otras medidas.\n\n3. **\u00bfCon qu\u00e9 frecuencia deben revisarse las medidas implementadas para prevenir la contaminaci\u00f3n cruzada y c\u00f3mo se debe llevar a cabo esta revisi\u00f3n?**\n   - Respuesta: Las medidas para prevenir la contaminaci\u00f3n cruzada y su efectividad deben ser verificadas peri\u00f3dicamente de acuerdo con los Procedimientos Operativos Est\u00e1ndar (SOPs).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Procedimientos Definidos:** La producci\u00f3n debe seguir procedimientos claramente establecidos que cumplan con las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n para asegurar la calidad del producto.\n\n2. **Manejo de Materiales:** Se deben seguir instrucciones escritas para todas las etapas del manejo de materiales y productos, incluyendo recepci\u00f3n, limpieza, almacenamiento, etiquetado, y distribuci\u00f3n.\n\n3. **Desviaciones:** Las desviaciones de los procedimientos deben ser evitadas y, si ocurren, deben ser autorizadas por una persona designada y, cuando sea necesario, involucrar al departamento de control de calidad.\n\n4. **Control de Calidad:** Se deben realizar verificaciones de rendimiento y reconciliaci\u00f3n de cantidades para evitar discrepancias.\n\n5. **Prevenci\u00f3n de Contaminaci\u00f3n:** No se deben realizar operaciones de diferentes productos simult\u00e1neamente en la misma \u00e1rea a menos que no haya riesgo de mezcla o contaminaci\u00f3n cruzada.\n\n6. **Etiquetado:** Todos los materiales y equipos deben estar etiquetados adecuadamente para identificar el producto, su fuerza y el n\u00famero de lote, as\u00ed como la etapa de producci\u00f3n.\n\n7. **Acceso Restringido:** El acceso a las \u00e1reas de producci\u00f3n debe ser limitado a personal autorizado.\n\n8. **Producci\u00f3n de Productos No Medicinales:** No se deben producir productos no medicinales en \u00e1reas o con equipos destinados a productos farmac\u00e9uticos.\n\n9. **Controles en Proceso:** Los controles en proceso se realizan dentro del \u00e1rea de producci\u00f3n y son esenciales para asegurar la calidad.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite el documento.\n- **Departamento de Control de Calidad (QC):** Involucrado en la autorizaci\u00f3n de desviaciones.\n- **Personal Autorizado:** Solo este grupo debe tener acceso a las instalaciones de producci\u00f3n.\n- **Productos Farmac\u00e9uticos:** El enfoque principal del documento.\n- **Productos No Medicinales:** Se menciona su producci\u00f3n y las restricciones asociadas.\n\nEste resumen destaca la importancia de seguir buenas pr\u00e1cticas en la producci\u00f3n farmac\u00e9utica para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: cross-contamination, bacterial contamination, production safety, pharmaceutical manufacturing, air control"}}, "66bda493-22aa-4818-b6ba-93abfbb77e68": {"node_ids": ["c136df7d-8c91-489a-ad09-0ca70ef663ad"], "metadata": {"page_label": "152", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing Operations\n\n16.14 Production areas where susceptible products are processed should undergo periodic environmental monitoring (e.g. for microbiological monitoring and particulate matter where appropriate).\n\n## Processing Operations\n\n16.15 Before any processing operation is started, steps should be taken to ensure that the work area and equipment are clean and free from any starting materials, products, product residues, labels or documents not required for the current operation.\n\n16.16 Any necessary in-process controls and environmental controls should be carried out and recorded.\n\n16.17 Means should be instituted of indicating failures of equipment or of services (e.g. water, gas) to equipment. Defective equipment should be withdrawn from use until the defect has been rectified. After use, production equipment should be cleaned without delay according to detailed written procedures and stored under clean and dry conditions in a separate area or in a manner that will prevent contamination.\n\n16.18 Time limits for storage of equipment after cleaning and before use should be stated and based on data.\n\n16.19 Containers for filling should be cleaned before filling. Attention should be given to avoiding and removing any contaminants such as glass fragments and metal particles.\n\n16.20 Any significant deviation from the expected yield should be recorded and investigated.\n\n16.21 Checks should be carried out to ensure that pipelines and other pieces of equipment used for the transportation of products from one area to another are connected in a correct manner.\n\n16.22 Pipes used for conveying distilled or deionized water and, where appropriate, other water pipes should be sanitized and stored according to written procedures that detail the action limits for microbiological contamination and the measures to be taken.\n\n16.23 Measuring, weighing, recording, and control equipment and instruments should be serviced and calibrated at prespecified intervals and records maintained. To ensure satisfactory functioning, instruments should be checked daily or prior to use for performing analytical tests. The date of calibration and servicing and the date when recalibration is due should be clearly indicated on a label attached to the instrument.\n\n16.24 Repair and maintenance operations should not present any hazard to the quality of the products.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las operaciones de procesamiento en \u00e1reas de producci\u00f3n de productos susceptibles. Se enfatiza la importancia de la limpieza y el monitoreo ambiental, as\u00ed como el control de equipos y procesos para garantizar la calidad y seguridad de los productos. Se establecen procedimientos para la limpieza de equipos, el almacenamiento adecuado, la calibraci\u00f3n de instrumentos y la gesti\u00f3n de desviaciones en los rendimientos esperados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la limpieza y almacenamiento de equipos de producci\u00f3n despu\u00e9s de su uso?**\n   - El contexto menciona que despu\u00e9s de usar el equipo de producci\u00f3n, este debe ser limpiado sin demora seg\u00fan procedimientos escritos detallados y almacenado en condiciones limpias y secas, en un \u00e1rea separada o de manera que se evite la contaminaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en caso de que se detecte un fallo en el equipo o en los servicios relacionados?**\n   - Se debe establecer un sistema para indicar fallos en el equipo o servicios (como agua o gas). El equipo defectuoso debe ser retirado de uso hasta que se haya rectificado el defecto.\n\n3. **\u00bfQu\u00e9 acciones se deben tomar si se observa una desviaci\u00f3n significativa del rendimiento esperado durante el procesamiento?**\n   - Cualquier desviaci\u00f3n significativa del rendimiento esperado debe ser registrada e investigada para determinar las causas y tomar las medidas correctivas necesarias.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre las operaciones de procesamiento en \u00e1reas de producci\u00f3n, destacando la importancia de la limpieza, el monitoreo ambiental y el control de equipos. Se establecen procedimientos para asegurar que el equipo est\u00e9 limpio y libre de contaminantes, as\u00ed como la necesidad de registrar y abordar cualquier desviaci\u00f3n en los procesos de producci\u00f3n. Adem\u00e1s, se enfatiza la calibraci\u00f3n y el mantenimiento de los instrumentos utilizados en el procesamiento para garantizar su correcto funcionamiento y la calidad del producto final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada:**\n   - Importancia de evitar la contaminaci\u00f3n de materiales y productos durante la producci\u00f3n, especialmente en el manejo de materiales secos que pueden generar polvo.\n\n2. **Contaminantes Peligrosos:**\n   - Identificaci\u00f3n de contaminantes altamente peligrosos, incluyendo materiales sensibilizantes, organismos vivos, hormonas, sustancias citot\u00f3xicas y otros materiales activos.\n\n3. **Productos de Alto Riesgo:**\n   - Enfoque en productos que se administran por inyecci\u00f3n, se aplican a heridas abiertas o se administran en grandes dosis y/o por per\u00edodos prolongados.\n\n4. **Medidas T\u00e9cnicas y Organizativas:**\n   - Estrategias para prevenir la contaminaci\u00f3n cruzada, como la producci\u00f3n en \u00e1reas dedicadas, limpieza adecuada, sistemas de aire controlados, uso de ropa protectora, y procedimientos de limpieza efectivos.\n\n5. **Revisi\u00f3n y Verificaci\u00f3n:**\n   - Necesidad de revisar peri\u00f3dicamente la efectividad de las medidas implementadas seg\u00fan Procedimientos Operativos Est\u00e1ndar (SOPs).\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos:** Incluyen penicilinas, vacunas vivas y otros biol\u00f3gicos.\n- **Contaminantes:** Materiales sensibilizantes, organismos vivos, hormonas, sustancias citot\u00f3xicas.\n- **Procedimientos Operativos Est\u00e1ndar (SOPs):** Normas para la revisi\u00f3n de medidas de prevenci\u00f3n.\n\nEste resumen destaca la importancia de la prevenci\u00f3n de la contaminaci\u00f3n en la producci\u00f3n farmac\u00e9utica y las medidas necesarias para garantizar la seguridad y eficacia de los productos.", "excerpt_keywords": "Keywords: processing operations, environmental monitoring, equipment cleaning, contamination prevention, quality control"}}, "c2578a11-a3ce-43df-bc2d-3ea5195cae6c": {"node_ids": ["10a304a3-12bb-4a33-ba8a-79c7c3f845df"], "metadata": {"page_label": "153", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Packaging Operations\n\n16.25 When the programme for packaging operations is being set up, particular attention should be given to minimizing the risk of cross-contamination, mix-ups or substitutions. Different products should not be packaged in close proximity unless there is physical segregation or an alternative system that will provide equal assurance.\n\n16.26 Before packaging operations are begun, steps should be taken to ensure that the work area, packaging lines, printing machines and other equipment are clean and free from any products, materials or documents used previously and which are not required for the current operation. The line clearance should be performed according to an appropriate procedure and checklist, and recorded.\n\n16.27 The name and batch number of the product being handled should be displayed at each packaging station or line.\n\n16.28 Normally, filling and sealing should be followed as quickly as possible by labelling. If labelling is delayed, appropriate procedures should be applied to ensure that no mix ups or mislabelling can occur.\n\n16.29 The correct performance of any printing (e.g. of code numbers or expiry dates) done separately or in the course of the packaging should be checked and recorded. Attention should be paid to printing by hand, which should be rechecked at regular intervals.\n\n16.30 Special care should be taken when cut labels are used and when overprinting is carried out off-line, and in hand-packaging operations. Roll feed labels are normally preferable to cut labels in helping to avoid mix ups. Online verification of all labels by automated electronic means can be helpful in preventing mix ups, but checks should be made to ensure that any electronic code readers, label counters, or similar devices are operating correctly. When labels are attached manually, in-process control checks should be performed more frequently.\n\n16.31 Printed and embossed information on packaging materials should be distinct and resistant to fading or erasing.\n\n16.32 Regular online control of the product during packaging should include at least checks on:\n\n- (a) the general appearance of the packages;\n- (b) whether the packages are complete;\n- (c) whether the correct products and packaging materials are used;\n- (d) whether any overprinting is correct;\n- (e) the correct functioning of line monitors.\n\nSamples taken away from the packaging line should not be returned.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior\n\n1. **Minimizaci\u00f3n de Riesgos en Operaciones de Empaque**: El documento enfatiza la importancia de establecer un programa de operaciones de empaque que minimice el riesgo de contaminaci\u00f3n cruzada, confusiones o sustituciones. Se requiere que los productos diferentes no se empaquen en proximidad a menos que haya segregaci\u00f3n f\u00edsica o un sistema alternativo que garantice la seguridad.\n\n2. **Limpieza y Preparaci\u00f3n del \u00c1rea de Trabajo**: Antes de iniciar las operaciones de empaque, es crucial asegurar que el \u00e1rea de trabajo y los equipos est\u00e9n limpios y libres de materiales no necesarios. Esto incluye la realizaci\u00f3n de un procedimiento de limpieza de l\u00ednea que debe ser documentado.\n\n3. **Control de Calidad Durante el Empaque**: Se deben realizar controles regulares durante el empaque para verificar la apariencia de los paquetes, la correcci\u00f3n de los productos y materiales utilizados, y el correcto funcionamiento de los monitores de l\u00ednea. Adem\u00e1s, se deben tomar precauciones especiales al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que el \u00e1rea de trabajo est\u00e9 limpia antes de comenzar las operaciones de empaque?**\n   - El documento menciona que se deben tomar pasos para garantizar que el \u00e1rea de trabajo, las l\u00edneas de empaque, las m\u00e1quinas de impresi\u00f3n y otros equipos est\u00e9n limpios y libres de productos, materiales o documentos no necesarios. Esto debe realizarse mediante un procedimiento de limpieza de l\u00ednea que debe ser registrado.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el uso de etiquetas en las operaciones de empaque?**\n   - Se recomienda tener especial cuidado al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea. Las etiquetas de alimentaci\u00f3n en rollo son preferibles a las etiquetas cortadas para evitar confusiones. Adem\u00e1s, se sugiere la verificaci\u00f3n en l\u00ednea de todas las etiquetas mediante medios electr\u00f3nicos automatizados y realizar controles m\u00e1s frecuentes cuando las etiquetas se adjuntan manualmente.\n\n3. **\u00bfQu\u00e9 aspectos se deben verificar durante el control en l\u00ednea del producto durante el empaque?**\n   - El control en l\u00ednea del producto debe incluir al menos las siguientes verificaciones: (a) la apariencia general de los paquetes; (b) si los paquetes est\u00e1n completos; (c) si se est\u00e1n utilizando los productos y materiales de empaque correctos; (d) si cualquier sobreimpresi\u00f3n es correcta; y (e) el correcto funcionamiento de los monitores de l\u00ednea.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo Ambiental**: Se requiere un monitoreo ambiental peri\u00f3dico en \u00e1reas de producci\u00f3n de productos susceptibles, incluyendo controles microbiol\u00f3gicos y de part\u00edculas.\n\n2. **Limpieza y Preparaci\u00f3n**: Antes de iniciar cualquier operaci\u00f3n de procesamiento, es esencial que el \u00e1rea de trabajo y el equipo est\u00e9n limpios y libres de materiales no necesarios.\n\n3. **Controles en Proceso**: Se deben realizar y registrar controles necesarios durante el proceso y en el ambiente.\n\n4. **Gesti\u00f3n de Fallos**: Deben establecerse medios para indicar fallos en el equipo o servicios. El equipo defectuoso debe ser retirado hasta que se solucione el problema.\n\n5. **Almacenamiento de Equipos**: Despu\u00e9s de su uso, el equipo debe limpiarse de inmediato y almacenarse en condiciones limpias y secas para evitar la contaminaci\u00f3n.\n\n6. **Desviaciones en Rendimiento**: Cualquier desviaci\u00f3n significativa del rendimiento esperado debe ser registrada e investigada.\n\n7. **Conexiones de Equipos**: Se deben verificar las conexiones de tuber\u00edas y equipos utilizados para el transporte de productos.\n\n8. **Sanitizaci\u00f3n de Tuber\u00edas**: Las tuber\u00edas que transportan agua destilada o desionizada deben ser sanitizadas y almacenadas seg\u00fan procedimientos escritos.\n\n9. **Calibraci\u00f3n de Instrumentos**: Los equipos de medici\u00f3n y control deben ser calibrados y mantenidos a intervalos preestablecidos, con registros adecuados.\n\n10. **Mantenimiento Seguro**: Las operaciones de reparaci\u00f3n y mantenimiento no deben comprometer la calidad de los productos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Equipos de Producci\u00f3n**: Herramientas y maquinaria utilizadas en el procesamiento.\n- **Contaminantes**: Elementos no deseados como fragmentos de vidrio y part\u00edculas met\u00e1licas.\n- **Procedimientos Escritos**: Documentaci\u00f3n que detalla los pasos a seguir para la limpieza y mantenimiento.\n- **Controles Microbiol\u00f3gicos**: Medidas para asegurar la calidad microbiol\u00f3gica de los productos.\n- **Instrumentos de Medici\u00f3n**: Equipos utilizados para realizar pruebas anal\u00edticas y controles de calidad. \n\nEste resumen destaca la importancia de la limpieza, el monitoreo y el control en las operaciones de procesamiento para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: packaging operations, cross-contamination, line clearance, quality control, labeling procedures"}}, "9baf9cfe-003e-4e10-a38b-b2b997f6c97b": {"node_ids": ["84e6010c-73b2-46f1-a102-bdc36f325fb8"], "metadata": {"page_label": "154", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 16.33 \nProducts that have been involved in an unusual event during packaging should be reintroduced into the process only after special inspection, investigation and approval by authorized personnel. A detailed record should be kept of this operation.\n\n16.34 \nAny significant or unusual discrepancy observed during reconciliation of the amount of bulk product and printed packaging materials and the number of units produced should be investigated, satisfactorily accounted for, and recorded before release.\n\n16.35 \nUpon completion of a packaging operation, any unused batch-coded packaging materials should be destroyed and the destruction recorded. A documented procedure requiring checks to be performed before returning unused materials should be followed if uncoded printed materials are returned to stock.\n\n16.36 \nProduction records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet production specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n# 17. Good practices in quality control\n\n17.1 \nQC is the part of GMP concerned with sampling, specifications and testing, and with the organization and documentation which ensure that the necessary and relevant tests are actually carried out and that materials are not released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. QC is not confined to laboratory operations, but may be involved in many decisions concerning the quality of the product.\n\n17.2 \nThe independence of QC from production is considered fundamental.\n\n17.3 \nEach manufacturer should have a QC function. The QC function should be independent of other departments and under the authority of a person with appropriate qualifications and experience, who has one or several control laboratories at his or her disposal. Adequate resources must be available to ensure that all the QC arrangements are effectively and reliably carried out. The basic requirements for QC are as follows:\n\n(a) adequate facilities, trained personnel and approved procedures must be available for sampling, inspecting, and testing starting materials,", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Procedimientos de Reintroducci\u00f3n de Productos**: Los productos que han experimentado eventos inusuales durante el empaquetado deben ser reintroducidos en el proceso solo despu\u00e9s de una inspecci\u00f3n especial, investigaci\u00f3n y aprobaci\u00f3n por parte del personal autorizado. Es fundamental mantener un registro detallado de esta operaci\u00f3n.\n\n2. **Investigaci\u00f3n de Discrepancias**: Cualquier discrepancia significativa observada durante la reconciliaci\u00f3n de productos y materiales de empaquetado debe ser investigada y registrada antes de la liberaci\u00f3n del producto. Esto incluye la revisi\u00f3n de registros de producci\u00f3n y la investigaci\u00f3n de cualquier divergencia en las especificaciones de producci\u00f3n.\n\n3. **Pr\u00e1cticas de Control de Calidad (QC)**: El control de calidad es una parte esencial de las Buenas Pr\u00e1cticas de Manufactura (GMP) que se ocupa de la muestreo, especificaciones y pruebas. La independencia del QC respecto a la producci\u00f3n es fundamental, y cada fabricante debe contar con una funci\u00f3n de QC que tenga recursos adecuados para llevar a cabo sus responsabilidades.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para reintroducir un producto en el proceso de empaquetado despu\u00e9s de un evento inusual?**\n   - La reintroducci\u00f3n de un producto en el proceso de empaquetado tras un evento inusual requiere una inspecci\u00f3n especial, una investigaci\u00f3n y la aprobaci\u00f3n de personal autorizado. Adem\u00e1s, se debe mantener un registro detallado de esta operaci\u00f3n.\n\n2. **\u00bfC\u00f3mo se debe manejar una discrepancia significativa observada durante la reconciliaci\u00f3n de productos?**\n   - Cualquier discrepancia significativa debe ser investigada, satisfactoriamente contabilizada y registrada antes de la liberaci\u00f3n del producto. Esto incluye revisar los registros de producci\u00f3n y, si es necesario, investigar otros lotes del mismo producto o productos asociados.\n\n3. **\u00bfCu\u00e1les son los requisitos b\u00e1sicos para una funci\u00f3n de control de calidad (QC) en un fabricante?**\n   - Los requisitos b\u00e1sicos para una funci\u00f3n de QC incluyen la disponibilidad de instalaciones adecuadas, personal capacitado y procedimientos aprobados para el muestreo, inspecci\u00f3n y prueba de materiales de inicio. Adem\u00e1s, la funci\u00f3n de QC debe ser independiente de otros departamentos y estar bajo la autoridad de una persona con las calificaciones y experiencia adecuadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n sobre Operaciones de Empaque\n\n1. **Minimizaci\u00f3n de Riesgos**: Se enfatiza la importancia de establecer un programa de operaciones de empaque que minimice el riesgo de contaminaci\u00f3n cruzada, confusiones o sustituciones. Se proh\u00edbe empaquetar productos diferentes en proximidad a menos que haya segregaci\u00f3n f\u00edsica o un sistema alternativo que garantice la seguridad.\n\n2. **Limpieza del \u00c1rea de Trabajo**: Antes de iniciar las operaciones de empaque, es esencial asegurar que el \u00e1rea de trabajo, las l\u00edneas de empaque, las m\u00e1quinas de impresi\u00f3n y otros equipos est\u00e9n limpios y libres de materiales no necesarios. Esto debe incluir un procedimiento de limpieza de l\u00ednea documentado.\n\n3. **Identificaci\u00f3n del Producto**: El nombre y el n\u00famero de lote del producto deben estar visibles en cada estaci\u00f3n o l\u00ednea de empaque.\n\n4. **Control de Etiquetado**: El llenado y sellado deben ser seguidos r\u00e1pidamente por el etiquetado. Si hay retrasos, se deben aplicar procedimientos para evitar confusiones o errores en el etiquetado.\n\n5. **Verificaci\u00f3n de Impresi\u00f3n**: Se debe verificar y registrar la correcta impresi\u00f3n de n\u00fameros de c\u00f3digo o fechas de caducidad, prestando especial atenci\u00f3n a la impresi\u00f3n manual.\n\n6. **Uso de Etiquetas**: Se debe tener cuidado al usar etiquetas cortadas y al realizar impresiones fuera de l\u00ednea. Las etiquetas de alimentaci\u00f3n en rollo son preferibles para evitar confusiones. Se recomienda la verificaci\u00f3n en l\u00ednea de etiquetas mediante medios electr\u00f3nicos automatizados y controles m\u00e1s frecuentes para etiquetas manuales.\n\n7. **Control de Calidad Durante el Empaque**: Se deben realizar verificaciones regulares durante el empaque que incluyan la apariencia de los paquetes, la completitud de los mismos, el uso correcto de productos y materiales de empaque, la correcci\u00f3n de sobreimpresiones y el funcionamiento de los monitores de l\u00ednea.\n\n8. **Manejo de Muestras**: Las muestras que se retiran de la l\u00ednea de empaque no deben ser devueltas.\n\n### Entidades Clave\n- **Productos**: Elementos que se empaquetan.\n- **L\u00ednea de Empaque**: Equipos y estaciones donde se realizan las operaciones de empaque.\n- **Etiquetas**: Material utilizado para identificar productos.\n- **Procedimientos de Limpieza**: Protocolos para asegurar la limpieza del \u00e1rea de trabajo.\n- **Control de Calidad**: Proceso de verificaci\u00f3n durante las operaciones de empaque. \n\nEste resumen destaca la importancia de la seguridad, limpieza y control de calidad en las operaciones de empaque para garantizar la integridad del producto.", "excerpt_keywords": "Keywords: packaging, quality control, inspection, discrepancies, Good Manufacturing Practices"}}, "188da637-1a00-4772-9d35-a7137bc7eb22": {"node_ids": ["6bc684c3-945a-494c-bbec-71e427f6b3a7"], "metadata": {"page_label": "155", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\npackaging materials, and intermediate, bulk, and finished products, \nand where appropriate for monitoring environmental conditions for \nGMP purposes; \n(b) samples of starting materials, packaging materials, intermediate \nproducts, bulk products and finished products must be taken by methods \nand personnel approved of by the QC department; \n(c) qualification and validation; \n(d) records must be made (manually and/or by recording instruments) \ndemonstrating that all the required sampling, inspecting and testing \nprocedures have actually been carried out and that any deviations have \nbeen fully recorded and investigated; \n(e) the finished products must contain ingredients complying with the \nqualitative and quantitative composition of the product described in \nthe marketing authorization; the ingredients must be of the required \npurity, in their proper container and correctly labelled; \n(f) records must be made of the results of inspecting and testing the materials \nand intermediate, bulk and finished products against specifications; \nproduct assessment must include a review and evaluation of the \nrelevant production documentation and an assessment of deviations \nfrom specified procedures; \n(g) sufficient samples of starting materials and products must be retained \nto permit future examination of the product if necessary; the retained \nproduct must be kept in its final pack unless the pack is exceptionally \nlarge. \n\n17.4 QC as a whole will also have other duties, such as to establish, \nvalidate and implement all QC procedures, to evaluate, maintain, and store \nthe reference standards for substances, to ensure the correct labelling of \ncontainers of materials and products, to ensure that the stability of the active \npharmaceutical ingredients (APIs) and products is monitored, to participate \nin the investigation of complaints related to the quality of the product, and \nto participate in environmental monitoring. All these operations should be \ncarried out in accordance with written procedures and, where necessary, \nrecorded. \n\n17.5 QC personnel must have access to production areas for sampling and \ninvestigation as appropriate. \n\n**Control of starting materials and intermediate, \nbulk and finished products**\n\n17.6 All tests should follow the instructions given in the relevant \nwritten test procedure for each material or product. The result should \nbe checked by the supervisor before the material or product is released \nor rejected.\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl texto se centra en los procedimientos de control de calidad (QC) en la producci\u00f3n farmac\u00e9utica, destacando la importancia de la toma de muestras, la validaci\u00f3n de procesos, el registro de resultados y la garant\u00eda de que los productos terminados cumplan con las especificaciones establecidas. Se enfatiza la necesidad de que el personal de QC tenga acceso a las \u00e1reas de producci\u00f3n y que todas las operaciones se realicen de acuerdo con procedimientos escritos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para la toma de muestras de materiales y productos en el contexto de control de calidad?**\n   - Respuesta: Las muestras de materiales y productos deben ser tomadas por m\u00e9todos y personal aprobados por el departamento de control de calidad (QC), asegurando que se sigan las instrucciones de los procedimientos de prueba escritos.\n\n2. **\u00bfQu\u00e9 registros son necesarios para demostrar que se han cumplido los procedimientos de muestreo, inspecci\u00f3n y prueba?**\n   - Respuesta: Se deben realizar registros manuales y/o mediante instrumentos de grabaci\u00f3n que demuestren que todos los procedimientos requeridos han sido llevados a cabo, y que cualquier desviaci\u00f3n ha sido completamente registrada e investigada.\n\n3. **\u00bfCu\u00e1les son algunas de las responsabilidades adicionales del departamento de control de calidad (QC) m\u00e1s all\u00e1 de la inspecci\u00f3n de productos?**\n   - Respuesta: Adem\u00e1s de la inspecci\u00f3n de productos, el departamento de QC tiene la responsabilidad de establecer, validar e implementar todos los procedimientos de QC, evaluar y mantener est\u00e1ndares de referencia, asegurar el etiquetado correcto de los envases, monitorear la estabilidad de los ingredientes farmac\u00e9uticos activos (APIs) y participar en la investigaci\u00f3n de quejas relacionadas con la calidad del producto.", "prev_section_summary": "### Temas Clave:\n\n1. **Reintroducci\u00f3n de Productos**: Los productos que han tenido eventos inusuales durante el empaquetado deben ser reintroducidos solo despu\u00e9s de una inspecci\u00f3n especial, investigaci\u00f3n y aprobaci\u00f3n por parte de personal autorizado, manteniendo un registro detallado de la operaci\u00f3n.\n\n2. **Investigaci\u00f3n de Discrepancias**: Cualquier discrepancia significativa observada durante la reconciliaci\u00f3n de productos y materiales de empaquetado debe ser investigada y registrada antes de la liberaci\u00f3n del producto. Esto incluye revisar los registros de producci\u00f3n y, si es necesario, investigar otros lotes relacionados.\n\n3. **Destrucci\u00f3n de Materiales No Utilizados**: Al finalizar una operaci\u00f3n de empaquetado, los materiales de empaquetado no utilizados deben ser destruidos y documentados adecuadamente.\n\n4. **Control de Calidad (QC)**: El control de calidad es esencial en las Buenas Pr\u00e1cticas de Manufactura (GMP) y se ocupa de muestreo, especificaciones y pruebas. La independencia del QC respecto a la producci\u00f3n es fundamental, y cada fabricante debe contar con una funci\u00f3n de QC con recursos adecuados.\n\n5. **Requisitos para la Funci\u00f3n de QC**: La funci\u00f3n de QC debe tener instalaciones adecuadas, personal capacitado y procedimientos aprobados para el muestreo, inspecci\u00f3n y prueba de materiales de inicio.\n\n### Entidades:\n\n- **Productos**: Elementos involucrados en el proceso de empaquetado.\n- **Personal Autorizado**: Individuos responsables de la inspecci\u00f3n y aprobaci\u00f3n de productos.\n- **Registros de Producci\u00f3n**: Documentaci\u00f3n que debe ser revisada durante el proceso de liberaci\u00f3n de lotes.\n- **Materiales de Empaque**: Incluyen materiales codificados y no codificados utilizados en el empaquetado de productos.\n- **Control de Calidad (QC)**: Funci\u00f3n que asegura que los productos cumplan con los est\u00e1ndares de calidad antes de su liberaci\u00f3n.\n- **Manufactura**: Proceso de producci\u00f3n que debe seguir las Buenas Pr\u00e1cticas de Manufactura (GMP).", "excerpt_keywords": "Keywords: control de calidad, muestreo, productos farmac\u00e9uticos, validaci\u00f3n, Buenas Pr\u00e1cticas de Manufactura"}}, "873ddd4a-bb00-402e-bb3f-cb0925e89263": {"node_ids": ["d8f70c88-8dfa-4c2f-b442-3875c39f0a69"], "metadata": {"page_label": "156", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 17.7 \nSamples should be representative of the batches of material from which they are taken in accordance with the approved written procedure.\n\n# 17.8 \nSampling should be carried out so as to avoid contamination or other adverse effects on quality. The containers that have been sampled should be marked accordingly and carefully resealed after sampling.\n\n# 17.9 \nCare should be taken during sampling to guard against contamination or mix up of, or by, the material being sampled. All sampling equipment that comes into contact with the material should be clean. Some particularly hazardous or potent materials may require special precautions.\n\n# 17.10 \nSampling equipment should be cleaned and, if necessary, sterilized before and after each use and stored separately from other laboratory equipment.\n\n# 17.11 \nEach sample container should bear a label indicating:\n\n(a) the name of the sampled material;  \n(b) the batch or lot number;  \n(c) the number of the container from which the sample has been taken;  \n(d) the number of the sample;  \n(e) the signature of the person who has taken the sample;  \n(f) the date of sampling.\n\n# 17.12 \nOut-of-specification results obtained during testing of materials or products should be investigated in accordance with an approved procedure. Records should be maintained.\n\n## Test requirements\n\n### Starting and packaging materials\n\n# 17.13 \nBefore releasing a starting or packaging material for use, the QC manager should ensure that the materials have been tested for conformity with specifications for identity, strength, purity and other quality parameters.\n\n# 17.14 \nAn identity test should be conducted on a sample from each container of starting material (see also section 14.14).\n\nIt is permissible to sample only a proportion of the containers where a validated procedure has been established to ensure that no single container of starting material has been incorrectly labelled.\n\nThis validation should take account of at least the following aspects:\n\n- the nature and status of the manufacturer and of the supplier and their understanding of the GMP requirements;\n- the QA system of the manufacturer of the starting material;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las directrices de muestreo y pruebas de materiales de inicio y empaquetado seg\u00fan las normas de Buenas Pr\u00e1cticas de Manufactura (GMP) establecidas por la OMS. Se enfatiza la importancia de que las muestras sean representativas, la limpieza y esterilizaci\u00f3n del equipo de muestreo, el etiquetado adecuado de los contenedores de muestra, y la necesidad de realizar pruebas de identidad y conformidad antes de liberar materiales para su uso. Tambi\u00e9n se menciona la investigaci\u00f3n de resultados fuera de especificaci\u00f3n y la validaci\u00f3n de procedimientos de muestreo.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar que las muestras sean representativas de los lotes de material?**\n   - La respuesta se puede encontrar en la secci\u00f3n 17.7, que establece que las muestras deben ser representativas de los lotes de material de acuerdo con un procedimiento escrito aprobado.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de cada contenedor de muestra?**\n   - Seg\u00fan la secci\u00f3n 17.11, cada contenedor de muestra debe llevar una etiqueta que indique el nombre del material muestreado, el n\u00famero de lote, el n\u00famero del contenedor, el n\u00famero de la muestra, la firma de la persona que tom\u00f3 la muestra y la fecha de muestreo.\n\n3. **\u00bfCu\u00e1les son los aspectos que deben considerarse al validar un procedimiento de muestreo para materiales de inicio?**\n   - La validaci\u00f3n debe tener en cuenta la naturaleza y el estado del fabricante y del proveedor, as\u00ed como su comprensi\u00f3n de los requisitos de GMP y el sistema de aseguramiento de calidad del fabricante del material de inicio, como se menciona en la secci\u00f3n 17.14.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Control de Calidad (QC):** Se enfatiza la importancia de los procedimientos de control de calidad en la producci\u00f3n farmac\u00e9utica, incluyendo la toma de muestras, la inspecci\u00f3n y la validaci\u00f3n de productos.\n\n2. **Muestreo de Materiales:** Se requiere que las muestras de materiales (iniciadores, empaques, productos intermedios, a granel y terminados) sean tomadas por m\u00e9todos y personal aprobados por el departamento de QC.\n\n3. **Registro de Procedimientos:** Es esencial llevar registros manuales y/o mediante instrumentos que demuestren que se han cumplido todos los procedimientos de muestreo, inspecci\u00f3n y prueba, as\u00ed como registrar cualquier desviaci\u00f3n.\n\n4. **Cumplimiento de Especificaciones:** Los productos terminados deben cumplir con la composici\u00f3n cualitativa y cuantitativa descrita en la autorizaci\u00f3n de comercializaci\u00f3n, y los ingredientes deben ser de la pureza requerida y correctamente etiquetados.\n\n5. **Responsabilidades del Departamento de QC:** Adem\u00e1s de la inspecci\u00f3n, el departamento de QC debe establecer y validar procedimientos, mantener est\u00e1ndares de referencia, monitorear la estabilidad de los ingredientes activos y participar en la investigaci\u00f3n de quejas sobre la calidad del producto.\n\n6. **Acceso a \u00c1reas de Producci\u00f3n:** El personal de QC debe tener acceso a las \u00e1reas de producci\u00f3n para realizar muestreos e investigaciones.\n\n7. **Procedimientos de Prueba:** Todos los tests deben seguir las instrucciones de los procedimientos de prueba escritos, y los resultados deben ser verificados por un supervisor antes de liberar o rechazar un material o producto.\n\n**Entidades:**\n\n- **Materiales:** Iniciadores, materiales de empaque, productos intermedios, productos a granel, productos terminados.\n- **Departamento de Control de Calidad (QC):** Responsable de la implementaci\u00f3n y supervisi\u00f3n de los procedimientos de control de calidad.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs):** Sustancias cuya estabilidad debe ser monitoreada.\n- **Documentaci\u00f3n de Producci\u00f3n:** Registros que deben ser revisados y evaluados como parte del proceso de control de calidad.\n\nEste resumen destaca la importancia de los procedimientos de control de calidad en la industria farmac\u00e9utica y las responsabilidades del personal involucrado en asegurar que los productos cumplan con los est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: muestreo, control de calidad, Buenas Pr\u00e1cticas de Manufactura, etiquetado, validaci\u00f3n"}}, "92024896-d8dc-40ec-8113-cfbf90b70e0f": {"node_ids": ["198e0c74-b97d-4d8e-8962-94cf7b764c26"], "metadata": {"page_label": "157", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the manufacturing conditions under which the starting material is produced and controlled; and  \n\u2014 the nature of the starting material and the medicinal products in which it will be used.\n\nUnder such a system it is possible that a validated procedure for exemption from the requirement for identity testing of each incoming container of starting material could be accepted for the following:\n\n\u2014 starting materials coming from a single product manufacturer or plant;  \nor  \n\u2014 starting materials coming directly from a manufacturer, or in the manufacturer\u2019s sealed container where there is a history of reliability, and regular audits of the manufacturer\u2019s QA system are conducted by the purchaser (the manufacturer of the medicinal product) or by an officially accredited body.\n\nIt is improbable that such a procedure could be satisfactorily validated for either:\n\n\u2014 starting materials supplied by intermediaries, such as brokers, where the source of manufacture is unknown or not audited; or  \n\u2014 starting materials for use in parenteral products.\n\n17.15 Each batch (lot) of printed packaging materials must be examined following receipt.\n\n17.16 In lieu of full testing by the manufacturer, a certificate of analysis may be accepted from the supplier, provided that the manufacturer establishes the reliability of the supplier\u2019s analysis through appropriate periodic validation of the supplier\u2019s test results (see sections 8.8 and 8.9) and through on-site audits of the supplier\u2019s capabilities. (This does not affect section 17.15.) Certificates must be originals (not photocopies) or otherwise have their authenticity assured. Certificates must contain at least the following information (7):\n\n(a) identification (name and address) of the issuing supplier;  \n(b) signature of the competent official, and statement of his or her qualifications;  \n(c) the name of the material tested;  \n(d) the batch number of the material tested;  \n(e) the specifications and methods used;  \n(f) the test results obtained;  \n(g) the date of testing.\n\n*In-process control*  \n17.17 In-process control records should be maintained and form a part of the batch records (see section 15.25).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento aborda las condiciones de fabricaci\u00f3n y control de los materiales de partida utilizados en la producci\u00f3n de productos medicinales. Se discuten procedimientos para la exenci\u00f3n de pruebas de identidad de los materiales de partida, especialmente en situaciones donde hay un historial de fiabilidad del fabricante. Tambi\u00e9n se menciona la aceptaci\u00f3n de certificados de an\u00e1lisis de proveedores, as\u00ed como la necesidad de mantener registros de control en proceso como parte de la documentaci\u00f3n de lotes.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede aceptar un procedimiento validado para la exenci\u00f3n de pruebas de identidad de los materiales de partida?**\n   - Respuesta: Se puede aceptar un procedimiento validado para la exenci\u00f3n de pruebas de identidad si los materiales de partida provienen de un \u00fanico fabricante o planta, o si provienen directamente de un fabricante en un contenedor sellado, siempre que haya un historial de fiabilidad y se realicen auditor\u00edas regulares del sistema de aseguramiento de calidad del fabricante.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe contener un certificado de an\u00e1lisis aceptado por el fabricante?**\n   - Respuesta: Un certificado de an\u00e1lisis debe contener la identificaci\u00f3n del proveedor, la firma de un funcionario competente, el nombre del material probado, el n\u00famero de lote, las especificaciones y m\u00e9todos utilizados, los resultados de las pruebas obtenidos y la fecha de la prueba.\n\n3. **\u00bfQu\u00e9 se debe hacer con cada lote de materiales de embalaje impresos tras su recepci\u00f3n?**\n   - Respuesta: Cada lote de materiales de embalaje impresos debe ser examinado tras su recepci\u00f3n, seg\u00fan lo indicado en la secci\u00f3n 17.15 del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Muestreo Representativo**:\n   - Las muestras deben ser representativas de los lotes de material, siguiendo un procedimiento escrito aprobado (Secci\u00f3n 17.7).\n\n2. **Prevenci\u00f3n de Contaminaci\u00f3n**:\n   - Se deben tomar medidas para evitar la contaminaci\u00f3n y otros efectos adversos en la calidad durante el muestreo (Secci\u00f3n 17.8 y 17.9).\n   - El equipo de muestreo debe estar limpio y, en caso necesario, esterilizado antes y despu\u00e9s de su uso (Secci\u00f3n 17.10).\n\n3. **Etiquetado de Contenedores de Muestra**:\n   - Cada contenedor de muestra debe estar etiquetado con informaci\u00f3n espec\u00edfica, incluyendo el nombre del material, n\u00famero de lote, n\u00famero del contenedor, n\u00famero de muestra, firma del muestreador y fecha de muestreo (Secci\u00f3n 17.11).\n\n4. **Investigaci\u00f3n de Resultados Fuera de Especificaci\u00f3n**:\n   - Los resultados que no cumplan con las especificaciones deben ser investigados de acuerdo con un procedimiento aprobado, y se deben mantener registros (Secci\u00f3n 17.12).\n\n5. **Requisitos de Prueba para Materiales de Inicio y Empaque**:\n   - Antes de liberar materiales para su uso, el gerente de control de calidad debe asegurarse de que se hayan probado para verificar su conformidad con las especificaciones de identidad, fuerza, pureza y otros par\u00e1metros de calidad (Secci\u00f3n 17.13).\n   - Se debe realizar una prueba de identidad en una muestra de cada contenedor de material de inicio, con la posibilidad de muestrear solo una proporci\u00f3n de los contenedores si se ha establecido un procedimiento validado (Secci\u00f3n 17.14).\n\n6. **Validaci\u00f3n de Procedimientos de Muestreo**:\n   - La validaci\u00f3n de los procedimientos de muestreo debe considerar la naturaleza y estado del fabricante y proveedor, su comprensi\u00f3n de los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) y el sistema de aseguramiento de calidad del fabricante del material de inicio (Secci\u00f3n 17.14).\n\n### Entidades Clave\n- **Organizaci\u00f3n**: OMS (Organizaci\u00f3n Mundial de la Salud)\n- **Documentos**: Buenas Pr\u00e1cticas de Manufactura (GMP), Procedimientos aprobados\n- **Roles**: Gerente de Control de Calidad (QC Manager)\n- **Materiales**: Materiales de inicio y empaquetado, Muestras, Contenedores de muestra\n- **Par\u00e1metros de Calidad**: Identidad, Fuerza, Pureza, Conformidad\n\nEste resumen destaca la importancia de seguir procedimientos rigurosos en el muestreo y pruebas de materiales para garantizar la calidad y seguridad en la manufactura.", "excerpt_keywords": "Keywords: starting materials, identity testing, certificate of analysis, quality assurance, in-process control"}}, "776d97f0-360c-427d-9a08-f443ae2a5d02": {"node_ids": ["007d50e8-a64a-459e-bd3f-aed6f0dece60"], "metadata": {"page_label": "158", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finished Products\n\n17.18 For each batch of medicines product, there should be an appropriate laboratory determination of satisfactory conformity to its finished product specification prior to release.\n\n17.19 Products failing to meet the established specifications or any other relevant quality criteria should be rejected.\n\n## Batch Record Review\n\n17.20 QC records should be reviewed as part of the approval process of batch release before transfer to the authorized person. Any divergence or failure of a batch to meet its specifications should be thoroughly investigated. The investigation should, if necessary, extend to other batches of the same product and other products that may have been associated with the specific failure or discrepancy. A written record of the investigation should be made and should include the conclusion and follow-up action.\n\n17.21 Retention samples from each batch of finished product should be kept for at least one year after the expiry date. Finished products should usually be kept in their final packaging and stored under the recommended conditions. If exceptionally large packages are produced, smaller samples might be stored in appropriate containers. Samples of active starting materials should be retained for at least one year beyond the expiry date of the corresponding finished product. Other starting materials (other than solvents, gases and water) should be retained for a minimum of two years if their stability allows. Retention samples of materials and products should be of a size sufficient to permit at least two full re-examinations.\n\n## Stability Studies\n\n17.22 QC should evaluate the quality and stability of finished pharmaceutical products and, when necessary, of starting materials and intermediate products.\n\n17.23 QC should establish expiry dates and shelf-life specifications on the basis of stability tests related to storage conditions.\n\n17.24 A written programme for ongoing stability determination should be developed and implemented to include elements such as:\n\n- (a) a complete description of the medicine involved in the study;\n- (b) the complete set of testing parameters and methods, describing all tests for potency, purity, and physical characteristics and documented evidence that these tests indicate stability;\n- (c) provision for the inclusion of a sufficient number of batches;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las normas y procedimientos relacionados con la calidad y la estabilidad de los productos farmac\u00e9uticos terminados. Se enfatiza la importancia de realizar determinaciones de conformidad en cada lote de medicamentos antes de su liberaci\u00f3n, as\u00ed como la necesidad de revisar los registros de control de calidad (QC) y llevar a cabo investigaciones en caso de discrepancias. Adem\u00e1s, se establecen directrices sobre la retenci\u00f3n de muestras y la realizaci\u00f3n de estudios de estabilidad para garantizar que los productos mantengan su calidad a lo largo de su vida \u00fatil.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si un lote de producto farmac\u00e9utico no cumple con las especificaciones establecidas?**\n   - Respuesta: Los productos que no cumplan con las especificaciones establecidas o cualquier otro criterio de calidad relevante deben ser rechazados. Adem\u00e1s, cualquier divergencia o fallo en un lote debe ser investigado a fondo, y la investigaci\u00f3n puede extenderse a otros lotes del mismo producto y a otros productos asociados.\n\n2. **\u00bfCu\u00e1nto tiempo deben conservarse las muestras de retenci\u00f3n de los productos terminados y de los materiales de partida activos?**\n   - Respuesta: Las muestras de retenci\u00f3n de cada lote de producto terminado deben conservarse durante al menos un a\u00f1o despu\u00e9s de la fecha de caducidad. Las muestras de materiales de partida activos deben conservarse durante al menos un a\u00f1o m\u00e1s all\u00e1 de la fecha de caducidad del producto terminado correspondiente.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un programa escrito para la determinaci\u00f3n continua de la estabilidad de los productos farmac\u00e9uticos?**\n   - Respuesta: El programa debe incluir una descripci\u00f3n completa del medicamento involucrado en el estudio, un conjunto completo de par\u00e1metros y m\u00e9todos de prueba que describan todas las pruebas de potencia, pureza y caracter\u00edsticas f\u00edsicas, as\u00ed como evidencia documentada de que estas pruebas indican estabilidad. Tambi\u00e9n debe haber provisiones para incluir un n\u00famero suficiente de lotes en el estudio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Condiciones de Fabricaci\u00f3n y Control:** Se discuten las condiciones bajo las cuales se producen y controlan los materiales de partida utilizados en la fabricaci\u00f3n de productos medicinales.\n2. **Exenci\u00f3n de Pruebas de Identidad:** Se establece un procedimiento validado para la exenci\u00f3n de pruebas de identidad de los materiales de partida, aplicable en situaciones espec\u00edficas, como cuando los materiales provienen de un \u00fanico fabricante confiable.\n3. **Certificados de An\u00e1lisis:** Se permite la aceptaci\u00f3n de certificados de an\u00e1lisis de proveedores en lugar de pruebas completas, siempre que se valide la fiabilidad del an\u00e1lisis del proveedor mediante auditor\u00edas y validaciones peri\u00f3dicas.\n4. **Examen de Materiales de Embalaje:** Cada lote de materiales de embalaje impresos debe ser examinado tras su recepci\u00f3n.\n5. **Registros de Control en Proceso:** Se enfatiza la importancia de mantener registros de control en proceso como parte de la documentaci\u00f3n de lotes.\n\n**Entidades:**\n- **Materiales de Partida:** Sustancias utilizadas en la fabricaci\u00f3n de productos medicinales.\n- **Fabricantes:** Entidades que producen los materiales de partida y los productos medicinales.\n- **Proveedores:** Entidades que suministran materiales y pueden emitir certificados de an\u00e1lisis.\n- **Auditor\u00edas:** Evaluaciones realizadas para asegurar la calidad y fiabilidad de los fabricantes y proveedores.\n- **Certificados de An\u00e1lisis:** Documentos que validan la calidad y especificaciones de los materiales probados.\n\nEste resumen destaca los aspectos fundamentales relacionados con la producci\u00f3n y control de materiales en la industria farmac\u00e9utica, as\u00ed como los procedimientos de validaci\u00f3n y documentaci\u00f3n necesarios para garantizar la calidad de los productos medicinales.", "excerpt_keywords": "Keywords: finished products, quality control, stability studies, batch record review, retention samples"}}, "495b6b00-0501-45ac-bb1c-45fb284f11b2": {"node_ids": ["e4a2c318-254b-4764-8456-bfab5a5ec9ad"], "metadata": {"page_label": "159", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "(d) the testing schedule for each medicine;  \n(e) provision for special storage conditions;  \n(f) provision for adequate sample retention;  \n(g) a summary of all the data generated, including the evaluation and the conclusions of the study.\n\n17.25 Stability should be determined prior to marketing and following any significant changes in processes, equipment, packaging materials, etc.\n\n# References\n\n1. Good manufacturing practices for pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003, Annex 4 (WHO Technical Report Series, No. 908).\n\n2. Validation of analytical procedures used in the examination of pharmaceutical materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 5 (WHO Technical Report Series, No. 823).\n\n3. EudraLex \u2014 Volume 4. Good manufacturing practice (GMP) Guidelines. European Commission. (http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm).\n\n4. Pharmaceutical Inspection Convention, Pharmaceutical Inspection Co-operation Scheme (PIC/S). In: Guide to good manufacturing practice for medicinal plants, Geneva, PIC/S Secretariat, 2000.\n\n5. *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007.\n\n6. Good manufacturing practices for pharmaceutical products, Part one. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report*. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 823); and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection*. Geneva, World Health Organization, 2007; and in: *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials*. Geneva, World Health Organization, 2010 (CD-ROM).\n\n7. Model certificate of analysis. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002, Annex 10 (WHO Technical Report Series, No. 902).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 aspectos se deben considerar en el programa de pruebas para cada medicamento seg\u00fan el documento?**\n   - **Respuesta:** El programa de pruebas debe incluir un cronograma de pruebas para cada medicamento, provisiones para condiciones de almacenamiento especiales, provisiones para la retenci\u00f3n adecuada de muestras y un resumen de todos los datos generados, incluyendo la evaluaci\u00f3n y las conclusiones del estudio.\n\n2. **\u00bfCu\u00e1ndo debe determinarse la estabilidad de un medicamento seg\u00fan las directrices de la OMS?**\n   - **Respuesta:** La estabilidad debe determinarse antes de la comercializaci\u00f3n y despu\u00e9s de cualquier cambio significativo en los procesos, equipos, materiales de embalaje, etc.\n\n3. **\u00bfCu\u00e1les son algunas de las referencias clave citadas en el documento sobre buenas pr\u00e1cticas de fabricaci\u00f3n?**\n   - **Respuesta:** Algunas referencias clave incluyen el \"Good manufacturing practices for pharmaceutical products\" de la OMS (2003), la \"Validation of analytical procedures\" (1992), y las \"Good manufacturing practice (GMP) Guidelines\" de la Comisi\u00f3n Europea (EudraLex, Volumen 4).\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS, \"Technical Report Series 961\", establece directrices sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos. Se enfatiza la importancia de un programa de pruebas que incluya un cronograma, condiciones de almacenamiento, retenci\u00f3n de muestras y un resumen de datos. Adem\u00e1s, se destaca que la estabilidad de los medicamentos debe evaluarse antes de su comercializaci\u00f3n y tras cambios significativos en los procesos de producci\u00f3n. Se citan varias referencias clave que respaldan estas directrices, incluyendo informes de la OMS y directrices de la Comisi\u00f3n Europea.\n\n### Preguntas Mejoradas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en el resumen de datos generados durante el estudio de un medicamento?**\n2. **\u00bfQu\u00e9 cambios en el proceso de fabricaci\u00f3n podr\u00edan requerir una nueva evaluaci\u00f3n de estabilidad seg\u00fan las directrices de la OMS?**\n3. **\u00bfCu\u00e1les son las implicaciones de no seguir las provisiones para condiciones de almacenamiento especiales en la fabricaci\u00f3n de medicamentos?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Determinaci\u00f3n de Conformidad**:\n   - Cada lote de productos farmac\u00e9uticos debe someterse a una evaluaci\u00f3n de conformidad en laboratorio antes de su liberaci\u00f3n.\n\n2. **Rechazo de Productos**:\n   - Los productos que no cumplan con las especificaciones establecidas o criterios de calidad relevantes deben ser rechazados.\n\n3. **Revisi\u00f3n de Registros de Control de Calidad (QC)**:\n   - Los registros de QC deben ser revisados como parte del proceso de aprobaci\u00f3n para la liberaci\u00f3n de lotes. Cualquier divergencia o fallo debe ser investigado exhaustivamente.\n\n4. **Muestras de Retenci\u00f3n**:\n   - Las muestras de cada lote de producto terminado deben conservarse durante al menos un a\u00f1o despu\u00e9s de la fecha de caducidad. Las muestras de materiales de partida activos deben conservarse por un a\u00f1o adicional.\n\n5. **Estudios de Estabilidad**:\n   - Se debe evaluar la calidad y estabilidad de los productos farmac\u00e9uticos terminados, as\u00ed como de los materiales de partida e intermedios, cuando sea necesario.\n\n6. **Programa de Determinaci\u00f3n de Estabilidad**:\n   - Se debe desarrollar un programa escrito que incluya:\n     - Descripci\u00f3n completa del medicamento.\n     - Conjunto completo de par\u00e1metros y m\u00e9todos de prueba.\n     - Provisi\u00f3n para incluir un n\u00famero suficiente de lotes en el estudio.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las normas y procedimientos.\n- **Control de Calidad (QC)**: Proceso que asegura la conformidad y calidad de los productos farmac\u00e9uticos.\n- **Lotes de Productos Farmac\u00e9uticos**: Unidades de producci\u00f3n que deben cumplir con especificaciones de calidad.\n- **Muestras de Retenci\u00f3n**: Muestras conservadas para futuras pruebas y verificaci\u00f3n de calidad.\n- **Estudios de Estabilidad**: Evaluaciones que determinan la duraci\u00f3n y condiciones de almacenamiento de los productos.", "excerpt_keywords": "Keywords: pharmaceutical stability, good manufacturing practices, quality assurance, testing schedule, sample retention"}}, "6c79e4ea-1009-489d-aa64-4f60c40339bd": {"node_ids": ["c31cf40e-8729-42f2-a82f-085214cb03f8"], "metadata": {"page_label": "160", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 4\n\n## WHO guidelines on good manufacturing practices for blood establishments\n\n1. Introduction\n\n2. Glossary and abbreviations\n\n3. Quality management  \n   3.1 Principles  \n   3.2 Quality assurance  \n       3.2.1 Good manufacturing practice in blood establishments  \n       3.2.2 Quality control  \n   3.3 Product quality review  \n   3.4 Quality risk management  \n   3.5 Change control  \n   3.6 Deviation evaluation and reporting  \n   3.7 Corrective and preventive actions  \n   3.8 Internal audits  \n   3.9 Complaints and product recall  \n       3.9.1 Complaints  \n       3.9.2 Recalls  \n   3.10 Process improvement  \n   3.11 Look-back  \n\n4. Personnel  \n   4.1 Organization and responsibilities  \n   4.2 Training  \n       4.2.1 Initial training  \n       4.2.2 Continuous training  \n       4.2.3 Competency  \n   4.3 Personal hygiene  \n\n5. Documentation  \n   5.1 Standard operating procedures and records  \n       5.1.1 Standard operating procedures  \n       5.1.2 Records  \n   5.2 Document control  \n       5.2.1 Document management  \n       5.2.2 Record retention and archiving  \n\n6. Premises and equipment  \n   6.1 Premises  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que el contexto proporcionado puede responder, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un anexo de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre. Incluye secciones sobre gesti\u00f3n de calidad, personal, documentaci\u00f3n, y premisas y equipos. Se abordan aspectos como la garant\u00eda de calidad, el control de calidad, la formaci\u00f3n del personal, la gesti\u00f3n de documentos y el mantenimiento de las instalaciones.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los principios fundamentales de la gesti\u00f3n de calidad seg\u00fan las directrices de la OMS para los establecimientos de sangre?**\n   - Esta pregunta busca detalles sobre los principios espec\u00edficos que gu\u00edan la gesti\u00f3n de calidad en el contexto de la fabricaci\u00f3n de productos sangu\u00edneos.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para la evaluaci\u00f3n y el informe de desviaciones en los procesos de fabricaci\u00f3n de sangre?**\n   - Esta pregunta se centra en los pasos y protocolos que deben implementarse cuando se producen desviaciones en los procesos, lo que es crucial para mantener la calidad y la seguridad.\n\n3. **\u00bfQu\u00e9 requisitos de formaci\u00f3n continua se establecen para el personal en los establecimientos de sangre?**\n   - Esta pregunta indaga sobre las expectativas y requisitos espec\u00edficos para la formaci\u00f3n continua del personal, lo que es esencial para asegurar que el personal est\u00e9 actualizado en las mejores pr\u00e1cticas y procedimientos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Programa de Pruebas para Medicamentos:**\n   - Importancia de un cronograma de pruebas.\n   - Necesidad de provisiones para condiciones de almacenamiento especiales.\n   - Requisitos para la retenci\u00f3n adecuada de muestras.\n   - Inclusi\u00f3n de un resumen de datos generados, evaluaciones y conclusiones del estudio.\n\n2. **Estabilidad de Medicamentos:**\n   - Evaluaci\u00f3n de la estabilidad antes de la comercializaci\u00f3n.\n   - Reevaluaci\u00f3n de la estabilidad tras cambios significativos en procesos, equipos o materiales de embalaje.\n\n3. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP):**\n   - Directrices y referencias sobre GMP proporcionadas por la OMS y la Comisi\u00f3n Europea.\n   - Importancia de seguir estas directrices para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre buenas pr\u00e1cticas de fabricaci\u00f3n y calidad de productos farmac\u00e9uticos.\n- **EudraLex:** Conjunto de directrices de la Comisi\u00f3n Europea sobre buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Pharmaceutical Inspection Convention (PIC/S):** Organizaci\u00f3n que proporciona gu\u00edas sobre buenas pr\u00e1cticas de fabricaci\u00f3n para plantas medicinales.\n- **Referencias Citadas:**\n  - WHO Technical Report Series (varios n\u00fameros).\n  - Informes de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n\nEste resumen destaca la importancia de seguir directrices rigurosas en la fabricaci\u00f3n y evaluaci\u00f3n de medicamentos para garantizar su calidad y eficacia.", "excerpt_keywords": "Keywords: blood establishments, good manufacturing practices, quality management, personnel training, documentation"}}, "3d2ffa7a-377d-43f4-8ed3-e56c2499ea1e": {"node_ids": ["4b0dcfcc-3205-4f86-bf26-7b4efb411e9c"], "metadata": {"page_label": "161", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n6.1.1 Design and construction  \n6.1.2 Donor areas  \n6.1.3 Production areas  \n6.1.4 Storage areas  \n6.1.5 Laboratories  \n6.1.6 Mobile collection sites  \n\n6.2 Equipment  \n6.2.1 Design and construction  \n6.2.2 Maintenance  \n6.2.3 Cleaning  \n6.2.4 Calibration  \n\n6.3 Computerized systems  \n\n7. Qualification and validation  \n7.1 Qualification of equipment  \n7.2 Validation of manufacturing processes  \n7.3 Choosing an appropriate test system to screen for infectious disease  \n7.4 Assay performance validation  \n\n8. Management of materials and reagents  \n8.1 Materials and reagents  \n8.2 Receipt and quarantine  \n8.3 Release of incoming production material and test reagents  \n8.4 Storage  \n8.5 Traceability of materials and reagents  \n8.6 Supplier/vendor management  \n\n9. Manufacturing  \n9.1 Donor registration  \n9.2 Donor selection  \n9.2.1 Epidemiological surveillance of the donor population  \n9.2.2 Information to donors  \n9.2.3 Questionnaire and interview  \n9.2.4 Deferral policy and deferral criteria  \n9.2.5 Physical examination, donor health criteria and donor acceptance  \n\n9.3 Collection  \n9.3.1 Whole blood collection  \n9.3.2 Collection by apheresis  \n9.3.3 Safety of donors  \n\n9.4 Component preparation  \n9.4.1 Starting material  \n9.4.2 Methods of production  \n9.4.2.1 Centrifugation  \n9.4.2.2 Separation  \n9.4.2.3 Freezing  \n9.4.2.4 Leukocyte reduction  \n9.4.2.5 Irradiation  \n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a entender mejor el contenido:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos t\u00e9cnicos relacionados con la recolecci\u00f3n, procesamiento y gesti\u00f3n de materiales en el \u00e1mbito de la salud, espec\u00edficamente en la donaci\u00f3n de sangre y la producci\u00f3n de componentes sangu\u00edneos. Se detallan las instalaciones necesarias, el equipo, la calificaci\u00f3n y validaci\u00f3n de procesos, as\u00ed como la gesti\u00f3n de materiales y la manufactura de productos derivados de la sangre.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos para la selecci\u00f3n de donantes seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los criterios y procedimientos que se deben seguir para seleccionar donantes, incluyendo aspectos como la vigilancia epidemiol\u00f3gica y la salud del donante.\n\n2. **\u00bfQu\u00e9 m\u00e9todos de producci\u00f3n se describen para la preparaci\u00f3n de componentes sangu\u00edneos y cu\u00e1les son sus prop\u00f3sitos?**\n   - Esta pregunta se centra en los m\u00e9todos espec\u00edficos mencionados en el documento, como la centrifugaci\u00f3n y la irradiaci\u00f3n, y su relevancia en el proceso de producci\u00f3n de componentes sangu\u00edneos.\n\n3. **\u00bfC\u00f3mo se gestiona la trazabilidad de los materiales y reactivos en el contexto de la manufactura de productos sangu\u00edneos?**\n   - Esta pregunta busca entender los procedimientos y sistemas implementados para asegurar la trazabilidad de los materiales y reactivos, lo cual es crucial para la seguridad y eficacia en la producci\u00f3n de componentes sangu\u00edneos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido t\u00e9cnico y detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento es un anexo de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n para establecimientos de sangre. A continuaci\u00f3n se presentan los temas clave y entidades mencionados en la secci\u00f3n:\n\n1. **Gesti\u00f3n de Calidad**:\n   - **Principios**: Fundamentos que gu\u00edan la gesti\u00f3n de calidad en la fabricaci\u00f3n de productos sangu\u00edneos.\n   - **Aseguramiento de Calidad**: Incluye buenas pr\u00e1cticas de fabricaci\u00f3n y control de calidad.\n   - **Revisi\u00f3n de Calidad del Producto**: Evaluaci\u00f3n sistem\u00e1tica de la calidad de los productos.\n   - **Gesti\u00f3n de Riesgos de Calidad**: Identificaci\u00f3n y mitigaci\u00f3n de riesgos asociados a la calidad.\n   - **Control de Cambios**: Procedimientos para gestionar cambios en los procesos.\n   - **Evaluaci\u00f3n y Reporte de Desviaciones**: Protocolos para manejar desviaciones en los procesos de fabricaci\u00f3n.\n   - **Acciones Correctivas y Preventivas**: Estrategias para abordar y prevenir problemas de calidad.\n   - **Auditor\u00edas Internas**: Evaluaciones peri\u00f3dicas para asegurar el cumplimiento de las normas.\n   - **Quejas y Retiro de Productos**: Manejo de quejas y procedimientos para el retiro de productos defectuosos.\n   - **Mejora de Procesos**: Estrategias para optimizar los procesos de fabricaci\u00f3n.\n   - **Look-back**: Revisi\u00f3n de procesos y productos anteriores para asegurar la calidad.\n\n2. **Personal**:\n   - **Organizaci\u00f3n y Responsabilidades**: Estructura organizativa y roles del personal.\n   - **Formaci\u00f3n**: Incluye formaci\u00f3n inicial, continua y evaluaci\u00f3n de competencias.\n   - **Higiene Personal**: Normas de higiene que el personal debe seguir.\n\n3. **Documentaci\u00f3n**:\n   - **Procedimientos Operativos Est\u00e1ndar y Registros**: Importancia de tener procedimientos claros y registros precisos.\n   - **Control de Documentos**: Gesti\u00f3n de documentos y retenci\u00f3n de registros.\n\n4. **Instalaciones y Equipos**:\n   - **Premisas**: Requisitos y est\u00e1ndares para las instalaciones donde se lleva a cabo la fabricaci\u00f3n.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades que producen y gestionan productos sangu\u00edneos.\n- **Calidad**: Concepto central en la fabricaci\u00f3n y gesti\u00f3n de productos sangu\u00edneos.\n\nEste resumen abarca los aspectos fundamentales de las directrices de la OMS sobre buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de los establecimientos de sangre.", "excerpt_keywords": "Keywords: donaci\u00f3n de sangre, fabricaci\u00f3n, calidad, gesti\u00f3n de materiales, validaci\u00f3n"}}, "5f0229e8-424c-48ed-8c2f-e256249407fb": {"node_ids": ["ea249425-34f3-41dc-b8e5-41e7ae7c7c8a"], "metadata": {"page_label": "162", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n- 9.4.3.1 Whole blood\n- 9.4.3.2 Red-cell concentrate\n- 9.4.3.3 Platelet concentrate\n- 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n- 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\n## 9.5 Laboratory testing\n### 9.5.1 Screening tests for infectious disease markers\n- 9.5.1.1 Testing requirements\n- 9.5.1.2 Handling of samples and data\n- 9.5.1.3 Testing and post-analytical procedures\n- 9.5.1.4 Test interpretation and follow-up of reactive results\n\n### 9.5.2 Blood group typing\n### 9.5.3 Retention samples\n\n## 9.6 Quality monitoring of blood and blood components\n\n## 9.7 Labelling\n- 9.7.1 Label information\n- 9.7.2 Product name\n- 9.7.3 Expiry date\n\n## 9.8 Release of product\n## 9.9 Storage\n## 9.10 Distribution\n## 9.11 Shipping\n## 9.12 Returns\n\n# 10. Contract manufacturing, analysis and services\n\n# 11. Authors and acknowledgements\n\n# 12. References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda diversos aspectos relacionados con la sangre y los componentes sangu\u00edneos, incluyendo su recolecci\u00f3n, pruebas de laboratorio, etiquetado, almacenamiento, distribuci\u00f3n y otros procesos relacionados. Se detallan los tipos de sangre y componentes, as\u00ed como los procedimientos de prueba para detectar marcadores de enfermedades infecciosas, la tipificaci\u00f3n de grupos sangu\u00edneos y el monitoreo de calidad. Tambi\u00e9n se mencionan aspectos log\u00edsticos como el env\u00edo y la gesti\u00f3n de devoluciones.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los requisitos de prueba para los marcadores de enfermedades infecciosas en la sangre, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los procedimientos y est\u00e1ndares espec\u00edficos que deben seguirse para realizar pruebas de enfermedades infecciosas en muestras de sangre.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los productos sangu\u00edneos, seg\u00fan las directrices del informe?**\n   - Esta pregunta se centra en los requisitos de etiquetado, que son cruciales para la identificaci\u00f3n y el manejo seguro de los productos sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 procedimientos se deben seguir para la liberaci\u00f3n y distribuci\u00f3n de productos sangu\u00edneos?**\n   - Esta pregunta busca entender los pasos y protocolos necesarios para asegurar que los productos sangu\u00edneos sean liberados y distribuidos de manera segura y eficiente, lo cual es vital para la salud p\u00fablica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que probablemente no se encuentre f\u00e1cilmente en otras fuentes, bas\u00e1ndose en el contenido del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" se centra en la recolecci\u00f3n, procesamiento y gesti\u00f3n de materiales en el contexto de la donaci\u00f3n de sangre y la producci\u00f3n de componentes sangu\u00edneos. A continuaci\u00f3n se presentan los temas clave y entidades relevantes de la secci\u00f3n:\n\n#### 1. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**\n   - **\u00c1reas de Donantes**: Espacios destinados a la recepci\u00f3n y atenci\u00f3n de donantes.\n   - **\u00c1reas de Producci\u00f3n**: Zonas donde se procesan los componentes sangu\u00edneos.\n   - **\u00c1reas de Almacenamiento**: Espacios para guardar materiales y productos.\n   - **Laboratorios**: Instalaciones para realizar pruebas y an\u00e1lisis.\n   - **Sitios de Recolecci\u00f3n M\u00f3vil**: Lugares temporales para la recolecci\u00f3n de sangre.\n\n#### 2. **Equipamiento**\n   - **Dise\u00f1o y Construcci\u00f3n**: Normas para la creaci\u00f3n de equipos adecuados.\n   - **Mantenimiento**: Procedimientos para asegurar el funcionamiento \u00f3ptimo del equipo.\n   - **Limpieza y Calibraci\u00f3n**: Protocolos para mantener la higiene y precisi\u00f3n de los equipos.\n\n#### 3. **Sistemas Computarizados**\n   - Implementaci\u00f3n de tecnolog\u00eda para la gesti\u00f3n de datos y procesos.\n\n#### 4. **Calificaci\u00f3n y Validaci\u00f3n**\n   - **Calificaci\u00f3n de Equipos**: Aseguramiento de que los equipos cumplen con los est\u00e1ndares requeridos.\n   - **Validaci\u00f3n de Procesos de Manufactura**: Confirmaci\u00f3n de que los procesos de producci\u00f3n son efectivos y seguros.\n   - **Selecci\u00f3n de Sistemas de Pruebas**: Elecci\u00f3n de m\u00e9todos adecuados para detectar enfermedades infecciosas.\n   - **Validaci\u00f3n del Rendimiento de Ensayos**: Evaluaci\u00f3n de la eficacia de los ensayos realizados.\n\n#### 5. **Gesti\u00f3n de Materiales y Reactivos**\n   - **Recepci\u00f3n y Cuarentena**: Proceso de manejo de materiales entrantes.\n   - **Liberaci\u00f3n de Materiales**: Procedimientos para autorizar el uso de materiales y reactivos.\n   - **Trazabilidad**: Mecanismos para rastrear el origen y uso de materiales.\n   - **Gesti\u00f3n de Proveedores**: Control y evaluaci\u00f3n de los proveedores de materiales.\n\n#### 6. **Manufactura**\n   - **Registro de Donantes**: Proceso de documentaci\u00f3n de donantes.\n   - **Selecci\u00f3n de Donantes**: Criterios y procedimientos para elegir donantes adecuados.\n   - **Recolecci\u00f3n de Sangre**: M\u00e9todos de recolecci\u00f3n, incluyendo sangre total y a trav\u00e9s de af\u00e9resis.\n   - **Preparaci\u00f3n de Componentes**: M\u00e9todos de producci\u00f3n como centrifugaci\u00f3n, separaci\u00f3n, congelaci\u00f3n, reducci\u00f3n de leucocitos e irradiaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Donantes**: Personas que ofrecen su sangre.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, como plaquetas y plasma.\n- **Equipos y Sistemas**: Herramientas y tecnolog\u00edas utilizadas en el proceso de donaci\u00f3n y manufactura.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos t\u00e9cnicos y organizativos tratados en el documento, destacando la importancia de cada secci\u00f3n en el contexto de la salud p\u00fablica y la seguridad en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood components, laboratory testing, infectious disease markers, quality monitoring, product labeling"}}, "0598e74c-934b-4034-9876-cf51a2e35cc2": {"node_ids": ["7315bb40-2807-462f-914e-2ac95901dec4"], "metadata": {"page_label": "163", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) requirements for the collection, processing and quality control of blood, blood components and plasma derivatives (1) define a quality assurance system based on (i) the existence of a national structure that is independent of manufacturers, (ii) compliance with the process of quality assurance for biological products \u2014 i.e. control of starting material(s), production processes and final product(s) \u2014 and (iii) strict adherence to the principles of good manufacturing practice (GMP). Since the last revision of these requirements in 1992, two relevant items have been reviewed and new recommendations adopted, namely on virus inactivation and removal of plasma derivatives (2004) (2) and human plasma for fractionation (2007) (3). However, a number of issues, such as the requirement for a quality assurance system in blood establishments, have not yet been addressed. The WHO Expert Committee on Biological Standardization (ECBS), therefore, considered that the development of WHO guidelines on GMP for blood establishments is of highest priority in assisting Member States to meet their needs in this area, as requested by the International Conference of Drug Regulatory Authorities in 2008 (4).\n\nThe importance of establishing reliable quality assurance systems for the whole chain of blood collection, processing and distribution of blood components in blood establishments was also emphasized by the Sixty-third World Health Assembly in resolution WHA63.12 on the availability, safety and quality of blood products (5). In that resolution, quality assurance was seen as a necessary measure that would contribute to increased global availability of plasma that meets internationally recognized standards.\n\nResolution WHA63.12 recognized that a special effort is needed to strengthen globally the technical capacity of national regulatory authorities (NRAs) to assure the appropriate control of blood products. The resolution recalls earlier related resolutions which urged Member States to promote the full implementation of well organized, nationally coordinated and sustainable blood programmes stressing the role of voluntary, non-remunerated blood donations from low-risk populations.\n\nIn recent years, safety and quality in the transfusion chain has become an important topic in many countries and regions (6). Blood establishments should establish and maintain quality systems, based on GMP principles, involving all activities that determine quality policy objectives and responsibilities, and should implement them by such means as quality planning, quality control, quality assurance and quality improvement. A GMP approach to manufacturing safe blood components that consistently meet predefined specifications and customers\u2019 expectations provides a model that allows for a documented system of incorporating quality into", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) establece requisitos para la recolecci\u00f3n, procesamiento y control de calidad de sangre y derivados. Se enfatiza la necesidad de un sistema de aseguramiento de calidad que incluya una estructura nacional independiente de los fabricantes, el cumplimiento de procesos de calidad para productos biol\u00f3gicos y la adherencia a las buenas pr\u00e1cticas de manufactura (GMP). Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado nuevas recomendaciones sobre inactivaci\u00f3n de virus y plasma humano para fraccionamiento, pero a\u00fan quedan temas por abordar, como la necesidad de un sistema de aseguramiento de calidad en los establecimientos de sangre. La resoluci\u00f3n WHA63.12 de la Asamblea Mundial de la Salud subraya la importancia de fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales para asegurar el control adecuado de los productos sangu\u00edneos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres componentes clave que definen el sistema de aseguramiento de calidad seg\u00fan la OMS para los productos sangu\u00edneos?**\n   - Respuesta: Los tres componentes clave son: (i) la existencia de una estructura nacional independiente de los fabricantes, (ii) el cumplimiento del proceso de aseguramiento de calidad para productos biol\u00f3gicos, y (iii) la estricta adherencia a los principios de buenas pr\u00e1cticas de manufactura (GMP).\n\n2. **\u00bfQu\u00e9 recomendaciones espec\u00edficas se han adoptado desde la \u00faltima revisi\u00f3n de los requisitos de la OMS en 1992?**\n   - Respuesta: Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado recomendaciones sobre la inactivaci\u00f3n de virus y la eliminaci\u00f3n de derivados plasm\u00e1ticos en 2004, as\u00ed como sobre el plasma humano para fraccionamiento en 2007.\n\n3. **\u00bfQu\u00e9 papel juega la resoluci\u00f3n WHA63.12 en el contexto de la calidad y seguridad de los productos sangu\u00edneos?**\n   - Respuesta: La resoluci\u00f3n WHA63.12 enfatiza la necesidad de establecer sistemas de aseguramiento de calidad confiables en toda la cadena de recolecci\u00f3n, procesamiento y distribuci\u00f3n de componentes sangu\u00edneos, y reconoce la importancia de fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales para asegurar el control adecuado de los productos sangu\u00edneos. Tambi\u00e9n promueve la implementaci\u00f3n de programas de sangre bien organizados y coordinados a nivel nacional, destacando la importancia de las donaciones de sangre voluntarias y no remuneradas de poblaciones de bajo riesgo.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Componentes de la sangre**:\n   - **Sangre total**: Se refiere a la sangre en su forma completa.\n   - **Concentrado de gl\u00f3bulos rojos**: Producto derivado de la sangre que contiene una alta concentraci\u00f3n de gl\u00f3bulos rojos.\n   - **Concentrado de plaquetas**: Producto que contiene plaquetas, esencial para la coagulaci\u00f3n.\n   - **Plasma**: Se menciona tanto para transfusi\u00f3n como para fraccionamiento, indicando su uso en tratamientos y producci\u00f3n de derivados.\n   - **Crioprecipitado y plasma pobre en crioprecipitado**: Productos derivados del plasma que tienen aplicaciones espec\u00edficas en medicina.\n\n2. **Pruebas de laboratorio**:\n   - **Pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas**: Incluye requisitos de prueba, manejo de muestras, procedimientos anal\u00edticos y seguimiento de resultados reactivos.\n   - **Tipificaci\u00f3n de grupos sangu\u00edneos**: Proceso para determinar el tipo de sangre de un donante o receptor.\n   - **Muestras de retenci\u00f3n**: Muestras que se conservan para futuras pruebas o verificaciones.\n\n3. **Monitoreo de calidad**: Se refiere a los procedimientos y est\u00e1ndares para asegurar la calidad de la sangre y sus componentes.\n\n4. **Etiquetado**:\n   - **Informaci\u00f3n de la etiqueta**: Detalles que deben incluirse en las etiquetas de los productos sangu\u00edneos, como el nombre del producto y la fecha de caducidad.\n\n5. **Log\u00edstica de productos sangu\u00edneos**:\n   - **Liberaci\u00f3n de productos**: Procedimientos para autorizar la distribuci\u00f3n de productos sangu\u00edneos.\n   - **Almacenamiento, distribuci\u00f3n, env\u00edo y devoluciones**: Aspectos log\u00edsticos que aseguran que los productos sangu\u00edneos se manejen de manera segura y eficiente.\n\n### Entidades clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Componentes sangu\u00edneos**: Sangre total, gl\u00f3bulos rojos, plaquetas, plasma, crioprecipitado.\n- **Pruebas de laboratorio**: Detecci\u00f3n de enfermedades, tipificaci\u00f3n sangu\u00ednea.\n- **Calidad y seguridad**: Monitoreo de calidad, etiquetado, procedimientos de liberaci\u00f3n y distribuci\u00f3n.\n\nEste resumen proporciona una visi\u00f3n general de los temas tratados en la secci\u00f3n, destacando los componentes de la sangre, los procedimientos de prueba y los aspectos log\u00edsticos relacionados con la gesti\u00f3n de productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood safety, quality assurance, good manufacturing practice, WHO guidelines, plasma derivatives"}}, "324df83e-586e-489a-b9d3-0030ca3f5322": {"node_ids": ["8d9b221d-13f3-4e45-96ff-207125d31a7f"], "metadata": {"page_label": "164", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the entire process. When collecting and processing blood and plasma from human donors, GMP considerations should be addressed in a biological context due to the specific characteristics of materials of human origin.\n\nThe guidelines in this document include:\n\n\u2014 general GMP topics such as quality management, personnel, documentation, premises and equipment, qualification and validation, materials management, contract manufacturing, and complaints and recalls;\n\n\u2014 GMP concepts such as quality risk management and product quality reviews;\n\n\u2014 topics specific to the manufacturing of blood components from donor selection to distribution of the final product.\n\nThey address current and widely accepted GMP principles that are relevant to the consistent production of safe and assured quality blood components in blood establishments, including related donor safety concerns. The document is intended to serve as guidance for both blood establishments and NRAs when implementing and enforcing these principles. It does not address the practice of transfusion medicine or management of emergencies or crises where specific policies defined by the NRA apply. Aspects of personnel and environmental protection are also not within the scope of this document.\n\nComplementary guidance, especially with respect to the production of plasma for fractionation, is available in the *WHO recommendations for the production, control and regulation of human plasma for fractionation* (3).\n\n## 2. Glossary and abbreviations\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**apheresis**  \nThe process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and/or filtration into its components, and returning those not required to the donor.\n\n**blood collection**  \nThe procedure whereby a single donation of blood is collected in an anticoagulant and/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and/or coagulation activation of the resulting blood donation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las Buenas Pr\u00e1cticas de Manufactura (GMP) en la recolecci\u00f3n y procesamiento de sangre y plasma de donantes humanos. Se enfoca en la calidad y seguridad de los componentes sangu\u00edneos, abarcando temas como gesti\u00f3n de calidad, documentaci\u00f3n, y gesti\u00f3n de riesgos. Adem\u00e1s, proporciona definiciones clave relacionadas con la recolecci\u00f3n de sangre y el proceso de af\u00e9resis, y aclara que no cubre la pr\u00e1ctica de la medicina transfusional ni la gesti\u00f3n de emergencias.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los temas generales de GMP que se abordan en el documento y por qu\u00e9 son relevantes para la producci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: El documento incluye temas como gesti\u00f3n de calidad, personal, documentaci\u00f3n, instalaciones y equipos, calificaci\u00f3n y validaci\u00f3n, gesti\u00f3n de materiales, fabricaci\u00f3n por contrato, y manejo de quejas y retiradas. Estos son relevantes para asegurar la producci\u00f3n consistente de componentes sangu\u00edneos seguros y de calidad.\n\n2. **\u00bfQu\u00e9 aspectos espec\u00edficos de la manufactura de componentes sangu\u00edneos se tratan en las directrices de la OMS?**\n   - Respuesta: Las directrices abordan desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final, asegurando que se sigan principios de GMP que garanticen la seguridad del donante y la calidad del producto.\n\n3. **\u00bfQu\u00e9 tipo de orientaci\u00f3n complementaria se menciona en el documento respecto a la producci\u00f3n de plasma para fraccionamiento?**\n   - Respuesta: Se menciona que hay orientaci\u00f3n complementaria disponible en las \"recomendaciones de la OMS para la producci\u00f3n, control y regulaci\u00f3n de plasma humano para fraccionamiento\", lo que sugiere que hay directrices espec\u00edficas para este proceso que no se detallan en el documento principal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS establece requisitos para la recolecci\u00f3n, procesamiento y control de calidad de sangre y derivados, enfatizando la importancia de un sistema de aseguramiento de calidad.\n\n2. **Sistema de Aseguramiento de Calidad**: Se basa en tres componentes clave:\n   - Existencia de una estructura nacional independiente de los fabricantes.\n   - Cumplimiento del proceso de aseguramiento de calidad para productos biol\u00f3gicos.\n   - Adherencia a las buenas pr\u00e1cticas de manufactura (GMP).\n\n3. **Revisiones y Recomendaciones**: Desde la \u00faltima revisi\u00f3n en 1992, se han adoptado nuevas recomendaciones sobre:\n   - Inactivaci\u00f3n de virus (2004).\n   - Plasma humano para fraccionamiento (2007).\n\n4. **Resoluci\u00f3n WHA63.12**: Esta resoluci\u00f3n de la Sixty-third World Health Assembly subraya la necesidad de:\n   - Establecer sistemas de aseguramiento de calidad en la cadena de recolecci\u00f3n, procesamiento y distribuci\u00f3n de componentes sangu\u00edneos.\n   - Fortalecer la capacidad t\u00e9cnica de las autoridades regulatorias nacionales (NRAs).\n   - Promover programas de sangre organizados y donaciones voluntarias de poblaciones de bajo riesgo.\n\n5. **Importancia de la Calidad y Seguridad**: La calidad y seguridad en la cadena de transfusi\u00f3n se han convertido en temas cruciales, y se recomienda que los establecimientos de sangre mantengan sistemas de calidad basados en principios GMP, que incluyan planificaci\u00f3n, control, aseguramiento y mejora de la calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece los requisitos y recomendaciones.\n- **NRAs (National Regulatory Authorities)**: Autoridades regulatorias nacionales que deben fortalecer su capacidad t\u00e9cnica.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre y sus componentes.", "excerpt_keywords": "Keywords: GMP, blood components, donor safety, apheresis, quality management"}}, "5d0756e1-9162-41fb-8455-9a451eae6330": {"node_ids": ["56c8b348-48d2-473a-8b98-a6f4850d09da"], "metadata": {"page_label": "165", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# blood component\n\nA constituent of blood (erythrocytes, leukocytes, platelets, cryoprecipitate and plasma) that can be prepared by various separation methods and under such conditions that it can be used either directly for therapeutic purposes or for further processing/manufacturing.\n\n# blood establishment\n\nAny structure, facility or body that is responsible for any aspect of the collection, testing, processing, storage, release and/or distribution of human blood or blood components when intended for transfusion or further industrial manufacturing.\n\n# blood products\n\nAny therapeutic substances derived from human blood, including whole blood, blood components and plasma-derived medicinal products.\n\n# calibration\n\nThe set of operations which establish, under specified conditions, the relationship between values indicated by a measuring instrument or measuring system, or values represented by a material measure, and the corresponding known values of a reference standard.\n\n# CJD/vCJD\n\nCreutzfeld-Jakob-Disease/variant Creutzfeld-Jakob-Disease.\n\n# closed system\n\nA system developed for aseptic collection and separation of blood and blood components, manufactured under clean conditions, sealed to the external environment and sterilized by a validated and approved method.\n\n# computerized system\n\nA system including the input of data, electronic processing and the output of information to be used either for reporting or for automatic control.\n\n# contract acceptor\n\nAn establishment or institution that performs particular work or services under a contract for a different institution.\n\n# contract giver\n\nAn establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.\n\n# donor\n\nA person in defined good health conditions who voluntarily donates blood or blood components, including plasma for fractionation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 caracter\u00edsticas debe tener un donante de sangre seg\u00fan el documento?**\n   - Respuesta: Un donante debe ser una persona en condiciones de buena salud definidas que voluntariamente dona sangre o componentes sangu\u00edneos, incluyendo plasma para fraccionamiento.\n\n2. **\u00bfCu\u00e1l es la diferencia entre un 'contract giver' y un 'contract acceptor' en el contexto de los establecimientos de sangre?**\n   - Respuesta: Un 'contract giver' es la instituci\u00f3n que subcontrata trabajos o servicios a otra instituci\u00f3n y establece un contrato que define las responsabilidades de cada parte. Por otro lado, un 'contract acceptor' es la instituci\u00f3n que realiza el trabajo o servicio espec\u00edfico bajo ese contrato.\n\n3. **\u00bfQu\u00e9 implica un 'sistema cerrado' en la recolecci\u00f3n y separaci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: Un 'sistema cerrado' es un sistema desarrollado para la recolecci\u00f3n y separaci\u00f3n as\u00e9ptica de sangre y componentes sangu\u00edneos, fabricado en condiciones limpias, sellado al medio ambiente externo y esterilizado mediante un m\u00e9todo validado y aprobado.\n\n### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Definici\u00f3n de componentes sangu\u00edneos y su uso:**\n   - Los componentes sangu\u00edneos son constituyentes de la sangre que pueden ser preparados mediante m\u00e9todos de separaci\u00f3n y utilizados directamente para fines terap\u00e9uticos o para procesamiento adicional.\n\n2. **Funciones de un establecimiento de sangre:**\n   - Un establecimiento de sangre es responsable de la recolecci\u00f3n, prueba, procesamiento, almacenamiento, liberaci\u00f3n y distribuci\u00f3n de sangre humana o componentes sangu\u00edneos destinados a transfusiones o manufactura industrial.\n\n3. **Importancia de los sistemas en la gesti\u00f3n de sangre:**\n   - Los sistemas, tanto cerrados como computarizados, son esenciales para asegurar la recolecci\u00f3n as\u00e9ptica y el manejo eficiente de datos en el proceso de donaci\u00f3n y distribuci\u00f3n de sangre.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, titulado \"WHO - Technical Report Series 961\", se centra en las Buenas Pr\u00e1cticas de Manufactura (GMP) aplicadas a la recolecci\u00f3n y procesamiento de sangre y plasma de donantes humanos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Importancia de las GMP en el contexto biol\u00f3gico de los materiales de origen humano.\n   - Temas generales de GMP: gesti\u00f3n de calidad, personal, documentaci\u00f3n, instalaciones y equipos, calificaci\u00f3n y validaci\u00f3n, gesti\u00f3n de materiales, fabricaci\u00f3n por contrato, y manejo de quejas y retiradas.\n   - Conceptos de GMP: gesti\u00f3n de riesgos de calidad y revisiones de calidad del producto.\n\n2. **Manufactura de Componentes Sangu\u00edneos**:\n   - Proceso desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final.\n   - Enfoque en la producci\u00f3n consistente de componentes sangu\u00edneos seguros y de calidad, as\u00ed como en la seguridad del donante.\n\n3. **Orientaci\u00f3n Complementaria**:\n   - Referencia a las recomendaciones de la OMS para la producci\u00f3n, control y regulaci\u00f3n de plasma humano para fraccionamiento.\n\n4. **Definiciones Clave**:\n   - **Af\u00e9resis**: Proceso de obtenci\u00f3n selectiva de componentes sangu\u00edneos de un donante.\n   - **Recolecci\u00f3n de Sangre**: Procedimiento para recolectar una donaci\u00f3n de sangre en condiciones que minimizan la contaminaci\u00f3n microbiana y el da\u00f1o celular.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n y procesamiento de sangre.\n- **Autoridades Reguladoras Nacionales (NRA)**: Organismos que implementan y hacen cumplir las GMP.\n\nEste resumen destaca la importancia de las GMP en la producci\u00f3n de componentes sangu\u00edneos y proporciona un marco para garantizar la calidad y seguridad en el manejo de materiales de origen humano.", "excerpt_keywords": "Keywords: blood components, blood establishment, blood products, donor, closed system"}}, "59dabd56-7c3f-41fa-859b-b3d7dc7a021f": {"node_ids": ["85c96ee5-597a-4573-9499-d05aca352d72"], "metadata": {"page_label": "166", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Distribution\n\nThe act of delivery of blood and blood components to other blood establishments, hospital blood banks or manufacturers of blood- and plasma-derived medicinal products. It does not include the issuing of blood or blood components for transfusion.\n\n# First-time (tested) Donor\n\nA donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.\n\n# Good Manufacturing Practice (GMP)\n\nAll elements in the established practice that will collectively lead to final products or services that consistently meet appropriate specifications and compliance with defined regulations.\n\n# HAV, Hepatitis A Virus\n\nA non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.\n\n# HBsAg, Hepatitis B Surface Antigen\n\nThe antigen on the periphery of the hepatitis B virus.\n\n# HBV, Hepatitis B Virus\n\nAn enveloped double-stranded DNA virus that is the causative agent of hepatitis B.\n\n# HCV, Hepatitis C Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of hepatitis C.\n\n# HIV, Human Immunodeficiency Virus\n\nAn enveloped, single-stranded RNA virus that is the causative agent of the acquired immunodeficiency syndrome (AIDS).\n\n# HTLV 1 and 2, Human T-cell Lymphotropic Virus, Types 1 and 2\n\nEnveloped, single stranded RNA viruses that are typically cell-associated.\n\n# Manufacture\n\nAll operational processes or steps \u2014 including purchase or selection of materials and products, production, quality control, release, storage and distribution of products and the related controls \u2014 used to produce a blood product. This includes also the donation process.\n\n# Mobile Site\n\nA unit or site used for the collection of blood and/or blood components, operating temporarily or at movable locations off-site from a permanent collection site, under the responsibility of a blood establishment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave relacionados con la donaci\u00f3n y el manejo de sangre y componentes sangu\u00edneos. Se definen t\u00e9rminos importantes como \"donante de primera vez\", \"buenas pr\u00e1cticas de manufactura\" (GMP), y se describen virus relevantes como el VIH, HBV, HCV, y otros. Tambi\u00e9n se menciona el proceso de distribuci\u00f3n de sangre y la operaci\u00f3n de sitios m\u00f3viles para la recolecci\u00f3n de sangre.\n\n### Preguntas\n1. **\u00bfQu\u00e9 se entiende por \"donante de primera vez\" en el contexto de la donaci\u00f3n de sangre?**\n   - Respuesta: Un donante de primera vez es aquel cuya sangre o plasma es probado por primera vez para marcadores de enfermedades infecciosas en un establecimiento de sangre.\n\n2. **\u00bfCu\u00e1les son los elementos que constituyen las Buenas Pr\u00e1cticas de Manufactura (GMP) en la producci\u00f3n de productos sangu\u00edneos?**\n   - Respuesta: Las GMP incluyen todos los elementos en la pr\u00e1ctica establecida que llevan a productos o servicios finales que cumplen consistentemente con especificaciones apropiadas y regulaciones definidas, abarcando desde la selecci\u00f3n de materiales hasta el control de calidad y distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 es un \"sitio m\u00f3vil\" y cu\u00e1l es su funci\u00f3n en la recolecci\u00f3n de sangre?**\n   - Respuesta: Un sitio m\u00f3vil es una unidad o lugar utilizado para la recolecci\u00f3n de sangre y/o componentes sangu\u00edneos, que opera temporalmente o en ubicaciones m\u00f3viles fuera de un sitio de recolecci\u00f3n permanente, bajo la responsabilidad de un establecimiento de sangre.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Componentes Sangu\u00edneos:**\n   - Definici\u00f3n: Constituyentes de la sangre (eritrocitos, leucocitos, plaquetas, crioprecipitado y plasma) que pueden ser preparados para uso terap\u00e9utico o procesamiento adicional.\n\n2. **Establecimiento de Sangre:**\n   - Funci\u00f3n: Estructura o entidad responsable de la recolecci\u00f3n, prueba, procesamiento, almacenamiento, liberaci\u00f3n y distribuci\u00f3n de sangre humana o componentes sangu\u00edneos para transfusiones o manufactura industrial.\n\n3. **Productos Sangu\u00edneos:**\n   - Definici\u00f3n: Sustancias terap\u00e9uticas derivadas de la sangre humana, incluyendo sangre total, componentes sangu\u00edneos y productos medicinales derivados del plasma.\n\n4. **Calibraci\u00f3n:**\n   - Proceso: Operaciones que establecen la relaci\u00f3n entre los valores indicados por un instrumento de medici\u00f3n y los valores conocidos de un est\u00e1ndar de referencia.\n\n5. **Enfermedades:**\n   - CJD/vCJD: Enfermedades relacionadas con la enfermedad de Creutzfeldt-Jakob y su variante.\n\n6. **Sistema Cerrado:**\n   - Definici\u00f3n: Sistema dise\u00f1ado para la recolecci\u00f3n y separaci\u00f3n as\u00e9ptica de sangre, fabricado en condiciones limpias y sellado al medio ambiente externo.\n\n7. **Sistema Computarizado:**\n   - Definici\u00f3n: Sistema que incluye la entrada de datos, procesamiento electr\u00f3nico y salida de informaci\u00f3n para reportes o control autom\u00e1tico.\n\n8. **Relaciones Contractuales:**\n   - **Contract Giver:** Instituci\u00f3n que subcontrata servicios y establece un contrato con otra instituci\u00f3n.\n   - **Contract Acceptor:** Instituci\u00f3n que realiza el trabajo o servicio bajo un contrato establecido.\n\n9. **Donante:**\n   - Definici\u00f3n: Persona en buenas condiciones de salud que dona sangre o componentes sangu\u00edneos de manera voluntaria.\n\n### Entidades Clave:\n- **Componentes Sangu\u00edneos**\n- **Establecimientos de Sangre**\n- **Productos Sangu\u00edneos**\n- **Sistemas (Cerrado y Computarizado)**\n- **Donantes**\n- **Relaciones Contractuales (Contract Giver y Contract Acceptor)**\n\nEste resumen abarca los conceptos y definiciones esenciales relacionados con la sangre y su manejo, as\u00ed como las entidades involucradas en el proceso de donaci\u00f3n y distribuci\u00f3n.", "excerpt_keywords": "Keywords: blood donation, Good Manufacturing Practice, infectious diseases, mobile collection site, blood components"}}, "3b3a2734-eb46-4005-ab47-4f286ff513ed": {"node_ids": ["fc389e87-1d90-4dbf-a300-bdd54ba928ff"], "metadata": {"page_label": "167", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# nucleic acid amplification techniques (NAT)\n\nA testing method to detect the presence of a targeted area of a defined microbial genome that uses amplification techniques such as polymerase chain reaction (PCR).\n\n# near-miss event\n\nAn incident that, if not detected in a timely manner, would have affected the safety of the recipients or donors.\n\n# national regulatory authority (NRA)\n\nWHO terminology for national medicines regulatory authorities. NRAs should promulgate and enforce medicines regulations.\n\n# plasma for fractionation\n\nThe liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.\n\n# production\n\nAll operations involved in the preparation of blood components, from collection through processing to completion as a finished product (blood component).\n\n# qualification\n\nA set of actions used to provide documented evidence that any piece of equipment, critical material or reagent used to produce the final product and that might affect the quality or safety of a product works reliably as intended or specified and leads to the expected results.\n\n# quality\n\nThe total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n\n# quality assurance\n\nA part of quality management focused on providing confidence that quality requirements will be met.\n\n# quality management\n\nThe coordinated activities that direct and control an organization with regard to quality.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda diversas definiciones y conceptos clave relacionados con la regulaci\u00f3n y la calidad en la producci\u00f3n de componentes sangu\u00edneos. Se destacan t\u00e9cnicas de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT) para la detecci\u00f3n de microorganismos, la importancia de las autoridades regulatorias nacionales (NRA), y los procesos de producci\u00f3n y aseguramiento de calidad en la fabricaci\u00f3n de productos sangu\u00edneos. Se enfatiza la necesidad de cumplir con requisitos de calidad y seguridad en todos los aspectos de la producci\u00f3n.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 papel desempe\u00f1an las autoridades regulatorias nacionales (NRA) en la producci\u00f3n de componentes sangu\u00edneos seg\u00fan la OMS?**\n   - Esta pregunta busca entender la funci\u00f3n espec\u00edfica de las NRA en la regulaci\u00f3n y supervisi\u00f3n de la calidad de los productos sangu\u00edneos, algo que puede no estar claramente definido en otros documentos.\n\n2. **\u00bfCu\u00e1les son los pasos involucrados en el proceso de calificaci\u00f3n de equipos y materiales en la producci\u00f3n de productos sangu\u00edneos?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que garantizan que los equipos y materiales utilizados en la producci\u00f3n cumplen con los est\u00e1ndares de calidad y seguridad.\n\n3. **\u00bfC\u00f3mo se define un evento de \"casi accidente\" en el contexto de la seguridad de los donantes y receptores de sangre?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de lo que constituye un \"casi accidente\" y su relevancia en la gesti\u00f3n de riesgos en la transfusi\u00f3n de sangre, un aspecto que puede no estar ampliamente discutido en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n del documento de la OMS aborda varios conceptos fundamentales relacionados con la donaci\u00f3n y manejo de sangre y sus componentes. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Distribuci\u00f3n**: Se refiere al proceso de entrega de sangre y componentes sangu\u00edneos a otros establecimientos de sangre, bancos de sangre hospitalarios o fabricantes de productos medicinales derivados de sangre y plasma. No incluye la emisi\u00f3n de sangre para transfusiones.\n\n2. **Donante de Primera Vez**: Se define como un donante cuya sangre o plasma es sometido a pruebas por primera vez para detectar marcadores de enfermedades infecciosas en un establecimiento de sangre.\n\n3. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Se describen como todos los elementos en la pr\u00e1ctica establecida que aseguran que los productos o servicios finales cumplan con especificaciones apropiadas y regulaciones definidas. Esto incluye procesos desde la selecci\u00f3n de materiales hasta el control de calidad y distribuci\u00f3n.\n\n4. **Virus Relacionados con Enfermedades**:\n   - **HAV (Virus de la Hepatitis A)**: Un virus ARN de cadena sencilla no envuelto, causante de hepatitis A.\n   - **HBsAg (Ant\u00edgeno de Superficie de Hepatitis B)**: Ant\u00edgeno presente en la periferia del virus de hepatitis B.\n   - **HBV (Virus de Hepatitis B)**: Un virus ADN de doble cadena envuelto, causante de hepatitis B.\n   - **HCV (Virus de Hepatitis C)**: Un virus ARN de cadena sencilla envuelto, causante de hepatitis C.\n   - **HIV (Virus de Inmunodeficiencia Humana)**: Un virus ARN de cadena sencilla envuelto, causante del s\u00edndrome de inmunodeficiencia adquirida (SIDA).\n   - **HTLV 1 y 2 (Virus Linfotr\u00f3pico Humano de C\u00e9lulas T, Tipos 1 y 2)**: Virus ARN de cadena sencilla envueltos, t\u00edpicamente asociados a c\u00e9lulas.\n\n5. **Manufactura**: Se refiere a todos los procesos operativos involucrados en la producci\u00f3n de productos sangu\u00edneos, incluyendo la selecci\u00f3n de materiales, producci\u00f3n, control de calidad, liberaci\u00f3n, almacenamiento y distribuci\u00f3n.\n\n6. **Sitio M\u00f3vil**: Se define como una unidad o lugar utilizado temporalmente para la recolecci\u00f3n de sangre y/o componentes sangu\u00edneos, que opera en ubicaciones m\u00f3viles fuera de un sitio de recolecci\u00f3n permanente, bajo la responsabilidad de un establecimiento de sangre.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y t\u00e9rminos clave relacionados con la donaci\u00f3n y manejo de sangre, as\u00ed como los virus relevantes en este contexto.", "excerpt_keywords": "Keywords: nucleic acid amplification, near-miss event, national regulatory authority, plasma fractionation, quality management"}}, "ecae8993-3ae8-4217-b48d-d6bb1114a11b": {"node_ids": ["4205fdaf-3bb3-403a-8462-aa5a645ed67e"], "metadata": {"page_label": "168", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\nA management system that directs and controls an organization with respect to quality and that ensures that steps, processes, procedures and policies related to quality activities are being followed.\n\n# Quality Risk Management (QRM)\n\nA systematic process for the assessment, control, communication and review of risks to the quality of the product across the product\u2019s life cycle.\n\n# Quarantine\n\nThe status of starting or packaging materials, intermediate, bulk or finished products that are isolated physically or by other means while a decision is awaited on their release for use or rejection.\n\n# Regular Donor\n\nA person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.\n\n# Repeat Donor\n\nA person who has donated before in the same establishment but not within the period of time considered as regular donation.\n\n# Repeatedly Reactive\n\nA donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.\n\n# Validation\n\nActions for proving that any operational procedure, process, activity or system leads to the expected results. Validation work is normally performed in advance according to a defined and approved protocol that describes tests and acceptance criteria.\n\n# WNV, West Nile Virus\n\nAn enveloped single-stranded RNA virus that is the causative agent of West Nile fever.\n\n## 3. Quality Management\n\n### 3.1 Principles\n\nQuality is the responsibility of all persons involved in the various processes of the blood establishment. The management of the blood establishment is responsible for a systematic approach to quality and the implementation and maintenance of a quality management system. A quality programme", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la gesti\u00f3n de calidad en los establecimientos de sangre, destacando la importancia de un sistema de gesti\u00f3n de calidad y la gesti\u00f3n de riesgos de calidad (QRM). Se definen t\u00e9rminos clave como \"donante regular\", \"donante repetido\" y \"reactivo repetido\", as\u00ed como la importancia de la validaci\u00f3n de procedimientos y la gesti\u00f3n de riesgos a lo largo del ciclo de vida del producto. Se enfatiza que la calidad es responsabilidad de todos los involucrados en los procesos del establecimiento de sangre.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la diferencia entre un donante regular y un donante repetido seg\u00fan el documento?**\n   - Respuesta: Un donante regular es una persona que dona sangre, componentes sangu\u00edneos o plasma de manera rutinaria en el mismo establecimiento de sangre, cumpliendo con los intervalos de tiempo m\u00ednimos. En cambio, un donante repetido es alguien que ha donado anteriormente en el mismo establecimiento, pero no dentro del per\u00edodo considerado para una donaci\u00f3n regular.\n\n2. **\u00bfQu\u00e9 implica el proceso de validaci\u00f3n mencionado en el contexto y por qu\u00e9 es importante?**\n   - Respuesta: La validaci\u00f3n implica acciones para demostrar que cualquier procedimiento operativo, proceso, actividad o sistema produce los resultados esperados. Es importante porque asegura que los procedimientos cumplen con los criterios de aceptaci\u00f3n definidos y aprobados, lo que contribuye a la calidad y seguridad de los productos sangu\u00edneos.\n\n3. **\u00bfC\u00f3mo se define la gesti\u00f3n de riesgos de calidad (QRM) en el contexto del ciclo de vida del producto?**\n   - Respuesta: La gesti\u00f3n de riesgos de calidad (QRM) se define como un proceso sistem\u00e1tico para la evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de los riesgos que afectan la calidad del producto a lo largo de su ciclo de vida, asegurando que se tomen medidas adecuadas para mitigar esos riesgos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en definiciones y conceptos fundamentales relacionados con la regulaci\u00f3n, producci\u00f3n y calidad de los componentes sangu\u00edneos, seg\u00fan la OMS. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **T\u00e9cnicas de Amplificaci\u00f3n de \u00c1cidos Nucleicos (NAT)**: M\u00e9todos de prueba que utilizan t\u00e9cnicas como la reacci\u00f3n en cadena de la polimerasa (PCR) para detectar microorganismos en el genoma.\n\n2. **Evento de \"Casi Accidente\"**: Incidentes que, si no se detectan a tiempo, podr\u00edan comprometer la seguridad de los donantes o receptores de sangre.\n\n3. **Autoridad Reguladora Nacional (NRA)**: Entidades responsables de promulgar y hacer cumplir las regulaciones sobre medicamentos a nivel nacional, seg\u00fan la terminolog\u00eda de la OMS.\n\n4. **Plasma para Fraccionamiento**: Parte l\u00edquida de la sangre humana que se utiliza para la fabricaci\u00f3n de productos sangu\u00edneos, obtenida tras la separaci\u00f3n de los elementos celulares.\n\n5. **Producci\u00f3n**: Conjunto de operaciones que abarcan desde la recolecci\u00f3n de sangre hasta la finalizaci\u00f3n de los componentes sangu\u00edneos.\n\n6. **Calificaci\u00f3n**: Proceso que proporciona evidencia documentada de que los equipos y materiales utilizados en la producci\u00f3n funcionan de manera confiable y cumplen con los est\u00e1ndares de calidad.\n\n7. **Calidad**: Conjunto de caracter\u00edsticas que determinan la capacidad de un producto o servicio para satisfacer necesidades espec\u00edficas, incluyendo atributos de seguridad y calidad.\n\n8. **Aseguramiento de la Calidad**: Parte de la gesti\u00f3n de calidad que se enfoca en garantizar que se cumplan los requisitos de calidad.\n\n9. **Gesti\u00f3n de Calidad**: Actividades coordinadas que dirigen y controlan una organizaci\u00f3n en relaci\u00f3n con la calidad.\n\n### Conclusi\u00f3n\nLa secci\u00f3n destaca la importancia de la regulaci\u00f3n, la calidad y la seguridad en la producci\u00f3n de componentes sangu\u00edneos, enfatizando la necesidad de cumplir con est\u00e1ndares rigurosos para proteger la salud de los donantes y receptores.", "excerpt_keywords": "Keywords: Quality Management, Quality Risk Management, Blood Donation, Validation, West Nile Virus"}}, "5c7146bf-73e2-42d7-befc-549a2c20a406": {"node_ids": ["4628ed41-9fc9-4b62-9ffe-98ad1080ba36"], "metadata": {"page_label": "169", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be designed to ensure that each product (including plasma for fractionation) is manufactured in the same manner from donor selection through to distribution of the final product.\n\nQuality management involves all activities that determine the quality policy, objectives and responsibilities, and their implementation through quality planning, quality control, quality assurance and quality improvement in order to assure the quality and safety of blood and blood components.\n\nThe attainment of the quality policy and objectives is the responsibility of the senior management of the blood establishment and requires the participation and commitment of all staff throughout the entire blood establishment. Senior management should review the quality system at regular intervals to verify its effectiveness and to introduce corrective measures if they are considered necessary.\n\nWithin the organizational structure of the blood establishment there should be a quality management unit comprising one or more persons. The quality management personnel should be responsible for ensuring that there is documented evidence that the quality policies, procedures and practices are being fulfilled. Senior management, in coordination with the quality management unit, should develop and implement quality assurance policies and objectives in a manner that provides clear direction to all staff. The quality assurance policies and objectives should be designed to ensure the highest levels of safety and quality in the blood components that are produced from each collection. The policies and procedures should comply with all national and, where appropriate, international regulations and requirements.\n\nStaff should be able to understand the intent of the quality objectives and their own role in accomplishing the objectives. The performance of the quality management system should be evaluated periodically by determining whether the objectives have been or are continuously being met. If there are shortcomings in the quality system, corrections should be made and the quality management unit should be held responsible for monitoring corrective action and continued compliance.\n\nWithin any blood establishment there should be independent functions for fulfilling quality assurance and quality control responsibilities. The quality assurance function should be independent of manufacturing operations and should assure that all processes are performed and documented. The quality assurance function should be involved in all quality-related matters and in the review and approval of all quality-related documents.\n\n### 3.2 Quality assurance\n\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of the product. It is the", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la importancia de un sistema de gesti\u00f3n de calidad en los establecimientos de sangre, que abarca desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final. Se enfatiza la responsabilidad de la alta direcci\u00f3n en la implementaci\u00f3n y revisi\u00f3n de pol\u00edticas de calidad, as\u00ed como la necesidad de un equipo de gesti\u00f3n de calidad independiente que asegure el cumplimiento de las normativas y la mejora continua. La calidad y seguridad de los componentes sangu\u00edneos son fundamentales y deben ser entendidas por todo el personal involucrado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de la alta direcci\u00f3n en el sistema de gesti\u00f3n de calidad de un establecimiento de sangre?**\n   - Respuesta: La alta direcci\u00f3n es responsable de la implementaci\u00f3n y revisi\u00f3n de la pol\u00edtica de calidad y objetivos, asegurando la participaci\u00f3n y compromiso de todo el personal. Debe revisar el sistema de calidad peri\u00f3dicamente para verificar su efectividad y tomar medidas correctivas si es necesario.\n\n2. **\u00bfQu\u00e9 funciones debe cumplir la unidad de gesti\u00f3n de calidad dentro de un establecimiento de sangre?**\n   - Respuesta: La unidad de gesti\u00f3n de calidad debe asegurarse de que haya evidencia documentada del cumplimiento de las pol\u00edticas, procedimientos y pr\u00e1cticas de calidad. Tambi\u00e9n es responsable de desarrollar e implementar pol\u00edticas y objetivos de aseguramiento de calidad que proporcionen direcci\u00f3n clara a todo el personal.\n\n3. **\u00bfPor qu\u00e9 es importante que la funci\u00f3n de aseguramiento de calidad sea independiente de las operaciones de fabricaci\u00f3n?**\n   - Respuesta: La funci\u00f3n de aseguramiento de calidad debe ser independiente para garantizar que todos los procesos se realicen y documenten adecuadamente, lo que permite una revisi\u00f3n objetiva de todos los asuntos relacionados con la calidad y la aprobaci\u00f3n de documentos relacionados con la calidad sin conflictos de inter\u00e9s.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Gesti\u00f3n de Calidad**: Se refiere a un sistema que dirige y controla una organizaci\u00f3n en relaci\u00f3n con la calidad, asegurando que se sigan los pasos, procesos, procedimientos y pol\u00edticas relacionados con las actividades de calidad.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**: Es un proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar los riesgos que afectan la calidad del producto a lo largo de su ciclo de vida.\n\n3. **Cuarentena**: Estado de materiales o productos que est\u00e1n aislados mientras se espera una decisi\u00f3n sobre su liberaci\u00f3n o rechazo.\n\n4. **Donante Regular**: Persona que dona sangre, componentes sangu\u00edneos o plasma de manera rutinaria en el mismo establecimiento, cumpliendo con intervalos de tiempo m\u00ednimos.\n\n5. **Donante Repetido**: Persona que ha donado anteriormente en el mismo establecimiento, pero no dentro del per\u00edodo considerado para una donaci\u00f3n regular.\n\n6. **Reactivo Repetido**: Una donaci\u00f3n que es considerada reactiva si se encuentra reactiva en una prueba de detecci\u00f3n y al menos una de las pruebas repetidas tambi\u00e9n es reactiva.\n\n7. **Validaci\u00f3n**: Acciones destinadas a demostrar que un procedimiento, proceso, actividad o sistema produce los resultados esperados, normalmente realizadas de acuerdo con un protocolo definido y aprobado.\n\n8. **Virus del Oeste del Nilo (WNV)**: Un virus de ARN de cadena simple que causa fiebre del Nilo Occidental.\n\n9. **Responsabilidad de la Calidad**: La calidad es responsabilidad de todas las personas involucradas en los procesos del establecimiento de sangre, y la gesti\u00f3n debe adoptar un enfoque sistem\u00e1tico para implementar y mantener un sistema de gesti\u00f3n de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Establecimiento de sangre.\n- **Productos**: Sangre, componentes sangu\u00edneos, plasma.\n- **Personas**: Donantes (regulares y repetidos), personal del establecimiento.\n- **Procesos**: Evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de riesgos de calidad.\n- **Protocolos**: Documentos que describen pruebas y criterios de aceptaci\u00f3n para la validaci\u00f3n. \n\nEste resumen destaca la importancia de la gesti\u00f3n de calidad y los procesos asociados en el contexto de los establecimientos de sangre, as\u00ed como la responsabilidad compartida de todos los involucrados en asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: quality management, blood establishment, quality assurance, donor selection, safety and quality"}}, "2fb7de1d-6242-4a98-bf57-066880b58888": {"node_ids": ["87d15081-3f3a-45ff-a397-0fa275df7566"], "metadata": {"page_label": "170", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "totality of arrangements that are made with the purpose of ensuring that products are of the quality required for their intended use. Quality assurance therefore incorporates GMP, and other elements, including those outside the scope of this guideline \u2014 such as product design and development (7).\n\nQuality assurance is that part of quality management that ensures that all critical processes are appropriately described in written instructions (see chapter 5), are performed in accordance with the principles of GMP and comply with the appropriate regulations. The quality assurance system should be fully documented, distributed and explained to everyone involved in the manufacturing processes.\n\nAll parts of the quality assurance system should be adequately resourced with competent personnel, suitable premises, and suitable and sufficient equipment and facilities to enable the manufacturing steps to be completed in a safe and quality-compliant manner.\n\n### 3.2.1 Good manufacturing practice in blood establishments\n\nGMP is the part of quality assurance that ensures that blood products are consistently produced and controlled to the quality standards appropriate to their intended use, as required by predefined specifications and, if applicable, by the marketing authorization. GMP is aimed primarily at diminishing the risks inherent in any blood establishment operation \u2014 such as contamination (including cross-contamination), mix-ups, disease transmission or other unexpected adverse outcomes resulting from the use of blood products. GMP is concerned with both production and quality control.\n\nThe basic requirements of GMP are the following:\n\n- All manufacturing processes are clearly defined by policies and standard operating procedures, are systematically reviewed in the light of experience, and are shown to be capable of consistently manufacturing products of the required quality that comply with their specifications.\n- Qualification of equipment and reagents and validation of processes and methods are performed prior to use in the manufacture of products intended for transfusion or further manufacturing.\n- All necessary resources are provided \u2014 including appropriately qualified and trained personnel, adequate premises, suitable equipment, appropriate materials, approved procedures and instructions, suitable storage and transport.\n- A system is available to maintain traceability of all released products in order to facilitate recall, if necessary, of any product suspected of not conforming to standards, and there is also a system to handle complaints.\n- A system is available that addresses process and quality improvement functions and activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS detalla la importancia de la garant\u00eda de calidad en la producci\u00f3n de productos sangu\u00edneos, enfatizando la pr\u00e1ctica de fabricaci\u00f3n adecuada (GMP) como un componente esencial del sistema de garant\u00eda de calidad. Se describen los requisitos b\u00e1sicos de GMP, que incluyen la definici\u00f3n clara de procesos, la calificaci\u00f3n de equipos, la provisi\u00f3n de recursos adecuados y la implementaci\u00f3n de sistemas para el seguimiento y mejora de la calidad. El objetivo principal de GMP es minimizar los riesgos asociados con la producci\u00f3n y el uso de productos sangu\u00edneos.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los elementos clave que deben estar documentados en un sistema de garant\u00eda de calidad seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca respuestas sobre la documentaci\u00f3n y los procesos espec\u00edficos que deben estar presentes en un sistema de garant\u00eda de calidad, que no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para garantizar la trazabilidad de los productos sangu\u00edneos liberados?**\n   - Esta pregunta se centra en las pr\u00e1cticas de trazabilidad y los sistemas necesarios para gestionar la retirada de productos, lo cual es crucial para la seguridad del paciente.\n\n3. **\u00bfC\u00f3mo se aborda la capacitaci\u00f3n del personal en el contexto de las buenas pr\u00e1cticas de fabricaci\u00f3n en los establecimientos de sangre?**\n   - Esta pregunta busca informaci\u00f3n sobre los requisitos de formaci\u00f3n y calificaci\u00f3n del personal involucrado en la producci\u00f3n de productos sangu\u00edneos, un aspecto que puede no estar ampliamente cubierto en otras directrices.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistema de Gesti\u00f3n de Calidad**: Se enfatiza la necesidad de un sistema de gesti\u00f3n de calidad en los establecimientos de sangre, que abarca desde la selecci\u00f3n de donantes hasta la distribuci\u00f3n del producto final.\n\n2. **Responsabilidad de la Alta Direcci\u00f3n**: La alta direcci\u00f3n es responsable de establecer y revisar la pol\u00edtica de calidad y los objetivos, asegurando la participaci\u00f3n de todo el personal y la efectividad del sistema de calidad.\n\n3. **Unidad de Gesti\u00f3n de Calidad**: Debe existir una unidad de gesti\u00f3n de calidad compuesta por uno o m\u00e1s miembros, encargada de garantizar el cumplimiento de las pol\u00edticas y procedimientos de calidad, as\u00ed como de documentar la evidencia de su implementaci\u00f3n.\n\n4. **Pol\u00edticas y Objetivos de Aseguramiento de Calidad**: Estas deben ser desarrolladas en coordinaci\u00f3n con la alta direcci\u00f3n y deben cumplir con las regulaciones nacionales e internacionales, asegurando la m\u00e1xima calidad y seguridad de los componentes sangu\u00edneos.\n\n5. **Evaluaci\u00f3n del Sistema de Calidad**: Se debe evaluar peri\u00f3dicamente el desempe\u00f1o del sistema de gesti\u00f3n de calidad para identificar y corregir deficiencias.\n\n6. **Independencia de la Funci\u00f3n de Aseguramiento de Calidad**: La funci\u00f3n de aseguramiento de calidad debe ser independiente de las operaciones de fabricaci\u00f3n para garantizar la objetividad en la revisi\u00f3n y aprobaci\u00f3n de documentos relacionados con la calidad.\n\n7. **Compromiso del Personal**: Todo el personal debe comprender los objetivos de calidad y su papel en su cumplimiento, lo que es fundamental para el \u00e9xito del sistema de gesti\u00f3n de calidad.\n\n### Entidades Clave:\n- **Establecimientos de Sangre**: Organizaciones encargadas de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre y componentes sangu\u00edneos.\n- **Alta Direcci\u00f3n**: Equipo de liderazgo responsable de la gesti\u00f3n y supervisi\u00f3n del establecimiento de sangre.\n- **Unidad de Gesti\u00f3n de Calidad**: Grupo encargado de implementar y monitorear las pol\u00edticas de calidad.\n- **Pol\u00edticas de Calidad**: Directrices que establecen los est\u00e1ndares de calidad y seguridad para los productos sangu\u00edneos.\n- **Regulaciones Nacionales e Internacionales**: Normativas que deben cumplirse para asegurar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: quality assurance, good manufacturing practice, blood products, traceability, quality management"}}, "9c4adfa4-2229-436c-913c-0cf7a3a24501": {"node_ids": ["d6e72dbe-6273-4322-8d55-a12a4a4c58ba"], "metadata": {"page_label": "171", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.2.2 Quality control\n\nQuality control is that part of GMP which is concerned with specifications, sampling and testing. Quality control is also concerned with the organization, documentation and release procedures which ensure that the necessary and relevant tests are carried out and that neither materials are released for use nor products released for supply until their quality has been judged to be satisfactory (7). For quality control programmes in blood establishments, refer to sections 9.5 and 9.6.\n\n# 3.3 Product quality review\n\nRegular periodic or rolling quality reviews should be conducted with the objective of verifying the consistency of the existing process and the appropriateness of current specifications in order to highlight trends and to identify improvements in both product and process.\n\nA product quality review may also be considered as an instrument for surveying the overall quality status of a blood component and its manufacturing processes, including the collection of starting materials. Such a review should normally be conducted annually and should be documented. In accordance with international and/or NRA requirements and recommendations it may include:\n\n- review of starting materials;\n- review of critical in-process controls;\n- review of results of quality control and quality monitoring;\n- review of all changes;\n- review of the qualification status of equipment;\n- review of technical agreements and contracts;\n- review of all significant deviations, errors and non-conformances, and the corrective actions implemented;\n- review of the findings of internal audits and other inspections, and the corrective actions implemented;\n- review of complaints and recalls;\n- review of donor acceptance criteria;\n- review of donor deferrals;\n- review of look-back cases.\n\n# 3.4 Quality risk management\n\nBlood establishments should ensure that blood components manufactured in their facilities are of the quality required for their intended use, comply with quality standard requirements, and do not place recipients at risk due to inadequate safety, quality or efficacy throughout the life-cycle of the product. In order to reliably achieve the quality objective, there should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda aspectos clave de la gesti\u00f3n de calidad en los establecimientos de sangre, centr\u00e1ndose en el control de calidad, la revisi\u00f3n de la calidad del producto y la gesti\u00f3n de riesgos de calidad. Se enfatiza la importancia de realizar revisiones peri\u00f3dicas para asegurar la consistencia de los procesos y la adecuaci\u00f3n de las especificaciones, as\u00ed como la necesidad de cumplir con los est\u00e1ndares de calidad para garantizar la seguridad y eficacia de los componentes sangu\u00edneos a lo largo de su ciclo de vida.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en una revisi\u00f3n de calidad del producto en un establecimiento de sangre?**\n   - La revisi\u00f3n de calidad del producto debe incluir la evaluaci\u00f3n de materiales de partida, controles cr\u00edticos en proceso, resultados de control de calidad, cambios significativos, estado de calificaci\u00f3n del equipo, acuerdos t\u00e9cnicos, desviaciones y no conformidades, hallazgos de auditor\u00edas internas, quejas y retiradas de productos, criterios de aceptaci\u00f3n de donantes, y casos de retroceso.\n\n2. **\u00bfCon qu\u00e9 frecuencia se deben realizar las revisiones de calidad del producto y qu\u00e9 documentaci\u00f3n se requiere?**\n   - Las revisiones de calidad del producto deben realizarse normalmente de manera anual y deben ser documentadas para cumplir con los requisitos internacionales y/o de la autoridad reguladora nacional (NRA).\n\n3. **\u00bfQu\u00e9 medidas deben tomar los establecimientos de sangre para garantizar que los componentes sangu\u00edneos no representen un riesgo para los receptores?**\n   - Los establecimientos de sangre deben asegurarse de que los componentes sangu\u00edneos fabricados cumplan con los requisitos de calidad necesarios para su uso previsto, y que no pongan en riesgo a los receptores debido a una seguridad, calidad o eficacia inadecuadas a lo largo del ciclo de vida del producto. Esto implica implementar un sistema de gesti\u00f3n de riesgos de calidad efectivo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Garant\u00eda de Calidad (Quality Assurance)**: Se refiere a los arreglos totales realizados para asegurar que los productos cumplan con los est\u00e1ndares de calidad requeridos para su uso previsto. Incluye pr\u00e1cticas de fabricaci\u00f3n adecuadas (GMP) y otros elementos como el dise\u00f1o y desarrollo de productos.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Parte fundamental de la garant\u00eda de calidad que asegura que los productos sangu\u00edneos se produzcan y controlen consistentemente seg\u00fan est\u00e1ndares de calidad. Su objetivo es minimizar riesgos como contaminaci\u00f3n, errores de mezcla y transmisi\u00f3n de enfermedades.\n\n3. **Documentaci\u00f3n y Procedimientos**: Es esencial que todos los procesos cr\u00edticos est\u00e9n claramente descritos en instrucciones escritas y que el sistema de garant\u00eda de calidad est\u00e9 completamente documentado y distribuido entre el personal involucrado.\n\n4. **Recursos Adecuados**: Se requiere personal competente, instalaciones adecuadas y equipos suficientes para completar los pasos de fabricaci\u00f3n de manera segura y conforme a la calidad.\n\n5. **Trazabilidad y Gesti\u00f3n de Quejas**: Es necesario contar con un sistema que mantenga la trazabilidad de los productos liberados para facilitar retiradas si es necesario, as\u00ed como un sistema para manejar quejas.\n\n6. **Mejora Continua**: Se debe implementar un sistema que aborde funciones y actividades de mejora de procesos y calidad.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre la garant\u00eda de calidad en la producci\u00f3n de productos sangu\u00edneos.\n- **Productos Sangu\u00edneos**: Productos que requieren est\u00e1ndares espec\u00edficos de calidad y control en su fabricaci\u00f3n.\n- **Personal Calificado**: Individuos que deben estar adecuadamente formados y capacitados para llevar a cabo procesos de fabricaci\u00f3n y control de calidad.\n- **Instalaciones y Equipos**: Infraestructura y herramientas necesarias para la producci\u00f3n segura y conforme a est\u00e1ndares de calidad.\n\nEste resumen destaca la importancia de la garant\u00eda de calidad y las buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de los establecimientos de sangre, as\u00ed como los requisitos y sistemas necesarios para asegurar la seguridad y eficacia de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: quality control, product quality review, blood establishments, quality risk management, good manufacturing practices"}}, "3cd32915-ddf5-48bc-95d3-5c5d5c7acd92": {"node_ids": ["4d7f8905-5915-4e87-9736-9c99ae8bbef4"], "metadata": {"page_label": "172", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be a comprehensively designed and correctly implemented system of quality assurance that incorporates GMP, quality control and quality risk management (QRM).\n\nAn effective QRM approach can ensure the quality of a product by providing proactive means to identify and control potential quality issues. It can also facilitate and improve the decision-making process in cases when quality problems or deviations from standard processes and specifications have to be assessed or planned changes need to be evaluated.\n\nThe two primary principles of QRM are:\n\n- The evaluation of the risk to quality and safety should be based on scientific knowledge and ultimately linked to the protection of the donor and/or recipient.\n- The level of effort, formality and documentation of the QRM process should be commensurate with the level of risk.\n\nExamples of the QRM processes and applications can be found in guidelines on QRM, such as the Q9 guideline of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (8). This describes processes and offers a selection of methods and tools for applying the QRM principles.\n\n### 3.5 Change control\n\nA formal change control system should be in place to plan, evaluate and document all changes that may affect the quality, traceability and availability of blood or blood components or that might have an impact on the safety of blood, blood components, donors or recipients. The change control system should guarantee a formal approval of a change before it is implemented. Furthermore, it should ensure that the impact of the proposed change is assessed and that all necessary measures \u2014 such as qualification and validation, training of personnel, adoption of working instructions, revision of contracts, definition of maintenance tasks, information for third parties and authorities \u2014 are defined and completed at the time the change is put into force. The need for additional testing and validation should be determined on a scientific basis. A risk analysis may be appropriate as part of the QRM.\n\nAfter the implementation of a change, a post-implementation evaluation should be carried out in order to determine whether the introduction of the change has been successful and effective.\n\nThe introduction of new equipment, processes and methods should be treated as a change.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Sistema de Aseguramiento de Calidad**: El texto enfatiza la importancia de un sistema de aseguramiento de calidad bien dise\u00f1ado que integre Buenas Pr\u00e1cticas de Manufactura (GMP), control de calidad y gesti\u00f3n de riesgos de calidad (QRM). Se destaca que un enfoque efectivo de QRM puede identificar y controlar proactivamente problemas de calidad, mejorando as\u00ed la toma de decisiones en situaciones de desviaciones de procesos est\u00e1ndar.\n\n2. **Principios de la Gesti\u00f3n de Riesgos de Calidad (QRM)**: Se presentan dos principios fundamentales de QRM: la evaluaci\u00f3n del riesgo debe basarse en el conocimiento cient\u00edfico y estar vinculada a la protecci\u00f3n de donantes y receptores, y el nivel de formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo.\n\n3. **Control de Cambios**: Se describe la necesidad de un sistema formal de control de cambios que planifique, eval\u00fae y documente todos los cambios que puedan afectar la calidad y seguridad de la sangre y sus componentes. Este sistema debe garantizar la aprobaci\u00f3n formal de los cambios antes de su implementaci\u00f3n y realizar una evaluaci\u00f3n posterior para verificar la efectividad de los cambios introducidos.\n\n### Preguntas espec\u00edficas que el contexto puede responder\n\n1. **\u00bfCu\u00e1les son los pasos necesarios para implementar un sistema de control de cambios en la gesti\u00f3n de calidad de sangre y componentes sangu\u00edneos?**\n   - El contexto detalla que un sistema de control de cambios debe incluir la planificaci\u00f3n, evaluaci\u00f3n y documentaci\u00f3n de cambios, asegurando la aprobaci\u00f3n formal antes de la implementaci\u00f3n y la evaluaci\u00f3n posterior para verificar la efectividad del cambio.\n\n2. **\u00bfC\u00f3mo se determina el nivel de esfuerzo y documentaci\u00f3n necesarios en el proceso de gesti\u00f3n de riesgos de calidad (QRM)?**\n   - Seg\u00fan el texto, el nivel de esfuerzo, formalidad y documentaci\u00f3n del proceso de QRM debe ser proporcional al nivel de riesgo asociado, lo que implica que se debe realizar una evaluaci\u00f3n del riesgo basada en el conocimiento cient\u00edfico.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse antes de implementar un cambio en los procesos relacionados con la sangre y sus componentes?**\n   - El contexto menciona que antes de implementar un cambio, se deben definir y completar medidas como la calificaci\u00f3n y validaci\u00f3n, capacitaci\u00f3n del personal, adopci\u00f3n de instrucciones de trabajo, revisi\u00f3n de contratos y definici\u00f3n de tareas de mantenimiento, adem\u00e1s de realizar un an\u00e1lisis de riesgo como parte del QRM.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de Calidad**: Parte de las Buenas Pr\u00e1cticas de Manufactura (GMP) que se ocupa de especificaciones, muestreo y pruebas. Asegura que los materiales y productos no se liberen hasta que su calidad sea considerada satisfactoria.\n\n2. **Revisi\u00f3n de Calidad del Producto**: Se deben realizar revisiones peri\u00f3dicas (normalmente anuales) para verificar la consistencia de los procesos y la adecuaci\u00f3n de las especificaciones. Estas revisiones deben documentarse y pueden incluir la evaluaci\u00f3n de materiales de partida, controles en proceso, resultados de calidad, cambios significativos, y m\u00e1s.\n\n3. **Gesti\u00f3n de Riesgos de Calidad**: Los establecimientos de sangre deben garantizar que los componentes sangu\u00edneos cumplan con los est\u00e1ndares de calidad y no representen un riesgo para los receptores a lo largo de su ciclo de vida. Esto implica implementar un sistema efectivo de gesti\u00f3n de riesgos.\n\n### Entidades:\n\n- **Establecimientos de Sangre**: Organizaciones que fabrican componentes sangu\u00edneos.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre que se utilizan para transfusiones y otros tratamientos m\u00e9dicos.\n- **Autoridad Reguladora Nacional (NRA)**: Entidad que establece y supervisa los est\u00e1ndares de calidad y seguridad en la fabricaci\u00f3n de productos de salud.\n- **Documentaci\u00f3n**: Registros necesarios para cumplir con los requisitos de calidad y auditor\u00eda.\n\n### Resumen:\nLa secci\u00f3n aborda la importancia del control de calidad, la revisi\u00f3n peri\u00f3dica de la calidad del producto y la gesti\u00f3n de riesgos en los establecimientos de sangre. Se enfatiza la necesidad de realizar revisiones anuales documentadas para asegurar la calidad y seguridad de los componentes sangu\u00edneos, cumpliendo con los est\u00e1ndares internacionales y regulaciones nacionales.", "excerpt_keywords": "Keywords: quality assurance, quality risk management, change control, blood components, GMP"}}, "6be07ce3-4a5f-49c6-bf1d-49da587b6c1a": {"node_ids": ["7303c467-b822-496f-b8aa-1185312b39da"], "metadata": {"page_label": "173", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.6 Deviation evaluation and reporting\n\nAny deviation from standard operating procedures, validated processes, or non-conformances with specifications or other quality-related requirements should be recorded and investigated. The potential impact on the quality of the product in question, or on other products, should be evaluated.\n\nThe evaluation of the cause of the deviation and of related processes that may also be implicated in the deviation should be documented. Review and approval of the investigation as completed should be documented by the quality assurance and/or quality control department as appropriate.\n\nAll deviations and non-conformances should be logged in a system that allows for appropriate data review. A data review should be carried out periodically in a manner that allows for tracking and trending of data and that facilitates process improvement.\n\nThe handling of deviations and non-conformances should be defined in writing. Actions should be taken within a reasonable time frame in order to avoid any impact on other products manufactured within the same establishment.\n\nUnder certain circumstances a product may be accepted after evaluation of a deviation. The documentation should include the justification or rationale for accepting a product manufactured in deviation from a specified requirement, and should be signed by the responsible person.\n\n# 3.7 Corrective and preventive actions\n\nA corrective and preventive action system should be established, implemented and maintained to ensure that there is continuous improvement at the blood establishment. The procedures should include the management of deviations and non-conformances, complaints, events and findings of the quality system management review, inspections and audits, and should ensure the proper recording of all corrective and preventive actions taken.\n\nThe corrective and preventive action system should ensure that each quality problem is addressed and corrected and that recurrence of the problem is prevented. Actions should be carried out within a reasonable predefined time frame. The management of the blood establishment should be involved in the review of corrective and preventive actions.\n\nThe blood establishment should have methods and procedures in place to collect, document and evaluate data on quality. Product or quality problems should be entered into the corrective and preventive action system. Quality data include all errors, deviations, non-conformances, accidents, near-miss events and complaints. Quality data also include the results of quality control tests.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS aborda la evaluaci\u00f3n y el reporte de desviaciones en procedimientos operativos est\u00e1ndar y la gesti\u00f3n de acciones correctivas y preventivas en establecimientos de sangre. Se enfatiza la importancia de registrar y evaluar cualquier desviaci\u00f3n o no conformidad, as\u00ed como la necesidad de un sistema que permita la revisi\u00f3n de datos para facilitar la mejora continua. Adem\u00e1s, se establece que las acciones correctivas deben ser documentadas y revisadas por la direcci\u00f3n del establecimiento, asegurando que se tomen dentro de un marco de tiempo razonable.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben considerar para aceptar un producto que ha sido fabricado en desviaci\u00f3n de un requisito especificado?**\n   - Esta pregunta busca detalles sobre los criterios espec\u00edficos que justifican la aceptaci\u00f3n de un producto a pesar de las desviaciones, que no se encuentran expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de datos deben ser ingresados en el sistema de acciones correctivas y preventivas, y c\u00f3mo se deben clasificar?**\n   - Esta pregunta se centra en la clasificaci\u00f3n y el tipo de datos que deben ser documentados en el sistema, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfCu\u00e1l es el papel espec\u00edfico del departamento de aseguramiento de calidad en la revisi\u00f3n y aprobaci\u00f3n de las investigaciones de desviaciones?**\n   - Esta pregunta busca aclarar las responsabilidades y el proceso que sigue el departamento de calidad en la gesti\u00f3n de desviaciones, un aspecto que puede no estar detallado en otros documentos.\n\n### Resumen adicional\n\nEl documento tambi\u00e9n menciona que la gesti\u00f3n de desviaciones y no conformidades debe estar claramente definida por escrito, y que se deben tomar acciones en un tiempo razonable para evitar impactos en otros productos. Adem\u00e1s, se destaca la importancia de involucrar a la direcci\u00f3n del establecimiento en la revisi\u00f3n de acciones correctivas y preventivas, lo que sugiere un enfoque colaborativo en la mejora de la calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Aseguramiento de Calidad**:\n   - Importancia de un sistema integral que incluya Buenas Pr\u00e1cticas de Manufactura (GMP), control de calidad y gesti\u00f3n de riesgos de calidad (QRM).\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**:\n   - **Principios Fundamentales**:\n     - Evaluaci\u00f3n del riesgo basada en conocimiento cient\u00edfico, vinculada a la protecci\u00f3n de donantes y receptores.\n     - Proporcionalidad entre el nivel de esfuerzo/documentaci\u00f3n y el nivel de riesgo.\n   - Referencia a la gu\u00eda Q9 de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) como fuente de procesos y herramientas para aplicar QRM.\n\n3. **Control de Cambios**:\n   - Necesidad de un sistema formal para planificar, evaluar y documentar cambios que afecten la calidad y seguridad de la sangre y sus componentes.\n   - Requisitos para la aprobaci\u00f3n formal de cambios antes de su implementaci\u00f3n.\n   - Evaluaci\u00f3n del impacto del cambio y definici\u00f3n de medidas necesarias (calificaci\u00f3n, validaci\u00f3n, capacitaci\u00f3n, etc.) antes de la implementaci\u00f3n.\n   - Importancia de realizar una evaluaci\u00f3n post-implementaci\u00f3n para verificar la efectividad del cambio.\n\n### Entidades Clave\n- **GMP**: Buenas Pr\u00e1cticas de Manufactura.\n- **QRM**: Gesti\u00f3n de Riesgos de Calidad.\n- **ICH**: Conferencia Internacional sobre Armonizaci\u00f3n de Requisitos T\u00e9cnicos para el Registro de Productos Farmac\u00e9uticos para Uso Humano.\n- **Sistema de Control de Cambios**: Proceso formal para gestionar cambios en la calidad de sangre y componentes sangu\u00edneos. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y basado en riesgos para garantizar la calidad y seguridad en la gesti\u00f3n de sangre y sus componentes.", "excerpt_keywords": "Keywords: deviations, quality assurance, corrective actions, blood establishment, non-conformances"}}, "f90085d3-510a-414c-9298-e6ed720bdb91": {"node_ids": ["35577413-a7da-4ece-b177-f597aec8c67d"], "metadata": {"page_label": "174", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Internal audits\n\nIn order to monitor implementation and compliance with the quality management system, regular internal audits should be performed according to an established procedure. Internal audits should be conducted by trained, independent and competent persons under the responsibility of the organization\u2019s quality assurance unit.\n\nInternal audits should be arranged according to a schedule and should cover all parts of the operations, including data processing systems. Each audit should be carried out according to an approved audit plan that assesses compliance with internal requirements and applicable national and/or international regulations.\n\nAll audit results should be documented and reported to the management. Appropriate corrective and preventive actions should be taken in a timely and effective manner and should be assessed for effectiveness after implementation.\n\nThe quality assurance department, where the internal audit function resides, should not audit itself but should be subject to an independent audit.\n\nInternal audits are not a substitute for official inspections performed by the competent national authorities who check compliance with national regulations.\n\n# Complaints and product recall\n\n## Complaints\n\nThere should be a system in place to ensure that all complaints are handled according to written \u2014 and approved \u2014 standard operating procedures. The review of the complaint should take account of whether the complaint relates to a quality defect in a blood component. The blood establishment should determine whether a recall should be initiated. The process should be defined in a standard operating procedure. Complaints, adverse events or reactions, as well as any information concerning potentially defective products, should be carefully reviewed and thoroughly investigated in order to find the root cause of the problem. Consideration should be given to determining whether other products are also affected. All investigations and actions should be carried out in a timely manner to ensure that the safety of the recipient is not compromised and that other products manufactured within the same establishment are not affected.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de realizar auditor\u00edas internas y gestionar quejas y retiradas de productos en el contexto de un sistema de gesti\u00f3n de calidad. Se establece que las auditor\u00edas internas deben ser realizadas por personas capacitadas e independientes, y deben seguir un plan de auditor\u00eda aprobado. Los resultados de las auditor\u00edas deben ser documentados y comunicados a la direcci\u00f3n, y se deben tomar acciones correctivas y preventivas de manera oportuna. Adem\u00e1s, se menciona que debe existir un sistema para manejar quejas, especialmente aquellas relacionadas con defectos de calidad en componentes sangu\u00edneos, y que las investigaciones deben llevarse a cabo de manera r\u00e1pida para garantizar la seguridad del receptor.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben considerarse al revisar una queja relacionada con un componente sangu\u00edneo?**\n   - La revisi\u00f3n de la queja debe tener en cuenta si est\u00e1 relacionada con un defecto de calidad en el componente sangu\u00edneo y determinar si es necesario iniciar un retiro del producto.\n\n2. **\u00bfCu\u00e1l es el papel de la unidad de aseguramiento de calidad en el proceso de auditor\u00eda interna?**\n   - La unidad de aseguramiento de calidad es responsable de llevar a cabo las auditor\u00edas internas, pero no debe auditarse a s\u00ed misma; debe estar sujeta a una auditor\u00eda independiente.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse despu\u00e9s de que se documentan los resultados de una auditor\u00eda interna?**\n   - Despu\u00e9s de documentar los resultados, se deben tomar acciones correctivas y preventivas de manera oportuna y efectiva, y estas acciones deben ser evaluadas para determinar su efectividad tras su implementaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n y Reporte de Desviaciones**:\n   - Importancia de registrar y investigar desviaciones de procedimientos operativos est\u00e1ndar y no conformidades.\n   - Evaluaci\u00f3n del impacto potencial en la calidad del producto afectado y otros productos.\n   - Documentaci\u00f3n de la causa de la desviaci\u00f3n y procesos relacionados.\n   - Necesidad de un sistema para registrar desviaciones y no conformidades, permitiendo la revisi\u00f3n de datos y mejora continua.\n   - Definici\u00f3n escrita del manejo de desviaciones y no conformidades, con acciones a tomar en un tiempo razonable.\n   - Posibilidad de aceptar productos fabricados en desviaci\u00f3n, con justificaci\u00f3n documentada y firma del responsable.\n\n2. **Acciones Correctivas y Preventivas**:\n   - Establecimiento y mantenimiento de un sistema de acciones correctivas y preventivas para la mejora continua en establecimientos de sangre.\n   - Inclusi\u00f3n de la gesti\u00f3n de desviaciones, quejas, eventos y hallazgos en el sistema de calidad.\n   - Documentaci\u00f3n y revisi\u00f3n de todas las acciones correctivas y preventivas.\n   - Involucramiento de la direcci\u00f3n en la revisi\u00f3n de acciones correctivas y preventivas.\n   - M\u00e9todos para recopilar, documentar y evaluar datos de calidad, incluyendo errores, desviaciones, no conformidades y resultados de pruebas de control de calidad.\n\n### Entidades\n\n- **Establecimientos de Sangre**: Organizaciones responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre.\n- **Departamento de Aseguramiento de Calidad**: Entidad encargada de revisar y aprobar investigaciones de desviaciones.\n- **Sistema de Acciones Correctivas y Preventivas**: Herramienta para gestionar problemas de calidad y asegurar la mejora continua.\n- **Documentaci\u00f3n**: Registros que justifican la aceptaci\u00f3n de productos en desviaci\u00f3n y acciones tomadas.\n\nEste resumen destaca la importancia de la gesti\u00f3n de desviaciones y acciones correctivas en el contexto de la calidad en los establecimientos de sangre, enfatizando la necesidad de documentaci\u00f3n y revisi\u00f3n sistem\u00e1tica para garantizar la mejora continua.", "excerpt_keywords": "Keywords: internal audits, quality management, complaints handling, blood components, corrective actions"}}, "a2a9afb3-0e0a-46ec-8bf7-821cfbe7c1a8": {"node_ids": ["02486149-6e2f-4aa5-9cf9-1684e888f0d3"], "metadata": {"page_label": "175", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Immediate corrective actions should be taken to address the root cause of the problem, and actions should be taken to prevent it from recurring. There should be active follow-up of the implementation of corrective actions (see section 3.7).\n\nDesignated personnel should be responsible for managing complaints and coordinating investigations, actions and measures to be taken within a defined time frame. The unit responsible for quality should be included in this process.\n\nAll complaints, with the original details, should be recorded. Records should be retained of all the decisions, investigations and measures taken as a result of a complaint. Complaint records should be reviewed regularly in order to check for unfavourable trends or recurring problems and to ensure continuous quality improvement.\n\nDepending on the national requirements the NRA should be informed.\n\n### 3.9.2 Recalls\n\nAn effective written recall procedure should be in place, including a description of the responsibilities and actions to be taken. A recall should always be initiated whenever it is discovered that a product does not meet the release criteria of the blood establishment and NRA. This may happen when information is obtained subsequent to the release of a product and, had this information been known in advance, it would have prevented the blood component from being released. A recall may also be indicated when it is discovered that personnel did not follow standard operating procedures. Corrective actions should take place within predefined time periods and should include the traceability of all relevant components and, where applicable, look-back procedures (see section 3.11).\n\nA qualified person within the blood establishment should be nominated to assess the need for product recall and to initiate, coordinate and document the necessary actions.\n\nRecall operations should be initiated promptly and at any time. Therefore the standard operating procedures should include emergency and \u201cout of hours\u201d contact details. Depending on the national requirements the NRA should be informed.\n\nRecalled products should be destroyed. If recalled products are not destroyed, they should be clearly identified and stored separately in a secure area.\n\n### 3.10 Process improvement\n\nIdeas for potential improvements to any of the systems may come from research, development, brainstorming, or from the management of non-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de quejas y la implementaci\u00f3n de acciones correctivas en el contexto de los establecimientos de sangre. Se enfatiza la importancia de registrar todas las quejas, realizar un seguimiento de las acciones correctivas y mantener un procedimiento de retiro efectivo para productos que no cumplen con los criterios de liberaci\u00f3n. Tambi\u00e9n se menciona la necesidad de mejorar continuamente los procesos a trav\u00e9s de la recopilaci\u00f3n de ideas y la gesti\u00f3n de no conformidades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para gestionar adecuadamente una queja en un establecimiento de sangre?**\n   - El contexto detalla que se deben tomar acciones correctivas inmediatas, designar personal responsable, registrar todas las quejas y revisar regularmente los registros para identificar tendencias desfavorables.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales se debe iniciar un procedimiento de retiro de productos en un establecimiento de sangre?**\n   - Un retiro debe iniciarse si se descubre que un producto no cumple con los criterios de liberaci\u00f3n, ya sea por nueva informaci\u00f3n obtenida despu\u00e9s de la liberaci\u00f3n o por incumplimiento de los procedimientos operativos est\u00e1ndar.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse con respecto a los productos que han sido retirados del mercado?**\n   - Los productos retirados deben ser destruidos o, si no se destruyen, deben ser claramente identificados y almacenados en un \u00e1rea segura, adem\u00e1s de que se debe informar a la autoridad nacional reguladora seg\u00fan los requisitos nacionales.", "prev_section_summary": "### Temas Clave\n\n1. **Auditor\u00edas Internas**:\n   - Importancia de realizar auditor\u00edas internas regulares para monitorear la implementaci\u00f3n y cumplimiento del sistema de gesti\u00f3n de calidad.\n   - Deben ser realizadas por personas capacitadas, independientes y competentes, bajo la responsabilidad de la unidad de aseguramiento de calidad.\n   - Las auditor\u00edas deben seguir un plan aprobado y cubrir todas las operaciones, incluyendo sistemas de procesamiento de datos.\n   - Los resultados de las auditor\u00edas deben ser documentados y reportados a la direcci\u00f3n, con acciones correctivas y preventivas implementadas de manera oportuna.\n   - La unidad de aseguramiento de calidad no debe auditarse a s\u00ed misma, sino que debe estar sujeta a auditor\u00edas independientes.\n   - Las auditor\u00edas internas no sustituyen las inspecciones oficiales de las autoridades nacionales competentes.\n\n2. **Gesti\u00f3n de Quejas y Retiradas de Productos**:\n   - Debe existir un sistema para manejar quejas, siguiendo procedimientos operativos est\u00e1ndar aprobados.\n   - La revisi\u00f3n de quejas debe considerar si est\u00e1n relacionadas con defectos de calidad en componentes sangu\u00edneos y determinar si es necesario iniciar un retiro del producto.\n   - Las quejas, eventos adversos y reacciones deben ser investigados a fondo para identificar la causa ra\u00edz del problema.\n   - Es importante evaluar si otros productos tambi\u00e9n pueden estar afectados y llevar a cabo investigaciones de manera oportuna para garantizar la seguridad del receptor.\n\n### Entidades\n\n- **Organizaci\u00f3n**: Establecimiento de sangre (Blood establishment).\n- **Unidad de Aseguramiento de Calidad**: Responsable de las auditor\u00edas internas.\n- **Autoridades Nacionales Competentes**: Encargadas de realizar inspecciones oficiales.\n- **Productos**: Componentes sangu\u00edneos y otros productos fabricados en el establecimiento. \n\nEste resumen destaca la importancia de las auditor\u00edas internas y la gesti\u00f3n de quejas en el contexto de un sistema de gesti\u00f3n de calidad, enfatizando la necesidad de procedimientos claros y la responsabilidad de las entidades involucradas.", "excerpt_keywords": "Keywords: quejas, retiradas, acciones correctivas, mejora continua, establecimiento de sangre"}}, "d8811a34-1223-436e-b383-97a8e5afb083": {"node_ids": ["419afb36-9875-4d41-a40b-27c62ae952ae"], "metadata": {"page_label": "176", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.11 Look-back\n\nA written system should be in place for carrying out a look-back procedure. This process should be able to trace the products collected from a donor to the final recipients and from the recipient back to the donor, preferably by means of a computer database.\n\nThis standard operating procedure should be followed when it is determined retrospectively that a blood or plasma donation should have been excluded from processing \u2014 for instance, because the unit was collected from a donor who was subsequently rejected for reactive viral marker, high-risk behaviour, exposure to CJD/vCJD or other risks related to infectious diseases (*donor look-back*) (3).\n\nIf a donor is confirmed to have a disease that is transmissible by blood products or has high-risk behaviour, the donor should be permanently excluded from further donation. All donations from such a donor should be traced and prevented from being used or further manufactured unless they have expired and therefore have already been destroyed. If donations have been used or further processed, procedures should be in place to define appropriate actions. Donor notification and counselling is recommended for purposes of donor health and for the safety of the blood supply.\n\nThere should be a process in place for investigating a report of a suspected transfusion-associated reaction in a recipient, in order to identify a potentially implicated donor (*recipient look-back*). The donor of products implicated in transmitting disease or causing recipient harm should be excluded from further donations. All other donations from the implicated donor should be traced and blood components removed from the inventory and recalled, if within the expiry date.\n\nAll post-donation information should be recorded and maintained. There should be a system in place to react accordingly and in time to remove unexpired products from distribution in order to assure the safety of recipients.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece la importancia de implementar un sistema de \"look-back\" para rastrear donaciones de sangre y plasma desde el donante hasta el receptor y viceversa. Este procedimiento es crucial para garantizar la seguridad de la transfusi\u00f3n, especialmente en casos donde se determina que una donaci\u00f3n deber\u00eda haber sido excluida debido a riesgos de enfermedades transmisibles. Se enfatiza la necesidad de excluir permanentemente a donantes con comportamientos de alto riesgo o enfermedades transmisibles, as\u00ed como la importancia de investigar reacciones adversas en receptores para identificar donantes potencialmente implicados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se determina que una donaci\u00f3n de sangre deber\u00eda haber sido excluida debido a un marcador viral reactivo?**\n   - El procedimiento implica rastrear todas las donaciones del donante, excluirlo de futuras donaciones y notificarlo, adem\u00e1s de tomar medidas para asegurar que las donaciones no sean utilizadas.\n\n2. **\u00bfQu\u00e9 acciones se deben tomar si se reporta una reacci\u00f3n transfusional en un receptor?**\n   - Se debe investigar el caso para identificar al donante potencialmente implicado, excluirlo de futuras donaciones y rastrear todas las donaciones realizadas por ese donante, retirando los componentes sangu\u00edneos del inventario si est\u00e1n dentro de la fecha de caducidad.\n\n3. **\u00bfCu\u00e1l es la importancia de mantener un registro de la informaci\u00f3n posterior a la donaci\u00f3n?**\n   - Mantener un registro es crucial para poder reaccionar de manera oportuna y retirar productos no caducados de la distribuci\u00f3n, asegurando as\u00ed la seguridad de los receptores de transfusiones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Acciones Correctivas Inmediatas**: Se deben tomar medidas inmediatas para abordar la causa ra\u00edz de los problemas identificados y prevenir su recurrencia. Es esencial realizar un seguimiento activo de la implementaci\u00f3n de estas acciones.\n\n2. **Gesti\u00f3n de Quejas**: Se designar\u00e1 personal responsable para gestionar las quejas y coordinar investigaciones y acciones dentro de un marco de tiempo definido. Todas las quejas deben ser registradas y los registros revisados regularmente para identificar tendencias desfavorables y asegurar la mejora continua de la calidad.\n\n3. **Procedimiento de Retiro**: Debe existir un procedimiento de retiro escrito y efectivo que describa las responsabilidades y acciones a seguir. Un retiro debe iniciarse si un producto no cumple con los criterios de liberaci\u00f3n, ya sea por nueva informaci\u00f3n o por incumplimiento de procedimientos operativos est\u00e1ndar.\n\n4. **Responsabilidad de Retiro**: Se debe nombrar a una persona calificada dentro del establecimiento de sangre para evaluar la necesidad de un retiro de producto y coordinar las acciones necesarias.\n\n5. **Destrucci\u00f3n de Productos Retirados**: Los productos retirados deben ser destruidos o, si no se destruyen, deben ser claramente identificados y almacenados en un \u00e1rea segura.\n\n6. **Mejora de Procesos**: Se fomenta la recopilaci\u00f3n de ideas para mejorar los sistemas a trav\u00e9s de la investigaci\u00f3n, el desarrollo y la gesti\u00f3n de no conformidades.\n\n### Entidades Clave\n\n- **Establecimientos de Sangre**: Organizaciones responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de productos sangu\u00edneos.\n- **Autoridad Nacional Reguladora (NRA)**: Entidad que debe ser informada seg\u00fan los requisitos nacionales sobre quejas y retiros de productos.\n- **Personal Designado**: Individuos responsables de la gesti\u00f3n de quejas y la implementaci\u00f3n de acciones correctivas.\n- **Productos Sangu\u00edneos**: Componentes que pueden ser objeto de quejas o retiros si no cumplen con los est\u00e1ndares establecidos. \n\nEste resumen destaca la importancia de la gesti\u00f3n de quejas y la implementaci\u00f3n de procedimientos de retiro para garantizar la calidad y seguridad en los establecimientos de sangre.", "excerpt_keywords": "Keywords: look-back procedure, blood donation, infectious diseases, donor exclusion, transfusion safety"}}, "656f6374-5534-4ee9-8da9-328cddd6b575": {"node_ids": ["69777f40-adaa-4a72-a751-1f1d2f3c633e"], "metadata": {"page_label": "177", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The recipients of any products identified in the look-back process should be counselled about the risk of having contracted a disease from the potentially contaminated products and should be offered disease marker testing, consultation and medical treatment if indicated. For plasma used for fractionation, the manufacturer of the medicinal product should be notified in case of a look-back (3).\n\n## 4. Personnel\n\nSufficient personnel should be available and should be qualified to perform their tasks. They should have the appropriate qualifications and experience and should be given initial and continuous training in order to assure the quality and safety of blood and blood components.\n\nOnly persons who are competent in the manufacturing process and have read and understood all relevant standard operating procedures should be involved in the manufacturing and distribution processes, including collection, quality control and quality assurance.\n\n### 4.1 Organization and responsibilities\n\nTasks and responsibilities should be clearly documented and understood. Personnel should have clear, current and written job descriptions. There should be an organizational chart showing the hierarchical structure of the blood establishment with clear delineation of lines of responsibility and reporting.\n\nKey personnel include the following functions and their substitutes:\n\n- a \u201cresponsible person\u201d (see functions and qualifications below);\n- a processing or operations manager, responsible for all processing and operations activities;\n- a quality control manager, responsible for all quality control activities;\n- a quality assurance manager, reporting findings or quality issues directly to the responsible person and empowered to discontinue operations if quality and safety expectations are not being fulfilled;\n- a physician with the responsibility to ensure the safety of donors and the safety of the distributed blood components.\n\nThe blood establishment should nominate a \u201cresponsible person\u201d who will be responsible for:\n\n- ensuring that approved donor selection criteria are followed;\n- ensuring that every unit of blood or blood components has been collected, tested, processed, stored and distributed in compliance with the national regulations in force;\n- providing information to the competent national authority;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de productos sangu\u00edneos, enfatizando la importancia de la capacitaci\u00f3n y la organizaci\u00f3n del personal en los establecimientos de sangre. Se destaca la necesidad de un \"responsable\" que garantice el cumplimiento de los criterios de selecci\u00f3n de donantes y la conformidad con las regulaciones nacionales. Adem\u00e1s, se menciona la importancia de informar a los receptores de productos potencialmente contaminados sobre los riesgos asociados y ofrecerles pruebas de marcadores de enfermedades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas del \"responsable\" en un establecimiento de sangre seg\u00fan el documento?**\n   - Respuesta: El \"responsable\" debe asegurarse de que se sigan los criterios de selecci\u00f3n de donantes aprobados, que cada unidad de sangre o componentes sangu\u00edneos se recojan, prueben, procesen, almacenen y distribuyan de acuerdo con las regulaciones nacionales vigentes, y proporcionar informaci\u00f3n a la autoridad nacional competente.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n se requiere para el personal involucrado en la fabricaci\u00f3n y distribuci\u00f3n de productos sangu\u00edneos?**\n   - Respuesta: El personal debe recibir formaci\u00f3n inicial y continua para asegurar la calidad y seguridad de la sangre y los componentes sangu\u00edneos. Solo deben participar en los procesos aquellos que sean competentes y que hayan le\u00eddo y comprendido todos los procedimientos operativos est\u00e1ndar relevantes.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse en caso de un \"look-back\" relacionado con productos sangu\u00edneos?**\n   - Respuesta: Los receptores de productos identificados en el proceso de \"look-back\" deben ser asesorados sobre el riesgo de haber contra\u00eddo una enfermedad a partir de productos potencialmente contaminados y se les debe ofrecer pruebas de marcadores de enfermedades, consulta y tratamiento m\u00e9dico si es necesario. Adem\u00e1s, el fabricante del producto medicinal debe ser notificado en caso de un \"look-back\" relacionado con plasma utilizado para fraccionamiento.", "prev_section_summary": "### Temas Clave:\n1. **Sistema de Look-back**: Importancia de implementar un procedimiento escrito para rastrear donaciones de sangre y plasma desde el donante hasta el receptor y viceversa.\n2. **Exclusi\u00f3n de Donantes**: Protocolo para excluir permanentemente a donantes que presenten enfermedades transmisibles o comportamientos de alto riesgo.\n3. **Investigaci\u00f3n de Reacciones Transfusionales**: Proceso para investigar reacciones adversas en receptores y rastrear donantes potencialmente implicados.\n4. **Registro de Informaci\u00f3n Post-Donaci\u00f3n**: Necesidad de mantener un registro detallado de la informaci\u00f3n posterior a la donaci\u00f3n para asegurar la seguridad de los receptores.\n\n### Entidades:\n- **Donante**: Persona que proporciona sangre o plasma.\n- **Receptor**: Persona que recibe transfusiones de sangre o componentes sangu\u00edneos.\n- **Enfermedades Transmisibles**: Enfermedades que pueden ser transmitidas a trav\u00e9s de productos sangu\u00edneos.\n- **Comportamientos de Alto Riesgo**: Conductas que aumentan el riesgo de transmisi\u00f3n de enfermedades a trav\u00e9s de donaciones.\n- **CJD/vCJD**: Enfermedades relacionadas con la transmisi\u00f3n de priones que pueden ser un riesgo en donaciones de sangre.\n- **Base de Datos**: Herramienta recomendada para el seguimiento y rastreo de donaciones.\n\n### Resumen:\nEl documento de la OMS enfatiza la necesidad de un sistema de \"look-back\" para rastrear donaciones de sangre y plasma, asegurando la seguridad de las transfusiones. Se establece que los donantes con enfermedades transmisibles o comportamientos de alto riesgo deben ser excluidos permanentemente, y se deben tomar medidas para rastrear y retirar sus donaciones. Adem\u00e1s, se destaca la importancia de investigar reacciones adversas en receptores para identificar donantes implicados y mantener un registro de la informaci\u00f3n post-donaci\u00f3n para garantizar la seguridad de los receptores.", "excerpt_keywords": "Keywords: blood safety, look-back process, personnel qualifications, donor selection, quality assurance"}}, "e5c7cb16-708c-44f1-8d1a-8d1a66077c24": {"node_ids": ["cf33c91c-93b4-4f85-aa36-9e3482c93466"], "metadata": {"page_label": "178", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 ensuring that the required initial and ongoing training of personnel is carried out;  \n\u2014 ensuring that a quality management system and a haemovigilance system (ensuring traceability as well as notification of serious adverse events and reactions) is in place in the blood establishment.\n\nThe responsible person should fulfil the qualification requirements according to the national regulations, or should fulfil the following minimum conditions of qualification:\n\n- He/she should hold a diploma, certificate or other evidence of formal qualification in the field of medical or biological sciences awarded on completion of a university course of study or a course recognized as equivalent.\n- He/she should have practical experience in relevant areas, preferably for at least two years, in one or more establishments which are authorized to undertake activities related to collection, testing, preparation, storage and distribution of blood and blood components.\n\nDepending on the national legislation, the name of the responsible person may need to be communicated to the NRA.\n\nThe quality assurance manager and the processing or operations manager should be different persons, functioning independently. The quality assurance manager is responsible for ensuring that there are appropriate quality systems and protocols in place for the safe and secure release of all materials, equipment, reagents and blood and blood components.\n\nThe processing or operations manager is responsible for ensuring that there are appropriate manufacturing and technical processes and procedures in place for the production of blood or blood components.\n\nThe physician should hold a relevant medical degree awarded on completion of a university course of study and should hold any registration or licensure that is required by the national authority.\n\nResponsibilities should be delegated only to individuals who have been trained for the task. Delegation should be in written form and should be reviewed regularly.\n\n## 4.2 Training\n\nPersonnel should receive initial and continuous training that is appropriate to their specific tasks. This training should be carried out by qualified personnel or trainers and should follow prearranged written programmes. Approved training programmes should be in place and should also include:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece requisitos y responsabilidades para el personal en establecimientos de sangre, enfatizando la importancia de la formaci\u00f3n inicial y continua, as\u00ed como la implementaci\u00f3n de sistemas de gesti\u00f3n de calidad y hemovigilancia. Se detallan las calificaciones necesarias para el responsable del establecimiento, el gerente de calidad y el gerente de operaciones, as\u00ed como la necesidad de que las responsabilidades se deleguen solo a personal capacitado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las calificaciones m\u00ednimas requeridas para la persona responsable en un establecimiento de sangre seg\u00fan el documento?**\n   - La persona responsable debe tener un diploma o certificado en ciencias m\u00e9dicas o biol\u00f3gicas y al menos dos a\u00f1os de experiencia pr\u00e1ctica en establecimientos autorizados para actividades relacionadas con la sangre.\n\n2. **\u00bfQu\u00e9 diferencias existen entre las responsabilidades del gerente de calidad y el gerente de operaciones en un establecimiento de sangre?**\n   - El gerente de calidad se encarga de asegurar que existan sistemas y protocolos de calidad adecuados para la liberaci\u00f3n segura de materiales y componentes sangu\u00edneos, mientras que el gerente de operaciones es responsable de los procesos t\u00e9cnicos y de fabricaci\u00f3n para la producci\u00f3n de sangre o componentes sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la formaci\u00f3n del personal en los establecimientos de sangre?**\n   - El personal debe recibir formaci\u00f3n inicial y continua adecuada a sus tareas espec\u00edficas, impartida por personal calificado, siguiendo programas escritos preestablecidos que deben estar aprobados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Productos Sangu\u00edneos**:\n   - Importancia de la capacitaci\u00f3n y organizaci\u00f3n del personal en los establecimientos de sangre.\n   - Necesidad de un \"responsable\" que garantice el cumplimiento de criterios de selecci\u00f3n de donantes y regulaciones nacionales.\n\n2. **Responsabilidades del Personal**:\n   - El personal debe estar calificado y recibir formaci\u00f3n inicial y continua.\n   - Solo personal competente y que haya comprendido los procedimientos operativos est\u00e1ndar debe participar en la fabricaci\u00f3n y distribuci\u00f3n.\n\n3. **Organizaci\u00f3n y Estructura**:\n   - Documentaci\u00f3n clara de tareas y responsabilidades.\n   - Descripciones de trabajo escritas y un organigrama que muestre la estructura jer\u00e1rquica del establecimiento de sangre.\n\n4. **Funciones Clave**:\n   - \"Responsable\" del establecimiento.\n   - Gerente de procesamiento u operaciones.\n   - Gerente de control de calidad.\n   - Gerente de aseguramiento de calidad.\n   - M\u00e9dico responsable de la seguridad de donantes y componentes sangu\u00edneos.\n\n5. **Proceso de \"Look-Back\"**:\n   - Asesoramiento a receptores sobre riesgos de enfermedades por productos potencialmente contaminados.\n   - Ofrecimiento de pruebas de marcadores de enfermedades y tratamiento m\u00e9dico si es necesario.\n   - Notificaci\u00f3n al fabricante del producto medicinal en caso de \"look-back\" relacionado con plasma utilizado para fraccionamiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Establecimientos de Sangre**: Entidades responsables de la recolecci\u00f3n, procesamiento y distribuci\u00f3n de sangre.\n- **Personal Clave**: Incluye al \"responsable\", gerentes de operaciones, control de calidad, aseguramiento de calidad y m\u00e9dicos.", "excerpt_keywords": "Keywords: formaci\u00f3n, gesti\u00f3n de calidad, hemovigilancia, establecimiento de sangre, calificaciones del personal"}}, "b094b263-565b-4f08-8136-97227814a88e": {"node_ids": ["a26a1888-c7e3-42d2-aa26-cc4ddc89315b"], "metadata": {"page_label": "179", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# \u2014 relevant principles of transfusion medicine;\n# \u2014 GMP;\n# \u2014 relevant knowledge in microbiology and hygiene.\n\nTraining should be documented and training records should be retained.\n\n## 4.2.1 Initial training\n\nProgrammes for the initial training of newly recruited personnel or personnel taking over new functions should take into account all relevant tasks and procedures, including general topics such as quality assurance, GMP and computerized systems. The same topics and principles apply to training aimed to reintroduce personnel after a longer absence from the workplace. The time frames should be defined.\n\nThe training records should identify at least the trainer, all the specified tasks (including the relevant standard operating procedures) and when the training was completed. The records should be signed by both the trainee and the trainer. Upon completing the training, the personnel should be competent in the tasks in which they have been trained. If a database is used the personnel training profile should be updated annually.\n\n## 4.2.2 Continuous training\n\nContinuous training programmes (theoretical and/or practical training) should be in place to ensure that personnel keep up the skills to carry out their assigned tasks. Such training programmes should take technical and scientific developments into account. Training should also include any changes to standard operating procedures and personnel requirements. Both internal and external training courses may be useful here.\n\n## 4.2.3 Competency\n\nThe overall competency of personnel is a result of education, experience and training. As a key factor for the quality and safety of blood and blood products, competency has to be carefully evaluated and continuously monitored.\n\nUpon completion of the initial training, the competency of the personnel should be evaluated and documented. After the initial competency is determined, there should be periodic assessment of competency. The contents of training programmes and their effectiveness should be periodically reviewed and assessed.\n\n## 4.3 Personal hygiene\n\nAll personnel, prior to being hired and during employment, as appropriate, should undergo health examinations. Any person shown at any time to", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda principios relevantes de la medicina transfusional, buenas pr\u00e1cticas de manufactura (GMP) y conocimientos en microbiolog\u00eda e higiene. Se enfatiza la importancia de la formaci\u00f3n del personal en estos temas, tanto en la capacitaci\u00f3n inicial como en la continua. Se requiere que los registros de formaci\u00f3n sean documentados y que se mantenga un seguimiento de la competencia del personal. Adem\u00e1s, se menciona la necesidad de ex\u00e1menes de salud para el personal antes de ser contratado y durante su empleo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en los registros de formaci\u00f3n del personal seg\u00fan el documento?**\n   - Los registros de formaci\u00f3n deben identificar al menos al formador, todas las tareas especificadas (incluyendo los procedimientos operativos est\u00e1ndar relevantes) y la fecha en que se complet\u00f3 la formaci\u00f3n. Adem\u00e1s, deben ser firmados por el trainee y el trainer.\n\n2. **\u00bfC\u00f3mo se eval\u00faa la competencia del personal despu\u00e9s de la formaci\u00f3n inicial?**\n   - La competencia del personal debe ser evaluada y documentada tras la finalizaci\u00f3n de la formaci\u00f3n inicial. Despu\u00e9s de determinar la competencia inicial, se deben realizar evaluaciones peri\u00f3dicas de la competencia.\n\n3. **\u00bfQu\u00e9 tipo de formaci\u00f3n continua se recomienda para el personal en el contexto de la medicina transfusional?**\n   - Se recomienda que existan programas de formaci\u00f3n continua (te\u00f3ricos y/o pr\u00e1cticos) que aseguren que el personal mantenga las habilidades necesarias para llevar a cabo sus tareas asignadas, teniendo en cuenta los desarrollos t\u00e9cnicos y cient\u00edficos, as\u00ed como cualquier cambio en los procedimientos operativos est\u00e1ndar y los requisitos del personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda varios aspectos fundamentales relacionados con la gesti\u00f3n y operaci\u00f3n de los establecimientos de sangre, destacando la importancia de la formaci\u00f3n del personal y la implementaci\u00f3n de sistemas de calidad. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n\n1. **Formaci\u00f3n del Personal**:\n   - Se requiere formaci\u00f3n inicial y continua para el personal, adecuada a sus tareas espec\u00edficas.\n   - La formaci\u00f3n debe ser impartida por personal calificado y seguir programas escritos aprobados.\n\n2. **Calificaciones del Personal Responsable**:\n   - La persona responsable debe tener un diploma en ciencias m\u00e9dicas o biol\u00f3gicas y al menos dos a\u00f1os de experiencia pr\u00e1ctica en establecimientos autorizados.\n\n3. **Roles y Responsabilidades**:\n   - **Gerente de Calidad**: Asegura la existencia de sistemas y protocolos de calidad para la liberaci\u00f3n segura de materiales y componentes sangu\u00edneos.\n   - **Gerente de Operaciones**: Responsable de los procesos t\u00e9cnicos y de fabricaci\u00f3n para la producci\u00f3n de sangre o componentes sangu\u00edneos.\n   - **M\u00e9dico**: Debe tener un t\u00edtulo m\u00e9dico relevante y cumplir con los requisitos de registro o licencia establecidos por la autoridad nacional.\n\n4. **Delegaci\u00f3n de Responsabilidades**:\n   - Las responsabilidades deben delegarse solo a personal capacitado, y la delegaci\u00f3n debe ser documentada y revisada regularmente.\n\n5. **Sistemas de Gesti\u00f3n de Calidad y Hemovigilancia**:\n   - Es esencial contar con un sistema de gesti\u00f3n de calidad y un sistema de hemovigilancia para garantizar la trazabilidad y la notificaci\u00f3n de eventos adversos graves.\n\n#### Entidades Mencionadas:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **NRA (Autoridad Reguladora Nacional)**: Puede requerir la comunicaci\u00f3n del nombre de la persona responsable seg\u00fan la legislaci\u00f3n nacional.\n\nEste resumen destaca la importancia de la formaci\u00f3n, las calificaciones necesarias y la clara divisi\u00f3n de responsabilidades en los establecimientos de sangre, asegurando as\u00ed la calidad y seguridad en la gesti\u00f3n de la sangre y sus componentes.", "excerpt_keywords": "Keywords: transfusion medicine, training, competency, quality assurance, personal hygiene"}}, "879717b8-6191-4454-a0ee-01d5fdee4f0b": {"node_ids": ["dc98f17c-9017-4569-84f5-3a09f7c59549"], "metadata": {"page_label": "180", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "have an illness or open lesions that may adversely affect the quality of the products and/or the safety of the donors should be excluded from the establishment\u2019s manufacturing processes until that person\u2019s condition is no longer judged to be a risk.\n\nAll personnel should be trained in personal hygiene. In particular, personnel should be instructed to wash and disinfect their hands before, during and after activities such as blood collection and production.\n\nSpecial attention should be drawn to the need to protect donors, employees and products from contamination \u2014 especially with blood and any other material of human origin.\n\nTo ensure protection of products, donors and employees from contamination, personnel should wear clean protective clothing appropriate for the duties they perform. Soiled protective clothing, if reusable, should be stored in a separate closed container until properly laundered and, if necessary, disinfected or sterilized. Where appropriate, disposable or sterile gloves should be worn when handling items that may come in contact with any blood or blood components.\n\nSmoking, eating, drinking, chewing, and keeping plants, food, drinks, smoking material and personal medicines should not be permitted in areas used for production, testing, storage or distribution, or in other areas where they might adversely affect product quality. Personal hygiene procedures, including the use of appropriate protective clothing and equipment, should apply to all persons entering production areas.\n\n# 5. Documentation\n\nThe documentation of procedures and records is essential to the quality assurance system. It ensures that work is performed in a standardized and uniform manner and ensures the traceability of all steps. Written instructions should include all applicable methods and procedures and should be accessible to all authorized personnel.\n\n## 5.1 Standard operating procedures and records\n\n### 5.1.1 Standard operating procedures\n\nAll critical procedures \u2014 such as purchase and receipt of starting materials, selection of donors, collection of blood, preparation of blood components, laboratory testing and associated quality control testing, product labelling, storage, release, dispatch, shipping, and recall of final products \u2014 should be specified in appropriate written instructions in accordance with the principles of GMP and relevant national regulations. Quality assurance", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las pr\u00e1cticas de higiene y documentaci\u00f3n necesarias en los procesos de manufactura relacionados con la recolecci\u00f3n y producci\u00f3n de sangre y componentes sangu\u00edneos. Se enfatiza la importancia de la higiene personal del personal, el uso de ropa protectora adecuada, y la prohibici\u00f3n de actividades que puedan contaminar el entorno de producci\u00f3n. Adem\u00e1s, se destaca la necesidad de documentaci\u00f3n rigurosa de los procedimientos para asegurar la calidad y trazabilidad de los productos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse si un miembro del personal presenta una enfermedad o lesiones abiertas?**\n   - El personal que tenga una enfermedad o lesiones abiertas que puedan afectar la calidad de los productos o la seguridad de los donantes debe ser excluido de los procesos de manufactura hasta que su condici\u00f3n ya no se considere un riesgo.\n\n2. **\u00bfCu\u00e1les son las pr\u00e1cticas de higiene personal que deben seguir los empleados durante la recolecci\u00f3n de sangre?**\n   - Todos los empleados deben ser capacitados en higiene personal, lo que incluye lavarse y desinfectarse las manos antes, durante y despu\u00e9s de actividades como la recolecci\u00f3n y producci\u00f3n de sangre.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para asegurar la calidad en los procesos de manufactura de sangre?**\n   - Se requiere que todos los procedimientos cr\u00edticos, como la compra y recepci\u00f3n de materiales, selecci\u00f3n de donantes, recolecci\u00f3n de sangre, y pruebas de laboratorio, est\u00e9n especificados en instrucciones escritas apropiadas que cumplan con los principios de Buenas Pr\u00e1cticas de Manufactura (GMP) y regulaciones nacionales relevantes.", "prev_section_summary": "### Temas Clave\n\n1. **Principios de Medicina Transfusional**: Se enfatiza la importancia de la formaci\u00f3n en principios relevantes de la medicina transfusional, buenas pr\u00e1cticas de manufactura (GMP) y conocimientos en microbiolog\u00eda e higiene.\n\n2. **Formaci\u00f3n del Personal**:\n   - **Formaci\u00f3n Inicial**: Programas dise\u00f1ados para el personal reci\u00e9n contratado o que asume nuevas funciones, que deben incluir temas como aseguramiento de calidad, GMP y sistemas computarizados. Los registros de formaci\u00f3n deben documentar al formador, las tareas especificadas y la fecha de finalizaci\u00f3n, firmados por el trainee y el trainer.\n   - **Formaci\u00f3n Continua**: Programas de formaci\u00f3n te\u00f3rica y pr\u00e1ctica para mantener las habilidades del personal, considerando desarrollos t\u00e9cnicos y cambios en procedimientos operativos est\u00e1ndar.\n\n3. **Competencia del Personal**: La competencia se eval\u00faa a trav\u00e9s de la educaci\u00f3n, experiencia y formaci\u00f3n. Se requiere una evaluaci\u00f3n inicial de competencia y evaluaciones peri\u00f3dicas posteriores para asegurar la calidad y seguridad de los productos sangu\u00edneos.\n\n4. **Higiene Personal**: Se deben realizar ex\u00e1menes de salud a todo el personal antes de ser contratado y durante su empleo, seg\u00fan sea necesario.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa relevante para la formaci\u00f3n y operaci\u00f3n en medicina transfusional.\n- **Personal de Medicina Transfusional**: Grupo objetivo de la formaci\u00f3n y evaluaci\u00f3n de competencia.\n- **Registros de Formaci\u00f3n**: Documentaci\u00f3n necesaria para el seguimiento de la formaci\u00f3n del personal.\n- **Procedimientos Operativos Est\u00e1ndar (SOP)**: Documentos que gu\u00edan las tareas y procesos en el \u00e1mbito transfusional. \n\nEste resumen destaca la importancia de la formaci\u00f3n y evaluaci\u00f3n continua del personal en el contexto de la medicina transfusional, as\u00ed como la necesidad de mantener est\u00e1ndares de higiene y salud.", "excerpt_keywords": "Keywords: hygiene, blood collection, quality assurance, documentation, standard operating procedures"}}, "a9a643c2-a51c-479c-9c93-18c16195f0fe": {"node_ids": ["9fd0b9ec-01f2-401d-8473-3b76d182180f"], "metadata": {"page_label": "181", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.1.2 Records\n\nEach activity that may affect the quality of blood and blood components should be documented and recorded at the time it takes place. Critical activities should be double-checked, either by a second person or electronically. There should be documentation to ensure that work is performed in a standardized manner according to standard operating procedures and that all critical steps in the process are traceable \u2014 especially those that have the potential to affect the quality of the product. The documentation should allow all steps and all data to be confirmed by independent review. All documentation should indicate the person performing the action, the date of the action and the equipment used in the action, where applicable.\n\nRecords should be legible, accurate, reliable and a true representation of the results and entries. The legibility of records is of great importance. Handwritten entry of data should be clear. Corrections to any records should be made in a manner that permits the reading and review of the previous entry, the correction, the date of correction and the person responsible for the correction.\n\nCritical manufacturing and laboratory testing records should be reviewed frequently for completeness, legibility and, when appropriate, accuracy by the manager or other designated person.\n\n# 5.2 Document control\n\nAll documents should be laid out in an orderly manner with a unique title and reference number, and should indicate the version and the effective date. The content of the document should be clear and should not include superfluous information. Title, nature, purpose and scope should be clearly outlined. Documents should be reviewed, approved, signed and dated by authorized persons. An audit trail should indicate the person responsible for each step of document control.\n\n## 5.2.1 Document management\n\nA document management system should be in place. Documents that outline specific manufacturing steps or other critical steps should be readily", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de la documentaci\u00f3n y el control de documentos en actividades relacionadas con la calidad de la sangre y sus componentes. Se enfatiza la necesidad de registrar cada actividad cr\u00edtica, asegurando que sean legibles, precisas y revisadas regularmente. Adem\u00e1s, se establece que todos los documentos deben estar organizados, ser claros y contar con un sistema de gesti\u00f3n de documentos que garantice la trazabilidad y la responsabilidad en cada paso del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en la documentaci\u00f3n de actividades cr\u00edticas relacionadas con la calidad de la sangre?**\n   - La documentaci\u00f3n debe incluir el nombre de la persona que realiza la acci\u00f3n, la fecha de la acci\u00f3n y el equipo utilizado, donde sea aplicable. Adem\u00e1s, debe ser legible, precisa y permitir la revisi\u00f3n independiente de todos los pasos y datos.\n\n2. **\u00bfC\u00f3mo deben manejarse las correcciones en los registros de datos?**\n   - Las correcciones deben hacerse de manera que se pueda leer y revisar la entrada anterior, la correcci\u00f3n, la fecha de la correcci\u00f3n y la persona responsable de la misma. Esto asegura la trazabilidad y la claridad en los registros.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para el control de documentos en el contexto de la calidad de la sangre?**\n   - Los documentos deben tener un t\u00edtulo \u00fanico y un n\u00famero de referencia, indicar la versi\u00f3n y la fecha de vigencia, y su contenido debe ser claro y sin informaci\u00f3n superflua. Adem\u00e1s, deben ser revisados, aprobados, firmados y fechados por personas autorizadas, y debe existir un rastro de auditor\u00eda que indique la responsabilidad en cada paso del control de documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Higiene Personal del Personal**:\n   - Importancia de la higiene personal en el proceso de recolecci\u00f3n y producci\u00f3n de sangre.\n   - Capacitaci\u00f3n del personal en pr\u00e1cticas de higiene, incluyendo el lavado y desinfecci\u00f3n de manos.\n\n2. **Contaminaci\u00f3n y Protecci\u00f3n**:\n   - Necesidad de proteger a donantes, empleados y productos de la contaminaci\u00f3n, especialmente con sangre y materiales de origen humano.\n   - Uso de ropa protectora limpia y adecuada para las tareas realizadas.\n   - Prohibici\u00f3n de actividades que puedan contaminar el entorno de producci\u00f3n (fumar, comer, beber, etc.).\n\n3. **Documentaci\u00f3n y Procedimientos**:\n   - La documentaci\u00f3n de procedimientos y registros es esencial para el sistema de aseguramiento de calidad.\n   - Instrucciones escritas deben incluir m\u00e9todos y procedimientos aplicables y ser accesibles al personal autorizado.\n   - Especificaci\u00f3n de procedimientos cr\u00edticos en conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP) y regulaciones nacionales.\n\n4. **Procedimientos Operativos Est\u00e1ndar (POE)**:\n   - Detalle de procedimientos cr\u00edticos como la compra de materiales, selecci\u00f3n de donantes, recolecci\u00f3n de sangre, pruebas de laboratorio, etiquetado de productos, almacenamiento y distribuci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Principios que gu\u00edan la documentaci\u00f3n y procedimientos.\n- **Personal de Salud**: Empleados involucrados en la recolecci\u00f3n y producci\u00f3n de sangre.\n- **Donantes**: Personas que contribuyen con sangre y componentes sangu\u00edneos.\n- **Productos Sangu\u00edneos**: Componentes que se producen y distribuyen a partir de la sangre recolectada. \n\nEste resumen destaca la importancia de la higiene, la protecci\u00f3n contra la contaminaci\u00f3n y la documentaci\u00f3n rigurosa en los procesos de manufactura de sangre, asegurando as\u00ed la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: documentation, blood quality, record keeping, document control, standard operating procedures"}}, "9ae82005-3760-4cad-8c67-37178410eff0": {"node_ids": ["ccf8a8df-5e70-428d-85e2-f6a9bdf869b5"], "metadata": {"page_label": "182", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Record retention and archiving\n\nAll records, including raw data, which are critical to the safety and quality of blood or blood components, should be kept in a secured storage area according to national regulations, or preferably for at least 10 years. A longer period for retention of records may be required by NRAs, international requirements or by specific contractual agreements. Records of permanently deferred donors should be kept indefinitely.\n\nOutdated standard operating procedures should also be kept in a historic file system. Documents should be archived in a secured area and should be readily accessible for retrieval by authorized personnel if required. The archival and retrieval process, especially if computerized systems are used, should be validated to ensure that all information can be retrieved and read at any time until the end of the required period of retention.\n\n# Premises and equipment\n\n## Premises\n\n### Design and construction\n\nPremises should be located, constructed, adapted and maintained to suit the operations that are to be carried out in them. Premises should be designed to permit effective cleaning and maintenance to minimize risk of contamination. The workflow should be designed and arranged to allow for a logical flow of staff, donors and products in order to minimize the risk of errors. Working areas should not be used as passageways or storage areas.\n\nAncillary areas should be separated from the donor evaluation area, and from the screening, collection and manufacturing areas. Washing and toilet facilities and, if required, facilities for changing or eating should be maintained in a hygienic and tidy condition.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la retenci\u00f3n y archivo de registros relacionados con la seguridad y calidad de la sangre y sus componentes. Se establece que todos los registros cr\u00edticos deben ser almacenados de manera segura durante al menos 10 a\u00f1os, aunque pueden requerirse per\u00edodos m\u00e1s largos seg\u00fan regulaciones nacionales o acuerdos espec\u00edficos. Adem\u00e1s, se menciona la importancia de mantener procedimientos operativos est\u00e1ndar obsoletos en un sistema de archivo hist\u00f3rico. Tambi\u00e9n se discuten las caracter\u00edsticas de dise\u00f1o y construcci\u00f3n de las instalaciones donde se llevan a cabo estas operaciones, enfatizando la necesidad de un flujo de trabajo l\u00f3gico y la separaci\u00f3n de \u00e1reas para minimizar riesgos de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de no cumplir con el per\u00edodo m\u00ednimo de retenci\u00f3n de registros de sangre seg\u00fan las regulaciones nacionales?**\n   - Esta pregunta busca explorar las consecuencias legales y de seguridad que pueden surgir si no se siguen las pautas de retenci\u00f3n de registros.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para validar el proceso de archivo y recuperaci\u00f3n de documentos en sistemas computarizados?**\n   - Aqu\u00ed se indaga sobre los procedimientos espec\u00edficos que deben implementarse para garantizar que la informaci\u00f3n archivada sea accesible y legible durante el per\u00edodo requerido.\n\n3. **\u00bfQu\u00e9 consideraciones de dise\u00f1o son esenciales para minimizar el riesgo de contaminaci\u00f3n en las instalaciones de recolecci\u00f3n de sangre?**\n   - Esta pregunta se centra en los aspectos pr\u00e1cticos del dise\u00f1o de instalaciones que son cruciales para mantener la seguridad y calidad en la recolecci\u00f3n y manejo de sangre. \n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n detallada que no se encuentra expl\u00edcitamente en el texto, pero que es relevante para la comprensi\u00f3n de las normativas y pr\u00e1cticas en la gesti\u00f3n de registros y dise\u00f1o de instalaciones en el contexto de la salud p\u00fablica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Documentaci\u00f3n de Actividades Cr\u00edticas**:\n   - Es esencial documentar cada actividad que pueda afectar la calidad de la sangre y sus componentes en el momento en que se realiza.\n   - Las actividades cr\u00edticas deben ser verificadas por una segunda persona o electr\u00f3nicamente.\n   - La documentaci\u00f3n debe ser estandarizada y permitir la trazabilidad de todos los pasos del proceso.\n\n2. **Requisitos de los Registros**:\n   - Los registros deben ser legibles, precisos, confiables y representar fielmente los resultados.\n   - Las correcciones en los registros deben ser claras y permitir la revisi\u00f3n de entradas anteriores, incluyendo la fecha y la persona responsable de la correcci\u00f3n.\n\n3. **Revisi\u00f3n de Registros**:\n   - Los registros de fabricaci\u00f3n y pruebas de laboratorio deben ser revisados frecuentemente por un gerente o persona designada para asegurar su integridad y legibilidad.\n\n4. **Control de Documentos**:\n   - Todos los documentos deben tener un t\u00edtulo \u00fanico, un n\u00famero de referencia, versi\u00f3n y fecha de vigencia.\n   - El contenido debe ser claro y conciso, sin informaci\u00f3n superflua.\n   - Los documentos deben ser revisados, aprobados, firmados y fechados por personas autorizadas, y debe existir un rastro de auditor\u00eda.\n\n5. **Sistema de Gesti\u00f3n de Documentos**:\n   - Se debe implementar un sistema de gesti\u00f3n de documentos que facilite la organizaci\u00f3n y el acceso a documentos cr\u00edticos relacionados con los pasos de fabricaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Calidad de la Sangre**: Tema central de la documentaci\u00f3n y control.\n- **Registros**: Documentos que deben ser precisos y legibles.\n- **Documentos**: Deben ser controlados y gestionados adecuadamente.\n- **Auditor\u00eda**: Proceso para asegurar la responsabilidad y trazabilidad en el control de documentos. \n\nEste resumen destaca la importancia de la documentaci\u00f3n y el control de documentos en la gesti\u00f3n de la calidad de la sangre, asegurando que todas las actividades cr\u00edticas sean registradas y revisadas adecuadamente.", "excerpt_keywords": "Keywords: record retention, blood safety, archiving, premises design, contamination prevention"}}, "8af85296-e848-4a28-bb9d-b14a938c6300": {"node_ids": ["89166a3f-0249-48e4-a48c-7db3bcf22dba"], "metadata": {"page_label": "183", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production, Testing, and Storage Areas\n\nProduction, testing, and storage areas should be secured against entry by unauthorized persons.\n\nLighting, temperature, humidity, and ventilation should be appropriate and should not adversely affect production or storage. Premises should be designed and equipped to afford maximum protection against the entry of animals, including insects.\n\nPremises should be carefully maintained and cleaned (see sections 6.2.2 and 6.2.3) and where appropriate disinfected according to detailed written standard operating procedures. Cleaning records should be retained.\n\n## 6.1.2 Donor Areas\n\nThe area for blood donors should be separated from all production and testing areas.\n\nThe design of premises should be adequate for the conduct of operations and should allow for the logical flow of donors, in one direction if possible, so that donors who have passed reception, screening, and donation do not have to return to a previous area.\n\nThe area for donor selection should permit confidential personal interviews to take place with due consideration for the safety of donors and personnel.\n\nRest and refreshment rooms for donors should be separated from donation or storage areas.\n\n## 6.1.3 Production Areas\n\nBlood processing should be carried out in adequate facilities that are suitable for the purpose. The donor area, and production and testing areas should be separated from each other.\n\nWhenever possible, closed systems should be used. Using a validated sterile connecting device creates a functionally closed system.\n\nWhen the use of a closed system is not possible or not appropriate, the risk of contamination or cross-contamination needs to be minimized. Therefore, the premises used for the processing of blood components in an open process should be designed and qualified as a grade A environment with a grade B background, as defined in the WHO GMP for sterile pharmaceutical products. A less stringent environment may be acceptable if the preparation of the product is directly combined with additional safety measures \u2014 such as immediate transfusion within a defined and limited time period after processing, or placing the product immediately into storage conditions that prohibit microbial growth. Personnel performing open processing should wear appropriate clothing (i.e., suitable coats, masks, or gloves) and should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS detalla las normas y directrices para las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de componentes sangu\u00edneos. Se enfatiza la importancia de la seguridad, la separaci\u00f3n de \u00e1reas, el control ambiental (iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n), y la limpieza y desinfecci\u00f3n de las instalaciones. Tambi\u00e9n se abordan las \u00e1reas destinadas a donantes, destacando la necesidad de privacidad y seguridad, as\u00ed como las condiciones adecuadas para el procesamiento de sangre, incluyendo el uso de sistemas cerrados y medidas de seguridad adicionales en caso de utilizar sistemas abiertos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las \u00e1reas de donantes para garantizar la privacidad y seguridad durante el proceso de selecci\u00f3n?**\n   - Respuesta: Las \u00e1reas de donantes deben permitir entrevistas personales confidenciales y estar dise\u00f1adas para garantizar la seguridad tanto de los donantes como del personal. Adem\u00e1s, deben estar separadas de las \u00e1reas de producci\u00f3n y almacenamiento.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si no es posible utilizar un sistema cerrado durante el procesamiento de componentes sangu\u00edneos?**\n   - Respuesta: Si no se puede utilizar un sistema cerrado, se debe minimizar el riesgo de contaminaci\u00f3n o contaminaci\u00f3n cruzada. Las instalaciones deben estar dise\u00f1adas y calificadas como un entorno de grado A con un fondo de grado B, y se deben implementar medidas de seguridad adicionales, como transfusiones inmediatas o almacenamiento en condiciones que proh\u00edban el crecimiento microbiano.\n\n3. **\u00bfQu\u00e9 tipo de registros deben mantenerse en relaci\u00f3n con la limpieza y desinfecci\u00f3n de las instalaciones?**\n   - Respuesta: Se deben retener registros de limpieza que documenten las actividades de mantenimiento y desinfecci\u00f3n de las instalaciones, de acuerdo con procedimientos operativos est\u00e1ndar escritos y detallados.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS establece directrices para asegurar que las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de sangre sean seguras y eficaces. Se enfatiza la separaci\u00f3n de \u00e1reas, el control ambiental y la limpieza rigurosa. Tambi\u00e9n se abordan las consideraciones espec\u00edficas para las \u00e1reas de donantes, asegurando la privacidad y la seguridad, as\u00ed como las mejores pr\u00e1cticas para el procesamiento de sangre, incluyendo el uso de sistemas cerrados y medidas de mitigaci\u00f3n en caso de utilizar sistemas abiertos.", "prev_section_summary": "### Temas Clave\n\n1. **Retenci\u00f3n y Archivo de Registros**:\n   - Importancia de mantener registros cr\u00edticos relacionados con la seguridad y calidad de la sangre.\n   - Per\u00edodo m\u00ednimo de retenci\u00f3n de 10 a\u00f1os, con posibles extensiones seg\u00fan regulaciones nacionales o acuerdos espec\u00edficos.\n   - Archivar procedimientos operativos est\u00e1ndar obsoletos en un sistema hist\u00f3rico.\n   - Validaci\u00f3n del proceso de archivo y recuperaci\u00f3n, especialmente en sistemas computarizados.\n\n2. **Dise\u00f1o y Construcci\u00f3n de Instalaciones**:\n   - Ubicaci\u00f3n y construcci\u00f3n de las instalaciones deben adaptarse a las operaciones realizadas.\n   - Necesidad de un dise\u00f1o que permita limpieza efectiva y minimice el riesgo de contaminaci\u00f3n.\n   - Organizaci\u00f3n del flujo de trabajo para reducir errores, evitando el uso de \u00e1reas de trabajo como pasillos o zonas de almacenamiento.\n   - Separaci\u00f3n de \u00e1reas auxiliares de las zonas de evaluaci\u00f3n de donantes y recolecci\u00f3n.\n\n3. **Condiciones Higi\u00e9nicas**:\n   - Mantenimiento de instalaciones de lavado, aseo y \u00e1reas de descanso en condiciones higi\u00e9nicas y ordenadas.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Regulaciones Nacionales (NRAs)**: Normativas que pueden influir en los per\u00edodos de retenci\u00f3n de registros.\n- **Donantes**: Individuos cuya informaci\u00f3n y registros deben ser gestionados adecuadamente.\n- **Procedimientos Operativos Est\u00e1ndar**: Documentos que gu\u00edan las pr\u00e1cticas en la recolecci\u00f3n y manejo de sangre.\n- **Instalaciones de Recolecci\u00f3n de Sangre**: Espacios f\u00edsicos donde se llevan a cabo las operaciones relacionadas con la sangre.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de registros y el dise\u00f1o de instalaciones para garantizar la seguridad y calidad en el manejo de sangre y sus componentes.", "excerpt_keywords": "Keywords: blood donation, production areas, contamination control, donor privacy, WHO guidelines"}}, "d9f9fbc9-784f-4996-932d-83f1e2a78153": {"node_ids": ["36c1df59-776b-4ef7-9ccc-cacf13ccaf9d"], "metadata": {"page_label": "184", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "receive regular training in aseptic manipulations. Aseptic processing should be validated. Environmental monitoring protocols should be applied and evaluated by the quality assurance unit.\n\nThe premises used for processing blood components should be kept in a clean and hygienic condition. Monitoring of the microbiological contamination load should be considered for critical equipment surfaces and environments where appropriate, according to a risk-based assessment of the process. Records should be available.\n\nEach area of processing and storage should be secured against entry by unauthorized persons and should be used only for the intended purpose.\n\n### 6.1.4 Storage areas\n\nStorage areas should provide adequate space and should be arranged in a way that allows for dry and orderly placement of stored materials.\n\nStorage conditions should be controlled, monitored and documented to show compliance with the specifications. Equal distribution of temperature throughout the storage facility should be guaranteed and documented. This is particularly important for the critical materials used in processing blood and blood components. Temperature checks should be carried out and recorded at least daily. Appropriate alarms at upper and lower temperature limits should be present and should be regularly checked; the checks should be recorded. Appropriate actions to be taken when there is an alarm should be defined in writing.\n\nIntermediate storage and transport should be carried out under defined conditions to ensure that specifications are met.\n\nStorage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and materials.\n\n### 6.1.5 Laboratories\n\nTesting laboratories should be designed and constructed so as to minimize the risk of errors and contamination. Laboratory areas should be separated from the processing and final product storage areas. Where nucleic acid amplification testing (NAT) technology warrants, separate premises (rooms) and air handling systems should be considered for performing NAT. Consideration should be given to constructing a separate room for specimen sampling and another room for amplification and nucleic acid detection in order to minimize the risk of contamination or false-positive test results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Capacitaci\u00f3n y Validaci\u00f3n en Procesos Asepticos**: Se enfatiza la importancia de la capacitaci\u00f3n regular en manipulaciones as\u00e9pticas y la validaci\u00f3n de los procesos as\u00e9pticos. Adem\u00e1s, se menciona que los protocolos de monitoreo ambiental deben ser aplicados y evaluados por la unidad de aseguramiento de calidad.\n\n2. **Condiciones de Almacenamiento**: Se describen las condiciones necesarias para las \u00e1reas de almacenamiento, incluyendo la necesidad de un espacio adecuado, control y documentaci\u00f3n de las condiciones de almacenamiento, y la importancia de la segregaci\u00f3n de materiales en cuarentena y rechazados.\n\n3. **Dise\u00f1o de Laboratorios**: Se establece que los laboratorios de pruebas deben ser dise\u00f1ados para minimizar errores y contaminaci\u00f3n, con \u00e1reas separadas para el procesamiento y almacenamiento de productos finales, as\u00ed como consideraciones espec\u00edficas para la tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT).\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de capacitaci\u00f3n se requiere para el personal que manipula componentes sangu\u00edneos y c\u00f3mo se valida el proceso de manipulaci\u00f3n as\u00e9ptica?**\n   - La capacitaci\u00f3n regular en manipulaciones as\u00e9pticas es esencial, y el proceso de manipulaci\u00f3n debe ser validado para asegurar su eficacia y seguridad.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que deben seguirse cuando se activa una alarma de temperatura en las \u00e1reas de almacenamiento de componentes sangu\u00edneos?**\n   - Se deben definir por escrito las acciones apropiadas a tomar cuando se activa una alarma, asegurando que se sigan los protocolos establecidos para mantener la integridad de los materiales almacenados.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al dise\u00f1ar laboratorios que utilizan tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT)?**\n   - Los laboratorios deben tener \u00e1reas separadas para la toma de muestras y para la amplificaci\u00f3n y detecci\u00f3n de \u00e1cidos nucleicos, as\u00ed como sistemas de manejo de aire independientes para minimizar el riesgo de contaminaci\u00f3n y resultados falsos positivos.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad de las \u00c1reas**: Las \u00e1reas de producci\u00f3n, pruebas y almacenamiento deben estar aseguradas contra el acceso de personas no autorizadas.\n  \n2. **Control Ambiental**: Es fundamental mantener condiciones adecuadas de iluminaci\u00f3n, temperatura, humedad y ventilaci\u00f3n para no afectar negativamente la producci\u00f3n o el almacenamiento.\n\n3. **Mantenimiento y Limpieza**: Las instalaciones deben ser mantenidas y limpiadas rigurosamente, siguiendo procedimientos operativos est\u00e1ndar escritos, y se deben conservar registros de limpieza.\n\n4. **\u00c1reas para Donantes**: Deben estar separadas de las \u00e1reas de producci\u00f3n y pruebas, permitiendo entrevistas personales confidenciales y garantizando la seguridad de donantes y personal.\n\n5. **Procesamiento de Sangre**: Se debe realizar en instalaciones adecuadas, separando las \u00e1reas de donantes, producci\u00f3n y pruebas. Se recomienda el uso de sistemas cerrados para minimizar el riesgo de contaminaci\u00f3n.\n\n6. **Medidas de Seguridad en Sistemas Abiertos**: Si no se puede usar un sistema cerrado, se deben implementar medidas adicionales para minimizar el riesgo de contaminaci\u00f3n, como transfusiones inmediatas o almacenamiento en condiciones que impidan el crecimiento microbiano.\n\n### Entidades\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que establece las directrices.\n- **\u00c1reas de Producci\u00f3n, Pruebas y Almacenamiento**: Espacios cr\u00edticos en el proceso de manejo de sangre.\n- **\u00c1reas de Donantes**: Espacios dise\u00f1ados para la selecci\u00f3n y donaci\u00f3n de sangre.\n- **Sistemas Cerrados y Abiertos**: M\u00e9todos de procesamiento de sangre que afectan el riesgo de contaminaci\u00f3n.\n- **Registros de Limpieza**: Documentaci\u00f3n necesaria para asegurar el cumplimiento de las normas de limpieza y desinfecci\u00f3n.\n\n### Resumen\n\nEl documento de la OMS establece directrices para asegurar la seguridad y eficacia en las \u00e1reas de producci\u00f3n, pruebas y almacenamiento de componentes sangu\u00edneos. Se enfatiza la importancia de la seguridad, el control ambiental, la limpieza rigurosa y la separaci\u00f3n de \u00e1reas, as\u00ed como la privacidad y seguridad en las \u00e1reas de donantes. Adem\u00e1s, se abordan las mejores pr\u00e1cticas para el procesamiento de sangre, destacando el uso de sistemas cerrados y las medidas de mitigaci\u00f3n necesarias en caso de utilizar sistemas abiertos.", "excerpt_keywords": "Keywords: aseptic processing, blood components, storage conditions, environmental monitoring, laboratory design"}}, "164c8882-b418-46dc-b721-92cbd3efb461": {"node_ids": ["3e5eeb5a-4909-44e1-8d87-57358e86f236"], "metadata": {"page_label": "185", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.1.6 Mobile collection sites\n\nPremises for mobile collection sites should be adequate in design for the conduct of operations and should allow for the logical flow of staff, donors, and products in order to minimize the risk of errors. The blood collection at mobile sites should be planned thoroughly. Ancillary areas (rest and refreshment rooms) should be separated from donation or storage areas, but observation of donors during post-donation refreshment should still be ensured.\n\nBefore premises are accepted for mobile donor sessions their suitability should be assessed against the following criteria:\n\n- Sufficient size to allow proper operation and ensure donor privacy;\n- Safety for staff and donors;\n- Ventilation, electrical supply, lighting, hand-washing facilities, reliable communication, sufficient space for blood storage and transport, and suitable temperature conditions.\n\nEach site should have an approved plan that details the site layout. The set-up of the mobile collection site should be carried out according to the approved plan.\n\n# 6.2 Equipment\n\n## 6.2.1 Design and construction\n\nAll equipment should be designed and installed to suit its intended purpose and should not present any hazard to donors, personnel or blood components. It should allow for effective cleaning, and disinfection is recommended for all surfaces in direct contact with the bag system.\n\nEquipment should be located in a suitable position (e.g. a balance should be positioned on a suitable even surface) where there is no negative impact from the surrounding environment (e.g. direct sunlight may have an impact on optical instruments such as apheresis systems or balances).\n\n## 6.2.2 Maintenance\n\nMaintenance, cleaning and calibration should be performed regularly and should be recorded. Maintenance of equipment should be carried out at intervals according to a documented schedule.\n\nThe maintenance programmes should be established on the basis of qualification activities. The intervals should be defined according to the instructions of the manufacturer of the equipment. Where intervals are not defined by the equipment manufacturer, maintenance should be carried out at least annually. Different intervals may be defined on the basis of a risk.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las directrices para la operaci\u00f3n de sitios de recolecci\u00f3n m\u00f3vil de sangre, enfatizando la importancia de un dise\u00f1o adecuado de las instalaciones y el equipo. Se establecen criterios para la aceptaci\u00f3n de los locales, incluyendo tama\u00f1o, seguridad y condiciones ambientales. Adem\u00e1s, se subraya la necesidad de un mantenimiento regular y un dise\u00f1o seguro del equipo para proteger a donantes y personal.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para aceptar un local destinado a sesiones de donaci\u00f3n de sangre m\u00f3vil?**\n   - El local debe ser de tama\u00f1o suficiente para permitir una operaci\u00f3n adecuada y garantizar la privacidad del donante, ser seguro para el personal y los donantes, y contar con ventilaci\u00f3n, suministro el\u00e9ctrico, iluminaci\u00f3n, instalaciones para lavado de manos, comunicaci\u00f3n confiable, espacio suficiente para el almacenamiento y transporte de sangre, y condiciones de temperatura adecuadas.\n\n2. **\u00bfQu\u00e9 recomendaciones se hacen respecto al mantenimiento del equipo utilizado en los sitios de recolecci\u00f3n m\u00f3vil?**\n   - El mantenimiento, limpieza y calibraci\u00f3n del equipo deben realizarse regularmente y registrarse. Debe llevarse a cabo de acuerdo con un programa documentado, con intervalos definidos seg\u00fan las instrucciones del fabricante. Si no hay intervalos definidos, el mantenimiento debe realizarse al menos una vez al a\u00f1o, y se pueden establecer diferentes intervalos basados en el riesgo.\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al dise\u00f1ar y ubicar el equipo en un sitio de recolecci\u00f3n m\u00f3vil?**\n   - Todo el equipo debe ser dise\u00f1ado e instalado para su prop\u00f3sito espec\u00edfico, sin presentar riesgos para donantes, personal o componentes sangu\u00edneos. Debe permitir una limpieza efectiva y estar ubicado en un lugar adecuado, evitando impactos negativos del entorno, como la luz solar directa que puede afectar instrumentos \u00f3pticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Capacitaci\u00f3n en Procesos Asepticos**:\n   - Importancia de la capacitaci\u00f3n regular en manipulaciones as\u00e9pticas.\n   - Validaci\u00f3n de los procesos as\u00e9pticos.\n   - Aplicaci\u00f3n y evaluaci\u00f3n de protocolos de monitoreo ambiental por la unidad de aseguramiento de calidad.\n\n2. **Condiciones de Almacenamiento**:\n   - Necesidad de espacios adecuados y ordenados para el almacenamiento de materiales.\n   - Control, monitoreo y documentaci\u00f3n de las condiciones de almacenamiento.\n   - Garant\u00eda de distribuci\u00f3n uniforme de temperatura y registro de controles diarios.\n   - Definici\u00f3n escrita de acciones a seguir ante alarmas de temperatura.\n   - Segregaci\u00f3n efectiva de materiales en cuarentena, liberados y rechazados.\n\n3. **Dise\u00f1o de Laboratorios**:\n   - Dise\u00f1o y construcci\u00f3n de laboratorios para minimizar errores y contaminaci\u00f3n.\n   - Separaci\u00f3n de \u00e1reas de laboratorio de las \u00e1reas de procesamiento y almacenamiento de productos finales.\n   - Consideraciones para la tecnolog\u00eda de amplificaci\u00f3n de \u00e1cidos nucleicos (NAT), incluyendo la creaci\u00f3n de habitaciones separadas para muestreo y amplificaci\u00f3n/detecci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Aseptic Processing**: Proceso cr\u00edtico en la manipulaci\u00f3n de componentes sangu\u00edneos.\n- **Environmental Monitoring**: Protocolos necesarios para asegurar la calidad.\n- **Laboratorios de Pruebas**: Espacios dise\u00f1ados para realizar an\u00e1lisis de manera segura y efectiva.\n- **NAT (Nucleic Acid Amplification Testing)**: Tecnolog\u00eda que requiere consideraciones especiales en el dise\u00f1o de laboratorios. \n\nEste resumen destaca la importancia de la capacitaci\u00f3n, las condiciones de almacenamiento y el dise\u00f1o de laboratorios en el contexto del procesamiento de componentes sangu\u00edneos, asegurando la calidad y seguridad en estos procesos.", "excerpt_keywords": "Keywords: mobile collection sites, blood donation, equipment maintenance, safety standards, donor privacy"}}, "3e41021e-cd49-4fed-840e-5589c34d2645": {"node_ids": ["a09e834a-3f48-42bb-a8b4-20b0fc211d65"], "metadata": {"page_label": "186", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "If no regular maintenance activities are recommended by the manufacturer, at least a functional control should be performed according to documented procedures. All maintenance activities should be documented. The maintenance reports of external technical services should be checked and countersigned by the staff of the blood establishment in order to decide if action needs to be taken as a result of the maintenance outcome. The maintenance documents should include sufficient information to determine what types of checks have been performed.\n\nMaintenance should also be carried out on equipment that is not in regular use, including back-up systems.\n\nInstructions for use, maintenance, service, cleaning and sanitization should be available in a language that is understood by the user. There should be written procedures for each type of equipment, detailing the actions to be taken when malfunctions or failures occur. Defective equipment, or equipment that is not in service, should be clearly labelled and if possible removed from the working area.\n\nThe maintenance of sterile connecting devices should include a check of the tensile strength. Furthermore, as it is a very critical piece of equipment, there should be regular functional checks of the integrity of the tubing weld.\n\nIn general, functional tests should also be considered for other pieces of equipment \u2014 such as balances before use after they have been moved or transported to a mobile site.\n\nA regular maintenance programme, including appropriate intervals, should be in place for all critical laboratory equipment or systems. A procedure should be implemented for releasing equipment after maintenance or intervention.\n\nIf the maintenance is contracted out (e.g. to the supplier) the work should be documented. Equipment should be evaluated to determine if it is still capable of expected performance prior to returning it to service for manufacturing blood components.\n\n### 6.2.3 Cleaning\n\nCleaning procedures should be established and described in a standard operating procedure. Cleaning of equipment should take into consideration the instructions of the manufacturer. A schedule for regular cleaning and disinfection, if necessary, is recommended for all surfaces with direct contact with the bag system (e.g. centrifuge, separator, storage shelves).\n\nDisinfectant solutions with sufficient and approved antimicrobial activity should be used. A cleaning plan should be established that specifies the cleaning intervals and methods to be used for the different equipment and surfaces.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mantenimiento de Equipos**: El documento establece la importancia de realizar controles funcionales y documentar todas las actividades de mantenimiento en equipos de laboratorio, especialmente en aquellos utilizados en la recolecci\u00f3n y procesamiento de componentes sangu\u00edneos. Se enfatiza la necesidad de mantener un programa de mantenimiento regular y de evaluar el rendimiento del equipo antes de su reingreso al servicio.\n\n2. **Limpieza y Desinfecci\u00f3n**: Se subraya la necesidad de establecer procedimientos de limpieza claros y programados para equipos que entran en contacto directo con sistemas de bolsas. Se recomienda el uso de soluciones desinfectantes aprobadas y un plan de limpieza que detalle los intervalos y m\u00e9todos a seguir.\n\n3. **Instrucciones y Procedimientos**: El documento destaca la importancia de tener instrucciones de uso y mantenimiento disponibles en un idioma comprensible para los usuarios, as\u00ed como la necesidad de etiquetar claramente el equipo defectuoso y establecer procedimientos para abordar fallas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para las actividades de mantenimiento de equipos en un establecimiento de sangre?**\n   - Se requiere que todas las actividades de mantenimiento est\u00e9n documentadas, incluyendo informes de servicios t\u00e9cnicos externos que deben ser revisados y contrasignados por el personal del establecimiento de sangre. Adem\u00e1s, los documentos de mantenimiento deben incluir informaci\u00f3n suficiente sobre los tipos de controles realizados.\n\n2. **\u00bfCu\u00e1les son las recomendaciones para el mantenimiento de dispositivos de conexi\u00f3n est\u00e9riles?**\n   - El mantenimiento de dispositivos de conexi\u00f3n est\u00e9riles debe incluir una verificaci\u00f3n de la resistencia a la tracci\u00f3n y realizar controles funcionales regulares de la integridad de la soldadura de los tubos, dado que son equipos cr\u00edticos.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un plan de limpieza para equipos en contacto con sistemas de bolsas?**\n   - Un plan de limpieza debe especificar los intervalos y m\u00e9todos de limpieza para los diferentes equipos y superficies, asegurando que se utilicen soluciones desinfectantes con actividad antimicrobiana suficiente y aprobada, y que se sigan las instrucciones del fabricante para la limpieza y desinfecci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Dise\u00f1o de Sitios de Recolecci\u00f3n M\u00f3vil**:\n   - Importancia de un dise\u00f1o adecuado para facilitar operaciones y minimizar errores.\n   - Separaci\u00f3n de \u00e1reas auxiliares (descanso y refrigerio) de las \u00e1reas de donaci\u00f3n y almacenamiento.\n\n2. **Criterios de Aceptaci\u00f3n de Locales**:\n   - Tama\u00f1o suficiente para operaci\u00f3n y privacidad del donante.\n   - Seguridad para el personal y donantes.\n   - Condiciones ambientales adecuadas: ventilaci\u00f3n, suministro el\u00e9ctrico, iluminaci\u00f3n, instalaciones de lavado de manos, comunicaci\u00f3n confiable, espacio para almacenamiento y transporte de sangre, y temperatura adecuada.\n\n3. **Planificaci\u00f3n y Configuraci\u00f3n**:\n   - Cada sitio debe tener un plan aprobado que detalle la disposici\u00f3n del lugar.\n   - La configuraci\u00f3n debe seguir el plan aprobado.\n\n4. **Equipamiento**:\n   - Dise\u00f1o y construcci\u00f3n del equipo para su prop\u00f3sito espec\u00edfico, sin riesgos para donantes o personal.\n   - Necesidad de limpieza efectiva y desinfecci\u00f3n de superficies en contacto con el sistema de bolsas.\n\n5. **Mantenimiento del Equipo**:\n   - Mantenimiento, limpieza y calibraci\u00f3n deben realizarse regularmente y registrarse.\n   - Programas de mantenimiento basados en actividades de calificaci\u00f3n y seg\u00fan instrucciones del fabricante.\n   - Mantenimiento al menos una vez al a\u00f1o si no hay intervalos definidos, con posibilidad de establecer diferentes intervalos seg\u00fan el riesgo.\n\n### Entidades:\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Componentes**: Donantes, personal, equipos de recolecci\u00f3n de sangre, \u00e1reas de descanso y refrigerio, instalaciones de lavado de manos.\n- **Condiciones**: Tama\u00f1o, seguridad, ventilaci\u00f3n, iluminaci\u00f3n, comunicaci\u00f3n, almacenamiento y transporte de sangre, temperatura. \n\nEste resumen abarca los aspectos esenciales sobre la operaci\u00f3n y mantenimiento de sitios de recolecci\u00f3n m\u00f3vil de sangre, as\u00ed como las consideraciones de dise\u00f1o y seguridad necesarias para proteger a donantes y personal.", "excerpt_keywords": "Keywords: maintenance, cleaning, blood establishment, equipment, procedures"}}, "0d5133d2-49e4-46d9-8302-26ecc58bb2a4": {"node_ids": ["1878db4f-8044-44a1-94df-fc895e491433"], "metadata": {"page_label": "187", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.2.4 Calibration\n\nMeasuring instruments and measuring systems used for the collection and further separation of blood and for quality control testing should be calibrated regularly according to the instructions of the manufacturer. Calibration should be carried out and documented according to established standard operating procedures and national regulations. Regular calibration is necessary for temperature probes (e.g. in refrigerators), pipettes, balances, timing devices and haemoglobinometer devices (using control blood and/or cuvettes from the manufacturer). The devices used for calibration, such as the control weight used for the calibration of balances, should be certified for accuracy (by testing against a known standard). If the calibration consists of using a comparison measurement approach with a second device, then the maximum allowed deviation between the two measurements should be defined.\n\n# 6.3 Computerized systems\n\nA computerized system may be described as a functional unit consisting of one or more computers and associated peripheral input and output devices, and associated software that uses common storage for all or part of a programme and for all parts of the data necessary for the execution of the programme (9). A computerized system executes user-written or user-designated programmes, performs user-designated data manipulation (including arithmetic operations and logic operations), and it can execute programmes that modify themselves during their execution. A computer system may be a stand-alone unit or may consist of several interconnected units.\n\nHardware and software should be protected against unauthorized use or changes.\n\nCritical computerized systems should be validated before use. The system is considered critical if:\n\n\u2014 it is directly linked to the decision-making process for blood product manufacturing, blood or blood product testing (donor/recipient), labelling and release;\n\u2014 it is used to handle or manipulate the related information;\n\u2014 it has an impact on product quality, information management, storage, or tools for operational decision-making and control.\n\nPeriodic revalidation or annual checks to ensure reliability should be performed on the basis of a risk assessment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Calibraci\u00f3n de Instrumentos**: La calibraci\u00f3n regular de instrumentos y sistemas de medici\u00f3n utilizados en la recolecci\u00f3n y separaci\u00f3n de sangre, as\u00ed como en pruebas de control de calidad, es esencial para garantizar la precisi\u00f3n y fiabilidad de los resultados. Esto incluye la calibraci\u00f3n de dispositivos como sondas de temperatura, pipetas y balances, siguiendo procedimientos operativos est\u00e1ndar y regulaciones nacionales.\n\n2. **Sistemas Computarizados**: Los sistemas computarizados son unidades funcionales que incluyen computadoras y dispositivos perif\u00e9ricos, junto con software que gestiona datos y programas. Es crucial validar estos sistemas, especialmente aquellos que impactan en la calidad del producto y en la toma de decisiones operativas relacionadas con la sangre y productos sangu\u00edneos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de dispositivos requieren calibraci\u00f3n regular seg\u00fan el documento y cu\u00e1les son los procedimientos recomendados para llevar a cabo esta calibraci\u00f3n?**\n   - Respuesta: Los dispositivos que requieren calibraci\u00f3n regular incluyen sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n y hemoglobinom\u00e9tricos. La calibraci\u00f3n debe realizarse y documentarse de acuerdo con procedimientos operativos est\u00e1ndar establecidos y regulaciones nacionales.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas que definen un sistema computarizado cr\u00edtico en el contexto de la fabricaci\u00f3n y prueba de productos sangu\u00edneos?**\n   - Respuesta: Un sistema computarizado se considera cr\u00edtico si est\u00e1 directamente vinculado al proceso de toma de decisiones para la fabricaci\u00f3n de productos sangu\u00edneos, pruebas de sangre o productos sangu\u00edneos (donante/receptor), etiquetado y liberaci\u00f3n; si se utiliza para manejar o manipular informaci\u00f3n relacionada; o si tiene un impacto en la calidad del producto, gesti\u00f3n de informaci\u00f3n, almacenamiento o herramientas para la toma de decisiones operativas y control.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para proteger el hardware y software de un sistema computarizado en el contexto de la recolecci\u00f3n y prueba de sangre?**\n   - Respuesta: El hardware y software deben ser protegidos contra el uso no autorizado o cambios. Adem\u00e1s, los sistemas computarizados cr\u00edticos deben ser validados antes de su uso y deben someterse a revalidaciones peri\u00f3dicas o chequeos anuales basados en una evaluaci\u00f3n de riesgos para asegurar su fiabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Equipos**:\n   - Importancia de realizar controles funcionales y documentar todas las actividades de mantenimiento.\n   - Evaluaci\u00f3n del rendimiento del equipo antes de su reingreso al servicio.\n   - Mantenimiento de equipos no utilizados y sistemas de respaldo.\n   - Documentaci\u00f3n de informes de servicios t\u00e9cnicos externos, que deben ser revisados y contrasignados por el personal del establecimiento de sangre.\n\n2. **Limpieza y Desinfecci\u00f3n**:\n   - Establecimiento de procedimientos de limpieza claros en un documento de procedimientos operativos est\u00e1ndar.\n   - Programaci\u00f3n de limpieza y desinfecci\u00f3n para superficies en contacto con sistemas de bolsas.\n   - Uso de soluciones desinfectantes aprobadas con actividad antimicrobiana suficiente.\n\n3. **Instrucciones y Procedimientos**:\n   - Disponibilidad de instrucciones de uso y mantenimiento en un idioma comprensible para los usuarios.\n   - Etiquetado claro de equipos defectuosos y procedimientos para abordar fallas.\n\n4. **Dispositivos de Conexi\u00f3n Est\u00e9riles**:\n   - Verificaci\u00f3n de la resistencia a la tracci\u00f3n y controles funcionales regulares de la integridad de la soldadura de los tubos.\n\n5. **Plan de Limpieza**:\n   - Especificaci\u00f3n de intervalos y m\u00e9todos de limpieza para diferentes equipos y superficies.\n\n### Entidades Clave\n- **Equipos de Laboratorio**: Incluye dispositivos de conexi\u00f3n est\u00e9riles, balances, centrifugadoras, separadores, estantes de almacenamiento.\n- **Establecimientos de Sangre**: Personal responsable de la revisi\u00f3n y contrasignaci\u00f3n de informes de mantenimiento.\n- **Soluciones Desinfectantes**: Deben tener actividad antimicrobiana aprobada.\n- **Documentaci\u00f3n**: Informes de mantenimiento, procedimientos operativos est\u00e1ndar, planes de limpieza. \n\nEste resumen destaca la importancia de un mantenimiento adecuado y documentado, as\u00ed como la limpieza y desinfecci\u00f3n de equipos cr\u00edticos en el contexto de la recolecci\u00f3n y procesamiento de componentes sangu\u00edneos.", "excerpt_keywords": "Keywords: calibration, computerized systems, blood collection, quality control, validation"}}, "6e339d98-3710-45ca-b1f2-297c69024dd0": {"node_ids": ["f5d1f4cc-f430-468b-9eb2-e7ed7be228f1"], "metadata": {"page_label": "188", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "There should be procedures for each type of software and hardware, detailing the action to be taken when malfunctions or failures occur. A back-up procedure should be in place to prevent loss of records in case of expected or unexpected downtime or function failures. The archival and retrieval process should be validated to ensure the accuracy of the stored and retrieved data.\n\nOnce in routine operation, critical computer systems should be maintained in a validated state. Any change should be handled through the formal change control system which includes qualification and/or validation activities. Applicable documentation should be revised and personnel should be trained before the change is introduced into routine use. Any software updates should be evaluated in advance and there should be procedures to validate or verify the acceptability of the update installation.\n\nThe manual entry of critical data, such as laboratory test results, should require independent verification and release by a second person. When a computerized system is used, an audit trail should be guaranteed.\n\n# 7. Qualification and validation\n\n## 7.1 Qualification of equipment\n\nAll equipment should be qualified and used in accordance with validated procedures.\n\nNew and repaired equipment should meet qualification requirements when installed and should be authorized before use. Qualification results should be documented.\n\nThe extent of qualification depends on the critical nature and complexity of the equipment. For some equipment, installation qualification and calibration may be sufficient. More complex equipment may need a more thorough approach to qualification and validation and should include the instruments, the associated operation(s) and the software involved.\n\nFurther guidance on qualification and validation is given in the WHO guidelines on validation (10) and in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) *Recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation* (11).\n\n## 7.2 Validation of manufacturing processes\n\nAll critical processes in the manufacture of blood and blood components should be validated before implementation according to a predefined protocol of tests and acceptance criteria. Critical processes include donor", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre la calificaci\u00f3n y validaci\u00f3n de equipos y procesos cr\u00edticos en la fabricaci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de tener procedimientos establecidos para el manejo de fallos en software y hardware, as\u00ed como la necesidad de mantener sistemas inform\u00e1ticos en un estado validado. Se requiere que todos los equipos sean calificados y que los procesos cr\u00edticos sean validados antes de su implementaci\u00f3n, siguiendo protocolos espec\u00edficos. Adem\u00e1s, se menciona la importancia de la verificaci\u00f3n independiente de datos cr\u00edticos y la existencia de un rastro de auditor\u00eda en sistemas computarizados.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar fallos en software y hardware seg\u00fan el documento?**\n   - El documento indica que deben existir procedimientos detallados para cada tipo de software y hardware, que incluyan acciones a tomar en caso de malfunciones o fallos. Tambi\u00e9n se debe tener un procedimiento de respaldo para prevenir la p\u00e9rdida de registros.\n\n2. **\u00bfC\u00f3mo se determina la extensi\u00f3n de la calificaci\u00f3n de un equipo?**\n   - La extensi\u00f3n de la calificaci\u00f3n depende de la naturaleza cr\u00edtica y la complejidad del equipo. Para algunos equipos, puede ser suficiente la calificaci\u00f3n de instalaci\u00f3n y calibraci\u00f3n, mientras que equipos m\u00e1s complejos requieren un enfoque m\u00e1s exhaustivo que incluya instrumentos, operaciones asociadas y el software involucrado.\n\n3. **\u00bfQu\u00e9 requisitos se establecen para la validaci\u00f3n de procesos cr\u00edticos en la fabricaci\u00f3n de componentes sangu\u00edneos?**\n   - Todos los procesos cr\u00edticos en la fabricaci\u00f3n de sangre y componentes sangu\u00edneos deben ser validados antes de su implementaci\u00f3n, siguiendo un protocolo predefinido de pruebas y criterios de aceptaci\u00f3n. Esto asegura que los procesos cumplan con los est\u00e1ndares necesarios para garantizar la calidad y seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calibraci\u00f3n de Instrumentos**:\n   - **Importancia**: La calibraci\u00f3n regular de instrumentos y sistemas de medici\u00f3n es esencial para asegurar la precisi\u00f3n y fiabilidad en la recolecci\u00f3n y separaci\u00f3n de sangre, as\u00ed como en las pruebas de control de calidad.\n   - **Dispositivos que requieren calibraci\u00f3n**: Sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n y hemoglobinom\u00e9tricos.\n   - **Procedimientos**: La calibraci\u00f3n debe seguir las instrucciones del fabricante y documentarse conforme a procedimientos operativos est\u00e1ndar y regulaciones nacionales. Se deben utilizar dispositivos certificados para la calibraci\u00f3n.\n\n2. **Sistemas Computarizados**:\n   - **Definici\u00f3n**: Un sistema computarizado es una unidad funcional que incluye computadoras, dispositivos perif\u00e9ricos y software que gestiona datos y programas.\n   - **Caracter\u00edsticas de sistemas cr\u00edticos**: Se consideran cr\u00edticos aquellos sistemas que impactan en la toma de decisiones sobre la fabricaci\u00f3n de productos sangu\u00edneos, pruebas de sangre, etiquetado y liberaci\u00f3n, as\u00ed como en la gesti\u00f3n de informaci\u00f3n y calidad del producto.\n   - **Protecci\u00f3n y validaci\u00f3n**: El hardware y software deben estar protegidos contra el uso no autorizado. Los sistemas cr\u00edticos deben ser validados antes de su uso y revalidados peri\u00f3dicamente bas\u00e1ndose en evaluaciones de riesgo.\n\n### Entidades Clave\n- **Instrumentos de Medici\u00f3n**: Sondas de temperatura, pipetas, balances, dispositivos de temporizaci\u00f3n, hemoglobinom\u00e9tricos.\n- **Sistemas Computarizados**: Unidades funcionales que incluyen hardware y software para la gesti\u00f3n de datos.\n- **Regulaciones**: Procedimientos operativos est\u00e1ndar y regulaciones nacionales que gu\u00edan la calibraci\u00f3n y validaci\u00f3n de sistemas.", "excerpt_keywords": "Keywords: qualification, validation, critical processes, software procedures, blood components"}}, "caf6c1ed-369a-41e1-83b9-f67d1d0dcf44": {"node_ids": ["7be22bce-e32c-4142-80bd-d05291c6fa24"], "metadata": {"page_label": "189", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Validation Studies and Test Systems\n\nValidation studies, including statistically based sampling where feasible, should be conducted to ensure that products are produced with consistent quality characteristics. Acceptance criteria should be based on a defined set of specifications for each blood component, including a set of quality control tests \u2014 such as measurement of weight respective to volume, residual blood cells (depending on product specifications), haemoglobin, and relevant coagulation factors (e.g. Factor VIII) and/or total protein/IgG content where applicable \u2014 established by the blood establishment or the NRA (see also sections 9.4.3 and 9.6). Data should be available to ensure that the final product is able to meet specifications.\n\nLikewise, apheresis systems, including software, should be qualified and maintained. Apheresis procedures should be validated. Validation criteria with regard to the quality of blood components may, depending on the product, include weight, yield, content of residual white blood cells, haemoglobin and relevant coagulation factors. Validation studies of new apheresis procedures should also evaluate possible risks of activation of the coagulation, fibrinolysis, and complement systems potentially induced by the material in contact with blood. Such studies are usually performed by the manufacturer of the apheresis systems to support the licensing by the regulatory authorities.\n\n## 7.3 Choosing an Appropriate Test System to Screen for Infectious Disease\n\nThe quality of the screening of blood donations for markers of infection depends on a number of conditions being fulfilled:\n\n- Only test systems designed and validated for blood donor screening should be used. Other systems, such as tests validated for diagnostic purposes only, should not be used.\n- All test systems should be validated by the manufacturer.\n- Before implementing a test system for routine analysis, the laboratory should prove by validation that the manufacturer\u2019s specifications are met (in principle this also applies if in-house tests are used).\n- The laboratory should show that, on routine application of test systems, specified performance is reached and is consistently maintained.\n\nScreening of blood donations generally requires such test systems to aim for high sensitivity even though this may be achieved at the expense of specificity. Although this may result in an increased proportion of false-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de Nivel Superior del Contexto\n\n1. **Importancia de los Estudios de Validaci\u00f3n**: Los estudios de validaci\u00f3n son esenciales para garantizar que los productos sangu\u00edneos se produzcan con caracter\u00edsticas de calidad consistentes. Esto incluye la realizaci\u00f3n de pruebas de control de calidad y la evaluaci\u00f3n de sistemas de af\u00e9resis.\n\n2. **Criterios de Aceptaci\u00f3n y Especificaciones**: Los criterios de aceptaci\u00f3n para los componentes sangu\u00edneos deben basarse en especificaciones definidas, que incluyen pruebas de calidad como el peso, los niveles de hemoglobina y factores de coagulaci\u00f3n.\n\n3. **Selecci\u00f3n de Sistemas de Prueba para Enfermedades Infecciosas**: La calidad del cribado de donaciones de sangre para marcadores de infecci\u00f3n depende de la utilizaci\u00f3n de sistemas de prueba dise\u00f1ados y validados espec\u00edficamente para este prop\u00f3sito, asegurando que se cumplan las especificaciones del fabricante.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas de control de calidad se deben realizar para cada componente sangu\u00edneo y qui\u00e9n establece estas especificaciones?**\n   - Las pruebas de control de calidad incluyen la medici\u00f3n del peso en relaci\u00f3n con el volumen, la cantidad de c\u00e9lulas sangu\u00edneas residuales, los niveles de hemoglobina y factores de coagulaci\u00f3n relevantes. Estas especificaciones son establecidas por el establecimiento de sangre o la autoridad reguladora nacional (NRA).\n\n2. **\u00bfCu\u00e1les son los riesgos potenciales que deben evaluarse durante los estudios de validaci\u00f3n de nuevos procedimientos de af\u00e9resis?**\n   - Los estudios de validaci\u00f3n deben evaluar los riesgos de activaci\u00f3n de la coagulaci\u00f3n, fibrinolisis y sistemas de complemento que pueden ser inducidos por el material en contacto con la sangre.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un sistema de prueba sea considerado adecuado para el cribado de donaciones de sangre?**\n   - Solo se deben utilizar sistemas de prueba dise\u00f1ados y validados para el cribado de donantes de sangre. Adem\u00e1s, todos los sistemas deben ser validados por el fabricante, y el laboratorio debe demostrar que se cumplen las especificaciones del fabricante antes de implementar el sistema para an\u00e1lisis rutinarios.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Procedimientos para Software y Hardware**:\n   - Se deben establecer procedimientos espec\u00edficos para cada tipo de software y hardware que detallen las acciones a tomar en caso de malfunciones o fallos.\n   - Es necesario contar con un procedimiento de respaldo para evitar la p\u00e9rdida de registros durante tiempos de inactividad.\n\n2. **Mantenimiento de Sistemas Cr\u00edticos**:\n   - Los sistemas inform\u00e1ticos cr\u00edticos deben mantenerse en un estado validado una vez que est\u00e9n en operaci\u00f3n rutinaria.\n   - Cualquier cambio en el sistema debe gestionarse a trav\u00e9s de un sistema formal de control de cambios que incluya actividades de calificaci\u00f3n y/o validaci\u00f3n.\n\n3. **Calificaci\u00f3n de Equipos**:\n   - Todos los equipos deben ser calificados y utilizados de acuerdo con procedimientos validados.\n   - La extensi\u00f3n de la calificaci\u00f3n depende de la naturaleza cr\u00edtica y complejidad del equipo, pudiendo requerir desde calificaci\u00f3n de instalaci\u00f3n y calibraci\u00f3n hasta un enfoque m\u00e1s exhaustivo.\n\n4. **Validaci\u00f3n de Procesos Cr\u00edticos**:\n   - Todos los procesos cr\u00edticos en la fabricaci\u00f3n de sangre y componentes sangu\u00edneos deben ser validados antes de su implementaci\u00f3n, siguiendo un protocolo predefinido de pruebas y criterios de aceptaci\u00f3n.\n\n5. **Verificaci\u00f3n Independiente de Datos**:\n   - La entrada manual de datos cr\u00edticos, como resultados de pruebas de laboratorio, debe ser verificada y liberada por una segunda persona.\n   - En sistemas computarizados, se debe garantizar un rastro de auditor\u00eda.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de las directrices.\n- **Pharmaceutical Inspection Co-operation Scheme (PIC/S)**: Proporciona recomendaciones sobre calificaci\u00f3n y validaci\u00f3n.\n- **Equipos Cr\u00edticos**: Equipos que requieren calificaci\u00f3n y validaci\u00f3n.\n- **Procesos de Fabricaci\u00f3n de Componentes Sangu\u00edneos**: Procesos que deben ser validados antes de su implementaci\u00f3n.\n\nEste resumen destaca la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la fabricaci\u00f3n de componentes sangu\u00edneos y el manejo de sistemas inform\u00e1ticos cr\u00edticos.", "excerpt_keywords": "Keywords: validation studies, blood components, quality control, apheresis systems, infectious disease screening"}}, "b57526c7-0e92-41bc-95e7-360a47327ef1": {"node_ids": ["6a2b970e-3b22-487f-acd6-6c52437eb955"], "metadata": {"page_label": "190", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "positive results, it is important in ensuring that all components with true-positive test results are detected and not released. In case of new assays or techniques, precise specifications must be established by testing samples of appropriate populations (e.g. donors, recipients, seroconverted recipients) and by comparing the results generated by the existing test system and by the new one.\n\nValidation of a test system involves four main elements:\n\n\u2014 assay reagents which should include quality control material (e.g. positive quality control sample, negative quality control sample, calibrators);\n\u2014 equipment;\n\u2014 software, if applicable;\n\u2014 procedure and handling (test method).\n\nValidation records should not only present proof that the scope and desired specifications are met, but should also provide precise descriptions of all key material, key equipment and conditions of processing (e.g. temperature and time of incubation, rounds per minute in centrifugation). In addition, instructions for handling and processing, by which assay specifications are met, should be put in writing and should be provided with the test system.\n\nTest system specifications that need to be established and/or met by the manufacturer are:\n\n\u2014 specificity;\n\u2014 sensitivity;\n\u2014 accuracy (degree of closeness of measurements to the true value);\n\u2014 repeatability (replicates of series);\n\u2014 reproducibility (replicates of series, variation by operator, by day or by lot of reagents);\n\u2014 known interferences (e.g. haemolytic sera, lipemic sera);\n\u2014 lower and upper limits of detection (serial dilution).\n\nApart from testing appropriate donor/recipient populations, appropriate reference materials should be used to define the performance specifications of a test system. These reference materials should be traceable to the WHO international standard or reference reagents, when available for a specific marker.\n\nThe necessary documentation should be available for each test system and should include at least the following information:\n\n\u2014 a description of the test system (reagents, controls, devices etc.), equipment and diluents (if applicable);\n\u2014 safety instructions;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la validaci\u00f3n de sistemas de pruebas diagn\u00f3sticas, enfatizando la importancia de establecer especificaciones precisas para nuevos ensayos y t\u00e9cnicas. La validaci\u00f3n implica cuatro elementos principales: reactivos de ensayo, equipo, software (si aplica) y procedimientos de manejo. Se requiere documentaci\u00f3n exhaustiva que incluya descripciones del sistema de prueba, instrucciones de seguridad y especificaciones de rendimiento como especificidad, sensibilidad y l\u00edmites de detecci\u00f3n.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los cuatro elementos principales involucrados en la validaci\u00f3n de un sistema de pruebas seg\u00fan el documento de la OMS?**\n   - Respuesta: Los cuatro elementos principales son: reactivos de ensayo (incluyendo material de control de calidad), equipo, software (si aplica) y procedimiento y manejo (m\u00e9todo de prueba).\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para cada sistema de prueba y qu\u00e9 informaci\u00f3n debe incluir?**\n   - Respuesta: La documentaci\u00f3n necesaria debe incluir al menos una descripci\u00f3n del sistema de prueba (reactivos, controles, dispositivos, etc.), equipo y diluyentes (si aplica), as\u00ed como instrucciones de seguridad.\n\n3. **\u00bfQu\u00e9 especificaciones de rendimiento deben establecerse y/o cumplirse por el fabricante de un sistema de prueba?**\n   - Respuesta: Las especificaciones de rendimiento que deben establecerse incluyen: especificidad, sensibilidad, precisi\u00f3n, repetibilidad, reproducibilidad, interferencias conocidas y l\u00edmites inferior y superior de detecci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Importancia de los Estudios de Validaci\u00f3n**: Los estudios de validaci\u00f3n son cruciales para asegurar que los productos sangu\u00edneos mantengan caracter\u00edsticas de calidad consistentes. Esto incluye la realizaci\u00f3n de pruebas de control de calidad y la validaci\u00f3n de procedimientos de af\u00e9resis.\n\n2. **Criterios de Aceptaci\u00f3n y Especificaciones**: Los criterios de aceptaci\u00f3n para los componentes sangu\u00edneos deben basarse en especificaciones definidas, que incluyen pruebas de calidad como el peso, los niveles de hemoglobina y factores de coagulaci\u00f3n.\n\n3. **Selecci\u00f3n de Sistemas de Prueba para Enfermedades Infecciosas**: La calidad del cribado de donaciones de sangre para marcadores de infecci\u00f3n depende de la utilizaci\u00f3n de sistemas de prueba dise\u00f1ados y validados espec\u00edficamente para este prop\u00f3sito, asegurando que se cumplan las especificaciones del fabricante.\n\n### Entidades\n\n- **Establecimiento de Sangre**: Entidad responsable de establecer especificaciones para los componentes sangu\u00edneos.\n- **Autoridad Reguladora Nacional (NRA)**: Entidad que puede establecer criterios de aceptaci\u00f3n y supervisar la calidad de los productos sangu\u00edneos.\n- **Sistemas de Af\u00e9resis**: Equipos y procedimientos utilizados para la recolecci\u00f3n de componentes sangu\u00edneos, que deben ser validados y mantenidos.\n- **Sistemas de Prueba**: Herramientas utilizadas para el cribado de donaciones de sangre, que deben ser dise\u00f1adas y validadas espec\u00edficamente para este fin.\n\n### Resumen\n\nLa secci\u00f3n aborda la necesidad de realizar estudios de validaci\u00f3n para garantizar la calidad de los productos sangu\u00edneos y la importancia de establecer criterios de aceptaci\u00f3n basados en especificaciones definidas. Tambi\u00e9n se enfatiza la validaci\u00f3n de sistemas de af\u00e9resis y la selecci\u00f3n de sistemas de prueba adecuados para el cribado de donaciones de sangre, asegurando que estos sistemas sean dise\u00f1ados y validados espec\u00edficamente para su uso en este contexto.", "excerpt_keywords": "Keywords: validation, test system, specifications, quality control, performance standards"}}, "9cca0e5b-d88c-4b61-8dba-1597582a0be4": {"node_ids": ["c2e0ac89-856f-4809-8cb9-0087f2dc5bf1"], "metadata": {"page_label": "191", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a description of the assay principle;\n- specifications;\n- a description of the sampling procedure, sampling plan, sample handling and test procedure;\n- internal quality controls (positive and negative), run with every series of donor samples;\n- recommended calibration material and calibration frequency (e.g. change of reagent lot);\n- primary reading of measurement (format e.g. optical density);\n- interpretation of the measurement and/or conversion to result;\n- acceptance criteria, cut-off, reference values, limits, pro-zone, grey zone.\n\nWhere feasible, the test system should be approved for blood screening by the NRA.\n\n## 7.4 Assay performance validation\n\nIn addition to the validation of the test system by the manufacturer, an on-site validation of the test system in the laboratory is required prior to its use in routine testing. This validation should demonstrate, that:\n\n- the performance specifications of the system established by the kit manufacturer are met by the laboratory;\n- laboratory personnel are thoroughly instructed, trained and competent to operate the test system.\n\nPrior to first-time use, critical equipment, including related computer systems, should be thoroughly qualified. Installation qualification, operational qualification and performance qualification should be carried out and fully documented. This work may involve suppliers and/or third parties. It is strongly recommended that any performance qualification should be performed by the end-user (and not by a third party) since this is intended to demonstrate that the process works as designed.\n\nIn addition, a demonstration showing that the test system performance specifications are constantly met in routine donor testing is required. The means by which this may be achieved are:\n\n- inclusion of internal and external quality control materials with every test series;\n- previously tested samples collected for use as an internal panel for periodical in-process quality control;\n- monitoring measurements of controls (for instance, graphically by using a Levi-Jennings diagram);\n- statistically establishing the standard deviation of control measurements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los pasos necesarios para validar un sistema de ensayo en un laboratorio antes de su uso en pruebas rutinarias?**\n   - Respuesta: La validaci\u00f3n en el laboratorio debe demostrar que las especificaciones de rendimiento del sistema establecidas por el fabricante del kit son cumplidas por el laboratorio, y que el personal del laboratorio est\u00e1 debidamente instruido, capacitado y es competente para operar el sistema de ensayo. Adem\u00e1s, se debe realizar una calificaci\u00f3n exhaustiva del equipo cr\u00edtico, incluyendo sistemas inform\u00e1ticos relacionados, y llevar a cabo la calificaci\u00f3n de instalaci\u00f3n, operaci\u00f3n y rendimiento, documentando todo el proceso.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para asegurar que las especificaciones de rendimiento del sistema de ensayo se mantengan durante las pruebas rutinarias de donantes?**\n   - Respuesta: Para asegurar que las especificaciones de rendimiento se mantengan, se pueden incluir materiales de control de calidad internos y externos con cada serie de pruebas, utilizar muestras previamente analizadas como un panel interno para el control de calidad en proceso, monitorear las mediciones de los controles (por ejemplo, utilizando un diagrama de Levi-Jennings) y establecer estad\u00edsticamente la desviaci\u00f3n est\u00e1ndar de las mediciones de control.\n\n3. **\u00bfQu\u00e9 tipo de controles de calidad se deben implementar en cada serie de muestras de donantes?**\n   - Respuesta: Se deben implementar controles de calidad internos, tanto positivos como negativos, que se ejecuten con cada serie de muestras de donantes. Esto asegura que el sistema de ensayo est\u00e9 funcionando correctamente y que los resultados sean confiables.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre la validaci\u00f3n y el control de calidad de los sistemas de ensayo utilizados en pruebas de sangre. Se enfatiza la importancia de la validaci\u00f3n tanto por parte del fabricante como en el laboratorio donde se utilizar\u00e1 el sistema. Se detallan los requisitos para la calificaci\u00f3n del equipo y la capacitaci\u00f3n del personal, as\u00ed como las medidas necesarias para garantizar que las especificaciones de rendimiento se mantengan durante las pruebas rutinarias. Adem\u00e1s, se menciona la necesidad de incluir controles de calidad en cada serie de pruebas para asegurar la fiabilidad de los resultados.", "prev_section_summary": "### Temas Clave:\n1. **Validaci\u00f3n de Sistemas de Pruebas**: Proceso esencial para asegurar que los resultados de las pruebas diagn\u00f3sticas sean precisos y confiables.\n2. **Elementos de Validaci\u00f3n**: Incluye reactivos de ensayo, equipo, software (si aplica) y procedimientos de manejo.\n3. **Documentaci\u00f3n Requerida**: Es fundamental tener registros que demuestren que se cumplen las especificaciones y que incluyan descripciones detalladas de materiales, equipos y condiciones de procesamiento.\n4. **Especificaciones de Rendimiento**: Deben establecerse y cumplirse especificaciones como especificidad, sensibilidad, precisi\u00f3n, repetibilidad, reproducibilidad, interferencias conocidas y l\u00edmites de detecci\u00f3n.\n5. **Materiales de Referencia**: Uso de materiales de referencia apropiados que sean trazables a est\u00e1ndares internacionales de la OMS para definir las especificaciones de rendimiento.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que proporciona directrices sobre la validaci\u00f3n de sistemas de pruebas.\n- **Reactivos de Ensayo**: Materiales utilizados en las pruebas diagn\u00f3sticas.\n- **Equipos y Software**: Herramientas necesarias para realizar las pruebas.\n- **Poblaciones de Donantes/Receptores**: Grupos de personas de los cuales se toman muestras para validar los ensayos.\n- **Especificaciones de Rendimiento**: Par\u00e1metros que definen la efectividad de un sistema de prueba.\n\n### Resumen:\nEl documento de la OMS aborda la validaci\u00f3n de sistemas de pruebas diagn\u00f3sticas, destacando la importancia de establecer especificaciones precisas y documentar todos los aspectos del proceso. La validaci\u00f3n incluye cuatro elementos clave: reactivos, equipo, software y procedimientos. Adem\u00e1s, se requiere documentaci\u00f3n que detalle el sistema de prueba y las especificaciones de rendimiento que deben cumplirse, como especificidad y sensibilidad. Tambi\u00e9n se enfatiza el uso de materiales de referencia trazables a est\u00e1ndares internacionales para asegurar la calidad de las pruebas.", "excerpt_keywords": "Keywords: assay validation, quality control, blood screening, performance specifications, laboratory training"}}, "777726ca-6a5a-4a02-992a-df367979d933": {"node_ids": ["cb12c49e-d315-4601-9d48-67b515892934"], "metadata": {"page_label": "192", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Management of materials and reagents\n\n## 8.1 Materials and reagents\n\nOnly reagents and materials from approved suppliers that meet documented requirements and specifications should be used. Materials and reagents should meet the legal requirements for medical devices. The management procedures for materials, reagents and supplies should define the specifications for acceptance of any elements that may influence the quality of the final blood component. Receipt logs or records for these critical materials should indicate their acceptability on the basis of the defined specifications and should identify the person accepting them.\n\n## 8.2 Receipt and quarantine\n\nAppropriate checks (e.g. attached certificates, expiry date, lot number, defects) should be performed on received goods in order to confirm that they correspond to the order and meet the specifications. Damaged containers should be carefully checked to detect possibly affected materials. Incoming critical materials (such as sterile solutions, blood bag systems and testing reagents) should be physically or administratively quarantined immediately after receipt and until they are released for use. Where the quarantine status is ensured by storage in separate areas, these areas should be clearly marked and their access restricted to authorized personnel. When labels are applied to the containers to indicate their status, the use of different colours may be helpful. Any system replacing physical quarantine (e.g. a computerized system) should provide equivalent security.\n\n## 8.3 Release of incoming production material and test reagents\n\nCritical material should be received under quarantine and then evaluated for acceptability. After acceptability has been determined, the materials should be released by an authorized person for use in manufacture. The actual release may be performed by an authorized person or under the guidance of a validated computer system. The minimum criteria for the release should be the availability \u2014 and check of \u2014 certificates or other acceptability records generated by the manufacturer and containing sufficient information to determine product acceptance.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de materiales y reactivos en el contexto de la producci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de utilizar solo materiales de proveedores aprobados que cumplan con requisitos documentados y especificaciones legales. Se describen procedimientos para la recepci\u00f3n, cuarentena y liberaci\u00f3n de materiales cr\u00edticos, asegurando que se realicen verificaciones adecuadas y que solo se utilicen materiales aceptables en la fabricaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de materiales y reactivos deben ser utilizados en la producci\u00f3n de componentes sangu\u00edneos seg\u00fan el documento?**\n   - Solo se deben utilizar reactivos y materiales de proveedores aprobados que cumplan con requisitos documentados y especificaciones legales para dispositivos m\u00e9dicos.\n\n2. **\u00bfCu\u00e1les son los pasos que deben seguirse al recibir materiales cr\u00edticos para asegurar su calidad?**\n   - Se deben realizar verificaciones adecuadas, como comprobar certificados, fechas de caducidad, n\u00fameros de lote y defectos. Adem\u00e1s, los materiales cr\u00edticos deben ser puestos en cuarentena inmediatamente despu\u00e9s de su recepci\u00f3n hasta que sean liberados para su uso.\n\n3. **\u00bfQui\u00e9n es responsable de liberar los materiales cr\u00edticos para su uso en la fabricaci\u00f3n?**\n   - La liberaci\u00f3n de los materiales debe ser realizada por una persona autorizada, y puede llevarse a cabo directamente por esta persona o bajo la gu\u00eda de un sistema inform\u00e1tico validado. Se requiere que existan certificados o registros de aceptaci\u00f3n generados por el fabricante para determinar la aceptaci\u00f3n del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n del Sistema de Ensayo**:\n   - Es necesario realizar una validaci\u00f3n en el laboratorio antes de usar el sistema de ensayo en pruebas rutinarias.\n   - La validaci\u00f3n debe demostrar que:\n     - Las especificaciones de rendimiento del fabricante son cumplidas por el laboratorio.\n     - El personal del laboratorio est\u00e1 capacitado y es competente para operar el sistema.\n\n2. **Calificaci\u00f3n del Equipo**:\n   - Antes del primer uso, el equipo cr\u00edtico y los sistemas inform\u00e1ticos relacionados deben ser calificados exhaustivamente.\n   - Se deben llevar a cabo y documentar la calificaci\u00f3n de instalaci\u00f3n, operaci\u00f3n y rendimiento.\n\n3. **Control de Calidad**:\n   - Se deben incluir controles de calidad internos (positivos y negativos) en cada serie de muestras de donantes.\n   - Se recomienda el uso de materiales de control de calidad internos y externos, as\u00ed como muestras previamente analizadas para el control de calidad en proceso.\n\n4. **Monitoreo y Estad\u00edsticas**:\n   - Es importante monitorear las mediciones de los controles, por ejemplo, utilizando un diagrama de Levi-Jennings.\n   - Se debe establecer estad\u00edsticamente la desviaci\u00f3n est\u00e1ndar de las mediciones de control.\n\n5. **Aprobaci\u00f3n del Sistema de Ensayo**:\n   - El sistema de ensayo debe estar aprobado para el tamizaje de sangre por la NRA (Autoridad Reguladora Nacional).\n\n### Entidades Clave:\n- **NRA**: Autoridad Reguladora Nacional.\n- **Levi-Jennings**: Diagrama utilizado para el monitoreo de controles de calidad.\n- **Personal del laboratorio**: Debe estar capacitado y competente.\n- **Equipo cr\u00edtico**: Incluye sistemas inform\u00e1ticos y otros equipos necesarios para el ensayo.\n\nEste resumen destaca la importancia de la validaci\u00f3n, el control de calidad y la capacitaci\u00f3n del personal en el contexto de los sistemas de ensayo utilizados en pruebas de sangre.", "excerpt_keywords": "Keywords: materials management, reagents, quality control, quarantine procedures, blood component production"}}, "f682a4b3-8dbe-435b-9e4a-273d2e5f89b9": {"node_ids": ["8567b9ff-c95c-47bc-8b2c-d19c8b3dd008"], "metadata": {"page_label": "193", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Similarly, each new lot of testing kits should be evaluated by the laboratory to check compliance with predetermined performance standards before release for routine analysis.\n\nThe manufacturers of sterile materials (e.g. blood bag systems, anticoagulant solutions) should provide a certificate of release for each batch. The blood establishment should define acceptance criteria for such certificates in writing, and should include at least the name of the material, the manufacturer, compliance with the relevant requirements (e.g. pharmacopoeia or medical device regulations) and confirmation that the materials are sterile and pyrogen-free.\n\n### 8.4 Storage\n\nMaterials and reagents should be stored under the conditions established by the manufacturer and in an orderly manner that permits segregation by batch or lot and stock rotation. Storage and use should follow the \u201cfirst-expiring first-out\u201d principle (i.e. the material that entered storage first should be used first). The use of the expiry date as an alternative inventory management technique is also acceptable.\n\nWhere special storage temperature conditions are required, these should be provided, checked and regularly monitored.\n\n### 8.5 Traceability of materials and reagents\n\nInventory records should be kept for traceability. The records should document which batch or lot of materials or reagents have been used for the collection, processing or testing of the blood units or blood components. Inventory of critical supplies such as donation labels with serial numbers should be strictly controlled to avoid mix-ups or mislabelling due to uncontrolled excess labels.\n\n### 8.6 Supplier/vendor management\n\nAll materials and reagents relevant for the quality of the products should be purchased or obtained only from qualified suppliers. The relationship between the two parties (i.e. contract giver and contract acceptor) should be defined in a contract. The blood establishment as contract giver is responsible for assessing the competence of the supplier (contract acceptor).\n\nThe contracting process should include:\n\n- a qualification review prior to awarding the contract to ensure that the supplier meets the organizational needs and complies with GMP requirements;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evaluaci\u00f3n de kits de prueba**: Cada nuevo lote de kits de prueba debe ser evaluado por el laboratorio para asegurar que cumpla con los est\u00e1ndares de rendimiento predeterminados antes de su liberaci\u00f3n para an\u00e1lisis rutinarios.\n\n2. **Certificaci\u00f3n de materiales est\u00e9riles**: Los fabricantes de materiales est\u00e9riles deben proporcionar un certificado de liberaci\u00f3n para cada lote, que debe incluir informaci\u00f3n sobre el material, el fabricante, y la confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n3. **Almacenamiento y trazabilidad**: Los materiales y reactivos deben ser almacenados bajo condiciones espec\u00edficas y de manera ordenada, permitiendo la segregaci\u00f3n por lote y la rotaci\u00f3n de stock. Adem\u00e1s, se deben mantener registros de inventario para asegurar la trazabilidad de los materiales utilizados.\n\n4. **Gesti\u00f3n de proveedores**: Todos los materiales y reactivos deben ser adquiridos solo de proveedores calificados, y la relaci\u00f3n entre el establecimiento de sangre y el proveedor debe estar definida en un contrato que incluya una revisi\u00f3n de calificaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben incluirse en el certificado de liberaci\u00f3n proporcionado por los fabricantes de materiales est\u00e9riles?**\n   - El certificado debe incluir el nombre del material, el fabricante, el cumplimiento con los requisitos relevantes (como la farmacopoeia o regulaciones de dispositivos m\u00e9dicos) y la confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n2. **\u00bfCu\u00e1l es el principio de gesti\u00f3n de inventario que se debe seguir para el almacenamiento de materiales y reactivos?**\n   - Se debe seguir el principio de \"primero en expirar, primero en salir\" (first-expiring first-out), lo que significa que el material que ingres\u00f3 al almacenamiento primero debe ser utilizado primero.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse en el proceso de contrataci\u00f3n para asegurar que un proveedor cumpla con los requisitos de GMP?**\n   - El proceso de contrataci\u00f3n debe incluir una revisi\u00f3n de calificaci\u00f3n antes de otorgar el contrato, para asegurar que el proveedor cumpla con las necesidades organizacionales y los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Materiales y Reactivos**:\n   - Solo se deben utilizar reactivos y materiales de proveedores aprobados.\n   - Deben cumplir con requisitos documentados y especificaciones legales para dispositivos m\u00e9dicos.\n\n2. **Gesti\u00f3n de Materiales**:\n   - Los procedimientos de gesti\u00f3n deben definir especificaciones para la aceptaci\u00f3n de materiales que influyan en la calidad del componente sangu\u00edneo final.\n   - Se deben llevar registros de recepci\u00f3n que indiquen la aceptabilidad de los materiales y la persona que los acepta.\n\n3. **Recepci\u00f3n y Cuarentena**:\n   - Se deben realizar verificaciones adecuadas al recibir materiales cr\u00edticos (certificados, fechas de caducidad, n\u00fameros de lote, defectos).\n   - Los materiales cr\u00edticos deben ser puestos en cuarentena inmediatamente tras su recepci\u00f3n.\n   - Las \u00e1reas de cuarentena deben estar claramente marcadas y restringidas a personal autorizado.\n\n4. **Liberaci\u00f3n de Materiales**:\n   - Los materiales cr\u00edticos deben ser evaluados para determinar su aceptabilidad antes de ser liberados para su uso.\n   - La liberaci\u00f3n debe ser realizada por una persona autorizada o bajo la gu\u00eda de un sistema inform\u00e1tico validado.\n   - Se requiere la disponibilidad de certificados o registros de aceptaci\u00f3n generados por el fabricante para determinar la aceptaci\u00f3n del producto.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Proveedores Aprobados**: Entidades que suministran materiales y reactivos.\n- **Materiales Cr\u00edticos**: Incluyen soluciones est\u00e9riles, sistemas de bolsas de sangre y reactivos de prueba.\n- **Personal Autorizado**: Individuos responsables de la aceptaci\u00f3n y liberaci\u00f3n de materiales.", "excerpt_keywords": "Keywords: testing kits, sterile materials, storage conditions, traceability, supplier management"}}, "25eae283-4f8c-4ea5-8de2-f69a343d349c": {"node_ids": ["9ab04849-237e-4c56-9fbd-f47b7c187ac2"], "metadata": {"page_label": "194", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Manufacturing\n\n## 9.1 Donor registration\n\nUpon presentation at the blood establishment, donors should positively identify themselves by stating their full name, address and date of birth. Each donor should also provide proof of a permanent place of residence, including a telephone number where appropriate, so that they can be contacted after donation, if necessary.\n\nProof of identity with a photograph \u2014 such as an identity card, passport or driver\u2019s licence \u2014 should be provided, especially in the case of first-time donors. A careful check of the identity of the donor should be repeated prior to each step that is relevant to the quality of the products and the safety of donors, but at least before donor selection and venipuncture.\n\nIf electronic databases are used to maintain donor information, double checks or another validated method to confirm accuracy of information entered manually should be implemented.\n\n## 9.2 Donor selection\n\nBlood and blood components should be obtained from healthy donors who are carefully selected using a systematic and validated process consisting of review of the donor\u2019s health assessment, social behaviour history (the donor questionnaire) and medical examination. This evaluation, along with a review of the results of the infectious disease screening laboratory test, should be used to make sure, prior to the release of any blood component, that the donor presents no increased risk for transmission of infectious agents. NRAs are pivotal in establishing a harmonized framework for donor selection criteria, taking into consideration the types of products, the relevant infectious risks, and the epidemiological data for disease prevalence in the country. The review of these combined data may be used in developing donor selection criteria. The NRA should also be part of", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los procedimientos para el registro y selecci\u00f3n de donantes de sangre. Se enfatiza la importancia de la identificaci\u00f3n adecuada de los donantes, la verificaci\u00f3n de su salud y comportamiento social, as\u00ed como la implementaci\u00f3n de procesos sistem\u00e1ticos y validados para garantizar la seguridad de la sangre donada. Tambi\u00e9n se menciona el papel crucial de las Autoridades Reguladoras Nacionales (NRAs) en el establecimiento de criterios de selecci\u00f3n de donantes, considerando los riesgos infecciosos y la prevalencia de enfermedades en el pa\u00eds.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para que un donante se registre en un establecimiento de sangre?**\n   - El donante debe presentar su nombre completo, direcci\u00f3n, fecha de nacimiento y prueba de identidad con fotograf\u00eda, como una tarjeta de identidad, pasaporte o licencia de conducir.\n\n2. **\u00bfCu\u00e1l es el proceso que se sigue para asegurar que un donante no represente un riesgo de transmisi\u00f3n de agentes infecciosos?**\n   - Se realiza una evaluaci\u00f3n sistem\u00e1tica que incluye la revisi\u00f3n de la salud del donante, su historial de comportamiento social a trav\u00e9s de un cuestionario, un examen m\u00e9dico y la revisi\u00f3n de los resultados de pruebas de laboratorio para detectar enfermedades infecciosas.\n\n3. **\u00bfQu\u00e9 papel juegan las Autoridades Reguladoras Nacionales (NRAs) en la selecci\u00f3n de donantes de sangre?**\n   - Las NRAs son fundamentales para establecer un marco armonizado de criterios de selecci\u00f3n de donantes, considerando los tipos de productos, los riesgos infecciosos relevantes y los datos epidemiol\u00f3gicos sobre la prevalencia de enfermedades en el pa\u00eds.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n de Kits de Prueba**:\n   - Cada nuevo lote de kits de prueba debe ser evaluado por el laboratorio para asegurar el cumplimiento de los est\u00e1ndares de rendimiento antes de su liberaci\u00f3n para an\u00e1lisis rutinarios.\n\n2. **Certificaci\u00f3n de Materiales Est\u00e9riles**:\n   - Los fabricantes de materiales est\u00e9riles, como sistemas de bolsas de sangre y soluciones anticoagulantes, deben proporcionar un certificado de liberaci\u00f3n para cada lote. Este certificado debe incluir:\n     - Nombre del material\n     - Fabricante\n     - Cumplimiento con requisitos relevantes (ej. farmacopoeia, regulaciones de dispositivos m\u00e9dicos)\n     - Confirmaci\u00f3n de que los materiales son est\u00e9riles y libres de pir\u00f3genos.\n\n3. **Almacenamiento**:\n   - Los materiales y reactivos deben ser almacenados seg\u00fan las condiciones establecidas por el fabricante, permitiendo la segregaci\u00f3n por lote y la rotaci\u00f3n de stock. Se debe seguir el principio de \"primero en expirar, primero en salir\" (first-expiring first-out) para la gesti\u00f3n de inventario.\n\n4. **Trazabilidad de Materiales y Reactivos**:\n   - Se deben mantener registros de inventario para asegurar la trazabilidad de los materiales utilizados en la recolecci\u00f3n, procesamiento o prueba de unidades de sangre. El inventario de suministros cr\u00edticos, como etiquetas de donaci\u00f3n con n\u00fameros de serie, debe ser controlado estrictamente.\n\n5. **Gesti\u00f3n de Proveedores**:\n   - Todos los materiales y reactivos deben ser adquiridos solo de proveedores calificados. La relaci\u00f3n entre el establecimiento de sangre y el proveedor debe estar definida en un contrato que incluya una revisi\u00f3n de calificaci\u00f3n para asegurar que el proveedor cumpla con las necesidades organizacionales y los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades Clave\n- **Kits de prueba**\n- **Materiales est\u00e9riles** (ej. sistemas de bolsas de sangre, soluciones anticoagulantes)\n- **Certificado de liberaci\u00f3n**\n- **Almacenamiento**\n- **Trazabilidad**\n- **Proveedores calificados**\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**\n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la evaluaci\u00f3n, certificaci\u00f3n, almacenamiento, trazabilidad y gesti\u00f3n de proveedores en el contexto de la calidad de los productos relacionados con la sangre.", "excerpt_keywords": "Keywords: donor registration, blood safety, infectious disease screening, regulatory authorities, donor selection criteria"}}, "d4026735-ef8b-4edc-81f6-fd111a0096cf": {"node_ids": ["f1cefe0e-d02f-4cae-811d-c1e30ff9e37c"], "metadata": {"page_label": "195", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "any decision-making process intended to modify the donor selection and donation-testing procedures.\n\nRegulatory agencies and professional organizations have respectively published regulations and recommendations on the criteria for the selection of donors of whole blood and blood components (see, for instance, the Council of Europe\u2019s *Guide to the preparation, use and quality assurance of blood components*) that can be used as a reference (13). Such guidance documents also explain critical points that should be considered when processing blood and blood components.\n\nWhenever possible, blood donations should be collected through a donation system involving regular and repeat donors. Obtaining blood from regular and repeat donors is a major contribution to ensuring optimal historical medical information about the donors, and therefore to detecting potential risk factors.\n\n### 9.2.1 Epidemiological surveillance of the donor population\n\nTo ensure optimal long-term safety of blood components, blood establishments should maintain continuous epidemiological surveillance of the donor population. The objective of this surveillance is to know, as precisely as possible, the prevalence and incidence, and their respective trends, of infectious markers that are relevant to the safety of blood components. This enables countermeasures to be taken in a timely manner. The system should be able to gather epidemiological data not only at national/regional levels but also among donor populations that provide blood at individual blood establishments within a country or region. Consideration should be given to the travelling patterns of the donor population with respect to possible transmission of infectious diseases (i.e. malaria, Chagas disease, vCJD, etc.).\n\nThe information from epidemiological surveillance can furthermore be used:\n\n- to detect, among donor populations of various collection centres, differences that may be associated with objective differences in viral markers within donor populations;\n- to detect differences in the donor selection and screening processes at collection centres;\n- to detect trends in infectious markers which may reflect either a change in the rate of viral markers in the population or a possible deviation in the donor selection or screening process at specific collection sites;\n- to assess the relevance of any preventive measures such as a strengthened donor selection process, additional deferral criteria, or implementation of additional screening tests to avoid contamination of blood components.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto aborda la importancia de la selecci\u00f3n de donantes de sangre y la vigilancia epidemiol\u00f3gica de la poblaci\u00f3n donante para garantizar la seguridad de los componentes sangu\u00edneos. Se menciona que las agencias regulatorias y organizaciones profesionales han establecido regulaciones y recomendaciones sobre los criterios de selecci\u00f3n de donantes. Se enfatiza la necesidad de recolectar sangre de donantes regulares y repetidos para asegurar informaci\u00f3n m\u00e9dica hist\u00f3rica \u00f3ptima. Adem\u00e1s, se destaca la importancia de mantener una vigilancia epidemiol\u00f3gica continua para conocer la prevalencia e incidencia de marcadores infecciosos relevantes, lo que permite tomar medidas preventivas adecuadas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los beneficios espec\u00edficos de recolectar sangre de donantes regulares y repetidos en comparaci\u00f3n con donantes ocasionales?**\n   - Esta pregunta busca profundizar en las ventajas concretas que ofrecen los donantes regulares en t\u00e9rminos de informaci\u00f3n m\u00e9dica y detecci\u00f3n de riesgos.\n\n2. **\u00bfQu\u00e9 tipo de datos epidemiol\u00f3gicos se deben recopilar para evaluar la seguridad de los componentes sangu\u00edneos y c\u00f3mo se pueden utilizar esos datos en la pr\u00e1ctica?**\n   - Esta pregunta se centra en los tipos de datos que son cruciales para la vigilancia epidemiol\u00f3gica y su aplicaci\u00f3n en la mejora de los procesos de selecci\u00f3n y pruebas de donantes.\n\n3. **\u00bfQu\u00e9 medidas preventivas se pueden implementar si se detectan tendencias preocupantes en los marcadores infecciosos dentro de una poblaci\u00f3n donante espec\u00edfica?**\n   - Esta pregunta busca explorar las acciones concretas que se pueden tomar en respuesta a hallazgos epidemiol\u00f3gicos que indiquen un aumento en los riesgos de transmisi\u00f3n de enfermedades infecciosas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Registro de Donantes**:\n   - **Identificaci\u00f3n**: Los donantes deben identificarse proporcionando su nombre completo, direcci\u00f3n, fecha de nacimiento y prueba de residencia permanente.\n   - **Documentaci\u00f3n**: Se requiere una prueba de identidad con fotograf\u00eda (tarjeta de identidad, pasaporte, licencia de conducir), especialmente para donantes primerizos.\n   - **Verificaci\u00f3n**: Se debe realizar una verificaci\u00f3n cuidadosa de la identidad del donante antes de cada paso relevante para la calidad de los productos y la seguridad de los donantes.\n\n2. **Selecci\u00f3n de Donantes**:\n   - **Proceso Sistem\u00e1tico**: La selecci\u00f3n de donantes se basa en una evaluaci\u00f3n sistem\u00e1tica que incluye la revisi\u00f3n de la salud del donante, su historial de comportamiento social y un examen m\u00e9dico.\n   - **Pruebas de Enfermedades Infecciosas**: Se revisan los resultados de las pruebas de laboratorio para asegurar que el donante no represente un riesgo aumentado de transmisi\u00f3n de agentes infecciosos.\n\n3. **Autoridades Reguladoras Nacionales (NRAs)**:\n   - **Marco Armonizado**: Las NRAs son fundamentales para establecer criterios de selecci\u00f3n de donantes, considerando los tipos de productos, los riesgos infecciosos y los datos epidemiol\u00f3gicos sobre la prevalencia de enfermedades en el pa\u00eds.\n\n### Entidades Clave:\n- **Donantes de Sangre**: Individuos que ofrecen su sangre para transfusiones.\n- **Establecimientos de Sangre**: Instituciones donde se lleva a cabo la recolecci\u00f3n y procesamiento de sangre.\n- **Autoridades Reguladoras Nacionales (NRAs)**: Organismos responsables de establecer y supervisar los criterios de selecci\u00f3n de donantes y la seguridad de la sangre.", "excerpt_keywords": "Keywords: blood donation, donor selection, epidemiological surveillance, infectious markers, safety of blood components"}}, "3aa21772-8d1d-4dd9-8633-83e24e17c5f8": {"node_ids": ["22010588-d73b-4a1a-ace3-35d2eebcf8ac"], "metadata": {"page_label": "196", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "When donations from first-time donors are used to prepare blood components, epidemiological data on this specific donor group should be included in the estimate of the risk for infectious diseases transmitted by blood. It has been shown that first-time donors, who may occasionally include test-seeking persons, constitute a group that in some situations is more likely to have bloodborne viral markers than regular donors who have already gone through a selection/deferral process.\n\nIt is currently advisable to collect and analyse epidemiological data at the collection sites for HIV1/HIV2, hepatitis C virus (HCV) and hepatitis B virus (HBV) since they historically represent the major pathogenic risks associated with blood components. It is the responsibility of the NRA to define whether this list should be modified or should include additional criteria such as emerging infectious agents, on the basis of local or regional epidemiology. For the current three recommended markers, only confirmed positive tests (i.e. tests which are repeatedly reactive in a screening test and positive in at least one confirmatory test) should be recorded, reported and analysed.\n\n### 9.2.2 Information to donors\n\nPotential new donors should be informed (ideally both verbally and in writing) that it is necessary to respond to questions about their medical history and personal behaviour so that it can be determined whether they are eligible for blood donation. Written information can be a leaflet explaining infectious risks associated with blood products, and the impact of social behaviour on infectious risks or infectious risk factors. This information is usually provided by a licensed physician, or by a designated qualified person under the direct supervision of a licensed physician. The information should clearly explain the deferral criteria that exclude a donor from donating blood or plasma. It is important to ensure that the reasons for deferral are well understood by the candidate donor.\n\nThe candidate donor should be asked to sign a form of informed consent to give blood in which he/she acknowledges understanding the moral and legal responsibilities and possible risks associated with donating blood, as well as the occasional complications that may occur. The declaration of consent should also include a statement that the donor authorizes the release of his/her blood and blood components for transfusion or further manufacturing.\n\nDonors should be informed to contact the blood establishment if there is an unexpected event after the donation, such as illness or the discovery of new information not disclosed during the health screening.\n\n### 9.2.3 Questionnaire and interview\n\nThe interview assessment of each donor should be carried out by a qualified person who is trained in the use of donor selection criteria using a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de recopilar y analizar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente aquellos que son donantes por primera vez. Se destaca que este grupo puede tener un mayor riesgo de transmitir enfermedades infecciosas, como el VIH y los virus de hepatitis. Adem\u00e1s, se enfatiza la necesidad de informar a los donantes sobre los riesgos asociados con la donaci\u00f3n de sangre, los criterios de exclusi\u00f3n y la importancia de dar su consentimiento informado. Tambi\u00e9n se menciona que la evaluaci\u00f3n de los donantes debe ser realizada por personal calificado.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfPor qu\u00e9 es importante recopilar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente los de primera vez?**\n   - La recopilaci\u00f3n de datos epidemiol\u00f3gicos es crucial porque los donantes de primera vez pueden tener un mayor riesgo de portar marcadores virales transmitidos por la sangre, lo que puede aumentar el riesgo de infecciones en los componentes sangu\u00edneos. Esto permite a las autoridades de regulaci\u00f3n ajustar sus criterios de selecci\u00f3n y deferral bas\u00e1ndose en la epidemiolog\u00eda local.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se debe proporcionar a los donantes potenciales antes de la donaci\u00f3n de sangre?**\n   - Los donantes potenciales deben recibir informaci\u00f3n verbal y escrita sobre la importancia de responder preguntas sobre su historial m\u00e9dico y comportamiento personal. Tambi\u00e9n deben ser informados sobre los riesgos infecciosos asociados con los productos sangu\u00edneos, los criterios de exclusi\u00f3n y la necesidad de firmar un consentimiento informado que reconozca los riesgos y responsabilidades de la donaci\u00f3n.\n\n3. **\u00bfQui\u00e9n es responsable de llevar a cabo la evaluaci\u00f3n de los donantes y qu\u00e9 criterios deben seguir?**\n   - La evaluaci\u00f3n de los donantes debe ser realizada por una persona calificada que est\u00e9 entrenada en el uso de criterios de selecci\u00f3n de donantes. Esta persona debe utilizar un cuestionario validado para garantizar que se sigan los procedimientos adecuados y se eval\u00fae correctamente la elegibilidad del donante.", "prev_section_summary": "### Temas Clave\n\n1. **Selecci\u00f3n de Donantes de Sangre**: La importancia de establecer criterios adecuados para la selecci\u00f3n de donantes de sangre y componentes sangu\u00edneos, basados en regulaciones y recomendaciones de agencias regulatorias y organizaciones profesionales.\n\n2. **Donantes Regulares y Repetidos**: Se enfatiza la necesidad de recolectar sangre de donantes regulares y repetidos para asegurar una mejor informaci\u00f3n m\u00e9dica hist\u00f3rica, lo que facilita la detecci\u00f3n de factores de riesgo.\n\n3. **Vigilancia Epidemiol\u00f3gica**: La necesidad de mantener una vigilancia epidemiol\u00f3gica continua de la poblaci\u00f3n donante para conocer la prevalencia e incidencia de marcadores infecciosos relevantes, permitiendo la implementaci\u00f3n de medidas preventivas oportunas.\n\n4. **Datos Epidemiol\u00f3gicos**: La recopilaci\u00f3n de datos epidemiol\u00f3gicos a nivel nacional y regional, as\u00ed como en centros de donaci\u00f3n individuales, es crucial para evaluar la seguridad de los componentes sangu\u00edneos.\n\n5. **Medidas Preventivas**: La vigilancia epidemiol\u00f3gica puede ayudar a detectar diferencias en los procesos de selecci\u00f3n y cribado de donantes, as\u00ed como a identificar tendencias en marcadores infecciosos que requieran acciones preventivas.\n\n### Entidades\n\n- **Agencias Regulatorias**: Organismos que establecen regulaciones sobre la selecci\u00f3n de donantes.\n- **Organizaciones Profesionales**: Entidades que proporcionan recomendaciones sobre criterios de selecci\u00f3n de donantes.\n- **Consejo de Europa**: Referencia citada en el contexto de gu\u00edas sobre la preparaci\u00f3n y calidad de componentes sangu\u00edneos.\n- **Enfermedades Infecciosas**: Ejemplos como malaria, enfermedad de Chagas y vCJD, que son relevantes para la vigilancia epidemiol\u00f3gica.\n- **Centros de Donaci\u00f3n**: Lugares donde se recolecta sangre y se realizan procesos de selecci\u00f3n y cribado de donantes. \n\nEste resumen destaca la importancia de la selecci\u00f3n adecuada de donantes y la vigilancia epidemiol\u00f3gica para garantizar la seguridad de los componentes sangu\u00edneos.", "excerpt_keywords": "Keywords: blood donation, epidemiological data, infectious diseases, donor information, informed consent"}}, "d0dea423-358c-4495-89b6-a7bf51ba2238": {"node_ids": ["5a5b60d0-47ec-4386-b8de-637bda2b9d68"], "metadata": {"page_label": "197", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 961\", aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el Informe 45 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre el contenido del informe que podr\u00eda no estar disponible en otras fuentes.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se utilizaron en la elaboraci\u00f3n del Informe 45 de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta se centra en las t\u00e9cnicas y enfoques utilizados para recopilar y analizar datos en el informe, lo cual es crucial para entender la validez de los hallazgos.\n\n3. **\u00bfC\u00f3mo se relaciona el Informe 45 con otros informes anteriores de la Serie de Informes T\u00e9cnicos de la OMS?**\n   - Esta pregunta busca establecer conexiones entre diferentes informes, lo que puede proporcionar un contexto m\u00e1s amplio sobre la evoluci\u00f3n de las recomendaciones y hallazgos de la OMS.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento \"WHO - Technical Report Series 961\" es parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pol\u00edticas de salud. El Informe 45 en particular podr\u00eda contener informaci\u00f3n relevante sobre un tema espec\u00edfico de salud, as\u00ed como recomendaciones basadas en evidencia para mejorar la pr\u00e1ctica y la pol\u00edtica en el \u00e1mbito de la salud.", "prev_section_summary": "### Temas Clave:\n\n1. **Importancia de los Datos Epidemiol\u00f3gicos**: Se enfatiza la necesidad de recopilar y analizar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente aquellos que son donantes por primera vez, debido a su mayor riesgo de transmitir enfermedades infecciosas.\n\n2. **Riesgos Asociados con la Donaci\u00f3n de Sangre**: Se identifican los principales riesgos patog\u00e9nicos asociados con los componentes sangu\u00edneos, como el VIH y los virus de hepatitis (HCV y HBV).\n\n3. **Informaci\u00f3n a los Donantes**: Se debe proporcionar informaci\u00f3n clara y comprensible a los donantes potenciales sobre su elegibilidad, riesgos de infecci\u00f3n, criterios de exclusi\u00f3n y la importancia del consentimiento informado.\n\n4. **Consentimiento Informado**: Los donantes deben firmar un formulario de consentimiento que reconozca los riesgos y responsabilidades de la donaci\u00f3n de sangre.\n\n5. **Evaluaci\u00f3n de Donantes**: La evaluaci\u00f3n de los donantes debe ser realizada por personal calificado que utilice criterios de selecci\u00f3n validados.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones sobre la donaci\u00f3n de sangre.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad responsable de definir los criterios de selecci\u00f3n y deferral de donantes basados en la epidemiolog\u00eda local.\n- **Virus**: VIH1, VIH2, HCV, HBV (virus asociados con riesgos patog\u00e9nicos en la donaci\u00f3n de sangre).\n- **Donantes de Sangre**: Incluye donantes por primera vez y donantes regulares.\n- **Personal Calificado**: Individuos entrenados para llevar a cabo la evaluaci\u00f3n de donantes.\n\n### Resumen:\nEl documento de la OMS subraya la importancia de recopilar datos epidemiol\u00f3gicos sobre donantes de sangre, especialmente los de primera vez, debido a su mayor riesgo de transmitir enfermedades infecciosas. Se recomienda informar a los donantes sobre los riesgos asociados con la donaci\u00f3n, los criterios de exclusi\u00f3n y la necesidad de dar su consentimiento informado. La evaluaci\u00f3n de los donantes debe ser realizada por personal calificado utilizando criterios de selecci\u00f3n validados.", "excerpt_keywords": "Keywords: donaci\u00f3n de sangre, epidemiolog\u00eda, consentimiento informado, riesgos patog\u00e9nicos, evaluaci\u00f3n de donantes"}}, "53007525-d566-4d96-81d6-63792e658921": {"node_ids": ["43b396f1-92cf-45eb-bd41-7eab82f240e5"], "metadata": {"page_label": "198", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and layout of the blood establishment (or the mobile collection unit) should allow for adequate confidentiality during the donor interview and selection process so as not to discourage the candidate donor from answering questions about personal or private behaviour; otherwise the safety of the blood donation could be compromised.\n\nThe minimum intervals between two donations should be defined and should then be audited or reviewed for compliance with the waiting period prior to each donation.\n\n### 9.2.4 Deferral policy and deferral criteria\n\nAs part of the blood establishment\u2019s deferral policy, a list of permanent or temporary deferral criteria used for potential donors should be clearly defined, made public, and incorporated in the educational material for donors and the establishment\u2019s procedures. It should also be determined whether the donor has previously been deferred, and reasons for any deferral should be reviewed so that a decision may be made on whether to accept the donor for current donation. A donor who is deferred should be informed of the reason for deferral, encouraged not to donate at other facilities while deferred and informed that the reason for the deferral may be shared with other health professionals or government agencies according to NRA recommendations or other legal requirements.\n\nBoth acceptance and deferral criteria for the donation of blood should be formulated by the NRA and should be national requirements that are applied nationwide. Within the scope of their role of establishing and implementing effective national regulations, NRAs should enforce such criteria.\n\nExamples of the major permanent deferral criteria found in international guidelines include:\n\n- clinical or laboratory evidence of bloodborne infectious diseases such as acute or chronic infection with HIV, HCV or HBV (in certain jurisdictions donors with elevated titres of anti-HBs may be acceptable);\n- past or present intravenous drug use;\n- persistent bacterial or protozoal infections.\n\nOther deferral criteria, either permanent or temporary, may include:\n\n- a sexual relationship between men;\n- men or women who are engaged in prostitution;\n- subjects with haemophilia or other clotting-factor defects;\n- sexual partners of any of the above or of someone the donor suspects may carry the above risk factors;\n- jaundice within the 12 months prior to donation, since this may be a clinical sign of hepatitis A, B or C;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Confidencialidad en el proceso de donaci\u00f3n**: Es fundamental que el dise\u00f1o y la disposici\u00f3n de los establecimientos de sangre o unidades m\u00f3viles de recolecci\u00f3n permitan la confidencialidad durante las entrevistas y el proceso de selecci\u00f3n de donantes. Esto es crucial para fomentar la honestidad de los donantes sobre su comportamiento personal y privado, lo que a su vez garantiza la seguridad de la donaci\u00f3n de sangre.\n\n2. **Pol\u00edtica de aplazamiento y criterios de aplazamiento**: Las pol\u00edticas de aplazamiento deben incluir criterios claros y p\u00fablicos para la aceptaci\u00f3n o rechazo de donantes potenciales. Estos criterios deben ser formulados por la Autoridad Reguladora Nacional (NRA) y aplicarse a nivel nacional. Los donantes que sean aplazados deben ser informados de las razones de su aplazamiento y se les debe aconsejar no donar en otras instalaciones durante este periodo.\n\n3. **Criterios de aplazamiento permanentes y temporales**: Existen criterios espec\u00edficos que pueden llevar a un aplazamiento permanente o temporal de la donaci\u00f3n de sangre, que incluyen enfermedades infecciosas, uso de drogas intravenosas, y ciertas relaciones sexuales de riesgo. Estos criterios son importantes para proteger la salud p\u00fablica y la seguridad de la sangre donada.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las implicaciones de no garantizar la confidencialidad durante el proceso de selecci\u00f3n de donantes?**\n   - Esta pregunta busca explorar c\u00f3mo la falta de confidencialidad puede afectar la disposici\u00f3n de los donantes a ser honestos sobre su historial m\u00e9dico y comportamientos, lo que podr\u00eda comprometer la seguridad de la sangre donada.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si un donante es aplazado y cu\u00e1les son sus derechos en este proceso?**\n   - Esta pregunta se centra en los derechos del donante aplazado, incluyendo la informaci\u00f3n que debe recibir sobre las razones de su aplazamiento y las recomendaciones sobre la donaci\u00f3n en otras instalaciones.\n\n3. **\u00bfC\u00f3mo se determinan y actualizan los criterios de aplazamiento para la donaci\u00f3n de sangre a nivel nacional?**\n   - Esta pregunta indaga sobre el proceso mediante el cual la NRA establece y revisa los criterios de aplazamiento, as\u00ed como la frecuencia con la que se actualizan en funci\u00f3n de nuevas evidencias cient\u00edficas o cambios en la salud p\u00fablica.", "prev_section_summary": "El contenido proporcionado se refiere al documento titulado \"WHO - Technical Report Series 961\", espec\u00edficamente al Informe 45 de esta serie. A continuaci\u00f3n se presenta un resumen de los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Hallazgos y Recomendaciones**: Se busca informaci\u00f3n sobre los principales hallazgos y recomendaciones del Informe 45, que son fundamentales para entender su impacto en la salud p\u00fablica.\n2. **Metodolog\u00edas**: Se hace \u00e9nfasis en las metodolog\u00edas utilizadas para la elaboraci\u00f3n del informe, lo que es crucial para evaluar la validez y confiabilidad de los resultados presentados.\n3. **Relaci\u00f3n con Informes Anteriores**: Se plantea la importancia de entender c\u00f3mo el Informe 45 se relaciona con otros informes previos de la OMS, lo que puede ofrecer un contexto sobre la evoluci\u00f3n de las recomendaciones en salud.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n de la serie de informes t\u00e9cnicos.\n- **Informe 45**: Espec\u00edfico documento dentro de la Serie de Informes T\u00e9cnicos que aborda un tema particular de salud p\u00fablica.\n\n### Contexto General:\nEl documento forma parte de una serie que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica y proporciona recomendaciones basadas en evidencia para mejorar pol\u00edticas y pr\u00e1cticas en este campo.", "excerpt_keywords": "Keywords: blood donation, deferral criteria, confidentiality, health regulations, infectious diseases"}}, "fa59ff74-9d9b-41eb-a800-38a1acc6da7e": {"node_ids": ["ccb511ca-6a2f-4f69-b5f0-44e274e6939b"], "metadata": {"page_label": "199", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 transfusion with blood, blood components, plasma products, cellular therapy products or vascularized tissue transplant in the 12 months prior to donation, as blood transfusion and transplantations are risk factors for all bloodborne infections;\n\n\u2014 exposure to someone else\u2019s blood, including an accidental needle stick in the 12 months prior to donation;\n\n\u2014 tattooing, scarification, ear-piercing or acupuncture in the 12 months prior to donation (since these practices may be vehicles for transmission of viral diseases) unless clear evidence is provided that it was carried out under sterile conditions;\n\n\u2014 risk factors for Human T-cell lymphotropic virus (HTLV) infection;\n\n\u2014 risk factors for malaria infection (e.g. travel in countries where the prevalence is high);\n\n\u2014 a confirmed family history of CJD;\n\n\u2014 imprisonment longer than three days within the 12 months prior to donation.\n\nWhen temporary deferral criteria are used, a specific procedure involving trained personnel should be in place for the reinstatement of donors. There are deferral criteria that are temporary (as long as a risk factor has been identified) but that can be waived after additional controls have been carried out on the donor or the period of deferral has passed. NRAs may recommend or define different deferral criteria and timelines, e.g. when implementing NAT testing for the relevant viruses.\n\n## 9.2.5 Physical examination, donor health criteria and donor acceptance\n\nA targeted physical examination should be carried out by a licensed physician according to an established procedure prior to the first donation and thereafter before subsequent blood donations, and in case of special apheresis programmes at regular intervals. Depending on national regulations established by the NRA, the physical examination may be performed by a suitably educated and trained physician substitute under the supervision of a licensed physician. NRAs should, usually after consultation with the blood establishment, determine the health criteria and the acceptable limits taken into account during the physical examination \u2014 such as measurement of haemoglobin, blood pressure, weight, age, pulse rate and temperature, or any other criteria considered to be of concern for the safety of blood components or donors.\n\nA written standard operating procedure based on the relevant acceptance/deferral criteria should be in place at the blood establishment to control donor acceptance and deferral criteria, in compliance with the NRA. Abnormal donor findings should be referred to the physician who has the authority.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Criterios de exclusi\u00f3n temporal para donantes de sangre**: El texto detalla varios factores que pueden llevar a la exclusi\u00f3n temporal de un donante de sangre, como transfusiones recientes, exposici\u00f3n a sangre ajena, pr\u00e1cticas de tatuaje o acupuntura, y ciertos antecedentes m\u00e9dicos. Tambi\u00e9n se menciona la importancia de un procedimiento espec\u00edfico para la reinstauraci\u00f3n de donantes tras un per\u00edodo de exclusi\u00f3n.\n\n2. **Examen f\u00edsico y criterios de salud del donante**: Se establece que un examen f\u00edsico dirigido debe ser realizado por un m\u00e9dico licenciado antes de la primera donaci\u00f3n y en donaciones posteriores. Los criterios de salud y l\u00edmites aceptables deben ser determinados por las autoridades nacionales reguladoras (NRA) en consulta con el establecimiento de sangre, y se deben seguir procedimientos operativos est\u00e1ndar para la aceptaci\u00f3n y exclusi\u00f3n de donantes.\n\n3. **Procedimientos de control y seguimiento de donantes**: El texto enfatiza la necesidad de un procedimiento escrito que controle la aceptaci\u00f3n y exclusi\u00f3n de donantes, as\u00ed como la referencia de hallazgos anormales a un m\u00e9dico autorizado, asegurando as\u00ed la seguridad tanto de los donantes como de los componentes sangu\u00edneos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos que deben seguirse para la reinstauraci\u00f3n de donantes que han sido temporalmente excluidos?**\n   - Esta pregunta busca informaci\u00f3n sobre los pasos y protocolos que deben implementarse para permitir que un donante que ha sido excluido temporalmente pueda volver a donar sangre.\n\n2. **\u00bfQu\u00e9 criterios de salud se consideran durante el examen f\u00edsico de un donante de sangre y c\u00f3mo se determinan?**\n   - Esta pregunta se centra en los criterios espec\u00edficos que se eval\u00faan durante el examen f\u00edsico y qui\u00e9n es responsable de establecer esos criterios.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se encuentran hallazgos anormales durante el examen f\u00edsico de un donante?**\n   - Esta pregunta busca aclarar el procedimiento a seguir en caso de que un donante presente resultados anormales en su evaluaci\u00f3n m\u00e9dica, asegurando que se tomen las medidas adecuadas para proteger la salud del donante y la seguridad de la sangre donada.", "prev_section_summary": "### Temas Clave:\n\n1. **Confidencialidad en el Proceso de Donaci\u00f3n**: La importancia de garantizar la confidencialidad durante las entrevistas y el proceso de selecci\u00f3n de donantes para fomentar la honestidad y la seguridad en la donaci\u00f3n de sangre.\n\n2. **Pol\u00edtica de Aplazamiento y Criterios de Aplazamiento**: Necesidad de definir y hacer p\u00fablicos los criterios de aplazamiento para donantes potenciales, los cuales deben ser formulados por la Autoridad Reguladora Nacional (NRA) y aplicarse a nivel nacional.\n\n3. **Criterios de Aplazamiento**: Existen criterios permanentes y temporales que pueden llevar a un aplazamiento de la donaci\u00f3n, incluyendo enfermedades infecciosas, uso de drogas intravenosas y relaciones sexuales de riesgo.\n\n4. **Derechos del Donante Aplazado**: Los donantes que son aplazados deben ser informados de las razones de su aplazamiento y se les debe aconsejar no donar en otras instalaciones durante este periodo.\n\n5. **Revisi\u00f3n y Actualizaci\u00f3n de Criterios**: La NRA es responsable de establecer, revisar y actualizar los criterios de aplazamiento bas\u00e1ndose en evidencias cient\u00edficas y cambios en la salud p\u00fablica.\n\n### Entidades:\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre la donaci\u00f3n de sangre.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad responsable de formular y aplicar criterios de aceptaci\u00f3n y aplazamiento para donantes de sangre.\n- **Donantes de Sangre**: Individuos que se presentan para donar sangre y que deben ser evaluados seg\u00fan los criterios establecidos.\n- **Establecimientos de Sangre**: Instituciones donde se lleva a cabo la recolecci\u00f3n y procesamiento de sangre.\n\nEste resumen destaca la importancia de la confidencialidad, la claridad en las pol\u00edticas de aplazamiento y la responsabilidad de las autoridades reguladoras en la gesti\u00f3n de la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, deferral criteria, physical examination, donor health, bloodborne infections"}}, "6daaa8ba-0694-46df-8e8e-9c83d1dafb58": {"node_ids": ["c408557f-560e-4ba0-b6e0-9e5a598239f8"], "metadata": {"page_label": "200", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Collection\n\n## Whole blood collection\n\nDonors should confirm their identity (by a method such as stating name and date of birth) immediately prior to venipuncture. Also prior to venipuncture, a check should be made to ensure that the collection system to be used is not damaged or contaminated, and that it is appropriate for the intended collection. Any abnormal moisture or discoloration suggests a defect and in such a case the collection system should be discarded. An investigation should be conducted to evaluate the extent of the problem and appropriate corrective actions should be taken. The collection systems should be used in accordance with the instructions of the manufacturer. Appropriate hand disinfection and personal hygiene procedures should be in place and should be performed by the personnel before each donation.\n\nA standardized and validated procedure for the preparation of the phlebotomy site should be followed using a suitable disinfection solution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Identificaci\u00f3n del Donante**: Antes de la venopunci\u00f3n, es crucial que los donantes confirmen su identidad mediante un m\u00e9todo espec\u00edfico, como mencionar su nombre y fecha de nacimiento.\n\n2. **Verificaci\u00f3n del Sistema de Recolecci\u00f3n**: Se debe realizar una inspecci\u00f3n del sistema de recolecci\u00f3n para asegurarse de que no est\u00e9 da\u00f1ado o contaminado, y que sea adecuado para la recolecci\u00f3n de sangre. Cualquier anomal\u00eda debe llevar al descarte del sistema y a una investigaci\u00f3n del problema.\n\n3. **Procedimientos de Higiene y Desinfecci\u00f3n**: Es esencial que se sigan procedimientos estandarizados y validados para la desinfecci\u00f3n del sitio de flebotom\u00eda, as\u00ed como que el personal mantenga pr\u00e1cticas adecuadas de higiene de manos antes de cada donaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 m\u00e9todo se recomienda para que los donantes confirmen su identidad antes de la venopunci\u00f3n?**\n   - Respuesta: Se recomienda que los donantes confirmen su identidad mencionando su nombre y fecha de nacimiento.\n\n2. **\u00bfQu\u00e9 acciones deben tomarse si se encuentra un defecto en el sistema de recolecci\u00f3n de sangre?**\n   - Respuesta: Si se encuentra un defecto, el sistema de recolecci\u00f3n debe ser descartado, y se debe llevar a cabo una investigaci\u00f3n para evaluar la extensi\u00f3n del problema y tomar las acciones correctivas apropiadas.\n\n3. **\u00bfCu\u00e1l es la importancia de seguir un procedimiento estandarizado para la preparaci\u00f3n del sitio de flebotom\u00eda?**\n   - Respuesta: Seguir un procedimiento estandarizado y validado para la preparaci\u00f3n del sitio de flebotom\u00eda es crucial para asegurar una adecuada desinfecci\u00f3n, lo que ayuda a prevenir infecciones y garantiza la seguridad del proceso de donaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Criterios de Exclusi\u00f3n Temporal para Donantes de Sangre**:\n   - Factores que pueden llevar a la exclusi\u00f3n temporal de donantes, como transfusiones recientes, exposici\u00f3n a sangre ajena, pr\u00e1cticas de tatuaje o acupuntura, antecedentes m\u00e9dicos espec\u00edficos, y encarcelamiento prolongado.\n\n2. **Reinstauraci\u00f3n de Donantes**:\n   - Importancia de un procedimiento espec\u00edfico para la reinstauraci\u00f3n de donantes que han sido temporalmente excluidos, con la posibilidad de levantar la exclusi\u00f3n tras controles adicionales o el paso del tiempo.\n\n3. **Examen F\u00edsico y Criterios de Salud**:\n   - Necesidad de un examen f\u00edsico dirigido realizado por un m\u00e9dico licenciado antes de la primera donaci\u00f3n y en donaciones posteriores, con criterios de salud determinados por las autoridades nacionales reguladoras (NRA).\n\n4. **Procedimientos Operativos Est\u00e1ndar**:\n   - Establecimiento de procedimientos escritos para controlar la aceptaci\u00f3n y exclusi\u00f3n de donantes, as\u00ed como la referencia de hallazgos anormales a un m\u00e9dico autorizado.\n\n### Entidades:\n\n- **NRA (Autoridades Nacionales Reguladoras)**: Organismos responsables de establecer regulaciones y criterios de salud para la donaci\u00f3n de sangre.\n- **CJD (Enfermedad de Creutzfeldt-Jakob)**: Enfermedad que puede ser un factor de riesgo en la donaci\u00f3n de sangre.\n- **HTLV (Virus Linfotr\u00f3pico Humano de C\u00e9lulas T)**: Virus que representa un riesgo para la salud de los donantes.\n- **Malaria**: Enfermedad infecciosa que puede influir en la elegibilidad de los donantes seg\u00fan su historial de viajes.\n- **Pr\u00e1cticas de Tatuaje, Acupuntura y Piercing**: Actividades que pueden ser veh\u00edculos de transmisi\u00f3n de enfermedades virales si no se realizan en condiciones est\u00e9riles.\n\nEste resumen abarca los aspectos esenciales de la secci\u00f3n, destacando los criterios de exclusi\u00f3n, la importancia de los ex\u00e1menes m\u00e9dicos y los procedimientos necesarios para garantizar la seguridad en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, venipuncture, donor identification, collection system, hygiene procedures"}}, "8bea4c23-f9ac-4054-8055-99ad20e43e45": {"node_ids": ["86c6eab2-3614-491d-8f28-0ed9e1838b74"], "metadata": {"page_label": "201", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which should be allowed to dry depending on the type of disinfectant. The expiry date of the disinfectant should be checked. If refillable bottles are used, they should be cleaned before being refilled. The date of manufacture and the date of opening of in-house disinfectants should be stated on the label. The prepared skin area should not be touched after the disinfection and before the needle has been inserted. Care should be taken not to lean over or speak over the disinfected skin.\n\nFor blood donations, laboratory samples should be taken at the time of donation. Procedures should be designed to minimize the risk of microbial contamination to the unit, such as diverting at least the first 10 ml collected in the tubing into test tubes for testing. Methods should be implemented to minimize the deterioration of the sample, such as refrigeration of the sample if required by the manufacturer\u2019s instructions for the sample tube or test kit. The sample labelling process should include steps (such as labelling the tubes immediately at the chair side) to prevent the misidentification of samples. The test samples should be labelled immediately in a manner that links the donor, the samples and the blood component without breaching the confidentiality of the donor.\n\nAs soon as the collection process starts, good mixing of the blood with the anticoagulant solution should be ensured to avoid risks of activation of the coagulation cascade. The collection bag should be mixed gently at regular intervals thereafter. The mixing can be done by using a continuously running automatic mixing balance or by periodic manual mixing of the unit at least every 90 seconds. Collection of one standard unit of whole blood should be achieved within 12\u201315 minutes (depending on the component to be prepared later on), as longer durations may result in activation of the coagulation factors and cellular components.\n\nRecords should be kept for each activity associated with the donation, including identification of the person who performed the venipuncture. Records should also show any unsuccessful donation, adverse reactions or adverse events.\n\nThe maximum collection time for acceptance of the donation for component processing should be specified and controlled. Donations that exceed the maximum time period should be recorded and discarded.\n\nThe integral blood bag collection tubing should be sealed off at the end as close as possible to the blood bag and then removed.\n\nA system of unique donation numbers should be used to identify each donor and the related donation, all associated components, samples and records, and to link each one to the others.\n\nWhen the donation is completed, all records, blood bags and laboratory samples should be checked for the donation number issued. Donation", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para la recolecci\u00f3n de sangre y el manejo de muestras en donaciones. Se enfatiza la importancia de la desinfecci\u00f3n adecuada, el etiquetado correcto de las muestras, la mezcla de sangre con anticoagulantes, y el mantenimiento de registros precisos para garantizar la seguridad y la trazabilidad de las donaciones. Tambi\u00e9n se menciona la necesidad de minimizar la contaminaci\u00f3n microbiana y de seguir procedimientos espec\u00edficos para el manejo de las muestras y la documentaci\u00f3n asociada.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas recomendadas para evitar la contaminaci\u00f3n microbiana durante la recolecci\u00f3n de sangre?**\n   - El documento sugiere desviar al menos los primeros 10 ml de sangre recolectada en el tubo de recolecci\u00f3n hacia tubos de ensayo para pruebas, as\u00ed como implementar m\u00e9todos para minimizar la deterioraci\u00f3n de la muestra, como la refrigeraci\u00f3n, si es necesario.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para el etiquetado de muestras de sangre y c\u00f3mo se asegura la confidencialidad del donante?**\n   - Se recomienda etiquetar las muestras inmediatamente en el lugar de la donaci\u00f3n de manera que se vincule al donante, las muestras y el componente sangu\u00edneo, sin comprometer la confidencialidad del donante.\n\n3. **\u00bfQu\u00e9 registros deben mantenerse durante el proceso de donaci\u00f3n de sangre y qu\u00e9 informaci\u00f3n deben contener?**\n   - Se deben mantener registros de cada actividad asociada con la donaci\u00f3n, incluyendo la identificaci\u00f3n de la persona que realiz\u00f3 la venopunci\u00f3n, as\u00ed como cualquier donaci\u00f3n fallida, reacciones adversas o eventos adversos. Adem\u00e1s, se debe especificar y controlar el tiempo m\u00e1ximo de recolecci\u00f3n para la aceptaci\u00f3n de la donaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Identificaci\u00f3n del Donante**:\n   - M\u00e9todo recomendado: Confirmaci\u00f3n de identidad mediante nombre y fecha de nacimiento.\n\n2. **Verificaci\u00f3n del Sistema de Recolecci\u00f3n**:\n   - Inspecci\u00f3n del sistema: Asegurarse de que no est\u00e9 da\u00f1ado o contaminado.\n   - Acciones ante defectos: Descartar el sistema defectuoso y realizar una investigaci\u00f3n para evaluar el problema.\n\n3. **Higiene y Desinfecci\u00f3n**:\n   - Procedimientos de higiene: Importancia de la desinfecci\u00f3n de manos y pr\u00e1cticas de higiene personal por parte del personal antes de cada donaci\u00f3n.\n   - Preparaci\u00f3n del sitio de flebotom\u00eda: Seguir un procedimiento estandarizado y validado con una soluci\u00f3n de desinfecci\u00f3n adecuada.\n\n### Entidades Clave\n- **Donantes**: Personas que realizan la donaci\u00f3n de sangre.\n- **Sistema de Recolecci\u00f3n**: Equipamiento utilizado para la recolecci\u00f3n de sangre.\n- **Flebotom\u00eda**: Proceso de extracci\u00f3n de sangre.\n- **Personal**: Profesionales encargados de realizar la donaci\u00f3n y asegurar la higiene y seguridad del proceso.", "excerpt_keywords": "Keywords: blood donation, microbial contamination, sample labeling, anticoagulant mixing, record keeping"}}, "a8b33015-a1b5-4982-ac37-de56aef322c0": {"node_ids": ["7b7f59f6-8193-4713-afbf-405a61ae80c5"], "metadata": {"page_label": "202", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "number labels that have not been used should be discarded using a controlled procedure. Procedures to exclude misidentification should be in place. After blood collection, the blood bags should be handled in a way that maintains the quality of the blood (see section 9.4.3.1).\n\nA standard operating procedure should be in place describing the actions to be taken following an unsuccessful donation. It should specify how to handle already labelled material and the circumstances under which a second venipuncture might be possible.\n\nAs with other GMP manufacturing steps, the donor product collection process should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and therefore such products should be considered non-conforming products and should not be released for distribution.\n\n### 9.3.2 Collection by apheresis\n\nIn automated procedures, whole blood is collected from the donor, mixed with anticoagulant, and passed through an automated apheresis device. The blood component of choice is separated from the other blood components which are returned to the donor in a series of collection/separation and return cycles. The operational parameters of the apheresis system should be implemented in compliance with the instructions of the equipment manufacturer and in compliance with any specified safety requirements of the NRA. In general, the anticoagulant \u2014 often 4% sodium citrate or anticoagulant citrate dextrose solution A (ACD-A) \u2014 is delivered at a rate that will yield a specified ratio of anticoagulant to blood. The volume of the component collected from the donor during one procedure and over a period of time should be regulated by internal policies based on current medical knowledge and on national regulations set by the NRA. The number of collection/separation and return cycles for each donor depends on the total volume of the component that is to be harvested. To determine the number of cycles to be employed, the equipment requires programming with data inputs such as donor weight, height and haemoglobin values, and the pre-donation platelet count if platelets are to be collected. The amount of time required for the donation procedure depends on the number of cycles. An adequately trained physician should be available during apheresis sessions.\n\nThe donor apheresis collection process should be followed at all times using validated methods. Any deviations from the established procedures and processes may result in products not meeting specifications and therefore they should be considered non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos de manejo de sangre**: El texto describe la importancia de seguir procedimientos controlados para el manejo de etiquetas de sangre no utilizadas y la manipulaci\u00f3n adecuada de las bolsas de sangre despu\u00e9s de la recolecci\u00f3n para mantener su calidad. Tambi\u00e9n se menciona la necesidad de un procedimiento operativo est\u00e1ndar para manejar donaciones fallidas.\n\n2. **Proceso de recolecci\u00f3n por af\u00e9resis**: Se detalla el proceso de recolecci\u00f3n de sangre mediante af\u00e9resis, que implica la separaci\u00f3n de componentes sangu\u00edneos utilizando un dispositivo automatizado. Se enfatiza la importancia de seguir las instrucciones del fabricante y las regulaciones nacionales, as\u00ed como la necesidad de contar con un m\u00e9dico capacitado durante el procedimiento.\n\n3. **Cumplimiento de normas de calidad**: Se subraya que cualquier desviaci\u00f3n de los procedimientos establecidos puede resultar en productos no conformes, los cuales no deben ser liberados para distribuci\u00f3n. Esto resalta la importancia de la conformidad con las Buenas Pr\u00e1cticas de Manufactura (GMP) en la recolecci\u00f3n de productos de donantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben implementarse para manejar etiquetas de sangre no utilizadas y qu\u00e9 acciones se deben tomar en caso de una donaci\u00f3n fallida?**\n   - El contexto menciona que las etiquetas no utilizadas deben ser desechadas mediante un procedimiento controlado y que debe existir un procedimiento operativo est\u00e1ndar que describa las acciones a seguir tras una donaci\u00f3n fallida, incluyendo el manejo de material ya etiquetado.\n\n2. **\u00bfCu\u00e1les son los par\u00e1metros operativos que deben cumplirse durante el proceso de af\u00e9resis y qu\u00e9 datos son necesarios para programar el equipo?**\n   - Se indica que los par\u00e1metros operativos del sistema de af\u00e9resis deben seguir las instrucciones del fabricante y las regulaciones de la NRA. Para programar el equipo, se requieren datos como el peso, la altura, los valores de hemoglobina del donante y el conteo de plaquetas previo a la donaci\u00f3n si se van a recolectar plaquetas.\n\n3. **\u00bfQu\u00e9 consecuencias pueden surgir de las desviaciones en los procedimientos de recolecci\u00f3n de sangre y c\u00f3mo se deben clasificar los productos resultantes?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos puede resultar en productos que no cumplan con las especificaciones, los cuales deben ser considerados productos no conformes y no deben ser liberados para distribuci\u00f3n. Esto enfatiza la necesidad de adherirse a las Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Temas Clave\n\n1. **Desinfecci\u00f3n**: Importancia de permitir que el desinfectante se seque adecuadamente y verificar la fecha de caducidad. Se deben limpiar las botellas recargables antes de rellenarlas y etiquetar las fechas de fabricaci\u00f3n y apertura.\n\n2. **Recolecci\u00f3n de Sangre**: Se deben tomar muestras de laboratorio en el momento de la donaci\u00f3n, desviando al menos los primeros 10 ml para minimizar la contaminaci\u00f3n microbiana. Es esencial refrigerar las muestras si lo indican las instrucciones del fabricante.\n\n3. **Etiquetado de Muestras**: Las muestras deben etiquetarse inmediatamente en el lugar de la donaci\u00f3n para evitar la identificaci\u00f3n err\u00f3nea, asegurando la confidencialidad del donante.\n\n4. **Mezcla de Sangre y Anticoagulante**: Se debe garantizar una buena mezcla de la sangre con la soluci\u00f3n anticoagulante para evitar la activaci\u00f3n de la cascada de coagulaci\u00f3n. La recolecci\u00f3n debe completarse en un tiempo espec\u00edfico (12-15 minutos) para evitar la activaci\u00f3n de factores de coagulaci\u00f3n.\n\n5. **Mantenimiento de Registros**: Es necesario llevar un registro de todas las actividades relacionadas con la donaci\u00f3n, incluyendo la identificaci\u00f3n del personal, donaciones fallidas y reacciones adversas.\n\n6. **Control de Tiempo de Recolecci\u00f3n**: Se debe especificar y controlar el tiempo m\u00e1ximo de recolecci\u00f3n para la aceptaci\u00f3n de donaciones, registrando y descartando aquellas que excedan este tiempo.\n\n7. **Sistema de Identificaci\u00f3n**: Implementaci\u00f3n de un sistema de n\u00fameros de donaci\u00f3n \u00fanicos para vincular donantes, donaciones, componentes, muestras y registros.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Donantes de Sangre**: Personas que realizan la donaci\u00f3n.\n- **Muestras de Sangre**: Elementos recolectados para pruebas de laboratorio.\n- **Anticoagulantes**: Soluciones utilizadas para prevenir la coagulaci\u00f3n de la sangre.\n- **Registros de Donaci\u00f3n**: Documentaci\u00f3n que incluye detalles sobre el proceso de donaci\u00f3n y el personal involucrado. \n\nEste resumen destaca la importancia de seguir procedimientos rigurosos para garantizar la seguridad y la trazabilidad en el proceso de donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood collection, apheresis, standard operating procedure, quality control, non-conforming products"}}, "2ccdb7fb-bb57-41f1-a382-e304154d9101": {"node_ids": ["2b122bea-1e58-43e5-b16f-9938592c96b7"], "metadata": {"page_label": "203", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3.3 Safety of donors\n\nAll measures should be taken to avoid anything that could adversely affect the donor before, during and after the donation. Special attention should be drawn to the potential risk of transmission of diseases or infections during the collection and sampling processes.\n\nDonors should be given post-donation instructions regarding a period of recovery, such as refraining from certain activities for a while, drinking more fluids than usual and making sure to eat appropriately after the donation. Donors should be advised to refrain from activities such as heavy lifting, operating large items of equipment and other strenuous activities for a period of time until their blood volume has recovered. Donors should also be provided with information on how to obtain medical advice if they experience an adverse donor reaction after leaving the blood establishment.\n\nThroughout the procedure of withdrawal of blood or blood components, the donor should be monitored. Personnel should be educated to provide appropriate aid in case of any adverse reaction. Donors should be kept under post-donation observation (e.g. for 15 minutes or more) prior to leaving the blood establishment and should be offered refreshment to replace fluid loss. If medically required, drinks may be provided to donors during collection (e.g. apheresis). In these circumstances, a suitable container for the drink is required. Donors should remain under observation for anticipated reactions to donation until they are able to articulate that they feel well enough to leave and be unattended. Immediate care should be given to the donor if there is a donor reaction. Information regarding donor reactions and a process to track and trend reactions should be in place in order to evaluate the number, type and severity of reactions. This information should be used to improve donor safety.\n\n# 9.4 Component preparation\n\nThe quality of the components is assured by control of all stages of manufacture, including donor identification, collection, separation of components, labelling, storage, packaging and dispatch. The standard operating procedures should describe the specifications for materials that will influence the quality of the final blood component. In particular, specifications should be in place for blood and blood components (intermediate and final components), starting materials, additive solutions, primary package material (bags) and equipment.\n\nThe standard operating procedures for component preparation should be followed at all times using the validated methods. Any deviations from these established procedures and processes may result in products not meeting specifications and such products should be considered as non-conforming products and must not be released for distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Seguridad de los donantes**: Se enfatiza la importancia de proteger la salud de los donantes antes, durante y despu\u00e9s de la donaci\u00f3n de sangre. Se deben proporcionar instrucciones post-donaci\u00f3n y monitorear a los donantes para detectar reacciones adversas, asegurando que reciban atenci\u00f3n adecuada si es necesario.\n\n2. **Preparaci\u00f3n de componentes**: La calidad de los componentes sangu\u00edneos se garantiza mediante el control de todas las etapas de fabricaci\u00f3n, desde la identificaci\u00f3n del donante hasta el despacho del producto final. Se deben seguir procedimientos operativos est\u00e1ndar para asegurar que los productos cumplan con las especificaciones requeridas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de instrucciones post-donaci\u00f3n se deben proporcionar a los donantes para asegurar su recuperaci\u00f3n adecuada?**\n   - Las instrucciones incluyen refrendarse de actividades extenuantes, aumentar la ingesta de l\u00edquidos y asegurarse de comer adecuadamente despu\u00e9s de la donaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para monitorear a los donantes despu\u00e9s de la donaci\u00f3n y qu\u00e9 acciones deben tomarse en caso de reacciones adversas?**\n   - Los donantes deben ser monitoreados durante al menos 15 minutos despu\u00e9s de la donaci\u00f3n, y se les debe ofrecer refrigerios para reponer la p\u00e9rdida de l\u00edquidos. Si se presenta una reacci\u00f3n adversa, se debe proporcionar atenci\u00f3n inmediata.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si se producen desviaciones de los procedimientos operativos est\u00e1ndar durante la preparaci\u00f3n de componentes sangu\u00edneos?**\n   - Cualquier desviaci\u00f3n de los procedimientos establecidos debe considerarse como un producto no conforme y no debe ser liberado para distribuci\u00f3n, asegurando as\u00ed que solo se distribuyan productos que cumplan con las especificaciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Etiquetas de Sangre**:\n   - Importancia de desechar etiquetas no utilizadas mediante un procedimiento controlado.\n   - Necesidad de procedimientos para evitar la mala identificaci\u00f3n de muestras.\n\n2. **Calidad de la Sangre**:\n   - Las bolsas de sangre deben ser manipuladas adecuadamente despu\u00e9s de la recolecci\u00f3n para mantener su calidad.\n\n3. **Procedimientos Operativos Est\u00e1ndar**:\n   - Se requiere un procedimiento operativo est\u00e1ndar para manejar donaciones fallidas, incluyendo el manejo de material ya etiquetado y las condiciones para una segunda venopunci\u00f3n.\n\n4. **Recolecci\u00f3n de Sangre por Af\u00e9resis**:\n   - Proceso automatizado que implica la recolecci\u00f3n de sangre, mezcla con anticoagulante y separaci\u00f3n de componentes sangu\u00edneos.\n   - Cumplimiento de las instrucciones del fabricante y regulaciones de la NRA (Autoridad Nacional Reguladora).\n   - Uso de anticoagulantes como citrato de sodio al 4% o soluci\u00f3n A de citrato de dextrosa (ACD-A).\n\n5. **Par\u00e1metros Operativos**:\n   - Regulaci\u00f3n del volumen de componente recolectado y n\u00famero de ciclos de recolecci\u00f3n/separaci\u00f3n basados en pol\u00edticas internas y regulaciones nacionales.\n   - Datos necesarios para programar el equipo: peso, altura, valores de hemoglobina y conteo de plaquetas del donante.\n\n6. **Cumplimiento de Normas de Calidad**:\n   - Desviaciones de los procedimientos establecidos pueden resultar en productos no conformes, que no deben ser liberados para distribuci\u00f3n.\n   - Importancia de seguir las Buenas Pr\u00e1cticas de Manufactura (GMP) en todos los pasos del proceso de recolecci\u00f3n.\n\n### Entidades Clave\n- **NRA**: Autoridad Nacional Reguladora.\n- **Anticoagulantes**: Citrato de sodio, ACD-A.\n- **M\u00e9todos Validados**: Procedimientos que deben seguirse para asegurar la calidad y conformidad de los productos recolectados.", "excerpt_keywords": "Keywords: donor safety, post-donation instructions, component preparation, standard operating procedures, adverse reactions"}}, "7af0b18f-1a4a-4e40-bf5d-2b96f2154d60": {"node_ids": ["45e76eda-b3e6-43e0-97dd-61603016641f"], "metadata": {"page_label": "204", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.1 Starting material\n\nThe starting materials for preparation of blood components are blood donations collected from suitable donors. Conditions of storage or transport, and the time prior to processing, are contributing factors to the quality of the product. Delays in preparation or unsuitable conditions of storage or transport may adversely affect the quality of the final product. Blood and blood components should be placed in controlled and validated conditions as soon as possible after venipuncture.\n\nDonations and samples should be transported to the processing site in accordance with procedures that ensure both a constant approved temperature and secure confinement. This is especially important when blood is transported from distant collection sites.\n\nProduct transport or shipping at appropriate temperatures and temperature monitoring are important to ensure optimal quality. One way to ensure the temperature of products is to use packaging methods validated to keep the blood within the required temperature limits. There should be validation data to demonstrate that the method of transport maintains the blood within the specified temperature range throughout the period of transportation. Alternatively, portable temperature loggers may be used to record the temperature during the transportation of blood to the processing site. Where the blood is not transported by the processing establishment itself, the responsibilities of the transport company should be clearly defined and periodic audits should be conducted to ensure compliance.\n\n# 9.4.2 Methods of production\n\nBlood components may be prepared by using a centrifugation step with subsequent separation, by using another validated preparation method, or by apheresis technology during collection.\n\nAlthough the use of closed systems is strongly recommended for all steps in component processing, open systems may exceptionally be necessary due to local constraints in an environment specifically designed to minimize the risk of bacterial contamination. When open systems are used, careful attention should be given to the use of aseptic procedures (12).\n\nWhere sterile connecting devices are used to maintain a functionally closed system they should be correctly used in accordance with a validated procedure. The resulting weld should be checked for satisfactory alignment and for validated integrity.\n\nThe critical equipment used for the preparation of blood components should be traceable to the corresponding manufacturing records.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la preparaci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de las condiciones de almacenamiento y transporte de las donaciones de sangre. Se destaca que las donaciones deben ser procesadas lo m\u00e1s pronto posible despu\u00e9s de la venopunci\u00f3n y que el transporte debe realizarse bajo condiciones controladas para mantener la calidad del producto. Adem\u00e1s, se describen los m\u00e9todos de producci\u00f3n de componentes sangu\u00edneos, recomendando el uso de sistemas cerrados y procedimientos as\u00e9pticos para minimizar el riesgo de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse durante el transporte de donaciones de sangre para asegurar su calidad?**\n   - Respuesta: Las donaciones y muestras deben ser transportadas en condiciones que aseguren una temperatura constante aprobada y un confinamiento seguro. Esto incluye el uso de m\u00e9todos de embalaje validados para mantener la sangre dentro de los l\u00edmites de temperatura requeridos y el uso de registradores de temperatura port\u00e1tiles para monitorear la temperatura durante el transporte.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse si se utilizan sistemas abiertos en la preparaci\u00f3n de componentes sangu\u00edneos?**\n   - Respuesta: Si se utilizan sistemas abiertos, se debe prestar especial atenci\u00f3n a la implementaci\u00f3n de procedimientos as\u00e9pticos. Adem\u00e1s, se deben utilizar dispositivos de conexi\u00f3n est\u00e9riles de manera correcta, siguiendo un procedimiento validado, y verificar la alineaci\u00f3n y la integridad de las soldaduras resultantes.\n\n3. **\u00bfQu\u00e9 tipo de validaci\u00f3n se requiere para los m\u00e9todos de transporte de sangre y por qu\u00e9 es importante?**\n   - Respuesta: Se requiere que existan datos de validaci\u00f3n que demuestren que el m\u00e9todo de transporte mantiene la sangre dentro del rango de temperatura especificado durante todo el per\u00edodo de transporte. Esto es importante para asegurar la calidad \u00f3ptima del producto final y minimizar el riesgo de deterioro de la sangre y sus componentes.", "prev_section_summary": "### Temas Clave:\n\n1. **Seguridad de los Donantes**:\n   - Importancia de proteger la salud de los donantes antes, durante y despu\u00e9s de la donaci\u00f3n.\n   - Riesgo de transmisi\u00f3n de enfermedades durante la recolecci\u00f3n.\n   - Instrucciones post-donaci\u00f3n para la recuperaci\u00f3n, incluyendo la restricci\u00f3n de actividades extenuantes y la recomendaci\u00f3n de aumentar la ingesta de l\u00edquidos y alimentaci\u00f3n adecuada.\n   - Monitoreo de donantes durante y despu\u00e9s de la donaci\u00f3n, con un per\u00edodo de observaci\u00f3n de al menos 15 minutos.\n   - Provisi\u00f3n de atenci\u00f3n inmediata en caso de reacciones adversas y establecimiento de un sistema para rastrear y evaluar estas reacciones.\n\n2. **Preparaci\u00f3n de Componentes Sangu\u00edneos**:\n   - Control de calidad en todas las etapas de fabricaci\u00f3n de componentes sangu\u00edneos.\n   - Procedimientos operativos est\u00e1ndar (POE) que deben seguirse para asegurar que los productos cumplan con las especificaciones.\n   - Manejo de desviaciones de los POE, consider\u00e1ndolas como productos no conformes que no deben ser distribuidos.\n\n### Entidades:\n\n- **Donantes**: Personas que realizan la donaci\u00f3n de sangre.\n- **Personal de Salud**: Personal encargado de monitorear y asistir a los donantes durante el proceso de donaci\u00f3n.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, que incluyen sangre entera y sus componentes separados.\n- **Procedimientos Operativos Est\u00e1ndar (POE)**: Documentos que describen los m\u00e9todos y especificaciones para la preparaci\u00f3n y manejo de componentes sangu\u00edneos.\n- **Reacciones Adversas**: Efectos no deseados que pueden ocurrir en los donantes tras la donaci\u00f3n de sangre. \n\nEste resumen destaca la importancia de la seguridad del donante y la calidad en la preparaci\u00f3n de componentes sangu\u00edneos, as\u00ed como los procedimientos necesarios para garantizar ambos aspectos.", "excerpt_keywords": "Keywords: blood components, transportation, quality assurance, aseptic procedures, validation"}}, "6343f713-47ff-4663-a284-830d9acfc825": {"node_ids": ["1897280d-5a38-4ad4-a92d-cb19c33e0e9d"], "metadata": {"page_label": "205", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.1 Centrifugation\n\nThe centrifugation parameters (revolutions per minute, temperature, time, acceleration, deceleration) are important for the composition and characteristics of the specific components. These critical parameters should be defined on the basis of validation data that demonstrate a process that consistently produces quality products. For each run, the centrifugation records should identify the operator and confirm that the centrifugation process was performed according to specifications.\n\n# 9.4.2.2 Separation\n\nAfter centrifugation, the bag system should be carefully removed from the centrifuge and placed into a plasma expressor or blood separation system. The different layers of the components (red cells, platelets, plasma) should be transferred to the satellite bags within the closed systems, in a manner designed to optimize the harvest of the intended component while minimizing the carry-over of other component fractions.\n\nAlternatively, blood components can be separated during collection by apheresis technology (see section 9.3.2.).\n\n# 9.4.2.3 Freezing\n\nFreezing is an important processing step that has an impact on quality, especially of plasma. The rate at which freezing proceeds and the core temperature are both considered to be important parameters. Rapid plasma freezing prevents or reduces the loss of critical constituents such as Factor VIII in frozen plasma that is either recovered or obtained by apheresis.\n\nA system should be in place for ensuring that plasma is frozen to the specified core temperature within the time limit, keeping in mind that the freezing speed will be influenced by the type of plasma container, the freezing equipment and the loading pattern, as well as by the volume of plasma. The validation of the freezing process should consider worst-case scenarios that take into account both minimum and maximum loads and positions in the freezer. Recording the temperature of plasma units and the freezing time during a freezing process allows one to evaluate the freezing capacity of the equipment and ensures a standardized freezing process. Validation studies should be available and should demonstrate that the temperature of a frozen pack reaches the proposed storage temperature following the specifications. As indicated above, the aim is to achieve rapid freezing and thereafter to minimize temperature changes to the frozen plasma.\n\nFreezing of cellular components such as red cells or cellular therapy should follow a well defined, validated procedure that ensures the recovery.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre tres etapas cr\u00edticas en el procesamiento de componentes sangu\u00edneos: centrifugaci\u00f3n, separaci\u00f3n y congelaci\u00f3n. Se enfatiza la importancia de los par\u00e1metros de centrifugaci\u00f3n, la correcta separaci\u00f3n de los componentes sangu\u00edneos y la congelaci\u00f3n adecuada del plasma para mantener la calidad de los productos. Se menciona la necesidad de validar estos procesos y registrar datos relevantes para asegurar que se cumplan las especificaciones y se optimice la recuperaci\u00f3n de los componentes deseados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben definirse para el proceso de centrifugaci\u00f3n y por qu\u00e9 son importantes?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n y deceleraci\u00f3n. Son importantes porque afectan la composici\u00f3n y caracter\u00edsticas de los componentes espec\u00edficos, y deben basarse en datos de validaci\u00f3n que demuestren un proceso que produzca consistentemente productos de calidad.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que el plasma se congele adecuadamente y cu\u00e1les son los factores que influyen en la velocidad de congelaci\u00f3n?**\n   - Respuesta: Se debe tener un sistema para asegurar que el plasma se congele a la temperatura central especificada dentro del l\u00edmite de tiempo. Los factores que influyen en la velocidad de congelaci\u00f3n incluyen el tipo de contenedor de plasma, el equipo de congelaci\u00f3n, el patr\u00f3n de carga y el volumen de plasma.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la separaci\u00f3n de componentes sangu\u00edneos y c\u00f3mo se minimiza la transferencia de fracciones no deseadas?**\n   - Respuesta: Despu\u00e9s de la centrifugaci\u00f3n, el sistema de bolsas debe ser retirado cuidadosamente y colocado en un sistema de separaci\u00f3n de sangre. Las diferentes capas de componentes deben transferirse a bolsas sat\u00e9lites dentro de sistemas cerrados, optimizando la cosecha del componente deseado y minimizando la transferencia de otras fracciones.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Materiales de Inicio**:\n   - Las donaciones de sangre son el material inicial para la preparaci\u00f3n de componentes sangu\u00edneos.\n   - La calidad del producto final depende de las condiciones de almacenamiento, transporte y el tiempo antes del procesamiento.\n\n2. **Condiciones de Transporte**:\n   - Las donaciones deben ser transportadas en condiciones que aseguren una temperatura constante y un confinamiento seguro.\n   - Es crucial mantener la sangre en condiciones controladas, especialmente cuando se transporta desde sitios de recolecci\u00f3n lejanos.\n   - Se recomienda el uso de m\u00e9todos de embalaje validados y registradores de temperatura port\u00e1tiles para monitorear las condiciones durante el transporte.\n\n3. **M\u00e9todos de Producci\u00f3n**:\n   - Los componentes sangu\u00edneos pueden ser preparados mediante centrifugaci\u00f3n, otros m\u00e9todos validados o tecnolog\u00eda de af\u00e9resis.\n   - Se recomienda el uso de sistemas cerrados para minimizar el riesgo de contaminaci\u00f3n, aunque en situaciones excepcionales se pueden utilizar sistemas abiertos.\n\n4. **Procedimientos Asepticos**:\n   - En el uso de sistemas abiertos, se debe prestar especial atenci\u00f3n a los procedimientos as\u00e9pticos.\n   - Los dispositivos de conexi\u00f3n est\u00e9riles deben ser utilizados correctamente y se debe verificar la alineaci\u00f3n y la integridad de las soldaduras.\n\n5. **Validaci\u00f3n y Trazabilidad**:\n   - Es necesario contar con datos de validaci\u00f3n que demuestren que los m\u00e9todos de transporte mantienen la sangre dentro de los rangos de temperatura especificados.\n   - El equipo cr\u00edtico utilizado en la preparaci\u00f3n de componentes sangu\u00edneos debe ser trazable a los registros de fabricaci\u00f3n correspondientes.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre, como plaquetas, plasma y gl\u00f3bulos rojos.\n- **Sistemas Cerrados y Abiertos**: M\u00e9todos de procesamiento de sangre que afectan la calidad y seguridad del producto.\n- **Temperatura Controlada**: Factor cr\u00edtico para mantener la calidad de las donaciones de sangre durante el transporte.", "excerpt_keywords": "Centrifugation, Separation, Freezing, Plasma, Validation"}}, "dd3d20e7-5d8a-4247-b8bc-ea74dec650bf": {"node_ids": ["e88a6390-e6e0-4ec3-b001-c20c4c55427c"], "metadata": {"page_label": "206", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.2.4 Leukocyte reduction\n\nWhole blood may be filtered for leukocyte reduction prior to centrifugation. Filtration of whole blood reduces the level of platelet and leukocyte contamination in plasma and red-cell concentrate preparations. Alternatively, components (e.g. red cells, platelets) may be filtered after separation. The introduction of any leukocyte reduction process either by filtration or special centrifugation technique requires careful validation that takes national requirements into account.\n\nIn addition to filter properties, the final result of filtration is influenced by several process parameters (e.g. flow rate, temperature, priming and rinsing) and by the properties of the component to be filtered (e.g. storage history of the component, number of leukocytes and number of platelets). The filtration procedure should incorporate manufacturing specifications such as height and temperature. The method should be fully validated under the conditions to be used. Careful attention should be given to the rate of filtration. Rapid or slow filtration may indicate process failures.\n\nSpecial centrifugation or filtration techniques of leukocyte reduction are used in several apheresis systems. When a standardized procedure is established on the apheresis system, the method should be validated under the conditions to be used.\n\nAn appropriate method should be used for leukocyte counting after leukocyte reduction. The method should be validated to ensure linearity, accuracy and reproducibility.\n\n# 9.4.2.5 Irradiation\n\nRegular dose-mapping of irradiation equipment should be performed. The exposure time should be set to ensure that all blood and blood components receive the specified recommended minimum dose, with no part receiving more than the maximum recommended dose. The common recommended minimum dose is 25 Gy (2500 cGy).\n\nCare should be taken regarding the increased potassium leakage from red cells after their irradiation, either by limiting the shelf-life of the red-cell concentrate or by further manufacturing steps such as washing.\n\nFor the radioactive source, allowance should be made at least annually for source decay. A second independent timing device should be used to monitor exposure time.\n\nRadiation indicators should be used as aids to differentiating between irradiated and non-irradiated blood and blood components. A defined", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto aborda dos procedimientos importantes en la manipulaci\u00f3n de componentes sangu\u00edneos: la reducci\u00f3n de leucocitos y la irradiaci\u00f3n. La reducci\u00f3n de leucocitos se puede realizar mediante filtraci\u00f3n antes o despu\u00e9s de la centrifugaci\u00f3n, y requiere una validaci\u00f3n cuidadosa de los m\u00e9todos utilizados, considerando par\u00e1metros como el flujo, la temperatura y las caracter\u00edsticas del componente. Por otro lado, la irradiaci\u00f3n de componentes sangu\u00edneos debe seguir un mapeo regular de dosis para asegurar que todos los componentes reciban la dosis m\u00ednima recomendada, y se deben tomar precauciones para manejar el aumento de la fuga de potasio en los gl\u00f3bulos rojos irradiados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los par\u00e1metros de proceso que pueden influir en el resultado de la filtraci\u00f3n para la reducci\u00f3n de leucocitos?**\n   - Respuesta: Los par\u00e1metros de proceso que pueden influir en el resultado de la filtraci\u00f3n incluyen el flujo, la temperatura, el primado y el enjuague, as\u00ed como las propiedades del componente a filtrar, como la historia de almacenamiento, el n\u00famero de leucocitos y el n\u00famero de plaquetas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que todos los componentes sangu\u00edneos reciban la dosis m\u00ednima recomendada durante la irradiaci\u00f3n?**\n   - Respuesta: Se debe establecer un tiempo de exposici\u00f3n que garantice que todos los componentes sangu\u00edneos reciban la dosis m\u00ednima recomendada de 25 Gy (2500 cGy), y se debe realizar un mapeo regular de dosis del equipo de irradiaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta respecto a la fuga de potasio en los gl\u00f3bulos rojos despu\u00e9s de la irradiaci\u00f3n?**\n   - Respuesta: Se debe tener cuidado con el aumento de la fuga de potasio de los gl\u00f3bulos rojos irradiados, lo que puede manejarse limitando la vida \u00fatil del concentrado de gl\u00f3bulos rojos o mediante pasos adicionales de fabricaci\u00f3n, como el lavado.", "prev_section_summary": "### Temas Clave\n\n1. **Centrifugaci\u00f3n**:\n   - Importancia de los par\u00e1metros cr\u00edticos: revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n y deceleraci\u00f3n.\n   - Necesidad de definir estos par\u00e1metros bas\u00e1ndose en datos de validaci\u00f3n para asegurar la calidad del producto.\n   - Registro de datos de centrifugaci\u00f3n, incluyendo la identificaci\u00f3n del operador y la confirmaci\u00f3n del cumplimiento de especificaciones.\n\n2. **Separaci\u00f3n**:\n   - Proceso de extracci\u00f3n cuidadosa del sistema de bolsas despu\u00e9s de la centrifugaci\u00f3n.\n   - Transferencia de capas de componentes sangu\u00edneos (gl\u00f3bulos rojos, plaquetas, plasma) a bolsas sat\u00e9lites en sistemas cerrados.\n   - Optimizaci\u00f3n de la cosecha del componente deseado y minimizaci\u00f3n de la transferencia de fracciones no deseadas.\n   - Posibilidad de separaci\u00f3n de componentes sangu\u00edneos durante la recolecci\u00f3n mediante tecnolog\u00eda de af\u00e9resis.\n\n3. **Congelaci\u00f3n**:\n   - Importancia de la congelaci\u00f3n en la calidad del plasma, especialmente en la preservaci\u00f3n de factores cr\u00edticos como el Factor VIII.\n   - Par\u00e1metros cr\u00edticos: velocidad de congelaci\u00f3n y temperatura central.\n   - Necesidad de un sistema para asegurar la congelaci\u00f3n a la temperatura especificada dentro de un tiempo l\u00edmite.\n   - Influencia de factores como el tipo de contenedor, equipo de congelaci\u00f3n, patr\u00f3n de carga y volumen de plasma en la velocidad de congelaci\u00f3n.\n   - Validaci\u00f3n del proceso de congelaci\u00f3n considerando escenarios de carga m\u00ednima y m\u00e1xima.\n   - Registro de temperatura y tiempo de congelaci\u00f3n para evaluar la capacidad del equipo y asegurar un proceso estandarizado.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: gl\u00f3bulos rojos, plaquetas, plasma.\n- **Par\u00e1metros de Procesamiento**: revoluciones por minuto, temperatura, tiempo, aceleraci\u00f3n, deceleraci\u00f3n.\n- **Tecnolog\u00eda de Af\u00e9resis**: m\u00e9todo alternativo para la separaci\u00f3n de componentes sangu\u00edneos.\n- **Factor VIII**: componente cr\u00edtico en el plasma que debe preservarse durante la congelaci\u00f3n.\n- **Sistemas de Bolsas y Equipos de Congelaci\u00f3n**: utilizados en el procesamiento y almacenamiento de componentes sangu\u00edneos. \n\nEste resumen destaca la importancia de seguir procedimientos validados y registrar datos relevantes en cada etapa del procesamiento de componentes sangu\u00edneos para garantizar la calidad y eficacia del producto final.", "excerpt_keywords": "Keywords: leukocyte reduction, irradiation, blood components, filtration, apheresis"}}, "e5c0a73a-0587-47f6-b40b-ee276295ae61": {"node_ids": ["738cd72e-7cae-4408-adeb-cc1f16412a00"], "metadata": {"page_label": "207", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3 Blood and blood components\n\nBlood components may be obtained using the methods described in section 9.4.2. However, the sequence and the combination of the methods used in the production of blood components may vary from one product to another.\n\nThe collection process itself is already crucial for the quality of blood components. Measures such as a reliable arm-cleaning and disinfection procedure, the use of closed and sterile collection systems, and appropriate microbiological controls should be implemented. Time limits should be defined for the processing of blood components.\n\nThere are detailed recommendations concerning the preparation and quality assurance of blood components. See for instance *Guide to the preparation, use and quality assurance of blood components* of the Council of Europe (13). In the following sections, examples of the most important blood components are described. Where NRA requirements exist, they should be followed. Specifications of a number of products are described below.\n\n## 9.4.3.1 Whole blood\n\nWhole blood for transfusion is blood that is taken from a donor who has been assessed and found suitable as meeting the blood establishment and NRA acceptance criteria. Whole blood is collected in sterile and pyrogen-free containers with a suitable anticoagulant. It may be used without further processing. In some cases, whole blood for transfusion may also be used after leukocyte reduction.\n\nThe temperature of whole blood stored for transfusion should remain controlled between 1\u00b0 and 6\u00b0C or in a more stringent range defined by the NRA. The storage time depends on the anticoagulant/preservative solution used.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage.\n\nThe primary use of whole blood is as a source material for the preparation of blood components. Transportation and further manufacturing processes", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, destacando la importancia del proceso de recolecci\u00f3n y las medidas necesarias para garantizar la calidad de estos componentes. Se menciona que la sangre total puede ser utilizada sin procesamiento adicional o despu\u00e9s de una reducci\u00f3n de leucocitos, y se establecen par\u00e1metros cr\u00edticos para el control de calidad, como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis al final del almacenamiento. Adem\u00e1s, se hace referencia a la necesidad de cumplir con los requisitos de las autoridades reguladoras nacionales (NRA) y se mencionan recomendaciones espec\u00edficas para la preparaci\u00f3n y aseguramiento de la calidad de los componentes sangu\u00edneos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben implementarse durante el proceso de recolecci\u00f3n de sangre para garantizar la calidad de los componentes sangu\u00edneos?**\n   - Esta pregunta busca detalles sobre los procedimientos de limpieza, desinfecci\u00f3n y control microbiol\u00f3gico que son cruciales para la calidad de la sangre recolectada.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos se deben verificar durante el control de calidad de la sangre total y por qu\u00e9 son importantes?**\n   - Esta pregunta se enfoca en la importancia de los par\u00e1metros como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis, y c\u00f3mo estos afectan la seguridad y eficacia de la sangre para transfusiones.\n\n3. **\u00bfQu\u00e9 condiciones de almacenamiento son necesarias para la sangre total destinada a transfusiones y c\u00f3mo var\u00edan seg\u00fan el anticoagulante utilizado?**\n   - Esta pregunta busca informaci\u00f3n sobre las especificaciones de temperatura y tiempo de almacenamiento, as\u00ed como la influencia del tipo de anticoagulante en la duraci\u00f3n de la sangre total.\n\n### Resumen de nivel superior\n\nEl documento proporciona directrices sobre la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, enfatizando la importancia de un proceso de recolecci\u00f3n adecuado y el cumplimiento de normativas. Se describen las caracter\u00edsticas de la sangre total, su almacenamiento y los controles de calidad necesarios para asegurar su idoneidad para transfusiones. Adem\u00e1s, se menciona la variabilidad en los m\u00e9todos de producci\u00f3n de componentes sangu\u00edneos y la necesidad de seguir las recomendaciones de las autoridades reguladoras.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Reducci\u00f3n de Leucocitos**:\n   - **M\u00e9todos**: Filtraci\u00f3n de sangre entera antes o despu\u00e9s de la centrifugaci\u00f3n.\n   - **Objetivo**: Reducir la contaminaci\u00f3n por plaquetas y leucocitos en preparaciones de plasma y concentrados de gl\u00f3bulos rojos.\n   - **Validaci\u00f3n**: Es esencial validar los procesos de reducci\u00f3n de leucocitos, considerando requisitos nacionales y par\u00e1metros como flujo, temperatura, primado y enjuague.\n   - **Par\u00e1metros de Proceso**: Incluyen la historia de almacenamiento del componente, n\u00famero de leucocitos y plaquetas.\n   - **Contaje de Leucocitos**: Se debe utilizar un m\u00e9todo validado para asegurar linealidad, precisi\u00f3n y reproducibilidad.\n\n2. **Irradiaci\u00f3n**:\n   - **Dosis M\u00ednima Recomendada**: Se recomienda una dosis m\u00ednima de 25 Gy (2500 cGy) para todos los componentes sangu\u00edneos.\n   - **Mapeo de Dosis**: Se debe realizar un mapeo regular del equipo de irradiaci\u00f3n para asegurar la correcta exposici\u00f3n.\n   - **Fugas de Potasio**: Se debe tener cuidado con el aumento de la fuga de potasio en gl\u00f3bulos rojos irradiados, limitando su vida \u00fatil o mediante pasos adicionales como el lavado.\n   - **Monitoreo**: Uso de un dispositivo de temporizaci\u00f3n independiente para controlar el tiempo de exposici\u00f3n y considerar la descomposici\u00f3n del fuente radiactiva al menos anualmente.\n\n3. **Indicadores de Radiaci\u00f3n**: Se deben utilizar para diferenciar entre sangre y componentes sangu\u00edneos irradiados y no irradiados.\n\n### Entidades Clave\n- **Componentes Sangu\u00edneos**: Sangre entera, plasma, concentrados de gl\u00f3bulos rojos, plaquetas.\n- **Par\u00e1metros de Proceso**: Flujo, temperatura, primado, enjuague.\n- **Dosis de Irradiaci\u00f3n**: 25 Gy (2500 cGy).\n- **Equipos**: Equipos de filtraci\u00f3n y de irradiaci\u00f3n.\n- **M\u00e9todos de Validaci\u00f3n**: M\u00e9todos para el conteo de leucocitos y procedimientos de irradiaci\u00f3n.", "excerpt_keywords": "Keywords: blood components, quality assurance, whole blood, storage conditions, leukocyte reduction"}}, "a7ab810a-10ff-42a5-86f8-a8cde489b2be": {"node_ids": ["c94d4fdd-433b-4588-92b8-2a8fc14e23a4"], "metadata": {"page_label": "208", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "should be developed to maximize the number of components that may be produced from a whole blood donation. After collection, whole blood should be kept at a controlled temperature appropriate to the intended component manufacture and should be delivered to the production site as quickly as possible. If whole blood is collected away from the production site, the validated transport systems should ensure that correct temperatures are maintained throughout the process and that the product is delivered within 24 hours. The period between collection and further processing depends on the product but should not exceed 24 hours.\n\nThe whole blood may also be filtrated to reduce leukocyte content prior to further processing.\n\nComponents should be manufactured by a method validated as meeting the predefined product specifications.\n\n### 9.4.3.2 Red-cell concentrate\n\nRed-cell concentrates are obtained from whole blood by centrifugation and removal of plasma with or without buffy coat, depending on the centrifugation parameters. After subsequent addition of an appropriate nutrient solution, the red cells should be stored at 1\u20136\u00b0C as soon as possible. Alternatively, red-cell concentrates may be obtained using an apheresis system and likewise stored at 1\u20136\u00b0C. Red-cell units that exceed 10\u00b0C after reaching the storage temperature should be discarded. The red-cell concentrate may be used for transfusion without further processing.\n\nTo obtain leukocyte-reduced red-cell concentrates, either whole blood filtration can be applied prior to separation or there can be a post-separation filtration of the red-cell concentrate. A fully validated procedure should be established to determine optimum conditions for use of a leukocyte reduction method.\n\nRed-cell concentrates are stored under the same storage conditions as whole blood. The storage time depends on the anticoagulant/preservative solution used.\n\nFurther methods of preparation, such as irradiation or washing, are applied to obtain specific red-cell products, depending on the clinical indication.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). Parameters measured depend on the type of red-cell concentrate product obtained. At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- haemoglobin or haematocrit;\n- haemolysis at the end of storage;\n- residual leukocytes, if leukocyte reduction is performed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto proporciona directrices sobre la recolecci\u00f3n, procesamiento y almacenamiento de componentes sangu\u00edneos, espec\u00edficamente concentrados de gl\u00f3bulos rojos. Se enfatiza la importancia de mantener la sangre entera a temperaturas controladas y de transportarla r\u00e1pidamente al sitio de producci\u00f3n. Se describen los m\u00e9todos de obtenci\u00f3n de concentrados de gl\u00f3bulos rojos, incluyendo la centrifugaci\u00f3n y la aferesis, as\u00ed como la necesidad de realizar controles de calidad peri\u00f3dicos para asegurar que los productos cumplan con las especificaciones predefinidas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los concentrados de gl\u00f3bulos rojos y qu\u00e9 sucede si se excede la temperatura m\u00e1xima permitida?**\n   - Respuesta: Los concentrados de gl\u00f3bulos rojos deben ser almacenados a una temperatura de 1\u20136\u00b0C. Si las unidades de gl\u00f3bulos rojos superan los 10\u00b0C despu\u00e9s de alcanzar la temperatura de almacenamiento, deben ser descartadas.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se pueden utilizar para reducir el contenido de leucocitos en los concentrados de gl\u00f3bulos rojos y cu\u00e1l es la importancia de validar estos m\u00e9todos?**\n   - Respuesta: Se pueden aplicar filtraciones de sangre entera antes de la separaci\u00f3n o filtraciones post-separaci\u00f3n del concentrado de gl\u00f3bulos rojos para reducir el contenido de leucocitos. Es crucial establecer un procedimiento completamente validado para determinar las condiciones \u00f3ptimas para el uso de un m\u00e9todo de reducci\u00f3n de leucocitos.\n\n3. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos deben ser verificados durante los ensayos de control de calidad de los concentrados de gl\u00f3bulos rojos?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos que deben ser verificados incluyen el volumen, la hemoglobina o hematocrito, la hem\u00f3lisis al final del almacenamiento y los leucocitos residuales, si se ha realizado una reducci\u00f3n de leucocitos.", "prev_section_summary": "### Temas Clave\n\n1. **Obtenci\u00f3n de Componentes Sangu\u00edneos**: Se describen los m\u00e9todos para obtener componentes sangu\u00edneos, destacando que la secuencia y combinaci\u00f3n de estos m\u00e9todos pueden variar seg\u00fan el producto.\n\n2. **Importancia del Proceso de Recolecci\u00f3n**: Se enfatiza que el proceso de recolecci\u00f3n es crucial para la calidad de los componentes sangu\u00edneos, incluyendo medidas de limpieza, desinfecci\u00f3n y controles microbiol\u00f3gicos.\n\n3. **Recomendaciones y Normativas**: Se mencionan recomendaciones detalladas para la preparaci\u00f3n y aseguramiento de la calidad de los componentes sangu\u00edneos, as\u00ed como la necesidad de cumplir con los requisitos de las autoridades reguladoras nacionales (NRA).\n\n4. **Sangre Total**: Se define la sangre total para transfusi\u00f3n, su recolecci\u00f3n en condiciones est\u00e9riles y su uso potencial sin procesamiento adicional o tras reducci\u00f3n de leucocitos.\n\n5. **Condiciones de Almacenamiento**: Se especifican las condiciones de temperatura (1\u00b0 a 6\u00b0C) para el almacenamiento de sangre total y c\u00f3mo estas pueden variar seg\u00fan el anticoagulante utilizado.\n\n6. **Control de Calidad**: Se establecen par\u00e1metros cr\u00edticos que deben verificarse durante el control de calidad, como el volumen, la hemoglobina o hematocrito, y la hem\u00f3lisis al final del almacenamiento.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: Sangre total y sus derivados.\n- **Autoridades Reguladoras Nacionales (NRA)**: Organismos que establecen criterios de aceptaci\u00f3n para la sangre y sus componentes.\n- **Anticoagulantes**: Sustancias utilizadas para prevenir la coagulaci\u00f3n de la sangre durante su almacenamiento.\n- **Contenedores Est\u00e9riles**: Recipientes utilizados para la recolecci\u00f3n y almacenamiento de sangre.\n- **Controles Microbiol\u00f3gicos**: Medidas implementadas para asegurar la ausencia de contaminantes en la sangre recolectada.\n\n### Resumen\n\nLa secci\u00f3n aborda la obtenci\u00f3n y calidad de los componentes sangu\u00edneos, subrayando la importancia del proceso de recolecci\u00f3n y las medidas necesarias para garantizar su calidad. Se define la sangre total y se establecen condiciones de almacenamiento y par\u00e1metros de control de calidad que deben cumplirse para asegurar su idoneidad para transfusiones. Adem\u00e1s, se hace hincapi\u00e9 en la necesidad de seguir las recomendaciones de las autoridades reguladoras.", "excerpt_keywords": "Keywords: blood components, red-cell concentrate, leukocyte reduction, quality control, storage conditions"}}, "513e3499-a3d9-41c2-8dea-ada5884b6527": {"node_ids": ["87e3ed6f-2352-4f9f-8e58-2cd116a10a4d"], "metadata": {"page_label": "209", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.3 Platelet concentrate\n\nPlatelet concentrates are derived from whole blood or are obtained by apheresis.\n\nAfter collection, whole blood can be kept for up to 24 hours in conditions that are consistent with the preparation of plasma (see section 9.4.3.4.) and validated to maintain a temperature between 20\u00b0C and 24\u00b0C, following international or NRA recommendations. The whole blood unit is centrifuged so that an optimal number of platelets remain in plasma (platelet-rich plasma, or PRP). Platelet concentrates are then obtained by hard-spin centrifugation of PRP and are then resuspended.\n\nHowever, if whole blood is centrifuged so that the blood platelets are primarily sedimented to the buffy coat layer, the buffy coat is separated and further processed to obtain a platelet concentrate. Either a single buffy coat or a pool of buffy coats is diluted with plasma or an appropriate nutrient solution, and platelets are concentrated by further centrifugation. The platelet content per unit depends on the method of preparation. Similarly, the residual leukocyte content will vary according to the centrifugation parameters.\n\nPlatelet concentrates (both from whole blood and apheresis) should be stored in conditions that guarantee that viability and haemostatic activities are optimally preserved. The storage temperature should be 20\u201324\u00b0C. Continuous gentle agitation of platelets during storage should be sufficient to guarantee the availability of oxygen to the platelets (but should be as gentle as possible). A storage time should be defined in accordance with national regulations set by the NRA; it should normally not exceed five days in the absence of additional measures.\n\nIn special circumstances, volume-reduced, split, washed or irradiated platelet concentrates can be prepared for specific treatments.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- platelet content;\n- residual leukocytes, if leukocyte reduction is performed;\n- pH, measured at the end of the recommended shelf-life.\n\n# 9.4.3.4 Plasma for transfusion and Plasma for fractionation\n\nPlasma for transfusion is prepared either from whole blood or from plasma collected by apheresis, and is frozen within a defined period of time to a temperature that should adequately maintain the labile coagulation factors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona informaci\u00f3n detallada sobre la obtenci\u00f3n, almacenamiento y control de calidad de los concentrados de plaquetas, que pueden derivarse de sangre total o ser obtenidos por af\u00e9resis. Se describen los procedimientos de centrifugaci\u00f3n para obtener plaquetas ricas en plasma y se enfatiza la importancia de mantener condiciones \u00f3ptimas de almacenamiento (20-24\u00b0C) para preservar la viabilidad y actividad hemost\u00e1tica de las plaquetas. Tambi\u00e9n se menciona la necesidad de realizar controles de calidad peri\u00f3dicos sobre el producto final, verificando par\u00e1metros cr\u00edticos como el volumen, contenido de plaquetas, leucocitos residuales y pH.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones de almacenamiento recomendadas para los concentrados de plaquetas y por qu\u00e9 son importantes?**\n   - Las condiciones de almacenamiento recomendadas para los concentrados de plaquetas son mantener una temperatura entre 20\u00b0C y 24\u00b0C, con agitaci\u00f3n continua y suave. Estas condiciones son importantes para garantizar la viabilidad y las actividades hemost\u00e1ticas \u00f3ptimas de las plaquetas.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos deben ser verificados durante el control de calidad de los concentrados de plaquetas?**\n   - Durante el control de calidad de los concentrados de plaquetas, se deben verificar al menos los siguientes par\u00e1metros cr\u00edticos: volumen, contenido de plaquetas, leucocitos residuales (si se realiza reducci\u00f3n de leucocitos) y pH, medido al final de la vida \u00fatil recomendada.\n\n3. **\u00bfQu\u00e9 m\u00e9todos se pueden utilizar para obtener concentrados de plaquetas a partir de sangre total y c\u00f3mo afecta esto al contenido de plaquetas?**\n   - Los concentrados de plaquetas se pueden obtener a partir de sangre total mediante centrifugaci\u00f3n para separar el plasma rico en plaquetas (PRP) o mediante la sedimentaci\u00f3n de plaquetas en la capa de buffy coat. El contenido de plaquetas por unidad depende del m\u00e9todo de preparaci\u00f3n utilizado, as\u00ed como de los par\u00e1metros de centrifugaci\u00f3n aplicados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recolecci\u00f3n y Transporte de Sangre Entera**:\n   - La sangre entera debe ser recolectada y mantenida a temperaturas controladas para maximizar la producci\u00f3n de componentes sangu\u00edneos.\n   - Debe ser transportada al sitio de producci\u00f3n r\u00e1pidamente, preferiblemente dentro de las 24 horas posteriores a la recolecci\u00f3n.\n\n2. **Filtraci\u00f3n de Sangre**:\n   - Se puede filtrar la sangre entera para reducir el contenido de leucocitos antes del procesamiento adicional.\n\n3. **Concentrados de Gl\u00f3bulos Rojos**:\n   - Se obtienen mediante centrifugaci\u00f3n y eliminaci\u00f3n del plasma, con o sin el buffy coat.\n   - Deben ser almacenados a temperaturas de 1\u20136\u00b0C. Las unidades que superen los 10\u00b0C deben ser descartadas.\n   - Pueden ser utilizados para transfusiones sin procesamiento adicional.\n\n4. **Reducci\u00f3n de Leucocitos**:\n   - Se pueden aplicar m\u00e9todos de filtraci\u00f3n antes o despu\u00e9s de la separaci\u00f3n para obtener concentrados de gl\u00f3bulos rojos con bajo contenido de leucocitos.\n   - Es esencial validar estos m\u00e9todos para asegurar su eficacia.\n\n5. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el producto final para asegurar la consistencia del proceso de fabricaci\u00f3n.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen:\n     - Volumen\n     - Hemoglobina o hematocrito\n     - Hem\u00f3lisis al final del almacenamiento\n     - Leucocitos residuales (si se realiz\u00f3 reducci\u00f3n de leucocitos)\n\n### Entidades Clave\n- **Sangre Entera**\n- **Concentrados de Gl\u00f3bulos Rojos**\n- **Leucocitos**\n- **Temperaturas de Almacenamiento (1\u20136\u00b0C, 10\u00b0C)**\n- **M\u00e9todos de Filtraci\u00f3n**\n- **Control de Calidad**\n- **Par\u00e1metros Cr\u00edticos (volumen, hemoglobina, hem\u00f3lisis, leucocitos residuales)**\n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas en la recolecci\u00f3n, procesamiento y almacenamiento de componentes sangu\u00edneos, as\u00ed como la necesidad de controles de calidad rigurosos para garantizar la seguridad y eficacia de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: platelet concentrates, whole blood, apheresis, quality control, storage conditions"}}, "e34f0a79-d386-4433-807d-460c1883d25b": {"node_ids": ["4c254fd3-695b-4356-b554-349e1610809e"], "metadata": {"page_label": "210", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in a functional state, consistent with the intended use of the plasma. In particular, Factor VIII content is critical both as a quality indicator and to assure the efficacy of cryoprecipitate.\n\nIf plasma is separated from a unit of whole blood that is refrigerated to 4\u00b0C, centrifugation should preferably take place within eight hours of collection (14,15,16).\n\nIf the whole blood unit is rapidly cooled to 20\u201324\u00b0C and maintained at this constant temperature after collection, separation can take place within 18\u201320 hours because such conditions have been found to protect Factor VIII (17).\n\nIf plasma is collected by apheresis, the freezing process should begin as soon as possible, and ideally not later than six hours after the completion of the apheresis process. In compliance with NRA requirements, consideration should be given to the time frames of processing with respect to the anticoagulant and device used and the product to be manufactured.\n\nThe freezing process should be validated and should take place in a system that will allow complete freezing to a predefined core temperature in a predefined time (see section 9.4.2.3).\n\nProduct stability is dependent on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (more than one year) the optimal storage temperature is minus 25\u00b0C or colder (18).\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays:\n\n- volume;\n- Factor VIII activity (especially if plasma is used to treat Factor VIII deficiencies);\n- residual leukocytes, if leukocyte reduction is performed;\n- leakage;\n- visual changes.\n\nVirus inactivation and/or quarantine of plasma for transfusion are applied in some countries. Further complementary guidance with respect to virus inactivation is available in *WHO guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products* (2), and in other publications (19,20).\n\nPlasma for transfusion is suitable as source material for the production of fractionated products, and particularly Factor VIII concentrates or other labile factors. Plasma prepared in other ways should meet the specifications of the plasma fractionators and the requirements of the pharmacopoeia.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Proceso de separaci\u00f3n y congelaci\u00f3n del plasma**: El plasma debe ser separado de la sangre entera bajo condiciones espec\u00edficas de temperatura y tiempo para preservar su calidad, especialmente el contenido de Factor VIII. La congelaci\u00f3n debe iniciarse r\u00e1pidamente despu\u00e9s de la recolecci\u00f3n, y se deben seguir protocolos validados para asegurar la estabilidad del producto.\n\n2. **Control de calidad del plasma**: Se deben realizar controles de calidad peri\u00f3dicos en el plasma final para garantizar la consistencia del proceso de fabricaci\u00f3n. Los par\u00e1metros cr\u00edticos incluyen el volumen, la actividad del Factor VIII, la reducci\u00f3n de leucocitos, y la detecci\u00f3n de cambios visuales.\n\n3. **Seguridad viral del plasma**: Existen directrices sobre la inactivaci\u00f3n de virus y el manejo del plasma para transfusiones, que son esenciales para asegurar la seguridad del producto. Estas directrices son complementarias a las especificaciones de los fraccionadores de plasma y los requisitos de la farmacopea.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones \u00f3ptimas de temperatura y tiempo para la separaci\u00f3n del plasma de la sangre entera, y c\u00f3mo afectan estas condiciones al contenido de Factor VIII?**\n   - Respuesta: Si el plasma se separa de una unidad de sangre entera refrigerada a 4\u00b0C, la centrifugaci\u00f3n debe realizarse preferiblemente dentro de las ocho horas posteriores a la recolecci\u00f3n. Si la sangre se enfr\u00eda r\u00e1pidamente a 20-24\u00b0C, la separaci\u00f3n puede realizarse dentro de 18-20 horas, lo que ayuda a proteger el Factor VIII.\n\n2. **\u00bfQu\u00e9 par\u00e1metros cr\u00edticos se deben verificar durante el control de calidad del plasma, y por qu\u00e9 son importantes?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos incluyen el volumen, la actividad del Factor VIII, los leucocitos residuales (si se realiza reducci\u00f3n de leucocitos), la fuga y los cambios visuales. Estos son importantes para asegurar que el plasma cumpla con los est\u00e1ndares de calidad y eficacia, especialmente en el tratamiento de deficiencias de Factor VIII.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la seguridad viral del plasma destinado a transfusiones?**\n   - Respuesta: En algunos pa\u00edses, se aplican procedimientos de inactivaci\u00f3n de virus y/o cuarentena del plasma. Se recomienda seguir las directrices de la OMS sobre la inactivaci\u00f3n y eliminaci\u00f3n de virus para asegurar la seguridad viral de los productos de plasma humano.", "prev_section_summary": "### Temas Clave\n\n1. **Obtenci\u00f3n de Concentrados de Plaquetas**:\n   - Derivados de sangre total o obtenidos por af\u00e9resis.\n   - M\u00e9todos de centrifugaci\u00f3n para separar plasma rico en plaquetas (PRP) y concentrados de plaquetas.\n\n2. **Condiciones de Almacenamiento**:\n   - Temperatura recomendada: 20\u00b0C a 24\u00b0C.\n   - Agitaci\u00f3n continua y suave para mantener la viabilidad y actividad hemost\u00e1tica de las plaquetas.\n   - Tiempo de almacenamiento no debe exceder cinco d\u00edas sin medidas adicionales.\n\n3. **Control de Calidad**:\n   - Importancia de realizar controles peri\u00f3dicos sobre el producto final.\n   - Par\u00e1metros cr\u00edticos a verificar: volumen, contenido de plaquetas, leucocitos residuales (si se realiza reducci\u00f3n de leucocitos) y pH.\n\n4. **Preparaciones Especiales**:\n   - Posibilidad de preparar concentrados de plaquetas reducidos en volumen, divididos, lavados o irradiados para tratamientos espec\u00edficos.\n\n### Entidades\n\n- **Concentrados de Plaquetas**: Producto derivado de la sangre utilizado en transfusiones.\n- **Sangre Total**: Fuente de donde se obtienen los concentrados de plaquetas.\n- **Af\u00e9resis**: M\u00e9todo de recolecci\u00f3n de componentes sangu\u00edneos.\n- **Plasma Rico en Plaquetas (PRP)**: Producto intermedio en la obtenci\u00f3n de concentrados de plaquetas.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad que establece regulaciones sobre el almacenamiento y manejo de productos sangu\u00edneos.\n- **Controles de Calidad**: Proceso para asegurar la consistencia y seguridad del producto final.", "excerpt_keywords": "Keywords: plasma separation, Factor VIII, quality control, virus inactivation, storage temperature"}}, "50124653-f4a5-4093-b81d-ece57fe9d2e3": {"node_ids": ["05b078ba-9f7d-475e-b691-6d5abcb01b4a"], "metadata": {"page_label": "211", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.4.3.5 Cryoprecipitate and Cryo-poor plasma\n\nCryoprecipitate is the cryoglobulin fraction of plasma and contains a major portion of the Factor VIII, von Willebrand factor, fibrinogen, Factor XIII and fibronectin present in plasma. Cryoprecipitate is obtained from fresh frozen plasma that is prepared in a way that protects Factor VIII stability. Plasma is allowed to thaw either overnight at 2\u20136\u00b0C or by a rapid-thaw technique. Following thawing, the supernatant cryo-poor plasma and the cryoprecipitate are separated by hard-spin centrifugation. The cryo-poor plasma is then expressed into a transfer bag. The two components are refrozen to the appropriate core temperature.\n\nStability during storage depends on the storage temperature. Storage temperature and shelf-life depend on the intended use of the product. For long-term storage (for two years or longer) the optimal storage temperature is minus 25\u00b0C or colder.\n\nPeriodic quality control should be performed on the final product to ensure that the manufacturing process is consistent (see 9.6). At a minimum, the following critical parameters should be checked during the quality control assays of cryoprecipitate:\n\n- volume;\n- Factor VIII activity;\n- clottable fibrinogen;\n- von Willebrand factor activity (if applicable).\n\nVirus inactivation and/or quarantine are applied in some countries.\n\nUnder certain circumstances the use of small pool preparations of cryoprecipitate (by pooling single-donor cryoprecipitate units) may be desired.\n\n# 9.5 Laboratory testing\n\n## 9.5.1 Screening tests for infectious disease markers\n\n### 9.5.1.1 Testing requirements\n\nThe following tests, which are considered mandatory by all regulatory agencies, are relevant to the preparation of blood components and should be performed on each individual blood donation:\n\n- an approved test for Hepatitis B surface antigen (HBsAg);\n- an approved test for anti-HIV1/HIV2;\n- an approved test for anti-HCV.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla la preparaci\u00f3n y almacenamiento de crioprecipitados y plasma pobre en crioprecipitados, destacando la importancia de la estabilidad de Factor VIII y otros componentes durante el proceso. Se menciona que el crioprecipitado se obtiene de plasma fresco congelado y que su almacenamiento a largo plazo debe ser a temperaturas de -25\u00b0C o m\u00e1s fr\u00edas. Tambi\u00e9n se enfatiza la necesidad de controles de calidad peri\u00f3dicos y la realizaci\u00f3n de pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas en cada donaci\u00f3n de sangre.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los par\u00e1metros cr\u00edticos que deben ser verificados durante los ensayos de control de calidad del crioprecipitado?**\n   - Respuesta: Los par\u00e1metros cr\u00edticos que deben ser verificados incluyen el volumen, la actividad del Factor VIII, el fibrin\u00f3geno coagulable y la actividad del factor von Willebrand (si es aplicable).\n\n2. **\u00bfQu\u00e9 condiciones de almacenamiento son \u00f3ptimas para el crioprecipitado destinado a almacenamiento a largo plazo?**\n   - Respuesta: Para el almacenamiento a largo plazo (por dos a\u00f1os o m\u00e1s), la temperatura \u00f3ptima de almacenamiento es de -25\u00b0C o m\u00e1s fr\u00eda.\n\n3. **\u00bfQu\u00e9 pruebas son obligatorias para cada donaci\u00f3n de sangre seg\u00fan las agencias regulatorias?**\n   - Respuesta: Las pruebas obligatorias incluyen una prueba aprobada para el ant\u00edgeno de superficie de Hepatitis B (HBsAg), una prueba aprobada para anti-HIV1/HIV2 y una prueba aprobada para anti-HCV.", "prev_section_summary": "### Temas Clave\n\n1. **Separaci\u00f3n y Congelaci\u00f3n del Plasma**: \n   - La separaci\u00f3n del plasma de la sangre entera debe realizarse bajo condiciones espec\u00edficas de temperatura y tiempo para preservar la calidad, especialmente el contenido de Factor VIII.\n   - La centrifugaci\u00f3n debe realizarse preferiblemente dentro de las ocho horas si la sangre se mantiene a 4\u00b0C, o dentro de 18-20 horas si se enfr\u00eda r\u00e1pidamente a 20-24\u00b0C.\n   - En el caso de la recolecci\u00f3n por af\u00e9resis, la congelaci\u00f3n debe comenzar idealmente dentro de seis horas despu\u00e9s de completar el proceso.\n\n2. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el plasma final para asegurar la consistencia del proceso de fabricaci\u00f3n.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen el volumen, la actividad del Factor VIII, la reducci\u00f3n de leucocitos, la fuga y los cambios visuales.\n\n3. **Seguridad Viral**:\n   - Se aplican procedimientos de inactivaci\u00f3n de virus y/o cuarentena del plasma en algunos pa\u00edses para garantizar la seguridad del producto.\n   - Existen directrices de la OMS sobre la inactivaci\u00f3n y eliminaci\u00f3n de virus que son esenciales para la seguridad del plasma destinado a transfusiones.\n\n4. **Estabilidad del Producto**:\n   - La estabilidad del plasma depende de la temperatura de almacenamiento, siendo \u00f3ptima para almacenamiento a largo plazo (m\u00e1s de un a\u00f1o) a -25\u00b0C o m\u00e1s fr\u00edo.\n\n### Entidades\n\n- **Factor VIII**: Un componente cr\u00edtico del plasma que act\u00faa como indicador de calidad y eficacia en tratamientos.\n- **Plasma**: Material biol\u00f3gico utilizado para transfusiones y producci\u00f3n de productos fraccionados.\n- **Af\u00e9resis**: Proceso de recolecci\u00f3n de plasma que requiere atenci\u00f3n especial en el tiempo de congelaci\u00f3n.\n- **Control de Calidad**: Proceso que asegura que el plasma cumpla con los est\u00e1ndares necesarios para su uso.\n- **Inactivaci\u00f3n Viral**: Procedimientos aplicados para asegurar la seguridad del plasma frente a virus.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente de directrices sobre la seguridad viral del plasma.\n\nEste resumen abarca los aspectos esenciales del manejo del plasma, desde su recolecci\u00f3n hasta su control de calidad y seguridad.", "excerpt_keywords": "Keywords: Cryoprecipitate, Factor VIII, Quality Control, Blood Donation, Virus Inactivation"}}, "d4916332-91ac-4d2b-99e2-19e058b2269d": {"node_ids": ["f62791f0-9b6c-4155-adce-c20748b7a87f"], "metadata": {"page_label": "212", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All three tests have to be negative. Initially reactive donations should be retested in duplicate by the same assay. Products from a repeatedly reactive donation should not be used for therapeutic applications and should normally be destroyed unless useful for non-therapeutic purposes or investigations. A sample of the donation should be evaluated by a confirmatory test. There should be a system for notifying and counselling the donor if confirmation is positive. It is recommended that national algorithms should be developed and used to enable consistent resolution of discordant/indeterminate or unconfirmed results.\n\nIn some countries, additional serological testing is required \u2014 for instance, anti-HBc testing may be performed on whole blood donations in order to further reduce the risk of exposure of recipients to HBV by contaminated blood or blood components (3). Additional testing for other agents or markers \u2014 such as anti-HTLV I/II, anti-T.cruzi or West Nile Virus (WNV) \u2014 may be required by the NRA, taking into account the epidemiological situation in any given region or country or the frequency of donating blood. In addition to testing for immunochemical-serological infectious disease markers, NAT testing of blood donations for the virus genomes has been introduced in some countries to increase the chance of identifying infected donors.\n\nDuring the natural course of infection, viraemia usually occurs significantly at a point earlier than that at which immunochemical markers (antibodies) can be detected in the infected serum. Thus, infection may be detected by NAT up to 50\u201360 days before seroconversion (i.e. to HCV) occurs. Testing for the presence of nucleic acid may be performed for viruses such as HCV, HBV, HIV, HAV, WNV (where appropriate) and/or Parvovirus B19, and the application of this technology may be extended to other transmissible microbes. NATs require a particularly sophisticated laboratory environment, special equipment and specially trained laboratory personnel. Mainly because of an extraordinary risk of false-positive results due to the so-called \u201ccarry-over\u201d (inadvertent transfer of the amplification product DNA to neat donor samples), very stringent handling and logistics are mandatory.\n\nIn contrast to testing for the serological markers of individual donor specimens, NAT testing may be performed following current practices by assembling various samples in mini-pools. However, this requires a thoroughly validated system of sample labelling/identification, a validated strategy and pooling process, and a validated algorithm to resolve pool results to individual donors. Hence, a specific logistics system may have to be established not only in the laboratory but also at the blood establishment in order to collect and suitably label samples. Contiguously tracing samples through the whole process from the donor, through pooling (if applicable), testing and release of the donation may present a particularly demanding challenge.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Pruebas de donaciones de sangre**: Se requiere que todas las pruebas de donaciones de sangre sean negativas. Las donaciones inicialmente reactivas deben ser retestadas y, si son repetidamente reactivas, no deben ser utilizadas para aplicaciones terap\u00e9uticas. Se recomienda el desarrollo de algoritmos nacionales para manejar resultados discordantes o indeterminados.\n\n2. **Pruebas serol\u00f3gicas adicionales**: En algunos pa\u00edses, se requieren pruebas serol\u00f3gicas adicionales, como la prueba anti-HBc, para reducir el riesgo de exposici\u00f3n a virus como el HBV. Tambi\u00e9n se pueden requerir pruebas para otros agentes infecciosos, dependiendo de la situaci\u00f3n epidemiol\u00f3gica.\n\n3. **Pruebas de NAT**: La prueba de \u00e1cidos nucleicos (NAT) se utiliza para detectar infecciones antes de que se produzcan anticuerpos. Esta t\u00e9cnica requiere un entorno de laboratorio sofisticado y un manejo riguroso para evitar resultados falsos positivos. La log\u00edstica de la recolecci\u00f3n y etiquetado de muestras es crucial para el \u00e9xito de estas pruebas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si una donaci\u00f3n de sangre resulta repetidamente reactiva?**\n   - Las donaciones que resultan repetidamente reactivas no deben ser utilizadas para aplicaciones terap\u00e9uticas y deben ser destruidas, a menos que sean \u00fatiles para prop\u00f3sitos no terap\u00e9uticos o investigaciones. Adem\u00e1s, se debe realizar una prueba confirmatoria y notificar al donante si la confirmaci\u00f3n es positiva.\n\n2. **\u00bfCu\u00e1l es la importancia de las pruebas de NAT en comparaci\u00f3n con las pruebas serol\u00f3gicas tradicionales?**\n   - Las pruebas de NAT son importantes porque pueden detectar infecciones hasta 50-60 d\u00edas antes de que se produzca la seroconversi\u00f3n, lo que permite identificar a donantes infectados m\u00e1s r\u00e1pidamente. Esto es crucial para reducir el riesgo de transmisi\u00f3n de infecciones a los receptores de sangre.\n\n3. **\u00bfQu\u00e9 desaf\u00edos log\u00edsticos se presentan al implementar pruebas de NAT en donaciones de sangre?**\n   - Los desaf\u00edos log\u00edsticos incluyen la necesidad de un sistema validado para el etiquetado e identificaci\u00f3n de muestras, un proceso de agrupamiento validado y un algoritmo para resolver los resultados de los grupos a donantes individuales. Adem\u00e1s, se requiere un seguimiento continuo de las muestras a lo largo de todo el proceso, desde la donaci\u00f3n hasta la liberaci\u00f3n de la sangre.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Crioprecipitado y Plasma Pobre en Crioprecipitados**:\n   - El crioprecipitado es la fracci\u00f3n de crioglobulina del plasma que contiene factores importantes como el Factor VIII, el factor von Willebrand, el fibrin\u00f3geno, el Factor XIII y la fibronectina.\n   - Se obtiene de plasma fresco congelado, el cual se prepara para mantener la estabilidad del Factor VIII.\n\n2. **Proceso de Preparaci\u00f3n**:\n   - El plasma se descongela a temperaturas controladas (2\u20136\u00b0C o mediante t\u00e9cnicas de descongelaci\u00f3n r\u00e1pida).\n   - Despu\u00e9s de la descongelaci\u00f3n, se separan el plasma pobre en crioprecipitados y el crioprecipitado mediante centrifugaci\u00f3n.\n\n3. **Condiciones de Almacenamiento**:\n   - La estabilidad del crioprecipitado depende de la temperatura de almacenamiento.\n   - Para almacenamiento a largo plazo (dos a\u00f1os o m\u00e1s), la temperatura \u00f3ptima es de -25\u00b0C o m\u00e1s fr\u00eda.\n\n4. **Control de Calidad**:\n   - Se deben realizar controles de calidad peri\u00f3dicos en el producto final.\n   - Los par\u00e1metros cr\u00edticos a verificar incluyen: volumen, actividad del Factor VIII, fibrin\u00f3geno coagulable y actividad del factor von Willebrand (si aplica).\n\n5. **Pruebas de Detecci\u00f3n de Enfermedades Infecciosas**:\n   - Se requieren pruebas obligatorias para cada donaci\u00f3n de sangre, que incluyen:\n     - Prueba para el ant\u00edgeno de superficie de Hepatitis B (HBsAg).\n     - Prueba para anti-HIV1/HIV2.\n     - Prueba para anti-HCV.\n\n6. **Consideraciones Adicionales**:\n   - En algunos pa\u00edses se aplican medidas de inactivaci\u00f3n de virus y/o cuarentena.\n   - Puede ser deseable el uso de preparaciones de crioprecipitado de peque\u00f1os grupos mediante la agrupaci\u00f3n de unidades de crioprecipitado de donantes individuales.\n\n### Entidades Clave:\n- **Crioprecipitado**\n- **Plasma Fresco Congelado**\n- **Factor VIII**\n- **Factor von Willebrand**\n- **Fibrin\u00f3geno**\n- **Factor XIII**\n- **Fibronectina**\n- **Controles de Calidad**\n- **Pruebas de Detecci\u00f3n de Enfermedades Infecciosas** (HBsAg, anti-HIV1/HIV2, anti-HCV)", "excerpt_keywords": "Keywords: blood donation, serological testing, NAT testing, infectious diseases, donor screening"}}, "f9043b08-a6e0-45b1-a69d-a1ce6103efa5": {"node_ids": ["a8f1f58a-9fdc-4d8e-9e95-13836736081a"], "metadata": {"page_label": "213", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A system should exist in the country or region for approval of test systems, such as an official approval system by the NRA or a delegated laboratory. The required minimal sensitivity of tests for the different antigens/antibodies or nucleic acids should be defined by the NRA.\n\n### 9.5.1.2 Handling of samples and data\n\nMultiple specimens may be collected from a donor in order to meet all testing requirements (i.e. ABO typing, viral markers, NAT testing). There should be written standard operating procedures that clearly describe the collection, transportation and labelling of donor samples (i.e. whole blood, sera, anti-coagulant, container tubes etc.) and which define the sampling procedure performed on material for analysis (e.g. how and by whom it is done, transfer of samples, accountability of samples). All screening activities, handling of donor specimens, sampling, analysis and data processing should be separated from patient diagnostic testing (21).\n\nSample labelling at the site of collection and identification during all subsequent processing is critical and should be under control at all times. Each step of handling and processing should be described, as should the conditions of pre-analytical treatment of specimens (e.g. centrifugation), storage and transportation (duration, temperature, type of container, storage after testing).\n\nSerological testing should be performed on samples transferred directly into the analyser from the original sample tube.\n\nSecondary aliquot samples may be used for NAT testing of mini-pools of individual samples.\n\nThe following practical points should be considered in order to ensure the traceability and integrity of samples and data:\n\n- At receipt of specimens at the laboratory, positive identification of those received versus those expected should be performed. The integrity of the sample should be checked for compliance with the recommendations made by the manufacturer of the test kit.\n- Aliquot samples for analysis should be withdrawn from the donor sample preferably by automated pipetting equipment.\n- To provide for positive identification of all aspects (donation, donor specimen, aliquot samples etc.) it may be advisable to use a barcode system. Hence, starting with the donation, barcodes should be used for labelling. In case of failure of the automatic barcode reader system and/or data processors, an appropriate system should be available for manual entry and tracing of data throughout the whole process until release of donations for transfusion. Manual handling of data should include independent repeat entry into the database; the data format should include a check-digit algorithm or an automated test for identity of the two sets of data.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Aprobaci\u00f3n de sistemas de prueba**: Se establece la necesidad de un sistema oficial en el pa\u00eds o regi\u00f3n para la aprobaci\u00f3n de sistemas de prueba, que debe ser definido por la Autoridad Reguladora Nacional (NRA). Esto incluye la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos.\n\n2. **Manejo de muestras y datos**: Se enfatiza la importancia de procedimientos operativos est\u00e1ndar escritos para la recolecci\u00f3n, transporte y etiquetado de muestras de donantes. Se debe garantizar la separaci\u00f3n de las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes, as\u00ed como la trazabilidad y la integridad de las muestras y datos a trav\u00e9s de un sistema de etiquetado, preferiblemente utilizando c\u00f3digos de barras.\n\n3. **Pr\u00e1cticas recomendadas para la integridad de las muestras**: Se sugieren pr\u00e1cticas espec\u00edficas para asegurar la identificaci\u00f3n positiva de las muestras y su integridad, incluyendo el uso de equipos automatizados para la toma de al\u00edcuotas y la implementaci\u00f3n de un sistema de entrada manual de datos en caso de fallos en el sistema automatizado.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para garantizar la integridad de las muestras desde su recolecci\u00f3n hasta su an\u00e1lisis?**\n   - El contexto detalla que deben existir procedimientos operativos est\u00e1ndar que describan la recolecci\u00f3n, transporte y etiquetado de las muestras, as\u00ed como la separaci\u00f3n de las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes. Tambi\u00e9n se menciona la importancia de la identificaci\u00f3n positiva y el control de la integridad de las muestras.\n\n2. **\u00bfC\u00f3mo se debe manejar la identificaci\u00f3n de muestras en caso de fallos en el sistema automatizado de c\u00f3digos de barras?**\n   - En caso de fallos en el sistema automatizado, se debe contar con un sistema adecuado para la entrada manual y el rastreo de datos a lo largo de todo el proceso, incluyendo la entrada independiente y repetida en la base de datos, as\u00ed como un algoritmo de verificaci\u00f3n de d\u00edgitos o una prueba automatizada para asegurar la identidad de los conjuntos de datos.\n\n3. **\u00bfQu\u00e9 papel juega la NRA en la aprobaci\u00f3n de sistemas de prueba y qu\u00e9 criterios se deben considerar?**\n   - La NRA debe definir un sistema oficial de aprobaci\u00f3n de pruebas que incluya la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos. Esto asegura que los sistemas de prueba cumplan con los est\u00e1ndares necesarios para su uso en el pa\u00eds o regi\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Pruebas de donaciones de sangre**:\n   - Todas las donaciones deben ser negativas en tres pruebas.\n   - Donaciones inicialmente reactivas deben ser retestadas y, si son repetidamente reactivas, no deben ser utilizadas para aplicaciones terap\u00e9uticas y deben ser destruidas, salvo para prop\u00f3sitos no terap\u00e9uticos o investigaciones.\n   - Se debe realizar una prueba confirmatoria y notificar al donante si la confirmaci\u00f3n es positiva.\n   - Se recomienda el desarrollo de algoritmos nacionales para manejar resultados discordantes o indeterminados.\n\n2. **Pruebas serol\u00f3gicas adicionales**:\n   - En algunos pa\u00edses, se requieren pruebas adicionales como la prueba anti-HBc para reducir el riesgo de exposici\u00f3n al virus de la hepatitis B (HBV).\n   - Otras pruebas pueden incluir anti-HTLV I/II, anti-T.cruzi y virus del Nilo Occidental (WNV), dependiendo de la situaci\u00f3n epidemiol\u00f3gica.\n\n3. **Pruebas de \u00e1cidos nucleicos (NAT)**:\n   - Las pruebas NAT permiten detectar infecciones antes de que se produzcan anticuerpos, hasta 50-60 d\u00edas antes de la seroconversi\u00f3n.\n   - Se pueden realizar pruebas para virus como HCV, HBV, HIV, HAV, WNV y Parvovirus B19.\n   - Requieren un entorno de laboratorio sofisticado, equipo especial y personal capacitado.\n   - Se deben seguir estrictos protocolos para evitar resultados falsos positivos debido a la transferencia inadvertida de productos de amplificaci\u00f3n.\n\n4. **Desaf\u00edos log\u00edsticos**:\n   - Implementar pruebas NAT requiere un sistema validado para el etiquetado e identificaci\u00f3n de muestras, un proceso de agrupamiento validado y un algoritmo para resolver resultados de grupos a donantes individuales.\n   - Es crucial el seguimiento continuo de las muestras desde la donaci\u00f3n hasta la liberaci\u00f3n de la sangre, lo que presenta un desaf\u00edo log\u00edstico significativo.\n\n### Entidades mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referencia impl\u00edcita en el documento.\n- **Virus**: HBV, HCV, HIV, HAV, WNV, Parvovirus B19.\n- **Pruebas**: Pruebas serol\u00f3gicas, pruebas NAT, pruebas anti-HBc.\n- **Donantes de sangre**: Sujetos a pruebas y notificaciones.\n- **Agencias reguladoras nacionales (NRA)**: Responsables de establecer requisitos de pruebas adicionales.", "excerpt_keywords": "Keywords: test systems, sample handling, data integrity, NRA approval, serological testing"}}, "daa84405-4dc6-4745-a741-5e208e91c2da": {"node_ids": ["3c016e80-aa13-450c-9350-6551c27afd58"], "metadata": {"page_label": "214", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Pipetting devices and machines should be validated before routine use, and validation reports should be available.\n- Calibration of the pipetting devices should be performed periodically and should be documented.\n\n### 9.5.1.3 Testing and post-analytical procedures\n\nTesting of blood components should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Modifications to the manufacturer\u2019s instructions or reagents for donor screening tests should be validated. Where required, prior approval of the NRA should be obtained before the modified method is used for release of a blood component. Laboratory reagents intended for prolonged use should be marked with the preparation date, expiry date, specific storage conditions and signature of the person who prepared them. Instructions for use and storage should be followed.\n\nScreening algorithms should be precisely defined in writing (i.e. standard operating procedures) to deal with initially reactive specimens and to resolve discrepancies in results after retesting. All available measures should be taken to ensure that blood and blood components that are repeat reactive upon screening for an infectious disease marker are excluded from therapeutic use. Repeat reactive material should be stored away from all other blood components in a separate dedicated storage area. Such material should eventually be destroyed to prevent inadvertent re-entry into the transfusion chain.\n\nTest algorithms should provide details for appropriate confirmatory testing. In the case of repeatedly reactive results, clearly defined follow-up instructions should be followed. Actions include:\n\n- notification and deferral of the donor;\n- disposal of the indicated donation and of concurrent products;\n- tracing and destruction of products which have not yet expired.\n\nIf products from the donor have been processed for further manufacture, there should be a procedure in place to assess both the safety of the manufactured products and whether a recall is needed.\n\nProcedures for donor- and/or recipient-initiated look-backs should also be defined. Look-backs should be designed in such a way that the transfusion chain of donor\u2013blood (or blood product)\u2013recipient can be unequivocally reconstructed. The procedure should comprise notification and counselling action where indicated.\n\nThe following practical points should be considered in order to ensure that the equipment used for virology testing performs appropriately:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de nivel superior del contexto\n\nEl documento de la OMS establece directrices sobre la validaci\u00f3n y calibraci\u00f3n de dispositivos de pipeteo, as\u00ed como sobre los procedimientos de prueba y post-anal\u00edticos para componentes sangu\u00edneos. Se enfatiza la importancia de seguir las recomendaciones del fabricante para los reactivos y kits de prueba, y se requiere la validaci\u00f3n de cualquier modificaci\u00f3n a estas instrucciones. Se deben definir algoritmos de cribado y procedimientos para manejar resultados reactivos, asegurando que los materiales repetidamente reactivos se excluyan del uso terap\u00e9utico. Adem\u00e1s, se deben establecer procedimientos para el seguimiento de donantes y receptores, as\u00ed como para la evaluaci\u00f3n de la seguridad de los productos manufacturados.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse si un donante presenta resultados repetidamente reactivos en las pruebas de detecci\u00f3n de marcadores de enfermedades infecciosas?**\n   - La respuesta debe incluir la notificaci\u00f3n y la suspensi\u00f3n del donante, la eliminaci\u00f3n de la donaci\u00f3n indicada y de los productos concurrentes, y el rastreo y destrucci\u00f3n de productos que no hayan expirado.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en las etiquetas de los reactivos de laboratorio destinados a un uso prolongado?**\n   - Las etiquetas deben incluir la fecha de preparaci\u00f3n, la fecha de caducidad, las condiciones espec\u00edficas de almacenamiento y la firma de la persona que los prepar\u00f3.\n\n3. **\u00bfCu\u00e1les son las consideraciones pr\u00e1cticas para asegurar que el equipo utilizado en las pruebas de virolog\u00eda funcione adecuadamente?**\n   - Aunque el contexto no proporciona detalles espec\u00edficos sobre estas consideraciones, se puede inferir que se deben seguir protocolos de mantenimiento y calibraci\u00f3n, as\u00ed como asegurar que el equipo est\u00e9 validado y documentado adecuadamente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Aprobaci\u00f3n de Sistemas de Prueba**:\n   - Es necesario un sistema oficial en el pa\u00eds o regi\u00f3n para la aprobaci\u00f3n de sistemas de prueba, definido por la Autoridad Reguladora Nacional (NRA).\n   - La NRA debe establecer la sensibilidad m\u00ednima requerida para diferentes ant\u00edgenos, anticuerpos o \u00e1cidos nucleicos.\n\n2. **Manejo de Muestras y Datos**:\n   - Se deben seguir procedimientos operativos est\u00e1ndar escritos para la recolecci\u00f3n, transporte y etiquetado de muestras de donantes.\n   - Es crucial separar las actividades de an\u00e1lisis de muestras de donantes de las pruebas diagn\u00f3sticas de pacientes.\n\n3. **Trazabilidad e Integridad de Muestras**:\n   - La identificaci\u00f3n positiva de las muestras y su integridad debe ser controlada en todo momento.\n   - Se recomienda el uso de un sistema de c\u00f3digos de barras para el etiquetado de muestras, con un plan de contingencia para la entrada manual de datos en caso de fallos en el sistema automatizado.\n\n4. **Pr\u00e1cticas Recomendadas**:\n   - Verificaci\u00f3n de la identidad de las muestras al recibirlas en el laboratorio.\n   - Preferencia por el uso de equipos automatizados para la toma de al\u00edcuotas.\n   - Implementaci\u00f3n de un sistema de entrada manual de datos que incluya verificaci\u00f3n de identidad.\n\n### Entidades Clave\n- **Autoridad Reguladora Nacional (NRA)**: Entidad responsable de la aprobaci\u00f3n de sistemas de prueba.\n- **Muestras de Donantes**: Incluyen sangre total, sueros y otros materiales biol\u00f3gicos.\n- **C\u00f3digos de Barras**: Sistema recomendado para la identificaci\u00f3n y trazabilidad de muestras.\n- **Procedimientos Operativos Est\u00e1ndar**: Documentaci\u00f3n necesaria para asegurar la correcta manipulaci\u00f3n de muestras.\n\nEste resumen destaca la importancia de la regulaci\u00f3n, el manejo adecuado de muestras y la implementaci\u00f3n de sistemas de trazabilidad para garantizar la integridad y la calidad en los procesos de an\u00e1lisis.", "excerpt_keywords": "Keywords: validation, pipetting, blood components, screening algorithms, donor safety"}}, "de4346e7-75de-4411-9bc6-d73ebf038597": {"node_ids": ["33bf4b0d-90b1-495d-9608-9988250a6d4c"], "metadata": {"page_label": "215", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- There should be a mechanism to ensure positive sample identification and linkage to the donor. The preferred method is by sample tubes with barcodes.\n- Ideally, the addition of reagent and samples and the testing process should be automated, in order to minimize risk of human errors and to ensure full traceability of the testing process.\n- If addition of reagents and samples or preparation of test plates are done manually, full documentation of each addition step should be kept, ensuring identification of the test plate and the location of the reaction well.\n\n### 9.5.1.4 Test interpretation and follow-up of reactive results\n\nThe transfer and interpretation of raw data is a critical step and should therefore be documented and reviewed by a responsible person, as should the test parameters. Traceability and archiving of raw data should be guaranteed (see section 5.2).\n\nThe data should be examined by the supervisor, or by another person authorized to do so, before being officially accepted. If computerized systems are used, accepted data should be downloaded directly to the server, or there should be a secure system for manual download which ensures positive release. Manual transcription of results is discouraged as mistakes may be introduced. Acceptance and rejection criteria should be specified.\n\nThe following should be given special attention:\n\n- Initial reactive results should be identified by means of a secure and validated system.\n- An acceptable system should be in place to confirm repeat reactive results, including sampling, labelling, testing and entry of results.\n- Computer algorithms should edit reactive status to repeat reactive, or the editing should be performed by two authorized staff members.\n- An appropriate deferral system should exist for repeat reactive results.\n- There should be appropriate documentation justifying the re-entry of deferred donors.\n- Donors should be informed of the reason for deferral and should be counselled about social behaviours and their status as a future donor.\n\n### 9.5.2 Blood group typing\n\nEach donation should be tested for ABO and RhD blood groups and at least all first-time donors should be tested for clinically significant irregular red-cell antibodies. When plasma is used for fractionation it should be tested in compliance with the specifications of the fractionator as agreed by the relevant NRA (3).\n\nTesting should be carried out in accordance with the recommendations of the manufacturer of reagents and test kits. Molecular methods may be used to determine blood groups, as necessary.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mecanismos de Identificaci\u00f3n y Trazabilidad**: Se enfatiza la importancia de un sistema seguro para la identificaci\u00f3n de muestras y su vinculaci\u00f3n con los donantes, preferiblemente mediante el uso de tubos de muestra con c\u00f3digos de barras. Se sugiere la automatizaci\u00f3n de procesos para minimizar errores humanos y asegurar la trazabilidad.\n\n2. **Interpretaci\u00f3n de Resultados y Seguimiento**: La transferencia e interpretaci\u00f3n de datos crudos son pasos cr\u00edticos que deben ser documentados y revisados por personal responsable. Se deben establecer criterios de aceptaci\u00f3n y rechazo, y se debe evitar la transcripci\u00f3n manual de resultados para prevenir errores.\n\n3. **Tipificaci\u00f3n de Grupos Sangu\u00edneos**: Cada donaci\u00f3n debe ser analizada para determinar los grupos sangu\u00edneos ABO y RhD, y se deben realizar pruebas adicionales para detectar anticuerpos irregulares en donantes primerizos. Las pruebas deben seguir las recomendaciones del fabricante de reactivos y kits de prueba.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la trazabilidad de las muestras en el proceso de donaci\u00f3n de sangre?**\n   - El contexto menciona que se debe implementar un mecanismo de identificaci\u00f3n positiva de muestras, preferiblemente mediante tubos de muestra con c\u00f3digos de barras, y que la automatizaci\u00f3n del proceso puede ayudar a minimizar errores y asegurar la trazabilidad.\n\n2. **\u00bfCu\u00e1les son los pasos recomendados para la interpretaci\u00f3n de resultados reactivos en pruebas de sangre?**\n   - Se debe documentar y revisar la transferencia e interpretaci\u00f3n de datos crudos por una persona responsable. Adem\u00e1s, los resultados iniciales reactivos deben ser identificados mediante un sistema seguro, y se debe contar con un sistema aceptable para confirmar resultados reactivos repetidos.\n\n3. **\u00bfQu\u00e9 pruebas deben realizarse en cada donaci\u00f3n de sangre y cu\u00e1les son las recomendaciones para su ejecuci\u00f3n?**\n   - Cada donaci\u00f3n debe ser probada para los grupos sangu\u00edneos ABO y RhD, y todos los donantes primerizos deben ser evaluados para anticuerpos irregulares cl\u00ednicamente significativos. Las pruebas deben llevarse a cabo de acuerdo con las recomendaciones del fabricante de reactivos y kits de prueba, y se pueden utilizar m\u00e9todos moleculares seg\u00fan sea necesario.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Validaci\u00f3n y Calibraci\u00f3n de Dispositivos de Pipeteo**:\n   - Los dispositivos y m\u00e1quinas de pipeteo deben ser validados antes de su uso rutinario, y los informes de validaci\u00f3n deben estar disponibles.\n   - La calibraci\u00f3n de estos dispositivos debe realizarse peri\u00f3dicamente y documentarse.\n\n2. **Procedimientos de Prueba y Post-Anal\u00edticos**:\n   - Las pruebas de componentes sangu\u00edneos deben seguir las recomendaciones del fabricante de reactivos y kits de prueba.\n   - Cualquier modificaci\u00f3n a las instrucciones del fabricante debe ser validada y, si es necesario, aprobada por la Autoridad Reguladora Nacional (NRA) antes de su uso.\n\n3. **Etiquetado de Reactivos de Laboratorio**:\n   - Los reactivos destinados a un uso prolongado deben incluir la fecha de preparaci\u00f3n, fecha de caducidad, condiciones de almacenamiento espec\u00edficas y la firma de la persona que los prepar\u00f3.\n\n4. **Algoritmos de Cribado**:\n   - Deben definirse por escrito para manejar muestras inicialmente reactivas y resolver discrepancias en los resultados.\n   - Se deben tomar medidas para excluir del uso terap\u00e9utico los componentes sangu\u00edneos que sean repetidamente reactivos.\n\n5. **Manejo de Resultados Repetidamente Reactivos**:\n   - Acciones a seguir incluyen la notificaci\u00f3n y suspensi\u00f3n del donante, eliminaci\u00f3n de la donaci\u00f3n y productos concurrentes, y rastreo y destrucci\u00f3n de productos no expirados.\n\n6. **Procedimientos de Seguimiento (Look-Backs)**:\n   - Deben establecerse procedimientos para el seguimiento de donantes y/o receptores, asegurando que la cadena de transfusi\u00f3n pueda reconstruirse claramente.\n\n7. **Consideraciones Pr\u00e1cticas para Pruebas de Virolog\u00eda**:\n   - Aunque no se detallan en el texto, se infiere que se deben seguir protocolos de mantenimiento y calibraci\u00f3n para asegurar el correcto funcionamiento del equipo.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **NRA (Autoridad Reguladora Nacional)**: Entidad que debe aprobar modificaciones a los m\u00e9todos de prueba.\n- **Donantes y Receptores**: Sujetos involucrados en el proceso de donaci\u00f3n y transfusi\u00f3n de sangre.\n- **Componentes Sangu\u00edneos**: Elementos que se prueban y transfunden, como sangre y productos derivados.", "excerpt_keywords": "Keywords: sample identification, test interpretation, blood group typing, traceability, reactive results"}}, "ac32a1bb-976b-42c1-8fae-c0b9068b583d": {"node_ids": ["f2629072-ea90-41ff-8292-188a93735ac8"], "metadata": {"page_label": "216", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The ABO and RhD blood group should be verified on each subsequent donation. A comparison should be made with the historically determined blood group. If a discrepancy is found, the applicable blood components should not be released until the discrepancy has been unequivocally resolved.\n\nDonors with a history of transfusions or pregnancy since the last donation should be tested for clinically significant irregular red-cell antibodies. If clinically significant red-cell antibodies are detected, and where applicable, the blood or blood component should be labelled accordingly.\n\nNRAs may set different (stronger) requirements.\n\nThe ABO/RhD labelling of the red-cell concentrates of all first-time donations should be based on two independent ABO/RhD tests.\n\n### 9.5.3 Retention samples\n\nAs specified by the NRA, an aliquot of the original testing sample should be retained from each donation and stored under conditions recommended by the test manufacturer that would permit retesting if indicated. The procedure for additional testing should be validated to ensure the integrity of the sample (including storage conditions) and the test results. The sample volume, the retention vial, the kind of specimen (serum or plasma), the storage conditions and length of storage should each be defined and should be included in the validation to ensure the integrity of test results.\n\n### 9.6 Quality monitoring of blood and blood components\n\nQuality control data should demonstrate that critical manufacturing processes are under control. Blood and blood components should comply with specifications and their testing should be performed using test methods approved by the NRA.\n\nAll processes \u2014 including data transfers and computerized systems \u2014 that have an influence on the quality of the products in the area of collection, preparation or testing of blood and blood components should be validated. For critical processes such as rapid freezing of plasma, the need for revalidation should be defined.\n\nQuality control of blood and blood components should be carried out according to a defined sampling plan based on statistical methods. The sampling plan should take into account different collection and production sites, transport, methods of preparation and equipment used. Acceptance criteria should be based on a defined specification for each type of blood component. As an example for fresh frozen plasma, these data may include monitoring of weight/volume, sterility, Factor VIII activity and residual cell", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS establece directrices sobre la verificaci\u00f3n de grupos sangu\u00edneos ABO y RhD en donaciones de sangre, la importancia de realizar pruebas para detectar anticuerpos irregulares en donantes con antecedentes de transfusiones o embarazo, y la necesidad de etiquetar adecuadamente los componentes sangu\u00edneos. Tambi\u00e9n se menciona la retenci\u00f3n de muestras para pruebas adicionales y la importancia del control de calidad en la fabricaci\u00f3n y prueba de componentes sangu\u00edneos, incluyendo la validaci\u00f3n de procesos cr\u00edticos y la implementaci\u00f3n de planes de muestreo basados en m\u00e9todos estad\u00edsticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si se encuentra una discrepancia en el grupo sangu\u00edneo ABO/RhD durante una donaci\u00f3n?**\n   - Respuesta: Si se encuentra una discrepancia en el grupo sangu\u00edneo ABO/RhD, los componentes sangu\u00edneos aplicables no deben ser liberados hasta que la discrepancia haya sido resuelta de manera inequ\u00edvoca.\n\n2. **\u00bfCu\u00e1les son los requisitos para la retenci\u00f3n de muestras de donaciones de sangre seg\u00fan la NRA?**\n   - Respuesta: Seg\u00fan la NRA, se debe retener un al\u00edcuota de la muestra de prueba original de cada donaci\u00f3n, almacenada bajo condiciones recomendadas por el fabricante del test que permitan la re-prueba si es necesario. Adem\u00e1s, se deben definir el volumen de la muestra, el vial de retenci\u00f3n, el tipo de muestra (suero o plasma), las condiciones de almacenamiento y la duraci\u00f3n del almacenamiento.\n\n3. **\u00bfC\u00f3mo se debe llevar a cabo el control de calidad de los componentes sangu\u00edneos y qu\u00e9 factores deben considerarse en el plan de muestreo?**\n   - Respuesta: El control de calidad de los componentes sangu\u00edneos debe realizarse de acuerdo con un plan de muestreo definido basado en m\u00e9todos estad\u00edsticos. Este plan debe tener en cuenta diferentes sitios de recolecci\u00f3n y producci\u00f3n, transporte, m\u00e9todos de preparaci\u00f3n y equipos utilizados. Los criterios de aceptaci\u00f3n deben basarse en especificaciones definidas para cada tipo de componente sangu\u00edneo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mecanismos de Identificaci\u00f3n y Trazabilidad**:\n   - Importancia de un sistema seguro para la identificaci\u00f3n de muestras y su vinculaci\u00f3n con los donantes.\n   - Uso preferido de tubos de muestra con c\u00f3digos de barras.\n   - Automatizaci\u00f3n del proceso de adici\u00f3n de reactivos y muestras para minimizar errores humanos y asegurar trazabilidad.\n\n2. **Interpretaci\u00f3n de Resultados y Seguimiento**:\n   - Documentaci\u00f3n y revisi\u00f3n de la transferencia e interpretaci\u00f3n de datos crudos por personal responsable.\n   - Establecimiento de criterios de aceptaci\u00f3n y rechazo.\n   - Evitar la transcripci\u00f3n manual de resultados para prevenir errores.\n   - Identificaci\u00f3n de resultados reactivos iniciales mediante un sistema seguro.\n   - Confirmaci\u00f3n de resultados reactivos repetidos con un sistema adecuado.\n\n3. **Tipificaci\u00f3n de Grupos Sangu\u00edneos**:\n   - Pruebas obligatorias para determinar los grupos sangu\u00edneos ABO y RhD en cada donaci\u00f3n.\n   - Evaluaci\u00f3n de anticuerpos irregulares en donantes primerizos.\n   - Cumplimiento de las recomendaciones del fabricante de reactivos y kits de prueba.\n   - Posibilidad de utilizar m\u00e9todos moleculares para determinar grupos sangu\u00edneos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las recomendaciones.\n- **Donantes de Sangre**: Sujetos de las pruebas y procesos descritos.\n- **Muestras de Sangre**: Elemento central del proceso de donaci\u00f3n y an\u00e1lisis.\n- **Reactivos y Kits de Prueba**: Herramientas necesarias para la tipificaci\u00f3n y an\u00e1lisis de sangre.\n- **Datos Crudos**: Informaci\u00f3n que debe ser documentada y revisada durante el proceso de pruebas. \n\nEste resumen destaca la importancia de la trazabilidad, la correcta interpretaci\u00f3n de resultados y las pruebas necesarias para garantizar la seguridad y eficacia en la donaci\u00f3n de sangre.", "excerpt_keywords": "Keywords: blood donation, ABO/RhD testing, quality control, retention samples, irregular antibodies"}}, "7d289599-0bdd-4cf7-b527-905dce8edd64": {"node_ids": ["9286d6c9-2277-42d0-9cb6-5e1c5c691985"], "metadata": {"page_label": "217", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Labelling\n\n## 9.7.1 Label Information\n\nThe collected blood, as well as intermediate and finished blood components, should be labelled with relevant information regarding their identity and release status. The type of label to be used, as well as the labelling methodology, should be established in written standard operating procedures. Whenever possible, machine-readable labels (barcodes) should be used.\n\nThe label for a finished blood component should comply with the requirements of the NRA or contain at least the following information:\n\n- The unique donation number (through the use of this number there should be traceability to the donor and all records of the manufacturing steps through to the final product);\n- The product name (see section 9.7.2.);\n\nCounts (platelets, leukocytes, erythrocytes). The sampling plan for testing of blood or blood components should take into account that most components are derived from one donor, and should be considered as a single batch.\n\nWhole blood or blood components should not be released for use if the quality control test indicates that the integrity of the product has been compromised.\n\nThe work record should identify the test(s) employed so as to ensure that entries, such as the calculation of results, are available for review.\n\nTest results that do not meet the acceptance criteria should be clearly identified to ensure that blood components of that donation remain in quarantine and that relevant samples are selected for further testing. An investigation should be conducted into the cause of failure prior to additional or repeat testing. Where possible, the performance of the test procedures should be regularly assessed by participation in a formal system of proficiency testing.\n\nWhere applicable, the practice of pooling samples before testing should be clearly stated and the donations used in the pooled sample should be recorded. Pooling of samples, such as for the measurement of Factor VIII activity in plasma, is acceptable only where comparative data of pooled samples and individual samples have demonstrated assurance of equivalence.\n\nThe results of quality monitoring testing should be subject to periodic review and trend analysis. If the results of quality monitoring suggest that the process is not meeting validated parameters and specifications, then corrective and preventive actions should be taken to correct identified problems before product manufacturing and distribution is continued.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece directrices sobre el etiquetado de sangre y componentes sangu\u00edneos, enfatizando la importancia de la trazabilidad, la calidad y la seguridad en el proceso de donaci\u00f3n y fabricaci\u00f3n. Se especifica que las etiquetas deben contener informaci\u00f3n clave como el n\u00famero de donaci\u00f3n \u00fanico, el nombre del producto y los recuentos celulares. Adem\u00e1s, se menciona la necesidad de procedimientos operativos est\u00e1ndar para el etiquetado y la importancia de realizar pruebas de control de calidad antes de liberar los productos para su uso. Tambi\u00e9n se aborda la pr\u00e1ctica de agrupar muestras para pruebas y la necesidad de revisar peri\u00f3dicamente los resultados de las pruebas de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la etiqueta de un componente sangu\u00edneo terminado para garantizar la trazabilidad y la conformidad con las regulaciones?**\n   - La etiqueta debe incluir el n\u00famero de donaci\u00f3n \u00fanico, el nombre del producto y los recuentos de plaquetas, leucocitos y eritrocitos.\n\n2. **\u00bfQu\u00e9 acciones deben tomarse si los resultados de las pruebas de control de calidad no cumplen con los criterios de aceptaci\u00f3n?**\n   - Los resultados que no cumplen deben ser claramente identificados, los componentes de esa donaci\u00f3n deben permanecer en cuarentena, y se debe investigar la causa de la falla antes de realizar pruebas adicionales.\n\n3. **\u00bfCu\u00e1l es la importancia de la pr\u00e1ctica de agrupar muestras antes de las pruebas y qu\u00e9 condiciones deben cumplirse para que sea aceptable?**\n   - La agrupaci\u00f3n de muestras es aceptable solo si hay datos comparativos que demuestren la equivalencia entre muestras agrupadas e individuales, y debe registrarse qu\u00e9 donaciones se utilizaron en la muestra agrupada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Verificaci\u00f3n de Grupos Sangu\u00edneos**:\n   - Se debe verificar el grupo sangu\u00edneo ABO y RhD en cada donaci\u00f3n subsiguiente.\n   - Comparar con el grupo sangu\u00edneo hist\u00f3ricamente determinado.\n   - Si hay discrepancias, no se deben liberar los componentes sangu\u00edneos hasta resolver la discrepancia.\n\n2. **Pruebas para Anticuerpos Irregulares**:\n   - Donantes con antecedentes de transfusiones o embarazo deben ser evaluados para detectar anticuerpos irregulares cl\u00ednicamente significativos.\n   - Si se detectan, los componentes sangu\u00edneos deben etiquetarse adecuadamente.\n\n3. **Requisitos de la NRA**:\n   - Las Autoridades Reguladoras Nacionales (NRA) pueden establecer requisitos m\u00e1s estrictos.\n\n4. **Etiquetado de Donaciones de Primeras Veces**:\n   - El etiquetado de concentrados de gl\u00f3bulos rojos de donaciones de primer vez debe basarse en dos pruebas independientes de ABO/RhD.\n\n5. **Retenci\u00f3n de Muestras**:\n   - Se debe retener una al\u00edcuota de la muestra de prueba original de cada donaci\u00f3n.\n   - Almacenamiento bajo condiciones recomendadas por el fabricante del test para permitir re-pruebas si es necesario.\n   - Definici\u00f3n de volumen de muestra, vial de retenci\u00f3n, tipo de muestra (suero o plasma), condiciones y duraci\u00f3n de almacenamiento.\n\n6. **Control de Calidad**:\n   - Los datos de control de calidad deben demostrar que los procesos de fabricaci\u00f3n cr\u00edticos est\u00e1n bajo control.\n   - Los componentes sangu\u00edneos deben cumplir con especificaciones y utilizar m\u00e9todos de prueba aprobados por la NRA.\n   - Validaci\u00f3n de todos los procesos que influyen en la calidad de los productos.\n   - Implementaci\u00f3n de un plan de muestreo basado en m\u00e9todos estad\u00edsticos que considere diferentes sitios de recolecci\u00f3n, producci\u00f3n, transporte y m\u00e9todos de preparaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **NRA (Autoridades Reguladoras Nacionales)**: Entidades que pueden establecer requisitos adicionales.\n- **Componentes Sangu\u00edneos**: Incluyen gl\u00f3bulos rojos, plasma, etc.\n- **Anticuerpos Irregulares**: Anticuerpos que pueden afectar la compatibilidad sangu\u00ednea.\n- **Muestras de Prueba**: Muestras retenidas para pruebas adicionales. \n\nEste resumen destaca la importancia de la verificaci\u00f3n, el control de calidad y la gesti\u00f3n de muestras en el contexto de la donaci\u00f3n de sangre y la seguridad transfusional.", "excerpt_keywords": "Keywords: labelling, blood components, quality control, traceability, standard operating procedures"}}, "37d81d42-e015-4bbe-ad11-d621aabb7b70": {"node_ids": ["f30cfd36-b3fa-431e-9881-e1524fc927e8"], "metadata": {"page_label": "218", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the required storage conditions;\n- the expiry date and, where appropriate, time (see section 9.7.3.);\n- the date of collection of the donation(s) from which the blood component was prepared and/or the production date and time (where appropriate);\n- the date and time of irradiation (where applicable);\n- the ABO and RhD blood group (where appropriate);\n- the name or other identification of the component preparation site.\n\nInformation regarding the use of the blood product may also be applicable.\n\nFor autologous blood components, the label should additionally contain the name and unique identification of the patient as well as the statement \u201cAutologous donation\u201d. In some countries the signature of the donor is also required.\n\n### 9.7.2 Product name\n\nThe name of the blood component should be clearly stated on the label and should indicate any further processing such as leukocyte reduction or irradiation.\n\nIn addition, the anticoagulant and/or any nutrient or preservative solution should be mentioned on the label.\n\n### 9.7.3 Expiry date\n\nAny final blood product should have its expiry date on its label. It should be also kept in mind that certain processing steps, such as irradiation, have an influence on the expiry date so that relabelling becomes necessary.\n\nThe definition of an expiry date should be validated and based on scientific data according to the processing steps applied and the storage conditions, or should be the subject of stability studies.\n\n### 9.8 Release of product\n\nEach blood establishment should be able to demonstrate that a blood component has been evaluated and approved for release by an authorized person, preferably assisted by validated computerized systems. The release criteria and specifications of blood components should be defined, validated, documented and approved by quality assurance. There should be a standard operating procedure that details the actions and criteria that determine whether the blood or blood component can be released. The decision to release the blood components should be made by the responsible person of the establishment; it should be clearly documented and traceability should be ensured. Electronic release of products should be fully validated.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla los requisitos para el etiquetado y liberaci\u00f3n de componentes sangu\u00edneos. Se especifican las condiciones de almacenamiento, la fecha de caducidad, la identificaci\u00f3n del donante y del sitio de preparaci\u00f3n, as\u00ed como la necesidad de un procedimiento estandarizado para la liberaci\u00f3n de productos sangu\u00edneos. Tambi\u00e9n se menciona la importancia de la validaci\u00f3n de los procesos y la documentaci\u00f3n adecuada para garantizar la trazabilidad y la calidad de los componentes sangu\u00edneos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica debe incluirse en la etiqueta de un componente sangu\u00edneo aut\u00f3logo?**\n   - La etiqueta debe incluir el nombre y la identificaci\u00f3n \u00fanica del paciente, as\u00ed como la declaraci\u00f3n \"Donaci\u00f3n aut\u00f3loga\". En algunos pa\u00edses, tambi\u00e9n se requiere la firma del donante.\n\n2. **\u00bfC\u00f3mo se determina la fecha de caducidad de un producto sangu\u00edneo y qu\u00e9 factores pueden influir en ella?**\n   - La fecha de caducidad debe estar validada y basada en datos cient\u00edficos que consideren los pasos de procesamiento aplicados y las condiciones de almacenamiento. Procesos como la irradiaci\u00f3n pueden influir en la fecha de caducidad, lo que puede requerir un nuevo etiquetado.\n\n3. **\u00bfQu\u00e9 procedimientos deben seguirse para la liberaci\u00f3n de un componente sangu\u00edneo en un establecimiento de sangre?**\n   - Cada establecimiento debe demostrar que un componente sangu\u00edneo ha sido evaluado y aprobado para su liberaci\u00f3n por una persona autorizada. Deben existir criterios de liberaci\u00f3n definidos, validados y documentados, y la decisi\u00f3n de liberar los componentes debe ser claramente documentada y asegurar la trazabilidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Sangre y Componentes Sangu\u00edneos**:\n   - Importancia de etiquetar adecuadamente la sangre y sus componentes para asegurar la trazabilidad y la conformidad con las regulaciones.\n\n2. **Informaci\u00f3n Requerida en las Etiquetas**:\n   - N\u00famero de donaci\u00f3n \u00fanico: Permite la trazabilidad al donante y a los registros de fabricaci\u00f3n.\n   - Nombre del producto: Identificaci\u00f3n del tipo de componente sangu\u00edneo.\n   - Recuentos celulares: Incluye plaquetas, leucocitos y eritrocitos.\n\n3. **Procedimientos Operativos Est\u00e1ndar**:\n   - Se deben establecer procedimientos escritos para el etiquetado y la metodolog\u00eda de etiquetado, preferiblemente utilizando etiquetas legibles por m\u00e1quina (c\u00f3digos de barras).\n\n4. **Control de Calidad**:\n   - Los componentes sangu\u00edneos no deben liberarse si las pruebas de control de calidad indican que la integridad del producto est\u00e1 comprometida.\n   - Los resultados de las pruebas que no cumplen con los criterios de aceptaci\u00f3n deben ser identificados y los componentes deben permanecer en cuarentena.\n\n5. **Agrupaci\u00f3n de Muestras**:\n   - La pr\u00e1ctica de agrupar muestras antes de las pruebas debe estar claramente documentada y solo es aceptable si hay datos que demuestren la equivalencia entre muestras agrupadas e individuales.\n\n6. **Revisi\u00f3n y An\u00e1lisis de Tendencias**:\n   - Los resultados de las pruebas de monitoreo de calidad deben revisarse peri\u00f3dicamente. Si se identifican problemas, se deben tomar acciones correctivas y preventivas antes de continuar con la fabricaci\u00f3n y distribuci\u00f3n del producto.\n\n### Entidades Clave\n- **NRA**: Autoridad Reguladora Nacional (National Regulatory Authority).\n- **Factor VIII**: Componente de la coagulaci\u00f3n que puede medirse en plasma.\n- **Componentes Sangu\u00edneos**: Incluyen sangre total, plaquetas, leucocitos y eritrocitos. \n\nEste resumen destaca la importancia del etiquetado, la trazabilidad, el control de calidad y la documentaci\u00f3n en el proceso de manejo de sangre y sus componentes.", "excerpt_keywords": "Keywords: blood components, labeling requirements, expiry date, quality assurance, autologous donation"}}, "a441866f-17cf-4d44-b960-f40be2e47565": {"node_ids": ["ce1fa88e-0f1c-4b3f-9b8b-10cb852626b3"], "metadata": {"page_label": "219", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The documented manufacturing processes should be followed at all times using validated methods and procedures. Any deviations from these established procedures and processes may result in products not meeting specifications, in which case they should be considered non-conforming products and must not be released for distribution.\n\nA review of the donor health record, collection and phlebotomy records, consent forms, records of production and test results should be performed and accepted (and should be recorded) prior to the release of the components. The release of products should be arranged in such a way that each component from the donation has been evaluated to ensure conformance with product specifications \u2014 such as platelet content in apheresis units, volume in plasma products or appearance for red blood cells \u2014 prior to release for distribution. The decision to release the component should not be made on the basis of a review of the collection processes alone.\n\nThere should be a system of administrative and physical quarantine for blood and blood components to ensure that components cannot be released until all mandatory requirements have been met.\n\nIn the absence of a computerized system for product status control:\n\n- the label of a blood component should identify the product status and should clearly distinguish released products from non-released (quarantined) ones;\n- records should demonstrate that, before a component is released, all current donor health records, collection and phlebotomy records, consent forms and test results have been verified and accepted by an authorized person.\n\nIf blood or blood components have been prepared from a donor who has donated on previous occasions, a comparison with previous records \u2014 specifically the ABO/RhD and infectious disease marker test results \u2014 should be made before final product release to ensure that current records accurately reflect the donor history.\n\nWhere release is subject to computer-derived information, the following points should be checked:\n\n- Computer systems should be validated so that they are fully secure against the possibility of blood and blood components which do not fulfil all test or donor selection criteria being released.\n- The manual entry of critical data, such as laboratory test results, should require independent verification by a second authorized person.\n- There should be a hierarchy of permitted access to enter, amend, read or print data. Methods of preventing unauthorized entry should be in place, such as personal identity codes or passwords which are changed on a regular basis.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl texto se centra en los procedimientos y requisitos necesarios para la liberaci\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de seguir procesos de fabricaci\u00f3n documentados y validados, as\u00ed como la revisi\u00f3n exhaustiva de los registros de salud del donante, los registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas antes de liberar cualquier componente. Tambi\u00e9n se menciona la necesidad de un sistema de cuarentena administrativa y f\u00edsica para asegurar que los componentes no se liberen hasta que se cumplan todos los requisitos obligatorios. En caso de no contar con un sistema computarizado, se establecen directrices sobre el etiquetado y la verificaci\u00f3n de registros. Adem\u00e1s, se abordan las medidas de seguridad necesarias para sistemas inform\u00e1ticos que gestionan la liberaci\u00f3n de productos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que un componente sangu\u00edneo no se libere si no cumple con las especificaciones?**\n   - La liberaci\u00f3n de un componente sangu\u00edneo debe basarse en una revisi\u00f3n completa de los registros de salud del donante, los registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas. Si hay alguna desviaci\u00f3n de los procedimientos establecidos, el producto debe considerarse no conforme y no debe liberarse.\n\n2. **\u00bfCu\u00e1les son las medidas que deben implementarse en un sistema computarizado para garantizar la seguridad en la liberaci\u00f3n de componentes sangu\u00edneos?**\n   - Los sistemas computarizados deben ser validados para asegurar que no se liberen componentes que no cumplan con todos los criterios de prueba o selecci\u00f3n del donante. Adem\u00e1s, la entrada manual de datos cr\u00edticos debe requerir verificaci\u00f3n independiente, y debe existir una jerarqu\u00eda de acceso para modificar o consultar datos.\n\n3. **\u00bfQu\u00e9 pasos se deben seguir si un donante ha donado en ocasiones anteriores antes de liberar un nuevo componente sangu\u00edneo?**\n   - Se debe realizar una comparaci\u00f3n con los registros anteriores del donante, espec\u00edficamente los resultados de las pruebas de ABO/RhD y marcadores de enfermedades infecciosas, para asegurarse de que los registros actuales reflejen con precisi\u00f3n la historia del donante antes de la liberaci\u00f3n del producto.", "prev_section_summary": "### Temas Clave:\n\n1. **Etiquetado de Componentes Sangu\u00edneos**:\n   - Informaci\u00f3n esencial que debe incluirse en la etiqueta, como condiciones de almacenamiento, fecha de caducidad, fecha de recolecci\u00f3n, grupo sangu\u00edneo ABO y RhD, y la identificaci\u00f3n del sitio de preparaci\u00f3n.\n\n2. **Componentes Sangu\u00edneos Aut\u00f3logos**:\n   - Requisitos espec\u00edficos para la etiqueta, que deben incluir el nombre y la identificaci\u00f3n \u00fanica del paciente, as\u00ed como la declaraci\u00f3n \"Donaci\u00f3n aut\u00f3loga\".\n\n3. **Nombre del Producto**:\n   - El nombre del componente sangu\u00edneo debe ser claro e indicar cualquier procesamiento adicional, como reducci\u00f3n de leucocitos o irradiaci\u00f3n, adem\u00e1s de mencionar soluciones anticoagulantes o preservativas.\n\n4. **Fecha de Caducidad**:\n   - Importancia de tener una fecha de caducidad validada, influenciada por procesos de tratamiento como la irradiaci\u00f3n, que puede requerir un nuevo etiquetado.\n\n5. **Liberaci\u00f3n de Productos Sangu\u00edneos**:\n   - Procedimientos que deben seguirse para la liberaci\u00f3n de componentes sangu\u00edneos, incluyendo la evaluaci\u00f3n y aprobaci\u00f3n por una persona autorizada, criterios de liberaci\u00f3n documentados y la necesidad de asegurar la trazabilidad.\n\n### Entidades:\n\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos**: WHO - Technical Report Series 961\n- **Componentes Sangu\u00edneos**: Sangre, componentes sangu\u00edneos aut\u00f3logos\n- **Procesos**: Recolecci\u00f3n, procesamiento, irradiaci\u00f3n, liberaci\u00f3n\n- **Identificaci\u00f3n**: Nombre del paciente, identificaci\u00f3n del sitio de preparaci\u00f3n, firma del donante (en algunos pa\u00edses)\n- **Criterios de Calidad**: Validaci\u00f3n, documentaci\u00f3n, trazabilidad, sistemas computarizados validados\n\nEste resumen destaca los aspectos fundamentales relacionados con el etiquetado y la liberaci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de la calidad y la trazabilidad en el manejo de productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood components, release procedures, donor health records, quality control, validation systems"}}, "da9e8f1c-ba83-4ead-b0e0-1dc12ba39f04": {"node_ids": ["69798271-cc9b-4c52-94dd-48153ebee1e0"], "metadata": {"page_label": "220", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Computer systems should prevent the release of all blood or blood components considered not acceptable for release. It should be possible to prevent the release of any future donation from a donor.\n\nIn the event that the final product fails release due to noncompliance with the specified requirements and therefore due to potential impact on recipient safety, all other implicated components should be identified and appropriate action should be taken. A check should be made to ensure that (if relevant) other components from the same donation(s) and components prepared from previous donations given by the donor(s) are identified. There should be an immediate updating of the donor record(s) to ensure that the donor(s) cannot make any further donation, if appropriate.\n\nThere should be a defined procedure for the exceptional release of nonstandard blood and blood components under a planned non-conformance system. The decision to allow such a release should be made by the responsible person; the decision should be clearly documented and traceability should be ensured. Products that cannot be released should be destroyed and the record of destruction should be retained.\n\n### 9.9 Storage\n\nStandard operating procedures should describe the receipt, handling and storage of material, blood and blood components. There should be a system in place to maintain and control storage conditions, including any transportation that may be required. Autologous blood and blood components should be stored separately. Storage areas for blood components to be dispatched should be located near an entrance or exit to facilitate dispatch and to limit the number of persons entering the main working areas. Only authorized persons should have access to storage areas.\n\nStorage conditions should be controlled, monitored and checked. The personnel authorized should be trained to be aware of the correct storage temperature ranges and alarm settings. Temperature records should be available to demonstrate that the blood components are stored at the required temperature throughout the storage area. A temperature monitoring and recording system that is independent from the temperature regulation system should be in place. Appropriate alarms should be present (upper and lower limits) and regularly checked; the checks should be recorded. Depending on the method of measuring the temperature, a delay of the alarm may be acceptable in order to avoid an alarm being triggered by opening a door or taking out a product, but any such delay should be reasonably justified. If the temperature sensor is placed in a reference solution, no delay of the alarm should be accepted. Appropriate actions on alarms should be defined, and a person should be authorized to decide on the use or rejection of affected", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Prevenci\u00f3n de liberaci\u00f3n de componentes sangu\u00edneos**: El documento establece que los sistemas inform\u00e1ticos deben evitar la liberaci\u00f3n de sangre o componentes sangu\u00edneos que no sean aceptables, y se deben tomar medidas para identificar y actuar sobre donaciones implicadas en caso de que un producto final no cumpla con los requisitos de seguridad.\n\n2. **Procedimientos de almacenamiento**: Se detallan los procedimientos est\u00e1ndar para la recepci\u00f3n, manejo y almacenamiento de sangre y componentes sangu\u00edneos, enfatizando la importancia de mantener condiciones de almacenamiento controladas y monitoreadas, as\u00ed como la capacitaci\u00f3n del personal en el manejo de temperaturas y alarmas.\n\n3. **Manejo de no conformidades**: Se menciona la necesidad de un procedimiento definido para la liberaci\u00f3n excepcional de componentes sangu\u00edneos no est\u00e1ndar, que debe ser documentado y autorizado por una persona responsable, asegurando la trazabilidad y el manejo adecuado de productos que no pueden ser liberados.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si un producto sangu\u00edneo no cumple con los requisitos de liberaci\u00f3n?**\n   - En caso de que un producto final falle en su liberaci\u00f3n, se deben identificar todos los componentes implicados, actualizar inmediatamente los registros del donante para evitar futuras donaciones y tomar las acciones apropiadas para garantizar la seguridad del receptor.\n\n2. **\u00bfCu\u00e1les son los requisitos para el almacenamiento de componentes sangu\u00edneos aut\u00f3logos?**\n   - Los componentes sangu\u00edneos aut\u00f3logos deben almacenarse por separado, y las \u00e1reas de almacenamiento deben estar ubicadas cerca de las entradas o salidas para facilitar el despacho y limitar el acceso a personas no autorizadas.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para el monitoreo de la temperatura en las \u00e1reas de almacenamiento de sangre?**\n   - Debe existir un sistema de monitoreo y registro de temperatura independiente del sistema de regulaci\u00f3n, con alarmas adecuadas que se revisen regularmente. Adem\u00e1s, el personal autorizado debe estar capacitado en los rangos de temperatura correctos y en la respuesta a las alarmas, asegurando que se tomen decisiones informadas sobre el uso o rechazo de productos afectados.", "prev_section_summary": "### Temas Clave\n\n1. **Procedimientos de Fabricaci\u00f3n**: Se enfatiza la importancia de seguir procesos documentados y validados para la fabricaci\u00f3n de componentes sangu\u00edneos. Cualquier desviaci\u00f3n de estos procedimientos puede resultar en productos no conformes.\n\n2. **Revisi\u00f3n de Registros**: Antes de liberar componentes sangu\u00edneos, es necesario realizar una revisi\u00f3n exhaustiva de los registros de salud del donante, registros de recolecci\u00f3n y flebotom\u00eda, formularios de consentimiento y resultados de pruebas.\n\n3. **Cuarentena Administrativa y F\u00edsica**: Se debe implementar un sistema de cuarentena para asegurar que los componentes no se liberen hasta que se cumplan todos los requisitos obligatorios.\n\n4. **Etiquetado y Verificaci\u00f3n**: En ausencia de un sistema computarizado, los componentes deben estar etiquetados para identificar su estado (liberados o en cuarentena) y los registros deben demostrar que se han verificado todos los documentos necesarios.\n\n5. **Comparaci\u00f3n de Registros de Donantes**: Si un donante ha donado anteriormente, se debe comparar su historial con los registros actuales, especialmente en lo que respecta a pruebas de ABO/RhD y marcadores de enfermedades infecciosas.\n\n6. **Seguridad en Sistemas Computarizados**: Los sistemas inform\u00e1ticos deben ser validados para prevenir la liberaci\u00f3n de componentes no conformes. La entrada manual de datos cr\u00edticos debe ser verificada independientemente, y debe existir una jerarqu\u00eda de acceso para proteger la informaci\u00f3n.\n\n### Entidades\n\n- **Componentes Sangu\u00edneos**: Productos derivados de la sangre que deben cumplir con especificaciones antes de su liberaci\u00f3n.\n- **Registros de Salud del Donante**: Documentaci\u00f3n que contiene informaci\u00f3n sobre la salud del donante.\n- **Registros de Recolecci\u00f3n y Flebotom\u00eda**: Documentos que registran el proceso de recolecci\u00f3n de sangre.\n- **Formularios de Consentimiento**: Documentos que confirman que el donante ha dado su consentimiento para la donaci\u00f3n.\n- **Resultados de Pruebas**: Informaci\u00f3n sobre las pruebas realizadas a los componentes sangu\u00edneos.\n- **Sistema de Cuarentena**: Proceso administrativo y f\u00edsico para asegurar que los productos no se liberen hasta cumplir con todos los requisitos.\n- **Sistemas Computarizados**: Herramientas tecnol\u00f3gicas utilizadas para gestionar la informaci\u00f3n y el estado de los productos sangu\u00edneos.", "excerpt_keywords": "Keywords: blood safety, storage procedures, donor records, nonconformance, temperature monitoring"}}, "6d3b0664-6556-42df-bb07-ec3b69427855": {"node_ids": ["01e6b08d-df45-44ba-a332-79b1f1966828"], "metadata": {"page_label": "221", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "products. Temperature excursions may occur and each event should be evaluated using the deviation management system (see section 3.5).\n\nAn alternative storage area of appropriate temperature is recommended for recovery in case of temperature control failure of the primary system. Areas for storage should be secured against the entry of unauthorized persons and should be used only for the intended purpose. Storage areas should provide effective segregation of quarantined and released materials or components. There should be a separate area for rejected components and material. If a temporary mechanical or electrical failure affects control of storage temperatures, an examination of the records should be made to evaluate the impact on plasma or blood component quality.\n\nFor the main blood components, the common storage temperatures are as follows:\n\n- red-cell concentrate: 1\u20136\u00b0C;\n- plasma for transfusion: minus 25\u00b0C or colder;\n- platelets: 20\u201324\u00b0C;\n\nor in a more stringent range defined by the NRA.\n\nHigher storage temperatures (e.g. minus 20\u00b0C) might be acceptable for plasma for transfusion but may result in a significantly shorter shelf-life.\n\nStorage of platelets should also be controlled. Besides the temperature, the continuous agitation is very important. Based on the manufacturer\u2019s instructions, the moving velocity should be set in a way that obtains an optimal quality of the product. The moving velocity should be part of the qualification of the equipment.\n\nDuring the whole collection and manufacturing process it should be ensured that blood or blood components are never placed in direct sunlight or near a heating source.\n\nAll storage equipment should be subject to qualification, cleaning and preventive maintenance. Thermometers or temperature sensors should be calibrated annually. The temperature deviation to the standard measuring device should not exceed 1\u00b0C.\n\n## 9.10 Distribution\n\nPrior to distribution, blood components should be visually inspected. There should be a record that identifies the person distributing and the customer receiving the components. Dispatch of blood components should be made by authorized personnel.\n\nAt the time of dispatch, there should be a procedure in place to ensure that all blood components being issued have been formally released for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre el almacenamiento y distribuci\u00f3n de componentes sangu\u00edneos, enfatizando la importancia de mantener temperaturas adecuadas y seguras para preservar la calidad de los productos. Se mencionan las temperaturas de almacenamiento recomendadas para diferentes componentes sangu\u00edneos, la necesidad de un \u00e1rea de almacenamiento alternativa en caso de fallos en el control de temperatura, y la importancia de la inspecci\u00f3n visual y el registro de distribuci\u00f3n antes de enviar los componentes. Tambi\u00e9n se destaca la necesidad de mantenimiento y calibraci\u00f3n de los equipos de almacenamiento.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las temperaturas de almacenamiento recomendadas para los diferentes componentes sangu\u00edneos y qu\u00e9 impacto puede tener un almacenamiento a temperaturas m\u00e1s altas?**\n   - Respuesta: Las temperaturas recomendadas son: concentrado de gl\u00f3bulos rojos a 1\u20136\u00b0C, plasma para transfusi\u00f3n a menos 25\u00b0C o m\u00e1s fr\u00edo, y plaquetas a 20\u201324\u00b0C. Almacenar plasma a temperaturas m\u00e1s altas, como menos 20\u00b0C, puede resultar en una vida \u00fatil significativamente m\u00e1s corta.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse en caso de un fallo temporal en el control de temperatura de los equipos de almacenamiento?**\n   - Respuesta: En caso de un fallo temporal, se debe realizar un examen de los registros para evaluar el impacto en la calidad de los componentes sangu\u00edneos, y se recomienda tener un \u00e1rea de almacenamiento alternativa de temperatura adecuada para la recuperaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en las \u00e1reas de almacenamiento de componentes sangu\u00edneos?**\n   - Respuesta: Las \u00e1reas de almacenamiento deben estar aseguradas contra la entrada de personas no autorizadas, y debe haber una efectiva segregaci\u00f3n entre materiales en cuarentena y aquellos liberados, as\u00ed como un \u00e1rea separada para componentes rechazados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Prevenci\u00f3n de Liberaci\u00f3n de Componentes Sangu\u00edneos**:\n   - Los sistemas inform\u00e1ticos deben impedir la liberaci\u00f3n de sangre o componentes sangu\u00edneos no aceptables.\n   - Se deben identificar todos los componentes implicados si un producto final no cumple con los requisitos de seguridad.\n   - Actualizaci\u00f3n inmediata de los registros del donante para evitar futuras donaciones.\n\n2. **Procedimientos de Manejo de No Conformidades**:\n   - Se requiere un procedimiento definido para la liberaci\u00f3n excepcional de componentes sangu\u00edneos no est\u00e1ndar.\n   - La decisi\u00f3n de liberar productos no conformes debe ser documentada y autorizada por una persona responsable.\n   - Los productos que no pueden ser liberados deben ser destruidos, y se debe mantener un registro de destrucci\u00f3n.\n\n3. **Almacenamiento de Componentes Sangu\u00edneos**:\n   - Se deben establecer procedimientos est\u00e1ndar para la recepci\u00f3n, manejo y almacenamiento de sangre y componentes sangu\u00edneos.\n   - Los componentes sangu\u00edneos aut\u00f3logos deben almacenarse por separado.\n   - Las \u00e1reas de almacenamiento deben estar ubicadas estrat\u00e9gicamente para facilitar el despacho y limitar el acceso a personal no autorizado.\n\n4. **Monitoreo de Condiciones de Almacenamiento**:\n   - Las condiciones de almacenamiento deben ser controladas y monitoreadas.\n   - El personal debe estar capacitado en los rangos de temperatura y configuraciones de alarma.\n   - Se debe implementar un sistema de monitoreo de temperatura independiente del sistema de regulaci\u00f3n, con alarmas adecuadas y registros de verificaci\u00f3n.\n\n### Entidades Clave\n- **Sistemas Inform\u00e1ticos**: Herramientas para prevenir la liberaci\u00f3n de componentes no aceptables.\n- **Donantes**: Personas que proporcionan sangre; sus registros deben actualizarse en caso de no conformidades.\n- **Productos Sangu\u00edneos**: Componentes que pueden ser liberados o destruidos seg\u00fan su conformidad con los requisitos de seguridad.\n- **Personal Autorizado**: Empleados capacitados para manejar y monitorear las condiciones de almacenamiento de sangre.\n- **Alarmas de Temperatura**: Dispositivos que alertan sobre condiciones de almacenamiento inadecuadas. \n\nEste resumen destaca la importancia de la seguridad en la gesti\u00f3n de sangre y componentes sangu\u00edneos, as\u00ed como la necesidad de procedimientos claros y capacitaci\u00f3n del personal.", "excerpt_keywords": "Keywords: blood components, storage temperatures, distribution procedures, temperature control, quality assurance"}}, "e58dd580-7d8c-4044-ac40-0fa6307d8153": {"node_ids": ["84d8155e-b19f-4da9-a9e5-bc5a7ef54060"], "metadata": {"page_label": "222", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.11 Shipping\n\nDistribution should take place in a safe and controlled way in order to assure product quality during transport. All transportation and intermediate storage actions, including receipt and distribution, should be defined by written standard operating procedures and specifications.\n\nThe shipping containers should be of sturdy construction in order to resist damage and should be validated to maintain acceptable storage conditions for the blood and blood components (e.g. by using appropriate cooling elements or insulation during transport). The transportation and storage conditions for blood components, the packaging format and the responsibilities of the persons involved should be in accordance with standard operating procedures agreed between the sites in question.\n\n# 9.12 Returns\n\nBlood components should not be returned to stock for subsequent distribution, unless:\n\n- the procedure for return of a blood component is regulated by contract;\n- for each returned blood component, it is proven that the agreed storage conditions have consistently been met;\n- the integrity of the container has been maintained (i.e. unopened);\n- sufficient material is available for compatibility testing.\n\nIn case of medical urgency, components may be returned and subsequently distributed using a defined procedure.\n\nThe records should indicate that the blood component has been inspected and found to be acceptable before re-issue.\n\n# 10. Contract manufacturing, analysis and services\n\nIn blood establishments, all tasks that have an influence on the quality of collected blood and the manufacture of blood components \u2014 such as component processing, testing or information technology support \u2014 and which are performed externally by another party, should be subject to a specific written contract. The contract should ensure that the contract acceptor meets GMP requirements in all disciplines relevant to the contract giver\u2019s activities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda las directrices sobre el transporte y la gesti\u00f3n de componentes sangu\u00edneos. Se enfatiza la importancia de mantener la calidad del producto durante el transporte mediante procedimientos operativos est\u00e1ndar. Tambi\u00e9n se establecen condiciones espec\u00edficas para la devoluci\u00f3n de componentes sangu\u00edneos y la necesidad de contratos escritos para cualquier tarea externa que afecte la calidad de la sangre y sus componentes.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las condiciones que deben cumplirse para que un componente sangu\u00edneo pueda ser devuelto a stock para su posterior distribuci\u00f3n?**\n   - La respuesta se encuentra en la secci\u00f3n sobre devoluciones, donde se especifican las condiciones que deben cumplirse, como la regulaci\u00f3n por contrato, el mantenimiento de las condiciones de almacenamiento, la integridad del contenedor y la disponibilidad de material para pruebas de compatibilidad.\n\n2. **\u00bfQu\u00e9 requisitos deben cumplir los contenedores de env\u00edo para asegurar la calidad de los componentes sangu\u00edneos durante el transporte?**\n   - El contexto menciona que los contenedores deben ser de construcci\u00f3n robusta y validados para mantener condiciones de almacenamiento aceptables, utilizando elementos de enfriamiento o aislamiento durante el transporte.\n\n3. **\u00bfQu\u00e9 tipo de acuerdos deben establecerse cuando se externalizan tareas que afectan la calidad de la sangre en los establecimientos de sangre?**\n   - Se requiere un contrato escrito que asegure que el aceptador del contrato cumpla con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP) en todas las disciplinas relevantes para las actividades del otorgante del contrato.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento de Componentes Sangu\u00edneos**:\n   - Importancia de mantener temperaturas adecuadas para preservar la calidad de los productos sangu\u00edneos.\n   - Temperaturas de almacenamiento recomendadas:\n     - **Concentrado de gl\u00f3bulos rojos**: 1\u20136\u00b0C\n     - **Plasma para transfusi\u00f3n**: menos 25\u00b0C o m\u00e1s fr\u00edo\n     - **Plaquetas**: 20\u201324\u00b0C\n   - Almacenamiento a temperaturas m\u00e1s altas (ej. menos 20\u00b0C para plasma) puede reducir significativamente la vida \u00fatil.\n\n2. **Gesti\u00f3n de Fallos en el Control de Temperatura**:\n   - Se recomienda tener un \u00e1rea de almacenamiento alternativa para recuperaci\u00f3n en caso de fallos en el sistema principal.\n   - Evaluaci\u00f3n del impacto en la calidad de los componentes sangu\u00edneos tras un fallo temporal.\n\n3. **Seguridad en \u00c1reas de Almacenamiento**:\n   - Las \u00e1reas deben estar aseguradas contra el acceso no autorizado.\n   - Segregaci\u00f3n efectiva entre materiales en cuarentena, liberados y rechazados.\n\n4. **Control de Almacenamiento de Plaquetas**:\n   - Importancia de la agitaci\u00f3n continua y la velocidad de movimiento seg\u00fan las instrucciones del fabricante.\n\n5. **Mantenimiento y Calibraci\u00f3n de Equipos**:\n   - Equipos de almacenamiento deben ser calificados, limpiados y mantenidos preventivamente.\n   - Term\u00f3metros y sensores de temperatura deben calibrarse anualmente, con una desviaci\u00f3n m\u00e1xima de 1\u00b0C respecto al dispositivo de medici\u00f3n est\u00e1ndar.\n\n6. **Distribuci\u00f3n de Componentes Sangu\u00edneos**:\n   - Inspecci\u00f3n visual de componentes antes de la distribuci\u00f3n.\n   - Registro de la persona que distribuye y del cliente que recibe los componentes.\n   - Procedimientos para asegurar que todos los componentes han sido formalmente liberados antes del despacho.\n\n### Entidades Clave\n- **Componentes Sangu\u00edneos**: concentrado de gl\u00f3bulos rojos, plasma, plaquetas.\n- **Temperaturas de Almacenamiento**: 1\u20136\u00b0C, menos 25\u00b0C, 20\u201324\u00b0C.\n- **Procedimientos de Seguridad**: acceso no autorizado, segregaci\u00f3n de materiales.\n- **Mantenimiento de Equipos**: calificaci\u00f3n, limpieza, calibraci\u00f3n.\n- **Distribuci\u00f3n**: inspecci\u00f3n visual, registro de distribuci\u00f3n, autorizaci\u00f3n.", "excerpt_keywords": "Keywords: shipping, blood components, returns, standard operating procedures, contract manufacturing"}}, "ac23648e-ee1f-455b-ab7f-0b11da796559": {"node_ids": ["b94f7827-9774-406a-9696-e254171e331a"], "metadata": {"page_label": "223", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The contract giver is ultimately responsible for ensuring that processes are in place to assure the control of outsourced activities and the quality of purchased materials. These processes should incorporate QRM and should include:\n\n- assessing (prior to outsourcing operations or selecting material suppliers) the suitability and competence of the other party to carry out the activity or provide the material using a defined supply chain (e.g. audits, material evaluations, qualification);\n- defining the responsibilities and communication processes for quality-related activities of the parties concerned;\n- monitoring and review of the performance of the contract acceptor or the quality of the material from the provider, and identification and implementation of any improvements needed;\n- monitoring of incoming ingredients and materials to ensure that they are from approved sources using the agreed supply chain.\n\nDetails should be specified in a technical quality agreement or contract.\n\nThe contract or agreement should:\n\n- clearly establish the duties of each party;\n- state the responsibilities of each party;\n- mention any technical arrangements;\n- define the flow of information, especially regarding deviations and changes;\n- define the handling and archiving of documents, samples and other relevant materials and information;\n- state that any of the duties given to the contract acceptor should not be passed to a third party without evaluation and approval of the contract giver;\n- permit the contract giver and competent authorities to visit and inspect the facilities of the contract acceptor.\n\nThe contract giver should provide the contract acceptor with all necessary information to enable compliance with expectations regarding services or goods. This assures that the work or service is performed in compliance with existing regulations. The overall responsibility for the work and duties carried out externally lies always with the contracting company.\n\nThe contract should be agreed and signed by quality assurance representatives from both parties and should be kept up to date.\n\n## 11. Authors and acknowledgements\n\nThese guidelines were developed under the coordination of Dr A Padilla, Scientist, Quality Assurance and Safety of Medicines (Blood Products and Related Biologicals), World Health Organization, Geneva, Switzerland.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Responsabilidad del contratante**: El contratante es responsable de asegurar que existan procesos adecuados para controlar las actividades externalizadas y la calidad de los materiales adquiridos. Esto incluye la evaluaci\u00f3n de la competencia de los proveedores, la definici\u00f3n de responsabilidades y la supervisi\u00f3n del rendimiento.\n\n2. **Acuerdo de calidad t\u00e9cnica**: Se debe formalizar un acuerdo t\u00e9cnico que detalle las obligaciones y responsabilidades de ambas partes, as\u00ed como los procedimientos de comunicaci\u00f3n y manejo de documentos. Este acuerdo debe ser firmado por representantes de aseguramiento de calidad de ambas partes y mantenerse actualizado.\n\n3. **Cumplimiento normativo**: El contratante debe proporcionar toda la informaci\u00f3n necesaria al contratista para garantizar que se cumplan las expectativas y regulaciones pertinentes. La responsabilidad final de las actividades externalizadas recae siempre en la empresa contratante.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que debe seguir el contratante para evaluar la competencia de un proveedor antes de externalizar operaciones?**\n   - El contratante debe realizar auditor\u00edas, evaluaciones de materiales y calificaciones para determinar la idoneidad y competencia del proveedor.\n\n2. **\u00bfQu\u00e9 elementos deben incluirse en un acuerdo t\u00e9cnico de calidad para asegurar una comunicaci\u00f3n efectiva entre las partes?**\n   - El acuerdo debe definir el flujo de informaci\u00f3n, especialmente en relaci\u00f3n con desviaciones y cambios, as\u00ed como el manejo y archivo de documentos y muestras relevantes.\n\n3. **\u00bfQu\u00e9 derechos tiene el contratante en relaci\u00f3n con la supervisi\u00f3n de las instalaciones del contratista?**\n   - El contratante tiene el derecho de visitar e inspeccionar las instalaciones del contratista, as\u00ed como de asegurarse de que las responsabilidades no sean transferidas a un tercero sin su evaluaci\u00f3n y aprobaci\u00f3n.", "prev_section_summary": "### Temas Clave:\n\n1. **Transporte de Componentes Sangu\u00edneos**:\n   - La distribuci\u00f3n debe realizarse de manera segura y controlada para asegurar la calidad del producto durante el transporte.\n   - Se requiere que todas las acciones de transporte y almacenamiento intermedio est\u00e9n definidas por procedimientos operativos est\u00e1ndar escritos.\n\n2. **Condiciones de Env\u00edo**:\n   - Los contenedores de env\u00edo deben ser robustos y validados para mantener condiciones de almacenamiento aceptables, utilizando elementos de enfriamiento o aislamiento.\n\n3. **Devoluciones de Componentes Sangu\u00edneos**:\n   - Existen condiciones espec\u00edficas bajo las cuales los componentes sangu\u00edneos pueden ser devueltos a stock, incluyendo regulaciones contractuales, mantenimiento de condiciones de almacenamiento, integridad del contenedor y disponibilidad para pruebas de compatibilidad.\n   - En situaciones de urgencia m\u00e9dica, se permite la devoluci\u00f3n y redistribuci\u00f3n bajo un procedimiento definido.\n\n4. **Contrataci\u00f3n Externa**:\n   - Todas las tareas que afectan la calidad de la sangre y sus componentes, realizadas externamente, deben estar sujetas a un contrato escrito que garantice el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Componentes Sangu\u00edneos**: Elementos que se transportan y gestionan seg\u00fan las directrices.\n- **Contenedores de Env\u00edo**: Estructuras utilizadas para el transporte de componentes sangu\u00edneos.\n- **Procedimientos Operativos Est\u00e1ndar (SOP)**: Documentos que definen las acciones de transporte y almacenamiento.\n- **Contratos**: Acuerdos escritos necesarios para la externalizaci\u00f3n de tareas relacionadas con la calidad de la sangre.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada del transporte y la devoluci\u00f3n de componentes sangu\u00edneos, as\u00ed como la necesidad de contratos claros para asegurar la calidad en las operaciones externas.", "excerpt_keywords": "Keywords: outsourcing, quality assurance, technical agreement, contract management, regulatory compliance"}}, "30494564-ff06-4f01-b4e5-c24c15f32ca0": {"node_ids": ["926dbb25-fc22-4d50-b08e-1901893ad282"], "metadata": {"page_label": "224", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The drafting group was formed of:  \nMr JW Atkins, National Institutes of Health (NIH), Bethesda, MD, USA; Dr A Padilla, World Health Organization, Geneva, Switzerland; Dr C Sch\u00e4rer, Swissmedic, Bern, Switzerland; Mrs D Schmidkunz Eggler, Swissmedic, Bern, Switzerland; Dr G Werner, Paul-Ehrlich-Institut (PEI), Langen, Germany.\n\nContributions were also solicited from:  \nMs S Douglas, Therapeutic Goods Administration (TGA), Melbourne, Australia; Mr L Fields, Food and Drug Administration (FDA), Rockville, MD, USA; Dr D Kaesermann, Swissmedic, Switzerland; Dr J Morenas and Dr F Teskrat, Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (AFSSAPS), Saint-Denis, France; Dr W Schwarz, PEI, Germany; Dr U Unkelbach, PEI, Germany; Dr L van Loosbroek, GMP Consultant, Netherlands; Mr L Young, Health Canada, Ottawa, Canada.\n\nComments, advice and information given during the preparation and consultation process for developing these guidelines were received from the following experts:\n\n- Dr F Agbanyo, Health Canada, Ottawa, Canada; Dr M Farag Ahmed, National Organization for Drug Control & Research (NODCAR), Agousa, Egypt; Lic. MP \u00c1lvarez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), La Habana, Cuba; Dr J Ansah, National Centre of Blood Transfusion, Accra, Ghana; Dr C Bianco, America\u2019s Blood Centers, Washington DC, USA; Dr V Bogdanova, Federal Medical and Biological Agency (FMBA), Moscow, Russian Federation; Dr T Burnouf, Human Protein Process Sciences, France; Dr M Cheraghali, Dr Amini and Dr Maqsoudloo, Iranian Blood Transfusion Organization, Tehran, Islamic Republic of Iran; Dr JR Cruz, Regional Advisor, WHO, AMRO/PAHO, Washington, USA; Dr F Darwish, Central Blood Bank, Manama, Kingdom of Bahrain; Dr R Davey, FDA, Rockville, MD, USA; Professor S Diop, National Centre of Blood Transfusion, Dakar, Senegal; Dr D El Sherif, Central Administration of Pharmaceutical Affairs (CAPA), Cairo, Egypt; Dr J Epstein, FDA, Rockville, MD, USA; Dr P Ganz, Health Canada, Ottawa, Canada; Mr A Gould, Medicines Prequalification Programme, WHO, Geneva, Switzerland; Dr I Hamaguchi, National Institute of Infectious Diseases (NIID), Tokyo, Japan; Dr M Heiden, PEI, Langen, Germany; Dr S Hindawi, Blood Transfusion Service, Jeddah, Saudi Arabia; Dr Ho Jung Oh, Korea Food and Drug Administration (KFDA), Seoul, Republic of Korea; Dr M Jutzi, Swissmedic, Bern, Switzerland; Dr H Klein, NIH, Bethesda, MD, USA; Mrs AC Madukwe, National Agency for Food and Drug Administration and Control (NAFDAC), Lagos, Nigeria; Ms GM Mahlangu, Medicines Control Authority, Harare, Zimbabwe; Dr G Michaud, FDA, Rockville, MD, USA; Dr F Moftah, Blood Transfusion Service, Ministry of Health and Population, Agousa, Egypt; Dr Z Mukhtar, National Institute of Health, Islamabad, Pakistan; Dr C Munk and Dr P Strengers, International Society of Blood Transfusion (ISBT), Amsterdam, Netherlands; Dr P Murray, NIH, Bethesda, MD, USA; Dr K Nabae, Ministry of Health, Labour and Welfare, Tokyo, Japan; Dr L Oliva, Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (ANMAT), Buenos Aires, Argentina; Dr R Perry, International Plasma Fractionation Association (IPFA), Amsterdam, Netherlands; Dr I Prosser, TGA, Canberra, Australia; Dr I Sainte-Marie, AFSSAPS, Paris, France; Professor R Seitz, PEI, Langen, Germany; Dr G Silvester, European Medicines Agency (EMA), London, UK; Dr G Smith, TGA, Canberra, Australia; Dr D Teo, Blood Services.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Composici\u00f3n del grupo de redacci\u00f3n**: El grupo de redacci\u00f3n del informe est\u00e1 compuesto por expertos de diversas organizaciones de salud y reguladoras de medicamentos de diferentes pa\u00edses, incluyendo la OMS, el NIH, y Swissmedic, entre otros.\n\n2. **Contribuciones de expertos**: Se solicit\u00f3 la colaboraci\u00f3n de numerosos expertos de distintas instituciones y pa\u00edses para proporcionar comentarios, asesor\u00eda e informaci\u00f3n durante el proceso de preparaci\u00f3n de las directrices.\n\n3. **Diversidad geogr\u00e1fica y de especializaci\u00f3n**: Los expertos que contribuyeron provienen de una amplia gama de pa\u00edses y especialidades, lo que refleja un enfoque global y multidisciplinario en el desarrollo de las directrices.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfQui\u00e9nes son los miembros clave del grupo de redacci\u00f3n y qu\u00e9 organizaciones representan?**\n   - Respuesta: El grupo de redacci\u00f3n incluye a Mr. JW Atkins (NIH, EE. UU.), Dr. A Padilla (OMS, Suiza), Dr. C Sch\u00e4rer (Swissmedic, Suiza), Mrs. D Schmidkunz Eggler (Swissmedic, Suiza) y Dr. G Werner (PEI, Alemania).\n\n2. **\u00bfQu\u00e9 tipo de contribuciones se recibieron de los expertos durante el proceso de desarrollo de las directrices?**\n   - Respuesta: Se recibieron comentarios, asesor\u00eda e informaci\u00f3n de expertos en diversas \u00e1reas relacionadas con la transfusi\u00f3n de sangre y la regulaci\u00f3n de medicamentos, provenientes de instituciones como Health Canada, FDA, y varias organizaciones internacionales.\n\n3. **\u00bfCu\u00e1l es la importancia de la diversidad geogr\u00e1fica en la composici\u00f3n del grupo de expertos?**\n   - Respuesta: La diversidad geogr\u00e1fica permite incorporar diferentes perspectivas y experiencias en la elaboraci\u00f3n de las directrices, asegurando que sean relevantes y aplicables a un contexto global, lo que es crucial para abordar problemas de salud p\u00fablica de manera efectiva.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidad del Contratante**: El contratante debe asegurar procesos para controlar actividades externalizadas y la calidad de los materiales adquiridos, incorporando la Gesti\u00f3n de Riesgos de Calidad (QRM).\n\n2. **Evaluaci\u00f3n de Proveedores**: Antes de externalizar operaciones o seleccionar proveedores, se debe evaluar la idoneidad y competencia de la otra parte mediante auditor\u00edas y evaluaciones de materiales.\n\n3. **Acuerdo T\u00e9cnico de Calidad**: Es esencial formalizar un acuerdo que detalle las obligaciones, responsabilidades y procedimientos de comunicaci\u00f3n entre las partes, as\u00ed como el manejo de documentos y muestras.\n\n4. **Supervisi\u00f3n y Monitoreo**: El contratante debe monitorear el rendimiento del contratista y la calidad de los materiales, asegurando que provengan de fuentes aprobadas.\n\n5. **Derechos del Contratante**: El contratante tiene derecho a visitar e inspeccionar las instalaciones del contratista y a asegurarse de que las responsabilidades no se transfieran a terceros sin su aprobaci\u00f3n.\n\n6. **Cumplimiento Normativo**: El contratante debe proporcionar informaci\u00f3n necesaria para garantizar el cumplimiento de regulaciones y expectativas.\n\n### Entidades\n\n- **Contratante**: Parte responsable de asegurar el control de actividades externalizadas.\n- **Contratista**: Parte que realiza las actividades externalizadas o proporciona materiales.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad que coordina el desarrollo de estas directrices.\n- **Dr. A. Padilla**: Cient\u00edfico que coordin\u00f3 el desarrollo de las directrices sobre Aseguramiento de Calidad y Seguridad de Medicamentos.\n\n### Resumen\n\nEl contratante es responsable de establecer procesos para controlar las actividades externalizadas y la calidad de los materiales, evaluando la competencia de los proveedores y formalizando un acuerdo t\u00e9cnico de calidad que detalle las responsabilidades y procedimientos de comunicaci\u00f3n. Adem\u00e1s, debe monitorear el rendimiento del contratista y garantizar el cumplimiento normativo, manteniendo el derecho de inspeccionar las instalaciones del contratista. Estas directrices fueron desarrolladas por la OMS bajo la coordinaci\u00f3n del Dr. A. Padilla.", "excerpt_keywords": "Keywords: drafting group, health organizations, expert contributions, global guidelines, regulatory affairs"}}, "3b9866aa-ad9a-4d06-9886-38c436f576ea": {"node_ids": ["38011d52-b428-4bb5-b796-e75a35c75644"], "metadata": {"page_label": "225", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. WHO Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. In: *WHO Expert Committee on Biological Standardization. Forty-third report*. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 840, Annex 2).\n\n2. WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. In: *WHO Expert Committee on Biological Standardization. Fifty-second report*. Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 924, Annex 4).\n\n3. WHO Recommendations for the production, control and regulation of human plasma for fractionation. In: *WHO Expert Committee on Biological Standardization. Fifty-sixth report*. Geneva, World Health Organization, 2007 (WHO Technical Report Series, No. 941, Annex 4).\n\n4. Recommendations of the 13th International Conference of Drug Regulatory Authorities (ICDRA), Bern, 16-19 September 2008. *WHO Drug Information*, 2008, 33(4) (http://www.who.int/medicines/areas/quality_safety/regulation_legislation/icdra/Recommendations_13ICDRA.pdf, accessed 11 January 2011).\n\n5. Resolution WHA63.12. Availability, safety and quality of blood products. In: *Sixty-third World Health Assembly, Geneva, 17-21 May 2010, Volume 1, Resolutions*. Geneva, World Health Organization, 2010 (WHA63/2010/REC/1).\n\n6. *Estandares de trabajo para servicios de sangre*. Washington, DC, Organizacion Panamericana de la Salud/Pan American Health Organization, Area de Tecnologia y Prestacion de Servicios de Salud, 2005.\n\n7. Good manufacturing practices for pharmaceutical products: main principles. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report*. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908, Annex 4).\n\n8. *ICH Q9: Guideline on quality risk management*. Geneva, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.\n\n9. ISBT guidelines for validation of automated systems in blood establishments. *Vox Sanguinis*, 2010, 98(1):1\u201319.\n\n10. Supplementary guidelines on good manufacturing practices: validation. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report*. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937, Annex 4).\n\n11. *PIC/S recommendations on validation master plan, installation and operational qualification, non-sterile process validation, cleaning validation*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en los requisitos y directrices para la recolecci\u00f3n, procesamiento y control de calidad de la sangre y sus derivados. Incluye referencias a varios informes y resoluciones de la OMS y otras organizaciones relacionadas con la seguridad y calidad de los productos sangu\u00edneos, as\u00ed como buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de riesgos. Se mencionan directrices espec\u00edficas sobre la inactivaci\u00f3n viral, la producci\u00f3n de plasma humano y la validaci\u00f3n de sistemas automatizados en establecimientos de sangre.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los principales principios de las buenas pr\u00e1cticas de fabricaci\u00f3n seg\u00fan el informe de la OMS?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los principios que rigen las buenas pr\u00e1cticas de fabricaci\u00f3n en el contexto de productos farmac\u00e9uticos, que se mencionan en el documento.\n\n2. **\u00bfQu\u00e9 recomendaciones se hicieron en la 13\u00aa Conferencia Internacional de Autoridades Reguladoras de Medicamentos (ICDRA) en 2008?**\n   - Esta pregunta se centra en las recomendaciones espec\u00edficas que se derivaron de esta conferencia, que pueden no estar ampliamente disponibles en otros documentos.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de sistemas automatizados en los establecimientos de sangre seg\u00fan las directrices de ISBT?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre los criterios y procesos de validaci\u00f3n que se deben seguir en los sistemas automatizados, un tema t\u00e9cnico que puede no estar ampliamente cubierto en otras fuentes.\n\n### Resumen de Nivel Superior\n\nEl informe de la OMS proporciona un marco integral para garantizar la seguridad y calidad de la sangre y sus derivados. Incluye directrices sobre la recolecci\u00f3n y procesamiento de sangre, la inactivaci\u00f3n de virus, y la producci\u00f3n de plasma, as\u00ed como recomendaciones sobre buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de riesgos. Adem\u00e1s, se hace referencia a resoluciones y recomendaciones de conferencias internacionales que abordan la regulaci\u00f3n y calidad de los productos sangu\u00edneos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Composici\u00f3n del Grupo de Redacci\u00f3n**:\n   - El grupo de redacci\u00f3n est\u00e1 formado por expertos de diversas organizaciones de salud y reguladoras de medicamentos, incluyendo:\n     - **Mr. JW Atkins** (NIH, EE. UU.)\n     - **Dr. A Padilla** (OMS, Suiza)\n     - **Dr. C Sch\u00e4rer** (Swissmedic, Suiza)\n     - **Mrs. D Schmidkunz Eggler** (Swissmedic, Suiza)\n     - **Dr. G Werner** (Paul-Ehrlich-Institut, Alemania)\n\n2. **Contribuciones de Expertos**:\n   - Se solicit\u00f3 la colaboraci\u00f3n de expertos de varias instituciones y pa\u00edses, tales como:\n     - **Ms. S Douglas** (TGA, Australia)\n     - **Mr. L Fields** (FDA, EE. UU.)\n     - **Dr. D Kaesermann** (Swissmedic, Suiza)\n     - **Dr. J Morenas** y **Dr. F Teskrat** (AFSSAPS, Francia)\n     - **Dr. W Schwarz** y **Dr. U Unkelbach** (PEI, Alemania)\n     - **Dr. L van Loosbroek** (Consultor GMP, Pa\u00edses Bajos)\n     - **Mr. L Young** (Health Canada, Canad\u00e1)\n\n3. **Comentarios y Asesor\u00eda**:\n   - Se recibieron comentarios y asesor\u00eda de un amplio grupo de expertos, incluyendo:\n     - **Dr. F Agbanyo** (Health Canada, Canad\u00e1)\n     - **Dr. M Farag Ahmed** (NODCAR, Egipto)\n     - **Lic. MP \u00c1lvarez** (CECMED, Cuba)\n     - **Dr. J Ansah** (Centro Nacional de Transfusi\u00f3n de Sangre, Ghana)\n     - **Dr. C Bianco** (America\u2019s Blood Centers, EE. UU.)\n     - **Dr. V Bogdanova** (FMBA, Rusia)\n     - **Dr. T Burnouf** (Human Protein Process Sciences, Francia)\n     - **Dr. JR Cruz** (OMS, AMRO/PAHO, EE. UU.)\n     - **Dr. R Perry** (IPFA, Pa\u00edses Bajos)\n     - **Dr. G Silvester** (EMA, Reino Unido)\n\n4. **Diversidad Geogr\u00e1fica y Especializaci\u00f3n**:\n   - La participaci\u00f3n de expertos de diferentes pa\u00edses y especialidades refleja un enfoque global y multidisciplinario en el desarrollo de las directrices, asegurando su relevancia y aplicabilidad en contextos diversos.\n\nEste resumen destaca la colaboraci\u00f3n internacional y la diversidad de expertos involucrados en la elaboraci\u00f3n de las directrices, lo que es fundamental para abordar los desaf\u00edos en la salud p\u00fablica y la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: blood safety, WHO guidelines, viral inactivation, good manufacturing practices, plasma production"}}, "5a3c4e9f-e84d-4080-98cc-3367f01251d0": {"node_ids": ["1f61e206-b0c6-4ff2-9336-24e054f0af4d"], "metadata": {"page_label": "226", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Geneva, Pharmaceutical Inspection Cooperation Scheme, 2007 (Document PI 006-3).\n\n12. Good manufacturing practices for sterile pharmaceutical products. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report*. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902, Annex 6).\n\n13. *Guide to the preparation, use and quality assurance of blood components*, 14th edition. Technical annex to Council of Europe Recommendation No. R (95) 15 on the preparation, use and quality assurance of blood components. Strasbourg, European Directorate for the Quality of Medicines and HealthCare (EDQM), 2008.\n\n14. Hughes C et al. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. *Transfusion*, 1988, 28:566.\n\n15. Carlebjork G, Blomback M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. *Vox Sanguinis*, 1983, 45:233.\n\n16. Nilsson L et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. *Transfusion*, 1983, 23:377.\n\n17. Pietersz RN et al. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. *Vox Sanguinis*, 1989, 56:145.\n\n18. Kottischke R et al. Stability of fresh frozen plasma: results of 36-month storage at -20\u00b0C, -25\u00b0C, -30\u00b0C and -40\u00b0C. *Infusionstherapie und Transfusionsmedizin*, 2000, 27:174.\n\n19. Klein HG. Pathogen inactivation technology: cleansing the blood supply. *Journal of Internal Medicine*, 2005, 257:224\u2013237.\n\n20. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. *Archives of pathology & laboratory medicine*, 2007, 131:719\u2013733.\n\n21. WHO guidelines for sampling of pharmaceutical products and related materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report*. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929, Annex 4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las pr\u00e1cticas de fabricaci\u00f3n y calidad de productos farmac\u00e9uticos, especialmente en relaci\u00f3n con componentes sangu\u00edneos y su procesamiento. Incluye referencias a buenas pr\u00e1cticas de fabricaci\u00f3n, gu\u00edas sobre la preparaci\u00f3n y uso de componentes sangu\u00edneos, y estudios sobre la estabilidad y calidad de la sangre y sus derivados. Tambi\u00e9n se mencionan tecnolog\u00edas de inactivaci\u00f3n de pat\u00f3genos como medidas de seguridad para el suministro de sangre.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las buenas pr\u00e1cticas de fabricaci\u00f3n recomendadas para productos farmac\u00e9uticos est\u00e9riles seg\u00fan el informe de la OMS?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las normas y procedimientos que deben seguirse para garantizar la calidad y seguridad de los productos farmac\u00e9uticos est\u00e9riles.\n\n2. **\u00bfQu\u00e9 impacto tiene el retraso en el procesamiento de sangre en el rendimiento del factor VIII en los concentrados de crioprecipitado?**\n   - Esta pregunta se centra en un estudio espec\u00edfico mencionado en el documento que analiza c\u00f3mo el tiempo de procesamiento afecta la calidad de un componente sangu\u00edneo crucial.\n\n3. **\u00bfQu\u00e9 recomendaciones proporciona la OMS sobre la duraci\u00f3n de almacenamiento de sangre y plasma en relaci\u00f3n con los factores de coagulaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las pautas de almacenamiento y su relaci\u00f3n con la estabilidad de los factores de coagulaci\u00f3n, un aspecto cr\u00edtico para la seguridad del suministro de sangre.\n\n### Resumen de Nivel Superior\nEl informe de la OMS proporciona directrices y estudios sobre la fabricaci\u00f3n y calidad de productos farmac\u00e9uticos, con un enfoque particular en componentes sangu\u00edneos. Se discuten las buenas pr\u00e1cticas de fabricaci\u00f3n, la preparaci\u00f3n y uso de componentes sangu\u00edneos, y se presentan investigaciones sobre la estabilidad y calidad de la sangre y sus derivados. Adem\u00e1s, se abordan tecnolog\u00edas para la inactivaci\u00f3n de pat\u00f3genos, destacando su importancia para la seguridad del suministro de sangre.\n\n### Preguntas Adicionales Basadas en el Resumen\n1. **\u00bfQu\u00e9 tecnolog\u00edas se mencionan en el informe como medidas para la inactivaci\u00f3n de pat\u00f3genos en el suministro de sangre?**\n   - Esta pregunta busca informaci\u00f3n sobre las innovaciones y m\u00e9todos espec\u00edficos que se utilizan para garantizar la seguridad de la sangre.\n\n2. **\u00bfC\u00f3mo se relacionan las pautas de la OMS sobre la calidad de los componentes sangu\u00edneos con las recomendaciones del Consejo de Europa?**\n   - Esta pregunta investiga la conexi\u00f3n y coherencia entre las directrices de diferentes organizaciones sobre la calidad y uso de componentes sangu\u00edneos.\n\n3. **\u00bfQu\u00e9 estudios se citan en el informe sobre la estabilidad del plasma fresco congelado y sus condiciones de almacenamiento?**\n   - Esta pregunta busca detalles sobre la investigaci\u00f3n espec\u00edfica que aborda la estabilidad del plasma y las condiciones \u00f3ptimas para su almacenamiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Requisitos y Directrices de la OMS:**\n   - Recolecci\u00f3n, procesamiento y control de calidad de sangre y sus derivados.\n   - Inactivaci\u00f3n y eliminaci\u00f3n de virus en productos de plasma humano.\n   - Producci\u00f3n y regulaci\u00f3n del plasma humano para fraccionamiento.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF):**\n   - Principios fundamentales de las BPF en productos farmac\u00e9uticos.\n   - Validaci\u00f3n de sistemas automatizados en establecimientos de sangre.\n\n3. **Regulaci\u00f3n y Seguridad:**\n   - Resoluciones de la Asamblea Mundial de la Salud sobre la disponibilidad, seguridad y calidad de productos sangu\u00edneos.\n   - Recomendaciones de conferencias internacionales sobre regulaci\u00f3n de medicamentos.\n\n4. **Gesti\u00f3n de Riesgos:**\n   - Directrices sobre gesti\u00f3n de riesgos en la producci\u00f3n y control de productos farmac\u00e9uticos.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Principal entidad responsable de establecer directrices y recomendaciones.\n- **Organizaci\u00f3n Panamericana de la Salud (OPS):** Involucrada en la estandarizaci\u00f3n de servicios de sangre.\n- **International Conference on Harmonisation (ICH):** Proporciona directrices sobre gesti\u00f3n de calidad y riesgos.\n- **International Society of Blood Transfusion (ISBT):** Establece directrices para la validaci\u00f3n de sistemas en establecimientos de sangre.\n- **Conferencias Internacionales de Autoridades Reguladoras de Medicamentos (ICDRA):** Proporcionan recomendaciones sobre regulaci\u00f3n de medicamentos.\n\nEste resumen destaca la importancia de las directrices y regulaciones en la seguridad y calidad de los productos sangu\u00edneos, as\u00ed como la necesidad de buenas pr\u00e1cticas y gesti\u00f3n de riesgos en su producci\u00f3n y control.", "excerpt_keywords": "Keywords: Good Manufacturing Practices, Blood Components, Pathogen Inactivation, Coagulation Factors, Pharmaceutical Quality Assurance"}}, "4853fcfb-31f6-41e7-93c2-ceadefae913c": {"node_ids": ["0ff45878-fc55-44db-afaa-8e475332184b"], "metadata": {"page_label": "227", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 5\n\n## Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms\n\n1. Introduction\n\n2. Scope of document\n\n3. Glossary\n\n4. Protection  \n   4.1 Products and personnel  \n   4.2 Air filtration  \n   4.3 Unidirectional airflow  \n   4.4 Infiltration  \n   4.5 Cross-contamination  \n   4.6 Displacement concept (low pressure differential, high airflow)  \n   4.7 Pressure differential concept (high pressure differential, low airflow)  \n   4.8 Physical barrier concept  \n   4.9 Temperature and relative humidity  \n\n5. Dust control\n\n6. Protection of the environment  \n   6.1 General  \n   6.2 Dust in exhaust air  \n   6.3 Vapour and fume removal  \n\n7. Design of HVAC systems and components  \n   7.1 General  \n   7.2 Air distribution  \n   7.3 Recirculation system  \n   7.4 Full fresh-air systems  \n   7.5 Additional system components  \n\n8. Commissioning, qualification and maintenance  \n   8.1 Commissioning  \n   8.2 Qualification  \n   8.3 Maintenance  \n\n9. Premises\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es una gu\u00eda suplementaria sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la producci\u00f3n de formas farmac\u00e9uticas no est\u00e9riles. Se abordan aspectos clave como la protecci\u00f3n de productos y personal, el control de polvo, el dise\u00f1o de sistemas HVAC, y los procedimientos de puesta en marcha, calificaci\u00f3n y mantenimiento. Tambi\u00e9n se discuten conceptos de flujo de aire y control de contaminaci\u00f3n, as\u00ed como la importancia de la temperatura y la humedad relativa en el entorno de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los conceptos de flujo de aire que se deben considerar en el dise\u00f1o de sistemas HVAC para productos farmac\u00e9uticos no est\u00e9riles?**\n   - Esta pregunta se centra en los conceptos espec\u00edficos mencionados en la secci\u00f3n 4, como el flujo unidireccional, la infiltraci\u00f3n y los conceptos de presi\u00f3n diferencial.\n\n2. **\u00bfQu\u00e9 medidas se recomiendan para el control de polvo en las instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos no est\u00e9riles?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las pr\u00e1cticas de control de polvo que se deben implementar, como se menciona en la secci\u00f3n 5 del documento.\n\n3. **\u00bfQu\u00e9 aspectos se deben tener en cuenta durante la fase de calificaci\u00f3n y mantenimiento de los sistemas HVAC en la producci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta se dirige a la secci\u00f3n 8, donde se discuten los procedimientos de calificaci\u00f3n y mantenimiento, proporcionando informaci\u00f3n sobre c\u00f3mo asegurar que los sistemas HVAC funcionen de manera efectiva y cumplan con las normativas de BPF.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**:\n   - Se mencionan las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir normas y procedimientos para garantizar la calidad y seguridad.\n\n2. **Componentes Sangu\u00edneos**:\n   - Se hace referencia a gu\u00edas sobre la preparaci\u00f3n, uso y aseguramiento de la calidad de componentes sangu\u00edneos, incluyendo un anexo t\u00e9cnico del Consejo de Europa.\n\n3. **Investigaciones sobre Factor VIII**:\n   - Se citan estudios que analizan el impacto del retraso en el procesamiento de sangre sobre el rendimiento del factor VIII en crioprecipitados y concentrados.\n\n4. **Estabilidad y Almacenamiento de Sangre y Plasma**:\n   - Se discuten investigaciones sobre la vida \u00fatil de la sangre y el plasma almacenado, as\u00ed como su relaci\u00f3n con los factores de coagulaci\u00f3n.\n\n5. **Tecnolog\u00edas de Inactivaci\u00f3n de Pat\u00f3genos**:\n   - Se mencionan tecnolog\u00edas para la inactivaci\u00f3n de pat\u00f3genos como medidas de seguridad para el suministro de sangre.\n\n6. **Directrices de la OMS**:\n   - Se citan directrices de la OMS sobre el muestreo de productos farmac\u00e9uticos y materiales relacionados, as\u00ed como informes t\u00e9cnicos sobre especificaciones para preparaciones farmac\u00e9uticas.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices y recomendaciones sobre pr\u00e1cticas farmac\u00e9uticas y de salud.\n- **Consejo de Europa**: Organizaci\u00f3n que proporciona recomendaciones sobre la calidad y uso de componentes sangu\u00edneos.\n- **European Directorate for the Quality of Medicines and HealthCare (EDQM)**: Entidad que contribuye a la calidad de los medicamentos y componentes sangu\u00edneos en Europa.\n- **Revistas Cient\u00edficas**: Se citan varias publicaciones como *Transfusion*, *Vox Sanguinis*, y *Journal of Internal Medicine*, que presentan investigaciones relevantes sobre la sangre y sus derivados.\n\nEste resumen destaca la importancia de las buenas pr\u00e1cticas en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos, especialmente en el contexto de componentes sangu\u00edneos, as\u00ed como la relevancia de la investigaci\u00f3n cient\u00edfica en este campo.", "excerpt_keywords": "Keywords: good manufacturing practices, HVAC systems, non-sterile pharmaceuticals, air filtration, dust control"}}, "294fb64f-8272-4854-ac81-abbbd16833d8": {"node_ids": ["9fa36202-33d7-4cc3-97c7-e163966777e4"], "metadata": {"page_label": "228", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nHeating, ventilation and air-conditioning (HVAC) play an important role in ensuring the manufacture of quality pharmaceutical products. A well designed HVAC system will also provide comfortable conditions for operators.\n\nThese guidelines mainly focus on recommendations for systems for manufacturers of solid dosage forms. The guidelines also refer to other systems or components which are not relevant to solid dosage form manufacturing plants, but which may assist in providing a comparison between the requirements for solid dosage-form plants and other systems.\n\nHVAC system design influences architectural layouts with regard to items such as airlock positions, doorways and lobbies. The architectural components have an effect on room pressure differential cascades and cross-contamination control. The prevention of contamination and cross-contamination is an essential design consideration of the HVAC system. In view of these critical aspects, the design of the HVAC system should be considered at the concept design stage of a pharmaceutical manufacturing plant.\n\nTemperature, relative humidity and ventilation should be appropriate and should not adversely affect the quality of pharmaceutical products during their manufacture and storage, or the accurate functioning of equipment.\n\nThis document aims to give guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems. These guidelines are intended to complement those provided in *Good manufacturing practices for pharmaceutical products* (1) and should be read in conjunction with the parent guide. The additional standards addressed by the present guidelines should, therefore, be considered supplementary to the general requirements set out in the parent guide.\n\n# 2. Scope of document\n\nThese guidelines focus primarily on the design and good manufacturing practices (GMP) requirements for HVAC systems for facilities for the manufacture of solid dosage forms. Most of the system design principles for facilities manufacturing solid dosage forms also apply to other facilities such as those manufacturing liquids, creams and ointments. These guidelines do not cover requirements for manufacturing sites for the production of sterile pharmaceutical products. These guidelines do not cover the specific requirements relating to facilities handling hazardous products. Guidelines for hazardous product facilities are covered in a separate WHO guideline.\n\nThese guidelines are intended as a basic guide for use by pharmaceutical manufacturers and GMP inspectors.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 961, se centra en las directrices para el dise\u00f1o, instalaci\u00f3n, calificaci\u00f3n y mantenimiento de sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la fabricaci\u00f3n de productos farmac\u00e9uticos, especialmente formas s\u00f3lidas. Se enfatiza la importancia de un sistema HVAC bien dise\u00f1ado para garantizar la calidad del producto y la comodidad de los operadores. Las directrices tambi\u00e9n abordan la influencia del dise\u00f1o del sistema HVAC en la arquitectura de las instalaciones y la prevenci\u00f3n de la contaminaci\u00f3n. Sin embargo, no cubren requisitos para productos est\u00e9riles o peligrosos, que est\u00e1n tratados en gu\u00edas separadas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los aspectos cr\u00edticos que deben considerarse en el dise\u00f1o de un sistema HVAC para la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: El dise\u00f1o del sistema HVAC debe considerar la prevenci\u00f3n de la contaminaci\u00f3n y la contaminaci\u00f3n cruzada, la influencia en la disposici\u00f3n arquitect\u00f3nica (como posiciones de airelock, puertas y vest\u00edbulos), y asegurar que la temperatura, la humedad relativa y la ventilaci\u00f3n sean apropiadas para no afectar negativamente la calidad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 tipo de instalaciones no est\u00e1n cubiertas por estas directrices de HVAC seg\u00fan el documento?**\n   - Respuesta: Las directrices no cubren los requisitos para sitios de fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles ni para instalaciones que manejan productos peligrosos. Estas \u00e1reas est\u00e1n abordadas en gu\u00edas separadas de la OMS.\n\n3. **\u00bfC\u00f3mo se relacionan estas directrices con las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos?**\n   - Respuesta: Estas directrices est\u00e1n destinadas a complementar las Buenas Pr\u00e1cticas de Manufactura (GMP) para productos farmac\u00e9uticos y deben leerse en conjunto con la gu\u00eda principal de GMP, considerando los est\u00e1ndares adicionales como suplementarios a los requisitos generales establecidos en la gu\u00eda principal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento proporciona directrices suplementarias sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) espec\u00edficamente para los sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en la producci\u00f3n de formas farmac\u00e9uticas no est\u00e9riles. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n1. **Introducci\u00f3n y Alcance**: Se establece el prop\u00f3sito del documento y su aplicabilidad en la industria farmac\u00e9utica.\n\n2. **Protecci\u00f3n**: \n   - **Productos y Personal**: Medidas para proteger tanto los productos farmac\u00e9uticos como al personal que trabaja en su fabricaci\u00f3n.\n   - **Filtraci\u00f3n de Aire**: Importancia de los sistemas de filtraci\u00f3n para mantener la calidad del aire.\n   - **Flujo Unidireccional**: Concepto de flujo de aire controlado para minimizar la contaminaci\u00f3n.\n   - **Infiltraci\u00f3n y Contaminaci\u00f3n Cruzada**: Estrategias para evitar la entrada de contaminantes externos.\n   - **Conceptos de Presi\u00f3n Diferencial**: Diferencias entre sistemas de baja y alta presi\u00f3n en relaci\u00f3n con el flujo de aire.\n   - **Barreras F\u00edsicas**: Uso de barreras para proteger \u00e1reas cr\u00edticas.\n   - **Temperatura y Humedad Relativa**: Control de estos par\u00e1metros para asegurar condiciones \u00f3ptimas de fabricaci\u00f3n.\n\n3. **Control de Polvo**: Estrategias y pr\u00e1cticas recomendadas para minimizar la acumulaci\u00f3n de polvo en las instalaciones.\n\n4. **Protecci\u00f3n del Medio Ambiente**: \n   - **Control de Polvo en Aire de Escape**: Medidas para gestionar el polvo que se libera al medio ambiente.\n   - **Eliminaci\u00f3n de Vapores y Humos**: M\u00e9todos para manejar emisiones nocivas.\n\n5. **Dise\u00f1o de Sistemas HVAC**: \n   - **Distribuci\u00f3n de Aire**: Consideraciones sobre c\u00f3mo se distribuye el aire en las instalaciones.\n   - **Sistemas de Recirculaci\u00f3n y Aire Fresco**: Diferencias y aplicaciones de cada tipo de sistema.\n   - **Componentes Adicionales**: Elementos que pueden ser necesarios para un funcionamiento eficiente.\n\n6. **Puesta en Marcha, Calificaci\u00f3n y Mantenimiento**: \n   - **Puesta en Marcha**: Procedimientos iniciales para asegurar que los sistemas funcionen correctamente.\n   - **Calificaci\u00f3n**: Validaci\u00f3n de que los sistemas cumplen con los est\u00e1ndares requeridos.\n   - **Mantenimiento**: Pr\u00e1cticas para asegurar el funcionamiento continuo y eficiente de los sistemas HVAC.\n\n7. **Premisas**: Consideraciones sobre las instalaciones donde se implementan estos sistemas.\n\n### Entidades Clave\n- **BPF (Buenas Pr\u00e1cticas de Fabricaci\u00f3n)**: Normativas que aseguran la calidad en la producci\u00f3n farmac\u00e9utica.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistemas cr\u00edticos para el control ambiental en la fabricaci\u00f3n.\n- **Contaminaci\u00f3n Cruzada**: Riesgo que se busca minimizar en el entorno de fabricaci\u00f3n.\n- **Temperatura y Humedad Relativa**: Factores ambientales que afectan la calidad del producto.\n\nEste resumen abarca los aspectos fundamentales del documento, proporcionando una visi\u00f3n general de las directrices para la implementaci\u00f3n de sistemas HVAC en la producci\u00f3n farmac\u00e9utica no est\u00e9ril.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical manufacturing, contamination control, good manufacturing practices, solid dosage forms"}}, "812b1ab3-5fb3-46ff-8154-033bfa006c7c": {"node_ids": ["f29dcee4-839a-44ec-93ca-5bcbd487fc9f"], "metadata": {"page_label": "229", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "They are not intended to be prescriptive in specifying requirements and design parameters. There are many parameters affecting a clean area condition and it is, therefore, difficult to lay down the specific requirements for one particular parameter in isolation.\n\nMany pharmaceutical manufacturers have their own engineering design and qualification standards and requirements may vary from one manufacturer to the next. Design parameters and user requirements should, therefore, be set realistically for each project, with a view to creating a cost-effective design, yet still complying with all regulatory standards and ensuring that product quality and safety are not compromised. The three primary aspects addressed in this manual are the roles that the HVAC system plays in product protection, personnel protection and environmental protection (Figure 1).\n\nCognisance should be taken of the products to be manufactured when establishing system design parameters. A facility manufacturing multiple different products may have more stringent design parameters with respect to cross-contamination control, compared with a single product facility.\n\n**Figure 1**\n\n**The guidelines address the various system criteria according to the sequence set out in this diagram**\n\n```\nGMP MANUFACTURING ENVIRONMENT\n    \u251c\u2500\u2500 PRODUCT PROTECTION\n    \u2502   \u251c\u2500\u2500 Contamination (Product & Staff)\n    \u2502   \u251c\u2500\u2500 Protect from Product Contamination\n    \u2502   \u2514\u2500\u2500 Correct Temperature & Humidity\n    \u251c\u2500\u2500 PERSONNEL PROTECTION\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Dust\n    \u2502   \u251c\u2500\u2500 Prevent Contact with Fumes\n    \u2502   \u2514\u2500\u2500 Acceptable Comfort Conditions\n    \u2514\u2500\u2500 PROTECTION OF EXTERNAL ENVIRONMENT\n        \u251c\u2500\u2500 Avoid Dust Discharge\n        \u251c\u2500\u2500 Avoid Fume Discharge\n        \u2514\u2500\u2500 Avoid Effluent Discharge\n\nSYSTEMS\n\nSYSTEM VALIDATION\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las consideraciones de dise\u00f1o y requisitos para sistemas de HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en entornos de fabricaci\u00f3n farmac\u00e9utica. Se enfatiza que no existen requisitos prescriptivos \u00fanicos, ya que las necesidades pueden variar entre fabricantes y proyectos. Se identifican tres \u00e1reas clave de protecci\u00f3n: la protecci\u00f3n del producto, la protecci\u00f3n del personal y la protecci\u00f3n del medio ambiente externo. Adem\u00e1s, se menciona la importancia de establecer par\u00e1metros de dise\u00f1o teniendo en cuenta los productos a fabricar y el riesgo de contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los tres aspectos principales que aborda el manual en relaci\u00f3n con el sistema HVAC en un entorno de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los tres aspectos principales son la protecci\u00f3n del producto, la protecci\u00f3n del personal y la protecci\u00f3n del medio ambiente externo.\n\n2. **\u00bfPor qu\u00e9 es importante considerar los productos a fabricar al establecer los par\u00e1metros de dise\u00f1o del sistema HVAC?**\n   - Respuesta: Es importante considerar los productos a fabricar porque una instalaci\u00f3n que produce m\u00faltiples productos puede requerir par\u00e1metros de dise\u00f1o m\u00e1s estrictos en cuanto al control de la contaminaci\u00f3n cruzada, en comparaci\u00f3n con una instalaci\u00f3n que fabrica un solo producto.\n\n3. **\u00bfQu\u00e9 se debe tener en cuenta al establecer requisitos de dise\u00f1o y par\u00e1metros para un proyecto de fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Se deben establecer de manera realista los par\u00e1metros de dise\u00f1o y los requisitos del usuario para cada proyecto, buscando un dise\u00f1o rentable que cumpla con todos los est\u00e1ndares regulatorios y garantice que la calidad y seguridad del producto no se vean comprometidas.", "prev_section_summary": "### Temas Clave:\n1. **Importancia del HVAC**: El sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) es crucial para la fabricaci\u00f3n de productos farmac\u00e9uticos de calidad y para proporcionar condiciones c\u00f3modas a los operadores.\n2. **Dise\u00f1o del Sistema HVAC**: El dise\u00f1o debe considerar la prevenci\u00f3n de la contaminaci\u00f3n y la contaminaci\u00f3n cruzada, as\u00ed como influir en la disposici\u00f3n arquitect\u00f3nica de las instalaciones.\n3. **Condiciones Ambientales**: La temperatura, la humedad relativa y la ventilaci\u00f3n deben ser adecuadas para no afectar la calidad de los productos farmac\u00e9uticos ni el funcionamiento del equipo.\n4. **Gu\u00edas y Buenas Pr\u00e1cticas de Manufactura (GMP)**: Las directrices est\u00e1n destinadas a complementar las GMP y deben leerse junto con la gu\u00eda principal.\n5. **Alcance de las Directrices**: Se centran en la fabricaci\u00f3n de formas s\u00f3lidas y no cubren productos est\u00e9riles ni instalaciones que manejen productos peligrosos.\n\n### Entidades:\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud, que emite las directrices.\n- **Productos farmac\u00e9uticos**: Incluye formas s\u00f3lidas, l\u00edquidas, cremas y ung\u00fcentos.\n- **Contaminaci\u00f3n y contaminaci\u00f3n cruzada**: Aspectos cr\u00edticos en el dise\u00f1o de sistemas HVAC.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativas que complementan las directrices de HVAC.\n\n### Resumen:\nEl documento de la OMS proporciona directrices sobre el dise\u00f1o, instalaci\u00f3n, calificaci\u00f3n y mantenimiento de sistemas HVAC en la fabricaci\u00f3n de productos farmac\u00e9uticos, con un enfoque en las formas s\u00f3lidas. Se destaca la importancia de un dise\u00f1o adecuado para prevenir la contaminaci\u00f3n y asegurar condiciones ambientales \u00f3ptimas. Las directrices son complementarias a las Buenas Pr\u00e1cticas de Manufactura y no abordan requisitos para productos est\u00e9riles o peligrosos.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical manufacturing, product protection, contamination control, regulatory standards"}}, "d2dc39a2-a25d-4cc2-9ee3-cfb11aa4bd07": {"node_ids": ["e538b7b3-9b0e-4908-99a0-d351cc532480"], "metadata": {"page_label": "230", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Glossary\n\nThe definitions given below apply to terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**  \nMeasurable terms under which a test result will be considered acceptable.\n\n**action limit**  \nThe action limit is reached when the acceptance criteria of a critical parameter have been exceeded. Results outside these limits will require specified action and investigation.\n\n**air changes per hour (ACPH)**  \nThe volume of air supplied to a room, in m\u00b3/hr, divided by the room volume, in m\u00b3.\n\n**air-handling unit (AHU)**  \nThe air-handling unit serves to condition the air and provide the required air movement within a facility.\n\n**airlock**  \nAn enclosed space with two or more doors, which is interposed between two or more rooms, e.g. of differing classes of cleanliness, for the purpose of controlling the airflow between those rooms when they need to be entered. An airlock is designed for and used by either people or goods (PAL, personnel airlock; MAL, material airlock).\n\n**alert limit**  \nThe alert limit is reached when the normal operating range of a critical parameter has been exceeded, indicating that corrective measures may need to be taken to prevent the action limit being reached.\n\n**as-built**  \nCondition where the installation is complete with all services connected and functioning but with no production equipment, materials or personnel present.\n\n**at-rest**  \nCondition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n**central air-conditioning unit (see air-handling unit)**\n\n**change control**  \nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 es un \"airlock\" y cu\u00e1l es su prop\u00f3sito en un entorno controlado?**\n   - Un \"airlock\" es un espacio cerrado con dos o m\u00e1s puertas que se encuentra entre dos o m\u00e1s habitaciones de diferentes clases de limpieza. Su prop\u00f3sito es controlar el flujo de aire entre esas habitaciones cuando se necesita acceder a ellas, minimizando la contaminaci\u00f3n cruzada. Existen dos tipos de airlocks: el airlock de personal (PAL) y el airlock de material (MAL).\n\n2. **\u00bfC\u00f3mo se determina si un resultado de prueba es aceptable seg\u00fan los criterios de aceptaci\u00f3n?**\n   - Los criterios de aceptaci\u00f3n son t\u00e9rminos medibles que definen las condiciones bajo las cuales un resultado de prueba se considerar\u00e1 aceptable. Si un resultado cumple con estos criterios, se considera que est\u00e1 dentro de los l\u00edmites aceptables.\n\n3. **\u00bfQu\u00e9 implica el t\u00e9rmino \"as-built\" en el contexto de instalaciones?**\n   - El t\u00e9rmino \"as-built\" se refiere a la condici\u00f3n en la que la instalaci\u00f3n est\u00e1 completa, con todos los servicios conectados y funcionando, pero sin la presencia de equipos de producci\u00f3n, materiales o personal. Esto indica que la infraestructura est\u00e1 lista para su uso, aunque no se est\u00e9 llevando a cabo ninguna operaci\u00f3n activa.\n\n### Resumen de nivel superior del contexto:\nEl contexto proporciona un glosario de t\u00e9rminos t\u00e9cnicos utilizados en directrices relacionadas con la calidad del aire y el control ambiental en instalaciones. Incluye definiciones clave que son esenciales para entender los par\u00e1metros cr\u00edticos en la operaci\u00f3n de sistemas de aire acondicionado y control de contaminaci\u00f3n, as\u00ed como los procedimientos de validaci\u00f3n y control de cambios en entornos regulados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las consideraciones de dise\u00f1o y requisitos para sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en entornos de fabricaci\u00f3n farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **No Prescriptividad**: Los requisitos y par\u00e1metros de dise\u00f1o no son \u00fanicos ni prescriptivos, ya que var\u00edan entre diferentes fabricantes y proyectos.\n2. **Variabilidad de Requisitos**: Cada fabricante puede tener sus propios est\u00e1ndares de dise\u00f1o e ingenier\u00eda, lo que implica que los requisitos pueden diferir significativamente.\n3. **Tres \u00c1reas de Protecci\u00f3n**:\n   - **Protecci\u00f3n del Producto**: Incluye el control de la contaminaci\u00f3n, la protecci\u00f3n contra la contaminaci\u00f3n del producto y el mantenimiento de condiciones adecuadas de temperatura y humedad.\n   - **Protecci\u00f3n del Personal**: Se enfoca en prevenir el contacto con polvo y vapores, as\u00ed como en garantizar condiciones de confort aceptables.\n   - **Protecci\u00f3n del Medio Ambiente Externo**: Busca evitar la descarga de polvo, vapores y efluentes al entorno exterior.\n4. **Par\u00e1metros de Dise\u00f1o**: La importancia de establecer par\u00e1metros de dise\u00f1o realistas, considerando los productos a fabricar y el riesgo de contaminaci\u00f3n cruzada, especialmente en instalaciones que producen m\u00faltiples productos.\n\n#### Entidades:\n- **HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Fabricantes Farmac\u00e9uticos**: Empresas que producen productos farmac\u00e9uticos y que pueden tener diferentes est\u00e1ndares de dise\u00f1o.\n- **Contaminaci\u00f3n Cruzada**: Riesgo asociado a la producci\u00f3n de m\u00faltiples productos en una misma instalaci\u00f3n.\n- **Regulaciones**: Normativas que deben cumplirse para garantizar la calidad y seguridad del producto.\n\nEste resumen destaca la importancia de un enfoque flexible y adaptado a las necesidades espec\u00edficas de cada proyecto en el dise\u00f1o de sistemas HVAC en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: acceptance criteria, airlock, air-handling unit, change control, alert limit"}}, "5ac418bc-2647-4ea9-b129-59e534642a12": {"node_ids": ["e5fa9463-f759-4cd6-ba07-7e94f10afb71"], "metadata": {"page_label": "231", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n**clean area (cleanroom)**\u00b9  \nAn area (or room or zone) with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n\n**closed system**  \nA system where the product or material is not exposed to the manufacturing environment.\n\n**commissioning**  \nCommissioning is the documented process of verifying that the equipment and systems are installed according to specifications, placing the equipment into active service and verifying its proper action. Commissioning takes place at the conclusion of project construction but prior to validation.\n\n**containment**  \nA process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.\n\n**contamination**  \nThe undesired introduction of impurities of a chemical or microbial nature, or of foreign matter, into or on to a starting material or intermediate, during production, sampling, packaging or repackaging, storage or transport.\n\n**controlled area**  \nAn area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n\n**critical parameter or component**  \nA processing parameter (such as temperature or relative humidity) that affects the quality of a product, or a component that may have a direct impact on the quality of the product.\n\n**critical quality attribute (CQA)**  \nA physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.\n\n----\n\n\u00b9 Note: Clean area standards, such as ISO 14644-1, provide details on how to classify air cleanliness by means of particle concentrations, whereas the GMP standards provide a grading for air cleanliness in terms of the condition (at-rest or operational), the permissible microbial concentrations, as well as other factors such as gowning requirements. GMP and clean area standards should be used in conjunction with each other to define and classify the different manufacturing environments.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es la diferencia entre un \"clean area\" y un \"controlled area\" seg\u00fan el documento?**\n   - **Respuesta:** Un \"clean area\" (cleanroom) es un espacio con control ambiental definido para minimizar la contaminaci\u00f3n particulada y microbiana, dise\u00f1ado para reducir la introducci\u00f3n y retenci\u00f3n de contaminantes. En cambio, un \"controlled area\" es un \u00e1rea dentro de la instalaci\u00f3n donde se definen, controlan y monitorean condiciones y procedimientos ambientales espec\u00edficos para prevenir la degradaci\u00f3n o la contaminaci\u00f3n cruzada del producto.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"commissioning\" y en qu\u00e9 etapa se lleva a cabo?**\n   - **Respuesta:** El \"commissioning\" es el proceso documentado de verificar que el equipo y los sistemas est\u00e1n instalados de acuerdo con las especificaciones, poner el equipo en servicio activo y verificar su correcto funcionamiento. Este proceso se lleva a cabo al final de la construcci\u00f3n del proyecto, pero antes de la validaci\u00f3n.\n\n3. **\u00bfQu\u00e9 son los \"critical quality attributes\" (CQA) y por qu\u00e9 son importantes en la producci\u00f3n?**\n   - **Respuesta:** Los \"critical quality attributes\" (CQA) son propiedades o caracter\u00edsticas f\u00edsicas, qu\u00edmicas, biol\u00f3gicas o microbiol\u00f3gicas que deben estar dentro de un l\u00edmite, rango o distribuci\u00f3n apropiados para asegurar la calidad deseada del producto. Son importantes porque afectan directamente la calidad del producto final y, por lo tanto, su seguridad y eficacia.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona definiciones clave relacionadas con la producci\u00f3n y el control de calidad en entornos regulados, como las \u00e1reas limpias y controladas, as\u00ed como procesos cr\u00edticos como el \"commissioning\". Se enfatiza la importancia de mantener condiciones ambientales espec\u00edficas para prevenir la contaminaci\u00f3n y asegurar que los atributos de calidad del producto se mantengan dentro de los l\u00edmites aceptables. Adem\u00e1s, se menciona la necesidad de utilizar est\u00e1ndares como ISO 14644-1 y GMP en conjunto para clasificar y definir los diferentes entornos de fabricaci\u00f3n.", "prev_section_summary": "La secci\u00f3n proporcionada es un glosario que define t\u00e9rminos t\u00e9cnicos relevantes para las directrices sobre calidad del aire y control ambiental en instalaciones. A continuaci\u00f3n se resumen los temas clave y entidades:\n\n### Temas Clave:\n1. **Criterios de Aceptaci\u00f3n**: Definiciones medibles que determinan si un resultado de prueba es aceptable.\n2. **L\u00edmites de Acci\u00f3n**: Umbrales que, al ser superados, requieren acciones espec\u00edficas e investigaciones.\n3. **Cambios de Aire por Hora (ACPH)**: Medida del volumen de aire suministrado a una habitaci\u00f3n en relaci\u00f3n con su volumen.\n4. **Unidad de Manejo de Aire (AHU)**: Equipos que acondicionan el aire y facilitan el movimiento del aire en una instalaci\u00f3n.\n5. **Airlock**: Espacio cerrado entre habitaciones de diferentes niveles de limpieza, dise\u00f1ado para controlar el flujo de aire y minimizar la contaminaci\u00f3n.\n6. **L\u00edmite de Alerta**: Umbral que, al ser superado, indica la necesidad de medidas correctivas para evitar alcanzar el l\u00edmite de acci\u00f3n.\n7. **Condici\u00f3n \"As-Built\"**: Estado en el que la instalaci\u00f3n est\u00e1 completa y funcional, pero sin equipos de producci\u00f3n ni personal presente.\n8. **Condici\u00f3n \"At-Rest\"**: Estado en el que la instalaci\u00f3n est\u00e1 operativa seg\u00fan lo acordado, pero sin personal presente.\n9. **Control de Cambios**: Sistema formal para revisar cambios propuestos que puedan afectar la validaci\u00f3n de procesos.\n\n### Entidades:\n- **PAL (Personnel Airlock)**: Airlock dise\u00f1ado para el paso de personas.\n- **MAL (Material Airlock)**: Airlock dise\u00f1ado para el paso de materiales.\n\nEste glosario es esencial para entender los par\u00e1metros cr\u00edticos en la operaci\u00f3n de sistemas de aire acondicionado y control de contaminaci\u00f3n, as\u00ed como los procedimientos de validaci\u00f3n y control de cambios en entornos regulados.", "excerpt_keywords": "Keywords: cleanroom, contamination, commissioning, critical quality attribute, controlled area"}}, "890be5fc-cea5-495f-b880-ffc6f70b7083": {"node_ids": ["1fbe2aec-c438-435c-bcfd-0118e979ddc8"], "metadata": {"page_label": "232", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# cross-contamination\n\nContamination of a starting material, intermediate product or finished product with another starting material or product during production.\n\n# design condition\n\nDesign condition relates to the specified range or accuracy of a controlled variable used by the designer as a basis for determining the performance requirements of an engineered system.\n\n# design qualification (DQ)\n\nDesign qualification is the documented check of planning documents and technical specifications for conformity of the design with the process, manufacturing, GMP and regulatory requirements.\n\n# direct impact system\n\nA system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.\n\n# exfiltration\n\nExfiltration is the egress of air from a controlled area to an external zone.\n\n# facility\n\nThe built environment within which the clean area installation and associated controlled environments operate together with their supporting infrastructure.\n\n# good engineering practice (GEP)\n\nEstablished engineering methods and standards that are applied throughout the project life-cycle to deliver appropriate, cost-effective solutions.\n\n# hazardous substance or product\n\nA product or substance that may present a substantial risk of injury to health or to the environment.\n\n# indirect impact system\n\nThis is a system that is not expected to have a direct impact on product quality, but typically will support a direct impact system. These systems are designed and commissioned according to GEP only.\n\n# infiltration\n\nInfiltration is the ingress of air from an external zone into a controlled area.\n\n# installation qualification (IQ)\n\nInstallation qualification is documented verification that the premises, HVAC system, supporting utilities and equipment have been built and installed in compliance with their approved design specification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfQu\u00e9 se entiende por \"sistema de impacto directo\" y c\u00f3mo se diferencia de un \"sistema de impacto indirecto\"?**\n   - **Respuesta:** Un \"sistema de impacto directo\" es aquel que se espera que tenga un impacto directo en la calidad del producto y se dise\u00f1a y comisiona de acuerdo con buenas pr\u00e1cticas de ingenier\u00eda (GEP), adem\u00e1s de estar sujeto a pr\u00e1cticas de calificaci\u00f3n. En contraste, un \"sistema de impacto indirecto\" no se espera que afecte directamente la calidad del producto, pero generalmente apoya a un sistema de impacto directo y se dise\u00f1a y comisiona solo seg\u00fan GEP.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de la \"calificaci\u00f3n de dise\u00f1o\" (DQ) en el contexto de la producci\u00f3n?**\n   - **Respuesta:** La \"calificaci\u00f3n de dise\u00f1o\" (DQ) es un proceso documentado que verifica que los documentos de planificaci\u00f3n y las especificaciones t\u00e9cnicas cumplen con los requisitos del dise\u00f1o en relaci\u00f3n con el proceso, la fabricaci\u00f3n, las buenas pr\u00e1cticas de manufactura (GMP) y los requisitos regulatorios.\n\n3. **\u00bfQu\u00e9 implica la \"calificaci\u00f3n de instalaci\u00f3n\" (IQ) y por qu\u00e9 es importante en la construcci\u00f3n de instalaciones controladas?**\n   - **Respuesta:** La \"calificaci\u00f3n de instalaci\u00f3n\" (IQ) implica la verificaci\u00f3n documentada de que las instalaciones, el sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), los servicios de apoyo y el equipo han sido construidos e instalados de acuerdo con las especificaciones de dise\u00f1o aprobadas. Es importante porque asegura que todos los componentes de la instalaci\u00f3n cumplen con los est\u00e1ndares requeridos para operar de manera segura y efectiva en un entorno controlado.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en t\u00e9rminos y definiciones clave relacionados con la producci\u00f3n en entornos controlados, especialmente en el \u00e1mbito de la calidad del producto y las buenas pr\u00e1cticas de ingenier\u00eda. Se abordan conceptos como la contaminaci\u00f3n cruzada, las condiciones de dise\u00f1o, la calificaci\u00f3n de dise\u00f1o e instalaci\u00f3n, y la diferencia entre sistemas de impacto directo e indirecto. Estos t\u00e9rminos son fundamentales para garantizar que los procesos de producci\u00f3n cumplan con los est\u00e1ndares de calidad y regulaciones necesarias para la seguridad y eficacia de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Definiciones de t\u00e9rminos clave**:\n   - **Clean Area (Cleanroom)**: Espacio con control ambiental para minimizar la contaminaci\u00f3n particulada y microbiana.\n   - **Closed System**: Sistema donde el producto no est\u00e1 expuesto al entorno de fabricaci\u00f3n.\n   - **Commissioning**: Proceso documentado para verificar la instalaci\u00f3n y funcionamiento adecuado de equipos y sistemas.\n   - **Containment**: Proceso o dispositivo que evita la fuga de productos o contaminantes a otras zonas.\n   - **Contamination**: Introducci\u00f3n no deseada de impurezas durante la producci\u00f3n o transporte.\n   - **Controlled Area**: \u00c1rea donde se controlan y monitorean condiciones ambientales espec\u00edficas para prevenir contaminaci\u00f3n.\n   - **Critical Parameter or Component**: Par\u00e1metro de procesamiento que afecta la calidad del producto.\n   - **Critical Quality Attribute (CQA)**: Propiedad que debe estar dentro de l\u00edmites adecuados para asegurar la calidad del producto.\n\n2. **Importancia de los est\u00e1ndares**:\n   - Se menciona la necesidad de utilizar est\u00e1ndares como **ISO 14644-1** y **GMP** en conjunto para clasificar y definir entornos de fabricaci\u00f3n, asegurando la calidad y seguridad del producto.\n\n3. **Enfoque en la calidad y control**:\n   - El documento enfatiza la importancia de mantener condiciones ambientales espec\u00edficas y de realizar procesos como el commissioning para asegurar que los atributos de calidad del producto se mantengan dentro de l\u00edmites aceptables.\n\n### Entidades:\n- **ISO 14644-1**: Est\u00e1ndar para clasificar la limpieza del aire.\n- **GMP (Good Manufacturing Practices)**: Buenas pr\u00e1cticas de manufactura que regulan la calidad en la producci\u00f3n. \n\nEste resumen destaca los conceptos fundamentales relacionados con la producci\u00f3n y control de calidad en entornos regulados, as\u00ed como la importancia de los est\u00e1ndares para garantizar la calidad del producto final.", "excerpt_keywords": "Keywords: cross-contamination, design qualification, good engineering practice, controlled area, installation qualification"}}, "101cd49b-3261-46e2-9745-4a3639211afd": {"node_ids": ["8da5f3cb-3b8b-473b-a41c-e4aec900272d"], "metadata": {"page_label": "233", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# no-impact system\nThis is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n\n# non-critical parameter or component\nA processing parameter or component within a system where the operation, contact, data control, alarm or failure will have an indirect impact or no impact on the quality of the product.\n\n# normal operating range\nThe range that the manufacturer selects as the acceptable values for a parameter during normal operations. This range must be within the operating range.\n\n# operating limits\nThe minimum and/or maximum values that will ensure that product and safety requirements are met.\n\n# operating range\nOperating range is the range of validated critical parameters within which acceptable products can be manufactured.\n\n# operational condition\nThis condition relates to carrying out room classification tests with the normal production process with equipment in operation, and the normal staff present in the room.\n\n# operational qualification (OQ)\nOperational qualification is the documentary evidence to verify that the equipment operates in accordance with its design specifications in its normal operating range and performs as intended throughout all anticipated operating ranges.\n\n# oral solid dosage (OSD)\nUsually refers to an OSD plant that manufactures medicinal products such as tablets, capsules and powders to be taken orally.\n\n# pass-through-hatch (PTH) or pass box (PB)\nA cabinet with two or more doors for passing equipment or product, whilst maintaining the pressure cascade and segregation between two controlled zones. A passive PTH has no air supply or extract. A dynamic PTH has an air supply into the chamber.\n\n# performance qualification (PQ)\nPerformance qualification is the documented verification that the process and/or the total process related to the system performs as intended throughout all anticipated operating ranges.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS, parte de la Serie de Informes T\u00e9cnicos 961, aborda conceptos clave relacionados con la calidad y el control en la producci\u00f3n de medicamentos, especialmente en plantas de dosificaci\u00f3n s\u00f3lida oral (OSD). Se definen t\u00e9rminos como \"sistema sin impacto\", \"par\u00e1metro no cr\u00edtico\", \"rango operativo\" y \"calificaci\u00f3n operativa\", que son esenciales para garantizar que los procesos de fabricaci\u00f3n cumplan con los est\u00e1ndares de calidad y seguridad. Adem\u00e1s, se discuten las condiciones operativas y la calificaci\u00f3n del rendimiento, que son fundamentales para validar que los equipos y procesos funcionen seg\u00fan lo previsto.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 criterios se utilizan para clasificar un sistema como \"sin impacto\" en la calidad del producto?**\n   - Esta pregunta busca entender los criterios espec\u00edficos que determinan que un sistema no afecte la calidad del producto, lo cual no se detalla en otras partes del documento.\n\n2. **\u00bfCu\u00e1les son las diferencias clave entre una \"calificaci\u00f3n operativa\" (OQ) y una \"calificaci\u00f3n de rendimiento\" (PQ) en el contexto de la producci\u00f3n de medicamentos?**\n   - Esta pregunta se centra en las diferencias entre dos tipos de calificaciones que son cruciales para la validaci\u00f3n de procesos, proporcionando claridad sobre sus objetivos y procedimientos.\n\n3. **\u00bfC\u00f3mo se define el \"rango operativo\" y por qu\u00e9 es importante para la fabricaci\u00f3n de productos aceptables?**\n   - Esta pregunta busca una explicaci\u00f3n detallada sobre el concepto de rango operativo y su relevancia en el contexto de la producci\u00f3n de medicamentos, lo que puede no estar claramente expuesto en otras secciones del documento. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del contenido que podr\u00edan no ser f\u00e1cilmente accesibles en otras fuentes.", "prev_section_summary": "El contenido de la secci\u00f3n aborda conceptos fundamentales relacionados con la producci\u00f3n en entornos controlados, especialmente en el contexto de la calidad del producto y las buenas pr\u00e1cticas de ingenier\u00eda. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n### Temas Clave\n\n1. **Contaminaci\u00f3n Cruzada**: Se refiere a la contaminaci\u00f3n de materiales o productos durante el proceso de producci\u00f3n.\n  \n2. **Condiciones de Dise\u00f1o**: Rango o precisi\u00f3n de una variable controlada que gu\u00eda el dise\u00f1o de un sistema ingenieril.\n\n3. **Calificaci\u00f3n de Dise\u00f1o (DQ)**: Verificaci\u00f3n documentada de que los documentos de planificaci\u00f3n y especificaciones t\u00e9cnicas cumplen con los requisitos de dise\u00f1o, fabricaci\u00f3n, buenas pr\u00e1cticas de manufactura (GMP) y regulaciones.\n\n4. **Sistemas de Impacto Directo**: Sistemas que afectan directamente la calidad del producto, dise\u00f1ados y comisionados seg\u00fan buenas pr\u00e1cticas de ingenier\u00eda (GEP) y sujetos a calificaci\u00f3n.\n\n5. **Sistemas de Impacto Indirecto**: Sistemas que no afectan directamente la calidad del producto, pero que apoyan a los sistemas de impacto directo, dise\u00f1ados solo seg\u00fan GEP.\n\n6. **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Verificaci\u00f3n documentada de que las instalaciones y equipos cumplen con las especificaciones de dise\u00f1o aprobadas.\n\n7. **Exfiltraci\u00f3n e Infiltraci\u00f3n**: Procesos de salida y entrada de aire entre \u00e1reas controladas y zonas externas, respectivamente.\n\n8. **Instalaciones**: Entorno construido donde operan las instalaciones de \u00e1reas limpias y sus infraestructuras de soporte.\n\n9. **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**: M\u00e9todos y est\u00e1ndares de ingenier\u00eda establecidos aplicados a lo largo del ciclo de vida del proyecto.\n\n10. **Sustancias o Productos Peligrosos**: Productos que pueden representar un riesgo significativo para la salud o el medio ambiente.\n\n### Entidades\n\n- **Sistemas de Impacto Directo e Indirecto**\n- **Calificaci\u00f3n de Dise\u00f1o (DQ)**\n- **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**\n- **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**\n- **Contaminaci\u00f3n Cruzada**\n- **Exfiltraci\u00f3n e Infiltraci\u00f3n**\n- **Instalaciones Controladas**\n\nEste resumen destaca la importancia de estos conceptos en la garant\u00eda de calidad y cumplimiento normativo en la producci\u00f3n de productos en entornos controlados.", "excerpt_keywords": "Keywords: no-impact system, operational qualification, performance qualification, oral solid dosage, operating range"}}, "e8de84f5-c3e2-4d92-b11a-28d545eb5a61": {"node_ids": ["aeba0ab0-52a8-4d5e-b7cf-3fd799f35fd7"], "metadata": {"page_label": "234", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# point extraction\n\nAir extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n\n# pressure cascade\n\nA process whereby air flows from one area, which is maintained at a higher pressure, to another area at a lower pressure.\n\n# qualification\n\nQualification is the planning, carrying out and recording of tests on equipment and a system, which forms part of the validated process, to demonstrate that it will perform as intended.\n\n# quality critical process parameter (CPP)\n\nA process parameter which could have an impact on the critical quality attribute.\n\n# relative humidity\n\nThe ratio of the actual water vapour pressure of the air to the saturated water vapour pressure of the air at the same temperature expressed as a percentage. More simply put, it is the ratio of the mass of moisture in the air, relative to the mass at 100% moisture saturation, at a given temperature.\n\n# standard operating procedure (SOP)\n\nAn authorized written procedure, giving instructions for performing operations, not necessarily specific to a given product or material, but of a more general nature (e.g. operation of equipment, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\n# turbulent flow\n\nTurbulent flow, or non-unidirectional airflow, is air distribution that is introduced into the controlled space and then mixes with room air by means of induction.\n\n# unidirectional airflow (UDAF)\n\nUnidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).\n\n# validation\n\nThe documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected results.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda varios conceptos clave relacionados con la calidad del aire y los procesos de validaci\u00f3n en entornos controlados. Se definen t\u00e9rminos como extracci\u00f3n de aire, cascada de presi\u00f3n, calificaci\u00f3n, par\u00e1metros cr\u00edticos de calidad del proceso, humedad relativa, procedimientos operativos est\u00e1ndar, flujo turbulento y flujo unidireccional. Estos conceptos son fundamentales para garantizar que los procesos y equipos en entornos regulados funcionen de manera efectiva y cumplan con los est\u00e1ndares de calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la importancia de la ubicaci\u00f3n del punto de extracci\u00f3n de aire en la eliminaci\u00f3n de polvo y c\u00f3mo se relaciona con la calidad del aire en entornos controlados?**\n   - Esta pregunta se centra en el concepto de \"punto de extracci\u00f3n\" y su impacto en la calidad del aire, lo cual no se detalla ampliamente en otras fuentes.\n\n2. **\u00bfC\u00f3mo se determina un par\u00e1metro cr\u00edtico de calidad (CPP) y qu\u00e9 implicaciones tiene en el proceso de validaci\u00f3n de un sistema?**\n   - Esta pregunta busca profundizar en la relaci\u00f3n entre los CPP y la validaci\u00f3n, un aspecto que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias existen entre el flujo turbulento y el flujo unidireccional (UDAF) en t\u00e9rminos de su aplicaci\u00f3n en entornos controlados?**\n   - Esta pregunta invita a explorar las caracter\u00edsticas y aplicaciones espec\u00edficas de ambos tipos de flujo, lo que puede no estar ampliamente discutido en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto del documento, lo que puede no estar disponible en otras referencias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema Sin Impacto (No-Impact System)**:\n   - Definici\u00f3n: Un sistema que no afecta la calidad del producto, dise\u00f1ado y comisionado seg\u00fan Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP).\n\n2. **Par\u00e1metro o Componente No Cr\u00edtico (Non-Critical Parameter or Component)**:\n   - Descripci\u00f3n: Par\u00e1metros o componentes cuyo funcionamiento tiene un impacto indirecto o nulo en la calidad del producto.\n\n3. **Rango Operativo Normal (Normal Operating Range)**:\n   - Definici\u00f3n: Valores aceptables seleccionados por el fabricante para un par\u00e1metro durante operaciones normales, dentro del rango operativo.\n\n4. **L\u00edmites Operativos (Operating Limits)**:\n   - Descripci\u00f3n: Valores m\u00ednimos y/o m\u00e1ximos que aseguran el cumplimiento de los requisitos de producto y seguridad.\n\n5. **Rango Operativo (Operating Range)**:\n   - Definici\u00f3n: Rango de par\u00e1metros cr\u00edticos validados dentro del cual se pueden fabricar productos aceptables.\n\n6. **Condici\u00f3n Operativa (Operational Condition)**:\n   - Descripci\u00f3n: Relacionada con pruebas de clasificaci\u00f3n de salas durante el proceso de producci\u00f3n normal, con equipos y personal en operaci\u00f3n.\n\n7. **Calificaci\u00f3n Operativa (Operational Qualification - OQ)**:\n   - Definici\u00f3n: Evidencia documental que verifica que el equipo opera seg\u00fan especificaciones de dise\u00f1o en su rango operativo normal.\n\n8. **Dosificaci\u00f3n S\u00f3lida Oral (Oral Solid Dosage - OSD)**:\n   - Descripci\u00f3n: Planta que fabrica productos medicinales como tabletas, c\u00e1psulas y polvos para administraci\u00f3n oral.\n\n9. **Cabina de Pasaje (Pass-Through Hatch - PTH) o Caja de Pasaje (Pass Box - PB)**:\n   - Definici\u00f3n: Mueble con dos o m\u00e1s puertas para pasar equipos o productos, manteniendo la segregaci\u00f3n entre zonas controladas.\n\n10. **Calificaci\u00f3n de Rendimiento (Performance Qualification - PQ)**:\n    - Descripci\u00f3n: Verificaci\u00f3n documentada de que el proceso relacionado con el sistema funciona como se espera en todos los rangos operativos anticipados.\n\n### Conclusi\u00f3n\nLa secci\u00f3n proporciona definiciones y descripciones de t\u00e9rminos clave relacionados con la calidad y control en la producci\u00f3n de medicamentos, enfatizando la importancia de los sistemas, par\u00e1metros y calificaciones en el proceso de fabricaci\u00f3n para asegurar la calidad y seguridad del producto.", "excerpt_keywords": "Keywords: air extraction, pressure cascade, qualification, quality critical process parameter, validation"}}, "e10cb40c-d0a9-41a3-bdb7-15575210f16c": {"node_ids": ["e356085d-3770-45ab-bfea-b8e38625f372"], "metadata": {"page_label": "235", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Protection\n\n## 4.1 Products and personnel\n\n4.1.1 Areas for the manufacture of pharmaceuticals, where pharmaceutical starting materials and products, utensils, primary packing materials and equipment are exposed to the environment, should be defined as \u201cclean areas\u201d, \u201cclean zones\u201d, \u201ccontrolled areas\u201d or \u201ccleanrooms\u201d.\n\n4.1.2 The achievement of a particular clean area condition depends on a number of criteria that should be addressed at the design and qualification stages. A suitable balance between the different criteria will be required in order to create an efficient clean area.\n\n4.1.3 Some of the basic criteria to be considered which affects room cleanliness should include:\n\n- building finishes and structure\n- air filtration\n- air change rate or flushing rate\n- room pressure\n- location of air terminals and directional airflow\n- temperature\n- relative humidity\n- material flow\n- personnel flow\n- gowning procedures\n- equipment movement\n- process being carried out (open or closed system)\n- outside air conditions\n- occupancy\n- type of product\n- cleaning standard operating procedures (SOPs).\n\n4.1.4 Air filtration and air change rates should be set to ensure that the defined clean area condition is attained.\n\n4.1.5 The air change rates should be determined by the manufacturer and designer, taking into account the various critical parameters using a risk-based approach with due consideration of capital and running costs and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de las \u00e1reas limpias en la fabricaci\u00f3n de productos farmac\u00e9uticos. Define las condiciones necesarias para mantener la limpieza en estas \u00e1reas, considerando diversos criterios como la estructura del edificio, la filtraci\u00f3n de aire, la presi\u00f3n de la sala, y los procedimientos de limpieza. Se enfatiza la necesidad de un enfoque basado en riesgos para determinar las tasas de cambio de aire y otros par\u00e1metros cr\u00edticos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los criterios b\u00e1sicos que deben considerarse para mantener la limpieza en las \u00e1reas de fabricaci\u00f3n farmac\u00e9utica?**\n   - El contexto menciona criterios como acabados y estructura del edificio, filtraci\u00f3n de aire, tasa de cambio de aire, presi\u00f3n de la sala, y procedimientos de limpieza, entre otros.\n\n2. **\u00bfQu\u00e9 enfoque se sugiere para determinar las tasas de cambio de aire en las \u00e1reas limpias?**\n   - Se sugiere un enfoque basado en riesgos que considere par\u00e1metros cr\u00edticos, as\u00ed como los costos de capital y operativos.\n\n3. **\u00bfQu\u00e9 factores pueden influir en la condici\u00f3n de limpieza de un \u00e1rea controlada durante el dise\u00f1o y la calificaci\u00f3n?**\n   - Factores como el flujo de materiales y personal, las condiciones del aire exterior, la ocupaci\u00f3n, y el tipo de producto son mencionados como influyentes en la limpieza del \u00e1rea.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" aborda conceptos fundamentales relacionados con la calidad del aire y los procesos de validaci\u00f3n en entornos controlados. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n1. **Extracci\u00f3n de Aire**:\n   - **Definici\u00f3n**: Proceso de eliminaci\u00f3n de polvo mediante un punto de extracci\u00f3n ubicado lo m\u00e1s cerca posible de la fuente de polvo.\n   - **Importancia**: Asegura la calidad del aire en entornos controlados.\n\n2. **Cascada de Presi\u00f3n**:\n   - **Definici\u00f3n**: Flujo de aire desde un \u00e1rea de mayor presi\u00f3n a otra de menor presi\u00f3n.\n   - **Aplicaci\u00f3n**: Utilizada para mantener condiciones controladas en espacios espec\u00edficos.\n\n3. **Calificaci\u00f3n**:\n   - **Definici\u00f3n**: Planificaci\u00f3n, ejecuci\u00f3n y registro de pruebas en equipos y sistemas para demostrar su funcionamiento adecuado dentro de un proceso validado.\n\n4. **Par\u00e1metro Cr\u00edtico de Calidad (CPP)**:\n   - **Definici\u00f3n**: Par\u00e1metro del proceso que puede impactar en la calidad cr\u00edtica del producto.\n   - **Relevancia**: Fundamental para la validaci\u00f3n de sistemas y procesos.\n\n5. **Humedad Relativa**:\n   - **Definici\u00f3n**: Relaci\u00f3n entre la presi\u00f3n de vapor de agua actual en el aire y la presi\u00f3n de vapor de saturaci\u00f3n a la misma temperatura, expresada como un porcentaje.\n\n6. **Procedimiento Operativo Est\u00e1ndar (SOP)**:\n   - **Definici\u00f3n**: Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones generales, no necesariamente espec\u00edficas de un producto.\n\n7. **Flujo Turbulento**:\n   - **Definici\u00f3n**: Distribuci\u00f3n de aire que se mezcla con el aire de la habitaci\u00f3n mediante inducci\u00f3n, caracterizada por un flujo no unidireccional.\n\n8. **Flujo Unidireccional (UDAF)**:\n   - **Definici\u00f3n**: Flujo de aire rectificado que mantiene una velocidad constante y l\u00edneas de corriente aproximadamente paralelas en una zona limpia.\n\n9. **Validaci\u00f3n**:\n   - **Definici\u00f3n**: Acto documentado de demostrar que un procedimiento, proceso, equipo o sistema produce los resultados esperados.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los procesos y equipos en entornos regulados funcionen de manera efectiva y cumplan con los est\u00e1ndares de calidad, lo que es crucial en industrias como la farmac\u00e9utica y la biotecnol\u00f3gica.", "excerpt_keywords": "Keywords: clean areas, air filtration, pharmaceutical manufacturing, risk-based approach, standard operating procedures"}}, "97818a69-4b47-421d-9ec2-c6d036cccab0": {"node_ids": ["9ef35ea5-48d4-4dfa-a5a4-afe5a77f4fa5"], "metadata": {"page_label": "236", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.6 Air Change Rates\n\nAir change rates are normally determined by the following considerations (could normally vary between 6 and 20 air changes per hour):\n\n- Area condition required: whether a specific room cleanliness condition is in fact required and whether the room condition is rated for an \u201cat rest\u201d condition or an \u201coperational\u201d condition (air change rate should be selected on need rather than tradition)\n- The product characteristics (e.g. odours, hygroscopicity, etc)\n- The quality and filtration of the supply air\n- Particulates generated by the manufacturing process\n- Particulates generated by the operators\n- Configuration of the room and air supply and extract locations\n- Sufficient air to achieve containment effect and to clean up the area\n- Sufficient air to cope with the room heat load\n- Sufficient air to balance extract rates\n- Sufficient air to maintain the required room pressure.\n\n# 4.1.7 Cleanroom Classification\n\nIf a cleanroom classification is specified the manufacturer should state whether this is achieved under \u201cas-built\u201d (Figure 2), \u201cat-rest\u201d (Figure 3) or \u201coperational\u201d (Figure 4) conditions.\n\n# 4.1.8 Room Classification Tests in the \u201cAs-Built\u201d Condition\n\nRoom classification tests in the \u201cas-built\u201d condition should be carried out on the bare room, in the absence of any equipment or personnel.\n\n# 4.1.9 Room Classification Tests in the \u201cAt-Rest\u201d Condition\n\nRoom classification tests in the \u201cat-rest\u201d condition should be carried out with the equipment operating where relevant, but without any operators. Because of the amounts of dust usually generated in a solid dosage facility, the clean area classifications would be rated for the \u201cat-rest\u201d condition.\n\n# 4.1.10 Room Classification Tests in the \u201cOperational\u201d Condition\n\nRoom classification tests in the \u201coperational\u201d condition are normally carried out during the normal production process with equipment operating, and the normal number of personnel present in the room. Generally a room that is tested for an \u201coperational\u201d condition should be able to be cleaned up to the \u201cat-rest\u201d clean area classification after a short clean-up time. The clean-up time should be determined through validation and is generally of the order of 20 minutes.\n\n# 4.1.11 Protection from Contamination\n\nMaterials and products should be protected from contamination and cross-contamination during all stages of manufacture (see also section 4.5 for cross-contamination control).\n\n*Note: contaminants may result from inappropriate premises (e.g. poor design, layout or finishing), poor cleaning procedures, contaminants brought in by personnel, poor manufacturing process and a poor HVAC system.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda aspectos cr\u00edticos relacionados con las tasas de cambio de aire y la clasificaci\u00f3n de salas limpias en entornos de fabricaci\u00f3n. Se discuten las condiciones bajo las cuales se deben realizar las pruebas de clasificaci\u00f3n de salas limpias, incluyendo las condiciones \"as-built\", \"at-rest\" y \"operational\". Adem\u00e1s, se enfatiza la importancia de proteger los materiales y productos de la contaminaci\u00f3n durante todas las etapas de fabricaci\u00f3n, destacando factores que pueden contribuir a la contaminaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los factores que determinan la tasa de cambio de aire en una sala limpia?**\n   - La tasa de cambio de aire se determina por consideraciones como la condici\u00f3n del \u00e1rea requerida, las caracter\u00edsticas del producto, la calidad y filtraci\u00f3n del aire de suministro, los particulados generados por el proceso de fabricaci\u00f3n y los operadores, la configuraci\u00f3n de la sala, y la necesidad de mantener la presi\u00f3n y el equilibrio de extracci\u00f3n.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para que una sala limpia sea clasificada como \"operational\"?**\n   - Una sala limpia se clasifica como \"operational\" cuando se realizan pruebas durante el proceso de producci\u00f3n normal, con el equipo en funcionamiento y el n\u00famero habitual de personal presente. Adem\u00e1s, debe ser capaz de limpiarse hasta alcanzar la clasificaci\u00f3n de \"at-rest\" en un tiempo de limpieza validado, generalmente alrededor de 20 minutos.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para proteger los materiales y productos de la contaminaci\u00f3n durante la fabricaci\u00f3n?**\n   - Se deben implementar procedimientos adecuados de dise\u00f1o, limpieza y control de procesos, as\u00ed como asegurar que el sistema HVAC sea eficiente. Tambi\u00e9n es crucial controlar la entrada de contaminantes por parte del personal y mantener un ambiente de trabajo que minimice la generaci\u00f3n de polvo y otros contaminantes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **\u00c1reas Limpias**: Se definen como espacios en la fabricaci\u00f3n de productos farmac\u00e9uticos donde los materiales y productos est\u00e1n expuestos al medio ambiente. Estos espacios pueden ser denominados \"\u00e1reas limpias\", \"zonas limpias\", \"\u00e1reas controladas\" o \"salas limpias\".\n\n2. **Criterios para la Limpieza**: Se enumeran varios criterios que afectan la limpieza de las \u00e1reas, que incluyen:\n   - Acabados y estructura del edificio\n   - Filtraci\u00f3n de aire\n   - Tasa de cambio de aire\n   - Presi\u00f3n de la sala\n   - Ubicaci\u00f3n de terminales de aire y flujo de aire direccional\n   - Temperatura y humedad relativa\n   - Flujo de materiales y personal\n   - Procedimientos de vestimenta\n   - Movimiento de equipos\n   - Tipo de proceso (sistema abierto o cerrado)\n   - Condiciones del aire exterior\n   - Ocupaci\u00f3n y tipo de producto\n   - Procedimientos operativos est\u00e1ndar de limpieza (SOPs)\n\n3. **Filtraci\u00f3n de Aire y Tasas de Cambio**: Se establece que la filtraci\u00f3n de aire y las tasas de cambio deben ser configuradas para alcanzar las condiciones definidas de limpieza en el \u00e1rea.\n\n4. **Enfoque Basado en Riesgos**: Se sugiere que las tasas de cambio de aire sean determinadas por el fabricante y el dise\u00f1ador, considerando par\u00e1metros cr\u00edticos y utilizando un enfoque basado en riesgos, as\u00ed como los costos de capital y operativos.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos Farmac\u00e9uticos**: Materias primas y productos que requieren condiciones de limpieza espec\u00edficas.\n- **\u00c1reas Limpias**: Espacios cr\u00edticos en la fabricaci\u00f3n farmac\u00e9utica.\n- **Criterios de Limpieza**: Factores que afectan la eficacia de las \u00e1reas limpias.\n\nEste resumen destaca la importancia de las \u00e1reas limpias en la industria farmac\u00e9utica y los criterios necesarios para mantener su eficacia y seguridad.", "excerpt_keywords": "Keywords: air change rates, cleanroom classification, contamination control, operational conditions, manufacturing processes"}}, "3531999e-5301-4cbf-b355-cc73b510a9e8": {"node_ids": ["e8b9607b-e8f2-4a10-a672-3eee7306b2b7"], "metadata": {"page_label": "237", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido que podr\u00eda estar relacionado:\n\n### Resumen del contexto:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que probablemente contiene informaci\u00f3n t\u00e9cnica y recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre un tema espec\u00edfico relacionado con la salud p\u00fablica. Sin embargo, el contenido espec\u00edfico no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe T\u00e9cnico 961 sobre la salud p\u00fablica?**\n   - Esta pregunta busca obtener detalles sobre las directrices o recomendaciones espec\u00edficas que la OMS ha emitido en este informe, que podr\u00edan ser relevantes para profesionales de la salud y responsables de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 temas espec\u00edficos se abordan en el documento \"WHO - Technical Report Series 961\"?**\n   - Esta pregunta se centra en identificar los temas o \u00e1reas de enfoque que se discuten en el informe, lo que podr\u00eda incluir enfermedades, tratamientos, pol\u00edticas de salud, etc.\n\n3. **\u00bfC\u00f3mo se estructura el contenido del \"WHO - Technical Report Series 961\" y qu\u00e9 secciones son m\u00e1s relevantes para los investigadores en salud p\u00fablica?**\n   - Esta pregunta busca entender la organizaci\u00f3n del documento y qu\u00e9 partes podr\u00edan ser m\u00e1s \u00fatiles para aquellos que investigan o trabajan en el campo de la salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que podr\u00eda no estar disponible en otras fuentes, bas\u00e1ndose en el contexto del documento de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Tasas de Cambio de Aire**: Se discuten los factores que determinan las tasas de cambio de aire en salas limpias, que pueden variar entre 6 y 20 cambios de aire por hora. Estos factores incluyen la condici\u00f3n del \u00e1rea, las caracter\u00edsticas del producto, la calidad del aire de suministro, y la configuraci\u00f3n de la sala.\n\n2. **Clasificaci\u00f3n de Salas Limpias**: Se especifican las condiciones bajo las cuales se debe clasificar una sala limpia: \"as-built\", \"at-rest\" y \"operational\". Cada una de estas condiciones tiene requisitos espec\u00edficos para las pruebas de clasificaci\u00f3n.\n\n3. **Pruebas de Clasificaci\u00f3n**: Se describen los procedimientos para realizar pruebas de clasificaci\u00f3n en las diferentes condiciones. Las pruebas \"as-built\" se realizan en una sala vac\u00eda, las \"at-rest\" con el equipo en funcionamiento pero sin personal, y las \"operational\" durante el proceso de producci\u00f3n normal.\n\n4. **Protecci\u00f3n contra Contaminaci\u00f3n**: Se enfatiza la importancia de proteger los materiales y productos de la contaminaci\u00f3n en todas las etapas de fabricaci\u00f3n, mencionando factores que pueden contribuir a la contaminaci\u00f3n, como el dise\u00f1o inadecuado, procedimientos de limpieza deficientes y un sistema HVAC ineficiente.\n\n### Entidades\n\n- **Tasas de Cambio de Aire**: 6 a 20 cambios por hora.\n- **Condiciones de Clasificaci\u00f3n**: \"as-built\", \"at-rest\", \"operational\".\n- **Tiempo de Limpieza**: Generalmente alrededor de 20 minutos para alcanzar la clasificaci\u00f3n \"at-rest\".\n- **Factores de Contaminaci\u00f3n**: Dise\u00f1o de instalaciones, limpieza, entrada de contaminantes por personal, procesos de fabricaci\u00f3n, sistema HVAC.\n\nEste resumen destaca los aspectos fundamentales relacionados con la ventilaci\u00f3n y la clasificaci\u00f3n de salas limpias, as\u00ed como la necesidad de mantener un ambiente controlado para evitar la contaminaci\u00f3n durante la fabricaci\u00f3n.", "excerpt_keywords": "Keywords: salud p\u00fablica, OMS, salas limpias, clasificaci\u00f3n, contaminaci\u00f3n"}}, "60ff69b6-debd-4d10-aa26-99b08eb55620": {"node_ids": ["88f68d68-1985-4b74-8e80-1e661785585a"], "metadata": {"page_label": "238", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 4\n**\u201cOperational\u201d condition**\n\n4.1.12 Airborne contaminants should be controlled through effective ventilation and filtration.\n\n4.1.13 External contaminants should be removed by effective filtration of the supply air (see Figure 5 for an example of a shell-like building layout to enhance containment and protection from external contaminants).\n\n4.1.14 Internal contaminants should be controlled by dilution and flushing of contaminants in the room, or by displacement airflow (See Figures 6 and 7 for examples of methods for the flushing of airborne contaminants).\n\n4.1.15 Airborne particulates and the degree of filtration should be considered critical parameters with reference to the level of product protection required.\n\n4.1.16 Personnel should not be a source of contamination.\n\n4.1.17 The level of protection and air cleanliness for different areas should be determined according to the product being manufactured, the process being used and the product\u2019s susceptibility to degradation (Table 1).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las condiciones operativas necesarias para controlar contaminantes en el aire en entornos de fabricaci\u00f3n. Se enfatiza la importancia de la ventilaci\u00f3n y filtraci\u00f3n efectivas para eliminar contaminantes externos e internos, as\u00ed como la necesidad de mantener la limpieza del aire y la protecci\u00f3n del producto. Tambi\u00e9n se menciona que el nivel de protecci\u00f3n debe adaptarse al tipo de producto y proceso, y que el personal no debe ser una fuente de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las estrategias recomendadas para controlar los contaminantes internos en un entorno de fabricaci\u00f3n?**\n   - Respuesta: Los contaminantes internos deben ser controlados mediante la diluci\u00f3n y el lavado de contaminantes en la habitaci\u00f3n, o mediante el uso de flujo de desplazamiento de aire.\n\n2. **\u00bfQu\u00e9 factores deben considerarse al determinar el nivel de protecci\u00f3n y limpieza del aire en diferentes \u00e1reas de producci\u00f3n?**\n   - Respuesta: El nivel de protecci\u00f3n y la limpieza del aire deben determinarse seg\u00fan el producto que se est\u00e1 fabricando, el proceso que se est\u00e1 utilizando y la susceptibilidad del producto a la degradaci\u00f3n.\n\n3. **\u00bfPor qu\u00e9 es importante que el personal no sea una fuente de contaminaci\u00f3n en el entorno de fabricaci\u00f3n?**\n   - Respuesta: Es crucial que el personal no sea una fuente de contaminaci\u00f3n para asegurar que la calidad del producto no se vea comprometida y se mantenga un ambiente controlado que minimice el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de la secci\u00f3n:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un documento de la Organizaci\u00f3n Mundial de la Salud (OMS) que probablemente aborda temas t\u00e9cnicos y recomendaciones relacionadas con la salud p\u00fablica. Sin embargo, no se incluye informaci\u00f3n espec\u00edfica sobre el contenido del informe, ya que se indica \"NO_CONTENT_HERE\".\n\n### Temas clave:\n- **Salud P\u00fablica**: El informe est\u00e1 relacionado con directrices y recomendaciones en este \u00e1mbito.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n\n### Entidades:\n- **WHO (OMS)**: Organizaci\u00f3n que emite el informe.\n- **Technical Report Series 961**: T\u00edtulo del documento espec\u00edfico que se est\u00e1 analizando.\n\n### Preguntas derivadas:\n1. Principales recomendaciones de la OMS en el informe.\n2. Temas espec\u00edficos abordados en el documento.\n3. Estructura del contenido y secciones relevantes para investigadores en salud p\u00fablica.\n\nEste resumen destaca la falta de contenido espec\u00edfico en la secci\u00f3n, pero proporciona un marco para entender el contexto y la relevancia del documento en el \u00e1mbito de la salud p\u00fablica.", "excerpt_keywords": "Keywords: airborne contaminants, ventilation, filtration, product protection, contamination control"}}, "d49a497d-093b-46dc-ac75-15f52dc73552": {"node_ids": ["730fa726-ef69-4ccc-9fa5-d7d92963bb90"], "metadata": {"page_label": "239", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Shell-like containment control concept\n\n!Shell-like containment control concept\n\n## 4.2 Air filtration\n\n*Note: The degree to which air is filtered plays an important role in the prevention of contamination and the control of cross-contamination.*\n\n### 4.2.1\n\nThe type of filters required for different applications depends on the quality of the ambient air and the return air (where applicable) and also on the air change rates. Table 2 gives the recommended filtration levels for different levels of protection in a pharmaceutical facility. Manufacturers should determine and prove the appropriate use of filters.\n\n### 4.2.2\n\nFilter classes should always be linked to the standard test method because referring to actual filter efficiencies can be very misleading (as different test methods each result in a different value for the same filter). (Referring to filter classifications such as an 85% filter or a 5 \u00b5m filter are not valid classifications and should not be used, as this can lead to the incorrect filter being installed. Only the EN 779 and EN 1822 classifications, as per the table below, should be used.)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Importancia de la filtraci\u00f3n de aire en instalaciones farmac\u00e9uticas**: La filtraci\u00f3n de aire es crucial para prevenir la contaminaci\u00f3n y controlar la contaminaci\u00f3n cruzada en entornos farmac\u00e9uticos. La calidad del aire ambiental y el aire de retorno, as\u00ed como las tasas de renovaci\u00f3n del aire, son factores determinantes en la selecci\u00f3n de filtros adecuados.\n\n2. **Clasificaci\u00f3n de filtros y su relevancia**: Es esencial que las clases de filtros se vinculen a m\u00e9todos de prueba est\u00e1ndar, ya que las eficiencias de los filtros pueden variar seg\u00fan el m\u00e9todo utilizado. Las clasificaciones incorrectas pueden llevar a la instalaci\u00f3n de filtros inapropiados, lo que podr\u00eda comprometer la seguridad y la eficacia de las instalaciones.\n\n3. **Recomendaciones para fabricantes**: Los fabricantes de filtros deben determinar y demostrar el uso apropiado de los filtros en funci\u00f3n de las necesidades espec\u00edficas de cada aplicaci\u00f3n en instalaciones farmac\u00e9uticas, siguiendo las clasificaciones estandarizadas como EN 779 y EN 1822.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los factores que determinan el tipo de filtro necesario para una instalaci\u00f3n farmac\u00e9utica?**\n   - La selecci\u00f3n del filtro depende de la calidad del aire ambiental, la calidad del aire de retorno (si aplica) y las tasas de renovaci\u00f3n del aire.\n\n2. **\u00bfPor qu\u00e9 es importante utilizar clasificaciones de filtros estandarizadas como EN 779 y EN 1822?**\n   - Estas clasificaciones son importantes porque proporcionan un m\u00e9todo de prueba est\u00e1ndar que asegura que las eficiencias de los filtros sean comparables y precisas, evitando confusiones que pueden surgir de clasificaciones no v\u00e1lidas.\n\n3. **\u00bfQu\u00e9 consecuencias puede tener la instalaci\u00f3n de un filtro incorrecto en una instalaci\u00f3n farmac\u00e9utica?**\n   - La instalaci\u00f3n de un filtro incorrecto puede llevar a una inadecuada filtraci\u00f3n del aire, lo que aumenta el riesgo de contaminaci\u00f3n y contaminaci\u00f3n cruzada, comprometiendo la seguridad y la calidad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Control de Contaminantes A\u00e9reos**:\n   - Se enfatiza la necesidad de controlar los contaminantes en el aire mediante ventilaci\u00f3n y filtraci\u00f3n efectivas.\n\n2. **Contaminantes Externos**:\n   - Se recomienda la filtraci\u00f3n efectiva del aire de suministro para eliminar contaminantes externos.\n\n3. **Contaminantes Internos**:\n   - Se sugiere el uso de diluci\u00f3n y lavado de contaminantes en el ambiente, as\u00ed como el flujo de desplazamiento de aire para su control.\n\n4. **Part\u00edculas A\u00e9reas**:\n   - Se considera cr\u00edtico el nivel de filtraci\u00f3n de part\u00edculas en relaci\u00f3n con la protecci\u00f3n del producto.\n\n5. **Personal y Contaminaci\u00f3n**:\n   - Se establece que el personal no debe ser una fuente de contaminaci\u00f3n para mantener la calidad del producto.\n\n6. **Determinaci\u00f3n del Nivel de Protecci\u00f3n**:\n   - El nivel de protecci\u00f3n y limpieza del aire debe adaptarse al tipo de producto, el proceso de fabricaci\u00f3n y la susceptibilidad del producto a la degradaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Contaminantes A\u00e9reos**: Elementos a controlar en el entorno de fabricaci\u00f3n.\n- **Ventilaci\u00f3n y Filtraci\u00f3n**: M\u00e9todos recomendados para el control de contaminantes.\n- **Productos Fabricados**: Sujeto a las condiciones de protecci\u00f3n y limpieza del aire.\n- **Personal**: Factor a considerar en la prevenci\u00f3n de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: air filtration, contamination control, pharmaceutical facilities, filter classifications, EN 779 EN 1822"}}, "fcdb506d-6edd-4cf9-bfb3-5f1fba46da33": {"node_ids": ["ca4c1f6f-ef3f-4e3f-8460-deb7a3a0ac9f"], "metadata": {"page_label": "240", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 6  \n**Turbulent dilution of dirty air**\n\n!Turbulent dilution of dirty air\n\nLow-level extract is ideal for dust suppression purposes, but is not essential. (Low-level extract is essential for Grade A, B & C areas.)\n\n# Figure 7  \n**Unidirectional displacement of dirty air**\n\n!Unidirectional displacement of dirty air", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento es un informe t\u00e9cnico de la OMS (Organizaci\u00f3n Mundial de la Salud) que incluye figuras relacionadas con la ventilaci\u00f3n y el control de la calidad del aire en entornos espec\u00edficos. En particular, se mencionan dos tipos de m\u00e9todos de ventilaci\u00f3n: la diluci\u00f3n turbulenta del aire sucio y el desplazamiento unidireccional del aire sucio. Se destaca que el extracto de bajo nivel es ideal para la supresi\u00f3n de polvo, aunque no es esencial, mientras que es esencial para \u00e1reas de Grado A, B y C.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las diferencias clave entre la diluci\u00f3n turbulenta y el desplazamiento unidireccional del aire en t\u00e9rminos de eficacia para el control de la calidad del aire?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre los dos m\u00e9todos mencionados, que no se aborda expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 criterios se utilizan para clasificar las \u00e1reas como Grado A, B y C en relaci\u00f3n con la necesidad de extracto de bajo nivel?**\n   - La pregunta se centra en los criterios de clasificaci\u00f3n que determinan la necesidad de un sistema de ventilaci\u00f3n espec\u00edfico, lo cual no se detalla en el contexto proporcionado.\n\n3. **\u00bfQu\u00e9 implicaciones tiene la falta de extracto de bajo nivel en \u00e1reas que no son de Grado A, B o C en t\u00e9rminos de salud y seguridad?**\n   - Esta pregunta explora las posibles consecuencias de no contar con un sistema de ventilaci\u00f3n adecuado en \u00e1reas que no requieren extracto de bajo nivel, lo que podr\u00eda no estar expl\u00edcitamente mencionado en el documento.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n1. **Filtraci\u00f3n de aire en instalaciones farmac\u00e9uticas**:\n   - La filtraci\u00f3n de aire es fundamental para prevenir la contaminaci\u00f3n y controlar la contaminaci\u00f3n cruzada en entornos farmac\u00e9uticos.\n\n2. **Factores determinantes para la selecci\u00f3n de filtros**:\n   - La elecci\u00f3n del tipo de filtro depende de:\n     - Calidad del aire ambiental.\n     - Calidad del aire de retorno (si aplica).\n     - Tasas de renovaci\u00f3n del aire.\n\n3. **Clasificaci\u00f3n de filtros**:\n   - Es crucial vincular las clases de filtros a m\u00e9todos de prueba est\u00e1ndar para evitar confusiones.\n   - Clasificaciones como \"filtro del 85%\" o \"filtro de 5 \u00b5m\" son consideradas inv\u00e1lidas.\n   - Se deben utilizar las clasificaciones estandarizadas **EN 779** y **EN 1822**.\n\n4. **Recomendaciones para fabricantes**:\n   - Los fabricantes deben determinar y demostrar el uso adecuado de los filtros seg\u00fan las necesidades espec\u00edficas de cada aplicaci\u00f3n en instalaciones farmac\u00e9uticas.\n\n5. **Consecuencias de la instalaci\u00f3n incorrecta de filtros**:\n   - La instalaci\u00f3n de un filtro inapropiado puede resultar en una filtraci\u00f3n inadecuada, aumentando el riesgo de contaminaci\u00f3n y comprometiendo la seguridad y calidad de los productos farmac\u00e9uticos.\n\n### Entidades clave:\n- **Filtraci\u00f3n de aire**\n- **Contaminaci\u00f3n**\n- **Contaminaci\u00f3n cruzada**\n- **Filtros**\n- **Calidad del aire**\n- **Tasas de renovaci\u00f3n del aire**\n- **Clasificaciones de filtros**: EN 779, EN 1822\n- **Fabricantes de filtros**", "excerpt_keywords": "Keywords: ventilation, air quality, dust suppression, WHO report, pharmaceutical facilities"}}, "3690a798-f7c6-4544-a17c-60ba973af53d": {"node_ids": ["98974cca-b28a-425c-af36-34c528d645d8"], "metadata": {"page_label": "241", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Table 1\n**Examples of levels of protection (based on ISPE oral solid dosage (OSD) Guideline criteria)**\n\n| Level   | Condition | Example of area                                                                                                                                                                                                 |\n|---------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1 | General   | Area with normal housekeeping and maintenance where there is no potential for product contamination, e.g. warehousing.                                                                                          |\n| Level 2 | Protected | Area in which steps are taken to protect the pharmaceutical starting material or product from direct or indirect contamination or degradation, e.g. secondary packing, warehousing, first stage change rooms. |\n| Level 3 | Controlled| Area in which specific environmental conditions are defined, controlled and monitored to prevent contamination or degradation of the pharmaceutical starting material or product, e.g. where product, starting materials and components are exposed to the room environment; plus equipment wash and storage areas for equipment product contact parts. |\n\n# Table 2\n**Levels of protection and recommended filtration**\n\n| Level of protection | Recommended filtration                                                                                                                                                                                                 |\n|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| Level 1             | Primary filters only (e.g. EN 779 G4 filters)                                                                                                                                                                          |\n| Level 2             | Protected areas operating on 100% outside air: primary plus secondary filters (e.g. EN 779 G4 plus F8 or F9 filters)                                                                                                   |\n| Level 3             | Production facility operating on recirculated plus ambient air, where potential for cross-contamination exists: Primary plus secondary plus tertiary filters (e.g. EN 779 G4 plus F8 plus EN 1822 H13 filters) (for full fresh air system, without recirculation, G4 and F8 or F9 filters are acceptable) |\n\n**Note:** The filter classifications referred to above relate to the EN 1822 and EN 779 test standards (EN 779 relates to filter classes G1 to F9 and EN 1822 relates to filter classes E10 to U17). Refer to Figure 8 for comparative classifications of other filter standards.\n\n4.2.3 In selecting filters, the manufacturer should have considered other factors, such as particularly contaminated ambient conditions, local regulations and specific product requirements. Good pre-filtration extends the life of the more expensive filters downstream.\n\n4.2.4 Materials for components of an HVAC system should be selected with care so that they do not become a source of contamination. Any component with the potential for liberating particulate or microbial contamination into the air stream should be located upstream of the final filters.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfQu\u00e9 tipo de filtros se recomiendan para un \u00e1rea de protecci\u00f3n de Nivel 2 que opera con aire 100% exterior?**\n   - **Respuesta:** Para un \u00e1rea de protecci\u00f3n de Nivel 2 que opera con aire 100% exterior, se recomiendan filtros primarios m\u00e1s filtros secundarios, espec\u00edficamente filtros de clase EN 779 G4 m\u00e1s filtros de clase F8 o F9.\n\n2. **\u00bfCu\u00e1les son las consideraciones que un fabricante debe tener en cuenta al seleccionar filtros para un sistema HVAC?**\n   - **Respuesta:** Al seleccionar filtros, el fabricante debe considerar factores como las condiciones ambientales particularmente contaminadas, las regulaciones locales y los requisitos espec\u00edficos del producto. Adem\u00e1s, una buena pre-filtraci\u00f3n puede extender la vida \u00fatil de los filtros m\u00e1s costosos que se encuentran aguas abajo.\n\n3. **\u00bfQu\u00e9 caracter\u00edsticas definen un \u00e1rea de protecci\u00f3n de Nivel 3 seg\u00fan las pautas de ISPE?**\n   - **Respuesta:** Un \u00e1rea de protecci\u00f3n de Nivel 3 se define como aquella en la que se establecen, controlan y monitorean condiciones ambientales espec\u00edficas para prevenir la contaminaci\u00f3n o degradaci\u00f3n del material o producto farmac\u00e9utico. Esto incluye \u00e1reas donde los productos, materiales de partida y componentes est\u00e1n expuestos al ambiente de la sala, as\u00ed como \u00e1reas de lavado y almacenamiento de equipos que tienen contacto con el producto.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre los niveles de protecci\u00f3n en entornos de fabricaci\u00f3n farmac\u00e9utica, espec\u00edficamente en relaci\u00f3n con la contaminaci\u00f3n de productos. Se describen tres niveles de protecci\u00f3n, cada uno con ejemplos de \u00e1reas y condiciones espec\u00edficas. Adem\u00e1s, se detallan las recomendaciones de filtraci\u00f3n para cada nivel, basadas en est\u00e1ndares de filtraci\u00f3n europeos. Tambi\u00e9n se enfatiza la importancia de seleccionar cuidadosamente los materiales de los componentes de los sistemas HVAC para evitar la contaminaci\u00f3n.\n\n### Preguntas adicionales basadas en el resumen:\n1. **\u00bfQu\u00e9 ejemplos de \u00e1reas se consideran para cada nivel de protecci\u00f3n en la fabricaci\u00f3n farmac\u00e9utica?**\n2. **\u00bfC\u00f3mo se relacionan las clasificaciones de filtros EN 1822 y EN 779 con los niveles de protecci\u00f3n?**\n3. **\u00bfPor qu\u00e9 es importante la selecci\u00f3n cuidadosa de materiales en un sistema HVAC en entornos farmac\u00e9uticos?**", "prev_section_summary": "La secci\u00f3n del documento de la OMS se centra en m\u00e9todos de ventilaci\u00f3n y control de la calidad del aire, destacando dos enfoques principales: la diluci\u00f3n turbulenta del aire sucio y el desplazamiento unidireccional del aire sucio. Se menciona que el extracto de bajo nivel es ideal para la supresi\u00f3n de polvo, aunque no es esencial en todos los contextos, siendo su uso obligatorio en \u00e1reas clasificadas como Grado A, B y C. \n\n### Temas clave:\n1. **M\u00e9todos de ventilaci\u00f3n**:\n   - Diluci\u00f3n turbulenta del aire sucio.\n   - Desplazamiento unidireccional del aire sucio.\n\n2. **Importancia del extracto de bajo nivel**:\n   - Ideal para la supresi\u00f3n de polvo.\n   - Esencial para \u00e1reas de Grado A, B y C.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Grados de \u00e1reas**: Clasificaci\u00f3n que determina la necesidad de sistemas de ventilaci\u00f3n espec\u00edficos (Grado A, B y C). \n\nEste resumen proporciona una visi\u00f3n general de los conceptos tratados en la secci\u00f3n, as\u00ed como de las entidades relevantes.", "excerpt_keywords": "Keywords: protection levels, pharmaceutical manufacturing, air filtration, HVAC systems, contamination control"}}, "25268c96-b926-4075-9bf7-ee6789f0b550": {"node_ids": ["2589ffd6-17cd-432c-a386-a829e451fbe9"], "metadata": {"page_label": "242", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 8\n## Comparison of filter test standards\n\n| Eurovent 4/5 Rating (superseded)\\<br/>Average Arrestance A (%) | ASHRAE 52.2 Merv Rating\\<br/>Average Dust Spot Efficiency E (%) | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1 | Eurovent 4/5 ASHRAE 52.1 BS6540 Part 1\\<br/>EN 779 & EN 1822 | |\n| - | - | - | - | - |\n| EU 14 | Merv 18 | | | U17 |\n| EU 13 | Merv 17 | | | U16 |\n| EU 12 | Merv 16 | | | U15 |\n| EU 11 | Merv 15 | | | H14 |\n| EU 10 | Merv 14 | | | H13 |\n| EU 9 | Merv 13 | | | E12 |\n| EU 8 | Merv 12 | | | E11 |\n| EU 7 | Merv 11 | | | E10 |\n| EU 6 | Merv 10 | | | F9 |\n| EU 5 | Merv 9 | | | F8 |\n| EU 4 | Merv 8 | | | F7 |\n| EU 3 | Merv 7 | | | F6 |\n| EU 2 | Merv 6 | | | F5 |\n| EU 1 | Merv 5 | | | G4 |\n| | Merv 4 | | | G3 |\n| | Merv 3 | | | G2 |\n| | Merv 2 | | | G1 |\n| | Merv 1 | | | |\n\n\n<p>MPPS = Most Penetrating Particle Size</p>", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una figura que compara diferentes est\u00e1ndares de pruebas de filtros de aire. La tabla presenta las clasificaciones de Eurovent y ASHRAE, mostrando la relaci\u00f3n entre la eficiencia de los filtros y su capacidad de retenci\u00f3n de part\u00edculas. Se mencionan las clasificaciones de Eurovent 4/5, el Merv de ASHRAE y otros est\u00e1ndares relacionados, as\u00ed como la eficiencia de captura de polvo.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es la relaci\u00f3n entre la clasificaci\u00f3n Eurovent 4/5 y el Merv de ASHRAE en t\u00e9rminos de eficiencia de filtraci\u00f3n?**\n   - La tabla muestra c\u00f3mo las clasificaciones Eurovent 4/5 se correlacionan con las clasificaciones Merv de ASHRAE, indicando que a medida que aumenta la clasificaci\u00f3n Eurovent, tambi\u00e9n lo hace la clasificaci\u00f3n Merv.\n\n2. **\u00bfQu\u00e9 clasificaci\u00f3n Eurovent 4/5 corresponde a un Merv 18 y qu\u00e9 nivel de eficiencia de captura de polvo se asocia con esta clasificaci\u00f3n?**\n   - Seg\u00fan la tabla, la clasificaci\u00f3n Eurovent 4/5 EU 14 corresponde a un Merv 18, aunque no se proporciona un valor espec\u00edfico de eficiencia de captura de polvo en la tabla.\n\n3. **\u00bfQu\u00e9 significa MPPS en el contexto de la filtraci\u00f3n de aire y c\u00f3mo se relaciona con los est\u00e1ndares de filtraci\u00f3n mencionados?**\n   - MPPS significa \"Most Penetrating Particle Size\" (Tama\u00f1o de Part\u00edcula M\u00e1s Penetrante), y se refiere al tama\u00f1o de part\u00edcula que es m\u00e1s dif\u00edcil de capturar por los filtros. Este concepto es relevante para entender la eficacia de los filtros en diferentes clasificaciones y est\u00e1ndares.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Niveles de Protecci\u00f3n**:\n   - **Nivel 1 (General)**: \u00c1reas con mantenimiento normal sin potencial de contaminaci\u00f3n del producto (ej. almacenamiento).\n   - **Nivel 2 (Protegido)**: \u00c1reas protegidas contra contaminaci\u00f3n directa o indirecta (ej. empaquetado secundario, vestuarios).\n   - **Nivel 3 (Controlado)**: \u00c1reas con condiciones ambientales definidas y controladas para prevenir contaminaci\u00f3n (ej. \u00e1reas de lavado de equipos, almacenamiento de partes en contacto con el producto).\n\n2. **Filtraci\u00f3n Recomendada**:\n   - **Nivel 1**: Filtros primarios (ej. filtros EN 779 G4).\n   - **Nivel 2**: Filtros primarios m\u00e1s secundarios (ej. filtros EN 779 G4 m\u00e1s F8 o F9).\n   - **Nivel 3**: Filtros primarios, secundarios y terciarios (ej. filtros EN 779 G4, F8 y EN 1822 H13). Para sistemas de aire fresco sin recirculaci\u00f3n, se aceptan filtros G4 y F8 o F9.\n\n3. **Normativas de Filtraci\u00f3n**:\n   - Clasificaciones de filtros seg\u00fan est\u00e1ndares europeos EN 1822 (clases E10 a U17) y EN 779 (clases G1 a F9).\n\n4. **Consideraciones para Selecci\u00f3n de Filtros**:\n   - Factores a considerar incluyen condiciones ambientales contaminadas, regulaciones locales y requisitos espec\u00edficos del producto. La pre-filtraci\u00f3n adecuada extiende la vida \u00fatil de filtros m\u00e1s costosos.\n\n5. **Materiales de Sistemas HVAC**:\n   - Importancia de seleccionar materiales que no liberen contaminaci\u00f3n en el aire. Componentes que puedan liberar part\u00edculas o contaminaci\u00f3n microbiana deben estar ubicados antes de los filtros finales.\n\n### Entidades Clave:\n- **ISPE**: Organizaci\u00f3n que proporciona directrices sobre la fabricaci\u00f3n farmac\u00e9utica.\n- **Filtros**: Clasificados seg\u00fan est\u00e1ndares EN 1822 y EN 779.\n- **\u00c1reas de Protecci\u00f3n**: Clasificadas en niveles 1, 2 y 3, cada uno con ejemplos espec\u00edficos.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en entornos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la protecci\u00f3n y filtraci\u00f3n en la fabricaci\u00f3n farmac\u00e9utica, as\u00ed como las consideraciones necesarias para mantener la calidad del producto y la seguridad en el ambiente de trabajo.", "excerpt_keywords": "Keywords: filtraci\u00f3n, Eurovent, ASHRAE, est\u00e1ndares, eficiencia"}}, "c7314169-b847-4aed-910b-2dda789ef23f": {"node_ids": ["15a3d6df-c9ab-4f17-acdd-abe6cb4ba82c"], "metadata": {"page_label": "243", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2.5\n\nWhere possible ventilation dampers, filters and other services should be designed and positioned so that they are accessible from outside the manufacturing areas (service voids or service corridors) for maintenance purposes.\n\n# 4.2.6\n\nDirectional airflow within production or primary packing areas should assist in preventing contamination. Airflows should be planned in conjunction with operator locations, so as to minimize contamination of the product by the operator and also to protect the operator from dust inhalation.\n\n# 4.2.7\n\nHVAC air distribution components should be designed, installed and located to prevent contaminants generated within the room from being spread.\n\n# 4.2.8\n\nSupply air diffusers should be selected with care taking consideration of, e.g. room requirements and positions of equipment and operators in the room. Supply air diffusers of the high induction type (e.g. those typically used for office-type air-conditioning) should where possible not be used in clean areas where dust is liberated. Air diffusers should be of the non-induction type, introducing air with the least amount of induction so as to maximize the flushing effect. In rooms where the process results in high dust liberation; perforated plates or low induction swirl diffusers with low level extract or return should be used (to contain the dust at the lower level of the room) (see Figures 9\u201311 for illustrations of the three types of diffuser). In cases where dust liberation is low, ceiling return air grilles may be acceptable.\n\n# 4.2.9\n\nInduction and certain swirl diffusers induce room air vertically up to the diffuser to mix with the supply air. These diffusers create good dilution of contaminants in the room and may be used in rooms where there is low dust liberation. However, if used in rooms where excessive dust is generated, the distribution of dust in the room could be hazardous for the operators in the room.\n\n# 4.3 Unidirectional airflow\n\n## 4.3.1\n\nUnidirectional airflow (UDAF) should be used for weighing booths or sampling booths to provide operator and product protection and should also have a slight air in-flow from the room to enhance containment. Dust containment at the weigh booth should be demonstrated by smoke airflow pattern tests, or other appropriate tests. UDAF can also be used to provide protection of other dusty processes.\n\n## 4.3.2\n\nSampling of materials such as starting materials, primary packaging materials and products, should be carried out in the same environmental conditions that are required for the further processing of the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las mejores pr\u00e1cticas para el dise\u00f1o y la instalaci\u00f3n de sistemas de ventilaci\u00f3n y distribuci\u00f3n de aire en \u00e1reas de producci\u00f3n y empaque. Se enfatiza la importancia de la accesibilidad de los componentes de ventilaci\u00f3n para el mantenimiento, la planificaci\u00f3n del flujo de aire para minimizar la contaminaci\u00f3n, y la selecci\u00f3n adecuada de difusores de aire para controlar la liberaci\u00f3n de polvo. Adem\u00e1s, se menciona el uso de flujo de aire unidireccional en cabinas de pesaje y muestreo para proteger tanto a los operadores como a los productos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de difusores de aire se recomienda evitar en \u00e1reas limpias donde se libera polvo, y cu\u00e1l es la raz\u00f3n detr\u00e1s de esta recomendaci\u00f3n?**\n   - Se recomienda evitar los difusores de aire de alta inducci\u00f3n, t\u00edpicamente utilizados en sistemas de aire acondicionado de oficina, en \u00e1reas limpias donde se libera polvo, ya que pueden contribuir a la dispersi\u00f3n de contaminantes en el ambiente.\n\n2. **\u00bfC\u00f3mo se debe demostrar la contenci\u00f3n de polvo en una cabina de pesaje seg\u00fan el documento?**\n   - La contenci\u00f3n de polvo en una cabina de pesaje debe ser demostrada mediante pruebas de patrones de flujo de aire con humo u otras pruebas apropiadas que verifiquen la efectividad del flujo de aire unidireccional.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar difusores de aire en funci\u00f3n de la liberaci\u00f3n de polvo en una sala?**\n   - Al seleccionar difusores de aire, se debe considerar el nivel de liberaci\u00f3n de polvo en la sala. En \u00e1reas con alta liberaci\u00f3n de polvo, se deben usar placas perforadas o difusores de remolino de baja inducci\u00f3n con extracci\u00f3n o retorno a nivel bajo, mientras que en \u00e1reas con baja liberaci\u00f3n de polvo, pueden ser aceptables las rejillas de retorno de aire en el techo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en la comparaci\u00f3n de est\u00e1ndares de pruebas de filtros de aire, espec\u00edficamente entre las clasificaciones Eurovent 4/5 y el Merv de ASHRAE. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n1. **Clasificaciones de Filtros**:\n   - **Eurovent 4/5**: Un sistema de clasificaci\u00f3n que eval\u00faa la eficiencia de los filtros de aire en t\u00e9rminos de su capacidad de retenci\u00f3n de part\u00edculas.\n   - **ASHRAE 52.2 Merv**: Un sistema de clasificaci\u00f3n que mide la eficiencia de los filtros en la captura de polvo, donde \"Merv\" significa \"Minimum Efficiency Reporting Value\".\n\n2. **Relaci\u00f3n entre Clasificaciones**:\n   - La tabla muestra c\u00f3mo las clasificaciones Eurovent se correlacionan con las clasificaciones Merv, indicando que a mayor clasificaci\u00f3n Eurovent, mayor es la clasificaci\u00f3n Merv.\n\n3. **Eficiencia de Captura de Polvo**:\n   - La tabla incluye clasificaciones espec\u00edficas y su correspondiente eficiencia de captura de polvo, aunque no se proporcionan valores exactos en todos los casos.\n\n4. **MPPS (Most Penetrating Particle Size)**:\n   - Se define como el tama\u00f1o de part\u00edcula m\u00e1s dif\u00edcil de capturar por los filtros, un concepto importante para evaluar la eficacia de los filtros en diferentes clasificaciones.\n\n### Entidades Clave\n- **Eurovent 4/5**: Sistema de clasificaci\u00f3n de filtros.\n- **ASHRAE 52.2**: Est\u00e1ndar de eficiencia de filtros.\n- **Merv**: Valor de eficiencia m\u00ednima.\n- **MPPS**: Tama\u00f1o de part\u00edcula m\u00e1s penetrante.\n\nEste resumen destaca la importancia de los est\u00e1ndares de filtraci\u00f3n en la evaluaci\u00f3n de la eficacia de los filtros de aire y su relaci\u00f3n con la calidad del aire interior.", "excerpt_keywords": "Keywords: ventilation, airflow, contamination, dust control, unidirectional airflow"}}, "ddf7c2ce-f6c9-4029-ada0-553705c31d5f": {"node_ids": ["03f46bcd-d627-475f-b6f8-f2e3ebc1474d"], "metadata": {"page_label": "244", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 9\n**Induction diffuser**\n\n!Induction diffuser\n\n*Enlarged View of Diffuser*\n\n----\n\n# Figure 10\n**Perforated plate diffuser**\n\n!Perforated plate diffuser\n\n*Enlarged Views of Diffusers*\n\n----\n\n232", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye figuras que ilustran diferentes tipos de difusores utilizados en aplicaciones t\u00e9cnicas. En particular, se presentan dos tipos de difusores: el difusor de inducci\u00f3n y el difusor de placa perforada, cada uno con una vista ampliada para facilitar su comprensi\u00f3n.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas principales del difusor de inducci\u00f3n seg\u00fan la figura 9 del informe?**\n   - Esta pregunta busca detalles espec\u00edficos sobre el dise\u00f1o y funcionamiento del difusor de inducci\u00f3n que podr\u00edan no estar disponibles en otras fuentes.\n\n2. **\u00bfEn qu\u00e9 aplicaciones se recomienda el uso del difusor de placa perforada, seg\u00fan la informaci\u00f3n presentada en la figura 10?**\n   - Esta pregunta se centra en las aplicaciones pr\u00e1cticas del difusor de placa perforada, lo que puede no estar claramente especificado en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias clave existen entre el difusor de inducci\u00f3n y el difusor de placa perforada en t\u00e9rminos de eficiencia y dise\u00f1o?**\n   - Esta pregunta busca una comparaci\u00f3n directa entre los dos tipos de difusores, lo que puede proporcionar informaci\u00f3n valiosa para la selecci\u00f3n de tecnolog\u00eda en aplicaciones espec\u00edficas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o y Mantenimiento de Sistemas de Ventilaci\u00f3n**:\n   - Los componentes de ventilaci\u00f3n, como compuertas y filtros, deben ser accesibles desde \u00e1reas externas para facilitar el mantenimiento.\n\n2. **Flujo de Aire Direccional**:\n   - Se debe planificar el flujo de aire en \u00e1reas de producci\u00f3n y empaque para prevenir la contaminaci\u00f3n, considerando la ubicaci\u00f3n de los operadores para proteger tanto al producto como a los trabajadores.\n\n3. **Componentes de Distribuci\u00f3n de Aire HVAC**:\n   - Deben ser dise\u00f1ados e instalados para evitar la propagaci\u00f3n de contaminantes generados en la sala.\n\n4. **Selecci\u00f3n de Difusores de Aire**:\n   - Se deben evitar difusores de alta inducci\u00f3n en \u00e1reas limpias donde se libera polvo. Se prefieren difusores de tipo no inducci\u00f3n para maximizar el efecto de limpieza.\n   - En \u00e1reas con alta liberaci\u00f3n de polvo, se recomiendan placas perforadas o difusores de remolino de baja inducci\u00f3n.\n\n5. **Flujo de Aire Unidireccional (UDAF)**:\n   - Se debe utilizar en cabinas de pesaje y muestreo para proteger a los operadores y productos, con pruebas de contenci\u00f3n de polvo necesarias para validar su efectividad.\n\n6. **Condiciones de Muestreo**:\n   - El muestreo de materiales debe realizarse en condiciones ambientales que coincidan con las requeridas para el procesamiento posterior del producto.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Sistemas de Ventilaci\u00f3n**: Incluye compuertas, filtros y difusores.\n- **Flujo de Aire**: Direccional y unidireccional, con \u00e9nfasis en la prevenci\u00f3n de contaminaci\u00f3n.\n- **Cabinas de Pesaje y Muestreo**: Espacios donde se aplica el flujo de aire unidireccional.\n- **Contaminantes**: Elementos que deben ser controlados para proteger la salud de los operadores y la calidad del producto. \n\nEste resumen destaca la importancia de un dise\u00f1o cuidadoso de los sistemas de ventilaci\u00f3n y el flujo de aire en entornos de producci\u00f3n para garantizar la seguridad y la calidad.", "excerpt_keywords": "Keywords: difusores, inducci\u00f3n, placa perforada, ventilaci\u00f3n, contaminaci\u00f3n"}}, "8b60474a-b1d1-4057-b813-f615d6b16c79": {"node_ids": ["7c4592f1-0f56-411a-b101-eca8b0240535"], "metadata": {"page_label": "245", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.3.3\n\nIn a weighing booth situation, the aim of the UDAF is to provide dust containment and operator protection.\n\n*Example:* In Figure 12 the dust generated at the weighing station is immediately extracted through the perforated worktop, thus protecting the operator from dust inhalation, but at the same time protecting the product from contamination by the operator by means of the vertical unidirectional airflow stream.\n\n# 4.3.4\n\nThe unidirectional flow velocity should be such that it does not disrupt the sensitivity of balances in weighing areas. Where necessary the velocity may be reduced to prevent inaccuracies during weighing, provided that sufficient airflow is maintained to provide containment. Conventional unidirectional airflow systems, where a Grade A condition is required, have a guidance airflow velocity of 0.36 to 0.54 m/s. However, in a weigh booth or sampling booth a lower velocity can be used as a Grade A condition is not required. It is often necessary to reduce velocities to a lower level in order not to influence balance readings. The airflow velocity and directional flow should still ensure product containment. For this type of application it is sometimes better to refer to the unit as an airflow protection booth (APB) rather than a UDAF, in order to avoid confusion, with a Grade A requirement.\n\n# 4.3.5\n\nThe position in which the operator stands relative to the source of dust liberation and airflow should be determined to ensure that the operator is not in the path of an airflow that could lead to contamination of the product (Figure 13).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las especificaciones y recomendaciones para el uso de cabinas de pesaje, espec\u00edficamente en relaci\u00f3n con el flujo de aire unidireccional (UDAF) y su funci\u00f3n en la contenci\u00f3n de polvo y protecci\u00f3n del operador. Se discuten aspectos como la velocidad del flujo de aire, la importancia de no interferir con la sensibilidad de las balanzas, y la posici\u00f3n del operador para evitar la contaminaci\u00f3n del producto.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es la velocidad de flujo de aire recomendada para sistemas de flujo unidireccional en cabinas de pesaje, y c\u00f3mo se ajusta esta velocidad en funci\u00f3n de la sensibilidad de las balanzas?**\n   - Respuesta: La velocidad de flujo de aire recomendada para sistemas de flujo unidireccional en condiciones de Grado A es de 0.36 a 0.54 m/s. Sin embargo, en cabinas de pesaje o muestreo, se puede utilizar una velocidad m\u00e1s baja para no influir en las lecturas de las balanzas, siempre que se mantenga un flujo de aire suficiente para garantizar la contenci\u00f3n del producto.\n\n2. **\u00bfPor qu\u00e9 se sugiere referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF en ciertas aplicaciones?**\n   - Respuesta: Se sugiere referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF para evitar confusiones, ya que en estas aplicaciones no se requiere una condici\u00f3n de Grado A.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta respecto a la posici\u00f3n del operador en relaci\u00f3n con la fuente de liberaci\u00f3n de polvo y el flujo de aire?**\n   - Respuesta: La posici\u00f3n del operador debe ser determinada de manera que no est\u00e9 en el camino de un flujo de aire que podr\u00eda llevar a la contaminaci\u00f3n del producto. Esto implica una planificaci\u00f3n cuidadosa del dise\u00f1o del espacio de trabajo para asegurar la protecci\u00f3n tanto del operador como del producto.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido de la secci\u00f3n se centra en la presentaci\u00f3n de dos tipos de difusores utilizados en aplicaciones t\u00e9cnicas, espec\u00edficamente:\n\n1. **Difusor de Inducci\u00f3n**:\n   - Se menciona en la Figura 9, donde se proporciona una vista ampliada para ilustrar sus caracter\u00edsticas y funcionamiento.\n\n2. **Difusor de Placa Perforada**:\n   - Se presenta en la Figura 10, tambi\u00e9n con una vista ampliada, lo que permite una mejor comprensi\u00f3n de su dise\u00f1o y aplicaciones.\n\n### Entidades:\n- **WHO - Technical Report Series 961**: T\u00edtulo del documento que contiene la informaci\u00f3n.\n- **Difusor de Inducci\u00f3n**: Tipo de difusor destacado en la figura 9.\n- **Difusor de Placa Perforada**: Tipo de difusor destacado en la figura 10.\n\n### Temas Clave:\n- Comparaci\u00f3n y caracter\u00edsticas de diferentes tipos de difusores.\n- Aplicaciones t\u00e9cnicas de los difusores presentados.\n- Importancia de la visualizaci\u00f3n ampliada para entender el dise\u00f1o de los difusores. \n\nEste resumen proporciona una visi\u00f3n general de los elementos discutidos en la secci\u00f3n, destacando la relevancia de los difusores en contextos t\u00e9cnicos.", "excerpt_keywords": "Keywords: UDAF, dust containment, operator protection, airflow velocity, weighing booth"}}, "25b0c416-f3fe-4e67-82b3-934db0e96d2b": {"node_ids": ["cec580f3-b046-4bd5-81ef-4fc658deda1c"], "metadata": {"page_label": "246", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator Protection at Weighing Station\n\n4.3.6 Once the system has been designed and qualified with a specific layout for operators and processes, this should be maintained in accordance with an SOP.\n\n4.3.7 There should be no obstructions in the path of a unidirectional flow air stream that may cause the operator to be exposed to dust.\n\nFigure 14 illustrates the incorrect use of a weighing scale which has a solid back. The back of the weighing scale should not block the return air path as this causes air to rise vertically, resulting in a hazardous situation for the operator.\n\nFigure 15 illustrates a situation where an open bin is placed below a vertical unidirectional flow distributor. The downward airflow should be prevented from entering the bin, and then being forced to rise again, as this would carry dust up towards the operator\u2019s face. In such an occurrence it may be necessary to add a partial cover over the bin to limit the entry of air. Point extraction could also be used but this can result in the excessive loss of product.\n\nFigure 16 shows that a solid worktop can sometimes cause deflection of the vertical unidirectional airflow resulting in a flow reversal. A possible solution would be to have a 100 mm gap between the back of the table and the wall, with the air being extracted here.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS aborda la protecci\u00f3n de los operadores en estaciones de pesaje, enfatizando la importancia de un dise\u00f1o adecuado del sistema de flujo de aire unidireccional para minimizar la exposici\u00f3n al polvo. Se destacan varios errores comunes en la disposici\u00f3n de equipos, como el uso de balanzas con respaldos s\u00f3lidos que obstruyen el flujo de aire, la colocaci\u00f3n de contenedores abiertos que permiten la entrada de aire y la deflexi\u00f3n del flujo de aire causada por superficies de trabajo s\u00f3lidas. Se sugieren soluciones pr\u00e1cticas, como mantener espacios adecuados entre los equipos y las paredes, as\u00ed como la implementaci\u00f3n de cubiertas parciales para limitar la entrada de aire.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consecuencias de tener un respaldo s\u00f3lido en una balanza en t\u00e9rminos de flujo de aire y seguridad del operador?**\n   - La presencia de un respaldo s\u00f3lido en una balanza puede bloquear el camino del aire de retorno, causando que el aire se eleve verticalmente, lo que resulta en una situaci\u00f3n peligrosa para el operador al aumentar la exposici\u00f3n al polvo.\n\n2. **\u00bfQu\u00e9 medidas se pueden tomar para evitar que el flujo de aire descendente entre en un contenedor abierto y cause problemas de seguridad?**\n   - Para prevenir que el flujo de aire descendente ingrese a un contenedor abierto, se puede agregar una cubierta parcial sobre el contenedor o considerar la extracci\u00f3n puntual, aunque esta \u00faltima opci\u00f3n puede resultar en una p\u00e9rdida excesiva de producto.\n\n3. **\u00bfC\u00f3mo puede la disposici\u00f3n de un \u00e1rea de trabajo afectar el flujo de aire unidireccional y qu\u00e9 soluci\u00f3n se propone para mitigar este problema?**\n   - Una superficie de trabajo s\u00f3lida puede desviar el flujo de aire unidireccional, provocando una reversi\u00f3n del flujo. Se sugiere mantener un espacio de 100 mm entre la parte posterior de la mesa y la pared para permitir la extracci\u00f3n adecuada del aire y evitar problemas de seguridad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Objetivo de la Cabina de Pesaje (UDAF)**:\n   - Proporcionar contenci\u00f3n de polvo y protecci\u00f3n al operador en situaciones de pesaje.\n\n2. **Extracci\u00f3n de Polvo**:\n   - Ejemplo de funcionamiento: el polvo generado en la estaci\u00f3n de pesaje es extra\u00eddo a trav\u00e9s de una superficie de trabajo perforada, protegiendo al operador de la inhalaci\u00f3n de polvo y evitando la contaminaci\u00f3n del producto mediante un flujo de aire unidireccional vertical.\n\n3. **Velocidad de Flujo de Aire**:\n   - La velocidad del flujo de aire unidireccional debe ser suficiente para no afectar la sensibilidad de las balanzas. \n   - Para condiciones de Grado A, la velocidad recomendada es de 0.36 a 0.54 m/s, pero en cabinas de pesaje o muestreo se puede utilizar una velocidad m\u00e1s baja para evitar influencias en las lecturas de las balanzas, siempre que se mantenga una contenci\u00f3n adecuada.\n\n4. **Terminolog\u00eda**:\n   - En ciertas aplicaciones, es preferible referirse a las cabinas de pesaje como cabinas de protecci\u00f3n de flujo de aire (APB) en lugar de UDAF para evitar confusiones relacionadas con los requisitos de Grado A.\n\n5. **Posici\u00f3n del Operador**:\n   - La ubicaci\u00f3n del operador debe ser cuidadosamente determinada para evitar que est\u00e9 en el camino de un flujo de aire que pueda contaminar el producto, lo que requiere una planificaci\u00f3n adecuada del espacio de trabajo.\n\n### Entidades Clave\n- **UDAF**: Unidad de flujo de aire unidireccional.\n- **APB**: Cabina de protecci\u00f3n de flujo de aire.\n- **Grado A**: Condici\u00f3n de calidad del aire en entornos controlados.\n- **Balances**: Instrumentos de medici\u00f3n de peso que requieren condiciones espec\u00edficas para su funcionamiento preciso.", "excerpt_keywords": "Keywords: operator protection, unidirectional airflow, weighing station, dust exposure, airflow design"}}, "d05d909d-1d1b-4f1b-8e50-4dd9b8e4ec67": {"node_ids": ["3536364c-71c6-4b1e-813a-b43f99fa7a1b"], "metadata": {"page_label": "247", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Operator protection by horizontal airflow\n\n4.3.8 The manufacturer should select either vertical or horizontal unidirectional flow (Figure 17) and an appropriate airflow pattern to provide the best protection for the particular application.\n\n4.3.9 Return or exhaust air grilles in rooms or at weigh or sampling booths should preferably be of the perforated grille types, which are easy to clean. Return/exhaust air filters can either be installed at the room terminal or in the air-handling unit. Maintenance and cleaning of filters and ducts should be addressed to ensure constant airflow.\n\n## 4.4 Infiltration\n\n4.4.1 Air infiltration of unfiltered air into a pharmaceutical plant should not be a source of contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl contexto se centra en las recomendaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre la protecci\u00f3n de los operadores en entornos farmac\u00e9uticos mediante el uso de flujos de aire unidireccionales, ya sea vertical u horizontal. Se enfatiza la importancia de seleccionar el patr\u00f3n de flujo de aire adecuado para garantizar la protecci\u00f3n en aplicaciones espec\u00edficas. Adem\u00e1s, se menciona la necesidad de utilizar rejillas de aire de tipo perforado en \u00e1reas de pesaje o muestreo, as\u00ed como la importancia del mantenimiento regular de filtros y conductos para asegurar un flujo de aire constante. Por \u00faltimo, se establece que la infiltraci\u00f3n de aire no filtrado en una planta farmac\u00e9utica no debe ser una fuente de contaminaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones que un fabricante debe tener en cuenta al seleccionar entre flujo de aire vertical u horizontal en un entorno farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre los criterios espec\u00edficos que gu\u00edan la elecci\u00f3n del tipo de flujo de aire, que no se abordan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de rejillas de aire se recomienda para las \u00e1reas de pesaje o muestreo y por qu\u00e9?**\n   - Esta pregunta se centra en las caracter\u00edsticas de las rejillas de aire recomendadas y su facilidad de limpieza, lo que podr\u00eda no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para garantizar que la infiltraci\u00f3n de aire no filtrado no contamine una planta farmac\u00e9utica?**\n   - Esta pregunta busca informaci\u00f3n sobre las pr\u00e1cticas o protocolos que se deben implementar para prevenir la contaminaci\u00f3n por aire no filtrado, que podr\u00eda no estar detallada en otros documentos.\n\n### Resumen adicional\n\nEl documento tambi\u00e9n aborda la importancia de mantener un ambiente controlado en las instalaciones farmac\u00e9uticas, donde el flujo de aire y la calidad del aire son cruciales para prevenir la contaminaci\u00f3n. Se subraya la necesidad de un mantenimiento regular de los sistemas de ventilaci\u00f3n y filtraci\u00f3n para asegurar que el aire que circula en estas \u00e1reas cumpla con los est\u00e1ndares de calidad requeridos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Protecci\u00f3n del Operador**: La secci\u00f3n se centra en la protecci\u00f3n de los operadores en estaciones de pesaje, destacando la importancia de un dise\u00f1o adecuado del sistema de flujo de aire unidireccional para minimizar la exposici\u00f3n al polvo.\n\n2. **Dise\u00f1o del Sistema**: Se enfatiza que una vez que el sistema ha sido dise\u00f1ado y calificado, debe mantenerse de acuerdo con un Procedimiento Operativo Est\u00e1ndar (SOP).\n\n3. **Flujo de Aire Unidireccional**: Se menciona la necesidad de evitar obstrucciones en el camino del flujo de aire unidireccional para proteger al operador de la exposici\u00f3n al polvo.\n\n4. **Errores Comunes**:\n   - **Respaldo S\u00f3lido en Balanzas**: Se ilustra que un respaldo s\u00f3lido en una balanza puede bloquear el flujo de aire de retorno, causando que el aire se eleve verticalmente y genere un riesgo para el operador.\n   - **Contenedores Abiertos**: La colocaci\u00f3n de un contenedor abierto debajo de un distribuidor de flujo vertical puede permitir que el aire descendente ingrese al contenedor, forzando el polvo hacia el rostro del operador.\n   - **Superficies de Trabajo S\u00f3lidas**: Estas pueden desviar el flujo de aire unidireccional, provocando una reversi\u00f3n del flujo.\n\n5. **Soluciones Propuestas**:\n   - **Cubiertas Parciales**: Se sugiere agregar cubiertas parciales sobre los contenedores abiertos para limitar la entrada de aire.\n   - **Extracci\u00f3n Puntual**: Aunque puede ser efectiva, esta opci\u00f3n puede resultar en una p\u00e9rdida excesiva de producto.\n   - **Espacio entre Mesa y Pared**: Se recomienda mantener un espacio de 100 mm entre la parte posterior de la mesa y la pared para facilitar la extracci\u00f3n adecuada del aire.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Estaciones de Pesaje**: Contexto espec\u00edfico donde se aplican las recomendaciones.\n- **SOP (Procedimiento Operativo Est\u00e1ndar)**: Protocolo para el mantenimiento del sistema.\n- **Flujo de Aire Unidireccional**: Concepto central en la protecci\u00f3n del operador.\n- **Contenedores y Balanzas**: Equipos mencionados en relaci\u00f3n con el flujo de aire y la seguridad del operador.", "excerpt_keywords": "Keywords: operator protection, unidirectional airflow, pharmaceutical plant, air filtration, contamination prevention"}}, "8edf9028-6288-416a-a610-605caa51533f": {"node_ids": ["e093f4b6-8e36-4d62-b775-40e9795a8306"], "metadata": {"page_label": "248", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1l es el enfoque principal del Informe T\u00e9cnico de la OMS en la Serie 961?**\n   - Esta pregunta busca obtener informaci\u00f3n sobre los temas o \u00e1reas espec\u00edficas que se abordan en el informe, lo que podr\u00eda incluir aspectos de salud p\u00fablica, investigaci\u00f3n m\u00e9dica o recomendaciones de pol\u00edticas.\n\n2. **\u00bfQu\u00e9 tipo de datos o hallazgos se presentan en la p\u00e1gina 248 del Informe T\u00e9cnico de la OMS?**\n   - Dado que se menciona una p\u00e1gina espec\u00edfica, esta pregunta se centra en los contenidos que podr\u00edan estar disponibles en esa p\u00e1gina, como estad\u00edsticas, estudios de caso o conclusiones relevantes.\n\n3. **\u00bfQu\u00e9 recomendaciones o directrices se ofrecen en el Informe T\u00e9cnico de la OMS para abordar problemas de salud global?**\n   - Esta pregunta busca identificar las sugerencias pr\u00e1cticas o pol\u00edticas que la OMS podr\u00eda proponer en el informe, lo que podr\u00eda ser \u00fatil para profesionales de la salud, investigadores o responsables de pol\u00edticas.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento mencionado es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el n\u00famero 961 de la Serie de Informes T\u00e9cnicos. Estos informes suelen abordar temas cr\u00edticos en el \u00e1mbito de la salud global, proporcionando an\u00e1lisis, recomendaciones y directrices basadas en la evidencia. Aunque no se proporciona contenido espec\u00edfico en el contexto, es probable que el informe contenga informaci\u00f3n valiosa sobre la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n1. **Protecci\u00f3n de operadores**: Se enfatiza la importancia de seleccionar un flujo de aire unidireccional (vertical u horizontal) para proporcionar la mejor protecci\u00f3n en entornos farmac\u00e9uticos.\n\n2. **Selecci\u00f3n de flujo de aire**: Los fabricantes deben considerar el tipo de flujo de aire adecuado para la aplicaci\u00f3n espec\u00edfica, aunque no se detallan los criterios espec\u00edficos en el texto.\n\n3. **Rejillas de aire**: Se recomienda el uso de rejillas de aire perforadas en \u00e1reas de pesaje o muestreo debido a su facilidad de limpieza.\n\n4. **Filtros de aire**: Los filtros de retorno/exhaustaci\u00f3n pueden instalarse en la terminal de la habitaci\u00f3n o en la unidad de manejo de aire, y se destaca la necesidad de mantenimiento regular para asegurar un flujo de aire constante.\n\n5. **Infiltraci\u00f3n de aire**: Se establece que la infiltraci\u00f3n de aire no filtrado en una planta farmac\u00e9utica no debe ser una fuente de contaminaci\u00f3n, aunque no se especifican medidas concretas para prevenirla.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona las recomendaciones.\n- **Flujo de aire unidireccional**: Concepto clave en la protecci\u00f3n de operadores.\n- **Rejillas de aire perforadas**: Tipo de rejilla recomendado para \u00e1reas espec\u00edficas.\n- **Filtros de aire**: Elementos esenciales para el mantenimiento de la calidad del aire.\n- **Planta farmac\u00e9utica**: Entorno donde se aplican estas recomendaciones. \n\nEste resumen destaca la importancia de un manejo adecuado del flujo de aire y la limpieza en entornos farmac\u00e9uticos para prevenir la contaminaci\u00f3n y proteger a los operadores.", "excerpt_keywords": "Keywords: OMS, Informe T\u00e9cnico, salud p\u00fablica, flujo de aire, contaminaci\u00f3n"}}, "edd88bd1-d9fc-47e4-bdb2-d1802eb17148": {"node_ids": ["d56d77a8-6a4f-4297-87e9-6325aea8d4a6"], "metadata": {"page_label": "249", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4.2\n\nManufacturing facilities should normally be maintained at a positive pressure relative to the outside, to limit the ingress of contaminants. Where facilities are to be maintained at negative pressures relative to the ambient pressure, special precautions should be taken. Refer to the WHO guideline for hazardous products, for further guidance on negative pressure facilities.\n\n4.4.3 The location of the negative pressure facility should be carefully considered with reference to the areas surrounding it, particular attention being given to ensuring that the building structure is well sealed.\n\n4.4.4 Negative pressure zones should, as far as possible, be encapsulated by surrounding areas with clean air supplies, so that only clean air can infiltrate into the controlled zone.\n\n# 4.5 Cross-contamination\n\n4.5.1 Where different products are manufactured at the same time, in different areas or cubicles, in a multiproduct OSD manufacturing site, measures should be taken to ensure that dust cannot move from one cubicle to another.\n\n4.5.2 Correct directional air movement and a pressure cascade system can assist in preventing cross-contamination. The pressure cascade should be such that the direction of airflow is from the clean corridor into the cubicles, resulting in dust containment.\n\n4.5.3 The corridor should be maintained at a higher pressure than the cubicles, and the cubicles at a higher pressure than atmospheric pressure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para el mantenimiento de instalaciones de fabricaci\u00f3n, especialmente en lo que respecta a la presi\u00f3n del aire y la prevenci\u00f3n de la contaminaci\u00f3n cruzada en sitios de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener presiones positivas en las instalaciones para limitar la entrada de contaminantes y se ofrecen directrices sobre el manejo de instalaciones de presi\u00f3n negativa. Adem\u00e1s, se discuten medidas para evitar la contaminaci\u00f3n cruzada entre diferentes productos fabricados simult\u00e1neamente, destacando la importancia de la direcci\u00f3n del flujo de aire y la presi\u00f3n en los corredores y cub\u00edculos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las precauciones especiales que se deben tomar al mantener instalaciones a presi\u00f3n negativa, seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las medidas que deben implementarse en instalaciones de presi\u00f3n negativa, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 caracter\u00edsticas debe tener la ubicaci\u00f3n de una instalaci\u00f3n de presi\u00f3n negativa para garantizar su eficacia en la contenci\u00f3n de contaminantes?**\n   - Esta pregunta se centra en los aspectos de dise\u00f1o y ubicaci\u00f3n de las instalaciones, que son cruciales para su funcionamiento seguro y que pueden no estar ampliamente discutidos en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe gestionar el flujo de aire y la presi\u00f3n en un entorno de fabricaci\u00f3n multiproducto para prevenir la contaminaci\u00f3n cruzada?**\n   - Esta pregunta busca detalles sobre la gesti\u00f3n del flujo de aire y la presi\u00f3n en un entorno espec\u00edfico de fabricaci\u00f3n, lo que puede no estar claramente definido en otras normativas o gu\u00edas.", "prev_section_summary": "El contenido proporcionado se refiere al Informe T\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS), espec\u00edficamente el n\u00famero 961 de la Serie de Informes T\u00e9cnicos. Aunque no se incluye contenido espec\u00edfico, se pueden identificar algunos temas clave y entidades relevantes:\n\n### Temas Clave:\n1. **Salud P\u00fablica**: El informe aborda cuestiones cr\u00edticas relacionadas con la salud global.\n2. **Investigaci\u00f3n M\u00e9dica**: Se espera que el documento incluya an\u00e1lisis y hallazgos relevantes en el \u00e1mbito de la investigaci\u00f3n.\n3. **Recomendaciones de Pol\u00edticas**: El informe probablemente ofrezca directrices y sugerencias para abordar problemas de salud a nivel global.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico de la OMS**: El tipo de documento que se est\u00e1 analizando, que proporciona informaci\u00f3n basada en evidencia sobre temas de salud.\n\n### Preguntas Potenciales:\n1. Enfoque principal del Informe T\u00e9cnico de la OMS en la Serie 961.\n2. Datos o hallazgos presentados en la p\u00e1gina 248 del informe.\n3. Recomendaciones o directrices ofrecidas para abordar problemas de salud global.\n\nEste resumen destaca la importancia del informe en el contexto de la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica, as\u00ed como su relevancia para profesionales y responsables de pol\u00edticas en el \u00e1mbito de la salud.", "excerpt_keywords": "Keywords: manufacturing facilities, positive pressure, negative pressure, cross-contamination, air flow management"}}, "efd474a7-c291-496f-a23d-04d0747f29b7": {"node_ids": ["249f01ba-f67d-480b-a9f2-3f53f29135b8"], "metadata": {"page_label": "250", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 17\n\n**Diagram indicating horizontal and vertical unidirectional flow**\n\n----\n\n4.5.4 Containment can normally be achieved by application of the displacement concept (low pressure differential, high airflow), or the pressure differential concept (high pressure differential, low airflow), or the physical barrier concept.\n\n4.5.5 The pressure cascade regime and the direction of airflow should be appropriate to the product and processing method used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos relacionados con el flujo unidireccional en entornos controlados, destacando la importancia de la contenci\u00f3n en procesos de manipulaci\u00f3n de productos. Se mencionan tres conceptos clave para lograr la contenci\u00f3n: el concepto de desplazamiento, el concepto de diferencial de presi\u00f3n y el concepto de barrera f\u00edsica. Adem\u00e1s, se enfatiza que el r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser adecuados para el producto y el m\u00e9todo de procesamiento utilizados.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los tres conceptos clave mencionados para lograr la contenci\u00f3n en entornos controlados?**\n   - Respuesta: Los tres conceptos clave son el concepto de desplazamiento (bajo diferencial de presi\u00f3n, alto flujo de aire), el concepto de diferencial de presi\u00f3n (alto diferencial de presi\u00f3n, bajo flujo de aire) y el concepto de barrera f\u00edsica.\n\n2. **\u00bfC\u00f3mo debe ser el r\u00e9gimen de presi\u00f3n y la direcci\u00f3n del flujo de aire en relaci\u00f3n con el producto y el m\u00e9todo de procesamiento?**\n   - Respuesta: El r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser apropiados para el producto y el m\u00e9todo de procesamiento utilizados.\n\n3. **\u00bfQu\u00e9 se entiende por el concepto de desplazamiento en el contexto de la contenci\u00f3n?**\n   - Respuesta: El concepto de desplazamiento se refiere a la creaci\u00f3n de un bajo diferencial de presi\u00f3n y un alto flujo de aire para lograr la contenci\u00f3n en entornos controlados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Presi\u00f3n en Instalaciones de Fabricaci\u00f3n**:\n   - Las instalaciones deben mantenerse normalmente a presi\u00f3n positiva para limitar la entrada de contaminantes.\n   - En caso de mantener presi\u00f3n negativa, se deben tomar precauciones especiales, referenciando las directrices de la OMS para productos peligrosos.\n\n2. **Ubicaci\u00f3n de Instalaciones de Presi\u00f3n Negativa**:\n   - La ubicaci\u00f3n debe ser cuidadosamente considerada, asegurando que la estructura del edificio est\u00e9 bien sellada.\n   - Las zonas de presi\u00f3n negativa deben estar rodeadas de \u00e1reas con suministro de aire limpio para evitar la infiltraci\u00f3n de contaminantes.\n\n3. **Prevenci\u00f3n de Contaminaci\u00f3n Cruzada**:\n   - En entornos de fabricaci\u00f3n multiproducto, se deben implementar medidas para evitar que el polvo se mueva entre cub\u00edculos.\n   - Se debe gestionar el flujo de aire y establecer un sistema de cascada de presi\u00f3n, donde el aire fluya desde un corredor limpio hacia los cub\u00edculos, manteniendo as\u00ed la contenci\u00f3n del polvo.\n   - Los corredores deben estar a una presi\u00f3n m\u00e1s alta que los cub\u00edculos, y estos a una presi\u00f3n superior a la atmosf\u00e9rica.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre pr\u00e1cticas de fabricaci\u00f3n.\n- **Instalaciones de fabricaci\u00f3n**: Espacios donde se producen productos farmac\u00e9uticos.\n- **Presi\u00f3n positiva y negativa**: Conceptos clave en el control de la contaminaci\u00f3n en entornos de fabricaci\u00f3n.\n- **Contaminaci\u00f3n cruzada**: Riesgo asociado a la fabricaci\u00f3n de m\u00faltiples productos simult\u00e1neamente. \n\nEste resumen destaca la importancia de la presi\u00f3n del aire y el dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: contenci\u00f3n, flujo unidireccional, presi\u00f3n diferencial, barrera f\u00edsica, procesamiento de productos"}}, "b3c157e6-e0ae-486c-a4c6-d05a707563ec": {"node_ids": ["624a286a-20fa-4c59-a601-11b20f05b9f2"], "metadata": {"page_label": "251", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "4.5.6 Highly potent products should be manufactured under a pressure cascade regime that is negative relative to atmospheric pressure.\n\n4.5.7 The pressure cascade for each facility should be individually assessed according to the product handled and level of protection required.\n\n4.5.8 Building structure should be given special attention to accommodate the pressure cascade design.\n\n4.5.9 Ceilings and walls, close fitting doors and sealed light fittings should be in place, to limit ingress or egress of air.\n\n## 4.6 Displacement concept (low pressure differential, high airflow)\n\n*Note: This method of containment is not the preferred method, as the measurement and monitoring of airflow velocities in doorways is difficult. This concept is commonly found in production processes where large amounts of dust are generated.*\n\n4.6.1 Under this concept the air should be supplied to the corridor, flow through the doorway, and be extracted from the back of the cubicle. Normally the cubicle door should be closed and the air should enter the cubicle through a door grille, although the concept can be applied to an opening without a door.\n\n4.6.2 The velocity should be high enough to prevent turbulence within the doorway resulting in dust escaping.\n\n4.6.3 This displacement airflow should be calculated as the product of the door area and the velocity, which generally results in fairly large air quantities.\n\n*Note: Although this method of containment may still exist on older facilities, it is not the preferred method, as the measurement and monitoring of doorway velocities is difficult. In addition, simultaneously maintaining the correct room pressure and the correct room air change rate is often not achieved.*\n\n## 4.7 Pressure differential concept (high pressure differential, low airflow)\n\n*Note: The pressure differential concept may normally be used in zones where little or no dust is being generated. It may be used alone or in combination with other containment control techniques and concepts, such as a double door airlock.*\n\n4.7.1 The high pressure differential between the clean and less clean zones should be generated by leakage through the gaps of the closed doors to the cubicle.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las pr\u00e1cticas de contenci\u00f3n y dise\u00f1o de instalaciones para la fabricaci\u00f3n de productos altamente potentes. Se discuten dos conceptos principales de contenci\u00f3n: el concepto de desplazamiento (bajo diferencial de presi\u00f3n y alto flujo de aire) y el concepto de diferencial de presi\u00f3n (alto diferencial de presi\u00f3n y bajo flujo de aire). Se enfatiza la importancia de mantener un r\u00e9gimen de cascada de presi\u00f3n negativo, as\u00ed como la necesidad de evaluar individualmente cada instalaci\u00f3n seg\u00fan el producto manejado y el nivel de protecci\u00f3n requerido. Tambi\u00e9n se menciona la importancia de la estructura del edificio y los elementos de dise\u00f1o que limitan la entrada y salida de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de la estructura de un edificio que alberga productos altamente potentes?**\n   - La estructura del edificio debe ser dise\u00f1ada para acomodar el r\u00e9gimen de cascada de presi\u00f3n, lo que incluye prestar especial atenci\u00f3n a los techos y paredes, as\u00ed como asegurar que las puertas cierren adecuadamente y que las luminarias est\u00e9n selladas para limitar la entrada o salida de aire.\n\n2. **\u00bfPor qu\u00e9 el concepto de desplazamiento no es el m\u00e9todo preferido para la contenci\u00f3n en instalaciones de producci\u00f3n?**\n   - Este m\u00e9todo no es preferido porque la medici\u00f3n y el monitoreo de las velocidades de flujo de aire en las puertas son dif\u00edciles. Adem\u00e1s, mantener simult\u00e1neamente la presi\u00f3n correcta de la habitaci\u00f3n y la tasa de cambio de aire adecuada es a menudo complicado.\n\n3. **\u00bfC\u00f3mo se genera el diferencial de presi\u00f3n en el concepto de diferencial de presi\u00f3n y en qu\u00e9 situaciones se recomienda su uso?**\n   - El alto diferencial de presi\u00f3n entre las zonas limpias y menos limpias se genera por la fuga a trav\u00e9s de las rendijas de las puertas cerradas del cub\u00edculo. Este concepto se recomienda en zonas donde se genera poco o ning\u00fan polvo y puede usarse solo o en combinaci\u00f3n con otras t\u00e9cnicas de control de contenci\u00f3n, como un vest\u00edbulo de doble puerta.\n\n### Resumen de nivel superior\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de productos altamente potentes, destacando la importancia de un dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la contenci\u00f3n. Se presentan dos enfoques para la contenci\u00f3n: el desplazamiento y el diferencial de presi\u00f3n, cada uno con sus propias caracter\u00edsticas y aplicaciones. Se enfatiza la necesidad de un an\u00e1lisis individualizado de cada instalaci\u00f3n y la atenci\u00f3n a los detalles estructurales para mantener un ambiente controlado y seguro.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Contenci\u00f3n en entornos controlados**: La secci\u00f3n aborda la importancia de la contenci\u00f3n en procesos de manipulaci\u00f3n de productos en entornos controlados, como laboratorios o instalaciones de producci\u00f3n.\n\n2. **Conceptos de contenci\u00f3n**:\n   - **Concepto de desplazamiento**: Se refiere a la creaci\u00f3n de un bajo diferencial de presi\u00f3n y un alto flujo de aire para lograr la contenci\u00f3n.\n   - **Concepto de diferencial de presi\u00f3n**: Implica un alto diferencial de presi\u00f3n y un bajo flujo de aire para mantener la contenci\u00f3n.\n   - **Concepto de barrera f\u00edsica**: Utiliza barreras f\u00edsicas para prevenir la contaminaci\u00f3n y asegurar la contenci\u00f3n.\n\n3. **R\u00e9gimen de presi\u00f3n y flujo de aire**: Se enfatiza que el r\u00e9gimen de cascada de presi\u00f3n y la direcci\u00f3n del flujo de aire deben ser adecuados y espec\u00edficos para el tipo de producto y el m\u00e9todo de procesamiento utilizado.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Documentos t\u00e9cnicos**: Referencia a la serie de informes t\u00e9cnicos de la OMS, espec\u00edficamente el informe 961.\n- **Flujo unidireccional**: Concepto clave en el manejo de aire en entornos controlados.\n- **Diferencial de presi\u00f3n**: Par\u00e1metro f\u00edsico importante en la contenci\u00f3n. \n\nEste resumen destaca los conceptos fundamentales y las entidades relevantes en la secci\u00f3n proporcionada, centr\u00e1ndose en la contenci\u00f3n y el manejo del flujo de aire en entornos controlados.", "excerpt_keywords": "Keywords: containment, pressure cascade, airflow, differential pressure, facility design"}}, "6deff116-2930-4a27-83e7-9a596b4e2365": {"node_ids": ["0281fcd1-728d-4d6c-8bf5-83ce8adffdf0"], "metadata": {"page_label": "252", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.7.2\n\nThe pressure differential should be of sufficient magnitude to ensure containment and prevention of flow reversal, but should not be so high as to create turbulence problems.\n\n# 4.7.3\n\nIn considering room pressure differentials, transient variations, such as machine extract systems, should be taken into consideration.\n\n# 4.7.4\n\nA pressure differential of 15 Pa is often used for achieving containment between two adjacent zones, but pressure differentials of between 5 Pa and 20 Pa may be acceptable. Where the design pressure differential is too low and tolerances are at opposite extremities, a flow reversal can take place. For example, where a control tolerance of \u00b1 3 Pa is specified, the implications of rooms being operated at the upper and lower tolerances should be evaluated. It is important to select pressures and tolerances such that a flow reversal is unlikely to occur.\n\n# 4.7.5\n\nThe pressure differential between adjacent rooms could be considered a critical parameter, depending on the outcome of risk analysis. The limits for the pressure differential between adjacent areas should be such that there is no risk of overlap in the acceptable operating range, e.g. 5 Pa to 15 Pa in one room and 15 Pa to 30 Pa in an adjacent room, resulting in the failure of the pressure cascade, where the first room is at the maximum pressure limit and the second room is at its minimum pressure limit.\n\n# 4.7.6\n\nLow pressure differentials may be acceptable when airlocks (pressure sinks or pressure bubbles) are used to segregate areas.\n\n# 4.7.7\n\nThe effect of room pressure tolerances are illustrated in Figure 18.\n\n# 4.7.8\n\nThe pressure control and monitoring devices used should be calibrated and qualified. Compliance with specifications should be regularly verified and the results recorded. Pressure control devices should be linked to an alarm system set according to the levels determined by a risk analysis.\n\n# 4.7.9\n\nManual control systems, where used, should be set up during commissioning, with set point marked, and should not change unless other system conditions change.\n\n# 4.7.10\n\nAirlocks can be important components in setting up and maintaining pressure cascade systems and also to limit cross-contamination.\n\n# 4.7.11\n\nAirlocks with different pressure cascade regimes include the cascade airlock, sink airlock and bubble airlock (Figures 19\u201321):\n\n- **Cascade airlock:** higher pressure on one side of the airlock and lower pressure on the other;\n- **Sink airlock:** lower pressure inside the airlock and higher pressure on both outer sides;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto aborda la importancia de los diferenciales de presi\u00f3n en entornos controlados, como laboratorios o instalaciones de bioseguridad. Se discuten los niveles de presi\u00f3n recomendados (entre 5 Pa y 20 Pa) para evitar el flujo inverso y garantizar la contenci\u00f3n. Tambi\u00e9n se menciona la necesidad de considerar variaciones transitorias y la calibraci\u00f3n de dispositivos de control de presi\u00f3n. Se destacan los sistemas de aire de presi\u00f3n, como los airlocks, que ayudan a mantener la segregaci\u00f3n de \u00e1reas y prevenir la contaminaci\u00f3n cruzada.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el rango de presi\u00f3n diferencial recomendado para evitar el flujo inverso entre dos zonas adyacentes, y qu\u00e9 implicaciones tiene un dise\u00f1o de presi\u00f3n demasiado bajo?**\n   - Respuesta: Se recomienda un diferencial de presi\u00f3n de 15 Pa, aunque se aceptan rangos entre 5 Pa y 20 Pa. Un dise\u00f1o de presi\u00f3n demasiado bajo puede resultar en un flujo inverso si las tolerancias est\u00e1n en extremos opuestos.\n\n2. **\u00bfQu\u00e9 papel juegan los airlocks en la gesti\u00f3n de los diferenciales de presi\u00f3n y c\u00f3mo se clasifican?**\n   - Respuesta: Los airlocks son componentes clave para establecer y mantener sistemas de cascada de presi\u00f3n y limitar la contaminaci\u00f3n cruzada. Se clasifican en tres tipos: airlock de cascada, airlock de hundimiento y airlock de burbuja.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para asegurar la efectividad de los dispositivos de control y monitoreo de presi\u00f3n?**\n   - Respuesta: Los dispositivos de control y monitoreo de presi\u00f3n deben ser calibrados y calificados, y su cumplimiento con las especificaciones debe ser verificado regularmente. Adem\u00e1s, deben estar vinculados a un sistema de alarma basado en un an\u00e1lisis de riesgo.", "prev_section_summary": "### Temas Clave\n\n1. **Contenci\u00f3n de Productos Altamente Potentes**: Se enfatiza la necesidad de un r\u00e9gimen de cascada de presi\u00f3n negativa para la fabricaci\u00f3n de productos altamente potentes, asegurando que las instalaciones est\u00e9n dise\u00f1adas para mantener un ambiente controlado.\n\n2. **Evaluaci\u00f3n Individual de Instalaciones**: Cada instalaci\u00f3n debe ser evaluada de manera individual seg\u00fan el producto manejado y el nivel de protecci\u00f3n requerido, lo que implica un an\u00e1lisis detallado de las caracter\u00edsticas espec\u00edficas de cada entorno.\n\n3. **Dise\u00f1o Estructural**: La estructura del edificio debe ser dise\u00f1ada para facilitar el r\u00e9gimen de cascada de presi\u00f3n, incluyendo techos, paredes, puertas ajustadas y luminarias selladas para limitar la entrada y salida de aire.\n\n4. **M\u00e9todos de Contenci\u00f3n**:\n   - **Concepto de Desplazamiento**: Este m\u00e9todo implica un bajo diferencial de presi\u00f3n y un alto flujo de aire, pero no es el preferido debido a la dificultad de medir y monitorear las velocidades de flujo de aire en las puertas.\n   - **Concepto de Diferencial de Presi\u00f3n**: Este m\u00e9todo se utiliza en zonas donde se genera poco o ning\u00fan polvo, generando un alto diferencial de presi\u00f3n a trav\u00e9s de fugas en las puertas cerradas.\n\n### Entidades\n\n- **Productos Altamente Potentes**: Productos que requieren un manejo cuidadoso debido a su potencia.\n- **R\u00e9gimen de Cascada de Presi\u00f3n**: Sistema de control de presi\u00f3n que debe ser negativo en relaci\u00f3n con la presi\u00f3n atmosf\u00e9rica.\n- **Zonas Limpias y Menos Limpias**: \u00c1reas dentro de la instalaci\u00f3n que requieren diferentes niveles de contenci\u00f3n y control de contaminaci\u00f3n.\n- **Vest\u00edbulo de Doble Puerta**: T\u00e9cnica de control de contenci\u00f3n que puede combinarse con el concepto de diferencial de presi\u00f3n.\n\n### Resumen General\n\nEl documento de la OMS proporciona directrices sobre la fabricaci\u00f3n de productos altamente potentes, destacando la importancia de un dise\u00f1o adecuado de las instalaciones para garantizar la seguridad y la contenci\u00f3n. Se presentan dos enfoques para la contenci\u00f3n: el desplazamiento y el diferencial de presi\u00f3n, cada uno con sus propias caracter\u00edsticas y aplicaciones. Se enfatiza la necesidad de un an\u00e1lisis individualizado de cada instalaci\u00f3n y la atenci\u00f3n a los detalles estructurales para mantener un ambiente controlado y seguro.", "excerpt_keywords": "Keywords: pressure differential, containment, airlocks, risk analysis, monitoring devices"}}, "a2144fde-ac86-4cde-8816-217f34d49dd2": {"node_ids": ["1c7048a8-cf00-45b8-99f3-10ec1efcd1b5"], "metadata": {"page_label": "253", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 18\n## Examples of pressure cascades\n\n!Image of room pressure gauge indicating colour coded normal, alert & action parameters\n\n### Diagram 1\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n### Diagram 2\n- **Typical Compartment**: 50 Pa \u00b1 5 Pa\n- **Typical Compartment**: 35 Pa \u00b1 5 Pa\n- **Decontamination**: 15 Pa \u00b1 5 Pa\n\n**Pressure Gradient**: 15 Pa (\u00b1 5 Pa)\n\n# Figure 19\n## Example of cascade airlock\n\n*(In most cases the internal pressure of the airlock is not critical. The pressure differential between the two outer sides is the important criteria.)*\n\n### Diagram\n- **Air Leakage**: \n  - Left: 15 Pa\n  - Right: 30 Pa\n- **Material Airlock**: 22.5 Pa\n- **Cascade Airlock**: \n\n**Pressure Differential**: Between 15 Pa and 30 Pa.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta informaci\u00f3n sobre la presi\u00f3n en compartimentos y sistemas de aire, espec\u00edficamente en relaci\u00f3n con las cascadas de presi\u00f3n y los airlocks (puertas de aire). Se describen dos diagramas que ilustran los niveles de presi\u00f3n t\u00edpicos en diferentes compartimentos, as\u00ed como un ejemplo de un airlock en cascada. Se enfatiza la importancia del diferencial de presi\u00f3n entre los lados exteriores de un airlock, en lugar de la presi\u00f3n interna.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la presi\u00f3n t\u00edpica recomendada para un compartimento de decontaminaci\u00f3n seg\u00fan los diagramas presentados?**\n   - Respuesta: La presi\u00f3n t\u00edpica recomendada para un compartimento de decontaminaci\u00f3n es de 15 Pa \u00b1 5 Pa.\n\n2. **En el contexto de un airlock, \u00bfcu\u00e1l es el rango de presi\u00f3n diferencial que se establece entre los dos lados exteriores seg\u00fan el ejemplo proporcionado?**\n   - Respuesta: El rango de presi\u00f3n diferencial establecido entre los dos lados exteriores del airlock es entre 15 Pa y 30 Pa.\n\n3. **\u00bfQu\u00e9 se considera m\u00e1s cr\u00edtico en el dise\u00f1o de un airlock, la presi\u00f3n interna o el diferencial de presi\u00f3n entre los lados exteriores?**\n   - Respuesta: En la mayor\u00eda de los casos, el diferencial de presi\u00f3n entre los dos lados exteriores es el criterio m\u00e1s importante, no la presi\u00f3n interna del airlock.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre la gesti\u00f3n de la presi\u00f3n en entornos controlados, destacando la importancia de mantener diferencias de presi\u00f3n adecuadas para prevenir la contaminaci\u00f3n y asegurar la seguridad en \u00e1reas de decontaminaci\u00f3n y en el uso de airlocks. Se presentan valores espec\u00edficos de presi\u00f3n para diferentes compartimentos y se discute la relevancia del diferencial de presi\u00f3n en el dise\u00f1o de sistemas de aire.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Diferenciales de Presi\u00f3n**: Se enfatiza la importancia de mantener un diferencial de presi\u00f3n adecuado para asegurar la contenci\u00f3n y prevenir el flujo inverso entre zonas adyacentes. Se recomienda un diferencial de 15 Pa, con un rango aceptable entre 5 Pa y 20 Pa.\n\n2. **Variaciones Transitorias**: Se deben considerar las variaciones transitorias en los sistemas de extracci\u00f3n de m\u00e1quinas al evaluar los diferenciales de presi\u00f3n en las habitaciones.\n\n3. **Riesgo de Flujo Inverso**: Un dise\u00f1o de presi\u00f3n demasiado bajo, combinado con tolerancias en extremos opuestos, puede resultar en un flujo inverso. Es crucial seleccionar presiones y tolerancias que minimicen este riesgo.\n\n4. **An\u00e1lisis de Riesgo**: El diferencial de presi\u00f3n entre habitaciones adyacentes es un par\u00e1metro cr\u00edtico que debe evaluarse mediante un an\u00e1lisis de riesgo para evitar la superposici\u00f3n en los rangos operativos aceptables.\n\n5. **Airlocks**: Los airlocks son componentes esenciales para mantener sistemas de cascada de presi\u00f3n y prevenir la contaminaci\u00f3n cruzada. Se clasifican en:\n   - **Airlock de Cascada**: Mayor presi\u00f3n en un lado y menor en el otro.\n   - **Airlock de Hundimiento**: Menor presi\u00f3n dentro del airlock y mayor presi\u00f3n en ambos lados exteriores.\n   - **Airlock de Burbuja**: (no se detalla en el texto, pero se menciona).\n\n6. **Control y Monitoreo de Presi\u00f3n**: Los dispositivos de control y monitoreo de presi\u00f3n deben ser calibrados y calificados, y su cumplimiento debe ser verificado regularmente. Deben estar conectados a un sistema de alarma basado en un an\u00e1lisis de riesgo.\n\n7. **Sistemas de Control Manual**: Los sistemas de control manual deben establecerse durante la puesta en marcha y no deben cambiar a menos que cambien otras condiciones del sistema.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Pa (Pascal)**: Unidad de medida utilizada para los diferenciales de presi\u00f3n.\n- **Airlocks**: Dispositivos utilizados para mantener la presi\u00f3n y prevenir la contaminaci\u00f3n cruzada.\n- **Riesgo**: Concepto clave en la evaluaci\u00f3n de los diferenciales de presi\u00f3n y su gesti\u00f3n. \n\nEste resumen destaca la importancia de los diferenciales de presi\u00f3n en entornos controlados y las medidas necesarias para garantizar su efectividad y seguridad.", "excerpt_keywords": "Keywords: presi\u00f3n, airlock, decontaminaci\u00f3n, diferencial, WHO"}}, "4d7c517a-dee7-4fc3-a7f9-a3d1f8552ee7": {"node_ids": ["0c6dc04a-f7bf-4a9d-8df8-aeb08491250d"], "metadata": {"page_label": "254", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 20\n**Example of sink airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      30 Pa        |      30 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   15 Pa               |\n+---------------------------------------+\n|                   Sink Airlock        |\n+---------------------------------------+\n```\n\n# Figure 21\n**Example of bubble airlock**\n\n```\n+-------------------+-------------------+\n|                   |                   |\n|      15 Pa        |      15 Pa        |\n|                   |                   |\n|  <--- Air Leakage | Air Leakage --->  |\n|                   |                   |\n+-------------------+-------------------+\n|                   Material Airlock    |\n|                   30 Pa               |\n+---------------------------------------+\n|                   Bubble Airlock      |\n+---------------------------------------+\n```", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye ejemplos de diferentes tipos de \"airlocks\" (compuertas de aire) utilizados en entornos controlados. Se presentan dos tipos espec\u00edficos: el \"sink airlock\" y el \"bubble airlock\", cada uno con sus respectivas caracter\u00edsticas de presi\u00f3n y manejo de fugas de aire. El \"sink airlock\" tiene una presi\u00f3n de 15 Pa en su interior y 30 Pa en el exterior, mientras que el \"bubble airlock\" tiene 30 Pa en su interior y 15 Pa en el exterior. Ambos dise\u00f1os est\u00e1n destinados a minimizar la fuga de aire entre diferentes \u00e1reas.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la diferencia en la presi\u00f3n entre el interior y el exterior del \"sink airlock\" y el \"bubble airlock\"?**\n   - Respuesta: El \"sink airlock\" tiene una presi\u00f3n de 15 Pa en su interior y 30 Pa en el exterior, mientras que el \"bubble airlock\" tiene 30 Pa en su interior y 15 Pa en el exterior.\n\n2. **\u00bfQu\u00e9 funci\u00f3n tienen las fugas de aire en el dise\u00f1o de los \"airlocks\" mencionados en el documento?**\n   - Respuesta: Las fugas de aire en el dise\u00f1o de los \"airlocks\" est\u00e1n destinadas a controlar el flujo de aire entre diferentes \u00e1reas, asegurando que la presi\u00f3n se mantenga adecuada y minimizando la contaminaci\u00f3n cruzada.\n\n3. **\u00bfC\u00f3mo se representan las fugas de aire en los diagramas de los \"airlocks\"?**\n   - Respuesta: En los diagramas, las fugas de aire se representan con flechas que indican la direcci\u00f3n del flujo de aire, mostrando que hay aire que se escapa hacia el exterior o que entra desde el exterior, dependiendo del tipo de \"airlock\".", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Cascadas de Presi\u00f3n**:\n   - Se presentan ejemplos de cascadas de presi\u00f3n en compartimentos, destacando la importancia de mantener niveles de presi\u00f3n adecuados para la seguridad y la prevenci\u00f3n de contaminaci\u00f3n.\n\n2. **Presiones T\u00edpicas en Compartimentos**:\n   - **Compartimento T\u00edpico**: 50 Pa \u00b1 5 Pa\n   - **Compartimento T\u00edpico**: 35 Pa \u00b1 5 Pa\n   - **Compartimento de Decontaminaci\u00f3n**: 15 Pa \u00b1 5 Pa\n   - Se establece un gradiente de presi\u00f3n de 15 Pa (\u00b1 5 Pa) entre los compartimentos.\n\n3. **Airlocks (Puertas de Aire)**:\n   - Se discute un ejemplo de un airlock en cascada, donde la presi\u00f3n interna no es cr\u00edtica, sino que el diferencial de presi\u00f3n entre los lados exteriores es el criterio m\u00e1s importante.\n   - **Diferencial de Presi\u00f3n**: Entre 15 Pa (lado izquierdo) y 30 Pa (lado derecho).\n   - **Material Airlock**: 22.5 Pa.\n\n4. **Importancia del Diferencial de Presi\u00f3n**:\n   - Se enfatiza que el diferencial de presi\u00f3n entre los lados exteriores de un airlock es fundamental para el dise\u00f1o y funcionamiento efectivo de estos sistemas, m\u00e1s que la presi\u00f3n interna.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que proporciona directrices sobre la gesti\u00f3n de la presi\u00f3n en entornos controlados.\n- **Pa (Pascal)**: Unidad de medida utilizada para expresar la presi\u00f3n en los compartimentos y airlocks.\n- **Compartimentos**: Espacios controlados donde se gestionan las presiones para asegurar la seguridad y la decontaminaci\u00f3n.\n- **Airlock (Puerta de Aire)**: Sistema dise\u00f1ado para controlar el flujo de aire y la presi\u00f3n entre diferentes \u00e1reas, crucial en entornos de decontaminaci\u00f3n. \n\nEste resumen destaca la relevancia de mantener presiones adecuadas y el dise\u00f1o de sistemas de aire para garantizar la seguridad en entornos controlados.", "excerpt_keywords": "Keywords: airlock, pressure differential, contamination control, WHO, technical report"}}, "e79ad889-4c4a-41b4-8cd0-589cc62d579b": {"node_ids": ["22282cf5-bb37-4382-bddb-de17e1509c45"], "metadata": {"page_label": "255", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- bubble airlock: higher pressure inside the airlock and lower pressure on both outer sides.\n\n*Note: The diagrams above and the differential pressures shown here are for illustration purposes only. Pressures indicated in these examples are absolute pressures, whereas the local pressure indication would most likely be pressure differential from room to room.*\n\n### 4.7.12\nDoors should open to the high pressure side, so that room pressure assists in holding the door closed and in addition be provided with self-closers. Should the doors open to the low pressure side, the door closer springs should be sufficient to hold the door closed and prevent the pressure differential from pushing the door open. There should be a method to indicate if both doors to airlocks are open at the same time, or alternatively these should be interlocked. The determination of which doors should be interlocked should be the subject of a risk assessment study.\n\n### 4.7.13\nCentral dust extraction systems should be interlocked with the appropriate air-handling systems, to ensure that they operate simultaneously.\n\n### 4.7.14\nRoom pressure differential between adjacent cubicles, which are linked by common dust extraction ducting, should be avoided.\n\n### 4.7.15\nAir should not flow through the dust extraction ducting or return air ducting from the room with the higher pressure to the room with the lower pressure (this would normally occur only if extract or return systems were inoperative). Systems should be designed to prevent dust flowing back in the opposite direction in the event of component failure or airflow failure.\n\n### 4.7.16\nAdequate room pressure differential indication should be provided so that each critical room pressure can be traced back to ambient pressure (by summation of the room pressure differentials), in order to determine the room actual absolute pressure. Room pressure indication gauges should have a range and graduation scale which enables the reading to an accuracy, as appropriate; normal operating range, alert and action limits should be defined and displayed at the point of indication. A colour coding gauge may be helpful.\n\nRoom pressure indication may be either analogue or digital, and may be represented as either pressure differentials or absolute pressures. Whichever system is used any out-of-specification condition should be easily identifiable.\n\n### 4.7.17\nMaterial pass-through-hatches (PTH) or pass boxes (PB) can also be used for separating two different zones. PTHs fall into two categories, namely a dynamic PTH or a passive PTH. Dynamic PTHs have an air supply to or extraction from them, and can then be used as bubble, sink or cascade PTHs.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1l es la funci\u00f3n principal de las puertas en un sistema de burbuja de aire (bubble airlock) seg\u00fan el documento?**\n   - **Respuesta:** Las puertas deben abrirse hacia el lado de alta presi\u00f3n para que la presi\u00f3n de la habitaci\u00f3n ayude a mantener la puerta cerrada. Adem\u00e1s, deben estar equipadas con mecanismos de cierre autom\u00e1tico. Si las puertas abren hacia el lado de baja presi\u00f3n, los resortes de cierre deben ser suficientes para mantener la puerta cerrada y evitar que la diferencia de presi\u00f3n la empuje hacia afuera.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para evitar el flujo de aire no deseado entre habitaciones de diferentes presiones?**\n   - **Respuesta:** Se debe evitar que el aire fluya a trav\u00e9s de los ductos de extracci\u00f3n de polvo o de retorno desde la habitaci\u00f3n de mayor presi\u00f3n hacia la de menor presi\u00f3n. Los sistemas deben estar dise\u00f1ados para prevenir el retroceso de polvo en caso de fallos en los componentes o en el flujo de aire.\n\n3. **\u00bfC\u00f3mo se debe indicar la presi\u00f3n diferencial de las habitaciones cr\u00edticas y qu\u00e9 caracter\u00edsticas deben tener los man\u00f3metros de presi\u00f3n?**\n   - **Respuesta:** Se debe proporcionar una indicaci\u00f3n adecuada de la presi\u00f3n diferencial de las habitaciones para que cada presi\u00f3n cr\u00edtica pueda rastrearse hasta la presi\u00f3n ambiente. Los man\u00f3metros deben tener un rango y una escala de graduaci\u00f3n que permitan lecturas precisas, y deben definirse y mostrarse los l\u00edmites de operaci\u00f3n normal, alerta y acci\u00f3n en el punto de indicaci\u00f3n. Un man\u00f3metro con codificaci\u00f3n por colores puede ser \u00fatil para identificar condiciones fuera de especificaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS detalla las mejores pr\u00e1cticas para el dise\u00f1o y funcionamiento de sistemas de control de presi\u00f3n en entornos cr\u00edticos, como laboratorios o instalaciones de bioseguridad. Se enfatiza la importancia de mantener diferencias de presi\u00f3n adecuadas entre habitaciones, el uso de puertas y sistemas de extracci\u00f3n de polvo interconectados, y la necesidad de indicadores precisos de presi\u00f3n para garantizar la seguridad y la eficacia operativa. Adem\u00e1s, se discuten las caracter\u00edsticas de los pasajes de materiales que pueden ayudar a separar diferentes zonas dentro de estas instalaciones.\n\n### Preguntas Generadas a Partir del Resumen\n\n1. **\u00bfPor qu\u00e9 es crucial mantener diferencias de presi\u00f3n adecuadas en entornos cr\u00edticos seg\u00fan el documento?**\n2. **\u00bfQu\u00e9 papel juegan los sistemas de extracci\u00f3n de polvo en la seguridad de las instalaciones descritas?**\n3. **\u00bfCu\u00e1les son las caracter\u00edsticas recomendadas para los pasajes de materiales en el contexto de separaci\u00f3n de zonas?**", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido proporcionado se centra en dos tipos de compuertas de aire (airlocks) utilizados en entornos controlados, espec\u00edficamente el \"sink airlock\" y el \"bubble airlock\". A continuaci\u00f3n se detallan los temas clave y las entidades relevantes:\n\n#### Temas Clave:\n1. **Tipos de Airlocks**:\n   - **Sink Airlock**: Dise\u00f1ado con una presi\u00f3n interna de 15 Pa y externa de 30 Pa, lo que permite un control espec\u00edfico de la fuga de aire hacia el exterior.\n   - **Bubble Airlock**: Presenta una presi\u00f3n interna de 30 Pa y externa de 15 Pa, lo que tambi\u00e9n facilita el manejo de la fuga de aire, pero en direcci\u00f3n opuesta al sink airlock.\n\n2. **Manejo de la Presi\u00f3n**:\n   - La diferencia de presi\u00f3n entre el interior y el exterior de cada tipo de airlock es fundamental para su funcionamiento, ayudando a prevenir la contaminaci\u00f3n cruzada y a mantener un ambiente controlado.\n\n3. **Fugas de Aire**:\n   - Las fugas de aire son representadas en los diagramas mediante flechas que indican la direcci\u00f3n del flujo, lo que es crucial para entender c\u00f3mo cada tipo de airlock gestiona el aire entre diferentes \u00e1reas.\n\n#### Entidades:\n- **Airlocks**: Compuertas de aire utilizadas en entornos controlados.\n- **Sink Airlock**: Un tipo espec\u00edfico de airlock con caracter\u00edsticas de presi\u00f3n definidas.\n- **Bubble Airlock**: Otro tipo de airlock, tambi\u00e9n con caracter\u00edsticas de presi\u00f3n espec\u00edficas.\n- **Presi\u00f3n (Pa)**: Unidad de medida utilizada para describir la presi\u00f3n en el interior y exterior de los airlocks.\n\nEste resumen destaca la importancia de los airlocks en el control de la contaminaci\u00f3n y la gesti\u00f3n del aire en entornos sensibles, as\u00ed como las diferencias clave entre los dos tipos presentados.", "excerpt_keywords": "Keywords: airlock, pressure differential, dust extraction, room pressure indication, pass-through-hatch"}}, "796f4878-e7f9-4ad3-8df4-f3c0e0266af8": {"node_ids": ["e650108a-0745-4f56-bd8f-2db170cda741"], "metadata": {"page_label": "256", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 Physical barrier concept\n\n4.8.1 Where appropriate, an impervious barrier to prevent cross-contamination between two zones, such as closed systems, pumped or vacuum transfer of materials, should be used.\n\n# 4.9 Temperature and relative humidity\n\n4.9.1 Where appropriate, temperature and relative humidity should be controlled, monitored and recorded, where relevant, to ensure compliance with requirements pertinent to the materials and products and provide a comfortable environment for the operator where necessary.\n\n4.9.2 Maximum and minimum room temperatures and relative humidity should be appropriate. Alert and action limits on temperatures and humidities should be set, as appropriate.\n\n4.9.3 The operating band, or tolerance, between the acceptable minimum and maximum temperatures should not be made too close. Tight control tolerances may be difficult to achieve and can also add unnecessary installation and running costs.\n\n4.9.4 Cubicles, or suites, in which products requiring low relative humidity are processed, should have well-sealed walls and ceilings and should also be separated from adjacent areas with higher relative humidity by means of suitable airlocks.\n\n4.9.5 Precautions should be taken to prevent moisture migration that increases the load on the HVAC system.\n\n4.9.6 Humidity control should be achieved by removing moisture from the air, or adding moisture to the air, as relevant.\n\n4.9.7 Dehumidification (moisture removal) may be achieved by means of either refrigerated dehumidifiers or chemical dehumidifiers.\n\n4.9.8 Appropriate cooling media for dehumidification such as low temperature chilled water/glycol mixture or refrigerant should be used.\n\n4.9.9 Humidifiers should be avoided if possible as they may become a source of contamination (e.g. microbiological growth). Where humidification is required, this should be achieved by appropriate means such as the injection of steam into the air stream. A product-contamination assessment should be done to determine whether pure or clean steam is required for the purposes of humidification.\n\n4.9.10 Where steam humidifiers are used, chemicals such as corrosion inhibitors or chelating agents, which could have a detrimental effect on", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos cr\u00edticos de control ambiental en la producci\u00f3n y manejo de materiales y productos, centr\u00e1ndose en la importancia de barreras f\u00edsicas para prevenir la contaminaci\u00f3n cruzada y el control de temperatura y humedad. Se enfatiza la necesidad de mantener condiciones adecuadas para garantizar la calidad de los productos y la comodidad de los operadores, as\u00ed como las precauciones necesarias para evitar la migraci\u00f3n de humedad y la contaminaci\u00f3n microbiol\u00f3gica.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el control de la humedad en \u00e1reas donde se procesan productos que requieren baja humedad relativa?**\n   - El documento sugiere que estas \u00e1reas deben tener paredes y techos bien sellados y estar separadas de zonas adyacentes con mayor humedad relativa mediante airlocks adecuados. Adem\u00e1s, se deben tomar precauciones para prevenir la migraci\u00f3n de humedad que aumente la carga en el sistema HVAC.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para la deshumidificaci\u00f3n y cu\u00e1les son los medios de enfriamiento apropiados para este proceso?**\n   - La deshumidificaci\u00f3n puede lograrse mediante deshumidificadores refrigerados o qu\u00edmicos. Se recomienda el uso de medios de enfriamiento apropiados, como una mezcla de agua/glicol enfriada a baja temperatura o refrigerantes.\n\n3. **\u00bfPor qu\u00e9 se deben evitar los humidificadores y qu\u00e9 alternativas se sugieren si la humidificaci\u00f3n es necesaria?**\n   - Los humidificadores deben evitarse porque pueden convertirse en una fuente de contaminaci\u00f3n, como el crecimiento microbiol\u00f3gico. Si se requiere humidificaci\u00f3n, se sugiere utilizar m\u00e9todos apropiados, como la inyecci\u00f3n de vapor en la corriente de aire, y realizar una evaluaci\u00f3n de contaminaci\u00f3n del producto para determinar si se necesita vapor puro o limpio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Presi\u00f3n Diferencial:**\n   - Importancia de mantener diferencias de presi\u00f3n adecuadas entre habitaciones para garantizar la seguridad y el control de contaminantes.\n\n2. **Puertas de Aire (Bubble Airlock):**\n   - Deben abrirse hacia el lado de alta presi\u00f3n para facilitar el cierre mediante la presi\u00f3n de la habitaci\u00f3n.\n   - Necesidad de mecanismos de cierre autom\u00e1tico y sistemas de interbloqueo para evitar la apertura simult\u00e1nea de puertas.\n\n3. **Sistemas de Extracci\u00f3n de Polvo:**\n   - Deben estar interconectados con sistemas de manejo de aire para asegurar su funcionamiento simult\u00e1neo.\n   - Se debe evitar el flujo de aire no deseado entre habitaciones de diferentes presiones.\n\n4. **Indicadores de Presi\u00f3n:**\n   - Se requiere una indicaci\u00f3n adecuada de la presi\u00f3n diferencial para rastrear la presi\u00f3n cr\u00edtica hasta la presi\u00f3n ambiente.\n   - Los man\u00f3metros deben tener escalas precisas y l\u00edmites de operaci\u00f3n claramente definidos, con opciones de codificaci\u00f3n por colores para facilitar la identificaci\u00f3n de condiciones fuera de especificaci\u00f3n.\n\n5. **Pasajes de Materiales:**\n   - Uso de pasajes de transferencia (PTH) o cajas de paso (PB) para separar zonas diferentes.\n   - Clasificaci\u00f3n de PTH en din\u00e1micos (con suministro o extracci\u00f3n de aire) y pasivos.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Fuente del documento.\n- **Sistemas de Control de Presi\u00f3n:** Elementos cr\u00edticos en entornos de bioseguridad.\n- **Puertas de Aire:** Componentes esenciales para el control de presi\u00f3n.\n- **Sistemas de Extracci\u00f3n de Polvo:** Elementos de seguridad en el manejo de contaminantes.\n- **Man\u00f3metros de Presi\u00f3n:** Dispositivos para medir y mostrar la presi\u00f3n diferencial.\n- **Pasajes de Transferencia (PTH):** Estructuras para la separaci\u00f3n de zonas en instalaciones cr\u00edticas. \n\nEste resumen destaca la importancia de los sistemas de control de presi\u00f3n y las medidas de seguridad necesarias en entornos cr\u00edticos, as\u00ed como las especificaciones t\u00e9cnicas para su implementaci\u00f3n.", "excerpt_keywords": "Keywords: cross-contamination, humidity control, dehumidification, airlocks, environmental monitoring"}}, "95b79d7b-cf4c-45fb-94ab-de9e28d1934c": {"node_ids": ["d21c7f4b-1b77-4276-98e1-bec3a161e481"], "metadata": {"page_label": "257", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Dust Control\n\n4.9.11 Humidification systems should be well drained. No condensate should accumulate in air-handling systems.\n\n4.9.12 Other humidification appliances such as evaporative systems, atomizers and water mist sprays, should not be used because of the potential risk of microbial contamination.\n\n4.9.13 Duct material in the vicinity of the humidifier should not add contaminants to air that will not be removed by filtration further downstream.\n\n4.6.14 Air filters should not be installed immediately downstream of humidifiers, as moisture on the filters could lead to bacterial growth.\n\n4.9.15 Cold surfaces should be insulated to prevent condensation within the clean area or on air-handling components.\n\n4.9.16 When specifying relative humidity, the associated temperature should also be specified.\n\n4.9.17 Chemical driers using silica gel or lithium chloride are acceptable, provided that they do not become sources of contamination.\n\n## 5. Dust Control\n\n5.1 Wherever possible, dust or vapour contamination should be removed at source. Point-of-use extraction, i.e. as close as possible to the point where the dust is generated, should be employed. Spot ventilation or capture hoods may be used as appropriate.\n\n5.2 Point-of-use extraction should be either in the form of a fixed high velocity extraction point or an articulated arm with movable hood or a fixed extraction hood.\n\n5.3 Dust extraction ducting should be designed with sufficient transfer velocity to ensure that dust is carried away, and does not settle in the ducting. Periodic checks should be performed to ensure that there is no build up of the dust in the ducting.\n\n5.4 The required transfer velocity should be determined: it is dependent on the density of the dust (the denser the dust, the higher the transfer velocity should be, e.g. 15\u201320 m/s).\n\n5.5 Airflow direction should be carefully chosen, to ensure that the operator does not contaminate the product, and also so that the operator is not put at risk by the product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las mejores pr\u00e1cticas para el control de la humedad y el polvo en entornos limpios. Se enfatiza la importancia de sistemas de humidificaci\u00f3n bien drenados y la eliminaci\u00f3n de contaminantes en el origen, utilizando extracci\u00f3n puntual. Tambi\u00e9n se discuten las especificaciones de dise\u00f1o para ductos de extracci\u00f3n de polvo y la direcci\u00f3n del flujo de aire para proteger tanto el producto como al operador.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones para el dise\u00f1o de ductos de extracci\u00f3n de polvo en relaci\u00f3n con la velocidad de transferencia?**\n   - La velocidad de transferencia debe ser suficiente para asegurar que el polvo sea transportado y no se asiente en los ductos. Se menciona que la velocidad requerida depende de la densidad del polvo, siendo recomendable una velocidad de 15\u201320 m/s para polvos m\u00e1s densos.\n\n2. **\u00bfQu\u00e9 precauciones se deben tomar al instalar filtros de aire en sistemas de humidificaci\u00f3n?**\n   - Los filtros de aire no deben instalarse inmediatamente despu\u00e9s de los humidificadores, ya que la humedad en los filtros puede favorecer el crecimiento bacteriano.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de extracci\u00f3n se recomiendan para la eliminaci\u00f3n de polvo en el lugar de generaci\u00f3n?**\n   - Se recomienda el uso de extracci\u00f3n puntual, que puede ser en forma de un punto de extracci\u00f3n de alta velocidad fijo, un brazo articulado con capucha m\u00f3vil o una capucha de extracci\u00f3n fija, para asegurar que el polvo se elimine lo m\u00e1s cerca posible de su fuente.", "prev_section_summary": "### Temas Clave:\n\n1. **Barreras F\u00edsicas**: Se enfatiza la importancia de utilizar barreras impermeables para prevenir la contaminaci\u00f3n cruzada entre diferentes zonas, especialmente en sistemas cerrados y en el transporte de materiales mediante bombeo o vac\u00edo.\n\n2. **Control de Temperatura y Humedad**: Se establece la necesidad de controlar, monitorear y registrar la temperatura y la humedad relativa en \u00e1reas relevantes para asegurar el cumplimiento de los requisitos de los materiales y productos, as\u00ed como para proporcionar un ambiente c\u00f3modo para los operadores.\n\n3. **Condiciones Ambientales**: Se deben establecer l\u00edmites de alerta y acci\u00f3n para las temperaturas y humedades, y se recomienda no tener tolerancias demasiado ajustadas para evitar costos innecesarios en la instalaci\u00f3n y operaci\u00f3n.\n\n4. **Dise\u00f1o de Espacios**: Las \u00e1reas donde se procesan productos que requieren baja humedad relativa deben tener paredes y techos bien sellados y estar separadas de \u00e1reas con mayor humedad mediante airlocks.\n\n5. **Prevenci\u00f3n de Migraci\u00f3n de Humedad**: Se deben tomar precauciones para evitar la migraci\u00f3n de humedad que pueda aumentar la carga en el sistema de HVAC.\n\n6. **M\u00e9todos de Deshumidificaci\u00f3n**: Se pueden utilizar deshumidificadores refrigerados o qu\u00edmicos, y se deben emplear medios de enfriamiento adecuados, como mezclas de agua/glicol enfriadas o refrigerantes.\n\n7. **Uso de Humidificadores**: Se recomienda evitar los humidificadores debido a su potencial de contaminaci\u00f3n, sugiriendo en su lugar la inyecci\u00f3n de vapor en la corriente de aire, con una evaluaci\u00f3n de contaminaci\u00f3n del producto para determinar la necesidad de vapor puro o limpio.\n\n### Entidades:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las recomendaciones.\n- **HVAC (Calefacci\u00f3n, Ventilaci\u00f3n y Aire Acondicionado)**: Sistema mencionado en relaci\u00f3n con el control de humedad.\n- **Deshumidificadores**: Equipos recomendados para el control de humedad.\n- **Airlocks**: Dispositivos para separar \u00e1reas con diferentes niveles de humedad.\n- **Vapor**: M\u00e9todo sugerido para la humidificaci\u00f3n controlada.\n\nEste resumen destaca los aspectos fundamentales del control ambiental en la producci\u00f3n y manejo de materiales, enfatizando la importancia de mantener condiciones adecuadas para la calidad del producto y la seguridad del operador.", "excerpt_keywords": "Keywords: dust control, humidification systems, point-of-use extraction, air filters, transfer velocity"}}, "3372f70f-eb5e-481d-b4d1-dce9e6b9a5ad": {"node_ids": ["039ac4c7-d9f9-4d71-8167-5a63d8718e84"], "metadata": {"page_label": "258", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.6 \nPoint extraction alone is usually not sufficient to capture all of the contaminants, and general directional airflow should be used to assist in removing dust and vapours from the room.\n\n5.7 \nTypically, in a room operating with turbulent airflow, the air should be introduced from ceiling diffusers, located at the door entry side of the room and extracted from the rear of the room at low level to help give a flushing effect in the room. Correct flushing of the rooms may be verified by airflow visualization smoke tests.\n\n5.8 \nWhen dealing with particularly harmful products, additional steps, such as handling the products in glove boxes or using barrier isolator technology, should be used.\n\n# 6. Protection of the environment\n\n## 6.1 General\n\n6.1.1 \nIt should be noted that protection of the environment is not addressed in this guideline, and discharges into the atmosphere should be compliant with relevant local and national environmental legislation and standards.\n\n6.1.2 \nDust, vapours and fumes could be possible sources of contamination; therefore, care should be taken when deciding on the location of the inlet and exhaust points relative to one other.\n\n## 6.2 Dust in exhaust air\n\n6.2.1 \nExhaust air discharge points on pharmaceutical equipment and facilities, such as from fluid bed driers and tablet-coating equipment, and exhaust air from dust extraction systems, carry heavy dust loads and should be provided with adequate filtration to prevent contamination of the ambient air.\n\n6.2.2 \nWhere the powders are not highly potent, final filters on a dust exhaust system should be fine dust filters with a filter classification of F9 according to EN 779 filter standards.\n\n6.2.3 \nWhere reverse-pulse dust collectors are used for removing dust from dust extraction systems, they should usually be equipped with cartridge filters containing a compressed air lance, and be capable of continuous operation without interrupting the airflow.\n\n6.2.4 \nAlternative types of dust collectors (such as those operating with a mechanical shaker, requiring that the fan be switched off when the mechanical shaker is activated) should be used in such a manner that there is no risk of cross-contamination. There should be no disruption of airflow during a production run as the loss of airflow could disrupt the pressure cascade.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la importancia de la extracci\u00f3n de contaminantes en entornos farmac\u00e9uticos, destacando que la extracci\u00f3n puntual no es suficiente y que se debe utilizar un flujo de aire direccional para eliminar polvo y vapores. Se recomienda la introducci\u00f3n de aire desde difusores en el techo y su extracci\u00f3n desde la parte trasera del cuarto para lograr un efecto de \"flushing\". Adem\u00e1s, se enfatiza la necesidad de cumplir con las normativas ambientales locales y nacionales, y se discuten las medidas para manejar el polvo en el aire de escape, incluyendo el uso de filtros adecuados y sistemas de recolecci\u00f3n de polvo que no interrumpan el flujo de aire.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se deben tomar al manejar productos particularmente da\u00f1inos en un entorno farmac\u00e9utico?**\n   - Respuesta: Se deben utilizar pasos adicionales como manejar los productos en cajas de guantes o emplear tecnolog\u00eda de aisladores de barrera.\n\n2. **\u00bfCu\u00e1l es la clasificaci\u00f3n de filtro recomendada para sistemas de extracci\u00f3n de polvo donde los polvos no son altamente potentes?**\n   - Respuesta: Se recomienda utilizar filtros de polvo fino con una clasificaci\u00f3n de filtro F9 seg\u00fan las normas de filtro EN 779.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de recolecci\u00f3n de polvo se deben evitar para prevenir la contaminaci\u00f3n cruzada durante la producci\u00f3n?**\n   - Respuesta: Se deben evitar los sistemas de recolecci\u00f3n de polvo que operan con un agitador mec\u00e1nico que requiera que el ventilador se apague cuando se activa el agitador, ya que esto puede interrumpir el flujo de aire y causar contaminaci\u00f3n cruzada.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave:\n1. **Sistemas de Humidificaci\u00f3n**:\n   - Importancia de un buen drenaje para evitar la acumulaci\u00f3n de condensado.\n   - Prohibici\u00f3n de ciertos dispositivos de humidificaci\u00f3n (sistemas evaporativos, atomizadores, sprays de agua) debido al riesgo de contaminaci\u00f3n microbiana.\n   - Materiales de ducto deben ser seleccionados para no introducir contaminantes en el aire.\n\n2. **Filtros de Aire**:\n   - No deben instalarse inmediatamente despu\u00e9s de los humidificadores para evitar el crecimiento bacteriano por la humedad.\n\n3. **Control de Polvo**:\n   - Se debe eliminar la contaminaci\u00f3n por polvo o vapor en la fuente, utilizando extracci\u00f3n puntual.\n   - Tipos de extracci\u00f3n recomendados: puntos de extracci\u00f3n de alta velocidad fijos, brazos articulados con capuchas m\u00f3viles o capuchas de extracci\u00f3n fijas.\n   - Dise\u00f1o de ductos de extracci\u00f3n de polvo debe asegurar una velocidad de transferencia adecuada para evitar la acumulaci\u00f3n de polvo.\n\n4. **Velocidad de Transferencia**:\n   - La velocidad de transferencia necesaria depende de la densidad del polvo, con recomendaciones de 15\u201320 m/s para polvos m\u00e1s densos.\n\n5. **Direcci\u00f3n del Flujo de Aire**:\n   - Debe ser cuidadosamente seleccionada para proteger tanto al operador como al producto de la contaminaci\u00f3n.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Sistemas de Humidificaci\u00f3n**: Equipos y tecnolog\u00edas discutidos.\n- **Contaminaci\u00f3n Microbiana**: Riesgo asociado a ciertos m\u00e9todos de humidificaci\u00f3n.\n- **Extracci\u00f3n Puntual**: M\u00e9todo recomendado para el control de polvo.\n- **Ductos de Extracci\u00f3n**: Componentes cr\u00edticos en el manejo de polvo.\n- **Velocidad de Transferencia**: Par\u00e1metro clave en el dise\u00f1o de sistemas de extracci\u00f3n de polvo. \n\nEste resumen destaca las mejores pr\u00e1cticas y consideraciones t\u00e9cnicas para el control de la humedad y el polvo en entornos limpios, enfatizando la importancia de la prevenci\u00f3n de la contaminaci\u00f3n y la seguridad del operador.", "excerpt_keywords": "Keywords: extraction, airflow, contamination, filtration, pharmaceutical"}}, "b5b2caf2-2fc0-485c-95ca-88723c4fcb25": {"node_ids": ["93184b82-c88f-4f1c-b385-9f845ee3fe56"], "metadata": {"page_label": "259", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.2.5\nMechanical-shaker dust collectors should not be used for applications where continuous airflow is required, in order to avoid unacceptable fluctuations in room pressures, except in the case where room pressures are automatically controlled.\n\n## 6.2.6\nWhen wet scrubbers are used, the dust-slurry should be removed by a suitable means, e.g. a drainage system or waste removal contractor.\n\n## 6.2.7\nThe quality of the exhaust air should be determined to see whether the filtration efficiency is adequate with all types of dust collectors and wet scrubbers.\n\n## 6.2.8\nWhere necessary, additional filtration may be provided downstream of the dust collector.\n\n## 6.3 Vapour and fume removal\n\n### 6.3.1\nVapour should be extracted at the point of generation. When planning the system for the extraction of residual vapours, the density of the vapour should be taken into account. If the vapour is lighter than air, the extract grilles should be at a high level, or possibly at both high and low levels.\n\n### 6.3.2\nThe systems for fume, dust and effluent control should be designed, installed and operated in such a manner that they do not become possible sources of contamination or cross-contamination, e.g. an exhaust-air discharge point located close to the HVAC system fresh air inlet.\n\n### 6.3.3\nFumes should be removed by means of wet scrubbers or dry chemical scrubbers (deep-bed scrubbers).\n\n### 6.3.4\nWet scrubbers for fume removal normally require the addition of various chemicals to the water to increase the adsorption efficiency.\n\n### 6.3.5\nDeep-bed scrubbers should be designed with activated carbon filters or granular chemical adsorption media. The chemical media for deep-bed scrubbers should be specific to the effluent being treated.\n\n### 6.3.6\nThe type and quantity of the vapours to be removed should be known to enable the appropriate filter media, as well as the volume of media required to be determined.\n\n## 7. Design of HVAC systems and components\n\n### 7.1 General\n\n#### 7.1.1\nThe required degree of air cleanliness in most OSD manufacturing facilities can normally be achieved without the use of high-efficiency particulate air (HEPA) filters, provided the air is not recirculated or", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento aborda las directrices para el control de polvo, vapores y humos en instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la importancia de la extracci\u00f3n adecuada de polvo y vapores, as\u00ed como el dise\u00f1o de sistemas de ventilaci\u00f3n y filtraci\u00f3n para evitar la contaminaci\u00f3n cruzada. Se mencionan diferentes m\u00e9todos de recolecci\u00f3n de polvo, como los colectores de polvo mec\u00e1nicos y los scrubbers h\u00famedos, y se discuten consideraciones sobre la calidad del aire de escape y la selecci\u00f3n de medios filtrantes.\n\n### Preguntas:\n1. **\u00bfPor qu\u00e9 no se deben utilizar colectores de polvo mec\u00e1nicos en aplicaciones que requieren un flujo de aire continuo?**\n   - Respuesta: Los colectores de polvo mec\u00e1nicos no deben usarse en aplicaciones con flujo de aire continuo debido a que pueden causar fluctuaciones inaceptables en las presiones de la sala, a menos que las presiones de la sala est\u00e9n controladas autom\u00e1ticamente.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los sistemas de control de humos y vapores no se conviertan en fuentes de contaminaci\u00f3n?**\n   - Respuesta: Los sistemas de control de humos, polvo y efluentes deben ser dise\u00f1ados, instalados y operados de manera que no se conviertan en fuentes de contaminaci\u00f3n o contaminaci\u00f3n cruzada, como evitar que los puntos de descarga de aire de escape est\u00e9n cerca de la entrada de aire fresco del sistema HVAC.\n\n3. **\u00bfQu\u00e9 factores deben considerarse al planificar un sistema de extracci\u00f3n de vapores residuales?**\n   - Respuesta: Al planificar un sistema de extracci\u00f3n de vapores residuales, se debe tener en cuenta la densidad del vapor. Si el vapor es m\u00e1s ligero que el aire, las rejillas de extracci\u00f3n deben estar ubicadas en un nivel alto, o posiblemente en niveles altos y bajos.", "prev_section_summary": "### Temas Clave:\n1. **Extracci\u00f3n de Contaminantes**: La extracci\u00f3n puntual no es suficiente para capturar todos los contaminantes; se debe utilizar un flujo de aire direccional para eliminar polvo y vapores.\n2. **Flujo de Aire en Habitaciones**: Se recomienda introducir aire desde difusores en el techo y extraerlo desde la parte trasera a nivel bajo para lograr un efecto de \"flushing\".\n3. **Manejo de Productos Peligrosos**: Para productos particularmente da\u00f1inos, se deben implementar medidas adicionales como el uso de cajas de guantes o tecnolog\u00eda de aisladores de barrera.\n4. **Protecci\u00f3n del Medio Ambiente**: Las descargas al ambiente deben cumplir con la legislaci\u00f3n y normativas ambientales locales y nacionales.\n5. **Filtraci\u00f3n de Aire de Escape**: Los sistemas de extracci\u00f3n de polvo deben contar con filtraci\u00f3n adecuada para evitar la contaminaci\u00f3n del aire ambiente, utilizando filtros de clasificaci\u00f3n F9 para polvos no altamente potentes.\n6. **Sistemas de Recolecci\u00f3n de Polvo**: Se deben evitar sistemas que interrumpan el flujo de aire durante la producci\u00f3n para prevenir la contaminaci\u00f3n cruzada.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad del documento.\n- **Normas EN 779**: Est\u00e1ndares de clasificaci\u00f3n de filtros.\n- **Cajas de Guantes**: Equipamiento recomendado para el manejo de productos peligrosos.\n- **Tecnolog\u00eda de Aisladores de Barrera**: M\u00e9todo adicional para manejar productos da\u00f1inos.\n- **Filtros de Polvo Fino**: Clasificaci\u00f3n recomendada para sistemas de extracci\u00f3n de polvo.\n- **Sistemas de Recolecci\u00f3n de Polvo**: Equipos utilizados para la extracci\u00f3n de polvo en entornos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de un manejo adecuado del aire y la filtraci\u00f3n en entornos farmac\u00e9uticos para garantizar la seguridad y la protecci\u00f3n del medio ambiente.", "excerpt_keywords": "Keywords: dust collection, vapour extraction, air quality, filtration systems, contamination control"}}, "4c6cbcaf-3e8f-4366-a260-5e9e56052bf2": {"node_ids": ["b3f8d196-fd27-446c-9a39-e53533711163"], "metadata": {"page_label": "260", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "in the case of a single-product facility. Many open product zones of OSD form facilities are capable of meeting ISO 14644-1 Class 8 or Grade D, \"at-rest\" condition, measured against particle sizes of 0.5 \u00b5m and 5 \u00b5m, but cleanliness may not necessarily be classified as such by manufacturers.\n\nA risk assessment should be carried out to determine the cleanroom conditions required and the extent of validation required.\n\n7.1.2 There are two basic concepts of air delivery to pharmaceutical production facilities: a recirculation system, and a full fresh air system (100% outside air supply). For recirculation systems the amount of fresh air should not be determined arbitrarily on a percentage basis, but, for example, by the following criteria:\n\n- sufficient fresh air to compensate for leakage from the facility and loss through exhaust air systems;\n- sufficient fresh air to comply with national building regulations; and[^2]\n- sufficient fresh air for odour control.\n\n7.1.3 Where automated monitoring systems are used, these should be capable of indicating any out-of-specification condition without delay by means of an alarm or similar system. Sophisticated computer-based data monitoring systems may be installed, which can aid with planning of preventive maintenance and can also provide trend logging.\n\n(This type of system is commonly referred to as a building management system (BMS), building automation system (BAS) or system control and data acquisition (SCADA) system.) If these systems are used for critical decision-making, they should be validated.\n\n7.1.4 Failure of a supply air fan, return air fan, exhaust air fan or dust extract system fan can cause a system imbalance, resulting in a pressure cascade malfunction with a resultant airflow reversal.\n\n7.1.5 All critical alarms should be easily identifiable and visible and/or audible to relevant personnel.\n\n7.1.6 Appropriate alarm systems should be in place to alert personnel if a critical fan fails. A fan interlock failure matrix should be set up, such that if a fan serving a high pressure zone fails, then any fans serving surrounding lower pressure areas should automatically stop, to prevent an airflow reversal and possible cross-contamination.\n\n[^2]: Depending on occupant density, between 1 and ACPH will often satisfy occupancy requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS aborda las condiciones de limpieza y los sistemas de entrega de aire en instalaciones de producci\u00f3n farmac\u00e9utica. Se discuten los requisitos de aire fresco, la importancia de los sistemas de monitoreo automatizados, y la gesti\u00f3n de fallos en los ventiladores para evitar problemas de contaminaci\u00f3n cruzada. Se enfatiza la necesidad de realizar evaluaciones de riesgo y de validar los sistemas utilizados para la toma de decisiones cr\u00edticas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben considerarse al determinar la cantidad de aire fresco en un sistema de recirculaci\u00f3n en instalaciones farmac\u00e9uticas?**\n   - Esta pregunta se centra en los criterios mencionados en el contexto, que no son comunes en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de sistemas de monitoreo automatizados se recomienda para las instalaciones de producci\u00f3n farmac\u00e9utica y qu\u00e9 funciones deben cumplir?**\n   - Esta pregunta busca detalles sobre los sistemas de monitoreo y su validaci\u00f3n, que son aspectos t\u00e9cnicos espec\u00edficos del contexto.\n\n3. **\u00bfC\u00f3mo se debe gestionar la falla de un ventilador en una instalaci\u00f3n de producci\u00f3n farmac\u00e9utica para prevenir la contaminaci\u00f3n cruzada?**\n   - Esta pregunta se enfoca en las medidas espec\u00edficas que deben implementarse en caso de fallos en los ventiladores, un tema que puede no estar ampliamente cubierto en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de Polvo**:\n   - **Colectores de Polvo Mec\u00e1nicos**: No son adecuados para aplicaciones con flujo de aire continuo debido a fluctuaciones en la presi\u00f3n de la sala, a menos que haya control autom\u00e1tico de presi\u00f3n.\n   - **Scrubbers H\u00famedos**: Deben tener un sistema adecuado para la eliminaci\u00f3n de lodos de polvo, como un sistema de drenaje.\n\n2. **Calidad del Aire de Escape**:\n   - Es esencial evaluar la eficiencia de filtraci\u00f3n de los colectores de polvo y scrubbers h\u00famedos.\n   - Puede ser necesaria filtraci\u00f3n adicional despu\u00e9s del colector de polvo.\n\n3. **Extracci\u00f3n de Vapores y Humos**:\n   - **Extracci\u00f3n en el Punto de Generaci\u00f3n**: Los vapores deben ser extra\u00eddos donde se generan, considerando su densidad para la ubicaci\u00f3n de las rejillas de extracci\u00f3n.\n   - **Dise\u00f1o de Sistemas**: Los sistemas de control de humos, polvo y efluentes deben evitar la contaminaci\u00f3n cruzada, evitando la proximidad de puntos de descarga de aire de escape a entradas de aire fresco.\n\n4. **M\u00e9todos de Eliminaci\u00f3n de Humos**:\n   - Uso de scrubbers h\u00famedos o scrubbers qu\u00edmicos secos (scrubbers de lecho profundo).\n   - Los scrubbers h\u00famedos requieren la adici\u00f3n de qu\u00edmicos para mejorar la eficiencia de adsorci\u00f3n.\n\n5. **Dise\u00f1o de Sistemas HVAC**:\n   - La limpieza del aire en instalaciones de fabricaci\u00f3n de productos farmac\u00e9uticos puede lograrse sin filtros HEPA, siempre que no haya recirculaci\u00f3n de aire.\n\n### Entidades Clave:\n- **Colectores de Polvo Mec\u00e1nicos**\n- **Scrubbers H\u00famedos**\n- **Scrubbers de Lecho Profundo**\n- **Filtros de Carb\u00f3n Activado**\n- **Sistemas HVAC**\n- **Vapores y Humos**\n- **Contaminaci\u00f3n Cruzada**\n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y la operaci\u00f3n de sistemas de control de polvo y vapores en entornos de fabricaci\u00f3n, as\u00ed como la necesidad de mantener la calidad del aire y evitar la contaminaci\u00f3n.", "excerpt_keywords": "Keywords: cleanroom conditions, air delivery systems, automated monitoring, contamination control, pharmaceutical production"}}, "674d7cdc-814c-455c-b346-9e9a6b6a629e": {"node_ids": ["25acc001-0e15-45bb-8675-a065758397b9"], "metadata": {"page_label": "261", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Air distribution\n\n7.2.1 The positioning of supply and extract grilles should be such as to provide effective room flushing. Low-level return or exhaust air grilles are usually preferred. However, where this is not possible, a higher air change rate may be needed to achieve a specified clean area condition, e.g. where ceiling return air grilles are used.\n\n7.2.2 There may be alternative locations for return air. For example, referring to Figure 22, Room 1 (low-level return air) and Room 2 (ceiling return air). The airflow diagram in Figure 22 is an example of a typical system with a lower clean area condition.\n\n**Figure 22**  \n*Air-handling system with high-efficiency particulate air filters in air-handling unit*\n\n!Air-handling system diagram\n\nThe airflow schematics of the two systems (Figures 22 and 23) indicate air-handling units with return air or recirculated air, having a percentage of fresh air added. Depending on product characteristics and dust loading it is sometimes preferable to fit filters on return air outlets or in return air ducting.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda la distribuci\u00f3n del aire en sistemas de manejo de aire, enfatizando la importancia de la ubicaci\u00f3n de las rejillas de suministro y extracci\u00f3n para lograr una adecuada renovaci\u00f3n del aire en espacios limpios. Se discuten las preferencias por rejillas de retorno de aire a nivel bajo y las alternativas disponibles, como las rejillas de retorno en el techo. Adem\u00e1s, se menciona la incorporaci\u00f3n de filtros de alta eficiencia en las unidades de manejo de aire y la consideraci\u00f3n de la carga de polvo y caracter\u00edsticas del producto al decidir la ubicaci\u00f3n de los filtros.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las ventajas de utilizar rejillas de retorno de aire a nivel bajo en comparaci\u00f3n con las rejillas de retorno en el techo en sistemas de manejo de aire?**\n   - Esta pregunta busca una comparaci\u00f3n espec\u00edfica que no se aborda de manera general en otros documentos.\n\n2. **En el contexto de la carga de polvo, \u00bfqu\u00e9 factores deben considerarse al decidir la ubicaci\u00f3n de los filtros en un sistema de manejo de aire?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos que afectan la eficiencia del sistema, lo cual puede no estar ampliamente discutido en otras fuentes.\n\n3. **\u00bfQu\u00e9 implicaciones tiene un mayor \u00edndice de renovaci\u00f3n de aire en la calidad del aire en \u00e1reas limpias cuando se utilizan rejillas de retorno en el techo?**\n   - Esta pregunta explora las consecuencias de las decisiones de dise\u00f1o en la calidad del aire, un tema que puede no ser tratado en profundidad en otros documentos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se encuentra en el contexto proporcionado, lo que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Condiciones de Limpieza en Instalaciones Farmac\u00e9uticas**:\n   - Se menciona que muchas zonas de productos abiertos en instalaciones de OSD pueden cumplir con la norma ISO 14644-1 Clase 8 o Grado D en condiciones \"en reposo\", aunque la limpieza puede no ser clasificada de esta manera por los fabricantes.\n\n2. **Evaluaci\u00f3n de Riesgos**:\n   - Se enfatiza la necesidad de realizar una evaluaci\u00f3n de riesgos para determinar las condiciones de limpieza requeridas y el alcance de la validaci\u00f3n necesaria.\n\n3. **Sistemas de Entrega de Aire**:\n   - Se describen dos conceptos b\u00e1sicos: sistemas de recirculaci\u00f3n y sistemas de aire fresco (100% aire exterior). \n   - Los criterios para determinar la cantidad de aire fresco en sistemas de recirculaci\u00f3n incluyen compensar p\u00e9rdidas por fugas, cumplir con regulaciones de construcci\u00f3n nacionales y controlar olores.\n\n4. **Sistemas de Monitoreo Automatizados**:\n   - Se recomienda el uso de sistemas de monitoreo automatizados que puedan indicar condiciones fuera de especificaci\u00f3n de inmediato mediante alarmas.\n   - Se mencionan sistemas avanzados como BMS, BAS o SCADA, que deben ser validados si se utilizan para decisiones cr\u00edticas.\n\n5. **Gesti\u00f3n de Fallos en Ventiladores**:\n   - Se discute c\u00f3mo la falla de ventiladores (suministro, retorno, extracci\u00f3n de aire) puede causar un desequilibrio en el sistema, resultando en un mal funcionamiento de la presi\u00f3n y reversi\u00f3n del flujo de aire.\n   - Se deben implementar sistemas de alarma adecuados para alertar al personal sobre fallos cr\u00edticos de ventiladores y establecer una matriz de interbloqueo para prevenir la contaminaci\u00f3n cruzada.\n\n### Entidades Clave:\n- **ISO 14644-1**: Norma que establece los requisitos de limpieza del aire en salas limpias.\n- **Sistemas de Monitoreo**: BMS (Building Management System), BAS (Building Automation System), SCADA (System Control and Data Acquisition).\n- **Condiciones de Limpieza**: Clase 8, Grado D.\n- **Criterios de Aire Fresco**: Compensaci\u00f3n de fugas, regulaciones de construcci\u00f3n, control de olores.\n- **Alarmas Cr\u00edticas**: Sistemas de alarma para ventiladores y gesti\u00f3n de fallos. \n\nEste resumen destaca los aspectos fundamentales relacionados con la limpieza, la entrega de aire, el monitoreo y la gesti\u00f3n de fallos en instalaciones de producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: air distribution, clean area condition, return air grilles, air-handling system, high-efficiency filters"}}, "90915b08-a8b6-40ee-9cf1-4819db141d87": {"node_ids": ["901a3fcd-606f-4d27-b4de-a098db0a466f"], "metadata": {"page_label": "262", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Figure 23 is a schematic diagram of an air-handling system serving rooms with horizontal unidirectional flow, vertical unidirectional flow and turbulent flow, for rooms 3, 4 and 5, respectively.\n\n### Figure 23\n**Horizontal unidirectional flow, vertical unidirectional flow and turbulent flow**\n\n----\n\n## 7.3 Recirculation system\n\n7.3.1 There should be no risk of contamination or cross-contamination (including by fumes and volatiles) due to recirculation of air.\n\n7.3.2 Depending on the airborne contaminants in the return-air system it may be acceptable to use recirculated air, provided that HEPA filters are installed in the supply air stream (or return air stream) to remove contaminants and thus prevent cross-contamination. The HEPA filters for this application should have an EN 1822 classification of H13.\n\n7.3.3 HEPA filters may not be required where the air-handling system is serving a single product facility and there is evidence that cross-contamination would not be possible.\n\n7.3.4 Recirculation of air from areas where pharmaceutical dust is not generated such as secondary packing, may not require HEPA filters in the system.\n\n7.3.5 HEPA filters may be located in the air-handling unit or placed terminally. Where HEPA filters are terminally mounted they should", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante\n\n1. **Sistema de manejo de aire**: El documento describe un sistema de manejo de aire que incluye diferentes tipos de flujos (horizontal unidireccional, vertical unidireccional y turbulento) para diversas salas, lo que es crucial para mantener la calidad del aire en entornos farmac\u00e9uticos.\n\n2. **Recirculaci\u00f3n de aire**: Se establecen directrices sobre la recirculaci\u00f3n de aire en instalaciones farmac\u00e9uticas, enfatizando la importancia de evitar la contaminaci\u00f3n cruzada y el uso de filtros HEPA para garantizar la pureza del aire.\n\n3. **Filtros HEPA**: Se discute el uso de filtros HEPA en sistemas de manejo de aire, especificando su clasificaci\u00f3n y las condiciones bajo las cuales pueden ser necesarios o no, dependiendo del tipo de instalaci\u00f3n y la generaci\u00f3n de contaminantes.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones bajo las cuales se puede utilizar aire recirculado en un sistema de manejo de aire en instalaciones farmac\u00e9uticas?**\n   - Respuesta: Se puede utilizar aire recirculado siempre que se instalen filtros HEPA en el flujo de aire de suministro o en el flujo de aire de retorno para eliminar contaminantes y prevenir la contaminaci\u00f3n cruzada.\n\n2. **\u00bfQu\u00e9 clasificaci\u00f3n deben tener los filtros HEPA utilizados en sistemas de manejo de aire seg\u00fan el documento?**\n   - Respuesta: Los filtros HEPA para esta aplicaci\u00f3n deben tener una clasificaci\u00f3n EN 1822 de H13.\n\n3. **\u00bfEn qu\u00e9 situaciones no se requieren filtros HEPA en un sistema de manejo de aire?**\n   - Respuesta: Los filtros HEPA pueden no ser necesarios en sistemas que sirven a instalaciones de un solo producto donde hay evidencia de que no ser\u00eda posible la contaminaci\u00f3n cruzada, o en \u00e1reas donde no se genera polvo farmac\u00e9utico, como en el empaque secundario.", "prev_section_summary": "### Resumen de la Secci\u00f3n 7.2: Distribuci\u00f3n del Aire\n\nLa secci\u00f3n 7.2 del documento de la OMS se centra en la distribuci\u00f3n del aire en sistemas de manejo de aire, destacando la importancia de la ubicaci\u00f3n de las rejillas de suministro y extracci\u00f3n para asegurar una adecuada renovaci\u00f3n del aire en \u00e1reas limpias. \n\n#### Temas Clave:\n1. **Posicionamiento de Rejillas**: Se enfatiza que las rejillas de retorno o extracci\u00f3n de aire deben estar posicionadas para proporcionar una efectiva renovaci\u00f3n del aire en la habitaci\u00f3n. Se prefieren las rejillas de retorno a nivel bajo, aunque en situaciones donde esto no es posible, se puede requerir un mayor \u00edndice de renovaci\u00f3n de aire.\n\n2. **Alternativas de Ubicaci\u00f3n**: Se presentan alternativas para la ubicaci\u00f3n de las rejillas de retorno, como las rejillas en el techo, y se ilustran en un diagrama (Figura 22) que compara dos habitaciones con diferentes configuraciones de retorno de aire.\n\n3. **Filtros de Alta Eficiencia**: Se menciona la instalaci\u00f3n de filtros de alta eficiencia en las unidades de manejo de aire, as\u00ed como la consideraci\u00f3n de las caracter\u00edsticas del producto y la carga de polvo al decidir la ubicaci\u00f3n de los filtros, ya sea en las salidas de aire de retorno o en el conducto de retorno.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Rejillas de Suministro y Extracci\u00f3n**: Elementos clave en la distribuci\u00f3n del aire.\n- **Aire Limpio**: Condici\u00f3n deseada en los espacios tratados.\n- **Filtros de Alta Eficiencia**: Dispositivos utilizados para mejorar la calidad del aire.\n- **Diagrama de Flujo de Aire**: Herramienta visual utilizada para ilustrar los sistemas de manejo de aire.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos t\u00e9cnicos y consideraciones de dise\u00f1o en la distribuci\u00f3n del aire, esenciales para mantener condiciones adecuadas en \u00e1reas limpias.", "excerpt_keywords": "Keywords: air-handling system, HEPA filters, recirculation, contamination prevention, pharmaceutical environments"}}, "202361ba-37f0-4f28-83e7-e884864bda45": {"node_ids": ["ca3468fa-2780-43d2-a01d-02f37cba594e"], "metadata": {"page_label": "263", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "preferably not be connected to the ducting by means of flexible ducting. Due to the high air pressure required for the terminal filter, this connection should preferably be a rigid duct connection. Where flexible ducting is used, it should be as short as possible and properly fixed to withstand duct pressure.\n\n7.3.6 Air containing dust from highly toxic processes and/or solvents or flammable vapours should never be recirculated to the HVAC system.\n\n## 7.4 Full fresh-air systems\n\nFigure 24 indicates a system operating on 100% fresh air and would normally be used in a facility dealing with toxic products or solvents, where recirculation of air with contaminants should be avoided.\n\n7.4.1 The required degree of filtration of the exhaust air depends on the exhaust air contaminants and local environmental regulations. HEPA filters in the exhaust system would normally only be required when handling hazardous materials.\n\n**Figure 24**  \n**Full fresh-air system**\n\n!Full fresh-air system diagram", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la importancia de los sistemas de ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos o solventes. Se enfatiza que las conexiones de ductos deben ser r\u00edgidas para soportar la alta presi\u00f3n de aire y que el aire contaminado no debe ser recirculado al sistema HVAC. Adem\u00e1s, se menciona que los sistemas de aire fresco completo son preferibles en estas situaciones, y que el grado de filtraci\u00f3n del aire de escape depende de los contaminantes presentes y de las regulaciones ambientales locales.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfPor qu\u00e9 se recomienda el uso de conexiones de ductos r\u00edgidos en lugar de ductos flexibles en sistemas de ventilaci\u00f3n para productos t\u00f3xicos?**\n   - Respuesta: Se recomienda el uso de conexiones de ductos r\u00edgidos debido a la alta presi\u00f3n de aire requerida para el filtro terminal, lo que asegura una mejor integridad estructural y resistencia a la presi\u00f3n del ducto.\n\n2. **\u00bfQu\u00e9 tipo de filtros se consideran necesarios en el sistema de escape cuando se manejan materiales peligrosos?**\n   - Respuesta: Normalmente, se requieren filtros HEPA en el sistema de escape cuando se manejan materiales peligrosos, ya que estos filtros son capaces de capturar part\u00edculas finas y contaminantes peligrosos.\n\n3. **\u00bfCu\u00e1les son las implicaciones de recircular aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables en un sistema HVAC?**\n   - Respuesta: Recircular aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables puede resultar en la contaminaci\u00f3n del ambiente de trabajo, poniendo en riesgo la salud de los trabajadores y violando regulaciones ambientales, por lo que nunca debe hacerse.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Manejo de Aire**:\n   - Se describe un sistema que incluye flujos de aire horizontal unidireccional, vertical unidireccional y turbulento, dise\u00f1ado para diferentes salas en entornos farmac\u00e9uticos.\n\n2. **Recirculaci\u00f3n de Aire**:\n   - Se establecen directrices para la recirculaci\u00f3n de aire, enfatizando la necesidad de evitar la contaminaci\u00f3n cruzada y el riesgo de contaminaci\u00f3n por vapores y vol\u00e1tiles.\n\n3. **Filtros HEPA**:\n   - Se discute la instalaci\u00f3n de filtros HEPA en sistemas de manejo de aire, especificando que deben tener una clasificaci\u00f3n EN 1822 de H13 para eliminar contaminantes y prevenir la contaminaci\u00f3n cruzada.\n\n4. **Excepciones para el Uso de Filtros HEPA**:\n   - Los filtros HEPA pueden no ser necesarios en instalaciones de un solo producto donde no se genere riesgo de contaminaci\u00f3n cruzada, o en \u00e1reas como el empaque secundario donde no se produzca polvo farmac\u00e9utico.\n\n### Entidades Clave\n\n- **Tipos de Flujo de Aire**: Horizontal unidireccional, vertical unidireccional, turbulento.\n- **Clasificaci\u00f3n de Filtros**: EN 1822 H13.\n- **Condiciones de Uso de Aire Recirculado**: Instalaci\u00f3n de filtros HEPA, ausencia de contaminaci\u00f3n cruzada.\n- **\u00c1reas de Excepci\u00f3n**: Instalaciones de un solo producto, \u00e1reas sin generaci\u00f3n de polvo farmac\u00e9utico. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos cr\u00edticos relacionados con el manejo de aire y la recirculaci\u00f3n en entornos farmac\u00e9uticos, as\u00ed como las especificaciones sobre el uso de filtros HEPA.", "excerpt_keywords": "Keywords: ventilation, toxic materials, HEPA filters, fresh-air systems, HVAC system"}}, "ffa23a9f-2520-401b-809a-a417c0db493c": {"node_ids": ["c622ac40-029f-4e66-9d85-0a7f4fce6ffd"], "metadata": {"page_label": "264", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 25  \n**Full fresh-air system with energy recovery**\n\n!Full fresh-air system with energy recovery\n\n7.4.2 Energy-recovery wheels if used in multiproduct facilities should have been subjected to a risk assessment to determine if there is any risk of cross-contamination. When such wheels are used they should not become a source of possible contamination (see Figure 25). *Note: Alternatives to the energy-recovery wheels, such as crossover plate heat exchangers and water-coil heat exchangers, may be used in multiproduct facilities.*\n\n7.4.3 The potential for air leakage between the supply air and exhaust air as it passes through the wheel should be prevented. The relative pressures between supply and exhaust air systems should be such that the exhaust air system operates at a lower pressure than the supply system.\n\n## 7.5 Additional system components\n\n7.5.1 A schematic diagram of the airflow for a typical system serving a low relative humidity suite is represented in Figure 26. Air can be dried with a chemical drier (e.g. a rotating desiccant wheel which is continuously regenerated by means of passing hot air through one segment of the wheel). Alternative methods of drying air are also available.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de los sistemas de aire fresco con recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto. Se enfatiza la necesidad de realizar evaluaciones de riesgo para evitar la contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda. Adem\u00e1s, se menciona la importancia de mantener diferencias de presi\u00f3n adecuadas entre los sistemas de aire de suministro y de escape para prevenir fugas de aire. Tambi\u00e9n se discuten m\u00e9todos alternativos para el secado del aire en sistemas de baja humedad.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas se deben tomar para evaluar el riesgo de contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto?**\n   - Respuesta: Se debe realizar una evaluaci\u00f3n de riesgo para determinar si hay alg\u00fan riesgo de contaminaci\u00f3n cruzada al utilizar ruedas de recuperaci\u00f3n de energ\u00eda en instalaciones multiproducto.\n\n2. **\u00bfCu\u00e1l es la presi\u00f3n relativa que debe mantenerse entre los sistemas de aire de suministro y de escape para evitar la fuga de aire?**\n   - Respuesta: La presi\u00f3n del sistema de escape debe ser inferior a la del sistema de suministro para prevenir la fuga de aire entre ambos.\n\n3. **\u00bfQu\u00e9 alternativas a las ruedas de recuperaci\u00f3n de energ\u00eda se pueden considerar en instalaciones multiproducto?**\n   - Respuesta: Se pueden considerar alternativas como intercambiadores de calor de placa cruzada y intercambiadores de calor de bobina de agua en instalaciones multiproducto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistemas de Ventilaci\u00f3n**: Se discute la importancia de los sistemas de ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos o solventes, enfatizando la necesidad de evitar la recirculaci\u00f3n de aire contaminado.\n\n2. **Conexiones de Ductos**: Se recomienda el uso de conexiones de ductos r\u00edgidos en lugar de flexibles debido a la alta presi\u00f3n de aire requerida para los filtros terminales. Las conexiones r\u00edgidas son m\u00e1s adecuadas para soportar esta presi\u00f3n.\n\n3. **Aire Contaminado**: Se establece que el aire que contiene polvo de procesos altamente t\u00f3xicos o vapores inflamables no debe ser recirculado al sistema HVAC, ya que esto puede comprometer la seguridad y la salud en el ambiente de trabajo.\n\n4. **Sistemas de Aire Fresco Completo**: Se menciona que los sistemas que operan con 100% de aire fresco son preferibles en instalaciones que manejan productos t\u00f3xicos, ya que evitan la recirculaci\u00f3n de aire contaminado.\n\n5. **Filtraci\u00f3n del Aire de Escape**: El grado de filtraci\u00f3n del aire de escape depende de los contaminantes presentes y de las regulaciones ambientales locales. Se indica que los filtros HEPA son necesarios cuando se manejan materiales peligrosos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que proporciona directrices sobre la ventilaci\u00f3n en instalaciones que manejan productos t\u00f3xicos.\n- **Filtros HEPA**: Tipo de filtro mencionado como necesario para la captura de part\u00edculas finas en sistemas de escape que manejan materiales peligrosos.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado que deben ser dise\u00f1ados para evitar la recirculaci\u00f3n de aire contaminado.\n\nEste resumen destaca la importancia de la ventilaci\u00f3n adecuada y el manejo seguro de aire en entornos donde se manipulan sustancias peligrosas.", "excerpt_keywords": "Keywords: energy recovery, cross-contamination, air leakage, multiproduct facilities, ventilation systems"}}, "fc6e2cd0-c24f-48b0-b795-4eda9ec3d3f7": {"node_ids": ["0199facb-18cd-4c05-b6ba-38f7a0805a82"], "metadata": {"page_label": "265", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Figure 26  \nAir-handling system with chemical drying\n\n7.5.2 The figure illustrates the chemical drier handling part of the fresh air/return air mixture on a bypass flow. The location of the chemical drier should be considered in the design phase. The practice of locating the complete chemical drier unit in the production cubicle is not recommended as this could be a source of contamination or cross-contamination. Examples of appropriate locations for the drying wheel could include:\n\n- full flow of fresh/return air;\n- partial handling of fresh/return air (bypass airflow);\n- return air only;\n- fresh air only; or\n- pre-cooled air with any of the above alternatives.\n\n7.5.3 Possible additional components that may be required in air handling should be considered depending on the climatic conditions and locations. These may include items such as:\n\n- frost coils on fresh air inlets in very cold climates to preheat the air;\n- reheaters for humidity control\n- automatic air volume control devices\n- sound attenuators", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Dise\u00f1o del sistema de manejo de aire**: El dise\u00f1o de un sistema de manejo de aire con secado qu\u00edmico es crucial para evitar la contaminaci\u00f3n en entornos de producci\u00f3n. La ubicaci\u00f3n del secador qu\u00edmico debe ser cuidadosamente considerada para garantizar la calidad del aire.\n\n2. **Componentes adicionales en el manejo de aire**: Dependiendo de las condiciones clim\u00e1ticas, pueden ser necesarios componentes adicionales en el sistema de manejo de aire, como bobinas de escarcha, reheaters y dispositivos de control de volumen de aire.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las implicaciones de ubicar el secador qu\u00edmico en la cub\u00edcula de producci\u00f3n?**\n   - La ubicaci\u00f3n del secador qu\u00edmico en la cub\u00edcula de producci\u00f3n puede ser una fuente de contaminaci\u00f3n o contaminaci\u00f3n cruzada, lo que podr\u00eda comprometer la calidad del producto y la seguridad del ambiente de trabajo.\n\n2. **\u00bfQu\u00e9 consideraciones clim\u00e1ticas deben tenerse en cuenta al dise\u00f1ar un sistema de manejo de aire?**\n   - Las condiciones clim\u00e1ticas pueden requerir la inclusi\u00f3n de componentes como bobinas de escarcha para precalentar el aire en climas muy fr\u00edos, as\u00ed como reheaters para el control de la humedad y dispositivos autom\u00e1ticos de control de volumen de aire.\n\n3. **\u00bfQu\u00e9 alternativas existen para el flujo de aire en el sistema de secado qu\u00edmico?**\n   - Las alternativas para el flujo de aire en el sistema de secado qu\u00edmico incluyen el manejo de aire fresco y de retorno en flujo completo, manejo parcial de aire fresco/retorno (flujo de bypass), manejo solo de aire de retorno, manejo solo de aire fresco, o aire precocido con cualquiera de las alternativas mencionadas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistemas de aire fresco con recuperaci\u00f3n de energ\u00eda**: Se discute la importancia de estos sistemas en instalaciones multiproducto, destacando su funci\u00f3n en la ventilaci\u00f3n y el control de la calidad del aire.\n\n2. **Evaluaci\u00f3n de riesgo**: Se enfatiza la necesidad de realizar una evaluaci\u00f3n de riesgo para identificar posibles contaminaciones cruzadas al utilizar ruedas de recuperaci\u00f3n de energ\u00eda.\n\n3. **Prevenci\u00f3n de contaminaci\u00f3n**: Se menciona que las ruedas de recuperaci\u00f3n de energ\u00eda no deben convertirse en fuentes de contaminaci\u00f3n.\n\n4. **Presiones relativas**: Se establece que la presi\u00f3n del sistema de escape debe ser inferior a la del sistema de suministro para evitar fugas de aire entre ambos.\n\n5. **Alternativas a las ruedas de recuperaci\u00f3n de energ\u00eda**: Se sugieren opciones como intercambiadores de calor de placa cruzada y intercambiadores de calor de bobina de agua para su uso en instalaciones multiproducto.\n\n6. **Secado del aire**: Se menciona el uso de deshidratadores qu\u00edmicos, como ruedas deshidratantes rotativas, y se indican m\u00e9todos alternativos para el secado del aire en sistemas de baja humedad.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **Ruedas de recuperaci\u00f3n de energ\u00eda**: Componente clave en el sistema de ventilaci\u00f3n.\n- **Intercambiadores de calor**: Alternativas mencionadas para la recuperaci\u00f3n de energ\u00eda.\n- **Sistemas de aire de suministro y de escape**: Elementos cr\u00edticos en la gesti\u00f3n de la calidad del aire.\n- **Deshidratadores qu\u00edmicos**: M\u00e9todos utilizados para controlar la humedad del aire.", "excerpt_keywords": "Keywords: air-handling system, chemical drying, contamination prevention, climatic conditions, humidity control"}}, "93632837-eab3-4f7b-ba24-094995b3ef23": {"node_ids": ["cf3a5a2e-a4ae-4fcd-bbb9-704f652c5467"], "metadata": {"page_label": "266", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Commissioning, qualification and maintenance\n\n## 8.1 Commissioning\n\n8.1.1 Commissioning should include the setting up, balancing, adjustment and testing of the entire HVAC system, to ensure that it meets all the requirements, as specified in the user requirement specification (URS), and capacities as specified by the designer or developer. The commissioning plan should start at the early stages of a project so that it can be integrated with qualification and verification procedures.\n\n8.1.2 The installation records of the system should provide documented evidence of all measured capacities of the system.\n\n8.1.3 Acceptance criteria should be set for all system parameters. The measured data should fall within the acceptance criteria.\n\n8.1.4 Acceptable tolerances for all system parameters should be specified prior to commencing the physical installation.\n\n8.1.5 Training should be provided to personnel after installation of the system, and should include operation and maintenance.\n\n8.1.6 Commissioning should be a precursor to system qualification and process validation.\n\n## 8.2 Qualification\n\n8.2.1 Validation is a many-faceted and extensive activity and is beyond the scope of these guidelines (2) (see also Figure 27).\n\nA risk-based approach should be used to identify the extent to which the HVAC system requires qualification and verification. The basic concepts of qualification of HVAC systems are set out below.\n\n8.2.2 The qualification of the HVAC system should be described in a validation master plan (VMP).\n\n8.2.3 It should define the nature and extent of testing and the test procedures and protocols to be followed.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda la importancia de la **comisionamiento**, **calificaci\u00f3n** y **mantenimiento** de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado). Se enfatiza que el comisionamiento debe incluir la configuraci\u00f3n, ajuste y prueba del sistema para cumplir con los requisitos especificados. Adem\u00e1s, se menciona que la calificaci\u00f3n del sistema debe ser parte de un plan maestro de validaci\u00f3n y que se debe adoptar un enfoque basado en riesgos para determinar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos clave que deben incluirse en un plan de comisionamiento para un sistema HVAC?**\n   - El plan de comisionamiento debe incluir la configuraci\u00f3n, balanceo, ajuste y prueba del sistema HVAC, asegurando que cumpla con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario (URS) y las capacidades definidas por el dise\u00f1ador.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para evidenciar la instalaci\u00f3n de un sistema HVAC?**\n   - Se deben mantener registros de instalaci\u00f3n que proporcionen evidencia documentada de todas las capacidades medidas del sistema.\n\n3. **\u00bfC\u00f3mo se debe abordar la calificaci\u00f3n de un sistema HVAC seg\u00fan el documento?**\n   - La calificaci\u00f3n del sistema HVAC debe ser descrita en un plan maestro de validaci\u00f3n (VMP) y debe definir la naturaleza y extensi\u00f3n de las pruebas, as\u00ed como los procedimientos y protocolos a seguir. Adem\u00e1s, se debe utilizar un enfoque basado en riesgos para identificar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Sistema de Manejo de Aire**: Se discute el dise\u00f1o de un sistema de manejo de aire que incluye un secador qu\u00edmico, enfatizando la importancia de su ubicaci\u00f3n para evitar la contaminaci\u00f3n en entornos de producci\u00f3n.\n\n2. **Ubicaci\u00f3n del Secador Qu\u00edmico**: Se desaconseja la colocaci\u00f3n del secador qu\u00edmico en la cub\u00edcula de producci\u00f3n debido al riesgo de contaminaci\u00f3n cruzada. Se sugieren ubicaciones alternativas, como:\n   - Flujo completo de aire fresco/retorno.\n   - Manejo parcial de aire fresco/retorno (flujo de bypass).\n   - Solo aire de retorno.\n   - Solo aire fresco.\n   - Aire precocido con cualquiera de las alternativas mencionadas.\n\n3. **Componentes Adicionales**: Se mencionan componentes que pueden ser necesarios en el sistema de manejo de aire, dependiendo de las condiciones clim\u00e1ticas, tales como:\n   - Bobinas de escarcha para precalentar el aire en climas fr\u00edos.\n   - Recalentadores para el control de la humedad.\n   - Dispositivos autom\u00e1ticos de control de volumen de aire.\n   - Atenuadores de sonido.\n\n### Entidades Clave\n- **Secador Qu\u00edmico**: Dispositivo utilizado para el manejo del aire en el sistema.\n- **Cub\u00edcula de Producci\u00f3n**: \u00c1rea donde se lleva a cabo la producci\u00f3n y que debe estar libre de contaminantes.\n- **Condiciones Clim\u00e1ticas**: Factores ambientales que influyen en el dise\u00f1o del sistema de manejo de aire.\n- **Componentes del Sistema**: Elementos adicionales que pueden ser necesarios para optimizar el manejo del aire, como bobinas de escarcha y reheaters.", "excerpt_keywords": "Keywords: commissioning, qualification, HVAC system, validation master plan, acceptance criteria"}}, "eac5488b-22bd-489e-afe9-13e7b32affd0": {"node_ids": ["ff4a8ef2-a926-4e12-a790-8ad10385dc56"], "metadata": {"page_label": "267", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification is a part of validation\n\n```\nEquipment 1  Equipment 2  Equipment 3  Equipment 4  Equipment 5  Equipment 6  Equipment 7\n     |            |            |            |            |            |            |\n     --------------------------------------------------------------\n                             |                                      |\n                          System 1                               System 2\n                             |                                      |\n                             ---------------------------------------\n                                         |\n                                       Process\n```\n\n8.2.4 Stages of the qualification of the HVAC system should include DQ, IQ, OQ and PQ.\n\n8.2.5 Critical and non-critical parameters should be determined by means of a risk analysis for all HVAC installation components, subsystems and controls.\n\n8.2.6 Any parameter that may affect the quality of the pharmaceutical product, or a direct impact component, should be considered a critical parameter.\n\n8.2.7 All critical parameters should be included in the qualification process. *Note: A realistic approach to differentiating between critical and noncritical parameters is required, to avoid making the validation process unnecessarily complex.*\n\n**Example:**\n\n- *The relative humidity of the room where the product is exposed should be considered a critical parameter when a humidity-sensitive product is being manufactured. The humidity sensors and the humidity monitoring system should, therefore, be qualified. The heat transfer system, chemical drier or steam humidifier, which is producing the humidity controlled air, is further removed from the product and may not require operational qualification.*\n\n- *A room cleanliness condition is a critical parameter and, therefore, the room air change rates and HEPA filters should be critical parameters and require qualification. Items such as the fan generating the airflow and the primary and secondary filters are non-critical parameters, and may not require operational qualification.*\n\n8.2.8 Non-critical systems and components should be subject to GEP and may not necessarily require qualification.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la calificaci\u00f3n de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en el contexto de la fabricaci\u00f3n farmac\u00e9utica. Se describen las etapas de calificaci\u00f3n, que incluyen DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o). Se enfatiza la importancia de realizar un an\u00e1lisis de riesgo para identificar par\u00e1metros cr\u00edticos y no cr\u00edticos que puedan afectar la calidad del producto farmac\u00e9utico. Se proporcionan ejemplos de c\u00f3mo determinar qu\u00e9 par\u00e1metros son cr\u00edticos y cu\u00e1les no, as\u00ed como la necesidad de aplicar Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP) a los sistemas no cr\u00edticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las etapas espec\u00edficas de la calificaci\u00f3n de un sistema HVAC seg\u00fan el documento?**\n   - Respuesta: Las etapas de la calificaci\u00f3n del sistema HVAC incluyen DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o).\n\n2. **\u00bfC\u00f3mo se determina si un par\u00e1metro es cr\u00edtico o no cr\u00edtico en el contexto de un sistema HVAC?**\n   - Respuesta: La determinaci\u00f3n de par\u00e1metros cr\u00edticos y no cr\u00edticos se realiza mediante un an\u00e1lisis de riesgo para todos los componentes, subsistemas y controles de la instalaci\u00f3n HVAC. Cualquier par\u00e1metro que pueda afectar la calidad del producto farmac\u00e9utico o que tenga un impacto directo se considera cr\u00edtico.\n\n3. **\u00bfQu\u00e9 ejemplos se proporcionan en el documento para ilustrar la diferencia entre par\u00e1metros cr\u00edticos y no cr\u00edticos?**\n   - Respuesta: Se menciona que la humedad relativa en una sala donde se expone un producto sensible a la humedad es un par\u00e1metro cr\u00edtico y, por lo tanto, los sensores de humedad y el sistema de monitoreo de humedad deben ser calificados. En contraste, el ventilador que genera el flujo de aire y los filtros primarios y secundarios son considerados par\u00e1metros no cr\u00edticos y pueden no requerir calificaci\u00f3n operativa.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Comisionamiento de Sistemas HVAC:**\n   - Incluye la configuraci\u00f3n, balanceo, ajuste y prueba del sistema.\n   - Debe cumplir con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario (URS) y las capacidades definidas por el dise\u00f1ador.\n   - Se deben establecer criterios de aceptaci\u00f3n y tolerancias antes de la instalaci\u00f3n.\n   - Se requiere documentaci\u00f3n de las capacidades medidas del sistema.\n   - Es esencial proporcionar capacitaci\u00f3n al personal sobre operaci\u00f3n y mantenimiento.\n   - El comisionamiento es un precursor de la calificaci\u00f3n del sistema y la validaci\u00f3n del proceso.\n\n2. **Calificaci\u00f3n de Sistemas HVAC:**\n   - La calificaci\u00f3n debe ser parte de un plan maestro de validaci\u00f3n (VMP).\n   - Se debe adoptar un enfoque basado en riesgos para determinar la extensi\u00f3n de la calificaci\u00f3n y verificaci\u00f3n necesaria.\n   - El VMP debe definir la naturaleza y extensi\u00f3n de las pruebas, as\u00ed como los procedimientos y protocolos a seguir.\n\n**Entidades:**\n\n- **Sistemas HVAC:** Calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Especificaci\u00f3n de Requisitos del Usuario (URS):** Documento que detalla los requisitos que debe cumplir el sistema.\n- **Plan Maestro de Validaci\u00f3n (VMP):** Documento que describe la calificaci\u00f3n del sistema HVAC y los procedimientos de prueba.\n- **Criterios de Aceptaci\u00f3n:** Par\u00e1metros establecidos que deben cumplirse para considerar que el sistema est\u00e1 funcionando correctamente.\n- **Tolerancias Aceptables:** L\u00edmites permitidos para los par\u00e1metros del sistema antes de la instalaci\u00f3n.\n\nEste resumen destaca la importancia del comisionamiento y la calificaci\u00f3n en la implementaci\u00f3n y mantenimiento de sistemas HVAC, as\u00ed como la necesidad de documentaci\u00f3n y capacitaci\u00f3n adecuada.", "excerpt_keywords": "Keywords: HVAC, qualification, critical parameters, risk analysis, pharmaceutical manufacturing"}}, "8fd1404a-701d-472d-9e7c-eb5736cf0acf": {"node_ids": ["72118518-036f-4ec6-b989-148216b470d0"], "metadata": {"page_label": "268", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.2.9 A change control procedure should be followed when changes are planned to the direct impact HVAC system, its components and controls that may affect critical parameters.\n\n8.2.10 The design condition, normal operating ranges, operating range and alert and action limits should be defined and be realistic.\n\n8.2.11 Out-of-limit results (e.g. action limit deviations) should be recorded and their impact should be investigated.\n\n8.2.12 The relationships between design conditions, normal operating range and validated acceptance criteria (also known as proven acceptable range) are given in Figure 28.\n\n**Figure 28**  \n**System operating ranges**\n\n| ACTION LIMIT | ALERT LIMIT | DESIGN SET-POINT | DESIGN SET-POINT | ALERT LIMIT | ACTION LIMIT |\n|--------------|-------------|------------------|------------------|-------------|--------------|\n\n- Design Condition\n- Normal Operating Range\n- Operating Range \u2013 Validated Acceptance Criteria\n\n8.2.13 For a pharmaceutical facility, based on a risk assessment, some of the typical HVAC system parameters that should be qualified may include:\n\n- temperature\n- relative humidity\n- supply air quantities for all diffusers\n- return air or exhaust air quantities\n- room air change rates\n- room pressures (pressure differentials)\n- room airflow patterns\n- unidirectional flow velocities\n- containment system velocities\n- HEPA filter penetration tests", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de un procedimiento de control de cambios en los sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en instalaciones farmac\u00e9uticas. Se enfatiza la necesidad de definir condiciones de dise\u00f1o, rangos operativos normales y l\u00edmites de alerta y acci\u00f3n. Tambi\u00e9n se menciona la importancia de registrar resultados fuera de los l\u00edmites y evaluar su impacto. Adem\u00e1s, se enumeran par\u00e1metros t\u00edpicos del sistema HVAC que deben ser calificados, basados en una evaluaci\u00f3n de riesgos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos recomendados en un procedimiento de control de cambios para un sistema HVAC en una instalaci\u00f3n farmac\u00e9utica?**\n   - Esta pregunta busca detalles sobre el proceso espec\u00edfico que se debe seguir al implementar cambios en el sistema HVAC, que no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al definir los l\u00edmites de alerta y acci\u00f3n para los par\u00e1metros del sistema HVAC?**\n   - Esta pregunta se centra en los factores que influyen en la determinaci\u00f3n de l\u00edmites espec\u00edficos, lo que podr\u00eda no estar claramente definido en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe documentar y evaluar el impacto de los resultados que se encuentran fuera de los l\u00edmites establecidos en un sistema HVAC?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso de documentaci\u00f3n y evaluaci\u00f3n de resultados an\u00f3malos, que podr\u00eda no estar ampliamente cubierto en otros documentos relacionados. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otros contextos, bas\u00e1ndose en el contenido del documento de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n de Sistemas HVAC**: Se detalla el proceso de calificaci\u00f3n de sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en la fabricaci\u00f3n farmac\u00e9utica, que incluye las etapas de DQ (Dise\u00f1o de Calificaci\u00f3n), IQ (Calificaci\u00f3n de Instalaci\u00f3n), OQ (Calificaci\u00f3n Operacional) y PQ (Calificaci\u00f3n de Desempe\u00f1o).\n\n2. **An\u00e1lisis de Riesgo**: Se enfatiza la importancia de realizar un an\u00e1lisis de riesgo para identificar par\u00e1metros cr\u00edticos y no cr\u00edticos en todos los componentes, subsistemas y controles de la instalaci\u00f3n HVAC.\n\n3. **Par\u00e1metros Cr\u00edticos y No Cr\u00edticos**: Se define que cualquier par\u00e1metro que pueda afectar la calidad del producto farmac\u00e9utico o que tenga un impacto directo debe ser considerado cr\u00edtico. Se proporciona orientaci\u00f3n sobre c\u00f3mo diferenciar entre par\u00e1metros cr\u00edticos y no cr\u00edticos para evitar complicaciones innecesarias en el proceso de validaci\u00f3n.\n\n4. **Ejemplos Pr\u00e1cticos**: Se ofrecen ejemplos espec\u00edficos que ilustran la clasificaci\u00f3n de par\u00e1metros, como la humedad relativa en salas de producci\u00f3n y las condiciones de limpieza del ambiente.\n\n5. **Buenas Pr\u00e1cticas de Ingenier\u00eda (GEP)**: Se menciona que los sistemas y componentes no cr\u00edticos deben estar sujetos a Buenas Pr\u00e1cticas de Ingenier\u00eda y pueden no requerir calificaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado en el contexto farmac\u00e9utico.\n- **Par\u00e1metros Cr\u00edticos**: Elementos que afectan directamente la calidad del producto farmac\u00e9utico.\n- **Par\u00e1metros No Cr\u00edticos**: Elementos que no afectan directamente la calidad del producto y pueden no requerir calificaci\u00f3n.\n- **Etapas de Calificaci\u00f3n**: DQ, IQ, OQ, PQ.\n- **Ejemplos de Par\u00e1metros**: Humedad relativa, tasas de cambio de aire, filtros HEPA, ventiladores.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes de la secci\u00f3n sobre la calificaci\u00f3n de sistemas HVAC en la fabricaci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: HVAC, pharmaceutical facility, change control procedure, risk assessment, operating ranges"}}, "23622f76-3be0-4fd5-8470-679ecccdd3c0": {"node_ids": ["6dcb2e44-3e00-4ade-867e-0512f5ca66fe"], "metadata": {"page_label": "269", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 room particle counts  \n\u2014 room clean-up rates  \n\u2014 microbiological air and surface counts where appropriate  \n\u2014 operation of de-dusting  \n\u2014 warning/alarm systems where applicable.  \n\n8.2.14 The maximum time interval between tests should be defined by the manufacturer. The type of facility under test and the product level of protection should be considered. Table 3 gives various tests that can be carried out. The required tests and intervals between testing should be determined through risk assessment.\n\n### Table 3  \n**Tests to demonstrate compliance**\n\n| Test parameter | Test procedure |\n| - | - |\n| Particle count test (Verification of cleanliness) | Dust particle counts to be carried out and result printouts produced. No. of readings and positions of tests to be in accordance with ISO 14644-1 Annex B5 |\n| Air pressure difference (To verify non cross-contamination) | Log of pressure differential readings to be produced or critical plants should be logged daily, preferably continuously. A 15 Pa pressure differential between different zones is recommended. In accordance with ISO 14644-3 Annex B5 |\n| Airflow volume (To verify air change rates) | Airflow readings for supply air and return air grilles to be measured and air change rates to be calculated. In accordance with ISO 14644-3 Annex B13 |\n| Airflow velocity (To verify unidirectional flow or containment conditions) | Air velocities for containment systems and unidirectional flow protection systems to be measured. In accordance with ISO 14644-3 Annex B4 |\n| Filter leakage tests (To verify filter integrity) | Filter penetration tests to be carried out by a competent person to demonstrate filter media, filter seal and filter frame integrity. Only required on HEPA filters. In accordance with ISO 14644-3 Annex B6 |\n| Containment leakage (To verify absence of cross-contamination) | Demonstrate that contaminant is maintained within a room by means of: \u2022 airflow direction smoke tests \u2022 room air pressures. In accordance with ISO 14644-3 Annex B4 |\n| Recovery (To verify clean-up time) | Test to establish time that a cleanroom takes to recover from a contaminated condition to the specified cleanroom condition. Should not take more than 15 min. In accordance with ISO 14644-3 Annex B13\\* |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla las pruebas necesarias para garantizar la conformidad de las instalaciones que requieren un control estricto de la contaminaci\u00f3n, como las salas limpias. Se menciona la importancia de realizar pruebas peri\u00f3dicas, definidas por el fabricante, y se proporciona una tabla con diferentes par\u00e1metros de prueba, procedimientos y normas ISO correspondientes. Las pruebas incluyen conteos de part\u00edculas, diferencias de presi\u00f3n de aire, vol\u00famenes y velocidades de flujo de aire, pruebas de integridad de filtros, y pruebas de recuperaci\u00f3n de la sala limpia.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre la diferencia de presi\u00f3n entre diferentes zonas en una instalaci\u00f3n cr\u00edtica, seg\u00fan el documento?**\n   - La recomendaci\u00f3n es mantener una diferencia de presi\u00f3n de 15 Pa entre diferentes zonas.\n\n2. **\u00bfQu\u00e9 procedimiento se debe seguir para verificar la integridad de los filtros HEPA en una sala limpia?**\n   - Se deben realizar pruebas de penetraci\u00f3n de filtros llevadas a cabo por una persona competente para demostrar la integridad del medio filtrante, el sello del filtro y el marco del filtro.\n\n3. **\u00bfCu\u00e1nto tiempo se considera aceptable para que una sala limpia recupere su condici\u00f3n especificada despu\u00e9s de una contaminaci\u00f3n?**\n   - El tiempo de recuperaci\u00f3n no debe exceder los 15 minutos.\n\n### Resumen de nivel superior\nEl documento de la OMS establece directrices para la evaluaci\u00f3n y el mantenimiento de la calidad del aire en instalaciones cr\u00edticas, como las salas limpias. Se enfatiza la necesidad de realizar pruebas regulares para asegurar que las condiciones de limpieza y la integridad de los sistemas de filtraci\u00f3n se mantengan dentro de los est\u00e1ndares establecidos. Las pruebas deben ser adaptadas a las caracter\u00edsticas espec\u00edficas de cada instalaci\u00f3n y deben ser realizadas por personal competente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Procedimiento de Control de Cambios**:\n   - Importancia de seguir un procedimiento de control de cambios para el sistema HVAC en instalaciones farmac\u00e9uticas.\n   - Cambios que pueden afectar par\u00e1metros cr\u00edticos deben ser gestionados adecuadamente.\n\n2. **Definici\u00f3n de Par\u00e1metros**:\n   - Necesidad de definir condiciones de dise\u00f1o, rangos operativos normales, y l\u00edmites de alerta y acci\u00f3n de manera realista.\n   - Relaci\u00f3n entre condiciones de dise\u00f1o, rangos operativos normales y criterios de aceptaci\u00f3n validados.\n\n3. **Registro y Evaluaci\u00f3n de Resultados Fuera de L\u00edmites**:\n   - Resultados que exceden los l\u00edmites establecidos deben ser documentados y su impacto investigado.\n\n4. **Par\u00e1metros T\u00edpicos del Sistema HVAC**:\n   - Identificaci\u00f3n de par\u00e1metros que deben ser calificados en funci\u00f3n de una evaluaci\u00f3n de riesgos, incluyendo:\n     - Temperatura\n     - Humedad relativa\n     - Cantidades de aire suministrado y retornado\n     - Tasas de cambio de aire en las habitaciones\n     - Presiones de las habitaciones (diferenciales de presi\u00f3n)\n     - Patrones de flujo de aire en las habitaciones\n     - Velocidades de flujo unidireccional\n     - Velocidades de sistemas de contenci\u00f3n\n     - Pruebas de penetraci\u00f3n de filtros HEPA\n\n5. **Figura 28 - Rangos Operativos del Sistema**:\n   - Representaci\u00f3n gr\u00e1fica que ilustra los l\u00edmites de acci\u00f3n, l\u00edmites de alerta, y puntos de ajuste de dise\u00f1o.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Sistema HVAC**: Sistema de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado relevante para instalaciones farmac\u00e9uticas.\n- **Par\u00e1metros Cr\u00edticos**: Elementos que afectan la calidad y seguridad en la producci\u00f3n farmac\u00e9utica.\n- **Riesgo**: Concepto utilizado para determinar qu\u00e9 par\u00e1metros deben ser calificados en el sistema HVAC.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de los sistemas HVAC en el contexto de la producci\u00f3n farmac\u00e9utica, enfatizando la necesidad de procedimientos claros y la evaluaci\u00f3n continua de los par\u00e1metros cr\u00edticos.", "excerpt_keywords": "Keywords: cleanroom, contamination control, ISO standards, air quality testing, HEPA filters"}}, "0081e52b-fd04-49c6-bc7a-cb0937059387": {"node_ids": ["8fd7f768-396a-4481-a9fa-090cc77be9cc"], "metadata": {"page_label": "270", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test parameter | Test procedure |\n| - | - |\n| Airflow visualization (To verify required airflow patterns) | * Tests to demonstrate air flows:\n* from clean to dirty areas\n* do not cause cross-contamination\n* uniformly from unidirectional airflow unitsDemonstrated by actual or video-taped smoke tests. In accordance with ISO 14644-3 Annex B7 |\n\n\n8.2.15 Requalification should also be done when any change, which could affect system performance, takes place.\n\n8.2.16 Clean-up or recovery times normally relate to the time it takes to \u201cclean up\u201d the room from one condition to another, e.g. the relationship between \u201cat-rest\u201d and \u201coperational\u201d conditions in the clean area may be used as the criteria for clean-up tests. Therefore, the clean-up time can be expressed as the time taken to change from an \u201coperational\u201d condition to an \u201cat rest\u201d condition.\n\n8.2.17 If energy-saving procedures such as reducing the airflow during non-production hours are used, precautionary measures should be in place to ensure that the systems are not operated outside the defined relevant environmental conditions.\n\nThese precautionary measures should be based on a risk assessment to ensure that there is no negative impact on the quality of the product.\n\n8.2.18 Documents that should be included in the qualification manuals should include system airflow schematics, room pressure cascade drawings, zone concept drawings, air-handling system allocation drawings, particle count mapping drawings, etc.\n\n# 8.3 Maintenance\n\n8.3.1 There should be a planned preventive maintenance programme, procedures and records for the HVAC system. Records should be kept.\n\n8.3.2 Operating and maintenance (O&M) manuals, schematic drawings, protocols and reports should be maintained as reference documents for any future changes and upgrades to the system. These documents should be kept up to date, containing any system revisions made.\n\n8.3.3 Maintenance personnel should receive appropriate training.\n\n8.3.4 HEPA filters should be changed either by a specialist or a trained person, and then followed by installed filter leakage testing.\n\n8.3.5 Any maintenance activity should be assessed critically to determine any impact on product quality including possible contamination.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la importancia de la calificaci\u00f3n y el mantenimiento de sistemas HVAC (calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado) en \u00e1reas limpias. Se enfatiza la necesidad de realizar pruebas de visualizaci\u00f3n del flujo de aire para garantizar que no haya contaminaci\u00f3n cruzada y que el aire fluya de \u00e1reas limpias a sucias. Adem\u00e1s, se discuten los tiempos de limpieza, la importancia de las medidas de precauci\u00f3n durante la reducci\u00f3n del flujo de aire y la necesidad de mantener documentaci\u00f3n adecuada y un programa de mantenimiento preventivo. Tambi\u00e9n se menciona la capacitaci\u00f3n del personal de mantenimiento y la importancia de evaluar el impacto de las actividades de mantenimiento en la calidad del producto.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas se deben realizar para verificar los patrones de flujo de aire en \u00e1reas limpias, y qu\u00e9 norma se menciona para estas pruebas?**\n   - Respuesta: Se deben realizar pruebas de visualizaci\u00f3n del flujo de aire, que demuestran que el aire fluye de \u00e1reas limpias a sucias, no causa contaminaci\u00f3n cruzada y es uniforme desde unidades de flujo de aire unidireccional. Estas pruebas deben ser realizadas de acuerdo con la norma ISO 14644-3, Anexo B7.\n\n2. **\u00bfQu\u00e9 documentos son esenciales para incluir en los manuales de calificaci\u00f3n de sistemas HVAC seg\u00fan el contexto?**\n   - Respuesta: Los documentos que deben incluirse en los manuales de calificaci\u00f3n son: esquemas de flujo de aire del sistema, dibujos de cascada de presi\u00f3n de la sala, dibujos del concepto de zonas, dibujos de asignaci\u00f3n del sistema de manejo de aire, y dibujos de mapeo de conteo de part\u00edculas.\n\n3. **\u00bfCu\u00e1les son las consideraciones que deben tenerse en cuenta al realizar actividades de mantenimiento en sistemas HVAC en relaci\u00f3n con la calidad del producto?**\n   - Respuesta: Cualquier actividad de mantenimiento debe ser evaluada cr\u00edticamente para determinar su impacto en la calidad del producto, incluyendo la posibilidad de contaminaci\u00f3n. Adem\u00e1s, se debe asegurar que los filtros HEPA sean cambiados por personal especializado o capacitado, seguido de pruebas de fuga de los filtros instalados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Pruebas de Conformidad:** El documento detalla las pruebas necesarias para asegurar que las instalaciones, como las salas limpias, cumplan con los est\u00e1ndares de calidad del aire y control de contaminaci\u00f3n.\n2. **Intervalos de Prueba:** Se establece que el intervalo m\u00e1ximo entre pruebas debe ser definido por el fabricante, considerando el tipo de instalaci\u00f3n y el nivel de protecci\u00f3n del producto.\n3. **Par\u00e1metros de Prueba:** Se presentan varios par\u00e1metros de prueba en una tabla, incluyendo conteos de part\u00edculas, diferencias de presi\u00f3n de aire, vol\u00famenes y velocidades de flujo de aire, pruebas de integridad de filtros y pruebas de recuperaci\u00f3n.\n4. **Normas ISO:** Las pruebas deben realizarse de acuerdo con las normas ISO pertinentes, como ISO 14644-1 y ISO 14644-3.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite el documento.\n- **ISO 14644-1 y ISO 14644-3:** Normas internacionales que regulan la clasificaci\u00f3n y el control de la contaminaci\u00f3n en salas limpias.\n- **Filtros HEPA:** Filtros de alta eficiencia que requieren pruebas espec\u00edficas de integridad.\n- **Par\u00e1metros de Prueba:**\n  - Conteo de part\u00edculas\n  - Diferencia de presi\u00f3n de aire\n  - Volumen de flujo de aire\n  - Velocidad de flujo de aire\n  - Pruebas de fuga de filtros\n  - Pruebas de contenci\u00f3n\n  - Tiempo de recuperaci\u00f3n\n\n**Recomendaciones Clave:**\n- Mantener una diferencia de presi\u00f3n de 15 Pa entre zonas cr\u00edticas.\n- Realizar pruebas de integridad de filtros HEPA por personal competente.\n- El tiempo de recuperaci\u00f3n de una sala limpia no debe exceder los 15 minutos tras una contaminaci\u00f3n. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes relacionados con el control de la contaminaci\u00f3n en instalaciones cr\u00edticas, as\u00ed como las pruebas necesarias para garantizar su conformidad.", "excerpt_keywords": "Keywords: HVAC, airflow visualization, cleanroom maintenance, HEPA filters, contamination control"}}, "92028b1f-4c79-4e65-a705-d7d49f988666": {"node_ids": ["fe8ee19e-04be-4e37-a6c7-f6f49b741e6b"], "metadata": {"page_label": "271", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "8.3.6 Maintenance activities should normally be scheduled to take place outside production hours, and any system stoppage should be assessed with a view to the possible need for requalification of an area as a result of an interruption of the service.\n\n## 9. Premises\n\n9.1 As the efficient operation of the air-handling system and cleanliness levels attained are reliant on the correct building layout and building finishes, the following items should be considered:\n\n- adequate airlocks, such as personnel airlocks (PAL) and/or material airlocks (MAL), change rooms and passages should be provided to protect passage between different cleanliness conditions. These should have supply and extract air systems as appropriate;\n- areas such as airlocks, change rooms and passages, should be designed so that the required pressure cascades can be achieved;\n- detailed diagrams depicting pressure cascades, air flow directions and flow routes for personnel and materials should be prepared and maintained;\n- where possible, personnel and materials should not move from a higher cleanliness zone to a lower cleanliness zone and back to a higher cleanliness zone; (if moving from a lower cleanliness zone to a higher cleanliness zone, changing/decontamination procedures should be followed); and\n- the final stage of the changing room should, in the \u201cat rest\u201d state, be the same GMP classification grade as the area into which it leads.\n\n## References\n\n1. Good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908), Annex 4. http://whqlibdoc.who.int/trs/WHO_TRS_908_eng.pdf; *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Volume 2, Second updated edition. Good manufacturing practices and inspection.* Geneva, World Health Organization, 2007; and *Quality assurance of pharmaceuticals. A compendium of guidelines and related materials.* Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. *Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 937). http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica, centr\u00e1ndose en la importancia de la planificaci\u00f3n de actividades de mantenimiento y el dise\u00f1o adecuado de las instalaciones. Se enfatiza la necesidad de mantener la limpieza y la presi\u00f3n adecuada en diferentes zonas de producci\u00f3n, as\u00ed como la correcta circulaci\u00f3n de personal y materiales entre \u00e1reas de diferentes niveles de limpieza. Se mencionan procedimientos espec\u00edficos para evitar la contaminaci\u00f3n cruzada y se proporcionan referencias a informes anteriores de la OMS sobre el tema.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las consideraciones clave para el dise\u00f1o de \u00e1reas de cambio y aire en instalaciones farmac\u00e9uticas seg\u00fan el documento?**\n   - Respuesta: El dise\u00f1o debe incluir adecuadas airlocks (tanto para personal como para materiales), asegurar que se logren las cascadas de presi\u00f3n requeridas, y preparar diagramas detallados que muestren las direcciones del flujo de aire y las rutas para el personal y los materiales.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse al mover personal y materiales entre zonas de limpieza diferente?**\n   - Respuesta: Se debe evitar el movimiento de personal y materiales de una zona de limpieza m\u00e1s alta a una m\u00e1s baja y viceversa. Si se debe mover de una zona de limpieza m\u00e1s baja a una m\u00e1s alta, se deben seguir procedimientos de cambio y descontaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 implicaciones tiene una interrupci\u00f3n del servicio en el \u00e1rea de producci\u00f3n seg\u00fan el documento?**\n   - Respuesta: Cualquier interrupci\u00f3n del servicio debe ser evaluada para determinar si es necesaria la revalidaci\u00f3n del \u00e1rea afectada, asegurando que se mantengan los est\u00e1ndares de GMP.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre las buenas pr\u00e1cticas de manufactura en la industria farmac\u00e9utica, destacando la importancia de la planificaci\u00f3n del mantenimiento y el dise\u00f1o de instalaciones para garantizar la limpieza y la calidad del aire. Se enfatiza la necesidad de evitar la contaminaci\u00f3n cruzada y de seguir procedimientos espec\u00edficos al mover personal y materiales entre diferentes zonas de limpieza. Adem\u00e1s, se subraya la importancia de la revalidaci\u00f3n de \u00e1reas tras interrupciones en el servicio.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n de Sistemas HVAC**: Importancia de realizar pruebas de visualizaci\u00f3n del flujo de aire para asegurar que el aire fluya de \u00e1reas limpias a sucias sin causar contaminaci\u00f3n cruzada. Se menciona la norma ISO 14644-3, Anexo B7 como referencia para estas pruebas.\n\n2. **Recalificaci\u00f3n**: Necesidad de realizar recalificaciones cuando ocurren cambios que pueden afectar el rendimiento del sistema.\n\n3. **Tiempos de Limpieza**: Definici\u00f3n de los tiempos de limpieza o recuperaci\u00f3n en funci\u00f3n de la transici\u00f3n entre condiciones \"operativas\" y \"en reposo\" en \u00e1reas limpias.\n\n4. **Medidas de Precauci\u00f3n**: Importancia de implementar medidas de precauci\u00f3n al reducir el flujo de aire durante horas no productivas, basadas en evaluaciones de riesgo para proteger la calidad del producto.\n\n5. **Documentaci\u00f3n**: Necesidad de mantener documentaci\u00f3n adecuada en los manuales de calificaci\u00f3n, incluyendo esquemas de flujo de aire, dibujos de presi\u00f3n, y mapeo de conteo de part\u00edculas.\n\n6. **Mantenimiento Preventivo**: Establecimiento de un programa de mantenimiento preventivo para el sistema HVAC, con registros y manuales de operaci\u00f3n y mantenimiento actualizados.\n\n7. **Capacitaci\u00f3n del Personal**: Importancia de la capacitaci\u00f3n adecuada para el personal de mantenimiento.\n\n8. **Cambio de Filtros HEPA**: Procedimientos para el cambio de filtros HEPA, que deben ser realizados por personal especializado o capacitado, seguido de pruebas de fuga.\n\n9. **Evaluaci\u00f3n de Impacto en la Calidad del Producto**: Evaluaci\u00f3n cr\u00edtica de cualquier actividad de mantenimiento para determinar su impacto en la calidad del producto y la posibilidad de contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **ISO 14644-3**: Norma mencionada para la verificaci\u00f3n de patrones de flujo de aire.\n- **Sistemas HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado discutidos en el contexto de \u00e1reas limpias.\n- **Filtros HEPA**: Filtros de alta eficiencia que requieren atenci\u00f3n especial durante el mantenimiento.\n- **Documentaci\u00f3n**: Incluye manuales de operaci\u00f3n, esquemas, y registros de mantenimiento.\n\nEste resumen destaca los aspectos esenciales relacionados con la calificaci\u00f3n y el mantenimiento de sistemas HVAC en \u00e1reas limpias, enfatizando la importancia de las pruebas, la documentaci\u00f3n y la capacitaci\u00f3n del personal para asegurar la calidad del producto.", "excerpt_keywords": "Keywords: GMP, air-handling system, cleanliness zones, maintenance activities, pharmaceutical facilities"}}, "66c9f6dc-5f35-4beb-81c5-617a16d8b683": {"node_ids": ["ae20f725-7154-4e5a-9603-0e539c19534e"], "metadata": {"page_label": "272", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Further reading\n\n**Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1.** Geneva, World Health Organization, 1997.\n\n**Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2, Second updated edition.** Good manufacturing practices and inspection. Geneva, World Health Organization, 2007. http://www.who.int/medicines/areas/quality_safety/quality_assurance/production/en/index.html; and Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\nWorld Health Organization. Supplements and updates available at: www.who.int/medicines.\n\n**ASHRAE handbook 1999. HVAC Applications, SI edition.** Atlanta, GA, ASHRAE, 2007. http://www.ashrae.org/technology/page/548.\n\n**ASHRAE handbook 2000. HVAC Systems and Equipment.** Atlanta, GA, ASHRAE, 2008. http://www.ashrae.org/technology/page/548.\n\nDaly BB. **Woods practical guide to fan engineering.** Colchester, Woods of Colchester Ltd. Third impression, June 1985. Cambridge, Cambridge University Press. www.flaktwoods.com.\n\nEuropean Commission. **The rules governing medicinal products in the European Community, Volume IV. Good manufacturing practice for medicinal products.** European Commission, Brussels, 2005. http://www.cen.eu/cenorm/sectors/sectors/healthcare/index.asp.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms,** Second Edition / November 2009, International Society for Pharmaceutical Engineering. http://www.ispe.org/.\n\n**ISPE Baseline\u00ae pharmaceutical engineering guides for new and renovated facilities, Volume 5. Commissioning and qualification,** 1st ed. Tampa, Fl, International Society for Pharmaceutical Engineering, 2001. http://www.ispe.org/.\n\n**International Cleanroom Standards, ISO 14644.** Geneva, International Organization for Standardization. http://www.iso.org/iso/standards_development.htm.\n\nLuwa. **Introduction to high efficiency filtration.** Bulletin 50.10.10, Sheet 020. Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme. **Guide to Good Manufacturing Practice for Medicinal Products.** PH 1/97 (Rev. 3), 15 January 2002.\n\nPIC/s GMP Guide (PE 009) http://www.picscheme.org/publication.php?id=4\n\nICH Q9: **\u201cQuality Risk Management\u201d**, November 2005 http://www.ich.org.\n\nWorld Health Organization. Draft working document QAS/10.376: **\u201cGuidelines on quality risk management\u201d**, 2010 (in preparation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de recursos y gu\u00edas sobre la garant\u00eda de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se mencionan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) y otras organizaciones relevantes, como la ASHRAE y la Comisi\u00f3n Europea, que abordan buenas pr\u00e1cticas de fabricaci\u00f3n, gesti\u00f3n de riesgos de calidad y est\u00e1ndares de limpieza en entornos de producci\u00f3n farmac\u00e9utica. Tambi\u00e9n se incluyen enlaces a documentos y gu\u00edas que pueden ser \u00fatiles para profesionales en el campo de la ingenier\u00eda farmac\u00e9utica y la calidad.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las dos ediciones de la \"Quality Assurance of Pharmaceuticals\" publicadas por la OMS y en qu\u00e9 a\u00f1os fueron publicadas?**\n   - Respuesta: La primera edici\u00f3n fue publicada en 1997 y la segunda edici\u00f3n, actualizada, fue publicada en 2007.\n\n2. **\u00bfQu\u00e9 gu\u00eda de la ISPE se menciona en el contexto y cu\u00e1l es su enfoque principal?**\n   - Respuesta: Se menciona la \"ISPE Baseline\u00ae pharmaceutical engineering guides, Volume 2. Oral solid dosage forms\", que se centra en las formas de dosificaci\u00f3n s\u00f3lida oral.\n\n3. **\u00bfQu\u00e9 documento de la OMS est\u00e1 en preparaci\u00f3n y qu\u00e9 tema aborda?**\n   - Respuesta: El documento en preparaci\u00f3n es el \"Draft working document QAS/10.376: Guidelines on quality risk management\", que aborda la gesti\u00f3n de riesgos de calidad.", "prev_section_summary": "### Temas Clave\n\n1. **Mantenimiento de Instalaciones**: Las actividades de mantenimiento deben programarse fuera del horario de producci\u00f3n y cualquier interrupci\u00f3n del servicio debe evaluarse para determinar si es necesaria la revalidaci\u00f3n del \u00e1rea afectada.\n\n2. **Dise\u00f1o de Instalaciones**: La eficiencia del sistema de manejo de aire y los niveles de limpieza dependen del dise\u00f1o adecuado de las instalaciones. Se deben considerar elementos como:\n   - Airlocks adecuados (para personal y materiales).\n   - Dise\u00f1o de \u00e1reas para lograr cascadas de presi\u00f3n requeridas.\n   - Diagramas detallados que muestren las direcciones del flujo de aire y las rutas para el personal y materiales.\n\n3. **Movimientos entre Zonas de Limpieza**: Se deben seguir procedimientos espec\u00edficos al mover personal y materiales entre zonas de diferentes niveles de limpieza, evitando movimientos de zonas m\u00e1s limpias a menos limpias sin las debidas precauciones.\n\n4. **Clasificaci\u00f3n de \u00c1reas**: La \u00faltima etapa del vestuario debe tener la misma clasificaci\u00f3n de Buenas Pr\u00e1cticas de Manufactura (GMP) que el \u00e1rea a la que conduce.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite directrices sobre buenas pr\u00e1cticas de manufactura.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que asegura la calidad y limpieza en la producci\u00f3n farmac\u00e9utica.\n- **Airlocks**: Sistemas de entrada/salida que protegen la integridad de las zonas de limpieza.\n- **Cascadas de presi\u00f3n**: Diferencias de presi\u00f3n necesarias para mantener la limpieza en diferentes \u00e1reas.\n- **Zonas de limpieza**: Clasificaciones que determinan el nivel de limpieza requerido en diferentes \u00e1reas de producci\u00f3n.\n\nEste resumen destaca la importancia del mantenimiento, el dise\u00f1o adecuado de las instalaciones y los procedimientos para evitar la contaminaci\u00f3n cruzada en la industria farmac\u00e9utica, seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: quality assurance, pharmaceuticals, good manufacturing practices, risk management, cleanroom standards"}}, "7bc36d2a-ab8c-4d8b-99d1-a4d32daef57c": {"node_ids": ["ada3baa9-2052-413b-8ca1-88a636fe891d"], "metadata": {"page_label": "273", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 6\n\n## WHO good manufacturing practices for sterile pharmaceutical products\n\n### Introduction\n\nFollowing implementation of these WHO good manufacturing practices (GMP) guidelines (1) within the context of the WHO Prequalification of Medicines Programme, clarifying, editorial modifications have been proposed. These changes were adopted for maintenance purposes. In order to ease reading the full guideline has been reproduced again as an Annex to the current report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.\n\n### WHO good manufacturing practices for sterile pharmaceutical products\n\n1. General considerations\n2. Quality control\n3. Sanitation\n4. Manufacture of sterile preparations\n5. Sterilization\n6. Terminal sterilization\n7. Aseptic processing and sterilization by filtration\n8. Isolator technology\n9. Blow/fill/seal technology\n10. Personnel\n11. Premises\n12. Equipment\n13. Finishing of sterile products\n\nReferences\n\nFurther reading", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un anexo del Informe T\u00e9cnico de la OMS (WHO - Technical Report Series 961) que presenta las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles. Se menciona que se han realizado modificaciones editoriales para facilitar la lectura y que estas pautas son parte del Programa de Precalificaci\u00f3n de Medicamentos de la OMS. El anexo incluye secciones sobre consideraciones generales, control de calidad, sanidad, fabricaci\u00f3n de preparaciones est\u00e9riles, m\u00e9todos de esterilizaci\u00f3n, tecnolog\u00eda de aislamiento, y otros aspectos relevantes para la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las secciones espec\u00edficas que abordan los m\u00e9todos de esterilizaci\u00f3n en las buenas pr\u00e1cticas de fabricaci\u00f3n para productos farmac\u00e9uticos est\u00e9riles seg\u00fan la OMS?**\n   - Esta pregunta busca detalles sobre los m\u00e9todos de esterilizaci\u00f3n mencionados en el documento, que son cruciales para la producci\u00f3n segura de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 cambios editoriales se han propuesto en las directrices de buenas pr\u00e1cticas de fabricaci\u00f3n y cu\u00e1l es su prop\u00f3sito?**\n   - Esta pregunta se centra en entender las modificaciones realizadas y su objetivo de facilitar la comprensi\u00f3n de las directrices.\n\n3. **\u00bfQu\u00e9 tecnolog\u00edas se mencionan en el documento para el procesamiento as\u00e9ptico y c\u00f3mo se diferencian entre s\u00ed?**\n   - Esta pregunta busca informaci\u00f3n sobre las tecnolog\u00edas espec\u00edficas, como la tecnolog\u00eda de aislamiento y la tecnolog\u00eda de blow/fill/seal, y sus diferencias en el contexto de la fabricaci\u00f3n est\u00e9ril.", "prev_section_summary": "### Resumen de temas clave y entidades\n\nLa secci\u00f3n \"Further reading\" del documento \"WHO - Technical Report Series 961\" proporciona una lista de recursos y gu\u00edas relevantes sobre la garant\u00eda de calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos. Los temas clave incluyen:\n\n1. **Garant\u00eda de Calidad**: Se destacan varias publicaciones de la Organizaci\u00f3n Mundial de la Salud (OMS) que abordan la calidad y las buenas pr\u00e1cticas en la producci\u00f3n farmac\u00e9utica.\n   - **Publicaciones de la OMS**:\n     - \"Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1\" (1997).\n     - \"Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2\" (2007).\n     - \"Guidelines on quality risk management\" (en preparaci\u00f3n, 2010).\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se mencionan gu\u00edas sobre BPF, incluyendo la publicaci\u00f3n de la Comisi\u00f3n Europea sobre productos medicinales.\n\n3. **Normas y Est\u00e1ndares**: Se hace referencia a est\u00e1ndares internacionales, como ISO 14644 para salas limpias y gu\u00edas de la ISPE sobre ingenier\u00eda farmac\u00e9utica.\n\n4. **Filtraci\u00f3n y Ventilaci\u00f3n**: Se incluye un recurso sobre filtraci\u00f3n de alta eficiencia y gu\u00edas de ingenier\u00eda de ventilaci\u00f3n de ASHRAE.\n\n5. **Gesti\u00f3n de Riesgos**: Se menciona el documento ICH Q9 sobre gesti\u00f3n de riesgos de calidad.\n\n### Entidades mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Publicaciones sobre garant\u00eda de calidad y buenas pr\u00e1cticas.\n- **ASHRAE**: Gu\u00edas sobre aplicaciones y sistemas HVAC.\n- **Comisi\u00f3n Europea**: Normativas sobre productos medicinales.\n- **International Society for Pharmaceutical Engineering (ISPE)**: Gu\u00edas sobre ingenier\u00eda farmac\u00e9utica.\n- **International Organization for Standardization (ISO)**: Est\u00e1ndares internacionales.\n- **Pharmaceutical Inspectorate Convention/Pharmaceutical Inspection Co-operation Scheme**: Gu\u00edas sobre buenas pr\u00e1cticas de fabricaci\u00f3n.\n\nEste resumen destaca la importancia de la calidad y las buenas pr\u00e1cticas en la industria farmac\u00e9utica, as\u00ed como los recursos disponibles para profesionales en el campo.", "excerpt_keywords": "Keywords: WHO, good manufacturing practices, sterile pharmaceutical products, sterilization, quality control"}}, "5e431ff8-1ca7-4e34-8aff-e1a70d84643c": {"node_ids": ["e2acf45d-b1a6-4000-bc5e-6b7104991009"], "metadata": {"page_label": "274", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. General considerations\n\n1.1 The production of sterile preparations should be carried out in clean areas, entry to which should be through airlocks for personnel and/or for equipment and materials. Clean areas should be maintained to an appropriate standard of cleanliness and supplied with air that has passed through filters of the required efficiency.\n\n1.2 The various operations of component preparation (such as those involving containers and closures), product preparation, filling and sterilization should be carried out in separate areas within the clean area. These areas are classified into four grades (see section 4).\n\n1.3 Manufacturing operations are divided here into two categories:\n\n- first, those where the product is terminally sterilized; and\n- second, those which are conducted aseptically at some or all stages.\n\n# 2. Quality control\n\n2.1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned.\n\n2.2 Samples taken for sterility testing should be representative of the whole of the batch but should, in particular, include samples taken from parts of the batch considered to be most at risk of contamination, for example:\n\n- for products that have been filled aseptically, samples should include containers filled at the beginning and end of the batch and after any significant interruption of work;\n- for products that have been heat sterilized in their final containers, consideration should be given to taking samples from that part of the load that is potentially the coolest.\n\n2.3 The sterility of the finished product is assured by validation of the sterilization cycle in the case of terminally sterilized products, and by \u201cmedia simulation\u201d or \u201cmedia fill\u201d runs for aseptically processed products. Batch-processing records and, in the case of aseptic processing, environmental quality records, should be examined in conjunction with the results of the sterility tests. The sterility test procedure should be validated for a given product. Pharmacopoeial methods should be used for the validation and performance of the sterility test. In those cases where parametric release has been authorized in place of sterility testing special attention should be paid to the validation and the monitoring of the entire manufacturing process.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Producci\u00f3n de Preparaciones Est\u00e9riles**: La producci\u00f3n de productos est\u00e9riles debe realizarse en \u00e1reas limpias que cumplan con est\u00e1ndares de limpieza espec\u00edficos y que est\u00e9n equipadas con sistemas de filtraci\u00f3n de aire. Las operaciones de preparaci\u00f3n de componentes, productos, llenado y esterilizaci\u00f3n deben realizarse en \u00e1reas separadas, clasificadas en cuatro grados.\n\n2. **Control de Calidad**: El control de la esterilidad de los productos terminados se basa en una serie de medidas, siendo la prueba de esterilidad la \u00faltima. Esta prueba debe ser validada y los muestreos deben ser representativos del lote, prestando especial atenci\u00f3n a las partes m\u00e1s susceptibles a la contaminaci\u00f3n. La validaci\u00f3n del ciclo de esterilizaci\u00f3n y los registros de procesamiento son esenciales para asegurar la esterilidad.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios para clasificar las \u00e1reas dentro de la producci\u00f3n de preparaciones est\u00e9riles?**\n   - Este contexto menciona que las \u00e1reas se clasifican en cuatro grados, pero no detalla los criterios espec\u00edficos para cada grado.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para validar la prueba de esterilidad en productos que han sido procesados asepticamente?**\n   - Aunque se menciona que la prueba de esterilidad debe ser validada, no se especifican los pasos o m\u00e9todos exactos que deben seguirse para la validaci\u00f3n en el caso de productos procesados asepticamente.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al tomar muestras para la prueba de esterilidad de productos que han sido llenados asepticamente?**\n   - El contexto proporciona ejemplos de c\u00f3mo tomar muestras, pero no detalla las consideraciones adicionales que podr\u00edan influir en la selecci\u00f3n de muestras para asegurar la representatividad y minimizar el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Tema Principal:** Buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para productos farmac\u00e9uticos est\u00e9riles.\n\n**Contexto:**\n- El documento es un anexo del Informe T\u00e9cnico de la OMS que presenta directrices sobre GMP en el contexto del Programa de Precalificaci\u00f3n de Medicamentos de la OMS.\n- Se han realizado modificaciones editoriales para facilitar la lectura y comprensi\u00f3n de las directrices.\n\n**Secciones Clave:**\n1. **Consideraciones Generales**\n2. **Control de Calidad**\n3. **Sanidad**\n4. **Fabricaci\u00f3n de Preparaciones Est\u00e9riles**\n5. **Esterilizaci\u00f3n**\n6. **Esterilizaci\u00f3n Terminal**\n7. **Procesamiento Aseptic y Esterilizaci\u00f3n por Filtraci\u00f3n**\n8. **Tecnolog\u00eda de Aislamiento**\n9. **Tecnolog\u00eda de Blow/Fill/Seal**\n10. **Personal**\n11. **Instalaciones**\n12. **Equipos**\n13. **Finalizaci\u00f3n de Productos Est\u00e9riles**\n\n**Referencias y Lecturas Adicionales:** Se menciona que hay referencias y lecturas adicionales disponibles, aunque no se detallan en el extracto.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Autoridad que establece las directrices.\n- **GMP (Buenas Pr\u00e1cticas de Fabricaci\u00f3n):** Conjunto de directrices para asegurar la calidad y seguridad en la producci\u00f3n de productos farmac\u00e9uticos.\n- **Programa de Precalificaci\u00f3n de Medicamentos:** Iniciativa de la OMS para evaluar la calidad de los medicamentos.\n\nEste resumen destaca los aspectos fundamentales del documento, incluyendo su prop\u00f3sito, estructura y las secciones que abordan temas cr\u00edticos para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.", "excerpt_keywords": "Keywords: sterile preparations, quality control, sterility testing, aseptic processing, manufacturing standards"}}, "48b051a2-6413-46c9-a232-bd916188f036": {"node_ids": ["7fde23c2-5965-4646-a4dd-be0439b874ef"], "metadata": {"page_label": "275", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4\n\nFor injectable products the water for injection and the intermediate, if appropriate, and finished products should be monitored for endotoxins, using an established pharmacopoeial method that has been validated for each type of product. For large-volume infusion solutions, such monitoring of water or intermediates should always be done, in addition to any tests required by an approved monograph for the finished product. When a sample fails a test, the cause of the failure should be investigated and necessary action should be taken. Alternative methods to those in the pharmacopoeias may be used if they are validated, justified and authorized.\n\n2.5 The use of rapid microbiological methods to replace the traditional microbiological methods, and to obtain earlier results on the microbiological quality of, for example, water, the environment or bioburden, could be considered if appropriately validated and if a comparative assessment of the proposed rapid method is performed against the pharmacopoeial method.\n\n# 3. Sanitation\n\n3.1 The sanitation of clean areas is particularly important. They should be cleaned frequently and thoroughly in accordance with an approved written programme. Where disinfectants are used, more than one type should be employed. Monitoring should be regularly undertaken to detect contamination or the presence of an organism against which the cleaning procedure is ineffective. Interactions between different cleaning materials should be validated. Appropriate cleaning validation should be carried out to ensure disinfectant residuals can be detected and are removed by the cleaning process.\n\n3.2 Disinfectants and detergents should be monitored for microbial contamination; dilutions should be kept in previously cleaned containers and should only be stored for defined periods unless sterilized. Disinfectants and detergents used in Grade A and B areas should be sterile before use.\n\n3.3 A disinfectant programme should also include a sporicidal agent since many common disinfectants are ineffective against spores. The effectiveness of cleaning and disinfectant procedures should be demonstrated.\n\n3.4 Fumigation of clean areas may be useful for reducing microbial contamination in inaccessible places.\n\n# 4. Manufacture of sterile preparations\n\n4.1 Clean areas for the manufacture of sterile products are classified according to the required characteristics of the environment. Each manufacturing operation requires an appropriate level of environmental", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen de Nivel Superior del Contexto\n\nEl documento de la OMS aborda las directrices para la fabricaci\u00f3n de productos inyectables y la importancia de la calidad microbiol\u00f3gica y la sanitizaci\u00f3n en \u00e1reas limpias. Se enfatiza la necesidad de monitorear el agua para inyecci\u00f3n y los productos intermedios y terminados para endotoxinas, as\u00ed como la implementaci\u00f3n de m\u00e9todos microbiol\u00f3gicos r\u00e1pidos, siempre que est\u00e9n validados. Adem\u00e1s, se discuten las pr\u00e1cticas de limpieza y desinfecci\u00f3n, incluyendo el uso de m\u00faltiples desinfectantes, la validaci\u00f3n de interacciones entre productos de limpieza y la necesidad de un programa de desinfecci\u00f3n que incluya agentes esporicidas. Finalmente, se menciona la clasificaci\u00f3n de \u00e1reas limpias seg\u00fan las caracter\u00edsticas ambientales requeridas para la fabricaci\u00f3n de productos est\u00e9riles.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 acciones deben tomarse si una muestra de agua para inyecci\u00f3n falla en la prueba de endotoxinas?**\n   - La causa de la falla debe ser investigada y se deben tomar las acciones necesarias para corregir el problema.\n\n2. **\u00bfPor qu\u00e9 es importante utilizar m\u00e1s de un tipo de desinfectante en las \u00e1reas limpias?**\n   - Es importante porque diferentes desinfectantes pueden ser efectivos contra diferentes tipos de microorganismos, y el uso de m\u00faltiples desinfectantes ayuda a asegurar una limpieza m\u00e1s completa y efectiva.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al utilizar m\u00e9todos microbiol\u00f3gicos r\u00e1pidos en lugar de m\u00e9todos tradicionales?**\n   - Los m\u00e9todos microbiol\u00f3gicos r\u00e1pidos deben ser apropiadamente validados y se debe realizar una evaluaci\u00f3n comparativa con el m\u00e9todo farmacopoeial para asegurar su eficacia y confiabilidad en la obtenci\u00f3n de resultados microbiol\u00f3gicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### 1. Producci\u00f3n de Preparaciones Est\u00e9riles\n- **\u00c1reas Limpias**: La producci\u00f3n debe realizarse en \u00e1reas limpias con acceso a trav\u00e9s de airlocks. Estas \u00e1reas deben mantener un est\u00e1ndar de limpieza y contar con sistemas de filtraci\u00f3n de aire.\n- **Clasificaci\u00f3n de \u00c1reas**: Las operaciones de preparaci\u00f3n de componentes, productos, llenado y esterilizaci\u00f3n se realizan en \u00e1reas separadas, clasificadas en cuatro grados.\n- **Categor\u00edas de Operaciones**: Se dividen en dos tipos: \n  - Productos que son esterilizados terminalmente.\n  - Productos procesados asepticamente en alguna o todas las etapas.\n\n#### 2. Control de Calidad\n- **Prueba de Esterilidad**: Considerada como la \u00faltima medida de control para asegurar la esterilidad. Debe ser validada para los productos espec\u00edficos.\n- **Muestreo para Pruebas de Esterilidad**: Las muestras deben ser representativas del lote, incluyendo partes con mayor riesgo de contaminaci\u00f3n. Ejemplos incluyen:\n  - Para productos llenados asepticamente: muestras de contenedores al inicio y al final del lote, y despu\u00e9s de interrupciones significativas.\n  - Para productos esterilizados por calor: considerar muestras de la parte m\u00e1s fr\u00eda del lote.\n- **Validaci\u00f3n del Ciclo de Esterilizaci\u00f3n**: Es esencial para productos esterilizados terminalmente, y se utilizan simulaciones de medios para productos procesados asepticamente. \n- **Registros de Procesamiento**: Deben ser revisados junto con los resultados de las pruebas de esterilidad. Se deben seguir m\u00e9todos farmacopoeiales para la validaci\u00f3n y ejecuci\u00f3n de la prueba de esterilidad.\n\n### Entidades Clave\n- **\u00c1reas Limpias**: Espacios controlados para la producci\u00f3n est\u00e9ril.\n- **Airlocks**: Sistemas de entrada para mantener la limpieza.\n- **Grados de Clasificaci\u00f3n**: Cuatro niveles de \u00e1reas limpias.\n- **Prueba de Esterilidad**: M\u00e9todo para asegurar la ausencia de microorganismos en productos terminados.\n- **Muestreo**: Proceso de recolecci\u00f3n de muestras representativas para pruebas.\n- **Validaci\u00f3n**: Proceso de asegurar que los m\u00e9todos y ciclos de esterilizaci\u00f3n son efectivos. \n\nEste resumen destaca los aspectos fundamentales de la producci\u00f3n de preparaciones est\u00e9riles y el control de calidad, as\u00ed como las entidades relevantes en el contexto de la normativa de la OMS.", "excerpt_keywords": "Keywords: injectable products, endotoxins, sanitation, microbiological methods, sterile preparations"}}, "6d0d0a6f-50b6-4c62-83f6-434fff41b09d": {"node_ids": ["ff43af36-43ed-4497-85b2-c0c5bcba89c3"], "metadata": {"page_label": "276", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "cleanliness in the operational state to minimize the risks of particulate or microbial contamination of the product or materials being handled.\n\n4.2 Detailed information on methods for determining the microbiological and particulate cleanliness of air, surfaces, etc., is not given in these guidelines.\n\nISO 14644-1 (2) should be used for classification of cleanliness according to concentration of airborne particles (determination of number of sample locations, calculation of sample size and evaluation of classification from the data obtained). Table 1 should also be used to define the levels to be used as the basis for monitoring clean areas for airborne particles.\n\n4.3 For the manufacture of sterile pharmaceutical preparations, four grades of clean areas are distinguished as follows:\n\n- **Grade A**: The local zone for high-risk operations, e.g. filling and making aseptic connections. Normally such conditions are achieved by using a unidirectional airflow workstation. Unidirectional airflow systems should provide a homogeneous air speed of 0.36\u20130.54 m/s (guidance value) at a defined test position 15\u201330 cm below the terminal filter or air distributor system. The velocity at working level should not be less than 0.36 m/s. The uniformity and effectiveness of the unidirectional airflow should be demonstrated by undertaking airflow visualization tests.\n\n- **Grade B**: In aseptic preparation and filling, this is the background environment for the Grade A zone.\n\n- **Grades C and D**: Clean areas for carrying out less critical stages in the manufacture of sterile products or carrying out activities during which the product is not directly exposed (i.e. aseptic connection with aseptic connectors and operations in a closed system).\n\nA unidirectional airflow and lower velocities may be used in closed isolators and glove boxes.\n\n4.4 In order to reach the B, C and D air grades the number of air changes should be appropriate for the size of the room and the equipment and personnel present in it.\n\n4.5 High-efficiency particulate air (HEPA) filters should be subjected to an installed filter leakage test in accordance with ISO 14644-3 (3) at a recommended interval of every 6 months, but not exceeding 12 months. The purpose of performing regular leak tests is to ensure the filter media, filter frame and filter seal are free from leaks. The aerosol selected for HEPA leak testing should not support microbial growth and should be composed of a sufficient number or mass of particles. HEPA filter patching is allowed at the filter manufacturer and in situ operation provided that the patch sizes and procedures follow the recommendations of ISO 1822-4 (4).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la limpieza en \u00e1reas operativas para minimizar la contaminaci\u00f3n microbiol\u00f3gica y de part\u00edculas en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles. Se definen cuatro grados de \u00e1reas limpias (A, B, C y D) seg\u00fan el riesgo de contaminaci\u00f3n, y se establecen directrices sobre el flujo de aire, la velocidad del aire, y la frecuencia de pruebas de fugas en filtros HEPA. Se enfatiza la importancia de mantener condiciones controladas para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que debe cumplir un sistema de flujo de aire unidireccional para ser considerado adecuado en un \u00e1rea de grado A?**\n   - Respuesta: Un sistema de flujo de aire unidireccional debe proporcionar una velocidad de aire homog\u00e9nea de 0.36\u20130.54 m/s a una posici\u00f3n de prueba definida de 15\u201330 cm por debajo del filtro terminal o sistema distribuidor de aire. La velocidad en el nivel de trabajo no debe ser inferior a 0.36 m/s, y se deben realizar pruebas de visualizaci\u00f3n del flujo de aire para demostrar su uniformidad y efectividad.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar para determinar el n\u00famero de cambios de aire necesarios en \u00e1reas de grado B, C y D?**\n   - Respuesta: El n\u00famero de cambios de aire debe ser apropiado para el tama\u00f1o de la habitaci\u00f3n, as\u00ed como para el equipo y el personal presentes en ella. Esto asegura que se mantengan las condiciones de limpieza necesarias para la fabricaci\u00f3n de productos est\u00e9riles.\n\n3. **\u00bfCon qu\u00e9 frecuencia se deben realizar las pruebas de fugas en los filtros HEPA y cu\u00e1l es el objetivo de estas pruebas?**\n   - Respuesta: Las pruebas de fugas en los filtros HEPA deben realizarse cada 6 meses, pero no deben exceder los 12 meses. El objetivo de estas pruebas es asegurar que el medio del filtro, el marco del filtro y el sello del filtro est\u00e9n libres de fugas, lo que es crucial para mantener la eficacia del sistema de filtraci\u00f3n y la calidad del aire en las \u00e1reas limpias.", "prev_section_summary": "### Temas Clave\n\n1. **Monitoreo de Endotoxinas**: Es esencial monitorear el agua para inyecci\u00f3n y los productos intermedios y terminados para endotoxinas, utilizando m\u00e9todos farmacopoeiales validados. En caso de que una muestra falle, se debe investigar la causa y tomar las acciones necesarias.\n\n2. **M\u00e9todos Microbiol\u00f3gicos R\u00e1pidos**: Se considera el uso de m\u00e9todos microbiol\u00f3gicos r\u00e1pidos como alternativa a los m\u00e9todos tradicionales, siempre que est\u00e9n validados y se realice una evaluaci\u00f3n comparativa con los m\u00e9todos farmacopoeiales.\n\n3. **Sanitizaci\u00f3n de \u00c1reas Limpias**: La limpieza y desinfecci\u00f3n de \u00e1reas limpias es crucial. Se deben seguir programas de limpieza aprobados, utilizar m\u00faltiples tipos de desinfectantes y validar las interacciones entre productos de limpieza.\n\n4. **Contaminaci\u00f3n Microbiana de Desinfectantes**: Los desinfectantes y detergentes deben ser monitoreados para detectar contaminaci\u00f3n microbiana y deben ser est\u00e9riles antes de su uso en \u00e1reas de Grado A y B.\n\n5. **Agentes Esporicidas**: Un programa de desinfecci\u00f3n debe incluir agentes esporicidas, ya que muchos desinfectantes comunes son ineficaces contra esporas.\n\n6. **Fumigaci\u00f3n**: La fumigaci\u00f3n puede ser \u00fatil para reducir la contaminaci\u00f3n microbiana en lugares de dif\u00edcil acceso.\n\n7. **Clasificaci\u00f3n de \u00c1reas Limpias**: Las \u00e1reas limpias para la fabricaci\u00f3n de productos est\u00e9riles se clasifican seg\u00fan las caracter\u00edsticas ambientales requeridas para cada operaci\u00f3n de fabricaci\u00f3n.\n\n### Entidades\n\n- **Productos Inyectables**: Incluyen agua para inyecci\u00f3n, productos intermedios y productos terminados.\n- **M\u00e9todos Microbiol\u00f3gicos**: M\u00e9todos tradicionales y r\u00e1pidos para evaluar la calidad microbiol\u00f3gica.\n- **Desinfectantes y Detergentes**: Productos utilizados para la limpieza y desinfecci\u00f3n de \u00e1reas limpias.\n- **Agentes Esporicidas**: Tipo espec\u00edfico de desinfectante efectivo contra esporas.\n- **\u00c1reas Limpias**: Espacios clasificados seg\u00fan su nivel de limpieza y requisitos ambientales para la fabricaci\u00f3n de productos est\u00e9riles.", "excerpt_keywords": "Keywords: cleanliness, sterile pharmaceutical, unidirectional airflow, HEPA filters, contamination control"}}, "5b3130d4-c8aa-482d-b53e-837029e266d0": {"node_ids": ["ee393476-b032-4a7f-b1b4-3e028c246730"], "metadata": {"page_label": "277", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean room and clean-air device classification\n\n4.6 Clean rooms and clean-air devices should be classified in accordance with ISO 14644 (2\u20133, 5\u20137).\n\n4.6.1 Classification should be clearly differentiated from operational process environmental monitoring. The maximum permitted airborne particle concentration for each grade is given in Table 1.\n\n**Table 1: Maximum permitted airborne particle concentration**\n\n| Grade\\<br/>0.5 \u00b5m | At rest\\<br/>5.0 \u00b5m | At rest\\<br/>In operation\\<br/>0.5 \u00b5m | In operation\\<br/>5.0 \u00b5m | |\n| - | - | - | - | - |\n| A | 3 520 | 20 | 3 520 | 20 |\n| B | 3 520 | 29 | 352 000 | 2 900 |\n| C | 352 000 | 2 900 | 3 520 000 | 29 000 |\n| D | 3 520 000 | 29 000 | Not defined | Not defined |\n\n\n<sup>a</sup> The \"at rest\" state is the condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present.\n\n<sup>b</sup> The \"in operation\" state is the condition where the installation is functioning in the defined operating mode and the specified number of personnel is present. The areas and their associated environmental control systems should be designed to achieve both the \"at rest\" and \"in operation\" states.\n\n4.6.2 For classification purposes in Grade A zones, a minimum sample volume of 1 m\u00b3 should be taken per sample location. Referring to Table 1, for Grade A the airborne particle classification is ISO 4.8 dictated by the limit for particles \u2265 5.0 \u00b5m. For Grade B (at rest) the airborne particle classification is ISO 5 for both particle sizes considered. For Grade C (at rest and in operation) the airborne particle classification is ISO 7 and ISO 8, respectively. For Grade D (at rest) the airborne particle classification is ISO 8. For classification purposes ISO 14644-1 (2) methodology defines both the minimum number of sample locations and the sample size based on the class limit of the largest particle size considered and the method of evaluation of the data collected. The sample volume should be determined according to ISO 14644-1 (2) clause B.4.2. However, for lower grades (Grade C in operation and Grade D at rest) the sample volume per location should be at least 2 litres and the sample time per location should be not less than 1 minute.\n\n4.6.3 Portable particle counters with a short length of sample tubing should be used for classification purposes to avoid the loss of particles \u2265 5.0 \u00b5m. Isokinetic sample heads should be used in unidirectional airflow systems.\n\n4.6.4 \u201cIn operation\u201d classification may be demonstrated during normal operations, simulated operations or during media fills as worst-case simulation.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento se centra en la clasificaci\u00f3n de salas limpias y dispositivos de aire limpio seg\u00fan la norma ISO 14644. Se detalla la diferencia entre la clasificaci\u00f3n y el monitoreo ambiental operativo, y se proporciona una tabla con las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D). Adem\u00e1s, se especifican los requisitos de muestreo y las condiciones para la clasificaci\u00f3n \"en reposo\" y \"en operaci\u00f3n\".\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para el grado A en estado \"en operaci\u00f3n\" y \"en reposo\"?**\n   - Respuesta: Para el grado A, la concentraci\u00f3n m\u00e1xima permitida es de 3,520 part\u00edculas de 0.5 \u00b5m y 20 part\u00edculas de 5.0 \u00b5m \"en reposo\", y se mantiene la misma concentraci\u00f3n de 3,520 part\u00edculas de 0.5 \u00b5m y 20 part\u00edculas de 5.0 \u00b5m \"en operaci\u00f3n\".\n\n2. **\u00bfQu\u00e9 volumen m\u00ednimo de muestra se debe tomar en las zonas de grado A para la clasificaci\u00f3n y cu\u00e1l es la clasificaci\u00f3n de part\u00edculas en el aire correspondiente?**\n   - Respuesta: En las zonas de grado A, se debe tomar un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra, y la clasificaci\u00f3n de part\u00edculas en el aire es ISO 4.8, dictada por el l\u00edmite para part\u00edculas \u2265 5.0 \u00b5m.\n\n3. **\u00bfQu\u00e9 tipo de equipos se recomienda utilizar para la clasificaci\u00f3n de salas limpias y por qu\u00e9?**\n   - Respuesta: Se recomienda utilizar contadores de part\u00edculas port\u00e1tiles con una longitud corta de tuber\u00eda de muestreo para evitar la p\u00e9rdida de part\u00edculas \u2265 5.0 \u00b5m, y se deben usar cabezales de muestreo isocin\u00e9tico en sistemas de flujo de aire unidireccional.", "prev_section_summary": "### Temas Clave\n\n1. **Limpieza en \u00c1reas Operativas**: Se enfatiza la importancia de mantener la limpieza para minimizar la contaminaci\u00f3n microbiol\u00f3gica y de part\u00edculas en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n2. **Clasificaci\u00f3n de \u00c1reas Limpias**: Se definen cuatro grados de \u00e1reas limpias (A, B, C y D) seg\u00fan el riesgo de contaminaci\u00f3n, con especificaciones sobre el flujo de aire y la velocidad del aire.\n\n3. **Flujo de Aire Unidireccional**: Para el \u00e1rea de grado A, se requiere un sistema de flujo de aire unidireccional que mantenga una velocidad homog\u00e9nea de 0.36\u20130.54 m/s.\n\n4. **Cambios de Aire**: Se establece que el n\u00famero de cambios de aire en las \u00e1reas de grado B, C y D debe ser adecuado al tama\u00f1o de la habitaci\u00f3n y a la cantidad de equipo y personal presente.\n\n5. **Filtros HEPA**: Se requiere realizar pruebas de fugas en los filtros HEPA cada 6 a 12 meses para asegurar su eficacia y evitar contaminaciones.\n\n### Entidades\n\n- **ISO 14644-1**: Norma utilizada para la clasificaci\u00f3n de limpieza seg\u00fan la concentraci\u00f3n de part\u00edculas en el aire.\n- **ISO 14644-3**: Norma que establece los procedimientos para las pruebas de fugas en filtros HEPA.\n- **ISO 1822-4**: Norma que proporciona recomendaciones sobre el parcheo de filtros HEPA.\n- **Grados de Limpieza**: Clasificaci\u00f3n de \u00e1reas limpias en Grado A, B, C y D.\n- **Filtros HEPA**: Filtros de aire de alta eficiencia que son cruciales para mantener la calidad del aire en \u00e1reas limpias.\n\n### Resumen General\nEl documento de la OMS establece directrices sobre la limpieza en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, definiendo grados de limpieza y especificaciones t\u00e9cnicas para asegurar un ambiente controlado y libre de contaminantes. Se subraya la importancia de los sistemas de flujo de aire, la frecuencia de pruebas de filtros HEPA y la adecuada gesti\u00f3n de cambios de aire en las \u00e1reas de producci\u00f3n.", "excerpt_keywords": "Keywords: clean rooms, ISO 14644, airborne particle concentration, classification, environmental monitoring"}}, "f9ab6a15-e7dd-46f1-9454-ec9047e93082": {"node_ids": ["c9de14c5-51f9-446d-9095-0e214338c624"], "metadata": {"page_label": "278", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Clean Room and Clean-Air Device Monitoring\n\n4.7 Clean rooms and clean-air devices should be routinely monitored while in operation. The monitoring locations should be based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean-air devices.\n\n## 4.7.1\n\nFor Grade A zones, particle monitoring should be undertaken for the full duration of critical processing, including equipment assembly, except where justified by contaminants in the process that would damage the particle counter or present a hazard, for example, live organisms and radiological hazards. In such cases, monitoring during routine equipment set-up operations should be undertaken before exposure to the risk. Monitoring during simulated operations should also be performed. The Grade A zone should be monitored at a frequency and sample size such that all interventions, transient events, and any system deterioration would be captured and alarms triggered if alert limits are exceeded. It is accepted that it may not always be possible to demonstrate low levels of \u2265 5.0 \u00b5m particles at the point of fill when filling is in progress, due to the generation of particles or droplets from the product itself.\n\n## 4.7.2\n\nIt is recommended that a similar system be used for Grade B zones, although the sample frequency may be decreased. The importance of the particle monitoring system should be determined by the effectiveness of the segregation between the adjacent Grade A and B zones. The Grade B zone should be monitored at a frequency and with a sample size such that changes in levels of contamination and any deterioration of the system would be captured and alarms triggered if alert limits are exceeded.\n\n## 4.7.3\n\nAirborne particle monitoring systems may consist of independent particle counters; a network of sequentially accessed sampling points connected by manifold to a single particle counter; or multiple small particle counters located near monitoring points and networked to a data acquisition system. Combinations of systems can also be used. The system selected should be appropriate for the particle size considered.\n\nWhere remote sampling systems are used, the length of tubing and the radii of any bends in the tubing should be considered in the context of particle losses in the tubing. The selection of the monitoring system should take account of any risk presented by the materials used in the manufacturing operation, for example, those involving live organisms or radiopharmaceuticals.\n\n## 4.7.4\n\nThe sizes of samples taken for monitoring purposes using automated systems will usually be a function of the sampling rate of the system used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS detalla las pautas para el monitoreo de salas limpias y dispositivos de aire limpio, enfatizando la importancia de realizar un an\u00e1lisis de riesgo formal para determinar los puntos de monitoreo. Se especifican diferentes protocolos para zonas de Grado A y Grado B, incluyendo la frecuencia de monitoreo y el tama\u00f1o de las muestras. Adem\u00e1s, se discuten los sistemas de monitoreo de part\u00edculas en el aire y las consideraciones t\u00e9cnicas para su implementaci\u00f3n, como la longitud de los tubos y el riesgo asociado con los materiales utilizados en las operaciones de fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 justificaciones se pueden considerar para no realizar el monitoreo de part\u00edculas en zonas de Grado A durante la configuraci\u00f3n del equipo?**\n   - Respuesta: El monitoreo puede no realizarse si hay contaminantes en el proceso que podr\u00edan da\u00f1ar el contador de part\u00edculas o presentar un riesgo, como organismos vivos o peligros radiol\u00f3gicos. En tales casos, se debe realizar el monitoreo antes de la exposici\u00f3n al riesgo.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia de monitoreo en zonas de Grado B y qu\u00e9 factores influyen en esta decisi\u00f3n?**\n   - Respuesta: La frecuencia de monitoreo en zonas de Grado B puede ser menor que en Grado A, y su importancia se determina por la efectividad de la segregaci\u00f3n entre las zonas adyacentes de Grado A y B. Se debe monitorear a una frecuencia y tama\u00f1o de muestra que capture cambios en los niveles de contaminaci\u00f3n y cualquier deterioro del sistema.\n\n3. **\u00bfQu\u00e9 consideraciones t\u00e9cnicas deben tenerse en cuenta al seleccionar un sistema de monitoreo de part\u00edculas en el aire?**\n   - Respuesta: Al seleccionar un sistema de monitoreo, se deben considerar la longitud de los tubos y los radios de cualquier curva en los tubos en relaci\u00f3n con las p\u00e9rdidas de part\u00edculas. Adem\u00e1s, se debe tener en cuenta el riesgo presentado por los materiales utilizados en la operaci\u00f3n de fabricaci\u00f3n, como aquellos que involucran organismos vivos o productos radiopharmaceuticals.", "prev_section_summary": "### Resumen de los temas clave y entidades de la secci\u00f3n:\n\n1. **Clasificaci\u00f3n de Salas Limpias y Dispositivos de Aire Limpio**:\n   - Las salas limpias y los dispositivos de aire limpio deben clasificarse de acuerdo con la norma ISO 14644.\n\n2. **Diferenciaci\u00f3n de Clasificaci\u00f3n y Monitoreo**:\n   - La clasificaci\u00f3n se distingue claramente del monitoreo ambiental operativo.\n\n3. **Concentraciones M\u00e1ximas Permitidas**:\n   - Se proporciona una tabla (Tabla 1) que detalla las concentraciones m\u00e1ximas permitidas de part\u00edculas en el aire para diferentes grados de limpieza (A, B, C y D) en condiciones \"en reposo\" y \"en operaci\u00f3n\".\n\n4. **Condiciones de Muestreo**:\n   - Para la clasificaci\u00f3n en zonas de grado A, se requiere un volumen m\u00ednimo de muestra de 1 m\u00b3 por ubicaci\u00f3n de muestra.\n   - Se especifican las clasificaciones de part\u00edculas en el aire correspondientes a cada grado.\n\n5. **Equipos de Muestreo**:\n   - Se recomienda el uso de contadores de part\u00edculas port\u00e1tiles con tuber\u00edas de muestreo cortas para evitar la p\u00e9rdida de part\u00edculas.\n   - Se deben utilizar cabezales de muestreo isocin\u00e9tico en sistemas de flujo de aire unidireccional.\n\n6. **Condiciones de \"En Reposo\" y \"En Operaci\u00f3n\"**:\n   - Se definen las condiciones de \"en reposo\" (sin personal presente) y \"en operaci\u00f3n\" (con personal presente) para la clasificaci\u00f3n.\n\n7. **Normativa ISO**:\n   - Se hace referencia a la metodolog\u00eda de la norma ISO 14644-1 para determinar el n\u00famero m\u00ednimo de ubicaciones de muestreo y el tama\u00f1o de la muestra.\n\n### Entidades Clave:\n- **Norma ISO 14644**: Est\u00e1ndar para la clasificaci\u00f3n de salas limpias.\n- **Grados de Limpieza**: A, B, C, D.\n- **Concentraciones de Part\u00edculas**: L\u00edmites establecidos para part\u00edculas de 0.5 \u00b5m y 5.0 \u00b5m.\n- **Contadores de Part\u00edculas**: Equipos recomendados para la clasificaci\u00f3n.\n- **Condiciones de Muestreo**: \"En reposo\" y \"en operaci\u00f3n\". \n\nEste resumen abarca los aspectos fundamentales de la secci\u00f3n, destacando la importancia de la clasificaci\u00f3n adecuada y los requisitos t\u00e9cnicos necesarios para mantener la calidad del aire en entornos controlados.", "excerpt_keywords": "Keywords: clean rooms, particle monitoring, Grade A zones, risk analysis, airborne particle monitoring systems"}}, "49aff1be-42d8-41ca-8f5e-43dfc0e26c21": {"node_ids": ["e56d3bc0-bc8d-4073-8193-c4b5a007a624"], "metadata": {"page_label": "279", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "It is not necessary for the sample volume to be the same as that used for formal classification of clean rooms and clean-air devices.\n\n4.7.5 The airborne particle conditions given in Table 1 for the \u201cat rest\u201d state should be achieved in the absence of the operating personnel after a short \u201cclean-up\u201d or \u201crecovery\u201d period of about 15\u201320 minutes (guidance value), after completion of the operations. The particulate conditions given in Table 1 for Grade A \u201cin operation\u201d should be maintained in the zone immediately surrounding the product whenever the product or open container is exposed to the environment. The \u201cclean-up\u201d or \u201crecovery\u201d test should demonstrate a change in particle concentration by a factor of 100 within the prescribed time (ISO 14644-3 clause B.12) (3).\n\n4.7.6 In order to demonstrate control of the cleanliness of the various clean areas during operation, they should be monitored for airborne particles and microbial contamination. In addition to \u201cat rest\u201d and \u201cin operation\u201d classification, airborne particles should be monitored periodically \u201cin operation\u201d at critical locations. The sampling plan need not be the same as that used for classification. Locations and sample sizes should be determined based on an assessment of the process and contamination risk.\n\n4.7.7 The monitoring of Grade C and D areas in operation should be performed in accordance with the principles of quality risk management. The requirements and alert/action limits will depend on the nature of the operations carried out, but the recommended \u201cclean-up period\u201d should be attained.\n\n4.7.8 Other characteristics such as temperature and relative humidity depend on the product and nature of the operations carried out. These parameters should not interfere with the defined cleanliness standard.\n\n4.7.9 Examples of operations to be carried out in the various grades are given in Table 2 (see also sections 4.12\u20134.20).\n\n**Table 2**\n\n**Examples of operations to be carried out in the various grades**\n\n| Grade | Examples of operations for terminally sterilized products (see sections 4.12\u20134.15) |\n| - | - |\n| A | Filling of products when unusually at risk |\n| C | Preparation of solutions when unusually at risk. Filling of products |\n| D | Preparation of solutions and components for subsequent filling |\n\n\n| Grade | Examples of operations for aseptic preparations (see sections 4.16\u20134.20) |\n| - | - |\n| A | Aseptic preparation and filling |\n| C | Preparation of solutions to be filtered |\n| D | Handling of components after washing |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Technical Report Series 961) aborda las condiciones de limpieza y monitoreo en \u00e1reas clasificadas como limpias, especialmente en relaci\u00f3n con la operaci\u00f3n de productos est\u00e9riles y preparaciones as\u00e9pticas. Se establecen directrices sobre c\u00f3mo lograr y mantener condiciones de part\u00edculas en el aire, as\u00ed como la importancia de un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" despu\u00e9s de las operaciones. Tambi\u00e9n se discuten los m\u00e9todos de monitoreo y los ejemplos de operaciones adecuadas para diferentes grados de limpieza.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" mencionado en el documento y cu\u00e1nto tiempo se recomienda?**\n   - El objetivo del per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" es alcanzar las condiciones de part\u00edculas en el aire especificadas para el estado \"en reposo\" en ausencia del personal operativo. Se recomienda un per\u00edodo de aproximadamente 15 a 20 minutos.\n\n2. **\u00bfQu\u00e9 factores deben considerarse al determinar los lugares y tama\u00f1os de muestra para el monitoreo de part\u00edculas en \u00e1reas limpias?**\n   - Los lugares y tama\u00f1os de muestra deben determinarse en funci\u00f3n de una evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n, lo que implica considerar la naturaleza de las operaciones realizadas.\n\n3. **\u00bfQu\u00e9 operaciones se recomiendan para el grado A en el contexto de productos est\u00e9riles y preparaciones as\u00e9pticas?**\n   - Para productos est\u00e9riles, se recomienda el llenado de productos cuando est\u00e1n en un riesgo inusualmente alto. Para preparaciones as\u00e9pticas, se recomienda la preparaci\u00f3n y llenado as\u00e9ptico.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo de Salas Limpias y Dispositivos de Aire Limpio**: Se enfatiza la necesidad de un monitoreo rutinario de las salas limpias y dispositivos de aire limpio durante su operaci\u00f3n, basado en un an\u00e1lisis de riesgo formal.\n\n2. **Zonas de Grado A y Grado B**: Se establecen protocolos espec\u00edficos para el monitoreo de part\u00edculas en zonas de Grado A y Grado B, incluyendo la duraci\u00f3n del monitoreo, la frecuencia y el tama\u00f1o de las muestras.\n\n3. **Contaminantes y Riesgos**: Se discuten las justificaciones para no realizar el monitoreo en ciertas situaciones, como la presencia de contaminantes que podr\u00edan da\u00f1ar los equipos de monitoreo o representar un riesgo.\n\n4. **Sistemas de Monitoreo de Part\u00edculas**: Se describen diferentes configuraciones de sistemas de monitoreo de part\u00edculas en el aire, as\u00ed como consideraciones t\u00e9cnicas como la longitud de los tubos y el riesgo asociado con los materiales utilizados en la fabricaci\u00f3n.\n\n5. **Tama\u00f1o de Muestras**: Se menciona que el tama\u00f1o de las muestras para el monitoreo automatizado depende de la tasa de muestreo del sistema utilizado.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las pautas.\n- **Salas Limpias**: Espacios controlados donde se minimiza la contaminaci\u00f3n.\n- **Dispositivos de Aire Limpio**: Equipos dise\u00f1ados para mantener la calidad del aire en entornos controlados.\n- **Zonas de Grado A y Grado B**: Clasificaciones que indican diferentes niveles de control de contaminaci\u00f3n.\n- **Contadores de Part\u00edculas**: Equipos utilizados para medir la cantidad de part\u00edculas en el aire.\n- **Organismos Vivos y Productos Radiopharmaceuticals**: Materiales que presentan riesgos espec\u00edficos en el contexto de monitoreo.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes y las entidades relevantes en la secci\u00f3n sobre el monitoreo de salas limpias y dispositivos de aire limpio.", "excerpt_keywords": "Keywords: clean rooms, airborne particles, monitoring, aseptic preparations, recovery period"}}, "762b4ae6-6973-4571-b9c7-5d6d99d0dd68": {"node_ids": ["d9274fd1-9dd6-4fcf-a291-b0050ff44d98"], "metadata": {"page_label": "280", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.8 \nTo control the microbiological cleanliness of Grades A\u2013D in operation, the clean areas should be monitored. Where aseptic operations are performed, monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates). Sampling methods used in operation should not interfere with zone protection. Results from monitoring should be considered when reviewing batch documentation for finished product release. Surfaces and personnel should be monitored after critical operations. Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitization.\n\n# 4.9 \nLevels of detection of microbial contamination should be established for the purpose of setting alert and action limits and for monitoring the trends in environmental cleanliness in the facility. Limits expressed in colony-forming units (CFU) for the microbiological monitoring of clean areas in operation are given in Table 3. The sampling methods and numerical values included in the table are not intended to represent specifications, but are for information only.\n\n**Table 3**\n\n### Recommended limits for microbial contamination<sup>a</sup>\n\n| Grade | Air sample (CFU/m) | Settle plates (diameter 90 mm) (CFU/4 hours) | Contact plates (diameter 55 mm) (CFU/plate) | Glove print (5 fingers) (CFU/glove) |\n| - | - | - | - | - |\n| A | < 1 | < 1 | < 1 | < 1 |\n| B | 10 | 5 | 5 | 5 |\n| C | 100 | 50 | 25 | \u2013 |\n| D | 200 | 100 | 50 | \u2013 |\n\n\nCFU, colony-forming units.  \n<sup>a</sup> These are average values.  \n<sup>b</sup> Individual settle plates may be exposed for less than 4 hours.\n\n# 4.10 \nAppropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If the action limits are exceeded or a trend is identified in the alert limits, investigation should be initiated and the appropriate corrective actions should be taken, as prescribed in the operating procedures.\n\n# 4.11 \nThe area grades as specified in sections 4.12 to 4.20 should be selected by the manufacturer on the basis of the nature of the process operations being performed and validation runs (e.g. aseptic media fills or others types of process simulations) are used to establish processing hold times and a maximum fill duration. The determination of an appropriate process area environment and a time limit should be based on the microbial contamination (bioburden) found.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para el control de la limpieza microbiol\u00f3gica en \u00e1reas clasificadas de A a D en operaciones de producci\u00f3n. Se enfatiza la importancia de monitorear frecuentemente estas \u00e1reas mediante m\u00e9todos como placas de asentamiento y muestreo de aire y superficies. Se definen l\u00edmites de detecci\u00f3n de contaminaci\u00f3n microbiana en unidades formadoras de colonias (CFU) y se recomienda establecer l\u00edmites de alerta y acci\u00f3n para la monitorizaci\u00f3n de la limpieza ambiental. Adem\u00e1s, se sugiere que los fabricantes seleccionen las clasificaciones de \u00e1rea bas\u00e1ndose en la naturaleza de las operaciones y la contaminaci\u00f3n microbiana encontrada.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 m\u00e9todos de muestreo se recomiendan para el monitoreo de la limpieza microbiol\u00f3gica en \u00e1reas de producci\u00f3n?**\n   - El documento menciona m\u00e9todos como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficies (por ejemplo, hisopos y placas de contacto).\n\n2. **\u00bfCu\u00e1les son los l\u00edmites recomendados para la contaminaci\u00f3n microbiana en las diferentes \u00e1reas clasificadas (A, B, C, D) seg\u00fan el documento?**\n   - Los l\u00edmites son los siguientes:\n     - **A:** < 1 CFU/m (aire), < 1 CFU/4 horas (placas de asentamiento), < 1 CFU/placa (placas de contacto), < 1 CFU/glove (guantes).\n     - **B:** 10 CFU/m, 5 CFU/4 horas, 5 CFU/placa, 5 CFU/glove.\n     - **C:** 100 CFU/m, 50 CFU/4 horas, 25 CFU/placa.\n     - **D:** 200 CFU/m, 100 CFU/4 horas, 50 CFU/placa.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se superan los l\u00edmites de acci\u00f3n establecidos para el monitoreo microbiol\u00f3gico?**\n   - Si se superan los l\u00edmites de acci\u00f3n o se identifica una tendencia en los l\u00edmites de alerta, se debe iniciar una investigaci\u00f3n y tomar las acciones correctivas apropiadas, seg\u00fan lo prescrito en los procedimientos operativos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n del documento de la OMS (Technical Report Series 961) se centra en las condiciones de limpieza y monitoreo en \u00e1reas clasificadas como limpias, especialmente en el contexto de productos est\u00e9riles y preparaciones as\u00e9pticas. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Condiciones de Part\u00edculas en el Aire**:\n   - Se establecen condiciones espec\u00edficas para el estado \"en reposo\" y \"en operaci\u00f3n\" de las \u00e1reas limpias.\n   - Se requiere un per\u00edodo de \"limpieza\" o \"recuperaci\u00f3n\" de 15 a 20 minutos despu\u00e9s de las operaciones.\n\n2. **Monitoreo de la Limpieza**:\n   - Es necesario monitorear las \u00e1reas limpias para part\u00edculas en el aire y contaminaci\u00f3n microbiana.\n   - Los planes de muestreo deben basarse en la evaluaci\u00f3n del proceso y el riesgo de contaminaci\u00f3n.\n\n3. **Clasificaci\u00f3n de \u00c1reas**:\n   - Se mencionan diferentes grados de limpieza (A, C, D) y las operaciones adecuadas para cada uno.\n   - Se enfatiza la importancia de mantener las condiciones de limpieza durante las operaciones.\n\n4. **Par\u00e1metros Adicionales**:\n   - Se discuten otros factores como la temperatura y la humedad relativa, que no deben interferir con los est\u00e1ndares de limpieza.\n\n5. **Ejemplos de Operaciones**:\n   - Se proporcionan ejemplos de operaciones espec\u00edficas para productos terminalmente esterilizados y preparaciones as\u00e9pticas seg\u00fan el grado de limpieza.\n\n#### Entidades Relevantes:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **ISO 14644-3**: Norma mencionada que se refiere a la clasificaci\u00f3n de la limpieza del aire.\n- **Grados de Limpieza**: A, C, D, que indican diferentes niveles de control de contaminaci\u00f3n.\n- **Operaciones**: Ejemplos incluyen el llenado de productos, preparaci\u00f3n de soluciones y manejo de componentes.\n\nEste resumen destaca la importancia de mantener condiciones controladas en \u00e1reas limpias y la necesidad de un monitoreo riguroso para asegurar la calidad y seguridad de los productos est\u00e9riles y las preparaciones as\u00e9pticas.", "excerpt_keywords": "Keywords: microbiological cleanliness, contamination limits, aseptic operations, environmental monitoring, clean areas"}}, "4900ee81-1cd4-4618-a0d2-7711a6325a19": {"node_ids": ["26adbbef-2876-4276-9a93-276724b3ad01"], "metadata": {"page_label": "281", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Terminally Sterilized Products\n\n4.12 Components and most products should be prepared in at least a Grade D environment to ensure low microbial bioburden and particulate counts prior to filtration and sterilization. Where the product is at unusual risk of microbial contamination (e.g., because it actively supports microbial growth, must be held for a long period before sterilization, or is necessarily processed mainly in open vessels), the preparation should generally be done in a Grade C environment.\n\n4.13 The filling of products for terminal sterilization should generally be done in at least a Grade C environment.\n\n4.14 Where the product is at unusual risk of contamination from the environment (e.g., because the filling operation is slow, the containers are wide-necked or are necessarily exposed for more than a few seconds before sealing), the filling should be done in a Grade A zone with at least a Grade C background.\n\n4.15 The preparation and filling of ointments, creams, suspensions and emulsions should generally be done in a Grade C environment before terminal sterilization.\n\n# Aseptic Preparation\n\n4.16 Components after washing should be handled in at least a Grade D environment. The handling of sterile starting materials and components, unless subjected to sterilization or filtration through a microorganism-retaining filter later in the process, should be undertaken in a Grade A environment with a Grade B background.\n\n4.17 The preparation of solutions which are to be sterile-filtered during the process should be undertaken in a Grade C environment (unless a closed system is used, in which case a Class D environment may be justifiable). If not sterile-filtered (therefore an aseptic manipulation) the preparation of materials and products should be undertaken in a Grade A environment with a Grade B background.\n\n4.18 The handling and filling of aseptically prepared products, as well as the handling of exposed sterile equipment, should be undertaken in a Grade A environment with a Grade B background.\n\n4.19 The transfer of partially closed containers, as used in freeze-drying, before stoppering is completed, should be undertaken either in a Grade A environment with a Grade B background or in sealed transfer trays in a Grade B environment.\n\n4.20 The preparation and filling of sterile ointments, creams, suspensions and emulsions should be undertaken in a Grade A environment with a Grade B background when the product is exposed and is not subsequently filtered.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las condiciones ambientales necesarias para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, tanto para la esterilizaci\u00f3n terminal como para la preparaci\u00f3n as\u00e9ptica. Se especifican diferentes \"grados\" de ambientes (A, B, C, D) que deben ser utilizados dependiendo del riesgo de contaminaci\u00f3n microbiana y la naturaleza del producto. Por ejemplo, los productos que est\u00e1n en riesgo inusual de contaminaci\u00f3n deben ser preparados en ambientes de mayor calidad (como el Grado C o A), mientras que otros productos pueden ser preparados en ambientes de menor calidad (como el Grado D).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que justifican el uso de un ambiente de Grado C en lugar de un ambiente de Grado D para la preparaci\u00f3n de productos?**\n   - Respuesta: Un ambiente de Grado C debe ser utilizado cuando el producto est\u00e1 en un riesgo inusual de contaminaci\u00f3n microbiana, como cuando apoya activamente el crecimiento microbiano, debe ser mantenido durante un largo per\u00edodo antes de la esterilizaci\u00f3n, o es procesado principalmente en recipientes abiertos.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse durante el llenado de productos que est\u00e1n en riesgo de contaminaci\u00f3n ambiental?**\n   - Respuesta: Para productos en riesgo de contaminaci\u00f3n ambiental, el llenado debe realizarse en una zona de Grado A con al menos un fondo de Grado C, especialmente si la operaci\u00f3n de llenado es lenta, los recipientes son de cuello ancho o est\u00e1n expuestos durante m\u00e1s de unos pocos segundos antes de sellarse.\n\n3. **\u00bfQu\u00e9 tipo de ambiente se recomienda para la preparaci\u00f3n y llenado de productos como ung\u00fcentos y emulsiones antes de la esterilizaci\u00f3n terminal?**\n   - Respuesta: La preparaci\u00f3n y el llenado de ung\u00fcentos, cremas, suspensiones y emulsiones deben realizarse generalmente en un ambiente de Grado C antes de la esterilizaci\u00f3n terminal.\n\n### Resumen de Nivel Superior\n\nEl documento establece directrices sobre los ambientes necesarios para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n microbiana. Se clasifican los ambientes en grados (A, B, C, D) y se proporcionan recomendaciones espec\u00edficas seg\u00fan el tipo de producto y el riesgo de contaminaci\u00f3n. Estas directrices son cruciales para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave:\n\n1. **Control de la Limpieza Microbiol\u00f3gica**: Se enfatiza la importancia de monitorear la limpieza microbiol\u00f3gica en \u00e1reas clasificadas de A a D durante las operaciones de producci\u00f3n.\n\n2. **M\u00e9todos de Monitoreo**: Se recomiendan m\u00e9todos de muestreo como placas de asentamiento, muestreo volum\u00e9trico de aire y muestreo de superficies (hisopos y placas de contacto) para asegurar la asepsia.\n\n3. **L\u00edmites de Contaminaci\u00f3n Microbiana**: Se establecen l\u00edmites de detecci\u00f3n de contaminaci\u00f3n microbiana expresados en unidades formadoras de colonias (CFU) para cada grado de \u00e1rea (A, B, C, D).\n\n4. **L\u00edmites de Alerta y Acci\u00f3n**: Se deben establecer l\u00edmites apropiados para alertar y tomar acciones correctivas si se superan los l\u00edmites de acci\u00f3n o se identifican tendencias preocupantes.\n\n5. **Selecci\u00f3n de Grados de \u00c1rea**: Los fabricantes deben seleccionar los grados de \u00e1rea bas\u00e1ndose en la naturaleza de las operaciones y la contaminaci\u00f3n microbiana encontrada, utilizando simulaciones de procesos para establecer tiempos de retenci\u00f3n y duraci\u00f3n m\u00e1xima de llenado.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de \u00c1rea**: Clasificaciones de limpieza microbiol\u00f3gica (A, B, C, D).\n- **M\u00e9todos de Muestreo**: Placas de asentamiento, muestreo de aire, hisopos, placas de contacto.\n- **Unidades Formadoras de Colonias (CFU)**: Unidad de medida para la contaminaci\u00f3n microbiana.\n- **L\u00edmites de Alerta y Acci\u00f3n**: Par\u00e1metros establecidos para la monitorizaci\u00f3n de la limpieza ambiental.\n- **Contaminaci\u00f3n Microbiana (Bioburden)**: Carga microbiana presente en el entorno de producci\u00f3n. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s relevantes del control de la limpieza microbiol\u00f3gica en entornos de producci\u00f3n, as\u00ed como las entidades involucradas en el proceso.", "excerpt_keywords": "Keywords: terminal sterilization, aseptic preparation, microbial contamination, Grade A environment, pharmaceutical products"}}, "f4ffe037-f0db-43c1-9870-d281aa2bd9da": {"node_ids": ["128aabad-5c09-487c-8166-3b44de5fcbd4"], "metadata": {"page_label": "282", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Processing\n\n4.21 Precautions to minimize contamination should be taken during all processing stages, including the stages before sterilization.\n\n4.22 In general, preparations containing live microorganisms should not be made, nor should containers be filled in areas used for the processing of other pharmaceutical products. However, if the manufacturer can demonstrate and validate effective containment and decontamination of the live microorganisms, the use of multiproduct facilities may be justifiable. Vaccines consisting of dead organisms or of bacterial extracts may be dispensed into containers in the same premises as other sterile pharmaceutical products, provided that the inactivation procedure has been properly validated.\n\nWhen multiproduct facilities are used to manufacture sterile preparations containing live microorganisms and other sterile pharmaceutical products, the manufacturer should demonstrate and validate the effective decontamination of the live microorganisms, in addition to precautions taken to minimize contamination.\n\n4.23 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill). Selection of the nutrient medium should be made based on dosage form of the product and selectivity, clarity, concentration and suitability for sterilization of the nutrient medium.\n\n4.24 The process simulation test should imitate as closely as possible the routine aseptic manufacturing steps except where the activity may lead to any potential microbial contamination.\n\n4.25 Process simulation tests should be performed as part of validation by running three consecutive satisfactory simulation tests. These tests should be repeated at defined intervals and after any significant modification to the heating, ventilation and air-conditioning (HVAC) system, equipment or process. Process simulation tests should incorporate activities and interventions known to occur during normal production as well as the worst-case situation. The process simulation tests should be representative of each shift and shift changeover to address any time-related and operational features.\n\n4.26 The number of containers used for media fills should be sufficient to enable a valid evaluation. For small batches the number of containers for media fills should at least equal the size of the product batch. The target should be zero growth and the following should apply:\n\n- When filling fewer than 5000 units, no contaminated units should be detected.\n- When filling 5000\u201310 000 units:\n  - One contaminated unit should result in an investigation, including consideration of a repeat media fill;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto se centra en las precauciones y procedimientos necesarios para minimizar la contaminaci\u00f3n durante el procesamiento de productos farmac\u00e9uticos, especialmente aquellos que contienen microorganismos vivos. Se enfatiza la importancia de la validaci\u00f3n de los procesos as\u00e9pticos, incluyendo pruebas de simulaci\u00f3n de procesos (media fill) que imitan los pasos de fabricaci\u00f3n as\u00e9ptica. Se establecen criterios espec\u00edficos para la evaluaci\u00f3n de la contaminaci\u00f3n en lotes peque\u00f1os y se menciona la necesidad de realizar pruebas de simulaci\u00f3n de manera regular y tras modificaciones significativas en el sistema de producci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios deben cumplirse para que un fabricante pueda justificar el uso de instalaciones multiproducto al procesar microorganismos vivos?**\n   - Respuesta: El fabricante debe demostrar y validar la contenci\u00f3n y decontaminaci\u00f3n efectivas de los microorganismos vivos, adem\u00e1s de tomar precauciones para minimizar la contaminaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los requisitos para la selecci\u00f3n del medio de cultivo utilizado en las pruebas de simulaci\u00f3n de procesos?**\n   - Respuesta: La selecci\u00f3n del medio de cultivo debe basarse en la forma de dosificaci\u00f3n del producto, as\u00ed como en la selectividad, claridad, concentraci\u00f3n y adecuaci\u00f3n para la esterilizaci\u00f3n del medio.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se detecta una unidad contaminada durante el llenado de entre 5000 y 10,000 unidades?**\n   - Respuesta: La detecci\u00f3n de una unidad contaminada debe resultar en una investigaci\u00f3n, que incluir\u00e1 la consideraci\u00f3n de repetir la prueba de media fill.", "prev_section_summary": "### Temas Clave\n\n1. **Ambientes de Preparaci\u00f3n**: Se especifican diferentes grados de ambientes (A, B, C, D) que deben ser utilizados para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, dependiendo del riesgo de contaminaci\u00f3n microbiana.\n\n2. **Esterilizaci\u00f3n Terminal**: \n   - Preparaci\u00f3n de componentes y productos en un ambiente de al menos Grado D.\n   - Uso de Grado C para productos con riesgo inusual de contaminaci\u00f3n.\n   - Llenado de productos en un ambiente de al menos Grado C, y en Grado A con fondo de Grado C para productos en alto riesgo de contaminaci\u00f3n ambiental.\n\n3. **Preparaci\u00f3n Aseptica**:\n   - Manejo de componentes lavados en un ambiente de al menos Grado D.\n   - Preparaci\u00f3n de soluciones que ser\u00e1n filtradas en un ambiente de Grado C, o Grado A con fondo de Grado B si no se filtran.\n   - Manejo y llenado de productos preparados asepticamente en un ambiente de Grado A con fondo de Grado B.\n\n4. **Transferencia de Contenedores**: Transferencia de contenedores parcialmente cerrados en ambientes controlados para evitar contaminaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Grados de Ambiente**: Clasificaci\u00f3n de ambientes (A, B, C, D) seg\u00fan el nivel de control de contaminaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen ung\u00fcentos, cremas, suspensiones y emulsiones que requieren condiciones espec\u00edficas de preparaci\u00f3n y llenado.\n- **Contaminaci\u00f3n Microbiana**: Riesgo asociado a la preparaci\u00f3n y llenado de productos que debe ser minimizado.\n\n### Resumen\n\nEl documento de la OMS establece directrices sobre las condiciones ambientales necesarias para la preparaci\u00f3n y llenado de productos farmac\u00e9uticos, enfatizando la importancia de minimizar la contaminaci\u00f3n microbiana. Se clasifican los ambientes en grados y se proporcionan recomendaciones espec\u00edficas seg\u00fan el tipo de producto y el riesgo de contaminaci\u00f3n, lo cual es crucial para garantizar la seguridad y eficacia de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: contamination, aseptic processing, validation, multiproduct facilities, media fill"}}, "4eed555b-950c-47f1-aba7-ac927a452ddb": {"node_ids": ["0e2ebebb-ea02-44ff-a686-c5d28a50e172"], "metadata": {"page_label": "283", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "```\n\u2014 two contaminated units are considered cause for revalidation \n  following investigation;\n- when filling more than 10 000 units:\n  \u2014 one contaminated unit should result in an investigation;\n  \u2014 two contaminated units are considered cause for revalidation \n    following investigation.\n\n4.27 For any run size, intermittent incidents of microbial contamination \nmay be indicative of low-level contamination that should be investigated. \nInvestigation of gross failures should include the potential impact on the \nsterility assurance of batches manufactured since the last successful media fill.\n\n4.28 Care should be taken to ensure that any validation does not \ncompromise the processes.\n\n4.29 Water sources, water-treatment equipment and treated water should \nbe monitored regularly for chemicals, biological contamination and \ncontamination with endotoxins to ensure that the water complies with the \nspecifications appropriate to its use. Records should be maintained of the \nresults of the monitoring and of any action taken (8).\n\n4.30 Activities in clean areas, especially when aseptic operations are in \nprogress, should be kept to a minimum and the movement of personnel should \nbe controlled and methodical, so as to avoid excessive shedding of particles and \norganisms due to over-vigorous activity. As far as possible, personnel should \nbe excluded from Grade A zones. The ambient temperature and humidity \nshould not be uncomfortably high because of the nature of the garments worn \nand to reduce the risk of contamination liberated from the personnel.\n\n4.31 The presence of containers and materials liable to generate fibres \nshould be minimized in clean areas and avoided completely when aseptic \nwork is in progress.\n\n4.32 Components, bulk-product containers and equipment should be \nhandled after the final cleaning process in such a way as to ensure that they \nare not recontaminated. The stage of processing of components as well as \nthe bulk-product containers and equipment should be properly identified.\n\n4.33 The interval between the washing and drying and the sterilization of \ncomponents, bulk-product containers and equipment, as well as between \nsterilization and use, should be as short as possible and subject to a time- \nlimit appropriate to the validated storage conditions.\n\n4.34 The time between the start of the preparation of a solution and its \nsterilization or filtration through a bacteria-retaining filter should be as short \nas possible. A maximum permissible time should be set for each product that \ntakes into account its composition and the prescribed method of storage.\n```\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda las pr\u00e1cticas de validaci\u00f3n y control de calidad en la producci\u00f3n de productos farmac\u00e9uticos, enfatizando la importancia de la contaminaci\u00f3n microbiana y la gesti\u00f3n del agua en \u00e1reas limpias. Se establecen directrices sobre c\u00f3mo manejar incidentes de contaminaci\u00f3n, la importancia de la validaci\u00f3n de procesos, y las medidas necesarias para mantener la esterilidad y la calidad del producto durante su fabricaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las acciones recomendadas cuando se detectan unidades contaminadas durante la producci\u00f3n de m\u00e1s de 10,000 unidades?**\n   - Respuesta: Se debe investigar cualquier unidad contaminada, y si se encuentran dos unidades contaminadas, esto se considera motivo para la revalidaci\u00f3n tras la investigaci\u00f3n.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse para asegurar que el agua utilizada en el proceso de producci\u00f3n cumpla con las especificaciones necesarias?**\n   - Respuesta: Las fuentes de agua, el equipo de tratamiento de agua y el agua tratada deben ser monitoreados regularmente para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas, y se deben mantener registros de los resultados del monitoreo y de cualquier acci\u00f3n tomada.\n\n3. **\u00bfQu\u00e9 precauciones deben tomarse en \u00e1reas limpias durante operaciones as\u00e9pticas para minimizar el riesgo de contaminaci\u00f3n?**\n   - Respuesta: Las actividades en \u00e1reas limpias deben ser m\u00ednimas, el movimiento del personal debe ser controlado y met\u00f3dico, y se debe evitar la presencia de materiales que generen fibras. Adem\u00e1s, se debe mantener una temperatura y humedad adecuadas para reducir el riesgo de contaminaci\u00f3n liberada por el personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Precauciones contra la Contaminaci\u00f3n**: Se enfatiza la importancia de tomar medidas para minimizar la contaminaci\u00f3n en todas las etapas del procesamiento de productos farmac\u00e9uticos, especialmente antes de la esterilizaci\u00f3n.\n\n2. **Uso de Instalaciones Multiproducto**: Generalmente, no se deben elaborar preparaciones que contengan microorganismos vivos en \u00e1reas donde se procesan otros productos farmac\u00e9uticos. Sin embargo, se permite el uso de instalaciones multiproducto si el fabricante puede demostrar la contenci\u00f3n y decontaminaci\u00f3n efectivas de los microorganismos vivos.\n\n3. **Validaci\u00f3n de Procesos Aseptic\u00f3s**: La validaci\u00f3n del procesamiento as\u00e9ptico debe incluir pruebas de simulaci\u00f3n de procesos (media fill) utilizando un medio de cultivo adecuado, que debe seleccionarse seg\u00fan la forma de dosificaci\u00f3n del producto y otros criterios como claridad y adecuaci\u00f3n para la esterilizaci\u00f3n.\n\n4. **Pruebas de Simulaci\u00f3n de Procesos**: Estas pruebas deben replicar lo m\u00e1s fielmente posible los pasos de fabricaci\u00f3n as\u00e9ptica y realizarse de manera regular, especialmente despu\u00e9s de modificaciones significativas en el sistema de producci\u00f3n.\n\n5. **Evaluaci\u00f3n de Contaminaci\u00f3n en Lotes Peque\u00f1os**: Se establecen criterios espec\u00edficos para la evaluaci\u00f3n de contaminaci\u00f3n en lotes peque\u00f1os, donde se espera que no se detecten unidades contaminadas en lotes de menos de 5000 unidades, y se requiere una investigaci\u00f3n si se encuentra una unidad contaminada en lotes de entre 5000 y 10,000 unidades.\n\n### Entidades Clave\n\n- **Microorganismos Vivos**: Organismos que deben ser manejados con precauciones especiales para evitar la contaminaci\u00f3n.\n- **Instalaciones Multiproducto**: Instalaciones que pueden procesar diferentes productos farmac\u00e9uticos, bajo ciertas condiciones de validaci\u00f3n.\n- **Pruebas de Simulaci\u00f3n de Procesos (Media Fill)**: M\u00e9todos utilizados para validar el procesamiento as\u00e9ptico.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar durante el procesamiento de productos farmac\u00e9uticos.\n- **Lotes Peque\u00f1os**: Referencia a la cantidad de unidades producidas que requieren atenci\u00f3n especial en t\u00e9rminos de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: contaminaci\u00f3n microbiana, validaci\u00f3n de procesos, \u00e1reas limpias, monitoreo de agua, esterilizaci\u00f3n"}}, "01e722a5-b8de-4775-b4f2-b325f1be6565": {"node_ids": ["01d12d1a-36b1-4d6c-bb76-c8ee2ff6015b"], "metadata": {"page_label": "284", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.35\nAny gas that is used to purge a solution or blanket a product should be passed through a sterilizing filter.\n\n4.36 The bioburden should be monitored before sterilization. There should be working limits on contamination immediately before sterilization, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled products and terminally sterilized products. Where overkill sterilization parameters are set for terminally sterilized products, bioburden might be monitored only at suitable scheduled intervals. For parametric release systems, bioburden assay should be performed on each batch and considered as an in-process test. Where appropriate, the level of endotoxins should be monitored. All solutions, in particular large-volume infusion fluids, should be passed through a microorganism-retaining filter, if possible sited immediately before filling.\n\n4.37 Components, bulk-product containers, equipment, and any other articles required in a clean area where aseptic work is in progress, should be sterilized and wherever possible passed into the area through double-ended sterilizers sealed into the wall. Other procedures that prevent the introduction of contamination may be acceptable in some circumstances.\n\n4.38 The efficacy of any new processing procedure should be validated and the validation should be repeated at regular intervals thereafter or when any significant change is made in the process or equipment.\n\n# 5. Sterilization\n\n5.1 Whenever possible products intended to be sterile should be terminally sterilized by heat in their final container. Where it is not possible to carry out terminal sterilization by heating due to the instability of a formulation or incompatibility of a pack type (necessary to the administration of the product, e.g. plastic eye-dropper bottles), a decision should be taken to use an alternative method of terminal sterilization following filtration and/or aseptic processing.\n\n5.2 Sterilization can be achieved by the use of moist or dry heat, by irradiation with ionizing radiation (noting that ultraviolet irradiation is not normally an acceptable method of sterilization), by ethylene oxide (or other suitable gaseous sterilizing agents), or by filtration with subsequent aseptic filling of sterile final containers. Each method has its advantages and disadvantages. Where possible and practicable, heat sterilization is the method of choice. In any case the sterilization process must be in accordance with the marketing and manufacturing authorizations.\n\n5.3 The microbial contamination of starting materials should be minimal and their bioburden should be monitored before sterilization. Specifications", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto proporciona directrices sobre el manejo de la biocarga y los procesos de esterilizaci\u00f3n en la producci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de monitorear la biocarga antes de la esterilizaci\u00f3n, el uso de filtros esterilizantes para gases y soluciones, y la necesidad de validar la eficacia de los procedimientos de procesamiento. Adem\u00e1s, se discuten diferentes m\u00e9todos de esterilizaci\u00f3n, como el calor, la irradiaci\u00f3n y el \u00f3xido de etileno, y se establece que, siempre que sea posible, se debe optar por la esterilizaci\u00f3n terminal por calor en el envase final.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los l\u00edmites de trabajo recomendados para la biocarga antes de la esterilizaci\u00f3n y c\u00f3mo se relacionan con la eficiencia del m\u00e9todo de esterilizaci\u00f3n utilizado?**\n   - Respuesta: Los l\u00edmites de trabajo sobre la biocarga deben establecerse en funci\u00f3n de la eficiencia del m\u00e9todo de esterilizaci\u00f3n que se va a utilizar. Esto implica que se deben definir niveles aceptables de contaminaci\u00f3n que no comprometan la eficacia del proceso de esterilizaci\u00f3n.\n\n2. **\u00bfQu\u00e9 procedimientos se pueden implementar para prevenir la introducci\u00f3n de contaminaci\u00f3n en \u00e1reas limpias donde se realiza trabajo as\u00e9ptico?**\n   - Respuesta: Se recomienda que los componentes, contenedores de productos a granel, equipos y otros art\u00edculos necesarios en un \u00e1rea limpia sean esterilizados y, siempre que sea posible, se introduzcan en el \u00e1rea a trav\u00e9s de esterilizadores de doble extremo sellados en la pared. Tambi\u00e9n se pueden aceptar otros procedimientos que minimicen la contaminaci\u00f3n.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al elegir un m\u00e9todo de esterilizaci\u00f3n alternativo cuando la esterilizaci\u00f3n terminal por calor no es viable?**\n   - Respuesta: Si la esterilizaci\u00f3n terminal por calor no es posible debido a la inestabilidad de la formulaci\u00f3n o la incompatibilidad del tipo de envase, se debe optar por un m\u00e9todo alternativo de esterilizaci\u00f3n que incluya filtraci\u00f3n y/o procesamiento as\u00e9ptico. Es crucial que cualquier m\u00e9todo alternativo cumpla con las autorizaciones de comercializaci\u00f3n y fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Contaminaci\u00f3n Microbiana**:\n   - Se establece que la detecci\u00f3n de unidades contaminadas durante la producci\u00f3n requiere acciones espec\u00edficas. Para lotes de m\u00e1s de 10,000 unidades, una unidad contaminada debe ser investigada y dos unidades contaminadas justifican la revalidaci\u00f3n.\n\n2. **Validaci\u00f3n de Procesos**:\n   - Es crucial que cualquier proceso de validaci\u00f3n no comprometa la calidad y la seguridad del producto. Se enfatiza la importancia de investigar incidentes de contaminaci\u00f3n para asegurar la esterilidad de los lotes producidos.\n\n3. **Monitoreo del Agua**:\n   - Las fuentes de agua y el equipo de tratamiento deben ser monitoreados regularmente para detectar contaminantes qu\u00edmicos, biol\u00f3gicos y endotoxinas. Se requiere mantener registros de los resultados y acciones tomadas.\n\n4. **Pr\u00e1cticas en \u00c1reas Limpias**:\n   - Se deben minimizar las actividades y controlar el movimiento del personal en \u00e1reas limpias, especialmente durante operaciones as\u00e9pticas, para reducir el riesgo de contaminaci\u00f3n. Se recomienda excluir al personal de zonas de Grado A y mantener condiciones ambientales adecuadas.\n\n5. **Manejo de Componentes y Equipos**:\n   - Los componentes y equipos deben ser manipulados adecuadamente despu\u00e9s de la limpieza final para evitar recontaminaci\u00f3n. Se debe reducir al m\u00ednimo el tiempo entre los procesos de lavado, secado, esterilizaci\u00f3n y uso.\n\n6. **Preparaci\u00f3n de Soluciones**:\n   - El tiempo entre la preparaci\u00f3n de una soluci\u00f3n y su esterilizaci\u00f3n o filtraci\u00f3n debe ser lo m\u00e1s corto posible, estableciendo un tiempo m\u00e1ximo permisible basado en la composici\u00f3n del producto y las condiciones de almacenamiento.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Contaminaci\u00f3n Microbiana**: Problema cr\u00edtico en la producci\u00f3n farmac\u00e9utica.\n- **Agua**: Elemento esencial que debe ser monitoreado para asegurar la calidad.\n- **\u00c1reas Limpias**: Espacios donde se llevan a cabo operaciones as\u00e9pticas que requieren estrictas medidas de control.\n- **Componentes y Equipos**: Elementos que deben ser manejados con cuidado para mantener la esterilidad.\n\nEste resumen destaca la importancia de la gesti\u00f3n de la contaminaci\u00f3n y la validaci\u00f3n de procesos en la producci\u00f3n farmac\u00e9utica, as\u00ed como las medidas necesarias para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: bioburden, sterilization, aseptic processing, contamination control, validation"}}, "b371a2ed-a0ea-4ef3-9a4d-e2aaa9fba7d3": {"node_ids": ["db5a0b0c-34fd-4e26-aadb-22d1cd057f66"], "metadata": {"page_label": "285", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nshould include requirements for microbiological quality when the need for this has been indicated by monitoring.\n\n5.4 All sterilization processes should be validated. Particular attention should be paid when the adopted sterilization method is not in accordance with pharmacopoeial standards or other national standards, or when it is used for a preparation that is not a simple aqueous or oily solution, for example, colloidal suspensions.\n\n5.5 Before any sterilization process is adopted, its suitability for the product and its efficacy in achieving the desired sterilizing conditions in all parts of each type of load to be processed should be demonstrated by physical measurements and by biological indicators, where appropriate. The validity of the process should be verified at scheduled intervals, at least annually, and whenever significant modifications have been made to the equipment. Records should be kept of the results.\n\n5.6 For effective sterilization the whole of the material should be subjected to the required treatment and the process should be designed to ensure that this is achieved.\n\n5.7 Biological indicators should be considered only as an additional method of monitoring the sterilization process. They should be stored and used according to the manufacturer's instructions, and their quality checked by positive controls. If they are used, strict precautions should be taken to avoid any transfer of microbial contamination from them.\n\n5.8 There should be a clear means of differentiating products that have not been sterilized from those which have. Each basket, tray, or other carrier of products or components should be clearly labelled with the name of the material, its batch number and an indication of whether or not it has been sterilized. Indicators such as autoclave tape may be used where appropriate to indicate whether or not a batch (or sub-batch) has passed through a sterilization process, but they do not give a reliable indication that the batch is in fact sterile.\n\n5.9 Validated loading patterns should be established for all sterilization processes.\n\n5.10 Sterilization records should be available for each sterilization run. They should be approved as part of the batch-release procedure.\n\n# 6. Terminal sterilization\n\n## Sterilization by heat\n\n6.1 Each heat-sterilization cycle should be recorded by means of appropriate equipment of suitable accuracy and precision, e.g. on a time/temperature chart with a suitably large scale. The temperature should\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre los procesos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, enfatizando la importancia de validar todos los m\u00e9todos de esterilizaci\u00f3n, asegurando que se cumplan los est\u00e1ndares microbiol\u00f3gicos y que se mantengan registros precisos de cada ciclo de esterilizaci\u00f3n. Se menciona la necesidad de utilizar indicadores biol\u00f3gicos como m\u00e9todo adicional de monitoreo y la importancia de etiquetar claramente los productos esterilizados y no esterilizados. Tambi\u00e9n se destaca la necesidad de establecer patrones de carga validados y de registrar cada ciclo de esterilizaci\u00f3n con equipos precisos.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para validar un proceso de esterilizaci\u00f3n que no se alinea con los est\u00e1ndares farmacopoeicos?**\n   - Esta pregunta busca detalles sobre los criterios de validaci\u00f3n que se deben considerar cuando un m\u00e9todo de esterilizaci\u00f3n no sigue las normas establecidas, lo cual no se detalla expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 tipo de registros se deben mantener para cada ciclo de esterilizaci\u00f3n y c\u00f3mo deben ser aprobados en el procedimiento de liberaci\u00f3n de lotes?**\n   - Esta pregunta se centra en la naturaleza espec\u00edfica de los registros requeridos y el proceso de aprobaci\u00f3n, que podr\u00eda no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se deben tomar para evitar la transferencia de contaminaci\u00f3n microbiana al utilizar indicadores biol\u00f3gicos en el proceso de esterilizaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre las precauciones pr\u00e1cticas que deben implementarse al usar indicadores biol\u00f3gicos, un aspecto que puede no estar ampliamente cubierto en otros documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Biocarga y Monitoreo**:\n   - Importancia de monitorear la biocarga antes de la esterilizaci\u00f3n.\n   - Establecimiento de l\u00edmites de trabajo relacionados con la eficiencia del m\u00e9todo de esterilizaci\u00f3n.\n   - Realizaci\u00f3n de ensayos de biocarga en cada lote de productos llenados as\u00e9pticamente y productos esterilizados terminalmente.\n\n2. **Filtraci\u00f3n y Esterilizaci\u00f3n**:\n   - Uso de filtros esterilizantes para gases y soluciones, especialmente en fluidos de infusi\u00f3n de gran volumen.\n   - Recomendaci\u00f3n de pasar soluciones a trav\u00e9s de filtros que retengan microorganismos antes del llenado.\n\n3. **Esterilizaci\u00f3n de Componentes**:\n   - Necesidad de esterilizar componentes, contenedores y equipos en \u00e1reas limpias.\n   - Uso de esterilizadores de doble extremo para minimizar la contaminaci\u00f3n.\n\n4. **Validaci\u00f3n de Procedimientos**:\n   - Validaci\u00f3n de la eficacia de nuevos procedimientos de procesamiento y repetici\u00f3n de la validaci\u00f3n a intervalos regulares o tras cambios significativos.\n\n5. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - Preferencia por la esterilizaci\u00f3n terminal por calor en el envase final, cuando sea posible.\n   - Alternativas a la esterilizaci\u00f3n por calor incluyen m\u00e9todos como calor h\u00famedo, radiaci\u00f3n ionizante, \u00f3xido de etileno y filtraci\u00f3n.\n   - Consideraciones sobre la estabilidad de formulaciones y compatibilidad de envases al elegir m\u00e9todos alternativos.\n\n6. **Contaminaci\u00f3n Microbiana**:\n   - Necesidad de mantener la contaminaci\u00f3n microbiana de los materiales de partida al m\u00ednimo y monitorear la biocarga antes de la esterilizaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Biocarga**: Concepto relacionado con la carga microbiana en productos antes de la esterilizaci\u00f3n.\n- **M\u00e9todos de Esterilizaci\u00f3n**: Calor, radiaci\u00f3n ionizante, \u00f3xido de etileno, filtraci\u00f3n.\n- **Esterilizadores de Doble Extremo**: Equipos recomendados para introducir materiales en \u00e1reas limpias.\n- **Validaci\u00f3n**: Proceso necesario para asegurar la eficacia de los procedimientos de esterilizaci\u00f3n y procesamiento.", "excerpt_keywords": "Keywords: sterilization, validation, microbiological quality, biological indicators, batch-release procedure"}}, "833de9f9-151d-4b36-83ee-8fae5c6ceed7": {"node_ids": ["c3327aef-df58-4257-8a21-8190ebd5de14"], "metadata": {"page_label": "286", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "be recorded by a probe situated at the coolest part of the load or loaded chamber, this point having been determined during the validation; the temperature should preferably be checked against a second independent temperature probe located at the same position. Sterilization records should be available for each sterilization run and should be approved as part of the batch release procedure. Chemical or biological indicators may also be used but should not take the place of physical controls.\n\n6.2 Sufficient time should be allowed for the whole of the load to reach the required temperature before measurement of the sterilizing time is started. This time should be determined for each type of load to be processed.\n\n6.3 After the high-temperature phase of a heat sterilization cycle, precautions should be taken against contamination of a sterilized load during cooling. Any cooling fluid or gas in contact with the product should be sterilized.\n\n**Sterilization by moist heat**\n\n6.4 Both temperature and pressure should be used to monitor the process. Control instrumentation should normally be independent of monitoring instrumentation and recording charts. Where automated control and monitoring systems are used for these applications they should be validated to ensure that critical process requirements are met. System and cycle faults should be registered by the system and observed by the operator. The reading of the independent temperature indicator should be routinely checked against the reading on the chart recorder during the sterilization period. For sterilizers fitted with a drain at the bottom of the chamber, it may also be necessary to record the temperature at this position throughout the sterilization period. There should be regular leak tests on the chamber when a vacuum phase is part of the cycle.\n\n6.5 The items to be sterilized, other than products in sealed containers, should be wrapped in a material that allows the removal of air and the penetration of steam but prevents recontamination after sterilization. Specially designed autoclavable stainless steel containers, that allow steam to enter and air to leave, can also be used. All parts of the load should be in contact with water or saturated steam at the required temperature for the required time.\n\n6.6 Care should be taken to ensure that the steam used for sterilization is of suitable quality (chemical, microbiological and endotoxin analysis of condensate and physical examination of steam (such as dryness, superheat, and non-condensable gases) and does not contain additives at a level that could cause contamination of the product or equipment. Steam used for sterilization should be tested regularly.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Monitoreo y Control del Proceso de Esterilizaci\u00f3n**: El proceso de esterilizaci\u00f3n debe ser monitoreado utilizando tanto temperatura como presi\u00f3n, con la necesidad de contar con instrumentos de control y monitoreo independientes. Se enfatiza la importancia de validar los sistemas automatizados y realizar pruebas de fugas en las c\u00e1maras de esterilizaci\u00f3n.\n\n2. **Preparaci\u00f3n y Manejo de Cargas Esterilizadas**: Se deben tomar precauciones para evitar la contaminaci\u00f3n de las cargas esterilizadas durante el enfriamiento. Los art\u00edculos a esterilizar deben estar envueltos en materiales que permitan la penetraci\u00f3n del vapor y la eliminaci\u00f3n del aire, y se debe asegurar que el vapor utilizado sea de calidad adecuada.\n\n3. **Requisitos de Calidad del Vapor**: El vapor utilizado para la esterilizaci\u00f3n debe ser analizado para asegurar que cumpla con est\u00e1ndares qu\u00edmicos, microbiol\u00f3gicos y de endotoxinas, y no debe contener aditivos que puedan contaminar los productos o equipos.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que la carga alcance la temperatura requerida antes de iniciar la medici\u00f3n del tiempo de esterilizaci\u00f3n?**\n   - Se debe permitir un tiempo suficiente para que toda la carga alcance la temperatura requerida, y este tiempo debe ser determinado para cada tipo de carga a procesar.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas que debe tener el material de envoltura de los art\u00edculos a esterilizar?**\n   - El material debe permitir la eliminaci\u00f3n del aire y la penetraci\u00f3n de vapor, pero debe prevenir la recontaminaci\u00f3n despu\u00e9s de la esterilizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de an\u00e1lisis se debe realizar para asegurar la calidad del vapor utilizado en el proceso de esterilizaci\u00f3n?**\n   - Se debe realizar un an\u00e1lisis qu\u00edmico, microbiol\u00f3gico y de endotoxinas del condensado, as\u00ed como una evaluaci\u00f3n f\u00edsica del vapor, que incluya aspectos como sequedad, sobrecalentamiento y gases no condensables.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Procesos de Esterilizaci\u00f3n**: Todos los procesos de esterilizaci\u00f3n deben ser validados, especialmente si no cumplen con los est\u00e1ndares farmacopoeicos o nacionales. Se requiere demostrar la idoneidad del m\u00e9todo para el producto y su eficacia en alcanzar las condiciones de esterilizaci\u00f3n deseadas.\n\n2. **Monitoreo y Registros**: Es esencial mantener registros precisos de cada ciclo de esterilizaci\u00f3n, que deben ser verificados al menos anualmente y cada vez que se realicen modificaciones significativas en el equipo. Estos registros son parte del procedimiento de liberaci\u00f3n de lotes.\n\n3. **Indicadores Biol\u00f3gicos**: Los indicadores biol\u00f3gicos son un m\u00e9todo adicional para monitorear el proceso de esterilizaci\u00f3n. Deben ser utilizados y almacenados seg\u00fan las instrucciones del fabricante, y se deben tomar precauciones estrictas para evitar la transferencia de contaminaci\u00f3n microbiana.\n\n4. **Etiquetado de Productos**: Los productos esterilizados y no esterilizados deben ser claramente diferenciados mediante etiquetado que incluya el nombre del material, el n\u00famero de lote y el estado de esterilizaci\u00f3n. Se pueden usar indicadores como cinta de autoclave, aunque no son una garant\u00eda de esterilidad.\n\n5. **Patrones de Carga Validados**: Se deben establecer patrones de carga validados para todos los procesos de esterilizaci\u00f3n, asegurando que todo el material reciba el tratamiento requerido.\n\n6. **Ciclo de Esterilizaci\u00f3n por Calor**: Cada ciclo de esterilizaci\u00f3n por calor debe ser registrado utilizando equipos precisos, como gr\u00e1ficos de tiempo/temperatura.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Fuente del documento.\n- **Est\u00e1ndares Farmacopoeicos**: Normas que gu\u00edan los procesos de esterilizaci\u00f3n.\n- **Indicadores Biol\u00f3gicos**: Herramientas para monitorear la eficacia de la esterilizaci\u00f3n.\n- **Registros de Esterilizaci\u00f3n**: Documentaci\u00f3n necesaria para cada ciclo de esterilizaci\u00f3n.\n- **Cinta de Autoclave**: Indicador visual utilizado en procesos de esterilizaci\u00f3n. \n\nEste resumen destaca la importancia de la validaci\u00f3n, el monitoreo y el etiquetado en los procesos de esterilizaci\u00f3n en el \u00e1mbito farmac\u00e9utico, as\u00ed como las pr\u00e1cticas recomendadas para garantizar la calidad microbiol\u00f3gica.", "excerpt_keywords": "Sterilization, Monitoring, Validation, Steam Quality, Contamination"}}, "a720a272-803d-46e1-bfb3-8446e3cf24fe": {"node_ids": ["12897d53-0be0-4c16-9174-ccc133af46b7"], "metadata": {"page_label": "287", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Sterilization by Dry Heat\n\n6.7 Sterilization by dry heat may be suitable for non-aqueous liquids or dry-powder products.\n\nThe process used should include air circulation within the chamber and the maintenance of a positive pressure to prevent the entry of non-sterile air. If air is supplied it should be passed through a microorganism-retaining filter (e.g. a HEPA filter). Where sterilization by dry heat is also intended to remove pyrogens, challenge tests using endotoxins are required as part of the validation.\n\n# Sterilization by Radiation\n\n6.8 Sterilization by radiation is used mainly for heat-sensitive materials and products. Many pharmaceutical products and some packaging materials are radiation-sensitive, so this method is permissible only when the absence of deleterious effects on the product has been confirmed experimentally. Ultraviolet irradiation is not an acceptable method for terminal sterilization.\n\n6.9 If sterilization by radiation is done by an outside contractor, the manufacturer is responsible for ensuring that the requirements of section 6.8 are met and that the sterilization process is validated.\n\n6.10 During the sterilization procedure the radiation dose should be measured. The dosimeters used for this purpose should be independent of the dose rate and should provide a quantitative measurement of the dose received by the product itself. Dosimeters should be inserted in the load in sufficient number and close enough together to ensure that there is always a dosimeter in the chamber. Where plastic dosimeters are used they should be used within the time-limit of their calibration. Dosimeter absorbance should be read shortly after exposure to radiation. Radiation-sensitive colour discs may be used to differentiate between packages that have been subjected to irradiation and those that have not; they are not indicators of successful sterilization. The information obtained should constitute part of the batch record.\n\n6.11 Validation procedures should ensure that consideration is given to the effects of variations in the density of the packages.\n\n6.12 Material-handling procedures should prevent any mix-up of irradiated and non-irradiated materials. Each package should carry a radiation-sensitive indicator to show whether or not it has been subjected to radiation treatment.\n\n6.13 The total radiation dose should be administered within a predetermined period.\n\n# Sterilization by Gases and Fumigants\n\n6.14 Sterilization by gases and fumigants should only be used for finished products where there is no suitable alternative.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre diferentes m\u00e9todos de esterilizaci\u00f3n utilizados en la industria farmac\u00e9utica, espec\u00edficamente la esterilizaci\u00f3n por calor seco, radiaci\u00f3n y gases/fumigantes. Se enfatiza la importancia de validar los procesos de esterilizaci\u00f3n, asegurando que se cumplan los requisitos espec\u00edficos para cada m\u00e9todo. Se mencionan aspectos t\u00e9cnicos como la circulaci\u00f3n de aire, el uso de filtros, la medici\u00f3n de dosis de radiaci\u00f3n y la prevenci\u00f3n de confusiones entre materiales irradiados y no irradiados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de productos son m\u00e1s adecuados para la esterilizaci\u00f3n por calor seco y qu\u00e9 condiciones deben cumplirse durante este proceso?**\n   - La esterilizaci\u00f3n por calor seco es adecuada para l\u00edquidos no acuosos o productos en polvo seco. Durante este proceso, es esencial mantener la circulaci\u00f3n de aire dentro de la c\u00e1mara y mantener una presi\u00f3n positiva para evitar la entrada de aire no est\u00e9ril. Si se suministra aire, debe pasar a trav\u00e9s de un filtro que retenga microorganismos, como un filtro HEPA.\n\n2. **\u00bfCu\u00e1les son los requisitos de validaci\u00f3n para la esterilizaci\u00f3n por radiaci\u00f3n, especialmente si se realiza a trav\u00e9s de un contratista externo?**\n   - Si la esterilizaci\u00f3n por radiaci\u00f3n es realizada por un contratista externo, el fabricante es responsable de garantizar que se cumplan los requisitos establecidos en la secci\u00f3n 6.8 y que el proceso de esterilizaci\u00f3n est\u00e9 validado. Esto incluye confirmar experimentalmente que no hay efectos perjudiciales en el producto debido a la radiaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas deben tomarse para evitar la confusi\u00f3n entre materiales irradiados y no irradiados durante el manejo de productos?**\n   - Se deben implementar procedimientos de manejo de materiales que prevengan cualquier confusi\u00f3n entre materiales irradiados y no irradiados. Cada paquete debe llevar un indicador sensible a la radiaci\u00f3n que muestre si ha sido sometido a tratamiento de radiaci\u00f3n. Adem\u00e1s, es importante que la dosis total de radiaci\u00f3n se administre dentro de un per\u00edodo predeterminado.", "prev_section_summary": "### Temas Clave:\n\n1. **Monitoreo y Control del Proceso de Esterilizaci\u00f3n**:\n   - Importancia de registrar la temperatura en el punto m\u00e1s fresco de la carga.\n   - Necesidad de contar con registros de esterilizaci\u00f3n aprobados como parte del procedimiento de liberaci\u00f3n de lotes.\n   - Uso de indicadores qu\u00edmicos o biol\u00f3gicos como complemento, pero no como sustituto de controles f\u00edsicos.\n\n2. **Preparaci\u00f3n y Manejo de Cargas Esterilizadas**:\n   - Permitir tiempo suficiente para que toda la carga alcance la temperatura requerida antes de iniciar la medici\u00f3n del tiempo de esterilizaci\u00f3n.\n   - Precauciones contra la contaminaci\u00f3n durante el enfriamiento de cargas esterilizadas.\n\n3. **Esterilizaci\u00f3n por Calor H\u00famedo**:\n   - Monitoreo del proceso mediante temperatura y presi\u00f3n, con instrumentos de control y monitoreo independientes.\n   - Validaci\u00f3n de sistemas automatizados y realizaci\u00f3n de pruebas de fugas en c\u00e1maras de esterilizaci\u00f3n.\n   - Requisitos para el material de envoltura de los art\u00edculos a esterilizar.\n\n4. **Calidad del Vapor**:\n   - An\u00e1lisis qu\u00edmico, microbiol\u00f3gico y de endotoxinas del vapor utilizado para la esterilizaci\u00f3n.\n   - Evaluaci\u00f3n f\u00edsica del vapor, incluyendo sequedad, sobrecalentamiento y gases no condensables.\n\n### Entidades:\n\n- **Instrumentos de Monitoreo**: Probes, chart recorders.\n- **Materiales de Envoltura**: Materiales que permiten la penetraci\u00f3n de vapor y eliminaci\u00f3n de aire.\n- **Contenedores**: Contenedores de acero inoxidable autoclavables.\n- **Calidad del Vapor**: An\u00e1lisis de condensado, caracter\u00edsticas f\u00edsicas del vapor.\n- **Registros de Esterilizaci\u00f3n**: Documentaci\u00f3n de cada ciclo de esterilizaci\u00f3n.\n\nEste resumen abarca los aspectos esenciales del proceso de esterilizaci\u00f3n, enfatizando la importancia del monitoreo, la preparaci\u00f3n adecuada de las cargas y la calidad del vapor utilizado.", "excerpt_keywords": "Keywords: sterilization, dry heat, radiation, validation, pharmaceutical"}}, "82b87288-e773-4512-9416-9b1c7bcde0de": {"node_ids": ["5872b667-0fbf-46a9-87bd-ea6dbe0253e2"], "metadata": {"page_label": "288", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.15\nVarious gases and fumigants may be used for sterilization (e.g. ethylene oxide and hydrogen peroxide vapour). Ethylene oxide should be used only when no other method is practicable. During process validation it should be shown that the gas has no damaging effect on the product and that the conditions and time allowed for degassing are such as to reduce any residual gas and reaction products to defined acceptable limits for the type of product or material concerned. These limits should be incorporated in the specifications.\n\n# 6.16\nDirect contact between gas and microorganisms is essential; precautions should, therefore, be taken to avoid the presence of organisms likely to be enclosed in materials such as crystals or dried protein. The nature and quantity of packaging materials can significantly affect the process.\n\n# 6.17\nBefore exposure to the gas, materials should be brought into equilibrium with the humidity and temperature required by the process. This requirement should be balanced against the need to minimize the waiting time before sterilization.\n\n# 6.18\nEach sterilization cycle should be monitored with suitable biological indicators, using the appropriate number of test pieces distributed throughout the load. The information thus obtained should form part of the batch record.\n\n# 6.19\nBiological indicators should be stored and used according to the manufacturer\u2019s instructions and their performance checked by positive controls.\n\n# 6.20\nFor each sterilization cycle, records should be made of the time taken to complete the cycle, of the pressure, temperature and humidity within the chamber during the process and of the gas concentration. The pressure and temperature should be recorded on a chart throughout the cycle. The records should form part of the batch record.\n\n# 6.21\nAfter sterilization, the load should be stored in a controlled manner in ventilated conditions to allow concentrations of residual gas and reaction products to fall to their prescribed levels. This process should be validated.\n\n# 7. Aseptic processing and sterilization by filtration\n\n## 7.1\nThe objective of aseptic processing is to maintain the sterility of a product that is assembled from components, each of which has been sterilized by one of the above methods (see sections 5 and 6).\n\n## 7.2\nThe operating conditions should be such as to prevent microbial contamination.\n\n## 7.3\nIn order to maintain the sterility of the components and the product during aseptic processing, careful attention needs to be given to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **M\u00e9todos de esterilizaci\u00f3n**: Se describen varios m\u00e9todos de esterilizaci\u00f3n, incluyendo el uso de gases como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno. Se enfatiza la importancia de validar el proceso para asegurar que no haya efectos da\u00f1inos en el producto y que los niveles de residuos sean aceptables.\n\n2. **Monitoreo y control del proceso**: Se establece la necesidad de monitorear cada ciclo de esterilizaci\u00f3n utilizando indicadores biol\u00f3gicos y de mantener registros detallados de las condiciones del proceso, como presi\u00f3n, temperatura y concentraci\u00f3n de gas.\n\n3. **Procesamiento as\u00e9ptico**: Se aborda el objetivo del procesamiento as\u00e9ptico, que es mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados. Se subraya la importancia de prevenir la contaminaci\u00f3n microbiana durante este proceso.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas que deben cumplirse durante la validaci\u00f3n del proceso de esterilizaci\u00f3n con \u00f3xido de etileno?**\n   - La validaci\u00f3n del proceso debe demostrar que el gas no tiene efectos da\u00f1inos en el producto y que las condiciones y el tiempo de desgasificaci\u00f3n son adecuados para reducir los residuos de gas y productos de reacci\u00f3n a niveles aceptables, que deben estar especificados.\n\n2. **\u00bfQu\u00e9 precauciones deben tomarse para asegurar el contacto directo entre el gas y los microorganismos durante la esterilizaci\u00f3n?**\n   - Es esencial evitar la presencia de organismos que puedan estar encerrados en materiales como cristales o prote\u00ednas secas, ya que esto puede afectar la eficacia del proceso de esterilizaci\u00f3n.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n debe registrarse durante cada ciclo de esterilizaci\u00f3n y por qu\u00e9 es importante?**\n   - Se deben registrar el tiempo de ciclo, la presi\u00f3n, la temperatura, la humedad dentro de la c\u00e1mara y la concentraci\u00f3n de gas. Esta informaci\u00f3n es crucial para formar parte del registro del lote y para asegurar que el proceso se ha llevado a cabo de acuerdo con las especificaciones establecidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - **Esterilizaci\u00f3n por Calor Seco**:\n     - Adecuada para l\u00edquidos no acuosos y productos en polvo seco.\n     - Requiere circulaci\u00f3n de aire y presi\u00f3n positiva en la c\u00e1mara.\n     - Uso de filtros (ej. HEPA) para evitar entrada de aire no est\u00e9ril.\n     - Pruebas de desaf\u00edo con endotoxinas necesarias si se busca eliminar pir\u00f3genos.\n\n   - **Esterilizaci\u00f3n por Radiaci\u00f3n**:\n     - Principalmente para materiales y productos sensibles al calor.\n     - Se debe confirmar experimentalmente que no hay efectos perjudiciales en el producto.\n     - No se acepta la irradiaci\u00f3n ultravioleta para esterilizaci\u00f3n terminal.\n     - Responsabilidad del fabricante de validar el proceso si se realiza por un contratista externo.\n     - Medici\u00f3n de la dosis de radiaci\u00f3n con dos\u00edmetros que deben estar en n\u00famero suficiente y calibrados.\n     - Indicadores sensibles a la radiaci\u00f3n deben estar presentes en cada paquete para evitar confusiones.\n\n   - **Esterilizaci\u00f3n por Gases y Fumigantes**:\n     - Solo se debe utilizar para productos terminados cuando no hay alternativas adecuadas.\n\n2. **Validaci\u00f3n y Procedimientos**:\n   - Importancia de la validaci\u00f3n de los procesos de esterilizaci\u00f3n.\n   - Consideraci\u00f3n de variaciones en la densidad de los paquetes durante la validaci\u00f3n.\n   - Procedimientos de manejo de materiales para prevenir confusiones entre materiales irradiados y no irradiados.\n\n3. **Entidades Clave**:\n   - **Filtros HEPA**: Utilizados para mantener la esterilidad del aire.\n   - **Dos\u00edmetros**: Dispositivos para medir la dosis de radiaci\u00f3n recibida por los productos.\n   - **Indicadores Sensibles a la Radiaci\u00f3n**: Se\u00f1alan si un paquete ha sido sometido a tratamiento de radiaci\u00f3n.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para garantizar la eficacia y seguridad de los m\u00e9todos de esterilizaci\u00f3n en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: sterilization, ethylene oxide, biological indicators, aseptic processing, gas concentration"}}, "b509ef7d-c8d7-4ee5-a41d-aabd5f2a9290": {"node_ids": ["f315fa59-f714-4257-9e26-5cee763bcdf6"], "metadata": {"page_label": "289", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 the environment;  \n\u2014 personnel;  \n\u2014 critical surfaces;  \n\u2014 container/closure sterilization and transfer procedures;  \n\u2014 the maximum holding period of the product before filling into the final container; and  \n\u2014 the sterilizing filter.  \n\n7.4 Certain solutions and liquids that cannot be sterilized in the final container can be filtered through a sterile filter of nominal pore size 0.22 micron (or less), or with at least equivalent microorganism-retaining properties, into a previously sterilized container. Such filters can remove bacteria and moulds, but not all viruses or mycoplasmas. Consideration should be given to complementing the filtration process with some degree of heat treatment. Filtration alone is not considered sufficient when sterilization in the final container is possible. Of the methods currently available, steam sterilization is preferred.\n\n7.5 Owing to the potential additional risks of the filtration method as compared with other sterilization processes, a double-filter layer or second filtration through a further sterilized microorganism-retaining filter immediately prior to filling may be advisable. The final sterile filtration should be carried out as close as possible to the filling point.\n\n7.6 The fibre-shedding characteristics of filters should be minimal (virtually zero). Asbestos-containing filters should not be used under any circumstances.\n\n7.7 The integrity of the sterilized filter should be verified before use and should be confirmed immediately after use by an appropriate method such as a bubble point, diffusive flow or pressure hold test. The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter should be determined during validation and any significant differences from these during routine manufacturing should be noted and investigated. Results of these checks should be included in the batch record. The integrity of critical gas and air vent filters should be confirmed after use. The integrity of other filters should be confirmed at appropriate intervals. Consideration should be given to increased monitoring of filter integrity in processes that involve harsh conditions, e.g. the circulation of high-temperature air.\n\n7.8 The same filter should not be used for more than one working day unless such use has been validated.\n\n7.9 The filter should not affect the product either by removing ingredients from it or by releasing substances into it.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl texto proporciona directrices sobre la filtraci\u00f3n y esterilizaci\u00f3n de soluciones y l\u00edquidos en el contexto de la producci\u00f3n farmac\u00e9utica. Se discuten los m\u00e9todos de filtraci\u00f3n, la importancia de la integridad de los filtros, y se enfatiza que la filtraci\u00f3n no debe ser el \u00fanico m\u00e9todo de esterilizaci\u00f3n cuando es posible utilizar la esterilizaci\u00f3n en el contenedor final. Tambi\u00e9n se mencionan las caracter\u00edsticas de los filtros, la verificaci\u00f3n de su integridad y las precauciones necesarias para su uso.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas que deben tener los filtros utilizados en el proceso de filtraci\u00f3n de soluciones y l\u00edquidos?**\n   - Respuesta: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas (pr\u00e1cticamente cero) y no deben contener asbesto bajo ninguna circunstancia.\n\n2. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para verificar la integridad de un filtro esterilizado antes y despu\u00e9s de su uso?**\n   - Respuesta: La integridad del filtro debe ser verificada antes de su uso y confirmada inmediatamente despu\u00e9s mediante m\u00e9todos apropiados como la prueba de punto de burbuja, flujo difusivo o prueba de retenci\u00f3n de presi\u00f3n.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar en cuenta al utilizar filtros en condiciones de trabajo severas, como la circulaci\u00f3n de aire a alta temperatura?**\n   - Respuesta: Se debe considerar un aumento en la monitorizaci\u00f3n de la integridad del filtro en procesos que involucran condiciones severas, como la circulaci\u00f3n de aire a alta temperatura, para asegurar su eficacia y seguridad.", "prev_section_summary": "### Temas Clave:\n\n1. **M\u00e9todos de Esterilizaci\u00f3n**:\n   - Uso de gases como el \u00f3xido de etileno y el vapor de per\u00f3xido de hidr\u00f3geno.\n   - Importancia de la validaci\u00f3n del proceso para asegurar que no haya efectos da\u00f1inos en el producto y que los residuos de gas se mantengan dentro de l\u00edmites aceptables.\n\n2. **Monitoreo del Proceso**:\n   - Necesidad de monitorear cada ciclo de esterilizaci\u00f3n con indicadores biol\u00f3gicos.\n   - Registro de condiciones del proceso (tiempo, presi\u00f3n, temperatura, humedad y concentraci\u00f3n de gas) como parte del registro del lote.\n\n3. **Condiciones de Contacto**:\n   - Importancia del contacto directo entre el gas y los microorganismos.\n   - Precauciones para evitar la presencia de organismos encerrados en materiales que puedan afectar la esterilizaci\u00f3n.\n\n4. **Almacenamiento Post-Esterilizaci\u00f3n**:\n   - Carga esterilizada debe ser almacenada en condiciones controladas para permitir que los residuos de gas y productos de reacci\u00f3n caigan a niveles prescritos.\n\n5. **Procesamiento Aseptic**:\n   - Objetivo de mantener la esterilidad de un producto ensamblado a partir de componentes previamente esterilizados.\n   - Prevenci\u00f3n de la contaminaci\u00f3n microbiana durante el procesamiento as\u00e9ptico.\n\n### Entidades:\n\n- **Gases/Fumigantes**: \u00d3xido de etileno, vapor de per\u00f3xido de hidr\u00f3geno.\n- **Indicadores Biol\u00f3gicos**: Herramientas para monitorear la eficacia de la esterilizaci\u00f3n.\n- **Condiciones de Proceso**: Humedad, temperatura, presi\u00f3n, concentraci\u00f3n de gas.\n- **Componentes**: Elementos que se ensamblan en el producto final y que deben ser esterilizados previamente.\n- **Registros**: Documentaci\u00f3n necesaria para validar el proceso de esterilizaci\u00f3n y asegurar su cumplimiento con las especificaciones.", "excerpt_keywords": "filtration, sterilization, integrity, pharmaceutical, microorganisms"}}, "04f62060-dd08-4c9d-8476-60cc3659d39f": {"node_ids": ["20c2267b-66d4-4c39-80df-bc61724d8140"], "metadata": {"page_label": "290", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 8. Isolator technology\n\n8.1 The use of isolator technology to minimize human interventions in processing areas may result in a significant decrease in the risk of microbial contamination of aseptically manufactured products from the environment. There are many possible designs of isolators and transfer devices. The isolator and the background environment should be designed so that the required air quality for each zone can be realized. Isolators are constructed of various materials more or less prone to puncture and leakage. Transfer devices may vary from single-door to double-door designs to fully-sealed systems incorporating sterilization mechanisms.\n\n8.2 The transfer of materials into and out of the unit is one of the greatest potential sources of contamination. In general the area inside the isolator is the local zone for high-risk manipulations, although it is recognized that unidirectional airflow may not exist in the working zone of all isolators and transfer devices.\n\n8.3 The air classification required for the background environment depends on the design of the isolator and its application. It should be controlled, and for aseptic processing it should be at least Grade D.\n\n8.4 Isolators should be introduced only after appropriate validation. Validation should take into account all critical factors of isolator technology, for example, the quality of the air inside and outside (background) the isolator, sanitization of the isolator, the transfer process and isolator integrity.\n\n8.5 Monitoring should be done routinely and should include frequent leak testing of the isolator and the glove/sleeve system.\n\n# 9. Blow/fill/seal technology\n\n9.1 Blow/fill/seal units are purpose-built machines in which, in one continuous operation, containers are formed from a thermoplastic granulate, filled and then sealed, all by the one automatic machine. Blow/fill/seal equipment used for aseptic production which is fitted with an effective Grade A air shower may be installed in at least a Grade C environment, provided that Grade A or B clothing is used. The environment should comply with the viable and non-viable limits at rest and the viable limit only when in operation. Blow/fill/seal equipment used for the production of products which are terminally sterilized should be installed in at least a Grade D environment.\n\n9.2 Because of this special technology, particular attention should be paid to at least the following:\n\n- equipment design and qualification;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento de la OMS aborda tecnolog\u00edas de aislamiento y de llenado/sellado, destacando la importancia de minimizar la intervenci\u00f3n humana en \u00e1reas de procesamiento para reducir el riesgo de contaminaci\u00f3n microbiana en productos fabricados as\u00e9pticamente. Se discuten los dise\u00f1os de los aisladores, la clasificaci\u00f3n del aire necesaria para el entorno de fondo, la validaci\u00f3n de los sistemas de aislamiento y la monitorizaci\u00f3n continua para garantizar la integridad del proceso.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que deben cumplirse para la validaci\u00f3n de los aisladores en el contexto de la fabricaci\u00f3n as\u00e9ptica?**\n   - Esta pregunta busca detalles sobre los factores cr\u00edticos que se deben considerar durante la validaci\u00f3n de los aisladores, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de dise\u00f1o de transferencias se recomienda para minimizar la contaminaci\u00f3n durante el proceso de transferencia de materiales en un aislador?**\n   - Esta pregunta se centra en los dise\u00f1os espec\u00edficos de dispositivos de transferencia que son m\u00e1s efectivos para reducir el riesgo de contaminaci\u00f3n, un aspecto que puede no estar ampliamente discutido en otros documentos.\n\n3. **\u00bfQu\u00e9 requisitos de calidad del aire son necesarios para el entorno de fondo de un aislador utilizado en procesamiento as\u00e9ptico?**\n   - Esta pregunta busca informaci\u00f3n sobre la clasificaci\u00f3n del aire y los est\u00e1ndares espec\u00edficos que deben cumplirse en el entorno de fondo de un aislador, lo cual es crucial para garantizar la seguridad del proceso de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Filtraci\u00f3n y Esterilizaci\u00f3n**: Se discuten m\u00e9todos de filtraci\u00f3n para soluciones y l\u00edquidos que no pueden ser esterilizados en el contenedor final. Se recomienda el uso de filtros est\u00e9riles con un tama\u00f1o de poro nominal de 0.22 micrones o menos.\n\n2. **Complemento de Procesos**: Se sugiere complementar la filtraci\u00f3n con tratamiento t\u00e9rmico, ya que la filtraci\u00f3n sola no es suficiente cuando la esterilizaci\u00f3n en el contenedor final es posible. La esterilizaci\u00f3n por vapor es el m\u00e9todo preferido.\n\n3. **Integridad de los Filtros**: La integridad de los filtros debe ser verificada antes y despu\u00e9s de su uso mediante m\u00e9todos como pruebas de punto de burbuja, flujo difusivo o pruebas de retenci\u00f3n de presi\u00f3n. Se deben registrar los resultados en el registro de lote.\n\n4. **Caracter\u00edsticas de los Filtros**: Los filtros deben tener caracter\u00edsticas de desprendimiento de fibras m\u00ednimas y no deben contener asbesto. Se recomienda el uso de una doble capa de filtraci\u00f3n o una segunda filtraci\u00f3n antes del llenado para mitigar riesgos adicionales.\n\n5. **Condiciones Severas**: En procesos que involucran condiciones severas, como la circulaci\u00f3n de aire a alta temperatura, se debe aumentar la monitorizaci\u00f3n de la integridad del filtro.\n\n6. **Uso de Filtros**: No se debe utilizar el mismo filtro por m\u00e1s de un d\u00eda laboral a menos que su uso haya sido validado. Adem\u00e1s, los filtros no deben afectar el producto, ya sea eliminando ingredientes o liberando sustancias en \u00e9l.\n\n### Entidades Clave\n- **Filtros**: Est\u00e9riles, con tama\u00f1o de poro de 0.22 micrones o menos, caracter\u00edsticas de desprendimiento de fibras m\u00ednimas, sin asbesto.\n- **M\u00e9todos de Verificaci\u00f3n**: Prueba de punto de burbuja, flujo difusivo, prueba de retenci\u00f3n de presi\u00f3n.\n- **Condiciones de Trabajo**: Circulaci\u00f3n de aire a alta temperatura.\n- **Procesos de Esterilizaci\u00f3n**: Filtraci\u00f3n, esterilizaci\u00f3n en el contenedor final, esterilizaci\u00f3n por vapor.", "excerpt_keywords": "Keywords: isolator technology, aseptic processing, microbial contamination, air quality classification, blow/fill/seal technology"}}, "21c4b7c1-2ca2-41f1-839d-a13aa2dea394": {"node_ids": ["918c61e7-8776-4bf3-a483-6501a1fe6385"], "metadata": {"page_label": "291", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Personnel\n\n10.1 Only the minimum number of personnel required should be present in clean areas; this is particularly important during aseptic processes. As far as possible, inspections and controls should be conducted from outside such areas.\n\n10.2 All personnel (including those concerned with cleaning and maintenance) employed in such areas should receive initial and regular training in disciplines relevant to the correct manufacture of sterile products, including hygiene and the basic elements of microbiology. When outside staff who have not received such training (e.g. building or maintenance contractors) need to be brought in, particular care should be taken over their instruction and supervision.\n\n10.3 Staff who have been engaged in the processing of animal-tissue materials or of cultures of microorganisms other than those used in the current manufacturing process should not enter sterile-product areas unless rigorous and clearly defined decontamination procedures have been followed.\n\n10.4 High standards of personal hygiene and cleanliness are essential and personnel involved in the manufacture of sterile preparations should be instructed to report any conditions that may cause the shedding of abnormal numbers or types of contaminants; periodic health checks for such conditions are desirable. The action to be taken in respect of personnel who might be introducing undue microbial hazards should be decided by a designated competent person.\n\n10.5 Changing and washing should follow a written procedure designed to minimize the contamination of clean-area clothing or the carry-through of contaminants to clean areas. The clothing and its quality should be appropriate for the process and the grade of the working area. It should be worn in such a way as to protect the product from contamination.\n\n10.6 Outdoor clothing should not be brought into changing rooms leading to Grade B and C rooms. For every worker in a Grade A/B area, clean sterile (sterilized or adequately sanitized) protective garments should be provided at each work session. Gloves should be regularly disinfected during production.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS establece directrices sobre el personal que trabaja en \u00e1reas limpias y en la fabricaci\u00f3n de productos est\u00e9riles. Se enfatiza la importancia de mantener un n\u00famero m\u00ednimo de personal en estas \u00e1reas, la necesidad de formaci\u00f3n regular en higiene y microbiolog\u00eda, y la implementaci\u00f3n de procedimientos rigurosos de descontaminaci\u00f3n. Tambi\u00e9n se abordan las normas de higiene personal, el uso adecuado de vestimenta y la prohibici\u00f3n de ropa exterior en \u00e1reas cr\u00edticas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n deben recibir los empleados que trabajan en \u00e1reas limpias y cu\u00e1les son los temas clave que deben abarcar?**\n   - Los empleados deben recibir formaci\u00f3n inicial y regular en disciplinas relevantes para la fabricaci\u00f3n correcta de productos est\u00e9riles, incluyendo higiene y los elementos b\u00e1sicos de microbiolog\u00eda.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse si se requiere la entrada de personal externo no capacitado en \u00e1reas est\u00e9riles?**\n   - Se debe tener especial cuidado en la instrucci\u00f3n y supervisi\u00f3n de estos trabajadores externos, asegurando que comprendan los procedimientos y riesgos asociados.\n\n3. **\u00bfCu\u00e1les son las recomendaciones sobre la vestimenta y el cambio de ropa para el personal que trabaja en \u00e1reas de grado A/B?**\n   - Se deben proporcionar prendas protectoras limpias y est\u00e9riles para cada sesi\u00f3n de trabajo, y se proh\u00edbe la entrada de ropa exterior en los vestuarios que conducen a las salas de grado B y C. Adem\u00e1s, los guantes deben desinfectarse regularmente durante la producci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Tecnolog\u00eda de Aisladores**:\n   - **Objetivo**: Minimizar la intervenci\u00f3n humana en \u00e1reas de procesamiento para reducir el riesgo de contaminaci\u00f3n microbiana en productos as\u00e9pticos.\n   - **Dise\u00f1os**: Existen diversos dise\u00f1os de aisladores y dispositivos de transferencia, que pueden incluir sistemas de una o dos puertas y mecanismos de esterilizaci\u00f3n.\n   - **Contaminaci\u00f3n**: La transferencia de materiales es una de las principales fuentes de contaminaci\u00f3n; el \u00e1rea dentro del aislador es considerada de alto riesgo.\n   - **Clasificaci\u00f3n del aire**: El entorno de fondo debe cumplir con una clasificaci\u00f3n de aire controlada, siendo al menos de Grado D para procesamiento as\u00e9ptico.\n   - **Validaci\u00f3n**: Los aisladores deben ser validados considerando factores cr\u00edticos como la calidad del aire, la sanitizaci\u00f3n, el proceso de transferencia y la integridad del aislador.\n   - **Monitoreo**: Se requiere monitoreo rutinario, incluyendo pruebas de fugas del aislador y del sistema de guantes/mangas.\n\n2. **Tecnolog\u00eda de Blow/Fill/Seal**:\n   - **Descripci\u00f3n**: M\u00e1quinas dise\u00f1adas para formar, llenar y sellar contenedores en una operaci\u00f3n continua.\n   - **Entorno de instalaci\u00f3n**: Equipos para producci\u00f3n as\u00e9ptica deben estar en un entorno de al menos Grado C, con ropa de Grado A o B, y cumplir con l\u00edmites viables y no viables.\n   - **Requisitos para productos esterilizados**: Equipos para productos que se esterilizan terminalmente deben estar en un entorno de al menos Grado D.\n   - **Atenci\u00f3n especial**: Se debe prestar atenci\u00f3n al dise\u00f1o y calificaci\u00f3n del equipo.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Aisladores**: Dispositivos utilizados para crear un entorno controlado.\n- **Dispositivos de transferencia**: Sistemas para mover materiales dentro y fuera de los aisladores.\n- **Clasificaci\u00f3n del aire**: Est\u00e1ndares de calidad del aire (Grado D, Grado C, Grado A, Grado B).\n- **Equipos Blow/Fill/Seal**: M\u00e1quinas espec\u00edficas para el llenado y sellado de productos.", "excerpt_keywords": "Keywords: personnel, sterile products, hygiene training, contamination control, clean areas"}}, "e6c1e64b-255c-48f4-85a7-5cc6b741bd50": {"node_ids": ["3c394d04-c360-45b5-afe0-d72f9d779f02"], "metadata": {"page_label": "292", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 10.7\n\nWrist-watches, cosmetics and jewellery should not be worn in clean areas.\n\n# 10.8\n\nThe clothing required for each grade is as follows:\n\n- **Grade D.** The hair and, where relevant, beard and moustache should be covered. Protective clothing and appropriate shoes or overshoes should be worn. Appropriate measures should be taken to avoid any contamination from outside the clean area.\n- **Grade C.** The hair and, where relevant, beard and moustache should be covered. A one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate shoes or overshoes should be worn. The clothing should shed virtually no fibres or particulate matter.\n- **Grades A and B.** Entry of personnel into Grade A areas should be minimized. Headgear should totally enclose the hair and, where relevant, beard and moustache. A one-piece jumpsuit, gathered at the wrists and with a high neck, should be worn. The headgear should be tucked into the neck of the suit. A facemask should be worn to prevent the shedding of droplets. Sterilized, non-powdered gloves of appropriate material and sterilized or disinfected footwear should be worn. Trouser-bottoms should be tucked inside the footwear and garment sleeves into the gloves. The protective clothing should shed virtually no fibres or particulate matter and should retain particles shed by the body.\n\n# 10.9\n\nClothing used in clean areas should be laundered or cleaned in such a way that it does not gather additional particulate contaminants that can later be shed. Separate laundry facilities for such clothing are desirable. If fibres are damaged by inappropriate cleaning or sterilization, there may be an increased risk of shedding particles. Washing and sterilization operations should follow standard operating procedures.\n\n# 11. Premises\n\n11.1 All premises should as far as possible be designed to avoid the unnecessary entry of supervisory or control personnel. Grade A and B areas should be designed so that all operations can be observed from outside.\n\n11.2 In clean areas all exposed surfaces should be smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and to permit the repeated application of cleaning agents and disinfectants, where used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la vestimenta y las condiciones de los locales en \u00e1reas limpias, que son esenciales para minimizar la contaminaci\u00f3n y la acumulaci\u00f3n de part\u00edculas. Se especifican los requisitos de vestimenta para diferentes grados de limpieza (A, B, C y D), as\u00ed como las caracter\u00edsticas de las instalaciones para asegurar un ambiente controlado y limpio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas de la vestimenta requerida para el personal que trabaja en \u00e1reas de Grado A y B, y por qu\u00e9 son importantes estas caracter\u00edsticas?**\n   - Respuesta: El personal en \u00e1reas de Grado A y B debe usar un traje de una sola pieza que se ajuste en las mu\u00f1ecas y el cuello, con un gorro que cubra completamente el cabello y, si es necesario, la barba y el bigote. Tambi\u00e9n deben usar una mascarilla, guantes esterilizados y calzado desinfectado. Estas caracter\u00edsticas son importantes para evitar la liberaci\u00f3n de part\u00edculas y microorganismos al ambiente, manteniendo as\u00ed la integridad del \u00e1rea limpia.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para el lavado y la limpieza de la ropa utilizada en \u00e1reas limpias, y por qu\u00e9 es crucial seguir estas medidas?**\n   - Respuesta: La ropa utilizada en \u00e1reas limpias debe ser lavada o limpiada de manera que no recoja contaminantes adicionales que puedan ser liberados posteriormente. Se recomienda tener instalaciones de lavander\u00eda separadas para esta ropa. Es crucial seguir estas medidas porque si las fibras se da\u00f1an por una limpieza inapropiada, puede aumentar el riesgo de liberaci\u00f3n de part\u00edculas contaminantes.\n\n3. **\u00bfC\u00f3mo deben estar dise\u00f1adas las instalaciones de las \u00e1reas limpias para minimizar la entrada de personal no esencial y facilitar la observaci\u00f3n de las operaciones?**\n   - Respuesta: Las instalaciones deben ser dise\u00f1adas para evitar la entrada innecesaria de personal de supervisi\u00f3n o control. En particular, las \u00e1reas de Grado A y B deben estar configuradas de tal manera que todas las operaciones puedan ser observadas desde el exterior, lo que ayuda a mantener la integridad del ambiente limpio y reduce el riesgo de contaminaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **N\u00famero M\u00ednimo de Personal:** Se debe mantener solo el personal necesario en \u00e1reas limpias, especialmente durante procesos as\u00e9pticos, y las inspecciones deben realizarse desde el exterior cuando sea posible.\n\n2. **Formaci\u00f3n del Personal:** Todos los empleados en \u00e1reas limpias deben recibir formaci\u00f3n inicial y continua en higiene y microbiolog\u00eda. Se debe prestar especial atenci\u00f3n a la instrucci\u00f3n y supervisi\u00f3n de personal externo no capacitado.\n\n3. **Descontaminaci\u00f3n:** El personal que haya trabajado con materiales de tejido animal o microorganismos diferentes a los utilizados en el proceso actual no debe ingresar a \u00e1reas est\u00e9riles sin seguir procedimientos de descontaminaci\u00f3n rigurosos.\n\n4. **Higiene Personal:** Se requieren altos est\u00e1ndares de higiene personal, y el personal debe informar sobre condiciones que puedan causar contaminaci\u00f3n. Se recomiendan chequeos de salud peri\u00f3dicos.\n\n5. **Procedimientos de Cambio y Lavado:** Deben seguirse procedimientos escritos para minimizar la contaminaci\u00f3n de la ropa de \u00e1rea limpia. La vestimenta debe ser adecuada para el proceso y el grado del \u00e1rea de trabajo.\n\n6. **Vestimenta en \u00c1reas Cr\u00edticas:** No se debe permitir la entrada de ropa exterior en vestuarios que conducen a salas de grado B y C. Se deben proporcionar prendas protectoras limpias y est\u00e9riles para cada sesi\u00f3n de trabajo, y los guantes deben desinfectarse regularmente.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **\u00c1reas Limpias:** Espacios donde se fabrican productos est\u00e9riles.\n- **Personal:** Empleados involucrados en la fabricaci\u00f3n, limpieza y mantenimiento en \u00e1reas limpias.\n- **Grados de \u00c1reas:** Clasificaci\u00f3n de \u00e1reas (A, B, C) seg\u00fan su nivel de limpieza y requisitos de control de contaminaci\u00f3n.", "excerpt_keywords": "Keywords: clean areas, protective clothing, contamination control, sterilization procedures, hygiene standards"}}, "6646fe25-720d-4a5a-9b1d-df14f4ab3d56": {"node_ids": ["66a5c9f3-e91f-478c-9d3f-ffa2a9f7c42a"], "metadata": {"page_label": "293", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 11.3 \nTo reduce the accumulation of dust and to facilitate cleaning, there should be no uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding doors may be undesirable for this reason. Swing doors should open to the high-pressure side and be provided with self-closers. Exceptions are permitted based on egress and site environmental, health and safety containment requirements.\n\n# 11.4 \nFalse ceilings should be sealed to prevent contamination from the void space above them.\n\n# 11.5 \nPipes and ducts and other utilities should be installed so that they do not create recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and fittings should be used and threaded pipe connections should be avoided.\n\n# 11.6 \nSinks and drains should be avoided wherever possible and should be excluded from Grade A and B areas where aseptic operations are carried out. Where installed they should be designed, located and maintained so as to minimize the risks of microbial contamination; they should be fitted with effective, easily cleanable traps and with air breaks to prevent backflow. Any floor channels should be open and easily cleanable and be connected to drains outside the area in a manner that prevents the ingress of microbial contaminants.\n\n# 11.7 \nChanging rooms should be designed as airlocks and used to provide physical separation of the different stages of changing and so minimize microbial and particulate contamination of protective clothing. They should be flushed effectively with filtered air. The final stage of the changing room should, in the at-rest state, be the same grade as the area into which it leads. The use of separate changing rooms for entering and leaving clean areas is sometimes desirable. In general hand-washing facilities should be provided only in the first stage of the changing rooms.\n\nThere should not be a change of more than one grade between airlocks or passages and changing rooms, i.e. a Grade D passage can lead to a Grade C airlock, which leads to a Grade B changing room, which leads to a Grade B clean room. Changing rooms should be of a sufficient size to allow for ease of changing. Changing rooms should be equipped with mirrors so that personnel can confirm the correct fit of garments before leaving the changing room.\n\n# 11.8 \nAirlock doors should not be opened simultaneously. An interlocking system and a visual and/or audible warning system should be operated to prevent the opening of more than one door at a time.\n\n# 11.9 \nA filtered air supply should be used to maintain a positive pressure and an airflow relative to surrounding areas of a lower grade under all operational conditions; it should flush the area effectively. Adjacent rooms", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl texto proporciona directrices sobre el dise\u00f1o y mantenimiento de \u00e1reas limpias y entornos controlados, enfatizando la importancia de minimizar la acumulaci\u00f3n de polvo y la contaminaci\u00f3n microbiana. Se abordan aspectos como el dise\u00f1o de puertas, la instalaci\u00f3n de techos falsos, la ubicaci\u00f3n de tuber\u00edas y desag\u00fces, el dise\u00f1o de vestuarios como \u00e1reas de aire de separaci\u00f3n, y la necesidad de un suministro de aire filtrado para mantener la presi\u00f3n positiva. Tambi\u00e9n se menciona la importancia de evitar cambios de grado inadecuados entre \u00e1reas y la implementaci\u00f3n de sistemas de interbloqueo para las puertas de aire.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las puertas en \u00e1reas limpias para evitar la acumulaci\u00f3n de polvo y facilitar la limpieza?**\n   - Respuesta: Las puertas deben estar dise\u00f1adas para evitar recovecos inalcanzables, preferiblemente deben ser puertas oscilantes que abran hacia el lado de alta presi\u00f3n y contar con mecanismos de cierre autom\u00e1tico.\n\n2. **\u00bfQu\u00e9 medidas deben tomarse en el dise\u00f1o de los vestuarios para minimizar la contaminaci\u00f3n microbiana y particulada?**\n   - Respuesta: Los vestuarios deben ser dise\u00f1ados como aire de separaci\u00f3n, deben ser eficaces en el flujo de aire filtrado, y no debe haber un cambio de m\u00e1s de un grado entre los pasillos y los vestuarios. Adem\u00e1s, deben ser lo suficientemente amplios y contar con espejos para que el personal pueda verificar el ajuste de la vestimenta.\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al instalar desag\u00fces y fregaderos en \u00e1reas de alta clasificaci\u00f3n?**\n   - Respuesta: Los fregaderos y desag\u00fces deben evitarse en \u00e1reas de Grado A y B, y si se instalan, deben estar dise\u00f1ados y mantenidos para minimizar el riesgo de contaminaci\u00f3n microbiana, incluyendo trampas de f\u00e1cil limpieza y sistemas de ruptura de aire para prevenir el retroceso.", "prev_section_summary": "### Temas Clave\n\n1. **Vestimenta en \u00c1reas Limpias:**\n   - Prohibici\u00f3n de relojes, cosm\u00e9ticos y joyas.\n   - Requisitos espec\u00edficos de vestimenta para diferentes grados de limpieza (A, B, C y D).\n   - Importancia de la vestimenta para minimizar la contaminaci\u00f3n y la liberaci\u00f3n de part\u00edculas.\n\n2. **Limpieza y Mantenimiento de Ropa:**\n   - Procedimientos para el lavado y limpieza de la ropa utilizada en \u00e1reas limpias.\n   - Necesidad de instalaciones de lavander\u00eda separadas.\n   - Riesgos asociados con la limpieza inapropiada que puede da\u00f1ar las fibras.\n\n3. **Dise\u00f1o de Instalaciones:**\n   - Dise\u00f1o de locales para evitar la entrada innecesaria de personal no esencial.\n   - Observaci\u00f3n de operaciones desde el exterior en \u00e1reas de Grado A y B.\n   - Caracter\u00edsticas de las superficies en \u00e1reas limpias para minimizar la acumulaci\u00f3n de part\u00edculas y microorganismos.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices.\n- **Grados de Limpieza:** Clasificaci\u00f3n de \u00e1reas (A, B, C, D) con requisitos espec\u00edficos de vestimenta y dise\u00f1o.\n- **Personal:** Trabajadores que deben cumplir con las normativas de vestimenta y limpieza.\n- **Superficies Expuestas:** Elementos del dise\u00f1o de instalaciones que deben ser lisos e impermeables.\n- **Procedimientos Operativos Est\u00e1ndar:** Normas que deben seguirse para el lavado y esterilizaci\u00f3n de la ropa. \n\nEste resumen destaca la importancia de las directrices de vestimenta y dise\u00f1o de instalaciones en la prevenci\u00f3n de la contaminaci\u00f3n en \u00e1reas limpias, as\u00ed como los procedimientos necesarios para mantener la integridad de estas \u00e1reas.", "excerpt_keywords": "Keywords: cleanroom design, contamination control, airlock systems, aseptic operations, filtered air supply"}}, "f87a4bd3-a097-4637-b479-b625edca762c": {"node_ids": ["e4d08e75-a422-44df-956e-93d1cb614c66"], "metadata": {"page_label": "294", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\nof different grades should have a pressure differential of approximately 10\u201315 Pascals (guidance value). Particular attention should be paid to the protection of the zone of greatest risk, i.e. the immediate environment to which the product and the cleaned components in contact with it are exposed. The recommendations regarding air supplies and pressure differentials may need to be modified where it becomes necessary to contain certain materials, e.g. pathogenic, highly toxic, radioactive or live viral or bacterial materials or products. The decontamination of the facilities and the treatment of air leaving a clean area may be necessary for some operations.\n\n11.10 It should be demonstrated that airflow patterns do not present a contamination risk; for example, care should be taken to ensure that particles from a particle-generating person, operation or machine are not conveyed to a zone of higher product risk.\n\n11.11 A warning system should be operated to indicate failure in the air supply. Indicators of pressure differentials should be fitted between areas where this difference is important, and the pressure differentials should be regularly recorded and failure alarmed.\n\n11.12 Consideration should be given to restricting unnecessary access to critical filling areas, e.g. Grade A filling zones, by means of a physical barrier.\n\n## 12. Equipment\n\n12.1 A conveyor belt should not pass through a partition between a Grade A or B clean area and a processing area of lower air cleanliness, unless the belt itself is continuously sterilized (e.g. in a sterilizing tunnel).\n\n12.2 Whenever possible, equipment used for processing sterile products should be chosen so that it can be effectively sterilized by steam or dry heat or other methods.\n\n12.3 As far as possible, equipment fittings and services should be designed and installed so that operations, maintenance and repairs can be carried out outside the clean area. Equipment that has to be taken apart for maintenance should be re-sterilized after complete reassembly, wherever possible.\n\n12.4 When equipment maintenance is carried out within a clean area, clean instruments and tools should be used and the area should be cleaned and disinfected again, where appropriate, before processing recommences, if the required standards of cleanliness and/or asepsis have not been maintained during the maintenance work.\n\n12.5 All equipment such as sterilizers, air-handling and filtration systems, air vent and gas filters, water treatment, generation, storage and distribution.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Recomendaciones sobre el control de la contaminaci\u00f3n en \u00e1reas limpias**: El documento establece directrices sobre c\u00f3mo mantener la calidad del aire y prevenir la contaminaci\u00f3n en \u00e1reas de procesamiento de productos est\u00e9riles. Se enfatiza la importancia de las diferencias de presi\u00f3n, el flujo de aire y la restricci\u00f3n de acceso a zonas cr\u00edticas.\n\n2. **Mantenimiento y esterilizaci\u00f3n de equipos**: Se detallan las mejores pr\u00e1cticas para el mantenimiento de equipos en \u00e1reas limpias, incluyendo la necesidad de esterilizaci\u00f3n de herramientas y equipos, as\u00ed como la importancia de realizar operaciones de mantenimiento fuera de estas \u00e1reas siempre que sea posible.\n\n3. **Equipos y sistemas de soporte**: Se menciona la importancia de seleccionar equipos que puedan ser esterilizados efectivamente y la necesidad de sistemas de manejo de aire y filtraci\u00f3n para mantener la calidad del aire en \u00e1reas de procesamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas para el mantenimiento de equipos dentro de un \u00e1rea limpia y qu\u00e9 procedimientos deben seguirse para garantizar la limpieza y la asepsia?**\n   - El documento indica que, al realizar mantenimiento dentro de un \u00e1rea limpia, se deben utilizar instrumentos y herramientas limpias, y el \u00e1rea debe ser limpiada y desinfectada nuevamente antes de reanudar el procesamiento, si no se han mantenido los est\u00e1ndares requeridos de limpieza y/o asepsia.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los patrones de flujo de aire no representen un riesgo de contaminaci\u00f3n en \u00e1reas de mayor riesgo de producto?**\n   - Se debe demostrar que los patrones de flujo de aire no presentan un riesgo de contaminaci\u00f3n, asegurando que las part\u00edculas generadas por personas, operaciones o m\u00e1quinas no se transporten a zonas de mayor riesgo de producto.\n\n3. **\u00bfQu\u00e9 tipo de equipos se recomienda utilizar para el procesamiento de productos est\u00e9riles y cu\u00e1les son las consideraciones para su instalaci\u00f3n y mantenimiento?**\n   - Se recomienda elegir equipos que puedan ser esterilizados efectivamente por m\u00e9todos como vapor o calor seco. Adem\u00e1s, los accesorios y servicios del equipo deben ser dise\u00f1ados para permitir operaciones, mantenimiento y reparaciones fuera del \u00e1rea limpia, y cualquier equipo que deba ser desensamblado para mantenimiento debe ser re-esterilizado despu\u00e9s de su reensamblaje.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dise\u00f1o de \u00c1reas Limpias**:\n   - Importancia de evitar recovecos inalcanzables y superficies dif\u00edciles de limpiar.\n   - Recomendaciones sobre el dise\u00f1o de puertas (puertas oscilantes, cierre autom\u00e1tico).\n\n2. **Techos Falsos**:\n   - Necesidad de sellar techos falsos para prevenir la contaminaci\u00f3n desde el espacio superior.\n\n3. **Instalaci\u00f3n de Tuber\u00edas y Ductos**:\n   - Deben evitarse recovecos y aberturas sin sellar.\n   - Uso de tuber\u00edas sanitarias y evitar conexiones roscadas.\n\n4. **Sistemas de Saneamiento**:\n   - Evitar fregaderos y desag\u00fces en \u00e1reas de Grado A y B.\n   - Si se instalan, deben minimizar el riesgo de contaminaci\u00f3n microbiana.\n\n5. **Dise\u00f1o de Vestuarios**:\n   - Deben funcionar como aire de separaci\u00f3n para minimizar la contaminaci\u00f3n.\n   - Importancia de un flujo de aire filtrado y la correcta clasificaci\u00f3n de \u00e1reas.\n\n6. **Interbloqueo de Puertas**:\n   - Sistemas para evitar la apertura simult\u00e1nea de puertas de aire.\n\n7. **Suministro de Aire Filtrado**:\n   - Mantener presi\u00f3n positiva y flujo de aire adecuado en \u00e1reas controladas.\n\n### Entidades Clave\n- **Grados de Clasificaci\u00f3n**: Grado A, B, C, D.\n- **Elementos de Dise\u00f1o**: Puertas, techos falsos, tuber\u00edas, fregaderos, vestuarios.\n- **Contaminaci\u00f3n Microbiana**: Riesgos asociados y medidas de mitigaci\u00f3n.\n- **Sistemas de Aire**: Filtraci\u00f3n y presi\u00f3n positiva. \n\nEste resumen destaca la importancia de un dise\u00f1o cuidadoso y la implementaci\u00f3n de medidas espec\u00edficas para mantener la limpieza y la seguridad en entornos controlados.", "excerpt_keywords": "Keywords: clean areas, sterilization, air quality, contamination control, equipment maintenance"}}, "24880c04-83f7-4990-93d7-fc302649b66d": {"node_ids": ["05e2c9db-6f03-4415-944c-dea324052c8b"], "metadata": {"page_label": "295", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Finishing of Sterile Products\n\n13.1 Containers should be closed by appropriately validated methods. Containers closed by fusion, e.g., glass or plastic ampoules, should be subject to 100% integrity testing. Samples of other containers should be checked for integrity according to appropriate procedures.\n\n13.2 The container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped into place on the stoppered vial. Crimping of the cap should, therefore, be performed as soon as possible after stopper insertion.\n\n13.3 As the equipment used to crimp vial caps can generate large quantities of non-viable particulates, the equipment should be located at a separate station equipped with adequate air extraction.\n\n13.4 Vial capping can be undertaken as an aseptic process using sterilized caps or as a clean process outside the aseptic core. Where this latter approach is adopted, vials should be protected by Grade A conditions up to the point of leaving the aseptic processing area, and thereafter stoppered vials should be protected with a Grade A air supply until the cap has been crimped.\n\n13.5 Vials with missing or displaced stoppers should be rejected prior to capping. Where human intervention is required at the capping station, appropriate technology should be used to prevent direct contact with the vials and to minimize microbial contamination.\n\n13.6 Restricted access barriers and isolators may be beneficial in assuring the required conditions and minimizing direct human interventions into the capping operation.\n\n13.7 Containers sealed under vacuum should be tested for maintenance of that vacuum after an appropriate, predetermined period.\n\n13.8 Filled containers of parenteral products should be inspected individually for extraneous contamination or other defects. When inspection is carried", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las pr\u00e1cticas recomendadas para el acabado de productos est\u00e9riles, centr\u00e1ndose en la integridad de los envases, el proceso de cierre de viales, y las medidas de control para minimizar la contaminaci\u00f3n microbiana. Se enfatiza la importancia de utilizar m\u00e9todos validados para cerrar los envases, la necesidad de realizar pruebas de integridad, y las condiciones de trabajo adecuadas para asegurar la calidad del producto final.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de pruebas de integridad se deben realizar en los envases cerrados por fusi\u00f3n, como ampollas de vidrio o pl\u00e1stico?**\n   - Respuesta: Los envases cerrados por fusi\u00f3n deben someterse a pruebas de integridad al 100%.\n\n2. **\u00bfCu\u00e1l es el procedimiento recomendado para el cierre de viales despu\u00e9s de la inserci\u00f3n del tap\u00f3n?**\n   - Respuesta: El crimpado de la tapa debe realizarse lo antes posible despu\u00e9s de la inserci\u00f3n del tap\u00f3n para asegurar que el sistema de cierre del envase sea completamente integral.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para minimizar la contaminaci\u00f3n microbiana durante el proceso de capping de viales?**\n   - Respuesta: Se deben utilizar tecnolog\u00edas apropiadas para evitar el contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana, adem\u00e1s de considerar el uso de barreras de acceso restringido y aisladores para asegurar las condiciones requeridas.\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices sobre el acabado de productos est\u00e9riles, destacando la importancia de m\u00e9todos validados para el cierre de envases, la realizaci\u00f3n de pruebas de integridad, y el control de la contaminaci\u00f3n microbiana durante el proceso de capping. Se enfatiza la necesidad de proteger los viales en condiciones de calidad adecuadas y de rechazar aquellos con tapones faltantes o desplazados antes del cierre.", "prev_section_summary": "### Temas Clave\n\n1. **Control de Contaminaci\u00f3n en \u00c1reas Limpias**: Se enfatiza la importancia de mantener diferencias de presi\u00f3n y patrones de flujo de aire adecuados para prevenir la contaminaci\u00f3n en zonas de alto riesgo, especialmente en \u00e1reas de procesamiento de productos est\u00e9riles.\n\n2. **Mantenimiento y Esterilizaci\u00f3n de Equipos**: Se establecen directrices sobre el mantenimiento de equipos en \u00e1reas limpias, destacando la necesidad de utilizar herramientas limpias y de desinfectar el \u00e1rea despu\u00e9s de cualquier trabajo de mantenimiento.\n\n3. **Selecci\u00f3n y Dise\u00f1o de Equipos**: Se recomienda elegir equipos que puedan ser esterilizados eficazmente y que est\u00e9n dise\u00f1ados para facilitar el mantenimiento fuera de las \u00e1reas limpias.\n\n4. **Sistemas de Alerta y Monitoreo**: Se sugiere implementar sistemas de advertencia para detectar fallos en el suministro de aire y registrar las diferencias de presi\u00f3n entre \u00e1reas cr\u00edticas.\n\n### Entidades\n\n- **\u00c1reas Limpias**: Clasificadas como Grado A y B, donde se procesan productos est\u00e9riles.\n- **Equipos**: Incluyen cintas transportadoras, esterilizadores, sistemas de manejo de aire y filtraci\u00f3n, y sistemas de tratamiento de agua.\n- **Materiales**: Pat\u00f3genos, t\u00f3xicos, radiactivos, y productos virales o bacterianos vivos.\n- **Procedimientos de Mantenimiento**: Uso de instrumentos limpios, limpieza y desinfecci\u00f3n del \u00e1rea, re-esterilizaci\u00f3n de equipos desensamblados.\n- **Sistemas de Monitoreo**: Indicadores de presi\u00f3n diferencial y sistemas de advertencia para fallos en el suministro de aire.", "excerpt_keywords": "Keywords: sterile products, container integrity, vial capping, microbial contamination, aseptic processing"}}, "8f43f4f3-fca5-4d79-8bef-c24ebfe0bf33": {"node_ids": ["2a1d7c0f-814b-45bb-8c31-cff45bc41183"], "metadata": {"page_label": "296", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# References\n\n1. Good manufacturing practices for sterile pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902), Annex 6; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; and in Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. Geneva, World Health Organization, 2010 (CD-ROM).\n\n2. ISO 14644-1. Clean rooms and associated controlled environments. Part 1: Classification of airborne particles. Geneva, International Organization for Standardization.\n\n3. ISO 14644-3. Clean rooms and associated controlled environments. Part 3: Test methods. Geneva, International Organization for Standardization.\n\n4. ISO 1822-4. High efficiency air filters (HEPA and ULPA). Determining leakage of filter elements (scan method).\n\n5. ISO 14644-4. Clean rooms and associated controlled environments. Part 4: Design, construction and start-up. Geneva, International Organization for Standardization.\n\n6. ISO 14644-2. Clean rooms and associated controlled environments. Part 2: Monitoring for continued compliance with ISO 14644-1. Geneva, International Organization for Standardization.\n\n7. ISO 14644-5 Clean rooms and associated controlled environments. Part 5: Cleanroom operations. Geneva, International Organization for Standardization.\n\n8. Good manufacturing practices for pharmaceutical products: water for pharmaceutical use. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 3; and in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2. 2nd updated ed. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007.\n\n# Further reading\n\n- FDA Guidance for Industry. *Sterile drug products produced by aseptic processing \u2014 cGMP*. US Food and Drug Administration, 2004.\n\n- Guidance for industry. *Sterile drug products produced by aseptic processing*. Japan, 2005.\n\n- Manufacture of sterile medicinal products. In: *The rules governing medicinal products in the European Union Vol. 4. EU guidelines to good manufacturing practice medicinal products for human and veterinary use*. Annex 1, Brussels, 2008.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las buenas pr\u00e1cticas de fabricaci\u00f3n (BPF) para productos farmac\u00e9uticos est\u00e9riles. Incluye referencias a normas internacionales, como las de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO), que abordan la clasificaci\u00f3n de part\u00edculas en salas limpias, m\u00e9todos de prueba, dise\u00f1o y operaci\u00f3n de estas instalaciones. Tambi\u00e9n se mencionan directrices adicionales de la FDA y regulaciones de la Uni\u00f3n Europea sobre la fabricaci\u00f3n de productos medicinales est\u00e9riles.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales normas ISO mencionadas en el documento y qu\u00e9 aspectos de las salas limpias abordan?**\n   - Esta pregunta busca respuestas sobre las normas ISO espec\u00edficas y su enfoque en la clasificaci\u00f3n, pruebas y operaci\u00f3n de salas limpias, que son cruciales para la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n\n2. **\u00bfQu\u00e9 se incluye en las buenas pr\u00e1cticas de fabricaci\u00f3n para el agua utilizada en productos farmac\u00e9uticos seg\u00fan el informe de la OMS?**\n   - Esta pregunta se centra en las directrices espec\u00edficas sobre el uso del agua en la fabricaci\u00f3n de productos farmac\u00e9uticos, un aspecto cr\u00edtico que puede no estar ampliamente documentado en otras fuentes.\n\n3. **\u00bfQu\u00e9 diferencias existen entre las directrices de la FDA y las de la OMS en relaci\u00f3n con la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles?**\n   - Esta pregunta busca explorar las variaciones en las regulaciones y directrices entre dos de las principales organizaciones de salud, lo que puede proporcionar una comprensi\u00f3n m\u00e1s profunda de las pr\u00e1cticas de fabricaci\u00f3n en diferentes contextos regulatorios.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **M\u00e9todos de Cierre de Envases**:\n   - Importancia de utilizar m\u00e9todos validados para cerrar los envases.\n   - Pruebas de integridad al 100% para envases cerrados por fusi\u00f3n (ampollas de vidrio o pl\u00e1stico).\n\n2. **Cierre de Viales**:\n   - El sistema de cierre de viales no es completamente integral hasta que la tapa de aluminio est\u00e9 crimpada.\n   - El crimpado debe realizarse lo antes posible despu\u00e9s de la inserci\u00f3n del tap\u00f3n.\n\n3. **Control de Contaminaci\u00f3n**:\n   - Equipos de crimpado deben estar en estaciones separadas con adecuada extracci\u00f3n de aire para minimizar part\u00edculas no viables.\n   - Uso de tecnolog\u00edas para evitar contacto directo con los viales y minimizar la contaminaci\u00f3n microbiana.\n\n4. **Condiciones de Protecci\u00f3n**:\n   - Viales deben ser protegidos bajo condiciones de Grado A hasta que se complete el crimpado.\n   - Barreras de acceso restringido y aisladores pueden ayudar a mantener las condiciones requeridas.\n\n5. **Rechazo de Viales**:\n   - Viales con tapones faltantes o desplazados deben ser rechazados antes del cierre.\n\n6. **Pruebas de Vac\u00edo**:\n   - Envases sellados al vac\u00edo deben ser probados para asegurar el mantenimiento del vac\u00edo despu\u00e9s de un per\u00edodo predeterminado.\n\n7. **Inspecci\u00f3n de Productos Parenterales**:\n   - Inspecci\u00f3n individual de envases llenos para detectar contaminaci\u00f3n extr\u00ednseca o defectos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Envases**: Incluyen ampollas de vidrio y pl\u00e1stico, viales.\n- **Contaminaci\u00f3n Microbiana**: Riesgo que se busca minimizar durante el proceso de capping.\n- **Grado A**: Clasificaci\u00f3n de condiciones de aire necesarias para la protecci\u00f3n de viales.\n- **Viales**: Contenedores utilizados para productos est\u00e9riles, especialmente parenterales.", "excerpt_keywords": "Keywords: buenas pr\u00e1cticas de fabricaci\u00f3n, productos farmac\u00e9uticos est\u00e9riles, salas limpias, normas ISO, regulaci\u00f3n sanitaria"}}, "9b94f19d-ceac-4f40-a2ad-ff8e943a4d6a": {"node_ids": ["39383a4f-621f-4401-9797-1eb11f33ffa7"], "metadata": {"page_label": "297", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 7\n\n## WHO guidelines on transfer of technology in pharmaceutical manufacturing\n\n1. Introduction\n2. Scope\n3. Glossary\n4. Organization and management\n5. Production: transfer (processing, packaging and cleaning)\n6. Quality control: analytical method transfer\n7. Premises and equipment\n8. Documentation\n9. Qualification and validation\n\nReferences", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una secci\u00f3n titulada \"Anexo 7\", que presenta directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica. Este anexo abarca varios aspectos clave, como la introducci\u00f3n al tema, el alcance de las directrices, un glosario de t\u00e9rminos, la organizaci\u00f3n y gesti\u00f3n del proceso, as\u00ed como detalles sobre la producci\u00f3n, control de calidad, instalaciones y equipos, documentaci\u00f3n, y los procesos de calificaci\u00f3n y validaci\u00f3n.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los principales componentes que se abordan en las directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica?**\n   - Respuesta: Los principales componentes incluyen la introducci\u00f3n, el alcance, un glosario, organizaci\u00f3n y gesti\u00f3n, producci\u00f3n, control de calidad, instalaciones y equipos, documentaci\u00f3n, y calificaci\u00f3n y validaci\u00f3n.\n\n2. **\u00bfQu\u00e9 aspectos se consideran en la secci\u00f3n de \"Producci\u00f3n\" de las directrices sobre transferencia de tecnolog\u00eda?**\n   - Respuesta: La secci\u00f3n de \"Producci\u00f3n\" aborda el proceso de transferencia, que incluye el procesamiento, el empaquetado y la limpieza.\n\n3. **\u00bfQu\u00e9 importancia tiene la \"calificaci\u00f3n y validaci\u00f3n\" en el contexto de la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica seg\u00fan las directrices de la OMS?**\n   - Respuesta: La \"calificaci\u00f3n y validaci\u00f3n\" son cruciales para asegurar que los procesos y equipos utilizados en la fabricaci\u00f3n farmac\u00e9utica cumplen con los est\u00e1ndares de calidad y eficacia requeridos, garantizando as\u00ed la seguridad y efectividad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**:\n   - El documento se centra en las BPF para productos farmac\u00e9uticos est\u00e9riles, destacando la importancia de seguir directrices espec\u00edficas para garantizar la calidad y seguridad de estos productos.\n\n2. **Normas ISO**:\n   - Se mencionan varias normas de la Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO) relacionadas con salas limpias y entornos controlados:\n     - **ISO 14644-1**: Clasificaci\u00f3n de part\u00edculas en el aire.\n     - **ISO 14644-2**: Monitoreo para el cumplimiento continuo.\n     - **ISO 14644-3**: M\u00e9todos de prueba.\n     - **ISO 14644-4**: Dise\u00f1o, construcci\u00f3n y puesta en marcha.\n     - **ISO 14644-5**: Operaciones en salas limpias.\n     - **ISO 1822-4**: Determinaci\u00f3n de fugas en filtros de alta eficiencia (HEPA y ULPA).\n\n3. **Agua para Uso Farmac\u00e9utico**:\n   - Se abordan las BPF espec\u00edficas para el agua utilizada en la fabricaci\u00f3n de productos farmac\u00e9uticos, subrayando su relevancia en el proceso de producci\u00f3n.\n\n4. **Referencias Adicionales**:\n   - Se incluyen gu\u00edas de la FDA y regulaciones de la Uni\u00f3n Europea sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, lo que proporciona un contexto m\u00e1s amplio sobre las normativas internacionales.\n\n5. **Entidades Involucradas**:\n   - **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y reportes sobre BPF.\n   - **Organizaci\u00f3n Internacional de Normalizaci\u00f3n (ISO)**: Establece normas para la clasificaci\u00f3n y operaci\u00f3n de salas limpias.\n   - **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Ofrece gu\u00edas sobre la producci\u00f3n de productos farmac\u00e9uticos est\u00e9riles.\n   - **Uni\u00f3n Europea**: Regula las buenas pr\u00e1cticas de fabricaci\u00f3n para productos medicinales.\n\nEste resumen destaca la importancia de las BPF y las normas ISO en la fabricaci\u00f3n de productos farmac\u00e9uticos est\u00e9riles, as\u00ed como las entidades que contribuyen a establecer y regular estas pr\u00e1cticas.", "excerpt_keywords": "Keywords: transfer of technology, pharmaceutical manufacturing, quality control, qualification and validation, WHO guidelines"}}, "c2c147a2-7f1b-43d0-bdf1-3461e9891d82": {"node_ids": ["ec11e5b2-352a-4546-9394-ef3460de2b5f"], "metadata": {"page_label": "298", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThese guiding principles on transfer of technology are intended to serve as a framework which can be applied in a flexible manner rather than as strict rigid guidance. Focus has been placed on the quality aspects, in line with WHO\u2019s mandate.\n\n1.1 Transfer of processes to an alternative site occurs at some stage in the life-cycle of most products, from development, scale-up, manufacturing, production and launch, to the post-approval phase.\n\n1.2 Transfer of technology is defined as \u201ca logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites\u201d. It is a systematic procedure that is followed in order to pass the documented knowledge and experience gained during development and or commercialization to an appropriate, responsible and authorized party. Technology transfer embodies both the transfer of documentation and the demonstrated ability of the receiving unit (RU) to effectively perform the critical elements of the transferred technology, to the satisfaction of all parties and any applicable regulatory bodies.\n\n1.3 Literature searches revealed little information on the subject originating from national or regional regulatory bodies. Guidance on intracompany transfers was prepared by the International Society for Pharmaceutical Engineering (ISPE) (1).\n\n1.4 The ever changing business strategies of pharmaceutical companies increasingly involve intra- and intercompany transfers of technology for reasons such as the need for additional capacity, relocation of operations or consolidations and mergers. The WHO Expert Committee on Specifications for Pharmaceutical Preparations, therefore, recommended in its forty-second report that WHO address this issue through preparation of WHO guidelines on this matter (2).\n\n1.5 Transfer of technology requires a documented, planned approach using trained and knowledgeable personnel working within a quality system, with documentation of data covering all aspects of development, production and quality control. Usually there is a sending unit (SU), a receiving unit and the unit managing the process, which may or may not be a separate entity. For \u201ccontract manufacturing\u201d please see good manufacturing practices (GMP) (3).\n\n1.6 For the transfer to be successful, the following general principles and requirements should be met:\n\n- the project plan should encompass the quality aspects of the project and be based upon the principles of quality risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece principios orientadores sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica. Se define la transferencia de tecnolog\u00eda como un procedimiento l\u00f3gico que controla el traspaso de procesos, documentaci\u00f3n y experiencia profesional entre el desarrollo y la fabricaci\u00f3n, o entre sitios de fabricaci\u00f3n. Se enfatiza la importancia de un enfoque documentado y planificado, el uso de personal capacitado y la necesidad de cumplir con los aspectos de calidad y gesti\u00f3n de riesgos. Adem\u00e1s, se menciona la creciente tendencia de las empresas farmac\u00e9uticas a realizar transferencias intra- e interempresariales debido a cambios en sus estrategias comerciales.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los elementos cr\u00edticos que deben ser transferidos durante el proceso de transferencia de tecnolog\u00eda seg\u00fan la OMS?**\n   - Esta pregunta busca detalles sobre los componentes espec\u00edficos que se consideran esenciales en la transferencia de tecnolog\u00eda, m\u00e1s all\u00e1 de la documentaci\u00f3n y la experiencia.\n\n2. **\u00bfQu\u00e9 papel juega la gesti\u00f3n de riesgos de calidad en la planificaci\u00f3n de un proyecto de transferencia de tecnolog\u00eda?**\n   - Esta pregunta se centra en c\u00f3mo se integran los principios de gesti\u00f3n de riesgos de calidad en el desarrollo del plan del proyecto, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 recomendaciones espec\u00edficas hizo el Comit\u00e9 de Expertos de la OMS sobre la transferencia de tecnolog\u00eda en su cuadrag\u00e9simo segundo informe?**\n   - Esta pregunta busca informaci\u00f3n sobre las recomendaciones concretas que la OMS ha hecho en relaci\u00f3n con la transferencia de tecnolog\u00eda, que podr\u00edan no estar disponibles en otros documentos o gu\u00edas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl \"Anexo 7\" del documento \"WHO - Technical Report Series 961\" presenta directrices de la OMS sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica. Los temas clave abordados en esta secci\u00f3n incluyen:\n\n1. **Introducci\u00f3n**: Presenta el contexto y la importancia de la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n2. **Alcance**: Define los l\u00edmites y la aplicabilidad de las directrices.\n3. **Glosario**: Proporciona definiciones de t\u00e9rminos relevantes utilizados en el documento.\n4. **Organizaci\u00f3n y gesti\u00f3n**: Describe la estructura organizativa y los procesos de gesti\u00f3n necesarios para implementar la transferencia de tecnolog\u00eda.\n5. **Producci\u00f3n**: Detalla el proceso de transferencia en la producci\u00f3n, que incluye el procesamiento, empaquetado y limpieza de productos farmac\u00e9uticos.\n6. **Control de calidad**: Se centra en la transferencia de m\u00e9todos anal\u00edticos para asegurar la calidad de los productos.\n7. **Instalaciones y equipos**: Aborda los requisitos y est\u00e1ndares para las instalaciones y equipos utilizados en la fabricaci\u00f3n.\n8. **Documentaci\u00f3n**: Enfatiza la importancia de la documentaci\u00f3n adecuada en todos los procesos de transferencia.\n9. **Calificaci\u00f3n y validaci\u00f3n**: Explica los procesos necesarios para asegurar que los sistemas y procesos cumplen con los est\u00e1ndares de calidad.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Fabricaci\u00f3n farmac\u00e9utica**: Sector industrial al que se aplican las directrices.\n- **Transferencia de tecnolog\u00eda**: Proceso central del documento que abarca varios aspectos de la producci\u00f3n y control de calidad.\n\nEste resumen destaca los componentes esenciales y las entidades involucradas en las directrices sobre la transferencia de tecnolog\u00eda en la fabricaci\u00f3n farmac\u00e9utica seg\u00fan la OMS.", "excerpt_keywords": "Keywords: technology transfer, pharmaceutical manufacturing, quality management, regulatory guidelines, process documentation"}}, "13a03394-23fc-4f92-92cb-7c5e59177645": {"node_ids": ["19da3a1e-32ce-43f2-b13b-152455619c80"], "metadata": {"page_label": "299", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- the capabilities of the SU and at the RU should be similar, but not necessarily identical, and facilities and equipment should operate according to similar operating principles;\n- a comprehensive technical gap analysis between the SU and RU including technical risk assessment and potential regulatory gaps, should be performed as needed;\n- adequately trained staff should be available or should be trained at the RU:\n  - regulatory requirements in the countries of the SU and the RU, and in any countries where the product is intended to be supplied, should be taken into account and interpreted consistently throughout any transfer programme project; and\n  - there should be effective process and product knowledge transfer.\n\n1.7 Technology transfer can be considered successful if there is documented evidence that the RU can routinely reproduce the transferred product, process or method against a predefined set of specifications as agreed with the SU.\n\n1.8 In the event that the RU identifies particular problems with the process during the transfer, the RU should communicate them back to the SU to ensure continuing knowledge management.\n\n1.9 Technology transfer projects, particularly those between different companies, have legal and economic implications. If such issues, which may include intellectual property rights, royalties, pricing, conflict of interest and confidentiality, are expected to impact on open communication of technical matters in any way, they should be addressed before and during planning and execution of the transfer.\n\n1.10 Any lack of transparency may lead to ineffective transfer of technology.\n\n1.11 Some of the principles outlined in this document may also be applicable to manufacturing investigational pharmaceutical products for clinical trials as part of research and development, but this is not the main focus of this guidance and has been excluded due to the complexity of the processes.\n\n1.12 Some of the responsibilities outlined in this document for the SU may also be considered to be part of the management unit responsibilities.\n\n## 2. Scope\n\n*Note:* This section specifically provides for transfer of quality control (QC) methods where a technical agreement exists (SU manufacturer to RU manufacturer or SU manufacturer to RU QC laboratory). Where no such technical agreements exist (e.g. testing by national laboratories or testing", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la transferencia de tecnolog\u00eda entre unidades de fabricaci\u00f3n (SU) y unidades receptoras (RU) en el contexto de productos farmac\u00e9uticos. Se enfatiza la importancia de que las capacidades de ambas unidades sean similares, la necesidad de realizar un an\u00e1lisis de brechas t\u00e9cnicas, y la formaci\u00f3n adecuada del personal en regulaciones pertinentes. Adem\u00e1s, se destaca que la transferencia de tecnolog\u00eda debe ser transparente y que cualquier problema identificado durante el proceso debe ser comunicado para asegurar una gesti\u00f3n del conocimiento efectiva. Tambi\u00e9n se mencionan las implicaciones legales y econ\u00f3micas que pueden surgir durante estos proyectos de transferencia.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 criterios se deben cumplir para considerar exitosa una transferencia de tecnolog\u00eda entre la SU y la RU?**\n   - La transferencia de tecnolog\u00eda se considera exitosa si hay evidencia documentada de que la RU puede reproducir rutinariamente el producto, proceso o m\u00e9todo transferido de acuerdo con un conjunto de especificaciones predefinidas acordadas con la SU.\n\n2. **\u00bfQu\u00e9 tipo de an\u00e1lisis se recomienda realizar entre la SU y la RU antes de iniciar un proyecto de transferencia de tecnolog\u00eda?**\n   - Se recomienda realizar un an\u00e1lisis t\u00e9cnico exhaustivo que incluya una evaluaci\u00f3n de riesgos t\u00e9cnicos y la identificaci\u00f3n de posibles brechas regulatorias.\n\n3. **\u00bfCu\u00e1les son algunas de las implicaciones legales y econ\u00f3micas que deben considerarse durante la transferencia de tecnolog\u00eda?**\n   - Las implicaciones incluyen derechos de propiedad intelectual, regal\u00edas, precios, conflictos de inter\u00e9s y confidencialidad, que deben ser abordados antes y durante la planificaci\u00f3n y ejecuci\u00f3n de la transferencia para asegurar una comunicaci\u00f3n abierta sobre asuntos t\u00e9cnicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de Tecnolog\u00eda**: Se define como un procedimiento l\u00f3gico que controla el traspaso de procesos, documentaci\u00f3n y experiencia profesional entre el desarrollo y la fabricaci\u00f3n, o entre sitios de fabricaci\u00f3n. Es un proceso sistem\u00e1tico que asegura que el conocimiento documentado y la experiencia se transfieran a una parte responsable y autorizada.\n\n2. **Importancia de la Calidad**: El documento enfatiza la necesidad de un enfoque documentado y planificado que utilice personal capacitado dentro de un sistema de calidad. Se destaca que la transferencia de tecnolog\u00eda debe cumplir con los aspectos de calidad y gesti\u00f3n de riesgos.\n\n3. **Estrategias Empresariales**: Se menciona que las empresas farmac\u00e9uticas est\u00e1n adoptando cada vez m\u00e1s estrategias que implican transferencias intra- e interempresariales debido a la necesidad de aumentar la capacidad, reubicar operaciones o realizar consolidaciones y fusiones.\n\n4. **Recomendaciones de la OMS**: El Comit\u00e9 de Expertos de la OMS recomend\u00f3 la elaboraci\u00f3n de directrices sobre la transferencia de tecnolog\u00eda en su cuadrag\u00e9simo segundo informe, reconociendo la falta de informaci\u00f3n en este \u00e1mbito por parte de organismos reguladores nacionales o regionales.\n\n5. **Unidades Involucradas**: En el proceso de transferencia, generalmente hay una unidad de env\u00edo (SU), una unidad receptora (RU) y una unidad que gestiona el proceso, que puede ser una entidad separada.\n\n6. **Principios Generales para el \u00c9xito**: Para que la transferencia sea exitosa, el plan del proyecto debe incluir aspectos de calidad y basarse en principios de gesti\u00f3n de riesgos de calidad.\n\n### Entidades Clave\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo que establece las directrices sobre la transferencia de tecnolog\u00eda.\n- **ISPE (International Society for Pharmaceutical Engineering)**: Entidad que ha preparado gu\u00edas sobre transferencias intracompany.\n- **Unidades de Transferencia**: Incluyen la unidad de env\u00edo (SU) y la unidad receptora (RU). \n\nEste resumen destaca los aspectos fundamentales de la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, as\u00ed como las recomendaciones y el marco propuesto por la OMS.", "excerpt_keywords": "Keywords: transferencia de tecnolog\u00eda, unidades de fabricaci\u00f3n, an\u00e1lisis de brechas t\u00e9cnicas, implicaciones legales, gesti\u00f3n del conocimiento"}}, "5f437563-b9a1-46e1-ac72-0ba3e714c271": {"node_ids": ["6fa5a13f-550d-45fb-ac55-41488b9658a1"], "metadata": {"page_label": "300", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.1\n\nThis document gives guidance in principle and provides general recommendations on the activities necessary to conduct a successful intra- or intersite transfer of technology as described in the Introduction to these guidelines. The intention is to address the basic considerations needed for a successful transfer in order to satisfy the regulatory authority defined for the transfer process.\n\n# 2.2\n\nThe guidelines will be applied to manufacturing active pharmaceutical ingredients (APIs), manufacturing and packaging of bulk materials, manufacturing and packaging of finished pharmaceutical products (FPPs) and/or performing analytical testing.\n\n# 2.3\n\nThe recommendations provided in these guidelines apply to all dosage forms but need to be adjusted on a case-by-case basis (e.g. by using risk management principles). Particularly close control of certain aspects will be required for certain formulations such as sterile products, and metered-dose aerosols. WHO guidance on manufacture of specific pharmaceutical products (4,5) will be useful in this regard.\n\n# 2.4\n\nThe guidelines address the following areas at the SU and the RU:\n\n- transfer of development and production (processing, packaging and cleaning);\n- transfer of analytical methods for quality assurance and quality control;\n- skills assessment and training;\n- organization and management of the transfer;\n- assessment of premises and equipment;\n- documentation; and\n- qualification and validation.\n\n# 2.5\n\nBecause each transfer project is unique, the provision of a comprehensive set of guidelines is beyond the scope of this document.\n\n# 2.6\n\nThese guidelines do not provide guidance on any legal, financial or commercial considerations associated with technology transfer projects.\n\n# 3. Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**acceptance criteria**\n\nMeasurable terms under which a test result will be considered acceptable.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS proporciona directrices generales para la transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo ingredientes activos, productos en estado bruto y productos farmac\u00e9uticos terminados. Se abordan aspectos clave como la transferencia de m\u00e9todos anal\u00edticos, la evaluaci\u00f3n de habilidades, la gesti\u00f3n del proceso de transferencia, y la documentaci\u00f3n necesaria. Las recomendaciones son aplicables a todas las formas de dosificaci\u00f3n, pero deben adaptarse a cada caso particular, especialmente para productos est\u00e9riles y aerosoles de dosis medida. El documento no cubre consideraciones legales, financieras o comerciales.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los aspectos espec\u00edficos que requieren un control m\u00e1s cercano durante la transferencia de tecnolog\u00eda para productos est\u00e9riles y aerosoles de dosis medida?**\n   - Esta pregunta busca detalles sobre las consideraciones especiales que deben tenerse en cuenta para ciertas formulaciones, que no se abordan en otras partes del documento.\n\n2. **\u00bfQu\u00e9 \u00e1reas espec\u00edficas se deben evaluar en las instalaciones y equipos durante el proceso de transferencia de tecnolog\u00eda seg\u00fan las directrices de la OMS?**\n   - Esta pregunta se centra en los criterios de evaluaci\u00f3n de las instalaciones y equipos, que son cruciales para garantizar el \u00e9xito de la transferencia.\n\n3. **\u00bfC\u00f3mo se deben ajustar las recomendaciones de las directrices de la OMS en funci\u00f3n de los principios de gesti\u00f3n de riesgos para diferentes proyectos de transferencia?**\n   - Esta pregunta busca una comprensi\u00f3n m\u00e1s profunda de c\u00f3mo aplicar los principios de gesti\u00f3n de riesgos en la pr\u00e1ctica, lo cual es esencial para adaptar las directrices a situaciones espec\u00edficas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS se centra en la **transferencia de tecnolog\u00eda** entre **unidades de fabricaci\u00f3n (SU)** y **unidades receptoras (RU)** en el \u00e1mbito de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n1. **Similitud de Capacidades**: Las capacidades de la SU y la RU deben ser similares, aunque no necesariamente id\u00e9nticas, y los equipos deben operar bajo principios operativos similares.\n   \n2. **An\u00e1lisis de Brechas T\u00e9cnicas**: Se debe realizar un an\u00e1lisis exhaustivo que incluya la evaluaci\u00f3n de riesgos t\u00e9cnicos y la identificaci\u00f3n de brechas regulatorias entre la SU y la RU.\n\n3. **Formaci\u00f3n del Personal**: Es esencial que el personal en la RU est\u00e9 adecuadamente capacitado en los requisitos regulatorios pertinentes y que haya una transferencia efectiva de conocimiento sobre procesos y productos.\n\n4. **\u00c9xito de la Transferencia**: La transferencia se considera exitosa si la RU puede reproducir el producto o proceso transferido de acuerdo con especificaciones predefinidas.\n\n5. **Comunicaci\u00f3n de Problemas**: La RU debe informar a la SU sobre cualquier problema identificado durante el proceso de transferencia para asegurar una gesti\u00f3n del conocimiento continua.\n\n6. **Implicaciones Legales y Econ\u00f3micas**: Los proyectos de transferencia de tecnolog\u00eda pueden tener implicaciones relacionadas con derechos de propiedad intelectual, regal\u00edas, precios, conflictos de inter\u00e9s y confidencialidad, que deben ser abordadas adecuadamente.\n\n7. **Transparencia**: La falta de transparencia puede resultar en una transferencia de tecnolog\u00eda ineficaz.\n\n8. **Aplicabilidad a Ensayos Cl\u00ednicos**: Algunos principios pueden ser aplicables a la fabricaci\u00f3n de productos farmac\u00e9uticos investigacionales para ensayos cl\u00ednicos, aunque este no es el enfoque principal del documento.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices sobre la transferencia de tecnolog\u00eda.\n- **Unidades de Fabricaci\u00f3n (SU)**: Entidades que producen el producto original.\n- **Unidades Receptoras (RU)**: Entidades que reciben y reproducen el producto o proceso.\n- **Regulaciones**: Normativas que deben ser consideradas en el proceso de transferencia.\n- **Proyectos de Transferencia de Tecnolog\u00eda**: Iniciativas que implican la transferencia de conocimientos y procesos entre diferentes entidades.\n\nEste resumen destaca la importancia de la planificaci\u00f3n, la formaci\u00f3n y la comunicaci\u00f3n en la transferencia de tecnolog\u00eda, as\u00ed como las consideraciones legales y regulatorias que deben tenerse en cuenta.", "excerpt_keywords": "Keywords: technology transfer, pharmaceutical manufacturing, regulatory guidelines, risk management, quality assurance"}}, "18991383-76df-4d26-a806-fb84871e3e00": {"node_ids": ["4cb66485-3dc5-41f7-9e3a-83cc7625652b"], "metadata": {"page_label": "301", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# active pharmaceutical ingredient (API)\n\nAny substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.\n\n# bracketing\n\nAn experimental design to test only the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.\n\n# change control (C/C)\n\nA formal system by which qualified representatives of appropriate disciplines review proposed or actual changes that might affect a validated status. The intent is to determine the need for action that would ensure that the system is maintained in a validated state.\n\n# commissioning\n\nThe setting up, adjustment and testing of equipment or a system to ensure that it meets all the requirements, as specified in the user requirement specification, and capacities as specified by the designer or developer. Commissioning is carried out before qualification and validation.\n\n# control strategy\n\nA planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to materials and components related to drug substances and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control (6).\n\n# corrective action (C/A)\n\nAny action to be taken when the results of monitoring at a critical control point indicate a loss of control.\n\n# critical\n\nHaving the potential to impact on product quality or performance in a significant way.\n\n# critical control point (CCP)\n\nA step at which control can be applied and is essential to prevent or eliminate a pharmaceutical quality hazard or to reduce it to an acceptable level.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la fabricaci\u00f3n y control de productos farmac\u00e9uticos. Se definen t\u00e9rminos como \"ingrediente farmac\u00e9utico activo\" (API), \"control cr\u00edtico\" y \"estrategia de control\", que son fundamentales para asegurar la calidad y eficacia de los medicamentos. Adem\u00e1s, se discuten procesos como el \"control de cambios\" y la \"comisionamiento\" de equipos, que son esenciales para mantener la validez y el rendimiento de los sistemas de producci\u00f3n farmac\u00e9utica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es la importancia de un \"punto de control cr\u00edtico\" (CCP) en el proceso de fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Respuesta: Un CCP es un paso en el proceso donde se puede aplicar control y es esencial para prevenir o eliminar un peligro de calidad farmac\u00e9utica o reducirlo a un nivel aceptable. Su identificaci\u00f3n y monitoreo son cruciales para garantizar la calidad del producto final.\n\n2. **\u00bfQu\u00e9 implica el proceso de \"comisionamiento\" y por qu\u00e9 es un paso previo a la calificaci\u00f3n y validaci\u00f3n de equipos?**\n   - Respuesta: El comisionamiento implica la configuraci\u00f3n, ajuste y prueba de equipos o sistemas para asegurar que cumplan con los requisitos especificados en la especificaci\u00f3n de requisitos del usuario. Este proceso es fundamental para garantizar que el equipo funcione correctamente antes de ser calificado y validado para su uso en la producci\u00f3n.\n\n3. **\u00bfC\u00f3mo se define una \"estrategia de control\" y qu\u00e9 elementos incluye para asegurar la calidad del producto farmac\u00e9utico?**\n   - Respuesta: Una estrategia de control es un conjunto planificado de controles derivados de la comprensi\u00f3n actual del producto y del proceso, que asegura el rendimiento del proceso y la calidad del producto. Incluye par\u00e1metros y atributos relacionados con materiales, condiciones operativas, controles en proceso, especificaciones del producto terminado y m\u00e9todos de monitoreo y control.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS, titulado \"WHO - Technical Report Series 961\", proporciona directrices generales para la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n#### Temas Clave:\n1. **Transferencia de Tecnolog\u00eda**: Directrices para la transferencia intra- e intersitio de tecnolog\u00eda, enfoc\u00e1ndose en la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs), productos en estado bruto y productos farmac\u00e9uticos terminados (FPPs).\n   \n2. **Adaptabilidad de las Recomendaciones**: Las directrices son aplicables a todas las formas de dosificaci\u00f3n, pero deben ajustarse seg\u00fan el contexto y los principios de gesti\u00f3n de riesgos, especialmente para productos est\u00e9riles y aerosoles de dosis medida.\n\n3. **\u00c1reas de Evaluaci\u00f3n**: Se abordan aspectos como:\n   - Transferencia de desarrollo y producci\u00f3n (procesamiento, envasado y limpieza).\n   - Transferencia de m\u00e9todos anal\u00edticos para aseguramiento y control de calidad.\n   - Evaluaci\u00f3n de habilidades y capacitaci\u00f3n.\n   - Organizaci\u00f3n y gesti\u00f3n del proceso de transferencia.\n   - Evaluaci\u00f3n de instalaciones y equipos.\n   - Documentaci\u00f3n necesaria.\n   - Calificaci\u00f3n y validaci\u00f3n.\n\n4. **Limitaciones del Documento**: Se aclara que no se proporcionan directrices sobre consideraciones legales, financieras o comerciales relacionadas con los proyectos de transferencia de tecnolog\u00eda.\n\n5. **Criterios de Aceptaci\u00f3n**: Se define el t\u00e9rmino \"criterios de aceptaci\u00f3n\" como los t\u00e9rminos medibles bajo los cuales un resultado de prueba se considerar\u00e1 aceptable.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Sustancias utilizadas en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Productos Farmac\u00e9uticos Terminados (FPPs)**: Productos finales listos para la distribuci\u00f3n y uso.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para asegurar la calidad y control de los productos farmac\u00e9uticos.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para garantizar una transferencia de tecnolog\u00eda efectiva y conforme a las regulaciones en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: active pharmaceutical ingredient, change control, commissioning, control strategy, critical control point"}}, "9f44f7d2-2903-45e8-b515-21b13212f5dd": {"node_ids": ["e751b12b-9e56-4949-8fcc-38f76ebb8e2e"], "metadata": {"page_label": "302", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# design qualification (DQ)\nDocumented evidence that the premises, supporting systems, utilities, equipment and processes have been designed in accordance with the requirements of good manufacturing practices (GMP).\n\n# design space\nThe multidimensional combination and interaction of input variables (e.g. material attributes) and process parameters that have been demonstrated to provide assurance of quality (7).\n\n# drug master file (DMF)\nDetailed information concerning a specific facility, process or product submitted to the medicines regulatory authority, intended for incorporation into the application for marketing authorization.\n\n# finished pharmaceutical product (FPP)\nA product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more APIs.\n\n# gap analysis\nIdentification of critical elements of a process which are available at the SU but are missing from the RU.\n\n# good manufacturing practices (GMP)\nThat part of quality assurance which ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization (3).\n\n# in-process control (IPC)\nChecks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control.\n\n# installation qualification (IQ)\nThe performance of tests to ensure that the installations (such as machines, measuring devices, utilities and manufacturing areas) used in a manufacturing process are appropriately selected and correctly installed and operate in accordance with established specifications.\n\n# intercompany transfer\nA transfer of technology between sites of different companies.\n\n# intracompany transfer\nA transfer of technology between sites of the same group of companies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS, \"Technical Report Series 961\", aborda conceptos clave relacionados con las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica. Se definen t\u00e9rminos esenciales como la calificaci\u00f3n de dise\u00f1o (DQ), el espacio de dise\u00f1o, el archivo maestro de medicamentos (DMF), el producto farmac\u00e9utico terminado (FPP), el an\u00e1lisis de brechas, el control en proceso (IPC), la calificaci\u00f3n de instalaci\u00f3n (IQ), y las transferencias de tecnolog\u00eda tanto interempresariales como intraempresariales. Estos conceptos son fundamentales para garantizar que los productos farmac\u00e9uticos se produzcan y controlen de acuerdo con los est\u00e1ndares de calidad requeridos.\n\n### Preguntas\n1. **\u00bfQu\u00e9 evidencia se requiere para demostrar que un proceso de fabricaci\u00f3n cumple con las buenas pr\u00e1cticas de manufactura (GMP)?**\n   - Respuesta: Se requiere documentaci\u00f3n que evidencie que las instalaciones, sistemas de soporte, utilidades, equipos y procesos han sido dise\u00f1ados de acuerdo con los requisitos de GMP, lo que se conoce como calificaci\u00f3n de dise\u00f1o (DQ).\n\n2. **\u00bfCu\u00e1l es la diferencia entre un producto farmac\u00e9utico terminado (FPP) y un ingrediente farmac\u00e9utico activo (API)?**\n   - Respuesta: Un producto farmac\u00e9utico terminado (FPP) es aquel que ha pasado por todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado en su contenedor final, y puede contener uno o m\u00e1s ingredientes farmac\u00e9uticos activos (API).\n\n3. **\u00bfQu\u00e9 implica la calificaci\u00f3n de instalaci\u00f3n (IQ) en el contexto de la manufactura farmac\u00e9utica?**\n   - Respuesta: La calificaci\u00f3n de instalaci\u00f3n (IQ) implica la realizaci\u00f3n de pruebas para asegurar que las instalaciones, como m\u00e1quinas y dispositivos de medici\u00f3n, est\u00e9n correctamente seleccionadas, instaladas y operando de acuerdo con las especificaciones establecidas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n aborda conceptos fundamentales en la fabricaci\u00f3n y control de productos farmac\u00e9uticos, destacando la importancia de asegurar la calidad y eficacia de los medicamentos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Ingrediente Farmac\u00e9utico Activo (API)**:\n   - Definici\u00f3n: Sustancia o mezcla utilizada en la fabricaci\u00f3n de formas farmac\u00e9uticas que proporciona actividad farmacol\u00f3gica o efecto directo en el diagn\u00f3stico, tratamiento o prevenci\u00f3n de enfermedades.\n\n2. **Bracketing**:\n   - Definici\u00f3n: Dise\u00f1o experimental que prueba solo los extremos de una variable (como la fuerza de dosificaci\u00f3n), asumiendo que estos extremos son representativos de todos los valores intermedios.\n\n3. **Control de Cambios (C/C)**:\n   - Definici\u00f3n: Sistema formal para revisar cambios propuestos o reales que puedan afectar el estado validado de un sistema, asegurando que se mantenga en un estado validado.\n\n4. **Comisionamiento**:\n   - Definici\u00f3n: Proceso de configuraci\u00f3n, ajuste y prueba de equipos o sistemas para garantizar que cumplan con los requisitos especificados antes de la calificaci\u00f3n y validaci\u00f3n.\n\n5. **Estrategia de Control**:\n   - Definici\u00f3n: Conjunto planificado de controles que asegura el rendimiento del proceso y la calidad del producto, incluyendo par\u00e1metros relacionados con materiales, condiciones operativas y especificaciones del producto terminado.\n\n6. **Acci\u00f3n Correctiva (C/A)**:\n   - Definici\u00f3n: Medidas a tomar cuando el monitoreo en un punto de control cr\u00edtico indica una p\u00e9rdida de control.\n\n7. **Punto de Control Cr\u00edtico (CCP)**:\n   - Definici\u00f3n: Paso en el proceso donde se puede aplicar control para prevenir o eliminar un peligro de calidad farmac\u00e9utica o reducirlo a un nivel aceptable.\n\n8. **Cr\u00edtico**:\n   - Definici\u00f3n: Cualquier aspecto que tenga el potencial de impactar significativamente en la calidad o rendimiento del producto.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar la calidad y seguridad en la producci\u00f3n de medicamentos, y su comprensi\u00f3n es fundamental para los profesionales del sector farmac\u00e9utico.", "excerpt_keywords": "Keywords: design qualification, good manufacturing practices, drug master file, finished pharmaceutical product, in-process control"}}, "4f41deae-a3cf-42c5-88b8-36d8ec03ea42": {"node_ids": ["1d3f3251-8fe7-46d6-ae19-9472374cd5c8"], "metadata": {"page_label": "303", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# operational qualification (OQ)\nDocumented verification that the system or subsystem performs as intended over all anticipated operating ranges.\n\n# performance qualification (PQ)\nDocumented verification that the equipment or system operates consistently and gives reproducibility within defined specifications and parameters for prolonged periods. (In the context of systems, the term \u201cprocess validation\u201d may also be used.)\n\n# process validation\nDocumented evidence which provides a high degree of assurance that a specific process will consistently result in a product that meets its predetermined specifications and quality characteristics.\n\n# qualification\nAction of proving and documenting that any premises, systems and equipment are properly installed, and/or work correctly and lead to the expected results. Qualification is often a part (the initial stage) of validation, but the individual qualification steps alone do not constitute process validation.\n\n# qualification batches\nThose batches produced by the RU to demonstrate its ability to reproduce the product (1).\n\n# quality assurance (QA)\nQuality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the objective of ensuring that pharmaceutical products are of the quality required for their intended use.\n\n# quality control (QC)\nQuality control covers all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.\n\n# quality planning\nPart of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives (6).\n\n# quality policy\nOverall intentions and direction of an organization related to quality as formally expressed by senior management (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda conceptos clave relacionados con la calidad en la industria farmac\u00e9utica. Se definen t\u00e9rminos como calificaci\u00f3n operativa (OQ), calificaci\u00f3n de rendimiento (PQ), validaci\u00f3n de procesos, y se diferencian los conceptos de aseguramiento de calidad (QA) y control de calidad (QC). Adem\u00e1s, se discuten los objetivos de planificaci\u00f3n de calidad y la pol\u00edtica de calidad de una organizaci\u00f3n, enfatizando la importancia de documentar y verificar que los sistemas y procesos cumplan con las especificaciones y caracter\u00edsticas de calidad predeterminadas.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la diferencia entre la calificaci\u00f3n operativa (OQ) y la calificaci\u00f3n de rendimiento (PQ) en el contexto de la validaci\u00f3n de sistemas?**\n   - Esta pregunta se centra en las definiciones espec\u00edficas de OQ y PQ, que son fundamentales para entender c\u00f3mo se verifica el funcionamiento de los sistemas en la industria farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 papel juega la validaci\u00f3n de procesos en la garant\u00eda de que un producto farmac\u00e9utico cumpla con sus especificaciones predeterminadas?**\n   - Esta pregunta busca profundizar en el concepto de validaci\u00f3n de procesos y su importancia en la producci\u00f3n de productos que cumplen con los est\u00e1ndares de calidad.\n\n3. **\u00bfC\u00f3mo se relacionan los conceptos de aseguramiento de calidad (QA) y control de calidad (QC) en el contexto de la gesti\u00f3n de calidad en la industria farmac\u00e9utica?**\n   - Esta pregunta permite explorar la interconexi\u00f3n entre QA y QC, dos aspectos cruciales para garantizar la calidad de los productos farmac\u00e9uticos, y c\u00f3mo cada uno contribuye al objetivo general de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento \"Technical Report Series 961\" de la OMS aborda varios conceptos fundamentales relacionados con las buenas pr\u00e1cticas de manufactura (GMP) en la industria farmac\u00e9utica. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Calificaci\u00f3n de Dise\u00f1o (DQ)**: Se refiere a la evidencia documentada que asegura que las instalaciones, sistemas de soporte, utilidades, equipos y procesos est\u00e1n dise\u00f1ados conforme a los requisitos de GMP.\n\n2. **Espacio de Dise\u00f1o**: Describe la combinaci\u00f3n multidimensional de variables de entrada y par\u00e1metros de proceso que garantizan la calidad del producto.\n\n3. **Archivo Maestro de Medicamentos (DMF)**: Informaci\u00f3n detallada sobre una instalaci\u00f3n, proceso o producto que se presenta a la autoridad reguladora de medicamentos para su inclusi\u00f3n en la solicitud de autorizaci\u00f3n de comercializaci\u00f3n.\n\n4. **Producto Farmac\u00e9utico Terminado (FPP)**: Un producto que ha completado todas las etapas de producci\u00f3n, incluyendo el envasado y etiquetado, y que puede contener uno o m\u00e1s ingredientes farmac\u00e9uticos activos (API).\n\n5. **An\u00e1lisis de Brechas**: Identificaci\u00f3n de elementos cr\u00edticos de un proceso que est\u00e1n disponibles en una unidad de producci\u00f3n (SU) pero que faltan en otra (RU).\n\n6. **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Parte de la garant\u00eda de calidad que asegura que los productos farmac\u00e9uticos se producen y controlan consistentemente seg\u00fan los est\u00e1ndares de calidad requeridos.\n\n7. **Control en Proceso (IPC)**: Verificaciones realizadas durante la producci\u00f3n para monitorear y ajustar el proceso, asegurando que el producto cumpla con sus especificaciones.\n\n8. **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Pruebas realizadas para asegurar que las instalaciones utilizadas en el proceso de manufactura est\u00e1n correctamente seleccionadas, instaladas y operan seg\u00fan las especificaciones establecidas.\n\n9. **Transferencia Interempresarial**: Transferencia de tecnolog\u00eda entre diferentes empresas.\n\n10. **Transferencia Intraempresarial**: Transferencia de tecnolog\u00eda entre diferentes sitios de la misma empresa o grupo de empresas.\n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos se desarrollen y mantengan de acuerdo con los est\u00e1ndares de calidad necesarios para su uso previsto.", "excerpt_keywords": "Keywords: operational qualification, performance qualification, process validation, quality assurance, quality control"}}, "ea35f195-1c39-4c57-b1af-4c75a97b49a9": {"node_ids": ["79cb584d-d8d1-49b1-b957-7881620b4364"], "metadata": {"page_label": "304", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "quality risk management (QRM)  \nQuality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life-cycle.\n\nreceiving unit (RU)  \nThe involved disciplines at an organization where a designated product, process or method is expected to be transferred.\n\nsending unit (SU)  \nThe involved disciplines at an organization from where a designated product, process or method is expected to be transferred.\n\nspiking  \nThe addition of a known amount of a compound to a standard, sample or placebo, typically for the purpose of confirming the performance of an analytical procedure.\n\nstandard operating procedure (SOP)  \nAn authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material (e.g. equipment operation, maintenance and cleaning, validation, cleaning of premises and environmental control, sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation.\n\ntechnology transfer report  \nA documented summary of a specific technology transfer project listing procedures, acceptance criteria, results achieved and conclusions. Any deviation should be discussed and justified.\n\nvalidation  \nAction of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.\n\nvalidation master plan (VMP)  \nA high-level document that establishes an umbrella validation plan for the entire project and summarizes the manufacturer\u2019s overall philosophy and approach, to be used for establishing performance adequacy. It provides information on the manufacturer\u2019s validation work programme and defines details of and timescales for the validation work to be performed, including a statement of the responsibilities of those implementing the plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal del Quality Risk Management (QRM) en la industria farmac\u00e9utica?**\n   - **Respuesta:** El prop\u00f3sito principal del Quality Risk Management (QRM) es llevar a cabo un proceso sistem\u00e1tico para la evaluaci\u00f3n, control, comunicaci\u00f3n y revisi\u00f3n de los riesgos que pueden afectar la calidad del producto farmac\u00e9utico a lo largo de su ciclo de vida.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en un Technology Transfer Report y por qu\u00e9 es importante?**\n   - **Respuesta:** Un Technology Transfer Report incluye un resumen documentado de un proyecto espec\u00edfico de transferencia de tecnolog\u00eda, que lista los procedimientos, criterios de aceptaci\u00f3n, resultados obtenidos y conclusiones. Es importante porque permite discutir y justificar cualquier desviaci\u00f3n del plan original, asegurando as\u00ed la transparencia y la trazabilidad en el proceso de transferencia.\n\n3. **\u00bfQu\u00e9 rol desempe\u00f1a el Validation Master Plan (VMP) en un proyecto de validaci\u00f3n?**\n   - **Respuesta:** El Validation Master Plan (VMP) desempe\u00f1a un rol crucial al establecer un plan de validaci\u00f3n general para todo el proyecto. Resume la filosof\u00eda y el enfoque del fabricante respecto a la validaci\u00f3n, proporciona informaci\u00f3n sobre el programa de trabajo de validaci\u00f3n y define los detalles y plazos para las actividades de validaci\u00f3n, as\u00ed como las responsabilidades de quienes implementan el plan.\n\n### Resumen de nivel superior del contexto:\nEl documento de la OMS, \"Technical Report Series 961\", aborda conceptos clave en la gesti\u00f3n de calidad y validaci\u00f3n en la industria farmac\u00e9utica. Se define el Quality Risk Management (QRM) como un proceso sistem\u00e1tico para manejar riesgos a lo largo del ciclo de vida del producto. Tambi\u00e9n se explican t\u00e9rminos como \"receiving unit\" y \"sending unit\", que se refieren a las disciplinas involucradas en la transferencia de productos o procesos. Adem\u00e1s, se discuten procedimientos como el \"spiking\", las \"standard operating procedures\" (SOP), y la importancia de los informes de transferencia de tecnolog\u00eda y los planes de validaci\u00f3n. Estos elementos son fundamentales para asegurar la calidad y la eficacia en la producci\u00f3n farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en conceptos fundamentales relacionados con la calidad en la industria farmac\u00e9utica, destacando la importancia de la documentaci\u00f3n y verificaci\u00f3n de procesos y sistemas. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Calificaci\u00f3n Operativa (OQ)**: Verificaci\u00f3n documentada de que un sistema o subsistema funciona como se espera en todos los rangos operativos anticipados.\n\n2. **Calificaci\u00f3n de Rendimiento (PQ)**: Verificaci\u00f3n documentada de que el equipo o sistema opera de manera consistente y reproducible dentro de especificaciones y par\u00e1metros definidos durante per\u00edodos prolongados.\n\n3. **Validaci\u00f3n de Procesos**: Evidencia documentada que asegura que un proceso espec\u00edfico resultar\u00e1 consistentemente en un producto que cumple con especificaciones y caracter\u00edsticas de calidad predeterminadas.\n\n4. **Calificaci\u00f3n**: Proceso de demostrar y documentar que las instalaciones, sistemas y equipos est\u00e1n correctamente instalados y funcionan adecuadamente.\n\n5. **Lotes de Calificaci\u00f3n**: Lotes producidos para demostrar la capacidad de reproducir un producto.\n\n6. **Aseguramiento de Calidad (QA)**: Concepto amplio que abarca todos los aspectos que influyen en la calidad de un producto, asegurando que los productos farmac\u00e9uticos cumplan con los est\u00e1ndares requeridos.\n\n7. **Control de Calidad (QC)**: Medidas tomadas para asegurar que los materiales y productos farmac\u00e9uticos cumplan con especificaciones establecidas en cuanto a identidad, fuerza, pureza y otras caracter\u00edsticas.\n\n8. **Planificaci\u00f3n de Calidad**: Parte de la gesti\u00f3n de calidad que se enfoca en establecer objetivos de calidad y especificar procesos operativos necesarios para cumplir con esos objetivos.\n\n9. **Pol\u00edtica de Calidad**: Intenciones y direcci\u00f3n general de una organizaci\u00f3n en relaci\u00f3n con la calidad, expresadas formalmente por la alta direcci\u00f3n.\n\n### Conclusi\u00f3n\nEstos conceptos son esenciales para garantizar que los productos farmac\u00e9uticos sean seguros y efectivos, cumpliendo con los est\u00e1ndares de calidad requeridos para su uso previsto. La documentaci\u00f3n y la verificaci\u00f3n son componentes cr\u00edticos en cada etapa del proceso de producci\u00f3n y gesti\u00f3n de calidad.", "excerpt_keywords": "Keywords: Quality Risk Management, Technology Transfer, Validation Master Plan, Standard Operating Procedure, Pharmaceutical Quality"}}, "73a5b4c6-baf3-4703-bb6c-8d2ef7e9dbb9": {"node_ids": ["bd04b1ce-7586-4fbc-a0a1-1a37e199e179"], "metadata": {"page_label": "305", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization and Management\n\n**Validation Protocol (or Plan) (VP)**  \nA document describing the activities to be performed in a validation, including the acceptance criteria for the approval of a manufacturing process \u2014 or a part thereof \u2014 for routine use.\n\n**Validation Report (VR)**  \nA document in which the records, results and evaluation of a completed validation programme are assembled and summarized. It may also contain proposals for the improvement of processes and or equipment.\n\n## 4. Organization and Management\n\n4.1 Transfer comprises an SU and an RU. In some circumstances there may be an additional unit which will be responsible for directing, managing and approving the transfer.\n\n4.2 There is a formal agreement between the parties, which specifies the responsibilities before, during and after transfer.\n\n4.3 Organization and management of a successful technology transfer need to ensure that the main steps have been executed and documented as described in section 1.6.\n\n4.4 There should be a project management plan which identifies and controls all the necessary activities identified at the start of the undertaking.\n\n4.5 The transfer protocol should list the intended sequential stages of the transfer. The protocol should include:\n\n- objective;\n- scope;\n- key personnel and their responsibilities;\n- a parallel comparison of materials, methods and equipment;\n- the transfer stages with documented evidence that each critical stage has been satisfactorily accomplished before the next commences;\n- identification of critical control points;\n- experimental design and acceptance criteria for analytical methods;\n- information on trial production batches, qualification batches and process validation;\n- change control for any process deviations encountered;\n- assessment of end-product;\n- arrangements for keeping retention samples of active ingredients, intermediates and finished products, and information on reference substances where applicable; and\n- conclusion, including signed-off approval by project manager.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la organizaci\u00f3n y gesti\u00f3n de la transferencia de tecnolog\u00eda en el \u00e1mbito de la fabricaci\u00f3n. Se define el protocolo de validaci\u00f3n y el informe de validaci\u00f3n, y se describen los elementos clave que deben incluirse en un plan de gesti\u00f3n de proyectos para asegurar una transferencia exitosa. Se enfatiza la importancia de un acuerdo formal entre las partes involucradas y la documentaci\u00f3n de cada etapa del proceso de transferencia.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 elementos espec\u00edficos deben incluirse en un protocolo de transferencia seg\u00fan el documento?**\n   - El protocolo de transferencia debe incluir el objetivo, el alcance, el personal clave y sus responsabilidades, una comparaci\u00f3n paralela de materiales, m\u00e9todos y equipos, las etapas de transferencia con evidencia documentada, identificaci\u00f3n de puntos de control cr\u00edticos, dise\u00f1o experimental y criterios de aceptaci\u00f3n para m\u00e9todos anal\u00edticos, informaci\u00f3n sobre lotes de producci\u00f3n de prueba y validaci\u00f3n de procesos, control de cambios, evaluaci\u00f3n del producto final, y disposiciones para mantener muestras de retenci\u00f3n.\n\n2. **\u00bfCu\u00e1l es la importancia de tener un acuerdo formal entre las partes involucradas en la transferencia de tecnolog\u00eda?**\n   - Un acuerdo formal especifica las responsabilidades de cada parte antes, durante y despu\u00e9s de la transferencia, lo que es crucial para asegurar que todas las actividades se realicen de manera coordinada y que se cumplan los requisitos establecidos para una transferencia exitosa.\n\n3. **\u00bfQu\u00e9 se entiende por \"puntos de control cr\u00edticos\" en el contexto de la transferencia de tecnolog\u00eda?**\n   - Los puntos de control cr\u00edticos son etapas o elementos dentro del proceso de transferencia que deben ser identificados y monitoreados para asegurar que se cumplan los est\u00e1ndares de calidad y que cada fase del proceso se complete satisfactoriamente antes de avanzar a la siguiente. Esto es esencial para garantizar la eficacia y seguridad del proceso de fabricaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Quality Risk Management (QRM)**: \n   - Proceso sistem\u00e1tico para evaluar, controlar, comunicar y revisar riesgos que afectan la calidad de productos farmac\u00e9uticos a lo largo de su ciclo de vida.\n\n2. **Receiving Unit (RU)**: \n   - Disciplinas involucradas en una organizaci\u00f3n donde se espera que un producto, proceso o m\u00e9todo designado sea transferido.\n\n3. **Sending Unit (SU)**: \n   - Disciplinas involucradas en una organizaci\u00f3n desde donde se espera que un producto, proceso o m\u00e9todo designado sea transferido.\n\n4. **Spiking**: \n   - Adici\u00f3n de una cantidad conocida de un compuesto a un est\u00e1ndar, muestra o placebo para confirmar el rendimiento de un procedimiento anal\u00edtico.\n\n5. **Standard Operating Procedure (SOP)**: \n   - Procedimiento escrito autorizado que proporciona instrucciones para realizar operaciones, no necesariamente espec\u00edficas a un producto o material.\n\n6. **Technology Transfer Report**: \n   - Resumen documentado de un proyecto de transferencia de tecnolog\u00eda que incluye procedimientos, criterios de aceptaci\u00f3n, resultados y conclusiones, con discusi\u00f3n de desviaciones.\n\n7. **Validation**: \n   - Acci\u00f3n de demostrar y documentar que un proceso, procedimiento o m\u00e9todo produce consistentemente los resultados esperados.\n\n8. **Validation Master Plan (VMP)**: \n   - Documento de alto nivel que establece un plan de validaci\u00f3n general para un proyecto, resumiendo la filosof\u00eda y enfoque del fabricante, y definiendo detalles y plazos para el trabajo de validaci\u00f3n.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Entidades que participan en la transferencia de productos, procesos o m\u00e9todos.\n- **Productos Farmac\u00e9uticos**: Objetos de calidad y validaci\u00f3n en el contexto de la industria farmac\u00e9utica.\n- **Procedimientos Anal\u00edticos**: M\u00e9todos utilizados para confirmar la calidad y eficacia de productos farmac\u00e9uticos.\n- **Documentaci\u00f3n**: Informes y planes que aseguran la trazabilidad y transparencia en los procesos de calidad y validaci\u00f3n. \n\nEste resumen destaca los conceptos y t\u00e9rminos esenciales relacionados con la gesti\u00f3n de calidad y validaci\u00f3n en la industria farmac\u00e9utica, tal como se presenta en el documento de la OMS.", "excerpt_keywords": "Keywords: validation protocol, technology transfer, project management, critical control points, pharmaceutical manufacturing"}}, "46afcb6d-2b39-47c6-86d1-b0de08358a85": {"node_ids": ["01b990a6-d92c-4b39-8952-b1eaf3d060bc"], "metadata": {"page_label": "306", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.6 \nThe SU should provide the necessary validation documentation for the process and its support functions. Usually, an established process is transferred, and such documentation is already available.\n\n# 4.7 \nThe SU should provide criteria and information on hazards and critical steps associated with the product, process or method to be transferred, to serve as a basis for a quality risk management (QRM) exercise at the RU (7\u201310).\n\n# 4.8 \nThe SU or third party should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms, quality control (QC) procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).\n\n# 4.9 \nThe SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:\n\n- Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and\n- Qualification of the rooms for both manufacture and packaging at the RU site.\n\n# 4.10 \nThe SU and the RU should jointly implement any training programmes that may be required specific to the product, process or method to be transferred, e.g. on analytical methods or equipment usage, and assess training outcomes.\n\n# 4.11 \nThe SU and the RU should jointly execute the transfer protocol according to a checklist and or flow diagram showing the sequence of steps to be carried out to effect an efficient transfer.\n\n# 4.12 \nAny changes and adaptations made during the course of the technology transfer should be fully documented.\n\n# 4.13 \nThe SU and the RU should jointly document the execution of the transfer protocol in a transfer of technology summary in a report.\n\n## Project team\n\n# 4.14 \nAny transfer project will be managed by a team comprising members with clearly defined key responsibilities. The team should be drawn from members of relevant disciplines from both the SU and RU sites.\n\n# 4.15 \nThe team members should have the necessary qualifications and experience to manage their particular aspect of the transfer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda el proceso de transferencia de tecnolog\u00eda en el \u00e1mbito farmac\u00e9utico. Se enfatiza la importancia de la documentaci\u00f3n de validaci\u00f3n, la evaluaci\u00f3n de la preparaci\u00f3n del sitio receptor (RU), la verificaci\u00f3n conjunta de protocolos de validaci\u00f3n, la implementaci\u00f3n de programas de capacitaci\u00f3n y la gesti\u00f3n del proyecto por un equipo multidisciplinario. Se destaca la necesidad de documentar cualquier cambio durante la transferencia y de llevar un registro detallado del proceso.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n de validaci\u00f3n debe proporcionar la SU antes de la transferencia?**\n   - La SU debe proporcionar la documentaci\u00f3n necesaria que valide el proceso y sus funciones de soporte, que generalmente ya est\u00e1 disponible si se trata de un proceso establecido.\n\n2. **\u00bfCu\u00e1les son los criterios que la SU debe proporcionar para la gesti\u00f3n de riesgos de calidad (QRM) en el RU?**\n   - La SU debe proporcionar criterios e informaci\u00f3n sobre los peligros y los pasos cr\u00edticos asociados con el producto, proceso o m\u00e9todo a transferir, que servir\u00e1n como base para un ejercicio de gesti\u00f3n de riesgos de calidad en el RU.\n\n3. **\u00bfQu\u00e9 aspectos deben ser verificados conjuntamente por la SU y el RU antes de la transferencia?**\n   - La SU y el RU deben verificar que est\u00e9n disponibles los protocolos de validaci\u00f3n completados, que incluyen datos de calificaci\u00f3n de instalaci\u00f3n (IQ) y calificaci\u00f3n operativa (OQ) para el equipo de fabricaci\u00f3n y envasado, as\u00ed como la calificaci\u00f3n de las salas de fabricaci\u00f3n y envasado en el sitio del RU.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Protocolo de Validaci\u00f3n (VP)**: Documento que describe las actividades y criterios de aceptaci\u00f3n para la aprobaci\u00f3n de un proceso de fabricaci\u00f3n.\n\n2. **Informe de Validaci\u00f3n (VR)**: Documento que compila y resume los registros, resultados y evaluaciones de un programa de validaci\u00f3n completado, incluyendo propuestas de mejora.\n\n3. **Transferencia de Tecnolog\u00eda**: Implica la colaboraci\u00f3n entre una Unidad de Suministro (SU) y una Unidad Receptora (RU), con la posibilidad de una unidad adicional para la gesti\u00f3n y aprobaci\u00f3n del proceso.\n\n4. **Acuerdo Formal**: Especifica las responsabilidades de las partes involucradas antes, durante y despu\u00e9s de la transferencia, asegurando una coordinaci\u00f3n efectiva.\n\n5. **Plan de Gesti\u00f3n de Proyectos**: Debe identificar y controlar todas las actividades necesarias desde el inicio del proceso de transferencia.\n\n6. **Protocolo de Transferencia**: Debe incluir elementos como objetivos, alcance, personal clave, comparaci\u00f3n de materiales y m\u00e9todos, etapas de transferencia, identificaci\u00f3n de puntos de control cr\u00edticos, dise\u00f1o experimental, informaci\u00f3n sobre lotes de producci\u00f3n y control de cambios.\n\n7. **Puntos de Control Cr\u00edticos**: Elementos clave que deben ser monitoreados para asegurar la calidad y eficacia del proceso de transferencia.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Unidad de Suministro (SU)**: Parte responsable de proporcionar los recursos necesarios para la transferencia.\n- **Unidad Receptora (RU)**: Parte que recibe y utiliza los recursos transferidos.\n- **Personal Clave**: Individuos responsables de las diferentes etapas del proceso de transferencia.\n- **Muestras de Retenci\u00f3n**: Muestras de ingredientes activos, intermedios y productos terminados que deben ser conservadas para referencia futura.\n\nEste resumen destaca la importancia de la organizaci\u00f3n, la documentaci\u00f3n y la gesti\u00f3n en el proceso de transferencia de tecnolog\u00eda en el \u00e1mbito de la fabricaci\u00f3n, seg\u00fan lo establecido por la OMS.", "excerpt_keywords": "Keywords: technology transfer, validation documentation, quality risk management, project team, pharmaceutical production"}}, "fc0302f0-c2a1-43ee-aabd-75b7a3be177a": {"node_ids": ["c993cbcf-4237-474e-b5a6-32eeedb0530a"], "metadata": {"page_label": "307", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Production: transfer (processing, packaging and cleaning)\n\n5.1 The RU should be able to accommodate the intended production capacity. If possible, it should be established at the outset whether the intention is to perform single-batch manufacture, continuous production or campaigns.\n\n5.2 Consideration should be given to the level and depth of detail to be transferred to support production and any further process development and optimization at the RU as intended under the transfer project plan.\n\n5.3 Consideration should be given to the technical expertise, site technology and site capabilities for the RU. It should be identified upfront by the SU of any process robustness issues so that plans may be put in place at the RU.\n\n5.4 The SU and the RU should jointly develop a protocol for the transfer of relevant information related to the process under consideration from the SU to the RU, as well as the development of a comparable process at the RU.\n\n## Starting materials\n\n5.5 The specifications and relevant functional characteristics of the starting materials (APIs and excipients) (I1, I2) to be used at the RU should be consistent with materials used at the SU. Any properties which are likely to influence the process or product should be identified and characterized.\n\n## Active pharmaceutical ingredients (API)\n\n5.6 The SU should provide the RU with the open (applicant\u2019s) part of the API master file (APIMF or drug master file (DMF) or active substance master file (ASMF)), or equivalent information and any relevant additional information on the API of importance for the manufacture of the pharmaceutical product. The following are examples of the information which may typically be provided; however the information needed in each specific case should be assessed using the principles of QRM:\n\n- Manufacturer and associated supply chain;\n- Step of the API to be transferred;\n- Flow chart of synthesis pathway, outlining the process, including entry points for raw materials, critical steps, process controls and intermediates;\n- Where relevant, definitive physical form of the API (including photomicrographs and other relevant data) and any polymorphic and solvate forms;\n- Solubility profile;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de transferencia de producci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en la capacidad de la unidad receptora (RU) para manejar la producci\u00f3n, la importancia de la transferencia de informaci\u00f3n t\u00e9cnica entre la unidad suministradora (SU) y la RU, y la necesidad de que los materiales iniciales y los ingredientes farmac\u00e9uticos activos (API) sean consistentes y bien documentados. Se enfatiza la colaboraci\u00f3n entre la SU y la RU para desarrollar protocolos que aseguren una transferencia efectiva y la optimizaci\u00f3n de procesos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 aspectos t\u00e9cnicos deben considerarse al evaluar la capacidad de producci\u00f3n de la unidad receptora (RU) en comparaci\u00f3n con la unidad suministradora (SU)?**\n   - Esta pregunta se centra en los detalles t\u00e9cnicos que pueden no estar expl\u00edcitamente mencionados en otros documentos, como la experiencia t\u00e9cnica y las capacidades del sitio.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n espec\u00edfica sobre el ingrediente farmac\u00e9utico activo (API) debe ser proporcionada por la unidad suministradora (SU) a la unidad receptora (RU) para asegurar una transferencia efectiva?**\n   - Esta pregunta busca detalles sobre la documentaci\u00f3n y la informaci\u00f3n cr\u00edtica que se requiere para la transferencia de API, que puede no estar disponible en otras fuentes.\n\n3. **\u00bfC\u00f3mo se debe abordar la identificaci\u00f3n y caracterizaci\u00f3n de propiedades de los materiales iniciales que pueden influir en el proceso de producci\u00f3n?**\n   - Esta pregunta se enfoca en el proceso de identificaci\u00f3n y caracterizaci\u00f3n de propiedades de los materiales iniciales, un aspecto que puede ser espec\u00edfico y no ampliamente discutido en otros contextos.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la transferencia de procesos de producci\u00f3n farmac\u00e9utica, destacando la importancia de la colaboraci\u00f3n entre las unidades suministradoras y receptoras. Se enfatiza la necesidad de que ambas partes desarrollen protocolos claros y compartan informaci\u00f3n t\u00e9cnica relevante, asegurando que los materiales utilizados sean consistentes y que se mantenga la calidad del producto final. La transferencia de informaci\u00f3n sobre los ingredientes farmac\u00e9uticos activos y las especificaciones de los materiales iniciales es crucial para el \u00e9xito del proceso de producci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Documentaci\u00f3n de Validaci\u00f3n**: La SU (Suministrador) debe proporcionar la documentaci\u00f3n necesaria para validar el proceso y sus funciones de soporte, que generalmente ya est\u00e1 disponible si se trata de un proceso establecido.\n\n2. **Gesti\u00f3n de Riesgos de Calidad (QRM)**: La SU debe ofrecer criterios e informaci\u00f3n sobre peligros y pasos cr\u00edticos asociados con el producto, proceso o m\u00e9todo a transferir, que servir\u00e1n como base para un ejercicio de QRM en el RU (Receptor).\n\n3. **Evaluaci\u00f3n de Preparaci\u00f3n del RU**: Antes de la transferencia, la SU o un tercero debe evaluar la idoneidad y el grado de preparaci\u00f3n del RU en t\u00e9rminos de instalaciones, equipos y servicios de soporte.\n\n4. **Verificaci\u00f3n de Protocolos de Validaci\u00f3n**: La SU y el RU deben verificar conjuntamente que se disponga de protocolos de validaci\u00f3n completados, incluyendo datos de calificaci\u00f3n de instalaci\u00f3n (IQ) y calificaci\u00f3n operativa (OQ) para el equipo de fabricaci\u00f3n y envasado.\n\n5. **Programas de Capacitaci\u00f3n**: Ambas partes deben implementar programas de capacitaci\u00f3n espec\u00edficos para el producto, proceso o m\u00e9todo a transferir y evaluar los resultados de dicha capacitaci\u00f3n.\n\n6. **Ejecuci\u00f3n del Protocolo de Transferencia**: La transferencia debe llevarse a cabo seg\u00fan un protocolo que incluya una lista de verificaci\u00f3n o un diagrama de flujo que muestre la secuencia de pasos a seguir.\n\n7. **Documentaci\u00f3n de Cambios**: Cualquier cambio o adaptaci\u00f3n durante la transferencia debe ser completamente documentado.\n\n8. **Gesti\u00f3n del Proyecto**: El proyecto de transferencia debe ser gestionado por un equipo multidisciplinario con responsabilidades claramente definidas, compuesto por miembros de ambas partes.\n\n### Entidades\n\n- **SU (Suministrador)**: Parte responsable de proporcionar la tecnolog\u00eda y la documentaci\u00f3n necesaria.\n- **RU (Receptor)**: Parte que recibe la tecnolog\u00eda y debe estar preparada para su implementaci\u00f3n.\n- **Protocolos de Validaci\u00f3n**: Documentos que aseguran que los equipos y procesos cumplen con los est\u00e1ndares requeridos.\n- **Equipo de Proyecto**: Grupo de personas con responsabilidades definidas que gestionan el proceso de transferencia.\n- **Calificaci\u00f3n de Instalaci\u00f3n (IQ)**: Proceso de verificaci\u00f3n de que los equipos est\u00e1n instalados correctamente.\n- **Calificaci\u00f3n Operativa (OQ)**: Proceso de verificaci\u00f3n de que los equipos funcionan seg\u00fan lo previsto.\n\nEste resumen destaca los aspectos esenciales del proceso de transferencia de tecnolog\u00eda en el \u00e1mbito farmac\u00e9utico, enfatizando la importancia de la documentaci\u00f3n, la capacitaci\u00f3n y la gesti\u00f3n adecuada del proyecto.", "excerpt_keywords": "Keywords: production transfer, active pharmaceutical ingredients, process optimization, technical expertise, starting materials"}}, "74cac053-556d-4880-bdc8-de6bf3a3470e": {"node_ids": ["71137471-68c8-4efe-8f9b-494a73bfe6d2"], "metadata": {"page_label": "308", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- if relevant, pH in solution;\n- partition coefficient, including the method of determination;\n- intrinsic dissolution rate, including the method of determination;\n- particle size and distribution, including the method of determination;\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate;\n- water content and determination of hygroscopicity, including water activity data and special handling requirements;\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the API supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements;\n- specifications and justification for release and end-of-life limits;\n- summary of stability studies conducted in conformity with current guidelines, including conclusions and recommendations on retest date;\n- list of potential and observed synthetic impurities, with data to support proposed specifications and typically observed levels;\n- information on degradants, with a list of potential and observed degradation products and data to support proposed specifications and typically observed levels;\n- potency factor, indicating observed purity and justification for any recommended adjustment to the input quantity of API for product manufacturing, providing example calculations; and\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets) and sensitivity to heat, light or moisture.\n\n# Excipients\n\n5.7 The excipients (I1) to be used have a potential impact on the final product. Their specifications and relevant functional characteristics should, therefore, be made available by the SU for transfer to the RU site. The following are examples of the information which may typically be provided; however, the information needed in each specific case should be assessed using the principles of QRM:\n\n- manufacturer and associated supply chain;\n- description of functionality, with justification for inclusion of any antioxidant, preservative or any excipient;\n- definitive form (particularly for solid and inhaled dosage forms);\n- solubility profile (particularly for inhaled and transdermal dosage forms);\n- partition coefficient, including the method of determination (for transdermal dosage forms);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para determinar el coeficiente de partici\u00f3n y la tasa de disoluci\u00f3n intr\u00ednseca de un API, y por qu\u00e9 son importantes estos par\u00e1metros en el desarrollo de productos farmac\u00e9uticos?**\n\n2. **\u00bfQu\u00e9 consideraciones microbiol\u00f3gicas deben tenerse en cuenta al evaluar un API, y c\u00f3mo se relacionan estas consideraciones con los requisitos de las farmacopeas nacionales, regionales o internacionales?**\n\n3. **\u00bfQu\u00e9 informaci\u00f3n sobre los excipientes es crucial para su transferencia desde el sitio del fabricante (SU) al sitio del usuario (RU), y c\u00f3mo se eval\u00faa la funcionalidad de estos excipientes en el contexto de la calidad del producto final?**\n\n### Res\u00famenes de nivel superior del contexto:\n\n1. **Par\u00e1metros de calidad del API:** El contexto detalla una serie de par\u00e1metros cr\u00edticos que deben evaluarse para un API, incluyendo propiedades fisicoqu\u00edmicas, microbiol\u00f3gicas y de estabilidad, as\u00ed como la necesidad de justificar especificaciones y l\u00edmites de liberaci\u00f3n.\n\n2. **Impacto de los excipientes:** Se enfatiza la importancia de los excipientes en la formulaci\u00f3n final del producto, destacando la necesidad de proporcionar informaci\u00f3n sobre su funcionalidad, cadena de suministro y caracter\u00edsticas espec\u00edficas, especialmente en formas de dosificaci\u00f3n s\u00f3lidas e inhaladas.\n\n3. **Principios de Gesti\u00f3n de Riesgos de Calidad (QRM):** Se menciona que la informaci\u00f3n requerida sobre los excipientes debe ser evaluada utilizando principios de QRM, lo que sugiere un enfoque sistem\u00e1tico para identificar y mitigar riesgos en el desarrollo de productos farmac\u00e9uticos.", "prev_section_summary": "### Temas Clave\n\n1. **Capacidad de Producci\u00f3n**: La unidad receptora (RU) debe ser capaz de manejar la capacidad de producci\u00f3n prevista, considerando si se realizar\u00e1 una fabricaci\u00f3n por lotes, producci\u00f3n continua o campa\u00f1as.\n\n2. **Transferencia de Informaci\u00f3n**: Es crucial establecer un protocolo conjunto entre la unidad suministradora (SU) y la RU para la transferencia de informaci\u00f3n t\u00e9cnica relevante, as\u00ed como para el desarrollo de un proceso comparable en la RU.\n\n3. **Materiales Iniciales**: Los materiales iniciales, incluidos los ingredientes farmac\u00e9uticos activos (API) y excipientes, deben ser consistentes con los utilizados en la SU. Se deben identificar y caracterizar las propiedades que puedan influir en el proceso o producto.\n\n4. **Ingredientes Farmac\u00e9uticos Activos (API)**: La SU debe proporcionar a la RU informaci\u00f3n detallada sobre el API, incluyendo el archivo maestro del API (APIMF, DMF o ASMF), la cadena de suministro, el flujo del proceso de s\u00edntesis, y las caracter\u00edsticas f\u00edsicas y perfil de solubilidad del API.\n\n5. **Colaboraci\u00f3n y Optimizaci\u00f3n**: Se enfatiza la importancia de la colaboraci\u00f3n entre la SU y la RU para optimizar los procesos y asegurar la calidad del producto final.\n\n### Entidades\n\n- **Unidad Receptora (RU)**: Entidad que recibe la transferencia de producci\u00f3n.\n- **Unidad Suministradora (SU)**: Entidad que proporciona la informaci\u00f3n y los materiales para la producci\u00f3n.\n- **Ingredientes Farmac\u00e9uticos Activos (API)**: Sustancias que tienen un efecto terap\u00e9utico en los productos farmac\u00e9uticos.\n- **Materiales Iniciales**: Incluyen tanto los API como los excipientes utilizados en la producci\u00f3n.\n- **Protocolos de Transferencia**: Documentos que establecen c\u00f3mo se compartir\u00e1 la informaci\u00f3n t\u00e9cnica entre la SU y la RU.\n\nEste resumen destaca la importancia de la planificaci\u00f3n y la colaboraci\u00f3n en el proceso de transferencia de producci\u00f3n farmac\u00e9utica, asegurando que se mantenga la calidad y la eficacia del producto final.", "excerpt_keywords": "Keywords: API, excipients, microbiological considerations, quality risk management, stability studies"}}, "7d8ffe89-0950-4099-b3c0-0c30069f1d6b": {"node_ids": ["7be3f6de-8651-4d41-99ca-1ef9ffcfa64e"], "metadata": {"page_label": "309", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- intrinsic dissolution rate, including the method of determination (for transdermal dosage forms);\n- particle size and distribution, including the method of determination (for solid, inhaled and transdermal dosage forms);\n- bulk physical properties, including data on bulk and tap density, surface area and porosity as appropriate (for solid and inhaled dosage forms);\n- compaction properties (for solid dosage forms);\n- melting point range (for semi-solid or topical dosage forms);\n- pH range (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- ionic strength (for parenteral dosage forms);\n- specific density or gravity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- viscosity and or viscoelasticity (for parenteral, semi-solid or topical, liquid and transdermal dosage forms);\n- osmolarity (for parenteral dosage forms);\n- water content and determination of hygroscopicity, including water activity data and special handling requirements (for solid and inhaled dosage forms);\n- moisture content range (for parenteral, semisolid or topical, liquid and transdermal dosage forms);\n- microbiological considerations (including sterility, bacterial endotoxins and bioburden levels where the excipient supports microbiological growth) in accordance with national, regional or international pharmacopoeial requirements, as applicable (for general and specific monographs);\n- specifications and justification for release and end-of-life limits;\n- information on adhesives supporting compliance with peel, sheer and adhesion design criteria (for transdermal dosage forms);\n- special considerations with implications for storage and or handling, including but not limited to safety and environmental factors (e.g. as specified in material safety data sheets (MSDS)) and sensitivity to heat, light or moisture; and\n- regulatory considerations, e.g. documentation to support compliance with transmissible animal spongiform encephalopathy certification requirements (where applicable).\n\n## Information on process and finished pharmaceutical products information\n\n5.8 The SU should provide a detailed characterization of the product, including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con res\u00famenes de nivel superior que pueden ayudar a generar mejores preguntas:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la caracterizaci\u00f3n de excipientes y productos farmac\u00e9uticos terminados. Se enfatiza la importancia de proporcionar informaci\u00f3n sobre propiedades f\u00edsicas, m\u00e9todos de fabricaci\u00f3n, controles en proceso, especificaciones y consideraciones microbiol\u00f3gicas, as\u00ed como aspectos regulatorios y de manejo seguro.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los m\u00e9todos recomendados para determinar la tasa de disoluci\u00f3n intr\u00ednseca en formas de dosificaci\u00f3n transd\u00e9rmica, y por qu\u00e9 es importante esta medida?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre los m\u00e9todos de determinaci\u00f3n de la tasa de disoluci\u00f3n intr\u00ednseca, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 consideraciones microbiol\u00f3gicas deben tenerse en cuenta al evaluar excipientes que pueden soportar el crecimiento microbiol\u00f3gico, y c\u00f3mo se alinean con los requisitos de las farmacopeas?**\n   - Esta pregunta se centra en las consideraciones microbiol\u00f3gicas y su relaci\u00f3n con las normativas, un aspecto que puede no estar ampliamente cubierto en otras fuentes.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica sobre la composici\u00f3n cualitativa y cuantitativa de un producto farmac\u00e9utico terminado es esencial para cumplir con los est\u00e1ndares de la OMS, y c\u00f3mo se relaciona esto con la seguridad y el manejo del producto?**\n   - Esta pregunta busca profundizar en los requisitos de caracterizaci\u00f3n de productos farmac\u00e9uticos, un tema que puede no ser tratado en detalle en otras gu\u00edas o documentos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto proporcionado, y que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Par\u00e1metros de Calidad del API:**\n   - Se enumeran par\u00e1metros cr\u00edticos para la evaluaci\u00f3n de un Ingrediente Farmac\u00e9utico Activo (API), que incluyen:\n     - pH en soluci\u00f3n.\n     - Coeficiente de partici\u00f3n y tasa de disoluci\u00f3n intr\u00ednseca, junto con sus m\u00e9todos de determinaci\u00f3n.\n     - Tama\u00f1o y distribuci\u00f3n de part\u00edculas.\n     - Propiedades f\u00edsicas a granel (densidad, \u00e1rea de superficie, porosidad).\n     - Contenido de agua y determinaci\u00f3n de higroscopicidad.\n     - Consideraciones microbiol\u00f3gicas (esterilidad, endotoxinas bacterianas, niveles de biocarga).\n     - Especificaciones y justificaci\u00f3n para l\u00edmites de liberaci\u00f3n y vida \u00fatil.\n     - Resumen de estudios de estabilidad y recomendaciones sobre fechas de rean\u00e1lisis.\n     - Impurezas sint\u00e9ticas potenciales y observadas.\n     - Productos de degradaci\u00f3n y especificaciones asociadas.\n     - Factor de potencia y ajustes recomendados en la cantidad de API para la fabricaci\u00f3n del producto.\n     - Consideraciones especiales para almacenamiento y manejo.\n\n2. **Impacto de los Excipientes:**\n   - Los excipientes tienen un impacto significativo en el producto final. La informaci\u00f3n relevante que debe ser transferida del sitio del fabricante (SU) al sitio del usuario (RU) incluye:\n     - Fabricante y cadena de suministro asociada.\n     - Descripci\u00f3n de la funcionalidad de los excipientes, incluyendo justificaci\u00f3n para antioxidantes y conservantes.\n     - Forma definitiva, especialmente para formas de dosificaci\u00f3n s\u00f3lidas e inhaladas.\n     - Perfil de solubilidad, particularmente para formas de dosificaci\u00f3n inhaladas y transd\u00e9rmicas.\n     - Coeficiente de partici\u00f3n y m\u00e9todo de determinaci\u00f3n para formas transd\u00e9rmicas.\n\n3. **Principios de Gesti\u00f3n de Riesgos de Calidad (QRM):**\n   - La informaci\u00f3n sobre los excipientes debe ser evaluada utilizando principios de QRM, lo que implica un enfoque sistem\u00e1tico para identificar y mitigar riesgos en el desarrollo de productos farmac\u00e9uticos.\n\n### Entidades Clave:\n- **API (Ingrediente Farmac\u00e9utico Activo)**\n- **Excipientes**\n- **Propiedades fisicoqu\u00edmicas**\n- **Estabilidad**\n- **Microbiolog\u00eda**\n- **Gesti\u00f3n de Riesgos de Calidad (QRM)**\n\nEste resumen destaca la importancia de los par\u00e1metros de calidad del API y la funcionalidad de los excipientes en el desarrollo de productos farmac\u00e9uticos, as\u00ed como la necesidad de un enfoque sistem\u00e1tico para la gesti\u00f3n de riesgos.", "excerpt_keywords": "Keywords: dissolution rate, microbiological considerations, excipients, pharmaceutical products, regulatory compliance"}}, "3b0c0b44-13af-459b-ba25-c1729e3166a2": {"node_ids": ["04c53214-34d1-49f9-9386-547d1ff551a9"], "metadata": {"page_label": "310", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 5.9\n\nThe SU should provide any information on the history of process development which may be required to enable the RU to perform any further development and or process optimization after successful transfer. Such information may include the following:\n\n- Information on clinical development, e.g. information on the rationale for the synthesis, route and form selection, technology selection, equipment, clinical tests, and product composition;\n- Information on scale-up activities: process optimization, statistical optimization of critical process parameters, critical quality attributes, pilot report and or information on pilot-scale development activities indicating the number and disposition of batches manufactured;\n- Information or report on full-scale development activities, indicating the number and disposition of batches manufactured, and deviation and change control (sometimes referred to as change management) reports which led to the current manufacturing process;\n- The change history and reasons, e.g. a change control log, indicating any changes to the process or primary packaging or analytical methods as a part of process optimization or improvement; and\n- Information on investigations of problems and the outcomes of the investigations.\n\n## 5.10\n\nThe SU should provide to the RU information on any health, safety and environmental issues associated with the manufacturing processes to be transferred, and the implications, e.g. need for gowning or protective clothing.\n\n## 5.11\n\nThe SU should provide to the RU information on current processing and testing, including but not limited to:\n\n- A detailed description of facility requirements and equipment;\n- Information on starting materials, applicable MSDS and storage requirements for raw materials and finished products;\n- Description of manufacturing steps (narrative and process maps or flow charts, and or master batch records), including qualification of in-processing hold times and conditions, order and method of raw material addition and bulk transfers between processing steps;\n- Description of analytical methods;\n- Identification and justification of control strategy (e.g. identification of critical performance aspects for specific dosage forms, identification of process control points, product quality attributes and qualification of critical processing parameter ranges, statistical process control (SPC) charts);\n- Design space, in cases where this has been defined;\n- Validation information, e.g. validation plans and reports;\n- Annual product quality reviews;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n sobre el desarrollo cl\u00ednico debe proporcionar la SU al RU para facilitar la optimizaci\u00f3n del proceso despu\u00e9s de la transferencia?**\n   - Esta pregunta se centra en los detalles espec\u00edficos que la SU debe compartir sobre el desarrollo cl\u00ednico, incluyendo la justificaci\u00f3n para la s\u00edntesis y la selecci\u00f3n de tecnolog\u00eda, que no se detalla en otras secciones del documento.\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en el informe de actividades de desarrollo a gran escala que la SU debe proporcionar al RU?**\n   - Esta pregunta busca informaci\u00f3n sobre los aspectos espec\u00edficos que deben ser documentados en el informe de desarrollo a gran escala, como la disposici\u00f3n de lotes fabricados y los informes de control de cambios, que son cruciales para entender el proceso de fabricaci\u00f3n actual.\n\n3. **\u00bfQu\u00e9 consideraciones de salud, seguridad y medio ambiente deben tener en cuenta el RU al recibir informaci\u00f3n sobre los procesos de fabricaci\u00f3n transferidos?**\n   - Esta pregunta se enfoca en los aspectos de salud y seguridad que la SU debe comunicar al RU, lo cual es esencial para garantizar un entorno de trabajo seguro y cumplir con las normativas pertinentes.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento proporciona directrices sobre la informaci\u00f3n que debe ser transferida de una Unidad de Suministro (SU) a una Unidad Receptora (RU) durante el proceso de transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos. Se enfatiza la importancia de compartir informaci\u00f3n sobre el desarrollo del proceso, la optimizaci\u00f3n, la seguridad y los requisitos de instalaci\u00f3n, as\u00ed como los m\u00e9todos anal\u00edticos y las estrategias de control. Esto asegura que el RU pueda continuar el desarrollo y la producci\u00f3n de manera efectiva y segura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Caracterizaci\u00f3n de Excipientes y Productos Farmac\u00e9uticos**:\n   - Importancia de la caracterizaci\u00f3n detallada de excipientes y productos terminados para garantizar la calidad y seguridad.\n\n2. **Propiedades F\u00edsicas**:\n   - Tasa de disoluci\u00f3n intr\u00ednseca, tama\u00f1o y distribuci\u00f3n de part\u00edculas, propiedades f\u00edsicas a granel (densidad, \u00e1rea de superficie, porosidad), propiedades de compactaci\u00f3n, rango de punto de fusi\u00f3n, pH, fuerza i\u00f3nica, densidad espec\u00edfica, viscosidad, osmolaridad, contenido de agua y humedad.\n\n3. **Consideraciones Microbiol\u00f3gicas**:\n   - Evaluaci\u00f3n de la esterilidad, endotoxinas bacterianas y niveles de biocarga, alineadas con requisitos de farmacopeas nacionales, regionales o internacionales.\n\n4. **Especificaciones y Justificaci\u00f3n**:\n   - Necesidad de especificaciones claras y justificaci\u00f3n para l\u00edmites de liberaci\u00f3n y fin de vida \u00fatil de los productos.\n\n5. **Adhesivos y Cumplimiento**:\n   - Informaci\u00f3n sobre adhesivos en formas de dosificaci\u00f3n transd\u00e9rmica y su cumplimiento con criterios de dise\u00f1o.\n\n6. **Consideraciones de Almacenamiento y Manejo**:\n   - Factores de seguridad y ambientales, sensibilidad a calor, luz o humedad, y requisitos de manejo especial.\n\n7. **Aspectos Regulatorios**:\n   - Documentaci\u00f3n necesaria para cumplir con requisitos regulatorios, como certificaciones relacionadas con encefalopat\u00edas espongiformes transmisibles.\n\n8. **Informaci\u00f3n sobre Productos Farmac\u00e9uticos Terminados**:\n   - Requisitos para la composici\u00f3n cualitativa y cuantitativa, descripci\u00f3n f\u00edsica, m\u00e9todo de fabricaci\u00f3n, controles en proceso, m\u00e9todos de control, especificaciones y consideraciones de seguridad y manejo.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece los est\u00e1ndares y requisitos.\n- **Excipientes**: Sustancias inactivas que acompa\u00f1an al principio activo en las formulaciones.\n- **Productos Farmac\u00e9uticos**: Formas de dosificaci\u00f3n que incluyen parenterales, semis\u00f3lidos, t\u00f3picos, l\u00edquidos y transd\u00e9rmicos.\n- **Farmacopeas**: Compendios de est\u00e1ndares de calidad y pruebas para medicamentos.\n- **Material Safety Data Sheets (MSDS)**: Documentos que proporcionan informaci\u00f3n sobre las propiedades de las sustancias qu\u00edmicas y su manejo seguro. \n\nEste resumen destaca los aspectos esenciales y las entidades relevantes en la caracterizaci\u00f3n de excipientes y productos farmac\u00e9uticos, seg\u00fan lo estipulado en el documento de la OMS.", "excerpt_keywords": "Keywords: process development, technology transfer, clinical development, manufacturing processes, quality control"}}, "b811555b-b31d-4c84-bfa7-fbbc64503be5": {"node_ids": ["443d8d01-ba6f-4610-be4d-385e3285b4bc"], "metadata": {"page_label": "311", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- stability information;\n- an authorized set of protocols and work instructions for manufacturing; and\n- environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.\n\n5.12 During the transfer process, the RU should identify any differences in facilities, systems and capabilities and communicate with the SU about these differences to understand the potential impact on ability to run the process to deliver good product quality. Differences should be understood and satisfactorily addressed to assure equivalent product quality. Based on the information received from the SU, the RU should consider its own capability to manufacture and pack the product to the required standards and should develop relevant plant operating procedures and documentation before the start of production. Process development at the RU should address the following tasks:\n\n- comparison and assessment of suitability and qualification of facility and equipment;\n- description of manufacturing process and flow of personnel and of materials at the RU (narrative and or process maps or flow charts);\n- determination of critical steps in manufacture, including hold times, end-points, sampling points and sampling techniques (13);\n- writing and approval of SOPs for all production operations (e.g. dispensing, granulation or blending or solution preparation, tablet compression, tablet coating, encapsulation, liquid filling, primary and secondary packaging and in-process quality control), packaging, cleaning, testing and storage;\n- evaluation of stability information, with generation of site-specific stability data if required (14); and\n- compliance with regulatory requirements for any changes made, e.g. in terms of batch size.\n\n# Packaging\n\n5.13 The transfer of packaging operations should follow the same procedural patterns as those of the production transfer.\n\n5.14 Information on packaging to be transferred from the SU to the RU includes specifications for a suitable container or closure system, as well as any relevant additional information on design, packing, processing or labelling requirements and tamper-evident and anti-counterfeiting measures needed for qualification of packaging components at the RU.\n\n5.15 For QC testing of packaging components, specifications should be provided for drawings, artwork and material (for example, glass, card or fibre board).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de transferencia de productos farmac\u00e9uticos entre unidades de producci\u00f3n (RU) y unidades de suministro (SU). Se enfatiza la importancia de identificar y comunicar diferencias en las instalaciones, sistemas y capacidades entre las dos unidades para asegurar la calidad del producto. Se detallan las tareas que deben realizarse en el RU, como la evaluaci\u00f3n de la idoneidad de las instalaciones, la descripci\u00f3n del proceso de fabricaci\u00f3n, la determinaci\u00f3n de pasos cr\u00edticos y la redacci\u00f3n de procedimientos operativos est\u00e1ndar (SOP). Tambi\u00e9n se menciona la transferencia de informaci\u00f3n sobre operaciones de envasado y los requisitos de calidad para los componentes de envasado.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 pasos cr\u00edticos deben determinarse durante el desarrollo del proceso en la RU para asegurar la calidad del producto?**\n   - La RU debe determinar los pasos cr\u00edticos en la fabricaci\u00f3n, que incluyen tiempos de espera, puntos finales, puntos de muestreo y t\u00e9cnicas de muestreo.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n sobre el envasado debe ser transferida del SU al RU?**\n   - La informaci\u00f3n incluye especificaciones para un sistema de contenedor o cierre adecuado, as\u00ed como detalles sobre dise\u00f1o, requisitos de etiquetado, y medidas de seguridad como tamper-evident y anti-counterfeiting.\n\n3. **\u00bfCu\u00e1les son las implicaciones de las diferencias en las capacidades de las instalaciones entre el RU y el SU?**\n   - Las diferencias deben ser entendidas y abordadas satisfactoriamente para asegurar una calidad de producto equivalente. Esto implica que el RU debe evaluar su propia capacidad para fabricar y empaquetar el producto seg\u00fan los est\u00e1ndares requeridos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Transferencia de Informaci\u00f3n**: La Unidad de Suministro (SU) debe proporcionar informaci\u00f3n cr\u00edtica a la Unidad Receptora (RU) para facilitar el desarrollo y la optimizaci\u00f3n de procesos despu\u00e9s de la transferencia.\n\n2. **Desarrollo Cl\u00ednico**: Se requiere informaci\u00f3n sobre el desarrollo cl\u00ednico, incluyendo:\n   - Justificaci\u00f3n para la s\u00edntesis.\n   - Selecci\u00f3n de rutas y formas.\n   - Selecci\u00f3n de tecnolog\u00eda y equipo.\n   - Composici\u00f3n del producto y pruebas cl\u00ednicas.\n\n3. **Actividades de Escalado**: La SU debe incluir detalles sobre:\n   - Optimizaci\u00f3n de procesos.\n   - Par\u00e1metros cr\u00edticos de calidad.\n   - Informes de actividades a escala piloto, incluyendo n\u00famero y disposici\u00f3n de lotes fabricados.\n\n4. **Desarrollo a Gran Escala**: Informaci\u00f3n sobre:\n   - Actividades de desarrollo a gran escala.\n   - Disposici\u00f3n de lotes fabricados.\n   - Informes de control de cambios y desviaciones.\n\n5. **Historial de Cambios**: Se debe proporcionar un registro de cambios que documente:\n   - Cambios en procesos, empaques primarios y m\u00e9todos anal\u00edticos.\n   - Razones detr\u00e1s de estos cambios.\n\n6. **Investigaciones de Problemas**: Informaci\u00f3n sobre problemas encontrados durante el proceso y los resultados de las investigaciones.\n\n7. **Salud, Seguridad y Medio Ambiente**: La SU debe informar sobre:\n   - Problemas de salud y seguridad asociados con los procesos de fabricaci\u00f3n.\n   - Implicaciones como la necesidad de ropa de protecci\u00f3n.\n\n8. **Requisitos de Procesamiento y Pruebas**: Informaci\u00f3n detallada sobre:\n   - Requisitos de instalaciones y equipos.\n   - Materiales iniciales y requisitos de almacenamiento.\n   - Pasos de fabricaci\u00f3n y m\u00e9todos anal\u00edticos.\n   - Estrategias de control y validaci\u00f3n.\n\n### Entidades Clave\n- **Unidad de Suministro (SU)**: Entidad responsable de proporcionar informaci\u00f3n.\n- **Unidad Receptora (RU)**: Entidad que recibe la informaci\u00f3n para continuar el desarrollo.\n- **Documentaci\u00f3n**: Informes sobre desarrollo cl\u00ednico, escalado, control de cambios, y validaci\u00f3n.\n- **Salud y Seguridad**: Consideraciones necesarias para un entorno de trabajo seguro.\n\nEste resumen destaca la importancia de la comunicaci\u00f3n efectiva y la documentaci\u00f3n detallada en el proceso de transferencia de tecnolog\u00eda en la fabricaci\u00f3n de productos.", "excerpt_keywords": "Keywords: transfer process, product quality, manufacturing protocols, packaging specifications, regulatory compliance"}}, "5084db76-55e4-47a8-a2f9-cb19cb8555d2": {"node_ids": ["4c9186f0-4779-4b7e-9b4f-57001dc50d39"], "metadata": {"page_label": "312", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.16 \nBased on the information provided, the RU should perform a suitability study for initial qualification of the packaging components. Packaging is considered suitable if it provides adequate protection (preventing degradation of the medicine due to environmental influences), safety (absence of undesirable substances released into the product), compatibility (absence of interaction possibly affecting medicine quality) and performance (functionality in terms of drug delivery).\n\n# Cleaning\n\n5.17 During the manufacturing process, pharmaceutical products and APIs can be contaminated by other pharmaceutical products or APIs if the plant is processing different products. To minimize the risk of contamination and cross-contamination, operator exposure and environmental effects, adequate cleaning procedures are essential.\n\n5.18 Cleaning procedures and their validation are site-specific. In order for the RU to define its cleaning strategy the SU should provide information on cleaning at the SU to minimize cross-contamination due to residues from previous manufacturing steps, operator exposure and environmental impact, including:\n\n- information on solubility of active ingredients, excipients and vehicles;\n- minimum therapeutic doses of active ingredients;\n- therapeutic category and toxicological assessment; and\n- existing cleaning procedures.\n\nAdditional information should be provided, as appropriate and where available, e.g.:\n\n- cleaning validation reports (chemical and microbiological);\n- information on cleaning agents used (efficacy, evidence that they do not interfere with analytical testing for residues of APIs, removal of residual cleaning agents); and\n- recovery studies to validate the sampling methodology.\n\n5.19 Before the transfer, the SU should provide information on limits for product residues, and the rationale for limit selection.\n\n5.20 Based on the information provided by the SU, cleaning procedures should be designed at the RU, taking into account relevant characteristics of the starting materials (e.g. potency, toxicity, solubility, corrosiveness and temperature sensitivity), manufacturing equipment design and configuration, cleaning agent and products residue.\n\n# Implementation of processing, packaging and cleaning systems\n\n5.21 Trial batch(es) (\u201cdemonstration batches\u201d) are normally produced to confirm process capability before initiating formal validation. Where trial", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento aborda la importancia de realizar estudios de idoneidad para la calificaci\u00f3n inicial de los componentes de embalaje en la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza la necesidad de procedimientos de limpieza adecuados para minimizar la contaminaci\u00f3n cruzada durante el proceso de fabricaci\u00f3n. Adem\u00e1s, se detalla la informaci\u00f3n que debe ser proporcionada por la unidad de suministro (SU) para definir estrategias de limpieza en la unidad receptora (RU), as\u00ed como la importancia de realizar lotes de prueba para confirmar la capacidad del proceso antes de la validaci\u00f3n formal.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 criterios se deben considerar para determinar si un componente de embalaje es adecuado para un producto farmac\u00e9utico?**\n   - La idoneidad del embalaje se basa en su capacidad para proporcionar protecci\u00f3n adecuada, seguridad, compatibilidad y rendimiento en t\u00e9rminos de entrega del medicamento.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe proporcionar la unidad de suministro (SU) para ayudar a la unidad receptora (RU) a definir su estrategia de limpieza?**\n   - La SU debe proporcionar informaci\u00f3n sobre la solubilidad de los ingredientes activos, dosis terap\u00e9uticas m\u00ednimas, categor\u00eda terap\u00e9utica, evaluaci\u00f3n toxicol\u00f3gica y procedimientos de limpieza existentes, as\u00ed como informes de validaci\u00f3n de limpieza y detalles sobre los agentes de limpieza utilizados.\n\n3. **\u00bfCu\u00e1l es el prop\u00f3sito de producir lotes de prueba antes de la validaci\u00f3n formal en el proceso de fabricaci\u00f3n?**\n   - Los lotes de prueba, o \"lotes de demostraci\u00f3n\", se producen para confirmar la capacidad del proceso antes de iniciar la validaci\u00f3n formal, asegurando que el proceso es capaz de producir productos de calidad consistente.", "prev_section_summary": "### Temas Clave\n\n1. **Transferencia de Productos Farmac\u00e9uticos**: El documento aborda el proceso de transferencia de productos entre unidades de producci\u00f3n (RU) y unidades de suministro (SU), enfatizando la necesidad de asegurar la calidad del producto durante este proceso.\n\n2. **Identificaci\u00f3n de Diferencias**: Se destaca la importancia de identificar y comunicar las diferencias en instalaciones, sistemas y capacidades entre RU y SU para entender su impacto en la calidad del producto.\n\n3. **Desarrollo de Procesos en la RU**: Se enumeran las tareas que la RU debe realizar, incluyendo la evaluaci\u00f3n de instalaciones, descripci\u00f3n del proceso de fabricaci\u00f3n, determinaci\u00f3n de pasos cr\u00edticos, redacci\u00f3n de procedimientos operativos est\u00e1ndar (SOP) y cumplimiento de requisitos regulatorios.\n\n4. **Transferencia de Informaci\u00f3n de Envasado**: Se menciona que la transferencia de informaci\u00f3n sobre operaciones de envasado debe seguir patrones similares a los de la producci\u00f3n, incluyendo especificaciones para sistemas de contenedores y requisitos de etiquetado.\n\n5. **Control de Calidad (QC)**: Se requiere que se proporcionen especificaciones para la prueba de calidad de los componentes de envasado, incluyendo dibujos y materiales.\n\n### Entidades\n\n- **RU (Unidad de Producci\u00f3n)**: La unidad responsable de la fabricaci\u00f3n y empaquetado del producto.\n- **SU (Unidad de Suministro)**: La unidad que proporciona la informaci\u00f3n y los productos a la RU.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Documentos que describen los procedimientos a seguir en las operaciones de producci\u00f3n.\n- **Estabilidad**: Informaci\u00f3n relacionada con la estabilidad del producto que debe ser evaluada y, si es necesario, generada en el sitio.\n- **Componentes de Envasado**: Elementos utilizados para empaquetar el producto, que deben cumplir con especificaciones de calidad y seguridad.\n\n### Resumen\nEl documento de la OMS detalla el proceso de transferencia de productos farmac\u00e9uticos entre unidades de producci\u00f3n y suministro, subrayando la importancia de identificar diferencias en capacidades y asegurar la calidad del producto. Se describen las tareas que la unidad de producci\u00f3n debe llevar a cabo, incluyendo la evaluaci\u00f3n de instalaciones y la redacci\u00f3n de procedimientos operativos est\u00e1ndar. Tambi\u00e9n se aborda la transferencia de informaci\u00f3n sobre envasado y los requisitos de control de calidad para los componentes de envasado.", "excerpt_keywords": "Keywords: packaging qualification, cleaning procedures, contamination prevention, pharmaceutical manufacturing, trial batches"}}, "9e3955db-8469-4935-8728-4610f5ade1e5": {"node_ids": ["8144d89d-0238-4e91-8f37-ef948a021a9e"], "metadata": {"page_label": "313", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Control: Analytical Method Transfer\n\n6.1 Transfer of analytical methods should accommodate all the analytical testing required to demonstrate compliance of the product to be transferred with the registered specification (15).\n\n6.2 Analytical methods used to test pharmaceutical products, starting materials, packaging components and cleaning (residue) samples, if applicable, should be implemented at the testing laboratory before testing of samples for process validation studies is performed by the RU. Process validation samples may be tested at the RU, the SU or a third laboratory.\n\n6.3 A protocol defining the steps should be prepared for transfer of analytical methods. The analytical methods transfer protocol should include a description of the objective, scope and responsibilities of the SU and the RU; a specification of materials and methods; the experimental design and acceptance criteria; documentation (including information to be supplied with the results, and report forms to be used, if any); procedure for the handling of deviations; references; signed approval; and details of reference samples (starting materials, intermediates and finished products).\n\n6.4 The SU\u2019s responsibilities for the transfer of analytical methods are to:\n\n- provide method-specific training for analysts and other quality control staff, if required;\n- assist in analysis of QC testing results;\n- define all methods to be transferred for testing a given product, starting material or cleaning sample;\n- define experimental design, sampling methods and acceptance criteria;\n- provide any validation reports for methods under transfer and demonstrate their robustness;\n- provide details of the equipment used, as necessary (part of validation report, if available) and any standard reference samples;\n- provide approved procedures used in testing; and\n- review and approve transfer reports.\n\n6.5 The RU\u2019s responsibilities are to:\n\n- review analytical methods provided by the SU, and formally agree on acceptance criteria before execution of the transfer protocol;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS aborda el proceso de transferencia de m\u00e9todos anal\u00edticos en el control de calidad de productos farmac\u00e9uticos. Se detalla la importancia de que los m\u00e9todos anal\u00edticos sean implementados en el laboratorio de pruebas antes de realizar estudios de validaci\u00f3n de procesos. Se establece un protocolo que define las responsabilidades tanto del laboratorio de origen (SU) como del laboratorio receptor (RU), incluyendo la capacitaci\u00f3n, el dise\u00f1o experimental y la revisi\u00f3n de informes de transferencia.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los elementos clave que debe incluir un protocolo de transferencia de m\u00e9todos anal\u00edticos?**\n   - El protocolo debe incluir una descripci\u00f3n del objetivo, el alcance y las responsabilidades de los laboratorios involucrados, especificaciones de materiales y m\u00e9todos, dise\u00f1o experimental y criterios de aceptaci\u00f3n, documentaci\u00f3n necesaria, procedimientos para manejar desviaciones, referencias, aprobaci\u00f3n firmada y detalles de muestras de referencia.\n\n2. **\u00bfQu\u00e9 responsabilidades tiene el laboratorio de origen (SU) en el proceso de transferencia de m\u00e9todos anal\u00edticos?**\n   - El SU es responsable de proporcionar capacitaci\u00f3n espec\u00edfica sobre el m\u00e9todo, asistir en el an\u00e1lisis de resultados de control de calidad, definir los m\u00e9todos a transferir, establecer el dise\u00f1o experimental y los criterios de aceptaci\u00f3n, proporcionar informes de validaci\u00f3n y detalles del equipo utilizado, as\u00ed como revisar y aprobar los informes de transferencia.\n\n3. **\u00bfQu\u00e9 pasos deben seguirse antes de que se realicen pruebas de validaci\u00f3n de procesos en el laboratorio receptor (RU)?**\n   - Antes de realizar pruebas de validaci\u00f3n de procesos, los m\u00e9todos anal\u00edticos deben ser implementados en el laboratorio de pruebas, y el RU debe revisar los m\u00e9todos anal\u00edticos proporcionados por el SU y acordar formalmente los criterios de aceptaci\u00f3n antes de ejecutar el protocolo de transferencia.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Idoneidad del embalaje**:\n   - Se requiere un estudio de idoneidad para la calificaci\u00f3n inicial de los componentes de embalaje.\n   - Criterios de idoneidad: protecci\u00f3n adecuada, seguridad, compatibilidad y rendimiento en la entrega del medicamento.\n\n2. **Procedimientos de limpieza**:\n   - Importancia de procedimientos de limpieza adecuados para minimizar la contaminaci\u00f3n cruzada durante la fabricaci\u00f3n.\n   - La validaci\u00f3n de los procedimientos de limpieza es espec\u00edfica para cada sitio.\n\n3. **Informaci\u00f3n requerida de la unidad de suministro (SU)**:\n   - La SU debe proporcionar datos sobre:\n     - Solubilidad de ingredientes activos, excipientes y veh\u00edculos.\n     - Dosis terap\u00e9uticas m\u00ednimas.\n     - Categor\u00eda terap\u00e9utica y evaluaci\u00f3n toxicol\u00f3gica.\n     - Procedimientos de limpieza existentes.\n   - Informaci\u00f3n adicional puede incluir informes de validaci\u00f3n de limpieza y detalles sobre agentes de limpieza utilizados.\n\n4. **L\u00edmites de residuos**:\n   - La SU debe proporcionar informaci\u00f3n sobre los l\u00edmites de residuos de productos y la justificaci\u00f3n para su selecci\u00f3n.\n\n5. **Dise\u00f1o de procedimientos de limpieza**:\n   - Los procedimientos de limpieza en la unidad receptora (RU) deben considerar caracter\u00edsticas relevantes de los materiales de partida, dise\u00f1o del equipo de fabricaci\u00f3n y residuos de agentes de limpieza.\n\n6. **Lotes de prueba**:\n   - Se producen lotes de prueba (\"lotes de demostraci\u00f3n\") para confirmar la capacidad del proceso antes de la validaci\u00f3n formal.\n\n### Entidades:\n- **RU**: Unidad receptora.\n- **SU**: Unidad de suministro.\n- **API**: Ingrediente farmac\u00e9utico activo.\n- **Procedimientos de limpieza**: M\u00e9todos para evitar la contaminaci\u00f3n cruzada.\n- **Lotes de prueba**: Producci\u00f3n inicial para validar la capacidad del proceso.", "excerpt_keywords": "Keywords: analytical methods, quality control, method transfer, pharmaceutical testing, validation procedures"}}, "dd987a76-4793-4a4f-9fa8-3eb89c396a3f": {"node_ids": ["92171587-7adb-4a2a-bbe5-5bd7f82917cc"], "metadata": {"page_label": "314", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- ensure that the necessary equipment for QC is available and qualified at the RU site. The equipment used by the RU during the analytical transfer should meet appropriate specifications to ensure the requirements of the method or specification are met;\n- ensure that adequately trained and experienced personnel are in place for analytical testing;\n- provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);\n- execute the transfer protocol;\n- perform the appropriate level of validation to support the implementation of the methods; and\n- generate and obtain approval of transfer reports.\n\n6.6 Appropriate training should be provided and all training activities and outcomes should be documented.\n\n6.7 Reference to compendial monographs (e.g. *The International Pharmacopoeia (15), European Pharmacopoeia, British Pharmacopoeia and United States Pharmacopeia*), where available, is expected.\n\n6.8 Possible experimental designs and acceptance criteria for the main analytical testing methods are shown in Table 1. Note that this table represents high-level guidance to apply the general principle that method transfers should account for the variability and sensitivity of the method and the specifications for the quality parameter. Alternative procedures and acceptance criteria may be applied based on science and the characteristics of the analytical method and the analyte.\n\n**Table 1**  \n**Possible experimental designs and acceptance criteria for analytical testing**\n\n| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Identity | Transfer should focus on sample preparation, instruments, data interpretation. Acceptable to include in assay transfer where relevant | One determination usually sufficient to demonstrate equivalence | | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son los requisitos clave para el equipo utilizado en la transferencia anal\u00edtica en un sitio de RU (Unidad de Referencia)?**\n   - El equipo utilizado por la RU durante la transferencia anal\u00edtica debe estar disponible y calificado en el sitio, cumpliendo con las especificaciones apropiadas para asegurar que se satisfacen los requisitos del m\u00e9todo o especificaci\u00f3n.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el proceso de transferencia anal\u00edtica?**\n   - Se requiere un sistema de documentaci\u00f3n capaz de registrar la recepci\u00f3n y prueba de muestras seg\u00fan las especificaciones requeridas, utilizando m\u00e9todos de prueba aprobados. Adem\u00e1s, debe incluir la capacidad de reportar, registrar y compilar datos, as\u00ed como designar el estado de las muestras (aprobadas, rechazadas, en cuarentena).\n\n3. **\u00bfQu\u00e9 consideraciones se deben tener en cuenta al dise\u00f1ar un protocolo de transferencia anal\u00edtica?**\n   - Al dise\u00f1ar un protocolo de transferencia anal\u00edtica, se debe considerar la variabilidad y sensibilidad del m\u00e9todo, as\u00ed como las especificaciones para el par\u00e1metro de calidad. Adem\u00e1s, se pueden aplicar procedimientos alternativos y criterios de aceptaci\u00f3n basados en la ciencia y las caracter\u00edsticas del m\u00e9todo anal\u00edtico y el analito.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS proporciona directrices sobre la transferencia anal\u00edtica, enfatizando la importancia de contar con el equipo adecuado, personal capacitado y un sistema de documentaci\u00f3n robusto. Tambi\u00e9n se menciona la necesidad de validar los m\u00e9todos y generar informes de transferencia aprobados. Se hace referencia a monograf\u00edas compendiales y se presentan consideraciones para el dise\u00f1o experimental y criterios de aceptaci\u00f3n en las pruebas anal\u00edticas, destacando que la transferencia debe tener en cuenta la variabilidad del m\u00e9todo y las especificaciones de calidad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Transferencia de M\u00e9todos Anal\u00edticos:** Se enfatiza la necesidad de que la transferencia de m\u00e9todos anal\u00edticos incluya todas las pruebas necesarias para demostrar que el producto cumple con las especificaciones registradas.\n\n2. **Implementaci\u00f3n Previa:** Los m\u00e9todos anal\u00edticos deben ser implementados en el laboratorio de pruebas antes de realizar estudios de validaci\u00f3n de procesos.\n\n3. **Protocolo de Transferencia:** Se requiere un protocolo que defina los pasos para la transferencia, incluyendo objetivos, alcance, responsabilidades, dise\u00f1o experimental, criterios de aceptaci\u00f3n y documentaci\u00f3n necesaria.\n\n4. **Responsabilidades del Laboratorio de Origen (SU):** Incluyen la capacitaci\u00f3n del personal, asistencia en el an\u00e1lisis de resultados, definici\u00f3n de m\u00e9todos a transferir, y revisi\u00f3n de informes de transferencia.\n\n5. **Responsabilidades del Laboratorio Receptor (RU):** Implican la revisi\u00f3n de m\u00e9todos anal\u00edticos y el acuerdo formal sobre los criterios de aceptaci\u00f3n antes de ejecutar el protocolo de transferencia.\n\n**Entidades:**\n\n- **Laboratorio de Origen (SU):** Responsable de proporcionar capacitaci\u00f3n, definir m\u00e9todos y revisar informes.\n- **Laboratorio Receptor (RU):** Encargado de revisar y acordar m\u00e9todos y criterios de aceptaci\u00f3n.\n- **M\u00e9todos Anal\u00edticos:** Herramientas utilizadas para evaluar productos farmac\u00e9uticos, materiales de partida y muestras de limpieza.\n- **Protocolo de Transferencia:** Documento que detalla el proceso de transferencia de m\u00e9todos anal\u00edticos.\n\nEste resumen destaca la importancia de un proceso estructurado y colaborativo en la transferencia de m\u00e9todos anal\u00edticos para asegurar la calidad y conformidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: transferencia anal\u00edtica, equipo de calidad, documentaci\u00f3n, validaci\u00f3n, m\u00e9todos anal\u00edticos"}}, "c8161264-b91f-4406-a437-5a82f63d0b4e": {"node_ids": ["c0a7d32a-1aa9-45db-8889-332f4b4020e0"], "metadata": {"page_label": "315", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test | Considerations for transfer | Replication of tests | Set-up | Acceptance criteria | Direct | Statistically derived |\n| - | - | - | - | - | - | - |\n| Assay for potency | * *Non-specific assay should not be used for stability testing.*\n* Bracketing may be appropriate for multiple strengths | At each site: 2 analysts \u00d7 3 lots, in triplicate (= 18 per site) | - Different sets of instruments and columns\n- Independent solution preparation | Comparison of mean and variability | Two one-sided t-tests with intersite differences \u2264 2%, 95% confidence | |\n| Content uniformity | If method is equivalent to assay method, separate transfer is not usually required | At each site: 2 analysts, \u00d7 1 lot (= 2 per site) | * Different sets of instruments and columns\n* Independent solution preparation | Mean at RU within \u00b1 3% of mean at SU; comparison of relative st. dev. | Two one-sided t-tests with intersite differences \u2264 3%, 95% confidence | |\n| Dissolution | Bracketing may be appropriate for multiple strengths | 6 units (12 if not routine at RU, and for extended release products) | | Mean at RU within \u00b1 5% of mean at SU | Compare profile (e.g., F\u2082), or Compare data at Q time points as for assay | |\n| Cleaning verification (recovery of residues from surfaces) | Confirm that same swabbing material is used at sending unit (SU) and receiving unit (RU) | | Use spiked samples, with levels within 3x validated st. dev. or within \u00b1 10% of specification (whichever is the greater) | - All samples spiked above specification should fail\n- 90% of samples spiked below specification should pass | | |\n| Microbiological testing (qualitative and quantitative limit tests) | * Execute common on-site validation protocol: rationale; method identity; validation parameters; data summary; acceptance criteria; methods of compiling and analysing data; handling of out-of-specification results; follow-up requirements\n* Use same materials, techniques, inoculum preparation | Validation in triplicate | Use different lots for each validation exercise | - Qualitative: Demonstrate recovery of microorganisms\n- Quantitative: Recovery levels within acceptance limits specified in protocol | | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 961 aborda las consideraciones para la transferencia de m\u00e9todos anal\u00edticos en el contexto de pruebas de calidad de productos farmac\u00e9uticos. Se detallan varios tipos de pruebas, como el ensayo de potencia, la uniformidad de contenido, la disoluci\u00f3n, la verificaci\u00f3n de limpieza y las pruebas microbiol\u00f3gicas. Para cada prueba, se especifican las consideraciones para la transferencia, la replicaci\u00f3n de pruebas, el establecimiento de criterios de aceptaci\u00f3n y los m\u00e9todos estad\u00edsticos aplicables.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para el ensayo de potencia y c\u00f3mo se determina la variabilidad intersitios?**\n   - Respuesta: Para el ensayo de potencia, se compara la media y la variabilidad entre los sitios. Se utilizan dos pruebas t de una sola cola con diferencias intersitios que deben ser \u2264 2% y un nivel de confianza del 95%.\n\n2. **\u00bfQu\u00e9 condiciones deben cumplirse para la verificaci\u00f3n de limpieza en la recuperaci\u00f3n de residuos de superficies?**\n   - Respuesta: Se debe confirmar que se utiliza el mismo material de muestreo en la unidad de env\u00edo (SU) y en la unidad receptora (RU). Adem\u00e1s, se deben usar muestras espaciadas, con niveles dentro de 3 veces la desviaci\u00f3n est\u00e1ndar validada o dentro del \u00b1 10% de la especificaci\u00f3n, siendo el mayor de los dos el que se considere.\n\n3. **\u00bfQu\u00e9 protocolo se debe seguir para las pruebas microbiol\u00f3gicas y qu\u00e9 aspectos deben ser considerados durante la validaci\u00f3n?**\n   - Respuesta: Se debe ejecutar un protocolo de validaci\u00f3n com\u00fan en el sitio que incluya la justificaci\u00f3n, la identidad del m\u00e9todo, los par\u00e1metros de validaci\u00f3n, un resumen de datos, criterios de aceptaci\u00f3n, m\u00e9todos de compilaci\u00f3n y an\u00e1lisis de datos, manejo de resultados fuera de especificaci\u00f3n y requisitos de seguimiento. La validaci\u00f3n debe realizarse en triplicado utilizando diferentes lotes para cada ejercicio de validaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Requisitos de Equipamiento**: \n   - Es esencial que el equipo de control de calidad (QC) est\u00e9 disponible y calificado en el sitio de la Unidad de Referencia (RU). Debe cumplir con especificaciones apropiadas para satisfacer los requisitos del m\u00e9todo anal\u00edtico.\n\n2. **Personal Capacitado**: \n   - Se debe contar con personal adecuadamente entrenado y con experiencia para llevar a cabo las pruebas anal\u00edticas.\n\n3. **Sistema de Documentaci\u00f3n**: \n   - Es necesario un sistema de documentaci\u00f3n que registre la recepci\u00f3n y prueba de muestras, utilizando m\u00e9todos de prueba aprobados. Este sistema debe permitir la reportaci\u00f3n, registro y compilaci\u00f3n de datos, as\u00ed como la designaci\u00f3n del estado de las muestras (aprobadas, rechazadas, en cuarentena).\n\n4. **Ejecuci\u00f3n del Protocolo de Transferencia**: \n   - Se debe ejecutar un protocolo de transferencia que incluya la validaci\u00f3n adecuada para respaldar la implementaci\u00f3n de los m\u00e9todos anal\u00edticos.\n\n5. **Generaci\u00f3n de Informes de Transferencia**: \n   - Es importante generar y obtener la aprobaci\u00f3n de los informes de transferencia.\n\n6. **Capacitaci\u00f3n Documentada**: \n   - Se debe proporcionar capacitaci\u00f3n adecuada y documentar todas las actividades y resultados de la capacitaci\u00f3n.\n\n7. **Referencias a Monograf\u00edas Compendiales**: \n   - Se espera hacer referencia a monograf\u00edas compendiales como *The International Pharmacopoeia*, *European Pharmacopoeia*, *British Pharmacopoeia* y *United States Pharmacopeia*, cuando est\u00e9n disponibles.\n\n8. **Dise\u00f1os Experimentales y Criterios de Aceptaci\u00f3n**: \n   - Se presentan consideraciones para el dise\u00f1o experimental y criterios de aceptaci\u00f3n en las pruebas anal\u00edticas, enfatizando que la transferencia debe considerar la variabilidad y sensibilidad del m\u00e9todo, as\u00ed como las especificaciones del par\u00e1metro de calidad.\n\n### Entidades Clave\n- **Organizaci\u00f3n**: Organizaci\u00f3n Mundial de la Salud (OMS)\n- **Documentos de Referencia**: Monograf\u00edas compendiales (International Pharmacopoeia, European Pharmacopoeia, British Pharmacopoeia, United States Pharmacopeia)\n- **Conceptos**: Transferencia anal\u00edtica, control de calidad (QC), validaci\u00f3n de m\u00e9todos, documentaci\u00f3n de procesos, capacitaci\u00f3n del personal. \n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado en la transferencia anal\u00edtica, asegurando que se cumplan los est\u00e1ndares de calidad y que se minimicen las variaciones en los resultados.", "excerpt_keywords": "Keywords: transfer methods, analytical testing, quality control, validation protocols, microbiological testing"}}, "05ccd945-9223-4c79-b45c-02c20166a010": {"node_ids": ["f54b5582-c94f-492d-8425-3644a2456280"], "metadata": {"page_label": "316", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Test\\<br/> | Considerations for transfer\\<br/> | Replication of tests\\<br/> | Set-up\\<br/> | Acceptance criteria\\<br/>Direct | Acceptance criteria\\<br/>Statistically derived |\n| - | - | - | - | - | - |\n| Impurity, degradation, residual solvents | \u2013 Confirm response factors for calculation relative to drug peak; \u2013 Confirm limit of quantitation at RU; \u2013 Compare chromatograms \u2013 Compare accuracy and precision for spiking experiments | At each site: 2 analysts x 3 lots, in duplicate (in triplicate if done together with assay) | \u2013 Different days, different sets of instruments and columns \u2013 Use samples of similar age, homogeneity, packaging, storage \u2013 Use spiked samples if necessary | (For low levels) Values at RU within \u00b1 25% of values at SU, or Mean at RU within \u00b1 0.05% of mean at SU (5%) | (For moderately high levels) Two one-sided t-tests, differences \u2264 10%, 95% confidence |\n\n\nst. dev., standard deviation.  \n*Note*: numbers in the table are given as examples only and should not be considered as recommendations.\n\nThe SU and the RU should execute the transfer protocol and jointly prepare a transfer report. The points to be addressed in the analytical methods transfer report are listed in these guidelines.\n\n# 7. Premises and equipment\n\n## Premises\n\n7.1 The SU should provide information to the RU on the layout, construction and finish of buildings and services (16,17) (heating, ventilation and air-conditioning (HVAC), temperature, relative humidity, water, power, and compressed air), which have an impact on the product, process or method to be transferred.\n\n7.2 The SU should provide information on relevant health, safety and environmental issues, including:\n\n- inherent risks of the manufacturing processes (e.g. reactive chemical hazards, exposure limits, fire and explosion risks);\n- health and safety requirements to minimize operator exposure (e.g. atmospheric containment of pharmaceutical dust);\n- emergency planning considerations (e.g. in case of gas or dust release, spillage, fire and firewater run-off); and\n- identification of waste streams and provisions for re-use, recycling and/or disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los criterios de aceptaci\u00f3n para la transferencia de m\u00e9todos anal\u00edticos en relaci\u00f3n con los niveles bajos y moderadamente altos de impurezas, degradaci\u00f3n y solventes residuales?**\n   - Respuesta: Para niveles bajos, los valores en el RU deben estar dentro de \u00b1 25% de los valores en el SU, o la media en el RU debe estar dentro de \u00b1 0.05% de la media en el SU. Para niveles moderadamente altos, se deben realizar dos pruebas t unilaterales, donde las diferencias deben ser \u2264 10% con un nivel de confianza del 95%.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n debe proporcionar la SU al RU en relaci\u00f3n con las instalaciones y el equipo antes de la transferencia de m\u00e9todos anal\u00edticos?**\n   - Respuesta: La SU debe proporcionar informaci\u00f3n sobre el dise\u00f1o, construcci\u00f3n y acabado de los edificios y servicios, incluyendo aspectos como calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC), temperatura, humedad relativa, agua, energ\u00eda y aire comprimido, que pueden impactar en el producto, proceso o m\u00e9todo a transferir.\n\n3. **\u00bfQu\u00e9 consideraciones de salud, seguridad y medio ambiente deben tener en cuenta la SU y la RU durante la transferencia de m\u00e9todos anal\u00edticos?**\n   - Respuesta: Deben considerar los riesgos inherentes de los procesos de fabricaci\u00f3n, los requisitos de salud y seguridad para minimizar la exposici\u00f3n del operador, la planificaci\u00f3n de emergencias en caso de liberaci\u00f3n de gases o polvo, derrames, incendios y escorrent\u00eda de agua de incendio, as\u00ed como la identificaci\u00f3n de flujos de desechos y las disposiciones para su reutilizaci\u00f3n, reciclaje y/o eliminaci\u00f3n.\n\n### Resumen de nivel superior del contexto:\nEl documento proporciona directrices sobre la transferencia de m\u00e9todos anal\u00edticos entre un sitio de origen (SU) y un sitio receptor (RU). Se detallan los criterios de aceptaci\u00f3n para la transferencia de pruebas relacionadas con impurezas y solventes residuales, as\u00ed como la necesidad de un informe de transferencia conjunto. Adem\u00e1s, se enfatiza la importancia de la informaci\u00f3n sobre las instalaciones y los equipos, as\u00ed como las consideraciones de salud, seguridad y medio ambiente que deben ser abordadas durante el proceso de transferencia.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n extra\u00edda del documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos 961 se centra en las consideraciones para la transferencia de m\u00e9todos anal\u00edticos en la evaluaci\u00f3n de la calidad de productos farmac\u00e9uticos. A continuaci\u00f3n se presentan los temas clave y las entidades relevantes:\n\n#### Temas Clave:\n1. **Transferencia de M\u00e9todos Anal\u00edticos**: Se discuten las consideraciones necesarias para transferir m\u00e9todos anal\u00edticos entre diferentes unidades de producci\u00f3n.\n2. **Tipos de Pruebas**:\n   - **Ensayo de Potencia**: Importancia de no utilizar ensayos no espec\u00edficos para pruebas de estabilidad.\n   - **Uniformidad de Contenido**: Condiciones bajo las cuales no se requiere una transferencia separada si el m\u00e9todo es equivalente.\n   - **Dissoluci\u00f3n**: Uso de bracketing para m\u00faltiples fortalezas y criterios de aceptaci\u00f3n.\n   - **Verificaci\u00f3n de Limpieza**: Protocolo para la recuperaci\u00f3n de residuos de superficies.\n   - **Pruebas Microbiol\u00f3gicas**: Protocolo de validaci\u00f3n com\u00fan y requisitos para la validaci\u00f3n.\n\n3. **Criterios de Aceptaci\u00f3n**: Se establecen criterios espec\u00edficos para cada tipo de prueba, incluyendo l\u00edmites de variabilidad y m\u00e9todos estad\u00edsticos para la comparaci\u00f3n de resultados.\n\n4. **Replicaci\u00f3n de Pruebas**: Se especifican los requisitos de replicaci\u00f3n para asegurar la validez de los resultados obtenidos en diferentes sitios.\n\n5. **M\u00e9todos Estad\u00edsticos**: Se mencionan pruebas estad\u00edsticas espec\u00edficas, como las pruebas t de una sola cola, para evaluar la variabilidad y la aceptaci\u00f3n de los resultados.\n\n#### Entidades Relevantes:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **M\u00e9todos Anal\u00edticos**: T\u00e9cnicas utilizadas para evaluar la calidad de los productos farmac\u00e9uticos.\n- **Unidades de Producci\u00f3n**: Referencia a las instalaciones donde se realizan las pruebas.\n- **Analistas**: Personal encargado de realizar las pruebas en los diferentes sitios.\n- **Lotes**: Cantidades espec\u00edficas de productos farmac\u00e9uticos sometidos a prueba.\n- **Criterios de Aceptaci\u00f3n**: Par\u00e1metros establecidos para determinar si los resultados de las pruebas son satisfactorios.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes tratados en la secci\u00f3n, destacando la importancia de la transferencia de m\u00e9todos anal\u00edticos y los criterios necesarios para asegurar la calidad en la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: transferencia de m\u00e9todos anal\u00edticos, criterios de aceptaci\u00f3n, salud y seguridad, instalaciones y equipos, impurezas y solventes residuales"}}, "0e1e6011-65d7-4925-ac6b-7f5d37bffcb6": {"node_ids": ["67905ef3-4462-48b2-851d-ddeb37cc2a6a"], "metadata": {"page_label": "317", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Equipment\n\n7.3 The SU should provide a list of equipment, makes and models involved in the manufacture, filling, packing and or control of the product, process or method to be transferred, together with existing qualification and validation documentation. Relevant documentation may include:\n\n- drawings;\n- manuals;\n- maintenance logs;\n- calibration logs; and\n- procedures (e.g. regarding equipment set-up, operation, cleaning, maintenance, calibration and storage).\n\n7.4 The RU should review the information provided by the SU together with its own inventory list including the qualification status (IQ, OQ, PQ) of all equipment and systems, and perform a side-by-side comparison of equipment at the two sites in terms of their functionality, makes, models and qualification status.\n\n7.5 The RU should perform a gap analysis to identify requirements for adaptation of existing equipment, or acquisition of new equipment, or a change in the process, to enable the RU to reproduce the process being transferred. GMP requirements should be satisfied and intended production volumes and batch sizes (e.g. same, scaled-up or campaign) should be considered. Factors to be compared include:\n\n- minimum and maximum capacity;\n- material of construction;\n- critical operating parameters;\n- critical equipment components (e.g. filters, screens, and temperature/pressure sensors);\n- critical quality attribute; and\n- range of intended use.\n\n7.6 The facility- and building-specific location of all equipment at the RU should be considered at the time of drawing up process maps or flow charts of the manufacturing process to be transferred, including flows of personnel and material.\n\n7.7 The impact of manufacturing new products on products currently manufactured with the same equipment should be determined.\n\n7.8 Any modification of existing equipment that needs to be adapted to become capable of reproducing the process being transferred should be documented in the transfer project plan.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS detalla los procedimientos y requisitos para la transferencia de procesos de fabricaci\u00f3n, enfatizando la importancia de la documentaci\u00f3n y la comparaci\u00f3n de equipos entre el sitio de origen (SU) y el sitio receptor (RU). Se abordan aspectos como la revisi\u00f3n de la calificaci\u00f3n del equipo, la realizaci\u00f3n de un an\u00e1lisis de brechas para identificar necesidades de adaptaci\u00f3n o adquisici\u00f3n de nuevos equipos, y la consideraci\u00f3n de la ubicaci\u00f3n espec\u00edfica de los equipos en el RU. Tambi\u00e9n se menciona la necesidad de evaluar el impacto de la fabricaci\u00f3n de nuevos productos en los productos existentes y la documentaci\u00f3n de cualquier modificaci\u00f3n necesaria en el equipo.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se considera relevante para la transferencia de procesos y qu\u00e9 ejemplos se proporcionan?**\n   - El contexto menciona que la documentaci\u00f3n relevante puede incluir dibujos, manuales, registros de mantenimiento, registros de calibraci\u00f3n y procedimientos relacionados con la configuraci\u00f3n, operaci\u00f3n, limpieza, mantenimiento, calibraci\u00f3n y almacenamiento del equipo.\n\n2. **\u00bfCu\u00e1les son los factores clave que el RU debe comparar al realizar un an\u00e1lisis de brechas entre el equipo del SU y el RU?**\n   - Los factores a comparar incluyen la capacidad m\u00ednima y m\u00e1xima, el material de construcci\u00f3n, los par\u00e1metros operativos cr\u00edticos, los componentes cr\u00edticos del equipo (como filtros y sensores), los atributos de calidad cr\u00edticos y el rango de uso previsto.\n\n3. **\u00bfQu\u00e9 se debe documentar en el plan del proyecto de transferencia si se requieren modificaciones en el equipo existente?**\n   - Cualquier modificaci\u00f3n del equipo existente que sea necesaria para reproducir el proceso transferido debe ser documentada en el plan del proyecto de transferencia, asegurando que se mantenga la conformidad con los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transferencia de M\u00e9todos Anal\u00edticos**:\n   - Se establece un protocolo de transferencia que debe ser ejecutado conjuntamente por el sitio de origen (SU) y el sitio receptor (RU).\n   - Se requiere la elaboraci\u00f3n de un informe de transferencia que aborde puntos espec\u00edficos.\n\n2. **Criterios de Aceptaci\u00f3n**:\n   - Para impurezas, degradaci\u00f3n y solventes residuales, se definen criterios de aceptaci\u00f3n:\n     - **Niveles bajos**: Valores en el RU deben estar dentro de \u00b1 25% de los valores en el SU, o la media en el RU dentro de \u00b1 0.05% de la media en el SU.\n     - **Niveles moderadamente altos**: Se deben realizar dos pruebas t unilaterales, donde las diferencias deben ser \u2264 10% con un nivel de confianza del 95%.\n\n3. **Premisas y Equipos**:\n   - La SU debe proporcionar informaci\u00f3n sobre el dise\u00f1o, construcci\u00f3n y acabados de las instalaciones, as\u00ed como sobre servicios como HVAC, temperatura, humedad, agua, energ\u00eda y aire comprimido.\n   - Se enfatiza la importancia de la salud, seguridad y consideraciones ambientales durante la transferencia.\n\n4. **Consideraciones de Salud y Seguridad**:\n   - Identificaci\u00f3n de riesgos inherentes a los procesos de fabricaci\u00f3n (ej. peligros qu\u00edmicos, l\u00edmites de exposici\u00f3n, riesgos de incendio).\n   - Requisitos para minimizar la exposici\u00f3n del operador y planificaci\u00f3n de emergencias.\n   - Identificaci\u00f3n de flujos de desechos y disposiciones para su manejo.\n\n### Entidades Clave:\n- **SU (Sitio de Origen)**: Entidad que proporciona informaci\u00f3n y realiza la transferencia.\n- **RU (Sitio Receptor)**: Entidad que recibe la transferencia y debe cumplir con los criterios establecidos.\n- **M\u00e9todos Anal\u00edticos**: Procesos que se transfieren entre SU y RU.\n- **Criterios de Aceptaci\u00f3n**: Est\u00e1ndares que deben cumplirse para validar la transferencia.\n- **Salud y Seguridad**: Consideraciones cr\u00edticas para la operaci\u00f3n segura durante la transferencia. \n\nEste resumen destaca los aspectos fundamentales y las entidades involucradas en el proceso de transferencia de m\u00e9todos anal\u00edticos seg\u00fan las directrices del documento de la OMS.", "excerpt_keywords": "Keywords: equipment transfer, gap analysis, qualification documentation, manufacturing process, GMP compliance"}}, "7617f773-ade7-4cc4-8bc3-f191c64faf7a": {"node_ids": ["02e54b8b-aa10-40f5-8cba-ccf7249561b2"], "metadata": {"page_label": "318", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Documentation\n\n8.1 The documentation required for the transfer project itself is wide-ranging. Examples of documentation commonly required are summarized in Table 2.\n\n8.2 The documented evidence that the transfer of technology has been considered successful should be formalized and stated in a technology transfer summary report. That report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU (preferably in a tabulated format) and the final conclusions of the transfer. Possible discrepancies should be listed and appropriate actions, where needed, taken to resolve them.\n\n**Table 2**  \nExamples of documentation for transfer of technology (TOT)\n\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Project definition | Project plan and quality plan (where separate documents), protocol, risk assessments, gap analysis | Project implementation plan TOT protocol |\n| Quality agreement | | |\n| Facility assessment | Plans and layout of facility, buildings (construction, finish) Qualification status (DQ, IQ, OQ) and reports | Side-by-side comparison with RU facility and buildings; gap analysis Qualification protocol and report |\n| Health & Safety assessment | Product-specific waste management plans Contingency plans | |\n| Skill set analysis and training | SOPs and training documentation (product-specific operations, analysis, testing) | Training protocols, assessment results |\n| Analytical method transfer | Analytical method specifications and validation, including in-process quality control | Analytical methods transfer protocol and report |\n| Starting material evaluation | Specifications and additional information on APIs, excipients | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la evaluaci\u00f3n de las instalaciones en un proyecto de transferencia de tecnolog\u00eda?**\n   - La documentaci\u00f3n requerida para la evaluaci\u00f3n de las instalaciones incluye los planos y el dise\u00f1o de la instalaci\u00f3n y los edificios (construcci\u00f3n y acabado), as\u00ed como el estado de calificaci\u00f3n (DQ, IQ, OQ) y los informes correspondientes. Adem\u00e1s, se debe realizar una comparaci\u00f3n lado a lado con la instalaci\u00f3n y los edificios de la unidad receptora (RU) y llevar a cabo un an\u00e1lisis de brechas, junto con un protocolo y un informe de calificaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito de un informe de resumen de transferencia de tecnolog\u00eda?**\n   - El informe de resumen de transferencia de tecnolog\u00eda tiene como prop\u00f3sito formalizar y documentar que la transferencia ha sido considerada exitosa. Debe resumir el alcance de la transferencia, los par\u00e1metros cr\u00edticos obtenidos en la unidad de origen (SU) y la unidad receptora (RU), preferiblemente en un formato tabulado, as\u00ed como las conclusiones finales de la transferencia. Tambi\u00e9n debe listar posibles discrepancias y las acciones apropiadas que se han tomado para resolverlas.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se debe proporcionar en relaci\u00f3n con el an\u00e1lisis de habilidades y la capacitaci\u00f3n durante la transferencia de tecnolog\u00eda?**\n   - En relaci\u00f3n con el an\u00e1lisis de habilidades y la capacitaci\u00f3n, se debe proporcionar documentaci\u00f3n de Procedimientos Operativos Est\u00e1ndar (SOPs) y documentaci\u00f3n de capacitaci\u00f3n que aborde operaciones espec\u00edficas del producto, an\u00e1lisis y pruebas. Adem\u00e1s, se deben incluir protocolos de capacitaci\u00f3n y resultados de evaluaci\u00f3n.\n\n### Resumen de nivel superior del contexto:\nEl contexto se centra en la documentaci\u00f3n necesaria para un proyecto de transferencia de tecnolog\u00eda, destacando la importancia de formalizar el \u00e9xito de la transferencia a trav\u00e9s de un informe de resumen. Se presenta una tabla que enumera ejemplos de documentaci\u00f3n requerida para diversas tareas clave, como la definici\u00f3n del proyecto, la evaluaci\u00f3n de instalaciones, la evaluaci\u00f3n de salud y seguridad, el an\u00e1lisis de habilidades y la transferencia de m\u00e9todos anal\u00edticos. Este enfoque sistem\u00e1tico asegura que todos los aspectos cr\u00edticos de la transferencia sean considerados y documentados adecuadamente.", "prev_section_summary": "### Temas Clave:\n\n1. **Documentaci\u00f3n Requerida**: Se enfatiza la importancia de proporcionar una lista detallada de equipos, incluyendo marcas y modelos, as\u00ed como la documentaci\u00f3n de calificaci\u00f3n y validaci\u00f3n existente. Ejemplos de documentaci\u00f3n relevante incluyen dibujos, manuales, registros de mantenimiento y procedimientos operativos.\n\n2. **Revisi\u00f3n y Comparaci\u00f3n de Equipos**: El sitio receptor (RU) debe revisar la informaci\u00f3n proporcionada por el sitio de origen (SU) y realizar una comparaci\u00f3n detallada de los equipos en t\u00e9rminos de funcionalidad, marcas, modelos y estado de calificaci\u00f3n.\n\n3. **An\u00e1lisis de Brechas**: Se debe llevar a cabo un an\u00e1lisis de brechas para identificar las necesidades de adaptaci\u00f3n de equipos existentes, adquisici\u00f3n de nuevos equipos o cambios en el proceso, asegurando que se cumplan los requisitos de Buenas Pr\u00e1cticas de Manufactura (GMP).\n\n4. **Factores de Comparaci\u00f3n**: Se deben considerar varios factores al realizar el an\u00e1lisis de brechas, como la capacidad de producci\u00f3n, el material de construcci\u00f3n, los par\u00e1metros operativos cr\u00edticos y los atributos de calidad.\n\n5. **Ubicaci\u00f3n del Equipo**: La ubicaci\u00f3n espec\u00edfica de los equipos en el RU debe ser considerada al elaborar mapas de procesos o diagramas de flujo, incluyendo el flujo de personal y material.\n\n6. **Impacto en Productos Existentes**: Es necesario evaluar c\u00f3mo la fabricaci\u00f3n de nuevos productos afectar\u00e1 a los productos que actualmente se fabrican con el mismo equipo.\n\n7. **Documentaci\u00f3n de Modificaciones**: Cualquier modificaci\u00f3n necesaria en el equipo existente para reproducir el proceso transferido debe ser documentada en el plan del proyecto de transferencia.\n\n### Entidades:\n\n- **SU (Sitio de Origen)**: El lugar donde se encuentra el proceso de fabricaci\u00f3n original.\n- **RU (Sitio Receptor)**: El lugar donde se transferir\u00e1 el proceso de fabricaci\u00f3n.\n- **Equipos**: Herramientas y maquinaria involucradas en la fabricaci\u00f3n, llenado, empaque y control del producto.\n- **Documentaci\u00f3n**: Incluye dibujos, manuales, registros de mantenimiento, registros de calibraci\u00f3n y procedimientos operativos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativas que deben cumplirse durante el proceso de transferencia.\n- **Capacidad de Producci\u00f3n**: M\u00ednima y m\u00e1xima capacidad de los equipos.\n- **Par\u00e1metros Cr\u00edticos**: Elementos esenciales que afectan la calidad y funcionamiento del proceso de fabricaci\u00f3n. \n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en el contexto de la transferencia de procesos de fabricaci\u00f3n seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: technology transfer, documentation, quality agreement, facility assessment, analytical methods"}}, "8aa848ba-e5fb-483d-a766-308e55eb1394": {"node_ids": ["d4530800-75bd-4c1b-9588-0837c4d290c7"], "metadata": {"page_label": "319", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Key task | Documentation provided by SU | Transfer documentation |\n| - | - | - |\n| Equipment selection and transfer | Inventory list of all equipment and systems, including makes, models, qualification status (IQ, OQ, PQ) Drawings, manuals, logs, SOPs (e.g. set-up, operation, cleaning, maintenance, calibration, storage) | Side-by-side comparison with RU equipment (makes, models, qualification status) Gap analysis **Qualification and validation protocol and report** |\n| Process transfer: manufacturing and packaging | Reference batches (clinical, dossier, biobatches) Development report (manufacturing process rationale) History of critical analytical data Rationale for specifications Change control documentation Critical manufacturing process parameters Process validation reports Drug master file API validation status and report(s) Product stability data Current master batch manufacturing and packaging records List of all batches produced Deviation reports Investigations, complaints, recalls Annual product review | History of process development at RU Experiences at RU should be recorded for future reference Provisional batch manufacturing document (RU to develop) Provisional batch packaging document (RU to develop) Description of process at RU (narrative, process map, flow chart) **Process validation protocol and report** |\n| Cleaning | Cleaning validation, including: Solubility information; therapeutic doses; category (toxicology); existing cleaning SOPs; validation reports \u2014 chemical and micro; agents used; recovery study | Product- and site-specific cleaning SOPs at RU **Cleaning validation protocol and report** |\n\n\nDQ, design qualification; IQ, installation qualification; OQ, operational qualification; API, active pharmaceutical ingredient; SOPs, standard operating procedures; RU, receiving unit.\n\n## 9. Qualification and validation\n\n### General\n\n9.1 The extent of qualification and or validation (18) to be performed should be determined on the basis of risk management principles.\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Technical Report Series 961) aborda la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, centr\u00e1ndose en la calificaci\u00f3n y validaci\u00f3n de equipos y procesos. Se detallan las tareas clave, la documentaci\u00f3n necesaria proporcionada por la unidad de suministro (SU) y la documentaci\u00f3n de transferencia requerida por la unidad receptora (RU). Se enfatiza la importancia de la gesti\u00f3n de riesgos en la determinaci\u00f3n del alcance de la calificaci\u00f3n y validaci\u00f3n.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la transferencia de equipos y sistemas desde la unidad de suministro (SU) a la unidad receptora (RU)?**\n   - La documentaci\u00f3n requerida incluye una lista de inventario de todos los equipos y sistemas, que abarca marcas, modelos y estado de calificaci\u00f3n (IQ, OQ, PQ), as\u00ed como dibujos, manuales, registros y procedimientos operativos est\u00e1ndar (SOPs).\n\n2. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en el protocolo y el informe de validaci\u00f3n del proceso durante la transferencia de fabricaci\u00f3n y empaquetado?**\n   - El protocolo y el informe de validaci\u00f3n del proceso deben incluir la historia del desarrollo del proceso en la RU, un documento provisional de fabricaci\u00f3n de lotes, un documento provisional de empaquetado, y una descripci\u00f3n del proceso en la RU, que puede ser en forma de narrativa, mapa de procesos o diagrama de flujo.\n\n3. **\u00bfQu\u00e9 aspectos se consideran en la validaci\u00f3n de limpieza y qu\u00e9 documentaci\u00f3n espec\u00edfica se requiere para la RU?**\n   - La validaci\u00f3n de limpieza debe incluir informaci\u00f3n sobre solubilidad, dosis terap\u00e9uticas, categor\u00eda (toxicolog\u00eda), SOPs de limpieza existentes y estudios de recuperaci\u00f3n. La RU debe proporcionar SOPs de limpieza espec\u00edficas para el producto y el sitio, as\u00ed como un protocolo y un informe de validaci\u00f3n de limpieza.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Documentaci\u00f3n para la Transferencia de Tecnolog\u00eda (TOT):** Se destaca la variedad de documentaci\u00f3n necesaria para llevar a cabo un proyecto de transferencia de tecnolog\u00eda, que incluye planes de proyecto, evaluaciones de riesgos, y an\u00e1lisis de brechas.\n  \n2. **Informe de Resumen de Transferencia de Tecnolog\u00eda:** Se enfatiza la importancia de formalizar el \u00e9xito de la transferencia mediante un informe que resuma el alcance, par\u00e1metros cr\u00edticos y conclusiones, as\u00ed como las discrepancias y acciones correctivas.\n\n3. **Evaluaci\u00f3n de Instalaciones:** Se requiere documentaci\u00f3n espec\u00edfica sobre la evaluaci\u00f3n de las instalaciones, incluyendo planos, estado de calificaci\u00f3n y comparaciones con la unidad receptora.\n\n4. **An\u00e1lisis de Habilidades y Capacitaci\u00f3n:** Se menciona la necesidad de documentaci\u00f3n sobre procedimientos operativos est\u00e1ndar y capacitaci\u00f3n relacionada con operaciones espec\u00edficas del producto.\n\n5. **Transferencia de M\u00e9todos Anal\u00edticos:** Se requiere documentaci\u00f3n sobre especificaciones y validaci\u00f3n de m\u00e9todos anal\u00edticos, as\u00ed como protocolos de transferencia.\n\n**Entidades:**\n- **SU (Unidad de Origen):** La unidad de donde se transfiere la tecnolog\u00eda.\n- **RU (Unidad Receptora):** La unidad que recibe la tecnolog\u00eda.\n- **Documentaci\u00f3n:** Incluye planes de proyecto, protocolos, informes de calificaci\u00f3n, SOPs, y resultados de evaluaci\u00f3n.\n- **Par\u00e1metros Cr\u00edticos:** Elementos esenciales que deben ser documentados y evaluados durante la transferencia.\n- **Calificaci\u00f3n (DQ, IQ, OQ):** Estado de calificaci\u00f3n de las instalaciones y procesos involucrados en la transferencia.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos fundamentales relacionados con la documentaci\u00f3n y los procesos necesarios para una transferencia de tecnolog\u00eda exitosa.", "excerpt_keywords": "Keywords: transferencia de tecnolog\u00eda, calificaci\u00f3n, validaci\u00f3n, documentaci\u00f3n, industria farmac\u00e9utica"}}, "8032ae35-979a-40bf-97a6-8c412d97d675": {"node_ids": ["35066ccf-6258-40de-b778-08dbb233a492"], "metadata": {"page_label": "320", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.2 Qualification and validation should be documented.\n\n## References\n\n1. **ISPE Good practice guide. Technology transfer.** Tampa, FL, International Society for Pharmaceutical Engineering, 2003.\n\n2. **WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-second report.** Geneva, World Health Organization, 2008 (WHO Technical Report Series, No. 948).\n\n3. **Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials, Volume 2,** second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007 and related updates; Quality Assurance of Pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n4. **Good manufacturing practices for sterile pharmaceutical products** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 957, 2010), Annex 4; WHO Technical Report Series, No. 961, 2011) Annex 6.\n\n5. **WHO good manufacturing practices: supplementary guidelines for the manufacture of investigational pharmaceutical products for clinical trials in humans.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization (WHO Technical Report Series, No. 863, 1996), Annex 7.\n\n6. **ISO 9000:2005, Quality management systems \u2014 Fundamentals and vocabulary.**\n\n7. **ICH Draft Consensus Guideline. Pharmaceutical Quality System. Q10.** Geneva, ICH Secretariat, 2008 (http://www.ich.org/LOB/media/MEDIA3917.pdf, last accessed 27 July 2010).\n\n8. **ICH Harmonized Tripartite Guideline. Pharmaceutical development. Q8 (2R). As revised in August 2009.** Geneva, ICH Secretariat, 2009 (http://www.ich.org/LOB/media/MEDIA4986.pdf last accessed 27 July 2010).\n\n9. **ICH Harmonized Tripartite Guideline. Quality Risk Management. Q9. November 2005.** Geneva, ICH Secretariat, 2005 (http://www.ich.org/LOB/media/MEDIA1957.pdf, last accessed 27 July 2010).\n\n10. **Application of hazard analysis and critical control point (HACCP) methodology to pharmaceuticals.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report. Geneva, World Health Organization (WHO Technical Report Series, No. 908, 2003), Annex 7.\n\n11. **WHO good manufacturing practices: supplementary guidelines for the manufacture of pharmaceutical excipients.** In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization (WHO Technical Report Series, No. 885, 1999), Annex 5.\n\n12. **WHO good manufacturing practices: Active pharmaceutical ingredients (bulk drug substances)** In: WHO Expert Committee on Specifications for", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS y se centra en la importancia de la calificaci\u00f3n y validaci\u00f3n en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfatiza que estos procesos deben ser documentados adecuadamente. Adem\u00e1s, se incluyen referencias a diversas gu\u00edas y normativas relacionadas con las buenas pr\u00e1cticas de fabricaci\u00f3n, la gesti\u00f3n de calidad y el desarrollo farmac\u00e9utico, que son esenciales para asegurar la calidad y seguridad de los productos farmac\u00e9uticos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las implicaciones de no documentar adecuadamente la calificaci\u00f3n y validaci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca explorar las consecuencias potenciales, como problemas de calidad, riesgos para la salud p\u00fablica y repercusiones legales.\n\n2. **\u00bfQu\u00e9 documentos o gu\u00edas espec\u00edficas se mencionan en el contexto que son fundamentales para la calificaci\u00f3n y validaci\u00f3n en la industria farmac\u00e9utica?**\n   - Esta pregunta se centra en identificar las referencias clave que pueden servir como recursos para los profesionales en el campo.\n\n3. **\u00bfC\u00f3mo se relacionan las gu\u00edas de la OMS y de la ICH en t\u00e9rminos de requisitos de calidad y gesti\u00f3n de riesgos en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca entender la interconexi\u00f3n entre diferentes normativas y c\u00f3mo se complementan para asegurar la calidad en la industria farmac\u00e9utica.\n\n### Resumen de Nivel Superior\n\nEl documento subraya la importancia de la calificaci\u00f3n y validaci\u00f3n en la producci\u00f3n farmac\u00e9utica, destacando que estos procesos deben ser documentados para garantizar la calidad y seguridad de los productos. Se citan m\u00faltiples referencias que ofrecen directrices y est\u00e1ndares sobre buenas pr\u00e1cticas de fabricaci\u00f3n y gesti\u00f3n de calidad, lo que es crucial para los profesionales del sector farmac\u00e9utico.", "prev_section_summary": "### Temas Clave:\n\n1. **Transferencia de Tecnolog\u00eda**: El documento se centra en la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, espec\u00edficamente en la calificaci\u00f3n y validaci\u00f3n de equipos y procesos.\n\n2. **Documentaci\u00f3n Requerida**: Se detallan las diferentes categor\u00edas de documentaci\u00f3n que deben ser proporcionadas por la unidad de suministro (SU) y la unidad receptora (RU) para asegurar una transferencia efectiva.\n\n3. **Gesti\u00f3n de Riesgos**: Se enfatiza la importancia de aplicar principios de gesti\u00f3n de riesgos para determinar el alcance de la calificaci\u00f3n y validaci\u00f3n.\n\n4. **Calificaci\u00f3n y Validaci\u00f3n**: Se describen los procesos de calificaci\u00f3n (DQ, IQ, OQ) y validaci\u00f3n necesarios para equipos, procesos de fabricaci\u00f3n y limpieza.\n\n### Entidades:\n\n- **SU (Unidad de Suministro)**: Entidad que proporciona la documentaci\u00f3n y equipos.\n- **RU (Unidad Receptora)**: Entidad que recibe la documentaci\u00f3n y equipos, y que debe desarrollar ciertos documentos provisionales.\n- **Documentaci\u00f3n**: Incluye listas de inventario, informes de desarrollo, protocolos de validaci\u00f3n, SOPs, y m\u00e1s.\n- **Equipos y Sistemas**: Se refiere a los equipos utilizados en la fabricaci\u00f3n y empaquetado de productos farmac\u00e9uticos.\n- **Proceso de Fabricaci\u00f3n y Empaque**: Incluye la transferencia de procesos cr\u00edticos y la documentaci\u00f3n asociada.\n- **Validaci\u00f3n de Limpieza**: Proceso que asegura que los procedimientos de limpieza son efectivos y seguros.\n\n### Resumen General:\nEl documento de la OMS (Technical Report Series 961) aborda la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica, destacando la importancia de la calificaci\u00f3n y validaci\u00f3n de equipos y procesos. Se especifica la documentaci\u00f3n necesaria para la transferencia, la cual debe ser proporcionada por la unidad de suministro y adaptada por la unidad receptora, todo bajo un enfoque de gesti\u00f3n de riesgos.", "excerpt_keywords": "Keywords: calificaci\u00f3n, validaci\u00f3n, buenas pr\u00e1cticas, farmac\u00e9uticos, gesti\u00f3n de calidad"}}, "fbabd06b-d065-4db2-be9d-76f63ff6ee24": {"node_ids": ["8a91e37a-4440-49fd-833a-96078a718fda"], "metadata": {"page_label": "321", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un breve resumen del contenido circundante:\n\n### Resumen del contexto:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica, y recomendaciones para pol\u00edticas de salud. Sin embargo, el contenido espec\u00edfico del documento no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe WHO - Technical Report Series 961?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el contenido del informe, que podr\u00eda incluir descubrimientos clave o directrices de salud p\u00fablica.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en la serie de informes t\u00e9cnicos de la OMS, y c\u00f3mo se relaciona el informe 961 con esos temas?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio de la serie de informes, permitiendo entender la relevancia del informe 961 dentro de la colecci\u00f3n.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el informe WHO - Technical Report Series 961 para abordar los problemas de salud discutidos?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos espec\u00edficos que el informe podr\u00eda emplear para analizar y presentar sus hallazgos, lo que puede ser crucial para la interpretaci\u00f3n de los resultados.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n que probablemente no se encuentre f\u00e1cilmente en otros documentos o fuentes, dado que se centran en el contenido espec\u00edfico del informe y su contexto dentro de la serie de la OMS.", "prev_section_summary": "### Temas Clave\n\n1. **Calificaci\u00f3n y Validaci\u00f3n**: Se enfatiza la importancia de documentar adecuadamente los procesos de calificaci\u00f3n y validaci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos para garantizar su calidad y seguridad.\n\n2. **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (BPF)**: Se mencionan diversas gu\u00edas y normativas que establecen est\u00e1ndares para la fabricaci\u00f3n de productos farmac\u00e9uticos, incluyendo la gesti\u00f3n de calidad y el desarrollo farmac\u00e9utico.\n\n3. **Gesti\u00f3n de Calidad y Riesgos**: Se hace referencia a la interconexi\u00f3n entre diferentes normativas, como las de la OMS y la ICH, que abordan los requisitos de calidad y la gesti\u00f3n de riesgos en la industria farmac\u00e9utica.\n\n### Entidades Mencionadas\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Proporciona directrices y est\u00e1ndares sobre buenas pr\u00e1cticas de fabricaci\u00f3n y calidad en productos farmac\u00e9uticos.\n  \n- **International Society for Pharmaceutical Engineering (ISPE)**: Ofrece gu\u00edas sobre la transferencia de tecnolog\u00eda en la industria farmac\u00e9utica.\n\n- **International Conference on Harmonisation (ICH)**: Desarrolla directrices sobre sistemas de calidad, desarrollo farmac\u00e9utico y gesti\u00f3n de riesgos.\n\n### Referencias Clave\n\n1. **ISPE Good Practice Guide**: Gu\u00eda sobre la transferencia de tecnolog\u00eda.\n2. **WHO Technical Report Series**: Incluye m\u00faltiples informes sobre especificaciones y buenas pr\u00e1cticas de fabricaci\u00f3n.\n3. **ISO 9000:2005**: Normativa sobre sistemas de gesti\u00f3n de calidad.\n4. **ICH Guidelines (Q8, Q9, Q10)**: Directrices sobre desarrollo farmac\u00e9utico, gesti\u00f3n de riesgos y sistemas de calidad.\n\nEste resumen destaca la relevancia de la documentaci\u00f3n en los procesos de calificaci\u00f3n y validaci\u00f3n, as\u00ed como la importancia de seguir las gu\u00edas y normativas establecidas para asegurar la calidad en la fabricaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: OMS, calidad, farmac\u00e9utica, buenas pr\u00e1cticas, validaci\u00f3n"}}, "3a20e2c8-d6dc-4b6c-a08f-3e5bf7c525a2": {"node_ids": ["b3ccef19-6656-46ab-92b1-ebb984cf7a12"], "metadata": {"page_label": "322", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 8\n\n## Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services\n\n### Background\n\n1. Introduction\n2. Underlying philosophy\n3. Definition of good pharmacy practice\n4. Requirements of good pharmacy practice\n5. Setting standards for good pharmacy practice\n6. Conclusions\n\n\u00a9 World Health Organization  \nWHO Technical Report Series, No. 961, 2011", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los principios fundamentales que sustentan las directrices conjuntas de la FIP/OMS sobre la buena pr\u00e1ctica farmac\u00e9utica?**\n   - Esta pregunta busca explorar la \"filosof\u00eda subyacente\" mencionada en el documento, que puede ofrecer una comprensi\u00f3n m\u00e1s profunda de los valores y principios que gu\u00edan la pr\u00e1ctica farmac\u00e9utica de calidad.\n\n2. **\u00bfQu\u00e9 requisitos espec\u00edficos se establecen para garantizar una buena pr\u00e1ctica farmac\u00e9utica seg\u00fan las directrices de la FIP/OMS?**\n   - Esta pregunta se centra en la secci\u00f3n que detalla los \"requisitos de buena pr\u00e1ctica farmac\u00e9utica\", lo que puede proporcionar informaci\u00f3n sobre las expectativas y est\u00e1ndares que deben cumplirse en el \u00e1mbito farmac\u00e9utico.\n\n3. **\u00bfC\u00f3mo se proponen establecer est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica en el contexto de los servicios de farmacia?**\n   - Esta pregunta indaga en la secci\u00f3n sobre \"establecimiento de est\u00e1ndares\", lo que puede revelar los m\u00e9todos y enfoques sugeridos para implementar y mantener est\u00e1ndares de calidad en los servicios farmac\u00e9uticos.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento es un informe t\u00e9cnico de la OMS que presenta directrices conjuntas con la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) sobre la buena pr\u00e1ctica farmac\u00e9utica. Estas directrices est\u00e1n dise\u00f1adas para establecer est\u00e1ndares de calidad en los servicios de farmacia, abordando aspectos como la definici\u00f3n de buena pr\u00e1ctica, los requisitos necesarios y la filosof\u00eda que gu\u00eda estas pr\u00e1cticas. El informe busca mejorar la calidad de los servicios farmac\u00e9uticos a nivel global, asegurando que se cumplan ciertos criterios y est\u00e1ndares en la atenci\u00f3n al paciente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento mencionado, \"WHO - Technical Report Series 961\", es parte de una serie de informes t\u00e9cnicos de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque el contenido espec\u00edfico no est\u00e1 disponible, se pueden inferir algunos temas clave y entidades relevantes:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**:\n   - Entidad responsable de la publicaci\u00f3n del informe, enfocada en la salud p\u00fablica y la investigaci\u00f3n m\u00e9dica a nivel global.\n\n2. **Informe T\u00e9cnico**:\n   - Parte de una serie que aborda diversos temas de salud p\u00fablica, proporcionando recomendaciones y hallazgos basados en investigaciones.\n\n3. **Salud P\u00fablica**:\n   - Tema central del informe, que podr\u00eda incluir aspectos como prevenci\u00f3n de enfermedades, pol\u00edticas de salud, y estrategias de intervenci\u00f3n.\n\n4. **Investigaci\u00f3n M\u00e9dica**:\n   - Posible enfoque del informe, que podr\u00eda presentar estudios, an\u00e1lisis de datos y metodolog\u00edas relacionadas con la salud.\n\n5. **Recomendaciones de Pol\u00edticas de Salud**:\n   - Es probable que el informe contenga directrices o sugerencias para mejorar la salud p\u00fablica y la atenci\u00f3n m\u00e9dica.\n\n### Temas Clave Potenciales:\n- Hallazgos sobre enfermedades espec\u00edficas o condiciones de salud.\n- Estrategias de prevenci\u00f3n y control de enfermedades.\n- Evaluaci\u00f3n de programas de salud p\u00fablica.\n- An\u00e1lisis de datos epidemiol\u00f3gicos.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades que podr\u00edan estar presentes en el informe, a pesar de la falta de contenido espec\u00edfico en el extracto proporcionado.", "excerpt_keywords": "Keywords: pharmacy practice, quality standards, WHO guidelines, FIP collaboration, healthcare services"}}, "4dc16ac7-5306-4f5f-a055-f7ac2e16621b": {"node_ids": ["fcf69961-d6b9-4cdb-8477-35c00c2d223d"], "metadata": {"page_label": "323", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Background\n\nUnder the World Health Organization (WHO)\u2019s Revised Drug Strategy adopted by the World Health Assembly in 1986, WHO organized two meetings on the role of the pharmacist, in Delhi, India in 1988 and in Tokyo, Japan in 1993. This was followed by the adoption, in May 1994, of the World Health Assembly Resolution WHA47.12 on the role of the pharmacist, in support of the WHO Revised Drug Strategy.\n\nIn 1992 the International Pharmaceutical Federation (FIP) developed standards for pharmacy services under the heading \u201cGood pharmacy practice in community and hospital pharmacy settings\u201d. The text on good pharmacy practice was also submitted to the WHO Expert Committee on Specifications for Pharmaceutical Preparations in 1994. Following the recommendations of the WHO Expert Committee and the endorsement of the FIP Council in 1997, the FIP/WHO joint document on good pharmacy practice (GPP) was published in 1999 in the thirty-fifth report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 885).\n\nSubsequently WHO organized two more meetings on the role of the pharmacist, in Vancouver, Canada in 1997 and in the Hague, the Netherlands in 1998. These meetings reinforced the need for pharmacy curricular reform and the added value of the pharmacist in self-care and self-medication.\n\nIn collaboration with WHO, the first edition of a practical handbook *Developing pharmacy practice \u2014 a focus on patient care* was launched in 2006. This handbook is designed to meet the changing needs of pharmacists, setting out a new paradigm for pharmacy practice and presenting a step-by-step approach to pharmaceutical care.\n\nWith the overall aim of improving standards and practice of distribution and use of medicines, using the FIP/WHO guidelines for GPP as the framework, FIP took the initiative to explore the possibilities for providing technical assistance to its Member Organizations in Cambodia, Moldova, Mongolia, Paraguay, Thailand, Uruguay and Viet Nam, in developing national standards for GPP in a pilot study from 2005 to 2007. In 2007 the \u201cBangkok declaration on good pharmacy practice in the community pharmacy settings\u201d in the South-East Asia Region was adopted by the FIP South-East Asia Pharmaceutical Forum and set out the commitment of its Member Associations towards raising standards of pharmacy services and professional practice.\n\nSince the adoption of the GPP guidelines in community and hospital settings, significant changes in practice, applied science and technology and pharmaceutical policy have occurred, including the relevance of more recent World Health Assembly resolutions: WHA54.11 (WHO Medicines", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Evoluci\u00f3n de la pr\u00e1ctica farmac\u00e9utica**: Desde la adopci\u00f3n de la Estrategia de Medicamentos Revisada de la OMS en 1986, ha habido un enfoque continuo en el papel del farmac\u00e9utico, con m\u00faltiples reuniones y la creaci\u00f3n de documentos clave que establecen est\u00e1ndares para la pr\u00e1ctica farmac\u00e9utica, como las directrices de Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP).\n\n2. **Colaboraci\u00f3n entre organizaciones**: La colaboraci\u00f3n entre la OMS y la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) ha sido fundamental para desarrollar y promover est\u00e1ndares de pr\u00e1ctica farmac\u00e9utica, incluyendo la creaci\u00f3n de manuales pr\u00e1cticos y la implementaci\u00f3n de estudios piloto en varios pa\u00edses para mejorar la calidad de los servicios farmac\u00e9uticos.\n\n3. **Impacto de las resoluciones de la OMS**: Las resoluciones de la Asamblea Mundial de la Salud han influido en la evoluci\u00f3n de la pr\u00e1ctica farmac\u00e9utica, destacando la importancia de la reforma curricular y el papel del farmac\u00e9utico en el autocuidado y la automedicaci\u00f3n.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les fueron los principales resultados de las reuniones organizadas por la OMS en Delhi y Tokio sobre el papel del farmac\u00e9utico?**\n   - Esta pregunta busca detalles sobre las conclusiones y recomendaciones espec\u00edficas que surgieron de estas reuniones, que pueden no estar documentadas en otros lugares.\n\n2. **\u00bfQu\u00e9 cambios significativos en la pr\u00e1ctica farmac\u00e9utica se han observado desde la adopci\u00f3n de las directrices de GPP en 1999?**\n   - Esta pregunta se centra en los cambios concretos en la pr\u00e1ctica y la pol\u00edtica farmac\u00e9utica que han ocurrido desde la publicaci\u00f3n de las directrices, proporcionando una perspectiva sobre la evoluci\u00f3n del campo.\n\n3. **\u00bfC\u00f3mo se implementaron las directrices de GPP en los pa\u00edses que participaron en el estudio piloto de 2005 a 2007?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el proceso y los resultados de la implementaci\u00f3n de las directrices de GPP en los pa\u00edses mencionados, lo que puede ofrecer ejemplos pr\u00e1cticos de su aplicaci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**T\u00edtulo del Documento:** WHO - Technical Report Series 961\n\n**Secci\u00f3n:** Anexo 8 - Directrices conjuntas de la FIP/OMS sobre buena pr\u00e1ctica farmac\u00e9utica: est\u00e1ndares para la calidad de los servicios de farmacia.\n\n**Temas Clave:**\n1. **Introducci\u00f3n:** Presentaci\u00f3n del contexto y la importancia de la buena pr\u00e1ctica farmac\u00e9utica.\n2. **Filosof\u00eda Subyacente:** Principios y valores que gu\u00edan la pr\u00e1ctica farmac\u00e9utica de calidad.\n3. **Definici\u00f3n de Buena Pr\u00e1ctica Farmac\u00e9utica:** Concepto y caracter\u00edsticas que definen lo que se considera buena pr\u00e1ctica en el \u00e1mbito farmac\u00e9utico.\n4. **Requisitos de Buena Pr\u00e1ctica Farmac\u00e9utica:** Expectativas y criterios espec\u00edficos que deben cumplirse para asegurar la calidad en los servicios farmac\u00e9uticos.\n5. **Establecimiento de Est\u00e1ndares:** M\u00e9todos y enfoques propuestos para implementar y mantener est\u00e1ndares de calidad en los servicios de farmacia.\n6. **Conclusiones:** Reflexiones finales sobre la importancia de seguir estas directrices para mejorar la atenci\u00f3n al paciente.\n\n**Entidades:**\n- **Organizaciones:** Organizaci\u00f3n Mundial de la Salud (OMS), Federaci\u00f3n Internacional Farmac\u00e9utica (FIP).\n- **A\u00f1o de Publicaci\u00f3n:** 2011.\n- **N\u00famero de Informe:** WHO Technical Report Series, No. 961.\n\nEste resumen destaca los elementos esenciales del documento, que busca mejorar la calidad de los servicios farmac\u00e9uticos a nivel global mediante la implementaci\u00f3n de est\u00e1ndares y buenas pr\u00e1cticas.", "excerpt_keywords": "Keywords: pharmacy practice, WHO, good pharmacy practice, pharmaceutical standards, healthcare reform"}}, "e93e1446-0faa-4853-96e4-69abba33e17a": {"node_ids": ["c8b20f1a-f70a-4bb1-bf4b-4f24c238dddd"], "metadata": {"page_label": "324", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe health of the public is fundamental to the happiness and welfare of all people. Barriers to good health include poor access to quality medical products, lack of access to trained health professionals and care, an inadequate health workforce, unaffordable cost of care and poor standards of education of health-care professionals.\n\nMedicines are an essential and critical part of health-care services in all cultures and societies. When accessed, medicines are often an essential component of many disease prevention programmes and virtually all disease treatment plans. The potential benefit of medicines is often not realized \u2014 there is a gap between the proven efficacy of medicines demonstrated in clinical trials and their actual effectiveness in practice. The reasons for this gap include problems with medicine selection and dosages, improper administration of medicines and lack of adherence by patients to prescribed treatment, medicine\u2013medicine and medicine\u2013food interactions, and adverse medicine events. Besides clinical problems associated with medicine-related problems, there are cost\n\n----\n\nFurthermore, in 2007 FIP established an initiative to investigate the need to update the guidelines on GPP to reflect contemporary standards of practice and thinking. An FIP working group on GPP first met on 15 October 2007 to identify key issues that needed to be considered in the revision of the guidelines.\n\nIn 2008 FIP organized an expert consultation in Basel, Switzerland during its 68th World Congress. Fifty participants attended the meeting, including the FIP Working Group (WG) on GPP, WHO staff from headquarters, representatives from the WHO Regional Office for the Eastern Mediterranean, country medicines advisers from Ghana, Nigeria and the United Republic of Tanzania, Presidents and Secretaries of the six FIP Regional Pharmaceutical Forums, FIP Member Organizations and several invited experts.\n\nFollowing this consultation, the FIP WG on GPP undertook an extensive review of the existing national standards on GPP in at least 37 countries and established a time frame that would allow sufficient consultation with all of FIP\u2019s 120 national Member Associations, relevant experts and WHO. A proposal for this initiative was presented to the forty-third meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 and an updated report was provided to the Expert Committee at its forty-fourth meeting in October 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Importancia de la salud p\u00fablica**: La salud p\u00fablica es esencial para el bienestar de las personas, y existen m\u00faltiples barreras que impiden el acceso a una atenci\u00f3n m\u00e9dica de calidad, incluyendo la falta de productos m\u00e9dicos adecuados, profesionales de salud capacitados y costos asequibles.\n\n2. **Medicamentos y su efectividad**: Los medicamentos son cruciales en los servicios de salud y en los programas de prevenci\u00f3n y tratamiento de enfermedades. Sin embargo, existe una brecha entre la eficacia demostrada en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica, debido a problemas como la selecci\u00f3n y dosificaci\u00f3n incorrectas, la administraci\u00f3n inapropiada y la falta de adherencia de los pacientes.\n\n3. **Iniciativa de la FIP para actualizar las gu\u00edas de buenas pr\u00e1cticas farmac\u00e9uticas (GPP)**: En 2007, la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 un esfuerzo para actualizar las gu\u00edas de GPP, llevando a cabo consultas y revisiones de est\u00e1ndares nacionales en varios pa\u00edses, con el objetivo de reflejar las pr\u00e1cticas contempor\u00e1neas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las principales barreras identificadas que afectan el acceso a medicamentos de calidad en la atenci\u00f3n m\u00e9dica?**\n   - Esta pregunta busca respuestas sobre los obst\u00e1culos espec\u00edficos que enfrentan las personas para acceder a medicamentos, que no se detallan exhaustivamente en otros documentos.\n\n2. **\u00bfQu\u00e9 factores contribuyen a la brecha entre la eficacia de los medicamentos en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica cl\u00ednica?**\n   - Esta pregunta se centra en los problemas espec\u00edficos que afectan la implementaci\u00f3n de tratamientos efectivos, proporcionando una visi\u00f3n m\u00e1s profunda de los desaf\u00edos en la adherencia y administraci\u00f3n de medicamentos.\n\n3. **\u00bfQu\u00e9 pasos se han tomado desde la consulta de 2008 para revisar las gu\u00edas de GPP y cu\u00e1les son los resultados esperados de esta revisi\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre el proceso y los resultados de la revisi\u00f3n de las gu\u00edas de GPP, as\u00ed como las expectativas de la FIP y la OMS en relaci\u00f3n con la mejora de las pr\u00e1cticas farmac\u00e9uticas a nivel global.", "prev_section_summary": "### Temas Clave\n\n1. **Estrategia de Medicamentos de la OMS**: La adopci\u00f3n de la Estrategia de Medicamentos Revisada en 1986 marc\u00f3 el inicio de un enfoque sistem\u00e1tico sobre el papel del farmac\u00e9utico, con reuniones clave en Delhi y Tokio.\n\n2. **Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP)**: La Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) desarroll\u00f3 est\u00e1ndares para la pr\u00e1ctica farmac\u00e9utica, culminando en la publicaci\u00f3n de un documento conjunto con la OMS en 1999 que establece directrices para la pr\u00e1ctica en entornos comunitarios y hospitalarios.\n\n3. **Reforma Curricular y Autocuidado**: Las reuniones posteriores en Vancouver y La Haya subrayaron la necesidad de reformar los planes de estudio de farmacia y el papel del farmac\u00e9utico en el autocuidado y la automedicaci\u00f3n.\n\n4. **Manual Pr\u00e1ctico de Pr\u00e1ctica Farmac\u00e9utica**: En 2006, se lanz\u00f3 un manual pr\u00e1ctico que establece un nuevo paradigma para la pr\u00e1ctica farmac\u00e9utica, enfocado en el cuidado del paciente.\n\n5. **Asistencia T\u00e9cnica y Estudio Piloto**: La FIP, en colaboraci\u00f3n con la OMS, llev\u00f3 a cabo un estudio piloto entre 2005 y 2007 en varios pa\u00edses para desarrollar est\u00e1ndares nacionales de GPP.\n\n6. **Declaraci\u00f3n de Bangkok**: En 2007, se adopt\u00f3 la Declaraci\u00f3n de Bangkok, que reafirma el compromiso de las asociaciones farmac\u00e9uticas en la regi\u00f3n de Asia Sudoriental para elevar los est\u00e1ndares de los servicios farmac\u00e9uticos.\n\n### Entidades Clave\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Instituci\u00f3n que lidera la estrategia y las reuniones sobre el papel del farmac\u00e9utico.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que desarroll\u00f3 est\u00e1ndares de pr\u00e1ctica y colabor\u00f3 con la OMS en la creaci\u00f3n de directrices.\n- **Asamblea Mundial de la Salud**: \u00d3rgano que adopt\u00f3 resoluciones relevantes para la pr\u00e1ctica farmac\u00e9utica, incluyendo la WHA47.12 y WHA54.11.\n- **Pa\u00edses Participantes**: Camboya, Moldavia, Mongolia, Paraguay, Tailandia, Uruguay y Vietnam, que participaron en el estudio piloto para el desarrollo de est\u00e1ndares de GPP. \n\nEste resumen destaca la evoluci\u00f3n y el impacto de la pr\u00e1ctica farmac\u00e9utica a trav\u00e9s de la colaboraci\u00f3n internacional y el establecimiento de est\u00e1ndares.", "excerpt_keywords": "Keywords: public health, medicines, guidelines, FIP, WHO"}}, "65332d51-d814-4342-a93d-7086fec28e32": {"node_ids": ["ee14ac38-b760-41b0-854c-8519d2bcf1f0"], "metadata": {"page_label": "325", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "implications. It has been estimated that the cost of problems with the use of medicines is equal to or greater than the cost of the medicines themselves.\n\nMedicines are also increasingly expensive and their cost is compromising the affordability of health care. Managing the costs of medicines is critical to making the best use of limited resources to maximize health care for as many people as possible.\n\nSubstandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/ counterfeit medicines are a growing problem that compromise health. There is a need for a system of assuring the integrity of the medicine supply chain to assure the value of medicines used for the prevention of disease and the treatment of patients.\n\nPharmacists[^1] are specifically educated and trained health professionals who are charged by their national or other appropriate (e.g. state or provincial) authorities with the management of the distribution of medicines to consumers and to engage in appropriate efforts to assure their safe and efficacious use. There is also increasing recognition that providing consumers with medicines alone is not sufficient to achieve the treatment goals. To address these medication-related needs, pharmacists are accepting greater responsibility for the outcomes of medicines use and are evolving their practices to provide patients with enhanced medicines-use services.\n\nAs health-care professionals, pharmacists play an important role in improving access to health care and in closing the gap between the potential benefit of medicines and the actual value realized and should be part of any comprehensive health system. In addition, the increasingly complex and diverse nature of pharmacists\u2019 roles in the health-care system and public health demands a continuous maintenance of the competence of pharmacists as health-care professionals who have up-to-date skills and expertise.\n\nNational pharmacy professional associations need to work together with their governing bodies and other health-care professional associations to support pharmacists in their countries through provision of continuing professional development activities, including distance-learning programmes, and establishing national standards of pharmacy services and practice objectives.\n\nThese guidelines are intended to provide a description of ways in which pharmacists can improve access to health care, health promotion and the use of medicines on behalf of the patients they serve. The role of FIP is to provide leadership for national pharmacy professional organizations,\n\n[^1]: Pharmacists are health-care professionals whose professional responsibilities and accountabilities include seeking to ensure that people derive maximum therapeutic benefit from their treatments with medicines. This requires them to keep abreast of developments in pharmacy practice and the pharmaceutical sciences, professional standards and requirements, the laws governing pharmacy and medicines and advances in knowledge and technology relating to use of medicines.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Costo y Accesibilidad de Medicamentos**: El aumento en el costo de los medicamentos est\u00e1 afectando la accesibilidad a la atenci\u00f3n m\u00e9dica. Se estima que los problemas relacionados con el uso de medicamentos pueden tener costos iguales o superiores a los de los propios medicamentos, lo que resalta la necesidad de gestionar estos costos de manera efectiva.\n\n2. **Problemas con Medicamentos**: Existe un creciente problema con medicamentos subest\u00e1ndar, adulterados y falsificados, lo que compromete la salud p\u00fablica. Se requiere un sistema que garantice la integridad de la cadena de suministro de medicamentos para asegurar su valor en la prevenci\u00f3n y tratamiento de enfermedades.\n\n3. **Rol de los Farmac\u00e9uticos**: Los farmac\u00e9uticos son profesionales de la salud capacitados que no solo distribuyen medicamentos, sino que tambi\u00e9n asumen una mayor responsabilidad en los resultados del uso de medicamentos. Su papel es crucial para mejorar el acceso a la atenci\u00f3n m\u00e9dica y cerrar la brecha entre el beneficio potencial de los medicamentos y su valor real.\n\n### Preguntas espec\u00edficas que el contexto puede responder:\n\n1. **\u00bfCu\u00e1les son las implicaciones econ\u00f3micas de los problemas relacionados con el uso de medicamentos en comparaci\u00f3n con su costo?**\n   - El contexto menciona que el costo de los problemas con el uso de medicamentos es igual o mayor que el costo de los propios medicamentos, lo que implica una carga econ\u00f3mica significativa en el sistema de salud.\n\n2. **\u00bfQu\u00e9 medidas se sugieren para asegurar la integridad de la cadena de suministro de medicamentos?**\n   - Se destaca la necesidad de un sistema que garantice la integridad de la cadena de suministro de medicamentos, aunque el texto no detalla las medidas espec\u00edficas, se puede inferir que se requiere una regulaci\u00f3n m\u00e1s estricta y mecanismos de control.\n\n3. **\u00bfC\u00f3mo est\u00e1n evolucionando las responsabilidades de los farmac\u00e9uticos en el sistema de salud?**\n   - Los farmac\u00e9uticos est\u00e1n asumiendo una mayor responsabilidad en los resultados del uso de medicamentos y est\u00e1n evolucionando sus pr\u00e1cticas para ofrecer servicios mejorados relacionados con el uso de medicamentos, lo que refleja un cambio hacia un enfoque m\u00e1s integral en la atenci\u00f3n al paciente.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Salud P\u00fablica**: La salud p\u00fablica es esencial para el bienestar general de las personas. Existen barreras significativas que afectan el acceso a atenci\u00f3n m\u00e9dica de calidad, incluyendo:\n   - Acceso limitado a productos m\u00e9dicos de calidad.\n   - Falta de profesionales de salud capacitados.\n   - Costos de atenci\u00f3n m\u00e9dica inasequibles.\n   - Est\u00e1ndares educativos deficientes para los profesionales de la salud.\n\n2. **Medicamentos**: Los medicamentos son fundamentales en los servicios de salud y en programas de prevenci\u00f3n y tratamiento de enfermedades. Sin embargo, hay una brecha entre la eficacia demostrada en ensayos cl\u00ednicos y su efectividad en la pr\u00e1ctica cl\u00ednica. Las razones de esta brecha incluyen:\n   - Problemas en la selecci\u00f3n y dosificaci\u00f3n de medicamentos.\n   - Administraci\u00f3n inapropiada de medicamentos.\n   - Falta de adherencia de los pacientes a los tratamientos prescritos.\n   - Interacciones entre medicamentos y alimentos, as\u00ed como eventos adversos relacionados con los medicamentos.\n\n3. **Iniciativa de la FIP sobre Buenas Pr\u00e1cticas Farmac\u00e9uticas (GPP)**: En 2007, la Federaci\u00f3n Internacional Farmac\u00e9utica (FIP) inici\u00f3 una iniciativa para actualizar las gu\u00edas de GPP. Los pasos clave incluyen:\n   - Formaci\u00f3n de un grupo de trabajo de la FIP sobre GPP.\n   - Consulta de expertos en 2008 en Basilea, Suiza, con la participaci\u00f3n de representantes de la OMS y asesores de medicamentos de varios pa\u00edses.\n   - Revisi\u00f3n exhaustiva de est\u00e1ndares nacionales de GPP en al menos 37 pa\u00edses.\n   - Presentaci\u00f3n de propuestas a la OMS en reuniones de expertos en 2008 y 2009.\n\n### Entidades Clave\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que lidera la iniciativa para actualizar las gu\u00edas de GPP.\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Colabora con la FIP en la revisi\u00f3n de est\u00e1ndares y gu\u00edas de pr\u00e1cticas farmac\u00e9uticas.\n- **Participantes de la Consulta de Expertos**: Incluyen representantes de la OMS, asesores de medicamentos de varios pa\u00edses y expertos en farmacolog\u00eda.", "excerpt_keywords": "Keywords: medicines, pharmacists, health care, supply chain integrity, professional development"}}, "ea34979e-ddff-4647-bf0c-4b09bdfaf008": {"node_ids": ["7eff5369-7e46-48a3-8625-1f43a3e01375"], "metadata": {"page_label": "326", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "which in turn provide the impetus for setting national standards. The vital element is the commitment of the pharmacy profession worldwide to promoting excellence in practice for the benefit of those served. The public and other professions will judge the pharmacy profession on how its members translate that commitment into practice in all settings, especially community and hospital pharmacy settings.\n\nIt is the policy of FIP and WHO to provide guidance to national pharmacy professional organizations regarding the development of their national GPP guidelines. The conditions of practice vary widely from country to country and each national pharmacy professional organization is best able to decide what can be achieved and within what time-scale.\n\n## 2. Underlying philosophy\n\nThe mission of pharmacy practice is to contribute to health improvement and to help patients with health problems to make the best use of their medicines.\n\nThere are six components to this mission:\n\n- being readily available to patients with or without an appointment;\n- identifying and managing or triaging health-related problems;\n- health promotion;\n- assuring effectiveness of medicines;\n- preventing harm from medicines; and\n- making responsible use of limited health-care resources.\n\nIn the community setting, pharmacists should be acknowledged as health-care professionals whom patients can consult for health-related problems. Because health-care products and services are available from the pharmacist, some problems can be managed at this point of care. Problems that require additional diagnostic skill or treatments not available from a pharmacist can be referred to an appropriate health-care professional or site of care, such as a hospital. This should be done in good collaboration between the health-care providers.\n\nTo improve the use of medicines, pharmacists have responsibilities for many aspects of the process of medicines use, each of which is important to achieve good outcomes from treatment. This begins with assuring the integrity of the medicine supply chain, including detecting spurious/falsely-labelled/falsified/counterfeit medicines, ensuring proper storage of medicines and quality preparation of medicines when needed. It also includes assuring the proper prescribing of medicines so that dose regimens and dosage forms\n\n----\n\n2 Throughout this document, the term \u201cnational standards\u201d includes laws, regulations, standards, ordinances or other requirements enacted or promulgated by an official body at any level of government, as well as guidelines, recommendations or other pronouncements of professional organizations of pharmacy.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Compromiso de la profesi\u00f3n farmac\u00e9utica**: La profesi\u00f3n farmac\u00e9utica a nivel mundial se compromete a promover la excelencia en la pr\u00e1ctica para beneficiar a la comunidad. Este compromiso se traduce en la implementaci\u00f3n de est\u00e1ndares nacionales que var\u00edan seg\u00fan las condiciones de pr\u00e1ctica en cada pa\u00eds.\n\n2. **Misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica**: La misi\u00f3n principal de la pr\u00e1ctica farmac\u00e9utica es contribuir a la mejora de la salud y ayudar a los pacientes a utilizar sus medicamentos de manera efectiva. Esto implica una serie de responsabilidades que incluyen la disponibilidad para los pacientes, la gesti\u00f3n de problemas de salud, la promoci\u00f3n de la salud y la prevenci\u00f3n de da\u00f1os relacionados con los medicamentos.\n\n3. **Responsabilidades del farmac\u00e9utico**: Los farmac\u00e9uticos tienen un papel crucial en el proceso de uso de medicamentos, que abarca desde asegurar la integridad de la cadena de suministro de medicamentos hasta garantizar la prescripci\u00f3n adecuada. Esto incluye la detecci\u00f3n de medicamentos falsificados y la colaboraci\u00f3n con otros profesionales de la salud.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los seis componentes de la misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica y c\u00f3mo se relacionan con la atenci\u00f3n al paciente?**\n   - Esta pregunta busca una respuesta detallada sobre los componentes espec\u00edficos que definen la misi\u00f3n de la pr\u00e1ctica farmac\u00e9utica y su impacto en la atenci\u00f3n al paciente.\n\n2. **\u00bfC\u00f3mo se determina el desarrollo de las gu\u00edas nacionales de buenas pr\u00e1cticas farmac\u00e9uticas (GPP) en diferentes pa\u00edses?**\n   - Esta pregunta se centra en el proceso y los criterios que utilizan las organizaciones profesionales farmac\u00e9uticas nacionales para establecer sus gu\u00edas de GPP, considerando las variaciones en las condiciones de pr\u00e1ctica.\n\n3. **\u00bfQu\u00e9 medidas deben tomar los farmac\u00e9uticos para asegurar la integridad de la cadena de suministro de medicamentos y prevenir el da\u00f1o a los pacientes?**\n   - Esta pregunta busca una respuesta espec\u00edfica sobre las acciones y responsabilidades que tienen los farmac\u00e9uticos en la gesti\u00f3n de la cadena de suministro de medicamentos y la prevenci\u00f3n de problemas relacionados con su uso.", "prev_section_summary": "### Temas Clave:\n\n1. **Costo y Accesibilidad de Medicamentos**: \n   - El aumento en el costo de los medicamentos est\u00e1 afectando la accesibilidad a la atenci\u00f3n m\u00e9dica. Los problemas relacionados con el uso de medicamentos pueden tener costos iguales o superiores a los de los propios medicamentos.\n\n2. **Problemas con Medicamentos**: \n   - La existencia de medicamentos subest\u00e1ndar, adulterados y falsificados representa un riesgo creciente para la salud p\u00fablica. Se requiere un sistema que garantice la integridad de la cadena de suministro de medicamentos.\n\n3. **Rol de los Farmac\u00e9uticos**: \n   - Los farmac\u00e9uticos son profesionales de la salud capacitados que no solo distribuyen medicamentos, sino que tambi\u00e9n asumen una mayor responsabilidad en los resultados del uso de medicamentos. Su papel es crucial para mejorar el acceso a la atenci\u00f3n m\u00e9dica y maximizar el beneficio de los tratamientos.\n\n4. **Desarrollo Profesional Continuo**: \n   - Es esencial que las asociaciones profesionales de farmac\u00e9uticos colaboren con organismos gubernamentales y otras asociaciones de salud para apoyar el desarrollo profesional continuo y establecer est\u00e1ndares nacionales de servicios farmac\u00e9uticos.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Referenciada en el documento como la fuente del informe.\n- **Farmac\u00e9uticos**: Profesionales de la salud responsables de la gesti\u00f3n y distribuci\u00f3n de medicamentos.\n- **Asociaciones Profesionales de Farmac\u00e9uticos**: Organizaciones que deben trabajar en conjunto para el desarrollo profesional y la mejora de los servicios farmac\u00e9uticos.\n- **FIP (Federaci\u00f3n Internacional Farmac\u00e9utica)**: Organizaci\u00f3n que proporciona liderazgo a las asociaciones nacionales de farmac\u00e9uticos.\n\nEste resumen destaca la importancia de gestionar los costos de los medicamentos, la necesidad de asegurar la calidad de los mismos y el papel fundamental de los farmac\u00e9uticos en el sistema de salud.", "excerpt_keywords": "Keywords: pharmacy practice, health improvement, national standards, medication management, professional guidelines"}}, "4ccb1c6d-a09f-4ea9-a187-4ef31116cc22": {"node_ids": ["c1903f8b-156d-4812-8c41-dc28cbc6de33"], "metadata": {"page_label": "327", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Definition of Good Pharmacy Practice\n\nGPP is the practice of pharmacy that responds to the needs of the people who use the pharmacists\u2019 services to provide optimal, evidence-based care. To support this practice it is essential that there be an established national framework of quality standards and guidelines.\n\n# Requirements of Good Pharmacy Practice\n\n- GPP requires that a pharmacist's first concern in all settings is the welfare of patients.\n- GPP requires that the core of the pharmacy activity is to help patients make the best use of medicines. Fundamental functions include the supply of medication and other health-care products of assured quality, the provision of appropriate information and advice to the patient, administration of medication, when required, and the monitoring of the effects of medication use.\n- GPP requires that an integral part of the pharmacist's contribution is the promotion of rational and economic prescribing, as well as dispensing.\n- GPP requires that the objective of each element of pharmacy service is relevant to the patient, is clearly defined and is effectively communicated to all those involved. Multidisciplinary collaboration among health-care professionals is the key factor for successfully improving patient safety.\n\nIn satisfying these requirements, the following conditions are necessary:\n\n- The well-being of patients should be the main philosophy underlying practice, even though it is accepted that ethical and economic factors are also important.\n- Pharmacists should have input into decisions about the use of medicines. A system should exist that enables pharmacists to report and to obtain feedback about adverse events, medicine-related problems, medication errors, misuse or medicine abuse, defects in product quality or detection.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS define la \"Buena Pr\u00e1ctica Farmac\u00e9utica\" (GPP) como la pr\u00e1ctica que responde a las necesidades de los pacientes, asegurando una atenci\u00f3n \u00f3ptima y basada en evidencia. Se establecen requisitos fundamentales para la GPP, que incluyen la prioridad en el bienestar del paciente, la promoci\u00f3n del uso racional de medicamentos, y la colaboraci\u00f3n multidisciplinaria entre profesionales de la salud. Adem\u00e1s, se enfatiza la importancia de que los farmac\u00e9uticos participen en decisiones sobre el uso de medicamentos y tengan un sistema para reportar problemas relacionados con medicamentos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las funciones fundamentales que debe cumplir un farmac\u00e9utico seg\u00fan la GPP?**\n   - Respuesta: Las funciones fundamentales incluyen el suministro de medicamentos y otros productos de salud de calidad asegurada, la provisi\u00f3n de informaci\u00f3n y asesoramiento apropiado al paciente, la administraci\u00f3n de medicamentos cuando sea necesario, y el monitoreo de los efectos del uso de medicamentos.\n\n2. **\u00bfQu\u00e9 papel juega la colaboraci\u00f3n multidisciplinaria en la GPP y por qu\u00e9 es importante?**\n   - Respuesta: La colaboraci\u00f3n multidisciplinaria entre profesionales de la salud es clave para mejorar la seguridad del paciente, ya que permite una comunicaci\u00f3n efectiva y un enfoque integral en la atenci\u00f3n al paciente.\n\n3. **\u00bfQu\u00e9 condiciones son necesarias para satisfacer los requisitos de la GPP?**\n   - Respuesta: Es necesario que el bienestar de los pacientes sea la filosof\u00eda principal de la pr\u00e1ctica, y que los farmac\u00e9uticos tengan la capacidad de participar en decisiones sobre el uso de medicamentos, as\u00ed como un sistema para reportar y recibir retroalimentaci\u00f3n sobre eventos adversos y problemas relacionados con medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Compromiso de la Profesi\u00f3n Farmac\u00e9utica**:\n   - La profesi\u00f3n farmac\u00e9utica a nivel mundial se compromete a promover la excelencia en la pr\u00e1ctica para el beneficio de la comunidad.\n   - Este compromiso se traduce en la creaci\u00f3n de est\u00e1ndares nacionales que var\u00edan seg\u00fan las condiciones de pr\u00e1ctica en cada pa\u00eds.\n\n2. **Misi\u00f3n de la Pr\u00e1ctica Farmac\u00e9utica**:\n   - Contribuir a la mejora de la salud y ayudar a los pacientes a utilizar sus medicamentos de manera efectiva.\n   - Se identifican seis componentes clave de esta misi\u00f3n:\n     - Disponibilidad para los pacientes.\n     - Identificaci\u00f3n y gesti\u00f3n de problemas de salud.\n     - Promoci\u00f3n de la salud.\n     - Aseguramiento de la efectividad de los medicamentos.\n     - Prevenci\u00f3n de da\u00f1os relacionados con los medicamentos.\n     - Uso responsable de los recursos de atenci\u00f3n m\u00e9dica limitados.\n\n3. **Rol del Farmac\u00e9utico en la Atenci\u00f3n al Paciente**:\n   - Los farmac\u00e9uticos son reconocidos como profesionales de la salud a los que los pacientes pueden consultar para problemas de salud.\n   - Pueden gestionar ciertos problemas en el punto de atenci\u00f3n y referir a otros profesionales de salud cuando sea necesario.\n\n4. **Responsabilidades en el Uso de Medicamentos**:\n   - Asegurar la integridad de la cadena de suministro de medicamentos, incluyendo la detecci\u00f3n de medicamentos falsificados.\n   - Garantizar el almacenamiento adecuado y la preparaci\u00f3n de medicamentos.\n   - Asegurar la prescripci\u00f3n correcta de medicamentos.\n\n5. **Pol\u00edtica de FIP y OMS**:\n   - FIP (Federaci\u00f3n Internacional Farmac\u00e9utica) y OMS (Organizaci\u00f3n Mundial de la Salud) proporcionan orientaci\u00f3n a las organizaciones profesionales farmac\u00e9uticas nacionales para el desarrollo de gu\u00edas nacionales de buenas pr\u00e1cticas farmac\u00e9uticas (GPP).\n\n### Entidades Clave\n- **FIP**: Federaci\u00f3n Internacional Farmac\u00e9utica.\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **Profesionales de la Salud**: Incluyendo farmac\u00e9uticos y otros proveedores de atenci\u00f3n m\u00e9dica. \n\nEste resumen destaca la importancia del compromiso de la profesi\u00f3n farmac\u00e9utica en la mejora de la salud p\u00fablica y el papel esencial de los farmac\u00e9uticos en la atenci\u00f3n al paciente y la gesti\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: Good Pharmacy Practice, patient welfare, multidisciplinary collaboration, medication management, evidence-based care"}}, "c5e75454-5341-48d9-bd7f-78661e3ef08e": {"node_ids": ["79ae37b1-921b-456a-ae45-2bb13d5e7cc4"], "metadata": {"page_label": "328", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "of counterfeit products. This reporting may include information about medicine use supplied by patients or health professionals, either directly or through pharmacists;\n\n- the relationship with other health professionals, particularly physicians, should be established as a therapeutic collaborative partnership that involves mutual trust and confidence in all matters relating to pharmacotherapy;\n\n- the relationship between pharmacists should be one of colleagues seeking to improve pharmacy service, rather than acting as competitors;\n\n- in reality, organizations, group practices and pharmacy managers should accept a share of responsibility for the definition, evaluation and improvement of quality;\n\n- the pharmacist should be aware of essential medical and pharmaceutical information (i.e. diagnosis, laboratory test results and medical history) about each patient. Obtaining such information is made easier if the patient chooses to use only one pharmacy or if the patient's medication profile is available;\n\n- the pharmacist needs evidence-based, unbiased, comprehensive, objective and current information about therapeutics, medicines and other health-care products in use, including potential environmental hazard caused by disposal of medicines\u2019 waste;\n\n- pharmacists in each practice setting should accept personal responsibility for maintaining and assessing their own competence throughout their professional working lives. While self-monitoring is important, an element of assessment and monitoring by the national pharmacy professional organizations would also be relevant in ensuring that pharmacists maintain standards and comply with requirements for continuous professional development;\n\n- educational programmes for entry into the profession should appropriately address both current and foreseeable changes in pharmacy practice; and\n\n- national standards of GPP should be specified and should be adhered to by practitioners.\n\nAt the national or appropriate (e.g. state or provincial) level, it is necessary to establish:\n\n- **A legal framework that:**\n  - defines who can practice pharmacy;\n  - defines the scope of pharmacy practice;\n  - ensures the integrity of the supply chain and the quality of medicines.\n\n- **A workforce framework that:**\n  - ensures the competence of pharmacy staff through continuing professional development (CPD or continuing education (CE)) programmes;\n  - defines the personnel resources needed to provide GPP.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior que puede ayudar a formularlas:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importancia de establecer relaciones colaborativas entre farmac\u00e9uticos y otros profesionales de la salud, as\u00ed como la necesidad de que los farmac\u00e9uticos mantengan un alto nivel de competencia y se adhieran a est\u00e1ndares nacionales de buenas pr\u00e1cticas de farmacia (GPP). Tambi\u00e9n se enfatiza la creaci\u00f3n de un marco legal y de fuerza laboral que garantice la calidad y la integridad en la pr\u00e1ctica farmac\u00e9utica.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son las responsabilidades compartidas que deben asumir las organizaciones y los gerentes de farmacia en relaci\u00f3n con la calidad de los servicios farmac\u00e9uticos?**\n   - Esta pregunta se centra en la parte del texto que menciona la responsabilidad de las organizaciones y gerentes en la definici\u00f3n, evaluaci\u00f3n y mejora de la calidad en la pr\u00e1ctica farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe tener un farmac\u00e9utico sobre cada paciente para proporcionar un servicio adecuado y seguro?**\n   - Esta pregunta se refiere a la necesidad de que los farmac\u00e9uticos est\u00e9n informados sobre el diagn\u00f3stico, resultados de laboratorio y la historia m\u00e9dica de los pacientes, lo que es crucial para la atenci\u00f3n farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 elementos deben incluirse en un marco legal para la pr\u00e1ctica de la farmacia seg\u00fan el informe?**\n   - Esta pregunta aborda los componentes espec\u00edficos que el documento sugiere que deben definirse en un marco legal, como qui\u00e9n puede practicar farmacia y el alcance de la pr\u00e1ctica farmac\u00e9utica. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Tema Principal: Buena Pr\u00e1ctica Farmac\u00e9utica (GPP)**  \nLa GPP se define como la pr\u00e1ctica farmac\u00e9utica que responde a las necesidades de los pacientes, asegurando una atenci\u00f3n \u00f3ptima y basada en evidencia. Es fundamental contar con un marco nacional de est\u00e1ndares de calidad y directrices para respaldar esta pr\u00e1ctica.\n\n**Requisitos de la GPP:**\n1. **Bienestar del Paciente:** La prioridad del farmac\u00e9utico debe ser siempre el bienestar de los pacientes.\n2. **Funciones Fundamentales del Farmac\u00e9utico:**\n   - Suministro de medicamentos y productos de salud de calidad asegurada.\n   - Provisi\u00f3n de informaci\u00f3n y asesoramiento adecuado al paciente.\n   - Administraci\u00f3n de medicamentos cuando sea necesario.\n   - Monitoreo de los efectos del uso de medicamentos.\n3. **Promoci\u00f3n de Prescripci\u00f3n Racional:** Fomentar la prescripci\u00f3n y dispensaci\u00f3n racional y econ\u00f3mica de medicamentos.\n4. **Colaboraci\u00f3n Multidisciplinaria:** La comunicaci\u00f3n efectiva y la colaboraci\u00f3n entre profesionales de la salud son esenciales para mejorar la seguridad del paciente.\n\n**Condiciones Necesarias para la GPP:**\n- El bienestar del paciente debe ser la filosof\u00eda central de la pr\u00e1ctica, considerando tambi\u00e9n factores \u00e9ticos y econ\u00f3micos.\n- Los farmac\u00e9uticos deben participar en decisiones sobre el uso de medicamentos y contar con un sistema para reportar y recibir retroalimentaci\u00f3n sobre eventos adversos y problemas relacionados con medicamentos.\n\n**Entidades Clave:**\n- **Farmac\u00e9uticos:** Profesionales responsables de la atenci\u00f3n y el uso adecuado de medicamentos.\n- **Pacientes:** Usuarios de los servicios farmac\u00e9uticos que requieren atenci\u00f3n y asesoramiento.\n- **Profesionales de la Salud:** Colaboradores en el proceso de atenci\u00f3n al paciente que trabajan en conjunto con farmac\u00e9uticos.\n\nEste resumen destaca la importancia de la GPP en la atenci\u00f3n farmac\u00e9utica y la necesidad de un enfoque colaborativo y centrado en el paciente.", "excerpt_keywords": "Keywords: pharmacy practice, good pharmacy practice, collaborative healthcare, professional development, legal framework"}}, "ef8b9609-f356-4b98-a91f-201b2a1025c0": {"node_ids": ["5c729dc2-f44e-40c0-b443-83348b6c93b6"], "metadata": {"page_label": "329", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- An economic framework that:\n  - provides sufficient resources and incentives that are effectively used to ensure the activities undertaken in GPP.\n\n## 5. Setting standards for good pharmacy practice\n\nGPP includes standards that often exceed those laid down by national legislation. Furthermore, legislation seldom gives precise instructions about how the services should be produced to meet the requirements. Therefore, national pharmacy professional associations have a role in setting standards required for GPP, which includes a quality management framework and a strategic plan for developing services. It is also recognized that in developing national standards for GPP, attention must be paid to both the needs of the users of health-care services and the capacity of national health-care systems to support these services.\n\nJust as pharmacy practice will vary among nations, it will also vary among practice locations. Therefore, standards should recognize the uniqueness of different pharmacy practice settings (e.g. community and hospital pharmacy). In addition, as medicines and needs change, the standards should acknowledge evolving practice settings and provide these developing services with guidance without negatively affecting the evolutionary nature of practice. At the same time, a baseline should be established for practice below which the activity cannot be considered \u201cpharmacy practice\u201d at all and, therefore, should not be condoned.\n\nWhen establishing minimum standards on GPP, FIP emphasizes the importance of first defining the roles played by pharmacists, as expected by patients and society. Secondly, relevant functions for which pharmacists have direct responsibility and accountability need to be determined within each role. Thirdly, minimum national standards should then be established, based upon the need to demonstrate competency in a set of activities supporting each function and role.\n\nThe minimum national standards for each activity are based on processes that need to be relevant and defined appropriately according to the local needs of the pharmacy practice environment and national profession aspirations. All national pharmacy professional associations should also adapt these roles and functions in accordance to their own requirements. The activities listed below can be further defined and measured by setting indicators of good practice within a national context and can be weighted by actual practice-setting priorities.\n\nIt is recommended that national pharmacy professional associations consider the following roles, functions and activities for pharmacists, where appropriate:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece un marco econ\u00f3mico para la pr\u00e1ctica farmac\u00e9utica, enfatizando la importancia de establecer est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica (GPP). Estos est\u00e1ndares deben ir m\u00e1s all\u00e1 de la legislaci\u00f3n nacional y adaptarse a las necesidades de los usuarios de servicios de salud y a la capacidad de los sistemas de salud nacionales. Se reconoce que la pr\u00e1ctica farmac\u00e9utica var\u00eda entre pa\u00edses y entornos, por lo que es crucial definir roles y funciones claras para los farmac\u00e9uticos, as\u00ed como establecer est\u00e1ndares m\u00ednimos que demuestren competencia en actividades espec\u00edficas.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son los elementos clave que deben considerarse al establecer est\u00e1ndares m\u00ednimos para la buena pr\u00e1ctica farmac\u00e9utica (GPP) en un pa\u00eds?**\n   - Respuesta: Los elementos clave incluyen la definici\u00f3n de los roles de los farmac\u00e9uticos, la determinaci\u00f3n de funciones relevantes con responsabilidad y rendici\u00f3n de cuentas, y el establecimiento de est\u00e1ndares nacionales m\u00ednimos basados en la competencia en actividades espec\u00edficas.\n\n2. **\u00bfC\u00f3mo deben adaptarse los est\u00e1ndares de GPP a las diferentes configuraciones de pr\u00e1ctica farmac\u00e9utica, como la farmacia comunitaria y la hospitalaria?**\n   - Respuesta: Los est\u00e1ndares deben reconocer la singularidad de cada entorno de pr\u00e1ctica, proporcionando orientaci\u00f3n que se ajuste a las necesidades cambiantes de los medicamentos y de los servicios, sin comprometer la naturaleza evolutiva de la pr\u00e1ctica farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las asociaciones profesionales farmac\u00e9uticas nacionales en el desarrollo de est\u00e1ndares para la buena pr\u00e1ctica farmac\u00e9utica?**\n   - Respuesta: Las asociaciones profesionales tienen la responsabilidad de establecer los est\u00e1ndares necesarios para GPP, que incluyen un marco de gesti\u00f3n de calidad y un plan estrat\u00e9gico para el desarrollo de servicios, adaptando roles y funciones seg\u00fan las necesidades locales y aspiraciones profesionales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda varios temas fundamentales relacionados con la pr\u00e1ctica farmac\u00e9utica y la colaboraci\u00f3n entre profesionales de la salud. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Colaboraci\u00f3n Profesional**: Se enfatiza la importancia de establecer relaciones de confianza y colaboraci\u00f3n entre farmac\u00e9uticos y otros profesionales de la salud, especialmente m\u00e9dicos, para mejorar la atenci\u00f3n farmac\u00e9utica.\n   \n2. **Responsabilidad Compartida**: Las organizaciones y gerentes de farmacia deben asumir la responsabilidad en la definici\u00f3n, evaluaci\u00f3n y mejora de la calidad de los servicios farmac\u00e9uticos.\n\n3. **Informaci\u00f3n del Paciente**: Los farmac\u00e9uticos deben estar informados sobre el diagn\u00f3stico, resultados de laboratorio y la historia m\u00e9dica de los pacientes para proporcionar un servicio seguro y adecuado.\n\n4. **Competencia Profesional**: Se requiere que los farmac\u00e9uticos mantengan y eval\u00faen su competencia a lo largo de su vida profesional, con un enfoque en el desarrollo profesional continuo.\n\n5. **Educaci\u00f3n y Formaci\u00f3n**: Los programas educativos para la entrada en la profesi\u00f3n deben abordar los cambios actuales y futuros en la pr\u00e1ctica farmac\u00e9utica.\n\n6. **Normas de Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se deben especificar y adherir a est\u00e1ndares nacionales de GPP para asegurar la calidad en la pr\u00e1ctica farmac\u00e9utica.\n\n7. **Marco Legal y de Fuerza Laboral**: Es necesario establecer un marco legal que defina qui\u00e9n puede practicar farmacia, el alcance de la pr\u00e1ctica y garantice la integridad de la cadena de suministro y la calidad de los medicamentos. Tambi\u00e9n se debe definir un marco de fuerza laboral que asegure la competencia del personal farmac\u00e9utico.\n\n#### Entidades Mencionadas:\n- **Organizaciones de Farmacia**: Se refiere a las entidades que regulan y supervisan la pr\u00e1ctica farmac\u00e9utica a nivel nacional.\n- **Profesionales de la Salud**: Incluye farmac\u00e9uticos, m\u00e9dicos y otros profesionales que colaboran en la atenci\u00f3n al paciente.\n- **Pacientes**: Los individuos que reciben atenci\u00f3n farmac\u00e9utica y cuyos datos m\u00e9dicos son relevantes para el farmac\u00e9utico.\n- **Medicamentos**: Productos farmac\u00e9uticos cuya calidad y uso deben ser monitoreados y regulados.\n\nEste resumen destaca la importancia de la colaboraci\u00f3n, la responsabilidad compartida y la necesidad de un marco legal y educativo s\u00f3lido para garantizar la calidad en la pr\u00e1ctica farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmacy practice, good pharmacy practice, standards, national associations, competency"}}, "aa26da2e-2915-420e-9f94-8b22bfc5767a": {"node_ids": ["f52e2a4c-c188-4ac8-b34b-796a2d2304ff"], "metadata": {"page_label": "330", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Role 1: Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products\n\n- **Function A: Prepare extemporaneous medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that medicine preparation areas are appropriately designed to permit ease of extemporaneous preparations and are maintained in a manner that minimizes the potential for medication errors and assures the cleanliness and safety of medical products.\n  - Pharmacists should ensure that compounded medicines are consistently prepared to comply with written formulas and quality standards for raw materials, equipment and preparation processes, including sterility where appropriate.\n\n- **Function B: Obtain, store and secure medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists who are responsible for procurement should ensure that the procurement process is transparent, professional and ethical so as to promote equity and access and to ensure accountability to relevant governing and legal entities.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by strong quality assurance principles to assure that substandard, adulterated, unlicensed and spurious/falsely-labelled/falsified/counterfeit medicines are not procured or allowed into the system.\n  - Pharmacists who are responsible for procurement should ensure that procurement is supported by a reliable information system which provides accurate, timely and accessible information.\n  - Pharmacists should establish contingency plans for shortages of medicines and for purchases in emergencies.\n  - Pharmacists should assure that proper storage conditions are provided for all medicines, especially for controlled substances, used in the pharmacy or health-care facility.\n\n- **Function C: Distribute medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  - Pharmacists should ensure that all medical products, including medicine samples, are handled and distributed in a manner that assures reliability and safety of the medicine supply.\n  - Pharmacists should establish an effective distribution system which includes a written procedure, to recall promptly and effectively.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre el papel de los farmac\u00e9uticos en la preparaci\u00f3n, obtenci\u00f3n, almacenamiento, seguridad, distribuci\u00f3n, administraci\u00f3n, dispensaci\u00f3n y eliminaci\u00f3n de productos m\u00e9dicos. Se enfatiza la necesidad de establecer est\u00e1ndares nacionales m\u00ednimos para estas actividades, asegurando la calidad, seguridad y accesibilidad de los medicamentos. Las funciones se dividen en tres \u00e1reas principales: preparaci\u00f3n de medicamentos, obtenci\u00f3n y almacenamiento, y distribuci\u00f3n de productos m\u00e9dicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas que deben tener las \u00e1reas de preparaci\u00f3n de medicamentos para minimizar errores y asegurar la limpieza?**\n   - El contexto menciona que las \u00e1reas de preparaci\u00f3n deben estar dise\u00f1adas adecuadamente para facilitar las preparaciones extempor\u00e1neas y mantenerse de manera que minimicen el potencial de errores de medicaci\u00f3n, asegurando la limpieza y seguridad de los productos m\u00e9dicos.\n\n2. **\u00bfQu\u00e9 principios deben seguir los farmac\u00e9uticos en el proceso de adquisici\u00f3n de medicamentos para garantizar la calidad y la \u00e9tica?**\n   - Los farmac\u00e9uticos responsables de la adquisici\u00f3n deben asegurar que el proceso sea transparente, profesional y \u00e9tico, promoviendo la equidad y el acceso, y garantizando la rendici\u00f3n de cuentas a las entidades gubernamentales y legales pertinentes. Adem\u00e1s, deben aplicar principios s\u00f3lidos de aseguramiento de la calidad para evitar la adquisici\u00f3n de medicamentos subest\u00e1ndar o falsificados.\n\n3. **\u00bfQu\u00e9 medidas deben implementarse para manejar la distribuci\u00f3n de productos m\u00e9dicos y asegurar su seguridad?**\n   - Los farmac\u00e9uticos deben garantizar que todos los productos m\u00e9dicos se manejen y distribuyan de manera que se asegure la fiabilidad y seguridad del suministro de medicamentos. Tambi\u00e9n deben establecer un sistema de distribuci\u00f3n efectivo que incluya procedimientos escritos para la recuperaci\u00f3n r\u00e1pida y efectiva de productos cuando sea necesario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Marco Econ\u00f3mico para la Pr\u00e1ctica Farmac\u00e9utica**: Se establece la necesidad de un marco que proporcione recursos e incentivos adecuados para asegurar que las actividades de buena pr\u00e1ctica farmac\u00e9utica (GPP) se realicen de manera efectiva.\n\n2. **Establecimiento de Est\u00e1ndares para la Buena Pr\u00e1ctica Farmac\u00e9utica (GPP)**:\n   - **Superaci\u00f3n de la Legislaci\u00f3n Nacional**: Los est\u00e1ndares de GPP deben ir m\u00e1s all\u00e1 de lo que establece la legislaci\u00f3n nacional, que a menudo no proporciona instrucciones precisas sobre la producci\u00f3n de servicios.\n   - **Rol de las Asociaciones Profesionales**: Las asociaciones profesionales farmac\u00e9uticas nacionales son responsables de establecer los est\u00e1ndares necesarios para GPP, incluyendo un marco de gesti\u00f3n de calidad y un plan estrat\u00e9gico para el desarrollo de servicios.\n\n3. **Adaptaci\u00f3n a Diferentes Entornos de Pr\u00e1ctica**: Se reconoce que la pr\u00e1ctica farmac\u00e9utica var\u00eda entre pa\u00edses y entornos (como farmacias comunitarias y hospitalarias), por lo que los est\u00e1ndares deben ser flexibles y adaptarse a estas diferencias.\n\n4. **Evoluci\u00f3n de la Pr\u00e1ctica Farmac\u00e9utica**: Los est\u00e1ndares deben reconocer y guiar el desarrollo de servicios en un contexto de cambios en medicamentos y necesidades, sin comprometer la naturaleza evolutiva de la pr\u00e1ctica.\n\n5. **Definici\u00f3n de Roles y Funciones**:\n   - **Roles de los Farmac\u00e9uticos**: Es fundamental definir los roles que desempe\u00f1an los farmac\u00e9uticos seg\u00fan las expectativas de los pacientes y la sociedad.\n   - **Responsabilidad y Rendici\u00f3n de Cuentas**: Se deben determinar las funciones relevantes para las cuales los farmac\u00e9uticos tienen responsabilidad directa.\n\n6. **Establecimiento de Est\u00e1ndares M\u00ednimos**: Los est\u00e1ndares nacionales m\u00ednimos deben basarse en la competencia en actividades espec\u00edficas, adapt\u00e1ndose a las necesidades locales y aspiraciones profesionales.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe y establece directrices sobre GPP.\n- **Federaci\u00f3n Internacional Farmac\u00e9utica (FIP)**: Organizaci\u00f3n que enfatiza la importancia de definir roles y establecer est\u00e1ndares m\u00ednimos para la pr\u00e1ctica farmac\u00e9utica.\n- **Asociaciones Profesionales Farmac\u00e9uticas Nacionales**: Entidades responsables de adaptar y establecer est\u00e1ndares de GPP en sus respectivos pa\u00edses. \n\nEste resumen destaca la importancia de un enfoque estructurado y adaptativo para la buena pr\u00e1ctica farmac\u00e9utica, asegurando que se satisfagan las necesidades de los usuarios de servicios de salud y se mantenga la calidad en la atenci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: pharmacists, medical products, procurement, distribution, quality assurance"}}, "9724ea0b-82de-4a4d-a81a-bcf136655a29": {"node_ids": ["68374f1d-8116-4e7c-bb16-2893dabb99ce"], "metadata": {"page_label": "331", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "medical products known or suspected to be defective or spurious/ falsely-labelled/falsified/counterfeit, with a designated person(s) responsible for recalls.\n\n\u2014 Pharmacists should develop with manufacturers, wholesalers and government agencies (where appropriate) an access plan for uninterrupted supply of essential medicines as part of a disaster or pandemic preparedness strategy.\n\n\u2014 As part of a disaster or pandemic preparedness strategy, national medicines regulatory agencies may introduce new medicines which are authorized for marketing with limited safety data; pharmacists have a responsibility to be aware of the safety issues and to institute necessary mechanisms for monitoring occurrence of adverse events.\n\n- **Function D: Administration of medicines, vaccines and other injectable medications**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should have a role in the preparation and administration of medicines, in establishing procedures in their work settings with respect to the administration, and in monitoring the outcomes of medication administration.\n\n  \u2014 Pharmacists should have an educator, facilitator and immunizer role, thus contributing to the prevention of diseases through participation in vaccination programmes, by ensuring vaccination coverage and by also ensuring vaccine safety.\n\n  \u2014 Pharmacists should participate in directly observed therapy (DOT) programmes in areas such as the management of drug addiction, HIV/ AIDS, tuberculosis and sexually transmitted diseases, where applicable.\n\n- **Function E: Dispensing of medical products**\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that appropriate facilities, trained personnel, standard dispensing practices and documentation procedures are in place in the pharmacy for the supply and dispensing of prescribed medicines and other health-care products.\n\n  \u2014 Pharmacists should assess and evaluate all paper or electronic prescriptions received, considering the therapeutic, social, economic and legal aspects of the prescribed indication(s) before supplying medical products to the patient. Where possible, generic substitution is recommended.\n\n  \u2014 Pharmacists should ensure patient confidentiality at the point of dispensing medical products and should provide advice to ensure that the patient receives and understands sufficient written and oral information to derive maximum benefit for the treatment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Responsabilidades de los farmac\u00e9uticos en situaciones de emergencia**: Los farmac\u00e9uticos deben colaborar con fabricantes, mayoristas y agencias gubernamentales para garantizar un suministro ininterrumpido de medicamentos esenciales durante desastres o pandemias. Tambi\u00e9n deben estar al tanto de los problemas de seguridad relacionados con nuevos medicamentos autorizados con datos de seguridad limitados.\n\n2. **Normas m\u00ednimas para la administraci\u00f3n y dispensaci\u00f3n de medicamentos**: Se deben establecer est\u00e1ndares nacionales m\u00ednimos para la administraci\u00f3n de medicamentos, vacunas y otros productos inyectables. Los farmac\u00e9uticos tienen un papel crucial en la preparaci\u00f3n, administraci\u00f3n y monitoreo de medicamentos, as\u00ed como en la dispensaci\u00f3n de productos m\u00e9dicos, asegurando la confidencialidad del paciente y la correcta informaci\u00f3n sobre el tratamiento.\n\n3. **Participaci\u00f3n en programas de salud p\u00fablica**: Los farmac\u00e9uticos deben desempe\u00f1ar roles educativos y de facilitaci\u00f3n en programas de vacunaci\u00f3n y terapia observada directamente (DOT) para el manejo de enfermedades como el VIH/SIDA y la tuberculosis, contribuyendo as\u00ed a la prevenci\u00f3n de enfermedades.\n\n### Preguntas espec\u00edficas que este contexto puede responder:\n\n1. **\u00bfQu\u00e9 papel deben desempe\u00f1ar los farmac\u00e9uticos en la preparaci\u00f3n y respuesta ante pandemias en relaci\u00f3n con el suministro de medicamentos?**\n   - Respuesta: Los farmac\u00e9uticos deben desarrollar un plan de acceso con fabricantes, mayoristas y agencias gubernamentales para garantizar un suministro ininterrumpido de medicamentos esenciales y estar al tanto de los problemas de seguridad de nuevos medicamentos autorizados con datos limitados.\n\n2. **\u00bfCu\u00e1les son las responsabilidades de los farmac\u00e9uticos en la administraci\u00f3n de medicamentos y vacunas?**\n   - Respuesta: Los farmac\u00e9uticos deben participar en la preparaci\u00f3n y administraci\u00f3n de medicamentos, establecer procedimientos en sus entornos de trabajo, monitorear los resultados de la administraci\u00f3n de medicamentos y contribuir a la prevenci\u00f3n de enfermedades a trav\u00e9s de programas de vacunaci\u00f3n.\n\n3. **\u00bfQu\u00e9 est\u00e1ndares deben cumplirse en la dispensaci\u00f3n de productos m\u00e9dicos por parte de los farmac\u00e9uticos?**\n   - Respuesta: Se deben establecer est\u00e1ndares m\u00ednimos que incluyan la disponibilidad de instalaciones adecuadas, personal capacitado, pr\u00e1cticas de dispensaci\u00f3n est\u00e1ndar y procedimientos de documentaci\u00f3n, as\u00ed como la evaluaci\u00f3n de las recetas considerando aspectos terap\u00e9uticos, sociales, econ\u00f3micos y legales. Adem\u00e1s, deben garantizar la confidencialidad del paciente y proporcionar informaci\u00f3n adecuada sobre el tratamiento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS aborda el papel fundamental de los farmac\u00e9uticos en la gesti\u00f3n de productos m\u00e9dicos, dividiendo sus responsabilidades en tres funciones principales:\n\n1. **Preparaci\u00f3n de Medicamentos**:\n   - Establecimiento de est\u00e1ndares nacionales m\u00ednimos para la preparaci\u00f3n de medicamentos extempor\u00e1neos.\n   - Dise\u00f1o adecuado de \u00e1reas de preparaci\u00f3n para minimizar errores y asegurar la limpieza.\n   - Cumplimiento de f\u00f3rmulas y est\u00e1ndares de calidad en la preparaci\u00f3n de medicamentos compuestos.\n\n2. **Obtenci\u00f3n, Almacenamiento y Seguridad**:\n   - Proceso de adquisici\u00f3n transparente, profesional y \u00e9tico para promover la equidad y el acceso a medicamentos.\n   - Aplicaci\u00f3n de principios de aseguramiento de calidad para evitar la adquisici\u00f3n de medicamentos subest\u00e1ndar o falsificados.\n   - Establecimiento de planes de contingencia para escasez de medicamentos y condiciones de almacenamiento adecuadas, especialmente para sustancias controladas.\n\n3. **Distribuci\u00f3n de Productos M\u00e9dicos**:\n   - Manejo y distribuci\u00f3n de productos m\u00e9dicos de manera que se garantice la fiabilidad y seguridad del suministro.\n   - Creaci\u00f3n de un sistema de distribuci\u00f3n efectivo con procedimientos escritos para la recuperaci\u00f3n de productos.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que establece las directrices.\n- **Farmac\u00e9uticos**: Profesionales responsables de la preparaci\u00f3n, obtenci\u00f3n, almacenamiento, distribuci\u00f3n y administraci\u00f3n de productos m\u00e9dicos.\n- **Medicamentos**: Productos m\u00e9dicos que deben ser preparados, almacenados y distribuidos de acuerdo con est\u00e1ndares de calidad y seguridad.\n- **Sistemas de Informaci\u00f3n**: Herramientas necesarias para asegurar la transparencia y la calidad en el proceso de adquisici\u00f3n de medicamentos. \n\nEste resumen destaca la importancia de establecer est\u00e1ndares y procedimientos claros para garantizar la calidad y seguridad en la gesti\u00f3n de productos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmacists, disaster preparedness, medication administration, vaccine safety, medical product dispensing"}}, "53a19ddc-c125-4f93-a410-f84c9aca8637": {"node_ids": ["804272a5-1dd2-4cc7-94f7-c7f69f05420b"], "metadata": {"page_label": "332", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- **Function F: Dispose of medicine preparations and medical products**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that regular monitoring of the medicines inventory is conducted and should always include medicines samples in the process of periodic inspection for expiration dates and removal of outdated stock.\n  \n  \u2014 Pharmacists should ensure that recalled medical products, including medicines samples, are immediately stored separately for subsequent disposal and prevented from being available for further dispensing or distribution.\n  \n  \u2014 Pharmacists should establish a safe way of medicines waste disposal at the hospital and/or community pharmacy so that patients and the public can be encouraged to return their expired or unwanted medicines and medical devices. Alternatively, pharmacists should provide appropriate information to patients on how to safely dispose of expired or unwanted medicines.\n\n# Role 2: Provide effective medication therapy management\n\n- **Function A: Assess patient health status and needs**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should ensure that health management, disease prevention and healthy lifestyle behaviour are incorporated into the patient assessment and care process.\n  \n  \u2014 Pharmacists should acknowledge unique patient considerations such as education level, cultural beliefs, literacy, native language and physical and mental capacity in all individual patient assessments.\n\n- **Function B: Manage patient medication therapy**\n\n  *Minimum national standards should be established for these activities.*\n  \n  \u2014 Pharmacists should maintain access to an appropriate evidence base relating to the safe, rational and cost-effective use of medicines such as reference books on medicines, journals, national essential medicines lists and standard treatment guidelines.\n  \n  \u2014 Pharmacists should ensure that medicine formulary system(s) (local, regional and/or national) are linked to standard treatment guidelines, protocols and treatment pathways based on the best available evidence.\n  \n  \u2014 Pharmacists should have a key role in educating prescribers on the access to and evidence for optimal and appropriate use of medicines including the required monitoring parameters and prescribing adjustments. Where appropriate, pharmacists should provide advice.\n\n----\n\n3. Medication therapy management is a distinct service or group of services that optimize therapeutic outcomes for individual patients. Medication therapy management services are independent of, but can occur in conjunction with, the provision of a medication product.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n### Preguntas y Respuestas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de los farmac\u00e9uticos en la gesti\u00f3n de productos m\u00e9dicos retirados del mercado?**\n   - Los farmac\u00e9uticos deben asegurarse de que los productos m\u00e9dicos retirados, incluidas las muestras de medicamentos, se almacenen de inmediato por separado para su posterior eliminaci\u00f3n y que no est\u00e9n disponibles para su dispensaci\u00f3n o distribuci\u00f3n. Esto implica un manejo cuidadoso y responsable de los productos que han sido objeto de un retiro.\n\n2. **\u00bfQu\u00e9 consideraciones deben tener en cuenta los farmac\u00e9uticos al evaluar la salud y las necesidades de los pacientes?**\n   - Los farmac\u00e9uticos deben incorporar la gesti\u00f3n de la salud, la prevenci\u00f3n de enfermedades y comportamientos de vida saludable en el proceso de evaluaci\u00f3n y atenci\u00f3n del paciente. Adem\u00e1s, deben reconocer consideraciones \u00fanicas del paciente, como el nivel educativo, creencias culturales, alfabetizaci\u00f3n, lengua nativa y capacidades f\u00edsicas y mentales en todas las evaluaciones individuales.\n\n3. **\u00bfQu\u00e9 tipo de recursos deben mantener los farmac\u00e9uticos para gestionar la terapia medicamentosa de los pacientes de manera efectiva?**\n   - Los farmac\u00e9uticos deben tener acceso a una base de evidencia adecuada relacionada con el uso seguro, racional y costo-efectivo de los medicamentos, que incluya libros de referencia sobre medicamentos, revistas, listas nacionales de medicamentos esenciales y gu\u00edas de tratamiento est\u00e1ndar. Esto les permite tomar decisiones informadas y basadas en la evidencia al gestionar la terapia medicamentosa.\n\n### Resumen de Nivel Superior\n\nEl contexto se centra en las funciones y responsabilidades de los farmac\u00e9uticos en la gesti\u00f3n de medicamentos y productos m\u00e9dicos, destacando la importancia de establecer est\u00e1ndares nacionales m\u00ednimos para estas actividades. Se enfatiza la necesidad de un manejo adecuado de los productos m\u00e9dicos retirados, la evaluaci\u00f3n integral de la salud del paciente y la gesti\u00f3n efectiva de la terapia medicamentosa. Los farmac\u00e9uticos juegan un papel crucial en la educaci\u00f3n de los prescriptores y en la promoci\u00f3n de pr\u00e1cticas seguras y efectivas en el uso de medicamentos.", "prev_section_summary": "### Temas Clave:\n\n1. **Responsabilidades de los farmac\u00e9uticos en emergencias**:\n   - Colaboraci\u00f3n con fabricantes, mayoristas y agencias gubernamentales para asegurar el suministro de medicamentos esenciales durante desastres o pandemias.\n   - Vigilancia de la seguridad de nuevos medicamentos autorizados con datos limitados.\n\n2. **Normas m\u00ednimas para la administraci\u00f3n de medicamentos**:\n   - Establecimiento de est\u00e1ndares nacionales para la preparaci\u00f3n, administraci\u00f3n y monitoreo de medicamentos y vacunas.\n   - Rol de los farmac\u00e9uticos como educadores y facilitadores en programas de vacunaci\u00f3n y terapia observada directamente (DOT).\n\n3. **Dispensaci\u00f3n de productos m\u00e9dicos**:\n   - Necesidad de instalaciones adecuadas, personal capacitado y pr\u00e1cticas de dispensaci\u00f3n est\u00e1ndar.\n   - Evaluaci\u00f3n de recetas considerando aspectos terap\u00e9uticos, sociales, econ\u00f3micos y legales.\n   - Garant\u00eda de la confidencialidad del paciente y provisi\u00f3n de informaci\u00f3n adecuada sobre el tratamiento.\n\n### Entidades:\n\n- **Farmac\u00e9uticos**: Profesionales responsables de la administraci\u00f3n y dispensaci\u00f3n de medicamentos, as\u00ed como de la educaci\u00f3n y prevenci\u00f3n de enfermedades.\n- **Fabricantes y mayoristas**: Entidades con las que los farmac\u00e9uticos deben colaborar para asegurar el suministro de medicamentos.\n- **Agencias gubernamentales y reguladoras**: Organismos que pueden introducir nuevos medicamentos y establecer normas para la pr\u00e1ctica farmac\u00e9utica.\n- **Medicamentos**: Productos m\u00e9dicos que deben ser administrados y dispensados de manera segura y efectiva.\n- **Programas de salud p\u00fablica**: Iniciativas en las que los farmac\u00e9uticos participan para promover la salud y prevenir enfermedades.", "excerpt_keywords": "Keywords: pharmacists, medication therapy management, medicine disposal, patient assessment, health standards"}}, "ee4a1e10-76fb-406c-a24e-3f3bdd66d064": {"node_ids": ["3bb7142d-1463-4a32-af87-88cbcf8bb6dc"], "metadata": {"page_label": "333", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Monitor patient progress and outcomes\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should consider patient diagnosis and patient-specific needs when assessing patient response to medicine therapy and intervene if necessary.\n- Pharmacists should document necessary clinical and patient data to assess and monitor medication therapy and to track patients\u2019 therapeutic outcomes.\n- Pharmacists should perform point-of-care testing for patients in order to monitor and adjust therapy, when needed.\n\n# Function D: Provide information about medicines and health-related issues\n\n**Minimum national standards should be established for these activities.**\n\n- Pharmacists should ensure that in every pharmacy there is a suitable place for discussing confidential information with the customers and patients.\n- Pharmacists should provide sufficient health, disease and medicine-specific information to patients for their participation in their decision-making process regarding a comprehensive care management plan. This information should aim at supporting adherence to treatment and empowerment of the patient.\n- Pharmacists should be proactive in reducing antimicrobial resistance by providing information about the appropriate use of antimicrobials to consumers and prescribers.\n\n# Role 3: Maintain and improve professional performance\n\n- **Function A: Plan and implement continuing professional development**[^4] strategies to improve current and future performance\n\n[^4]: The concept of continuing professional development (CPD) can be defined as \"the responsibility of individual pharmacists for systematic maintenance, development and broadening of knowledge, skills and attitudes, to ensure continuing competence as a professional, throughout their careers.\"", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece est\u00e1ndares m\u00ednimos para las funciones de los farmac\u00e9uticos en la monitorizaci\u00f3n del progreso y resultados de los pacientes, la provisi\u00f3n de informaci\u00f3n sobre medicamentos y temas de salud, y la mejora del rendimiento profesional. Se enfatiza la importancia de considerar las necesidades espec\u00edficas del paciente, documentar datos cl\u00ednicos, realizar pruebas en el punto de atenci\u00f3n, y fomentar la educaci\u00f3n sobre el uso adecuado de antimicrobianos. Adem\u00e1s, se menciona la responsabilidad de los farmac\u00e9uticos en su desarrollo profesional continuo.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las responsabilidades espec\u00edficas de los farmac\u00e9uticos al monitorizar la terapia de medicamentos en los pacientes?**\n   - Respuesta: Los farmac\u00e9uticos deben considerar el diagn\u00f3stico del paciente y sus necesidades espec\u00edficas al evaluar la respuesta a la terapia, documentar datos cl\u00ednicos y del paciente, y realizar pruebas en el punto de atenci\u00f3n para ajustar la terapia seg\u00fan sea necesario.\n\n2. **\u00bfQu\u00e9 medidas deben tomar los farmac\u00e9uticos para garantizar la confidencialidad al proporcionar informaci\u00f3n a los pacientes?**\n   - Respuesta: Los farmac\u00e9uticos deben asegurarse de que en cada farmacia haya un lugar adecuado para discutir informaci\u00f3n confidencial con los clientes y pacientes.\n\n3. **\u00bfC\u00f3mo pueden los farmac\u00e9uticos contribuir a la reducci\u00f3n de la resistencia a los antimicrobianos?**\n   - Respuesta: Los farmac\u00e9uticos deben ser proactivos en proporcionar informaci\u00f3n sobre el uso adecuado de antimicrobianos tanto a los consumidores como a los prescriptores, con el fin de reducir la resistencia a estos medicamentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Funciones de los Farmac\u00e9uticos**:\n   - **Eliminaci\u00f3n de Preparaciones Medicinales y Productos M\u00e9dicos**:\n     - Establecimiento de est\u00e1ndares nacionales m\u00ednimos para la gesti\u00f3n de medicamentos.\n     - Monitoreo regular del inventario de medicamentos, incluyendo la inspecci\u00f3n de fechas de caducidad.\n     - Almacenamiento separado de productos m\u00e9dicos retirados para su eliminaci\u00f3n segura.\n     - Promoci\u00f3n de la devoluci\u00f3n de medicamentos caducados o no deseados por parte de pacientes y el p\u00fablico.\n\n2. **Gesti\u00f3n Efectiva de la Terapia Medicamentosa**:\n   - **Evaluaci\u00f3n del Estado de Salud y Necesidades del Paciente**:\n     - Incorporaci\u00f3n de la gesti\u00f3n de salud, prevenci\u00f3n de enfermedades y promoci\u00f3n de estilos de vida saludables en la evaluaci\u00f3n del paciente.\n     - Consideraci\u00f3n de factores \u00fanicos del paciente como educaci\u00f3n, creencias culturales y capacidades f\u00edsicas y mentales.\n\n   - **Manejo de la Terapia Medicamentosa**:\n     - Acceso a una base de evidencia sobre el uso seguro y efectivo de medicamentos.\n     - Aseguramiento de que los sistemas de formularios de medicamentos est\u00e9n alineados con gu\u00edas de tratamiento basadas en evidencia.\n     - Educaci\u00f3n a los prescriptores sobre el uso \u00f3ptimo de medicamentos y ajustes necesarios en la prescripci\u00f3n.\n\n3. **Definici\u00f3n de Gesti\u00f3n de Terapia Medicamentosa**:\n   - Se describe como un servicio que optimiza los resultados terap\u00e9uticos para pacientes individuales, independiente pero complementario a la provisi\u00f3n de productos medicinales.\n\n### Entidades Clave\n- **Farmac\u00e9uticos**: Profesionales responsables de la gesti\u00f3n de medicamentos y productos m\u00e9dicos.\n- **Medicamentos**: Sustancias utilizadas para tratar enfermedades y condiciones de salud.\n- **Productos M\u00e9dicos**: Incluyen dispositivos y otros productos relacionados con la salud.\n- **Pacientes**: Personas que reciben atenci\u00f3n m\u00e9dica y cuyos medicamentos deben ser gestionados adecuadamente.\n- **Est\u00e1ndares Nacionales**: Normativas que deben establecerse para asegurar la calidad y seguridad en la gesti\u00f3n de medicamentos. \n\nEste resumen destaca la importancia de las funciones de los farmac\u00e9uticos en la gesti\u00f3n de medicamentos y la atenci\u00f3n al paciente, enfatizando la necesidad de est\u00e1ndares y pr\u00e1cticas seguras en el manejo de productos m\u00e9dicos.", "excerpt_keywords": "Keywords: pharmacists, medication therapy, patient outcomes, antimicrobial resistance, professional development"}}, "7975bd48-7abc-4e9a-801e-3624e4da99ca": {"node_ids": ["7eb0bec4-3af4-4ba1-8069-eebeccc5609e"], "metadata": {"page_label": "334", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Minimum national standards should be established for these activities.\n\n\u2014 Pharmacists should perceive continuing education as being lifelong and be able to demonstrate evidence of continuing education or continuing professional development to improve clinical knowledge, skills and performance.\n\n\u2014 Pharmacists should take steps to update their knowledge and skills about complementary and alternative therapies such as traditional Chinese medicines, health supplements, acupuncture, homeopathy and naturopathy.\n\n\u2014 Pharmacists should take steps to update their knowledge and be engaged in implementation of new technology and automation in pharmacy practice, where feasible.\n\n\u2014 Pharmacists should take steps to become informed and update their knowledge on changes to information on medical products.\n\n# Role 4: Contribute to improve effectiveness of the health-care system and public health\n\n- **Function A:** Disseminate evaluated information about medicines and various aspects of self-care\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should ensure that the information provided to patients, other health-care professionals and the public is evidence-based, objective, understandable, non-promotional, accurate and appropriate.\n\n  \u2014 Pharmacists should develop and/or use educational materials for health management, health promotion and disease prevention programmes that are applicable to a wide range of patient populations, age groups and health literacy levels.\n\n  \u2014 Pharmacists should educate patients on how to evaluate and use web-based or other forms of health-care information (including medicines information) and strongly encourage them to be advised by a pharmacist regarding the information they find, particularly if obtained from the Internet.\n\n  \u2014 Pharmacists should assist patients and their care providers to obtain and critically analyse information to meet their individual needs.\n\n- **Function B:** Engage in preventive care activities and services\n\n  *Minimum national standards should be established for these activities.*\n\n  \u2014 Pharmacists should engage in preventive care activities that promote public health and prevent disease, i.e. in areas such as smoking cessation, infectious and sexually transmitted diseases.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS establece est\u00e1ndares m\u00ednimos para la educaci\u00f3n continua de los farmac\u00e9uticos y su papel en la mejora del sistema de salud y la salud p\u00fablica. Se enfatiza la importancia de que los farmac\u00e9uticos mantengan actualizados sus conocimientos sobre terapias complementarias, nuevas tecnolog\u00edas y cambios en la informaci\u00f3n de productos m\u00e9dicos. Adem\u00e1s, se destacan dos funciones clave: la difusi\u00f3n de informaci\u00f3n evaluada sobre medicamentos y la participaci\u00f3n en actividades de atenci\u00f3n preventiva.\n\n### Preguntas Espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de educaci\u00f3n continua se espera que los farmac\u00e9uticos realicen para mejorar su desempe\u00f1o cl\u00ednico?**\n   - Los farmac\u00e9uticos deben percibir la educaci\u00f3n continua como un proceso de por vida y demostrar evidencia de su desarrollo profesional continuo para mejorar sus conocimientos, habilidades y desempe\u00f1o cl\u00ednico.\n\n2. **\u00bfCu\u00e1les son las \u00e1reas espec\u00edficas en las que los farmac\u00e9uticos deben actualizar sus conocimientos seg\u00fan el documento?**\n   - Los farmac\u00e9uticos deben actualizar sus conocimientos sobre terapias complementarias y alternativas, como la medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda y naturopat\u00eda, as\u00ed como sobre la implementaci\u00f3n de nuevas tecnolog\u00edas y automatizaci\u00f3n en la pr\u00e1ctica farmac\u00e9utica.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an los farmac\u00e9uticos en la promoci\u00f3n de la salud p\u00fablica y la prevenci\u00f3n de enfermedades?**\n   - Los farmac\u00e9uticos deben participar en actividades de atenci\u00f3n preventiva que promuevan la salud p\u00fablica y prevengan enfermedades, incluyendo \u00e1reas como la cesaci\u00f3n del tabaquismo y la prevenci\u00f3n de enfermedades infecciosas y de transmisi\u00f3n sexual.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Monitorizaci\u00f3n del Progreso y Resultados de los Pacientes:**\n   - Establecimiento de est\u00e1ndares nacionales m\u00ednimos.\n   - Evaluaci\u00f3n de la respuesta a la terapia considerando el diagn\u00f3stico y necesidades del paciente.\n   - Documentaci\u00f3n de datos cl\u00ednicos y seguimiento de resultados terap\u00e9uticos.\n   - Realizaci\u00f3n de pruebas en el punto de atenci\u00f3n para ajustar la terapia.\n\n2. **Provisi\u00f3n de Informaci\u00f3n sobre Medicamentos y Temas de Salud:**\n   - Creaci\u00f3n de espacios adecuados para discutir informaci\u00f3n confidencial en farmacias.\n   - Suministro de informaci\u00f3n espec\u00edfica sobre salud, enfermedades y medicamentos para la toma de decisiones del paciente.\n   - Promoci\u00f3n del uso adecuado de antimicrobianos para reducir la resistencia.\n\n3. **Mejora del Rendimiento Profesional:**\n   - Planificaci\u00f3n e implementaci\u00f3n de estrategias de desarrollo profesional continuo (CPD).\n   - Responsabilidad de los farmac\u00e9uticos en el mantenimiento y desarrollo de sus competencias profesionales.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que establece los est\u00e1ndares y directrices.\n- **Farmac\u00e9uticos:** Profesionales responsables de la monitorizaci\u00f3n de la terapia, provisi\u00f3n de informaci\u00f3n y desarrollo profesional.\n- **Pacientes:** Sujetos de la atenci\u00f3n farmac\u00e9utica que requieren seguimiento y educaci\u00f3n sobre su tratamiento.\n- **Antimicrobianos:** Medicamentos cuyo uso adecuado es crucial para prevenir la resistencia.\n\nEste resumen destaca la importancia de la funci\u00f3n de los farmac\u00e9uticos en la atenci\u00f3n al paciente, la confidencialidad y el desarrollo profesional continuo, as\u00ed como su papel en la lucha contra la resistencia a los antimicrobianos.", "excerpt_keywords": "Keywords: pharmacists, continuing education, public health, preventive care, complementary therapies"}}, "4896154a-41cf-46f3-ba30-c4219d760818": {"node_ids": ["b8c4581a-0858-4299-8e48-71f9c05b4f37"], "metadata": {"page_label": "335", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Function C: Comply with national professional obligations, guidelines and legislations\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should take steps to ensure that they comply with the provisions of a national code of ethics for pharmacists.\n\n# Function D: Advocate and support national policies that promote improved health outcomes\n\n*Minimum national standards should be established for these activities.*\n\n- Pharmacists should contribute to public and professional groups to promote, evaluate and improve health in the community.\n- Pharmacists should collaborate with other health-care professionals in their efforts to improve health outcomes.\n\n## Conclusions\n\nThere are four main roles where pharmacists\u2019 involvement or supervision is expected by society and the individuals they serve:\n\n1. Prepare, obtain, store, secure, distribute, administer, dispense and dispose of medical products.\n2. Provide effective medication therapy management.\n3. Maintain and improve professional performance.\n4. Contribute to improve effectiveness of the health-care system and public health.\n\nThese roles may vary for each individual pharmacist depending on their practice responsibilities.\n\nSpecific standards of GPP can be developed only within a national pharmacy professional organization framework.\n\nThis guidance is recommended as a set of professional goals to be met in the interest of the patients and other key stakeholders in the pharmaceutical sector. Responsibility for moving the project forward will rest with each national pharmacy professional association. Achieving specific standards of GPP for each nation within these recommendations may require considerable time and effort. As health professionals, pharmacists have a duty to begin the process without delay.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices sobre las funciones y responsabilidades de los farmac\u00e9uticos en el contexto de la atenci\u00f3n sanitaria. Se destacan dos funciones principales: cumplir con las obligaciones profesionales y abogar por pol\u00edticas nacionales que mejoren los resultados de salud. Se enfatiza la necesidad de establecer est\u00e1ndares nacionales m\u00ednimos y la importancia de la colaboraci\u00f3n entre farmac\u00e9uticos y otros profesionales de la salud. Adem\u00e1s, se identifican cuatro roles clave de los farmac\u00e9uticos en la sociedad, que incluyen la gesti\u00f3n de productos m\u00e9dicos, la terapia farmacol\u00f3gica, el mantenimiento del rendimiento profesional y la mejora del sistema de salud.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que deben seguir los farmac\u00e9uticos para cumplir con el c\u00f3digo de \u00e9tica nacional, y c\u00f3mo se pueden medir estos pasos?**\n   - Esta pregunta busca detalles sobre la implementaci\u00f3n pr\u00e1ctica del c\u00f3digo de \u00e9tica y los criterios de evaluaci\u00f3n que podr\u00edan no estar claramente definidos en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de colaboraci\u00f3n se espera entre los farmac\u00e9uticos y otros profesionales de la salud para mejorar los resultados de salud, y qu\u00e9 ejemplos concretos se pueden dar?**\n   - Esta pregunta se centra en ejemplos espec\u00edficos de colaboraci\u00f3n interprofesional que podr\u00edan no estar documentados en otras fuentes.\n\n3. **\u00bfQu\u00e9 desaf\u00edos espec\u00edficos enfrentan las asociaciones profesionales de farmac\u00e9uticos al intentar establecer est\u00e1ndares de Buenas Pr\u00e1cticas de Farmacia (GPP) en sus respectivos pa\u00edses?**\n   - Esta pregunta busca explorar los obst\u00e1culos \u00fanicos que pueden surgir en el proceso de establecimiento de est\u00e1ndares, que pueden no ser evidentes en otros contextos o documentos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos espec\u00edficos del rol de los farmac\u00e9uticos y los est\u00e1ndares profesionales, proporcionando informaci\u00f3n que puede no estar disponible en otros lugares.", "prev_section_summary": "### Temas Clave:\n\n1. **Educaci\u00f3n Continua de los Farmac\u00e9uticos:**\n   - Importancia de la educaci\u00f3n continua como un proceso de por vida.\n   - Necesidad de demostrar evidencia de desarrollo profesional continuo para mejorar conocimientos, habilidades y desempe\u00f1o cl\u00ednico.\n\n2. **Actualizaci\u00f3n de Conocimientos:**\n   - Necesidad de actualizar conocimientos sobre terapias complementarias y alternativas (medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda, naturopat\u00eda).\n   - Importancia de estar al tanto de nuevas tecnolog\u00edas y automatizaci\u00f3n en la pr\u00e1ctica farmac\u00e9utica.\n   - Mantenerse informado sobre cambios en la informaci\u00f3n de productos m\u00e9dicos.\n\n3. **Contribuci\u00f3n a la Salud P\u00fablica:**\n   - Rol de los farmac\u00e9uticos en la mejora de la efectividad del sistema de salud y la salud p\u00fablica.\n   - Funci\u00f3n de diseminar informaci\u00f3n evaluada sobre medicamentos y autocuidado.\n   - Participaci\u00f3n en actividades de atenci\u00f3n preventiva para promover la salud p\u00fablica y prevenir enfermedades (ej. cesaci\u00f3n del tabaquismo, prevenci\u00f3n de enfermedades infecciosas y de transmisi\u00f3n sexual).\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Emisora del documento y responsable de establecer est\u00e1ndares.\n- **Farmac\u00e9uticos:** Profesionales de la salud que deben actualizar sus conocimientos y participar en la educaci\u00f3n continua.\n- **Terapias Complementarias y Alternativas:** Incluyen medicina tradicional china, suplementos de salud, acupuntura, homeopat\u00eda y naturopat\u00eda.\n- **Tecnolog\u00eda y Automatizaci\u00f3n:** Elementos clave en la pr\u00e1ctica farmac\u00e9utica moderna.\n- **Salud P\u00fablica:** \u00c1rea en la que los farmac\u00e9uticos deben involucrarse activamente a trav\u00e9s de actividades preventivas. \n\nEste resumen destaca la importancia de la educaci\u00f3n continua y la actualizaci\u00f3n de conocimientos en el \u00e1mbito farmac\u00e9utico, as\u00ed como el papel crucial de los farmac\u00e9uticos en la promoci\u00f3n de la salud p\u00fablica.", "excerpt_keywords": "Keywords: pharmacists, national standards, health outcomes, professional ethics, medication management"}}, "d8dd7fbe-8bac-4591-9ace-be8504f6f024": {"node_ids": ["ebdbacc2-1670-4315-8666-1da19fc441ba"], "metadata": {"page_label": "336", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 9\n\n## Model guidance for the storage and transport of time- and temperature\u2013sensitive pharmaceutical products\n\n- Abbreviations\n- Background\n- Key to conventions used\n- Glossary\n- Introduction\n- Key to conventions used\n\n### 1. Importation\n\n1.1 Port handling and customs clearance  \n  1.1.1 Port of entry  \n  1.1.2 Offloading  \n  1.1.3 Temporary storage at port of entry  \n  1.1.4 Customs clearance  \n\n### 2. Warehousing sites\n\n2.1 Site layout  \n  2.1.1 Natural hazards  \n  2.1.2 Site access  \n2.2 Site security  \n2.3 Site cleanliness  \n\n### 3. Storage buildings\n\n3.1 Construction standards  \n3.2 Accommodation and layout  \n3.3 Loading and receiving bays  \n  3.3.1 Loading bays  \n  3.3.2 Receiving bays  \n3.4 Goods assembly and quarantine areas  \n  3.4.1 Goods assembly areas  \n  3.4.2 Holding area for incoming goods  \n  3.4.3 Quarantine area  \n3.5 Environmental control of ancillary areas  \n3.6 Building security  \n  3.6.1 General building security  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que el contexto proporcionado puede responder, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye una gu\u00eda modelo para el almacenamiento y transporte de productos farmac\u00e9uticos sensibles al tiempo y la temperatura. Se abordan aspectos clave como la importaci\u00f3n, el manejo en puertos, la seguridad y limpieza de los sitios de almacenamiento, as\u00ed como los est\u00e1ndares de construcci\u00f3n y control ambiental en los edificios de almacenamiento. La gu\u00eda est\u00e1 dise\u00f1ada para asegurar que estos productos se manejen adecuadamente a lo largo de toda la cadena de suministro.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la limpieza y seguridad de los sitios de almacenamiento de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta se centra en los detalles sobre las pr\u00e1cticas de limpieza y los protocolos de seguridad que deben seguirse en los sitios de almacenamiento, que son cruciales para mantener la integridad de los productos.\n\n2. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al seleccionar un puerto de entrada para la importaci\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta busca informaci\u00f3n sobre los factores que influyen en la elecci\u00f3n de un puerto, como la infraestructura, la capacidad de manejo y las regulaciones aduaneras.\n\n3. **\u00bfQu\u00e9 \u00e1reas espec\u00edficas se deben establecer en un edificio de almacenamiento para garantizar la correcta gesti\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta se enfoca en las \u00e1reas funcionales dentro de un edificio de almacenamiento, como las zonas de cuarentena, las \u00e1reas de ensamblaje de mercanc\u00edas y las \u00e1reas de recepci\u00f3n, que son esenciales para el manejo adecuado de estos productos.", "prev_section_summary": "### Temas Clave\n\n1. **Cumplimiento de Obligaciones Profesionales**: Se enfatiza la importancia de que los farmac\u00e9uticos cumplan con un c\u00f3digo de \u00e9tica nacional y se establezcan est\u00e1ndares m\u00ednimos para estas actividades.\n\n2. **Abogac\u00eda por Pol\u00edticas de Salud**: Los farmac\u00e9uticos deben contribuir a grupos p\u00fablicos y profesionales para promover y mejorar la salud en la comunidad, as\u00ed como colaborar con otros profesionales de la salud.\n\n3. **Roles de los Farmac\u00e9uticos**: Se identifican cuatro roles principales que los farmac\u00e9uticos deben desempe\u00f1ar:\n   - Gesti\u00f3n de productos m\u00e9dicos (preparaci\u00f3n, obtenci\u00f3n, almacenamiento, distribuci\u00f3n, administraci\u00f3n, dispensaci\u00f3n y eliminaci\u00f3n).\n   - Manejo efectivo de la terapia farmacol\u00f3gica.\n   - Mantenimiento y mejora del rendimiento profesional.\n   - Contribuci\u00f3n a la efectividad del sistema de salud y la salud p\u00fablica.\n\n4. **Desarrollo de Est\u00e1ndares de Buenas Pr\u00e1cticas de Farmacia (GPP)**: Se menciona que los est\u00e1ndares espec\u00edficos de GPP deben desarrollarse dentro del marco de organizaciones profesionales nacionales de farmacia, y que esto puede requerir tiempo y esfuerzo considerable.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento y directrices.\n- **Farmac\u00e9uticos**: Profesionales responsables de cumplir con las obligaciones \u00e9ticas y colaborar en la mejora de la salud p\u00fablica.\n- **Asociaciones Profesionales de Farmac\u00e9uticos**: Entidades responsables de establecer y promover est\u00e1ndares de GPP en sus respectivos pa\u00edses.\n\nEste resumen destaca la importancia del cumplimiento \u00e9tico y la colaboraci\u00f3n interprofesional en el \u00e1mbito farmac\u00e9utico, as\u00ed como la necesidad de establecer est\u00e1ndares claros para mejorar la atenci\u00f3n sanitaria.", "excerpt_keywords": "Keywords: pharmaceutical storage, temperature-sensitive products, importation guidelines, warehousing security, environmental control"}}, "a837d3a5-79e3-4cc2-9b51-17ab687b2bd1": {"node_ids": ["47c1a897-28bf-4b7c-9c95-0fae78c38f66"], "metadata": {"page_label": "337", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 3.6.2 Controlled and hazardous substances areas\n\n### 3.7 Fire protection\n- **3.7.1** Fire protection equipment\n- **3.7.2** Fire prevention, detection and control procedures\n\n### 3.8 Building hygiene\n- **3.8.1** Building cleanliness\n- **3.8.2** Pest control\n\n### 3.9 Power supply\n- **3.9.1** Uninterrupted power supply\n- **3.9.2** Power failure contingency plan\n\n### 3.10 Building maintenance\n\n## 4. Temperature-controlled storage\n\n### 4.1 Normative references\n\n### 4.2 Storage capacity of temperature-controlled stores\n\n### 4.3 Temperature-controlled storage\n\n### 4.4 Temperature-controlled storage for controlled and hazardous products\n\n### 4.5 Temperature and humidity control and monitoring in storage\n- **4.5.1** Temperature control\n- **4.5.2** Temperature monitoring\n- **4.5.3** Humidity control\n- **4.5.4** Humidity monitoring\n\n### 4.6 Alarm systems\n- **4.6.1** Temperature alarms\n- **4.6.2** Humidity alarms\n\n### 4.7 Qualification of temperature-controlled stores\n\n### 4.8 Cleanliness of temperature-controlled stores\n\n### 4.9 Refrigeration equipment maintenance\n\n### 4.10 Calibration and verification of control and monitoring devices\n- **4.10.1** Calibration of temperature control and monitoring devices\n- **4.10.2** Calibration of humidity control and monitoring devices\n- **4.10.3** Alarm equipment verification\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\n## 6. Transport and delivery\n\n### 6.1 Normative references\n\n### 6.2 Product stability profiles\n\n### 6.3 Transport route profiling and qualification\n\n### 6.4 Temperature-controlled transport\n- **6.4.1** Air and sea transport\n- **6.4.2** Temperature-controlled road vehicles operated by common carriers\n- **6.4.3** Temperature-controlled road vehicles generally\n- **6.4.4** Transport of controlled TTSPPs and TTSPPs with high illicit value", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS, \"Technical Report Series 961\", aborda diversas normativas y procedimientos relacionados con la gesti\u00f3n de sustancias controladas y peligrosas, as\u00ed como el almacenamiento y transporte de productos que requieren control de temperatura. Se detallan aspectos como la protecci\u00f3n contra incendios, la higiene de los edificios, el suministro de energ\u00eda, el mantenimiento de equipos de refrigeraci\u00f3n, y la calibraci\u00f3n de dispositivos de control y monitoreo. Tambi\u00e9n se discuten las caracter\u00edsticas del transporte de productos sensibles a la temperatura, incluyendo veh\u00edculos de transporte y rutas de entrega.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la prevenci\u00f3n, detecci\u00f3n y control de incendios en \u00e1reas que manejan sustancias controladas y peligrosas?**\n   - Esta pregunta se centra en los subtemas espec\u00edficos de protecci\u00f3n contra incendios mencionados en el documento, que son cruciales para la seguridad en el manejo de sustancias peligrosas.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar la limpieza y el control de plagas en instalaciones que almacenan productos controlados y peligrosos?**\n   - Esta pregunta aborda la importancia de la higiene en el almacenamiento de productos sensibles, un aspecto que puede no ser ampliamente discutido en otros documentos.\n\n3. **\u00bfQu\u00e9 requisitos existen para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de control y monitoreo en almacenes de temperatura controlada?**\n   - Esta pregunta se enfoca en los procedimientos t\u00e9cnicos espec\u00edficos que garantizan la eficacia de los sistemas de control de temperatura y humedad, un tema que es fundamental para la integridad de los productos almacenados. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada y espec\u00edfica que puede no estar disponible en otros contextos o documentos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl **Anexo 9** del documento \"WHO - Technical Report Series 961\" proporciona una gu\u00eda modelo para el almacenamiento y transporte de productos farmac\u00e9uticos que son sensibles al tiempo y la temperatura. A continuaci\u00f3n se presentan los temas clave y entidades abordados en esta secci\u00f3n:\n\n#### Temas Clave:\n\n1. **Importaci\u00f3n**:\n   - Manejo en puertos y procesos de despacho aduanero.\n   - Consideraciones para la selecci\u00f3n del puerto de entrada, offloading, almacenamiento temporal y procedimientos de aduanas.\n\n2. **Sitios de Almacenamiento**:\n   - Dise\u00f1o y disposici\u00f3n del sitio, incluyendo la evaluaci\u00f3n de riesgos naturales y acceso al sitio.\n   - Protocolos de seguridad y limpieza necesarios para mantener la integridad de los productos.\n\n3. **Edificios de Almacenamiento**:\n   - Est\u00e1ndares de construcci\u00f3n y dise\u00f1o de las instalaciones.\n   - \u00c1reas espec\u00edficas dentro del edificio, como:\n     - **Bays de carga y recepci\u00f3n**: Espacios dedicados para la carga y descarga de productos.\n     - **\u00c1reas de ensamblaje y cuarentena**: Zonas para la preparaci\u00f3n y aislamiento de productos entrantes.\n     - **Control ambiental**: Mantenimiento de condiciones adecuadas en \u00e1reas auxiliares.\n     - **Seguridad del edificio**: Medidas generales para proteger las instalaciones.\n\n#### Entidades:\n\n- **Productos farmac\u00e9uticos**: Enfocados en aquellos sensibles al tiempo y la temperatura.\n- **Puertos de entrada**: Infraestructura cr\u00edtica para la importaci\u00f3n.\n- **Sitios de almacenamiento**: Espacios dise\u00f1ados para la conservaci\u00f3n de productos farmac\u00e9uticos.\n- **Edificios de almacenamiento**: Estructuras que deben cumplir con est\u00e1ndares espec\u00edficos para garantizar la calidad de los productos.\n\nEste resumen destaca la importancia de seguir directrices espec\u00edficas para asegurar que los productos farmac\u00e9uticos sensibles sean manejados adecuadamente a lo largo de toda la cadena de suministro, desde la importaci\u00f3n hasta el almacenamiento.", "excerpt_keywords": "Keywords: controlled substances, fire protection, temperature-controlled storage, building hygiene, materials handling"}}, "dc722788-7530-4bcf-999e-db8ae7c6a668": {"node_ids": ["81e475a8-8919-4748-9b00-41fcebfc9d1d"], "metadata": {"page_label": "338", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.5 Temperature and humidity control and monitoring during transit\n6.5.1 Temperature control in temperature-controlled road vehicles  \n6.5.2 Temperature monitoring in temperature-controlled road vehicles  \n6.5.3 Humidity monitoring in temperature-controlled road vehicles  \n6.5.4 Temperature monitoring in passive and active shipping containers  \n\n# 6.6 Qualification of temperature-controlled road vehicles\n\n# 6.7 Calibration and verification of transport monitoring devices\n6.7.1 Calibration of transport temperature control devices  \n6.7.2 Calibration of transport temperature monitoring devices  \n6.7.3 Calibration of transport humidity monitoring devices  \n6.7.4 Verification of transport alarm equipment  \n\n# 6.8 Shipping containers\n6.8.1 Container selection generally  \n6.8.2 Uninsulated containers  \n6.8.3 Qualification of insulated passive containers  \n6.8.4 Qualification of active containers  \n\n# 6.9 Shipping container packing\n\n# 6.10 Product handling during packing and transport\n\n# 6.11 Cleaning road vehicles and transport containers\n\n# 6.12 Transport of returned and recalled TTSPPs\n6.12.1 Transport of returned TTSPPs  \n6.12.2 Transport of recalled TTSPPs  \n\n# 7. Labelling\n7.1 Normative references  \n7.2 Labelling  \n  7.2.1 Labelling generally  \n  7.2.2 Labelling air-freighted shipments  \n\n# 8. Stock management\n8.1 Stock control systems  \n  8.1.1 General stock control systems and procedures  \n  8.1.2 Stock control procedures for controlled and hazardous TTSPPs  \n\n8.2 Incoming goods  \n  8.2.1 Product arrival checks  \n  8.2.2 Actions following arrival checks  \n\n8.3 Outgoing goods (external deliveries)  \n  8.3.1 Management of outgoing goods  \n  8.3.2 Actions following dispatch  \n\n8.4 Product complaint procedures  \n\n8.5 Suspect product procedures  \n  8.5.1 Suspect products  \n\n8.6 Product return, recall, withdrawal and disposal procedures  \n  8.6.1 Return procedures  \n  8.6.2 Recall procedures  \n  8.6.3 Disposal procedures  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda las directrices y procedimientos relacionados con el control y monitoreo de temperatura y humedad durante el transporte de productos farmac\u00e9uticos y otros productos sensibles. Se detalla la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo, la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, as\u00ed como la gesti\u00f3n de existencias y procedimientos para el manejo de productos devueltos o retirados. Tambi\u00e9n se incluyen aspectos sobre el etiquetado y la limpieza de veh\u00edculos y contenedores de transporte.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los procedimientos recomendados para la calibraci\u00f3n de dispositivos de monitoreo de temperatura y humedad en veh\u00edculos de transporte?**\n   - Esta pregunta se centra en la secci\u00f3n 6.7 del documento, que detalla la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo.\n\n2. **\u00bfQu\u00e9 criterios se deben considerar al seleccionar contenedores de env\u00edo para productos que requieren control de temperatura?**\n   - Esta pregunta se relaciona con la secci\u00f3n 6.8, que aborda la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, tanto aislados como no aislados.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse tras la llegada de productos a un almac\u00e9n seg\u00fan las directrices del informe?**\n   - Esta pregunta se refiere a la secci\u00f3n 8.2, que describe los procedimientos de verificaci\u00f3n y acciones a seguir despu\u00e9s de la llegada de productos. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en el contenido detallado del documento.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"Technical Report Series 961\" de la OMS aborda varios aspectos cr\u00edticos relacionados con la gesti\u00f3n de sustancias controladas y peligrosas, as\u00ed como el almacenamiento y transporte de productos que requieren control de temperatura. A continuaci\u00f3n se presentan los temas clave y las entidades relevantes de la secci\u00f3n:\n\n#### Temas Clave:\n\n1. **\u00c1reas de Sustancias Controladas y Peligrosas**:\n   - Normativas y procedimientos para el manejo seguro de sustancias peligrosas.\n\n2. **Protecci\u00f3n Contra Incendios**:\n   - Equipos de protecci\u00f3n contra incendios.\n   - Procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios.\n\n3. **Higiene de Edificios**:\n   - Limpieza de instalaciones.\n   - Control de plagas.\n\n4. **Suministro de Energ\u00eda**:\n   - Provisi\u00f3n de energ\u00eda ininterrumpida.\n   - Planes de contingencia ante fallos de energ\u00eda.\n\n5. **Mantenimiento de Edificios**:\n   - Estrategias para el mantenimiento adecuado de las instalaciones.\n\n6. **Almacenamiento Controlado por Temperatura**:\n   - Referencias normativas y capacidad de almacenamiento.\n   - Control y monitoreo de temperatura y humedad.\n   - Sistemas de alarma para temperatura y humedad.\n   - Mantenimiento de equipos de refrigeraci\u00f3n.\n   - Calibraci\u00f3n y verificaci\u00f3n de dispositivos de control.\n\n7. **Manejo de Materiales**:\n   - Equipos utilizados para el manejo de materiales.\n\n8. **Transporte y Entrega**:\n   - Referencias normativas y perfiles de estabilidad de productos.\n   - Calificaci\u00f3n de rutas de transporte.\n   - Transporte controlado por temperatura, incluyendo veh\u00edculos y m\u00e9todos de transporte.\n\n#### Entidades Relevantes:\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las normativas.\n- **Sustancias Controladas y Peligrosas**: Productos que requieren manejo especial.\n- **Equipos de Protecci\u00f3n Contra Incendios**: Herramientas y dispositivos para la seguridad contra incendios.\n- **Dispositivos de Control y Monitoreo**: Equipos utilizados para asegurar condiciones adecuadas de almacenamiento.\n- **Veh\u00edculos de Transporte Controlado por Temperatura**: Medios de transporte dise\u00f1ados para mantener condiciones espec\u00edficas de temperatura.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos m\u00e1s importantes tratados en la secci\u00f3n, destacando la importancia de la seguridad, la higiene y el control en el manejo de sustancias sensibles y peligrosas.", "excerpt_keywords": "Keywords: temperature control, humidity monitoring, shipping containers, stock management, calibration procedures"}}, "b41dd8a2-cec6-4dee-b6bf-5e7666b7404b": {"node_ids": ["48c37ecc-1564-4833-ac64-47499fe8b50c"], "metadata": {"page_label": "339", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. General procedures and record-keeping\n\n9.1 Emergencies and contingency planning  \n9.2 General record-keeping  \n    9.2.1 Record-keeping  \n    9.2.2 Content of records  \n    9.2.3 Record review and retention  \n9.3 Temperature and humidity records  \n    9.3.1 Temperature records  \n    9.3.2 Humidity records  \n\n# 10. Environmental management\n\n10.1 Normative references  \n10.2 Environmental management of refrigeration equipment  \n\n# 11. Quality management\n\n11.1 Normative references  \n11.2 Organizational structure  \n11.3 Quality systems  \n    11.3.1 Quality system  \n    11.3.2 Self inspections  \n    11.3.3 Contractors subject to service level agreements  \n11.4 Management of documents and standard operating procedures  \n    11.4.1 Standard operating procedures  \n11.5 Document control  \n\n# 12. Personnel/training\n\n12.1 Training  \n    12.1.1 General training  \n    12.1.2 Specialist training  \n\nKey references  \n\nFurther reading  \n\nTask force membership  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" aborda procedimientos generales y mantenimiento de registros, gesti\u00f3n ambiental, gesti\u00f3n de calidad y formaci\u00f3n del personal en el contexto de la salud p\u00fablica. Se detallan aspectos como la planificaci\u00f3n de emergencias, el mantenimiento de registros de temperatura y humedad, la gesti\u00f3n de equipos de refrigeraci\u00f3n, y la estructura organizativa necesaria para asegurar la calidad. Tambi\u00e9n se menciona la importancia de la formaci\u00f3n general y especializada del personal involucrado en estos procesos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los componentes clave que deben incluirse en los registros de temperatura y humedad seg\u00fan el documento?**\n   - Esta pregunta busca detalles espec\u00edficos sobre los requisitos de registro que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 procedimientos se sugieren para la gesti\u00f3n de documentos y procedimientos operativos est\u00e1ndar en el contexto de la gesti\u00f3n de calidad?**\n   - Esta pregunta se centra en los procedimientos espec\u00edficos que se deben seguir para asegurar la calidad en la documentaci\u00f3n, lo cual es crucial para la implementaci\u00f3n efectiva de sistemas de calidad.\n\n3. **\u00bfQu\u00e9 tipo de formaci\u00f3n se recomienda para el personal involucrado en la gesti\u00f3n ambiental y de calidad, y c\u00f3mo se diferencia entre la formaci\u00f3n general y la especializada?**\n   - Esta pregunta busca informaci\u00f3n sobre los enfoques de formaci\u00f3n que se deben adoptar, lo que puede ser esencial para la capacitaci\u00f3n efectiva del personal en estos \u00e1mbitos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Control y Monitoreo de Temperatura y Humedad**:\n   - Secci\u00f3n 6.5 aborda el control y monitoreo de temperatura y humedad durante el transporte, incluyendo veh\u00edculos de carretera y contenedores de env\u00edo.\n\n2. **Calificaci\u00f3n de Veh\u00edculos de Transporte**:\n   - Secci\u00f3n 6.6 se centra en la calificaci\u00f3n de veh\u00edculos de transporte que mantienen condiciones de temperatura controlada.\n\n3. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos**:\n   - Secci\u00f3n 6.7 detalla los procedimientos para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo de temperatura y humedad, as\u00ed como equipos de alarma.\n\n4. **Contenedores de Env\u00edo**:\n   - Secci\u00f3n 6.8 trata sobre la selecci\u00f3n y calificaci\u00f3n de contenedores de env\u00edo, diferenciando entre contenedores aislados y no aislados.\n\n5. **Manejo de Productos**:\n   - Secciones 6.9 a 6.12 abordan el empaquetado de contenedores, manejo de productos durante el transporte, limpieza de veh\u00edculos y contenedores, y el transporte de productos devueltos o retirados.\n\n6. **Etiquetado**:\n   - Secci\u00f3n 7 se refiere a las referencias normativas y procedimientos de etiquetado, incluyendo env\u00edos por aire.\n\n7. **Gesti\u00f3n de Existencias**:\n   - Secci\u00f3n 8 cubre sistemas de control de existencias, procedimientos para la llegada y salida de productos, manejo de quejas y procedimientos para productos sospechosos, as\u00ed como devoluciones y retiradas.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y otros productos sensibles al transporte.\n- **Dispositivos de Monitoreo**: Equipos utilizados para controlar temperatura y humedad.\n- **Contenedores de Env\u00edo**: Estructuras utilizadas para el transporte de productos, que pueden ser activos o pasivos.\n- **Veh\u00edculos de Transporte**: Medios de transporte que requieren control de temperatura.\n- **Procedimientos de Gesti\u00f3n**: Protocolos para el manejo de productos, incluyendo devoluciones y quejas.\n\nEste resumen proporciona una visi\u00f3n general de los temas y entidades clave abordados en la secci\u00f3n del documento, destacando la importancia de la gesti\u00f3n adecuada de productos sensibles durante el transporte.", "excerpt_keywords": "Keywords: record-keeping, environmental management, quality management, training, emergencies"}}, "e7dec974-a9c1-46e0-9321-c694daf0faf3": {"node_ids": ["dadbf5a0-7a85-40bc-831f-34ebe40a71c2"], "metadata": {"page_label": "340", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Abbreviations\n\n| Abbreviation | Description |\n|--------------|-------------|\n| CAPA         | corrective and preventive action (procedures) |\n| DCVMN        | Developing Countries Vaccine Manufacturers Network |\n| EEFO         | earliest-expiry-first-out. Used in this document as equivalent to FEFO (first to expire-first-out) |\n| FIFO         | first-in-first-out |\n| GDP          | good distribution practice |\n| GMP          | good manufacturing practice |\n| GPS          | global positioning system |\n| GSP          | good storage practice |\n| HVAC         | heating ventilating and air-conditioning (system) |\n| IATA         | International Air Transport Association |\n| IFPMA        | International Federation of Pharmaceutical Manufacturers and Associations |\n| IQ           | installation qualification |\n| PCCIG        | Pharmaceutical Cold Chain Interest Group |\n| PDA          | Parenteral Drug Association |\n| SKU          | stock-keeping unit |\n| SLA          | service level agreement |\n| SMS          | short message service |\n| SOP          | standard operating procedure |\n| TTSPP        | time- and temperature-sensitive pharmaceutical product |\n| UPS          | uninterrupted power supply |\n| USP          | United States Pharmacopeia |\n\n# Background\n\nThese guidelines set out the principal requirements for the safe storage and distribution of time- and temperature-sensitive pharmaceutical products (TTSPPs). They are based upon existing regulations and best practice guidance from a wide range of international sources (see References), while accepting that local legislation and regulations will continue to take precedence. The target audience includes regulators, logisticians and pharmaceutical professionals in industry, government and the international agencies.\n\nThe document has been prepared in close consultation with the WHO Task Force on Regulatory Oversight on Pharmaceutical Cold Chain Management which has been central to the review process. A full list of members is given at the end of this annex.\n\nThe intention is that the guidance in this document should be directly applicable in less-developed countries as well as in the industrialized world. To this end, supplementary materials will be developed to show", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento \"WHO - Technical Report Series 961\" establece directrices sobre los requisitos principales para el almacenamiento y distribuci\u00f3n seguros de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs). Estas directrices se basan en regulaciones existentes y mejores pr\u00e1cticas de diversas fuentes internacionales, reconociendo que la legislaci\u00f3n local tiene prioridad. Est\u00e1 dirigido a reguladores, logistas y profesionales farmac\u00e9uticos en diferentes sectores. Se ha elaborado en consulta con el Grupo de Trabajo de la OMS sobre Supervisi\u00f3n Regulatoria en la Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica, y se busca que sea aplicable tanto en pa\u00edses en desarrollo como en el mundo industrializado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las principales diferencias en las regulaciones de almacenamiento y distribuci\u00f3n de TTSPPs entre pa\u00edses en desarrollo y pa\u00edses industrializados, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre c\u00f3mo las directrices se adaptan a diferentes contextos regulatorios y log\u00edsticos.\n\n2. **\u00bfQu\u00e9 papel desempe\u00f1a el Grupo de Inter\u00e9s de la Cadena de Fr\u00edo Farmac\u00e9utica (PCCIG) en la elaboraci\u00f3n de estas directrices y cu\u00e1les son sus principales recomendaciones?**\n   - Esta pregunta se centra en el papel de un grupo espec\u00edfico mencionado en el documento y sus contribuciones a las directrices.\n\n3. **\u00bfQu\u00e9 materiales suplementarios se planean desarrollar para facilitar la implementaci\u00f3n de estas directrices en pa\u00edses menos desarrollados?**\n   - Esta pregunta busca detalles sobre los recursos adicionales que se ofrecer\u00e1n para ayudar a la aplicaci\u00f3n de las directrices en contextos espec\u00edficos.\n\n### Resumen de Nivel Superior\n\nEl documento proporciona un marco para la gesti\u00f3n segura de productos farmac\u00e9uticos sensibles a la temperatura, destacando la importancia de seguir regulaciones y mejores pr\u00e1cticas internacionales. Se enfoca en la necesidad de que estas directrices sean aplicables en diversas realidades, desde pa\u00edses en desarrollo hasta naciones industrializadas, y enfatiza la colaboraci\u00f3n con organismos internacionales y grupos de inter\u00e9s en el sector farmac\u00e9utico.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Procedimientos Generales y Mantenimiento de Registros**:\n   - **Planificaci\u00f3n de Emergencias**: Estrategias para manejar situaciones cr\u00edticas.\n   - **Mantenimiento de Registros**: Incluye la creaci\u00f3n, contenido, revisi\u00f3n y retenci\u00f3n de registros.\n   - **Registros de Temperatura y Humedad**: Importancia de llevar un control adecuado de estos par\u00e1metros.\n\n2. **Gesti\u00f3n Ambiental**:\n   - **Referencias Normativas**: Normas y regulaciones que gu\u00edan la gesti\u00f3n ambiental.\n   - **Gesti\u00f3n de Equipos de Refrigeraci\u00f3n**: Pr\u00e1cticas para asegurar el funcionamiento adecuado y sostenible de estos equipos.\n\n3. **Gesti\u00f3n de Calidad**:\n   - **Estructura Organizativa**: Organizaci\u00f3n necesaria para implementar sistemas de calidad.\n   - **Sistemas de Calidad**: Incluye autoinspecciones y acuerdos de nivel de servicio con contratistas.\n   - **Gesti\u00f3n de Documentos y Procedimientos Operativos Est\u00e1ndar**: Importancia de tener procedimientos claros y controlados.\n\n4. **Formaci\u00f3n del Personal**:\n   - **Capacitaci\u00f3n General y Especializada**: Diferenciaci\u00f3n entre los tipos de formaci\u00f3n que se deben proporcionar al personal involucrado en la gesti\u00f3n ambiental y de calidad.\n\n### Entidades Clave:\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el informe.\n- **Registros de Temperatura y Humedad**: Elementos cr\u00edticos para la gesti\u00f3n de calidad y seguridad.\n- **Equipos de Refrigeraci\u00f3n**: Elementos que requieren gesti\u00f3n ambiental adecuada.\n- **Sistemas de Calidad**: Estructuras y procedimientos que aseguran la calidad en procesos de salud p\u00fablica.\n- **Personal**: Recurso humano que necesita formaci\u00f3n adecuada para cumplir con los est\u00e1ndares establecidos. \n\nEste resumen destaca los componentes esenciales y las entidades relevantes en el contexto de la salud p\u00fablica seg\u00fan el documento \"WHO - Technical Report Series 961\".", "excerpt_keywords": "Keywords: pharmaceutical products, cold chain management, storage guidelines, temperature-sensitive, regulatory oversight"}}, "681e3c2f-a98e-499d-b892-683be2ab6287": {"node_ids": ["7ce447c5-e03d-458c-96e5-4fce75c00442"], "metadata": {"page_label": "341", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Key to conventions used\n\nThe following conventions are used in the requirements clauses:\n\n- The imperative voice is used to denote a mandatory or highly desirable requirement. For example: \u201cEnsure that\u2026\u201d, \u201cProvide\u2026\u201d and the like.\n- The words \u201cwhere possible\u201d or \u201cpreferably\u201d are used to denote an optional but desirable requirement.\n- Many clauses are followed by a brief explanation setting out the underlying reason for including the clause.\n\n# Glossary\n\nThe definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.\n\n**active systems**  \nActively powered systems using electricity or other fuel source to maintain a temperature-controlled environment inside an insulated enclosure under thermostatic regulation (e.g. cold rooms, refrigerators, temperature-controlled trucks, refrigerated ocean and air containers).\n\n**change control**  \nThe processes and procedures to manage system changes.\n\n**common carrier**  \nA seller of distribution services.\n\n**controlled or hazardous time- and temperature-sensitive pharmaceutical products**  \nTime- and temperature-sensitive pharmaceutical products (TTSPPs) with high illicit value: poisons, narcotics, psychotropic products, inflammable or explosive substances and radioactive materials.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la OMS que establece directrices sobre el manejo de productos farmac\u00e9uticos sensibles al tiempo y la temperatura. Se utilizan convenciones espec\u00edficas para denotar requisitos obligatorios y opcionales, y se proporciona un glosario de t\u00e9rminos clave relacionados con sistemas activos, control de cambios, transportistas comunes y productos farmac\u00e9uticos peligrosos.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 tipo de sistemas se consideran \"sistemas activos\" seg\u00fan las directrices de la OMS?**\n   - Respuesta: Los \"sistemas activos\" son aquellos que utilizan electricidad u otra fuente de combustible para mantener un ambiente controlado en temperatura dentro de un recinto aislado bajo regulaci\u00f3n termost\u00e1tica, como c\u00e1maras fr\u00edas, refrigeradores y camiones de temperatura controlada.\n\n2. **\u00bfCu\u00e1l es la importancia del \"control de cambios\" en el contexto de la gesti\u00f3n de productos farmac\u00e9uticos sensibles?**\n   - Respuesta: El \"control de cambios\" se refiere a los procesos y procedimientos necesarios para gestionar cambios en los sistemas, lo cual es crucial para garantizar la integridad y seguridad de los productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n\n3. **\u00bfQu\u00e9 se entiende por \"productos farmac\u00e9uticos controlados o peligrosos\" en el contexto de este informe?**\n   - Respuesta: Los \"productos farmac\u00e9uticos controlados o peligrosos\" son aquellos productos farmac\u00e9uticos sensibles al tiempo y la temperatura que tienen un alto valor il\u00edcito, incluyendo sustancias como venenos, narc\u00f3ticos, productos psicotr\u00f3picos, sustancias inflamables o explosivas y materiales radiactivos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Directrices para TTSPPs:** El documento establece requisitos para el almacenamiento y distribuci\u00f3n seguros de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs).\n2. **Regulaciones y Mejores Pr\u00e1cticas:** Se basa en regulaciones existentes y mejores pr\u00e1cticas de diversas fuentes internacionales, reconociendo la primac\u00eda de la legislaci\u00f3n local.\n3. **Audiencia Objetivo:** Est\u00e1 dirigido a reguladores, logistas y profesionales farmac\u00e9uticos en la industria, el gobierno y agencias internacionales.\n4. **Colaboraci\u00f3n con la OMS:** Se elabor\u00f3 en consulta con el Grupo de Trabajo de la OMS sobre Supervisi\u00f3n Regulatoria en la Gesti\u00f3n de la Cadena de Fr\u00edo Farmac\u00e9utica.\n5. **Aplicabilidad Global:** Las directrices buscan ser aplicables tanto en pa\u00edses en desarrollo como en el mundo industrializado, con planes para desarrollar materiales suplementarios.\n\n**Entidades Mencionadas:**\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Organismo que proporciona las directrices.\n- **PCCIG (Pharmaceutical Cold Chain Interest Group):** Grupo que ha colaborado en la elaboraci\u00f3n de las directrices.\n- **DCVMN (Developing Countries Vaccine Manufacturers Network):** Red de fabricantes de vacunas en pa\u00edses en desarrollo.\n- **IFPMA (International Federation of Pharmaceutical Manufacturers and Associations):** Federaci\u00f3n internacional de fabricantes de productos farmac\u00e9uticos.\n- **PDA (Parenteral Drug Association):** Asociaci\u00f3n que se enfoca en productos farmac\u00e9uticos parenterales.\n\nEste resumen destaca la importancia de las directrices para la gesti\u00f3n de productos farmac\u00e9uticos sensibles y la colaboraci\u00f3n internacional necesaria para su implementaci\u00f3n efectiva.", "excerpt_keywords": "Keywords: pharmaceutical guidelines, temperature-sensitive products, active systems, change control, hazardous materials"}}, "f7a0ac2e-2396-47b1-a62e-a4aca54ce7aa": {"node_ids": ["22ff7347-4f6d-4bb4-b176-20e7c2a8ee3a"], "metadata": {"page_label": "342", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# dunnage\n\nLoose packing material used to protect TTSPPs from damage during transport.\n\n# external distribution\n\nTransport of TTSPPs through various steps in the customer\u2019s supply chain (i.e. transport from a pharmaceutical manufacturer\u2019s distribution centre to commercial customers (including wholesalers, retailers and buying groups), to clinical facilities or direct to the patient).\n\n# installation qualification\n\nThe process of obtaining and documenting evidence that equipment has been provided and installed in accordance with its specifications and that it functions within predetermined limits when operated in accordance with the operating instructions.\n\n# internal distribution\n\nTransport of a TTSPP within a pharmaceutical manufacturer\u2019s internal supply chain (i.e. all internal transports from manufacturing facility to packaging facility to warehouse to distribution centre).\n\n# net storage capacity\n\nThe total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.\n\n# passive systems\n\nSystems which maintain a temperature-controlled environment inside an insulated enclosure, with or without thermostatic regulation, using a finite amount of pre-conditioned coolant in the form of chilled or frozen gel packs, phase change materials, dry ice or others.\n\n# pests\n\nIncludes birds, bats, rodents and insects whose uncontrolled presence affects hygiene and cleanliness.\n\n# pharmaceutical product\n\nAny product intended for human use or veterinary product intended for administration to food-producing animals, presented in its finished dosage form, that is subject to control by pharmaceutical legislation in either the exporting or the importing state and includes products for which a prescription is required, products which may be sold to patients without a prescription, biologicals and vaccines. It does not, however, include medical devices. \n\n----\n\n1 Definition from *Revision of WHO good distribution practices for pharmaceutical products*. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 5.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda las buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos, definiendo t\u00e9rminos clave relacionados con el transporte y almacenamiento de productos farmac\u00e9uticos. Se discuten conceptos como \"dunnage\" (material de embalaje suelto), \"distribuci\u00f3n externa\" e \"interna\", \"calificaci\u00f3n de instalaci\u00f3n\", \"capacidad de almacenamiento neta\", \"sistemas pasivos\", \"plagas\" y \"producto farmac\u00e9utico\". Estas definiciones son esenciales para garantizar la integridad y seguridad de los productos durante su transporte y almacenamiento.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios se deben cumplir para que un equipo sea considerado instalado correctamente seg\u00fan el proceso de calificaci\u00f3n de instalaci\u00f3n?**\n   - Esta pregunta busca detalles sobre los requisitos espec\u00edficos que deben documentarse para validar la instalaci\u00f3n de equipos en el contexto de la distribuci\u00f3n de productos farmac\u00e9uticos.\n\n2. **\u00bfCu\u00e1les son las implicaciones de la presencia de plagas en el transporte y almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en las consecuencias que pueden derivarse de la presencia de plagas y c\u00f3mo pueden afectar la higiene y la calidad de los productos farmac\u00e9uticos.\n\n3. **\u00bfC\u00f3mo se determina la capacidad de almacenamiento neta en un almac\u00e9n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca una explicaci\u00f3n sobre los factores que se consideran al calcular la capacidad de almacenamiento, incluyendo el tipo de sistema de soporte de carga y el factor de utilizaci\u00f3n.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que puede no estar disponible en otras fuentes, bas\u00e1ndose en las definiciones y conceptos presentados en el documento de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Convenciones de Requisitos**:\n   - Se utilizan diferentes voces para indicar la obligatoriedad o deseabilidad de los requisitos en las directrices.\n   - La voz imperativa se\u00f1ala requisitos obligatorios, mientras que expresiones como \"donde sea posible\" indican requisitos opcionales pero deseables.\n\n2. **Glosario de T\u00e9rminos**:\n   - **Sistemas Activos**: Sistemas que utilizan electricidad o combustibles para mantener un ambiente controlado en temperatura, como c\u00e1maras fr\u00edas y camiones refrigerados.\n   - **Control de Cambios**: Procesos y procedimientos para gestionar cambios en los sistemas, esenciales para la seguridad de los productos farmac\u00e9uticos.\n   - **Transportista Com\u00fan**: Vendedor de servicios de distribuci\u00f3n.\n   - **Productos Farmac\u00e9uticos Controlados o Peligrosos**: Productos farmac\u00e9uticos sensibles al tiempo y la temperatura con alto valor il\u00edcito, incluyendo venenos, narc\u00f3ticos y materiales radiactivos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Productos Farmac\u00e9uticos**: Incluyen productos sensibles al tiempo y la temperatura.\n- **Sistemas de Refrigeraci\u00f3n**: Ejemplos de sistemas activos mencionados en el documento.\n\nEste resumen destaca los conceptos fundamentales y las definiciones relevantes que se presentan en la secci\u00f3n del documento.", "excerpt_keywords": "Keywords: dunnage, external distribution, installation qualification, net storage capacity, pharmaceutical product"}}, "3b78f7af-17e8-4728-9416-fd528200309f": {"node_ids": ["25f2ef48-c9bb-4654-997c-9af8fad4f475"], "metadata": {"page_label": "343", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Qualification\n\nDocumented testing that demonstrates, with a high degree of assurance, that a specific process will meet its predetermined acceptance criteria.\u00b2\n\n# Refrigeration Equipment\n\nThe term \u201crefrigeration\u201d or \u201crefrigeration equipment\u201d means any equipment whose purpose is to lower air and product temperatures and/or to control relative humidity.\n\n# Service Level Agreement (SLA)\n\nA service level agreement or contract is a negotiated agreement between the customer and service provider that defines the common understanding about materials or service quality specifications, responsibilities, guarantees and communication mechanisms. It can either be legally binding, or an information agreement. The SLA may also specify the target and minimum level performance, operation or other service attributes.\u00b3\n\n# Standard Operating Procedure (SOP)\n\nA set of instructions having the force of a directive, covering those features of operations that lend themselves to a definite or standardized procedure without loss of effectiveness.\n\n# Storage Temperature\n\nThe temperature range listed on the TTSPP label, and within the regulatory documentation, for long-term storage.\n\n# Storage Unit Temperature/Humidity Distribution\n\nThe range and pattern of temperatures and/or humidity within a temperature-controlled storage unit during normal operation.\n\n# Suspect Product\n\nA TTSPP whose presentation and/or pharmacological formulation indicates that it has not been manufactured by the company named on the packaging. A TTSPP that shows visible or pharmacological evidence of tampering.\n\n# Temperature-Controlled\n\nIncludes any environment in which the temperature is actively or passively controlled at a level different from that of the surrounding environment within precise predefined limits.\n\n# Temperature Excursion\n\nAn excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and/or transport. Temperature ranges for\n\n----\n\n\u00b2 Definition from the Parenteral Drug Association (PDA) Technical Report No. 39, 2007.  \n\u00b3 Definition from International Air Transport Association (IATA), Chapter 17, 9th ed., June 2009.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en la serie de informes t\u00e9cnicos 961 aborda diversos t\u00e9rminos y definiciones relacionados con la calificaci\u00f3n de procesos, equipos de refrigeraci\u00f3n, acuerdos de nivel de servicio (SLA), procedimientos operativos est\u00e1ndar (SOP), y aspectos cr\u00edticos del almacenamiento y manejo de productos farmac\u00e9uticos. Se enfatiza la importancia de mantener condiciones controladas de temperatura y humedad para asegurar la calidad y seguridad de los productos durante su almacenamiento y transporte.\n\n### Preguntas\n1. **\u00bfQu\u00e9 se entiende por \"calificaci\u00f3n\" en el contexto de los procesos farmac\u00e9uticos y por qu\u00e9 es importante?**\n   - La calificaci\u00f3n se refiere a las pruebas documentadas que demuestran, con un alto grado de certeza, que un proceso espec\u00edfico cumplir\u00e1 con sus criterios de aceptaci\u00f3n predeterminados. Esto es crucial para garantizar que los procesos utilizados en la fabricaci\u00f3n y manejo de productos farmac\u00e9uticos sean seguros y efectivos.\n\n2. **\u00bfCu\u00e1l es la definici\u00f3n de un \"producto sospechoso\" seg\u00fan el documento y qu\u00e9 implicaciones tiene para la seguridad del paciente?**\n   - Un producto sospechoso es aquel cuyo etiquetado o formulaci\u00f3n farmacol\u00f3gica indica que no ha sido fabricado por la empresa mencionada en el empaque, o que muestra evidencia visible o farmacol\u00f3gica de manipulaci\u00f3n. Esto tiene implicaciones serias para la seguridad del paciente, ya que puede indicar un riesgo de calidad o efectividad del producto.\n\n3. **\u00bfQu\u00e9 criterios se deben considerar para definir un \"entorno controlado por temperatura\" y por qu\u00e9 es relevante en el almacenamiento de productos farmac\u00e9uticos?**\n   - Un entorno controlado por temperatura es aquel en el que la temperatura se controla activa o pasivamente a un nivel diferente del entorno circundante dentro de l\u00edmites predefinidos. Esto es relevante para el almacenamiento de productos farmac\u00e9uticos, ya que mantener condiciones adecuadas es esencial para preservar la estabilidad y eficacia de los productos a lo largo de su vida \u00fatil.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Dunnage**: Material de embalaje suelto utilizado para proteger los productos farmac\u00e9uticos durante el transporte.\n\n2. **Distribuci\u00f3n Externa**: Proceso de transporte de productos farmac\u00e9uticos a trav\u00e9s de la cadena de suministro del cliente, desde el centro de distribuci\u00f3n del fabricante hasta los clientes comerciales, instalaciones cl\u00ednicas o directamente al paciente.\n\n3. **Calificaci\u00f3n de Instalaci\u00f3n**: Proceso de obtenci\u00f3n y documentaci\u00f3n de evidencia que asegura que el equipo ha sido instalado de acuerdo con sus especificaciones y que funciona dentro de l\u00edmites predeterminados.\n\n4. **Distribuci\u00f3n Interna**: Transporte de productos farmac\u00e9uticos dentro de la cadena de suministro interna de un fabricante, abarcando todos los traslados internos desde la instalaci\u00f3n de fabricaci\u00f3n hasta el centro de distribuci\u00f3n.\n\n5. **Capacidad de Almacenamiento Neta**: Volumen total disponible para almacenar productos farmac\u00e9uticos, considerando el tipo de sistema de soporte de carga y el factor de utilizaci\u00f3n.\n\n6. **Sistemas Pasivos**: Sistemas que mantienen un ambiente controlado en temperatura dentro de un recinto aislado, utilizando refrigerantes precondicionados como geles, materiales de cambio de fase o hielo seco.\n\n7. **Plagas**: Incluye aves, murci\u00e9lagos, roedores e insectos cuya presencia incontrolada afecta la higiene y limpieza.\n\n8. **Producto Farmac\u00e9utico**: Cualquier producto destinado para uso humano o veterinario, presentado en su forma de dosificaci\u00f3n final y sujeto a control por legislaci\u00f3n farmac\u00e9utica, excluyendo dispositivos m\u00e9dicos.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad que establece las buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n- **TTSPP (Therapeutic and Technical Support Pharmaceutical Products)**: T\u00e9rmino utilizado para referirse a los productos farmac\u00e9uticos en el contexto del documento.\n- **Legislaci\u00f3n Farmac\u00e9utica**: Normativa que regula la producci\u00f3n y distribuci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen proporciona una visi\u00f3n general de los conceptos y definiciones esenciales relacionados con la distribuci\u00f3n y almacenamiento de productos farmac\u00e9uticos, tal como se detalla en el documento de la OMS.", "excerpt_keywords": "Keywords: Qualification, Refrigeration Equipment, Service Level Agreement, Standard Operating Procedure, Temperature-Controlled"}}, "fa014ee9-f1e6-4f71-a158-0a13c7e7aadb": {"node_ids": ["cab84831-2f53-4e2d-a046-e36e389b3368"], "metadata": {"page_label": "344", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Importation\n\n## Port handling and customs clearance\n\n### Port of entry\n\nImport TTSPPs through a port of entry that is equipped to handle such products. Where this is not possible, ensure that arrangements are in place to provide the necessary level of protection and security.\n\n*Reason:* To minimize the risk of damage.\n\n### Offloading\n\nAs soon as possible after arrival, remove TTSPP shipments from the wharf or airport apron to a safe and suitable temperature-controlled storage location.\n\n----\n\n**temperature-modified**\n\nIncludes any environment in which the temperature is predictably maintained at a level different from that of the surrounding environment, but is not actively or passively controlled within precise predefined limits.\n\n**time- and temperature-sensitive pharmaceutical product (TTSPP)**\n\nAny pharmaceutical good or product which, when not stored or transported within predefined environmental conditions and/or within predefined time limits, is degraded to the extent that it no longer performs as originally intended.\n\n**transport temperature profile**\n\nAnticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.\n\n**utilization factor**\n\nThe percentage of the total volume available for storing TTSPPs that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store.\n\n**validation**\n\nDocumented testing performed under highly controlled conditions, demonstrating that processes, methods, and systems consistently produce results meeting predetermined acceptance criteria. [^4]\n\n[^4]: Definition from PDA Technical Report No. 39, 2007.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda la importaci\u00f3n de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPP). Se enfatiza la importancia de manejar adecuadamente la entrada y el despacho de estos productos en puertos equipados, as\u00ed como la necesidad de trasladarlos r\u00e1pidamente a un almacenamiento controlado en temperatura para evitar su degradaci\u00f3n. Se definen t\u00e9rminos clave relacionados con el manejo y almacenamiento de TTSPP, como \"temperatura modificada\", \"perfil de temperatura de transporte\", \"factor de utilizaci\u00f3n\" y \"validaci\u00f3n\".\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse al importar TTSPPs a un puerto que no est\u00e1 equipado para manejarlos?**\n   - Respuesta: Se deben hacer arreglos para proporcionar el nivel necesario de protecci\u00f3n y seguridad para minimizar el riesgo de da\u00f1o a los productos.\n\n2. **\u00bfQu\u00e9 se debe hacer inmediatamente despu\u00e9s de la llegada de un env\u00edo de TTSPP?**\n   - Respuesta: Los env\u00edos de TTSPP deben ser retirados lo antes posible del muelle o la pista del aeropuerto y trasladados a un lugar de almacenamiento seguro y adecuado que mantenga la temperatura controlada.\n\n3. **\u00bfC\u00f3mo se define el \"factor de utilizaci\u00f3n\" en el contexto del almacenamiento de TTSPPs?**\n   - Respuesta: El \"factor de utilizaci\u00f3n\" se refiere al porcentaje del volumen total disponible para almacenar TTSPPs que se puede lograr de manera confiable en la pr\u00e1ctica, considerando los tipos de unidades de mantenimiento de existencias (SKU), los sistemas de soporte de carga y los sistemas de gesti\u00f3n de existencias utilizados en el almac\u00e9n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n**: Proceso de pruebas documentadas que aseguran que un proceso espec\u00edfico cumple con criterios de aceptaci\u00f3n predeterminados, esencial para la seguridad y efectividad en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Equipos de Refrigeraci\u00f3n**: Equipos dise\u00f1ados para reducir temperaturas y controlar la humedad relativa, fundamentales para el almacenamiento adecuado de productos sensibles.\n\n3. **Acuerdo de Nivel de Servicio (SLA)**: Contrato que define las expectativas entre el cliente y el proveedor de servicios, incluyendo especificaciones de calidad, responsabilidades y niveles de rendimiento.\n\n4. **Procedimiento Operativo Est\u00e1ndar (SOP)**: Conjunto de instrucciones que gu\u00edan operaciones de manera estandarizada, asegurando eficacia sin p\u00e9rdida de calidad.\n\n5. **Temperatura de Almacenamiento**: Rango de temperatura especificado para el almacenamiento a largo plazo de productos, cr\u00edtico para mantener su integridad.\n\n6. **Distribuci\u00f3n de Temperatura/Humedad en la Unidad de Almacenamiento**: Patr\u00f3n de temperaturas y humedad dentro de una unidad de almacenamiento controlada, importante para la estabilidad del producto.\n\n7. **Producto Sospechoso**: Producto que presenta indicios de no haber sido fabricado por la empresa indicada o que muestra evidencia de manipulaci\u00f3n, lo que plantea riesgos para la seguridad del paciente.\n\n8. **Control de Temperatura**: Entorno donde la temperatura se mantiene dentro de l\u00edmites predefinidos, esencial para la conservaci\u00f3n de productos farmac\u00e9uticos.\n\n9. **Excursi\u00f3n de Temperatura**: Evento en el que un producto se expone a temperaturas fuera de los rangos prescritos, lo que puede comprometer su calidad y eficacia.\n\n### Entidades\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Parenteral Drug Association (PDA)**: Fuente de la definici\u00f3n de calificaci\u00f3n.\n- **International Air Transport Association (IATA)**: Fuente de la definici\u00f3n de SLA. \n\nEste resumen destaca la importancia de mantener est\u00e1ndares rigurosos en la manipulaci\u00f3n y almacenamiento de productos farmac\u00e9uticos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: importation, TTSPP, temperature-controlled storage, validation, customs clearance"}}, "6fa8416a-de44-43ef-8df7-a215ce99f304": {"node_ids": ["8f4a2c9a-fc33-4b23-8292-dfa8efe897de"], "metadata": {"page_label": "345", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.1.3 Temporary storage at port of entry\n\nStore TTSPP shipments in a secure warehouse under the conditions recommended by the product manufacturer, until the shipment has been authorized for removal by customs.\u2075\n\n*Reason:* To avoid risk of theft or damage during temporary storage.\n\n# 1.1.4 Customs clearance\n\nDraw up procedures and memoranda of understanding to ensure that TTSPP shipments are cleared through customs as rapidly as possible. This can be facilitated by a pre-clearance procedure carried out by the local health agency, clearing agent or freight forwarder in collaboration with customs. Alternatively, the clearance process should be conducted by customs staff, supported by personnel with suitable pharmaceutical training, especially when clearance involves the opening and resealing of temperature-controlled packaging.\n\n*Reason:* To avoid delays during customs clearance that may cause temperature excursions and place TTSPPs at risk.\n\n# 2. Warehousing sites\n\n## 2.1 Site layout\n\n### 2.1.1 Natural hazards\n\nSelect and/or develop storage sites to minimize risks from natural hazards such as floods, landslides and earthquakes and extreme weather conditions such as hurricanes and tornadoes.\n\n*Reason:* To protect against loss of valuable pharmaceutical products, to ensure continued supply to patients in the market and to protect personnel working in the store.\n\n### 2.1.2 Site access\n\nProvide vehicular access to storage buildings sufficient to accommodate the largest vehicles visiting the site, including emergency vehicles.\n\n*Reason:* To ensure convenient operation of the facility.\n\n----\n\n\u2075 In some situations, arrangements can be made for formal customs clearance to take place away from the port of entry \u2014 for example, at a national vaccine store. In situations where the port of entry is not equipped with suitable cold storage facilities, this can reduce the risk of temperature excursions.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la gesti\u00f3n de env\u00edos de productos farmac\u00e9uticos sensibles a la temperatura (TTSPP) en t\u00e9rminos de almacenamiento temporal en puertos de entrada, procedimientos de despacho aduanero y la disposici\u00f3n de sitios de almacenamiento. Se enfatiza la importancia de seguir las recomendaciones del fabricante para el almacenamiento, la rapidez en el proceso de despacho aduanero para evitar riesgos de temperatura, y la selecci\u00f3n de sitios de almacenamiento que minimicen los riesgos de desastres naturales y que permitan un acceso adecuado para veh\u00edculos, incluyendo emergencias.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones espec\u00edficas del fabricante que deben seguirse para el almacenamiento temporal de env\u00edos TTSPP en un puerto de entrada?**\n   - Esta pregunta busca detalles sobre las condiciones espec\u00edficas que los fabricantes sugieren para el almacenamiento, que no se mencionan expl\u00edcitamente en el texto.\n\n2. **\u00bfQu\u00e9 procedimientos se sugieren para facilitar el proceso de despacho aduanero de los env\u00edos TTSPP y qui\u00e9nes deben estar involucrados en este proceso?**\n   - Esta pregunta se centra en los pasos concretos y las partes interesadas que deben participar en el proceso de despacho aduanero, m\u00e1s all\u00e1 de lo que se menciona en el contexto.\n\n3. **\u00bfQu\u00e9 medidas espec\u00edficas se pueden tomar para mitigar los riesgos de desastres naturales en los sitios de almacenamiento de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n sobre estrategias o pr\u00e1cticas espec\u00edficas que se pueden implementar para proteger los sitios de almacenamiento de desastres naturales, que no se detallan en el texto. \n\nEstas preguntas est\u00e1n dise\u00f1adas para profundizar en aspectos que pueden no estar completamente cubiertos en el documento, proporcionando as\u00ed un enfoque m\u00e1s detallado sobre la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Importaci\u00f3n de TTSPPs**: El documento se centra en la importaci\u00f3n de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPP), destacando la importancia de un manejo adecuado durante la entrada y el despacho en puertos.\n\n2. **Manejo en puertos**:\n   - **Puerto de entrada**: Se debe importar TTSPPs a trav\u00e9s de puertos equipados para su manejo. Si no es posible, se deben hacer arreglos para garantizar la protecci\u00f3n y seguridad de los productos.\n   - **Descarga**: Es crucial retirar los env\u00edos de TTSPP del muelle o pista del aeropuerto lo antes posible y trasladarlos a un almacenamiento controlado en temperatura.\n\n3. **Definiciones clave**:\n   - **Temperatura modificada**: Entorno donde la temperatura se mantiene a un nivel diferente al del ambiente circundante, sin control preciso.\n   - **TTSPP**: Productos farmac\u00e9uticos que se degradan si no se almacenan o transportan dentro de condiciones ambientales y l\u00edmites de tiempo predefinidos.\n   - **Perfil de temperatura de transporte**: Variaci\u00f3n de temperatura y duraci\u00f3n a la que un TTSPP puede estar expuesto durante el transporte.\n   - **Factor de utilizaci\u00f3n**: Porcentaje del volumen total disponible para almacenar TTSPPs que se puede lograr de manera confiable, considerando diferentes factores log\u00edsticos.\n   - **Validaci\u00f3n**: Pruebas documentadas que demuestran que los procesos y sistemas producen resultados que cumplen con criterios de aceptaci\u00f3n predefinidos.\n\n4. **Objetivo principal**: Minimizar el riesgo de da\u00f1o a los TTSPPs durante su importaci\u00f3n y asegurar su integridad a trav\u00e9s de un manejo y almacenamiento adecuados.", "excerpt_keywords": "Keywords: TTSPP, customs clearance, temporary storage, natural hazards, pharmaceutical logistics"}}, "767d9fd5-1d5e-4816-98f2-a5c9b9afe358": {"node_ids": ["3422c813-05f3-478a-8f71-f4dd4e756060"], "metadata": {"page_label": "346", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 2.2 Site security\n\nProvide perimeter protection to ensure security of the grounds and storage buildings against anticipated risks.\n\n**Reason:** To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and the value of goods stored there.\n\n## 2.3 Site cleanliness\n\nKeep the site free of accumulated dust, dirt, waste and debris. Ensure that pests are kept under control within the site area. Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\n**Reason:** To help protect storage buildings against ingress by dust, dirt and pests.\n\n# 3. Storage buildings\n\n## 3.1 Construction standards\n\nConstruct or procure storage buildings that are:\n\n- purpose-designed for the storage of TTSPPs, or well-adapted for this purpose;\n- designed to suit the prevailing climate, making maximum use of passive heating, cooling and ventilation;\n- designed and equipped to minimize the consumption of electricity and other fuel sources;\n- constructed using materials and finishes that are robust, easy to clean and which are selected to minimize long-term maintenance;\n- constructed using locally available materials and building technologies; and\n- built to minimize hiding and nesting places for pests.\n\n**Reasons:** Storage in unsuitable and poorly-designed buildings places TTSPPs at risk and increases storage costs. Buildings constructed using inappropriate materials and technologies are difficult to operate and maintain in resource-constrained settings.\n\n## 3.2 Accommodation and layout\n\nEnsure that the storage buildings are well laid out and contain all the necessary storage areas, goods assembly, receiving and dispatch bays and office accommodation needed for efficient operation of the TTSPP store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la seguridad y limpieza de los sitios de almacenamiento, as\u00ed como los est\u00e1ndares de construcci\u00f3n y dise\u00f1o de los edificios de almacenamiento para productos farmac\u00e9uticos y otros productos t\u00e9cnicos. Se enfatiza la importancia de proteger los sitios contra riesgos como el vandalismo y el robo, mantener la limpieza para evitar la acumulaci\u00f3n de desechos y plagas, y asegurar que los edificios de almacenamiento est\u00e9n dise\u00f1ados adecuadamente para su prop\u00f3sito, el clima y la eficiencia energ\u00e9tica.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener los edificios de almacenamiento para garantizar la seguridad de los TTSPPs?**\n   - Respuesta: Los edificios deben ser dise\u00f1ados espec\u00edficamente para el almacenamiento de TTSPPs, adaptarse al clima local, minimizar el consumo de energ\u00eda, utilizar materiales robustos y de f\u00e1cil mantenimiento, y construirse con tecnolog\u00edas y materiales disponibles localmente.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para mantener la limpieza del sitio de almacenamiento y por qu\u00e9 es importante?**\n   - Respuesta: Se debe mantener el sitio libre de polvo, suciedad, desechos y escombros, controlar las plagas y recoger los desechos en contenedores cerrados para su disposici\u00f3n segura. Esto es importante para proteger los edificios de almacenamiento contra la entrada de polvo, suciedad y plagas.\n\n3. **\u00bfQu\u00e9 tipo de protecci\u00f3n perimetral se recomienda para los sitios de almacenamiento y cu\u00e1l es su prop\u00f3sito?**\n   - Respuesta: Se recomienda proporcionar protecci\u00f3n perimetral para asegurar la seguridad de los terrenos y edificios de almacenamiento contra riesgos anticipados, como vandalismo y robo. Las medidas de seguridad deben ser apropiadas para la ubicaci\u00f3n del sitio y el valor de los bienes almacenados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Almacenamiento Temporal en Puertos de Entrada**\n   - **Recomendaciones del Fabricante:** Los env\u00edos de productos farmac\u00e9uticos sensibles a la temperatura (TTSPP) deben almacenarse en un almac\u00e9n seguro bajo las condiciones recomendadas por el fabricante hasta que sean autorizados para su remoci\u00f3n por la aduana.\n   - **Raz\u00f3n:** Evitar el riesgo de robo o da\u00f1o durante el almacenamiento temporal.\n\n2. **Despacho Aduanero**\n   - **Procedimientos Sugeridos:** Se deben elaborar procedimientos y memorandos de entendimiento para asegurar que los env\u00edos TTSPP sean despachados aduanalmente lo m\u00e1s r\u00e1pido posible. Esto puede incluir un procedimiento de pre-despeje realizado por agencias de salud locales o agentes de carga en colaboraci\u00f3n con la aduana.\n   - **Personal Involucrado:** El proceso de despacho debe ser realizado por personal aduanero, apoyado por personal con formaci\u00f3n farmac\u00e9utica adecuada, especialmente cuando se requiere abrir y volver a sellar empaques controlados por temperatura.\n   - **Raz\u00f3n:** Evitar retrasos que puedan causar excursiones de temperatura y poner en riesgo los TTSPP.\n\n3. **Sitios de Almacenamiento**\n   - **Dise\u00f1o del Sitio:** Seleccionar y/o desarrollar sitios de almacenamiento para minimizar riesgos de desastres naturales (inundaciones, deslizamientos de tierra, terremotos, huracanes, tornados).\n   - **Raz\u00f3n:** Proteger contra la p\u00e9rdida de productos farmac\u00e9uticos valiosos, asegurar el suministro continuo a los pacientes y proteger al personal.\n   - **Acceso al Sitio:** Proveer acceso vehicular adecuado a los edificios de almacenamiento para acomodar veh\u00edculos grandes, incluyendo veh\u00edculos de emergencia.\n   - **Raz\u00f3n:** Asegurar la operaci\u00f3n conveniente de la instalaci\u00f3n.\n\n### Entidades Clave\n- **TTSPP:** Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Agencias de Salud Locales:** Entidades que pueden facilitar el proceso de despacho aduanero.\n- **Personal Aduanero:** Personal encargado de realizar el despacho aduanero.\n- **Sitios de Almacenamiento:** Instalaciones donde se almacenan los TTSPP, que deben ser seleccionadas cuidadosamente para minimizar riesgos. \n\nEste resumen destaca la importancia de seguir procedimientos adecuados para el almacenamiento y despacho de productos farmac\u00e9uticos sensibles, as\u00ed como la necesidad de considerar factores de seguridad y accesibilidad en los sitios de almacenamiento.", "excerpt_keywords": "Keywords: site security, storage buildings, TTSPPs, cleanliness, construction standards"}}, "161142ff-566d-41c8-8691-6d537c8d48a5": {"node_ids": ["e6d91171-4386-46fa-8960-0d5a201ddfeb"], "metadata": {"page_label": "347", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.3 Loading and receiving bays\n\n## 3.3.1 Loading bays\n\nEnsure that receiving and dispatch bays are designed to avoid conflict between incoming and outgoing goods and are protected from direct sunlight, dust, dirt, rain, snow and wind, and from extremes of heat, cold and solar radiation that could damage TTSPPs, and measures are taken to minimize pest activity in these areas.\n\n*Reason:* Protection against damage and maintenance of product quality.\n\n## 3.3.2 Receiving bays\n\nProvide receiving areas with suitable equipment to clean reusable transport containers after their contents have been unloaded, and before the containers are stored for re-use.\n\n*Reason:* Protection against contamination of outgoing TTSPPs.\n\n# 3.4 Goods assembly and quarantine areas\n\n## 3.4.1 Goods assembly areas\n\nProvide sufficient space to receive, assemble and pack TTSPPs for dispatch under temperature-modified conditions. Preferably, these areas should be physically close to the temperature-controlled storage area.\n\n*Reason:* Protection of TTSPPs during arrival, order assembly and dispatch.\n\n## 3.4.2 Holding area for incoming goods\n\nProvide a temperature-controlled holding area for incoming TTSPPs pending their acceptance into the main storage area. The holding area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement. Where goods are held in bond in the warehouse, awaiting customs clearance, they must be physically separated and secured.\n\n*Reason:* Incoming items may need inspection and/or regulatory clearance, including laboratory testing.\n\n## 3.4.3 Quarantine area\n\nProvide a quarantine area for the isolation of returned, faulty, recalled and otherwise withdrawn goods pending a decision on disposal or re-stocking by the qualified person or department. Materials within quarantine areas must be clearly identified with their status.\n\n- with temperature control, for items returned for re-stocking;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) aborda las mejores pr\u00e1cticas para el dise\u00f1o y la operaci\u00f3n de \u00e1reas de carga y recepci\u00f3n en instalaciones que manejan productos farmac\u00e9uticos y biol\u00f3gicos. Se enfatiza la importancia de proteger los productos de da\u00f1os y contaminaci\u00f3n, as\u00ed como la necesidad de \u00e1reas espec\u00edficas para la asamblea de bienes, el almacenamiento temporal y la cuarentena de productos devueltos o retirados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener las \u00e1reas de carga y recepci\u00f3n para proteger los TTSPPs?**\n   - El contexto menciona que las \u00e1reas de carga y recepci\u00f3n deben evitar conflictos entre bienes entrantes y salientes, y estar protegidas de la luz solar directa, polvo, suciedad, lluvia, nieve, viento y extremos de temperatura. Esto es crucial para mantener la calidad del producto.\n\n2. **\u00bfQu\u00e9 equipo se recomienda para las \u00e1reas de recepci\u00f3n y cu\u00e1l es su prop\u00f3sito?**\n   - Se sugiere que las \u00e1reas de recepci\u00f3n cuenten con equipos adecuados para limpiar los contenedores de transporte reutilizables despu\u00e9s de descargar su contenido. Esto es esencial para prevenir la contaminaci\u00f3n de los TTSPPs que se enviar\u00e1n posteriormente.\n\n3. **\u00bfC\u00f3mo se debe gestionar el \u00e1rea de cuarentena para productos devueltos o retirados?**\n   - El contexto indica que debe haber un \u00e1rea de cuarentena para aislar productos devueltos, defectuosos o retirados, donde se espera una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento. Adem\u00e1s, los materiales en estas \u00e1reas deben estar claramente identificados con su estado, y se menciona que los art\u00edculos devueltos para reabastecimiento deben estar bajo control de temperatura.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Seguridad del sitio:**\n   - **Protecci\u00f3n perimetral:** Se recomienda implementar medidas de seguridad para proteger los terrenos y edificios de almacenamiento contra riesgos como vandalismo y robo.\n   - **Importancia:** La seguridad debe ser adecuada a la ubicaci\u00f3n del sitio y al valor de los bienes almacenados.\n\n2. **Limpieza del sitio:**\n   - **Mantenimiento:** Es esencial mantener el sitio libre de polvo, suciedad, desechos y plagas.\n   - **Gesti\u00f3n de residuos:** Los desechos deben ser recogidos en contenedores cerrados y desechados de manera segura y frecuente.\n   - **Objetivo:** Proteger los edificios de almacenamiento de la entrada de contaminantes y plagas.\n\n3. **Edificios de almacenamiento:**\n   - **Est\u00e1ndares de construcci\u00f3n:** Los edificios deben ser dise\u00f1ados espec\u00edficamente para el almacenamiento de productos t\u00e9cnicos y farmac\u00e9uticos (TTSPPs), adapt\u00e1ndose al clima local y optimizando el uso de recursos energ\u00e9ticos.\n   - **Materiales y tecnolog\u00eda:** Se deben utilizar materiales robustos y de f\u00e1cil mantenimiento, preferiblemente de origen local, para minimizar costos y facilitar el mantenimiento.\n   - **Dise\u00f1o y distribuci\u00f3n:** Los edificios deben tener una disposici\u00f3n eficiente que incluya \u00e1reas de almacenamiento, recepci\u00f3n, despacho y oficinas.\n\n### Entidades:\n- **TTSPPs:** Productos t\u00e9cnicos y farmac\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento.\n- **OMS:** Organizaci\u00f3n Mundial de la Salud, responsable de establecer directrices para la gesti\u00f3n de la salud p\u00fablica y el almacenamiento seguro de productos.\n- **Riesgos:** Vandalismo, robo, acumulaci\u00f3n de desechos y plagas que pueden afectar la integridad de los productos almacenados. \n\nEste resumen destaca la importancia de la seguridad, limpieza y est\u00e1ndares de construcci\u00f3n en la gesti\u00f3n de sitios de almacenamiento para productos sensibles.", "excerpt_keywords": "Keywords: loading bays, receiving bays, TTSPPs, quarantine area, temperature control"}}, "b6371738-eb6f-4bcd-9ecb-cf45a2d10bb3": {"node_ids": ["d1b3e2da-7bd2-4018-a237-b2d147d2100b"], "metadata": {"page_label": "348", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 with temperature control, for items recalled for testing;  \n\u2014 without temperature control, for items awaiting disposal.\n\nThe quarantine area may be a physically separated zone, or it may be defined using a suitable stock control information system, or by a combination arrangement.\n\n*Reason:* Items for re-stocking, testing and disposal should be kept separate to avoid the risk of inappropriate use.\n\n## 3.5 Environmental control of ancillary areas\n\nEnsure, where possible, that ancillary areas where TTSPPs are temporarily held during arrival, order assembly or dispatch are:\n\n\u2014 maintained within the temperature range specified for the goods being handled;  \n\u2014 maintained within the humidity range specified for goods that are adversely affected by high relative humidity and are not sufficiently protected by their packaging;[^6]  \n\u2014 protected from undue exposure to direct sunlight;  \n\u2014 protected from the weather;  \n\u2014 protected against dust, dirt and waste accumulation;  \n\u2014 adequately ventilated;  \n\u2014 adequately lit to enable operations to be carried out accurately and safely;  \n\u2014 monitored during the times when TTSPPs are handled; and monitored during the times when TTSPPs are handled (see 4.5.1\u20134.5.4).\n\n*Reason:* Protection of TTSPP quality during arrival, order assembly or dispatch.\n\n## 3.6 Building security\n\n### 3.6.1 General building security\n\nEnsure that buildings used to store TTSPPs have sufficient security to prevent unauthorized access and to prevent misappropriation of goods.\n\n*Reason:* To protect against vandalism, theft and other illegal incursions. Security arrangements should be appropriate to the site location and to the value of goods stored there.\n\n### 3.6.2 Controlled and hazardous substances areas\n\nEnsure that all areas that are used to store controlled or hazardous TTSPPs are:\n\n[^6]: Active environmental control of ancillary areas may not be needed if all TTSPPs are kept in temperature-controlled packaging and/or humidity-protective packaging when passing through these areas.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n y control de productos farmac\u00e9uticos y otros productos relacionados con la salud (TTSPPs) en t\u00e9rminos de su almacenamiento, control ambiental y seguridad. Se enfatiza la importancia de mantener \u00e1reas de cuarentena, controlar las condiciones ambientales en \u00e1reas auxiliares, y asegurar la protecci\u00f3n de los edificios donde se almacenan estos productos. Tambi\u00e9n se menciona la necesidad de separar los productos en cuarentena para evitar su uso inapropiado y la importancia de la seguridad para prevenir el acceso no autorizado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones ambientales espec\u00edficas que deben mantenerse en las \u00e1reas auxiliares donde se manejan TTSPPs?**\n   - Respuesta: Las \u00e1reas auxiliares deben mantenerse dentro del rango de temperatura y humedad especificados para los productos, protegidas de la luz solar directa, el clima, el polvo y la acumulaci\u00f3n de desechos, adem\u00e1s de estar adecuadamente ventiladas y iluminadas.\n\n2. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en los edificios que almacenan TTSPPs?**\n   - Respuesta: Los edificios deben tener suficiente seguridad para prevenir el acceso no autorizado y la apropiaci\u00f3n indebida de bienes, con arreglos de seguridad apropiados seg\u00fan la ubicaci\u00f3n del sitio y el valor de los productos almacenados.\n\n3. **\u00bfPor qu\u00e9 es importante mantener separados los productos en cuarentena y cu\u00e1les son las categor\u00edas de productos mencionadas?**\n   - Respuesta: Es importante mantener separados los productos en cuarentena para evitar el riesgo de uso inapropiado. Las categor\u00edas mencionadas incluyen productos para reabastecimiento, pruebas y disposici\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **\u00c1reas de Carga y Recepci\u00f3n**:\n   - **Dise\u00f1o de \u00c1reas**: Las \u00e1reas de carga y recepci\u00f3n deben estar dise\u00f1adas para evitar conflictos entre bienes entrantes y salientes, y deben estar protegidas de factores ambientales adversos como luz solar, polvo, lluvia, nieve, viento y temperaturas extremas.\n   - **Protecci\u00f3n de TTSPPs**: Se enfatiza la importancia de proteger los productos farmac\u00e9uticos y biol\u00f3gicos (TTSPPs) de da\u00f1os y mantener su calidad.\n\n2. **Equipamiento en \u00c1reas de Recepci\u00f3n**:\n   - **Limpieza de Contenedores**: Se recomienda que las \u00e1reas de recepci\u00f3n cuenten con equipos adecuados para limpiar los contenedores de transporte reutilizables despu\u00e9s de su uso, para prevenir la contaminaci\u00f3n de los TTSPPs.\n\n3. **\u00c1reas de Ensamblaje y Cuarentena**:\n   - **Espacio para Ensamblaje**: Se debe proporcionar suficiente espacio para recibir, ensamblar y empaquetar TTSPPs bajo condiciones de temperatura controlada, preferiblemente cerca de las \u00e1reas de almacenamiento controlado por temperatura.\n   - **\u00c1rea de Sostenimiento**: Se debe contar con un \u00e1rea de sostenimiento controlada por temperatura para los TTSPPs entrantes que esperan aceptaci\u00f3n en el \u00e1rea de almacenamiento principal.\n   - **\u00c1rea de Cuarentena**: Es necesario establecer un \u00e1rea de cuarentena para aislar productos devueltos, defectuosos o retirados, donde se espera una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento. Los materiales en estas \u00e1reas deben estar claramente identificados.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y biol\u00f3gicos que requieren protecci\u00f3n y manejo cuidadoso.\n- **\u00c1reas de Carga y Recepci\u00f3n**: Espacios dise\u00f1ados para la entrada y salida de bienes.\n- **Equipos de Limpieza**: Herramientas necesarias para mantener la higiene de los contenedores reutilizables.\n- **\u00c1reas de Ensamblaje y Cuarentena**: Espacios espec\u00edficos para la preparaci\u00f3n y gesti\u00f3n de productos, incluyendo el manejo de productos devueltos o defectuosos. \n\nEste resumen destaca la importancia de un dise\u00f1o adecuado y pr\u00e1cticas operativas en la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos para garantizar su calidad y seguridad.", "excerpt_keywords": "Keywords: TTSPPs, environmental control, quarantine area, building security, temperature management"}}, "eeeb5a3b-b6b5-41b4-ab03-e092921dd207": {"node_ids": ["6f0afbee-f0fb-481b-8792-a90b13c62316"], "metadata": {"page_label": "349", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Fire Protection\n\n## 3.7 Fire protection\n\n### 3.7.1 Fire protection equipment\n\nProvide suitable fire detection and fire-fighting equipment, including fire hydrants, in all TTSPP storage areas and ensure that:\n\n- systems and equipment are appropriate for the class of occupancy and product storage arrangements and are approved by the local fire authority; and\n- equipment is regularly serviced in accordance with the equipment manufacturers\u2019 recommendations and local regulations.\n\n*Reason:* Protection of property and life.\n\n### 3.7.2 Fire prevention, detection and control procedures\n\nFollow standard operating procedures (SOPs) for fire prevention, detection and control. Train staff and carry out regular fire drills. Prohibit smoking in all areas.\n\n*Reason:* Protection of property and life.\n\n## 3.8 Building hygiene\n\n### 3.8.1 Building cleanliness\n\nImplement a cleaning programme for all areas:\n\n- do not allow the accumulation of dust, dirt and waste, including packaging waste;\n- take precautions against spillage or breakage, and cross-contamination;\n\n----\n\n7 Zoned sprinkler systems are recommended to control fires and to localize product damage in the event of system activation.\n\n8 Explosion-proof stores must have a blast roof or wall. Preferably, explosive substances should be stored in an independent building, well separated from the main store.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la protecci\u00f3n contra incendios en \u00e1reas de almacenamiento de productos, enfatizando la importancia de contar con equipos de detecci\u00f3n y extinci\u00f3n de incendios adecuados, as\u00ed como la implementaci\u00f3n de procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios. Tambi\u00e9n se menciona la necesidad de mantener la limpieza en los edificios para evitar la acumulaci\u00f3n de desechos y la contaminaci\u00f3n cruzada.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de equipos de protecci\u00f3n contra incendios se recomienda instalar en las \u00e1reas de almacenamiento de TTSPP?**\n   - Respuesta: Se recomienda proporcionar equipos de detecci\u00f3n y extinci\u00f3n de incendios adecuados, incluyendo hidrantes, que sean apropiados para la clase de ocupaci\u00f3n y las disposiciones de almacenamiento de productos, y que est\u00e9n aprobados por la autoridad local de incendios.\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para prevenir incendios en las instalaciones de almacenamiento?**\n   - Respuesta: Se deben seguir procedimientos operativos est\u00e1ndar (SOP) para la prevenci\u00f3n, detecci\u00f3n y control de incendios, capacitar al personal, realizar simulacros de incendio regularmente y prohibir fumar en todas las \u00e1reas.\n\n3. **\u00bfQu\u00e9 precauciones se deben tomar en relaci\u00f3n con la limpieza de las instalaciones de almacenamiento?**\n   - Respuesta: Se debe implementar un programa de limpieza que evite la acumulaci\u00f3n de polvo, suciedad y desechos, incluyendo desechos de embalaje, y tomar precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de Cuarentena:**\n   - Se requiere mantener separados los productos en cuarentena, que incluyen:\n     - Productos con control de temperatura para pruebas.\n     - Productos sin control de temperatura para disposici\u00f3n.\n   - La zona de cuarentena puede ser f\u00edsica o definida por un sistema de control de stock.\n\n2. **Control Ambiental en \u00c1reas Auxiliares:**\n   - Las \u00e1reas donde se manejan productos farmac\u00e9uticos y relacionados (TTSPPs) deben cumplir con condiciones espec\u00edficas:\n     - Rango de temperatura y humedad adecuados.\n     - Protecci\u00f3n contra luz solar directa, clima, polvo y acumulaci\u00f3n de desechos.\n     - Ventilaci\u00f3n y iluminaci\u00f3n adecuadas.\n     - Monitoreo durante el manejo de TTSPPs.\n\n3. **Seguridad de Edificios:**\n   - Los edificios que almacenan TTSPPs deben tener medidas de seguridad suficientes para prevenir el acceso no autorizado y la apropiaci\u00f3n indebida de bienes.\n   - Las medidas de seguridad deben ser apropiadas seg\u00fan la ubicaci\u00f3n y el valor de los productos almacenados.\n\n4. **Sustancias Controladas y Peligrosas:**\n   - Se deben implementar medidas espec\u00edficas para el almacenamiento de TTSPPs controlados o peligrosos.\n\n### Entidades Clave:\n- **TTSPPs (Productos Farmac\u00e9uticos y Relacionados):** Productos que requieren manejo y almacenamiento cuidadoso.\n- **\u00c1reas de Cuarentena:** Espacios designados para productos en espera de pruebas o disposici\u00f3n.\n- **Condiciones Ambientales:** Temperatura, humedad, ventilaci\u00f3n, y protecci\u00f3n contra contaminantes.\n- **Seguridad del Edificio:** Medidas para prevenir vandalismo y robo.\n- **Sustancias Controladas y Peligrosas:** Productos que requieren un manejo y almacenamiento especial debido a su naturaleza. \n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de TTSPPs en t\u00e9rminos de control ambiental, seguridad y separaci\u00f3n de productos en cuarentena para garantizar su calidad y prevenir el uso inapropiado.", "excerpt_keywords": "Keywords: fire protection, TTSPP storage, fire prevention, building hygiene, safety equipment"}}, "f41c4458-6c59-4417-a034-b6ff4c8334ed": {"node_ids": ["9e89cac9-3bb3-4aa4-9ea1-6e82ad1b406f"], "metadata": {"page_label": "350", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- collect waste in designated closed containers and arrange for safe disposal at frequent intervals;\n- do not permit consumption of food or beverages other than in designated areas; and\n- maintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and to minimize the risk of pest infestation.\n\n### 3.8.2 Pest control\n\nImplement a programme to keep all areas free of pests. This should include enclosed receiving and loading bays. Maintain records to demonstrate compliance with a robust pest control programme.\n\n*Reason:* Protection against damage and contamination of TTSPPs.\n\n## 3.9 Power supply\n\n### 3.9.1 Uninterrupted power supply\n\nWhere possible, and where necessary, ensure that all temperature-controlling equipment for TTSPP storage (i.e. refrigerators, freezers, building management systems, heating, ventilation and air-conditioning (HVAC) systems, compressors, air-handling units, monitoring systems, alarms and related computer equipment) are connected to an uninterrupted power supply (UPS) system. Where a generator and associated control equipment is used it should:\n\n- be able to manage the combined start-up load of all connected temperature-controlling and temperature-monitoring equipment;\n- not exceed the defined parameters of the mains power supply;\n- be equipped with automatic mains failure start-up and automatic shutdown when power is restored; and\n- have adequate fuel tank capacity and sufficient fuel to cover a prolonged power outage.\n\nRegularly test and service UPS equipment and generators. Maintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n----\n\n9. UPS systems may be unnecessary in countries with a very reliable electricity supply. In smaller stores in countries where electricity is only available for a limited period each day, or is entirely absent, an alternative approach to UPS is to use refrigeration equipment with extended holdover capacity, for example, ice-lined refrigerators, or gas, kerosene or solar-powered refrigerators.\n\n10. The installed capacity of the UPS system can be minimized by fitting electronic controls which reduce compressor start-up loads.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto:\n\n1. **Manejo de Residuos y Control de Plagas**: Se enfatiza la importancia de recolectar residuos en contenedores cerrados y deshacerse de ellos de manera segura para proteger los productos farmac\u00e9uticos y minimizar el riesgo de infestaci\u00f3n de plagas. Tambi\u00e9n se requiere mantener registros de limpieza y un programa robusto de control de plagas.\n\n2. **Suministro de Energ\u00eda Ininterrumpido**: Se recomienda que todos los equipos de control de temperatura para el almacenamiento de productos farmac\u00e9uticos est\u00e9n conectados a un sistema de suministro de energ\u00eda ininterrumpido (UPS). Se detallan las especificaciones que debe cumplir un generador en caso de ser utilizado, as\u00ed como la necesidad de realizar pruebas y mantenimiento regular.\n\n3. **Alternativas a los Sistemas UPS**: En regiones con un suministro el\u00e9ctrico confiable, los sistemas UPS pueden no ser necesarios. En lugares donde la electricidad es limitada, se sugiere el uso de equipos de refrigeraci\u00f3n con capacidad de retenci\u00f3n prolongada, como refrigeradores con hielo o alimentados por gas, queroseno o energ\u00eda solar.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que debe tener un generador utilizado en un sistema de suministro de energ\u00eda ininterrumpido (UPS) para el almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: El generador debe ser capaz de manejar la carga de arranque combinada de todos los equipos conectados, no exceder los par\u00e1metros definidos del suministro el\u00e9ctrico, estar equipado con un arranque autom\u00e1tico en caso de fallo de la red y tener una capacidad de tanque de combustible adecuada para cubrir cortes prolongados de energ\u00eda.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para garantizar la limpieza y el control de plagas en las \u00e1reas de almacenamiento de productos farmac\u00e9uticos?**\n   - Respuesta: Se deben recolectar residuos en contenedores cerrados y deshacerse de ellos de manera segura, no permitir el consumo de alimentos o bebidas fuera de \u00e1reas designadas, y mantener registros de limpieza. Adem\u00e1s, se debe implementar un programa de control de plagas que incluya \u00e1reas de recepci\u00f3n y carga cerradas, con registros que demuestren el cumplimiento.\n\n3. **\u00bfQu\u00e9 alternativas existen para los sistemas UPS en lugares donde la electricidad es limitada o intermitente?**\n   - Respuesta: En lugares con suministro el\u00e9ctrico limitado, se pueden utilizar equipos de refrigeraci\u00f3n con capacidad de retenci\u00f3n prolongada, como refrigeradores con hielo, o refrigeradores alimentados por gas, queroseno o energ\u00eda solar, en lugar de depender de un sistema UPS.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Protecci\u00f3n contra incendios**:\n   - Importancia de contar con equipos adecuados de detecci\u00f3n y extinci\u00f3n de incendios en \u00e1reas de almacenamiento de TTSPP.\n   - Equipos deben ser aprobados por la autoridad local de incendios y adecuados para la clase de ocupaci\u00f3n.\n\n2. **Equipos de protecci\u00f3n contra incendios**:\n   - Se recomienda la instalaci\u00f3n de hidrantes y sistemas de rociadores zonificados para controlar incendios y minimizar da\u00f1os a productos.\n\n3. **Procedimientos de prevenci\u00f3n, detecci\u00f3n y control de incendios**:\n   - Implementaci\u00f3n de procedimientos operativos est\u00e1ndar (SOP).\n   - Capacitaci\u00f3n del personal y realizaci\u00f3n de simulacros de incendio.\n   - Prohibici\u00f3n de fumar en todas las \u00e1reas.\n\n4. **Higiene del edificio**:\n   - Necesidad de un programa de limpieza para evitar la acumulaci\u00f3n de polvo, suciedad y desechos.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n\n5. **Almacenamiento de sustancias explosivas**:\n   - Almacenes a prueba de explosiones deben tener techos o paredes resistentes a explosiones.\n   - Preferencia por almacenar sustancias explosivas en edificios independientes, separados del almac\u00e9n principal.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite el documento.\n- **TTSPP (Productos Terap\u00e9uticos y de Salud P\u00fablica)**: Tipo de productos mencionados en el contexto de almacenamiento.\n- **Autoridad local de incendios**: Entidad responsable de la aprobaci\u00f3n de equipos de protecci\u00f3n contra incendios.", "excerpt_keywords": "Keywords: waste management, pest control, uninterrupted power supply, temperature control, pharmaceutical storage"}}, "58ccd3d8-9628-4fef-962d-04433a0035dc": {"node_ids": ["e270facf-1c08-44b6-90dc-0039cdebdfb7"], "metadata": {"page_label": "351", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 3.9.2 Power failure contingency plan\n\nDevelop and maintain a contingency plan to protect TTSPPs in the event of power failure which places products at risk. Alternative emergency cooling systems (e.g. liquid nitrogen or dry ice) are acceptable.\n\n*Reason:* Loss prevention.\n\n# 3.10 Building maintenance\n\nImplement a planned preventive maintenance programme to ensure that storage buildings and building utilities are well maintained. Keep records to demonstrate compliance with the programme.\n\n*Reason:* To ensure that storage buildings continue to protect stored products against damage.\n\n# 4. Temperature-controlled storage\n\n## 4.1 Normative references\n\n- EN 60068-3 parts 5, 6, 7 and 11: *Environmental testing. Guidance. Confirmation of the performance of temperature chambers*\n- International Air Transport Association (IATA) *Perishable cargo regulations chapter 17. 10th ed, July 2010*\n- USP <1079> *Good storage and shipping practices*\n- USP <1118> *Monitoring devices \u2014 time, temperature and humidity*\n\n## 4.2 Storage capacity of temperature-controlled stores\n\nEnsure that the net storage capacity of the temperature-controlled stores is sufficient to accommodate peak TTSPP stock levels and their associated transit temperature protection components (i.e. freezer blocks, flexible ice blankets, refrigerated gel packs, phase change materials and insulated packaging, if retained), under correct temperature conditions and in a manner which enables efficient and correct stock management operations to take place.\n\n*Reason:* To avoid the risks associated with overstocking and to ensure that good warehousing practices can be adopted (i.e. first in-first out (FIFO) or earliest expiry-first out (EEFO)). Overstocking makes FIFO or EEFO handling difficult or impossible and hinders accurate physical stock counts.\n\n## 4.3 Temperature-controlled storage\n\nEnsure that TTSPPs are stored in temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers which comply with the following requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Incluye directrices sobre la planificaci\u00f3n de contingencias ante fallos de energ\u00eda, el mantenimiento de edificios de almacenamiento y los requisitos para el almacenamiento controlado de temperatura. Se enfatiza la importancia de mantener condiciones adecuadas para proteger los productos almacenados y evitar riesgos asociados con el manejo inadecuado de inventarios.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 medidas espec\u00edficas se deben implementar en un plan de contingencia para proteger los TTSPPs durante un fallo de energ\u00eda?**\n   - Respuesta: Se debe desarrollar y mantener un plan de contingencia que incluya sistemas de enfriamiento de emergencia alternativos, como nitr\u00f3geno l\u00edquido o hielo seco, para proteger los TTSPPs en caso de un fallo de energ\u00eda.\n\n2. **\u00bfCu\u00e1les son las referencias normativas que se deben considerar al establecer un almacenamiento controlado de temperatura para TTSPPs?**\n   - Respuesta: Las referencias normativas incluyen EN 60068-3 (pruebas ambientales), las regulaciones de carga perecedera de la IATA (cap\u00edtulo 17), y las pr\u00e1cticas de almacenamiento y env\u00edo de la USP, as\u00ed como los dispositivos de monitoreo de tiempo, temperatura y humedad de la USP.\n\n3. **\u00bfQu\u00e9 pr\u00e1cticas de gesti\u00f3n de inventario se deben seguir para evitar problemas asociados con el sobrealmacenamiento de TTSPPs?**\n   - Respuesta: Se deben adoptar buenas pr\u00e1cticas de almacenamiento, como el m\u00e9todo de primero en entrar, primero en salir (FIFO) o el de primero en expirar, primero en salir (EEFO), para evitar los riesgos del sobrealmacenamiento y facilitar conteos f\u00edsicos precisos del inventario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Residuos**:\n   - Importancia de recolectar residuos en contenedores cerrados.\n   - Disposici\u00f3n segura de residuos a intervalos frecuentes.\n   - Prohibici\u00f3n de consumo de alimentos y bebidas fuera de \u00e1reas designadas.\n   - Mantenimiento de registros de limpieza para demostrar cumplimiento.\n\n2. **Control de Plagas**:\n   - Implementaci\u00f3n de un programa para mantener \u00e1reas libres de plagas.\n   - Inclusi\u00f3n de \u00e1reas de recepci\u00f3n y carga cerradas en el programa.\n   - Mantenimiento de registros que demuestren el cumplimiento del programa de control de plagas.\n\n3. **Suministro de Energ\u00eda Ininterrumpido (UPS)**:\n   - Conexi\u00f3n de equipos de control de temperatura a un sistema UPS.\n   - Especificaciones para generadores utilizados en sistemas UPS:\n     - Capacidad para manejar la carga de arranque combinada.\n     - No exceder par\u00e1metros del suministro el\u00e9ctrico.\n     - Arranque autom\u00e1tico en caso de fallo de la red.\n     - Capacidad de tanque de combustible adecuada para cortes prolongados.\n   - Importancia de pruebas y mantenimiento regular de equipos UPS y generadores.\n\n4. **Alternativas a los Sistemas UPS**:\n   - En pa\u00edses con suministro el\u00e9ctrico confiable, los sistemas UPS pueden no ser necesarios.\n   - Uso de refrigeradores con capacidad de retenci\u00f3n prolongada (ej. refrigeradores con hielo, alimentados por gas, queroseno o energ\u00eda solar) en lugares con electricidad limitada.\n\n### Entidades Clave\n- **TTSPP**: Productos farmac\u00e9uticos que requieren control de temperatura.\n- **UPS**: Sistema de suministro de energ\u00eda ininterrumpido.\n- **HVAC**: Sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado.\n- **Generadores**: Equipos para proporcionar energ\u00eda en caso de fallo del suministro el\u00e9ctrico.\n- **Contenedores cerrados**: Elementos para la recolecci\u00f3n de residuos.\n- **Programa de control de plagas**: Estrategia para mantener \u00e1reas libres de infestaciones. \n\nEste resumen destaca las pr\u00e1cticas recomendadas para el manejo de residuos, control de plagas y suministro de energ\u00eda en el contexto del almacenamiento de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: TTSPPs, temperature-controlled storage, contingency plan, building maintenance, overstocking"}}, "30587ff2-ef25-48c4-a1d9-04bb06793b35": {"node_ids": ["9866f1b2-f068-4e7b-ad4b-05b9e059e49e"], "metadata": {"page_label": "352", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Temperature-controlled rooms, cold rooms and freezer rooms should be:\n\n- Capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced at the store location;\n- Preferably equipped with an auto-defrost circuit which has a minimal effect on temperature within the unit during the defrost cycle and maintains temperature within specification for this period;\n- Equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- Connected to a UPS as described in clause 3.9.1;\n- Equipped with a calibrated continuous temperature monitoring system with sensors located at points representing greatest temperature variability and temperature extremes;\n- Preferably equipped with continuous humidity monitoring devices with sensors located at points representing humidity extremes;\n- Equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors, or an access control system, as necessary; locks must have a safety device so that doors can be freely opened from the inside; and\n- Qualified as defined in clause 4.7.\n\n# Refrigerators and freezers should be:\n\n- Purpose-designed for the storage of TTSPPs; household-style units are only acceptable if they have been independently tested and found to comply with the temperature control requirements of a recognized standard for pharmaceutical refrigerators and freezers;[^11]\n- Capable of maintaining the temperature range specified by the TTSPP manufacturer over the full annual ambient temperature range experienced at the storage site;\n- Equipped with calibrated temperature monitoring devices appropriate to the level of risk but preferably capable of continuous recording and with sensor(s) located at a point or points within the cabinet which most accurately represents the temperature profile of the equipment during normal operation;\n- Preferably equipped with alarms to indicate temperature excursions and/or refrigeration failure;\n- Fitted with lockable doors or lids, or access control system, as necessary; and\n- Qualified and/or tested as defined in clause 4.7.\n\n[^11]: For example, WHO PQS standards for refrigerators and freezers are available at: http://www.who.int/immunization_standards/vaccine_quality/pqs_e03_fridges_freezers/en/index.html.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices para el dise\u00f1o y operaci\u00f3n de habitaciones controladas por temperatura, as\u00ed como de refrigeradores y congeladores destinados al almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se detallan requisitos espec\u00edficos que estos equipos deben cumplir, como la capacidad de mantener rangos de temperatura adecuados, la inclusi\u00f3n de sistemas de monitoreo de temperatura y humedad, alarmas para detectar fallos, y la necesidad de que sean dise\u00f1ados espec\u00edficamente para su prop\u00f3sito.\n\n### Preguntas espec\u00edficas\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas espec\u00edficas que deben tener las habitaciones controladas por temperatura para garantizar la seguridad de los TTSPPs?**\n   - Respuesta: Las habitaciones deben ser capaces de mantener el rango de temperatura definido, estar equipadas con un circuito de autodescongelaci\u00f3n, contar con un circuito de protecci\u00f3n contra bajas temperaturas, estar conectadas a un UPS, tener un sistema de monitoreo de temperatura calibrado, y alarmas para indicar excursiones de temperatura, entre otros requisitos.\n\n2. **\u00bfQu\u00e9 tipo de refrigeradores y congeladores son aceptables para el almacenamiento de TTSPPs seg\u00fan la OMS?**\n   - Respuesta: Solo se aceptan unidades dise\u00f1adas espec\u00edficamente para el almacenamiento de TTSPPs. Las unidades de estilo dom\u00e9stico son aceptables solo si han sido probadas de manera independiente y cumplen con los requisitos de control de temperatura de un est\u00e1ndar reconocido para refrigeradores y congeladores farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 medidas de seguridad se deben implementar en los refrigeradores y congeladores para proteger los TTSPPs?**\n   - Respuesta: Los refrigeradores y congeladores deben estar equipados con puertas o tapas que se puedan bloquear, sistemas de control de acceso seg\u00fan sea necesario, y los mecanismos de bloqueo deben tener un dispositivo de seguridad que permita abrir las puertas desde el interior en caso de emergencia.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Plan de contingencia ante fallos de energ\u00eda (3.9.2)**:\n   - Importancia de desarrollar y mantener un plan para proteger los productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs) en caso de interrupciones de energ\u00eda.\n   - Se aceptan sistemas de enfriamiento de emergencia alternativos, como nitr\u00f3geno l\u00edquido o hielo seco.\n   - **Objetivo**: Prevenci\u00f3n de p\u00e9rdidas.\n\n2. **Mantenimiento de edificios (3.10)**:\n   - Implementaci\u00f3n de un programa de mantenimiento preventivo planificado para asegurar que los edificios de almacenamiento y sus utilidades est\u00e9n en buen estado.\n   - Registro de cumplimiento del programa de mantenimiento.\n   - **Objetivo**: Proteger los productos almacenados contra da\u00f1os.\n\n3. **Almacenamiento controlado de temperatura (4)**:\n   - **Referencias normativas (4.1)**: Incluye normas y regulaciones relevantes como EN 60068-3, regulaciones de la IATA y pr\u00e1cticas de la USP.\n   - **Capacidad de almacenamiento (4.2)**: Asegurar que la capacidad neta de los almacenes controlados por temperatura sea suficiente para manejar los niveles m\u00e1ximos de stock de TTSPPs y sus componentes de protecci\u00f3n t\u00e9rmica.\n     - **Objetivo**: Evitar riesgos de sobrealmacenamiento y facilitar buenas pr\u00e1cticas de gesti\u00f3n de inventario (FIFO y EEFO).\n   - **Requisitos de almacenamiento (4.3)**: Asegurar que los TTSPPs se almacenen en habitaciones y equipos controlados por temperatura que cumplan con los requisitos establecidos.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sistemas de enfriamiento**: Nitr\u00f3geno l\u00edquido, hielo seco.\n- **Normas y regulaciones**: EN 60068-3, IATA, USP.\n- **Pr\u00e1cticas de gesti\u00f3n de inventario**: FIFO (primero en entrar, primero en salir), EEFO (primero en expirar, primero en salir). \n\nEste resumen destaca la importancia de la planificaci\u00f3n, el mantenimiento y el cumplimiento normativo en la gesti\u00f3n de productos farmac\u00e9uticos sensibles a la temperatura.", "excerpt_keywords": "Keywords: temperature control, pharmaceutical storage, TTSPPs, refrigeration standards, monitoring systems"}}, "e3baed74-35a3-4267-98d9-b0129c46da3f": {"node_ids": ["110fcc70-98f0-4267-bdd6-dd184fcc2f74"], "metadata": {"page_label": "353", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.4 Temperature-controlled storage for controlled and hazardous products\n\nEnsure that controlled and hazardous TTSPPs are securely stored:\n\n- Provide dedicated temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers for these TTSPPs, in separate secure areas, as described in clause 3.6.2.\n- Alternatively, but only if acceptable to the regulatory authority, bulk stocks of TTSPPs with high illicit-value may be stored in a securely locked section of a general temperature-controlled storage area.\n\n*Reason:* To protect this category of TTSPPs against theft and misuse and to safeguard workers and general storage areas in the event of an accident involving hazardous substances.\n\n# 4.5 Temperature and humidity control and monitoring in storage\n\n## 4.5.1 Temperature control\n\nProvide thermostatic temperature control systems for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n- System able continuously to maintain air temperatures within the set point limits throughout the validated storage volume;\n- Control sensors accurate to \u00b1 0.5 \u00b0C or better;\n- Control sensors calibrated as described in clause 4.10.1;\n- Control sensors located in areas where greatest variability in temperature is expected to occur in order to maximize available safe storage volume;\n- Control sensors positioned at the hot and cold spots determined by temperature mapping, even if affected by door opening, unless recommendations are being made not to store products in such areas; and\n- Control sensors independent of the temperature monitoring system.\n\n## 4.5.2 Temperature monitoring\n\nProvide air temperature monitoring systems and devices for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n**General requirements**\n\n- Monitoring sensors accurate to \u00b1 0.5 \u00b0C or better for electronic devices and \u00b1 1 \u00b0C or better for alcohol, bi-metal gas or vapour pressure thermometers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Informe T\u00e9cnico 961) establece directrices sobre el almacenamiento controlado de productos farmac\u00e9uticos y peligrosos (TTSPPs). Se enfatiza la necesidad de contar con instalaciones de almacenamiento con control de temperatura y humedad, as\u00ed como sistemas de monitoreo para garantizar la seguridad y eficacia de estos productos. Se detallan requisitos espec\u00edficos para el control y monitoreo de la temperatura, incluyendo la precisi\u00f3n de los sensores y su ubicaci\u00f3n estrat\u00e9gica.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los requisitos m\u00ednimos para los sistemas de control de temperatura en las habitaciones de almacenamiento de TTSPPs?**\n   - Respuesta: Los sistemas deben mantener continuamente las temperaturas del aire dentro de los l\u00edmites establecidos, contar con sensores de control precisos a \u00b1 0.5 \u00b0C o mejor, estar calibrados adecuadamente, ubicarse en \u00e1reas con mayor variabilidad de temperatura y ser independientes del sistema de monitoreo de temperatura.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para proteger los TTSPPs controlados y peligrosos contra el robo y el uso indebido?**\n   - Respuesta: Se deben proporcionar habitaciones de temperatura controlada dedicadas, as\u00ed como \u00e1reas de almacenamiento seguras. Alternativamente, si es aceptable para la autoridad reguladora, se pueden almacenar existencias a granel de TTSPPs de alto valor il\u00edcito en una secci\u00f3n cerrada de un \u00e1rea de almacenamiento general controlada por temperatura.\n\n3. **\u00bfQu\u00e9 precisi\u00f3n deben tener los sensores de monitoreo de temperatura para cumplir con los requisitos establecidos en el documento?**\n   - Respuesta: Los sensores de monitoreo deben ser precisos a \u00b1 0.5 \u00b0C o mejor para dispositivos electr\u00f3nicos, y a \u00b1 1 \u00b0C o mejor para term\u00f3metros de alcohol, bi-metal, gas o de presi\u00f3n de vapor.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Requisitos para Habitaciones Controladas por Temperatura:**\n   - Capacidad para mantener el rango de temperatura definido.\n   - Equipamiento con circuitos de autodescongelaci\u00f3n y protecci\u00f3n contra bajas temperaturas.\n   - Conexi\u00f3n a un sistema de alimentaci\u00f3n ininterrumpida (UPS).\n   - Monitoreo continuo de temperatura y humedad.\n   - Alarmas para detectar excursiones de temperatura y fallos en la refrigeraci\u00f3n.\n   - Seguridad en el acceso mediante puertas bloqueables.\n\n2. **Requisitos para Refrigeradores y Congeladores:**\n   - Dise\u00f1o espec\u00edfico para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - Capacidad para mantener el rango de temperatura especificado por el fabricante de TTSPPs.\n   - Equipamiento con dispositivos de monitoreo de temperatura calibrados.\n   - Alarmas para detectar problemas de temperatura y refrigeraci\u00f3n.\n   - Seguridad en el acceso mediante puertas o tapas bloqueables.\n\n**Entidades:**\n\n- **TTSPPs:** Productos farmac\u00e9uticos sensibles a la temperatura.\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad que establece las directrices.\n- **UPS (Sistema de Alimentaci\u00f3n Ininterrumpida):** Dispositivo para asegurar el suministro el\u00e9ctrico continuo.\n- **PQS (Prequalification of Vaccines):** Est\u00e1ndares de la OMS para refrigeradores y congeladores.\n\nEste resumen destaca la importancia de mantener condiciones adecuadas de temperatura y seguridad para el almacenamiento de productos farmac\u00e9uticos, as\u00ed como los est\u00e1ndares que deben seguir los equipos utilizados en estos procesos.", "excerpt_keywords": "Keywords: temperature control, hazardous products, storage requirements, monitoring systems, TTSPPs"}}, "f7bc63ee-6b2c-422d-8a81-aa20f18dff20": {"node_ids": ["ef1c1ddc-b372-421d-9596-6d5c9bd64211"], "metadata": {"page_label": "354", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Monitoring sensors calibrated as described in clause 4.10.1.\n- Monitoring sensors located in areas where greatest variability in temperature is expected to occur within the qualified and/or tested storage volume as defined in clause 4.7.\n- Monitoring sensors positioned so as to be minimally affected by transient events such as door opening.\n- Temperature monitoring devices, temperature traces or electronic temperature records manually checked at least twice a day, in the morning and evening, seven days a week, including public holidays.\n\n**Temperature-controlled rooms, cold rooms and freezer rooms**\n- Provide a temperature record with a minimum recording frequency of six times per hour for each monitoring sensor position.\n- Provide documentation for each monitoring sensor position which can be stored and accessed.\n- Continue to operate independently in the event of a power failure.\u00b9\u00b2\n\n**Refrigerators and freezers**\n- Preferably, connect refrigerators and freezers to a multipoint monitoring system with a minimum recording frequency of six times per hour for each sensor position which can operate independently in the event of a power failure.\n- Alternatively use battery-powered portable temperature monitoring devices with a minimum recording frequency of six times per hour.\n- The least preferred option is a thermometer or maximum/minimum thermometer.\n- Provide documentation for each appliance which can be stored and accessed.\n\n**Reasons:** To maintain labelled TTSPP temperatures during long-term storage. Thermometers provide only limited and discontinuous temperature information. For this reason, continuous recording devices are preferable.\n\n### 4.5.3 Humidity control\n\nProvide humidity control in temperature-controlled rooms that are used to store TTSPPs which are adversely affected by high relative humidity and are not sufficiently protected by their packaging. Such products are typically labelled \u201cstore in a dry place\u201d, or carry similar wording and require a humidity-controlled environment.\n\n----\n\n\u00b9\u00b2 Where there is no UPS, the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para el monitoreo de temperatura y humedad en el almacenamiento de productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la temperatura (TTSPP). Se enfatiza la importancia de utilizar sensores de monitoreo calibrados, ubicados estrat\u00e9gicamente y con un registro continuo de temperatura. Adem\u00e1s, se requiere un control de humedad en entornos donde los productos pueden verse afectados por la humedad relativa alta. Se sugieren diferentes m\u00e9todos de monitoreo, priorizando sistemas que operen de manera independiente en caso de fallos de energ\u00eda.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las caracter\u00edsticas clave que deben tener los sensores de monitoreo de temperatura en las habitaciones controladas por temperatura?**\n   - Respuesta: Los sensores deben estar calibrados, ubicados en \u00e1reas con mayor variabilidad de temperatura, posicionados para minimizar el impacto de eventos transitorios (como la apertura de puertas) y deben ser verificados manualmente al menos dos veces al d\u00eda.\n\n2. **\u00bfQu\u00e9 se debe hacer en caso de un fallo de energ\u00eda en los refrigeradores y congeladores utilizados para almacenar TTSPP?**\n   - Respuesta: Los refrigeradores y congeladores deben estar conectados a un sistema de monitoreo multipunto que funcione de manera independiente en caso de un fallo de energ\u00eda, o utilizar dispositivos de monitoreo de temperatura port\u00e1tiles con bater\u00eda que registren al menos seis veces por hora.\n\n3. **\u00bfQu\u00e9 tipo de productos requieren un control de humedad en las habitaciones de almacenamiento y c\u00f3mo se identifican?**\n   - Respuesta: Los productos que son adversamente afectados por alta humedad relativa y que no est\u00e1n suficientemente protegidos por su embalaje requieren control de humedad. Estos productos suelen estar etiquetados con instrucciones como \"almacenar en un lugar seco\" o frases similares.", "prev_section_summary": "### Temas Clave:\n\n1. **Almacenamiento Controlado de Productos**: Se enfatiza la importancia de almacenar productos farmac\u00e9uticos y peligrosos (TTSPPs) en condiciones de temperatura controlada para prevenir el robo, el uso indebido y accidentes.\n\n2. **Requisitos de Control de Temperatura**: Se establecen requisitos espec\u00edficos para los sistemas de control de temperatura en habitaciones de almacenamiento, incluyendo la capacidad de mantener temperaturas dentro de l\u00edmites establecidos y la precisi\u00f3n de los sensores.\n\n3. **Monitoreo de Temperatura**: Se detallan las especificaciones para los sistemas de monitoreo de temperatura, incluyendo la precisi\u00f3n de los sensores y su ubicaci\u00f3n estrat\u00e9gica para maximizar la seguridad del almacenamiento.\n\n4. **Seguridad en el Almacenamiento**: Se menciona la necesidad de \u00e1reas de almacenamiento seguras y dedicadas para TTSPPs, as\u00ed como la posibilidad de almacenar productos de alto valor il\u00edcito en secciones cerradas de \u00e1reas de almacenamiento general.\n\n### Entidades:\n\n- **TTSPPs**: Productos farmac\u00e9uticos y peligrosos que requieren almacenamiento controlado.\n- **Sistemas de Control de Temperatura**: Equipos necesarios para mantener condiciones adecuadas en el almacenamiento.\n- **Sensores de Control y Monitoreo**: Dispositivos utilizados para medir y asegurar la temperatura en las \u00e1reas de almacenamiento.\n- **Autoridad Reguladora**: Entidad que puede aceptar alternativas en el almacenamiento de TTSPPs de alto valor il\u00edcito.\n- **Habitaciones de Almacenamiento**: Espacios dedicados para el almacenamiento seguro de TTSPPs, incluyendo habitaciones de temperatura controlada, c\u00e1maras fr\u00edas, y congeladores. \n\n### Resumen:\nEl documento de la OMS establece directrices para el almacenamiento seguro de productos farmac\u00e9uticos y peligrosos, enfatizando la necesidad de control y monitoreo de temperatura. Se especifican requisitos para los sistemas de control y sensores, as\u00ed como medidas de seguridad para proteger estos productos contra el robo y el uso indebido.", "excerpt_keywords": "Keywords: temperature monitoring, humidity control, TTSPPs, storage guidelines, continuous recording devices"}}, "29c12703-2440-47ac-93ff-d413c8b07ed5": {"node_ids": ["7684478d-1fb9-4f82-8c13-10e3d257660c"], "metadata": {"page_label": "355", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.5.4 Humidity monitoring\n\nProvide humidity monitoring systems and devices in temperature-controlled rooms that are used to store TTSPPs which require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% RH;\n- Sensors calibrated as per clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the qualified storage volume defined in clause 4.7;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- Provides a humidity record with a minimum recording frequency of six times per hour for each sensor position;\n- Provides documentation for each sensor position which can be stored and accessed; and\n- Continues to operate independently in the event of a power failure.13\n\n*Reason:* To maintain labelled TTSPP humidity conditions during long-term storage.\n\n# 4.6 Alarm systems\n\n## 4.6.1 Temperature alarms\n\nProvide temperature alarm systems for temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, used to store TTSPPs. Comply with the following minimum requirements:\n\n### General requirements\n\n- Sensors accurate to \u00b1 0.5 \u00b0C.\n- Sensors calibrated as described in clause 4.10.1.\n- Sensors located to monitor worst-case temperatures within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the temperature monitoring system, sensors should be located close to the temperature monitoring sensors.\n- Sensors positioned so as to be minimally affected by transient events such as door opening.\n\n### Temperature-controlled rooms, cold rooms and freezer rooms\n\n- High/low alarms set points to trigger appropriately located visual alarm(s).\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s).\n\n----\n\n13 Where there is no UPS the autonomy period for the device should be matched to the maximum length of anticipated power outages.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece requisitos m\u00ednimos para los sistemas de monitoreo de humedad y alarmas de temperatura en habitaciones controladas por temperatura, donde se almacenan productos farmac\u00e9uticos y terap\u00e9uticos (TTSPPs). Se especifican las caracter\u00edsticas de los sensores, su ubicaci\u00f3n, la frecuencia de registro de datos y la necesidad de operar de manera independiente en caso de fallos de energ\u00eda. Adem\u00e1s, se detallan los requisitos para los sistemas de alarma de temperatura, incluyendo la precisi\u00f3n de los sensores y la necesidad de alarmas visuales y auditivas.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las especificaciones de precisi\u00f3n requeridas para los sensores de humedad y temperatura en el almacenamiento de TTSPPs?**\n   - Respuesta: Los sensores de humedad deben ser precisos a \u00b1 5% RH, mientras que los sensores de temperatura deben ser precisos a \u00b1 0.5 \u00b0C.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar que los sensores de humedad y temperatura no se vean afectados por eventos transitorios como la apertura de puertas?**\n   - Respuesta: Los sensores deben ser posicionados de tal manera que sean m\u00ednimamente afectados por eventos transitorios, como la apertura de puertas.\n\n3. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para cada posici\u00f3n de sensor de humedad y c\u00f3mo debe ser accesible?**\n   - Respuesta: Se debe proporcionar documentaci\u00f3n para cada posici\u00f3n de sensor que pueda ser almacenada y accesible, asegurando que se mantenga un registro adecuado de las condiciones de humedad.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Monitoreo de Temperatura:**\n   - Importancia de utilizar sensores de monitoreo calibrados.\n   - Ubicaci\u00f3n estrat\u00e9gica de los sensores en \u00e1reas con mayor variabilidad de temperatura.\n   - Verificaci\u00f3n manual de registros de temperatura al menos dos veces al d\u00eda.\n   - Registro continuo de temperatura con una frecuencia m\u00ednima de seis veces por hora.\n\n2. **Almacenamiento en Habitaciones Controladas por Temperatura:**\n   - Requisitos para el funcionamiento independiente de los dispositivos en caso de fallos de energ\u00eda.\n   - Preferencia por sistemas de monitoreo multipunto o dispositivos port\u00e1tiles de monitoreo de temperatura.\n\n3. **Control de Humedad:**\n   - Necesidad de controlar la humedad en habitaciones que almacenan productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la humedad.\n   - Identificaci\u00f3n de productos que requieren control de humedad a trav\u00e9s de etiquetas que indican \"almacenar en un lugar seco\".\n\n4. **Documentaci\u00f3n:**\n   - Requerimiento de documentaci\u00f3n accesible para cada posici\u00f3n de sensor y cada aparato de almacenamiento.\n\n**Entidades:**\n\n- **Organizaci\u00f3n:** Organizaci\u00f3n Mundial de la Salud (OMS).\n- **Tipos de Productos:** Productos farmac\u00e9uticos y biol\u00f3gicos sensibles a la temperatura (TTSPP).\n- **Dispositivos de Monitoreo:** Sensores de temperatura, dispositivos de monitoreo port\u00e1tiles, term\u00f3metros.\n- **Condiciones de Almacenamiento:** Habitaciones controladas por temperatura, c\u00e1maras fr\u00edas, congeladores.\n- **Frecuencia de Registro:** M\u00ednimo seis veces por hora.\n- **Condiciones de Humedad:** Alta humedad relativa, productos etiquetados para almacenamiento en un lugar seco.\n\nEste resumen destaca la importancia de un monitoreo riguroso y continuo de temperatura y humedad para garantizar la integridad de los productos sensibles, as\u00ed como la necesidad de documentaci\u00f3n adecuada y preparaci\u00f3n para fallos de energ\u00eda.", "excerpt_keywords": "Keywords: humidity monitoring, temperature alarms, TTSPPs, sensor calibration, storage conditions"}}, "1abcd144-b47a-4196-a137-4f6905fdbcba": {"node_ids": ["d35e192b-d33a-4aaf-8e5f-2d6e4b0117f1"], "metadata": {"page_label": "356", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n**Refrigerators and freezers**\n- Preferably there should be a visual and/or audible alarm system; this may be integrated with a portable continuous temperature monitoring device.\n\n*Reason:* Loss prevention.\n\n### 4.6.2 Humidity alarms\n\nProvide humidity alarm systems for temperature-controlled rooms used to store TTSPPs that require a humidity-controlled environment. Comply with the following minimum requirements:\n\n- Sensors accurate to \u00b1 5% relative humidity (RH);\n- Sensors calibrated as described in clause 4.10.2;\n- Sensors located to monitor worst-case humidity levels within the validated storage volume defined in clause 4.7; where the alarm system is not integrated with the humidity monitoring system, sensors should be located close to the humidity monitoring sensors;\n- Sensors positioned so as to be minimally affected by transient events such as door opening;\n- High/low alarms set points to trigger appropriately located visual alarm(s);\n- Preferably there should also be appropriately located audible alarm(s) in addition to the visual alarm(s); and\n- Preferably there should be an automatic telephone dial-up or SMS text warning system to alert on-call personnel when an alarm is triggered outside working hours.\n\n*Reason:* Loss prevention.\n\n### 4.7 Qualification of temperature-controlled stores\n\nQualify new temperature-controlled storage areas and new refrigeration equipment before it becomes operational. The qualification procedure should:\n\n- Demonstrate the air temperature profile throughout the storage area or equipment cabinet, when empty and in a normal loaded condition;\n- Define zones which should not be used for storage of TTSPPs (for example areas in close proximity to cooling coils, cold air streams or heat sources); and\n- Demonstrate the time taken for temperatures to exceed the designated limits in the event of power failure.\n\nFully document the initial qualification. Carry out additional qualification exercises whenever modifications are made to the storage area that may...", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que pueden ser respondidas por el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece directrices para la gesti\u00f3n de ambientes controlados de temperatura y humedad, especialmente en el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se enfatiza la importancia de sistemas de alarma para la detecci\u00f3n de cambios en la temperatura y la humedad, as\u00ed como la necesidad de calificar adecuadamente las \u00e1reas de almacenamiento antes de su uso. Las recomendaciones incluyen la instalaci\u00f3n de alarmas visuales y audibles, as\u00ed como sistemas de alerta autom\u00e1tica para el personal de guardia.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son las especificaciones m\u00ednimas requeridas para los sensores de humedad en las habitaciones de almacenamiento controladas por temperatura?**\n   - Respuesta: Los sensores deben ser precisos a \u00b1 5% de humedad relativa (RH), calibrados seg\u00fan lo descrito en la cl\u00e1usula 4.10.2, y ubicados para monitorear los niveles de humedad en el volumen de almacenamiento validado.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para calificar nuevas \u00e1reas de almacenamiento controladas por temperatura antes de que se vuelvan operativas?**\n   - Respuesta: La calificaci\u00f3n debe demostrar el perfil de temperatura del aire en el \u00e1rea de almacenamiento, definir zonas que no deben usarse para el almacenamiento de TTSPPs y demostrar el tiempo que tardan las temperaturas en exceder los l\u00edmites designados en caso de fallo de energ\u00eda.\n\n3. **\u00bfQu\u00e9 tipo de sistemas de alarma se recomiendan para los refrigeradores y congeladores utilizados en el almacenamiento de TTSPPs?**\n   - Respuesta: Se recomienda un sistema de alarma visual y/o audible, que puede integrarse con un dispositivo de monitoreo de temperatura continuo port\u00e1til, as\u00ed como un sistema autom\u00e1tico de marcado telef\u00f3nico o de alerta por SMS para notificar al personal de guardia cuando se activa una alarma fuera del horario laboral.", "prev_section_summary": "### Temas clave:\n\n1. **Monitoreo de Humedad**:\n   - Sistemas y dispositivos de monitoreo de humedad en habitaciones controladas por temperatura para almacenar productos farmac\u00e9uticos y terap\u00e9uticos (TTSPPs).\n   - Requisitos de precisi\u00f3n y calibraci\u00f3n de sensores.\n   - Ubicaci\u00f3n de sensores para monitorear niveles de humedad en condiciones desfavorables.\n   - Registro de datos de humedad con frecuencia m\u00ednima.\n   - Documentaci\u00f3n accesible para cada posici\u00f3n de sensor.\n   - Operaci\u00f3n independiente en caso de fallos de energ\u00eda.\n\n2. **Sistemas de Alarmas de Temperatura**:\n   - Sistemas de alarma para habitaciones controladas por temperatura, c\u00e1maras fr\u00edas, congeladores y refrigeradores.\n   - Especificaciones de precisi\u00f3n y calibraci\u00f3n de sensores de temperatura.\n   - Ubicaci\u00f3n de sensores para monitorear temperaturas en condiciones desfavorables.\n   - Alarmas visuales y auditivas para alertar sobre temperaturas fuera de rango.\n\n### Entidades:\n\n- **TTSPPs**: Productos farmac\u00e9uticos y terap\u00e9uticos que requieren condiciones espec\u00edficas de almacenamiento.\n- **Sensores**: Dispositivos utilizados para medir humedad y temperatura, con requisitos espec\u00edficos de precisi\u00f3n y ubicaci\u00f3n.\n- **Documentaci\u00f3n**: Registros necesarios para cada sensor que deben ser accesibles.\n- **Alarmas**: Sistemas de alerta que incluyen alarmas visuales y auditivas para condiciones de temperatura inadecuadas.\n\n### Resumen:\nEl documento de la OMS establece requisitos m\u00ednimos para el monitoreo de humedad y sistemas de alarma de temperatura en el almacenamiento de TTSPPs. Se detallan especificaciones sobre la precisi\u00f3n y calibraci\u00f3n de los sensores, su ubicaci\u00f3n para evitar interferencias, la frecuencia de registro de datos y la necesidad de documentaci\u00f3n accesible. Adem\u00e1s, se enfatiza la importancia de que los sistemas contin\u00faen operando de manera independiente durante cortes de energ\u00eda.", "excerpt_keywords": "Keywords: temperature control, humidity monitoring, alarm systems, TTSPPs, storage qualification"}}, "f6d4527f-9ca5-40f7-bacd-c2fb6f4b955f": {"node_ids": ["9f77e6d9-e8ca-4ab9-8714-cbb068e314ef"], "metadata": {"page_label": "357", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "increase loading or affect air circulation, or when changes are made to the refrigeration equipment, such as a change in the set point. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\nQualification may not be required for equipment which requires little or no site assembly or commissioning, such as vaccine refrigerators and freezers that have been independently tested and found suitable for the storage of TTSPPs. Independent testing must be carried out between the chosen set points and under the ambient temperature conditions to which the equipment will be exposed during operation. Prequalified equipment of this type must be correctly installed in each location in accordance with written guidance.\n\n*Reason:* To ensure that labelled TTSPP temperatures can be maintained during long-term storage and that the facility can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n### 4.8 Cleanliness of temperature-controlled stores\n\nImplement a cleaning and decontamination programme for all temperature-controlled rooms:\n\n- Ensure that floor areas are fully accessible for cleaning. Do not store goods directly on the floor.\n- Do not permit storage of any non-pharmaceutical products except transport-related items such as icepacks, gel packs and the like.\n- Do not allow the accumulation of dust, dirt and waste, including packaging waste.\n- Take precautions against spillage or breakage, and cross-contamination.\n- Do not allow accumulation of frost and ice, particularly ice contaminated by spillages.\n- Collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers, arising from spillage or breakage.\n\n### 4.9 Refrigeration equipment maintenance\n\nImplement a maintenance programme for all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers:\n\n- Carry out regular planned preventive maintenance on all temperature-controlling equipment.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Calificaci\u00f3n y Recalificaci\u00f3n de Equipos de Refrigeraci\u00f3n**: Se establece que la calificaci\u00f3n de equipos de refrigeraci\u00f3n, como refrigeradores y congeladores de vacunas, puede no ser necesaria si han sido probados de manera independiente y se instalan correctamente. Sin embargo, se debe considerar la recalificaci\u00f3n si hay variaciones inexplicables en la temperatura o humedad.\n\n2. **Limpieza de Almacenes Controlados por Temperatura**: Se requiere un programa de limpieza y descontaminaci\u00f3n para las habitaciones controladas por temperatura, asegurando que no se acumulen residuos, polvo o productos no farmac\u00e9uticos, y que se tomen precauciones contra derrames y contaminaci\u00f3n cruzada.\n\n3. **Mantenimiento de Equipos de Refrigeraci\u00f3n**: Se debe implementar un programa de mantenimiento preventivo regular para todos los equipos de control de temperatura, garantizando su funcionamiento adecuado y la protecci\u00f3n de los productos farmac\u00e9uticos sensibles a la temperatura.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 condiciones espec\u00edficas deben cumplirse para que no sea necesaria la calificaci\u00f3n de los refrigeradores y congeladores de vacunas?**\n   - Respuesta: La calificaci\u00f3n puede no ser necesaria si los equipos requieren poca o ninguna ensambladura o puesta en marcha en el sitio, han sido probados de manera independiente y se consideran adecuados para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n\n2. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para evitar la acumulaci\u00f3n de contaminantes en las habitaciones controladas por temperatura?**\n   - Respuesta: Se deben implementar medidas como asegurar que las \u00e1reas del suelo sean completamente accesibles para la limpieza, no permitir el almacenamiento de productos no farmac\u00e9uticos, evitar la acumulaci\u00f3n de polvo y residuos, y tomar precauciones contra derrames y contaminaci\u00f3n cruzada.\n\n3. **\u00bfQu\u00e9 tipo de mantenimiento se recomienda para los equipos de refrigeraci\u00f3n y con qu\u00e9 frecuencia debe realizarse?**\n   - Respuesta: Se recomienda llevar a cabo un mantenimiento preventivo planificado regularmente en todos los equipos de control de temperatura, incluyendo habitaciones fr\u00edas, congeladores y refrigeradores, para asegurar su correcto funcionamiento y la protecci\u00f3n de los TTSPPs.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Sistemas de Alarma**:\n   - Se recomienda la instalaci\u00f3n de sistemas de alarma visual y/o audible para refrigeradores y congeladores utilizados en el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - Se sugiere un sistema autom\u00e1tico de marcado telef\u00f3nico o de alerta por SMS para notificar al personal de guardia cuando se activa una alarma fuera del horario laboral.\n\n2. **Alarmas de Humedad**:\n   - Se deben proporcionar sistemas de alarma de humedad en habitaciones controladas por temperatura que almacenan TTSPPs que requieren un ambiente con control de humedad.\n   - Los sensores de humedad deben cumplir con especificaciones m\u00ednimas, incluyendo precisi\u00f3n de \u00b1 5% de humedad relativa, calibraci\u00f3n adecuada y ubicaci\u00f3n estrat\u00e9gica para monitorear los niveles de humedad.\n\n3. **Calificaci\u00f3n de Almacenes Controlados por Temperatura**:\n   - Es necesario calificar nuevas \u00e1reas de almacenamiento controladas por temperatura y nuevos equipos de refrigeraci\u00f3n antes de que se vuelvan operativos.\n   - La calificaci\u00f3n debe incluir la demostraci\u00f3n del perfil de temperatura del aire, la definici\u00f3n de zonas no aptas para el almacenamiento de TTSPPs y la evaluaci\u00f3n del tiempo que tardan las temperaturas en exceder los l\u00edmites designados en caso de fallo de energ\u00eda.\n\n4. **Prevenci\u00f3n de P\u00e9rdidas**:\n   - La implementaci\u00f3n de estos sistemas y procedimientos tiene como objetivo principal la prevenci\u00f3n de p\u00e9rdidas en el almacenamiento de productos sensibles a la temperatura y humedad.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sensores de Humedad**: Dispositivos utilizados para monitorear la humedad en ambientes controlados.\n- **Sistemas de Alarma**: Mecanismos para alertar sobre cambios en las condiciones de almacenamiento.\n- **Calificaci\u00f3n de Almacenes**: Proceso de validaci\u00f3n de \u00e1reas de almacenamiento y equipos de refrigeraci\u00f3n.", "excerpt_keywords": "Keywords: refrigeration, temperature-controlled storage, maintenance, cleanliness, qualification"}}, "4407880f-81c8-44ad-b4f5-4d725cbbb5ca": {"node_ids": ["6257a5f0-a145-452e-99b4-ef5978999f7a"], "metadata": {"page_label": "358", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Make arrangements to ensure that emergency maintenance is carried out within a time period that does not place TTSPPs at risk of damage.\n- Ensure that there is a contingency plan to move products stored in non-functioning equipment to a safe location before damage to the product occurs in the event that equipment cannot be repaired in a timely manner.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* Loss prevention.\n\n## 4.10 Calibration and verification of control and monitoring devices\n\n### 4.10.1 Calibration of temperature control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified. Calibration should demonstrate the accuracy of the unit across the entire temperature range over which the device is designed to be used. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.2 Calibration of humidity control and monitoring devices\n\nCalibrate devices against a certified, traceable reference standard at least once a year unless otherwise justified. Single-use devices that are supplied with a manufacturer\u2019s calibration certificate do not need to be re-calibrated.\n\n### 4.10.3 Alarm equipment verification\n\nCheck functionality of temperature and humidity alarms at least once every six months at the designated set points.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that labelled TTSPP storage temperatures and humidity control can be maintained during long-term storage and that the store can demonstrate to the regulatory authorities and other interested parties that due diligence has been observed.\n\n## 5. Materials handling\n\n### 5.1 Materials handling equipment\n\nWhere powered materials handling equipment is used in temperature-controlled rooms, cold rooms or freezer rooms, select equipment which is certified for safe use in confined spaces.\n\n*Reason:* Protection of the workforce.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Mantenimiento de Equipos y Planificaci\u00f3n de Contingencias**: Se enfatiza la importancia de realizar mantenimiento de emergencia en equipos que almacenan productos sensibles, asegurando que no se pongan en riesgo. Adem\u00e1s, se requiere un plan de contingencia para mover productos a un lugar seguro si el equipo no puede ser reparado a tiempo.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos de Control**: Se establecen directrices para la calibraci\u00f3n de dispositivos de control de temperatura y humedad, que deben realizarse al menos una vez al a\u00f1o. Tambi\u00e9n se requiere la verificaci\u00f3n de alarmas de temperatura y humedad cada seis meses para garantizar el cumplimiento de las normativas.\n\n3. **Manejo de Materiales**: Se especifica que el equipo de manejo de materiales utilizado en habitaciones controladas por temperatura debe estar certificado para su uso seguro en espacios confinados, priorizando la protecci\u00f3n del personal.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse si un equipo de almacenamiento de productos no funciona y no puede ser reparado a tiempo?**\n   - El contexto menciona que se debe tener un plan de contingencia para mover los productos almacenados en equipos no funcionales a una ubicaci\u00f3n segura antes de que ocurra da\u00f1o al producto.\n\n2. **\u00bfCon qu\u00e9 frecuencia deben calibrarse los dispositivos de control de temperatura y humedad, y qu\u00e9 excepciones existen?**\n   - Los dispositivos deben calibrarse al menos una vez al a\u00f1o, a menos que se justifique lo contrario. Los dispositivos de un solo uso que vienen con un certificado de calibraci\u00f3n del fabricante no necesitan ser recalibrados.\n\n3. **\u00bfQu\u00e9 tipo de equipo de manejo de materiales se debe utilizar en habitaciones controladas por temperatura?**\n   - Se debe seleccionar equipo de manejo de materiales que est\u00e9 certificado para su uso seguro en espacios confinados, especialmente en habitaciones controladas por temperatura, c\u00e1maras fr\u00edas o congeladores, para proteger al personal.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Calificaci\u00f3n y Recalificaci\u00f3n de Equipos de Refrigeraci\u00f3n**:\n   - **Condiciones para la no calificaci\u00f3n**: Equipos que requieren poca o ninguna ensambladura, que han sido probados independientemente y son adecuados para el almacenamiento de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - **Importancia de la recalificaci\u00f3n**: Necesaria si hay variaciones inexplicables en la temperatura o humedad.\n\n2. **Limpieza de Almacenes Controlados por Temperatura**:\n   - **Programa de limpieza y descontaminaci\u00f3n**: Debe incluir la accesibilidad de las \u00e1reas del suelo, prohibici\u00f3n de almacenamiento de productos no farmac\u00e9uticos, y medidas contra la acumulaci\u00f3n de residuos y contaminaci\u00f3n cruzada.\n   - **Precauciones**: Evitar acumulaciones de polvo, derrames y hielo contaminado.\n\n3. **Mantenimiento de Equipos de Refrigeraci\u00f3n**:\n   - **Programa de mantenimiento preventivo**: Debe ser regular y planificado para todos los equipos de control de temperatura, incluyendo habitaciones fr\u00edas, congeladores y refrigeradores.\n   - **Objetivo**: Asegurar el correcto funcionamiento de los equipos y la protecci\u00f3n de los TTSPPs.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Equipos de Refrigeraci\u00f3n**: Refrigeradores y congeladores, especialmente para vacunas.\n- **Regulaciones**: Normativas que deben cumplirse para demostrar el debido cuidado ante autoridades regulatorias.\n\n### Razones Fundamentales\n- **Protecci\u00f3n de TTSPPs**: Asegurar que las temperaturas etiquetadas se mantengan durante el almacenamiento a largo plazo.\n- **Seguridad de los Trabajadores**: Minimizar riesgos de da\u00f1os y contaminaci\u00f3n por derrames o roturas.", "excerpt_keywords": "Keywords: maintenance, calibration, temperature control, materials handling, TTSPPs"}}, "4ce659d3-381d-4df8-aa5f-a829932d760e": {"node_ids": ["4a87a2e1-9e07-4e33-a630-d5ab40fe196e"], "metadata": {"page_label": "359", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6. Transport and delivery\n\n## 6.1 Normative references\n\n- Directive 94/62/EC. *European Parliament and Council Directive of 20 December 1994 on packaging and packaging waste*. 1994.\n- EN 13428:2004. *Packaging. Requirements specific to manufacturing and composition. Prevention by source reduction*.\n- EN 13430:2004. *Packaging. Requirements for packaging recoverable by material recycling*.\n- EN 13431:2004. *Packaging. Requirements for packaging recoverable in the form of energy recovery, including specification of minimum inferior calorific value*.\n- EN 13432:2000. *Packaging. Requirements for packaging recoverable through composting and biodegradation. Test scheme and evaluation criteria for the final acceptance of packaging*.\n- IATA Perishable Cargo Regulations Chapter 17, 9th Edition, July 2009. *Isothermal and refrigerating containers for health products \u2014 Thermal performance qualification method*.\n- ISTA \u2014 5B: *Focused Simulation Guide for Thermal Performance Testing of Temperature Controlled Transport Packaging*.\n- ISTA \u2014 7D: *Thermal Controlled Transport Packaging for Parcel Delivery System Shipment. Basic Requirements: atmospheric conditioning, vibration and shock testing*.\n- WHO Technical Report Series, No. 937, 2006. Annex 5: *Good distribution practices for pharmaceutical products*.\n\n## 6.2 Product stability profiles\n\nTransport TTSPPs in such a manner that transport temperatures meet local regulatory requirements at the sending and receiving sites and/or so that temperature excursions above or below the manufacturer\u2019s labelled storage temperature range do not adversely affect product quality. Product stability data must demonstrate the acceptable temperature excursion time during transport.\n\n*Reason*: Protection of TTSPPs against degradation.\n\n## 6.3 Transport route profiling and qualification\n\nProfile and qualify transport routes:\n\n- Select the most suitable methods for protecting TTSPPs against anticipated ambient temperature and humidity conditions throughout the year.\n- Use suitable methods, including published standards, weather data, laboratory tests and field tests to select suitable transport equipment and shipping containers.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) en su Serie de Informes T\u00e9cnicos No. 961 aborda el transporte y la entrega de productos farmac\u00e9uticos, enfatizando la importancia de cumplir con las normativas y est\u00e1ndares para garantizar la estabilidad y calidad de los productos durante el transporte. Se mencionan referencias normativas clave, la necesidad de mantener las temperaturas adecuadas durante el transporte y la importancia de perfilar y calificar las rutas de transporte para proteger los productos farmac\u00e9uticos de condiciones ambientales adversas.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las normativas espec\u00edficas que deben seguirse para el transporte de productos farmac\u00e9uticos seg\u00fan el documento de la OMS?**\n   - Esta pregunta se centra en las referencias normativas mencionadas en la secci\u00f3n 6.1, que incluyen directivas y est\u00e1ndares relevantes para el embalaje y el transporte de productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 datos de estabilidad del producto son necesarios para garantizar que los TTSPPs no se degraden durante el transporte?**\n   - Esta pregunta se relaciona con la secci\u00f3n 6.2, donde se discute la importancia de demostrar la aceptabilidad de las excursiones de temperatura durante el transporte y c\u00f3mo esto afecta la calidad del producto.\n\n3. **\u00bfQu\u00e9 m\u00e9todos se recomiendan para perfilar y calificar las rutas de transporte de productos farmac\u00e9uticos?**\n   - Esta pregunta se refiere a la secci\u00f3n 6.3, que detalla los m\u00e9todos adecuados para proteger los productos farmac\u00e9uticos de las condiciones ambientales, incluyendo el uso de datos meteorol\u00f3gicos y pruebas de laboratorio.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Mantenimiento de Equipos**:\n   - Importancia de realizar mantenimiento de emergencia para evitar da\u00f1os a productos sensibles.\n   - Necesidad de un plan de contingencia para mover productos a un lugar seguro si el equipo no puede ser reparado a tiempo.\n\n2. **Calibraci\u00f3n y Verificaci\u00f3n de Dispositivos**:\n   - **Dispositivos de Control de Temperatura**: Deben calibrarse al menos una vez al a\u00f1o, salvo justificaci\u00f3n en contrario. Los dispositivos de un solo uso con certificado de calibraci\u00f3n del fabricante no requieren recalibraci\u00f3n.\n   - **Dispositivos de Control de Humedad**: Igual que los de temperatura, deben calibrarse anualmente, con la misma excepci\u00f3n para dispositivos de un solo uso.\n   - **Verificaci\u00f3n de Alarmas**: Se debe comprobar la funcionalidad de alarmas de temperatura y humedad cada seis meses.\n\n3. **Manejo de Materiales**:\n   - Equipos de manejo de materiales en habitaciones controladas por temperatura deben estar certificados para su uso seguro en espacios confinados, priorizando la protecci\u00f3n del personal.\n\n### Entidades Clave\n- **TTSPPs**: Productos sensibles a la temperatura.\n- **Dispositivos de Control**: Incluyen dispositivos de temperatura y humedad.\n- **Equipos de Manejo de Materiales**: Equipos utilizados en entornos controlados.\n- **Reguladores**: Autoridades que supervisan el cumplimiento normativo.\n\n### Razones Clave\n- **Prevenci\u00f3n de P\u00e9rdidas**: Mantener la integridad de los productos almacenados.\n- **Protecci\u00f3n del Personal**: Asegurar un entorno de trabajo seguro.", "excerpt_keywords": "Keywords: transport, pharmaceutical products, temperature control, regulatory compliance, product stability"}}, "f1482fd4-de70-4fdb-90be-5cbac8082963": {"node_ids": ["e237ac85-56f2-43d1-89d4-18a7ffaa893c"], "metadata": {"page_label": "360", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.4 Temperature-controlled transport\n\n## 6.4.1 Air and sea transport\n\nEnsure that any carrier contracted to transport TTSPPs by air or by sea operates under the terms of a formal service level agreement (SLA) drawn up between the parties. The carrier is to be made responsible for maintaining load temperatures within the transport temperature profile defined for each product.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\nTemperature-controlled road vehicles operated by common carriers\n\nTemperature control in vehicles operated by a common carrier must be qualified and the details and responsibilities for this process should be set out in a formal SLA drawn up between the parties.\n\n*Reason:* To ensure that the carrier is made responsible for maintaining load temperatures within the transport temperature profile defined for each product and that compliance can be demonstrated to the contracting organization, the regulatory authorities and other interested parties.\n\n## 6.4.2 Temperature-controlled road vehicles generally\n\nEnsure that temperature-controlled road vehicles used for the transport of TTSPPs are:\n\n- capable of maintaining the temperature range defined by the system set points over the full annual ambient temperature range experienced over known distribution routes and when the vehicle is in motion, or parked with the main engine stopped;\n- equipped with a low temperature protection circuit in cold climates where there is a risk of breaching the low temperature set point for TTSPPs that are damaged by exposure to low temperatures;\n- equipped with calibrated temperature monitoring devices with sensors located at points representing temperature extremes;\n- equipped with alarms to alert the driver in the event of temperature excursions and/or refrigeration unit failure;\n- fitted with doors with security seals and/or security locks that protect against unauthorized access during transit;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el transporte controlado por temperatura de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Se enfatiza la importancia de establecer acuerdos de nivel de servicio (SLA) con los transportistas, ya sea por aire, mar o carretera, para garantizar que se mantengan las temperaturas adecuadas durante el transporte. Adem\u00e1s, se detallan las caracter\u00edsticas que deben tener los veh\u00edculos de transporte por carretera, incluyendo la capacidad de mantener rangos de temperatura, dispositivos de monitoreo, alarmas y medidas de seguridad.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 medidas deben incluirse en un SLA para el transporte de TTSPPs por aire o mar?**\n   - El SLA debe incluir la responsabilidad del transportista de mantener las temperaturas de carga dentro del perfil de temperatura definido para cada producto, as\u00ed como la capacidad de demostrar el cumplimiento a la organizaci\u00f3n contratante y a las autoridades regulatorias.\n\n2. **\u00bfCu\u00e1les son las caracter\u00edsticas esenciales que deben tener los veh\u00edculos de transporte por carretera para TTSPPs?**\n   - Los veh\u00edculos deben ser capaces de mantener el rango de temperatura definido, estar equipados con un circuito de protecci\u00f3n contra bajas temperaturas, tener dispositivos de monitoreo calibrados, alarmas para alertar sobre excursiones de temperatura y contar con medidas de seguridad como sellos y cerraduras en las puertas.\n\n3. **\u00bfPor qu\u00e9 es importante que los transportistas sean responsables de mantener las temperaturas de carga durante el transporte de TTSPPs?**\n   - Es crucial para garantizar la integridad y eficacia de los productos farmac\u00e9uticos, as\u00ed como para cumplir con las regulaciones y demostrar el cumplimiento a las partes interesadas, incluyendo organizaciones contratantes y autoridades regulatorias.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n 6: Transporte y entrega\n\n1. **Normativas y Referencias Normativas**:\n   - Se enumeran diversas directivas y est\u00e1ndares que regulan el embalaje y el transporte de productos farmac\u00e9uticos, incluyendo:\n     - **Directiva 94/62/EC**: Relativa al embalaje y residuos de embalaje.\n     - **Normas EN**: Que abordan requisitos espec\u00edficos para el embalaje, reciclaje y biodegradaci\u00f3n.\n     - **Regulaciones IATA**: Para el transporte de carga perecedera.\n     - **Normas ISTA**: Para pruebas de rendimiento t\u00e9rmico en embalajes controlados por temperatura.\n     - **Informe T\u00e9cnico de la OMS No. 937**: Buenas pr\u00e1cticas de distribuci\u00f3n para productos farmac\u00e9uticos.\n\n2. **Perfiles de Estabilidad del Producto**:\n   - Se enfatiza la necesidad de transportar productos farmac\u00e9uticos (TTSPPs) manteniendo las temperaturas adecuadas seg\u00fan las regulaciones locales y las especificaciones del fabricante.\n   - Se requiere demostrar que las excursiones de temperatura durante el transporte no afectan negativamente la calidad del producto.\n\n3. **Perfilado y Calificaci\u00f3n de Rutas de Transporte**:\n   - Se deben perfilar y calificar las rutas de transporte para proteger los TTSPPs de condiciones ambientales adversas.\n   - Se recomienda seleccionar m\u00e9todos adecuados basados en est\u00e1ndares publicados, datos meteorol\u00f3gicos, y pruebas de laboratorio y de campo para elegir el equipo de transporte y los contenedores de env\u00edo apropiados.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Directivas y Normas**: Incluyen la Directiva 94/62/EC, normas EN, regulaciones IATA, y normas ISTA.\n- **TTSPPs**: T\u00e9rmino que se refiere a productos farmac\u00e9uticos que requieren condiciones espec\u00edficas de transporte.\n- **Condiciones Ambientales**: Factores como temperatura y humedad que pueden afectar la calidad de los productos durante el transporte. \n\nEste resumen destaca la importancia de seguir normativas espec\u00edficas y de implementar pr\u00e1cticas adecuadas para asegurar la calidad y estabilidad de los productos farmac\u00e9uticos durante su transporte.", "excerpt_keywords": "Keywords: temperature-controlled transport, TTSPPs, service level agreement, temperature monitoring, pharmaceutical logistics"}}, "db3bf11d-3918-4f14-a8f6-93e14ff03324": {"node_ids": ["b5e365a0-7a8c-4505-83fb-df4d965cb6c3"], "metadata": {"page_label": "361", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- qualified as defined in clause 6.6; and\n- regularly calibrated and maintained and records kept to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.4.3 Transport of controlled TTSPPs and TTSPPs with high illicit value\n\nEnsure that controlled TTSPPs and TTSPPs with high illicit value are transported in the following manner:\n\n- Transport practices comply with all relevant local legislation and regulations.\n- Vehicles are equipped with lockable doors and an intruder alarm.\n- Vehicles use unique seal lock indicating devices such as cable seal locks with unique identifiers that are tamper-resistant to protect against unauthorized access during transit. [^14]\n- Security-cleared delivery drivers are employed.\n- All deliveries are documented and tracked.\n- Signed dispatch and arrival records are kept.\n- Shipments are fitted with security equipment appropriate to the product being transported and the assessed security risk, such as global positioning system (GPS) devices located in the vehicle and/or hidden in the product.\n- Drivers are informed about the perishability of the product and the maximum acceptable transport time.\n\n*Reason:* To prevent theft and misappropriation of this category of TTSPP and to ensure the security and safety of the driver.\n\n### 6.5 Temperature and humidity control and monitoring during transit\n\n#### 6.5.1 Temperature control in temperature-controlled road vehicles\n\nProvide thermostatic temperature control systems for all temperature-controlled vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- system able continuously to maintain air temperatures within the set point limits throughout the validated storage volume defined in clause 6.6;\n- control sensors accurate to \u00b1 0.5 \u00b0C;\n- control sensors calibrated as described in clause 6.7.1;\n\n[^14]: Refer to ISO/PAS 17712: *Freight containers \u2014 Mechanical seals.*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Transporte de TTSPPs Controlados**: El documento establece directrices espec\u00edficas para el transporte de productos terap\u00e9uticos y de salud (TTSPPs) controlados y de alto valor il\u00edcito, enfatizando la necesidad de cumplir con la legislaci\u00f3n local, asegurar los veh\u00edculos y documentar todas las entregas para prevenir el robo y garantizar la seguridad.\n\n2. **Control de Temperatura y Humedad**: Se requiere que los veh\u00edculos utilizados para el transporte de TTSPPs mantengan un control de temperatura adecuado, con sistemas que aseguren que las temperaturas se mantengan dentro de los l\u00edmites establecidos y que los sensores de control sean precisos y calibrados.\n\n3. **Mantenimiento de Registros y Cumplimiento**: Es fundamental mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura, as\u00ed como documentaci\u00f3n de las entregas, para demostrar el cumplimiento ante las autoridades reguladoras.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos m\u00ednimos para los sistemas de control de temperatura en veh\u00edculos de transporte de TTSPPs?**\n   - Respuesta: Los sistemas deben ser capaces de mantener continuamente las temperaturas del aire dentro de los l\u00edmites establecidos, contar con sensores de control precisos a \u00b1 0.5 \u00b0C y estar calibrados seg\u00fan lo descrito en la cl\u00e1usula 6.7.1.\n\n2. **\u00bfQu\u00e9 medidas de seguridad se deben implementar para el transporte de TTSPPs con alto valor il\u00edcito?**\n   - Respuesta: Se deben utilizar veh\u00edculos con puertas cerradas con llave y alarmas, dispositivos de sellado \u00fanicos y resistentes a manipulaciones, emplear conductores con autorizaci\u00f3n de seguridad, documentar y rastrear todas las entregas, y equipar los env\u00edos con dispositivos de seguridad adecuados, como GPS.\n\n3. **\u00bfPor qu\u00e9 es importante mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura?**\n   - Respuesta: Es crucial para demostrar el cumplimiento de las regulaciones ante las autoridades y otras partes interesadas, asegurando que los TTSPPs se transporten de manera segura dentro de los perfiles de temperatura definidos.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Transporte controlado por temperatura**: La secci\u00f3n se centra en el transporte de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs) y la necesidad de mantener condiciones adecuadas durante su transporte.\n\n2. **Acuerdos de nivel de servicio (SLA)**: Se enfatiza la importancia de establecer SLAs formales con los transportistas, tanto para el transporte a\u00e9reo como mar\u00edtimo, donde se detalla la responsabilidad del transportista de mantener las temperaturas de carga dentro de los perfiles definidos para cada producto.\n\n3. **Veh\u00edculos de transporte por carretera**: Se describen las caracter\u00edsticas esenciales que deben tener los veh\u00edculos de transporte por carretera, incluyendo:\n   - Capacidad para mantener el rango de temperatura definido.\n   - Circuito de protecci\u00f3n contra bajas temperaturas.\n   - Dispositivos de monitoreo de temperatura calibrados.\n   - Alarmas para alertar sobre excursiones de temperatura o fallos en la unidad de refrigeraci\u00f3n.\n   - Medidas de seguridad como sellos y cerraduras en las puertas.\n\n4. **Responsabilidad del transportista**: Se subraya la importancia de que los transportistas sean responsables de mantener las temperaturas adecuadas, lo cual es crucial para la integridad y eficacia de los TTSPPs, as\u00ed como para cumplir con las regulaciones y demostrar el cumplimiento a las partes interesadas.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Transportistas**: Empresas o individuos encargados del transporte de TTSPPs.\n- **Organizaci\u00f3n contratante**: Entidad que contrata los servicios de transporte.\n- **Autoridades regulatorias**: Organismos que supervisan el cumplimiento de normativas relacionadas con el transporte de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: TTSPPs, temperature control, transport security, compliance, calibration"}}, "8f3b27ee-2718-4801-a25a-a0ce32d59729": {"node_ids": ["8c7c56d5-e107-45c6-9e62-83b65a4dcf4c"], "metadata": {"page_label": "362", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- control sensors located to control worst-case temperatures in order to maximize available safe storage volume;\n- control sensors positioned in the return air stream; and\n- control sensors independent of the temperature monitoring system.\n\n### 6.5.2 Temperature monitoring in temperature-controlled road vehicles\n\nProvide air temperature monitoring systems and devices for vehicles used to transport TTSPPs. Comply with the following minimum requirements:\n\n- monitoring sensors accurate to \u00b1 0.5 \u00b0C;\n- monitoring sensors calibrated as described in clause 6.7.2;\n- monitoring sensors located to monitor worst-case temperatures within the qualified storage zone defined in clause 6.6;\n- monitoring sensors positioned so as to monitor worst-case positions;\n- provide a temperature record with a minimum recording frequency of six times per hour for each sensor position;[^15] and\n- provide documentation which can be stored and accessed.\n\nEstablish transit temperature specifications and document transit temperatures for every internal and external shipment.\n\n### 6.5.3 Humidity monitoring in temperature-controlled road vehicles\n\nPreferably provide humidity monitoring systems and devices for temperature-controlled vehicles which are used to transport TTSPPs that require a humidity-controlled environment. Systems and devices should comply with the following minimum requirements:\n\n- sensors accurate to \u00b1 5% RH;\n- sensors calibrated as described in clause 6.7.3;\n- sensors located to monitor worst-case humidity levels within the qualified storage zone defined in clause 6.6;\n- sensors positioned so as to be minimally affected by transient events such as door opening;\n- provide a humidity record with a minimum recording frequency of six times per hour for each sensor position; and\n- provide documentation which can be stored and accessed.\n\nEstablish transit humidity specifications and document transit humidity conditions for internal and external shipments where required.\n\n[^15]: Recording frequency should take account of the storage capacity of the data logger and the expected transport period.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monitoreo de Temperatura en Veh\u00edculos de Transporte**: Se establecen requisitos espec\u00edficos para los sistemas de monitoreo de temperatura en veh\u00edculos que transportan productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs). Esto incluye la precisi\u00f3n de los sensores, su calibraci\u00f3n, ubicaci\u00f3n y frecuencia de registro de datos.\n\n2. **Monitoreo de Humedad en Veh\u00edculos de Transporte**: Se detallan las especificaciones para los sistemas de monitoreo de humedad en veh\u00edculos que transportan TTSPPs que requieren un ambiente controlado en t\u00e9rminos de humedad. Se especifican los requisitos de precisi\u00f3n, calibraci\u00f3n, ubicaci\u00f3n y frecuencia de registro de los sensores de humedad.\n\n3. **Documentaci\u00f3n y Especificaciones de Tr\u00e1nsito**: Se enfatiza la importancia de establecer especificaciones de temperatura y humedad durante el tr\u00e1nsito, as\u00ed como la necesidad de documentar estas condiciones para cada env\u00edo interno y externo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las ubicaciones recomendadas para instalar los sensores de temperatura en veh\u00edculos de transporte de TTSPPs para garantizar la monitorizaci\u00f3n de las temperaturas m\u00e1s desfavorables?**\n   - Esta pregunta busca informaci\u00f3n sobre la ubicaci\u00f3n estrat\u00e9gica de los sensores, que no se detalla en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para el registro de las condiciones de temperatura y humedad durante el transporte de TTSPPs, y c\u00f3mo debe ser accesible?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de documentaci\u00f3n que pueden no estar claramente definidos en otras fuentes.\n\n3. **\u00bfQu\u00e9 consideraciones deben tenerse en cuenta al establecer las especificaciones de temperatura y humedad para el tr\u00e1nsito de productos farmac\u00e9uticos sensibles?**\n   - Esta pregunta busca profundizar en los factores que influyen en la definici\u00f3n de las especificaciones de tr\u00e1nsito, que pueden no ser evidentes en otras partes del texto o en documentos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transporte de TTSPPs Controlados y de Alto Valor Il\u00edcito**:\n   - Se establecen directrices para el transporte seguro de productos terap\u00e9uticos y de salud (TTSPPs) que son controlados o tienen un alto valor il\u00edcito.\n   - Se enfatiza la necesidad de cumplir con la legislaci\u00f3n local y de implementar medidas de seguridad adecuadas.\n\n2. **Requisitos de Seguridad para el Transporte**:\n   - Los veh\u00edculos deben tener puertas cerradas con llave, alarmas, y dispositivos de sellado \u00fanicos y resistentes a manipulaciones.\n   - Se requiere que los conductores tengan autorizaci\u00f3n de seguridad y que todas las entregas sean documentadas y rastreadas.\n\n3. **Control de Temperatura y Humedad**:\n   - Los veh\u00edculos de transporte deben contar con sistemas de control de temperatura que mantengan las condiciones adecuadas durante el transporte.\n   - Los sensores de control deben ser precisos (\u00b1 0.5 \u00b0C) y calibrados regularmente.\n\n4. **Mantenimiento de Registros**:\n   - Es fundamental mantener registros de calibraci\u00f3n y mantenimiento de los sistemas de control de temperatura, as\u00ed como documentaci\u00f3n de las entregas, para demostrar el cumplimiento ante las autoridades reguladoras.\n\n### Entidades Clave\n- **TTSPPs**: Productos terap\u00e9uticos y de salud.\n- **Legislaci\u00f3n Local**: Normativas que regulan el transporte de productos controlados.\n- **Dispositivos de Seguridad**: Incluyen alarmas, sellos de seguridad y sistemas GPS.\n- **Conductores**: Personal de entrega que debe estar autorizado y capacitado.\n- **Sensores de Control**: Equipos utilizados para monitorear la temperatura en los veh\u00edculos de transporte. \n\nEste resumen destaca la importancia de la seguridad, el cumplimiento normativo y el control de condiciones durante el transporte de productos sensibles.", "excerpt_keywords": "Keywords: temperature monitoring, humidity monitoring, TTSPPs, transport regulations, sensor calibration"}}, "c0ba0514-3b1d-4937-b612-8adbf59142e5": {"node_ids": ["864e23a5-35f8-4088-b8ea-cd1147bdbc2e"], "metadata": {"page_label": "363", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 6.5.4 Temperature monitoring in passive and active shipping containers\n\nUse chemical or electronic freeze indicators, electronic loggers (with or without alarms) and/or other suitable indicators to monitor temperature and/or humidity exposure during internal distribution. Preferably use these devices for external distribution. Monitor and document indicator status upon arrival.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n## 6.6 Qualification of temperature-controlled road vehicles\n\nWhere temperature-controlled vehicles are directly owned and/or operated, qualify each vehicle before it becomes operational, wherever possible. The qualification procedure should:\n\n- Demonstrate that the air temperature distribution is maintained within the limits specified throughout the temperature-controlled compartment for both air and product temperatures for commonly used load layouts and at the ambient temperature extremes anticipated during normal operation over known routes;\n- Demonstrate the humidity distribution throughout the temperature-controlled compartment for commonly used load layouts, where products are being transported that require a humidity-controlled environment;\n- Define zones within the vehicle\u2019s payload area which should not be packed with TTSPPs (for example areas in close proximity to cooling coils or cold air streams);\n- Demonstrate the time taken for temperatures to exceed the designated maximum in the event that the temperature-controlling unit fails; and\n- Document the qualification exercise.\n\nAn alternative approach is to perform an initial full qualification on each trailer/refrigeration unit type combined with an installation qualification (IQ) for each example when a new vehicle becomes operational.\n\nCarry out additional qualification exercises whenever significant modifications are made to the vehicle. Consider the need for requalification whenever temperature and/or humidity monitoring shows unexplained variability that is greater than normal.\n\n**Reason:** To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Monitoreo de temperatura en contenedores de env\u00edo**: Se enfatiza la importancia de utilizar indicadores qu\u00edmicos o electr\u00f3nicos para monitorear la temperatura y la humedad durante la distribuci\u00f3n de productos termol\u00e1biles. Esto es crucial para garantizar que los productos se transporten dentro de un perfil de temperatura seguro y que se pueda demostrar el cumplimiento ante las autoridades regulatorias.\n\n2. **Calificaci\u00f3n de veh\u00edculos de transporte controlados por temperatura**: Se detalla un procedimiento de calificaci\u00f3n para veh\u00edculos que transportan productos sensibles a la temperatura. Este procedimiento incluye la evaluaci\u00f3n de la distribuci\u00f3n de temperatura y humedad, la identificaci\u00f3n de zonas prohibidas para el empaquetado de productos, y la documentaci\u00f3n de los resultados de la calificaci\u00f3n. Se menciona la necesidad de requalificaci\u00f3n tras modificaciones significativas o variaciones inexplicables en el monitoreo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de dispositivos se recomienda utilizar para el monitoreo de temperatura y humedad en la distribuci\u00f3n interna y externa de productos termol\u00e1biles?**\n   - Respuesta: Se recomienda el uso de indicadores qu\u00edmicos o electr\u00f3nicos, loggers electr\u00f3nicos (con o sin alarmas) y otros indicadores adecuados para monitorear la temperatura y/o la humedad durante la distribuci\u00f3n.\n\n2. **\u00bfCu\u00e1les son los criterios que deben cumplirse durante la calificaci\u00f3n de un veh\u00edculo de transporte controlado por temperatura?**\n   - Respuesta: La calificaci\u00f3n debe demostrar que la distribuci\u00f3n de temperatura y humedad se mantiene dentro de los l\u00edmites especificados, definir zonas dentro del \u00e1rea de carga que no deben ser empaquetadas con productos termol\u00e1biles, y documentar el ejercicio de calificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 acciones se deben tomar si se observa una variabilidad inexplicable en el monitoreo de temperatura y/o humedad?**\n   - Respuesta: Se debe considerar la necesidad de requalificaci\u00f3n del veh\u00edculo siempre que el monitoreo de temperatura y/o humedad muestre una variabilidad inexplicable que sea mayor de lo normal. Adem\u00e1s, se deben llevar a cabo ejercicios de calificaci\u00f3n adicionales siempre que se realicen modificaciones significativas en el veh\u00edculo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monitoreo de Temperatura en Veh\u00edculos de Transporte**:\n   - **Objetivo**: Asegurar el transporte seguro de productos farmac\u00e9uticos sensibles a la temperatura (TTSPPs).\n   - **Requisitos**:\n     - Sensores de temperatura con precisi\u00f3n de \u00b1 0.5 \u00b0C.\n     - Calibraci\u00f3n de sensores seg\u00fan especificaciones.\n     - Ubicaci\u00f3n estrat\u00e9gica de sensores para monitorear temperaturas m\u00e1s desfavorables.\n     - Frecuencia m\u00ednima de registro de temperatura: seis veces por hora.\n     - Documentaci\u00f3n accesible y almacenable.\n\n2. **Monitoreo de Humedad en Veh\u00edculos de Transporte**:\n   - **Objetivo**: Controlar la humedad en veh\u00edculos que transportan TTSPPs que requieren un ambiente espec\u00edfico.\n   - **Requisitos**:\n     - Sensores de humedad con precisi\u00f3n de \u00b1 5% RH.\n     - Calibraci\u00f3n de sensores seg\u00fan especificaciones.\n     - Ubicaci\u00f3n de sensores para monitorear niveles de humedad m\u00e1s desfavorables.\n     - Frecuencia m\u00ednima de registro de humedad: seis veces por hora.\n     - Documentaci\u00f3n accesible y almacenable.\n\n3. **Especificaciones de Tr\u00e1nsito**:\n   - **Importancia**: Establecer y documentar especificaciones de temperatura y humedad para cada env\u00edo interno y externo.\n   - **Documentaci\u00f3n**: Se requiere un registro claro de las condiciones de temperatura y humedad durante el transporte.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles a la temperatura.\n- **Sensores**: Dispositivos utilizados para monitorear temperatura y humedad.\n- **Documentaci\u00f3n**: Registros que deben ser accesibles y almacenables para cumplir con los requisitos de transporte. \n\nEste resumen destaca la importancia de un monitoreo riguroso y la documentaci\u00f3n adecuada para garantizar la integridad de los productos farmac\u00e9uticos durante el transporte.", "excerpt_keywords": "Keywords: temperature monitoring, TTSPPs, qualification, humidity control, transportation compliance"}}, "04b5bf76-2147-49a9-9637-744810d0cdc2": {"node_ids": ["c5f408ff-3f6f-4247-a250-688732341413"], "metadata": {"page_label": "364", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.7 Calibration and verification of transport monitoring devices\n\n## 6.7.1 Calibration of transport temperature control devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.2 Calibration of transport temperature monitoring devices\nCalibrate devices against a certified, traceable reference standard at least once a year, unless otherwise justified.\n\n## 6.7.3 Calibration of transport humidity monitoring devices\nCalibrate devices against a certified, traceable, reference standard at least once a year, unless otherwise justified.\n\n## 6.7.4 Verification of transport alarm equipment\nCheck functionality of temperature and humidity alarms at the designated set points. Check functionality of security alarm systems. Carry out these checks at least once a year, unless otherwise justified.\n\nMaintain records to demonstrate compliance.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.8 Shipping containers\n\n## 6.8.1 Container selection generally\nSelect shipping containers that:\n\n- comply with applicable national and international standards relevant to the product type and the chosen transport route and mode(s);\n- protect personnel and the general public from hazards arising from spillage, leakage or excessive internal pressure;\n- protect the product being transported against mechanical damage and the anticipated ambient temperature range that will be encountered in transit; and\n- can be closed in a manner that allows the recipient of the consignment to establish that the product has not been tampered with during transport.\n\n*Reason:* Quality assurance and safety.\n\n## 6.8.2 Uninsulated containers\nEnsure that uninsulated containers are correctly used, in a manner which protects their contents:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las directrices para la calibraci\u00f3n y verificaci\u00f3n de dispositivos de monitoreo de transporte, as\u00ed como la selecci\u00f3n de contenedores de env\u00edo. Se enfatiza la importancia de calibrar dispositivos de control de temperatura y humedad al menos una vez al a\u00f1o y de verificar el funcionamiento de los sistemas de alarma. Adem\u00e1s, se establecen criterios para la selecci\u00f3n de contenedores que garanticen la seguridad y calidad de los productos durante el transporte.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1l es la frecuencia recomendada para la calibraci\u00f3n de dispositivos de monitoreo de temperatura y humedad en el transporte?**\n   - La calibraci\u00f3n de dispositivos de control de temperatura y humedad debe realizarse al menos una vez al a\u00f1o, a menos que se justifique lo contrario.\n\n2. **\u00bfQu\u00e9 criterios deben cumplirse al seleccionar contenedores de env\u00edo seg\u00fan las directrices de la OMS?**\n   - Los contenedores de env\u00edo deben cumplir con est\u00e1ndares nacionales e internacionales aplicables, proteger al personal y al p\u00fablico de peligros, resguardar el producto contra da\u00f1os mec\u00e1nicos y temperaturas extremas, y permitir que el destinatario verifique que el producto no ha sido manipulado.\n\n3. **\u00bfQu\u00e9 registros se deben mantener para demostrar el cumplimiento de las directrices de calibraci\u00f3n y verificaci\u00f3n?**\n   - Se deben mantener registros que demuestren la calibraci\u00f3n y verificaci\u00f3n de los dispositivos de monitoreo, as\u00ed como la funcionalidad de los sistemas de alarma, para asegurar que se cumplen las normativas y se puede demostrar la conformidad ante las autoridades reguladoras y otras partes interesadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Monitoreo de Temperatura en Contenedores de Env\u00edo**:\n   - **Dispositivos Recomendados**: Indicadores qu\u00edmicos o electr\u00f3nicos, loggers electr\u00f3nicos (con o sin alarmas) y otros indicadores adecuados.\n   - **Objetivo**: Asegurar que los productos termol\u00e1biles (TTSPPs) se transporten dentro de un perfil de temperatura seguro y demostrar cumplimiento ante autoridades regulatorias.\n\n2. **Calificaci\u00f3n de Veh\u00edculos de Transporte Controlados por Temperatura**:\n   - **Procedimiento de Calificaci\u00f3n**:\n     - Evaluar la distribuci\u00f3n de temperatura y humedad en el compartimento controlado por temperatura.\n     - Definir zonas prohibidas para el empaquetado de productos sensibles.\n     - Documentar los resultados de la calificaci\u00f3n.\n   - **Acciones Adicionales**: Realizar ejercicios de calificaci\u00f3n adicionales tras modificaciones significativas o si se observa variabilidad inexplicable en el monitoreo.\n\n3. **Importancia de la Documentaci\u00f3n**:\n   - La documentaci\u00f3n de los procedimientos de calificaci\u00f3n y monitoreo es crucial para demostrar el cumplimiento con las normativas y asegurar la seguridad en el transporte de productos termol\u00e1biles.\n\n### Entidades Clave\n- **TTSPPs**: Productos termol\u00e1biles que requieren un control estricto de temperatura y humedad durante el transporte.\n- **Regulaciones**: Normativas que deben cumplirse para garantizar la seguridad y eficacia en el transporte de productos sensibles.\n- **Veh\u00edculos de Transporte Controlados por Temperatura**: Veh\u00edculos dise\u00f1ados para mantener condiciones espec\u00edficas de temperatura y humedad durante el transporte.", "excerpt_keywords": "Keywords: calibration, transport monitoring, shipping containers, temperature control, compliance"}}, "3cf6a336-ea6b-454a-8c69-64330f430667": {"node_ids": ["5d0c05b6-e7bd-4a6d-be3c-fbb8693d6cf5"], "metadata": {"page_label": "365", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- transport uninsulated containers in a qualified temperature-controlled environment such as an actively or passively temperature-controlled vehicle;\n- ensure that the transport system is able to maintain the temperature of the TTSPP within the product\u2019s stability profile as stated by the product manufacturer and/or to maintain the TTSPP within the transit temperature specification requirements specified by the regulatory authorities at both the sending and receiving locations.\n\n*Reason:* Quality assurance and safety.\n\n### 6.8.3 Qualification of insulated passive containers\n\nQualify insulated passive containers, including any and all necessary ancillary packaging such as temperature stabilizing medium, dry ice, ice or gel packs, cool water packs or warm packs, phase change materials, partitions, bubble wrap and dunnage:\n\n- ensure that the qualified packaging system is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer. Container qualification should include full details of the packaging assembly, the thermal conditioning regime and the minimum and maximum shipping volume, weight and thermal mass that can safely be accommodated in the container. Qualification should also include the correct placement of temperature monitors where these are used;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can safely be transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.\n\n### 6.8.4 Qualification of active containers\n\nQualify active containers:\n\n- ensure that the container is capable of maintaining the TTSPP within the temperature range needed to meet the product stability profile as stated by the product manufacturer;\n- take account of the transport route and of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of arrival in the recipient\u2019s temperature-controlled store.\n\n*Reason:* To ensure that TTSPPs can be safely transported within the transport temperature profile defined for each product and that compliance can be demonstrated to the regulatory authorities and other interested parties.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (WHO - Technical Report Series 961) aborda la importancia de mantener la temperatura adecuada durante el transporte de productos termol\u00e1biles (TTSPP). Se detallan los requisitos para la calificaci\u00f3n de contenedores pasivos e activos, as\u00ed como la necesidad de asegurar que los sistemas de transporte mantengan la temperatura dentro de los perfiles de estabilidad del producto. Se enfatiza la importancia de cumplir con las especificaciones de temperatura establecidas por los fabricantes y las autoridades regulatorias, as\u00ed como la necesidad de documentar y demostrar el cumplimiento de estos requisitos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 elementos deben incluirse en la calificaci\u00f3n de contenedores pasivos para garantizar que mantengan la temperatura adecuada durante el transporte?**\n   - La calificaci\u00f3n debe incluir detalles sobre el ensamblaje del empaque, el r\u00e9gimen de acondicionamiento t\u00e9rmico, y el volumen, peso y masa t\u00e9rmica que el contenedor puede acomodar de manera segura. Tambi\u00e9n debe considerar la colocaci\u00f3n correcta de los monitores de temperatura.\n\n2. **\u00bfCu\u00e1les son las consideraciones clave al calificar contenedores activos para el transporte de TTSPP?**\n   - Es fundamental asegurarse de que el contenedor pueda mantener la temperatura dentro del rango necesario para cumplir con el perfil de estabilidad del producto, as\u00ed como tener en cuenta la ruta de transporte y el perfil de temperatura ambiental anticipado durante el transporte.\n\n3. **\u00bfPor qu\u00e9 es crucial demostrar el cumplimiento de los requisitos de temperatura durante el transporte de TTSPP ante las autoridades regulatorias?**\n   - Demostrar el cumplimiento es esencial para garantizar que los TTSPP se transporten de manera segura dentro del perfil de temperatura definido para cada producto, lo que a su vez asegura la calidad y la seguridad del producto, cumpliendo con las expectativas de los reguladores y otras partes interesadas.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Calibraci\u00f3n de dispositivos de monitoreo de transporte**:\n   - **Frecuencia**: Al menos una vez al a\u00f1o para dispositivos de control de temperatura y humedad, a menos que se justifique lo contrario.\n   - **Est\u00e1ndares**: Los dispositivos deben calibrarse contra un est\u00e1ndar de referencia certificado y trazable.\n\n2. **Verificaci\u00f3n de equipos de alarma de transporte**:\n   - **Funcionalidad**: Se debe verificar el funcionamiento de alarmas de temperatura, humedad y sistemas de seguridad al menos una vez al a\u00f1o.\n   - **Registros**: Es necesario mantener registros que demuestren el cumplimiento de estas verificaciones.\n\n3. **Selecci\u00f3n de contenedores de env\u00edo**:\n   - **Criterios**: Los contenedores deben cumplir con est\u00e1ndares nacionales e internacionales, proteger al personal y al p\u00fablico, resguardar el producto de da\u00f1os mec\u00e1nicos y temperaturas extremas, y permitir la verificaci\u00f3n de que no ha habido manipulaci\u00f3n durante el transporte.\n\n4. **Contenedores no aislados**:\n   - **Uso adecuado**: Se debe asegurar que los contenedores no aislados se utilicen correctamente para proteger su contenido.\n\n### Entidades clave:\n- **Dispositivos de monitoreo de temperatura y humedad**: Equipos que requieren calibraci\u00f3n y verificaci\u00f3n.\n- **Alarmas de temperatura y humedad**: Sistemas que deben ser funcionales y verificados.\n- **Contenedores de env\u00edo**: Elementos cr\u00edticos para el transporte seguro de productos.\n- **Normativas nacionales e internacionales**: Est\u00e1ndares que deben cumplirse en la selecci\u00f3n de contenedores.\n\n### Raz\u00f3n de las directrices:\nAsegurar que los productos sensibles a la temperatura y humedad (TTSPPs) sean transportados de manera segura y conforme a las regulaciones, garantizando la calidad y seguridad durante el transporte.", "excerpt_keywords": "Keywords: temperature control, transport qualification, TTSPP, passive containers, active containers"}}, "199872c4-c733-4e4a-85ee-01cf906c2615": {"node_ids": ["a1904806-ba76-4daf-8166-3e64d8f9c5e7"], "metadata": {"page_label": "366", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 6.9 Shipping container packing\n\nPack TTSPP shipping containers to:\n\n- the exact specified configuration to ensure that the correct TTSPP temperature range is maintained;\n- minimize the risk of theft and fraud and assure the recipient that the goods have not been tampered with while in transit, for example by using locked containers or shrink-wrapped pallets;\n- minimize the risk of mechanical damage during transport;\n- protect freeze-sensitive products against temperatures below 0 \u00b0C when frozen packs are used;\n- protect products against light, moisture and contamination or attack by microorganisms and pests;\n- protect products against adverse effects when dry ice is used as a coolant;\n- clearly label containers to identify the correct transport temperature range and to show correct orientation for handling; and\n- ensure that packages containing dangerous goods (including dry ice) are labelled in compliance with relevant transport regulations and requirements.\n\n*Reason:* To ensure that shipping containers are systematically used in the manner defined during the container qualification process and that this can be demonstrated to the regulatory authorities and other interested parties.\n\n# 6.10 Product handling during packing and transport\n\nHandle TTSPPs correctly during packing and transport:\n\n- pack TTSPPs in an area set aside for the assembly and packaging of these products as specified in clause 3.3.1;\n- take precautions against spillage or breakage, contamination and cross-contamination;\n- deliver TTSPPs to outside recipients by the most suitable mode(s) of transport available in order to minimize delivery time; and\n- ensure that patients receiving TTSPP deliveries are given clear advice on correct storage of the product before use.\n\n*Reason:* To maintain TTSPP quality during transport.\n\n# 6.11 Cleaning road vehicles and transport containers\n\nImplement a cleaning and decontamination programme for all road vehicles and reusable shipping containers used to transport TTSPPs:\n\n- ensure that all internal surfaces of load compartments are regularly cleaned;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla las mejores pr\u00e1cticas para el embalaje, manejo y limpieza de veh\u00edculos y contenedores de transporte de productos terap\u00e9uticos sensibles a la temperatura (TTSPP). Se enfatiza la importancia de mantener la temperatura adecuada, prevenir el robo y la contaminaci\u00f3n, y asegurar que los productos sean entregados en condiciones \u00f3ptimas. Tambi\u00e9n se menciona la necesidad de etiquetar correctamente los contenedores y seguir regulaciones espec\u00edficas para el transporte de mercanc\u00edas peligrosas.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que se deben tomar para proteger los productos sensibles a la temperatura durante el transporte?**\n   - Esta pregunta busca detalles sobre las pr\u00e1cticas de embalaje y las condiciones necesarias para mantener la calidad de los TTSPP, que no se encuentran f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de etiquetado es necesario para los contenedores que transportan productos peligrosos, y por qu\u00e9 es importante?**\n   - Esta pregunta se centra en la importancia del etiquetado adecuado y las regulaciones que deben seguirse, lo cual es crucial para la seguridad durante el transporte.\n\n3. **\u00bfQu\u00e9 procedimientos de limpieza se deben implementar para los veh\u00edculos y contenedores que transportan TTSPP, y con qu\u00e9 frecuencia deben realizarse?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre el programa de limpieza y desinfecci\u00f3n, que es fundamental para prevenir la contaminaci\u00f3n y asegurar la calidad del producto durante el transporte.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Transporte de Productos Termol\u00e1biles (TTSPP):** La secci\u00f3n se centra en la importancia de mantener la temperatura adecuada durante el transporte de productos que son sensibles a la temperatura.\n\n2. **Calificaci\u00f3n de Contenedores:**\n   - **Contenedores Pasivos:** Se requiere calificaci\u00f3n de contenedores aislados, incluyendo el uso de materiales estabilizadores de temperatura (hielo seco, gel packs, etc.), y la consideraci\u00f3n de factores como el volumen, peso y colocaci\u00f3n de monitores de temperatura.\n   - **Contenedores Activos:** Se enfatiza la necesidad de que estos contenedores mantengan la temperatura adecuada y consideren la ruta de transporte y el perfil de temperatura ambiental.\n\n3. **Cumplimiento Regulatorio:** Es crucial demostrar que se cumplen los requisitos de temperatura establecidos por los fabricantes y las autoridades regulatorias para garantizar la calidad y seguridad de los productos transportados.\n\n4. **Documentaci\u00f3n y Verificaci\u00f3n:** La calificaci\u00f3n de los contenedores debe incluir documentaci\u00f3n detallada que demuestre el cumplimiento de los est\u00e1ndares de temperatura y estabilidad del producto.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite directrices sobre el transporte de productos termol\u00e1biles.\n- **TTSPP (Productos Termol\u00e1biles):** Productos que requieren condiciones espec\u00edficas de temperatura durante el transporte.\n- **Contenedores Pasivos y Activos:** Tipos de contenedores utilizados para el transporte de TTSPP, cada uno con requisitos espec\u00edficos de calificaci\u00f3n.\n- **Reguladores y Autoridades:** Entidades que establecen y supervisan el cumplimiento de las normativas de transporte de productos sensibles a la temperatura.\n\nEste resumen destaca la importancia de la calificaci\u00f3n adecuada de los contenedores y el cumplimiento de las normativas para garantizar la seguridad y calidad de los productos durante su transporte.", "excerpt_keywords": "Keywords: TTSPP, shipping containers, temperature control, product handling, cleaning protocols"}}, "3cecdb73-bdbc-4f7b-b82d-4380b3c903ba": {"node_ids": ["5db4884c-878d-4a8a-8075-1e05e17f046d"], "metadata": {"page_label": "367", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- do not allow the accumulation of dust, dirt and waste, including packaging waste in load compartments, or in reusable shipping containers;\n- take precautions against spillage or breakage, and cross-contamination;\n- do not allow accumulation of frost and ice in refrigerated vehicles, particularly ice contaminated by spillages; and\n- collect waste in designated closed containers and arrange for safe disposal at frequent intervals.\n\nMaintain cleaning records for vehicles and reusable shipping containers to demonstrate compliance.\n\n*Reason:* Protection against damage and contamination of TTSPPs and hazards to workers arising from spillage or breakage.\n\n## 6.12 Transport of returned and recalled TTSPPs\n\n### 6.12.1 Transport of returned TTSPPs\n\nEnsure that returned TTSPPs are transported under the same conditions as those used for the initial delivery:\n\n- the sender and recipient must work together so that the product is maintained within the temperature range needed to meet the manufacturer\u2019s stated product stability profile;\n- take account of the anticipated ambient temperature profile over the duration of transport, measured from the point of departure to the point of return; and\n- quarantine returned TTSPPs in temperature-controlled storage pending a decision by the quality control department or qualified person to dispose of the product or to return it to stock.\n\n*Reason:* To ensure that returned and recalled TTSPPs are maintained within the correct transport temperature profile so that they can safely be re-stocked if a decision to do so is made.\n\n### 6.12.2 Transport of recalled TTSPPs\n\nEnsure that recalled TTSPPs are:\n\n- marked for disposal as either \u201crecalled\u201d or \u201cwithdrawn\u201d;\n- transported back from the recipient and quarantined under secure conditions pending a final decision on disposal as described in clause 8.6.3.\n\n## 7. Labelling\n\n### 7.1 Normative references\n\n- IATA Perishable Cargo Regulations Chapter 17th Edition, July 2009. Clauses 17.10.5 and 17.10.6.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda las directrices para el transporte de productos farmac\u00e9uticos y biol\u00f3gicos, espec\u00edficamente los productos terap\u00e9uticos y de salud p\u00fablica (TTSPPs). Se enfatiza la importancia de mantener condiciones adecuadas durante el transporte para evitar la contaminaci\u00f3n, el da\u00f1o y garantizar la seguridad de los trabajadores. Se detallan procedimientos para el transporte de TTSPPs devueltos y retirados, incluyendo la necesidad de mantener la temperatura adecuada y el manejo seguro de productos que han sido retirados del mercado. Tambi\u00e9n se menciona la importancia de la limpieza y el mantenimiento de registros para demostrar el cumplimiento de estas normativas.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1les son las medidas espec\u00edficas que deben tomarse para evitar la contaminaci\u00f3n y el da\u00f1o a los TTSPPs durante el transporte?**\n   - Respuesta: Se deben evitar la acumulaci\u00f3n de polvo, suciedad y desechos en los compartimentos de carga y contenedores reutilizables, tomar precauciones contra derrames y roturas, y no permitir la acumulaci\u00f3n de escarcha e hielo en veh\u00edculos refrigerados. Adem\u00e1s, se debe recolectar la basura en contenedores cerrados designados y disponer de ella de manera segura con frecuencia.\n\n2. **\u00bfQu\u00e9 procedimientos deben seguirse para el transporte de TTSPPs devueltos y c\u00f3mo se asegura su correcta conservaci\u00f3n?**\n   - Respuesta: Los TTSPPs devueltos deben transportarse bajo las mismas condiciones que se usaron para la entrega inicial, manteniendo la temperatura adecuada y considerando el perfil de temperatura ambiental durante el transporte. Adem\u00e1s, deben ser puestos en cuarentena en almacenamiento controlado por temperatura hasta que se tome una decisi\u00f3n sobre su disposici\u00f3n o reabastecimiento.\n\n3. **\u00bfQu\u00e9 etiquetado es necesario para los TTSPPs que han sido retirados del mercado y cu\u00e1les son los pasos a seguir para su transporte?**\n   - Respuesta: Los TTSPPs retirados deben estar marcados para su disposici\u00f3n como \"retirados\" o \"retirados del mercado\". Deben ser transportados de regreso desde el destinatario y puestos en cuarentena bajo condiciones seguras hasta que se tome una decisi\u00f3n final sobre su disposici\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Embalaje de Contenedores de Transporte**:\n   - Importancia de seguir configuraciones espec\u00edficas para mantener la temperatura adecuada de los productos terap\u00e9uticos sensibles a la temperatura (TTSPP).\n   - Medidas para prevenir el robo y la manipulaci\u00f3n de los productos durante el transporte, como el uso de contenedores cerrados y paletas envueltas.\n   - Protecci\u00f3n de los productos contra da\u00f1os mec\u00e1nicos, temperaturas extremas, luz, humedad, contaminaci\u00f3n, microorganismos y plagas.\n   - Etiquetado claro de los contenedores para indicar la temperatura de transporte y la orientaci\u00f3n correcta.\n   - Cumplimiento de regulaciones para el etiquetado de mercanc\u00edas peligrosas, incluyendo el hielo seco.\n\n2. **Manejo de Productos Durante el Embalaje y Transporte**:\n   - Protocolo para el embalaje de TTSPP en \u00e1reas designadas.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n   - Selecci\u00f3n de modos de transporte adecuados para minimizar el tiempo de entrega.\n   - Instrucciones claras para los pacientes sobre el almacenamiento correcto de los productos.\n\n3. **Limpieza de Veh\u00edculos y Contenedores de Transporte**:\n   - Implementaci\u00f3n de un programa de limpieza y desinfecci\u00f3n para veh\u00edculos y contenedores reutilizables.\n   - Mantenimiento regular de las superficies internas de los compartimentos de carga.\n\n### Entidades Clave:\n- **TTSPP**: Productos terap\u00e9uticos sensibles a la temperatura.\n- **Contenedores de Transporte**: Elementos utilizados para el env\u00edo de TTSPP.\n- **Regulaciones de Transporte**: Normativas que rigen el etiquetado y manejo de mercanc\u00edas peligrosas.\n- **Hielo Seco**: Material utilizado como refrigerante que requiere etiquetado espec\u00edfico.\n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas de embalaje, manejo y limpieza para garantizar la calidad y seguridad de los productos durante el transporte.", "excerpt_keywords": "Keywords: transporte, TTSPPs, contaminaci\u00f3n, limpieza, etiquetado"}}, "ff7d50f3-e153-44d6-82d6-25997e2a22b4": {"node_ids": ["256d9946-a0b5-4105-8909-8cf623f31d06"], "metadata": {"page_label": "368", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7.2 Labelling\n\n## 7.2.1 Labelling generally\n\nLabel internal shipping and external distribution containers containing TTSPPs as follows:\n\n- Identify the product in accordance with all national and international labelling requirements relevant to the container content, transport route and mode(s);\n- Identify hazardous products in accordance with relevant national and international labelling conventions; and\n- Indicate the appropriate temperature and humidity ranges within which the product is to be transported and/or stored.\n\n## 7.2.2 Labelling air-freighted shipments\n\nIn cases where TTSPPs are to be air-freighted, the package(s) should be labelled using the standard International Air Transport Association (IATA) time and temperature-sensitive symbol, in accordance with the conditions outlined in Chapter 17 of the IATA Perishable Cargo Regulations. Apply the label to the outer surface of individual shipping packages, overpacks or bulk containers.\n\n*Reason:* To ensure that products are correctly and safely handled at all points in the supply chain.\n\n# 8. Stock management\n\n## 8.1 Stock control systems\n\n### 8.1.1 General stock control systems and procedures\n\nTTSPP stock control systems and procedures meet the following minimum requirements:\n\n- Allow access only to authorized persons;\n- Record all receipts and dispatches;\n- Record batch numbers and expiry dates;\n- Record short-dated and expired products;\n- Record product status (i.e. released, quarantined, hold, reject);\n- Record all product returns, recalls, withdrawals, damage and disposals;\n- Manage the issue of products in EEFO order; and\n- Take regular physical inventories and reconcile stock records with the actual physical count. Investigate and report on stock discrepancies in accordance with agreed procedures. Preferably physical counts should be made at least twice a year.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la etiquetaci\u00f3n y gesti\u00f3n de existencias de productos farmac\u00e9uticos sensibles al tiempo y la temperatura (TTSPPs). Se establecen requisitos para la etiquetaci\u00f3n de envases, tanto para el transporte interno como para la distribuci\u00f3n externa, incluyendo la identificaci\u00f3n de productos y condiciones de almacenamiento. Adem\u00e1s, se describen los sistemas de control de existencias necesarios para garantizar la seguridad y la precisi\u00f3n en la gesti\u00f3n de estos productos.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos para la etiquetaci\u00f3n de productos peligrosos seg\u00fan el documento?**\n   - Respuesta: Los productos peligrosos deben ser identificados de acuerdo con las convenciones de etiquetado nacionales e internacionales relevantes.\n\n2. **\u00bfQu\u00e9 procedimientos se deben seguir para el control de existencias de TTSPPs seg\u00fan el documento?**\n   - Respuesta: Los procedimientos deben incluir el acceso restringido a personas autorizadas, el registro de todas las recepciones y despachos, el seguimiento de n\u00fameros de lote y fechas de caducidad, y la gesti\u00f3n de productos en orden EEFO (Primero en Expirar, Primero en Salir).\n\n3. **\u00bfQu\u00e9 s\u00edmbolo debe utilizarse para etiquetar env\u00edos a\u00e9reos de TTSPPs y qu\u00e9 regulaciones se deben seguir?**\n   - Respuesta: Se debe utilizar el s\u00edmbolo est\u00e1ndar de tiempo y temperatura sensible de la Asociaci\u00f3n Internacional de Transporte A\u00e9reo (IATA), siguiendo las condiciones establecidas en el Cap\u00edtulo 17 de las Regulaciones de Carga Perecedera de la IATA.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Transporte de Productos Terap\u00e9uticos y de Salud P\u00fablica (TTSPPs)**:\n   - Importancia de mantener condiciones adecuadas durante el transporte para evitar contaminaci\u00f3n y da\u00f1o.\n\n2. **Medidas de Prevenci\u00f3n**:\n   - Evitar acumulaci\u00f3n de polvo, suciedad y desechos en compartimentos de carga y contenedores reutilizables.\n   - Precauciones contra derrames, roturas y contaminaci\u00f3n cruzada.\n   - No permitir acumulaci\u00f3n de escarcha e hielo en veh\u00edculos refrigerados.\n   - Recolecci\u00f3n de desechos en contenedores cerrados y disposici\u00f3n segura frecuente.\n\n3. **Registros de Limpieza**:\n   - Mantener registros de limpieza para veh\u00edculos y contenedores reutilizables como evidencia de cumplimiento.\n\n4. **Transporte de TTSPPs Devueltos**:\n   - Deben transportarse bajo las mismas condiciones que la entrega inicial.\n   - Colaboraci\u00f3n entre remitente y destinatario para mantener la temperatura adecuada.\n   - Consideraci\u00f3n del perfil de temperatura ambiental durante el transporte.\n   - Cuarentena en almacenamiento controlado por temperatura hasta decisi\u00f3n sobre disposici\u00f3n o reabastecimiento.\n\n5. **Transporte de TTSPPs Retirados**:\n   - Marcado como \"retirados\" o \"retirados del mercado\".\n   - Transporte de regreso bajo condiciones seguras y cuarentena hasta decisi\u00f3n final sobre disposici\u00f3n.\n\n6. **Normativas de Etiquetado**:\n   - Referencias normativas de la IATA sobre el transporte de carga perecedera.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **TTSPPs (Productos Terap\u00e9uticos y de Salud P\u00fablica)**: Productos cuyo transporte se regula.\n- **IATA (Asociaci\u00f3n Internacional de Transporte A\u00e9reo)**: Referencia normativa para el transporte de carga perecedera. \n\nEste resumen destaca la importancia de las pr\u00e1cticas adecuadas en el transporte de productos sensibles, as\u00ed como las normativas que deben seguirse para garantizar la seguridad y calidad de los TTSPPs.", "excerpt_keywords": "Keywords: labelling, TTSPPs, stock management, IATA, temperature-sensitive"}}, "da6b2abe-804d-4b37-8bc8-6806c5b54a28": {"node_ids": ["b292d080-4542-432a-8a36-f101b395aa25"], "metadata": {"page_label": "369", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "## 8.1.2 Stock control procedures for controlled and hazardous TTSPPs\n\nIn addition to the requirements set out in clause 8.1.1, implement the following procedures:\n\n- Institute a customer verification process to ensure that all recipients of these products are authorized to receive them.\n- Maintain stock records which specifically identify products in these categories.\n- Carry out regular audits and make audit reports available to the responsible authorities.\n- Comply with all record-keeping procedures specified in local legislation and regulations. Retain product transaction and delivery records for at least the minimum time period required by local regulations.\n\n*Reason:* To ensure that accurate and complete stock records are kept at all times and to satisfy the requirements of the regulatory authorities.\n\n## 8.2 Incoming goods\n\n### 8.2.1 Product arrival checks\n\nCheck and record the following for all incoming TTSPPs:\n\n- product name, item code (identifier), strength, and batch/lot number;\n- quantity received against order;\n- name and address of the supplying site;\n- examine containers for tampering, damage or contamination;\n- examine expiry dates \u2014 accept short-dated products only if prior agreement has been reached with the supplier; do not accept products that have expired or which are so close to their expiry date that this date is likely to occur before use by the consumer;\n- delays encountered during transport;\n- status of any attached temperature recording device(s) and/or time/temperature indicators; and\n- verify that required storage and transport conditions have been maintained.\n\n### 8.2.2 Actions following arrival checks\n\n- Enter product details, including product name/number, strength, batch numbers, quantities received, expiry dates and acceptance status into the stock recording system.\n- Store checked goods under the correct temperature and security regime immediately upon receipt.\n- Quarantine defective or potentially defective products, products with incomplete or missing paperwork, products that experienced unacceptable temperature excursions during transport, or products suspected to be counterfeit. Do not release until checks have been completed satisfactorily.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece procedimientos para el control de existencias de productos farmac\u00e9uticos controlados y peligrosos (TTSPPs). Se enfatiza la importancia de verificar a los clientes, mantener registros precisos, realizar auditor\u00edas regulares y cumplir con la legislaci\u00f3n local. Adem\u00e1s, se detallan los pasos a seguir al recibir productos, incluyendo la verificaci\u00f3n de la informaci\u00f3n del producto, el estado de los envases y las condiciones de transporte. Se requiere que los productos defectuosos o sospechosos sean puestos en cuarentena hasta que se completen las verificaciones necesarias.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 procedimientos se deben implementar para verificar que los clientes est\u00e1n autorizados a recibir TTSPPs?**\n   - El documento menciona que se debe instituir un proceso de verificaci\u00f3n de clientes para asegurar que todos los destinatarios de estos productos est\u00e9n autorizados para recibirlos.\n\n2. **\u00bfCu\u00e1les son los criterios para aceptar productos con fechas de caducidad cercanas?**\n   - Se deben aceptar productos con fechas de caducidad cercanas solo si se ha llegado a un acuerdo previo con el proveedor; no se deben aceptar productos que ya han expirado o que est\u00e1n tan cerca de su fecha de caducidad que es probable que expiren antes de ser utilizados por el consumidor.\n\n3. **\u00bfQu\u00e9 acciones deben tomarse si se encuentran productos defectuosos o sospechosos durante la verificaci\u00f3n de llegada?**\n   - Los productos defectuosos o potencialmente defectuosos, aquellos con documentaci\u00f3n incompleta o faltante, productos que experimentaron excursiones de temperatura inaceptables durante el transporte, o productos sospechosos de ser falsificados deben ser puestos en cuarentena y no se deben liberar hasta que se completen las verificaciones de manera satisfactoria.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Etiquetado de Productos Sensibles al Tiempo y Temperatura (TTSPPs)**:\n   - **Requisitos Generales**: \n     - Identificaci\u00f3n del producto seg\u00fan normativas nacionales e internacionales.\n     - Identificaci\u00f3n de productos peligrosos conforme a convenciones de etiquetado.\n     - Indicaci\u00f3n de rangos de temperatura y humedad para transporte y almacenamiento.\n   - **Etiquetado de Env\u00edos A\u00e9reos**: \n     - Uso del s\u00edmbolo de tiempo y temperatura sensible de la IATA.\n     - Cumplimiento de las regulaciones de carga perecedera de la IATA.\n\n2. **Gesti\u00f3n de Existencias**:\n   - **Sistemas de Control de Existencias**:\n     - Acceso restringido a personal autorizado.\n     - Registro de recepciones, despachos, n\u00fameros de lote, fechas de caducidad y estado del producto.\n     - Gesti\u00f3n de productos en orden EEFO (Primero en Expirar, Primero en Salir).\n     - Realizaci\u00f3n de inventarios f\u00edsicos regulares y conciliaci\u00f3n de registros.\n\n3. **Objetivos**:\n   - Asegurar el manejo correcto y seguro de los productos a lo largo de la cadena de suministro.\n   - Mantener registros de existencias precisos y completos.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos sensibles al tiempo y la temperatura.\n- **IATA**: Asociaci\u00f3n Internacional de Transporte A\u00e9reo.\n- **Regulaciones de Carga Perecedera**: Normativas que rigen el transporte de productos perecederos.\n- **EEFO**: M\u00e9todo de gesti\u00f3n de existencias (Primero en Expirar, Primero en Salir). \n\nEste resumen destaca los aspectos esenciales relacionados con la etiquetaci\u00f3n y gesti\u00f3n de existencias de productos sensibles, as\u00ed como las normativas y procedimientos necesarios para su manejo adecuado.", "excerpt_keywords": "Keywords: stock control, TTSPPs, customer verification, product arrival checks, quarantine procedures"}}, "71390f54-4539-420e-9c33-20727114f280": {"node_ids": ["6a813e00-31d7-414f-812f-98ba8d15a54e"], "metadata": {"page_label": "370", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "All unacceptable temperature excursions should be evaluated to determine their effect on the product.\n\n- Report any defects to the supplying store or holder of the marketing authorization.\n- Do not transfer to saleable stock until all relevant disposition procedures have been completed.\n\n*Reason:* To ensure that incoming TTSPPs are in acceptable condition, accurately recorded and correctly stored and that defective and/or incorrect shipments are followed up with the supplier.\n\n## 8.3 Outgoing goods (external deliveries)\n\n### 8.3.1 Management of outgoing goods\n\nImplement outgoing goods procedures to ensure that:\n\n- Transport vehicle conformity, including conformity with SLA or quality assurance (QA) agreements, is checked before loading goods.\n- Expired products are never issued.\n- Products with short expiry dates are not issued unless the recipient accepts that they can be consumed before the expiry date is reached.\n- Products are distributed in strict EEFO order unless a product-based time-temperature exposure indicator, such as a vaccine vial monitor, demonstrates that a batch should be distributed ahead of its EEFO order.\n- Details of any temperature monitoring devices packed with the external distributions are recorded.\n- Details of outgoing products, including product name/number, strength, batch numbers, expiry dates and quantities distributed, are entered into the stock recording system.\n\n### 8.3.2 Actions following dispatch\n\nMonitor TTSPPs following dispatch in order to:\n\n- Trace products to their intended destination;\n- Record and retain records to provide assurance of goods arrival status. A suitable delivery report from the carrier is an acceptable alternative; and\n- Take appropriate action in the event of returns, recalls or complaints.\n\n*Reason:* To ensure that outgoing TTSPPs are in acceptable condition, that short-dated stock does not accumulate in the store and that evidence is kept to demonstrate that correct quantities are distributed and received in good condition.\n\n## 8.4 Product complaint procedures\n\nManage product complaints as follows:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) establece procedimientos para la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, centr\u00e1ndose en la evaluaci\u00f3n de excursiones de temperatura, la gesti\u00f3n de bienes salientes y la gesti\u00f3n de quejas de productos. Se enfatiza la importancia de asegurar que los productos lleguen en condiciones aceptables, se registren adecuadamente y se manejen de acuerdo con las normativas de calidad y seguridad.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 procedimientos deben seguirse para asegurar que los productos salientes no est\u00e9n caducados y se distribuyan correctamente?**\n   - Respuesta: Los procedimientos incluyen verificar la conformidad del veh\u00edculo de transporte, no emitir productos caducados, no emitir productos con fechas de caducidad cortas a menos que el destinatario acepte su uso, y distribuir productos en estricto orden EEFO, a menos que un indicador de exposici\u00f3n a temperatura demuestre que un lote debe ser distribuido antes de su orden EEFO.\n\n2. **\u00bfQu\u00e9 acciones se deben tomar en caso de que se detecten excursiones de temperatura inaceptables en los productos?**\n   - Respuesta: Se deben evaluar todas las excursiones de temperatura inaceptables para determinar su efecto en el producto, reportar cualquier defecto al almac\u00e9n proveedor o al titular de la autorizaci\u00f3n de comercializaci\u00f3n, y no transferir los productos a stock vendible hasta que se hayan completado todos los procedimientos de disposici\u00f3n relevantes.\n\n3. **\u00bfC\u00f3mo se debe gestionar el seguimiento de los productos despu\u00e9s de su despacho?**\n   - Respuesta: Se debe monitorear los productos para rastrear su destino, registrar y conservar los registros que proporcionen garant\u00eda sobre el estado de llegada de los bienes, y tomar las acciones apropiadas en caso de devoluciones, retiradas o quejas. Un informe de entrega adecuado del transportista es una alternativa aceptable para demostrar la llegada de los productos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Control de existencias de TTSPPs**:\n   - Se establecen procedimientos espec\u00edficos para el control de productos farmac\u00e9uticos controlados y peligrosos (TTSPPs).\n   - Importancia de la verificaci\u00f3n de clientes para asegurar que solo los autorizados reciban estos productos.\n\n2. **Mantenimiento de registros**:\n   - Se requiere llevar registros de existencias que identifiquen claramente los productos en estas categor\u00edas.\n   - Realizaci\u00f3n de auditor\u00edas regulares y disponibilidad de informes para las autoridades responsables.\n   - Cumplimiento de la legislaci\u00f3n local en cuanto a la conservaci\u00f3n de registros de transacciones y entregas.\n\n3. **Verificaci\u00f3n de llegada de productos**:\n   - Proceso de chequeo al recibir productos, que incluye la verificaci\u00f3n de nombre del producto, c\u00f3digo, fuerza, n\u00famero de lote, cantidad recibida, y estado de los envases.\n   - Examen de fechas de caducidad y condiciones de transporte, con criterios espec\u00edficos para aceptar productos con fechas cercanas a la caducidad.\n\n4. **Acciones tras la verificaci\u00f3n de llegada**:\n   - Registro de detalles del producto en el sistema de control de existencias.\n   - Almacenamiento inmediato de los productos bajo condiciones adecuadas de temperatura y seguridad.\n   - Cuarentena de productos defectuosos, sospechosos o con documentaci\u00f3n incompleta hasta que se completen las verificaciones necesarias.\n\n### Entidades clave:\n- **TTSPPs**: Productos farmac\u00e9uticos controlados y peligrosos.\n- **Regulaciones locales**: Normativas que rigen el manejo y almacenamiento de productos farmac\u00e9uticos.\n- **Autoridades responsables**: Entidades que supervisan el cumplimiento de las normativas y procedimientos establecidos. \n\nEste resumen destaca la importancia de los procedimientos de control y verificaci\u00f3n en la gesti\u00f3n de productos farmac\u00e9uticos, as\u00ed como la necesidad de cumplir con las regulaciones locales para garantizar la seguridad y eficacia de estos productos.", "excerpt_keywords": "Keywords: temperature excursions, outgoing goods management, product complaints, TTSPPs, quality assurance"}}, "6af8dcfd-c0d8-4fbd-8883-f09d41d4aed7": {"node_ids": ["4d6aef1d-f58f-49d0-a42e-db2d140b93b0"], "metadata": {"page_label": "371", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- If a product defect is discovered or suspected in a batch of TTSPPs, cooperate with the regulatory authority to determine whether other batches are affected and recall products if required to do so by the regulatory authority.\n- Where complaints or defects relate to a product or its packaging, immediately notify the holder of the marketing authorization for the product.\n- Where complaints or defects arise as a result of errors or omissions within the organization, immediately evaluate the causes and take remedial measures to prevent a recurrence.\n- Record all complaints and the remedial actions taken. Monitor and analyse trends in the complaint records.\n\n*Reason:* Protection of the public and of the reputation of the supplying organization.\n\n## 8.5 Suspect product procedures\n\n### 8.5.1 Suspect products\n\nImplement systems for identifying and managing suspect products found in the supply chain as follows:\n\n- Physically segregate any suspect TTSPPs found in the supply chain and store securely until legal investigations are complete.\n- Label them clearly as \u201cNot for use\u201d or other similar phrase;\n- Immediately notify the regulatory authority or authorities and any other relevant authorities, as well as the holder of the marketing authorization of the product.\n- Cooperate with regulatory authorities to assist with investigating the source of suspect products and implement appropriate remedial action(s).\n- Document the decision-making process for disposal or return of condemned or defective TTSPPs and make these records available to the relevant authorities.\n\n*Reason:* Protection of the public, protection of legitimate suppliers and manufacturers and conformity with regulatory requirements.\n\n## 8.6 Product return, recall, withdrawal and disposal procedures\n\n### 8.6.1 Return procedures\n\nManage product returns as follows:\n\n- Quarantine returned TTSPPs in a suitable temperature-controlled area and under the security conditions applicable to the product type.\n- Do not return to saleable stock unless storage and transport temperature conditions after dispatch from the distribution site have been fully verified and documented, including the return leg to the distribution site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Procedimientos para productos defectuosos**: El documento establece directrices sobre c\u00f3mo manejar productos defectuosos o sospechosos en la cadena de suministro, enfatizando la cooperaci\u00f3n con las autoridades regulatorias y la importancia de documentar todas las quejas y acciones correctivas.\n\n2. **Manejo de productos sospechosos**: Se describen los pasos a seguir para identificar y gestionar productos sospechosos, incluyendo la segregaci\u00f3n f\u00edsica, el etiquetado adecuado y la notificaci\u00f3n a las autoridades pertinentes.\n\n3. **Procedimientos de devoluci\u00f3n y retiro de productos**: Se detallan las medidas que deben tomarse al gestionar devoluciones de productos, incluyendo el almacenamiento en condiciones controladas y la verificaci\u00f3n de las condiciones de temperatura antes de devolver los productos a la venta.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para documentar la decisi\u00f3n de disposici\u00f3n de productos condenados o defectuosos?**\n   - El contexto menciona que se debe documentar el proceso de toma de decisiones para la disposici\u00f3n o retorno de productos condenados o defectuosos, y que estos registros deben estar disponibles para las autoridades relevantes.\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento y transporte que deben verificarse antes de devolver productos a la venta?**\n   - Se indica que no se deben devolver productos a la venta a menos que se hayan verificado y documentado completamente las condiciones de temperatura de almacenamiento y transporte despu\u00e9s del despacho desde el sitio de distribuci\u00f3n, incluyendo el trayecto de retorno.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar si se descubre un defecto en un lote de TTSPPs?**\n   - Se debe cooperar con la autoridad regulatoria para determinar si otros lotes est\u00e1n afectados y realizar un retiro de productos si as\u00ed lo requiere la autoridad regulatoria. Adem\u00e1s, se deben notificar inmediatamente las quejas o defectos al titular de la autorizaci\u00f3n de comercializaci\u00f3n del producto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Excursiones de Temperatura:**\n   - Evaluaci\u00f3n de excursiones de temperatura inaceptables para determinar su impacto en los productos.\n   - Reporte de defectos al almac\u00e9n proveedor o al titular de la autorizaci\u00f3n de comercializaci\u00f3n.\n   - Prohibici\u00f3n de transferir productos a stock vendible hasta completar los procedimientos de disposici\u00f3n.\n\n2. **Procedimientos para Bienes Salientes:**\n   - Verificaci\u00f3n de la conformidad del veh\u00edculo de transporte antes de cargar productos.\n   - Prohibici\u00f3n de emitir productos caducados.\n   - Emisi\u00f3n de productos con fechas de caducidad cortas solo con aceptaci\u00f3n del destinatario.\n   - Distribuci\u00f3n de productos en orden EEFO, salvo indicaciones de exposici\u00f3n a temperatura que justifiquen un cambio en el orden.\n   - Registro de detalles de dispositivos de monitoreo de temperatura y productos salientes en el sistema de registro de stock.\n\n3. **Acciones Posteriores al Despacho:**\n   - Monitoreo de productos para rastrear su destino.\n   - Registro y conservaci\u00f3n de documentos que aseguren el estado de llegada de los bienes.\n   - Acciones apropiadas en caso de devoluciones, retiradas o quejas, incluyendo la aceptaci\u00f3n de informes de entrega del transportista.\n\n4. **Procedimientos de Quejas de Productos:**\n   - Gesti\u00f3n de quejas de productos, aunque no se detallan en el extracto proporcionado.\n\n### Entidades Clave:\n- **TTSPPs:** Productos farmac\u00e9uticos y biol\u00f3gicos que requieren seguimiento y gesti\u00f3n.\n- **SLA:** Acuerdos de nivel de servicio relacionados con la calidad y conformidad del transporte.\n- **EEFO:** Estrategia de distribuci\u00f3n que prioriza la salida de productos con fechas de caducidad m\u00e1s cercanas.\n\n### Conclusi\u00f3n:\nEl documento enfatiza la importancia de seguir procedimientos rigurosos para asegurar la calidad y seguridad de los productos farmac\u00e9uticos y biol\u00f3gicos, desde su recepci\u00f3n hasta su distribuci\u00f3n y gesti\u00f3n de quejas.", "excerpt_keywords": "Keywords: product defects, regulatory authority, suspect products, product recall, temperature control"}}, "c92f3df4-199d-4d6b-838c-42881f5e3608": {"node_ids": ["21544908-0f1c-4360-b228-12b610aebc39"], "metadata": {"page_label": "372", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- Where appropriate, obtain written advice from the holder of the marketing authorization regarding handling and/or disposal of the returned TTSPP.\n- If returned stock is re-issued, distribute in EEFO order or in accordance with the exposure status of any product-mounted time-temperature indicator device.\n- Quarantine returned TTSPPs that have been exposed to unacceptable storage and/or transport temperatures and mark for disposal.\n- Maintain records of all returned TTSPPs.\n\n*Reason:* Protection of the public.\n\n### 8.6.2 Recall procedures\n\nManage product recalls as follows:\n\n- Conduct urgent and non-urgent TTSPP recalls in accordance with an agreed emergency plan.\n- Notify the local regulatory authority or authorities.\n- Notify overseas regulatory counterparts where the product has been exported.\n- Notify all affected customers as applicable.\n- Quarantine any remaining inventory of recalled TTSPPs and mark for further investigation before disposal.\n- Maintain records of all TTSPP recalls, including reconciliation of quantity sold, quantity returned, quantity remaining or quantity consumed.\n\n*Reason:* Protection of the public and conformity with regulatory requirements.\n\n### 8.6.3 Disposal procedures\n\nManage product awaiting board of survey or disposal as follows:\n\n- Ensure that rejected and/or recalled or withdrawn TTSPPs cannot be used, released or cause contamination to other products. Store separately from other products, in accordance with local regulations, to await destruction or return to the supplier.\n- Safely dispose of rejected and/or recalled/withdrawn products in accordance with local regulations, including where relevant, regulations covering the disposal of hazardous and controlled drugs.\n- Maintain disposal records.\n\n*Reason:* Protection of the public and the environment.\n\n### 8.7 Traceability or stock tracking\n\nEnsure that stock and distribution records enable traceability, or stock tracking, of TTSPPs from the point of supply to the end-user or patient.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos relacionados con la gesti\u00f3n de productos farmac\u00e9uticos, espec\u00edficamente los productos terap\u00e9uticos y de salud p\u00fablica (TTSPP). Se detallan las pr\u00e1cticas recomendadas para el manejo de devoluciones, retiros de productos, procedimientos de disposici\u00f3n y la importancia de la trazabilidad de los productos desde el punto de suministro hasta el usuario final. Se enfatiza la protecci\u00f3n del p\u00fablico y el cumplimiento de las regulaciones locales en cada uno de estos procesos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos deben seguirse para manejar un TTSPP que ha sido devuelto y ha estado expuesto a temperaturas inaceptables?**\n   - Respuesta: Los TTSPP devueltos que han estado expuestos a temperaturas inaceptables deben ser puestos en cuarentena y marcados para su disposici\u00f3n. Adem\u00e1s, se debe mantener un registro de todos los TTSPP devueltos.\n\n2. **\u00bfCu\u00e1les son las obligaciones de notificaci\u00f3n en caso de un retiro de producto no urgente?**\n   - Respuesta: En caso de un retiro de producto no urgente, se debe notificar a la autoridad reguladora local, a los contrapartes regulatorios en el extranjero si el producto ha sido exportado, y a todos los clientes afectados seg\u00fan sea aplicable.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para garantizar que los TTSPP rechazados o retirados no causen contaminaci\u00f3n a otros productos?**\n   - Respuesta: Los TTSPP rechazados o retirados deben almacenarse por separado de otros productos, de acuerdo con las regulaciones locales, para evitar su uso o liberaci\u00f3n, y deben estar preparados para su destrucci\u00f3n o devoluci\u00f3n al proveedor. Adem\u00e1s, se deben mantener registros de disposici\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Defectuosos**:\n   - Procedimientos para identificar y gestionar productos defectuosos o sospechosos en la cadena de suministro.\n   - Importancia de la cooperaci\u00f3n con las autoridades regulatorias para determinar el impacto en otros lotes y realizar retiros si es necesario.\n   - Notificaci\u00f3n inmediata al titular de la autorizaci\u00f3n de comercializaci\u00f3n sobre quejas o defectos.\n\n2. **Procedimientos para Productos Sospechosos**:\n   - Implementaci\u00f3n de sistemas para la identificaci\u00f3n y gesti\u00f3n de productos sospechosos.\n   - Segregaci\u00f3n f\u00edsica y almacenamiento seguro de productos sospechosos hasta que se completen las investigaciones legales.\n   - Etiquetado claro de los productos como \"No para uso\" y notificaci\u00f3n a las autoridades pertinentes.\n\n3. **Devoluciones y Retiro de Productos**:\n   - Procedimientos para gestionar devoluciones de productos, incluyendo el almacenamiento en \u00e1reas controladas por temperatura.\n   - Verificaci\u00f3n y documentaci\u00f3n de las condiciones de temperatura de almacenamiento y transporte antes de devolver productos a la venta.\n\n### Entidades Clave:\n- **TTSPPs**: Productos farmac\u00e9uticos y de salud en la cadena de suministro.\n- **Autoridades Regulatorias**: Entidades responsables de la supervisi\u00f3n y regulaci\u00f3n de productos en el mercado.\n- **Titular de la Autorizaci\u00f3n de Comercializaci\u00f3n**: Entidad que posee la autorizaci\u00f3n para comercializar un producto espec\u00edfico.\n\n### Razones para los Procedimientos:\n- Protecci\u00f3n del p\u00fablico y de la reputaci\u00f3n de la organizaci\u00f3n proveedora.\n- Protecci\u00f3n de proveedores y fabricantes leg\u00edtimos.\n- Conformidad con los requisitos regulatorios.", "excerpt_keywords": "Keywords: TTSPP, product recall, disposal procedures, traceability, regulatory compliance"}}, "734e37d3-a592-4ffc-875a-ce92d938e6a1": {"node_ids": ["8909c322-fe28-46c3-8315-959451b24de1"], "metadata": {"page_label": "373", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Traceability should include records of the temperature exposure of the product during internal shipping and storage. These records should include:\n\n- for incoming goods: status of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of receipt;\n- for outgoing goods: type of shipping indicators used (if any), status of product-based time-temperature indicators (if any) and physical condition of goods and time of dispatch.\n\nMonitor, record, and investigate discrepancies.\n\n*Reason:* To demonstrate that TTSPPs have been correctly distributed and to facilitate product recalls and detect theft and fraud.\n\n## 9. General procedures and record-keeping\n\n### 9.1 Emergencies and contingency planning\n\nMake contingency arrangements for the safe storage of TTSPPs in the event of emergencies, including, but not confined to:\n\n- extended power supply outages;\n- equipment failure; and\n- vehicle breakdown during transport of TTSPPs.\n\nPrepare action plans to deal with products subjected to temperature excursions.\n\nEnsure that the responsible staff know, and have rehearsed, the appropriate actions to be taken in the event of the identified emergency scenarios.\n\n*Reason:* Loss prevention.\n\n### 9.2 General record-keeping\n\n#### 9.2.1 Record-keeping\n\nMaintain comprehensive records and ensure that they are laid out in an orderly fashion and are easy to check.\n\nPaper records must be:\n\n- stored and maintained so that they are accessible and easily retrievable;\n- labelled, dated and filed for easy identification;\n- protected against deterioration and loss due to fire, flood or other hazards;\n- kept secure and protected against unauthorized access; and\n- signed and dated by authorized persons and not changed without due authorization.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la trazabilidad y el registro de productos farmac\u00e9uticos, enfatizando la importancia de mantener registros de la exposici\u00f3n a la temperatura durante el transporte y almacenamiento interno. Se detallan procedimientos para manejar emergencias y la planificaci\u00f3n de contingencias, as\u00ed como la necesidad de mantener registros organizados y accesibles. Se subraya la importancia de la monitorizaci\u00f3n y la investigaci\u00f3n de discrepancias para prevenir p\u00e9rdidas y facilitar la recuperaci\u00f3n de productos en caso de problemas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de indicadores de env\u00edo se deben registrar para los productos entrantes y salientes, y por qu\u00e9 es importante esta informaci\u00f3n?**\n   - Esta pregunta se centra en los detalles espec\u00edficos de los indicadores de env\u00edo y su relevancia para la trazabilidad y la seguridad del producto.\n\n2. **\u00bfCu\u00e1les son las acciones espec\u00edficas que el personal debe conocer y ensayar en caso de un corte de energ\u00eda prolongado o falla de equipo?**\n   - Esta pregunta busca informaci\u00f3n sobre los procedimientos de emergencia espec\u00edficos que deben seguirse, lo que no se detalla en el contexto.\n\n3. **\u00bfQu\u00e9 medidas se deben tomar para proteger los registros en papel contra la p\u00e9rdida o deterioro, y qui\u00e9n es responsable de su autorizaci\u00f3n?**\n   - Esta pregunta se enfoca en las pr\u00e1cticas de conservaci\u00f3n de registros y la responsabilidad de la autorizaci\u00f3n, aspectos que pueden no estar claramente definidos en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Manejo de Productos Devueltos (TTSPP)**:\n   - Obtener asesor\u00eda escrita del titular de la autorizaci\u00f3n de comercializaci\u00f3n sobre el manejo y disposici\u00f3n de TTSPP devueltos.\n   - Poner en cuarentena los TTSPP expuestos a temperaturas inaceptables y marcarlos para su disposici\u00f3n.\n   - Mantener registros de todos los TTSPP devueltos.\n\n2. **Procedimientos de Retiro de Productos**:\n   - Realizar retiros de TTSPP (urgentes y no urgentes) seg\u00fan un plan de emergencia acordado.\n   - Notificar a la autoridad reguladora local y a contrapartes regulatorias en el extranjero si el producto ha sido exportado.\n   - Informar a todos los clientes afectados y poner en cuarentena el inventario restante de productos retirados.\n\n3. **Procedimientos de Disposici\u00f3n**:\n   - Asegurar que los TTSPP rechazados o retirados no puedan ser utilizados o causar contaminaci\u00f3n a otros productos.\n   - Almacenar estos productos por separado y disponer de ellos de acuerdo con las regulaciones locales.\n   - Mantener registros de disposici\u00f3n.\n\n4. **Trazabilidad y Seguimiento de Stock**:\n   - Asegurar que los registros de stock y distribuci\u00f3n permitan la trazabilidad de los TTSPP desde el punto de suministro hasta el usuario final.\n\n### Entidades Clave:\n- **TTSPP**: Productos Terap\u00e9uticos y de Salud P\u00fablica.\n- **Autoridades Reguladoras**: Entidades responsables de la regulaci\u00f3n de productos farmac\u00e9uticos.\n- **Clientes Afectados**: Usuarios o entidades que han recibido productos retirados.\n- **Regulaciones Locales**: Normativas que rigen el manejo y disposici\u00f3n de productos farmac\u00e9uticos en cada jurisdicci\u00f3n. \n\n### Razones Fundamentales:\n- Protecci\u00f3n del p\u00fablico.\n- Conformidad con los requisitos regulatorios.\n- Protecci\u00f3n del medio ambiente.", "excerpt_keywords": "Keywords: traceability, temperature exposure, emergency planning, record-keeping, product recalls"}}, "777245b2-8aad-40f0-bae7-38559b41654f": {"node_ids": ["0e170f1e-debe-4b09-b766-725b6a3104ba"], "metadata": {"page_label": "374", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Computer records must be:\n\n- logically filed for easy identification and retrieval;\n- kept secure and protected against unauthorized access;\n- where feasible, manually signed, dated and scanned or when electronically archived dated, encrypted and with check-sum;[^16]\n- regularly backed-up and archived on media that are independent of the record-keeping computer system(s). Back-up media may be a separate secure server, a separate hard disc, a flash drive or other digital media appropriate to the scale of the operation.\n\n## 9.2.2 Content of records\n\nEnsure that the following traceability data is recorded for each TTSPP batch number, as applicable:\n\n- status of product on arrival;\n- temperature and humidity records including records of excursions outside labelled storage and/or transit temperature specification conditions;\n- general TTSPP stock transactions, including purchase and sale records;\n- controlled drug audits;\n- audits for products with high illicit value;\n- audits for hazardous products;\n- stock tracking;\n- return, recall, withdrawal and disposal reports, where relevant;\n- product complaint reports, where relevant; and\n- counterfeit product reports, where relevant.\n\nMaintain all records in accordance with local legislation and regulations.\n\n## 9.2.3 Record review and retention\n\nEnsure that records are reviewed and approved on a regular basis by a designated member of the quality management team. Ensure that records are accessible for review by end-users, the regulatory authority and other interested parties. Retain records for the minimum period required under local legislation, but for not less than three years.\n\n**Reason:** Internal quality control, transparency and external inspection by the regulatory authorities and other interested parties.\n\n[^16]: Electronic records from data loggers are usually encrypted and protected by check-sums. This ensures compliance with FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures; Final Rule (1997).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de registros inform\u00e1ticos en el \u00e1mbito de la salud, enfatizando la importancia de la organizaci\u00f3n, seguridad y accesibilidad de los registros. Se detallan los tipos de datos que deben ser registrados para cada lote de productos, as\u00ed como los procedimientos para la revisi\u00f3n y retenci\u00f3n de estos registros. Se subraya la necesidad de cumplir con la legislaci\u00f3n local y se menciona la importancia de la transparencia y el control de calidad interno.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomarse para garantizar la seguridad de los registros inform\u00e1ticos?**\n   - Los registros inform\u00e1ticos deben ser mantenidos de manera segura y protegidos contra accesos no autorizados. Adem\u00e1s, deben ser firmados manualmente, fechados y escaneados cuando sea posible, o, si est\u00e1n archivados electr\u00f3nicamente, deben estar fechados, encriptados y contar con un check-sum.\n\n2. **\u00bfQu\u00e9 tipo de datos de trazabilidad se deben registrar para cada n\u00famero de lote de TTSPP?**\n   - Se deben registrar datos como el estado del producto a la llegada, registros de temperatura y humedad, transacciones de stock, auditor\u00edas de drogas controladas, auditor\u00edas de productos de alto valor il\u00edcito, auditor\u00edas de productos peligrosos, seguimiento de stock, y reportes de devoluciones, retiradas, quejas de productos y productos falsificados.\n\n3. **\u00bfCu\u00e1l es el per\u00edodo m\u00ednimo de retenci\u00f3n de registros seg\u00fan las directrices de la OMS?**\n   - Los registros deben ser retenidos por el per\u00edodo m\u00ednimo requerido por la legislaci\u00f3n local, pero no por menos de tres a\u00f1os. Esto es esencial para el control de calidad interno y para facilitar la inspecci\u00f3n externa por parte de autoridades regulatorias y otras partes interesadas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Trazabilidad de Productos**:\n   - Importancia de mantener registros de la exposici\u00f3n a la temperatura durante el transporte y almacenamiento interno de productos farmac\u00e9uticos.\n   - Registros necesarios para productos entrantes y salientes, incluyendo indicadores de env\u00edo y condiciones f\u00edsicas.\n\n2. **Monitoreo y Discrepancias**:\n   - Necesidad de monitorear, registrar e investigar discrepancias en la distribuci\u00f3n de productos para prevenir robos y fraudes, as\u00ed como facilitar recuperaciones de productos.\n\n3. **Procedimientos Generales y Mantenimiento de Registros**:\n   - Planificaci\u00f3n de contingencias para el almacenamiento seguro de productos en caso de emergencias (cortes de energ\u00eda, fallas de equipo, descomposturas de veh\u00edculos).\n   - Preparaci\u00f3n de planes de acci\u00f3n para productos que experimenten excursiones de temperatura.\n\n4. **Mantenimiento de Registros**:\n   - Importancia de mantener registros organizados, accesibles y protegidos contra deterioro y acceso no autorizado.\n   - Requisitos para registros en papel: etiquetado, fecha, archivo, seguridad y autorizaci\u00f3n.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos que requieren trazabilidad.\n- **Indicadores de Env\u00edo**: Herramientas utilizadas para monitorear condiciones durante el transporte.\n- **Emergencias**: Situaciones que requieren planes de contingencia, como cortes de energ\u00eda y fallas de equipo.\n- **Registros**: Documentaci\u00f3n que debe ser mantenida de manera ordenada y segura. \n\nEste resumen destaca la importancia de la trazabilidad, el manejo de emergencias y la adecuada conservaci\u00f3n de registros en el contexto de la distribuci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: registros inform\u00e1ticos, trazabilidad, seguridad de datos, auditor\u00edas, retenci\u00f3n de registros"}}, "7397c490-5cea-4483-81e9-e9c467c85cd7": {"node_ids": ["671c90b1-1f49-49aa-82be-adb24fe18b2b"], "metadata": {"page_label": "375", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9.3 Temperature and humidity records\n\n## 9.3.1 Temperature records\n\nMonitor and record storage temperatures in all temperature-controlled rooms, cold rooms, freezer rooms, refrigerators and freezers, as follows:\n\n- Check and record temperatures at least twice daily \u2014 in the morning and evening \u2014 and preferably continuously.\n- Review temperature records monthly and take action to rectify systematic excursions.\n- Systematically file temperature records for each storage environment or piece of equipment to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n## 9.3.2 Humidity records\n\nWhen storing products which are adversely affected by high relative humidity (see clause 4.5.3), monitor and record humidity levels in all temperature-controlled rooms as follows:\n\n- Record humidity at least twice every 24 hours or preferably continuously.\n- Check humidity records daily.\n- Review humidity records monthly and take action to rectify systematic excursions.\n- Systematically file humidity records for each temperature-controlled room to ensure traceability. Keep records for at least one year after the end of the shelf-life of the stored material or product, or as long as required by national legislation.\n\n*Reason:* Internal quality assurance and availability of records for review by the regulatory authorities and other interested parties.\n\n# 10. Environmental management\n\n## 10.1 Normative references\n\n- ISO 14001: 2004. *Environmental management systems \u2014 Requirements with guidance for use*.\n- *The Montreal Protocol on Substances that Deplete the Ozone Layer*. UNEP, 2000.\n\n## 10.2 Environmental management of refrigeration equipment\n\nEnsure that all new refrigeration equipment for temperature-controlled storage and transport is specified to:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices sobre el monitoreo y registro de temperaturas y niveles de humedad en entornos de almacenamiento controlados, como c\u00e1maras fr\u00edas y congeladores. Se enfatiza la importancia de realizar registros sistem\u00e1ticos para asegurar la trazabilidad y cumplir con las normativas nacionales. Adem\u00e1s, se menciona la gesti\u00f3n ambiental de los equipos de refrigeraci\u00f3n, haciendo referencia a est\u00e1ndares como ISO 14001 y el Protocolo de Montreal.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfCon qu\u00e9 frecuencia se deben revisar los registros de temperatura y qu\u00e9 acciones se deben tomar si se detectan excursiones sistem\u00e1ticas?**\n   - Se deben revisar los registros de temperatura mensualmente y tomar medidas para rectificar cualquier excursi\u00f3n sistem\u00e1tica que se haya detectado.\n\n2. **\u00bfQu\u00e9 requisitos se establecen para el almacenamiento de productos que son sensibles a la humedad?**\n   - Para productos que se ven afectados por alta humedad relativa, se deben registrar los niveles de humedad al menos dos veces cada 24 horas, preferiblemente de manera continua, y revisar estos registros diariamente.\n\n3. **\u00bfCu\u00e1nto tiempo deben conservarse los registros de temperatura y humedad despu\u00e9s de que finalice la vida \u00fatil del material almacenado?**\n   - Los registros deben conservarse durante al menos un a\u00f1o despu\u00e9s de que finalice la vida \u00fatil del material o producto almacenado, o por el tiempo que exija la legislaci\u00f3n nacional.", "prev_section_summary": "### Temas Clave\n\n1. **Seguridad de Registros Inform\u00e1ticos**: Se enfatiza la necesidad de mantener los registros inform\u00e1ticos organizados, seguros y protegidos contra accesos no autorizados. Se sugiere la firma manual y el escaneo de documentos, as\u00ed como el uso de encriptaci\u00f3n y check-sums para registros electr\u00f3nicos.\n\n2. **Contenido de los Registros**: Se especifican los datos de trazabilidad que deben ser registrados para cada lote de productos, incluyendo el estado del producto, registros de temperatura y humedad, transacciones de stock, auditor\u00edas de drogas controladas y productos peligrosos, as\u00ed como reportes de quejas y productos falsificados.\n\n3. **Revisi\u00f3n y Retenci\u00f3n de Registros**: Se establece la importancia de la revisi\u00f3n regular de los registros por parte del equipo de gesti\u00f3n de calidad y la accesibilidad de estos para las partes interesadas. Se menciona que los registros deben ser retenidos por un m\u00ednimo de tres a\u00f1os, conforme a la legislaci\u00f3n local.\n\n4. **Cumplimiento Normativo**: Se destaca la necesidad de cumplir con la legislaci\u00f3n local y las regulaciones pertinentes, as\u00ed como la importancia de la transparencia y el control de calidad interno.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **TTSPP**: T\u00e9rmino relacionado con los productos que requieren trazabilidad.\n- **FDA**: Referencia a la normativa de la Administraci\u00f3n de Alimentos y Medicamentos de EE. UU. sobre registros electr\u00f3nicos y firmas electr\u00f3nicas.\n- **Equipo de Gesti\u00f3n de Calidad**: Grupo responsable de la revisi\u00f3n y aprobaci\u00f3n de registros.\n- **Partes Interesadas**: Incluye usuarios finales y autoridades regulatorias que pueden revisar los registros.\n\nEste resumen abarca los aspectos fundamentales y las entidades relevantes en la gesti\u00f3n de registros inform\u00e1ticos en el contexto de la salud, seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: temperature records, humidity records, environmental management, traceability, quality assurance"}}, "c298ebf1-9fc9-48be-9903-9dd238946b52": {"node_ids": ["179cac5f-1988-4b79-aba6-3e78642c9eda"], "metadata": {"page_label": "376", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management\n\n## 11.1 Normative References\n\n- ICH, 2005: *ICH Harmonized Tripartite Guideline: Quality risk management Q9*\n- ISO 9000:2005. *Quality management systems \u2014 Fundamentals and vocabulary*\n- ISO 9001:2008. *Quality management systems \u2014 Requirements*\n- ISO 9004:2000. *Quality management systems \u2014 Guidelines for performance improvements*\n- ISO 10005:2005. *Quality management systems \u2014 Guidelines for quality plans*\n- ISO 19011:2002. *Guidelines for quality and/or environmental management systems auditing*\n\n## 11.2 Organizational Structure\n\nEstablish, document and maintain an organizational structure for the TTSPP storage and shipping and distribution operations which clearly identifies all key management responsibilities, and the personnel who are accountable.\n\n*Reason:* Quality management.\n\n## 11.3 Quality Systems\n\n### 11.3.1 Quality System\n\nEstablish, document and maintain a quality system for the management of TTSPPs including, the following, as applicable:\n\n- standard quality system(s) and associated auditing procedures;\n- written procedures and specifications;\n- record storage, record retention and record destruction programme;\n- risk management;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" aborda la gesti\u00f3n de calidad en el contexto de los productos farmac\u00e9uticos y su distribuci\u00f3n. Se mencionan referencias normativas clave, la importancia de establecer una estructura organizativa clara para las operaciones de almacenamiento y distribuci\u00f3n, y la necesidad de implementar un sistema de calidad que incluya procedimientos, especificaciones y gesti\u00f3n de riesgos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las normas ISO mencionadas en el documento y qu\u00e9 aspectos de la gesti\u00f3n de calidad abordan?**\n   - Respuesta: Las normas ISO mencionadas son ISO 9000:2005 (Fundamentos y vocabulario de sistemas de gesti\u00f3n de calidad), ISO 9001:2008 (Requisitos de sistemas de gesti\u00f3n de calidad), ISO 9004:2000 (Directrices para mejoras del rendimiento), ISO 10005:2005 (Directrices para planes de calidad) e ISO 19011:2002 (Directrices para auditor\u00edas de sistemas de gesti\u00f3n de calidad y/o medioambientales).\n\n2. **\u00bfQu\u00e9 elementos son esenciales para establecer un sistema de calidad para la gesti\u00f3n de TTSPPs seg\u00fan el documento?**\n   - Respuesta: Los elementos esenciales incluyen sistemas de calidad est\u00e1ndar y procedimientos de auditor\u00eda asociados, procedimientos y especificaciones documentadas, un programa de almacenamiento, retenci\u00f3n y destrucci\u00f3n de registros, y gesti\u00f3n de riesgos.\n\n3. **\u00bfCu\u00e1l es la raz\u00f3n principal para establecer y mantener una estructura organizativa en las operaciones de almacenamiento y distribuci\u00f3n de TTSPPs?**\n   - Respuesta: La raz\u00f3n principal es asegurar una gesti\u00f3n de calidad efectiva, lo que implica identificar claramente todas las responsabilidades clave de gesti\u00f3n y el personal responsable en las operaciones.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Monitoreo de Temperatura y Humedad**:\n   - Se establecen directrices para el monitoreo y registro de temperaturas y niveles de humedad en entornos de almacenamiento controlados, como c\u00e1maras fr\u00edas y congeladores.\n   - La frecuencia de registro es al menos dos veces al d\u00eda para temperaturas y al menos dos veces cada 24 horas para humedad.\n\n2. **Acciones Correctivas**:\n   - Se requiere revisar los registros mensualmente y tomar medidas para rectificar cualquier excursi\u00f3n sistem\u00e1tica detectada en los registros de temperatura y humedad.\n\n3. **Conservaci\u00f3n de Registros**:\n   - Los registros de temperatura y humedad deben conservarse durante al menos un a\u00f1o despu\u00e9s de que finalice la vida \u00fatil del material o producto almacenado, o seg\u00fan lo exija la legislaci\u00f3n nacional.\n\n4. **Gesti\u00f3n Ambiental**:\n   - Se menciona la importancia de la gesti\u00f3n ambiental de los equipos de refrigeraci\u00f3n, haciendo referencia a normas como ISO 14001 y el Protocolo de Montreal.\n\n5. **Normativas y Referencias**:\n   - Se citan normativas relevantes que gu\u00edan la gesti\u00f3n ambiental y el manejo de sustancias que afectan la capa de ozono.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite las directrices.\n- **ISO 14001:2004**: Norma sobre sistemas de gesti\u00f3n ambiental.\n- **Protocolo de Montreal**: Acuerdo internacional sobre sustancias que agotan la capa de ozono. \n\nEste resumen destaca la importancia del monitoreo sistem\u00e1tico y la gesti\u00f3n ambiental en el almacenamiento de productos sensibles a la temperatura y humedad.", "excerpt_keywords": "Keywords: Quality Management, ISO Standards, Organizational Structure, Quality Systems, Risk Management"}}, "cb003069-afee-409f-80dc-4563de93186d": {"node_ids": ["014cbe89-7a69-46cb-8dba-bd96b8f77cd1"], "metadata": {"page_label": "377", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Quality Management System\n\n- calibration programme;\n- stability programme;\n- qualification and validation programme;\n- deviation and root cause investigation programme;\n- corrective and preventive action (CAPA) procedures;\n- training programme;\n- periodic temperature-controlled process assessment;\n- change control programme;\n- maintenance programme;\n- management controls;\n- product return and recall/withdrawal policies, including emergency recalls;\n- product complaint policies;\n- material destruction programme;\n- warehouse and storage programme;\n- shipping and distribution programme;\n- notification systems for regulatory agencies; boards of health and ministries of health; and\n- self-inspection programme and continuous quality improvement.\n\nCarry out annual reviews of the quality management system to ensure that it remains appropriate, relevant, and effective.\n\n*Reason:* Quality assurance.\n\n## 11.3.2 Self Inspections\n\nConduct regular self-inspections to ensure continuing compliance with quality management standards GSP and GDP; record results, follow-up with the corrective actions needed to rectify areas of non-compliance and document the changes made.\n\n## 11.3.3 Contractors Subject to Service Level Agreements\n\nEnsure that every contractor with whom there is an SLA provides periodic evidence of compliance with the GSP and/or GDP standards incorporated into the SLA.\n\n*Reason:* To demonstrate compliance with applicable quality management standards.\n\n## 11.4 Management of Documents and Standard Operating Procedures\n\n### 11.4.1 Standard Operating Procedures\n\nDevelop and maintain SOPs covering correct storage, internal shipping and external distribution of TTSPPs, including, but not limited to, the following topics:", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un breve resumen del contenido:\n\n### Resumen del Contexto\nEl documento se centra en el Sistema de Gesti\u00f3n de Calidad (SGC) y detalla varios programas y procedimientos necesarios para asegurar la calidad en la gesti\u00f3n de productos. Incluye la importancia de realizar revisiones anuales del SGC, llevar a cabo autoinspecciones regulares, y la gesti\u00f3n de documentos y procedimientos operativos est\u00e1ndar (SOP). Tambi\u00e9n se menciona la necesidad de que los contratistas cumplan con los est\u00e1ndares de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Almacenamiento (GSP).\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 procedimientos se deben seguir para manejar las desviaciones y las investigaciones de causa ra\u00edz dentro del Sistema de Gesti\u00f3n de Calidad?**\n   - Respuesta: Se debe implementar un programa de desviaci\u00f3n y de investigaci\u00f3n de causa ra\u00edz que permita identificar y documentar las causas de las no conformidades, as\u00ed como las acciones correctivas necesarias para rectificarlas.\n\n2. **\u00bfCu\u00e1l es la importancia de realizar autoinspecciones regulares y qu\u00e9 se debe hacer con los resultados obtenidos?**\n   - Respuesta: Las autoinspecciones son cruciales para asegurar el cumplimiento continuo con los est\u00e1ndares de GSP y GDP. Los resultados deben ser registrados, y se deben seguir las acciones correctivas necesarias para abordar cualquier \u00e1rea de no conformidad, documentando los cambios realizados.\n\n3. **\u00bfQu\u00e9 aspectos deben cubrir los Procedimientos Operativos Est\u00e1ndar (SOP) en relaci\u00f3n con el almacenamiento y distribuci\u00f3n de productos?**\n   - Respuesta: Los SOP deben abordar el almacenamiento correcto, el env\u00edo interno y la distribuci\u00f3n externa de productos, asegurando que se sigan las mejores pr\u00e1cticas para mantener la calidad y la integridad de los productos durante su manejo.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Gesti\u00f3n de Calidad**: La secci\u00f3n se centra en la importancia de establecer un sistema de gesti\u00f3n de calidad para los productos farmac\u00e9uticos, espec\u00edficamente en el contexto de almacenamiento y distribuci\u00f3n de TTSPPs (productos farmac\u00e9uticos de calidad).\n\n2. **Referencias Normativas**: Se mencionan varias normas ISO y directrices del ICH que son fundamentales para la gesti\u00f3n de calidad:\n   - **ICH Q9**: Gesti\u00f3n de riesgos de calidad.\n   - **ISO 9000:2005**: Fundamentos y vocabulario de sistemas de gesti\u00f3n de calidad.\n   - **ISO 9001:2008**: Requisitos de sistemas de gesti\u00f3n de calidad.\n   - **ISO 9004:2000**: Directrices para mejoras del rendimiento.\n   - **ISO 10005:2005**: Directrices para planes de calidad.\n   - **ISO 19011:2002**: Directrices para auditor\u00edas de sistemas de gesti\u00f3n de calidad y medioambientales.\n\n3. **Estructura Organizativa**: Se enfatiza la necesidad de establecer y documentar una estructura organizativa clara que defina las responsabilidades de gesti\u00f3n y el personal responsable en las operaciones de almacenamiento y distribuci\u00f3n.\n\n4. **Sistema de Calidad**: Se requiere la creaci\u00f3n y mantenimiento de un sistema de calidad que incluya:\n   - Sistemas de calidad est\u00e1ndar y procedimientos de auditor\u00eda.\n   - Procedimientos y especificaciones documentadas.\n   - Programa para el almacenamiento, retenci\u00f3n y destrucci\u00f3n de registros.\n   - Gesti\u00f3n de riesgos.\n\n### Entidades Clave\n- **TTSPPs**: Productos farmac\u00e9uticos de calidad.\n- **Normas ISO**: Conjunto de est\u00e1ndares internacionales que gu\u00edan la gesti\u00f3n de calidad.\n- **ICH**: Consejo Internacional de Armonizaci\u00f3n, que proporciona directrices para la gesti\u00f3n de calidad en la industria farmac\u00e9utica. \n\nEste resumen destaca la importancia de la gesti\u00f3n de calidad en la industria farmac\u00e9utica y los elementos necesarios para establecer un sistema efectivo.", "excerpt_keywords": "Keywords: Quality Management System, Self Inspections, Standard Operating Procedures, Good Distribution Practices, Corrective Actions"}}, "40e85c16-40a2-448a-a4c3-423625087924": {"node_ids": ["ba5cbc2e-68a1-4fd6-a7cd-be1ba1d89326"], "metadata": {"page_label": "378", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\u2014 security, including management of controlled and hazardous TTSPPs;  \n\u2014 safe handling of TTSPPs;  \n\u2014 temperature monitoring;  \n\u2014 calibration of temperature and humidity monitoring devices and alarm systems;  \n\u2014 qualification and validation procedures, including temperature mapping;  \n\u2014 maintenance of controlled-temperature equipment;  \n\u2014 facility cleaning and pest control;  \n\u2014 facility maintenance;  \n\u2014 product arrival (receiving) procedures and records;  \n\u2014 stock storage and warehousing procedures (put away, replenishment, order fulfilment, packing);  \n\u2014 stock control procedures and records;  \n\u2014 distribution procedures and records;  \n\u2014 management of temperature excursions;  \n\u2014 product return and recall/withdrawal procedures and records;  \n\u2014 product complaint procedures and records;  \n\u2014 safe disposal of damaged, expired and quarantined products and records which are no longer required;  \n\u2014 temperature-controlled packaging and route qualification;  \n\u2014 temperature-controlled vehicle operation, including management of security locks and seals;  \n\u2014 emergency response procedures; and  \n\u2014 environmental management.  \n\nEnsure that all documents are clear and unambiguous and that document change control procedures are in place as specified in clause 11.5.  \n\n*Reason:* Quality management and staff training.  \n\n## 11.5 Document control\n\nEnsure that all quality manuals, SOPs and similar documents are:\n\n\u2014 authorized by an appropriate person;  \n\u2014 recorded in a document register;  \n\u2014 regularly reviewed and kept up to date, with all changes recorded and authorized;  \n\u2014 version controlled;  \n\u2014 issued to all relevant personnel; and  \n\u2014 withdrawn when superseded.  \n\nWithdraw superseded documents and retain record copies for document history files and for the minimum period(s) required by the regulatory authorities and for duty-of-care purposes.  \n\n*Reason:* Good quality management practice.  ", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos, centr\u00e1ndose en la seguridad, el manejo adecuado, el monitoreo de temperatura y la gesti\u00f3n de documentos. Se enfatiza la importancia de tener procedimientos claros para el control de calidad, la capacitaci\u00f3n del personal y el mantenimiento de registros. Adem\u00e1s, se establece un protocolo para el control de documentos, asegurando que todos los manuales y procedimientos operativos est\u00e1ndar (SOP) sean autorizados, revisados y actualizados regularmente.\n\n### Preguntas Espec\u00edficas:\n1. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos mencionados para la gesti\u00f3n de productos farmac\u00e9uticos y biol\u00f3gicos en condiciones controladas?**\n   - Respuesta: Los procedimientos incluyen la gesti\u00f3n de la seguridad de TTSPPs, el manejo seguro de TTSPPs, el monitoreo de temperatura, la calibraci\u00f3n de dispositivos de monitoreo, mantenimiento de equipos de temperatura controlada, y procedimientos de recepci\u00f3n y almacenamiento de productos, entre otros.\n\n2. **\u00bfQu\u00e9 medidas se deben tomar para asegurar el control de documentos seg\u00fan la cl\u00e1usula 11.5?**\n   - Respuesta: Se deben autorizar los documentos por una persona apropiada, registrarlos en un registro de documentos, revisarlos regularmente, mantener un control de versiones, emitirlos a todo el personal relevante y retirarlos cuando sean superados.\n\n3. **\u00bfCu\u00e1l es la raz\u00f3n principal para implementar procedimientos de control de documentos y gesti\u00f3n de calidad en el manejo de productos farmac\u00e9uticos?**\n   - Respuesta: La raz\u00f3n principal es asegurar una buena pr\u00e1ctica de gesti\u00f3n de calidad y proporcionar capacitaci\u00f3n adecuada al personal, lo que contribuye a la seguridad y eficacia en el manejo de productos farmac\u00e9uticos y biol\u00f3gicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido se centra en el **Sistema de Gesti\u00f3n de Calidad (SGC)** y abarca varios programas y procedimientos esenciales para garantizar la calidad en la gesti\u00f3n de productos. A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n1. **Programas del SGC**:\n   - Programa de calibraci\u00f3n\n   - Programa de estabilidad\n   - Programa de calificaci\u00f3n y validaci\u00f3n\n   - Programa de desviaci\u00f3n e investigaci\u00f3n de causa ra\u00edz\n   - Procedimientos de acci\u00f3n correctiva y preventiva (CAPA)\n   - Programa de formaci\u00f3n\n   - Evaluaci\u00f3n peri\u00f3dica de procesos controlados por temperatura\n   - Programa de control de cambios\n   - Programa de mantenimiento\n   - Controles de gesti\u00f3n\n   - Pol\u00edticas de devoluci\u00f3n y retiro de productos, incluyendo retiros de emergencia\n   - Pol\u00edticas de quejas de productos\n   - Programa de destrucci\u00f3n de materiales\n   - Programa de almacenamiento y almac\u00e9n\n   - Programa de env\u00edo y distribuci\u00f3n\n   - Sistemas de notificaci\u00f3n para agencias regulatorias y ministerios de salud\n   - Programa de autoinspecci\u00f3n y mejora continua de la calidad\n\n2. **Revisiones Anuales**:\n   - Se enfatiza la necesidad de realizar revisiones anuales del SGC para asegurar su relevancia y efectividad.\n\n3. **Autoinspecciones**:\n   - Se deben llevar a cabo autoinspecciones regulares para garantizar el cumplimiento de los est\u00e1ndares de Buenas Pr\u00e1cticas de Distribuci\u00f3n (GDP) y Buenas Pr\u00e1cticas de Almacenamiento (GSP). Los resultados deben ser documentados y seguidos de acciones correctivas.\n\n4. **Contratistas y Acuerdos de Nivel de Servicio (SLA)**:\n   - Se requiere que los contratistas proporcionen evidencia peri\u00f3dica de cumplimiento con los est\u00e1ndares GSP y/o GDP establecidos en los SLA.\n\n5. **Gesti\u00f3n de Documentos y Procedimientos Operativos Est\u00e1ndar (SOP)**:\n   - Se deben desarrollar y mantener SOP que aborden el almacenamiento correcto, el env\u00edo interno y la distribuci\u00f3n externa de productos.\n\n### Entidades Clave\n- **GSP**: Buenas Pr\u00e1cticas de Almacenamiento\n- **GDP**: Buenas Pr\u00e1cticas de Distribuci\u00f3n\n- **SLA**: Acuerdos de Nivel de Servicio\n- **CAPA**: Acci\u00f3n Correctiva y Preventiva\n\nEste resumen destaca la importancia de un enfoque sistem\u00e1tico y documentado para la gesti\u00f3n de la calidad en la distribuci\u00f3n y almacenamiento de productos, asegurando el cumplimiento de normativas y est\u00e1ndares establecidos.", "excerpt_keywords": "Keywords: quality management, document control, temperature monitoring, pharmaceutical safety, SOPs"}}, "227de9f2-0ea6-41fc-950a-ccd00fd2c345": {"node_ids": ["43457019-1d65-49b8-9461-ccfd9a35f78f"], "metadata": {"page_label": "379", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12. Personnel/training\n\n## 12.1 Training\n\n### 12.1.1 General training\n\nProvide regular and systematic training for all relevant personnel responsible for storage, loading and unloading areas used for non-hazardous TTSPPs, covering the following:\n\n- applicable pharmaceutical legislation and regulations;\n- SOPs and safety issues; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Provide similar training for drivers who are responsible for transporting these substances. Maintain individual training records to demonstrate compliance and regularly evaluate the effectiveness of training programmes.\n\n*Reason:* To ensure that all relevant personnel are competent to carry out their duties.\n\n### 12.1.2 Specialist training\n\nIn addition to the training described in clause 12.1.1, provide regular and systematic additional training for relevant personnel responsible for storage, loading and unloading of controlled or hazardous TTSPPs. Training should cover the following:\n\n- applicable legislation and regulations;\n- security and safety risks; and\n- response to emergencies.\n\nEnsure that each employee understands his or her specific responsibilities. Maintain training records to demonstrate compliance and perform effectiveness checks on training. Provide similar training for drivers who are responsible for transporting these substances.\n\n*Reason:* To ensure that all relevant personnel are competent to handle controlled or hazardous TTSPPs.\n\n## Key references\n\nWorld Health Organization/United Nations Children\u2019s Fund/United Nations Development Programme/United Nations Population Fund/World Bank  \n* A model quality assurance system for procurement agencies.* Geneva, World Health Organization, 2007 (WHO/PSM/PAR/2007.3).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda la capacitaci\u00f3n del personal involucrado en el almacenamiento, carga y descarga de productos farmac\u00e9uticos no peligrosos y peligrosos. Se enfatiza la importancia de proporcionar formaci\u00f3n regular y sistem\u00e1tica que cubra la legislaci\u00f3n farmac\u00e9utica aplicable, procedimientos operativos est\u00e1ndar (SOPs), cuestiones de seguridad y respuesta a emergencias. Adem\u00e1s, se requiere mantener registros de capacitaci\u00f3n y evaluar la efectividad de los programas de formaci\u00f3n. La capacitaci\u00f3n especializada es necesaria para el manejo de productos farmac\u00e9uticos controlados o peligrosos, asegurando que el personal comprenda sus responsabilidades espec\u00edficas.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de legislaci\u00f3n y regulaciones deben conocer los empleados responsables del manejo de TTSPPs no peligrosos?**\n   - La capacitaci\u00f3n debe incluir legislaci\u00f3n y regulaciones farmac\u00e9uticas aplicables, as\u00ed como procedimientos operativos est\u00e1ndar (SOPs) y cuestiones de seguridad.\n\n2. **\u00bfCu\u00e1l es la raz\u00f3n principal para mantener registros individuales de capacitaci\u00f3n para el personal?**\n   - La raz\u00f3n principal es demostrar el cumplimiento de los requisitos de capacitaci\u00f3n y evaluar regularmente la efectividad de los programas de formaci\u00f3n.\n\n3. **\u00bfQu\u00e9 aspectos adicionales se deben cubrir en la capacitaci\u00f3n especializada para el manejo de TTSPPs controlados o peligrosos?**\n   - La capacitaci\u00f3n especializada debe incluir legislaci\u00f3n y regulaciones aplicables, riesgos de seguridad y seguridad, as\u00ed como la respuesta a emergencias.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Gesti\u00f3n de Productos Farmac\u00e9uticos y Biol\u00f3gicos:**\n   - Seguridad en el manejo de productos farmac\u00e9uticos y biol\u00f3gicos (TTSPPs).\n   - Procedimientos para el manejo seguro y control de temperatura.\n\n2. **Monitoreo y Mantenimiento:**\n   - Monitoreo de temperatura y calibraci\u00f3n de dispositivos.\n   - Mantenimiento de equipos de temperatura controlada y limpieza de instalaciones.\n\n3. **Procedimientos Operativos:**\n   - Recepci\u00f3n, almacenamiento, control de inventario y distribuci\u00f3n de productos.\n   - Manejo de excursiones de temperatura y procedimientos de devoluci\u00f3n y retiro de productos.\n\n4. **Control de Documentos:**\n   - Importancia de tener procedimientos claros para la gesti\u00f3n de documentos.\n   - Requisitos para la autorizaci\u00f3n, revisi\u00f3n y control de versiones de documentos.\n\n5. **Capacitaci\u00f3n y Buenas Pr\u00e1cticas:**\n   - Necesidad de capacitaci\u00f3n del personal y buenas pr\u00e1cticas de gesti\u00f3n de calidad.\n\n**Entidades:**\n- **TTSPPs:** Productos farmac\u00e9uticos y biol\u00f3gicos controlados y peligrosos.\n- **SOPs:** Procedimientos Operativos Est\u00e1ndar.\n- **Regulatory Authorities:** Autoridades regulatorias que establecen requisitos de retenci\u00f3n de documentos.\n- **Document Register:** Registro donde se registran todos los documentos relevantes.\n\nEste resumen destaca la importancia de la gesti\u00f3n adecuada de productos farmac\u00e9uticos y biol\u00f3gicos, as\u00ed como la necesidad de un control riguroso de documentos y capacitaci\u00f3n del personal para asegurar la calidad y seguridad en su manejo.", "excerpt_keywords": "Keywords: training, pharmaceutical legislation, TTSPPs, safety, compliance"}}, "0b47360d-b606-4a29-9119-c74d91a5b743": {"node_ids": ["bef04473-0a6c-45c3-adb2-541a859d9df2"], "metadata": {"page_label": "380", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Therapeutic Goods Administration *Australian code of good wholesaling practice for therapeutic goods for human use*. Commonwealth of Australia, Canberra ACT, Draft Revision \u2014 June 2006.\n\n*Protocol for the control of storage temperatures of medicinal products*. London, British Association of Pharmaceutical Wholesalers, 1999.\n\nThe Council of the European Communities. Council Directive 92/25/EEC of 31 March 1992 on the wholesale distribution of medicinal products for human use. *Official Journal L 113 , 30/04/1992 p. 0001 \u2014 0004*.\n\nThe Council of the European Communities. EU Council Directive 92/27/EEC of 31 March 1992 on the labelling of medicinal products for human use and on package leaflets. *Official Journal L 113 , 30/04/1992 p. 0008 \u2014 0012*.\n\nState Food and Drug Administration of the People's Republic of China. *Drug administration law of the People's Republic of China*. 2001.\n\nEU 94/C 63/03. *Guidelines on good distribution practice of medicinal products for human use*. 1994.\n\nThe European Parliament and the Council of the European Union. EU Directive 2004/27/EC. Community code relating to medicinal products for human use. *Official Journal L 136/34/2004*.\n\nEU Regulation 4/2007. *Good distribution practices for pharmaceutical wholesalers*. 2007.\n\nGUIDE-0069: *Guidelines for temperature control of drug products during storage and transportation*. Ottawa, Ontario, Health Canada. Health Products and Food Branch Inspectorate, 2005.\n\n*IATA Perishable Cargo Regulations Chapter 17*. 9th ed, International Air Transport Association, 2009.\n\nInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: *ICH Harmonised Tripartite Guideline: Quality Risk Management Q9*. November 2005.\n\nIrish Medicines Board. *Guide to control and monitoring of storage and transportation temperature conditions for medicinal products and active substances*. Edition IND-003 Version 1, March 2006.\n\n*Best practices for repositories*. International Society for Biological and Environmental Repositories, 2008.\n\nMedicines and Healthcare products Regulatory Agency. *Rules and guidance for pharmaceutical manufacturers and distributors*. London, Pharmaceutical Press, 2007.\n\nPDA: Technical report 39: *Guidance for Temperature Controlled Medicinal Products: Maintaining the quality of temperature-sensitive medicinal products through the transportation environment*. Parenteral Drug Association, 2007.\n\n*Guidance notes on good distribution practices*. Singapore Health Sciences Authority: 2008.\n\nTaylor, J. *Recommendations on the control and monitoring of storage and transportation temperatures of medicinal products*. London, Medicines and Healthcare products Regulatory Agency, 2001.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales. Incluye referencias a diversas directrices y regulaciones internacionales, como las de la Uni\u00f3n Europea, la Administraci\u00f3n de Alimentos y Medicamentos de China, y otras organizaciones relevantes. Se abordan temas como el control de temperaturas durante el almacenamiento y transporte de productos medicinales, as\u00ed como las normativas que rigen la distribuci\u00f3n y etiquetado de estos productos.\n\n### Preguntas Espec\u00edficas\n1. **\u00bfCu\u00e1les son las principales directrices mencionadas en el documento para el control de temperaturas de productos medicinales durante su almacenamiento y transporte?**\n   - Respuesta: El documento menciona varias directrices, incluyendo el \"GUIDE-0069\" de Health Canada sobre el control de temperatura, y el \"PDA Technical Report 39\" que proporciona orientaci\u00f3n sobre productos medicinales sensibles a la temperatura.\n\n2. **\u00bfQu\u00e9 regulaciones de la Uni\u00f3n Europea se citan en el documento en relaci\u00f3n con la distribuci\u00f3n y etiquetado de productos medicinales?**\n   - Respuesta: Se citan la Directiva 92/25/EEC sobre la distribuci\u00f3n mayorista y la Directiva 92/27/EEC sobre el etiquetado y prospectos de productos medicinales, as\u00ed como la Directiva 2004/27/EC que establece el c\u00f3digo comunitario para productos medicinales.\n\n3. **\u00bfQu\u00e9 organizaciones han emitido gu\u00edas sobre las buenas pr\u00e1cticas de distribuci\u00f3n de productos medicinales seg\u00fan el documento?**\n   - Respuesta: Entre las organizaciones mencionadas se encuentran la Therapeutic Goods Administration de Australia, la Medicines and Healthcare products Regulatory Agency del Reino Unido, y la International Society for Biological and Environmental Repositories, entre otras.\n\n### Resumen de Nivel Superior\nEl documento proporciona un marco normativo y directrices sobre las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales, enfatizando la importancia del control de temperatura y el cumplimiento de regulaciones internacionales. Se citan m\u00faltiples fuentes y directrices que abordan la calidad y seguridad de los productos durante su transporte y almacenamiento, lo que es crucial para mantener su eficacia y seguridad para el uso humano.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**Temas clave:**\n\n1. **Capacitaci\u00f3n del personal:**\n   - Importancia de la formaci\u00f3n regular y sistem\u00e1tica para el personal involucrado en el almacenamiento, carga y descarga de productos farmac\u00e9uticos (TTSPPs).\n   - Diferenciaci\u00f3n entre capacitaci\u00f3n general para TTSPPs no peligrosos y capacitaci\u00f3n especializada para TTSPPs controlados o peligrosos.\n\n2. **Contenido de la capacitaci\u00f3n:**\n   - **Capacitaci\u00f3n general:**\n     - Legislaci\u00f3n y regulaciones farmac\u00e9uticas aplicables.\n     - Procedimientos operativos est\u00e1ndar (SOPs).\n     - Cuestiones de seguridad y respuesta a emergencias.\n   - **Capacitaci\u00f3n especializada:**\n     - Legislaci\u00f3n y regulaciones espec\u00edficas para productos controlados o peligrosos.\n     - Riesgos de seguridad y medidas de seguridad.\n     - Respuesta a emergencias.\n\n3. **Responsabilidades y registros:**\n   - Asegurar que cada empleado comprenda sus responsabilidades espec\u00edficas.\n   - Mantenimiento de registros individuales de capacitaci\u00f3n para demostrar cumplimiento y evaluar la efectividad de los programas de formaci\u00f3n.\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices sobre la capacitaci\u00f3n del personal.\n- **TTSPPs (Productos farmac\u00e9uticos no peligrosos y peligrosos):** Sustancias que requieren manejo especializado y capacitaci\u00f3n.\n- **SOPs (Procedimientos Operativos Est\u00e1ndar):** Documentos que gu\u00edan las pr\u00e1cticas de trabajo seguras y efectivas.\n- **Referencias clave:** \n  - \"A model quality assurance system for procurement agencies.\" (WHO/PSM/PAR/2007.3) - Documento de referencia que respalda las directrices de capacitaci\u00f3n.\n\nEste resumen destaca la importancia de la capacitaci\u00f3n adecuada del personal en el manejo de productos farmac\u00e9uticos, asegurando la competencia y la seguridad en las operaciones.", "excerpt_keywords": "Keywords: medicinal products, temperature control, good distribution practices, regulatory guidelines, pharmaceutical storage"}}, "cd18a2a6-89a0-43c3-9ba2-f6413dd56639": {"node_ids": ["85406487-299c-4930-9155-949b1e88e664"], "metadata": {"page_label": "381", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Ozone Secretariat United Nations Environment Programme. *The Montreal Protocol on Substances that Deplete the Ozone Layer.* Nairobi, UNEP, 2000.\n\nUSP <1079> *Good storage and shipping practices.* United States Pharmacopeia, 2009.\n\nUSP 32-NF 27, *General Notices and requirements.* United States Pharmacopeia 2009.\n\nUSP <1118> *Monitoring Devices\u2013Time, Temperature, and Humidity.* United States Pharmacopeia, 2007.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-sixth report.* Geneva, World Health Organization, 2002 (WHO Technical Report Series, No. 902).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh report.* Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 908).\n\nGood trade and distribution practices for pharmaceutical starting materials. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report.* Geneva, World Health Organization, 2004 (WHO Technical Report Series, No. 917) Annex 2.\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth report.* Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937).\n\n*WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report.* Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957) Annex 5.\n\n# Further reading\n\n**Bishara, R.** A simple answer to cold chain chaos. *World Pharmaceutical Frontiers,* 2008, 5:65\u201366.\n\nEuropean Parliament and Council Directive 94/62/EC of 20 December 1994 on packaging and packaging waste. Official Journal L 365, 31/12/1994 P. 0010 \u2014 0023.\n\n**Falconer P, Drury J.** *Building and planning for industrial storage and distribution.* Architectural Press, London, 2003.\n\nGermanischer Lloyd Certification & Cool Chain Association. *Cool Chain Quality Indicator Standard (CCQI)* 20th June 2007, Version 1.5.\n\n**Kartoglu U, Ganivet S, Guichard S, Aiyar V, Bollen P, Maire D, Altay B.** Use of cool water packs to prevent freezing during vaccine transportation at the country level. *PDA Journal of Pharmaceutical Science and Technology,* 2009, 63:11-26\n\nManagement Sciences for Health. *Managing Drug Supply.* Kumarian Press, pp. 11-26,1997.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que se centra en las especificaciones para preparaciones farmac\u00e9uticas y buenas pr\u00e1cticas de almacenamiento y distribuci\u00f3n. Incluye referencias a varios informes de la OMS y la Farmacopea de los Estados Unidos, as\u00ed como lecturas adicionales sobre la gesti\u00f3n de la cadena de fr\u00edo y la regulaci\u00f3n de envases. Se abordan temas como la importancia de mantener condiciones adecuadas de temperatura y humedad durante el transporte de productos farmac\u00e9uticos, as\u00ed como la normativa relacionada con el envasado y los residuos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las recomendaciones clave del informe de la OMS sobre las pr\u00e1cticas de almacenamiento y distribuci\u00f3n de materiales farmac\u00e9uticos?**\n   - Esta pregunta busca respuestas espec\u00edficas sobre las directrices y recomendaciones que se mencionan en los informes de la OMS, que pueden no estar disponibles en otras fuentes.\n\n2. **\u00bfQu\u00e9 papel juega el \"Cool Chain Quality Indicator Standard (CCQI)\" en la gesti\u00f3n de la cadena de fr\u00edo para productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en un est\u00e1ndar espec\u00edfico mencionado en el contexto y busca detalles sobre su aplicaci\u00f3n y relevancia en la industria farmac\u00e9utica.\n\n3. **\u00bfC\u00f3mo se utilizan los paquetes de agua fr\u00eda para prevenir el congelamiento durante el transporte de vacunas, seg\u00fan el estudio mencionado en el contexto?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre la metodolog\u00eda y los resultados del estudio citado, que puede no estar ampliamente documentada en otras fuentes.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y t\u00e9cnica que se encuentra en el contexto proporcionado, lo que puede no estar disponible en otras partes de la literatura.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las buenas pr\u00e1cticas de distribuci\u00f3n y almacenamiento de productos medicinales, destacando la importancia del control de temperaturas durante su transporte y almacenamiento. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Control de Temperaturas**: Se enfatiza la necesidad de mantener condiciones adecuadas de temperatura para asegurar la calidad y eficacia de los productos medicinales.\n2. **Regulaciones Internacionales**: Se citan diversas directrices y regulaciones que rigen la distribuci\u00f3n, etiquetado y almacenamiento de productos medicinales.\n3. **Buenas Pr\u00e1cticas de Distribuci\u00f3n**: Se abordan las mejores pr\u00e1cticas que deben seguir los distribuidores y fabricantes para garantizar la seguridad y calidad de los productos.\n\n#### Entidades Mencionadas:\n1. **Therapeutic Goods Administration (Australia)**: Emisora del \"Australian code of good wholesaling practice\".\n2. **British Association of Pharmaceutical Wholesalers**: Autores del \"Protocol for the control of storage temperatures\".\n3. **Consejo de las Comunidades Europeas**: Cita de las Directivas 92/25/EEC y 92/27/EEC sobre distribuci\u00f3n y etiquetado de productos medicinales.\n4. **Administraci\u00f3n Estatal de Alimentos y Medicamentos de China**: Referencia a la \"Drug administration law\".\n5. **Health Canada**: Emisores de las \"GUIDE-0069\" sobre control de temperatura.\n6. **International Air Transport Association (IATA)**: Proveedores de regulaciones para el transporte de carga perecedera.\n7. **International Conference on Harmonisation (ICH)**: Emisores de la gu\u00eda sobre gesti\u00f3n de riesgos de calidad.\n8. **Medicines and Healthcare products Regulatory Agency (MHRA, Reino Unido)**: Autores de varias gu\u00edas y regulaciones sobre pr\u00e1cticas de distribuci\u00f3n.\n9. **Parenteral Drug Association (PDA)**: Autores del \"Technical report 39\" sobre productos medicinales sensibles a la temperatura.\n10. **Singapore Health Sciences Authority**: Emisores de notas de orientaci\u00f3n sobre buenas pr\u00e1cticas de distribuci\u00f3n.\n\nEste resumen destaca la relevancia de las regulaciones y directrices internacionales en la gesti\u00f3n de productos medicinales, as\u00ed como la colaboraci\u00f3n de diversas entidades para establecer est\u00e1ndares de calidad y seguridad.", "excerpt_keywords": "Keywords: pharmaceutical preparations, cold chain management, storage practices, WHO guidelines, temperature control"}}, "98716d2f-5b54-4de9-b2df-031fda86dc8f": {"node_ids": ["97ca69d7-af96-4826-8b0b-65ca5ae9c3ac"], "metadata": {"page_label": "382", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Task force membership\n\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Henry Ames | Sensitech | Temperature monitoring | United States of America |\n| Claude Ammann | Topotarget | Manufacturer | Switzerland |\n| Erik van Asselt | PDA PCCIG | PDA | Netherlands (the) |\n| Anthony Battersby | FBA Health Systems | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| Rafik Bishara | PDA PCCIG | PDA | United States of America |\n| Richard Brown | TGA | Regulatory | Australia |\n| Linda Carducci | Johnson & Johnson | IFPMA | United States of America |\n| G\u00e9rald Cavalier | Cemafroid | IIR | France |\n| Isabelle Clamou | EFPIA | IFPMA | Belgium |\n| Michael Eakins | USP | Regulatory | United States of America |\n| Chris T Forrest | AstraZenca | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n| Juliman Fuad | BioFarma | Manufacturer | Indonesia |\n| Andreas Giger | Berlinger | Temperature monitoring | Switzerland |\n| Andre Haeusermann | Novartis Pharma | IFPMA | Switzerland |\n| Rodney L Horder | Abbott | IFPMA | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de miembros de un grupo de trabajo que abarca diversas organizaciones y categor\u00edas relacionadas con la salud y la regulaci\u00f3n. Los miembros provienen de diferentes pa\u00edses y representan a fabricantes, consultores, organizaciones regulatorias y asociaciones de la industria farmac\u00e9utica.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas en el grupo de trabajo y qu\u00e9 categor\u00edas de participaci\u00f3n tienen sus miembros?**\n   - Respuesta: Las organizaciones representadas incluyen Sensitech, Topotarget, PDA PCCIG, FBA Health Systems, TGA, Johnson & Johnson, Cemafroid, EFPIA, USP, AstraZeneca, BioFarma, Berlinger, Novartis Pharma y Abbott. Las categor\u00edas de participaci\u00f3n incluyen temperatura monitoreo, fabricante, PDA, consultor, regulador e IFPMA.\n\n2. **\u00bfCu\u00e1les son los pa\u00edses de origen de los miembros del grupo de trabajo y cu\u00e1ntos miembros provienen de cada pa\u00eds?**\n   - Respuesta: Los pa\u00edses de origen de los miembros incluyen Estados Unidos de Am\u00e9rica (5 miembros), Suiza (3 miembros), Reino Unido (4 miembros), Australia (1 miembro), B\u00e9lgica (1 miembro), Francia (1 miembro) e Indonesia (1 miembro).\n\n3. **\u00bfQui\u00e9nes son los miembros del grupo de trabajo que representan a organizaciones reguladoras y cu\u00e1les son sus respectivas organizaciones?**\n   - Respuesta: Los miembros que representan a organizaciones reguladoras son Richard Brown de TGA (Australia) y Michael Eakins de USP (Estados Unidos de Am\u00e9rica).", "prev_section_summary": "La secci\u00f3n proporcionada se centra en las especificaciones y buenas pr\u00e1cticas relacionadas con el almacenamiento y distribuci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de mantener condiciones adecuadas durante el transporte. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Regulaciones y Normativas**:\n   - Protocolo de Montreal sobre sustancias que agotan la capa de ozono.\n   - Buenas pr\u00e1cticas de almacenamiento y env\u00edo seg\u00fan la Farmacopea de los Estados Unidos (USP).\n   - Directrices de la OMS sobre especificaciones para preparaciones farmac\u00e9uticas.\n\n2. **Informes de la OMS**:\n   - M\u00faltiples informes de la OMS que abordan especificaciones y buenas pr\u00e1cticas en la industria farmac\u00e9utica, incluyendo los informes 36, 37, 38, 40 y 44.\n\n3. **Cadena de Fr\u00edo**:\n   - Importancia de la temperatura y la humedad en el transporte de productos farmac\u00e9uticos.\n   - Uso de paquetes de agua fr\u00eda para prevenir el congelamiento de vacunas durante el transporte.\n\n4. **Est\u00e1ndares de Calidad**:\n   - Introducci\u00f3n del \"Cool Chain Quality Indicator Standard (CCQI)\" para asegurar la calidad en la cadena de fr\u00edo.\n\n5. **Gesti\u00f3n de Residuos**:\n   - Directiva de la Uni\u00f3n Europea sobre envases y residuos de envases.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad en la regulaci\u00f3n de pr\u00e1cticas farmac\u00e9uticas.\n- **Farmacopea de los Estados Unidos (USP)**: Fuente de est\u00e1ndares y pr\u00e1cticas recomendadas.\n- **Secretar\u00eda del Ozono**: Parte del Programa de las Naciones Unidas para el Medio Ambiente (UNEP).\n- **Publicaciones y Autores**: \n  - R. Bishara, P. Falconer, J. Drury, y otros autores que contribuyen a la literatura sobre gesti\u00f3n de la cadena de fr\u00edo y almacenamiento industrial.\n\nEste resumen destaca la relevancia de las buenas pr\u00e1cticas en la industria farmac\u00e9utica y la necesidad de cumplir con las normativas para garantizar la eficacia y seguridad de los productos.", "excerpt_keywords": "Keywords: task force, membership, regulatory, pharmaceutical, temperature monitoring"}}, "6a31f036-beec-4d53-938e-b11fbabb7b1d": {"node_ids": ["d73aa760-852c-419e-8925-5abc34efd4c9"], "metadata": {"page_label": "383", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name                   | Organization                                      | Category               | Country                                           |\n|------------------------|---------------------------------------------------|------------------------|---------------------------------------------------|\n| Laila Jarrar           | Food & Drug Administration                        | Regulatory             | Jordan                                            |\n| Ryoko Krause           | IFPMA                                             | IFPMA                  | Switzerland                                       |\n| Santosh Kutty          | CDL Kasauli                                       | Regulatory             | India                                             |\n| Gilles Labranque       | Sofrigam                                          | IIR                    | France                                            |\n| Adrien Lehideux        | ColdPack                                          | Passive cooling        | France                                            |\n| Zhang Lei              | National Biotec Group (Chengdu Institute)         | DCVMN                  | China                                             |\n| Eric Lindquist         | Organization                                      | Category               | Passive cooling Country United States of America  |\n| K\u00e5re Lindroos          | Huure                                             | Active cooling         | Finland                                           |\n| Gianluca Minestrini    | Hoffmann-La Roche                                 | IFPMA                  | Switzerland                                       |\n| Ali Musa Muhaidat      | Vaccine & Sera Department                         | Ministry of Health     | Jordan                                            |\n| Fernand Muller         | Dometic                                           | Active cooling         | Luxembourg                                        |\n| Kevin O.Donnell        | IATA                                              | IATA                   | United States of America                          |\n| Girolamo Panozzo       | ITC/CNR                                           | IIR                    | Italy                                             |\n| Stefanie Pluschkell    | Pfizer                                            | IFPMA                  | United States of America                          |\n| Fabian De Paoli        | GSK Biologicals                                   | IFPMA                  | Belgium                                           |\n| Cristiane Frensch Pereira | Bio-Manguinhos                                 | DCVMN                  | Brazil                                            |\n| Thadeus Prusik         | TempTime                                          | Temperature monitoring | United States of America                          |\n| Eric Raemdonnck        | IATA                                              | IATA                   | Canada                                            |\n| Joanie Robertson       | PATH                                              | PATH                   | United States of America                          |\n| Isabel Rojas           | CIGB/ Cuba                                        | DCVMN                  | Cuba                                              |\n| Wolfram Schlimme       | Crucell                                           | IFPMA                  | Switzerland                                       |\n| Inder Jit Sharma       | Serum Institute of India Ltd                      | DCVMN                  | India                                             |\n| Sarah Skuce            | Health Canada                                     | Regulatory             | Canada                                            |\n| Engko Sosilaine        | National Agency of Drug and Food Control          | Regulatory             | Indonesia                                         |\n| John Taylor            | MHRA                                              | Regulatory             | United Kingdom of Great Britain and Northern Ireland |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una lista de profesionales y representantes de diversas organizaciones relacionadas con la regulaci\u00f3n y el desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos. La tabla presenta informaci\u00f3n sobre el nombre, la organizaci\u00f3n, la categor\u00eda y el pa\u00eds de cada individuo. Las organizaciones abarcan desde agencias regulatorias hasta empresas farmac\u00e9uticas y de transporte, reflejando una amplia gama de actores en el \u00e1mbito de la salud global.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas por los profesionales que trabajan en el \u00e1mbito de la regulaci\u00f3n de productos biol\u00f3gicos y farmac\u00e9uticos en el contexto del informe?**\n   - Esta pregunta busca identificar las diversas organizaciones mencionadas en la tabla, lo que puede proporcionar una visi\u00f3n sobre la colaboraci\u00f3n internacional en la regulaci\u00f3n de la salud.\n\n2. **\u00bfCu\u00e1les son las categor\u00edas de especializaci\u00f3n de los representantes listados en el informe y qu\u00e9 pa\u00edses est\u00e1n m\u00e1s representados en cada categor\u00eda?**\n   - Esta pregunta permite analizar la diversidad de especializaciones y la representaci\u00f3n geogr\u00e1fica en el \u00e1mbito de la salud, lo que puede ser \u00fatil para entender las fortalezas y debilidades en diferentes regiones.\n\n3. **\u00bfQu\u00e9 papel desempe\u00f1an las organizaciones de transporte, como IATA, en el contexto de la regulaci\u00f3n y distribuci\u00f3n de productos biol\u00f3gicos seg\u00fan el informe?**\n   - Esta pregunta se centra en el papel espec\u00edfico de las organizaciones de transporte en la cadena de suministro de productos biol\u00f3gicos, lo que puede no ser evidente en otros documentos relacionados con la salud p\u00fablica.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y relevante que puede no estar disponible en otros contextos, aprovechando la informaci\u00f3n \u00fanica presentada en el documento.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl documento \"WHO - Technical Report Series 961\" presenta una lista de miembros de un grupo de trabajo compuesto por representantes de diversas organizaciones relacionadas con la salud y la regulaci\u00f3n. Los temas clave incluyen:\n\n- **Organizaciones Representadas**: \n  - Sensitech\n  - Topotarget\n  - PDA PCCIG\n  - FBA Health Systems\n  - TGA\n  - Johnson & Johnson\n  - Cemafroid\n  - EFPIA\n  - USP\n  - AstraZeneca\n  - BioFarma\n  - Berlinger\n  - Novartis Pharma\n  - Abbott\n\n- **Categor\u00edas de Participaci\u00f3n**:\n  - Monitoreo de temperatura\n  - Fabricante\n  - PDA (Pharmaceutical Development Association)\n  - Consultor\n  - Regulador\n  - IFPMA (International Federation of Pharmaceutical Manufacturers & Associations)\n\n- **Pa\u00edses de Origen de los Miembros**:\n  - Estados Unidos de Am\u00e9rica\n  - Suiza\n  - Reino Unido\n  - Australia\n  - B\u00e9lgica\n  - Francia\n  - Indonesia\n\n- **Miembros de Organizaciones Reguladoras**:\n  - Richard Brown (TGA, Australia)\n  - Michael Eakins (USP, Estados Unidos de Am\u00e9rica)\n\nEste grupo de trabajo refleja una colaboraci\u00f3n internacional en el \u00e1mbito de la salud, con un enfoque en la regulaci\u00f3n y la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: WHO, Technical Report, regulation, biopharmaceuticals, international collaboration"}}, "4efcbbe3-ace6-44bf-a9ef-07112f806ba6": {"node_ids": ["5dc38c12-b045-432b-a563-c88add55127e"], "metadata": {"page_label": "384", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\n| Name | Organization | Category | Country |\n| - | - | - | - |\n| Mahbouba Vladakhani | Biological Dept Pharmaceutical & Narcotics | Regulatory | Iran (Islamic Republic of) |\n| Lisette Vromans | Merck | IFPMA | Netherlands (the) |\n\n\n### World Health Organization Performance, Quality and Safety Secretariat\n\n| | | | |\n| - | - | - | - |\n| Andrew Garnett | Author \u2014 Group leader | Consultant | United Kingdom of Great Britain and Northern Ireland |\n| \u00dcmit Karto\\_lu | Family and Community Health/ Quality, Safety and Standards-Chair | WHO | Switzerland |\n| Denis Maire | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n\n\n### World Health Organization\n\n| | | | |\n| - | - | - | - |\n| Lahouari Belgharbi | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Ivana Knezevic | Family and Community Health/ Quality, Safety and Standards | WHO | Switzerland |\n| Sabine Kopp | Health Systems and Services/ Essential Medicines and Pharmaceutical Policies/Quality Assurance and Safety: Medicines | WHO | Switzerland |\n\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". En \u00e9l se presentan diversas contribuciones de expertos y representantes de diferentes organizaciones y pa\u00edses en el \u00e1mbito de la salud, la calidad y la seguridad de los medicamentos. Se destacan los roles de varios individuos en la OMS y otras organizaciones, as\u00ed como su pa\u00eds de origen y su categor\u00eda profesional.\n\n### Preguntas\n\n1. **\u00bfCu\u00e1l es el papel espec\u00edfico de Andrew Garnett en el contexto del informe de la OMS?**\n   - Respuesta: Andrew Garnett es el autor y l\u00edder del grupo consultor en el informe, lo que indica que tiene un papel clave en la direcci\u00f3n y contenido del documento.\n\n2. **\u00bfQu\u00e9 organizaciones est\u00e1n representadas por los individuos mencionados en el informe y qu\u00e9 categor\u00edas profesionales tienen?**\n   - Respuesta: Las organizaciones representadas incluyen el Departamento Biol\u00f3gico de Productos Farmac\u00e9uticos y Narc\u00f3ticos de Ir\u00e1n, Merck, y la OMS. Las categor\u00edas profesionales incluyen regulador, IFPMA (Federaci\u00f3n Internacional de Asociaciones de Fabricantes y Asociaciones) y varios roles en calidad, seguridad y est\u00e1ndares de salud.\n\n3. **\u00bfQu\u00e9 pa\u00edses est\u00e1n representados por los expertos mencionados en el informe y qu\u00e9 \u00e1reas de salud abordan?**\n   - Respuesta: Los pa\u00edses representados son Ir\u00e1n, los Pa\u00edses Bajos y el Reino Unido, as\u00ed como Suiza (donde se encuentra la OMS). Las \u00e1reas de salud que abordan incluyen la calidad y seguridad de los medicamentos, as\u00ed como pol\u00edticas farmac\u00e9uticas esenciales.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento \"WHO - Technical Report Series 961\" presenta una lista de profesionales y representantes de diversas organizaciones involucradas en la regulaci\u00f3n y desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos. A continuaci\u00f3n se resumen los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Regulaci\u00f3n de Productos Biol\u00f3gicos y Farmac\u00e9uticos**: La secci\u00f3n destaca la importancia de la regulaci\u00f3n en el \u00e1mbito de la salud global, con un enfoque en la colaboraci\u00f3n entre diferentes organizaciones y pa\u00edses.\n  \n2. **Diversidad de Organizaciones**: Se incluyen agencias regulatorias, empresas farmac\u00e9uticas, organizaciones de transporte y otras entidades que desempe\u00f1an un papel crucial en la cadena de suministro de productos biol\u00f3gicos.\n\n3. **Colaboraci\u00f3n Internacional**: La representaci\u00f3n de m\u00faltiples pa\u00edses y organizaciones sugiere un esfuerzo conjunto para abordar los desaf\u00edos en la regulaci\u00f3n y distribuci\u00f3n de productos de salud.\n\n#### Entidades Mencionadas:\n- **Organizaciones Regulatorias**:\n  - Food & Drug Administration (FDA) - Jordania\n  - Health Canada - Canad\u00e1\n  - MHRA - Reino Unido\n  - National Agency of Drug and Food Control - Indonesia\n\n- **Empresas Farmac\u00e9uticas**:\n  - Pfizer - Estados Unidos\n  - GSK Biologicals - B\u00e9lgica\n  - Hoffmann-La Roche - Suiza\n  - Bio-Manguinhos - Brasil\n\n- **Organizaciones de Transporte**:\n  - IATA - Estados Unidos y Canad\u00e1\n\n- **Instituciones de Investigaci\u00f3n y Desarrollo**:\n  - Serum Institute of India Ltd - India\n  - National Biotec Group (Chengdu Institute) - China\n\n- **Otras Entidades**:\n  - PATH - Estados Unidos\n  - Sofrigam - Francia\n  - TempTime - Estados Unidos\n\nEste resumen proporciona una visi\u00f3n general de los actores clave en el \u00e1mbito de la regulaci\u00f3n y desarrollo de productos biol\u00f3gicos y farmac\u00e9uticos, as\u00ed como la diversidad geogr\u00e1fica y organizativa presente en el documento.", "excerpt_keywords": "Keywords: WHO, pharmaceutical regulation, quality assurance, international collaboration, health safety"}}, "8cb7399f-8b8a-428b-80de-956778644a1a": {"node_ids": ["29ea72a5-32cc-46cb-8385-5189e774f49e"], "metadata": {"page_label": "385", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 10\n\n## Procedure for prequalification of pharmaceutical products\n\n1. Introduction\n2. Glossary\n3. Purpose and principles\n4. Steps of the procedure\n5. Invitation for expressions of interest\n6. Data and information to be submitted\n7. Screening of dossiers submitted\n8. Dossier assessment\n9. Site inspection\n10. Reporting and communication of the results of the evaluation\n11. Outcome of the prequalification procedure\n12. Maintenance of prequalification status\n13. Cost recovery\n14. Confidentiality undertaking\n15. Conflict of interest\n\n### Appendix 1\nFlowchart of WHO prequalification of pharmaceutical products\n\n### Appendix 2\nCharacteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos que se siguen en el procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan el documento de la OMS?**\n   - Esta pregunta busca detalles sobre el proceso, que incluye desde la invitaci\u00f3n para expresiones de inter\u00e9s hasta la comunicaci\u00f3n de los resultados de la evaluaci\u00f3n.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n y datos deben ser presentados por los solicitantes durante el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de documentaci\u00f3n y datos que los fabricantes deben proporcionar para que sus productos sean considerados para la precalificaci\u00f3n.\n\n3. **\u00bfQu\u00e9 medidas se toman para mantener el estatus de precalificaci\u00f3n de un producto farmac\u00e9utico una vez que ha sido aprobado por la OMS?**\n   - Esta pregunta aborda el tema de la sostenibilidad y el mantenimiento del estatus de precalificaci\u00f3n, lo cual es crucial para asegurar que los productos contin\u00faen cumpliendo con los est\u00e1ndares establecidos.\n\n### Resumen de nivel superior del contexto circundante:\nEl documento de la OMS detalla el procedimiento para la precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye una serie de pasos desde la presentaci\u00f3n de solicitudes hasta la evaluaci\u00f3n y el mantenimiento del estatus de precalificaci\u00f3n. Tambi\u00e9n se menciona la importancia de la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en este proceso. Adem\u00e1s, se incluyen ap\u00e9ndices que ofrecen un flujo de trabajo visual y caracter\u00edsticas de los productos precalificados que estar\u00e1n disponibles p\u00fablicamente.", "prev_section_summary": "El contenido proporcionado es un extracto del informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) titulado \"WHO - Technical Report Series 961\". Este informe incluye contribuciones de expertos y representantes de diversas organizaciones y pa\u00edses en el \u00e1mbito de la salud, la calidad y la seguridad de los medicamentos. \n\n### Temas Clave:\n1. **Contribuciones de Expertos**: Se destacan los roles de varios individuos en la OMS y otras organizaciones, enfatizando su experiencia en \u00e1reas relacionadas con la calidad y seguridad de los medicamentos.\n2. **Organizaciones Representadas**: Incluye el Departamento Biol\u00f3gico de Productos Farmac\u00e9uticos y Narc\u00f3ticos de Ir\u00e1n, Merck y la OMS.\n3. **Categor\u00edas Profesionales**: Los participantes tienen roles en regulaci\u00f3n, consultor\u00eda y est\u00e1ndares de calidad y seguridad en salud.\n4. **Pa\u00edses Representados**: Los expertos provienen de Ir\u00e1n, los Pa\u00edses Bajos, el Reino Unido y Suiza, lo que refleja una colaboraci\u00f3n internacional en temas de salud.\n\n### Entidades:\n- **Organizaciones**: \n  - Biological Dept Pharmaceutical & Narcotics (Ir\u00e1n)\n  - Merck (Pa\u00edses Bajos)\n  - Organizaci\u00f3n Mundial de la Salud (Suiza)\n  \n- **Expertos**:\n  - Mahbouba Vladakhani (Ir\u00e1n)\n  - Lisette Vromans (Pa\u00edses Bajos)\n  - Andrew Garnett (Reino Unido)\n  - \u00dcmit Karto\u011flu (Suiza)\n  - Denis Maire (Suiza)\n  - Lahouari Belgharbi (Suiza)\n  - Ivana Knezevic (Suiza)\n  - Sabine Kopp (Suiza)\n\nEste resumen destaca la colaboraci\u00f3n internacional y la diversidad de expertos involucrados en la mejora de la calidad y seguridad de los medicamentos a nivel global.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, evaluation procedure, confidentiality"}}, "38190395-f646-4c5b-aa0b-b3a65fbc2944": {"node_ids": ["281ba61c-8e2c-453e-907a-f52be2ce464c"], "metadata": {"page_label": "386", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies with advice on the acceptability, in principle, of pharmaceutical products for procurement by such agencies.\n\nThis activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality. WHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the manufacturers of such products or other applicants, and on an inspection of the corresponding manufacturing facilities and clinical sites. This is done through a standardized procedure which is based on WHO-recommended quality standards. The quality of pharmaceutical products is obviously crucial for the safety and efficacy of such products.\n\nThe pharmaceutical products found to meet the WHO-recommended quality standards are included in the list of medicines, as manufactured at the specified manufacturing sites, which are considered to be acceptable, in principle, for procurement by United Nations agencies. The list of prequalified pharmaceutical products is principally intended for use by United Nations agencies \u2014 including the Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children\u2019s Fund (UNICEF) and United Nations Population Fund (UNFPA) \u2014 to guide their procurement decisions. The growing list of pharmaceutical products that have been found to meet WHO-recommended standards may, however, also be of interest to other organizations and countries wishing to engage in the bulk procurement of pharmaceutical products.\n\nInclusion in the list does not imply any approval by WHO of the pharmaceutical products and manufacturing sites in question (which is the sole prerogative of national authorities). Moreover, inclusion in the list does not constitute an endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety and/or efficacy in the treatment of specific diseases.\n\n# 2. Glossary\n\nThe definitions given below apply to the terms used in this procedure. They may have different meanings in other contexts.\n\n**active pharmaceutical ingredient (API)**  \nA substance used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) aborda la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos para su adquisici\u00f3n por agencias de las Naciones Unidas. La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de estos productos, bas\u00e1ndose en informaci\u00f3n de los fabricantes y en inspecciones de las instalaciones de fabricaci\u00f3n. Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS son incluidos en una lista destinada a guiar las decisiones de compra de agencias como UNAIDS, UNICEF y UNFPA. Sin embargo, la inclusi\u00f3n en esta lista no implica aprobaci\u00f3n o garant\u00eda de la OMS sobre la idoneidad de los productos para usos espec\u00edficos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el proceso que sigue la OMS para evaluar la calidad de los productos farmac\u00e9uticos antes de incluirlos en la lista de precalificaci\u00f3n?**\n   - La OMS lleva a cabo una evaluaci\u00f3n integral que incluye la revisi\u00f3n de la informaci\u00f3n proporcionada por los fabricantes y la inspecci\u00f3n de las instalaciones de fabricaci\u00f3n y sitios cl\u00ednicos, todo ello basado en procedimientos estandarizados y normas de calidad recomendadas por la OMS.\n\n2. **\u00bfQu\u00e9 implicaciones tiene la inclusi\u00f3n de un producto farmac\u00e9utico en la lista de precalificaci\u00f3n de la OMS para las agencias de la ONU?**\n   - La inclusi\u00f3n en la lista permite a las agencias de la ONU, como UNAIDS, UNICEF y UNFPA, tomar decisiones informadas sobre la adquisici\u00f3n de medicamentos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS, facilitando as\u00ed el acceso a medicamentos esenciales.\n\n3. **\u00bfQu\u00e9 limitaciones existen en cuanto a la interpretaci\u00f3n de la inclusi\u00f3n de productos en la lista de la OMS?**\n   - La inclusi\u00f3n en la lista no implica aprobaci\u00f3n por parte de la OMS de los productos o sitios de fabricaci\u00f3n, ya que esta es una prerrogativa exclusiva de las autoridades nacionales. Adem\u00e1s, no se considera un respaldo o garant\u00eda de la OMS sobre la idoneidad de los productos para un prop\u00f3sito espec\u00edfico, incluyendo su seguridad y eficacia en el tratamiento de enfermedades.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n\n\n**Tema Principal:**\n- Procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos seg\u00fan la OMS.\n\n**Estructura del Procedimiento:**\n1. **Introducci\u00f3n:** Contexto general del procedimiento.\n2. **Glosario:** Definiciones de t\u00e9rminos relevantes.\n3. **Prop\u00f3sito y principios:** Objetivos y fundamentos del procedimiento.\n4. **Pasos del procedimiento:** Descripci\u00f3n detallada de las etapas a seguir.\n5. **Invitaci\u00f3n para expresiones de inter\u00e9s:** Proceso para invitar a los fabricantes a participar.\n6. **Datos e informaci\u00f3n a presentar:** Requisitos de documentaci\u00f3n para los solicitantes.\n7. **Filtrado de expedientes:** Evaluaci\u00f3n inicial de las solicitudes recibidas.\n8. **Evaluaci\u00f3n del expediente:** An\u00e1lisis detallado de la documentaci\u00f3n presentada.\n9. **Inspecci\u00f3n del sitio:** Verificaci\u00f3n de las instalaciones del fabricante.\n10. **Informe y comunicaci\u00f3n de resultados:** Proceso de notificaci\u00f3n de los resultados de la evaluaci\u00f3n.\n11. **Resultado del procedimiento de precalificaci\u00f3n:** Determinaci\u00f3n final sobre la precalificaci\u00f3n.\n12. **Mantenimiento del estatus de precalificaci\u00f3n:** Requisitos para conservar la aprobaci\u00f3n.\n13. **Recuperaci\u00f3n de costos:** Aspectos financieros del procedimiento.\n14. **Compromiso de confidencialidad:** Protecci\u00f3n de la informaci\u00f3n sensible.\n15. **Conflicto de inter\u00e9s:** Gesti\u00f3n de posibles conflictos en el proceso.\n\n**Ap\u00e9ndices:**\n- **Ap\u00e9ndice 1:** Diagrama de flujo del procedimiento de precalificaci\u00f3n.\n- **Ap\u00e9ndice 2:** Caracter\u00edsticas de los productos farmac\u00e9uticos precalificados que se publicar\u00e1n en el sitio web de la OMS.\n\n**Entidades Clave:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Entidad responsable del procedimiento de precalificaci\u00f3n.\n- **Productos farmac\u00e9uticos:** Objetos de evaluaci\u00f3n y precalificaci\u00f3n.\n- **Fabricantes:** Solicitantes del proceso de precalificaci\u00f3n.\n\nEste resumen destaca los componentes esenciales del procedimiento de precalificaci\u00f3n de productos farmac\u00e9uticos, as\u00ed como las entidades involucradas y los requisitos establecidos por la OMS.", "excerpt_keywords": "Keywords: WHO, pharmaceutical products, prequalification, quality standards, United Nations agencies"}}, "bc46a659-b482-46d9-92e2-51b58bc4d3b3": {"node_ids": ["12f4ae41-e427-4736-a7ab-aacf333d0e0c"], "metadata": {"page_label": "387", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "direct effect in restoring, correcting or modifying physiological functions in human beings.\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s).\n\n**contract research organization (CRO)**  \nAn organization (commercial, academic or other) to which an applicant may have transferred some of its tasks and obligations in relation to the conduct of clinical studies with the product submitted to WHO for assessment under the current procedure.\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling.\n\n**invitation for expressions of interest (EOIs) or invitation**  \nInvitation calling upon interested parties (e.g. manufacturers or other applicants) to submit an expression of interest (EOI) to WHO by a specified deadline for the purpose of participating in the WHO prequalification procedure in respect of the product(s) listed in the invitation. Such an EOI should be accompanied by the required documentation on the product(s) in question.\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products.\n\n**pharmaceutical product**  \nAny substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.\n\n**prequalification**  \nStandardized quality assessment procedure of WHO to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Agencies using information resulting from the prequalification procedure should perform additional steps of qualification prior to purchasing, such as ensuring financial stability and standing of the supplier, ability to supply the required quantities, security of the supply chain, preshipment quality control and other related aspects.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) describe procedimientos relacionados con la precalificaci\u00f3n de productos farmac\u00e9uticos. Define t\u00e9rminos clave como \"solicitante\", \"organizaci\u00f3n de investigaci\u00f3n por contrato (CRO)\", \"producto farmac\u00e9utico terminado (FPP)\", \"invitaci\u00f3n para expresiones de inter\u00e9s (EOIs)\", \"fabricante\", \"producto farmac\u00e9utico\" y \"precalificaci\u00f3n\". La precalificaci\u00f3n es un procedimiento estandarizado de evaluaci\u00f3n de calidad que permite a las agencias de las Naciones Unidas evaluar la aceptabilidad de productos farmac\u00e9uticos para su compra.\n\n### Preguntas\n1. **\u00bfQu\u00e9 documentaci\u00f3n debe presentar un solicitante junto con su expresi\u00f3n de inter\u00e9s (EOI) para participar en el procedimiento de precalificaci\u00f3n de la OMS?**\n   - Respuesta: El solicitante debe presentar la documentaci\u00f3n requerida sobre los productos listados en la invitaci\u00f3n junto con su expresi\u00f3n de inter\u00e9s (EOI).\n\n2. **\u00bfCu\u00e1l es el papel de una organizaci\u00f3n de investigaci\u00f3n por contrato (CRO) en el proceso de evaluaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS?**\n   - Respuesta: Una CRO es una organizaci\u00f3n a la que el solicitante puede haber transferido algunas de sus tareas y obligaciones relacionadas con la realizaci\u00f3n de estudios cl\u00ednicos del producto que se presenta a la OMS para su evaluaci\u00f3n.\n\n3. **\u00bfQu\u00e9 pasos adicionales deben realizar las agencias que utilizan la informaci\u00f3n de la precalificaci\u00f3n de la OMS antes de realizar una compra?**\n   - Respuesta: Las agencias deben llevar a cabo pasos adicionales de calificaci\u00f3n, como asegurar la estabilidad financiera y la reputaci\u00f3n del proveedor, la capacidad de suministrar las cantidades requeridas, la seguridad de la cadena de suministro, el control de calidad previo al env\u00edo y otros aspectos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS asesora a las agencias de las Naciones Unidas sobre la aceptabilidad de productos farmac\u00e9uticos para su adquisici\u00f3n.\n\n2. **Evaluaci\u00f3n de Calidad**: La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos, que incluye:\n   - Revisi\u00f3n de informaci\u00f3n proporcionada por los fabricantes.\n   - Inspecci\u00f3n de instalaciones de fabricaci\u00f3n y sitios cl\u00ednicos.\n   - Procedimientos estandarizados basados en normas de calidad recomendadas por la OMS.\n\n3. **Lista de Precalificaci\u00f3n**: Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS son incluidos en una lista destinada a guiar las decisiones de compra de agencias de la ONU, como:\n   - Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (UNAIDS).\n   - Fondo de las Naciones Unidas para la Infancia (UNICEF).\n   - Fondo de Poblaci\u00f3n de las Naciones Unidas (UNFPA).\n\n4. **Limitaciones de la Inclusi\u00f3n**: La inclusi\u00f3n en la lista no implica:\n   - Aprobaci\u00f3n de la OMS sobre los productos o sitios de fabricaci\u00f3n (esto es prerrogativa de las autoridades nacionales).\n   - Respaldo o garant\u00eda de la OMS sobre la idoneidad de los productos para usos espec\u00edficos, incluyendo su seguridad y eficacia en el tratamiento de enfermedades.\n\n5. **Ingrediente Farmac\u00e9utico Activo (API)**: Se define como una sustancia utilizada en un producto farmac\u00e9utico terminado que tiene actividad farmacol\u00f3gica o efecto directo en el diagn\u00f3stico, tratamiento o prevenci\u00f3n de enfermedades.\n\n### Entidades Clave\n- **OMS**: Organizaci\u00f3n Mundial de la Salud.\n- **Agencias de la ONU**: Incluyen UNAIDS, UNICEF y UNFPA.\n- **Productos Farmac\u00e9uticos**: Medicamentos que cumplen con los est\u00e1ndares de calidad de la OMS.\n- **Autoridades Nacionales**: Entidades responsables de la aprobaci\u00f3n de productos farmac\u00e9uticos en sus respectivos pa\u00edses.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical product, expression of interest, contract research organization, WHO"}}, "31786909-1a60-4d8a-b031-3fbeee0ddf5b": {"node_ids": ["0d35f700-67ae-435e-8719-cd0947ff5ce0"], "metadata": {"page_label": "388", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Stringent Regulatory Authority (SRA)\n\nFor the purpose of this procedure, a stringent regulatory authority (SRA) is:\n\n- The medicines regulatory authority in a country which is: \n  - (a) a member of the International Conference on Harmonisation (ICH) (European Union (EU) Japan and the United States of America); or \n  - (b) an ICH Observer, being the European Free Trade Association (EFTA) as represented by SwissMedic and Health Canada (as may be updated from time to time); or \n  - (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time); and\n- Only in relation to good manufacturing practices (GMP) inspections: a medicine regulatory authority that is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) as specified at http://www.picscheme.org.\n\n## 3. Purpose and Principles\n\nThe purpose of this WHO procedure is to evaluate whether certain pharmaceutical products (considered by WHO to be vital for the prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis, malaria and other diseases, or for reproductive health) meet the requirements recommended by WHO and are manufactured in compliance with current good manufacturing practices (hereinafter referred to as GMP).\n\nThis procedure established by WHO is based on the following principles:\n\n- The medicines eligible for prequalification are listed in invitations for EOI published on the WHO web site (http://who.int/prequal/info_applicants/info_for_applicants_EOIs.htm);\n- A general understanding of the production and quality control activities of the manufacturer;\n- Assessment of pharmaceutical product data and information on safety, efficacy and quality submitted by the manufacturer, including product formulation, manufacture and test data and results;\n- Inspection of finished pharmaceutical product (FPP) and active pharmaceutical ingredient (API) manufacturing site(s) for compliance with GMP;\n- Inspection of clinical testing units or contract research organizations (CROs) performing clinical trials for compliance with current good clinical practices (hereinafter referred to as GCP) and current good laboratory practices (hereinafter referred to as GLP);\n- Reliance on the information supplied by stringent national medicines regulatory authorities.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS establece definiciones y procedimientos relacionados con las autoridades regulatorias estrictas (SRA) y su papel en la evaluaci\u00f3n de productos farmac\u00e9uticos. Se centra en la pre-calificaci\u00f3n de medicamentos esenciales para el tratamiento de enfermedades como el VIH/SIDA, tuberculosis y malaria, asegurando que cumplan con las buenas pr\u00e1cticas de manufactura (GMP). El procedimiento incluye la evaluaci\u00f3n de datos de seguridad, eficacia y calidad, as\u00ed como inspecciones de sitios de fabricaci\u00f3n y ensayos cl\u00ednicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios definen a una autoridad regulatoria estricta (SRA) seg\u00fan la OMS?**\n   - La OMS define una SRA como una autoridad regulatoria de medicamentos en un pa\u00eds que es miembro de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), un observador de la ICH, o una autoridad asociada a un miembro de la ICH mediante un acuerdo de reconocimiento mutuo. Adem\u00e1s, en relaci\u00f3n con las inspecciones de GMP, debe ser miembro del esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica (PIC/S).\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito principal del procedimiento establecido por la OMS en relaci\u00f3n con los productos farmac\u00e9uticos?**\n   - El prop\u00f3sito principal es evaluar si ciertos productos farmac\u00e9uticos, considerados vitales para la prevenci\u00f3n y tratamiento de enfermedades como el VIH/SIDA, tuberculosis y malaria, cumplen con los requisitos recomendados por la OMS y son fabricados de acuerdo con las buenas pr\u00e1cticas de manufactura (GMP).\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n se eval\u00faa durante el proceso de pre-calificaci\u00f3n de medicamentos seg\u00fan la OMS?**\n   - Durante el proceso de pre-calificaci\u00f3n, se eval\u00faa la informaci\u00f3n sobre la producci\u00f3n y control de calidad del fabricante, as\u00ed como datos sobre la seguridad, eficacia y calidad del producto farmac\u00e9utico, incluyendo formulaciones, datos de fabricaci\u00f3n y resultados de pruebas. Tambi\u00e9n se realizan inspecciones de los sitios de fabricaci\u00f3n y de las unidades de ensayo cl\u00ednico para verificar el cumplimiento de las buenas pr\u00e1cticas cl\u00ednicas (GCP) y de laboratorio (GLP).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, definiendo varios t\u00e9rminos y conceptos esenciales relacionados con este procedimiento. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n1. **Solicitante (Applicant)**: Persona o entidad que presenta una expresi\u00f3n de inter\u00e9s (EOI) para participar en el procedimiento de precalificaci\u00f3n, junto con la documentaci\u00f3n requerida sobre los productos.\n\n2. **Organizaci\u00f3n de Investigaci\u00f3n por Contrato (CRO)**: Entidad a la que el solicitante puede haber delegado algunas de sus tareas y obligaciones en la realizaci\u00f3n de estudios cl\u00ednicos del producto que se eval\u00faa.\n\n3. **Producto Farmac\u00e9utico Terminado (FPP)**: Forma de dosificaci\u00f3n final de un producto farmac\u00e9utico que ha completado todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado y etiquetado.\n\n4. **Invitaci\u00f3n para Expresiones de Inter\u00e9s (EOIs)**: Convocatoria a partes interesadas (como fabricantes) para que presenten una EOI a la OMS dentro de un plazo espec\u00edfico, acompa\u00f1ada de la documentaci\u00f3n requerida.\n\n5. **Fabricante (Manufacturer)**: Empresa responsable de la producci\u00f3n, empaquetado, reempaquetado, etiquetado y/o reetiquetado de productos farmac\u00e9uticos.\n\n6. **Producto Farmac\u00e9utico (Pharmaceutical Product)**: Sustancia o combinaci\u00f3n de sustancias comercializadas para tratar o prevenir enfermedades en humanos, realizar diagn\u00f3sticos m\u00e9dicos o modificar funciones fisiol\u00f3gicas.\n\n7. **Precalificaci\u00f3n (Prequalification)**: Procedimiento estandarizado de evaluaci\u00f3n de calidad de la OMS para determinar la aceptabilidad de productos farmac\u00e9uticos para la compra por agencias de las Naciones Unidas. Este proceso incluye pasos adicionales de calificaci\u00f3n antes de la compra.\n\n### Conclusi\u00f3n\nEl documento establece un marco claro para la participaci\u00f3n en el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, definiendo roles y responsabilidades de los solicitantes, fabricantes y organizaciones involucradas en la investigaci\u00f3n y evaluaci\u00f3n de estos productos.", "excerpt_keywords": "Keywords: regulatory authority, prequalification, good manufacturing practices, pharmaceutical products, WHO"}}, "40f03c60-2c61-4687-ae54-fc20c1534fe7": {"node_ids": ["bf89d188-c06e-402a-9c1f-7b3fe3b6a438"], "metadata": {"page_label": "389", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the Procedure\n\nWHO undertakes a comprehensive evaluation of the quality of pharmaceutical products, based on information submitted by the applicants, and inspection of the relevant manufacturing and clinical sites. (A flowchart showing the prequalification process is provided in Appendix 1.)\n\nAt regular intervals, and also taking into consideration pertinent input received from relevant United Nations agencies, WHO will publish an invitation to interested parties, requesting them to voluntarily participate in this procedure in respect of the products mentioned in the invitation.\n\nBy submitting an EOI, the applicant undertakes to share information with WHO on all relevant aspects of manufacture and control of the specified products along with changes made and/or planned. Interested applicants provide the necessary information to WHO by submitting a product dossier in the prescribed format, and other information as requested.\n\nThe procedure will normally include:\n\n- Assessment of product dossiers, which must include product data and information as specified in the guidelines for submission, available on the WHO website (http://apps.who.int/prequal/);\n- Inspection of manufacturing sites of FPPs and active pharmaceutical ingredients (APIs), to assess compliance with GMP;\n- Inspection of clinical sites (if applicable), to assess compliance with GCP and GLP as appropriate.\n\nIf the evaluation above demonstrates that a product and its corresponding manufacturing (and clinical) site(s) meet WHO-recommended standards, WHO may collaborate with national medicines regulatory authorities (NMRAs) regarding dossier assessments and inspections. Subject to the terms of section 4 below, the prequalification of a product may also be based on approval by a stringent regulatory authority (SRA).\n\nWHO recommends that applicants expressing interest in participation in the prequalification procedure inform the NMRAs in the country of manufacture of their intention and request them to collaborate with WHO in the quality assessment process. It is recommended that applicants provide the NMRAs with the necessary authorization to discuss the relevant product files with WHO representatives during dossier assessment and site inspections (subject to appropriate confidentiality provisions, if necessary).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nLa Organizaci\u00f3n Mundial de la Salud (OMS) lleva a cabo una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos a trav\u00e9s de la revisi\u00f3n de la informaci\u00f3n presentada por los solicitantes y la inspecci\u00f3n de los sitios de fabricaci\u00f3n y cl\u00ednicos relevantes. El proceso de precalificaci\u00f3n incluye la evaluaci\u00f3n de expedientes de productos, inspecciones de sitios de fabricaci\u00f3n y cl\u00ednicas, y la colaboraci\u00f3n con autoridades regulatorias nacionales. Se recomienda que los solicitantes informen a las autoridades regulatorias sobre su intenci\u00f3n de participar en el proceso de precalificaci\u00f3n.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe incluir un expediente de producto para ser evaluado por la OMS?**\n   - La OMS requiere que el expediente de producto incluya datos e informaci\u00f3n espec\u00edficos seg\u00fan las pautas de presentaci\u00f3n disponibles en su sitio web.\n\n2. **\u00bfCu\u00e1l es el papel de las autoridades regulatorias nacionales (NMRAs) en el proceso de precalificaci\u00f3n de la OMS?**\n   - Las NMRAs colaboran con la OMS en la evaluaci\u00f3n de expedientes y en las inspecciones de los sitios de fabricaci\u00f3n y cl\u00ednicos, y se recomienda que los solicitantes les informen sobre su intenci\u00f3n de participar en el proceso.\n\n3. **\u00bfQu\u00e9 condiciones deben cumplirse para que un producto sea precalificado por la OMS?**\n   - Un producto y sus sitios de fabricaci\u00f3n y cl\u00ednicos deben cumplir con los est\u00e1ndares recomendados por la OMS, y la precalificaci\u00f3n tambi\u00e9n puede basarse en la aprobaci\u00f3n por parte de una autoridad reguladora estricta (SRA).", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Autoridad Regulatoria Estricta (SRA):**\n   - Definici\u00f3n de SRA como la autoridad regulatoria de medicamentos en pa\u00edses miembros de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), observadores de la ICH, o autoridades asociadas mediante acuerdos de reconocimiento mutuo.\n   - Inclusi\u00f3n de miembros del esquema de cooperaci\u00f3n de inspecci\u00f3n farmac\u00e9utica (PIC/S) en relaci\u00f3n con las inspecciones de buenas pr\u00e1cticas de manufactura (GMP).\n\n2. **Prop\u00f3sito del Procedimiento de la OMS:**\n   - Evaluar productos farmac\u00e9uticos vitales para el tratamiento de enfermedades como VIH/SIDA, tuberculosis y malaria, asegurando que cumplan con los requisitos de la OMS y las GMP.\n\n3. **Principios del Procedimiento:**\n   - Inclusi\u00f3n de medicamentos elegibles en invitaciones publicadas en el sitio web de la OMS.\n   - Evaluaci\u00f3n de la producci\u00f3n y control de calidad del fabricante.\n   - Inspecciones de sitios de fabricaci\u00f3n y unidades de ensayo cl\u00ednico para verificar el cumplimiento de las GMP, buenas pr\u00e1cticas cl\u00ednicas (GCP) y buenas pr\u00e1cticas de laboratorio (GLP).\n\n**Entidades:**\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Responsable de establecer el procedimiento y los criterios de evaluaci\u00f3n.\n- **Conferencia Internacional sobre Armonizaci\u00f3n (ICH):** Incluye a la Uni\u00f3n Europea, Jap\u00f3n y Estados Unidos.\n- **Asociaci\u00f3n Europea de Libre Comercio (EFTA):** Representada por SwissMedic y Health Canada.\n- **Esquema de Cooperaci\u00f3n de Inspecci\u00f3n Farmac\u00e9utica (PIC/S):** Relacionado con las inspecciones de GMP.\n- **Productos Farmac\u00e9uticos:** Medicamentos considerados esenciales para la salud p\u00fablica y su evaluaci\u00f3n para la pre-calificaci\u00f3n. \n\nEste resumen destaca los elementos esenciales del procedimiento de la OMS en relaci\u00f3n con las autoridades regulatorias y la evaluaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, regulatory authorities, quality assessment"}}, "f3d83edb-b907-4083-baf1-c23cefa36fb7": {"node_ids": ["f6e1407b-1c99-440b-bead-f26c0c0cdaaa"], "metadata": {"page_label": "390", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "the product will be included in the list of pharmaceutical products that are considered to be acceptable, in principle, for procurement by United Nations agencies.\n\nWHO reserves the right to terminate the evaluation of a specific product if the applicant is not able to provide the required information, and/or is unable to implement any corrective actions which WHO may require within a specified time period, or when the information supplied is inadequate to complete this procedure.\n\nWHO recognizes the evaluation of relevant products by SRAs which apply standards for quality equivalent to those recommended by WHO. Provided that the NMRA is willing to share certain information with WHO on the products in question, WHO will consider such products for inclusion in the list of WHO-prequalified products. It will do so as and when information about such products becomes available to WHO and when the holders of the regulatory approval of such products express their interest in having these products prequalified by WHO. These products will be added to the list of products prequalified by WHO, on the basis of the scientific assessment and inspections conducted by the regulatory authority concerned, and the exchange of relevant information between the regulatory authority and WHO.\n\nAn inspection of a manufacturer or CRO may not be required if:\n\n1. There has been an inspection by an SRA; and\n2. The inspection was conducted within the last three years; and\n3. Information on the inspection (including inspection report and responses to any deficiencies) is available for review by WHO; and\n4. Based on this and other available information, it is determined that the site(s) in question meet(s) the applicable WHO-recommended standards.\n\nWith a view to coordinating inspection activities, avoiding duplication and promoting information sharing without prejudice to the protection of any confidential and or proprietary information of the applicants and manufacturers in accordance with the terms of this procedure, WHO may disclose inspection related information to regulatory authorities of WHO Member States as well as to regulatory authorities that are members of the PIC/S.\n\n## 5. Invitation for expressions of interest\n\nThe pharmaceutical products listed in an invitation for EOIs are considered by WHO to be vital for the effective treatment and prevention of the\n\n----\n\n1 Taking into account any known specific risk(s) associated with the product(s), the results of previous inspections conducted by WHO or an SRA, any complaints (if known), the scope and detail of the inspection report, the number and type of any GMP deficiencies reported, the comprehensiveness of the manufacturer\u2019s response and the timelines for implementation of corrective action(s).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece los procedimientos para la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos destinados a la adquisici\u00f3n por parte de agencias de las Naciones Unidas. Se menciona que la OMS puede terminar la evaluaci\u00f3n de un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa las acciones correctivas necesarias. Adem\u00e1s, se reconoce la evaluaci\u00f3n de productos por parte de Autoridades Reguladoras de Salud (SRA) que aplican est\u00e1ndares de calidad equivalentes a los de la OMS. Tambi\u00e9n se detalla que, bajo ciertas condiciones, no se requiere una inspecci\u00f3n de un fabricante si se ha realizado una inspecci\u00f3n reciente por una SRA. Finalmente, se invita a expresar inter\u00e9s en productos farmac\u00e9uticos considerados vitales para el tratamiento y prevenci\u00f3n de enfermedades.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas bajo las cuales la OMS puede decidir no realizar una inspecci\u00f3n de un fabricante o CRO?**\n   - Esta pregunta busca detalles sobre los criterios que permiten a la OMS omitir una inspecci\u00f3n, lo cual no se detalla en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n debe compartir una Autoridad Nacional Reguladora de Medicamentos (NMRA) con la OMS para que sus productos sean considerados para la pre-calificaci\u00f3n?**\n   - Esta pregunta se centra en los requisitos de informaci\u00f3n que deben cumplirse para la inclusi\u00f3n en la lista de productos pre-calificados, un aspecto que puede no estar claramente definido en otros documentos.\n\n3. **\u00bfQu\u00e9 factores se consideran al evaluar los riesgos espec\u00edficos asociados con un producto farmac\u00e9utico durante el proceso de pre-calificaci\u00f3n?**\n   - Esta pregunta busca profundizar en los criterios de evaluaci\u00f3n de riesgos que la OMS utiliza, lo cual puede no estar disponible en otras fuentes de informaci\u00f3n.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona un marco para la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos, destacando la importancia de la calidad y la transparencia en el proceso. Se enfatiza la colaboraci\u00f3n entre la OMS y las autoridades reguladoras nacionales, as\u00ed como la necesidad de compartir informaci\u00f3n relevante para garantizar que los productos cumplan con los est\u00e1ndares internacionales. Adem\u00e1s, se menciona la importancia de las inspecciones y la evaluaci\u00f3n de riesgos en la toma de decisiones sobre la inclusi\u00f3n de productos en la lista de pre-calificaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Calidad**: La OMS realiza una evaluaci\u00f3n exhaustiva de la calidad de los productos farmac\u00e9uticos, que incluye la revisi\u00f3n de informaci\u00f3n presentada por los solicitantes y la inspecci\u00f3n de sitios de fabricaci\u00f3n y cl\u00ednicos.\n\n2. **Proceso de Precalificaci\u00f3n**: El proceso incluye la evaluaci\u00f3n de expedientes de productos, inspecciones de sitios de fabricaci\u00f3n y cl\u00ednicas, y la colaboraci\u00f3n con autoridades regulatorias nacionales.\n\n3. **Documentaci\u00f3n Requerida**: Los solicitantes deben presentar un expediente de producto que contenga datos e informaci\u00f3n espec\u00edficos seg\u00fan las pautas de la OMS.\n\n4. **Colaboraci\u00f3n con NMRAs**: Se recomienda que los solicitantes informen a las autoridades regulatorias nacionales (NMRAs) sobre su intenci\u00f3n de participar en el proceso de precalificaci\u00f3n y que busquen su colaboraci\u00f3n.\n\n5. **Cumplimiento de Normas**: Para que un producto sea precalificado, debe cumplir con los est\u00e1ndares recomendados por la OMS, y la precalificaci\u00f3n tambi\u00e9n puede depender de la aprobaci\u00f3n por parte de una autoridad reguladora estricta (SRA).\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades Regulatorias Nacionales (NMRAs)**: Organismos que colaboran con la OMS en la evaluaci\u00f3n de la calidad de los productos.\n- **Autoridades Reguladoras Estrictas (SRA)**: Entidades que pueden influir en la precalificaci\u00f3n de un producto basado en su aprobaci\u00f3n.\n\nEste resumen destaca los aspectos fundamentales del proceso de precalificaci\u00f3n de la OMS y las entidades involucradas en la evaluaci\u00f3n de la calidad de los productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, regulatory authorities, inspection standards"}}, "4e7f686d-acd8-4588-962f-aa1a84b537ef": {"node_ids": ["1fc5e80d-8172-46a6-9692-691b69114ea4"], "metadata": {"page_label": "391", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "specified diseases (including HIV/AIDS, malaria and tuberculosis) or for reproductive health. These products are normally included in either the WHO Model List of Essential Medicines or the relevant WHO treatment guidelines and recommendations (or both).\n\nThe products included in the WHO Model List of Essential Medicines are those that satisfy the priority health-care needs of a population. They are selected, among other criteria, on the basis of disease prevalence, evidence on efficacy and safety, and analysis of comparative cost-effectiveness. Products included in WHO treatment guidelines are selected on the basis of an assessment of the evidence for benefits, risks, costs and appropriateness for use in a variety of situations, taking into account the needs of special populations and the values and preferences of the groups (professional and patient) using them.\n\nEach invitation will be open and transparent, inviting all relevant parties to submit an EOI for the pharmaceutical products listed. Such an invitation will normally be published on the WHO web site and possibly also through other media, such as the international press.\n\nIn situations of high public health concern as determined by WHO, the Organization may also directly invite relevant parties to submit specified product dossiers for evaluation by WHO under this procedure without publication of an invitation for EOI.\n\n## 6. Data and information to be submitted\n\nInterested parties are expected to submit documentation on the pharmaceutical products as called for in the invitation for EOIs. Applicants should submit their product dossiers with the required information to the WHO focal point, before the deadline specified in the invitation. Guidance and instructions developed for the submission of the dossiers are made available on the WHO web site.\n\nNormally the applicants who participate in the WHO prequalification scheme for pharmaceutical products are the manufacturers of the FPPs, as specified in the invitations for EOIs. In the case that an applicant is not the manufacturer of the FPP, all relevant documentation, including (but not limited to) contract manufacturing documentation, should be submitted, demonstrating that the applicant is in full control of the manufacturing process for, and quality assurance of, the products submitted for prequalification.\n\nIn submitting an EOI for product evaluation, the applicant should send the following to the WHO focal point:\n\n- a covering letter, expressing interest in participating in the WHO prequalification procedure and confirming that the information submitted in the product dossier is complete and correct;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS detalla el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye la invitaci\u00f3n a partes interesadas a presentar expresiones de inter\u00e9s (EOI) para productos que satisfacen necesidades de salud prioritarias, como el VIH/SIDA, la malaria y la tuberculosis. Los productos se seleccionan en funci\u00f3n de criterios como la prevalencia de enfermedades, la eficacia, la seguridad y el costo-efectividad. Se requiere que los solicitantes presenten documentaci\u00f3n completa y precisa, y se especifican los requisitos para aquellos que no son fabricantes directos de los productos.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos que utiliza la OMS para seleccionar los productos que se incluir\u00e1n en la Lista Modelo de Medicamentos Esenciales?**\n   - Esta pregunta busca detalles sobre los criterios de selecci\u00f3n que no se mencionan expl\u00edcitamente en otros documentos.\n\n2. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere de los solicitantes que no son fabricantes directos de los productos farmac\u00e9uticos?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos para los solicitantes que act\u00faan como intermediarios, lo cual puede no estar claramente definido en otros contextos.\n\n3. **\u00bfC\u00f3mo se determina si una situaci\u00f3n de salud p\u00fablica es de alta preocupaci\u00f3n y qu\u00e9 implica esto para el proceso de evaluaci\u00f3n de productos?**\n   - Esta pregunta indaga sobre el proceso de evaluaci\u00f3n y las decisiones de la OMS en situaciones cr\u00edticas, lo que puede no estar ampliamente discutido en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Evaluaci\u00f3n y Pre-calificaci\u00f3n de Productos Farmac\u00e9uticos**:\n   - La OMS establece procedimientos para la evaluaci\u00f3n de productos farmac\u00e9uticos que pueden ser adquiridos por agencias de la ONU.\n   - Los productos que cumplen con los est\u00e1ndares de calidad recomendados por la OMS pueden ser considerados para la lista de productos pre-calificados.\n\n2. **Derecho de la OMS**:\n   - La OMS se reserva el derecho de terminar la evaluaci\u00f3n de un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa acciones correctivas en el tiempo especificado.\n\n3. **Colaboraci\u00f3n con Autoridades Reguladoras**:\n   - La OMS reconoce la evaluaci\u00f3n de productos por parte de Autoridades Reguladoras de Salud (SRA) que aplican est\u00e1ndares equivalentes a los de la OMS.\n   - Se requiere que las Autoridades Nacionales Reguladoras de Medicamentos (NMRA) compartan informaci\u00f3n relevante para que sus productos sean considerados para la pre-calificaci\u00f3n.\n\n4. **Condiciones para Omitir Inspecciones**:\n   - No se requiere una inspecci\u00f3n de un fabricante o CRO si se cumplen ciertas condiciones, como la realizaci\u00f3n de una inspecci\u00f3n reciente por una SRA y la disponibilidad de informaci\u00f3n sobre dicha inspecci\u00f3n.\n\n5. **Transparencia y Compartici\u00f3n de Informaci\u00f3n**:\n   - La OMS puede compartir informaci\u00f3n relacionada con inspecciones con autoridades reguladoras de Estados Miembros de la OMS y miembros de PIC/S, respetando la confidencialidad de la informaci\u00f3n de los solicitantes y fabricantes.\n\n6. **Invitaci\u00f3n para Expresiones de Inter\u00e9s (EOIs)**:\n   - Se invita a expresar inter\u00e9s en productos farmac\u00e9uticos considerados vitales para el tratamiento y prevenci\u00f3n de enfermedades.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos.\n- **SRA (Autoridades Reguladoras de Salud)**: Entidades que eval\u00faan productos farmac\u00e9uticos y cuyos est\u00e1ndares son reconocidos por la OMS.\n- **NMRA (Autoridad Nacional Reguladora de Medicamentos)**: Entidad que debe compartir informaci\u00f3n con la OMS para la pre-calificaci\u00f3n de productos.\n- **PIC/S (Pharmaceutical Inspection Co-operation Scheme)**: Organizaci\u00f3n que promueve la cooperaci\u00f3n en inspecciones de productos farmac\u00e9uticos. \n\nEste resumen destaca la importancia de la calidad, la transparencia y la colaboraci\u00f3n en el proceso de evaluaci\u00f3n y pre-calificaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS.", "excerpt_keywords": "Keywords: prequalification, essential medicines, WHO, pharmaceutical products, public health"}}, "ffe3a2c0-0d0d-4e6d-bd8f-e8cdf3a34a93": {"node_ids": ["9bed7da8-4e7a-464a-9445-feeb81bdd9df"], "metadata": {"page_label": "392", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "- a product dossier, in the format specified in the WHO guidance documents on submitting product data and information;\n- product samples, to enable visual examination and chemical and pharmaceutical analysis;\n- a site master file (SMF) for each manufacturing site listed in the product dossier, in the format specified in the WHO guidance documents for submitting an SMF; and\n- a contract research organization master file (CROMF) for each clinical site listed in the dossier, in the format specified in the WHO guidance documents for submitting a CROMF.\n\nAll documentation should be submitted in English.\n\nFor the purposes of this procedure, different requirements for documentation to be submitted apply to the following categories of products:\n\n- multisource (generic) FPPs to be assessed by WHO;\n- innovator FPPs approved by SRAs; and\n- multisource (generic) FPPs approved by SRAs.\n\nThe documentation requirements for each of the above categories can be found on the WHO web site at: http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nMultisource generic products must be shown, either directly or indirectly, to be therapeutically equivalent to the comparator product if they are to be considered interchangeable. WHO will maintain and make public the list of comparator products for this purpose. The WHO web site provides guidance on the evidence needed for a product to be considered equivalent without the need for in vivo equivalence studies (i.e. application of biowaiver).\n\nIf considered necessary or desirable by either party, and before the actual evaluation process starts, a discussion may be held between the manufacturer and WHO. This meeting should be scheduled as early as possible with a predefined agenda to address questions sent in advance to WHO by the manufacturer.\n\n## 7. Screening of dossiers submitted\n\nEach product dossier submitted by an applicant will be screened for completeness before being evaluated. Dossiers submitted for products which are not listed in an invitation for EOIs or have not otherwise been invited by WHO will not be accepted for assessment.\n\nSimilarly WHO will not consider dossiers that are incomplete. The applicant will be informed that an incomplete dossier has been received.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece los requisitos para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, incluyendo la necesidad de un dossier de producto, muestras del producto, un archivo maestro del sitio de fabricaci\u00f3n (SMF) y un archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF). Se especifican diferentes requisitos de documentaci\u00f3n seg\u00fan el tipo de producto (multisource, innovador, etc.) y se menciona la importancia de demostrar la equivalencia terap\u00e9utica para los productos gen\u00e9ricos. Adem\u00e1s, se indica que los dossiers ser\u00e1n revisados por su integridad antes de la evaluaci\u00f3n y que no se aceptar\u00e1n aquellos que no cumplan con los criterios establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere espec\u00edficamente para los productos multisource (gen\u00e9ricos) que se eval\u00faan por la OMS?**\n   - La OMS requiere un dossier de producto, muestras del producto, un archivo maestro del sitio de fabricaci\u00f3n (SMF) y un archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF) para los productos multisource.\n\n2. **\u00bfC\u00f3mo puede un producto gen\u00e9rico ser considerado intercambiable con un producto de referencia seg\u00fan la OMS?**\n   - Un producto gen\u00e9rico debe demostrar, directa o indirectamente, que es terap\u00e9uticamente equivalente al producto de referencia para ser considerado intercambiable. La OMS mantiene una lista p\u00fablica de productos de referencia para este prop\u00f3sito.\n\n3. **\u00bfQu\u00e9 sucede si un dossier presentado a la OMS est\u00e1 incompleto?**\n   - Si un dossier est\u00e1 incompleto, la OMS no lo considerar\u00e1 para evaluaci\u00f3n y el solicitante ser\u00e1 informado de que se ha recibido un dossier incompleto.\n\n### Resumen de Nivel Superior\n\nEl documento de la OMS proporciona directrices sobre la presentaci\u00f3n de documentaci\u00f3n para la evaluaci\u00f3n de productos farmac\u00e9uticos, diferenciando entre productos gen\u00e9ricos e innovadores. Se enfatiza la necesidad de cumplir con requisitos espec\u00edficos y de demostrar equivalencia terap\u00e9utica para los productos gen\u00e9ricos. Adem\u00e1s, se establece un proceso de revisi\u00f3n de la integridad de los dossiers antes de su evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Proceso de Precalificaci\u00f3n de Productos Farmac\u00e9uticos**: El documento describe el procedimiento de la OMS para la precalificaci\u00f3n de productos farmac\u00e9uticos, que incluye la invitaci\u00f3n a partes interesadas a presentar expresiones de inter\u00e9s (EOI) para productos que abordan necesidades de salud prioritarias.\n\n2. **Enfermedades Espec\u00edficas**: Se mencionan enfermedades como el VIH/SIDA, malaria y tuberculosis, as\u00ed como la salud reproductiva, como \u00e1reas de enfoque para la inclusi\u00f3n de productos en la Lista Modelo de Medicamentos Esenciales de la OMS.\n\n3. **Criterios de Selecci\u00f3n**: Los productos se seleccionan bas\u00e1ndose en la prevalencia de enfermedades, la evidencia de eficacia y seguridad, y el an\u00e1lisis de costo-efectividad. Tambi\u00e9n se consideran las necesidades de poblaciones especiales y las preferencias de los grupos involucrados.\n\n4. **Transparencia en el Proceso**: Las invitaciones para presentar EOIs son abiertas y transparentes, public\u00e1ndose en el sitio web de la OMS y, potencialmente, en otros medios.\n\n5. **Situaciones de Alta Preocupaci\u00f3n de Salud P\u00fablica**: La OMS puede invitar directamente a partes relevantes a presentar dossiers de productos para evaluaci\u00f3n sin necesidad de una invitaci\u00f3n p\u00fablica en situaciones de alta preocupaci\u00f3n.\n\n6. **Documentaci\u00f3n Requerida**: Los solicitantes deben presentar documentaci\u00f3n completa y precisa, incluyendo cartas de presentaci\u00f3n que confirmen la veracidad de la informaci\u00f3n en el dossier del producto.\n\n7. **Fabricantes y Control de Calidad**: Normalmente, los solicitantes son los fabricantes de los productos farmac\u00e9uticos. Si un solicitante no es el fabricante, debe proporcionar documentaci\u00f3n que demuestre el control total sobre el proceso de fabricaci\u00f3n y la garant\u00eda de calidad.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable del proceso de precalificaci\u00f3n.\n- **Productos Farmac\u00e9uticos**: Incluyen medicamentos para enfermedades espec\u00edficas y salud reproductiva.\n- **Solicitantes**: Pueden ser fabricantes o intermediarios que deben cumplir con requisitos espec\u00edficos de documentaci\u00f3n.\n- **Lista Modelo de Medicamentos Esenciales**: Un listado de productos que satisfacen las necesidades de salud prioritarias de la poblaci\u00f3n.", "excerpt_keywords": "Keywords: product dossier, WHO guidelines, therapeutic equivalence, multisource generic products, documentation requirements"}}, "41c1b8e8-39ba-44b4-a432-d95966915e77": {"node_ids": ["92180ee0-466e-4b38-8b20-74cc275fdbf3"], "metadata": {"page_label": "393", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "and will be requested to complete the dossier within a specified time period. In the event of non-compliance, the dossier may be rejected on grounds of incompleteness and returned to the applicant. Dossiers that are considered complete as the result of the screening will be retained by WHO for assessment.\n\nAfter screening, if the dossier is accepted for assessment the applicant will be informed of this, including the dossier reference number, by letter. This letter will serve as an agreement between WHO and the applicant for the participation in prequalification and a commitment to comply with the provisions of the prequalification procedure.\n\n## 8. Dossier assessment\n\nThe product information submitted in the dossiers will be assessed by teams of experts (assessors) appointed by WHO. The assessors involved in dossier assessment must have the relevant qualifications and experience in the fields of pharmaceutical development, quality assessment of pharmaceutical products, quality assurance, biopharmaceutics and other relevant fields. The assessors will be appointed in accordance with a standard operating procedure (SOP) established by WHO. The assessors should preferably be from NMRAs and they will act as temporary advisers to WHO. The assessors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure.\n\nThe assessment of product dossiers will be done in accordance with SOPs established by WHO for that purpose so as to ensure uniformity in evaluation and timeliness of assessment activities. If needed, WHO may provide training to these experts.\n\nFollowing the assessment of each part of the dossier, a report will be provided to the applicant. Applicants are expected to submit responses to comments and any additional information that may be requested as soon as possible. Within one month, the applicant should inform WHO of the estimated time frame required to address and respond to all queries. The procedure is usually suspended (i.e. WHO will not undertake any further action) until all required responses and any additional information is received by WHO.\n\nEach applicant may request a hearing or meeting with the WHO experts involved in the assessment of this applicant\u2019s dossier to clarify issues identified by the WHO experts. WHO may provide technical assistance to applicants regarding appropriate product information to be submitted as well as production and control requirements.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento describe el proceso de evaluaci\u00f3n de dossiers para la precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla el procedimiento que deben seguir los solicitantes, incluyendo la presentaci\u00f3n de informaci\u00f3n del producto, la evaluaci\u00f3n por expertos designados por la OMS, y la comunicaci\u00f3n de resultados y requerimientos adicionales. Tambi\u00e9n se menciona la posibilidad de que los solicitantes soliciten reuniones con los expertos de la OMS para aclarar dudas y recibir asistencia t\u00e9cnica.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si un solicitante no cumple con el plazo para completar su dossier?**\n   - En caso de no cumplimiento, el dossier puede ser rechazado por incompleto y devuelto al solicitante.\n\n2. **\u00bfQu\u00e9 tipo de formaci\u00f3n pueden recibir los evaluadores designados por la OMS?**\n   - La OMS puede proporcionar formaci\u00f3n a los expertos evaluadores si es necesario, para asegurar que est\u00e9n adecuadamente preparados para la evaluaci\u00f3n de los dossiers.\n\n3. **\u00bfCu\u00e1l es el procedimiento que debe seguir un solicitante si desea aclarar dudas sobre su dossier?**\n   - El solicitante puede solicitar una audiencia o reuni\u00f3n con los expertos de la OMS involucrados en la evaluaci\u00f3n de su dossier para aclarar los problemas identificados.\n\n### Resumen de nivel superior\n\nEl proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la OMS implica la presentaci\u00f3n de un dossier por parte del solicitante, que ser\u00e1 evaluado por expertos en diversas \u00e1reas relacionadas con el desarrollo y la calidad de productos farmac\u00e9uticos. La OMS establece procedimientos operativos est\u00e1ndar para garantizar la uniformidad y la eficiencia en la evaluaci\u00f3n. Los solicitantes deben responder a los comentarios y solicitudes de informaci\u00f3n adicional en un plazo determinado, y tienen la opci\u00f3n de solicitar reuniones para discutir su dossier.", "prev_section_summary": "### Temas Clave\n\n1. **Requisitos de Documentaci\u00f3n**: Se especifican los documentos necesarios para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, que incluyen:\n   - Dossier de producto.\n   - Muestras del producto.\n   - Archivo maestro del sitio de fabricaci\u00f3n (SMF).\n   - Archivo maestro de la organizaci\u00f3n de investigaci\u00f3n por contrato (CROMF).\n\n2. **Categor\u00edas de Productos**: Se diferencian los requisitos de documentaci\u00f3n seg\u00fan el tipo de producto:\n   - Productos multisource (gen\u00e9ricos) a ser evaluados por la OMS.\n   - Productos innovadores aprobados por Autoridades Reguladoras de Salud (SRA).\n   - Productos multisource aprobados por SRA.\n\n3. **Equivalencia Terap\u00e9utica**: Para que un producto gen\u00e9rico sea considerado intercambiable con un producto de referencia, debe demostrar equivalencia terap\u00e9utica, ya sea de forma directa o indirecta.\n\n4. **Proceso de Evaluaci\u00f3n**: Los dossiers ser\u00e1n revisados por su integridad antes de la evaluaci\u00f3n. No se aceptar\u00e1n dossiers incompletos ni aquellos que no est\u00e9n en la lista de invitaciones de la OMS.\n\n5. **Comunicaci\u00f3n Previa**: Se sugiere que, si es necesario, se realice una discusi\u00f3n entre el fabricante y la OMS antes del inicio del proceso de evaluaci\u00f3n.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n y aprobaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Formulaci\u00f3n Farmac\u00e9utica de Producto)**: T\u00e9rmino utilizado para referirse a los productos farmac\u00e9uticos en evaluaci\u00f3n.\n- **SRA (Autoridades Reguladoras de Salud)**: Organismos que aprueban productos innovadores y multisource.\n- **Dossier de Producto**: Documento que contiene informaci\u00f3n sobre el producto farmac\u00e9utico.\n- **SMF (Site Master File)**: Archivo que proporciona informaci\u00f3n sobre el sitio de fabricaci\u00f3n.\n- **CROMF (Contract Research Organization Master File)**: Archivo que contiene informaci\u00f3n sobre los sitios cl\u00ednicos de investigaci\u00f3n.\n\nEste resumen abarca los aspectos esenciales y las entidades mencionadas en la secci\u00f3n del documento de la OMS.", "excerpt_keywords": "Keywords: dossier assessment, WHO prequalification, pharmaceutical products, expert evaluators, compliance requirements"}}, "104dc4d6-b559-40e9-b95e-adf0d6bec6ab": {"node_ids": ["7bf7ab8f-2fcf-4c74-a7fc-fbff69205b04"], "metadata": {"page_label": "394", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Site inspection\n\nWHO will plan and coordinate, in accordance with SOPs established by WHO and based on quality risk management (QRM) principles, the performance of inspections of the site(s) of manufacture of the API(s) and the FPP, and of the clinical testing units or CROs.\n\nThe following factors will be taken into account when planning inspections:\n\n- the results of previous inspection(s) by WHO or an SRA, and history of compliance of the company or facility with GMP, GCP and or GLP as appropriate;\n- the outcome of the assessment of data submitted to WHO;\n- complexity of the site, processes and product;\n- number and significance of known quality defects (e.g. complaints, recalls);\n- major changes to, e.g. buildings, equipment, processes, key personnel;\n- site experience with manufacturing and testing of a product; and\n- test results of official control laboratories.\n\nThe inspections of the manufacturing site(s) are conducted to assess compliance with GMP as recommended by WHO and include data verification. SMFs submitted by the applicant will be reviewed before an inspection is performed.\n\nThe inspections of clinical testing units or CROs are carried out to assess compliance with GCP and GLP, and to perform data verification.\n\nThe WHO norms and standards applicable to inspections of APIs and FPPs, and of clinical testing units or CROs, can be found on the WHO web site at http://who.int/prequal/assessment_inspect/info_inspection.htm#2. These requirements may be revised from time to time.\n\nThe inspections will be performed by a team of inspectors usually including experts appointed by WHO, preferably from NMRA inspectorates, who will act as temporary advisers to WHO. The inspectors must have the relevant qualifications and experience to perform such inspections, be competent in areas such as production and quality control of pharmaceuticals, and have appropriate experience in GMP and GCP or GLP. The inspectors must comply with the confidentiality and conflict of interest rules of WHO, as laid down in the relevant sections of this procedure. If needed, WHO may provide training to these experts.\n\nA WHO staff member will coordinate the team and will normally lead the inspection team. Each team will perform the inspections and report its findings to WHO in accordance with SOPs established by WHO for that purpose so as to ensure a standard harmonized approach. A representative", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Res\u00famenes de nivel superior del contexto\n\n1. **Objetivo de las Inspecciones**: La Organizaci\u00f3n Mundial de la Salud (OMS) coordina inspecciones de sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos terminados (FPP), as\u00ed como de unidades de pruebas cl\u00ednicas o CROs, para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP).\n\n2. **Factores Considerados para la Inspecci\u00f3n**: Al planificar las inspecciones, la OMS toma en cuenta varios factores, incluyendo el historial de cumplimiento de la instalaci\u00f3n, la complejidad del sitio y los procesos, y los resultados de pruebas de laboratorios de control oficial.\n\n3. **Equipo de Inspecci\u00f3n**: Las inspecciones son realizadas por un equipo de inspectores con experiencia y calificaciones relevantes, coordinados por un miembro del personal de la OMS. Se espera que los inspectores cumplan con normas de confidencialidad y conflicto de intereses.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de formaci\u00f3n puede recibir el personal de inspecci\u00f3n designado por la OMS?**\n   - La OMS puede proporcionar formaci\u00f3n a los expertos que act\u00faan como inspectores temporales, asegurando que tengan las competencias necesarias para llevar a cabo las inspecciones de acuerdo con los est\u00e1ndares establecidos.\n\n2. **\u00bfC\u00f3mo se determina la frecuencia y el enfoque de las inspecciones de un sitio espec\u00edfico?**\n   - La frecuencia y el enfoque de las inspecciones se determinan en funci\u00f3n de varios factores, como los resultados de inspecciones anteriores, el historial de cumplimiento de la instalaci\u00f3n, la complejidad del sitio y los procesos, as\u00ed como la cantidad y significancia de defectos de calidad conocidos.\n\n3. **\u00bfQu\u00e9 medidas se toman si se encuentran defectos de calidad durante una inspecci\u00f3n?**\n   - Aunque el texto no detalla espec\u00edficamente las medidas a tomar, se infiere que los defectos de calidad significativos podr\u00edan influir en la evaluaci\u00f3n de cumplimiento de GMP, GCP o GLP, y podr\u00edan llevar a acciones correctivas o a una revisi\u00f3n m\u00e1s exhaustiva de las pr\u00e1cticas de la instalaci\u00f3n.", "prev_section_summary": "### Temas Clave\n\n1. **Proceso de Dossier**: Los solicitantes deben completar un dossier dentro de un plazo espec\u00edfico. Si no cumplen, el dossier puede ser rechazado por incompleto.\n\n2. **Aceptaci\u00f3n y Comunicaci\u00f3n**: Si el dossier es aceptado tras la revisi\u00f3n inicial, el solicitante recibe una carta que confirma la aceptaci\u00f3n y establece un acuerdo con la OMS.\n\n3. **Evaluaci\u00f3n del Dossier**: Equipos de expertos designados por la OMS eval\u00faan la informaci\u00f3n del producto presentada en los dossiers. Los evaluadores deben tener experiencia en desarrollo farmac\u00e9utico, evaluaci\u00f3n de calidad y otros campos relevantes.\n\n4. **Procedimientos Operativos Est\u00e1ndar (SOP)**: La evaluaci\u00f3n se realiza de acuerdo con SOP establecidos por la OMS para asegurar uniformidad y eficiencia.\n\n5. **Informe y Respuestas**: Despu\u00e9s de la evaluaci\u00f3n, se proporciona un informe al solicitante, quien debe responder a los comentarios y solicitudes de informaci\u00f3n adicional en un plazo determinado.\n\n6. **Suspensi\u00f3n del Proceso**: El proceso se suspende hasta que la OMS reciba todas las respuestas y la informaci\u00f3n adicional requerida.\n\n7. **Reuniones y Asistencia T\u00e9cnica**: Los solicitantes pueden solicitar reuniones con los expertos de la OMS para aclarar dudas y recibir asistencia t\u00e9cnica sobre la informaci\u00f3n del producto y requisitos de producci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Solicitantes**: Empresas o individuos que presentan dossiers para la precalificaci\u00f3n.\n- **Expertos Evaluadores**: Profesionales designados por la OMS con experiencia en \u00e1reas relevantes para la evaluaci\u00f3n de productos farmac\u00e9uticos.\n- **Dossier**: Documento que contiene la informaci\u00f3n del producto que se eval\u00faa para la precalificaci\u00f3n.\n- **NMRAs (National Medicines Regulatory Authorities)**: Autoridades nacionales de regulaci\u00f3n de medicamentos que pueden participar como evaluadores.", "excerpt_keywords": "Keywords: inspections, WHO, GMP, GCP, quality risk management"}}, "136170ca-c500-487e-b337-22d8b495d2aa": {"node_ids": ["aee75c72-6eea-48bf-bd03-f117fafdcbf7"], "metadata": {"page_label": "395", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Reporting and Communication of the Results of the Evaluation\n\nEach assessment and inspection team will finalize its reports according to the established WHO SOP and format, describing the findings and including recommendations to the applicant, manufacturer(s) and/or CROs where relevant.\n\nThe findings from the dossier assessment including, but not limited to, deficiencies of the documentation and data submitted, shall be communicated in writing to the applicant requesting submission of the missing data and information, as appropriate.\n\nThe inspection report will be communicated to the manufacturer or CRO as applicable. With the written agreement of the manufacturer or CRO, a copy of the inspection report may also be provided to the applicant (if other than the manufacturer or CRO). If any additional information is required, or corrective action has to be taken by the manufacturer or CRO, WHO will postpone its decision on the acceptability of the site(s) concerned until such information has been evaluated or the corrective action has been taken and found satisfactory in light of the specified standards.\n\nWHO reserves the right to terminate this procedure for a specific product if the applicant is not able to provide the required information or implement the corrective actions within a specified time period, or if the information supplied is inadequate to complete this procedure.\n\nIn the event of any disagreement between an applicant and WHO, an SOP established by WHO for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the prequalification procedure, the ownership of the reports lies with WHO. Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any commercially", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe el proceso de evaluaci\u00f3n y comunicaci\u00f3n de resultados por parte de la OMS en relaci\u00f3n con la precalificaci\u00f3n de productos. Se detalla c\u00f3mo los equipos de evaluaci\u00f3n e inspecci\u00f3n finalizan sus informes, la comunicaci\u00f3n de hallazgos y deficiencias a los solicitantes, y el manejo de la informaci\u00f3n adicional o acciones correctivas necesarias. Tambi\u00e9n se menciona el derecho de la OMS a terminar el procedimiento si no se cumplen los requisitos y c\u00f3mo se manejan los desacuerdos entre los solicitantes y la OMS.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si un solicitante no puede proporcionar la informaci\u00f3n requerida dentro del plazo especificado?**\n   - La OMS se reserva el derecho de terminar el procedimiento para un producto espec\u00edfico si el solicitante no puede proporcionar la informaci\u00f3n requerida o implementar las acciones correctivas dentro del tiempo especificado.\n\n2. **\u00bfC\u00f3mo se maneja la comunicaci\u00f3n de los hallazgos de la evaluaci\u00f3n a los solicitantes?**\n   - Los hallazgos de la evaluaci\u00f3n del expediente, incluyendo deficiencias en la documentaci\u00f3n y datos presentados, se comunican por escrito al solicitante, solicitando la presentaci\u00f3n de los datos e informaci\u00f3n faltantes seg\u00fan sea apropiado.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS sobre los informes generados durante el proceso de evaluaci\u00f3n?**\n   - La OMS es responsable del procedimiento de precalificaci\u00f3n y, por lo tanto, posee los informes generados. Tiene el derecho de usar y publicar dichos informes, siempre que se protejan los intereses comerciales involucrados.", "prev_section_summary": "### Temas Clave\n\n1. **Objetivo de las Inspecciones**: La OMS coordina inspecciones para asegurar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) y Buenas Pr\u00e1cticas de Laboratorio (GLP) en sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (API) y productos farmac\u00e9uticos terminados (FPP), as\u00ed como en unidades de pruebas cl\u00ednicas o CROs.\n\n2. **Factores para la Planificaci\u00f3n de Inspecciones**: Se consideran varios factores al planificar las inspecciones, incluyendo:\n   - Resultados de inspecciones anteriores.\n   - Historial de cumplimiento de la instalaci\u00f3n.\n   - Complejidad del sitio y procesos.\n   - N\u00famero y significancia de defectos de calidad conocidos.\n   - Cambios importantes en la instalaci\u00f3n.\n   - Experiencia del sitio en la fabricaci\u00f3n y pruebas de productos.\n   - Resultados de laboratorios de control oficial.\n\n3. **Equipo de Inspecci\u00f3n**: Las inspecciones son realizadas por un equipo de inspectores con experiencia y calificaciones relevantes, coordinados por un miembro del personal de la OMS. Se espera que los inspectores cumplan con normas de confidencialidad y conflicto de intereses.\n\n4. **Normas y Est\u00e1ndares**: Las normas y est\u00e1ndares aplicables a las inspecciones est\u00e1n disponibles en el sitio web de la OMS y pueden ser revisadas peri\u00f3dicamente.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de coordinar las inspecciones.\n- **API (Ingredientes Farmac\u00e9uticos Activos)**: Sustancias que se utilizan en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Productos Farmac\u00e9uticos Terminados)**: Productos que est\u00e1n listos para ser distribuidos y utilizados.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidades que realizan pruebas cl\u00ednicas.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran que los productos se fabriquen de manera consistente y controlada.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)**: Normas que aseguran la calidad y la \u00e9tica en la investigaci\u00f3n cl\u00ednica.\n- **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normas que aseguran la calidad y la integridad de los datos de laboratorio.", "excerpt_keywords": "Keywords: WHO, evaluation, inspection report, prequalification, communication"}}, "663771ba-3789-4434-93c1-4aca524c9bb9": {"node_ids": ["7c0e73e4-2f49-434c-a4e2-8f447b024200"], "metadata": {"page_label": "396", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "\nsensitive confidential information of the applicant, manufacturer(s) and/or testing organization(s). \"Confidential information\" in this context means:\n\n- confidential intellectual property, know-how and trade secrets (including, e.g. formulas, processes or information contained or embodied in a product, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans of a company).\n\nProvisions of confidentiality will be contained in the exchange of letters, to be concluded before the assessment of the product dossier or inspection of the manufacturing and clinical sites, between WHO and each applicant, manufacturer or CRO.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full assessment and inspection reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n## 11. Outcome of the prequalification procedure\n\nOnce WHO is satisfied that this procedure is complete for the relevant product, and that the WHO-recommended standards are met, the product, as manufactured at the specified manufacturing site(s), will be included in the list of prequalified pharmaceutical products. The list of prequalified pharmaceutical products will be compiled in accordance with an SOP established by WHO for final decision-making on inclusion in the list. The list will be published on the WHO web site and will specify the characteristics of the prequalified pharmaceutical products, as described in Appendix 2 to this procedure.\n\nEach applicant will receive a letter of prequalification from WHO informing it of the outcome of the quality assessment process in regard of the submitted product(s). Once the product(s) are included in the list of prequalified pharmaceutical products, the applicant shall be responsible for keeping WHO continuously updated on all relevant aspects of the manufacture and control of such product(s) and to meet any requirements, as agreed with WHO.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any commercially sensitive confidential information \u2014 publish WHO Public Assessment Reports (WHOPAR(s)) on the product dossier assessments and WHO Public Inspection Reports (WHOPIR(s)) on the manufacturers and CROs, that were found to be in compliance with WHO-recommended guidelines and standards. These reports will be published on the WHO web site. Subject always to the protection of commercially sensitive confidential\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla el procedimiento de precalificaci\u00f3n para productos farmac\u00e9uticos. Se enfatiza la importancia de la confidencialidad de la informaci\u00f3n sensible relacionada con los solicitantes, fabricantes y organizaciones de pruebas. La OMS se compromete a proteger la propiedad intelectual y los secretos comerciales, pero tambi\u00e9n se reserva el derecho de compartir informes de evaluaci\u00f3n con autoridades pertinentes. Una vez que un producto cumple con los est\u00e1ndares recomendados por la OMS, se incluir\u00e1 en una lista de productos farmac\u00e9uticos precalificados, y los solicitantes recibir\u00e1n una carta informativa sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se considera \"confidencial\" seg\u00fan el documento de la OMS y c\u00f3mo se protege durante el proceso de precalificaci\u00f3n?**\n   - Esta pregunta busca detalles sobre la definici\u00f3n de informaci\u00f3n confidencial y las medidas espec\u00edficas que se toman para protegerla durante el proceso de evaluaci\u00f3n.\n\n2. **\u00bfCu\u00e1l es el proceso que sigue la OMS para decidir la inclusi\u00f3n de un producto en la lista de productos farmac\u00e9uticos precalificados?**\n   - Esta pregunta se centra en el procedimiento espec\u00edfico que la OMS utiliza para evaluar y decidir sobre la precalificaci\u00f3n de un producto, incluyendo los criterios y pasos involucrados.\n\n3. **\u00bfQu\u00e9 obligaciones tienen los solicitantes una vez que su producto ha sido precalificado por la OMS?**\n   - Esta pregunta busca informaci\u00f3n sobre las responsabilidades continuas de los solicitantes despu\u00e9s de que su producto ha sido incluido en la lista de productos precalificados, as\u00ed como cualquier requisito adicional que deban cumplir.", "prev_section_summary": "### Temas Clave\n\n1. **Finalizaci\u00f3n de Informes**: Los equipos de evaluaci\u00f3n e inspecci\u00f3n de la OMS finalizan sus informes siguiendo procedimientos operativos est\u00e1ndar (SOP) establecidos, que incluyen hallazgos y recomendaciones.\n\n2. **Comunicaci\u00f3n de Hallazgos**: Los hallazgos de la evaluaci\u00f3n, incluidas las deficiencias en la documentaci\u00f3n, se comunican por escrito al solicitante, quien debe proporcionar la informaci\u00f3n faltante.\n\n3. **Informes de Inspecci\u00f3n**: Los informes de inspecci\u00f3n se env\u00edan al fabricante o CRO correspondiente, y pueden ser compartidos con el solicitante con el consentimiento por escrito del fabricante o CRO.\n\n4. **Acciones Correctivas y Evaluaci\u00f3n**: Si se requieren acciones correctivas o informaci\u00f3n adicional, la OMS pospone su decisi\u00f3n sobre la aceptabilidad del sitio hasta que se eval\u00fae la nueva informaci\u00f3n o se implementen las acciones correctivas.\n\n5. **Terminaci\u00f3n del Procedimiento**: La OMS puede terminar el procedimiento para un producto si el solicitante no proporciona la informaci\u00f3n requerida o no implementa las acciones correctivas en el tiempo especificado.\n\n6. **Manejo de Desacuerdos**: En caso de desacuerdos entre un solicitante y la OMS, se seguir\u00e1 un SOP establecido para resolver el problema.\n\n7. **Propiedad de los Informes**: La OMS es propietaria de los informes generados durante el proceso de precalificaci\u00f3n y tiene derecho a usarlos y publicarlos, protegiendo los intereses comerciales involucrados.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable del procedimiento de precalificaci\u00f3n y de la evaluaci\u00f3n de productos.\n- **Solicitante**: Parte que presenta la documentaci\u00f3n y datos para la evaluaci\u00f3n.\n- **Fabricante**: Entidad que produce el producto evaluado.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad que puede estar involucrada en el proceso de evaluaci\u00f3n y fabricaci\u00f3n.\n- **SOP (Procedimientos Operativos Est\u00e1ndar)**: Normas establecidas por la OMS para la evaluaci\u00f3n y manejo de informes y desacuerdos.", "excerpt_keywords": "Keywords: prequalification, confidentiality, WHO, pharmaceutical products, assessment reports"}}, "7ab705b2-4cc3-4f1a-bb68-e26733afbf78": {"node_ids": ["c73c7897-f0c0-48f9-8398-7aaaa55cf5fc"], "metadata": {"page_label": "397", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "The decision to list a pharmaceutical product is made based upon information available to WHO at that time, i.e. information in the submitted dossier and on the status of GMP, GLP and GCP at the facilities used in the manufacture and testing of the product at the time of the site inspection(s) conducted by WHO or at the time of the site inspection(s) conducted by an SRA, the outcome of which has been determined by WHO to meet the applicable WHO-recommended standards, in accordance with the terms of this procedure. This decision is subject to change on the basis of new information that may become available to WHO. If serious safety and/or quality concerns arise in relation to a prequalified product, WHO may delist the product after evaluation of the new evidence and a risk\u2013benefit assessment, or may suspend the product until results of further investigations become available and are evaluated by WHO.\n\n## 12. Maintenance of prequalification status\n\nApplicants are required to communicate details to WHO of any changes (variations) in manufacture and control that may have an impact on the safety, efficacy and quality of the product.\n\nGuidance on variations to prequalified dossiers as can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time.\n\nIt is the applicant\u2019s responsibility to provide WHO with the appropriate documentation (referring to relevant parts of the dossier) to prove that any intended or implemented variation will not have a negative impact on the quality of the product that has been prequalified. WHO will undertake an evaluation of variations according to the established WHO guidelines and SOPs and communicate the outcome to the applicant within the prescribed time lines. Adherence to the reporting requirements will be verified during the inspections carried out by WHO.\n\nRandom samples of prequalified products supplied by listed manufacturers or applicants will be taken for independent testing of final product characteristics. Certificates of analysis of final products released by the manufacturer and specifications for test methods should be provided by the manufacturer or applicant to WHO for review upon request. In the event of failure to meet the established criteria for testing, WHO will investigate the problem and communicate the outcome of this investigation to the manufacturer and applicant, if other than the manufacturer.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la OMS establece el proceso y los criterios para la inclusi\u00f3n y el mantenimiento del estado de precalificaci\u00f3n de productos farmac\u00e9uticos. La decisi\u00f3n de listar un producto se basa en la informaci\u00f3n disponible en el momento de la evaluaci\u00f3n, incluyendo el estado de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Laboratorio (GLP) y Buenas Pr\u00e1cticas Cl\u00ednicas (GCP). La OMS puede cambiar su decisi\u00f3n si surgen nuevas evidencias sobre la seguridad o calidad del producto. Adem\u00e1s, los solicitantes deben informar sobre cualquier cambio en la fabricaci\u00f3n que pueda afectar la calidad del producto y proporcionar la documentaci\u00f3n necesaria para demostrar que dichos cambios no impactar\u00e1n negativamente en la calidad. La OMS tambi\u00e9n realiza pruebas independientes de muestras de productos precalificados y puede investigar problemas si los productos no cumplen con los criterios establecidos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentaci\u00f3n debe proporcionar un solicitante a la OMS para demostrar que una variaci\u00f3n en la fabricaci\u00f3n no afectar\u00e1 negativamente la calidad del producto?**\n   - La documentaci\u00f3n debe referirse a las partes relevantes del dossier y demostrar que la variaci\u00f3n no tendr\u00e1 un impacto negativo en la calidad del producto precalificado.\n\n2. **\u00bfQu\u00e9 acciones puede tomar la OMS si surgen preocupaciones serias sobre la seguridad o calidad de un producto precalificado?**\n   - La OMS puede delistar el producto tras una evaluaci\u00f3n de nuevas evidencias y un an\u00e1lisis de riesgo-beneficio, o puede suspender el producto hasta que se completen investigaciones adicionales.\n\n3. **\u00bfC\u00f3mo verifica la OMS el cumplimiento de los requisitos de reporte por parte de los solicitantes?**\n   - La OMS verifica el cumplimiento de los requisitos de reporte durante las inspecciones realizadas en las instalaciones de fabricaci\u00f3n y control de los productos.\n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o fuentes, bas\u00e1ndose en los detalles proporcionados en el contexto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Confidencialidad de la Informaci\u00f3n**:\n   - Se define la \"informaci\u00f3n confidencial\" como propiedad intelectual, secretos comerciales y confidencias comerciales.\n   - La OMS establece medidas para proteger esta informaci\u00f3n durante el proceso de precalificaci\u00f3n, incluyendo el intercambio de cartas de confidencialidad con solicitantes, fabricantes y organizaciones de pruebas.\n\n2. **Proceso de Precalificaci\u00f3n**:\n   - La OMS eval\u00faa productos farmac\u00e9uticos para determinar si cumplen con los est\u00e1ndares recomendados.\n   - Una vez completada la evaluaci\u00f3n y verificaci\u00f3n de cumplimiento, el producto se incluye en una lista de productos farmac\u00e9uticos precalificados.\n   - La lista se publica en el sitio web de la OMS y detalla las caracter\u00edsticas de los productos precalificados.\n\n3. **Obligaciones de los Solicitantes**:\n   - Los solicitantes reciben una carta de precalificaci\u00f3n que informa sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n   - Tienen la responsabilidad de mantener a la OMS actualizada sobre todos los aspectos relevantes de la fabricaci\u00f3n y control de los productos precalificados.\n\n4. **Publicaci\u00f3n de Informes**:\n   - La OMS publicar\u00e1 informes de evaluaci\u00f3n p\u00fablica (WHOPAR) y de inspecci\u00f3n p\u00fablica (WHOPIR) sobre los productos y fabricantes que cumplan con las directrices y est\u00e1ndares recomendados, protegiendo la informaci\u00f3n confidencial sensible.\n\n### Entidades Mencionadas:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del procedimiento de precalificaci\u00f3n.\n- **Solicitantes**: Empresas o individuos que presentan productos para la precalificaci\u00f3n.\n- **Fabricantes**: Entidades que producen los productos farmac\u00e9uticos.\n- **Organizaciones de Pruebas (CROs)**: Organizaciones que realizan pruebas y evaluaciones de productos. \n\nEste resumen destaca los aspectos clave del procedimiento de precalificaci\u00f3n de la OMS, as\u00ed como las responsabilidades y derechos de las partes involucradas.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO guidelines, safety and quality, manufacturing variations"}}, "9a5e0369-cc47-4cd1-a0a3-f90ca71347c7": {"node_ids": ["fe238e7f-95cd-4532-8c7f-c2dd097a1ae5"], "metadata": {"page_label": "398", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Complaints concerning prequalified pharmaceutical products communicated to WHO will be investigated in accordance with an SOP established by WHO for that purpose. After investigation, WHO will provide a written report of the problem and include recommendations for action where relevant. WHO will make the report available to the applicant/manufacturer, and to the NMRA of the country where the manufacturing site is located. Subject always to the protection of commercially sensitive information as referred to above, WHO shall be entitled to make such reports public. In addition, WHO reserves the right to share the full report with the relevant authorities of interested Member States of the Organization and interested United Nations agencies.\n\nManufacturers of prequalified pharmaceutical products and associated API manufacturers will be re-inspected at regular intervals as determined by WHO, but normally at least once every three years. Re-inspections are conducted to verify compliance with GMP as recommended by WHO and include data verification.\n\nFurthermore, in order to maintain their prequalification status, WHO will arrange for prequalified pharmaceutical products to be requalified at regular intervals.\n\nEvery five years from the date of prequalification, or when requested to do so by the WHO Prequalification of Medicines Programme, the holder of a prequalified product is required to submit data and information in relation to the product to WHO for assessment. The purpose of this assessment is to verify that the product conforms to information and data submitted in relation to prequalification, conforms to current norms and standards, and to verify the consistency of the quality of the product and its manufacturing process(es) over the identified period.\n\nThe procedure and guidelines on the requalification of prequalified products can be found on the WHO web site at http://who.int/prequal/info_applicants/info_for_applicants_guidelines.htm. These requirements may be revised from time to time. Re-inspection and/or requalification may also be performed:\n\n- if any fraud or omissions by the applicant, manufacturer(s) of an FPP or API, or CROs in the initial assessment procedure or during the follow-up activities, become evident; and\n- if WHO or any United Nations agency considers that a batch or batches of supplied prequalified pharmaceutical products are not in compliance with the specifications which were found to be applicable upon prequalification.\n\nIf, as a result of re-inspection or requalification, it is found that a product and/or specified manufacturing site no longer complies with the WHO-", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\nEl documento de la OMS establece procedimientos para investigar quejas sobre productos farmac\u00e9uticos prequalificados. La OMS realiza inspecciones regulares a los fabricantes para verificar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) y la calidad de los productos. Cada cinco a\u00f1os, los titulares de productos prequalificados deben presentar datos para su evaluaci\u00f3n. La OMS tambi\u00e9n tiene el derecho de hacer p\u00fablicos los informes de las investigaciones, siempre que se proteja la informaci\u00f3n comercial sensible.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si se encuentra que un producto farmac\u00e9utico precalificado ya no cumple con las normas de la OMS durante una re-inspecci\u00f3n?**\n   - Si se determina que un producto o un sitio de fabricaci\u00f3n ya no cumple con las normas de la OMS, se pueden tomar medidas correctivas, que pueden incluir la suspensi\u00f3n de la precalificaci\u00f3n del producto y la notificaci\u00f3n a las autoridades pertinentes.\n\n2. **\u00bfCon qu\u00e9 frecuencia se realizan las re-inspecciones de los fabricantes de productos farmac\u00e9uticos prequalificados?**\n   - Las re-inspecciones se realizan normalmente al menos una vez cada tres a\u00f1os, aunque la OMS puede determinar intervalos diferentes seg\u00fan sea necesario.\n\n3. **\u00bfQu\u00e9 tipo de informaci\u00f3n deben presentar los titulares de productos prequalificados a la OMS cada cinco a\u00f1os?**\n   - Los titulares deben presentar datos e informaci\u00f3n que verifiquen que el producto sigue cumpliendo con la informaci\u00f3n y datos presentados durante la precalificaci\u00f3n, as\u00ed como con las normas y est\u00e1ndares actuales, y que la calidad del producto y su proceso de fabricaci\u00f3n se mantienen consistentes durante el per\u00edodo identificado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Decisi\u00f3n de Listado de Productos Farmac\u00e9uticos**:\n   - La inclusi\u00f3n de un producto farmac\u00e9utico en la lista de la OMS se basa en la informaci\u00f3n disponible en el momento de la evaluaci\u00f3n, que incluye el dossier presentado y el estado de las Buenas Pr\u00e1cticas de Manufactura (GMP), Buenas Pr\u00e1cticas de Laboratorio (GLP) y Buenas Pr\u00e1cticas Cl\u00ednicas (GCP).\n   - La decisi\u00f3n puede cambiar si surgen nuevas evidencias sobre la seguridad o calidad del producto.\n\n2. **Mantenimiento del Estado de Precalificaci\u00f3n**:\n   - Los solicitantes deben informar a la OMS sobre cualquier cambio en la fabricaci\u00f3n que pueda afectar la seguridad, eficacia y calidad del producto.\n   - Es responsabilidad del solicitante proporcionar la documentaci\u00f3n adecuada que demuestre que las variaciones no impactar\u00e1n negativamente en la calidad del producto precalificado.\n\n3. **Evaluaci\u00f3n de Variaciones**:\n   - La OMS evaluar\u00e1 las variaciones seg\u00fan sus directrices y procedimientos operativos est\u00e1ndar (SOPs) y comunicar\u00e1 los resultados al solicitante dentro de los plazos establecidos.\n\n4. **Pruebas Independientes**:\n   - Se tomar\u00e1n muestras aleatorias de productos precalificados para pruebas independientes de sus caracter\u00edsticas finales.\n   - Los fabricantes deben proporcionar certificados de an\u00e1lisis y especificaciones de m\u00e9todos de prueba a la OMS cuando se solicite.\n\n5. **Investigaci\u00f3n de Problemas**:\n   - Si un producto no cumple con los criterios establecidos, la OMS investigar\u00e1 el problema y comunicar\u00e1 los resultados a los fabricantes y solicitantes.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normas que aseguran que los productos se fabriquen de manera consistente y controlada.\n- **GLP (Buenas Pr\u00e1cticas de Laboratorio)**: Normas que garantizan la calidad y la integridad de los datos generados en laboratorios.\n- **GCP (Buenas Pr\u00e1cticas Cl\u00ednicas)**: Normas \u00e9ticas y cient\u00edficas para el dise\u00f1o, realizaci\u00f3n, registro y reporte de ensayos cl\u00ednicos que involucran la participaci\u00f3n de sujetos humanos.\n- **Solicitantes**: Empresas o entidades que presentan productos para su precalificaci\u00f3n ante la OMS.", "excerpt_keywords": "Keywords: prequalified pharmaceutical products, WHO, re-inspection, GMP compliance, requalification"}}, "5caf1014-b62a-419f-a5d7-8c46a665f51e": {"node_ids": ["3a5813ae-b462-4e22-9733-aa5c33b3f7b8"], "metadata": {"page_label": "399", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 13. Cost recovery\n\nWHO reserves the right to charge for this procedure on a cost-recovery basis.\n\n# 14. Confidentiality undertaking\n\nThe assessors and inspectors will treat all information to which they will gain access during the assessments and inspections, or otherwise in connection with the discharge of their responsibilities in regard to the above-mentioned project, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set forth below.\n\nAssessors and inspectors will take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the assessment/inspection activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nAssessors and inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by manufacturers); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by manufacturers); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n# 15. Conflict of interest\n\nBefore undertaking the work, each assessor and inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is no risk of a real or perceived conflict of interest (or it is", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda varios aspectos relacionados con la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en el contexto de evaluaciones e inspecciones. Se establece que la OMS tiene el derecho de cobrar por estos procedimientos en base a la recuperaci\u00f3n de costos. Adem\u00e1s, se enfatiza la importancia de mantener la confidencialidad de la informaci\u00f3n a la que los evaluadores e inspectores tienen acceso, as\u00ed como la necesidad de firmar una declaraci\u00f3n de intereses para evitar conflictos de inter\u00e9s.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas deben tomar los evaluadores e inspectores para garantizar la confidencialidad de la informaci\u00f3n a la que tienen acceso?**\n   - Los evaluadores e inspectores deben asegurarse de que la informaci\u00f3n confidencial no se utilice para ning\u00fan prop\u00f3sito que no sea las actividades de evaluaci\u00f3n o inspecci\u00f3n descritas en el documento y que no se divulgue a personas no vinculadas por obligaciones similares de confidencialidad.\n\n2. **\u00bfBajo qu\u00e9 circunstancias los evaluadores e inspectores no estar\u00e1n obligados por las obligaciones de confidencialidad y no uso?**\n   - No estar\u00e1n obligados si pueden demostrar que la informaci\u00f3n confidencial ya era conocida por ellos antes de la divulgaci\u00f3n, estaba en el dominio p\u00fablico en el momento de la divulgaci\u00f3n, se ha convertido en parte del dominio p\u00fablico sin culpa de su parte, o ha sido obtenida de un tercero que no est\u00e1 en violaci\u00f3n de obligaciones legales de confidencialidad.\n\n3. **\u00bfQu\u00e9 procedimiento deben seguir los evaluadores e inspectores antes de comenzar su trabajo en relaci\u00f3n con los conflictos de inter\u00e9s?**\n   - Antes de comenzar su trabajo, cada evaluador e inspector debe firmar una declaraci\u00f3n de inter\u00e9s para asegurar que no existe un riesgo de conflicto de inter\u00e9s real o percibido.", "prev_section_summary": "### Temas Clave\n\n1. **Investigaci\u00f3n de Quejas**: La OMS investiga quejas sobre productos farmac\u00e9uticos prequalificados siguiendo un procedimiento operativo est\u00e1ndar (SOP). Se emite un informe escrito con recomendaciones y se comparte con el fabricante y la autoridad reguladora nacional (NMRA) del pa\u00eds donde se encuentra el sitio de fabricaci\u00f3n.\n\n2. **Re-inspecciones**: Los fabricantes de productos farmac\u00e9uticos prequalificados son re-inspeccionados al menos cada tres a\u00f1os para verificar el cumplimiento de las Buenas Pr\u00e1cticas de Manufactura (GMP) y la calidad del producto.\n\n3. **Recalificaci\u00f3n**: Cada cinco a\u00f1os, los titulares de productos prequalificados deben presentar datos a la OMS para evaluar la conformidad del producto con las normas actuales y la consistencia de su calidad y procesos de fabricaci\u00f3n.\n\n4. **Publicaci\u00f3n de Informes**: La OMS tiene el derecho de hacer p\u00fablicos los informes de las investigaciones, protegiendo la informaci\u00f3n comercial sensible.\n\n5. **Condiciones para Re-inspecci\u00f3n/Recalificaci\u00f3n**: Se pueden realizar re-inspecciones o recalificaciones si se detectan fraudes, omisiones o si se considera que un lote de productos no cumple con las especificaciones.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organismo responsable de la investigaci\u00f3n de quejas y la supervisi\u00f3n de la calidad de los productos farmac\u00e9uticos prequalificados.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que recibe informes sobre quejas y problemas relacionados con productos farmac\u00e9uticos en su pa\u00eds.\n- **Fabricantes de Productos Farmac\u00e9uticos Prequalificados**: Empresas que producen medicamentos que han sido evaluados y aprobados por la OMS.\n- **CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que pueden estar involucradas en el proceso de evaluaci\u00f3n inicial y seguimiento de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: cost recovery, confidentiality, conflict of interest, assessors, inspections"}}, "42dfc961-226b-487c-bbeb-86d81c61c7f8": {"node_ids": ["270cf6ee-a4c3-49d2-bac1-1fb268ac46f9"], "metadata": {"page_label": "400", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "felt that there is only an insignificant and/or irrelevant conflict of interest), and it is thus deemed appropriate for the assessor or inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each assessor and inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll inspectors furthermore agree that, at the manufacturer\u2019s or CRO\u2019s request, WHO will advise the manufacturer or CRO, in advance, of the identity of each inspector and the composition of the team performing the site inspection, and provide curricula vitae of the inspectors. The manufacturer or CRO then has the opportunity to express possible concerns regarding any of the inspectors to WHO before the visit. If such concerns cannot be resolved in consultation with WHO, the manufacturer or CRO may object to a team member\u2019s participation in the site visit. Such an objection must be made known to WHO by the manufacturer or CRO within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel all or part of its agreement with, and the activities to be undertaken by, that inspector.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de conflictos de inter\u00e9s para los inspectores y evaluadores que trabajan en nombre de la organizaci\u00f3n. Se requiere que estos profesionales declaren cualquier conflicto de inter\u00e9s y notifiquen a la OMS sobre cualquier cambio en su situaci\u00f3n. Adem\u00e1s, se detalla el proceso mediante el cual los fabricantes o CROs pueden expresar preocupaciones sobre los inspectores asignados a las inspecciones de sitios, as\u00ed como el derecho de la OMS a cancelar la participaci\u00f3n de un inspector si surgen objeciones.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 procedimientos deben seguir los inspectores para declarar conflictos de inter\u00e9s y c\u00f3mo deben notificar a la OMS sobre cambios en su situaci\u00f3n?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos de declaraci\u00f3n de conflictos de inter\u00e9s y el proceso de notificaci\u00f3n a la OMS.\n\n2. **\u00bfCu\u00e1l es el plazo que tienen los fabricantes o CROs para expresar objeciones sobre los inspectores asignados antes de una visita de inspecci\u00f3n?**\n   - Esta pregunta aborda el tiempo l\u00edmite que tienen los fabricantes o CROs para comunicar sus preocupaciones sobre los inspectores.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS en caso de que un fabricante o CRO exprese una objeci\u00f3n sobre un inspector asignado?**\n   - Esta pregunta explora las acciones que puede tomar la OMS si se presenta una objeci\u00f3n por parte de un fabricante o CRO respecto a un inspector.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Recuperaci\u00f3n de Costos**:\n   - La OMS se reserva el derecho de cobrar por los procedimientos de evaluaci\u00f3n e inspecci\u00f3n en base a la recuperaci\u00f3n de costos.\n\n2. **Confidencialidad**:\n   - Los evaluadores e inspectores deben tratar toda la informaci\u00f3n a la que acceden como confidencial y propietaria de la OMS o de sus colaboradores.\n   - Se establecen medidas para asegurar que la informaci\u00f3n confidencial no se utilice para otros prop\u00f3sitos ni se divulgue a personas no autorizadas.\n   - Existen excepciones a las obligaciones de confidencialidad si la informaci\u00f3n ya era conocida, estaba en el dominio p\u00fablico, se volvi\u00f3 p\u00fablica sin culpa de los evaluadores, o fue obtenida de un tercero sin violar obligaciones de confidencialidad.\n\n3. **Conflicto de Inter\u00e9s**:\n   - Antes de comenzar su trabajo, cada evaluador e inspector debe firmar una declaraci\u00f3n de intereses para asegurar que no existe un riesgo de conflicto de inter\u00e9s real o percibido.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de establecer las pol\u00edticas de confidencialidad y recuperaci\u00f3n de costos.\n- **Evaluadores e Inspectores**: Profesionales encargados de llevar a cabo las evaluaciones e inspecciones bajo las directrices de la OMS. \n\nEste resumen destaca la importancia de la confidencialidad y la gesti\u00f3n de conflictos de inter\u00e9s en el contexto de las evaluaciones realizadas por la OMS.", "excerpt_keywords": "Keywords: conflictos de inter\u00e9s, inspectores, OMS, evaluaci\u00f3n, fabricantes"}}, "cd25c970-03cd-4d06-a610-617279aec832": {"node_ids": ["872752dd-d2bf-40c9-ba56-5ffe35407718"], "metadata": {"page_label": "401", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 1\n\n## Flowchart of WHO prequalification of pharmaceutical products\n\n1. **EOI** by applicant to participate in WHO Prequalification of Medicines Programme\n\n2. **Receipt and processing of EOIs** and accompanying documentation by WHO Prequalification of Medicines Programme\n\n### 3A. Assessment of dossiers\nby WHO in two parallel tracks:\n- quality part\n- clinical part\n\n**Communication with the applicant**  \nResults from dossier assessment (including deficiencies found) are communicated to the applicant. If corrective actions are required, WHO will postpone its decision on the acceptability of data and information presented.\n\n### 3B. Inspection\nin three parallel tracks:\n- manufacturing site of FPPs\n- manufacturing site of APIs\n- clinical research sites\n\n**Communication with the applicant, manufacturer and CRO**  \nResults from inspections are communicated to the manufacturer or CRO, as applicable. If corrective actions are required, WHO will postpone its decision on the acceptability of the respective sites.\n\n4. **Final decision on prequalification**  \nIn the case that the product dossier and inspected manufacturing and clinical sites are found to be acceptable (i.e. to be in compliance with WHO-recommended standards).\n\n5. **Listing of prequalified product**  \nand manufacturing site(s) on the WHO web site  \nPublication of WHOPIRS and WHOPARs.\n\n6. **Maintenance of list of prequalified products**  \nSampling and testing, handling of variations and complaints, re-inspection, requalification, etc. WHO may suspend or remove products from the list.\n\n----\n\n**EOI**: expression of interest;  \n**FPP**: finished pharmaceutical product;  \n**API**: active pharmaceutical ingredient;  \n**CRO**: contract research organization;  \n**WHOPIR**: public inspection report;  \n**WHOPAR**: public assessment report.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe el flujo del proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Este proceso incluye la presentaci\u00f3n de una expresi\u00f3n de inter\u00e9s (EOI) por parte del solicitante, la evaluaci\u00f3n de los expedientes en dos partes (calidad y cl\u00ednica), inspecciones de los sitios de fabricaci\u00f3n y de investigaci\u00f3n cl\u00ednica, y la decisi\u00f3n final sobre la precalificaci\u00f3n. Si se cumplen los est\u00e1ndares recomendados por la OMS, el producto se lista en el sitio web de la OMS y se mantiene un seguimiento continuo de los productos precalificados.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 sucede si se encuentran deficiencias durante la evaluaci\u00f3n del expediente por parte de la OMS?**\n   - Respuesta: Si se encuentran deficiencias durante la evaluaci\u00f3n del expediente, la OMS comunica los resultados al solicitante y, si se requieren acciones correctivas, pospone su decisi\u00f3n sobre la aceptabilidad de los datos e informaci\u00f3n presentados.\n\n2. **\u00bfCu\u00e1les son los tres tipos de inspecciones que realiza la OMS durante el proceso de precalificaci\u00f3n?**\n   - Respuesta: La OMS realiza inspecciones en tres tipos de sitios: el sitio de fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs), el sitio de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs) y los sitios de investigaci\u00f3n cl\u00ednica.\n\n3. **\u00bfQu\u00e9 implica la \"mantenimiento de la lista de productos precalificados\" por parte de la OMS?**\n   - Respuesta: El mantenimiento de la lista de productos precalificados implica actividades como muestreo y pruebas, manejo de variaciones y quejas, re-inspecciones y re-calificaciones. La OMS tambi\u00e9n puede suspender o eliminar productos de la lista si es necesario.", "prev_section_summary": "### Temas Clave:\n1. **Conflictos de Inter\u00e9s**: Se establece la obligaci\u00f3n de los inspectores y evaluadores de declarar cualquier conflicto de inter\u00e9s y notificar a la OMS sobre cambios en su situaci\u00f3n.\n2. **Proceso de Inspecci\u00f3n**: Se detalla el procedimiento que deben seguir los fabricantes o CROs para expresar preocupaciones sobre los inspectores asignados a las inspecciones de sitios.\n3. **Derechos de la OMS**: La OMS tiene la autoridad para cancelar la participaci\u00f3n de un inspector si se presentan objeciones por parte de un fabricante o CRO.\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de supervisar y regular los conflictos de inter\u00e9s y las inspecciones.\n- **Inspectores y Evaluadores**: Profesionales que realizan funciones de asesor\u00eda y evaluaci\u00f3n en nombre de la OMS.\n- **Fabricantes y CROs (Organizaciones de Investigaci\u00f3n por Contrato)**: Entidades que pueden expresar preocupaciones sobre los inspectores asignados a sus inspecciones.\n\n### Resumen:\nEl documento de la OMS establece directrices sobre la gesti\u00f3n de conflictos de inter\u00e9s para inspectores y evaluadores, quienes deben declarar y notificar cualquier cambio en su situaci\u00f3n. Adem\u00e1s, se describe el proceso mediante el cual los fabricantes o CROs pueden expresar preocupaciones sobre los inspectores antes de una visita de inspecci\u00f3n, as\u00ed como el derecho de la OMS a cancelar la participaci\u00f3n de un inspector si surgen objeciones.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, inspection, assessment"}}, "cd3f3f91-808e-4877-92ff-e233f4f7c290": {"node_ids": ["43100b44-fcba-4fff-832a-aa6fd9f3b74d"], "metadata": {"page_label": "402", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix 2\n\n**Characteristics of the prequalified pharmaceutical product to be made available for public access on the WHO web site**\n\n- WHO product reference number\n- International Nonproprietary Name (INN) of active pharmaceutical ingredient(s) (API(s))\n- Dosage form and strength\n- Trade name(s) of the product (if applicable)\n- Name of applicant and official address\n- Name of manufacturer of finished pharmaceutical product (FPP)\n- Physical address of manufacturing site(s) (and unit, if applicable)\n- Name of API manufacturer, physical address of manufacturing site(s) (and unit, if applicable)\n- Product description (as in FPP specifications, i.e. coated, scored, etc.)\n- Pack size(s), primary and secondary packaging material(s)\n- Storage conditions\n- Shelf-life (provisional, if applicable)\n- Summary of product characteristics\n- Package leaflet\n- Labelling", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento \"WHO - Technical Report Series 961\" incluye un ap\u00e9ndice que detalla las caracter\u00edsticas de los productos farmac\u00e9uticos precalificados que se har\u00e1n disponibles para el acceso p\u00fablico en el sitio web de la OMS. Este ap\u00e9ndice enumera informaci\u00f3n clave que debe ser proporcionada para cada producto, incluyendo el nombre del fabricante, la forma de dosificaci\u00f3n, las condiciones de almacenamiento y otros detalles relevantes.\n\n### Preguntas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n espec\u00edfica se requiere sobre el fabricante del producto farmac\u00e9utico precalificado?**\n   - Esta pregunta busca detalles sobre los requisitos de informaci\u00f3n relacionados con el fabricante, como el nombre y la direcci\u00f3n f\u00edsica del sitio de fabricaci\u00f3n.\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento y la vida \u00fatil que deben ser reportadas para un producto farmac\u00e9utico precalificado?**\n   - Esta pregunta se centra en los aspectos log\u00edsticos y de conservaci\u00f3n del producto, que son cruciales para su manejo y distribuci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n adicional se debe incluir junto con la descripci\u00f3n del producto farmac\u00e9utico en el sitio web de la OMS?**\n   - Esta pregunta indaga sobre los documentos complementarios que deben acompa\u00f1ar la informaci\u00f3n del producto, como el prospecto y el etiquetado, que son esenciales para el usuario final.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento presenta un flujo de trabajo detallado sobre el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Los temas clave incluyen:\n\n1. **Expresi\u00f3n de Inter\u00e9s (EOI)**: El proceso comienza con la presentaci\u00f3n de una EOI por parte del solicitante para participar en el programa de precalificaci\u00f3n de medicamentos de la OMS.\n\n2. **Recepci\u00f3n y Procesamiento de EOIs**: La OMS recibe y procesa las EOIs y la documentaci\u00f3n correspondiente.\n\n3. **Evaluaci\u00f3n de Dossiers**: La evaluaci\u00f3n se realiza en dos partes paralelas:\n   - Parte de calidad\n   - Parte cl\u00ednica  \n   Si se encuentran deficiencias, la OMS comunica los resultados al solicitante y puede posponer su decisi\u00f3n.\n\n4. **Inspecciones**: Se llevan a cabo inspecciones en tres tipos de sitios:\n   - Sitios de fabricaci\u00f3n de productos farmac\u00e9uticos terminados (FPPs)\n   - Sitios de fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs)\n   - Sitios de investigaci\u00f3n cl\u00ednica  \n   Los resultados de las inspecciones tambi\u00e9n se comunican a los involucrados, y se pueden requerir acciones correctivas.\n\n5. **Decisi\u00f3n Final sobre Precalificaci\u00f3n**: Se toma una decisi\u00f3n final si el expediente del producto y los sitios inspeccionados cumplen con los est\u00e1ndares recomendados por la OMS.\n\n6. **Listado de Productos Precalificados**: Los productos que cumplen son listados en el sitio web de la OMS, junto con la publicaci\u00f3n de informes de inspecci\u00f3n y evaluaci\u00f3n.\n\n7. **Mantenimiento de la Lista de Productos Precalificados**: Incluye actividades como muestreo, pruebas, manejo de quejas, re-inspecciones y re-calificaciones. La OMS tiene la autoridad para suspender o eliminar productos de la lista.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable del proceso de precalificaci\u00f3n.\n- **EOI (Expresi\u00f3n de Inter\u00e9s)**: Solicitud inicial para participar en el programa.\n- **FPP (Producto Farmac\u00e9utico Terminado)**: Producto final que se eval\u00faa.\n- **API (Ingrediente Farmac\u00e9utico Activo)**: Componente activo de los productos farmac\u00e9uticos.\n- **CRO (Organizaci\u00f3n de Investigaci\u00f3n por Contrato)**: Entidad que puede estar involucrada en la investigaci\u00f3n cl\u00ednica.\n- **WHOPIR (Informe P\u00fablico de Inspecci\u00f3n)**: Informe sobre la inspecci\u00f3n de productos.\n- **WHOPAR (Informe P\u00fablico de Evaluaci\u00f3n)**: Informe sobre la evaluaci\u00f3n de productos. \n\nEste resumen proporciona una visi\u00f3n general del proceso de precalificaci\u00f3n de la OMS y las entidades involucradas en \u00e9l.", "excerpt_keywords": "Keywords: prequalified pharmaceuticals, WHO, product characteristics, manufacturing information, storage conditions"}}, "04dc2aec-2f84-4178-97cb-b2e9cb25d29a": {"node_ids": ["b21ec205-87d0-4fc2-ab7c-fdcc4c97179b"], "metadata": {"page_label": "403", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 11\n\n## Guidelines on submission of documentation for prequalification of innovator<sup>1</sup> finished pharmaceutical products approved by stringent regulatory authorities<sup>2</sup>\n\nThe World Health Organization (WHO) recognizes the scientific evaluation of innovator finished pharmaceutical products (FPPs) by regulatory authorities, which apply similarly stringent standards for quality, safety and efficacy to those recommended by WHO. Where an applicant and a stringent regulatory authority (SRA) can agree to share the following information on an innovator FPP with WHO, WHO will consider such an FPP for inclusion in the list of WHO prequalified products, as and when information about such a product becomes available to WHO and when the applicant in question expresses his or her interest in the product being prequalified by WHO.\n\nThe following should be submitted:\n\n1. **A covering letter, which should include:**\n   - A statement indicating that the information submitted is true and correct;\n   - A statement confirming that, for WHO prequalification, the product, including composition, formulation, strength, specifications, packaging will at the time of submission be the same in all respects as the product registered with the relevant SRA; and\n   - The name of the person responsible for communication with WHO on any issues related to the product.\n\n2. **An original or certified copy of the current WHO-type Certificate of a Pharmaceutical Product issued and fully completed, including answers to each question, by the relevant SRA, together with the latest approved summary of product characteristics (SmPC), or an equivalent thereof, as well as the patient information leaflet (PIL) and the labelling.**\n\n----\n\n<sup>1</sup> Generally, the innovator pharmaceutical product is that which was first authorized for marketing, on the basis of documentation of quality, safety and efficacy (WHO Technical Report Series, No. 937, Annex 7, 2006).\n\n<sup>2</sup> Stringent regulatory authority (SRA): a regulatory authority which is: (a) a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or (b) an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic and Health Canada (as may be updated from time to time); or (c) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (as may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) establece directrices para la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados innovadores que han sido aprobados por autoridades regulatorias estrictas. Se reconoce la evaluaci\u00f3n cient\u00edfica de estos productos y se detalla la informaci\u00f3n que debe ser presentada para su consideraci\u00f3n en la lista de productos precalificados por la OMS.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la carta de presentaci\u00f3n para la precalificaci\u00f3n de un producto farmac\u00e9utico innovador?**\n   - La carta debe incluir una declaraci\u00f3n de veracidad de la informaci\u00f3n, una confirmaci\u00f3n de que el producto es id\u00e9ntico al registrado con la autoridad regulatoria, y el nombre de la persona responsable de la comunicaci\u00f3n con la OMS.\n\n2. **\u00bfQu\u00e9 documentos espec\u00edficos se requieren para la presentaci\u00f3n de un producto farmac\u00e9utico innovador a la OMS?**\n   - Se requiere un original o copia certificada del Certificado de Producto Farmac\u00e9utico tipo OMS, junto con el resumen de caracter\u00edsticas del producto (SmPC), el folleto de informaci\u00f3n para el paciente (PIL) y el etiquetado.\n\n3. **\u00bfC\u00f3mo se define una autoridad regulatoria estricta (SRA) seg\u00fan el documento de la OMS?**\n   - Una SRA es una autoridad que es miembro de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH), un observador de la ICH, o una autoridad asociada a un miembro de la ICH mediante un acuerdo de reconocimiento mutuo legalmente vinculante.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nLa secci\u00f3n del ap\u00e9ndice del documento \"WHO - Technical Report Series 961\" se centra en las caracter\u00edsticas que deben ser proporcionadas para los productos farmac\u00e9uticos precalificados que estar\u00e1n disponibles en el sitio web de la OMS. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas:\n\n#### Temas Clave:\n1. **Informaci\u00f3n del Producto**:\n   - N\u00famero de referencia del producto de la OMS.\n   - Nombre no propietario internacional (INN) de los ingredientes activos (API).\n   - Forma de dosificaci\u00f3n y concentraci\u00f3n.\n\n2. **Informaci\u00f3n del Fabricante**:\n   - Nombre y direcci\u00f3n oficial del solicitante.\n   - Nombre y direcci\u00f3n f\u00edsica del fabricante del producto farmac\u00e9utico terminado (FPP).\n   - Informaci\u00f3n sobre el fabricante del API, incluyendo direcci\u00f3n f\u00edsica.\n\n3. **Detalles del Producto**:\n   - Descripci\u00f3n del producto seg\u00fan las especificaciones del FPP (ej. recubierto, ranurado).\n   - Tama\u00f1os de empaque y materiales de empaque primario y secundario.\n\n4. **Condiciones de Almacenamiento y Vida \u00datil**:\n   - Condiciones de almacenamiento requeridas.\n   - Vida \u00fatil del producto (provisional si es aplicable).\n\n5. **Documentaci\u00f3n Adicional**:\n   - Resumen de las caracter\u00edsticas del producto.\n   - Prospecto del producto.\n   - Etiquetado del producto.\n\n#### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n y regulaci\u00f3n de los productos farmac\u00e9uticos.\n- **Ingredientes Activos (API)**: Componentes farmac\u00e9uticos que tienen un efecto terap\u00e9utico.\n- **Producto Farmac\u00e9utico Terminado (FPP)**: Producto final que se ofrece al consumidor.\n- **Solicitante**: Entidad o persona que presenta la solicitud para la precalificaci\u00f3n del producto.\n\nEste resumen destaca la importancia de la transparencia y la regulaci\u00f3n en la disponibilidad de productos farmac\u00e9uticos, asegurando que la informaci\u00f3n relevante est\u00e9 accesible para el p\u00fablico y los profesionales de la salud.", "excerpt_keywords": "Keywords: prequalification, pharmaceutical products, WHO, regulatory authorities, documentation"}}, "5536d671-c208-43c8-b192-afe434b0b1c9": {"node_ids": ["0560e4e4-098f-480e-afe7-48e96c02ee58"], "metadata": {"page_label": "404", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Document Requirements\n\n3. An assessment report issued by the relevant SRA: a publicly available scientific assessment report, such as the Scientific Discussion of the European Public Assessment Report (EPAR), issued by the relevant SRA is also acceptable.\n\n4. A certified copy of the marketing authorization issued by the relevant SRA. If applicable a certified copy of the latest renewal of the marketing authorization should also be provided.\n\n5. A list of the SRA-approved manufacturer(s) of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n6. A list of the SRA-approved manufacturer(s) of the active pharmaceutical ingredient(s) (API(s)) used in the manufacture of the FPP, with the physical address of the manufacturing site(s) (and unit if applicable).\n\n7. A sample(s) of the product in market packaging(s) should be provided with the submission to enable a visual inspection to be made. The respective certificate of analysis should be attached.\n\nPlease note that the submission must be in English, which includes certified English translations of the SmPC and other documents. These documents should be made available both as hard copies and electronically. The SmPC and PIL should be submitted as Word files.\n\nVariations to and renewal of the marketing authorization of a product that has been prequalified by WHO based on the approval by an SRA, remain the responsibility of the relevant SRA.\n\nOnce the product has been prequalified, WHO should be provided with a copy of the regulatory acceptance letter of any changes to the main characteristics of the product \u2014 such as the labelling for storage, the nature and contents of the container, the shelf-life, manufacturing site(s) of the FPP or API, or any other relevant change to the product information \u2014 immediately after the variation has been approved by the relevant SRA. The main characteristics of the product will be listed in the Letter of Prequalification.\n\nThe preferred storage condition for WHO prequalified products is \u201cdo not store above 30 \u00b0C\u201d. If this is not indicated on the SmPC, PIL and labels of the innovator product, applicants are encouraged to apply for a variation in this respect with the relevant SRA. This could also be done after prequalification of the product.\n\nProducts that received tentative approval from the United States Food and Drug Administration (FDA) or positive opinions under Article 58 of European Union Regulation (EC) No. 726/2004 or the Canada S.C. 2004, c. 23 (Bill C-9) procedure are not within the scope of this guideline. Such products can be co-listed on the WHO List of Prequalified Products in accordance with mutual agreements between WHO and these regulatory authorities. \n\n----\n\n3 Information and the full text of the relevant WHO documents can be found on the web site http://apps.who.int/prequal/.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la presentaci\u00f3n de productos farmac\u00e9uticos que buscan la precalificaci\u00f3n. Incluye la necesidad de informes de evaluaci\u00f3n de la autoridad reguladora correspondiente (SRA), copias certificadas de autorizaciones de comercializaci\u00f3n, listas de fabricantes aprobados y muestras del producto. Adem\u00e1s, se enfatiza que toda la documentaci\u00f3n debe estar en ingl\u00e9s y que las variaciones en la autorizaci\u00f3n de comercializaci\u00f3n son responsabilidad de la SRA. Tambi\u00e9n se menciona que los productos con aprobaci\u00f3n tentativa de la FDA o bajo ciertas regulaciones de la UE y Canad\u00e1 no est\u00e1n dentro del alcance de estas pautas.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de informe de evaluaci\u00f3n es aceptable para la presentaci\u00f3n de un producto farmac\u00e9utico a la OMS?**\n   - Se acepta un informe de evaluaci\u00f3n emitido por la SRA relevante, como el Informe de Discusi\u00f3n Cient\u00edfica del Informe de Evaluaci\u00f3n P\u00fablica Europea (EPAR).\n\n2. **\u00bfCu\u00e1les son las condiciones de almacenamiento preferidas para los productos precalificados por la OMS?**\n   - La condici\u00f3n de almacenamiento preferida es \"no almacenar por encima de 30 \u00b0C\". Si esto no est\u00e1 indicado en el SmPC, PIL y etiquetas del producto innovador, se alienta a los solicitantes a solicitar una variaci\u00f3n.\n\n3. **\u00bfQu\u00e9 documentos deben presentarse en ingl\u00e9s y en qu\u00e9 formato deben estar disponibles?**\n   - Todos los documentos, incluidas las traducciones certificadas del SmPC y otros documentos, deben estar en ingl\u00e9s y disponibles tanto en copias f\u00edsicas como electr\u00f3nicas. El SmPC y el PIL deben presentarse en archivos de Word.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **Precalificaci\u00f3n de productos farmac\u00e9uticos innovadores:** Directrices de la OMS para la presentaci\u00f3n de documentaci\u00f3n necesaria para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados que han sido aprobados por autoridades regulatorias estrictas.\n2. **Evaluaci\u00f3n cient\u00edfica:** Reconocimiento de la evaluaci\u00f3n realizada por autoridades regulatorias que cumplen con est\u00e1ndares rigurosos de calidad, seguridad y eficacia.\n3. **Documentaci\u00f3n requerida:** Detalles sobre la informaci\u00f3n y documentos que deben ser presentados, incluyendo una carta de presentaci\u00f3n y un Certificado de Producto Farmac\u00e9utico tipo OMS.\n4. **Definici\u00f3n de autoridad regulatoria estricta (SRA):** Criterios que determinan qu\u00e9 entidades se consideran SRA, incluyendo membres\u00eda en la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y acuerdos de reconocimiento mutuo.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad que establece las directrices para la precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **Autoridades regulatorias estrictas (SRA):** Incluyen miembros de la ICH, observadores de la ICH y autoridades asociadas mediante acuerdos de reconocimiento mutuo.\n- **Productos farmac\u00e9uticos terminados innovadores (FPPs):** Productos que han sido autorizados para comercializaci\u00f3n bas\u00e1ndose en documentaci\u00f3n de calidad, seguridad y eficacia. \n\nEste resumen abarca los aspectos esenciales de la secci\u00f3n, destacando la importancia de la documentaci\u00f3n y la evaluaci\u00f3n regulatoria en el proceso de precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: precalification, regulatory authority, marketing authorization, pharmaceutical products, WHO guidelines"}}, "256f0a30-1a17-47f8-89bb-e2dcb5e12ee2": {"node_ids": ["07259642-448f-457e-9bb1-cd4b758a4a54"], "metadata": {"page_label": "405", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 12\n\n**Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies**\n\n## Introduction\n\n1. **Steps of the procedure**\n   1.1 Publication of invitation for Expressions of Interest  \n   1.2 Submission of Expressions of Interest and laboratory information  \n   1.3 Screening of submitted laboratory information  \n   1.4 Evaluation of the laboratory information  \n   1.5 Site inspection  \n   1.6 Report and outcome of inspection  \n   1.7 Results of assessment  \n   1.8 Monitoring of prequalified quality control laboratories  \n   1.9 Monitoring of complaint(s)  \n   1.10 Cost recovery  \n   1.11 Confidentiality undertaking  \n   1.12 Conflict of interest  \n\n## References", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un anexo del Informe T\u00e9cnico de la OMS que detalla el procedimiento para la precalificaci\u00f3n de laboratorios de control de calidad que ser\u00e1n utilizados por agencias de las Naciones Unidas. Se describen los pasos del proceso, que incluyen la publicaci\u00f3n de invitaciones, la evaluaci\u00f3n de la informaci\u00f3n del laboratorio, inspecciones en el sitio y el monitoreo de los laboratorios precalificados.\n\n### Preguntas:\n\n1. **\u00bfCu\u00e1les son los pasos espec\u00edficos involucrados en el proceso de precalificaci\u00f3n de laboratorios de control de calidad seg\u00fan el documento?**\n   - Respuesta: Los pasos incluyen la publicaci\u00f3n de invitaciones para expresiones de inter\u00e9s, la presentaci\u00f3n de informaci\u00f3n del laboratorio, la evaluaci\u00f3n y el monitoreo de los laboratorios, entre otros.\n\n2. **\u00bfQu\u00e9 medidas se toman para asegurar la confidencialidad y evitar conflictos de inter\u00e9s durante el proceso de evaluaci\u00f3n de laboratorios?**\n   - Respuesta: El documento menciona la existencia de un compromiso de confidencialidad y la necesidad de abordar posibles conflictos de inter\u00e9s como parte del procedimiento.\n\n3. **\u00bfC\u00f3mo se lleva a cabo el monitoreo de los laboratorios de control de calidad que han sido precalificados?**\n   - Respuesta: El monitoreo incluye la supervisi\u00f3n continua de los laboratorios precalificados y la gesti\u00f3n de quejas que puedan surgir, asegurando as\u00ed que mantengan los est\u00e1ndares requeridos.", "prev_section_summary": "### Temas Clave\n\n1. **Requisitos de Documentaci\u00f3n**: Se detallan los documentos necesarios para la presentaci\u00f3n de productos farmac\u00e9uticos que buscan la precalificaci\u00f3n por parte de la OMS, incluyendo informes de evaluaci\u00f3n, copias certificadas de autorizaciones de comercializaci\u00f3n, listas de fabricantes aprobados y muestras del producto.\n\n2. **Idioma y Formato de Presentaci\u00f3n**: Todos los documentos deben estar en ingl\u00e9s, incluyendo traducciones certificadas, y deben presentarse tanto en formato f\u00edsico como electr\u00f3nico. El SmPC y el PIL deben ser enviados en archivos de Word.\n\n3. **Variaciones y Renovaciones**: Las variaciones y renovaciones de la autorizaci\u00f3n de comercializaci\u00f3n son responsabilidad de la SRA correspondiente. Se requiere notificaci\u00f3n a la OMS sobre cualquier cambio en las caracter\u00edsticas principales del producto tras la aprobaci\u00f3n de la SRA.\n\n4. **Condiciones de Almacenamiento**: La condici\u00f3n de almacenamiento preferida para los productos precalificados es \"no almacenar por encima de 30 \u00b0C\". Se alienta a los solicitantes a solicitar variaciones si esta informaci\u00f3n no est\u00e1 indicada en la documentaci\u00f3n del producto.\n\n5. **Exclusiones**: Productos con aprobaci\u00f3n tentativa de la FDA o bajo ciertas regulaciones de la UE y Canad\u00e1 no est\u00e1n dentro del alcance de estas pautas, aunque pueden ser co-listados en la lista de productos precalificados de la OMS bajo acuerdos mutuos.\n\n### Entidades\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad que establece los requisitos de precalificaci\u00f3n.\n- **SRA (Autoridad Reguladora Correspondiente)**: La autoridad que emite la autorizaci\u00f3n de comercializaci\u00f3n y eval\u00faa los productos.\n- **FDA (Administraci\u00f3n de Alimentos y Medicamentos de EE. UU.)**: Mencionada en el contexto de productos con aprobaci\u00f3n tentativa.\n- **Regulaci\u00f3n de la UE (Reglamento (CE) No. 726/2004)**: Referenciada en relaci\u00f3n con productos aprobados bajo ciertas condiciones.\n- **Canad\u00e1 (S.C. 2004, c. 23)**: Mencionada en el contexto de procedimientos de aprobaci\u00f3n de productos.\n\nEste resumen proporciona una visi\u00f3n general de los requisitos y procedimientos establecidos por la OMS para la precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: prequalification, quality control laboratories, United Nations, assessment procedure, confidentiality"}}, "15b3f0de-dbb5-484b-b0ac-458ba3699965": {"node_ids": ["104f2637-a7e8-4633-af7e-6744ff1ed9a7"], "metadata": {"page_label": "406", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Introduction\n\nThe World Health Organization (WHO) provides United Nations agencies, on request, with advice on the acceptability, in principle, of quality control laboratories that are found to meet WHO recommended quality standards for such laboratories, i.e. *Good practices for pharmaceutical quality control laboratories* (GPCL) (1) and the relevant parts of good manufacturing practices (GMP) (2). This is done through a standardized quality assessment procedure. The purpose of the quality assessment procedure is to evaluate whether the quality control laboratories to be used for the quality control of pharmaceutical products meet the requirements recommended by WHO for such laboratories.\n\nParticipation in the prequalification procedure is voluntary and any pharmaceutical quality control laboratory (governmental or private) could participate. Certification such as ISO (in terms of ISO/IEC17025) is encouraged and will also be considered in the prequalification procedure. It is recommended that laboratories should work towards obtaining certification.\n\nThe quality assessment procedure established by WHO is based on the following principles:\n\n- Commitment of the laboratory to providing services of testing of pharmaceutical products to United Nations agencies;\n- A general understanding of the quality assurance management and quality control testing activities of the laboratory;\n- Evaluation of information submitted by the laboratory;\n- Assessment of compliance with WHO recommended quality standards for quality control laboratories, i.e. GPCL (1) and the relevant parts of GMP (2); and\n- Monitoring of performance of prequalified laboratories.\n\nWHO invites the national medicines regulatory authority (NMRA) having regulatory oversight over a laboratory participating in the prequalification procedure, to join as an observer in the inspection of the laboratory\u2019s compliance with WHO recommended standards for quality control laboratories. WHO recommends that laboratories expressing an interest in participating in the prequalification procedure, inform the regulatory authority of the country in which they are established as well as relevant networks (e.g. the Official Medicines Control Laboratories (OMCL) network) of their submission for prequalification.\n\nThis procedure is to be followed for prequalification of quality control laboratories for use by the United Nations agencies.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento de la Organizaci\u00f3n Mundial de la Salud (OMS) describe el procedimiento de evaluaci\u00f3n de calidad para laboratorios de control de calidad farmac\u00e9utica que desean participar en el proceso de precalificaci\u00f3n para su uso por agencias de las Naciones Unidas. Este procedimiento es voluntario y se basa en principios que incluyen el compromiso del laboratorio, la comprensi\u00f3n de la gesti\u00f3n de calidad, la evaluaci\u00f3n de la informaci\u00f3n presentada, el cumplimiento de est\u00e1ndares recomendados y el monitoreo del desempe\u00f1o. Adem\u00e1s, se invita a las autoridades reguladoras nacionales a participar como observadores en las inspecciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los est\u00e1ndares espec\u00edficos que deben cumplir los laboratorios para ser considerados en el procedimiento de precalificaci\u00f3n de la OMS?**\n   - Respuesta: Los laboratorios deben cumplir con las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* (GPCL) y las partes relevantes de las *buenas pr\u00e1cticas de manufactura* (GMP) recomendadas por la OMS.\n\n2. **\u00bfQu\u00e9 papel juegan las autoridades reguladoras nacionales en el proceso de precalificaci\u00f3n de laboratorios seg\u00fan la OMS?**\n   - Respuesta: Las autoridades reguladoras nacionales (NMRA) son invitadas a participar como observadores en la inspecci\u00f3n de los laboratorios que buscan la precalificaci\u00f3n, asegurando que se cumplan los est\u00e1ndares recomendados por la OMS.\n\n3. **\u00bfQu\u00e9 tipo de certificaci\u00f3n se recomienda a los laboratorios que desean participar en el procedimiento de precalificaci\u00f3n?**\n   - Respuesta: Se recomienda que los laboratorios trabajen hacia la obtenci\u00f3n de certificaciones como la ISO, espec\u00edficamente en t\u00e9rminos de ISO/IEC 17025, que ser\u00e1 considerada en el procedimiento de precalificaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n**Tema Principal:**\n- Precalificaci\u00f3n de laboratorios de control de calidad para su uso por agencias de las Naciones Unidas.\n\n**Pasos del Procedimiento:**\n1. **Publicaci\u00f3n de invitaciones**: Se invita a laboratorios a presentar expresiones de inter\u00e9s.\n2. **Presentaci\u00f3n de informaci\u00f3n**: Los laboratorios env\u00edan su informaci\u00f3n relevante.\n3. **Filtrado de informaci\u00f3n**: Se revisa la informaci\u00f3n presentada para determinar su adecuaci\u00f3n.\n4. **Evaluaci\u00f3n**: Se eval\u00faa la informaci\u00f3n del laboratorio para verificar su calidad.\n5. **Inspecci\u00f3n en el sitio**: Se realizan visitas a los laboratorios para inspeccionar sus instalaciones y procesos.\n6. **Informe y resultados**: Se elabora un informe sobre la inspecci\u00f3n y se comunican los resultados.\n7. **Monitoreo**: Se lleva a cabo un seguimiento continuo de los laboratorios precalificados.\n8. **Gesti\u00f3n de quejas**: Se monitorean y gestionan las quejas que puedan surgir.\n9. **Recuperaci\u00f3n de costos**: Se establecen mecanismos para la recuperaci\u00f3n de costos asociados al proceso.\n10. **Compromiso de confidencialidad**: Se asegura la confidencialidad de la informaci\u00f3n durante el proceso.\n11. **Conflictos de inter\u00e9s**: Se abordan y gestionan posibles conflictos de inter\u00e9s.\n\n**Entidades Clave:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del documento.\n- **Agencias de las Naciones Unidas**: Usuarios finales de los laboratorios precalificados.\n- **Laboratorios de control de calidad**: Sujetos del proceso de precalificaci\u00f3n.\n\nEste resumen destaca los pasos del procedimiento y las entidades involucradas en el proceso de precalificaci\u00f3n de laboratorios, as\u00ed como las medidas para asegurar la calidad y la integridad del proceso.", "excerpt_keywords": "Keywords: WHO, quality control laboratories, prequalification, GMP, pharmaceutical standards"}}, "fda169f1-d6e6-4c31-a68f-7a48980c3267": {"node_ids": ["ce315e9f-dd54-4731-830f-40d2e91b484e"], "metadata": {"page_label": "407", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Steps of the procedure\n\nWHO requires information related to the activities of, and quality control of pharmaceutical products in, laboratories interested in being assessed under this procedure. Interested quality control laboratories should submit the information about their activities as requested by WHO (see point 1.2 below). In addition to the evaluation of the information submitted, a site inspection (or inspections) may be performed.\n\nIf, due to insufficient resources and time constraints, WHO has to set priorities in the assessment of interested laboratories, then priority will be given to quality control laboratories in areas where United Nations agencies identify the need for testing of the quality of pharmaceutical products, and to national quality control laboratories and laboratories providing testing services to governments.\n\nWHO reserves the right to terminate the quality assessment of a laboratory when the laboratory is not able to provide, or fails to provide, the required information, when the information supplied is inadequate to complete the quality assessment effectively, the laboratory fails to collaborate in inspections required by WHO and/or is unable to implement corrective actions which WHO may require within a specified time period.\n\n## 1.1 Publication of invitation for Expressions of Interest\n\nWHO will publish an invitation to quality control laboratories to submit an Expression of Interest (EOI) to participate in the prequalification procedure. Such an invitation will specify the scope of quality control testing which is subject to prequalification and will be published widely, i.e. on the WHO web site and possibly also through other media, such as the international press. The invitation will be open and transparent, inviting all interested quality control laboratories to submit the EOI for prequalification.\n\n## 1.2 Submission of Expressions of Interest and laboratory information\n\nEach interested laboratory should provide the WHO focal point indicated in the invitation for EOIs with:\n\n- a letter expressing interest in participating in the prequalification procedure; and\n- the relevant laboratory information.\n\nWHO will record the receipt of the EOI from each laboratory in a register.\n\nGuidelines for the submission of EOIs and for the preparation and submission of the relevant information are available on the WHO web site.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS describe el procedimiento para la evaluaci\u00f3n y precalificaci\u00f3n de laboratorios de control de calidad de productos farmac\u00e9uticos. Se requiere que los laboratorios interesados env\u00eden informaci\u00f3n sobre sus actividades y colaboren en inspecciones. La OMS prioriza la evaluaci\u00f3n de laboratorios en \u00e1reas donde hay una necesidad identificada por agencias de la ONU. Adem\u00e1s, se establece un proceso para la publicaci\u00f3n de invitaciones a laboratorios para presentar su inter\u00e9s y la informaci\u00f3n relevante.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 criterios utiliza la OMS para priorizar la evaluaci\u00f3n de laboratorios de control de calidad?**\n   - La OMS prioriza laboratorios en \u00e1reas donde las agencias de la ONU identifican la necesidad de pruebas de calidad de productos farmac\u00e9uticos, as\u00ed como laboratorios nacionales y aquellos que brindan servicios de prueba a gobiernos.\n\n2. **\u00bfQu\u00e9 sucede si un laboratorio no puede proporcionar la informaci\u00f3n requerida durante el proceso de evaluaci\u00f3n?**\n   - La OMS se reserva el derecho de terminar la evaluaci\u00f3n de calidad de un laboratorio si este no puede proporcionar la informaci\u00f3n requerida, si la informaci\u00f3n es inadecuada, si no colabora en las inspecciones o si no implementa las acciones correctivas solicitadas en un plazo especificado.\n\n3. **\u00bfD\u00f3nde se publicar\u00e1 la invitaci\u00f3n para que los laboratorios presenten su Expresi\u00f3n de Inter\u00e9s (EOI)?**\n   - La invitaci\u00f3n se publicar\u00e1 ampliamente, incluyendo el sitio web de la OMS y posiblemente otros medios, como la prensa internacional, para asegurar que todos los laboratorios interesados tengan la oportunidad de participar.", "prev_section_summary": "### Temas Clave\n\n1. **Evaluaci\u00f3n de Calidad de Laboratorios**: La OMS establece un procedimiento de evaluaci\u00f3n de calidad para laboratorios de control de calidad farmac\u00e9utica que desean participar en el proceso de precalificaci\u00f3n para su uso por agencias de las Naciones Unidas.\n\n2. **Participaci\u00f3n Voluntaria**: La participaci\u00f3n en el procedimiento de precalificaci\u00f3n es voluntaria y est\u00e1 abierta a laboratorios gubernamentales y privados.\n\n3. **Est\u00e1ndares Recomendados**: Los laboratorios deben cumplir con las *Buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica* (GPCL) y las partes relevantes de las *buenas pr\u00e1cticas de manufactura* (GMP).\n\n4. **Certificaci\u00f3n**: Se recomienda que los laboratorios busquen certificaciones como la ISO/IEC 17025, que ser\u00e1 considerada en el procedimiento de precalificaci\u00f3n.\n\n5. **Principios de Evaluaci\u00f3n**: La evaluaci\u00f3n se basa en el compromiso del laboratorio, la comprensi\u00f3n de la gesti\u00f3n de calidad, la evaluaci\u00f3n de la informaci\u00f3n presentada, el cumplimiento de est\u00e1ndares recomendados y el monitoreo del desempe\u00f1o.\n\n6. **Rol de las Autoridades Reguladoras**: Las autoridades reguladoras nacionales (NMRA) son invitadas a participar como observadores en las inspecciones de los laboratorios que buscan la precalificaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de establecer los est\u00e1ndares y procedimientos de evaluaci\u00f3n.\n- **Agencias de las Naciones Unidas**: Entidades que utilizan los laboratorios precalificados.\n- **Laboratorios de Control de Calidad Farmac\u00e9utica**: Entidades que buscan participar en el procedimiento de precalificaci\u00f3n.\n- **Autoridades Reguladoras Nacionales (NMRA)**: Entidades que supervisan la regulaci\u00f3n de los laboratorios en sus respectivos pa\u00edses.\n- **Red de Laboratorios de Control de Medicamentos Oficiales (OMCL)**: Redes relevantes que pueden ser informadas sobre la participaci\u00f3n en el procedimiento de precalificaci\u00f3n.", "excerpt_keywords": "Keywords: WHO, quality control laboratories, prequalification procedure, Expressions of Interest, pharmaceutical products"}}, "b9ac2e99-1c90-4d1f-8bf4-8bdf00425dae": {"node_ids": ["b2cb0e6d-1cd3-4336-92ac-841d45e3bb86"], "metadata": {"page_label": "408", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "at http://apps.who.int/prequal/ and will be sent to interested laboratories upon request.\n\nIf the laboratory has documented its quality system as a quality manual, this can be submitted, provided that it is supplemented with the information required for the laboratory information file (LIF, see below) that is not provided in the quality manual.\n\nIf there is no quality manual, the information should be submitted as described in the document *Guidelines for preparing a laboratory information file* (3) and contain information on the areas listed below:\n\n- General information on the laboratory, including activities proposed for prequalification;\n- Quality management system implemented, and inspections and external audits performed in the laboratory;\n- Participation in proficiency testing schemes and/or collaborative trials;\n- Internal audits;\n- Control of documentation and records;\n- Personnel;\n- Premises;\n- Equipment;\n- Reagents, reference substances and reference materials;\n- Subcontracting of testing (where applicable);\n- Handling of samples;\n- Validation of analytical procedures;\n- Investigation of out-of-specification (OOS) results;\n- Stability testing (where applicable); and\n- Microbiological testing (where applicable).\n\n### 1.3 Screening of submitted laboratory information\n\nThe information submitted by the laboratory will be screened for completeness against the *Guidelines for preparing a laboratory information file* (3). Incomplete information will not be considered for evaluation. The laboratory will be informed that incomplete information has been received, and be requested to complete it within a specified time period. In the event of noncompliance with this request, the laboratory information will in principle be rejected on grounds of incompleteness and returned to the laboratory.\n\n### 1.4 Evaluation of the laboratory information\n\nLaboratory information that complies with the requirements set out in section 1.2 above will be evaluated in accordance with a standard operating", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio (LIF) que debe ser presentado por los laboratorios que buscan la precalificaci\u00f3n. Se detalla la informaci\u00f3n necesaria que debe incluirse, ya sea en un manual de calidad o en un formato alternativo si no se dispone de dicho manual. Adem\u00e1s, se describe el proceso de revisi\u00f3n de la informaci\u00f3n presentada, enfatizando la importancia de la completitud y la conformidad con las directrices establecidas.\n\n### Preguntas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 informaci\u00f3n adicional se requiere si un laboratorio presenta un manual de calidad?**\n   - Se requiere que el manual de calidad sea complementado con la informaci\u00f3n que no se proporciona en \u00e9l, seg\u00fan lo estipulado en las directrices para preparar un archivo de informaci\u00f3n de laboratorio (LIF).\n\n2. **\u00bfQu\u00e9 sucede si un laboratorio presenta informaci\u00f3n incompleta?**\n   - Si la informaci\u00f3n presentada es incompleta, el laboratorio ser\u00e1 informado y se le solicitar\u00e1 que complete la informaci\u00f3n dentro de un per\u00edodo de tiempo especificado. Si no cumple con esta solicitud, la informaci\u00f3n ser\u00e1 rechazada por incompletitud y devuelta al laboratorio.\n\n3. **\u00bfCu\u00e1les son algunos de los aspectos que deben incluirse en el archivo de informaci\u00f3n del laboratorio?**\n   - El archivo debe incluir informaci\u00f3n sobre la gesti\u00f3n de calidad implementada, auditor\u00edas internas, control de documentaci\u00f3n, personal, instalaciones, equipos, manejo de muestras, validaci\u00f3n de procedimientos anal\u00edticos, entre otros aspectos relevantes.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n\n1. **Evaluaci\u00f3n y precalificaci\u00f3n de laboratorios**: La OMS establece un procedimiento para evaluar y precalificar laboratorios de control de calidad de productos farmac\u00e9uticos, requiriendo informaci\u00f3n sobre sus actividades.\n\n2. **Prioridades en la evaluaci\u00f3n**: La OMS prioriza la evaluaci\u00f3n de laboratorios en \u00e1reas donde las agencias de la ONU identifican la necesidad de pruebas de calidad, as\u00ed como laboratorios nacionales y aquellos que ofrecen servicios de prueba a gobiernos.\n\n3. **Requisitos de informaci\u00f3n**: Los laboratorios interesados deben enviar informaci\u00f3n espec\u00edfica y colaborar en inspecciones. La OMS puede terminar la evaluaci\u00f3n si la informaci\u00f3n es insuficiente o si el laboratorio no colabora.\n\n4. **Publicaci\u00f3n de invitaciones**: La OMS publicar\u00e1 invitaciones para que los laboratorios presenten su Expresi\u00f3n de Inter\u00e9s (EOI), especificando el alcance de las pruebas de control de calidad.\n\n5. **Proceso de presentaci\u00f3n de EOIs**: Los laboratorios deben enviar una carta de inter\u00e9s y la informaci\u00f3n relevante a un punto focal de la OMS, que registrar\u00e1 la recepci\u00f3n de la EOI.\n\n**Entidades:**\n\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: La entidad responsable de la evaluaci\u00f3n y precalificaci\u00f3n de laboratorios.\n- **Laboratorios de control de calidad**: Entidades que realizan pruebas de calidad de productos farmac\u00e9uticos y que est\u00e1n interesadas en participar en el procedimiento de precalificaci\u00f3n.\n- **Agencias de la ONU**: Organismos que identifican necesidades de pruebas de calidad en diferentes \u00e1reas.", "excerpt_keywords": "Keywords: laboratory information file, quality management system, prequalification, WHO guidelines, evaluation process"}}, "628dd9b3-21da-4ea8-9141-e2dc6f642e5f": {"node_ids": ["1a9ed0d6-542f-4367-ba5b-14d0c70bf078"], "metadata": {"page_label": "409", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Dado el contexto proporcionado sobre el documento \"WHO - Technical Report Series 961\", aqu\u00ed tienes tres preguntas que podr\u00edan tener respuestas espec\u00edficas en este informe:\n\n1. **\u00bfCu\u00e1les son las principales recomendaciones de la OMS en el Informe T\u00e9cnico 961 sobre la salud p\u00fablica y la seguridad sanitaria?**\n   - Esta pregunta busca obtener informaci\u00f3n espec\u00edfica sobre las directrices o recomendaciones que la OMS ha emitido en este informe, que pueden no estar disponibles en otros documentos.\n\n2. **\u00bfQu\u00e9 metodolog\u00edas se describen en el Informe T\u00e9cnico 961 para la evaluaci\u00f3n de riesgos en la salud p\u00fablica?**\n   - Esta pregunta se centra en las t\u00e9cnicas o enfoques espec\u00edficos que la OMS propone para evaluar riesgos, lo cual puede ser un aspecto \u00fanico del informe.\n\n3. **\u00bfQu\u00e9 datos o estad\u00edsticas relevantes se presentan en el Informe T\u00e9cnico 961 sobre enfermedades infecciosas y su impacto global?**\n   - Esta pregunta busca informaci\u00f3n cuantitativa o cualitativa que el informe pueda contener sobre la prevalencia o el impacto de enfermedades infecciosas, que podr\u00eda no estar disponible en otras fuentes.\n\n### Resumen de nivel superior del contexto circundante:\nEl \"WHO - Technical Report Series 961\" es un documento t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. Este tipo de informes suelen incluir recomendaciones, metodolog\u00edas de evaluaci\u00f3n, y datos estad\u00edsticos sobre diversas cuestiones de salud global, lo que los convierte en recursos valiosos para investigadores, profesionales de la salud y responsables de pol\u00edticas.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Objetivo del Documento**: Establecer directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio (LIF) que los laboratorios deben presentar para la precalificaci\u00f3n.\n\n2. **Calidad del Laboratorio**:\n   - Se permite la presentaci\u00f3n de un manual de calidad, pero debe complementarse con informaci\u00f3n adicional requerida.\n   - Si no hay un manual de calidad, se debe seguir el formato descrito en las *Directrices para preparar un archivo de informaci\u00f3n de laboratorio*.\n\n3. **Informaci\u00f3n Requerida**: \n   - Informaci\u00f3n general sobre el laboratorio y actividades propuestas.\n   - Sistema de gesti\u00f3n de calidad y auditor\u00edas realizadas.\n   - Participaci\u00f3n en pruebas de competencia y ensayos colaborativos.\n   - Auditor\u00edas internas y control de documentaci\u00f3n.\n   - Detalles sobre personal, instalaciones, equipos, reactivos y materiales de referencia.\n   - Procedimientos de validaci\u00f3n anal\u00edtica y manejo de muestras.\n   - Investigaci\u00f3n de resultados fuera de especificaci\u00f3n (OOS) y pruebas de estabilidad.\n\n4. **Proceso de Revisi\u00f3n**:\n   - La informaci\u00f3n presentada ser\u00e1 revisada por su completitud.\n   - Si la informaci\u00f3n es incompleta, el laboratorio ser\u00e1 notificado y deber\u00e1 completarla en un plazo determinado.\n   - La falta de cumplimiento resultar\u00e1 en el rechazo de la informaci\u00f3n.\n\n5. **Evaluaci\u00f3n**: La informaci\u00f3n que cumpla con los requisitos ser\u00e1 evaluada seg\u00fan un procedimiento operativo est\u00e1ndar.\n\n### Entidades Clave:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Autoridad que emite las directrices.\n- **Laboratorios**: Entidades que buscan la precalificaci\u00f3n y deben presentar el LIF.\n- **Archivo de Informaci\u00f3n de Laboratorio (LIF)**: Documento que debe ser preparado y presentado por los laboratorios.\n- **Sistema de Gesti\u00f3n de Calidad**: Estructura que los laboratorios deben tener documentada.\n- **Auditor\u00edas**: Inspecciones internas y externas que los laboratorios deben realizar. \n\nEste resumen destaca los aspectos esenciales y las entidades involucradas en el proceso de precalificaci\u00f3n de laboratorios seg\u00fan las directrices de la OMS.", "excerpt_keywords": "Keywords: OMS, salud p\u00fablica, precalificaci\u00f3n, laboratorio, evaluaci\u00f3n de riesgos"}}, "612f8d6e-7bef-4f3a-81a4-6cdcc610ad3c": {"node_ids": ["6b8f8fa9-7c21-45af-8fde-88740d8d6fff"], "metadata": {"page_label": "410", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Report and outcome of inspection\n\nThe inspector or inspection team will finalize a report describing the findings according to the established WHO SOP and format. The report will be communicated by WHO to the laboratory and a copy will be sent to the NMRA having regulatory oversight over the laboratory.\n\nIf any additional information is required, or if a corrective action has to be taken by the laboratory, WHO will postpone its decision on the acceptability of the laboratory concerned until the additional information has been evaluated, or the corrective action has been taken, and found satisfactory. If the decision cannot be made based on the information received, a follow-up inspection will be performed.\n\nIn the event of any disagreement between a laboratory and WHO, an SOP for the handling of such disagreements will be followed to discuss and resolve the issue.\n\nAs WHO is responsible for the quality assessment procedure, the ownership of the reports lies with WHO (without prejudice, however, to any confidential and proprietary information of the laboratory contained in this report). Thus, WHO shall be entitled to use and publish such reports subject always, however, to the protection of any confidential and proprietary information of the laboratory. \u201cConfidential information\u201d in this context means:\n\n- confidential intellectual property, \u201cknow-how\u201d and trade secrets (including, e.g. programs, processes or methods, unpublished aspects of trade marks, patents, etc.); and\n- commercial confidences (e.g. structures and development plans).\n\nProvisions of confidentiality will be contained in the letters exchanged between WHO and the laboratory, to be agreed upon before the evaluation of the information and site inspection.\n\nNotwithstanding the foregoing, WHO reserves the right to share the full reports with the relevant authorities of any interested Member State of the Organization and interested United Nations agencies.\n\n# 1.7 Results of assessment\n\nOnce WHO is satisfied that the quality assessment process for the laboratory is complete, and that the laboratory is acceptable in principle for use by United Nations agencies (i.e. it has been found to meet the WHO recommended quality standards for quality control laboratories), the laboratory at the specified site will be included in a list referred to as \u201cList of prequalified quality control laboratories\u201d.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento describe el proceso de inspecci\u00f3n y evaluaci\u00f3n de laboratorios por parte de la Organizaci\u00f3n Mundial de la Salud (OMS). Se detalla c\u00f3mo se elabora un informe tras la inspecci\u00f3n, el manejo de la informaci\u00f3n confidencial, y el procedimiento a seguir en caso de desacuerdos entre un laboratorio y la OMS. Adem\u00e1s, se menciona que una vez que un laboratorio cumple con los est\u00e1ndares de calidad recomendados por la OMS, se incluir\u00e1 en una lista de laboratorios de control de calidad precalificados para su uso por agencias de las Naciones Unidas.\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 sucede si un laboratorio necesita realizar acciones correctivas despu\u00e9s de una inspecci\u00f3n de la OMS?**\n   - La OMS pospondr\u00e1 su decisi\u00f3n sobre la aceptabilidad del laboratorio hasta que se eval\u00fae la informaci\u00f3n adicional o se tomen las acciones correctivas necesarias y se consideren satisfactorias.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n se considera \"confidencial\" seg\u00fan el contexto del informe de la OMS?**\n   - La informaci\u00f3n confidencial incluye propiedad intelectual, \"know-how\", secretos comerciales, y confidencias comerciales, como estructuras y planes de desarrollo.\n\n3. **\u00bfCu\u00e1l es el proceso que sigue la OMS en caso de desacuerdo con un laboratorio?**\n   - Se seguir\u00e1 un procedimiento operativo est\u00e1ndar (SOP) para manejar y resolver el desacuerdo entre el laboratorio y la OMS.", "prev_section_summary": "El contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que aborda temas relevantes en el \u00e1mbito de la salud p\u00fablica. A continuaci\u00f3n se resumen los temas clave y entidades mencionadas:\n\n### Temas Clave:\n1. **Recomendaciones de la OMS**: El informe incluye directrices y recomendaciones sobre salud p\u00fablica y seguridad sanitaria.\n2. **Metodolog\u00edas de Evaluaci\u00f3n de Riesgos**: Se describen t\u00e9cnicas y enfoques espec\u00edficos para la evaluaci\u00f3n de riesgos en la salud p\u00fablica.\n3. **Datos y Estad\u00edsticas sobre Enfermedades Infecciosas**: Se presentan datos relevantes sobre la prevalencia y el impacto global de enfermedades infecciosas.\n\n### Entidades:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: La entidad responsable de la elaboraci\u00f3n del informe.\n- **Informe T\u00e9cnico 961**: El documento espec\u00edfico que se analiza, que forma parte de la serie de informes t\u00e9cnicos de la OMS.\n\nEste informe es un recurso valioso para investigadores, profesionales de la salud y responsables de pol\u00edticas, ya que proporciona informaci\u00f3n crucial sobre la salud global.", "excerpt_keywords": "Keywords: inspection, quality assessment, confidentiality, corrective actions, prequalified laboratories"}}, "6dcfe2a2-125c-49ac-9f0c-429d64377f5d": {"node_ids": ["bfaaf6ba-66cd-4bfc-b3e7-d4c3bd250570"], "metadata": {"page_label": "411", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Laboratories on the list will be considered to be able to test products in compliance with WHO recommended quality standards for quality control laboratories. Inclusion in the list does not, however, imply any approval by WHO of the laboratories (which is the sole prerogative of national authorities).\n\nEach laboratory will receive a letter from WHO informing it of the outcome of the quality assessment process for that particular laboratory.\n\nA copy of this letter will be sent to the NMRA of the country where the laboratory is located. The list of prequalified laboratories will be published on the WHO web site and will specify the areas of expertise assessed and considered prequalified. The list will be updated whenever new relevant information is obtained.\n\nIn accordance with World Health Assembly Resolution WHA57.14 of 22 May 2004, WHO will \u2014 subject to the protection of any confidential and proprietary information \u2014 publish WHO Public Inspection Reports (WHOPIR(s)) on the laboratories considered to meet WHO recommended quality standards for quality control laboratories. These reports will be published on the WHO web site.\n\n### 1.8 Monitoring of prequalified quality control laboratories\n\nOnce the laboratory is included in the list of prequalified quality control laboratories, it should inform WHO without delay about any implemented changes which may have an impact on the prequalification of the laboratory (such as changes to facility, equipment or key personnel) and should submit an updated LIF.\n\nEach prequalified quality control laboratory will be re-evaluated on a routine basis at regular intervals (annually) or earlier, when information requiring re-evaluation is obtained by WHO.\n\nTo enable WHO to carry out re-evaluation, all prequalified laboratories are requested to submit a brief annual report on their activities. The report should cover all activities related to quality control of medicines within the preceding calendar year and should be submitted by the end of March of the subsequent year. The following items should be included in the report:\n\n- a summary of services provided to United Nations agencies, other public health organizations procuring medicines and other customers;\n- a summary of number of samples analysed, differentiating between compliant and non-compliant samples;\n- a list of analytical methods used;\n- a summary of complaints concerning results of analyses performed by the laboratory received from customers;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS establece un proceso para la inclusi\u00f3n de laboratorios en una lista de laboratorios de control de calidad precalificados, que cumplen con los est\u00e1ndares de calidad recomendados por la OMS. La inclusi\u00f3n en esta lista no implica aprobaci\u00f3n por parte de la OMS, ya que esta es prerrogativa de las autoridades nacionales. Los laboratorios deben informar a la OMS sobre cualquier cambio que pueda afectar su precalificaci\u00f3n y presentar informes anuales sobre sus actividades relacionadas con el control de calidad de medicamentos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 tipo de cambios deben informar los laboratorios a la OMS para mantener su estatus de precalificaci\u00f3n?**\n   - Los laboratorios deben informar a la OMS sin demora sobre cualquier cambio que pueda impactar su precalificaci\u00f3n, como modificaciones en las instalaciones, equipos o personal clave.\n\n2. **\u00bfCon qu\u00e9 frecuencia se re-evaluar\u00e1n los laboratorios precalificados y qu\u00e9 informaci\u00f3n deben proporcionar para esta re-evaluaci\u00f3n?**\n   - Los laboratorios precalificados ser\u00e1n re-evaluados de manera rutinaria a intervalos regulares (anualmente) o antes si se obtiene informaci\u00f3n que requiera una re-evaluaci\u00f3n. Deben presentar un informe anual que incluya un resumen de servicios, n\u00famero de muestras analizadas, m\u00e9todos anal\u00edticos utilizados y quejas recibidas.\n\n3. **\u00bfQu\u00e9 informaci\u00f3n se publicar\u00e1 en los informes de inspecci\u00f3n p\u00fablica de la OMS (WHOPIR) sobre los laboratorios precalificados?**\n   - Los WHOPIR publicar\u00e1n informaci\u00f3n sobre los laboratorios que cumplen con los est\u00e1ndares de calidad recomendados por la OMS, especificando las \u00e1reas de experiencia evaluadas y consideradas precalificadas, siempre que se protejan la informaci\u00f3n confidencial y propietaria.", "prev_section_summary": "### Temas Clave:\n\n1. **Proceso de Inspecci\u00f3n y Reporte**: La OMS lleva a cabo inspecciones de laboratorios y elabora un informe que describe los hallazgos, el cual se comunica al laboratorio y a la autoridad reguladora correspondiente.\n\n2. **Acciones Correctivas**: Si un laboratorio necesita realizar acciones correctivas, la OMS pospone su decisi\u00f3n sobre la aceptabilidad del laboratorio hasta que se eval\u00faen las acciones correctivas o se reciba informaci\u00f3n adicional.\n\n3. **Manejo de Desacuerdos**: En caso de desacuerdo entre un laboratorio y la OMS, se seguir\u00e1 un procedimiento operativo est\u00e1ndar (SOP) para resolver el conflicto.\n\n4. **Confidencialidad**: La OMS es responsable de la propiedad de los informes, pero debe proteger la informaci\u00f3n confidencial y propietaria del laboratorio, que incluye propiedad intelectual y secretos comerciales.\n\n5. **Resultados de la Evaluaci\u00f3n**: Una vez que un laboratorio cumple con los est\u00e1ndares de calidad recomendados por la OMS, se incluye en una lista de laboratorios de control de calidad precalificados para su uso por agencias de las Naciones Unidas.\n\n### Entidades:\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la evaluaci\u00f3n de calidad de laboratorios.\n- **Laboratorios**: Entidades que son objeto de inspecci\u00f3n y evaluaci\u00f3n por parte de la OMS.\n- **NMRA (Autoridad Reguladora Nacional de Medicamentos)**: Entidad que tiene supervisi\u00f3n regulatoria sobre los laboratorios.\n- **Agencias de las Naciones Unidas**: Organismos que pueden utilizar los laboratorios precalificados.\n- **Informaci\u00f3n Confidencial**: Incluye propiedad intelectual, \"know-how\", secretos comerciales y confidencias comerciales. \n\nEste resumen abarca los aspectos esenciales del proceso de inspecci\u00f3n y evaluaci\u00f3n de laboratorios por parte de la OMS, as\u00ed como las implicaciones de confidencialidad y resoluci\u00f3n de desacuerdos.", "excerpt_keywords": "Keywords: prequalified laboratories, WHO standards, quality control, annual report, inspection reports"}}, "02d8ebd5-3a6b-4df0-bd03-1384a053601d": {"node_ids": ["2a5bde92-8d17-46b4-925e-67cf5acd90c1"], "metadata": {"page_label": "412", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "NO_CONTENT_HERE", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que podr\u00edan derivarse del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento mencionado es el \"WHO - Technical Report Series 961\", que forma parte de una serie de informes t\u00e9cnicos publicados por la Organizaci\u00f3n Mundial de la Salud (OMS). Estos informes suelen abordar temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y recomendaciones para pr\u00e1cticas de salud a nivel global. Sin embargo, el contenido espec\u00edfico del informe en la p\u00e1gina 412 no est\u00e1 disponible en el contexto proporcionado.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los principales hallazgos o recomendaciones presentados en el informe de la OMS en la p\u00e1gina 412 del \"Technical Report Series 961\"?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica que podr\u00eda estar contenida en esa p\u00e1gina del informe.\n\n2. **\u00bfQu\u00e9 temas de salud p\u00fablica se abordan en el \"Technical Report Series 961\" y c\u00f3mo se relacionan con las pol\u00edticas de salud global?**\n   - Esta pregunta se enfoca en el contexto m\u00e1s amplio del informe y su relevancia en el \u00e1mbito de la salud p\u00fablica.\n\n3. **\u00bfQu\u00e9 metodolog\u00edas se utilizan en el \"Technical Report Series 961\" para evaluar la efectividad de las intervenciones de salud recomendadas?**\n   - Esta pregunta indaga sobre los enfoques y m\u00e9todos que la OMS podr\u00eda haber utilizado en el informe para respaldar sus recomendaciones.\n\nEstas preguntas est\u00e1n dise\u00f1adas para obtener informaci\u00f3n espec\u00edfica que probablemente no se encuentre en otras fuentes, dado que se centran en el contenido particular del informe de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n1. **Precalificaci\u00f3n de Laboratorios:** Los laboratorios que cumplen con los est\u00e1ndares de calidad recomendados por la OMS pueden ser incluidos en una lista de laboratorios precalificados, lo que les permite realizar pruebas de productos.\n2. **Proceso de Inclusi\u00f3n:** La inclusi\u00f3n en la lista no implica aprobaci\u00f3n por parte de la OMS, ya que esta es prerrogativa de las autoridades nacionales.\n3. **Comunicaci\u00f3n de Resultados:** Cada laboratorio recibe una carta de la OMS informando sobre el resultado del proceso de evaluaci\u00f3n de calidad.\n4. **Informes de Inspecci\u00f3n P\u00fablica (WHOPIR):** La OMS publicar\u00e1 informes sobre laboratorios que cumplen con los est\u00e1ndares, protegiendo la informaci\u00f3n confidencial.\n5. **Monitoreo y Re-evaluaci\u00f3n:** Los laboratorios precalificados deben informar sobre cambios que afecten su estatus y presentar informes anuales sobre sus actividades relacionadas con el control de calidad de medicamentos.\n6. **Contenido del Informe Anual:** Los informes deben incluir un resumen de servicios, n\u00famero de muestras analizadas, m\u00e9todos anal\u00edticos utilizados y quejas recibidas.\n\n**Entidades:**\n- **OMS (Organizaci\u00f3n Mundial de la Salud):** Organismo responsable de establecer est\u00e1ndares y evaluar laboratorios.\n- **NMRA (Autoridad Nacional Reguladora de Medicamentos):** Entidad que recibe copias de las cartas enviadas a los laboratorios.\n- **Laboratorios de Control de Calidad:** Entidades que realizan pruebas de calidad de medicamentos y deben cumplir con los est\u00e1ndares de la OMS.\n\nEste resumen destaca los aspectos fundamentales del proceso de precalificaci\u00f3n de laboratorios y la importancia de la comunicaci\u00f3n y el monitoreo continuo para garantizar el cumplimiento de los est\u00e1ndares de calidad.", "excerpt_keywords": "Keywords: OMS, precalificaci\u00f3n, laboratorios, control de calidad, salud p\u00fablica"}}, "c699624b-62e6-4b9d-9cd5-23b7f3889c73": {"node_ids": ["aa594a97-4c8e-460e-9857-cfcbc702f189"], "metadata": {"page_label": "413", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "After conducting its investigation, WHO will provide a written report of the problem, which may, where appropriate, include recommendations for action to the laboratory under investigation and to the NMRA having the regulatory oversight over the laboratory.\n\n### 1.10 Cost recovery\n\nWHO reserves the right to charge for the quality assessment procedure on a cost-recovery basis.\n\n### 1.11 Confidentiality undertaking\n\nWHO will require any external inspectors (acting as temporary advisers to WHO) to treat all information to which they gain access during the inspections of the laboratory, or otherwise in connection with the discharge of their responsibilities in regard to the prequalification procedure, as confidential and proprietary to WHO or parties collaborating with WHO in accordance with the terms set out below.\n\nSuch inspectors will be required to take all reasonable measures to ensure that confidential information:\n\n- is not used for any purpose other than the activities described in this document; and\n- is not disclosed or provided to any person who is not bound by similar obligations of confidentiality and non-use as contained herein.\n\nExternal inspectors will not, however, be bound by any obligations of confidentiality and non-use to the extent they are clearly able to demonstrate that any part of the confidential information:\n\n- was known to them prior to any disclosure by or on behalf of WHO (including by laboratories); or\n- was in the public domain at the time of disclosure by or on behalf of WHO (including by laboratories); or\n- has become part of the public domain through no fault of theirs; or\n- has become available to them from a third party not in breach of any legal obligations of confidentiality.\n\n### 1.12 Conflict of interest\n\nBefore undertaking the work, each external inspector will also (in addition to the above-mentioned confidentiality undertaking) be required to sign a declaration of interest. If, based on this declaration of interest, it is felt that there is no risk of a real or perceived conflict of interest (or it is felt that there is only an insignificant and/or irrelevant conflict of interest), and", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece procedimientos y directrices para la evaluaci\u00f3n de calidad de laboratorios, incluyendo la confidencialidad de la informaci\u00f3n, la recuperaci\u00f3n de costos y la gesti\u00f3n de conflictos de inter\u00e9s. Se menciona que la OMS proporcionar\u00e1 un informe escrito tras una investigaci\u00f3n, que puede incluir recomendaciones para el laboratorio y la autoridad reguladora correspondiente. Adem\u00e1s, se requiere que los inspectores externos firmen un compromiso de confidencialidad y una declaraci\u00f3n de intereses antes de realizar su trabajo.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfQu\u00e9 medidas espec\u00edficas debe tomar un inspector externo para garantizar la confidencialidad de la informaci\u00f3n durante la evaluaci\u00f3n de calidad?**\n   - La OMS exige que los inspectores externos tomen todas las medidas razonables para asegurar que la informaci\u00f3n confidencial no se utilice para ning\u00fan prop\u00f3sito distinto a las actividades descritas en el documento y que no se divulgue a personas no vinculadas por obligaciones similares de confidencialidad.\n\n2. **\u00bfCu\u00e1les son las condiciones bajo las cuales un inspector externo puede no estar obligado por las obligaciones de confidencialidad?**\n   - Un inspector externo no estar\u00e1 obligado por las obligaciones de confidencialidad si puede demostrar que la informaci\u00f3n confidencial ya era conocida por ellos antes de la divulgaci\u00f3n, estaba en el dominio p\u00fablico en el momento de la divulgaci\u00f3n, ha pasado al dominio p\u00fablico sin culpa de su parte, o ha sido obtenida de un tercero que no est\u00e1 en violaci\u00f3n de obligaciones legales de confidencialidad.\n\n3. **\u00bfQu\u00e9 criterios se utilizan para evaluar si existe un conflicto de inter\u00e9s significativo para un inspector externo?**\n   - Antes de comenzar su trabajo, cada inspector externo debe firmar una declaraci\u00f3n de inter\u00e9s. Si, tras revisar esta declaraci\u00f3n, se determina que no hay riesgo de un conflicto de inter\u00e9s real o percibido, o que el conflicto es insignificante o irrelevante, el inspector puede proceder con su evaluaci\u00f3n.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\nEl contenido proporcionado se refiere al \"WHO - Technical Report Series 961\", un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS). Aunque no se presenta informaci\u00f3n espec\u00edfica de la p\u00e1gina 412, se pueden identificar algunos temas y entidades clave relacionados con el documento:\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la publicaci\u00f3n del informe, que se centra en la salud p\u00fablica y las recomendaciones para mejorar las pr\u00e1cticas de salud a nivel global.\n\n2. **Informe T\u00e9cnico**: Parte de una serie de informes que abordan diversos temas de salud p\u00fablica, investigaci\u00f3n m\u00e9dica y pol\u00edticas de salud.\n\n3. **Salud P\u00fablica**: Tema central del informe, que incluye hallazgos y recomendaciones relevantes para la salud global.\n\n4. **Metodolog\u00edas de Evaluaci\u00f3n**: Posibles enfoques utilizados en el informe para evaluar la efectividad de las intervenciones de salud.\n\n5. **Pol\u00edticas de Salud Global**: Relaci\u00f3n entre los hallazgos del informe y su impacto en las pol\u00edticas de salud a nivel internacional.\n\n### Resumen:\nEl \"WHO - Technical Report Series 961\" es un informe de la OMS que aborda temas de salud p\u00fablica y recomendaciones para mejorar las pr\u00e1cticas de salud. Aunque no se dispone de contenido espec\u00edfico de la p\u00e1gina 412, se destacan la importancia de la OMS, la relevancia de la salud p\u00fablica, y la posible utilizaci\u00f3n de metodolog\u00edas para evaluar intervenciones de salud.", "excerpt_keywords": "Keywords: WHO, quality assessment, confidentiality, conflict of interest, cost recovery"}}, "109584fe-8657-4c8e-8680-8bf6d55c267b": {"node_ids": ["382acb42-391c-4002-bc97-7c613ebd858b"], "metadata": {"page_label": "414", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "it is thus deemed appropriate for the inspector in question to undertake this work, he/she will discharge his/her functions exclusively as adviser to WHO. In this connection, each inspector is required to confirm that the information disclosed by him/her in the declaration of interest is correct and complete, and that he/she will immediately notify WHO of any change in this information.\n\nAll external inspectors furthermore agree that, at the laboratory\u2019s request, WHO will advise the laboratory in advance of the identity of each such inspector and the composition of the team performing the site inspection and provide curricula vitae of the external inspectors. The laboratory then has the opportunity to express possible concerns regarding any of the external inspectors to WHO prior to the visit. If such concerns cannot be resolved in consultation with WHO, the laboratory may object to an external inspector\u2019s participation in the site visit. Such an objection must be made known to WHO by the laboratory within 10 days of receipt of the proposed team composition. In the event of such an objection, WHO reserves the right to cancel its agreement with the inspector in question and the activities to be undertaken by that inspector, in whole or in part.\n\n# References\n\n1. Good practices for pharmaceutical quality control laboratories. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 1.\n\n2. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. Vol. 2, Second updated edition. Good manufacturing practices and inspection. Geneva, World Health Organization, 2007; Quality assurance of pharmaceuticals. A compendium of guidelines and related materials. World Health Organization, 2010 (CD-ROM) (http://apps.who.int/medicinedocs/en/q/).\n\n3. WHO guidelines for preparing a laboratory information file. Revision. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-eighth report. Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl texto se refiere a las responsabilidades y procedimientos que deben seguir los inspectores externos que trabajan con la Organizaci\u00f3n Mundial de la Salud (OMS) en el contexto de las inspecciones de laboratorios farmac\u00e9uticos. Se establece que los inspectores deben confirmar la veracidad de su declaraci\u00f3n de intereses y notificar cualquier cambio a la OMS. Adem\u00e1s, se menciona que los laboratorios tienen la oportunidad de expresar preocupaciones sobre los inspectores propuestos y pueden objetar su participaci\u00f3n si no se resuelven dichas preocupaciones. La OMS se reserva el derecho de cancelar el acuerdo con el inspector en caso de objeciones.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 pasos debe seguir un inspector externo si hay un cambio en su declaraci\u00f3n de intereses?**\n   - Respuesta: El inspector debe notificar inmediatamente a la OMS sobre cualquier cambio en la informaci\u00f3n divulgada en su declaraci\u00f3n de intereses.\n\n2. **\u00bfCu\u00e1l es el plazo que tiene un laboratorio para expresar preocupaciones sobre un inspector externo propuesto?**\n   - Respuesta: El laboratorio tiene un plazo de 10 d\u00edas desde la recepci\u00f3n de la composici\u00f3n del equipo propuesto para hacer conocer sus preocupaciones a la OMS.\n\n3. **\u00bfQu\u00e9 derechos tiene la OMS en caso de que un laboratorio objete la participaci\u00f3n de un inspector externo?**\n   - Respuesta: La OMS se reserva el derecho de cancelar su acuerdo con el inspector en cuesti\u00f3n y las actividades que este debe realizar, total o parcialmente, si no se pueden resolver las objeciones planteadas por el laboratorio. \n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para proporcionar informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos o contextos, centr\u00e1ndose en los procedimientos y derechos relacionados con la inspecci\u00f3n de laboratorios farmac\u00e9uticos por parte de la OMS.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Informe de Investigaci\u00f3n**: La OMS proporcionar\u00e1 un informe escrito tras la investigaci\u00f3n de un laboratorio, que puede incluir recomendaciones para el laboratorio y la autoridad reguladora correspondiente (NMRA).\n\n2. **Recuperaci\u00f3n de Costos**: La OMS se reserva el derecho de cobrar por el procedimiento de evaluaci\u00f3n de calidad en base a la recuperaci\u00f3n de costos.\n\n3. **Compromiso de Confidencialidad**:\n   - Los inspectores externos deben tratar toda la informaci\u00f3n a la que accedan como confidencial y propietaria de la OMS.\n   - Se les exige tomar medidas razonables para asegurar que la informaci\u00f3n confidencial no se utilice para otros prop\u00f3sitos ni se divulgue a personas no autorizadas.\n   - Excepciones a la confidencialidad: informaci\u00f3n conocida previamente, en dominio p\u00fablico, o recibida de un tercero sin violaci\u00f3n de obligaciones de confidencialidad.\n\n4. **Conflicto de Inter\u00e9s**:\n   - Los inspectores externos deben firmar una declaraci\u00f3n de inter\u00e9s antes de comenzar su trabajo.\n   - Se evaluar\u00e1 si existe un riesgo de conflicto de inter\u00e9s real o percibido, permitiendo que el inspector proceda si se considera que el conflicto es insignificante o irrelevante.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la evaluaci\u00f3n de calidad y la regulaci\u00f3n de laboratorios.\n- **NMRA (Autoridad Nacional de Regulaci\u00f3n de Medicamentos)**: Entidad que tiene la supervisi\u00f3n regulatoria sobre los laboratorios investigados.\n- **Inspectores Externos**: Asesores temporales de la OMS encargados de realizar las evaluaciones de calidad.", "excerpt_keywords": "Keywords: WHO, external inspectors, laboratory inspections, declaration of interest, quality assurance"}}, "a222ab60-a84f-43ff-bb26-720100fea95d": {"node_ids": ["bf647959-772e-40b2-bbd3-1de908615478"], "metadata": {"page_label": "415", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 13\n\n## WHO guidelines for preparing a laboratory information file\n\n### Background\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations adopted in its thirty-eighth report in 2003 the *Guidelines for preparing a laboratory information file* (WHO Technical Report Series, No. 917, 2003, Annex 5).\n\nThe content of these guidelines is closely related to *WHO guidelines on good practices for pharmaceutical quality control laboratories*, which have recently been revised (the revised version was adopted by the WHO Expert Committee at its forty-fourth meeting in 2009).\n\nThe WHO Expert Committee on Specifications for Pharmaceutical Preparations discussed the need for a revision of both sets of guidelines at its forty-third meeting in 2008 and recommended that if the *Guidelines for good practices for national pharmaceutical control laboratories* were revised, the *Guidelines for preparing a laboratory information file* should be revised accordingly.\n\nOn the basis of the above and following the usual consultation process, the following text will replace the previously published guidelines.\n\n1. General information on the laboratory\n2. Quality management system\n3. Control of documentation and records\n4. Personnel\n5. Premises\n6. Equipment\n7. Materials\n8. Subcontracting of testing\n9. Handling of samples\n10. Validation of analytical procedures\n11. Investigation of out-of-specification results\n12. Stability testing (where applicable)\n13. Microbiological testing (where applicable)", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un anexo de las directrices de la OMS para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio, adoptadas en 2003 y revisadas en 2009. Estas directrices est\u00e1n relacionadas con las buenas pr\u00e1cticas en laboratorios de control de calidad farmac\u00e9utica y abordan aspectos clave como la gesti\u00f3n de calidad, el control de documentaci\u00f3n, el personal, las instalaciones, el equipo, los materiales, y otros procedimientos anal\u00edticos y de muestreo.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en un archivo de informaci\u00f3n de laboratorio seg\u00fan las directrices de la OMS?**\n   - Respuesta: Los elementos clave incluyen informaci\u00f3n general sobre el laboratorio, sistema de gesti\u00f3n de calidad, control de documentaci\u00f3n y registros, personal, instalaciones, equipo, materiales, subcontrataci\u00f3n de pruebas, manejo de muestras, validaci\u00f3n de procedimientos anal\u00edticos, investigaci\u00f3n de resultados fuera de especificaci\u00f3n, pruebas de estabilidad y pruebas microbiol\u00f3gicas (cuando sea aplicable).\n\n2. **\u00bfQu\u00e9 relaci\u00f3n existe entre las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio y las buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica?**\n   - Respuesta: El contenido de las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio est\u00e1 estrechamente relacionado con las directrices sobre buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica, que han sido recientemente revisadas. Ambas gu\u00edas buscan asegurar la calidad y la conformidad en los laboratorios farmac\u00e9uticos.\n\n3. **\u00bfQu\u00e9 recomendaciones hizo el Comit\u00e9 de Expertos de la OMS en su reuni\u00f3n de 2008 respecto a las directrices de laboratorio?**\n   - Respuesta: En su reuni\u00f3n de 2008, el Comit\u00e9 de Expertos discuti\u00f3 la necesidad de revisar ambas directrices y recomend\u00f3 que si se revisaban las *Directrices para buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional*, las *Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio* tambi\u00e9n deber\u00edan ser revisadas en consecuencia.", "prev_section_summary": "### Temas Clave\n\n1. **Responsabilidades de los Inspectores Externos**: Los inspectores deben actuar como asesores de la OMS y confirmar la veracidad de su declaraci\u00f3n de intereses.\n  \n2. **Notificaci\u00f3n de Cambios**: Los inspectores est\u00e1n obligados a notificar a la OMS cualquier cambio en su declaraci\u00f3n de intereses de manera inmediata.\n\n3. **Derechos de los Laboratorios**: Los laboratorios tienen el derecho de conocer la identidad de los inspectores y expresar preocupaciones sobre ellos antes de la visita.\n\n4. **Proceso de Objeci\u00f3n**: Si un laboratorio tiene preocupaciones que no se resuelven, puede objetar la participaci\u00f3n de un inspector, con un plazo de 10 d\u00edas para hacerlo.\n\n5. **Derechos de la OMS**: La OMS puede cancelar su acuerdo con un inspector si hay objeciones no resueltas por parte del laboratorio.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable de la regulaci\u00f3n y supervisi\u00f3n de las inspecciones de laboratorios.\n- **Inspectores Externos**: Profesionales que realizan las inspecciones en laboratorios farmac\u00e9uticos.\n- **Laboratorios Farmac\u00e9uticos**: Entidades que son objeto de las inspecciones y que pueden expresar preocupaciones sobre los inspectores.\n- **Declaraci\u00f3n de Intereses**: Documento que los inspectores deben completar y mantener actualizado.\n\nEste resumen destaca los procedimientos y derechos relacionados con la inspecci\u00f3n de laboratorios farmac\u00e9uticos por parte de la OMS, as\u00ed como las responsabilidades de los inspectores y los derechos de los laboratorios.", "excerpt_keywords": "Keywords: WHO, laboratory information file, quality management, pharmaceutical preparations, good practices"}}, "ac9950a3-7acb-48c2-be65-b9d6be556fe7": {"node_ids": ["d405ea25-1bdf-4254-81ce-0f8c9cbff216"], "metadata": {"page_label": "416", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "A laboratory information file (LIF) is a document prepared by the laboratory. It contains specific and factual information about the operations carried out at the named site and any closely integrated operations of the laboratory. If only some of the operations are carried out on the site, the LIF needs to describe only those operations, e.g. sampling, chemical analysis or stability testing.\n\nAn LIF should be written in English, succinct and, if possible, should not exceed 30 A4 pages, excluding appendices.\n\nThe laboratory should give a short description of its activities under each of the following headings. Policy or essential steps for each activity should be described and reference to a standard operating procedure (SOP) or other supporting documents should be given, where applicable. Where appropriate, supportive documentation should be appended.\n\n1. **General information on the laboratory**\n\n   1.1 Brief information on the laboratory (including name, physical (location) and mailing address, contact details and brief history). If the laboratory is part of an organization or company, provide details of its position within the organization or company, including reporting lines (e.g. organizational chart).\n\n   1.2 Summary of all laboratory activities, including objectives of the laboratory, categories of customers, types of sample tested. In addition, state the relation (if any) to a manufacturing site.\n\n   1.3 Areas of expertise proposed for prequalification (list methods and tests, for examples see the List of Prequalified Quality Control Laboratories).[^1]\n\n   | Type of analysis | Finished products | Active pharmaceutical ingredients |\n| - | - | - |\n| Physical/chemical analysis | | |\n| Identification | | |\n| Assay, impurities and related substances | | |\n| Microbiological tests | | |\n| Bacterial endotoxin testing (BET) | | |\n| Stability testing | | |\n\n\n   1.4 Brief description of a policy for participation in proficiency testing schemes and collaborative trials and for the evaluation of the performance. Attach the list of tests in which the laboratory has participated in the last three years, including the organizer and results.\n\n[^1]: http://www.who.int/prequal/lists/PQ_QCLabsList.pdf.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son los elementos clave que deben incluirse en la secci\u00f3n de \"Informaci\u00f3n general sobre el laboratorio\" en un archivo de informaci\u00f3n del laboratorio (LIF)?**\n   - Esta pregunta se centra en los detalles espec\u00edficos que se requieren para describir adecuadamente un laboratorio, como su nombre, direcci\u00f3n, actividades y relaci\u00f3n con otros sitios.\n\n2. **\u00bfQu\u00e9 tipo de an\u00e1lisis y pruebas se consideran para la precalificaci\u00f3n en un laboratorio, seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre las \u00e1reas de especializaci\u00f3n que un laboratorio puede proponer para la precalificaci\u00f3n, lo que incluye los tipos de an\u00e1lisis y pruebas que se realizan.\n\n3. **\u00bfQu\u00e9 pol\u00edtica debe seguir un laboratorio en relaci\u00f3n con la participaci\u00f3n en esquemas de pruebas de competencia y ensayos colaborativos?**\n   - Esta pregunta se enfoca en la pol\u00edtica que un laboratorio debe tener respecto a la evaluaci\u00f3n de su desempe\u00f1o en pruebas de competencia, as\u00ed como la documentaci\u00f3n que debe adjuntarse.\n\n### Res\u00famenes de nivel superior del contexto circundante:\n\n1. **Descripci\u00f3n del Archivo de Informaci\u00f3n del Laboratorio (LIF):** \n   El LIF es un documento que proporciona informaci\u00f3n detallada sobre las operaciones de un laboratorio, incluyendo su ubicaci\u00f3n, actividades, y procedimientos operativos est\u00e1ndar. Debe ser conciso y no exceder las 30 p\u00e1ginas, excluyendo ap\u00e9ndices.\n\n2. **Estructura de la Informaci\u00f3n en el LIF:**\n   El LIF debe incluir secciones que describan la informaci\u00f3n general del laboratorio, un resumen de sus actividades, \u00e1reas de especializaci\u00f3n para la precalificaci\u00f3n y pol\u00edticas sobre pruebas de competencia. Cada secci\u00f3n debe ser respaldada por documentos de apoyo cuando sea necesario.\n\n3. **Importancia de la Precalificaci\u00f3n y Pruebas de Competencia:**\n   La precalificaci\u00f3n y la participaci\u00f3n en pruebas de competencia son esenciales para asegurar la calidad y la fiabilidad de los an\u00e1lisis realizados por el laboratorio. Esto incluye la necesidad de documentar la participaci\u00f3n en ensayos colaborativos y los resultados obtenidos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n1. **Directrices de la OMS**: Se presentan las *Directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio*, adoptadas en 2003 y revisadas en 2009, que forman parte de la *Serie de Informes T\u00e9cnicos de la OMS*.\n\n2. **Relaci\u00f3n con otras directrices**: Estas directrices est\u00e1n estrechamente relacionadas con las *Directrices sobre buenas pr\u00e1cticas para laboratorios de control de calidad farmac\u00e9utica*, que tambi\u00e9n han sido revisadas.\n\n3. **Recomendaciones del Comit\u00e9 de Expertos**: En 2008, el Comit\u00e9 de Expertos discuti\u00f3 la necesidad de revisar ambas directrices y recomend\u00f3 que cualquier revisi\u00f3n de las directrices de buenas pr\u00e1cticas para laboratorios de control farmac\u00e9utico nacional deber\u00eda incluir una revisi\u00f3n de las directrices para la preparaci\u00f3n de un archivo de informaci\u00f3n de laboratorio.\n\n4. **Elementos clave del archivo de informaci\u00f3n de laboratorio**:\n   - Informaci\u00f3n general sobre el laboratorio\n   - Sistema de gesti\u00f3n de calidad\n   - Control de documentaci\u00f3n y registros\n   - Personal\n   - Instalaciones\n   - Equipos\n   - Materiales\n   - Subcontrataci\u00f3n de pruebas\n   - Manejo de muestras\n   - Validaci\u00f3n de procedimientos anal\u00edticos\n   - Investigaci\u00f3n de resultados fuera de especificaci\u00f3n\n   - Pruebas de estabilidad (cuando sea aplicable)\n   - Pruebas microbiol\u00f3gicas (cuando sea aplicable)\n\n### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Organizaci\u00f3n responsable de la adopci\u00f3n de las directrices.\n- **Comit\u00e9 de Expertos en Especificaciones para Preparaciones Farmac\u00e9uticas**: Grupo que revisa y adopta las directrices.\n- **Laboratorios de control de calidad farmac\u00e9utica**: Entidades que deben seguir estas directrices para asegurar la calidad y conformidad en sus operaciones.", "excerpt_keywords": "Keywords: laboratory information file, prequalification, proficiency testing, quality control, standard operating procedures"}}, "c8bc243a-d811-4a07-8528-6d5f342a1d1d": {"node_ids": ["15ada0bf-f678-4c82-89f3-ee03f5510e5a"], "metadata": {"page_label": "417", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2. Quality management system\n\n2.1 Short description of the quality management system implemented in the laboratory, including reference to the standard used (such as WHO good practices for pharmaceutical quality control laboratories, ISO 17025, good manufacturing practices) and existence of a quality manual.\n\n2.2 Information on inspections carried out by national or regional authorities and external audits performed in the laboratory in the last three years, including reference to valid accreditation, certificate, authorization or licence.\n\n2.3 Brief description of the procedures for internal audits, implementation of corrective and preventive actions and complaints.\n\n# 3. Control of documentation and records\n\n3.1 Brief description of the procedures for the control of and changes to documents that form a part of the quality documentation. Attach a list of valid SOPs.\n\n3.2 Brief description of the procedures for the preparation, revision and distribution of necessary documentation for specifications, standard test procedures, analyst workbooks or worksheets.\n\n3.3 Brief description of any other documentation related to product testing, including reports, records, arrangements for the handling of results (including laboratory information management systems (LIMS), where used).\n\n3.4 Brief description of the procedures for release of certificates and analytical reports.\n\n# 4. Personnel\n\n4.1 Number of employees engaged in the following activities:\n\n| Activity | Number |\n| - | - |\n| Supervisors | |\n| Chemical sector | |\n| \u00a0\u00a0\u00a0\u00a0analysts | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Microbiological sector | |\n| \u00a0\u00a0\u00a0\u00a0microbiologists | |\n| \u00a0\u00a0\u00a0\u00a0technicians | |\n| Quality assurance staff | |\n| Staff trained for sampling | |\n| Other | |\n| Total number of employees in the laboratory: | |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior del contenido:\n\n### Resumen de nivel superior:\nEl documento se centra en la gesti\u00f3n de la calidad en laboratorios de control de calidad farmac\u00e9utica, describiendo los sistemas de gesti\u00f3n de calidad implementados, el control de la documentaci\u00f3n y los registros, y la estructura del personal involucrado en estas actividades. Se mencionan est\u00e1ndares relevantes como las buenas pr\u00e1cticas de la OMS, ISO 17025 y buenas pr\u00e1cticas de fabricaci\u00f3n. Tambi\u00e9n se abordan las auditor\u00edas internas, la gesti\u00f3n de quejas y la documentaci\u00f3n relacionada con las pruebas de productos.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 est\u00e1ndares espec\u00edficos se mencionan en el contexto como referencia para el sistema de gesti\u00f3n de calidad del laboratorio, y c\u00f3mo se implementan en la pr\u00e1ctica?**\n   - Esta pregunta busca detalles sobre la aplicaci\u00f3n pr\u00e1ctica de los est\u00e1ndares mencionados, lo que puede no estar disponible en otras fuentes.\n\n2. **\u00bfCu\u00e1les son los procedimientos espec\u00edficos para la realizaci\u00f3n de auditor\u00edas internas y la implementaci\u00f3n de acciones correctivas y preventivas en el laboratorio?**\n   - Esta pregunta se centra en los procedimientos internos del laboratorio, que pueden no estar documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 tipo de documentaci\u00f3n se requiere para la preparaci\u00f3n y distribuci\u00f3n de especificaciones y procedimientos de prueba est\u00e1ndar, y c\u00f3mo se controla su modificaci\u00f3n?**\n   - Esta pregunta busca informaci\u00f3n sobre el manejo espec\u00edfico de la documentaci\u00f3n, que puede ser \u00fanica para el laboratorio en cuesti\u00f3n y no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Archivo de Informaci\u00f3n del Laboratorio (LIF)**:\n   - Documento que proporciona informaci\u00f3n espec\u00edfica y factual sobre las operaciones de un laboratorio.\n   - Debe ser conciso, escrito en ingl\u00e9s y no exceder las 30 p\u00e1ginas (excluyendo ap\u00e9ndices).\n\n2. **Estructura del LIF**:\n   - **Informaci\u00f3n General sobre el Laboratorio**:\n     - Nombre, direcci\u00f3n f\u00edsica y de correo, detalles de contacto y breve historia.\n     - Posici\u00f3n dentro de una organizaci\u00f3n, incluyendo l\u00edneas de reporte.\n   - **Resumen de Actividades del Laboratorio**:\n     - Objetivos, categor\u00edas de clientes y tipos de muestras analizadas.\n     - Relaci\u00f3n con sitios de manufactura, si aplica.\n   - **\u00c1reas de Especializaci\u00f3n para Precalificaci\u00f3n**:\n     - M\u00e9todos y pruebas que el laboratorio propone para precalificaci\u00f3n, incluyendo an\u00e1lisis f\u00edsico/qu\u00edmico, identificaci\u00f3n, ensayos, pruebas microbiol\u00f3gicas, pruebas de endotoxinas bacterianas y pruebas de estabilidad.\n   - **Pol\u00edtica de Participaci\u00f3n en Pruebas de Competencia**:\n     - Descripci\u00f3n de la pol\u00edtica para participar en esquemas de pruebas de competencia y ensayos colaborativos.\n     - Inclusi\u00f3n de una lista de pruebas en las que el laboratorio ha participado en los \u00faltimos tres a\u00f1os, junto con los organizadores y resultados.\n\n3. **Importancia de la Precalificaci\u00f3n y Pruebas de Competencia**:\n   - Asegura la calidad y fiabilidad de los an\u00e1lisis realizados por el laboratorio.\n   - Requiere documentaci\u00f3n de la participaci\u00f3n en ensayos colaborativos y evaluaci\u00f3n del desempe\u00f1o.\n\n### Entidades Clave:\n- **Laboratorio**: Entidad que realiza an\u00e1lisis y pruebas.\n- **Organizaci\u00f3n/Compa\u00f1\u00eda**: Estructura a la que pertenece el laboratorio.\n- **Clientes**: Categor\u00edas de usuarios de los servicios del laboratorio.\n- **M\u00e9todos y Pruebas**: Tipos de an\u00e1lisis que el laboratorio puede realizar y proponer para precalificaci\u00f3n.\n- **Esquemas de Pruebas de Competencia**: Programas en los que el laboratorio participa para evaluar su desempe\u00f1o.", "excerpt_keywords": "Keywords: quality management system, pharmaceutical quality control, internal audits, documentation control, laboratory personnel"}}, "e948d067-ee7c-4787-9c16-e934d3780167": {"node_ids": ["7d9e119e-b302-41f7-b535-937cc39c8d13"], "metadata": {"page_label": "418", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.2 Organization chart showing the arrangements, responsibilities and reporting lines in the laboratory.\n\n4.3 Qualifications, experience and responsibilities of key personnel.\n\n4.4 Outline of arrangements for initial and ongoing training and its recording.\n\n# 5. Premises\n\n5.1 Simple plan or description of the layout of the laboratory areas with an indication of scale (architectural or engineering drawings not required, but photographs may be submitted if available).\n\n5.2 Nature of construction and finishing.\n\n5.3 Brief description of ventilation systems including those for microbiological testing areas, storage areas, etc. (Include reference to air circulation and control of temperature and relative humidity.)\n\n5.4 Brief description of special areas for the handling and storage of hazardous materials such as highly toxic (including genotoxic), poisonous and flammable materials.\n\n5.5 Description of planned programmes for preventive maintenance of the premises and the system for recording maintenance activities.\n\n5.6 Brief description of the procedures for cleaning of areas and equipment.\n\n5.7 Short description of the storage areas (size, location) including arrangements for the storage of materials and retention samples.\n\n# 6. Equipment\n\n6.1 Brief description of the main equipment used in the laboratory. Attach a list of equipment in use, in tabular form, indicating the equipment and its brand model and date of installation.\n\n6.2 Brief description of the planned programme for the preventive maintenance of equipment and the system for recording the maintenance activities.\n\n6.3 Brief description of arrangements and status for qualification of equipment (installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ)) as well as calibration of measuring equipment, including the recording system.\n\n6.4 Brief description of computer system and its validation and data integrity management, including access to data and frequency of back-up.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos clave relacionados con la organizaci\u00f3n y operaci\u00f3n de laboratorios, incluyendo la estructura organizativa, las calificaciones y responsabilidades del personal, la formaci\u00f3n continua, las instalaciones del laboratorio, el equipo utilizado, y los procedimientos de mantenimiento y limpieza. Se detallan tambi\u00e9n las caracter\u00edsticas de las \u00e1reas de almacenamiento, la gesti\u00f3n de materiales peligrosos y la validaci\u00f3n de sistemas inform\u00e1ticos.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los requisitos espec\u00edficos de calificaci\u00f3n y experiencia para el personal clave en el laboratorio seg\u00fan el informe?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las calificaciones y experiencias necesarias que no se pueden encontrar f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipo de mantenimiento preventivo se recomienda para las instalaciones del laboratorio y c\u00f3mo se debe registrar?**\n   - Esta pregunta se centra en los programas de mantenimiento preventivo, que son cruciales para la operaci\u00f3n segura y eficiente del laboratorio, y que pueden no estar ampliamente documentados en otros lugares.\n\n3. **\u00bfQu\u00e9 procedimientos se sugieren para la limpieza de \u00e1reas y equipos en el laboratorio, y c\u00f3mo se asegura su efectividad?**\n   - Esta pregunta busca detalles sobre los procedimientos espec\u00edficos de limpieza y su importancia en la prevenci\u00f3n de contaminaci\u00f3n, que pueden no estar disponibles en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Sistema de gesti\u00f3n de calidad**:\n   - Descripci\u00f3n del sistema de gesti\u00f3n de calidad implementado en el laboratorio.\n   - Referencia a est\u00e1ndares como las buenas pr\u00e1cticas de la OMS, ISO 17025 y buenas pr\u00e1cticas de fabricaci\u00f3n.\n   - Existencia de un manual de calidad.\n\n2. **Inspecciones y auditor\u00edas**:\n   - Informaci\u00f3n sobre inspecciones realizadas por autoridades nacionales o regionales.\n   - Detalles sobre auditor\u00edas externas en los \u00faltimos tres a\u00f1os.\n   - Referencia a acreditaciones, certificados, autorizaciones o licencias v\u00e1lidas.\n\n3. **Auditor\u00edas internas y acciones correctivas**:\n   - Procedimientos para auditor\u00edas internas.\n   - Implementaci\u00f3n de acciones correctivas y preventivas.\n   - Gesti\u00f3n de quejas.\n\n4. **Control de documentaci\u00f3n y registros**:\n   - Procedimientos para el control y cambios en la documentaci\u00f3n de calidad.\n   - Preparaci\u00f3n, revisi\u00f3n y distribuci\u00f3n de documentaci\u00f3n necesaria (especificaciones, procedimientos de prueba est\u00e1ndar, etc.).\n   - Documentaci\u00f3n relacionada con pruebas de productos, incluyendo informes y sistemas de gesti\u00f3n de informaci\u00f3n de laboratorio (LIMS).\n   - Procedimientos para la liberaci\u00f3n de certificados e informes anal\u00edticos.\n\n5. **Personal**:\n   - Desglose del n\u00famero de empleados en diversas actividades, incluyendo supervisores, analistas, t\u00e9cnicos, microbi\u00f3logos, personal de aseguramiento de calidad y personal capacitado para muestreo.\n   - Total de empleados en el laboratorio.\n\n### Entidades:\n- **Est\u00e1ndares**: OMS, ISO 17025, buenas pr\u00e1cticas de fabricaci\u00f3n.\n- **Tipos de personal**: Supervisores, analistas, t\u00e9cnicos, microbi\u00f3logos, personal de calidad.\n- **Documentaci\u00f3n**: Manual de calidad, SOPs (Procedimientos Operativos Est\u00e1ndar), informes anal\u00edticos, certificados. \n\nEste resumen proporciona una visi\u00f3n general de los aspectos clave relacionados con la gesti\u00f3n de calidad en laboratorios de control de calidad farmac\u00e9utica, as\u00ed como la estructura del personal y los procedimientos documentales.", "excerpt_keywords": "Keywords: laboratory management, quality assurance, preventive maintenance, personnel qualifications, equipment validation"}}, "03a3a8d3-4b8f-4df9-9303-a76d54e86ef2": {"node_ids": ["92ae8602-c007-4512-8323-02717be0ff33"], "metadata": {"page_label": "419", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 7. Materials\n\n7.1 Brief description of general policy for purchasing and handling of materials (including chemicals and reagents and availability of safety data sheets) and for handling of waste. Brief description of the procedure for selection and evaluation of suppliers.\n\n7.2 Brief description of the water system in the laboratory, its qualification and arrangements for the sampling and testing of the water.\n\n7.3 Brief description of the system for purchasing, preparation, handling and storage of reference substances and reference materials.\n\n# 8. Subcontracting of testing\n\n8.1 List of activities contracted out to other laboratories, including names and addresses of subcontractors of subcontractors. Description of the way in which the compliance with standards for activities contracted out is assessed.\n\n# 9. Handling of samples\n\n9.1 Brief description of general policy for sampling. If the laboratory is responsible for sampling describe briefly the procedures used and standards applied.\n\n9.2 Brief description of the procedures for handling of samples from their receipt to storage after completion of testing. Where possible, flow charts describing important steps and work allocation in the laboratory should be supplied.\n\n# 10. Validation of analytical procedures\n\n10.1 Brief description of general policy for validation of analytical methods, including verification of pharmacopoeial methods or analytical procedures validated by manufacturers.\n\n# 11. Investigation of out-of-specification results\n\n11.1 Brief description of the procedure for recording and investigation of out-of-specification results.\n\n# 12. Stability testing (where applicable)\n\n12.1 Brief description of the stability testing procedure.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda varios aspectos cr\u00edticos relacionados con la gesti\u00f3n de laboratorios, incluyendo pol\u00edticas para la compra y manejo de materiales, procedimientos de muestreo, validaci\u00f3n de m\u00e9todos anal\u00edticos, y manejo de resultados fuera de especificaci\u00f3n. Se detallan las pr\u00e1cticas para la selecci\u00f3n de proveedores, el manejo de muestras, y la realizaci\u00f3n de pruebas de estabilidad, as\u00ed como la subcontrataci\u00f3n de actividades de laboratorio.\n\n### Preguntas\n1. **\u00bfCu\u00e1l es la pol\u00edtica general para la compra y manejo de materiales en el laboratorio, y c\u00f3mo se asegura la disponibilidad de hojas de datos de seguridad?**\n   - Esta pregunta busca informaci\u00f3n espec\u00edfica sobre las pol\u00edticas y procedimientos que el laboratorio sigue para la adquisici\u00f3n y manejo seguro de materiales, as\u00ed como la gesti\u00f3n de residuos.\n\n2. **\u00bfQu\u00e9 procedimientos se utilizan para la validaci\u00f3n de m\u00e9todos anal\u00edticos, y c\u00f3mo se verifica la conformidad con los m\u00e9todos farmacopoeiales?**\n   - Esta pregunta se centra en los procesos de validaci\u00f3n de m\u00e9todos anal\u00edticos, un aspecto crucial para garantizar la calidad y precisi\u00f3n de los resultados en un laboratorio.\n\n3. **\u00bfC\u00f3mo se lleva a cabo la investigaci\u00f3n de resultados fuera de especificaci\u00f3n y qu\u00e9 procedimientos se siguen para documentar estos casos?**\n   - Esta pregunta busca detalles sobre el manejo de resultados que no cumplen con los est\u00e1ndares establecidos, lo que es fundamental para la integridad de los procesos de laboratorio y la confianza en los resultados obtenidos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n del Laboratorio**\n   - **Estructura Organizativa**: Se menciona un organigrama que detalla las responsabilidades y l\u00edneas de reporte del personal en el laboratorio.\n   - **Personal Clave**: Se requiere informaci\u00f3n sobre las calificaciones, experiencia y responsabilidades del personal esencial.\n\n2. **Formaci\u00f3n**\n   - **Capacitaci\u00f3n Inicial y Continua**: Se describe la organizaci\u00f3n de la formaci\u00f3n y su registro, asegurando que el personal est\u00e9 adecuadamente capacitado.\n\n3. **Instalaciones del Laboratorio**\n   - **Dise\u00f1o y Construcci\u00f3n**: Se solicita un plano simple o descripci\u00f3n del layout del laboratorio, as\u00ed como detalles sobre la construcci\u00f3n y acabados.\n   - **Sistemas de Ventilaci\u00f3n**: Se requiere una breve descripci\u00f3n de los sistemas de ventilaci\u00f3n, incluyendo control de temperatura y humedad.\n   - **Manejo de Materiales Peligrosos**: Se abordan \u00e1reas especiales para el manejo y almacenamiento de materiales altamente t\u00f3xicos y peligrosos.\n   - **Mantenimiento Preventivo**: Se describe un programa de mantenimiento preventivo para las instalaciones y un sistema para registrar las actividades de mantenimiento.\n   - **Procedimientos de Limpieza**: Se detallan los procedimientos para la limpieza de \u00e1reas y equipos, asegurando su efectividad.\n   - **\u00c1reas de Almacenamiento**: Se proporciona una descripci\u00f3n de las \u00e1reas de almacenamiento, incluyendo tama\u00f1o y ubicaci\u00f3n.\n\n4. **Equipamiento del Laboratorio**\n   - **Descripci\u00f3n del Equipamiento**: Se requiere una lista de los equipos principales utilizados en el laboratorio, incluyendo marca, modelo y fecha de instalaci\u00f3n.\n   - **Mantenimiento del Equipamiento**: Se describe un programa de mantenimiento preventivo para el equipo y un sistema de registro de actividades.\n   - **Calificaci\u00f3n del Equipamiento**: Se abordan los procesos de calificaci\u00f3n del equipo (IQ, OQ, PQ) y la calibraci\u00f3n de equipos de medici\u00f3n.\n   - **Sistema Inform\u00e1tico**: Se menciona la validaci\u00f3n del sistema inform\u00e1tico y la gesti\u00f3n de la integridad de los datos, incluyendo acceso y frecuencia de respaldo.\n\n### Entidades Clave\n- **Laboratorio**: Entidad principal donde se llevan a cabo las actividades descritas.\n- **Personal Clave**: Individuos con calificaciones y responsabilidades espec\u00edficas.\n- **Equipamiento**: Herramientas y m\u00e1quinas utilizadas en el laboratorio.\n- **Materiales Peligrosos**: Sustancias que requieren manejo especial debido a su toxicidad o peligrosidad.\n- **Sistemas de Ventilaci\u00f3n**: Infraestructura cr\u00edtica para el control ambiental del laboratorio. \n\nEste resumen abarca los aspectos fundamentales de la organizaci\u00f3n, mantenimiento y operaci\u00f3n de laboratorios seg\u00fan el documento de la OMS.", "excerpt_keywords": "Keywords: laboratory management, analytical procedures, sample handling, stability testing, subcontracting"}}, "705df9e9-98a2-4d99-87d9-ced452bce29c": {"node_ids": ["8e520bfa-475b-450b-98c9-c8f4a20e3ce3"], "metadata": {"page_label": "420", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 12.2 \nBrief description of the conditions under which samples are kept, the arrangements for monitoring and the equipment used.\n\n# 13. Microbiological testing (where applicable)\n\n13.1 Brief description of the activities for microbiological testing.\n\n13.2 Brief description of preparation and control of media and types of media used.\n\n13.3 Brief description of the procedure in place for positive and negative controls.\n\n13.4 Brief description of validation policy.\n\n13.5 Brief description of arrangements for waste disposal.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior:\nEl documento \"WHO - Technical Report Series 961\" aborda aspectos relacionados con la conservaci\u00f3n de muestras y las pruebas microbiol\u00f3gicas. Se detalla c\u00f3mo se mantienen las muestras, los equipos utilizados, las actividades de pruebas microbiol\u00f3gicas, la preparaci\u00f3n y control de medios, as\u00ed como los procedimientos de control positivo y negativo, la pol\u00edtica de validaci\u00f3n y la gesti\u00f3n de residuos.\n\n### Preguntas:\n1. **\u00bfCu\u00e1les son las condiciones espec\u00edficas bajo las cuales se deben almacenar las muestras y qu\u00e9 tipo de equipo se utiliza para monitorear estas condiciones?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las condiciones de almacenamiento y el equipo de monitoreo, que probablemente no se encuentre en otras fuentes.\n\n2. **\u00bfQu\u00e9 tipos de medios se utilizan en las pruebas microbiol\u00f3gicas y c\u00f3mo se lleva a cabo su preparaci\u00f3n y control?**\n   - Esta pregunta se centra en los aspectos t\u00e9cnicos de la preparaci\u00f3n de medios, que son cruciales para la validez de las pruebas microbiol\u00f3gicas.\n\n3. **\u00bfQu\u00e9 procedimientos se implementan para garantizar la efectividad de los controles positivos y negativos en las pruebas microbiol\u00f3gicas?**\n   - Esta pregunta indaga sobre los procedimientos espec\u00edficos que aseguran la fiabilidad de los resultados de las pruebas, un aspecto fundamental en la microbiolog\u00eda que puede no estar ampliamente documentado en otras fuentes.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Pol\u00edtica de Materiales**:\n   - **Compra y Manejo**: Se describe la pol\u00edtica general para la adquisici\u00f3n y manejo de materiales, incluyendo productos qu\u00edmicos y reactivos, as\u00ed como la disponibilidad de hojas de datos de seguridad.\n   - **Manejo de Residuos**: Incluye procedimientos para la gesti\u00f3n de desechos generados en el laboratorio.\n   - **Selecci\u00f3n de Proveedores**: Proceso para la evaluaci\u00f3n y selecci\u00f3n de proveedores de materiales.\n\n2. **Sistema de Agua**:\n   - **Calificaci\u00f3n y Muestreo**: Descripci\u00f3n del sistema de agua en el laboratorio, incluyendo su calificaci\u00f3n y los arreglos para el muestreo y pruebas del agua.\n\n3. **Sustancias de Referencia**:\n   - **Compra y Almacenamiento**: Procedimientos para la compra, preparaci\u00f3n, manejo y almacenamiento de sustancias y materiales de referencia.\n\n4. **Subcontrataci\u00f3n**:\n   - **Actividades Contratadas**: Listado de actividades subcontratadas a otros laboratorios, incluyendo nombres y direcciones de los subcontratistas.\n   - **Cumplimiento de Normas**: Descripci\u00f3n de c\u00f3mo se eval\u00faa el cumplimiento de est\u00e1ndares en actividades subcontratadas.\n\n5. **Manejo de Muestras**:\n   - **Pol\u00edtica de Muestreo**: Procedimientos generales para el muestreo, incluyendo est\u00e1ndares aplicados.\n   - **Manejo de Muestras**: Procedimientos desde la recepci\u00f3n hasta el almacenamiento de muestras despu\u00e9s de las pruebas, con posibilidad de incluir diagramas de flujo.\n\n6. **Validaci\u00f3n de M\u00e9todos Anal\u00edticos**:\n   - **Pol\u00edtica de Validaci\u00f3n**: Descripci\u00f3n de la pol\u00edtica para la validaci\u00f3n de m\u00e9todos anal\u00edticos, incluyendo la verificaci\u00f3n de m\u00e9todos farmacopoeiales.\n\n7. **Resultados Fuera de Especificaci\u00f3n**:\n   - **Investigaci\u00f3n y Documentaci\u00f3n**: Procedimientos para registrar e investigar resultados que no cumplen con las especificaciones establecidas.\n\n8. **Pruebas de Estabilidad**:\n   - **Procedimiento de Estabilidad**: Descripci\u00f3n del procedimiento para realizar pruebas de estabilidad, cuando sea aplicable.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Laboratorio**: Entidad que implementa las pol\u00edticas y procedimientos descritos.\n- **Proveedores**: Entidades externas que suministran materiales y reactivos.\n- **Subcontratistas**: Laboratorios externos que realizan actividades contratadas.\n- **Sustancias de Referencia**: Materiales utilizados para calibraci\u00f3n y control de calidad en el laboratorio. \n\nEste resumen abarca los aspectos fundamentales de la gesti\u00f3n de laboratorios seg\u00fan el documento de la OMS, destacando las pol\u00edticas y procedimientos esenciales para asegurar la calidad y seguridad en las operaciones de laboratorio.", "excerpt_keywords": "Keywords: microbiological testing, sample storage, media preparation, validation policy, waste disposal"}}, "8e8ad89d-6cf5-4b15-b1a7-9e9d5a9f42b4": {"node_ids": ["7ef3aa49-8532-4e58-b2a7-006293d91d3c"], "metadata": {"page_label": "421", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 14\n\n## WHO guidelines for drafting a site master file\n\n1. Introduction\n2. Purpose\n3. Scope\n4. Content of site master file\n\n### Appendix\nContent of a site master file\n\n----\n\n\u00b9 Based on the *Explanatory notes for pharmaceutical manufacturers on the preparation of a site master file* of the Pharmaceutical Inspection Convention.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento \"WHO - Technical Report Series 961\" incluye una secci\u00f3n titulada \"Annex 14\", que proporciona directrices de la Organizaci\u00f3n Mundial de la Salud (OMS) para la elaboraci\u00f3n de un archivo maestro del sitio (site master file). Este archivo es un documento esencial para los fabricantes farmac\u00e9uticos, ya que detalla la informaci\u00f3n relevante sobre las instalaciones y procesos de producci\u00f3n. La secci\u00f3n abarca la introducci\u00f3n, el prop\u00f3sito, el alcance y el contenido que debe incluirse en el archivo maestro del sitio, adem\u00e1s de un ap\u00e9ndice que detalla el contenido espec\u00edfico.\n\n### Preguntas:\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal de un archivo maestro del sitio seg\u00fan las directrices de la OMS?**\n   - Esta pregunta busca una respuesta espec\u00edfica sobre la funci\u00f3n y la importancia del archivo maestro del sitio en el contexto de la fabricaci\u00f3n farmac\u00e9utica.\n\n2. **\u00bfQu\u00e9 se incluye en el contenido del archivo maestro del sitio seg\u00fan el documento mencionado?**\n   - Esta pregunta se centra en los elementos espec\u00edficos que deben ser parte del archivo maestro del sitio, lo que puede no estar claramente definido en otras fuentes.\n\n3. **\u00bfQu\u00e9 se menciona en el ap\u00e9ndice del documento sobre el contenido del archivo maestro del sitio?**\n   - Esta pregunta busca detalles sobre la informaci\u00f3n adicional o espec\u00edfica que se proporciona en el ap\u00e9ndice, que podr\u00eda no estar disponible en otros documentos relacionados.", "prev_section_summary": "### Resumen de Temas Clave y Entidades:\n\n1. **Condiciones de Almacenamiento de Muestras**:\n   - Descripci\u00f3n de las condiciones espec\u00edficas bajo las cuales se mantienen las muestras biol\u00f3gicas.\n   - Arreglos para el monitoreo de estas condiciones.\n   - Equipos utilizados para asegurar la integridad de las muestras.\n\n2. **Pruebas Microbiol\u00f3gicas**:\n   - Actividades relacionadas con la realizaci\u00f3n de pruebas microbiol\u00f3gicas.\n   - Preparaci\u00f3n y control de medios de cultivo, incluyendo los tipos de medios utilizados.\n   - Procedimientos para controles positivos y negativos, asegurando la validez de los resultados.\n   - Pol\u00edtica de validaci\u00f3n que respalda los m\u00e9todos de prueba.\n   - Disposici\u00f3n de residuos generados durante las pruebas microbiol\u00f3gicas.\n\n### Entidades Clave:\n- **Muestras**: Elementos biol\u00f3gicos que se almacenan y analizan.\n- **Equipos de Monitoreo**: Herramientas utilizadas para supervisar las condiciones de almacenamiento.\n- **Medios de Cultivo**: Sustancias utilizadas para el crecimiento de microorganismos en pruebas microbiol\u00f3gicas.\n- **Controles Positivos y Negativos**: Procedimientos que garantizan la fiabilidad de las pruebas.\n- **Pol\u00edtica de Validaci\u00f3n**: Normativas que aseguran la efectividad de los m\u00e9todos de prueba.\n- **Gesti\u00f3n de Residuos**: Proceso de disposici\u00f3n de desechos generados en el laboratorio.\n\nEste resumen proporciona una visi\u00f3n general de los aspectos cr\u00edticos relacionados con la conservaci\u00f3n de muestras y las pruebas microbiol\u00f3gicas, as\u00ed como las entidades involucradas en estos procesos.", "excerpt_keywords": "Keywords: site master file, WHO guidelines, pharmaceutical manufacturing, document preparation, technical report"}}, "984cb7ef-d327-4df6-bc45-1c410e296bd6": {"node_ids": ["81facdc1-e569-4803-af5e-049d8dc6a18d"], "metadata": {"page_label": "422", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n1.1 The site master file (SMF) is prepared by the pharmaceutical manufacturer and should contain specific information about the quality management policies and activities of the site, the production and/or quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, an SMF need only describe those operations, e.g. analysis, packaging, etc.\n\n1.2 When submitted to a regulatory authority, the SMF should provide clear information on the manufacturer\u2019s good manufacturing practices (GMP)-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.\n\n1.3 An SMF should contain adequate information but, as far as possible, not exceed 25\u201330 pages plus appendices. Simple plans, outline drawings or schematic layouts are preferred instead of narratives. The SMF, including appendices, should be readable when printed on A4 paper sheets.\n\n1.4 The SMF should be a part of documentation belonging to the quality management system of the manufacturer and kept updated accordingly. The SMF should have an edition number, the date it becomes effective and the date by which it has to be reviewed. It should be subject to regular review to ensure that it is up to date and representative of current activities. Each annex can have an individual effective date, allowing for independent updating.\n\n# 2. Purpose\n\nThe aim of these explanatory notes is to guide the manufacturer of medicinal products in the preparation of an SMF that is useful to the regulatory authority in planning and conducting GMP inspections.\n\n# 3. Scope\n\nThese explanatory notes apply to the preparation and content of the SMF. Manufacturers should refer to regional and or national regulatory requirements to establish whether it is mandatory for manufacturers of medicinal products to prepare an SMF.\n\nThese explanatory notes apply for all kinds of manufacturing operations such as production, packaging and labelling, testing, relabelling and repackaging of all types of medicinal products. The outlines of this guide could also be used in the preparation of an SMF or corresponding document by blood and tissue establishments and manufacturers of active pharmaceutical ingredients (APIs).\n\n# 4. Content of site master file\n\nRefer to the Appendix for the format to be used.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento se centra en la elaboraci\u00f3n del archivo maestro del sitio (SMF) por parte de los fabricantes de productos farmac\u00e9uticos. El SMF debe contener informaci\u00f3n sobre las pol\u00edticas de gesti\u00f3n de calidad y las actividades del sitio, as\u00ed como detalles sobre las operaciones de fabricaci\u00f3n y control de calidad. Se establece que el SMF debe ser claro, conciso y estar actualizado, y se menciona su importancia para las inspecciones de buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) por parte de las autoridades regulatorias. Adem\u00e1s, se indica que el SMF debe seguir un formato espec\u00edfico y puede aplicarse a diversas operaciones de fabricaci\u00f3n.\n\n### Preguntas\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n espec\u00edfica debe incluirse en el archivo maestro del sitio (SMF) para cumplir con los requisitos de las autoridades regulatorias?**\n   - Esta pregunta busca detalles sobre los elementos espec\u00edficos que deben estar presentes en el SMF, m\u00e1s all\u00e1 de lo que se menciona en el resumen.\n\n2. **\u00bfCu\u00e1les son las implicaciones de no mantener actualizado el archivo maestro del sitio (SMF) seg\u00fan las directrices establecidas?**\n   - Esta pregunta se centra en las consecuencias de no cumplir con los requisitos de actualizaci\u00f3n del SMF, lo que podr\u00eda no estar expl\u00edcitamente mencionado en otros documentos.\n\n3. **\u00bfQu\u00e9 diferencias existen en la preparaci\u00f3n del SMF para diferentes tipos de operaciones de fabricaci\u00f3n, como la producci\u00f3n de medicamentos frente a la fabricaci\u00f3n de ingredientes farmac\u00e9uticos activos (APIs)?**\n   - Esta pregunta busca aclarar c\u00f3mo var\u00edan los requisitos del SMF seg\u00fan el tipo de operaci\u00f3n de fabricaci\u00f3n, lo que podr\u00eda no estar claramente delineado en otros contextos.", "prev_section_summary": "### Resumen de temas clave y entidades:\n\n**Tema clave:**\n- **Archivo Maestro del Sitio (Site Master File):** Documento esencial para los fabricantes farmac\u00e9uticos que proporciona informaci\u00f3n detallada sobre las instalaciones y procesos de producci\u00f3n.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Autoridad que emite las directrices para la elaboraci\u00f3n del archivo maestro del sitio.\n- **Pharmaceutical Inspection Convention:** Fuente de las notas explicativas que sirven de base para las directrices de la OMS.\n\n**Estructura del contenido:**\n1. **Introducci\u00f3n:** Presentaci\u00f3n del tema y su relevancia.\n2. **Prop\u00f3sito:** Objetivos del archivo maestro del sitio.\n3. **Alcance:** \u00c1reas y aspectos cubiertos por el documento.\n4. **Contenido del archivo maestro del sitio:** Detalles sobre la informaci\u00f3n que debe incluirse.\n5. **Ap\u00e9ndice:** Informaci\u00f3n adicional sobre el contenido espec\u00edfico del archivo maestro del sitio.\n\nEste resumen destaca la importancia del archivo maestro del sitio en la industria farmac\u00e9utica y la gu\u00eda proporcionada por la OMS para su elaboraci\u00f3n.", "excerpt_keywords": "Keywords: Site Master File, pharmaceutical manufacturing, good manufacturing practices, quality management system, regulatory authority"}}, "197a0af0-4bad-4f48-b8cf-581a986f26a0": {"node_ids": ["4b1f93f6-8271-43b4-93f8-8d526d920a48"], "metadata": {"page_label": "423", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Appendix\n\n## Content of a site master file\n\n1. **General information on the manufacturer**\n\n   1.1 **Contact information on the manufacturer**\n   \n   - Name and official address of the manufacturer;\n   - Names and street addresses of the site, buildings and production units located on the site;\n   - Contact information of the manufacturer including 24-hour telephone number of the contact personnel in the case of product defects or recalls; and\n   - Identification number of the site as e.g. global positioning system (GPS) details, D-U-N-S (Data Universal Numbering System) number (a unique identification number provided by Dun & Bradstreet) of the site or any other geographical location system.\n\n   1.2 **Authorized pharmaceutical manufacturing activities of the site**\n   \n   - Copy of the valid manufacturing authorization issued by the relevant competent authority in Annex 1; or when applicable, reference to the EudraGMP database. If the competent authority does not issue manufacturing authorizations, this should be stated;\n   - Brief description of manufacture, import, export, distribution and other activities as authorized by the relevant competent authorities including foreign authorities with authorized dosage forms/activities, respectively; where not covered by the manufacturing authorization;\n   - Type of products currently manufactured on-site (list in Annex 2) where not covered by Annex 1 or the EudraGMP database; and\n   - List of GMP inspections of the site within the last five years; including dates and name/country of the competent authority having performed the inspection. A copy of the current GMP certificate (Annex 3) or reference to the EudraGMP database should be included, if available.\n\n   1.3 **Any other manufacturing activities carried out on the site**\n   \n   - Description of nonpharmaceutical activities on site, if any.\n\n2. **Quality management**\n\n   2.1 **The quality management system of the manufacturer**\n   \n   - Brief description of the quality management systems run by the company and reference to the standards used;", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es un ap\u00e9ndice del Informe T\u00e9cnico de la OMS (Serie 961) que detalla el contenido de un archivo maestro del sitio (site master file) para fabricantes de productos farmac\u00e9uticos. Se divide en secciones que abordan la informaci\u00f3n general sobre el fabricante, incluyendo datos de contacto, actividades de fabricaci\u00f3n autorizadas, y el sistema de gesti\u00f3n de calidad implementado por la empresa. Tambi\u00e9n se menciona la necesidad de documentaci\u00f3n espec\u00edfica, como autorizaciones de fabricaci\u00f3n y certificados de buenas pr\u00e1cticas de manufactura (GMP).\n\n### Preguntas espec\u00edficas:\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n de contacto debe incluirse en el archivo maestro del sitio seg\u00fan el documento?**\n   - El archivo debe incluir el nombre y direcci\u00f3n oficial del fabricante, direcciones de los edificios y unidades de producci\u00f3n, informaci\u00f3n de contacto con un n\u00famero telef\u00f3nico de 24 horas para casos de defectos o retiradas de productos, y un n\u00famero de identificaci\u00f3n del sitio, como detalles GPS o un n\u00famero D-U-N-S.\n\n2. **\u00bfQu\u00e9 documentaci\u00f3n se requiere para las actividades de fabricaci\u00f3n autorizadas en el sitio?**\n   - Se requiere una copia de la autorizaci\u00f3n de fabricaci\u00f3n v\u00e1lida emitida por la autoridad competente, una descripci\u00f3n breve de las actividades autorizadas (fabricaci\u00f3n, importaci\u00f3n, exportaci\u00f3n, distribuci\u00f3n), un listado de los productos fabricados actualmente en el sitio, y un registro de las inspecciones GMP realizadas en los \u00faltimos cinco a\u00f1os.\n\n3. **\u00bfQu\u00e9 aspectos del sistema de gesti\u00f3n de calidad del fabricante se deben describir en el archivo maestro del sitio?**\n   - Se debe proporcionar una breve descripci\u00f3n de los sistemas de gesti\u00f3n de calidad que opera la empresa, as\u00ed como una referencia a los est\u00e1ndares utilizados en dichos sistemas.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Archivo Maestro del Sitio (SMF)**:\n   - Definici\u00f3n: Documento preparado por el fabricante farmac\u00e9utico que contiene informaci\u00f3n sobre las pol\u00edticas de gesti\u00f3n de calidad y las actividades del sitio.\n   - Contenido: Debe incluir detalles sobre la producci\u00f3n y control de calidad, as\u00ed como operaciones integradas en edificios cercanos.\n\n2. **Importancia del SMF**:\n   - Utilidad: Proporciona informaci\u00f3n clara sobre las buenas pr\u00e1cticas de fabricaci\u00f3n (GMP) para facilitar la supervisi\u00f3n y planificaci\u00f3n de inspecciones por parte de autoridades regulatorias.\n   - Extensi\u00f3n: Debe ser conciso, no excediendo 25-30 p\u00e1ginas m\u00e1s ap\u00e9ndices, y preferiblemente incluir esquemas en lugar de narrativas.\n\n3. **Mantenimiento y Actualizaci\u00f3n**:\n   - Requisitos: El SMF debe ser parte del sistema de gesti\u00f3n de calidad del fabricante, actualizado regularmente y con un n\u00famero de edici\u00f3n y fechas de efectividad y revisi\u00f3n.\n\n4. **Prop\u00f3sito y Alcance**:\n   - Gu\u00eda: Las notas explicativas tienen como objetivo ayudar a los fabricantes en la preparaci\u00f3n del SMF para que sea \u00fatil en las inspecciones GMP.\n   - Aplicaci\u00f3n: Se aplica a diversas operaciones de fabricaci\u00f3n, incluyendo producci\u00f3n, envasado, etiquetado, y tambi\u00e9n puede ser utilizado por fabricantes de ingredientes farmac\u00e9uticos activos (APIs) y establecimientos de sangre y tejidos.\n\n5. **Formato**:\n   - Referencia: Se menciona que el formato espec\u00edfico para el SMF se encuentra en un ap\u00e9ndice del documento.\n\n### Entidades Clave\n- **Fabricante farmac\u00e9utico**: Entidad responsable de la preparaci\u00f3n del SMF.\n- **Autoridades regulatorias**: Entidades que supervisan y realizan inspecciones basadas en el SMF.\n- **Buenas Pr\u00e1cticas de Fabricaci\u00f3n (GMP)**: Normativas que gu\u00edan las operaciones de fabricaci\u00f3n y control de calidad.\n- **Medicamentos**: Productos cuya fabricaci\u00f3n y control son objeto del SMF.\n- **Ingredientes farmac\u00e9uticos activos (APIs)**: Tipo de producto que tambi\u00e9n puede requerir un SMF.", "excerpt_keywords": "Keywords: site master file, pharmaceutical manufacturing, quality management, GMP inspections, manufacturing authorization"}}, "4c4408f7-71f8-4442-aca8-c48541ab3e6d": {"node_ids": ["9316ad7c-8446-4a74-955e-7f6272f7996e"], "metadata": {"page_label": "424", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.2 Release procedure of finished products\n\n\u2014 detailed description of qualification requirements (education and work experience) of the authorized person(s)/qualified person(s) responsible for batch certification and releasing procedures;  \n\u2014 general description of batch certification and releasing procedure;  \n\u2014 role of authorized person/qualified person in quarantine and release of finished products and in assessment of compliance with the marketing authorization;  \n\u2014 the arrangements between authorized persons/qualified persons when several authorized persons/qualified persons are involved; and  \n\u2014 statement on whether the control strategy employs process analytical technology (PAT) and/or real-time release or parametric release.  \n\n# 2.3 Management of suppliers and contractors\n\n\u2014 a brief summary of the establishment/knowledge of supply chain and the external audit programme;  \n\u2014 a brief description of the qualification system of contractors, manufacturers of APIs and other critical materials suppliers;  \n\u2014 measures taken to ensure that products manufactured are compliant with transmitting animal spongiform encephalopathy (TSE) guidance;[^1]  \n\u2014 measures adopted where substandard/spurious/falsely-labelled/falsified/counterfeit medical products, bulk products (i.e. unpacked tablets), APIs or excipients are suspected or identified;  \n\u2014 use of outside scientific, analytical or other technical assistance in relation to manufacture and analysis;  \n\u2014 list of contract manufacturers and laboratories including the addresses and contact information and flowcharts of supply chains for outsourced manufacturing and QC activities, e.g. sterilization of primary packaging material for aseptic processes, testing of starting raw materials, etc., should be presented in Annex 4; and  \n\u2014 brief overview of the responsibility sharing between the contract giver and acceptor with respect to compliance with the marketing authorization (where not included under 2.2).  \n\n[^1]: For further information please see: http://www.who.int/bloodproducts/tse.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda procedimientos cr\u00edticos en la gesti\u00f3n de productos farmac\u00e9uticos terminados, centr\u00e1ndose en la certificaci\u00f3n de lotes y la liberaci\u00f3n de productos, as\u00ed como en la gesti\u00f3n de proveedores y contratistas. Se detallan los requisitos de calificaci\u00f3n para las personas autorizadas responsables de la certificaci\u00f3n de lotes, el proceso de liberaci\u00f3n, y las medidas para garantizar la conformidad con las normativas, incluyendo la gesti\u00f3n de la cadena de suministro y la auditor\u00eda externa.\n\n### Preguntas\n1. **\u00bfCu\u00e1les son los requisitos de calificaci\u00f3n espec\u00edficos para las personas autorizadas responsables de la certificaci\u00f3n y liberaci\u00f3n de lotes de productos farmac\u00e9uticos?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre la educaci\u00f3n y experiencia laboral necesarias para estas personas, que no se encuentra f\u00e1cilmente en otras fuentes.\n\n2. **\u00bfQu\u00e9 medidas se implementan para asegurar que los productos fabricados cumplan con las directrices sobre la encefalopat\u00eda espongiforme transmisible (TSE)?**\n   - La respuesta a esta pregunta proporcionar\u00e1 informaci\u00f3n espec\u00edfica sobre las pr\u00e1cticas de fabricaci\u00f3n y control de calidad que se deben seguir para cumplir con estas directrices.\n\n3. **\u00bfC\u00f3mo se gestionan las responsabilidades entre el contratista y el contratante en relaci\u00f3n con el cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n?**\n   - Esta pregunta se centra en la divisi\u00f3n de responsabilidades en la relaci\u00f3n contractual, un aspecto que puede no estar claramente definido en otros documentos o normativas. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n espec\u00edfica y detallada que se encuentra en el contexto proporcionado, y que puede no estar disponible en otras fuentes.", "prev_section_summary": "### Resumen de temas clave y entidades de la secci\u00f3n:\n\n1. **Archivo Maestro del Sitio (Site Master File)**:\n   - Documento esencial para fabricantes de productos farmac\u00e9uticos que detalla la informaci\u00f3n relevante sobre el sitio de fabricaci\u00f3n.\n\n2. **Informaci\u00f3n General sobre el Fabricante**:\n   - **Datos de Contacto**: Incluye nombre, direcci\u00f3n oficial, direcciones de edificios y unidades de producci\u00f3n, informaci\u00f3n de contacto (n\u00famero telef\u00f3nico de 24 horas) y n\u00famero de identificaci\u00f3n del sitio (GPS, D-U-N-S).\n   - **Actividades de Fabricaci\u00f3n Autorizadas**: Requiere copia de la autorizaci\u00f3n de fabricaci\u00f3n, descripci\u00f3n de actividades autorizadas (fabricaci\u00f3n, importaci\u00f3n, exportaci\u00f3n, distribuci\u00f3n), lista de productos fabricados y registro de inspecciones GMP en los \u00faltimos cinco a\u00f1os.\n   - **Otras Actividades de Fabricaci\u00f3n**: Descripci\u00f3n de actividades no farmac\u00e9uticas realizadas en el sitio.\n\n3. **Gesti\u00f3n de Calidad**:\n   - **Sistema de Gesti\u00f3n de Calidad**: Breve descripci\u00f3n de los sistemas de gesti\u00f3n de calidad implementados por el fabricante y referencia a los est\u00e1ndares utilizados.\n\n### Entidades Clave:\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Emisora del documento.\n- **D-U-N-S**: Sistema de numeraci\u00f3n \u00fanico proporcionado por Dun & Bradstreet.\n- **EudraGMP**: Base de datos de autorizaciones de fabricaci\u00f3n en Europa.\n- **GMP (Buenas Pr\u00e1cticas de Manufactura)**: Normativa que regula la fabricaci\u00f3n de productos farmac\u00e9uticos.\n\nEste resumen destaca los elementos esenciales que deben incluirse en un archivo maestro del sitio, as\u00ed como la importancia de la documentaci\u00f3n y el cumplimiento de las normativas de calidad en la industria farmac\u00e9utica.", "excerpt_keywords": "Keywords: batch certification, release procedure, qualified person, supply chain management, TSE compliance"}}, "4b7b0220-8915-48d1-8928-546b959adca6": {"node_ids": ["e2b847a1-3c8c-4dc6-b816-c787d7048ab6"], "metadata": {"page_label": "425", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 2.4 Quality risk management\n\n- brief description of quality risk management (QRM) methodologies used by the manufacturer; and\n- scope and focus of QRM including brief description of any activities which are performed at corporate level, and those which are performed locally. Any application of the QRM system to assess continuity of supply should be mentioned.\n\n# 2.5 Product quality reviews\n\n- brief description of methodologies used.\n\n# 3. Personnel\n\n- organization chart showing the arrangements for quality management, production and quality control positions/titles in Annex 5, including senior management and authorized person(s)/qualified person(s); and\n- number of employees engaged in the quality management, production, quality control, storage and distribution, respectively.\n\n# 4. Premises and equipment\n\n## 4.1 Premises\n\n- short description of plant: size of the site and list of buildings. If the production for different markets, i.e. for local country or regional economic areas, takes place in different buildings on the site, the buildings should be listed with destined markets identified (if not identified under 1.1);\n- simple plan or description of manufacturing areas with indication of scale (architectural or engineering drawings are not required);\n- layouts and flowcharts of the production areas (in Annex 6) showing the room classification and pressure differentials between adjoining areas and indicating the production activities (i.e. compounding, filling, storage, packaging, etc.) in the rooms;\n- layouts of warehouses and storage areas, with special areas for the storage and handling of highly toxic, hazardous and sensitizing materials indicated, if applicable; and\n- brief description of specific storage conditions if applicable, but not indicated on the layouts.\n\n### 4.1.1 Brief description of heating, ventilation and air-conditioning (HVAC) systems\n\n- principles for defining the air supply, temperature, humidity, pressure differentials and air-change rates, policy of air recirculation (%).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que pueden proporcionar respuestas espec\u00edficas basadas en el contexto proporcionado:\n\n1. **\u00bfCu\u00e1les son las metodolog\u00edas espec\u00edficas de gesti\u00f3n de riesgos de calidad (QRM) que utiliza el fabricante y c\u00f3mo se aplican a la continuidad del suministro?**\n   - Esta pregunta busca detalles sobre las metodolog\u00edas de QRM que no se mencionan expl\u00edcitamente en otros documentos y c\u00f3mo estas metodolog\u00edas impactan la capacidad del fabricante para mantener un suministro constante de productos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el organigrama de calidad y cu\u00e1ntos empleados est\u00e1n involucrados en cada \u00e1rea de gesti\u00f3n de calidad, producci\u00f3n y control de calidad?**\n   - Esta pregunta se centra en la estructura organizativa y la distribuci\u00f3n del personal, lo que puede no estar disponible en otros informes o documentos.\n\n3. **\u00bfCu\u00e1les son las condiciones espec\u00edficas de almacenamiento requeridas para materiales altamente t\u00f3xicos y c\u00f3mo se gestionan en las instalaciones?**\n   - Esta pregunta busca informaci\u00f3n detallada sobre las pr\u00e1cticas de almacenamiento y manejo de materiales peligrosos, que puede no estar ampliamente documentada en otras fuentes.\n\n### Resumen de nivel superior del contexto:\n\nEl documento proporciona directrices sobre la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, incluyendo la gesti\u00f3n de riesgos de calidad, revisiones de calidad del producto, organizaci\u00f3n del personal y descripciones de las instalaciones y equipos. Se enfatiza la importancia de un enfoque sistem\u00e1tico para asegurar la calidad en todas las etapas de producci\u00f3n, as\u00ed como la necesidad de un dise\u00f1o adecuado de las instalaciones para cumplir con los est\u00e1ndares de calidad y seguridad. Adem\u00e1s, se menciona la importancia de los sistemas de calefacci\u00f3n, ventilaci\u00f3n y aire acondicionado (HVAC) en el mantenimiento de condiciones \u00f3ptimas para la producci\u00f3n y almacenamiento de productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n#### Temas Clave\n\n1. **Procedimiento de Liberaci\u00f3n de Productos Terminados (Secci\u00f3n 2.2)**\n   - **Requisitos de Calificaci\u00f3n**: Se especifican las calificaciones necesarias (educaci\u00f3n y experiencia laboral) para las personas autorizadas o calificadas responsables de la certificaci\u00f3n y liberaci\u00f3n de lotes.\n   - **Descripci\u00f3n General del Procedimiento**: Se proporciona una visi\u00f3n general del proceso de certificaci\u00f3n y liberaci\u00f3n de lotes.\n   - **Rol de las Personas Autorizadas**: Se detalla el papel de estas personas en la cuarentena, liberaci\u00f3n de productos terminados y evaluaci\u00f3n de la conformidad con la autorizaci\u00f3n de comercializaci\u00f3n.\n   - **Colaboraci\u00f3n entre Personas Autorizadas**: Se abordan los arreglos entre varias personas autorizadas involucradas en el proceso.\n   - **Estrategia de Control**: Se menciona si se emplea tecnolog\u00eda anal\u00edtica de procesos (PAT) y/o liberaci\u00f3n en tiempo real o liberaci\u00f3n param\u00e9trica.\n\n2. **Gesti\u00f3n de Proveedores y Contratistas (Secci\u00f3n 2.3)**\n   - **Cadena de Suministro y Auditor\u00eda Externa**: Resumen sobre el conocimiento de la cadena de suministro y el programa de auditor\u00eda externa.\n   - **Sistema de Calificaci\u00f3n de Contratistas**: Descripci\u00f3n del sistema de calificaci\u00f3n para contratistas y fabricantes de ingredientes farmac\u00e9uticos activos (APIs).\n   - **Cumplimiento de Directrices TSE**: Medidas para asegurar que los productos fabricados cumplan con las directrices sobre encefalopat\u00eda espongiforme transmisible (TSE).\n   - **Manejo de Productos Subest\u00e1ndar**: Medidas adoptadas ante la sospecha o identificaci\u00f3n de productos m\u00e9dicos subest\u00e1ndar o falsificados.\n   - **Asistencia T\u00e9cnica Externa**: Uso de asistencia cient\u00edfica o t\u00e9cnica externa en la fabricaci\u00f3n y an\u00e1lisis.\n   - **Responsabilidad Compartida**: Resumen de la divisi\u00f3n de responsabilidades entre el contratista y el contratante respecto al cumplimiento de la autorizaci\u00f3n de comercializaci\u00f3n.\n\n#### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Entidad responsable del documento.\n- **Personas Autorizadas/Calificadas**: Profesionales responsables de la certificaci\u00f3n y liberaci\u00f3n de productos.\n- **Contratistas y Proveedores**: Entidades involucradas en la fabricaci\u00f3n y suministro de productos farmac\u00e9uticos.\n- **Ingredientes Farmac\u00e9uticos Activos (APIs)**: Materiales cr\u00edticos en la producci\u00f3n de medicamentos.\n- **Directrices sobre TSE**: Normativas relacionadas con la encefalopat\u00eda espongiforme transmisible.\n\nEste resumen destaca los aspectos fundamentales y las entidades relevantes en el contexto de la gesti\u00f3n de productos farmac\u00e9uticos y la relaci\u00f3n con proveedores y contratistas.", "excerpt_keywords": "Keywords: Quality Risk Management, Product Quality Reviews, Personnel Organization, Premises and Equipment, HVAC Systems"}}, "a007a30e-a754-4c12-8119-7e843a152aae": {"node_ids": ["fed06ec9-82d1-4fda-a83f-785b21621fba"], "metadata": {"page_label": "426", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 4.1.2 Brief description of water systems\n\n- quality references of water produced; and\n- schematic drawings of the systems in Annex 7.\n\n# 4.1.3 Brief description of other relevant utilities such as steam, compressed air, nitrogen, etc.\n\n# 4.2 Equipment\n\n4.2.1 Listing of major production and control laboratory equipment with critical pieces of equipment identified should be provided in Annex 8.\n\n## 4.2.2 Cleaning and sanitation\n\n- brief description of cleaning and sanitation methods of product contact surfaces (i.e. manual cleaning, automatic clean-in-place, etc.).\n\n## 4.2.3 Good manufacturing practices critical computerized systems\n\n- description of GMP critical computerized systems (excluding equipment-specific programmable logic controllers (PLCs)).\n\n# 5. Documentation\n\n- description of documentation system (i.e. electronic, manual); and\n- when documents and records are stored or archived off-site (including pharmacovigilance data, when applicable): list of types of documents/records; name and address of storage site; and an estimate of time required to retrieve documents from the off-site archive.\n\n# 6. Production\n\n## 1.1 Type of products\n\nReferences to Annex 1 or 2 can be made.\n\n- type of products manufactured including:\n  - list of dosage forms of both human and veterinary products which are manufactured on the site\n  - list of dosage forms of investigational medicinal products (IMP) manufactured for any clinical trials on the site, and when different from the commercial manufacturing, information on production areas and personnel;\n- toxic or hazardous substances handled (e.g. with high pharmacological activity and/or with sensitizing properties);", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda aspectos clave de la producci\u00f3n y control de calidad en instalaciones farmac\u00e9uticas. Se enfoca en la descripci\u00f3n de sistemas de agua, equipos de producci\u00f3n, m\u00e9todos de limpieza y saneamiento, sistemas de documentaci\u00f3n, y tipos de productos fabricados, incluyendo tanto productos humanos como veterinarios. Tambi\u00e9n se menciona la gesti\u00f3n de sustancias t\u00f3xicas y peligrosas.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de m\u00e9todos de limpieza y saneamiento se describen para las superficies de contacto con el producto en las instalaciones?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las pr\u00e1cticas de limpieza y saneamiento que se implementan, que son cruciales para garantizar la calidad del producto.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se debe incluir en el listado de equipos de producci\u00f3n y control de laboratorio seg\u00fan el documento?**\n   - Esta pregunta se centra en los requisitos espec\u00edficos para la documentaci\u00f3n de equipos, lo que puede ser vital para auditor\u00edas y cumplimiento normativo.\n\n3. **\u00bfCu\u00e1les son los tipos de productos que se fabrican en el sitio y c\u00f3mo se gestionan las sustancias t\u00f3xicas o peligrosas?**\n   - Esta pregunta busca informaci\u00f3n sobre la gama de productos fabricados y las medidas de seguridad relacionadas con el manejo de sustancias que pueden representar un riesgo, lo que es esencial para la seguridad en el entorno de producci\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades de la Secci\u00f3n\n\n1. **Gesti\u00f3n de Riesgos de Calidad (QRM)**:\n   - Descripci\u00f3n breve de las metodolog\u00edas de QRM utilizadas por el fabricante.\n   - Alcance y enfoque de QRM, incluyendo actividades a nivel corporativo y local.\n   - Aplicaci\u00f3n del sistema QRM para evaluar la continuidad del suministro.\n\n2. **Revisiones de Calidad del Producto**:\n   - Descripci\u00f3n breve de las metodolog\u00edas empleadas para las revisiones de calidad.\n\n3. **Personal**:\n   - Organigrama que muestra la disposici\u00f3n de los puestos/t\u00edtulos en gesti\u00f3n de calidad, producci\u00f3n y control de calidad.\n   - N\u00famero de empleados en las \u00e1reas de gesti\u00f3n de calidad, producci\u00f3n, control de calidad, almacenamiento y distribuci\u00f3n.\n\n4. **Instalaciones y Equipos**:\n   - Descripci\u00f3n breve de la planta, incluyendo tama\u00f1o y lista de edificios.\n   - Plan o descripci\u00f3n simple de las \u00e1reas de fabricaci\u00f3n y sus actividades (compounding, filling, almacenamiento, empaque, etc.).\n   - Layouts de \u00e1reas de almacenamiento, incluyendo zonas para materiales altamente t\u00f3xicos y peligrosos.\n   - Descripci\u00f3n de condiciones espec\u00edficas de almacenamiento, si es aplicable.\n\n5. **Sistemas de HVAC**:\n   - Principios para definir el suministro de aire, temperatura, humedad, diferenciales de presi\u00f3n y tasas de cambio de aire.\n   - Pol\u00edtica de recirculaci\u00f3n de aire.\n\n### Entidades Clave:\n- **Fabricante**: Entidad responsable de la producci\u00f3n y gesti\u00f3n de calidad.\n- **Personal**: Empleados involucrados en diversas \u00e1reas de gesti\u00f3n de calidad y producci\u00f3n.\n- **Instalaciones**: Plantas y edificios donde se lleva a cabo la producci\u00f3n.\n- **Materiales**: Incluye materiales altamente t\u00f3xicos y peligrosos que requieren manejo especial.\n- **Sistemas de HVAC**: Infraestructura cr\u00edtica para mantener condiciones \u00f3ptimas en la producci\u00f3n y almacenamiento. \n\nEste resumen destaca los aspectos fundamentales de la gesti\u00f3n de calidad en la producci\u00f3n farmac\u00e9utica, enfatizando la importancia de un enfoque sistem\u00e1tico y la infraestructura adecuada para garantizar la calidad y seguridad de los productos.", "excerpt_keywords": "Keywords: water systems, cleaning and sanitation, production equipment, documentation system, hazardous substances"}}, "34d0166b-75ba-435b-be75-60c48bf5be46": {"node_ids": ["e7f0b0cc-57cb-406e-95fa-491304cf3b96"], "metadata": {"page_label": "427", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Process Validation\n\n- Brief description of general policy for process validation; and\n- Policy for reprocessing or reworking.\n\n## Material Management and Warehousing\n\n- Arrangements for the handling of starting materials, packaging materials, bulk and finished products including sampling, quarantine, release and storage; and\n- Arrangements for the handling of rejected materials and products.\n\n# Quality Control\n\n- Description of the QC activities carried out on the site in terms of physical, chemical and microbiological and biological testing.\n\n# Distribution, Complaints, Product Defects and Recalls\n\n## Distribution (to the part under the responsibility of the manufacturer)\n\n- Types (wholesale licence holders, manufacturing licence holders, etc.) and locations (countries or regional economic areas) of the companies to which the products are shipped from the site;\n- Description of the system used to verify that each customer/recipient is legally entitled to receive medicinal products from the manufacturer;\n- Brief description of the system to ensure appropriate environmental conditions during transit, e.g. temperature monitoring/control;\n- Arrangements for product distribution and methods by which product traceability is maintained; and\n- Measures taken to prevent manufacturers\u2019 products entering into the illegal supply chain.\n\n## Complaints, Product Defects and Recalls\n\n- Brief description of the system for handling complaints, product defects and recalls.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda aspectos clave de la validaci\u00f3n de procesos, la gesti\u00f3n de materiales, el control de calidad y la distribuci\u00f3n de productos farmac\u00e9uticos. Se detalla la pol\u00edtica de validaci\u00f3n de procesos, la gesti\u00f3n de materiales desde su recepci\u00f3n hasta su almacenamiento, las actividades de control de calidad realizadas en el sitio, y los procedimientos para la distribuci\u00f3n de productos, as\u00ed como la gesti\u00f3n de quejas, defectos de productos y retiradas del mercado.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es la pol\u00edtica general de validaci\u00f3n de procesos mencionada en el documento y c\u00f3mo se aborda el reprocesamiento o reworking?**\n   - Esta pregunta busca detalles espec\u00edficos sobre las pol\u00edticas de validaci\u00f3n de procesos y las directrices para el reprocesamiento, que son fundamentales para garantizar la calidad y la seguridad de los productos farmac\u00e9uticos.\n\n2. **\u00bfQu\u00e9 medidas se describen para asegurar que las condiciones ambientales durante el transporte de productos farmac\u00e9uticos sean adecuadas?**\n   - Esta pregunta se centra en las pr\u00e1cticas de monitoreo y control de temperatura durante el transporte, lo cual es crucial para mantener la integridad de los productos.\n\n3. **\u00bfC\u00f3mo se gestiona el sistema de quejas y defectos de productos seg\u00fan el documento?**\n   - Esta pregunta busca informaci\u00f3n sobre el procedimiento espec\u00edfico para manejar quejas y defectos, lo que es esencial para la mejora continua y la seguridad del paciente. \n\nEstas preguntas est\u00e1n dise\u00f1adas para extraer informaci\u00f3n detallada que puede no estar disponible en otras fuentes, centr\u00e1ndose en aspectos cr\u00edticos de la gesti\u00f3n de calidad y la seguridad en la industria farmac\u00e9utica.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Serie de Informes T\u00e9cnicos 961) aborda varios aspectos fundamentales relacionados con la producci\u00f3n y el control de calidad en instalaciones farmac\u00e9uticas. A continuaci\u00f3n se presentan los temas clave y las entidades mencionadas en la secci\u00f3n:\n\n#### Temas Clave:\n\n1. **Sistemas de Agua**:\n   - Referencias de calidad del agua producida.\n   - Diagramas esquem\u00e1ticos de los sistemas (ver Anexo 7).\n\n2. **Utilidades Relevantes**:\n   - Descripci\u00f3n de otras utilidades como vapor, aire comprimido y nitr\u00f3geno.\n\n3. **Equipos**:\n   - Listado de equipos de producci\u00f3n y control de laboratorio, con identificaci\u00f3n de equipos cr\u00edticos (ver Anexo 8).\n\n4. **Limpieza y Saneamiento**:\n   - M\u00e9todos de limpieza y saneamiento para superficies de contacto con el producto (ej. limpieza manual, limpieza autom\u00e1tica en el lugar).\n\n5. **Sistemas Computarizados Cr\u00edticos de Buenas Pr\u00e1cticas de Manufactura (GMP)**:\n   - Descripci\u00f3n de sistemas computarizados cr\u00edticos, excluyendo controladores l\u00f3gicos programables espec\u00edficos de equipos.\n\n6. **Documentaci\u00f3n**:\n   - Sistema de documentaci\u00f3n (electr\u00f3nico, manual).\n   - Almacenamiento y archivo de documentos y registros fuera del sitio, incluyendo datos de farmacovigilancia.\n\n7. **Producci\u00f3n**:\n   - Tipos de productos fabricados, incluyendo formas de dosificaci\u00f3n de productos humanos y veterinarios.\n   - Productos investigacionales fabricados para ensayos cl\u00ednicos.\n   - Manejo de sustancias t\u00f3xicas o peligrosas.\n\n#### Entidades:\n\n- **Anexos**: \n  - Anexo 7 (esquemas de sistemas de agua).\n  - Anexo 8 (listado de equipos).\n\n- **Tipos de Productos**:\n  - Productos humanos.\n  - Productos veterinarios.\n  - Productos medicinales investigacionales (IMP).\n\n- **Sustancias**:\n  - Sustancias t\u00f3xicas o peligrosas con alta actividad farmacol\u00f3gica o propiedades sensibilizantes.\n\nEste resumen proporciona una visi\u00f3n general de los elementos esenciales que se abordan en la secci\u00f3n, destacando la importancia de la calidad, la seguridad y la documentaci\u00f3n en el contexto de la producci\u00f3n farmac\u00e9utica.", "excerpt_keywords": "Keywords: process validation, quality control, material management, product distribution, complaints handling"}}, "33f7c5b4-4150-435f-867f-37b1608f061a": {"node_ids": ["ec70265e-82f2-4863-bc39-9e7aa7cfb544"], "metadata": {"page_label": "428", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 9. Self-inspections\n\n\u2014 short description of the self-inspection system with focus on criteria used for selection of the areas to be covered during planned inspections, practical arrangements and follow-up activities.\n\n## Annexes to a submission of a site master file\n\n- **Annex 1**: Copy of valid manufacturing authorization\n- **Annex 2**: List of dosage forms manufactured including the International Nonproprietary Names (INN) or common name (as available) of APIs used\n- **Annex 3**: Copy of valid GMP certificate\n- **Annex 4**: List of contract manufacturers and laboratories including the addresses and contact information, and flowcharts of the supply chains for these outsourced activities\n- **Annex 5**: Organizational charts\n- **Annex 6**: Layouts of production areas including material and personnel flows, general flowcharts of manufacturing processes of each product type (dosage form)\n- **Annex 7**: Schematic drawings of water systems\n- **Annex 8**: List of major production and laboratory equipment", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento \"WHO - Technical Report Series 961\" aborda el sistema de autoinspecci\u00f3n en el contexto de la fabricaci\u00f3n de productos farmac\u00e9uticos. Se enfoca en los criterios utilizados para seleccionar las \u00e1reas a inspeccionar, as\u00ed como en los arreglos pr\u00e1cticos y las actividades de seguimiento. Adem\u00e1s, se enumeran los anexos que deben acompa\u00f1ar la presentaci\u00f3n de un archivo maestro del sitio, que incluyen autorizaciones de fabricaci\u00f3n, certificados de Buenas Pr\u00e1cticas de Manufactura (GMP), listas de formas de dosificaci\u00f3n, y esquemas de equipos y sistemas de agua.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los criterios espec\u00edficos utilizados para seleccionar las \u00e1reas a ser cubiertas durante las autoinspecciones en la fabricaci\u00f3n de productos farmac\u00e9uticos?**\n   - Esta pregunta busca detalles sobre los criterios de selecci\u00f3n que no se mencionan expl\u00edcitamente en el resumen.\n\n2. **\u00bfQu\u00e9 tipo de informaci\u00f3n se requiere en el \"Anexo 4\" sobre los fabricantes y laboratorios contratados, y por qu\u00e9 es importante incluir esta informaci\u00f3n en la presentaci\u00f3n del archivo maestro del sitio?**\n   - Esta pregunta se centra en la importancia de la informaci\u00f3n sobre contratistas y su relevancia para la calidad y la seguridad en la fabricaci\u00f3n.\n\n3. **\u00bfQu\u00e9 tipo de flujos de materiales y personal se deben incluir en el \"Anexo 6\" y c\u00f3mo pueden afectar estos flujos a la eficiencia de la producci\u00f3n?**\n   - Esta pregunta busca profundizar en los detalles sobre la disposici\u00f3n de las \u00e1reas de producci\u00f3n y su impacto en la operaci\u00f3n general, lo cual no se detalla en el contexto proporcionado.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Validaci\u00f3n de Procesos**:\n   - Pol\u00edticas generales para la validaci\u00f3n de procesos.\n   - Directrices para el reprocesamiento o reworking de productos.\n\n2. **Gesti\u00f3n de Materiales y Almacenamiento**:\n   - Procedimientos para el manejo de materiales iniciales, materiales de embalaje, productos a granel y productos terminados, incluyendo muestreo, cuarentena, liberaci\u00f3n y almacenamiento.\n   - Manejo de materiales y productos rechazados.\n\n3. **Control de Calidad (QC)**:\n   - Actividades de control de calidad realizadas en el sitio, abarcando pruebas f\u00edsicas, qu\u00edmicas, microbiol\u00f3gicas y biol\u00f3gicas.\n\n4. **Distribuci\u00f3n, Quejas, Defectos de Productos y Retiradas**:\n   - **Distribuci\u00f3n**:\n     - Tipos y ubicaciones de las empresas que reciben productos.\n     - Sistema para verificar la legalidad de los clientes/recipientes para recibir productos medicinales.\n     - Monitoreo y control de condiciones ambientales durante el transporte.\n     - M\u00e9todos para mantener la trazabilidad de los productos.\n     - Medidas para prevenir la entrada de productos en la cadena de suministro ilegal.\n   \n   - **Quejas, Defectos de Productos y Retiradas**:\n     - Sistema para manejar quejas, defectos de productos y retiradas del mercado.\n\n### Entidades Clave\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el documento.\n- **Productos Farmac\u00e9uticos**: Enfocados en la calidad y seguridad.\n- **Materiales**: Incluyendo materiales iniciales, de embalaje y productos terminados.\n- **Clientes/Recipientes**: Empresas que reciben productos farmac\u00e9uticos.\n- **Sistema de Quejas**: Procedimientos para la gesti\u00f3n de quejas y defectos.\n\nEste resumen destaca los aspectos fundamentales de la gesti\u00f3n de calidad y la seguridad en la industria farmac\u00e9utica, seg\u00fan lo establecido en el documento de la OMS.", "excerpt_keywords": "Keywords: self-inspection, GMP certificate, manufacturing authorization, contract manufacturers, production layouts"}}, "4760e4e7-5963-444f-9cb8-d6a5e2c7849e": {"node_ids": ["6e619cf2-52e5-438d-a504-94a7b23a85f4"], "metadata": {"page_label": "429", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Annex 15\n\n## Guidelines on submission of documentation for a multisource (generic) finished product. General format: preparation of product dossiers in common technical document format\n\n1. **Introduction**\n   1.1 Background  \n   1.2 Objectives  \n   1.3 Scope  \n   1.4 General principles  \n\n2. **Glossary**\n\n3. **Organization of a product dossier for a multisource pharmaceutical product in common technical document format**\n\n4. **Modules (including Module 1) of a product dossier for a multisource pharmaceutical product**\n\n5. **Module 3 \u2014 quality**\n\n6. **Module 5 of a product dossier for a multisource pharmaceutical product**\n\n7. **Guidance on format and presentation of a product dossier in common technical document format**\n   7.1 Guidance on format  \n   7.2 Guidance on presentation  \n\n8. **Variations**\n\n**References**", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfCu\u00e1l es el objetivo principal de las directrices en el Anexo 15 del informe de la OMS?**\n   - **Respuesta:** El objetivo principal de las directrices en el Anexo 15 es proporcionar un marco para la presentaci\u00f3n de la documentaci\u00f3n necesaria para productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan, asegurando que se sigan principios generales y se cumplan los requisitos de calidad.\n\n2. **\u00bfQu\u00e9 m\u00f3dulos se incluyen en el dossier de producto para un producto farmac\u00e9utico multisource seg\u00fan el Anexo 15?**\n   - **Respuesta:** El dossier de producto para un producto farmac\u00e9utico multisource incluye varios m\u00f3dulos, entre ellos el M\u00f3dulo 1, que abarca aspectos administrativos y de informaci\u00f3n general, el M\u00f3dulo 3, que se centra en la calidad del producto, y el M\u00f3dulo 5, que trata sobre la eficacia y seguridad del producto.\n\n3. **\u00bfQu\u00e9 tipo de orientaci\u00f3n se proporciona en la secci\u00f3n 7 del Anexo 15?**\n   - **Respuesta:** En la secci\u00f3n 7 del Anexo 15 se proporciona orientaci\u00f3n sobre el formato y la presentaci\u00f3n de un dossier de producto en el formato de documento t\u00e9cnico com\u00fan. Esto incluye directrices espec\u00edficas sobre c\u00f3mo estructurar la informaci\u00f3n y presentarla de manera clara y coherente.\n\n### Resumen de nivel superior del contexto:\nEl Anexo 15 del informe de la OMS establece directrices para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan. Incluye secciones sobre la organizaci\u00f3n del dossier, m\u00f3dulos espec\u00edficos que abordan calidad y eficacia, y proporciona orientaci\u00f3n sobre el formato y la presentaci\u00f3n de la documentaci\u00f3n. Tambi\u00e9n se menciona la importancia de las variaciones en el contexto de la presentaci\u00f3n de estos dossiers.", "prev_section_summary": "### Resumen de la Secci\u00f3n 9: Autoinspecciones\n\nLa secci\u00f3n aborda el sistema de autoinspecci\u00f3n en la fabricaci\u00f3n de productos farmac\u00e9uticos, destacando los criterios para seleccionar las \u00e1reas a inspeccionar, as\u00ed como los arreglos pr\u00e1cticos y las actividades de seguimiento que deben llevarse a cabo. \n\n#### Anexos a la Presentaci\u00f3n del Archivo Maestro del Sitio\n\nSe enumeran los siguientes anexos que deben acompa\u00f1ar la presentaci\u00f3n del archivo maestro del sitio:\n\n1. **Anexo 1**: Copia de la autorizaci\u00f3n de fabricaci\u00f3n v\u00e1lida.\n2. **Anexo 2**: Lista de formas de dosificaci\u00f3n fabricadas, incluyendo los Nombres Comunes Internacionales (INN) o nombres comunes de los ingredientes activos (APIs) utilizados.\n3. **Anexo 3**: Copia del certificado de Buenas Pr\u00e1cticas de Manufactura (GMP) v\u00e1lido.\n4. **Anexo 4**: Lista de fabricantes y laboratorios contratados, incluyendo direcciones, informaci\u00f3n de contacto y diagramas de flujo de las cadenas de suministro para estas actividades externalizadas.\n5. **Anexo 5**: Organigramas de la empresa.\n6. **Anexo 6**: Disposici\u00f3n de las \u00e1reas de producci\u00f3n, incluyendo flujos de materiales y personal, as\u00ed como diagramas de flujo generales de los procesos de fabricaci\u00f3n de cada tipo de producto.\n7. **Anexo 7**: Dibujos esquem\u00e1ticos de los sistemas de agua.\n8. **Anexo 8**: Lista de equipos de producci\u00f3n y laboratorio principales.\n\n### Temas Clave\n\n- **Sistema de Autoinspecci\u00f3n**: Importancia de la autoevaluaci\u00f3n en la calidad de la fabricaci\u00f3n.\n- **Criterios de Selecci\u00f3n**: Necesidad de criterios espec\u00edficos para determinar las \u00e1reas a inspeccionar.\n- **Documentaci\u00f3n Requerida**: Importancia de la documentaci\u00f3n y los anexos para garantizar la conformidad y la calidad en la fabricaci\u00f3n.\n\n### Entidades\n\n- **Organizaci\u00f3n Mundial de la Salud (OMS)**: Autoridad que emite el informe.\n- **Fabricantes y Laboratorios Contratados**: Entidades externas involucradas en la producci\u00f3n.\n- **Ingredientes Activos (APIs)**: Componentes esenciales en la fabricaci\u00f3n de productos farmac\u00e9uticos.\n- **Buenas Pr\u00e1cticas de Manufactura (GMP)**: Normativa que asegura la calidad en la producci\u00f3n.", "excerpt_keywords": "Keywords: guidelines, multisource, pharmaceutical, documentation, quality"}}, "1a7e0389-5ef6-4163-b777-93f2a862a24a": {"node_ids": ["01234734-a600-4434-a226-79650cdb5e92"], "metadata": {"page_label": "430", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1. Introduction\n\n## 1.1 Background\n\nIn its forty-fifth report, the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations published the *Procedure for prequalification of pharmaceutical products (1)* which outlines the procedure and considerations for the process undertaken by WHO in providing United Nations agencies with advice on the acceptability in principle of pharmaceutical products for procurement by such agencies. The above-mentioned report states:\n\n> \"This activity of WHO aims to facilitate access to priority essential medicines that meet WHO-recommended norms and standards of acceptable quality\".\n\nAs mentioned in this report, when submitting an Expression of Interest (EOI) for product evaluation, the applicant should send to the WHO focal point (together with the other data requirements) a product dossier (PD), in the format specified in the WHO guidance documents on submitting product data and information.\n\nThrough the International Conference on Harmonisation (ICH) process, considerable harmonization has been achieved in the organization of the registration documents with the issuance of the common technical document (CTD) guideline (2-5). This recommended format in the CTD guideline for registration applications has become widely accepted by regulatory authorities both within and beyond the ICH Regions.\n\nThis document provides recommendations on the format and presentation for these types of PDs.\n\n## 1.2 Objectives\n\nThese guidelines are intended to:\n\n- Assist applicants in the preparation of PDs for multisource products by providing clear general guidance on the format of these dossiers;\n- Fully adopt the modular format of the CTD as developed by ICH; and\n- Provide guidance on the location of regional information (Module 1) and other general data requirements.\n\nThese measures are intended to promote effective and efficient processes for the development of these PDs and the subsequent assessment procedures.\n\n## 1.3 Scope\n\nThese guidelines apply to PDs for multisource pharmaceutical products containing existing active pharmaceutical ingredients (APIs) of synthetic origin.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento es un informe de la Organizaci\u00f3n Mundial de la Salud (OMS) que detalla el procedimiento para la precalificaci\u00f3n de productos farmac\u00e9uticos. Se centra en la preparaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource que contienen ingredientes activos existentes de origen sint\u00e9tico. El informe tambi\u00e9n menciona la importancia de seguir el formato del Documento T\u00e9cnico Com\u00fan (CTD) para facilitar la evaluaci\u00f3n y aprobaci\u00f3n de estos productos por parte de las agencias de la ONU.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito principal de la actividad de la OMS en relaci\u00f3n con la precalificaci\u00f3n de productos farmac\u00e9uticos?**\n   - La actividad de la OMS tiene como objetivo facilitar el acceso a medicamentos esenciales prioritarios que cumplan con las normas y est\u00e1ndares de calidad recomendados por la OMS.\n\n2. **\u00bfQu\u00e9 formato se recomienda para la presentaci\u00f3n de los Dossiers de Producto (PD) seg\u00fan el informe?**\n   - Se recomienda adoptar completamente el formato modular del Documento T\u00e9cnico Com\u00fan (CTD) desarrollado por la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) para la preparaci\u00f3n de los Dossiers de Producto.\n\n3. **\u00bfA qu\u00e9 tipo de productos farmac\u00e9uticos se aplican estas directrices?**\n   - Estas directrices se aplican a los Dossiers de Producto para productos farmac\u00e9uticos multisource que contienen ingredientes activos farmac\u00e9uticos (APIs) existentes de origen sint\u00e9tico.", "prev_section_summary": "El Anexo 15 del informe de la OMS se centra en las directrices para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en un formato de documento t\u00e9cnico com\u00fan. Los temas clave incluyen:\n\n1. **Introducci\u00f3n**: Proporciona el contexto, objetivos, alcance y principios generales de las directrices.\n2. **Glosario**: Define t\u00e9rminos relevantes utilizados en el documento.\n3. **Organizaci\u00f3n del dossier de producto**: Describe c\u00f3mo debe estructurarse un dossier para un producto farmac\u00e9utico multisource.\n4. **M\u00f3dulos del dossier**: Incluye detalles sobre los m\u00f3dulos espec\u00edficos, como el M\u00f3dulo 1 (informaci\u00f3n administrativa), el M\u00f3dulo 3 (calidad) y el M\u00f3dulo 5 (eficacia y seguridad).\n5. **Orientaci\u00f3n sobre formato y presentaci\u00f3n**: Ofrece directrices sobre c\u00f3mo presentar la informaci\u00f3n de manera clara y coherente.\n6. **Variaciones**: Aborda la importancia de las variaciones en la presentaci\u00f3n de los dossiers.\n\nLas entidades clave incluyen \"productos farmac\u00e9uticos multisource\", \"dossier de producto\", \"M\u00f3dulo 1\", \"M\u00f3dulo 3\", \"M\u00f3dulo 5\", y \"documento t\u00e9cnico com\u00fan\". Estas directrices son fundamentales para asegurar la calidad y la conformidad en la presentaci\u00f3n de productos gen\u00e9ricos.", "excerpt_keywords": "Keywords: WHO, prequalification, pharmaceutical products, product dossier, CTD"}}, "3a151fca-debd-4c53-a595-bc5635401999": {"node_ids": ["ed5782ff-d0d5-4a36-a3e0-a7f0ab049f98"], "metadata": {"page_label": "431", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "or semi-synthetic origin and their corresponding finished pharmaceutical products (FPPs). For the purposes of these guidelines, an existing API is one that has been previously authorized through a finished product by a stringent regulatory authority (SRA).<sup>1</sup> APIs from fermentation, biological, biotechnological or herbal origin are covered by other guidelines.\n\nThese guidelines primarily address the organization of the information to be presented in PDs for multisource products. They are not intended to indicate what studies are required. They merely indicate an appropriate format for the data that have been acquired. Applicants should not modify the overall organization of the CTD as outlined in the guidelines.\n\n### 1.4 General principles\n\nThese guidelines present the agreed-upon common format for the preparation of a well-structured CTD for PDs that will be submitted to WHO. A common format for the technical documentation will significantly reduce the time and resources needed to compile PDs for the prequalification of multisource pharmaceutical products and will ease the preparation of electronic submissions. Assessments and communication with the applicant will be facilitated by a standard document containing common elements. In addition, exchange of regulatory information between national medicine regulatory authorities (NMRAs) and with WHO will be simplified.\n\nUltimately, this is intended to support the objectives of the WHO-managed Prequalification of Medicines Programme in listing pharmaceutical products of acceptable safety, efficacy and quality in the interest of public health.\n\nThese general filing guidelines should be read in conjunction with other applicable WHO and ICH reference documents and guidelines that provide further guidance and recommendations on the topic-specific content requirements for multisource products, notably:\n\n- *Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability* (6);\n- *Bioequivalence trial information form (BTIF)* (7);\n- *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8);\n- *Quality overall summary \u2014 product dossier (QOS\u2013PD)* (9).\n\n----\n\n<sup>1</sup> Stringent regulatory authority (SRA): a regulatory authority which is:\n- a member of the International Conference on Harmonisation (ICH) (as specified on www.ich.org); or\n- an ICH observer, being the European Free Trade Association (EFTA), as represented by Swissmedic, Health Canada and World Health Organization (WHO), and may be updated from time to time); or\n- a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement including Australia, Iceland, Liechtenstein and Norway (may be updated from time to time).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, as\u00ed como un resumen de nivel superior:\n\n### Resumen de nivel superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) establece directrices para la preparaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource (gen\u00e9ricos). Se enfoca en la organizaci\u00f3n de la informaci\u00f3n y el formato del Dossier T\u00e9cnico Com\u00fan (CTD) que debe ser presentado a la OMS. Estas directrices buscan facilitar la precalificaci\u00f3n de productos farmac\u00e9uticos, asegurando que cumplan con est\u00e1ndares de seguridad, eficacia y calidad. Adem\u00e1s, se menciona la importancia de seguir otras gu\u00edas y documentos de referencia de la OMS y la Conferencia Internacional sobre Armonizaci\u00f3n (ICH).\n\n### Preguntas espec\u00edficas\n1. **\u00bfQu\u00e9 se entiende por un \"API existente\" seg\u00fan las directrices de la OMS y c\u00f3mo se relaciona con las autoridades regulatorias estrictas (SRA)?**\n   - Respuesta: Un \"API existente\" es aquel que ha sido previamente autorizado a trav\u00e9s de un producto terminado por una autoridad regulatoria estricta (SRA). Esto implica que el API ha pasado por un proceso de evaluaci\u00f3n riguroso que garantiza su calidad y seguridad.\n\n2. **\u00bfCu\u00e1l es el prop\u00f3sito principal de las directrices sobre la presentaci\u00f3n de Dossiers de Producto (PD) para productos farmac\u00e9uticos multisource?**\n   - Respuesta: El prop\u00f3sito principal es establecer un formato com\u00fan para la preparaci\u00f3n de Dossiers de Producto que facilite la compilaci\u00f3n y presentaci\u00f3n de informaci\u00f3n t\u00e9cnica, reduciendo el tiempo y los recursos necesarios para la precalificaci\u00f3n de productos farmac\u00e9uticos y mejorando la comunicaci\u00f3n entre las autoridades regulatorias y la OMS.\n\n3. **\u00bfQu\u00e9 documentos y gu\u00edas adicionales deben considerarse junto con estas directrices al preparar un Dossier de Producto para productos farmac\u00e9uticos multisource?**\n   - Respuesta: Adem\u00e1s de estas directrices, se deben considerar otros documentos de la OMS y de la ICH, como las gu\u00edas sobre productos farmac\u00e9uticos multisource, formularios de informaci\u00f3n de ensayos de bioequivalencia, y la parte de calidad del Dossier de Producto para productos farmac\u00e9uticos gen\u00e9ricos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Organizaci\u00f3n Mundial de la Salud (OMS)**: La OMS es la entidad responsable de la publicaci\u00f3n del informe y de la precalificaci\u00f3n de productos farmac\u00e9uticos.\n\n2. **Precalificaci\u00f3n de Productos Farmac\u00e9uticos**: El informe detalla el procedimiento que la OMS sigue para evaluar la aceptabilidad de productos farmac\u00e9uticos para su adquisici\u00f3n por agencias de la ONU, con el objetivo de facilitar el acceso a medicamentos esenciales de calidad.\n\n3. **Dossier de Producto (PD)**: Se menciona la importancia de enviar un Dossier de Producto al solicitar una Evaluaci\u00f3n de Inter\u00e9s (EOI), siguiendo las directrices de la OMS.\n\n4. **Documento T\u00e9cnico Com\u00fan (CTD)**: Se recomienda adoptar el formato modular del CTD, que ha sido ampliamente aceptado por las autoridades regulatorias, para la presentaci\u00f3n de los Dossiers de Producto.\n\n5. **Objetivos de las Directrices**: Las directrices tienen como objetivo ayudar a los solicitantes en la preparaci\u00f3n de Dossiers de Producto para productos multisource, promoviendo procesos eficientes para su desarrollo y evaluaci\u00f3n.\n\n6. **Alcance**: Las directrices se aplican a productos farmac\u00e9uticos multisource que contienen ingredientes activos existentes de origen sint\u00e9tico.\n\n### Entidades Clave\n- **World Health Organization (WHO)**: Organizaci\u00f3n responsable del informe.\n- **International Conference on Harmonisation (ICH)**: Entidad que desarroll\u00f3 el formato CTD.\n- **Agencias de la ONU**: Entidades que adquieren productos farmac\u00e9uticos precalificados.\n\nEste resumen destaca los aspectos fundamentales del informe, incluyendo su prop\u00f3sito, el formato recomendado para la presentaci\u00f3n de documentos y el tipo de productos a los que se aplican las directrices.", "excerpt_keywords": "Keywords: WHO, pharmaceutical products, guidelines, prequalification, CTD"}}, "a905d89a-adfb-4fd1-9447-18d950119f11": {"node_ids": ["46a1d47c-105b-4cd4-a8e5-46ecf5b8bf9a"], "metadata": {"page_label": "432", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Together, these guidelines, templates and reference documents mentioned within them are intended to assist applicants and WHO by harmonizing with international approaches and facilitating the preparation and subsequent assessment procedures for PDs through the integration of the internationally accepted CTD format and, where possible, terminology.\n\nOnce implemented these guidelines will supersede the following guidelines and template which were in use previously:\n\n- *Guideline on submission of documentation for prequalification of multi-source (generic) finished pharmaceutical products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis*;\n  - Supplement 1 \u2014 Dissolution testing;\n  - Supplement 2 \u2014 Extension of the WHO List of Stable (not easily degradable ARV) APIs;\n- *Pharmaceutical Quality Information Form (PQIF)*.\n\n## 2. Glossary\n\n**active pharmaceutical ingredient (API)**  \nAny substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings (1).\n\n**applicant**  \nThe person or entity who, by the deadline mentioned in the invitation, submits an expression of interest (EOI) to participate in this procedure in respect of the product(s) listed in the invitation, together with the required documentation on such product(s) (1).\n\n**finished pharmaceutical product (FPP)**  \nA finished dosage form of a pharmaceutical product, which has undergone all stages of manufacture, including packaging in its final container and labelling (1).\n\n**manufacturer**  \nA company that produces, packages, repackages, labels and/or relabels pharmaceutical products (1).\n\n**multisource (generic) pharmaceutical products**  \nPharmaceutically equivalent or pharmaceutically alternative products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable (6).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) presenta nuevas directrices, plantillas y documentos de referencia destinados a ayudar a los solicitantes y a la OMS en la armonizaci\u00f3n de enfoques internacionales para la preparaci\u00f3n y evaluaci\u00f3n de documentos de productos farmac\u00e9uticos. Estas nuevas directrices reemplazar\u00e1n las anteriores relacionadas con la precalificaci\u00f3n de productos farmac\u00e9uticos gen\u00e9ricos utilizados en el tratamiento de enfermedades como el VIH/SIDA, la malaria y la tuberculosis. Adem\u00e1s, se incluye un glosario que define t\u00e9rminos clave como \"ingrediente farmac\u00e9utico activo\" (API), \"producto farmac\u00e9utico terminado\" (FPP) y \"productos farmac\u00e9uticos multisource\".\n\n### Preguntas Espec\u00edficas\n1. **\u00bfQu\u00e9 documentos y directrices anteriores ser\u00e1n reemplazados por las nuevas directrices de la OMS?**\n   - Las nuevas directrices reemplazar\u00e1n la \"Gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos)\" utilizados en el tratamiento de VIH/SIDA, malaria y tuberculosis, as\u00ed como el \"Formulario de Informaci\u00f3n de Calidad Farmac\u00e9utica (PQIF)\" y sus suplementos relacionados.\n\n2. **\u00bfCu\u00e1l es la definici\u00f3n de un \"producto farmac\u00e9utico terminado\" (FPP) seg\u00fan el documento?**\n   - Un \"producto farmac\u00e9utico terminado\" (FPP) se define como una forma de dosificaci\u00f3n final de un producto farmac\u00e9utico que ha pasado por todas las etapas de fabricaci\u00f3n, incluyendo el empaquetado en su contenedor final y el etiquetado.\n\n3. **\u00bfQu\u00e9 se entiende por \"productos farmac\u00e9uticos multisource\" y c\u00f3mo se relacionan con la equivalencia terap\u00e9utica?**\n   - Los \"productos farmac\u00e9uticos multisource\" son productos que son farmac\u00e9uticamente equivalentes o alternativamente farmac\u00e9uticos, que pueden o no ser terap\u00e9uticamente equivalentes. Aquellos que son terap\u00e9uticamente equivalentes son intercambiables.", "prev_section_summary": "### Resumen de temas clave y entidades\n\n**Temas clave:**\n1. **API existente:** Se define como un ingrediente farmac\u00e9utico activo que ha sido autorizado previamente a trav\u00e9s de un producto terminado por una autoridad regulatoria estricta (SRA).\n2. **Directrices para Dossiers de Producto (PD):** Se centran en la organizaci\u00f3n y formato del Dossier T\u00e9cnico Com\u00fan (CTD) para productos farmac\u00e9uticos multisource (gen\u00e9ricos), sin especificar los estudios requeridos.\n3. **Objetivos de las directrices:** Facilitar la precalificaci\u00f3n de productos farmac\u00e9uticos, asegurando que cumplan con est\u00e1ndares de seguridad, eficacia y calidad, y mejorar la comunicaci\u00f3n entre las autoridades regulatorias y la OMS.\n4. **Documentaci\u00f3n adicional:** Se deben considerar otras gu\u00edas y documentos de referencia de la OMS y la ICH para el contenido espec\u00edfico de los productos multisource.\n\n**Entidades:**\n- **Organizaci\u00f3n Mundial de la Salud (OMS):** Entidad responsable de establecer las directrices.\n- **Autoridades regulatorias estrictas (SRA):** Incluyen miembros de la Conferencia Internacional sobre Armonizaci\u00f3n (ICH) y otras autoridades asociadas.\n- **Dossier T\u00e9cnico Com\u00fan (CTD):** Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n t\u00e9cnica.\n- **Programa de Precalificaci\u00f3n de Medicamentos de la OMS:** Iniciativa para listar productos farmac\u00e9uticos que cumplen con los est\u00e1ndares de calidad y seguridad.\n\nEste resumen destaca la importancia de seguir un formato com\u00fan en la documentaci\u00f3n de productos farmac\u00e9uticos y la colaboraci\u00f3n entre diferentes entidades regulatorias para garantizar la salud p\u00fablica.", "excerpt_keywords": "Keywords: guidelines, pharmaceutical, prequalification, active pharmaceutical ingredient, multisource"}}, "6b763825-5d5a-47c3-b589-3188a396fda6": {"node_ids": ["5bacb323-f328-4ec5-b58a-152dc7408b1a"], "metadata": {"page_label": "433", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Organization of a product dossier for a multisource product in common technical document format\n\nThe CTD is organized into five modules. Module 1 is region-specific. Modules 2, 3, 4 and 5 are intended to be common for all regions. Conformance with these guidelines should ensure that Modules 2, 3, 4 and 5 are provided in a format acceptable to WHO and to regulatory authorities.\n\nThis section provides an overview of module contents for a multisource product in greater detail.\n\n- **Module 1: Administrative information and prescribing information**\n  - This module should contain documents specific to WHO and each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by WHO and the relevant regulatory authorities.\n  - A summary of the bioequivalence/bioavailability information should be provided according to WHO\u2019s *Bioequivalence Trial Information Form (BTIF)* (7).\n  - Quality information summary (QIS): see WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* for instructions (8).\n\n- **Module 2: CTD summaries**\n  - This Module should begin with a general introduction to the pharmaceutical, including its pharmacological class, mode of action and proposed clinical use. In general, the Introduction should not exceed one page.\n  - A summary of the quality information should be provided according to WHO\u2019s *Quality overall summary \u2014 product dossier (QOS\u2013PD)* template (9).\n  - The organization of these summaries is described in Guidelines for ICH M4, M4Q and M4S (3-5).\n\n- **Module 3: Quality**\n  - Information on quality should be presented in the structured format described in ICH M4Q and WHO\u2019s *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part* (8).\n\n- **Module 4: Nonclinical study reports**\n  - Generally not applicable for multisource products (some exceptions may apply).\n\n- **Module 5: Clinical study reports**\n  - The human study reports and related information should be presented in the order described in ICH M4E (3) and WHO\u2019s *Multisource (generic)*.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento describe la organizaci\u00f3n de un dossier de producto para un producto multisource en formato de documento t\u00e9cnico com\u00fan (CTD). Se divide en cinco m\u00f3dulos, donde el M\u00f3dulo 1 es espec\u00edfico para cada regi\u00f3n y los M\u00f3dulos 2, 3, 4 y 5 son comunes para todas las regiones. Cada m\u00f3dulo tiene requisitos espec\u00edficos sobre la informaci\u00f3n que debe incluirse, como informaci\u00f3n administrativa, res\u00famenes de calidad, informes de estudios no cl\u00ednicos y cl\u00ednicos.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 tipo de documentos se deben incluir en el M\u00f3dulo 1 del dossier de producto para un producto multisource?**\n   - El M\u00f3dulo 1 debe contener documentos espec\u00edficos para la OMS y cada regi\u00f3n, como formularios de solicitud y la etiqueta propuesta para uso en la regi\u00f3n. Tambi\u00e9n debe incluir un resumen de la informaci\u00f3n de bioequivalencia/bioavailability seg\u00fan el Formulario de Informaci\u00f3n de Ensayo de Bioequivalencia (BTIF) de la OMS y un resumen de informaci\u00f3n de calidad (QIS).\n\n2. **\u00bfCu\u00e1l es la estructura recomendada para el resumen de calidad en el M\u00f3dulo 2?**\n   - El M\u00f3dulo 2 debe comenzar con una introducci\u00f3n general al producto farmac\u00e9utico, que incluya su clase farmacol\u00f3gica, modo de acci\u00f3n y uso cl\u00ednico propuesto. Adem\u00e1s, debe incluir un resumen de la informaci\u00f3n de calidad seg\u00fan la plantilla de Resumen General de Calidad \u2014 dossier de producto (QOS\u2013PD) de la OMS.\n\n3. **\u00bfQu\u00e9 se debe considerar en el M\u00f3dulo 4 respecto a los informes de estudios no cl\u00ednicos para productos multisource?**\n   - En general, el M\u00f3dulo 4 no es aplicable para productos multisource, aunque pueden existir algunas excepciones. Esto implica que, en la mayor\u00eda de los casos, no se requerir\u00e1n informes de estudios no cl\u00ednicos para estos productos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) aborda la implementaci\u00f3n de nuevas directrices y documentos de referencia que buscan facilitar la preparaci\u00f3n y evaluaci\u00f3n de productos farmac\u00e9uticos. Estos son algunos de los temas y entidades clave:\n\n1. **Nuevas Directrices**: Se introducen directrices y plantillas que armonizan los enfoques internacionales para la evaluaci\u00f3n de productos farmac\u00e9uticos, integrando el formato CTD (Common Technical Document).\n\n2. **Documentos Reemplazados**: Las nuevas directrices reemplazar\u00e1n las anteriores, que inclu\u00edan:\n   - Gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para la precalificaci\u00f3n de productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos) para el tratamiento de VIH/SIDA, malaria y tuberculosis.\n   - Formulario de Informaci\u00f3n de Calidad Farmac\u00e9utica (PQIF) y sus suplementos.\n\n3. **Glosario de T\u00e9rminos Clave**:\n   - **Ingrediente Farmac\u00e9utico Activo (API)**: Sustancia que proporciona actividad farmacol\u00f3gica en un producto farmac\u00e9utico terminado (FPP).\n   - **Solicitante**: Persona o entidad que presenta una expresi\u00f3n de inter\u00e9s para participar en el procedimiento de precalificaci\u00f3n.\n   - **Producto Farmac\u00e9utico Terminado (FPP)**: Forma de dosificaci\u00f3n final que ha pasado por todas las etapas de fabricaci\u00f3n.\n   - **Fabricante**: Empresa que produce y etiqueta productos farmac\u00e9uticos.\n   - **Productos Farmac\u00e9uticos Multisource**: Productos que son farmac\u00e9uticamente equivalentes o alternativamente farmac\u00e9uticos, que pueden ser intercambiables si son terap\u00e9uticamente equivalentes.\n\n4. **Objetivo General**: Las nuevas directrices tienen como objetivo mejorar la calidad y la consistencia en la evaluaci\u00f3n de productos farmac\u00e9uticos, especialmente aquellos utilizados en el tratamiento de enfermedades cr\u00edticas como el VIH/SIDA, la malaria y la tuberculosis. \n\nEste resumen destaca la importancia de la armonizaci\u00f3n en la presentaci\u00f3n de documentaci\u00f3n y la definici\u00f3n clara de t\u00e9rminos clave en el contexto de la precalificaci\u00f3n de productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: product dossier, multisource product, common technical document, WHO guidelines, regulatory authorities"}}, "f1cb2359-9cf6-49a8-bcfe-303468a1b5fc": {"node_ids": ["f1ead976-e54a-44fe-80f4-df1d4fc1457c"], "metadata": {"page_label": "434", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "pharmaceutical products: guidelines on registration requirements to establish interchangeability (6).\n\nThe overall organization of the CTD is presented in Figure 1.\n\n### Figure 1  \n**Organization of the CTD**\n\n```\n          Not part of the CTD\n              (Module 1)\n          ___________________\n         |                   |\n         | Module 1          |\n         | Regional          |\n         | Administrative    |\n         | Information       |\n         |___________________|\n         | CTD Table of      |\n         | Contents          |\n         | 2.1               |\n         |___________________|\n         | CTD Introduction  |\n         | 2.2               |\n         |___________________|\n         | Quality Overall   |\n         | Summary           |\n         | 2.3               |\n         |___________________|\n         | Nonclinical       |\n         | Overview          |\n         | 2.4               |\n         |___________________|\n         | Nonclinical       |\n         | Written and       |\n         | Tabulated         |\n         | Summaries         |\n         | 2.6               |\n         |___________________|\n         | Clinical Overview |\n         | 2.5               |\n         |___________________|\n         | Clinical Summary  |\n         | 2.7               |\n         |___________________|\n         | Module 3          |\n         | Quality           |\n         | 3.0               |\n         |___________________|\n         | Module 4          |\n         | Nonclinical       |\n         | Study Reports     |\n         | 4.0               |\n         |___________________|\n         | Module 5          |\n         | Clinical Study    |\n         | Reports           |\n         | 5.0               |\n         |___________________|\n```\n\nThis figure is reproduced with the kind permission of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).\n\nIn preparing PDs for multisource products, it is acknowledged that certain modules or sections of the CTD would generally **not be applicable** (e.g. Module 4 \u2014 nonclinical study reports, although some exceptions may apply) and should be marked as such.\n\n### 4. Modules (including Module 1) of a product dossier for a multisource pharmaceutical product\n\nThis section outlines filing considerations for PDs in the CTD format. Table 1 provides an overview of the presentation of the PD, including modular structure and main headings.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del contexto\n\nEl documento se centra en las pautas de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre los requisitos de registro para establecer la intercambiabilidad de productos farmac\u00e9uticos. Se presenta la organizaci\u00f3n del Dossier de Producto (PD) en formato CTD (Common Technical Document), que incluye varios m\u00f3dulos, como informaci\u00f3n administrativa, res\u00famenes de calidad, y reportes de estudios cl\u00ednicos y no cl\u00ednicos. Se menciona que ciertos m\u00f3dulos pueden no ser aplicables para productos multisource, como el m\u00f3dulo 4, y se deben marcar como tales.\n\n### Preguntas espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los m\u00f3dulos que generalmente no son aplicables al preparar Dossiers de Producto para productos multisource, y por qu\u00e9?**\n   - Respuesta: Generalmente, el M\u00f3dulo 4 (reportes de estudios no cl\u00ednicos) no es aplicable al preparar Dossiers de Producto para productos multisource, aunque pueden existir excepciones. Esto se debe a que los productos multisource suelen basarse en estudios de bioequivalencia en lugar de estudios no cl\u00ednicos extensivos.\n\n2. **\u00bfQu\u00e9 informaci\u00f3n se incluye en el M\u00f3dulo 1 del Dossier de Producto seg\u00fan el formato CTD?**\n   - Respuesta: El M\u00f3dulo 1 incluye informaci\u00f3n administrativa regional, la tabla de contenidos del CTD, la introducci\u00f3n del CTD, y res\u00famenes de calidad, no cl\u00ednicos y cl\u00ednicos, entre otros.\n\n3. **\u00bfQu\u00e9 figura se presenta en el documento y qu\u00e9 informaci\u00f3n proporciona sobre la organizaci\u00f3n del CTD?**\n   - Respuesta: La figura presentada es la \"Organizaci\u00f3n del CTD\", que ilustra la estructura modular del Dossier de Producto, destacando los diferentes m\u00f3dulos y sus respectivas secciones, as\u00ed como la distinci\u00f3n de que el M\u00f3dulo 1 no forma parte del CTD en s\u00ed. \n\nEstas preguntas y respuestas est\u00e1n dise\u00f1adas para proporcionar informaci\u00f3n espec\u00edfica que no se puede encontrar f\u00e1cilmente en otros documentos, centr\u00e1ndose en detalles sobre la estructura y requisitos del Dossier de Producto en el contexto de productos farmac\u00e9uticos multisource.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n**Temas Clave:**\n\n1. **Estructura del Dossier de Producto:**\n   - El dossier se organiza en cinco m\u00f3dulos: M\u00f3dulo 1 (espec\u00edfico para la regi\u00f3n) y M\u00f3dulos 2, 3, 4 y 5 (comunes para todas las regiones).\n\n2. **Contenido de los M\u00f3dulos:**\n   - **M\u00f3dulo 1:** Informaci\u00f3n administrativa y de prescripci\u00f3n, incluyendo documentos espec\u00edficos para la OMS y cada regi\u00f3n, res\u00famenes de bioequivalencia/bioavailability y un resumen de informaci\u00f3n de calidad (QIS).\n   - **M\u00f3dulo 2:** Res\u00famenes CTD que incluyen una introducci\u00f3n general al producto y un resumen de la informaci\u00f3n de calidad (QOS\u2013PD).\n   - **M\u00f3dulo 3:** Informaci\u00f3n de calidad presentada en un formato estructurado.\n   - **M\u00f3dulo 4:** Informes de estudios no cl\u00ednicos, generalmente no aplicables para productos multisource.\n   - **M\u00f3dulo 5:** Informes de estudios cl\u00ednicos presentados en el orden especificado por ICH M4E.\n\n3. **Conformidad con Directrices:**\n   - Se enfatiza la necesidad de cumplir con las directrices de la OMS y las autoridades regulatorias para asegurar que los m\u00f3dulos sean aceptables.\n\n**Entidades:**\n\n- **WHO (Organizaci\u00f3n Mundial de la Salud):** Autoridad que establece las directrices para la presentaci\u00f3n de documentaci\u00f3n.\n- **CTD (Common Technical Document):** Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n sobre productos farmac\u00e9uticos.\n- **M\u00f3dulos:** Seis secciones del dossier (M\u00f3dulo 1 a M\u00f3dulo 5) que abordan diferentes aspectos de la informaci\u00f3n del producto.\n- **Bioequivalence Trial Information Form (BTIF):** Formulario de la OMS para resumir informaci\u00f3n de bioequivalencia/bioavailability.\n- **Quality overall summary (QOS\u2013PD):** Plantilla de la OMS para resumir la informaci\u00f3n de calidad del producto.\n- **ICH (International Council for Harmonisation):** Consejo que proporciona directrices sobre la organizaci\u00f3n de los res\u00famenes y la informaci\u00f3n de calidad.\n\nEste resumen destaca la organizaci\u00f3n y los requisitos espec\u00edficos para la presentaci\u00f3n de un dossier de producto multisource, as\u00ed como la importancia de seguir las directrices establecidas por la OMS y otras autoridades regulatorias.", "excerpt_keywords": "Keywords: pharmaceutical products, CTD, product dossier, interchangeability, regulatory guidelines"}}, "94bce007-7d32-4c48-8cdf-739101c4e263": {"node_ids": ["1315c207-b295-420a-9879-f2f1f78fb554"], "metadata": {"page_label": "435", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# Modular format of PDs for multisource products in CTD format\n\n| Module 1 \u2014 Administrative information and prescribing information |\n| - |\n| 1.0 Cover letter |\n| 1.1 Table of contents of the application including Module 1 (Modules 1\u20135) |\n| 1.2 Application information: |\n| 1.2.1 Copy of the expression of interest (EOI) |\n| 1.2.2 Manufacturing and marketing authorization(s)/international registration status and/or the WHO certificate of pharmaceutical product (CPP) |\n| 1.2.3 Copy of certificate(s) of suitability of the *European Pharmacopoeia* (CEP) (including any annexes) |\n| 1.2.4 Letters of access for active pharmaceutical ingredient master files (APIMFs) |\n| 1.2.5 Good manufacturing practices (GMP) information |\n| 1.2.6 Biowaiver requests in relation to conducting a comparative bioavailability study |\n| 1.3 Product information: |\n| 1.3.1 Summary of product characteristics (SmPC) |\n| 1.3.2 Labelling (outer and inner labels) |\n| 1.3.3 Package leaflet (also known as patient information leaflet or PIL) |\n| 1.4 Regional summaries: |\n| 1.4.1 Bioequivalence trial information form (BTIF) |\n| 1.4.2 Quality information summary (QIS) |\n| 1.5 Electronic review documents (e.g. product information, BTIF, QIS, QOS\u2013PD) |\n| 1.6 Samples (e.g. FPP, device(s), certificates of analysis) |\n\n\n| Module 2 \u2014 Common technical document (CTD) summaries |\n| - |\n| 2.1 CTD Table of contents (Modules 2\u20135) |\n| 2.2 CTD Introduction |\n| 2.3 Quality overall summary \u2014 product dossier (QOS\u2013PD) |\n| 2.4 Nonclinical overview \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.5 Clinical overview |\n| 2.6 Nonclinical written and tabulated summaries \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| 2.7 Clinical summary |\n\n\n| Module 3 \u2014 Quality |\n| - |\n| 3.1 Table of contents of Module 3 |\n| 3.2 Body of data |\n| 3.3 Literature references |\n", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden formular a partir del contexto proporcionado, junto con sus respuestas espec\u00edficas:\n\n1. **\u00bfQu\u00e9 tipo de informaci\u00f3n se requiere en la secci\u00f3n 1.2.2 del M\u00f3dulo 1 del formato modular para productos multisource?**\n   - **Respuesta:** En la secci\u00f3n 1.2.2 se requiere informaci\u00f3n sobre las autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n, el estado de registro internacional y/o el certificado de producto farmac\u00e9utico de la OMS (CPP).\n\n2. **\u00bfCu\u00e1l es la finalidad de la secci\u00f3n 2.4 en el M\u00f3dulo 2 del documento?**\n   - **Respuesta:** La secci\u00f3n 2.4, titulada \"Nonclinical overview\", generalmente no es aplicable para productos multisource, aunque pueden existir algunas excepciones. Su finalidad es proporcionar un resumen de los datos no cl\u00ednicos relevantes para la evaluaci\u00f3n del producto.\n\n3. **\u00bfQu\u00e9 tipo de documentos se incluyen en la secci\u00f3n 1.5 del M\u00f3dulo 1?**\n   - **Respuesta:** En la secci\u00f3n 1.5 se incluyen documentos de revisi\u00f3n electr\u00f3nica, tales como informaci\u00f3n del producto, el formulario de informaci\u00f3n del ensayo de bioequivalencia (BTIF), el resumen de informaci\u00f3n de calidad (QIS) y el resumen del dossier de calidad (QOS\u2013PD).\n\n### Resumen de nivel superior del contexto:\nEl documento \"WHO - Technical Report Series 961\" presenta un formato modular para los documentos de producto (PDs) de productos multisource en formato de documento t\u00e9cnico com\u00fan (CTD). Se divide en varios m\u00f3dulos que incluyen informaci\u00f3n administrativa, res\u00famenes t\u00e9cnicos comunes, y datos de calidad. Cada m\u00f3dulo contiene secciones espec\u00edficas que detallan la informaci\u00f3n requerida para la evaluaci\u00f3n y autorizaci\u00f3n de productos farmac\u00e9uticos, incluyendo aspectos como la informaci\u00f3n de fabricaci\u00f3n, caracter\u00edsticas del producto, y res\u00famenes cl\u00ednicos y no cl\u00ednicos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Tema Principal**: \n   - Pautas de la Organizaci\u00f3n Mundial de la Salud (OMS) sobre los requisitos de registro para establecer la intercambiabilidad de productos farmac\u00e9uticos.\n\n2. **Estructura del Dossier de Producto (PD)**:\n   - Se presenta la organizaci\u00f3n del Dossier de Producto en formato CTD (Common Technical Document), que incluye varios m\u00f3dulos.\n\n3. **M\u00f3dulos del CTD**:\n   - **M\u00f3dulo 1**: Informaci\u00f3n administrativa regional, tabla de contenidos, introducci\u00f3n, res\u00famenes de calidad, no cl\u00ednicos y cl\u00ednicos.\n   - **M\u00f3dulo 3**: Calidad.\n   - **M\u00f3dulo 4**: Reportes de estudios no cl\u00ednicos (generalmente no aplicable para productos multisource).\n   - **M\u00f3dulo 5**: Reportes de estudios cl\u00ednicos.\n\n4. **Excepciones**:\n   - Se menciona que ciertos m\u00f3dulos, como el M\u00f3dulo 4, no son aplicables al preparar Dossiers de Producto para productos multisource, aunque pueden existir excepciones.\n\n5. **Figura 1**: \n   - Ilustra la organizaci\u00f3n del CTD, destacando la estructura modular y la distinci\u00f3n de que el M\u00f3dulo 1 no forma parte del CTD en s\u00ed.\n\n6. **Entidades**:\n   - **OMS**: Organizaci\u00f3n Mundial de la Salud.\n   - **CTD**: Common Technical Document.\n   - **IFPMA**: Federaci\u00f3n Internacional de Asociaciones de Fabricantes de Productos Farmac\u00e9uticos.\n\nEste resumen destaca los aspectos clave relacionados con la organizaci\u00f3n y requisitos del Dossier de Producto en el contexto de productos farmac\u00e9uticos multisource, as\u00ed como las entidades relevantes involucradas en el proceso.", "excerpt_keywords": "Keywords: WHO, Technical Report, multisource products, CTD format, pharmaceutical registration"}}, "1fa5f1ae-e269-43d7-9cf7-18c7a65d69e6": {"node_ids": ["59f62c0c-d266-4a67-845d-142022f3f7a6"], "metadata": {"page_label": "436", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "| Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) | Module 4 \u2014 Nonclinical study reports \u2014 generally not applicable for multisource products (some exceptions may apply) |\n| - | - |\n| 4.1 | Table of contents of Module 4 |\n| 4.2 | Study reports |\n| 4.3 | Literature references |\n| Module 5 \u2014 Clinical study reports | |\n| 5.1 | Table of contents of Module 5 |\n| 5.2 | Tabular listing of all clinical studies |\n| 5.3 | Clinical study reports |\n| 5.3.1 | Reports of biopharmaceutical studies |\n| 5.3.7 | Case-report forms and individual patient listings |\n| 5.4 | Literature references |\n\n\nAdditional guidance for some of the sections to be included in Module 1 is provided below:\n\n### 1.0 Cover letter\n\nThe cover letter submitted with the PD should include a clear statement by the responsible person submitting the PD, indicating that the information submitted is true and correct.\n\n### 1.2.2 Manufacturing and marketing authorization(s)/international registration status\n\nList the countries in which:\n\n- the FPP (or set of FPPs) has been granted a marketing authorization;\n- the FPP (or one or more of the set of FPPs) has been withdrawn from the market; and\n- an application for the marketing of the FPP (or one or more of the set of FPPs) has been rejected, deferred or withdrawn.\n\nFor further guidance see section 3.2.P.3.1 of the *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)*.\n\n### 1.4 Regional summaries\n\nThe regional summaries should be prepared in accordance with the available WHO templates, which are available on the WHO Prequalification website.\n\n### 1.5 Electronic review documents\n\nElectronic submission of documentation (CD or DVD) should be submitted in Microsoft Word (required for templates/summaries, e.g. QOS\u2013PD, QIS, BTIF) or text-selectable PDF format (other documentation).", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder espec\u00edficamente con la informaci\u00f3n proporcionada en el contexto, junto con un resumen de nivel superior:\n\n### Resumen de nivel superior:\nEl documento es parte de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961) y se centra en los m\u00f3dulos de informes no cl\u00ednicos y cl\u00ednicos para productos farmac\u00e9uticos multisource (gen\u00e9ricos). Se detallan las secciones que deben incluirse en la presentaci\u00f3n de documentaci\u00f3n para productos farmac\u00e9uticos terminados (FPP), as\u00ed como las pautas para la presentaci\u00f3n de documentos electr\u00f3nicos y res\u00famenes regionales. Se enfatiza la importancia de la veracidad de la informaci\u00f3n presentada y se proporcionan directrices sobre autorizaciones de comercializaci\u00f3n y el estado de registro internacional.\n\n### Preguntas:\n1. **\u00bfQu\u00e9 informaci\u00f3n debe incluirse en la carta de presentaci\u00f3n al enviar la documentaci\u00f3n para un producto farmac\u00e9utico terminado (FPP)?**\n   - La carta de presentaci\u00f3n debe incluir una declaraci\u00f3n clara por parte de la persona responsable que indique que la informaci\u00f3n presentada es verdadera y correcta.\n\n2. **\u00bfCu\u00e1les son los requisitos para listar el estado de autorizaci\u00f3n de comercializaci\u00f3n de un FPP en diferentes pa\u00edses?**\n   - Se debe listar los pa\u00edses donde el FPP ha recibido autorizaci\u00f3n de comercializaci\u00f3n, aquellos donde ha sido retirado del mercado, y aquellos donde la solicitud de comercializaci\u00f3n ha sido rechazada, diferida o retirada.\n\n3. **\u00bfQu\u00e9 formatos se requieren para la presentaci\u00f3n electr\u00f3nica de documentos relacionados con la evaluaci\u00f3n de productos farmac\u00e9uticos?**\n   - La presentaci\u00f3n electr\u00f3nica debe realizarse en formato Microsoft Word (para plantillas y res\u00famenes) o en formato PDF seleccionable por texto (para otra documentaci\u00f3n).", "prev_section_summary": "La secci\u00f3n del documento \"WHO - Technical Report Series 961\" se centra en el formato modular para los documentos de producto (PDs) de productos multisource en el contexto del formato de documento t\u00e9cnico com\u00fan (CTD). A continuaci\u00f3n se presentan los temas clave y entidades relevantes:\n\n### Temas Clave:\n1. **Formato Modular**: Se establece un formato estructurado para la presentaci\u00f3n de informaci\u00f3n sobre productos farmac\u00e9uticos multisource.\n2. **M\u00f3dulos Espec\u00edficos**: El documento se divide en varios m\u00f3dulos, cada uno con secciones que abordan diferentes aspectos de la evaluaci\u00f3n y autorizaci\u00f3n de productos.\n   - **M\u00f3dulo 1**: Informaci\u00f3n administrativa y de prescripci\u00f3n, que incluye detalles sobre autorizaciones, informaci\u00f3n del producto y documentos de revisi\u00f3n electr\u00f3nica.\n   - **M\u00f3dulo 2**: Res\u00famenes del documento t\u00e9cnico com\u00fan, que abordan la calidad, la no cl\u00ednica y la informaci\u00f3n cl\u00ednica.\n   - **M\u00f3dulo 3**: Datos de calidad, que incluyen el cuerpo de datos y referencias bibliogr\u00e1ficas.\n\n### Entidades:\n- **Secciones del M\u00f3dulo 1**:\n  - **1.2**: Informaci\u00f3n de la aplicaci\u00f3n, que incluye autorizaciones de fabricaci\u00f3n y comercializaci\u00f3n, certificados de la OMS, y buenas pr\u00e1cticas de manufactura (GMP).\n  - **1.3**: Informaci\u00f3n del producto, que abarca caracter\u00edsticas del producto, etiquetado y folletos informativos.\n  - **1.5**: Documentos de revisi\u00f3n electr\u00f3nica, como el resumen de informaci\u00f3n de calidad (QIS) y el resumen del dossier de calidad (QOS\u2013PD).\n\n- **Secciones del M\u00f3dulo 2**:\n  - **2.4**: Resumen no cl\u00ednico, que generalmente no se aplica a productos multisource, pero puede tener excepciones.\n  - **2.5**: Resumen cl\u00ednico.\n\n- **Secciones del M\u00f3dulo 3**:\n  - **3.1**: Tabla de contenidos del m\u00f3dulo de calidad.\n  - **3.2**: Cuerpo de datos que respalda la calidad del producto.\n\n### Conclusi\u00f3n:\nEl documento proporciona una gu\u00eda detallada sobre la informaci\u00f3n necesaria para la evaluaci\u00f3n de productos farmac\u00e9uticos multisource, estructurada en un formato modular que facilita la revisi\u00f3n y autorizaci\u00f3n por parte de las autoridades competentes.", "excerpt_keywords": "Keywords: WHO, Technical Report, multisource products, clinical study reports, electronic submission"}}, "633835fa-fe82-4309-a401-2fdb012acd53": {"node_ids": ["61d47c0d-a1be-4d36-ba8a-75078adddd2a"], "metadata": {"page_label": "437", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 1.6 Samples (e.g. FPP, device(s))\n\nA sample and certificate of analysis of the FPP(s) and devices(s) should be provided to enable visual inspection of the pharmaceutical product, the packaging materials and the label as well as comparison of the data with those in the SmPC, labelling and the package leaflet.\n\nDraft labelling may be submitted at the time of dossier submission when labelling for marketing has not been finalized. For guidance regarding labelling, refer to the information on WHO public assessment reports (WHOPARs) available on the Prequalification web site under Information for Applicants (Prequalification Guidelines).\n\n## 5. Module 3 \u2014 quality\n\nFor Module 3.2.S Drug substance (or active pharmaceutical ingredient (API)), there are three options to satisfy the information requirements for APIs within the Prequalification Programme. In brief these are:\n\n- **Option 1**: certificate of suitability of the *European Pharmacopoeia* (CEP) procedure;\n- **Option 2**: active pharmaceutical ingredient master file (APIMF) procedure; or\n- **Option 3**: full details in the PD.\n\nAll options require the submission of information in CTD format (3.2.S), although the content may differ in places. The *Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part (8)* provides detailed guidance on this issue and on the preparation of the FPP information by the applicant.\n\n## 6. Module 5 of a product dossier for a multisource pharmaceutical product\n\nThe majority of PDs for multisource products are supported by one or more pivotal comparative bioavailability studies. When filing a PD in the CTD format, it is anticipated that only the following relevant sections of Module 5 will normally be required.\n\n**Module 5: Clinical study reports**\n\n- 5.1 Table of contents for Module 5\n- 5.2 Tabular listing of all clinical studies\n- 5.3 Clinical study reports\n  - 5.3.1 Reports of biopharmaceutical studies\n    - 5.3.1.2 Comparative bioavailability and bioequivalence study reports", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas que se pueden responder con el contexto proporcionado, junto con un resumen de nivel superior:\n\n### Resumen de Nivel Superior\nEl documento de la OMS (Organizaci\u00f3n Mundial de la Salud) detalla los requisitos para la presentaci\u00f3n de un dossier de productos farmac\u00e9uticos, espec\u00edficamente para productos farmac\u00e9uticos terminados (FPP) y dispositivos. Se enfatiza la importancia de proporcionar muestras y certificados de an\u00e1lisis para permitir la inspecci\u00f3n visual y la comparaci\u00f3n de datos. Adem\u00e1s, se describen las opciones para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas (API) y se mencionan los m\u00f3dulos relevantes para la presentaci\u00f3n de informes de estudios cl\u00ednicos, especialmente en el contexto de productos farmac\u00e9uticos multisource.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfCu\u00e1les son los tres m\u00e9todos aceptables para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas (API) en el Programa de Precalificaci\u00f3n de la OMS?**\n   - Respuesta: Los tres m\u00e9todos son: \n     - Opci\u00f3n 1: Certificado de idoneidad del procedimiento de la Farmacopea Europea (CEP).\n     - Opci\u00f3n 2: Procedimiento de archivo maestro de ingrediente farmac\u00e9utico activo (APIMF).\n     - Opci\u00f3n 3: Detalles completos en el dossier del producto (PD).\n\n2. **\u00bfQu\u00e9 se debe incluir en la presentaci\u00f3n de un dossier de producto (PD) para un producto farmac\u00e9utico multisource en relaci\u00f3n con los estudios de bioequivalencia?**\n   - Respuesta: Se debe incluir una tabla de contenido para el M\u00f3dulo 5, un listado tabular de todos los estudios cl\u00ednicos y los informes de estudios cl\u00ednicos, espec\u00edficamente los informes de estudios biofarmac\u00e9uticos y los informes de estudios de bioequivalencia y comparativa.\n\n3. **\u00bfQu\u00e9 se debe proporcionar junto con las muestras de productos farmac\u00e9uticos y dispositivos para facilitar la inspecci\u00f3n visual?**\n   - Respuesta: Se debe proporcionar un certificado de an\u00e1lisis de los FPP y dispositivos, que permita la inspecci\u00f3n visual del producto farmac\u00e9utico, los materiales de embalaje y la etiqueta, as\u00ed como la comparaci\u00f3n de los datos con los que se encuentran en el Resumen de las Caracter\u00edsticas del Producto (SmPC), el etiquetado y el prospecto.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\nEl contenido de la secci\u00f3n se centra en las pautas y requisitos para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos multisource (gen\u00e9ricos) en el contexto de la Serie de Informes T\u00e9cnicos de la OMS (WHO - Technical Report Series 961). A continuaci\u00f3n se presentan los temas clave y entidades mencionadas:\n\n#### Temas Clave:\n1. **M\u00f3dulos de Informes**:\n   - **M\u00f3dulo 4**: Informes de estudios no cl\u00ednicos, generalmente no aplicables para productos multisource, con algunas excepciones.\n   - **M\u00f3dulo 5**: Informes de estudios cl\u00ednicos, que incluye listados tabulares y reportes de estudios biopharmaceuticals.\n\n2. **Carta de Presentaci\u00f3n**:\n   - Debe incluir una declaraci\u00f3n de veracidad de la informaci\u00f3n presentada por la persona responsable.\n\n3. **Autorizaci\u00f3n de Comercializaci\u00f3n**:\n   - Requisitos para listar el estado de autorizaci\u00f3n de comercializaci\u00f3n en diferentes pa\u00edses, incluyendo autorizaciones, retiradas y solicitudes rechazadas.\n\n4. **Res\u00famenes Regionales**:\n   - Deben prepararse de acuerdo con las plantillas disponibles en el sitio web de Precalificaci\u00f3n de la OMS.\n\n5. **Documentos Electr\u00f3nicos**:\n   - La presentaci\u00f3n electr\u00f3nica debe realizarse en formatos espec\u00edficos: Microsoft Word para plantillas y res\u00famenes, y PDF seleccionable por texto para otra documentaci\u00f3n.\n\n#### Entidades:\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de las directrices y est\u00e1ndares mencionados.\n- **FPP (Producto Farmac\u00e9utico Terminado)**: Producto cuyo estado de autorizaci\u00f3n se debe detallar en la documentaci\u00f3n.\n- **M\u00f3dulos 4 y 5**: Secciones espec\u00edficas del documento que abordan estudios no cl\u00ednicos y cl\u00ednicos, respectivamente.\n\nEste resumen destaca la estructura y los requisitos esenciales para la presentaci\u00f3n de documentaci\u00f3n relacionada con productos farmac\u00e9uticos, enfatizando la importancia de la precisi\u00f3n y el cumplimiento de las normativas establecidas por la OMS.", "excerpt_keywords": "Keywords: pharmaceutical products, WHO guidelines, active pharmaceutical ingredient, bioequivalence studies, product dossier"}}, "c79f3868-0e6b-458a-a17e-354a38d4f9ae": {"node_ids": ["b8f2ba95-4466-4310-8433-176fcae01627"], "metadata": {"page_label": "438", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "# 5.3.1.3 In vitro\u2013in vivo correlation study reports if available\n# 5.3.1.4 Reports of bioanalytical and analytical method for human studies<sup>2</sup>\n\n\u2014 5.3.7 Case-report forms (CRFs) and individual patient listings: only CRFs for subjects who experienced serious adverse events should be included. All CRFs should be available upon request.\n\n- 5.4 Literature references\n\nFor guidance regarding biowaivers, refer to the biowaiver implementation documents available on the Prequalification web site. For guidance regarding comparator products, refer to the information available under Guidance on bioequivalence studies on the Prequalification web site.\n\n## 7. Guidance on format and presentation of a product dossier in common technical document format\n\n### 7.1 Guidance on format\n\nThroughout the CTD, the information should be displayed in an unambiguous and transparent manner. Text and tables should be prepared using margins that allow the document to be printed on both A4-sized paper (European Union and Japan) and 8.5 \u00d7 11-inch paper (US). The left-hand margin should be sufficiently large that information is not obscured whatever the method of binding. Fonts for text and tables should be of a style and size large enough to be easily legible, even after photocopying. Times New Roman, 12-point font is recommended for narrative text.\n\nAcronyms and abbreviations should be defined the first time they are used in each module.\n\nReferences should be cited in accordance with the current edition of the *Uniform requirements for manuscripts submitted to biomedical journals*, International Committee of Medical Journal Editors (ICMJE).<sup>3</sup> Copies of relevant pages of references should be provided, with a copy of the full article in the case of a publication. English translations should be provided as necessary.\n\n### 7.2 Guidance on presentation\n\nThe paper copies of the application should be bound for easy access to information.\n\n----\n\n<sup>2</sup> Bioanalytical or analytical methods for BA/BE or in vitro dissolution studies should ordinarily be provided in the individual clinical study reports. However, where a method is used in multiple studies, the method and its validation should only be included once in section 5.3.1.4 and referenced in the appropriate individual clinical study reports.\n\n<sup>3</sup> The first edition of the *Uniform requirements for manuscripts submitted to biomedical journals* was conceived by the Vancouver Group and was published in 1979.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas que se pueden responder con la informaci\u00f3n proporcionada en el contexto, junto con res\u00famenes de nivel superior que pueden ayudar a formularlas:\n\n### Resumen de nivel superior:\nEl documento proporciona directrices sobre la presentaci\u00f3n y formato de un dossier de producto en el formato del documento t\u00e9cnico com\u00fan (CTD). Incluye secciones espec\u00edficas sobre estudios de correlaci\u00f3n in vitro-in vivo, m\u00e9todos bioanal\u00edticos y anal\u00edticos, formularios de informes de casos (CRFs) y referencias literarias. Tambi\u00e9n se menciona la importancia de la claridad y legibilidad en la presentaci\u00f3n de la informaci\u00f3n, as\u00ed como la necesidad de cumplir con las normas de citaci\u00f3n establecidas por el Comit\u00e9 Internacional de Editores de Revistas M\u00e9dicas.\n\n### Preguntas:\n\n1. **\u00bfQu\u00e9 tipo de formularios de informes de casos (CRFs) deben incluirse en el dossier de producto y cu\u00e1les son las condiciones para su inclusi\u00f3n?**\n   - Respuesta: Solo se deben incluir los CRFs de los sujetos que experimentaron eventos adversos graves, y todos los CRFs deben estar disponibles a solicitud.\n\n2. **\u00bfCu\u00e1l es la recomendaci\u00f3n sobre el formato y la presentaci\u00f3n de la informaci\u00f3n en el dossier del producto seg\u00fan el documento?**\n   - Respuesta: La informaci\u00f3n debe presentarse de manera clara y transparente, utilizando m\u00e1rgenes adecuados para la impresi\u00f3n en papel A4 y 8.5 \u00d7 11 pulgadas, con un tama\u00f1o de fuente de 12 puntos en Times New Roman para asegurar la legibilidad.\n\n3. **\u00bfC\u00f3mo deben citarse las referencias en el dossier del producto y qu\u00e9 se debe proporcionar junto con ellas?**\n   - Respuesta: Las referencias deben citarse de acuerdo con la edici\u00f3n actual de los *Uniform requirements for manuscripts submitted to biomedical journals* del ICMJE, y se deben proporcionar copias de las p\u00e1ginas relevantes de las referencias, as\u00ed como una copia del art\u00edculo completo en caso de publicaciones, junto con traducciones al ingl\u00e9s si es necesario.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Muestras y Certificados de An\u00e1lisis**:\n   - Se requiere la presentaci\u00f3n de muestras y certificados de an\u00e1lisis de productos farmac\u00e9uticos terminados (FPP) y dispositivos para permitir la inspecci\u00f3n visual y la comparaci\u00f3n de datos con el Resumen de las Caracter\u00edsticas del Producto (SmPC), etiquetado y prospecto.\n\n2. **Opciones para Sustancias Activas (API)**:\n   - Existen tres m\u00e9todos aceptables para cumplir con los requisitos de informaci\u00f3n sobre sustancias activas en el Programa de Precalificaci\u00f3n de la OMS:\n     - **Opci\u00f3n 1**: Certificado de idoneidad del procedimiento de la Farmacopea Europea (CEP).\n     - **Opci\u00f3n 2**: Procedimiento de archivo maestro de ingrediente farmac\u00e9utico activo (APIMF).\n     - **Opci\u00f3n 3**: Detalles completos en el dossier del producto (PD).\n\n3. **M\u00f3dulo 5 del Dossier de Producto**:\n   - Para productos farmac\u00e9uticos multisource, se requiere la presentaci\u00f3n de secciones espec\u00edficas del M\u00f3dulo 5, que incluye:\n     - Tabla de contenido para el M\u00f3dulo 5.\n     - Listado tabular de todos los estudios cl\u00ednicos.\n     - Informes de estudios cl\u00ednicos, incluyendo estudios biofarmac\u00e9uticos y de bioequivalencia.\n\n4. **Formato de Presentaci\u00f3n**:\n   - Todos los documentos deben ser presentados en formato CTD (Common Technical Document), aunque el contenido puede variar.\n\n### Entidades Clave\n- **OMS (Organizaci\u00f3n Mundial de la Salud)**: Entidad responsable de la regulaci\u00f3n y precalificaci\u00f3n de productos farmac\u00e9uticos.\n- **FPP (Finished Pharmaceutical Product)**: Producto farmac\u00e9utico terminado que se eval\u00faa.\n- **API (Active Pharmaceutical Ingredient)**: Sustancia activa en un producto farmac\u00e9utico.\n- **CEP (Certificate of Suitability)**: Certificado que asegura que un producto cumple con los est\u00e1ndares de la Farmacopea Europea.\n- **APIMF (Active Pharmaceutical Ingredient Master File)**: Archivo maestro que contiene informaci\u00f3n sobre el ingrediente farmac\u00e9utico activo.\n- **CTD (Common Technical Document)**: Formato est\u00e1ndar para la presentaci\u00f3n de informaci\u00f3n t\u00e9cnica sobre productos farmac\u00e9uticos. \n\nEste resumen destaca los requisitos y procedimientos clave para la presentaci\u00f3n de dossiers de productos farmac\u00e9uticos, as\u00ed como las entidades y t\u00e9rminos relevantes en el contexto de la regulaci\u00f3n de medicamentos.", "excerpt_keywords": "Keywords: dossier, bioanalytical methods, case-report forms, CTD format, literature references"}}, "b4a14a89-c3a5-4803-acc4-0b1094d5d162": {"node_ids": ["54298ac0-53f7-4c73-9d3c-ef9514bc5b5f"], "metadata": {"page_label": "439", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Each binder should be labelled with the proprietary name (if applicable) and the non-proprietary name of the FPP (e.g. \u201cName ABC\u201d Abacavir (as sulfate) 300 mg tablets) and the company name of the applicant. For ease of reference, the following information could also be included on the label of each binder (space permitting): the volume number for that binder (out of the total number of volumes for that module), the section(s) contained within each volume and the date of the application (month and year), e.g.:\n\n```\nFPP \u201cName ABC\u201d\nNonproprietary name\nApplicant \u201cXYZ\u201d\nModule 3 \u2014 Quality\nVolume 1 of 3\nModule 3.1 \u2014 3.2.S.3\nMonth/year\n```\n\n8. **Variations**\n\nAll variation applications should be submitted using the CTD format, regardless of the original PD format.\n\nIn the case of the filing of a variation, applicants would normally provide only the relevant modules or sections affected by the change. For example, if the variation was for a change in the shelf-life of the FPP, only those sections affected by the change would need to be submitted (10).\n\nAn updated and annotated QIS should be provided with each variation application.\n\n# References\n\n1. Procedure for prequalification of pharmaceutical products. Revision. In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.* Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 10.\n\n2. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Efficacy (ICH M4E) together with the complementary ICH Questions and Answers documents for the above mentioned guidelines.\n\n3. Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (ICH M4) (2003): Efficacy.\n\n4. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality (ICH M4Q) (2003): Quality.\n\n5. Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety (ICH M4S) (2003): Safety.\n\n6. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability In: *WHO Expert Committee on*", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "### Resumen del Contexto\n\nEl documento proporciona directrices sobre c\u00f3mo etiquetar los archivos de solicitudes de productos farmac\u00e9uticos, espec\u00edficamente en el contexto de la presentaci\u00f3n de variaciones en la documentaci\u00f3n regulatoria. Se enfatiza la importancia de incluir tanto el nombre comercial como el nombre no propietario del producto farmac\u00e9utico, as\u00ed como informaci\u00f3n adicional que facilite la identificaci\u00f3n del contenido del archivo. Adem\u00e1s, se establece que todas las solicitudes de variaciones deben seguir el formato del Documento T\u00e9cnico Com\u00fan (CTD) y que solo se deben presentar los m\u00f3dulos o secciones relevantes que se vean afectados por el cambio.\n\n### Preguntas Espec\u00edficas\n\n1. **\u00bfQu\u00e9 informaci\u00f3n adicional se sugiere incluir en la etiqueta de cada carpeta, adem\u00e1s del nombre del FPP y el nombre del solicitante?**\n   - Se sugiere incluir el n\u00famero de volumen de la carpeta (de un total de vol\u00famenes para ese m\u00f3dulo), las secciones contenidas en cada volumen y la fecha de la solicitud (mes y a\u00f1o).\n\n2. **\u00bfQu\u00e9 se debe proporcionar junto con cada solicitud de variaci\u00f3n y por qu\u00e9 es importante?**\n   - Se debe proporcionar un QIS (Resumen de Informaci\u00f3n de Calidad) actualizado y anotado con cada solicitud de variaci\u00f3n. Esto es importante para asegurar que la informaci\u00f3n sobre la calidad del producto se mantenga actualizada y refleje los cambios realizados.\n\n3. **\u00bfCu\u00e1l es el procedimiento recomendado para la presentaci\u00f3n de solicitudes de variaciones en comparaci\u00f3n con la presentaci\u00f3n original?**\n   - Todas las solicitudes de variaciones deben ser presentadas utilizando el formato CTD, independientemente del formato original de la presentaci\u00f3n. Adem\u00e1s, solo se deben presentar los m\u00f3dulos o secciones que se vean afectados por el cambio, lo que simplifica el proceso de revisi\u00f3n.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Estudios de Correlaci\u00f3n In Vitro-In Vivo**:\n   - Secci\u00f3n 5.3.1.3 menciona la inclusi\u00f3n de informes de estudios de correlaci\u00f3n in vitro-in vivo si est\u00e1n disponibles.\n\n2. **M\u00e9todos Bioanal\u00edticos y Anal\u00edticos**:\n   - Secci\u00f3n 5.3.1.4 se refiere a los informes de m\u00e9todos bioanal\u00edticos y anal\u00edticos para estudios en humanos.\n\n3. **Formularios de Informes de Casos (CRFs)**:\n   - Secci\u00f3n 5.3.7 establece que solo se deben incluir CRFs de sujetos que experimentaron eventos adversos graves, y que todos los CRFs deben estar disponibles a solicitud.\n\n4. **Referencias Literarias**:\n   - Secci\u00f3n 5.4 menciona la necesidad de incluir referencias literarias y proporciona orientaci\u00f3n sobre biowaivers y productos comparadores.\n\n5. **Formato y Presentaci\u00f3n del Dossier del Producto**:\n   - Secci\u00f3n 7 proporciona directrices sobre el formato y la presentaci\u00f3n del dossier en el formato del documento t\u00e9cnico com\u00fan (CTD).\n   - Se recomienda el uso de m\u00e1rgenes adecuados para impresi\u00f3n en papel A4 y 8.5 \u00d7 11 pulgadas, y el uso de la fuente Times New Roman en tama\u00f1o 12 puntos para asegurar la legibilidad.\n\n6. **Citaci\u00f3n de Referencias**:\n   - Las referencias deben citarse seg\u00fan los *Uniform requirements for manuscripts submitted to biomedical journals* del ICMJE, y se deben proporcionar copias de las p\u00e1ginas relevantes y traducciones al ingl\u00e9s si es necesario.\n\n7. **Accesibilidad de la Informaci\u00f3n**:\n   - Se sugiere que las copias en papel de la solicitud est\u00e9n encuadernadas para facilitar el acceso a la informaci\u00f3n.\n\n### Entidades Clave\n- **WHO (Organizaci\u00f3n Mundial de la Salud)**: Autoridad del documento.\n- **CTD (Common Technical Document)**: Formato para la presentaci\u00f3n de informaci\u00f3n sobre productos.\n- **CRFs (Case-Report Forms)**: Formularios utilizados para documentar eventos adversos en estudios cl\u00ednicos.\n- **ICMJE (International Committee of Medical Journal Editors)**: Comit\u00e9 que establece normas para la citaci\u00f3n de referencias en publicaciones biom\u00e9dicas.\n- **Biowaivers**: Exenciones relacionadas con estudios de bioequivalencia.\n\nEste resumen destaca los aspectos m\u00e1s relevantes y las entidades mencionadas en la secci\u00f3n del documento, proporcionando una visi\u00f3n clara de su contenido y directrices.", "excerpt_keywords": "Keywords: pharmaceutical regulation, Common Technical Document, variation applications, quality information summary, product labeling"}}, "69a9048c-3ef4-4ec1-8d12-bb6788c37667": {"node_ids": ["5f237146-bcd6-4eb1-8099-40a0bdbb7324"], "metadata": {"page_label": "440", "file_name": "WHO_TRS_961_REPORTE 45.pdf", "file_path": "raw_data/WHO_TRS_961_REPORTE 45.pdf", "image_path": "", "parsed_text_markdown": "Specifications for Pharmaceutical Preparations. Fortieth report. Geneva, World Health Organization, 2006 (WHO Technical Report Series, No. 937), Annex 7.\n\n7. Bioequivalence trial information form (BTIF) on: http://apps.who.int/prequal/.\n\n8. Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part: on: http://apps.who.int/prequal/.\n\n9. Quality overall summary - product dossier (QOS-PD): on: http://apps.who.int/prequal/.\n\n10. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products In: *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* Geneva, World Health Organization, 2009 (WHO Technical Report Series, No. 953), Annex 2.", "parsed_text": "", "document_title": "WHO - Technical Report Series 961", "questions_this_excerpt_can_answer": "Aqu\u00ed tienes tres preguntas espec\u00edficas basadas en el contexto proporcionado, junto con sus respuestas:\n\n1. **\u00bfCu\u00e1l es el prop\u00f3sito del formulario de informaci\u00f3n sobre ensayos de bioequivalencia (BTIF) mencionado en el documento?**\n   - El formulario de informaci\u00f3n sobre ensayos de bioequivalencia (BTIF) tiene como prop\u00f3sito recopilar y estandarizar la informaci\u00f3n necesaria para evaluar la bioequivalencia de productos farmac\u00e9uticos gen\u00e9ricos en comparaci\u00f3n con los productos de referencia. Esto es esencial para garantizar que los medicamentos gen\u00e9ricos sean equivalentes en t\u00e9rminos de eficacia y seguridad.\n\n2. **\u00bfD\u00f3nde se puede encontrar la gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para productos farmac\u00e9uticos terminados multisource (gen\u00e9ricos)?**\n   - La gu\u00eda sobre la presentaci\u00f3n de documentaci\u00f3n para un producto farmac\u00e9utico terminado multisource (gen\u00e9rico) se puede encontrar en el sitio web de la Organizaci\u00f3n Mundial de la Salud (OMS) en la siguiente direcci\u00f3n: http://apps.who.int/prequal/.\n\n3. **\u00bfQu\u00e9 informe de la OMS se menciona en relaci\u00f3n con las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados?**\n   - Se menciona el informe de la OMS titulado *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-third report.* publicado en 2009 (WHO Technical Report Series, No. 953), que incluye un anexo sobre las pruebas de estabilidad de ingredientes farmac\u00e9uticos activos y productos farmac\u00e9uticos terminados.\n\n### Resumen de nivel superior del contexto:\nEl documento es un informe t\u00e9cnico de la Organizaci\u00f3n Mundial de la Salud (OMS) que proporciona especificaciones para preparaciones farmac\u00e9uticas, destacando la importancia de la bioequivalencia y la calidad en los productos farmac\u00e9uticos gen\u00e9ricos. Incluye referencias a formularios y gu\u00edas disponibles en el sitio web de la OMS, as\u00ed como a informes anteriores que abordan temas relacionados con la estabilidad de los productos farmac\u00e9uticos.", "prev_section_summary": "### Resumen de Temas Clave y Entidades\n\n1. **Etiquetado de Carpetas**:\n   - Cada carpeta debe llevar la siguiente informaci\u00f3n:\n     - Nombre comercial (si aplica) y nombre no propietario del producto farmac\u00e9utico (FPP).\n     - Nombre de la empresa solicitante.\n     - N\u00famero de volumen de la carpeta (de un total de vol\u00famenes para ese m\u00f3dulo).\n     - Secciones contenidas en cada volumen.\n     - Fecha de la solicitud (mes y a\u00f1o).\n\n   **Ejemplo de Etiqueta**:\n   ```\n   FPP \u201cName ABC\u201d\n   Nonproprietary name\n   Applicant \u201cXYZ\u201d\n   Module 3 \u2014 Quality\n   Volume 1 of 3\n   Module 3.1 \u2014 3.2.S.3\n   Month/year\n   ```\n\n2. **Solicitudes de Variaciones**:\n   - Todas las solicitudes de variaciones deben presentarse utilizando el formato del Documento T\u00e9cnico Com\u00fan (CTD), sin importar el formato original.\n   - Solo se deben presentar los m\u00f3dulos o secciones relevantes que se vean afectados por el cambio (por ejemplo, cambios en la vida \u00fatil del FPP).\n   - Es necesario proporcionar un Resumen de Informaci\u00f3n de Calidad (QIS) actualizado y anotado con cada solicitud de variaci\u00f3n.\n\n3. **Importancia del QIS**:\n   - Mantiene la informaci\u00f3n sobre la calidad del producto actualizada y refleja los cambios realizados en la solicitud.\n\n### Entidades Clave\n- **FPP**: Producto Farmac\u00e9utico Final.\n- **CTD**: Documento T\u00e9cnico Com\u00fan.\n- **QIS**: Resumen de Informaci\u00f3n de Calidad.\n- **WHO**: Organizaci\u00f3n Mundial de la Salud.\n- **M\u00f3dulos**: Secciones espec\u00edficas dentro de la documentaci\u00f3n regulatoria. \n\nEste resumen destaca la importancia del etiquetado adecuado y el cumplimiento de los formatos establecidos para la presentaci\u00f3n de solicitudes de variaciones en productos farmac\u00e9uticos.", "excerpt_keywords": "Keywords: bioequivalence, pharmaceutical preparations, WHO guidelines, stability testing, generic products"}}}}
\ No newline at end of file